APPROVED DRUG PRODUCTS
With Therapeutic Equivalence Evaluations

The "Orange Book"

FDA data supplied by DrugPatentWatch.com

FDA data supplied by DrugPatentWatch.com



APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

22nd EDITION

THE PRODUCTS IN THIS LIST HAVE BEEN APPROVED UNDER SECTION 505 OF THE FEDERAL FOOD, DRUG, AND COSMETIC ACT.

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH
OFFICE OF INFORMATION TECHNOLOGY
DIVISION OF DATA MANAGEMENT AND SERVICES

2002

FDA data supplied by DrugPatentWatch.com

FDA data supplied by DrugPatentWatch.com

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

The products in this list have been approved under section 505 of the Federal Food, Drug, and Cosmetic Act. This volume is current through December 31, 2001.

22ND EDITION

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH
OFFICE OF INFORMATION TECHNOLOGY
DIVISION OF DATA MANAGEMENT AND SERVICES

2002

FDA data supplied by DrugPatentWatch.com

FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH
APPROVED DRUG PRODUCTS
with
Therapeutic Equivalence Evaluations

CONTENTS

		PAGE
PREFACE TO TWENTY SECOND EDITION		v
1.	INTRODUCTION	vii
1.1	Content and Exclusion	vii
1.2	Therapeutic Equivalence-Related Terms	vii
1.3	Statistical Criteria for Bioequivalence	ix
1.4	Reference Listed Drug	x
1.5	General Policies and Legal Status	xi
1.6	Practitioner/User Responsibilities	xii
1.7	Therapeutic Equivalence Evaluations Codes	xiii
1.8	Description of Special Situations	xx
1.9	Therapeutic Equivalence Code Change for a Drug Entity	xxi
1.10	Change of the Therapeutic Equivalence Evaluation for a Single Product	xxii
1.11	Availability of Internal Policy and Procedure Guides	xxii
1.12	Discontinued Section	xxii
2.	HOW TO USE THE DRUG PRODUCTS LISTS	2-1
2.1	Key Sections for Using the Drug Product Lists	2-1
2.2	Drug Product Illustration	2-3
2.3	Therapeutic Equivalence Evaluations Illustration	2-4
DRUG PRODUCT LISTS		
	Prescription Drug Product List	3-1
	OTC Drug Product List	4-1
	Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List	5-1
	Discontinued Drug Product List	6-1
	Orphan Products Designations and Approvals List	7-1
	Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution	8-1
APPENDICES		
	A. Product Name Index	A-1
	B. Product Name Index Listed by Applicant	B-1
	C. Uniform Terms	C-1
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM		AD1
	A. Patent and Exclusivity Lists	ADA1
	B. Patent and Exclusivity Terms	ADB1

FDA data supplied by DrugPatentWatch.com

FDA data supplied by DrugPatentWatch.com

FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH
APPROVED DRUG PRODUCTS
with
Therapeutic Equivalence Evaluations

PREFACE TO TWENTY SECOND EDITION

The publication, *Approved Drug Products with Therapeutic Equivalence Evaluations* (the List), identifies drug products approved on the basis of safety and effectiveness by the Food and Drug Administration (FDA) under the Federal Food, Drug, and Cosmetic Act (the Act). Drugs on the market approved only on the basis of safety (covered by the ongoing Drug Efficacy Study Implementation [DESI] review [e.g., Donnatal® Tablets and Librax® Capsules] or pre-1938 drugs [e.g., Phenobarbital Tablets]) are not included in this publication. The main criterion for the inclusion of any product is that the product is the subject of an application with an effective approval that has not been withdrawn for safety or efficacy reasons. Inclusion of products on the List is independent of any current regulatory action through administrative or judicial means against a drug product. In addition, the List contains therapeutic equivalence evaluations for approved multisource prescription drug products. These evaluations have been prepared to serve as public information and advice to state health agencies, prescribers, and pharmacists to promote public education in the area of drug product selection and to foster containment of health care costs. Therapeutic equivalence evaluations in this publication are not official FDA actions affecting the legal status of products under the Act.

Background of the Publication. To contain drug costs, virtually every state has adopted laws and/or regulations that encourage the substitution of drug products. These state laws generally require either that substitution be limited to drugs on a specific list (the positive formulary approach) or that it be permitted for all drugs except those prohibited by a particular list (the negative formulary approach). Because of the number of requests in the late 1970s for FDA assistance in preparing both positive and negative formularies, it became apparent that FDA could not serve the needs of each state on an individual basis. The Agency also recognized that providing a single list based on common criteria would be preferable to evaluating drug products on the basis of differing definitions and criteria in various state laws. As a result, on May 31, 1978, the Commissioner of the Food and Drug Administration sent a letter to officials of each state stating FDA's intent to provide a list of all prescription drug products that are approved by FDA for safety and effectiveness, along with therapeutic equivalence determinations for multisource prescription products.

The List was distributed as a proposal in January 1979. It included only currently marketed prescription drug products approved by FDA through new drug applications (NDAs) and abbreviated new drug applications (ANDAs) under the provisions of Section 505 of the Act.

The therapeutic equivalence evaluations in the List reflect FDA's application of specific criteria to the approved multisource prescription drug products on the List. These evaluations are presented in the form of code letters that indicate the basis for the evaluation made. An explanation of the code appears in the *Introduction*.

A complete discussion of the background and basis of FDA's therapeutic equivalence evaluation policy was published in the *Federal Register* on January 12, 1979 (44 FR 2932). The final rule, which includes FDA's responses to the public comments on the proposal, was published in the *Federal Register* on October 31, 1980 (45 FR 72582). The first publication, October 1980, of the final

FDA data supplied by DrugPatentWatch.com

version of the List incorporated appropriate corrections and additions. Each subsequent edition has included the new approvals and made appropriate changes in data.

On September 24, 1984, the President signed into law the Drug Price Competition and Patent Term Restoration Act (1984 Amendments). The 1984 Amendments require that FDA, among other things, make publicly available a list of approved drug products with monthly supplements. The *Approved Drug Products with Therapeutic Equivalence Evaluations* publication and its monthly Cumulative Supplements satisfy this requirement. The *Addendum* to this publication identifies drugs that qualify under the 1984 Amendments for periods of exclusivity (during which ANDAs or applications described in Section 505(b)(2) of the Act for those drugs may not be submitted for a specified period of time and, if allowed to be submitted, would be tentatively approved) and provides patent information concerning the listed drugs which also may delay the approval of ANDAs or Section 505(b)(2) applications. The *Addendum* also provides additional information that may be helpful to those submitting a new drug application to the Agency.

The Agency intends to use this publication to further its objective of obtaining input and comment on the publication itself and related Agency procedures. Therefore, if you have comments on how the publication can be improved, please send them to the Director, Division of Data Management and Services , Office of Information Technology, Center for Drug and Evaluation and Research, HFD-90, 5600 Fishers Lane, Rockville, MD 20857. Comments received are publicly available to the extent allowable under the Freedom of Information regulations.

FDA data supplied by DrugPatentWatch.com

1. INTRODUCTION

1.1 Content and Exclusion

The List is composed of four parts: (1) approved prescription drug products with therapeutic equivalence evaluations; (2) approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; (3) drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and (4) a cumulative list of approved products that have never been marketed, have been discontinued from marketing, or have had their approvals withdrawn for other than safety or efficacy reasons subsequent to being discontinued from marketing. This publication also includes indices of prescription and OTC drug products by trade or established name (if no trade name exists) and by applicant name (holder of the approved application). All established names for active ingredients generally conform to official compendial names or *United States Adopted Names* (USAN) as prescribed in (21 CFR 299.4(e)). The latter list includes applicants' names as abbreviated in this publication; in addition, a list of uniform terms is provided. An *Addendum* contains drug patent and exclusivity information for the Prescription and OTC Drug Product Lists, and for the Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research.

This publication also includes additional information, such as Orphan Drug Product Designations and other data that the Agency deems appropriate to disseminate.

Prior to the 6th Edition, the publication had excluded OTC drug products and drug products with approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research because the main purpose of the publication was to provide information to states regarding FDA's recommendation as to which generic prescription drug products were acceptable candidates for drug product selection. The 1984 Amendments required the Agency to begin publishing an up-to-date list of all marketed drug products, OTC as well as prescription, that have been approved for safety and efficacy and for which new drug applications are required.

Under the 1984 Amendments, some drug products were given tentative approvals. Prior to the effective date, the Agency will not include drug products with tentative approval in the List; however, they are available in the *FDA Drug Product Approvals List* on the Internet World Wide Web. When the tentative approval becomes a full approval through a subsequent action letter to the application holder, the Agency will list the drug product and the final, effective approval date in the appropriate approved drug product list.

Distributors or repackagers of products on the List are not identified. Because distributors or repackagers are not required to notify FDA when they shift their sources of supply from one approved manufacturer to another, it is not possible to maintain complete information linking product approval with the distributor or repackager handling the products.

1.2 Therapeutic Equivalence-Related Terms

Pharmaceutical Equivalents. Drug products are considered pharmaceutical equivalents if they contain the same active ingredient(s), are of the same dosage form, route of administration and are identical in strength or concentration (e.g., chlordiazepoxide hydrochloride, 5mg capsules). Pharmaceutically equivalent drug products are formulated to contain the same amount of active ingredient in the same dosage form and to meet the same or compendial or other applicable standards (i.e., strength, quality, purity, and identity), but they may differ in characteristics such as shape, scoring configuration, release mechanisms, packaging, excipients (including colors, flavors, preservatives), expiration time, and, within certain limits, labeling.

Pharmaceutical Alternatives. Drug products are considered pharmaceutical alternatives if they contain the same therapeutic moiety, but are different salts, esters, or complexes of that moiety, or are different dosage forms or

FDA data supplied by DrugPatentWatch.com

strengths (e.g., tetracycline hydrochloride, 250mg capsules vs. tetracycline phosphate complex, 250mg capsules; quinidine sulfate, 200mg tablets vs. quinidine sulfate, 200mg capsules). Data are generally not available for FDA to make the determination of tablet to capsule bioequivalence. Different dosage forms and strengths within a product line by a single manufacturer are thus pharmaceutical alternatives, as are extended-release products when compared with immediate- or standard-release formulations of the same active ingredient.

Therapeutic Equivalents. Drug products are considered to be therapeutic equivalents only if they are pharmaceutical equivalents and if they can be expected to have the same clinical effect and safety profile when administered to patients under the conditions specified in the labeling.

FDA classifies as therapeutically equivalent those products that meet the following general criteria: (1) they are approved as safe and effective; (2) they are pharmaceutical equivalents in that they (a) contain identical amounts of the same active drug ingredient in the same dosage form and route of administration, and (b) meet compendial or other applicable standards of strength, quality, purity, and identity; (3) they are bioequivalent in that (a) they do not present a known or potential bioequivalence problem, and they meet an acceptable *in vitro* standard, or (b) if they do present such a known or potential problem, they are shown to meet an appropriate bioequivalence standard; (4) they are adequately labeled; and (5) they are manufactured in compliance with Current Good Manufacturing Practice regulations. *The concept of therapeutic equivalence, as used to develop the List, applies only to drug products containing the same active ingredient(s) and does not encompass a comparison of different therapeutic agents used for the same condition (e.g., propoxyphene hydrochloride vs. pentazocine hydrochloride for the treatment of pain)*. Any drug product in the List repackaged and/or distributed by other than the application holder is considered to be therapeutically equivalent to the application holder's drug product even if the application holder's drug product is single source or coded as non-equivalent (e.g., **BN**). Also, distributors or repackagers of an application holder's drug product are considered to have the same code as the application holder. Therapeutic equivalence determinations are not made for unapproved, off-label indications.

FDA considers drug products to be therapeutically equivalent if they meet the criteria outlined above, even though they may differ in certain other characteristics such as shape, scoring configuration, release mechanisms, packaging, excipients (including colors, flavors, preservatives), expiration date/time and minor aspects of labeling (e.g., the presence of specific pharmacokinetic information) and storage conditions. When such differences are important in the care of a particular patient, it may be appropriate for the prescribing physician to require that a particular brand be dispensed as a medical necessity. With this limitation, however, FDA believes that products classified as therapeutically equivalent can be substituted with the full expectation that the substituted product will produce the same clinical effect and safety profile as the prescribed product.

Bioavailability. This term means the rate and extent to which the active ingredient or active moiety is absorbed from a drug product and becomes available at the site of action. For drug products that are not intended to be absorbed into the bloodstream, bioavailability may be assessed by measurements intended to reflect the rate and extent to which the active ingredient or active moiety becomes available at the site of action.

Bioequivalent Drug Products. This term describes pharmaceutical equivalent or pharamaceutical alternative products that display comparable bioavailability when studied under similar experimental conditions. Section 505 (j)(7)(B) of the Act describes one set of conditions under which a test and reference listed drug (see Section 1.4) shall be considered bioequivalent:

> the rate and extent of absorption of the test drug do not show a significant difference from the rate and extent of absorption of the reference drug when administered at the same molar dose of the therapeutic ingredient under similar experimental conditions in either a single dose or multiple doses; or
>
> the extent of absorption of the test drug does not show a significant difference from the extent of absorption of the reference drug when administered at the same molar dose of the

FDA data supplied by DrugPatentWatch.com

therapeutic ingredient under similar experimental conditions in either a single dose or multiple doses and the difference from the reference drug in the rate of absorption of the drug is intentional, is reflected in its proposed labeling, is not essential to the attainment of effective body drug concentrations on chronic use, and is considered medically insignificant for the drug.

Where these above methods are not applicable (e.g., for drug products that are not intended to be absorbed into the bloodstream), other *in vivo* or *in vitro* test methods to demonstrate bioequivalence may be appropriate.

Bioequivalence may sometimes be demonstrated using an *in vitro* bioequivalence standard, especially when such an *in vitro* test has been correlated with human *in vivo* bioavailability data. In other situations, bioequivalence may sometimes be demonstrated through comparative clinical trials or pharmacodynamic studies.

1.3 Statistical Criteria for Bioequivalence

Under the Drug Price Competition and Patent Term Restoration Act of 1984, manufacturers seeking approval to market a generic drug product must submit data demonstrating that the drug product is bioequivalent to the pioneer (innovator) drug product. A major premise underlying the 1984 law is that bioequivalent drug products are therapeutically equivalent, and therefore, interchangeable.

Bioavailability refers to the rate and extent to which the active ingredient or therapeutic ingredient is absorbed from a drug product and becomes available at the site of drug action (Federal Food, Drug and Cosmetic Act, section 505(j)(8)). Bioequivalence refers to equivalent release of the same drug substance from two or more drug products or formulations. This leads to an equivalent rate and extent of absorption from these formulations. Underlying the concept of bioequivalence is the thesis that, if a drug product contains a drug substance that is chemically identical and is delivered to the site of action at the same rate and extent as another drug product, then it is equivalent and can be substituted for that drug product. Methods used to define bioequivalence can be found in 21 CFR 320.24, and include (1) pharmacokinetic (PK) studies, (2) pharmacodynamic (PD) studies, (3) comparative clinical trials, and (4) in-vitro studies. The choice of study used is based on the site of action of the drug and the ability of the study design to compare drug delivered to that site by the two products.

The standard bioequivalence (PK) study is conducted using a two-treatment crossover study design in a limited number of volunteers, usually 24 to 36 adults. Alternately, a four-period, replicate design crossover study may also be used. Single doses of the test and reference drug products are administered and blood or plasma levels of the drug are measured over time. Pharmacokinetic parameters characterizing rate and extent of drug absorption are evaluated statistically. The PK parameters of interest are the resulting area under the plasma concentration-time curve (AUC), calculated to the last measured concentration ($AUC_{(0-t)}$) and extrapolated to infinity ($AUC_{(0-inf)}$), for extent of absorption; and the maximum or peak drug concentrations (Cmax), for rate of absorption. Crossover studies may not be practical in drugs with a long half-life in the body, and a parallel study design may be used instead. Alternate study methods, such as in-vitro studies or equivalence studies with clinical or pharmacodynamic endpoints, are used for drug products where plasma concentrations are not useful to determine delivery of the drug substance to the site of activity (such as inhalers, nasal sprays and topical products applied to the skin).

The statistical methodology for analyzing these bioequivalence studies is called the two one-sided test procedure. Two situations are tested with this statistical methodology. The first of the two one-sided tests determines whether a generic product (test), when substituted for a brand-name product (reference) is significantly less bioavailable. The second of the two one-sided tests determines whether a brand-name product when substituted for a generic product is significantly less bioavailable. Based on the opinions of FDA medical experts, a difference of greater than 20% for each of the above tests was determined to be significant, and therefore, undesirable for all drug products. Numerically, this is expressed as a limit of test-product average/reference-

FDA data supplied by DrugPatentWatch.com

product average of 80% for the first statistical test and a limit of reference-product average/test-product average of 80% for the second statistical test. By convention, all data is expressed as a ratio of the average response (AUC and Cmax) for test/reference, so the limit expressed in the second statistical test is 125% (reciprocal of 80%).

For statistical reasons, all data is log-transformed prior to conducting statistical testing. In practice, these statistical tests are carried out using an analysis of variance procedure (ANOVA) and calculating a 90% confidence interval for each pharmacokinetic parameter (Cmax and AUC). The confidence interval for both pharmacokinetic parameters, AUC and Cmax, must be entirely within the 80% to 125% boundaries cited above. Because the mean of the study data lies in the center of the 90% confidence interval, the mean of the data is usually close to 100% (a test/reference ratio of 1). Different statistical criteria are sometimes used when bioequivalence is demonstrated through comparative clinical trials, pharmacodynamic studies, or comparative in-vitro methodology.

The bioequivalence methodology and criteria described above simultaneously control for both, differences in the average response between test and reference, as well as the precision with which the average response in the population is estimated. This precision depends on the within-subject (normal volunteer or patient) variability in the pharmacokinetic parameters (AUC and Cmax) of the two products and on the number of subjects in the study. The width of the 90% confidence interval is a reflection in part of the within-subject variability of the test and reference products in the bioequivalence study. A test product with no differences in the average response when compared to the reference might still fail to pass the bioequivalence criteria if the variability of one or both products is high and the bioequivalence study has insufficient statistical power (i.e., insufficient number of subjects). Likewise, a test product with low variability may pass the bioequivalence criteria, when there are somewhat larger differences in the average response.

This system of assessing bioequivalence of generic products assures that these substitutable products do not deviate substantially in in-vivo performance from the reference product. The Office of Generic Drugs has conducted two surveys to quantify the differences between generic and brand name products. The first survey included 224 bioequivalence studies submitted in approved applications during 1985 and 1986. The observed average differences between reference and generic products for AUC was 3.5% (JAMA, Sept. 4, 1987, Vol. 258, No. 9). The second survey included 127 bioequivalence studies submitted to the agency in 273 ANDAs approved in 1997. The three measures reviewed include $AUC_{(0-t)}$, $AUC_{(0-inf)}$, and Cmax. The observed average differences between the reference and generic products were $\pm$ 3.47% (SD 2.84) for $AUC_{(0-t)}$, $\pm$ 3.25% (SD 2.97) for $AUC_{(0-inf)}$, and $\pm$ 4.29% (SD 3.72) for Cmax (JAMA, Dec. 1, 1999, Vol. 282, No. 21).

The primary concern from the regulatory point of view is the protection of the patient against approval of products that are not bioequivalent. The current practice of carrying out two one-sided tests at the 0.05 level of significance ensures that there is no more than a 5% chance that a generic product that is not truly equivalent to the reference will be approved.

1.4 Reference Listed Drug

A reference listed drug (21 CFR 314.94(a)(3)) means the listed drug identified by FDA as the drug product upon which an applicant relies in seeking approval of its ANDA.

FDA has identified in the Prescription Drug Product and OTC Drug Product Lists those reference listed drugs to which the *in vivo* bioequivalence and, in some instances, the *in vitro* bioequivalence of the applicant's product is compared. By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. Such variations could result if generic drugs were compared to different reference listed drugs. However, in some instances when multiple NDAs are approved for a single drug product, a product not designated as the reference listed drug and not shown to be bioequivalent to the reference listed drug may be shielded from generic competition. A firm wishing to market a generic version of an NDA listed drug that is not designated as the

FDA data supplied by DrugPatentWatch.com

reference listed may petition the Agency through the Citizen Petition procedure (see 21 CFR 10.25(a) and CFR 10.30). When the Citizen Petition is approved, the second NDA will be designated as an additional reference listed drug and the petitioner may submit an Abbreviated New Drug Application citing the designated reference listed drug. Section 1.7, *Therapeutic Equivalence Evaluations Codes — Products meeting necessary bioequivalence requirements* explains the ***(AB, AB1, AB2, AB3...*** coding system for multisource drug products listed under the same heading with two reference listed drugs.

In addition, there are two situations in which two listed drugs that have been shown to be bioequivalent to each other may both be designated as reference listed drugs. The first situation occurs when the *in vivo* determination of bioequivalence is self-evident and a waiver of the *in vivo* bioequivalence may be granted. The second situation occurs when the bioequivalence of two NDA drug products may be determined through *in vitro* methodology. The reference listed drug is identified by the symbol "+" in the Prescription and Over-the Counter (OTC) Drug Product Lists. These identified reference listed drugs represent the best judgment of the Division of Bioequivalence at this time. The Prescription and OTC Drug Product Lists identify reference drugs for oral dosage forms, injectables, ophthalmics, otics, and topical products. It is recommended that a firm planning to conduct an *in vivo* bioequivalence study, or planning to manufacture a batch of a drug product for which an *in vivo* waiver of bioequivalence will be requested, contact the Division of Bioequivalence, Office of Generic Drugs, to confirm the appropriate reference listed drug.

Acyclovir 200MG Tablet-Reference Listed. Novopharm's single source acyclovir tablets have been declared to be a reference listed drug for the 200 mg tablet in addition to the acylcovir (Zovirax) 800 mg tablet of the innovator. A generic firm wishing to submit an ANDA for a duplicate of the 200 mg acyclovir tablet will be eligible for a waiver of the *in vivo* determination of bioequivalence (1) if their product is proportionally similar in its active and inactive ingredients to their own 800 mg acyclovir tablet and (2) by doing an acceptable comparative dissolution test (dissolution profile) against Novopharm's 200 mg acyclovir reference listed drug.

Before a waiver of the *in vivo* determination of bioequivalence can be granted for the 200 mg acyclovir tablet, the generic firm must have completed an acceptable fasting and fed study comparing their acyclovir 800 mg tablet against the Zovirax 800 mg tablet.

For further information on the study designs, you should contact the Division of Bioequivalence, Office of Generic Drugs.

1.5 General Policies and Legal Status

The List contains public information and advice. It does not mandate the drug products which may be purchased, prescribed, dispensed, or substituted for one another, nor does it, conversely, mandate the products that should be avoided. To the extent that the List sets forth FDA's evaluations of the therapeutic equivalence of drug products that have been approved, it contains FDA's advice to the public, to practitioners and to the states regarding drug product selection. These evaluations do not constitute determinations that any product is in violation of the Act or that any product is preferable to any other. Therapeutic equivalence evaluations are a scientific judgment based upon evidence, while generic substitution may involve social and economic policy administered by the states, intended to reduce the cost of drugs to consumers. To the extent that the List identifies drug products approved under Section 505 of the Act, it sets forth information that the Agency is required to publish and that the public is entitled to under the Freedom of Information Act. Exclusion of a drug product from the List does not necessarily mean that the drug product is either in violation of Section 505 of the Act, or that such a product is not safe or effective, or that such a product is not therapeutically equivalent to other drug products. Rather, the exclusion is based on the fact that FDA has not evaluated the safety, effectiveness, and quality of the drug product.

FDA data supplied by DrugPatentWatch.com

1.6 Practitioner/User Responsibilities

Professional care and judgment should be exercised in using the List. Evaluations of therapeutic equivalence for prescription drugs are based on scientific and medical evaluations by FDA. Products evaluated as therapeutically equivalent can be expected, in the judgment of FDA, to have equivalent clinical effect and no difference in their potential for adverse effects when used under the conditions of their labeling. However, these products may differ in other characteristics such as shape, scoring configuration, release mechanisms, packaging, excipients (including colors, flavors, preservatives), expiration date/time, and, in some instances, labeling. If products with such differences are substituted for each other, there is a potential for patient confusion due to differences in color or shape of tablets, inability to provide a given dose using a partial tablet if the proper scoring configuration is not available, or decreased patient acceptance of certain products because of flavor. There may also be better stability of one product over another under adverse storage conditions, or allergic reactions in rare cases due to a coloring or a preservative ingredient, as well as differences in cost to the patient.

FDA evaluation of therapeutic equivalence in no way relieves practitioners of their professional responsibilities in prescribing and dispensing such products with due care and with appropriate information to individual patients. In those circumstances where the characteristics of a specific product, other than its active ingredient, are important in the therapy of a particular patient, the physician's specification of that product is appropriate. Pharmacists must also be familiar with the expiration dates/times and labeling directions for storage of the different products, particularly for reconstituted products, to assure that patients are properly advised when one product is substituted for another.

Multisource and single-source drug products. FDA has evaluated for therapeutic equivalence only multisource prescription drug products, which in most instances means those pharmaceutical equivalents available from more than one manufacturer. For such products, a therapeutic equivalence code is included and, in addition, product information is highlighted in bold face and underlined. Those products with approved applications that are single-source (i.e., there is only one approved product available for that active ingredient, dosage form and route of administration) are also included on the List, but no therapeutic equivalence code is included with such products. Any drug product in the List repackaged and/or distributed by other than the application holder is considered to be therapeutically equivalent to the application holder's drug product even if the application holder's drug product is single source or coded as non-equivalent (e.g., **BN**). Also, although not identified in the List, distributors or repackagers of an application holder's drug product are considered to have the same code as the application holder. The details of these codes and the policies underlying them are discussed in Section 1.7, *Therapeutic Equivalence Evaluations Codes.*

Products on the List are identified by the names of the holders of approved applications (applicants) who may not necessarily be the manufacturer of the product. The applicant may have had its product manufactured by a contract manufacturer and may simply be distributing the product for which it has obtained approval. In most instances, however, the manufacturer of the product is also the applicant. The name of the manufacturer is permitted by regulation to appear on the label, even when the manufacturer is not the marketer.

Although the products on the List are identified by the names of the applicants, circumstances, such as changing corporate ownership, have sometimes made identification of the applicant difficult. The Agency believes, based on continuing document review and communication with firms, that the applicant designations on the List are, in most cases, correct.

To relate firm name information on a product label to that on the List, the following should be noted: the applicant's name always appears on the List. This applies whether the applicant (firm name on the Form FDA 356h in the application) is the marketer (firm name in largest letters on the label) or not. However, the applicant's name may not always appear on the label of the product.

FDA data supplied by DrugPatentWatch.com

If the applicant is the marketer, its name appears on the List and on the label; if the applicant is not the marketer, and the Agency is aware of a corporate relationship (e.g., parent and subsidiary) between the applicant and the marketer, the name of the applicant appears on the List and both firm names may appear on the label. Firms with known corporate relationships are displayed in Appendix B. If there is no known corporate relationship between the applicant and the marketer, the applicant's name appears on the List; however, unless the applicant is the manufacturer, packager, or distributor, the applicant's name may not appear on the label. In this case, the practitioner, from labeling alone, will not be able to relate the marketed product to an applicant cited in the List, and hence to a specific approved drug product. In such cases, to assure that the product in question is the subject of an approved application, the firm named on the label should be contacted.

To relate trade name (proprietary name) information on a product label to that on the List, the following should be noted: if the applicant is the marketer, its name appears on the List and on the label; if the Agency is aware of a corporate relationship between the applicant and the marketer, the trade name (proprietary name) of the drug product (established drug name if no trade name exists) appears on the List. If a corporate relationship exists between an application holder and a marketer and both firms are distributing the drug product, the FDA reserves the right to select the trade name of either the marketer or the application holder to appear on the List. If there is no known corporate relationship between the applicant and the marketer, the established drug name appears on the List.

Every product on the List is subject at all times to regulatory action. From time to time, approved products may be found in violation of one or more provisions of the Act. In such circumstances, the Agency will commence appropriate enforcement action to correct the violation, if necessary, by securing removal of the product from the market by voluntary recall, seizure, or other enforcement actions. Such regulatory actions are, however, independent of the inclusion of a product on the List. The main criterion for inclusion of a product is that it has an application with an effective approval that has not been withdrawn for safety or efficacy reasons. FDA believes that retention of a violative product on the List will not have any significant adverse health consequences, because other legal mechanisms are available to the Agency to prevent the product's actual marketing. FDA may however, change a product's therapeutic equivalence rating if the circumstances giving rise to the violation change or otherwise call into question the data upon which the Agency's assessment of whether a product meets the criteria for therapeutic equivalence was made.

1.7 Therapeutic Equivalence Evaluations Codes

The coding system for therapeutic equivalence evaluations is constructed to allow users to determine quickly whether the Agency has evaluated a particular approved product as therapeutically equivalent to other pharmaceutically equivalent products (first letter) and to provide additional information on the basis of FDA's evaluations (second letter). With few exceptions, the therapeutic equivalence evaluation date is the same as the approval date.

The two basic categories into which multisource drugs have been placed are indicated by the first letter as follows:

A — Drug products that FDA considers to be <u>therapeutically equivalent</u> to other pharmaceutically equivalent products, i.e., drug products for which:

(1) there are no known or suspected bioequivalence problems. These are designated **AA**, **AN**, **AO**, **AP**, or **AT**, depending on the dosage form; or

(2) actual or potential bioequivalence problems have been resolved with adequate *in vivo* and/or *in vitro* evidence supporting bioequivalence. These are designated **AB**.

FDA data supplied by DrugPatentWatch.com

B — Drug products that FDA at this time, considers not to be therapeutically equivalent to other pharmaceutically equivalent products, i.e.,

drug products for which actual or potential bioequivalence problems have not been resolved by adequate evidence of bioequivalence. Often the problem is with specific dosage forms rather than with the active ingredients. These are designated **BC**, **BD**, **BE**, **BN**, **BP**, **BR**, **BS**, **BT**, **BX**, or **B***.

Individual drug products have been evaluated as therapeutically equivalent to the reference product in accordance with the definitions and policies outlined below:

"A" CODES

Drug products that are considered to be therapeutically equivalent to other pharmaceutically equivalent products.

"**A**" products are those for which actual or potential bioequivalence problems have been resolved with adequate *in vivo* and/or *in vitro* evidence supporting bio- equivalence. Drug products designated with an "**A**" code fall under one of two main policies:

(1) for those active ingredients or dosage forms for which no *in vivo* bioequivalence issue is known or suspected, the information necessary to show bioequivalence between pharmaceutically equivalent products is presumed and considered self-evident based on other data in the application for some dosage forms (e.g., solutions) or satisfied for solid oral dosage forms by a showing that an acceptable *in vitro* dissolution standard is met. A therapeutically equivalent rating is assigned such products so long as they are manufactured in accordance with Current Good Manufacturing Practice regulations and meet the other requirements of their approved applications (these are designated **AA**, **AN**, **AO**, **AP**, or **AT**, depending on the dosage form, as described below); or

(2) for those DESI drug products containing active ingredients or dosage forms that have been identified by FDA as having actual or potential bioequivalence problems, and for post-1962 drug products in a dosage form presenting a potential bioequivalence problem, an evaluation of therapeutic equivalence is assigned to pharmaceutical equivalents only if the approved application contains adequate scientific evidence establishing through *in vivo* and/or *in vitro* studies the bioequivalence of the product to a selected reference product (these products are designated as **AB**).

There are some general principles that may affect the substitution of pharmaceutically equivalent products in specific cases. Prescribers and dispensers of drugs should be alert to these principles so as to deal appropriately with situations that require professional judgment and discretion.

There may be labeling differences among pharmaceutically equivalent products that require attention on the part of the health professional. For example, pharmaceutically equivalent powders to be reconstituted for administration as oral or injectable liquids may vary with respect to their expiration time or storage conditions after reconstitution. An FDA evaluation that such products are therapeutically equivalent is applicable only when each product is reconstituted, stored, and used under the conditions specified in the labeling of that product.

FDA data supplied by DrugPatentWatch.com

The Agency will use notes in this publication to point out special situations such as potential differences between two drug products that have been evaluated as bioequivalent and otherwise therapeutically equivalent, when they should be brought to the attention of health professionals. These notes are contained in Section 1.8, *Description of Special Situations*.

For example, in rare instances, there may be variations among therapeutically equivalent products in their use or in conditions of administration. Such differences may be due to patent or exclusivity rights associated with such use. When such variations may, in the Agency's opinion, affect prescribing or substitution decisions by health professionals, a note will be added to Section 1.8.

Also, occasionally a situation may arise in which changes in a listed drug product after its approval (for example, a change in dosing interval) may have an impact on the substitutability of already approved generic versions of that product that were rated by the Agency as therapeutically equivalent to the listed product. When such changes in the listed drug product are considered by the Agency to have a significant impact on therapeutic equivalence, the Agency will change the therapeutic equivalence ratings for other versions of the drug product unless the manufacturers of those other versions of the product provide additional information to assure equivalence under the changed conditions. Pending receipt of the additional data, the Agency may add a note to Section 1.8, or, in rare cases, may even change the therapeutic equivalence rating.

In some cases (e.g., Isolyte® S w/ Dextrose 5% in Plastic Container and Plasma-Lyte® 148 and Dextrose 5% in Plastic Container), closely related products are listed as containing the same active ingredients, but in somewhat different amounts. In determining which of these products are pharmaceutically equivalent, the Agency has considered products to be pharmaceutically equivalent with labeled strengths of an ingredient that do not vary by more than 1%.

Different salts and esters of the same therapeutic moiety are regarded as pharmaceutical alternatives. For the purpose of this publication, such products are not considered to be therapeutically equivalent. There are no instances in this List where pharmaceutical alternatives are evaluated or coded with regard to therapeutic equivalence. Anhydrous and hydrated entities, as well as different polymorphs, are considered pharmaceutical equivalents and must meet the same standards and, where necessary, as in the case of ampicillin/ampicillin trihydrate, their equivalence is supported by appropriate bioavailability/bioequivalence studies.

The codes in this book are not intended to preclude health care professionals from converting pharmaceutically different concentrations into pharmaceutical equivalents using accepted professional practice.

Where package size variations have therapeutic implications, products so packaged have not been considered pharmaceutically equivalent. For example, some oral contraceptives are supplied in 21-tablet and 28-tablet packets; the 28-tablet packets contain 7 placebo or iron tablets. These two packaging configurations are not regarded as pharmaceutically equivalent; thus, they are not designated as therapeutically equivalent.

Preservatives may differ among some therapeutically equivalent drug products. Differences in preservatives and other inactive ingredients do not affect FDA's evaluation of therapeutic equivalence except in cases where these components may influence bioequivalence or routes of administration.

The specific sub-codes for those drugs evaluated as therapeutically equivalent and the policies underlying these sub-codes follow:

AA — Products in conventional dosage forms not presenting bioequivalence problems

Products coded as **AA** contain active ingredients and dosage forms that are not regarded as presenting either actual or potential bioequivalence problems or drug quality or standards issues. However, all oral dosage forms must, nonetheless, meet an appropriate *in vitro* bioequivalence standard that is acceptable to the Agency in order to be approved.

FDA data supplied by DrugPatentWatch.com

AB, AB1, AB2, AB3... — Products meeting necessary bioequivalence requirements

Multisource drug products listed under the same heading (i.e., identical active ingredients(s), dosage form, and route(s) of administration) and having the same strength (see Section 1.2, *Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents)* generally will be coded **AB** if a study is submitted demonstrating bioequivalence.

In certain instances, a number is added to the end of the **AB** code to make a three character code (i.e., **AB1, AB2, AB3, etc.**). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against. For example, Adalat® CC (Miles) and Procardia XL® (Pfizer), extended-release tablets, are listed under the active ingredient nifedipine. These drug products, listed under the same heading, are not bioequivalent to each other. Once generic drug products deemed by FDA to be bioequivalent to either Adalat® CC or Procardia XL® are approved, Adalat® CC and Procardia XL® would be assigned ratings of **AB1** and **AB2**, respectively. The generic drug products bioequivalent to Adalat® CC would be assigned a rating of **AB1** and those bioequivalent to Procardia XL® would be assigned a rating of **AB2**. (The assignment of an **AB1** or **AB2** rating to a specific product does not imply product preference.) Even though drug products of distributors and/or repackagers are not included in the List, they are considered therapeutically equivalent to the application holder's drug product if the application holder's drug product is rated either with an **AB** or three-character code or is single source in the List. Drugs coded as **AB** under a heading are considered therapeutically equivalent only to other drugs coded as **AB** under that heading. Drugs coded with a three-character code under a heading are considered therapeutically equivalent only to other drugs coded with the same three-character code under that heading.

AN — Solutions and powders for aerosolization

Uncertainty regarding the therapeutic equivalence of aerosolized products arises primarily because of differences in the drug delivery system. Solutions and powders intended for aerosolization that are marketed for use in any of several delivery systems are considered to be pharmaceutically and therapeutically equivalent and are coded **AN**. Those products that are compatible only with a specific delivery system or those products that are packaged in and with a specific delivery system are coded **BN**, unless they have met an appropriate bioequivalence standard. Solutions or suspensions in a specific delivery system will be coded **AN** if the bioequivalence standard is based upon *in vitro* methodology, if bioequivalence needs to be demonstrated by *in vivo* methodology then the drug products will be coded **AB**.

AO — Injectable oil solutions

The absorption of drugs in injectable (parenteral) oil solutions may vary substantially with the type of oil employed as a vehicle and the concentration of the active ingredient. Injectable oil solutions are therefore considered to be pharmaceutically and therapeutically equivalent only when the active ingredient, its concentration, and the type of oil used as a vehicle are all identical.

FDA data supplied by DrugPatentWatch.com

AP — Injectable aqueous solutions and, in certain instances, intravenous non-aqueous solutions

It should be noted that even though injectable (parenteral) products under a specific listing may be evaluated as therapeutically equivalent, there may be important differences among the products in the general category, *Injectable; Injection*. For example, some injectable products that are rated therapeutically equivalent are labeled for different routes of administration. In addition, some products evaluated as therapeutically equivalent may have different preservatives or no preservatives at all. Injectable products available as dry powders for reconstitution, concentrated sterile solutions for dilution, or sterile solutions ready for injection are all considered to be pharmaceutically and therapeutically equivalent provided they are designed to produce the same concentration prior to injection and are similarly labeled. Consistent with accepted professional practice, it is the responsibility of the prescriber, dispenser, or individual administering the product to be familiar with a product's labeling to assure that it is given only by the route(s) of administration stated in the labeling.

Certain commonly used large volume intravenous products in glass containers are not included on the List (e.g., dextrose injection 5%, dextrose injection 10%, sodium chloride injection 0.9%) since these products are on the market without FDA approval and the FDA has not published conditions for marketing such parenteral products under approved NDAs. When packaged in plastic containers, however, FDA regulations require approved applications prior to marketing. Approval then depends on, among other things, the extent of the available safety data involving the specific plastic component of the product. All large volume parenteral products are manufactured under similar standards, regardless of whether they are packaged in glass or plastic. Thus, FDA has no reason to believe that the packaging container of large volume parenteral drug products that are pharmaceutically equivalent would have any effect on their therapeutic equivalence.

AT — Topical products

There are a variety of topical dosage forms available for dermatologic, ophthalmic, otic, rectal, and vaginal administration, including solutions, creams, ointments, gels, lotions, pastes, sprays, and suppositories. Even though different topical dosage forms may contain the same active ingredient and potency, these dosage forms are not considered pharmaceutically equivalent. Therefore, they are not considered therapeutically equivalent. All solutions and DESI drug products containing the same active ingredient in the same topical dosage form for which a waiver of *in vivo* bioequivalence has been granted and for which chemistry and manufacturing processes are adequate to demonstrate bioequivalence, are considered therapeutically equivalent and coded **AT**. Pharmaceutically equivalent topical products that raise questions of bioequivalence, including all post-1962 non-solution topical drug products, are coded **AB** when supported by adequate bioequivalence data, and **BT** in the absence of such data.

FDA data supplied by DrugPatentWatch.com

"B" CODES

Drug products that FDA, at this time, considers not to be therapeutically equivalent to other pharmaceutically equivalent products.

"B" products, for which actual or potential bioequivalence problems have not been resolved by adequate evidence of bioequivalence, often have a problem with specific dosage forms rather than with the active ingredients. Drug products designated with a "B" code fall under one of three main policies:

(1) the drug products contain active ingredients or are manufactured in dosage forms that have been identified by the Agency as having documented bio- equivalence problems or a significant potential for such problems and for which no adequate studies demonstrating bioequivalence have been submitted to FDA; or

(2) the quality standards are inadequate or FDA has an insufficient basis to determine therapeutic equivalence; or

(3) the drug products are under regulatory review.

The specific coding definitions and policies for the "B" sub-codes are as follows:

B* — Drug products requiring further FDA investigation and review to determine therapeutic equivalence

The code **B*** is assigned to products previously assigned an **A** or **B** code when FDA receives new information that raises a significant question regarding therapeutic equivalence that can be resolved only through further Agency investigation and/or review of data and information submitted by the applicant. The **B*** code signifies that the Agency will take no position regarding the therapeutic equivalence of the product until the Agency completes its investigation and review.

BC — Extended-release dosage forms (capsules, injectables and tablets)

An extended-release dosage form is defined by the official compendia as one that allows at least a twofold reduction in dosing frequency as compared to that drug presented as a conventional dosage form (e.g., as a solution or a prompt drug-releasing, conventional solid dosage form).

Although bioavailability studies have been conducted on these dosage forms, they may be subject to bioavailability differences, primarily because firms developing extended-release products for the same active ingredient rarely employ the same formulation approach. FDA, therefore, does not consider different extended-release dosage forms containing the same active ingredient in equal strength to be therapeutically equivalent unless equivalence between individual products in both rate and extent has been specifically demonstrated through appropriate bioequivalence studies. Extended-release products for which such bioequivalence data have not been submitted are coded **BC**, while those for which such data are available have been coded **AB**.

FDA data supplied by DrugPatentWatch.com

BD — Active ingredients and dosage forms with documented bioequivalence problems

The **BD** code denotes products containing active ingredients with known bioequivalence problems and for which adequate studies have not been submitted to FDA demonstrating bioequivalence. Where studies showing bioequivalence have been submitted, the product has been coded **AB**.

BE — Delayed-release oral dosage forms

A delayed-release dosage form is defined by the official compendia as one that releases a drug (or drugs) at a time other than promptly after administration. Enteric-coated articles are delayed-release dosage forms.

Drug products in delayed-release dosage forms containing the same active ingredients are subject to significant differences in absorption. Unless otherwise specifically noted, the Agency considers different delayed-release products containing the same active ingredients as presenting a potential bioequivalence problem and codes these products **BE** in the absence of *in vivo* studies showing bioequivalence. If adequate *in vivo* studies have demonstrated the bioequivalence of specific delayed-release products, such products are coded **AB**.

BN — Products in aerosol-nebulizer drug delivery systems

This code applies to drug solutions or powders that are marketed only as a component of, or as compatible with, a specific drug delivery system. There may, for example, be significant differences in the dose of drug and particle size delivered by different products of this type. Therefore, the Agency does not consider different metered aerosol dosage forms containing the same active ingredient(s) in equal strengths to be therapeutically equivalent unless the drug products meet an appropriate bioequivalence standard.

BP — Active ingredients and dosage forms with potential bioequivalence problems

FDA's bioequivalence regulations (21 CFR 320.33) contain criteria and procedures for determining whether a specific active ingredient in a specific dosage form has a potential for causing a bioequivalence problem. It is FDA's policy to consider an ingredient meeting these criteria as having a potential bioequivalence problem even in the absence of positive data demonstrating inequivalence. Pharmaceutically equivalent products containing these ingredients in oral dosage forms are coded **BP** until adequate *in vivo* bioequivalence data are submitted. Injectable suspensions containing an active ingredient suspended in an aqueous or oleaginous vehicle have also been coded **BP**. Injectable suspensions are subject to bioequivalence problems because differences in particle size, polymorphic structure of the suspended active ingredient, or the suspension formulation can significantly affect the rate of release and absorption. FDA does not consider pharmaceutical equivalents of these products bioequivalent without adequate evidence of bioequivalence.

BR — Suppositories or enemas that deliver drugs for systemic absorption

The absorption of active ingredients from suppositories or enemas that are intended to have a systemic effect (as distinct from suppositories administered for local effect) can vary significantly from product to product. Therefore, FDA considers pharmaceutically equivalent systemic

FDA data supplied by DrugPatentWatch.com

suppositories or enemas bio- equivalent only if *in vivo* evidence of bioequivalence is available. In those cases where *in vivo* evidence is available, the product is coded **AB**. If such evidence is not available, the products are coded **BR**.

BS — Products having drug standard deficiencies

If the drug standards for an active ingredient in a particular dosage form are found by FDA to be deficient so as to prevent an FDA evaluation of either pharmaceutical or therapeutic equivalence, all drug products containing that active ingredient in that dosage form are coded **BS**. For example, if the standards permit a wide variation in pharmacologically active components of the active ingredient such that pharmaceutical equivalence is in question, all products containing that active ingredient in that dosage form are coded **BS**.

BT — Topical products with bioequivalence issues

This code applies mainly to post-1962 dermatologic, ophthalmic, otic, rectal, and vaginal products for topical administration, including creams, ointments, gels, lotions, pastes, and sprays, as well as suppositories not intended for systemic drug absorption. Topical products evaluated as having acceptable clinical performance, but that are not bioequivalent to other pharmaceutically equivalent products or that lack sufficient evidence of bioequivalence, will be coded **BT**.

BX — Drug products for which the data are insufficient to determine therapeutic equivalence

The code **BX** is assigned to specific drug products for which the data that have been reviewed by the Agency are insufficient to determine therapeutic equivalence under the policies stated in this document. In these situations, the drug products are presumed to be therapeutically inequivalent until the Agency has determined that there is adequate information to make a full evaluation of therapeutic equivalence.

1.8 Description of Special Situations

Certain drugs listed in the Orange Book present special situations that merit further discussion. Following is a description of those special situations:

Amino Acid and Protein Hydrolysate Injections. These products differ in the amount and kinds of amino acids they contain and, therefore, are not considered pharmaceutical equivalents. For this reason, these products are not considered therapeutically equivalent. At the same time, the Agency believes that it is appropriate to point out that where nitrogen balance is the sole therapeutic objective and individual amino acid content is not a consideration, pharmaceutical alternatives with the same total amount of nitrogen content may be considered therapeutically equivalent.

Diclofenac Sodium Ophthalmic Solution 0.1%. Two NDAs have been approved for diclofenac sodium ophthalmic solution 0.1% (DSOS), (1) Ciba's NDA 20-037 for Voltaren and (2) Falcon Pharms' (Alcon) NDA 20-809 for DSOS. Alcon was required to do a study comparing their DSOS to Voltaren and to a placebo control in post cataract surgical inflammation. This study was necessary to demonstrate that the different formulation of the Alcon drug product did not affect the safety and/or effectiveness of the proposed drug product for this indication. Prior to the approval of Alcon's DSOS Ciba did clinical studies and was approved for two additional indications for the temporary relief of pain and photophobia in patients undergoing corneal refractive surgery. Three years of Waxman-Hatch marketing exclusivity was granted to Ciba for these two new uses.

FDA data supplied by DrugPatentWatch.com

Since the treatment of pain has a different site of action than the anti-inflammatory or photophobia indications the Agency did not have information to support a recommendation that the Alcon and Ciba DSOS are therapeutically equivalent for the treatment of pain. The designation of therapeutic equivalence at this time applies only to the anti-inflammatory indication. The therapeutic equivalence designation will apply to the photophobia indication upon expiration of Ciba's marketing exclusivity.

Ribavirin 200MG Oral Capsule. Indicated for use and comarketed with interferon alfa-2b, recombinant (Intron A), as Rebetron Combination Therapy.

Follitropin Alfa and Beta. Based on available data derived from physico-chemical tests and bioassay, follitropin alfa and follitropin beta are indistinguishable.

Gaviscon®. Gaviscon® is an OTC product which has been marketed since September 1970. The active ingredients in this product, aluminum hydroxide and magnesium trisilicate, were reviewed by the Agency's OTC Antacid Panel and were considered to be safe and effective ingredients (Category I) by that Panel. However, the tablet failed to pass the antacid test which is required of all antacid products. The Agency, therefore, placed the tablet in Category III for lack of effectiveness. A full NDA with clinical studies was submitted by Marion Laboratories, Inc., and approved by FDA on December 9, 1983. Gaviscon® 's activity in treating reflux acidity is made possible by the physical-chemical properties of the inactive ingredients, sodium bicarbonate and alginic acid. Therefore, *all ANDAs which cite Gaviscon® tablets as the listed drug must contain the inactive ingredients sodium bicarbonate and alginic acid.* A full NDA will be required to support the effectiveness of the drug product if different inactive ingredients are to be substituted for sodium bicarbonate or alginic acid or if different proportions of these ingredients are to be used.

Metaxalone Tablets. In Cumulative Supplement 6 of the Approved Drug Products with Therapeutic Equivalence Evaluations, 21st Edition, (the Orange Book), the Agency proposed to reclassifiy metaxalone tablets from a drug product not presenting bioequivalence problems to one that has a known or potential bioequivalence problem that requires an in vivo demonstration of bioequivalence as a condtiion of approval for an ANDA. The Agency solicited comments from interested persons to be received no later than November 30, 2001. No comments were received. Accordingly, the therapeutic equivalence category for metaxalone tablets will be changed from a "nonbioproblem drug" to a "bioproblem drug." An ANDA for metaxalone tablets must include acceptable in vivo bioequivalence study or studies. As long as metaxalone tablets are a single source drug product, no therapeutic equivalence code will be assigned to the product in the Orange Book. If the Agency approves an ANDA for metaxalone tablets, the innovator's NDA for metaxalone (Skelaxin) tablets and the approved ANDA will both be coded as "AB".

1.9 Therapeutic Equivalence Code Change for a Drug Entity

The Agency will use the following procedures when, in response to a petition or on its own initiative, it is considering a change in the therapeutic equivalence code for approved multi-source drug products. Such changes will generally occur when the Agency becomes aware of new scientific information affecting the therapeutic equivalence of an entire category of drug products in the List (e.g., information concerning the active ingredient or the dosage form), rather than information concerning a single drug product within the category. These procedures will be used when a change in therapeutic equivalence code is under consideration for all drug products found in the Prescription Drug Product List under a specific drug entity and dosage form. The change may be from the code signifying that the drug does not present a bioequivalence problem (e.g., **AA**) to a code signifying a bioequivalence problem (e.g., **BP**), or vice versa. This procedure does not apply to a change of a particular product code (e.g., a change from **BP** to **AB** or from **AB** to **BX**).

Before making a change in a therapeutic equivalence code for an entire category of drugs, the Agency will announce in the *Introduction* to the Cumulative Supplement that it is considering the change, and will invite comment. Comments, along with scientific data, may be sent to the Director, Division of Bioequivalence, Office of Generic Drugs, Center for Drug Evaluation

FDA data supplied by DrugPatentWatch.com

and Research, (MPN-2) HFD-650, 7500 Standish Place, Rockville, MD 20855. The comment period will generally be 60 days in length, and the closing date for comments will be listed in the description of the proposed change for each drug entity.

The most useful type of scientific data submission is an *in vivo* bioavailability/bioequivalence study conducted on batches of the subject drug products. These submissions should present a full description of the analytical procedures and equipment used, a validation of the analytical methodology, including the standard curve, a description of the method of calculating results, and a description of the pharmacokinetic and statistical models used in analyzing the data. Anecdotal or testimonial information is the least useful to the Agency, and such submissions are discouraged. Copies of supporting reports published in the scientific literature or unpublished material, however, are welcome.

1.10 Change of the Therapeutic Equivalence Evaluation for a Single Product

The aforementioned procedure does not apply to a change in a single drug product code. For example, a change in a single drug product's code from **BP** to **AB** as a result of the submission of a bioequivalence study ordinarily will not be the subject of notice and comment. Likewise, a change in a single drug product's code from **AB** to **BX** (e.g., as a result of new information raising a significant question as to bioequivalence) does not require notice and comment. The Agency's responsibility to provide the public with the Agency's most current information related to therapeutic equivalence may require a change in a drug product's code prior to any formal notice and opportunity for the applicant to be heard. The publication in the *Federal Register* of a proposal to withdraw approval of a drug product will ordinarily result in a change in a product's code from **AB** to **BX** if this action has not already been taken.

1.11 Availability of Internal Policy and Procedure Guides

The Office of Generic Drugs maintains internal policy and procedure guides. Although these guides are designed for Office personnel and are subject to change without public notice, they are available to members of the public who may wish to know more about the Office's policies and procedures. Copies of these guides may be obtained from the FDA, Center for Drug Evaluation and Research, HFD-210, Division of Communications Management, Drug Information Branch, 5600 Fishers Lane, Rockville, MD 20857. The Agency welcomes public comment on the policies, procedures, and practices employed in the approval of generic drugs. Such comments may be sent to the Director, Office of Generic Drugs, (MPN-2) HFD-600, 7500 Standish Place, Rockville, MD 20855.

1.12 Discontinued Section

Those drug products in the Discontinued Section of the Orange Book in which a determination has already been made that the products were not marketed or withdrawn for safety or efficacy reasons have been designated by the symbol "*". Those drug products with the symbol "*" are only reflective of citizen petitions approved since 1995.

The identification of these drug products in the Discontinued Section of the Orange Book with the symbol "*" should avoid the submission of multiple citizen petitions for the same drug product.

FDA data supplied by DrugPatentWatch.com

2. HOW TO USE THE DRUG PRODUCT LISTS

2.1 Key Sections for Using the Drug Product Lists

This publication contains illustrations, along with Drug Product Lists, indices, and lists of abbreviations and terms which facilitate their use.

Illustrations. The annotated *Drug Product Illustration*, see Section 2.2, and the *Therapeutic Equivalence Evaluations Illustration*, see Section 2.3, are offered to provide further clarification. These depict the format found in the Prescription Drug Product List (the only list in which therapeutic equivalence evaluation codes are displayed).

Drug Product Lists. The Drug Product Lists, arranged alphabetically by active ingredient, contain product identification information (active ingredients, dosage forms, routes of administration, product names, application holders, strengths) for single and multiple ingredient drug products. Also shown are the application number and drug product number (FDA internal computer data use only) and approval dates for those drug products approved on or after January 1, 1982.

If a prescription drug product is available from more than one source (multisource), a therapeutic equivalence code will appear in front of the applicant's name. If a product is therapeutically equivalent to one or more products or to an appropriate reference, it will be designated with a code beginning with "**A**" and the entry will be underlined and printed in bold font for emphasis.

Active ingredient headings for multiple ingredient (combination) drug products are arranged alphabetically. For purposes of this publication, this alphabetical sort takes precedence over United States Pharmacopeia official monograph order (i.e., Reserpine, Hydralazine Hydrochloride, Hydrochlorothiazide). For example, product information labeled as Reserpine, Hydrochlorothiazide and Hydralazine Hydrochloride appears under the active ingredient heading *Hydralazine Hydrochloride; Hydrochlorothiazide; Reserpine.* A cross-reference to the product information (for prescription and OTC products) appears for each additional active ingredient in the product. For combination drug products, the ingredient strengths are separated by semicolons and appear in the same relative sequence as the ingredients in the heading. Available strengths of the dosage form from an applicant appear on separate lines.

To use the Drug Product Lists, determine by alphabetical order the ingredient under which the product information is listed, using the Product Name Index, if necessary. Then, find the ingredient in the applicable Drug Product List. Proceed to the dosage form and route of administration and compare products within that ingredient heading only. Therapeutic equivalence or inequivalence for prescription products is determined on the basis of the therapeutic equivalence codes provided within that specific dosage form heading. The OTC Drug Product List, Discontinued Drug Product List, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List have their data arranged similarly. The Discontinued Drug Product List contains approved products that have never been marketed, have been discontinued from marketing, or have had their approvals withdrawn for other than safety or efficacy reasons subsequent to being discontinued from marketing. All products having a "@" in the 12th Cumulative Supplement of the 18th Edition List have been added to the Discontinued Drug Product List appearing in the 19th Edition.

Orphan Drug Product Designations. Drugs and biologicals that have been granted Orphan Designation pursuant to Section 526 as amended by the Orphan Drug Act [P.L. 97-414, January 4, 1983] are listed in Section 3.5.

Product Name Index (Prescription and OTC Drug Product Lists). This is an index of drug products by established or trade name. The second term of each entry indicates the active ingredient name under which product information can be found in the appropriate Drug Product List. For those drug products with multiple active ingredients, only the first active ingredient (in alphabetical order) will appear. OTC products are so designated.

FDA data supplied by DrugPatentWatch.com

Product Name Index Listed by Applicant (Prescription and OTC Drug Product Lists). This is an index that cross-references applicants to drug products. The bolded and underlined entry represents the applicant name abbreviation used in this publication. Each complete applicant name that is represented by the abbreviated name is marked with an asterisk (*). Listed under each complete applicant name is the first alphabetically arranged ingredient under which product information can be found in the appropriate Drug Product List. OTC products are so designated. To use the Drug Product Lists, determine by alphabetical order the ingredient under which the product information is listed, using the Product Name Index, if appropriate.

Uniform Terms. To improve readability, uniform terms are used to designate dosage forms, routes of administration, and abbreviations used to express strengths. These terms are listed in Appendix C. In some cases, the terms used may differ from those used in product labels and other labeling.

FDA data supplied by DrugPatentWatch.com

FDA data supplied by DrugPatentWatch.com

2.2 DRUG PRODUCT ILLUSTRATION

SINGLE INGREDIENT



MULTIPLE INGREDIENTS WITH PRODUCT INFORMATION



WITH CROSS-REFERENCE



THIS EXAMPLE IS FOR PURPOSES OF ILLUSTRATION ONLY. IT DOES NOT REPRESENT ACTUAL PRODUCTS FROM THE PRESCRIPTION DRUG PRODUCT LIST.

FDA data supplied by DrugPatentWatch.com

2.3 THERAPEUTIC EQUIVALENCE EVALUATIONS ILLUSTRATION

DRUG PRODUCTS CODED **AB** (OR ANY CODE BEGINNING WITH AN **"A"**) UNDER AN INGREDIENT AND DOSAGE FORM HEADING ARE CONSIDERED THERAPEUTICALLY EQUIVALENT ONLY TO OTHER PRODUCTS CODED **AB** (OR ANY CODE BEGINNING WITH AN **A"**) AND **NOT** TO THOSE CODED **BP** (OR ANY CODE BEGINNING WITH **"B"**) AND ANY PRODUCTS NOT LISTED. DRUG PRODUCTS CODED **BP** (OR ANY CODE BEGINNING WITH A **"B"**) ARE **NOT** CONSIDERED THERAPEUTICALLY EQUIVALENT TO ANY OTHER PRODUCT. FOR A COMPLETE EXPLANATION OF THE **TE** CODES REFER TO SECTION 1.7 OF THE *INTRODUCTION.*



NOTE: BOLD FONT AND UNDERLINING DENOTES MULTISOURCE PRODUCTS WHICH ARE CONSIDERED THERAPEUTICALLY EQUIVALENT.

THIS EXAMPLE IS FOR PURPOSES OF ILLUSTRATION ONLY. IT DOES NOT REPRESENT ACTUAL PRODUCTS FROM THE PRESCRIPTION DRUG PRODUCT LIST.

FDA data supplied by DrugPatentWatch.com

FDA data supplied by DrugPatentWatch.com

ABACAVIR SULFATE

SOLUTION; ORAL
ZIAGEN
+ GLAXOSMITHKLINE — EQ 20MG BASE/ML — N20978 001 DEC 17, 1998

TABLET; ORAL
ZIAGEN
+ GLAXOSMITHKLINE — EQ 300MG BASE — N20977 001 DEC 17, 1998

ABACAVIR SULFATE; LAMIVUDINE; ZIDOVUDINE

TABLET; ORAL
TRIZIVIR
+ GLAXOSMITHKLINE — EQ 300MG BASE;150MG;300MG — N21205 001 NOV 14, 2000

ACARBOSE

TABLET; ORAL
PRECOSE
BAYER — 25MG — N20482 004 MAY 29, 1997
50MG — N20482 001 SEP 06, 1995
+ 100MG — N20482 002 SEP 06, 1995

ACEBUTOLOL HYDROCHLORIDE

CAPSULE; ORAL
ACEBUTOLOL HCL
AB MYLAN — **EQ 200MG BASE** — **N74288 001** APR 24, 1995
AB — **EQ 400MG BASE** — **N74288 002** APR 24, 1995
AB PAR PHARM — **EQ 200MG BASE** — **N75047 001** DEC 30, 1999
AB — **EQ 400MG BASE** — **N75047 002** DEC 30, 1999
AB WATSON LABS — **EQ 200MG BASE** — **N74007 001** OCT 18, 1995
AB — **EQ 400MG BASE** — **N74007 002** OCT 18, 1995

ACEBUTOLOL HYDROCHLORIDE

CAPSULE; ORAL
SECTRAL
AB WYETH AYERST — **EQ 200MG BASE** — **N18917 001** DEC 28, 1984
AB + — **EQ 400MG BASE** — **N18917 003** DEC 28, 1984

ACETAMINOPHEN; ASPIRIN; CODEINE PHOSPHATE

CAPSULE; ORAL
ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE
+ MIKART — 150MG;180MG;30MG — N81096 001 OCT 26, 1990

ACETAMINOPHEN; BUTALBITAL

CAPSULE; ORAL
BUCET
AB MALLINCKRODT — **650MG;50MG** — **N88991 001** JUN 28, 1985
PHRENILIN FORTE
AB + AMARIN PHARMS — **650MG;50MG** — **N88831 001** JUN 19, 1985
TENCON
AB MALLINCKRODT — **650MG;50MG** — **N89405 001** MAY 15, 1990

TABLET; ORAL
BUTAPAP
AB MIKART — **325MG;50MG** — **N89987 001** OCT 26, 1992
AB — **650MG;50MG** — **N89988 001** OCT 26, 1992
PHRENILIN
AB + AMARIN PHARMS — **325MG;50MG** — **N87811 001** JUN 19, 1985
SEDAPAP
AB + MAYRAND — **650MG;50MG** — **N88944 001** OCT 17, 1985

FDA data supplied by DrugPatentWatch.com

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

		ACETAMINOPHEN, BUTALBITAL AND CAFFEINE			
AB	+	GILBERT LABS	325MG;50MG;40MG	**N88825 001**	DEC 05, 1984
		ACETAMINOPHEN, BUTALBITAL, AND CAFFEINE			
AB		MIKART	325MG;50MG;40MG	**N89007 001**	MAR 17, 1986
		BUTALBITAL, ACETAMINOPHEN AND CAFFEINE			
AB		WEST WARD	500MG;50MG;40MG	**N40261 001**	OCT 28, 1998
		ESGIC-PLUS			
AB	+	MIKART	500MG;50MG;40MG	**N40085 001**	MAR 28, 1996

TABLET; ORAL

		BUTALBITAL, ACETAMINOPHEN AND CAFFEINE			
AB		ABLE	325MG;50MG;40MG	**N40390 001**	JUL 23, 2001
AB			500MG;50MG;40MG	**N40394 001**	JUL 23, 2001
AB		MALLINCKRODT	325MG;50MG;40MG	**N87804 001**	JAN 24, 1985
AB		MIKART	325MG;50MG;40MG	**N89175 001**	JAN 21, 1987
AB	+		500MG;50MG;40MG	**N89451 001**	MAY 23, 1988
AB		WATSON LABS	500MG;50MG;40MG	**N40267 001**	JUL 30, 1998
AB		WEST WARD	325MG;50MG;40MG	**N89718 001**	JUN 12, 1995
		BUTALBITAL, ACETAMINOPHEN, AND CAFFEINE			
AB		WEST WARD	500MG;50MG;40MG	**N40336 001**	AUG 18, 1999
		BUTALBITAL, APAP, AND CAFFEINE			
AB		HALSEY	325MG;50MG;40MG	**N89536 001**	FEB 16, 1988
		FIORICET			
AB	+	NOVARTIS	325MG;50MG;40MG	**N88616 001**	NOV 09, 1984

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

		BUTALBITAL; ACETAMINOPHEN; AND CAFFEINE WITH CODEINE PHOSPHATE			
AB		WEST WARD	325MG;50MG;40MG;30MG	**N75618 001**	MAR 23, 2001

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

		FIORICET W/ CODEINE			
AB	+	NOVARTIS	325MG;50MG;40MG;30MG	**N20232 001**	JUL 30, 1992
		PHRENILIN WITH CAFFEINE AND CODEINE			
AB		AMARIN PHARMS	325MG;50MG;40MG;30MG	**N74911 001**	AUG 22, 2001

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE; ORAL

		ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE		
	+	MIKART	356.4MG;30MG;16MG	N40109 001 AUG 26, 1997

TABLET; ORAL

		ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE		
	+	MIKART	712.8MG;60MG;32MG	N40316 001 APR 28, 1999

ACETAMINOPHEN; CODEINE PHOSPHATE

CAPSULE; ORAL

		PHENAPHEN W/ CODEINE NO. 2		
	+	ROBINS AH	325MG;15MG	N84444 001
		PHENAPHEN W/ CODEINE NO. 3		
	+	ROBINS AH	325MG;30MG	N84445 001
		PHENAPHEN W/ CODEINE NO. 4		
	+	ROBINS AH	325MG;60MG	N84446 001

SOLUTION; ORAL

		ACETAMINOPHEN AND CODEINE PHOSPHATE			
AA		ALPHARMA	120MG/5ML;12MG/5ML	**N85861 001**	
AA		HI TECH PHARMA	120MG/5ML;12MG/5ML	**N40119 001**	APR 26, 1996
AA		MIKART	120MG/5ML;12MG/5ML	**N89450 001**	OCT 27, 1992
AA		MORTON GROVE	120MG/5ML;12MG/5ML	**N87006 001**	
AA		MOVA	120MG/5ML;12MG/5ML	**N40098 001**	SEP 20, 1996
AA		PHARM ASSOC	120MG/5ML;12MG/5ML	**N87508 001**	
		ACETAMINOPHEN W/ CODEINE			
AA		ROXANE	120MG/5ML;12MG/5ML	**N86366 001**	
		TYLENOL W/ CODEINE			
AA	+	JOHNSON RW	120MG/5ML;12MG/5ML	**N85057 001**	

FDA data supplied by DrugPatentWatch.com

ACETAMINOPHEN; CODEINE PHOSPHATE

SUSPENSION; ORAL

	ACETAMINOPHEN AND CODEINE PHOSPHATE			
AA	AMARIN PHARMS	120MG/5ML;12MG/5ML	N86024 001	
	CAPITAL AND CODEINE			
AA	ALPHARMA	120MG/5ML;12MG/5ML	N85883 001	

TABLET; ORAL

	ACETAMINOPHEN AND CODEINE PHOSPHATE			
AA	DURAMED	300MG;15MG	N40223 001	NOV 18, 1997
AA		300MG;30MG	N40223 002	NOV 18, 1997
AA		300MG;60MG	N40223 003	NOV 18, 1997
AA	GENEVA PHARMS	300MG;30MG	N81250 001	JUL 16, 1992
AA		300MG;60MG	N81249 001	JUL 16, 1992
AA	IVAX PHARMS	300MG;60MG	N87083 001	
AA	MALLINCKRODT	300MG;15MG	N40419 001	MAY 31, 2001
AA		300MG;30MG	N40419 002	MAY 31, 2001
AA		300MG;60MG	N40419 003	MAY 31, 2001
AA	MIKART	300MG;30MG	N89238 001	FEB 25, 1986
+		650MG;30MG	N89231 001	MAR 03, 1986
+		650MG;60MG	N89363 001	SEP 09, 1991
AA	MUTUAL PHARM	300MG;15MG	N89671 001	FEB 10, 1988
AA		300MG;30MG	N89672 001	FEB 10, 1988
AA		300MG;60MG	N89673 001	FEB 10, 1988
AA	PHARMERAL	300MG;30MG	N87762 001	DEC 10, 1982
AA	PUREPAC PHARM	300MG;30MG	N86681 001	
AA		300MG;60MG	N86683 001	
AA	TEVA	300MG;15MG	N88627 001	MAR 06, 1985
AA		300MG;30MG	N88628 001	MAR 06, 1985
AA		300MG;60MG	N88629 001	MAR 06, 1985

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET; ORAL

	ACETAMINOPHEN AND CODEINE PHOSPHATE			
AA	VINTAGE PHARMS	300MG;15MG	N89990 001	SEP 30, 1988
AA		300MG;30MG	N89805 001	SEP 30, 1988
AA		300MG;60MG	N89828 001	SEP 30, 1988
AA	WATSON LABS	300MG;15MG	N89997 001	DEC 28, 1994
AA		300MG;30MG	N89998 001	DEC 28, 1994
AA		300MG;60MG	N89999 001	DEC 28, 1994
	ACETAMINOPHEN AND CODEINE PHOSPHATE #2			
AA	SUPERPHARM	300MG;15MG	N89183 001	OCT 18, 1985
	ACETAMINOPHEN W/ CODEINE NO. 3			
AA	ROXANE	300MG;30MG	N84656 001	
	ACETAMINOPHEN W/ CODEINE PHOSPHATE #3			
AA	IVAX PHARMS	300MG;30MG	N85868 001	
	TYLENOL W/ CODEINE NO. 1			
+	JOHNSON RW	300MG;7.5MG	N85055 001	
	TYLENOL W/ CODEINE NO. 2			
AA +	JOHNSON RW	300MG;15MG	N85055 002	
	TYLENOL W/ CODEINE NO. 3			
AA +	JOHNSON RW	300MG;30MG	N85055 003	
	TYLENOL W/ CODEINE NO. 4			
AA +	JOHNSON RW	300MG;60MG	N85055 004	

ACETAMINOPHEN; HYDROCODONE BITARTRATE

CAPSULE; ORAL

	ACETAMINOPHEN AND HYDROCODONE BITARTRATE			
AA	CENT PHARMS	500MG;5MG	N88898 001	MAR 27, 1985
	ALLAY			
AA	IVAX PHARMS	500MG;5MG	N89907 001	JAN 13, 1989
	HYDROCET			
AA	MALLINCKRODT	500MG;5MG	N89006 001	AUG 09, 1985
	HYDROCODONE BITARTRATE AND ACETAMINOPHEN			
AA	MALLINCKRODT	500MG;5MG	N88956 001	JUL 19, 1985

FDA data supplied by DrugPatentWatch.com

ACETAMINOPHEN; HYDROCODONE BITARTRATE

CAPSULE; ORAL

	HYDROCODONE BITARTRATE AND ACETAMINOPHEN			
AA	MIKART	500MG;5MG	N81067 001	NOV 30, 1989
AA		500MG;5MG	N81068 001	NOV 30, 1989
AA		500MG;5MG	N81069 001	NOV 30, 1989
AA		500MG;5MG	N81070 001	NOV 30, 1989
AA		500MG;5MG	N89008 001	FEB 21, 1986
	LORCET-HD			
AA	+ MALLINCKRODT	500MG;5MG	N87336 001	JUL 08, 1982

SOLUTION; ORAL

	HYDROCODONE BITARTRATE AND ACETAMINOPHEN			
AA	MALLINCKRODT	500MG/15ML;7.5MG/15ML	N40418 001	JUN 27, 2001
AA	+ MIKART	500MG/15ML;7.5MG/15ML	N81051 001	AUG 28, 1992
		500MG/15ML;5MG/15ML	N81226 001	OCT 27, 1992
	+	500MG/15ML;5MG/15ML	N89557 001	APR 29, 1992
AA	PHARM ASSOC	500MG/15ML;7.5MG/15ML	N40182 001	MAR 13, 1998

TABLET; ORAL

	ANEXSIA			
AA	MALLINCKRODT	500MG;5MG	N89160 001	APR 23, 1987
	ANEXSIA 10/660			
AA	+ MALLINCKRODT	660MG;10MG	N40084 003	JUL 29, 1996
	ANEXSIA 5/325			
AA	MALLINCKRODT	325MG;5MG	N40409 001	OCT 20, 2000
	ANEXSIA 7.5/325			
AA	MALLINCKRODT	325MG;7.5MG	N40405 001	SEP 08, 2000
	ANEXSIA 7.5/650			
AA	MALLINCKRODT	650MG;7.5MG	N89725 001	SEP 30, 1987
	CO-GESIC			
AA	SCHWARZ PHARMA	500MG;5MG	N87757 001	MAY 03, 1982

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

	HY-PHEN			
AA	ASCHER	500MG;5MG	N87677 001	MAY 03, 1982
	HYDROCODONE BITARTRATE AND ACETAMINOPHEN			
AA	BARR	500MG;2.5MG	N40307 001	JUL 26, 2000
AA		500MG;5MG	N40308 001	JUL 26, 2000
AA		500MG;7.5MG	N40307 002	JUL 26, 2000
AA		500MG;10MG	N40309 001	JUL 26, 2000
AA		650MG;7.5MG	N40307 003	JUL 26, 2000
AA		650MG;10MG	N40307 004	JUL 26, 2000
AA		750MG;7.5MG	N40308 002	JUL 26, 2000
AA	ENDO PHARMS	500MG;5MG	N40281 001	SEP 30, 1998
AA		500MG;7.5MG	N40280 001	SEP 30, 1998
AA		650MG;7.5MG	N40280 002	SEP 30, 1998
AA		650MG;10MG	N40280 003	SEP 30, 1998
AA		750MG;7.5MG	N40281 002	SEP 30, 1998
	+	400MG;5MG	N40288 001	NOV 27, 1998
	+	400MG;7.5MG	N40288 002	NOV 27, 1998
	+	400MG;10MG	N40288 003	NOV 27, 1998
AA	EON	500MG;5MG	N40149 001	JAN 27, 1997
AA		750MG;7.5MG	N40149 002	JAN 27, 1997
AA	HALSEY	500MG;5MG	N40236 001	SEP 25, 1997
AA		650MG;7.5MG	N40240 002	NOV 26, 1997
AA		650MG;10MG	N40240 001	NOV 26, 1997
AA		750MG;7.5MG	N40236 002	SEP 25, 1997

FDA data supplied by DrugPatentWatch.com

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

		HYDROCODONE BITARTRATE AND ACETAMINOPHEN		
AA	IVAX PHARMS	500MG;5MG	N89696 001	APR 21, 1988
AA	MALLINCKRODT	325MG;10MG	N40400 001	JUL 26, 2000
AA		500MG;5MG	N40084 002	JUN 01, 1995
AA		500MG;7.5MG	N40201 001	FEB 27, 1998
AA		500MG;10MG	N40201 002	FEB 27, 1998
AA		650MG;10MG	N40084 004	OCT 16, 1996
AA		750MG;7.5MG	N40084 001	JUN 01, 1995
AA +	MIKART	500MG;2.5MG	N89698 001	AUG 25, 1989
AA		500MG;5MG	N89271 001	JUL 16, 1986
AA		500MG;5MG	N89697 001	JAN 28, 1992
AA +		500MG;7.5MG	N89699 001	AUG 25, 1989
AA +		650MG;7.5MG	N89689 001	JUN 29, 1988
AA +		650MG;10MG	N81223 001	MAY 29, 1992
AA	PEACHTREE	500MG;10MG	N40210 001	AUG 13, 1997
AA	UCB	650MG;7.5MG	N40134 001	NOV 21, 1996
AA	VINTAGE PHARMS	325MG;10MG	N40355 001	MAY 31, 2000
AA		500MG;2.5MG	N40144 002	APR 25, 1997
AA		500MG;5MG	N89831 001	SEP 07, 1988
AA		500MG;5MG	N89971 001	DEC 02, 1988
AA		500MG;7.5MG	N40144 001	FEB 22, 1996
AA		500MG;10MG	N40356 001	MAY 31, 2000
AA		650MG;7.5MG	N40155 001	APR 14, 1997

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

		HYDROCODONE BITARTRATE AND ACETAMINOPHEN		
AA	VINTAGE PHARMS	650MG;10MG	N40143 001	FEB 22, 1996
AA		660MG;10MG	N40358 001	MAY 31, 2000
AA		750MG;7.5MG	N40157 001	APR 12, 1996
AA	WATSON LABS	325MG;10MG	N40248 002	APR 28, 2000
AA		500MG;2.5MG	N40123 003	MAR 04, 1996
AA		500MG;2.5MG	N81079 001	AUG 30, 1991
AA		500MG;5MG	N40122 001	MAR 04, 1996
AA		500MG;5MG	N89883 001	DEC 01, 1988
AA		500MG;7.5MG	N40123 004	MAR 04, 1996
AA		500MG;7.5MG	N81080 001	AUG 30, 1991
AA		500MG;10MG	N40148 002	FEB 14, 1997
AA		650MG;7.5MG	N40094 001	SEP 29, 1995
AA		650MG;7.5MG	N40123 001	MAR 04, 1996
AA		650MG;10MG	N40094 002	SEP 29, 1995
AA		650MG;10MG	N40123 002	MAR 04, 1996
AA		660MG;10MG	N40094 003	AUG 08, 2000
AA		750MG;7.5MG	N40122 002	MAR 04, 1996
AA		750MG;7.5MG	N81083 001	AUG 30, 1991
+		750MG;10MG	N40094 004	MAR 22, 1999

LORTAB

AA	MALLINCKRODT	500MG;5MG	N87722 001	JUL 09, 1982
AA +	UCB	500MG;10MG	N40100 001	JAN 26, 1996
AA +	WATSON LABS	325MG;5MG	N40099 001	JUN 25, 1997

FDA data supplied by DrugPatentWatch.com

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

		NORCO			
AA	+	WATSON LABS	325MG;7.5MG	**N40148 003**	SEP 12, 2000
AA	+		325MG;10MG	**N40148 001**	FEB 14, 1997
		VICODIN			
AA	+	ABBOTT	500MG;5MG	**N88058 001**	JAN 07, 1983
		VICODIN ES			
AA	+	ABBOTT	750MG;7.5MG	**N89736 001**	DEC 09, 1988
		VICODIN HP			
AA		ABBOTT	660MG;10MG	**N40117 001**	SEP 23, 1996

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

CAPSULE; ORAL

		OXYCODONE AND ACETAMINOPHEN			
AA		AMIDE PHARM	500MG;5MG	**N40199 001**	DEC 30, 1998
AA		BARR	500MG;5MG	**N40304 001**	OCT 02, 2000
AA		DURAMED	500MG;5MG	**N40289 001**	MAR 16, 1999
AA		ENDO PHARMS	500MG;5MG	**N40303 001**	DEC 30, 1999
AA		HALSEY	500MG;5MG	**N40219 001**	JAN 22, 1998
AA		MALLINCKRODT	500MG;5MG	**N40257 001**	AUG 04, 1998
AA		VINTAGE PHARMS	500MG;5MG	**N40106 001**	JUL 30, 1996
AA		WATSON LABS	500MG;5MG	**N40234 001**	OCT 30, 1997
		ROXILOX			
AA		ROXANE	500MG;5MG	**N40061 001**	JUL 03, 1995
		TYLOX			
AA	+	JOHNSON RW	500MG;5MG	**N88790 001**	DEC 12, 1984

SOLUTION; ORAL

		ROXICET			
		ROXANE	325MG/5ML;5MG/5ML	N89351 001	DEC 03, 1986

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

		OXYCET			
AA		MALLINCKRODT	325MG;5MG	**N87463 001**	DEC 07, 1983
		OXYCODONE AND ACETAMINOPHEN			
AA		AMIDE PHARM	325MG;5MG	**N40203 001**	MAR 15, 1999
AA		BARR	325MG;5MG	**N87406 001**	
AA		DURAMED	325MG;5MG	**N40272 001**	JUN 30, 1998
AA		VINTAGE PHARMS	325MG;5MG	**N40105 001**	JUL 30, 1996
AA		WATSON LABS	325MG;5MG	**N40171 001**	OCT 30, 1997
AA			500MG;7.5MG	**N40371 001**	DEC 29, 2000
AA			650MG;10MG	**N40371 002**	DEC 29, 2000
		PERCOCET			
AA		ENDO PHARMS	325MG;5MG	**N40330 002**	JUN 25, 1999
AA	+		325MG;5MG	**N85106 002**	
AA	+		500MG;7.5MG	**N40341 001**	JUL 26, 1999
AA	+		650MG;10MG	**N40341 002**	JUL 26, 1999
	+		325MG;2.5MG	N40330 001	JUN 25, 1999
	+		325MG;7.5MG	N40434 001	NOV 23, 2001
	+		325MG;10MG	N40434 002	NOV 23, 2001
		ROXICET			
AA		ROXANE	325MG;5MG	**N87003 001**	
		ROXICET 5/500			
	+	ROXANE	500MG;5MG	N89775 001	JAN 12, 1989

ACETAMINOPHEN; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL

		PENTAZOCINE HCL AND ACETAMINOPHEN			
AB		WATSON LABS	650MG;EQ 25MG BASE	**N74699 001**	MAR 24, 2000
		TALACEN			
AB	+	SANOFI SYNTHELABO	650MG;EQ 25MG BASE	**N18458 001**	SEP 23, 1982

FDA data supplied by DrugPatentWatch.com

ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE

TABLET; ORAL

	PROPOXYPHENE HCL AND ACETAMINOPHEN			
AA	GENEVA PHARMS	650MG;65MG	**N89959 001**	
			JUL 18, 1989	
AA	MYLAN	650MG;65MG	**N83978 001**	
AA	WATSON LABS	650MG;65MG	**N40139 001**	
			DEC 16, 1996	
	WYGESIC			
AA	+ WOMEN FIRST HLTHCARE	650MG;65MG	**N84999 001**	

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL

	DARVOCET-N 100			
AB	+ LILLY	650MG;100MG	**N17122 002**	
	DARVOCET-N 50			
AB	LILLY	325MG;50MG	**N17122 001**	
	PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN			
AB	ABLE	650MG;100MG	**N75838 001**	
			JUL 11, 2001	
AB	GENEVA PHARMS	650MG;100MG	**N70443 001**	
			JAN 23, 1986	
AB	HALSEY	650MG;100MG	**N70615 001**	
			MAR 21, 1986	
AB		650MG;100MG	**N70771 001**	
			MAR 21, 1986	
AB		650MG;100MG	**N70775 001**	
			MAR 21, 1986	
AB	IVAX PHARMS	650MG;100MG	**N70146 001**	
			AUG 02, 1985	
AB	MALLINCKRODT	650MG;100MG	**N75738 001**	
			FEB 02, 2001	
AB	MYLAN	650MG;100MG	**N70145 001**	
			JUN 12, 1985	
AB		650MG;100MG	**N72195 001**	
			FEB 16, 1988	
AB	PUREPAC PHARM	650MG;100MG	**N70910 001**	
			JAN 02, 1987	
AB	TEVA	650MG;100MG	**N74119 001**	
			DEC 19, 1994	
AB	VINTAGE PHARMS	325MG;50MG	**N74843 002**	
			FEB 15, 2001	
AB		650MG;100MG	**N74843 001**	
			FEB 12, 1997	

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET; ORAL

	ULTRACET		
+	JOHNSON RW	325MG;37.5MG	N21123 001
			AUG 15, 2001

ACETAZOLAMIDE

CAPSULE, EXTENDED RELEASE; ORAL

	DIAMOX		
+	LEDERLE	500MG	N12945 003
			APR 25, 1995

TABLET; ORAL

	ACETAZOLAMIDE		
AB	DANBURY PHARMA	250MG	**N88882 001**
			OCT 22, 1985
AB	LANNETT	250MG	**N84840 001**
AB	MUTUAL PHARM	125MG	**N89752 001**
			JUN 22, 1988
AB		250MG	**N89753 001**
			JUN 22, 1988
AB	TARO	125MG	**N40195 001**
			MAY 28, 1997
AB		250MG	**N40195 002**
			MAY 28, 1997
	DIAMOX		
AB	LEDERLE	125MG	**N08943 001**
AB	+	250MG	**N08943 002**

ACETAZOLAMIDE SODIUM

INJECTABLE; INJECTION

	ACETAZOLAMIDE SODIUM		
AP	ABBOTT	EQ 500MG BASE/VIAL	**N40108 001**
			OCT 30, 1995
AP	BEDFORD	EQ 500MG BASE/VIAL	**N40089 001**
			FEB 28, 1995
	DIAMOX		
AP	+ LEDERLE	EQ 500MG BASE/VIAL	**N09388 001**
			DEC 05, 1990

FDA data supplied by DrugPatentWatch.com

ACETIC ACID, GLACIAL

SOLUTION; IRRIGATION, URETHRAL

ACETIC ACID 0.25% IN PLASTIC CONTAINER

AT	ABBOTT	250MG/100ML	N17656 001	
AT	B BRAUN	250MG/100ML	N18161 001	
AT	BAXTER HLTHCARE	250MG/100ML	N18523 001	FEB 19, 1982

SOLUTION/DROPS; OTIC

	ACETASOL			
AT	ALPHARMA	2%	N87146 001	
	ACETIC ACID			
AT	MORTON GROVE	2%	N40166 001	JUL 26, 1996
AT	THAMES	2%	N88638 001	SEP 06, 1984
	VOSOL			
AT	+ WALLACE LABS	2%	N12179 001	

ACETIC ACID, GLACIAL; ALUMINUM ACETATE

SOLUTION/DROPS; OTIC

	ACETIC ACID 2% IN AQUEOUS ALUMINUM ACETATE			
AT	BAUSCH AND LOMB	2%;0.79%	N40063 001	FEB 25, 1994
	DOMEBORO			
AT	+ BAYER	2%;0.79%	N84476 001	

ACETIC ACID, GLACIAL; HYDROCORTISONE

SOLUTION/DROPS; OTIC

	ACETASOL HC			
AT	ALPHARMA	2%;1%	N87143 001	JAN 13, 1982
	HYDROCORTISONE AND ACETIC ACID			
AT	MORTON GROVE	2%;1%	N40168 001	AUG 30, 1996
AT	THAMES	2%;1%	N88759 001	MAR 04, 1985
	VOSOL HC			
AT	+ WALLACE LABS	2%;1%	N12770 001	

ACETIC ACID, GLACIAL; HYDROCORTISONE; NEOMYCIN SULFATE

SUSPENSION/DROPS; OTIC

	NEO-CORT-DOME		
+	BAYER	2%;1%;EQ 0.35% BASE	N50238 001

ACETOHEXAMIDE

TABLET; ORAL

	ACETOHEXAMIDE			
AB	BARR	250MG	N70869 001	FEB 09, 1987
AB	+	500MG	N70870 001	FEB 09, 1987
AB	DANBURY PHARMA	250MG	N71893 001	NOV 25, 1987
AB		500MG	N71894 001	NOV 25, 1987

ACETOHYDROXAMIC ACID

TABLET; ORAL

	LITHOSTAT		
+	MISSION PHARMA	250MG	N18749 001 MAY 31, 1983

ACETYLCHOLINE CHLORIDE

FOR SOLUTION; OPHTHALMIC

	MIOCHOL		
+	NOVARTIS	20MG/VIAL	N16211 001
	MIOCHOL-E		
+	NOVARTIS	20MG/VIAL	N20213 001 SEP 22, 1993

ACETYLCYSTEINE

SOLUTION; INHALATION, ORAL

	ACETYLCYSTEINE			
AN	ABBOTT	10%	N73664 001	AUG 30, 1994
AN		20%	N74037 001	AUG 30, 1994
AN	BEDFORD	10%	N72323 001	APR 30, 1992

FDA data supplied by DrugPatentWatch.com

ACETYLCYSTEINE

SOLUTION; INHALATION, ORAL

	ACETYLCYSTEINE			
AN	BEDFORD	20%	N72324 001	APR 30, 1992
AN	FAULDING	10%	N71364 001	MAY 01, 1989
AN		20%	N71365 001	MAY 01, 1989
AN	LUITPOLD	10%	N72489 001	JUL 28, 1995
AN		20%	N72547 001	JUL 28, 1995
AN	ROXANE	10%	N72621 001	SEP 30, 1992
AN		20%	N72622 001	SEP 30, 1992
	MUCOMYST			
AN	+ APOTHECON	10%	N13601 002	
AN	+	20%	N13601 001	
	MUCOSIL-10			
AN	DEY	10%	N70575 001	OCT 14, 1986
	MUCOSIL-20			
AN	DEY	20%	N70576 001	OCT 14, 1986

ACITRETIN

CAPSULE; ORAL

	SORIATANE			
	HLR	10MG	N19821 001	OCT 28, 1996
	+	25MG	N19821 002	OCT 28, 1996

ACRIVASTINE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE; ORAL

	SEMPREX-D			
	+ CELLTECH PHARMS	8MG;60MG	N19806 001	MAR 25, 1994

ACYCLOVIR

CAPSULE; ORAL

	ACYCLOVIR			
AB	AESGEN	200MG	N74833 001	APR 22, 1997
AB	APOTHECON	200MG	N74889 001	OCT 31, 1997
AB	COPLEY PHARM	200MG	N74914 001	NOV 26, 1997
AB	ESI LEDERLE	200MG	N74872 001	APR 22, 1997
AB	GENPHARM	200MG	N74977 001	APR 13, 1998
AB	IVAX PHARMS	200MG	N74674 001	APR 22, 1997
AB	MYLAN	200MG	N74727 001	APR 22, 1997
AB	PUREPAC PHARM	200MG	N74906 001	AUG 26, 1997
AB	RANBAXY	200MG	N74975 001	SEP 30, 1998
AB	STASON	200MG	N75090 001	JAN 26, 1999
AB	TEVA	200MG	N74578 001	APR 22, 1997
AB		200MG	N74828 001	APR 22, 1997
AB	WATSON LABS	200MG	N75101 001	APR 15, 1998
	ZOVIRAX			
AB	+ GLAXOSMITHKLINE	200MG	N18828 001	JAN 25, 1985

OINTMENT; TOPICAL

	ZOVIRAX			
	+ GLAXOSMITHKLINE	5%	N18604 001	MAR 29, 1982

SUSPENSION; ORAL

	ACYCLOVIR			
AB	ALPHARMA	200MG/5ML	N74738 001	APR 28, 1997
	ZOVIRAX			
AB	+ GLAXOSMITHKLINE	200MG/5ML	N19909 001	DEC 22, 1989

TABLET; ORAL

	ACYCLOVIR			
AB	AESGEN	400MG	N74946 001	NOV 19, 1997

FDA data supplied by DrugPatentWatch.com

ACYCLOVIR

TABLET; ORAL

ACYCLOVIR

AB	AESGEN	800MG	N74946 002	NOV 19, 1997
AB	APOTHECON	400MG	N74891 001	OCT 31, 1997
AB		800MG	N74891 002	OCT 31, 1997
AB	CARLSBAD	400MG	N75382 001	APR 30, 1999
AB		800MG	N75382 002	APR 30, 1999
AB	COPLEY PHARM	400MG	N75021 001	MAR 18, 1998
AB		800MG	N75021 002	MAR 18, 1998
AB	ESI LEDERLE	400MG	N74834 001	APR 24, 1997
AB		800MG	N74834 002	APR 24, 1997
AB	GENPHARM	400MG	N74976 001	APR 13, 1998
AB		800MG	N74976 002	APR 13, 1998
AB	IVAX PHARMS	400MG	N74836 001	APR 22, 1997
AB		800MG	N74836 002	APR 22, 1997
AB	MYLAN	400MG	N75211 001	SEP 28, 1998
AB		800MG	N75211 002	SEP 28, 1998
AB	PUREPAC PHARM	400MG	N74870 001	JUN 05, 1997
AB		800MG	N74870 002	JUN 05, 1997
AB	RANBAXY	400MG	N74980 001	SEP 30, 1998
AB		800MG	N74980 002	SEP 30, 1998
AB	TEVA	400MG	N74556 002	APR 22, 1997
AB		800MG	N74556 003	APR 22, 1997

ZOVIRAX

AB	GLAXOSMITHKLINE	400MG	N20089 001	APR 30, 1991

ACYCLOVIR

TABLET; ORAL

ZOVIRAX

AB	+ GLAXOSMITHKLINE	800MG	N20089 002	APR 30, 1991

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

ACYCLOVIR

AP	ABBOTT	EQ 50MG BASE/ML	N75114 001	JUL 26, 1999
AP	GENSIA SICOR PHARMS	EQ 50MG BASE/ML	N75627 001	MAR 28, 2001
	ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE			
	+ ESI LEDERLE	EQ 500MG BASE/VIAL	N74885 001	DEC 19, 1997
		EQ 1GM BASE/VIAL	N74885 002	DEC 19, 1997

ACYCLOVIR SODIUM

AP	ABBOTT	EQ 500MG BASE/VIAL	N74663 001	APR 22, 1997
AP		EQ 500MG BASE/VIAL	N74758 001	APR 22, 1997
AP		EQ 1GM BASE/VIAL	N74663 002	APR 22, 1997
AP		EQ 1GM BASE/VIAL	N74758 002	APR 22, 1997
AP	+ AM PHARM PARTNERS	EQ 50MG BASE/ML	N74930 001	MAY 13, 1998
AP		EQ 500MG BASE/VIAL	N75015 001	APR 30, 1998
AP	BEDFORD	EQ 500MG BASE/VIAL	N74596 002	APR 22, 1997
AP		EQ 1GM BASE/VIAL	N74596 001	APR 22, 1997
AP	ESI LEDERLE	EQ 500MG BASE/VIAL	N74913 001	OCT 15, 1997
AP		EQ 1GM BASE/VIAL	N74913 002	OCT 15, 1997
	+ FAULDING	EQ 25MG BASE/ML	N74720 001	APR 22, 1997
AP	GENSIA SICOR PHARMS	EQ 500MG BASE/VIAL	N74969 001	AUG 26, 1997
AP		EQ 1GM BASE/VIAL	N74969 002	AUG 26, 1997

FDA data supplied by DrugPatentWatch.com

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

	ACYCLOVIR SODIUM			
AP	MERIDIAN MEDCL TECHN	**EQ 50MG BASE/ML**	**N75065 001**	
			FEB 25, 1999	
	ZOVIRAX			
AP	+ GLAXOSMITHKLINE	**EQ 500MG BASE/VIAL**	**N18603 001**	
			OCT 22, 1982	
AP	+	**EQ 1GM BASE/VIAL**	**N18603 002**	
			JUN 29, 1989	

ADAPALENE

CREAM; TOPICAL

	DIFFERIN		
+	GALDERMA LABS LP	0.1%	N20748 001
			MAY 26, 2000

GEL; TOPICAL

	DIFFERIN		
+	GALDERMA LABS LP	0.1%	N20380 001
			MAY 31, 1996

SOLUTION; TOPICAL

	DIFFERIN		
+	GALDERMA LABS LP	0.1%	N20338 001
			MAY 31, 1996

ADENOSINE

INJECTABLE; INJECTION

	ADENOCARD		
+	FUJISAWA HLTHCARE	3MG/ML	N19937 002
			OCT 30, 1989
	ADENOSCAN		
+	FUJISAWA HLTHCARE	3MG/ML	N20059 001
			MAY 18, 1995

ALATROFLOXACIN MESYLATE

INJECTABLE; INJECTION

	TROVAN PRESERVATIVE FREE		
	PFIZER	EQ 200MG BASE/VIAL	N20760 001
			DEC 18, 1997

ALATROFLOXACIN MESYLATE

INJECTABLE; INJECTION

	TROVAN PRESERVATIVE FREE		
+	PFIZER	EQ 300MG BASE/VIAL	N20760 002
			DEC 18, 1997

ALBENDAZOLE

TABLET; ORAL

	ALBENZA		
+	GLAXOSMITHKLINE	200MG	N20666 001
			JUN 11, 1996

ALBUMIN CHROMATED CR-51 SERUM

INJECTABLE; INJECTION

	CHROMALBIN		
	ISO TEX	100 uCi/VIAL	N17835 001

ALBUMIN HUMAN

INJECTABLE; INJECTION

	OPTISON		
+	MALLINCKRODT	10MG/ML	N20899 001
			DEC 31, 1997

ALBUMIN IODINATED I-125 SERUM

INJECTABLE; INJECTION

	RADIOIODINATED SERUM ALBUMIN (HUMAN) IHSA I 125		
	MALLINCKRODT	6.67 uCi/ML	N17844 003
		10 uCi/ML	N17844 001
		100 uCi/ML	N17844 002

ALBUMIN IODINATED I-131 SERUM

INJECTABLE; INJECTION

	MEGATOPE		
	ISO TEX	0.5mCi/VIAL	N17837 001
		1mCi/VIAL	N17837 002

FDA data supplied by DrugPatentWatch.com

ALBUTEROL

AEROSOL, METERED; INHALATION

	ALBUTEROL			
AB	ARMSTRONG PHARMS	**0.09MG/INH**	**N72273 001**	AUG 14, 1996
AB	GENPHARM	**0.09MG/INH**	**N73045 001**	AUG 19, 1997
AB	IVAX PHARMS	**0.09MG/INH**	**N73272 001**	DEC 28, 1995
AB	SIDMAK LABS	**0.09MG/INH**	**N74072 001**	AUG 01, 1996
	PROVENTIL			
BN	SCHERING	0.09MG/INH	N17559 001	
	VENTOLIN			
AB	+ GLAXOSMITHKLINE	**0.09MG/INH**	**N18473 001**	

ALBUTEROL SULFATE

AEROSOL, METERED; INHALATION

	PROVENTIL-HFA			
	+ 3M	EQ 0.09MG BASE/INH	N20503 001	AUG 15, 1996
	VENTOLIN HFA			
	+ GLAXOSMITHKLINE	EQ 0.09MG BASE/INH	N20983 001	APR 19, 2001

SOLUTION; INHALATION

	ACCUNEB			
	+ DEY	EQ 0.021% BASE	N20949 002	APR 30, 2001
	+	EQ 0.042% BASE	N20949 001	APR 30, 2001
	ALBUTEROL SULFATE			
AN	ALPHARMA	**EQ 0.083% BASE**	**N73533 001**	SEP 26, 1995
AN	BAUSCH AND LOMB	**EQ 0.083% BASE**	**N75358 001**	MAR 29, 2000
AN		**EQ 0.5% BASE**	**N75050 001**	JUN 18, 1998
AN	DEY	**EQ 0.083% BASE**	**N72652 001**	FEB 21, 1992
AN	HI TECH PHARMA	**EQ 0.083% BASE**	**N75063 001**	FEB 09, 1999
AN		**EQ 0.5% BASE**	**N74543 001**	JAN 15, 1998
AN	IVAX PHARMS	**EQ 0.083% BASE**	**N75343 001**	NOV 09, 1999

ALBUTEROL SULFATE

SOLUTION; INHALATION

	ALBUTEROL SULFATE			
AN	MORTON GROVE	**EQ 0.083% BASE**	**N75394 001**	NOV 22, 1999
AN	NEPHRON	**EQ 0.083% BASE**	**N74880 001**	SEP 17, 1997
AN		**EQ 0.5% BASE**	**N75664 001**	JUN 26, 2001
AN	ROXANE	**EQ 0.083% BASE**	**N75129 001**	FEB 13, 2001
	PROVENTIL			
AN	+ SCHERING	**EQ 0.083% BASE**	**N19243 002**	JAN 14, 1987
AN	+	**EQ 0.5% BASE**	**N19243 001**	JAN 14, 1987

SYRUP; ORAL

	ALBUTEROL SULFATE			
AA	ALPHARMA	**EQ 2MG BASE/5ML**	**N74454 001**	SEP 25, 1995
AA	HI TECH PHARMA	**EQ 2MG BASE/5ML**	**N74749 001**	JAN 30, 1998
AA	TEVA	**EQ 2MG BASE/5ML**	**N73419 001**	MAR 30, 1992
AA	UDL	**EQ 2MG BASE/5ML**	**N75262 001**	MAR 30, 1999
	PROVENTIL			
AA	+ SCHERING	**EQ 2MG BASE/5ML**	**N18062 001**	JAN 19, 1983

TABLET; ORAL

	ALBUTEROL SULFATE			
AB	DANBURY PHARMA	**EQ 2MG BASE**	**N72629 001**	JAN 31, 1991
AB		**EQ 4MG BASE**	**N72630 001**	JAN 31, 1991
AB	GENEVA PHARMS	**EQ 2MG BASE**	**N72151 001**	DEC 05, 1989
AB		**EQ 4MG BASE**	**N72152 001**	DEC 05, 1989
AB	LEDERLE	**EQ 2MG BASE**	**N72859 001**	DEC 20, 1989
AB		**EQ 4MG BASE**	**N72860 001**	DEC 20, 1989
AB	MUTUAL PHARM	**EQ 2MG BASE**	**N72636 001**	DEC 05, 1989

FDA data supplied by DrugPatentWatch.com

ALBUTEROL SULFATE

TABLET; ORAL

	ALBUTEROL SULFATE			
AB	MUTUAL PHARM	**EQ 4MG BASE**	**N72637 001**	DEC 05, 1989
AB	MYLAN	**EQ 2MG BASE**	**N72893 001**	JAN 17, 1991
AB		**EQ 4MG BASE**	**N72894 001**	JAN 17, 1991
AB	SIDMAK LABS NJ	**EQ 2MG BASE**	**N72316 001**	DEC 05, 1989
AB		**EQ 4MG BASE**	**N72317 001**	DEC 05, 1989
AB	TEVA	**EQ 2MG BASE**	**N72619 001**	DEC 05, 1989
AB		**EQ 2MG BASE**	**N72779 001**	JUN 25, 1993
AB		**EQ 2MG BASE**	**N72938 001**	MAR 30, 1990
AB		**EQ 4MG BASE**	**N72620 001**	DEC 05, 1989
AB		**EQ 4MG BASE**	**N72780 001**	JUN 25, 1993
AB		**EQ 4MG BASE**	**N72939 001**	MAR 30, 1990
AB	WATSON LABS	**EQ 2MG BASE**	**N72764 001**	AUG 28, 1991
AB		**EQ 4MG BASE**	**N72765 001**	AUG 28, 1991
	PROVENTIL			
AB	SCHERING	**EQ 2MG BASE**	**N17853 001**	MAY 07, 1982
AB	+	**EQ 4MG BASE**	**N17853 002**	MAY 07, 1982

TABLET, EXTENDED RELEASE; ORAL

	PROVENTIL			
BC	SCHERING	EQ 4MG BASE	N19383 001	JUL 13, 1987
	VOLMAX			
BC	+ MURO	EQ 4MG BASE	N19604 002	DEC 23, 1992
	+	EQ 8MG BASE	N19604 001	DEC 23, 1992

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

AEROSOL, METERED; INHALATION

COMBIVENT			
+	BOEHRINGER INGELHEIM	EQ 0.09MG BASE/INH; 0.018MG/INH	N20291 001 OCT 24, 1996

SOLUTION; INHALATION

DUONEB			
+	DEY	EQ 0.083% BASE;0.017%	N20950 001 MAR 21, 2001

ALCLOMETASONE DIPROPIONATE

CREAM; TOPICAL

ACLOVATE			
+	GLAXOSMITHKLINE	0.05%	N18707 001 DEC 14, 1982

OINTMENT; TOPICAL

ACLOVATE			
+	GLAXOSMITHKLINE	0.05%	N18702 001 DEC 14, 1982

ALCOHOL; DEXTROSE

INJECTABLE; INJECTION

ALCOHOL 10% AND DEXTROSE 5%			
+	B BRAUN	10ML/100ML;5GM/100ML	N04589 006
ALCOHOL 5% AND DEXTROSE 5%			
AP +	B BRAUN	**5ML/100ML;5GM/100ML**	**N04589 004**
ALCOHOL 5% IN D5-W			
AP	ABBOTT	**5ML/100ML;5GM/100ML**	**N83263 001**

ALENDRONATE SODIUM

TABLET; ORAL

FOSAMAX			
	MERCK	EQ 5MG BASE	N20560 003 APR 25, 1997
		EQ 10MG BASE	N20560 001 SEP 29, 1995
		EQ 35MG BASE	N20560 004 OCT 20, 2000

FDA data supplied by DrugPatentWatch.com

ALENDRONATE SODIUM

TABLET; ORAL
FOSAMAX
MERCK — EQ 40MG BASE — N20560 002 SEP 29, 1995
\+ — EQ 70MG BASE — N20560 005 OCT 20, 2000

ALFENTANIL HYDROCHLORIDE

INJECTABLE; INJECTION
ALFENTA
AP + AKORN — **EQ 0.5MG BASE/ML** — **N19353 001** DEC 29, 1986

ALFENTANIL
AP ABBOTT — **EQ 0.5MG BASE/ML** — **N75221 001** OCT 28, 1999

ALGLUCERASE

INJECTABLE; INJECTION
CEREDASE
GENZYME — 10 UNITS/ML — N20057 004 MAY 08, 1992
\+ — 80 UNITS/ML — N20057 003 APR 05, 1991

ALITRETINOIN

GEL; TOPICAL
PANRETIN
\+ LIGAND — EQ 0.1% BASE — N20886 001 FEB 02, 1999

ALLOPURINOL

TABLET; ORAL
ALLOPURINOL
AB DANBURY PHARMA — **100MG** — **N18832 002** SEP 28, 1984
AB — **300MG** — **N18877 001** SEP 28, 1984
AB GENEVA PHARMS — **100MG** — **N70268 001** DEC 31, 1985

ALLOPURINOL

TABLET; ORAL
ALLOPURINOL
AB GENEVA PHARMS — **300MG** — **N70269 001** DEC 31, 1985
AB MUTUAL PHARM — **100MG** — **N71449 001** JAN 09, 1987
AB — **300MG** — **N71450 001** JAN 09, 1987
AB MYLAN — **100MG** — **N18659 001** OCT 24, 1986
AB — **300MG** — **N18659 002** OCT 24, 1986
AB PAR PHARM — **100MG** — **N70150 001** DEC 10, 1985
AB — **300MG** — **N70147 001** DEC 10, 1985
AB SUPERPHARM — **300MG** — **N70951 001** NOV 30, 1988

LOPURIN
AB BASF — **100MG** — **N71586 001** APR 02, 1987
AB — **300MG** — **N71587 001** APR 02, 1987

ZYLOPRIM
AB PROMETHEUS LABS — **100MG** — **N16084 001**
AB + — **300MG** — **N16084 002**

ALLOPURINOL SODIUM

INJECTABLE; INJECTION
ALOPRIM
\+ CATALYTICA PHARMS — EQ 500MG BASE/VIAL — N20298 001 MAY 17, 1996

ALMOTRIPTAN MALATE

TABLET; ORAL
AXERT
PHARMACIA AND UPJOHN — EQ 6.25MG BASE — N21001 001 MAY 07, 2001
\+ — EQ 12.5MG BASE — N21001 002 MAY 07, 2001

FDA data supplied by DrugPatentWatch.com

ALOSETRON HYDROCHLORIDE

TABLET; ORAL
LOTRONEX
+ GLAXOSMITHKLINE — EQ 1MG BASE — N21107 001 FEB 09, 2000

ALPHA-TOCOPHEROL; ASCORBIC ACID; BIOTIN, D-; CHOLECALCIFEROL; CYANOCOBALAMIN; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A

INJECTABLE; INJECTION
CERNEVIT-12
+ BAXTER HLTHCARE — 11.2 IU/VIAL;125MG/VIAL;60 UGM/VIAL; 200 IU/VIAL;5.5MG/VIAL;414 UGM/VIAL; 46MG/VIAL;17.25MG/VIAL;4.53MG/VIAL; 4.14MG/VIAL;3.51MG/VIAL; 3,500 IU/VIAL — N20924 001 APR 06, 1999

ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE

INJECTABLE; INJECTION
MULTI-12
+ SABEX — 2 IU/ML;20MG/ML;12 UGM/ML;40 IU/ML; 1 UGM/ML;3MG/ML;80 UGM/ML;8MG/ML; 0.8MG/ML;0.72MG/ML;0.6MG/ML; 600 IU/ML — N21163 001 MAY 18, 2000

ALPRAZOLAM

CONCENTRATE; ORAL
ALPRAZOLAM
+ ROXANE — 1MG/ML — N74312 001 OCT 31, 1993

TABLET; ORAL
ALPRAZOLAM

AB	ALPHAPHARM	0.25MG	**N74046 001** OCT 19, 1993
AB		0.5MG	**N74046 002** OCT 19, 1993

ALPRAZOLAM

TABLET; ORAL
ALPRAZOLAM

AB	ALPHAPHARM	1MG	**N74046 003** OCT 19, 1993
AB		2MG	**N74046 004** MAY 07, 1997
AB	GENEVA PHARMS	0.25MG	**N74112 001** DEC 29, 1995
AB		0.5MG	**N74112 002** DEC 29, 1995
AB		1MG	**N74112 003** DEC 29, 1995
AB		2MG	**N74909 001** MAR 25, 1998
AB	IVAX PHARMS	0.25MG	**N74294 001** JUL 29, 1994
AB		0.5MG	**N74294 002** JUL 29, 1994
AB		1MG	**N74294 003** JUL 29, 1994
AB		2MG	**N74294 004** JUL 29, 1994
AB	LEDERLE	0.25MG	**N74174 001** OCT 19, 1993
AB		0.5MG	**N74174 002** OCT 19, 1993
AB		1MG	**N74174 003** OCT 19, 1993
AB		2MG	**N74174 004** OCT 19, 1993
AB	MYLAN	0.25MG	**N74215 001** JAN 27, 1994
AB		0.5MG	**N74215 002** JAN 27, 1994
AB		1MG	**N74215 003** JAN 27, 1994
AB		2MG	**N74215 004** JAN 27, 1994
AB	PUREPAC PHARM	0.25MG	**N74342 001** OCT 31, 1993
AB		0.5MG	**N74342 002** OCT 31, 1993
AB		1MG	**N74342 003** OCT 31, 1993
AB		2MG	**N74342 004** OCT 31, 1993

FDA data supplied by DrugPatentWatch.com

ALPRAZOLAM

TABLET; ORAL

	ALPRAZOLAM				
AB	TEVA	**0.25MG**	**N74085 001**		
			FEB 16, 1994		
AB		**0.5MG**	**N74085 002**		
			FEB 16, 1994		
AB		**1MG**	**N74085 003**		
			FEB 16, 1994		
AB		**2MG**	**N74085 004**		
			FEB 26, 1996		
AB	WATSON LABS	**0.25MG**	**N74456 001**		
			AUG 31, 1995		
AB		**0.25MG**	**N74479 001**		
			JAN 21, 1997		
AB		**0.5MG**	**N74456 002**		
			AUG 31, 1995		
AB		**0.5MG**	**N74479 002**		
			JAN 21, 1997		
AB		**1MG**	**N74456 003**		
			AUG 31, 1995		
AB		**1MG**	**N74479 003**		
			JAN 21, 1997		
	XANAX				
AB	PHARMACIA AND UPJOHN	**0.25MG**	**N18276 001**		
AB		**0.5MG**	**N18276 002**		
AB	+	**1MG**	**N18276 003**		
AB		**2MG**	**N18276 004**		
			NOV 27, 1985		

ALPROSTADIL

INJECTABLE; INJECTION

	ALPROSTADIL				
AP	BEDFORD	**0.5MG/ML**	**N74815 001**		
			JAN 20, 1998		
AP	GENSIA SICOR PHARMS	**0.5MG/ML**	**N75196 001**		
			APR 30, 1999		
	CAVERJECT				
AP	PHARMACIA AND UPJOHN	**0.01MG/VIAL**	**N20379 001**		
			JUL 06, 1995		
AP		**0.02MG/VIAL**	**N20379 002**		
			JUL 06, 1995		
AP	+	**0.04MG/VIAL**	**N20379 004**		
			MAY 19, 1997		
		0.005MG/VIAL	N20379 003		
			JUN 27, 1996		

ALPROSTADIL

INJECTABLE; INJECTION

	CAVERJECT				
	PHARMACIA AND UPJOHN	0.01MG/ML	N20755 002		
			OCT 01, 1997		
	+	0.02MG/ML	N20755 003		
			OCT 01, 1997		
	EDEX				
AP	SCHWARZ PHARMA	**0.01MG/VIAL**	**N20649 002**		
			JUN 12, 1997		
AP		**0.02MG/VIAL**	**N20649 003**		
			JUN 12, 1997		
AP	+	**0.04MG/VIAL**	**N20649 004**		
			JUN 12, 1997		
	+	0.01MG/VIAL	N20649 005		
			JUL 30, 1998		
	+	0.02MG/VIAL	N20649 006		
			JUL 30, 1998		
	+	0.04MG/VIAL	N20649 007		
			JUL 30, 1998		
	PROSTIN VR PEDIATRIC				
AP	+ PHARMACIA AND UPJOHN	**0.5MG/ML**	**N18484 001**		

SUPPOSITORY; URETHRAL

	MUSE				
	VIVUS	0.125MG	N20700 001		
			NOV 19, 1996		
		0.25MG	N20700 002		
			NOV 19, 1996		
		0.5MG	N20700 003		
			NOV 19, 1996		
	+	1MG	N20700 004		
			NOV 19, 1996		

ALTRETAMINE

CAPSULE; ORAL

	HEXALEN				
	+ MGI PHARMA INC	50MG	N19926 001		
			DEC 26, 1990		

ALUMINUM ACETATE; *MULTIPLE*

SEE ACETIC ACID, GLACIAL; ALUMINUM ACETATE

FDA data supplied by DrugPatentWatch.com

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL

	AMANTADINE HCL			
AB	GENEVA PHARMS TECH	100MG	**N71293 001** FEB 18, 1987	
AB +	USL PHARMA	100MG	**N70589 001** AUG 05, 1986	

SYRUP; ORAL

	AMANTADINE HCL			
AA	ALPHARMA	50MG/5ML	**N72655 001** OCT 30, 1990	
AA	COPLEY PHARM	50MG/5ML	**N73115 001** AUG 23, 1991	
AA	HI TECH PHARMA	50MG/5ML	**N74170 001** OCT 28, 1994	
AA	MIKART	50MG/5ML	**N74028 001** JUN 28, 1993	
AA	MORTON GROVE	50MG/5ML	**N75060 001** DEC 24, 1998	
AA	PHARM ASSOC	50MG/5ML	**N74509 001** JUL 17, 1995	
	SYMMETREL			
AA +	ENDO PHARMS	50MG/5ML	**N16023 002**	

TABLET; ORAL

	SYMMETREL			
+	ENDO PHARMS	100MG	N18101 001	

AMBENONIUM CHLORIDE

TABLET; ORAL

	MYTELASE			
+	SANOFI SYNTHELABO	10MG	N10155 002	

AMCINONIDE

CREAM; TOPICAL

	CYCLOCORT			
+	FUJISAWA HLTHCARE	0.1%	N18116 002	

LOTION; TOPICAL

	CYCLOCORT			
+	FUJISAWA HLTHCARE	0.1%	N19729 001 JUN 13, 1988	

AMCINONIDE

OINTMENT; TOPICAL

	CYCLOCORT			
+	FUJISAWA HLTHCARE	0.1%	N18498 001	

AMIFOSTINE

INJECTABLE; INJECTION

	ETHYOL			
	MEDIMMUNE ONCOLOGY	375MG/VIAL	N20221 002 SEP 10, 1999	
+		500MG/VIAL	N20221 001 DEC 08, 1995	

AMIKACIN SULFATE

INJECTABLE; INJECTION

	AMIKACIN SULFATE			
AP	ABBOTT	EQ 50MG BASE/ML	**N63263 001** NOV 30, 1994	
AP		EQ 250MG BASE/ML	**N63264 001** NOV 30, 1994	
AP		EQ 250MG BASE/ML	**N64098 001** JUN 26, 1995	
		EQ 62.5MG BASE/ML	N63283 001 OCT 31, 1994	
AP	BEDFORD	EQ 50MG BASE/ML	**N63313 001** APR 11, 1994	
AP		EQ 250MG BASE/ML	**N63315 001** APR 11, 1994	
AP	FAULDING	EQ 50MG BASE/ML	**N63350 001** JUL 30, 1993	
AP		EQ 250MG BASE/ML	**N63350 002** JUL 30, 1993	
AP	GENSIA SICOR PHARMS	EQ 50MG BASE/ML	**N64045 001** SEP 28, 1993	
AP		EQ 250MG BASE/ML	**N64045 002** SEP 28, 1993	

AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

ABBOTT	EQ 500MG BASE/100ML	N64146 001 APR 02, 1997	

	AMIKIN			
AP +	APOTHECON	EQ 50MG BASE/ML	**N62311 001**	
AP +		EQ 250MG BASE/ML	**N62311 002**	

FDA data supplied by DrugPatentWatch.com

AMILORIDE HYDROCHLORIDE

TABLET; ORAL

	AMILORIDE HCL			
AB	PAR PHARM	**5MG**	**N70346 001**	JAN 22, 1986
	MIDAMOR			
AB	+ MERCK	**5MG**	**N18200 001**	

AMILORIDE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

	AMILORIDE HCL AND HYDROCHLOROTHIAZIDE			
AB	BARR	**EQ 5MG ANHYDROUS;50MG**	**N71111 001**	MAY 10, 1988
AB	GENEVA PHARMS	**EQ 5MG ANHYDROUS;50MG**	**N73357 001**	NOV 27, 1991
AB	MYLAN	**EQ 5MG ANHYDROUS;50MG**	**N73209 001**	OCT 31, 1991
AB	TEVA	**EQ 5MG ANHYDROUS;50MG**	**N70795 001**	APR 17, 1988
AB	WATSON LABS	**EQ 5MG ANHYDROUS;50MG**	**N73334 001**	JUL 19, 1991
	HYDRO-RIDE			
AB	PAR PHARM	**EQ 5MG ANHYDROUS;50MG**	**N70347 001**	DEC 25, 1990
	MODURETIC 5-50			
AB	+ MERCK	**EQ 5MG ANHYDROUS;50MG**	**N18201 001**	

AMINO ACIDS

INJECTABLE; INJECTION

AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE			
FRESENIUS KABI	5.2%	N18901 001	APR 06, 1984
AMINOSYN 10%			
ABBOTT	10%	N17673 003	
AMINOSYN 10% (PH6)			
ABBOTT	10%	N17673 008	NOV 18, 1985
AMINOSYN 3.5%			
ABBOTT	3.5%	N17789 004	
AMINOSYN 5%			
ABBOTT	5%	N17673 001	
AMINOSYN 7%			
ABBOTT	7%	N17673 002	

AMINO ACIDS

INJECTABLE; INJECTION

AMINOSYN 7% (PH6)			
ABBOTT	7%	N17673 006	NOV 18, 1985
AMINOSYN 8.5%			
ABBOTT	8.5%	N17673 004	
AMINOSYN 8.5% (PH6)			
ABBOTT	8.5%	N17673 007	NOV 18, 1985
AMINOSYN II 10%			
ABBOTT	10%	N19438 005	APR 03, 1986
AMINOSYN II 10% IN PLASTIC CONTAINER			
ABBOTT	10%	N20015 001	DEC 19, 1991
AMINOSYN II 15% IN PLASTIC CONTAINER			
ABBOTT	15%	N20041 001	DEC 19, 1991
AMINOSYN II 3.5%			
ABBOTT	3.5%	N19438 001	APR 03, 1986
AMINOSYN II 7%			
ABBOTT	7%	N19438 003	APR 03, 1986
AMINOSYN II 8.5%			
ABBOTT	8.5%	N19438 004	APR 03, 1986
AMINOSYN-HBC 7%			
ABBOTT	7%	N19374 001	JUL 12, 1985
AMINOSYN-HF 8%			
ABBOTT	8%	N20345 001	APR 04, 1996
AMINOSYN-PF 10%			
ABBOTT	10%	N19492 002	OCT 17, 1986
AMINOSYN-PF 7%			
ABBOTT	7%	N19398 001	SEP 06, 1985
AMINOSYN-RF 5.2%			
ABBOTT	5.2%	N18429 001	
BRANCHAMIN 4%			
BAXTER HLTHCARE	4%	N18678 001	SEP 28, 1984
BRANCHAMIN 4% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	4%	N18684 001	SEP 28, 1984

FDA data supplied by DrugPatentWatch.com

AMINO ACIDS

INJECTABLE; INJECTION

CLINISOL 15% SULFITE FREE IN PLASTIC CONTAINER			
CLINTEC NUTR	15%	N20512 001	AUG 30, 1996
FREAMINE HBC 6.9%			
B BRAUN	6.9%	N16822 006	MAY 17, 1983
FREAMINE III 10%			
B BRAUN	10%	N16822 005	
FREAMINE III 8.5%			
B BRAUN	8.5%	N16822 004	
HEPATAMINE 8%			
B BRAUN	8%	N18676 001	AUG 03, 1982
HEPATASOL 8%			
BAXTER HLTHCARE	8%	N20360 001	APR 04, 1996
NEPHRAMINE 5.4%			
B BRAUN	5.4%	N17766 001	
NOVAMINE 11.4%			
FRESENIUS KABI	11.4%	N17957 003	AUG 09, 1982
NOVAMINE 15%			
FRESENIUS KABI	15%	N17957 004	NOV 28, 1986
PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER			
+ BAXTER HLTHCARE	20%	N20849 001	AUG 26, 1998
RENAMIN W/O ELECTROLYTES			
BAXTER HLTHCARE	6.5%	N17493 007	OCT 15, 1982
TRAVASOL 10% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	10%	N18931 003	AUG 23, 1984
TRAVASOL 10% W/O ELECTROLYTES			
BAXTER HLTHCARE	10%	N17493 006	
TRAVASOL 5.5% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	5.5%	N18931 001	AUG 23, 1984
TRAVASOL 5.5% W/O ELECTROLYTES			
BAXTER HLTHCARE	5.5%	N17493 004	
TRAVASOL 8.5% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	8.5%	N18931 002	AUG 23, 1984
TRAVASOL 8.5% W/O ELECTROLYTES			
BAXTER HLTHCARE	8.5%	N17493 005	

AMINO ACIDS

INJECTABLE; INJECTION

TROPHAMINE			
+ B BRAUN	6%	N19018 001	JUL 20, 1984
TROPHAMINE 10%			
+ B BRAUN	10%	N19018 003	SEP 07, 1988

AMINO ACIDS; CALCIUM ACETATE; GLYCERIN; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

PROCALAMINE			
B BRAUN	3%;26MG/100ML;3GM/100ML;54MG/100ML; 41MG/100ML;150MG/100ML;200MG/100ML; 120MG/100ML	N18582 001	MAY 08, 1982

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER			
ABBOTT	3.5%;36.8MG/100ML;25GM/100ML; 51MG/100ML;22.4MG/100ML;261MG/100ML; 205MG/100ML	N19683 001	NOV 07, 1988
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER			
ABBOTT	4.25%;36.8MG/100ML;20GM/100ML; 51MG/100ML;22.4MG/100ML;261MG/100ML; 205MG/100ML	N19683 002	NOV 07, 1988
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER			
ABBOTT	4.25%;36.8MG/100ML;25GM/100ML; 51MG/100ML;22.4MG/100ML;261MG/100ML; 205MG/100ML	N19683 003	NOV 07, 1988

FDA data supplied by DrugPatentWatch.com

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

CLINIMIX E 2.75/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER
+ BAXTER HLTHCARE 2.75%;33MG/100ML;10GM/100ML; 51MG/100ML;261MG/100ML;217MG/100ML; 112MG/100ML N20678 002 MAR 26, 1997

CLINIMIX E 2.75/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER
+ BAXTER HLTHCARE 2.75%;33MG/100ML;25GM/100ML; 51MG/100ML;261MG/100ML;217MG/100ML; 112MG/100ML N20678 005 MAR 26, 1997

CLINIMIX E 2.75/5 SULFITE-FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER
+ BAXTER HLTHCARE 2.75%;33MG/100ML;5GM/100ML; 51MG/100ML;261MG/100ML;217MG/100ML; 112MG/100ML N20678 001 MAR 26, 1997

CLINIMIX E 4.25/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER
+ BAXTER HLTHCARE 4.25%;33MG/100ML;10GM/100ML; 51MG/100ML;261MG/100ML;297MG/100ML; 77MG/100ML N20678 009 MAR 26, 1997

CLINIMIX E 4.25/20 SULFITE-FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER
+ BAXTER HLTHCARE 4.25%;33MG/100ML;20GM/100ML; 51MG/100ML;261MG/100ML;297MG/100ML; 77MG/100ML N20678 011 MAR 26, 1997

CLINIMIX E 4.25/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER
+ BAXTER HLTHCARE 4.25%;33MG/100ML;25GM/100ML; 51MG/100ML;261MG/100ML;297MG/100ML; 77MG/100ML N20678 012 MAR 26, 1997

CLINIMIX E 4.25/5 SULFITE-FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER
+ BAXTER HLTHCARE 4.25%;33MG/100ML;5GM/100ML; 51MG/100ML;261MG/100ML;297MG/100ML; 77MG/100ML N20678 008 MAR 26, 1997

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

CLINIMIX E 5/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER
+ BAXTER HLTHCARE 5%;33MG/100ML;10GM/100ML;51MG/100ML; 261MG/100ML;340MG/100ML; 59MG/100ML N20678 016 MAR 26, 1997

CLINIMIX E 5/15 SULFITE-FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER
+ BAXTER HLTHCARE 5%;33MG/100ML;15GM/100ML;51MG/100ML; 261MG/100ML;340MG/100ML; 59MG/100ML N20678 017 MAR 26, 1997

CLINIMIX E 5/20 SULFITE-FREE W/ ELECT IN 20% DEXTROSE W/ CALCIUM IN PLASTIC CONTAINER
+ BAXTER HLTHCARE 5%;33MG/100ML;20GM/100ML;51MG/100ML; 261MG/100ML;340MG/100ML; 59MG/100ML N20678 018 MAR 26, 1997

CLINIMIX E 5/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER
+ BAXTER HLTHCARE 5%;33MG/100ML;25GM/100ML;51MG/100ML; 261MG/100ML;340MG/100ML; 59MG/100ML N20678 019 MAR 26, 1997

CLINIMIX E 5/35 SULFITE FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER
+ BAXTER HLTHCARE 5%;33MG/100ML;35GM/100ML;51MG/100ML; 261MG/100ML;340MG/100ML; 59MG/100ML N20678 021 MAR 26, 1997

AMINO ACIDS; DEXTROSE

INJECTABLE; INJECTION

AMINOSYN II 3.5% IN DEXTROSE 25% IN PLASTIC CONTAINER
ABBOTT 3.5%;25GM/100ML N19681 001 NOV 01, 1988

AMINOSYN II 3.5% IN DEXTROSE 5% IN PLASTIC CONTAINER
ABBOTT 3.5%;5GM/100ML N19681 002 NOV 01, 1988

AMINOSYN II 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER
ABBOTT 4.25%;10GM/100ML N19681 004 NOV 01, 1988

FDA data supplied by DrugPatentWatch.com

AMINO ACIDS; DEXTROSE

INJECTABLE; INJECTION

AMINOSYN II 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER
ABBOTT 4.25%;20GM/100ML N19681 005 NOV 01, 1988

AMINOSYN II 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER
ABBOTT 4.25%;25GM/100ML N19681 003 NOV 01, 1988

AMINOSYN II 5% IN DEXTROSE 25% IN PLASTIC CONTAINER
ABBOTT 5%;25GM/100ML N19681 006 NOV 01, 1988

CLINIMIX 2.75/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER
BAXTER HLTHCARE 2.75%;10% N20734 002 SEP 29, 1997

CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER
BAXTER HLTHCARE 2.75%;25GM/100ML N20734 005 SEP 29, 1997

CLINIMIX 2.75/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER
BAXTER HLTHCARE 2.75%;5GM/100ML N20734 001 SEP 29, 1997

CLINIMIX 4.25/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER
BAXTER HLTHCARE 4.25%;10GM/100ML N20734 008 SEP 29, 1997

CLINIMIX 4.25/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER
BAXTER HLTHCARE 4.25%;20GM/100ML N20734 010 SEP 29, 1997

CLINIMIX 4.25/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER
BAXTER HLTHCARE 4.25%;25GM/100ML N20734 011 SEP 29, 1997

CLINIMIX 4.25/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER
BAXTER HLTHCARE 4.25%;5GM/100ML N20734 007 SEP 29, 1997

CLINIMIX 5/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER
BAXTER HLTHCARE 5%;10GM/100ML N20734 014 SEP 29, 1997

CLINIMIX 5/15 SULFITE FREE IN DEXTROSE 15% IN PLASTIC CONTAINER
BAXTER HLTHCARE 5%;15GM/100ML N20734 015 SEP 29, 1997

AMINO ACIDS; DEXTROSE

INJECTABLE; INJECTION

CLINIMIX 5/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER
BAXTER HLTHCARE 5%;20GM/100ML N20734 016 SEP 29, 1997

CLINIMIX 5/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER
BAXTER HLTHCARE 5%;25GM/100ML N20734 017 SEP 29, 1997

CLINIMIX 5/35 SULFITE FREE IN DEXTROSE 35% IN PLASTIC CONTAINER
BAXTER HLTHCARE 5%;35GM/100ML N20734 018 SEP 29, 1997

TRAVASOL 2.75% IN DEXTROSE 10% IN PLASTIC CONTAINER
BAXTER HLTHCARE 2.75%;10GM/100ML N19520 002 SEP 23, 1988

TRAVASOL 2.75% IN DEXTROSE 15% IN PLASTIC CONTAINER
BAXTER HLTHCARE 2.75%;15GM/100ML N19520 003 SEP 23, 1988

TRAVASOL 2.75% IN DEXTROSE 20% IN PLASTIC CONTAINER
BAXTER HLTHCARE 2.75%;20GM/100ML N19520 004 SEP 23, 1988

TRAVASOL 2.75% IN DEXTROSE 25% IN PLASTIC CONTAINER
BAXTER HLTHCARE 2.75%;25GM/100ML N19520 005 SEP 23, 1988

TRAVASOL 2.75% IN DEXTROSE 5% IN PLASTIC CONTAINER
BAXTER HLTHCARE 2.75%;5GM/100ML N19520 001 SEP 23, 1988

TRAVASOL 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER
BAXTER HLTHCARE 4.25%;10GM/100ML N19520 007 SEP 23, 1988

TRAVASOL 4.25% IN DEXTROSE 15% IN PLASTIC CONTAINER
BAXTER HLTHCARE 4.25%;15GM/100ML N19520 008 SEP 23, 1988

TRAVASOL 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER
BAXTER HLTHCARE 4.25%;20GM/100ML N19520 009 SEP 23, 1988

TRAVASOL 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER
BAXTER HLTHCARE 4.25%;25GM/100ML N19520 010 SEP 23, 1988

TRAVASOL 4.25% IN DEXTROSE 5% IN PLASTIC CONTAINER
BAXTER HLTHCARE 4.25%;5GM/100ML N19520 006 SEP 23, 1988

FDA data supplied by DrugPatentWatch.com

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INJECTION

AMINOSYN II 3.5% M IN DEXTROSE 5% IN PLASTIC CONTAINER
ABBOTT 3.5%;5GM/100ML;30MG/100ML; 97MG/100ML;120MG/100ML; 49.3MG/100ML N19682 001 NOV 01, 1988

AMINOSYN II 4.25% M IN DEXTROSE 10% IN PLASTIC CONTAINER
ABBOTT 4.25%;5GM/100ML;30MG/100ML; 97MG/100ML;120MG/100ML; 49.3MG/100ML N19682 002 NOV 01, 1988

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 10% IN PLASTIC CONTAINER
BAXTER HLTHCARE 2.75%;10GM/100ML;51MG/100ML; 261MG/100ML;216MG/100ML; 112MG/100ML N20147 002 OCT 23, 1995

TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER
BAXTER HLTHCARE 2.75%;15GM/100ML;51MG/100ML; 261MG/100ML;216MG/100ML; 112MG/100ML N20147 003 OCT 23, 1995

TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 20% IN PLASTIC CONTAINER
BAXTER HLTHCARE 2.75%;20GM/100ML;51MG/100ML; 261MG/100ML;216MG/100ML; 112MG/100ML N20147 004 OCT 23, 1995

TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER
BAXTER HLTHCARE 2.75%;25GM/100ML;51MG/100ML; 261MG/100ML;216MG/100ML; 112MG/100ML N20147 005 OCT 23, 1995

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 5% IN PLASTIC CONTAINER
BAXTER HLTHCARE 2.75%;5GM/100ML;51MG/100ML; 261MG/100ML;216MG/100ML; 112MG/100ML N20147 001 OCT 23, 1995

TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 10% IN PLASTIC CONTAINER
BAXTER HLTHCARE 4.25%;10GM/100ML;51MG/100ML; 261MG/100ML;297MG/100ML; 77MG/100ML N20147 007 OCT 23, 1995

TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER
BAXTER HLTHCARE 4.25%;15GM/100ML;51MG/100ML; 261MG/100ML;297MG/100ML; 77MG/100ML N20147 008 OCT 23, 1995

TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 20% IN PLASTIC CONTAINER
BAXTER HLTHCARE 4.25%;20GM/100ML;51MG/100ML; 261MG/100ML;297MG/100ML; 77MG/100ML N20147 009 OCT 23, 1995

TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER
BAXTER HLTHCARE 4.25%;25GM/100ML;51MG/100ML; 261MG/100ML;297MG/100ML; 77MG/100ML N20147 010 OCT 23, 1995

TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 5% IN PLASTIC CONTAINER
BAXTER HLTHCARE 4.25%;5GM/100ML;51MG/100ML; 261MG/100ML;297MG/100ML; 77MG/100ML N20147 006 OCT 23, 1995

FDA data supplied by DrugPatentWatch.com

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; POTASSIUM CHLORIDE; SODIUM ACETATE

INJECTABLE; INJECTION
FREAMINE III 8.5% W/ ELECTROLYTES
B BRAUN 8.5%;110MG/100ML;230MG/100ML; 10MG/100ML;440MG/100ML; 690MG/100ML N16822 007
JUL 01, 1988

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION
AMINOSYN 3.5% M
ABBOTT 3.5%;21MG/100ML;40MG/100ML; 128MG/100ML;234MG/100ML N17789 003

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION
FREAMINE III 3% W/ ELECTROLYTES
B BRAUN 3%;54MG/100ML;40MG/100ML; 150MG/100ML;200MG/100ML; 120MG/100ML N16822 003

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION
AMINOSYN II 10% W/ ELECTROLYTES
ABBOTT 10%;102MG/100ML;45MG/100ML; 522MG/100ML;410MG/100ML N19437 004
APR 03, 1986
AMINOSYN II 8.5% W/ ELECTROLYTES
ABBOTT 8.5%;102MG/100ML;45MG/100ML; 522MG/100ML;410MG/100ML N19437 005
APR 03, 1986

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION
TRAVASOL 3.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER
BAXTER HLTHCARE 3.5%;51MG/100ML;131MG/100ML; 218MG/100ML;35MG/100ML N20177 001
OCT 23, 1995
TRAVASOL 3.5% W/ ELECTROLYTES
BAXTER HLTHCARE 3.5%;51MG/100ML;131MG/100ML; 218MG/100ML;35MG/100ML N17493 003
TRAVASOL 5.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER
BAXTER HLTHCARE 5.5%;102MG/100ML;522MG/100ML; 431MG/100ML;224MG/100ML N20173 001
OCT 27, 1995
TRAVASOL 5.5% W/ ELECTROLYTES
BAXTER HLTHCARE 5.5%;102MG/100ML;522MG/100ML; 431MG/100ML;224MG/100ML N17493 001
TRAVASOL 8.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER
BAXTER HLTHCARE 8.5%;102MG/100ML;522MG/100ML; 594MG/100ML;154MG/100ML N20173 002
OCT 27, 1995
TRAVASOL 8.5% W/ ELECTROLYTES
BAXTER HLTHCARE 8.5%;102MG/100ML;522MG/100ML; 594MG/100ML;154MG/100ML N17493 002

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION
AMINOSYN 7% W/ ELECTROLYTES
ABBOTT 7%;102MG/100ML;522MG/100ML; 410MG/100ML N17789 002
AMINOSYN 8.5% W/ ELECTROLYTES
ABBOTT 8.5%;102MG/100ML;522MG/100ML; 410MG/100ML N17673 005

AMINOCAPROIC ACID

INJECTABLE; INJECTION
AMICAR
AP + XANODYNE PHARM **250MG/ML** **N15229 002**
AMINOCAPROIC ACID
AP ABBOTT **250MG/ML** **N70888 001**
JUN 16, 1988

FDA data supplied by DrugPatentWatch.com

AMINOCAPROIC ACID

INJECTABLE; INJECTION

	AMINOCAPROIC ACID			
AP	+ ELKINS SINN	250MG/ML	N18590 001	
			OCT 29, 1982	
AP	LUITPOLD	250MG/ML	N71192 001	
			DEC 01, 1987	
	AMINOCAPROIC ACID IN PLASTIC CONTAINER			
AP	ABBOTT	250MG/ML	N70010 001	
			MAR 09, 1987	

SYRUP; ORAL

	AMICAR			
AA	+ XANODYNE PHARM	1.25GM/5ML	N15230 002	
	AMINOCAPROIC ACID			
AA	MIKART	1.25GM/5ML	N74759 001	
			SEP 02, 1998	

TABLET; ORAL

	AMICAR			
AB	+ XANODYNE PHARM	500MG	N15197 001	
	AMINOCAPROIC			
AB	MIKART	500MG	N75602 001	
			MAY 24, 2001	

AMINOGLUTETHIMIDE

TABLET; ORAL

	CYTADREN			
	+ NOVARTIS	250MG	N18202 001	

AMINOHIPPURATE SODIUM

INJECTABLE; INJECTION

	AMINOHIPPURATE SODIUM			
	+ MERCK	20%	N05619 001	

AMINOLEVULINIC ACID HYDROCHLORIDE

SOLUTION; TOPICAL

	LEVULAN			
	+ DUSA	20%	N20965 001	
			DEC 03, 1999	

AMINOPHYLLINE

INJECTABLE; INJECTION

	AMINOPHYLLINE			
AP	ABBOTT	25MG/ML	N87242 001	
			OCT 26, 1983	
AP		25MG/ML	N87601 001	
			JUL 23, 1982	
AP	+ ELKINS SINN	25MG/ML	N87239 001	
AP	GENSIA SICOR PHARMS	25MG/ML	N81142 001	
			SEP 25, 1991	
AP	INTL MEDICATION	25MG/ML	N87209 001	
			FEB 01, 1982	
AP	LUITPOLD	25MG/ML	N87240 001	
AP		25MG/ML	N87600 001	
AP	PHARMA SERVE NY	25MG/ML	N87392 001	
			DEC 15, 1983	
	AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%			
	+ ABBOTT	100MG/100ML	N88147 002	
			MAY 03, 1983	
	+	200MG/100ML	N88147 003	
			MAY 03, 1983	

SOLUTION; ORAL

	AMINOPHYLLINE			
AA	+ ROXANE	105MG/5ML	N88126 001	
			AUG 19, 1983	
	AMINOPHYLLINE DYE FREE			
AA	+ ALPHARMA	105MG/5ML	N87727 001	
			APR 16, 1982	

SUPPOSITORY; RECTAL

	TRUPHYLLINE			
	G AND W LABS	250MG	N85498 001	
			MAR 23, 1983	
	+	500MG	N85498 002	
			JAN 03, 1983	

TABLET; ORAL

	AMINOPHYLLINE			
AB	GENEVA PHARMS	100MG	N85262 002	
AB		200MG	N85261 002	
AB	+ ROXANE	100MG	N87500 001	
			FEB 09, 1982	
AB	+	200MG	N87501 001	
			FEB 09, 1982	
AB	WEST WARD	100MG	N84540 001	
AB		200MG	N85003 001	

FDA data supplied by DrugPatentWatch.com

AMINOSALICYLATE SODIUM

TABLET; ORAL
SODIUM P.A.S.
+ LANNETT 500MG N80138 002

AMINOSALICYLIC ACID

GRANULE, DELAYED RELEASE; ORAL
PASER
+ JACOBUS 4GM/PACKET N74346 001
JUN 30, 1994

AMIODARONE HYDROCHLORIDE

INJECTABLE; INJECTION
CORDARONE
+ WYETH AYERST 50MG/ML N20377 001
AUG 03, 1995

TABLET; ORAL
AMIODARONE HCL

AB	ALPHAPHARM	**200MG**	**N75188 001** FEB 24, 1999
AB	BARR	**200MG**	**N75389 001** JAN 25, 2001
AB	COPLEY PHARM	**200MG**	**N74739 001** NOV 30, 1998
AB	EON	**200MG**	**N75315 001** DEC 23, 1998
	+	400MG	N75315 002 JUN 30, 2000
AB	TARO	**200MG**	**N75424 001** MAR 30, 2001
AB	TEVA	**200MG**	**N74895 001** APR 16, 1999

CORDARONE

AB	+ WYETH AYERST	**200MG**	**N18972 001** DEC 24, 1985

PACERONE

AB	UPSHER SMITH	**200MG**	**N75135 001** APR 30, 1998

AMITRIPTYLINE HYDROCHLORIDE

CONCENTRATE; ORAL
ENDEP
+ ROCHE 40MG/ML N85749 001

INJECTABLE; INJECTION
ELAVIL
+ ASTRAZENECA 10MG/ML N12704 001

TABLET; ORAL
AMITRIPTYLINE HCL

	CELLTECH PHARMS	75MG	N86337 001
AB	GENEVA PHARMS	**10MG**	**N85969 001**
AB		**25MG**	**N85966 001**
AB		**50MG**	**N85968 001**
AB		**75MG**	**N85971 001**
AB		**100MG**	**N85967 001**
AB		**150MG**	**N85970 001**
AB	MUTUAL PHARM	**10MG**	**N89398 001** JUL 14, 1987
AB		**25MG**	**N89399 001** JUL 14, 1987
AB		**50MG**	**N89400 001** JUL 14, 1987
AB		**75MG**	**N89401 001** JUL 14, 1987
AB		**100MG**	**N89402 001** JUL 14, 1987
AB		**150MG**	**N89403 001** JUL 14, 1987
AB	MYLAN	**10MG**	**N86157 001**
AB		**25MG**	**N86010 001**
AB		**50MG**	**N86009 001**
AB		**75MG**	**N86011 001**
AB		**100MG**	**N86158 001**
AB		**150MG**	**N86153 001**
AB	SIDMAK LABS NJ	**10MG**	**N88883 001** SEP 26, 1984
AB		**25MG**	**N88884 001** SEP 26, 1984
AB		**50MG**	**N88885 001** SEP 26, 1984
AB		**75MG**	**N88886 001** SEP 26, 1984
AB		**100MG**	**N88887 001** SEP 26, 1984
AB		**150MG**	**N88888 001** SEP 26, 1984

FDA data supplied by DrugPatentWatch.com

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

	AMITRIPTYLINE HCL			
AB	SUPERPHARM	10MG	N88853 001	NOV 13, 1984
AB		25MG	N88854 001	NOV 13, 1984
AB		50MG	N88855 001	NOV 13, 1984
AB		75MG	N88856 001	NOV 13, 1984
AB		100MG	N88857 001	NOV 13, 1984
AB	TEVA	10MG	N84910 003	
AB		25MG	N85031 001	
AB		50MG	N85032 001	
AB		100MG	N85836 001	
	AMITRIPTYLINE HYDROCHLORIDE			
AB	VINTAGE PHARMS	10MG	N40218 001	SEP 11, 1997
AB		25MG	N40218 002	SEP 11, 1997
AB		50MG	N40218 003	SEP 11, 1997
AB		75MG	N40218 004	SEP 11, 1997
AB		100MG	N40218 005	SEP 11, 1997
AB		150MG	N40218 006	SEP 11, 1997
	ELAVIL			
AB	ASTRAZENECA	10MG	N12703 001	
AB	+	25MG	N12703 003	
AB		50MG	N12703 004	
AB		75MG	N12703 005	
AB		100MG	N12703 006	
AB		150MG	N12703 007	

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET; ORAL

	CHLORDIAZEPOXIDE AND AMITRIPTYLINE HCL			
AB	DANBURY PHARMA	EQ 12.5MG BASE;5MG	N72052 001	DEC 16, 1988
AB		EQ 25MG BASE;10MG	N72053 001	DEC 16, 1988
AB	MYLAN	EQ 12.5MG BASE;5MG	N71296 001	DEC 10, 1986
AB		EQ 25MG BASE;10MG	N71297 001	DEC 10, 1986
AB	PAR PHARM	EQ 12.5MG BASE;5MG	N72277 001	MAY 09, 1988
AB		EQ 25MG BASE;10MG	N72278 001	MAY 09, 1988
	LIMBITROL			
AB	ICN	EQ 12.5MG BASE;5MG	N16949 001	
	LIMBITROL DS			
AB	+ ICN	EQ 25MG BASE;10MG	N16949 002	

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET; ORAL

	ETRAFON 2-10		
BP	SCHERING	10MG;2MG	N14713 007
	ETRAFON 2-25		
BP	SCHERING	25MG;2MG	N14713 004
	ETRAFON-FORTE		
BP	SCHERING	25MG;4MG	N14713 006
	PERPHENAZINE AND AMITRIPTYLINE HCL		
AB	GENEVA PHARMS	10MG;2MG	N71062 001 NOV 27, 1987
AB		10MG;4MG	N71862 001 DEC 21, 1987
AB		25MG;2MG	N71063 001 NOV 27, 1987
AB		25MG;4MG	N71064 001 NOV 27, 1987
AB		50MG;4MG	N71863 001 DEC 21, 1987
AB	MYLAN	10MG;2MG	N70336 001 NOV 10, 1988
AB		10MG;4MG	N71442 001 NOV 10, 1988
AB		25MG;2MG	N70337 001 NOV 10, 1988
AB	+	25MG;4MG	N70338 001 NOV 10, 1988
AB	+	50MG;4MG	N71443 001 NOV 10, 1988

FDA data supplied by DrugPatentWatch.com

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET; ORAL
PERPHENAZINE AND AMITRIPTYLINE HCL

AB	WATSON LABS	**10MG;2MG**	**N73007 001**	OCT 17, 1991
AB		**10MG;4MG**	**N73009 001**	OCT 17, 1991
AB		**25MG;2MG**	**N73008 001**	OCT 17, 1991
AB		**25MG;4MG**	**N73010 001**	OCT 17, 1991

AMLEXANOX

PASTE; DENTAL
APHTHASOL

+	GLAXOSMITHKLINE	5%	N20511 001	DEC 17, 1996

AMLODIPINE BESYLATE

TABLET; ORAL
NORVASC

	PFIZER	EQ 2.5MG BASE	N19787 001	JUL 31, 1992
		EQ 5MG BASE	N19787 002	JUL 31, 1992
+		EQ 10MG BASE	N19787 003	JUL 31, 1992

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE; ORAL
LOTREL

	NOVARTIS	EQ 2.5MG BASE;10MG	N20364 002	MAR 03, 1995
		EQ 5MG BASE;10MG	N20364 003	MAR 03, 1995
+		EQ 5MG BASE;20MG	N20364 004	MAR 03, 1995

AMMONIUM CHLORIDE

INJECTABLE; INJECTION
AMMONIUM CHLORIDE IN PLASTIC CONTAINER

+	ABBOTT	5MEQ/ML	N88366 001	JUN 13, 1984

AMMONIUM LACTATE

CREAM; TOPICAL
LAC-HYDRIN

+	WESTWOOD SQUIBB	EQ 12% BASE	N20508 001	AUG 29, 1996

LOTION; TOPICAL
LAC-HYDRIN

+	WESTWOOD SQUIBB	EQ 12% BASE	N19155 001	APR 24, 1985

AMOXAPINE

TABLET; ORAL
AMOXAPINE

AB	DANBURY PHARMA	**25MG**	**N72688 001**	AUG 28, 1992
AB		**50MG**	**N72689 001**	AUG 28, 1992
AB		**100MG**	**N72690 001**	AUG 28, 1992
AB		**150MG**	**N72691 001**	AUG 28, 1992
AB	GENEVA PHARMS	**25MG**	**N72943 001**	JUN 28, 1991
AB		**50MG**	**N72944 001**	JUN 28, 1991
AB		**100MG**	**N72878 001**	JUN 28, 1991
AB		**150MG**	**N72879 001**	JUN 28, 1991
AB	WATSON LABS	**25MG**	**N72418 001**	MAY 11, 1989
AB		**50MG**	**N72419 001**	MAY 11, 1989
AB		**100MG**	**N72420 001**	MAY 11, 1989
AB	+	**150MG**	**N72421 001**	MAY 11, 1989

FDA data supplied by DrugPatentWatch.com

AMOXICILLIN

CAPSULE; ORAL

	AMOXICILLIN			
AB	BIOCHEMIE	250MG	N64076 001	
			SEP 30, 1994	
AB		500MG	N64076 002	
			SEP 30, 1994	
AB	CLONMEL	250MG	N62884 001	
			FEB 25, 1988	
AB		500MG	N62881 001	
			FEB 25, 1988	
AB	CONSOLIDATED PHARM	250MG	N62058 001	
AB		500MG	N62058 002	
AB	RANBAXY	250MG	N65016 001	
			APR 08, 1999	
AB		500MG	N65016 002	
			APR 08, 1999	
AB	TEVA	250MG	N61926 001	
AB		250MG	N62853 001	
			DEC 22, 1987	
AB		500MG	N61926 003	
AB		500MG	N62854 001	
			DEC 22, 1987	
	AMOXIL			
AB	GLAXOSMITHKLINE	250MG	N62216 001	
AB	+	500MG	N62216 004	
	TRIMOX			
AB	APOTHECON	250MG	N61885 001	
AB		500MG	N61885 002	

FOR SUSPENSION; ORAL

	AMOXICILLIN			
AB	CLONMEL	125MG/5ML	N62927 001	
			NOV 25, 1988	
AB		250MG/5ML	N62927 002	
			NOV 25, 1988	
AB	CONSOLIDATED PHARM	125MG/5ML	N62059 001	
AB		250MG/5ML	N62059 002	
AB	TEVA	125MG/5ML	N61931 001	
AB		125MG/5ML	N62946 001	
			NOV 01, 1988	
AB		250MG/5ML	N61931 002	
AB		250MG/5ML	N63001 001	
			JAN 06, 1989	
	AMOXICILLIN PEDIATRIC			
AB	TEVA	50MG/ML	N61931 003	
			DEC 01, 1982	
	AMOXIL			
AB	GLAXOSMITHKLINE	125MG/5ML	N62226 001	

AMOXICILLIN

FOR SUSPENSION; ORAL

	AMOXIL			
AB	+ GLAXOSMITHKLINE	250MG/5ML	N62226 002	
AB	+	50MG/ML	N62226 005	
		200MG/5ML	N50760 001	
			APR 15, 1999	
	+	400MG/5ML	N50760 002	
			APR 15, 1999	
	LAROTID			
AB	GLAXOSMITHKLINE	125MG/5ML	N62226 003	
AB		250MG/5ML	N62226 004	
	TRIMOX			
AB	APOTHECON	125MG/5ML	N62885 001	
			MAR 08, 1988	
AB		250MG/5ML	N62885 002	
			MAR 08, 1988	
	WYMOX			
AB	WYETH AYERST	125MG/5ML	N62131 001	
AB		250MG/5ML	N62131 002	

TABLET; ORAL

	AMOXICILLIN			
AB	RANBAXY	500MG	N65059 001	
			NOV 24, 2000	
AB		875MG	N65059 002	
			NOV 24, 2000	
AB	TEVA	500MG	N65056 001	
			SEP 18, 2000	
AB		875MG	N65056 002	
			SEP 18, 2000	
	AMOXIL			
AB	GLAXOSMITHKLINE	500MG	N50754 002	
			JUL 10, 1998	
AB	+	875MG	N50754 001	
			JUL 10, 1998	

TABLET, CHEWABLE; ORAL

	AMOXICILLIN			
AB	APOTHECON	125MG	N64131 001	
			MAY 06, 1996	
AB		250MG	N64131 002	
			MAY 06, 1996	
AB	CLONMEL	125MG	N64139 001	
			JAN 29, 1996	
AB		250MG	N64139 002	
			JAN 29, 1996	

FDA data supplied by DrugPatentWatch.com

AMOXICILLIN

TABLET, CHEWABLE; ORAL

	AMOXICILLIN			
AB	RANBAXY	125MG	**N65021 001**	DEC 23, 1999
AB		200MG	**N65060 001**	NOV 29, 2000
AB		250MG	**N65021 002**	DEC 23, 1999
AB		400MG	**N65060 002**	NOV 29, 2000
AB	TEVA	125MG	**N64013 002**	SEP 11, 1995
AB		125MG	**N64031 001**	DEC 19, 1996
AB		250MG	**N64013 001**	DEC 22, 1992
AB		250MG	**N64031 002**	DEC 19, 1996
	AMOXIL			
AB	GLAXOSMITHKLINE	125MG	**N50542 002**	
AB		200MG	**N50761 001**	APR 15, 1999
AB		250MG	**N50542 001**	
AB +		400MG	**N50761 002**	APR 15, 1999

AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE

CAPSULE, TABLET, CAPSULE, EXTENDED RELEASE; ORAL

PREVPAC			
+ TAP PHARM	500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A,30MG	N50757 001	DEC 02, 1997

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION; ORAL

AUGMENTIN '125'			
GLAXOSMITHKLINE	125MG/5ML; EQ 31.25MG BASE/5ML	N50575 001	AUG 06, 1984
AUGMENTIN '200'			
GLAXOSMITHKLINE	200MG/5ML; EQ 28.5MG BASE/5ML	N50725 001	MAY 31, 1996

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION; ORAL

AUGMENTIN '250'			
+ GLAXOSMITHKLINE	250MG/5ML; EQ 62.5MG BASE/5ML	N50575 002	AUG 06, 1984
AUGMENTIN '400'			
+ GLAXOSMITHKLINE	400MG/5ML; EQ 57MG BASE/5ML	N50725 002	MAY 31, 1996
AUGMENTIN ES-600			
+ GLAXOSMITHKLINE	600MG/5ML; EQ 42.9MG BASE/5ML	N50755 001	JUN 22, 2001

TABLET; ORAL

AUGMENTIN '250'			
GLAXOSMITHKLINE	250MG;EQ 125MG BASE	N50564 001	AUG 06, 1984
AUGMENTIN '500'			
GLAXOSMITHKLINE	500MG;EQ 125MG BASE	N50564 002	AUG 06, 1984
AUGMENTIN '875'			
+ GLAXOSMITHKLINE	875MG;EQ 125MG BASE	N50720 001	FEB 13, 1996

TABLET, CHEWABLE; ORAL

AUGMENTIN '125'			
GLAXOSMITHKLINE	125MG;EQ 31.25MG BASE	N50597 001	JUL 22, 1985
AUGMENTIN '200'			
GLAXOSMITHKLINE	200MG;EQ 28.5MG BASE	N50726 001	MAY 31, 1996
AUGMENTIN '250'			
+ GLAXOSMITHKLINE	250MG;EQ 62.5MG BASE	N50597 002	JUL 22, 1985
AUGMENTIN '400'			
+ GLAXOSMITHKLINE	400MG;EQ 57MG BASE	N50726 002	MAY 31, 1996

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

ADDERALL XR 10			
SHIRE LABS	2.5MG;2.5MG;2.5MG;2.5MG	N21303 001	OCT 11, 2001

FDA data supplied by DrugPatentWatch.com

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

ADDERALL XR 20			
SHIRE LABS	5MG;5MG;5MG;5MG	N21303 002	
		OCT 11, 2001	
ADDERALL XR 30			
+ SHIRE LABS	7.5MG;7.5MG;7.5MG;7.5MG	N21303 003	
		OCT 11, 2001	

TABLET; ORAL

ADDERALL 10			
SHIRE LABS	2.5MG;2.5MG;2.5MG;2.5MG	N11522 007	
		FEB 13, 1996	
ADDERALL 12.5			
SHIRE LABS	3.125MG;3.125MG;3.125MG; 3.125MG	N11522 012	
		AUG 31, 2000	
ADDERALL 15			
SHIRE LABS	3.75MG;3.75MG;3.75MG; 3.75MG	N11522 013	
		AUG 31, 2000	
ADDERALL 20			
SHIRE LABS	5MG;5MG;5MG;5MG	N11522 008	
		FEB 13, 1996	
ADDERALL 30			
+ SHIRE LABS	7.5MG;7.5MG;7.5MG;7.5MG	N11522 010	
		MAY 12, 1997	
ADDERALL 5			
SHIRE LABS	1.25MG;1.25MG;1.25MG; 1.25MG	N11522 009	
		MAY 12, 1997	
ADDERALL 7.5			
SHIRE LABS	1.875MG;1.875MG;1.875MG; 1.875MG	N11522 011	
		AUG 31, 2000	

AMPHETAMINE SULFATE; *MULTIPLE*

SEE AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

AMPHOTERICIN B

CREAM; TOPICAL

FUNGIZONE			
+ APOTHECON	3%	N50314 001	

AMPHOTERICIN B

INJECTABLE; INJECTION

	AMPHOTERICIN B			
AP	GENSIA SICOR PHARMS	**50MG/VIAL**	**N64062 001**	
			MAR 31, 1995	
AP	PHARMA TEK	**50MG/VIAL**	**N63206 001**	
			APR 29, 1992	
	FUNGIZONE			
AP	+ APOTHECON	**50MG/VIAL**	**N60517 001**	

INJECTABLE, LIPID COMPLEX; INJECTION

ABELCET			
+ LIPOSOME	5MG/ML	N50724 001	
		NOV 20, 1995	
AMPHOTEC			
+ INTERMUNE PHARMS	50MG/VIAL	N50729 001	
		NOV 22, 1996	
+	100MG/VIAL	N50729 002	
		NOV 22, 1996	

INJECTABLE, LIPOSOMAL; INJECTION

AMBISOME			
+ FUJISAWA HLTHCARE	50MG/VIAL	N50740 001	
		AUG 11, 1997	

LOTION; TOPICAL

FUNGIZONE			
+ APOTHECON	3%	N60570 001	

SUSPENSION; ORAL

FUNGIZONE			
+ BRISTOL MYERS SQUIBB	100MG/ML	N50341 003	

AMPICILLIN SODIUM

INJECTABLE; INJECTION

	AMPICILLIN SODIUM			
AP	APOTHECON	**EQ 125MG BASE/VIAL**	**N61395 001**	
AP		**EQ 125MG BASE/VIAL**	**N62860 001**	
			FEB 05, 1988	
AP		**EQ 250MG BASE/VIAL**	**N61395 002**	
AP		**EQ 250MG BASE/VIAL**	**N62860 002**	
			FEB 05, 1988	
AP		**EQ 500MG BASE/VIAL**	**N61395 003**	
AP		**EQ 500MG BASE/VIAL**	**N62860 003**	
			FEB 05, 1988	
AP		**EQ 1GM BASE/VIAL**	**N61395 004**	

FDA data supplied by DrugPatentWatch.com

AMPICILLIN SODIUM

INJECTABLE; INJECTION

AMPICILLIN SODIUM

AP	APOTHECON	EQ 1GM BASE/VIAL	N62738 001	FEB 19, 1987
AP		EQ 1GM BASE/VIAL	N62860 004	FEB 05, 1988
AP		EQ 2GM BASE/VIAL	N61395 005	
AP		EQ 2GM BASE/VIAL	N62738 002	FEB 19, 1987
AP		EQ 2GM BASE/VIAL	N62860 005	FEB 05, 1988
AP		EQ 10GM BASE/VIAL	N61395 006	
AP	IBI	EQ 250MG BASE/VIAL	N62719 001	MAY 12, 1987
AP		EQ 500MG BASE/VIAL	N62719 003	MAY 12, 1987
AP		EQ 1GM BASE/VIAL	N62719 002	MAY 12, 1987
AP	MARSAM PHARMS LLC	EQ 125MG BASE/VIAL	N62816 001	OCT 24, 1988
AP		EQ 250MG BASE/VIAL	N62816 002	OCT 24, 1988
AP		EQ 500MG BASE/VIAL	N62816 003	OCT 24, 1988
AP		EQ 1GM BASE/VIAL	N62816 004	OCT 24, 1988
AP		EQ 2GM BASE/VIAL	N62816 005	OCT 24, 1988

OMNIPEN-N

AP	+ WYETH AYERST	EQ 125MG BASE/VIAL	N60626 001	
AP	+	EQ 250MG BASE/VIAL	N60626 002	
AP	+	EQ 500MG BASE/VIAL	N60626 003	
AP	+	EQ 1GM BASE/VIAL	N60626 004	
AP	+	EQ 2GM BASE/VIAL	N60626 005	

TOTACILLIN-N

AP	GLAXOSMITHKLINE	EQ 125MG BASE/VIAL	N60677 001	
AP		EQ 250MG BASE/VIAL	N60677 002	
AP		EQ 500MG BASE/VIAL	N60677 003	
AP		EQ 1GM BASE/VIAL	N60677 004	
AP		EQ 2GM BASE/VIAL	N60677 005	
		EQ 10GM BASE/VIAL	N60677 006	

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE; INJECTION

UNASYN

+	PFIZER	EQ 1GM BASE/VIAL; EQ 500MG BASE/VIAL	N50608 002	DEC 31, 1986
		EQ 1GM BASE/VIAL; EQ 500MG BASE/VIAL	N62901 001	NOV 23, 1988
+		EQ 2GM BASE/VIAL; EQ 1GM BASE/VIAL	N50608 001	DEC 31, 1986
+		EQ 10GM BASE/VIAL; EQ 5GM BASE/VIAL	N50608 005	DEC 10, 1993

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE; ORAL

AMPICILLIN TRIHYDRATE

AB	CLONMEL	EQ 250MG BASE	N62883 001	FEB 25, 1988
AB		EQ 500MG BASE	N62882 001	FEB 25, 1988
AB	CONSOLIDATED PHARM	EQ 250MG BASE	N61602 001	
AB		EQ 500MG BASE	N61602 002	
AB	PUREPAC PHARM	EQ 500MG BASE	N61853 002	
AB	TEVA	EQ 250MG BASE	N61502 001	
AB		EQ 500MG BASE	N61502 002	

OMNIPEN (AMPICILLIN)

AB	WYETH AYERST	250MG	N60624 001	
AB		500MG	N60624 002	

PRINCIPEN

AB	APOTHECON	EQ 250MG BASE	N61392 001	
AB		EQ 500MG BASE	N61392 002	
AB		EQ 250MG BASE	N62888 001	MAR 04, 1988
AB	+	EQ 500MG BASE	N62888 002	MAR 04, 1988

TOTACILLIN

AB	GLAXOSMITHKLINE	EQ 250MG BASE	N62212 001	
AB		EQ 500MG BASE	N62212 002	

FOR SUSPENSION; ORAL

AMPICILLIN TRIHYDRATE

AB	CLONMEL	EQ 125MG BASE/5ML	N62982 001	FEB 10, 1989

FDA data supplied by DrugPatentWatch.com

AMPICILLIN/AMPICILLIN TRIHYDRATE

FOR SUSPENSION; ORAL

	AMPICILLIN TRIHYDRATE			
AB	CLONMEL	EQ 250MG BASE/5ML	N62982 002	FEB 10, 1989
AB	CONSOLIDATED PHARM	EQ 125MG BASE/5ML	N61601 001	
AB		EQ 250MG BASE/5ML	N61601 002	
AB	PUREPAC PHARM	EQ 250MG BASE/5ML	N61980 002	
AB	TEVA	EQ 125MG BASE/5ML	N61370 001	
AB		EQ 250MG BASE/5ML	N61370 002	
	OMNIPEN (AMPICILLIN)			
AB	WYETH AYERST	100MG/ML	N60625 001	
AB		125MG/5ML	N60625 002	
AB		250MG/5ML	N60625 003	
	PRINCIPEN			
AB	APOTHECON	EQ 100MG BASE/ML	N61394 001	
AB		EQ 125MG BASE/5ML	N61394 002	
AB +		EQ 250MG BASE/5ML	N61394 003	

AMPRENAVIR

CAPSULE; ORAL

	AGENERASE			
	GLAXOSMITHKLINE	50MG	N21007 001	APR 15, 1999
+		150MG	N21007 002	APR 15, 1999

SOLUTION; ORAL

	AGENERASE			
+	GLAXOSMITHKLINE	15MG/ML	N21039 001	APR 15, 1999

ANAGRELIDE HYDROCHLORIDE

CAPSULE; ORAL

	AGRYLIN			
	SHIRE LABS	EQ 0.5MG BASE	N20333 001	MAR 14, 1997
+		EQ 1MG BASE	N20333 002	MAR 14, 1997

ANASTROZOLE

TABLET; ORAL

	ARIMIDEX			
+	ASTRAZENECA	1MG	N20541 001	DEC 27, 1995

ANISINDIONE

TABLET; ORAL

	MIRADON			
+	SCHERING	50MG	N10909 003	

APRACLONIDINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

	IOPIDINE			
+	ALCON	EQ 0.5% BASE	N20258 001	JUL 30, 1993
+		EQ 1% BASE	N19779 001	DEC 31, 1987

APROTININ BOVINE

INJECTABLE; INJECTION

	TRASYLOL			
+	BAYER	10,000KIU/ML	N20304 001	DEC 29, 1993

ARGATROBAN

INJECTABLE; INJECTION

	ARGATROBAN			
+	TX BIOTECH	100MG/ML	N20883 001	JUN 30, 2000

ARGININE HYDROCHLORIDE

INJECTABLE; INJECTION

	R-GENE 10			
+	PHARMACIA AND UPJOHN	10GM/100ML	N16931 001	

FDA data supplied by DrugPatentWatch.com

ARSENIC TRIOXIDE

INJECTABLE; INJECTION
TRISENOX
+ CELL THERAP 1MG/ML N21248 001
SEP 25, 2000

ARTICAINE HYDROCHLORIDE; EPINEPHRINE

INJECTABLE; INJECTION
SEPTOCAINE
+ DEPROCO 4%;EQ 0.01MG BASE/ML N20971 001
APR 03, 2000

ASCORBIC ACID; *MULTIPLE*
SEE ALPHA-TOCOPHEROL; ASCORBIC ACID; BIOTIN, D-; CHOLECALCIFEROL; CYANOCOBALAMIN; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A
SEE ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE

ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

INJECTABLE; IV (INFUSION)
INFUVITE PEDIATRIC
+ SABEX 80MG/VIAL;0.02MG/VIAL;400 IU/VIAL; 0.001MG/VIAL;5MG/VIAL;0.14MG/VIAL; 17MG/VIAL;1MG/VIAL;1.4MG/VIAL; 1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL; 0.2MG/VIAL N21265 001
FEB 21, 2001

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PHYTONADIONE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

FOR SOLUTION; IV (INFUSION)
M.V.I. PEDIATRIC
+ NEOSAN PHARMS 80MG/VIAL;0.02MG/VIAL;0.001MG/VIAL; 5MG/VIAL;0.01MG/VIAL;0.14MG/VIAL; 17MG/VIAL;0.2MG/VIAL;1MG/VIAL; 1.4MG/VIAL;EQ 1.2MG BASE/VIAL; 0.7MG/VIAL;7MG/VIAL N18920 001
SEP 21, 2000

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION
M.V.I.-12
AP + NEOSAN PHARMS **10MG/ML;0.006MG/ML;0.5 UGM/ML; 1.5MG/ML;20 IU/ML;0.04MG/ML;4MG/ML; 0.4MG/ML;0.36MG/ML;0.3MG/ML; 330 UNITS/ML;1 IU/ML** **N08809 004**
AUG 08, 1985

ASPIRIN; *MULTIPLE*
SEE ACETAMINOPHEN; ASPIRIN; CODEINE PHOSPHATE

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL
FIORINAL
AB + NOVARTIS **325MG;50MG;40MG** **N17534 005**
APR 16, 1986

LANORINAL
AB LANNETT **325MG;50MG;40MG** **N86996 002**
OCT 11, 1985

TABLET; ORAL
ASPIRIN AND CAFFEINE W/ BUTALBITAL
AB PUREPAC PHARM **325MG;50MG;40MG** **N86710 002**
AUG 23, 1983

BUTAL COMPOUND
AB GENEVA PHARMS **325MG;50MG;40MG** **N86398 002**
APR 06, 1984

FDA data supplied by DrugPatentWatch.com

ASPIRIN; BUTALBITAL; CAFFEINE

TABLET; ORAL

	BUTALBITAL W/ ASPIRIN & CAFFEINE				
AB	PHARMERAL	325MG;50MG;40MG		**N87048 002**	DEC 09, 1983
	BUTALBITAL, ASPIRIN AND CAFFEINE				
AB	WEST WARD	325MG;50MG;40MG		**N86162 002**	FEB 16, 1984
	FIORINAL				
AB	+ NOVARTIS	325MG;50MG;40MG		**N17534 003**	APR 16, 1986

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

	BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE				
AB	ANABOLIC	325MG;50MG;40MG;30MG		**N75231 001**	NOV 30, 2001
AB	ENDO PHARMS	325MG;50MG;40MG;30MG		**N75351 001**	MAR 05, 1999
AB	STEVENS J	325MG;50MG;40MG;30MG		**N74951 001**	AUG 31, 1998
AB	WATSON LABS	325MG;50MG;40MG;30MG		**N74359 001**	AUG 31, 1995
	FIORINAL W/CODEINE NO 3				
AB	+ NOVARTIS	325MG;50MG;40MG;30MG		**N19429 003**	OCT 26, 1990

ASPIRIN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE; ORAL

	SYNALGOS-DC				
	+ WOMEN FIRST HLTHCARE	356.4MG;30MG;16MG		N11483 004	SEP 06, 1983

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET; ORAL

	INVAGESIC				
AB	GENEVA PHARMS TECH	385MG;30MG;25MG		**N74817 001**	NOV 27, 1996
	INVAGESIC FORTE				
AB	GENEVA PHARMS TECH	770MG;60MG;50MG		**N74817 002**	NOV 27, 1996

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET; ORAL

	NORGESIC				
AB	3M	385MG;30MG;25MG		**N13416 003**	OCT 27, 1982
	NORGESIC FORTE				
AB	+ 3M	770MG;60MG;50MG		**N13416 004**	OCT 27, 1982
	ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE				
AB	EON	385MG;30MG;25MG		**N74654 001**	DEC 31, 1996
AB		770MG;60MG;50MG		**N74654 002**	DEC 31, 1996
AB	STEVENS J	385MG;30MG;25MG		**N74988 001**	APR 30, 1999
AB		770MG;60MG;50MG		**N74988 002**	APR 30, 1999
	ORPHENGESIC				
AB	PAR PHARM	385MG;30MG;25MG		**N75141 001**	MAY 29, 1998
	ORPHENGESIC FORTE				
AB	PAR PHARM	770MG;60MG;50MG		**N75141 002**	MAY 29, 1998

ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

	DARVON COMPOUND				
	+ LILLY	389MG;32.4MG;32MG		N10996 006	MAR 08, 1983
	DARVON COMPOUND-65				
AA	+ LILLY	389MG;32.4MG;65MG		**N10996 007**	MAR 08, 1983
	PROPOXYPHENE COMPOUND 65				
AA	TEVA	389MG;32.4MG;65MG		**N89025 001**	MAR 29, 1985

ASPIRIN; CARISOPRODOL

TABLET; ORAL

	CARISOPRODOL AND ASPIRIN				
AB	AMIDE PHARM	325MG;200MG		**N40252 001**	DEC 10, 1997
AB	EON	325MG;200MG		**N40116 001**	APR 25, 1996

FDA data supplied by DrugPatentWatch.com

ASPIRIN; CARISOPRODOL

TABLET; ORAL

CARISOPRODOL AND ASPIRIN

AB		PAR PHARM	325MG;200MG	N89594 001 MAR 31, 1989

SOMA COMPOUND

AB	+	WALLACE PHARMS	325MG;200MG	N12365 005 JUL 11, 1983

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

TABLET; ORAL

CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE

AB		AMIDE PHARM	325MG;200MG;16MG	N40283 001 DEC 29, 1998
AB		EON	325MG;200MG;16MG	N40118 001 APR 16, 1996

SOMA COMPOUND W/ CODEINE

AB	+	WALLACE PHARMS	325MG;200MG;16MG	N12366 002 JUL 11, 1983

ASPIRIN; DIPYRIDAMOLE

CAPSULE, EXTENDED RELEASE; ORAL

AGGRENOX

	+	BOEHRINGER INGELHEIM	25MG;200MG	N20884 001 NOV 22, 1999

ASPIRIN; HYDROCODONE BITARTRATE

TABLET; ORAL

AZDONE

	+	CENT PHARMS	500MG;5MG	N89420 001 JAN 25, 1988

ASPIRIN; MEPROBAMATE

TABLET; ORAL

EQUAGESIC

AB	+	WOMEN FIRST HLTHCARE	325MG;200MG	N11702 003 DEC 29, 1983

MICRAININ

AB		WALLACE PHARMS	325MG;200MG	N84978 001

ASPIRIN; METHOCARBAMOL

TABLET; ORAL

METHOCARBAMOL AND ASPIRIN

AB		IVAX PHARMS	325MG;400MG	N87211 001 DEC 22, 1982
AB		PAR PHARM	325MG;400MG	N89657 001 NOV 04, 1988
AB		STEVENS J	325MG;400MG	N81145 001 JAN 31, 1995

ROBAXISAL

AB	+	ROBINS AH	325MG;400MG	N12281 001

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

TABLET; ORAL

OXYCODONE AND ASPIRIN

AA		HALSEY	325MG;4.5MG;0.38MG	N40260 001 JUL 17, 1998
AA			325MG;4.5MG;0.38MG	N87794 001 MAY 26, 1982
AA		WATSON LABS	325MG;4.5MG;0.38MG	N40255 001 FEB 27, 1998

PERCODAN

AA	+	ENDO PHARMS	325MG;4.5MG;0.38MG	N07337 006

PERCODAN-DEMI

AA	+	ENDO PHARMS	325MG;2.25MG;0.19MG	N07337 005

ASPIRIN; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL

TALWIN COMPOUND

	+	SANOFI SYNTHELABO	325MG;EQ 12.5MG BASE	N16891 001

ASPIRIN; PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

DARVON W/ ASA

	+	LILLY	325MG;65MG	N10996 005

ATENOLOL

INJECTABLE; INJECTION

TENORMIN

	+	ASTRAZENECA	0.5MG/ML	N19058 001 SEP 13, 1989

FDA data supplied by DrugPatentWatch.com

ATENOLOL

TABLET; ORAL
ATENOLOL

AB	COPLEY PHARM	50MG	**N74120 001** FEB 24, 1995
AB		100MG	**N74120 002** FEB 24, 1995
AB	DANBURY PHARMA	50MG	**N73352 001** DEC 27, 1991
AB		100MG	**N73353 001** DEC 27, 1991
AB	GENEVA PHARMS	25MG	**N74052 001** MAY 01, 1992
AB		50MG	**N73025 001** SEP 17, 1991
AB		100MG	**N73026 001** SEP 17, 1991
AB	GENEVA PHARMS TECH	25MG	**N74265 001** FEB 28, 1994
AB		50MG	**N74265 002** FEB 28, 1994
AB		100MG	**N74265 003** FEB 28, 1994
AB	IPR	25MG	**N73646 001** JUL 31, 1992
AB		50MG	**N72303 001** JUL 15, 1988
AB		100MG	**N72304 001** JUL 15, 1988
AB	LEDERLE	25MG	**N74099 001** APR 28, 1992
AB		50MG	**N73542 001** DEC 19, 1991
AB		100MG	**N73543 001** DEC 19, 1991
AB	MARTEC	50MG	**N74127 001** FEB 21, 1995
AB		100MG	**N74127 002** FEB 21, 1995
AB	MUTUAL PHARM	25MG	**N74499 001** JUL 30, 1997
AB		50MG	**N73475 001** MAR 30, 1993
AB		100MG	**N73476 001** MAR 30, 1993
AB	MYLAN	50MG	**N73456 001** JAN 24, 1992

ATENOLOL

TABLET; ORAL
ATENOLOL

AB	MYLAN	100MG	**N73457 001** JAN 24, 1992
		25MG	N73457 002 APR 26, 1999
AB	SCS	50MG	**N73676 001** OCT 30, 1992
AB		100MG	**N73676 002** OCT 30, 1992
AB	SIDMAK LABS NJ	25MG	**N74101 001** JUL 17, 1997
AB		50MG	**N74101 002** JUL 17, 1997
AB		100MG	**N74101 003** JUL 17, 1997
AB	TEVA	50MG	**N73315 001** MAY 28, 1993
AB		50MG	**N74056 001** JAN 18, 1995
AB		100MG	**N73316 001** MAY 28, 1993
AB		100MG	**N74056 002** JAN 18, 1995

TENORMIN

AB	ASTRAZENECA	25MG	**N18240 004** APR 09, 1990
AB		50MG	**N18240 001**
AB	+	100MG	**N18240 002**

ATENOLOL; CHLORTHALIDONE

TABLET; ORAL
ATENOLOL AND CHLORTHALIDONE

AB	DANBURY PHARMA	50MG;25MG	**N73665 001** JUL 02, 1992
AB		100MG;25MG	**N73665 002** JUL 02, 1992
AB	IPR	50MG;25MG	**N72301 001** MAY 31, 1990
AB		100MG;25MG	**N72302 001** MAY 31, 1990
AB	MARTEC	50MG;25MG	**N74404 001** MAY 14, 1998
AB		100MG;25MG	**N74404 002** MAY 14, 1998

FDA data supplied by DrugPatentWatch.com

ATENOLOL; CHLORTHALIDONE

TABLET; ORAL

	ATENOLOL AND CHLORTHALIDONE			
AB	MUTUAL PHARM	50MG;25MG	**N73581 001**	APR 29, 1993
AB		100MG;25MG	**N73582 001**	APR 29, 1993
AB	MYLAN	50MG;25MG	**N74203 001**	OCT 31, 1993
AB		100MG;25MG	**N74203 002**	OCT 31, 1993
AB	SIDMAK LABS NJ	50MG;25MG	**N74107 001**	SEP 24, 1997
AB		100MG;25MG	**N74107 002**	SEP 24, 1997
	TENORETIC 100			
AB	+ ASTRAZENECA	100MG;25MG	**N18760 001**	JUN 08, 1984
	TENORETIC 50			
AB	ASTRAZENECA	50MG;25MG	**N18760 002**	JUN 08, 1984

ATORVASTATIN CALCIUM

TABLET; ORAL

	LIPITOR			
	PFIZER	EQ 10MG BASE	N20702 001	DEC 17, 1996
		EQ 20MG BASE	N20702 002	DEC 17, 1996
		EQ 40MG BASE	N20702 003	DEC 17, 1996
	+	EQ 80MG BASE	N20702 004	APR 07, 2000

ATOVAQUONE

SUSPENSION; ORAL

	MEPRON			
	+ GLAXOSMITHKLINE	750MG/5ML	N20500 001	FEB 08, 1995

TABLET; ORAL

	MEPRON			
	+ GLAXOSMITHKLINE	250MG	N20259 001	NOV 25, 1992

ATOVAQUONE; PROGUANIL HYDROCHLORIDE

TABLET; ORAL

	MALARONE			
	+ GLAXOSMITHKLINE	250MG;100MG	N21078 001	JUL 14, 2000
	MALARONE PEDIATRIC			
	+ GLAXOSMITHKLINE	62.5MG;25MG	N21078 002	JUL 14, 2000

ATRACURIUM BESYLATE

INJECTABLE; INJECTION

	ATRACURIUM BESYLATE			
AP	ABBOTT	10MG/ML	**N74632 001**	DEC 23, 1996
AP	BAXTER HLTHCARE CORP	10MG/ML	**N74753 001**	JAN 23, 1997
AP	BEDFORD	10MG/ML	**N74901 001**	JUL 18, 1997
AP	ESI LEDERLE	10MG/ML	**N74824 001**	SEP 30, 1997
AP	FAULDING	10MG/ML	**N74740 001**	MAR 28, 1997
AP	GENSIA SICOR PHARMS	10MG/ML	**N74784 001**	JUN 11, 1997
AP	MARSAM PHARMS LLC	10MG/ML	**N74945 001**	JUL 28, 1998
	ATRACURIUM BESYLATE PRESERVATIVE FREE			
AP	ABBOTT	10MG/ML	**N74633 001**	DEC 23, 1996
AP		10MG/ML	**N74639 001**	MAR 25, 1997
AP	BAXTER HLTHCARE CORP	10MG/ML	**N74768 001**	JAN 23, 1997
AP	BEDFORD	10MG/ML	**N74900 001**	JUL 18, 1997
AP	ESI LEDERLE	10MG/ML	**N74825 001**	SEP 30, 1997
AP	FAULDING	10MG/ML	**N74741 001**	MAR 28, 1997
AP	MARSAM PHARMS LLC	10MG/ML	**N74944 001**	JUL 28, 1998
	TRACRIUM			
AP	+ ABBOTT	10MG/ML	**N18831 002**	JUN 20, 1985
	TRACRIUM PRESERVATIVE FREE			
AP	+ ABBOTT	10MG/ML	**N18831 001**	NOV 23, 1983

FDA data supplied by DrugPatentWatch.com

ATROPINE

INJECTABLE; INJECTION
ATROPEN
+ MERIDIAN MEDCL TECHN EQ 2MG SULFATE/0.7ML N17106 001

ATROPINE SULFATE

INJECTABLE; IM-IV-SC
ATROPINE SULFATE ANSYR PLASTIC SYRINGE
ABBOTT 0.05MG/ML N21146 002 JUL 09, 2001
+ 0.1MG/ML N21146 001 JUL 09, 2001

ATROPINE SULFATE; DIFENOXIN HYDROCHLORIDE

TABLET; ORAL
MOTOFEN
+ AMARIN PHARMS 0.025MG;1MG N17744 002

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

CAPSULE; ORAL
DIPHENOXYLATE HCL W/ ATROPINE SULFATE
SCHERER RP 0.025MG;2.5MG N86440 001

SOLUTION; ORAL
DIPHENOXYLATE HCL AND ATROPINE SULFATE
AA ROXANE **0.025MG/5ML;2.5MG/5ML** **N87708 001** MAY 03, 1982

LOMOTIL
AA + GD SEARLE LLC **0.025MG/5ML;2.5MG/5ML** **N12699 001**

TABLET; ORAL
DIPHENOXYLATE HCL AND ATROPINE SULFATE
AA ABLE **0.025MG;2.5MG** **N40395 001** NOV 27, 2000
AA LANNETT **0.025MG;2.5MG** **N85372 001**
AA MYLAN **0.025MG;2.5MG** **N85762 001**
AA PAR PHARM **0.025MG;2.5MG** **N40357 001** MAY 02, 2000

DIPHENOXYLATE HCL W/ ATROPINE SULFATE
AA EON **0.025MG;2.5MG** **N86173 001**
AA IVAX PHARMS **0.025MG;2.5MG** **N86727 001**

LOMOTIL
AA + GD SEARLE LLC **0.025MG;2.5MG** **N12462 001**

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET; ORAL
LONOX
AA GENEVA PHARMS **0.025MG;2.5MG** **N85311 002**

ATROPINE SULFATE; EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION
ENLON-PLUS
+ BAXTER HLTHCARE CORP 0.14MG/ML;10MG/ML N19677 001 NOV 06, 1991
+ 0.14MG/ML;10MG/ML N19678 001 NOV 06, 1991

ATROPINE SULFATE; MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
ATROPINE AND DEMEROL
+ ABBOTT 0.4MG/ML;50MG/ML N87853 001 NOV 26, 1982
+ 0.4MG/ML;75MG/ML N87847 001 NOV 26, 1982
+ 0.4MG/ML;100MG/ML N87848 001 NOV 26, 1982

AURANOFIN

CAPSULE; ORAL
RIDAURA
+ PROMETHEUS LABS 3MG N18689 001 MAY 24, 1985

AZATADINE MALEATE

TABLET; ORAL
OPTIMINE
+ SCHERING 1MG N17601 001

AZATADINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL
TRINALIN
+ SCHERING 1MG;120MG N18506 001 MAR 23, 1982

FDA data supplied by DrugPatentWatch.com

AZATHIOPRINE

TABLET; ORAL

	AZATHIOPRINE			
AB	APPLIED ANAL	**50MG**	**N75252 001**	JUN 07, 1999
AB	GENPHARM	**50MG**	**N75568 001**	DEC 13, 1999
AB	ROXANE	**50MG**	**N74069 001**	FEB 16, 1996
	IMURAN			
AB +	PROMETHEUS LABS	**50MG**	**N16324 001**	

AZATHIOPRINE SODIUM

INJECTABLE; INJECTION

	AZATHIOPRINE SODIUM			
AP	BEDFORD	**EQ 100MG BASE/VIAL**	**N74419 001**	MAR 31, 1995
	IMURAN			
AP +	PROMETHEUS LABS	**EQ 100MG BASE/VIAL**	**N17391 001**	

AZELAIC ACID

CREAM; TOPICAL

	AZELEX			
+	ALLERGAN	20%	N20428 001	SEP 13, 1995

AZELASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

	OPTIVAR			
+	ASTA	0.05%	N21127 001	MAY 22, 2000

SPRAY, METERED; NASAL

	ASTELIN			
+	WALLACE PHARMS	EQ 0.125MG BASE/SPRAY	N20114 001	NOV 01, 1996

AZITHROMYCIN DIHYDRATE

CAPSULE; ORAL

	ZITHROMAX			
+	PFIZER	EQ 250MG BASE	N50670 001	NOV 01, 1991

FOR SUSPENSION; ORAL

	ZITHROMAX			
+	PFIZER	EQ 1GM BASE/PACKET	N50693 001	SEP 28, 1994
		EQ 100MG BASE/5ML	N50710 001	OCT 19, 1995
+		EQ 200MG BASE/5ML	N50710 002	OCT 19, 1995

INJECTABLE; INJECTION

	ZITHROMAX			
+	PFIZER	EQ 500MG BASE/VIAL	N50733 001	JAN 30, 1997

TABLET; ORAL

	ZITHROMAX			
	PFIZER	EQ 250MG BASE	N50711 001	JUL 18, 1996
+		EQ 600MG BASE	N50730 001	JUN 12, 1996

AZTREONAM

INJECTABLE; INJECTION

	AZACTAM			
+	BRISTOL MYERS SQUIBB	500MG/VIAL	N50580 001	DEC 31, 1986
+		1GM/VIAL	N50580 002	DEC 31, 1986
+		2GM/VIAL	N50580 003	DEC 31, 1986
	AZACTAM IN PLASTIC CONTAINER			
+	BRISTOL MYERS SQUIBB	20MG/ML	N50632 002	MAY 24, 1989
+		40MG/ML	N50632 001	MAY 24, 1989

FDA data supplied by DrugPatentWatch.com

BACAMPICILLIN HYDROCHLORIDE

FOR SUSPENSION; ORAL

	SPECTROBID			
	+ PFIZER	125MG/5ML	N50556 001	MAR 23, 1982

TABLET; ORAL

	SPECTROBID			
	+ PFIZER	400MG	N50520 001	

BACITRACIN

INJECTABLE; INJECTION

	BACIIM			
AP	PHARMA TEK	**50,000 UNITS/VIAL**	**N64153 001**	MAY 09, 1997
	BACITRACIN			
AP	+ PHARMACIA AND UPJOHN	**50,000 UNITS/VIAL**	**N60733 002**	
		10,000 UNITS/VIAL	N60733 001	

OINTMENT; OPHTHALMIC

	BACITRACIN			
	+ ALTANA	500 UNITS/GM	N61212 001	

POWDER; FOR RX COMPOUNDING

	BACI-RX			
AA	PHARMA TEK	**5,000,000 UNITS/BOT**	**N61580 001**	
	BACITRACIN			
AA	APOTHEKERNES	**5,000,000 UNITS/BOT**	**N61699 001**	

BACITRACIN; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

	BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE			
	+ PHARMADERM	400 UNITS/GM;1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM	N62166 002	

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

	CORTISPORIN			
AT	+ MONARCH PHARMS	**400 UNITS/GM;1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM**	**N50416 002**	

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

	NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE			
AT	BAUSCH AND LOMB	**400 UNITS/GM;1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM**	**N64068 001**	OCT 30, 1995

OINTMENT; TOPICAL

	CORTISPORIN			
	+ MONARCH PHARMS	400 UNITS/GM;1%;EQ 3.5MG BASE/GM; 5,000 UNITS/GM	N50168 002	MAY 04, 1984

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

	BACITRACIN-NEOMYCIN-POLYMYXIN			
AT	ALTANA	**400 UNITS/GM;EQ 3.5MG BASE/GM; 10,000 UNITS/GM**	**N60764 002**	
	NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC			
AT	BAUSCH AND LOMB	**400 UNITS/GM;EQ 3.5MG BASE/GM; 10,000 UNITS/GM**	**N64064 001**	OCT 30, 1995
	NEOSPORIN			
AT	+ MONARCH PHARMS	**400 UNITS/GM;EQ 3.5MG BASE/GM; 10,000 UNITS/GM**	**N50417 001**	

BACITRACIN ZINC; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

	BACITRACIN ZINC AND POLYMYXIN B SULFATE			
AT	AKORN	**500 UNITS/GM; 10,000 UNITS/GM**	**N64028 001**	JAN 30, 1995
AT	BAUSCH AND LOMB	**500 UNITS/GM; 10,000 UNITS/GM**	**N64046 001**	JAN 26, 1995
	POLYSPORIN			
AT	+ MONARCH PHARMS	**500 UNITS/GM; 10,000 UNITS/GM**	**N61229 001**	

FDA data supplied by DrugPatentWatch.com

BACLOFEN

INJECTABLE; INTRATHECAL

	LIORESAL			
	+ MEDTRONIC	0.05MG/ML	N20075 003	NOV 07, 1996
	+	0.5MG/ML	N20075 001	JUN 17, 1992
	+	2MG/ML	N20075 002	JUN 17, 1992

TABLET; ORAL

	BACLOFEN			
AB	DANBURY PHARMA	**10MG**	**N72824 001**	SEP 18, 1991
AB		**20MG**	**N72825 001**	SEP 18, 1991
AB	IVAX PHARMS	**10MG**	**N72234 001**	JUL 21, 1988
AB		**20MG**	**N72235 001**	JUL 21, 1988
AB	USL PHARMA	**10MG**	**N74584 001**	AUG 19, 1996
AB		**20MG**	**N74584 002**	AUG 19, 1996
AB	WATSON LABS	**10MG**	**N73092 001**	JAN 28, 1994
AB		**10MG**	**N74698 001**	AUG 20, 1996
AB +		**20MG**	**N73093 001**	JAN 28, 1994
AB		**20MG**	**N74698 002**	AUG 20, 1996

BALSALAZIDE DISODIUM

CAPSULE; ORAL

	COLAZAL			
	+ SALIX	750MG	N20610 001	JUL 18, 2000

BECLOMETHASONE DIPROPIONATE

AEROSOL, METERED; INHALATION

	BECLOVENT			
BN	GLAXOSMITHKLINE	0.042MG/INH	N18153 001	

BECLOMETHASONE DIPROPIONATE

AEROSOL, METERED; INHALATION

	QVAR 40			
	+ 3M	0.04MG/INH	N20911 002	SEP 15, 2000
	QVAR 80			
	+ 3M	0.08MG/INH	N20911 001	SEP 15, 2000
	VANCERIL			
BN	+ SCHERING	0.042MG/INH	N17573 001	
	VANCERIL DOUBLE STRENGTH			
	+ SCHERING	0.084MG/INH	N20486 001	DEC 24, 1996

AEROSOL, METERED; NASAL

	BECONASE			
BN	+ GLAXOSMITHKLINE	0.042MG/INH	N18584 001	
	VANCENASE			
BN	SCHERING	0.042MG/INH	N18521 001	

BECLOMETHASONE DIPROPIONATE MONOHYDRATE

SPRAY, METERED; NASAL

	BECONASE AQ			
BN	+ GLAXOSMITHKLINE	EQ 0.042MG DIPROP/SPRAY	N19389 001	JUL 27, 1987
	VANCENASE AQ			
BN	+ SCHERING	EQ 0.042MG DIPROP/SPRAY	N19589 001	DEC 23, 1987
	+	EQ 0.084MG DIPROP/SPRAY	N20469 001	JUN 26, 1996

BENAZEPRIL HYDROCHLORIDE

TABLET; ORAL

LOTENSIN			
NOVARTIS	5MG	N19851 001	JUN 25, 1991
	10MG	N19851 002	JUN 25, 1991
	20MG	N19851 003	JUN 25, 1991
+	40MG	N19851 004	JUN 25, 1991

BENAZEPRIL HYDROCHLORIDE; *MULTIPLE*
SEE AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

	LOTENSIN HCT			
	NOVARTIS	5MG;6.25MG	N20033 001	MAY 19, 1992
		10MG;12.5MG	N20033 002	MAY 19, 1992
		20MG;12.5MG	N20033 004	MAY 19, 1992
+		20MG;25MG	N20033 003	MAY 19, 1992

BENDROFLUMETHIAZIDE

TABLET; ORAL

	NATURETIN-10			
+	APOTHECON	10MG	N12164 003	
	NATURETIN-5			
	APOTHECON	5MG	N12164 002	

BENDROFLUMETHIAZIDE; NADOLOL

TABLET; ORAL

	CORZIDE			
	KING PHARMS	5MG;40MG	N18647 001	MAY 25, 1983
+		5MG;80MG	N18647 002	MAY 25, 1983

BENZONATATE

CAPSULE; ORAL

	BENZONATATE			
AA	BANNER PHARMACAPS	**100MG**	**N81297 001**	JAN 29, 1993
	TESSALON			
AA +	FOREST LABS	**100MG**	**N11210 001**	

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL; TOPICAL

	BENZACLIN			
+	DERMIK LABS	5%;EQ 1% BASE	N50756 001	DEC 21, 2000

BENZOYL PEROXIDE; ERYTHROMYCIN

GEL; TOPICAL

	BENZAMYCIN			
+	DERMIK LABS	5%;3%	N50557 001	OCT 26, 1984
	BENZAMYCIN PAK			
+	DERMIK LABS	5%;3%	N50769 001	NOV 27, 2000

BENZPHETAMINE HYDROCHLORIDE

TABLET; ORAL

	DIDREX			
+	PHARMACIA AND UPJOHN	50MG	N12427 002	

BENZQUINAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

	EMETE-CON			
+	PFIZER	EQ 50MG BASE/VIAL	N16820 001	

BENZTROPINE MESYLATE

INJECTABLE; INJECTION

	COGENTIN			
+	MERCK	1MG/ML	N12015 001	

TABLET; ORAL

	BENZTROPINE MESYLATE			
AA	GENEVA PHARMS TECH	**0.5MG**	**N72264 001**	FEB 27, 1989
AA		**1MG**	**N72265 001**	FEB 27, 1989
AA		**2MG**	**N72266 001**	FEB 27, 1989
AA	MUTUAL PHARM	**1MG**	**N81264 001**	JAN 23, 1992
AA		**2MG**	**N81265 001**	JAN 23, 1992
AA	PAR PHARM	**0.5MG**	**N88877 001**	APR 11, 1985
AA		**1MG**	**N88894 001**	APR 11, 1985
AA		**2MG**	**N88895 001**	APR 11, 1985

FDA data supplied by DrugPatentWatch.com

BENZTROPINE MESYLATE

TABLET; ORAL

	BENZTROPINE MESYLATE			
AA	SIDMAK LABS NJ	0.5MG	N89058 001	AUG 10, 1988
AA		1MG	N89059 001	AUG 10, 1988
AA		2MG	N89060 001	AUG 10, 1988
AA	USL PHARMA	0.5MG	N40103 001	DEC 12, 1996
AA		1MG	N40103 002	DEC 12, 1996
AA		2MG	N40103 003	DEC 12, 1996
	COGENTIN			
AA	+ MERCK	0.5MG	N09193 004	
AA	+	1MG	N09193 003	
AA	+	2MG	N09193 002	

BENZYL PENICILLOYL-POLYLYSINE

INJECTABLE; INJECTION
PRE-PEN

+	HOLLISTER STIER LABS	60 UMOLAR	N50114 001

BEPRIDIL HYDROCHLORIDE

TABLET; ORAL
VASCOR

	JOHNSON RW	200MG	N19002 001	DEC 28, 1990
+		300MG	N19002 002	DEC 28, 1990

BERACTANT

SUSPENSION; INTRATRACHEAL
SURVANTA

+	ROSS LABS	25MG/ML	N20032 001	JUL 01, 1991

BETAINE, ANHYDROUS

FOR SOLUTION; ORAL
CYSTADANE

+	ORPHAN MEDCL	1GM/SCOOPFUL	N20576 001	OCT 25, 1996

BETAMETHASONE

SYRUP; ORAL
CELESTONE

+	SCHERING	0.6MG/5ML	N14215 002	

TABLET; ORAL
CELESTONE

+	SCHERING	0.6MG	N12657 003	

BETAMETHASONE ACETATE; BETAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION
CELESTONE SOLUSPAN

+	SCHERING	3MG/ML;EQ 3MG BASE/ML	N14602 001	

BETAMETHASONE DIPROPIONATE

CREAM; TOPICAL

	ALPHATREX			
AB	SAVAGE LABS	EQ 0.05% BASE	N19138 001	JUN 26, 1984
	BETAMETHASONE DIPROPIONATE			
AB	FOUGERA	EQ 0.05% BASE	N19137 001	JUN 26, 1984
AB	NMC	EQ 0.05% BASE	N70885 001	FEB 03, 1987
AB	TARO	EQ 0.05% BASE	N73552 001	APR 30, 1992
AB	TEVA	EQ 0.05% BASE	N71476 001	AUG 10, 1987
AB	THAMES	EQ 0.05% BASE	N71143 001	JUN 17, 1987
	DIPROSONE			
AB	+ SCHERING	EQ 0.05% BASE	N17536 001	

CREAM, AUGMENTED; TOPICAL
DIPROLENE AF

+	SCHERING	EQ 0.05% BASE	N19555 001	APR 27, 1987

FDA data supplied by DrugPatentWatch.com

BETAMETHASONE DIPROPIONATE

GEL; TOPICAL

	DIPROLENE			
+	SCHERING	EQ 0.05% BASE	N19408 002	NOV 22, 1991

LOTION; TOPICAL

	ALPHATREX			
AB	SAVAGE LABS	**EQ 0.05% BASE**	**N70273 001**	AUG 12, 1985
	BETAMETHASONE DIPROPIONATE			
AB	ALPHARMA	**EQ 0.05% BASE**	**N70281 001**	JUL 31, 1985
AB	CLAY PARK	**EQ 0.05% BASE**	**N72538 001**	JAN 31, 1990
AB	COPLEY PHARM	**EQ 0.05% BASE**	**N71882 001**	JUN 06, 1988
AB	FOUGERA	**EQ 0.05% BASE**	**N70275 001**	AUG 12, 1985
AB	TARO	**EQ 0.05% BASE**	**N74272 001**	SEP 30, 1994
AB	TEVA	**EQ 0.05% BASE**	**N71467 001**	AUG 10, 1987
AB	THAMES	**EQ 0.05% BASE**	**N72276 001**	AUG 24, 1988
	DIPROSONE			
AB	+ SCHERING	**EQ 0.05% BASE**	**N17781 001**	

LOTION, AUGMENTED; TOPICAL

	DIPROLENE			
+	SCHERING	EQ 0.05% BASE	N19716 001	AUG 01, 1988

OINTMENT; TOPICAL

	ALPHATREX			
AB	SAVAGE LABS	**EQ 0.05% BASE**	**N19143 001**	SEP 04, 1984
	BETAMETHASONE DIPROPIONATE			
AB	FOUGERA	**EQ 0.05% BASE**	**N19141 001**	SEP 04, 1984
AB	NMC	**EQ 0.05% BASE**	**N71012 001**	FEB 03, 1987
AB	TARO	**EQ 0.05% BASE**	**N74271 001**	SEP 15, 1994
AB	TEVA	**EQ 0.05% BASE**	**N71477 001**	AUG 10, 1987
	DIPROSONE			
AB	+ SCHERING	**EQ 0.05% BASE**	**N17691 001**	

BETAMETHASONE DIPROPIONATE

OINTMENT, AUGMENTED; TOPICAL

	BETAMETHASONE DIPROPIONATE			
AB	ALTANA	**EQ 0.05% BASE**	**N75373 001**	JUN 22, 1999
AB	NMC	**EQ 0.05% BASE**	**N74304 001**	AUG 31, 1995
	DIPROLENE			
AB	+ SCHERING	**EQ 0.05% BASE**	**N18741 001**	JUL 27, 1983

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

CREAM; TOPICAL

	CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE			
AB	ALTANA	**EQ 0.05% BASE;1%**	**N75502 001**	JUN 05, 2001
AB	TARO	**EQ 0.05% BASE;1%**	**N75673 001**	MAY 29, 2001
	LOTRISONE			
AB	+ SCHERING	**EQ 0.05% BASE;1%**	**N18827 001**	JUL 10, 1984

LOTION; TOPICAL

	LOTRISONE			
+	SCHERING PLOUGH RES	EQ 0.05% BASE;1%	N20010 001	DEC 08, 2000

BETAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

	BETAMETHASONE SODIUM PHOSPHATE			
AP	STERIS	**EQ 3MG BASE/ML**	**N85738 001**	
	CELESTONE			
AP	+ SCHERING	**EQ 3MG BASE/ML**	**N17561 001**	

BETAMETHASONE SODIUM PHOSPHATE; *MULTIPLE*

SEE BETAMETHASONE ACETATE; BETAMETHASONE SODIUM PHOSPHATE

BETAMETHASONE VALERATE

AEROSOL; TOPICAL

	LUXIQ			
+	CONNETICS	EQ 0.12% BASE	N20934 001	FEB 28, 1999

FDA data supplied by DrugPatentWatch.com

BETAMETHASONE VALERATE

CREAM; TOPICAL

	BETA-VAL			
AB	TEVA	EQ 0.1% BASE	N18642 001	MAR 24, 1983
	BETADERM			
AB	ROACO	EQ 0.1% BASE	N18839 001	JUN 30, 1983
	BETAMETHASONE VALERATE			
AB	+ FOUGERA	EQ 0.1% BASE	N18861 001	AUG 31, 1983
AB	THAMES	EQ 0.1% BASE	N70062 001	MAY 14, 1985
	BETATREX			
AB	SAVAGE LABS	EQ 0.1% BASE	N18862 001	AUG 31, 1983
	DERMABET			
AB	TARO	EQ 0.1% BASE	N72041 001	JAN 06, 1988
	VALNAC			
AB	NMC	EQ 0.1% BASE	N70050 001	OCT 10, 1984

LOTION; TOPICAL

	BETA-VAL			
AB	TEVA	EQ 0.1% BASE	N70072 001	JUN 27, 1985
	BETAMETHASONE VALERATE			
AB	ALPHARMA	EQ 0.1% BASE	N70052 001	JUL 31, 1985
AB	COPLEY PHARM	EQ 0.1% BASE	N71883 001	APR 22, 1988
AB	+ FOUGERA	EQ 0.1% BASE	N18866 001	AUG 31, 1983
	BETATREX			
AB	SAVAGE LABS	EQ 0.1% BASE	N18867 001	AUG 31, 1983

OINTMENT; TOPICAL

	BETA-VAL			
AB	TEVA	EQ 0.1% BASE	N70069 001	DEC 19, 1985
	BETAMETHASONE VALERATE			
AB	+ FOUGERA	EQ 0.1% BASE	N18865 001	AUG 31, 1983
AB	NMC	EQ 0.1% BASE	N70051 001	OCT 10, 1984

BETAMETHASONE VALERATE

OINTMENT; TOPICAL

	BETATREX			
AB	SAVAGE LABS	EQ 0.1% BASE	N18863 001	AUG 31, 1983

BETAXOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

	BETAXOLOL			
AT	AKORN	EQ 0.5% BASE	N75386 001	JUN 30, 2000
AT	NOVEX	EQ 0.5% BASE	N75446 001	SEP 28, 2000
	BETAXOLOL HCL			
AT	BAUSCH AND LOMB	EQ 0.5% BASE	N75630 001	APR 12, 2001
	BETOPTIC			
AT	+ ALCON	EQ 0.5% BASE	N19270 001	AUG 30, 1985

SUSPENSION/DROPS; OPHTHALMIC

	BETOPTIC S			
	+ ALCON	EQ 0.25% BASE	N19845 001	DEC 29, 1989

TABLET; ORAL

	BETAXOLOL HCL			
AB	AMIDE PHARM	10MG	N75541 001	OCT 22, 1999
AB		20MG	N75541 002	OCT 22, 1999
	KERLONE			
AB	LOREX	10MG	N19507 001	OCT 27, 1989
AB	+	20MG	N19507 002	OCT 27, 1989

BETAXOLOL HYDROCHLORIDE; CHLORTHALIDONE

TABLET; ORAL

	KERLEDEX			
	LOREX	5MG;12.5MG	N19807 001	OCT 30, 1992
	+	10MG;12.5MG	N19807 002	OCT 30, 1992

FDA data supplied by DrugPatentWatch.com

BETAXOLOL HYDROCHLORIDE; PILOCARPINE HYDROCHLORIDE

SUSPENSION/DROPS; OPHTHALMIC
BETOPTIC PILO
+ ALCON — EQ 0.25% BASE;1.75% — N20619 001 APR 17, 1997

BETHANECHOL CHLORIDE

TABLET; ORAL
URECHOLINE
+ ODYSSEY PHARMS — 5MG — N89095 001 DEC 19, 1985
+ — 10MG — N88440 001 MAY 29, 1984
+ — 25MG — N88441 001 MAY 29, 1984
+ — 50MG — N89096 001 DEC 19, 1985

BEXAROTENE

CAPSULE; ORAL
TARGRETIN
+ LIGAND — 75MG — N21055 001 DEC 29, 1999

GEL; TOPICAL
TARGRETIN
+ LIGAND — 1% — N21056 001 JUN 28, 2000

BICALUTAMIDE

TABLET; ORAL
CASODEX
+ ASTRAZENECA — 50MG — N20498 001 OCT 04, 1995

BIMATOPROST

SOLUTION/DROPS; OPHTHALMIC
LUMIGAN
+ ALLERGAN — 0.03% — N21275 001 MAR 16, 2001

BIOTIN; *MULTIPLE*
SEE ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE
SEE ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K
SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PHYTONADIONE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E
SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

BIOTIN, D-; *MULTIPLE*
SEE ALPHA-TOCOPHEROL; ASCORBIC ACID; BIOTIN, D-; CHOLECALCIFEROL; CYANOCOBALAMIN; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A

BIPERIDEN HYDROCHLORIDE

TABLET; ORAL
AKINETON
+ ABBOTT — 2MG — N12003 001

BIPERIDEN LACTATE

INJECTABLE; INJECTION
AKINETON
+ ABBOTT — 5MG/ML — N12418 002

BISMUTH SUBSALICYLATE; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE

TABLET, CHEWABLE, TABLET, CAPSULE; ORAL
HELIDAC
+ PROMETHEUS LABS — 262.4MG,N/A,N/A;N/A,250MG,N/A;N/A,N/A,500MG — N50719 001 AUG 15, 1996

FDA data supplied by DrugPatentWatch.com

BISOPROLOL FUMARATE

TABLET; ORAL

	BISOPROLOL FUMARATE			
AB	COPLEY PHARM	5MG	**N75644 001**	JUN 26, 2001
AB		10MG	**N75644 002**	JUN 26, 2001
AB	EON	5MG	**N75643 001**	NOV 16, 2000
AB		10MG	**N75643 002**	NOV 16, 2000
	ZEBETA			
AB	LEDERLE	5MG	**N19982 002**	JUL 31, 1992
AB +		10MG	**N19982 001**	JUL 31, 1992

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

	BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE			
AB	EON	2.5MG;6.25MG	**N75579 001**	SEP 25, 2000
AB		5MG;6.25MG	**N75579 002**	SEP 25, 2000
AB		10MG;6.25MG	**N75579 003**	SEP 25, 2000
AB	GENEVA PHARMS TECH	2.5MG;6.25MG	**N75527 001**	SEP 25, 2000
AB		5MG;6.25MG	**N75527 003**	SEP 25, 2000
AB		10MG;6.25MG	**N75527 002**	SEP 25, 2000
AB	IVAX PHARMS	2.5MG;6.25MG	**N75632 001**	SEP 27, 2000
AB		5MG;6.25MG	**N75632 002**	SEP 27, 2000
AB		10MG;6.25MG	**N75632 003**	SEP 27, 2000
AB	MYLAN	2.5MG;6.25MG	**N75768 001**	SEP 25, 2000
AB		5MG;6.25MG	**N75768 002**	SEP 25, 2000
AB		10MG;6.25MG	**N75768 003**	SEP 25, 2000
AB	PUREPAC PHARM	2.5MG;6.25MG	**N75672 001**	SEP 25, 2000

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

	BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE			
AB	PUREPAC PHARM	5MG;6.25MG	**N75672 002**	SEP 25, 2000
AB		10MG;6.25MG	**N75672 003**	SEP 25, 2000
AB	TEVA	2.5MG;6.25MG	**N75686 001**	JAN 19, 2001
AB		5MG;6.25MG	**N75686 002**	JAN 19, 2001
AB		10MG;6.25MG	**N75686 003**	JAN 19, 2001
AB	WATSON LABS	2.5MG;6.25MG	**N75469 001**	SEP 25, 2000
AB		5MG;6.25MG	**N75469 002**	SEP 25, 2000
AB		10MG;6.25MG	**N75469 003**	SEP 25, 2000
	ZIAC			
AB	LEDERLE	2.5MG;6.25MG	**N20186 003**	MAR 26, 1993
AB		5MG;6.25MG	**N20186 001**	MAR 26, 1993
AB +		10MG;6.25MG	**N20186 002**	MAR 26, 1993

BITOLTEROL MESYLATE

AEROSOL, METERED; INHALATION

	TORNALATE			
+	SANOFI SYNTHELABO	0.37MG/INH	N18770 001	DEC 28, 1984

SOLUTION; INHALATION

	TORNALATE			
	SANOFI SYNTHELABO	0.2%	N19548 001	FEB 19, 1992

BIVALIRUDIN

INJECTABLE; INTRAVENOUS

	ANGIOMAX			
+	MEDS (TMC)	250MG/VIAL	N20873 001	DEC 15, 2000

FDA data supplied by DrugPatentWatch.com

BLEOMYCIN SULFATE

INJECTABLE; INJECTION

		BLENOXANE			
AP	+	BRISTOL MYERS SQUIBB	**EQ 15 UNITS BASE/VIAL**	**N50443 001**	
AP	+		**EQ 30 UNITS BASE/VIAL**	**N50443 002**	SEP 07, 1995
		BLEOMYCIN			
AP		BEDFORD	**EQ 15 UNITS BASE/VIAL**	**N65042 002**	OCT 17, 2001
AP			**EQ 30 UNITS BASE/VIAL**	**N65042 001**	OCT 17, 2001
AP		FAULDING	**EQ 15 UNITS BASE/VIAL**	**N65031 001**	MAR 10, 2000
AP			**EQ 30 UNITS BASE/VIAL**	**N65031 002**	MAR 10, 2000
AP		GENSIA SICOR PHARMS	**EQ 15 UNITS BASE/VIAL**	**N65033 001**	JUN 27, 2000
AP			**EQ 30 UNITS BASE/VIAL**	**N65033 002**	JUN 27, 2000
		BLEOMYCIN SULFATE			
AP		PHARMACIA AND UPJOHN	**EQ 15 UNITS BASE/VIAL**	**N64084 001**	JUN 01, 1996
AP			**EQ 30 UNITS BASE/VIAL**	**N64084 002**	JUN 01, 1996

BOSENTAN

TABLET; ORAL

	TRACLEER			
	ACTELION	62.5MG	N21290 001	NOV 20, 2001
+		125MG	N21290 002	NOV 20, 2001

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION

		BRETYLIUM TOSYLATE			
AP	+	ABBOTT	**50MG/ML**	**N19033 001**	APR 29, 1986
AP		ELKINS SINN	**50MG/ML**	**N70545 001**	MAY 14, 1986
AP			**50MG/ML**	**N70546 001**	MAY 14, 1986
AP		INTL MEDICATION	**50MG/ML**	**N70119 001**	APR 29, 1986

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION

		BRETYLIUM TOSYLATE			
AP		LUITPOLD	**50MG/ML**	**N70891 001**	JUL 26, 1988
		BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER			
AP	+	ABBOTT	**200MG/100ML**	**N19008 002**	APR 29, 1986
AP	+		**400MG/100ML**	**N19008 003**	APR 29, 1986
AP	+	B BRAUN	**200MG/100ML**	**N19121 002**	APR 29, 1986
AP	+		**400MG/100ML**	**N19121 003**	APR 29, 1986
	+		100MG/100ML	N19121 001	APR 29, 1986
		BRETYLIUM TOSYLATE IN PLASTIC CONTAINER			
AP	+	ABBOTT	**50MG/ML**	**N19030 001**	APR 29, 1986

BRIMONIDINE TARTRATE

SOLUTION/DROPS; OPHTHALMIC

	ALPHAGAN			
+	ALLERGAN	0.2%	N20613 001	SEP 06, 1996
	ALPHAGAN P			
+	ALLERGAN	0.15%	N21262 001	MAR 16, 2001

BRINZOLAMIDE

SUSPENSION/DROPS; OPHTHALMIC

	AZOPT			
+	ALCON	1%	N20816 001	APR 01, 1998

BROMOCRIPTINE MESYLATE

CAPSULE; ORAL

	PARLODEL			
+	NOVARTIS	EQ 5MG BASE	N17962 002	MAR 01, 1982

TABLET; ORAL

	PARLODEL		
+	NOVARTIS	EQ 2.5MG BASE	N17962 001

FDA data supplied by DrugPatentWatch.com

BROMODIPHENHYDRAMINE HYDROCHLORIDE; CODEINE PHOSPHATE

SYRUP; ORAL

	AMBENYL			
AA	+ FORREST LABS	12.5MG/5ML;10MG/5ML	N09319 006	JAN 10, 1984
	BROMANYL			
AA	ALPHARMA	12.5MG/5ML;10MG/5ML	N88343 001	AUG 15, 1984
	MYBANIL			
AA	MORTON GROVE	12.5MG/5ML;10MG/5ML	N88626 001	OCT 12, 1984

BROMPHENIRAMINE MALEATE

ELIXIR; ORAL

	BROMPHENIRAMINE MALEATE			
	+ KV PHARM	2MG/5ML	N85466 001	

INJECTABLE; INJECTION

	BROMPHENIRAMINE MALEATE			
	+ STERIS	10MG/ML	N83821 001	

TABLET; ORAL

	BROMPHENIRAMINE MALEATE			
AA	NYLOS	4MG	N85592 001	
AA	PHOENIX LABS NY	4MG	N85521 001	
AA	PVT FORM	4MG	N85888 001	
	VELTANE			
AA	LANNETT	4MG	N84088 001	

BROMPHENIRAMINE MALEATE; CODEINE PHOSPHATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

SYRUP; ORAL

	BROMANATE DC			
AA	ALPHARMA	2MG/5ML;10MG/5ML; 12.5MG/5ML	N88723 001	FEB 25, 1985
	MYPHETANE DC			
AA	+ MORTON GROVE	2MG/5ML;10MG/5ML; 12.5MG/5ML	N88904 001	FEB 21, 1985

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP; ORAL

	BROMANATE DM			
AA	ALPHARMA	2MG/5ML;10MG/5ML;30MG/5ML	N88722 001	MAR 07, 1985
	BROMFED-DM			
AA	MURO	2MG/5ML;10MG/5ML;30MG/5ML	N89681 001	DEC 22, 1988
	DIMETANE-DX			
AA	+ ROBINS AH	2MG/5ML;10MG/5ML;30MG/5ML	N19279 001	AUG 24, 1984
	MYPHETANE DX			
AA	MORTON GROVE	2MG/5ML;10MG/5ML;30MG/5ML	N88811 001	JUN 07, 1985

BUDESONIDE

AEROSOL, METERED; NASAL

	RHINOCORT			
	+ ASTRAZENECA	0.032MG/INH	N20233 001	FEB 14, 1994

CAPSULE; ORAL

	ENTOCORT EC			
	+ ASTRAZENECA	3MG	N21324 001	OCT 02, 2001

POWDER, METERED; INHALATION

	PULMICORT			
	+ ASTRAZENECA	0.16MG/INH	N20441 002	JUN 24, 1997

SPRAY, METERED; NASAL

	RHINOCORT			
	ASTRAZENECA	0.032MG/INH	N20746 001	OCT 01, 1999
	+	0.064MG/INH	N20746 002	OCT 01, 1999

SUSPENSION; INHALATION

	PULMICORT RESPULES			
	ASTRAZENECA	0.25MG/2ML	N20929 001	AUG 08, 2000
	+	0.5MG/2ML	N20929 002	AUG 08, 2000

FDA data supplied by DrugPatentWatch.com

BUMETANIDE

INJECTABLE; INJECTION

	BUMETANIDE			
AP	ABBOTT	0.25MG/ML	N74160 001	OCT 30, 1997
AP		0.25MG/ML	N74332 001	OCT 31, 1994
AP	BEDFORD	0.25MG/ML	N74441 001	JAN 27, 1995
AP	GENSIA SICOR PHARMS	0.25MG/ML	N74613 001	NOV 18, 1997
	BUMEX			
AP	+ ROCHE	0.25MG/ML	N18226 001	FEB 28, 1983

TABLET; ORAL

	BUMETANIDE			
AB	EON	0.5MG	N74700 001	NOV 21, 1996
AB		1MG	N74700 002	NOV 21, 1996
AB		2MG	N74700 003	NOV 21, 1996
AB	IVAX PHARMS	0.5MG	N74225 001	APR 24, 1995
AB		1MG	N74225 002	APR 24, 1995
AB		2MG	N74225 003	APR 24, 1995
	BUMEX			
AB	ROCHE	0.5MG	N18225 002	FEB 28, 1983
AB		1MG	N18225 001	FEB 28, 1983
AB	+	2MG	N18225 003	JUN 14, 1985

BUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

	BUPIVACAINE HCL			
AP	ABBOTT	0.25%	N18053 002	
AP		0.25%	N70583 001	FEB 17, 1987
AP		0.25%	N70586 001	MAR 03, 1987

BUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

	BUPIVACAINE HCL			
AP	ABBOTT	0.25%	N70590 001	FEB 17, 1987
AP		0.5%	N18053 001	
AP		0.5%	N70584 001	FEB 17, 1986
AP		0.5%	N70597 001	MAR 03, 1987
AP		0.5%	N70609 001	MAR 03, 1987
AP		0.75%	N18053 003	
AP		0.75%	N70585 001	MAR 03, 1987
AP		0.75%	N70587 001	MAR 03, 1987
	BUPIVACAINE HCL KIT			
	ABBOTT	0.075%	N19978 001	SEP 03, 1992
		0.114%	N19978 002	SEP 03, 1992
		0.23%	N19978 003	SEP 03, 1992
	MARCAINE HCL			
AP	+ ABBOTT	0.25%	N16964 001	
AP	+	0.5%	N16964 006	
	MARCAINE HCL PRESERVATIVE FREE			
AP	+ ABBOTT	0.25%	N16964 012	
AP	+	0.5%	N16964 005	
AP	+	0.75%	N16964 009	
	SENSORCAINE			
AP	ASTRAZENECA	0.25%	N18304 001	
AP		0.25%	N70552 001	MAY 21, 1986
AP		0.5%	N18304 002	
AP		0.5%	N70553 001	MAY 21, 1986
AP		0.75%	N18304 003	
AP		0.75%	N70554 001	MAY 21, 1986

INJECTABLE; SPINAL

	BUPIVACAINE			
AP	ABBOTT	0.75%	N71810 001	DEC 11, 1987
	MARCAINE			
AP	+ ABBOTT	0.75%	N18692 001	MAY 04, 1984

FDA data supplied by DrugPatentWatch.com

BUPIVACAINE HYDROCHLORIDE

INJECTABLE; SPINAL

SENSORCAINE

AP	ASTRAZENECA	**0.75%**	**N71202 001** APR 15, 1987	

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE

INJECTABLE; INJECTION

BUPIVACAINE HCL AND EPINEPHRINE

+	ABBOTT	0.25%;0.005MG/ML	N71165 001 JUN 16, 1988	
		0.25%;0.005MG/ML	N71166 001 JUN 16, 1988	
		0.25%;0.005MG/ML	N71167 001 JUN 16, 1988	
+		0.5%;0.005MG/ML	N71168 001 JUN 16, 1988	
		0.5%;0.005MG/ML	N71169 001 JUN 16, 1988	
		0.5%;0.005MG/ML	N71170 001 JUN 16, 1988	
+		0.75%;0.005MG/ML	N71171 001 JUN 16, 1988	

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

MARCAINE HCL W/ EPINEPHRINE

AP	+ ABBOTT	**0.25%;0.0091MG/ML**	**N16964 004**	
AP	+	**0.5%;0.0091MG/ML**	**N16964 008**	

MARCAINE HCL W/ EPINEPHRINE PRESERVATIVE FREE

AP	+ ABBOTT	**0.25%;0.0091MG/ML**	**N16964 013**	
AP	+	**0.5%;0.0091MG/ML**	**N16964 007**	
AP	+	**0.75%;0.0091MG/ML**	**N16964 010**	

SENSORCAINE

AP	ASTRAZENECA	**0.25%;0.0091MG/ML**	**N70966 001** OCT 13, 1987	
AP		**0.25%;0.0091MG/ML**	**N70967 001** OCT 13, 1987	
AP		**0.5%;0.0091MG/ML**	**N18304 004** SEP 02, 1983	
AP		**0.5%;0.0091MG/ML**	**N70968 001** OCT 13, 1987	
AP		**0.75%;0.0091MG/ML**	**N18304 005** SEP 02, 1983	

BUPRENORPHINE HYDROCHLORIDE

INJECTABLE; INJECTION

BUPRENEX

AP	+ RECKITT BENCKISER	**EQ 0.3MG BASE/ML**	**N18401 001**	

BUPRENORPHINE HCL

AP	ABBOTT	**EQ 0.3MG BASE/ML**	**N74137 001** JUN 03, 1996	

BUPROPION HYDROCHLORIDE

TABLET; ORAL

BUPROPION HCL

AB	EON	**75MG**	**N75613 002** OCT 10, 2000	
AB		**100MG**	**N75613 001** OCT 10, 2000	
AB	GENEVA PHARMS TECH	**75MG**	**N75584 001** FEB 07, 2000	
AB		**100MG**	**N75584 002** FEB 07, 2000	
AB	MYLAN	**75MG**	**N75491 001** APR 17, 2000	
AB		**100MG**	**N75491 002** APR 17, 2000	
AB	TEVA	**75MG**	**N75310 001** NOV 29, 1999	
AB		**100MG**	**N75310 002** NOV 29, 1999	

WELLBUTRIN

AB	GLAXOSMITHKLINE	**75MG**	**N18644 002** DEC 30, 1985	
AB	+	**100MG**	**N18644 003** DEC 30, 1985	

TABLET, EXTENDED RELEASE; ORAL

WELLBUTRIN SR

	GLAXOSMITHKLINE	50MG	N20358 001 OCT 04, 1996	
		100MG	N20358 002 OCT 04, 1996	
+		150MG	N20358 003 OCT 04, 1996	

ZYBAN

+	GLAXOSMITHKLINE	150MG	N20711 003 MAY 14, 1997	

FDA data supplied by DrugPatentWatch.com

BUSPIRONE HYDROCHLORIDE

CAPSULE; ORAL

	BUSPAR			
	BRISTOL MYERS SQUIBB	5MG	N21190 001	DEC 20, 2000
		7.5MG	N21190 002	DEC 20, 2000
		10MG	N21190 003	DEC 20, 2000
+		15MG	N21190 004	DEC 20, 2000

TABLET; ORAL

	BUSPAR			
AB	BRISTOL MYERS SQUIBB	**5MG**	**N18731 001**	SEP 29, 1986
AB		**10MG**	**N18731 002**	SEP 29, 1986
AB		**15MG**	**N18731 003**	APR 22, 1996
AB	+	**30MG**	**N18731 004**	APR 22, 1996
	BUSPIRONE HCL			
AB	DANBURY PHARMA	**5MG**	**N74253 001**	MAR 28, 2001
AB		**10MG**	**N74253 002**	MAR 28, 2001
AB	MYLAN	**15MG**	**N75272 003**	MAR 28, 2001
AB	MYLAN TECHNOLOGIES	**30MG**	**N76008 001**	JUN 28, 2001
AB	PAR PHARM	**7.5MG**	**N75467 002**	MAR 28, 2001

BUSULFAN

INJECTABLE; INJECTION

	BUSULFEX			
+	ORPHAN MEDCL	6MG/ML	N20954 001	FEB 04, 1999

TABLET; ORAL

	MYLERAN			
+	GLAXOSMITHKLINE	2MG	N09386 001	

BUTABARBITAL SODIUM

ELIXIR; ORAL

	BUTISOL SODIUM			
+	WALLACE LABS	30MG/5ML	N85380 001	

TABLET; ORAL

	BUTABARBITAL			
AA	BUNDY	**30MG**	**N85550 001**	
	BUTISOL SODIUM			
AA +	WALLACE LABS	**30MG**	**N00793 004**	
+		15MG	N00793 002	
+		50MG	N00793 003	
+		100MG	N00793 005	
	SODIUM BUTABARBITAL			
	MARSHALL PHARMA	16.2MG	N83524 001	
		32.4MG	N83858 001	

BUTALBITAL; *MULTIPLE*

SEE ACETAMINOPHEN; BUTALBITAL
SEE ACETAMINOPHEN; BUTALBITAL; CAFFEINE
SEE ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE
SEE ASPIRIN; BUTALBITAL; CAFFEINE
SEE ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

BUTENAFINE HYDROCHLORIDE

CREAM; TOPICAL

	MENTAX			
+	BERTEK PHARMS	1%	N20524 001	OCT 18, 1996

BUTOCONAZOLE NITRATE

CREAM; VAGINAL

	GYNAZOLE-1			
+	KV PHARM	2%	N19881 001	FEB 07, 1997

BUTORPHANOL TARTRATE

INJECTABLE; INJECTION

	BUTORPHANOL TARTRATE			
AP	ABBOTT	**1MG/ML**	**N75559 001**	MAR 20, 2000

FDA data supplied by DrugPatentWatch.com

BUTORPHANOL TARTRATE

INJECTABLE; INJECTION

	BUTORPHANOL TARTRATE			
AP	ABBOTT	2MG/ML	**N75559 002**	MAR 20, 2000
AP	APOTEX	2MG/ML	**N75697 001**	OCT 23, 2001
AP	BEDFORD	2MG/ML	**N75046 001**	AUG 12, 1998
AP	MERIDIAN MEDCL TECHN	1MG/ML	**N75342 001**	NOV 04, 1999
AP		2MG/ML	**N75342 002**	NOV 04, 1999
	BUTORPHANOL TARTRATE PRESERVATIVE FREE			
AP	ABBOTT	1MG/ML	**N74620 001**	JAN 22, 1997
AP		1MG/ML	**N74626 001**	JAN 23, 1997
AP		2MG/ML	**N74620 002**	JAN 22, 1997
AP		2MG/ML	**N74626 002**	JAN 23, 1997
AP	APOTEX	1MG/ML	**N75695 001**	OCT 23, 2001
AP		2MG/ML	**N75695 002**	OCT 23, 2001
AP	BEDFORD	1MG/ML	**N75045 001**	AUG 12, 1998
AP		2MG/ML	**N75045 002**	AUG 12, 1998
AP	FAULDING	1MG/ML	**N75170 001**	SEP 28, 1998
AP		2MG/ML	**N75170 002**	SEP 28, 1998
	STADOL			
AP +	APOTHECON	2MG/ML	**N17857 004**	
	STADOL PRESERVATIVE FREE			
AP +	APOTHECON	1MG/ML	**N17857 001**	
AP +		2MG/ML	**N17857 002**	

SPRAY, METERED; NASAL

	BUTORPHANOL TARTRATE			
AB	MYLAN	1MG/SPRAY	**N75759 001**	AUG 08, 2001
	STADOL			
AB +	BRISTOL MYERS SQUIBB	1MG/SPRAY	**N19890 001**	DEC 12, 1991

CABERGOLINE

TABLET; ORAL

	DOSTINEX			
+	PHARMACIA AND UPJOHN	0.5MG	N20664 001	DEC 23, 1996

CAFFEINE; *MULTIPLE*

SEE ACETAMINOPHEN; BUTALBITAL; CAFFEINE
SEE ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE
SEE ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE
SEE ASPIRIN; BUTALBITAL; CAFFEINE
SEE ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE
SEE ASPIRIN; CAFFEINE; DIHYDROCODEINE BITARTRATE
SEE ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE
SEE ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE

CAFFEINE; ERGOTAMINE TARTRATE

SUPPOSITORY; RECTAL

	CAFERGOT			
+	NOVARTIS	100MG;2MG	N09000 002	

TABLET; ORAL

	ERCATAB			
AA +	GENEVA PHARMS	**100MG;1MG**	**N84294 001**	
	WIGRAINE			
AA	ORGANON	**100MG;1MG**	**N86562 001**	

CAFFEINE CITRATE

SOLUTION; INTRAVENOUS, ORAL

	CAFCIT			
+	OPR DEVELOP LP	EQ 10MG BASE/ML	N20793 001	SEP 21, 1999

CALCIFEDIOL

CAPSULE; ORAL

	CALDEROL			
	ORGANON	0.02MG	N18312 001	
+		0.05MG	N18312 002	

FDA data supplied by DrugPatentWatch.com

CALCIPOTRIENE

CREAM; TOPICAL
DOVONEX
+ BRISTOL MYERS SQUIBB 0.005% N20554 001 JUL 22, 1996

OINTMENT; TOPICAL
DOVONEX
+ WESTWOOD SQUIBB 0.005% N20273 001 DEC 29, 1993

SOLUTION; TOPICAL
DOVONEX
+ WESTWOOD SQUIBB 0.005% N20611 001 MAR 03, 1997

CALCITONIN, SALMON

INJECTABLE; INJECTION
CALCIMAR
AP + AVENTIS 200 IU/ML N17769 001
MIACALCIN
AP + NOVARTIS 200 IU/ML N17808 002 MAR 29, 1991

SPRAY, METERED; NASAL
MIACALCIN
+ NOVARTIS 200 IU/SPRAY N20313 002 AUG 17, 1995

CALCITRIOL

CAPSULE; ORAL
CALCITRIOL
AB TEVA 0.25 UGM N75765 001 OCT 12, 2001
AB 0.5 UGM N75765 002 OCT 12, 2001

ROCALTROL
AB ROCHE 0.25 UGM N18044 001
AB + 0.5 UGM N18044 002

INJECTABLE; INJECTION
CALCIJEX
+ ABBOTT 0.001MG/ML N18874 001 SEP 25, 1986

CALCITRIOL

INJECTABLE; INJECTION
CALCIJEX
+ ABBOTT 0.002MG/ML N18874 002 SEP 25, 1986

SOLUTION; ORAL
ROCALTROL
+ ROCHE 1 UGM/ML N21068 001 NOV 20, 1998

CALCIUM ACETATE

CAPSULE; ORAL
PHOSLO GELCAPS
+ BRAINTREE EQ 169MG CALCIUM N21160 003 APR 02, 2001

TABLET; ORAL
PHOSLO
+ BRAINTREE EQ 169MG CALCIUM N19976 001 DEC 10, 1990

CALCIUM ACETATE; *MULTIPLE*
SEE AMINO ACIDS; CALCIUM ACETATE; GLYCERIN; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

CALCIUM CHLORIDE

INJECTABLE; INJECTION
CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER
+ ABBOTT 100MG/ML N21117 001 JAN 28, 2000

CALCIUM CHLORIDE; *MULTIPLE*
SEE AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE
SEE AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

FDA data supplied by DrugPatentWatch.com

CALCIUM CHLORIDE; DEXTROSE; GLUTATHIONE DISULFIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

SOLUTION; IRRIGATION

BSS PLUS

AT ALCON **0.154MG/ML;0.92MG/ML;0.184MG/ML; 0.2MG/ML;0.38MG/ML;2.1MG/ML; 7.14MG/ML;0.42MG/ML** **N18469 001**

ENDOSOL EXTRA

AT AKORN **0.154MG/ML;0.92MG/ML;0.184MG/ML; 0.2MG/ML;0.38MG/ML;2.1MG/ML; 7.14MG/ML;0.42MG/ML** **N20079 001** NOV 27, 1991

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN 37MG/100ML;5GM/100ML;31MG/100ML; 120MG/100ML;330MG/100ML; 88MG/100ML N19864 001 JUN 10, 1993

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

INJECTABLE; INJECTION

ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN 35MG/100ML;5GM/100ML;30MG/100ML; 74MG/100ML;640MG/100ML;500MG/100ML; 74MG/100ML N19867 001 DEC 20, 1993

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

PLASMA-LYTE M AND DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE 37MG/100ML;5GM/100ML;30MG/100ML; 119MG/100ML;161MG/100ML;94MG/100ML; 138MG/100ML N17390 001

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SOLUTION; INTRAPERITONEAL

DIALYTE CONCENTRATE W/ DEXTROSE 30% IN PLASTIC CONTAINER

B BRAUN 510MG/100ML;30GM/100ML;200MG/100ML; 9.2GM/100ML;9.6GM/100ML N18807 001 AUG 26, 1983

510MG/100ML;30GM/100ML;200MG/100ML; 9.4GM/100ML;11GM/100ML N18807 003 AUG 26, 1983

DIALYTE CONCENTRATE W/ DEXTROSE 50% IN PLASTIC CONTAINER

B BRAUN 510MG/100ML;50GM/100ML;200MG/100ML; 9.2GM/100ML;9.6GM/100ML N18807 002 AUG 26, 1983

510MG/100ML;50GM/100ML;200MG/100ML; 9.4GM/100ML;11GM/100ML N18807 004 AUG 26, 1983

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

DELFLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

AT FRESENIUS MEDCL **25.7MG/100ML;1.5GM/100ML; 15.2MG/100ML;567MG/100ML; 392MG/100ML** **N18379 002**

AT **25.7MG/100ML;1.5GM/100ML; 15.2MG/100ML;567MG/100ML; 392MG/100ML** **N18883 001** NOV 30, 1984

DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM IN PLASTIC CONTAINER

AT FRESENIUS MEDCL **25.7MG/100ML;1.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML** **N18883 004** NOV 30, 1984

DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER

AT FRESENIUS MEDCL **18.4MG/100ML;1.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML** **N20171 001** AUG 19, 1992

DELFLEX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

AT FRESENIUS MEDCL **25.7MG/100ML;2.5GM/100ML; 15.2MG/100ML;567MG/100ML; 392MG/100ML** **N18379 003**

FDA data supplied by DrugPatentWatch.com

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

DELFLEX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

AT FRESENIUS MEDCL 25.7MG/100ML;2.5GM/100ML; 15.2MG/100ML;567MG/100ML; 392MG/100ML **N18883 002** NOV 30, 1984

DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM IN PLASTIC CONTAINER

AT FRESENIUS MEDCL 25.7MG/100ML;2.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML **N18883 005** NOV 30, 1984

DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER

AT FRESENIUS MEDCL 18.4MG/100ML;2.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML **N20171 002** AUG 19, 1992

DELFLEX W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

AT FRESENIUS MEDCL 25.7MG/100ML;3.5GM/100ML; 15.2MG/100ML;567MG/100ML; 392MG/100ML **N18379 007** JUN 24, 1988

DELFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

AT FRESENIUS MEDCL 25.7MG/100ML;4.25GM/100ML; 15.2MG/100ML;567MG/100ML; 392MG/100ML **N18379 001**

AT 25.7MG/100ML;4.25GM/100ML; 15.2MG/100ML;567MG/100ML; 392MG/100ML **N18883 003** NOV 30, 1984

DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM IN PLASTIC CONTAINER

AT FRESENIUS MEDCL 25.7MG/100ML;4.25GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML **N18883 006** NOV 30, 1984

DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER

AT FRESENIUS MEDCL 18.4MG/100ML;4.25GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML **N20171 003** AUG 19, 1992

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

AT FRESENIUS MEDCL 25.7MG/100ML;1.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML **N18379 004** JUL 07, 1982

DELFLEX-LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

AT FRESENIUS MEDCL 25.7MG/100ML;2.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML **N18379 005** JUL 07, 1982

DELFLEX-LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

AT FRESENIUS MEDCL 25.7MG/100ML;3.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML **N18379 008** JUN 24, 1988

DELFLEX-LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

AT FRESENIUS MEDCL 25.7MG/100ML;4.25GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML **N18379 006** JUL 07, 1982

DIALYTE LM/ DEXTROSE 1.5% IN PLASTIC CONTAINER

B BRAUN 26MG/100ML;1.5GM/100ML;5MG/100ML; 530MG/100ML;450MG/100ML N18460 007 JAN 29, 1986

DIALYTE LM/ DEXTROSE 2.5% IN PLASTIC CONTAINER

B BRAUN 26MG/100ML;2.5GM/100ML;5MG/100ML; 530MG/100ML;450MG/100ML N18460 005 NOV 02, 1983

DIALYTE LM/ DEXTROSE 4.25% IN PLASTIC CONTAINER

B BRAUN 26MG/100ML;4.25GM/100ML;5MG/100ML; 530MG/100ML;450MG/100ML N18460 009 JAN 29, 1986

DIANEAL 137 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

AT BAXTER HLTHCARE 25.7MG/100ML;1.5GM/100ML; 15.2MG/100ML;567MG/100ML; 392MG/100ML **N17512 001**

DIANEAL 137 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

AT BAXTER HLTHCARE 25.7MG/100ML;2.5GM/100ML; 15.2MG/100ML;567MG/100ML; 392MG/100ML **N17512 003**

DIANEAL 137 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

AT BAXTER HLTHCARE 25.7MG/100ML;4.25GM/100ML; 15.2MG/100ML;567MG/100ML; 392MG/100ML **N17512 002**

FDA data supplied by DrugPatentWatch.com

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

AT BAXTER HLTHCARE 18.3MG/100ML;1.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML N20183 001 DEC 04, 1992

DIANEAL LOW CALCIUM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

AT BAXTER HLTHCARE 18.3MG/100ML;2.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML N20183 002 DEC 04, 1992

DIANEAL LOW CALCIUM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

AT BAXTER HLTHCARE 18.3MG/100ML;3.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML N20183 003 DEC 04, 1992

DIANEAL LOW CALCIUM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

AT BAXTER HLTHCARE 18.3MG/100ML;4.25GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML N20183 004 DEC 04, 1992

DIANEAL PD-1 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

AT BAXTER HLTHCARE 25.7MG/100ML;1.5GM/100ML; 15.2MG/100ML;567MG/100ML; 392MG/100ML N17512 007 JUL 09, 1984

DIANEAL PD-1 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

AT BAXTER HLTHCARE 25.7MG/100ML;2.5GM/100ML; 15.2MG/100ML;567MG/100ML; 392MG/100ML N17512 008 JUL 09, 1984

DIANEAL PD-1 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

AT BAXTER HLTHCARE 25.7MG/100ML;3.5GM/100ML; 15.2MG/100ML;567MG/100ML; 392MG/100ML N17512 010 NOV 18, 1985

DIANEAL PD-1 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

AT BAXTER HLTHCARE 25.7MG/100ML;4.25GM/100ML; 15.2MG/100ML;567MG/100ML; 392MG/100ML N17512 009 JUL 09, 1984

DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

AT BAXTER HLTHCARE 18.3MG/100ML;1.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML N17512 004

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

AT BAXTER HLTHCARE 25.7MG/100ML;1.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML N20163 001 DEC 04, 1992

DIANEAL PD-2 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

AT BAXTER HLTHCARE 25.7MG/100ML;2.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML N17512 005

AT 25.7MG/100ML;2.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML N20163 002 DEC 04, 1992

DIANEAL PD-2 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

AT BAXTER HLTHCARE 25.7MG/100ML;3.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML N17512 011 NOV 18, 1985

DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

AT BAXTER HLTHCARE 25.7MG/100ML;4.25GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML N17512 006

AT 25.7MG/100ML;4.25GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML N20163 003 DEC 04, 1992

INPERSOL-LC/LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

AT FRESENIUS 18.4MG/100ML;1.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML N20374 001 JUN 13, 1994

INPERSOL-LC/LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

AT FRESENIUS 18.4MG/100ML;2.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML N20374 002 JUN 13, 1994

INPERSOL-LC/LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

AT FRESENIUS 18.4MG/100ML;3.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML N20374 003 JUN 13, 1994

FDA data supplied by DrugPatentWatch.com

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

INPERSOL-LC/LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

AT	FRESENIUS	18.4MG/100ML;4.25GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML	N20374 004 JUN 13, 1994

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INTRATHECAL

ELLIOTTS B SOLUTION

+	ORPHAN MEDCL	0.2MG/ML;0.8MG/ML;0.3MG/ML;0.3MG/ML; 1.9MG/ML;7.3MG/ML; 0.2MG/ML	N20577 001 SEP 27, 1996

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5% IN ACETATED RINGER'S IN PLASTIC CONTAINER

	B BRAUN	20MG/100ML;5GM/100ML;30MG/100ML; 380MG/100ML;600MG/100ML	N18258 001

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5% AND RINGER'S IN PLASTIC CONTAINER

AP	ABBOTT	33MG/100ML;5GM/100ML;30MG/100ML; 860MG/100ML	N18254 001

DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER

AP	B BRAUN	33MG/100ML;5GM/100ML;30MG/100ML; 860MG/100ML	N18256 001
AP		33MG/100ML;5GM/100ML;30MG/100ML; 860MG/100ML	N20000 001 APR 17, 1992
AP	BAXTER HLTHCARE	33MG/100ML;5GM/100ML;30MG/100ML; 860MG/100ML	N16695 001

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER

	B BRAUN	10MG/100ML;2.5GM/100ML;15MG/100ML; 300MG/100ML;160MG/100ML	N19634 001 FEB 24, 1988

DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP	ABBOTT	20MG/100ML;5GM/100ML;30MG/100ML; 600MG/100ML;310MG/100ML	N17608 001

DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER

AP	B BRAUN	20MG/100ML;5GM/100ML;30MG/100ML; 600MG/100ML;310MG/100ML	N19634 003 FEB 24, 1988

LACTATED RINGER'S AND DEXTROSE 5% IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	20MG/100ML;5GM/100ML;30MG/100ML; 600MG/100ML;310MG/100ML	N16679 001

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

	BAXTER HLTHCARE	20MG/100ML;5GM/100ML;105MG/100ML; 600MG/100ML;310MG/100ML	N19367 002 APR 05, 1985
		20MG/100ML;5GM/100ML;179MG/100ML; 600MG/100ML;310MG/100ML	N19367 003 APR 05, 1985

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	20MG/100ML;5GM/100ML;254MG/100ML; 600MG/100ML;310MG/100ML	N19367 006 APR 05, 1985

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP	ABBOTT	20MG/100ML;5GM/100ML;179MG/100ML; 600MG/100ML;310MG/100ML	N19685 002 OCT 17, 1988
AP		20MG/100ML;5GM/100ML;328MG/100ML; 600MG/100ML;310MG/100ML	N19685 008 OCT 17, 1988
AP	BAXTER HLTHCARE	20MG/100ML;5GM/100ML;179MG/100ML; 600MG/100ML;310MG/100ML	N19367 004 APR 05, 1985
AP		20MG/100ML;5GM/100ML;328MG/100ML; 600MG/100ML;310MG/100ML	N19367 005 APR 05, 1985

FDA data supplied by DrugPatentWatch.com

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	**20MG/100ML;5GM/100ML;254MG/100ML; 600MG/100ML;310MG/100ML**	**N19367 007**	APR 05, 1985

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP	ABBOTT	**20MG/100ML;5GM/100ML;328MG/100ML; 600MG/100ML;310MG/100ML**	**N19685 004**	OCT 17, 1988
AP	BAXTER HLTHCARE	**20MG/100ML;5GM/100ML;328MG/100ML; 600MG/100ML;310MG/100ML**	**N19367 008**	APR 05, 1985

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

	BAXTER HLTHCARE	20MG/100ML;5GM/100ML;105MG/100ML; 600MG/100ML;310MG/100ML	N19367 001	APR 05, 1985

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

TPN ELECTROLYTES IN PLASTIC CONTAINER

	ABBOTT	16.5MG/ML;25.4MG/ML;74.6MG/ML; 121MG/ML;16.1MG/ML	N18895 001 JUL 20, 1984

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

INJECTABLE; INJECTION

ISOLYTE E IN PLASTIC CONTAINER

	B BRAUN	35MG/100ML;30MG/100ML;74MG/100ML; 640MG/100ML;500MG/100ML; 74MG/100ML	N19718 001 SEP 29, 1989

SOLUTION; IRRIGATION

BSS

+	ALCON	0.48MG/ML;0.3MG/ML;0.75MG/ML; 3.9MG/ML;6.4MG/ML; 1.7MG/ML	N20742 001 DEC 10, 1997

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

PLASMA-LYTE R IN PLASTIC CONTAINER

	BAXTER HLTHCARE	36.8MG/100ML;30.5MG/100ML; 74.6MG/100ML;640MG/100ML; 496MG/100ML;89.6MG/100ML	N17438 001

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

SOLUTION; PERFUSION, CARDIAC

CARDIOPLEGIC IN PLASTIC CONTAINER

AT	BAXTER HLTHCARE	**17.6MG/100ML;325.3MG/100ML; 119.3MG/100ML;643MG/100ML**	**N75323 001**	APR 21, 2000

PLEGISOL IN PLASTIC CONTAINER

AT	+	ABBOTT	**17.6MG/100ML;325.3MG/100ML; 119.3MG/100ML;643MG/100ML**	**N18608 001**	FEB 26, 1982

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

RINGER'S IN PLASTIC CONTAINER

AP	ABBOTT	**33MG/100ML;30MG/100ML; 860MG/100ML**	**N18251 001**	
AP	B BRAUN	**33MG/100ML;30MG/100ML; 860MG/100ML**	**N18721 001**	NOV 09, 1982
AP		**33MG/100ML;30MG/100ML; 860MG/100ML**	**N20002 001**	APR 17, 1992
AP	BAXTER HLTHCARE	**33MG/100ML;30MG/100ML; 860MG/100ML**	**N16693 001**	

SOLUTION; IRRIGATION

RINGER'S IN PLASTIC CONTAINER

AT	ABBOTT	**33MG/100ML;30MG/100ML; 860MG/100ML**	**N17635 001**	
AT	B BRAUN	**33MG/100ML;30MG/100ML; 860MG/100ML**	**N18156 001**	
AT	BAXTER HLTHCARE	**33MG/100ML;30MG/100ML; 860MG/100ML**	**N18495 001**	FEB 19, 1982

FDA data supplied by DrugPatentWatch.com

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION
LACTATED RINGER'S IN PLASTIC CONTAINER

AP	ABBOTT	20MG/100ML;30MG/100ML;600MG/100ML; 310MG/100ML	N17641 001
AP	B BRAUN	20MG/100ML;30MG/100ML;600MG/100ML; 310MG/100ML	N19632 001 FEB 29, 1988
AP	BAXTER HLTHCARE	20MG/100ML;30MG/100ML;600MG/100ML; 310MG/100ML	N16682 001

SOLUTION; IRRIGATION
LACTATED RINGER'S IN PLASTIC CONTAINER

AT	ABBOTT	20MG/100ML;30MG/100ML;600MG/100ML; 310MG/100ML	N19416 001 JAN 17, 1986
AT	B BRAUN	20MG/100ML;30MG/100ML;600MG/100ML; 310MG/100ML	N18681 001 DEC 27, 1982
AT	BAXTER HLTHCARE	20MG/100ML;30MG/100ML;600MG/100ML; 310MG/100ML	N18494 001 FEB 19, 1982
AT		20MG/100ML;30MG/100ML;600MG/100ML; 310MG/100ML	N18921 001 APR 03, 1984
AT		20MG/100ML;30MG/100ML;600MG/100ML; 310MG/100ML	N19933 001 AUG 29, 1989

CALFACTANT

SUSPENSION; INTRATRACHEAL
INFASURF PRESERVATIVE FREE

+	ONY	35MG/ML	N20521 001 JUL 01, 1998

CANDESARTAN CILEXETIL

TABLET; ORAL
ATACAND

	ASTRAZENECA	4MG	N20838 001 JUN 04, 1998
		8MG	N20838 002 JUN 04, 1998
		16MG	N20838 003 JUN 04, 1998
+		32MG	N20838 004 JUN 04, 1998

CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL
ATACAND HCT

	ASTRAZENECA	16MG;12.5MG	N21093 001 SEP 05, 2000
+		32MG;12.5MG	N21093 002 SEP 05, 2000

CAPECITABINE

TABLET; ORAL
XELODA

	HLR	150MG	N20896 001 APR 30, 1998
+		500MG	N20896 002 APR 30, 1998

CAPREOMYCIN SULFATE

INJECTABLE; INJECTION
CAPASTAT SULFATE

+	LILLY	EQ 1GM BASE/VIAL	N50095 001

CAPTOPRIL

TABLET; ORAL
CAPOTEN

AB	BRISTOL MYERS SQUIBB	12.5MG	N18343 005 JAN 17, 1985
AB		25MG	N18343 002
AB		50MG	N18343 001
AB +		100MG	N18343 003
	CAPTOPRIL		
AB	APOTHECON	12.5MG	N74472 001 MAR 31, 1995

FDA data supplied by DrugPatentWatch.com

CAPTOPRIL

TABLET; ORAL
CAPTOPRIL

AB	APOTHECON	25MG	N74472 002	MAR 31, 1995
AB		50MG	N74472 003	MAR 31, 1995
AB		100MG	N74472 004	MAR 31, 1995
AB	COPLEY PHARM	12.5MG	N74462 001	FEB 13, 1996
AB		25MG	N74462 002	FEB 13, 1996
AB		50MG	N74462 003	FEB 13, 1996
AB		100MG	N74462 004	FEB 13, 1996
AB	DANBURY PHARMA	12.5MG	N74386 001	MAY 23, 1996
AB		25MG	N74386 002	MAY 23, 1996
AB		50MG	N74386 003	MAY 23, 1996
AB		100MG	N74386 004	MAY 23, 1996
AB	EGIS PHARMS	12.5MG	N74748 004	MAY 29, 1997
AB		25MG	N74748 002	MAY 29, 1997
AB		50MG	N74748 001	MAY 29, 1997
AB		100MG	N74748 003	MAY 29, 1997
AB	ENDO LABS	12.5MG	N74418 001	FEB 13, 1996
AB		25MG	N74418 002	FEB 13, 1996
AB		50MG	N74418 003	FEB 13, 1996
AB		100MG	N74418 004	FEB 13, 1996
AB	EON	12.5MG	N74519 001	FEB 13, 1996
AB		25MG	N74519 002	FEB 13, 1996
AB		50MG	N74519 003	FEB 13, 1996

CAPTOPRIL

TABLET; ORAL
CAPTOPRIL

AB	EON	100MG	N74519 004	FEB 13, 1996
AB	GENEVA PHARMS	12.5MG	N74363 001	NOV 09, 1995
AB		25MG	N74363 002	NOV 09, 1995
AB		50MG	N74363 003	NOV 09, 1995
AB		100MG	N74363 004	NOV 09, 1995
AB	GENEVA PHARMS TECH	12.5MG	N74481 001	FEB 13, 1996
AB		25MG	N74481 002	FEB 13, 1996
AB		50MG	N74481 003	FEB 13, 1996
AB		100MG	N74481 004	FEB 13, 1996
AB	HALLMARK PHARMS	12.5MG	N74477 001	FEB 13, 1996
AB		25MG	N74477 002	FEB 13, 1996
AB		50MG	N74477 003	FEB 13, 1996
AB		100MG	N74477 004	FEB 13, 1996
AB	IVAX PHARMS	12.5MG	N74590 004	AUG 30, 1996
AB		25MG	N74590 002	AUG 30, 1996
AB		50MG	N74590 001	AUG 30, 1996
AB		100MG	N74590 003	AUG 30, 1996
AB	MOVA	12.5MG	N74423 001	FEB 13, 1996
AB		25MG	N74423 002	FEB 13, 1996
AB		50MG	N74423 003	FEB 13, 1996
AB		100MG	N74423 004	FEB 13, 1996
AB	MYLAN	12.5MG	N74434 001	FEB 13, 1996

FDA data supplied by DrugPatentWatch.com

CAPTOPRIL

TABLET; ORAL

CAPTOPRIL				
AB	MYLAN	25MG	**N74434 002**	FEB 13, 1996
AB		50MG	**N74434 003**	FEB 13, 1996
AB		100MG	**N74434 004**	FEB 13, 1996
AB	PAR PHARM	12.5MG	**N74493 001**	FEB 13, 1996
AB		25MG	**N74493 002**	FEB 13, 1996
AB		50MG	**N74493 003**	FEB 13, 1996
AB		100MG	**N74493 004**	FEB 13, 1996
AB	STASON	12.5MG	**N74677 004**	MAY 30, 1997
AB		25MG	**N74677 002**	MAY 30, 1997
AB		50MG	**N74677 001**	MAY 30, 1997
AB		100MG	**N74677 003**	MAY 30, 1997
AB	TEVA	12.5MG	**N74322 001**	FEB 13, 1996
AB		12.5MG	**N74433 001**	FEB 13, 1996
AB		12.5MG	**N74483 001**	FEB 13, 1996
AB		25MG	**N74322 002**	FEB 13, 1996
AB		25MG	**N74433 002**	FEB 13, 1996
AB		25MG	**N74483 002**	FEB 13, 1996
AB		50MG	**N74322 003**	FEB 13, 1996
AB		50MG	**N74433 003**	FEB 13, 1996
AB		50MG	**N74483 003**	FEB 13, 1996
AB		100MG	**N74322 004**	FEB 13, 1996
AB		100MG	**N74433 004**	FEB 13, 1996

CAPTOPRIL

TABLET; ORAL

CAPTOPRIL				
AB	TEVA	100MG	**N74483 004**	FEB 13, 1996
AB	TORPHARM	12.5MG	**N74737 001**	OCT 28, 1998
AB		25MG	**N74737 002**	OCT 28, 1998
AB		50MG	**N74737 003**	OCT 28, 1998
AB		100MG	**N74737 004**	OCT 28, 1998
AB	WATSON LABS	12.5MG	**N74451 001**	FEB 13, 1996
AB		12.5MG	**N74576 001**	APR 23, 1996
AB		25MG	**N74451 002**	FEB 13, 1996
AB		25MG	**N74576 002**	APR 23, 1996
AB		50MG	**N74451 003**	FEB 13, 1996
AB		50MG	**N74576 003**	APR 23, 1996
AB		100MG	**N74451 004**	FEB 13, 1996
AB		100MG	**N74576 004**	APR 23, 1996
AB	WEST WARD	12.5MG	**N74505 001**	FEB 13, 1996
AB		25MG	**N74505 002**	FEB 13, 1996
AB		50MG	**N74505 003**	FEB 13, 1996
AB		100MG	**N74505 004**	FEB 13, 1996
AB	WOCKHARDT	12.5MG	**N74532 001**	MAR 28, 1997
AB		25MG	**N74532 002**	MAR 28, 1997
AB		50MG	**N74532 003**	MAR 28, 1997
AB		100MG	**N74532 004**	MAR 28, 1997

FDA data supplied by DrugPatentWatch.com

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

	CAPOZIDE 25/15			
AB	APOTHECON	25MG;15MG	**N18709 001**	OCT 12, 1984
	CAPOZIDE 25/25			
AB	+ APOTHECON	25MG;25MG	**N18709 002**	OCT 12, 1984
	CAPOZIDE 50/15			
AB	+ APOTHECON	50MG;15MG	**N18709 004**	OCT 12, 1984
	CAPOZIDE 50/25			
AB	APOTHECON	50MG;25MG	**N18709 003**	OCT 12, 1984
	CAPTOPRIL AND HYDROCHLOROTHIAZIDE			
AB	ENDO LABS	25MG;15MG	**N74788 001**	DEC 29, 1997
AB		25MG;25MG	**N74788 002**	DEC 29, 1997
AB		50MG;15MG	**N74788 004**	DEC 29, 1997
AB		50MG;25MG	**N74788 003**	DEC 29, 1997
AB	IVAX PHARMS	25MG;15MG	**N75055 001**	JUN 18, 1998
AB		25MG;25MG	**N75055 002**	JUN 18, 1998
AB		50MG;15MG	**N75055 004**	JUN 18, 1998
AB		50MG;25MG	**N75055 003**	JUN 18, 1998
AB	MYLAN	25MG;15MG	**N74896 001**	DEC 29, 1997
AB		25MG;25MG	**N74896 002**	DEC 29, 1997
AB		50MG;15MG	**N74896 004**	DEC 29, 1997
AB		50MG;25MG	**N74896 003**	DEC 29, 1997
AB	TEVA	25MG;15MG	**N74827 001**	DEC 29, 1997
AB		25MG;25MG	**N74827 002**	DEC 29, 1997
AB		50MG;15MG	**N74827 004**	DEC 29, 1997
AB		50MG;25MG	**N74827 003**	DEC 29, 1997

CARBACHOL

SOLUTION; INTRAOCULAR

	CARBASTAT			
AT	NOVARTIS	0.01%	**N73677 001**	APR 28, 1995
	MIOSTAT			
AT	+ ALCON	0.01%	**N16968 001**	

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE; ORAL

	CARBATROL			
	+ SHIRE LABS	100MG	N20712 003	DEC 22, 1999
	+	200MG	N20712 001	SEP 30, 1997
	+	300MG	N20712 002	SEP 30, 1997

SUSPENSION; ORAL

	CARBAMAZEPINE			
AB	TARO	100MG/5ML	**N75875 001**	DEC 21, 2000
	TEGRETOL			
AB	+ NOVARTIS	100MG/5ML	**N18927 001**	DEC 18, 1987

TABLET; ORAL

	CARBAMAZEPINE			
AB	INWOOD LABS	200MG	**N70231 001**	AUG 14, 1986
AB	PUREPAC PHARM	200MG	**N71696 001**	NOV 09, 1987
AB	SIDMAK LABS NJ	200MG	**N71479 001**	JUL 24, 1987
AB	TARO	200MG	**N74649 001**	OCT 03, 1996
	EPITOL			
AB	TEVA	200MG	**N70541 001**	SEP 17, 1986
	TEGRETOL			
AB	+ NOVARTIS	200MG	**N16608 001**	

TABLET, CHEWABLE; ORAL

	CARBAMAZEPINE			
AB	CARACO	100MG	**N75712 001**	JUL 05, 2001

FDA data supplied by DrugPatentWatch.com

CARBAMAZEPINE

TABLET, CHEWABLE; ORAL

	CARBAMAZEPINE			
AB	TARO PHARM INDS	**100MG**	**N75687 001**	OCT 24, 2000
AB	WARNER CHILCOTT	**100MG**	**N71940 001**	FEB 01, 1988
	EPITOL			
AB	TEVA	**100MG**	**N73524 001**	JUL 29, 1992
	TEGRETOL			
AB	+ NOVARTIS	**100MG**	**N18281 001**	

TABLET, EXTENDED RELEASE; ORAL

TEGRETOL-XR			
NOVARTIS	100MG	N20234 001	MAR 25, 1996
	200MG	N20234 002	MAR 25, 1996
+	400MG	N20234 003	MAR 25, 1996

CARBENICILLIN INDANYL SODIUM

TABLET; ORAL

GEOCILLIN			
+ PFIZER	EQ 382MG BASE	N50435 001	

CARBIDOPA

TABLET; ORAL

LODOSYN			
+ BRISTOL MYERS SQUIBB	25MG	N17830 001	

CARBIDOPA; LEVODOPA

TABLET; ORAL

	CARBIDOPA AND LEVODOPA			
AB	GENEVA PHARMS	**10MG;100MG**	**N73586 001**	JUN 29, 1995
AB		**25MG;100MG**	**N73587 001**	JUN 29, 1995
AB		**25MG;250MG**	**N73620 001**	JUN 29, 1995

CARBIDOPA; LEVODOPA

TABLET; ORAL

	CARBIDOPA AND LEVODOPA			
AB	PUREPAC PHARM	**10MG;100MG**	**N74260 001**	SEP 03, 1993
AB		**25MG;100MG**	**N74260 002**	SEP 03, 1993
AB		**25MG;250MG**	**N74260 003**	SEP 03, 1993
AB	TEVA	**10MG;100MG**	**N73618 001**	AUG 28, 1992
AB		**25MG;100MG**	**N73589 001**	AUG 28, 1992
AB		**25MG;250MG**	**N73607 001**	AUG 28, 1992
	SINEMET			
AB	BRISTOL MYERS SQUIBB	**10MG;100MG**	**N17555 001**	
AB		**25MG;100MG**	**N17555 003**	
AB	+	**25MG;250MG**	**N17555 002**	

TABLET, EXTENDED RELEASE; ORAL

	CARBIDOPA AND LEVODOPA			
AB	MYLAN	**25MG;100MG**	**N75091 002**	APR 21, 2000
AB		**50MG;200MG**	**N75091 001**	SEP 30, 1999
	SINEMET CR			
AB	BRISTOL MYERS SQUIBB	**25MG;100MG**	**N19856 002**	DEC 24, 1992
AB	+	**50MG;200MG**	**N19856 001**	MAY 30, 1991

CARBOPLATIN

INJECTABLE; INJECTION

PARAPLATIN				
+	BRISTOL MYERS SQUIBB	50MG/VIAL	N19880 001	MAR 03, 1989
+		150MG/VIAL	N19880 002	MAR 03, 1989
+		450MG/VIAL	N19880 003	MAR 03, 1989

FDA data supplied by DrugPatentWatch.com

CARBOPROST TROMETHAMINE

INJECTABLE; INJECTION
HEMABATE
+ PHARMACIA AND UPJOHN EQ 0.25MG BASE/ML N17989 001

CARISOPRODOL

TABLET; ORAL
CARISOPRODOL

AA	ABLE	350MG	**N40421 001** JUN 21, 2001
AA	AMIDE PHARM	350MG	**N40188 001** MAR 07, 1997
AA	COREPHARMA	350MG	**N40397 001** SEP 21, 2000
AA	DANBURY PHARMA	350MG	**N87499 001** APR 20, 1982
AA	GENEVA PHARMS	350MG	**N81025 001** APR 13, 1989
AA	MUTUAL PHARM	350MG	**N89346 001** OCT 17, 1991
AA	VINTAGE PHARMS	350MG	**N40245 001** SEP 08, 1997
AA	WATSON LABS	350MG	**N40152 001** DEC 03, 1996
AA		350MG	**N86179 001**
AA	WEST WARD	350MG	**N40124 001** JAN 24, 1996

SOMA

AA +	WALLACE LABS	350MG	**N11792 001**

CARISOPRODOL; *MULTIPLE*
SEE ASPIRIN; CARISOPRODOL
SEE ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

CARMUSTINE

IMPLANT; INTRACRANIAL
GLIADEL

+	GUILFORD PHARMS	7.7MG	N20637 001 SEP 23, 1996

INJECTABLE; INJECTION
BICNU

+	BRISTOL	100MG/VIAL	N17422 001

CARTEOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
CARTEOLOL HCL

AT	ALCON	1%	**N75476 001** JAN 03, 2000
AT	BAUSCH AND LOMB	1%	**N75546 001** JAN 20, 2000

OCUPRESS

AT +	NOVARTIS	1%	**N19972 001** MAY 23, 1990

TABLET; ORAL
CARTROL

	ABBOTT	2.5MG	N19204 001 DEC 28, 1988
	+	5MG	N19204 002 DEC 28, 1988

CARVEDILOL

TABLET; ORAL
COREG

	GLAXOSMITHKLINE	3.125MG	N20297 004 MAY 29, 1997
		6.25MG	N20297 003 SEP 14, 1995
		12.5MG	N20297 002 SEP 14, 1995
	+	25MG	N20297 001 SEP 14, 1995

CASPOFUNGIN ACETATE

INJECTABLE; IV (INFUSION)
CANCIDAS

+	MERCK RES	50MG/VIAL	N21227 001 JAN 26, 2001
+		70MG/VIAL	N21227 002 JAN 26, 2001

CEFACLOR

CAPSULE; ORAL
CECLOR

AB	CEPH INTL	EQ 250MG BASE	**N62205 001**

FDA data supplied by DrugPatentWatch.com

CEFACLOR

CAPSULE; ORAL

	CECLOR			
AB	CEPH INTL	EQ 500MG BASE	N62205 002	
AB	LILLY	EQ 250MG BASE	N50521 001	
AB	+	EQ 500MG BASE	N50521 002	
	CEFACLOR			
AB	IVAX PHARMS	EQ 250MG BASE	N64061 001	APR 27, 1995
AB		EQ 500MG BASE	N64061 002	APR 27, 1995
AB	MARSAM PHARMS LLC	EQ 250MG BASE	N64148 001	MAY 23, 1996
AB		EQ 500MG BASE	N64148 002	MAY 23, 1996
AB	RANBAXY	EQ 250MG BASE	N64156 001	AUG 28, 1997
AB		EQ 500MG BASE	N64156 002	AUG 28, 1997
AB	TEVA	EQ 250MG BASE	N64145 001	JUN 24, 1996
AB		EQ 500MG BASE	N64145 002	JUN 24, 1996

FOR SUSPENSION; ORAL

	CECLOR			
AB	LILLY	EQ 125MG BASE/5ML	N50522 001	
AB		EQ 125MG BASE/5ML	N62206 001	
AB		EQ 187MG BASE/5ML	N62206 003	APR 20, 1988
AB	+	EQ 250MG BASE/5ML	N50522 002	
AB		EQ 250MG BASE/5ML	N62206 002	
AB	+	EQ 375MG BASE/5ML	N62206 004	APR 20, 1988
	CEFACLOR			
AB	IVAX PHARMS	EQ 375MG BASE/5ML	N64070 001	APR 28, 1995
AB	MARSAM PHARMS LLC	EQ 125MG BASE/5ML	N64204 001	FEB 18, 1998
AB		EQ 187MG BASE/5ML	N64205 001	FEB 18, 1998
AB		EQ 250MG BASE/5ML	N64206 001	FEB 18, 1998
AB		EQ 375MG BASE/5ML	N64207 001	FEB 18, 1998
AB	RANBAXY	EQ 125MG BASE/5ML	N64166 001	OCT 02, 1997

CEFACLOR

FOR SUSPENSION; ORAL

	CEFACLOR			
AB	RANBAXY	EQ 187MG BASE/5ML	N64165 001	OCT 02, 1997
AB		EQ 250MG BASE/5ML	N64164 001	OCT 02, 1997
AB		EQ 375MG BASE/5ML	N64155 001	OCT 02, 1997

TABLET, EXTENDED RELEASE; ORAL

	CECLOR CD			
AB	+ LILLY	EQ 500MG BASE	N50673 002	JUN 28, 1996
		EQ 375MG BASE	N50673 001	JUN 28, 1996
	CEFACLOR			
AB	IVAX PHARMS	EQ 500MG BASE	N65057 001	JAN 05, 2001

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE; ORAL

	CEFADROXIL			
AB	APOTHECON	EQ 500MG BASE	N62291 001	
AB	BARR	EQ 500MG BASE	N65015 001	JUN 22, 1999
AB	IVAX PHARMS	EQ 500MG BASE	N62766 001	MAR 03, 1987
	DURICEF			
AB	+ BRISTOL MYERS SQUIBB	EQ 500MG BASE	N50512 001	

FOR SUSPENSION; ORAL

DURICEF			
	BRISTOL MYERS SQUIBB	EQ 125MG BASE/5ML	N50527 002
		EQ 250MG BASE/5ML	N50527 003
+		EQ 500MG BASE/5ML	N50527 001

TABLET; ORAL

	CEFADROXIL			
AB	RANBAXY	EQ 1GM BASE	N65018 001	APR 23, 1999
	DURICEF			
AB	+ BRISTOL MYERS SQUIBB	EQ 1GM BASE	N50528 001	

FDA data supplied by DrugPatentWatch.com

CEFAMANDOLE NAFATE

INJECTABLE; INJECTION

	MANDOL			
+	LILLY	EQ 1GM BASE/VIAL	N50504 002	
+		EQ 2GM BASE/VIAL	N50504 003	
+		EQ 10GM BASE/VIAL	N50504 004	

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

	ANCEF			
AP	+ GLAXOSMITHKLINE	**EQ 500MG BASE/VIAL**	**N50461 002**	
AP	+	**EQ 1GM BASE/VIAL**	**N50461 003**	
AP	+	**EQ 5GM BASE/VIAL**	**N50461 004**	
AP	+	**EQ 10GM BASE/VIAL**	**N50461 005**	
	ANCEF IN PLASTIC CONTAINER			
+	BAXTER HLTHCARE	EQ 10MG BASE/ML	N63002 001	MAR 28, 1991
+		EQ 20MG BASE/ML	N63002 002	MAR 28, 1991
	CEFAZOLIN AND DEXTROSE			
+	B BRAUN	EQ 500MG BASE/VIAL	N50779 001	JUL 27, 2000
+		EQ 1GM BASE/VIAL	N50779 002	JUL 27, 2000
	CEFAZOLIN SODIUM			
AP	AM PHARM PARTNERS	**EQ 1GM BASE/VIAL**	**N64169 002**	AUG 14, 1998
AP		**EQ 10GM BASE/VIAL**	**N64170 001**	MAR 18, 1998
AP		**EQ 20GM BASE/VIAL**	**N64170 002**	MAR 18, 1998
AP		**EQ 500MG BASE/VIAL**	**N64169 001**	AUG 14, 1998
AP	APOTHECON	**EQ 500MG BASE/VIAL**	**N62831 001**	DEC 09, 1988
AP		**EQ 1GM BASE/VIAL**	**N62831 002**	DEC 09, 1988
AP		**EQ 10GM BASE/VIAL**	**N62831 003**	SEP 25, 1992
AP	GLAXOSMITHKLINE	**EQ 1GM BASE/VIAL**	**N64033 001**	OCT 31, 1993
AP	HANFORD GC	**EQ 1GM BASE/VIAL**	**N63207 001**	DEC 27, 1991
AP		**EQ 1GM BASE/VIAL**	**N63208 001**	DEC 27, 1991

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

	CEFAZOLIN SODIUM			
AP	HANFORD GC	**EQ 10GM BASE/VIAL**	**N63209 001**	DEC 27, 1991
AP		**EQ 500MG BASE/VIAL**	**N63214 001**	DEC 27, 1991
AP		**EQ 500MG BASE/VIAL**	**N63216 001**	DEC 27, 1991
AP	MARSAM PHARMS LLC	**EQ 1GM BASE/VIAL**	**N62988 003**	DEC 29, 1989
AP		**EQ 5GM BASE/VIAL**	**N62989 001**	DEC 29, 1989
AP		**EQ 10GM BASE/VIAL**	**N62989 002**	DEC 29, 1989
AP		**EQ 20GM BASE/VIAL**	**N62989 003**	DEC 29, 1989
AP		**EQ 250MG BASE/VIAL**	**N62988 001**	DEC 29, 1989
AP		**EQ 500MG BASE/VIAL**	**N62988 002**	DEC 29, 1989
AP	TEVA	**EQ 5GM BASE/VIAL**	**N63018 001**	MAR 05, 1990
AP		**EQ 10GM BASE/VIAL**	**N63018 002**	MAR 05, 1990
AP	WESTWARD	**EQ 500MG BASE/VIAL**	**N65047 001**	SEP 18, 2001
AP		**EQ 1GM BASE/VIAL**	**N65047 002**	SEP 18, 2001
	KEFZOL			
AP	+ LILLY	**EQ 250MG BASE/VIAL**	**N61773 001**	
AP		**EQ 500MG BASE/VIAL**	**N61773 002**	
AP		**EQ 1GM BASE/VIAL**	**N61773 003**	
AP		**EQ 10GM BASE/VIAL**	**N61773 004**	
AP	+	**EQ 20GM BASE/VIAL**	**N61773 005**	SEP 08, 1987

CEFDINIR

CAPSULE; ORAL

	OMNICEF			
+	ABBOTT	300MG	N50739 001	DEC 04, 1997

FOR SUSPENSION; ORAL

	OMNICEF			
+	ABBOTT	125MG/5ML	N50749 001	DEC 04, 1997

FDA data supplied by DrugPatentWatch.com

CEFDITOREN PIVOXIL

TABLET; ORAL
SPECTRACEF
+ TAP PHARM 200MG N21222 001 AUG 29, 2001

CEFEPIME HYDROCHLORIDE (ARGININE FORMULATION)

INJECTABLE; INJECTION
MAXIPIME
+ BRISTOL MYERS SQUIBB EQ 500MG BASE/VIAL N50679 001 JAN 18, 1996
+ EQ 1GM BASE/VIAL N50679 002 JAN 18, 1996
+ EQ 2GM BASE/VIAL N50679 003 JAN 18, 1996

CEFIXIME

FOR SUSPENSION; ORAL
SUPRAX
+ LEDERLE 100MG/5ML N50622 001 APR 28, 1989

TABLET; ORAL
SUPRAX
+ LEDERLE 200MG N50621 001 APR 28, 1989
+ 400MG N50621 002 APR 28, 1989

CEFMETAZOLE SODIUM

INJECTABLE; INJECTION
ZEFAZONE
+ PHARMACIA AND UPJOHN EQ 1GM BASE/VIAL N50637 001 DEC 11, 1989

CEFOPERAZONE SODIUM

INJECTABLE; INJECTION
CEFOBID
+ PFIZER EQ 1GM BASE/VIAL N50551 001 NOV 18, 1982
+ EQ 2GM BASE/VIAL N50551 002 NOV 18, 1982
+ EQ 10GM BASE/VIAL N50551 003 MAR 05, 1990

CEFOBID IN PLASTIC CONTAINER
+ PFIZER EQ 20MG BASE/ML N50613 002 JUL 31, 1987
+ EQ 40MG BASE/ML N50613 001 JUL 23, 1986

CEFORANIDE

INJECTABLE; INJECTION
PRECEF
+ BRISTOL 500MG/VIAL N50554 001 MAY 24, 1984
+ 1GM/VIAL N50554 002 MAY 24, 1984
+ 2GM/VIAL N50554 003 MAY 24, 1984
+ 10GM/VIAL N50554 004 MAY 24, 1984
+ 20GM/VIAL N50554 005 MAY 24, 1984

CEFOTAXIME SODIUM

INJECTABLE; INJECTION
CEFOTAXIME
AP AM PHARM PARTNERS **EQ 500MG BASE/VIAL** **N64200 001** MAR 24, 2000
AP **EQ 1GM BASE/VIAL** **N64200 002** MAR 24, 2000
AP **EQ 2GM BASE/VIAL** **N64200 003** MAR 24, 2000
AP **EQ 10GM BASE/VIAL** **N64201 001** MAR 24, 2000
+ EQ 20GM BASE/VIAL N64201 002 MAR 24, 2000

CLAFORAN
AP + AVENTIS PHARMS **EQ 500MG BASE/VIAL** **N50547 001**
AP + **EQ 1GM BASE/VIAL** **N50547 002**
AP + **EQ 2GM BASE/VIAL** **N50547 003**

FDA data supplied by DrugPatentWatch.com

CEFOTAXIME SODIUM

INJECTABLE; INJECTION
CLAFORAN

AP	+ AVENTIS PHARMS	**EQ 10GM BASE/VIAL**	**N50547 004**	DEC 29, 1983
		EQ 1GM BASE/VIAL	N62659 001	JAN 13, 1987
		EQ 2GM BASE/VIAL	N62659 002	JAN 13, 1987

CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER

+ AVENTIS PHARMS	EQ 20MG BASE/ML	N50596 002	MAY 20, 1985
+	EQ 40MG BASE/ML	N50596 004	MAY 20, 1985

CLAFORAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

+ AVENTIS PHARMS	EQ 20MG BASE/ML	N50596 001	MAY 20, 1985
+	EQ 40MG BASE/ML	N50596 003	MAY 20, 1985

CEFOTETAN DISODIUM

INJECTABLE; INJECTION
CEFOTAN

+ ASTRAZENECA	EQ 1GM BASE/VIAL	N50588 001	DEC 27, 1985
	EQ 1GM BASE/VIAL	N63293 001	APR 29, 1993
+	EQ 2GM BASE/VIAL	N50588 002	DEC 27, 1985
	EQ 2GM BASE/VIAL	N63293 002	APR 29, 1993
+	EQ 10GM BASE/VIAL	N50588 003	APR 25, 1988

CEFOTAN IN PLASTIC CONTAINER

+ ASTRAZENECA	EQ 20MG BASE/ML	N50694 002	JUL 30, 1993
+	EQ 40MG BASE/ML	N50694 001	JUL 30, 1993

CEFOXITIN SODIUM

INJECTABLE; INJECTION
CEFOXITIN

AP	AM PHARM PARTNERS	**EQ 1GM BASE/VIAL**	**N65012 001**	JUL 03, 2000

CEFOXITIN SODIUM

INJECTABLE; INJECTION
CEFOXITIN

AP	AM PHARM PARTNERS	**EQ 2GM BASE/2VIAL**	**N65012 002**	JUL 03, 2000
AP		**EQ 10GM BASE/VIAL**	**N65011 001**	JUL 03, 2000
AP	ESI LEDERLE	**EQ 1GM BASE/VIAL**	**N65051 001**	SEP 11, 2000
AP		**EQ 2GM BASE/VIAL**	**N65051 002**	SEP 11, 2000
AP		**EQ 10GM BASE/VIAL**	**N65050 001**	SEP 11, 2000

MEFOXIN

AP	+ MERCK	**EQ 1GM BASE/VIAL**	**N50517 001**	
AP		**EQ 1GM BASE/VIAL**	**N62757 001**	JAN 08, 1987
AP	+	**EQ 2GM BASE/VIAL**	**N50517 002**	
AP		**EQ 2GM BASE/VIAL**	**N62757 002**	JAN 08, 1987
AP	+	**EQ 10GM BASE/VIAL**	**N50517 003**	

MEFOXIN IN PLASTIC CONTAINER

MERCK	EQ 20MG BASE/ML	N63182 001	JAN 25, 1993
	EQ 40MG BASE/ML	N63182 002	JAN 25, 1993

CEFPODOXIME PROXETIL

FOR SUSPENSION; ORAL
VANTIN

PHARMACIA AND UPJOHN	EQ 50MG BASE/5ML	N50675 001	AUG 07, 1992
+	EQ 100MG BASE/5ML	N50675 002	AUG 07, 1992

TABLET; ORAL
VANTIN

PHARMACIA AND UPJOHN	EQ 100MG BASE	N50674 001	AUG 07, 1992
+	EQ 200MG BASE	N50674 002	AUG 07, 1992

FDA data supplied by DrugPatentWatch.com

CEFPROZIL

FOR SUSPENSION; ORAL
CEFZIL

	BRISTOL MYERS SQUIBB	125MG/5ML	N50665 001	
			DEC 23, 1991	
+		250MG/5ML	N50665 002	
			DEC 23, 1991	

TABLET; ORAL
CEFZIL

	BRISTOL MYERS SQUIBB	250MG	N50664 001	
			DEC 23, 1991	
+		500MG	N50664 002	
			DEC 23, 1991	

CEFTAZIDIME

INJECTABLE; INJECTION
FORTAZ

AP	+	GLAXOSMITHKLINE	**500MG/VIAL**	**N50578 001**	
				JUL 19, 1985	
AP	+		**1GM/VIAL**	**N50578 002**	
				JUL 19, 1985	
AP	+		**2GM/VIAL**	**N50578 003**	
				JUL 19, 1985	
AP	+		**6GM/VIAL**	**N50578 004**	
				JUL 19, 1985	

TAZICEF

AP	ABBOTT	**500MG/VIAL**	**N62662 001**	
			MAR 06, 1986	
AP		**1GM/VIAL**	**N62662 002**	
			MAR 06, 1986	
AP		**1GM/VIAL**	**N64032 001**	
			OCT 31, 1993	
AP		**2GM/VIAL**	**N62662 003**	
			MAR 06, 1986	
AP		**2GM/VIAL**	**N64032 002**	
			OCT 31, 1993	
AP		**6GM/VIAL**	**N62662 004**	
			MAR 06, 1986	

TAZIDIME

AP	LILLY	**1GM/VIAL**	**N62640 002**	
			NOV 20, 1985	
AP		**1GM/VIAL**	**N62655 001**	
			NOV 20, 1985	
AP		**2GM/VIAL**	**N62640 003**	
			NOV 20, 1985	

CEFTAZIDIME

INJECTABLE; INJECTION
TAZIDIME

AP	LILLY	**2GM/VIAL**	**N62655 002**	
			NOV 20, 1985	
AP		**500MG/VIAL**	**N62640 001**	
			NOV 20, 1985	

CEFTAZIDIME (ARGININE FORMULATION)

INJECTABLE; INJECTION
CEPTAZ

+	GLAXOSMITHKLINE	1GM/VIAL	N50646 002	
			SEP 27, 1990	
+		2GM/VIAL	N50646 003	
			SEP 27, 1990	
+		10GM/VIAL	N50646 004	
			SEP 27, 1990	

CEFTAZIDIME SODIUM

INJECTABLE; INJECTION
CEFTAZIDIME SODIUM IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	**EQ 20MG BASE/ML**	**N63221 002**	
			APR 29, 1993	
AP		**EQ 40MG BASE/ML**	**N63221 003**	
			APR 29, 1993	
+		EQ 10MG BASE/ML	N63221 001	
			APR 29, 1993	

FORTAZ IN PLASTIC CONTAINER

AP	+ GLAXOSMITHKLINE	**EQ 20MG BASE/ML**	**N50634 002**	
			APR 28, 1989	
AP	+	**EQ 40MG BASE/ML**	**N50634 003**	
			APR 28, 1989	

CEFTIBUTEN DIHYDRATE

CAPSULE; ORAL
CEDAX

+	BIOVAIL	EQ 400MG BASE	N50685 002	
			DEC 20, 1995	

FOR SUSPENSION; ORAL
CEDAX

	BIOVAIL	EQ 90MG BASE/5ML	N50686 001	
			DEC 20, 1995	

FDA data supplied by DrugPatentWatch.com

CEFTIBUTEN DIHYDRATE

FOR SUSPENSION; ORAL
CEDAX
+ BIOVAIL — EQ 180MG BASE/5ML — N50686 002 DEC 20, 1995

CEFTIZOXIME SODIUM

INJECTABLE; INJECTION
CEFIZOX
AM PHARM PARTNERS — EQ 1GM BASE/VIAL — N63294 002 MAR 31, 1994
EQ 2GM BASE/VIAL — N63294 003 MAR 31, 1994
+ FUJISAWA HLTHCARE — EQ 500MG BASE/VIAL — N50560 001 SEP 15, 1983
+ EQ 1GM BASE/VIAL — N50560 002 SEP 15, 1983
+ EQ 2GM BASE/VIAL — N50560 003 SEP 15, 1983
EQ 10GM BASE/VIAL — N50560 005 MAR 19, 1993

CEFIZOX IN PLASTIC CONTAINER
+ FUJISAWA HLTHCARE — EQ 20MG BASE/ML — N50589 003 APR 13, 1995
+ EQ 40MG BASE/ML — N50589 004 APR 13, 1995

CEFTRIAXONE SODIUM

INJECTABLE; INJECTION
ROCEPHIN
+ HLR — EQ 250MG BASE/VIAL — N50585 001 DEC 21, 1984
EQ 250MG BASE/VIAL — N63239 001 AUG 13, 1993
+ EQ 500MG BASE/VIAL — N50585 002 DEC 21, 1984
EQ 500MG BASE/VIAL — N63239 002 AUG 13, 1993
+ EQ 1GM BASE/VIAL — N50585 003 DEC 21, 1984
EQ 1GM BASE/VIAL — N62654 002 APR 30, 1987
EQ 1GM BASE/VIAL — N63239 003 AUG 13, 1993

CEFTRIAXONE SODIUM

INJECTABLE; INJECTION
ROCEPHIN
+ HLR — EQ 2GM BASE/VIAL — N50585 004 DEC 21, 1984
EQ 2GM BASE/VIAL — N62654 003 APR 30, 1987
+ EQ 10GM BASE/VIAL — N50585 005 DEC 21, 1984

ROCEPHIN W/ DEXTROSE IN PLASTIC CONTAINER
+ HLR — EQ 20MG BASE/ML — N50624 002 FEB 11, 1987
+ EQ 40MG BASE/ML — N50624 003 FEB 11, 1987

CEFTRIAXONE SODIUM; LIDOCAINE

INJECTABLE; INJECTION
ROCEPHIN KIT
+ HLR — EQ 1GM BASE/VIAL,N/A;N/A, 1% — N50585 006 MAY 08, 1996
+ EQ 500MG BASE/VIAL,N/A;N/A, 1% — N50585 007 MAY 08, 1996

CEFUROXIME AXETIL

FOR SUSPENSION; ORAL
CEFTIN
GLAXOSMITHKLINE — EQ 125MG BASE/5ML — N50672 001 JUN 30, 1994
+ EQ 250MG BASE/5ML — N50672 002 APR 29, 1997

TABLET; ORAL
CEFTIN
GLAXOSMITHKLINE — EQ 125MG BASE — N50605 001 DEC 28, 1987
EQ 250MG BASE — N50605 002 DEC 28, 1987
+ EQ 500MG BASE — N50605 003 DEC 28, 1987

FDA data supplied by DrugPatentWatch.com

CEFUROXIME SODIUM

INJECTABLE; IM-IV

	CEFUROXIME			
AB	AM PHARM PARTNERS	EQ 750MG BASE/VIAL	**N65001 001**	MAY 30, 2001
AB	TEVA	EQ 750MG BASE/VIAL	**N64192 002**	APR 16, 1998
	CEFUROXIME SODIUM			
AB	HANFORD GC	EQ 750MG BASE/VIAL	**N64125 001**	MAY 30, 1997
AB	MARSAM PHARMS LLC	EQ 750MG BASE/VIAL	**N64035 001**	FEB 26, 1993
	KEFUROX			
AB	LILLY	EQ 750MG BASE/VIAL	**N62591 001**	JAN 10, 1986
	ZINACEF			
AB	+ GLAXOSMITHKLINE	EQ 750MG BASE/VIAL	**N50558 002**	OCT 19, 1983

INJECTABLE; INJECTION

	CEFUROXIME			
AP	AM PHARM PARTNERS	EQ 1.5GM BASE/VIAL	**N65001 002**	MAY 30, 2001
AP	TEVA	EQ 1.5GM BASE/VIAL	**N64192 001**	APR 16, 1998
AP		EQ 7.5GM BASE/VIAL	**N64191 001**	APR 16, 1998
	CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER			
	+ B BRAUN	EQ 15MG BASE/ML	N50780 001	FEB 21, 2001
	+	EQ 30MG BASE/ML	N50780 002	FEB 21, 2001
	CEFUROXIME SODIUM			
AP	AM PHARM PARTNERS	EQ 7.5GM BASE/VIAL	**N65002 001**	SEP 28, 1998
AP	HANFORD GC	EQ 1.5GM BASE/VIAL	**N64125 002**	MAY 30, 1997
AP		EQ 7.5GM BASE/VIAL	**N64124 001**	MAY 30, 1997
AP	MARSAM PHARMS LLC	EQ 1.5GM BASE/VIAL	**N64035 002**	FEB 26, 1993
AP		EQ 7.5GM BASE/VIAL	**N64036 001**	FEB 26, 1993
	KEFUROX			
AP	LILLY	EQ 1.5GM BASE/VIAL	**N62591 002**	JAN 10, 1986
AP		EQ 1.5GM BASE/VIAL	**N62592 002**	JAN 10, 1986

CEFUROXIME SODIUM

INJECTABLE; INJECTION

	KEFUROX			
AP	LILLY	EQ 7.5GM BASE/VIAL	**N62591 003**	DEC 17, 1987
	ZINACEF			
AP	+ GLAXOSMITHKLINE	EQ 1.5GM BASE/VIAL	**N50558 003**	OCT 19, 1983
AP	+	EQ 7.5GM BASE/VIAL	**N50558 004**	OCT 23, 1986
	ZINACEF IN PLASTIC CONTAINER			
	+ GLAXOSMITHKLINE	EQ 15MG BASE/ML	N50643 001	APR 28, 1989
	+	EQ 30MG BASE/ML	N50643 002	APR 28, 1989

INJECTABLE; INTRAVENOUS

	KEFUROX			
AP	LILLY	EQ 750MG BASE/VIAL	**N62592 001**	JAN 10, 1986

CELECOXIB

CAPSULE; ORAL

	CELEBREX			
	GD SEARLE LLC	100MG	N20998 001	DEC 31, 1998
	+	200MG	N20998 002	DEC 31, 1998

CELLULOSE SODIUM PHOSPHATE

POWDER; ORAL

	CALCIBIND			
	+ MISSION PHARMA	300GM/BOT	N18757 003	OCT 16, 1984

CEPHALEXIN

CAPSULE; ORAL

	CEPHALEXIN			
AB	APOTHECON	EQ 250MG BASE	**N63063 001**	SEP 29, 1989
AB		EQ 250MG BASE	**N63186 001**	DEC 30, 1994

FDA data supplied by DrugPatentWatch.com

CEPHALEXIN

CAPSULE; ORAL

CEPHALEXIN

AB	APOTHECON	EQ 500MG BASE	N63063 002	SEP 29, 1989
AB		EQ 500MG BASE	N63186 002	DEC 30, 1994
AB	BARR	EQ 250MG BASE	N62773 001	JUN 26, 1987
AB		EQ 500MG BASE	N62775 001	APR 22, 1987
AB	IVAX PHARMS	EQ 250MG BASE	N61969 001	
AB		EQ 500MG BASE	N61969 002	
AB	LABS ATRAL	EQ 250MG BASE	N62713 001	JUL 15, 1988
AB		EQ 500MG BASE	N62713 002	JUL 15, 1988
AB	MJ PHARMS	EQ 250MG BASE	N62791 001	JUN 11, 1987
AB		EQ 500MG BASE	N62791 002	JUN 11, 1987
AB	RANBAXY	EQ 250MG BASE	N65007 001	SEP 16, 1999
AB		EQ 500MG BASE	N65007 002	SEP 16, 1999
AB	STEVENS J	EQ 250MG BASE	N62870 001	MAR 17, 1988
AB	TEVA	EQ 250MG BASE	N62702 001	FEB 13, 1987
AB		EQ 250MG BASE	N62760 001	APR 24, 1987
AB		EQ 250MG BASE	N62821 001	FEB 05, 1988
AB		EQ 500MG BASE	N62702 002	FEB 13, 1987
AB		EQ 500MG BASE	N62761 001	APR 24, 1987

KEFLEX

AB	CEPH INTL	EQ 250MG BASE	N62118 001	
AB		EQ 500MG BASE	N62118 002	
AB	LILLY	EQ 250MG BASE	N50405 002	
AB +		EQ 500MG BASE	N50405 003	

FOR SUSPENSION; ORAL

CEPHALEXIN

AB	APOTHECON	EQ 125MG BASE/5ML	N62986 001	APR 18, 1991

CEPHALEXIN

FOR SUSPENSION; ORAL

CEPHALEXIN

AB	APOTHECON	EQ 250MG BASE/5ML	N62987 001	JUL 25, 1989
AB	BARR	EQ 250MG BASE/5ML	N62777 001	AUG 06, 1987
AB	RANBAXY	EQ 125MG BASE/5ML	N65081 001	JUL 27, 2001
AB		EQ 250MG BASE/5ML	N65081 002	JUL 27, 2001
AB	TEVA	EQ 125MG BASE/5ML	N62703 001	FEB 13, 1987
AB		EQ 125MG BASE/5ML	N62767 001	JUN 16, 1987
AB		EQ 125MG BASE/5ML	N62873 001	MAY 23, 1988
AB		EQ 250MG BASE/5ML	N62703 002	FEB 13, 1987
AB		EQ 250MG BASE/5ML	N62768 001	JUN 16, 1987
AB		EQ 250MG BASE/5ML	N62867 001	APR 15, 1988

KEFLEX

AB	CEPH INTL	EQ 125MG BASE/5ML	N62117 002	
AB +		EQ 250MG BASE/5ML	N62117 003	
+		EQ 100MG BASE/ML	N62117 001	

TABLET; ORAL

CEPHALEXIN

AB	TEVA	EQ 250MG BASE	N63023 001	JAN 12, 1989
AB		EQ 500MG BASE	N63024 001	JAN 12, 1989

KEFLET

AB	LILLY	EQ 250MG BASE	N50440 003	FEB 26, 1987
AB +		EQ 500MG BASE	N50440 001	
+		EQ 1GM BASE	N50440 002	

CEPHALEXIN HYDROCHLORIDE

TABLET; ORAL

KEFTAB

+	LILLY	EQ 500MG BASE	N50614 002	OCT 29, 1987

FDA data supplied by DrugPatentWatch.com

CEPHALOGLYCIN

CAPSULE; ORAL					
KAFOCIN					
+ LILLY	250MG	N50219 001			

CEPHALOTHIN SODIUM

INJECTABLE; INJECTION					
CEPHALOTHIN SODIUM					
AP BRISTOL	**EQ 1GM BASE/VIAL**	**N62464 001**			
		MAY 07, 1984			
AP	**EQ 2GM BASE/VIAL**	**N62464 002**			
		MAY 07, 1984			
AP	**EQ 4GM BASE/VIAL**	**N62464 003**			
		MAY 07, 1984			
KEFLIN					
AP + LILLY	**EQ 1GM BASE/VIAL**	**N50482 001**			
AP +	**EQ 2GM BASE/VIAL**	**N50482 002**			
AP +	**EQ 4GM BASE/VIAL**	**N50482 003**			
+	EQ 20GM BASE/VIAL	N50482 007			

CEPHAPIRIN SODIUM

INJECTABLE; INJECTION					
CEFADYL					
APOTHECON	EQ 500MG BASE/VIAL	N62961 001			
		SEP 20, 1988			
	EQ 1GM BASE/VIAL	N61769 001			
	EQ 1GM BASE/VIAL	N62961 002			
		SEP 20, 1988			
	EQ 2GM BASE/VIAL	N61769 002			
	EQ 2GM BASE/VIAL	N62961 003			
		SEP 20, 1988			
	EQ 4GM BASE/VIAL	N61769 003			
	EQ 4GM BASE/VIAL	N62961 004			
		SEP 20, 1988			

CEPHRADINE

CAPSULE; ORAL					
ANSPOR					
AB GLAXOSMITHKLINE	**250MG**	**N61859 001**			
AB	**500MG**	**N61859 002**			
CEPHRADINE					
AB TEVA	**250MG**	**N62683 001**			
		JAN 09, 1987			

CEPHRADINE

CAPSULE; ORAL					
CEPHRADINE					
AB TEVA	**500MG**	**N62683 002**			
		JAN 09, 1987			
VELOSEF					
AB APOTHECON	**250MG**	**N61764 001**			
AB +	**500MG**	**N61764 002**			
FOR SUSPENSION; ORAL					
ANSPOR					
AB GLAXOSMITHKLINE	**125MG/5ML**	**N61866 001**			
AB	**250MG/5ML**	**N61866 002**			
CEPHRADINE					
AB TEVA	**125MG/5ML**	**N62693 001**			
		JAN 09, 1987			
AB	**250MG/5ML**	**N62693 002**			
		JAN 09, 1987			
VELOSEF '125'					
AB + APOTHECON	**125MG/5ML**	**N61763 001**			
VELOSEF '250'					
AB + APOTHECON	**250MG/5ML**	**N61763 002**			

CERIVASTATIN SODIUM

TABLET; ORAL					
BAYCOL					
BAYER	0.2MG	N20740 003			
		JUN 26, 1997			
	0.3MG	N20740 004			
		JUN 26, 1997			
	0.4MG	N20740 005			
		MAY 24, 1999			
+	0.8MG	N20740 006			
		JUL 24, 2000			

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL					
ZYRTEC					
+ PFIZER	5MG/5ML	N20346 001			
		SEP 27, 1996			
TABLET; ORAL					
ZYRTEC					
PFIZER	5MG	N19835 001			
		DEC 08, 1995			

FDA data supplied by DrugPatentWatch.com

CETIRIZINE HYDROCHLORIDE

TABLET; ORAL
ZYRTEC
+ PFIZER — 10MG — N19835 002 DEC 08, 1995

CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
ZYRTEC-D 12 HOUR
+ PFIZER — 5MG;120MG — N21150 001 AUG 10, 2001

CETRORELIX

INJECTABLE; INJECTION
CETROTIDE
+ SERONO INC — EQ 0.25MG BASE/ML — N21197 001 AUG 11, 2000
+ — EQ 3MG BASE/ML — N21197 002 AUG 11, 2000

CETYL ALCOHOL; COLFOSCERIL PALMITATE; TYLOXAPOL

FOR SUSPENSION; INTRATRACHEAL
EXOSURF NEONATAL
+ GLAXOSMITHKLINE — 12MG/VIAL;108MG/VIAL; 8MG/VIAL — N20044 001 AUG 02, 1990

CEVIMELINE HYDROCHLORIDE

CAPSULE; ORAL
EVOXAC
+ DAIICHI — EQ 30MG BASE — N20989 002 JAN 11, 2000

CHLORAMBUCIL

TABLET; ORAL
LEUKERAN
+ GLAXOSMITHKLINE — 2MG — N10669 002

CHLORAMPHENICOL

CAPSULE; ORAL
MYCHEL
+ ARMENPHARM — 250MG — N60851 001

FOR SOLUTION; OPHTHALMIC
CHLOROMYCETIN
+ PARKEDALE — 25MG/VIAL — N50143 001

OINTMENT; OPHTHALMIC
CHLORAMPHENICOL
AT ALTANA — **1%** — **N60133 001**
CHLOROMYCETIN
AT + PARKEDALE — **1%** — **N50156 001**
CHLOROPTIC S.O.P.
AT ALLERGAN — **1%** — **N61187 001**

SOLUTION/DROPS; OPHTHALMIC
CHLOROPTIC
+ ALLERGAN — 0.5% — N50091 001

SOLUTION/DROPS; OTIC
CHLOROMYCETIN
+ PARKEDALE — 0.5% — N50205 001

CHLORAMPHENICOL; DESOXYRIBONUCLEASE; FIBRINOLYSIN

OINTMENT; TOPICAL
ELASE-CHLOROMYCETIN
+ PARKE DAVIS — 10MG/GM;666 UNITS/GM; 1 UNIT/GM — N50294 001

CHLORAMPHENICOL; HYDROCORTISONE ACETATE

FOR SUSPENSION; OPHTHALMIC
CHLOROMYCETIN HYDROCORTISONE
+ PARKEDALE — 12.5MG/VIAL;25MG/VIAL — N50202 001

CHLORAMPHENICOL PALMITATE

SUSPENSION; ORAL
CHLOROMYCETIN PALMITATE
+ PARKE DAVIS — EQ 150MG BASE/5ML — N50152 001

FDA data supplied by DrugPatentWatch.com

CHLORAMPHENICOL SODIUM SUCCINATE

INJECTABLE; INJECTION

	CHLORAMPHENICOL SODIUM SUCCINATE			
AP	AM PHARM PARTNERS	EQ 1GM BASE/VIAL	N62365 001	
			AUG 25, 1982	
AP	GRUPPO LEPETIT	EQ 1GM BASE/VIAL	N62278 001	
	CHLOROMYCETIN			
AP	+ PARKEDALE	EQ 1GM BASE/VIAL	N50155 001	

CHLORDIAZEPOXIDE; *MULTIPLE*

SEE AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL

	CHLORDIAZEPOXIDE HCL			
AB	BARR	5MG	N84768 001	
AB		10MG	N83116 001	
AB		25MG	N84769 001	
AB	IMPAX LABS	10MG	N85113 001	
AB	USL PHARMA	10MG	N84623 001	
AB	WATSON LABS	5MG	N86383 001	
AB		10MG	N86294 001	
AB		25MG	N86382 001	
	LIBRIUM			
AB	ICN	5MG	N85461 001	
AB		10MG	N85472 001	
AB	+	25MG	N85475 001	

INJECTABLE; INJECTION

	LIBRIUM			
	+ ICN	100MG/AMP	N12301 001	

CHLORHEXIDINE GLUCONATE

SOLUTION; DENTAL

	CHLORHEXIDINE GLUCONATE			
AT	ALPHARMA	0.12%	N74291 001	
			DEC 28, 1995	
AT	HI TECH PHARMA	0.12%	N74356 001	
			MAY 07, 1996	
AT	NOVEX	0.12%	N75561 001	
			NOV 14, 2000	
AT	TEVA	0.12%	N74522 001	
			DEC 15, 1995	

CHLORHEXIDINE GLUCONATE

SOLUTION; DENTAL

	PERIDEX			
AT	+ ZILA	0.12%	N19028 001	
			AUG 13, 1986	
	PERIOGARD			
AT	COLGATE	0.12%	N73695 001	
			JAN 14, 1994	

TABLET; DENTAL

	PERIOCHIP			
	+ DEXCEL PHARMA	2.5MG	N20774 001	
			MAY 15, 1998	

CHLORMEZANONE

TABLET; ORAL

	TRANCOPAL			
	+ SANOFI SYNTHELABO	100MG	N11467 003	
	+	200MG	N11467 005	

CHLOROPROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

	CHLOROPROCAINE HCL			
AP	ABBOTT	2%	N87447 001	
			APR 16, 1982	
AP		3%	N87446 001	
			APR 16, 1982	
AP	BEDFORD	2%	N40273 001	
			SEP 09, 1998	
AP		3%	N40273 002	
			SEP 09, 1998	
	NESACAINE			
	+ ASTRAZENECA	1%	N09435 001	
		2%	N09435 002	
	NESACAINE-MPF			
AP	+ ASTRAZENECA	2%	N09435 006	
			MAY 02, 1996	
AP	+	3%	N09435 007	
			MAY 02, 1996	

FDA data supplied by DrugPatentWatch.com

CHLOROQUINE HYDROCHLORIDE

INJECTABLE; INJECTION

	ARALEN HCL				
	+ SANOFI SYNTHELABO	EQ 40MG BASE/ML	N06002 002		

CHLOROQUINE PHOSPHATE

TABLET; ORAL

	ARALEN				
AA	+ SANOFI SYNTHELABO	**EQ 300MG BASE**	**N06002 001**		
	CHLOROQUINE PHOSPHATE				
AA	+ DANBURY PHARMA	**EQ 150MG BASE**	**N87979 001**		
			DEC 21, 1982		
AA		**EQ 300MG BASE**	**N88030 001**		
			DEC 21, 1982		
AA	IMPAX LABS	**EQ 150MG BASE**	**N80880 001**		
AA	WEST WARD	**EQ 150MG BASE**	**N83082 001**		
AA		**EQ 300MG BASE**	**N83082 002**		
			SEP 17, 1999		

CHLOROTHIAZIDE

SUSPENSION; ORAL

	DIURIL				
	+ MERCK	250MG/5ML	N11870 001		

TABLET; ORAL

	CHLOROTHIAZIDE				
AB	MYLAN	**250MG**	**N84388 001**		
AB		**500MG**	**N84217 001**		
AB	WEST WARD	**250MG**	**N86028 001**		
			JUL 14, 1982		
AB		**500MG**	**N87736 001**		
			JUL 14, 1982		
	DIURIL				
AB	MERCK	**250MG**	**N11145 004**		
AB	+	**500MG**	**N11145 002**		

CHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

	ALDOCLOR-150				
	MERCK	150MG;250MG	N16016 001		
	ALDOCLOR-250				
	+ MERCK	250MG;250MG	N16016 002		

CHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

	CHLOROTHIAZIDE AND RESERPINE				
BP	WEST WARD	250MG;0.125MG	N88557 001		
			DEC 22, 1983		
BP		500MG;0.125MG	N88365 001		
			DEC 22, 1983		
	CHLOROTHIAZIDE-RESERPINE				
BP	MYLAN	250MG;0.125MG	N87744 001		
			MAY 06, 1982		
BP		500MG;0.125MG	N87745 001		
			MAY 06, 1982		
	DIUPRES-250				
BP	MERCK	250MG;0.125MG	N11635 003		
			AUG 26, 1987		
	DIUPRES-500				
BP	+ MERCK	500MG;0.125MG	N11635 006		
			AUG 26, 1987		

CHLOROTHIAZIDE SODIUM

INJECTABLE; INJECTION

	DIURIL				
	+ MERCK	EQ 500MG BASE/VIAL	N11145 005		

CHLOROTRIANISENE

CAPSULE; ORAL

	TACE				
	+ AVENTIS PHARMS	12MG	N08102 004		

CHLOROXINE

SHAMPOO; TOPICAL

	CAPITROL				
	+ WESTWOOD SQUIBB	2%	N17594 001		

CHLORPHENESIN CARBAMATE

TABLET; ORAL

	MAOLATE				
	+ PHARMACIA AND UPJOHN	400MG	N14217 002		

FDA data supplied by DrugPatentWatch.com

CHLORPHENIRAMINE MALEATE

TABLET; ORAL

		CHLORPHENIRAMINE MALEATE			
AA	+	ICN	**4MG**	**N80598 001**	
AA		MARSHALL PHARMA	**4MG**	**N83286 001**	
AA		PHOENIX LABS NY	**4MG**	**N85522 001**	
AA		SUPERPHARM	**4MG**	**N87747 001**	
				APR 20, 1982	
AA		TABLICAPS	**4MG**	**N83394 001**	

CHLORPHENIRAMINE POLISTIREX; HYDROCODONE POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL

		TUSSIONEX		
	+	CELLTECH PHARMS	EQ 8MG MALEATE/5ML; EQ 10MG BITARTRATE/5ML	N19111 001
				DEC 31, 1987

CHLORPROMAZINE

SUPPOSITORY; RECTAL

		THORAZINE		
	+	GLAXOSMITHKLINE	25MG	N09149 024
	+		100MG	N09149 033

CHLORPROMAZINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

		THORAZINE		
	+	GLAXOSMITHKLINE	30MG	N11120 016
	+		75MG	N11120 017
	+		150MG	N11120 018
	+		200MG	N11120 019
	+		300MG	N11120 020

CONCENTRATE; ORAL

		CHLORPROMAZINE HCL		
AA		ALPHARMA	**100MG/ML**	**N86863 001**
AA		PHARM ASSOC	**30MG/ML**	**N40231 001**
				DEC 30, 1999
AA			**100MG/ML**	**N40224 001**
				JAN 26, 1999
		CHLORPROMAZINE HCL INTENSOL		
AA		ROXANE	**30MG/ML**	**N88157 001**
				APR 27, 1983

CHLORPROMAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

		CHLORPROMAZINE HCL INTENSOL		
AA		ROXANE	**100MG/ML**	**N88158 001**
				APR 27, 1983
		SONAZINE		
AA		GENEVA PHARMS	**30MG/ML**	**N80983 004**
AA			**100MG/ML**	**N80983 005**
		THORAZINE		
AA	+	GLAXOSMITHKLINE	**30MG/ML**	**N09149 032**
AA	+		**100MG/ML**	**N09149 043**

INJECTABLE; INJECTION

		CHLORPROMAZINE HCL		
AP		ELKINS SINN PHARM	**25MG/ML**	**N83329 001**
		THORAZINE		
AP	+	GLAXOSMITHKLINE	**25MG/ML**	**N09149 011**

SYRUP; ORAL

		SONAZINE		
AA		GENEVA PHARMS	**10MG/5ML**	**N83040 001**
		THORAZINE		
AA	+	GLAXOSMITHKLINE	**10MG/5ML**	**N09149 022**

TABLET; ORAL

		CHLORPROMAZINE HCL		
BP		GENEVA PHARMS	10MG	N80439 001
BP			25MG	N80439 002
BP			50MG	N80439 003
BP			100MG	N80439 004
BP			200MG	N80439 005
BP		LEDERLE	10MG	N84803 001
BP		USL PHARMA	10MG	N83386 001
BP			25MG	N84112 001
BP			50MG	N84113 001
BP			100MG	N84114 001
BP			200MG	N84115 001
		THORAZINE		
BP	+	GLAXOSMITHKLINE	10MG	N09149 002
BP			25MG	N09149 007
BP			50MG	N09149 013
BP	+		100MG	N09149 018
BP			200MG	N09149 020

FDA data supplied by DrugPatentWatch.com

CHLORPROPAMIDE

TABLET; ORAL

CHLORPROPAMIDE

AB	DANBURY PHARMA	100MG	N88852 001	SEP 26, 1984
AB		250MG	N88826 001	SEP 26, 1984
AB	GENEVA PHARMS	100MG	N88725 001	AUG 31, 1984
AB		250MG	N88726 001	AUG 31, 1984
AB	LEDERLE	100MG	N89561 001	SEP 04, 1987
AB		250MG	N89562 001	SEP 04, 1987
AB	MYLAN	100MG	N88548 001	JUN 01, 1984
AB		250MG	N88549 001	JUN 01, 1984
AB	PAR PHARM	100MG	N88175 001	FEB 27, 1984
AB		250MG	N88176 001	FEB 27, 1984
AB	SIDMAK LABS NJ	100MG	N88921 001	APR 12, 1985
AB		250MG	N88922 001	APR 12, 1985
AB	SUPERPHARM	100MG	N88694 001	SEP 17, 1984

DIABINESE

AB	PFIZER	100MG	N11641 003	
AB	+	250MG	N11641 006	

CHLORTETRACYCLINE HYDROCHLORIDE

OINTMENT; OPHTHALMIC

AUREOMYCIN

+	LEDERLE	1%	N50404 001	

CHLORTHALIDONE

TABLET; ORAL

CHLORTHALIDONE

AB	GENEVA PHARMS	50MG	N87381 001	
AB	IVAX PHARMS	25MG	N88164 001	JAN 09, 1984

CHLORTHALIDONE

TABLET; ORAL

CHLORTHALIDONE

AB	IVAX PHARMS	50MG	N87176 001	
AB	MUTUAL PHARM	25MG	N89285 001	JUL 21, 1986
AB		50MG	N89286 001	JUL 21, 1986
AB	MYLAN	25MG	N87180 001	
AB		50MG	N86831 001	
AB	SIDMAK LABS NJ	25MG	N88902 001	SEP 19, 1985
AB		50MG	N88903 001	SEP 19, 1985
AB	USL PHARMA	25MG	N89051 001	JUN 01, 1987
AB	WATSON LABS	25MG	N87100 001	

HYGROTON

AB	AVENTIS PHARMS	25MG	N12283 004	
AB	+	50MG	N12283 003	

THALITONE

BX	MONARCH PHARMS	25MG	N19574 002	FEB 12, 1992
	+	15MG	N19574 001	DEC 20, 1988

CHLORTHALIDONE; *MULTIPLE*

SEE ATENOLOL; CHLORTHALIDONE

SEE BETAXOLOL HYDROCHLORIDE; CHLORTHALIDONE

CHLORTHALIDONE; CLONIDINE HYDROCHLORIDE

TABLET; ORAL

CLONIDINE HCL AND CHLORTHALIDONE

AB	PAR PHARM	15MG;0.1MG	N71179 001	DEC 16, 1987
AB		15MG;0.2MG	N71178 001	DEC 16, 1987
AB		15MG;0.3MG	N71142 001	DEC 16, 1987

CLORPRES

AB	MYLAN	15MG;0.1MG	N71323 001	FEB 09, 1987
AB		15MG;0.2MG	N71324 001	FEB 09, 1987

FDA data supplied by DrugPatentWatch.com

CHLORTHALIDONE; CLONIDINE HYDROCHLORIDE

TABLET; ORAL

	CLORPRES			
AB	MYLAN	15MG;0.3MG	N71325 001	FEB 09, 1987
	COMBIPRES			
AB	BOEHRINGER INGELHEIM	15MG;0.1MG	N17503 001	
AB		15MG;0.2MG	N17503 002	
AB +		15MG;0.3MG	N17503 003	APR 10, 1984

CHLORTHALIDONE; RESERPINE

TABLET; ORAL

	DEMI-REGROTON		
	AVENTIS PHARMS	25MG;0.125MG	N15103 002
	REGROTON		
+	AVENTIS PHARMS	50MG;0.25MG	N15103 001

CHLORZOXAZONE

TABLET; ORAL

	CHLORZOXAZONE			
AA	AMIDE PHARM	250MG	N88928 001	MAY 08, 1987
AA		500MG	N40113 001	SEP 29, 1995
AA	BARR	500MG	N89895 001	MAY 04, 1988
AA	GENEVA PHARMS	250MG	N89852 001	MAY 04, 1988
AA		500MG	N89853 001	MAY 04, 1988
AA	MUTUAL PHARM	500MG	N89970 001	SEP 27, 1990
AA	OHM LABS	250MG	N81298 001	DEC 29, 1993
AA		500MG	N81299 001	DEC 29, 1993
AA	PAR PHARM	250MG	N87981 001	SEP 20, 1983
AA	TEVA	500MG	N89859 001	MAY 04, 1988
AA	WATSON LABS	500MG	N40137 001	AUG 09, 1996

CHLORZOXAZONE

TABLET; ORAL

	CHLORZOXAZONE			
AA	WATSON LABS	500MG	N81040 001	AUG 22, 1989
	PARAFON FORTE DSC			
AA +	JOHNSON RW	500MG	N11529 002	JUN 15, 1987
	STRIFON FORTE DSC			
AA	FERNDALE LABS	500MG	N81008 001	DEC 23, 1988

CHOLECALCIFEROL; *MULTIPLE*

SEE ALPHA-TOCOPHEROL; ASCORBIC ACID; BIOTIN, D-; CHOLECALCIFEROL; CYANOCOBALAMIN; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A

SEE ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE

SEE ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

CHOLESTYRAMINE

POWDER; ORAL

	CHOLESTYRAMINE			
AB	COPLEY PHARM	EQ 4GM RESIN/PACKET	N74554 001	OCT 02, 1996
AB		EQ 4GM RESIN/SCOOPFUL	N74554 002	OCT 02, 1996
AB	EON	EQ 4GM RESIN/PACKET	N74557 001	AUG 15, 1996
AB		EQ 4GM RESIN/SCOOPFUL	N74557 002	AUG 15, 1996
AB	IVAX PHARMS	EQ 4GM RESIN/PACKET	N74771 001	JUL 09, 1997
AB		EQ 4GM RESIN/SCOOPFUL	N74771 002	JUL 09, 1997
AB	TEVA	EQ 4GM RESIN/PACKET	N74347 001	MAY 28, 1998

FDA data supplied by DrugPatentWatch.com

CHOLESTYRAMINE

POWDER; ORAL

	CHOLESTYRAMINE			
AB	TEVA	EQ 4GM RESIN/SCOOPFUL	N74347 002	
			MAY 28, 1998	
	CHOLESTYRAMINE LIGHT			
AB	COPLEY PHARM	EQ 4GM RESIN/PACKET	N74555 001	
			SEP 30, 1998	
AB		EQ 4GM RESIN/SCOOPFUL	N74555 002	
			SEP 30, 1998	
AB	EON	EQ 4GM RESIN/PACKET	N74558 001	
			AUG 15, 1996	
AB		EQ 4GM RESIN/SCOOPFUL	N74558 002	
			AUG 15, 1996	
AB	TEVA	EQ 4GM RESIN/PACKET	N74348 001	
			MAY 28, 1998	
AB		EQ 4GM RESIN/SCOOPFUL	N74348 002	
			MAY 28, 1998	
	LOCHOLEST			
AB	EON	EQ 4GM RESIN/PACKET	N74561 001	
			AUG 15, 1996	
AB		EQ 4GM RESIN/SCOOPFUL	N74561 002	
			AUG 15, 1996	
	LOCHOLEST LIGHT			
AB	EON	EQ 4GM RESIN/PACKET	N74562 001	
			AUG 15, 1996	
AB		EQ 4GM RESIN/SCOOPFUL	N74562 002	
			AUG 15, 1996	
	PREVALITE			
AB	UPSHER SMITH	EQ 4GM RESIN/PACKET	N73263 001	
			FEB 22, 1996	
	QUESTRAN			
AB	+ BRISTOL MYERS	EQ 4GM RESIN/PACKET	N16640 001	
AB		EQ 4GM RESIN/SCOOPFUL	N16640 003	
	QUESTRAN LIGHT			
AB	BRISTOL MYERS	EQ 4GM RESIN/PACKET	N19669 001	
			DEC 05, 1988	
AB		EQ 4GM RESIN/SCOOPFUL	N19669 003	
			DEC 05, 1988	

TABLET; ORAL

	QUESTRAN		
+	APOTHECON	EQ 800MG RESIN	N73403 002
			DEC 27, 1999

CHORIOGONADOTROPIN ALFA

INJECTABLE; INJECTION

	OVIDREL		
+	SERONO	0.25MG/VIAL	N21149 001
			SEP 20, 2000

CHROMIC CHLORIDE

INJECTABLE; INJECTION

	CHROMIC CHLORIDE IN PLASTIC CONTAINER		
+	ABBOTT	EQ 0.004MG CHROMIUM/ML	N18961 001
			JUN 26, 1986

CHROMIC PHOSPHATE, P-32

INJECTABLE; INJECTION

	PHOSPHOCOL P32		
+	MALLINCKRODT	5mCi/ML	N17084 001

CHYMOPAPAIN

INJECTABLE; INJECTION

	CHYMODIACTIN		
+	ABBOTT	4,000 UNITS/VIAL	N18663 002
			AUG 21, 1984

CHYMOTRYPSIN

FOR SOLUTION; OPHTHALMIC

	ZOLYSE		
+	ALCON	750 UNITS/VIAL	N11903 001

CICLOPIROX

CREAM; TOPICAL

	LOPROX		
+	MEDICIS	0.77%	N18748 001
			DEC 30, 1982

GEL; TOPICAL

	LOPROX		
+	MEDICIS	0.77%	N20519 001
			JUL 21, 1997

FDA data supplied by DrugPatentWatch.com

CICLOPIROX

LOTION; TOPICAL				
LOPROX				
+ MEDICIS	0.77%	N19824 001 DEC 30, 1988		
SOLUTION; TOPICAL				
PENLAC				
+ AVENTIS PHARMS	8%	N21022 001 DEC 17, 1999		

CIDOFOVIR

INJECTABLE; INJECTION				
VISTIDE				
+ GILEAD	EQ 75MG BASE/ML	N20638 001 JUN 26, 1996		

CILASTATIN SODIUM; IMIPENEM

INJECTABLE; INJECTION				
PRIMAXIN				
+ MERCK	EQ 250MG BASE/VIAL; 250MG/VIAL	N50587 001 NOV 26, 1985		
	EQ 250MG BASE/VIAL; 250MG/VIAL	N62756 001 JAN 08, 1987		
+	EQ 500MG BASE/VIAL; 500MG/VIAL	N50587 002 NOV 26, 1985		
	EQ 500MG BASE/VIAL; 500MG/VIAL	N50630 001 DEC 14, 1990		
	EQ 500MG BASE/VIAL; 500MG/VIAL	N62756 002 JAN 08, 1987		
+	EQ 750MG BASE/VIAL; 750MG/VIAL	N50630 002 DEC 14, 1990		

CILOSTAZOL

TABLET; ORAL				
PLETAL				
OTSUKA	50MG	N20863 001 JAN 15, 1999		
+	100MG	N20863 002 JAN 15, 1999		

CIMETIDINE

SOLUTION; ORAL				
CIMETIDINE HCL				
AA DURAMED	**300MG/5ML**	**N75110 001** JUN 18, 1998		
TABLET; ORAL				
CIMETIDINE				
AB DANBURY PHARMA	**200MG**	**N74349 001** AUG 30, 1996		
AB	**300MG**	**N74349 002** AUG 30, 1996		
AB	**400MG**	**N74349 003** AUG 30, 1996		
AB	**800MG**	**N74316 001** FEB 28, 1996		
AB ENDO PHARMS	**200MG**	**N74281 001** MAY 17, 1994		
AB	**300MG**	**N74281 002** MAY 17, 1994		
AB	**400MG**	**N74281 003** MAY 17, 1994		
AB	**800MG**	**N74329 001** MAY 17, 1994		
AB GENEVA PHARMS	**200MG**	**N74100 001** JAN 31, 1995		
AB	**300MG**	**N74100 002** JAN 31, 1995		
AB	**400MG**	**N74100 003** JAN 31, 1995		
AB	**800MG**	**N74100 004** JAN 31, 1995		
AB GENEVA PHARMS TECH	**200MG**	**N74506 001** JAN 24, 1996		
AB	**300MG**	**N74506 002** JAN 24, 1996		
AB	**400MG**	**N74506 003** JAN 24, 1996		

FDA data supplied by DrugPatentWatch.com

CIMETIDINE

TABLET; ORAL

CIMETIDINE

AB	GENEVA PHARMS TECH	800MG	N74506 004	JAN 24, 1996
AB	IVAX PHARMS	200MG	N74401 001	MAY 30, 1995
AB		200MG	N74424 001	JUL 28, 1995
AB		300MG	N74401 002	MAY 30, 1995
AB		300MG	N74424 002	JUL 28, 1995
AB		400MG	N74401 003	MAY 30, 1995
AB		400MG	N74424 003	JUL 28, 1995
AB		800MG	N74402 001	MAY 30, 1995
AB		800MG	N74424 004	JUL 28, 1995
AB	MOVA	300MG	N74340 001	JUN 23, 1995
AB		400MG	N74340 002	JUN 23, 1995
AB		800MG	N74339 001	JUN 23, 1995
AB	MYLAN	200MG	N74246 001	MAY 17, 1994
AB		300MG	N74246 002	MAY 17, 1994
AB		400MG	N74246 003	MAY 17, 1994
AB		800MG	N74246 004	MAY 17, 1994
AB	SIDMAK LABS NJ	200MG	N74568 001	FEB 27, 1997
AB		300MG	N74568 002	FEB 27, 1997
AB		400MG	N74568 003	FEB 27, 1997
AB		800MG	N74566 001	FEB 27, 1997
AB	TEVA	200MG	N74151 001	MAY 17, 1994
AB		200MG	N74365 001	FEB 28, 1995

CIMETIDINE

TABLET; ORAL

CIMETIDINE

AB	TEVA	300MG	N74151 002	MAY 17, 1994
AB		300MG	N74365 002	FEB 28, 1995
AB		400MG	N74151 003	MAY 17, 1994
AB		400MG	N74365 003	FEB 28, 1995
AB		800MG	N74365 004	FEB 28, 1995
AB		800MG	N74463 001	MAY 17, 1994
AB	TORPHARM	200MG	N74890 001	DEC 18, 1998
AB		300MG	N74890 002	DEC 18, 1998
AB		400MG	N74890 003	DEC 18, 1998
AB		800MG	N74890 004	DEC 18, 1998

TAGAMET

AB	GLAXOSMITHKLINE	200MG	N17920 002	
AB		300MG	N17920 003	
AB		400MG	N17920 004	DEC 14, 1983
AB +		800MG	N17920 005	APR 30, 1986

CIMETIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

CIMETIDINE HCL

AP	ABBOTT	EQ 300MG BASE/2ML	N74296 001	MAR 28, 1997
AP		EQ 300MG BASE/2ML	N74344 001	JAN 31, 1995
AP		EQ 300MG BASE/2ML	N74345 001	JAN 31, 1995
AP		EQ 300MG BASE/2ML	N74412 001	MAR 28, 1997
AP		EQ 300MG BASE/2ML	N74422 001	JAN 31, 1995
AP	ENDO PHARMS	EQ 300MG BASE/2ML	N74005 001	AUG 31, 1994

FDA data supplied by DrugPatentWatch.com

CIMETIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

CIMETIDINE HCL

AP		GENSIA SICOR PHARMS	EQ 300MG BASE/2ML	N74252 001 NOV 26, 1997
AP		LUITPOLD	EQ 300MG BASE/2ML	N74353 001 DEC 20, 1994
AP		MOVA	EQ 300MG BASE/2ML	N74428 001 APR 25, 1996

CIMETIDINE HCL IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP		ABBOTT	EQ 6MG BASE/ML	N74269 001 DEC 27, 1994
	+		EQ 90MG BASE/100ML	N74468 005 DEC 29, 1994
	+		EQ 120MG BASE/100ML	N74468 006 DEC 29, 1994
	+		EQ 180MG BASE/100ML	N74468 003 DEC 29, 1994
	+		EQ 240MG BASE/100ML	N74468 004 DEC 29, 1994
	+		EQ 360MG BASE/100ML	N74468 001 DEC 29, 1994
	+		EQ 480MG BASE/100ML	N74468 002 DEC 29, 1994

TAGAMET

AP	+	GLAXOSMITHKLINE	EQ 300MG BASE/2ML	N17939 002

TAGAMET HCL IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	+	GLAXOSMITHKLINE	EQ 6MG BASE/ML	N19434 001 OCT 31, 1985

SOLUTION; ORAL

CIMETIDINE HCL

AA		ALPHARMA	EQ 300MG BASE/5ML	N74176 001 JUN 01, 1994
AA		COPLEY PHARM	EQ 300MG BASE/5ML	N74859 001 JUL 09, 1998
AA		ENDO PHARMS	EQ 300MG BASE/5ML	N74251 001 DEC 22, 1994
AA		HI TECH PHARMA	EQ 300MG BASE/5ML	N74664 001 OCT 28, 1997
AA		MORTON GROVE	EQ 300MG BASE/5ML	N74757 001 OCT 17, 1997
AA		NOVEX	EQ 300MG BASE/5ML	N75560 001 MAR 15, 2000
AA		PHARM ASSOC	EQ 300MG BASE/5ML	N74553 001 JAN 27, 1997
AA		ROXANE	EQ 300MG BASE/5ML	N74541 001 AUG 05, 1997

CIMETIDINE HYDROCHLORIDE

SOLUTION; ORAL

CIMETIDINE HCL

AA		TEVA	EQ 300MG BASE/5ML	N74610 001 SEP 26, 1996

TAGAMET

AA	+	GLAXOSMITHKLINE	EQ 300MG BASE/5ML	N17924 001

CINOXACIN

CAPSULE; ORAL

CINOBAC

		LILLY	250MG	N18067 001
	+		500MG	N18067 002

CIPROFLOXACIN

FOR SUSPENSION; ORAL

CIPRO

		BAYER	250MG/5ML	N20780 001 SEP 26, 1997
	+		500MG/5ML	N20780 002 SEP 26, 1997

INJECTABLE; INJECTION

CIPRO

	+	BAYER	10MG/ML	N19847 001 DEC 26, 1990

CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER

	+	BAYER	200MG/100ML	N19857 001 DEC 26, 1990

CIPROFLOXACIN HYDROCHLORIDE

OINTMENT; OPHTHALMIC

CILOXAN

	+	ALCON	EQ 0.3% BASE	N20369 001 MAR 30, 1998

SOLUTION/DROPS; OPHTHALMIC

CILOXAN

	+	ALCON	EQ 0.3% BASE	N19992 001 DEC 31, 1990

FDA data supplied by DrugPatentWatch.com

CIPROFLOXACIN HYDROCHLORIDE

TABLET; ORAL
CIPRO

	BAYER	EQ 100MG BASE	N19537 001	APR 08, 1996
		EQ 250MG BASE	N19537 002	OCT 22, 1987
		EQ 500MG BASE	N19537 003	OCT 22, 1987
+		EQ 750MG BASE	N19537 004	OCT 22, 1987

CIPROFLOXACIN HYDROCHLORIDE; HYDROCORTISONE

SUSPENSION/DROPS; OTIC
CIPRO HC

+	ALCON	EQ 0.2% BASE;1%	N20805 001	FEB 10, 1998

CISATRACURIUM BESYLATE

INJECTABLE; INJECTION
NIMBEX

+	ABBOTT	EQ 2MG BASE/ML	N20551 001	DEC 15, 1995

NIMBEX PRESERVATIVE FREE

+	ABBOTT	EQ 2MG BASE/ML	N20551 003	DEC 15, 1995
+		EQ 10MG BASE/ML	N20551 002	DEC 15, 1995

CISPLATIN

INJECTABLE; INJECTION
CISPLATIN

AP	AM PHARM PARTNERS	**1MG/ML**	**N74735 001**	JUL 16, 1999
AP	BEDFORD	**1MG/ML**	**N75036 001**	NOV 07, 2000
AP		**10MG/VIAL**	**N74713 001**	NOV 14, 2000
AP		**50MG/VIAL**	**N74713 002**	NOV 14, 2000
AP	GENSIA SICOR PHARMS	**1MG/ML**	**N74814 001**	MAY 16, 2000

CISPLATIN

INJECTABLE; INJECTION
CISPLATIN

AP	PHARMACHEMIE	**1MG/ML**	**N74656 001**	MAY 16, 2000

PLATINOL

AP	+ BRISTOL MYERS	**10MG/VIAL**	**N18057 001**	
AP	+	**50MG/VIAL**	**N18057 002**	

PLATINOL-AQ

AP	+ BRISTOL MYERS	**1MG/ML**	**N18057 004**	NOV 08, 1988

CITALOPRAM HYDROBROMIDE

SOLUTION; ORAL
CELEXA

+	FOREST LABS	EQ 10MG BASE/5ML	N21046 001	DEC 22, 1999

TABLET; ORAL
CELEXA

	FOREST LABS	EQ 10MG BASE	N20822 001	APR 27, 2000
		EQ 20MG BASE	N20822 002	JUL 17, 1998
+		EQ 40MG BASE	N20822 003	JUL 17, 1998

CITRIC ACID; GLUCONOLACTONE; MAGNESIUM CARBONATE

SOLUTION; IRRIGATION
RENACIDIN

	UNITED GUARDIAN	6.602GM/100ML;198MG/100ML; 3.177GM/100ML	N19481 001	OCT 02, 1990

CITRIC ACID; MAGNESIUM OXIDE; SODIUM CARBONATE

SOLUTION; IRRIGATION
IRRIGATING SOLUTION G IN PLASTIC CONTAINER

AT	BAXTER HLTHCARE	**3.24GM/100ML;380MG/100ML; 430MG/100ML**	**N18519 001**	JUN 22, 1982

FDA data supplied by DrugPatentWatch.com

CITRIC ACID; MAGNESIUM OXIDE; SODIUM CARBONATE

SOLUTION; IRRIGATION
UROLOGIC G IN PLASTIC CONTAINER

AT	ABBOTT	**3.24GM/100ML;380MG/100ML; 430MG/100ML**	**N18904 001**	MAY 27, 1983

CLADRIBINE

INJECTABLE; INJECTION
CLADRIBINE

AP	BEDFORD	**1MG/ML**	**N75405 001**	FEB 28, 2000
	LEUSTATIN			
	+ JOHNSON RW	1MG/ML	N20229 001	FEB 26, 1993

CLARITHROMYCIN

FOR SUSPENSION; ORAL
BIAXIN

	ABBOTT	125MG/5ML	N50698 001	DEC 23, 1993
		187MG/5ML	N50698 003	SEP 30, 1998
	+	250MG/5ML	N50698 002	DEC 23, 1993

TABLET; ORAL
BIAXIN

	+ ABBOTT	250MG	N50662 001	OCT 31, 1991
	+	500MG	N50662 002	OCT 31, 1991

TABLET, EXTENDED RELEASE; ORAL
BIAXIN XL

	+ ABBOTT	500MG	N50775 001	MAR 03, 2000

CLARITHROMYCIN; *MULTIPLE*
SEE AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE

CLAVULANATE POTASSIUM; *MULTIPLE*
SEE AMOXICILLIN; CLAVULANATE POTASSIUM

CLAVULANATE POTASSIUM; TICARCILLIN DISODIUM

INJECTABLE; INJECTION
TIMENTIN

	+ GLAXOSMITHKLINE	EQ 100MG BASE/VIAL; EQ 3GM BASE/VIAL	N50590 001	APR 01, 1985
		EQ 100MG BASE/VIAL; EQ 3GM BASE/VIAL	N62691 001	DEC 19, 1986
	+	EQ 200MG BASE/VIAL; EQ 3GM BASE/VIAL	N50590 002	APR 01, 1985
	+	EQ 1GM BASE/VIAL; EQ 30GM BASE/VIAL	N50590 003	AUG 18, 1987

TIMENTIN IN PLASTIC CONTAINER

	+ GLAXOSMITHKLINE	EQ 100MG BASE/100ML; EQ 3GM BASE/100ML	N50658 001	DEC 15, 1989

CLEMASTINE FUMARATE

SYRUP; ORAL
CLEMASTINE FUMARATE

AA	ALPHARMA	**EQ 0.5MG BASE/5ML**	**N74075 001**	OCT 31, 1993
AA	COPLEY PHARM	**EQ 0.5MG BASE/5ML**	**N73095 001**	APR 21, 1992
AA	MORTON GROVE	**EQ 0.5MG BASE/5ML**	**N74863 001**	MAR 13, 1998
AA	NOVEX	**EQ 0.5MG BASE/5ML**	**N75703 001**	NOV 27, 2000
AA	SILARX	**EQ 0.5MG BASE/5ML**	**N74884 001**	DEC 17, 1997
AA	TEVA	**EQ 0.5MG BASE/5ML**	**N73399 001**	JUN 30, 1994
	TAVIST			
AA	+ NOVARTIS	**EQ 0.5MG BASE/5ML**	**N18675 001**	JUN 28, 1985

TABLET; ORAL
CLEMASTINE FUMARATE

AB	GENEVA PHARMS	**2.68MG**	**N73459 001**	OCT 31, 1993
AB	TEVA	**2.68MG**	**N73283 001**	JAN 31, 1992
	TAVIST			
AB	+ NOVARTIS	**2.68MG**	**N17661 001**	

FDA data supplied by DrugPatentWatch.com

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL

	CLEOCIN HCL			
AB	PHARMACIA AND UPJOHN	EQ 75MG BASE	N50162 001	
AB		EQ 150MG BASE	N50162 002	
AB	+	EQ 300MG BASE	N50162 003	
			APR 14, 1988	
	CLINDAMYCIN HCL			
AB	DANBURY PHARMA	EQ 150MG BASE	N63083 001	
			JUL 31, 1991	
AB	RANBAXY	EQ 150MG BASE	N65061 001	
			FEB 02, 2001	
AB		EQ 300MG BASE	N65061 002	
			FEB 02, 2001	
AB	TEVA	EQ 75MG BASE	N63027 001	
			SEP 20, 1989	
AB		EQ 150MG BASE	N63029 001	
			SEP 20, 1989	

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION; ORAL

CLEOCIN			
	PHARMACIA AND UPJOHN	EQ 75MG BASE/5ML	N62644 001
			APR 07, 1986

CLINDAMYCIN PHOSPHATE

CREAM; VAGINAL

CLEOCIN			
+	PHARMACIA AND UPJOHN	EQ 2% BASE	N50680 002
			MAR 02, 1998

GEL; TOPICAL

	CLEOCIN T			
AB	+ PHARMACIA AND UPJOHN	EQ 1% BASE	N50615 001	
			JAN 07, 1987	
	CLINDAMYCIN PHOSPHATE			
AB	ALTANA	EQ 1% BASE	N64160 001	
			JAN 28, 2000	
BT	GALDERMA LABS LP	EQ 1% BASE	N50782 001	
			NOV 27, 2000	

INJECTABLE; INJECTION

	CLEOCIN PHOSPHATE			
AP	+ PHARMACIA AND UPJOHN	EQ 150MG BASE/ML	N50441 001	
AP	PHARMACIA AND UPJOHN	EQ 150MG BASE/ML	N62803 001	
			OCT 16, 1987	
	CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER			
AP	+ PHARMACIA AND UPJOHN	EQ 6MG BASE/ML	N50639 001	
			AUG 30, 1989	
AP	+	EQ 12MG BASE/ML	N50639 002	
			AUG 30, 1989	
AP	+	EQ 18MG BASE/ML	N50639 003	
			APR 10, 1991	
	CLINDAMYCIN PHOSPHATE			
AP	ABBOTT	EQ 150MG BASE/ML	N62800 001	
			JUL 24, 1987	
AP		EQ 150MG BASE/ML	N62801 001	
			JUL 24, 1987	
AP	LEDERLE	EQ 150MG BASE/ML	N62889 001	
			APR 25, 1988	
AP	LOCH	EQ 150MG BASE/ML	N62905 001	
			MAY 09, 1988	
	CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%			
AP	+ AM PHARM PARTNERS	EQ 900MG BASE/100ML	N50635 001	
			DEC 22, 1989	
	CLINDAMYCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER			
AP	ABBOTT	EQ 6MG BASE/ML	N65027 001	
			JUN 29, 2001	
AP		EQ 12MG BASE/ML	N65027 002	
			JUN 29, 2001	
AP		EQ 18MG BASE/ML	N65027 003	
			JUN 29, 2001	
AP	+ BAXTER HLTHCARE	EQ 6MG BASE/ML	N50648 001	
			DEC 29, 1989	
AP	+	EQ 900MG BASE/100ML	N50648 003	
			DEC 29, 1989	
AP	+	EQ 12MG BASE/ML	N50648 002	
			DEC 29, 1989	

LOTION; TOPICAL

CLEOCIN T			
+	PHARMACIA AND UPJOHN	EQ 1% BASE	N50600 001
			MAY 31, 1989

SOLUTION; TOPICAL

	CLEOCIN T			
AT	+ PHARMACIA AND UPJOHN	EQ 1% BASE	N50537 001	
	CLINDA-DERM			
AT	PADDOCK	EQ 1% BASE	N63329 001	
			SEP 30, 1992	

FDA data supplied by DrugPatentWatch.com

CLINDAMYCIN PHOSPHATE

SOLUTION; TOPICAL

	CLINDAMYCIN PHOSPHATE			
AT	ALPHARMA	**EQ 1% BASE**	**N62811 001**	SEP 01, 1988
AT	CLAY PARK	**EQ 1% BASE**	**N64050 001**	NOV 30, 1995
AT		**EQ 1% BASE**	**N65049 001**	MAY 25, 2000
AT	FOUGERA	**EQ 1% BASE**	**N64159 001**	JUN 05, 1997
AT	MORTON GROVE	**EQ 1% BASE**	**N63304 001**	JUL 15, 1997
AT	STIEFEL	**EQ 1% BASE**	**N64108 001**	SEP 27, 1996

SUPPOSITORY; VAGINAL

	CLEOCIN		
+	PHARMACIA AND UPJOHN	100MG	N50767 001 AUG 13, 1999

SWAB; TOPICAL

	CLEOCIN			
AT	PHARMACIA AND UPJOHN	**EQ 1% BASE**	**N50537 002**	FEB 22, 1994
	CLINDETS			
AT	STIEFEL	**EQ 1% BASE**	**N64136 001**	SEP 30, 1996

CLINDAMYCIN PHOSPHATE; *MULTIPLE*

SEE BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

CLOBETASOL PROPIONATE

AEROSOL; TOPICAL

	OLUX FOAM			
+	CONNETICS	0.05%	N21142 001	MAY 26, 2000

CREAM; TOPICAL

	CLOBETASOL PROPIONATE			
AB1	ALPHARMA US PHARM	**0.05%**	**N74139 001**	AUG 03, 1994
AB1	COPLEY PHARM	**0.05%**	**N74087 001**	FEB 16, 1994

CLOBETASOL PROPIONATE

CREAM; TOPICAL

	CLOBETASOL PROPIONATE			
AB1	FOUGERA	**0.05%**	**N74392 001**	SEP 30, 1996
AB1	STIEFEL	**0.05%**	**N75338 001**	FEB 09, 2001
AB2		**0.05%**	**N75733 001**	AUG 22, 2001
AB1	TARO	**0.05%**	**N74249 001**	JUL 08, 1996
	CLOBETASOL PROPIONATE (EMOLLIENT)			
AB2	ALTANA	**0.05%**	**N75430 001**	MAY 26, 1999
AB2	TARO	**0.05%**	**N75633 001**	MAY 17, 2000
	CORMAX			
AB1	HEALTHPOINT	**0.05%**	**N74220 001**	MAY 16, 1997
	EMBELINE E			
AB2	HEALTHPOINT	**0.05%**	**N75325 001**	DEC 24, 1998
	TEMOVATE			
AB1 +	GLAXOSMITHKLINE	**0.05%**	**N19322 001**	DEC 27, 1985
	TEMOVATE E			
AB2 +	GLAXOSMITHKLINE	**0.05%**	**N20340 001**	JUN 17, 1994

GEL; TOPICAL

	CLOBETASOL PROPIONATE			
AB	ALTANA	**0.05%**	**N75368 001**	FEB 15, 2000
AB	STIEFEL	**0.05%**	**N75027 001**	OCT 31, 1997
AB	TARO	**0.05%**	**N75279 001**	MAY 28, 1999
	TEMOVATE			
AB +	GLAXOSMITHKLINE	**0.05%**	**N20337 001**	APR 29, 1994

OINTMENT; TOPICAL

	CLOBETASOL PROPIONATE			
AB	COPLEY PHARM	**0.05%**	**N74089 001**	FEB 16, 1994
AB	FOUGERA	**0.05%**	**N74407 001**	FEB 23, 1996

FDA data supplied by DrugPatentWatch.com

CLOBETASOL PROPIONATE

OINTMENT; TOPICAL

	CLOBETASOL PROPIONATE			
AB	NMC	0.05%	N74128 001	AUG 03, 1994
AB	STIEFEL	0.05%	N75057 001	AUG 12, 1998
AB	TARO	0.05%	N74248 001	JUL 12, 1996
	EMBELINE			
AB	HEALTHPOINT	0.05%	N74221 001	MAR 31, 1995
	TEMOVATE			
AB	+ GLAXOSMITHKLINE	0.05%	N19323 001	DEC 27, 1985

SOLUTION; TOPICAL

	CLOBETASOL PROPIONATE			
AT	ALTANA	0.05%	N75391 001	FEB 08, 1999
AT	MORTON GROVE	0.05%	N75205 001	NOV 13, 1998
AT	NMC	0.05%	N74331 001	DEC 15, 1995
AT	TARO	0.05%	N75224 001	NOV 16, 1998
AT	THAMES	0.05%	N75363 001	DEC 29, 2000
	EMBELINE			
AT	DPT	0.05%	N74222 001	DEC 06, 1995
	TEMOVATE			
AT	+ GLAXOSMITHKLINE	0.05%	N19966 001	FEB 22, 1990

CLOCORTOLONE PIVALATE

CREAM; TOPICAL

	CLODERM		
	+ HEALTHPOINT	0.1%	N17765 001

CLOFAZIMINE

CAPSULE; ORAL

	LAMPRENE			
	NOVARTIS	50MG	N19500 002	DEC 15, 1986

CLOFAZIMINE

CAPSULE; ORAL

	LAMPRENE			
	+ NOVARTIS	100MG	N19500 001	DEC 15, 1986

CLOFIBRATE

CAPSULE; ORAL

	ATROMID-S			
AB	+ WYETH AYERST	500MG	N16099 002	
	CLOFIBRATE			
AB	BANNER PHARMACAPS	500MG	N73396 001	MAR 20, 1992
AB	TEVA	500MG	N72600 001	JUL 25, 1991
AB	USL PHARMA	500MG	N70531 001	JUN 16, 1986

CLOMIPHENE CITRATE

TABLET; ORAL

	CLOMID			
AB	+ AVENTIS PHARMS	50MG	N16131 002	
	CLOMIPHENE CITRATE			
AB	PAR PHARM	50MG	N75528 001	AUG 30, 1999
	MILOPHENE			
AB	MILEX	50MG	N72196 001	DEC 20, 1988
	SEROPHENE			
AB	SERONO	50MG	N18361 001	MAR 22, 1982

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL

	ANAFRANIL			
AB	TYCO HLTHCARE	25MG	N19906 001	DEC 29, 1989
AB	+	50MG	N19906 002	DEC 29, 1989
AB		75MG	N19906 003	DEC 29, 1989

FDA data supplied by DrugPatentWatch.com

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL

CLOMIPRAMINE HCL

AB	GENEVA PHARMS	25MG	N74364 001	MAR 29, 1996
AB		50MG	N74364 002	MAR 29, 1996
AB		75MG	N74364 003	MAR 29, 1996
AB	GENEVA PHARMS TECH	25MG	N74953 001	JUN 25, 1997
AB		50MG	N74953 002	JUN 25, 1997
AB		75MG	N74953 003	JUN 25, 1997
AB	MYLAN	25MG	N74947 001	APR 30, 1998
AB		50MG	N74947 002	APR 30, 1998
AB		75MG	N74947 003	APR 30, 1998
AB	TARO	25MG	N74694 001	DEC 31, 1996
AB		50MG	N74694 002	DEC 31, 1996
AB		75MG	N74694 003	DEC 31, 1996
AB	TEVA	25MG	N74849 001	APR 04, 1997
AB		25MG	N74958 001	AUG 26, 1997
AB		50MG	N74849 002	APR 04, 1997
AB		50MG	N74958 002	AUG 26, 1997
AB		75MG	N74849 003	APR 04, 1997
AB		75MG	N74958 003	AUG 26, 1997
AB	WATSON LAB	25MG	N74600 001	NOV 27, 1996
AB		50MG	N74600 002	NOV 27, 1996
AB		75MG	N74600 003	NOV 27, 1996
AB	WATSON LABS	25MG	N74751 001	SEP 30, 1998

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL

CLOMIPRAMINE HCL

AB	WATSON LABS	50MG	N74751 002	SEP 30, 1998
AB		75MG	N74751 003	SEP 30, 1998

CLONAZEPAM

TABLET; ORAL

CLONAZEPAM

AB	ALPHAPHARM	0.5MG	N74940 001	OCT 30, 1997
AB		1MG	N74940 002	OCT 30, 1997
AB		2MG	N74940 003	OCT 30, 1997
AB	CARACO	0.5MG	N75423 001	APR 27, 2001
AB		1MG	N75423 002	APR 27, 2001
AB		2MG	N75423 003	APR 27, 2001
AB	EON	0.5MG	N74979 001	AUG 29, 1997
AB		1MG	N74979 002	AUG 29, 1997
AB		2MG	N74979 003	AUG 29, 1997
AB	GENEVA PHARMS TECH	0.5MG	N74925 001	SEP 30, 1997
AB		1MG	N74925 002	SEP 30, 1997
AB		2MG	N74925 003	SEP 30, 1997
AB	MYLAN	0.5MG	N75150 001	OCT 05, 1998
AB		1MG	N75150 002	OCT 05, 1998
AB		2MG	N75150 003	OCT 05, 1998
AB	PUREPAC PHARM	0.5MG	N74869 001	OCT 31, 1996
AB		1MG	N74869 002	OCT 31, 1996

FDA data supplied by DrugPatentWatch.com

CLONAZEPAM

TABLET; ORAL

	CLONAZEPAM				
AB	PUREPAC PHARM	2MG	N74869 003	OCT 31, 1996	
AB	TEVA	0.5MG	N74569 001	SEP 10, 1996	
AB		0.5MG	N74920 001	AUG 04, 1998	
AB		1MG	N74569 002	SEP 10, 1996	
AB		1MG	N74920 002	AUG 04, 1998	
AB		2MG	N74569 003	SEP 10, 1996	
AB		2MG	N74920 003	AUG 04, 1998	
AB	TORPHARM	0.5MG	N75468 001	OCT 06, 2000	
AB		1MG	N75468 002	OCT 06, 2000	
AB		2MG	N75468 003	OCT 06, 2000	
AB	WATSON LABS	0.5MG	N74964 001	DEC 30, 1997	
AB		1MG	N74964 002	DEC 30, 1997	
AB		2MG	N74964 003	DEC 30, 1997	
	KLONOPIN				
AB	ROCHE	0.5MG	N17533 001		
AB	+	1MG	N17533 002		
AB	+	2MG	N17533 003		
	+	0.125MG	N17533 005	APR 09, 1997	
		0.25MG	N17533 006	APR 09, 1997	

TABLET, ORALLY DISINTEGRATING; ORAL

	KLONOPIN RAPIDLY DISINTEGRATING			
	+ ROCHE	0.125MG	N20813 001	DEC 23, 1997
		0.25MG	N20813 002	DEC 23, 1997
		0.5MG	N20813 003	DEC 23, 1997
	+	1MG	N20813 004	DEC 23, 1997

CLONAZEPAM

TABLET, ORALLY DISINTEGRATING; ORAL

	KLONOPIN RAPIDLY DISINTEGRATING			
	ROCHE	2MG	N20813 005	DEC 23, 1997

CLONIDINE

FILM, EXTENDED RELEASE; TRANSDERMAL

	CATAPRES-TTS-1			
	+ BOEHRINGER INGELHEIM	0.1MG/24HR	N18891 001	OCT 10, 1984
	CATAPRES-TTS-2			
	+ BOEHRINGER INGELHEIM	0.2MG/24HR	N18891 002	OCT 10, 1984
	CATAPRES-TTS-3			
	+ BOEHRINGER INGELHEIM	0.3MG/24HR	N18891 003	OCT 10, 1984

CLONIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

	DURACLON			
	+ ELAN PHARMS	0.1MG/ML	N20615 001	OCT 02, 1996

TABLET; ORAL

	CATAPRES				
AB	BOEHRINGER INGELHEIM	0.1MG	N17407 001		
AB		0.2MG	N17407 002		
AB	+	0.3MG	N17407 003		
	CLONIDINE HCL				
AB	DANBURY PHARMA	0.1MG	N70965 001	JUL 08, 1986	
AB		0.2MG	N70964 001	JUL 08, 1986	
AB		0.3MG	N70963 001	JUL 08, 1986	
AB	GENEVA PHARMS	0.1MG	N70887 001	AUG 31, 1988	
AB		0.2MG	N70886 001	AUG 31, 1988	
AB		0.3MG	N71294 001	AUG 31, 1988	
AB	HALSEY	0.1MG	N70925 001	SEP 04, 1987	

FDA data supplied by DrugPatentWatch.com

CLONIDINE HYDROCHLORIDE

TABLET; ORAL
CLONIDINE HCL

AB	LEDERLE	0.1MG	N71783 001	APR 05, 1988
AB		0.2MG	N71784 001	APR 05, 1988
AB		0.3MG	N71785 001	APR 05, 1988
AB	MYLAN	0.1MG	N70315 001	JUN 09, 1987
AB		0.2MG	N70316 001	JUN 09, 1987
AB		0.3MG	N70317 001	JUN 09, 1987
AB	PUREPAC PHARM	0.1MG	N70974 001	DEC 16, 1986
AB		0.2MG	N70975 001	DEC 16, 1986
AB		0.3MG	N70976 001	DEC 16, 1986

CLONIDINE HYDROCHLORIDE; *MULTIPLE*
SEE CHLORTHALIDONE; CLONIDINE HYDROCHLORIDE

CLOPIDOGREL BISULFATE

TABLET; ORAL
PLAVIX

+	SANOFI SYNTHELABO	EQ 75MG BASE	N20839 001	NOV 17, 1997

CLORAZEPATE DIPOTASSIUM

CAPSULE; ORAL
CLORAZEPATE DIPOTASSIUM

AB	GENEVA PHARMS	3.75MG	N72219 001	AUG 26, 1988
AB		7.5MG	N72220 001	AUG 26, 1988
AB		15MG	N72112 001	AUG 26, 1988
AB	LEDERLE	3.75MG	N71742 001	DEC 14, 1987

CLORAZEPATE DIPOTASSIUM

CAPSULE; ORAL
CLORAZEPATE DIPOTASSIUM

AB	LEDERLE	7.5MG	N71743 001	DEC 14, 1987
AB		15MG	N71744 001	DEC 14, 1987
AB	MYLAN	3.75MG	N71509 001	OCT 19, 1987
AB		7.5MG	N71510 001	OCT 19, 1987
AB	+	15MG	N71511 001	OCT 19, 1987

TABLET; ORAL
CLORAZEPATE DIPOTASSIUM

AB	ABLE	3.75MG	N71780 001	JUN 26, 1987
AB		7.5MG	N71781 001	JUN 26, 1987
AB		15MG	N71782 001	JUN 26, 1987
AB	GENEVA PHARMS	7.5MG	N72513 001	MAY 11, 1990
AB		15MG	N72514 001	MAY 11, 1990
AB	MYLAN	3.75MG	N71856 001	JUL 17, 1987
AB		7.5MG	N71857 001	JUL 17, 1987
AB		15MG	N71858 001	JUL 17, 1987
AB	TARO	3.75MG	N75731 003	APR 27, 2000
AB		7.5MG	N75731 002	APR 27, 2000
AB		15MG	N75731 001	APR 27, 2000
AB	WATSON LABS	3.75MG	N71852 001	FEB 09, 1988
AB		7.5MG	N71853 001	FEB 09, 1988
AB		15MG	N71854 001	FEB 09, 1988
	GEN-XENE			
AB	ALRA	3.75MG	N71787 001	APR 26, 1988

FDA data supplied by DrugPatentWatch.com

CLORAZEPATE DIPOTASSIUM

TABLET; ORAL

	GEN-XENE			
AB	ALRA	**7.5MG**	**N71788 001**	
			APR 26, 1988	
AB		**15MG**	**N71789 001**	
			APR 26, 1988	
	TRANXENE			
AB	ABBOTT	**3.75MG**	**N17105 006**	
AB		**7.5MG**	**N17105 007**	
AB	+	**15MG**	**N17105 008**	
	TRANXENE SD			
	ABBOTT	11.25MG	N17105 005	
	+	22.5MG	N17105 004	

CLOTRIMAZOLE

CREAM; TOPICAL

	CLOTRIMAZOLE			
AB	TARO	**1%**	**N72640 001**	
			AUG 31, 1993	
	LOTRIMIN			
AB	+ SCHERING PLOUGH	**1%**	**N17619 001**	
	MYCELEX			
BT	BAYER	1%	N18183 001	

LOTION; TOPICAL

	LOTRIMIN			
	+ SCHERING	1%	N18813 001	
			FEB 17, 1984	

SOLUTION; TOPICAL

	CLOTRIMAZOLE			
AT	TARO	**1%**	**N74580 001**	
			JUL 29, 1996	
AT	TEVA	**1%**	**N73306 001**	
			FEB 28, 1995	
	LOTRIMIN			
AT	+ SCHERING PLOUGH	**1%**	**N17613 001**	
	MYCELEX			
AT	+ BAYER	**1%**	**N18181 001**	

TROCHE/LOZENGE; ORAL

	MYCELEX			
	+ BAYER	10MG	N18713 001	
			JUN 17, 1983	

CLOTRIMAZOLE; *MULTIPLE*
SEE BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

CLOXACILLIN SODIUM

CAPSULE; ORAL

	CLOXACILLIN SODIUM			
AB	TEVA	**EQ 250MG BASE**	**N62240 001**	
AB		**EQ 500MG BASE**	**N62240 002**	
	CLOXAPEN			
AB	GLAXOSMITHKLINE	**EQ 250MG BASE**	**N61806 001**	
AB	+	**EQ 500MG BASE**	**N61806 002**	

FOR SOLUTION; ORAL

	CLOXACILLIN SODIUM			
	+ TEVA	EQ 125MG BASE/5ML	N62268 001	

CLOZAPINE

TABLET; ORAL

	CLOZAPINE			
AB	IVAX PHARMS	**25MG**	**N74949 001**	
			NOV 26, 1997	
AB		**100MG**	**N74949 002**	
			NOV 26, 1997	
AB	MYLAN	**25MG**	**N75417 001**	
			MAY 27, 1999	
AB		**100MG**	**N75417 002**	
			MAY 27, 1999	
	CLOZARIL			
AB	+ NOVARTIS	**25MG**	**N19758 001**	
			SEP 26, 1989	
AB		**100MG**	**N19758 002**	
			SEP 26, 1989	

COBALT CHLORIDE, CO-57; CYANOCOBALAMIN; CYANOCOBALAMIN, CO-57; INTRINSIC FACTOR

N/A; N/A

RUBRATOPE-57 KIT			
BRACCO	N/A;N/A;N/A;N/A	N16089 001	

CODEINE PHOSPHATE; *MULTIPLE*
SEE ACETAMINOPHEN; ASPIRIN; CODEINE PHOSPHATE
SEE ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE
SEE ACETAMINOPHEN; CODEINE PHOSPHATE
SEE ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

FDA data supplied by DrugPatentWatch.com

CODEINE PHOSPHATE; *MULTIPLE*
SEE ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE
SEE BROMODIPHENHYDRAMINE HYDROCHLORIDE; CODEINE PHOSPHATE
SEE BROMPHENIRAMINE MALEATE; CODEINE PHOSPHATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PHENERGAN VC W/ CODEINE

AA	+	WYETH AYERST	**10MG/5ML;5MG/5ML; 6.25MG/5ML**	**N08306 005** APR 02, 1984

PROMETH VC W/ CODEINE

AA		ALPHARMA	**10MG/5ML;5MG/5ML; 6.25MG/5ML**	**N88764 001** OCT 31, 1984

PROMETHAZINE VC W/ CODEINE

AA		MORTON GROVE	**10MG/5ML;5MG/5ML; 6.25MG/5ML**	**N88896 001** JAN 04, 1985

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PHENERGAN W/ CODEINE

AA	+	WYETH AYERST	**10MG/5ML;6.25MG/5ML**	**N08306 004** APR 02, 1984

PROMETH W/ CODEINE

AA		ALPHARMA	**10MG/5ML;6.25MG/5ML**	**N88763 001** OCT 31, 1984

PROMETHAZINE HCL AND CODEINE PHOSPHATE

AA		HI TECH PHARMA	**10MG/5ML;6.25MG/5ML**	**N40151 001** AUG 26, 1997
AA		PHARM ASSOC	**10MG/5ML;6.25MG/5ML**	**N89647 001** DEC 22, 1988

PROMETHAZINE W/ CODEINE

AA		MORTON GROVE	**10MG/5ML;6.25MG/5ML**	**N88875 001** DEC 17, 1984

CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

SYRUP; ORAL

TRIACIN-C

AA		ALPHARMA	**10MG/5ML;30MG/5ML; 1.25MG/5ML**	**N88704 001** MAR 22, 1985

TRIPROLIDINE HCL, PSEUDOEPHEDRINE HCL AND CODEINE PHOSPHATE

AA	+	MORTON GROVE	**10MG/5ML;30MG/5ML; 1.25MG/5ML**	**N88833 001** NOV 16, 1984

COLCHICINE; PROBENECID

TABLET; ORAL

COL-PROBENECID

BP		DANBURY PHARMA	0.5MG;500MG	N84279 001

COLBENEMID

BP	+	MERCK	0.5MG;500MG	N12383 001

PROBENECID AND COLCHICINE

BP		IVAX PHARMS	0.5MG;500MG	N83734 001

COLESEVELAM HYDROCHLORIDE

CAPSULE; ORAL

WELCHOL

	+	SANKYO	375MG	N21141 001 MAY 26, 2000

TABLET; ORAL

WELCHOL

	+	SANKYO	625MG	N21176 001 MAY 26, 2000

COLESTIPOL HYDROCHLORIDE

GRANULE; ORAL

COLESTID

		PHARMACIA AND UPJOHN	5GM/SCOOPFUL	N17563 003 SEP 22, 1995
	+		5GM/PACKET	N17563 004 SEP 22, 1995

FLAVORED COLESTID

	+	PHARMACIA AND UPJOHN	5GM/PACKET	N17563 001
			5GM/SCOOPFUL	N17563 002

FDA data supplied by DrugPatentWatch.com

COLESTIPOL HYDROCHLORIDE

TABLET; ORAL
COLESTID
PHARMACIA AND UPJOHN 1GM — N20222 001 — JUL 19, 1994

COLFOSCERIL PALMITATE; *MULTIPLE*
SEE CETYL ALCOHOL; COLFOSCERIL PALMITATE; TYLOXAPOL

COLISTIMETHATE SODIUM

INJECTABLE; INJECTION
COLISTIMETHATE
AP PHARMA TEK — **EQ 150MG BASE/VIAL** — **N64216 001** — FEB 26, 1999

COLY-MYCIN M
AP + PARKEDALE — **EQ 150MG BASE/VIAL** — **N50108 002**

COLISTIN SULFATE; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; THONZONIUM BROMIDE

SUSPENSION/DROPS; OTIC
COLY-MYCIN S
+ PARKEDALE — EQ 3MG BASE/ML;10MG/ML; EQ 3.3MG BASE/ML;0.5MG/ML — N50356 001

COPPER

INTRAUTERINE DEVICE; INTRAUTERINE
COPPER T MODEL TCU 380A
+ POPULATION COUNCIL — 309MG/COPPER — N18680 001 — NOV 15, 1984

CORTICORELIN OVINE TRIFLUTATE

INJECTABLE; INJECTION
ACTHREL
+ FERRING — EQ 0.1MG BASE/VIAL — N20162 001 — MAY 23, 1996

CORTICOTROPIN

INJECTABLE; INJECTION
CORTICOTROPIN
BC ORGANICS LAGRANGE — 40 UNITS/ML — N10831 001
BC — 80 UNITS/ML — N10831 002
H.P. ACTHAR GEL
BC + QUESTCOR PHARMS — 40 UNITS/ML — N08372 006
BC + — 80 UNITS/ML — N08372 008

CORTISONE ACETATE

INJECTABLE; INJECTION
CORTONE
MERCK — 25MG/ML — N07110 002
+ — 50MG/ML — N07110 003

TABLET; ORAL
CORTISONE ACETATE
BP PHARMACIA AND UPJOHN — 25MG — N08126 001
5MG — N08126 003
10MG — N08126 004
BP WEST WARD — 25MG — N80776 002
CORTONE
BP + MERCK — 25MG — N07750 003

COSYNTROPIN

INJECTABLE; INJECTION
CORTROSYN
+ ORGANON — 0.25MG/VIAL — N16750 001

CROMOLYN SODIUM

AEROSOL, METERED; INHALATION
INTAL
+ AVENTIS — 0.8MG/INH — N18887 001 — DEC 05, 1985

SOLUTION; INHALATION
CROMOLYN SODIUM
AN ALPHARMA — **10MG/ML** — **N75067 001** — JUL 19, 1999
AN BAUSCH AND LOMB — **10MG/ML** — **N75585 001** — DEC 21, 2000

FDA data supplied by DrugPatentWatch.com

CROMOLYN SODIUM

SOLUTION; INHALATION

	CROMOLYN SODIUM			
AN	DEY	10MG/ML	**N74209 001**	APR 26, 1994
AN	IVAX PHARMS	10MG/ML	**N75271 001**	JAN 18, 2000
AN	MORTON GROVE	10MG/ML	**N75346 001**	OCT 25, 1999
AN	ROXANE	10MG/ML	**N75175 001**	SEP 30, 1999
AN	WARRICK PHARMS	10MG/ML	**N75437 001**	APR 21, 2000
	INTAL			
AN	+ AVENTIS PHARMS	10MG/ML	**N18596 001**	MAY 28, 1982

SOLUTION, CONCENTRATE; ORAL

GASTROCROM			
+	CELLTECH PHARMS	100MG/5ML	N20479 001 FEB 29, 1996

SOLUTION/DROPS; OPHTHALMIC

	CROLOM			
AT	BAUSCH AND LOMB	4%	**N74443 001**	JAN 30, 1995
	CROMOLYN SODIUM			
AT	AKORN	4%	**N74706 001**	APR 29, 1998
AT	ALCON	4%	**N75282 001**	JUN 16, 1999
AT	NOVEX	4%	**N75615 001**	JAN 26, 2001
	CROMOPTIC			
AT	KING PHARMS	4%	**N75088 001**	APR 27, 1999
	OPTICROM			
AT	+ ALLERGAN	4%	**N18155 001**	OCT 03, 1984

CROTAMITON

CREAM; TOPICAL

EURAX			
+	WESTWOOD SQUIBB	10%	N06927 001

LOTION; TOPICAL

	CROTAN		
AT	SUMMERS	10%	**N87204 001**

CROTAMITON

LOTION; TOPICAL

	EURAX		
AT	+ WESTWOOD SQUIBB	10%	**N09112 003**

CUPRIC CHLORIDE

INJECTABLE; INJECTION

CUPRIC CHLORIDE IN PLASTIC CONTAINER			
+	ABBOTT	EQ 0.4MG COPPER/ML	N18960 001 JUN 26, 1986

CYANOCOBALAMIN

GEL, METERED; NASAL

NASCOBAL			
+	NASTECH PHARM	0.5MG/INH	N19722 001 NOV 05, 1996

INJECTABLE; INJECTION

	CYANOCOBALAMIN			
AP	AM PHARM PARTNERS	0.1MG/ML	**N80557 002**	
AP	ELKINS SINN	1MG/ML	**N80515 002**	
AP	LUITPOLD	1MG/ML	**N80737 001**	
AP	STERIS	0.1MG/ML	**N80573 002**	
AP		1MG/ML	**N80573 001**	
AP		1MG/ML	**N83120 002**	
AP	WYETH AYERST	0.1MG/ML	**N80554 001**	
AP		1MG/ML	**N80554 002**	
	RUBRAMIN PC			
AP	+ BRISTOL MYERS SQUIBB	1MG/ML	**N06799 010**	APR 28, 1988
	VIBISONE			
AP	AM PHARM PARTNERS	1MG/ML	**N80557 003**	

TABLET; ORAL

CYANOCOBALAMIN			
+	WEST WARD	1MG	N84264 001

CYANOCOBALAMIN; *MULTIPLE*

SEE ALPHA-TOCOPHEROL; ASCORBIC ACID; BIOTIN, D-; CHOLECALCIFEROL; CYANOCOBALAMIN; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A

FDA data supplied by DrugPatentWatch.com

CYANOCOBALAMIN; *MULTIPLE*
SEE ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE
SEE ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K
SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PHYTONADIONE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E
SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E
SEE COBALT CHLORIDE, CO-57; CYANOCOBALAMIN; CYANOCOBALAMIN, CO-57; INTRINSIC FACTOR

CYANOCOBALAMIN; CYANOCOBALAMIN, CO-57; CYANOCOBALAMIN, CO-58

N/A; N/A
DICOPAC KIT
AMERSHAM HLTH N/A;N/A;N/A N17406 001

CYANOCOBALAMIN; CYANOCOBALAMIN, CO-57; INTRINSIC FACTOR

N/A; N/A
CYANOCOBALAMIN CO 57 SCHILLING TEST KIT
MALLINCKRODT 0.1MG;0.5 uCi;60MG N16635 001

CYANOCOBALAMIN, CO-57

CAPSULE; ORAL
RUBRATOPE-57
BRACCO 0.5-1 uCi N16089 002

CYANOCOBALAMIN, CO-57; *MULTIPLE*
SEE COBALT CHLORIDE, CO-57; CYANOCOBALAMIN; CYANOCOBALAMIN, CO-57; INTRINSIC FACTOR
SEE CYANOCOBALAMIN; CYANOCOBALAMIN, CO-57; CYANOCOBALAMIN, CO-58
SEE CYANOCOBALAMIN; CYANOCOBALAMIN, CO-57; INTRINSIC FACTOR

CYANOCOBALAMIN, CO-58; *MULTIPLE*
SEE CYANOCOBALAMIN; CYANOCOBALAMIN, CO-57; CYANOCOBALAMIN, CO-58

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL

	CYCLOBENZAPRINE HCL			
AB	DANBURY PHARMA	10MG	**N71611 001**	MAY 03, 1989
AB	GENEVA PHARMS	10MG	**N72854 001**	NOV 19, 1991
AB	GENEVA PHARMS TECH	10MG	**N73683 001**	FEB 26, 1993
AB	HALSEY	10MG	**N73541 001**	MAY 23, 1995
AB	MYLAN	10MG	**N73144 001**	MAY 30, 1991
AB	SIDMAK LABS NJ	10MG	**N74421 001**	SEP 29, 1995
AB	WATSON LABS	10MG	**N73143 001**	NOV 27, 1991
AB		10MG	**N74436 001**	NOV 30, 1994
	FLEXERIL			
AB +	MERCK	10MG	**N17821 002**	

CYCLOPENTOLATE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

	AKPENTOLATE			
AT	AKORN	1%	**N40164 001**	JAN 13, 1997
AT		2%	**N40165 001**	JAN 13, 1997
	CYCLOGYL			
AT +	ALCON	0.5%	**N84109 001**	
AT +		1%	**N84110 001**	
AT +		2%	**N84108 001**	
	CYCLOPENTOLATE HCL			
AT	ALCON UNIVERSAL	1%	**N89162 001**	JAN 24, 1991
	PENTOLAIR			
AT	BAUSCH AND LOMB	1%	**N40075 001**	APR 29, 1994

FDA data supplied by DrugPatentWatch.com

CYCLOPENTOLATE HYDROCHLORIDE; PHENYLEPHRINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

	CYCLOMYDRIL			
+	ALCON	0.2%;1%		N84300 001

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION

	CYCLOPHOSPHAMIDE			
AP	ASTA	**1GM/VIAL**		**N88374 001**
				SEP 24, 1986
AP		**100MG/VIAL**		**N88371 001**
				JUL 03, 1986
AP		**200MG/VIAL**		**N88372 001**
				JUL 03, 1986
AP		**500MG/VIAL**		**N88373 001**
				JUL 03, 1986
	LYOPHILIZED CYTOXAN			
AP	+ BRISTOL MYERS SQUIBB	**100MG/VIAL**		**N12142 006**
				DEC 05, 1985
AP	+	**200MG/VIAL**		**N12142 007**
				DEC 10, 1985
AP	+	**500MG/VIAL**		**N12142 008**
				JAN 04, 1984
AP	+	**1GM/VIAL**		**N12142 010**
				SEP 24, 1985
AP	+	**2GM/VIAL**		**N12142 009**
				DEC 10, 1984
	NEOSAR			
AP	PHARMACIA AND UPJOHN	**100MG/VIAL**		**N40015 001**
				APR 29, 1993
AP		**100MG/VIAL**		**N87442 001**
				FEB 16, 1982
AP		**200MG/VIAL**		**N40015 002**
				APR 29, 1993
AP		**200MG/VIAL**		**N87442 002**
				FEB 16, 1982
AP		**500MG/VIAL**		**N40015 003**
				APR 29, 1993
AP		**500MG/VIAL**		**N87442 003**
				FEB 16, 1982
AP		**1GM/VIAL**		**N40015 004**
				APR 29, 1993
AP		**1GM/VIAL**		**N87442 004**
				JUL 08, 1983
AP		**2GM/VIAL**		**N40015 005**
				APR 29, 1993

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION

	NEOSAR			
AP	PHARMACIA AND UPJOHN	**2GM/VIAL**		**N87442 005**
				MAR 30, 1989

TABLET; ORAL

	CYCLOPHOSPHAMIDE			
AB	ROXANE	**25MG**		**N40032 001**
				AUG 17, 1999
AB		**50MG**		**N40032 002**
				AUG 17, 1999
	CYTOXAN			
AB	BRISTOL MYERS SQUIBB	**25MG**		**N12141 002**
AB	+	**50MG**		**N12141 001**

CYCLOSERINE

CAPSULE; ORAL

	SEROMYCIN			
+	LILLY	250MG		N60593 001

CYCLOSPORINE

CAPSULE; ORAL

	CYCLOSPORINE			
AB	ABBOTT	**25MG**		**N65003 001**
				MAY 12, 2000
AB		**100MG**		**N65003 003**
				MAY 12, 2000
		50MG		N65003 002
				MAY 12, 2000
AB	EON	**25MG**		**N65017 002**
				JAN 13, 2000
AB		**100MG**		**N65017 001**
				JAN 13, 2000
AB	SIDMAK LABS	**25MG**		**N65044 002**
				DEC 20, 2000
AB		**100MG**		**N65044 001**
				DEC 20, 2000
	NEORAL			
AB	NOVARTIS	**25MG**		**N50715 001**
				JUL 14, 1995
AB	+	**100MG**		**N50715 002**
				JUL 14, 1995

FDA data supplied by DrugPatentWatch.com

CYCLOSPORINE

CAPSULE; ORAL

	SANDIMMUNE			
BX	NOVARTIS	25MG	N50625 001	MAR 02, 1990
BX		50MG	N50625 003	NOV 23, 1992
BX	+	100MG	N50625 002	MAR 02, 1990

INJECTABLE; INJECTION

	CYCLOSPORINE			
AP	BEDFORD	**50MG/ML**	**N65004 001**	OCT 29, 1999
	SANDIMMUNE			
AP	+ NOVARTIS	**50MG/ML**	**N50573 001**	NOV 14, 1983

SOLUTION; ORAL

	CYCLOSPORINE			
AB	SIDMAK LABS	**100MG/ML**	**N65054 001**	DEC 18, 2001
	NEORAL			
AB	+ NOVARTIS	**100MG/ML**	**N50716 001**	JUL 14, 1995
	SANDIMMUNE			
BX	+ NOVARTIS	100MG/ML	N50574 001	NOV 14, 1983

CYPROHEPTADINE HYDROCHLORIDE

SYRUP; ORAL

	CYPROHEPTADINE HCL			
AA	ALPHARMA	**2MG/5ML**	**N86833 001**	
	PERIACTIN			
AA	+ MERCK	**2MG/5ML**	**N13220 002**	

TABLET; ORAL

	CYPROHEPTADINE HCL			
AA	ABC HOLDING	**4MG**	**N88212 001**	MAY 26, 1983
AA	IVAX PHARMS	**4MG**	**N87056 001**	
AA	PAR PHARM	**4MG**	**N87129 001**	
AA	SIDMAK LABS NJ	**4MG**	**N88205 001**	JUL 26, 1983
	PERIACTIN			
AA	+ MERCK	**4MG**	**N12649 001**	

CYSTEAMINE BITARTRATE

CAPSULE; ORAL

	CYSTAGON			
	MYLAN	EQ 50MG BASE	N20392 001	AUG 15, 1994
	+	EQ 150MG BASE	N20392 002	AUG 15, 1994

CYTARABINE

INJECTABLE; INJECTION

	CYTARABINE			
AP	BEDFORD	**1GM/VIAL**	**N74245 001**	AUG 31, 1994
AP		**2GM/VIAL**	**N74245 002**	AUG 31, 1994
AP		**100MG/VIAL**	**N71471 001**	AUG 02, 1989
AP		**500MG/VIAL**	**N71472 001**	AUG 02, 1989
AP	FAULDING	**2GM/VIAL**	**N75383 001**	NOV 22, 1999
	+	20MG/ML	N71868 001	JUN 04, 1990
	+	20MG/ML	N72168 001	AUG 31, 1990
	+	20MG/ML	N72945 001	FEB 28, 1994
AP	GENSIA SICOR PHARMS	**100MG/VIAL**	**N75206 001**	DEC 30, 1998
AP	+	**500MG/VIAL**	**N75206 002**	DEC 30, 1998
AP		**1GM/VIAL**	**N75206 004**	DEC 30, 1998
AP		**2GM/VIAL**	**N75206 003**	DEC 30, 1998
	CYTOSAR-U			
AP	+ PHARMACIA AND UPJOHN	**100MG/VIAL**	**N16793 001**	
AP	+	**500MG/VIAL**	**N16793 002**	
AP	+	**1GM/VIAL**	**N16793 003**	DEC 21, 1987
AP	+	**2GM/VIAL**	**N16793 004**	DEC 21, 1987

INJECTABLE, LIPOSOMAL; INJECTION

	DEPOCYT			
	+ SKYEPHARMA	10MG/ML	N21041 001	APR 01, 1999

FDA data supplied by DrugPatentWatch.com

DACARBAZINE

INJECTABLE; INJECTION

	DACARBAZINE			
AP	AM PHARM PARTNERS	100MG/VIAL	N75371 001	AUG 27, 1999
AP		200MG/VIAL	N75371 002	AUG 27, 1999
AP	BEDFORD	200MG/VIAL	N75812 001	JUN 15, 2001
AP	FAULDING	200MG/VIAL	N75940 001	OCT 18, 2001
AP	GENSIA SICOR PHARMS	200MG/VIAL	N75259 002	AUG 27, 1998
AP		500MG/VIAL	N75259 001	SEP 22, 2000
	DTIC-DOME			
AP +	BAYER	100MG/VIAL	N17575 001	
AP +		200MG/VIAL	N17575 002	

DACTINOMYCIN

INJECTABLE; INJECTION

	COSMEGEN			
+	MERCK	0.5MG/VIAL	N50682 001	

DALFOPRISTIN; QUINUPRISTIN

INJECTABLE; IV (INFUSION)

	SYNERCID			
	AVENTIS	350MG/VIAL;150MG/VIAL	N50748 001	SEP 21, 1999
+		420MG/VIAL;180MG/VIAL	N50748 002	AUG 24, 2000

DALTEPARIN SODIUM

INJECTABLE; INJECTION

	FRAGMIN			
+	PHARMACIA AND UPJOHN	10,000 IU/ML	N20287 004	JAN 30, 1998
+		2,500 IU/0.2ML	N20287 001	DEC 22, 1994
+		5,000 IU/0.2ML	N20287 003	MAR 18, 1996

DANAPAROID SODIUM

INJECTABLE; INJECTION

	ORGARAN			
+	ORGANON	750 UNITS/0.6ML	N20430 001	DEC 24, 1996

DANAZOL

CAPSULE; ORAL

	DANAZOL			
AB	BARR	50MG	N74582 003	MAY 29, 1998
AB		100MG	N74582 002	MAY 29, 1998
AB		200MG	N74582 001	AUG 09, 1996
	DANOCRINE			
AB	SANOFI SYNTHELABO	50MG	N17557 003	
AB		100MG	N17557 004	
AB +		200MG	N17557 002	

DANTROLENE SODIUM

CAPSULE; ORAL

	DANTRIUM			
	PROCTER AND GAMBLE	25MG	N17443 001	
		50MG	N17443 003	
+		100MG	N17443 002	

INJECTABLE; INJECTION

	DANTRIUM			
+	PROCTER AND GAMBLE	20MG/VIAL	N18264 001	

DAPIPRAZOLE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

	REV-EYES			
+	ANGELINI	0.5%	N19849 001	DEC 31, 1990

DAPSONE

TABLET; ORAL

	DAPSONE			
	JACOBUS	25MG	N86841 001	

FDA data supplied by DrugPatentWatch.com

DAPSONE

TABLET; ORAL
DAPSONE
+ JACOBUS 100MG N86842 001

DAUNORUBICIN CITRATE

INJECTABLE, LIPOSOMAL; INJECTION
DAUNOXOME
+ GILEAD EQ 2MG BASE/ML N50704 002
APR 08, 1996

DAUNORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION
CERUBIDINE
AP + BEDFORD **EQ 20MG BASE/VIAL** **N64103 001**
FEB 03, 1995

DAUNORUBICIN HCL
AP + BEDFORD **EQ 5MG BASE/ML** **N50731 001**
JAN 30, 1998
AP BIGMAR **EQ 20MG BASE/VIAL** **N65000 001**
MAY 25, 1999
AP GENSIA SICOR PHARMS **EQ 5MG BASE/ML** **N65035 001**
JAN 24, 2000
AP **EQ 20MG BASE/VIAL** **N64212 001**
JUN 23, 1998
+ EQ 50MG BASE/VIAL N64212 002
MAY 03, 1999
AP SUPERGEN **EQ 5MG BASE/VIAL** **N65034 001**
NOV 20, 2001

DEFEROXAMINE MESYLATE

INJECTABLE; INJECTION
DESFERAL
+ NOVARTIS 2MG/VIAL N16267 002
MAY 25, 2000
+ 500MG/VIAL N16267 001

DELAVIRDINE MESYLATE

TABLET; ORAL
RESCRIPTOR
AGOURON 100MG N20705 001
APR 04, 1997
+ 200MG N20705 002
JUL 14, 1999

DEMECARIUM BROMIDE

SOLUTION/DROPS; OPHTHALMIC
HUMORSOL
+ MERCK 0.125% N11860 002
+ 0.25% N11860 001

DEMECLOCYCLINE HYDROCHLORIDE

TABLET; ORAL
DECLOMYCIN
LEDERLE 75MG N50261 001
150MG N50261 002
+ 300MG N50261 003

DESERPIDINE; METHYCLOTHIAZIDE

TABLET; ORAL
ENDURONYL
ABBOTT 0.25MG;5MG N12775 001
ENDURONYL FORTE
+ ABBOTT 0.5MG;5MG N12775 002

DESFLURANE

LIQUID; INHALATION
SUPRANE
BAXTER HLTHCARE CORP 99.9% N20118 001
SEP 18, 1992

DESIPRAMINE HYDROCHLORIDE

TABLET; ORAL
DESIPRAMINE HCL
AB EON **10MG** **N74430 001**
FEB 09, 1996

FDA data supplied by DrugPatentWatch.com

DESIPRAMINE HYDROCHLORIDE

TABLET; ORAL

	DESIPRAMINE HCL			
AB	EON	25MG	N71601 001	JUN 05, 1987
AB		50MG	N71588 001	JUN 05, 1987
AB		75MG	N71602 001	OCT 05, 1987
AB		100MG	N71766 001	OCT 05, 1987
AB		150MG	N74430 002	FEB 09, 1996
AB	GENEVA PHARMS	10MG	N72099 001	MAY 24, 1988
AB		25MG	N72100 001	MAY 24, 1988
AB		50MG	N72101 001	MAY 24, 1988
AB		75MG	N72102 001	JUN 20, 1988
AB		100MG	N72103 001	JUN 20, 1988
AB		150MG	N72104 001	JUN 20, 1988
AB	SIDMAK LABS NJ	25MG	N71800 001	DEC 08, 1987
AB		50MG	N71801 001	DEC 08, 1987
AB		75MG	N71802 001	DEC 08, 1987
AB		100MG	N71803 001	MAY 29, 1997
AB		150MG	N71804 001	MAY 29, 1997
	NORPRAMIN			
AB	AVENTIS PHARMS	10MG	N14399 007	FEB 11, 1982
AB		25MG	N14399 001	
AB	+	50MG	N14399 003	
AB		75MG	N14399 004	
AB	+	100MG	N14399 005	
AB		150MG	N14399 006	

DESLORATADINE

TABLET; ORAL

	CLARINEX			
	+ SCHERING PLOUGH	5MG	N21165 001	DEC 21, 2001

DESMOPRESSIN ACETATE

INJECTABLE; INJECTION

	DDAVP			
AP	+ AVENTIS	0.004MG/ML	N18938 001	MAR 30, 1984
	+	0.015MG/ML	N18938 002	APR 25, 1995
	DESMOPRESSIN ACETATE			
AP	ABBOTT	0.004MG/ML	N75220 001	AUG 28, 2000
AP	BEDFORD	0.004MG/ML	N74575 001	FEB 18, 2000
AP	GENSIA SICOR PHARMS	0.004MG/ML	N74888 001	OCT 15, 1997
	DESMOPRESSIN ACETATE PRESERVATIVE FREE			
AP	BEDFORD	0.004MG/ML	N74574 001	FEB 18, 2000

SOLUTION; NASAL

	CONCENTRAID			
BX	FERRING	0.01%	N19776 001	DEC 26, 1990
	DDAVP			
BX	+ AVENTIS	0.01%	N17922 001	

SPRAY, METERED; NASAL

	DDAVP			
AB	+ AVENTIS	0.01MG/SPRAY	N17922 002	FEB 06, 1989
	DDAVP (NEEDS NO REFRIGERATION)			
AB	+ AVENTIS	0.01MG/SPRAY	N17922 003	AUG 07, 1996
	DESMOPRESSIN ACETATE			
AB	BAUSCH AND LOMB	0.01MG/SPRAY	N74830 001	JAN 25, 1999
	STIMATE			
	+ AVENTIS BEHRING	0.15MG/SPRAY	N20355 001	MAR 07, 1994

FDA data supplied by DrugPatentWatch.com

DESMOPRESSIN ACETATE

TABLET; ORAL
DDAVP
AVENTIS 0.1MG N19955 001 SEP 06, 1995
\+ 0.2MG N19955 002 SEP 06, 1995

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-21
DESOGESTREL AND ETHINYL ESTRADIOL
AB DURAMED **0.15MG;0.03MG** **N75256 001** AUG 12, 1999
ORTHO-CEPT
AB + JOHNSON RW **0.15MG;0.03MG** **N20301 001** DEC 14, 1992

TABLET; ORAL-28
CYCLESSA
\+ ORGANON INC 0.1MG,0.125MG,0.15MG;0.025MG, 0.025MG,0.025MG N21090 001 DEC 20, 2000
DESOGEN
AB ORGANON **0.15MG;0.03MG** **N20071 002** DEC 10, 1992
DESOGESTREL AND ETHINYL ESTRADIOL
AB DURAMED **0.15MG;0.03MG** **N75256 002** AUG 12, 1999
MIRCETTE
\+ ORGANON 0.15MG,N/A;0.02MG,0.01MG N20713 001 APR 22, 1998
ORTHO-CEPT
AB JOHNSON RW **0.15MG;0.03MG** **N20301 002** DEC 14, 1992

DESONIDE

CREAM; TOPICAL
DESONIDE
AB COPLEY PHARM **0.05%** **N74027 001** SEP 28, 1992
AB TARO **0.05%** **N73548 001** JUN 30, 1992
DESOWEN
AB GALDERMA LABS LP **0.05%** **N19048 001** DEC 14, 1984

DESONIDE

CREAM; TOPICAL
TRIDESILON
AB + CLAY PARK **0.05%** **N17010 001**

LOTION; TOPICAL
DESOWEN
\+ GALDERMA LABS LP 0.05% N72354 001 JAN 24, 1992

OINTMENT; TOPICAL
DESONIDE
AB ALTANA **0.05%** **N75751 001** MAR 12, 2001
AB TARO **0.05%** **N74254 001** AUG 03, 1994
DESOWEN
AB GALDERMA LABS LP **0.05%** **N71425 001** JUN 15, 1988
TRIDESILON
AB + CLAY PARK **0.05%** **N17426 001**

DESOXIMETASONE

CREAM; TOPICAL
DESOXIMETASONE
AB TARO **0.05%** **N73210 001** NOV 30, 1990
AB **0.25%** **N73193 001** NOV 30, 1990
TOPICORT
AB + MEDICIS **0.25%** **N17856 001**
TOPICORT LP
AB + MEDICIS **0.05%** **N18309 001**

GEL; TOPICAL
DESOXIMETASONE
AB TARO **0.05%** **N74904 001** JUL 14, 1998
TOPICORT
AB + MEDICIS **0.05%** **N18586 001** MAR 29, 1982

OINTMENT; TOPICAL
DESOXIMETASONE
AB ALTANA **0.25%** **N73440 001** APR 01, 1998

FDA data supplied by DrugPatentWatch.com

DESOXIMETASONE

OINTMENT; TOPICAL

	DESOXIMETASONE			
AB	TARO	**0.25%**	**N74286 001**	
			JUN 07, 1996	
	TOPICORT			
AB	+ MEDICIS	**0.25%**	**N18763 001**	
			SEP 30, 1983	

DESOXYRIBONUCLEASE; *MULTIPLE*

SEE CHLORAMPHENICOL; DESOXYRIBONUCLEASE; FIBRINOLYSIN

DEXAMETHASONE

CONCENTRATE; ORAL

	DEXAMETHASONE INTENSOL		
	+ ROXANE	1MG/ML	N88252 001
			SEP 01, 1983

DISC; TOPICAL

	DECASPRAY		
	+ MERCK	0.04%	N12731 002

ELIXIR; ORAL

	DECADRON		
AA	+ MERCK	**0.5MG/5ML**	**N12376 002**
	DEXAMETHASONE		
AA	ALPHARMA	**0.5MG/5ML**	**N84754 001**
	HEXADROL		
AA	ORGANON	**0.5MG/5ML**	**N12674 001**
	MYMETHASONE		
AA	MORTON GROVE	**0.5MG/5ML**	**N88254 001**
			JUL 27, 1983

SOLUTION; ORAL

	DEXAMETHASONE		
	+ ROXANE	0.5MG/5ML	N88248 001
			SEP 01, 1983

SUSPENSION/DROPS; OPHTHALMIC

	MAXIDEX		
	+ ALCON	0.1%	N13422 001

TABLET; ORAL

	DECADRON		
AB	MERCK	**0.5MG**	**N11664 001**

DEXAMETHASONE

TABLET; ORAL

	DECADRON			
AB	+ MERCK	**0.75MG**	**N11664 002**	
AB		**1.5MG**	**N11664 003**	
AB		**4MG**	**N11664 005**	
BP		0.25MG	N11664 004	
BP	+	6MG	N11664 006	
			JUL 30, 1982	
	DEXAMETHASONE			
BP	DANBURY PHARMA	0.25MG	N85455 001	
BP		0.5MG	N85458 001	
BP		1.5MG	N85456 001	
BP	PAR PHARM	0.25MG	N88149 001	
			APR 28, 1983	
BP		0.5MG	N88148 001	
			APR 28, 1983	
BP		0.75MG	N88160 001	
			APR 28, 1983	
BP		1.5MG	N88237 001	
			APR 28, 1983	
BP		4MG	N88238 001	
			APR 28, 1983	
BP		6MG	N88481 001	
			NOV 28, 1983	
AB	ROXANE	**0.5MG**	**N84611 001**	
AB		**0.75MG**	**N84613 001**	
AB		**1.5MG**	**N84610 001**	
AB		**4MG**	**N84612 001**	
BP		6MG	N88316 001	
			SEP 15, 1983	
		1MG	N88306 001	
			SEP 15, 1983	
		2MG	N87916 001	
			AUG 26, 1982	
	HEXADROL			
BP	ORGANON	4MG	N12675 010	

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

	MAXITROL			
AT	+ FALCON PHARMS	**0.1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM**	**N50065 002**	
	NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE			
AT	BAUSCH AND LOMB	**0.1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM**	**N64063 001**	
			JUL 25, 1994	

FDA data supplied by DrugPatentWatch.com

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE

AT		FOUGERA	0.1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM	N62938 001 JUL 31, 1989

SUSPENSION/DROPS; OPHTHALMIC

DEXACIDIN

AT		NOVARTIS	0.1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N62544 001 OCT 29, 1984

DEXASPORIN

AT		BAUSCH AND LOMB	0.1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N64135 001 SEP 13, 1995

MAXITROL

AT		ALCON	0.1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N62341 001 MAY 22, 1984
AT	+	FALCON PHARMS	0.1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N50023 002

NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE

AT		ALCON UNIVERSAL	0.1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N62721 001 NOV 17, 1986

DEXAMETHASONE; TOBRAMYCIN

OINTMENT; OPHTHALMIC

TOBRADEX

	+	ALCON	0.1%;0.3%	N50616 001 SEP 28, 1988

SUSPENSION/DROPS; OPHTHALMIC

TOBRADEX

AB	+	ALCON	0.1%;0.3%	N50592 001 AUG 18, 1988

TOBRAMYCIN AND DEXAMETHASONE

AB		BAUSCH AND LOMB	0.1%;0.3%	N64134 001 OCT 27, 1999

DEXAMETHASONE ACETATE

INJECTABLE; INJECTION

DECADRON-LA

BP	+	MERCK	EQ 8MG BASE/ML	N16675 001

DEXAMETHASONE ACETATE

INJECTABLE; INJECTION

DEXAMETHASONE ACETATE

BP		STERIS	EQ 8MG BASE/ML	N84315 001
	+		EQ 16MG BASE/ML	N87711 001 MAY 24, 1982

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

DECADRON

AP	+	MERCK	EQ 4MG PHOSPHATE/ML	N12071 002
	+		EQ 24MG PHOSPHATE/ML	N12071 004

DEXAMETHASONE

AP		AM PHARM PARTNERS	EQ 10MG PHOSPHATE/ML	N88469 001 JAN 25, 1984
AP		ELKINS SINN	EQ 4MG PHOSPHATE/ML	N84282 001
AP			EQ 10MG PHOSPHATE/ML	N87702 001 SEP 07, 1982

DEXAMETHASONE SODIUM PHOSPHATE

AP		AM PHARM PARTNERS	EQ 4MG PHOSPHATE/ML	N84916 001
AP		GENSIA SICOR PHARMS	EQ 10MG PHOSPHATE/ML	N81126 001 AUG 31, 1990
AP		LUITPOLD	EQ 4MG PHOSPHATE/ML	N87440 001 JUL 21, 1982
AP		STERIS	EQ 4MG PHOSPHATE/ML	N89169 001 APR 09, 1986
AP			EQ 10MG PHOSPHATE/ML	N87668 001 JUL 01, 1982

HEXADROL

AP	+	ORGANON	EQ 4MG PHOSPHATE/ML	N14694 002
AP	+		EQ 10MG PHOSPHATE/ML	N14694 003

OINTMENT; OPHTHALMIC

MAXIDEX

	+	ALCON	EQ 0.05% PHOSPHATE	N83342 001

SOLUTION/DROPS; OPHTHALMIC, OTIC

DECADRON

AT	+	MERCK	EQ 0.1% PHOSPHATE	N11984 001

DEXAMETHASONE SODIUM PHOSPHATE

AT		ALCON UNIVERSAL	EQ 0.1% PHOSPHATE	N88771 001 JAN 16, 1985
AT		BAUSCH AND LOMB	EQ 0.1% PHOSPHATE	N40069 001 JUL 26, 1996

FDA data supplied by DrugPatentWatch.com

DEXAMETHASONE SODIUM PHOSPHATE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
DECADRON W/ XYLOCAINE
+ MERCK — EQ 4MG PHOSPHATE/ML; 10MG/ML — N13334 002

DEXAMETHASONE SODIUM PHOSPHATE; NEOMYCIN SULFATE

SOLUTION/DROPS; OPHTHALMIC
NEODECADRON
+ MERCK — EQ 0.1% PHOSPHATE; EQ 3.5MG BASE/ML — N50322 001

DEXCHLORPHENIRAMINE MALEATE

SYRUP; ORAL
MYLARAMINE
AA MORTON GROVE — **2MG/5ML** — **N88251 001** MAR 23, 1984

POLARAMINE
AA SCHERING — **2MG/5ML** — **N86837 001** JUL 19, 1982

TABLET; ORAL
DEXCHLORPHENIRAMINE MALEATE
AA SIDMAK LABS NJ — **2MG** — **N88682 001** JAN 17, 1986

POLARAMINE
AA + SCHERING — **2MG** — **N86835 001**

DEXMEDETOMIDINE

INJECTABLE; INJECTION
PRECEDEX
+ ABBOTT — EQ 100 UGM BASE/ML — N21038 001 DEC 17, 1999

DEXMETHYLPHENIDATE HYDROCHLORIDE

TABLET; ORAL
FOCALIN
NOVARTIS — 2.5MG — N21278 001 NOV 13, 2001

DEXMETHYLPHENIDATE HYDROCHLORIDE

TABLET; ORAL
FOCALIN
NOVARTIS — 5MG — N21278 002 NOV 13, 2001
+ — 10MG — N21278 003 NOV 13, 2001

DEXPANTHENOL; *MULTIPLE*
SEE ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE
SEE ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K
SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PHYTONADIONE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E
SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

DEXRAZOXANE HYDROCHLORIDE

INJECTABLE; INJECTION
ZINECARD
+ PHARMACIA AND UPJOHN — EQ 250MG BASE/VIAL — N20212 001 MAY 26, 1995
+ — EQ 500MG BASE/VIAL — N20212 002 MAY 26, 1995

DEXTROAMPHETAMINE SACCHARATE; *MULTIPLE*
SEE AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL
DEXEDRINE
+ GLAXOSMITHKLINE — 5MG — N17078 001

FDA data supplied by DrugPatentWatch.com

DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

	DEXEDRINE				
	+ GLAXOSMITHKLINE	10MG		N17078 002	
	+	15MG		N17078 003	

TABLET; ORAL

	DEXEDRINE				
AA	GLAXOSMITHKLINE	**5MG**		**N84935 001**	
	DEXTROAMPHETAMINE SULFATE				
AA	BARR	**5MG**		**N40361 001**	
				JAN 31, 2001	
AA		**10MG**		**N40361 002**	
				JAN 31, 2001	
AA	ENDO PHARMS	**5MG**		**N40299 001**	
				MAY 13, 1999	
	DEXTROSTAT				
AA	+ SHIRE RICHWOOD	**5MG**		**N84051 001**	
AA	+	**10MG**		**N84051 002**	

DEXTROAMPHETAMINE SULFATE; *MULTIPLE*

SEE AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

DEXTROMETHORPHAN HYDROBROMIDE; *MULTIPLE*

SEE BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

	PHENERGAN W/ DEXTROMETHORPHAN				
AA	+ WYETH AYERST	**15MG/5ML;6.25MG/5ML**		**N11265 002**	
				APR 02, 1984	
	PROMETH W/ DEXTROMETHORPHAN				
AA	ALPHARMA	**15MG/5ML;6.25MG/5ML**		**N88762 001**	
				OCT 31, 1984	
	PROMETHAZINE HCL AND DEXTROMETHORPHAN HYDROBROMIDE				
AA	HI TECH PHARMA	**15MG/5ML;6.25MG/5ML**		**N40027 001**	
				JUL 31, 1996	
	PROMETHAZINE W/ DEXTROMETHORPHAN				
AA	MORTON GROVE	**15MG/5ML;6.25MG/5ML**		**N88864 001**	
				JAN 04, 1985	

DEXTROSE

INJECTABLE; INJECTION

	DEXTROSE 10% IN PLASTIC CONTAINER				
AP	ABBOTT	**10GM/100ML**		**N18080 001**	
AP	B BRAUN	**10GM/100ML**		**N18046 001**	
AP		**10GM/100ML**		**N19626 004**	
				FEB 02, 1988	
AP	BAXTER HLTHCARE	**10GM/100ML**		**N16694 001**	
	DEXTROSE 2.5% IN PLASTIC CONTAINER				
	B BRAUN	2.5GM/100ML		N18358 001	
	DEXTROSE 20% IN PLASTIC CONTAINER				
AP	ABBOTT	**20GM/100ML**		**N18564 001**	
				MAR 23, 1982	
AP	BAXTER HLTHCARE	**20GM/100ML**		**N17521 004**	
	DEXTROSE 25%				
	ABBOTT	250MG/ML		N19445 002	
				NOV 23, 1998	
	DEXTROSE 30% IN PLASTIC CONTAINER				
AP	ABBOTT	**30GM/100ML**		**N19345 001**	
				JAN 26, 1985	
AP	BAXTER HLTHCARE	**30GM/100ML**		**N17521 003**	
	DEXTROSE 40% IN PLASTIC CONTAINER				
AP	ABBOTT	**40GM/100ML**		**N18562 001**	
				MAR 23, 1982	
AP	BAXTER HLTHCARE	**40GM/100ML**		**N17521 002**	
	DEXTROSE 5% IN PLASTIC CONTAINER				
AP	ABBOTT	**5GM/100ML**		**N19466 001**	
				JUL 15, 1985	
AP		**5GM/100ML**		**N19479 001**	
				SEP 17, 1985	
AP		**50MG/ML**		**N16367 002**	
AP		**50MG/ML**		**N19222 001**	
				JUL 13, 1984	
AP	B BRAUN	**5GM/100ML**		**N16730 001**	
AP		**5GM/100ML**		**N19626 002**	
				FEB 02, 1988	
AP		**50MG/ML**		**N16730 002**	
AP	BAXTER HLTHCARE	**5GM/100ML**		**N16673 001**	
AP		**50MG/ML**		**N16673 003**	
				OCT 30, 1985	
AP		**5GM/100ML**		**N20179 001**	
				DEC 07, 1992	
AP		**50MG/ML**		**N20179 002**	
				DEC 07, 1992	
AP	DHL	**5GM/100ML**		**N19971 001**	
				SEP 28, 1995	
	DEXTROSE 50% IN PLASTIC CONTAINER				
AP	ABBOTT	**50GM/100ML**		**N18563 001**	
				MAR 23, 1982	

FDA data supplied by DrugPatentWatch.com

DEXTROSE

INJECTABLE; INJECTION

DEXTROSE 50% IN PLASTIC CONTAINER

AP	ABBOTT	50GM/100ML	N19894 001 DEC 26, 1989
AP	BAXTER HLTHCARE	50GM/100ML	N17521 001
AP		50GM/100ML	N20047 001 JUL 02, 1991

DEXTROSE 60% IN PLASTIC CONTAINER

AP	ABBOTT	60GM/100ML	N19346 001 JAN 25, 1985
AP	BAXTER HLTHCARE	60GM/100ML	N17521 005 MAR 26, 1982

DEXTROSE 70% IN PLASTIC CONTAINER

AP	ABBOTT	70GM/100ML	N18561 001 MAR 23, 1982
AP		70GM/100ML	N19893 001 DEC 26, 1989
AP	BAXTER HLTHCARE	70GM/100ML	N17521 006 MAR 26, 1982
AP		70GM/100ML	N20047 003 JUL 02, 1991

DEXTROSE; *MULTIPLE*

SEE ALCOHOL; DEXTROSE

SEE AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

SEE AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

SEE AMINO ACIDS; DEXTROSE

SEE AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

SEE AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

SEE CALCIUM CHLORIDE; DEXTROSE; GLUTATHIONE DISULFIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE

SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

DEXTROSE; *MULTIPLE*

SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

SEE CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SEE CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

SEE CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

DEXTROSE; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

NORMOSOL-M AND DEXTROSE 5% IN PLASTIC CONTAINER

ABBOTT	5GM/100ML;21MG/100ML;128MG/100ML; 234MG/100ML	N17610 001

DEXTROSE; MAGNESIUM ACETATE TETRAHYDRATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

PLASMA-LYTE 56 AND DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	5GM/100ML;32MG/100ML;128MG/100ML; 234MG/100ML	N17385 001

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE

INJECTABLE; INJECTION

ISOLYTE P IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;31MG/100ML;130MG/100ML; 26MG/100ML;320MG/100ML	N19873 001 JUN 10, 1993

ISOLYTE P W/ DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;31MG/100ML;130MG/100ML; 26MG/100ML;320MG/100ML	N19025 001 DEC 27, 1984

FDA data supplied by DrugPatentWatch.com

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS

INJECTABLE; INJECTION
IONOSOL B AND DEXTROSE 5% IN PLASTIC CONTAINER
ABBOTT 5GM/100ML;53MG/100ML;100MG/100ML; 100MG/100ML;180MG/100ML;280MG/100ML; 16MG/100ML N19515 001 MAY 08, 1986

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION
DEXTROSE 5% AND ELECTROLYTE NO.48 IN PLASTIC CONTAINER
BAXTER HLTHCARE 5GM/100ML;31MG/100ML;141MG/100ML; 20MG/100ML;12MG/100ML; 260MG/100ML N17484 001

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS

INJECTABLE; INJECTION
IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER
ABBOTT 5GM/100ML;30MG/100ML;141MG/100ML; 15MG/100ML;260MG/100ML; 25MG/100ML N19513 001 MAY 08, 1986

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION
ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;30MG/100ML;97MG/100ML; 220MG/100ML;140MG/100ML N19844 001 JUN 10, 1993
ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;30MG/100ML;97MG/100ML; 220MG/100ML;140MG/100ML N18273 001

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION
ISOLYTE S IN DEXTROSE 5% IN PLASTIC CONTAINER
AP B BRAUN **5GM/100ML;30MG/100ML;37MG/100ML; 370MG/100ML;530MG/100ML; 500MG/100ML N19843 001** AUG 09, 1993
ISOLYTE S W/ DEXTROSE 5% IN PLASTIC CONTAINER
AP B BRAUN **5GM/100ML;30MG/100ML;37MG/100ML; 370MG/100ML;530MG/100ML; 500MG/100ML N18274 001**
NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER
ABBOTT 5GM/100ML;30MG/100ML;37MG/100ML; 222MG/100ML;526MG/100ML; 502MG/100ML N17609 001
PLASMA-LYTE 148 AND DEXTROSE 5% IN PLASTIC CONTAINER
AP BAXTER HLTHCARE **5GM/100ML;30MG/100ML;37MG/100ML; 368MG/100ML;526MG/100ML; 502MG/100ML N17451 001**

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE; INJECTION
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER
AP BRISTOL MYERS SQUIBB **5GM/100ML;75MG/100ML N17634 004**
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER
AP BRISTOL MYERS SQUIBB **5GM/100ML;150MG/100ML N17634 001**
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER
AP BRISTOL MYERS SQUIBB **5GM/100ML;224MG/100ML N17634 003**
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
AP BRISTOL MYERS SQUIBB **5GM/100ML;300MG/100ML N17634 002**
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% IN PLASTIC CONTAINER
AP B BRAUN **5GM/100ML;75MG/100ML N18744 001** NOV 09, 1982
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER
AP B BRAUN **5GM/100ML;150MG/100ML N18744 002** NOV 09, 1982
AP **5GM/100ML;150MG/100ML N19699 004** SEP 29, 1989

FDA data supplied by DrugPatentWatch.com

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE; INJECTION
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;220MG/100ML N18744 003
NOV 09, 1982

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER

AP B BRAUN **5GM/100ML;300MG/100ML** **N18744 004**
NOV 09, 1982

AP **5GM/100ML;300MG/100ML** **N19699 006**
SEP 29, 1989

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER
ABBOTT 5GM/100ML;149MG/100ML N18371 001

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER

AP ABBOTT **5GM/100ML;224MG/100ML** **N18371 003**

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER
ABBOTT 5GM/100ML;298MG/100ML N18371 002

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM LACTATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS

INJECTABLE; INJECTION
IONOSOL T AND DEXTROSE 5% IN PLASTIC CONTAINER
ABBOTT 5GM/100ML;111MG/100ML;256MG/100ML;
146MG/100ML;207MG/100ML N19514 001
MAY 08, 1986

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION
ISOLYTE M IN DEXTROSE 5% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;150MG/100ML;130MG/100ML;
280MG/100ML;91MG/100ML N19870 001
JUN 10, 1993

ISOLYTE M W/ DEXTROSE 5% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;150MG/100ML;130MG/100ML;
280MG/100ML;91MG/100ML N18270 001

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION
DEXTROSE 5% AND ELECTROLYTE NO 75 IN PLASTIC CONTAINER
BAXTER HLTHCARE 5GM/100ML;205MG/100ML;100MG/100ML;
120MG/100ML;220MG/100ML N18840 001
JUN 29, 1983

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 10MEQ

AP BAXTER HLTHCARE **5GM/100ML;75MG/100ML; 200MG/100ML** **N18037 006**
APR 13, 1982

AP **5GM/100ML;150MG/100ML; 200MG/100ML** **N18037 007**
APR 13, 1982

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 15MEQ (K)

AP BAXTER HLTHCARE **5GM/100ML;224MG/100ML; 200MG/100ML** **N18037 004**

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ

AP BAXTER HLTHCARE **5GM/100ML;150MG/100ML; 200MG/100ML** **N18037 008**
APR 13, 1982

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ (K)

AP BAXTER HLTHCARE **5GM/100ML;300MG/100ML; 200MG/100ML** **N18037 001**

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 30MEQ

AP BAXTER HLTHCARE **5GM/100ML;224MG/100ML; 200MG/100ML** **N18037 005**
APR 13, 1982

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 40MEQ

AP BAXTER HLTHCARE **5GM/100ML;300MG/100ML; 200MG/100ML** **N18037 009**
APR 13, 1982

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ

AP BAXTER HLTHCARE **5GM/100ML;75MG/100ML; 200MG/100ML** **N18037 002**

FDA data supplied by DrugPatentWatch.com

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ (K)

AP BAXTER HLTHCARE 5GM/100ML;150MG/100ML; 200MG/100ML N18037 003

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER

AP BAXTER HLTHCARE 5GM/100ML;75MG/100ML; 330MG/100ML N18629 005 MAR 23, 1982

AP 5GM/100ML;150MG/100ML; 330MG/100ML N18629 002 MAR 23, 1982

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER

AP BAXTER HLTHCARE 5GM/100ML;224MG/100ML; 330MG/100ML N18629 003 MAR 23, 1982

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER

AP BAXTER HLTHCARE 5GM/100ML;150MG/100ML; 330MG/100ML N18629 004 MAR 23, 1982

AP 5GM/100ML;300MG/100ML; 330MG/100ML N18629 006 MAR 23, 1982

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER

AP BAXTER HLTHCARE 5GM/100ML;224MG/100ML; 330MG/100ML N18629 007 MAR 23, 1982

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER

AP BAXTER HLTHCARE 5GM/100ML;300MG/100ML; 330MG/100ML N18629 008 MAR 23, 1982

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER

AP BAXTER HLTHCARE 5GM/100ML;75MG/100ML; 330MG/100ML N18629 001 MAR 23, 1982

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ (K) IN PLASTIC CONTAINER

AP BAXTER HLTHCARE 5GM/100ML;300MG/100ML; 450MG/100ML N18008 010

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

B BRAUN 10GM/100ML;37MG/100ML; 200MG/100ML N19630 031 FEB 17, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

B BRAUN 10GM/100ML;37MG/100ML; 450MG/100ML N19630 037 FEB 17, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

B BRAUN 10GM/100ML;37MG/100ML; 900MG/100ML N19630 043 FEB 17, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER

B BRAUN 5GM/100ML;37MG/100ML; 110MG/100ML N19630 001 FEB 17, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

B BRAUN 5GM/100ML;37MG/100ML; 200MG/100ML N19630 007 FEB 17, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER

B BRAUN 5GM/100ML;37MG/100ML; 330MG/100ML N19630 013 FEB 17, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

B BRAUN 5GM/100ML;37MG/100ML; 450MG/100ML N19630 019 FEB 17, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

B BRAUN 5GM/100ML;37MG/100ML; 900MG/100ML N19630 025 FEB 17, 1988

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

B BRAUN 10GM/100ML;75MG/100ML; 200MG/100ML N19630 032 FEB 17, 1988

FDA data supplied by DrugPatentWatch.com

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;75MG/100ML; 450MG/100ML N19630 038 FEB 17, 1988

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;75MG/100ML; 900MG/100ML N19630 044 FEB 17, 1988

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
B BRAUN 3.3GM/100ML;75MG/100ML; 300MG/100ML N19630 049 MAY 07, 1992

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;75MG/100ML; 110MG/100ML N19630 002 FEB 17, 1988

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
AP B BRAUN **5GM/100ML;75MG/100ML; 200MG/100ML N19630 008** FEB 17, 1988

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER
AP B BRAUN **5GM/100ML;75MG/100ML; 330MG/100ML N19630 014** FEB 17, 1988

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
AP B BRAUN **5GM/100ML;75MG/100ML; 450MG/100ML N19630 020** FEB 17, 1988

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
AP B BRAUN **5GM/100ML;75MG/100ML; 900MG/100ML N19630 026** FEB 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;110MG/100ML; 200MG/100ML N19630 033 FEB 17, 1988

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;110MG/100ML; 450MG/100ML N19630 039 FEB 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;110MG/100ML; 900MG/100ML N19630 045 FEB 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
B BRAUN 3.3GM/100ML;110MG/100ML; 300MG/100ML N19630 050 MAY 07, 1992

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;110MG/100ML; 110MG/100ML N19630 003 FEB 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;110MG/100ML; 200MG/100ML N19630 009 FEB 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;110MG/100ML; 330MG/100ML N19630 015 FEB 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;110MG/100ML; 450MG/100ML N19630 021 FEB 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;110MG/100ML; 900MG/100ML N19630 027 FEB 17, 1988

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;150MG/100ML; 200MG/100ML N19630 034 FEB 17, 1988

FDA data supplied by DrugPatentWatch.com

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;150MG/100ML; 450MG/100ML N19630 040 FEB 17, 1988

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;150MG/100ML; 900MG/100ML N19630 046 FEB 17, 1988

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
B BRAUN 3.3GM/100ML;150MG/100ML; 300MG/100ML N19630 051 MAY 07, 1992

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;150MG/100ML; 110MG/100ML N19630 004 FEB 17, 1988

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
AP B BRAUN **5GM/100ML;150MG/100ML; 200MG/100ML N19630 010** FEB 17, 1988

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER
AP B BRAUN **5GM/100ML;150MG/100ML; 330MG/100ML N19630 016** FEB 17, 1988

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
AP B BRAUN **5GM/100ML;150MG/100ML; 450MG/100ML N19630 022** FEB 17, 1988

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
AP B BRAUN **5GM/100ML;150MG/100ML; 900MG/100ML N19630 028** FEB 17, 1988

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;220MG/100ML; 200MG/100ML N19630 035 FEB 17, 1988

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;220MG/100ML; 450MG/100ML N19630 041 FEB 17, 1988

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;220MG/100ML; 900MG/100ML N19630 047 FEB 17, 1988

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
B BRAUN 3.3GM/100ML;220MG/100ML; 300MG/100ML N19630 052 MAY 07, 1992

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;220MG/100ML; 110MG/100ML N19630 005 FEB 17, 1988

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;220MG/100ML; 200MG/100ML N19630 011 FEB 17, 1988

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;220MG/100ML; 330MG/100ML N19630 017 FEB 17, 1988

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;220MG/100ML; 450MG/100ML N19630 023 FEB 17, 1988

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;220MG/100ML; 900MG/100ML N19630 029 FEB 17, 1988

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;300MG/100ML; 200MG/100ML N19630 036 FEB 17, 1988

FDA data supplied by DrugPatentWatch.com

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

	B BRAUN	10GM/100ML;300MG/100ML; 450MG/100ML	N19630 042 FEB 17, 1988

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	B BRAUN	10GM/100ML;300MG/100ML; 900MG/100ML	N19630 048 FEB 17, 1988

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

	B BRAUN	3.3GM/100ML;300MG/100ML; 300MG/100ML	N19630 053 MAY 07, 1992

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER

	B BRAUN	5GM/100ML;300MG/100ML; 110MG/100ML	N19630 006 FEB 17, 1988

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

AP	B BRAUN	**5GM/100ML;300MG/100ML; 200MG/100ML**	**N19630 012** FEB 17, 1988

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER

AP	B BRAUN	**5GM/100ML;300MG/100ML; 330MG/100ML**	**N19630 018** FEB 17, 1988

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	B BRAUN	**5GM/100ML;300MG/100ML; 450MG/100ML**	**N19630 024** FEB 17, 1988

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	B BRAUN	**5GM/100ML;300MG/100ML; 900MG/100ML**	**N19630 030** FEB 17, 1988

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

	ABBOTT	5GM/100ML;74.5MG/100ML; 225MG/100ML	N18365 002 JUL 05, 1983

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

	ABBOTT	5GM/100ML;149MG/100ML; 225MG/100ML	N18365 006 MAR 28, 1988

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

	ABBOTT	5GM/100ML;74.5MG/100ML; 300MG/100ML	N18876 001 JAN 17, 1986
		5GM/100ML;149MG/100ML; 300MG/100ML	N18876 006 MAR 28, 1988

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	ABBOTT	**5GM/100ML;74.5MG/100ML; 450MG/100ML**	**N18362 005** MAR 28, 1988
AP		**5GM/100ML;74.5MG/100ML; 450MG/100ML**	**N18362 009** JUL 05, 1983
AP	BAXTER HLTHCARE	**5GM/100ML;75MG/100ML; 450MG/100ML**	**N18008 005** APR 28, 1982
AP		**5GM/100ML;150MG/100ML; 450MG/100ML**	**N18008 006** APR 28, 1982

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	ABBOTT	**5GM/100ML;74.5MG/100ML; 900MG/100ML**	**N19691 002** MAR 24, 1988
AP		**5GM/100ML;149MG/100ML; 900MG/100ML**	**N19691 004** MAR 24, 1988
AP	BAXTER HLTHCARE	**5GM/100ML;75MG/100ML; 900MG/100ML**	**N19308 004** APR 05, 1985
AP		**5GM/100ML;150MG/100ML; 900MG/100ML**	**N19308 002** APR 05, 1985

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

	ABBOTT	5GM/100ML;224MG/100ML; 225MG/100ML	N18365 008 MAR 28, 1988

FDA data supplied by DrugPatentWatch.com

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

	ABBOTT	5GM/100ML;224MG/100ML; 300MG/100ML	N18876 007 MAR 28, 1988

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	ABBOTT	**5GM/100ML;224MG/100ML; 450MG/100ML**	**N18362 006** MAR 28, 1988

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	ABBOTT	**5GM/100ML;224MG/100ML; 900MG/100ML**	**N19691 006** MAR 24, 1988

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

	ABBOTT	5GM/100ML;149MG/100ML; 225MG/100ML	N18365 001
		5GM/100ML;298MG/100ML; 225MG/100ML	N18365 009 MAR 28, 1988

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

	ABBOTT	5GM/100ML;298MG/100ML; 300MG/100ML	N18876 008 MAR 28, 1988

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	ABBOTT	**5GM/100ML;149MG/100ML; 450MG/100ML**	**N18362 010** JUL 05, 1983
AP		**5GM/100ML;298MG/100ML; 450MG/100ML**	**N18362 007** MAR 28, 1988
AP	BAXTER HLTHCARE	**5GM/100ML;150MG/100ML; 450MG/100ML**	**N18008 007** APR 28, 1982

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	ABBOTT	**5GM/100ML;149MG/100ML; 900MG/100ML**	**N19691 005** MAR 24, 1988
AP		**5GM/100ML;298MG/100ML; 900MG/100ML**	**N19691 008** MAR 24, 1988

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	**5GM/100ML;150MG/100ML; 900MG/100ML**	**N19308 005** APR 05, 1985
AP		**5GM/100ML;300MG/100ML; 900MG/100ML**	**N19308 003** APR 05, 1985

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

	ABBOTT	5GM/100ML;149MG/100ML; 300MG/100ML	N18876 002 JAN 17, 1986

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

	ABBOTT	5GM/100ML;224MG/100ML; 225MG/100ML	N18365 003 JUL 05, 1983

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

	ABBOTT	5GM/100ML;224MG/100ML; 300MG/100ML	N18876 003 JAN 17, 1986

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	ABBOTT	**5GM/100ML;224MG/100ML; 450MG/100ML**	**N18362 002**
AP	BAXTER HLTHCARE	**5GM/100ML;224MG/100ML; 450MG/100ML**	**N18008 008** APR 28, 1982

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	ABBOTT	**5GM/100ML;224MG/100ML; 900MG/100ML**	**N19691 007** MAR 24, 1988
AP	BAXTER HLTHCARE	**5GM/100ML;224MG/100ML; 900MG/100ML**	**N19308 006** APR 05, 1985

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

	ABBOTT	5GM/100ML;298MG/100ML; 225MG/100ML	N18365 004 JUL 05, 1983

FDA data supplied by DrugPatentWatch.com

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

	ABBOTT	5GM/100ML;298MG/100ML; 300MG/100ML	N18876 004	MAR 28, 1988

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	ABBOTT	**5GM/100ML;298MG/100ML; 450MG/100ML**	**N18362 003**	
AP	BAXTER HLTHCARE	**5GM/100ML;300MG/100ML; 450MG/100ML**	**N18008 009**	APR 28, 1982

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	ABBOTT	**5GM/100ML;298MG/100ML; 900MG/100ML**	**N19691 009**	MAR 24, 1988
AP	BAXTER HLTHCARE	**5GM/100ML;300MG/100ML; 900MG/100ML**	**N19308 007**	APR 05, 1985

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

	ABBOTT	5GM/100ML;74.5MG/100ML; 225MG/100ML	N18365 005	MAR 28, 1988
		5GM/100ML;149MG/100ML; 225MG/100ML	N18365 007	MAR 28, 1988

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

	ABBOTT	5GM/100ML;74.5MG/100ML; 300MG/100ML	N18876 005	MAR 28, 1988
		5GM/100ML;149MG/100ML; 300MG/100ML	N18876 009	MAR 28, 1988

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	ABBOTT	**5GM/100ML;74.5MG/100ML; 450MG/100ML**	**N18362 008**	MAR 28, 1988
AP		**5GM/100ML;149MG/100ML; 450MG/100ML**	**N18362 004**	MAR 28, 1988
AP	BAXTER HLTHCARE	**5GM/100ML;150MG/100ML; 450MG/100ML**	**N18008 004**	

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	ABBOTT	**5GM/100ML;74.5MG/100ML; 900MG/100ML**	**N19691 001**	MAR 24, 1988
AP		**5GM/100ML;149MG/100ML; 900MG/100ML**	**N19691 003**	MAR 24, 1988
AP	BAXTER HLTHCARE	**5GM/100ML;150MG/100ML; 900MG/100ML**	**N19308 001**	APR 05, 1985

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 10% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER

	B BRAUN	10GM/100ML;110MG/100ML	N19631 011	FEB 24, 1988

DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

	B BRAUN	10GM/100ML;200MG/100ML	N19631 012	FEB 24, 1988

DEXTROSE 10% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER

	B BRAUN	10GM/100ML;330MG/100ML	N19631 013	FEB 24, 1988

DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

	B BRAUN	10GM/100ML;450MG/100ML	N19631 014	FEB 24, 1988

DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	B BRAUN	**10GM/100ML;900MG/100ML**	**N19631 015**	FEB 24, 1988
AP	BAXTER HLTHCARE	**10GM/100ML;900MG/100ML**	**N16696 001**	

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER

	B BRAUN	2.5GM/100ML;110MG/100ML	N19631 001	FEB 24, 1988

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

	B BRAUN	2.5GM/100ML;200MG/100ML	N19631 002	FEB 24, 1988

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER

	B BRAUN	2.5GM/100ML;330MG/100ML	N19631 003	FEB 24, 1988

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	ABBOTT	**2.5GM/100ML;450MG/100ML**	**N18096 001**	

FDA data supplied by DrugPatentWatch.com

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	B BRAUN	2.5GM/100ML;450MG/100ML	N19631 004	FEB 24, 1988
AP	BAXTER HLTHCARE	2.5GM/100ML;450MG/100ML	N16697 001	

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	B BRAUN	2.5GM/100ML;900MG/100ML	N19631 005	FEB 24, 1988

DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

	B BRAUN	3.3GM/100ML;300MG/100ML	N19631 016	JAN 19, 1990

DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER

	B BRAUN	5GM/100ML;110MG/100ML	N19631 006	FEB 24, 1988

DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

AP	B BRAUN	5GM/100ML;200MG/100ML	N19631 007	FEB 24, 1988

DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

	ABBOTT	5GM/100ML;225MG/100ML	N17606 001	

DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

	ABBOTT	5GM/100ML;300MG/100ML	N17799 001	

DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER

AP	B BRAUN	5GM/100ML;330MG/100ML	N19631 008	FEB 24, 1988

DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	ABBOTT	5GM/100ML;450MG/100ML	N17607 001	
AP	B BRAUN	5GM/100ML;450MG/100ML	N19631 009	FEB 24, 1988

DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	ABBOTT	5GM/100ML;900MG/100ML	N17585 001	
AP	B BRAUN	5GM/100ML;900MG/100ML	N19631 010	FEB 24, 1988

DEXTROSE 5% IN SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	5GM/100ML;200MG/100ML	N16689 001	

DEXTROSE 5% IN SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	5GM/100ML;330MG/100ML	N16687 001	

DEXTROSE 5% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	5GM/100ML;450MG/100ML	N16683 001	

DEXTROSE 5% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	5GM/100ML;900MG/100ML	N16678 001	

DIATRIZOATE MEGLUMINE

INJECTABLE; INJECTION

DIATRIZOATE MEGLUMINE

+	BRACCO	76%	N10040 017	

DIATRIZOATE MEGLUMINE

INJECTABLE; INJECTION

HYPAQUE

AP	+ AMERSHAM HLTH	30%	N16403 002	
AP	+	60%	N16403 001	

RENO-60

AP	+ BRACCO	60%	N10040 016	

RENO-DIP

AP	+ BRACCO	30%	N10040 012	

SOLUTION; URETERAL

RENO-30

	BRACCO	30%	N10040 021	

SOLUTION; URETHRAL

CYSTOGRAFIN

AT	BRACCO	30%	N10040 018	

CYSTOGRAFIN DILUTE

	BRACCO	18%	N10040 022	NOV 09, 1982

HYPAQUE-CYSTO

AT	AMERSHAM HLTH	30%	N16403 003	

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

INJECTABLE; INJECTION

HYPAQUE-76

AP	AMERSHAM HLTH	66%;10%	N86505 001	

MD-76R

AP	+ MALLINCKRODT	66%;10%	N19292 001	SEP 29, 1989

RENOCAL-76

AP	BRACCO	66%;10%	N89347 001	JUN 01, 1988

RENOGRAFIN-60

+	BRACCO	52%;8%	N10040 006	

RENOGRAFIN-76

AP	+ BRACCO	66%;10%	N10040 001	

RENOVIST

+	BRACCO	34.3%;35%	N10040 020	

RENOVIST II

+	BRACCO	28.5%;29.1%	N10040 019	

SOLUTION; ORAL, RECTAL

GASTROGRAFIN

AA	+ BRACCO	66%;10%	N11245 003	

MD-GASTROVIEW

AA	MALLINCKRODT	66%;10%	N87388 001	

FDA data supplied by DrugPatentWatch.com

DIATRIZOATE MEGLUMINE; IODIPAMIDE MEGLUMINE

SOLUTION; INTRAUTERINE
SINOGRAFIN
BRACCO 52.7%;26.8% N11324 002

DIATRIZOATE SODIUM

FOR SOLUTION; ORAL, RECTAL
HYPAQUE
AMERSHAM HLTH 100% N11386 001

INJECTABLE; INJECTION
HYPAQUE
+ AMERSHAM HLTH 25% N09561 003
+ 50% N09561 001

SOLUTION; ORAL, RECTAL
HYPAQUE
AMERSHAM HLTH 40% N11386 003

SOLUTION; URETERAL
HYPAQUE SODIUM 20%
+ AMERSHAM HLTH 20% N09561 002

DIATRIZOATE SODIUM; *MULTIPLE*
SEE DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

DIAZEPAM

CONCENTRATE; ORAL
DIAZEPAM INTENSOL
+ ROXANE 5MG/ML N71415 001 APR 03, 1987

GEL; RECTAL
DIASTAT
+ XCEL PHARMS 2.5MG/0.5ML N20648 001 JUL 29, 1997
5MG/ML N20648 002 JUL 29, 1997
10MG/2ML N20648 003 JUL 29, 1997
15MG/3ML N20648 004 JUL 29, 1997

DIAZEPAM

GEL; RECTAL
DIASTAT
+ XCEL PHARMS 20MG/4ML N20648 005 JUL 29, 1997

INJECTABLE; INJECTION
DIAZEPAM
AP ABBOTT **5MG/ML** **N71583 001** OCT 13, 1987
AP **5MG/ML** **N71584 001** OCT 13, 1987
AP **5MG/ML** **N72079 001** DEC 20, 1988
AP ELKINS SINN **5MG/ML** **N70311 001** DEC 16, 1985
AP **5MG/ML** **N70312 001** DEC 16, 1985
AP **5MG/ML** **N70313 001** DEC 16, 1985
AP LEDERLE **5MG/ML** **N71309 001** JUL 17, 1987
AP **5MG/ML** **N71310 001** JUL 17, 1987
AP MARSAM PHARMS LLC **5MG/ML** **N72370 001** JAN 29, 1993
AP **5MG/ML** **N72397 001** JAN 29, 1993
AP STERIS **5MG/ML** **N70296 001** FEB 12, 1986

VALIUM
AP + ROCHE **5MG/ML** **N16087 001**

SOLUTION; ORAL
DIAZEPAM
+ ROXANE 5MG/5ML N70928 001 APR 03, 1987

TABLET; ORAL
DIAZEPAM
AB BARR **2MG** **N70152 001** NOV 01, 1985
AB **5MG** **N70153 001** NOV 01, 1985
AB **10MG** **N70154 001** NOV 01, 1985
AB DANBURY PHARMA **2MG** **N71134 001** FEB 03, 1987

FDA data supplied by DrugPatentWatch.com

DIAZEPAM

TABLET; ORAL

DIAZEPAM

AB	DANBURY PHARMA	5MG	**N71135 001**	FEB 03, 1987
AB		10MG	**N71136 001**	FEB 03, 1987
AB	GENEVA PHARMS	2MG	**N70302 001**	DEC 20, 1985
AB		5MG	**N70303 001**	DEC 20, 1985
AB		10MG	**N70304 001**	DEC 20, 1985
AB	IVAX PHARMS	2MG	**N71307 001**	DEC 10, 1986
AB		5MG	**N71321 001**	DEC 10, 1986
AB		10MG	**N71322 001**	DEC 10, 1986
AB	LEDERLE	2MG	**N70226 001**	SEP 26, 1985
AB		5MG	**N70227 001**	SEP 26, 1985
AB		10MG	**N70228 001**	SEP 26, 1985
AB	MYLAN	2MG	**N70323 001**	SEP 04, 1985
AB		5MG	**N70324 001**	SEP 04, 1985
AB		10MG	**N70325 001**	SEP 04, 1985
AB	PAR PHARM	2MG	**N70462 001**	FEB 25, 1986
AB		5MG	**N70463 001**	FEB 25, 1986
AB		10MG	**N70464 001**	FEB 25, 1986
AB	PUREPAC PHARM	2MG	**N70781 001**	MAR 19, 1986
AB		5MG	**N70706 001**	MAR 19, 1986
AB		10MG	**N70707 001**	MAR 19, 1986

VALIUM

AB	ROCHE	2MG	**N13263 002**	
AB		5MG	**N13263 004**	
AB	+	10MG	**N13263 006**	

DIAZOXIDE

CAPSULE; ORAL

PROGLYCEM

+	BAKER NORTON	50MG	N17425 001	

INJECTABLE; INJECTION

HYPERSTAT

+	SCHERING	15MG/ML	N16996 001	

SUSPENSION; ORAL

PROGLYCEM

+	BAKER NORTON	50MG/ML	N17453 001	

DICHLORPHENAMIDE

TABLET; ORAL

DARANIDE

+	MERCK	50MG	N11366 001	

DICLOFENAC POTASSIUM

TABLET; ORAL

CATAFLAM

AB	+ NOVARTIS	50MG	**N20142 002**	NOV 24, 1993

DICLOFENAC POTASSIUM

AB	EON	50MG	**N75582 001**	FEB 23, 2001
AB	GENEVA PHARMS TECH	50MG	**N75229 001**	NOV 20, 1998
AB	MYLAN	50MG	**N75463 001**	JUL 26, 1999
AB	TEVA	50MG	**N75219 001**	AUG 06, 1998
AB	WATSON LABS	50MG	**N75152 001**	NOV 27, 1998

DICLOFENAC SODIUM

GEL; TOPICAL

SOLARAZE

+	BIOGLAN PHARMA PLC	3%	N21005 001	OCT 16, 2000

FDA data supplied by DrugPatentWatch.com

DICLOFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC

	VOLTAREN			
+	NOVARTIS	0.1%	N20037 001	MAR 28, 1991

TABLET, DELAYED RELEASE; ORAL

	DICLOFENAC SODIUM			
AB	CARLSBAD	**25MG**	**N75185 002**	NOV 13, 1998
AB		**50MG**	**N75185 003**	NOV 13, 1998
AB		**75MG**	**N75185 001**	NOV 13, 1998
AB	COPLEY PHARM	**25MG**	**N74459 001**	JUN 25, 1997
AB		**50MG**	**N74459 002**	JUN 25, 1997
AB		**75MG**	**N74459 003**	JUN 25, 1997
AB	GENEVA PHARMS	**25MG**	**N74376 001**	SEP 28, 1995
AB		**50MG**	**N74376 002**	SEP 28, 1995
AB		**75MG**	**N74394 001**	NOV 30, 1995
AB	MARTEC	**50MG**	**N74986 001**	FEB 26, 1999
AB		**75MG**	**N74986 002**	FEB 26, 1999
AB	PUREPAC PHARM	**50MG**	**N74514 001**	MAR 26, 1996
AB		**75MG**	**N74514 002**	MAR 26, 1996
AB	ROXANE	**25MG**	**N74391 001**	JUN 29, 1995
AB		**50MG**	**N74391 002**	JUN 29, 1995
AB		**75MG**	**N74391 003**	JUN 29, 1995
AB	SIDMAK LABS NJ	**50MG**	**N74432 002**	JUL 29, 1999
AB		**75MG**	**N74432 003**	JUL 29, 1999
AB	TEVA	**50MG**	**N74723 001**	MAR 30, 1999
AB		**75MG**	**N74390 001**	AUG 15, 1996

DICLOFENAC SODIUM

TABLET, DELAYED RELEASE; ORAL

	VOLTAREN			
AB	+ NOVARTIS	**25MG**	**N19201 001**	JUL 28, 1988
AB	+	**50MG**	**N19201 002**	JUL 28, 1988
AB	+	**75MG**	**N19201 003**	JUL 28, 1988

TABLET, EXTENDED RELEASE; ORAL

	DICLOFENAC SODIUM			
AB	BIOVAIL	**100MG**	**N75492 001**	FEB 11, 2000
AB	MYLAN	**100MG**	**N76152 001**	DEC 13, 2001
	VOLTAREN-XR			
AB	+ NOVARTIS	**100MG**	**N20254 001**	MAR 08, 1996

DICLOFENAC SODIUM; MISOPROSTOL

TABLET, DELAYED RELEASE; ORAL

	ARTHROTEC			
+	GD SEARLE LLC	50MG;0.2MG	N20607 001	DEC 24, 1997
+		75MG;0.2MG	N20607 002	DEC 24, 1997

DICLOXACILLIN SODIUM

CAPSULE; ORAL

	DICLOXACILLIN SODIUM			
AB	APOTHECON	**EQ 250MG BASE**	**N61454 001**	
AB	+	**EQ 500MG BASE**	**N61454 003**	
		EQ 125MG BASE	N61454 002	
AB	TEVA	**EQ 250MG BASE**	**N62286 001**	JUN 03, 1982
AB		**EQ 500MG BASE**	**N62286 002**	JUN 03, 1982
	PATHOCIL			
AB	WYETH AYERST	**EQ 250MG BASE**	**N50011 002**	
AB		**EQ 500MG BASE**	**N50011 003**	MAR 28, 1983

FOR SUSPENSION; ORAL

	DICLOXACILLIN SODIUM			
AB	+ APOTHECON	**EQ 62.5MG BASE/5ML**	**N61455 001**	

FDA data supplied by DrugPatentWatch.com

DICLOXACILLIN SODIUM

FOR SUSPENSION; ORAL

	PATHOCIL			
AB	WYETH AYERST	**EQ 62.5MG BASE/5ML**	**N50092 001**	

DICUMAROL

TABLET; ORAL

	DICUMAROL			
+	ABBOTT	25MG	N05545 003	

DICYCLOMINE HYDROCHLORIDE

CAPSULE; ORAL

	BENTYL			
AB	+ AVENTIS PHARMS	**10MG**	**N07409 003**	OCT 15, 1984
	DICYCLOMINE HCL			
AB	LANNETT	**10MG**	**N84285 001**	
AB	MYLAN	**10MG**	**N40319 001**	SEP 07, 1999
AB	WATSON LABS	**10MG**	**N85082 001**	JUN 19, 1986
AB	WEST WARD	**10MG**	**N40204 001**	FEB 28, 1997

INJECTABLE; INJECTION

	BENTYL			
AP	+ AVENTIS PHARMS	**10MG/ML**	**N08370 001**	OCT 15, 1984
	BENTYL PRESERVATIVE FREE			
AP	+ AVENTIS PHARMS	**10MG/ML**	**N08370 002**	OCT 15, 1984

SYRUP; ORAL

	BENTYL			
+	AVENTIS PHARMS	10MG/5ML	N07961 002	OCT 15, 1984

TABLET; ORAL

	BENTYL			
AB	+ AVENTIS PHARMS	**20MG**	**N07409 001**	OCT 15, 1984
	DICYCLOMINE HCL			
AB	LANNETT	**20MG**	**N40230 001**	FEB 26, 1999

DICYCLOMINE HYDROCHLORIDE

TABLET; ORAL

	DICYCLOMINE HCL			
AB	MYLAN	**20MG**	**N40317 001**	SEP 07, 1999
AB	WATSON LABS	**20MG**	**N85223 001**	JUL 30, 1986
AB	WEST WARD	**20MG**	**N40161 001**	OCT 01, 1996

DIDANOSINE

CAPSULE, DELAYED REL PELLETS; ORAL

	VIDEX EC			
+	BRISTOL MYERS SQUIBB	125MG	N21183 001	OCT 31, 2000
+		200MG	N21183 002	OCT 31, 2000
+		250MG	N21183 003	OCT 31, 2000
+		400MG	N21183 004	OCT 31, 2000

FOR SOLUTION; ORAL

	VIDEX			
	BRISTOL MYERS SQUIBB	10MG/ML	N20156 001	OCT 09, 1991
		100MG/PACKET	N20155 003	OCT 09, 1991
		167MG/PACKET	N20155 004	OCT 09, 1991
+		250MG/PACKET	N20155 005	OCT 09, 1991

TABLET, CHEWABLE; ORAL

	VIDEX			
+	BRISTOL MYERS SQUIBB	25MG	N20154 002	OCT 09, 1991
		50MG	N20154 003	OCT 09, 1991
		100MG	N20154 004	OCT 09, 1991
		150MG	N20154 005	OCT 09, 1991
		200MG	N20154 006	OCT 28, 1999

FDA data supplied by DrugPatentWatch.com

DIENESTROL

CREAM; VAGINAL
DIENESTROL
+ JOHNSON RW 0.01% N06110 005

DIETHYLPROPION HYDROCHLORIDE

TABLET; ORAL
DIETHYLPROPION HCL
AA ABC HOLDING **25MG** **N88267 001** AUG 25, 1983
AA **25MG** **N88268 001** AUG 25, 1983

TENUATE
AA + AVENTIS PHARMS **25MG** **N11722 002**

TABLET, EXTENDED RELEASE; ORAL
TENUATE DOSPAN
+ AVENTIS PHARMS 75MG N12546 001

DIFENOXIN HYDROCHLORIDE; *MULTIPLE*
SEE ATROPINE SULFATE; DIFENOXIN HYDROCHLORIDE

DIFLORASONE DIACETATE

CREAM; TOPICAL
DIFLORASONE DIACETATE
AB ALTANA **0.05%** **N75187 001** MAR 30, 1998
AB TARO **0.05%** **N75508 001** APR 24, 2000

FLORONE
BX + PHARMACIA AND UPJOHN 0.05% N17741 001
FLORONE E
BX + PHARMACIA AND UPJOHN 0.05% N19259 001 AUG 28, 1985

PSORCON
AB + DERMIK LABS **0.05%** **N20205 001** NOV 20, 1992

OINTMENT; TOPICAL
DIFLORASONE DIACETATE
AB ALTANA **0.05%** **N75374 001** APR 27, 1999

DIFLORASONE DIACETATE

OINTMENT; TOPICAL
DIFLORASONE DIACETATE
AB TARO **0.05%** **N75331 001** MAY 14, 1999

FLORONE
+ PHARMACIA AND UPJOHN 0.05% N17994 001
PSORCON
AB + PHARMACIA AND UPJOHN **0.05%** **N19260 001** AUG 28, 1985

DIFLUNISAL

TABLET; ORAL
DIFLUNISAL
AB DANBURY PHARMA **250MG** **N74400 001** JUL 17, 1997
AB **500MG** **N74400 002** JUL 17, 1997
AB GENEVA PHARMS **500MG** **N74604 001** JUN 10, 1996
AB ROXANE **250MG** **N73562 001** NOV 27, 1992
AB **500MG** **N73563 001** NOV 27, 1992
AB TEVA **250MG** **N73679 001** JUL 31, 1992
AB **500MG** **N73673 001** JUL 31, 1992

DOLOBID
AB MERCK **250MG** **N18445 001** APR 19, 1982
AB + **500MG** **N18445 002** APR 19, 1982

DIGOXIN

CAPSULE; ORAL
LANOXICAPS
GLAXO WELLCOME 0.05MG N18118 002 JUL 26, 1982
0.1MG N18118 003 JUL 26, 1982
+ 0.2MG N18118 001 JUL 26, 1982

FDA data supplied by DrugPatentWatch.com

DIGOXIN

INJECTABLE; INJECTION

	DIGOXIN			
AP	ABBOTT	0.25MG/ML	N40093 001	MAY 16, 1996
AP		0.25MG/ML	N40206 001	AUG 28, 1998
AP	ELKINS SINN	0.25MG/ML	N83391 001	
AP	WYETH AYERST	0.25MG/ML	N84386 001	
	DIGOXIN PEDIATRIC			
AP	ABBOTT	0.1MG/ML	N40092 001	APR 25, 1996
	LANOXIN			
AP	+ GLAXOSMITHKLINE	0.25MG/ML	N09330 002	
	LANOXIN PEDIATRIC			
AP	+ GLAXOSMITHKLINE	0.1MG/ML	N09330 004	

TABLET; ORAL

	DIGOXIN			
AB	AMIDE PHARM	0.125MG	N40282 001	DEC 23, 1999
AB		0.25MG	N40282 002	DEC 23, 1999
	LANOXIN			
AB	GLAXO WELLCOME	0.125MG	N20405 002	SEP 30, 1997
AB	+	0.25MG	N20405 004	SEP 30, 1997

DIHYDROCODEINE BITARTRATE; *MULTIPLE*

SEE ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE
SEE ASPIRIN; CAFFEINE; DIHYDROCODEINE BITARTRATE

DIHYDROERGOTAMINE MESYLATE

INJECTABLE; INJECTION

	D.H.E. 45			
+	NOVARTIS	1MG/ML	N05929 001	

SPRAY, METERED; NASAL

	MIGRANAL			
+	NOVARTIS	0.5MG/INH	N20148 001	DEC 08, 1997

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

	CARDIZEM CD			
AB3	+ AVENTIS PHARMS	120MG	N20062 001	AUG 10, 1992
AB3	+	180MG	N20062 002	DEC 27, 1991
AB3	+	240MG	N20062 003	DEC 27, 1991
AB3	+	300MG	N20062 004	DEC 27, 1991
	CARDIZEM SR			
AB1	+ AVENTIS PHARMS	60MG	N19471 001	JAN 23, 1989
AB1	+	90MG	N19471 002	JAN 23, 1989
AB1	+	120MG	N19471 003	JAN 23, 1989
	CARTIA XT			
AB3	ANDRX PHARMS	120MG	N74752 002	JUL 09, 1998
AB3		180MG	N74752 001	JUL 09, 1998
AB3		240MG	N74752 003	JUL 09, 1998
AB3		300MG	N74752 004	JUL 09, 1998
	DILACOR XR			
AB2	+ WATSON LABS	120MG	N20092 001	MAY 29, 1992
AB2	+	180MG	N20092 002	MAY 29, 1992
AB2	+	240MG	N20092 003	MAY 29, 1992
	DILTIAZEM HCL			
AB2	ANDRX	120MG	N74852 001	OCT 10, 1997
AB2		180MG	N74852 002	OCT 10, 1997
AB2		240MG	N74852 003	OCT 10, 1997
AB1	BIOVAIL	60MG	N74845 001	SEP 15, 1999
AB1		90MG	N74845 002	SEP 15, 1999
AB3		120MG	N20939 001	JAN 28, 2000

FDA data supplied by DrugPatentWatch.com

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

	DILTIAZEM HCL			
AB1	BIOVAIL	120MG	**N74845 003**	SEP 15, 1999
AB3		120MG	**N75116 001**	DEC 23, 1999
AB3		180MG	**N20939 002**	JAN 28, 2000
AB3		180MG	**N75116 002**	DEC 23, 1999
AB3		240MG	**N20939 003**	JAN 28, 2000
AB3		240MG	**N75116 003**	DEC 23, 1999
AB3		300MG	**N20939 004**	JAN 28, 2000
AB3		300MG	**N75116 004**	DEC 23, 1999
AB1	MYLAN	60MG	**N74910 001**	MAY 02, 1997
AB1		90MG	**N74910 002**	MAY 02, 1997
AB1		120MG	**N74910 003**	MAY 02, 1997
AB2		120MG	**N75124 002**	MAR 18, 1998
AB2		180MG	**N75124 003**	MAR 18, 1998
AB2		240MG	**N75124 001**	MAR 18, 1998
AB3	PUREPAC PHARM	120MG	**N74984 001**	DEC 20, 1999
AB3		180MG	**N74984 002**	DEC 20, 1999
AB3		240MG	**N74984 003**	DEC 20, 1999
AB3		300MG	**N74984 004**	DEC 20, 1999
AB1	TEVA	60MG	**N74079 001**	NOV 30, 1993
AB1		90MG	**N74079 002**	NOV 30, 1993
AB1		120MG	**N74079 003**	NOV 30, 1993
AB2	TORPHARM	120MG	**N74943 003**	DEC 19, 2000

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

	DILTIAZEM HCL			
AB2	TORPHARM	180MG	**N74943 002**	DEC 19, 2000
AB2		240MG	**N74943 001**	AUG 06, 1998
	TIAZAC			
BC +	BIOVAIL	120MG	N20401 001	SEP 11, 1995
BC +		180MG	N20401 002	SEP 11, 1995
BC +		240MG	N20401 003	SEP 11, 1995
BC +		300MG	N20401 004	SEP 11, 1995
+		360MG	N20401 005	SEP 11, 1995
+		420MG	N20401 006	OCT 16, 1998

INJECTABLE; INJECTION

	CARDIZEM			
AP +	AVENTIS PHARMS	5MG/ML	**N20027 001**	OCT 24, 1991
AP +		100MG/VIAL	**N20792 001**	SEP 05, 1997
+		25MG/VIAL	N20027 003	AUG 18, 1995
	DILTIAZEM HCL			
AP	ABBOTT	5MG/ML	**N74941 001**	APR 15, 1998
AP		5MG/ML	**N75004 001**	FEB 16, 2000
AP	APOTEX	5MG/ML	**N75375 001**	SEP 30, 1999
AP	BEDFORD	5MG/ML	**N74617 001**	FEB 28, 1996
AP	GENSIA SICOR PHARMS	5MG/ML	**N74894 001**	AUG 26, 1997
AP	INTL MEDICATION	5MG/ML	**N75749 001**	NOV 21, 2001
AP	MERIDIAN MEDCL TECHN	5MG/ML	**N75106 001**	APR 29, 1999
AP	TAYLOR PHARMA	5MG/ML	**N75086 001**	APR 09, 1998

FDA data supplied by DrugPatentWatch.com

DILTIAZEM HYDROCHLORIDE

TABLET; ORAL

CARDIZEM

AB	AVENTIS PHARMS	30MG	N18602 001	NOV 05, 1982
AB		60MG	N18602 002	NOV 05, 1982
AB		90MG	N18602 003	DEC 08, 1986
AB	+	120MG	N18602 004	DEC 08, 1986

DILTIAZEM HCL

AB	APOTHECON	30MG	N74051 001	MAR 31, 1993
AB		60MG	N74051 002	MAR 31, 1993
AB		90MG	N74051 003	MAR 31, 1993
AB		120MG	N74051 004	MAR 31, 1993
AB	COPLEY PHARM	30MG	N74067 001	NOV 05, 1992
AB		60MG	N74067 002	NOV 05, 1992
AB		90MG	N74067 003	NOV 05, 1992
AB		120MG	N74067 004	NOV 05, 1992
AB	IVAX PHARMS	30MG	N74168 001	MAR 03, 1995
AB		60MG	N74168 002	MAR 03, 1995
AB		90MG	N74168 003	MAR 03, 1995
AB		120MG	N74168 004	MAR 03, 1995
AB	LEDERLE	30MG	N74093 001	NOV 05, 1992
AB		60MG	N74093 002	NOV 05, 1992
AB		90MG	N74093 003	NOV 05, 1992
AB		120MG	N74093 004	NOV 05, 1992
AB	MYLAN	30MG	N73185 001	NOV 05, 1992
AB		60MG	N73186 001	NOV 05, 1992

DILTIAZEM HYDROCHLORIDE

TABLET; ORAL

DILTIAZEM HCL

AB	MYLAN	90MG	N72837 001	NOV 05, 1992
AB		120MG	N72838 001	NOV 05, 1992
AB	TEVA	30MG	N74185 001	MAY 31, 1995
AB		60MG	N74185 002	MAY 31, 1995
AB		90MG	N74185 003	MAY 31, 1995
AB		120MG	N74185 004	MAY 31, 1995

DILTIAZEM MALATE

TABLET, EXTENDED RELEASE; ORAL

TIAMATE

+	MERCK	EQ 120MG HCL	N20506 001	OCT 04, 1996
+		EQ 180MG HCL	N20506 002	OCT 04, 1996
+		EQ 240MG HCL	N20506 003	OCT 04, 1996

DILTIAZEM MALATE; ENALAPRIL MALEATE

TABLET, EXTENDED RELEASE; ORAL

TECZEM

+	MERCK	EQ 180MG HCL;5MG	N20507 001	OCT 04, 1996

DIMENHYDRINATE

INJECTABLE; INJECTION

DIMENHYDRINATE

AP	+ STERIS	50MG/ML	N80615 001	
AP	+ WYETH AYERST	50MG/ML	N84316 001	

FDA data supplied by DrugPatentWatch.com

DIMERCAPROL

INJECTABLE; INJECTION
BAL
+ AKORN 10% N05939 001

DIMETHYL SULFOXIDE

SOLUTION; INTRAVESICAL
RIMSO-50
+ RES INDS 50% N17788 001

DINOPROSTONE

GEL; ENDOCERVICAL
PREPIDIL
+ PHARMACIA AND UPJOHN 0.5MG/3GM N19617 001 DEC 09, 1992

INSERT, EXTENDED RELEASE; VAGINAL
CERVIDIL
+ CONTROLLED THERAP 10MG N20411 001 MAR 30, 1995

SUPPOSITORY; VAGINAL
PROSTIN E2
+ PHARMACIA AND UPJOHN 20MG N17810 001

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL
DIPHENHYDRAMINE HCL

AA	BARR	50MG	N80738 001	
AA	DANBURY PHARMA	25MG	N80728 001	
AA		50MG	N80727 001	
AA	+ GENEVA PHARMS	25MG	N80832 001	
AA	+	50MG	N80832 002	
AA	HALSEY	25MG	N84506 001	
AA	ICN	25MG	N80596 001	
AA		50MG	N80592 001	
AA	IMPAX LABS	25MG	N80807 001	
AA	LNK	25MG	N87977 001	JAN 27, 1983
AA		50MG	N87978 001	JAN 27, 1983
AA	MK LABS	25MG	N83087 001	

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL
DIPHENHYDRAMINE HCL

AA	MK LABS	50MG	N83087 002	
AA	MUTUAL PHARM	25MG	N89488 001	JAN 02, 1987
AA		50MG	N89489 001	JAN 02, 1987
AA	PVT FORM	25MG	N83027 001	
AA		50MG	N83027 002	
AA	SUPERPHARM	25MG	N89040 001	MAY 15, 1985

ELIXIR; ORAL
DIPHENHYDRAMINE HCL

AA	LANNETT	12.5MG/5ML	N80939 002	
AA	MK LABS	12.5MG/5ML	N83088 002	
AA	PHARM ASSOC	12.5MG/5ML	N87513 001	FEB 10, 1982
AA	+ ROXANE	12.5MG/5ML	N80643 001	

INJECTABLE; INJECTION
BENADRYL

AP	+ PARKE DAVIS	50MG/ML	N06146 002	

BENADRYL PRESERVATIVE FREE

AP	+ PARKE DAVIS	50MG/ML	N09486 001	

DIPHENHYDRAMINE HCL

AP	ABBOTT	50MG/ML	N40140 001	NOV 20, 1998
AP	ELKINS SINN	50MG/ML	N80817 002	
AP	STERIS	50MG/ML	N80873 002	
	+	10MG/ML	N80873 001	
AP	WYETH AYERST	50MG/ML	N80577 001	

DIPHENHYDRAMINE HCL PRESERVATIVE FREE

AP	INTL MEDICATION	50MG/ML	N84094 001	
AP	STERIS	50MG/ML	N80873 003	

DIPHENIDOL HYDROCHLORIDE

TABLET; ORAL
VONTROL
+ GLAXOSMITHKLINE EQ 25MG BASE N16033 001

DIPHENOXYLATE HYDROCHLORIDE; *MULTIPLE*
SEE ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

DIPIVEFRIN HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

	AKPRO				
AT	AKORN	0.1%	**N74382 001**		
			SEP 29, 1995		
	DIPIVEFRIN HCL				
AT	BAUSCH AND LOMB	0.1%	**N74188 001**		
			MAY 19, 1995		
AT	FALCON PHARMS	0.1%	**N73636 001**		
			JUN 30, 1994		
	PROPINE				
AT	+ ALLERGAN	0.1%	**N18239 001**		

DIPYRIDAMOLE

INJECTABLE; INJECTION

	DIPYRIDAMOLE				
AP	ABBOTT	5MG/ML	**N74601 001**		
			DEC 19, 1997		
AP	AM PHARM PARTNERS	5MG/ML	**N74956 001**		
			SEP 30, 1998		
AP	BEDFORD	5MG/ML	**N74939 001**		
			APR 13, 1998		
AP	ELKINS SINN	5MG/ML	**N74521 001**		
			OCT 18, 1996		
AP	GENSIA SICOR PHARMS	5MG/ML	**N74952 001**		
			NOV 26, 1997		
	IV PERSANTINE				
AP	+ BOEHRINGER INGELHEIM	5MG/ML	**N19817 001**		
			DEC 13, 1990		

TABLET; ORAL

	DIPYRIDAMOLE				
AB	BARR	25MG	**N87184 001**		
			OCT 03, 1990		
AB		50MG	**N87716 001**		
			OCT 03, 1990		
AB		75MG	**N87717 001**		
			OCT 03, 1990		
AB	GENEVA PHARMS	25MG	**N86944 002**		
			APR 16, 1991		
AB		50MG	**N87562 001**		
			FEB 25, 1992		
AB		75MG	**N87561 001**		
			FEB 25, 1992		
AB	LEDERLE	25MG	**N88999 001**		
			FEB 05, 1991		

DIPYRIDAMOLE

TABLET; ORAL

	DIPYRIDAMOLE				
AB	LEDERLE	50MG	**N89000 001**		
			FEB 05, 1991		
AB		75MG	**N89001 001**		
			FEB 05, 1991		
AB	PUREPAC PHARM	25MG	**N89425 001**		
			JUL 12, 1990		
AB	WATSON LABS	50MG	**N87160 001**		
			JUN 07, 1996		
	PERSANTINE				
AB	BOEHRINGER INGELHEIM	25MG	**N12836 003**		
			DEC 22, 1986		
AB	+	50MG	**N12836 004**		
			FEB 06, 1987		
AB		75MG	**N12836 005**		
			FEB 06, 1987		

DIPYRIDAMOLE; *MULTIPLE*
SEE ASPIRIN; DIPYRIDAMOLE

DIRITHROMYCIN

TABLET, DELAYED RELEASE; ORAL

	DYNABAC				
	+ LILLY RES LABS	250MG	N50678 001		
			JUN 19, 1995		

DISOPYRAMIDE PHOSPHATE

CAPSULE; ORAL

	DISOPYRAMIDE PHOSPHATE				
AB	DANBURY PHARMA	EQ 100MG BASE	**N70173 001**		
			MAY 31, 1985		
AB		EQ 150MG BASE	**N70174 001**		
			MAY 31, 1985		
AB	GENEVA PHARMS	EQ 100MG BASE	**N70470 001**		
			DEC 10, 1985		
AB		EQ 150MG BASE	**N70471 001**		
			DEC 10, 1985		
AB	IVAX PHARMS	EQ 100MG BASE	**N70186 001**		
			NOV 18, 1985		
AB		EQ 150MG BASE	**N70187 001**		
			NOV 18, 1985		

FDA data supplied by DrugPatentWatch.com

DISOPYRAMIDE PHOSPHATE

CAPSULE; ORAL
DISOPYRAMIDE PHOSPHATE

AB	SUPERPHARM	EQ 100MG BASE	N70940 001	FEB 09, 1987
AB	TEVA	EQ 100MG BASE	N70101 001	FEB 22, 1985
AB		EQ 150MG BASE	N70102 001	FEB 22, 1985

NORPACE

AB	GD SEARLE LLC	EQ 100MG BASE	N17447 001	
AB	+	EQ 150MG BASE	N17447 002	

CAPSULE, EXTENDED RELEASE; ORAL
DISOPYRAMIDE PHOSPHATE

AB	KV PHARM	EQ 150MG BASE	N71200 001	DEC 15, 1987

NORPACE CR

AB	+ GD SEARLE LLC	EQ 150MG BASE	N18655 002	JUL 20, 1982
		EQ 100MG BASE	N18655 001	JUL 20, 1982

DISULFIRAM

TABLET; ORAL
ANTABUSE

	ODYSSEY PHARMS	250MG	N88482 001	DEC 08, 1983
	+	500MG	N88483 001	DEC 08, 1983

DIVALPROEX SODIUM

CAPSULE, DELAYED REL PELLETS; ORAL
DEPAKOTE

	+ ABBOTT	EQ 125MG VALPROIC ACID	N19680 001	SEP 12, 1989

TABLET, DELAYED RELEASE; ORAL
DEPAKOTE

	+ ABBOTT	EQ 125MG VALPROIC ACID	N18723 003	OCT 26, 1984
	+	EQ 250MG VALPROIC ACID	N18723 001	MAR 10, 1983

DIVALPROEX SODIUM

TABLET, DELAYED RELEASE; ORAL
DEPAKOTE

	+ ABBOTT	EQ 500MG VALPROIC ACID	N18723 002	MAR 10, 1983

TABLET, EXTENDED RELEASE; ORAL
DEPAKOTE ER

	+ ABBOTT	EQ 500MG VALPROIC ACID	N21168 001	AUG 04, 2000

DOBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
DOBUTAMINE HCL

AP	ABBOTT	EQ 1.25GM BASE/100ML	N74634 001	SEP 27, 1996
AP		EQ 12.5MG BASE/ML	N74086 001	NOV 29, 1993
AP		EQ 12.5MG BASE/ML	N74292 001	FEB 16, 1995
AP	ASTRAZENECA	EQ 12.5MG BASE/ML	N74098 001	FEB 21, 1995
AP	BEDFORD	EQ 12.5MG BASE/ML	N74277 001	OCT 31, 1994
AP	ELKINS SINN	EQ 12.5MG BASE/ML	N74381 001	SEP 26, 1996
AP	GENSIA SICOR PHARMS	EQ 12.5MG BASE/ML	N74206 001	OCT 19, 1993
AP	LUITPOLD	EQ 12.5MG BASE/ML	N74545 001	JUN 25, 1998
AP	MARSAM PHARMS LLC	EQ 12.5MG BASE/ML	N74279 001	FEB 18, 1998
AP		EQ 12.5MG BASE/ML	N74995 001	MAR 31, 1998
AP	STERIS	EQ 12.5MG BASE/ML	N74114 001	NOV 30, 1993

DOBUTAMINE HCL IN DEXTROSE 5%

AP	+ ABBOTT	EQ 50MG BASE/100ML	N20269 001	OCT 19, 1993
AP	+	EQ 100MG BASE/100ML	N20269 002	OCT 19, 1993
AP	+	EQ 200MG BASE/100ML	N20269 003	OCT 19, 1993

DOBUTAMINE HCL IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	+ ABBOTT	EQ 50MG BASE/100ML	N20201 003	OCT 19, 1993

FDA data supplied by DrugPatentWatch.com

DOBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
DOBUTAMINE HCL IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	+	ABBOTT	**EQ 100MG BASE/100ML**	**N20201 002** OCT 19, 1993
AP	+		**EQ 200MG BASE/100ML**	**N20201 001** OCT 19, 1993
AP	+		**EQ 400MG BASE/100ML**	**N20201 006** JUL 07, 1994
AP	+	BAXTER HLTHCARE	**EQ 50MG BASE/100ML**	**N20255 001** OCT 19, 1993
AP	+		**EQ 100MG BASE/100ML**	**N20255 003** OCT 19, 1993
AP	+		**EQ 200MG BASE/100ML**	**N20255 004** OCT 19, 1993
AP	+		**EQ 400MG BASE/100ML**	**N20255 005** OCT 19, 1993

DOBUTREX

AP	+	LILLY	**EQ 12.5MG BASE/ML**	**N17820 002**

DOCETAXEL

INJECTABLE; INJECTION
TAXOTERE

	+	AVENTIS	EQ 40MG BASE/ML	N20449 001 MAY 14, 1996

DOFETILIDE

CAPSULE; ORAL
TIKOSYN

		PFIZER	0.125MG	N20931 001 OCT 01, 1999
			0.25MG	N20931 002 OCT 01, 1999
	+		0.5MG	N20931 003 OCT 01, 1999

DOLASETRON MESYLATE MONOHYDRATE

INJECTABLE; INJECTION
ANZEMET

	+	AVENTIS PHARMS	EQ 20MG BASE/ML	N20624 001 SEP 11, 1997

DOLASETRON MESYLATE MONOHYDRATE

TABLET; ORAL
ANZEMET

		AVENTIS PHARMS	EQ 50MG BASE	N20623 001 SEP 11, 1997
	+		EQ 100MG BASE	N20623 002 SEP 11, 1997

DONEPEZIL HYDROCHLORIDE

TABLET; ORAL
ARICEPT

		EISAI	5MG	N20690 002 NOV 25, 1996
	+		10MG	N20690 001 NOV 25, 1996

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
DOPAMINE HCL

AP	+	ABBOTT	**80MG/100ML**	**N18132 002** FEB 04, 1982
AP	+		**160MG/100ML**	**N18132 003** FEB 04, 1982
AP	+		**40MG/ML**	**N18132 001**
AP			**40MG/ML**	**N74403 001** MAY 23, 1996
AP	+		**80MG/ML**	**N18132 004** JUL 09, 1982
AP		AM PHARM PARTNERS	**80MG/ML**	**N70013 001** JUN 12, 1985
AP	+	ASTRAZENECA	**40MG/ML**	**N18656 001** JUN 28, 1983
AP			**80MG/ML**	**N70091 001** OCT 23, 1985
AP			**160MG/ML**	**N70092 001** OCT 23, 1985
AP	+	ELKINS SINN	**40MG/ML**	**N18398 001**
AP	+		**80MG/ML**	**N18398 002** MAR 22, 1982
AP		GENSIA SICOR PHARMS	**40MG/ML**	**N72999 001** OCT 23, 1991
AP			**80MG/ML**	**N73000 001** OCT 23, 1991
AP	+	INTL MEDICATION	**40MG/ML**	**N18014 001**

FDA data supplied by DrugPatentWatch.com

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

		DOPAMINE HCL		
AP		LUITPOLD	**40MG/ML**	**N70799 001** FEB 11, 1987
AP			**80MG/ML**	**N70820 001** FEB 11, 1987
AP			**160MG/ML**	**N70826 001** FEB 11, 1987
		DOPAMINE HCL AND DEXTROSE 5%		
AP	+	B BRAUN	**80MG/100ML**	**N19099 002** OCT 15, 1986
AP	+		**320MG/100ML**	**N19099 004** OCT 15, 1986
		DOPAMINE HCL AND DEXTROSE 5% IN PLASTIC CONTAINER		
AP	+	B BRAUN	**160MG/100ML**	**N19099 003** OCT 15, 1986
	+		40MG/100ML	N19099 001 OCT 15, 1986
		DOPAMINE HCL IN DEXTROSE 5%		
AP	+	ABBOTT	**1.6MG/ML**	**N20542 001** AUG 30, 1995
		DOPAMINE HCL IN DEXTROSE 5% IN PLASTIC CONTAINER		
AP	+	ABBOTT	**80MG/100ML**	**N18826 001** SEP 30, 1983
AP	+		**160MG/100ML**	**N18826 002** SEP 30, 1983
AP	+		**320MG/100ML**	**N18826 003** SEP 30, 1983
AP	+	BAXTER HLTHCARE	**80MG/100ML**	**N19615 001** MAR 27, 1987
AP	+		**160MG/100ML**	**N19615 002** MAR 27, 1987
AP	+		**320MG/100ML**	**N19615 003** MAR 27, 1987
	+		640MG/100ML	N19615 004 MAR 27, 1987
		INTROPIN		
AP	+	FAULDING	**40MG/ML**	**N17395 001**
AP	+		**80MG/ML**	**N17395 002**
AP	+		**160MG/ML**	**N17395 003**

DORZOLAMIDE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

		TRUSOPT		
	+	MERCK	EQ 2% BASE	N20408 001 DEC 09, 1994

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

		COSOPT		
	+	MERCK	EQ 2% BASE;EQ 0.5% BASE	N20869 001 APR 07, 1998

DOXACURIUM CHLORIDE

INJECTABLE; INJECTION

		NUROMAX		
	+	ABBOTT	EQ 1MG BASE/ML	N19946 001 MAR 07, 1991

DOXAPRAM HYDROCHLORIDE

INJECTABLE; INJECTION

		DOPRAM		
AP	+	ROBINS AH	**20MG/ML**	**N14879 001**
		DOXAPRAM HCL		
AP		STERIS	**20MG/ML**	**N73529 001** JAN 30, 1992

DOXAZOSIN MESYLATE

TABLET; ORAL

		CARDURA		
AB	+	PFIZER	**EQ 1MG BASE**	**N19668 001** NOV 02, 1990
AB			**EQ 2MG BASE**	**N19668 002** NOV 02, 1990
AB			**EQ 4MG BASE**	**N19668 003** NOV 02, 1990
AB			**EQ 8MG BASE**	**N19668 004** NOV 02, 1990
		DOXAZOSIN MESYLATE		
AB		EON	**EQ 1MG BASE**	**N75646 001** OCT 18, 2000
AB			**EQ 2MG BASE**	**N75646 002** OCT 18, 2000
AB			**EQ 4MG BASE**	**N75646 003** OCT 18, 2000
AB			**EQ 8MG BASE**	**N75646 004** OCT 18, 2000
AB		GENEVA PHARMS TECH	**EQ 1MG BASE**	**N75432 001** OCT 18, 2000

FDA data supplied by DrugPatentWatch.com

DOXAZOSIN MESYLATE

TABLET; ORAL

	DOXAZOSIN MESYLATE			
AB	GENEVA PHARMS TECH	EQ 2MG BASE	N75432 002	OCT 18, 2000
AB		EQ 4MG BASE	N75432 003	OCT 18, 2000
AB		EQ 8MG BASE	N75432 004	OCT 18, 2000
AB	GENPHARM	EQ 1MG BASE	N75466 001	OCT 18, 2000
AB		EQ 2MG BASE	N75466 002	OCT 18, 2000
AB		EQ 4MG BASE	N75466 003	OCT 18, 2000
AB		EQ 8MG BASE	N75466 004	OCT 18, 2000
AB	IVAX PHARMS	EQ 1MG BASE	N75453 001	OCT 18, 2000
AB		EQ 2MG BASE	N75453 002	OCT 18, 2000
AB		EQ 4MG BASE	N75453 003	OCT 18, 2000
AB		EQ 8MG BASE	N75453 004	OCT 18, 2000
AB	KV PHARM	EQ 1MG BASE	N75609 001	OCT 18, 2000
AB		EQ 2MG BASE	N75609 002	OCT 18, 2000
AB		EQ 4MG BASE	N75609 003	OCT 18, 2000
AB		EQ 8MG BASE	N75609 004	OCT 18, 2000
AB	MYLAN	EQ 1MG BASE	N75509 001	OCT 19, 2000
AB		EQ 2MG BASE	N75509 002	OCT 19, 2000
AB		EQ 4MG BASE	N75509 003	OCT 19, 2000
AB		EQ 8MG BASE	N75509 004	OCT 19, 2000
AB	PUREPAC PHARM	EQ 1MG BASE	N75574 001	OCT 18, 2000
AB		EQ 2MG BASE	N75574 002	OCT 18, 2000
AB		EQ 4MG BASE	N75574 003	OCT 18, 2000

DOXAZOSIN MESYLATE

TABLET; ORAL

	DOXAZOSIN MESYLATE			
AB	PUREPAC PHARM	EQ 8MG BASE	N75574 004	OCT 18, 2000
AB	SIDMAK LABS	EQ 1MG BASE	N75750 001	JUN 08, 2001
AB		EQ 2MG BASE	N75750 002	JUN 08, 2001
AB		EQ 4MG BASE	N75750 003	JUN 08, 2001
AB		EQ 8MG BASE	N75750 004	JUN 08, 2001
AB	TEVA	EQ 1MG BASE	N75353 001	JAN 12, 2001
AB		EQ 1MG BASE	N75536 001	OCT 18, 2000
AB		EQ 2MG BASE	N75353 002	JAN 12, 2001
AB		EQ 2MG BASE	N75536 002	OCT 18, 2000
AB		EQ 4MG BASE	N75353 003	JAN 12, 2001
AB		EQ 4MG BASE	N75536 003	OCT 18, 2000
AB		EQ 8MG BASE	N75353 004	JAN 12, 2001
AB		EQ 8MG BASE	N75536 004	OCT 18, 2000
AB	TORPHARM	EQ 1MG BASE	N75580 001	OCT 18, 2000
AB		EQ 2MG BASE	N75580 002	OCT 18, 2000
AB		EQ 4MG BASE	N75580 003	OCT 18, 2000
AB		EQ 8MG BASE	N75580 004	OCT 18, 2000
AB	WATSON LABS	EQ 1MG BASE	N75426 001	OCT 18, 2000
AB		EQ 2MG BASE	N75426 002	OCT 18, 2000
AB		EQ 4MG BASE	N75426 003	OCT 18, 2000
AB		EQ 8MG BASE	N75426 004	OCT 18, 2000

FDA data supplied by DrugPatentWatch.com

DOXEPIN HYDROCHLORIDE

CAPSULE; ORAL
DOXEPIN HCL

AB	DANBURY PHARMA	EQ 10MG BASE	N71485 001	APR 30, 1987
AB		EQ 25MG BASE	N71486 001	APR 30, 1987
AB		EQ 50MG BASE	N71238 001	APR 30, 1987
AB		EQ 75MG BASE	N71326 001	APR 30, 1987
AB		EQ 100MG BASE	N71239 001	APR 30, 1987
AB	GENEVA PHARMS	EQ 10MG BASE	N71487 001	MAR 02, 1987
AB		EQ 25MG BASE	N70827 001	MAY 15, 1986
AB		EQ 50MG BASE	N70828 001	MAY 15, 1986
AB		EQ 75MG BASE	N70825 001	MAY 15, 1986
AB		EQ 100MG BASE	N71562 001	MAR 02, 1987
AB	LEDERLE	EQ 10MG BASE	N71685 001	JAN 05, 1988
AB		EQ 25MG BASE	N71686 001	JAN 05, 1988
AB		EQ 50MG BASE	N71673 001	JAN 05, 1988
AB		EQ 75MG BASE	N71674 001	JAN 05, 1988
AB		EQ 100MG BASE	N71675 001	JAN 05, 1988
AB		EQ 150MG BASE	N71676 001	JAN 05, 1988
AB	MYLAN	EQ 10MG BASE	N70789 001	MAY 13, 1986
AB		EQ 25MG BASE	N70790 001	MAY 13, 1986
AB		EQ 50MG BASE	N70791 001	MAY 13, 1986
AB		EQ 75MG BASE	N70792 001	MAY 13, 1986
AB		EQ 100MG BASE	N70793 001	MAY 13, 1986
AB	PAR PHARM	EQ 10MG BASE	N71697 001	NOV 09, 1987

DOXEPIN HYDROCHLORIDE

CAPSULE; ORAL
DOXEPIN HCL

AB	PAR PHARM	EQ 25MG BASE	N71437 001	NOV 09, 1987
AB		EQ 50MG BASE	N71595 001	NOV 09, 1987
AB		EQ 75MG BASE	N71608 001	NOV 09, 1987
AB		EQ 100MG BASE	N71422 001	NOV 09, 1987
AB		EQ 150MG BASE	N71669 001	NOV 09, 1987
AB	WATSON LABS	EQ 10MG BASE	N72985 001	MAR 29, 1991
AB		EQ 25MG BASE	N72986 001	MAR 29, 1991
AB		EQ 50MG BASE	N72987 001	MAR 29, 1991

SINEQUAN

AB	PFIZER	EQ 10MG BASE	N16798 003	
AB +		EQ 25MG BASE	N16798 001	
AB		EQ 50MG BASE	N16798 002	
AB		EQ 75MG BASE	N16798 006	
AB +		EQ 100MG BASE	N16798 005	
AB		EQ 150MG BASE	N16798 007	

CONCENTRATE; ORAL
DOXEPIN HCL

AA	COPLEY PHARM	EQ 10MG BASE/ML	N71609 001	NOV 09, 1987
AA	MORTON GROVE	EQ 10MG BASE/ML	N71918 001	JUL 20, 1988
AA	SILARX	EQ 10MG BASE/ML	N74721 001	DEC 29, 1998

SINEQUAN

AA +	PFIZER	EQ 10MG BASE/ML	N17516 001	

CREAM; TOPICAL
ZONALON

+	BIOGLAN PHARMA	5%	N20126 001 APR 01, 1994

FDA data supplied by DrugPatentWatch.com

DOXERCALCIFEROL

CAPSULE; ORAL				
HECTOROL				
+ BONE CARE		2.5 UGM	N20862 001	
			JUN 09, 1999	
INJECTABLE; INJECTION				
HECTOROL				
+ BONE CARE		2 UGM/ML	N21027 001	
			APR 06, 2000	

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION				
ADRIAMYCIN PFS				
AP +	PHARMACIA AND UPJOHN	**2MG/ML**	**N50629 001**	
			DEC 23, 1987	
AP +		**200MG/100ML**	**N50629 002**	
			MAY 03, 1988	
AP		**2MG/ML**	**N63165 001**	
			JAN 30, 1991	
AP		**200MG/100ML**	**N63165 002**	
			JAN 30, 1991	
ADRIAMYCIN RDF				
AP +	PHARMACIA AND UPJOHN	**10MG/VIAL**	**N50467 001**	
AP +		**20MG/VIAL**	**N50467 003**	
			MAY 20, 1985	
AP +		**50MG/VIAL**	**N50467 002**	
+		150MG/VIAL	N50467 004	
			JUL 22, 1987	
DOXORUBICIN HCL				
AP	AM PHARM PARTNERS	**2MG/ML**	**N63277 001**	
			OCT 26, 1995	
AP	BEDFORD	**2MG/ML**	**N62975 001**	
			MAR 17, 1989	
AP		**200MG/100ML**	**N64097 001**	
			SEP 13, 1994	
AP		**10MG/VIAL**	**N62921 001**	
			MAR 17, 1989	
AP		**20MG/VIAL**	**N62921 002**	
			MAR 17, 1989	
AP		**50MG/VIAL**	**N62921 003**	
			MAR 17, 1989	
AP	GENSIA SICOR PHARMS	**2MG/ML**	**N64140 001**	
			JUL 28, 1995	
AP		**200MG/100ML**	**N64140 002**	
			JUL 28, 1995	

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION				
DOXORUBICIN HCL				
AP	PHARMACHEMIE	**2MG/ML**	**N63336 001**	
			FEB 28, 1995	
AP		**200MG/100ML**	**N63336 004**	
			FEB 28, 1995	
AP		**10MG/VIAL**	**N63097 001**	
			MAY 21, 1990	
AP		**20MG/VIAL**	**N63097 002**	
			MAY 21, 1990	
AP		**50MG/VIAL**	**N63097 003**	
			MAY 21, 1990	
RUBEX				
AP	BRISTOL MYERS SQUIBB	**10MG/VIAL**	**N62926 001**	
			APR 13, 1989	
AP		**50MG/VIAL**	**N62926 002**	
			APR 13, 1989	
		100MG/VIAL	N62926 003	
			APR 13, 1989	
INJECTABLE, LIPOSOMAL; INJECTION				
DOXIL				
+ ALZA		2MG/ML	N50718 001	
			NOV 17, 1995	

DOXYCYCLINE

CAPSULE; ORAL				
DOXYCYCLINE				
AB	EON	**EQ 50MG BASE**	**N65032 001**	
			JUN 30, 2000	
AB		**EQ 100MG BASE**	**N65032 002**	
			JUN 30, 2000	
AB	HALSEY	**EQ 50MG BASE**	**N65041 001**	
			APR 28, 2000	
AB		**EQ 100MG BASE**	**N65041 002**	
			APR 28, 2000	
AB	PAR PHARM	**EQ 50MG BASE**	**N65055 001**	
			DEC 01, 2000	
AB		**EQ 100MG BASE**	**N65055 002**	
			DEC 01, 2000	
AB	RANBAXY	**EQ 50MG BASE**	**N65053 001**	
			NOV 22, 2000	
AB		**EQ 100MG BASE**	**N65053 002**	
			NOV 22, 2000	

FDA data supplied by DrugPatentWatch.com

DOXYCYCLINE

CAPSULE; ORAL

	MONODOX			
AB	OCLASSEN	EQ 50MG BASE	N50641 002	FEB 10, 1992
AB +		EQ 100MG BASE	N50641 001	DEC 29, 1989

FOR SUSPENSION; ORAL

	VIBRAMYCIN		
+	PFIZER	EQ 25MG BASE/5ML	N50006 001

TABLET; ORAL

	DOXYCYCLINE		
	PAR PHARM	EQ 50MG BASE	N65070 001 DEC 15, 2000
+		EQ 100MG BASE	N65070 002 DEC 15, 2000

DOXYCYCLINE CALCIUM

SUSPENSION; ORAL

	VIBRAMYCIN		
+	PFIZER	EQ 50MG BASE/5ML	N50480 001

DOXYCYCLINE HYCLATE

CAPSULE; ORAL

	DOXYCYCLINE HYCLATE		
AB	DANBURY PHARMA	EQ 50MG BASE	N62031 002 OCT 13, 1982
AB		EQ 100MG BASE	N62031 001
AB	HALSEY	EQ 50MG BASE	N61717 001
AB		EQ 100MG BASE	N61717 002
AB	IVAX PHARMS	EQ 50MG BASE	N62500 001 SEP 11, 1984
AB		EQ 100MG BASE	N62500 002 SEP 11, 1984
AB	MUTUAL PHARM	EQ 50MG BASE	N62675 001 JUL 10, 1986
AB		EQ 100MG BASE	N62676 001 JUL 10, 1986
AB	MYLAN	EQ 50MG BASE	N62337 001 MAR 29, 1982
AB		EQ 100MG BASE	N62337 002 MAR 29, 1982

DOXYCYCLINE HYCLATE

CAPSULE; ORAL

	DOXYCYCLINE HYCLATE		
AB	WEST WARD	EQ 50MG BASE	N62396 002 NOV 07, 1984
AB		EQ 100MG BASE	N62396 001 MAY 07, 1984
	PERIOSTAT		
+	COLLAGENEX	EQ 20MG BASE	N50744 001 SEP 30, 1998
	VIBRAMYCIN		
AB	PFIZER	EQ 50MG BASE	N50007 001
AB +		EQ 100MG BASE	N50007 002

CAPSULE, COATED PELLETS; ORAL

	DORYX		
AB +	FAULDING	EQ 100MG BASE	N50582 001 JUL 22, 1985
AB	WARNER CHILCOTT	EQ 100MG BASE	N62653 001 OCT 30, 1985

INJECTABLE; INJECTION

	DOXY 100		
AP	AM PHARM PARTNERS	EQ 100MG BASE/VIAL	N62475 001 DEC 09, 1983
	DOXY 200		
AP	AM PHARM PARTNERS	EQ 200MG BASE/VIAL	N62475 002 DEC 09, 1983
	VIBRAMYCIN		
AP +	PFIZER	EQ 100MG BASE/VIAL	N50442 002
AP +		EQ 200MG BASE/VIAL	N50442 001

LIQUID, EXTENDED RELEASE; PERIODONTAL

	ATRIDOX		
+	ATRIX	EQ 10% W/W	N50751 001 SEP 03, 1998

TABLET; ORAL

	DOXYCYCLINE HYCLATE		
AB	DANBURY PHARMA	EQ 100MG BASE	N62421 001 FEB 02, 1983
AB	HALSEY	EQ 100MG BASE	N62269 001
AB		EQ 100MG BASE	N62269 002 NOV 08, 1982
AB	IVAX PHARMS	EQ 100MG BASE	N62505 001 SEP 11, 1984
AB	MUTUAL PHARM	EQ 100MG BASE	N62677 001 JUL 10, 1986

FDA data supplied by DrugPatentWatch.com

DOXYCYCLINE HYCLATE

TABLET; ORAL

	DOXYCYCLINE HYCLATE			
AB	MYLAN	**EQ 100MG BASE**	**N62432 001**	
			FEB 15, 1983	
AB	VINTAGE PHARMS	**EQ 100MG BASE**	**N62538 001**	
			APR 07, 1986	
	PERIOSTAT			
+	COLLAGENEX PHARMS	20MG	N50783 001	
			FEB 02, 2001	
	VIBRA-TABS			
AB	+ PFIZER	**EQ 100MG BASE**	**N50533 001**	

DRONABINOL

CAPSULE; ORAL

	MARINOL			
	UNIMED	2.5MG	N18651 001	
			MAY 31, 1985	
		5MG	N18651 002	
			MAY 31, 1985	
+		10MG	N18651 003	
			MAY 31, 1985	

DROPERIDOL

INJECTABLE; INJECTION

	DROPERIDOL			
AP	ABBOTT	**2.5MG/ML**	**N71981 001**	
			FEB 29, 1988	
AP		**2.5MG/ML**	**N72272 001**	
			AUG 31, 1995	
AP	FAULDING	**2.5MG/ML**	**N71645 001**	
			APR 07, 1988	
AP	LUITPOLD	**2.5MG/ML**	**N72123 001**	
			OCT 24, 1988	
AP		**2.5MG/ML**	**N72335 001**	
			OCT 24, 1988	
	INAPSINE			
AP	+ AKORN	**2.5MG/ML**	**N16796 001**	

DROPERIDOL; FENTANYL CITRATE

INJECTABLE; INJECTION

	FENTANYL CITRATE AND DROPERIDOL			
AP	+ ABBOTT	**2.5MG/ML; EQ 0.05MG BASE/ML**	**N71982 001**	
			MAY 04, 1988	
AP	ASTRAZENECA	**2.5MG/ML; EQ 0.05MG BASE/ML**	**N72026 001**	
			APR 13, 1989	

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET; ORAL-28

	YASMIN			
+	BERLEX LABS	3MG;0.03MG	N21098 001	
			MAY 11, 2001	

DUTASTERIDE

CAPSULE; ORAL

	DUTASTERIDE			
+	GLAXOSMITHKLINE	0.5MG	N21319 001	
			NOV 20, 2001	

DYPHYLLINE

TABLET; ORAL

	DILOR			
BP	SAVAGE LABS	200MG	N84514 001	
	DILOR-400			
BP +	SAVAGE LABS	400MG	N84751 001	
	LUFYLLIN			
BP	WALLACE LABS	200MG	N84566 001	
BP		400MG	N84566 002	

ECHOTHIOPHATE IODIDE

FOR SOLUTION; OPHTHALMIC

	PHOSPHOLINE IODIDE			
+	AYERST	0.03%	N11963 002	
+		0.06%	N11963 004	
+		0.125%	N11963 001	
+		0.25%	N11963 003	

FDA data supplied by DrugPatentWatch.com

ECONAZOLE NITRATE

CREAM; TOPICAL
SPECTAZOLE
+ JOHNSON AND JOHNSON 1% N18751 001 DEC 23, 1982

EDETATE CALCIUM DISODIUM

INJECTABLE; INJECTION
CALCIUM DISODIUM VERSENATE
+ 3M 200MG/ML N08922 001

EDETATE DISODIUM

INJECTABLE; INJECTION
EDETATE DISODIUM
AP STERIS **150MG/ML** **N80391 001**
ENDRATE
AP + ABBOTT **150MG/ML** **N11355 001**

EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION
EDROPHONIUM CHLORIDE
AP ABBOTT **10MG/ML** **N40131 001** FEB 24, 1998

ENLON
AP BAXTER HLTHCARE CORP **10MG/ML** **N88873 001** AUG 06, 1985

REVERSOL
AP ORGANON **10MG/ML** **N89624 001** MAY 13, 1988

TENSILON
AP + ICN **10MG/ML** **N07959 001**
TENSILON PRESERVATIVE FREE
AP + ICN **10MG/ML** **N07959 002**

EDROPHONIUM CHLORIDE; *MULTIPLE*
SEE ATROPINE SULFATE; EDROPHONIUM CHLORIDE

EFAVIRENZ

CAPSULE; ORAL
SUSTIVA
BRISTOL MYERS SQUIBB 50MG N20972 001 SEP 17, 1998
100MG N20972 002 SEP 17, 1998
+ 200MG N20972 003 SEP 17, 1998

EFLORNITHINE HYDROCHLORIDE

CREAM; TOPICAL
VANIQA
+ WESTWOOD SQUIBB CLTN 13.9% N21145 001 JUL 27, 2000

EMEDASTINE DIFUMARATE

SOLUTION/DROPS; OPHTHALMIC
EMADINE
+ ALCON 0.05% N20706 001 DEC 29, 1997

ENALAPRIL MALEATE

TABLET; ORAL
ENALAPRIL MALEATE
AB APOTHECON **2.5MG** **N75583 001** AUG 22, 2000
AB **5MG** **N75583 002** AUG 22, 2000
AB **10MG** **N75583 003** AUG 22, 2000
AB **20MG** **N75583 004** AUG 22, 2000
AB EON **2.5MG** **N75621 001** AUG 22, 2000
AB **5MG** **N75621 002** AUG 22, 2000
AB **10MG** **N75621 003** AUG 22, 2000
AB **20MG** **N75621 004** AUG 22, 2000

FDA data supplied by DrugPatentWatch.com

ENALAPRIL MALEATE

TABLET; ORAL

ENALAPRIL MALEATE

AB	GENEVA PHARMS	2.5MG	N75048 001 AUG 22, 2000
AB		5MG	N75048 002 AUG 22, 2000
AB		10MG	N75048 003 AUG 22, 2000
AB		20MG	N75048 004 AUG 22, 2000
AB	GENPHARM	2.5MG	N75472 001 AUG 22, 2000
AB		5MG	N75472 002 AUG 22, 2000
AB		10MG	N75472 003 AUG 22, 2000
AB		20MG	N75472 004 AUG 22, 2000
AB	IVAX PHARMS	2.5MG	N75482 001 AUG 22, 2000
AB		5MG	N75482 002 AUG 22, 2000
AB		10MG	N75482 003 AUG 22, 2000
AB		20MG	N75482 004 AUG 22, 2000
AB	KRKA DD NOVO MESTO	2.5MG	N75370 001 AUG 22, 2000
AB		5MG	N75370 002 AUG 22, 2000
AB		10MG	N75369 001 AUG 22, 2000
AB		20MG	N75369 002 AUG 22, 2000
AB	LEK PHARM	2.5MG	N75496 001 AUG 22, 2000
AB		5MG	N75496 002 AUG 22, 2000
AB		10MG	N75459 001 AUG 22, 2000
AB		20MG	N75459 002 AUG 22, 2000
AB	MYLAN	2.5MG	N75480 001 AUG 22, 2000
AB		5MG	N75480 002 AUG 22, 2000

ENALAPRIL MALEATE

TABLET; ORAL

ENALAPRIL MALEATE

AB	MYLAN	10MG	N75480 003 AUG 22, 2000
AB		20MG	N75480 004 AUG 22, 2000
AB	RANBAXY	2.5MG	N75556 001 AUG 22, 2000
AB		5MG	N75556 002 AUG 22, 2000
AB		10MG	N75556 003 AUG 22, 2000
AB		20MG	N75556 004 AUG 22, 2000
AB	TARO	2.5MG	N75657 001 JAN 23, 2001
AB		5MG	N75657 002 JAN 23, 2001
AB		10MG	N75657 003 JAN 23, 2001
AB		20MG	N75657 004 JAN 23, 2001
AB	TEVA	2.5MG	N75479 001 AUG 22, 2000
AB		5MG	N75479 002 AUG 22, 2000
AB		10MG	N75479 003 AUG 22, 2000
AB		20MG	N75479 004 AUG 22, 2000
AB	TORPHARM	2.5MG	N75178 002 MAR 23, 2001
AB		5MG	N75178 001 MAR 23, 2001
AB		10MG	N75178 003 MAR 23, 2001
AB		20MG	N75178 004 MAR 23, 2001
AB	WATSON LABS	2.5MG	N75501 001 AUG 22, 2000
AB		5MG	N75501 002 AUG 22, 2000
AB		10MG	N75501 003 AUG 22, 2000
AB		20MG	N75501 004 AUG 22, 2000

FDA data supplied by DrugPatentWatch.com

ENALAPRIL MALEATE

TABLET; ORAL

ENALAPRIL MALEATE

AB	WOCKHARDT	2.5MG	N75483 001	AUG 22, 2000
AB		5MG	N75483 002	AUG 22, 2000
AB		10MG	N75483 003	AUG 22, 2000
AB		20MG	N75483 004	AUG 22, 2000

VASOTEC

AB	MERCK	2.5MG	N18998 005	JUL 26, 1988
AB		5MG	N18998 001	DEC 24, 1985
AB		10MG	N18998 002	DEC 24, 1985
AB +		20MG	N18998 003	DEC 24, 1985

ENALAPRIL MALEATE; *MULTIPLE*

SEE DILTIAZEM MALATE; ENALAPRIL MALEATE

ENALAPRIL MALEATE; FELODIPINE

TABLET, EXTENDED RELEASE; ORAL

LEXXEL

+	ASTRAZENECA	5MG;2.5MG	N20668 002	OCT 28, 1998
+		5MG;5MG	N20668 001	DEC 27, 1996

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

AB	DR REDDYS LABS LTD	5MG;12.5MG	N75909 001	OCT 15, 2001
AB		10MG;25MG	N75909 002	OCT 15, 2001
AB	EON	5MG;12.5MG	N76116 001	SEP 19, 2001
AB		10MG;25MG	N76116 002	SEP 19, 2001

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

AB	MYLAN	5MG;12.5MG	N75624 001	SEP 18, 2001
AB		10MG;25MG	N75624 002	SEP 18, 2001
AB	TARO PHARM INDS	5MG;12.5MG	N75788 001	SEP 18, 2001
AB		10MG;25MG	N75788 002	SEP 18, 2001
AB	TEVA	5MG;12.5MG	N75727 001	SEP 18, 2001
AB		10MG;25MG	N75727 002	SEP 18, 2001

VASERETIC

AB	MERCK	5MG;12.5MG	N19221 003	JUL 12, 1995
AB +		10MG;25MG	N19221 001	OCT 31, 1986

ENALAPRILAT

INJECTABLE; INJECTION

ENALAPRILAT

AP	ABBOTT	1.25MG/ML	N75456 001	AUG 22, 2000
AP		1.25MG/ML	N75458 001	AUG 22, 2000
AP	BEDFORD	1.25MG/ML	N75634 001	AUG 22, 2000
AP	FAULDING	1.25MG/ML	N75571 001	AUG 22, 2000
AP	GENSIA SICOR PHARMS	1.25MG/ML	N75578 001	AUG 22, 2000

VASOTEC

AP +	MERCK	1.25MG/ML	N19309 001	FEB 09, 1988

ENFLURANE

LIQUID; INHALATION

ENFLURANE

AN	ABBOTT	99.9%	N70803 001	SEP 08, 1987

FDA data supplied by DrugPatentWatch.com

ENFLURANE

LIQUID; INHALATION

	ENFLURANE				
AN	MINRAD	**99.9%**		**N74396 001**	JUL 29, 1994
	ETHRANE				
AN	+ BAXTER HLTHCARE CORP	**99.9%**		**N17087 001**	

ENOXACIN

TABLET; ORAL

	PENETREX			
	AVENTIS	200MG	N19616 004	DEC 31, 1991
	+	400MG	N19616 005	DEC 31, 1991

ENOXAPARIN SODIUM

INJECTABLE; SUBCUTANEOUS

	LOVENOX			
	+ AVENTIS	30MG/0.3ML	N20164 001	MAR 29, 1993
	+	40MG/0.4ML	N20164 002	JAN 30, 1998
	+	60MG/0.6ML	N20164 003	MAR 27, 1998
	+	80MG/0.8ML	N20164 004	MAR 27, 1998
	+	100MG/ML	N20164 005	MAR 27, 1998
	+	90MG/0.6ML	N20164 006	JUN 02, 2000
	+	120MG/0.8ML	N20164 007	JUN 02, 2000
	+	150MG/ML	N20164 008	JUN 02, 2000

ENTACAPONE

TABLET; ORAL

	COMTAN			
	+ ORION	200MG	N20796 001	OCT 19, 1999

EPINEPHRINE

INJECTABLE; INJECTION

	SUS-PHRINE SULFITE-FREE			
	FORREST LABS	1.5MG/AMP	N07942 003	FEB 05, 1999
	+	5MG/ML	N07942 001	

INJECTABLE; INTRAMUSCULAR

	EPI E Z PEN JR			
	+ MERIDIAN MEDCL TECHN	0.15MG/DELIVERY	N19430 004	AUG 03, 1995
	EPIPEN			
	+ MERIDIAN MEDCL TECHN	0.3MG/DELIVERY	N19430 001	DEC 22, 1987
	EPIPEN E Z PEN			
	+ MERIDIAN MEDCL TECHN	0.3MG/DELIVERY	N19430 003	AUG 03, 1995
	EPIPEN JR.			
	+ MERIDIAN MEDCL TECHN	0.15MG/DELIVERY	N19430 002	DEC 22, 1987

EPINEPHRINE; *MULTIPLE*

SEE ARTICAINE HYDROCHLORIDE; EPINEPHRINE

SEE BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

	LIDOCAINE HCL AND EPINEPHRINE			
AP	ABBOTT	**0.005MG/ML;0.5%**	**N89635 001**	JUN 21, 1988
AP		**0.005MG/ML;1%**	**N89649 001**	JUN 21, 1988
AP		**0.005MG/ML;1.5%**	**N88571 001**	SEP 13, 1985
AP		**0.005MG/ML;1.5%**	**N89645 001**	JUN 21, 1988
AP		**0.005MG/ML;1.5%**	**N89650 001**	JUN 21, 1988
AP		**0.005MG/ML;2%**	**N89651 001**	JUN 21, 1988
AP		**0.01MG/ML;1%**	**N89644 001**	JUN 21, 1988
AP		**0.01MG/ML;2%**	**N89646 001**	JUN 21, 1988

FDA data supplied by DrugPatentWatch.com

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HCL AND EPINEPHRINE

AP		EASTMAN KODAK	0.01MG/ML;2%	N40057 002 FEB 26, 1993
AP			0.02MG/ML;2%	N40057 001 FEB 26, 1993
AP		ELKINS SINN	0.01MG/ML;1%	N80406 001
AP			0.01MG/ML;2%	N80406 002
AP		GRAHAM CHEM	0.01MG/ML;2%	N80504 004 OCT 19, 1983
AP			0.02MG/ML;2%	N80504 005 OCT 19, 1983

LIDOCAINE HCL W/ EPINEPHRINE

AP		DELL LABS	0.01MG/ML;1%	N83389 001
AP			0.01MG/ML;2%	N83390 001

LIDOCATON

AP		PHARMATON	0.01MG/ML;2%	N84729 001 AUG 17, 1983

OCTOCAINE

AP		SEPTODONT	0.01MG/ML;2%	N84048 001
AP	+		0.02MG/ML;2%	N84048 002

XYLOCAINE W/ EPINEPHRINE

AP	+	ASTRAZENECA	0.005MG/ML;0.5%	N06488 012
AP	+		0.005MG/ML;1%	N06488 018 NOV 13, 1986
AP	+		0.005MG/ML;1.5%	N06488 017
AP	+		0.005MG/ML;2%	N06488 019 NOV 13, 1986
AP	+		0.01MG/ML;1%	N06488 004
	+	DENTSPLY PHARM	0.01MG/ML;2%	N21381 001
			0.02MG/ML;2%	N21381 002

SOLUTION; IONTOPHORESIS

IONTOCAINE

+	IOMED	0.01MG/ML;2%	N20530 001 DEC 21, 1995

EPINEPHRINE BITARTRATE; *MULTIPLE*

SEE BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

EPINEPHRINE BITARTRATE; ETIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

DURANEST

+	ASTRAZENECA	0.005MG/ML;1%	N17751 006

EPINEPHRINE BITARTRATE; ETIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

DURANEST

+	DENTSPLY PHARM	0.005MG/ML;1.5%	N21384 001

EPINEPHRINE BITARTRATE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIGNOSPAN FORTE

+	DEPROCO	EQ 0.02MG BASE/ML;2%	N88389 001 JAN 22, 1985

LIGNOSPAN STANDARD

+	DEPROCO	EQ 0.01MG BASE/ML;2%	N88390 001 JAN 22, 1985

EPINEPHRINE BITARTRATE; PRILOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CITANEST FORTE

+	DENTSPLY PHARM	0.005MG/ML;4%	N21383 001

EPIRUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

ELLENCE

+	PHARMACIA AND UPJOHN	2MG/ML	N50778 001 SEP 15, 1999

EPOPROSTENOL SODIUM

INJECTABLE; INJECTION

FLOLAN

+	GLAXOSMITHKLINE	EQ 0.5MG BASE/VIAL	N20444 001 SEP 20, 1995
+		EQ 1.5MG BASE/VIAL	N20444 002 SEP 20, 1995

EPROSARTAN MESYLATE

TABLET; ORAL

TEVETEN

	UNIMED PHARMS	EQ 300MG BASE	N20738 004 DEC 22, 1997

FDA data supplied by DrugPatentWatch.com

EPROSARTAN MESYLATE

TABLET; ORAL
TEVETEN
UNIMED PHARMS EQ 400MG BASE N20738 005 DEC 22, 1997
+ EQ 600MG BASE N20738 006 MAY 27, 1999

EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL
TEVETEN HCT
UNIMED PHARMS 600MG;12.5MG N21268 001 NOV 01, 2001
+ 600MG;25MG N21268 002 NOV 01, 2001

EPTIFIBATIDE

INJECTABLE; INJECTION
INTEGRILIN
+ COR 75MG/100ML N20718 002 MAY 18, 1998
+ 2MG/ML N20718 001 MAY 18, 1998

ERGOCALCIFEROL

CAPSULE; ORAL
DRISDOL
AA + SANOFI SYNTHELABO **50,000 IU** **N03444 001**
VITAMIN D
AA BANNER PHARMACAPS **50,000 IU** **N80704 001**

ERGOCALCIFEROL; *MULTIPLE*
SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PHYTONADIONE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E
SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

ERGOLOID MESYLATES

CAPSULE; ORAL
HYDERGINE LC
+ NOVARTIS 1MG N18706 001 JAN 18, 1983

SOLUTION; ORAL
HYDERGINE
NOVARTIS 1MG/ML N18418 001

TABLET; ORAL
ERGOLOID MESYLATES
AB MUTUAL PHARM **1MG** **N81113 001** OCT 31, 1991
HYDERGINE
AB + NOVARTIS **1MG** **N17993 001**

TABLET; SUBLINGUAL
ERGOLOID MESYLATES
AA DANBURY PHARMA **0.5MG** **N87233 001**
GERIMAL
AA WATSON LABS **0.5MG** **N86189 001**
AA **1MG** **N86188 001**
HYDERGINE
AA + NOVARTIS **0.5MG** **N09087 002**
AA + **1MG** **N09087 001**
HYDROGENATED ERGOT ALKALOIDS
AA IVAX PHARMS **1MG** **N87185 001**

ERGOTAMINE TARTRATE

TABLET; SUBLINGUAL
ERGOMAR
+ NEW RIVER 2MG N87693 001 FEB 24, 1983

ERGOTAMINE TARTRATE; *MULTIPLE*
SEE CAFFEINE; ERGOTAMINE TARTRATE

ERTAPENEM SODIUM

INJECTABLE; INTRAMUSCULAR, IV (INFUSION)
INVANZ
+ MERCK EQ 1GM BASE/VIAL N21337 001 NOV 21, 2001

FDA data supplied by DrugPatentWatch.com

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS; ORAL

	ERYC			
AB	+ FAULDING	**250MG**	**N50536 001**	
	ERYTHROMYCIN			
AB	ABBOTT	**250MG**	**N62746 001**	DEC 22, 1986
AB	BARR	**250MG**	**N63098 001**	MAY 04, 1989

GEL; TOPICAL

	EMGEL			
AT	GLAXOSMITHKLINE	**2%**	**N63107 001**	AUG 23, 1991
	ERYGEL			
AT	+ ALLERGAN HERBERT	**2%**	**N50617 001**	OCT 21, 1987
	ERYTHROMYCIN			
AT	ALTANA	**2%**	**N64184 001**	SEP 30, 1997
AT	STIEFEL	**2%**	**N63211 001**	JAN 29, 1993

LOTION; TOPICAL

	E-SOLVE 2			
	+ SYOSSET	2%	N62467 001	JUL 03, 1985

OINTMENT; OPHTHALMIC

	ERYTHROMYCIN			
AT	AKORN	**0.5%**	**N64030 001**	JUL 18, 1996
AT	BAUSCH AND LOMB	**0.5%**	**N64067 001**	JUL 29, 1994
AT	FOUGERA	**0.5%**	**N62447 001**	SEP 26, 1983
	ILOTYCIN			
AT	+ DISTA	**0.5%**	**N50368 001**	

OINTMENT; TOPICAL

	AKNE-MYCIN			
	+ HEALTHPOINT	2%	N50584 001	JAN 10, 1985

SOLUTION; TOPICAL

	A/T/S			
AT	AVENTIS PHARMS	**2%**	**N62405 001**	NOV 18, 1982

ERYTHROMYCIN

SOLUTION; TOPICAL

	C-SOLVE-2			
AT	BIOGLAN PHARMA	**2%**	**N62468 001**	JUL 03, 1985
	ERYDERM			
AT	ABBOTT	**2%**	**N62290 001**	
	ERYMAX			
AT	ALLERGAN HERBERT	**2%**	**N62508 002**	JUL 11, 1985
	ERYTHRA-DERM			
AT	PADDOCK	**2%**	**N62687 001**	FEB 05, 1988
	ERYTHRO-STATIN			
AT	HI TECH PHARMA	**2%**	**N64101 001**	OCT 22, 1996
	ERYTHROMYCIN			
AT	ALPHARMA	**2%**	**N62326 001**	APR 19, 1982
AT	ALTANA	**2%**	**N64187 001**	SEP 30, 1997
AT	BAUSCH AND LOMB	**2%**	**N64039 001**	JAN 27, 1994
AT	CLAY PARK	**2%**	**N63038 001**	JAN 11, 1991
AT	MORTON GROVE	**2%**	**N62825 001**	OCT 23, 1987
AT	STIEFEL	**2%**	**N64127 001**	FEB 14, 1997
	SANSAC			
AT	HEALTHPOINT	**2%**	**N62522 001**	JAN 24, 1985
	STATICIN			
AT	+ WESTWOOD SQUIBB	**1.5%**	**N50526 001**	
	T-STAT			
AT	+ WESTWOOD SQUIBB	**2%**	**N62436 001**	MAR 09, 1983

SWAB; TOPICAL

	C-SOLVE-2			
AT	IVAX PHARMS	**2%**	**N62751 001**	JUL 30, 1993
	ERYCETTE			
AT	+ J AND J	**2%**	**N50594 001**	FEB 15, 1985
	ERYTHROMYCIN			
AT	STIEFEL	**2%**	**N64126 001**	JUL 03, 1996

FDA data supplied by DrugPatentWatch.com

ERYTHROMYCIN

SWAB; TOPICAL
ERYTHROMYCIN
AT STIEFEL 2% N64128 001 JUL 03, 1996

T-STAT
AT WESTWOOD SQUIBB 2% N62748 001 JUL 23, 1987

TABLET; ORAL
ERYTHROMYCIN
ABBOTT 250MG N61621 001
\+ 500MG N61621 002

TABLET, COATED PARTICLES; ORAL
PCE
ABBOTT 333MG N50611 001 SEP 09, 1986
\+ 500MG N50611 002 AUG 22, 1990

TABLET, DELAYED RELEASE; ORAL
E-BASE
AB BARR 333MG N63086 001 MAY 15, 1990
AB 500MG N62999 001 NOV 25, 1988

E-MYCIN
AB ABBOTT 250MG N60272 001
AB 333MG N60272 002

ERY-TAB
AB \+ ABBOTT 250MG N62298 001
AB \+ 333MG N62298 003 MAR 29, 1982
AB \+ 500MG N62298 002

ERYTHROMYCIN; *MULTIPLE*
SEE BENZOYL PEROXIDE; ERYTHROMYCIN

ERYTHROMYCIN ESTOLATE

CAPSULE; ORAL
ERYTHROMYCIN ESTOLATE
\+ BARR EQ 250MG BASE N62162 002

ERYTHROMYCIN ESTOLATE

SUSPENSION; ORAL
ERYTHROMYCIN ESTOLATE
AB ALPHARMA EQ 125MG BASE/5ML N62353 001 NOV 18, 1982
AB EQ 250MG BASE/5ML N62409 001 DEC 16, 1982

ILOSONE
AB LILLY EQ 125MG BASE/5ML N50010 001
AB \+ EQ 250MG BASE/5ML N50010 002

ERYTHROMYCIN ETHYLSUCCINATE

GRANULE; ORAL
E.E.S.
AB ABBOTT EQ 200MG BASE/5ML N50207 001

ERYPED
AB ABBOTT EQ 200MG BASE/5ML N50207 003 MAR 30, 1987
\+ EQ 400MG BASE/5ML N50207 002

ERYTHROMYCIN ETHYLSUCCINATE
AB BARR EQ 200MG BASE/5ML N62055 001

SUSPENSION; ORAL
E.E.S. 200
AB ABBOTT EQ 200MG BASE/5ML N61639 001

E.E.S. 400
AB \+ ABBOTT EQ 400MG BASE/5ML N61639 002

ERYTHROMYCIN ETHYLSUCCINATE
AB ALPHARMA EQ 200MG BASE/5ML N62200 001
AB EQ 400MG BASE/5ML N62200 002

PEDIAMYCIN
AB ROSS LABS EQ 200MG BASE/5ML N62304 001

PEDIAMYCIN 400
AB ROSS LABS EQ 400MG BASE/5ML N62304 002

TABLET; ORAL
E.E.S. 400
AB \+ ABBOTT EQ 400MG BASE N61905 002 AUG 12, 1982

ERYTHROMYCIN ETHYLSUCCINATE
AB MYLAN EQ 400MG BASE N62847 001 SEP 14, 1988

TABLET, CHEWABLE; ORAL
E.E.S.
AB \+ ABBOTT EQ 200MG BASE N50297 002

FDA data supplied by DrugPatentWatch.com

ERYTHROMYCIN ETHYLSUCCINATE

TABLET, CHEWABLE; ORAL

	ERYPED			
AB	ABBOTT	EQ 200MG BASE	N50297 003	JUL 05, 1988

ERYTHROMYCIN ETHYLSUCCINATE; SULFISOXAZOLE ACETYL

GRANULE; ORAL

	ERYTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYL			
AB	BARR	EQ 200MG BASE/5ML; EQ 600MG BASE/5ML	N62759 001	MAY 20, 1988
	ERYZOLE			
AB	ALRA	EQ 200MG BASE/5ML; EQ 600MG BASE/5ML	N62758 001	JUN 15, 1988
	PEDIAZOLE			
AB	+ ROSS LABS	EQ 200MG BASE/5ML; EQ 600MG BASE/5ML	N50529 001	

ERYTHROMYCIN LACTOBIONATE

INJECTABLE; INJECTION

	ERYTHROCIN			
AP	+ ABBOTT	EQ 500MG BASE/VIAL	N50182 002	
AP		EQ 500MG BASE/VIAL	N50609 001	SEP 24, 1986
AP		EQ 500MG BASE/VIAL	N62638 001	OCT 31, 1986
AP	+	EQ 1GM BASE/VIAL	N50182 003	
AP		EQ 1GM BASE/VIAL	N50609 002	SEP 24, 1986
AP		EQ 1GM BASE/VIAL	N62638 002	OCT 31, 1986
	ERYTHROMYCIN			
AP	ELKINS SINN	EQ 500MG BASE/VIAL	N62563 001	MAR 28, 1985
AP		EQ 1GM BASE/VIAL	N62563 002	MAR 28, 1985
	ERYTHROMYCIN LACTOBIONATE			
AP	GENSIA SICOR PHARMS	EQ 500MG BASE/VIAL	N63253 001	JUL 30, 1993
AP		EQ 1GM BASE/VIAL	N63253 002	JUL 30, 1993

ERYTHROMYCIN LACTOBIONATE

INJECTABLE; INJECTION

	ERYTHROMYCIN LACTOBIONATE			
AP	LEDERLE	EQ 500MG BASE/VIAL	N62993 001	MAY 09, 1989
AP		EQ 1GM BASE/VIAL	N62993 002	MAY 09, 1989

ERYTHROMYCIN STEARATE

TABLET; ORAL

	ERYTHROCIN STEARATE			
AB	ABBOTT	EQ 250MG BASE	N60359 001	
AB	+	EQ 500MG BASE	N60359 003	
	ERYTHROMYCIN STEARATE			
AB	BARR	EQ 250MG BASE	N61591 001	
AB	MYLAN	EQ 250MG BASE	N61505 001	
AB		EQ 500MG BASE	N61505 002	
AB	WATSON LABS	EQ 250MG BASE	N62121 002	
AB		EQ 500MG BASE	N62121 001	

ESMOLOL HYDROCHLORIDE

INJECTABLE; INJECTION

	BREVIBLOC			
	+ BAXTER HLTHCARE CORP	10MG/ML	N19386 001	AUG 15, 1988
	+	250MG/ML	N19386 002	DEC 31, 1986

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS; ORAL

	NEXIUM			
	+ ASTRAZENECA	EQ 20MG BASE	N21153 001	FEB 20, 2001
	+	EQ 40MG BASE	N21153 002	FEB 20, 2001

ESTAZOLAM

TABLET; ORAL

	ESTAZOLAM			
AB	IVAX PHARMS	1MG	N74826 001	JUL 03, 1997

FDA data supplied by DrugPatentWatch.com

ESTAZOLAM

TABLET; ORAL

	ESTAZOLAM			
AB	IVAX PHARMS	2MG	**N74826 002**	JUL 03, 1997
AB	TEVA	1MG	**N74921 001**	JUL 10, 1997
AB		2MG	**N74921 002**	JUL 10, 1997
AB	WATSON LABS	1MG	**N74818 001**	AUG 19, 1997
AB		2MG	**N74818 002**	AUG 19, 1997
	PROSOM			
AB	ABBOTT	1MG	**N19080 001**	DEC 26, 1990
AB +		2MG	**N19080 002**	DEC 26, 1990

ESTRADIOL

CREAM; VAGINAL

	ESTRACE			
+	WARNER CHILCOTT	0.01%	N86069 001	JAN 31, 1984

FILM, EXTENDED RELEASE; TRANSDERMAL

	ALORA			
BX	WATSON LABS	0.05MG/24HR	N20655 001	DEC 20, 1996
BX		0.075MG/24HR	N20655 002	DEC 20, 1996
BX		0.1MG/24HR	N20655 003	DEC 20, 1996
	CLIMARA			
AB2 +	BERLEX LABS	**0.05MG/24HR**	**N20375 001**	DEC 22, 1994
AB2 +		**0.1MG/24HR**	**N20375 002**	DEC 22, 1994
BX +		0.025MG/24HR	N20375 004	MAR 05, 1999
BX +		0.075MG/24HR	N20375 003	MAR 23, 1998
	ESCLIM			
BX	WOMEN FIRST HLTHCARE	0.025MG/24HR	N20847 001	AUG 04, 1998

ESTRADIOL

FILM, EXTENDED RELEASE; TRANSDERMAL

	ESCLIM			
BX	WOMEN FIRST HLTHCARE	0.0375MG/24HR	N20847 002	AUG 04, 1998
BX		0.05MG/24HR	N20847 003	AUG 04, 1998
BX		0.075MG/24HR	N20847 004	AUG 04, 1998
BX		0.1MG/24HR	N20847 005	AUG 04, 1998
	ESTRADERM			
BX +	NOVARTIS	0.05MG/24HR	N19081 002	SEP 10, 1986
BX +		0.1MG/24HR	N19081 003	SEP 10, 1986
	ESTRADIOL			
AB2	MYLAN TECHNOLOGIES	**0.05MG/24HR**	**N75233 001**	FEB 24, 2000
AB2		**0.1MG/24HR**	**N75182 001**	FEB 24, 2000
	FEMPATCH			
BX +	PARKE DAVIS	0.025MG/24HR	N20417 001	DEC 03, 1996
	VIVELLE			
AB1 +	NOVARTIS	**0.0375MG/24HR**	**N20323 001**	OCT 28, 1994
AB1 +		**0.05MG/24HR**	**N20323 002**	OCT 28, 1994
AB1 +		**0.075MG/24HR**	**N20323 003**	OCT 28, 1994
AB1 +		**0.1MG/24HR**	**N20323 004**	OCT 28, 1994
+		0.025MG/24HR	N20323 005	AUG 16, 2000
	VIVELLE-DOT			
AB1	NOVARTIS	**0.0375MG/24HR**	**N20538 005**	JAN 08, 1999
AB1		**0.05MG/24HR**	**N20538 006**	JAN 08, 1999
AB1		**0.075MG/24HR**	**N20538 007**	JAN 08, 1999
AB1		**0.1MG/24HR**	**N20538 008**	JAN 08, 1999

INSERT, EXTENDED RELEASE; VAGINAL

	ESTRING			
+	PHARMACIA AND UPJOHN	0.0075MG/24HR	N20472 001	APR 26, 1996

FDA data supplied by DrugPatentWatch.com

ESTRADIOL

TABLET; ORAL

	ESTRACE			
AB	BRISTOL MYERS SQUIBB	0.5MG	N81295 001	JUN 30, 1993
AB		1MG	N84499 001	
AB	+	2MG	N84500 001	
	ESTRADIOL			
AB	APPLIED ANAL	0.5MG	N40138 001	JAN 30, 1998
AB		1MG	N40138 002	JAN 30, 1998
AB		2MG	N40138 003	JAN 30, 1998
AB	BARR	0.5MG	N40197 001	OCT 22, 1997
AB		1MG	N40197 002	OCT 22, 1997
AB		2MG	N40197 003	OCT 22, 1997
AB	ESI LEDERLE	0.5MG	N40275 001	DEC 29, 1998
AB		1MG	N40275 002	DEC 29, 1998
AB		2MG	N40275 003	DEC 29, 1998
AB	MYLAN	0.5MG	N40326 001	APR 21, 1999
AB		1MG	N40326 002	APR 21, 1999
AB		2MG	N40326 003	APR 21, 1999
AB	WATSON LABS	0.5MG	N40114 003	MAR 14, 1996
AB		1MG	N40114 001	MAR 14, 1996
AB		2MG	N40114 002	MAR 14, 1996
	GYNODIOL			
AB	DURAMED	0.5MG	N40212 001	DEC 29, 1997
AB		1MG	N40212 002	DEC 29, 1997
AB		2MG	N40212 004	DEC 29, 1997
		1.5MG	N40212 003	DEC 29, 1997

ESTRADIOL

TABLET; ORAL

	INNOFEM			
AB	NOVO NORDISK	0.5MG	N40312 001	NOV 19, 1999
AB		1MG	N40312 002	NOV 19, 1999
AB		2MG	N40312 003	NOV 19, 1999

TABLET; VAGINAL

	VAGIFEM			
+	NOVO NORDISK	25 UGM	N20908 001	MAR 26, 1999

ESTRADIOL; NORETHINDRONE ACETATE

FILM, EXTENDED RELEASE; TRANSDERMAL

	COMBIPATCH			
	NOVARTIS	0.05MG/24HR;0.14MG/24HR	N20870 001	AUG 07, 1998
+		0.05MG/24HR;0.25MG/24HR	N20870 002	AUG 07, 1998

TABLET; ORAL

	ACTIVELLE			
+	NOVO NORDISK	1MG;0.5MG	N20907 001	NOV 18, 1998

ESTRADIOL; NORGESTIMATE

TABLET; ORAL

	ORTHO-PREFEST			
+	JOHNSON RW	1MG,1MG;0.09MG,N/A	N21040 001	OCT 22, 1999

ESTRADIOL CYPIONATE

INJECTABLE; INJECTION

	DEPO-ESTRADIOL		
AO +	PHARMACIA AND UPJOHN	5MG/ML	N85470 003
	ESTRADIOL CYPIONATE		
AO	STERIS	5MG/ML	N85620 001

FDA data supplied by DrugPatentWatch.com

ESTRADIOL CYPIONATE; MEDROXYPROGESTERONE ACETATE

INJECTABLE; INTRAMUSCULAR
LUNELLE
\+ PHARMACIA AND UPJOHN 5MG/0.5ML;25MG/0.5ML N20874 001
OCT 05, 2000

ESTRADIOL CYPIONATE; TESTOSTERONE CYPIONATE

INJECTABLE; INJECTION
DEPO-TESTADIOL
AO + PHARMACIA AND UPJOHN **2MG/ML;50MG/ML** **N17968 001**
TESTOSTERONE CYPIONATE-ESTRADIOL CYPIONATE
AO STERIS **2MG/ML;50MG/ML** **N85603 001**
MAR 13, 1986

ESTRADIOL VALERATE

INJECTABLE; INJECTION
DELESTROGEN
AO + KING PHARMS **20MG/ML** **N09402 004**
AO + **40MG/ML** **N09402 003**
\+ 10MG/ML N09402 002
ESTRADIOL VALERATE
AO STERIS **20MG/ML** **N83547 001**
AO **40MG/ML** **N83714 001**

ESTRADIOL VALERATE; TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION
DITATE-DS
\+ SAVAGE LABS 8MG/ML;180MG/ML N86423 001
TESTOSTERONE ENANTHATE AND ESTRADIOL VALERATE
\+ STERIS 4MG/ML;90MG/ML N85865 001

ESTRAMUSTINE PHOSPHATE SODIUM

CAPSULE; ORAL
EMCYT
\+ PHARMACIA AND UPJOHN EQ 140MG PHOSPHATE N18045 001

ESTROGENS, CONJUGATED

CREAM; TOPICAL, VAGINAL
PREMARIN
\+ AYERST 0.625MG/GM N20216 001

INJECTABLE; INJECTION
PREMARIN
\+ WYETH AYERST 25MG/VIAL N10402 001

TABLET; ORAL
PREMARIN
WYETH AYERST 0.3MG N04782 003
\+ 0.625MG N04782 004
0.9MG N04782 005
JAN 26, 1984
\+ 1.25MG N04782 001
2.5MG N04782 002

ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE

TABLET; ORAL-28
PREMPHASE (PREMARIN;CYCRIN 14/14)
\+ WYETH AYERST 0.625MG,0.625MG;N/A,5MG N20303 002
DEC 30, 1994
PREMPHASE 14/14
\+ WYETH AYERST 0.625MG,0.625MG;N/A,5MG N20527 002
NOV 17, 1995
PREMPRO
\+ WYETH AYERST 0.625MG,0.625MG;2.5MG, 2.5MG N20527 001
NOV 17, 1995
\+ 0.625MG,0.625MG;5MG,5MG N20527 003
JAN 09, 1998
PREMPRO (PREMARIN;CYCRIN)
\+ WYETH AYERST 0.625MG,0.625MG;2.5MG, 2.5MG N20303 001
DEC 30, 1994

ESTROGENS, CONJUGATED; MEPROBAMATE

TABLET; ORAL
PMB 200
\+ WYETH AYERST 0.45MG;200MG N10971 005
PMB 400
\+ WYETH AYERST 0.45MG;400MG N10971 003

FDA data supplied by DrugPatentWatch.com

ESTROGENS, CONJUGATED SYNTHETIC A

TABLET; ORAL

CENESTIN				
DURAMED	0.625MG	N20992 002		
		MAR 24, 1999		
	0.9MG	N20992 003		
		MAR 24, 1999		
+	1.25MG	N20992 004		
		MAR 13, 2000		

ESTROGENS, ESTERIFIED

TABLET; ORAL

MENEST				
+ MONARCH PHARMS	0.3MG	N84951 001		
	0.625MG	N84948 001		
	1.25MG	N84950 001		
+	2.5MG	N84949 001		

ESTRONE

INJECTABLE; INJECTION

ESTRONE				
+ STERIS	5MG/ML	N85239 001		

ESTROPIPATE

CREAM; VAGINAL

OGEN				
+ PHARMACIA AND UPJOHN	1.5MG/GM	N84710 001		

TABLET; ORAL

ESTROPIPATE				
AB BARR	**0.75MG**	**N40135 001**		
		NOV 27, 1996		
AB	**1.5MG**	**N40135 002**		
		NOV 27, 1996		
AB	**3MG**	**N40135 003**		
		NOV 27, 1996		
AB DURAMED	**0.75MG**	**N40296 001**		
		NOV 01, 1999		
AB	**1.5MG**	**N40296 002**		
		NOV 01, 1999		
AB	**3MG**	**N40296 003**		
		NOV 01, 1999		

ESTROPIPATE

TABLET; ORAL

ESTROPIPATE				
AB MYLAN	**0.75MG**	**N40359 001**		
		AUG 26, 1999		
AB	**1.5MG**	**N40359 002**		
		AUG 26, 1999		
AB	**3MG**	**N40359 003**		
		AUG 26, 1999		
AB WATSON LABS	**0.75MG**	**N81213 001**		
		SEP 23, 1993		
AB	**1.5MG**	**N81214 001**		
		SEP 23, 1993		
AB	**3MG**	**N81215 001**		
		SEP 23, 1993		
AB	**6MG**	**N81216 001**		
		SEP 23, 1993		
OGEN .625				
AB PHARMACIA AND UPJOHN	**0.75MG**	**N83220 001**		
OGEN 1.25				
AB PHARMACIA AND UPJOHN	**1.5MG**	**N83220 002**		
OGEN 2.5				
AB + PHARMACIA AND UPJOHN	**3MG**	**N83220 003**		
OGEN 5				
AB PHARMACIA AND UPJOHN	**6MG**	**N83220 004**		
ORTHO-EST				
AB WOMEN FIRST HLTHCARE	**0.75MG**	**N89567 001**		
		FEB 27, 1991		
AB	**1.5MG**	**N89582 001**		
		JUL 17, 1991		

ETHACRYNATE SODIUM

INJECTABLE; INJECTION

EDECRIN		
+ MERCK	EQ 50MG BASE/VIAL	N16093 001

ETHACRYNIC ACID

TABLET; ORAL

EDECRIN		
MERCK	25MG	N16092 001
+	50MG	N16092 002

FDA data supplied by DrugPatentWatch.com

ETHAMBUTOL HYDROCHLORIDE

TABLET; ORAL

	ETHAMBUTOL HCL			
AB	BARR	**400MG**	**N76057 001**	
			NOV 26, 2001	
AB	WEST WARD	**100MG**	**N75095 001**	
			NOV 30, 1999	
AB		**400MG**	**N75095 002**	
			NOV 30, 1999	
	MYAMBUTOL			
AB	LEDERLE	**100MG**	**N16320 001**	
AB	+	**400MG**	**N16320 003**	

ETHANOLAMINE OLEATE

INJECTABLE; INJECTION

	ETHAMOLIN		
+	QUESTCOR PHARMS	50MG/ML	N19357 001
			DEC 22, 1988

ETHCHLORVYNOL

CAPSULE; ORAL

	PLACIDYL		
+	ABBOTT	200MG	N10021 007
+		500MG	N10021 002
+		750MG	N10021 010

ETHINYL ESTRADIOL

TABLET; ORAL

	ESTINYL		
	SCHERING	0.02MG	N05292 001
		0.05MG	N05292 002
+		0.5MG	N05292 003

ETHINYL ESTRADIOL; *MULTIPLE*

SEE DESOGESTREL; ETHINYL ESTRADIOL
SEE DROSPIRENONE; ETHINYL ESTRADIOL

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

TABLET; ORAL-21

	DEMULEN 1/35-21			
AB	+ GD SEARLE LLC	**0.035MG;1MG**	**N18168 001**	
	DEMULEN 1/50-21			
AB	+ GD SEARLE LLC	**0.05MG;1MG**	**N16927 001**	
	ZOVIA 1/35E-21			
AB	WATSON LABS	**0.035MG;1MG**	**N72720 001**	
			DEC 30, 1991	
	ZOVIA 1/50E-21			
AB	WATSON LABS	**0.05MG;1MG**	**N72722 001**	
			DEC 30, 1991	

TABLET; ORAL-28

	DEMULEN 1/35-28			
AB	GD SEARLE LLC	**0.035MG;1MG**	**N18160 001**	
	DEMULEN 1/50-28			
AB	GD SEARLE LLC	**0.05MG;1MG**	**N16936 001**	
	ZOVIA 1/35E-28			
AB	WATSON LABS	**0.035MG;1MG**	**N72721 001**	
			DEC 30, 1991	
	ZOVIA 1/50E-28			
AB	WATSON LABS	**0.05MG;1MG**	**N72723 001**	
			DEC 30, 1991	

ETHINYL ESTRADIOL; ETONOGESTREL

RING; VAGINAL

	NUVARING		
+	ORGANON INC	0.015MG;0.12MG	N21187 001
			OCT 03, 2001

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL

	PREVEN EMERGENCY CONTRACEPTIVE KIT		
+	GYNETICS	0.05MG;0.25MG	N20946 001
			SEP 01, 1998

TABLET; ORAL-21

	ALESSE			
AB	+ WYETH AYERST	**0.02MG;0.1MG**	**N20683 001**	
			MAR 27, 1997	
	AVIANE-21			
AB	DURAMED	**0.02MG;0.1MG**	**N75796 002**	
			APR 30, 2001	

FDA data supplied by DrugPatentWatch.com

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL-21

	ENPRESSE-21			
AB	DURAMED	**0.03MG,0.05MG,0.075MG;0.04MG,0.03MG, 0.125MG**	**N75809 001** JUL 16, 2001	
	LEVLITE			
BX	+ BERLEX LABS	0.02MG;0.1MG	N20860 001 JUL 13, 1998	
	LEVORA 0.15/30-21			
AB	WATSON LABS	**0.03MG;0.15MG**	**N73592 001** DEC 13, 1993	
	NORDETTE-21			
AB	+ WYETH AYERST	**0.03MG;0.15MG**	**N18668 001** MAY 10, 1982	
	TRIPHASIL-21			
AB	+ WYETH AYERST	**0.03MG,0.04MG,0.03MG;0.05MG,0.075MG, 0.125MG**	**N19192 001** NOV 01, 1984	
	TRIVORA-21			
AB	WATSON LABS	**0.03MG,0.04MG,0.03MG;0.05MG,0.075MG, 0.125MG**	**N74538 001** DEC 18, 1997	

TABLET; ORAL-28

	ALESSE			
AB	WYETH AYERST	**0.02MG;0.1MG**	**N20683 002** MAR 27, 1997	
	AVIANE-28			
AB	DURAMED	**0.02MG;0.1MG**	**N75796 001** APR 30, 2001	
	ENPRESSE-28			
AB	DURAMED	**0.03MG,0.03MG,0.075MG;0.04MG,0.05MG, 0.125MG**	**N75809 002** JUL 16, 2001	
	LEVLITE			
BX	BERLEX LABS	0.02MG;0.1MG	N20860 002 JUL 13, 1998	
	LEVORA 0.15/30-28			
AB	WATSON LABS	**0.03MG;0.15MG**	**N73594 001** DEC 13, 1993	
	NORDETTE-28			
AB	WYETH AYERST	**0.03MG;0.15MG**	**N18782 001** JUL 21, 1982	
	TRIPHASIL-28			
AB	WYETH AYERST	**0.03MG,0.04MG,0.03MG;0.05MG,0.075MG, 0.125MG**	**N19190 001** NOV 01, 1984	

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL-28

	TRIVORA-28			
AB	WATSON LABS	**0.03MG,0.04MG,0.03MG;0.05MG,0.075MG, 0.125MG**	**N74538 002** DEC 18, 1997	

ETHINYL ESTRADIOL; NORELGESTROMIN

FILM, EXTENDED RELEASE; TRANSDERMAL

	ORTHO EVRA			
	+ JOHNSON RW	0.02MG/24HR;0.015MG/24HR	N21180 001 NOV 20, 2001	

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

	BREVICON 21-DAY			
AB	WATSON LABS	**0.035MG;0.5MG**	**N17566 001**	
	GENCEPT 0.5/35-21			
AB	BARR	**0.035MG;0.5MG**	**N72692 001** FEB 28, 1992	
	GENCEPT 1/35-21			
AB	BARR	**0.035MG;1MG**	**N72693 001** FEB 28, 1992	
	GENCEPT 10/11-21			
AB	BARR	**0.035MG,0.035MG;0.5MG,1MG**	**N72694 001** FEB 28, 1992	
	MODICON 21			
AB	+ JOHNSON RW	**0.035MG;0.5MG**	**N17488 001**	
	NORCEPT-E 1/35 21			
AB	GYNOPHARMA	**0.035MG;1MG**	**N71545 001** FEB 09, 1989	
	NORETHIN 1/35E-21			
AB	WATSON LABS	**0.035MG;1MG**	**N71480 001** APR 12, 1988	
	NORETHINDRONE AND ETHINYL ESTRADIOL			
AB	WATSON LABS	**0.035MG;0.5MG**	**N70684 001** JAN 29, 1987	
AB		**0.035MG;1MG**	**N70685 001** JAN 29, 1987	
	NORETHINDRONE AND ETHINYL ESTRADIOL (10/11)			
AB	WATSON LABS	**0.035MG,0.035MG;0.5MG,1MG**	**N71043 001** APR 01, 1988	
	NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)			
AB	+ WATSON LABS	**0.035MG,0.035MG;0.5MG,1MG**	**N71041 001** SEP 24, 1991	

FDA data supplied by DrugPatentWatch.com

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

	NORINYL 1+35 21-DAY			
AB	WATSON LABS	0.035MG;1MG	N17565	001
	ORTHO-NOVUM 1/35-21			
AB	+ JOHNSON RW	0.035MG;1MG	N17489	002
	ORTHO-NOVUM 10/11-21			
AB	+ JOHNSON RW	0.035MG,0.035MG;0.5MG,1MG	N18354	001 JAN 11, 1982
	ORTHO-NOVUM 7/7/7-21			
	+ JOHNSON RW	0.035MG,0.035MG,0.035MG;0.5MG, 0.75MG,1MG	N18985	001 APR 04, 1984
	OVCON-35			
	+ WARNER CHILCOTT	0.035MG;0.4MG	N18127	001
	TRI-NORINYL 21-DAY			
	+ WATSON LABS	0.035MG,0.035MG;0.5MG,1MG	N18977	001 APR 13, 1984

TABLET; ORAL-28

	BREVICON 28-DAY			
AB	WATSON LABS	0.035MG;0.5MG	N17743	001
	GENCEPT 0.5/35-28			
AB	BARR	0.035MG;0.5MG	N72695	001 FEB 28, 1992
	GENCEPT 1/35-28			
AB	BARR	0.035MG;1MG	N72696	001 FEB 28, 1992
	GENCEPT 10/11-28			
AB	BARR	0.035MG,0.035MG;0.5MG,1MG	N72697	001 FEB 28, 1992
	MODICON 28			
AB	JOHNSON RW	0.035MG;0.5MG	N17735	001
	NORCEPT-E 1/35 28			
AB	GYNOPHARMA	0.035MG;1MG	N71546	001 FEB 09, 1989
	NORETHIN 1/35E-28			
AB	WATSON LABS	0.035MG;1MG	N71481	001 APR 12, 1988
	NORETHINDRONE AND ETHINYL ESTRADIOL			
AB	WATSON LABS	0.035MG;0.5MG	N70686	001 JAN 29, 1987
AB		0.035MG;1MG	N70687	001 JAN 29, 1987
	NORETHINDRONE AND ETHINYL ESTRADIOL (10/11)			
AB	WATSON LABS	0.035MG,0.035MG;0.5MG,1MG	N71044	001 APR 01, 1988

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-28

	NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)			
AB	WATSON LABS	0.035MG,0.035MG;0.5MG,1MG	N71042	001 SEP 24, 1991
	NORINYL 1+35 28-DAY			
AB	WATSON LABS	0.035MG;1MG	N17565	002
	ORTHO-NOVUM 1/35-28			
AB	JOHNSON RW	0.035MG;1MG	N17919	002
	ORTHO-NOVUM 10/11-28 IN PLASTIC CONTAINER			
AB	JOHNSON RW	0.035MG,0.035MG;0.5MG,1MG	N18354	002 JAN 11, 1982
	ORTHO-NOVUM 7/14-28			
AB	+ JOHNSON RW	0.035MG,0.035MG;0.5MG,1MG	N19004	002 APR 04, 1984
	ORTHO-NOVUM 7/7/7-28			
	JOHNSON RW	0.035MG,0.035MG,0.035MG;0.5MG, 0.75MG,1MG	N18985	002 APR 04, 1984
	OVCON-35			
	WARNER CHILCOTT	0.035MG;0.4MG	N17716	001
	OVCON-50			
	WARNER CHILCOTT	0.05MG;1MG	N17576	001
	TRI-NORINYL 28-DAY			
	WATSON LABS	0.035MG,0.035MG;0.5MG,1MG	N18977	002 APR 13, 1984

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL

	FEMHRT			
	+ PARKE DAVIS PHARMS	0.005MG;1MG	N21065	002 OCT 15, 1999

TABLET; ORAL-21

	ESTROSTEP 21			
	+ PARKE DAVIS	0.02MG,0.03MG,0.035MG;1MG,1MG, 1MG	N20130	001 OCT 09, 1996
	LOESTRIN 21 1.5/30			
	+ PARKE DAVIS	0.03MG;1.5MG	N17875	001
	LOESTRIN 21 1/20			
	+ PARKE DAVIS	0.02MG;1MG	N17876	001

TABLET; ORAL-28

	ESTROSTEP FE			
	+ PARKE DAVIS	0.02MG,0.03MG,0.035MG;1MG,1MG, 1MG	N20130	002 OCT 09, 1996

FDA data supplied by DrugPatentWatch.com

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL-28

	LOESTRIN FE 1.5/30			
AB	+ PARKE DAVIS	**0.03MG;1.5MG**	**N17355 001**	
	LOESTRIN FE 1/20			
AB	+ PARKE DAVIS	**0.02MG;1MG**	**N17354 001**	
	MICROGESTIN FE 1.5/30			
AB	WATSON LABS	**0.03MG;1.5MG**	**N75548 001**	FEB 05, 2001
	MICROGESTIN FE 1/20			
AB	WATSON LABS	**0.02MG;1MG**	**N75647 001**	FEB 05, 2001

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET; ORAL-21

	ORTHO CYCLEN-21			
	+ JOHNSON RW	0.035MG;0.25MG	N19653 001	DEC 29, 1989
	ORTHO TRI-CYCLEN			
	+ JOHNSON RW	0.035MG,0.035MG,0.035MG;0.18MG, 0.215MG,0.25MG	N19697 002	JUL 03, 1992

TABLET; ORAL-28

	ORTHO CYCLEN-28			
	JOHNSON RW	0.035MG;0.25MG	N19653 002	DEC 29, 1989
	ORTHO TRI-CYCLEN			
	JOHNSON RW	0.035MG,0.035MG,0.035MG;0.18MG, 0.215MG,0.25MG	N19697 001	JUL 03, 1992

ETHINYL ESTRADIOL; NORGESTREL

TABLET; ORAL-21

	CRYSELLE			
AB	DURAMED	**0.03MG;0.3MG**	**N75840 001**	NOV 30, 2001
	LO/OVRAL			
AB	+ WYETH AYERST	**0.03MG;0.3MG**	**N17612 001**	
	LOW-OGESTREL-21			
AB	WATSON LABS	**0.03MG;0.3MG**	**N75288 001**	JUL 28, 1999
	OGESTREL 0.5/50-21			
AB	SCS	**0.05MG;0.5MG**	**N75406 001**	DEC 15, 1999

ETHINYL ESTRADIOL; NORGESTREL

TABLET; ORAL-21

	OVRAL			
AB	+ WYETH AYERST	**0.05MG;0.5MG**	**N16672 001**	

TABLET; ORAL-28

	CRYSELLE			
AB	DURAMED	**0.03MG;0.3MG**	**N75840 002**	NOV 30, 2001
	LO/OVRAL-28			
AB	WYETH AYERST	**0.03MG;0.3MG**	**N17802 001**	
	LOW-OGESTREL-28			
AB	WATSON LABS	**0.03MG;0.3MG**	**N75288 002**	JUL 28, 1999
	OGESTREL 0.5/50-28			
AB	SCS	**0.05MG;0.5MG**	**N75406 002**	DEC 15, 1999
	OVRAL-28			
AB	WYETH AYERST	**0.05MG;0.5MG**	**N16806 001**	

ETHIODIZED OIL

OIL; INTRALYMPHATIC, INTRAUTERINE

	ETHIODOL		
	SAVAGE LABS	99%	N09190 001

ETHIONAMIDE

TABLET; ORAL

	TRECATOR-SC		
	+ WYETH AYERST	250MG	N13026 002

ETHOSUXIMIDE

CAPSULE; ORAL

	ZARONTIN		
	+ PARKE DAVIS	250MG	N12380 001

SYRUP; ORAL

	ETHOSUXIMIDE			
AA	COPLEY PHARM	**250MG/5ML**	**N81306 001**	JUL 30, 1993
AA	PHARM ASSOC	**250MG/5ML**	**N40253 001**	NOV 22, 2000
	ZARONTIN			
AA	+ PARKE DAVIS	**250MG/5ML**	**N80258 001**	

FDA data supplied by DrugPatentWatch.com

ETHOTOIN

TABLET; ORAL
PEGANONE
ABBOTT 250MG N10841 001
\+ 500MG N10841 003

ETHYNODIOL DIACETATE; *MULTIPLE*
SEE ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

ETIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
DURANEST
\+ ASTRAZENECA 1% N17751 005

ETIDOCAINE HYDROCHLORIDE; *MULTIPLE*
SEE EPINEPHRINE BITARTRATE; ETIDOCAINE HYDROCHLORIDE

ETIDRONATE DISODIUM

INJECTABLE; INJECTION
DIDRONEL
\+ MGI PHARMA INC 50MG/ML N19545 001
APR 20, 1987

TABLET; ORAL
DIDRONEL
PROCTER AND GAMBLE 200MG N17831 001
\+ 400MG N17831 002

ETODOLAC

CAPSULE; ORAL
ETODOLAC

AB	AESGEN	**300MG**	**N74929 001** JAN 30, 1998
AB	ENDO PHARMS	**200MG**	**N74842 001** JUL 17, 1997
AB		**300MG**	**N74842 002** JUL 17, 1997
AB	GENEVA PHARMS	**200MG**	**N74840 001** AUG 29, 1997
AB		**300MG**	**N74840 002** AUG 29, 1997
AB	GENEVA PHARMS TECH	**200MG**	**N74942 001** SEP 30, 1997
AB		**300MG**	**N74942 002** SEP 30, 1997
AB	GENPHARM	**200MG**	**N75071 001** SEP 30, 1998
AB		**300MG**	**N75071 002** SEP 30, 1998
AB	IVAX PHARMS	**200MG**	**N74899 001** JUL 08, 1997
AB		**300MG**	**N74899 002** JUL 08, 1997
AB	MYLAN	**200MG**	**N74932 001** MAY 16, 1997
AB		**300MG**	**N74932 002** MAY 16, 1997
AB	TARO	**200MG**	**N75078 001** APR 30, 1998
AB		**300MG**	**N75078 002** APR 30, 1998
AB	TEVA	**200MG**	**N75126 001** SEP 16, 1999
AB		**300MG**	**N75126 002** SEP 16, 1999
AB	TORPHARM	**200MG**	**N75419 001** JUL 28, 2000
AB		**300MG**	**N75419 002** JUL 28, 2000
AB	WATSON LABS	**200MG**	**N74844 001** DEC 23, 1997
AB		**300MG**	**N74844 002** DEC 23, 1997

LODINE

AB	WYETH AYERST	**200MG**	**N18922 002** JAN 31, 1991
AB	+	**300MG**	**N18922 003** JAN 31, 1991

TABLET; ORAL
ETODOLAC

AB	AESGEN	**400MG**	**N74927 001** OCT 30, 1997

FDA data supplied by DrugPatentWatch.com

ETODOLAC

TABLET; ORAL
ETODOLAC

AB	ENDO PHARMS	400MG	**N74841 001**	JUN 27, 1997
AB	EON	400MG	**N74903 001**	APR 11, 1997
AB		500MG	**N74903 002**	APR 19, 1999
AB	GENEVA PHARMS	400MG	**N74839 001**	JUL 11, 1997
AB	GENEVA PHARMS TECH	400MG	**N74846 001**	FEB 28, 1997
AB	GENPHARM	400MG	**N75012 001**	SEP 30, 1998
AB		500MG	**N75012 002**	SEP 30, 1998
AB	IVAX PHARMS	400MG	**N74883 001**	FEB 28, 1997
AB		500MG	**N74883 002**	NOV 20, 1998
AB	MYLAN	400MG	**N75104 001**	FEB 06, 1998
AB		500MG	**N75104 002**	NOV 20, 1998
AB	PUREPAC PHARM	400MG	**N74819 001**	FEB 28, 1997
AB	RANBAXY	400MG	**N75226 001**	NOV 24, 1998
AB		500MG	**N75226 002**	NOV 24, 1998
AB	TARO PHARM INDS	400MG	**N75074 001**	MAR 11, 1998
AB		500MG	**N75074 002**	APR 25, 2000
AB	TEVA	400MG	**N74847 001**	APR 23, 1999
AB		400MG	**N75009 001**	NOV 26, 1997
AB		500MG	**N74847 002**	APR 23, 1999
AB		500MG	**N75009 002**	DEC 28, 1999
AB	WATSON LABS	400MG	**N74892 001**	APR 16, 1997
AB		400MG	**N75069 001**	APR 16, 1998

ETODOLAC

TABLET; ORAL
ETODOLAC

AB	WATSON LABS	500MG	**N74892 002**	OCT 29, 1998

LODINE

AB	WYETH AYERST	400MG	**N18922 004**	JUL 29, 1993
AB +		500MG	**N18922 005**	JUN 28, 1996

TABLET, EXTENDED RELEASE; ORAL
ETODOLAC

AB	ANDRX PHARM	400MG	**N75829 001**	NOV 30, 2001
AB		500MG	**N75829 002**	NOV 30, 2001
AB	POINT HOLDINGS	400MG	**N75696 001**	JUL 31, 2000
AB	TEVA	400MG	**N75665 003**	FEB 05, 2001
AB		500MG	**N75665 002**	JUL 31, 2000
AB		600MG	**N75665 001**	JUL 31, 2000

LODINE XL

AB +	WYETH AYERST	400MG	**N20584 001**	OCT 25, 1996
AB +		500MG	**N20584 003**	JAN 20, 1998
AB +		600MG	**N20584 002**	OCT 25, 1996

ETOMIDATE

INJECTABLE; INJECTION
AMIDATE

AP +	ABBOTT	2MG/ML	**N18227 001**	SEP 07, 1982

ETOMIDATE

AP	BEDFORD	2MG/ML	**N74593 001**	NOV 04, 1996

ETONOGESTREL; *MULTIPLE*
SEE ETHINYL ESTRADIOL; ETONOGESTREL

FDA data supplied by DrugPatentWatch.com

ETOPOSIDE

CAPSULE; ORAL

	ETOPOSIDE			
AB	GENPHARM	50MG	**N75635 001**	SEP 19, 2001
	VEPESID			
AB	+ BRISTOL	50MG	**N19557 001**	DEC 30, 1986

INJECTABLE; INJECTION

	ETOPOSIDE			
AP	ABBOTT	20MG/ML	**N74320 001**	AUG 30, 1995
AP		20MG/ML	**N74351 001**	AUG 30, 1995
AP	AM PHARM PARTNERS	20MG/ML	**N74983 001**	SEP 30, 1998
AP	BEDFORD	20MG/ML	**N74290 001**	JUL 17, 1995
AP	GENSIA SICOR PHARMS	20MG/ML	**N74284 001**	FEB 10, 1994
AP		20MG/ML	**N74529 001**	JUL 24, 1996
AP	MARSAM PHARMS LLC	20MG/ML	**N74968 001**	JAN 09, 1998
AP	PHARMACHEMIE	20MG/ML	**N74227 001**	FEB 22, 1996
AP	SUPERGEN	20MG/ML	**N74513 001**	MAR 14, 1996
	TOPOSAR			
AP	PHARMACIA AND UPJOHN	20MG/ML	**N74166 001**	FEB 27, 1995
	VEPESID			
AP	+ BRISTOL MYERS SQUIBB	20MG/ML	**N18768 001**	NOV 10, 1983

ETOPOSIDE PHOSPHATE

INJECTABLE; INJECTION

	ETOPOPHOS PRESERVATIVE FREE			
	+ BRISTOL MYERS SQUIBB	EQ 100MG BASE/VIAL	N20457 001	MAY 17, 1996

EXEMESTANE

TABLET; ORAL

	AROMASIN			
	+ PHARMACIA AND UPJOHN	25MG	N20753 001	OCT 21, 1999

FAMCICLOVIR

TABLET; ORAL

	FAMVIR			
	NOVARTIS	125MG	N20363 003	DEC 11, 1995
		250MG	N20363 001	APR 26, 1996
	+	500MG	N20363 002	JUN 29, 1994

FAMOTIDINE

FOR SUSPENSION; ORAL

	PEPCID			
	+ MERCK	40MG/5ML	N19527 001	FEB 02, 1987

INJECTABLE; INJECTION

	FAMOTIDINE			
AP	ABBOTT	10MG/ML	**N75870 001**	NOV 23, 2001
AP		10MG/ML	**N75905 001**	NOV 23, 2001
AP	AM PHARM PARTNERS	10MG/ML	**N75709 001**	APR 16, 2001
AP	BEDFORD	10MG/ML	**N75651 001**	APR 16, 2001
AP		10MG/ML	**N75684 001**	APR 16, 2001
AP	ESI LEDERLE	10MG/ML	**N75488 001**	APR 16, 2001
AP	FAULDING	10MG/ML	**N75705 001**	APR 16, 2001
	FAMOTIDINE PRESERVATIVE FREE			
AP	AM PHARM PARTNERS	10MG/ML	**N75813 001**	APR 16, 2001
AP	BEDFORD	10MG/ML	**N75622 001**	APR 16, 2001

FDA data supplied by DrugPatentWatch.com

FAMOTIDINE

INJECTABLE; INJECTION

FAMOTIDINE PRESERVATIVE FREE

AP	BEN VENUE	10MG/ML	N75825 001	APR 17, 2001
AP	ESI LEDERLE	10MG/ML	N75486 001	APR 16, 2001
AP	FAULDING	10MG/ML	N75669 001	APR 16, 2001

FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER

AP	ABBOTT	0.4MG/ML	N75729 001	DEC 17, 2001
AP	BAXTER HLTHCARE	0.4MG/ML	N75591 001	MAY 10, 2001

PEPCID

AP	+ MERCK	10MG/ML	N19510 001	NOV 04, 1986

PEPCID PRESERVATIVE FREE

AP	+ MERCK	10MG/ML	N19510 004	NOV 04, 1986

PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER

AP	+ MERCK	0.4MG/ML	N20249 001	FEB 18, 1994

TABLET; ORAL

FAMOTIDINE

AB	CARLSBAD	20MG	N75805 001	APR 16, 2001
AB		40MG	N75805 002	APR 16, 2001
AB	DANBURY PHARMA	20MG	N75062 002	APR 16, 2001
AB		40MG	N75062 001	APR 16, 2001
AB	DR REDDYS LABS LTD	20MG	N75718 001	APR 16, 2001
AB		40MG	N75718 002	APR 16, 2001
AB	EON	20MG	N75793 001	APR 16, 2001
AB		40MG	N75793 002	APR 16, 2001
AB	GENEVA PHARMS	20MG	N75302 001	APR 16, 2001
AB		40MG	N75302 002	APR 16, 2001
AB	GENPHARM	20MG	N75457 001	APR 18, 2001

FAMOTIDINE

TABLET; ORAL

FAMOTIDINE

AB	GENPHARM	40MG	N75457 002	APR 18, 2001
AB	INVAMED	20MG	N75607 001	MAY 10, 2001
AB		40MG	N75607 002	MAY 10, 2001
AB	IVAX PHARMS	20MG	N75511 001	APR 16, 2001
AB		40MG	N75511 002	APR 16, 2001
AB	MUTUAL PHARM	20MG	N75639 002	DEC 12, 2001
AB		40MG	N75639 001	DEC 12, 2001
AB	MYLAN	20MG	N75704 001	APR 16, 2001
AB		40MG	N75704 002	APR 16, 2001
AB	PUREPAC PHARM	20MG	N75650 001	SEP 14, 2001
AB		40MG	N75650 002	SEP 14, 2001
AB	TEVA	20MG	N75311 001	APR 16, 2001
AB		40MG	N75311 002	APR 16, 2001
AB	TORPHARM	20MG	N75611 001	JUL 23, 2001
AB		40MG	N75611 002	JUL 23, 2001
AB	WOCKHARDT	20MG	N75786 001	APR 16, 2001
AB		40MG	N75786 002	APR 16, 2001

PEPCID

AB	MERCK	20MG	N19462 001	OCT 15, 1986
AB	+	40MG	N19462 002	OCT 15, 1986

FDA data supplied by DrugPatentWatch.com

FELBAMATE

SUSPENSION; ORAL				
FELBATOL				
+ WALLACE LABS	600MG/5ML	N20189 003 JUL 29, 1993		
TABLET; ORAL				
FELBATOL				
WALLACE LABS	400MG	N20189 001 JUL 29, 1993		
+	600MG	N20189 002 JUL 29, 1993		

FELODIPINE

TABLET, EXTENDED RELEASE; ORAL				
PLENDIL				
ASTRAZENECA	2.5MG	N19834 004 SEP 22, 1994		
	5MG	N19834 001 JUL 25, 1991		
+	10MG	N19834 002 JUL 25, 1991		

FELODIPINE; *MULTIPLE*
SEE ENALAPRIL MALEATE; FELODIPINE

FENOFIBRATE

CAPSULE; ORAL				
TRICOR (MICRONIZED)				
ABBOTT	67MG	N19304 002 FEB 09, 1998		
	134MG	N19304 003 JUN 30, 1999		
+	200MG	N19304 004 JUN 30, 1999		
TABLET; ORAL				
TRICOR				
ABBOTT	54MG	N21203 001 SEP 04, 2001		
+	160MG	N21203 003 SEP 04, 2001		

FENOLDOPAM MESYLATE

INJECTABLE; INJECTION				
CORLOPAM				
+ ABBOTT	EQ 10MG BASE/ML	N19922 001 SEP 23, 1997		

FENOPROFEN CALCIUM

CAPSULE; ORAL				
FENOPROFEN CALCIUM				
AB GENEVA PHARMS	**EQ 200MG BASE**	**N72394 001** OCT 17, 1988		
AB	**EQ 300MG BASE**	**N72395 001** OCT 17, 1988		
AB PAR PHARM	**EQ 200MG BASE**	**N72437 001** AUG 22, 1988		
AB	**EQ 300MG BASE**	**N72438 001** AUG 22, 1988		
NALFON				
AB + DISTA	**EQ 300MG BASE**	**N17604 002**		
NALFON 200				
AB DISTA	**EQ 200MG BASE**	**N17604 003**		
TABLET; ORAL				
FENOPROFEN CALCIUM				
AB DANBURY PHARMA	**EQ 600MG BASE**	**N72602 001** OCT 11, 1988		
AB GENEVA PHARMS	**EQ 600MG BASE**	**N72396 001** OCT 17, 1988		
AB IVAX PHARMS	**EQ 600MG BASE**	**N72557 001** AUG 29, 1988		
AB LEDERLE	**EQ 600MG BASE**	**N72326 001** AUG 17, 1988		
AB MUTUAL PHARM	**EQ 600MG BASE**	**N72902 001** DEC 21, 1990		
AB MYLAN	**EQ 600MG BASE**	**N72267 001** AUG 17, 1988		
AB PAR PHARM	**EQ 600MG BASE**	**N72429 001** AUG 17, 1988		
AB PUREPAC PHARM	**EQ 600MG BASE**	**N72274 001** MAY 02, 1988		
AB WATSON LABS	**EQ 600MG BASE**	**N72407 001** AUG 17, 1988		
NALFON				
AB + DISTA	**EQ 600MG BASE**	**N17710 001**		

FDA data supplied by DrugPatentWatch.com

FENTANYL

FILM, EXTENDED RELEASE; TRANSDERMAL
DURAGESIC
+ ALZA 0.6MG/24HR N19813 004 AUG 07, 1990
1.2MG/24HR N19813 003 AUG 07, 1990
1.8MG/24HR N19813 002 AUG 07, 1990
2.4MG/24HR N19813 001 AUG 07, 1990

FENTANYL CITRATE

INJECTABLE; INJECTION
FENTANYL CITRATE
AP ABBOTT **EQ 0.05MG BASE/ML** **N19115 001** JAN 12, 1985

FENTANYL CITRATE PRESERVATIVE FREE
AP ABBOTT **EQ 0.05MG BASE/ML** **N72786 001** SEP 24, 1991
AP + ELKINS SINN **EQ 0.05MG BASE/ML** **N19101 001** JUL 11, 1984

SUBLIMAZE PRESERVATIVE FREE
AP + AKORN MFG **EQ 0.05MG BASE/ML** **N16619 001**

TROCHE/LOZENGE; ORAL
ACTIQ
ANESTA EQ 0.2MG BASE N20747 001 NOV 04, 1998
EQ 0.4MG BASE N20747 002 NOV 04, 1998
EQ 0.6MG BASE N20747 003 NOV 04, 1998
EQ 0.8MG BASE N20747 004 NOV 04, 1998
EQ 1.2MG BASE N20747 005 NOV 04, 1998
+ EQ 1.6MG BASE N20747 006 NOV 04, 1998

FENTANYL
ANESTA EQ 0.1MG BASE N20195 007 OCT 30, 1995
EQ 0.2MG BASE N20195 001 OCT 04, 1993
EQ 0.3MG BASE N20195 002 OCT 04, 1993

FENTANYL CITRATE

TROCHE/LOZENGE; ORAL
FENTANYL
+ ANESTA EQ 0.4MG BASE N20195 003 OCT 04, 1993

FENTANYL CITRATE; *MULTIPLE*
SEE DROPERIDOL; FENTANYL CITRATE

FERRIC AMMONIUM CITRATE

FOR SOLUTION; ORAL
FERRISELTZ
+ AMERSHAM HLTH 600MG/PACKET N20292 001 OCT 14, 1997

FERUMOXIDES

INJECTABLE; INJECTION
FERIDEX I.V.
+ ADV MAGNETICS EQ 11.2MG IRON/ML N20416 001 AUG 30, 1996

FERUMOXSIL

SUSPENSION; ORAL
GASTROMARK
+ ADV MAGNETICS EQ 0.175MG IRON/ML N20410 001 DEC 06, 1996

FEXOFENADINE HYDROCHLORIDE

CAPSULE; ORAL
ALLEGRA
+ AVENTIS PHARMS 60MG N20625 001 JUL 25, 1996

TABLET; ORAL
ALLEGRA
AVENTIS PHARMS 30MG N20872 001 FEB 25, 2000
60MG N20872 002 FEB 25, 2000

FDA data supplied by DrugPatentWatch.com

FEXOFENADINE HYDROCHLORIDE

TABLET; ORAL
ALLEGRA
+ AVENTIS PHARMS 180MG N20872 004 FEB 25, 2000

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
ALLEGRA-D
+ AVENTIS PHARMS 60MG;120MG N20786 001 DEC 24, 1997

FIBRINOLYSIN; *MULTIPLE*
SEE CHLORAMPHENICOL; DESOXYRIBONUCLEASE; FIBRINOLYSIN

FINASTERIDE

TABLET; ORAL
PROPECIA
+ MERCK 1MG N20788 001 DEC 19, 1997

PROSCAR
+ MERCK 5MG N20180 001 JUN 19, 1992

FLAVOXATE HYDROCHLORIDE

TABLET; ORAL
URISPAS
+ GLAXOSMITHKLINE 100MG N16769 001

FLECAINIDE ACETATE

TABLET; ORAL
FLECAINIDE ACETATE
AB ALPHAPHARM **50MG** **N75442 001** JUL 31, 2001
AB **100MG** **N75442 002** JUL 31, 2001
AB **150MG** **N75442 003** JUL 31, 2001

FLECAINIDE ACETATE

TABLET; ORAL
TAMBOCOR
AB 3M **50MG** **N18830 004** AUG 23, 1988
AB **100MG** **N18830 001** OCT 31, 1985
AB + **150MG** **N18830 003** JUN 03, 1988

FLOXURIDINE

INJECTABLE; INJECTION
FLOXURIDINE
AP AM PHARM PARTNERS **500MG/VIAL** **N75837 001** FEB 22, 2001
AP BEDFORD **500MG/VIAL** **N75387 001** APR 16, 2000

FUDR
AP + ROCHE **500MG/VIAL** **N16929 001**

FLUCONAZOLE

FOR SUSPENSION; ORAL
DIFLUCAN
PFIZER 50MG/5ML N20090 001 DEC 23, 1993
+ 200MG/5ML N20090 002 DEC 23, 1993

INJECTABLE; INJECTION
DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER
+ PFIZER 200MG/100ML N19950 003 SEP 29, 1992

DIFLUCAN IN SODIUM CHLORIDE 0.9%
+ PFIZER 200MG/100ML N19950 001 JAN 29, 1990

DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
+ PFIZER 200MG/100ML N19950 002 JAN 29, 1990

TABLET; ORAL
DIFLUCAN
PFIZER 50MG N19949 001 JAN 29, 1990

FDA data supplied by DrugPatentWatch.com

FLUCONAZOLE

TABLET; ORAL

DIFLUCAN				
PFIZER	100MG	N19949 002 JAN 29, 1990		
	150MG	N19949 004 JUN 30, 1994		
+	200MG	N19949 003 JAN 29, 1990		

FLUCYTOSINE

CAPSULE; ORAL

ANCOBON				
ICN	250MG	N17001 001		
+	500MG	N17001 002		

FLUDARABINE PHOSPHATE

INJECTABLE; INJECTION

FLUDARA				
+ BERLEX	50MG/VIAL	N20038 001 APR 18, 1991		

FLUDEOXYGLUCOSE, F-18

INJECTABLE; INJECTION

FLUDEOXYGLUCOSE F 18				
+ DOWNSTATE CLINCL	4-40mCi/ML	N20306 001 AUG 19, 1994		
+	4-90mCi/ML	N20306 002 SEP 25, 2001		

FLUDROCORTISONE ACETATE

TABLET; ORAL

FLORINEF				
+ KING PHARMS	0.1MG	N10060 001		

FLUMAZENIL

INJECTABLE; INJECTION

ROMAZICON				
+ HLR	0.1MG/ML	N20073 001 DEC 20, 1991		

FLUNISOLIDE

AEROSOL, METERED; INHALATION

AEROBID				
+ SYNTEX (USA) INC LLC	0.25MG/INH	N18340 001 AUG 17, 1984		

SPRAY, METERED; NASAL

NASALIDE				
BX + IVAX RES	0.025MG/SPRAY	N18148 001		
NASAREL				
BX + IVAX RES	0.025MG/SPRAY	N20409 001 MAR 08, 1995		

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL

	FLUOCINOLONE ACETONIDE			
AT	FOUGERA	**0.01%**	**N88170 001** DEC 16, 1982	
AT		**0.025%**	**N88169 001** DEC 16, 1982	
AT	G AND W LABS	**0.01%**	**N89526 001** JUL 26, 1988	
AT		**0.025%**	**N89525 001** JUL 26, 1988	
AT	TARO	**0.01%**	**N40035 001** OCT 31, 1994	
AT		**0.025%**	**N40042 001** OCT 31, 1994	
AT	THAMES	**0.01%**	**N87102 001** APR 27, 1982	
AT		**0.025%**	**N87104 001** APR 27, 1982	
	SYNALAR			
AT +	MEDICIS	**0.01%**	**N12787 004**	
AT +		**0.025%**	**N12787 002**	
AT +		**0.025%**	**N12787 005**	
	SYNALAR-HP			
+	MEDICIS	0.2%	N16161 002	

FDA data supplied by DrugPatentWatch.com

FLUOCINOLONE ACETONIDE

OIL; TOPICAL

	DERMA-SMOOTHE/FS			
+	HILL DERMAC	0.01%	N19452 001	FEB 03, 1988

OINTMENT; TOPICAL

	FLUOCINOLONE ACETONIDE			
AT	FOUGERA	**0.025%**	**N88168 001**	DEC 16, 1982
AT	G AND W LABS	**0.025%**	**N89524 001**	JUL 26, 1988
AT	TARO	**0.025%**	**N40041 001**	SEP 15, 1994
	SYNALAR			
AT +	MEDICIS	**0.025%**	**N13960 001**	

SHAMPOO; TOPICAL

	FS SHAMPOO			
+	GALDERMA LABS LP	0.01%	N20001 001	AUG 27, 1990

SOLUTION; TOPICAL

	FLUOCINOLONE ACETONIDE			
AT	ALPHARMA	**0.01%**	**N87159 001**	JUN 16, 1982
AT	FOUGERA	**0.01%**	**N88167 001**	DEC 16, 1982
AT	THAMES	**0.01%**	**N89124 001**	SEP 11, 1985
	FLUONID			
AT	ALLERGAN HERBERT	**0.01%**	**N87158 001**	MAR 17, 1983
	SYNALAR			
AT +	MEDICIS	**0.01%**	**N15296 001**	

FLUOCINONIDE

CREAM; TOPICAL

	FLUOCINONIDE			
AB	DRAXIS HLTH	**0.05%**	**N72494 001**	JAN 19, 1989
AB	FOUGERA	**0.05%**	**N73030 001**	OCT 17, 1994
AB	NMC	**0.05%**	**N73085 001**	FEB 14, 1992

FLUOCINONIDE

CREAM; TOPICAL

	FLUOCINONIDE			
AB	TARO	**0.05%**	**N19117 001**	JUN 26, 1984
AB	TEVA	**0.05%**	**N72488 001**	FEB 06, 1989
AB		**0.05%**	**N72490 001**	FEB 07, 1989
AB	THAMES	**0.05%**	**N71500 001**	JUN 10, 1987
	FLUOCINONIDE EMULSIFIED BASE			
AB	NMC	**0.05%**	**N74204 001**	JUN 13, 1995
	LIDEX			
AB +	MEDICIS	**0.05%**	**N16908 002**	
	LIDEX-E			
AB	MEDICIS	**0.05%**	**N16908 003**	

GEL; TOPICAL

	FLUOCINONIDE			
AB	FOUGERA	**0.05%**	**N72933 001**	DEC 30, 1994
AB	TARO	**0.05%**	**N74935 001**	JUL 29, 1997
AB	TEVA	**0.05%**	**N72537 001**	FEB 07, 1989
	LIDEX			
AB +	MEDICIS	**0.05%**	**N17373 001**	

OINTMENT; TOPICAL

	FLUOCINONIDE			
AB	ALTANA	**0.05%**	**N74905 001**	AUG 26, 1997
AB	TARO	**0.05%**	**N75008 001**	JUN 30, 1999
AB	TEVA	**0.05%**	**N73481 001**	DEC 27, 1991
	LIDEX			
AB +	MEDICIS	**0.05%**	**N16909 002**	

SOLUTION; TOPICAL

	FLUOCINONIDE			
AT	ALPHARMA	**0.05%**	**N71535 001**	DEC 02, 1988
AT	COPLEY PHARM	**0.05%**	**N72522 001**	SEP 28, 1990

FDA data supplied by DrugPatentWatch.com

FLUOCINONIDE

SOLUTION; TOPICAL

	FLUOCINONIDE			
AT	FOUGERA	**0.05%**	**N72934 001**	
			FEB 27, 1995	
AT	TARO	**0.05%**	**N74799 001**	
			DEC 31, 1996	
AT	TEVA	**0.05%**	**N72511 001**	
			FEB 07, 1989	
AT	THAMES	**0.05%**	**N72857 001**	
			AUG 02, 1989	
	LIDEX			
AT	+ MEDICIS	**0.05%**	**N18849 001**	
			APR 06, 1984	

FLUORESCEIN SODIUM

INJECTABLE; INJECTION

	FUNDUSCEIN-25		
	+ NOVARTIS	25%	N17869 001

FLUOROMETHOLONE

OINTMENT; OPHTHALMIC

	FML		
	+ ALLERGAN	0.1%	N17760 001
			SEP 04, 1985

SUSPENSION; OPHTHALMIC

	FLUOR-OP		
AB	NOVARTIS	**0.1%**	**N70185 001**
			FEB 27, 1986

SUSPENSION/DROPS; OPHTHALMIC

	FML		
AB	+ ALLERGAN	**0.1%**	**N16851 002**
			JUL 28, 1982
	FML FORTE		
	ALLERGAN	0.25%	N19216 001
			APR 23, 1986

FLUOROMETHOLONE; SULFACETAMIDE SODIUM

SUSPENSION/DROPS; OPHTHALMIC

	FML-S		
	+ ALLERGAN	0.1%;10%	N19525 001
			SEP 29, 1989

FLUOROMETHOLONE ACETATE

SUSPENSION/DROPS; OPHTHALMIC

	FLAREX		
	+ ALCON	0.1%	N19079 001
			FEB 11, 1986

FLUOROMETHOLONE ACETATE; TOBRAMYCIN

SUSPENSION/DROPS; OPHTHALMIC

	TOBRASONE		
	+ ALCON	0.1%;0.3%	N50628 001
			JUL 21, 1989

FLUOROURACIL

CREAM; TOPICAL

	CARAC		
	+ DERMIK LABS	0.5%	N20985 001
			OCT 27, 2000
	EFUDEX		
	+ ICN	5%	N16831 003
	FLUOROPLEX		
	+ ALLERGAN HERBERT	1%	N16988 001

INJECTABLE; INJECTION

	ADRUCIL		
AP	PHARMACIA AND UPJOHN	**50MG/ML**	**N40023 001**
			OCT 18, 1991
AP	+	**50MG/ML**	**N81225 001**
			AUG 28, 1991
	FLUOROURACIL		
AP	AM PHARM PARTNERS	**50MG/ML**	**N40278 001**
			SEP 30, 1998
AP		**50MG/ML**	**N40279 001**
			SEP 30, 1998
AP	BEDFORD	**50MG/ML**	**N89508 001**
			JAN 26, 1988

FDA data supplied by DrugPatentWatch.com

FLUOROURACIL

INJECTABLE; INJECTION

FLUOROURACIL

AP	BIGMAR	**50MG/ML**	**N40291 001**	MAR 24, 1999
AP		**50MG/ML**	**N40379 001**	NOV 15, 2000
AP	GENSIA SICOR PHARMS	**50MG/ML**	**N40333 001**	JAN 27, 2000
AP		**50MG/ML**	**N40334 001**	FEB 25, 2000
AP +	ICN PUERTO RICO	**50MG/ML**	**N12209 001**	
AP	STERIS	**50MG/ML**	**N87792 001**	OCT 13, 1982

SOLUTION; TOPICAL

EFUDEX

+	ICN	2%	N16831 001
+		5%	N16831 002

FLUOROPLEX

+	ALLERGAN HERBERT	1%	N16765 001

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL

FLUOXETINE

AB	BARR	**EQ 20MG BASE**	**N74803 001**	AUG 02, 2001
AB	DR REDDYS LABS LTD	**EQ 40MG BASE**	**N75465 003**	AUG 02, 2001
AB	GENEVA PHARMS	**EQ 10MG BASE**	**N75049 001**	AUG 02, 2001

PROZAC

AB	LILLY	**EQ 10MG BASE**	**N18936 006**	DEC 23, 1992
AB		**EQ 20MG BASE**	**N18936 001**	DEC 29, 1987
AB +		**EQ 40MG BASE**	**N18936 003**	JUN 15, 1999

SARAFEM

	LILLY	EQ 10MG BASE	N18936 007	JUL 06, 2000
+		EQ 20MG BASE	N18936 008	JUL 06, 2000

CAPSULE, DELAYED REL PELLETS; ORAL

PROZAC WEEKLY

+	LILLY	EQ 90MG BASE	N21235 001	FEB 26, 2001

FLUOXETINE HYDROCHLORIDE

SOLUTION; ORAL

FLUOXETINE

AA	TEVA	**EQ 20MG BASE/5ML**	**N75506 001**	AUG 02, 2001

PROZAC

AA +	LILLY	**EQ 20MG BASE/5ML**	**N20101 001**	APR 24, 1991

TABLET; ORAL

FLUOXETINE HCL

AB	ALPHAPHARM	**EQ 10MG BASE**	**N75755 001**	AUG 02, 2001
+		EQ 20MG BASE	N75755 002	AUG 02, 2001

PROZAC

AB +	LILLY	**EQ 10MG BASE**	**N20974 001**	MAR 09, 1999

FLUOXYMESTERONE

TABLET; ORAL

FLUOXYMESTERONE

BP	USL PHARMA	10MG	N88342 001	OCT 21, 1983

HALOTESTIN

BP +	PHARMACIA AND UPJOHN	10MG	N10611 010	
		2MG	N10611 002	
		5MG	N10611 006	

FLUPHENAZINE DECANOATE

INJECTABLE; IM-SC

FLUPHENAZINE DECANOATE

AO	APOTEX	**25MG/ML**	**N75918 001**	AUG 17, 2001

INJECTABLE; INJECTION

FLUPHENAZINE DECANOATE

AO	AM PHARM PARTNERS	**25MG/ML**	**N71413 001**	JUL 14, 1987
AO	BEDFORD	**25MG/ML**	**N74531 001**	AUG 30, 1996
AO	GENSIA SICOR PHARMS	**25MG/ML**	**N74795 001**	SEP 10, 1996

FDA data supplied by DrugPatentWatch.com

FLUPHENAZINE DECANOATE

INJECTABLE; INJECTION

	FLUPHENAZINE DECANOATE			
AO	KING PHARMS	25MG/ML	**N74966 001**	APR 16, 1998
	PROLIXIN DECANOATE			
AO	+ BRISTOL MYERS SQUIBB	25MG/ML	**N16727 001**	

FLUPHENAZINE ENANTHATE

INJECTABLE; INJECTION

	PROLIXIN ENANTHATE		
	+ APOTHECON	25MG/ML	N16110 001

FLUPHENAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

	FLUPHENAZINE HCL			
AA	COPLEY PHARM	5MG/ML	**N73058 001**	AUG 30, 1991
AA	PHARM ASSOC	5MG/ML	**N74725 001**	SEP 16, 1996
	PERMITIL			
AA	+ SCHERING	5MG/ML	**N16008 001**	
	PROLIXIN			
AA	APOTHECON	5MG/ML	**N70533 001**	NOV 07, 1985

ELIXIR; ORAL

	FLUPHENAZINE HCL			
AA	COPLEY PHARM	2.5MG/5ML	**N81310 001**	APR 29, 1993
AA	PHARM ASSOC	2.5MG/5ML	**N40146 001**	AUG 21, 1996
	PROLIXIN			
AA	+ APOTHECON	2.5MG/5ML	**N12145 003**	

INJECTABLE; INJECTION

	FLUPHENAZINE HCL			
AP	AM PHARM PARTNERS	2.5MG/ML	**N89556 001**	APR 16, 1987
	PROLIXIN			
AP	+ APOTHECON	2.5MG/ML	**N11751 005**	

TABLET; ORAL

	FLUPHENAZINE HCL			
AB	GENEVA PHARMS	1MG	**N89583 001**	OCT 16, 1987

FLUPHENAZINE HYDROCHLORIDE

TABLET; ORAL

	FLUPHENAZINE HCL			
AB	GENEVA PHARMS	2.5MG	**N89584 001**	OCT 16, 1987
AB		5MG	**N89585 001**	OCT 16, 1987
AB		10MG	**N89586 001**	OCT 16, 1987
AB	MYLAN	1MG	**N89801 001**	AUG 12, 1988
AB		2.5MG	**N89802 001**	AUG 12, 1988
AB		5MG	**N89803 001**	AUG 12, 1988
AB		10MG	**N89804 001**	AUG 12, 1988
AB	PAR PHARM	1MG	**N89740 001**	AUG 25, 1988
AB		2.5MG	**N89741 001**	AUG 25, 1988
AB		5MG	**N89742 001**	AUG 25, 1988
AB		10MG	**N89743 001**	AUG 25, 1988
	PERMITIL			
BP	SCHERING	2.5MG	N12034 004	
BP		5MG	N12034 005	
	PROLIXIN			
AB	APOTHECON	1MG	**N11751 004**	
AB		2.5MG	**N11751 001**	
AB		5MG	**N11751 003**	
AB	+	10MG	**N11751 002**	

FLURANDRENOLIDE

CREAM; TOPICAL

	CORDRAN SP		
	+ OCLASSEN	0.025%	N12806 003
	+	0.05%	N12806 002

LOTION; TOPICAL

	CORDRAN			
AT	+ OCLASSEN	0.05%	**N13790 001**	

OINTMENT; TOPICAL

	CORDRAN		
	+ OCLASSEN	0.025%	N12806 004

FDA data supplied by DrugPatentWatch.com

FLURANDRENOLIDE

OINTMENT; TOPICAL

	CORDRAN			
+	OCLASSEN	0.05%	N12806 001	

TAPE; TOPICAL

	CORDRAN			
+	OCLASSEN	0.004MG/SQ CM	N16455 001	

FLURAZEPAM HYDROCHLORIDE

CAPSULE; ORAL

	DALMANE			
AB	ICN	**15MG**	**N16721 001**	
AB	+	**30MG**	**N16721 002**	
	FLURAZEPAM HCL			
AB	DANBURY PHARMA	**15MG**	**N71205 001**	NOV 25, 1986
AB		**30MG**	**N71068 001**	NOV 25, 1986
AB	GENEVA PHARMS	**15MG**	**N71716 001**	JUL 31, 1991
AB		**30MG**	**N71717 001**	JUL 31, 1991
AB	MYLAN	**15MG**	**N70344 001**	NOV 27, 1985
AB		**30MG**	**N70345 001**	NOV 27, 1985
AB	PAR PHARM	**15MG**	**N70444 001**	MAR 20, 1986
AB		**30MG**	**N70445 001**	MAR 20, 1986
AB	WATSON LABS	**30MG**	**N72369 001**	MAR 30, 1989
AB	WEST WARD	**15MG**	**N71107 001**	DEC 08, 1986
AB		**30MG**	**N71108 001**	DEC 08, 1986

FLURBIPROFEN

TABLET; ORAL

	ANSAID			
AB	PHARMACIA AND UPJOHN	**50MG**	**N18766 002**	OCT 31, 1988

FLURBIPROFEN

TABLET; ORAL

	ANSAID			
AB	+ PHARMACIA AND UPJOHN	**100MG**	**N18766 003**	OCT 31, 1988
	FLURBIPROFEN			
AB	CARACO	**50MG**	**N75058 001**	APR 27, 2001
AB		**100MG**	**N75058 002**	APR 27, 2001
AB	GENEVA PHARMS	**50MG**	**N74448 001**	JUL 28, 1995
AB		**100MG**	**N74448 002**	JUL 28, 1995
AB	IVAX PHARMS	**50MG**	**N74411 001**	MAY 31, 1995
AB		**100MG**	**N74411 002**	MAY 31, 1995
AB	MYLAN	**50MG**	**N74358 001**	JUN 20, 1994
AB		**100MG**	**N74358 002**	JUN 20, 1994
AB	SIDMAK LABS NJ	**50MG**	**N74647 001**	APR 01, 1997
AB		**100MG**	**N74647 002**	APR 01, 1997
AB	TEVA	**50MG**	**N74405 002**	MAY 24, 1995
AB		**100MG**	**N74405 001**	MAY 24, 1995
AB		**100MG**	**N74431 001**	MAY 31, 1995
AB	WARNER CHILCOTT	**100MG**	**N74560 002**	MAY 16, 1997

FLURBIPROFEN SODIUM

SOLUTION/DROPS; OPHTHALMIC

	FLURBIPROFEN SODIUM			
AT	AVENTIS BEHRING	**0.03%**	**N74447 001**	JAN 04, 1995
	OCUFEN			
AT	+ ALLERGAN	**0.03%**	**N19404 001**	DEC 31, 1986

FDA data supplied by DrugPatentWatch.com

FLUTAMIDE

CAPSULE; ORAL

	EULEXIN			
AB	+ SCHERING	**125MG**	**N18554 001**	JAN 27, 1989
	FLUTAMIDE			
AB	BARR	**125MG**	**N75820 001**	SEP 18, 2001
AB	EON	**125MG**	**N75818 001**	SEP 18, 2001
AB	IVAX PHARMS	**125MG**	**N75780 001**	SEP 19, 2001
AB	TEVA	**125MG**	**N75298 001**	SEP 18, 2001

FLUTICASONE PROPIONATE

AEROSOL, METERED; INHALATION

	FLOVENT		
	GLAXOSMITHKLINE	0.044MG/INH	N20548 001 MAR 27, 1996
		0.11MG/INH	N20548 002 MAR 27, 1996
+		0.22MG/INH	N20548 003 MAR 27, 1996

CREAM; TOPICAL

	CUTIVATE		
+	GLAXOSMITHKLINE	0.05%	N19958 001 DEC 18, 1990

OINTMENT; TOPICAL

	CUTIVATE		
+	GLAXOSMITHKLINE	0.005%	N19957 001 DEC 14, 1990

POWDER; INHALATION

	FLOVENT		
+	GLAXOSMITHKLINE	0.044MG/INH	N20549 001 NOV 07, 1997
+		0.088MG/INH	N20549 002 NOV 07, 1997
+		0.22MG/INH	N20549 003 NOV 07, 1997
	FLOVENT DISKUS 100		
+	GLAXOSMITHKLINE	0.1MG/INH	N20833 002 SEP 29, 2000

FLUTICASONE PROPIONATE

POWDER; INHALATION

	FLOVENT DISKUS 250		
+	GLAXOSMITHKLINE	0.25MG/INH	N20833 003 SEP 29, 2000
	FLOVENT DISKUS 50		
+	GLAXOSMITHKLINE	0.05MG/INH	N20833 001 SEP 29, 2000

SPRAY, METERED; NASAL

	FLONASE		
+	GLAXOSMITHKLINE	0.05MG/SPRAY	N20121 001 OCT 19, 1994

FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE

POWDER; INHALATION

	ADVAIR DISKUS 100/50		
+	GLAXOSMITHKLINE	0.1MG/INH; EQ 0.05MG BASE/INH	N21077 001 AUG 24, 2000
	ADVAIR DISKUS 250/50		
+	GLAXOSMITHKLINE	0.25MG/INH; EQ 0.05MG BASE/INH	N21077 002 AUG 24, 2000
	ADVAIR DISKUS 500/50		
+	GLAXOSMITHKLINE	0.5MG/INH; EQ 0.05MG BASE/INH	N21077 003 AUG 24, 2000

FLUVASTATIN SODIUM

CAPSULE; ORAL

	LESCOL		
	NOVARTIS	EQ 20MG BASE	N20261 001 DEC 31, 1993
+		EQ 40MG BASE	N20261 002 DEC 31, 1993

TABLET, EXTENDED RELEASE; ORAL

	LESCOL XL		
+	NOVARTIS	80MG	N21192 001 OCT 06, 2000

FDA data supplied by DrugPatentWatch.com

FLUVOXAMINE MALEATE

TABLET; ORAL

FLUVOXAMINE MALEATE

AB	BARR	25MG	N75897 001	JAN 25, 2001
AB		50MG	N75897 002	JAN 25, 2001
AB		100MG	N75897 003	JAN 25, 2001
AB	EON	25MG	N75888 001	NOV 29, 2000
AB		50MG	N75888 002	NOV 29, 2000
AB		100MG	N75888 003	NOV 29, 2000
AB	GENPHARM	50MG	N75950 001	OCT 15, 2001
AB		100MG	N75950 002	OCT 15, 2001
AB	INVAMED	25MG	N75887 001	JAN 05, 2001
AB		50MG	N75887 002	JAN 05, 2001
AB		100MG	N75887 003	JAN 05, 2001
AB	IVAX PHARMS	25MG	N75898 001	MAR 12, 2001
AB		50MG	N75898 002	MAR 12, 2001
AB		100MG	N75898 003	MAR 12, 2001
AB	MYLAN	25MG	N75889 001	NOV 29, 2000
AB		50MG	N75889 002	NOV 29, 2000
AB		100MG	N75889 003	NOV 29, 2000
AB	PUREPAC PHARM	25MG	N75901 001	DEC 28, 2000
AB		50MG	N75901 002	DEC 28, 2000
AB		100MG	N75901 003	DEC 28, 2000
AB	SYNTHON PHARMS	25MG	N75899 001	JAN 17, 2001
AB		50MG	N75899 002	JAN 17, 2001

FLUVOXAMINE MALEATE

TABLET; ORAL

FLUVOXAMINE MALEATE

AB	SYNTHON PHARMS	100MG	N75899 003	JAN 17, 2001
AB	TORPHARM	25MG	N75902 001	MAY 07, 2001
AB		50MG	N75902 002	MAY 07, 2001
AB		100MG	N75902 003	MAY 07, 2001
AB	WATSON LABS	25MG	N75894 001	APR 18, 2001
AB		50MG	N75894 002	APR 18, 2001
AB		100MG	N75894 003	APR 18, 2001

LUVOX

AB	SOLVAY	25MG	N20243 001	DEC 05, 1994
AB		50MG	N20243 002	DEC 05, 1994
AB +		100MG	N20243 003	DEC 05, 1994

FOLIC ACID

INJECTABLE; INJECTION

FOLIC ACID

AP	AM PHARM PARTNERS	5MG/ML	N89202 001	FEB 18, 1986
AP	LOCH	5MG/ML	N81066 001	DEC 29, 1993

FOLVITE

AP +	LEDERLE	5MG/ML	N05897 008	

TABLET; ORAL

FOLIC ACID

AA +	DANBURY PHARMA	1MG	N80680 001	
AA	ICN	1MG	N80903 001	
AA	IVAX PHARMS	1MG	N83000 001	
AA	MK LABS	1MG	N83526 001	
AA	PVT FORM	1MG	N85061 001	
AA	TABLICAPS	1MG	N83133 002	
AA	WEST WARD	1MG	N80600 001	

FOLICET

AA	MISSION PHARMA	1MG	N87438 001	

FDA data supplied by DrugPatentWatch.com

FOLIC ACID; *MULTIPLE*

SEE ALPHA-TOCOPHEROL; ASCORBIC ACID; BIOTIN, D-; CHOLECALCIFEROL; CYANOCOBALAMIN; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A

SEE ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE

SEE ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PHYTONADIONE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

FOLLITROPIN ALFA

INJECTABLE; INJECTION

GONAL-F			
+ SERONO	1,200 IU/VIAL		N20378 004 FEB 28, 2001

FOLLITROPIN ALFA/BETA

INJECTABLE; INJECTION

FOLLISTIM			
BX ORGANON	75 IU/VIAL		N20582 001 SEP 29, 1997
BX	150 IU/VIAL		N20582 002 SEP 29, 1997
GONAL-F			
BX SERONO	75 IU/VIAL		N20378 001 SEP 29, 1997
BX	150 IU/VIAL		N20378 002 SEP 29, 1997
	37.5 IU/VIAL		N20378 003 MAY 25, 2000

FOMEPIZOLE

INJECTABLE; INJECTION

ANTIZOL		
+ ORPHAN MEDCL	1GM/ML	N20696 001 DEC 04, 1997

FOMIVIRSEN SODIUM

INJECTABLE; INJECTION

VITRAVENE PRESERVATIVE FREE		
+ NOVARTIS	6.6MG/ML	N20961 001 AUG 26, 1998

FONDAPARINUX SODIUM

INJECTABLE; SUBCUTANEOUS

ARIXTRA		
+ FONDA BV	2.5MG/0.5ML	N21345 001 DEC 07, 2001

FORMOTEROL FUMARATE

CAPSULE; INHALATION

FORADIL		
+ NOVARTIS	0.012MG/INH	N20831 001 FEB 16, 2001

FOSCARNET SODIUM

INJECTABLE; INJECTION

FOSCAVIR		
+ ASTRAZENECA	2.4GM/100ML	N20068 001 SEP 27, 1991

FOSFOMYCIN TROMETHAMINE

FOR SUSPENSION; ORAL

MONUROL		
+ ZAMBON	EQ 3GM BASE/PACKET	N50717 001 DEC 19, 1996

FDA data supplied by DrugPatentWatch.com

FOSINOPRIL SODIUM

TABLET; ORAL
MONOPRIL
BRISTOL MYERS SQUIBB 10MG N19915 002 MAY 16, 1991
20MG N19915 003 MAY 16, 1991
+ 40MG N19915 004 MAR 28, 1995

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET; ORAL
MONOPRIL-HCT
BRISTOL MYERS SQUIBB 10MG;12.5MG N20286 002 NOV 30, 1994
+ 20MG;12.5MG N20286 001 NOV 30, 1994

FOSPHENYTOIN SODIUM

INJECTABLE; INJECTION
CEREBYX
+ PARKE DAVIS EQ 50MG PHENYTOIN NA/ML N20450 001 AUG 05, 1996

FROVATRIPTAN SUCCINATE

TABLET; ORAL
FROVA
+ ELAN PHARMS EQ 2.5MG BASE N21006 001 NOV 08, 2001

FURAZOLIDONE

SUSPENSION; ORAL
FUROXONE
+ SHIRE LABS 50MG/15ML N11323 002

TABLET; ORAL
FUROXONE
+ SHIRE LABS 100MG N11270 002

FUROSEMIDE

INJECTABLE; INJECTION
FUROSEMIDE

AP	ABBOTT	10MG/ML	**N18667 001**	MAY 28, 1982
AP		10MG/ML	**N70578 001**	JUL 08, 1987
AP		10MG/ML	**N72080 001**	AUG 13, 1991
AP		10MG/ML	**N74337 001**	OCT 31, 1994
AP		10MG/ML	**N75241 001**	MAY 28, 1999
AP	AM PHARM PARTNERS	10MG/ML	**N18902 001**	MAY 22, 1984
AP	ELKINS SINN	10MG/ML	**N18267 001**	
AP	INTL MEDICATION	10MG/ML	**N18025 001**	
AP	LEDERLE	10MG/ML	**N71439 001**	SEP 14, 1990
AP	LUITPOLD	10MG/ML	**N18579 001**	NOV 30, 1983
AP	MARSAM PHARMS LLC	10MG/ML	**N74017 001**	JUN 30, 1994

LASIX

AP	+ AVENTIS PHARMS	10MG/ML	**N16363 001**	

SOLUTION; ORAL
FUROSEMIDE

AA	MORTON GROVE	10MG/ML	**N70655 001**	OCT 02, 1987
AA	ROXANE	10MG/ML	**N70434 001**	APR 22, 1987
		40MG/5ML	N70433 001	APR 22, 1987

LASIX

AA	+ AVENTIS PHARMS	10MG/ML	**N17688 001**	

TABLET; ORAL
FUROSEMIDE

AB	DANBURY PHARMA	20MG	**N70412 001**	FEB 26, 1986
AB		40MG	**N70413 001**	FEB 26, 1986
AB		80MG	**N71594 001**	FEB 09, 1988
AB	GENEVA PHARMS	20MG	**N18569 002**	
AB		40MG	**N18569 001**	

FDA data supplied by DrugPatentWatch.com

FUROSEMIDE

TABLET; ORAL

	FUROSEMIDE			
AB	GENEVA PHARMS	80MG	N18569 005	AUG 14, 1984
AB	INTL MEDICATION	20MG	N18753 001	FEB 28, 1984
AB		40MG	N18753 002	FEB 28, 1984
AB	IVAX PHARMS	20MG	N18413 001	NOV 30, 1983
AB		40MG	N18413 002	NOV 30, 1983
AB	KALAPHARM	20MG	N18868 001	JUN 28, 1983
AB		40MG	N18868 002	JUN 28, 1983
AB	LEDERLE	20MG	N18415 001	JUL 27, 1982
AB		40MG	N18415 002	JUL 27, 1982
AB		80MG	N18415 003	NOV 26, 1984
AB	MYLAN	20MG	N18487 001	
AB		40MG	N18487 002	
AB		80MG	N70082 001	OCT 29, 1986
AB	ROXANE	20MG	N18823 001	NOV 10, 1983
AB		40MG	N18823 002	NOV 10, 1983
AB		80MG	N70086 001	JAN 24, 1986
AB	WATSON LABS	20MG	N70449 001	NOV 22, 1985
AB		20MG	N71379 001	JAN 02, 1987
AB		40MG	N70450 001	NOV 22, 1985
AB		80MG	N70528 001	JAN 07, 1986
	LASIX			
AB	AVENTIS PHARMS	20MG	N16273 002	
AB		40MG	N16273 001	
AB	+	80MG	N16273 003	

GABAPENTIN

CAPSULE; ORAL

	NEURONTIN			
	PFIZER	100MG	N20235 001	DEC 30, 1993
		300MG	N20235 002	DEC 30, 1993
+		400MG	N20235 003	DEC 30, 1993

SOLUTION; ORAL

	NEURONTIN			
+	PARKE DAVIS	250MG/5ML	N21129 001	MAR 02, 2000

TABLET; ORAL

	NEURONTIN			
	PARKE DAVIS	600MG	N20882 001	OCT 09, 1998
+		800MG	N20882 002	OCT 09, 1998

GADODIAMIDE

INJECTABLE; INJECTION

	OMNISCAN			
+	AMERSHAM HLTH	287MG/ML	N20123 001	JAN 08, 1993

GADOPENTETATE DIMEGLUMINE

INJECTABLE; INJECTION

	MAGNEVIST			
+	BERLEX	469.01MG/ML	N19596 001	JUN 02, 1988
+	BERLEX LABS	469.01MG/ML	N21037 001	MAR 10, 2000

GADOTERIDOL

INJECTABLE; INJECTION

	PROHANCE			
+	BRACCO	279.3MG/ML	N20131 001	NOV 16, 1992

FDA data supplied by DrugPatentWatch.com

GADOVERSETAMIDE

INJECTABLE; INJECTION				
OPTIMARK				
+	MALLINCKRODT	330.9MG/ML	N20937 001	DEC 08, 1999
+		330.9MG/ML	N20975 001	DEC 08, 1999
OPTIMARK IN PLASTIC CONTAINER				
+	MALLINCKRODT	330.9MG/ML	N20976 001	DEC 08, 1999

GALANTAMINE HYDROBROMIDE

SOLUTION; ORAL				
REMINYL				
+	JANSSEN	4MG/ML	N21224 001	JUN 22, 2001
TABLET; ORAL				
REMINYL				
	JANSSEN	EQ 4MG BASE	N21169 001	FEB 28, 2001
		EQ 8MG BASE	N21169 002	FEB 28, 2001
+		EQ 12MG BASE	N21169 003	FEB 28, 2001

GALLIUM CITRATE, GA-67

INJECTABLE; INJECTION				
GALLIUM CITRATE GA 67				
BS	BRISTOL MYERS SQUIBB	2mCi/ML	N17478 001	
BS	MALLINCKRODT	2mCi/ML	N18058 001	
NEOSCAN				
BS	AMERSHAM HLTH	2mCi/ML	N17655 001	

GANCICLOVIR

CAPSULE; ORAL				
CYTOVENE				
	SYNTEX (USA) INC LLC	250MG	N20460 001	DEC 22, 1994
+		500MG	N20460 002	DEC 12, 1997

GANCICLOVIR

IMPLANT; IMPLANTATION				
VITRASERT				
+	BAUSCH AND LOMB	4.5MG	N20569 001	MAR 04, 1996

GANCICLOVIR SODIUM

INJECTABLE; INJECTION				
CYTOVENE IV				
+	SYNTEX (USA) INC LLC	EQ 500MG BASE/VIAL	N19661 001	JUN 23, 1989

GANIRELIX ACETATE

INJECTABLE; INJECTION				
ANTAGON				
+	ORGANON INC	EQ 250 UGM BASE/0.5ML	N21057 001	JUL 29, 1999

GATIFLOXACIN

INJECTABLE; INJECTION				
TEQUIN				
+	BRISTOL MYERS SQUIBB	200MG/VIAL	N21062 001	DEC 17, 1999
+		400MG/VIAL	N21062 002	DEC 17, 1999
TABLET; ORAL				
TEQUIN				
	BRISTOL MYERS SQUIBB	200MG	N21061 001	DEC 17, 1999
+		400MG	N21061 002	DEC 17, 1999

GEMCITABINE HYDROCHLORIDE

INJECTABLE; INJECTION				
GEMZAR				
+	LILLY	EQ 200MG BASE/VIAL	N20509 001	MAY 15, 1996
+		EQ 1GM BASE/VIAL	N20509 002	MAY 15, 1996

FDA data supplied by DrugPatentWatch.com

GEMFIBROZIL

TABLET; ORAL

	GEMFIBROZIL			
AB	GENEVA PHARMS TECH	600MG	N74615 001	SEP 29, 1995
AB	LEDERLE	600MG	N74270 001	SEP 27, 1993
AB	MYLAN	600MG	N74452 001	FEB 16, 1995
AB	TEVA	600MG	N74256 001	OCT 31, 1993
AB	TORPHARM	600MG	N75034 001	JUL 20, 1998
AB	WATSON LABS	600MG	N74442 001	APR 28, 1995
	LOPID			
AB	+ PARKE DAVIS PHARMS	600MG	N18422 003	NOV 20, 1986

GEMTUZUMAB OZOGAMICIN

INJECTABLE; INJECTION

	MYLOTARG			
	+ WYETH AYERST	5MG/VIAL	N21174 001	MAY 17, 2000

GENTAMICIN SULFATE

CREAM; TOPICAL

	GARAMYCIN			
AT	+ SCHERING	EQ 0.1% BASE	N60462 001	
	GENTAMICIN			
AT	CLAY PARK	EQ 0.1% BASE	N62307 001	
	GENTAMICIN SULFATE			
AT	FOUGERA	EQ 0.1% BASE	N62531 001	JUL 05, 1984
AT	THAMES	EQ 0.1% BASE	N62427 001	MAY 26, 1983

INJECTABLE; INJECTION

	GARAMYCIN			
AP	+ SCHERING	EQ 1MG BASE/ML	N61716 002	
AP	+	EQ 40MG BASE/ML	N61716 001	
	GENTAMICIN SULFATE			
AP	ABBOTT	EQ 10MG BASE/ML	N62420 001	AUG 15, 1983

GENTAMICIN SULFATE

INJECTABLE; INJECTION

	GENTAMICIN SULFATE			
AP	ABBOTT	EQ 10MG BASE/ML	N62612 004	FEB 20, 1986
AP		EQ 40MG BASE/ML	N62420 002	AUG 15, 1983
AP	AM PHARM PARTNERS	EQ 10MG BASE/ML	N62356 001	MAR 04, 1982
AP		EQ 40MG BASE/ML	N62356 002	MAR 04, 1982
AP		EQ 40MG BASE/ML	N62366 001	AUG 04, 1983
AP	+ ELKINS SINN	EQ 10MG BASE/ML	N62251 002	
AP		EQ 40MG BASE/ML	N62251 001	
AP	KALAPHARM	EQ 40MG BASE/ML	N62354 001	APR 05, 1982
AP	PHARM SPEC	EQ 40MG BASE/ML	N62340 001	MAR 28, 1983

GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	ABBOTT	EQ 60MG BASE/100ML	N62414 006	AUG 15, 1983
AP		EQ 70MG BASE/100ML	N62414 007	AUG 15, 1983
AP		EQ 80MG BASE/100ML	N62414 008	AUG 15, 1983
AP		EQ 90MG BASE/100ML	N62414 009	AUG 15, 1983
AP		EQ 100MG BASE/100ML	N62414 010	AUG 15, 1983
AP		EQ 1.2MG BASE/ML	N62414 001	AUG 15, 1983
AP		EQ 1.4MG BASE/ML	N62414 002	AUG 15, 1983
AP		EQ 1.6MG BASE/ML	N62414 003	AUG 15, 1983
AP		EQ 1.8MG BASE/ML	N62414 004	AUG 15, 1983
AP		EQ 2MG BASE/ML	N62414 005	AUG 15, 1983
AP	B BRAUN	EQ 40MG BASE/100ML	N62814 008	AUG 28, 1987
AP		EQ 60MG BASE/100ML	N62814 009	AUG 28, 1987
AP		EQ 70MG BASE/100ML	N62814 010	AUG 28, 1987

FDA data supplied by DrugPatentWatch.com

GENTAMICIN SULFATE

INJECTABLE; INJECTION

GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	B BRAUN	EQ 0.8MG BASE/ML	N62814 001	AUG 28, 1987
AP		EQ 80MG BASE/100ML	N62814 011	AUG 28, 1987
AP		EQ 90MG BASE/100ML	N62814 012	AUG 28, 1987
AP		EQ 100MG BASE/100ML	N62814 013	AUG 28, 1987
AP		EQ 1.2MG BASE/ML	N62814 002	AUG 28, 1987
AP		EQ 120MG BASE/100ML	N62814 014	AUG 28, 1987
AP		EQ 1.4MG BASE/ML	N62814 003	AUG 28, 1987
AP		EQ 1.6MG BASE/ML	N62814 004	AUG 28, 1987
AP		EQ 1.8MG BASE/ML	N62814 005	AUG 28, 1987
AP		EQ 2MG BASE/ML	N62814 006	AUG 28, 1987
AP		EQ 2.4MG BASE/ML	N62814 007	AUG 28, 1987

ISOTONIC GENTAMICIN SULFATE IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	EQ 40MG BASE/100ML	N62373 003	SEP 07, 1982
AP		EQ 60MG BASE/100ML	N62373 004	SEP 07, 1982
AP		EQ 0.8MG BASE/ML	N62373 001	SEP 07, 1982
AP		EQ 80MG BASE/100ML	N62373 002	SEP 07, 1982
AP		EQ 100MG BASE/100ML	N62373 005	SEP 07, 1982
AP		EQ 120MG BASE/100ML	N62373 006	SEP 07, 1982
AP		EQ 1.2MG BASE/ML	N62373 007	SEP 07, 1982
AP		EQ 1.6MG BASE/ML	N62373 008	SEP 07, 1982
AP		EQ 2MG BASE/ML	N62373 009	SEP 07, 1982
AP		EQ 2.4MG BASE/ML	N62373 010	SEP 07, 1982

GENTAMICIN SULFATE

OINTMENT; OPHTHALMIC

GARAMYCIN

AT	+ SCHERING	EQ 0.3% BASE	N50425 001	

GENTAMICIN SULFATE

AT	AKORN	EQ 0.3% BASE	N64093 001	AUG 31, 1995

OINTMENT; TOPICAL

GENTAMICIN

AT	+ CLAY PARK	EQ 0.1% BASE	N62351 001	FEB 18, 1982

GENTAMICIN SULFATE

AT	FOUGERA	EQ 0.1% BASE	N62533 001	OCT 05, 1984
AT	THAMES	EQ 0.1% BASE	N62477 001	DEC 23, 1983

SOLUTION; OPHTHALMIC

GARAMYCIN

AT	+ SCHERING	EQ 0.3% BASE	N50039 002	

SOLUTION/DROPS; OPHTHALMIC

GENOPTIC

AT	ALLERGAN	EQ 0.3% BASE	N62452 001	OCT 10, 1984

GENTACIDIN

AT	NOVARTIS	EQ 0.3% BASE	N62480 001	MAR 30, 1984

GENTAK

AT	AKORN	EQ 0.3% BASE	N64163 001	OCT 12, 2001

GENTAMICIN SULFATE

AT	AKORN	EQ 0.3% BASE	N62635 001	JAN 08, 1987
AT	BAUSCH AND LOMB	EQ 0.3% BASE	N64048 001	MAY 11, 1994
AT	FALCON PHARMS	EQ 0.3% BASE	N62196 001	

GENTAMICIN SULFATE; PREDNISOLONE ACETATE

OINTMENT; OPHTHALMIC

PRED-G

+	ALLERGAN	EQ 0.3% BASE;0.6%	N50612 001	DEC 01, 1989

FDA data supplied by DrugPatentWatch.com

GENTAMICIN SULFATE; PREDNISOLONE ACETATE

SUSPENSION/DROPS; OPHTHALMIC

	PRED-G			
+	ALLERGAN	EQ 0.3% BASE;1%	N50586 001	JUN 10, 1988

GENTIAN VIOLET

SUPPOSITORY; VAGINAL

	GVS			
+	SAVAGE LABS	0.4%	N83513 001	

GLATIRAMER ACETATE

INJECTABLE; INJECTION

	COPAXONE			
+	TEVA	20MG/VIAL	N20622 001	DEC 20, 1996

GLIMEPIRIDE

TABLET; ORAL

	AMARYL			
	AVENTIS PHARMS	1MG	N20496 001	NOV 30, 1995
		2MG	N20496 002	NOV 30, 1995
+		4MG	N20496 003	NOV 30, 1995

GLIPIZIDE

TABLET; ORAL

	GLIPIZIDE			
AB	ALPHAPHARM	**5MG**	**N74438 001**	JUN 20, 1995
AB		**10MG**	**N74438 002**	JUN 20, 1995
AB	DURAMED	**5MG**	**N74550 001**	SEP 11, 1997
AB		**10MG**	**N74550 002**	SEP 11, 1997
AB	ENDO PHARMS	**5MG**	**N74378 001**	NOV 28, 1994

GLIPIZIDE

TABLET; ORAL

	GLIPIZIDE			
AB	ENDO PHARMS	**10MG**	**N74378 002**	NOV 28, 1994
AB	GENEVA PHARMS	**5MG**	**N74305 001**	APR 07, 1995
AB		**10MG**	**N74305 002**	APR 07, 1995
AB	GENEVA PHARMS TECH	**5MG**	**N74542 001**	JUN 20, 1995
AB		**10MG**	**N74542 002**	JUN 20, 1995
AB	IVAX PHARMS	**5MG**	**N74497 001**	AUG 31, 1995
AB		**10MG**	**N74497 002**	AUG 31, 1995
AB	MYLAN	**5MG**	**N74226 001**	MAY 10, 1994
AB		**10MG**	**N74226 002**	MAY 10, 1994
AB	SIDMAK LABS NJ	**5MG**	**N74619 001**	APR 04, 1997
AB		**10MG**	**N74619 002**	APR 04, 1997
AB	TEVA	**5MG**	**N74387 001**	MAR 04, 1996
AB		**10MG**	**N74387 002**	MAR 04, 1996
AB	TORPHARM	**5MG**	**N75795 001**	JUN 13, 2001
AB		**10MG**	**N75795 002**	JUN 13, 2001
AB	WATSON LAB	**5MG**	**N74370 001**	NOV 22, 1994
AB		**10MG**	**N74370 002**	NOV 22, 1994
AB	WATSON LABS	**5MG**	**N74223 001**	FEB 27, 1995
AB		**10MG**	**N74223 002**	FEB 27, 1995
	GLUCOTROL			
AB	PFIZER	**5MG**	**N17783 001**	MAY 08, 1984
AB	+	**10MG**	**N17783 002**	MAY 08, 1984

FDA data supplied by DrugPatentWatch.com

GLIPIZIDE

TABLET, EXTENDED RELEASE; ORAL
GLUCOTROL XL
+ PFIZER 2.5MG N20329 003 AUG 10, 1999
+ 5MG N20329 001 APR 26, 1994
+ 10MG N20329 002 APR 26, 1994

GLUCAGON HYDROCHLORIDE

INJECTABLE; INJECTION
GLUCAGON
+ LILLY EQ 1MG BASE/VIAL N12122 001

GLUCAGON HYDROCHLORIDE RECOMBINANT

INJECTABLE; INJECTION
GLUCAGEN
+ NOVO NORDISK EQ 1MG BASE/VIAL N20918 001 JUN 22, 1998

GLUCAGON RECOMBINANT

INJECTABLE; INJECTION
GLUCAGON
+ LILLY 1MG/VIAL N20928 001 SEP 11, 1998

GLUCONOLACTONE; *MULTIPLE*
SEE CITRIC ACID; GLUCONOLACTONE; MAGNESIUM CARBONATE

GLUTATHIONE DISULFIDE; *MULTIPLE*
SEE CALCIUM CHLORIDE; DEXTROSE; GLUTATHIONE DISULFIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

GLYBURIDE

TABLET; ORAL
DIABETA
BX AVENTIS PHARMS 1.25MG N17532 001 MAY 01, 1984
BX 2.5MG N17532 002 MAY 01, 1984
BX 5MG N17532 003 MAY 01, 1984

GLYBURIDE
AB TEVA **1.25MG** **N74388 001** AUG 29, 1995
AB **2.5MG** **N74388 002** AUG 29, 1995
AB **5MG** **N74388 003** AUG 29, 1995

GLYBURIDE (MICRONIZED)
AB AVENTIS PHARMS **1.5MG** **N20055 001** APR 17, 1992
AB **3MG** **N20055 002** APR 17, 1992
AB **6MG** **N20055 003** MAR 08, 2000
AB GENEVA PHARMS TECH **1.5MG** **N75174 001** JUN 22, 1998
AB **3MG** **N75174 002** JUN 22, 1998
AB MOVA **1.5MG** **N74591 001** DEC 22, 1997
AB **3MG** **N74591 002** DEC 22, 1997
AB **4.5MG** **N74591 003** DEC 22, 1997
AB **6MG** **N74591 004** DEC 22, 1997
AB MYLAN **1.5MG** **N74792 001** JUN 26, 1998
AB **3MG** **N74792 002** JUN 26, 1998
AB **6MG** **N74792 003** AUG 17, 1999
AB TEVA **1.5MG** **N74686 001** APR 20, 1999
AB **3MG** **N74686 002** APR 20, 1999
AB **4.5MG** **N74686 003** APR 20, 1999

FDA data supplied by DrugPatentWatch.com

GLYBURIDE

TABLET; ORAL

	GLYBURIDE (MICRONIZED)				
AB	TEVA	**6MG**	**N74686 004** APR 20, 1999		
	GLYNASE				
AB	PHARMACIA AND UPJOHN	**1.5MG**	**N20051 001** MAR 04, 1992		
AB		**3MG**	**N20051 002** MAR 04, 1992		
AB +		**6MG**	**N20051 004** SEP 24, 1993		
	MICRONASE				
AB	PHARMACIA AND UPJOHN	**1.25MG**	**N17498 001** MAY 01, 1984		
AB		**2.5MG**	**N17498 002** MAY 01, 1984		
AB +		**5MG**	**N17498 003** MAY 01, 1984		

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLUCOVANCE			
	BRISTOL MYERS SQUIBB	1.25MG;250MG	N21178 001 JUL 31, 2000
		2.5MG;500MG	N21178 002 JUL 31, 2000
+		5MG;500MG	N21178 003 JUL 31, 2000

GLYCERIN; *MULTIPLE*

SEE AMINO ACIDS; CALCIUM ACETATE; GLYCERIN; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

GLYCINE

SOLUTION; IRRIGATION

	AMINOACETIC ACID 1.5% IN PLASTIC CONTAINER		
AT	BAXTER HLTHCARE	**1.5GM/100ML**	**N17865 001**
	GLYCINE 1.5% IN PLASTIC CONTAINER		
AT	ABBOTT	**1.5GM/100ML**	**N17633 001**
AT		**1.5GM/100ML**	**N18315 001**
AT	B BRAUN	**1.5GM/100ML**	**N16784 001**

GLYCOPYRROLATE

INJECTABLE; INJECTION

	GLYCOPYRROLATE		
AP	LUITPOLD	**0.2MG/ML**	**N89335 001** JUL 23, 1986
	ROBINUL		
AP +	ROBINS AH	**0.2MG/ML**	**N17558 001**

TABLET; ORAL

	ROBINUL		
+	FIRST HORIZON	1MG	N12827 001
	ROBINUL FORTE		
+	FIRST HORIZON	2MG	N12827 002

GONADORELIN ACETATE

INJECTABLE; INJECTION

	LUTREPULSE KIT		
+	FERRING	0.8MG/VIAL	N19687 001 OCT 10, 1989
+		3.2MG/VIAL	N19687 002 OCT 10, 1989

GONADORELIN HYDROCHLORIDE

INJECTABLE; INJECTION

	FACTREL		
+	WYETH AYERST	EQ 0.1MG BASE/VIAL	N18123 001 SEP 30, 1982
+		EQ 0.5MG BASE/VIAL	N18123 003 SEP 30, 1982

GONADOTROPIN, CHORIONIC

INJECTABLE; INJECTION

	A.P.L.			
AP +	WYETH AYERST	**5,000 UNITS/VIAL**	**N17055 001**
AP +		**10,000 UNITS/VIAL**	**N17055 002**
+		20,000 UNITS/VIAL	N17055 003
	CHORIONIC GONADOTROPIN		
AP +	AM PHARM PARTNERS	**10,000 UNITS/VIAL**	**N17067 002**
AP +	STERIS	**5,000 UNITS/VIAL**	**N17016 006**
AP +		**10,000 UNITS/VIAL**	**N17016 007**
+		2,000 UNITS/VIAL	N17016 011 FEB 16, 1990

FDA data supplied by DrugPatentWatch.com

GONADOTROPIN, CHORIONIC

INJECTABLE; INJECTION

	PREGNYL			
AP	+ ORGANON	**10,000 UNITS/VIAL**	**N17692 001**	

GOSERELIN ACETATE

IMPLANT; IMPLANTATION

	ZOLADEX			
	+ ASTRAZENECA	EQ 3.6MG BASE	N19726 001	DEC 29, 1989
	+	EQ 10.8MG BASE	N20578 001	JAN 11, 1996

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OPHTHALMIC

	NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN			
AT	BAUSCH AND LOMB	**0.025MG/ML;EQ 1.75MG BASE/ML; 10,000 UNITS/ML**	**N64047 001**	JAN 31, 1996
	NEOSPORIN			
AT	+ MONARCH PHARMS	**0.025MG/ML;EQ 1.75MG BASE/ML; 10,000 UNITS/ML**	**N60582 001**	

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION

	KYTRIL			
	+ ROCHE	EQ 1MG BASE/ML	N20239 002	MAR 11, 1994

SOLUTION; ORAL

	KYTRIL			
	+ ROCHE	EQ 2MG BASE/10ML	N21238 001	JUN 27, 2001

TABLET; ORAL

	KYTRIL			
	+ ROCHE	EQ 1MG BASE	N20305 001	MAR 16, 1995

GREPAFLOXACIN HYDROCHLORIDE

TABLET; ORAL

	RAXAR			
	OTSUKA	EQ 200MG BASE	N20695 001	NOV 06, 1997
		EQ 400MG BASE	N20695 002	MAY 14, 1998
	+	EQ 600MG BASE	N20695 003	MAY 14, 1998

GRISEOFULVIN, MICROCRYSTALLINE

CAPSULE; ORAL

	GRISACTIN		
	+ WYETH AYERST	250MG	N50051 001

SUSPENSION; ORAL

	GRIFULVIN V			
	+ J AND J	125MG/5ML	N62483 001	JAN 26, 1984

TABLET; ORAL

	FULVICIN-U/F		
AB	SCHERING	**250MG**	**N60569 002**
AB	+	**500MG**	**N60569 001**
	GRIFULVIN V		
AB	J AND J	**250MG**	**N62279 002**
AB		**500MG**	**N62279 003**
		125MG	N62279 001
	GRISACTIN		
AB	WYETH AYERST	**500MG**	**N60212 001**

GRISEOFULVIN, ULTRAMICROCRYSTALLINE

TABLET; ORAL

	FULVICIN P/G			
AB	SCHERING	**125MG**	**N61996 001**	
AB	+	**250MG**	**N61996 002**	
	FULVICIN P/G 165			
AB	SCHERING	**165MG**	**N61996 003**	APR 06, 1982
	FULVICIN P/G 330			
AB	+ SCHERING	**330MG**	**N61996 004**	APR 06, 1982
	GRIS-PEG			
AB	PEDINOL	**125MG**	**N50475 001**	

FDA data supplied by DrugPatentWatch.com

GRISEOFULVIN, ULTRAMICROCRYSTALLINE

TABLET; ORAL				
GRIS-PEG				
AB	PEDINOL	250MG	N50475 002	
GRISACTIN ULTRA				
AB	WYETH AYERST	165MG	N62438 001	NOV 17, 1983
AB		330MG	N62438 002	NOV 17, 1983

GUANABENZ ACETATE

TABLET; ORAL				
GUANABENZ ACETATE				
AB	COPLEY PHARM	EQ 4MG BASE	N74267 001	JUN 01, 1994
AB		EQ 8MG BASE	N74267 002	JUN 01, 1994
AB	EON	EQ 4MG BASE	N74517 001	SEP 30, 1998
AB		EQ 8MG BASE	N74517 002	SEP 30, 1998
AB	IVAX PHARMS	EQ 4MG BASE	N74149 001	APR 07, 1995
AB		EQ 8MG BASE	N74149 002	APR 07, 1995
AB	WATSON LABS	EQ 4MG BASE	N74025 001	FEB 28, 1994
AB		EQ 8MG BASE	N74025 002	FEB 28, 1994
WYTENSIN				
AB	WYETH AYERST	EQ 4MG BASE	N18587 001	SEP 07, 1982
AB +		EQ 8MG BASE	N18587 002	SEP 07, 1982

GUANADREL SULFATE

TABLET; ORAL				
HYLOREL				
	PHARMACIA AND UPJOHN	10MG	N18104 001	DEC 29, 1982
+		25MG	N18104 002	DEC 29, 1982

GUANETHIDINE MONOSULFATE

TABLET; ORAL				
ISMELIN				
	NOVARTIS	EQ 10MG SULFATE	N12329 001	
+		EQ 25MG SULFATE	N12329 002	

GUANFACINE HYDROCHLORIDE

TABLET; ORAL				
GUANFACINE HCL				
AB	AMIDE PHARM	EQ 1MG BASE	N74673 001	FEB 28, 1997
AB		EQ 2MG BASE	N74673 002	FEB 28, 1997
AB	GENPHARM	EQ 1MG BASE	N75109 001	NOV 25, 1998
AB		EQ 2MG BASE	N75109 002	NOV 25, 1998
AB	MYLAN	EQ 1MG BASE	N74796 001	JAN 27, 1997
AB		EQ 2MG BASE	N74796 002	JAN 27, 1997
AB	WATSON LABS	EQ 1MG BASE	N74145 001	OCT 17, 1995
AB		EQ 1MG BASE	N74762 001	JUN 25, 1997
AB		EQ 2MG BASE	N74145 002	OCT 17, 1995
AB		EQ 2MG BASE	N74762 002	JUN 25, 1997
TENEX				
AB	WYETH AYERST	EQ 1MG BASE	N19032 001	OCT 27, 1986
AB +		EQ 2MG BASE	N19032 002	NOV 07, 1988

GUANIDINE HYDROCHLORIDE

TABLET; ORAL				
GUANIDINE HCL				
	SCHERING	125MG	N01546 001	

FDA data supplied by DrugPatentWatch.com

HALAZEPAM

TABLET; ORAL

PAXIPAM					
SCHERING	20MG	N17736 003	AB		
+	40MG	N17736 004	AB		

HALCINONIDE

CREAM; TOPICAL

HALOG					
+ WESTWOOD SQUIBB	0.1%	N17556 001	AB		
HALOG-E					
WESTWOOD SQUIBB	0.1%	N18234 001	AB		

OINTMENT; TOPICAL

HALOG					
+ WESTWOOD SQUIBB	0.1%	N17824 001	AB		

SOLUTION; TOPICAL

HALOG					
WESTWOOD SQUIBB	0.1%	N17823 001	AB		

HALOBETASOL PROPIONATE

CREAM; TOPICAL

ULTRAVATE					
+ WESTWOOD SQUIBB	0.05%	N19967 001 DEC 27, 1990	AB		

OINTMENT; TOPICAL

ULTRAVATE					
+ WESTWOOD SQUIBB	0.05%	N19968 001 DEC 17, 1990	AB		

HALOPERIDOL

TABLET; ORAL

HALDOL						
AB ORTHO MCNEIL	**0.5MG**	**N15921 001**	**AB**	DANBURY PHARMA	**0.5MG**	**N70981 001** MAR 06, 1987
AB	**1MG**	**N15921 002**	**AB**		**2MG**	**N70983 001** MAR 06, 1987
AB	**2MG**	**N15921 003**	**AB**		**5MG**	**N70984 001** MAR 06, 1987
AB +	**5MG**	**N15921 004**	**AB**	GENEVA PHARMS	**0.5MG**	**N71206 001** NOV 17, 1986
AB	**10MG**	**N15921 005**	**AB**		**1MG**	**N71207 001** NOV 17, 1986
AB +	**20MG**	**N15921 006** FEB 02, 1982	**AB**		**2MG**	**N71208 001** NOV 17, 1986
			AB		**5MG**	**N71209 001** NOV 17, 1986
			AB		**10MG**	**N71210 001** MAR 11, 1988
			AB		**20MG**	**N71211 001** MAR 11, 1988
			AB	MYLAN	**0.5MG**	**N70276 001** JUN 10, 1986
			AB		**1MG**	**N70277 001** JUN 10, 1986
			AB		**2MG**	**N70278 001** JUN 10, 1986
			AB		**5MG**	**N70279 001** JUN 10, 1986
			AB	PAR PHARM	**0.5MG**	**N71233 001** NOV 03, 1986
			AB		**1MG**	**N71234 001** NOV 03, 1986
			AB		**2MG**	**N71235 001** NOV 03, 1986
			AB		**5MG**	**N71236 001** NOV 03, 1986
			AB		**10MG**	**N71237 001** JUL 20, 1987

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION

HALDOL				
AO + ORTHO MCNEIL	**EQ 50MG BASE/ML**	**N18701 001** JAN 14, 1986		

FDA data supplied by DrugPatentWatch.com

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION

	HALDOL			
AO	+ ORTHO MCNEIL	EQ 100MG BASE/ML	N18701 002	JAN 31, 1997
	HALOPERIDOL DECANOATE			
AO	AM PHARM PARTNERS	EQ 50MG BASE/ML	N74893 001	DEC 19, 1997
AO		EQ 100MG BASE/ML	N74893 002	DEC 19, 1997
AO	APOTEX	EQ 50MG BASE/ML	N75440 001	FEB 28, 2000
AO		EQ 100MG BASE/ML	N75440 002	FEB 28, 2000
AO	BEDFORD	EQ 50MG BASE/ML	N74811 001	JAN 30, 1998
AO		EQ 100MG BASE/ML	N75305 001	SEP 28, 1998
AO	GENSIA SICOR PHARMS	EQ 50MG BASE/ML	N75393 001	MAY 11, 1999
AO		EQ 100MG BASE/ML	N75393 002	MAY 11, 1999
AO	KING PHARMS	EQ 50MG BASE/ML	N75176 001	FEB 09, 2000
AO		EQ 100MG BASE/ML	N75176 002	FEB 09, 2000

HALOPERIDOL LACTATE

CONCENTRATE; ORAL

	HALDOL			
AA	+ ORTHO MCNEIL	EQ 2MG BASE/ML	N15922 001	
	HALOPERIDOL			
AA	ALPHARMA	EQ 2MG BASE/ML	N70318 001	APR 11, 1986
AA	COPLEY PHARM	EQ 2MG BASE/ML	N71617 001	DEC 01, 1988
AA	PHARM ASSOC	EQ 2MG BASE/ML	N73037 001	FEB 26, 1993
AA	SILARX	EQ 2MG BASE/ML	N73364 001	SEP 28, 1993
AA	TEVA	EQ 2MG BASE/ML	N71015 001	AUG 25, 1987

INJECTABLE; INJECTION

	HALDOL			
AP	+ ORTHO MCNEIL	EQ 5MG BASE/ML	N15923 001	

HALOPERIDOL LACTATE

INJECTABLE; INJECTION

	HALOPERIDOL			
AP	AM PHARM PARTNERS	EQ 5MG BASE/ML	N75689 001	MAR 09, 2001
AP	BEDFORD	EQ 5MG BASE/ML	N75858 001	JUN 18, 2001
AP	GENSIA SICOR PHARMS	EQ 5MG BASE/ML	N76035 001	AUG 29, 2001
AP	STERIS	EQ 5MG BASE/ML	N70714 001	MAY 17, 1988

SOLUTION; ORAL

	HALOPERIDOL LACTATE			
	UDL	EQ 1MG BASE/ML	N74536 001	NOV 02, 1995

HALOTHANE

LIQUID; INHALATION

	FLUOTHANE			
AN	+ WYETH AYERST	99.99%	N11338 001	
	HALOTHANE			
AN	ABBOTT	99.99%	N83254 001	
AN	HALOCARBON	99.99%	N80810 001	

HEPARIN SODIUM

INJECTABLE; INJECTION

	HEP-LOCK			
AP	ELKINS SINN	10 UNITS/ML	N17037 007	
AP		100 UNITS/ML	N17037 006	
	HEP-LOCK U/P			
AP	ELKINS SINN	10 UNITS/ML	N17037 010	JUN 10, 1983
AP		100 UNITS/ML	N17037 011	JUN 10, 1983
	HEPARIN LOCK FLUSH			
AP	ABBOTT	10 UNITS/ML	N05264 001	
AP		10 UNITS/ML	N40082 001	FEB 28, 1995
AP		10 UNITS/ML	N88097 001	APR 28, 1983
AP		10 UNITS/ML	N88346 001	MAY 18, 1983

FDA data supplied by DrugPatentWatch.com

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN LOCK FLUSH

AP		ABBOTT	100 UNITS/ML	N40082 002
				FEB 28, 1995
AP			100 UNITS/ML	N88098 001
				APR 28, 1983
AP			100 UNITS/ML	N88347 001
				MAY 18, 1983
AP		AM PHARM PARTNERS	10 UNITS/ML	N17029 007
				MAY 06, 1982
AP			100 UNITS/ML	N17029 006
AP	+	WYETH AYERST	10 UNITS/ML	N17007 008
AP	+		100 UNITS/ML	N17007 009

HEPARIN LOCK FLUSH IN PLASTIC CONTAINER

AP		ABBOTT	10 UNITS/ML	N05264 015
				MAY 21, 1985
AP			100 UNITS/ML	N05264 016
				MAY 21, 1985

HEPARIN SODIUM

AP		ABBOTT	2,500 UNITS/ML	N88099 001
				APR 28, 1983
AP			5,000 UNITS/ML	N88100 001
				APR 28, 1983
AP		AM PHARM PARTNERS	1,000 UNITS/ML	N17029 001
AP			1,000 UNITS/ML	N17979 001
AP			5,000 UNITS/ML	N17651 006
AP			10,000 UNITS/ML	N17029 003
AP			10,000 UNITS/ML	N17979 002
AP			20,000 UNITS/ML	N17029 004
AP		ELKINS SINN	1,000 UNITS/ML	N17037 001
AP			5,000 UNITS/ML	N17037 002
AP			10,000 UNITS/ML	N17037 003
AP			5,000 UNITS/0.5ML	N17037 013
				APR 07, 1986
AP		LILLY	10,000 UNITS/ML	N05521 002
AP		MARSAM PHARMS LLC	1,000 UNITS/ML	N40007 001
				JUN 07, 1996
AP			1,000 UNITS/ML	N40008 001
				OCT 10, 1995
AP	+	PHARMACIA AND UPJOHN	1,000 UNITS/ML	N04570 001
AP	+		5,000 UNITS/ML	N04570 002
AP	+		10,000 UNITS/ML	N04570 003
AP		WYETH AYERST	1,000 UNITS/ML	N17007 001
AP	+		2,500 UNITS/ML	N17007 007
AP			5,000 UNITS/ML	N17007 002
AP			10,000 UNITS/ML	N17007 004
AP			5,000 UNITS/0.5ML	N17007 010

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM

AP	+	WYETH AYERST	20,000 UNITS/ML	N17007 006
	+		7,500 UNITS/ML	N17007 003

HEPARIN SODIUM 1,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	200 UNITS/100ML	N18609 001
				APR 28, 1982

HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP		ABBOTT	200 UNITS/100ML	N18916 010
				JUN 23, 1989
AP		B BRAUN	200 UNITS/100ML	N19953 001
				JUL 20, 1992

HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER

AP		ABBOTT	10,000 UNITS/100ML	N19339 003
				MAR 27, 1985

HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER

	ABBOTT	5,000 UNITS/100ML	N19339 001
			MAR 27, 1985

HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

	ABBOTT	5,000 UNITS/100ML	N18916 006
			JAN 31, 1984

HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	200 UNITS/100ML	N18609 002
				APR 28, 1982

HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP		ABBOTT	200 UNITS/100ML	N18916 011
				JUN 23, 1989

HEPARIN SODIUM 20,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	4,000 UNITS/100ML	N18814 001
				OCT 31, 1983

HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER

AP		ABBOTT	4,000 UNITS/100ML	N19805 001
				JAN 25, 1989
AP		B BRAUN	4,000 UNITS/100ML	N19952 001
				JUL 20, 1992

HEPARIN SODIUM 25,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	5,000 UNITS/100ML	N18814 003
				JUL 09, 1985

FDA data supplied by DrugPatentWatch.com

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM 25,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	10,000 UNITS/100ML	N18814 004 JUL 02, 1987	

HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	ABBOTT	5,000 UNITS/100ML	N19339 004 MAR 27, 1985	
AP		5,000 UNITS/100ML	N19805 002 JAN 25, 1989	
AP		10,000 UNITS/100ML	N19339 002 MAR 27, 1985	
AP	B BRAUN	5,000 UNITS/100ML	N19952 004 JUL 20, 1992	
AP		10,000 UNITS/100ML	N19952 005 JUL 20, 1992	

HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

ABBOTT	5,000 UNITS/100ML	N18916 007 JAN 31, 1984	
	10,000 UNITS/100ML	N18916 008 JAN 31, 1984	

HEPARIN SODIUM IN PLASTIC CONTAINER

AP	AM PHARM PARTNERS	1,000 UNITS/ML	N17029 013 DEC 05, 1985	
AP		5,000 UNITS/ML	N17029 014 DEC 05, 1985	
AP		10,000 UNITS/ML	N17029 015 DEC 05, 1985	
AP		20,000 UNITS/ML	N17029 016 DEC 05, 1985	

HEPARIN SODIUM PRESERVATIVE FREE

AP	+ ABBOTT	2,500 UNITS/ML	N05264 014 APR 07, 1986	
AP	+	10,000 UNITS/ML	N89522 001 MAY 04, 1987	
	+	2,000 UNITS/ML	N05264 013 APR 07, 1986	
AP	+ AM PHARM PARTNERS	1,000 UNITS/ML	N17029 010 APR 28, 1986	
AP	MARSAM PHARMS LLC	1,000 UNITS/ML	N89464 001 JUN 03, 1986	

HEPFLUSH-10

AP	AM PHARM PARTNERS	10 UNITS/ML	N17651 009 JUN 26, 1984	

SODIUM HEPARIN

AP	BAXTER HLTHCARE	1,000 UNITS/ML	N17036 001	

HEXACHLOROPHENE

EMULSION; TOPICAL

PHISOHEX

	+ SANOFI SYNTHELABO	3%	N06882 001	

SOAP; TOPICAL

GAMOPHEN

	+ ARBROOK	2%	N06270 003	

SPONGE; TOPICAL

E-Z SCRUB

	+ BECTON DICKINSON	450MG	N17452 001	

PRE-OP

AT	+ DAVIS AND GECK	480MG	N17433 001	

PRE-OP II

AT	DAVIS AND GECK	480MG	N17433 002	

HISTRELIN ACETATE

INJECTABLE; INJECTION

SUPPRELIN

	+ SHIRE LABS	EQ 0.2MG BASE/ML	N19836 001 DEC 24, 1991	
	+	EQ 0.5MG BASE/ML	N19836 002 DEC 24, 1991	
	+	EQ 1MG BASE/ML	N19836 003 DEC 24, 1991	

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP; ORAL

HYCODAN

AA	+ ENDO PHARMS	1.5MG/5ML;5MG/5ML	N05213 002 JUL 26, 1988	

HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE

AA	HALSEY	1.5MG/5ML;5MG/5ML	N40285 001 JUL 19, 1999	

HYDROCODONE COMPOUND

AA	ALPHARMA	1.5MG/5ML;5MG/5ML	N88017 001 JUL 05, 1983	

MYCODONE

AA	MORTON GROVE	1.5MG/5ML;5MG/5ML	N88008 001 MAR 03, 1983	

TABLET; ORAL

HOMATROPRINE METHYLBROMIDE AND HYDROCODONE BITARTRATE

AA	AMIDE PHARM	1.5MG;5MG	N40295 001 DEC 01, 2000	

FDA data supplied by DrugPatentWatch.com

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

TABLET; ORAL

		HYCODAN			
AA	+	ENDO PHARMS	1.5MG;5MG	N05213 001	JUL 26, 1988
		TUSSIGON			
AA		JONES PHARMA	1.5MG;5MG	N88508 001	JUL 30, 1985

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

		HYDRALAZINE HCL			
AP		AM PHARM PARTNERS	20MG/ML	N40388 001	MAR 13, 2001
AP		GENSIA SICOR PHARMS	20MG/ML	N40373 001	FEB 23, 2000
AP	+	LUITPOLD	20MG/ML	N40136 001	JUN 30, 1997

TABLET; ORAL

		APRESOLINE			
AA	+	NOVARTIS	10MG	N08303 004	
AA	+		25MG	N08303 001	
AA	+		50MG	N08303 002	
AA	+		100MG	N08303 005	
		HYDRALAZINE HCL			
AA		ABC HOLDING	10MG	N88846 001	FEB 26, 1985
AA			25MG	N88847 001	FEB 26, 1985
AA			50MG	N88848 001	FEB 26, 1985
AA			100MG	N88849 001	FEB 26, 1985
AA		DANBURY PHARMA	25MG	N84504 001	
AA			50MG	N84503 001	
AA		GENEVA PHARMS	10MG	N83241 001	
AA			25MG	N83560 001	
AA			50MG	N83561 001	
AA		IMPAX LABS	50MG	N84923 001	
AA		LEDERLE	25MG	N86243 001	
AA			50MG	N86242 002	
AA		MUTUAL PHARM	10MG	N89359 001	JUL 25, 1986
AA			25MG	N89258 001	MAY 05, 1986

HYDRALAZINE HYDROCHLORIDE

TABLET; ORAL

		HYDRALAZINE HCL			
AA		MUTUAL PHARM	50MG	N89259 001	MAY 05, 1986
AA		PAR PHARM	10MG	N87836 001	OCT 05, 1982
AA			25MG	N86961 002	
AA			50MG	N86962 001	
AA			100MG	N88391 001	SEP 27, 1983
AA		SIDMAK LABS NJ	10MG	N89097 001	DEC 18, 1985
AA			25MG	N88467 001	MAY 01, 1984
AA			50MG	N88468 001	MAY 01, 1984
AA			100MG	N89098 001	DEC 18, 1985

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

		APRESAZIDE			
AB		NOVARTIS	25MG;25MG	N84735 001	
AB			50MG;50MG	N84810 001	
		HYDRA-ZIDE			
AB		PAR PHARM	25MG;25MG	N88957 001	OCT 21, 1985
AB			50MG;50MG	N88946 001	OCT 21, 1985
	+		100MG;50MG	N88961 001	OCT 21, 1985
		HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE			
AB		SUPERPHARM	50MG;50MG	N89201 001	FEB 09, 1987

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

		HYDROCHLOROTHIAZIDE			
AB		MYLAN	12.5MG	N75640 001	JAN 28, 2000
		MICROZIDE			
AB	+	WATSON LABS	12.5MG	N20504 001	DEC 27, 1996

FDA data supplied by DrugPatentWatch.com

HYDROCHLOROTHIAZIDE

SOLUTION; ORAL
HYDROCHLOROTHIAZIDE
+ ROXANE 50MG/5ML N88587 001 JUL 02, 1984

TABLET; ORAL
ESIDRIX
AB NOVARTIS **25MG** **N11793 005**
AB **50MG** **N11793 008**
AB **100MG** **N11793 009**
HYDROCHLOROTHIAZIDE
AB ABC HOLDING **25MG** **N85683 001**
AB **50MG** **N83965 001**
AB **50MG** **N85672 001**
AB DANBURY PHARMA **25MG** **N81189 001** JAN 24, 1992
AB **100MG** **N81190 001** JAN 24, 1992
AB EON **50MG** **N85219 001**
AB GENEVA PHARMS **25MG** **N87565 001** MAR 09, 1982
AB **50MG** **N84912 001**
AB IVAX PHARMS **25MG** **N83177 001**
AB **50MG** **N83177 002**
AB **100MG** **N85022 001**
AB LEDERLE **25MG** **N87059 001**
AB **50MG** **N87068 001**
AB **100MG** **N87060 001**
AB PUREPAC PHARM **25MG** **N85054 002**
AB **50MG** **N85208 001**
AB PVT FORM **25MG** **N85181 001**
AB **50MG** **N85182 001**
AB ROXANE **50MG** **N84536 002**
HYDRODIURIL
AB MERCK **25MG** **N11835 003**
AB + **50MG** **N11835 006**
AB **100MG** **N11835 007**
ORETIC
AB ABBOTT **25MG** **N11971 001**
AB **50MG** **N11971 002**

HYDROCHLOROTHIAZIDE; *MULTIPLE*
SEE AMILORIDE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE
SEE BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE
SEE BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE
SEE CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE
SEE CAPTOPRIL; HYDROCHLOROTHIAZIDE
SEE ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

HYDROCHLOROTHIAZIDE; *MULTIPLE*
SEE EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE
SEE FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE
SEE HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL
AVALIDE
SANOFI SYNTHELABO 12.5MG;150MG N20758 002 SEP 30, 1997
+ 12.5MG;300MG N20758 003 AUG 31, 1998

HYDROCHLOROTHIAZIDE; LISINOPRIL

TABLET; ORAL
PRINZIDE
AB MERCK **12.5MG;10MG** **N19778 003** NOV 18, 1993
AB **12.5MG;20MG** **N19778 001** FEB 16, 1989
AB + **25MG;20MG** **N19778 002** FEB 16, 1989
ZESTORETIC
AB ASTRAZENECA **12.5MG;10MG** **N19888 003** NOV 18, 1993
AB **12.5MG;20MG** **N19888 001** SEP 20, 1990
AB **25MG;20MG** **N19888 002** JUL 20, 1989

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL
HYZAAR
MERCK 12.5MG;50MG N20387 001 APR 28, 1995
+ 25MG;100MG N20387 002 NOV 10, 1998

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL
ALDORIL 15
AB MERCK **15MG;250MG** **N13402 001**

FDA data supplied by DrugPatentWatch.com

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

	ALDORIL 25			
AB	MERCK	25MG;250MG	N13402 002	
	ALDORIL D30			
AB	MERCK	30MG;500MG	N13402 003	
	ALDORIL D50			
AB	+ MERCK	50MG;500MG	N13402 004	
	METHYLDOPA AND HYDROCHLOROTHIAZIDE			
AB	DANBURY PHARMA	15MG;250MG	N70958 001 FEB 06, 1989	
AB		25MG;250MG	N70959 001 JAN 19, 1989	
AB		30MG;500MG	N71069 001 JAN 19, 1989	
AB		50MG;500MG	N70960 001 FEB 06, 1989	
AB	GENEVA PHARMS	15MG;250MG	N70182 001 JAN 15, 1986	
AB		25MG;250MG	N70183 001 JAN 15, 1986	
AB		30MG;500MG	N70543 001 JAN 15, 1986	
AB		50MG;500MG	N70544 001 JAN 15, 1986	
AB	LEDERLE	15MG;250MG	N72507 001 JUN 02, 1989	
AB		25MG;250MG	N72508 001 JUN 02, 1989	
AB		30MG;500MG	N72509 001 JUN 02, 1989	
AB		50MG;500MG	N72510 001 JUN 02, 1989	
AB	MYLAN	15MG;250MG	N70264 001 JAN 23, 1986	
AB		25MG;250MG	N70265 001 JAN 23, 1986	
AB	PAR PHARM	15MG;250MG	N70616 001 FEB 02, 1987	
AB		25MG;250MG	N70612 001 FEB 02, 1987	
AB		30MG;500MG	N70613 001 FEB 02, 1987	
AB		50MG;500MG	N70614 001 FEB 02, 1987	

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET; ORAL

	LOPRESSOR HCT			
	NOVARTIS	25MG;50MG	N18303 001 DEC 31, 1984	
		25MG;100MG	N18303 002 DEC 31, 1984	
	+	50MG;100MG	N18303 003 DEC 31, 1984	

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL

UNIRETIC			
SCHWARZ PHARMA	12.5MG;7.5MG	N20729 001 JUN 27, 1997	
+	25MG;15MG	N20729 002 JUN 27, 1997	

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

INDERIDE LA 120/50			
+ WYETH AYERST	50MG;120MG	N19059 002 JUL 03, 1985	
INDERIDE LA 160/50			
+ WYETH AYERST	50MG;160MG	N19059 003 JUL 03, 1985	
INDERIDE LA 80/50			
+ WYETH AYERST	50MG;80MG	N19059 001 JUL 03, 1985	

TABLET; ORAL

	INDERIDE-40/25			
AB	WYETH AYERST	25MG;40MG	N18031 001	
	INDERIDE-80/25			
AB	+ WYETH AYERST	25MG;80MG	N18031 002	
	PROPRANOLOL HCL AND HYDROCHLOROTHIAZIDE			
AB	BARR	25MG;40MG	N70704 001 OCT 01, 1986	
AB		25MG;80MG	N70705 001 OCT 01, 1986	
AB	GENEVA PHARMS	25MG;40MG	N71060 001 AUG 26, 1987	
AB		25MG;80MG	N71061 001 AUG 26, 1987	

FDA data supplied by DrugPatentWatch.com

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

PROPRANOLOL HCL AND HYDROCHLOROTHIAZIDE

AB	MYLAN	**25MG;40MG**	**N70946 001**	MAR 04, 1987
AB		**25MG;80MG**	**N70947 001**	APR 01, 1987
AB	PUREPAC PHARM	**25MG;40MG**	**N70851 001**	MAY 15, 1986
AB		**25MG;80MG**	**N70852 001**	MAY 15, 1986
AB	SIDMAK LABS NJ	**25MG;40MG**	**N72042 001**	MAR 14, 1988
AB		**25MG;80MG**	**N72043 001**	MAR 14, 1988
AB	WATSON LABS	**25MG;40MG**	**N70301 001**	APR 18, 1986
AB		**25MG;80MG**	**N70305 001**	APR 18, 1986

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

ACCURETIC

	PARKE DAVIS	12.5MG;EQ 10MG BASE	N20125 001	DEC 28, 1999
		12.5MG;EQ 20MG BASE	N20125 002	DEC 28, 1999
+		25MG;EQ 20MG BASE	N20125 003	DEC 28, 1999

HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

HYDROPRES 25

BP	MERCK	25MG;0.125MG	N11958 002	

HYDROPRES 50

BP	+ MERCK	50MG;0.125MG	N11958 003	

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET; ORAL

ALDACTAZIDE

AB	GD SEARLE LLC	**25MG;25MG**	**N12616 004**	DEC 30, 1982

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET; ORAL

ALDACTAZIDE

+	GD SEARLE LLC	50MG;50MG	N12616 005	DEC 30, 1982

SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE

AB	GENEVA PHARMS	**25MG;25MG**	**N86881 001**	
AB	HALSEY	**25MG;25MG**	**N87267 001**	
AB	MUTUAL PHARM	**25MG;25MG**	**N89534 001**	JUL 02, 1987
AB	MYLAN	**25MG;25MG**	**N86513 001**	

SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE

AB	PARKE DAVIS	**25MG;25MG**	**N87948 001**	FEB 22, 1983

SPIRONOLACTONE/HYDROCHLOROTHIAZIDE

AB	DANBURY PHARMA	**25MG;25MG**	**N87398 001**	

HYDROCHLOROTHIAZIDE; TELMISARTAN

TABLET; ORAL

MICARDIS HCT

	BOEHRINGER INGELHEIM	12.5MG;40MG	N21162 001	NOV 17, 2000
+		12.5MG;80MG	N21162 002	NOV 17, 2000

HYDROCHLOROTHIAZIDE; TIMOLOL MALEATE

TABLET; ORAL

TIMOLIDE 10-25

+	MERCK	25MG;10MG	N18061 001	

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL

DYAZIDE

AB	+ GLAXOSMITHKLINE	**25MG;37.5MG**	**N16042 003**	MAR 03, 1994

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

AB	BARR	**25MG;37.5MG**	**N74970 001**	JAN 06, 1998
AB	DURAMED	**25MG;37.5MG**	**N75052 001**	JUN 18, 1999
AB	GENEVA PHARMS	**25MG;37.5MG**	**N74821 001**	JUN 05, 1997

FDA data supplied by DrugPatentWatch.com

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

AB	+ GENEVA PHARMS	25MG;50MG	N73191 001	JUL 31, 1991
AB	IVAX PHARMS	25MG;50MG	N74259 001	MAR 30, 1995
AB	MYLAN	25MG;37.5MG	N74701 001	JUN 07, 1996

TABLET; ORAL

MAXZIDE

AB	+ MYLAN	50MG;75MG	N19129 001	OCT 22, 1984

MAXZIDE-25

AB	MYLAN	25MG;37.5MG	N19129 003	MAY 13, 1988

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

AB	BARR	25MG;37.5MG	N71251 002	MAY 05, 1998
AB		50MG;75MG	N71251 001	APR 17, 1988
AB	DANBURY PHARMA	50MG;75MG	N71969 001	APR 17, 1988
AB	GENEVA PHARMS	25MG;37.5MG	N73281 001	APR 30, 1992
AB		50MG;75MG	N72011 001	JUN 17, 1988
AB	SIDMAK LABS NJ	25MG;37.5MG	N74026 001	APR 26, 1996
AB		50MG;75MG	N73467 001	JAN 31, 1996
AB	WATSON LABS	25MG;37.5MG	N73449 001	SEP 23, 1993
AB		50MG;75MG	N71851 001	NOV 30, 1988

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

DIOVAN HCT

	NOVARTIS	12.5MG;80MG	N20818 001	MAR 06, 1998
+		12.5MG;160MG	N20818 002	MAR 06, 1998

HYDROCODONE BITARTRATE; *MULTIPLE*

SEE ACETAMINOPHEN; HYDROCODONE BITARTRATE

HYDROCODONE BITARTRATE; *MULTIPLE*

SEE ASPIRIN; HYDROCODONE BITARTRATE

SEE HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET; ORAL

VICOPROFEN

+	ABBOTT	7.5MG;200MG	N20716 001	SEP 23, 1997

HYDROCODONE BITARTRATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

SYRUP; ORAL

CODAMINE

AA	ALPHARMA	5MG/5ML;25MG/5ML	N75103 001	SEP 29, 2000

HYCOMINE

AA	+ ENDO PHARMS	5MG/5ML;25MG/5ML	N19410 001	AUG 17, 1990

HYCOMINE PEDIATRIC

	ENDO PHARMS	2.5MG/5ML;12.5MG/5ML	N19411 001	AUG 17, 1990

HYDROCODONE POLISTIREX; *MULTIPLE*

SEE CHLORPHENIRAMINE POLISTIREX; HYDROCODONE POLISTIREX

HYDROCORTISONE

CREAM; TOPICAL

ALA-CORT

AT	DEL RAY LABS	1%	N80706 006

ANUSOL HC

AT	PARKEDALE	2.5%	N88250 001 JUN 06, 1984

HI-COR

AT	C AND M PHARMA	2.5%	N80483 001

HYDROCORTISONE

AT	ALPHARMA	2.5%	N89682 001 MAR 10, 1988
AT	ALPHARMA US PHARM	1%	N87795 001 MAY 03, 1983
AT	ALTANA	0.5%	N80848 002
AT		1%	N80848 003
AT	CLAY PARK	2.5%	N85025 001

FDA data supplied by DrugPatentWatch.com

HYDROCORTISONE

CREAM; TOPICAL

	HYDROCORTISONE			
AT	EVERYLIFE	1%	N80452 002	
AT	FOUGERA	1%	N80693 003	
AT		2.5%	N89414 001	
			DEC 16, 1986	
AT	INGRAM PHARM	0.5%	N80456 002	
AT		1%	N80456 003	
AT	PHARMADERM	2.5%	N89413 001	
			DEC 16, 1986	
AT	SYOSSET	0.5%	N85527 001	
AT	THAMES	1%	N86155 001	
AT		2.5%	N88799 001	
			NOV 09, 1984	
	HYTONE			
AT	+ DERMIK LABS	1%	N80472 003	
AT	+	2.5%	N80472 004	
	PENECORT			
AT	ALLERGAN HERBERT	1%	N88216 001	
			JUN 06, 1984	
	SYNACORT			
AT	MEDICIS	1%	N87458 001	
AT		2.5%	N87457 001	

ENEMA; RECTAL

	COLOCORT			
AB	PADDOCK	100MG/60ML	N75172 001	
			DEC 03, 1999	
	CORTENEMA			
AB	+ SOLVAY	100MG/60ML	N16199 001	
	HYDROCORTISONE			
AB	COPLEY PHARM	100MG/60ML	N74171 001	
			MAY 27, 1994	

LOTION; TOPICAL

	ALA-CORT			
AT	DEL RAY LABS	1%	N83201 001	
	ALA-SCALP			
	DEL RAY LABS	2%	N83231 001	
	CETACORT			
AT	HEALTHPOINT	0.5%	N80426 002	
AT		1%	N80426 001	
	EPICORT			
AT	BLULINE	0.5%	N83219 002	
	HYDROCORTISONE			
AT	ALTANA	2.5%	N40351 001	
			JUL 25, 2000	

HYDROCORTISONE

LOTION; TOPICAL

	HYDROCORTISONE			
AT	THAMES	2.5%	N40247 001	
			JUL 23, 1999	
	HYTONE			
AT	+ DERMIK LABS	1%	N80473 003	
AT	+	2.5%	N80473 004	
			NOV 30, 1982	
	NUTRACORT			
AT	HEALTHPOINT	1%	N80443 003	
AT		2.5%	N87644 001	
			AUG 24, 1982	
	STIE-CORT			
AT	STIEFEL	1%	N89066 001	
			NOV 25, 1985	
AT		2.5%	N89074 001	
			NOV 26, 1985	

OINTMENT; TOPICAL

	CORTRIL			
AT	+ PFIPHARMECS	1%	N09176 001	
AT	+	2.5%	N09176 002	
	HYDROCORTISONE			
AT	ALTANA	1%	N80489 003	
AT		1%	N80692 001	
AT	CLAY PARK	2.5%	N85027 001	
AT	FOUGERA	2.5%	N81203 001	
			MAY 28, 1993	
AT	NMC	1%	N87796 001	
			OCT 13, 1982	
AT	THAMES	1%	N86257 001	
AT		2.5%	N40310 001	
			DEC 29, 2000	
	HYDROCORTISONE IN ABSORBASE			
AT	CAROLINA MEDCL	1%	N88138 001	
			SEP 06, 1985	

POWDER; FOR RX COMPOUNDING

	HYDROCORTISONE			
AA	PADDOCK	100%	N88082 001	
			APR 08, 1983	
AA	PHARMA TEK	100%	N85982 001	

SOLUTION; TOPICAL

	PENECORT			
AT	ALLERGAN HERBERT	1%	N88214 001	
			JUN 06, 1984	

FDA data supplied by DrugPatentWatch.com

HYDROCORTISONE

SOLUTION; TOPICAL

		TEXACORT		
AT	+	SIRIUS LABS	**1%**	**N80425 001**
	+		2.5%	N81271 001
				APR 17, 1992

TABLET; ORAL

		CORTEF		
BP		PHARMACIA AND UPJOHN	10MG	N08697 001
BP			20MG	N08697 002
			5MG	N08697 003
		HYDROCORTISONE		
BP		WEST WARD	20MG	N83365 001
		HYDROCORTONE		
BP		MERCK	10MG	N08506 007
BP	+		20MG	N08506 011

HYDROCORTISONE; *MULTIPLE*

SEE ACETIC ACID, GLACIAL; HYDROCORTISONE

SEE ACETIC ACID, GLACIAL; HYDROCORTISONE; NEOMYCIN SULFATE

SEE BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SEE CIPROFLOXACIN HYDROCHLORIDE; HYDROCORTISONE

HYDROCORTISONE; NEOMYCIN SULFATE

CREAM; TOPICAL

		NEO-CORT-DOME		
	+	BAYER	0.5%;EQ 3.5MG BASE/GM	N50237 006
				JUN 05, 1984
	+		1%;EQ 3.5MG BASE/GM	N50237 005
				JUN 05, 1984

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OTIC

		CORTISPORIN		
AT	+	MONARCH PHARMS	**1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML**	**N50479 001**
		NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE		
AT		BAUSCH AND LOMB	**1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML**	**N64053 001**
				DEC 29, 1995

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION/DROPS; OPHTHALMIC

		CORTISPORIN		
	+	MONARCH PHARMS	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N50169 001

SUSPENSION/DROPS; OTIC

		CORTISPORIN		
AT	+	MONARCH PHARMS	**1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML**	**N60613 001**
		OTICAIR		
AT		BAUSCH AND LOMB	**1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML**	**N64065 001**
				AUG 28, 1996
		PEDIOTIC		
AT		MONARCH PHARMS	**1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML**	**N62822 001**
				SEP 29, 1987

HYDROCORTISONE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OTIC

		OTOBIOTIC		
	+	SCHERING	5MG/ML; EQ 10,000 UNITS BASE/ML	N62302 001

HYDROCORTISONE; TETRACYCLINE HYDROCHLORIDE

OINTMENT; OPHTHALMIC

		ACHROMYCIN		
	+	LEDERLE	1.5%;1%	N50272 001

HYDROCORTISONE ACETATE

AEROSOL, METERED; RECTAL

		CORTIFOAM		
	+	SCHWARZ PHARMA	10%	N17351 001
				FEB 10, 1982

CREAM; TOPICAL

		HYDROCORTISONE ACETATE		
	+	FERNDALE LABS	2.5%	N40259 001
				JUL 29, 1999
		MICORT-HC		
		FERNDALE LABS	2.5%	N40396 001
				FEB 27, 2001

FDA data supplied by DrugPatentWatch.com

HYDROCORTISONE ACETATE

INJECTABLE; INJECTION
HYDROCORTISONE ACETATE
BP STERIS 25MG/ML N83128 001
HYDROCORTONE
BP MERCK 25MG/ML N08228 001
\+ 50MG/ML N08228 004

LOTION; TOPICAL
DRICORT
\+ INGRAM PHARM 0.5% N86207 001

OINTMENT; OPHTHALMIC
HYDROCORTISONE ACETATE
\+ ALTANA 0.5% N80828 001

PASTE; TOPICAL
ORABASE HCA
COLGATE 0.5% N83205 001

POWDER; FOR RX COMPOUNDING
HYDROCORTISONE ACETATE
PHARMA TEK 100% N85981 001

HYDROCORTISONE ACETATE; *MULTIPLE*
SEE BACITRACIN; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SEE CHLORAMPHENICOL; HYDROCORTISONE ACETATE
SEE COLISTIN SULFATE; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; THONZONIUM BROMIDE

HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

CREAM; TOPICAL
CORTISPORIN
\+ MONARCH PHARMS 0.5%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM N50218 001 AUG 09, 1985

HYDROCORTISONE ACETATE; OXYTETRACYCLINE HYDROCHLORIDE

SUSPENSION/DROPS; OPHTHALMIC
TERRA-CORTRIL
\+ PFIZER 1.5%;EQ 5MG BASE/ML N61016 001

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

AEROSOL, METERED; TOPICAL
EPIFOAM
BX SCHWARZ PHARMA 1%;1% N86457 001
HYDROCORTISONE ACETATE 1% AND PRAMOXINE HCL 1%
BX COPLEY PHARM 1%;1% N89440 001 MAY 17, 1988
PROCTOFOAM HC
BX SCHWARZ PHARMA 1%;1% N86195 001

CREAM; TOPICAL
PRAMOSONE
FERNDALE LABS 0.5%;1% N83778 001
1%;1% N85368 001

LOTION; TOPICAL
PRAMOSONE
FERNDALE LABS 1%;1% N85980 001
2.5%;1% N85979 001

HYDROCORTISONE ACETATE; UREA

CREAM; TOPICAL
CARMOL HC
AT \+ KENWOOD LABS **1%;10%** **N80505 001**
U-CORT
AT THAMES **1%;10%** **N89472 001** JUN 13, 1988

HYDROCORTISONE BUTYRATE

CREAM; TOPICAL
LOCOID
\+ YAMANOUCHI 0.1% N18514 001 MAR 31, 1982
LOCOID LIPOCREAM
\+ YAMANOUCHI 0.1% N20769 001 SEP 08, 1997

OINTMENT; TOPICAL
LOCOID
\+ YAMANOUCHI 0.1% N18652 001 OCT 29, 1982

SOLUTION; TOPICAL
LOCOID
\+ FERNDALE LABS 0.1% N19116 001 FEB 25, 1987

FDA data supplied by DrugPatentWatch.com

HYDROCORTISONE CYPIONATE

SUSPENSION; ORAL

	CORTEF			
+	PHARMACIA AND UPJOHN	EQ 10MG BASE/5ML	N09900 001	

HYDROCORTISONE PROBUTATE

CREAM; TOPICAL

	PANDEL			
+	SAVAGE LABS	0.1%	N20453 001	FEB 28, 1997

HYDROCORTISONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

	HYDROCORTONE			
+	MERCK	EQ 50MG BASE/ML	N12052 001	

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION

	A-HYDROCORT			
AP	ABBOTT	**EQ 1GM BASE/VIAL**	**N85932 001**	
AP		**EQ 100MG BASE/VIAL**	**N85929 001**	
AP		**EQ 250MG BASE/VIAL**	**N85930 001**	
AP		**EQ 500MG BASE/VIAL**	**N85931 001**	
	HYDROCORTISONE SODIUM SUCCINATE			
AP	INTL MEDICATION	**EQ 100MG BASE/VIAL**	**N87532 001**	MAR 19, 1982
	SOLU-CORTEF			
AP	+ PHARMACIA AND UPJOHN	**EQ 100MG BASE/VIAL**	**N09866 001**	
AP	+	**EQ 250MG BASE/VIAL**	**N09866 002**	
AP	+	**EQ 500MG BASE/VIAL**	**N09866 003**	
AP	+	**EQ 1GM BASE/VIAL**	**N09866 004**	

HYDROCORTISONE VALERATE

CREAM; TOPICAL

	HYDROCORTISONE VALERATE			
AB	CLAY PARK	**0.2%**	**N75666 001**	MAY 24, 2000
AB	COPLEY PHARM	**0.2%**	**N74489 001**	AUG 12, 1998

HYDROCORTISONE VALERATE

CREAM; TOPICAL

	HYDROCORTISONE VALERATE			
AB	TARO	**0.2%**	**N75042 001**	AUG 25, 1998
	WESTCORT			
AB	+ WESTWOOD SQUIBB	**0.2%**	**N17950 001**	

OINTMENT; TOPICAL

	HYDROCORTISONE VALERATE			
AB	ALTANA	**0.2%**	**N75085 001**	JUL 31, 2001
AB	TARO	**0.2%**	**N75043 001**	AUG 25, 1998
	WESTCORT			
AB	+ WESTWOOD SQUIBB	**0.2%**	**N18726 001**	AUG 08, 1983

HYDROFLUMETHIAZIDE

TABLET; ORAL

	DIUCARDIN			
AB	WYETH AYERST	**50MG**	**N83383 001**	
	HYDROFLUMETHIAZIDE			
AB	PAR PHARM	**50MG**	**N88850 001**	MAY 31, 1985
	SALURON			
AB	+ SHIRE LABS	**50MG**	**N11949 001**	

HYDROFLUMETHIAZIDE; RESERPINE

TABLET; ORAL

	RESERPINE AND HYDROFLUMETHIAZIDE			
BP	PAR PHARM	50MG;0.125MG	N88907 001	SEP 20, 1985
	SALUTENSIN			
BP	+ SHIRE LABS	50MG;0.125MG	N12359 003	
	SALUTENSIN-DEMI			
	SHIRE LABS	25MG;0.125MG	N12359 004	

HYDROMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION

	DILAUDID-HP			
AP	+ ABBOTT	**10MG/ML**	**N19034 001**	JAN 11, 1984

FDA data supplied by DrugPatentWatch.com

HYDROMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION

	DILAUDID-HP			
	+ ABBOTT	250MG/VIAL	N19034 002	AUG 04, 1994
	HYDROMORPHONE HCL			
AP	ABBOTT	**10MG/ML**	**N74598 001**	JUN 19, 1997
AP	STERIS	**10MG/ML**	**N74317 001**	AUG 23, 1995

SOLUTION; ORAL

	DILAUDID			
AA	+ ABBOTT	**5MG/5ML**	**N19891 001**	DEC 07, 1992
	HYDROMORPHONE HCL			
AA	ROXANE	**5MG/5ML**	**N74653 001**	JUL 29, 1998

TABLET; ORAL

	DILAUDID			
AB	+ ABBOTT	**8MG**	**N19892 001**	DEC 07, 1992
	HYDROMORPHONE HCL			
AB	ROXANE	**8MG**	**N74597 001**	JUL 29, 1998

HYDROXOCOBALAMIN

INJECTABLE; INJECTION

	HYDROXOCOBALAMIN		
	+ STERIS	1MG/ML	N85998 001

HYDROXYAMPHETAMINE HYDROBROMIDE

SOLUTION/DROPS; OPHTHALMIC

	PAREDRINE		
	+ AKORN	1%	N00004 004

HYDROXYAMPHETAMINE HYDROBROMIDE; TROPICAMIDE

SOLUTION/DROPS; OPHTHALMIC

	PAREMYD			
	+ AKORN	1%;0.25%	N19261 001	JAN 30, 1992

HYDROXYCHLOROQUINE SULFATE

TABLET; ORAL

	HYDROXYCHLOROQUINE SULFATE			
AB	MYLAN	**200MG**	**N40274 001**	MAY 29, 1998
	HYDROXYCHLOROQUINE SULFATE			
AB	COPLEY PHARM	**200MG**	**N40081 001**	SEP 30, 1994
AB	GENEVA PHARMS	**200MG**	**N40104 001**	NOV 30, 1995
AB	GENEVA PHARMS TECH	**200MG**	**N40150 001**	JAN 27, 1996
AB	WATSON LABS	**200MG**	**N40133 001**	NOV 30, 1995
	PLAQUENIL			
AB	+ SANOFI SYNTHELABO	**200MG**	**N09768 001**	

HYDROXYPROGESTERONE CAPROATE

INJECTABLE; INJECTION

	HYDROXYPROGESTERONE CAPROATE		
	+ STERIS	250MG/ML	N17439 002

HYDROXYPROPYL CELLULOSE

INSERT; OPHTHALMIC

	LACRISERT		
	+ MERCK	5MG	N18771 001

HYDROXYUREA

CAPSULE; ORAL

	DROXIA			
	BRISTOL MYERS SQUIBB	200MG	N16295 002	FEB 25, 1998
		300MG	N16295 003	FEB 25, 1998
	+	400MG	N16295 004	FEB 25, 1998
	HYDREA			
AB	+ BRISTOL MYERS SQUIBB	**500MG**	**N16295 001**	
	HYDROXYUREA			
AB	BARR	**250MG**	**N75143 002**	SEP 21, 2000

FDA data supplied by DrugPatentWatch.com

HYDROXYUREA

CAPSULE; ORAL

	HYDROXYUREA				
AB	BARR	500MG	N75143 001		
			OCT 16, 1998		
AB	+ DURAMED	250MG	N75020 002		
			JUN 26, 2000		
AB		500MG	N75020 001		
			JUL 30, 1998		
AB	PAR PHARM	500MG	N75340 001		
			FEB 24, 1999		
AB	ROXANE	500MG	N74476 001		
			AUG 18, 1995		

TABLET; ORAL

	HYDROXYUREA		
	+ BARR	1GM	N75734 001
			AUG 29, 2000

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION

	HYDROXYZINE		
AP	ELKINS SINN	50MG/ML	N85551 002
	HYDROXYZINE HCL		
AP	ABBOTT	25MG/ML	N87416 001
AP		50MG/ML	N87546 001
AP	AM PHARM PARTNERS	25MG/ML	N87329 001
AP		50MG/ML	N87329 002
AP	ELKINS SINN	25MG/ML	N85551 001
AP	LUITPOLD	25MG/ML	N87408 001
AP		50MG/ML	N87408 002
AP	STERIS	50MG/ML	N85779 001
	VISTARIL		
AP	+ PFIZER	25MG/ML	N11111 001
AP	+	50MG/ML	N11111 002

SYRUP; ORAL

	ATARAX		
AA	+ ROERIG	10MG/5ML	N10485 001
	HYDROXYZINE HCL		
AA	ALPHARMA	10MG/5ML	N86880 001
AA	HI TECH PHARMA	10MG/5ML	N40010 001
			OCT 28, 1994
AA	MORTON GROVE	10MG/5ML	N87294 001
			APR 12, 1982

HYDROXYZINE HYDROCHLORIDE

TABLET; ORAL

	ATARAX				
AB	+ ROERIG	10MG	N10392 001		
AB	+	25MG	N10392 004		
AB	+	50MG	N10392 006		
AB	+	100MG	N10392 005		
	HYDROXYZINE HCL				
AB	DANBURY PHARMA	10MG	N88348 001		
			SEP 15, 1983		
AB		25MG	N88349 001		
			SEP 15, 1983		
AB		50MG	N88350 001		
			SEP 15, 1983		
AB	GENEVA PHARMS	10MG	N87869 001		
			DEC 20, 1982		
AB		25MG	N87870 001		
			DEC 20, 1982		
AB		50MG	N87871 001		
			DEC 20, 1982		
AB	MUTUAL PHARM	10MG	N89381 001		
			MAY 19, 1986		
AB		25MG	N89382 001		
			MAY 19, 1986		
AB		50MG	N89383 001		
			MAY 19, 1986		
AB	SIDMAK LABS NJ	10MG	N88617 001		
			JAN 10, 1986		
AB		25MG	N88618 001		
			JAN 10, 1986		
AB		50MG	N88619 001		
			JAN 10, 1986		
AB		100MG	N81054 001		
			SEP 25, 1995		
AB	WATSON LABS	10MG	N81149 001		
			MAR 18, 1994		
AB		25MG	N81150 001		
			MAR 18, 1994		
AB		50MG	N81151 001		
			MAR 18, 1994		

HYDROXYZINE PAMOATE

CAPSULE; ORAL

	HYDROXYZINE PAMOATE		
AB	BARR	EQ 25MG HCL	N88496 001
			JUN 15, 1984

FDA data supplied by DrugPatentWatch.com

HYDROXYZINE PAMOATE

CAPSULE; ORAL

	HYDROXYZINE PAMOATE			
AB	BARR	**EQ 50MG HCL**	**N88487 001**	
			JUN 15, 1984	
AB		**EQ 100MG HCL**	**N88488 001**	
			JUN 15, 1984	
AB	DANBURY PHARMA	**EQ 25MG HCL**	**N81165 001**	
			JUL 31, 1991	
AB	EON	**EQ 25MG HCL**	**N87479 001**	
AB		**EQ 50MG HCL**	**N86183 001**	
AB	GENEVA PHARMS	**EQ 25MG HCL**	**N81127 001**	
			JUN 28, 1991	
AB	IVAX PHARMS	**EQ 25MG HCL**	**N87761 001**	
			MAR 05, 1982	
AB		**EQ 50MG HCL**	**N87760 001**	
			MAR 05, 1982	
AB	WATSON LABS	**EQ 25MG HCL**	**N40156 001**	
			JUL 15, 1996	
AB		**EQ 50MG HCL**	**N40156 002**	
			JUL 15, 1996	
	VISTARIL			
AB	PFIZER	**EQ 25MG HCL**	**N11459 002**	
AB	+	**EQ 50MG HCL**	**N11459 004**	
AB		**EQ 100MG HCL**	**N11459 006**	

SUSPENSION; ORAL

	VISTARIL			
	PFIZER	EQ 25MG HCL/5ML	N11795 001	

IBUPROFEN

SUSPENSION; ORAL

	CHILDREN'S ADVIL			
BX	WHITEHALL ROBINS	100MG/5ML	N19833 002	
			SEP 19, 1989	
	IBUPROFEN			
AB	ALPHARMA	**100MG/5ML**	**N74978 001**	
			MAR 25, 1998	
	MOTRIN			
AB	+ MCNEIL CONS	**100MG/5ML**	**N19842 001**	
			SEP 19, 1989	

SUSPENSION/DROPS; ORAL

	MOTRIN			
	+ MCNEIL	40MG/ML	N20476 001	
			MAY 25, 1995	

IBUPROFEN

TABLET; ORAL

	IBU			
AB	BASF	**400MG**	**N18197 001**	
AB		**400MG**	**N70083 001**	
			FEB 22, 1985	
AB		**600MG**	**N70099 001**	
			MAR 29, 1985	
AB		**800MG**	**N70745 001**	
			JUL 23, 1986	
		600MG	N70088 001	
			FEB 08, 1985	
	IBU-TAB			
AB	ALRA	**400MG**	**N71058 001**	
			AUG 11, 1988	
AB		**600MG**	**N71059 001**	
			AUG 11, 1988	
	IBUPROFEN			
AB	BASF	**400MG**	**N75682 001**	
			NOV 14, 2001	
AB		**600MG**	**N75682 002**	
			NOV 14, 2001	
AB		**800MG**	**N75682 003**	
			NOV 14, 2001	
AB	DANBURY PHARMA	**400MG**	**N70436 001**	
			AUG 21, 1985	
AB		**600MG**	**N70437 001**	
			AUG 21, 1985	
AB		**800MG**	**N71547 001**	
			JUL 02, 1987	
AB	DR REDDYS LABS INC	**400MG**	**N76112 001**	
			OCT 31, 2001	
AB		**600MG**	**N76112 002**	
			OCT 31, 2001	
AB		**800MG**	**N76112 003**	
			OCT 31, 2001	
AB	GENEVA PHARMS	**300MG**	**N70734 001**	
			JUN 12, 1986	
AB		**400MG**	**N70735 001**	
			JUN 12, 1986	
AB		**600MG**	**N70736 001**	
			JUN 12, 1986	
AB		**800MG**	**N72169 001**	
			DEC 11, 1987	
AB	INTERPHARM	**400MG**	**N71334 001**	
			NOV 25, 1986	
AB		**600MG**	**N71335 001**	
			NOV 25, 1986	

FDA data supplied by DrugPatentWatch.com

IBUPROFEN

TABLET; ORAL

	IBUPROFEN			
AB	INTERPHARM	800MG	**N71935 001**	OCT 13, 1987
AB	IVAX PHARMS	400MG	**N71145 001**	SEP 23, 1986
AB		600MG	**N71146 001**	SEP 23, 1986
AB		800MG	**N71769 001**	MAY 08, 1987
AB	MUTUAL PHARM	300MG	**N71230 001**	OCT 22, 1986
AB		400MG	**N71231 001**	OCT 22, 1986
AB		600MG	**N71232 001**	OCT 22, 1986
AB		800MG	**N72004 001**	NOV 18, 1987
AB	MYLAN	400MG	**N70045 001**	SEP 24, 1985
AB		600MG	**N70057 001**	SEP 24, 1985
AB		800MG	**N71999 001**	DEC 03, 1987
AB	OHM LABS	400MG	**N70818 001**	DEC 26, 1985
AB	PAR PHARM	400MG	**N70329 001**	AUG 06, 1985
AB		600MG	**N70330 001**	AUG 06, 1985
AB		800MG	**N70986 001**	JUL 25, 1986
AB	PVT FORM	300MG	**N71266 001**	OCT 15, 1986
AB		400MG	**N71267 001**	OCT 15, 1986
AB		600MG	**N71268 001**	OCT 15, 1986
AB		800MG	**N72300 001**	JUL 01, 1988
AB	SIDMAK LABS NJ	400MG	**N71666 001**	JUN 18, 1987
AB		600MG	**N71667 001**	JUN 18, 1987
AB		800MG	**N71668 001**	JUN 18, 1987

IBUPROFEN

TABLET; ORAL

	IBUPROFEN			
AB	VINTAGE PHARMS	400MG	**N71644 001**	FEB 01, 1988
	IBUPROHM			
AB	OHM LABS	400MG	**N70469 001**	AUG 29, 1985
	MOTRIN			
AB	MCNEIL CONS	300MG	**N17463 003**	
AB		400MG	**N17463 002**	
AB		600MG	**N17463 004**	
AB	+	800MG	**N17463 005**	MAY 22, 1985
		100MG	N20418 001	NOV 16, 1994

TABLET, CHEWABLE; ORAL

MOTRIN			
MCNEIL CONS	50MG	N20135 001	NOV 16, 1994
+	100MG	N20135 002	NOV 16, 1994

IBUPROFEN; *MULTIPLE*

SEE HYDROCODONE BITARTRATE; IBUPROFEN

IBUTILIDE FUMARATE

INJECTABLE; INJECTION

CORVERT				
+	PHARMACIA AND UPJOHN	0.1MG/ML	N20491 001	DEC 28, 1995

IDARUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

IDAMYCIN				
+	PHARMACIA AND UPJOHN	5MG/VIAL	N50661 002	SEP 27, 1990
+		10MG/VIAL	N50661 001	SEP 27, 1990
+		20MG/VIAL	N50661 003	APR 25, 1995

FDA data supplied by DrugPatentWatch.com

IDARUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION
IDAMYCIN PFS
+ PHARMACIA AND UPJOHN 1MG/ML N50734 001 FEB 17, 1997

IDOXURIDINE

SOLUTION/DROPS; OPHTHALMIC
DENDRID
AT + ALCON 0.1% **N14169 001**
HERPLEX
AT + ALLERGAN 0.1% **N13935 002**

IFOSFAMIDE; MESNA

INJECTABLE; INJECTION
IFEX/MESNEX KIT
+ BRISTOL MYERS SQUIBB 1GM/VIAL;100MG/ML N19763 003 OCT 10, 1992
+ 3GM/VIAL;100MG/ML N19763 004 OCT 10, 1992

IMATINIB MESYLATE

CAPSULE; ORAL
GLEEVEC
NOVARTIS 50MG N21335 001 MAY 10, 2001
+ 100MG N21335 002 MAY 10, 2001

IMIGLUCERASE

INJECTABLE; INJECTION
CEREZYME
GENZYME 200 UNITS/VIAL N20367 001 MAY 23, 1994
+ 400 UNITS/VIAL N20367 002 SEP 22, 1999

IMIPENEM; *MULTIPLE*
SEE CILASTATIN SODIUM; IMIPENEM

IMIPRAMINE HYDROCHLORIDE

CONCENTRATE; ORAL
IMIPRAMINE HCL
NOVARTIS 25MG/ML N86765 001

TABLET; ORAL
IMIPRAMINE HCL
AB GENEVA PHARMS **10MG** **N84936 002**
AB **25MG** **N83745 001**
AB **50MG** **N84937 001**
AB MUTUAL PHARM **10MG** **N81048 001** JUN 05, 1990
AB **25MG** **N81049 001** JUN 05, 1990
AB **50MG** **N81050 001** JUN 05, 1990
AB PAR PHARM **10MG** **N88292 001** OCT 21, 1983
AB **10MG** **N89422 001** JUL 14, 1987
AB **25MG** **N88262 001** OCT 21, 1983
AB **25MG** **N89497 001** JUL 14, 1987
AB **50MG** **N88276 001** OCT 21, 1983
AB ROXANE **10MG** **N83799 001**
AB TEVA **10MG** **N83729 001**
AB **25MG** **N83729 004**
AB **50MG** **N83729 003**
TOFRANIL
AB TYCO HLTHCARE **10MG** **N87844 001** MAY 22, 1984
AB **25MG** **N87845 001** MAY 22, 1984
AB + **50MG** **N87846 001** MAY 22, 1984

IMIPRAMINE PAMOATE

CAPSULE; ORAL
TOFRANIL-PM
TYCO HLTHCARE EQ 75MG HCL N17090 001
EQ 100MG HCL N17090 004
EQ 125MG HCL N17090 003
+ EQ 150MG HCL N17090 002

FDA data supplied by DrugPatentWatch.com

IMIQUIMOD

CREAM; TOPICAL
ALDARA
\+ 3M — 5% — N20723 001 — FEB 27, 1997

INAMRINONE LACTATE

INJECTABLE; INJECTION

	AMRINONE			
AP	ABBOTT	EQ 5MG BASE/ML	**N74616 001**	AUG 03, 1998
AP	BEDFORD	EQ 5MG BASE/ML	**N75513 001**	MAY 09, 2000
	AMRINONE LACTATE			
AP	BAXTER HLTHCARE CORP	EQ 5MG BASE/ML	**N75542 001**	MAY 10, 2000
	INOCOR			
AP	+ SANOFI SYNTHELABO	EQ 5MG BASE/ML	**N18700 001**	JUL 31, 1984

INDAPAMIDE

TABLET; ORAL

	INDAPAMIDE			
AB	ALPHAPHARM	1.25MG	**N75105 001**	JUL 23, 1998
AB		2.5MG	**N75105 002**	JUL 23, 1998
AB	GENEVA PHARMS TECH	1.25MG	**N74594 001**	MAY 23, 1996
AB		2.5MG	**N74594 002**	MAY 23, 1996
AB	IVAX PHARMS	1.25MG	**N74299 002**	APR 29, 1996
AB		2.5MG	**N74299 001**	JUL 27, 1995
AB	MYLAN	1.25MG	**N74461 002**	MAR 26, 1997
AB		2.5MG	**N74461 001**	MAR 27, 1996
AB	PUREPAC PHARM	1.25MG	**N74722 001**	JUN 17, 1996
AB		2.5MG	**N74722 002**	JUN 17, 1996

INDAPAMIDE

TABLET; ORAL

	INDAPAMIDE			
AB	TEVA	1.25MG	**N74498 002**	FEB 12, 1998
AB		2.5MG	**N74498 001**	OCT 31, 1996
AB	TRIGEN	1.25MG	**N75201 001**	DEC 04, 1998
AB		2.5MG	**N75201 002**	DEC 04, 1998
AB	WATSON LABS	1.25MG	**N74585 001**	SEP 26, 1996
AB		2.5MG	**N74585 002**	SEP 26, 1996
	LOZOL			
AB	AVENTIS	1.25MG	**N18538 002**	APR 29, 1993
AB	+	2.5MG	**N18538 001**	JUL 06, 1983

INDINAVIR SULFATE

CAPSULE; ORAL
CRIXIVAN
MERCK

EQ 100MG BASE	N20685 006	APR 19, 2000
EQ 200MG BASE	N20685 003	MAR 13, 1996
EQ 333MG BASE	N20685 005	DEC 17, 1998
+ EQ 400MG BASE	N20685 001	MAR 13, 1996

INDIUM IN-111 OXYQUINOLINE

INJECTABLE; INJECTION
INDIUM IN-111 OXYQUINOLINE
AMERSHAM HLTH — 1mCi/ML — N19044 001 — DEC 24, 1985

FDA data supplied by DrugPatentWatch.com

INDIUM IN-111 PENTETATE DISODIUM

INJECTABLE; INTRATHECAL
MPI INDIUM DTPA IN 111
AMERSHAM HLTH 1mCi/ML N17707 001 FEB 18, 1982

INDIUM IN-111 PENTETREOTIDE KIT

INJECTABLE; INJECTION
OCTREOSCAN
MALLINCKRODT 3mCi/ML N20314 001 JUN 02, 1994

INDOCYANINE GREEN

INJECTABLE; INJECTION
CARDIO-GREEN
+ AKORN 25MG/VIAL N11525 001
+ 50MG/VIAL N11525 002

INDOMETHACIN

CAPSULE; ORAL
INDO-LEMMON
AB TEVA 25MG **N70266 001** NOV 07, 1985
AB 50MG **N70267 001** NOV 07, 1985

INDOCIN
AB MERCK 25MG **N16059 001**
AB + 50MG **N16059 002**

INDOMETHACIN
AB AMERSHAM HLTH 25MG **N18829 002** AUG 06, 1984
AB 50MG **N18829 001** AUG 06, 1984
AB GENEVA PHARMS 25MG **N70673 001** APR 29, 1987
AB 50MG **N70674 001** APR 29, 1987
AB IVAX PHARMS 25MG **N70719 001** FEB 12, 1986
AB 50MG **N70756 001** FEB 12, 1986

INDOMETHACIN

CAPSULE; ORAL
INDOMETHACIN
AB LEDERLE 25MG **N18851 001** MAY 18, 1984
AB 50MG **N18851 002** MAY 18, 1984
AB MUTUAL PHARM 25MG **N70899 001** FEB 09, 1987
AB 50MG **N70900 001** FEB 09, 1987
AB MYLAN 25MG **N18858 001** APR 20, 1984
AB 50MG **N18858 002** APR 20, 1984
AB 50MG **N70624 001** SEP 04, 1985
AB PAR PHARM 50MG **N70651 001** MAR 05, 1986
AB SIDMAK LABS NJ 25MG **N71148 001** MAR 18, 1987
AB 50MG **N71149 001** MAR 18, 1987
AB TEVA 25MG **N71342 001** APR 18, 1988
AB 50MG **N71343 001** APR 18, 1988

CAPSULE, EXTENDED RELEASE; ORAL
INDOCIN SR
AB + EON 75MG **N74464 001** MAY 28, 1998

INDOMETHACIN
AB INWOOD LABS 75MG **N72410 001** MAR 15, 1989

SUPPOSITORY; RECTAL
INDOCIN
AB + MERCK 50MG **N17814 001** AUG 13, 1984

INDOMETHEGAN
AB G AND W LABS 50MG **N73314 001** AUG 31, 1992

SUSPENSION; ORAL
INDOCIN
AB + MERCK 25MG/5ML **N18332 001** OCT 10, 1985

FDA data supplied by DrugPatentWatch.com

INDOMETHACIN

SUSPENSION; ORAL
INDOMETHACIN
AB ROXANE **25MG/5ML** **N71412 001**
MAR 18, 1987

INDOMETHACIN SODIUM

INJECTABLE; INJECTION
INDOCIN I.V.
\+ MERCK EQ 1MG BASE/VIAL N18878 001
JAN 30, 1985

INSULIN ASPART

INJECTABLE; SUBCUTANEOUS
NOVOLOG
\+ NOVO NORDISK 100 UNITS/ML N20986 001
JUN 07, 2000

INSULIN ASPART; INSULIN ASPART PROTAMINE

INJECTABLE; SUBCUTANEOUS
NOVOLOG MIX 70/30
\+ NOVO NORDISK 30 UNITS/ML;70 UNITS/ML N21172 001
NOV 01, 2001

INSULIN ASPART PROTAMINE; *MULTIPLE*
SEE INSULIN ASPART; INSULIN ASPART PROTAMINE

INSULIN GLARGINE

INJECTABLE; INJECTION
LANTUS
\+ AVENTIS PHARMS 100 UNITS/ML N21081 001
APR 20, 2000

INSULIN LISPRO

INJECTABLE; INJECTION
HUMALOG
\+ LILLY 100 UNITS/ML N20563 001
JUN 14, 1996

INSULIN LISPRO

INJECTABLE; INJECTION
HUMALOG PEN
\+ LILLY 100 UNITS/ML N20563 002
AUG 06, 1998

INSULIN LISPRO; INSULIN LISPRO PROTAMINE

INJECTABLE; INJECTION
HUMALOG MIX 50/50
\+ LILLY 50 UNITS/ML;50 UNITS/ML N21018 001
DEC 22, 1999

HUMALOG MIX 75/25
\+ LILLY 25 UNITS/ML;75 UNITS/ML N21017 001
DEC 22, 1999

INSULIN LISPRO PROTAMINE; *MULTIPLE*
SEE INSULIN LISPRO; INSULIN LISPRO PROTAMINE

INSULIN PORK

INJECTABLE; INJECTION
ILETIN I
\+ LILLY 500 UNITS/ML N17931 001

INSULIN PURIFIED PORK

INJECTABLE; INJECTION
ILETIN II
\+ LILLY 500 UNITS/ML N18344 002

INSULIN RECOMBINANT HUMAN

INJECTABLE; INJECTION
HUMULIN R
\+ LILLY 500 UNITS/ML N18780 004
MAR 31, 1994

VELOSULIN BR
\+ NOVO NORDISK 100 UNITS/ML N21028 001
JUL 19, 1999

INTRINSIC FACTOR; *MULTIPLE*
SEE COBALT CHLORIDE, CO-57; CYANOCOBALAMIN; CYANOCOBALAMIN, CO-57; INTRINSIC FACTOR

FDA data supplied by DrugPatentWatch.com

INTRINSIC FACTOR; *MULTIPLE*
SEE CYANOCOBALAMIN; CYANOCOBALAMIN, CO-57; INTRINSIC FACTOR

INULIN

INJECTABLE; INJECTION
INULIN AND SODIUM CHLORIDE
+ QUESTCOR PHARMS 100MG/ML N02282 001

IOBENGUANE SULFATE I 131

INJECTABLE; INJECTION
IOBENGUANE SULFATE I 131
CIS 2.3mCi/ML N20084 001
MAR 25, 1994

IODIPAMIDE MEGLUMINE

INJECTABLE; INJECTION
CHOLOGRAFIN MEGLUMINE
+ BRACCO 10.3% N09321 007
+ 52% N09321 003

IODIPAMIDE MEGLUMINE; *MULTIPLE*
SEE DIATRIZOATE MEGLUMINE; IODIPAMIDE MEGLUMINE

IODIXANOL

INJECTABLE; INJECTION
VISIPAQUE 270
+ AMERSHAM HLTH 55% N20351 001
MAR 22, 1996
55% N20808 001
AUG 29, 1997

VISIPAQUE 320
+ AMERSHAM HLTH 65.2% N20351 002
MAR 22, 1996
65.2% N20808 002
AUG 29, 1997

IODOHIPPURATE SODIUM, I-131

INJECTABLE; INJECTION
HIPPURAN I 131
MALLINCKRODT 0.25mCi/ML N16666 001

IOFETAMINE HYDROCHLORIDE I-123

INJECTABLE; INJECTION
SPECTAMINE
IMP 1mCi/ML N19432 001
DEC 24, 1987

IOHEXOL

INJECTABLE; INJECTION
OMNIPAQUE 140
+ AMERSHAM HLTH 30.2% N18956 005
NOV 30, 1988

OMNIPAQUE 210
+ AMERSHAM HLTH 45.3% N18956 006
JUN 30, 1989

SOLUTION; INJECTION, ORAL
OMNIPAQUE 350
+ AMERSHAM HLTH 75.5% N18956 004
DEC 26, 1985
75.5% N20608 003
OCT 24, 1995

SOLUTION; INJECTION, ORAL, RECTAL
OMNIPAQUE 180
+ AMERSHAM HLTH 38.8% N18956 001
DEC 26, 1985

OMNIPAQUE 240
+ AMERSHAM HLTH 51.8% N18956 002
DEC 26, 1985
51.8% N20608 001
OCT 24, 1995

OMNIPAQUE 300
+ AMERSHAM HLTH 64.7% N18956 003
DEC 26, 1985
64.7% N20608 002
OCT 24, 1995

SOLUTION; URETHRAL
OMNIPAQUE 70
+ AMERSHAM HLTH 15.1% N18956 007
JUN 01, 1994

FDA data supplied by DrugPatentWatch.com

IOPAMIDOL

INJECTABLE; INJECTION

	IOPAMIDOL			
AP	ELKINS SINN PHARM	41%	**N74629 001**	NOV 06, 1996
AP		51%	**N74629 004**	MAR 31, 1998
AP		61%	**N74629 002**	NOV 06, 1996
AP		76%	**N74629 003**	NOV 06, 1996
AP	FAULDING	61%	**N74734 001**	DEC 10, 1996
AP		76%	**N74734 002**	DEC 10, 1996
	IOPAMIDOL-200			
AP	ABBOTT	41%	**N74898 001**	DEC 30, 1997
AP	COOK IMAGING	41%	**N74881 001**	JUL 28, 2000
	IOPAMIDOL-200 IN PLASTIC CONTAINER			
AP	ABBOTT	41%	**N74636 001**	DEC 30, 1997
	IOPAMIDOL-250			
AP	ABBOTT	51%	**N74898 002**	DEC 30, 1997
AP		51%	**N75005 001**	FEB 24, 1998
AP	AM PHARM PARTNERS	51%	**N74679 001**	APR 02, 1997
AP	COOK IMAGING	51%	**N74881 002**	JUL 28, 2000
	IOPAMIDOL-250 IN PLASTIC CONTAINER			
AP	ABBOTT	51%	**N74636 002**	DEC 30, 1997
	IOPAMIDOL-300			
AP	ABBOTT	61%	**N74898 003**	DEC 30, 1997
AP		61%	**N75005 002**	FEB 24, 1998
AP	AM PHARM PARTNERS	61%	**N74679 002**	APR 02, 1997
AP	COOK IMAGING	61%	**N74881 003**	JUL 28, 2000
	IOPAMIDOL-300 IN PLASTIC CONTAINER			
AP	ABBOTT	61%	**N74636 003**	DEC 30, 1997

IOPAMIDOL

INJECTABLE; INJECTION

	IOPAMIDOL-300 IN PLASTIC CONTAINER			
AP	ABBOTT	61%	**N74637 001**	APR 03, 1997
	IOPAMIDOL-370			
AP	ABBOTT	76%	**N74898 004**	DEC 30, 1997
AP		76%	**N75005 003**	FEB 24, 1998
AP	AM PHARM PARTNERS	76%	**N74679 003**	APR 02, 1997
AP	COOK IMAGING	76%	**N74881 004**	JUL 28, 2000
	IOPAMIDOL-370 IN PLASTIC CONTAINER			
AP	ABBOTT	76%	**N74636 004**	DEC 30, 1997
	ISOVUE-128			
+	BRACCO	26%	N18735 005	OCT 21, 1986
	ISOVUE-200			
AP +	BRACCO	41%	**N18735 006**	JUL 07, 1987
	ISOVUE-250			
AP +	BRACCO	51%	**N18735 007**	JUL 06, 1992
AP +		51%	**N20327 002**	OCT 12, 1994
	ISOVUE-300			
AP +	BRACCO	61%	**N18735 002**	DEC 31, 1985
AP +		61%	**N20327 003**	OCT 12, 1994
	ISOVUE-370			
AP +	BRACCO	76%	**N18735 003**	DEC 31, 1985
AP +		76%	**N20327 004**	OCT 12, 1994
	ISOVUE-M 200			
+	BRACCO	41%	N18735 001	DEC 31, 1985
	ISOVUE-M 300			
+	BRACCO	61%	N18735 004	DEC 31, 1985

FDA data supplied by DrugPatentWatch.com

IOPANOIC ACID

TABLET; ORAL
TELEPAQUE
+ AMERSHAM HLTH 500MG N08032 001

IOPROMIDE

INJECTABLE; INJECTION
ULTRAVIST 150
+ BERLEX LABS 31.2% N20220 004 MAY 10, 1995
ULTRAVIST 240
+ BERLEX LABS 49.9% N20220 003 MAY 10, 1995
ULTRAVIST 300
+ BERLEX LABS 62.3% N20220 002 MAY 10, 1995
ULTRAVIST 370
+ BERLEX LABS 76.9% N20220 001 MAY 10, 1995

IOTHALAMATE MEGLUMINE

INJECTABLE; INJECTION
CONRAY
+ MALLINCKRODT 60% N13295 001
CONRAY 30
+ MALLINCKRODT 30% N16983 001
CONRAY 43
+ MALLINCKRODT 43% N13295 002

SOLUTION; INTRAVESICAL
CYSTO-CONRAY II
MALLINCKRODT 17.2% N17057 002

SOLUTION; INTRAVESICAL, URETERAL
CYSTO-CONRAY
MALLINCKRODT 43% N17057 001

IOTHALAMATE MEGLUMINE; IOTHALAMATE SODIUM

INJECTABLE; INJECTION
VASCORAY
+ MALLINCKRODT 52%;26% N16783 001

IOTHALAMATE SODIUM

INJECTABLE; INJECTION
CONRAY 325
+ MALLINCKRODT 54.3% N17685 001
CONRAY 400
+ MALLINCKRODT 66.8% N14295 001

IOTHALAMATE SODIUM; *MULTIPLE*
SEE IOTHALAMATE MEGLUMINE; IOTHALAMATE SODIUM

IOTHALAMATE SODIUM, I-125

INJECTABLE; INJECTION
GLOFIL-125
QUESTCOR PHARMS 250-300 uCi/ML N17279 001

IOVERSOL

INJECTABLE; INJECTION
OPTIRAY 160
+ MALLINCKRODT 34% N19710 003 DEC 30, 1988
OPTIRAY 240
+ MALLINCKRODT 51% N19710 002 DEC 30, 1988
+ 51% N20923 001 MAY 28, 1998
OPTIRAY 300
+ MALLINCKRODT 64% N19710 004 JAN 22, 1992
OPTIRAY 320
+ MALLINCKRODT 68% N19710 001 DEC 30, 1988
+ 68% N20923 002 MAY 29, 1998
OPTIRAY 350
+ MALLINCKRODT 74% N19710 005 JAN 22, 1992
+ 74% N20923 003 MAY 28, 1998

FDA data supplied by DrugPatentWatch.com

IOXAGLATE MEGLUMINE; IOXAGLATE SODIUM

INJECTABLE; INJECTION
HEXABRIX
+ MALLINCKRODT 39.3%;19.6% N18905 002 JUL 26, 1985

IOXAGLATE SODIUM; *MULTIPLE*
SEE IOXAGLATE MEGLUMINE; IOXAGLATE SODIUM

IOXILAN

INJECTABLE; INJECTION
OXILAN-300
COOK IMAGING 62% N20316 001 DEC 21, 1995

OXILAN-350
COOK IMAGING 73% N20316 002 DEC 21, 1995

IPODATE SODIUM

CAPSULE; ORAL
ORAGRAFIN SODIUM
+ BRACCO 500MG N12967 001

IPRATROPIUM BROMIDE

AEROSOL, METERED; INHALATION
ATROVENT
+ BOEHRINGER INGELHEIM 0.018MG/INH N19085 001 DEC 29, 1986

SOLUTION; INHALATION
ATROVENT
AN + BOEHRINGER INGELHEIM **0.02%** **N20228 001** SEP 29, 1993

IPRATROPIUM BROMIDE
AN ALPHARMA **0.02%** **N75111 001** APR 22, 1999
AN ASLUNG PHARM **0.02%** **N75693 001** JAN 26, 2001
AN BAUSCH AND LOMB **0.02%** **N75835 001** OCT 15, 2001

IPRATROPIUM BROMIDE

SOLUTION; INHALATION
IPRATROPIUM BROMIDE
AN DEY **0.02%** **N74755 001** JAN 10, 1997
AN IVAX PHARMS **0.02%** **N75313 001** FEB 07, 2000
AN NEPHRON **0.02%** **N75562 001** SEP 27, 2001
AN NOVEX **0.02%** **N75441 001** MAR 28, 2001
AN WARRICK PHARMS **0.02%** **N75507 001** JAN 19, 2001

SPRAY, METERED; NASAL
ATROVENT
+ BOEHRINGER INGELHEIM 0.021MG/SPRAY N20393 001 OCT 20, 1995
+ 0.042MG/SPRAY N20394 001 OCT 20, 1995

IPRATROPIUM BROMIDE; *MULTIPLE*
SEE ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

IRBESARTAN

TABLET; ORAL
AVAPRO
SANOFI SYNTHELABO 75MG N20757 001 SEP 30, 1997
150MG N20757 002 SEP 30, 1997
+ 300MG N20757 003 SEP 30, 1997

IRBESARTAN; *MULTIPLE*
SEE HYDROCHLOROTHIAZIDE; IRBESARTAN

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION
CAMPTOSAR
+ PHARMACIA AND UPJOHN 20MG/ML N20571 001 JUN 14, 1996

FDA data supplied by DrugPatentWatch.com

IRON DEXTRAN

INJECTABLE; INJECTION

	DEXFERRUM			
BP	LUITPOLD	EQ 50MG IRON/ML	N40024 001	FEB 23, 1996
	INFED			
BP	+ SCHEIN	EQ 50MG IRON/ML	N17441 001	
	PROFERDEX			
BP	NEW RIVER	EQ 50MG IRON/ML	N17807 001	

IRON SUCROSE

INJECTABLE; INTRAVENOUS

	VENOFER			
	+ LUITPOLD	EQ 20MG BASE/ML	N21135 001	NOV 06, 2000

ISOCARBOXAZID

TABLET; ORAL

	MARPLAN			
	+ OXFORD PHARM	10MG	N11961 001	

ISOETHARINE HYDROCHLORIDE

SOLUTION; INHALATION

	BETA-2			
AN	NEPHRON	**1%**	**N86711 001**	
	ISOETHARINE HCL			
	DEY	0.1%	N87389 001	
	INTL MEDICATION	0.08%	N86651 002	
		0.143%	N86651 004	
AN	+ ROXANE	**1%**	**N86899 001**	
	+	0.167%	N88226 001	SEP 16, 1983
	+	0.2%	N87324 001	

ISOFLURANE

LIQUID; INHALATION

	FORANE			
AN	+ BAXTER HLTHCARE CORP	**99.9%**	**N17624 001**	
	ISOFLURANE			
AN	ABBOTT	**99.9%**	**N74097 001**	JAN 25, 1993

ISOFLURANE

LIQUID; INHALATION

	ISOFLURANE			
AN	HALOCARBON PRODS	**99.9%**	**N75225 001**	OCT 20, 1999
AN	MARSAM PHARMS LLC	**99.9%**	**N74393 001**	MAY 12, 1995
AN	MINRAD	**99.9%**	**N74416 001**	SEP 30, 1994
AN	RHODIA	**99.9%**	**N74502 001**	JUN 27, 1995

ISONIAZID

INJECTABLE; INJECTION

	NYDRAZID			
	+ APOTHECON	100MG/ML	N08662 001	

SYRUP; ORAL

	ISONIAZID			
	+ CAROLINA MEDCL	50MG/5ML	N88235 001	NOV 10, 1983

TABLET; ORAL

	ISONIAZID			
AA	BARR	**100MG**	**N80936 001**	
AA		**300MG**	**N80937 002**	
AA	DANBURY PHARMA	**300MG**	**N80521 001**	
AA	DURAMED	**300MG**	**N88119 001**	MAR 17, 1983
AA	+ EON	**100MG**	**N08678 002**	
AA	+	**300MG**	**N08678 003**	
AA	HALSEY	**300MG**	**N83633 001**	
AA	MIKART	**100MG**	**N40090 001**	JUN 26, 1997
AA		**300MG**	**N40090 002**	JUN 26, 1997
AA	WEST WARD	**100MG**	**N80212 001**	
AA		**300MG**	**N87425 001**	
	LANIAZID			
AA	LANNETT	**100MG**	**N80140 002**	
AA		**300MG**	**N89776 001**	JUN 13, 1988
		50MG	N80140 001	

FDA data supplied by DrugPatentWatch.com

ISONIAZID; PYRAZINAMIDE; RIFAMPIN

TABLET; ORAL

	RIFATER			
+	AVENTIS PHARMS	50MG;300MG;120MG	N50705 001 MAY 31, 1994	

ISONIAZID; RIFAMPIN

CAPSULE; ORAL

	RIFAMATE			
+	AVENTIS PHARMS	150MG;300MG	N61884 001	

ISOPROTERENOL HYDROCHLORIDE

AEROSOL, METERED; INHALATION

	ISOPROTERENOL HCL			
+	3M	0.12MG/INH	N10375 004	

INJECTABLE; INJECTION

	ISOPROTERENOL HCL			
AP	ABBOTT	**0.2MG/ML**	**N83346 001**	
		0.02MG/ML	N83283 001	
AP	ELKINS SINN	**0.2MG/ML**	**N83486 001**	
AP	INTL MEDICATION	**0.2MG/ML**	**N83724 001**	
	ISUPREL			
AP +	ABBOTT	**0.2MG/ML**	**N10515 001**	

ISOPROTERENOL SULFATE

AEROSOL, METERED; INHALATION

	MEDIHALER-ISO			
+	3M	0.08MG/INH	N10375 003	

ISOSORBIDE

SOLUTION; ORAL

	ISMOTIC			
	ALCON	100GM/220ML	N17063 001	

ISOSORBIDE DINITRATE

CAPSULE, EXTENDED RELEASE; ORAL

	DILATRATE-SR			
BC	SCHWARZ PHARMA	40MG	N19790 001 SEP 02, 1988	
	ISORDIL			
BC +	WYETH AYERST	40MG	N12882 002 JUL 29, 1988	

TABLET; ORAL

	ISORDIL			
AB	WYETH AYERST	**5MG**	**N12093 007** JUL 29, 1988	
AB		**10MG**	**N12093 002** JUL 29, 1988	
AB		**20MG**	**N12093 006** JUL 29, 1988	
AB +		**30MG**	**N12093 005** JUL 29, 1988	
AB		**40MG**	**N12093 001** JUL 29, 1988	
	ISOSORBIDE DINITRATE			
AB	DANBURY PHARMA	**5MG**	**N86034 001** JAN 06, 1988	
AB		**10MG**	**N86032 001** JAN 07, 1988	
AB	GENEVA PHARMS	**5MG**	**N86221 001** JAN 07, 1988	
AB		**10MG**	**N86223 001** JAN 07, 1988	
AB		**20MG**	**N89367 001** APR 07, 1988	
AB	PAR PHARM	**5MG**	**N86923 001** MAR 12, 1987	
AB		**10MG**	**N86925 001** MAR 12, 1987	
AB		**20MG**	**N87537 001** OCT 02, 1987	
AB		**30MG**	**N87946 001** JAN 12, 1988	
AB	WEST WARD	**5MG**	**N86067 001** OCT 29, 1987	
AB		**10MG**	**N86066 001** OCT 29, 1987	
AB		**20MG**	**N88088 001** NOV 02, 1987	
	SORBITRATE			
AB	ASTRAZENECA	**20MG**	**N86405 002** AUG 21, 1990	

FDA data supplied by DrugPatentWatch.com

ISOSORBIDE DINITRATE

TABLET; ORAL

	SORBITRATE			
AB	ASTRAZENECA	40MG	N88125 001	AUG 21, 1990
BX		5MG	N16192 001	APR 01, 1996
BX		10MG	N16192 002	APR 01, 1996

TABLET; SUBLINGUAL

	ISORDIL			
AB	WYETH AYERST	2.5MG	N12940 004	JUL 29, 1988
AB		5MG	N12940 003	JUL 29, 1988
+		10MG	N12940 005	JUL 29, 1988
	ISOSORBIDE DINITRATE			
AB	DANBURY PHARMA	2.5MG	N86033 001	FEB 26, 1988
AB		5MG	N86031 001	SEP 29, 1987
AB	GENEVA PHARMS	2.5MG	N86225 001	FEB 19, 1988
AB		5MG	N86222 001	FEB 19, 1988
AB	WEST WARD	2.5MG	N86054 001	OCT 29, 1987
AB		5MG	N86055 001	NOV 02, 1987

TABLET, CHEWABLE; ORAL

	SORBITRATE			
	ASTRAZENECA	5MG	N16776 002	APR 01, 1996
+		10MG	N16776 003	APR 01, 1996

TABLET, EXTENDED RELEASE; ORAL

	ISOSORBIDE DINITRATE			
+	INWOOD LABS	40MG	N40009 001	DEC 30, 1998

ISOSORBIDE MONONITRATE

TABLET; ORAL

	ISMO			
AB	ROBINS AH	20MG	N19091 001	DEC 30, 1991
	ISOSORBIDE MONONITRATE			
AB	PUREPAC PHARM	10MG	N75037 002	OCT 30, 1998
AB		20MG	N75037 001	OCT 30, 1998
AB	TEVA	20MG	N75147 001	NOV 27, 1998
AB	WEST WARD	20MG	N75361 001	OCT 05, 2000
	MONOKET			
AB	SCHWARZ	10MG	N20215 002	JUN 30, 1993
AB +		20MG	N20215 001	JUN 30, 1993

TABLET, EXTENDED RELEASE; ORAL

	IMDUR			
AB +	SCHERING	30MG	N20225 001	AUG 12, 1993
AB +		60MG	N20225 002	AUG 12, 1993
AB +		120MG	N20225 003	MAR 30, 1995
	ISOSORBIDE MONONITRATE			
AB	BRIGHTSTONE	60MG	N75166 001	OCT 07, 1999
AB	DEXCEL LTD	60MG	N75522 001	APR 17, 2000
AB	ELAN PHARM	60MG	N75041 001	SEP 22, 1998
AB	IVAX PHARMS	30MG	N75448 002	AUG 07, 2001
AB		60MG	N75448 001	JUN 19, 2000
AB		120MG	N75448 003	AUG 07, 2001
AB	KREMERS URBAN	30MG	N75155 002	JAN 13, 2000
AB		60MG	N75155 001	OCT 30, 1998
AB		120MG	N75155 003	AUG 04, 2000

FDA data supplied by DrugPatentWatch.com

ISOSORBIDE MONONITRATE

TABLET, EXTENDED RELEASE; ORAL

	ISOSORBIDE MONONITRATE			
AB	KV PHARM	**30MG**	**N75395 001**	
			MAR 16, 2000	
AB		**60MG**	**N75395 002**	
			MAR 16, 2000	
AB		**120MG**	**N75395 003**	
			MAR 16, 2000	
AB	PUREPAC PHARM	**30MG**	**N75306 001**	
			DEC 31, 1998	
AB		**60MG**	**N75306 002**	
			DEC 31, 1998	

ISOSULFAN BLUE

INJECTABLE; INJECTION

	LYMPHAZURIN		
+	US SURGCL	1%	N18310 001

ISOTRETINOIN

CAPSULE; ORAL

	ACCUTANE		
	HLR	10MG	N18662 002
			MAY 07, 1982
+		20MG	N18662 004
			MAR 28, 1983
+		40MG	N18662 003
			MAY 07, 1982

ISRADIPINE

CAPSULE; ORAL

	DYNACIRC		
	NOVARTIS	2.5MG	N19546 001
			DEC 20, 1990
+		5MG	N19546 002
			DEC 20, 1990

TABLET, EXTENDED RELEASE; ORAL

	DYNACIRC CR		
+	NOVARTIS	5MG	N20336 001
			JUN 01, 1994

ISRADIPINE

TABLET, EXTENDED RELEASE; ORAL

	DYNACIRC CR		
+	NOVARTIS	10MG	N20336 002
			JUN 01, 1994

ITRACONAZOLE

CAPSULE; ORAL

	SPORANOX		
+	JANSSEN	100MG	N20083 001
			SEP 11, 1992

INJECTABLE; INJECTION

	SPORANOX		
+	JANSSEN	10MG/ML	N20966 001
			MAR 30, 1999

SOLUTION; ORAL

	SPORANOX		
+	JANSSEN	10MG/ML	N20657 001
			FEB 21, 1997

IVERMECTIN

TABLET; ORAL

	STROMECTOL		
	MERCK	3MG	N50742 002
			OCT 08, 1998
+		6MG	N50742 001
			NOV 22, 1996

KANAMYCIN SULFATE

CAPSULE; ORAL

	KANTREX		
+	APOTHECON	EQ 500MG BASE	N62726 001
			MAR 06, 1987

INJECTABLE; INJECTION

	KANTREX		
+	APOTHECON	EQ 75MG BASE/2ML	N61901 003
+		EQ 500MG BASE/2ML	N61901 001
+		EQ 1GM BASE/3ML	N61901 002

FDA data supplied by DrugPatentWatch.com

KETAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

	KETALAR			
AP	+ PARKEDALE	EQ 50MG BASE/ML	N16812 002	
AP	+	EQ 100MG BASE/ML	N16812 003	
	+	EQ 10MG BASE/ML	N16812 001	
	KETAMINE HCL			
AP	ABBOTT	EQ 50MG BASE/ML	N74549 001	JUN 27, 1996
AP		EQ 100MG BASE/ML	N74549 002	JUN 27, 1996
AP	BEDFORD	EQ 50MG BASE/ML	N74524 001	MAR 22, 1996
AP		EQ 100MG BASE/ML	N74524 002	MAR 22, 1996
AP	BIONICHE (CANADA)	EQ 50MG BASE/ML	N76092 002	DEC 28, 2001

KETOCONAZOLE

CREAM; TOPICAL

	KETOCONAZOLE			
AB	TEVA	2%	N75581 001	APR 25, 2000
	NIZORAL			
AB	+ JANSSEN	2%	N19084 001	DEC 31, 1985

SHAMPOO; TOPICAL

	NIZORAL			
	+ MCNEIL CONS	2%	N19927 001	AUG 31, 1990

TABLET; ORAL

	KETOCONAZOLE			
AB	APPLIED ANAL	200MG	N75341 001	JUL 27, 1999
AB	MUTUAL PHARMA	200MG	N75314 001	JUN 15, 1999
AB	MYLAN	200MG	N75597 001	DEC 23, 1999
AB	SIDMAK LABS	200MG	N75362 001	JUN 15, 1999
AB	TARO	200MG	N75319 001	JUN 15, 1999
AB	TEVA	200MG	N74971 001	JUN 15, 1999

KETOCONAZOLE

TABLET; ORAL

	KETOCONAZOLE			
AB	TEVA	200MG	N75273 001	JUN 15, 1999
	NIZORAL			
AB	+ JANSSEN	200MG	N18533 001	

KETOPROFEN

CAPSULE; ORAL

	KETOPROFEN			
AB	GENEVA PHARMS	50MG	N74024 001	DEC 29, 1995
AB		75MG	N74024 002	DEC 29, 1995
AB	LEDERLE	25MG	N74014 001	JAN 29, 1993
AB		50MG	N74014 002	JAN 29, 1993
AB		75MG	N74014 003	JAN 29, 1993
AB	MYLAN	50MG	N74035 002	DEC 31, 1996
AB		75MG	N74035 003	DEC 31, 1996
AB	TEVA	25MG	N73515 001	DEC 22, 1992
AB		50MG	N73516 001	DEC 22, 1992
AB		75MG	N73517 001	DEC 22, 1992
	ORUDIS			
AB	WYETH AYERST	25MG	N18754 001	JUL 31, 1987
AB		50MG	N18754 002	JAN 09, 1986
AB	+	75MG	N18754 003	JAN 09, 1986

CAPSULE, EXTENDED RELEASE; ORAL

	KETOPROFEN			
AB	ANDRX PHARMS	100MG	N75270 002	MAR 24, 1999
AB		150MG	N75270 003	MAR 24, 1999

FDA data supplied by DrugPatentWatch.com

KETOPROFEN

CAPSULE, EXTENDED RELEASE; ORAL

	KETOPROFEN			
AB	ANDRX PHARMS	200MG	N75270 001	MAR 24, 1999
AB	ELAN PHARM	200MG	N74879 001	DEC 10, 1997
	ORUVAIL			
AB	WYETH AYERST	100MG	N19816 003	FEB 08, 1995
AB		150MG	N19816 002	FEB 08, 1995
AB	+	200MG	N19816 001	SEP 24, 1993

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION

	KETOROLAC TROMETHAMINE			
AP	ABBOTT	15MG/ML	N74801 001	JUN 05, 1997
AP		15MG/ML	N74802 001	JUN 05, 1997
AP		15MG/ML	N74993 001	JAN 27, 1999
AP		30MG/ML	N74801 002	JUN 05, 1997
AP		30MG/ML	N74802 002	JUN 05, 1997
AP		30MG/ML	N74993 002	JAN 27, 1999
AP	APOTEX	15MG/ML	N75631 002	JUN 29, 2001
AP		30MG/ML	N75626 001	JUL 24, 2001
AP		30MG/ML	N75631 001	JUN 29, 2001
AP	BAXTER HLTHCARE CORP	15MG/ML	N75299 001	NOV 03, 1999
AP		30MG/ML	N75299 002	NOV 03, 1999
AP	BEDFORD	15MG/ML	N75222 001	APR 26, 1999
AP		30MG/ML	N75222 002	APR 26, 1999
AP		30MG/ML	N75228 001	APR 26, 1999

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION

	TORADOL			
AP	+ SYNTEX (USA) INC LLC	15MG/ML	N19698 001	NOV 30, 1989
AP	+	30MG/ML	N19698 002	NOV 30, 1989

SOLUTION/DROPS; OPHTHALMIC

	ACULAR			
+	ALLERGAN	0.5%	N19700 001	NOV 09, 1992
	ACULAR PRESERVATIVE FREE			
+	ALLERGAN	0.5%	N20811 001	NOV 03, 1997

TABLET; ORAL

	KETOROLAC TROMETHAMINE			
AB	MYLAN	10MG	N74761 001	MAY 16, 1997
AB	SIDMAK LABS	10MG	N75284 001	JUN 23, 1999
AB	TEVA	10MG	N74754 001	MAY 16, 1997
AB	WATSON LABS	10MG	N74955 001	SEP 19, 1997
	TORADOL			
AB	+ SYNTEX (USA) INC LLC	10MG	N19645 001	DEC 20, 1991

KETOTIFEN FUMARATE

SOLUTION/DROPS; OPHTHALMIC

	ZADITOR			
+	NOVARTIS	EQ 0.025% BASE	N21066 001	JUL 02, 1999

KRYPTON, KR-81M

GAS; INHALATION

	MPI KRYPTON 81M GAS GENERATOR			
	AMERSHAM HLTH	N/A	N18088 001	

FDA data supplied by DrugPatentWatch.com

LABETALOL HYDROCHLORIDE

INJECTABLE; INJECTION

	LABETALOL HCL			
AP	ABBOTT	5MG/ML	N75239 001	NOV 29, 1999
AP		5MG/ML	N75240 001	NOV 29, 1999
AP	BEDFORD	5MG/ML	N75303 001	MAY 28, 1999
AP	FAULDING	5MG/ML	N75242 001	SEP 30, 1999
AP	TAYLOR	5MG/ML	N75431 001	NOV 29, 1999
AP		5MG/ML	N75524 001	NOV 29, 1999
	NORMODYNE			
AP	+ SCHERING	5MG/ML	N18686 001	AUG 01, 1984
	TRANDATE			
AP	+ PROMETHEUS LABS	5MG/ML	N19425 001	DEC 31, 1985

TABLET; ORAL

	LABETALOL HCL			
AB	APOTHECON	100MG	N75223 001	NOV 20, 1998
AB		200MG	N75223 002	NOV 20, 1998
AB		300MG	N75223 003	NOV 20, 1998
AB	EON	100MG	N75113 001	AUG 04, 1998
AB		200MG	N75113 002	AUG 04, 1998
AB		300MG	N75113 003	AUG 04, 1998
AB	IVAX PHARMS	100MG	N74787 001	AUG 03, 1998
AB		200MG	N74787 002	AUG 03, 1998
AB		300MG	N74787 003	AUG 03, 1998
AB	MUTUAL PHARM	100MG	N75215 001	JUL 29, 1999
AB		200MG	N75215 002	JUL 29, 1999
AB		300MG	N75215 003	JUL 29, 1999

LABETALOL HYDROCHLORIDE

TABLET; ORAL

	LABETALOL HCL			
AB	TEVA	100MG	N74989 001	SEP 30, 1998
AB		200MG	N74989 002	SEP 30, 1998
AB		300MG	N74989 003	SEP 30, 1998
AB	WATSON LABS	100MG	N75133 001	AUG 03, 1998
AB		200MG	N75133 002	AUG 03, 1998
AB		300MG	N75133 003	AUG 03, 1998
	NORMODYNE			
AB	SCHERING	100MG	N18687 001	AUG 31, 1987
AB		200MG	N18687 002	AUG 01, 1984
AB	+	300MG	N18687 003	AUG 01, 1984
	TRANDATE			
AB	PROMETHEUS LABS	100MG	N18716 001	MAY 24, 1985
AB		200MG	N18716 002	AUG 01, 1984
AB		300MG	N18716 003	AUG 01, 1984

LACTULOSE

FOR SOLUTION; ORAL

	LACTULOSE			
	+ INALCO	10GM/PACKET	N74712 001	DEC 10, 1997
	+	20GM/PACKET	N74712 002	DEC 10, 1997

SOLUTION; ORAL

	CHRONULAC			
AA	+ AVENTIS PHARMS	10GM/15ML	N17884 001	
	CONSTILAC			
AA	ALRA	10GM/15ML	N71054 001	JUL 26, 1988
	CONSTULOSE			
AA	ALPHARMA	10GM/15ML	N70288 001	AUG 15, 1988

FDA data supplied by DrugPatentWatch.com

LACTULOSE

SOLUTION; ORAL

	EVALOSE			
AA	COPLEY PHARM	10GM/15ML	N73497 001	
			MAY 28, 1993	
	LACTULOSE			
AA	HI TECH PHARMA	10GM/15ML	N74076 001	
			JUL 03, 1995	
AA	LACHMAN CONSULT	10GM/15ML	N74138 001	
			SEP 30, 1992	
AA	MORTON GROVE	10GM/15ML	N74602 001	
			NOV 14, 1996	
AA	PHARM ASSOC	10GM/15ML	N74623 001	
			JUL 30, 1996	
AA	ROXANE	10GM/15ML	N73591 001	
			MAY 29, 1992	
AA	VINTAGE PHARMS	10GM/15ML	N75993 001	
			JUL 26, 2001	
	LAXILOSE			
AA	TECHNILAB	10GM/15ML	N73686 001	
			MAY 28, 1993	

SOLUTION; ORAL, RECTAL

	ACILAC			
AA	TECHNILAB	10GM/15ML	N73685 001	
			MAY 28, 1993	
	CEPHULAC			
AA	+ AVENTIS PHARMS	10GM/15ML	N17657 001	
	CHOLAC			
AA	ALRA	10GM/15ML	N71331 001	
			JUL 26, 1988	
	ENULOSE			
AA	ALPHARMA	10GM/15ML	N71548 001	
			AUG 15, 1988	
	GENERLAC			
AA	MORTON GROVE	10GM/15ML	N74603 001	
			OCT 31, 1996	
	HEPTALAC			
AA	COPLEY PHARM	10GM/15ML	N73504 001	
			MAY 28, 1993	
	LACTULOSE			
AA	HI TECH PHARMA	10GM/15ML	N74077 001	
			JUL 03, 1995	

LAMIVUDINE

SOLUTION; ORAL

	EPIVIR			
+	GLAXOSMITHKLINE	10MG/ML	N20596 001	
			NOV 17, 1995	
	EPIVIR-HBV			
+	GLAXOSMITHKLINE	5MG/ML	N21004 001	
			DEC 08, 1998	

TABLET; ORAL

	EPIVIR			
+	GLAXOSMITHKLINE	150MG	N20564 001	
			NOV 17, 1995	
	EPIVIR-HBV			
+	GLAXOSMITHKLINE	100MG	N21003 001	
			DEC 08, 1998	

LAMIVUDINE; *MULTIPLE*
SEE ABACAVIR SULFATE; LAMIVUDINE; ZIDOVUDINE

LAMIVUDINE; ZIDOVUDINE

TABLET; ORAL

	COMBIVIR			
+	GLAXOSMITHKLINE	150MG;300MG	N20857 001	
			SEP 26, 1997	

LAMOTRIGINE

TABLET; ORAL

	LAMICTAL			
	GLAXOSMITHKLINE	25MG	N20241 005	
			DEC 27, 1994	
		100MG	N20241 001	
			DEC 27, 1994	
		150MG	N20241 002	
			DEC 27, 1994	
+		200MG	N20241 003	
			DEC 27, 1994	

TABLET, CHEWABLE; ORAL

	LAMICTAL CD			
	GLAXOSMITHKLINE	2MG	N20764 004	
			SEP 08, 2000	

FDA data supplied by DrugPatentWatch.com

LAMOTRIGINE

TABLET, CHEWABLE; ORAL
LAMICTAL CD

	GLAXOSMITHKLINE	5MG	N20764 001 AUG 24, 1998
		25MG	N20764 002 AUG 24, 1998
+		100MG	N20764 003 AUG 24, 1998

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL
PREVACID

	TAP PHARM	15MG	N20406 001 MAY 10, 1995
+		30MG	N20406 002 MAY 10, 1995

FOR SUSPENSION, EXTENDED RELEASE; ORAL
PREVACID

	TAP PHARM	15MG/PACKET	N21281 001 MAY 03, 2001
+		30MG/PACKET	N21281 002 MAY 03, 2001

LANSOPRAZOLE; *MULTIPLE*
SEE AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE

LATANOPROST

SOLUTION/DROPS; OPHTHALMIC
XALATAN

+	PHARMACIA AND UPJOHN	0.005%	N20597 001 JUN 05, 1996

LEFLUNOMIDE

TABLET; ORAL
ARAVA

	AVENTIS PHARMS	10MG	N20905 001 SEP 10, 1998
		20MG	N20905 002 SEP 10, 1998

LEFLUNOMIDE

TABLET; ORAL
ARAVA

+	AVENTIS PHARMS	100MG	N20905 003 SEP 10, 1998

LEPIRUDIN

INJECTABLE; INJECTION
REFLUDAN

+	BERLEX LABS	50MG/VIAL	N20807 001 MAR 06, 1998

LETROZOLE

TABLET; ORAL
FEMARA

+	NOVARTIS	2.5MG	N20726 001 JUL 25, 1997

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION
LEUCOVORIN CALCIUM

AP		BEDFORD	**EQ 50MG BASE/VIAL**	**N89384 001** SEP 14, 1987
AP			**EQ 100MG BASE/VIAL**	**N89717 001** MAR 28, 1988
AP		ELKINS SINN	**EQ 50MG BASE/VIAL**	**N70480 001** JAN 02, 1987
AP			**EQ 100MG BASE/VIAL**	**N81224 001** JUN 03, 1994
AP		GENSIA SICOR PHARMS	**EQ 50MG BASE/VIAL**	**N81278 001** SEP 28, 1993
AP			**EQ 100MG BASE/VIAL**	**N81277 001** SEP 28, 1993
AP			**EQ 350MG BASE/VIAL**	**N40174 001** JUN 12, 1997
AP	+	IMMUNEX	**EQ 50MG BASE/VIAL**	**N08107 002**
AP	+		**EQ 100MG BASE/VIAL**	**N08107 004** MAY 23, 1988
AP	+		**EQ 350MG BASE/VIAL**	**N08107 005** APR 05, 1989
AP		PHARMACHEMIE	**EQ 350MG BASE/VIAL**	**N40262 001** DEC 15, 1999

FDA data supplied by DrugPatentWatch.com

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION

	LEUCOVORIN CALCIUM			
AP	PHARMACHEMIE USA	EQ 50MG BASE/VIAL	N89628 001	APR 17, 1997
AP		EQ 100MG BASE/VIAL	N89915 001	APR 17, 1997
	LEUCOVORIN CALCIUM PRESERVATIVE FREE			
AP	+ ABBOTT	EQ 10MG BASE/ML	N40147 001	JUN 25, 1997
AP	BEDFORD	EQ 10MG BASE/ML	N40347 001	APR 25, 2000
AP	+	EQ 200MG BASE/VIAL	N40056 001	MAY 23, 1995
AP		EQ 350MG BASE/VIAL	N40335 001	APR 20, 2000
AP	BIGMAR	EQ 200MG BASE/VIAL	N40258 001	FEB 26, 1999
	+	EQ 500MG BASE/VIAL	N40286 001	FEB 26, 1999
AP	GENSIA SICOR PHARMS	EQ 10MG BASE/ML	N40332 001	JUN 28, 1999
AP	LUITPOLD	EQ 50MG BASE/VIAL	N40338 001	JAN 31, 2001
	WELLCOVORIN			
	+ GLAXOSMITHKLINE	EQ 5MG BASE/ML	N87439 001	OCT 19, 1982

TABLET; ORAL

	LEUCOVORIN CALCIUM			
AB	BARR	EQ 5MG BASE	N71198 001	SEP 24, 1987
AB		EQ 25MG BASE	N71199 001	SEP 24, 1987
AB	GENEVA PHARMS TECH	EQ 15MG BASE	N75327 001	MAR 24, 1999
AB	IMMUNEX	EQ 10MG BASE	N71962 001	NOV 19, 1987
AB		EQ 15MG BASE	N71104 001	MAR 04, 1987
BX		EQ 5MG BASE	N18459 001	JAN 30, 1986
AB	PAR PHARM	EQ 5MG BASE	N74544 001	AUG 28, 1997
AB		EQ 25MG BASE	N74544 002	AUG 28, 1997
AB	PHARMACHEMIE	EQ 5MG BASE	N73099 001	MAR 28, 1997

LEUCOVORIN CALCIUM

TABLET; ORAL

	LEUCOVORIN CALCIUM			
AB	PHARMACHEMIE	EQ 25MG BASE	N73101 001	MAR 28, 1997
AB	ROXANE	EQ 5MG BASE	N72733 001	FEB 22, 1993
AB		EQ 10MG BASE	N72734 001	FEB 22, 1993
AB		EQ 15MG BASE	N72735 001	FEB 22, 1993
AB	+	EQ 25MG BASE	N72736 001	FEB 22, 1993

LEUPROLIDE ACETATE

IMPLANT; IMPLANTATION

	VIADUR			
	+ ALZA	EQ 65MG BASE	N21088 001	MAR 03, 2000

INJECTABLE; INJECTION

	LEUPROLIDE ACETATE			
AP	BEDFORD LABS	1MG/0.2ML	N74728 001	AUG 04, 1998
AP	GENSIA SICOR PHARMS	1MG/0.2ML	N75471 001	OCT 25, 2000
AP	GENZYME	1MG/0.2ML	N75721 001	NOV 29, 2001
	LUPRON			
AP	+ TAP PHARM	1MG/0.2ML	N19010 001	APR 09, 1985
	LUPRON DEPOT			
	+ TAP PHARM	3.75MG/VIAL	N20011 001	OCT 22, 1990
	+	7.5MG/VIAL	N19732 001	JAN 26, 1989
	+	22.5MG/VIAL	N20517 001	DEC 22, 1995
	LUPRON DEPOT-3			
	+ TAP PHARM	11.25MG/VIAL	N20708 001	MAR 07, 1997
	LUPRON DEPOT-4			
	+ TAP PHARM	30MG/VIAL	N20517 002	MAY 30, 1997
	LUPRON DEPOT-PED			
	+ TAP PHARM	7.5MG/VIAL	N20263 002	APR 16, 1993

FDA data supplied by DrugPatentWatch.com

LEUPROLIDE ACETATE

INJECTABLE; INJECTION

LUPRON DEPOT-PED

+	TAP PHARM	11.25MG/VIAL	N20263 005 JAN 21, 1994			
+		15MG/VIAL	N20263 006 JAN 21, 1994			

LEVALBUTEROL HYDROCHLORIDE

SOLUTION; INHALATION

XOPENEX

+	SEPRACOR	EQ 0.021% BASE	N20837 001 MAR 25, 1999
+		EQ 0.042% BASE	N20837 002 MAR 25, 1999

LEVAMISOLE HYDROCHLORIDE

TABLET; ORAL

ERGAMISOL

+	JANSSEN	EQ 50MG BASE	N20035 001 JUN 18, 1990

LEVETIRACETAM

TABLET; ORAL

KEPPRA

	UCB	250MG	N21035 001 NOV 30, 1999
		500MG	N21035 002 NOV 30, 1999
+		750MG	N21035 003 NOV 30, 1999

LEVOBETAXOLOL HYDROCHLORIDE

SUSPENSION/DROPS; OPHTHALMIC

BETAXON

+	ALCON	EQ 0.5% BASE	N21114 001 FEB 23, 2000

LEVOBUNOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

AKBETA

AT		AKORN	0.25%	**N74779 001**	OCT 29, 1996
AT			0.5%	**N74780 001**	OCT 29, 1996

BETAGAN

AT	+	ALLERGAN	0.25%	**N19814 001**	JUN 28, 1989
AT	+		0.5%	**N19219 002**	DEC 19, 1985

LEVOBUNOLOL HCL

AT		BAUSCH AND LOMB	0.25%	**N74307 001**	MAR 04, 1994
AT			0.5%	**N74326 001**	MAR 04, 1994
AT		FALCON PHARMS	0.25%	**N74851 001**	OCT 28, 1996
AT			0.5%	**N74850 001**	OCT 28, 1996
AT		NOVEX	0.25%	**N75473 001**	AUG 03, 2000
AT			0.5%	**N75475 001**	AUG 03, 2000

LEVOBUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CHIROCAINE

	PURDUE PHARMA LP	EQ 2.5MG BASE/ML	N20997 001 AUG 05, 1999
		EQ 5MG BASE/ML	N20997 002 AUG 05, 1999
+		EQ 7.5MG BASE/ML	N20997 003 AUG 05, 1999

LEVOCABASTINE HYDROCHLORIDE

SUSPENSION/DROPS; OPHTHALMIC

LIVOSTIN

+	NOVARTIS	EQ 0.05% BASE	N20219 001 NOV 10, 1993

FDA data supplied by DrugPatentWatch.com

LEVOCARNITINE

INJECTABLE; INJECTION

	CARNITOR			
AP	+ SIGMA TAU	**200MG/ML**	**N20182 001**	DEC 16, 1992
	LEVOCARNITINE			
AP	BEDFORD	**200MG/ML**	**N75567 001**	MAR 29, 2001
AP	GENSIA SICOR PHARMS	**200MG/ML**	**N75881 001**	MAR 29, 2001
AP	LUITPOLD	**200MG/ML**	**N75861 001**	JUN 22, 2001

SOLUTION; ORAL

CARNITOR			
+ SIGMA TAU	1GM/10ML	N18948 002	APR 27, 1988
+	1GM/10ML	N19257 001	APR 10, 1986

TABLET; ORAL

CARNITOR			
+ SIGMA TAU	330MG	N18948 001	DEC 27, 1985

LEVODOPA

TABLET; ORAL

LARODOPA			
ROCHE	100MG	N16912 005	
	250MG	N16912 003	
+	500MG	N16912 004	

LEVODOPA; *MULTIPLE*
SEE CARBIDOPA; LEVODOPA

LEVOFLOXACIN

INJECTABLE; INJECTION

LEVAQUIN			
+ JOHNSON RW	25MG/ML	N20635 001	DEC 20, 1996
LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER			
+ JOHNSON RW	5MG/ML	N20635 002	DEC 20, 1996

LEVOFLOXACIN

INJECTABLE; INJECTION

LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER			
+ JOHNSON RW	500MG/100ML	N20635 003	DEC 20, 1996

SOLUTION/DROPS; OPHTHALMIC

QUIXIN			
+ SANTEN	0.5%	N21199 001	AUG 18, 2000

TABLET; ORAL

LEVAQUIN			
JOHNSON RW	250MG	N20634 001	DEC 20, 1996
	500MG	N20634 002	DEC 20, 1996
+	750MG	N20634 003	SEP 08, 2000

LEVOMETHADYL ACETATE HYDROCHLORIDE

CONCENTRATE; ORAL

ORLAAM			
+ ROXANE	10MG/ML	N20315 001	JUL 09, 1993

LEVONORDEFRIN; MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

	CARBOCAINE W/ NEO-COBEFRIN			
AP	+ EASTMAN KODAK	**0.05MG/ML;2%**	**N12125 002**	
	ISOCAINE HCL W/ LEVONORDEFRIN			
AP	NOVOCOL	**0.05MG/ML;2%**	**N84697 001**	
	MEPIVACAINE HCL W/ LEVONORDEFRIN			
AP	GRAHAM CHEM	**0.05MG/ML;2%**	**N84850 002**	OCT 21, 1983
	POLOCAINE W/ LEVONORDEFRIN			
AP	DENTSPLY PHARM	**0.05MG/ML;2%**	**N89517 001**	APR 14, 1988
	SCANDONEST L			
AP	DEPROCO	**0.05MG/ML;2%**	**N88388 001**	OCT 10, 1984

FDA data supplied by DrugPatentWatch.com

LEVONORGESTREL

IMPLANT; IMPLANTATION
LEVONORGESTREL
BX + WYETH AYERST 75MG/IMPLANT N20627 001 AUG 15, 1996

NORPLANT II
BX POPULATION COUNCIL 75MG/IMPLANT N20544 001 NOV 01, 1996

NORPLANT SYSTEM IN PLASTIC CONTAINER
+ WYETH AYERST 36MG/IMPLANT N20088 001 DEC 10, 1990

INTRAUTERINE DEVICE; INTRAUTERINE
MIRENA
+ BERLEX LABS 52MG N21225 001 DEC 06, 2000

TABLET; ORAL
PLAN B
+ WOMENS CAPITAL 0.75MG N21045 001 JUL 28, 1999

LEVONORGESTREL; *MULTIPLE*
SEE ETHINYL ESTRADIOL; LEVONORGESTREL

LEVORPHANOL TARTRATE

INJECTABLE; INJECTION
LEVO-DROMORAN
+ ICN 2MG/ML N08719 001 DEC 19, 1991

TABLET; ORAL
LEVO-DROMORAN
AB + ICN **2MG** **N08720 001** DEC 19, 1991

LEVORPHANOL TARTRATE
AB ROXANE **2MG** **N74278 001** MAR 31, 2000

LEVOTHYROXINE SODIUM

TABLET; ORAL
LEVOXYL
BX JONES PHARMA 0.025MG N21301 001 MAY 25, 2001

LEVOTHYROXINE SODIUM

TABLET; ORAL
LEVOXYL
BX JONES PHARMA 0.05MG N21301 002 MAY 25, 2001
BX 0.075MG N21301 003 MAY 25, 2001
BX 0.088MG N21301 004 MAY 25, 2001
BX 0.1MG N21301 005 MAY 25, 2001
BX 0.112MG N21301 006 MAY 25, 2001
BX 0.125MG N21301 007 MAY 25, 2001
BX 0.137MG N21301 008 MAY 25, 2001
BX 0.15MG N21301 009 MAY 25, 2001
BX 0.175MG N21301 010 MAY 25, 2001
BX 0.2MG N21301 011 MAY 25, 2001
BX + 0.3MG N21301 012 MAY 25, 2001

UNITHROID
BX STEVENS J 0.025MG N21210 001 AUG 21, 2000
BX 0.05MG N21210 002 AUG 21, 2000
BX 0.075MG N21210 003 AUG 21, 2000
BX 0.088MG N21210 004 AUG 21, 2000
BX 0.1MG N21210 005 AUG 21, 2000
BX 0.112MG N21210 006 AUG 21, 2000
BX 0.125MG N21210 007 AUG 21, 2000
BX 0.15MG N21210 008 AUG 21, 2000
BX 0.175MG N21210 009 AUG 21, 2000
BX 0.2MG N21210 010 AUG 21, 2000
BX + 0.3MG N21210 011 AUG 21, 2000

FDA data supplied by DrugPatentWatch.com

LIDOCAINE

AEROSOL; ORAL
XYLOCAINE
+ ASTRAZENECA 10% N14394 001

FILM, EXTENDED RELEASE; BUCCAL
LIDOCAINE
+ NOVEN 23MG/PATCH N20575 001 MAY 21, 1996
+ 46.1MG/PATCH N20575 002 MAY 21, 1996

FILM, EXTENDED RELEASE; TOPICAL
LIDODERM
+ TEIKOKU PHARMA USA 700MG/12HR N20612 001 MAR 19, 1999

OINTMENT; TOPICAL
ALPHACAINE
AT CARLISLE **5%** **N84947 001**
LIDOCAINE
AT FOUGERA **5%** **N80198 001**
AT GRAHAM CHEM **5%** **N80210 001**
AT THAMES **5%** **N86724 001**
XYLOCAINE
AT + ASTRAZENECA **5%** **N08048 001**

SOLUTION; TOPICAL
XYLOCAINE
+ ASTRAZENECA 5% N14127 001

LIDOCAINE; *MULTIPLE*
SEE CEFTRIAXONE SODIUM; LIDOCAINE

LIDOCAINE; PRILOCAINE

CREAM; TOPICAL
EMLA
+ ASTRAZENECA 2.5%;2.5% N19941 001 DEC 30, 1992

DISC; TOPICAL
EMLA
+ ASTRAZENECA 2.5%;2.5% N20962 001 FEB 04, 1998

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
LIDOCAINE HCL
AP ABBOTT **0.5%** **N88328 001** MAY 17, 1984
AP **1%** **N40013 001** JUN 23, 1995
AP **1%** **N83158 001**
AP **1%** **N88329 001** MAY 17, 1984
AP **2%** **N40078 001** JUN 23, 1995
AP **2%** **N83158 002**
AP **2%** **N88294 001** MAY 17, 1984
AP **2%** **N88331 001** MAY 17, 1984
AP **20%** **N83158 003**
AP ELKINS SINN **1%** **N80407 001**
AP **2%** **N80407 002**
AP GRAHAM CHEM **2%** **N80504 001**
AP INTL MEDICATION **1%** **N83173 001**
AP **2%** **N83173 002**
AP LUITPOLD **1%** **N80850 001**
AP **2%** **N83198 001**
AP WYETH AYERST **1%** **N83083 001**
AP **2%** **N83083 002**

LIDOCAINE HCL 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER
AP B BRAUN **200MG/100ML** **N18967 001** MAR 30, 1984
AP **200MG/100ML** **N19830 002** APR 08, 1992
AP BAXTER HLTHCARE **200MG/100ML** **N18461 002**

LIDOCAINE HCL 0.2% IN DEXTROSE 5%
AP ABBOTT **200MG/100ML** **N83158 005**

LIDOCAINE HCL 0.2% IN DEXTROSE 5% IN PLASTIC CONTAINER
AP ABBOTT **200MG/100ML** **N18388 001**

LIDOCAINE HCL 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER
AP B BRAUN **400MG/100ML** **N18967 002** MAR 30, 1984
AP **400MG/100ML** **N19830 003** APR 08, 1992
AP BAXTER HLTHCARE **400MG/100ML** **N18461 003**

LIDOCAINE HCL 0.4% IN DEXTROSE 5%
AP ABBOTT **400MG/100ML** **N83158 006**

LIDOCAINE HCL 0.4% IN DEXTROSE 5% IN PLASTIC CONTAINER
AP ABBOTT **400MG/100ML** **N18388 002**

FDA data supplied by DrugPatentWatch.com

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HCL 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER

AP		B BRAUN	800MG/100ML	N18967 003
				MAR 30, 1984
AP			800MG/100ML	N19830 004
				APR 08, 1992
AP		BAXTER HLTHCARE	800MG/100ML	N18461 004
				FEB 22, 1982

LIDOCAINE HCL 0.8% IN DEXTROSE 5% IN PLASTIC CONTAINER

AP		ABBOTT	800MG/100ML	N18388 003
				NOV 05, 1982

LIDOCAINE HCL IN PLASTIC CONTAINER

AP		ABBOTT	0.5%	N88325 001
				JUL 31, 1984
AP			1%	N88299 001
				JUL 31, 1984
AP			1.5%	N88326 001
				JUL 31, 1984
AP			2%	N88327 001
				JUL 31, 1984
AP			10%	N88367 001
				JUL 31, 1984
AP			20%	N88368 001
				JUL 31, 1984
AP		AM PHARM PARTNERS	1%	N88586 001
				JUL 24, 1985

LIDOCAINE HCL PRESERVATIVE FREE

AP		ABBOTT	1%	N80408 001
AP			1.5%	N80408 002
AP			4%	N88295 001
				MAY 17, 1984
AP		AM PHARM PARTNERS	1%	N80404 002
AP			2%	N17584 001
AP			2%	N80404 003
AP			4%	N17584 002
AP		ELKINS SINN	1%	N84625 001
AP			2%	N84625 002
AP		INTL MEDICATION	20%	N17702 001

LIDOCAINE HCL PRESERVATIVE FREE IN PLASTIC CONTAINER

AP		ABBOTT	1%	N40302 001
				SEP 28, 1998
AP			2%	N40302 002
				SEP 28, 1998

LIDOPEN

AP		MERIDIAN MEDCL TECHN	10%	N17549 001

XYLOCAINE

AP	+	ASTRAZENECA	0.5%	N06488 008

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

XYLOCAINE

AP	+	ASTRAZENECA	1%	N06488 007
AP	+		1.5%	N06488 010
AP	+	DENTSPLY PHARM	2%	N21380 001

XYLOCAINE 4% PRESERVATIVE FREE

AP	+	ASTRAZENECA	4%	N10417 001

XYLOCAINE PRESERVATIVE FREE

AP		ASTRAZENECA	1%	N16801 005
				JAN 19, 1988
AP			2%	N16801 001
AP			4%	N16801 002
AP	+		10%	N16801 003
AP	+		20%	N16801 004

INJECTABLE; SPINAL

LIDOCAINE HCL 5% AND DEXTROSE 7.5%

AP		ABBOTT	5%	N83914 001

XYLOCAINE 1.5% W/ DEXTROSE 7.5%

	+	ASTRAZENECA	1.5%	N16297 001

XYLOCAINE 5% W/ GLUCOSE 7.5%

AP	+	ASTRAZENECA	5%	N10496 002
				JUL 07, 1982

JELLY; TOPICAL

LIDOCAINE HCL

AT		COPLEY PHARM	2%	N81318 001
				APR 29, 1993
AT		INTL MEDICATION	2%	N86283 001

XYLOCAINE

AT	+	ASTRAZENECA	2%	N08816 001

SOLUTION; ORAL

LIDOCAINE HCL

AT		HI TECH PHARMA	2%	N40014 001
				JUL 10, 1995
AT		MORTON GROVE	2%	N87872 001
				NOV 18, 1982

LIDOCAINE HCL VISCOUS

AT		ALPHARMA	2%	N86578 001

LIDOCAINE VISCOUS

AT		ROXANE	2%	N88802 001
				APR 26, 1985

XYLOCAINE VISCOUS

AT	+	ASTRAZENECA	2%	N09470 001

SOLUTION; TOPICAL

ANESTACON

AT	+	POLYMEDICA	2%	N80429 001

FDA data supplied by DrugPatentWatch.com

LIDOCAINE HYDROCHLORIDE

SOLUTION; TOPICAL

	LARYNG-O-JET KIT			
AT	INTL MEDICATION	4%	**N86364 001**	
	LIDOCAINE HCL			
AT	MORTON GROVE	4%	**N87881 001**	NOV 18, 1982
AT	ROXANE	4%	**N88803 001**	APR 03, 1985
	LTA II KIT			
AT	ABBOTT	4%	**N80409 001**	
AT		4%	**N88542 001**	JUL 31, 1984
	PEDIATRIC LTA KIT			
AT	ABBOTT	2%	**N85995 001**	
	XYLOCAINE 4% PRESERVATIVE FREE			
AT +	ASTRAZENECA	4%	**N10417 002**	

LIDOCAINE HYDROCHLORIDE; *MULTIPLE*

SEE DEXAMETHASONE SODIUM PHOSPHATE; LIDOCAINE HYDROCHLORIDE
SEE EPINEPHRINE; LIDOCAINE HYDROCHLORIDE
SEE EPINEPHRINE BITARTRATE; LIDOCAINE HYDROCHLORIDE

LIDOCAINE HYDROCHLORIDE; OXYTETRACYCLINE

INJECTABLE; INJECTION

TERRAMYCIN			
PFIZER	2%;50MG/ML	N60567 001	
	2%;125MG/ML	N60567 002	

LINCOMYCIN HYDROCHLORIDE

CAPSULE; ORAL

LINCOCIN			
PHARMACIA AND UPJOHN	EQ 250MG BASE	N50316 001	
+	EQ 500MG BASE	N50316 002	

INJECTABLE; INJECTION

LINCOCIN			
+ PHARMACIA AND UPJOHN	EQ 300MG BASE/ML	N50317 001	

LINDANE

LOTION; TOPICAL

	LINDANE			
AT +	ALPHARMA	1%	**N87313 001**	
AT	MORTON GROVE	1%	**N88190 001**	AUG 16, 1984

SHAMPOO; TOPICAL

	LINDANE			
AT +	ALPHARMA	1%	**N87266 001**	
AT	MORTON GROVE	1%	**N88191 001**	SEP 18, 1984

LINEZOLID

FOR SUSPENSION; ORAL

ZYVOX			
+ PHARMACIA AND UPJOHN	100MG/5ML	N21132 001	APR 18, 2000

INJECTABLE; INJECTION

ZYVOX			
+ PHARMACIA AND UPJOHN	200MG/100ML	N21131 001	APR 18, 2000

TABLET; ORAL

ZYVOX			
PHARMACIA AND UPJOHN	400MG	N21130 001	APR 18, 2000
+	600MG	N21130 002	APR 18, 2000

LIOTHYRONINE SODIUM

INJECTABLE; INJECTION

TRIOSTAT			
+ JONES PHARMA	EQ 0.01MG BASE/ML	N20105 001	DEC 31, 1991

TABLET; ORAL

CYTOMEL			
JONES PHARMA	EQ 0.005MG BASE	N10379 001	
	EQ 0.025MG BASE	N10379 002	
+	EQ 0.05MG BASE	N10379 003	

FDA data supplied by DrugPatentWatch.com

LIOTRIX (T4;T3)

TABLET; ORAL

	THYROLAR-0.25			
	FORREST LABS	0.0125MG;0.0031MG	N16807 001	
	THYROLAR-0.5			
	FORREST LABS	0.025MG;0.00625MG	N16807 005	
	THYROLAR-1			
	FORREST LABS	0.05MG;0.0125MG	N16807 004	
	THYROLAR-2			
	FORREST LABS	0.1MG;0.025MG	N16807 002	
	THYROLAR-3			
+	FORREST LABS	0.15MG;0.0375MG	N16807 003	

LISINOPRIL

TABLET; ORAL

	PRINIVIL			
AB	MERCK	**2.5MG**	**N19558 006**	
			JAN 28, 1994	
AB		**5MG**	**N19558 001**	
			DEC 29, 1987	
AB		**10MG**	**N19558 002**	
			DEC 29, 1987	
AB		**20MG**	**N19558 003**	
			DEC 29, 1987	
AB		**40MG**	**N19558 004**	
			OCT 25, 1988	
	ZESTRIL			
AB	ASTRAZENECA	**2.5MG**	**N19777 005**	
			APR 29, 1993	
AB		**5MG**	**N19777 001**	
			MAY 19, 1988	
AB		**10MG**	**N19777 002**	
			MAY 19, 1988	
AB		**20MG**	**N19777 003**	
			MAY 19, 1988	
AB	+	**40MG**	**N19777 004**	
			MAY 19, 1988	
		30MG	N19777 006	
			JAN 20, 1999	

LISINOPRIL; *MULTIPLE*
SEE HYDROCHLOROTHIAZIDE; LISINOPRIL

LITHIUM CARBONATE

CAPSULE; ORAL

	ESKALITH			
AB	GLAXOSMITHKLINE	**300MG**		**N16860 001**
	LITHIUM CARBONATE			
AB	ABLE	**300MG**		**N76121 001**
				SEP 27, 2001
AB	ROXANE	**300MG**		**N17812 001**
		150MG		N17812 002
				JAN 28, 1987
	+	600MG		N17812 003
				JAN 28, 1987

TABLET; ORAL

	LITHIUM CARBONATE			
AB	+ PFIZER	**300MG**		**N16834 001**
AB	ROXANE	**300MG**		**N18558 001**
				JAN 29, 1982

TABLET, EXTENDED RELEASE; ORAL

	ESKALITH CR		
+	GLAXOSMITHKLINE	450MG	N18152 001
			MAR 29, 1982
	LITHOBID		
+	SOLVAY	300MG	N18027 001

LITHIUM CITRATE

SYRUP; ORAL

	LITHIUM CITRATE			
AA	MORTON GROVE	**EQ 300MG CARBONATE/5ML**		**N70755 001**
				MAY 21, 1986
AA	+ ROXANE	**EQ 300MG CARBONATE/5ML**		**N18421 001**

LODOXAMIDE TROMETHAMINE

SOLUTION/DROPS; OPHTHALMIC

	ALOMIDE		
+	ALCON	EQ 0.1% BASE	N20191 001
			SEP 23, 1993

FDA data supplied by DrugPatentWatch.com

LOMEFLOXACIN HYDROCHLORIDE

TABLET; ORAL				
MAXAQUIN				
+ UNIMED PHARMS	EQ 400MG BASE	N20013 001		
		FEB 21, 1992		

LOMUSTINE

CAPSULE; ORAL				
CEENU				
BRISTOL MYERS SQUIBB	10MG	N17588 001		
	40MG	N17588 002		
+	100MG	N17588 003		

LOPERAMIDE HYDROCHLORIDE

CAPSULE; ORAL				
IMODIUM				
AB + MCNEIL CONS	**2MG**	**N17694 001**		
LOPERAMIDE HCL				
AB GENEVA PHARMS	**2MG**	**N72993 001**		
		AUG 28, 1992		
AB MYLAN	**2MG**	**N72741 001**		
		SEP 18, 1991		
AB TEVA	**2MG**	**N73122 001**		
		AUG 30, 1991		
AB	**2MG**	**N73192 001**		
		APR 30, 1992		

LOPINAVIR; RITONAVIR

CAPSULE; ORAL				
KALETRA				
+ ABBOTT	133.3MG;33.3MG	N21226 001		
		SEP 15, 2000		
SOLUTION; ORAL				
KALETRA				
+ ABBOTT	80MG/ML;20MG/ML	N21251 001		
		SEP 15, 2000		

LORACARBEF

CAPSULE; ORAL				
LORABID				
KING PHARMS	200MG	N50668 001		
		DEC 31, 1991		
+	400MG	N50668 002		
		APR 05, 1996		
FOR SUSPENSION; ORAL				
LORABID				
KING PHARMS	100MG/5ML	N50667 001		
		DEC 31, 1991		
+	200MG/5ML	N50667 002		
		DEC 31, 1991		

LORATADINE

SYRUP; ORAL				
CLARITIN				
+ SCHERING	1MG/ML	N20641 001		
		OCT 10, 1996		
TABLET; ORAL				
CLARITIN				
AB + SCHERING	**10MG**	**N19658 001**		
		APR 12, 1993		
TABLET, ORALLY DISINTEGRATING; ORAL				
CLARITIN REDITABS				
+ SCHERING	10MG	N20704 001		
		DEC 23, 1996		

LORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL				
CLARITIN-D				
+ SCHERING	5MG;120MG	N19670 001		
		NOV 14, 1994		
CLARITIN-D 24 HOUR				
+ SCHERING	10MG;240MG	N20470 001		
		AUG 23, 1996		

FDA data supplied by DrugPatentWatch.com

LORAZEPAM

CONCENTRATE; ORAL

	LORAZEPAM INTENSOL			
	ROXANE	2MG/ML	N72755 001	JUN 28, 1991

INJECTABLE; INJECTION

	ATIVAN			
AP	+ WYETH AYERST	**2MG/ML**	**N18140 001**	
AP	+	**4MG/ML**	**N18140 002**	
	LORAZEPAM			
AP	ABBOTT	**2MG/ML**	**N74243 001**	APR 12, 1994
AP		**2MG/ML**	**N74280 001**	MAY 27, 1994
AP		**2MG/ML**	**N74282 001**	MAY 27, 1994
AP		**2MG/ML**	**N74300 001**	APR 12, 1994
AP		**4MG/ML**	**N74243 002**	APR 12, 1994
AP		**4MG/ML**	**N74280 002**	MAY 27, 1994
AP		**4MG/ML**	**N74282 002**	MAY 27, 1994
AP		**4MG/ML**	**N74300 003**	MAR 19, 1997
AP	AKORN	**2MG/ML**	**N74974 001**	JUL 23, 1998
AP	ELKINS SINN	**2MG/ML**	**N74496 001**	SEP 28, 1998
AP		**4MG/ML**	**N74496 002**	SEP 28, 1998
AP	MARSAM PHARMS LLC	**2MG/ML**	**N74535 001**	SEP 12, 1996
AP		**2MG/ML**	**N74551 001**	SEP 12, 1996
AP		**1MG/0.5ML**	**N74551 003**	SEP 12, 1996
AP		**4MG/ML**	**N74535 002**	SEP 12, 1996
AP		**4MG/ML**	**N74551 002**	SEP 12, 1996
AP	MOVA	**2MG/ML**	**N74793 001**	MAR 16, 2000
AP		**4MG/ML**	**N74793 002**	MAR 16, 2000

LORAZEPAM

INJECTABLE; INJECTION

	LORAZEPAM			
AP	STERIS	**2MG/ML**	**N74276 001**	APR 15, 1994
AP		**4MG/ML**	**N74276 002**	APR 15, 1994
AP	TAYLOR	**2MG/ML**	**N75025 001**	JUL 23, 1998

SOLUTION; ORAL

	LORAZEPAM			
	+ ROXANE	0.5MG/5ML	N74648 001	MAR 18, 1997

TABLET; ORAL

	ATIVAN			
AB	WYETH AYERST	**0.5MG**	**N17794 001**	
AB		**1MG**	**N17794 002**	
AB	+	**2MG**	**N17794 003**	
	LORAZEPAM			
AB	DANBURY PHARMA	**0.5MG**	**N71117 001**	JUL 24, 1986
AB		**1MG**	**N71118 001**	JUL 24, 1986
AB		**2MG**	**N71110 001**	JUL 24, 1986
AB	GENEVA PHARMS	**0.5MG**	**N71193 001**	APR 15, 1988
AB		**1MG**	**N71194 001**	APR 15, 1988
AB		**2MG**	**N71195 001**	APR 15, 1988
AB	MUTUAL PHARM	**0.5MG**	**N72553 001**	MAR 29, 1991
AB		**1MG**	**N72554 001**	MAR 29, 1991
AB		**2MG**	**N72555 001**	MAR 29, 1991
AB	MYLAN	**0.5MG**	**N71589 001**	OCT 13, 1987
AB		**1MG**	**N71590 001**	OCT 13, 1987
AB		**2MG**	**N71591 001**	OCT 13, 1987
AB	PUREPAC PHARM	**0.5MG**	**N71403 001**	APR 21, 1987

FDA data supplied by DrugPatentWatch.com

LORAZEPAM

TABLET; ORAL
LORAZEPAM

AB	PUREPAC PHARM	1MG	**N71404 001** APR 21, 1987
AB		2MG	**N71141 001** APR 21, 1987
AB	RANBAXY	0.5MG	**N76045 001** AUG 29, 2001
AB		1MG	**N76045 002** AUG 29, 2001
AB		2MG	**N76045 003** AUG 29, 2001
AB	WATSON LABS	0.5MG	**N72926 001** OCT 31, 1991
AB		1MG	**N71087 001** MAR 23, 1987
AB		1MG	**N72927 001** OCT 31, 1991
AB		2MG	**N71088 001** MAR 23, 1987
AB		2MG	**N72928 001** OCT 31, 1991

LOSARTAN POTASSIUM

TABLET; ORAL
COZAAR

	MERCK	25MG	N20386 001 APR 14, 1995
		50MG	N20386 002 APR 14, 1995
+		100MG	N20386 003 OCT 13, 1998

LOSARTAN POTASSIUM; *MULTIPLE*
SEE HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

LOTEPREDNOL ETABONATE

SUSPENSION/DROPS; OPHTHALMIC
ALREX

+	BAUSCH AND LOMB	0.2%	N20803 001 MAR 09, 1998

LOTEPREDNOL ETABONATE

SUSPENSION/DROPS; OPHTHALMIC
LOTEMAX

+	BAUSCH AND LOMB	0.5%	N20583 001 MAR 09, 1998

LOVASTATIN

TABLET; ORAL
LOVASTATIN

AB	EON	10MG	**N75636 001** DEC 17, 2001
AB		20MG	**N75636 002** DEC 17, 2001
AB		40MG	**N75636 003** DEC 17, 2001
AB	GENEVA PHARMS	10MG	**N75300 001** DEC 17, 2001
AB		20MG	**N75300 002** DEC 17, 2001
AB		40MG	**N75300 003** DEC 17, 2001
AB	GENPHARM	10MG	**N75935 001** DEC 17, 2001
AB		20MG	**N75935 002** DEC 17, 2001
AB		40MG	**N75935 003** DEC 17, 2001
AB	MYLAN	10MG	**N75451 001** DEC 17, 2001
AB		20MG	**N75451 002** DEC 17, 2001
AB		40MG	**N75451 003** DEC 17, 2001
AB	PUREPAC PHARM	10MG	**N75828 001** DEC 17, 2001
AB		20MG	**N75828 002** DEC 17, 2001
AB		40MG	**N75828 003** DEC 17, 2001
AB	TEVA	10MG	**N75551 003** DEC 17, 2001
AB		20MG	**N75551 002** DEC 17, 2001
AB		40MG	**N75551 001** DEC 17, 2001

FDA data supplied by DrugPatentWatch.com

LOVASTATIN

TABLET; ORAL
MEVACOR

AB	MERCK	10MG	N19643 002	MAR 28, 1991
AB		20MG	N19643 003	AUG 31, 1987
AB	+	40MG	N19643 004	DEC 14, 1988

LOVASTATIN; NIACIN

TABLET, EXTENDED RELEASE; ORAL
ADVICOR

	KOS	20MG;500MG	N21249 001	DEC 17, 2001
		20MG;750MG	N21249 002	DEC 17, 2001
	+	20MG;1GM	N21249 003	DEC 17, 2001

LOXAPINE HYDROCHLORIDE

CONCENTRATE; ORAL
LOXITANE C

+	WATSON LABS	EQ 25MG BASE/ML	N17658 001

INJECTABLE; INJECTION
LOXITANE IM

+	WATSON LABS	EQ 50MG BASE/ML	N18039 001

LOXAPINE SUCCINATE

CAPSULE; ORAL
LOXAPINE SUCCINATE

AB	WATSON LABS	EQ 5MG BASE	N72204 001	JUN 15, 1988
AB		EQ 10MG BASE	N72205 001	JUN 15, 1988
AB		EQ 25MG BASE	N72206 001	JUN 15, 1988
AB		EQ 50MG BASE	N72062 001	JUN 15, 1988

LOXITANE

AB	WATSON LABS	EQ 5MG BASE	N17525 001

LOXAPINE SUCCINATE

CAPSULE; ORAL
LOXITANE

AB	WATSON LABS	EQ 10MG BASE	N17525 002	
AB	+	EQ 25MG BASE	N17525 003	
AB		EQ 50MG BASE	N17525 004	

MAFENIDE ACETATE

CREAM; TOPICAL
SULFAMYLON

+	BERTEK PHARMS	EQ 85MG BASE/GM	N16763 001

FOR SOLUTION; TOPICAL
SULFAMYLON

+	MYLAN	5%	N19832 003 JUN 05, 1998

MAGNESIUM ACETATE; *MULTIPLE*
SEE AMINO ACIDS; CALCIUM ACETATE; GLYCERIN; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE
SEE AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; POTASSIUM CHLORIDE; SODIUM ACETATE
SEE AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; SODIUM CHLORIDE
SEE AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE
SEE DEXTROSE; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE

MAGNESIUM ACETATE TETRAHYDRATE; *MULTIPLE*
SEE DEXTROSE; MAGNESIUM ACETATE TETRAHYDRATE; POTASSIUM ACETATE; SODIUM CHLORIDE

MAGNESIUM ACETATE TETRAHYDRATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION
PLASMA-LYTE 56 IN PLASTIC CONTAINER

	BAXTER HLTHCARE	32MG/100ML;128MG/100ML; 234MG/100ML	N19047 001 JUN 15, 1984

FDA data supplied by DrugPatentWatch.com

MAGNESIUM CARBONATE; *MULTIPLE*
SEE CITRIC ACID; GLUCONOLACTONE; MAGNESIUM CARBONATE

MAGNESIUM CHLORIDE; *MULTIPLE*
SEE AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE
SEE AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE
SEE AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE
SEE AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE
SEE AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE
SEE AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE
SEE AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE
SEE CALCIUM CHLORIDE; DEXTROSE; GLUTATHIONE DISULFIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE
SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE
SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE
SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE
SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE
SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE
SEE CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE
SEE CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE
SEE CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE
SEE CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE
SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE
SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS
SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE

MAGNESIUM CHLORIDE; *MULTIPLE*
SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS
SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE
SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INJECTION
ISOLYTE S PH 7.4 IN PLASTIC CONTAINER
B BRAUN 30MG/100ML;37MG/100ML;0.82MG/100ML; 370MG/100ML;530MG/100ML;500MG/100ML; 12MG/100ML N19696 001 SEP 29, 1989

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION
ISOLYTE S IN PLASTIC CONTAINER
AP B BRAUN **30MG/100ML;37MG/100ML;370MG/100ML; 530MG/100ML;500MG/100ML N18252 001**
AP **30MG/100ML;37MG/100ML;370MG/100ML; 530MG/100ML;500MG/100ML N19711 001** SEP 29, 1989

NORMOSOL-R IN PLASTIC CONTAINER
ABBOTT 30MG/100ML;37MG/100ML;222MG/100ML; 526MG/100ML;502MG/100ML N17586 001

PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER
AP BAXTER HLTHCARE **30MG/100ML;37MG/100ML;368MG/100ML; 526MG/100ML;502MG/100ML N17378 001**

PLASMA-LYTE A IN PLASTIC CONTAINER
AP BAXTER HLTHCARE **30MG/100ML;37MG/100ML;368MG/100ML; 526MG/100ML;502MG/100ML N17378 002** NOV 22, 1982

SOLUTION; IRRIGATION
PHYSIOLYTE IN PLASTIC CONTAINER
B BRAUN 30MG/100ML;37MG/100ML;370MG/100ML; 530MG/100ML;500MG/100ML N19024 001 JUN 08, 1984

FDA data supplied by DrugPatentWatch.com

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

SOLUTION; IRRIGATION
PHYSIOSOL IN PLASTIC CONTAINER
ABBOTT 30MG/100ML;37MG/100ML;222MG/100ML; 526MG/100ML;502MG/100ML N17637 002 JUL 08, 1982

PHYSIOSOL PH 7.4 IN PLASTIC CONTAINER
ABBOTT 30MG/100ML;37MG/100ML;222MG/100ML; 526MG/100ML;502MG/100ML N18406 002 JUL 08, 1982

MAGNESIUM OXIDE; *MULTIPLE*
SEE CITRIC ACID; MAGNESIUM OXIDE; SODIUM CARBONATE

MAGNESIUM SULFATE

INJECTABLE; INJECTION
MAGNESIUM SULFATE
AP ABBOTT **500MG/ML** **N75151 001** APR 25, 2000

AP + AM PHARM PARTNERS **500MG/ML** **N19316 001** SEP 08, 1986

MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER
\+ ABBOTT 1GM/100ML N20488 001 JUL 11, 1995

\+ 2GM/100ML N20488 002 JUL 11, 1995

MAGNESIUM SULFATE IN PLASTIC CONTAINER
\+ ABBOTT 4GM/100ML N20309 001 JUN 24, 1994

\+ 80MG/ML N20309 002 JUN 24, 1994

MAGNESIUM SULFATE; *MULTIPLE*
SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

MAGNESIUM SULFATE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM PHOSPHATE

SOLUTION; IRRIGATION
TIS-U-SOL
AT BAXTER HLTHCARE **20MG/100ML;40MG/100ML;6.25MG/100ML; 800MG/100ML;8.75MG/100ML** **N18508 001** FEB 19, 1982

TIS-U-SOL IN PLASTIC CONTAINER
AT BAXTER HLTHCARE **20MG/100ML;40MG/100ML;6.25MG/100ML; 800MG/100ML;8.75MG/100ML** **N18336 001**

MALATHION

LOTION; TOPICAL
OVIDE
\+ MEDICIS 0.5% N18613 001 AUG 02, 1982

MANGAFODIPIR TRISODIUM

INJECTABLE; INJECTION
TESLASCAN
\+ AMERSHAM HLTH 37.9MG/ML N20652 001 NOV 26, 1997

MANGANESE CHLORIDE

INJECTABLE; INJECTION
MANGANESE CHLORIDE IN PLASTIC CONTAINER
ABBOTT EQ 0.1MG MANGANESE/ML N18962 001 JUN 26, 1986

MANGANESE CHLORIDE TETRAHYDRATE

FOR SOLUTION; ORAL
LUMENHANCE
\+ BRACCO 3.49MG/GM N20686 001 DEC 19, 1997

MANNITOL

INJECTABLE; INJECTION
MANNITOL 10%
AP B BRAUN **10GM/100ML** **N16080 002**

FDA data supplied by DrugPatentWatch.com

MANNITOL

INJECTABLE; INJECTION

	MANNITOL 10% IN PLASTIC CONTAINER			
AP	ABBOTT	10GM/100ML	N19603 002	
			JAN 08, 1987	
AP	B BRAUN	10GM/100ML	N20006 002	
			JUL 26, 1993	
	MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER			
AP	B BRAUN	10GM/100ML	N16080 006	
	MANNITOL 15%			
AP	B BRAUN	15GM/100ML	N16080 003	
	MANNITOL 15% IN PLASTIC CONTAINER			
AP	ABBOTT	15GM/100ML	N19603 003	
			JAN 08, 1990	
AP	B BRAUN	15GM/100ML	N20006 003	
			JUL 26, 1993	
	MANNITOL 15% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.45%			
AP	B BRAUN	15GM/100ML	N16080 005	
	MANNITOL 20%			
AP	B BRAUN	20GM/100ML	N14738 001	
AP		20GM/100ML	N16080 004	
	MANNITOL 20% IN PLASTIC CONTAINER			
AP	ABBOTT	20GM/100ML	N19603 004	
			JAN 08, 1990	
AP	B BRAUN	20GM/100ML	N20006 004	
			JUL 26, 1993	
	MANNITOL 25%			
AP	ABBOTT	12.5GM/50ML	N16269 006	
			AUG 25, 1994	
AP	AM PHARM PARTNERS	12.5GM/50ML	N80677 001	
AP	ASTRAZENECA	12.5GM/50ML	N89239 001	
			MAY 06, 1987	
AP	INTL MEDICATION	12.5GM/50ML	N83051 001	
AP	LUITPOLD	12.5GM/50ML	N87409 001	
			JAN 21, 1982	
	MANNITOL 5%			
AP	B BRAUN	5GM/100ML	N16080 001	
	MANNITOL 5% IN PLASTIC CONTAINER			
AP	ABBOTT	5GM/100ML	N19603 001	
			JAN 08, 1987	
AP	B BRAUN	5GM/100ML	N20006 001	
			JUL 26, 1993	
	MANNITOL 5% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.12%			
AP	B BRAUN	5GM/100ML	N16080 007	
	OSMITROL 10% IN WATER			
AP	BAXTER HLTHCARE	10GM/100ML	N13684 002	
	OSMITROL 10% IN WATER IN PLASTIC CONTAINER			
AP	BAXTER HLTHCARE	10GM/100ML	N13684 006	

MANNITOL

INJECTABLE; INJECTION

	OSMITROL 15% IN WATER		
AP	BAXTER HLTHCARE	15GM/100ML	N13684 004
	OSMITROL 15% IN WATER IN PLASTIC CONTAINER		
AP	BAXTER HLTHCARE	15GM/100ML	N13684 008
	OSMITROL 20% IN WATER		
AP	BAXTER HLTHCARE	20GM/100ML	N13684 003
	OSMITROL 20% IN WATER IN PLASTIC CONTAINER		
AP	BAXTER HLTHCARE	20GM/100ML	N13684 007
	OSMITROL 5% IN WATER		
AP	BAXTER HLTHCARE	5GM/100ML	N13684 001
	OSMITROL 5% IN WATER IN PLASTIC CONTAINER		
AP	BAXTER HLTHCARE	5GM/100ML	N13684 005

SOLUTION; IRRIGATION

	RESECTISOL IN PLASTIC CONTAINER		
	B BRAUN	5GM/100ML	N16772 002

MANNITOL; SORBITOL

SOLUTION; IRRIGATION

	SORBITOL-MANNITOL IN PLASTIC CONTAINER		
AT	ABBOTT	540MG/100ML;2.7GM/100ML	N17636 001
AT		540MG/100ML;2.7GM/100ML	N18316 001

MAPROTILINE HYDROCHLORIDE

TABLET; ORAL

	LUDIOMIL			
AB	NOVARTIS	25MG	N17543 001	
AB	+	50MG	N17543 002	
AB		75MG	N17543 003	
			SEP 30, 1982	
	MAPROTILINE HCL			
AB	MYLAN	25MG	N72284 001	
			OCT 03, 1988	
AB		50MG	N72285 001	
			OCT 03, 1988	
AB		75MG	N72286 001	
			OCT 03, 1988	
AB	WATSON LABS	25MG	N72162 001	
			JUN 01, 1988	
AB		50MG	N72163 001	
			JUN 01, 1988	

FDA data supplied by DrugPatentWatch.com

MAPROTILINE HYDROCHLORIDE

TABLET; ORAL
MAPROTILINE HCL

AB	WATSON LABS	**75MG**	**N72164 001**		
			JUN 01, 1988		

MASOPROCOL

CREAM; TOPICAL
ACTINEX

+	UNIV AZ CANCER CTR	10%	N19940 001		
			SEP 04, 1992		

MAZINDOL

TABLET; ORAL
MAZANOR

BP	WYETH AYERST	1MG	N17980 002		

SANOREX

BP	NOVARTIS	1MG	N17247 001		
+		2MG	N17247 002		

MEBENDAZOLE

TABLET, CHEWABLE; ORAL
MEBENDAZOLE

AB	COPLEY PHARM	**100MG**	**N73580 001**		
			JAN 04, 1995		

VERMOX

AB	+ MCNEIL CONS	**100MG**	**N17481 001**		

MECAMYLAMINE HYDROCHLORIDE

TABLET; ORAL
INVERSINE

+	LAYTON	2.5MG	N10251 001		

MECHLORETHAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
MUSTARGEN

+	MERCK	10MG/VIAL	N06695 001		

MECLIZINE HYDROCHLORIDE

TABLET; ORAL
ANTIVERT

AA	+ PFIZER	**12.5MG**	**N10721 006**		
AA	+	**25MG**	**N10721 004**		
AA	+	**50MG**	**N10721 001**		
			JAN 20, 1982		

MECLIZINE HCL

AA	ABC HOLDING	**12.5MG**	**N85253 001**		
AA		**25MG**	**N85252 001**		
AA	BUNDY	**12.5MG**	**N84382 001**		
AA		**25MG**	**N84872 001**		
AA	GENEVA PHARMS	**12.5MG**	**N84843 002**		
			MAY 22, 1989		
AA		**25MG**	**N84092 003**		
			MAY 22, 1989		
AA	IVAX PHARMS	**12.5MG**	**N84975 001**		
AA		**25MG**	**N84657 001**		
AA	PAR PHARM	**12.5MG**	**N87127 001**		
AA		**25MG**	**N87128 001**		
AA		**50MG**	**N89674 001**		
			MAR 31, 1988		
AA	SIDMAK LABS NJ	**12.5MG**	**N88732 001**		
			DEC 11, 1985		
AA		**25MG**	**N88734 001**		
			DEC 11, 1985		
AA	VINTAGE PHARMS	**12.5MG**	**N40179 001**		
			JAN 30, 1997		
AA		**25MG**	**N40179 002**		
			JAN 30, 1997		
AA	WATSON LABS	**25MG**	**N85740 001**		

TABLET, CHEWABLE; ORAL
ANTIVERT

AA	+ PFIZER	**25MG**	**N10721 005**		

MECLIZINE HCL

AA	SIDMAK LABS NJ	**25MG**	**N88733 001**		
			DEC 11, 1985		

MECLOFENAMATE SODIUM

CAPSULE; ORAL
MECLOFENAMATE SODIUM

AB	DANBURY PHARMA	**EQ 50MG BASE**	**N71468 001**		
			APR 15, 1987		
AB		**EQ 100MG BASE**	**N71469 001**		
			APR 15, 1987		

FDA data supplied by DrugPatentWatch.com

MECLOFENAMATE SODIUM

CAPSULE; ORAL

	MECLOFENAMATE SODIUM			
AB	GENEVA PHARMS	EQ 50MG BASE	N72262 001	
			NOV 29, 1988	
AB		EQ 100MG BASE	N72263 001	
			NOV 29, 1988	
AB	MYLAN	EQ 50MG BASE	N71080 001	
			SEP 03, 1986	
AB		EQ 100MG BASE	N71081 001	
			SEP 03, 1986	
	MECLOMEN			
AB	PARKE DAVIS	EQ 50MG BASE	N18006 001	
AB +		EQ 100MG BASE	N18006 002	

MEDROXYPROGESTERONE ACETATE

INJECTABLE; INJECTION

	DEPO-PROVERA			
	+ PHARMACIA AND UPJOHN	150MG/ML	N20246 001	
			OCT 29, 1992	
	+	400MG/ML	N12541 003	

TABLET; ORAL

	AMEN			
BP	AMARIN PHARMS	10MG	N83242 001	
	MEDROXYPROGESTERONE ACETATE			
AB	BARR	2.5MG	N40159 001	
			AUG 09, 1996	
AB		5MG	N40159 002	
			AUG 09, 1996	
AB		10MG	N40159 003	
			AUG 09, 1996	
AB	DURAMED	2.5MG	N40311 001	
			DEC 01, 1999	
AB		5MG	N40311 002	
			DEC 01, 1999	
AB		10MG	N40311 003	
			DEC 01, 1999	
BP	USL PHARMA	10MG	N88484 001	
			JUL 26, 1984	
	PROVERA			
AB	PHARMACIA AND UPJOHN	2.5MG	N11839 001	
AB		5MG	N11839 003	
AB +		10MG	N11839 004	

MEDROXYPROGESTERONE ACETATE; *MULTIPLE*
SEE ESTRADIOL CYPIONATE; MEDROXYPROGESTERONE ACETATE

MEDROXYPROGESTERONE ACETATE; *MULTIPLE*
SEE ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE

MEDRYSONE

SUSPENSION; OPHTHALMIC

HMS			
+	ALLERGAN	1%	N16624 003

MEFENAMIC ACID

CAPSULE; ORAL

PONSTEL			
+	FIRST HORIZON	250MG	N15034 003

MEFLOQUINE HYDROCHLORIDE

TABLET; ORAL

LARIAM			
+	ROCHE	250MG	N19591 001
			MAY 02, 1989

MEGESTROL ACETATE

SUSPENSION; ORAL

	MEGACE			
AB +	BRISTOL MYERS SQUIBB	40MG/ML	N20264 001	
			SEP 10, 1993	
	MEGESTROL ACETATE			
AB	PAR PHARM	40MG/ML	N75671 001	
			JUL 25, 2001	

TABLET; ORAL

	MEGACE			
AB	BRISTOL MYERS SQUIBB	20MG	N16979 001	
AB +		40MG	N16979 002	
	MEGESTROL ACETATE			
AB	BARR	20MG	N74621 002	
			AUG 16, 1996	
AB		40MG	N74621 001	
			NOV 30, 1995	
AB	PAR PHARM	20MG	N72422 001	
			AUG 08, 1988	
AB		40MG	N72423 001	
			AUG 08, 1988	

FDA data supplied by DrugPatentWatch.com

MEGESTROL ACETATE

TABLET; ORAL

	MEGESTROL ACETATE			
AB	ROXANE	20MG	N74458 001	SEP 29, 1995
AB		40MG	N74458 002	SEP 29, 1995
AB	TEVA	40MG	N74745 001	FEB 27, 1998

MELOXICAM

TABLET; ORAL

	MOBIC			
	BOEHRINGER INGELHEIM	7.5MG	N20938 001	APR 13, 2000
+		15MG	N20938 002	AUG 23, 2000

MELPHALAN

TABLET; ORAL

	ALKERAN			
+	GLAXOSMITHKLINE	2MG	N14691 002	

MELPHALAN HYDROCHLORIDE

INJECTABLE; INJECTION

	ALKERAN			
+	GLAXOSMITHKLINE	EQ 50MG BASE/VIAL	N20207 001	NOV 18, 1992

MENOTROPINS (FSH;LH)

INJECTABLE; INJECTION

	PERGONAL			
BX +	SERONO	75 IU/AMP;75 IU/AMP	N17646 001	
BX +		150 IU/AMP;150 IU/AMP	N17646 002	MAY 20, 1985
	REPRONEX			
BX	FERRING	75 IU/VIAL;75 IU/VIAL	N21047 001	AUG 27, 1999
BX		150 IU/VIAL;150 IU/VIAL	N21047 002	AUG 27, 1999

MEPENZOLATE BROMIDE

TABLET; ORAL

	CANTIL			
+	AVENTIS PHARMS	25MG	N10679 003	

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

	DEMEROL			
AP +	ABBOTT	25MG/ML	N21171 001	
AP +		50MG/ML	N21171 002	
AP +		75MG/ML	N21171 003	
AP +		100MG/ML	N21171 004	
	MEPERIDINE HCL			
AP	ELKINS SINN	25MG/ML	N80445 001	
AP		50MG/ML	N80445 002	
AP		75MG/ML	N80445 003	
AP		100MG/ML	N80445 004	
AP	STERIS	50MG/ML	N73444 001	MAR 17, 1992
AP		100MG/ML	N73445 001	MAR 17, 1992
AP	WYETH AYERST	25MG/ML	N80455 007	
AP		50MG/ML	N80455 008	
AP		75MG/ML	N80455 009	
AP		100MG/ML	N80455 010	
	MEPERIDINE HCL PRESERVATIVE FREE			
AP +	ABBOTT	10MG/ML	N88432 001	AUG 16, 1984
AP	ASTRAZENECA	10MG/ML	N81002 001	JUL 30, 1993
AP	FAULDING	10MG/ML	N40305 001	MAR 10, 1999
AP	INTL MEDICATION	10MG/ML	N81309 001	AUG 30, 1993
AP	MALLINCKRODT	10MG/ML	N40163 001	MAY 12, 1997
AP	STERIS	10MG/ML	N73443 001	MAR 17, 1992

SYRUP; ORAL

	DEMEROL			
AA +	SANOFI SYNTHELABO	50MG/5ML	N05010 005	
	MEPERIDINE HCL			
AA	ROXANE	50MG/5ML	N88744 001	JAN 30, 1985

FDA data supplied by DrugPatentWatch.com

MEPERIDINE HYDROCHLORIDE

TABLET; ORAL

		DEMEROL			
AA	+	SANOFI SYNTHELABO	50MG	**N05010 001**	
AA	+		100MG	**N05010 004**	
		MEPERIDINE HCL			
AA		AMIDE PHARM	50MG	**N40331 001**	MAY 28, 1999
AA			100MG	**N40331 002**	MAY 28, 1999
AA		BARR	50MG	**N88639 001**	JUL 02, 1984
AA			100MG	**N88640 001**	SEP 19, 1984
AA		DURAMED	50MG	**N40318 001**	OCT 05, 1999
AA			100MG	**N40318 002**	OCT 05, 1999
AA		HALSEY	50MG	**N80448 001**	
AA			100MG	**N80448 002**	
AA		MALLINCKRODT	50MG	**N40352 001**	JUN 13, 2000
AA			100MG	**N40352 002**	JUN 13, 2000
AA		ROXANE	50MG	**N40110 001**	MAR 12, 1997
AA			100MG	**N40110 002**	MAR 12, 1997
AA		VINTAGE PHARMS	50MG	**N40191 001**	DEC 17, 1998
AA			100MG	**N40191 002**	DEC 17, 1998
AA		WATSON LABS	50MG	**N40186 001**	JUN 30, 1997
AA			100MG	**N40186 002**	JUN 30, 1997
AA		WYETH AYERST	50MG	**N80454 001**	

MEPERIDINE HYDROCHLORIDE; *MULTIPLE*
SEE ATROPINE SULFATE; MEPERIDINE HYDROCHLORIDE

MEPERIDINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

		MEPERGAN		
	+	WYETH AYERST	25MG/ML;25MG/ML	N11730 001

MEPHENTERMINE SULFATE

INJECTABLE; INJECTION

		WYAMINE SULFATE		
	+	WYETH AYERST	EQ 15MG BASE/ML	N08248 002

MEPHENYTOIN

TABLET; ORAL

		MESANTOIN		
	+	NOVARTIS	100MG	N06008 001

MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

		CARBOCAINE			
AP	+	EASTMAN KODAK	3%	**N12125 003**	
AP	+	STERLING WINTHROP	1%	**N12250 001**	
AP	+		1.5%	**N12250 005**	
AP	+		2%	**N12250 002**	
		ISOCAINE HCL			
AP		NOVOCOL	3%	**N80925 001**	
		MEPIVACAINE HCL			
AP		GRAHAM CHEM	3%	**N83559 001**	
AP		STERIS	1%	**N88769 001**	NOV 20, 1984
AP			2%	**N88770 001**	NOV 20, 1984
		POLOCAINE			
AP		ASTRAZENECA	1%	**N89407 001**	DEC 01, 1986
AP			2%	**N89410 001**	DEC 01, 1986
AP		DENTSPLY PHARM	3%	**N88653 001**	AUG 21, 1984
		POLOCAINE-MPF			
AP		ASTRAZENECA	1%	**N89406 001**	DEC 01, 1986
AP			1.5%	**N89408 001**	DEC 01, 1986
AP			2%	**N89409 001**	DEC 01, 1986
		SCANDONEST PLAIN			
AP		DEPROCO	3%	**N88387 001**	OCT 10, 1984

MEPIVACAINE HYDROCHLORIDE; *MULTIPLE*
SEE LEVONORDEFRIN; MEPIVACAINE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

MEPROBAMATE

TABLET; ORAL

		EQUANIL			
AA	+	WYETH AYERST	200MG	N10028	005
AA	+		400MG	N10028	004
		MEPROBAMATE			
AA		DANBURY PHARMA	200MG	N83304	001
AA			400MG	N83308	001
AA		EON	200MG	N14547	002
AA			400MG	N14547	001
AA		GENEVA PHARMS	400MG	N80655	001
AA		MYLAN	400MG	N83618	001
AA		ROXANE	600MG	N84332	001
AA		SCHERER LABS	400MG	N83343	001
AA		TABLICAPS	400MG	N83494	001
AA		WATSON LABS	200MG	N85720	001
AA			400MG	N85721	001
AA		WEST WARD	200MG	N15417	003
AA			400MG	N15417	002
		MILTOWN			
AA		WALLACE LABS	200MG	N09698	004
AA			400MG	N09698	002
AA	+	WALLACE PHARMS	600MG	N83919	001
		TRANMEP			
AA		SOLVAY	400MG	N16249	001

MEPROBAMATE; *MULTIPLE*
SEE ASPIRIN; MEPROBAMATE
SEE ESTROGENS, CONJUGATED; MEPROBAMATE

MEQUINOL; TRETINOIN

SOLUTION; TOPICAL

		SOLAGE		
	+	WESTWOOD SQUIBB	2%;0.01%	N20922 001 DEC 10, 1999

MERCAPTOPURINE

TABLET; ORAL

		PURINETHOL		
	+	GLAXOSMITHKLINE	50MG	N09053 002

MEROPENEM

INJECTABLE; INJECTION

		MERREM I.V.		
	+	ASTRAZENECA	500MG/VIAL	N50706 003 JUN 21, 1996
	+		1GM/VIAL	N50706 001 JUN 21, 1996

MESALAMINE

CAPSULE, EXTENDED RELEASE; ORAL

		PENTASA		
	+	SHIRE LABS	250MG	N20049 001 MAY 10, 1993

ENEMA; RECTAL

		ROWASA		
	+	SOLVAY	4GM/60ML	N19618 001 DEC 24, 1987

SUPPOSITORY; RECTAL

		CANASA		
	+	AXCAN SCANDIPHARM	500MG	N21252 001 JAN 05, 2001

TABLET, DELAYED RELEASE; ORAL

		ASACOL		
	+	PROCTER AND GAMBLE	400MG	N19651 001 JAN 31, 1992

MESNA

INJECTABLE; INTRAVENOUS

		MESNA		
AP		AM PHARM PARTNERS	100MG/ML	**N75811 001** APR 26, 2001
AP		GENSIA SICOR PHARMS	100MG/ML	**N75764 001** APR 27, 2001
		MESNEX		
AP	+	ASTA	100MG/ML	**N19884 001** DEC 30, 1988

MESNA; *MULTIPLE*
SEE IFOSFAMIDE; MESNA

FDA data supplied by DrugPatentWatch.com

MESORIDAZINE BESYLATE

CONCENTRATE; ORAL					
SERENTIL					
+ NOVARTIS	EQ 25MG BASE/ML	N16997 001			
INJECTABLE; INJECTION					
SERENTIL					
+ NOVARTIS	EQ 25MG BASE/ML	N16775 001			
TABLET; ORAL					
SERENTIL					
NOVARTIS	EQ 10MG BASE	N16774 001			
	EQ 25MG BASE	N16774 002			
	EQ 50MG BASE	N16774 003			
+	EQ 100MG BASE	N16774 004			

MESTRANOL; NORETHINDRONE

TABLET; ORAL-21			
NORETHIN 1/50M-21			
AB WATSON LABS	**0.05MG;1MG**	**N71539 001**	APR 12, 1988
NORETHINDRONE AND MESTRANOL			
AB WATSON LABS	**0.05MG;1MG**	**N70758 001**	JUL 01, 1988
NORINYL 1+50 21-DAY			
AB WATSON LABS	**0.05MG;1MG**	**N13625 002**	
ORTHO-NOVUM 1/50 21			
AB + JOHNSON RW	**0.05MG;1MG**	**N12728 004**	
TABLET; ORAL-28			
NORETHIN 1/50M-28			
AB WATSON LABS	**0.05MG;1MG**	**N71540 001**	APR 12, 1988
NORETHINDRONE AND MESTRANOL			
AB WATSON LABS	**0.05MG;1MG**	**N70759 001**	JUL 01, 1988
NORINYL 1+50 28-DAY			
AB GD SEARLE LLC	**0.05MG;1MG**	**N16659 001**	
ORTHO-NOVUM 1/50 28			
AB JOHNSON RW	**0.05MG;1MG**	**N16709 001**	

METAPROTERENOL SULFATE

AEROSOL, METERED; INHALATION			
ALUPENT			
+ BOEHRINGER INGELHEIM	0.65MG/INH	N16402 001	

METAPROTERENOL SULFATE

SOLUTION; INHALATION				
ALUPENT				
AN + BOEHRINGER INGELHEIM	**0.4%**	**N18761 002**	OCT 10, 1986
AN +	**0.6%**	**N18761 001**	JUN 30, 1983
+	5%	N17659 001	
METAPROTERENOL SULFATE			
AN DEY	**0.4%**	**N71786 001**	AUG 05, 1988
AN	**0.6%**	**N70804 001**	AUG 17, 1987
AN NEPHRON	**0.4%**	**N71855 001**	JUL 14, 1988
AN	**0.6%**	**N71726 001**	JUL 14, 1988
AN NOVEX	**0.4%**	**N75402 001**	FEB 28, 2001
AN	**0.6%**	**N75403 001**	FEB 28, 2001
SYRUP; ORAL			
METAPROTERENOL SULFATE			
AA + MORTON GROVE	**10MG/5ML**	**N74702 001**	MAR 24, 1997
AA NOVEX	**10MG/5ML**	**N75235 001**	JAN 27, 2000
AA SILARX	**10MG/5ML**	**N73632 001**	JUL 22, 1992
TABLET; ORAL			
ALUPENT			
AB BOEHRINGER INGELHEIM	**10MG**	**N15874 002**	
AB +	**20MG**	**N15874 001**	
METAPROTERENOL SULFATE			
AB DANBURY PHARMA	**10MG**	**N73013 001**	JAN 31, 1991
AB	**20MG**	**N72795 001**	JAN 31, 1991
AB PAR PHARM	**10MG**	**N72024 001**	JUN 28, 1988
AB	**20MG**	**N72025 001**	JUN 28, 1988
AB TEVA	**10MG**	**N72519 001**	MAR 30, 1990
AB	**20MG**	**N72520 001**	MAR 30, 1990

FDA data supplied by DrugPatentWatch.com

METARAMINOL BITARTRATE

INJECTABLE; INJECTION

	ARAMINE			
AP	+ MERCK	EQ 10MG BASE/ML	N09509 002	
			DEC 22, 1987	
	METARAMINOL BITARTRATE			
AP	AM PHARM PARTNERS	EQ 10MG BASE/ML	N80722 001	

METAXALONE

TABLET; ORAL

	SKELAXIN		
	+ CARNRICK	400MG	N13217 001

METFORMIN HYDROCHLORIDE

TABLET; ORAL

	GLUCOPHAGE		
	BRISTOL MYERS SQUIBB	500MG	N20357 001
			MAR 03, 1995
		850MG	N20357 002
			MAR 03, 1995
	+	1GM	N20357 005
			NOV 05, 1998

TABLET, EXTENDED RELEASE; ORAL

	GLUCOPHAGE XR		
	+ BRISTOL MYERS SQUIBB	500MG	N21202 001
			OCT 13, 2000

METFORMIN HYDROCHLORIDE; *MULTIPLE*
SEE GLYBURIDE; METFORMIN HYDROCHLORIDE

METHACHOLINE CHLORIDE

FOR SOLUTION; INHALATION

	PROVOCHOLINE		
	METHAPHARM	100MG/VIAL	N19193 001
			OCT 31, 1986

METHADONE HYDROCHLORIDE

CONCENTRATE; ORAL

	METHADONE HCL		
AA	ROXANE	**10MG/ML**	**N40180 001**
			APR 30, 1998
AA	UDL	**10MG/ML**	**N40088 001**
			NOV 30, 1994
	METHADONE HCL INTENSOL		
AA	ROXANE	**10MG/ML**	**N89897 001**
			SEP 06, 1988
	METHADOSE		
AA	+ MALLINCKRODT	**10MG/ML**	**N17116 002**

INJECTABLE; INJECTION

	DOLOPHINE HCL		
	+ ROXANE	10MG/ML	N06134 006

POWDER; FOR RX COMPOUNDING

	METHADONE HCL		
	MALLINCKRODT	50GM/BOT	N06383 002
		100GM/BOT	N06383 003
		500GM/BOT	N06383 004

SOLUTION; ORAL

	METHADONE HCL		
	+ ROXANE	5MG/5ML	N87393 001
	+	10MG/5ML	N87997 001
			AUG 30, 1982

SYRUP; ORAL

	DOLOPHINE HCL		
	+ ROXANE	10MG/30ML	N06134 004

TABLET; ORAL

	DOLOPHINE HCL		
AA	+ ROXANE	**5MG**	**N06134 002**
AA	+	**10MG**	**N06134 010**
	METHADONE HCL		
AA	EON	**5MG**	**N40241 001**
			MAY 29, 1998
AA		**10MG**	**N40241 002**
			MAY 29, 1998
AA		**40MG**	**N75082 001**
			MAR 25, 1998
AA	ROXANE	**5MG**	**N88108 001**
			MAR 08, 1983
AA		**10MG**	**N88109 001**
			MAR 08, 1983

FDA data supplied by DrugPatentWatch.com

METHADONE HYDROCHLORIDE

TABLET; ORAL

	METHADONE HCL				
AA	+ ROXANE	**40MG**	**N17058 001**		
AA		**40MG**	**N74081 001**		
			APR 28, 1995		
	METHADOSE				
AA	MALLINCKRODT	**5MG**	**N40050 001**		
			APR 15, 1993		
AA		**10MG**	**N40050 002**		
			APR 15, 1993		
AA		**40MG**	**N74184 001**		
			APR 29, 1993		

METHAMPHETAMINE HYDROCHLORIDE

TABLET; ORAL

	DESOXYN		
	+ ABBOTT	5MG	N05378 002

TABLET, EXTENDED RELEASE; ORAL

	DESOXYN		
	+ ABBOTT	5MG	N05378 004
	+	10MG	N05378 003
	+	15MG	N05378 005

METHANTHELINE BROMIDE

TABLET; ORAL

	BANTHINE		
	+ SHIRE LABS	50MG	N07390 001

METHAZOLAMIDE

TABLET; ORAL

	METHAZOLAMIDE				
AB	COPLEY PHARM	**25MG**	**N40001 001**		
			JUN 30, 1993		
AB		**50MG**	**N40001 002**		
			JUN 30, 1993		
AB	GENEVA PHARMS	**25MG**	**N40036 001**		
			JUN 30, 1993		
AB		**50MG**	**N40036 002**		
			JUN 30, 1993		

METHAZOLAMIDE

TABLET; ORAL

	METHAZOLAMIDE				
AB	INVAMED	**25MG**	**N40102 001**		
			AUG 28, 1996		
AB		**50MG**	**N40102 002**		
			AUG 28, 1996		
AB	MIKART	**25MG**	**N40062 001**		
			JAN 27, 1994		
AB		**50MG**	**N40062 002**		
			JAN 27, 1994		
	NEPTAZANE				
AB	LEDERLE	**25MG**	**N11721 002**		
			NOV 25, 1991		
AB	+	**50MG**	**N11721 001**		

METHENAMINE HIPPURATE

TABLET; ORAL

	HIPREX				
AB	+ AVENTIS PHARMS	**1GM**	**N17681 001**		
	UREX				
AB	3M	**1GM**	**N16151 001**		

METHIMAZOLE

TABLET; ORAL

	METHIMAZOLE				
AB	EON	**5MG**	**N40411 001**		
			MAR 27, 2001		
AB		**10MG**	**N40411 002**		
			MAR 27, 2001		
AB	GENPHARM	**5MG**	**N40350 001**		
			MAR 29, 2000		
AB		**10MG**	**N40350 002**		
			MAR 29, 2000		
	+	20MG	N40350 003		
			JUN 07, 2001		
AB	JONES PHARMA	**5MG**	**N40320 001**		
			MAR 31, 2000		
AB		**10MG**	**N40320 002**		
			MAR 31, 2000		
	TAPAZOLE				
AB	LILLY	**5MG**	**N07517 002**		
AB	+	**10MG**	**N07517 004**		

FDA data supplied by DrugPatentWatch.com

METHOCARBAMOL

INJECTABLE; INJECTION

	METHOCARBAMOL				
AP	STERIS	100MG/ML	N86459	001	
	ROBAXIN				
AP	+ ROBINS AH	100MG/ML	N11790	001	

TABLET; ORAL

	METHOCARBAMOL				
AA	DANBURY PHARMA	500MG	N84277	001	
AA		750MG	N84276	002	
AA	EON	500MG	N87283	001	
AA		750MG	N87282	001	
AA	GENEVA PHARMS	500MG	N84616	001	
AA		750MG	N84615	001	
AA	IMPAX LABS	500MG	N84927	001	
AA		750MG	N84928	001	
AA	LANNETT	750MG	N84756	001	
AA	LEDERLE	500MG	N85961	001	
AA		750MG	N85963	001	
AA	NYLOS	750MG	N85033	001	
AA	PAR PHARM	500MG	N86989	001	
AA		750MG	N86988	001	
AA	SUPERPHARM	500MG	N87589	001	JAN 22, 1982
AA		750MG	N87590	001	JAN 22, 1982
AA	TABLICAPS	500MG	N84846	001	
AA	WATSON LABS	500MG	N85180	001	
AA		750MG	N85192	001	
AA	WEST WARD	500MG	N85159	001	
AA		750MG	N85123	001	
	ROBAXIN				
AA	+ SCHWARZ PHARMA	500MG	N11011	004	
	ROBAXIN-750				
AA	+ SCHWARZ PHARMA	750MG	N11011	006	

METHOCARBAMOL; *MULTIPLE*
SEE ASPIRIN; METHOCARBAMOL

METHOHEXITAL SODIUM

INJECTABLE; INJECTION

	BREVITAL SODIUM				
	+ LILLY	500MG/VIAL	N11559	001	
	+	2.5GM/VIAL	N11559	002	

METHOHEXITAL SODIUM

INJECTABLE; INJECTION

	BREVITAL SODIUM				
	+ LILLY	5GM/VIAL	N11559	003	

METHOTREXATE SODIUM

INJECTABLE; INJECTION

	FOLEX				
AP	PHARMACIA AND UPJOHN	EQ 50MG BASE/VIAL	N87695	002	APR 08, 1983
AP		EQ 100MG BASE/VIAL	N87695	003	APR 08, 1983
		EQ 25MG BASE/VIAL	N87695	001	APR 08, 1983
		EQ 250MG BASE/VIAL	N88954	001	OCT 24, 1985
	METHOTREXATE				
AP	BIGMAR	EQ 25MG BASE/ML	N40263	001	FEB 26, 1999
	METHOTREXATE LPF				
AP	+ LEDERLE	EQ 25MG BASE/ML	N11719	007	MAR 31, 1982
	METHOTREXATE PRESERVATIVE FREE				
AP	BIGMAR	EQ 1GM BASE/VIAL	N40266	001	FEB 26, 1999
AP		EQ 25MG BASE/ML	N40265	001	FEB 26, 1999
	METHOTREXATE SODIUM				
AP	BEDFORD	EQ 25MG BASE/ML	N89340	001	SEP 16, 1986
AP		EQ 25MG BASE/ML	N89341	001	SEP 16, 1986
AP		EQ 25MG BASE/ML	N89342	001	SEP 16, 1986
AP		EQ 25MG BASE/ML	N89343	001	SEP 16, 1986
AP	+ LEDERLE	EQ 25MG BASE/ML	N11719	005	
AP	+	EQ 50MG BASE/VIAL	N11719	003	
AP	+	EQ 100MG BASE/VIAL	N11719	006	
	+	EQ 2.5MG BASE/ML	N11719	004	
	+	EQ 20MG BASE/VIAL	N11719	001	
AP	NORBROOK	EQ 25MG BASE/ML	N88648	001	MAY 09, 1986
AP	PHARMACHEMIE USA	EQ 25MG BASE/ML	N89158	001	JUL 08, 1988

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION DRUG PRODUCT LIST

METHOTREXATE SODIUM

INJECTABLE; INJECTION

	METHOTREXATE SODIUM PRESERVATIVE FREE			
AP	+ LEDERLE	**EQ 1GM BASE/VIAL**	**N11719 009**	
			APR 07, 1988	
	MEXATE-AQ			
AP	BRISTOL MYERS	**EQ 25MG BASE/ML**	**N88760 001**	
			FEB 14, 1985	

TABLET; ORAL

	METHOTREXATE SODIUM			
AB	BARR	**EQ 2.5MG BASE**	**N81099 001**	
			OCT 15, 1990	
AB	DURAMED	**EQ 2.5MG BASE**	**N40233 001**	
			JUN 17, 1999	
AB	+ LEDERLE	**EQ 2.5MG BASE**	**N08085 002**	
AB	MYLAN	**EQ 2.5MG BASE**	**N81235 001**	
			MAY 15, 1992	
AB	ROXANE	**EQ 2.5MG BASE**	**N40054 001**	
			AUG 01, 1994	
	TREXALL			
	BARR	EQ 5MG BASE	N40385 001	
			MAR 21, 2001	
		EQ 7.5MG BASE	N40385 002	
			MAR 21, 2001	
		EQ 10MG BASE	N40385 003	
			MAR 21, 2001	
	+	EQ 15MG BASE	N40385 004	
			MAR 21, 2001	

METHOXSALEN

CAPSULE; ORAL

	8-MOP		
	+ ICN	10MG	N09048 001
	OXSORALEN-ULTRA		
	+ ICN	10MG	N19600 001
			OCT 30, 1986

INJECTABLE; INJECTION

	UVADEX		
	+ THERAKOS	0.02MG/ML	N20969 001
			FEB 25, 1999

LOTION; TOPICAL

	OXSORALEN		
	+ ICN	1%	N09048 002

METHSCOPOLAMINE BROMIDE

TABLET; ORAL

	PAMINE		
	+ BRADLEY PHARMS	2.5MG	N08848 001

METHSUXIMIDE

CAPSULE; ORAL

	CELONTIN		
	PARKE DAVIS	150MG	N10596 007
	+	300MG	N10596 008

METHYCLOTHIAZIDE

TABLET; ORAL

	AQUATENSEN			
AB	WALLACE LABS	**5MG**	**N17364 001**	
	ENDURON			
AB	ABBOTT	**2.5MG**	**N12524 001**	
AB	+	**5MG**	**N12524 004**	
	METHYCLOTHIAZIDE			
AB	GENEVA PHARMS	**2.5MG**	**N89835 001**	
			AUG 18, 1988	
AB		**5MG**	**N89837 001**	
			AUG 18, 1988	
AB	IVAX PHARMS	**2.5MG**	**N87913 001**	
			JUN 03, 1982	
AB	MYLAN	**5MG**	**N87672 001**	
			AUG 17, 1982	
AB	WATSON LABS	**5MG**	**N88724 001**	
			SEP 06, 1984	

METHYCLOTHIAZIDE; *MULTIPLE*

SEE DESERPIDINE; METHYCLOTHIAZIDE

METHYCLOTHIAZIDE; RESERPINE

TABLET; ORAL

	DIUTENSEN-R		
	+ WALLACE LABS	2.5MG;0.1MG	N12708 005

FDA data supplied by DrugPatentWatch.com

METHYLDOPA

SUSPENSION; ORAL

	ALDOMET			
+	MERCK	250MG/5ML	N18389 001	

TABLET; ORAL

	ALDOMET			
AB	MERCK	125MG	N13400 003	
AB		250MG	N13400 001	
AB	+	500MG	N13400 002	
	METHYLDOPA			
AB	DANBURY PHARMA	250MG	N70703 001	JUN 06, 1986
AB		500MG	N70625 001	JUN 06, 1986
AB	GENEVA PHARMS	125MG	N71700 001	MAR 02, 1988
AB		250MG	N18934 001	JUN 29, 1984
AB		500MG	N18934 002	JUN 29, 1984
AB	IVAX PHARMS	250MG	N70098 001	FEB 20, 1986
AB		500MG	N70343 001	FEB 20, 1986
AB	LEDERLE	250MG	N70084 001	OCT 15, 1985
AB		500MG	N70085 001	OCT 15, 1985
AB	MYLAN	250MG	N70075 001	APR 18, 1985
AB		500MG	N70076 001	APR 18, 1985
AB	PAR PHARM	125MG	N70535 001	JAN 02, 1987
AB		250MG	N70536 001	JAN 02, 1987
AB		500MG	N70537 001	JAN 02, 1987
AB	SIDMAK LABS NJ	125MG	N72126 001	JUL 07, 1988
AB		250MG	N72127 001	JUL 07, 1988
AB		500MG	N72128 001	JUL 07, 1988
AB	SUPERPHARM	250MG	N70669 001	JUN 23, 1989

METHYLDOPA

TABLET; ORAL

	METHYLDOPA			
AB	SUPERPHARM	500MG	N70670 001	JUN 23, 1989

METHYLDOPA; *MULTIPLE*

SEE CHLOROTHIAZIDE; METHYLDOPA

SEE HYDROCHLOROTHIAZIDE; METHYLDOPA

METHYLDOPATE HYDROCHLORIDE

INJECTABLE; INJECTION

	ALDOMET			
AP	+ MERCK	50MG/ML	N13401 001	
	METHYLDOPATE HCL			
AP	ABBOTT	50MG/ML	N70698 001	JUN 15, 1987
AP		50MG/ML	N70699 001	JUN 15, 1987
AP	ELKINS SINN	50MG/ML	N70291 001	JUL 01, 1986
AP	GENSIA SICOR PHARMS	50MG/ML	N72974 001	NOV 22, 1991
AP	LUITPOLD	50MG/ML	N71279 001	OCT 02, 1987

METHYLERGONOVINE MALEATE

INJECTABLE; INJECTION

	METHERGINE		
+	NOVARTIS	0.2MG/ML	N06035 004

TABLET; ORAL

	METHERGINE		
	NOVARTIS	0.2MG	N06035 003

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

	METADATE CD		
+	CELLTECH PHARMS	20MG	N21259 001 APR 03, 2001

FDA data supplied by DrugPatentWatch.com

METHYLPHENIDATE HYDROCHLORIDE

TABLET; ORAL

	METHYLPHENIDATE HCL			
AB	ABLE	5MG	**N40404 001**	MAR 29, 2001
AB		10MG	**N40404 002**	MAR 29, 2001
AB		20MG	**N40404 003**	MAR 29, 2001
AB	CELLTECH MFG	5MG	**N86429 001**	
AB		10MG	**N85799 001**	
AB		20MG	**N86428 001**	
AB	DANBURY PHARMA	5MG	**N40220 001**	AUG 29, 1997
AB		10MG	**N40220 002**	AUG 29, 1997
AB		20MG	**N40220 003**	AUG 29, 1997
AB	MALLINCKRODT	5MG	**N40300 001**	NOV 27, 1998
AB		10MG	**N40300 002**	NOV 27, 1998
AB		20MG	**N40300 003**	NOV 27, 1998
	RITALIN			
AB	NOVARTIS	5MG	**N10187 003**	
AB		10MG	**N10187 006**	
AB	+	20MG	**N10187 010**	

TABLET, EXTENDED RELEASE; ORAL

	CONCERTA			
	+ ALZA	18MG	N21121 001	AUG 01, 2000
	+	36MG	N21121 002	AUG 01, 2000
	+	54MG	N21121 003	DEC 08, 2000
	METADATE ER			
AB	+ CELLTECH MFG	20MG	**N89601 001**	JUN 01, 1988
AB	CELLTECH PHARMS	10MG	**N40306 001**	OCT 20, 1999
	METHYLIN ER			
AB	MALLINCKRODT	10MG	**N75629 001**	MAY 09, 2000
AB		20MG	**N75629 002**	MAY 09, 2000

METHYLPHENIDATE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

	METHYLPHENIDATE HCL			
AB	ABLE	20MG	**N76032 001**	MAY 09, 2001
AB	DANBURY PHARMA	20MG	**N40410 001**	FEB 09, 2001
AB	PUREPAC PHARM	20MG	**N75450 001**	DEC 21, 2001
	RITALIN-SR			
AB	NOVARTIS	20MG	**N18029 001**	MAR 30, 1982

METHYLPREDNISOLONE

TABLET; ORAL

	MEDROL			
AB	PHARMACIA AND UPJOHN	4MG	**N11153 001**	
AB		8MG	**N11153 004**	
AB		16MG	**N11153 003**	
AB		24MG	**N11153 005**	
AB	+	32MG	**N11153 006**	
		2MG	N11153 002	
	METHYLPREDNISOLONE			
AB	DURAMED	4MG	**N88497 001**	FEB 21, 1984
AB	GENEVA PHARMS TECH	4MG	**N40194 001**	OCT 31, 1997
AB	PAR PHARM	16MG	**N89207 001**	APR 25, 1988
AB		24MG	**N89208 001**	APR 25, 1988
AB		32MG	**N89209 001**	APR 25, 1988
AB	TRIGEN	4MG	**N40189 001**	OCT 31, 1997
AB		8MG	**N40189 002**	OCT 31, 1997
AB	VINTAGE PHARMS	4MG	**N40183 001**	DEC 22, 1998
AB	WATSON LABS	4MG	**N40232 001**	OCT 16, 1997

FDA data supplied by DrugPatentWatch.com

METHYLPREDNISOLONE ACETATE

INJECTABLE; INJECTION

	DEPO-MEDROL				
BP	PHARMACIA AND UPJOHN	20MG/ML	N11757 002		
BP +		80MG/ML	N11757 004		
		40MG/ML	N11757 001		
	METHYLPREDNISOLONE ACETATE				
BP	STERIS	20MG/ML	N85597 001		
BP		80MG/ML	N85595 001		

OINTMENT; TOPICAL

MEDROL ACETATE			
+	PHARMACIA AND UPJOHN	0.25%	N12421 001

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION

	A-METHAPRED			
AP	ABBOTT	**EQ 40MG BASE/VIAL**	**N85853 001**	
AP		**EQ 125MG BASE/VIAL**	**N85855 001**	
AP		**EQ 500MG BASE/VIAL**	**N85854 001**	
AP		**EQ 500MG BASE/VIAL**	**N89173 001**	AUG 18, 1987
AP		**EQ 1GM BASE/VIAL**	**N85852 001**	
AP		**EQ 1GM BASE/VIAL**	**N89174 001**	AUG 18, 1987
	METHYLPREDNISOLONE SODIUM SUCCINATE			
AP	GENSIA SICOR PHARMS	**EQ 125MG BASE/VIAL**	**N81266 001**	NOV 30, 1992
	SOLU-MEDROL			
AP +	PHARMACIA AND UPJOHN	**EQ 40MG BASE/VIAL**	**N11856 003**	
AP +		**EQ 125MG BASE/VIAL**	**N11856 004**	
AP +		**EQ 500MG BASE/VIAL**	**N11856 005**	
AP +		**EQ 1GM BASE/VIAL**	**N11856 006**	
+		EQ 2GM BASE/VIAL	N11856 007	FEB 27, 1985

METHYLTESTOSTERONE

CAPSULE; ORAL

	TESTRED			
BP +	ICN	10MG	N83976 001	
	VIRILON			
BP	STAR PHARMS FL	10MG	N87750 001	NOV 24, 1982

METHYLTESTOSTERONE

TABLET; ORAL

	ANDROID 10			
AB	ICN	**10MG**	**N86450 001**	
	ANDROID 25			
AB +	ICN	**25MG**	**N87147 001**	
	METHYLTESTOSTERONE			
BP	IMPAX LABS	10MG	N80767 002	
BP		25MG	N84310 001	
BP	LANNETT	10MG	N87092 001	NOV 05, 1982
BP		25MG	N87111 001	JAN 27, 1983

METHYSERGIDE MALEATE

TABLET; ORAL

	SANSERT		
+	NOVARTIS	2MG	N12516 001

METIPRANOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

	METIPRANOLOL			
AT	FALCON PHARMS	**0.3%**	**N75720 001**	AUG 06, 2001
	OPTIPRANOLOL			
AT +	BAUSCH AND LOMB	**0.3%**	**N19907 001**	DEC 29, 1989

METOCLOPRAMIDE HYDROCHLORIDE

CONCENTRATE; ORAL

	METOCLOPRAMIDE INTENSOL		
	ROXANE	EQ 10MG BASE/ML	N72995 001 JAN 30, 1992

INJECTABLE; INJECTION

	METOCLOPRAMIDE HCL			
AP	ABBOTT	**EQ 5MG BASE/ML**	**N70505 001**	JUN 23, 1989
AP		**EQ 5MG BASE/ML**	**N73117 001**	JAN 17, 1991
AP		**EQ 5MG BASE/ML**	**N73118 001**	JAN 17, 1991

FDA data supplied by DrugPatentWatch.com

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

	METOCLOPRAMIDE HCL			
AP	ABBOTT	EQ 5MG BASE/ML	N74147 001	AUG 02, 1996
AP	FAULDING	EQ 5MG BASE/ML	N70847 001	NOV 07, 1988
AP		EQ 5MG BASE/ML	N71291 001	MAR 03, 1989
AP	GENSIA SICOR PHARMS	EQ 5MG BASE/ML	N73135 001	NOV 27, 1991
	REGLAN			
AP	+ ROBINS AH	EQ 5MG BASE/ML	N17862 001	

SOLUTION; ORAL

	METOCLOPRAMIDE			
AA	JVL	EQ 5MG BASE/5ML	N74703 001	OCT 31, 1997
AA	UDL	EQ 5MG BASE/5ML	N75051 001	JAN 26, 2001
	METOCLOPRAMIDE HCL			
AA	ALPHARMA	EQ 5MG BASE/5ML	N71340 001	AUG 18, 1988
AA	PHARM ASSOC	EQ 5MG BASE/5ML	N72744 001	MAY 28, 1991
AA	PHARM VENTURES	EQ 5MG BASE/5ML	N71402 001	JUN 25, 1993
AA	ROXANE	EQ 5MG BASE/5ML	N72038 001	DEC 05, 1988
AA	SILARX	EQ 5MG BASE/5ML	N73680 001	OCT 27, 1992
AA	TEVA	EQ 5MG BASE/5ML	N70819 001	JUL 10, 1987
AA		EQ 5MG BASE/5ML	N71315 001	JUN 30, 1993
	REGLAN			
AA	+ ROBINS AH	EQ 5MG BASE/5ML	N18821 001	MAR 25, 1983

TABLET; ORAL

	METOCLOPRAMIDE HCL			
AB	DANBURY PHARMA	EQ 10MG BASE	N70511 001	JAN 22, 1986
AB	GENEVA PHARMS	EQ 10MG BASE	N72215 001	JAN 30, 1990
AB	GENEVA PHARMS TECH	EQ 5MG BASE	N74478 001	OCT 05, 1995

METOCLOPRAMIDE HYDROCHLORIDE

TABLET; ORAL

	METOCLOPRAMIDE HCL			
AB	GENEVA PHARMS TECH	EQ 10MG BASE	N74478 002	OCT 05, 1995
AB	LEDERLE	EQ 10MG BASE	N72639 001	MAY 09, 1991
AB	PUREPAC PHARM	EQ 10MG BASE	N70581 001	OCT 17, 1985
AB	SIDMAK LABS NJ	EQ 5MG BASE	N72750 001	DEC 28, 1995
AB		EQ 10MG BASE	N71250 001	FEB 03, 1988
AB	TEVA	EQ 5MG BASE	N72801 001	JUN 15, 1993
AB		EQ 10MG BASE	N70184 001	JUL 29, 1985
	REGLAN			
AB	SCHWARZ PHARMA	EQ 5MG BASE	N17854 002	MAY 05, 1987
AB	+	EQ 10MG BASE	N17854 001	

METOLAZONE

TABLET; ORAL

	MYKROX		
+	CELLTECH PHARMS	0.5MG	N19532 001 OCT 30, 1987
	ZAROXOLYN		
+	CELLTECH PHARMS	2.5MG	N17386 001
		5MG	N17386 002
+		10MG	N17386 003

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

	TOPROL-XL		
	ASTRAZENECA	EQ 25MG TARTRATE	N19962 004 FEB 05, 2001
+		EQ 50MG TARTRATE	N19962 001 JAN 10, 1992
		EQ 100MG TARTRATE	N19962 002 JAN 10, 1992
+		EQ 200MG TARTRATE	N19962 003 JAN 10, 1992

FDA data supplied by DrugPatentWatch.com

METOPROLOL TARTRATE

INJECTABLE; INJECTION

LOPRESSOR

AP	+ NOVARTIS	1MG/ML	N18704 001	MAR 30, 1984

METOPROLOL TARTRATE

AP	ABBOTT	1MG/ML	N74133 001	DEC 21, 1993
AP		1MG/ML	N75160 001	JUL 06, 1998
AP	STERIS	1MG/ML	N74032 001	DEC 21, 1993

TABLET; ORAL

LOPRESSOR

AB	NOVARTIS	50MG	N17963 001	
AB	+	100MG	N17963 002	

METOPROLOL TARTRATE

AB	APOTHECON	50MG	N74258 001	JAN 27, 1994
AB		100MG	N74258 002	JAN 27, 1994
AB	CARACO	50MG	N74644 001	DEC 10, 1996
AB		100MG	N74644 002	DEC 10, 1996
AB	COPLEY PHARM	50MG	N74333 001	JAN 27, 1994
AB		100MG	N74333 002	JAN 27, 1994
AB	GENEVA PHARMS	50MG	N73288 001	MAR 25, 1994
AB		100MG	N73289 001	MAR 25, 1994
AB	MUTUAL PHARM	50MG	N73653 001	DEC 21, 1993
AB		100MG	N73654 001	DEC 21, 1993
AB	MYLAN	50MG	N73666 001	DEC 21, 1993
AB		100MG	N73666 002	DEC 21, 1993
AB	PAR PHARM	50MG	N74453 001	APR 27, 1995
AB		100MG	N74453 002	APR 27, 1995
AB	TEVA	50MG	N74141 001	JAN 31, 1995

METOPROLOL TARTRATE

TABLET; ORAL

METOPROLOL TARTRATE

AB	TEVA	50MG	N74143 001	SEP 30, 1994
AB		100MG	N74141 002	JAN 31, 1995
AB		100MG	N74143 002	SEP 30, 1994
AB	WATSON LABS	50MG	N74217 001	MAY 27, 1994
AB		100MG	N74217 002	MAY 27, 1994

METOPROLOL TARTRATE; *MULTIPLE*

SEE HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

METRONIDAZOLE

CAPSULE; ORAL

FLAGYL

+	GD SEARLE LLC	375MG	N20334 001 MAY 03, 1995

CREAM; TOPICAL

METROCREAM

+	GALDERMA LABS LP	0.75%	N20531 001 SEP 20, 1995

NORITATE

+	DERMIK LABS	1%	N20743 001 SEP 26, 1997

GEL; TOPICAL

METROGEL

+	GALDERMA LABS LP	0.75%	N19737 001 NOV 22, 1988

GEL; VAGINAL

METROGEL-VAGINAL

+	3M	0.75%	N20208 001 AUG 17, 1992

INJECTABLE; INJECTION

FLAGYL I.V. RTU IN PLASTIC CONTAINER

AP	+ BAXTER HLTHCARE	500MG/100ML	N18657 001	
AP	+ SCS	500MG/100ML	N18353 002	

FDA data supplied by DrugPatentWatch.com

METRONIDAZOLE

INJECTABLE; INJECTION

	METRO I.V. IN PLASTIC CONTAINER			
AP	+ B BRAUN	500MG/100ML	**N18900 001**	
			SEP 29, 1983	
	METRONIDAZOLE IN PLASTIC CONTAINER			
AP	+ ABBOTT	500MG/100ML	**N18890 002**	
			NOV 18, 1983	

LOTION; TOPICAL

	METROLOTION		
	+ GALDERMA LABS LP	0.75%	N20901 001
			NOV 24, 1998

TABLET; ORAL

	FLAGYL			
AB	GD SEARLE LLC	250MG	**N12623 001**	
AB	+	500MG	**N12623 003**	
	METROMIDOL			
AB	LABS AF	250MG	**N74523 001**	
			OCT 24, 1996	
AB		500MG	**N74523 002**	
			OCT 24, 1996	
	METRONIDAZOLE			
AB	DANBURY PHARMA	250MG	**N18764 001**	
			SEP 17, 1982	
AB		500MG	**N18764 002**	
			DEC 20, 1982	
AB	EON	250MG	**N18620 001**	
			MAR 04, 1982	
AB		500MG	**N18620 002**	
			JUN 02, 1983	
AB	GENEVA PHARMS	250MG	**N18740 001**	
			OCT 22, 1982	
AB		500MG	**N18740 002**	
			OCT 22, 1982	
AB	IVAX PHARMS	250MG	**N18517 001**	
AB		500MG	**N18517 002**	
			MAY 05, 1982	
AB	LNK	250MG	**N19029 001**	
			APR 10, 1984	
AB	MUTUAL PHARM	250MG	**N70772 001**	
			JUL 16, 1986	
AB		500MG	**N70773 001**	
			JUL 16, 1986	
AB	PAR PHARM	250MG	**N18845 001**	
			AUG 18, 1983	

METRONIDAZOLE

TABLET; ORAL

	METRONIDAZOLE			
AB	PAR PHARM	250MG	**N70040 001**	
			JAN 29, 1985	
AB		500MG	**N18930 001**	
			AUG 18, 1983	
AB		500MG	**N70039 001**	
			JAN 29, 1985	
AB	SIDMAK LABS NJ	250MG	**N70027 001**	
			NOV 06, 1984	
AB		500MG	**N70033 001**	
			DEC 06, 1984	
AB	TEVA	250MG	**N70035 001**	
			DEC 20, 1984	
AB		500MG	**N70044 001**	
			FEB 08, 1985	

TABLET, EXTENDED RELEASE; ORAL

	FLAGYL ER		
	+ GD SEARLE LLC	750MG	N20868 001
			NOV 26, 1997

METRONIDAZOLE; *MULTIPLE*

SEE BISMUTH SUBSALICYLATE; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE

METRONIDAZOLE HYDROCHLORIDE

INJECTABLE; INJECTION

	FLAGYL I.V.		
	+ SCS	EQ 500MG BASE/VIAL	N18353 001

METYRAPONE

CAPSULE; ORAL

	METOPIRONE		
	+ NOVARTIS	250MG	N12911 002
			AUG 09, 1996

METYROSINE

CAPSULE; ORAL

	DEMSER		
	+ MERCK	250MG	N17871 001

FDA data supplied by DrugPatentWatch.com

MEXILETINE HYDROCHLORIDE

CAPSULE; ORAL

	MEXILETINE HCL			
AB	DANBURY PHARMA	150MG	**N74865 001**	APR 13, 1998
AB		200MG	**N74865 002**	APR 13, 1998
AB		250MG	**N74865 003**	APR 13, 1998
AB	GENEVA PHARMS	150MG	**N74450 001**	MAY 16, 1996
AB		200MG	**N74450 002**	MAY 16, 1996
AB		250MG	**N74450 003**	MAY 16, 1996
AB	TEVA	150MG	**N74377 001**	MAY 16, 1995
AB		200MG	**N74377 002**	MAY 16, 1995
AB		250MG	**N74377 003**	MAY 16, 1995
AB	WATSON LABS	150MG	**N74711 001**	FEB 26, 1997
AB		200MG	**N74711 002**	FEB 26, 1997
AB		250MG	**N74711 003**	FEB 26, 1997
	MEXITIL			
AB	BOEHRINGER INGELHEIM	150MG	**N18873 002**	DEC 30, 1985
AB		200MG	**N18873 003**	DEC 30, 1985
AB +		250MG	**N18873 004**	DEC 30, 1985

MEZLOCILLIN SODIUM MONOHYDRATE

INJECTABLE; INJECTION

	MEZLIN			
+	BAYER	EQ 1GM BASE/VIAL	N50549 001	
+		EQ 2GM BASE/VIAL	N50549 002	
+		EQ 3GM BASE/VIAL	N50549 003	
		EQ 3GM BASE/VIAL	N62697 001	JAN 22, 1987
+		EQ 4GM BASE/VIAL	N50549 004	
		EQ 4GM BASE/VIAL	N62697 002	JAN 22, 1987

MEZLOCILLIN SODIUM MONOHYDRATE

INJECTABLE; INJECTION

	MEZLIN		
+	BAYER	EQ 20GM BASE/VIAL	N50549 005 MAR 02, 1988

MICONAZOLE NITRATE

CREAM; TOPICAL

	MONISTAT-DERM		
+	JOHNSON AND JOHNSON	2%	N17494 001

INSERT, CREAM; VAGINAL, TOPICAL

	MONISTAT DUAL- PAK		
+	PERSONAL PRODS	1.2GM,2%	N20968 001 JUN 30, 1999

SUPPOSITORY; VAGINAL

	MICONAZOLE NITRATE		
AB	ALPHARMA US PHARM	200MG	**N73508 001** NOV 19, 1993
	MONISTAT 3		
AB +	JOHNSON RW	200MG	**N18888 001** AUG 15, 1984

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

	MIDAZOLAM HCL		
AP	ABBOTT	EQ 1MG BASE/ML	**N75293 001** JUN 20, 2000
AP		EQ 1MG BASE/ML	**N75409 002** JUN 20, 2000
AP		EQ 5MG BASE/ML	**N75293 002** JUN 20, 2000
AP		EQ 5MG BASE/ML	**N75409 001** JUN 20, 2000
AP	AM PHARM PARTNERS	EQ 1MG BASE/ML	**N75154 002** JUN 20, 2000
AP		EQ 5MG BASE/ML	**N75154 001** JUN 20, 2000
AP	APOTEX	EQ 1MG BASE/ML	**N75637 001** OCT 31, 2000
AP		EQ 5MG BASE/ML	**N75637 002** OCT 31, 2000

FDA data supplied by DrugPatentWatch.com

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION
MIDAZOLAM HCL

AP	BAXTER HLTHCARE CORP	**EQ 1MG BASE/ML**	**N75324 001**	JUN 20, 2000
AP		**EQ 5MG BASE/ML**	**N75324 002**	JUN 20, 2000
AP	BEDFORD	**EQ 1MG BASE/ML**	**N75247 002**	JUN 23, 2000
AP		**EQ 5MG BASE/ML**	**N75247 001**	JUN 23, 2000
AP	BEN VENUE	**EQ 1MG BASE/ML**	**N75421 002**	JUN 20, 2000
AP		**EQ 5MG BASE/ML**	**N75421 001**	JUN 20, 2000
AP	ESI LEDERLE	**EQ 1MG BASE/ML**	**N75243 001**	JUN 20, 2000
AP		**EQ 5MG BASE/ML**	**N75243 002**	JUN 20, 2000
AP	FAULDING	**EQ 1MG BASE/ML**	**N75396 001**	JUN 20, 2000
AP		**EQ 5MG BASE/ML**	**N75396 002**	JUN 20, 2000
AP		**EQ 5MG BASE/ML**	**N75484 001**	JUN 20, 2000
AP	TAYLOR	**EQ 5MG BASE/ML**	**N75481 001**	JUN 30, 2000
AP	TAYLOR PHARMA	**EQ 1MG BASE/ML**	**N75494 001**	JUN 30, 2000
AP		**EQ 5MG BASE/ML**	**N75494 002**	JUN 30, 2000

VERSED

AP	+ HLR	**EQ 1MG BASE/ML**	**N18654 002**	MAY 26, 1987
AP	+	**EQ 5MG BASE/ML**	**N18654 001**	DEC 20, 1985

SYRUP; ORAL
VERSED

	+ ROCHE	EQ 2MG BASE/ML	N20942 001	OCT 15, 1998

MIDODRINE HYDROCHLORIDE

TABLET; ORAL
PROAMATINE

	SHIRE PHARM	2.5MG	N19815 001	SEP 06, 1996

MIDODRINE HYDROCHLORIDE

TABLET; ORAL
PROAMATINE

	+ SHIRE PHARM	5MG	N19815 002	SEP 06, 1996

MIFEPRISTONE

TABLET; ORAL
MIFEPREX

	+ POPULATION COUNCIL	200MG	N20687 001	SEP 28, 2000

MIGLITOL

TABLET; ORAL
GLYSET

	PHARMACIA AND UPJOHN	25MG	N20682 001	DEC 18, 1996
		50MG	N20682 002	DEC 18, 1996
	+	100MG	N20682 003	DEC 18, 1996

MILRINONE LACTATE

INJECTABLE; INJECTION
PRIMACOR

	+ SANOFI SYNTHELABO	EQ 1MG BASE/ML	N19436 001	DEC 31, 1987

PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER

	+ SANOFI SYNTHELABO	EQ 20MG BASE/100ML	N20343 003	AUG 09, 1994

MINOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL
MINOCIN

AB	LEDERLE	**EQ 50MG BASE**	**N50649 001**	MAY 31, 1990
AB		**EQ 75MG BASE**	**N50649 003**	FEB 12, 2001
AB	+	**EQ 100MG BASE**	**N50649 002**	MAY 31, 1990

FDA data supplied by DrugPatentWatch.com

MINOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL

	MINOCYCLINE HCL			
AB	DANBURY PHARMA	**EQ 50MG BASE**	**N63181 001**	DEC 30, 1991
AB		**EQ 75MG BASE**	**N63065 002**	JUN 10, 1999
AB		**EQ 100MG BASE**	**N63065 001**	DEC 30, 1991
AB	IMPAX LABS	**EQ 50MG BASE**	**N65005 001**	MAR 23, 1999
AB		**EQ 75MG BASE**	**N65005 003**	APR 18, 2001
AB		**EQ 100MG BASE**	**N65005 002**	MAR 23, 1999
AB	RANBAXY	**EQ 50MG BASE**	**N65062 001**	NOV 30, 2000
AB		**EQ 75MG BASE**	**N65062 002**	NOV 30, 2000
AB		**EQ 100MG BASE**	**N65062 003**	NOV 30, 2000
AB	TEVA	**EQ 50MG BASE**	**N63011 001**	MAR 02, 1992
AB		**EQ 100MG BASE**	**N63009 001**	MAR 02, 1992
	VECTRIN			
AB	MEDICIS	**EQ 50MG BASE**	**N63066 001**	AUG 14, 1990

INJECTABLE; INJECTION

	MINOCIN		
+	LEDERLE	EQ 100MG BASE/VIAL	N50444 001

POWDER, EXTENDED RELEASE; DENTAL

	ARESTIN		
+	ORAPHARMA	EQ 1MG BASE	N50781 001 FEB 16, 2001

SUSPENSION; ORAL

	MINOCIN		
+	LEDERLE	EQ 50MG BASE/5ML	N50445 001

MINOXIDIL

TABLET; ORAL

	LONITEN		
AB	PHARMACIA AND UPJOHN	**2.5MG**	**N18154 001**

MINOXIDIL

TABLET; ORAL

	LONITEN		
AB +	PHARMACIA AND UPJOHN	**10MG**	**N18154 003**
	MINOXIDIL		
AB	DANBURY PHARMA	**2.5MG**	**N71344 001** MAR 03, 1987
AB		**10MG**	**N71345 001** MAR 03, 1987
AB	MUTUAL PHARM	**2.5MG**	**N72708 001** DEC 14, 1995
AB		**10MG**	**N72709 001** DEC 14, 1995
AB	PAR PHARM	**2.5MG**	**N71826 001** NOV 14, 1988
AB		**10MG**	**N71839 001** NOV 14, 1988

MIRTAZAPINE

TABLET; ORAL

	REMERON		
+	ORGANON	15MG	N20415 001 JUN 14, 1996
		30MG	N20415 002 JUN 14, 1996
		45MG	N20415 003 MAR 17, 1997

TABLET, ORALLY DISINTEGRATING; ORAL

	REMERON SOLTAB		
+	ORGANON INC	15MG	N21208 001 JAN 12, 2001
		30MG	N21208 002 JAN 12, 2001
		45MG	N21208 003 JAN 12, 2001

MISOPROSTOL

TABLET; ORAL

	CYTOTEC		
	GD SEARLE LLC	0.1MG	N19268 003 SEP 21, 1990
+		0.2MG	N19268 001 DEC 27, 1988

FDA data supplied by DrugPatentWatch.com

MISOPROSTOL; *MULTIPLE*
SEE DICLOFENAC SODIUM; MISOPROSTOL

MITOMYCIN

INJECTABLE; INJECTION

	MITOMYCIN			
AP	BEDFORD	**5MG/VIAL**	**N64117 001**	APR 19, 1995
AP		**20MG/VIAL**	**N64117 002**	APR 19, 1995
AP	ESI LEDERLE	**5MG/VIAL**	**N64180 001**	DEC 23, 1999
AP		**20MG/VIAL**	**N64180 002**	DEC 23, 1999
AP	FAULDING	**20MG/VIAL**	**N64106 001**	NOV 29, 1995
AP	SUPERGEN	**5MG/VIAL**	**N64144 001**	APR 30, 1998
AP		**20MG/VIAL**	**N64144 002**	APR 30, 1998
	MUTAMYCIN			
AP	+ BRISTOL MYERS	**5MG/VIAL**	**N62336 001**	
AP	+	**20MG/VIAL**	**N62336 002**	
	+	40MG/VIAL	N62336 003	MAR 10, 1988

MITOTANE

TABLET; ORAL

	LYSODREN		
+	BRISTOL	500MG	N16885 001

MITOXANTRONE HYDROCHLORIDE

INJECTABLE; INJECTION

	NOVANTRONE			
+	IMMUNEX	EQ 2MG BASE/ML	N19297 001	DEC 23, 1987

MIVACURIUM CHLORIDE

INJECTABLE; INJECTION

	MIVACRON			
+	ABBOTT	EQ 2MG BASE/ML	N20098 001	JAN 22, 1992

MIVACURIUM CHLORIDE

INJECTABLE; INJECTION

	MIVACRON IN DEXTROSE 5% IN PLASTIC CONTAINER			
+	ABBOTT	EQ 0.5MG BASE/ML	N20098 002	JAN 22, 1992
+		EQ 50MG BASE/100ML	N20098 003	JAN 22, 1992

MODAFINIL

TABLET; ORAL

	PROVIGIL			
	CEPHALON	100MG	N20717 001	DEC 24, 1998
+		200MG	N20717 002	DEC 24, 1998

MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL

	UNIVASC			
	SCHWARZ PHARMA	7.5MG	N20312 001	APR 19, 1995
+		15MG	N20312 002	APR 19, 1995

MOEXIPRIL HYDROCHLORIDE; *MULTIPLE*
SEE HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

MOLINDONE HYDROCHLORIDE

CONCENTRATE; ORAL

	MOBAN			
+	ENDO PHARMS	20MG/ML	N17938 001	

TABLET; ORAL

	MOBAN			
	ENDO PHARMS	5MG	N17111 004	
		10MG	N17111 005	
+		25MG	N17111 006	
		50MG	N17111 007	
+		100MG	N17111 008	

FDA data supplied by DrugPatentWatch.com

MOMETASONE FUROATE

CREAM; TOPICAL
ELOCON
+ SCHERING 0.1% N19625 001 MAY 06, 1987

LOTION; TOPICAL
ELOCON
+ SCHERING 0.1% N19796 001 MAR 30, 1989

OINTMENT; TOPICAL
ELOCON
+ SCHERING 0.1% N19543 001 APR 30, 1987

MOMETASONE FUROATE MONOHYDRATE

SPRAY, METERED; NASAL
NASONEX
+ SCHERING PLOUGH EQ 0.05MG BASE/SPRAY N20762 001 OCT 01, 1997

MONOBENZONE

CREAM; TOPICAL
BENOQUIN
+ ICN 20% N08173 003

MONOCTANOIN

LIQUID; PERFUSION, BILIARY
MOCTANIN
ETHITEK 100% N19368 001 OCT 29, 1985

MONTELUKAST SODIUM

TABLET; ORAL
SINGULAIR
+ MERCK EQ 10MG BASE N20829 002 FEB 20, 1998

MONTELUKAST SODIUM

TABLET, CHEWABLE; ORAL
SINGULAIR
MERCK EQ 4MG BASE N20830 002 MAR 03, 2000
+ EQ 5MG BASE N20830 001 FEB 20, 1998

MORICIZINE HYDROCHLORIDE

TABLET; ORAL
ETHMOZINE
SHIRE LABS 200MG N19753 001 JUN 19, 1990
250MG N19753 002 JUN 19, 1990
+ 300MG N19753 003 JUN 19, 1990

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL
KADIAN
+ FAULDING PHARMS 20MG N20616 001 JUL 03, 1996
+ 30MG N20616 004 MAR 09, 2001
+ 50MG N20616 002 JUL 03, 1996
+ 60MG N20616 005 MAR 09, 2001
+ 100MG N20616 003 JUL 03, 1996

INJECTABLE; INJECTION
ASTRAMORPH PF
AP ASTRAZENECA **0.5MG/ML** **N71050 001** OCT 07, 1986
AP **0.5MG/ML** **N71051 001** OCT 07, 1986
AP **1MG/ML** **N71052 001** OCT 07, 1986
AP **1MG/ML** **N71053 001** OCT 07, 1986

DURAMORPH PF
AP + ELKINS SINN **0.5MG/ML** **N18565 001** SEP 18, 1984

FDA data supplied by DrugPatentWatch.com

MORPHINE SULFATE

INJECTABLE; INJECTION

		DURAMORPH PF			
AP	+	ELKINS SINN	**1MG/ML**	**N18565 002**	SEP 18, 1984
		INFUMORPH			
	+	ELKINS SINN	10MG/ML	N18565 003	JUL 19, 1991
	+		25MG/ML	N18565 004	JUL 19, 1991
		MORPHINE SULFATE			
AP	+	ABBOTT	**0.5MG/ML**	**N19917 001**	OCT 30, 1992
AP			**0.5MG/ML**	**N71849 001**	MAY 11, 1988
AP			**0.5MG/ML**	**N73509 001**	SEP 30, 1992
AP	+		**1MG/ML**	**N19916 001**	OCT 30, 1992
AP			**1MG/ML**	**N71850 001**	MAY 11, 1988
AP			**1MG/ML**	**N73510 001**	SEP 30, 1992
AP		MALLINCKRODT	**1MG/ML**	**N20631 001**	JUL 03, 1996
	+		2MG/ML	N20631 002	JUL 03, 1996
	+	MERIDIAN MEDCL TECHN	15MG/ML	N19999 001	JUL 12, 1990
AP		STERIS	**0.5MG/ML**	**N73373 001**	SEP 30, 1991
AP			**0.5MG/ML**	**N73375 001**	SEP 30, 1991
AP			**1MG/ML**	**N73374 001**	SEP 30, 1991
AP			**1MG/ML**	**N73376 001**	SEP 30, 1991

TABLET, EXTENDED RELEASE; ORAL

	MORPHINE SULFATE			
AB	AB GENERICS	**15MG**	**N74862 001**	JUL 07, 1998
AB		**30MG**	**N74862 002**	JUL 07, 1998
AB		**60MG**	**N74862 003**	JUL 07, 1998
AB		**100MG**	**N74769 001**	JUL 02, 1998

MORPHINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

	MORPHINE SULFATE			
AB	AB GENERICS	**200MG**	**N74769 002**	JUL 02, 1998
AB	ENDO PHARMS	**15MG**	**N75295 001**	OCT 28, 1998
AB		**30MG**	**N75295 002**	OCT 28, 1998
AB		**60MG**	**N75295 003**	OCT 28, 1998
AB		**100MG**	**N75295 004**	SEP 15, 2000
AB		**200MG**	**N75295 005**	SEP 15, 2000
AB	ESI LEDERLE	**15MG**	**N75407 001**	JAN 28, 2000
AB	WATSON LABS	**100MG**	**N75656 001**	JAN 30, 2001
	MS CONTIN			
AB	+ PURDUE FREDERICK	**15MG**	**N19516 003**	SEP 12, 1989
AB	+	**30MG**	**N19516 001**	MAY 29, 1987
AB	+	**60MG**	**N19516 002**	APR 08, 1988
AB	+	**100MG**	**N19516 004**	JAN 16, 1990
AB	+	**200MG**	**N19516 005**	NOV 08, 1993
	ORAMORPH SR			
BC	ELAN PHARMS	15MG	N19977 004	NOV 23, 1994
BC		30MG	N19977 001	AUG 15, 1991
BC		60MG	N19977 002	AUG 15, 1991
BC		100MG	N19977 003	AUG 15, 1991

MOXIFLOXACIN HYDROCHLORIDE

INJECTABLE; IV (INFUSION)

AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER

+	BAYER	160MG/100ML	N21277 001 NOV 30, 2001

FDA data supplied by DrugPatentWatch.com

MOXIFLOXACIN HYDROCHLORIDE

TABLET; ORAL
AVELOX
+ BAYER — EQ 400MG BASE — N21085 001 DEC 10, 1999

MUPIROCIN

OINTMENT; TOPICAL
BACTROBAN
+ GLAXOSMITHKLINE — 2% — N50591 001 DEC 31, 1987

MUPIROCIN CALCIUM

CREAM, AUGMENTED; TOPICAL
BACTROBAN
+ GLAXOSMITHKLINE — 2% — N50746 001 DEC 11, 1997

OINTMENT; NASAL
BACTROBAN
+ GLAXOSMITHKLINE — EQ 2% BASE — N50703 001 SEP 18, 1995

MYCOPHENOLATE MOFETIL

CAPSULE; ORAL
CELLCEPT
+ ROCHE GLOBAL DEV — 250MG — N50722 001 MAY 03, 1995

SUSPENSION; ORAL
CELLCEPT
+ ROCHE GLOBAL DEV — 200MG/ML — N50759 001 OCT 01, 1998

TABLET; ORAL
CELLCEPT
+ ROCHE GLOBAL DEV — 500MG — N50723 001 JUN 19, 1997

MYCOPHENOLATE MOFETIL HYDROCHLORIDE

INJECTABLE; INJECTION
CELLCEPT
+ ROCHE GLOBAL DEV — 500MG/VIAL — N50758 001 AUG 12, 1998

NABUMETONE

TABLET; ORAL
NABUMETONE

AB		COPLEY PHARM	**750MG**	**N75179 001** JUN 06, 2000
AB		TEVA	**500MG**	**N75189 001** MAY 26, 2000
AB			**750MG**	**N75189 002** SEP 24, 2001

RELAFEN

AB		GLAXOSMITHKLINE	**500MG**	**N19583 001** DEC 24, 1991
AB	+		**750MG**	**N19583 002** DEC 24, 1991

NADOLOL

TABLET; ORAL
CORGARD

AB		APOTHECON	**20MG**	**N18063 005** OCT 28, 1986
AB			**40MG**	**N18063 001**
AB			**80MG**	**N18063 002**
AB			**120MG**	**N18063 003**
AB	+		**160MG**	**N18063 004**

NADOLOL

AB		COPLEY PHARM	**80MG**	**N74368 001** AUG 31, 1994
AB			**120MG**	**N74368 002** AUG 31, 1994
AB			**160MG**	**N74368 003** AUG 31, 1994
AB		GENEVA PHARMS TECH	**20MG**	**N74501 001** NOV 09, 1995
AB			**40MG**	**N74501 002** NOV 09, 1995
AB			**80MG**	**N74501 003** NOV 09, 1995

FDA data supplied by DrugPatentWatch.com

NADOLOL

TABLET; ORAL
NADOLOL

AB	IVAX PHARMS	**20MG**	**N74229 001**	AUG 30, 1996
AB		**40MG**	**N74229 002**	AUG 30, 1996
AB		**80MG**	**N74255 001**	JAN 24, 1996
AB		**120MG**	**N74255 002**	JAN 24, 1996
AB		**160MG**	**N74255 003**	JAN 24, 1996
AB	MYLAN	**20MG**	**N74172 001**	OCT 31, 1993
AB		**40MG**	**N74172 002**	OCT 31, 1993
AB		**80MG**	**N74172 003**	OCT 31, 1993

NADOLOL; *MULTIPLE*
SEE BENDROFLUMETHIAZIDE; NADOLOL

NAFARELIN ACETATE

SPRAY, METERED; NASAL
SYNAREL

+	GD SEARLE LLC	EQ 0.2MG BASE/SPRAY	N19886 001 FEB 13, 1990

NAFCILLIN SODIUM

CAPSULE; ORAL
UNIPEN

+	WYETH AYERST	EQ 250MG BASE	N50111 001

INJECTABLE; INJECTION
NAFCILLIN SODIUM

AP	APOTHECON	**EQ 1GM BASE/VIAL**	**N62527 002**	AUG 02, 1984
AP		**EQ 1GM BASE/VIAL**	**N62732 001**	DEC 23, 1986
AP		**EQ 2GM BASE/VIAL**	**N62527 003**	AUG 02, 1984

NAFCILLIN SODIUM

INJECTABLE; INJECTION
NAFCILLIN SODIUM

AP	APOTHECON	**EQ 2GM BASE/VIAL**	**N62732 002**	DEC 23, 1986
AP		**EQ 10GM BASE/VIAL**	**N62527 004**	AUG 02, 1984
+		EQ 500MG BASE/VIAL	N62527 001	AUG 02, 1984

NALLPEN IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	EQ 20MG BASE/ML	N50655 001	OCT 31, 1989
+		EQ 2GM BASE/100ML	N50655 002	OCT 31, 1989

NAFTIFINE HYDROCHLORIDE

CREAM; TOPICAL
NAFTIN

+	ALLERGAN HERBERT	1%	N19599 001	FEB 29, 1988

GEL; TOPICAL
NAFTIN

+	ALLERGAN HERBERT	1%	N19356 001	JUN 18, 1990

NALBUPHINE HYDROCHLORIDE

INJECTABLE; INJECTION
NALBUPHINE HCL

AP	ABBOTT	**10MG/ML**	**N70914 001**	FEB 03, 1989
AP		**10MG/ML**	**N70915 001**	FEB 03, 1989
AP		**20MG/ML**	**N70916 001**	FEB 03, 1989
AP		**20MG/ML**	**N70917 001**	FEB 03, 1989
AP		**20MG/ML**	**N70918 001**	FEB 03, 1989
+		1.5MG/ML	N20200 001	MAR 12, 1993
AP	KING PHARMS	**10MG/ML**	**N74471 001**	MAR 19, 1998

FDA data supplied by DrugPatentWatch.com

NALBUPHINE HYDROCHLORIDE

INJECTABLE; INJECTION

	NALBUPHINE HCL				
AP	KING PHARMS	20MG/ML	N74471 002		
			MAR 19, 1998		
	NUBAIN				
AP	+ ENDO PHARMS	10MG/ML	N18024 001		
AP	+	20MG/ML	N18024 002		
			MAY 27, 1982		

NALIDIXIC ACID

SUSPENSION; ORAL

	NEGGRAM		
	+ SANOFI SYNTHELABO	250MG/5ML	N17430 001

TABLET; ORAL

	NALIDIXIC ACID		
AB	DANBURY PHARMA	1GM	N71919 001
			JUN 29, 1988
AB		250MG	N71936 001
			JUN 29, 1988
AB		500MG	N72061 001
			JUN 29, 1988
	NEGGRAM		
AB	SANOFI SYNTHELABO	250MG	N14214 002
AB		500MG	N14214 004
AB	+	1GM	N14214 005

NALMEFENE HYDROCHLORIDE

INJECTABLE; INJECTION

	REVEX		
	+ BAXTER HLTHCARE CORP	EQ 0.1MG BASE/ML	N20459 001
			APR 17, 1995
	+	EQ 1MG BASE/ML	N20459 002
			APR 17, 1995

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION

	NALOXONE		
AP	ELKINS SINN	0.4MG/ML	N70299 001
			SEP 24, 1986

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION

	NALOXONE		
AP	ELKINS SINN PHARM	0.4MG/ML	N70298 001
			SEP 24, 1986
	NALOXONE HCL		
AP	ABBOTT	0.02MG/ML	N70171 001
			SEP 24, 1986
AP		0.02MG/ML	N70252 001
			JAN 16, 1987
AP		0.02MG/ML	N70253 001
			JAN 16, 1987
AP		0.4MG/ML	N70254 001
			JAN 07, 1987
AP		0.4MG/ML	N70255 001
			JAN 07, 1987
AP		0.4MG/ML	N70256 001
			JAN 07, 1987
AP		0.4MG/ML	N70257 001
			JAN 07, 1987
AP	ELKINS SINN	0.02MG/ML	N71272 001
			MAY 24, 1988
AP		1MG/ML	N71273 001
			MAY 24, 1988
AP		1MG/ML	N71274 001
			MAY 24, 1988
AP		1MG/ML	N71287 001
			MAY 24, 1988
AP	INTL MEDICATION	0.4MG/ML	N70639 001
			SEP 24, 1986
AP		1MG/ML	N72076 001
			MAR 24, 1988
	NARCAN		
AP	+ ENDO PHARMS	0.02MG/ML	N16636 002
AP	+	0.4MG/ML	N16636 001
AP	+	1MG/ML	N16636 003
			JUN 14, 1982

NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL

	NALOXONE HCL AND PENTAZOCAINE		
AB	AMIDE PHARM	EQ 0.5MG BASE; EQ 50MG BASE	N75735 001
			JUL 11, 2001

FDA data supplied by DrugPatentWatch.com

NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL

	PENTAZOCINE AND NALOXONE HYDROCHLORIDES			
AB	RANBAXY	EQ 0.5MG BASE; EQ 50MG BASE	N75523 001	MAR 17, 2000
AB	WATSON LABS	EQ 0.5MG BASE; EQ 50MG BASE	N74736 001	JAN 21, 1997
	TALWIN NX			
AB +	SANOFI SYNTHELABO	EQ 0.5MG BASE; EQ 50MG BASE	N18733 001	DEC 16, 1982

NALTREXONE HYDROCHLORIDE

TABLET; ORAL

	NALTREXONE HCL			
AB	AMIDE PHARM	50MG	N75274 001	MAY 26, 1999
AB	BARR	50MG	N74918 001	MAY 08, 1998
AB	EON	50MG	N75434 001	MAR 08, 2000
	REVIA			
AB +	BRISTOL MYERS SQUIBB	50MG	N18932 001	NOV 20, 1984

NANDROLONE DECANOATE

INJECTABLE; INJECTION

	DECA-DURABOLIN			
AO +	ORGANON	50MG/ML	N13132 001	JUN 12, 1986
AO +		100MG/ML	N13132 002	JUN 12, 1986
AO +		200MG/ML	N13132 003	JUN 12, 1986
	NANDROLONE DECANOATE			
AO	STERIS	50MG/ML	N86385 001	JAN 13, 1984
AO		100MG/ML	N86598 001	JAN 13, 1984
AO		200MG/ML	N88128 001	DEC 05, 1983

NAPHAZOLINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

	ALBALON			
AT +	ALLERGAN	0.1%	N80248 001	
	NAFAZAIR			
AT	BAUSCH AND LOMB	0.1%	N40073 001	MAY 25, 1994
	NAPHAZOLINE HCL			
AT	TAYLOR	0.1%	N83590 001	
	VASOCON			
AT	NOVARTIS	0.1%	N80235 002	MAR 24, 1983

NAPROXEN

SUSPENSION; ORAL

	NAPROSYN			
AB +	SYNTEX (USA) INC LLC	25MG/ML	N18965 001	MAR 23, 1987
	NAPROXEN			
AB	ROXANE	25MG/ML	N74190 001	MAR 30, 1994

TABLET; ORAL

	NAPROSYN			
AB	SYNTEX (USA) INC LLC	250MG	N17581 002	
AB		375MG	N17581 003	
AB +		500MG	N17581 004	APR 15, 1982
	NAPROXEN			
AB	COPLEY PHARM	250MG	N74207 001	DEC 21, 1993
AB		375MG	N74207 002	DEC 21, 1993
AB		500MG	N74207 003	DEC 21, 1993
AB	DANBURY PHARMA	250MG	N74163 001	FEB 10, 1995
AB		375MG	N74163 002	FEB 10, 1995
AB		500MG	N74163 003	FEB 10, 1995
AB	GENEVA PHARMS	250MG	N74140 001	DEC 21, 1993
AB		375MG	N74140 002	DEC 21, 1993

FDA data supplied by DrugPatentWatch.com

NAPROXEN

TABLET; ORAL

NAPROXEN

AB	GENEVA PHARMS	500MG	N74140 003	DEC 21, 1993
AB	INTERPHARM	250MG	N75927 001	DEC 18, 2001
AB		375MG	N75927 002	DEC 18, 2001
AB		500MG	N75927 003	DEC 18, 2001
AB	IVAX PHARMS	250MG	N74111 001	FEB 28, 1995
AB		375MG	N74111 002	FEB 28, 1995
AB		500MG	N74111 003	FEB 28, 1995
AB	LEDERLE	250MG	N74105 001	DEC 21, 1993
AB		375MG	N74105 002	DEC 21, 1993
AB		500MG	N74105 003	DEC 21, 1993
AB	MOVA	250MG	N74410 001	APR 28, 1995
AB		375MG	N74410 002	APR 28, 1995
AB		500MG	N74410 003	APR 28, 1995
AB	MYLAN	250MG	N74121 001	DEC 21, 1993
AB		375MG	N74121 002	DEC 21, 1993
AB		500MG	N74121 003	DEC 21, 1993
AB	PUREPAC PHARM	250MG	N74263 001	DEC 21, 1993
AB		375MG	N74263 002	DEC 21, 1993
AB		500MG	N74263 003	DEC 21, 1993
AB	ROXANE	250MG	N74211 001	FEB 28, 1994
AB		375MG	N74211 002	FEB 28, 1994
AB		500MG	N74211 003	FEB 28, 1994

NAPROXEN

TABLET; ORAL

NAPROXEN

AB	SIDMAK LABS NJ	250MG	N74182 001	JUN 27, 1996
AB		375MG	N74182 002	JUN 27, 1996
AB		500MG	N74182 003	JUN 27, 1996
AB	TEVA	250MG	N74129 001	DEC 21, 1993
AB		250MG	N74201 001	DEC 21, 1993
AB		250MG	N74216 001	APR 11, 1996
AB		375MG	N74129 002	DEC 21, 1993
AB		375MG	N74201 002	DEC 21, 1993
AB		375MG	N74216 002	APR 11, 1996
AB		500MG	N74129 003	DEC 21, 1993
AB		500MG	N74201 003	DEC 21, 1993
AB		500MG	N74216 003	APR 11, 1996
AB	WATSON LABS	250MG	N74457 001	MAY 31, 1995
AB		375MG	N74457 002	MAY 31, 1995
AB		500MG	N74457 003	MAY 31, 1995

TABLET, DELAYED RELEASE; ORAL

EC-NAPROSYN

AB	+ SYNTEX (USA) INC LLC	375MG	N20067 002	OCT 14, 1994
AB	+	500MG	N20067 003	OCT 14, 1994

NAPROXEN

AB	GENEVA PHARMS TECH	375MG	N75061 001	FEB 18, 1998
AB		500MG	N75061 002	FEB 18, 1998
AB	PUREPAC PHARM	375MG	N74936 001	FEB 24, 1998

FDA data supplied by DrugPatentWatch.com

NAPROXEN

TABLET, DELAYED RELEASE; ORAL

	NAPROXEN			
AB	PUREPAC PHARM	500MG	N74936 002	FEB 24, 1998
AB	SIDMAK LABS	375MG	N75337 001	MAY 26, 1999
AB		500MG	N75337 002	MAY 26, 1999
AB	TEVA	375MG	N75227 001	JUN 30, 1998
AB		500MG	N75227 002	JUN 30, 1998

TABLET, EXTENDED RELEASE; ORAL

	NAPROXEN			
AB	+ ALPHAPHARM	375MG	N75390 001	APR 19, 2001
AB	+	500MG	N75390 002	APR 19, 2001

NAPROXEN SODIUM

TABLET; ORAL

	ANAPROX			
AB	SYNTEX (USA) INC LLC	EQ 250MG BASE	N18164 001	
	ANAPROX DS			
AB	+ SYNTEX (USA) INC LLC	EQ 500MG BASE	N18164 003	SEP 30, 1987
	NAPROXEN SODIUM			
AB	AL HIKMA	EQ 250MG BASE	N74480 002	FEB 18, 1998
AB		EQ 500MG BASE	N74480 001	MAY 14, 1996
AB	COPLEY PHARM	EQ 250MG BASE	N74289 001	JAN 27, 1994
AB		EQ 500MG BASE	N74289 002	JAN 27, 1994
AB	DANBURY PHARMA	EQ 250MG BASE	N74195 001	DEC 21, 1993
AB		EQ 500MG BASE	N74195 002	DEC 21, 1993
AB	GENEVA PHARMS	EQ 250MG BASE	N74162 001	DEC 21, 1993
AB		EQ 500MG BASE	N74162 002	DEC 21, 1993

NAPROXEN SODIUM

TABLET; ORAL

	NAPROXEN SODIUM			
AB	GENEVA PHARMS TECH	EQ 250MG BASE	N74495 001	DEC 05, 1994
AB		EQ 500MG BASE	N74495 002	DEC 05, 1994
AB	IVAX PHARMS	EQ 250MG BASE	N74230 001	MAR 14, 1995
AB		EQ 500MG BASE	N74230 002	MAR 14, 1995
AB	MYLAN	EQ 250MG BASE	N74367 001	AUG 31, 1994
AB		EQ 500MG BASE	N74367 002	AUG 31, 1994
AB	ROXANE	EQ 250MG BASE	N74257 001	DEC 21, 1993
AB		EQ 500MG BASE	N74257 002	DEC 21, 1993
AB	SIDMAK LABS NJ	EQ 250MG BASE	N74242 001	JUN 20, 1996
AB		EQ 500MG BASE	N74242 002	JUN 20, 1996
AB	TEVA	EQ 250MG BASE	N74142 001	DEC 21, 1993
AB		EQ 250MG BASE	N74198 001	DEC 21, 1993
AB		EQ 500MG BASE	N74142 002	DEC 21, 1993
AB		EQ 500MG BASE	N74198 002	DEC 21, 1993
AB	WATSON LABS	EQ 250MG BASE	N74455 001	MAY 31, 1995
AB		EQ 500MG BASE	N74455 002	MAY 31, 1995

TABLET, EXTENDED RELEASE; ORAL

	NAPRELAN			
+	ELAN PHARM	EQ 375MG BASE	N20353 001	JAN 05, 1996
+		EQ 500MG BASE	N20353 002	JAN 05, 1996
+		EQ 750MG BASE	N20353 003	JAN 05, 1996

FDA data supplied by DrugPatentWatch.com

NARATRIPTAN HYDROCHLORIDE

TABLET; ORAL
AMERGE
GLAXOSMITHKLINE EQ 1MG BASE N20763 002 FEB 10, 1998
\+ EQ 2.5MG BASE N20763 001 FEB 10, 1998

NATAMYCIN

SUSPENSION; OPHTHALMIC
NATACYN
\+ ALCON 5% N50514 001

NATEGLINIDE

TABLET; ORAL
STARLIX
NOVARTIS 60MG N21204 001 DEC 22, 2000
\+ 120MG N21204 002 DEC 22, 2000

NEDOCROMIL SODIUM

AEROSOL, METERED; INHALATION
TILADE
\+ AVENTIS 1.75MG/INH N19660 001 DEC 30, 1992

SOLUTION/DROPS; OPHTHALMIC
ALOCRIL
\+ ALLERGAN 2% N21009 001 DEC 08, 1999

NEFAZODONE HYDROCHLORIDE

TABLET; ORAL
SERZONE
BRISTOL MYERS SQUIBB 50MG N20152 001 DEC 22, 1994
100MG N20152 002 DEC 22, 1994

NEFAZODONE HYDROCHLORIDE

TABLET; ORAL
SERZONE
BRISTOL MYERS SQUIBB 150MG N20152 003 DEC 22, 1994
200MG N20152 004 DEC 22, 1994
\+ 250MG N20152 005 DEC 22, 1994

NELFINAVIR MESYLATE

FOR SUSPENSION; ORAL
VIRACEPT
\+ AGOURON EQ 50MG BASE/SCOOPFUL N20778 001 MAR 14, 1997

TABLET; ORAL
VIRACEPT
\+ AGOURON EQ 250MG BASE N20779 001 MAR 14, 1997

NEOMYCIN SULFATE

POWDER; FOR RX COMPOUNDING
NEO-RX
AA PHARMA TEK **100%** **N61579 001**

SOLUTION; ORAL
MYCIFRADIN
\+ PHARMACIA AND UPJOHN EQ 87.5MG BASE/5ML N50285 001

TABLET; ORAL
NEOMYCIN SULFATE
\+ TEVA EQ 350MG BASE N60304 001

NEOMYCIN SULFATE; *MULTIPLE*
SEE ACETIC ACID, GLACIAL; HYDROCORTISONE; NEOMYCIN SULFATE
SEE BACITRACIN; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SEE BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SEE BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SEE COLISTIN SULFATE; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; THONZONIUM BROMIDE
SEE DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SEE DEXAMETHASONE SODIUM PHOSPHATE; NEOMYCIN SULFATE

FDA data supplied by DrugPatentWatch.com

NEOMYCIN SULFATE; *MULTIPLE*
SEE GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SEE HYDROCORTISONE; NEOMYCIN SULFATE
SEE HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SEE HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC
STATROL
+ ALCON — EQ 3.5MG BASE/GM; 10,000 UNITS/GM — N50344 002

SOLUTION; IRRIGATION
NEOSPORIN G.U. IRRIGANT
+ MONARCH PHARMS — EQ 40MG BASE/ML; 200,000 UNITS/ML — N60707 001

SOLUTION/DROPS; OPHTHALMIC
STATROL
+ ALCON — EQ 3.5MG BASE/ML; 16,250 UNITS/ML — N50456 001

NEOMYCIN SULFATE; POLYMYXIN B SULFATE; PREDNISOLONE ACETATE

SUSPENSION/DROPS; OPHTHALMIC
POLY-PRED
+ ALLERGAN — EQ 0.35% BASE;10,000 UNITS/ML; 0.5% — N50081 002

NESIRITIDE

FOR SOLUTION; INTRAVENOUS
NATRECOR
+ SCIOS — 1.5MG/VIAL — N20920 001 AUG 10, 2001

NEVIRAPINE

SUSPENSION; ORAL
VIRAMUNE
+ BOEHRINGER INGELHEIM — 50MG/5ML — N20933 001 SEP 11, 1998

NEVIRAPINE

TABLET; ORAL
VIRAMUNE
+ BOEHRINGER INGELHEIM — 200MG — N20636 001 JUN 21, 1996

NIACIN

TABLET; ORAL
NIACIN
AA MK LABS — **500MG** — **N83525 001**
AA TABLICAPS — **500MG** — **N84237 001**
AA WOCKHARDT — **500MG** — **N81134 001**
APR 28, 1992

NIACOR
AA UPSHER SMITH — **500MG** — **N40378 001** MAY 03, 2000

NICOLAR
AA + AVENTIS — **500MG** — **N83823 001**

TABLET, EXTENDED RELEASE; ORAL
NIASPAN
+ KOS — 375MG — N20381 001 JUL 28, 1997
+ — 500MG — N20381 002 JUL 28, 1997
+ — 750MG — N20381 003 JUL 28, 1997
+ — 1GM — N20381 004 JUL 28, 1997

NIASPAN TITRATION STARTER PACK
+ KOS — 375MG;500MG;750MG — N20381 005 JUL 28, 1997

NIACIN; *MULTIPLE*
SEE LOVASTATIN; NIACIN

NIACINAMIDE; *MULTIPLE*
SEE ALPHA-TOCOPHEROL; ASCORBIC ACID; BIOTIN, D-; CHOLECALCIFEROL; CYANOCOBALAMIN; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A
SEE ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE

FDA data supplied by DrugPatentWatch.com

NIACINAMIDE; *MULTIPLE*

SEE ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PHYTONADIONE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

NICARDIPINE HYDROCHLORIDE

CAPSULE; ORAL

CARDENE

AB	SYNTEX (USA) INC LLC	**20MG**	**N19488 001**	DEC 21, 1988
AB	+	**30MG**	**N19488 002**	DEC 21, 1988

NICARDIPINE HCL

AB	GENPHARM	**20MG**	**N74928 001**	MAR 19, 1998
AB		**30MG**	**N74928 002**	MAR 19, 1998
AB	IVAX PHARMS	**20MG**	**N74439 001**	DEC 10, 1996
AB		**30MG**	**N74439 002**	DEC 10, 1996
AB	MYLAN	**20MG**	**N74642 001**	JUL 18, 1996
AB		**30MG**	**N74642 002**	JUL 18, 1996
AB	TEVA	**20MG**	**N74540 001**	OCT 28, 1996
AB		**30MG**	**N74540 002**	OCT 28, 1996
AB	WATSON LABS	**20MG**	**N74670 001**	OCT 28, 1996
AB		**30MG**	**N74670 002**	OCT 28, 1996

CAPSULE, EXTENDED RELEASE; ORAL

CARDENE SR

+	SYNTEX (USA) INC LLC	30MG	N20005 001	FEB 21, 1992
+		45MG	N20005 002	FEB 21, 1992
+		60MG	N20005 003	FEB 21, 1992

INJECTABLE; INJECTION

CARDENE

+	SYNTEX (USA) INC LLC	2.5MG/ML	N19734 001	JAN 30, 1992

NICOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL

NICOTINE

SANO	7MG/24HR	N74645 001	OCT 20, 1997
	14MG/24HR	N74611 001	OCT 20, 1997
	21MG/24HR	N74612 001	OCT 20, 1997

INHALANT; INHALATION

NICOTROL

+	PHARMACIA AND UPJOHN	4MG/CARTRIDGE	N20714 001	MAY 02, 1997

SPRAY, METERED; NASAL

NICOTROL

+	PHARMACIA AND UPJOHN	0.5MG/SPRAY	N20385 001	MAR 22, 1996

NIFEDIPINE

CAPSULE; ORAL

ADALAT

AB	BAYER	**10MG**	**N19478 001**	NOV 27, 1985
AB		**20MG**	**N19478 002**	SEP 17, 1986

NIFEDIPINE

AB	FLEMINGTON PHARM	**10MG**	**N72781 001**	JUL 30, 1993

FDA data supplied by DrugPatentWatch.com

NIFEDIPINE

CAPSULE; ORAL

	NIFEDIPINE			
AB	PUREPAC PHARM	10MG	**N72579 001**	JAN 08, 1991
AB		20MG	**N72556 001**	SEP 20, 1990
AB	SCHERER RP	10MG	**N73250 001**	OCT 08, 1991
AB		20MG	**N74045 001**	APR 30, 1992
AB	TEVA	10MG	**N72651 001**	FEB 19, 1992
	PROCARDIA			
AB	PFIZER	10MG	**N18482 001**	
AB +		20MG	**N18482 002**	JUL 24, 1986

TABLET, EXTENDED RELEASE; ORAL

	ADALAT CC			
AB1	BAYER	30MG	**N20198 001**	APR 21, 1993
AB1 +		60MG	**N20198 002**	APR 21, 1993
BC +		90MG	N20198 003	APR 21, 1993
	NIFEDIPINE			
AB1	BIOVAIL	30MG	**N75269 001**	DEC 04, 2000
AB2		30MG	**N75289 002**	FEB 06, 2001
AB1		60MG	**N75269 002**	DEC 04, 2000
AB2		60MG	**N75289 001**	SEP 27, 2000
AB1	ELAN PHARM	30MG	**N75128 001**	MAR 10, 2000
AB1		60MG	**N75659 001**	OCT 26, 2001
	PROCARDIA XL			
AB2 +	PFIZER	30MG	**N19684 001**	SEP 06, 1989
AB2 +		60MG	**N19684 002**	SEP 06, 1989
BC +		90MG	N19684 003	SEP 06, 1989

NILUTAMIDE

TABLET; ORAL

	NILANDRON		
	AVENTIS PHARMS	50MG	N20169 001 SEP 19, 1996
+		150MG	N20169 002 APR 30, 1999

NIMODIPINE

CAPSULE; ORAL

	NIMOTOP		
+	BAYER	30MG	N18869 001 DEC 28, 1988

NISOLDIPINE

TABLET, EXTENDED RELEASE; ORAL

	SULAR		
+	ASTRAZENECA	10MG	N20356 001 FEB 02, 1995
+		20MG	N20356 002 FEB 02, 1995
+		30MG	N20356 003 FEB 02, 1995
+		40MG	N20356 004 FEB 02, 1995

NITRIC OXIDE

GAS; INHALATION

	INOMAX		
	INO	100PPM	N20845 002 DEC 23, 1999
+		800PPM	N20845 003 DEC 23, 1999

NITROFURANTOIN

SUSPENSION; ORAL

	FURADANTIN		
+	DURA	25MG/5ML	N09175 001

TABLET; ORAL

	FURADANTIN		
AB	PROCTER AND GAMBLE	50MG	**N08693 001**

FDA data supplied by DrugPatentWatch.com

NITROFURANTOIN

TABLET; ORAL

	FURADANTIN			
AB	+ PROCTER AND GAMBLE	100MG	N08693 002	
	NITROFURANTOIN			
AB	WATSON LAB	50MG	N80447 001	
AB	WHITEWORTH TOWN PLSN	100MG	N84085 002	

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

	MACROBID			
	+ PROCTER AND GAMBLE	75MG;25MG	N20064 001	DEC 24, 1991

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

	MACRODANTIN			
AB	PROCTER AND GAMBLE	25MG	N16620 003	
AB		50MG	N16620 001	
AB	+	100MG	N16620 002	
	NITROFURANTION			
AB	MYLAN	100MG	N74967 002	JUL 09, 1997
	NITROFURANTOIN			
AB	DANBURY PHARMA	25MG	N73696 001	DEC 31, 1992
AB		50MG	N73696 002	DEC 31, 1992
AB		100MG	N73696 003	DEC 31, 1992
AB	GENEVA PHARMS	25MG	N74336 001	JAN 25, 1995
AB		50MG	N74336 002	JAN 25, 1995
AB		100MG	N74336 003	JAN 25, 1995
AB	IVAX PHARMS	50MG	N73671 001	JAN 28, 1993
AB		100MG	N73652 001	JAN 28, 1993
AB	MYLAN	50MG	N74967 001	JUL 09, 1997

NITROFURANTOIN, MACROCRYSTALLINE; *MULTIPLE*
SEE NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

NITROFURAZONE

CREAM; TOPICAL

	FURACIN			
	+ SHIRE LABS	0.2%	N83789 001	

OINTMENT; TOPICAL

	FURACIN			
AT	+ SHIRE LABS	0.2%	N05795 001	
	NITROFURAZONE			
AT	THAMES	0.2%	N86156 001	
AT	WENDT	0.2%	N86766 001	

SOLUTION; TOPICAL

	NITROFURAZONE			
	+ WENDT	0.2%	N87081 001	

NITROGLYCERIN

FILM, EXTENDED RELEASE; TRANSDERMAL

	MINITRAN			
AB1	3M	0.1MG/HR	N89771 001	AUG 30, 1996
AB1		0.2MG/HR	N89772 001	AUG 30, 1996
AB1		0.4MG/HR	N89773 001	AUG 30, 1996
AB1		0.6MG/HR	N89774 001	AUG 30, 1996
	NITRO-DUR			
AB1	+ KEY PHARMS	0.1MG/HR	N20145 001	APR 04, 1995
AB1	+	0.2MG/HR	N20145 002	APR 04, 1995
AB1	+	0.4MG/HR	N20145 004	APR 04, 1995
AB1	+	0.6MG/HR	N20145 005	APR 04, 1995
BX	+	0.8MG/HR	N20145 006	APR 04, 1995
	+	0.3MG/HR	N20145 003	APR 04, 1995
	NITROGLYCERIN			
AB2	HERCON LABS	0.2MG/HR	N89884 001	OCT 30, 1998
AB2		0.4MG/HR	N89885 001	OCT 30, 1998

FDA data supplied by DrugPatentWatch.com

NITROGLYCERIN

FILM, EXTENDED RELEASE; TRANSDERMAL

	NITROGLYCERIN			
AB2	HERCON LABS	0.6MG/HR	**N89886 001**	OCT 30, 1998
AB2	MYLAN	0.1MG/HR	**N75033 001**	FEB 06, 1998
AB2		0.2MG/HR	**N74609 001**	AUG 30, 1996
AB2		0.4MG/HR	**N74607 001**	AUG 30, 1996
AB2		0.6MG/HR	**N74559 001**	AUG 30, 1996
AB1	MYLAN TECHNOLOGIES	0.1MG/HR	**N75076 001**	NOV 12, 1999
AB1		0.2MG/HR	**N75073 001**	NOV 12, 1999
AB1		0.4MG/HR	**N75075 001**	NOV 12, 1999
AB1		0.6MG/HR	**N74992 001**	NOV 12, 1999
	TRANSDERM-NITRO			
AB2	+ NOVARTIS	0.1MG/HR	**N20144 001**	FEB 27, 1996
AB2	+	0.2MG/HR	**N20144 002**	FEB 27, 1996
AB2	+	0.4MG/HR	**N20144 003**	FEB 27, 1996
AB2	+	0.6MG/HR	**N20144 004**	FEB 27, 1996
BX	+	0.8MG/HR	N20144 005	FEB 27, 1996

INJECTABLE; INJECTION

	NITRO-BID			
AP	+ AVENTIS PHARMS	5MG/ML	**N18621 001**	JAN 05, 1982
	NITROGLYCERIN			
AP	+ ABBOTT	5MG/ML	**N18531 001**	
AP	LUITPOLD	5MG/ML	**N72034 001**	MAY 24, 1988
	NITROGLYCERIN IN DEXTROSE 5%			
AP	ABBOTT	10MG/100ML	**N71846 001**	AUG 31, 1990
AP		0.1MG/ML	**N74083 001**	OCT 26, 1994
AP		20MG/100ML	**N71847 001**	AUG 31, 1990

NITROGLYCERIN

INJECTABLE; INJECTION

	NITROGLYCERIN IN DEXTROSE 5%			
AP	ABBOTT	40MG/100ML	**N71848 001**	AUG 31, 1990
AP	+ BAXTER HLTHCARE	10MG/100ML	**N19970 001**	DEC 29, 1989
AP	+	20MG/100ML	**N19970 002**	DEC 29, 1989
AP	+	40MG/100ML	**N19970 003**	DEC 29, 1989
	TRIDIL			
AP	+ FAULDING	5MG/ML	**N18537 001**	
	+	0.5MG/ML	N18537 002	JUN 16, 1983

OINTMENT; TRANSDERMAL

	NITROGLYCERIN		
	+ ALTANA	2%	N87355 001 JUL 08, 1988

SPRAY, METERED; SUBLINGUAL

	NITROLINGUAL PUMPSPRAY		
	+ POHL BOSKAMP	0.4MG/SPRAY	N18705 002 JAN 10, 1997

TABLET; SUBLINGUAL

	NITROSTAT		
	PARKE DAVIS	0.3MG	N21134 001 MAY 01, 2000
		0.4MG	N21134 002 MAY 01, 2000
	+	0.6MG	N21134 003 MAY 01, 2000

NIZATIDINE

CAPSULE; ORAL

	AXID		
	LILLY	150MG	N19508 001 APR 12, 1988
	+	300MG	N19508 002 APR 12, 1988

NORELGESTROMIN; *MULTIPLE*

SEE ETHINYL ESTRADIOL; NORELGESTROMIN

FDA data supplied by DrugPatentWatch.com

NOREPINEPHRINE BITARTRATE

INJECTABLE; INJECTION
LEVOPHED
+ ABBOTT — EQ 1MG BASE/ML — N07513 001

NORETHINDRONE

TABLET; ORAL
NOR-QD
+ WATSON LABS — 0.35MG — N17060 001

TABLET; ORAL-28
MICRONOR
+ JOHNSON RW — 0.35MG — N16954 001

NORETHINDRONE; *MULTIPLE*
SEE ETHINYL ESTRADIOL; NORETHINDRONE
SEE MESTRANOL; NORETHINDRONE

NORETHINDRONE ACETATE

TABLET; ORAL
AYGESTIN
AB + WYETH AYERST — **5MG** — **N18405 001** APR 21, 1982

NORETHINDRONE ACETATE
AB BARR — **5MG** — **N75951 001** MAY 25, 2001

NORETHINDRONE ACETATE; *MULTIPLE*
SEE ESTRADIOL; NORETHINDRONE ACETATE
SEE ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

NORFLOXACIN

SOLUTION/DROPS; OPHTHALMIC
CHIBROXIN
+ MERCK — 0.3% — N19757 001 JUN 17, 1991

TABLET; ORAL
NOROXIN
+ MERCK — 400MG — N19384 002 OCT 31, 1986

NORGESTIMATE; *MULTIPLE*
SEE ESTRADIOL; NORGESTIMATE
SEE ETHINYL ESTRADIOL; NORGESTIMATE

NORGESTREL

TABLET; ORAL
OVRETTE
+ WYETH AYERST — 0.075MG — N17031 001

NORGESTREL; *MULTIPLE*
SEE ETHINYL ESTRADIOL; NORGESTREL

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE; ORAL
AVENTYL HCL

BD	LILLY	EQ 10MG BASE	N14684 001
BD		EQ 25MG BASE	N14684 002
	NORTRIPTYLINE HCL		
AB	DANBURY PHARMA	**EQ 10MG BASE**	**N73553 001** MAR 30, 1992
AB		**EQ 25MG BASE**	**N73554 001** MAR 30, 1992
AB		**EQ 50MG BASE**	**N73555 001** MAR 30, 1992
AB		**EQ 75MG BASE**	**N73556 001** MAR 30, 1992
AB	GENEVA PHARMS	**EQ 10MG BASE**	**N74054 001** DEC 31, 1992
AB		**EQ 25MG BASE**	**N74054 002** DEC 31, 1992
AB		**EQ 50MG BASE**	**N74054 003** DEC 31, 1992
AB		**EQ 75MG BASE**	**N74054 004** DEC 31, 1992
AB	GENEVA PHARMS TECH	**EQ 10MG BASE**	**N74835 001** JUN 30, 1997
AB		**EQ 25MG BASE**	**N74835 002** JUN 30, 1997
AB		**EQ 50MG BASE**	**N74835 003** JUN 30, 1997
AB		**EQ 75MG BASE**	**N74835 004** JUN 30, 1997
AB	MYLAN	**EQ 10MG BASE**	**N74234 001** JUL 26, 1993

FDA data supplied by DrugPatentWatch.com

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE; ORAL

	NORTRIPTYLINE HCL			
AB	MYLAN	EQ 25MG BASE	N74234 002	JUL 26, 1993
AB		EQ 50MG BASE	N74234 003	JUL 26, 1993
AB		EQ 75MG BASE	N74234 004	JUL 26, 1993
AB	TARO	EQ 10MG BASE	N75520 004	MAY 08, 2000
AB		EQ 25MG BASE	N75520 003	MAY 08, 2000
AB		EQ 50MG BASE	N75520 001	MAY 08, 2000
AB		EQ 75MG BASE	N75520 002	MAY 08, 2000
AB	TEVA	EQ 10MG BASE	N73667 001	APR 11, 1996
AB		EQ 10MG BASE	N74132 001	MAR 27, 1995
AB		EQ 25MG BASE	N73667 002	APR 11, 1996
AB		EQ 25MG BASE	N74132 002	MAR 27, 1995
AB		EQ 50MG BASE	N73667 003	APR 11, 1996
AB		EQ 50MG BASE	N74132 003	MAR 27, 1995
AB		EQ 75MG BASE	N73667 004	APR 11, 1996
AB		EQ 75MG BASE	N74132 004	MAR 27, 1995
	PAMELOR			
AB	TYCO HLTHCARE	EQ 10MG BASE	N18013 001	
AB		EQ 25MG BASE	N18013 002	
AB		EQ 50MG BASE	N18013 004	
AB	+	EQ 75MG BASE	N18013 003	

SOLUTION; ORAL

	AVENTYL HCL			
AA	+ LILLY	EQ 10MG BASE/5ML	N14685 001	
	NORTRIPTYLINE HCL			
AA	PHARM ASSOC	EQ 10MG BASE/5ML	N75606 001	AUG 28, 2000
	PAMELOR			
AA	TYCO HLTHCARE	EQ 10MG BASE/5ML	N18012 001	

NOVOBIOCIN SODIUM

CAPSULE; ORAL

	ALBAMYCIN			
	+ PHARMACIA AND UPJOHN	EQ 250MG BASE	N50339 001	

NYSTATIN

CREAM; TOPICAL

	MYCOSTATIN			
AT	+ WESTWOOD SQUIBB	100,000 UNITS/GM	N60575 001	
	NYSTATIN			
AT	ALPHARMA	100,000 UNITS/GM	N62949 001	JUN 13, 1988
AT	ALTANA	100,000 UNITS/GM	N62129 001	
AT	CLAY PARK	100,000 UNITS/GM	N62225 001	
AT	TARO	100,000 UNITS/GM	N64022 001	JAN 29, 1993
AT	THAMES	100,000 UNITS/GM	N62457 001	JUL 28, 1983

OINTMENT; TOPICAL

	NYSTATIN			
AT	ALPHARMA	100,000 UNITS/GM	N62840 001	NOV 13, 1987
AT	+ ALTANA	100,000 UNITS/GM	N62124 002	SEP 23, 1982
AT	CLAY PARK	100,000 UNITS/GM	N62472 001	FEB 13, 1984

PASTILLE; ORAL

	MYCOSTATIN			
	+ BRISTOL MYERS SQUIBB	200,000 UNITS	N50619 001	APR 09, 1987

POWDER; ORAL

	NILSTAT			
AA	+ LEDERLE	100%	N50576 001	DEC 22, 1983
	NYSTATIN			
AA	PADDOCK	100%	N62613 001	NOV 26, 1985

POWDER; TOPICAL

	MYCOSTATIN			
AT	+ WESTWOOD SQUIBB	100,000 UNITS/GM	N60578 001	
	NYSTOP			
AT	PADDOCK	100,000 UNITS/GM	N64118 001	AUG 16, 1996

FDA data supplied by DrugPatentWatch.com

NYSTATIN

SUSPENSION; ORAL

	MYCOSTATIN			
AA	+ APOTHECON	100,000 UNITS/ML	N61533 001	
	NILSTAT			
AA	+ LEDERLE	100,000 UNITS/ML	N50299 001	
	NYSTATIN			
AA	ALPHARMA	100,000 UNITS/ML	N62349 001	JUL 14, 1982
AA	BAUSCH AND LOMB	100,000 UNITS/ML	N64042 001	FEB 28, 1994
AA	FOUGERA	100,000 UNITS/ML	N62517 001	JUN 07, 1984
AA	MORTON GROVE	100,000 UNITS/ML	N62512 001	OCT 29, 1984
AA	UDL	100,000 UNITS/ML	N64142 001	JUN 25, 1998
	NYSTEX			
AA	SAVAGE LABS	100,000 UNITS/ML	N62519 001	JUL 06, 1984

TABLET; ORAL

	MYCOSTATIN			
AA	+ APOTHECON	500,000 UNITS	N60574 001	
	NILSTAT			
AA	LEDERLE	500,000 UNITS	N61151 001	
	NYSTATIN			
AA	MUTUAL PHARM	500,000 UNITS	N62838 001	DEC 22, 1988
AA	PAR PHARM	500,000 UNITS	N62474 001	DEC 22, 1983
AA	TEVA	500,000 UNITS	N62506 001	JAN 16, 1984

TABLET; VAGINAL

	NILSTAT			
AT	LEDERLE	100,000 UNITS	N61325 001	
	NYSTATIN			
AT	FOUGERA	100,000 UNITS	N62459 001	NOV 09, 1983
AT	ODYSSEY PHARMS	100,000 UNITS	N62615 001	OCT 17, 1985
AT	PHARMADERM	100,000 UNITS	N62460 001	NOV 09, 1983

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

	MYCO-TRIACET II			
AT	TEVA	100,000 UNITS/GM;0.1%	N61954 002	SEP 20, 1985
	MYCOLOG-II			
AT	+ APOTHECON	100,000 UNITS/GM;0.1%	N62606 001	MAY 15, 1985
	MYKACET			
AT	ALPHARMA US PHARM	100,000 UNITS/GM;0.1%	N62367 001	MAY 28, 1985
	MYTREX F			
AT	SAVAGE LABS	100,000 UNITS/GM;0.1%	N62597 001	OCT 08, 1985
	NYSTATIN AND TRIAMCINOLONE ACETONIDE			
AT	TARO	100,000 UNITS/GM;0.1%	N62364 001	DEC 22, 1987
AT	THAMES	100,000 UNITS/GM;0.1%	N62347 001	MAR 30, 1987
	NYSTATIN-TRIAMCINOLONE ACETONIDE			
AT	FOUGERA	100,000 UNITS/GM;0.1%	N62599 001	OCT 08, 1985

OINTMENT; TOPICAL

	MYCOLOG-II			
AT	+ APOTHECON	100,000 UNITS/GM;0.1%	N60572 001	JUN 28, 1985
	MYKACET			
AT	NMC	100,000 UNITS/GM;0.1%	N62733 001	MAR 09, 1987
	MYTREX F			
AT	SAVAGE LABS	100,000 UNITS/GM;0.1%	N62601 001	OCT 09, 1985
	NYSTATIN AND TRIAMCINOLONE ACETONIDE			
AT	TARO	100,000 UNITS/GM;0.1%	N63305 001	MAR 29, 1993
	NYSTATIN-TRIAMCINOLONE ACETONIDE			
AT	FOUGERA	100,000 UNITS/GM;0.1%	N62602 001	OCT 09, 1985

OCTREOTIDE ACETATE

INJECTABLE; INJECTION

	SANDOSTATIN			
	+ NOVARTIS	EQ 0.05MG BASE/ML	N19667 001	OCT 21, 1988

FDA data supplied by DrugPatentWatch.com

OCTREOTIDE ACETATE

INJECTABLE; INJECTION			
SANDOSTATIN			
+ NOVARTIS	EQ 0.1MG BASE/ML	N19667 002	OCT 21, 1988
+	EQ 0.2MG BASE/ML	N19667 004	JUN 12, 1991
+	EQ 0.5MG BASE/ML	N19667 003	OCT 21, 1988
+	EQ 1MG BASE/ML	N19667 005	JUN 12, 1991
SANDOSTATIN LAR			
+ NOVARTIS	EQ 10MG BASE/VIAL	N21008 001	NOV 25, 1998
+	EQ 20MG BASE/VIAL	N21008 002	NOV 25, 1998
+	EQ 30MG BASE/VIAL	N21008 003	NOV 25, 1998

OFLOXACIN

INJECTABLE; INJECTION			
FLOXIN			
+ JOHNSON RW	20MG/ML	N20087 002	MAR 31, 1992
+	40MG/ML	N20087 003	MAR 31, 1992
FLOXIN IN DEXTROSE 5%			
+ JOHNSON RW	400MG/100ML	N20087 001	MAR 31, 1992
FLOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER			
+ JOHNSON RW	4MG/ML	N20087 004	MAR 31, 1992
+	400MG/100ML	N20087 005	MAR 31, 1992
SOLUTION/DROPS; OPHTHALMIC			
OCUFLOX			
+ ALLERGAN	0.3%	N19921 001	JUL 30, 1993
SOLUTION/DROPS; OTIC			
FLOXIN			
+ DAIICHI	0.3%	N20799 001	DEC 16, 1997

OFLOXACIN

TABLET; ORAL			
FLOXIN			
JOHNSON RW	200MG	N19735 001	DEC 28, 1990
	300MG	N19735 002	DEC 28, 1990
+	400MG	N19735 003	DEC 28, 1990

OLANZAPINE

TABLET; ORAL			
ZYPREXA			
+ LILLY	2.5MG	N20592 001	SEP 30, 1996
	5MG	N20592 002	SEP 30, 1996
	7.5MG	N20592 003	SEP 30, 1996
	10MG	N20592 004	SEP 30, 1996
	15MG	N20592 005	SEP 09, 1997
+	20MG	N20592 006	SEP 09, 1997
TABLET, ORALLY DISINTEGRATING; ORAL			
ZYPREXA ZYDIS			
LILLY	5MG	N21086 001	APR 06, 2000
	10MG	N21086 002	APR 06, 2000
	15MG	N21086 003	APR 06, 2000
+	20MG	N21086 004	APR 06, 2000

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC			
PATANOL			
+ ALCON	EQ 0.1% BASE	N20688 001	DEC 18, 1996

FDA data supplied by DrugPatentWatch.com

OLSALAZINE SODIUM

CAPSULE; ORAL

	DIPENTUM			
	+ PHARMACIA AND UPJOHN	250MG	N19715 001	JUL 31, 1990

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL

	OMEPRAZOLE			
AB	ANDRX PHARMS	**10MG**	**N75347 001**	NOV 16, 2001
AB		**20MG**	**N75347 002**	NOV 16, 2001
AB		**40MG**	**N75347 003**	NOV 16, 2001
	PRILOSEC			
AB	ASTRAZENECA	**10MG**	**N19810 003**	OCT 05, 1995
AB +		**20MG**	**N19810 001**	SEP 14, 1989
AB +		**40MG**	**N19810 002**	JAN 15, 1998

ONDANSETRON

TABLET, ORALLY DISINTEGRATING; ORAL

ZOFRAN ODT			
GLAXOSMITHKLINE	EQ 4MG BASE	N20781 001	JAN 27, 1999
+	EQ 8MG BASE	N20781 002	JAN 27, 1999

ONDANSETRON HYDROCHLORIDE

INJECTABLE; INJECTION

ZOFRAN			
+ GLAXOSMITHKLINE	EQ 2MG BASE/ML	N20007 001	JAN 04, 1991
ZOFRAN IN PLASTIC CONTAINER			
+ GLAXOSMITHKLINE	EQ 0.64MG BASE/ML	N20403 001	JAN 31, 1995
ZOFRAN PRESERVATIVE FREE			
+ GLAXOSMITHKLINE	EQ 2MG BASE/ML	N20007 003	DEC 10, 1993

ONDANSETRON HYDROCHLORIDE

SOLUTION; ORAL

ZOFRAN			
+ GLAXOSMITHKLINE	EQ 4MG BASE/5ML	N20605 001	JAN 24, 1997

TABLET; ORAL

ZOFRAN			
GLAXOSMITHKLINE	EQ 4MG BASE	N20103 001	DEC 31, 1992
	EQ 8MG BASE	N20103 002	DEC 31, 1992
+	EQ 24MG BASE	N20103 003	AUG 27, 1999

ORLISTAT

CAPSULE; ORAL

XENICAL			
+ HLR	120MG	N20766 001	APR 23, 1999

ORPHENADRINE CITRATE

INJECTABLE; INJECTION

	NORFLEX			
AP	+ 3M	**30MG/ML**	**N13055 001**	
	ORPHENADRINE CITRATE			
AP	STERIS	**30MG/ML**	**N84779 001**	MAR 15, 1982
AP		**30MG/ML**	**N87062 001**	

TABLET, EXTENDED RELEASE; ORAL

	NORFLEX			
AB	+ 3M	**100MG**	**N12157 001**	
	ORPHENADRINE CITRATE			
AB	EON	**100MG**	**N40327 001**	FEB 15, 2000
AB	GENEVA PHARMS TECH	**100MG**	**N40284 001**	JUN 19, 1998
AB	IMPAX PHARM	**100MG**	**N40368 001**	JUN 23, 2000
AB	KIEL	**100MG**	**N40249 001**	JAN 29, 1999

ORPHENADRINE CITRATE; *MULTIPLE*
SEE ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

FDA data supplied by DrugPatentWatch.com

OSELTAMIVIR PHOSPHATE

CAPSULE; ORAL
TAMIFLU
+ ROCHE — EQ 75MG BASE — N21087 001 OCT 27, 1999

FOR SUSPENSION; ORAL
TAMIFLU
+ ROCHE — EQ 12MG BASE/ML — N21246 001 DEC 14, 2000

OXACILLIN SODIUM

CAPSULE; ORAL
BACTOCILL

AB		GLAXOSMITHKLINE	**EQ 250MG BASE**	**N61336 001**
AB			**EQ 250MG BASE**	**N62241 001**
AB	+		**EQ 500MG BASE**	**N61336 002**
AB			**EQ 500MG BASE**	**N62241 002**

OXACILLIN SODIUM

AB		TEVA	**EQ 250MG BASE**	**N62222 001**
AB			**EQ 500MG BASE**	**N62222 002**

FOR SOLUTION; ORAL
BACTOCILL

AA		GLAXOSMITHKLINE	**EQ 250MG BASE/5ML**	**N62321 001**

OXACILLIN SODIUM

AA		APOTHECON	**EQ 250MG BASE/5ML**	**N61457 001**
AA		TEVA	**EQ 250MG BASE/5ML**	**N62252 001**

INJECTABLE; INJECTION
BACTOCILL IN PLASTIC CONTAINER

	+	BAXTER HLTHCARE	EQ 20MG BASE/ML	N50640 001 OCT 26, 1989
	+		EQ 40MG BASE/ML	N50640 002 OCT 26, 1989

OXACILLIN SODIUM

AP		APOTHECON	**EQ 250MG BASE/VIAL**	**N61490 001**
AP	+		**EQ 500MG BASE/VIAL**	**N61490 002**
AP	+		**EQ 1GM BASE/VIAL**	**N61490 003**
AP			**EQ 1GM BASE/VIAL**	**N62737 001** DEC 23, 1986
AP	+		**EQ 2GM BASE/VIAL**	**N62737 002** DEC 23, 1986
AP	+		**EQ 10GM BASE/VIAL**	**N61490 006** MAY 09, 1991

OXACILLIN SODIUM

INJECTABLE; INJECTION
OXACILLIN SODIUM

AP		MARSAM PHARMS LLC	**EQ 1GM BASE/VIAL**	**N62856 003** OCT 26, 1988
AP			**EQ 2GM BASE/VIAL**	**N62856 004** OCT 26, 1988
AP			**EQ 10GM BASE/VIAL**	**N62984 001** SEP 29, 1988
AP			**EQ 250MG BASE/VIAL**	**N62856 001** OCT 26, 1988
AP			**EQ 500MG BASE/VIAL**	**N62856 002** OCT 26, 1988
			EQ 4GM BASE/VIAL	N62856 005 OCT 26, 1988

OXAMNIQUINE

CAPSULE; ORAL
VANSIL
+ PFIZER — 250MG — N18069 001

OXANDROLONE

TABLET; ORAL
OXANDRIN
+ BIO TECH GEN — 2.5MG — N13718 001

OXAPROZIN

TABLET; ORAL
DAYPRO

AB	+	GD SEARLE LLC	**600MG**	**N18841 004** OCT 29, 1992

OXAPROZIN

AB		DR REDDYS LABS LTD	**600MG**	**N75855 001** JAN 31, 2001
AB		EON	**600MG**	**N75845 001** JAN 31, 2001
AB		GENEVA PHARMS	**600MG**	**N75850 001** APR 27, 2001
AB		GENPHARM	**600MG**	**N75847 001** FEB 28, 2001
AB		INVAMED	**600MG**	**N75842 001** APR 12, 2001

FDA data supplied by DrugPatentWatch.com

OXAPROZIN

TABLET; ORAL

OXAPROZIN

AB	MYLAN	**600MG**	**N75851 001**	AUG 17, 2001
AB	PUREPAC PHARM	**600MG**	**N75843 001**	OCT 03, 2001
AB	WATSON LABS	**600MG**	**N75848 001**	FEB 09, 2001

OXAZEPAM

CAPSULE; ORAL

OXAZEPAM

AB	DANBURY PHARMA	**10MG**	**N72952 001**	SEP 28, 1990
AB		**15MG**	**N72953 001**	SEP 28, 1990
AB		**30MG**	**N72954 001**	SEP 28, 1990
AB	GENEVA PHARMS	**10MG**	**N71813 001**	APR 19, 1988
AB		**15MG**	**N71756 001**	APR 19, 1988
AB		**30MG**	**N71814 001**	APR 19, 1988
AB	IVAX PHARMS	**10MG**	**N70943 001**	AUG 03, 1987
AB		**15MG**	**N70944 001**	AUG 03, 1987
AB		**30MG**	**N70945 001**	AUG 03, 1987
AB	PUREPAC PHARM	**10MG**	**N72251 001**	APR 14, 1988
AB		**15MG**	**N72252 001**	APR 14, 1988
AB		**30MG**	**N72253 001**	APR 14, 1988

SERAX

AB	FAULDING PHARMS	**10MG**	**N15539 002**	
AB		**15MG**	**N15539 004**	
AB	+	**30MG**	**N15539 006**	

TABLET; ORAL

SERAX

+	FAULDING PHARMS	15MG	N15539 008	

OXCARBAZEPINE

SUSPENSION; ORAL

TRILEPTAL

+	NOVARTIS	300MG/5ML	N21285 001	MAY 25, 2001

TABLET; ORAL

TRILEPTAL

	NOVARTIS	150MG	N21014 001	JAN 14, 2000
		300MG	N21014 002	JAN 14, 2000
+		600MG	N21014 003	JAN 14, 2000

OXICONAZOLE NITRATE

CREAM; TOPICAL

OXISTAT

+	GLAXOSMITHKLINE	EQ 1% BASE	N19828 001	DEC 30, 1988

LOTION; TOPICAL

OXISTAT

+	GLAXOSMITHKLINE	EQ 1% BASE	N20209 001	SEP 30, 1992

OXTRIPHYLLINE

TABLET, EXTENDED RELEASE; ORAL

CHOLEDYL SA

+	PARKE DAVIS	400MG	N87863 001	MAY 24, 1983
+	WARNER CHILCOTT	600MG	N86742 001	

OXYBUTYNIN CHLORIDE

SYRUP; ORAL

DITROPAN

AA	+ ALZA	**5MG/5ML**	**N18211 001**	

OXYBUTYNIN CHLORIDE

AA	MIKART	**5MG/5ML**	**N75039 001**	JAN 29, 1999
AA	MORTON GROVE	**5MG/5ML**	**N74868 001**	FEB 12, 1997

FDA data supplied by DrugPatentWatch.com

OXYBUTYNIN CHLORIDE

SYRUP; ORAL

	OXYBUTYNIN CHLORIDE			
AA	NOVEX	**5MG/5ML**	**N74997 001**	
			OCT 15, 1997	
AA	PHARM ASSOC	**5MG/5ML**	**N75137 001**	
			DEC 18, 1998	
AA	SILARX	**5MG/5ML**	**N74520 001**	
			MAR 29, 1996	

TABLET; ORAL

	DITROPAN			
AB	+ ALZA	**5MG**	**N17577 001**	
	OXYBUTYNIN CHLORIDE			
AB	SIDMAK LABS NJ	**5MG**	**N71655 001**	
			NOV 14, 1988	
AB	USL PHARMA	**5MG**	**N74625 001**	
			JUL 31, 1996	
AB	VINTAGE PHARMS	**5MG**	**N75079 001**	
			OCT 31, 1997	

TABLET, EXTENDED RELEASE; ORAL

	DITROPAN XL			
	+ ALZA	5MG	N20897 001	
			DEC 16, 1998	
	+	10MG	N20897 002	
			DEC 16, 1998	
	+	15MG	N20897 003	
			JUN 22, 1999	

OXYCODONE HYDROCHLORIDE

TABLET; ORAL

	ROXICODONE			
	ELAN PHARMS	15MG	N21011 001	
			AUG 31, 2000	
	+	30MG	N21011 002	
			AUG 31, 2000	

TABLET, EXTENDED RELEASE; ORAL

	OXYCONTIN			
	PURDUE PHARMA LP	10MG	N20553 001	
			DEC 12, 1995	
		20MG	N20553 002	
			DEC 12, 1995	
	+	40MG	N20553 003	
			DEC 12, 1995	

OXYCODONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

	OXYCONTIN			
	+ PURDUE PHARMA LP	80MG	N20553 004	
			JAN 06, 1997	

OXYCODONE HYDROCHLORIDE; *MULTIPLE*
SEE ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE
SEE ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

OXYCODONE TEREPHTHALATE; *MULTIPLE*
SEE ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

OXYMETHOLONE

TABLET; ORAL

	ANADROL-50		
	+ UNIMED	50MG	N16848 001

OXYMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION

	NUMORPHAN		
	+ ENDO PHARMS	1MG/ML	N11707 002
	+	1.5MG/ML	N11707 001

SUPPOSITORY; RECTAL

	NUMORPHAN		
	+ ENDO PHARMS	5MG	N11738 004

OXYTETRACYCLINE; *MULTIPLE*
SEE LIDOCAINE HYDROCHLORIDE; OXYTETRACYCLINE

OXYTETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL

	TERRAMYCIN		
	+ PFIZER	EQ 250MG BASE	N50286 002

OXYTETRACYCLINE HYDROCHLORIDE; *MULTIPLE*
SEE HYDROCORTISONE ACETATE; OXYTETRACYCLINE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

OXYTETRACYCLINE HYDROCHLORIDE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC
TERRAMYCIN W/ POLYMYXIN B SULFATE

+	PFIZER	EQ 5MG BASE/GM; 10,000 UNITS/GM		N61015 001

OXYTOCIN

INJECTABLE; INJECTION

	OXYTOCIN			
AP	AM PHARM PARTNERS	**10 USP UNITS/ML**		**N18248 001**
	PITOCIN			
AP	+ PARKEDALE	**10 USP UNITS/ML**		**N18261 001**
	SYNTOCINON			
AP	NOVARTIS	**10 USP UNITS/ML**		**N18245 001**

PACLITAXEL

INJECTABLE; INJECTION

	PACLITAXEL			
AP	BAKER NORTON	**6MG/ML**	**N75184 001**	SEP 15, 2000
AP	BEDFORD	**6MG/ML**	**N75190 001**	JUL 27, 2001
AP	IVAX PHARMS	**6MG/ML**	**N75297 001**	MAR 27, 2001
AP	MYLAN	**6MG/ML**	**N75278 001**	JUL 23, 2001
	TAXOL			
AP	+ BRISTOL MYERS SQUIBB	**6MG/ML**	**N20262 001**	DEC 29, 1992

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION

	AREDIA			
AP	+ NOVARTIS	**30MG/VIAL**	**N20036 001**	OCT 31, 1991
AP	+	**90MG/VIAL**	**N20036 004**	MAY 06, 1993
	+	60MG/VIAL	N20036 003	MAY 06, 1993
	PAMIDRONATE DISODIUM			
AP	BEDFORD	**30MG/VIAL**	**N75290 001**	APR 30, 2001

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION

	PAMIDRONATE DISODIUM			
AP	BEDFORD	**90MG/VIAL**	**N75290 003**	APR 30, 2001

PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)

CAPSULE; ORAL
COTAZYM

+	ORGANON	30,000 USP UNITS;8,000 USP UNITS; 30,000 USP UNITS	N20580 001 DEC 09, 1996

PANCURONIUM BROMIDE

INJECTABLE; INJECTION

	PANCURONIUM			
AP	ELKINS SINN	**1MG/ML**	**N72058 001**	MAR 23, 1988
AP		**2MG/ML**	**N72059 001**	MAR 23, 1988
AP		**2MG/ML**	**N72060 001**	MAR 23, 1988
	PANCURONIUM BROMIDE			
AP	ABBOTT	**1MG/ML**	**N72320 001**	JAN 19, 1989
AP		**2MG/ML**	**N72321 001**	JAN 19, 1989
AP	GENSIA SICOR PHARMS	**1MG/ML**	**N72759 001**	JUL 31, 1990
AP		**2MG/ML**	**N72760 001**	JUL 31, 1990
	PAVULON			
AP	+ ORGANON	**1MG/ML**	**N17015 002**	
AP	+	**2MG/ML**	**N17015 001**	

PANTOPRAZOLE SODIUM

INJECTABLE; IV (INFUSION)
PROTONIX IV

+	WYETH AYERST	EQ 40MG BASE/VIAL	N20988 001 MAR 22, 2001

FDA data supplied by DrugPatentWatch.com

PANTOPRAZOLE SODIUM

TABLET, DELAYED RELEASE; ORAL
PROTONIX
+ WYETH AYERST — EQ 20MG BASE — N20987 002 JUN 12, 2001
+ — EQ 40MG BASE — N20987 001 FEB 02, 2000

PANTOTHENIC ACID; *MULTIPLE*
SEE ALPHA-TOCOPHEROL; ASCORBIC ACID; BIOTIN, D-; CHOLECALCIFEROL; CYANOCOBALAMIN; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A

PARAMETHADIONE

CAPSULE; ORAL
PARADIONE
+ ABBOTT — 150MG — N06800 003
— 300MG — N06800 001

PARICALCITOL

INJECTABLE; INJECTION
ZEMPLAR
+ ABBOTT — 0.005MG/ML — N20819 001 APR 17, 1998

PAROMOMYCIN SULFATE

CAPSULE; ORAL
HUMATIN
AA + PARKEDALE — **EQ 250MG BASE** — **N62310 001**
PAROMOMYCIN SULFATE
AA CARACO — **EQ 250MG BASE** — **N64171 001** JUN 30, 1997

PAROXETINE HYDROCHLORIDE

SUSPENSION; ORAL
PAXIL
+ GLAXOSMITHKLINE — EQ 10MG BASE/5ML — N20710 001 JUN 25, 1997

PAROXETINE HYDROCHLORIDE

TABLET; ORAL
PAXIL
GLAXOSMITHKLINE — EQ 10MG BASE — N20031 001 DEC 29, 1992
— EQ 20MG BASE — N20031 002 DEC 29, 1992
— EQ 30MG BASE — N20031 003 DEC 29, 1992
+ — EQ 40MG BASE — N20031 005 DEC 29, 1992

TABLET, EXTENDED RELEASE; ORAL
PAXIL CR
+ GLAXOSMITHKLINE — EQ 12.5MG BASE — N20936 001 FEB 16, 1999
+ — EQ 25MG BASE — N20936 002 FEB 16, 1999
+ — EQ 37.5MG BASE — N20936 003 DEC 06, 2000

PEGADEMASE BOVINE

INJECTABLE; INJECTION
ADAGEN
+ ENZON — 250 UNITS/ML — N19818 001 MAR 21, 1990

PEMIROLAST POTASSIUM

SOLUTION/DROPS; OPHTHALMIC
ALAMAST
+ SANTEN — 0.1% — N21079 001 SEP 24, 1999

PEMOLINE

TABLET; ORAL
CYLERT
AB + ABBOTT — **18.75MG** — **N16832 001**
AB — **37.5MG** — **N16832 002**
AB + — **75MG** — **N16832 003**
PEMOLINE
AB AMIDE PHARM — **18.75MG** — **N75595 001** FEB 28, 2000

FDA data supplied by DrugPatentWatch.com

PEMOLINE

TABLET; ORAL

	PEMOLINE			
AB	AMIDE PHARM	37.5MG	N75595 002	FEB 28, 2000
AB		75MG	N75595 003	FEB 28, 2000
AB	COPLEY PHARM	18.75MG	N75030 003	FEB 22, 2000
AB		37.5MG	N75030 001	JAN 29, 1999
AB		75MG	N75030 002	JAN 29, 1999
AB	GENEVA PHARMS TECH	18.75MG	N75286 001	DEC 27, 1999
AB		37.5MG	N75286 002	JUN 30, 1999
AB		75MG	N75286 003	JUN 30, 1999
AB	MALLINCKRODT	18.75MG	N75726 003	MAR 30, 2001
AB		37.5MG	N75726 002	MAR 30, 2001
AB		75MG	N75726 001	MAR 30, 2001
AB	VINTAGE PHARMS	18.75MG	N75328 001	APR 19, 2000
AB		37.5MG	N75328 002	APR 19, 2000
AB		75MG	N75328 003	APR 19, 2000
AB	WATSON LABS	18.75MG	N75287 001	JUN 13, 2001
AB		37.5MG	N75287 002	SEP 18, 2000
AB		75MG	N75287 003	SEP 18, 2000

TABLET, CHEWABLE; ORAL

	CYLERT			
AB	+ ABBOTT	37.5MG	N17703 001	
	PEMOLINE			
AB	AMIDE PHARM	37.5MG	N75678 001	JUL 26, 2000
AB	COPLEY PHARM	37.5MG	N75555 001	FEB 18, 2000

PENBUTOLOL SULFATE

TABLET; ORAL

	LEVATOL		
	+ SCHWARZ PHARMA	20MG	N18976 004 JAN 05, 1989

PENCICLOVIR SODIUM

CREAM; TOPICAL

	DENAVIR		
	+ NOVARTIS	1%	N20629 001 SEP 24, 1996

PENICILLAMINE

CAPSULE; ORAL

	CUPRIMINE		
	MERCK	125MG	N19853 002
	+	250MG	N19853 001

TABLET; ORAL

	DEPEN		
	+ WALLACE LABS	250MG	N19854 001

PENICILLIN G BENZATHINE

INJECTABLE; INJECTION

	BICILLIN L-A		
BC	+ KING PHARMS	600,000 UNITS/ML	N50141 001
	+	300,000 UNITS/ML	N50141 003
	PERMAPEN		
BC	PFIZER	600,000 UNITS/ML	N60014 001

PENICILLIN G BENZATHINE; PENICILLIN G PROCAINE

INJECTABLE; INJECTION

	BICILLIN C-R		
	+ KING PHARMS	150,000 UNITS/ML; 150,000 UNITS/ML	N50138 002
	+	300,000 UNITS/ML; 300,000 UNITS/ML	N50138 001
	BICILLIN C-R 900/300		
	+ KING PHARMS	900,000 UNITS/2ML; 300,000 UNITS/2ML	N50138 003

FDA data supplied by DrugPatentWatch.com

PENICILLIN G POTASSIUM

INJECTABLE; INJECTION

	PENICILLIN G POTASSIUM			
AP	MARSAM PHARMS LLC	1,000,000 UNITS/VIAL	N62991 001	
			SEP 13, 1988	
AP		5,000,000 UNITS/VIAL	N62991 002	
			SEP 13, 1988	
AP		10,000,000 UNITS/VIAL	N62991 003	
			SEP 13, 1988	
AP		20,000,000 UNITS/VIAL	N62991 004	
			SEP 13, 1988	
AP	PFIZER	20,000,000 UNITS/VIAL	N60074 003	
	PENICILLIN G POTASSIUM	IN PLASTIC CONTAINER		
+	BAXTER HLTHCARE	20,000 UNITS/ML	N50638 001	
			JUN 25, 1990	
+		40,000 UNITS/ML	N50638 002	
			JUN 25, 1990	
+		60,000 UNITS/ML	N50638 003	
			JUN 25, 1990	
	PFIZERPEN			
AP +	PFIZER	1,000,000 UNITS/VIAL	N60657 001	
AP +		5,000,000 UNITS/VIAL	N60657 002	
AP +		20,000,000 UNITS/VIAL	N60657 003	

TABLET; ORAL

PENICILLIN G POTASSIUM			
WYETH AYERST	200,000 UNITS	N60413 001	
	250,000 UNITS	N60413 002	
+	400,000 UNITS	N60413 003	

PENICILLIN G PROCAINE

INJECTABLE; INJECTION

WYCILLIN			
+ KING PHARMS	300,000 UNITS/ML	N60101 002	
+	600,000 UNITS/ML	N60101 001	

PENICILLIN G PROCAINE; *MULTIPLE*

SEE PENICILLIN G BENZATHINE; PENICILLIN G PROCAINE

PENICILLIN G SODIUM

INJECTABLE; IM-IV

PENICILLIN G SODIUM			
+ BIOCHEMIE	5,000,000 UNITS/VIAL	N65068 001	
		FEB 26, 2001	

PENICILLIN V POTASSIUM

FOR SOLUTION; ORAL

	BEEPEN-VK			
AA	GLAXOSMITHKLINE	EQ 125MG BASE/5ML	N62270 001	
AA		EQ 250MG BASE/5ML	N62270 002	
	LEDERCILLIN VK			
AA	LEDERLE	EQ 125MG BASE/5ML	N60136 001	
AA		EQ 250MG BASE/5ML	N60136 002	
	PEN-VEE K			
AA	WYETH AYERST	EQ 125MG BASE/5ML	N60007 001	
AA		EQ 250MG BASE/5ML	N60007 002	
	PENICILLIN V POTASSIUM			
AA	CLONMEL	EQ 125MG BASE/5ML	N62981 001	
			FEB 10, 1989	
AA		EQ 250MG BASE/5ML	N62981 002	
			FEB 10, 1989	
AA	CONSOLIDATED PHARM	EQ 125MG BASE/5ML	N61529 001	
AA		EQ 250MG BASE/5ML	N61529 002	
	PENICILLIN-VK			
AA	TEVA	EQ 125MG BASE/5ML	N60456 001	
AA		EQ 250MG BASE/5ML	N60456 002	
	VEETIDS			
AA	APOTHECON	EQ 125MG BASE/5ML	N61410 001	
AA		EQ 250MG BASE/5ML	N61410 002	

TABLET; ORAL

	BEEPEN-VK			
AB	GLAXOSMITHKLINE	EQ 250MG BASE	N62273 001	
AB		EQ 500MG BASE	N62273 002	
	BETAPEN-VK			
AB	BRISTOL	EQ 250MG BASE	N61150 001	
AB		EQ 500MG BASE	N61150 002	
	LEDERCILLIN VK			
AB	LEDERLE	EQ 250MG BASE	N60134 001	
AB		EQ 500MG BASE	N60134 002	
	PEN-VEE K			
AB	WYETH AYERST	EQ 250MG BASE	N60006 002	
AB +		EQ 500MG BASE	N60006 003	
	PENICILLIN V POTASSIUM			
AB	BIOCHEMIE	EQ 250MG BASE	N64071 001	
			NOV 30, 1995	
AB +		EQ 500MG BASE	N64071 002	
			NOV 30, 1995	
AB	CLONMEL	EQ 250MG BASE	N62936 001	
			NOV 25, 1988	
AB		EQ 500MG BASE	N62935 001	
			NOV 23, 1988	
AB	CONSOLIDATED PHARM	EQ 250MG BASE	N61528 001	

FDA data supplied by DrugPatentWatch.com

PENICILLIN V POTASSIUM

TABLET; ORAL

	PENICILLIN V POTASSIUM			
AB	CONSOLIDATED PHARM	**EQ 500MG BASE**	**N61528 002**	
	PENICILLIN-VK			
AB	TEVA	**EQ 250MG BASE**	**N60711 002**	
AB		**EQ 500MG BASE**	**N60711 003**	
	UTICILLIN VK			
AB	PHARMACIA AND UPJOHN	**EQ 250MG BASE**	**N61651 001**	
	VEETIDS			
AB	APOTHECON	**EQ 250MG BASE**	**N61411 001**	
AB		**EQ 500MG BASE**	**N61411 002**	

PENTAGASTRIN

INJECTABLE; INJECTION

	PEPTAVLON			
	+ WYETH AYERST	0.25MG/ML	N17048 001	

PENTAMIDINE ISETHIONATE

FOR SOLUTION; INHALATION

	NEBUPENT			
	+ AM PHARM PARTNERS	300MG/VIAL	N19887 001	
			JUN 15, 1989	
		600MG/VIAL	N19887 002	
			MAR 22, 1996	

INJECTABLE; INJECTION

	PENTAM			
AP	+ AM PHARM PARTNERS	**300MG/VIAL**	**N19264 001**	
			OCT 16, 1984	
	PENTAMIDINE ISETHIONATE			
AP	ABBOTT	**300MG/VIAL**	**N73479 001**	
			JUN 30, 1992	
AP	ELKINS SINN	**300MG/VIAL**	**N73617 001**	
			DEC 18, 1995	
AP	STERIS	**300MG/VIAL**	**N74303 001**	
			AUG 17, 1995	

PENTAZOCINE HYDROCHLORIDE; *MULTIPLE*

SEE ACETAMINOPHEN; PENTAZOCINE HYDROCHLORIDE

SEE ASPIRIN; PENTAZOCINE HYDROCHLORIDE

SEE NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE

PENTAZOCINE LACTATE

INJECTABLE; INJECTION

	TALWIN			
	+ ABBOTT	EQ 30MG BASE/ML	N16194 001	

PENTOBARBITAL SODIUM

CAPSULE; ORAL

	NEMBUTAL SODIUM			
AA	+ ABBOTT	**100MG**	**N83245 001**	
	+	30MG	N84095 001	
	SODIUM PENTOBARBITAL			
AA	ICN	**100MG**	**N83264 001**	

INJECTABLE; INJECTION

	NEMBUTAL SODIUM			
AP	+ ABBOTT	**50MG/ML**	**N83246 001**	
	SODIUM PENTOBARBITAL			
AP	WYETH AYERST	**50MG/ML**	**N83261 001**	

PENTOSAN POLYSULFATE SODIUM

CAPSULE; ORAL

	ELMIRON			
	+ ALZA	100MG	N20193 001	
			SEP 26, 1996	

PENTOSTATIN

INJECTABLE; INJECTION

	NIPENT			
	+ SUPERGEN	10MG/VIAL	N20122 001	
			OCT 11, 1991	

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE; ORAL

	PENTOXIFYLLINE			
AB	BIOVAIL	**400MG**	**N75028 001**	
			JUL 20, 1998	
AB	ESI LEDERLE	**400MG**	**N74877 001**	
			JUL 08, 1997	
AB	IMPAX LABS	**400MG**	**N75093 001**	
			AUG 10, 1999	

FDA data supplied by DrugPatentWatch.com

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE; ORAL

	PENTOXIFYLLINE			
AB	MYLAN	400MG	**N74425 001**	JUL 08, 1997
AB	PUREPAC PHARM	400MG	**N74878 001**	JUL 09, 1997
AB	SIDMAK LABS NJ	400MG	**N74874 001**	MAY 25, 1999
AB	TEVA	400MG	**N75199 001**	SEP 03, 1999
AB	TORPHARM	400MG	**N75191 001**	JUN 09, 1999
AB	WATSON LABS	400MG	**N75107 001**	SEP 04, 1998
	PENTOXIL			
AB	UPSHER SMITH	400MG	**N74962 001**	MAR 31, 1999
	TRENTAL			
AB	+ AVENTIS PHARMS	400MG	**N18631 001**	AUG 30, 1984

PERFLUOROPOLYMETHYLISOPROPYL ETHER; POLYTETRAFLUOROETHYLENE

PASTE; TOPICAL

SKIN EXPOSURE REDUCTION PASTE AGAINST CHEMICAL WARFARE AGENTS

+	US ARMY	50%;50%	N21084 001 FEB 17, 2000

PERFLUTREN

INJECTABLE; INTRAVENOUS

DEFINITY

+	BRISTOL MYERS SQUIBB	6.52MG/ML	N21064 001 JUL 31, 2001

PERGOLIDE MESYLATE

TABLET; ORAL

PERMAX

+	LILLY	EQ 0.05MG BASE	N19385 001 DEC 30, 1988
		EQ 0.25MG BASE	N19385 002 DEC 30, 1988

PERGOLIDE MESYLATE

TABLET; ORAL

PERMAX

	LILLY	EQ 1MG BASE	N19385 003 DEC 30, 1988

PERINDOPRIL ERBUMINE

TABLET; ORAL

ACEON

	SOLVAY PHARMA	2MG	N20184 001 DEC 30, 1993
		4MG	N20184 002 DEC 30, 1993
	+	8MG	N20184 003 DEC 30, 1993

PERMETHRIN

CREAM; TOPICAL

ELIMITE

AB	+	ALLERGAN	5%	**N19855 001** AUG 25, 1989
		PERMETHRIN		
AB		ALPHARMA	5%	**N74806 001** JAN 23, 1998

PERPHENAZINE

CONCENTRATE; ORAL

PERPHENAZINE

+	PHARM ASSOC	16MG/5ML	N40360 001 MAY 25, 2001

INJECTABLE; INJECTION

TRILAFON

+	SCHERING	5MG/ML	N11213 002

TABLET; ORAL

PERPHENAZINE

AB		GENEVA PHARMS	2MG	**N89683 001** DEC 08, 1988
AB			4MG	**N89684 001** DEC 08, 1988

FDA data supplied by DrugPatentWatch.com

PERPHENAZINE

TABLET; ORAL

	PERPHENAZINE			
AB	GENEVA PHARMS	8MG	N89685 001	DEC 08, 1988
AB		16MG	N89686 001	DEC 08, 1988
AB	IVAX PHARMS	2MG	N89707 001	SEP 10, 1987
AB		4MG	N89708 001	SEP 10, 1987
AB		8MG	N89456 001	SEP 10, 1987
AB		16MG	N89457 001	SEP 10, 1987
AB	VINTAGE PHARMS	2MG	N40226 001	DEC 31, 1998
AB		4MG	N40226 002	DEC 31, 1998
AB		8MG	N40226 003	DEC 31, 1998
AB		16MG	N40226 004	DEC 31, 1998
	TRILAFON			
AB	SCHERING	2MG	N10775 001	
AB		4MG	N10775 002	
AB		8MG	N10775 003	
AB	+	16MG	N10775 004	

PERPHENAZINE; *MULTIPLE*

SEE AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

PHENACEMIDE

TABLET; ORAL

	PHENURONE		
+	ABBOTT	500MG	N07707 001

PHENAZOPYRIDINE HYDROCHLORIDE; SULFAMETHOXAZOLE; TRIMETHOPRIM

TABLET; ORAL

	SULFAMETHOXAZOLE AND TRIMETHOPRIM AND PENAZOPYRIDINE HCL		
+	ABLE	N/A,200MG;800MG,N/A;160MG, N/A	N21105 001 JUN 26, 2001

PHENDIMETRAZINE TARTRATE

CAPSULE; ORAL

	PHENDIMETRAZINE TARTRATE			
AA	+ EON	35MG	N85695 001	
	X-TROZINE			
AA	SHIRE RICHWOOD	35MG	N87394 001	SEP 22, 1982

CAPSULE, EXTENDED RELEASE; ORAL

	BONTRIL			
BC	MALLINCKRODT	105MG	N88021 001	SEP 21, 1982
	PHENDIMETRAZINE TARTRATE			
BC	+ EON	105MG	N18074 001	
	X-TROZINE L.A.			
BC	SHIRE RICHWOOD	105MG	N87371 001	AUG 24, 1982

TABLET; ORAL

	BONTRIL PDM			
AA	AMARIN PHARMS	35MG	N85272 001	
	CAM-METRAZINE			
AA	+ ABC HOLDING	35MG	N83922 001	
AA		35MG	N85318 001	
AA		35MG	N85320 001	
AA		35MG	N85321 001	
AA		35MG	N85511 001	
AA	CAMALL	35MG	N85756 001	
	PHENDIMETRAZINE TARTRATE			
AA	ABC HOLDING	35MG	N85761 001	
AA		35MG	N85941 001	JUN 27, 1983
AA	EON	35MG	N85588 001	
AA		35MG	N85830 001	
	X-TROZINE			
AA	SHIRE RICHWOOD	35MG	N86553 001	
AA		35MG	N86554 001	

PHENELZINE SULFATE

TABLET; ORAL

	NARDIL		
+	PARKE DAVIS	EQ 15MG BASE	N11909 002

FDA data supplied by DrugPatentWatch.com

PHENOXYBENZAMINE HYDROCHLORIDE

CAPSULE; ORAL

	DIBENZYLINE			
	+ WELLSPRING PHARM	10MG	N08708 001	

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

	ADIPEX-P			
AA	+ TEVA	**37.5MG**	**N88023 001**	AUG 02, 1983
	ONA-MAST			
AA	MAST MM	**30MG**	**N86511 001**	
AA		**30MG**	**N86516 001**	
	PHENTERMINE HCL			
AA	ABC HOLDING	**30MG**	**N85417 001**	
AA		**30MG**	**N86732 002**	
AA		**30MG**	**N87215 001**	
AA		**37.5MG**	**N87915 001**	DEC 22, 1983
AA		**37.5MG**	**N87918 001**	DEC 22, 1983
AA		**37.5MG**	**N87930 001**	OCT 14, 1983
AA		**37.5MG**	**N88610 001**	JUN 04, 1984
AA		**37.5MG**	**N88611 001**	JUN 04, 1984
AA		**37.5MG**	**N88625 001**	AUG 23, 1984
		18.75MG	N88576 001	MAY 23, 1984
AA	ABLE	**30MG**	**N40403 001**	AUG 30, 2001
AA		**30MG**	**N40427 001**	AUG 30, 2001
AA	AMIDE PHARM	**30MG**	**N40227 001**	JUN 18, 1997
AA		**37.5MG**	**N40228 001**	JUN 19, 1997
AA	CAMALL	**15MG**	**N86735 001**	
AA		**30MG**	**N87226 001**	
AA	+ EON	**15MG**	**N87301 001**	
AA	+	**30MG**	**N86945 001**	JUL 20, 1983
AA		**30MG**	**N87190 001**	
AA		**30MG**	**N87208 001**	

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

	PHENTERMINE HCL			
AA	EON	**30MG**	**N87223 001**	
AA	KING PHARMS	**30MG**	**N40083 001**	MAR 07, 1997
AA	USL PHARMA	**30MG**	**N88797 001**	DEC 10, 1984

TABLET; ORAL

	ADIPEX-P			
AA	+ TEVA	**37.5MG**	**N85128 001**	
	ONA MAST			
AA	MAST MM	**8MG**	**N86260 001**	
	PHENTERMINE HCL			
AA	+ ABC HOLDING	**8MG**	**N83923 001**	
AA		**8MG**	**N85319 001**	
AA		**37.5MG**	**N87805 001**	DEC 06, 1982
AA		**37.5MG**	**N88596 001**	APR 04, 1984
AA	ABLE	**37.5MG**	**N40402 001**	AUG 30, 2001
AA	AMIDE PHARM	**37.5MG**	**N40190 001**	MAY 30, 1997
	+ EON	30MG	N88605 001	SEP 28, 1987
AA	PUREPAC PHARM	**37.5MG**	**N40276 001**	NOV 25, 1998
AA	USL PHARMA	**8MG**	**N83804 001**	
AA		**37.5MG**	**N88910 001**	JUL 17, 1985
AA		**37.5MG**	**N88917 001**	JUL 17, 1985

PHENTERMINE RESIN COMPLEX

CAPSULE, EXTENDED RELEASE; ORAL

IONAMIN			
CELLTECH PHARMS	EQ 15MG BASE		N11613 004
+	EQ 30MG BASE		N11613 002

FDA data supplied by DrugPatentWatch.com

PHENTOLAMINE MESYLATE

INJECTABLE; INJECTION

	PHENTOLAMINE MESYLATE			
AP	BEDFORD	**5MG/VIAL**	**N40235 001**	MAR 11, 1998
	REGITINE			
AP	+ NOVARTIS	**5MG/VIAL**	**N08278 003**	

PHENYLEPHRINE HYDROCHLORIDE; *MULTIPLE*

SEE CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SEE CYCLOPENTOLATE HYDROCHLORIDE; PHENYLEPHRINE HYDROCHLORIDE

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

	PHENERGAN VC			
AA	+ WYETH AYERST	**5MG/5ML;6.25MG/5ML**	**N08604 003**	APR 02, 1984
	PROMETH VC PLAIN			
AA	ALPHARMA	**5MG/5ML;6.25MG/5ML**	**N88761 001**	NOV 08, 1984
	PROMETHAZINE VC PLAIN			
AA	MORTON GROVE	**5MG/5ML;6.25MG/5ML**	**N88897 001**	JAN 04, 1985

PHENYLEPHRINE HYDROCHLORIDE; PYRILAMINE MALEATE

SOLUTION/DROPS; OPHTHALMIC

	PREFRIN-A		
	ALLERGAN	0.12%;0.1%	N07953 001

PHENYLPROPANOLAMINE HYDROCHLORIDE; *MULTIPLE*

SEE BROMPHENIRAMINE MALEATE; CODEINE PHOSPHATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

SEE HYDROCODONE BITARTRATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

PHENYTOIN

SUSPENSION; ORAL

	DILANTIN-125			
AB	+ PARKE DAVIS	**125MG/5ML**	**N08762 001**	

PHENYTOIN

SUSPENSION; ORAL

	PHENYTOIN			
AB	ALPHARMA	**125MG/5ML**	**N89892 001**	SEP 25, 1992
AB	UDL	**125MG/5ML**	**N40342 001**	JAN 31, 2001

TABLET, CHEWABLE; ORAL

	DILANTIN		
	+ PARKE DAVIS	50MG	N84427 001

PHENYTOIN SODIUM

INJECTABLE; INJECTION

	DILANTIN			
AP	+ PARKE DAVIS	**50MG/ML**	**N10151 001**	
	PHENYTOIN			
AP	ELKINS SINN	**50MG/ML**	**N84307 001**	
	PHENYTOIN SODIUM			
AP	ABBOTT	**50MG/ML**	**N89521 001**	MAR 17, 1987
AP		**50MG/ML**	**N89744 001**	DEC 18, 1987

PHENYTOIN SODIUM, EXTENDED

CAPSULE; ORAL

	DILANTIN			
AB	+ PARKE DAVIS	**100MG**	**N84349 002**	
	+	30MG	N84349 001	
	EXTENDED PHENYTOIN SODIUM			
AB	MYLAN	**100MG**	**N40298 001**	DEC 28, 1998
	PHENYTEK			
	+ MYLAN	200MG	N40298 002	DEC 06, 2001
	+	300MG	N40298 003	DEC 06, 2001

PHENYTOIN SODIUM, PROMPT

CAPSULE; ORAL

	PROMPT PHENYTOIN SODIUM		
	+ IVAX PHARMS	100MG	N80259 001

FDA data supplied by DrugPatentWatch.com

PHOSPHORIC ACID; *MULTIPLE*
SEE AMINO ACIDS; CALCIUM ACETATE; GLYCERIN; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE
SEE AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; POTASSIUM CHLORIDE; SODIUM ACETATE
SEE AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; SODIUM CHLORIDE
SEE AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

PHYTONADIONE

INJECTABLE; INJECTION
AQUAMEPHYTON
BP + MERCK 1MG/0.5ML N12223 002
BP + 10MG/ML N12223 001
PHYTONADIONE
BP INTL MEDICATION 1MG/0.5ML N83722 001
VITAMIN K1
BP ABBOTT 1MG/0.5ML N87954 001 JUL 25, 1983
BP 10MG/ML N87955 001 JUL 25, 1983

TABLET; ORAL
MEPHYTON
+ MERCK 5MG N10104 003

PHYTONADIONE; *MULTIPLE*
SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PHYTONADIONE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

PILOCARPINE

DRUG DELIVERY SYSTEM; OPHTHALMIC
OCUSERT PILO-40
+ AKORN 11MG N17548 001

INSERT, EXTENDED RELEASE; OPHTHALMIC
OCUSERT PILO-20
+ AKORN 5MG N17431 001

PILOCARPINE HYDROCHLORIDE

GEL; OPHTHALMIC
PILOPINE HS
+ ALCON 4% N18796 001 OCT 01, 1984

TABLET; ORAL
SALAGEN
+ MGI PHARMA INC 5MG N20237 001 MAR 22, 1994

PILOCARPINE HYDROCHLORIDE; *MULTIPLE*
SEE BETAXOLOL HYDROCHLORIDE; PILOCARPINE HYDROCHLORIDE

PIMECROLIMUS

CREAM; TOPICAL
ELIDEL
+ NOVARTIS 1% N21302 001 DEC 13, 2001

PIMOZIDE

TABLET; ORAL
ORAP
TEVA 1MG N17473 003 AUG 27, 1997
+ 2MG N17473 001 JUL 31, 1984

PINDOLOL

TABLET; ORAL
PINDOLOL
AB GENEVA PHARMS **5MG** **N73608 001** MAR 29, 1993
AB **10MG** **N73609 001** MAR 29, 1993
AB GENPHARM **5MG** **N74013 001** SEP 24, 1992
AB **10MG** **N74018 001** SEP 24, 1992
AB IVAX PHARMS **5MG** **N73687 001** FEB 26, 1993

FDA data supplied by DrugPatentWatch.com

PINDOLOL

TABLET; ORAL

	PINDOLOL			
AB	IVAX PHARMS	10MG	N73687 002	FEB 26, 1993
AB	MARTEC	5MG	N74474 001	OCT 28, 1996
AB		10MG	N74474 002	OCT 28, 1996
AB	MUTUAL PHARM	5MG	N74063 001	JAN 27, 1994
AB		10MG	N74063 002	JAN 27, 1994
AB	MYLAN	5MG	N74019 001	SEP 03, 1992
AB		10MG	N74019 002	SEP 03, 1992
AB	TEVA	5MG	N73661 001	OCT 31, 1993
AB		5MG	N74123 001	APR 17, 1997
AB		10MG	N73661 002	OCT 31, 1993
AB		10MG	N74123 002	APR 17, 1997
AB	WATSON LABS	5MG	N74437 001	FEB 27, 1995
AB		10MG	N74437 002	FEB 27, 1995
	VISKEN			
AB	NOVARTIS	5MG	N18285 001	SEP 03, 1982
AB +		10MG	N18285 002	SEP 03, 1982

PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

	ACTOS			
	TAKEDA PHARMS NA	EQ 15MG BASE	N21073 001	JUL 15, 1999
		EQ 30MG BASE	N21073 002	JUL 15, 1999
+		EQ 45MG BASE	N21073 003	JUL 15, 1999

PIPECURONIUM BROMIDE

INJECTABLE; INJECTION

	ARDUAN			
+	ORGANON	10MG/VIAL	N19638 001	JUN 26, 1990

PIPERACILLIN SODIUM

INJECTABLE; INJECTION

	PIPRACIL			
+	LEDERLE	EQ 2GM BASE/VIAL	N50545 002	
		EQ 2GM BASE/VIAL	N62750 001	OCT 13, 1987
+		EQ 3GM BASE/VIAL	N50545 003	
		EQ 3GM BASE/VIAL	N62750 002	OCT 13, 1987
+		EQ 4GM BASE/VIAL	N50545 004	
		EQ 4GM BASE/VIAL	N62750 003	OCT 13, 1987

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE; INJECTION

	ZOSYN			
+	WYETH AYERST	EQ 2GM BASE/VIAL; EQ 250MG BASE/VIAL	N50684 001	OCT 22, 1993
+		EQ 3GM BASE/VIAL; EQ 375MG BASE/VIAL	N50684 002	OCT 22, 1993
+		EQ 4GM BASE/VIAL; EQ 500MG BASE/VIAL	N50684 003	OCT 22, 1993
+		EQ 36GM BASE/VIAL; EQ 4.5GM BASE/VIAL	N50684 004	OCT 22, 1993
	ZOSYN IN PLASTIC CONTAINER			
+	LEDERLE	EQ 40MG BASE/ML; EQ 5MG BASE/ML	N50750 001	FEB 24, 1998
+		EQ 4GM BASE/100ML; EQ 500MG BASE/100ML	N50750 003	FEB 24, 1998
+		EQ 60MG BASE/ML; EQ 7.5MG BASE/ML	N50750 002	FEB 24, 1998

FDA data supplied by DrugPatentWatch.com

PIPERAZINE CITRATE

SYRUP; ORAL

	MULTIFUGE			
AA	+ BLULINE	**EQ 500MG BASE/5ML**	**N09452 001**	
	PIPERAZINE CITRATE			
AA	LUITPOLD	**EQ 500MG BASE/5ML**	**N80671 001**	

PIRBUTEROL ACETATE

AEROSOL, METERED; INHALATION

	MAXAIR			
	+ 3M	EQ 0.2MG BASE/INH	N19009 001	DEC 30, 1986
	+	EQ 0.2MG BASE/INH	N20014 001	NOV 30, 1992

PIROXICAM

CAPSULE; ORAL

	FELDENE			
AB	PFIZER	**10MG**	**N18147 002**	APR 06, 1982
AB	+	**20MG**	**N18147 003**	APR 06, 1982
	PIROXICAM			
AB	COPLEY PHARM	**10MG**	**N74103 001**	AUG 28, 1992
AB		**20MG**	**N74103 002**	AUG 28, 1992
AB	DANBURY PHARMA	**10MG**	**N74287 001**	MAY 16, 1996
AB		**20MG**	**N74287 002**	MAY 16, 1996
AB	EGIS	**10MG**	**N74808 001**	JUL 08, 1997
AB		**20MG**	**N74808 002**	JUL 08, 1997
AB	GENPHARM	**10MG**	**N74043 001**	SEP 22, 1992
AB		**20MG**	**N74043 002**	SEP 22, 1992
AB	IVAX PHARMS	**10MG**	**N74148 001**	JUN 03, 1996
AB		**20MG**	**N74148 002**	JUN 03, 1996

PIROXICAM

CAPSULE; ORAL

	PIROXICAM			
AB	MEPHA	**10MG**	**N74116 001**	JUN 15, 1993
AB		**20MG**	**N74118 001**	JUN 15, 1993
AB	MUTUAL PHARM	**10MG**	**N73535 001**	MAR 12, 1993
AB		**20MG**	**N73536 001**	MAR 12, 1993
AB	MYLAN	**10MG**	**N74102 001**	JUL 31, 1992
AB		**20MG**	**N74102 002**	JUL 31, 1992
AB	SCS	**10MG**	**N74036 001**	MAY 29, 1992
AB		**20MG**	**N74036 002**	MAY 29, 1992
AB	TEVA	**10MG**	**N73637 001**	JAN 28, 1994
AB		**10MG**	**N74131 001**	DEC 11, 1992
AB		**20MG**	**N73638 001**	JAN 28, 1994
AB		**20MG**	**N74131 002**	DEC 11, 1992
AB	WATSON LABS	**10MG**	**N74460 001**	SEP 29, 1995
AB		**20MG**	**N74460 002**	SEP 29, 1995

PLICAMYCIN

INJECTABLE; INJECTION

	MITHRACIN		
	+ PFIZER	2.5MG/VIAL	N50109 001

PODOFILOX

GEL; TOPICAL

	CONDYLOX		
	+ OCLASSEN	0.5%	N20529 001 MAR 13, 1997

FDA data supplied by DrugPatentWatch.com

PODOFILOX

SOLUTION; TOPICAL
CONDYLOX
+ OCLASSEN 0.5% N19795 001 DEC 13, 1990

POLYETHYLENE GLYCOL 3350

FOR SOLUTION; ORAL
MIRALAX
+ BRAINTREE 17GM/SCOOPFUL N20698 001 FEB 18, 1999

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION; ORAL
NULYTELY
+ BRAINTREE 420GM/BOT;1.48GM/BOT;5.72GM/BOT; 11.2GM/BOT N19797 001 APR 22, 1991

NULYTELY-FLAVORED
+ BRAINTREE 420GM/BOT;1.48GM/BOT;5.72GM/BOT; 11.2GM/BOT N19797 002 NOV 18, 1994

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE

SOLUTION; ORAL
OCL
+ ABBOTT 6GM/100ML;75MG/100ML;168MG/100ML; 146MG/100ML;1.29GM/100ML N19284 001 APR 30, 1986

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE, ANHYDROUS

FOR SOLUTION; ORAL
COLYTE
AA + SCHWARZ PHARMA **227.1GM/BOT;2.82GM/BOT;6.36GM/BOT; 5.53GM/BOT;21.5GM/BOT N18983 010** JAN 31, 1989

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE, ANHYDROUS

FOR SOLUTION; ORAL
COLYTE
AA + SCHWARZ PHARMA **240GM/BOT;2.98GM/BOT;6.72GM/BOT; 5.84GM/BOT;22.72GM/BOT N18983 007** JUN 12, 1987

COLYTE WITH FLAVOR PACKS
AA + SCHWARZ PHARMA **240GM/BOT;2.98GM/BOT;6.72GM/BOT; 5.84GM/BOT;22.72GM/BOT N18983 012** OCT 08, 1998

COLYTE-FLAVORED
AA + SCHWARZ PHARMA **227.1GM/BOT;2.82GM/BOT;6.36GM/BOT; 5.53GM/BOT;21.5GM/BOT N18983 008** NOV 14, 1991

AA + **240GM/BOT;2.98GM/BOT;6.72GM/BOT; 5.84GM/BOT;22.72GM/BOT N18983 009** NOV 14, 1991

GOLYTELY
AA + BRAINTREE **227.1GM/PACKET;2.82GM/PACKET; 6.36GM/PACKET;5.53GM/PACKET; 21.5GM/PACKET N19011 002** JUN 02, 1992

AA + **236GM/BOT;2.97GM/BOT;6.74GM/BOT; 5.86GM/BOT;22.74GM/BOT N19011 001** JUL 13, 1984

FOR SUSPENSION; ORAL
CO-LAV
AA COPLEY PHARM **240GM/BOT;2.98GM/BOT;6.72GM/BOT; 5.84GM/BOT;22.72GM/BOT N73428 001** JAN 28, 1992

COLOVAGE
AA DYNAPHARM **227.1GM/PACKET;2.82GM/PACKET; 6.36GM/PACKET;5.53GM/PACKET; 21.5GM/PACKET N71320 001** APR 20, 1988

E-Z-EM PREP LYTE
AA E Z EM **236GM/BOT;2.97GM/BOT;6.74GM/BOT; 5.86GM/BOT;22.74GM/BOT N71278 001** NOV 21, 1988

GLYCOPREP
AA GOLDLINE **236GM/BOT;2.97GM/BOT;6.74GM/BOT; 5.86GM/BOT;22.74GM/BOT N72319 001** DEC 23, 1988

FDA data supplied by DrugPatentWatch.com

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE, ANHYDROUS

FOR SUSPENSION; ORAL

	GO-EVAC			
AA	COPLEY PHARM	**236GM/BOT;2.97GM/BOT;6.74GM/BOT; 5.86GM/BOT;22.74GM/BOT**	**N73433 001** APR 28, 1992	

POLYMYXIN B SULFATE

INJECTABLE; INJECTION

	POLYMYXIN B SULFATE			
AP	+ BEDFORD	**EQ 500,000 U BASE/VIAL**	**N60716 001**	
AP	PHARMA TEK	**EQ 500,000 U BASE/VIAL**	**N63000 001** SEP 30, 1994	

POWDER; FOR RX COMPOUNDING

	POLY-RX		
+	PHARMA TEK	100,000,000 UNITS/BOT	N61578 001

POLYMYXIN B SULFATE; *MULTIPLE*

SEE BACITRACIN; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SEE BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SEE BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SEE BACITRACIN ZINC; POLYMYXIN B SULFATE
SEE DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SEE GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SEE HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SEE HYDROCORTISONE; POLYMYXIN B SULFATE
SEE HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SEE NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SEE NEOMYCIN SULFATE; POLYMYXIN B SULFATE; PREDNISOLONE ACETATE
SEE OXYTETRACYCLINE HYDROCHLORIDE; POLYMYXIN B SULFATE

POLYMYXIN B SULFATE; TRIMETHOPRIM

SOLUTION/DROPS; OPHTHALMIC

	TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE			
AT	TAYLOR PHARMA	**10,000 UNITS/ML; EQ 1MG BASE/ML**	**N65006 001** DEC 17, 1998	

POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

SOLUTION/DROPS; OPHTHALMIC

	POLYTRIM			
AT	+ ALLERGAN	**10,000 UNITS/ML; EQ 1MG BASE/ML**	**N50567 001** OCT 20, 1988	
	TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE			
AT	BAUSCH AND LOMB	**10,000 UNITS/ML; EQ 1MG BASE/ML**	**N64120 001** FEB 14, 1997	
AT	FALCON PHARMS	**10,000 UNITS/ML; EQ 1MG BASE/ML**	**N64211 001** APR 13, 1998	

POLYTETRAFLUOROETHYLENE; *MULTIPLE*

SEE PERFLUOROPOLYMETHYLISOPROPYL ETHER; POLYTETRAFLUOROETHYLENE

POLYTHIAZIDE

TABLET; ORAL

	RENESE		
	PFIZER	1MG	N12845 001
		2MG	N12845 002
+		4MG	N12845 003

POLYTHIAZIDE; PRAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

	MINIZIDE		
	PFIZER	0.5MG;EQ 1MG BASE	N17986 001
		0.5MG;EQ 2MG BASE	N17986 002
+		0.5MG;EQ 5MG BASE	N17986 003

POLYTHIAZIDE; RESERPINE

TABLET; ORAL

	RENESE-R		
+	PFIZER	2MG;0.25MG	N13636 001

FDA data supplied by DrugPatentWatch.com

PORACTANT ALFA

SUSPENSION; INTRATRACHEAL

CUROSURF					
+ DEY	80MG/ML	N20744 001 NOV 18, 1999			

PORFIMER SODIUM

INJECTABLE; INJECTION

PHOTOFRIN					
+ AXCAN SCANDIPHARM	75MG/VIAL	N20451 001 DEC 27, 1995			

POTASSIUM ACETATE

INJECTABLE; INJECTION

POTASSIUM ACETATE IN PLASTIC CONTAINER					
+ ABBOTT	2MEQ/ML	N18896 001 JUL 20, 1984			

POTASSIUM ACETATE; *MULTIPLE*

SEE AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; POTASSIUM CHLORIDE; SODIUM ACETATE

SEE AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; SODIUM CHLORIDE

SEE DEXTROSE; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE

SEE DEXTROSE; MAGNESIUM ACETATE TETRAHYDRATE; POTASSIUM ACETATE; SODIUM CHLORIDE

SEE MAGNESIUM ACETATE TETRAHYDRATE; POTASSIUM ACETATE; SODIUM CHLORIDE

POTASSIUM AMINOSALICYLATE

CAPSULE; ORAL

PASKALIUM					
+ GLENWOOD	500MG	N09395 004	AP		

TABLET; ORAL

PASKALIUM					
+ GLENWOOD	1GM	N09395 003			

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

MICRO-K					
	KV PHARM	**8MEQ**			**N18238 001**
MICRO-K 10					
+	KV PHARM	**10MEQ**			**N18238 002** MAY 14, 1984
POTASSIUM CHLORIDE					
	KV PHARM	**10MEQ**			**N70980 001** FEB 17, 1987
	TEVA	**8MEQ**			**N73531 001** APR 26, 1996
		10MEQ			**N73532 001** APR 26, 1996

INJECTABLE; INJECTION

POTASSIUM CHLORIDE					
+	ABBOTT	**2MEQ/ML**			**N80205 001**
		2MEQ/ML			**N83345 002**
+		1.5MEQ/ML			N83345 001
	AM PHARM PARTNERS	**2MEQ/ML**			**N80225 001**
		2MEQ/ML			**N87817 001** OCT 20, 1982
+		3MEQ/ML			N80225 003
	B BRAUN	**2MEQ/ML**			**N85870 001**
	BAXTER HLTHCARE	**2MEQ/ML**			**N85499 001**
	INTL MEDICATION	**2MEQ/ML**			**N83163 001**
	LUITPOLD	**2MEQ/ML**			**N87584 001**
		2MEQ/ML			**N87585 001**
	PHARMA SERVE NY	**2MEQ/ML**			**N86297 001**
		2MEQ/ML			**N87362 001** MAR 08, 1983
POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER					
+	BAXTER HLTHCARE	746MG/100ML			N19904 005 DEC 17, 1990
+		14.9MG/ML			N19904 001 DEC 26, 1989
POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER					
+	ABBOTT	**29.8MG/ML**			**N20161 006** AUG 11, 1998
+	BAXTER HLTHCARE	**29.8MG/ML**			**N19904 002** DEC 26, 1989
+		1.49GM/100ML			N19904 006 DEC 17, 1990
POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER					
+	ABBOTT	**2.24GM/100ML**			**N20161 003** AUG 11, 1998

FDA data supplied by DrugPatentWatch.com

POTASSIUM CHLORIDE

INJECTABLE; INJECTION

	POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER			
AP	+ BAXTER HLTHCARE	2.24GM/100ML	N19904 003	DEC 26, 1989
	POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER			
AP	+ ABBOTT	2.98GM/100ML	N20161 004	AUG 11, 1998
AP	+ BAXTER HLTHCARE	2.98GM/100ML	N19904 004	DEC 26, 1989
	POTASSIUM CHLORIDE IN PLASTIC CONTAINER			
AP	AM PHARM PARTNERS	2MEQ/ML	N88901 001	JAN 25, 1985
AP		2MEQ/ML	N88908 001	JAN 25, 1985

TABLET, EXTENDED RELEASE; ORAL

	K+10			
BC	ALRA	10MEQ	N70999 001	OCT 22, 1987
	K+8			
AB	ALRA	8MEQ	N70998 001	JAN 25, 1993
	K-DUR 10			
AB	KEY PHARMS	10MEQ	N19439 002	JUN 13, 1986
	K-DUR 20			
AB	+ KEY PHARMS	20MEQ	N19439 001	JUN 13, 1986
	K-TAB			
BC	ABBOTT	10MEQ	N18279 001	
	KLOR-CON			
AB	UPSHER SMITH	8MEQ	N19123 001	APR 17, 1986
BC		10MEQ	N19123 002	APR 17, 1986
	KLOR-CON M10			
AB	UPSHER SMITH	10MEQ	N74726 002	AUG 09, 2000
	KLOR-CON M20			
AB	UPSHER SMITH	20MEQ	N74726 001	NOV 20, 1998
	KLOTRIX			
BC	APOTHECON	10MEQ	N17850 001	
	POTASSIUM CHLORIDE			
BC	ABBOTT	8MEQ	N18279 002	AUG 01, 1988

POTASSIUM CHLORIDE

TABLET, EXTENDED RELEASE; ORAL

	POTASSIUM CHLORIDE			
AB	COPLEY PHARM	8MEQ	N70618 001	SEP 09, 1987
	SLOW-K			
AB	+ NOVARTIS	8MEQ	N17476 002	

POTASSIUM CHLORIDE; *MULTIPLE*

SEE AMINO ACIDS; CALCIUM ACETATE; GLYCERIN; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SEE AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

SEE AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

SEE AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; POTASSIUM CHLORIDE; SODIUM ACETATE

SEE AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SEE AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

SEE CALCIUM CHLORIDE; DEXTROSE; GLUTATHIONE DISULFIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE

SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

SEE CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SEE CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

SEE CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SEE CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SEE CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

SEE CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE

FDA data supplied by DrugPatentWatch.com

POTASSIUM CHLORIDE; *MULTIPLE*
SEE CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE
SEE CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE
SEE CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE
SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE
SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS
SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE
SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS
SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE
SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE
SEE DEXTROSE; POTASSIUM CHLORIDE
SEE DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM LACTATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS
SEE DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE
SEE DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE
SEE DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE
SEE MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE
SEE MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE
SEE MAGNESIUM SULFATE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM PHOSPHATE
SEE POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE
SEE POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE
SEE POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE, ANHYDROUS

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	B BRAUN	**150MG/100ML;900MG/100ML**	**N19708 004**	SEP 29, 1989

POTASSIUM CHLORIDE 20MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	ABBOTT	**149MG/100ML;900MG/100ML**	**N19686 001**	OCT 17, 1988

POTASSIUM CHLORIDE 40MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	ABBOTT	**298MG/100ML;900MG/100ML**	**N19686 002**	OCT 17, 1988

SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	**150MG/100ML;900MG/100ML**	**N17648 001**	
	SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.224%			
	BAXTER HLTHCARE	224MG/100ML;900MG/100ML	N17648 003	

SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	**300MG/100ML;900MG/100ML**	**N17648 002**	

POTASSIUM CITRATE

TABLET, EXTENDED RELEASE; ORAL

POTASSIUM CITRATE

	MISSION PHARMA	5MEQ	N19071 001	AUG 30, 1985
+		10MEQ	N19071 002	AUG 31, 1992

POTASSIUM LACTATE; *MULTIPLE*
SEE DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM LACTATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS

POTASSIUM PERCHLORATE

CAPSULE; ORAL

PERCHLORACAP

+	MALLINCKRODT	200MG	N17551 001

POTASSIUM PHOSPHATE, DIBASIC; *MULTIPLE*
SEE AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

FDA data supplied by DrugPatentWatch.com

POTASSIUM PHOSPHATE, DIBASIC; *MULTIPLE*

SEE AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

SEE AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

SEE AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

SEE AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

SEE AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE

SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS

SEE DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

POTASSIUM PHOSPHATE, MONOBASIC; *MULTIPLE*

SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE

SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS

SEE DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE

SEE MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

SEE MAGNESIUM SULFATE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM PHOSPHATE

POVIDONE-IODINE

SOLUTION/DROPS; OPHTHALMIC

	BETADINE			
+	ALCON	5%		N18634 001 DEC 17, 1986

PRALIDOXIME CHLORIDE

INJECTABLE; INJECTION

	PRALIDOXIME CHLORIDE			
+	MERIDIAN MEDCL TECHN	300MG/ML		N18986 001 APR 26, 1983
	PROTOPAM CHLORIDE			
+	WYETH AYERST	1GM/VIAL		N14134 001

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET; ORAL

	MIRAPEX			
+	PHARMACIA AND UPJOHN	0.125MG		N20667 001 JUL 01, 1997
		0.25MG		N20667 002 JUL 01, 1997
		0.5MG		N20667 006 FEB 12, 1998
		1MG		N20667 003 JUL 01, 1997
+		1.5MG		N20667 005 JUL 01, 1997

PRAMOXINE HYDROCHLORIDE; *MULTIPLE*

SEE HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

PRAVASTATIN SODIUM

TABLET; ORAL

	PRAVACHOL			
	BRISTOL MYERS SQUIBB	10MG		N19898 002 OCT 31, 1991
		20MG		N19898 003 OCT 31, 1991
+		40MG		N19898 004 MAR 22, 1993

PRAZIQUANTEL

TABLET; ORAL

	BILTRICIDE			
+	BAYER	600MG		N18714 001 DEC 29, 1982

FDA data supplied by DrugPatentWatch.com

PRAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

	MINIPRESS			
AB	PFIZER	EQ 1MG BASE	N17442 002	
AB	+	EQ 2MG BASE	N17442 003	
AB		EQ 5MG BASE	N17442 001	
	PRAZOSIN HCL			
AB	DANBURY PHARMA	EQ 1MG BASE	N72352 001	MAY 16, 1989
AB		EQ 2MG BASE	N72333 001	MAY 16, 1989
AB		EQ 5MG BASE	N72609 001	MAY 16, 1989
AB	GENEVA PHARMS	EQ 1MG BASE	N72576 001	MAY 16, 1989
AB		EQ 2MG BASE	N72577 001	MAY 16, 1989
AB		EQ 5MG BASE	N72578 001	MAY 16, 1989
AB	IVAX PHARMS	EQ 1MG BASE	N71994 001	SEP 12, 1988
AB		EQ 2MG BASE	N71995 001	SEP 12, 1988
AB		EQ 5MG BASE	N71745 001	SEP 12, 1988
AB	LEDERLE	EQ 1MG BASE	N72705 001	MAY 16, 1989
AB		EQ 2MG BASE	N72706 001	MAY 16, 1989
AB		EQ 5MG BASE	N72707 001	MAY 16, 1989
AB	MYLAN	EQ 1MG BASE	N72573 001	MAY 16, 1989
AB		EQ 2MG BASE	N72574 001	MAY 16, 1989
AB		EQ 5MG BASE	N72575 001	MAY 16, 1989

TABLET, EXTENDED RELEASE; ORAL

	MINIPRESS XL			
	+ PFIZER	2.5MG	N19775 001	JAN 29, 1992
	+	5MG	N19775 002	JAN 29, 1992

PRAZOSIN HYDROCHLORIDE; *MULTIPLE*
SEE POLYTHIAZIDE; PRAZOSIN HYDROCHLORIDE

PREDNICARBATE

CREAM; TOPICAL

	DERMATOP			
	+ AVENTIS PHARMS	0.1%	N20279 001	OCT 29, 1993

OINTMENT; TOPICAL

	DERMATOP			
	+ AVENTIS PHARMS	0.1%	N19568 001	SEP 23, 1991

PREDNISOLONE

SYRUP; ORAL

	PREDNISOLONE			
AA	COPLEY PHARM	15MG/5ML	N40322 001	JAN 19, 2000
AA	HALSEY	15MG/5ML	N40287 001	MAY 28, 1999
AA	KV PHARM	5MG/5ML	N40423 001	OCT 22, 2001
AA	UDL	15MG/5ML	N40323 001	MAY 13, 1999
AA	WE PHARMS	15MG/5ML	N40192 001	MAY 28, 1998
	PRELONE			
AA	+ MURO	5MG/5ML	N89654 001	JAN 17, 1989
AA	+	15MG/5ML	N89081 001	FEB 04, 1986

TABLET; ORAL

	PREDNISOLONE		
BX	+ DANBURY PHARMA	5MG	N80354 001
BX	EVERYLIFE	2.5MG	N84439 002
BX		5MG	N84439 003
BX	LANNETT	5MG	N80531 002
BX	MARSHALL PHARMA	5MG	N80307 001
BX	SPERTI	2.5MG	N80358 002
BX		5MG	N80358 003
		1MG	N80358 001

PREDNISOLONE ACETATE

INJECTABLE; INJECTION

	PREDNISOLONE ACETATE		
	+ STERIS	25MG/ML	N83398 001

FDA data supplied by DrugPatentWatch.com

PREDNISOLONE ACETATE

INJECTABLE; INJECTION
PREDNISOLONE ACETATE
STERIS 50MG/ML N83764 001
\+ 50MG/ML N85781 001

SUSPENSION/DROPS; OPHTHALMIC
ECONOPRED
\+ ALCON 0.125% N17468 001
ECONOPRED PLUS
AB FALCON PHARMS **1%** **N17469 001**
PRED FORTE
AB \+ ALLERGAN **1%** **N17011 001**
PRED MILD
\+ ALLERGAN 0.12% N17100 001

PREDNISOLONE ACETATE; *MULTIPLE*
SEE GENTAMICIN SULFATE; PREDNISOLONE ACETATE
SEE NEOMYCIN SULFATE; POLYMYXIN B SULFATE; PREDNISOLONE ACETATE

PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM

OINTMENT; OPHTHALMIC
BLEPHAMIDE S.O.P.
\+ ALLERGAN 0.2%;10% N87748 001 DEC 03, 1986
CETAPRED
\+ ALCON 0.25%;10% N87771 001 AUG 06, 1993
METIMYD
AT \+ SCHERING **0.5%;10%** **N10210 002** SEP 09, 1984
VASOCIDIN
AT NOVARTIS **0.5%;10%** **N88791 001** OCT 05, 1984

SUSPENSION; OPHTHALMIC
BLEPHAMIDE
\+ ALLERGAN 0.2%;10% N12813 002

SUSPENSION/DROPS; OPHTHALMIC
ISOPTO CETAPRED
\+ ALCON 0.25%;10% N87547 001
METIMYD
\+ SCHERING 0.5%;10% N10210 001

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION; ORAL
ORAPRED
\+ ASCENT PEDS EQ 15MG BASE/5ML N75117 001 DEC 14, 2000
PEDIAPRED
\+ CELLTECH PHARMS EQ 5MG BASE/5ML N19157 001 MAY 28, 1986

SOLUTION/DROPS; OPHTHALMIC
INFLAMASE FORTE
AT \+ NOVARTIS **EQ 0.9% PHOSPHATE** **N80751 002**
INFLAMASE MILD
AT \+ NOVARTIS **EQ 0.11% PHOSPHATE** **N80751 001**
PREDNISOLONE SODIUM PHOSPHATE
AT BAUSCH AND LOMB **EQ 0.11% PHOSPHATE** **N40065 001** JUL 29, 1994
AT **EQ 0.9% PHOSPHATE** **N40070 001** JUL 29, 1994

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC
SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE
AT ALCON UNIVERSAL **EQ 0.23% PHOSPHATE;10%** **N73630 001** MAY 27, 1993
AT BAUSCH AND LOMB **EQ 0.23% PHOSPHATE;10%** **N74449 001** DEC 29, 1995
VASOCIDIN
AT \+ NOVARTIS **EQ 0.23% PHOSPHATE;10%** **N18988 001** AUG 26, 1988

PREDNISOLONE TEBUTATE

INJECTABLE; INJECTION
HYDELTRA-TBA
\+ MERCK 20MG/ML N10562 001

PREDNISONE

SOLUTION; ORAL
PREDNISONE
\+ ROXANE 5MG/5ML N88703 001 NOV 08, 1984

FDA data supplied by DrugPatentWatch.com

PREDNISONE

SOLUTION; ORAL
PREDNISONE INTENSOL

	+	ROXANE	5MG/ML	N88810 001	FEB 20, 1985

TABLET; ORAL
DELTASONE

AB	+	PHARMACIA AND UPJOHN	**2.5MG**	**N09986 005**	
AB	+		**5MG**	**N09986 002**	
AB	+		**10MG**	**N09986 006**	
AB	+		**20MG**	**N09986 007**	
AB	+		**50MG**	**N09986 008**	

PREDNISONE

AB		DANBURY PHARMA	**5MG**	**N80356 001**	
AB			**10MG**	**N85162 001**	
AB			**20MG**	**N85161 001**	
AB		GENEVA PHARMS	**10MG**	**N89983 001**	JAN 12, 1989
AB			**20MG**	**N85813 001**	
AB			**50MG**	**N89984 001**	JAN 12, 1989
BX		LANNETT	5MG	N80514 001	
BX		MARSHALL PHARMA	5MG	N80301 001	
AB		MUTUAL PHARM	**5MG**	**N89245 001**	DEC 04, 1985
AB			**10MG**	**N89246 001**	DEC 04, 1985
AB			**20MG**	**N89247 001**	DEC 04, 1985
AB		PVT FORM	**5MG**	**N80209 001**	
AB	+	ROXANE	**1MG**	**N87800 001**	APR 22, 1982
AB			**2.5MG**	**N87801 001**	APR 22, 1982
AB			**5MG**	**N80352 001**	
AB			**10MG**	**N84122 001**	
AB			**20MG**	**N87342 001**	
AB			**50MG**	**N84283 001**	
AB		TRIGEN	**5MG**	**N40362 002**	AUG 29, 2001
AB			**10MG**	**N40362 001**	AUG 29, 2001
AB		WATSON LABS	**10MG**	**N87773 001**	JUL 13, 1982
AB			**20MG**	**N86813 001**	
AB			**50MG**	**N87772 001**	JUL 13, 1982

PREDNISONE

TABLET; ORAL
PREDNISONE

AB		WEST WARD	**5MG**	**N80292 001**	
AB			**10MG**	**N88832 001**	DEC 04, 1985
AB			**20MG**	**N83677 001**	
AB			**50MG**	**N88465 001**	JUN 01, 1984

PRILOCAINE; *MULTIPLE*
SEE LIDOCAINE; PRILOCAINE

PRILOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
CITANEST PLAIN

	+	DENTSPLY PHARM	4%	N21382 001

PRILOCAINE HYDROCHLORIDE; *MULTIPLE*
SEE EPINEPHRINE BITARTRATE; PRILOCAINE HYDROCHLORIDE

PRIMAQUINE PHOSPHATE

TABLET; ORAL
PRIMAQUINE

	+	SANOFI SYNTHELABO	EQ 15MG BASE	N08316 001

PRIMIDONE

SUSPENSION; ORAL
MYSOLINE

	+	XCEL PHARMS	250MG/5ML	N10401 001

TABLET; ORAL
MYSOLINE

AB		XCEL PHARMS	**50MG**	**N09170 003**	
AB	+		**250MG**	**N09170 002**	

PRIMIDONE

AB		DANBURY PHARMA	**250MG**	**N83551 001**	
AB		LANNETT	**50MG**	**N84903 002**	MAY 24, 2001
AB			**250MG**	**N84903 001**	

FDA data supplied by DrugPatentWatch.com

PROBENECID

TABLET; ORAL

	PROBALAN			
AB	LANNETT	500MG	N80966 001	
	PROBENECID			
AB	DANBURY PHARMA	500MG	N84442 004	MAR 29, 1983
AB	IVAX PHARMS	500MG	N83740 001	MAY 09, 1984
AB +	MYLAN	500MG	N84211 002	

PROBENECID; *MULTIPLE*
SEE COLCHICINE; PROBENECID

PROCAINAMIDE HYDROCHLORIDE

CAPSULE; ORAL

	PROCAINAMIDE HCL			
AB	DANBURY PHARMA	250MG	N83287 001	
AB		375MG	N84403 001	
AB		500MG	N84280 001	
AB	GENEVA PHARMS	250MG	N89219 001	JUL 01, 1986
AB		375MG	N89220 001	JUL 01, 1986
AB		500MG	N89221 001	JUL 01, 1986
AB	IVAX PHARMS	250MG	N84604 001	
AB		375MG	N84595 001	
AB		500MG	N84606 001	
AB	LANNETT	250MG	N83693 001	
	PRONESTYL			
AB	APOTHECON	250MG	N07335 001	
AB		375MG	N07335 004	
AB +		500MG	N07335 003	

INJECTABLE; INJECTION

	PROCAINAMIDE HCL			
AP	ABBOTT	100MG/ML	N89069 001	FEB 12, 1986
AP		500MG/ML	N89070 001	FEB 12, 1986
AP		500MG/ML	N89537 001	AUG 25, 1987
AP	ELKINS SINN	100MG/ML	N89029 001	APR 17, 1986

PROCAINAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

	PROCAINAMIDE HCL			
AP	ELKINS SINN	500MG/ML	N89030 001	APR 17, 1986
AP	INTL MEDICATION	100MG/ML	N88636 001	JUL 31, 1984
AP		500MG/ML	N88637 001	JUL 31, 1984
	PRONESTYL			
AP +	APOTHECON	100MG/ML	N07335 002	
AP +		500MG/ML	N07335 005	

TABLET; ORAL

	PRONESTYL		
	APOTHECON	250MG	N17371 001
		375MG	N17371 002
+		500MG	N17371 003

TABLET, EXTENDED RELEASE; ORAL

	PROCAINAMIDE HCL			
AB	COPLEY PHARM	1GM	N40111 001	DEC 13, 1996
AB		500MG	N88974 001	JUL 22, 1985
AB		750MG	N89438 001	MAR 23, 1987
AB	DANBURY PHARMA	250MG	N89026 001	OCT 22, 1985
AB		500MG	N89027 001	OCT 22, 1985
AB		750MG	N89042 001	OCT 22, 1985
AB	GENEVA PHARMS	250MG	N89369 001	AUG 14, 1987
AB		500MG	N89370 001	JAN 09, 1987
AB		750MG	N89371 001	AUG 14, 1987
AB	SIDMAK LABS NJ	500MG	N88959 001	DEC 02, 1985
	PROCANBID			
+	KING PHARMS	500MG	N20545 001	JAN 31, 1996
+		1GM	N20545 002	JAN 31, 1996
	PRONESTYL-SR			
BC	APOTHECON	500MG	N87361 001	

FDA data supplied by DrugPatentWatch.com

PROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

	NOVOCAIN				
AP	+ ABBOTT	1%	N85362 003		
AP	+	2%	N85362 004		
	+	10%	N86797 001		
	PROCAINE HCL				
AP	ABBOTT	1%	N80416 001		
AP		2%	N80416 002		
AP	AM PHARM PARTNERS	1%	N80421 001		
AP		2%	N80421 002		
AP	ELKINS SINN	1%	N83315 001		
AP		2%	N83315 002		
AP	STERIS	1%	N80658 001		
AP		2%	N80658 002		

PROCARBAZINE HYDROCHLORIDE

CAPSULE; ORAL

MATULANE			
+	SIGMA TAU	EQ 50MG BASE	N16785 001

PROCHLORPERAZINE

SUPPOSITORY; RECTAL

	COMPAZINE		
AB	GLAXOSMITHKLINE	2.5MG	N11127 003
AB		5MG	N11127 001
AB	+	25MG	N11127 002
	COMPRO		
AB	PADDOCK	25MG	N40246 001 JUN 28, 2000
	PROCHLORPERAZINE		
AB	ABLE	2.5MG	N40407 001 JUL 11, 2001
AB		5MG	N40407 002 JUL 11, 2001
AB		25MG	N40407 003 JUL 11, 2001
AB	G AND W LABS	25MG	N40058 001 NOV 24, 1993

PROCHLORPERAZINE EDISYLATE

INJECTABLE; INJECTION

	COMPAZINE		
AP	+ GLAXOSMITHKLINE	EQ 5MG BASE/ML	N10742 002
	PROCHLORPERAZINE		
AP	ELKINS SINN	EQ 5MG BASE/ML	N87759 001 OCT 01, 1982
	PROCHLORPERAZINE EDISYLATE		
AP	ABBOTT	EQ 5MG BASE/ML	N89703 001 APR 07, 1988
AP	ELKINS SINN	EQ 5MG BASE/ML	N89903 001 AUG 29, 1989
AP	STERIS	EQ 5MG BASE/ML	N89530 001 JUL 08, 1987

SYRUP; ORAL

COMPAZINE			
	GLAXOSMITHKLINE	EQ 5MG BASE/5ML	N11188 001

PROCHLORPERAZINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL

COMPAZINE			
+	GLAXOSMITHKLINE	EQ 10MG BASE	N11000 001
		EQ 10MG BASE	N21019 001 OCT 06, 1999
+		EQ 15MG BASE	N11000 002
		EQ 15MG BASE	N21019 002 OCT 06, 1999
+		EQ 30MG BASE	N11000 003

TABLET; ORAL

	COMPAZINE		
AB	GLAXOSMITHKLINE	EQ 5MG BASE	N10571 001
AB		EQ 10MG BASE	N10571 002
AB	+	EQ 25MG BASE	N10571 003
	PROCHLORPERAZINE MALEATE		
AB	COPLEY PHARM	EQ 5MG BASE	N40120 001 JUL 11, 1996
AB		EQ 10MG BASE	N40120 002 JUL 11, 1996
AB	DURAMED	EQ 5MG BASE	N40207 001 MAY 01, 1997
AB		EQ 10MG BASE	N40207 002 MAY 01, 1997
AB	GENEVA PHARMS TECH	EQ 5MG BASE	N40101 001 JUL 19, 1996

FDA data supplied by DrugPatentWatch.com

PROCHLORPERAZINE MALEATE

TABLET; ORAL
PROCHLORPERAZINE MALEATE

AB	GENEVA PHARMS TECH	EQ 10MG BASE	**N40101 002**	JUL 19, 1996
AB		EQ 25MG BASE	**N40101 003**	JUL 19, 1996
AB	IVAX PHARMS	EQ 5MG BASE	**N40162 001**	JAN 20, 1998
AB		EQ 10MG BASE	**N40162 002**	JAN 20, 1998
AB	MYLAN	EQ 5MG BASE	**N40185 002**	OCT 28, 1996
AB		EQ 10MG BASE	**N40185 001**	OCT 28, 1996
AB	TRIGEN	EQ 5MG BASE	**N40268 001**	FEB 27, 1998
AB		EQ 10MG BASE	**N40268 002**	FEB 27, 1998

PROCYCLIDINE HYDROCHLORIDE

TABLET; ORAL
KEMADRIN

+	MONARCH PHARMS	5MG	N09818 003

PROGESTERONE

CAPSULE; ORAL
PROMETRIUM

	UNIMED PHARMS	100MG	N19781 001 MAY 14, 1998
+		200MG	N19781 002 OCT 15, 1999

GEL; VAGINAL
CRINONE

	COLUMBIA RES LABS	4%	N20701 001 JUL 31, 1997
+		8%	N20701 002 JUL 31, 1997
+		8%	N20756 001 MAY 13, 1997

INJECTABLE; INJECTION
PROGESTERONE

AO	AM PHARM PARTNERS	50MG/ML	**N75906 001** APR 25, 2001

PROGESTERONE

INJECTABLE; INJECTION
PROGESTERONE

AO	+ SCHEIN	50MG/ML	**N17362 002**

INSERT, EXTENDED RELEASE; INTRAUTERINE
PROGESTASERT

ALZA	38MG	N17553 001

PROGUANIL HYDROCHLORIDE; *MULTIPLE*
SEE ATOVAQUONE; PROGUANIL HYDROCHLORIDE

PROMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION
SPARINE

+ WYETH AYERST	50MG/ML	N10349 006

TABLET; ORAL
SPARINE

WYETH AYERST	25MG	N10348 001
+	50MG	N10348 002

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION
PHENERGAN

AP	+ WYETH AYERST	25MG/ML	**N08857 002**
AP	+	50MG/ML	**N08857 003**
	PROMETHAZINE HCL		
AP	ABBOTT	25MG/ML	**N40372 001** JUN 08, 2000
AP		50MG/ML	**N40372 002** JUN 08, 2000
AP		50MG/ML	**N83838 002**
AP	ELKINS SINN	25MG/ML	**N83312 001**
AP		50MG/ML	**N83312 002**
AP	STERIS	25MG/ML	**N84591 001**
AP		50MG/ML	**N80629 002**

SUPPOSITORY; RECTAL
PHENERGAN

BR	+ WYETH AYERST	25MG	N10926 001
BR	+	50MG	N11689 001
		12.5MG	N10926 002

FDA data supplied by DrugPatentWatch.com

PROMETHAZINE HYDROCHLORIDE

SUPPOSITORY; RECTAL

	PROMETHACON			
BR	POLYMEDICA	25MG	N84901 001	
	PROMETHEGAN			
BR	G AND W LABS	50MG	N87165 001	
			AUG 14, 1987	

SYRUP; ORAL

	PHENERGAN FORTIS			
	+ WYETH AYERST	25MG/5ML	N08381 003	
	PHENERGAN PLAIN			
AA	+ WYETH AYERST	**6.25MG/5ML**	**N08381 004**	
			APR 18, 1984	
	PROMETH PLAIN			
AA	ALPHARMA	**6.25MG/5ML**	**N85953 001**	
	PROMETHAZINE HCL			
AA	HI TECH PHARMA	**6.25MG**	**N40026 001**	
			SEP 25, 1998	
AA	WHITEWORTH TOWN PLSN	**6.25MG/5ML**	**N86395 001**	
	PROMETHAZINE PLAIN			
AA	MORTON GROVE	**6.25MG/5ML**	**N87953 001**	
			NOV 15, 1982	

TABLET; ORAL

	PHENERGAN			
BP	WYETH AYERST	25MG	N07935 003	
BP	+	50MG	N07935 004	
		12.5MG	N07935 002	
	PROMETHAZINE HCL			
BP	DANBURY PHARMA	25MG	N83426 001	
BP		50MG	N83711 001	
BP	GENEVA PHARMS	25MG	N84234 001	
BP		50MG	N84176 001	

PROMETHAZINE HYDROCHLORIDE; *MULTIPLE*

SEE CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SEE CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SEE DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SEE MEPERIDINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SEE PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

PROPAFENONE HYDROCHLORIDE

TABLET; ORAL

	PROPAFENONE HCL			
AB	MUTUAL PHARM	**150MG**	**N75998 001**	
			NOV 29, 2001	
AB		**225MG**	**N75998 002**	
			NOV 29, 2001	
AB		**300MG**	**N75998 003**	
			NOV 29, 2001	
AB	WATSON LABS	**150MG**	**N75203 001**	
			OCT 24, 2000	
AB		**225MG**	**N75203 002**	
			OCT 24, 2000	
	RYTHMOL			
AB	ABBOTT	**150MG**	**N19151 001**	
			NOV 27, 1989	
AB		**225MG**	**N19151 003**	
			NOV 20, 1992	
AB	+	**300MG**	**N19151 002**	
			NOV 27, 1989	

PROPANTHELINE BROMIDE

TABLET; ORAL

	PRO-BANTHINE			
BP	+ SHIRE LABS	7.5MG	N08732 003	
BP	+	15MG	N08732 002	
	PROPANTHELINE BROMIDE			
BP	ROXANE	7.5MG	N80927 001	
BP		15MG	N80927 002	

PROPARACAINE HYDROCHLORIDE

SOLUTION; OPHTHALMIC

	PROPARACAINE HCL			
AT	TAYLOR PHARMA	**0.5%**	**N40277 001**	
			MAR 16, 2000	

SOLUTION/DROPS; OPHTHALMIC

	ALCAINE			
AT	ALCON	**0.5%**	**N80027 001**	
	OPHTHAINE			
AT	+ APOTHECON	**0.5%**	**N08883 001**	
	OPHTHETIC			
AT	+ ALLERGAN	**0.5%**	**N12583 001**	

FDA data supplied by DrugPatentWatch.com

PROPARACAINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

	PARACAINE			
AT	OPTOPICS	0.5%	N87681 001	AUG 05, 1982
	PROPARACAINE HCL			
AT	BAUSCH AND LOMB	0.5%	N40074 001	SEP 29, 1995

PROPOFOL

INJECTABLE; INJECTION

	DIPRIVAN			
AB	+ ASTRAZENECA	10MG/ML	N19627 002	JUN 11, 1996
	PROPOFOL			
AB	GENSIA SICOR PHARMS	10MG/ML	N75102 001	JAN 04, 1999
AB		10MG/ML	N75392 001	SEP 19, 2000

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

	DARVON			
AA	+ LILLY	32MG	N10997 001	
AA	+	65MG	N10997 003	
	DOLENE			
AA	LEDERLE	65MG	N80530 001	
	KESSO-GESIC			
AA	MK LABS	65MG	N83544 001	
	PROPOXYPHENE HCL			
AA	ICN	65MG	N80783 001	
AA	IVAX PHARMS	65MG	N80269 001	
AA	MYLAN	32MG	N83528 001	
AA	TEVA	65MG	N88615 001	OCT 22, 1984
AA	WEST WARD	65MG	N83501 001	
AA	WHITEWORTH TOWN PLSN	65MG	N84551 001	

PROPOXYPHENE HYDROCHLORIDE; *MULTIPLE*
SEE ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE
SEE ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE
SEE ASPIRIN; PROPOXYPHENE HYDROCHLORIDE

PROPOXYPHENE NAPSYLATE

SUSPENSION; ORAL

	DARVON-N			
	+ LILLY	50MG/5ML	N16861 001	

TABLET; ORAL

	DARVON-N			
	+ LILLY	100MG	N16862 002	

PROPOXYPHENE NAPSYLATE; *MULTIPLE*
SEE ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

	INDERAL LA			
	WYETH AYERST	60MG	N18553 004	MAR 18, 1987
		80MG	N18553 002	APR 19, 1983
		120MG	N18553 003	APR 19, 1983
	+	160MG	N18553 001	APR 19, 1983

CONCENTRATE; ORAL

	PROPRANOLOL HCL INTENSOL			
	+ ROXANE	80MG/ML	N71388 001	MAY 15, 1987

INJECTABLE; INJECTION

	INDERAL			
AP	+ WYETH AYERST	1MG/ML	N16419 001	
	PROPRANOLOL HCL			
AP	BEDFORD	1MG/ML	N75792 001	AUG 29, 2000

SOLUTION; ORAL

	PROPRANOLOL HCL			
	+ ROXANE	20MG/5ML	N70979 001	MAY 15, 1987
	+	40MG/5ML	N70690 001	MAY 15, 1987

TABLET; ORAL

	INDERAL			
AB	+ WYETH AYERST	10MG	N16418 001	

FDA data supplied by DrugPatentWatch.com

PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

	INDERAL			
AB	WYETH AYERST	20MG	**N16418 003**	
AB		40MG	**N16418 002**	
AB		60MG	**N16418 009**	OCT 18, 1982
AB	+	80MG	**N16418 004**	
	PROPRANOLOL HCL			
AB	DANBURY PHARMA	10MG	**N70175 001**	MAY 13, 1986
AB		20MG	**N70176 001**	MAY 13, 1986
AB		40MG	**N70177 001**	MAY 13, 1986
AB		80MG	**N70178 001**	MAY 13, 1986
AB	GENEVA PHARMS	10MG	**N70663 001**	JUN 13, 1986
AB		20MG	**N70664 001**	JUN 13, 1986
AB		40MG	**N70665 001**	JUN 13, 1986
AB		60MG	**N70666 001**	OCT 10, 1986
AB		80MG	**N70667 001**	JUN 13, 1986
AB	LEDERLE	60MG	**N71495 001**	DEC 31, 1987
AB		80MG	**N70128 001**	JUL 30, 1985
AB		90MG	**N71496 001**	DEC 31, 1987
AB	MYLAN	10MG	**N70211 001**	NOV 19, 1985
AB		20MG	**N70212 001**	NOV 19, 1985
AB		40MG	**N70213 001**	NOV 19, 1985
AB		80MG	**N70214 001**	NOV 19, 1985
AB	PAR PHARM	10MG	**N70217 001**	AUG 01, 1986
AB		20MG	**N70218 001**	AUG 01, 1986
AB		40MG	**N70219 001**	AUG 01, 1986

PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

	PROPRANOLOL HCL			
AB	PAR PHARM	60MG	**N70220 001**	SEP 24, 1986
AB		80MG	**N70221 001**	APR 14, 1986
AB		90MG	**N71288 001**	OCT 22, 1986
AB	PUREPAC PHARM	10MG	**N70814 001**	NOV 03, 1986
AB		20MG	**N70815 001**	NOV 03, 1986
AB		40MG	**N70816 001**	NOV 03, 1986
AB		60MG	**N70817 001**	NOV 03, 1986
AB		80MG	**N70757 001**	NOV 03, 1986
AB	SIDMAK LABS NJ	10MG	**N71972 001**	APR 06, 1988
AB		20MG	**N71973 001**	APR 06, 1988
AB		40MG	**N71974 001**	APR 06, 1988
AB		60MG	**N71975 001**	APR 06, 1988
AB		80MG	**N71976 001**	APR 06, 1988
AB		90MG	**N71977 001**	APR 06, 1988
AB	TEVA	40MG	**N70234 001**	JUN 23, 1986
AB	WATSON LABS	10MG	**N70548 001**	JUL 10, 1986
AB		40MG	**N70550 001**	APR 11, 1986
AB		60MG	**N71791 001**	JUL 15, 1987
AB		80MG	**N70551 001**	JUL 10, 1986
AB		90MG	**N71792 001**	JUL 15, 1987

PROPRANOLOL HYDROCHLORIDE; *MULTIPLE*
SEE HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

PROPYLTHIOURACIL

TABLET; ORAL
PROPYLTHIOURACIL

BD		IMPAX LABS	50MG	N80159 001
BD	+	LEDERLE	50MG	N06188 001
BD		PUREPAC PHARM	50MG	N80172 001
BD		WEST WARD	50MG	N80154 001

PROTAMINE SULFATE

INJECTABLE; INJECTION
PROTAMINE SULFATE

AP		AM PHARM PARTNERS	**10MG/ML**	**N89454 001** APR 07, 1987
AP		ELKINS SINN	**10MG/ML**	**N89474 001** NOV 05, 1986
AP			**10MG/ML**	**N89475 001** NOV 05, 1986
AP	+	LILLY	**10MG/ML**	**N06460 002**

PROTIRELIN

INJECTABLE; INJECTION
THYREL TRH

	+	FERRING	0.5MG/ML	N18087 001

PROTRIPTYLINE HYDROCHLORIDE

TABLET; ORAL
VIVACTIL

AB		ODYSSEY PHARMS	**5MG**	**N73644 001** AUG 24, 1995
AB	+		**10MG**	**N73645 001** AUG 24, 1995

PSEUDOEPHEDRINE HYDROCHLORIDE; *MULTIPLE*
SEE ACRIVASTINE; PSEUDOEPHEDRINE HYDROCHLORIDE
SEE BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE
SEE CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE
SEE CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE
SEE FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

TABLET; ORAL
CORPHED

AA		GENEVA PHARMS	**60MG;2.5MG**	**N88602 001** APR 11, 1985

PSEUDOEPHEDRINE HCL AND TRIPROLIDINE HCL

AA	+	EON	**60MG;2.5MG**	**N88193 001** MAY 17, 1983

TRILITRON

AA		NEWTRON PHARMS	**60MG;2.5MG**	**N88515 001** JAN 09, 1985

TRIPROLIDINE HCL AND PSEUDOEPHEDRINE HCL

AA		SUPERPHARM	**60MG;2.5MG**	**N88578 001** FEB 21, 1985

PSEUDOEPHEDRINE SULFATE; *MULTIPLE*
SEE AZATADINE MALEATE; PSEUDOEPHEDRINE SULFATE
SEE LORATADINE; PSEUDOEPHEDRINE SULFATE

PYRAZINAMIDE

TABLET; ORAL
PYRAZINAMIDE

AB	+	LEDERLE	**500MG**	**N80157 001**
AB		MIKART	**500MG**	**N81319 001** JUN 30, 1992

PYRAZINAMIDE; *MULTIPLE*
SEE ISONIAZID; PYRAZINAMIDE; RIFAMPIN

PYRIDOSTIGMINE BROMIDE

INJECTABLE; INJECTION
MESTINON

AP	+	ICN	**5MG/ML**	**N09830 001**

REGONOL

AP	+	ORGANON	**5MG/ML**	**N17398 001**

SYRUP; ORAL
MESTINON

	+	ICN	60MG/5ML	N15193 001

TABLET; ORAL
MESTINON

	+	ICN	60MG	N09829 002

FDA data supplied by DrugPatentWatch.com

PYRIDOSTIGMINE BROMIDE

TABLET, EXTENDED RELEASE; ORAL
MESTINON
+ ICN 180MG N11665 001

PYRIDOXINE; *MULTIPLE*
SEE ALPHA-TOCOPHEROL; ASCORBIC ACID; BIOTIN, D-; CHOLECALCIFEROL; CYANOCOBALAMIN; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A
SEE ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

PYRIDOXINE HYDROCHLORIDE

INJECTABLE; INJECTION
PYRIDOXINE HCL
AP AM PHARM PARTNERS **100MG/ML** **N80618 001**
AP + STERIS **100MG/ML** **N80572 001**

PYRIDOXINE HYDROCHLORIDE; *MULTIPLE*
SEE ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE
SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PHYTONADIONE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E
SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

PYRILAMINE MALEATE

TABLET; ORAL
PYRILAMINE MALEATE
+ IMPAX LABS 25MG N80808 001

PYRILAMINE MALEATE; *MULTIPLE*
SEE PHENYLEPHRINE HYDROCHLORIDE; PYRILAMINE MALEATE

PYRIMETHAMINE

TABLET; ORAL
DARAPRIM
+ GLAXOSMITHKLINE 25MG N08578 001

PYRIMETHAMINE; SULFADOXINE

TABLET; ORAL
FANSIDAR
+ ROCHE 25MG;500MG N18557 001

QUAZEPAM

TABLET; ORAL
DORAL
WALLACE LABS 7.5MG N18708 003 FEB 26, 1987
+ 15MG N18708 001 DEC 27, 1985

QUETIAPINE FUMARATE

TABLET; ORAL
SEROQUEL
ASTRAZENECA EQ 25MG BASE N20639 001 SEP 26, 1997
EQ 100MG BASE N20639 002 SEP 26, 1997
EQ 150MG BASE N20639 004 DEC 20, 1998
EQ 200MG BASE N20639 003 SEP 26, 1997
+ EQ 300MG BASE N20639 005 JUL 26, 2000

QUINAPRIL HYDROCHLORIDE

TABLET; ORAL
ACCUPRIL
PARKE DAVIS EQ 5MG BASE N19885 001 NOV 19, 1991
EQ 10MG BASE N19885 002 NOV 19, 1991

FDA data supplied by DrugPatentWatch.com

QUINAPRIL HYDROCHLORIDE

TABLET; ORAL
ACCUPRIL
PARKE DAVIS — EQ 20MG BASE — N19885 003 NOV 19, 1991
\+ — EQ 40MG BASE — N19885 004 NOV 19, 1991

QUINAPRIL HYDROCHLORIDE; *MULTIPLE*
SEE HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

QUINETHAZONE

TABLET; ORAL
HYDROMOX
\+ LEDERLE — 50MG — N13264 001

QUINIDINE GLUCONATE

INJECTABLE; INJECTION
QUINIDINE GLUCONATE
\+ LILLY — 80MG/ML — N07529 002 FEB 10, 1989

TABLET, EXTENDED RELEASE; ORAL
QUINAGLUTE
BX + BERLEX LABS — 324MG — N16647 001
QUINIDINE GLUCONATE
BX DANBURY PHARMA — 324MG — N87810 001 SEP 29, 1982
BX MUTUAL PHARM — 324MG — N89338 001 FEB 11, 1987

QUINIDINE SULFATE

TABLET; ORAL
QUINIDINE SULFATE
AB DANBURY PHARMA — **200MG** — **N83288 001**
AB — **300MG** — **N85583 001**
AB EON — **200MG** — **N84631 001**
AB — **300MG** — **N88072 001**
SEP 26, 1983
AB GENEVA PHARMS — **200MG** — **N84914 001**

QUINIDINE SULFATE

TABLET; ORAL
QUINIDINE SULFATE
AB GENEVA PHARMS — **300MG** — **N89839 001** SEP 29, 1988
AB KING PHARMS — **200MG** — **N85175 001**
AB LANNETT — **200MG** — **N83743 001**
AB LEDERLE — **200MG** — **N87011 001**
AB MUTUAL PHARM — **100MG** — **N81029 001** APR 14, 1989
AB — **200MG** — **N81030 001** APR 14, 1989
AB PVT FORM — **200MG** — **N83808 001**
AB + ROXANE — **200MG** — **N83640 001**
AB + — **300MG** — **N85632 001**
AB SUPERPHARM — **200MG** — **N88973 001** APR 10, 1985
AB WATSON LABS — **200MG** — **N85140 002**

TABLET, EXTENDED RELEASE; ORAL
QUINIDEX
AB + ROBINS AH — **300MG** — **N12796 002**
QUINIDINE SULFATE
AB COPLEY PHARM — **300MG** — **N40045 001** JUN 30, 1994

QUINUPRISTIN; *MULTIPLE*
SEE DALFOPRISTIN; QUINUPRISTIN

RABEPRAZOLE SODIUM

TABLET, DELAYED RELEASE; ORAL
ACIPHEX
\+ EISAI — 20MG — N20973 002 AUG 19, 1999

RALOXIFENE HYDROCHLORIDE

TABLET; ORAL
EVISTA
\+ LILLY — 60MG — N20815 001 DEC 09, 1997

FDA data supplied by DrugPatentWatch.com

RAMIPRIL

CAPSULE; ORAL

ALTACE				
KING PHARMS	1.25MG	N19901 001		JAN 28, 1991
	2.5MG	N19901 002		JAN 28, 1991
	5MG	N19901 003		JAN 28, 1991
+	10MG	N19901 004		JAN 28, 1991

RANITIDINE HYDROCHLORIDE

CAPSULE; ORAL

RANITIDINE HCL				
AB DR REDDYS LABS LTD	**EQ 150MG BASE**	**N75742 001**		NOV 29, 2000
AB	**EQ 300MG BASE**	**N75742 002**		NOV 29, 2000
AB GENEVA PHARMS	**EQ 150MG BASE**	**N74655 001**		OCT 22, 1997
AB	**EQ 300MG BASE**	**N74655 002**		OCT 22, 1997
AB GENPHARM	**EQ 150MG BASE**	**N75564 001**		OCT 27, 2000
AB	**EQ 300MG BASE**	**N75564 002**		OCT 27, 2000
ZANTAC 300				
AB + GLAXOSMITHKLINE	**EQ 300MG BASE**	**N20095 002**		MAR 08, 1994

GRANULE, EFFERVESCENT; ORAL

ZANTAC 150				
+ GLAXOSMITHKLINE	EQ 150MG BASE/PACKET	N20251 002		MAR 31, 1994

INJECTABLE; INJECTION

ZANTAC				
+ GLAXOSMITHKLINE	EQ 25MG BASE/ML	N19090 001		OCT 19, 1984
ZANTAC IN PLASTIC CONTAINER				
+ GLAXOSMITHKLINE	EQ 1MG BASE/ML	N19593 002		SEP 27, 1991

SYRUP; ORAL

ZANTAC				
+ GLAXOSMITHKLINE	EQ 15MG BASE/ML	N19675 001		DEC 30, 1988

RANITIDINE HYDROCHLORIDE

TABLET; ORAL

RANITIDINE				
AB RANBAXY	**EQ 150MG BASE**	**N75439 001**		APR 19, 2000
AB	**EQ 300MG BASE**	**N75439 002**		APR 19, 2000
RANITIDINE HCL				
AB GENEVA PHARMS	**EQ 150MG BASE**	**N74467 001**		AUG 29, 1997
AB	**EQ 300MG BASE**	**N74467 002**		AUG 29, 1997
AB GENPHARM	**EQ 150MG BASE**	**N74023 001**		AUG 22, 1997
AB	**EQ 300MG BASE**	**N74023 002**		AUG 22, 1997
AB IVAX PHARMS	**EQ 150MG BASE**	**N75165 001**		SEP 30, 1998
AB	**EQ 300MG BASE**	**N75165 002**		SEP 30, 1998
AB MYLAN	**EQ 150MG BASE**	**N74552 001**		JUL 30, 1998
AB	**EQ 300MG BASE**	**N74552 002**		JUL 30, 1998
AB PAR PHARM	**EQ 150MG BASE**	**N75180 001**		JAN 28, 1999
AB	**EQ 300MG BASE**	**N75180 002**		JAN 28, 1999
AB RANBAXY	**EQ 150MG BASE**	**N75000 001**		JAN 30, 1998
AB	**EQ 300MG BASE**	**N75000 002**		JAN 30, 1998
AB TEVA	**EQ 150MG BASE**	**N74488 001**		JUL 31, 1997
AB	**EQ 300MG BASE**	**N74488 002**		JUL 31, 1997
AB TORPHARM	**EQ 150MG BASE**	**N74680 001**		SEP 12, 1997
AB	**EQ 300MG BASE**	**N74680 002**		SEP 12, 1997
AB WATSON LABS	**EQ 150MG BASE**	**N74864 001**		OCT 20, 1997
AB	**EQ 300MG BASE**	**N74864 002**		OCT 20, 1997
AB WOCKHARDT	**EQ 150MG BASE**	**N75208 001**		DEC 17, 1998
AB	**EQ 300MG BASE**	**N75208 002**		DEC 17, 1998

FDA data supplied by DrugPatentWatch.com

RANITIDINE HYDROCHLORIDE

TABLET; ORAL					
ZANTAC 150					
AB	GLAXOSMITHKLINE	**EQ 150MG BASE**	**N18703 001**		
			JUN 09, 1983		
ZANTAC 300					
AB +	GLAXOSMITHKLINE	**EQ 300MG BASE**	**N18703 002**		
			DEC 09, 1985		
TABLET, EFFERVESCENT; ORAL					
ZANTAC 150					
+	GLAXOSMITHKLINE	EQ 150MG BASE	N20251 001		
			MAR 31, 1994		

RAPACURONIUM BROMIDE

INJECTABLE; INJECTION			
RAPLON			
	ORGANON	100MG/VIAL	N20984 001
			AUG 18, 1999
+		200MG/VIAL	N20984 002
			AUG 18, 1999

REMIFENTANIL HYDROCHLORIDE

INJECTABLE; INJECTION			
ULTIVA			
	ABBOTT	EQ 1MG BASE/VIAL	N20630 001
			JUL 12, 1996
		EQ 2MG BASE/VIAL	N20630 002
			JUL 12, 1996
+		EQ 5MG BASE/VIAL	N20630 003
			JUL 12, 1996

REPAGLINIDE

TABLET; ORAL			
PRANDIN			
	NOVO NORDISK	0.5MG	N20741 001
			DEC 22, 1997
		1MG	N20741 002
			DEC 22, 1997
+		2MG	N20741 003
			DEC 22, 1997

RESCINNAMINE

TABLET; ORAL			
MODERIL			
	PFIZER	0.25MG	N10686 003
+		0.5MG	N10686 006

RESERPINE

TABLET; ORAL				
RESERPINE				
BP	EON	0.1MG		N09838 001
BP +		0.25MG		N09838 002
SERPALAN				
BP	LANNETT	0.1MG		N10124 001
BP		0.25MG		N10124 002

RESERPINE; *MULTIPLE*

SEE CHLOROTHIAZIDE; RESERPINE
SEE CHLORTHALIDONE; RESERPINE
SEE HYDROCHLOROTHIAZIDE; RESERPINE
SEE HYDROFLUMETHIAZIDE; RESERPINE
SEE METHYCLOTHIAZIDE; RESERPINE
SEE POLYTHIAZIDE; RESERPINE

RESERPINE; TRICHLORMETHIAZIDE

TABLET; ORAL			
METATENSIN #2			
	AVENTIS PHARMS	0.1MG;2MG	N12972 001
METATENSIN #4			
+	AVENTIS PHARMS	0.1MG;4MG	N12972 002

RIBAVIRIN

CAPSULE; ORAL			
REBETOL			
+	SCHERING PLOUGH RES	200MG	N20903 001
			JUN 03, 1998
+		200MG	N20903 002
			JUL 25, 2001
FOR SOLUTION; INHALATION			
VIRAZOLE			
+	ICN	6GM/VIAL	N18859 001
			DEC 31, 1985

FDA data supplied by DrugPatentWatch.com

RIBOFLAVIN; *MULTIPLE*
SEE ALPHA-TOCOPHEROL; ASCORBIC ACID; BIOTIN, D-; CHOLECALCIFEROL; CYANOCOBALAMIN; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A
SEE ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

RIBOFLAVIN PHOSPHATE SODIUM; *MULTIPLE*
SEE ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE
SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PHYTONADIONE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E
SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

RIFABUTIN

CAPSULE; ORAL
MYCOBUTIN
\+ PHARMACIA AND UPJOHN 150MG — N50689 001 DEC 23, 1992

RIFAMPIN

CAPSULE; ORAL
RIFADIN
AB AVENTIS PHARMS **150MG** — **N62303 001**
AB \+ **300MG** — **N50420 001**
RIFAMPIN
AB EON **150MG** — **N64150 002** JAN 02, 1998
AB **300MG** — **N64150 001** MAY 28, 1997
AB VERSAPHARM **150MG** — **N65028 001** MAR 14, 2001

RIFAMPIN

CAPSULE; ORAL
RIFAMPIN
AB VERSAPHARM **300MG** — **N65028 002** MAR 14, 2001
RIMACTANE
AB GENEVA PHARMS **300MG** — **N50429 001**

INJECTABLE; INJECTION
RIFADIN
AP \+ AVENTIS PHARMS **600MG/VIAL** — **N50627 001** MAY 25, 1989
RIFAMPIN
AP BEDFORD **600MG/VIAL** — **N64217 001** OCT 29, 1999

RIFAMPIN; *MULTIPLE*
SEE ISONIAZID; PYRAZINAMIDE; RIFAMPIN
SEE ISONIAZID; RIFAMPIN

RIFAPENTINE

TABLET; ORAL
PRIFTIN
\+ AVENTIS PHARMS 150MG — N21024 001 JUN 22, 1998

RILUZOLE

TABLET; ORAL
RILUTEK
\+ AVENTIS 50MG — N20599 001 DEC 12, 1995

RIMANTADINE HYDROCHLORIDE

SYRUP; ORAL
FLUMADINE
\+ FOREST LABS 50MG/5ML — N19650 001 SEP 17, 1993

TABLET; ORAL
FLUMADINE
AB \+ FOREST LABS **100MG** — **N19649 001** SEP 17, 1993

FDA data supplied by DrugPatentWatch.com

RIMANTADINE HYDROCHLORIDE

TABLET; ORAL
RIMANTADINE HCL

AB	COREPHARMA	100MG	N75916 001	NOV 02, 2001

RIMEXOLONE

SUSPENSION/DROPS; OPHTHALMIC
VEXOL

+	ALCON	1%	N20474 001	DEC 30, 1994

RISEDRONATE SODIUM

TABLET; ORAL
ACTONEL

	PROCTER AND GAMBLE	5MG	N20835 002	APR 14, 2000
+		30MG	N20835 001	MAR 27, 1998

RISPERIDONE

SOLUTION; ORAL
RISPERDAL

+	JANSSEN	1MG/ML	N20588 001	JUN 10, 1996

TABLET; ORAL
RISPERDAL

	JANSSEN	0.25MG	N20272 008	MAY 10, 1999
		0.5MG	N20272 007	JAN 27, 1999
+		1MG	N20272 001	DEC 29, 1993
		2MG	N20272 002	DEC 29, 1993
		3MG	N20272 003	DEC 29, 1993
		4MG	N20272 004	DEC 29, 1993

RITODRINE HYDROCHLORIDE

INJECTABLE; INJECTION
RITODRINE HCL

+	ABBOTT	10MG/ML	N71618 001 FEB 28, 1991
+		15MG/ML	N71619 001 FEB 28, 1991

RITODRINE HCL IN DEXTROSE 5% IN PLASTIC CONTAINER

+	ABBOTT	30MG/100ML	N71438 001 JAN 22, 1991

RITONAVIR

CAPSULE; ORAL
NORVIR

+	ABBOTT	100MG	N20680 001 MAR 01, 1996
		100MG	N20945 001 JUN 29, 1999

SOLUTION; ORAL
NORVIR

+	ABBOTT	80MG/ML	N20659 001 MAR 01, 1996

RITONAVIR; *MULTIPLE*
SEE LOPINAVIR; RITONAVIR

RIVASTIGMINE TARTRATE

CAPSULE; ORAL
EXELON

	NOVARTIS	EQ 1.5MG BASE	N20823 003	APR 21, 2000
		EQ 3MG BASE	N20823 004	APR 21, 2000
		EQ 4.5MG BASE	N20823 005	APR 21, 2000
+		EQ 6MG BASE	N20823 006	APR 21, 2000

SOLUTION; ORAL
EXELON

+	NOVARTIS	EQ 2MG BASE/ML	N21025 001	APR 21, 2000

FDA data supplied by DrugPatentWatch.com

RIZATRIPTAN BENZOATE

TABLET; ORAL			
MAXALT			
MERCK	EQ 5MG BASE	N20864 001	JUN 29, 1998
+	EQ 10MG BASE	N20864 002	JUN 29, 1998
TABLET, ORALLY DISINTEGRATING; ORAL			
MAXALT-MLT			
MERCK	EQ 5MG BASE	N20865 001	JUN 29, 1998
+	EQ 10MG BASE	N20865 002	JUN 29, 1998

ROCURONIUM BROMIDE

INJECTABLE; INJECTION			
ZEMURON			
+ ORGANON	10MG/ML	N20214 002	MAR 17, 1994
ZEMURON (P/F)			
+ ORGANON	10MG/ML	N20214 001	MAR 17, 1994

ROFECOXIB

SUSPENSION; ORAL			
VIOXX			
MERCK	12.5MG/5ML	N21052 001	MAY 20, 1999
+	25MG/5ML	N21052 002	MAY 20, 1999
TABLET; ORAL			
VIOXX			
MERCK	12.5MG	N21042 001	MAY 20, 1999
	25MG	N21042 002	MAY 20, 1999
+	50MG	N21042 003	FEB 25, 2000

ROPINIROLE HYDROCHLORIDE

TABLET; ORAL			
REQUIP			
+ GLAXOSMITHKLINE	EQ 0.25MG BASE	N20658 001	SEP 19, 1997
	EQ 0.5MG BASE	N20658 002	SEP 19, 1997
	EQ 1MG BASE	N20658 003	SEP 19, 1997
	EQ 2MG BASE	N20658 004	SEP 19, 1997
	EQ 3MG BASE	N20658 006	JAN 27, 1999
	EQ 4MG BASE	N20658 007	JAN 27, 1999
+	EQ 5MG BASE	N20658 005	SEP 19, 1997

ROPIVACAINE HYDROCHLORIDE MONOHYDRATE

INJECTABLE; INJECTION			
NAROPIN			
ASTRAZENECA	2MG/ML	N20533 001	SEP 24, 1996
	5MG/ML	N20533 003	SEP 24, 1996
	7.5MG/ML	N20533 004	SEP 24, 1996
+	10MG/ML	N20533 005	SEP 24, 1996

ROSIGLITAZONE MALEATE

TABLET; ORAL			
AVANDIA			
GLAXOSMITHKLINE	EQ 2MG BASE	N21071 002	MAY 25, 1999
	EQ 4MG BASE	N21071 003	MAY 25, 1999
+	EQ 8MG BASE	N21071 004	MAY 25, 1999

FDA data supplied by DrugPatentWatch.com

RUBIDIUM CHLORIDE RB-82

INJECTABLE; INJECTION
CARDIOGEN-82
BRACCO N/A N19414 001 DEC 29, 1989

SACROSIDASE

SOLUTION; ORAL
SUCRAID
+ ORPHAN MEDCL 8,500 IU/ML N20772 001 APR 09, 1998

SAFFLOWER OIL; SOYBEAN OIL

INJECTABLE; INJECTION
LIPOSYN II 10%
+ ABBOTT 5%;5% N18997 001 AUG 27, 1984

LIPOSYN II 20%
+ ABBOTT 10%;10% N18991 001 AUG 27, 1984

SALMETEROL XINAFOATE

AEROSOL, METERED; INHALATION
SEREVENT
+ GLAXOSMITHKLINE EQ 0.021MG BASE/INH N20236 001 FEB 04, 1994

POWDER; INHALATION
SEREVENT
+ GLAXOSMITHKLINE EQ 0.046MG BASE/INH N20692 001 SEP 19, 1997

SALMETEROL XINAFOATE; *MULTIPLE*
SEE FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE

SAMARIUM SM 153 LEXIDRONAM PENTASODIUM

INJECTABLE; INJECTION
QUADRAMET
+ CYTOGEN 50mCi/ML N20570 001 MAR 28, 1997

SAQUINAVIR

CAPSULE; ORAL
FORTOVASE
+ HLR 200MG N20828 001 NOV 07, 1997

SAQUINAVIR MESYLATE

CAPSULE; ORAL
INVIRASE
+ HLR EQ 200MG BASE N20628 001 DEC 06, 1995

SCOPOLAMINE

FILM, EXTENDED RELEASE; TRANSDERMAL
TRANSDERM SCOP
+ NOVARTIS 1MG/72HR N17874 001

SECOBARBITAL SODIUM

CAPSULE; ORAL
SECOBARBITAL SODIUM
AA EVERYLIFE **100MG** **N85895 001**
SECONAL SODIUM
AA + LILLY **100MG** **N86101 002** OCT 03, 1983
\+ 50MG N86101 001 OCT 03, 1983
SODIUM SECOBARBITAL
AA WEST WARD **100MG** **N84926 001**

INJECTABLE; INJECTION
SECOBARBITAL SODIUM
+ ELKINS SINN 100MG/VIAL N83281 001
SODIUM SECOBARBITAL
+ WYETH AYERST 50MG/ML N83262 001

SELEGILINE HYDROCHLORIDE

CAPSULE; ORAL
ELDEPRYL
AB + SOMERSET **5MG** **N20647 001** MAY 15, 1996

FDA data supplied by DrugPatentWatch.com

SELEGILINE HYDROCHLORIDE

CAPSULE; ORAL

	SELEGILINE HCL			
AB	ESI LEDERLE	5MG	**N75352 001**	NOV 30, 1998
AB	TORPHARM	5MG	**N75321 001**	DEC 04, 1998

TABLET; ORAL

	SELEGILINE HCL			
AB	ALPHAPHARM	5MG	**N74866 001**	NOV 26, 1997
AB	APOTEX	5MG	**N74871 001**	JUN 06, 1997
AB	APOTHECON	5MG	**N74672 001**	APR 01, 1997
AB	ENDO PHARMS	5MG	**N74565 001**	AUG 02, 1996
AB	ESI LEDERLE	5MG	**N74641 001**	AUG 02, 1996
AB	IVAX PHARMS	5MG	**N74756 001**	NOV 25, 1998
AB +	SOMERSET	5MG	**N19334 001**	JUN 05, 1989
AB	STASON	5MG	**N74912 001**	APR 30, 1998
AB	TEVA	5MG	**N74537 001**	AUG 02, 1996
AB		5MG	**N74744 001**	JAN 27, 1997

SELENIUM SULFIDE

LOTION/SHAMPOO; TOPICAL

	EXSEL		
AT	ALLERGAN HERBERT	2.5%	**N83892 001**
	SELENIUM SULFIDE		
AT	ALPHARMA	2.5%	**N84394 001**
AT	CLAY PARK	2.5%	**N89996 001**
AT	MORTON GROVE	2.5%	JAN 10, 1991 **N88228 001**
	SELSUN		SEP 01, 1983
AT +	ABBOTT	2.5%	**N07936 001**

SELENOMETHIONINE, SE-75

INJECTABLE; INJECTION

	SELENOMETHIONINE SE 75		
+	CIS	500 uCi/ML	N17322 001

SERMORELIN ACETATE

INJECTABLE; INJECTION

	GEREF		
+	SERONO	EQ 0.05MG BASE/AMP	N19863 001 DEC 28, 1990
+		EQ 0.5MG BASE/VIAL	N20443 001 SEP 26, 1997
+		EQ 1MG BASE/VIAL	N20443 002 SEP 26, 1997

SERTRALINE HYDROCHLORIDE

CONCENTRATE; ORAL

	ZOLOFT		
+	PFIZER	EQ 20MG BASE/ML	N20990 001 DEC 07, 1999

TABLET; ORAL

	ZOLOFT		
	PFIZER	EQ 25MG BASE	N19839 005 MAR 06, 1996
		EQ 50MG BASE	N19839 001 DEC 30, 1991
+		EQ 100MG BASE	N19839 002 DEC 30, 1991

SEVELAMER HYDROCHLORIDE

CAPSULE; ORAL

	RENAGEL		
+	GELTEX	403MG	N20926 001 OCT 30, 1998

TABLET; ORAL

	RENAGEL		
	GELTEX	400MG	N21179 001 JUL 12, 2000
+		800MG	N21179 002 JUL 12, 2000

FDA data supplied by DrugPatentWatch.com

SEVOFLURANE

LIQUID; INHALATION
ULTANE
+ ABBOTT 100% N20478 001 JUN 07, 1995

SIBUTRAMINE HYDROCHLORIDE

CAPSULE; ORAL
MERIDIA
ABBOTT 5MG N20632 001 NOV 22, 1997
10MG N20632 002 NOV 22, 1997
+ 15MG N20632 003 NOV 22, 1997

SILDENAFIL CITRATE

TABLET; ORAL
VIAGRA
PFIZER 25MG N20895 001 MAR 27, 1998
50MG N20895 002 MAR 27, 1998
+ 100MG N20895 003 MAR 27, 1998

SILVER SULFADIAZINE

CREAM; TOPICAL
SILVADENE
AB + KING PHARMS **1%** **N17381 001**
SSD
AB BASF **1%** **N18578 001** FEB 25, 1982
SSD AF
BX BASF 1% N18578 003 JUL 11, 1990
THERMAZENE
AB KENDALL LP **1%** **N18810 001** DEC 23, 1985

SIMETHICONE-CELLULOSE

SUSPENSION; ORAL
SONORX
+ BRACCO 7.5MG/ML N20773 001 OCT 29, 1998

SIMVASTATIN

TABLET; ORAL
ZOCOR
MERCK 5MG N19766 001 DEC 23, 1991
10MG N19766 002 DEC 23, 1991
20MG N19766 003 DEC 23, 1991
40MG N19766 004 DEC 23, 1991
+ 80MG N19766 005 JUL 10, 1998

SINCALIDE

INJECTABLE; INJECTION
KINEVAC
+ BRACCO 0.005MG/VIAL N17697 001

SIROLIMUS

SOLUTION; ORAL
RAPAMUNE
+ WYETH AYERST 1MG/ML N21083 001 SEP 15, 1999

SODIUM ACETATE; *MULTIPLE*
SEE AMINO ACIDS; CALCIUM ACETATE; GLYCERIN; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE
SEE AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE
SEE AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE
SEE AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; POTASSIUM CHLORIDE; SODIUM ACETATE

FDA data supplied by DrugPatentWatch.com

SODIUM ACETATE; *MULTIPLE*
SEE AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE
SEE AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE
SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE
SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE
SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE
SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE
SEE CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE
SEE CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE
SEE CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE
SEE CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE
SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE
SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE
SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE
SEE DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE
SEE MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE
SEE MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

SODIUM ACETATE, ANHYDROUS

INJECTABLE; INJECTION
SODIUM ACETATE IN PLASTIC CONTAINER

+	ABBOTT	2MEQ/ML	N18893 001	MAY 04, 1983

SODIUM BENZOATE; SODIUM PHENYLACETATE

SOLUTION; ORAL
UCEPHAN

+	B BRAUN	100MG/ML;100MG/ML	N19530 001	DEC 23, 1987

SODIUM BICARBONATE; *MULTIPLE*
SEE CALCIUM CHLORIDE; DEXTROSE; GLUTATHIONE DISULFIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE
SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE
SEE POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE
SEE POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE
SEE POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE, ANHYDROUS

SODIUM BICARBONATE; TARTARIC ACID

GRANULE, EFFERVESCENT; ORAL
BAROS

	LAFAYETTE PHARMS	460MG/GM;420MG/GM	N18509 001	AUG 07, 1985

SODIUM CARBONATE; *MULTIPLE*
SEE CITRIC ACID; MAGNESIUM OXIDE; SODIUM CARBONATE

SODIUM CHLORIDE

INJECTABLE; INJECTION
BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	+	ABBOTT	**9MG/ML**	**N18800 001**	OCT 29, 1982
AP		AM PHARM PARTNERS	**9MG/ML**	**N88911 001**	FEB 07, 1985

SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	ABBOTT	**450MG/100ML**	**N18090 001**	
AP		**450MG/100ML**	**N19759 001**	JUN 08, 1988
AP	B BRAUN	**450MG/100ML**	**N19635 001**	MAR 09, 1988
AP	BAXTER HLTHCARE	**450MG/100ML**	**N18016 001**	

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	ABBOTT	**900MG/100ML**	**N16366 001**	
AP		**9MG/ML**	**N18803 001**	OCT 29, 1982
AP		**9MG/ML**	**N19217 001**	JUL 13, 1984

FDA data supplied by DrugPatentWatch.com

SODIUM CHLORIDE

INJECTABLE; INJECTION

	SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
AP	ABBOTT	900MG/100ML	N19465 001	
			JUL 15, 1985	
AP		9MG/ML	N19465 002	
			JUL 15, 1985	
AP		900MG/100ML	N19480 001	
			SEP 17, 1985	
AP	AM PHARM PARTNERS	9MG/ML	N88912 001	
			JAN 10, 1985	
AP	B BRAUN	900MG/100ML	N17464 001	
AP		900MG/100ML	N19635 002	
			MAR 09, 1988	
AP	BAXTER HLTHCARE	900MG/100ML	N16677 001	
AP +		9MG/ML	N16677 004	
			OCT 30, 1985	
AP		900MG/100ML	N20178 001	
			DEC 07, 1992	
AP		9MG/ML	N20178 002	
			DEC 07, 1992	
	SODIUM CHLORIDE 3% IN PLASTIC CONTAINER			
	BAXTER HLTHCARE	3GM/100ML	N19022 001	
			NOV 01, 1983	
	SODIUM CHLORIDE 5% IN PLASTIC CONTAINER			
	BAXTER HLTHCARE	5GM/100ML	N19022 002	
			NOV 01, 1983	
	SODIUM CHLORIDE IN PLASTIC CONTAINER			
	ABBOTT	2.5MEQ/ML	N18897 001	
			JUL 20, 1984	

SOLUTION FOR SLUSH; IRRIGATION

	SODIUM CHLORIDE 0.9% IN STERILE PLASTIC CONTAINER			
	BAXTER HLTHCARE	900MG/100ML	N19319 002	
			MAY 17, 1985	

SOLUTION; IRRIGATION

	SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER			
AT	ABBOTT	450MG/100ML	N17670 001	
AT	BAXTER HLTHCARE	450MG/100ML	N17864 001	
	SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
AT	ABBOTT	900MG/100ML	N17514 001	
AT		900MG/100ML	N18314 001	
AT	B BRAUN	900MG/100ML	N16733 001	
AT	BAXTER HLTHCARE	900MG/100ML	N17427 001	
AT		900MG/100ML	N17867 001	

SODIUM CHLORIDE; *MULTIPLE*

SEE AMINO ACIDS; CALCIUM ACETATE; GLYCERIN; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SEE AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

SEE AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

SEE AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

SEE AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

SEE AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; SODIUM CHLORIDE

SEE AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SEE AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

SEE AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

SEE AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

SEE CALCIUM CHLORIDE; DEXTROSE; GLUTATHIONE DISULFIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE

SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

SEE CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SEE CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

SEE CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SEE CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SEE CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

FDA data supplied by DrugPatentWatch.com

SODIUM CHLORIDE; *MULTIPLE*
- SEE CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE
- SEE CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE
- SEE CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE
- SEE CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE
- SEE DEXTROSE; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE
- SEE DEXTROSE; MAGNESIUM ACETATE TETRAHYDRATE; POTASSIUM ACETATE; SODIUM CHLORIDE
- SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS
- SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE
- SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE
- SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE
- SEE DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM LACTATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS
- SEE DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE
- SEE DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE
- SEE DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE
- SEE DEXTROSE; SODIUM CHLORIDE
- SEE MAGNESIUM ACETATE TETRAHYDRATE; POTASSIUM ACETATE; SODIUM CHLORIDE
- SEE MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE
- SEE MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE
- SEE MAGNESIUM SULFATE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM PHOSPHATE
- SEE POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE
- SEE POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE
- SEE POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE, ANHYDROUS
- SEE POTASSIUM CHLORIDE; SODIUM CHLORIDE

SODIUM CHROMATE, CR-51

INJECTABLE; INJECTION

CHROMITOPE SODIUM			
	BRACCO	200 uCi/ML	N13993 001
SODIUM CHROMATE CR 51			
	MALLINCKRODT	100 uCi/ML	N16708 001

SODIUM CITRATE; *MULTIPLE*
- SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE
- SEE CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

SODIUM FERRIC GLUCONATE COMPLEX

INJECTABLE; INJECTION

FERRLECIT				
+	R AND D LABS	62.5MG/5ML		N20955 001
				FEB 18, 1999

SODIUM GLUCONATE; *MULTIPLE*
- SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE
- SEE MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE
- SEE MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

SODIUM IODIDE, I-123

CAPSULE; ORAL

SODIUM IODIDE I 123				
AA	AMERSHAM HLTH	**100 uCi**		**N17630 001**
AA	MALLINCKRODT	**100 uCi**		**N71909 001**
				FEB 28, 1989
AA		**200 uCi**		**N71910 001**
				FEB 28, 1989
AA	SYNCOR PHARMS	**100 uCi**		**N18671 001**
				MAY 27, 1982
AA		**200 uCi**		**N18671 002**
				MAY 27, 1982

SOLUTION; ORAL

SODIUM IODIDE I 123			
	AMERSHAM HLTH	2mCi/ML	N17630 002

FDA data supplied by DrugPatentWatch.com

SODIUM IODIDE, I-131

CAPSULE; ORAL

	IODOTOPE			
+	BRACCO	1-130mCi	N10929	001
+		1-150mCi	N10929	003
	SODIUM IODIDE I 131			
+	MALLINCKRODT	15-100 uCi	N16517	002
+		0.8-100mCi	N16517	001

SOLUTION; ORAL

	IODOTOPE			
+	BRACCO	7-106mCi/BOT	N10929	002
	SODIUM IODIDE I 131			
+	CIS	50mCi/ML	N17315	001
+	MALLINCKRODT	3.5-150mCi/VIAL	N16515	001

SODIUM LACTATE

INJECTABLE; INJECTION

	SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER			
AP	ABBOTT	**1.87GM/100ML**	**N18249**	**001**
AP	BAXTER HLTHCARE	**1.87GM/100ML**	**N16692**	**001**
	SODIUM LACTATE 1/6 MOLAR IN PLASTIC CONTAINER			
AP	B BRAUN	**1.87GM/100ML**	**N20004**	**001**
			APR 21, 1992	
	SODIUM LACTATE IN PLASTIC CONTAINER			
	ABBOTT	5MEQ/ML	N18947	001
			SEP 05, 1984	

SODIUM LACTATE; *MULTIPLE*

SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE

SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SEE CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SEE CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE

SEE CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS

SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE

SODIUM LACTATE; *MULTIPLE*

SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS

SEE DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE

SODIUM NITROPRUSSIDE

INJECTABLE; INJECTION

	NITROPRESS			
AP	+ ABBOTT	**25MG/ML**	**N71961**	**001**
			AUG 01, 1988	
AP		**50MG/VIAL**	**N70566**	**001**
			JUN 09, 1986	
	SODIUM NITROPRUSSIDE			
AP	+ ELKINS SINN	**50MG/VIAL**	**N18581**	**001**
			JUL 28, 1982	
AP	GENSIA SICOR PHARMS	**25MG/ML**	**N73465**	**001**
			MAR 30, 1992	

SODIUM PHENYLACETATE; *MULTIPLE*

SEE SODIUM BENZOATE; SODIUM PHENYLACETATE

SODIUM PHENYLBUTYRATE

POWDER; ORAL

	BUPHENYL			
+	MEDICIS	3GM/TEASPOONFUL	N20573	001
			APR 30, 1996	

TABLET; ORAL

	BUPHENYL			
+	MEDICIS	500MG	N20572	001
			MAY 13, 1996	

SODIUM PHOSPHATE; *MULTIPLE*

SEE CALCIUM CHLORIDE; DEXTROSE; GLUTATHIONE DISULFIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

SEE MAGNESIUM SULFATE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM PHOSPHATE

FDA data supplied by DrugPatentWatch.com

SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE

TABLET; ORAL
VISICOL
\+ INKINE 0.398GM;1.102GM N21097 001
SEP 21, 2000

SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE; *MULTIPLE*
SEE AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE
SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE
SEE MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS

INJECTABLE; INJECTION
SODIUM PHOSPHATES IN PLASTIC CONTAINER
ABBOTT 142MG/ML;276MG/ML N18892 001
MAY 10, 1983

SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS; *MULTIPLE*
SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS
SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS
SEE DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM LACTATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS
SEE SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS

SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE; *MULTIPLE*
SEE SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE

SODIUM PHOSPHATE, P-32

SOLUTION; INJECTION, ORAL
SODIUM PHOSPHATE P 32
MALLINCKRODT 0.67mCi/ML N11777 001

SODIUM POLYSTYRENE SULFONATE

POWDER; ORAL, RECTAL
KAYEXALATE
AA \+ SANOFI SYNTHELABO **453.6GM/BOT** **N11287 001**
KIONEX
AA PADDOCK **454GM/BOT** **N40029 001**
FEB 06, 1998
SODIUM POLYSTYRENE SULFONATE
AA CAROLINA MEDCL **454GM/BOT** **N89910 001**
JAN 19, 1989

SUSPENSION; ORAL, RECTAL
SODIUM POLYSTYRENE SULFONATE
AA ROXANE **15GM/60ML** **N89049 001**
NOV 17, 1986
SPS
AA \+ CAROLINA MEDCL **15GM/60ML** **N87859 001**
DEC 08, 1982

SODIUM SULFATE; *MULTIPLE*
SEE POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE

SODIUM SULFATE, ANHYDROUS; *MULTIPLE*
SEE POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE, ANHYDROUS

SODIUM THIOSULFATE

INJECTABLE; INJECTION
SODIUM THIOSULFATE
\+ US ARMY 250MG/ML N20166 001
FEB 14, 1992

FDA data supplied by DrugPatentWatch.com

SOMATREM

	INJECTABLE; INJECTION			
	PROTROPIN			
+	GENENTECH	5MG/VIAL	N19107 001	OCT 17, 1985
+		10MG/VIAL	N19107 002	OCT 24, 1989

SOMATROPIN RECOMBINANT

	INJECTABLE; INJECTION			
	BIO-TROPIN			
+	BIO TECH GEN	4.8MG/VIAL	N19774 001	MAY 25, 1995
	GENOTROPIN			
+	PHARMACIA AND UPJOHN	5.8MG/VIAL	N20280 006	AUG 24, 1995
+		13.8MG/VIAL	N20280 007	OCT 23, 1996
	GENOTROPIN PRESERVATIVE FREE			
	PHARMACIA AND UPJOHN	0.2MG/VIAL	N20280 001	JAN 27, 1998
		0.4MG/VIAL	N20280 002	JAN 27, 1998
		0.6MG/VIAL	N20280 003	JAN 27, 1998
		0.8MG/VIAL	N20280 005	JAN 27, 1998
		1MG/VIAL	N20280 008	JAN 27, 1998
		1.2MG/VIAL	N20280 009	JAN 27, 1998
		1.4MG/VIAL	N20280 010	JAN 27, 1998
		1.5MG/VIAL	N20280 004	AUG 24, 1995
		1.6MG/VIAL	N20280 011	JAN 27, 1998
		1.8MG/VIAL	N20280 012	JAN 27, 1998
+		2MG/VIAL	N20280 013	JAN 27, 1998
	HUMATROPE			
BX +	LILLY	5MG/VIAL	N19640 004	MAR 08, 1987
BX		6MG/VIAL	N19640 005	FEB 04, 1999

SOMATROPIN RECOMBINANT

	INJECTABLE; INJECTION			
	HUMATROPE			
+	LILLY	12MG/VIAL	N19640 006	FEB 04, 1999
+		24MG/VIAL	N19640 007	FEB 04, 1999
	NORDITROPIN			
BX +	NOVO NORDISK	4MG/VIAL	N19721 001	MAY 08, 1995
		5MG/1.5ML	N21148 001	JUN 20, 2000
		10MG/1.5ML	N21148 002	JUN 20, 2000
+		8MG/VIAL	N19721 002	MAY 08, 1995
+		15MG/1.5ML	N21148 003	JUN 20, 2000
	NUTROPIN			
BX	GENENTECH	5MG/VIAL	N20168 001	NOV 17, 1993
+		10MG/VIAL	N20168 002	NOV 17, 1993
	NUTROPIN AQ			
+	GENENTECH	5MG/ML	N20522 001	DEC 29, 1995
	NUTROPIN DEPOT			
+	GENENTECH	13.5MG/VIAL	N21075 001	DEC 22, 1999
+		18MG/VIAL	N21075 002	DEC 22, 1999
+		22.5MG/VIAL	N21075 003	DEC 22, 1999
	SAIZEN			
BX	SERONO	5MG/VIAL	N19764 002	OCT 08, 1996
BX		6MG/VIAL	N19764 001	OCT 08, 1996
	SEROSTIM			
BX	SERONO	4MG/VIAL	N20604 003	JUL 25, 1997
BX		5MG/VIAL	N20604 002	AUG 23, 1996
BX +		6MG/VIAL	N20604 001	AUG 23, 1996
	INJECTABLE; INTRAMUSCULAR, SUBCUTANEOUS			
	SAIZEN			
+	SERONO	8.8MG/VIAL	N19764 003	AUG 29, 2000

FDA data supplied by DrugPatentWatch.com

SORBITOL

SOLUTION; IRRIGATION

SORBITOL 3% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	3GM/100ML	N17863 001		
SORBITOL 3.3% IN PLASTIC CONTAINER				
B BRAUN	3.3GM/100ML	N16741 001		

SORBITOL; *MULTIPLE*

SEE MANNITOL; SORBITOL

SOTALOL HYDROCHLORIDE

TABLET; ORAL

BETAPACE				
AB BERLEX LABS	**80MG**	**N19865 001**		
		OCT 30, 1992		
AB	**120MG**	**N19865 005**		
		APR 20, 1994		
AB +	**160MG**	**N19865 002**		
		OCT 30, 1992		
AB	**240MG**	**N19865 003**		
		OCT 30, 1992		
BETAPACE AF				
BERLEX LABS	80MG	N21151 001		
		FEB 22, 2000		
	120MG	N21151 002		
		FEB 22, 2000		
+	160MG	N21151 003		
		FEB 22, 2000		
SORINE				
AB UPSHER SMITH	**80MG**	**N75500 001**		
		APR 27, 2001		
AB	**120MG**	**N75500 004**		
		APR 27, 2001		
AB	**160MG**	**N75500 002**		
		APR 27, 2001		
AB	**240MG**	**N75500 003**		
		APR 27, 2001		
SOTALOL HCL				
AB EON	**80MG**	**N75366 001**		
		MAY 01, 2000		
AB	**120MG**	**N75366 002**		
		MAY 01, 2000		
AB	**160MG**	**N75366 003**		
		MAY 01, 2000		

SOTALOL HYDROCHLORIDE

TABLET; ORAL

SOTALOL HCL				
AB EON	**240MG**	**N75366 004**		
		MAY 01, 2000		
AB GENPHARM	**80MG**	**N75237 001**		
		MAY 01, 2000		
AB	**120MG**	**N75237 002**		
		MAY 01, 2000		
AB	**160MG**	**N75237 003**		
		MAY 01, 2000		
AB	**240MG**	**N75237 004**		
		MAY 01, 2000		
AB IMPAX PHARM	**80MG**	**N75663 001**		
		NOV 07, 2000		
AB	**120MG**	**N75663 002**		
		NOV 07, 2000		
AB	**160MG**	**N75663 003**		
		NOV 07, 2000		
AB	**240MG**	**N75663 004**		
		NOV 07, 2000		
AB MUTUAL PHARM	**80MG**	**N75515 001**		
		OCT 15, 2001		
AB	**120MG**	**N75515 004**		
		OCT 15, 2001		
AB	**160MG**	**N75515 002**		
		OCT 15, 2001		
AB	**240MG**	**N75515 003**		
		OCT 15, 2001		
AB MYLAN	**80MG**	**N75725 001**		
		DEC 19, 2000		
AB	**120MG**	**N75725 002**		
		DEC 19, 2000		
AB	**160MG**	**N75725 003**		
		DEC 19, 2000		
AB	**240MG**	**N75725 004**		
		DEC 19, 2000		
AB TEVA	**80MG**	**N75429 001**		
		MAY 01, 2000		
AB	**120MG**	**N75429 002**		
		MAY 01, 2000		
AB	**160MG**	**N75429 003**		
		MAY 01, 2000		
AB	**240MG**	**N75429 004**		
		MAY 01, 2000		
AB WATSON LABS	**80MG**	**N75238 001**		
		JUL 13, 2000		

FDA data supplied by DrugPatentWatch.com

SOTALOL HYDROCHLORIDE

TABLET; ORAL

	SOTALOL HCL			
AB	WATSON LABS	120MG	N75238 002	JUL 13, 2000
AB		160MG	N75238 003	JUL 13, 2000
AB		240MG	N75238 004	JUL 13, 2000

SOYBEAN OIL

INJECTABLE; INJECTION

	INTRALIPID 10%			
AP	+ FRESENIUS KABI	10%	N17643 001	
	INTRALIPID 20%			
AP	+ FRESENIUS KABI	20%	N18449 001	
AP	+	20%	N20248 001	AUG 07, 1996
	INTRALIPID 30%			
AP	+ FRESENIUS KABI	30%	N19942 001	DEC 30, 1993
	LIPOSYN III 10%			
AP	+ ABBOTT	10%	N18969 001	SEP 24, 1984
	LIPOSYN III 20%			
AP	+ ABBOTT	20%	N18970 001	SEP 25, 1984
	LIPOSYN III 30%			
AP	+ ABBOTT	30%	N20181 001	JAN 13, 1998
	NUTRILIPID 10%			
AP	+ B BRAUN	10%	N19531 001	MAY 28, 1993
	NUTRILIPID 20%			
AP	+ B BRAUN	20%	N19531 002	MAY 28, 1993
	SOYACAL 10%			
AP	+ ALPHA THERA	10%	N18465 001	JUN 29, 1983
	SOYACAL 20%			
AP	+ ALPHA THERA	20%	N18786 001	JUN 29, 1983

SOYBEAN OIL; *MULTIPLE*
SEE SAFFLOWER OIL; SOYBEAN OIL

SPARFLOXACIN

TABLET; ORAL

	ZAGAM			
	+ MYLAN	200MG	N20677 001	DEC 19, 1996

SPECTINOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

	TROBICIN			
	+ PHARMACIA AND UPJOHN	EQ 2GM BASE/VIAL	N50347 001	
	+	EQ 4GM BASE/VIAL	N50347 002	

SPIRONOLACTONE

TABLET; ORAL

	ALDACTONE			
AB	GD SEARLE LLC	25MG	N12151 009	DEC 30, 1983
AB		50MG	N12151 008	DEC 30, 1982
AB	+	100MG	N12151 010	DEC 30, 1983
	SPIRONOLACTONE			
AB	GENEVA PHARMS	25MG	N86809 001	
AB	HALSEY	25MG	N87265 001	
AB	MUTUAL PHARM	25MG	N89424 001	JUL 23, 1986
AB		50MG	N89424 002	AUG 11, 1999
AB		100MG	N89424 003	AUG 11, 1999
AB	MYLAN	25MG	N40424 001	AUG 20, 2001
AB		25MG	N87086 001	
AB		50MG	N40424 002	AUG 20, 2001
AB		100MG	N40424 003	AUG 20, 2001
AB	PUREPAC PHARM	50MG	N40353 001	JUL 29, 1999
AB		100MG	N40353 002	JUL 29, 1999
AB	SUPERPHARM	25MG	N89364 001	NOV 07, 1986

FDA data supplied by DrugPatentWatch.com

SPIRONOLACTONE; *MULTIPLE*
SEE HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

STANOZOLOL

TABLET; ORAL
WINSTROL
+ SANOFI SYNTHELABO 2MG N12885 001 MAY 14, 1984

STAVUDINE

CAPSULE; ORAL
ZERIT
BRISTOL MYERS SQUIBB 15MG N20412 002 JUN 24, 1994
20MG N20412 003 JUN 24, 1994
30MG N20412 004 JUN 24, 1994
+ 40MG N20412 005 JUN 24, 1994

FOR SOLUTION; ORAL
ZERIT
+ BRISTOL MYERS SQUIBB 1MG/ML N20413 001 SEP 06, 1996

STREPTOMYCIN SULFATE

INJECTABLE; INJECTION
STREPTOMYCIN SULFATE
+ PFIZER EQ 1GM BASE/2.5ML N60111 001
+ PHARMA TEK EQ 1GM BASE/VIAL N64210 001 JUN 30, 1998

STREPTOZOCIN

INJECTABLE; INJECTION
ZANOSAR
+ PHARMACIA AND UPJOHN 1GM/VIAL N50577 001 MAY 07, 1982

STRONTIUM CHLORIDE, SR-89

INJECTABLE; INJECTION
METASTRON
+ AMERSHAM HLTH 1mCi/ML N20134 001 JUN 18, 1993

SUCCIMER

CAPSULE; ORAL
CHEMET
+ SANOFI SYNTHELABO 100MG N19998 002 JAN 30, 1991

SUCCINYLCHOLINE CHLORIDE

INJECTABLE; INJECTION
ANECTINE
AP + GLAXOSMITHKLINE **20MG/ML** **N08453 002**
+ 500MG/VIAL N08453 001
+ 1GM/VIAL N08453 004
QUELICIN
AP + ABBOTT **20MG/ML** **N08845 006**
QUELICIN PRESERVATIVE FREE
AP + ABBOTT **20MG/ML** **N08845 001**
+ 50MG/ML N08845 002
+ 100MG/ML N08845 004
SUCCINYLCHOLINE CHLORIDE
AP ORGANON **20MG/ML** **N80997 001**

SUCRALFATE

SUSPENSION; ORAL
CARAFATE
+ AVENTIS PHARMS 1GM/10ML N19183 001 DEC 16, 1993

TABLET; ORAL
CARAFATE
AB + BLUE RIDGE **1GM** **N18333 001**
SUCRALFATE
AB RATIOPHARM **1GM** **N74415 001** JUN 08, 1998
AB TEVA **1GM** **N70848 001** MAR 29, 1996

FDA data supplied by DrugPatentWatch.com

SUFENTANIL CITRATE

INJECTABLE; INJECTION

	SUFENTA			
AP	+ AKORN	EQ 0.05MG BASE/ML	N19050 001	MAY 04, 1984
	SUFENTANIL CITRATE			
AP	ELKINS SINN	EQ 0.05MG BASE/ML	N74413 001	DEC 15, 1995
	SULFENTANIL CITRATE			
AP	ABBOTT	EQ 0.05MG BASE/ML	N74534 001	DEC 11, 1996

SULBACTAM SODIUM; *MULTIPLE*
SEE AMPICILLIN SODIUM; SULBACTAM SODIUM

SULCONAZOLE NITRATE

CREAM; TOPICAL

	EXELDERM			
	+ WESTWOOD SQUIBB	1%	N18737 001	FEB 28, 1989

SULFACETAMIDE SODIUM

LOTION; TOPICAL

	KLARON			
	+ DERMIK LABS	10%	N19931 001	DEC 23, 1996

OINTMENT; OPHTHALMIC

	CETAMIDE			
AT	+ ALCON	10%	N80021 001	
	SULFACETAMIDE SODIUM			
AT	ALTANA	10%	N80029 001	

SOLUTION/DROPS; OPHTHALMIC

	BLEPH-10			
AT	+ ALLERGAN	10%	N80028 001	
	BLEPH-30			
AT	+ ALLERGAN	30%	N80028 002	
	ISOPTO CETAMIDE			
AT	+ ALCON	15%	N80020 002	
	OCUSULF-10			
AT	MIZA PHARMS USA	10%	N80660 001	
	SULF-10			
AT	NOVARTIS	10%	N80025 001	

SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC

	SULF-15			
AT	NOVARTIS	15%	N89047 001	OCT 31, 1995
	SULFACEL-15			
AT	OPTOPICS	15%	N80024 001	
	SULFACETAMIDE SODIUM			
AT	AKORN	10%	N40215 001	MAY 25, 1999
AT		30%	N40216 001	MAY 25, 1999
AT	ALCON UNIVERSAL	10%	N89560 001	OCT 18, 1988
AT	BAUSCH AND LOMB	10%	N40066 001	DEC 28, 1994
AT	STERIS	30%	N89068 001	MAY 05, 1987

SULFACETAMIDE SODIUM; *MULTIPLE*
SEE FLUOROMETHOLONE; SULFACETAMIDE SODIUM
SEE PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM
SEE PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SULFACYTINE

TABLET; ORAL

	RENOQUID		
	+ GLENWOOD	250MG	N17569 001

SULFADIAZINE

TABLET; ORAL

	SULFADIAZINE		
	+ EON	500MG	N40091 001 JUL 29, 1994

SULFADOXINE; *MULTIPLE*
SEE PYRIMETHAMINE; SULFADOXINE

FDA data supplied by DrugPatentWatch.com

SULFAMETHIZOLE

TABLET; ORAL

	THIOSULFIL			
+	WYETH AYERST	500MG		N08565 004

SULFAMETHOXAZOLE

TABLET; ORAL

	GANTANOL			
+	ROCHE	500MG		N12715 002

SULFAMETHOXAZOLE; *MULTIPLE*

SEE PHENAZOPYRIDINE HYDROCHLORIDE; SULFAMETHOXAZOLE; TRIMETHOPRIM

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE; INJECTION

	BACTRIM			
AP	+ WOMEN FIRST HLTHCARE	**80MG/ML;16MG/ML**		**N18374 001**
	SEPTRA			
AP	+ MONARCH PHARMS	**80MG/ML;16MG/ML**		**N18452 001**
	SULFAMETHOXAZOLE AND TRIMETHOPRIM			
AP	ABBOTT	**80MG/ML;16MG/ML**		**N73199 001** SEP 11, 1992
AP	ELKINS SINN	**80MG/ML;16MG/ML**		**N70627 001** DEC 29, 1987
AP		**80MG/ML;16MG/ML**		**N70628 001** DEC 29, 1987
AP	GENSIA SICOR PHARMS	**80MG/ML;16MG/ML**		**N73303 001** OCT 31, 1991

SUSPENSION; ORAL

	BACTRIM PEDIATRIC			
AB	+ WOMEN FIRST HLTHCARE	**200MG/5ML;40MG/5ML**		**N17560 002**
	SEPTRA			
AB	MONARCH PHARMS	**200MG/5ML;40MG/5ML**		**N17598 001**
	SEPTRA GRAPE			
AB	MONARCH PHARMS	**200MG/5ML;40MG/5ML**		**N17598 002** FEB 12, 1986
	SULFAMETHOXAZOLE AND TRIMETHOPRIM			
AB	HI TECH PHARMA	**200MG/5ML;40MG/5ML**		**N74650 001** DEC 29, 1997
AB	TEVA	**200MG/5ML;40MG/5ML**		**N18812 001** JAN 28, 1983

SULFAMETHOXAZOLE; TRIMETHOPRIM

SUSPENSION; ORAL

	SULFAMETHOXAZOLE AND TRIMETHOPRIM			
AB	TEVA	**200MG/5ML;40MG/5ML**		**N18812 002** JUN 10, 1983
AB		**200MG/5ML;40MG/5ML**		**N70028 001** JUN 02, 1987
	SULFATRIM			
AB	ALPHARMA	**200MG/5ML;40MG/5ML**		**N18615 002** JAN 07, 1983
	SULFATRIM PEDIATRIC			
AB	ALPHARMA	**200MG/5ML;40MG/5ML**		**N18615 001** JAN 07, 1983

TABLET; ORAL

	BACTRIM			
AB	WOMEN FIRST HLTHCARE	**400MG;80MG**		**N17377 001**
	BACTRIM DS			
AB	+ WOMEN FIRST HLTHCARE	**800MG;160MG**		**N17377 002**
	COTRIM			
AB	TEVA	**400MG;80MG**		**N70034 001** MAY 16, 1985
	COTRIM D.S.			
AB	TEVA	**800MG;160MG**		**N70048 001** MAR 18, 1985
	SEPTRA			
AB	MONARCH PHARMS	**400MG;80MG**		**N17376 001**
	SEPTRA DS			
AB	MONARCH PHARMS	**800MG;160MG**		**N17376 002**
	SULFAMETHOPRIM			
AB	PAR PHARM	**400MG;80MG**		**N70022 001** FEB 15, 1985
	SULFAMETHOPRIM-DS			
AB	PAR PHARM	**800MG;160MG**		**N70032 001** FEB 15, 1985
	SULFAMETHOXAZOLE AND TRIMETHOPRIM			
AB	DANBURY PHARMA	**400MG;80MG**		**N18852 001** MAY 09, 1983
AB	GENEVA PHARMS	**400MG;80MG**		**N70889 001** NOV 13, 1986
AB		**800MG;160MG**		**N70890 001** NOV 13, 1986
AB	MUTUAL PHARM	**400MG;80MG**		**N71016 001** AUG 25, 1986
AB		**800MG;160MG**		**N71017 001** AUG 25, 1986
AB	SIDMAK LABS NJ	**400MG;80MG**		**N70215 001** SEP 10, 1985

FDA data supplied by DrugPatentWatch.com

SULFAMETHOXAZOLE; TRIMETHOPRIM

TABLET; ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM

AB	SIDMAK LABS NJ	800MG;160MG	N70216 001	SEP 10, 1985

SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH

AB	DANBURY PHARMA	800MG;160MG	N18854 001	MAY 09, 1983
AB	EON	800MG;160MG	N18598 004	MAY 19, 1982
AB	TEVA	800MG;160MG	N70037 001	JUN 02, 1987

SULFAMETHOXAZOLE AND TRIMETHOPRIM SINGLE STRENGTH

AB	PLANTEX	400MG;80MG	N70030 001	JUN 02, 1987

SULFANILAMIDE

CREAM; VAGINAL

AVC

AT	+ NOVAVAX	15%	N06530 003	JAN 27, 1987

SULFANILAMIDE

AT	TEVA	15%	N88718 001	SEP 19, 1985

SUPPOSITORY; VAGINAL

AVC

	+ NOVAVAX	1.05GM	N06530 004	JAN 27, 1987

SULFAPYRIDINE

TABLET; ORAL

SULFAPYRIDINE

	+ LILLY	500MG	N00159 001	

SULFASALAZINE

SUSPENSION; ORAL

AZULFIDINE

	+ PHARMACIA AND UPJOHN	250MG/5ML	N86983 001	

TABLET; ORAL

AZULFIDINE

AB	+ PHARMACIA AND UPJOHN	500MG	N07073 001	

SULFASALAZINE

TABLET; ORAL

SULFASALAZINE

AB	DANBURY PHARMA	500MG	N87197 001	
AB	MUTUAL PHARM	500MG	N89590 001	OCT 19, 1987
AB	WATSON LABS	500MG	N85828 001	

TABLET, DELAYED RELEASE; ORAL

AZULFIDINE EN-TABS

	+ PHARMACIA AND UPJOHN	500MG	N07073 002	APR 06, 1983

SULFINPYRAZONE

CAPSULE; ORAL

ANTURANE

AB	+ NOVARTIS	200MG	N11556 004	

SULFINPYRAZONE

AB	BARR	200MG	N87666 001	SEP 17, 1982
AB	IVAX PHARMS	200MG	N87770 001	NOV 19, 1982
AB	PAR PHARM	200MG	N88934 001	SEP 06, 1985

TABLET; ORAL

ANTURANE

AB	+ NOVARTIS	100MG	N11556 003	

SULFINPYRAZONE

AB	BARR	100MG	N87665 001	SEP 17, 1982
AB	PAR PHARM	100MG	N88933 001	SEP 06, 1985

SULFISOXAZOLE

TABLET; ORAL

SOSOL

AB	MK LABS	500MG	N80036 001	

SULFISOXAZOLE

AB	ICN	500MG	N80268 002	
AB	+ IVAX PHARMS	500MG	N80142 001	
AB	ROXANE	500MG	N80082 001	

FDA data supplied by DrugPatentWatch.com

SULFISOXAZOLE ACETYL

SUSPENSION; ORAL
GANTRISIN PEDIATRIC
+ ROCHE — EQ 500MG BASE/5ML — N09182 004

SYRUP; ORAL
GANTRISIN
+ ROCHE — EQ 500MG BASE/5ML — N09182 002

SULFISOXAZOLE ACETYL; *MULTIPLE*
SEE ERYTHROMYCIN ETHYLSUCCINATE; SULFISOXAZOLE ACETYL

SULINDAC

TABLET; ORAL
CLINORIL

AB	MERCK	**150MG**	**N17911 001**
AB	+	**200MG**	**N17911 002**

SULINDAC

AB	DANBURY PHARMA	**150MG**	**N71891 001** APR 03, 1990
AB		**200MG**	**N71795 001** APR 03, 1990
AB	GENEVA PHARMS	**150MG**	**N72712 001** AUG 30, 1991
AB		**200MG**	**N72713 001** AUG 30, 1991
AB	LEDERLE	**150MG**	**N73261 001** SEP 06, 1991
AB		**200MG**	**N73262 001** SEP 06, 1991
AB	MUTUAL PHARM	**150MG**	**N72050 001** APR 17, 1991
AB		**200MG**	**N72051 001** APR 17, 1991
AB	MYLAN	**150MG**	**N73038 001** JUN 22, 1993
AB		**200MG**	**N73039 001** JUN 22, 1993
AB	TEVA	**150MG**	**N72972 001** FEB 28, 1992
AB		**200MG**	**N72973 001** FEB 28, 1992
AB	WARNER CHILCOTT	**150MG**	**N72710 001** MAR 25, 1991

SULINDAC

TABLET; ORAL
SULINDAC

AB	WARNER CHILCOTT	**200MG**	**N72711 001** MAR 25, 1991

SUMATRIPTAN

SPRAY; NASAL
IMITREX

+	GLAXOSMITHKLINE	5MG/SPRAY	N20626 001 AUG 26, 1997
+		10MG/SPRAY	N20626 002 AUG 26, 1997
+		20MG/SPRAY	N20626 003 AUG 26, 1997

SUMATRIPTAN SUCCINATE

INJECTABLE; INJECTION
IMITREX

+	GLAXOSMITHKLINE	EQ 6MG BASE/0.5ML	N20080 001 DEC 28, 1992

TABLET; ORAL
IMITREX

	GLAXOSMITHKLINE	EQ 25MG BASE	N20132 002 JUN 01, 1995
+		EQ 50MG BASE	N20132 003 JUN 01, 1995

SUPROFEN

SOLUTION/DROPS; OPHTHALMIC
PROFENAL

+	ALCON	1%	N19387 001 DEC 23, 1988

TACRINE HYDROCHLORIDE

CAPSULE; ORAL
COGNEX

	FIRST HORIZON	EQ 10MG BASE	N20070 001 SEP 09, 1993

FDA data supplied by DrugPatentWatch.com

TACRINE HYDROCHLORIDE

CAPSULE; ORAL
COGNEX
FIRST HORIZON — EQ 20MG BASE — N20070 002 SEP 09, 1993
EQ 30MG BASE — N20070 003 SEP 09, 1993
\+ EQ 40MG BASE — N20070 004 SEP 09, 1993

TACROLIMUS

CAPSULE; ORAL
PROGRAF
FUJISAWA HLTHCARE — EQ 0.5MG BASE — N50708 003 AUG 24, 1998
EQ 1MG BASE — N50708 001 APR 08, 1994
\+ EQ 5MG BASE — N50708 002 APR 08, 1994

INJECTABLE; INJECTION
PROGRAF
\+ FUJISAWA HLTHCARE — EQ 5MG BASE/ML — N50709 001 APR 08, 1994

OINTMENT; TOPICAL
PROTOPIC
FUJISAWA HLTHCARE — 0.03% — N50777 001 DEC 08, 2000
\+ 0.1% — N50777 002 DEC 08, 2000

TALC

AEROSOL, METERED; INTRAPLEURAL
SCLEROSOL
\+ BRYAN — 400MG/SPRAY — N20587 001 DEC 24, 1997

TAMOXIFEN CITRATE

TABLET; ORAL
NOLVADEX
AB \+ ASTRAZENECA — **EQ 20MG BASE** — **N17970 002** MAR 21, 1994

TAMOXIFEN CITRATE

TABLET; ORAL
NOLVADEX
ASTRAZENECA — EQ 10MG BASE — N17970 001

TAMSULOSIN HYDROCHLORIDE

CAPSULE; ORAL
FLOMAX
\+ BOEHRINGER INGELHEIM — 0.4MG — N20579 001 APR 15, 1997

TARTARIC ACID; *MULTIPLE*
SEE SODIUM BICARBONATE; TARTARIC ACID

TAZAROTENE

CREAM; TOPICAL
TAZORAC
\+ ALLERGAN — 0.05% — N21184 001 SEP 29, 2000
\+ 0.1% — N21184 002 SEP 29, 2000

GEL; TOPICAL
TAZORAC
\+ ALLERGAN — 0.05% — N20600 001 JUN 13, 1997
\+ 0.1% — N20600 002 JUN 13, 1997

TAZOBACTAM SODIUM; *MULTIPLE*
SEE PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT

INJECTABLE; INJECTION
MACROTEC
BS BRACCO — N/A — N17833 001
PULMOLITE
BS CIS — N/A — N17776 001
TECHNESCAN MAA
BS MALLINCKRODT — N/A — N17842 001

FDA data supplied by DrugPatentWatch.com

TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT

INJECTABLE; INJECTION
TECHNETIUM TC 99M ALBUMIN AGGREGATED KIT

BS	DRAXIMAGE	N/A	N17881 001	DEC 30, 1987

TECHNETIUM TC-99M ALBUMIN COLLOID KIT

INJECTABLE; INJECTION
MICROLITE

CIS	N/A	N18263 001	MAR 25, 1983

TECHNETIUM TC-99M ALBUMIN KIT

INJECTABLE; INJECTION
TECHNETIUM TC 99M HSA

AMERSHAM HLTH	N/A	N17775 001	

TECHNETIUM TC-99M APCITIDE

INJECTABLE; INJECTION
ACUTECT

DIATIDE RES LABS	N/A	N20887 001	SEP 14, 1998

TECHNETIUM TC-99M BICISATE KIT

INJECTABLE; INJECTION
NEUROLITE

BRISTOL MYERS SQUIBB	N/A	N20256 001	NOV 23, 1994

TECHNETIUM TC-99M DEPREOTIDE

INJECTABLE; INJECTION
NEO TECT KIT

+	DIATIDE RES LABS	N/A	N21012 001	AUG 03, 1999

TECHNETIUM TC-99M DISOFENIN KIT

INJECTABLE; INJECTION
HEPATOLITE

CIS	N/A	N18467 001	MAR 16, 1982

TECHNETIUM TC-99M EXAMETAZIME KIT

INJECTABLE; INJECTION
CERETEC

AMERSHAM HLTH	N/A	N19829 001	DEC 30, 1988

TECHNETIUM TC-99M GLUCEPTATE KIT

INJECTABLE; INJECTION
TECHNESCAN GLUCEPTATE

DRAXIMAGE	N/A	N18272 001	JAN 27, 1982

TECHNETIUM TC-99M MEBROFENIN KIT

INJECTABLE; INJECTION
CHOLETEC

BRACCO	N/A	N18963 001	JAN 21, 1987

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE; INJECTION

	CIS-MDP			
AP	CIS	**N/A**	**N18124 001**	
	MDP-BRACCO			
AP	BRACCO	**N/A**	**N18107 001**	
	OSTEOLITE			
AP	CIS	**N/A**	**N17972 001**	
	TECHNESCAN MDP KIT			
AP	DRAXIMAGE	**N/A**	**N18035 001**	
	TECHNETIUM TC 99M MPI MDP			
AP	AMERSHAM HLTH	**N/A**	**N18141 001**	

FDA data supplied by DrugPatentWatch.com

TECHNETIUM TC-99M MERTIATIDE KIT

INJECTABLE; INJECTION
TECHNESCAN MAG3
MALLINCKRODT N/A N19882 001 JUN 15, 1990

TECHNETIUM TC-99M OXIDRONATE KIT

INJECTABLE; INJECTION
TECHNESCAN HDP
MALLINCKRODT N/A N18321 001

TECHNETIUM TC-99M PENTETATE KIT

INJECTABLE; INJECTION
AN-DTPA
AP CIS **N/A** **N17714 001**
DTPA
AP DRAXIMAGE **N/A** **N18511 001** DEC 29, 1989
TECHNETIUM TC-99M PENTETATE KIT
AP AMERSHAM HLTH **N/A** **N17264 002**

TECHNETIUM TC-99M PYRO/TRIMETA PHOSPHATES KIT

INJECTABLE; INJECTION
PYROLITE
CIS N/A N17684 001

TECHNETIUM TC-99M PYROPHOSPHATE KIT

INJECTABLE; INJECTION
CIS-PYRO
AP CIS **N/A** **N19039 001** JUN 30, 1987
PHOSPHOTEC
AP BRACCO **N/A** **N17680 001**
TECHNESCAN PYP KIT
AP MALLINCKRODT **N/A** **N17538 001**

TECHNETIUM TC-99M RED BLOOD CELL KIT

INJECTABLE; INJECTION
RBC-SCAN
CADEMA N/A N20063 001 JUN 11, 1992
ULTRATAG
MALLINCKRODT N/A N19981 001 JUN 10, 1991

TECHNETIUM TC-99M SESTAMIBI KIT

INJECTABLE; INJECTION
CARDIOLITE
BRISTOL MYERS SQUIBB N/A N19785 001 DEC 21, 1990
MIRALUMA
BRISTOL MYERS SQUIBB N/A N19785 003 MAY 23, 1997

TECHNETIUM TC-99M SODIUM PERTECHNETATE

SOLUTION; INJECTION, ORAL
SODIUM PERTECHNETATE TC 99M
MALLINCKRODT 10-60mCi/ML N17725 001

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR

SOLUTION; INJECTION, ORAL
TECHNELITE
BRISTOL MYERS SQUIBB 0.0083-2.7 CI/GENERATOR N17771 001
TECHNETIUM TC 99M GENERATOR
AMERSHAM HLTH 830-16,600mCi/GENERATOR N17693 001
ULTRA-TECHNEKOW FM
MALLINCKRODT 0.25-3 CI/GENERATOR N17243 002

TECHNETIUM TC-99M SUCCIMER KIT

INJECTABLE; INJECTION
MPI DMSA KIDNEY REAGENT
AMERSHAM HLTH N/A N17944 001 MAY 18, 1982

FDA data supplied by DrugPatentWatch.com

TECHNETIUM TC-99M SULFUR COLLOID KIT

SOLUTION; INJECTION, ORAL

	AN-SULFUR COLLOID			
AP	CIS	N/A	**N17858 001**	
	TECHNECOLL			
AP	MALLINCKRODT	N/A	**N17059 001**	

TECHNETIUM TC-99M TEBOROXIME KIT

INJECTABLE; INJECTION

CARDIOTEC			
BRACCO	N/A	N19928 001	DEC 19, 1990

TECHNETIUM TC-99M TETROFOSMIN KIT

INJECTABLE; INJECTION

MYOVIEW			
AMERSHAM HLTH	N/A	N20372 001	FEB 09, 1996

TELMISARTAN

TABLET; ORAL

MICARDIS				
+	BOEHRINGER INGELHEIM	20MG	N20850 003	APR 04, 2000
		40MG	N20850 001	NOV 10, 1998
+		80MG	N20850 002	NOV 10, 1998

TELMISARTAN; *MULTIPLE*

SEE HYDROCHLOROTHIAZIDE; TELMISARTAN

TEMAZEPAM

CAPSULE; ORAL

	RESTORIL			
AB	TYCO HLTHCARE	**15MG**	**N18163 001**	
AB	+	**30MG**	**N18163 002**	
		7.5MG	N18163 003	OCT 25, 1991

TEMAZEPAM

CAPSULE; ORAL

	TEMAZEPAM			
AB	DANBURY PHARMA	15MG	**N71446 001**	MAY 21, 1993
AB		30MG	**N71447 001**	MAY 21, 1993
AB	GENEVA PHARMS	15MG	**N71427 001**	JAN 12, 1988
AB		30MG	**N71428 001**	JAN 12, 1988
AB	MYLAN	15MG	**N70919 001**	JUL 07, 1986
AB		30MG	**N70920 001**	JUL 10, 1986
AB	PAR PHARM	15MG	**N71456 001**	APR 21, 1987
AB		30MG	**N71457 001**	APR 21, 1987
AB	PUREPAC PHARM	15MG	**N71638 001**	AUG 07, 1987
AB		30MG	**N71620 001**	AUG 07, 1987

TEMOZOLOMIDE

CAPSULE; ORAL

TEMODAR				
SCHERING		5MG	N21029 001	AUG 11, 1999
		20MG	N21029 002	AUG 11, 1999
		100MG	N21029 003	AUG 11, 1999
+		250MG	N21029 004	AUG 11, 1999

TENIPOSIDE

INJECTABLE; INJECTION

VUMON				
+	BRISTOL MYERS SQUIBB	10MG/ML	N20119 001	JUL 14, 1992

FDA data supplied by DrugPatentWatch.com

TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

	VIREAD				
+	GILEAD	300MG	N21356 001 OCT 26, 2001		

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

	HYTRIN				
AB	ABBOTT	**EQ 1MG BASE**	**N20347 001** DEC 14, 1994		
AB	+	**EQ 2MG BASE**	**N20347 002** DEC 14, 1994		
AB		**EQ 5MG BASE**	**N20347 003** DEC 14, 1994		
AB		**EQ 10MG BASE**	**N20347 004** DEC 14, 1994		
	TERAZOSIN HCL				
AB	GENEVA PHARMS	**EQ 1MG BASE**	**N74823 001** MAR 30, 1998		
AB		**EQ 2MG BASE**	**N74823 002** MAR 30, 1998		
AB		**EQ 5MG BASE**	**N74823 003** MAR 30, 1998		
AB		**EQ 10MG BASE**	**N74823 004** MAR 30, 1998		
AB	INVAMED	**EQ 1MG BASE**	**N75667 001** JUL 28, 2000		
AB		**EQ 2MG BASE**	**N75667 002** JUL 28, 2000		
AB		**EQ 5MG BASE**	**N75667 003** JUL 28, 2000		
AB		**EQ 10MG BASE**	**N75667 004** JUL 28, 2000		
AB	IVAX PHARMS	**EQ 1MG BASE**	**N75614 002** JAN 30, 2001		
AB		**EQ 2MG BASE**	**N75614 001** JAN 30, 2001		
AB		**EQ 5MG BASE**	**N75614 003** JAN 30, 2001		
AB		**EQ 10MG BASE**	**N75614 004** JAN 30, 2001		
AB	MYLAN	**EQ 1MG BASE**	**N75140 002** FEB 11, 2000		
AB		**EQ 2MG BASE**	**N75140 003** FEB 11, 2000		

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

	TERAZOSIN HCL				
AB	MYLAN	**EQ 5MG BASE**	**N75140 001** FEB 11, 2000		
AB		**EQ 10MG BASE**	**N75140 004** FEB 11, 2000		
AB	MYLAN TECHNOLOGIES	**EQ 1MG BASE**	**N75384 001** DEC 01, 2000		
AB		**EQ 2MG BASE**	**N75384 002** DEC 01, 2000		
AB		**EQ 5MG BASE**	**N75384 003** DEC 01, 2000		
AB		**EQ 10MG BASE**	**N75384 004** DEC 01, 2000		
AB	TORPHARM	**EQ 1MG BASE**	**N75498 001** APR 12, 2001		
AB		**EQ 2MG BASE**	**N75498 002** APR 12, 2001		
AB		**EQ 5MG BASE**	**N75498 003** APR 12, 2001		
AB		**EQ 10MG BASE**	**N75498 004** APR 12, 2001		

TABLET; ORAL

	HYTRIN				
AB	ABBOTT	**EQ 1MG BASE**	**N19057 001** AUG 07, 1987		
AB	+	**EQ 2MG BASE**	**N19057 002** AUG 07, 1987		
AB		**EQ 5MG BASE**	**N19057 003** AUG 07, 1987		
AB		**EQ 10MG BASE**	**N19057 004** AUG 07, 1987		
	TERAZOSIN HCL				
AB	GENEVA PHARMS	**EQ 1MG BASE**	**N74315 001** DEC 31, 1998		
AB		**EQ 2MG BASE**	**N74315 002** DEC 31, 1998		
AB		**EQ 5MG BASE**	**N74315 003** DEC 31, 1998		
AB		**EQ 10MG BASE**	**N74315 004** DEC 31, 1998		
AB	INVAMED	**EQ 1MG BASE**	**N74657 001** APR 28, 2000		
AB		**EQ 2MG BASE**	**N74657 002** APR 28, 2000		

FDA data supplied by DrugPatentWatch.com

TERAZOSIN HYDROCHLORIDE

TABLET; ORAL
TERAZOSIN HCL

AB	INVAMED	EQ 5MG BASE	N74657 003 APR 28, 2000
AB		EQ 10MG BASE	N74657 004 APR 28, 2000
AB	IVAX PHARMS	EQ 1MG BASE	N74530 001 APR 21, 2000
AB		EQ 2MG BASE	N74530 002 APR 21, 2000
AB		EQ 5MG BASE	N74530 003 APR 21, 2000
AB		EQ 10MG BASE	N74530 004 APR 21, 2000
AB	TEVA	EQ 1MG BASE	N74446 001 MAY 18, 2000
AB		EQ 2MG BASE	N74446 002 MAY 18, 2000
AB		EQ 5MG BASE	N74446 003 MAY 18, 2000
AB		EQ 10MG BASE	N74446 004 MAY 18, 2000

TERBINAFINE

GEL; TOPICAL
LAMISIL

+	NOVARTIS	1%	N20846 001 APR 29, 1998

TERBINAFINE HYDROCHLORIDE

CREAM; TOPICAL
LAMISIL

+	NOVARTIS	1%	N20192 001 DEC 30, 1992

SOLUTION; TOPICAL
LAMISIL

+	NOVARTIS	1%	N20749 001 OCT 17, 1997

TABLET; ORAL
LAMISIL

+	NOVARTIS	EQ 250MG BASE	N20539 001 MAY 10, 1996

TERBUTALINE SULFATE

INJECTABLE; INJECTION
BRETHINE

+	NOVARTIS	1MG/ML	N18571 001

TABLET; ORAL
BRETHINE

AB	NOVARTIS	2.5MG	N17849 001
AB +		5MG	N17849 002

TERBUTALINE SULFATE

AB	IMPAX LABS	2.5MG	N75877 001 JUN 26, 2001
AB		5MG	N75877 002 JUN 26, 2001

TERCONAZOLE

CREAM; VAGINAL
TERAZOL 3

+	JOHNSON RW	0.8%	N19964 001 FEB 21, 1991

TERAZOL 7

+	JOHNSON RW	0.4%	N19579 001 DEC 31, 1987

SUPPOSITORY; VAGINAL
TERAZOL 3

+	JOHNSON RW	80MG	N19641 001 MAY 24, 1988

TESTOLACTONE

TABLET; ORAL
TESLAC

+	BRISTOL MYERS SQUIBB	50MG	N16118 001

TESTOSTERONE

FILM, EXTENDED RELEASE; TRANSDERMAL
ANDRODERM

BX +	WATSON LABS	5MG/24HR	N20489 002 MAY 02, 1997
+		2.5MG/24HR	N20489 001 SEP 29, 1995

FDA data supplied by DrugPatentWatch.com

TESTOSTERONE

FILM, EXTENDED RELEASE; TRANSDERMAL
TESTODERM
BX + ALZA 5MG/24HR N20791 001 DEC 18, 1997
+ 4MG/24HR N19762 001 OCT 12, 1993
+ 6MG/24HR N19762 002 OCT 12, 1993

GEL; TOPICAL
ANDROGEL
+ UNIMED PHARMS 1% N21015 001 FEB 28, 2000

INJECTABLE; INJECTION
TESTOSTERONE
+ STERIS 100MG/ML N86417 001 JUL 07, 1983

PELLET; IMPLANTATION
TESTOSTERONE
BARTOR 75MG N80911 001

TESTOSTERONE CYPIONATE

INJECTABLE; INJECTION
DEPO-TESTOSTERONE
AO + PHARMACIA AND UPJOHN **100MG/ML** **N85635 002**
AO + **200MG/ML** **N85635 003**
TESTOSTERONE CYPIONATE
AO STERIS **100MG/ML** **N86029 001**
AO **200MG/ML** **N86030 001**

TESTOSTERONE CYPIONATE; *MULTIPLE*
SEE ESTRADIOL CYPIONATE; TESTOSTERONE CYPIONATE

TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION
DELATESTRYL
AO + BTG **200MG/ML** **N09165 003**
TESTOSTERONE ENANTHATE
AO STERIS **200MG/ML** **N85598 001**

TESTOSTERONE ENANTHATE; *MULTIPLE*
SEE ESTRADIOL VALERATE; TESTOSTERONE ENANTHATE

TESTOSTERONE PROPIONATE

INJECTABLE; INJECTION
TESTOSTERONE PROPIONATE
+ STERIS 25MG/ML N80188 001
50MG/ML N80188 002
+ 100MG/ML N80188 003

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL
ACHROMYCIN V
AB LEDERLE **250MG** **N50278 003**
AB + **500MG** **N50278 001**
BRISTACYCLINE
AB BRISTOL **250MG** **N61658 001**
AB **250MG** **N61888 001**
AB **500MG** **N61658 002**
AB **500MG** **N61888 002**
SUMYCIN
AB APOTHECON **250MG** **N60429 001**
AB **500MG** **N60429 003**
TETRACYCLINE HCL
AB BARR **250MG** **N61837 001**
AB **500MG** **N61837 002**
AB HALSEY **250MG** **N60736 001**
AB **500MG** **N60736 002**
AB IMPAX LABS **250MG** **N60469 001**
AB **500MG** **N60469 003**
100MG N60469 002
AB IVAX PHARMS **250MG** **N60704 001**
AB **500MG** **N60704 002**
AB LABS ATRAL **250MG** **N62752 001** AUG 12, 1988
AB **500MG** **N62752 002** AUG 12, 1988
AB MAST MM **250MG** **N62085 001**
AB MYLAN **250MG** **N60783 001**
AB **500MG** **N60783 002**
AB ROXANE **500MG** **N61214 002**

FIBER, EXTENDED RELEASE; PERIODONTAL
ACTISITE
+ ON SITE ALZA 12.7MG/FIBER N50653 001 MAR 25, 1994

FDA data supplied by DrugPatentWatch.com

TETRACYCLINE HYDROCHLORIDE

FOR SOLUTION; TOPICAL
TOPICYCLINE
+ SHIRE LABS 2.2MG/ML N50493 001

INJECTABLE; INJECTION
ACHROMYCIN
+ LEDERLE 250MG/VIAL N50273 002
500MG/VIAL N50273 003

SUSPENSION; ORAL
ACHROMYCIN V
AB + LEDERLE 125MG/5ML N50263 002
SUMYCIN
AB APOTHECON 125MG/5ML N60400 001

TABLET; ORAL
SUMYCIN
APOTHECON 250MG N61147 001
+ 500MG N61147 004

TETRACYCLINE HYDROCHLORIDE; *MULTIPLE*
SEE BISMUTH SUBSALICYLATE; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE
SEE HYDROCORTISONE; TETRACYCLINE HYDROCHLORIDE

TETRACYCLINE PHOSPHATE COMPLEX

CAPSULE; ORAL
TETREX
BRISTOL EQ 100MG HCL N61653 001
EQ 250MG HCL N61653 002
EQ 250MG HCL N61889 002
+ EQ 500MG HCL N61653 003
EQ 500MG HCL N61889 001

TETRAHYDROZOLINE HYDROCHLORIDE

SOLUTION; NASAL
TYZINE
+ KENWOOD LABS 0.05% N86576 002
0.1% N86576 001

SPRAY; NASAL
TYZINE
+ KENWOOD LABS 0.1% N86576 003

THALIDOMIDE

CAPSULE; ORAL
THALOMID
+ CELGENE 50MG N20785 001
JUL 16, 1998

THALLOUS CHLORIDE, TL-201

INJECTABLE; INJECTION
THALLOUS CHLORIDE TL 201
AP + AMERSHAM HLTH 1mCi/ML N18110 002
FEB 27, 1996
AP + BRISTOL MYERS SQUIBB 1mCi/ML N17806 001
AP + MALLINCKRODT 1mCi/ML N18150 001
AP MOUNT SINAI MEDCTR 1mCi/ML N75569 001
NOV 21, 2001

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL
AEROLATE III
+ FLEMING PHARMS 65MG N85075 003
NOV 24, 1986

AEROLATE JR
BC FLEMING PHARMS 130MG N85075 002
NOV 24, 1986

AEROLATE SR
BC FLEMING PHARMS 260MG N85075 001
NOV 24, 1986

SLO-BID
AB AVENTIS 100MG N87892 001
JAN 31, 1985
AB 125MG N89540 001
MAY 10, 1989
AB 200MG N87893 001
JAN 31, 1985
AB + 300MG N87894 001
JAN 31, 1985

BC + 50MG N88269 001
JAN 31, 1985
BC 75MG N89539 001
MAY 10, 1989

THEO-24
BC UCB 100MG N87942 001
AUG 22, 1983

FDA data supplied by DrugPatentWatch.com

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL

	THEO-24			
BC	UCB	200MG	N87943 001	AUG 22, 1983
BC		300MG	N87944 001	AUG 22, 1983
		400MG	N81034 001	FEB 28, 1992
	THEOPHYLLINE			
AB	INWOOD LABS	**100MG**	**N40052 001**	FEB 14, 1994
AB		**125MG**	**N40052 002**	FEB 14, 1994
AB		**200MG**	**N40052 003**	FEB 14, 1994
AB		**300MG**	**N40052 004**	FEB 14, 1994

ELIXIR; ORAL

	ELIXOPHYLLIN			
AA	FORREST LABS	**80MG/15ML**	**N85186 001**	
	THEOPHYLLINE			
AA	ALPHARMA	**80MG/15ML**	**N85863 001**	
AA	MORTON GROVE	**80MG/15ML**	**N86748 001**	
AA	PHARM ASSOC	**80MG/15ML**	**N86720 001**	
AA	THAMES	**80MG/15ML**	**N89626 001**	OCT 28, 1988

INJECTABLE; INJECTION

	THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER			
AP	+ B BRAUN	**40MG/100ML**	**N19826 001**	AUG 14, 1992
	THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER			
AP	+ B BRAUN	**80MG/100ML**	**N19826 002**	AUG 14, 1992
	THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER			
AP	+ B BRAUN	**160MG/100ML**	**N19826 003**	AUG 14, 1992
	THEOPHYLLINE 0.32% AND DEXTROSE 5% IN PLASTIC CONTAINER			
AP	+ B BRAUN	**320MG/100ML**	**N19826 006**	AUG 14, 1992
	THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER			
AP	+ BAXTER HLTHCARE	**40MG/100ML**	**N18649 001**	JUL 26, 1982
AP	+	**80MG/100ML**	**N18649 002**	JUL 26, 1982

THEOPHYLLINE

INJECTABLE; INJECTION

	THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER			
AP	+ BAXTER HLTHCARE	**160MG/100ML**	**N18649 003**	JUL 26, 1982
AP	+	**200MG/100ML**	**N18649 004**	JUL 26, 1982
AP	+	**320MG/100ML**	**N18649 006**	NOV 13, 1985
AP	+	**400MG/100ML**	**N18649 005**	JUL 26, 1982
AP	+	**4MG/ML**	**N18649 007**	JUL 26, 1982
	THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER			
AP	+ ABBOTT	**40MG/100ML**	**N19211 001**	DEC 14, 1984
AP	+	**80MG/100ML**	**N19211 002**	DEC 14, 1984
AP	+	**160MG/100ML**	**N19211 003**	DEC 14, 1984
AP	+	**200MG/100ML**	**N19211 004**	DEC 14, 1984
AP	+	**320MG/100ML**	**N19211 006**	JAN 20, 1988
AP	+	**400MG/100ML**	**N19211 005**	DEC 14, 1984
AP	+	**4MG/ML**	**N19211 007**	DEC 14, 1984

SOLUTION; ORAL

	AEROLATE			
	+ FLEMING PHARMS	150MG/15ML	N89141 001	DEC 03, 1986
	THEOLAIR			
AA	+ 3M	**80MG/15ML**	**N86107 001**	
	THEOPHYLLINE			
AA	ROXANE	**80MG/15ML**	**N87449 001**	SEP 15, 1983

SYRUP; ORAL

	SLO-PHYLLIN			
AA	+ AVENTIS	**80MG/15ML**	**N85187 001**	

TABLET; ORAL

	QUIBRON-T			
	+ MONARCH PHARMS	300MG	N88656 001	AUG 22, 1985
	SLO-PHYLLIN			
	+ AVENTIS	100MG	N85202 001	

FDA data supplied by DrugPatentWatch.com

THEOPHYLLINE

	TABLET; ORAL				
	SLO-PHYLLIN				
	+ AVENTIS	200MG	N85204 001		
	THEOLAIR				
	+ 3M	125MG	N86399 001		
	+	250MG	N86399 002		
	TABLET, EXTENDED RELEASE; ORAL				
	QUIBRON-T/SR				
BC	MONARCH PHARMS	300MG	N87563 001 JUN 21, 1983		
	T-PHYL				
BC	PURDUE FREDERICK	200MG	N88253 001 AUG 17, 1983		
	THEO-DUR				
AB	+ KEY PHARMS	**100MG**	**N85328 001**		
AB	+	**200MG**	**N86998 001**		
AB	+	**300MG**	**N85328 002**		
AB	+	**450MG**	**N89131 001** JUN 25, 1986		
	THEOCHRON				
AB	INWOOD LABS	**100MG**	**N88320 001** FEB 21, 1985		
AB		**200MG**	**N88321 001** FEB 21, 1985		
AB		**300MG**	**N87400 002** JAN 11, 1983		
	THEOLAIR-SR				
BC	3M	200MG	N88369 001 JUL 16, 1987		
BC		300MG	N88364 001 JUL 16, 1987		
		250MG	N86363 002 JUL 16, 1987		
	+	500MG	N89132 001 JUL 16, 1987		
	THEOPHYLLINE				
AB	INWOOD LABS	**450MG**	**N40034 001** APR 28, 1995		
AB	SIDMAK LABS NJ	**100MG**	**N89807 001** APR 30, 1990		
AB		**200MG**	**N89808 001** APR 30, 1990		
AB		**300MG**	**N89763 001** APR 30, 1990		
AB		**450MG**	**N81236 001** NOV 09, 1992		

THEOPHYLLINE

	TABLET, EXTENDED RELEASE; ORAL				
	UNI-DUR				
BC	+ SCHERING	400MG			N89822 001 JAN 04, 1995
BC	+	600MG			N89823 001 JAN 04, 1995
	UNIPHYL				
BC	PURDUE FREDERICK	400MG			N87571 001 SEP 01, 1982
BC		600MG			N40086 001 APR 15, 1996

THIABENDAZOLE

	SUSPENSION; ORAL				
	MINTEZOL				
	+ MERCK	500MG/5ML			N16097 001
	TABLET, CHEWABLE; ORAL				
	MINTEZOL				
	+ MERCK	500MG			N16096 001

THIAMINE; *MULTIPLE*

SEE ALPHA-TOCOPHEROL; ASCORBIC ACID; BIOTIN, D-; CHOLECALCIFEROL; CYANOCOBALAMIN; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A

SEE ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

THIAMINE HYDROCHLORIDE

	INJECTABLE; INJECTION				
	THIAMINE HCL				
AP	ABBOTT	**100MG/ML**			**N40079 001** MAY 03, 1996
AP	+ AM PHARM PARTNERS	**100MG/ML**			**N80556 001**
AP	ELKINS SINN	**100MG/ML**			**N80575 001**
AP	STERIS	**100MG/ML**			**N80571 001**
	+	200MG/ML			N80571 002
AP	WYETH AYERST	**100MG/ML**			**N80553 001**

FDA data supplied by DrugPatentWatch.com

THIAMINE HYDROCHLORIDE; *MULTIPLE*

SEE ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE

SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PHYTONADIONE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

THIETHYLPERAZINE MALATE

INJECTABLE; INJECTION

TORECAN				
+ NOVARTIS	5MG/ML	N12754 002		

THIETHYLPERAZINE MALEATE

SUPPOSITORY; RECTAL

TORECAN				
+ NOVARTIS	10MG	N13247 001		

TABLET; ORAL

TORECAN				
+ NOVARTIS	10MG	N12753 001		

THIOGUANINE

TABLET; ORAL

THIOGUANINE				
+ GLAXOSMITHKLINE	40MG	N12429 001		

THIORIDAZINE

SUSPENSION; ORAL

MELLARIL-S				
NOVARTIS	EQ 25MG HCL/5ML	N17923 001		
+	EQ 100MG HCL/5ML	N17923 002		

THIORIDAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

MELLARIL				
AA	+ NOVARTIS	30MG/ML	**N11808 012**	
AA	+	100MG/ML	**N11808 018**	
THIORIDAZINE HCL				
AA	ALPHARMA	100MG/ML	**N88229 001**	AUG 23, 1983
AA	COPLEY PHARM	30MG/ML	**N89602 001**	NOV 09, 1987
AA		100MG/ML	**N89603 001**	NOV 09, 1987
AA	HI TECH PHARMA	30MG/ML	**N40125 001**	AUG 16, 1996
AA		100MG/ML	**N40126 001**	AUG 16, 1996
AA	PHARM ASSOC	30MG/ML	**N40187 001**	AUG 28, 1997
AA		100MG/ML	**N40213 001**	MAY 29, 1998
THIORIDAZINE HCL INTENSOL				
AA	ROXANE	30MG/ML	**N88941 001**	DEC 16, 1985
AA		100MG/ML	**N88942 001**	DEC 16, 1985

TABLET; ORAL

MELLARIL				
AB	NOVARTIS	10MG	**N11808 003**	
AB		15MG	**N11808 016**	
AB	+	25MG	**N11808 006**	
AB		50MG	**N11808 011**	
AB	+	100MG	**N11808 009**	
AB		150MG	**N11808 017**	
AB	+	200MG	**N11808 015**	
THIORIDAZINE HCL				
AB	DANBURY PHARMA	10MG	**N88476 001**	NOV 08, 1983
AB		15MG	**N88477 001**	NOV 08, 1983
AB		25MG	**N88478 001**	NOV 08, 1983
AB		50MG	**N88479 001**	NOV 08, 1983
AB		100MG	**N88736 001**	JUL 24, 1984
AB		150MG	**N88869 001**	JUN 28, 1985

FDA data supplied by DrugPatentWatch.com

THIORIDAZINE HYDROCHLORIDE

TABLET; ORAL

THIORIDAZINE HCL

AB	DANBURY PHARMA	200MG	N88872 001	APR 26, 1985
AB	GENEVA PHARMS	10MG	N88131 001	AUG 30, 1983
AB		15MG	N88132 001	AUG 30, 1983
AB		25MG	N88133 001	AUG 30, 1983
AB		50MG	N88134 001	AUG 30, 1983
AB		100MG	N88135 001	NOV 20, 1984
AB		150MG	N88136 001	SEP 17, 1986
AB		200MG	N88137 001	SEP 17, 1986
AB	HALSEY	50MG	N88370 001	NOV 18, 1983
AB	IVAX PHARMS	10MG	N88270 001	APR 14, 1983
AB		15MG	N88271 001	APR 14, 1983
AB		25MG	N88272 001	APR 14, 1983
AB	MUTUAL PHARM	10MG	N89431 001	AUG 01, 1986
AB		25MG	N89432 001	AUG 01, 1986
AB		50MG	N89433 001	AUG 01, 1986
AB		100MG	N89953 001	OCT 07, 1988
AB	MYLAN	10MG	N88001 001	MAR 15, 1983
AB		25MG	N88002 001	MAR 15, 1983
AB		50MG	N88003 001	MAR 15, 1983
AB		100MG	N88004 001	NOV 18, 1983
AB	TEVA	100MG	N88456 001	MAY 17, 1985
AB	WATSON LABS	25MG	N88567 001	MAY 11, 1984

THIORIDAZINE HYDROCHLORIDE

TABLET; ORAL

THIORIDAZINE HCL

AB	WATSON LABS	50MG	N88563 001	MAY 11, 1984
AB		100MG	N88564 001	MAY 11, 1984

THIOTEPA

INJECTABLE; INJECTION

THIOPLEX

AP	+ IMMUNEX	15MG/VIAL	N20058 001	DEC 22, 1994

THIOTEPA

AP	AAIPHARMA	15MG/VIAL	N75698 001	SEP 20, 2001
AP	BEDFORD	15MG/VIAL	N75547 001	APR 02, 2001
AP	GENSIA SICOR PHARMS	15MG/VIAL	N75730 001	APR 20, 2001
	+	30MG/VIAL	N75730 002	APR 20, 2001

THIOTHIXENE

CAPSULE; ORAL

NAVANE

AB	ROERIG	1MG	N16584 001	
AB		2MG	N16584 002	
AB	+	5MG	N16584 003	
AB		10MG	N16584 004	
		20MG	N16584 005	

THIOTHIXENE

AB	DANBURY PHARMA	1MG	N70600 001	JUN 05, 1987
AB		2MG	N70601 001	JUN 05, 1987
AB		5MG	N70602 001	JUN 05, 1987
AB		10MG	N70603 001	JUN 05, 1987
AB	GENEVA PHARMS	1MG	N71610 001	JUN 24, 1987
AB		2MG	N71570 001	JUN 24, 1987

FDA data supplied by DrugPatentWatch.com

THIOTHIXENE

CAPSULE; ORAL

	THIOTHIXENE			
AB	GENEVA PHARMS	5MG	N71529 001	JUN 24, 1987
AB		10MG	N71530 001	JUN 24, 1987
AB	MYLAN	1MG	N71090 001	JUN 23, 1987
AB		2MG	N71091 001	JUN 23, 1987
AB		5MG	N71092 001	JUN 23, 1987
AB		10MG	N71093 001	JUN 23, 1987

THIOTHIXENE HYDROCHLORIDE

CONCENTRATE; ORAL

	NAVANE			
AA	+ ROERIG	EQ 5MG BASE/ML	N16758 001	
	THIOTHIXENE HCL			
AA	COPLEY PHARM	EQ 5MG BASE/ML	N71554 001	OCT 16, 1987
	THIOTHIXENE HCL INTENSOL			
AA	ROXANE	EQ 5MG BASE/ML	N73494 001	JUN 30, 1992

INJECTABLE; INJECTION

NAVANE			
+	ROERIG	EQ 10MG BASE/VIAL	N16904 002

THONZONIUM BROMIDE; *MULTIPLE*
SEE COLISTIN SULFATE; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; THONZONIUM BROMIDE

THYROTROPIN ALFA

INJECTABLE; INJECTION

THYROGEN				
+	GENZYME	1.1MG/VIAL	N20898 001	NOV 30, 1998

TIAGABINE HYDROCHLORIDE

TABLET; ORAL

GABITRIL				
+	CEPHALON	2MG	N20646 005	APR 16, 1999
		4MG	N20646 001	SEP 30, 1997
		12MG	N20646 002	SEP 30, 1997
		16MG	N20646 003	SEP 30, 1997
+		20MG	N20646 004	SEP 30, 1997

TICARCILLIN DISODIUM

INJECTABLE; INJECTION

TICAR				
+	GLAXOSMITHKLINE	EQ 1GM BASE/VIAL	N50497 001	
+		EQ 3GM BASE/VIAL	N50497 002	
+		EQ 20GM BASE/VIAL	N50497 004	
+		EQ 30GM BASE/VIAL	N50497 005	APR 04, 1984

TICARCILLIN DISODIUM; *MULTIPLE*
SEE CLAVULANATE POTASSIUM; TICARCILLIN DISODIUM

TICLOPIDINE HYDROCHLORIDE

TABLET; ORAL

	TICLID			
AB	+ SYNTEX (USA) INC LLC	250MG	N19979 002	OCT 31, 1991
	TICLOPIDINE HCL			
AB	DANBURY PHARMA	250MG	N75309 001	APR 26, 2000
AB	EON	250MG	N75326 001	AUG 20, 1999
AB	GENEVA PHARMS TECH	250MG	N75318 001	AUG 20, 1999
AB	GENPHARM	250MG	N75161 001	SEP 13, 1999
AB	MYLAN	250MG	N75316 001	NOV 02, 1999

FDA data supplied by DrugPatentWatch.com

TICLOPIDINE HYDROCHLORIDE

TABLET; ORAL

	TICLOPIDINE HCL			
AB	PUREPAC PHARM	250MG	N75253 001	AUG 20, 1999
AB	TEVA	250MG	N75149 001	AUG 20, 1999
AB	TORPHARM	250MG	N75089 001	JUL 01, 1999

TILUDRONATE DISODIUM

TABLET; ORAL

	SKELID			
+	SANOFI SYNTHELABO	EQ 200MG BASE	N20707 001	MAR 07, 1997

TIMOLOL

SOLUTION/DROPS; OPHTHALMIC

	BETIMOL			
+	SANTEN OY	EQ 0.25% BASE	N20439 001	MAR 31, 1995
+		EQ 0.5% BASE	N20439 002	MAR 31, 1995

TIMOLOL MALEATE

SOLUTION, GEL FORMING/DROPS; OPHTHALMIC

	TIMOLOL MALEATE			
AB	FALCON PHARMS	EQ 0.25% BASE	N20963 001	OCT 21, 1998
AB		EQ 0.5% BASE	N20963 002	OCT 21, 1998
	TIMOPTIC-XE			
AB	+ MERCK	EQ 0.25% BASE	N20330 001	NOV 04, 1993
AB	+	EQ 0.5% BASE	N20330 002	NOV 04, 1993

SOLUTION/DROPS; OPHTHALMIC

	TIMOLOL MALEATE			
AT	AKORN	EQ 0.25% BASE	N74465 001	MAR 25, 1997

TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

	TIMOLOL MALEATE			
AT	AKORN	EQ 0.25% BASE	N74515 001	MAR 25, 1997
AT		EQ 0.5% BASE	N74466 001	MAR 25, 1997
AT		EQ 0.5% BASE	N74516 001	MAR 25, 1997
AT	BAUSCH AND LOMB	EQ 0.25% BASE	N74778 001	MAR 25, 1997
AT		EQ 0.5% BASE	N74776 001	MAR 25, 1997
AT	FOUGERA	EQ 0.25% BASE	N74667 001	MAR 25, 1997
AT		EQ 0.5% BASE	N74668 001	MAR 25, 1997
AT	NOVEX	EQ 0.25% BASE	N75411 001	SEP 08, 2000
AT		EQ 0.5% BASE	N75412 001	SEP 08, 2000
AT	PACIFIC PHARMA	EQ 0.25% BASE	N74746 001	MAR 25, 1997
AT		EQ 0.5% BASE	N74747 001	MAR 25, 1997
	TIMOPTIC			
AT	+ MERCK	EQ 0.25% BASE	N18086 001	
AT	+	EQ 0.5% BASE	N18086 002	
	TIMOPTIC IN OCUDOSE			
	+ MERCK	EQ 0.25% BASE	N19463 001	NOV 05, 1986
	+	EQ 0.5% BASE	N19463 002	NOV 05, 1986

TABLET; ORAL

	BLOCADREN			
AB	MERCK	5MG	N18017 001	
AB		10MG	N18017 002	
AB	+	20MG	N18017 004	
	TIMOLOL MALEATE			
AB	DANBURY PHARMA	5MG	N72917 001	JUL 31, 1991
AB		10MG	N72918 001	JUL 31, 1991
AB		20MG	N72919 001	JUL 31, 1991
AB	GENEVA PHARMS	5MG	N72550 001	APR 13, 1989

FDA data supplied by DrugPatentWatch.com

TIMOLOL MALEATE

TABLET; ORAL
TIMOLOL MALEATE

AB	GENEVA PHARMS	10MG	**N72551 001** APR 13, 1989	
AB		20MG	**N72552 001** APR 13, 1989	
AB	MYLAN	5MG	**N72666 001** JUN 08, 1990	
AB		10MG	**N72667 001** JUN 08, 1990	
AB		20MG	**N72668 001** JUN 08, 1990	

TIMOLOL MALEATE; *MULTIPLE*
SEE DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE
SEE HYDROCHLOROTHIAZIDE; TIMOLOL MALEATE

TINZAPARIN SODIUM

INJECTABLE; INJECTION
INNOHEP

+	BRISTOL MYERS SQUIBB	20,000 IU/ML	N20484 001 JUL 14, 2000

TIOPRONIN

TABLET; ORAL
TIOPRONIN

+	MISSION PHARMA	100MG	N19569 001 AUG 11, 1988

TIROFIBAN HYDROCHLORIDE

INJECTABLE; INJECTION
AGGRASTAT

+	MERCK	EQ 0.05MG BASE/ML	N20913 001 MAY 14, 1998
+		EQ 0.25MG BASE/ML	N20912 001 MAY 14, 1998

TIZANIDINE HYDROCHLORIDE

TABLET; ORAL
ZANAFLEX

	ELAN PHARMS	EQ 2MG BASE	N20397 002 FEB 04, 2000
+		EQ 4MG BASE	N20397 001 NOV 27, 1996

TOBRAMYCIN

OINTMENT; OPHTHALMIC
TOBREX

+	ALCON	0.3%	N50555 001

SOLUTION; INHALATION
TOBI

+	CHIRON	300MG/5ML	N50753 001 DEC 22, 1997

SOLUTION/DROPS; OPHTHALMIC
AKTOB

AT	AKORN	0.3%	**N64096 001** JAN 31, 1996

TOBRAMYCIN

AT	ALTANA	0.3%	**N65026 001** SEP 11, 2001
AT	BAUSCH AND LOMB	0.3%	**N64052 001** NOV 29, 1993

TOBREX

AT	ALCON	0.3%	**N62535 001** DEC 13, 1984
AT +	FALCON PHARMS	0.3%	**N50541 001**

TOBRAMYCIN; *MULTIPLE*
SEE DEXAMETHASONE; TOBRAMYCIN
SEE FLUOROMETHOLONE ACETATE; TOBRAMYCIN

TOBRAMYCIN SULFATE

INJECTABLE; INJECTION
NEBCIN

AP +	LILLY	EQ 1.2GM BASE/VIAL	**N50519 001**
AP +		EQ 10MG BASE/ML	**N50477 005**
AP		EQ 10MG BASE/ML	**N62008 004**

FDA data supplied by DrugPatentWatch.com

TOBRAMYCIN SULFATE

INJECTABLE; INJECTION

	NEBCIN			
AP	LILLY	EQ 10MG BASE/ML	**N62707 001** APR 29, 1987	
AP	+	EQ 40MG BASE/ML	**N62008 001**	
	TOBRAMYCIN			
AP	PHARMA TEK	EQ 1.2GM BASE/VIAL	**N65013 001** AUG 17, 2001	
	TOBRAMYCIN SULFATE			
AP	ABBOTT	EQ 10MG BASE/ML	**N63080 001** APR 30, 1991	
AP		EQ 10MG BASE/ML	**N63112 001** APR 30, 1991	
AP		EQ 40MG BASE/ML	**N63111 001** APR 30, 1991	
AP	+	EQ 40MG BASE/ML	**N63116 001** MAY 18, 1992	
AP		EQ 40MG BASE/ML	**N63161 001** MAY 29, 1991	
AP	APOTHECON	EQ 10MG BASE/ML	**N64021 001** MAY 31, 1994	
AP		EQ 40MG BASE/ML	**N64021 002** MAY 31, 1994	
AP	ASTRAZENECA	EQ 40MG BASE/ML	**N63120 001** OCT 31, 1994	
AP		EQ 40MG BASE/ML	**N63122 001** OCT 31, 1994	
AP	GENSIA SICOR PHARMS	EQ 40MG BASE/ML	**N63100 001** JAN 30, 1992	
AP	LEDERLE	EQ 40MG BASE/ML	**N63117 001** APR 26, 1991	
AP		EQ 40MG BASE/ML	**N63118 001** JUL 29, 1991	
AP	MARSAM PHARMS LLC	EQ 10MG BASE/ML	**N62945 001** AUG 09, 1989	
AP		EQ 40MG BASE/ML	**N62945 002** AUG 09, 1989	

TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

+	ABBOTT	EQ 80MG BASE/100ML	N63081 001 JUL 31, 1990
+		EQ 1.2MG BASE/ML	N63081 003 JUL 31, 1990
+		EQ 1.6MG BASE/ML	N63081 006 JUN 02, 1993

TOCAINIDE HYDROCHLORIDE

TABLET; ORAL

	TONOCARD		
	ASTRAZENECA	400MG	N18257 001 NOV 09, 1984
+		600MG	N18257 002 NOV 09, 1984

TOCOPHEROL ACETATE; *MULTIPLE*

SEE ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

TOLAZAMIDE

TABLET; ORAL

	TOLAZAMIDE			
AB	DANBURY PHARMA	**100MG**	**N70513 001** JAN 09, 1986	
AB		**250MG**	**N70514 001** JAN 09, 1986	
AB		**500MG**	**N70515 001** JAN 09, 1986	
AB	GENEVA PHARMS	**100MG**	**N71633 001** DEC 09, 1987	
AB		**250MG**	**N70289 001** MAR 13, 1986	
AB		**500MG**	**N70290 001** MAR 13, 1986	
AB	IVAX PHARMS	**100MG**	**N18894 001** NOV 02, 1984	
AB		**250MG**	**N18894 002** NOV 02, 1984	
AB		**500MG**	**N18894 003** NOV 02, 1984	
AB	MUTUAL PHARM	**100MG**	**N71357 001** JUL 16, 1987	
AB		**250MG**	**N71358 001** JUL 16, 1987	
AB		**500MG**	**N71359 001** JUL 16, 1987	
AB	MYLAN	**250MG**	**N70259 001** JAN 02, 1986	
AB		**500MG**	**N70913 001** MAR 17, 1986	

FDA data supplied by DrugPatentWatch.com

TOLAZAMIDE

TABLET; ORAL

	TOLAZAMIDE			
AB	PAR PHARM	100MG	N70159 001	JAN 06, 1986
AB		250MG	N70160 001	JAN 06, 1986
AB		500MG	N70161 001	JAN 06, 1986
	TOLINASE			
AB	PHARMACIA AND UPJOHN	100MG	N15500 002	
AB		250MG	N15500 004	
AB	+	500MG	N15500 005	

TOLAZOLINE HYDROCHLORIDE

INJECTABLE; INJECTION

	PRISCOLINE			
	+ NOVARTIS	25MG/ML	N06403 005	FEB 22, 1985

TOLBUTAMIDE

TABLET; ORAL

	TOLBUTAMIDE			
AB	DANBURY PHARMA	500MG	N87318 001	
AB	GENEVA PHARMS	500MG	N86574 001	
AB	IVAX PHARMS	500MG	N87093 001	
AB	LEDERLE	500MG	N86926 001	
AB	MYLAN	500MG	N86445 001	
AB	+ WATSON LABS	500MG	N86109 001	

TOLBUTAMIDE SODIUM

INJECTABLE; INJECTION

	ORINASE DIAGNOSTIC			
	+ PHARMACIA AND UPJOHN	EQ 1GM BASE/VIAL	N12095 001	

TOLCAPONE

TABLET; ORAL

	TASMAR			
	ROCHE	100MG	N20697 001	JAN 29, 1998

TOLCAPONE

TABLET; ORAL

	TASMAR			
+	ROCHE	200MG	N20697 002	JAN 29, 1998

TOLMETIN SODIUM

CAPSULE; ORAL

	TOLECTIN DS			
AB	+ JOHNSON RW	EQ 400MG BASE	N18084 001	
	TOLMETIN SODIUM			
AB	IVAX PHARMS	EQ 400MG BASE	N73392 001	JAN 24, 1992
AB	MUTUAL PHARM	EQ 400MG BASE	N73311 001	NOV 27, 1991
AB	MYLAN	EQ 400MG BASE	N73393 001	MAY 27, 1993
AB	PUREPAC PHARM	EQ 400MG BASE	N73308 001	JAN 24, 1992
AB	TEVA	EQ 400MG BASE	N73290 001	NOV 27, 1991
AB		EQ 400MG BASE	N73519 001	MAY 29, 1992

TABLET; ORAL

	TOLECTIN			
AB	JOHNSON RW	EQ 200MG BASE	N17628 001	
	TOLECTIN 600			
AB	+ JOHNSON RW	EQ 600MG BASE	N17628 002	MAR 08, 1989
	TOLMETIN SODIUM			
AB	GENEVA PHARMS	EQ 200MG BASE	N73588 001	JUL 31, 1992
AB		EQ 600MG BASE	N74002 001	SEP 27, 1993
AB	IVAX PHARMS	EQ 600MG BASE	N74399 001	MAR 28, 1996
AB	MUTUAL PHARM	EQ 200MG BASE	N73310 001	NOV 27, 1991
AB	MYLAN	EQ 600MG BASE	N74473 001	AUG 30, 1994
AB	PUREPAC PHARM	EQ 600MG BASE	N73527 001	JUN 30, 1992

FDA data supplied by DrugPatentWatch.com

TOLTERODINE TARTRATE

CAPSULE, EXTENDED RELEASE; ORAL			
DETROL LA			
+ PHARMACIA AND UPJOHN	2MG	N21228 001	DEC 22, 2000
+	4MG	N21228 002	DEC 22, 2000
TABLET; ORAL			
DETROL			
PHARMACIA AND UPJOHN	1MG	N20771 001	MAR 25, 1998
+	2MG	N20771 002	MAR 25, 1998

TOPIRAMATE

CAPSULE; ORAL			
TOPAMAX SPRINKLE			
ORTHO MCNEIL	15MG	N20844 001	OCT 26, 1998
+	25MG	N20844 002	OCT 26, 1998
TABLET; ORAL			
TOPAMAX			
+ ORTHO MCNEIL	25MG	N20505 004	DEC 24, 1996
	100MG	N20505 001	DEC 24, 1996
	200MG	N20505 002	DEC 24, 1996

TOPOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION			
HYCAMTIN			
+ GLAXOSMITHKLINE	EQ 4MG BASE/VIAL	N20671 001	MAY 28, 1996

TOREMIFENE CITRATE

TABLET; ORAL			
FARESTON			
+ ORION	EQ 60MG BASE	N20497 001	MAY 29, 1997

TORSEMIDE

INJECTABLE; INJECTION			
DEMADEX			
+ ROCHE	10MG/ML	N20137 002	AUG 23, 1993
TABLET; ORAL			
DEMADEX			
ROCHE	5MG	N20136 001	AUG 23, 1993
	10MG	N20136 002	AUG 23, 1993
+	20MG	N20136 003	AUG 23, 1993
	100MG	N20136 004	AUG 23, 1993

TRAMADOL HYDROCHLORIDE

TABLET; ORAL			
ULTRAM			
+ JOHNSON RW	50MG	N20281 002	MAR 03, 1995

TRAMADOL HYDROCHLORIDE; *MULTIPLE*
SEE ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TRANDOLAPRIL

TABLET; ORAL			
MAVIK			
ABBOTT	1MG	N20528 001	APR 26, 1996
	2MG	N20528 002	APR 26, 1996
+	4MG	N20528 003	APR 26, 1996

TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL			
TARKA			
+ ABBOTT	1MG;240MG	N20591 003	OCT 22, 1996

FDA data supplied by DrugPatentWatch.com

TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
TARKA

+	ABBOTT	2MG;180MG	N20591 001	OCT 22, 1996
+		2MG;240MG	N20591 004	OCT 22, 1996
+		4MG;240MG	N20591 002	OCT 22, 1996

TRANEXAMIC ACID

INJECTABLE; INJECTION
CYKLOKAPRON

+	PHARMACIA AND UPJOHN	100MG/ML	N19281 001	DEC 30, 1986

TRANYLCYPROMINE SULFATE

TABLET; ORAL
PARNATE

+	GLAXOSMITHKLINE	EQ 10MG BASE	N12342 003	AUG 16, 1985

TRAVOPROST

SOLUTION/DROPS; OPHTHALMIC
TRAVATAN

+	ALCON UNIVERSAL	0.004%	N21257 001	MAR 16, 2001

TRAZODONE HYDROCHLORIDE

TABLET; ORAL
DESYREL

AB	APOTHECON	**50MG**	**N18207 001**	
AB		**100MG**	**N18207 002**	
AB		**150MG**	**N18207 003**	MAR 25, 1985
AB	+	**300MG**	**N18207 004**	NOV 07, 1988

TRAZODONE HCL

AB	BARR	**50MG**	**N71258 001**	MAR 25, 1987

TRAZODONE HYDROCHLORIDE

TABLET; ORAL
TRAZODONE HCL

AB	BARR	**100MG**	**N71196 001**	MAR 25, 1987
AB		**150MG**	**N71196 002**	APR 26, 1999
AB		**300MG**	**N71196 003**	APR 26, 1999
AB	DANBURY PHARMA	**50MG**	**N70857 001**	OCT 10, 1986
AB		**100MG**	**N70858 001**	OCT 10, 1986
AB	GENEVA PHARMS	**50MG**	**N72484 001**	APR 30, 1990
AB		**100MG**	**N72483 001**	APR 30, 1990
AB	MUTUAL PHARM	**50MG**	**N73136 001**	MAR 24, 1993
AB		**100MG**	**N73137 001**	MAR 24, 1993
AB		**150MG**	**N73138 001**	DEC 22, 1995
AB	MYLAN	**50MG**	**N71405 001**	FEB 27, 1991
AB		**100MG**	**N71406 001**	FEB 27, 1991
AB	PUREPAC PHARM	**50MG**	**N71636 001**	APR 18, 1988
AB		**100MG**	**N71514 001**	APR 18, 1988
AB	SIDMAK LABS NJ	**50MG**	**N71523 001**	DEC 11, 1987
AB		**100MG**	**N71524 001**	DEC 11, 1987
AB		**150MG**	**N71525 001**	MAR 09, 1988
AB	TEVA	**50MG**	**N72192 001**	FEB 02, 1989
AB		**100MG**	**N72193 001**	FEB 02, 1989
AB		**150MG**	**N74357 001**	APR 30, 1997

FDA data supplied by DrugPatentWatch.com

TRETINOIN

CAPSULE; ORAL

	VESANOID			
	+ ROCHE	10MG	N20438 001	
			NOV 22, 1995	

CREAM; TOPICAL

	AVITA			
AB	BERTEK PHARMS	**0.025%**	**N20404 003**	
			JAN 14, 1997	
	RENOVA			
	+ JOHNSON AND JOHNSON	0.02%	N21108 001	
			AUG 31, 2000	
	RETIN-A			
AB	+ JOHNSON AND JOHNSON	**0.025%**	**N19049 001**	
			SEP 16, 1988	
AB	+	**0.05%**	**N17522 001**	
AB	+	**0.1%**	**N17340 001**	
	TRETINOIN			
AB	SPEAR PHARMS	**0.025%**	**N75264 001**	
			DEC 24, 1998	
AB		**0.05%**	**N75265 001**	
			DEC 24, 1998	
AB		**0.1%**	**N75213 001**	
			DEC 24, 1998	

CREAM, AUGMENTED; TOPICAL

	RENOVA			
	+ JOHNSON AND JOHNSON	0.05%	N19963 001	
			DEC 29, 1995	

GEL; TOPICAL

	AVITA			
BT	BERTEK PHARMS	0.025%	N20400 001	
			JAN 29, 1998	
	RETIN-A			
AB	+ JOHNSON AND JOHNSON	**0.025%**	**N17579 002**	
	+	0.01%	N17955 001	
	RETIN-A MICRO			
	+ JOHNSON AND JOHNSON	0.1%	N20475 001	
			FEB 07, 1997	
	TRETINOIN			
AB	SPEAR PHARMS	**0.025%**	**N75529 001**	
			FEB 22, 2000	

SOLUTION; TOPICAL

	RETIN-A			
AT	+ JOHNSON AND JOHNSON	**0.05%**	**N16921 001**	

TRETINOIN

SOLUTION; TOPICAL

	TRETINOIN			
AT	COPLEY PHARM	**0.05%**	**N74873 001**	
			JUN 19, 1998	
AT	MORTON GROVE	**0.05%**	**N75260 001**	
			JAN 25, 1999	

TRETINOIN; *MULTIPLE*
SEE MEQUINOL; TRETINOIN

TRIAMCINOLONE

TABLET; ORAL

	ARISTOCORT			
BP	FUJISAWA HLTHCARE	4MG	N11161 007	
BP	+	8MG	N11161 011	
		1MG	N11161 009	
		2MG	N11161 004	
	KENACORT			
BP	BRISTOL MYERS SQUIBB	4MG	N11283 006	
BP		8MG	N11283 010	
	TRIAMCINOLONE			
BP	DANBURY PHARMA	4MG	N84270 001	

TRIAMCINOLONE ACETONIDE

AEROSOL, METERED; INHALATION

	AZMACORT			
	+ AVENTIS	0.1MG/INH	N18117 001	
			APR 23, 1982	

AEROSOL, METERED; NASAL

	NASACORT			
	+ AVENTIS	0.055MG/INH	N19798 001	
			JUL 11, 1991	

CREAM; TOPICAL

	ARISTOCORT			
AT	FUJISAWA HLTHCARE	**0.025%**	**N83017 003**	
AT		**0.1%**	**N83016 004**	
AT		**0.5%**	**N83015 002**	
	ARISTOCORT A			
AT	FUJISAWA HLTHCARE	**0.025%**	**N83017 004**	

FDA data supplied by DrugPatentWatch.com

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

		ARISTOCORT A			
AT		FUJISAWA HLTHCARE	0.025%	N88818 001	
				OCT 16, 1984	
AT			0.1%	N83016 005	
AT			0.1%	N88819 001	
				OCT 16, 1984	
AT			0.5%	N83015 003	
AT			0.5%	N88820 001	
				OCT 16, 1984	
		KENALOG			
AT	+	APOTHECON	0.025%	N11601 003	
AT	+		0.1%	N11601 006	
AT	+		0.5%	N83943 001	
		TRIACET			
AT		TEVA	0.025%	N84908 001	
AT			0.1%	N84908 002	
AT			0.5%	N84908 003	
		TRIAMCINOLONE ACETONIDE			
AT		ALTANA	0.025%	N85692 001	
AT			0.1%	N85692 003	
AT			0.5%	N85692 002	
AT		AMBIX	0.025%	N87932 001	
				MAY 09, 1983	
AT		CLAY PARK	0.025%	N86415 001	
AT			0.1%	N86414 001	
AT			0.5%	N86413 001	
AT		G AND W LABS	0.025%	N89797 001	
				MAY 31, 1991	
AT			0.1%	N89798 001	
				MAY 31, 1991	
AT		NMC	0.1%	N87798 001	
				JUN 04, 1982	
AT		TARO	0.1%	N40039 001	
				NOV 26, 1997	
AT		THAMES	0.025%	N86277 001	
AT			0.1%	N86276 001	
AT			0.5%	N86275 001	
		TRIDERM			
AT		DEL RAY LABS	0.1%	N88042 001	
				MAR 19, 1984	
		TRYMEX			
AT		SAVAGE LABS	0.025%	N88196 001	
				MAR 25, 1983	
AT			0.1%	N88197 001	
				MAR 25, 1983	

TRIAMCINOLONE ACETONIDE

INJECTABLE; INJECTION

		KENALOG-10			
	+	APOTHECON	10MG/ML	N12041 001	
		KENALOG-40			
BP		APOTHECON	40MG/ML	N14901 001	
		TRIAMCINOLONE ACETONIDE			
		PARNELL	3MG/ML	N19503 001	
				OCT 16, 1987	
BP		STERIS	40MG/ML	N85825 001	

LOTION; TOPICAL

		KENALOG			
AT		APOTHECON	0.025%	N84343 001	
AT	+		0.1%	N84343 002	
		TRIAMCINOLONE ACETONIDE			
AT		MORTON GROVE	0.025%	N88450 001	
				APR 01, 1985	
AT			0.1%	N88451 001	
				APR 03, 1985	
AT		THAMES	0.1%	N89129 001	
				AUG 14, 1986	

OINTMENT; TOPICAL

		ARISTOCORT			
AT		FUJISAWA HLTHCARE	0.1%	N80750 004	
		ARISTOCORT A			
AT		FUJISAWA HLTHCARE	0.1%	N80750 003	
AT			0.1%	N88780 001	
				OCT 01, 1984	
		KENALOG			
AT		APOTHECON	0.025%	N11600 003	
AT			0.1%	N11600 001	
		TRIAMCINOLONE ACETONIDE			
AT		ALTANA	0.025%	N85691 001	
AT			0.1%	N85691 003	
AT			0.5%	N85691 002	
AT	+	CLAY PARK	0.025%	N87356 001	
AT	+		0.1%	N87357 001	
AT	+		0.5%	N87385 001	
AT		NMC	0.1%	N87799 001	
				JUN 07, 1982	
AT		TARO	0.025%	N40040 001	
				SEP 30, 1994	
AT			0.1%	N40037 001	
				SEP 30, 1994	
AT		THAMES	0.025%	N40374 001	
				JUN 05, 2001	

FDA data supplied by DrugPatentWatch.com

TRIAMCINOLONE ACETONIDE

OINTMENT; TOPICAL

	TRIAMCINOLONE ACETONIDE			
AT	THAMES	**0.1%**	**N87902 001**	
			DEC 27, 1982	
AT		**0.5%**	**N40386 001**	
			JUN 05, 2001	
	TRIAMCINOLONE ACETONIDE IN ABSORBASE			
+	CAROLINA MEDCL	0.05%	N89595 001	
			MAR 23, 1995	
	TRYMEX			
AT	SAVAGE LABS	**0.025%**	**N88693 001**	
			AUG 02, 1984	
AT		**0.1%**	**N88691 001**	
			AUG 02, 1984	

PASTE; DENTAL

	KENALOG IN ORABASE			
AT +	APOTHECON	**0.1%**	**N12097 001**	
	ORACORT			
AT	TARO	**0.1%**	**N70730 001**	
			OCT 01, 1986	
	ORALONE			
AT	THAMES	**0.1%**	**N71383 001**	
			JUL 06, 1987	

SPRAY; TOPICAL

	KENALOG		
+	APOTHECON	0.147MG/GM	N12104 001

SPRAY, METERED; NASAL

	NASACORT AQ			
+	AVENTIS	0.055MG/SPRAY	N20468 001	
			MAY 20, 1996	
	TRI-NASAL			
+	MURO	0.05MG/SPRAY	N20120 001	
			FEB 04, 2000	

TRIAMCINOLONE ACETONIDE; *MULTIPLE*
SEE NYSTATIN; TRIAMCINOLONE ACETONIDE

TRIAMCINOLONE DIACETATE

INJECTABLE; INJECTION

	ARISTOCORT			
BP +	LEDERLE	40MG/ML	N12802 001	
+	LEDERLE	25MG/ML	N11685 003	
	TRIAMCINOLONE DIACETATE			
BP	STERIS	40MG/ML	N84072 001	

SYRUP; ORAL

	ARISTOCORT		
	FUJISAWA HLTHCARE	2MG/5ML	N11960 004

TRIAMCINOLONE HEXACETONIDE

INJECTABLE; INJECTION

	ARISTOSPAN		
+	LEDERLE	5MG/ML	N16466 001
+		20MG/ML	N16466 002

TRIAMTERENE

CAPSULE; ORAL

	DYRENIUM		
	WELLSPRING PHARM	50MG	N13174 001
+		100MG	N13174 002

TRIAMTERENE; *MULTIPLE*
SEE HYDROCHLOROTHIAZIDE; TRIAMTERENE

TRIAZOLAM

TABLET; ORAL

	HALCION			
AB	PHARMACIA AND UPJOHN	**0.125MG**	**N17892 003**	
			APR 26, 1985	
AB +		**0.25MG**	**N17892 001**	
			NOV 15, 1982	
	TRIAZOLAM			
AB	ALPHAPHARM	**0.125MG**	**N74031 001**	
			MAR 25, 1994	
AB		**0.25MG**	**N74031 002**	
			MAR 25, 1994	
AB	ROXANE	**0.125MG**	**N74224 001**	
			JUN 01, 1994	

FDA data supplied by DrugPatentWatch.com

TRIAZOLAM

TABLET; ORAL
TRIAZOLAM

AB	ROXANE	**0.25MG**	**N74224 002**	
			JUN 01, 1994	
AB	WATSON LABS	**0.125MG**	**N74445 001**	
			OCT 20, 1995	
AB		**0.25MG**	**N74445 002**	
			OCT 20, 1995	

TRICHLORMETHIAZIDE

TABLET; ORAL
METAHYDRIN

BP	AVENTIS PHARMS	2MG	N12594 001	
			JUN 16, 1988	
BP		4MG	N12594 002	
			JUN 16, 1988	

NAQUA

BP	+ SCHERING	4MG	N12265 002	

TRICHLORMETHIAZIDE

BP	ABC HOLDING	4MG	N85568 001	
BP	PAR PHARM	2MG	N87007 001	
BP		4MG	N87005 001	

TRICHLORMETHIAZIDE; *MULTIPLE*
SEE RESERPINE; TRICHLORMETHIAZIDE

TRIENTINE HYDROCHLORIDE

CAPSULE; ORAL
SYPRINE

+	MERCK	250MG	N19194 001	
			NOV 08, 1985	

TRIFLUOPERAZINE HYDROCHLORIDE

CONCENTRATE; ORAL
STELAZINE

AA	+ GLAXOSMITHKLINE	**EQ 10MG BASE/ML**	**N11552 006**	

INJECTABLE; INJECTION
STELAZINE

+	GLAXOSMITHKLINE	EQ 2MG BASE/ML	N11552 005	

TRIFLUOPERAZINE HYDROCHLORIDE

TABLET; ORAL
STELAZINE

AB	GLAXOSMITHKLINE	**EQ 1MG BASE**	**N11552 001**	
AB		**EQ 2MG BASE**	**N11552 002**	
AB		**EQ 5MG BASE**	**N11552 003**	
AB	+	**EQ 10MG BASE**	**N11552 004**	

TRIFLUOPERAZINE HCL

AB	GENEVA PHARMS	**EQ 1MG BASE**	**N85785 001**	
AB		**EQ 2MG BASE**	**N85786 001**	
AB		**EQ 5MG BASE**	**N85789 001**	
AB		**EQ 10MG BASE**	**N85788 001**	
AB	GENEVA PHARMS TECH	**EQ 1MG BASE**	**N40153 001**	
			OCT 25, 1996	
AB		**EQ 2MG BASE**	**N40153 002**	
			OCT 25, 1996	
AB		**EQ 5MG BASE**	**N40153 003**	
			OCT 25, 1996	
AB		**EQ 10MG BASE**	**N40153 004**	
			OCT 25, 1996	
AB	MYLAN	**EQ 1MG BASE**	**N40209 001**	
			JUL 07, 1997	
AB		**EQ 2MG BASE**	**N40209 002**	
			JUL 07, 1997	
AB		**EQ 5MG BASE**	**N40209 003**	
			JUL 07, 1997	
AB		**EQ 10MG BASE**	**N40209 004**	
			JUL 07, 1997	

TRIFLUPROMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION
VESPRIN

+	APOTHECON	10MG/ML	N11325 004
+		20MG/ML	N11325 001

TRIFLURIDINE

SOLUTION/DROPS; OPHTHALMIC
TRIFLURIDINE

AT	ALCON	**1%**	**N74311 001**	
			OCT 06, 1995	

VIROPTIC

AT	+ MONARCH PHARMS	**1%**	**N18299 001**	

FDA data supplied by DrugPatentWatch.com

TRIHEXYPHENIDYL HYDROCHLORIDE

ELIXIR; ORAL

	ARTANE			
AA	+ LEDERLE	2MG/5ML	N06773 009	
	TRIHEXYPHENIDYL HCL			
AA	MIKART	2MG/5ML	N40251 001	SEP 27, 1999
AA	PHARM ASSOC	2MG/5ML	N40177 001	APR 17, 1997
AA	PHARM VENTURES	2MG/5ML	N89514 001	APR 07, 1989

TABLET; ORAL

	ARTANE			
AA	+ LEDERLE	2MG	N06773 005	
AA	+	5MG	N06773 003	
	TRIHEXYPHENIDYL HCL			
AA	DANBURY PHARMA	2MG	N84363 001	
AA		5MG	N84364 001	
AA	NYLOS	5MG	N85622 001	
AA	VINTAGE PHARMS	2MG	N40254 001	DEC 24, 1998
AA		5MG	N40254 002	DEC 24, 1998
AA	WATSON LAB	2MG	N40184 001	FEB 06, 1998
AA		5MG	N40184 002	FEB 06, 1998
AA	WEST WARD	2MG	N40337 002	FEB 16, 2000
AA		5MG	N40337 001	FEB 16, 2000

TRIMETHADIONE

CAPSULE; ORAL

	TRIDIONE		
+	ABBOTT	300MG	N05856 005

SOLUTION; ORAL

	TRIDIONE		
	ABBOTT	200MG/5ML	N05856 002

TABLET; ORAL

	TRIDIONE		
+	ABBOTT	150MG	N05856 009

TRIMETHOBENZAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

	TIGAN			
AP	+ KING PHARMS	100MG/ML	N17530 001	
	TRIMETHOBENZAMIDE HCL			
AP	ABBOTT	100MG/ML	N88804 001	APR 03, 1987
AP	STERIS	100MG/ML	N87939 001	DEC 28, 1982

TRIMETHOPRIM

TABLET; ORAL

	PROLOPRIM			
AB	MONARCH PHARMS	100MG	N17943 001	
AB	+	200MG	N17943 003	JUL 14, 1982
	TRIMETHOPRIM			
AB	DANBURY PHARMA	100MG	N70049 001	JUN 06, 1985
AB	TEVA	100MG	N18679 001	JUL 30, 1982
AB		200MG	N71259 001	JUN 18, 1987
	TRIMPEX			
AB	ROCHE	100MG	N17952 001	

TRIMETHOPRIM; *MULTIPLE*
SEE PHENAZOPYRIDINE HYDROCHLORIDE; SULFAMETHOXAZOLE; TRIMETHOPRIM
SEE POLYMYXIN B SULFATE; TRIMETHOPRIM
SEE SULFAMETHOXAZOLE; TRIMETHOPRIM

TRIMETHOPRIM HYDROCHLORIDE

SOLUTION; ORAL

	PRIMSOL			
+	ASCENT PEDS	EQ 50MG BASE/5ML	N74973 001	JAN 24, 2000

TRIMETHOPRIM SULFATE; *MULTIPLE*

SEE POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

FDA data supplied by DrugPatentWatch.com

TRIMETREXATE GLUCURONATE

INJECTABLE; INJECTION

	NEUTREXIN			
+	MEDIMMUNE ONCOLOGY	EQ 25MG BASE/VIAL	N20326 001	
			DEC 17, 1993	
+		EQ 200MG BASE/VIAL	N20326 002	
			JUL 31, 1998	

TRIMIPRAMINE MALEATE

CAPSULE; ORAL

	SURMONTIL		
	SIDMAK LABS	EQ 25MG BASE	N16792 001
		EQ 50MG BASE	N16792 002
+		EQ 100MG BASE	N16792 003
			SEP 15, 1982

TRIOXSALEN

TABLET; ORAL

	TRISORALEN		
+	ICN	5MG	N12697 001

TRIPELENNAMINE CITRATE

ELIXIR; ORAL

	PBZ		
	NOVARTIS	EQ 25MG HCL/5ML	N05914 004

TRIPELENNAMINE HYDROCHLORIDE

TABLET; ORAL

	PBZ		
AA +	NOVARTIS	**50MG**	**N05914 002**
+		25MG	N83149 001
	TRIPELENNAMINE HCL		
AA	DANBURY PHARMA	**50MG**	**N80713 001**
AA	LANNETT	**50MG**	**N83557 001**
AA	NYLOS	**50MG**	**N85412 001**

TABLET, EXTENDED RELEASE; ORAL

PBZ-SR		
NOVARTIS	100MG	N10533 001

TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE;SULFATHIAZOLE)

CREAM; VAGINAL

	GYNE-SULF			
AT	G AND W LABS	**3.7%;2.86%;3.42%**	**N88607 001**	
			JUN 09, 1986	
	SULTRIN			
AT +	JOHNSON RW	**3.7%;2.86%;3.42%**	**N05794 001**	
	TRIPLE SULFA			
AT	ALPHARMA	**3.7%;2.86%;3.42%**	**N87864 001**	
			SEP 01, 1982	
AT	CLAY PARK	**3.7%;2.86%;3.42%**	**N87285 001**	
			NOV 15, 1982	
	TRYSUL			
AT	SAVAGE LABS	**3.7%;2.86%;3.42%**	**N87887 001**	
			JUL 23, 1982	

TABLET; VAGINAL

	SULTRIN		
+	JOHNSON RW	184MG;143.75MG;172.5MG	N05794 002

TRIPROLIDINE HYDROCHLORIDE; *MULTIPLE*

SEE CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

SEE PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

TRIPTORELIN PAMOATE

INJECTABLE; INTRAMUSCULAR

	TRELSTAR		
+	PHARMACIA AND UPJOHN	11.25MG/VIAL	N21288 001
			JUN 29, 2001
	TRELSTAR DEPOT		
+	PHARMACIA AND UPJOHN	EQ 3.75MG BASE/VIAL	N20715 001
			JUN 15, 2000

TRISULFAPYRIMIDINES (SULFADIAZINE;SULFAMERAZINE;SULFAMETHAZINE)

TABLET; ORAL

	TRIPLE SULFOID		
+	PAL PAK	167MG;167MG;167MG	N80094 001

FDA data supplied by DrugPatentWatch.com

TROLAMINE POLYPEPTIDE OLEATE CONDENSATE

SOLUTION/DROPS; OTIC
CERUMENEX
+ PURDUE FREDERICK 10% N11340 002

TROLEANDOMYCIN

CAPSULE; ORAL
TAO
+ PFIZER EQ 250MG BASE N50336 002

TROMETHAMINE

INJECTABLE; INJECTION
THAM
+ ABBOTT 3.6GM/100ML N13025 002

TROPICAMIDE

SOLUTION/DROPS; OPHTHALMIC
MYDRIACYL
AT + ALCON **0.5%** **N84305 001**
AT + **1%** **N84306 001**
TROPICACYL
AT AKORN **0.5%** **N40314 001** SEP 29, 2000
AT **1%** **N40315 001** SEP 29, 2000
TROPICAMIDE
AT ALCON UNIVERSAL **1%** **N89172 001** DEC 28, 1990
AT BAUSCH AND LOMB **0.5%** **N40067 001** JUL 27, 1994
AT **1%** **N40064 001** JUL 27, 1994
AT MIZA PHARMS USA **0.5%** **N87636 001** JUL 30, 1982
AT **1%** **N87637 001** AUG 09, 1982

TROPICAMIDE; *MULTIPLE*
SEE HYDROXYAMPHETAMINE HYDROBROMIDE; TROPICAMIDE

TROVAFLOXACIN MESYLATE

TABLET; ORAL
TROVAN
PFIZER EQ 100MG BASE N20759 001 DEC 18, 1997
+ EQ 200MG BASE N20759 002 DEC 18, 1997

TUBOCURARINE CHLORIDE

INJECTABLE; INJECTION
TUBOCURARINE CHLORIDE
AP + ABBOTT **3MG/ML** **N06095 001**
AP + BRISTOL MYERS SQUIBB **3MG/ML** **N05657 001**

TYLOXAPOL; *MULTIPLE*
SEE CETYL ALCOHOL; COLFOSCERIL PALMITATE; TYLOXAPOL

UNOPROSTONE ISOPROPYL

SOLUTION/DROPS; OPHTHALMIC
RESCULA
+ NOVARTIS 0.15% N21214 001 AUG 03, 2000

UREA

INJECTABLE; INJECTION
UREAPHIL
+ ABBOTT 40GM/VIAL N12154 001

UREA; *MULTIPLE*
SEE HYDROCORTISONE ACETATE; UREA

UREA, C-13

FOR SOLUTION; ORAL
BREATHTEK UBT FOR H-PYLORI
+ MERETEK EQ 75MG /POUCHE N20586 002 MAY 10, 2001
HELICOSOL
+ METABOLIC SOLUTIONS 125MG/VIAL N21092 001 DEC 17, 1999

FDA data supplied by DrugPatentWatch.com

UREA, C-13

FOR SOLUTION; ORAL
PYLORI-CHEK BREATH TEST

+	ALIMENTERICS	100MG/VIAL	N20900 001	FEB 04, 1999

UREA, C-14

CAPSULE; ORAL
PYTEST

+	BALLARD MEDCL	1 uCi	N20617 001	MAY 09, 1997

PYTEST KIT

+	BALLARD MEDCL	1 uCi	N20617 002	MAY 09, 1997

UROFOLLITROPIN

INJECTABLE; SUBCUTANEOUS
FERTINEX

+	SERONO	75 IU/AMP	N19415 005	AUG 23, 1996
		150 IU/AMP	N19415 004	AUG 23, 1996

URSODIOL

CAPSULE; ORAL
ACTIGALL

AB	+ NOVARTIS	**300MG**	**N19594 002**	DEC 31, 1987

URSODIOL

AB	AMIDE PHARM	**300MG**	**N75517 001**	MAR 14, 2000
AB	COPLEY PHARM	**300MG**	**N75592 001**	MAY 25, 2000

TABLET; ORAL
URSO

+	AXCAN SCANDIPHARM	250MG	N20675 001	DEC 10, 1997

VALACYCLOVIR HYDROCHLORIDE

TABLET; ORAL
VALTREX

	GLAXOSMITHKLINE	EQ 500MG BASE	N20550 001	DEC 15, 1995
+		EQ 1GM BASE	N20550 002	DEC 15, 1995

VALDECOXIB

TABLET; ORAL
BEXTRA

	GD SEARLE LLC	10MG	N21341 002	NOV 16, 2001
+		20MG	N21341 003	NOV 16, 2001

VALGANCICLOVIR HYDROCHLORIDE

TABLET; ORAL
VALCYTE

+	SYNTEX (USA) INC LLC	EQ 450MG BASE	N21304 001	MAR 29, 2001

VALPROATE SODIUM

INJECTABLE; INJECTION
DEPACON

+	ABBOTT	EQ 100MG BASE/ML	N20593 001	DEC 30, 1996

VALPROIC ACID

CAPSULE; ORAL
DEPAKENE

AB	+ ABBOTT	**250MG**	**N18081 001**	

VALPROIC ACID

AB	BANNER PHARMACAPS	**250MG**	**N73484 001**	JUN 29, 1993
AB	SCHERER RP	**250MG**	**N73229 001**	OCT 29, 1991
AB	USL PHARMA	**250MG**	**N70631 001**	JUN 11, 1987

FDA data supplied by DrugPatentWatch.com

VALPROIC ACID

SYRUP; ORAL

	DEPAKENE			
AA	+ ABBOTT	**250MG/5ML**	**N18082 001**	
	MYPROIC ACID			
AA	MORTON GROVE	**250MG/5ML**	**N70868 001**	JUL 01, 1986
	VALPROIC ACID			
AA	COPLEY PHARM	**250MG/5ML**	**N73178 001**	AUG 25, 1992
AA	HIGH TECH PHARMA	**250MG/5ML**	**N74060 001**	JAN 13, 1995
AA	PHARM ASSOC	**250MG/5ML**	**N75379 001**	DEC 15, 2000
AA	UDL	**250MG/5ML**	**N75782 001**	DEC 22, 2000

VALRUBICIN

SOLUTION; INTRAVESICAL

	VALSTAR PRESERVATIVE FREE		
	+ ANTHRA	40MG/ML	N20892 001 SEP 25, 1998

VALSARTAN

CAPSULE; ORAL

	DIOVAN		
	NOVARTIS	80MG	N20665 001 DEC 23, 1996
	+	160MG	N20665 002 DEC 23, 1996

TABLET; ORAL

	DIOVAN		
	NOVARTIS	80MG	N21283 001 JUL 18, 2001
		160MG	N21283 002 JUL 18, 2001
	+	320MG	N21283 003 JUL 18, 2001

VALSARTAN; *MULTIPLE*

SEE HYDROCHLOROTHIAZIDE; VALSARTAN

VANCOMYCIN HYDROCHLORIDE

CAPSULE; ORAL

	VANCOCIN HCL		
	LILLY	EQ 125MG BASE	N50606 001 APR 15, 1986
	+	EQ 250MG BASE	N50606 002 APR 15, 1986

FOR SOLUTION; ORAL

	VANCOCIN HCL		
AA	LILLY	**EQ 250MG BASE/5ML**	**N61667 002** JUL 13, 1983
	+	EQ 500MG BASE/6ML	N61667 001
	VANCOLED		
AA	LEDERLE	**EQ 250MG BASE/5ML**	**N63321 002** OCT 15, 1993

INJECTABLE; INJECTION

	VANCOCIN HCL			
AP	+ LILLY	**EQ 500MG BASE/VIAL**	**N60180 001**	
AP		**EQ 500MG BASE/VIAL**	**N62476 001**	MAR 15, 1984
AP		**EQ 500MG BASE/VIAL**	**N62716 001**	MAR 13, 1987
AP		**EQ 500MG BASE/VIAL**	**N62812 001**	NOV 17, 1987
AP	+	**EQ 1GM BASE/VIAL**	**N60180 002**	MAR 21, 1986
AP		**EQ 1GM BASE/VIAL**	**N62476 002**	MAR 21, 1986
AP		**EQ 1GM BASE/VIAL**	**N62716 002**	MAR 13, 1987
AP		**EQ 1GM BASE/VIAL**	**N62812 002**	NOV 17, 1987
AP	+	**EQ 10GM BASE/VIAL**	**N62812 003**	NOV 17, 1987
	VANCOCIN HCL IN PLASTIC CONTAINER			
	+ BAXTER HLTHCARE	EQ 500MG BASE/100ML	N50671 001	APR 29, 1993
	VANCOLED			
AP	+ LEDERLE	**EQ 500MG BASE/VIAL**	**N62682 001**	JUL 22, 1986
AP	+	**EQ 1GM BASE/VIAL**	**N62682 002**	MAR 30, 1988
AP	+	**EQ 5GM BASE/VIAL**	**N62682 004**	MAY 11, 1988
AP	+	**EQ 10GM BASE/VIAL**	**N62682 005**	MAY 11, 1988

FDA data supplied by DrugPatentWatch.com

VANCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

	VANCOLED			
+	LEDERLE	EQ 2GM BASE/VIAL		N62682 003
				MAY 11, 1988
	VANCOMYCIN HCL			
AP	ABBOTT	**EQ 1GM BASE/VIAL**		**N62912 001**
				AUG 04, 1988
AP		**EQ 1GM BASE/VIAL**		**N62933 001**
				OCT 29, 1992
AP		**EQ 5GM BASE/VIAL**		**N63076 001**
				DEC 21, 1990
AP		**EQ 500MG BASE/VIAL**		**N62911 001**
				AUG 04, 1988
AP		**EQ 500MG BASE/VIAL**		**N62931 001**
				OCT 29, 1992
AP	AM PHARM PARTNERS	**EQ 500MG BASE/VIAL**		**N62663 001**
				MAR 17, 1987
AP		**EQ 1GM BASE/VIAL**		**N62663 002**
				JUL 31, 1987
AP		**EQ 5GM BASE/VIAL**		**N62663 003**
				JUN 03, 1988
AP		**EQ 10GM BASE/VIAL**		**N62663 004**
				NOV 28, 1997

VECURONIUM BROMIDE

INJECTABLE; INJECTION

	NORCURON			
AP	+ ORGANON	**10MG/VIAL**		**N18776 002**
				APR 30, 1984
AP	+	**20MG/VIAL**		**N18776 003**
				JAN 03, 1992
	VECURONIUM BROMIDE			
AP	ABBOTT	**10MG/VIAL**		**N75164 001**
				OCT 21, 1999
AP		**20MG/VIAL**		**N75164 002**
				OCT 21, 1999
	+	4MG/VIAL		N75558 001
				SEP 11, 2001
AP	BEDFORD	**10MG/VIAL**		**N75549 001**
				JUN 13, 2000
AP		**20MG/VIAL**		**N75549 002**
				JUN 13, 2000
AP	ESI LEDERLE	**10MG/VIAL**		**N75218 001**
				AUG 23, 1999

VECURONIUM BROMIDE

INJECTABLE; INJECTION

	VECURONIUM BROMIDE			
AP	ESI LEDERLE	**20MG/VIAL**		**N75218 002**
				AUG 23, 1999
AP	GENSIA	**10MG/VIAL**		**N74688 001**
				AUG 25, 1999
AP		**20MG/VIAL**		**N74688 002**
				AUG 25, 1999
AP	STERIS	**10MG/VIAL**		**N74334 001**
				AUG 31, 1995
AP		**20MG/VIAL**		**N74334 002**
				AUG 31, 1995

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

	EFFEXOR XR		
+	WYETH AYERST	EQ 37.5MG BASE	N20699 001
			OCT 20, 1997
+		EQ 75MG BASE	N20699 002
			OCT 20, 1997
+		EQ 150MG BASE	N20699 004
			OCT 20, 1997

TABLET; ORAL

	EFFEXOR		
+	WYETH AYERST	EQ 25MG BASE	N20151 002
			DEC 28, 1993
		EQ 37.5MG BASE	N20151 006
			DEC 28, 1993
		EQ 50MG BASE	N20151 003
			DEC 28, 1993
		EQ 75MG BASE	N20151 004
			DEC 28, 1993
+		EQ 100MG BASE	N20151 005
			DEC 28, 1993

VERAPAMIL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

	VERAPAMIL HCL			
AB	MYLAN	**120MG**		**N75138 001**
				APR 20, 1999
AB		**180MG**		**N75138 002**
				APR 20, 1999

FDA data supplied by DrugPatentWatch.com

VERAPAMIL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

	VERAPAMIL HCL				
AB	MYLAN	240MG	N75138 003	APR 20, 1999	
	VERELAN				
AB	+ ELAN PHARM	120MG	N19614 001	MAY 29, 1990	
AB	+	180MG	N19614 003	JAN 09, 1992	
AB	+	240MG	N19614 002	MAY 29, 1990	
	+	360MG	N19614 004	MAY 10, 1996	
	VERELAN PM				
	+ ELAN PHARM	100MG	N20943 001	NOV 25, 1998	
	+	200MG	N20943 002	NOV 25, 1998	
	+	300MG	N20943 003	NOV 25, 1998	

INJECTABLE; INJECTION

	ISOPTIN				
AP	+ ABBOTT	2.5MG/ML	N18485 001		
	VERAPAMIL HCL				
AP	ABBOTT	2.5MG/ML	N70577 001	FEB 02, 1987	
AP		2.5MG/ML	N70737 001	MAY 06, 1987	
AP		2.5MG/ML	N70738 001	MAY 06, 1987	
AP		2.5MG/ML	N70739 001	MAY 06, 1987	
AP		2.5MG/ML	N70740 001	MAY 06, 1987	
AP		2.5MG/ML	N75136 001	OCT 20, 1998	
AP	BEDFORD	2.5MG/ML	N72888 001	JUL 28, 1995	
AP	INTL MEDICATION	2.5MG/ML	N70451 001	DEC 16, 1985	
AP	LUITPOLD	2.5MG/ML	N70225 001	NOV 12, 1985	
AP		2.5MG/ML	N70617 001	NOV 12, 1985	

VERAPAMIL HYDROCHLORIDE

TABLET; ORAL

	CALAN				
AB	GD SEARLE LLC	40MG	N18817 003	FEB 23, 1988	
AB		80MG	N18817 001	SEP 10, 1984	
AB		120MG	N18817 002	SEP 10, 1984	
	ISOPTIN				
AB	ABBOTT	40MG	N18593 003	NOV 23, 1987	
AB		80MG	N18593 001	MAR 08, 1982	
AB	+	120MG	N18593 002	MAR 08, 1982	
	VERAPAMIL HCL				
AB	DANBURY PHARMA	80MG	N70855 001	SEP 24, 1986	
AB		120MG	N70856 001	SEP 24, 1986	
AB	GENEVA PHARMS	40MG	N73168 001	JUL 31, 1992	
AB		80MG	N71423 001	MAY 24, 1988	
AB		120MG	N71424 001	MAY 25, 1988	
AB	LEDERLE	80MG	N71880 001	APR 05, 1988	
AB		120MG	N71881 001	APR 05, 1988	
AB	MUTUAL PHARM	80MG	N71488 001	JAN 13, 1988	
AB		120MG	N71489 001	JAN 13, 1988	
AB	MYLAN	80MG	N71482 001	FEB 15, 1989	
AB		120MG	N71483 001	FEB 15, 1989	
AB	PUREPAC PHARM	80MG	N71019 001	SEP 24, 1986	
AB		120MG	N70468 001	SEP 24, 1986	
AB	SIDMAK LABS NJ	40MG	N72751 001	FEB 23, 1996	
AB		80MG	N72124 001	JAN 26, 1989	

FDA data supplied by DrugPatentWatch.com

VERAPAMIL HYDROCHLORIDE

TABLET; ORAL

VERAPAMIL HCL

AB	SIDMAK LABS NJ	**120MG**	**N72125 001**	JAN 26, 1989
AB	WATSON LABS	**40MG**	**N72923 001**	JUN 29, 1993
AB		**40MG**	**N72924 001**	JUN 29, 1993
AB		**80MG**	**N70995 001**	OCT 01, 1986
AB		**80MG**	**N71366 001**	OCT 01, 1986
AB		**120MG**	**N70994 001**	OCT 01, 1986
AB		**120MG**	**N71367 001**	OCT 01, 1986

TABLET, EXTENDED RELEASE; ORAL

COVERA-HS

BC	+ GD SEARLE LLC	180MG	N20552 001	FEB 26, 1996
BC	+	240MG	N20552 002	FEB 26, 1996

ISOPTIN SR

AB	+ ABBOTT	**120MG**	**N19152 003**	MAR 06, 1991
AB	+	**180MG**	**N19152 002**	DEC 15, 1989
AB	+	**240MG**	**N19152 001**	DEC 16, 1986

VERAPAMIL HCL

AB	IVAX PHARMS	**120MG**	**N73568 002**	OCT 10, 1997
AB		**180MG**	**N74330 001**	JAN 31, 1994
AB		**240MG**	**N73568 001**	JUL 31, 1992
AB	MYLAN	**120MG**	**N74587 002**	FEB 21, 1997
AB		**180MG**	**N74587 003**	SEP 09, 1997
AB		**240MG**	**N74587 001**	MAR 23, 1996
AB	SIDMAK LABS NJ	**240MG**	**N72922 001**	MAR 01, 1996

VERAPAMIL HYDROCHLORIDE; *MULTIPLE*

SEE TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE

VERTEPORFIN

INJECTABLE; INJECTION

VISUDYNE

	+ QLT	15MG/VIAL	N21119 001	APR 12, 2000

VIDARABINE

OINTMENT; OPHTHALMIC

VIRA-A

	+ PARKEDALE	3%	N50486 001	

VINBLASTINE SULFATE

INJECTABLE; INJECTION

VINBLASTINE SULFATE

	+ AM PHARM PARTNERS	1MG/ML	N89515 001	APR 29, 1987
AP	+ BEDFORD	**10MG/VIAL**	**N89395 001**	APR 09, 1987
AP	FAULDING	**10MG/VIAL**	**N89565 001**	AUG 18, 1987

VINCRISTINE SULFATE

INJECTABLE; INJECTION

ONCOVIN

AP	+ LILLY	**1MG/ML**	**N14103 003**	MAR 07, 1984

VINCASAR PFS

AP	PHARMACIA AND UPJOHN	**1MG/ML**	**N71426 001**	JUL 17, 1987

VINCRISTINE SULFATE PFS

AP	FAULDING	**1MG/ML**	**N71484 001**	APR 19, 1988
AP	GENSIA SICOR PHARMS	**1MG/ML**	**N75493 001**	SEP 01, 1999

VINORELBINE TARTRATE

INJECTABLE; INJECTION

NAVELBINE

	+ GLAXOSMITHKLINE	EQ 10MG BASE/ML	N20388 001	DEC 23, 1994

FDA data supplied by DrugPatentWatch.com

VITAMIN A

CAPSULE; ORAL
VITAMIN A
\+ WEST WARD 50,000 USP UNITS N80985 001

VITAMIN A; *MULTIPLE*
SEE ALPHA-TOCOPHEROL; ASCORBIC ACID; BIOTIN, D-; CHOLECALCIFEROL; CYANOCOBALAMIN; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A
SEE ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K
SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PHYTONADIONE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E
SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

VITAMIN A PALMITATE

CAPSULE; ORAL
VITAMIN A
AA MK LABS **EQ 50,000 UNITS BASE** **N83457 001**
EQ 25,000 UNITS BASE N83457 002
VITAMIN A PALMITATE
AA ARCUM **EQ 50,000 UNITS BASE** **N83311 001**
AA **EQ 50,000 UNITS BASE** **N83321 001**

INJECTABLE; INJECTION
AQUASOL A
\+ NEOSAN PHARMS EQ 50,000 UNITS BASE/ML N06823 001

VITAMIN A PALMITATE; *MULTIPLE*
SEE ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE

VITAMIN E; *MULTIPLE*
SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PHYTONADIONE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E
SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

VITAMIN K; *MULTIPLE*
SEE ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

WARFARIN SODIUM

INJECTABLE; INJECTION
COUMADIN
\+ BRISTOL MYERS SQUIBB 5MG/VIAL N09218 024
FEB 07, 1995

TABLET; ORAL
COUMADIN
AB BRISTOL MYERS SQUIBB **1MG** **N09218 022**
MAR 01, 1990
AB **2MG** **N09218 013**
AB **2.5MG** **N09218 018**
AB **3MG** **N09218 025**
NOV 18, 1996
AB **4MG** **N09218 023**
AUG 24, 1993
AB **5MG** **N09218 007**
AB **6MG** **N09218 026**
NOV 18, 1996
AB **7.5MG** **N09218 016**
AB \+ **10MG** **N09218 005**
WARFARIN SODIUM
AB BARR **1MG** **N40145 001**
MAR 26, 1997
AB **2MG** **N40145 002**
MAR 26, 1997
AB **2.5MG** **N40145 003**
MAR 26, 1997
AB **3MG** **N40145 008**
NOV 05, 1998

FDA data supplied by DrugPatentWatch.com

WARFARIN SODIUM

TABLET; ORAL
WARFARIN SODIUM

AB	BARR	4MG	N40145 004	MAR 26, 1997
AB		5MG	N40145 005	MAR 26, 1997
AB		6MG	N40145 009	NOV 05, 1998
AB		7.5MG	N40145 006	MAR 26, 1997
AB		10MG	N40145 007	MAR 26, 1997
AB	GENEVA PHARMS TECH	1MG	N40196 001	SEP 30, 1997
AB		2MG	N40196 002	SEP 30, 1997
AB		2.5MG	N40196 003	SEP 30, 1997
AB		3MG	N40196 008	JUL 26, 2000
AB		4MG	N40196 004	SEP 30, 1997
AB		5MG	N40196 005	SEP 30, 1997
AB		6MG	N40196 009	JUL 26, 2000
AB		7.5MG	N40196 006	SEP 30, 1997
AB		10MG	N40196 007	SEP 30, 1997
AB	TARO	1MG	N40301 002	JUL 15, 1999
AB		2MG	N40301 003	JUL 15, 1999
AB		2.5MG	N40301 004	JUL 15, 1999
AB		3MG	N40301 005	JUL 15, 1999
AB		4MG	N40301 006	JUL 15, 1999
AB		5MG	N40301 007	JUL 15, 1999
AB		6MG	N40301 008	JUL 15, 1999
AB		7.5MG	N40301 009	JUL 15, 1999

WARFARIN SODIUM

TABLET; ORAL
WARFARIN SODIUM

AB	TARO	10MG	N40301 001 JUL 15, 1999

WATER FOR INJECTION, STERILE

LIQUID; N/A
BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER

AP	ABBOTT	100%	N18802 001 OCT 27, 1982

STERILE WATER FOR INJECTION IN PLASTIC CONTAINER

AP	ABBOTT	100%	N18233 001
AP		100%	N18801 001 OCT 27, 1982
AP		100%	N19869 001 DEC 26, 1989
AP	AM PHARM PARTNERS	100%	N88400 001 JAN 16, 1984
AP	B BRAUN	100%	N19077 001 MAR 02, 1984
AP		100%	N19633 001 FEB 29, 1988
AP	BAXTER HLTHCARE	100%	N18632 001 JUN 30, 1982
AP		100%	N18632 002 APR 19, 1988

WATER FOR IRRIGATION, STERILE

LIQUID; IRRIGATION
STERILE WATER

AT	BAXTER HLTHCARE	100%	N17428 001

STERILE WATER IN PLASTIC CONTAINER

AT	ABBOTT	100%	N17513 001
AT		100%	N18313 001
AT	B BRAUN	100%	N16734 001
AT	BAXTER HLTHCARE	100%	N17866 001

XENON, XE-127

GAS; INHALATION
XENON XE 127

MALLINCKRODT	5mCi/VIAL	N18536 001 OCT 01, 1982

FDA data supplied by DrugPatentWatch.com

XENON, XE-127

GAS; INHALATION
XENON XE 127
MALLINCKRODT 10mCi/VIAL N18536 002 OCT 01, 1982

XENON, XE-133

GAS; INHALATION
XENON XE 133
AA BRISTOL MYERS SQUIBB **10mCi/VIAL** **N17284 001**
AA **20mCi/VIAL** **N17284 002**
GEN ELECTRIC 1-2.5 CI/AMP N17550 003
5 CI/CYLINDER N17550 001
AA MALLINCKRODT **10mCi/VIAL** **N18327 001** MAR 09, 1982
AA **20mCi/VIAL** **N18327 002** MAR 09, 1982

XYLOSE

POWDER; ORAL
XYLOSE
+ LYNE 25GM/BOT N18856 001 MAR 26, 1987

ZAFIRLUKAST

TABLET; ORAL
ACCOLATE
ASTRAZENECA 10MG N20547 003 SEP 17, 1999
+ 20MG N20547 001 SEP 26, 1996

ZALCITABINE

TABLET; ORAL
HIVID
ROCHE 0.375MG N20199 001 JUN 19, 1992
+ 0.75MG N20199 002 JUN 19, 1992

ZALEPLON

CAPSULE; ORAL
SONATA
WYETH AYERST 5MG N20859 001 AUG 13, 1999
+ 10MG N20859 002 AUG 13, 1999

ZANAMIVIR

CAPSULE; INHALATION
RELENZA
+ GLAXOSMITHKLINE 5MG N21036 001 JUL 26, 1999

ZIDOVUDINE

CAPSULE; ORAL
RETROVIR
+ GLAXOSMITHKLINE 100MG N19655 001 MAR 19, 1987

INJECTABLE; INJECTION
RETROVIR
+ GLAXOSMITHKLINE 10MG/ML N19951 001 FEB 02, 1990

SYRUP; ORAL
RETROVIR
GLAXOSMITHKLINE 50MG/5ML N19910 001 SEP 28, 1989

TABLET; ORAL
RETROVIR
+ GLAXOSMITHKLINE 300MG N20518 002 OCT 04, 1996

ZIDOVUDINE; *MULTIPLE*
SEE ABACAVIR SULFATE; LAMIVUDINE; ZIDOVUDINE
SEE LAMIVUDINE; ZIDOVUDINE

FDA data supplied by DrugPatentWatch.com

ZILEUTON

TABLET; ORAL
ZYFLO
ABBOTT 300MG N20471 001 DEC 09, 1996
\+ 600MG N20471 003 DEC 09, 1996

ZINC ACETATE

CAPSULE; ORAL
GALZIN
TEVA EQ 25MG ZINC N20458 001 JAN 28, 1997
\+ EQ 50MG ZINC N20458 002 JAN 28, 1997

ZINC CHLORIDE

INJECTABLE; INJECTION
ZINC CHLORIDE IN PLASTIC CONTAINER
\+ ABBOTT EQ 1MG ZINC/ML N18959 001 JUN 26, 1986

ZIPRASIDONE HYDROCHLORIDE

CAPSULE; ORAL
GEODON
PFIZER 20MG N20825 001 FEB 05, 2001
40MG N20825 002 FEB 05, 2001
60MG N20825 003 FEB 05, 2001
\+ 80MG N20825 004 FEB 05, 2001

ZOLEDRONIC ACID

INJECTABLE; IV (INFUSION)
ZOMETA
\+ NOVARTIS EQ 4MG BASE/VIAL N21223 001 AUG 20, 2001

ZOLMITRIPTAN

TABLET; ORAL
ZOMIG
IPR 2.5MG N20768 001 NOV 25, 1997
\+ 5MG N20768 002 NOV 25, 1997

TABLET, ORALLY DISINTEGRATING; ORAL
ZOMIG-ZMT
ASTRAZENECA 2.5MG N21231 001 FEB 13, 2001

ZOLPIDEM TARTRATE

TABLET; ORAL
AMBIEN
LOREX 5MG N19908 001 DEC 16, 1992
\+ 10MG N19908 002 DEC 16, 1992

ZONISAMIDE

CAPSULE; ORAL
ZONEGRAN
\+ DAINIPPON 100MG N20789 001 MAR 27, 2000

FDA data supplied by DrugPatentWatch.com

FDA data supplied by DrugPatentWatch.com

ACETAMINOPHEN

SUPPOSITORY; RECTAL

ACEPHEN			
G AND W LABS	120MG	N18060 001	
	120MG	N72218 001	MAR 27, 1992
	325MG	N18060 003	DEC 18, 1986
	325MG	N72344 001	MAR 27, 1992
	650MG	N18060 002	
	650MG	N72237 001	MAR 27, 1992
ACETAMINOPHEN			
ALPHARMA US PHARM	120MG	N18337 003	SEP 12, 1983
	325MG	N18337 002	
+	650MG	N18337 001	
SUPPOSITORIA	120MG	N70607 001	APR 06, 1987
	650MG	N70608 001	DEC 01, 1986
INFANTS' FEVERALL			
ALPHARMA US PHARM	80MG	N18337 004	AUG 26, 1992
NEOPAP			
POLYMEDICA	120MG	N16401 001	

TABLET, EXTENDED RELEASE; ORAL

ACETAMINOPHEN			
PERRIGO	650MG	N75077 001	FEB 25, 2000
TYLENOL			
+ MCNEIL	650MG	N19872 001	JUN 08, 1994

ACETAMINOPHEN; ASPIRIN; CAFFEINE

TABLET; ORAL

ACETAMINOPHEN, ASPIRIN AND CAFFEINE			
PERRIGO	250MG;250MG;65MG	N75794 001	NOV 26, 2001
EXCEDRIN (MIGRAINE)			
+ BRISTOL MYERS	250MG;250MG;65MG	N20802 001	JAN 14, 1998

ACETAMINOPHEN; CLEMASTINE FUMARATE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET; ORAL

TAVIST ALLERGY/SINUS/HEADACHE			
+ NOVARTIS	500MG;EQ 0.25MG BASE;30MG	N21082 001	MAR 01, 2001

ACETAMINOPHEN; DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

DRIXORAL PLUS			
+ SCHERING PLOUGH	500MG;3MG;60MG	N19453 001	MAY 22, 1987

ALCOHOL; CHLORHEXIDINE GLUCONATE

SOLUTION; TOPICAL

AVAGARD			
+ 3M	61%;1%	N21074 001	JUN 07, 2001

ALUMINUM HYDROXIDE; MAGNESIUM TRISILICATE

TABLET, CHEWABLE; ORAL

FOAMCOAT			
GUARDIAN DRUG	80MG;20MG	N71793 001	SEP 04, 1987
FOAMICON			
GENEVA PHARMS TECH	80MG;20MG	N72687 001	JUN 28, 1989
GAVISCON			
AVENTIS PHARMS	80MG;20MG	N18685 001	DEC 09, 1983
+	160MG;40MG	N18685 002	DEC 09, 1983

ANTAZOLINE PHOSPHATE; NAPHAZOLINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

VASOCON-A			
+ NOVARTIS	0.5%;0.05%	N18746 002	JUL 11, 1994

FDA data supplied by DrugPatentWatch.com

ASPIRIN

TABLET; ORAL
BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN
+ BAYER 500MG N21317 001
OCT 18, 2001

ASPIRIN; *MULTIPLE*
SEE ACETAMINOPHEN; ASPIRIN; CAFFEINE

AVOBENZONE; OCTYL METHOXYCINNAMATE; OXYBENZONE

LOTION; TOPICAL
SHADE UVAGUARD
+ SCHERING PLOUGH 3%;7.5%;3% N20045 001
DEC 07, 1992

BACITRACIN

OINTMENT; TOPICAL
BACITRACIN
+ NASKA 500 UNITS/GM N62857 001
NOV 13, 1987

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; TOPICAL
BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE
+ NASKA 400 UNITS/GM;EQ 3.5MG BASE/GM;
5,000 UNITS/GM N62833 001
NOV 09, 1987

BACITRACIN ZINC; POLYMYXIN B SULFATE

OINTMENT; TOPICAL
BACITRACIN ZINC-POLYMYXIN B SULFATE
+ NASKA 500 UNITS/GM;
10,000 UNITS/GM N62849 001
NOV 13, 1987

BENTOQUATAM

LOTION; TOPICAL
IVY BLOCK
+ ENVIRODERM 5% N20532 001
AUG 26, 1996

BROMPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

ELIXIR; ORAL
DIMETAPP
+ WHITEHALL ROBINS 2MG/5ML;12.5MG/5ML N13087 003
MAR 29, 1984

TABLET, EXTENDED RELEASE; ORAL
DIMETAPP
+ WHITEHALL ROBINS 12MG;75MG N12436 003
MAY 14, 1985

BROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
EFIDAC 24 PSEUDOEPHEDRINE HCL/BROMPHENIRAMINE MALEATE
+ ALZA 16MG;240MG N19672 001
MAR 29, 1996

BUTENAFINE HYDROCHLORIDE

CREAM; TOPICAL
LOTRIMIN ULTRA
+ SCHERING PLOUGH 1% N21307 001
DEC 07, 2001

BUTOCONAZOLE NITRATE

CREAM; VAGINAL
FEMSTAT 3
+ SYNTEX (USA) INC LLC 2% N20421 001
DEC 21, 1995

CAFFEINE; *MULTIPLE*
SEE ACETAMINOPHEN; ASPIRIN; CAFFEINE

FDA data supplied by DrugPatentWatch.com

CALCIUM CARBONATE, PRECIPITATED; FAMOTIDINE; MAGNESIUM HYDROXIDE

TABLET, CHEWABLE; ORAL
PEPCID COMPLETE
+ MERCK 800MG;10MG;165MG N20958 001 OCT 16, 2000

CHLORHEXIDINE GLUCONATE

AEROSOL, METERED; TOPICAL
EXIDINE
+ XTTRIUM 4% N19127 001 DEC 24, 1984

SOLUTION; TOPICAL
BRIAN CARE
SOAPCO 4% N71419 001 DEC 17, 1987

CHG SCRUB
ECOLAB 4% N19258 002 JUL 22, 1986

CIDA-STAT
ECOLAB 2% N19258 001 JUL 22, 1986

DYNA-HEX
XTTRIUM 0.75% N20111 001 SEP 11, 1997

EXIDINE
+ XTTRIUM 2% N19422 001 DEC 17, 1985
4% N19125 001 DEC 24, 1984

HIBICLENS
+ SSL INTL 4% N17768 001

HIBISTAT
+ SSL INTL 0.5% N18300 001

MICRODERM
J AND J 4% N72255 001 APR 15, 1991

PREVACARE R
J AND J 0.5% N72292 001 JAN 28, 1992

STERI-STAT
MATRIX MEDCL 4% N70104 001 JUL 24, 1986

SPONGE; TOPICAL
BIOSCRUB
GRIFFEN 4% N19822 001 MAR 31, 1989

CHLORHEXIDINE GLUCONATE

SPONGE; TOPICAL
CHLORHEXIDINE GLUCONATE
DESERET 4% N72525 001 OCT 24, 1989
KENDALL IL 4% N19490 001 MAR 27, 1987

E-Z SCRUB
BECTON DICKINSON 4% N73416 001 MAR 14, 2000

HIBICLENS
+ SSL INTL 4% N18423 001

MICRODERM
J AND J 4% N72295 001 FEB 28, 1991

PHARMASEAL SCRUB CARE
PHARMASEAL 4% N19793 001 DEC 02, 1988

CHLORHEXIDINE GLUCONATE; *MULTIPLE*
SEE ALCOHOL; CHLORHEXIDINE GLUCONATE

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SPONGE; TOPICAL
CHLORAPREP
+ MEDI FLEX HOSP 2%;70% N20832 001 JUL 14, 2000

CHLORPHENIRAMINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL
CHLORPHENIRAMINE MALEATE
+ GENEVA PHARMS 12MG N70797 001 AUG 12, 1988

TABLET, EXTENDED RELEASE; ORAL
CHLOR-TRIMETON
+ SCHERING PLOUGH 8MG N07638 001
+ 12MG N07638 002

EFIDAC 24 CHLORPHENIRAMINE MALEATE
ALZA 16MG N19746 002 NOV 18, 1994

FDA data supplied by DrugPatentWatch.com

CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

CONTAC			
+ GLAXOSMITHKLINE	8MG;75MG	N18099 001	
PHENYLPROPANOLAMINE HCL W/ CHLORPHENIRAMINE MALEATE			
+ CENT PHARMS	8MG;75MG	N18809 001	MAY 07, 1984

TABLET, EXTENDED RELEASE; ORAL

CONTAC			
+ NOVARTIS	12MG;75MG	N19613 001	JUN 13, 1986
DEMAZIN			
+ SCHERING PLOUGH	4MG;25MG	N18556 001	MAY 14, 1984

CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

PSEUDOEPHEDRINE HCL AND CHLORPHENIRAMINE MALEATE			
+ CENT PHARMS	8MG;120MG	N19428 001	AUG 02, 1988

CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

CHLOR-TRIMETON		
+ SCHERING PLOUGH	8MG;120MG	N18397 001

CIMETIDINE

SUSPENSION; ORAL

TAGAMET HB 200			
+ GLAXOSMITHKLINE	200MG/20ML	N20951 001	JUL 09, 1999

TABLET; ORAL

CIMETIDINE			
DANBURY PHARMA	200MG	N75425 001	JUL 29, 1999
IVAX PHARMS	200MG	N75345 001	JUN 16, 1999
LEINER	200MG	N74961 001	JUN 19, 1998

CIMETIDINE

TABLET; ORAL

CIMETIDINE			
LEK PHARM	100MG	N75122 001	JUN 19, 1998
	200MG	N75122 002	JUN 19, 1998
PERRIGO	200MG	N75285 001	OCT 29, 1998
PHARM FORM	200MG	N74963 001	JUN 19, 1998
TORPHARM	100MG	N74948 001	JUN 19, 1998
TAGAMET HB			
+ GLAXOSMITHKLINE	200MG	N20238 002	AUG 21, 1996

CLEMASTINE FUMARATE

TABLET; ORAL

CLEMASTINE FUMARATE			
GENEVA PHARMS	1.34MG	N73458 001	OCT 31, 1993
PERRIGO	1.34MG	N74512 001	NOV 22, 1995
TEVA	1.34MG	N73282 002	DEC 03, 1992
TAVIST-1			
+ NOVARTIS	1.34MG	N20925 001	AUG 21, 1992

CLEMASTINE FUMARATE; *MULTIPLE*

SEE ACETAMINOPHEN; CLEMASTINE FUMARATE; PSEUDOEPHEDRINE HYDROCHLORIDE

CLOTRIMAZOLE

CREAM; TOPICAL

CLOTRIMAZOLE			
TARO	1%	N72640 002	AUG 31, 1993
LOTRIMIN AF			
+ SCHERING PLOUGH	1%	N20888 001	OCT 27, 1989

FDA data supplied by DrugPatentWatch.com

CLOTRIMAZOLE

CREAM; TOPICAL

MYCELEX			
BAYER	1%	N18183 002	APR 01, 1991

CREAM; VAGINAL

CLOTRIMAZOLE			
NMC	1%	N74165 001	JUL 16, 1993
TARO	1%	N72641 001	DEC 04, 1995
GYNE-LOTRIMIN			
+ SCHERING PLOUGH	1%	N18052 002	NOV 30, 1990
GYNE-LOTRIMIN 3			
+ SCHERING PLOUGH	2%	N20574 001	NOV 24, 1998
MYCELEX-7			
BAYER	1%	N18230 002	DEC 26, 1991
TRIVAGIZOLE 3			
TARO	2%	N21143 001	APR 12, 2000

CREAM, TABLET; TOPICAL, VAGINAL

GYNE-LOTRIMIN 3 COMBINATION PACK			
+ SCHERING PLOUGH	1%,200MG	N20526 002	JUL 29, 1996
GYNE-LOTRIMIN COMBINATION PACK			
+ SCHERING PLOUGH	1%,100MG	N20289 002	APR 26, 1993
MYCELEX-7 COMBINATION PACK			
BAYER	1%,100MG	N20389 002	JUN 23, 1994

LOTION; TOPICAL

LOTRIMIN AF			
+ SCHERING PLOUGH	1%	N20889 001	OCT 27, 1989

SOLUTION; TOPICAL

LOTRIMIN AF			
+ SCHERING PLOUGH	1%	N20890 001	OCT 27, 1989
MYCELEX			
BAYER	1%	N18181 002	APR 01, 1991

CLOTRIMAZOLE

TABLET; VAGINAL

GYNE-LOTRIMIN			
+ SCHERING PLOUGH	100MG	N17717 002	NOV 30, 1990
GYNE-LOTRIMIN 3			
+ SCHERING PLOUGH	200MG	N20525 001	JUL 29, 1996
GYNIX			
COPLEY PHARM	100MG	N73249 001	FEB 13, 1998
MYCELEX-7			
BAYER	100MG	N18182 002	DEC 26, 1991

CROMOLYN SODIUM

SPRAY, METERED; NASAL

CROMOLYN SODIUM			
ALPHARMA	5.2MG/INH	N74800 001	JUL 26, 2001
BAUSCH AND LOMB	5.2MG/SPRAY	N75702 001	JUL 03, 2001
PERRIGO	5.2MG/SPRAY	N75427 001	DEC 12, 2001
NASALCROM			
+ PHARMACIA UPJOHN	5.2MG/SPRAY	N20463 001	JAN 03, 1997

DEXBROMPHENIRAMINE MALEATE; *MULTIPLE*

SEE ACETAMINOPHEN; DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

BROMPHERIL			
COPLEY PHARM	6MG;120MG	N89116 001	JAN 22, 1987
DISOPHROL			
SCHERING PLOUGH	6MG;120MG	N13483 004	SEP 13, 1982
DRIXORAL			
+ SCHERING PLOUGH	6MG;120MG	N13483 003	SEP 13, 1982

FDA data supplied by DrugPatentWatch.com

DEXTROMETHORPHAN POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL

DELSYM			
+ CELLTECH PHARMS	EQ 30MG HBR/5ML	N18658 001	OCT 08, 1982

DOCOSANOL

CREAM; TOPICAL

ABREVA			
+ GLAXOSMITHKLINE	10%	N20941 001	JUL 25, 2000

DOXYLAMINE SUCCINATE

TABLET; ORAL

DOXYLAMINE SUCCINATE			
COPLEY PHARM	25MG	N88900 002	FEB 12, 1988
PERRIGO	25MG	N40167 001	SEP 18, 1996
UNISOM			
+ PFIZER	25MG	N18066 001	

EPINEPHRINE

AEROSOL, METERED; INHALATION

BRONKAID MIST			
+ STERLING	0.25MG/INH	N16803 001	
EPINEPHRINE			
ALPHARMA	0.2MG/INH	N87907 001	MAY 23, 1984
PRIMATENE MIST			
+ WHITEHALL ROBINS	0.2MG/INH	N16126 001	

EPINEPHRINE BITARTRATE

AEROSOL, METERED; INHALATION

BRONITIN MIST			
WHITEHALL ROBINS	0.3MG/INH	N16126 002	

FAMOTIDINE

TABLET; ORAL

FAMOTIDINE			
DANBURY PHARMA	10MG	N75404 001	NOV 28, 2001
DR REDDYS LABS LTD	10MG	N75758 001	AUG 17, 2001
GENPHARM	10MG	N75674 001	DEC 21, 2001
IVAX PHARMS	10MG	N75512 001	JUL 26, 2001
TEVA	10MG	N75312 001	MAY 31, 2001
PEPCID AC			
+ MERCK	10MG	N20325 001	APR 28, 1995
	10MG	N20902 001	AUG 05, 1999

TABLET, CHEWABLE; ORAL

PEPCID AC			
+ MERCK	10MG	N20801 001	SEP 24, 1998

FAMOTIDINE; *MULTIPLE*

SEE CALCIUM CARBONATE, PRECIPITATED; FAMOTIDINE; MAGNESIUM HYDROXIDE

IBUPROFEN

CAPSULE; ORAL

IBUPROFEN			
+ PHARM FORM	200MG	N74782 001	JUL 06, 1998

SUSPENSION; ORAL

CHILDREN'S ADVIL			
WHITEHALL ROBINS	100MG/5ML	N20589 001	JUN 27, 1996
CHILDREN'S ADVIL-FLAVORED			
WHITEHALL ROBINS	100MG/5ML	N20589 002	NOV 07, 1997
CHILDREN'S IBUPROFEN			
PERRIGO	100MG/5ML	N74937 001	DEC 22, 1998

FDA data supplied by DrugPatentWatch.com

IBUPROFEN

SUSPENSION; ORAL		
CHILDREN'S MOTRIN		
+ MCNEIL	100MG/5ML	N20516 001 JUN 16, 1995
IBUPROFEN		
ALPHARMA	100MG/5ML	N74916 001 APR 30, 1999
SUSPENSION/DROPS; ORAL		
CHILDREN'S MOTRIN		
+ MCNEIL	40MG/ML	N20603 001 JUN 10, 1996
IBUPROFEN		
PERRIGO	40MG/ML	N75217 001 DEC 16, 1998
PEDIATRIC ADVIL		
+ WHITEHALL ROBINS	100MG/2.5ML	N20812 001 JAN 30, 1998
TABLET; ORAL		
ADVIL		
WHITEHALL LABS	200MG	N18989 001 MAY 18, 1984
CAP-PROFEN		
PERRIGO	200MG	N72097 001 DEC 08, 1987
IBU-TAB 200		
ALRA	200MG	N71057 001 AUG 11, 1988
IBUPROFEN		
BASF	200MG	N75661 001 DEC 12, 2001
DANBURY PHARMA	200MG	N70435 001 MAR 05, 1986
DR REDDYS LABS INC	100MG	N76117 001 NOV 20, 2001
GENEVA PHARMS	200MG	N70733 001 SEP 19, 1986
INTERPHARM	200MG	N71333 001 FEB 17, 1987
	200MG	N72199 001 MAY 23, 1988
INVAMED	200MG	N71807 001 FEB 25, 1988
	200MG	N74525 001 DEC 15, 1995

IBUPROFEN

TABLET; ORAL		
IBUPROFEN		
INVAMED	200MG	N74533 001 DEC 15, 1995
IVAX PHARMS	200MG	N71144 001 JAN 20, 1987
	200MG	N72901 001 DEC 19, 1991
	200MG	N72903 001 DEC 19, 1991
LEINER	200MG	N74931 001 JUL 20, 1998
LNK	200MG	N75010 001 MAR 01, 1999
	200MG	N75139 001 MAR 01, 1999
MCNEIL	200MG	N73019 001 MAR 30, 1994
MUTUAL PHARM	200MG	N71229 001 APR 01, 1987
	200MG	N72249 001 JAN 10, 1989
MYLAN	200MG	N71870 001 MAY 05, 1988
OHM	200MG	N71163 001 JUL 15, 1986
PAR PHARM	200MG	N70481 001 SEP 24, 1986
	200MG	N70985 001 OCT 02, 1987
	200MG	N71575 001 MAY 08, 1987
PERRIGO	200MG	N72096 001 DEC 08, 1987
	200MG	N72098 001 DEC 08, 1987
PVT FORM	200MG	N71732 001 SEP 10, 1987
	200MG	N71735 001 SEP 10, 1987
	200MG	N72299 001 JUL 01, 1988
	200MG	N73691 001 FEB 25, 1994
VINTAGE PHARMS	200MG	N71639 001 FEB 02, 1988

FDA data supplied by DrugPatentWatch.com

IBUPROFEN

TABLET; ORAL

IBUPROHM			
OHM LABS	200MG	N71214 001	DEC 01, 1986
JUNIOR STRENGTH ADVIL			
WHITEHALL ROBINS	100MG	N20267 002	DEC 13, 1996
JUNIOR STRENGTH IBUPROFEN			
PERRIGO	100MG	N75367 001	APR 22, 1999
JUNIOR STRENGTH MOTRIN			
+ MCNEIL	100MG	N20602 001	JUN 10, 1996
MEDIPREN			
MCNEIL	200MG	N70475 001	FEB 06, 1986
	200MG	N71215 001	JUN 26, 1986
MOTRIN IB			
+ MCNEIL	200MG	N19012 003	DEC 17, 1990
MOTRIN MIGRAINE PAIN			
+ MCNEIL	200MG	N19012 004	FEB 25, 2000
PROFEN			
PVT FORM	200MG	N71265 001	OCT 15, 1986
TAB-PROFEN			
PERRIGO	200MG	N72095 001	DEC 08, 1987

TABLET, CHEWABLE; ORAL

CHILDREN'S ADVIL			
WHITEHALL ROBINS	50MG	N20944 001	DEC 18, 1998
CHILDREN'S MOTRIN			
MCNEIL	50MG	N20601 001	NOV 15, 1996
JUNIOR STRENGTH ADVIL			
WHITEHALL ROBINS	100MG	N20944 002	DEC 18, 1998
JUNIOR STRENGTH MOTRIN			
+ MCNEIL	100MG	N20601 003	NOV 15, 1996

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

SUSPENSION; ORAL

CHILDREN'S MOTRIN COLD			
+ MCNEIL CONS	100MG/5ML;15MG/5ML	N21128 001	AUG 01, 2000

TABLET; ORAL

ADVIL COLD AND SINUS			
+ WHITEHALL LABS	200MG;30MG	N19771 001	SEP 19, 1989
IBUPROHM COLD AND SINUS			
OHM LABS	200MG;30MG	N74567 001	APR 17, 2001
SINE-AID IB			
MCNEIL	200MG;30MG	N19899 001	DEC 31, 1992

IBUPROFEN POTASSIUM

CAPSULE; ORAL

ADVIL LIQUI-GELS			
+ WHITEHALL ROBINS	200MG	N20402 001	APR 20, 1995
ADVIL MIGRAINE LIQUI-GELS			
+ WHITEHALL ROBINS	200MG	N20402 002	MAR 16, 2000

INSULIN PURIFIED PORK

INJECTABLE; INJECTION

REGULAR ILETIN II (PORK)			
+ LILLY	100 UNITS/ML	N18344 001	
REGULAR PURIFIED PORK INSULIN			
+ NOVO NORDISK	100 UNITS/ML	N18381 001	

INSULIN RECOMBINANT HUMAN

INJECTABLE; INJECTION

HUMULIN R			
+ LILLY	100 UNITS/ML	N18780 001	OCT 28, 1982
HUMULIN R PEN			
+ LILLY	100 UNITS/ML	N18780 005	AUG 06, 1998

FDA data supplied by DrugPatentWatch.com

INSULIN RECOMBINANT HUMAN

INJECTABLE; INJECTION
NOVOLIN R
+ NOVO NORDISK 100 UNITS/ML N19938 001 JUN 25, 1991

INSULIN RECOMBINANT HUMAN; INSULIN SUSP ISOPHANE RECOMBINANT HUMAN

INJECTABLE; INJECTION
HUMULIN 50/50
+ LILLY 50 UNITS/ML;50 UNITS/ML N20100 001 APR 29, 1992

HUMULIN 70/30
+ LILLY 30 UNITS/ML;70 UNITS/ML N19717 001 APR 25, 1989

HUMULIN 70/30 PEN
+ LILLY 30 UNITS/ML;70 UNITS/ML N19717 002 AUG 06, 1998

NOVOLIN 70/30
+ NOVO NORDISK 30 UNITS/ML;70 UNITS/ML N19991 001 JUN 25, 1991

INSULIN SUSP ISOPHANE BEEF

INJECTABLE; INJECTION
NPH INSULIN
+ NOVO NORDISK 100 UNITS/ML N17929 003

INSULIN SUSP ISOPHANE BEEF/PORK

INJECTABLE; INJECTION
NPH ILETIN I (BEEF-PORK)
+ LILLY 100 UNITS/ML N17936 002

INSULIN SUSP ISOPHANE PURIFIED PORK

INJECTABLE; INJECTION
NPH ILETIN II (PORK)
+ LILLY 100 UNITS/ML N18345 001

NPH PURIFIED PORK ISOPHANE INSULIN
+ NOVO NORDISK 100 UNITS/ML N18623 001

INSULIN SUSP ISOPHANE RECOMBINANT HUMAN

INJECTABLE; INJECTION
HUMULIN N
+ LILLY 100 UNITS/ML N18781 001 OCT 28, 1982

NOVOLIN N
NOVO NORDISK 100 UNITS/ML N19959 001 JUL 01, 1991

INSULIN SUSP ISOPHANE RECOMBINANT HUMAN; *MULTIPLE*
SEE INSULIN RECOMBINANT HUMAN; INSULIN SUSP ISOPHANE RECOMBINANT HUMAN

INSULIN ZINC SUSP EXTENDED RECOMBINANT HUMAN

INJECTABLE; INJECTION
HUMULIN U
+ LILLY 100 UNITS/ML N19571 002 JUN 10, 1987

INSULIN ZINC SUSP PURIFIED PORK

INJECTABLE; INJECTION
LENTE
NOVO NORDISK 100 UNITS/ML N18383 001

LENTE ILETIN II (PORK)
+ LILLY 100 UNITS/ML N18347 001

INSULIN ZINC SUSP RECOMBINANT HUMAN

INJECTABLE; INJECTION
HUMULIN L
+ LILLY 100 UNITS/ML N19377 002 SEP 30, 1985

NOVOLIN L
NOVO NORDISK 100 UNITS/ML N19965 001 JUN 25, 1991

ISOPROPYL ALCOHOL; *MULTIPLE*
SEE CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

FDA data supplied by DrugPatentWatch.com

KETOCONAZOLE

SHAMPOO; TOPICAL			
NIZORAL A-D			
+ MCNEIL CONS	1%	N20310 001	OCT 10, 1997

KETOPROFEN

TABLET; ORAL			
ACTRON			
BAYER	12.5MG	N20499 001	OCT 06, 1995
ORUDIS KT			
+ WHITEHALL ROBINS	12.5MG	N20429 001	OCT 06, 1995

LOPERAMIDE HYDROCHLORIDE

SOLUTION; ORAL			
IMODIUM A-D			
+ MCNEIL	1MG/5ML	N19487 001	MAR 01, 1988
LOPERAMIDE HCL			
DURAMED	1MG/5ML	N74991 001	DEC 29, 1997
HI TECH PHARMA	1MG/5ML	N74352 001	NOV 17, 1995
MORTON GROVE	1MG/5ML	N74730 001	AUG 28, 1997
PERRIGO	1MG/5ML	N73243 001	JAN 21, 1992
ROXANE	1MG/5ML	N73079 001	APR 30, 1992
TEVA	1MG/5ML	N73478 001	JUN 23, 1995
TABLET; ORAL			
IMODIUM A-D			
+ MCNEIL	2MG	N19860 001	NOV 22, 1989
LOPERAMIDE HCL			
LEINER	2MG	N73254 001	JUL 30, 1993
OHM LABS	2MG	N74091 001	DEC 10, 1992

LOPERAMIDE HYDROCHLORIDE

TABLET; ORAL			
LOPERAMIDE HCL			
PERRIGO	2MG	N74194 001	OCT 30, 1992
	2MG	N75232 001	JAN 06, 2000
TABLET, CHEWABLE; ORAL			
IMODIUM A-D			
+ MCNEIL	2MG	N20448 001	JUL 24, 1997

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

TABLET; ORAL			
IMODIUM ADVANCED			
MCNEIL CONS	2MG;125MG	N21140 001	NOV 30, 2000
TABLET, CHEWABLE; ORAL			
IMODIUM ADVANCED			
+ MCNEIL	2MG;125MG	N20606 001	JUN 26, 1996

MAGNESIUM HYDROXIDE; *MULTIPLE*

SEE CALCIUM CARBONATE, PRECIPITATED; FAMOTIDINE; MAGNESIUM HYDROXIDE

MAGNESIUM TRISILICATE; *MULTIPLE*

SEE ALUMINUM HYDROXIDE; MAGNESIUM TRISILICATE

MICONAZOLE NITRATE

CREAM; TOPICAL, VAGINAL			
MONISTAT 3 COMBINATION PACK			
+ PERSONAL PRODS	2%,4%	N21261 001	FEB 02, 2001
CREAM; VAGINAL			
MICONAZOLE 7			
ALPHARMA US PHARM	2%	N74164 001	MAR 29, 1996

FDA data supplied by DrugPatentWatch.com

MICONAZOLE NITRATE

CREAM; VAGINAL

MICONAZOLE NITRATE			
COPLEY PHARM	2%	N74030 001	OCT 30, 1992
G AND W LABS	2%	N74366 001	FEB 22, 1996
PERRIGO	2%	N74760 001	MAY 15, 1997
TARO	2%	N74444 001	JAN 13, 1997
TEVA	2%	N74136 001	JAN 04, 1995
MONISTAT 3			
+ ADVANCED CARE PRODS	4%	N20827 001	MAR 30, 1998
MONISTAT 7			
+ ADV CARE	2%	N17450 002	FEB 15, 1991

CREAM, SUPPOSITORY; TOPICAL, VAGINAL

M-ZOLE 3 COMBINATION PACK			
ALPHARMA US PHARM	2%,200MG	N74926 001	APR 16, 1999
M-ZOLE 7 DUAL PACK			
ALPHARMA	2%,100MG	N74586 001	JUL 17, 1997
MICONAZOLE NITRATE COMBINATION PACK			
PERRIGO	2%,200MG	N75329 001	APR 20, 1999
MONISTAT 7 COMBINATION PACK			
+ ADV CARE	2%,100MG	N20288 002	APR 26, 1993
MONISTAT-3 COMBINATION PACK			
+ ADV CARE	2%,200MG	N20670 002	APR 16, 1996

SUPPOSITORY; VAGINAL

MICONAZOLE NITRATE			
ALPHARMA US PHARM	100MG	N73507 001	NOV 19, 1993
G AND W LABS	100MG	N74414 001	APR 30, 1997
+ PERRIGO	100MG	N74395 001	MAR 20, 1997
MONISTAT 7			
+ ADVANCED CARE PRODS	100MG	N18520 002	FEB 15, 1991

MINOXIDIL

SOLUTION; TOPICAL

MINOXIDIL (FOR MEN)			
ALPHARMA	2%	N74588 001	APR 05, 1996
BAUSCH AND LOMB	2%	N74643 001	APR 09, 1996
COPLEY PHARM	2%	N74500 001	MAY 23, 1996
HI TECH PHARMA	2%	N74731 001	DEC 24, 1996
MORTON GROVE	2%	N74767 001	FEB 28, 1997
NOVEX	2%	N74924 001	APR 29, 1998
PERRIGO	2%	N75357 001	JUL 30, 1999
SIGHT PHARMS	2%	N74743 002	OCT 18, 1996
TEVA	2%	N74589 001	APR 05, 1996
MINOXIDIL (FOR WOMEN)			
NOVEX	2%	N74924 002	APR 29, 1998
PERRIGO	2%	N75357 002	JUL 30, 1999
SIGHT PHARMS	2%	N74743 001	OCT 18, 1996
MINOXIDIL EXTRA STRENGTH (FOR MEN)			
ALPHARMA	5%	N75518 001	NOV 17, 2000
PERRIGO	5%	N75598 001	JUN 13, 2001
TEVA	5%	N75619 001	NOV 17, 2000
MINOXIDIL EXTRA STRENGTH FOR MEN			
NOVEX	5%	N75839 001	OCT 01, 2001
ROGAINE (FOR MEN)			
+ PHARMACIA AND UPJOHN	2%	N19501 002	FEB 09, 1996
ROGAINE (FOR WOMEN)			
+ PHARMACIA AND UPJOHN	2%	N19501 003	FEB 09, 1996
ROGAINE EXTRA STRENGTH (FOR MEN)			
+ PHARMACIA AND UPJOHN	5%	N20834 001	NOV 14, 1997

FDA data supplied by DrugPatentWatch.com

NAPHAZOLINE HYDROCHLORIDE; *MULTIPLE*
SEE ANTAZOLINE PHOSPHATE; NAPHAZOLINE HYDROCHLORIDE

NAPHAZOLINE HYDROCHLORIDE; PHENIRAMINE MALEATE

SOLUTION/DROPS; OPHTHALMIC

NAPHCON-A			
+ ALCON	0.025%;0.3%	N20226 001	JUN 08, 1994
OPCON-A			
+ BAUSCH AND LOMB	0.02675%;0.315%	N20065 001	JUN 08, 1994
VISINE-A			
PFIZER	0.025%;0.3%	N20485 001	JAN 31, 1996

NAPROXEN SODIUM

TABLET; ORAL

ALEVE			
+ BAYER	EQ 200MG BASE	N20204 002	JAN 11, 1994
NAPROXEN SODIUM			
INVAMED	EQ 200MG BASE	N74646 001	JAN 13, 1997
LEINER	EQ 200MG BASE	N74635 001	JAN 13, 1997
PAR PHARM	EQ 200MG BASE	N75168 001	JUL 28, 1998
PERRIGO	EQ 200MG BASE	N74661 001	JAN 13, 1997
PVT FORM	EQ 200MG BASE	N74789 001	FEB 27, 1997

NAPROXEN SODIUM; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

ALEVE COLD AND SINUS			
+ BAYER	EQ 200MG BASE;120MG	N21076 001	NOV 29, 1999

NEOMYCIN SULFATE; *MULTIPLE*
SEE BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

NICOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL

HABITROL			
+ NOVARTIS	7MG/24HR	N20076 004	NOV 12, 1999
+	14MG/24HR	N20076 005	NOV 12, 1999
+	21MG/24HR	N20076 006	NOV 12, 1999
NICODERM CQ			
+ AVENTIS PHARMS	7MG/24HR	N20165 006	AUG 02, 1996
+	14MG/24HR	N20165 005	AUG 02, 1996
+	21MG/24HR	N20165 004	AUG 02, 1996
NICOTROL			
+ PHARMACIA AND UPJOHN	15MG/16HR	N20536 001	JUL 03, 1996
PROSTEP			
+ ELAN PHARM	11MG/24HR	N19983 003	DEC 23, 1998
+	22MG/24HR	N19983 004	DEC 23, 1998

NICOTINE POLACRILEX

GUM, CHEWING; BUCCAL

NICORETTE			
+ GLAXOSMITHKLINE	EQ 2MG BASE	N18612 002	FEB 09, 1996
+	EQ 4MG BASE	N20066 002	FEB 09, 1996
NICORETTE (ORANGE)			
+ GLAXOSMITHKLINE	EQ 4MG BASE	N20066 004	SEP 25, 2000
NICORETTE (MINT)			
+ GLAXOSMITHKLINE	EQ 2MG BASE	N18612 003	DEC 23, 1998
+	EQ 4MG BASE	N20066 003	DEC 23, 1998
NICORETTE (ORANGE)			
+ GLAXOSMITHKLINE	EQ 2MG BASE	N18612 004	SEP 25, 2000
NICOTINE POLACRILEX			
WATSON LAB	EQ 2MG BASE	N74507 001	MAR 15, 1999

FDA data supplied by DrugPatentWatch.com

NICOTINE POLACRILEX

GUM, CHEWING; BUCCAL
NICOTINE POLACRILEX
WATSON LAB EQ 4MG BASE N74707 001 MAR 19, 1999

NIZATIDINE

TABLET; ORAL
AXID AR
+ WHITEHALL ROBINS 75MG N20555 001 MAY 09, 1996

OCTYL METHOXYCINNAMATE; *MULTIPLE*
SEE AVOBENZONE; OCTYL METHOXYCINNAMATE; OXYBENZONE

OXYBENZONE; *MULTIPLE*
SEE AVOBENZONE; OCTYL METHOXYCINNAMATE; OXYBENZONE

OXYMETAZOLINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
OCUCLEAR
SCHERING PLOUGH 0.025% N18471 001 MAY 30, 1986

VISINE L.R.
+ PFIZER 0.025% N19407 001 MAR 31, 1989

PERMETHRIN

LOTION; TOPICAL
NIX
+ WARNER LAMBERT 1% N19918 001 MAY 02, 1990

PERMETHRIN
ALPHARMA 1% N75014 001 MAR 28, 2000

CLAY PARK 1% N76090 001 DEC 20, 2001

PHENIRAMINE MALEATE; *MULTIPLE*
SEE NAPHAZOLINE HYDROCHLORIDE; PHENIRAMINE MALEATE

PHENYLPROPANOLAMINE HYDROCHLORIDE; *MULTIPLE*
SEE BROMPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE
SEE CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

PIPERONYL BUTOXIDE; PYRETHRINS

AEROSOL; TOPICAL
RID MOUSSE
+ PFIZER 4%;EQ 0.33% BASE N21043 001 MAR 07, 2000

POLYMYXIN B SULFATE; *MULTIPLE*
SEE BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SEE BACITRACIN ZINC; POLYMYXIN B SULFATE

POTASSIUM IODIDE

TABLET; ORAL
IOSAT
ANBEX 130MG N18664 001 OCT 14, 1982

THYRO-BLOCK
+ WALLACE LABS 130MG N18307 001

POVIDONE-IODINE

SOLUTION; TOPICAL
E-Z PREP
+ BECTON DICKINSON 10% N19382 001 JUL 25, 1989

POVIDONE IODINE
+ ALLEGIANCE HLTHCARE 1% N19522 001 MAR 31, 1989

SPONGE; TOPICAL
E-Z PREP
+ BECTON DICKINSON 5% N19382 002 JUL 25, 1989

E-Z PREP 220
+ BECTON DICKINSON 5% N19382 003 JUL 25, 1989

E-Z SCRUB 201
+ BECTON DICKINSON 20% N19240 001 NOV 29, 1985

FDA data supplied by DrugPatentWatch.com

POVIDONE-IODINE

SPONGE; TOPICAL
E-Z SCRUB 241
+ BECTON DICKINSON 10% N19476 001 JAN 07, 1987

PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
EFIDAC 24 PSEUDOEPHEDRINE HCL
+ ALZA 240MG N20021 002 DEC 15, 1992

PSEUDOEPHEDRINE HCL
PERRIGO 120MG N75153 001 FEB 26, 1999

SUDAFED 12 HOUR
+ WARNER WELLCOME 120MG N73585 001 OCT 31, 1991

PSEUDOEPHEDRINE HYDROCHLORIDE; *MULTIPLE*
SEE ACETAMINOPHEN; CLEMASTINE FUMARATE; PSEUDOEPHEDRINE HYDROCHLORIDE
SEE BROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE
SEE CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE
SEE IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE
SEE NAPROXEN SODIUM; PSEUDOEPHEDRINE HYDROCHLORIDE

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES
+ KV PHARM 120MG;5MG N72758 001 NOV 25, 1991

PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL
AFRINOL
+ SCHERING PLOUGH 120MG N18191 001

PSEUDOEPHEDRINE SULFATE; *MULTIPLE*
SEE ACETAMINOPHEN; DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE
SEE CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE
SEE DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

PYRETHRINS; *MULTIPLE*
SEE PIPERONYL BUTOXIDE; PYRETHRINS

RANITIDINE HYDROCHLORIDE

TABLET; ORAL
RANITIDINE
DR REDDYS LABS LTD EQ 75MG BASE N75294 001 MAR 28, 2000
GENPHARM EQ 75MG BASE N75497 001 JAN 14, 2000
IVAX PHARMS EQ 75MG BASE N75296 001 JAN 14, 2000
LEINER EQ 75MG BASE N75094 001 JUN 21, 1999
RANBAXY EQ 75MG BASE N75132 001 JAN 14, 2000
EQ 75MG BASE N75254 001 JAN 14, 2000
TORPHARM EQ 75MG BASE N75167 001 MAY 04, 2000
WATSON LABS EQ 75MG BASE N75212 001 JAN 14, 2000

ZANTAC 75
+ WARNER LAMBERT EQ 75MG BASE N20520 001 DEC 19, 1995

SIMETHICONE; *MULTIPLE*
SEE LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

SODIUM CHLORIDE

AEROSOL, METERED; INHALATION
BRONCHO SALINE
+ BLAIREX 0.9% N19912 001 SEP 03, 1992

SODIUM FLUORIDE; TRICLOSAN

PASTE; DENTAL
COLGATE TOTAL
+ COLGATE PALMOLIVE 0.24%;0.3% N20231 001 JUL 11, 1997

FDA data supplied by DrugPatentWatch.com

SODIUM MONOFLUOROPHOSPHATE

GEL; DENTAL

EXTRA-STRENGTH AIM		
+ CHESEBROUGH PONDS	1.2%	N19518 002 AUG 06, 1986

PASTE; DENTAL

EXTRA-STRENGTH AIM		
+ CHESEBROUGH PONDS	1.2%	N19518 001 JUN 03, 1987

TERBINAFINE HYDROCHLORIDE

CREAM; TOPICAL

LAMISIL		
+ NOVARTIS	1%	N20980 001 MAR 09, 1999

SOLUTION; TOPICAL

LAMISIL AT		
+ NOVARTIS	1%	N21124 001 MAR 17, 2000

TIOCONAZOLE

OINTMENT; VAGINAL

TIOCONAZOLE		
PERRIGO	6.5%	N75915 001 NOV 21, 2001
VAGISTAT-1		
+ BRISTOL MYERS SQUIBB	6.5%	N20676 001 FEB 11, 1997

TRICLOSAN; *MULTIPLE*
SEE SODIUM FLUORIDE; TRICLOSAN

TRIPROLIDINE HYDROCHLORIDE; *MULTIPLE*
SEE PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

TRIPROLIDINE HYDROCHLORIDE; *MULTIPLE*
SEE PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

ANTICOAGULANT CITRATE DEXTROSE SOLUTION (ACD)

INJECTABLE; INJECTION
ACD-A SOLUTION — ANDA
GAMBRO BCT, INC — N010228
FEB 25, 2002

ANTICOAGULANT CITRATE DEXTROSE SOLUTION (ACD)

INJECTABLE; INJECTION
ANTICOAGULANT CITRATE DEXTROSE SOLUTION FORMULA A — ANDA
HAEMONETICS CORP — N980728
FEB 6, 2002

ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP

INJECTABLE; INJECTION
NONE
MEDSEP CORPORATION — N710497
(ANDA)

ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP

INJECTABLE; INJECTION
NONE
MILES, INC. — N100102
DEC 14, 1961

ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP

INJECTABLE; INJECTION
NONE
FRESENIUS USA, INC — N110912
SEP 02, 1959

ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP

INJECTABLE; INJECTION
NONE
BAXTER HEALTHCARE CORP - FENWAL DIVISION — N100855
JUN 03, 1959

ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP

INJECTABLE; INJECTION
NONE
BAXTER HEALTHCARE CORP - FENWAL DIVISION — N160918
MAR 17, 1978

ANTICOAGULANT CITRATE PHOSPHATE 2X DEXTROSE SOLUTION (CP2D)

INJECTABLE; INJECTION
CITRATE PHOSPHATE DOUBLE DEXTROSE/ADDITIVE SOLUTION 3
HAEMONETICS CORP — N000127
JAN 18, 2002

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE SOLUTION

INJECTABLE; INJECTION
NONE
FRESENIUS USA, INC — N780519
APR 23, 1980

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE SOLUTION

INJECTABLE; INJECTION
NONE
TERUMO MEDICAL CORP — N820528
NOV 03, 1982

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE SOLUTION USP

INJECTABLE; INJECTION
BLOOD PACK UNIT CPDA-1 IN PLASTIC CONTAINER
BAXTER HEALTHCARE CORP - FENWAL DIVISION — N940404
JUL 28, 1994

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE-1 SOLUTION

INJECTABLE; INJECTION
NONE
MEDSEP CORPORATION — N800077
NOV 06, 1980

FDA data supplied by DrugPatentWatch.com

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP

INJECTABLE; INJECTION
NONE
MILES, INC — N160527
JUN 22, 1970

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP

INJECTABLE; INJECTION
NONE
MEDSEP CORPORATION — N800222
AUG 23, 1982

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP

INJECTABLE; INJECTION
NONE
FRESENIUS USA, INC — N160907
MAY 16, 1973

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP

INJECTABLE; INJECTION
NONE
TERUMO MEDICAL CORP — N781211
JUN 10, 1981

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP

INJECTABLE; INJECTION
NONE
BAXTER HEALTHCARE CORP - FENWAL DIVISION — N170401
DEC 06, 1977

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP

INJECTABLE; INJECTION
NONE
BAXTER HEALTHCARE CORP - FENWAL DIVISION — N811012
JUN 28, 1983

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP WITH: AS-1: DEXTROSE USP; SODIUM CHLORIDE USP; MANNITOL USP; ADENINE

INJECTABLE; INJECTION
ADSOL RED BLOOD CELL PRESERVATIVE SOLUTION
BAXTER HLTHCARE FENWAL DIV — 2.2GM/100ML;0.9GM/100ML; 0.75GM/100ML;0.027GM/100ML — N811104
MAY 16, 1983

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP WITH: AS-5: DEXTROSE USP; SODIUM CHLORIDE USP; MANNITOL USP; ADENINE

INJECTABLE; INJECTION
OPTISOL RED BLOOD CELL PRESERVATIVE SOLUTION
TERUMO MEDICAL CORP — 0.9GM/100ML;0.877GM/100ML; 0.525GM/100ML;0.03GM/100ML — N880217
OCT 07, 1988

FDA data supplied by DrugPatentWatch.com

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

ANTICOAGULANT CITRATE PHOSPHATE DOUBLE DEXTROSE SOLUTION WITH: AS-2: CITRIC ACID USP; DIBASIC SODIUM PHOSPHATE USP; SODIUM CHLORIDE USP; ADENINE; DEXTROSE USP; SODIUM CITRATE USP

INJECTABLE; INJECTION
AS-2 NUTRICEL ADDITIVE SYSTEM
MEDSEP CORP — 0.042GM/100ML;0.285GM/100ML; 0.718GM/100ML;0.017GM/100ML; 0.396GM/100ML;0.588GM/100ML — N820915 SEP 22, 1983

ANTICOAGULANT CITRATE PHOSPHATE DOUBLE DEXTROSE SOLUTION WITH: AS-3: CITRIC ACID USP; MONOBASIC SODIUM PHOSPHATE USP; SODIUM CHLORIDE USP; ADENINE; DEXTROSE USP; SODIUM CITRATE USP

INJECTABLE; INJECTION
AS-3 NUTRICEL ADDITIVE SYSTEM
MEDSEP CORP — 0.042GM/100ML;0.276GM/100ML; 0.410GM/100ML;0.30GM/100ML; 1.10GM/100ML;0.588GM/100ML — N820915 OCT 19, 1984

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION

INJECTABLE; INJECTION
CDP BLOOD BAG UNIT IN PLASTIC CONTAINER — N900224
BAXTER HLTHCARE - FENWAL DIVISION — DEC 27, 1991

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION

INJECTABLE; INJECTION
ADSOL IN PLASTIC CONTAINER
BAXTER HLTH CARE - FENWAL DIVISION — N900223 DEC 27, 1991

ANTICOAGULANT HEPARIN SOLUTION USP

INJECTABLE; INJECTION
NONE
FRESENIUS USA, INC — N770822 MAY 17, 1978

ANTICOAGULANT 4% SODIUM CITRATE SOLUTION USP

INJECTABLE; INJECTION
NONE
MEDSEP CORPORATION — N760305 JUN 30, 1978

ANTICOAGULANT SODIUM CITRATE 4% SOLUTION

INJECTABLE; INJECTION
NONE
HAEMONETICS CORPORATION — N980123 MAR 3, 2000

ANTICOAGULANT SODIUM CITRATE SOLUTION USP

INJECTABLE; INJECTION
NONE
ALPHA THERPTC — N810416 APR 06, 1983

ANTICOAGULANT SODIUM CITRATE SOLUTION USP

INJECTABLE; INJECTION
NONE
FRESENIUS USA, INC — N160702 DEC 28, 1970

ANTICOAGULANT SODIUM CITRATE SOLUTION USP

INJECTABLE; INJECTION
NONE
TERUMO MEDICAL CORP — N781214 FEB 08, 1980

FDA data supplied by DrugPatentWatch.com

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

ANTICOAGULANT SODIUM CITRATE SOLUTION USP

INJECTABLE; INJECTION
NONE
BAXTER HEALTHCARE CORP - FENWAL DIVISION — N770923
JAN 20, 1978

DEXTRAN 1 IN SODIUM CHLORIDE 0.6%

INJECTABLE; INJECTION
PROMIT
PHARMALINK BASLAKEMEDEL AB — N830715
OCT 30, 1984

DEXTRAN 40, 10% W/V DEXTRAN 40 IN 0.8% NACL 500 ML PVC BAGS

INJECTABLE, INJECTION
RHEOMACRODEX
PHARMALINK BASLAKEMEDEL AB — N830527
MAR 27, 1985

DEXTRAN 40, 10% W/V DEXTRAN 40 IN 5% DEXTROSE 500 ML PVC BAGS

INJECTABLE, INJECTION
RHEOMACRODEX
PHARMALINK BASLAKEMEDEL AB — N830627
MAR 27, 1985

DEXTRAN 40, 10% IN DEXTROSE 5%

INJECTABLE; INJECTION
GENTRAN 40
BAXTER HLTHCARE IV SYSTEMS — 10GM/100ML;5GM/100ML — N840619
FEB 22, 1985

DEXTRAN 40, 10% IN DEXTROSE 5%

INJECTABLE; INJECTION
LMD IN PLASTIC CONTAINER — ANDA
ABBOTT LABS — 10GM/100ML;5GM/100ML — N720563
OCT 30, 1992

DEXTRAN 40, 10% IN DEXTROSE 5%

INJECTABLE; INJECTION
NONE
ABBOTT LABS — 10GM/100ML;5GM/100ML — N160375
JUL 25, 1967

DEXTRAN 40, 10% IN DEXTROSE 5%

INJECTABLE; INJECTION
NONE
MCGAW, INC — 10GM/100ML;5GM/100ML — N160767
APR 6, 1970

DEXTRAN 40, 10% IN DEXTROSE 5%

INJECTABLE; INJECTION
NONE
MILES, INC — 10GM/100ML;5GM/100ML — N160653
SEP 23, 1969

DEXTRAN 40, 10% IN DEXTROSE 5%

INJECTABLE; INJECTION
NONE
PHARMACHEM — 10GM/100ML;5GM/100ML — N160836
NOV 14, 1972

FDA data supplied by DrugPatentWatch.com

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

DEXTRAN 40, 10% IN DEXTROSE 5%

INJECTABLE; INJECTION
RHEOMACRODEX
PHARMALINK BASLAKEMEDEL AB — 10GM/100ML;5GM/100ML — N140716 — JAN 18, 1967

DEXTRAN 40, 10% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION
GENTRAN 40
BAXTER HLTHCARE IV SYSTEMS — 10GM/100ML;0.9GM/100ML — N840620 — FEB 22, 1985

DEXTRAN 40, 10% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION
LMD IN PLASTIC CONTAINER
ABBOTT LABS — 10GM/100ML;0.9GM/100ML — ANDA N720562 — OCT 30, 1992

DEXTRAN 40, 10% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION
RHEOMACRODEX
PHARMALINK BASLAKEMEDEL AB — 10GM/100ML;0.9GM/100ML — N140716 — JAN 18, 1967

DEXTRAN 40, 10% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION
NONE
ABBOTT LABS — 10GM/100ML;0.9GM/100ML — N160375 — JUL 25, 1967

DEXTRAN 40, 10% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION
NONE
MILES, INC — 10GM/100ML;0.9GM/100ML — N160653 — SEP 23, 1969

DEXTRAN 40, 10% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION
NONE
PHARMACHEM — 10GM/100ML;0.9GM/100ML — N160836 — NOV 14, 1972

DEXTRAN 40, 10% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION
NONE
MCGAW, INC — 10GM/100ML;0.9GM/100ML — N160767 — APR 6, 1970

DEXTRAN 70, 6% W/V DEXTRAN 70 IN 0.9% NACL IN 500 ML PVC BAGS

INJECTABLE; INJECTION
MACRODEX
PHARMALINK BASLAKEMEDEL AB — N830613 — MAR 27, 1985

DEXTRAN 70, 6% W/V DEXTRAN 70 IN 5% DEXTROSE

INJECTABLE; INJECTION
MACRODEX
PHARMALINK BASLAKEMEDEL AB — N830629 — MAR 27, 1985

FDA data supplied by DrugPatentWatch.com

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

DEXTRAN 70, 6% IN DEXTROSE 5%

INJECTABLE; INJECTION
MACRODEX

PHARMALINK	6GM/100ML;5GM/100ML	N060826
BASLAKEMEDEL AB		JUN 8, 1954

DEXTRAN 70, 6% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION
MACRODEX

PHARMALINK	6GM/100ML;5GM/100ML	N060826
BASLAKEMEDEL AB		JUN 8, 1954

DEXTRAN 70, 6% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION
NONE

MCGAW, INC	6GM/100ML;0.9 GM/100ML	N090024
		AUG 18, 1969

DEXTRAN 70, 6% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION
NONE

MILES, INC	6GM/100ML;0.9 GM/100ML	N080716
		MAR 13, 1953

DEXTRAN 70, 6% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION
GENTRAIN 70

BAXTER HLTHCARE	6GM/100ML;0.9 GM/100ML	N160607
IV SYSTEMS		JAN 26, 1970

DEXTRAN 70, 6% IN DEXTROSE 5%

INJECTABLE; INJECTION
NONE

ABBOTT LABS	6GM/100ML;5GM/100ML	N080819
		MAR 31, 1953

DEXTRAN 75, 6% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION
NONE

PHARMACHEM	6GM/100ML;0.9GM/100ML	N080564
		SEP 19, 1952

DEXTRAN 75, 6% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION
NONE

PHARMACHEM	6GM/100ML;0.9GM/100ML	N160759
		AUG 19, 1970

HETASTARCH 6% IN SODIUM CHLORIDE 0.9% NACL 500 ML GLASS BOTTLES

INJECTABLE; INJECTION
NONE

ABBOTT LABORATORIES - HOSPITAL PRODUCTS DIV		ANDA N720746
		FEB 07, 1996

HETASTARCH 6% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION
HESPAN

MCGAW, INC	6GM/100ML;0.9GM/100ML	N160889
		JUL 17, 1972

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

HETASTARCH 6% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION
HESPAN IN PLASTIC CONTAINER
MCGAW, INC 6GM/100ML;0.9GM/100ML N890105
APR 04, 1991

HETASTARCH 6% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION
6% HETASTARCH IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
ABBOTT 6GM/100ML;0.9GM/100ML ANDA
N740193
JAN 30, 1995

HETASTARCH 6% IN 0.9% NACL

INJECTABLE; INJECTION
NONE ANDA
GENSIA LABS, INC 6GM/100ML;0.9GM/100ML N740592
NOV 12, 1998

HETASTARCH 6% IN 0.9% NACL

INJECTABLE; INJECTION
NONE ANDA
MCGAW, INC 6GM/100ML;0.9GM/100ML N740283
OCT 21, 1998

HETASTARCH 6% IN LACTATED ELECTROLYTE INJECTION

INJECTABLE; INJECTION
HEXTEND
BIOTIME, INC 6GM/100ML N200952
MAR 31, 1999

INDIUM IN^{111} CHLORIDE

SOLUTION; INJECTION
INDICLOR
MEDI-PHYSICS N/A N19862
DEC 29, 1992

INDIUM IN^{111} CHLORIDE STERILE SOLUTION

INJECTABLE; INJECTION ULTRAPURE
ULTRAPURE
MALLINCKRODT N/A N19841
SEP 27, 1994

PENTASTARCH 10% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION
PENTASPAN
MCGAW, INC 10GM/100ML;0.9GM/100ML N841207
MAY 19, 1987

PENTASTARCH 10% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION
PENTASPAN IN PLASTIC CONTAINER
MCGAW, INC 10GM/100ML;0.9GM/100ML N890104
APR 04, 1991

PERFLUORODECALIN; PERFLUOROTRI-N-PROPYLAMINE

INJECTABLE; INJECTION
FLUOSOL
ALPHA THERPTC 17.5GM/100ML;7.5GM/100ML N860909
DEC 26, 1989

FDA data supplied by DrugPatentWatch.com

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

RED BLOOD CELL PROCESSING SOLUTION

INJECATABLE; INJECTION
REJUVESOL
CYTOSOL LABS, INCN/A — N950522 FEB 26, 1997

UROKINASE

INJECTABLE; INJECTION
ABBOKINASE OPEN-CATHETER
ABBOTT LABS 5,000 IU/VIAL — N761021 DEC 15, 1983

UROKINASE

INJECTABLE; INJECTION
ABBOKINASE
ABBOTT LABS 9,000 IU/VIAL — N761021

UROKINASE

INJECTABLE; INJECTION
ABBOKINASE
ABBOTT LABS 250,000 IU/VIAL — N761021

FDA data supplied by DrugPatentWatch.com

ACETAMINOPHEN

INJECTABLE; INJECTION
INJECTAPAP
JOHNSON RW 100MG/ML N17785 001 MAR 07, 1986

SUPPOSITORY; RECTAL
ACETAMINOPHEN
ABLE 120MG N73106 001 FEB 27, 1995
325MG N73107 001 FEB 27, 1995
650MG N73108 001 FEB 27, 1995
ROXANE 120MG N71010 001 MAY 12, 1987
650MG N71011 001 MAY 12, 1987
TYLENOL
MCNEIL 120MG N17756 002
650MG N17756 001

ACETAMINOPHEN; ASPIRIN; CODEINE PHOSPHATE

CAPSULE; ORAL
ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE
MIKART 150MG;180MG;15MG N81095 001 OCT 26, 1990
150MG;180MG;60MG N81097 001 OCT 26, 1990
CODEINE, ASPIRIN, APAP FORMULA NO. 2
SCHERER LABS 150MG;180MG;15MG N85640 001
CODEINE, ASPIRIN, APAP FORMULA NO. 3
SCHERER LABS 150MG;180MG;30MG N85639 001
CODEINE, ASPIRIN, APAP FORMULA NO. 4
SCHERER LABS 150MG;180MG;60MG N85638 001

ACETAMINOPHEN; BUTALBITAL

CAPSULE; ORAL
BANCAP
FOREST PHARMS 325MG;50MG N88889 001 JAN 16, 1986
TRIAPRIN
DUNHALL 325MG;50MG N89268 001 JUL 02, 1987

ACETAMINOPHEN; BUTALBITAL

TABLET; ORAL
BUTALBITAL AND ACETAMINOPHEN
DANBURY PHARMA 325MG;50MG N87550 001 OCT 19, 1984
HALSEY 325MG;50MG N89568 001 OCT 05, 1988

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL
ANOQUAN
SHIRE PHARM 325MG;50MG;40MG N87628 001 OCT 01, 1986
BUTALBITAL, ACETAMINOPHEN, CAFFEINE
GRAHAM DM 325MG;50MG;40MG N88743 001 JUL 18, 1985
325MG;50MG;40MG N88765 001 MAR 27, 1985
325MG;50MG;40MG N89067 001 APR 19, 1985
MALLINCKRODT 325MG;50MG;40MG N88758 001 MAR 27, 1985
FEMCET
MALLINCKRODT 325MG;50MG;40MG N89102 001 JUN 19, 1985
MEDIGESIC PLUS
US CHEM 325MG;50MG;40MG N89115 001 JAN 14, 1986
TRIAD
MALLINCKRODT 325MG;50MG;40MG N89023 001 JUN 19, 1985

TABLET; ORAL
ACETAMINOPHEN, BUTALBITAL AND CAFFEINE
GILBERT LABS 325MG;50MG;40MG N87629 001 NOV 13, 1984
ESGIC
FOREST PHARMS 325MG;50MG;40MG N89660 001 DEC 23, 1988

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE; ORAL
DHC PLUS
PURDUE FREDERICK 356.4MG;30MG;16MG N88584 001 MAR 04, 1986

FDA data supplied by DrugPatentWatch.com

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE; ORAL			
SYNALGOS-DC-A			
WOMEN FIRST HLTHCARE	356.4MG;30MG;16MG	N89166	001
		MAY 14, 1986	

ACETAMINOPHEN; CODEINE PHOSPHATE

CAPSULE; ORAL			
ACETAMINOPHEN AND CODEINE PHOSPHATE			
TEVA	300MG;30MG	N88324	001
		DEC 29, 1983	
ACETAMINOPHEN W/ CODEINE #2			
TEVA	300MG;15MG	N88537	001
		JUN 04, 1984	
ACETAMINOPHEN W/ CODEINE #4			
TEVA	300MG;60MG	N88599	001
		JUN 01, 1984	
PROVAL #3			
SOLVAY	325MG;30MG	N85685	001
TYLENOL W/ CODEINE NO. 3			
JOHNSON RW	300MG;30MG	N87422	001
TYLENOL W/ CODEINE NO. 4			
JOHNSON RW	300MG;60MG	N87421	001
TABLET; ORAL			
ACETAMINOPHEN AND CODEINE PHOSPHATE			
DURAMED	300MG;15MG	N88353	001
		FEB 06, 1984	
	300MG;30MG	N88354	001
		FEB 06, 1984	
	300MG;60MG	N88355	001
		FEB 06, 1984	
EON	300MG;15MG	N87433	001
	300MG;30MG	N85917	001
	300MG;60MG	N87423	001
GENEVA PHARMS	300MG;30MG	N85291	002
	300MG;60MG	N85964	001
HALSEY	300MG;15MG	N85795	001
	300MG;30MG	N85794	001
	300MG;60MG	N86549	001
KV PHARM	300MG;30MG	N85288	001
	300MG;60MG	N85365	001
	325MG;15MG	N85364	001
*	325MG;45MG	N85363	001
MIKART	300MG;60MG	N89244	001
		FEB 25, 1986	

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET; ORAL			
ACETAMINOPHEN AND CODEINE PHOSPHATE			
ROXANE	500MG;15MG	N89511	001
		APR 25, 1989	
	500MG;30MG	N89512	001
		APR 25, 1989	
	500MG;60MG	N89513	001
		APR 25, 1989	
WARNER CHILCOTT	300MG;15MG	N85992	001
	300MG;30MG	N85218	002
ACETAMINOPHEN AND CODEINE PHOSPHATE #3			
PUREPAC PHARM	300MG;30MG	N89080	001
		JUL 17, 1986	
SUPERPHARM	300MG;30MG	N89184	001
		OCT 18, 1985	
	300MG;30MG	N89253	001
		MAY 19, 1986	
ACETAMINOPHEN AND CODEINE PHOSPHATE #4			
SUPERPHARM	300MG;60MG	N89185	001
		OCT 18, 1985	
	300MG;60MG	N89254	001
		MAY 19, 1986	
ACETAMINOPHEN AND CODEINE PHOSPHATE NO. 2			
AM THERAP	300MG;15MG	N89478	001
		MAR 03, 1987	
	300MG;15MG	N89481	001
		MAR 03, 1987	
ACETAMINOPHEN AND CODEINE PHOSPHATE NO. 3			
AM THERAP	300MG;30MG	N89479	001
		MAR 03, 1987	
	300MG;30MG	N89482	001
		MAR 03, 1987	
ACETAMINOPHEN AND CODEINE PHOSPHATE NO. 4			
AM THERAP	300MG;60MG	N89480	001
		MAR 03, 1987	
	300MG;60MG	N89483	001
		MAR 03, 1987	
ROXANE	300MG;60MG	N84667	001
ACETAMINOPHEN W/ CODEINE			
HALSEY	300MG;60MG	N87653	001
		APR 13, 1982	
LEDERLE	300MG;30MG	N87141	001
ACETAMINOPHEN W/ CODEINE NO. 2			
ROXANE	300MG;15MG	N84659	001
ACETAMINOPHEN W/ CODEINE PHOSPHATE			
HALSEY	300MG;15MG	N83871	001
	300MG;30MG	N83872	001

FDA data supplied by DrugPatentWatch.com

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET; ORAL			
ACETAMINOPHEN W/ CODEINE PHOSPHATE			
USL PHARMA	300MG;30MG	N87919 001	JUN 22, 1982
	300MG;60MG	N87920 001	JUN 22, 1982
VITARINE	300MG;30MG	N85676 001	
WARNER CHILCOTT	300MG;60MG	N87306 001	
WATSON LABS	300MG;15MG	N87277 001	MAY 26, 1982
	300MG;30MG	N87276 001	MAY 26, 1982
	300MG;60MG	N87275 001	MAY 26, 1982
WHITEWORTH TOWN PLSN	300MG;30MG	N84360 001	
	300MG;60MG	N85607 001	
APAP W/ CODEINE PHOSPHATE			
EVERYLIFE	325MG;30MG	N85217 001	
CAPITAL WITH CODEINE			
CARNRICK	325MG;30MG	N83643 001	
CODEINE PHOSPHATE AND ACETAMINOPHEN			
ICN	300MG;30MG	N85896 001	
EMPRACET W/ CODEINE PHOSPHATE #3			
GLAXOSMITHKLINE	300MG;30MG	N83951 001	
EMPRACET W/ CODEINE PHOSPHATE #4			
GLAXOSMITHKLINE	300MG;60MG	N83951 002	
PAPA-DEINE #3			
VANGARD	300MG;30MG	N88037 001	MAR 20, 1984
PAPA-DEINE #4			
VANGARD	300MG;60MG	N88715 001	MAR 20, 1984
PHENAPHEN-650 W/ CODEINE			
ROBINS AH	650MG;30MG	N85856 001	
TYLENOL W/ CODEINE			
JOHNSON RW	325MG;7.5MG	N85056 001	
	325MG;15MG	N85056 002	
	325MG;30MG	N85056 003	
	325MG;60MG	N85056 004	

ACETAMINOPHEN; HYDROCODONE BITARTRATE

CAPSULE; ORAL			
BANCAP HC			
FOREST PHARMS	500MG;5MG	N87961 001	MAR 17, 1983

ACETAMINOPHEN; HYDROCODONE BITARTRATE

CAPSULE; ORAL			
CO-GESIC			
CENT PHARMS	500MG;5MG	N89360 001	MAR 02, 1988
TABLET; ORAL			
DURADYNE DHC			
FOREST PHARMS	500MG;5MG	N87809 001	MAR 17, 1983
HYDROCODONE BITARTRATE AND ACETAMINOPHEN			
BARR	500MG;5MG	N88577 001	DEC 21, 1984
HALSEY	500MG;5MG	N89554 001	JUN 12, 1987
USL PHARMA	500MG;5MG	N89290 001	MAY 29, 1987
	500MG;5MG	N89291 001	MAY 29, 1987
WATSON LABS	325MG;7.5MG	N40248 001	APR 28, 2000
NORCET			
ABANA	500MG;5MG	N88871 001	MAY 15, 1986
TYCOLET			
JOHNSON RW	500MG;5MG	N89385 001	AUG 27, 1986
VICODIN			
ABBOTT	500MG;5MG	N85667 001	

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

CAPSULE; ORAL			
OXYCODONE AND ACETAMINOPHEN			
HALSEY	500MG;5MG	N89994 001	MAY 04, 1989
TYLOX-325			
JOHNSON RW	325MG;5MG	N88246 001	NOV 08, 1984
TABLET; ORAL			
OXYCODONE 2.5/APAP 500			
BRISTOL MYERS SQUIBB	500MG;2.5MG	N85910 001	
OXYCODONE 5/APAP 500			
BRISTOL MYERS SQUIBB	500MG;5MG	N85911 001	

FDA data supplied by DrugPatentWatch.com

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

CAPSULE; ORAL			
TYLOX			
JOHNSON RW	500MG;4.5MG;0.38MG	N85375	001

ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE

TABLET; ORAL			
DARVOCET			
LILLY	325MG;32.5MG	N16844	001
DOLENE AP-65			
LEDERLE	650MG;65MG	N85100	001
PROPOXYPHENE HCL AND ACETAMINOPHEN			
MYLAN	325MG;32MG	N83689	001

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL			
PROPACET 100			
TEVA	650MG;100MG	N70107	001
		JUN 12, 1985	
PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN			
HALSEY	325MG;50MG	N70115	001
		JUN 12, 1985	
	325MG;50MG	N72105	001
		MAY 13, 1988	
	650MG;100MG	N70116	001
		JUN 12, 1985	
	650MG;100MG	N72106	001
		MAY 13, 1988	
SUPERPHARM	650MG;100MG	N71319	001
		JAN 06, 1987	
TEVA	650MG;100MG	N70732	001
		JAN 03, 1986	
WATSON LAB	325MG;50MG	N70398	001
		DEC 18, 1986	
	650MG;100MG	N70399	001
		DEC 18, 1986	

ACETAZOLAMIDE

CAPSULE, EXTENDED RELEASE; ORAL			
DIAMOX			
LEDERLE	500MG	N12945	001

ACETAZOLAMIDE

TABLET; ORAL			
ACETAZOLAMIDE			
ALRA	250MG	N83320	001
ASCOT	250MG	N87686	001
		OCT 20, 1982	
VANGARD	250MG	N87654	001
		FEB 05, 1982	
WATSON LAB	250MG	N84498	002

ACETAZOLAMIDE SODIUM

INJECTABLE; INJECTION			
ACETAZOLAMIDE SODIUM			
QUAD PHARMS	EQ 500MG BASE/VIAL	N89619	001
		JAN 13, 1988	

ACETIC ACID, GLACIAL

SOLUTION/DROPS; OTIC			
ACETIC ACID			
KV PHARM	2%	N85493	001
ORLEX			
PROCTER AND GAMBLE	2%	N86845	001

ACETIC ACID, GLACIAL; ALUMINUM ACETATE

SOLUTION/DROPS; OTIC			
BOROFAIR			
PHARMAFAIR	2%;0.79%	N88606	001
		AUG 21, 1985	

ACETIC ACID, GLACIAL; DESONIDE

SOLUTION/DROPS; OTIC			
TRIDESILON			
BAYER	2%;0.05%	N17914	001

ACETIC ACID, GLACIAL; HYDROCORTISONE

SOLUTION/DROPS; OTIC			
ACETIC ACID W/ HYDROCORTISONE			
KV PHARM	2%;1%	N85492	001

FDA data supplied by DrugPatentWatch.com

ACETIC ACID, GLACIAL; HYDROCORTISONE

SOLUTION/DROPS; OTIC
HYDROCORTISONE AND ACETIC ACID
BAUSCH AND LOMB 2%;1% N40097 001 OCT 31, 1994

ORLEX HC
PROCTER AND GAMBLE 2%;1% N86844 001

ACETOHEXAMIDE

TABLET; ORAL
ACETOHEXAMIDE
USL PHARMA 250MG N70753 001 NOV 03, 1986
500MG N70754 001 NOV 03, 1986

DYMELOR
LILLY 250MG N13378 002
500MG N13378 001

ACETOPHENAZINE MALEATE

TABLET; ORAL
TINDAL
SCHERING 20MG N12254 002

ACETRIZOATE SODIUM

SOLUTION; INTRAURETERINE
SALPIX
JOHNSON RW 53% N09008 001

ACETYLCYSTEINE

SOLUTION; INHALATION, ORAL
ACETYLCYSTEINE
QUAD PHARMS 10% N71740 001 AUG 11, 1987
20% N71741 001 AUG 11, 1987

ACETYLCYSTEINE; ISOPROTERENOL HYDROCHLORIDE

SOLUTION; INHALATION
MUCOMYST W/ ISOPROTERENOL
MEAD JOHNSON 10%;0.05% N17366 001

ACETYLDIGITOXIN

TABLET; ORAL
ACYLANID
NOVARTIS 0.1MG N09436 001

ACRISORCIN

CREAM; TOPICAL
AKRINOL
SCHERING 2MG/GM N12470 001

ACYCLOVIR

CAPSULE; ORAL
ACYCLOVIR
LEK PHARM 200MG N74750 001 APR 22, 1997
ROXANE 200MG N74570 002 APR 22, 1997

TABLET; ORAL
ACYCLOVIR
LEK PHARM 400MG N74658 001 APR 22, 1997
800MG N74658 002 APR 22, 1997
* TEVA 200MG N74556 001 APR 22, 1997

ACYCLOVIR SODIUM

INJECTABLE; INJECTION
ACYCLOVIR SODIUM
APOTHECON EQ 500MG BASE/VIAL N74897 001 FEB 27, 1998
EQ 1GM BASE/VIAL N74897 002 FEB 27, 1998

FDA data supplied by DrugPatentWatch.com

ACYCLOVIR SODIUM

INJECTABLE; INJECTION
ZOVIRAX
GLAXOSMITHKLINE — EQ 250MG BASE/VIAL — N18603 003 AUG 30, 1983

ALBUMIN CHROMATED CR-51 SERUM

INJECTABLE; INJECTION
CHROMALBIN
ISO TEX — 250 uCi/VIAL — N17835 002
500 uCi/VIAL — N17835 003

ALBUMIN IODINATED I-125 SERUM

INJECTABLE; INJECTION
ALBUMOTOPE 125 I
ISO TEX — 5-50 uCi/AMP — N17836 001
RADIO-IODINATED (I 125) SERUM ALBUMIN (HUMAN)
BAYER — 2.5 uCi/AMP — N17846 001

ALBUMIN IODINATED I-131 SERUM

INJECTABLE; INJECTION
MEGATOPE
ISO TEX — 5 uCi/AMP — N17837 004
20 uCi/AMP — N17837 005
2mCi/VIAL — N17837 003

ALBUTEROL SULFATE

CAPSULE; INHALATION
VENTOLIN ROTACAPS
GLAXOSMITHKLINE — EQ 0.2MG BASE — N19489 001 MAY 04, 1988

SOLUTION; INHALATION
ALBUTEROL SULFATE
COPLEY PHARM — EQ 0.083% BASE — N73495 001 MAY 28, 1993
EQ 0.5% BASE — N73307 001 NOV 27, 1991
VENTOLIN
GLAXOSMITHKLINE — EQ 0.083% BASE — N19773 001 APR 23, 1992

ALBUTEROL SULFATE

SOLUTION; INHALATION
VENTOLIN
GLAXOSMITHKLINE — EQ 0.5% BASE — N19269 002 JAN 16, 1987

SYRUP; ORAL
ALBUTEROL SULFATE
MOVA — EQ 2MG BASE/5ML — N74302 001 SEP 30, 1994
WATSON LABS — EQ 2MG BASE/5ML — N73165 001 APR 29, 1993
VENTOLIN
GLAXOSMITHKLINE — EQ 2MG BASE/5ML — N19621 001 JUN 10, 1987

TABLET; ORAL
ALBUTEROL SULFATE
AM THERAP — EQ 2MG BASE — N72449 001 DEC 05, 1989
EQ 4MG BASE — N72450 001 DEC 05, 1989
CELLTECH PHARMS — EQ 2MG BASE — N73120 001 SEP 29, 1992
EQ 4MG BASE — N73121 001 SEP 29, 1992
COPLEY PHARM — EQ 2MG BASE — N72966 001 NOV 22, 1991
EQ 4MG BASE — N72967 001 NOV 22, 1991
WARNER CHILCOTT — EQ 2MG BASE — N72817 001 JAN 09, 1990
EQ 4MG BASE — N72818 001 JAN 09, 1990
VENTOLIN
GLAXOSMITHKLINE — EQ 2MG BASE — N19112 001 JUL 10, 1986
EQ 4MG BASE — N19112 002 JUL 10, 1986

ALCOHOL

INJECTABLE; INJECTION
ALCOHOL 5% IN DEXTROSE 5%
MILES — 5ML/100ML — N83483 001

FDA data supplied by DrugPatentWatch.com

ALCOHOL; DEXTROSE

INJECTABLE; INJECTION
ALCOHOL 5% IN DEXTROSE 5% IN WATER
BAXTER HLTHCARE 5ML/100ML;5GM/100ML N83256 001

ALKAVERVIR

TABLET; ORAL
VERILOID
3M 2MG N07336 002
3MG N07336 003

ALLOPURINOL

TABLET; ORAL
ALLOPURINOL
HALSEY 100MG N70466 001 DEC 24, 1985
300MG N70467 001 DEC 24, 1985
PUREPAC PHARM 100MG N70579 001 APR 14, 1986
300MG N70580 001 APR 14, 1986
SUPERPHARM 100MG N70950 001 NOV 30, 1988
WATSON LAB 100MG N18241 001 NOV 16, 1984
300MG N18241 002 NOV 16, 1984
WATSON LABS 100MG N18785 001 SEP 28, 1984
300MG N18785 002 SEP 28, 1984
LOPURIN
ABBOTT 100MG N18297 001
300MG N18297 002

ALPRAZOLAM

SOLUTION; ORAL
ALPRAZOLAM
ROXANE 0.5MG/5ML N74314 001 OCT 31, 1993

ALPRAZOLAM

TABLET; ORAL
ALPRAZOLAM
ROXANE 0.25MG N74199 001 OCT 19, 1993
0.5MG N74199 002 OCT 19, 1993
1MG N74199 003 OCT 19, 1993

ALPROSTADIL

INJECTABLE; INJECTION
CAVERJECT
PHARMACIA AND UPJOHN 0.005MG/ML N20755 001 OCT 31, 1997
EDEX
SCHWARZ PHARMA 0.005MG/VIAL N20649 001 JUN 12, 1997

ALSEROXYLON

TABLET; ORAL
RAUTENSIN
NOVARTIS 2MG N09215 001
RAUWILOID
3M 2MG N08867 001

ALUMINUM ACETATE; *MULTIPLE*
SEE ACETIC ACID, GLACIAL; ALUMINUM ACETATE

ALUMINUM HYDROXIDE; MAGNESIUM TRISILICATE

TABLET, CHEWABLE; ORAL
ALUMINUM HYDROXIDE AND MAGNESIUM TRISILICATE
PENNEX 80MG;20MG N89449 001 NOV 27, 1987

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL
AMANTADINE HCL
WATSON LAB 100MG N71382 001 JAN 21, 1987

FDA data supplied by DrugPatentWatch.com

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL		
SYMADINE		
SOLVAY	100MG	N71000 001
		SEP 04, 1986
SYMMETREL		
ENDO PHARMS	100MG	N16020 001

AMCINONIDE

CREAM; TOPICAL		
CYCLOCORT		
FUJISAWA HLTHCARE	0.025%	N18116 001

AMDINOCILLIN

INJECTABLE; INJECTION		
COACTIN		
ROCHE	250MG/VIAL	N50565 001
		DEC 21, 1984
	500MG/VIAL	N50565 002
		DEC 21, 1984
	1GM/VIAL	N50565 003
		DEC 21, 1984

AMIKACIN SULFATE

INJECTABLE; INJECTION		
AMIKACIN SULFATE		
ABBOTT	EQ 250MG BASE/ML	N63265 001
		NOV 30, 1994
	EQ 250MG BASE/ML	N63266 001
		OCT 31, 1994
	EQ 250MG BASE/ML	N64099 001
		JUN 20, 1995
ASTRAZENECA	EQ 50MG BASE/ML	N63167 001
		DEC 14, 1995
	EQ 250MG BASE/ML	N63169 001
		DEC 14, 1995
ELKINS SINN	EQ 50MG BASE/ML	N63274 001
		MAY 18, 1992
	EQ 250MG BASE/ML	N63275 001
		MAY 18, 1992
AMIKIN		
APOTHECON	EQ 50MG BASE/ML	N50495 001

AMIKACIN SULFATE

INJECTABLE; INJECTION		
AMIKIN		
APOTHECON	EQ 50MG BASE/ML	N62562 001
		SEP 20, 1984
	EQ 250MG BASE/ML	N50495 002
	EQ 250MG BASE/ML	N62562 002
		SEP 20, 1984
AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER		
APOTHECON	EQ 5MG BASE/ML	N50618 002
		NOV 30, 1987
	EQ 10MG BASE/ML	N50618 001
		NOV 30, 1987

AMINO ACIDS

INJECTABLE; INJECTION		
AMINOSYN 3.5% IN PLASTIC CONTAINER		
ABBOTT	3.5%	N18804 001
		MAY 15, 1984
	3.5%	N18875 001
		AUG 08, 1984
AMINOSYN II 3.5% IN PLASTIC CONTAINER		
ABBOTT	3.5%	N19491 001
		OCT 10, 1986
AMINOSYN II 5%		
ABBOTT	5%	N19438 002
		APR 03, 1986
AMINOSYN-HBC 7% IN PLASTIC CONTAINER		
ABBOTT	7%	N19400 001
		JUL 23, 1986
FREAMINE 8.5%		
B BRAUN	8.5%	N16822 001
FREAMINE II 8.5%		
B BRAUN	8.5%	N16822 002
NEOPHAM 6.4%		
FRESENIUS KABI	6.4%	N18792 001
		JAN 17, 1984
NOVAMINE 15% SULFITE FREE IN PLASTIC CONTAINER		
BAXTER HLTHCARE	15%	N20107 001
		FEB 05, 1993
NOVAMINE 8.5%		
FRESENIUS KABI	8.5%	N17957 002
		AUG 09, 1982

FDA data supplied by DrugPatentWatch.com

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER

ABBOTT	3.5%;36.8MG/100ML;25GM/100ML; 51MG/100ML;22.4MG/100ML;261MG/100ML; 205MG/100ML	N19714 001 SEP 12, 1988

AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER

ABBOTT	4.25%;36.8MG/100ML;20GM/100ML; 51MG/100ML;22.4MG/100ML;261MG/100ML; 205MG/100ML	N19714 002 SEP 12, 1988

AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER

ABBOTT	4.25%;36.8MG/100ML;25GM/100ML; 51MG/100ML;22.4MG/100ML;261MG/100ML; 205MG/100ML	N19714 004 SEP 12, 1988

AMINOSYN II 5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER

ABBOTT	5%;36.8MG/100ML;25GM/100ML; 51MG/100ML;22.4MG/100ML;261MG/100ML; 205MG/100ML	N19683 004 NOV 07, 1988
	5%;36.8MG/100ML;25GM/100ML; 51MG/100ML;22.4MG/100ML;261MG/100ML; 205MG/100ML	N19714 003 SEP 12, 1988

AMINO ACIDS; DEXTROSE

INJECTABLE; INJECTION

AMINOSYN 3.5% W/ DEXTROSE 25% IN PLASTIC CONTAINER

ABBOTT	3.5%;25GM/100ML	N19118 001 OCT 11, 1984

AMINOSYN 3.5% W/ DEXTROSE 5% IN PLASTIC CONTAINER

ABBOTT	3.5%;5GM/100ML	N19120 001 OCT 11, 1984

AMINOSYN 4.25% W/ DEXTROSE 25% IN PLASTIC CONTAINER

ABBOTT	4.25%;25GM/100ML	N19119 001 OCT 11, 1984

AMINOSYN II 3.5% IN DEXTROSE 25% IN PLASTIC CONTAINER

ABBOTT	3.5%;25GM/100ML	N19505 002 NOV 07, 1986

AMINO ACIDS; DEXTROSE

INJECTABLE; INJECTION

AMINOSYN II 3.5% IN DEXTROSE 25% IN PLASTIC CONTAINER

ABBOTT	3.5%;25GM/100ML	N19713 006 SEP 09, 1988

AMINOSYN II 3.5% IN DEXTROSE 5% IN PLASTIC CONTAINER

ABBOTT	3.5%;5GM/100ML	N19506 001 NOV 07, 1986
	3.5%;5GM/100ML	N19713 002 SEP 09, 1988

AMINOSYN II 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER

ABBOTT	4.25%;10GM/100ML	N19713 001 SEP 09, 1988

AMINOSYN II 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER

ABBOTT	4.25%;20GM/100ML	N19713 004 SEP 09, 1988

AMINOSYN II 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER

ABBOTT	4.25%;25GM/100ML	N19504 002 NOV 07, 1986
	4.25%;25GM/100ML	N19713 005 SEP 09, 1988

AMINOSYN II 5% IN DEXTROSE 25% IN PLASTIC CONTAINER

ABBOTT	5%;25GM/100ML	N19565 001 DEC 17, 1986
	5%;25GM/100ML	N19713 003 SEP 09, 1988

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM ACETATE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN II 4.25% W/ ELECT AND ADJUSTED PHOSPHATE IN DEXTROSE 10% IN PLASTIC CONTAINER

ABBOTT	4.25%;10GM/100ML;51MG/100ML; 176.5MG/100ML;22.4MG/100ML; 104.5MG/100ML;205MG/100ML	N19682 003 NOV 01, 1988
	4.25%;10GM/100ML;51MG/100ML; 176.5MG/100ML;22.4MG/100ML; 104.5MG/100ML;205MG/100ML	N19712 002 SEP 08, 1988

FDA data supplied by DrugPatentWatch.com

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION
AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER
ABBOTT 3.5%;25GM/100ML;51MG/100ML; 22.4MG/100ML;261MG/100ML; 205MG/100ML N19564 002 DEC 16, 1986

AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER
ABBOTT 4.25%;25GM/100ML;51MG/100ML; 22.4MG/100ML;261MG/100ML; 205MG/100ML N19564 004 DEC 16, 1986

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INJECTION
AMINOSYN II 3.5% M IN DEXTROSE 5% IN PLASTIC CONTAINER
ABBOTT 3.5%;5GM/100ML;30MG/100ML; 97MG/100ML;120MG/100ML; 49.3MG/100ML N19564 001 DEC 16, 1986

3.5%;5GM/100ML;30MG/100ML; 97MG/100ML;120MG/100ML; 49.3MG/100ML N19712 001 SEP 08, 1988

AMINOSYN II 4.25% M IN DEXTROSE 10% IN PLASTIC CONTAINER
ABBOTT 4.25%;10GM/100ML;30MG/100ML; 97MG/100ML;120MG/100ML; 49.3MG/100ML N19564 003 DEC 16, 1986

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION
AMINOSYN 3.5% M IN PLASTIC CONTAINER
ABBOTT 3.5%;21MG/100ML;40MG/100ML; 128MG/100ML;234MG/100ML N18804 002 MAY 15, 1984

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION
AMINOSYN 3.5% M IN PLASTIC CONTAINER
ABBOTT 3.5%;21MG/100ML;40MG/100ML; 128MG/100ML;234MG/100ML N18875 002 AUG 08, 1984

AMINO ACIDS; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION
AMINOSYN 3.5% M
ABBOTT 3.5%;21MG/100ML;128MG/100ML; 234MG/100ML N17789 005

AMINO ACIDS; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INJECTION
AMINOSYN II 3.5% M IN PLASTIC CONTAINER
ABBOTT 3.5%;32MG/100ML;128MG/100ML; 222MG/100ML;49MG/100ML N19493 001 OCT 16, 1986

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM ACETATE; POTASSIUM CHLORIDE; SODIUM ACETATE

INJECTABLE; INJECTION
VEINAMINE 8%
FRESENIUS KABI 8%;61MG/100ML;211MG/100ML; 56MG/100ML;388MG/100ML N17957 001

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION
AMINOSYN II 7% W/ ELECTROLYTES
ABBOTT 7%;102MG/100ML;45MG/100ML; 522MG/100ML;410MG/100ML N19437 006 APR 03, 1986

FDA data supplied by DrugPatentWatch.com

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INJECTION		
AMINOSYN II 3.5% M		
ABBOTT	3.5%;30MG/100ML;97MG/100ML; 120MG/100ML;49MG/100ML	N19437 007 APR 03, 1986

AMINOCAPROIC ACID

INJECTABLE; INJECTION		
AMINOCAPROIC ACID		
AM PHARM PARTNERS	250MG/ML	N70522 001 JUN 17, 1986
QUAD PHARMS	250MG/ML	N70694 001 MAR 04, 1986

AMINOHIPPURATE SODIUM

INJECTABLE; INJECTION		
AMINOHIPPURATE SODIUM		
QUAD PHARMS	20%	N89821 001 JUL 14, 1988

AMINOPHYLLINE

ENEMA; RECTAL		
SOMOPHYLLIN		
FISONS	300MG/5ML	N18232 001 APR 02, 1982
INJECTABLE; INJECTION		
AMINOPHYLLIN		
GD SEARLE LLC	25MG/ML	N87243 001 MAY 24, 1982
	25MG/ML	N87621 001 MAY 24, 1982
AMINOPHYLLINE		
AM PHARM PARTNERS	25MG/ML	N84568 001
	25MG/ML	N87200 001
	25MG/ML	N87250 001 JAN 06, 1982
	25MG/ML	N87431 001
	25MG/ML	N87886 001 AUG 30, 1983

AMINOPHYLLINE

INJECTABLE; INJECTION		
AMINOPHYLLINE		
AM PHARM PARTNERS	25MG/ML	N88407 001 JAN 25, 1984
INTL MEDICATION	25MG/ML	N87867 001 NOV 10, 1983
	25MG/ML	N87868 001 NOV 10, 1983
KING PHARMS	25MG/ML	N86606 001
PHARMA SERVE NY	25MG/ML	N87387 001 JUN 03, 1983
SMITH AND NEPHEW	25MG/ML	N88429 001 MAY 30, 1985
	25MG/ML	N88749 001 MAY 30, 1985
AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER		
ABBOTT	100MG/100ML	N18924 001 DEC 12, 1984
	200MG/100ML	N18924 002 DEC 12, 1984
	400MG/100ML	N18924 003 DEC 12, 1984
	500MG/100ML	N18924 004 DEC 12, 1984
SOLUTION; ORAL		
AMINOPHYLLINE		
MORTON GROVE	105MG/5ML	N88156 001 DEC 05, 1983
SOMOPHYLLIN		
FISONS	105MG/5ML	N86466 001
SOMOPHYLLIN-DF		
FISONS	105MG/5ML	N87045 001
TABLET; ORAL		
AMINOPHYLLIN		
GD SEARLE LLC	100MG	N02386 002
	200MG	N02386 003
AMINOPHYLLINE		
ASCOT	100MG	N87522 001 FEB 12, 1982
	200MG	N87523 001 FEB 12, 1982
BARR	100MG	N88297 001 AUG 19, 1983
	200MG	N88298 001 AUG 19, 1983

FDA data supplied by DrugPatentWatch.com

AMINOPHYLLINE

TABLET; ORAL			
AMINOPHYLLINE			
DURAMED	100MG	N88182	001
		MAR 31, 1983	
	200MG	N88183	001
		MAR 31, 1983	
GENEVA PHARMS	100MG	N85261	003
HALSEY	100MG	N84674	001
ICN	200MG	N84563	001
IMPAX LABS	100MG	N84574	001
	200MG	N84576	001
KV PHARM	100MG	N85284	001
	200MG	N85289	001
LANNETT	100MG	N84588	001
	200MG	N84588	002
PAL PAK	100MG	N84533	001
PANRAY	100MG	N84552	001
	200MG	N84552	002
PUREPAC PHARM	100MG	N84699	001
	200MG	N85333	001
VANGARD	100MG	N88314	001
		OCT 03, 1983	
	200MG	N88319	001
		OCT 03, 1983	
VINTAGE PHARMS	100MG	N85409	001
	200MG	N85410	001
WATSON LABS	100MG	N85567	001
	200MG	N85564	001
TABLET, DELAYED RELEASE; ORAL			
AMINOPHYLLINE			
IMPAX LABS	100MG	N84577	001
	200MG	N84575	001
TABLICAPS	100MG	N84632	002
VALE	100MG	N84531	001
	200MG	N84530	001
TABLET, EXTENDED RELEASE; ORAL			
PHYLLOCONTIN			
PURDUE FREDERICK	225MG	N86760	001

AMINOSALICYLATE SODIUM

POWDER; ORAL			
P.A.S. SODIUM			
CENTURY PHARMS	4GM/PACKET	N80947	001
POWDER; ORAL			
SODIUM AMINOSALICYLATE			
HEXCEL	100%	N80097	001
TABLET; ORAL			
PARASAL SODIUM			
PANRAY	500MG	N06811	006
	1GM	N06811	011
TEEBACIN			
CONSOLIDATED MIDLAND	500MG	N07320	002

AMINOSALICYLATE SODIUM; AMINOSALICYLIC ACID

TABLET; ORAL			
NEOPASALATE			
WALLACE LABS	846MG;112MG	N80059	002

AMINOSALICYLIC ACID

TABLET; ORAL			
PARASAL			
PANRAY	500MG	N06811	001
	1GM	N06811	002

AMINOSALICYLIC ACID; *MULTIPLE*

SEE AMINOSALICYLATE SODIUM; AMINOSALICYLIC ACID

AMINOSALICYLIC ACID RESIN COMPLEX

POWDER; ORAL			
REZIPAS			
BRISTOL MYERS SQUIBB	EQ 500MG BASE/GM	N09052	001

AMITRIPTYLINE HYDROCHLORIDE

INJECTABLE; INJECTION			
AMITRIPTYLINE HCL			
STERIS	10MG/ML	N85594	001
TABLET; ORAL			
AMITID			
BRISTOL MYERS SQUIBB	10MG	N86454	001

FDA data supplied by DrugPatentWatch.com

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

AMITID		
BRISTOL MYERS SQUIBB	25MG	N86454 002
	50MG	N86454 003
	75MG	N86454 004
	100MG	N86454 005
AMITRIL		
WARNER CHILCOTT	10MG	N83939 001
	25MG	N83937 001
	50MG	N83938 002
	75MG	N84957 001
	100MG	N85093 001
	150MG	N86295 001
AMITRIPTYLINE HCL		
AM THERAP	25MG	N88672 001
		NOV 20, 1984
	50MG	N88673 001
		NOV 20, 1984
	75MG	N88674 001
		NOV 20, 1984
	100MG	N88675 001
		NOV 20, 1984
CELLTECH PHARMS	10MG	N85864 001
	25MG	N85935 001
	50MG	N85936 001
	100MG	N86336 001
	150MG	N86335 001
COPLEY PHARM	10MG	N88421 001
		APR 30, 1984
	25MG	N88422 001
		APR 30, 1984
	50MG	N88423 001
		APR 30, 1984
	75MG	N88424 001
		APR 30, 1984
	100MG	N88425 001
		APR 30, 1984
	150MG	N88426 001
		APR 30, 1984
DANBURY PHARMA	10MG	N88620 001
		MAR 02, 1984
	25MG	N88621 001
		MAR 02, 1984
	50MG	N88622 001
		MAR 02, 1984
	75MG	N88633 001
		MAR 02, 1984

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

AMITRIPTYLINE HCL		
DANBURY PHARMA	100MG	N88634 001
		MAR 02, 1984
	150MG	N88635 001
		MAR 02, 1984
HALSEY	10MG	N85744 001
	10MG	N85923 001
	25MG	N85627 001
	25MG	N85922 001
	50MG	N85745 001
	50MG	N85925 001
	50MG	N87557 001
		MAR 05, 1982
	75MG	N85743 001
	75MG	N85926 001
		MAY 20, 1983
	100MG	N85742 002
		MAY 11, 1982
	100MG	N85927 001
		MAY 20, 1983
	150MG	N89423 001
		FEB 17, 1987
LEDERLE	10MG	N86744 001
	10MG	N87366 001
		JAN 04, 1982
	25MG	N86746 001
	25MG	N87367 001
		MAY 03, 1982
	50MG	N86743 001
	50MG	N87181 001
		JAN 04, 1982
	75MG	N86745 001
	75MG	N87369 001
		JAN 04, 1982
	100MG	N86747 001
	100MG	N87368 001
		MAY 03, 1982
	150MG	N87370 001
		JAN 04, 1982
PAR PHARM	10MG	N88697 001
		SEP 25, 1984
	25MG	N88698 001
		SEP 25, 1984
	50MG	N88699 001
		SEP 25, 1984

FDA data supplied by DrugPatentWatch.com

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

AMITRIPTYLINE HCL		
PAR PHARM	75MG	N88700 001
		SEP 25, 1984
	100MG	N88701 001
		SEP 25, 1984
	150MG	N88702 001
		SEP 25, 1984
PUREPAC PHARM	10MG	N88075 001
		SEP 16, 1983
	10MG	N88084 001
		JUL 18, 1983
	25MG	N88076 001
		MAY 20, 1983
	25MG	N88085 001
		JUL 18, 1983
	50MG	N88077 001
		SEP 16, 1983
	50MG	N88105 001
		JUL 18, 1983
	75MG	N88078 001
		SEP 16, 1983
	75MG	N88106 001
		JUL 18, 1983
	100MG	N88079 001
		SEP 16, 1983
	100MG	N88107 001
		JUL 18, 1983
ROXANE	10MG	N86002 001
	10MG	N86144 001
	25MG	N85944 001
	25MG	N86145 001
	50MG	N85945 001
	50MG	N86143 001
	75MG	N86004 001
	75MG	N86147 001
	100MG	N86003 001
	100MG	N86146 001
	150MG	N86090 001
	150MG	N86148 001
TEVA	10MG	N86610 001
	25MG	N86859 001
	50MG	N86857 001
	75MG	N85030 001
	75MG	N86860 001
	100MG	N86854 001
	150MG	N86853 001

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

AMITRIPTYLINE HCL		
USL PHARMA	25MG	N87775 001
		FEB 10, 1982
VANGARD	10MG	N87632 001
		FEB 01, 1982
	50MG	N87616 001
		FEB 08, 1982
	75MG	N87617 001
		FEB 05, 1982
	100MG	N87639 001
		FEB 08, 1982
WATSON LABS	10MG	N85816 001
	25MG	N85817 001
	50MG	N85815 001
	75MG	N85819 001
	100MG	N85820 001
	150MG	N85821 001
WEST WARD	10MG	N87647 001
		MAR 05, 1982
	25MG	N87278 001
ENDEP		
ROCHE	10MG	N83639 001
	25MG	N83639 002
	50MG	N83639 003
	75MG	N83639 004
	100MG	N83639 005
	150MG	N85303 001

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET; ORAL

CHLORDIAZEPOXIDE AND AMITRIPTYLINE HCL		
HALSEY	EQ 12.5MG BASE;5MG	N70765 001
		DEC 10, 1986
	EQ 25MG BASE;10MG	N70766 001
		DEC 10, 1986
USL PHARMA	EQ 12.5MG BASE;5MG	N70477 001
		JAN 12, 1988
	EQ 25MG BASE;10MG	N70478 001
		JAN 12, 1988

FDA data supplied by DrugPatentWatch.com

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET; ORAL

ETRAFON-A		
SCHERING	10MG;4MG	N14713 002
PERPHENAZINE AND AMITRIPTYLINE HCL		
DANBURY PHARMA	10MG;2MG	N72539 001 FEB 15, 1989
	10MG;4MG	N72540 001 FEB 15, 1989
	25MG;2MG	N72541 001 FEB 15, 1989
	25MG;4MG	N72134 001 FEB 15, 1989
	50MG;4MG	N72135 001 FEB 15, 1989
HALSEY	10MG;2MG	N71077 001 NOV 12, 1986
	10MG;4MG	N71078 001 NOV 12, 1986
	25MG;2MG	N70297 001 NOV 12, 1986
	25MG;4MG	N71079 001 NOV 12, 1986
IVAX PHARMS	10MG;2MG	N70935 001 SEP 11, 1986
	10MG;4MG	N70937 001 SEP 11, 1986
	25MG;2MG	N70936 001 SEP 11, 1986
	25MG;4MG	N70938 001 SEP 11, 1986
	50MG;4MG	N70939 001 SEP 12, 1986
PAR PHARM	10MG;2MG	N70565 001 SEP 11, 1986
	10MG;4MG	N70620 001 SEP 11, 1986
	25MG;2MG	N70621 001 SEP 11, 1986
	25MG;4MG	N70595 001 SEP 11, 1986
	50MG;4MG	N70574 001 SEP 11, 1986
WATSON LAB	10MG;2MG	N70373 001 AUG 25, 1986
	10MG;4MG	N70375 001 AUG 25, 1986

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET; ORAL

PERPHENAZINE AND AMITRIPTYLINE HCL		
WATSON LAB	25MG;2MG	N70374 001 AUG 25, 1986
	25MG;4MG	N70376 001 AUG 25, 1986
	50MG;4MG	N70377 001 NOV 04, 1986
WATSON LABS	50MG;4MG	N71558 001 MAR 02, 1987
TRIAVIL 2-10		
NEW RIVER	10MG;2MG	N14715 004
TRIAVIL 2-25		
NEW RIVER	25MG;2MG	N14715 002
TRIAVIL 4-10		
NEW RIVER	10MG;4MG	N14715 003
TRIAVIL 4-25		
NEW RIVER	25MG;4MG	N14715 005
TRIAVIL 4-50		
NEW RIVER	50MG;4MG	N14715 006

AMMONIUM CHLORIDE

INJECTABLE; INJECTION

AMMONIUM CHLORIDE		
ABBOTT	5MEQ/ML	N83130 001
GD SEARLE LLC	3MEQ/ML	N86205 001
AMMONIUM CHLORIDE 0.9%	IN NORMAL SALINE	
MCGAW	900MG/100ML	N06580 001
AMMONIUM CHLORIDE 2.14%		
B BRAUN	40MEQ/100ML	N85734 001

AMODIAQUINE HYDROCHLORIDE

TABLET; ORAL

CAMOQUIN HCL		
PARKE DAVIS	EQ 200MG BASE	N06441 001

AMOXAPINE

TABLET; ORAL

ASENDIN		
LEDERLE	25MG	N18021 001
	50MG	N18021 002

FDA data supplied by DrugPatentWatch.com

AMOXAPINE

TABLET; ORAL			
ASENDIN			
LEDERLE	100MG	N18021	003
	150MG	N18021	004

AMOXICILLIN

CAPSULE; ORAL			
AMOXICILLIN			
LABS ATRAL	250MG	N62528	001
		AUG 07, 1985	
	500MG	N62528	002
		AUG 07, 1985	
MYLAN	250MG	N62067	001
	500MG	N62067	002
TEVA	250MG	N63030	001
		FEB 28, 1989	
	500MG	N63031	001
		FEB 28, 1989	
AMOXIL			
GLAXOSMITHKLINE	250MG	N50459	001
	250MG	N62216	003
	500MG	N50459	002
TRIMOX			
APOTHECON	250MG	N62098	001
	250MG	N62152	001
	250MG	N63099	001
		MAR 20, 1992	
	500MG	N62098	002
	500MG	N62152	002
	500MG	N63099	002
		MAR 20, 1992	
UTIMOX			
PARKE DAVIS	250MG	N62107	001
	500MG	N62107	002
WYMOX			
WYETH AYERST	250MG	N62120	001
	500MG	N62120	002
FOR SUSPENSION; ORAL			
AMOXICILLIN			
MYLAN	125MG/5ML	N62090	001
	250MG/5ML	N62090	002
AMOXIL			
GLAXOSMITHKLINE	125MG/5ML	N50460	001
	250MG/5ML	N50460	002

AMOXICILLIN

FOR SUSPENSION; ORAL			
AMOXIL			
GLAXOSMITHKLINE	50MG/ML	N50460	005
LAROTID			
GLAXOSMITHKLINE	50MG/ML	N50460	006
POLYMOX			
APOTHECON	125MG/5ML	N61851	001
	125MG/5ML	N62323	001
	250MG/5ML	N61851	002
	250MG/5ML	N62323	002
TRIMOX			
APOTHECON	125MG/5ML	N61886	002
	125MG/5ML	N62099	001
	125MG/5ML	N62154	001
	50MG/ML	N61886	001
	250MG/5ML	N61886	003
	250MG/5ML	N62099	002
	250MG/5ML	N62154	002
UTIMOX			
PARKE DAVIS	125MG/5ML	N62127	001
	250MG/5ML	N62127	002

AMPHETAMINE ADIPATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE ADIPATE; DEXTROAMPHETAMINE SULFATE

CAPSULE; ORAL			
DELCOBESE			
TEVA	1.25MG;1.25MG;1.25MG; 1.25MG	N83564	001
	2.5MG;2.5MG;2.5MG;2.5MG	N83564	002
	3.75MG;3.75MG;3.75MG; 3.75MG	N83564	003
	5MG;5MG;5MG;5MG	N83564	004
TABLET; ORAL			
DELCOBESE			
TEVA	1.25MG;1.25MG;1.25MG; 1.25MG	N83563	004
	2.5MG;2.5MG;2.5MG;2.5MG	N83563	003
	3.75MG;3.75MG;3.75MG; 3.75MG	N83563	002
	5MG;5MG;5MG;5MG	N83563	001

FDA data supplied by DrugPatentWatch.com

AMPHETAMINE RESIN COMPLEX; DEXTROAMPHETAMINE RESIN COMPLEX

CAPSULE, EXTENDED RELEASE; ORAL			
BIPHETAMINE 12.5			
CELLTECH PHARMS	EQ 6.25MG BASE; EQ 6.25MG BASE	N10093	007
BIPHETAMINE 20			
CELLTECH PHARMS	EQ 10MG BASE;EQ 10MG BASE	N10093	003
BIPHETAMINE 7.5			
CELLTECH PHARMS	EQ 3.75MG BASE; EQ 3.75MG BASE	N10093	009

AMPHETAMINE SULFATE

TABLET; ORAL			
AMPHETAMINE SULFATE			
LANNETT	5MG	N83901	001
		AUG 31, 1984	
	10MG	N83901	002
		AUG 31, 1984	

AMPHETAMINE SULFATE; *MULTIPLE*

SEE AMPHETAMINE ADIPATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE ADIPATE; DEXTROAMPHETAMINE SULFATE

AMPHOTERICIN B

INJECTABLE; INJECTION			
AMPHOTERICIN B			
ABBOTT	50MG/VIAL	N64141	001
		DEC 23, 1996	
AM PHARM PARTNERS	50MG/VIAL	N62728	001
		APR 13, 1987	
OINTMENT; TOPICAL			
FUNGIZONE			
APOTHECON	3%	N50313	001

AMPICILLIN SODIUM

INJECTABLE; INJECTION			
AMPICILLIN SODIUM			
CONSOLIDATED PHARM	EQ 125MG BASE/VIAL	N61936	005
	EQ 250MG BASE/VIAL	N61936	001
	EQ 500MG BASE/VIAL	N61936	002

AMPICILLIN SODIUM

INJECTABLE; INJECTION			
AMPICILLIN SODIUM			
CONSOLIDATED PHARM	EQ 1GM BASE/VIAL	N61936	003
	EQ 2GM BASE/VIAL	N61936	004
ELKINS SINN	EQ 125MG BASE/VIAL	N62692	001
		JUN 24, 1986	
	EQ 250MG BASE/VIAL	N62692	002
		JUN 24, 1986	
	EQ 500MG BASE/VIAL	N62692	003
		JUN 24, 1986	
	EQ 1GM BASE/VIAL	N62692	004
		JUN 24, 1986	
	EQ 2GM BASE/VIAL	N62692	005
		JUN 24, 1986	
	EQ 10GM BASE/VIAL	N62692	006
		JUN 24, 1986	
HANFORD GC	EQ 1GM BASE/VIAL	N62772	001
		APR 15, 1993	
	EQ 1GM BASE/VIAL	N63139	001
		APR 15, 1993	
	EQ 2GM BASE/VIAL	N63140	001
		APR 15, 1993	
	EQ 2GM BASE/VIAL	N63141	001
		APR 15, 1993	
	EQ 10GM BASE/VIAL	N63142	001
		APR 15, 1993	
	EQ 125MG BASE/VIAL	N63143	001
		APR 15, 1993	
	EQ 250MG BASE/VIAL	N63145	001
		APR 15, 1993	
	EQ 500MG BASE/VIAL	N63146	001
		APR 15, 1993	
	EQ 500MG BASE/VIAL	N63147	001
		APR 15, 1993	
IBI	EQ 125MG BASE/VIAL	N62797	001
		JUL 12, 1993	
	EQ 2GM BASE/VIAL	N62797	002
		JUL 12, 1993	
INTL MEDICATION	EQ 1GM BASE/VIAL	N62634	002
		JAN 09, 1987	
	EQ 2GM BASE/VIAL	N62634	003
		JAN 09, 1987	
LILLY	EQ 500MG BASE/VIAL	N62565	001
		APR 04, 1985	
	EQ 1GM BASE/VIAL	N62565	002
		APR 04, 1985	

FDA data supplied by DrugPatentWatch.com

AMPICILLIN SODIUM

INJECTABLE; INJECTION

AMPICILLIN SODIUM		
LILLY	EQ 2GM BASE/VIAL	N62565 003
		JUN 24, 1986
MARSAM PHARMS LLC	EQ 10GM BASE/VIAL	N62994 001
		SEP 15, 1988
OMNIPEN-N		
WYETH AYERST	EQ 125MG BASE/VIAL	N62718 001
		DEC 16, 1986
	EQ 250MG BASE/VIAL	N62718 002
		DEC 16, 1986
	EQ 500MG BASE/VIAL	N62718 003
		DEC 16, 1986
	EQ 1GM BASE/VIAL	N62718 004
		DEC 16, 1986
	EQ 2GM BASE/VIAL	N62718 005
		DEC 16, 1986
PENBRITIN-S		
WYETH AYERST	EQ 125MG BASE/VIAL	N50072 001
	EQ 250MG BASE/VIAL	N50072 002
	EQ 500MG BASE/VIAL	N50072 003
	EQ 1GM BASE/VIAL	N50072 004
	EQ 2GM BASE/VIAL	N50072 005
	EQ 4GM BASE/VIAL	N50072 006
POLYCILLIN-N		
BRISTOL	EQ 125MG BASE/VIAL	N50309 001
	EQ 250MG BASE/VIAL	N50309 002
	EQ 500MG BASE/VIAL	N50309 003
	EQ 1GM BASE/VIAL	N50309 004
	EQ 2GM BASE/VIAL	N50309 005
TOTACILLIN-N		
GLAXOSMITHKLINE	EQ 1GM BASE/VIAL	N62727 001
		DEC 19, 1986
	EQ 2GM BASE/VIAL	N62727 002
		DEC 19, 1986

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE; INJECTION

UNASYN		
PFIZER	EQ 500MG BASE/VIAL; EQ 250MG BASE/VIAL	N50608 003
		DEC 31, 1986

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE; ORAL

AMCILL		
PARKE DAVIS	EQ 250MG BASE	N62041 001
	EQ 500MG BASE	N62041 002
AMPICILLIN		
LEDERLE	EQ 250MG BASE	N62208 001
	EQ 500MG BASE	N62208 002
VITARINE	EQ 250MG BASE	N61387 001
	EQ 500MG BASE	N61387 003
AMPICILLIN TRIHYDRATE		
BIOCHEMIE	EQ 250MG BASE	N64082 001
		AUG 29, 1995
	EQ 500MG BASE	N64082 002
		AUG 29, 1995
IVAX PHARMS	EQ 250MG BASE	N60765 001
	EQ 500MG BASE	N60765 002
MYLAN	EQ 250MG BASE	N61755 001
	EQ 500MG BASE	N61755 002
PUREPAC PHARM	EQ 250MG BASE	N61853 001
PENBRITIN		
WYETH AYERST	EQ 250MG BASE	N60908 001
	EQ 500MG BASE	N60908 002
PFIZERPEN-A		
PFIZER	EQ 250MG BASE	N62050 001
	EQ 500MG BASE	N62050 002
POLYCILLIN		
BRISTOL	EQ 250MG BASE	N50310 001
	EQ 500MG BASE	N50310 002
PRINCIPEN '250'		
APOTHECON	EQ 250MG BASE	N50056 001
	EQ 250MG BASE	N62157 002
PRINCIPEN '500'		
APOTHECON	EQ 500MG BASE	N50056 002
	EQ 500MG BASE	N62157 001
TOTACILLIN		
GLAXOSMITHKLINE	EQ 250MG BASE	N60060 001
	EQ 500MG BASE	N60060 002

FOR SUSPENSION; ORAL

AMCILL		
PARKE DAVIS	EQ 125MG BASE/5ML	N62030 001
	EQ 250MG BASE/5ML	N62030 002
AMPICILLIN TRIHYDRATE		
MYLAN	EQ 125MG BASE/5ML	N61829 002
	EQ 250MG BASE/5ML	N61829 001
PUREPAC PHARM	EQ 125MG BASE/5ML	N61980 001
OMNIPEN (AMPICILLIN)		
WYETH AYERST	500MG/5ML	N60625 004

FDA data supplied by DrugPatentWatch.com

AMPICILLIN/AMPICILLIN TRIHYDRATE

FOR SUSPENSION; ORAL			
PENBRITIN			
WYETH AYERST	EQ 100MG BASE/ML	N50019	001
	EQ 125MG BASE/5ML	N50019	002
	EQ 250MG BASE/5ML	N50019	003
PFIZERPEN-A			
PFIZER	EQ 125MG BASE/5ML	N62049	001
	EQ 250MG BASE/5ML	N62049	002
POLYCILLIN			
APOTHECON	EQ 125MG BASE/5ML	N62297	001
	EQ 250MG BASE/5ML	N62297	002
BRISTOL	EQ 125MG BASE/5ML	N50308	001
	EQ 250MG BASE/5ML	N50308	002
	EQ 500MG BASE/5ML	N50308	003
	EQ 100MG BASE/ML	N50308	004
PRINCIPEN '125'			
APOTHECON	EQ 125MG BASE/5ML	N60127	002
	EQ 125MG BASE/5ML	N62151	001
PRINCIPEN '250'			
APOTHECON	EQ 250MG BASE/5ML	N60127	001
	EQ 250MG BASE/5ML	N62151	002
TOTACILLIN			
GLAXOSMITHKLINE	EQ 125MG BASE/5ML	N60666	001
	EQ 125MG BASE/5ML	N62223	001
	EQ 250MG BASE/5ML	N60666	002
	EQ 250MG BASE/5ML	N62223	002
TABLET, CHEWABLE; ORAL			
POLYCILLIN			
BRISTOL	EQ 125MG BASE	N50093	001

AMPICILLIN/AMPICILLIN TRIHYDRATE; PROBENECID

CAPSULE; ORAL			
PRINCIPEN W/ PROBENECID			
APOTHECON	EQ 389MG BASE;111MG	N50488	001
	EQ 389MG BASE;111MG	N62150	001
FOR SUSPENSION; ORAL			
POLYCILLIN-PRB			
APOTHECON	EQ 3.5GM BASE/BOT;1GM/BOT	N61898	001
BRISTOL	EQ 3.5GM BASE/BOT;1GM/BOT	N50457	001
PROBAMPACIN			
TEVA	EQ 3.5GM BASE/BOT;1GM/BOT	N61741	001

ANILERIDINE HYDROCHLORIDE

TABLET; ORAL			
LERITINE			
MERCK	EQ 25MG BASE	N10585	002

ANILERIDINE PHOSPHATE

INJECTABLE; INJECTION			
LERITINE			
MERCK	25MG/ML	N10520	003

ANISOTROPINE METHYLBROMIDE

TABLET; ORAL			
ANISOTROPINE METHYLBROMIDE			
WATSON LAB	50MG	N86046	001
VALPIN 50			
ENDO PHARMS	50MG	N13428	001

ARBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION			
GENESA			
GENSIA AUTOMEDICS	0.05MG/ML	N20420	001
		SEP 12, 1997	

ARDEPARIN SODIUM

INJECTABLE; INJECTION			
NORMIFLO			
PHARMACIA AND UPJOHN	5,000 UNITS/0.5ML	N20227	002
		MAY 23, 1997	
	10,000 UNITS/0.5ML	N20227	001
		MAY 23, 1997	

FDA data supplied by DrugPatentWatch.com

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION
M.V.I.-12 LYOPHILIZED

ASTRAZENECA	100MG/VIAL;0.06MG/VIAL;0.005MG/VIAL; 15MG/VIAL;5 UGM/VIAL;0.4MG/VIAL; 40MG/VIAL;4MG/VIAL;3.6MG/VIAL; 3MG/VIAL;1MG/VIAL; 10MG/VIAL	N18933 002 AUG 08, 1985

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION
M.V.C. 9+3

AM PHARM PARTNERS	10MG/ML;0.006MG/ML;0.5 UGM/ML; 1.5MG/ML;20 IU/ML;0.04MG/ML;4MG/ML; 0.4MG/ML;0.36MG/ML;0.3MG/ML; 330 UNITS/ML;1 IU/ML	N18440 002 AUG 08, 1985

MVC PLUS

STERIS	10MG/ML;0.006MG/ML;0.5 UGM/ML; 1.5MG/ML;20 IU/ML;0.04MG/ML;4MG/ML; 0.4MG/ML;0.36MG/ML;0.3MG/ML; 330 UNITS/ML;1 IU/ML	N18439 002 AUG 08, 1985

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN E

INJECTABLE; INJECTION
BEROCCA PN

ROCHE	50MG/ML;0.03MG/ML;0.0025MG/ML; 7.5MG/ML;100 IU/ML;0.2MG/ML;20MG/ML; 2MG/ML;1.8MG/ML;1.5MG/ML; 1,650 IU/ML;5 IU/ML	N06071 003 OCT 10, 1985

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PHYTONADIONE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A PALMITATE; VITAMIN E

INJECTABLE; INJECTION
VITAPED

FRESENIUS KABI	N/A,80MG/VIAL;N/A,0.02MG/VIAL;N/A, 0.001MG/VIAL;400 IU/10ML,N/A;N/A, 0.14MG/VIAL;N/A,17MG/VIAL;N/A, 5MG/VIAL;0.2MG/10ML,N/A;N/A, 1MG/VIAL;N/A,1.4MG/VIAL;N/A, 1.2MG/VIAL;EQ 2,300 UNITS BASE/10ML, N/A;7 IU/10ML,N/A	N20176 001 DEC 29, 1993

ASPIRIN

TABLET, EXTENDED RELEASE; ORAL
8-HOUR BAYER

BAYER	650MG	N16030 001

MEASURIN

BAYER	650MG	N16030 002

ASPIRIN; *MULTIPLE*
SEE ACETAMINOPHEN; ASPIRIN; CODEINE PHOSPHATE

ASPIRIN; BUTALBITAL

TABLET; ORAL
AXOTAL

SAVAGE LABS	650MG;50MG	N88305 001 OCT 13, 1983

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL
BUTALBITAL, ASPIRIN AND CAFFEINE

WATSON LABS	325MG;50MG;40MG	N86231 002 FEB 12, 1985

TABLET; ORAL
BUTALBITAL ASPIRIN AND CAFFEINE

QUANTUM PHARMICS	325MG;50MG;40MG	N88972 001 JUN 18, 1985

FDA data supplied by DrugPatentWatch.com

ASPIRIN; BUTALBITAL; CAFFEINE

TABLET; ORAL

BUTALBITAL COMPOUND		
IVAX PHARMS	325MG;50MG;40MG	N85441 002 OCT 31, 1984
BUTALBITAL, ASPIRIN & CAFFEINE		
HALSEY	325MG;50MG;40MG	N89448 001 DEC 01, 1986
BUTALBITAL, ASPIRIN AND CAFFEINE		
WATSON LABS	325MG;50MG;40MG	N86237 002 MAR 23, 1984
LANORINAL		
LANNETT	325MG;50MG;40MG	N86986 002 OCT 18, 1985

ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

COMPOUND 65		
ALRA	389MG;32.4MG;65MG	N84553 002 AUG 17, 1983
PROPOXYPHENE COMPOUND 65		
EON	389MG;32.4MG;65MG	N80044 002 SEP 16, 1983
IVAX PHARMS	389MG;32.4MG;65MG	N83077 002 DEC 07, 1984
PROPOXYPHENE COMPOUND-65		
GENEVA PHARMS	389MG;32.4MG;65MG	N83101 002 JUN 24, 1985
PROPOXYPHENE HCL W/ ASPIRIN AND CAFFEINE		
WATSON LABS	389MG;32.4MG;65MG	N85732 002 SEP 03, 1984

ASPIRIN; CARISOPRODOL

TABLET; ORAL

CARISOPRODOL COMPOUND		
WATSON LAB	325MG;200MG	N88809 001 OCT 03, 1985

ASPIRIN; HYDROCODONE BITARTRATE

TABLET; ORAL

VICOPRIN		
ABBOTT	500MG;5MG	N86333 001 SEP 14, 1983

ASPIRIN; MEPROBAMATE

TABLET; ORAL

MEPRO-ASPIRIN		
EON	325MG;200MG	N89127 001 MAR 02, 1987
MEPROBAMATE AND ASPIRIN		
PAR PHARM	325MG;200MG	N89126 001 AUG 19, 1986
Q-GESIC		
QUANTUM PHARMICS	325MG;200MG	N88740 001 JUN 01, 1984

ASPIRIN; METHOCARBAMOL

TABLET; ORAL

METHOCARBAMOL AND ASPIRIN		
MCNEIL	325MG;400MG	N89193 001 FEB 12, 1986

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

TABLET; ORAL

CODOXY		
HALSEY	325MG;4.5MG;0.38MG	N87464 001 JUL 01, 1982
OXYCODONE AND ASPIRIN (HALF-STRENGTH)		
ROXANE	325MG;2.25MG;0.19MG	N87742 001 JUN 04, 1982
ROXIPRIN		
ROXANE	325MG;4.5MG;0.38MG	N87743 001 JUN 04, 1982

ASPIRIN; PROPOXYPHENE NAPSYLATE

CAPSULE; ORAL

DARVON-N W/ ASA		
LILLY	325MG;100MG	N16829 001

TABLET; ORAL

DARVON-N W/ ASA		
LILLY	325MG;100MG	N16863 001

FDA data supplied by DrugPatentWatch.com

ATENOLOL

TABLET; ORAL		
ATENOLOL		
APOTHECON	50MG	N73317 001 MAR 20, 1992
	100MG	N73318 001 MAR 20, 1992
GENPHARM	25MG	N74126 003 AUG 26, 1998
	50MG	N74126 001 MAR 23, 1994
	100MG	N74126 002 MAR 23, 1994

ATROPINE

INJECTABLE; INJECTION		
ATROPINE		
SOLVAY	EQ 2MG SULFATE/0.7ML	N71295 001 JAN 30, 1987

ATROPINE SULFATE

AEROSOL, METERED; INHALATION		
ATROPINE SULFATE		
US ARMY	EQ 0.36MG BASE/INH	N20056 001 SEP 19, 1990

ATROPINE SULFATE; DIFENOXIN HYDROCHLORIDE

TABLET; ORAL		
MOTOFEN HALF-STRENGTH		
AMARIN PHARMS	0.025MG;0.5MG	N17744 001

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

SOLUTION; ORAL		
COLONAID		
WALLACE LABS	0.025MG/5ML;2.5MG/5ML	N85735 001
LOMANATE		
ALPHARMA	0.025MG/5ML;2.5MG/5ML	N85746 001
TABLET; ORAL		
COLONAID		
WALLACE LABS	0.025MG;2.5MG	N85737 001

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET; ORAL		
DI-ATRO		
MD PHARM	0.025MG;2.5MG	N85266 001
DIPHENOXYLATE HCL AND ATROPINE SULFATE		
ASCOT	0.025MG;2.5MG	N87934 001 JUL 19, 1983
HALSEY	0.025MG;2.5MG	N85506 001
HEATHER	0.025MG;2.5MG	N86798 001
INWOOD LABS	0.025MG;2.5MG	N85509 001
LEDERLE	0.025MG;2.5MG	N86950 001
PARKE DAVIS	0.025MG;2.5MG	N87131 001
R AND S PHARMA	0.025MG;2.5MG	N85035 001
ROXANE	0.025MG;2.5MG	N86057 001
WATSON LABS	0.025MG;2.5MG	N85876 001
WEST WARD	0.025MG;2.5MG	N87765 001 MAR 15, 1982
DIPHENOXYLATE HCL W/ ATROPINE SULFATE		
ICN	0.025MG;2.5MG	N87195 001 FEB 16, 1982
KV PHARM	0.025MG;2.5MG	N85659 001
PVT FORM	0.025MG;2.5MG	N85766 001
USL PHARMA	0.025MG;2.5MG	N87842 001 MAR 29, 1982
LO-TROL		
VANGARD	0.025MG;2.5MG	N88009 001 MAR 25, 1983
LOGEN		
SUPERPHARM	0.025MG;2.5MG	N88962 001 MAY 10, 1985
LOW-QUEL		
HALSEY	0.025MG;2.5MG	N85211 001

ATROPINE SULFATE; MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION		
MEPERIDINE AND ATROPINE SULFATE		
WYETH AYERST	0.4MG/ML;50MG/ML	N85121 001
	0.4MG/ML;75MG/ML	N85121 002
	0.4MG/ML;100MG/ML	N85121 003

AZATHIOPRINE

TABLET; ORAL		
IMURAN		
PROMETHEUS LABS	25MG	N16324 002

FDA data supplied by DrugPatentWatch.com

AZATHIOPRINE SODIUM

INJECTABLE; INJECTION
AZATHIOPRINE

QUAD PHARMS	EQ 100MG BASE/VIAL	N71056 001 JUN 08, 1988

AZITHROMYCIN DIHYDRATE; TROVAFLOXACIN MESYLATE

FOR SUSPENSION, TABLET; ORAL
TROVAN/ZITHROMAX COMPLIANCE PAK

PFIZER	EQ 1GM BASE,N/A;N/A, EQ 100MG BASE	N50762 001 DEC 18, 1998

AZLOCILLIN SODIUM

INJECTABLE; INJECTION
AZLIN

BAYER	EQ 2GM BASE/VIAL	N50562 001 SEP 03, 1982
	EQ 2GM BASE/VIAL	N62388 001 SEP 08, 1982
	EQ 2GM BASE/VIAL	N62417 001 OCT 12, 1982
	EQ 3GM BASE/VIAL	N50562 002 SEP 03, 1982
	EQ 3GM BASE/VIAL	N62388 002 SEP 08, 1982
	EQ 3GM BASE/VIAL	N62417 002 OCT 12, 1982
	EQ 4GM BASE/VIAL	N50562 003 SEP 03, 1982
	EQ 4GM BASE/VIAL	N62388 003 SEP 08, 1982
	EQ 4GM BASE/VIAL	N62417 003 OCT 12, 1982

AZTREONAM

INJECTABLE; INJECTION
AZACTAM IN PLASTIC CONTAINER

BRISTOL MYERS SQUIBB	10MG/ML	N50632 003 MAY 24, 1989

BACAMPICILLIN HYDROCHLORIDE

TABLET; ORAL
SPECTROBID

PFIZER	800MG	N50520 002 SEP 12, 1983

BACITRACIN

INJECTABLE; INJECTION
BACITRACIN

PFIZER	50,000 UNITS/VIAL	N60282 001
QUAD PHARMS	10,000 UNITS/VIAL	N62696 001 APR 17, 1987
	50,000 UNITS/VIAL	N62696 002 APR 17, 1987

OINTMENT; OPHTHALMIC
BACIGUENT

PHARMACIA AND UPJOHN	500 UNITS/GM	N60734 001

BACITRACIN

LILLY	500 UNITS/GM	N60687 001
PHARMADERM	500 UNITS/GM	N62158 001
PHARMAFAIR	500 UNITS/GM	N62453 001 MAR 28, 1984

OINTMENT; TOPICAL
BACITRACIN

COMBE	500 UNITS/GM	N62799 001 MAY 14, 1987

POWDER; FOR RX COMPOUNDING
BACITRACIN

PADDOCK	5,000,000 UNITS/BOT	N62456 001 JUL 27, 1983

BACITRACIN; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC
BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE

ALTANA	400 UNITS/GM;1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM	N60731 002

FDA data supplied by DrugPatentWatch.com

BACITRACIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC
MYCITRACIN
PHARMACIA AND UPJOHN 500 UNITS/GM;EQ 3.5MG BASE/GM; 10,000 UNITS/GM N61048 001

BACITRACIN; POLYMYXIN B SULFATE

DISC; TOPICAL
LANABIOTIC
COMBE 500 UNITS/GM; 5,000 UNITS/GM N50598 001 SEP 22, 1986

BACITRACIN ZINC

POWDER; FOR RX COMPOUNDING
ZIBA-RX
PHARMA TEK 500,000 UNITS/BOT N61737 001

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC
ZINC BACITRACIN,NEOMYCIN SULFATE,POLYMYXIN B SULFATE & HYDROCORTISONE
PHARMAFAIR 400 UNITS/GM;1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM N62389 001 JUL 02, 1982

OINTMENT; TOPICAL
NEOMYCIN & POLYMYXIN B SULFATES & BACITRACIN ZINC & HYDROCORTISONE
PHARMAFAIR 400 UNITS/GM;1%;EQ 3.5MG BASE/GM; 5,000 UNITS/GM N62381 001 SEP 06, 1985

BACITRACIN ZINC; LIDOCAINE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; TOPICAL
LANABIOTIC
COMBE 400 UNITS/GM;40MG/GM;EQ 5MG BASE/GM; 5,000 UNITS/GM N62499 001 JUN 03, 1985

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC
BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE
PHARMAFAIR 400 UNITS/GM;EQ 3.5MG BASE/GM; 10,000 UNITS/GM N62386 001 SEP 09, 1982
BACITRACIN-NEOMYCIN-POLYMYXIN
PHARMADERM 400 UNITS/GM;EQ 3.5MG BASE/GM; 5,000 UNITS/GM N62167 001
NEO-POLYCIN
DOW PHARM 500 UNITS/GM;EQ 3.5MG BASE/GM; 10,000 UNITS/GM N60647 001

BACITRACIN ZINC; POLYMYXIN B SULFATE

AEROSOL; TOPICAL
POLYSPORIN
GLAXOSMITHKLINE 10,000 UNITS/GM; 2,000,000 UNITS/GM N50167 002 MAR 01, 1985

OINTMENT; OPHTHALMIC
OCUMYCIN
PHARMAFAIR 500 UNITS/GM; 10,000 UNITS/GM N62430 001 APR 08, 1983

BACLOFEN

TABLET; ORAL
BACLOFEN
TEVA 10MG N73043 001 FEB 27, 1992
20MG N73044 001 FEB 27, 1992
USL PHARMA 10MG N71260 001 MAY 06, 1988
20MG N71261 001 MAY 06, 1988
LIORESAL
NOVARTIS 10MG N17851 001
20MG N17851 003 JAN 20, 1982

FDA data supplied by DrugPatentWatch.com

BENDROFLUMETHIAZIDE

TABLET; ORAL
NATURETIN-2.5
APOTHECON 2.5MG N12164 001

BENOXINATE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
BENOXINATE HCL
SOLA BARNES HIND 0.4% N84149 001

BENTIROMIDE

SOLUTION; ORAL
CHYMEX
SAVAGE LABS 500MG/7.5ML N18366 001
DEC 29, 1983

BENZPHETAMINE HYDROCHLORIDE

TABLET; ORAL
DIDREX
PHARMACIA AND UPJOHN 25MG N12427 003

BENZQUINAMIDE HYDROCHLORIDE

SUPPOSITORY; RECTAL
EMETE-CON
ROERIG EQ 100MG BASE N16818 006

BENZTHIAZIDE

TABLET; ORAL
AQUATAG
SOLVAY 25MG N16001 001
50MG N16001 002
BENZTHIAZIDE
PVT FORM 50MG N83206 001
EXNA
AH ROBINS INC 50MG N12489 001
FOVANE
PFIZER 50MG N12128 002
URESE
PFIZER 25MG N12128 003

BENZTROPINE MESYLATE

TABLET; ORAL
BENZTROPINE MESYLATE
QUANTUM PHARMICS 0.5MG N88514 001
JAN 31, 1984
1MG N88510 001
JAN 31, 1984
2MG N88511 001
JAN 31, 1984
USL PHARMA 0.5MG N89211 001
JUN 14, 1988
1MG N89212 001
JUN 14, 1988
2MG N89213 001
JUN 14, 1988

BENZYL BENZOATE

EMULSION; TOPICAL
BENZYL BENZOATE
LANNETT 50% N84535 001

BEPRIDIL HYDROCHLORIDE

TABLET; ORAL
BEPADIN
WALLACE LABS 200MG N19001 001
DEC 28, 1990
300MG N19001 002
DEC 28, 1990
400MG N19001 003
DEC 28, 1990
VASCOR
JOHNSON RW 400MG N19002 003
DEC 28, 1990

BETA-CAROTENE

CAPSULE; ORAL
SOLATENE
ROCHE 30MG N17589 001

FDA data supplied by DrugPatentWatch.com

BETAMETHASONE

CREAM; TOPICAL
CELESTONE
SCHERING 0.2% N14762 001

BETAMETHASONE BENZOATE

CREAM; TOPICAL
UTICORT
PARKE DAVIS 0.025% N16998 002

GEL; TOPICAL
UTICORT
PARKE DAVIS 0.025% N17244 001

LOTION; TOPICAL
UTICORT
PARKE DAVIS 0.025% N17528 001

OINTMENT; TOPICAL
UTICORT
PARKE DAVIS 0.025% N18089 001

BETAMETHASONE DIPROPIONATE

CREAM; TOPICAL
BETAMETHASONE DIPROPIONATE
CLAY PARK EQ 0.05% BASE N72536 001 JAN 31, 1990
EQ 0.05% BASE N74579 001 NOV 26, 1997
PHARMADERM EQ 0.05% BASE N19136 001 JUN 26, 1984

CREAM, AUGMENTED; TOPICAL
DIPROLENE
SCHERING EQ 0.05% BASE N19408 001 JAN 31, 1986

DISC; TOPICAL
DIPROSONE
SCHERING EQ 0.1% BASE N17829 001

LOTION; TOPICAL
BETAMETHASONE DIPROPIONATE
ALPHARMA EQ 0.05% BASE N71085 001 FEB 03, 1987

BETAMETHASONE DIPROPIONATE

LOTION; TOPICAL
BETAMETHASONE DIPROPIONATE
PHARMADERM EQ 0.05% BASE N70274 001 AUG 12, 1985

OINTMENT; TOPICAL
BETAMETHASONE DIPROPIONATE
CLAY PARK EQ 0.05% BASE N72526 001 JAN 31, 1990
PHARMADERM EQ 0.05% BASE N19140 001 SEP 04, 1984

BETAMETHASONE VALERATE

CREAM; TOPICAL
BETAMETHASONE VALERATE
CLAY PARK EQ 0.1% BASE N70053 001 JUN 10, 1986
PHARMADERM EQ 0.1% BASE N18860 002 AUG 31, 1983
PHARMAFAIR EQ 0.1% BASE N70485 001 MAY 29, 1987
VALISONE
SCHERING EQ 0.01% BASE N16322 002
EQ 0.1% BASE N16322 001

LOTION; TOPICAL
BETAMETHASONE VALERATE
PHARMADERM EQ 0.1% BASE N18870 001 AUG 31, 1983
PHARMAFAIR EQ 0.1% BASE N70484 001 MAY 29, 1987
VALISONE
SCHERING EQ 0.1% BASE N16932 001

OINTMENT; TOPICAL
BETAMETHASONE VALERATE
CLAY PARK EQ 0.1% BASE N71478 001 DEC 23, 1987
PHARMADERM EQ 0.1% BASE N18864 001 AUG 31, 1983
PHARMAFAIR EQ 0.1% BASE N70486 001 MAY 29, 1987
VALISONE
SCHERING EQ 0.1% BASE N16740 001

FDA data supplied by DrugPatentWatch.com

BETAZOLE HYDROCHLORIDE

INJECTABLE; INJECTION			
HISTALOG			
LILLY	50MG/ML	N09344	001

BETHANECHOL CHLORIDE

INJECTABLE; INJECTION			
BETHANECHOL CHLORIDE			
QUAD PHARMS	5MG/ML	N89815	001
		APR 12, 1988	
URECHOLINE			
* SIDMAK LABS	5MG/ML	N06536	001
TABLET; ORAL			
BETHANECHOL CHLORIDE			
ASCOT	10MG	N88288	001
		JUN 08, 1983	
	25MG	N88289	001
		JUN 08, 1983	
DANBURY PHARMA	5MG	N84402	001
	10MG	N84408	001
	25MG	N84441	001
	50MG	N87444	001
EON	5MG	N84353	001
	10MG	N84378	001
	10MG	N84379	001
	25MG	N84383	001
	25MG	N84384	001
IVAX PHARMS	25MG	N84689	001
LANNETT	5MG	N84702	001
	10MG	N84712	001
	25MG	N84074	001
WATSON LAB	5MG	N85230	002
	10MG	N85228	001
	25MG	N85229	001
	50MG	N87397	001
WATSON LABS	5MG	N85841	001
	10MG	N85842	001
	25MG	N85839	001
DUVOID			
WELLSPRING PHARM	10MG	N86262	001
	25MG	N86263	001
	50MG	N85882	003
MYOTONACHOL			
GLENWOOD	5MG	N84188	001
	10MG	N84188	003

BETHANECHOL CHLORIDE

TABLET; ORAL			
MYOTONACHOL			
GLENWOOD	25MG	N84188	004
URECHOLINE			
* SIDMAK LABS	5MG	N06536	003
*	10MG	N06536	002
*	25MG	N06536	004
*	50MG	N06536	005

BETHANIDINE SULFATE

TABLET; ORAL			
TENATHAN			
ROBINS AH	10MG	N17675	001
	25MG	N17675	002

BIOTIN; *MULTIPLE*

SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE; VITAMIN A; VITAMIN E

SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN E

SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PHYTONADIONE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A PALMITATE; VITAMIN E

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL			
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE			
APOTHECON	2.5MG;6.25MG	N75642	002
		DEC 27, 2000	
	5MG;6.25MG	N75642	001
		DEC 27, 2000	
	10MG;6.25MG	N75642	003
		DEC 27, 2000	

FDA data supplied by DrugPatentWatch.com

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION			
BRETYLIUM TOSYLATE			
AM PHARM PARTNERS	50MG/ML	N70134 001	APR 29, 1986
	100MG/ML	N71298 001	FEB 13, 1987
ASTRAZENECA	50MG/ML	N71151 001	AUG 10, 1987
	50MG/ML	N71152 001	AUG 10, 1987
	50MG/ML	N71153 001	AUG 10, 1987
QUAD PHARMS	50MG/ML	N71181 001	FEB 16, 1988
BRETYLIUM TOSYLATE IN DEXTROSE 5%			
ABBOTT	200MG/100ML	N19005 002	APR 29, 1986
	400MG/100ML	N19005 003	APR 29, 1986
	800MG/100ML	N19005 001	APR 29, 1986
BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER			
ABBOTT	800MG/100ML	N19008 001	APR 29, 1986
BAXTER HLTHCARE	200MG/100ML	N19837 002	APR 12, 1989
	400MG/100ML	N19837 001	APR 12, 1989
BRETYLOL			
FAULDING	50MG/ML	N17954 001	

BRIMONIDINE TARTRATE

SOLUTION/DROPS; OPHTHALMIC			
ALPHAGAN			
ALLERGAN	0.5%	N20490 001	MAR 13, 1997

BROMOCRIPTINE MESYLATE

CAPSULE; ORAL			
BROMOCRIPTINE MESYLATE			
LEK PHARM	EQ 5MG BASE	N75100 001	DEC 10, 1998

BROMOCRIPTINE MESYLATE

TABLET; ORAL			
BROMOCRIPTINE MESYLATE			
LEK PHARM	EQ 2.5MG BASE	N74631 001	JAN 13, 1998

BROMODIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL			
AMBODRYL			
PARKE DAVIS	25MG	N07984 001	

BROMPHENIRAMINE MALEATE

ELIXIR; ORAL			
BROMPHENIRAMINE MALEATE			
ALPHARMA	2MG/5ML	N86936 001	
PHARM ASSOC	2MG/5ML	N87517 001	
USL PHARMA	2MG/5ML	N87964 001	JAN 25, 1983
INJECTABLE; INJECTION			
BROMPHENIRAMINE MALEATE			
STERIS	100MG/ML	N83820 001	
DIMETANE-TEN			
WYETH AYERST	10MG/ML	N11418 002	
TABLET; ORAL			
BROMPHENIRAMINE MALEATE			
ANABOLIC	4MG	N86187 001	
BARR	4MG	N84468 001	
DANBURY PHARMA	4MG	N83123 001	
GENEVA PHARMS	4MG	N83215 001	
IVAX PHARMS	4MG	N84351 001	
NEWTRON PHARMS	4MG	N86987 001	
PAR PHARM	4MG	N87009 001	
PIONEER PHARMS	4MG	N88604 001	JUL 13, 1984
VITARINE	4MG	N85850 001	
WATSON LABS	4MG	N85769 001	
DIMETANE			
WHITEHALL ROBINS	4MG	N10799 003	
TABLET, EXTENDED RELEASE; ORAL			
DIMETANE			
WHITEHALL ROBINS	8MG	N10799 010	JUN 10, 1983

FDA data supplied by DrugPatentWatch.com

BROMPHENIRAMINE MALEATE

TABLET, EXTENDED RELEASE; ORAL

DIMETANE			
WHITEHALL ROBINS	12MG	N10799 011	JUN 10, 1983

BROMPHENIRAMINE MALEATE; CODEINE PHOSPHATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

SYRUP; ORAL

DIMETANE-DC			
ROBINS AH	2MG/5ML;10MG/5ML; 12.5MG/5ML	N11694 006	MAR 29, 1984

BROMPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

ELIXIR; ORAL

BIPHETAP			
MORTON GROVE	4MG/5ML;25MG/5ML	N88687 001	SEP 26, 1984
BROMANATE			
ALPHARMA	4MG/5ML;25MG/5ML	N88688 001	FEB 06, 1985

TABLET, EXTENDED RELEASE; ORAL

BROMATAPP			
COPLEY PHARM	12MG;75MG	N71099 001	JUL 02, 1987

BUCLIZINE HYDROCHLORIDE

TABLET; ORAL

BUCLADIN-S			
STUART PHARMS	50MG	N10911 006	

BUDESONIDE

POWDER, METERED; INHALATION

PULMICORT			
ASTRAZENECA	0.32MG/INH	N20441 003	JUN 24, 1997

BUDESONIDE

SUSPENSION; INHALATION

PULMICORT RESPULES			
ASTRAZENECA	1MG/2ML	N20929 003	AUG 08, 2000

BUPROPION HYDROCHLORIDE

TABLET; ORAL

WELLBUTRIN			
GLAXOSMITHKLINE	50MG	N18644 001	DEC 30, 1985

TABLET, EXTENDED RELEASE; ORAL

ZYBAN			
GLAXOSMITHKLINE	100MG	N20711 002	MAY 14, 1997

BUTABARBITAL SODIUM

CAPSULE; ORAL

BUTICAPS			
WALLACE LABS	15MG	N85381 001	
	30MG	N85381 002	
	50MG	N85381 003	
	100MG	N85381 004	

ELIXIR; ORAL

BUTABARB			
ALPHARMA	30MG/5ML	N85873 001	
BUTABARBITAL SODIUM			
MORTON GROVE	30MG/5ML	N85383 001	
BUTALAN			
LANNETT	33.3MG/5ML	N85880 001	
SARISOL			
HALSEY	30MG/5ML	N84723 001	

TABLET; ORAL

BUTABARBITAL SODIUM			
EON	15MG	N85938 001	
	30MG	N85934 001	
GENEVA PHARMS	15MG	N84292 003	FEB 09, 1982
	30MG	N84272 002	
SOLVAY	16.2MG	N83606 001	
	32.4MG	N83898 001	

FDA data supplied by DrugPatentWatch.com

BUTABARBITAL SODIUM

TABLET; ORAL
- BUTABARBITAL SODIUM
  - SOLVAY — 48.6MG — N83897 001
  - SOLVAY — 97.2MG — N83896 001
  - TEVA — 15MG — N88632 001 — MAY 18, 1985
  - TEVA — 30MG — N88631 001 — MAY 01, 1985
  - WATSON LABS — 15MG — N85764 001
  - WATSON LABS — 30MG — N85772 001
  - WHITEWORTH TOWN PLSN — 15MG — N83325 002
  - WHITEWORTH TOWN PLSN — 30MG — N83337 001
- SARISOL NO. 1
  - HALSEY — 15MG — N84719 001
- SARISOL NO. 2
  - HALSEY — 30MG — N84719 002
- SODIUM BUTABARBITAL
  - IVAX PHARMS — 15MG — N83484 001
  - IVAX PHARMS — 30MG — N84040 001
  - LANNETT — 15MG — N85849 001
  - LANNETT — 30MG — N85866 001
  - LANNETT — 100MG — N85881 001
  - WEST WARD — 15MG — N85418 001
  - WEST WARD — 30MG — N85432 001

BUTALBITAL; *MULTIPLE*
- SEE ACETAMINOPHEN; BUTALBITAL
- SEE ACETAMINOPHEN; BUTALBITAL; CAFFEINE
- SEE ASPIRIN; BUTALBITAL
- SEE ASPIRIN; BUTALBITAL; CAFFEINE

BUTOCONAZOLE NITRATE

CREAM; VAGINAL
- FEMSTAT
  - SYNTEX (USA) INC LLC 2% — N19215 001 — NOV 25, 1985

SUPPOSITORY; VAGINAL
- FEMSTAT
  - SYNTEX (USA) INC LLC 100MG — N19359 001 — NOV 25, 1985

CAFFEINE; *MULTIPLE*
- SEE ACETAMINOPHEN; BUTALBITAL; CAFFEINE
- SEE ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE
- SEE ASPIRIN; BUTALBITAL; CAFFEINE
- SEE ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE

CAFFEINE; ERGOTAMINE TARTRATE

SUPPOSITORY; RECTAL
- MIGERGOT
  - G AND W LABS — 100MG;2MG — N86557 001 — OCT 04, 1983

TABLET; ORAL
- CAFERGOT
  - NOVARTIS — 100MG;1MG — N06620 001

CALCITONIN HUMAN

INJECTABLE; INJECTION
- CIBACALCIN
  - NOVARTIS — 0.5MG/VIAL — N18470 001 — OCT 31, 1986

CALCITONIN, SALMON

INJECTABLE; INJECTION
- CALCIMAR
  - AVENTIS — 400 IU/VIAL — N17497 001
- CALCITONIN-SALMON
  - ASTRAZENECA — 200 IU/ML — N73690 001 — APR 14, 1995
- MIACALCIN
  - NOVARTIS — 100 IU/ML — N17808 001 — JUL 03, 1986

CALCIUM; MEGLUMINE; METRIZOIC ACID

INJECTABLE; INJECTION
- ISOPAQUE 280
  - AMERSHAM HLTH — 0.35MG/ML;140.1MG/ML; 461.8MG/ML — N17506 001

FDA data supplied by DrugPatentWatch.com

CALCIUM ACETATE

CAPSULE; ORAL
PHOSLO
BRAINTREE EQ 84.5MG CALCIUM N21160 001
APR 02, 2001
EQ 169MG CALCIUM N21160 002
APR 02, 2001

CALCIUM CHLORIDE; *MULTIPLE*
SEE AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION
ISOLYTE R W/ DEXTROSE 5% IN PLASTIC CONTAINER
B BRAUN 37MG/100ML;5GM/100ML;31MG/100ML;
120MG/100ML;330MG/100ML;
88MG/100ML N18271 001

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

INJECTABLE; INJECTION
ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER
B BRAUN 35MG/100ML;5GM/100ML;30MG/100ML;
74MG/100ML;640MG/100ML;500MG/100ML;
74MG/100ML N18269 002
JAN 17, 1983

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SOLUTION; INTRAPERITONEAL
DIALYTE LM/ DEXTROSE 2.5% IN PLASTIC CONTAINER
B BRAUN 29MG/100ML;2.5GM/100ML;15MG/100ML;
610MG/100ML;560MG/100ML N18460 006
JAN 29, 1986
DIALYTE W/ DEXTROSE 1.5% IN PLASTIC CONTAINER
B BRAUN 29MG/100ML;1.5GM/100ML;15MG/100ML;
610MG/100ML;560MG/100ML N18460 001

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SOLUTION; INTRAPERITONEAL
DIALYTE W/ DEXTROSE 4.25% IN PLASTIC CONTAINER
B BRAUN 29MG/100ML;4.25GM/100ML;15MG/100ML;
610MG/100ML;560MG/100ML N18460 003

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL
DIALYTE LM/ DEXTROSE 1.5% IN PLASTIC CONTAINER
B BRAUN 26MG/100ML;1.5GM/100ML;15MG/100ML;
560MG/100ML;390MG/100ML N18460 002
DIALYTE LM/ DEXTROSE 2.5% IN PLASTIC CONTAINER
B BRAUN 26MG/100ML;5GM/100ML;5MG/100ML;
530MG/100ML;450MG/100ML N18460 008
JAN 29, 1986
DIALYTE LM/ DEXTROSE 4.25% IN PLASTIC CONTAINER
B BRAUN 26MG/100ML;4.25GM/100ML;15MG/100ML;
560MG/100ML;390MG/100ML N18460 004

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION
DEXTROSE 4% IN MODIFIED LACTATED RINGER'S IN PLASTIC CONTAINER
B BRAUN 4MG/100ML;4GM/100ML;6MG/100ML;
120MG/100ML;62MG/100ML N19634 002
FEB 24, 1988
DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER
B BRAUN 20MG/100ML;5GM/100ML;30MG/100ML;
600MG/100ML;310MG/100ML N17510 001
MILES 20MG/100ML;5GM/100ML;30MG/100ML;
600MG/100ML;310MG/100ML N18499 001
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER
ABBOTT 20MG/100ML;5GM/100ML;104MG/100ML;
600MG/100ML;310MG/100ML N19685 005
OCT 17, 1988
20MG/100ML;5GM/100ML;179MG/100ML;
600MG/100ML;310MG/100ML N19685 006
OCT 17, 1988

FDA data supplied by DrugPatentWatch.com

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER
ABBOTT 20MG/100ML;5GM/100ML;254MG/100ML; 600MG/100ML;310MG/100ML N19685 007 OCT 17, 1988

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER
ABBOTT 20MG/100ML;5GM/100ML;254MG/100ML; 600MG/100ML;310MG/100ML N19685 003 OCT 17, 1988

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER
ABBOTT 20MG/100ML;5GM/100ML;104MG/100ML; 600MG/100ML;310MG/100ML N19685 001 OCT 17, 1988

CALCIUM CHLORIDE; DEXTROSE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL
INPERSOL-ZM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER
FRESENIUS MEDCL 25.7MG/100ML;1.5GM/100ML; 538MG/100ML;448MG/100ML N19395 001 MAR 26, 1986

INPERSOL-ZM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER
FRESENIUS MEDCL 25.7MG/100ML;2.5GM/100ML; 538MG/100ML;448MG/100ML N19395 002 MAR 26, 1986

INPERSOL-ZM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER
FRESENIUS MEDCL 25.7MG/100ML;4.25GM/100ML; 538MG/100ML;448MG/100ML N19395 003 MAR 26, 1986

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION
TPN ELECTROLYTES IN PLASTIC CONTAINER
ABBOTT 16.5MG/ML;25.4MG/ML;74.6MG/ML; 121MG/ML;16.1MG/ML N19399 001 JUN 16, 1986

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

INJECTABLE; INJECTION
ISOLYTE E IN PLASTIC CONTAINER
B BRAUN 35MG/100ML;30MG/100ML;74MG/100ML; 640MG/100ML;500MG/100ML; 74MG/100ML N18899 001 OCT 31, 1983

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION
ACETATED RINGER'S IN PLASTIC CONTAINER
B BRAUN 20MG/100ML;30MG/100ML;380MG/100ML; 600MG/100ML N18725 001 NOV 29, 1982

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

SOLUTION; IRRIGATION
RINGER'S IN PLASTIC CONTAINER
ABBOTT 33MG/100ML;30MG/100ML; 860MG/100ML N18462 001

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION
LACTATED RINGER'S IN PLASTIC CONTAINER
ABBOTT 20MG/100ML;30MG/100ML;600MG/100ML; 310MG/100ML N19485 001 OCT 24, 1985

B BRAUN 20MG/100ML;30MG/100ML;600MG/100ML; 310MG/100ML N18023 001

MILES 20MG/100ML;30MG/100ML;600MG/100ML; 310MG/100ML N18417 001

CALCIUM GLUCEPTATE

INJECTABLE; INJECTION
CALCIUM GLUCEPTATE
ABBOTT EQ 90MG CALCIUM/5ML N80001 001
EQ 90MG CALCIUM/5ML N83159 001

FDA data supplied by DrugPatentWatch.com

CALCIUM GLUCEPTATE

INJECTABLE; INJECTION			
CALCIUM GLUCEPTATE			
AM PHARM PARTNERS	EQ 90MG CALCIUM/5ML	N89373 001	APR 30, 1987
LILLY	EQ 90MG CALCIUM/5ML	N06470 001	

CALCIUM METRIZOATE; MEGLUMINE METRIZOATE; METRIZOATE MAGNESIUM; METRIZOATE SODIUM

INJECTABLE; INJECTION			
ISOPAQUE 440			
AMERSHAM HLTH	0.78MG/ML;75.9MG/ML;0.15MG/ML; 16.6MG/ML	N16847 001	

CANDICIDIN

OINTMENT; VAGINAL			
VANOBID			
AVENTIS PHARMS	0.6MG/GM	N61596 001	
TABLET; VAGINAL			
VANOBID			
AVENTIS PHARMS	3MG	N61613 001	

CAPTOPRIL

TABLET; ORAL			
CAPOTEN			
BRISTOL MYERS SQUIBB	37.5MG	N18343 006	SEP 17, 1986
	75MG	N18343 007	JUN 13, 1995
	150MG	N18343 004	JUN 13, 1995
CAPTOPRIL			
PUREPAC PHARM	12.5MG	N74640 001	MAR 31, 1997
	25MG	N74640 002	MAR 31, 1997
	50MG	N74640 003	MAR 31, 1997
	100MG	N74640 004	MAR 31, 1997

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL			
CAPTOPRIL AND HYDROCHLOROTHIAZIDE			
DANBURY PHARMA	50MG;25MG	N74832 001	DEC 29, 1997

CARBACHOL

SOLUTION; INTRAOCULAR			
CARBACHOL			
PHARMAFAIR	0.01%	N70292 001	MAY 21, 1986

CARBAMAZEPINE

TABLET; ORAL			
CARBAMAZEPINE			
USL PHARMA	200MG	N70300 001	MAY 15, 1986
WARNER CHILCOTT	200MG	N70429 001	JAN 02, 1987

CARBENICILLIN DISODIUM

INJECTABLE; INJECTION			
GEOPEN			
ROERIG	EQ 1GM BASE/VIAL	N50306 001	
	EQ 2GM BASE/VIAL	N50306 004	
	EQ 5GM BASE/VIAL	N50306 002	
	EQ 10GM BASE/VIAL	N50306 006	
	EQ 30GM BASE/VIAL	N50306 007	
PYOPEN			
GLAXOSMITHKLINE	EQ 1GM BASE/VIAL	N50298 001	
	EQ 2GM BASE/VIAL	N50298 002	
	EQ 5GM BASE/VIAL	N50298 003	
	EQ 10GM BASE/VIAL	N50298 006	
	EQ 20GM BASE/VIAL	N50298 007	

CARBIDOPA; LEVODOPA

TABLET; ORAL			
CARBIDOPA AND LEVODOPA			
SCS	10MG;100MG	N74080 001	MAR 25, 1994

FDA data supplied by DrugPatentWatch.com

CARBIDOPA; LEVODOPA

TABLET; ORAL			
CARBIDOPA AND LEVODOPA			
SCS	25MG;100MG	N74080 002	MAR 25, 1994
	25MG;250MG	N74080 003	MAR 25, 1994
WATSON LABS	10MG;100MG	N73381 001	SEP 28, 1993
	25MG;100MG	N73382 001	SEP 28, 1993
	25MG;250MG	N73383 001	SEP 28, 1993

CARBINOXAMINE MALEATE

ELIXIR; ORAL			
CLISTIN			
MCNEIL	4MG/5ML	N08955 001	
TABLET; ORAL			
CLISTIN			
* JOHNSON RW	4MG	N08915 001	

CARISOPRODOL

CAPSULE; ORAL			
SOMA			
WALLACE LABS	250MG	N11792 003	
TABLET; ORAL			
CARISOPRODOL			
EON	350MG	N89566 001	AUG 30, 1988
PIONEER PHARMS	350MG	N89390 001	OCT 13, 1988
WATSON LAB	350MG	N85433 001	
RELA			
SCHERING	350MG	N12155 001	

CARISOPRODOL; *MULTIPLE*
SEE ASPIRIN; CARISOPRODOL

CARPHENAZINE MALEATE

CONCENTRATE; ORAL			
PROKETAZINE			
WYETH AYERST	50MG/ML	N14173 001	
TABLET; ORAL			
PROKETAZINE			
WYETH AYERST	12.5MG	N12768 001	
	25MG	N12768 002	
	50MG	N12768 004	

CARPROFEN

TABLET; ORAL			
RIMADYL			
ROCHE	100MG	N18550 002	DEC 31, 1987
	150MG	N18550 003	DEC 31, 1987

CARTEOLOL HYDROCHLORIDE

TABLET; ORAL			
CARTROL			
ABBOTT	10MG	N19204 003	DEC 28, 1988

CEFACLOR

CAPSULE; ORAL			
CEFACLOR			
LEDERLE	EQ 250MG BASE	N64107 001	APR 27, 1995
	EQ 500MG BASE	N64107 002	APR 27, 1995
TEVA	EQ 250MG BASE	N64081 001	SEP 16, 1996
	EQ 500MG BASE	N64081 002	SEP 16, 1996
FOR SUSPENSION; ORAL			
CEFACLOR			
IVAX PHARMS	EQ 125MG BASE/5ML	N64087 001	APR 28, 1995

FDA data supplied by DrugPatentWatch.com

CEFACLOR

FOR SUSPENSION; ORAL

CEFACLOR			
IVAX PHARMS	EQ 187MG BASE/5ML	N64086 001	APR 28, 1995
	EQ 250MG BASE/5ML	N64085 001	APR 28, 1995
LEDERLE	EQ 125MG BASE/5ML	N64114 001	APR 28, 1995
	EQ 187MG BASE/5ML	N64115 001	APR 28, 1995
	EQ 250MG BASE/5ML	N64116 001	APR 28, 1995
	EQ 375MG BASE/5ML	N64110 001	APR 28, 1995

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE; ORAL

CEFADROXIL			
PUREPAC PHARM	EQ 500MG BASE	N63017 001	JAN 05, 1989
TEVA	EQ 500MG BASE	N62695 001	FEB 10, 1989
DURICEF			
BRISTOL MYERS SQUIBB	EQ 250MG BASE	N50512 002	
ULTRACEF			
BRISTOL	EQ 500MG BASE	N62378 001	MAR 16, 1982

FOR SUSPENSION; ORAL

CEFADROXIL			
APOTHECON	EQ 125MG BASE/5ML	N62334 001	
	EQ 250MG BASE/5ML	N62334 002	
	EQ 500MG BASE/5ML	N62334 003	
TEVA	EQ 125MG BASE/5ML	N62698 001	MAR 01, 1989
	EQ 250MG BASE/5ML	N62698 002	MAR 01, 1989
	EQ 500MG BASE/5ML	N62698 003	MAR 01, 1989
ULTRACEF			
BRISTOL	EQ 125MG BASE/5ML	N62376 001	MAR 16, 1982
	EQ 250MG BASE/5ML	N62376 002	MAR 16, 1982

CEFADROXIL/CEFADROXIL HEMIHYDRATE

FOR SUSPENSION; ORAL

ULTRACEF			
BRISTOL	EQ 500MG BASE/5ML	N62376 003	MAR 16, 1982

TABLET; ORAL

CEFADROXIL			
IVAX PHARMS	EQ 1GM BASE	N62774 001	APR 08, 1987
ULTRACEF			
APOTHECON	EQ 1GM BASE	N62390 001	JUN 10, 1982
BRISTOL	EQ 1GM BASE	N62408 001	AUG 31, 1982

CEFAMANDOLE NAFATE

INJECTABLE; INJECTION

MANDOL			
LILLY	EQ 1GM BASE/VIAL	N62560 001	SEP 10, 1985
	EQ 2GM BASE/VIAL	N62560 002	SEP 10, 1985
	EQ 500MG BASE/VIAL	N50504 001	

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

ANCEF			
GLAXOSMITHKLINE	EQ 250MG BASE/VIAL	N50461 001	
ANCEF IN DEXTROSE 5% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	EQ 10MG BASE/ML	N50566 003	JUN 08, 1983
	EQ 20MG BASE/ML	N50566 004	JUN 08, 1983
ANCEF IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	EQ 10MG BASE/ML	N50566 001	JUN 08, 1983
	EQ 20MG BASE/ML	N50566 002	JUN 08, 1983
CEFAZOLIN SODIUM			
AM PHARM PARTNERS	EQ 500MG BASE/VIAL	N62688 002	NOV 17, 1986
	EQ 1GM BASE/VIAL	N62688 003	NOV 17, 1986

FDA data supplied by DrugPatentWatch.com

CEFAZOLIN SODIUM

INJECTABLE; INJECTION
CEFAZOLIN SODIUM

AM PHARM PARTNERS	EQ 10GM BASE/VIAL	N62688 004 NOV 17, 1986
	EQ 20GM BASE/VIAL	N62688 005 AUG 03, 1987
BEDFORD	EQ 250MG BASE/VIAL	N62894 001 JUL 21, 1988
	EQ 500MG BASE/VIAL	N62894 002 JUL 21, 1988
	EQ 1GM BASE/VIAL	N62894 003 JUL 21, 1988
	EQ 5GM BASE/VIAL	N62894 004 JUL 21, 1988
	EQ 10GM BASE/VIAL	N62894 005 JUL 21, 1988
ELKINS SINN	EQ 250MG BASE/VIAL	N62807 001 JAN 12, 1988
	EQ 500MG BASE/VIAL	N62807 002 JAN 12, 1988
	EQ 1GM BASE/VIAL	N62807 003 JAN 12, 1988
	EQ 5GM BASE/VIAL	N62807 004 JAN 12, 1988
	EQ 10GM BASE/VIAL	N62807 005 JAN 12, 1988
	EQ 20GM BASE/VIAL	N62807 006 JAN 12, 1988
TEVA	EQ 250MG BASE/VIAL	N63016 001 MAR 14, 1989
	EQ 500MG BASE/VIAL	N63016 002 MAR 14, 1989
	EQ 1GM BASE/VIAL	N63016 003 MAR 14, 1989
KEFZOL		
LILLY	EQ 500MG BASE/VIAL	N62557 001 SEP 10, 1985
	EQ 1GM BASE/VIAL	N62557 002 SEP 10, 1985

CEFMENOXIME HYDROCHLORIDE

INJECTABLE; INJECTION
CEFMAX

TAP PHARM	EQ 500MG BASE/VIAL	N50571 001 DEC 30, 1987

CEFMENOXIME HYDROCHLORIDE

INJECTABLE; INJECTION
CEFMAX

TAP PHARM	EQ 1GM BASE/VIAL	N50571 002 DEC 30, 1987
	EQ 2GM BASE/VIAL	N50571 003 DEC 30, 1987

CEFMETAZOLE SODIUM

INJECTABLE; INJECTION
ZEFAZONE

PHARMACIA AND UPJOHN	EQ 2GM BASE/VIAL	N50637 002 DEC 11, 1989

ZEFAZONE IN PLASTIC CONTAINER

PHARMACIA AND UPJOHN	EQ 20MG BASE/ML	N50683 001 DEC 29, 1992
	EQ 40MG BASE/ML	N50683 002 DEC 29, 1992

CEFONICID SODIUM

INJECTABLE; INJECTION
MONOCID

GLAXOSMITHKLINE	EQ 1GM BASE/VIAL	N50579 002 MAY 23, 1984
	EQ 1GM BASE/VIAL	N63295 001 JUL 26, 1993
	EQ 2GM BASE/VIAL	N50579 003 MAY 23, 1984
	EQ 10GM BASE/VIAL	N50579 004 MAY 23, 1984
	EQ 500MG BASE/VIAL	N50579 001 MAY 23, 1984

CEFOPERAZONE SODIUM

INJECTABLE; INJECTION
CEFOBID

PFIZER	EQ 1GM BASE/VIAL	N63333 001 MAR 31, 1995
	EQ 2GM BASE/VIAL	N63333 002 MAR 31, 1995

FDA data supplied by DrugPatentWatch.com

CEFORANIDE

INJECTABLE; INJECTION
PRECEF

APOTHECON	500MG/VIAL	N62579 001 NOV 26, 1984
	1GM/VIAL	N62579 002 NOV 26, 1984
	2GM/VIAL	N62579 003 NOV 26, 1984
	10GM/VIAL	N62579 004 NOV 26, 1984
	20GM/VIAL	N62579 005 NOV 26, 1984

CEFOTIAM HYDROCHLORIDE

INJECTABLE; INJECTION
CERADON

TAKEDA	EQ 1GM BASE/VIAL	N50601 001 DEC 30, 1988

CEFOXITIN SODIUM

INJECTABLE; INJECTION
MEFOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER

MERCK	EQ 20MG BASE/ML	N50581 003 SEP 20, 1984
	EQ 40MG BASE/ML	N50581 004 SEP 20, 1984

MEFOXIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

MERCK	EQ 20MG BASE/ML	N50581 002 SEP 20, 1984
	EQ 40MG BASE/ML	N50581 001 SEP 20, 1984

CEFPIRAMIDE SODIUM

INJECTABLE; INJECTION
CEFPIRAMIDE SODIUM

WYETH AYERST	EQ 1GM BASE/VIAL	N50633 002 JAN 31, 1989
	EQ 2GM BASE/VIAL	N50633 003 JAN 31, 1989
	EQ 10GM BASE/VIAL	N50633 005 JAN 31, 1989

CEFPODOXIME PROXETIL

FOR SUSPENSION; ORAL
BANAN

SANKYO	EQ 50MG BASE/5ML	N50688 002 AUG 07, 1992
	EQ 100MG BASE/5ML	N50688 001 AUG 07, 1992

TABLET; ORAL
BANAN

SANKYO	EQ 100MG BASE	N50687 001 AUG 07, 1992
	EQ 200MG BASE	N50687 002 AUG 07, 1992

CEFTAZIDIME

INJECTABLE; INJECTION
TAZIDIME IN PLASTIC CONTAINER

LILLY	1GM/VIAL	N62739 001 JUL 10, 1986
	2GM/VIAL	N62739 002 JUL 10, 1986

CEFTAZIDIME (ARGININE FORMULATION)

INJECTABLE; INJECTION
CEPTAZ

GLAXOSMITHKLINE	500MG/VIAL	N50646 001 SEP 27, 1990

PENTACEF

GLAXOSMITHKLINE	1GM/VIAL	N63322 001 NOV 07, 1995
	1GM/VIAL	N64006 001 MAR 31, 1992
	2GM/VIAL	N63322 002 NOV 07, 1995
	2GM/VIAL	N64006 002 MAR 31, 1992
	6GM/VIAL	N64008 001 MAR 31, 1992
	10GM/VIAL	N64008 002 MAR 31, 1992

FDA data supplied by DrugPatentWatch.com

CEFTAZIDIME SODIUM

INJECTABLE; INJECTION
FORTAZ IN PLASTIC CONTAINER

GLAXOSMITHKLINE	EQ 10MG BASE/ML	N50634 001 APR 28, 1989

CEFTIZOXIME SODIUM

INJECTABLE; INJECTION
CEFIZOX IN DEXTROSE 5% IN PLASTIC CONTAINER

FUJISAWA HLTHCARE	EQ 20MG BASE/ML	N50589 001 OCT 03, 1984
	EQ 40MG BASE/ML	N50589 002 OCT 03, 1984

CEFTRIAXONE SODIUM

INJECTABLE; INJECTION
ROCEPHIN

HLR	EQ 500MG BASE/VIAL	N62654 001 APR 30, 1987
ROCHE	EQ 250MG BASE/VIAL	N62510 001 MAR 12, 1985
	EQ 500MG BASE/VIAL	N62510 002 MAR 12, 1985
	EQ 1GM BASE/VIAL	N62510 003 MAR 12, 1985

ROCEPHIN W/ DEXTROSE IN PLASTIC CONTAINER

HLR	EQ 10MG BASE/ML	N50624 001 FEB 11, 1987

CEFUROXIME SODIUM

INJECTABLE; INJECTION
KEFUROX IN PLASTIC CONTAINER

LILLY	EQ 1.5GM BASE/VIAL	N62590 002 JAN 10, 1986

INJECTABLE; INTRAVENOUS
KEFUROX IN PLASTIC CONTAINER

LILLY	EQ 750MG BASE/VIAL	N62590 001 JAN 10, 1986

CELLULOSE SODIUM PHOSPHATE

POWDER; ORAL
CALCIBIND

MISSION PHARMA	2.5GM/PACKET	N18757 002 DEC 28, 1982

CEPHALEXIN

CAPSULE; ORAL
CEPHALEXIN

APOTHECON	EQ 250MG BASE	N62973 001 NOV 08, 1988
	EQ 500MG BASE	N62974 001 NOV 23, 1988
PUREPAC PHARM	EQ 250MG BASE	N62809 001 APR 22, 1987
	EQ 500MG BASE	N62809 002 APR 22, 1987
STEVENS J	EQ 500MG BASE	N62869 001 MAR 17, 1988
TEVA	EQ 500MG BASE	N62823 001 FEB 05, 1988
YOSHITOMI	EQ 250MG BASE	N62872 001 JUN 20, 1988
	EQ 500MG BASE	N62871 001 JUL 05, 1988

FOR SUSPENSION; ORAL
CEPHALEXIN

BARR	EQ 125MG BASE/5ML	N62778 001 AUG 06, 1987
VITARINE	EQ 125MG BASE/5ML	N62779 001 DEC 22, 1987
	EQ 250MG BASE/5ML	N62781 001 DEC 22, 1987

KEFLEX

LILLY	EQ 125MG BASE/5ML	N50406 001
	EQ 250MG BASE/5ML	N50406 002
	EQ 100MG BASE/ML	N50406 003

TABLET; ORAL
CEPHALEXIN

BARR	EQ 250MG BASE	N62826 001 AUG 17, 1987
	EQ 500MG BASE	N62827 001 AUG 17, 1987

FDA data supplied by DrugPatentWatch.com

CEPHALEXIN

TABLET; ORAL
CEPHALEXIN
VITARINE — EQ 250MG BASE — N62863 001 AUG 11, 1988
EQ 500MG BASE — N62863 002 AUG 11, 1988
EQ 1GM BASE — N62863 003 AUG 11, 1988
KEFLET
LILLY — EQ 250MG BASE — N62745 001 DEC 01, 1986
EQ 500MG BASE — N62745 002 DEC 01, 1986

CEPHALEXIN HYDROCHLORIDE

TABLET; ORAL
KEFTAB
LILLY — EQ 250MG BASE — N50614 001 OCT 29, 1987
EQ 333MG BASE — N50614 003 MAY 16, 1988

CEPHALOTHIN SODIUM

INJECTABLE; INJECTION
CEPHALOTHIN
INTL MEDICATION — EQ 500MG BASE/VIAL — N62426 001 MAY 03, 1985
EQ 1GM BASE/VIAL — N62426 002 MAY 03, 1985
EQ 2GM BASE/VIAL — N62426 003 MAY 03, 1985
EQ 4GM BASE/VIAL — N62426 004 MAY 03, 1985
CEPHALOTHIN SODIUM
ABBOTT — EQ 1GM BASE/VIAL — N62547 001 SEP 11, 1985
EQ 1GM BASE/VIAL — N62548 001 SEP 11, 1985
EQ 2GM BASE/VIAL — N62547 002 SEP 11, 1985
EQ 2GM BASE/VIAL — N62548 002 SEP 11, 1985

CEPHALOTHIN SODIUM

INJECTABLE; INJECTION
CEPHALOTHIN SODIUM
AM PHARM PARTNERS — EQ 1GM BASE/VIAL — N62666 002 JUN 10, 1987
EQ 2GM BASE/VIAL — N62666 001 JUN 10, 1987
CEPHALOTHIN SODIUM W/ DEXTROSE IN PLASTIC CONTAINER
BAXTER HLTHCARE — EQ 20MG BASE/ML — N62422 003 JAN 31, 1984
EQ 20MG BASE/ML — N62422 005 JUL 16, 1991
EQ 20MG BASE/ML — N62730 001 MAR 05, 1987
EQ 40MG BASE/ML — N62422 004 JAN 31, 1984
EQ 40MG BASE/ML — N62422 006 JUL 16, 1991
EQ 40MG BASE/ML — N62730 002 MAR 05, 1987
CEPHALOTHIN SODIUM W/ SODIUM CHLORIDE IN PLASTIC CONTAINER
BAXTER HLTHCARE — EQ 20MG BASE/ML — N62422 001 JAN 31, 1984
EQ 40MG BASE/ML — N62422 002 JAN 31, 1984
KEFLIN IN PLASTIC CONTAINER
LILLY — EQ 1GM BASE/VIAL — N62549 001 SEP 10, 1985
EQ 2GM BASE/VIAL — N62549 002 SEP 10, 1985
SEFFIN
GLAXOSMITHKLINE — EQ 1GM BASE/VIAL — N62435 001 NOV 15, 1983
EQ 2GM BASE/VIAL — N62435 002 NOV 15, 1983
EQ 10GM BASE/VIAL — N62435 003 NOV 15, 1983

CEPHAPIRIN SODIUM

INJECTABLE; INJECTION
CEFADYL
APOTHECON — EQ 500MG BASE/VIAL — N50446 005
EQ 1GM BASE/VIAL — N50446 001
EQ 1GM BASE/VIAL — N62724 001 DEC 23, 1986
EQ 2GM BASE/VIAL — N50446 002

FDA data supplied by DrugPatentWatch.com

CEPHAPIRIN SODIUM

INJECTABLE; INJECTION

CEFADYL		
APOTHECON	EQ 2GM BASE/VIAL	N62724 002 DEC 23, 1986
	EQ 4GM BASE/VIAL	N50446 003
	EQ 20GM BASE/VIAL	N50446 004
CEPHAPIRIN SODIUM		
AM PHARM PARTNERS	EQ 500MG BASE/VIAL	N62723 001 NOV 17, 1986
	EQ 1GM BASE/VIAL	N62723 002 NOV 17, 1986
	EQ 2GM BASE/VIAL	N62723 003 NOV 17, 1986
	EQ 4GM BASE/VIAL	N62723 004 NOV 17, 1986
	EQ 20GM BASE/VIAL	N62723 005 NOV 17, 1986
ELKINS SINN	EQ 500MG BASE/VIAL	N62720 001 JUL 02, 1987
	EQ 1GM BASE/VIAL	N62720 002 JUL 02, 1987
	EQ 2GM BASE/VIAL	N62720 003 JUL 02, 1987
	EQ 20GM BASE/VIAL	N62720 004 JUL 02, 1987

CEPHRADINE

CAPSULE; ORAL

CEPHRADINE		
BARR	250MG	N62850 001 APR 22, 1988
	500MG	N62851 001 APR 22, 1988
IVAX PHARMS	250MG	N62762 001 MAR 06, 1987
	500MG	N62762 002 MAR 06, 1987
VITARINE	250MG	N62813 001 FEB 25, 1988
	500MG	N62813 002 FEB 25, 1988
VELOSEF '250'		
ERSANA	250MG	N50548 001
VELOSEF '500'		
ERSANA	500MG	N50548 002

CEPHRADINE

FOR SUSPENSION; ORAL

CEPHRADINE		
BARR	125MG/5ML	N62858 001 MAY 19, 1988
	250MG/5ML	N62859 001 MAY 19, 1988

INJECTABLE; INJECTION

VELOSEF		
APOTHECON	250MG/VIAL	N61976 001
	500MG/VIAL	N61976 002
	1GM/VIAL	N61976 004
	2GM/VIAL	N61976 003
	4GM/VIAL	N61976 005

TABLET; ORAL

VELOSEF		
BRISTOL MYERS SQUIBB	1GM	N50530 001

CERIVASTATIN SODIUM

TABLET; ORAL

BAYCOL		
BAYER	0.05MG	N20740 001 JUN 26, 1997
	0.1MG	N20740 002 JUN 26, 1997

CERULETIDE DIETHYLAMINE

INJECTABLE; INJECTION

TYMTRAN		
PHARMACIA AND UPJOHN	0.02MG/ML	N18296 001

CHENODIOL

TABLET; ORAL

CHENIX		
AXCAN SCANDIPHARM	250MG	N18513 002 JUL 28, 1983

FDA data supplied by DrugPatentWatch.com

CHLOPHEDIANOL HYDROCHLORIDE

SYRUP; ORAL
ULO
3M 25MG/5ML N12126 001

CHLORAMPHENICOL

CAPSULE; ORAL
AMPHICOL
FERRANTE 100MG N60058 001
250MG N60058 002
CHLORAMPHENICOL
IVAX PHARMS 250MG N62247 001
CHLOROMYCETIN
PARKEDALE 50MG N60591 001
100MG N60591 003
250MG N60591 002

CREAM; TOPICAL
CHLOROMYCETIN
PARKE DAVIS 1% N50183 001

INJECTABLE; INJECTION
CHLOROMYCETIN
PARKE DAVIS 250MG/ML N50153 001

OINTMENT; OPHTHALMIC
CHLOROFAIR
PHARMAFAIR 1% N62439 001
APR 21, 1983
ECONOCHLOR
ALCON 1% N61648 001

SOLUTION/DROPS; OPHTHALMIC
CHLORAMPHENICOL
AKORN 0.5% N62042 001
ALCON 0.5% N62628 001
SEP 25, 1985
CHLOROFAIR
PHARMAFAIR 0.5% N62437 001
APR 14, 1983
ECONOCHLOR
ALCON 0.5% N61645 001
OPHTHOCHLOR
PARKEDALE 0.5% N61220 001
OPTOMYCIN
OPTOPICS 0.5% N62171 001
MAR 31, 1982

CHLORAMPHENICOL; HYDROCORTISONE ACETATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC
OPHTHOCORT
PARKEDALE 10MG/GM;5MG/GM; 10,000 UNITS/GM N50201 002

CHLORAMPHENICOL; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC
CHLOROMYXIN
PARKE DAVIS 1%;10,000 UNITS/GM N50203 002

CHLORAMPHENICOL; PREDNISOLONE

OINTMENT; OPHTHALMIC
CHLOROPTIC-P S.O.P.
ALLERGAN 1%;0.5% N61188 001

CHLORAMPHENICOL PALMITATE

SUSPENSION; ORAL
CHLOROMYCETIN PALMITATE
PARKE DAVIS EQ 150MG BASE/5ML N62301 001

CHLORAMPHENICOL SODIUM SUCCINATE

INJECTABLE; INJECTION
CHLORAMPHENICOL
ELKINS SINN EQ 1GM BASE/VIAL N62406 001
NOV 09, 1982
MYCHEL-S
ANGUS EQ 1GM BASE/VIAL N60132 001

CHLORDIAZEPOXIDE

CAPSULE, EXTENDED RELEASE; ORAL
LIBRELEASE
ICN 30MG N17813 001
SEP 12, 1983

TABLET; ORAL
LIBRITABS
ICN 5MG N85482 001

FDA data supplied by DrugPatentWatch.com

CHLORDIAZEPOXIDE

TABLET; ORAL			
LIBRITABS			
ICN	10MG	N85481	001
	25MG	N85488	001

CHLORDIAZEPOXIDE; *MULTIPLE*
SEE AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

CHLORDIAZEPOXIDE; ESTROGENS, ESTERIFIED

TABLET; ORAL			
MENRIUM 10-4			
ROCHE	10MG;0.4MG	N14740	006
MENRIUM 5-2			
ROCHE	5MG;0.2MG	N14740	002
MENRIUM 5-4			
ROCHE	5MG;0.4MG	N14740	004

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL			
A-POXIDE			
ABBOTT	5MG	N85447	001
	5MG	N85517	001
	10MG	N85447	002
	10MG	N85518	001
	25MG	N85447	003
	25MG	N85513	001
CHLORDIAZACHEL			
RACHELLE	5MG	N85086	001
	10MG	N84639	001
	25MG	N85087	001
CHLORDIAZEPOXIDE HCL			
ASCOT	5MG	N87525	001
		JAN 07, 1982	
	10MG	N87524	001
		JAN 07, 1982	
	25MG	N87512	001
		JAN 07, 1982	
EON	5MG	N84919	001
	10MG	N84920	001
	25MG	N84823	001
FERRANTE	5MG	N85118	001
	10MG	N85119	001

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL			
CHLORDIAZEPOXIDE HCL			
FERRANTE	25MG	N85120	001
GENEVA PHARMS	5MG	N84678	001
	10MG	N84041	001
	25MG	N84679	002
HALSEY	5MG	N85340	001
	10MG	N85339	001
	25MG	N84685	001
IMPAX LABS	5MG	N86213	001
	25MG	N86212	001
IVAX PHARMS	5MG	N83741	001
	10MG	N83742	001
	25MG	N83570	001
LEDERLE	5MG	N86892	001
	5MG	N87234	001
	10MG	N86876	001
	10MG	N87037	001
	25MG	N86893	001
	25MG	N87231	001
MAST MM	10MG	N86217	001
MYLAN	5MG	N84886	001
	10MG	N84601	001
	25MG	N84887	001
PARKE DAVIS	5MG	N85163	001
	10MG	N84598	001
	25MG	N85164	001
PIONEER PHARMS	10MG	N89533	001
		JUL 15, 1988	
	25MG	N89558	001
		JUL 15, 1988	
PUREPAC PHARM	5MG	N85155	001
	10MG	N84939	002
	25MG	N85144	001
ROXANE	5MG	N84706	001
	10MG	N84700	001
	25MG	N84705	001
SUPERPHARM	5MG	N88987	001
		APR 25, 1985	
	10MG	N88986	001
		APR 25, 1985	
	25MG	N88988	001
		APR 25, 1985	
TEVA	5MG	N88705	001
		JAN 18, 1985	
	10MG	N88706	001
		JAN 18, 1985	

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL			
CHLORDIAZEPOXIDE HCL			
TEVA	25MG	N86494 001	
	25MG	N88707 001	
		JAN 18, 1985	
USL PHARMA	5MG	N84644 001	
	25MG	N84645 001	
VANGARD	5MG	N88129 001	
		MAR 28, 1983	
	10MG	N88010 001	
		MAR 28, 1983	
	25MG	N88130 001	
		MAR 28, 1983	
WEST WARD	5MG	N85014 001	
	10MG	N85000 001	
	25MG	N85294 001	
LIBRIUM			
ICN	5MG	N12249 002	
	10MG	N12249 001	
	25MG	N12249 003	
LYGEN			
ALRA	5MG	N85107 001	
	10MG	N85009 001	
	25MG	N85108 001	

CHLORHEXIDINE GLUCONATE

SOLUTION; TOPICAL		
EXIDINE		
XTTRIUM	2.5%	N19421 001
		DEC 17, 1985

CHLORMERODRIN, HG-197

INJECTABLE; INJECTION		
CHLORMERODRIN HG 197		
BRACCO	0.6-1.4mCi/ML	N17269 001

CHLOROPROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION		
NESACAINE-MPF		
ASTRAZENECA	2%	N09435 003
	3%	N09435 004

CHLOROQUINE PHOSPHATE

TABLET; ORAL		
CHLOROQUINE PHOSPHATE		
MD PHARM	EQ 150MG BASE	N87228 001
PUREPAC PHARM	EQ 150MG BASE	N80886 001
TEVA	EQ 150MG BASE	N87504 001
		JAN 13, 1982

CHLOROQUINE PHOSPHATE; PRIMAQUINE PHOSPHATE

TABLET; ORAL		
ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE		
SANOFI SYNTHELABO	EQ 300MG BASE; EQ 45MG BASE	N14860 002

CHLOROTHIAZIDE

TABLET; ORAL		
CHLOROTHIAZIDE		
ABC HOLDING	250MG	N85569 001
DANBURY PHARMA	250MG	N85173 001
EON	250MG	N85485 001
LEDERLE	250MG	N86940 001
	500MG	N86938 001
WATSON LAB	250MG	N85165 001
	500MG	N84026 001
		SEP 01, 1982
WATSON LABS	250MG	N86795 001
		AUG 15, 1983
	500MG	N86796 001
		AUG 15, 1983

CHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL		
METHYLDOPA AND CHLOROTHIAZIDE		
PAR PHARM	150MG;250MG	N70783 001
		NOV 06, 1987
	250MG;250MG	N70654 001
		NOV 06, 1987

FDA data supplied by DrugPatentWatch.com

CHLOROTHIAZIDE; RESERPINE

TABLET; ORAL			
CHLOROTHIAZIDE W/ RESERPINE			
WATSON LAB	250MG;0.125MG	N84853	001
	500MG;0.125MG	N88151	001
		JUN 09, 1983	

CHLOROTRIANISENE

CAPSULE; ORAL			
CHLOROTRIANISENE			
BANNER PHARMACAPS	12MG	N84652	001
TACE			
AVENTIS PHARMS	25MG	N11444	001
	72MG	N16235	001

CHLORPHENIRAMINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL			
TELDRIN			
GLAXOSMITHKLINE	8MG	N17369	001
	12MG	N17369	002
INJECTABLE; INJECTION			
CHLOR-TRIMETON			
SCHERING PLOUGH	10MG/ML	N08826	001
	100MG/ML	N08794	001
CHLORPHENIRAMINE MALEATE			
BEL MAR	10MG/ML	N80821	001
ELKINS SINN	10MG/ML	N80797	001
STERIS	10MG/ML	N83593	001
	10MG/ML	N86096	001
	100MG/ML	N86095	001
PYRIDAMAL 100			
BEL MAR	100MG/ML	N83733	001
SYRUP; ORAL			
CHLOR-TRIMETON			
SCHERING	2MG/5ML	N06921	006
CHLORPHENIRAMINE MALEATE			
PHARM ASSOC	2MG/5ML	N87520	001
		FEB 10, 1982	
TABLET; ORAL			
ANTAGONATE			
BAYER	4MG	N83381	001

CHLORPHENIRAMINE MALEATE

TABLET; ORAL			
CHLOR-TRIMETON			
SCHERING	4MG	N06921	002
CHLORPHENIRAMINE MALEATE			
ANABOLIC	4MG	N83078	001
BELL PHARMA	4MG	N83062	001
DANBURY PHARMA	4MG	N80696	001
ELKINS SINN	4MG	N80938	001
GENEVA PHARMS	4MG	N80961	001
HALSEY	4MG	N80700	001
IMPAX LABS	4MG	N80809	001
IVAX PHARMS	4MG	N80779	001
KV PHARM	4MG	N87164	001
LEDERLE	4MG	N86941	001
NEWTRON PHARMS	4MG	N86519	001
PANRAY	4MG	N83243	001
PHARMAVITE	4MG	N85104	001
PHARMERAL	4MG	N83753	001
PIONEER PHARMS	4MG	N88556	001
		JUL 13, 1984	
PUREPAC PHARM	4MG	N86306	001
PVT FORM	4MG	N80786	001
ROXANE	4MG	N80626	001
VITARINE	4MG	N85837	001
WATSON LAB	4MG	N80791	001
WATSON LABS	4MG	N85139	001
WEST WARD	4MG	N83787	001
KLOROMIN			
HALSEY	4MG	N83629	001
PHENETRON			
LANNETT	4MG	N80846	001

CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL			
CHLOROHENIRAMINE MALEATE AND PHENYLPROPANOLAMINE HCL			
WATSON LABS	12MG;75MG	N88681	001
		SEP 29, 1987	
CHLORPHENIRAMINE MALEATE AND PHENYLPROPANOLAMINE HCL			
GENEVA PHARMS	12MG;75MG	N88940	001
		JAN 26, 1989	
COLD CAPSULE IV			
GRAHAM DM	12MG;75MG	N18793	001
		APR 25, 1985	
COLD CAPSULE V			
GRAHAM DM	8MG;75MG	N18794	001
		APR 23, 1985	

FDA data supplied by DrugPatentWatch.com

CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

DRIZE		
ASCHER	12MG;75MG	N88359 001
		FEB 13, 1986
ORNADE		
GLAXOSMITHKLINE	12MG;75MG	N12152 004

TABLET, EXTENDED RELEASE; ORAL

TRIAMINIC-12		
NOVARTIS	12MG;75MG	N18115 001

CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

CODIMAL-L.A. 12		
SCHWARZ PHARMA	12MG;120MG	N18935 001
		APR 15, 1985
ISOCLOR		
FISONS	8MG;120MG	N18747 001
		MAR 06, 1986
PSEUDOEPHEDRINE HCL AND CHLORPHENIRAMINE MALEATE		
KV PHARM	12MG;120MG	N71455 001
		MAR 01, 1989
PSEUDOEPHEDRINE HCL/CHLORPHENIRAMINE MALEATE		
GRAHAM DM	8MG;120MG	N18844 001
		MAR 20, 1985
	12MG;120MG	N18843 001
		MAR 18, 1985

CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL

PENNTUSS		
FISONS	EQ 4MG MALEATE/5ML; EQ 10MG BASE/5ML	N18928 001
		AUG 14, 1985

CHLORPHENIRAMINE POLISTIREX; PHENYLPROPANOLAMINE POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL

CORSYM		
CELLTECH PHARMS	EQ 4MG MALEATE/5ML; EQ 37.5MG HCL/5ML	N18050 001
		JAN 04, 1984

CHLORPHENTERMINE HYDROCHLORIDE

TABLET; ORAL

PRE-SATE		
PARKE DAVIS	EQ 65MG BASE	N14696 001

CHLORPROMAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

CHLORPROMAZINE HCL		
MORTON GROVE	30MG/ML	N87032 001
		JUL 08, 1982
	100MG/ML	N87053 001

INJECTABLE; INJECTION

CHLORPROMAZINE HCL		
AM PHARM PARTNERS	25MG/ML	N84911 001
MARSAM PHARMS LLC	25MG/ML	N89563 001
		APR 15, 1988
STERIS	25MG/ML	N80365 001
	25MG/ML	N85591 001
WYETH AYERST	25MG/ML	N80370 001

SYRUP; ORAL

CHLORPROMAZINE HCL		
ALPHARMA	10MG/5ML	N86712 001

TABLET; ORAL

CHLORPROMAZINE HCL		
ABBOTT	10MG	N84414 001
	25MG	N84415 001
	50MG	N84411 001
	100MG	N84412 001
	200MG	N84413 001
IVAX PHARMS	10MG	N83549 001
	25MG	N83549 002
	50MG	N83549 003
	100MG	N83574 001
	200MG	N83575 001
KV PHARM	10MG	N85750 002
		JAN 04, 1982
	25MG	N85751 001
	50MG	N85484 001
	100MG	N85752 001
	200MG	N85748 002
		JAN 04, 1982
LEDERLE	25MG	N84801 001
	50MG	N84800 001

FDA data supplied by DrugPatentWatch.com

CHLORPROMAZINE HYDROCHLORIDE

TABLET; ORAL

CHLORPROMAZINE HCL		
LEDERLE	100MG	N84789 001
	200MG	N84802 001
PUREPAC PHARM	10MG	N80403 004
	25MG	N80403 001
	50MG	N80403 002
	100MG	N80403 003
	200MG	N80403 005
PVT FORM	25MG	N80340 001
	50MG	N80340 002
	200MG	N80340 003
ROXANE	10MG	N85331 001
	25MG	N85331 002
	50MG	N85331 003
	100MG	N85331 004
	200MG	N85331 005
VANGARD	10MG	N88038 001 AUG 16, 1982
	25MG	N87645 001
	50MG	N87646 001
WATSON LABS	10MG	N85959 001
	25MG	N85956 001
	50MG	N85960 001
	100MG	N85957 001
	200MG	N85958 001
WEST WARD	10MG	N87783 001 SEP 16, 1982
	25MG	N87865 001 SEP 16, 1982
	50MG	N87878 001 SEP 15, 1982
	100MG	N87884 001 SEP 15, 1982
	200MG	N87880 001 SEP 16, 1982
PROMAPAR		
PARKE DAVIS	10MG	N86886 001
	25MG	N84423 001
	50MG	N86887 001
	100MG	N86888 001
	200MG	N86885 001

CHLORPROPAMIDE

TABLET; ORAL

CHLORPROPAMIDE		
BARR	100MG	N88812 001 OCT 19, 1984
	100MG	N89446 001 NOV 17, 1986
	250MG	N88813 001 OCT 19, 1984
	250MG	N89447 001 NOV 17, 1986
DURAMED	100MG	N88918 001 OCT 16, 1984
	250MG	N88919 001 OCT 16, 1984
EON	250MG	N84669 001
HALSEY	100MG	N89321 001 JAN 16, 1986
	250MG	N88662 001 JAN 09, 1986
IVAX PHARMS	100MG	N88840 001 OCT 25, 1984
	250MG	N87353 001
SUPERPHARM	250MG	N88695 001 SEP 17, 1984
TEVA	100MG	N88768 001 OCT 11, 1984
USL PHARMA	100MG	N88708 001 AUG 30, 1984
	250MG	N88709 001 AUG 30, 1984
WATSON LAB	100MG	N88608 001 APR 12, 1984
	250MG	N88568 001 APR 12, 1984
WATSON LABS	100MG	N86865 001 SEP 24, 1984
	250MG	N86866 001
GLUCAMIDE		
TEVA	250MG	N88641 001 OCT 11, 1984

CHLORPROTHIXENE

CONCENTRATE; ORAL

TARACTAN		
ROCHE	100MG/5ML	N16149 002

FDA data supplied by DrugPatentWatch.com

CHLORPROTHIXENE

INJECTABLE; INJECTION		
TARACTAN		
ROCHE	12.5MG/ML	N12487 001
TABLET; ORAL		
TARACTAN		
ROCHE	10MG	N12486 005
	25MG	N12486 004
	50MG	N12486 003
	100MG	N12486 001

CHLORTHALIDONE

TABLET; ORAL		
CHLORTHALIDONE		
ABBOTT	25MG	N87364 001
	50MG	N87384 001
ASCOT	25MG	N87698 001
		OCT 20, 1982
	50MG	N87699 001
		OCT 20, 1982
DANBURY PHARMA	25MG	N87296 001
	25MG	N87706 001
	50MG	N87521 001
	50MG	N87689 001
EON	50MG	N87118 001
GENEVA PHARMS	25MG	N87380 001
HALSEY	25MG	N87292 001
	50MG	N87293 001
IVAX PHARMS	25MG	N87555 001
	50MG	N87947 001
		FEB 27, 1984
KV PHARM	25MG	N87311 001
	50MG	N87312 001
LEDERLE	25MG	N87451 001
	50MG	N87450 001
MUTUAL PHARM	25MG	N89738 001
		SEP 19, 1988
	50MG	N89739 001
		SEP 19, 1988
PIONEER PHARMS	50MG	N89591 001
		JUL 21, 1988
PUREPAC PHARM	25MG	N88139 001
		JUL 16, 1986
	50MG	N88140 001
		AUG 11, 1983

CHLORTHALIDONE

TABLET; ORAL		
CHLORTHALIDONE		
SUPERPHARM	25MG	N87473 001
		FEB 09, 1983
	50MG	N87247 001
		FEB 09, 1983
TEVA	50MG	N88651 001
		MAY 30, 1985
USL PHARMA	50MG	N89052 001
		JUN 01, 1987
VANGARD	25MG	N88012 001
		JUL 14, 1982
	50MG	N88073 001
		MAR 25, 1983
WARNER CHILCOTT	25MG	N87515 001
		JAN 24, 1983
	50MG	N87516 001
		FEB 09, 1983
WATSON LAB	25MG	N87050 001
	50MG	N87029 001
WATSON LABS	50MG	N87082 001
THALITONE		
MONARCH PHARMS	25MG	N88051 001
		NOV 12, 1982

CHLORTHALIDONE; METOPROLOL TARTRATE

CAPSULE; ORAL		
LOPRESSIDONE		
NOVARTIS	25MG;100MG	N19451 001
		DEC 31, 1987
	25MG;200MG	N19451 002
		DEC 31, 1987

CHLORZOXAZONE

TABLET; ORAL		
CHLORZOXAZONE		
DANBURY PHARMA	250MG	N86901 001
	500MG	N81019 001
		JUL 29, 1991
PIONEER PHARMS	250MG	N89592 001
		JAN 06, 1989
	500MG	N89948 001
		JAN 06, 1989

FDA data supplied by DrugPatentWatch.com

CHLORZOXAZONE

TABLET; ORAL
CHLORZOXAZONE
WATSON LABS 250MG N86948 001 AUG 09, 1982

PARAFLEX
JOHNSON RW 250MG N11300 003

CHOLESTYRAMINE

BAR, CHEWABLE; ORAL
CHOLYBAR
PARKE DAVIS EQ 4GM RESIN/BAR N71621 001 MAY 26, 1988
EQ 4GM RESIN/BAR N71739 001 MAY 26, 1988

TABLET; ORAL
QUESTRAN
APOTHECON EQ 1GM RESIN N73403 001 APR 28, 1994

CHROMIC CHLORIDE

INJECTABLE; INJECTION
CHROMIC CHLORIDE
AM PHARM PARTNERS EQ 0.004MG CHROMIUM/ML N19271 001 MAY 05, 1987

CHYMOPAPAIN

INJECTABLE; INJECTION
CHYMODIACTIN
ABBOTT 10,000 UNITS/VIAL N18663 001 NOV 10, 1982

DISCASE
ABBOTT 12,500 UNITS/VIAL N18625 001 JAN 18, 1984

CHYMOTRYPSIN

FOR SOLUTION; OPHTHALMIC
ALPHA CHYMAR
SOLA BARNES HIND 750 UNITS/VIAL N11837 001

CHYMOTRYPSIN

FOR SOLUTION; OPHTHALMIC
CATARASE
CIBA 300 UNITS/VIAL N16938 001
NOVARTIS 150 UNITS/VIAL N18121 001

CIMETIDINE

TABLET; ORAL
CIMETIDINE
LEK LJUBLJANA 200MG N74250 001 JUN 29, 1995
300MG N74250 002 JUN 29, 1995
400MG N74250 003 JUN 29, 1995
800MG N74250 004 JUN 29, 1995
PERRIGO 100MG N74972 001 JUN 19, 1998
ROXANE 300MG N74361 001 DEC 23, 1994
400MG N74361 002 DEC 23, 1994
800MG N74371 001 DEC 23, 1994

TAGAMET HB
* GLAXOSMITHKLINE 100MG N20238 001 JUN 19, 1995

CINOXACIN

CAPSULE; ORAL
CINOXACIN
TEVA 250MG N73005 001 FEB 28, 1992
500MG N73006 001 FEB 28, 1992

CIPROFLOXACIN

INJECTABLE; INJECTION
CIPRO IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
BAYER 200MG/100ML N19858 001 DEC 26, 1990

FDA data supplied by DrugPatentWatch.com

CISAPRIDE MONOHYDRATE

SUSPENSION; ORAL

PROPULSID		
JANSSEN	EQ 1MG BASE/ML	N20398 001 SEP 15, 1995

TABLET; ORAL

PROPULSID		
JANSSEN	EQ 10MG BASE	N20210 001 JUL 29, 1993
	EQ 20MG BASE	N20210 002 DEC 23, 1993

TABLET, ORALLY DISINTEGRATING; ORAL

PROPULSID QUICKSOLV		
JANSSEN	EQ 20MG BASE	N20767 001 NOV 07, 1997

CISPLATIN

INJECTABLE; INJECTION

PLATINOL-AQ		
BRISTOL MYERS	0.5MG/ML	N18057 003 JUL 18, 1984

CITALOPRAM HYDROBROMIDE

TABLET; ORAL

CELEXA		
FOREST LABS	EQ 60MG BASE	N20822 004 JUL 17, 1998

CLEMASTINE FUMARATE

TABLET; ORAL

CLEMASTINE FUMARATE		
TEVA	1.34MG	N73282 001 JAN 31, 1992
TAVIST-1		
NOVARTIS	1.34MG	N17661 002
	1.34MG	N17661 003 AUG 21, 1992

CLEMASTINE FUMARATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

TAVIST D		
NOVARTIS	EQ 1MG BASE;75MG	N18298 001 DEC 15, 1982
TAVIST-D		
NOVARTIS	1.34MG;75MG	N18298 002 AUG 21, 1992
	1.34MG;75MG	N20640 001 AUG 09, 1996

CLIDINIUM BROMIDE

CAPSULE; ORAL

QUARZAN		
ROCHE	2.5MG	N10355 001
	5MG	N10355 002

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL

CLEOCIN		
PHARMACIA AND UPJOHN	EQ 75MG BASE	N61809 001
	EQ 150MG BASE	N61809 002
CLINDAMYCIN HCL		
DANBURY PHARMA	EQ 75MG BASE	N63082 001 JUL 31, 1991

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION; ORAL

CLEOCIN		
PHARMACIA AND UPJOHN	EQ 75MG BASE/5ML	N61827 001

CLINDAMYCIN PHOSPHATE

CREAM; VAGINAL

CLEOCIN		
PHARMACIA AND UPJOHN	EQ 2% BASE	N50680 001 AUG 11, 1992

INJECTABLE; INJECTION

CLEOCIN PHOSPHATE		
PHARMACIA AND UPJOHN	EQ 150MG BASE/ML	N61839 001

FDA data supplied by DrugPatentWatch.com

CLINDAMYCIN PHOSPHATE

INJECTABLE; INJECTION
CLINDAMYCIN PHOSPHATE

ABBOTT	EQ 150MG BASE/ML	N62943 001 SEP 29, 1988
AM PHARM PARTNERS	EQ 150MG BASE/ML	N62747 001 JUN 03, 1988
ASTRAZENECA	EQ 150MG BASE/ML	N62928 001 FEB 13, 1989
BEDFORD	EQ 150MG BASE/ML	N63163 001 JUN 30, 1994
BRISTOL MYERS SQUIBB	EQ 150MG BASE/ML	N62908 001 FEB 01, 1989
ELKINS SINN	EQ 150MG BASE/ML	N62806 001 OCT 15, 1987
	EQ 150MG BASE/ML	N62953 001 APR 21, 1988
GENSIA SICOR PHARMS	EQ 150MG BASE/ML	N63041 001 DEC 29, 1989
	EQ 150MG BASE/ML	N63282 001 MAY 29, 1992
LEDERLE	EQ 150MG BASE/ML	N63068 001 AUG 28, 1989
MARSAM PHARMS LLC	EQ 150MG BASE/ML	N62913 001 OCT 20, 1988
QUAD PHARMS	EQ 150MG BASE/ML	N62795 001 DEC 21, 1987
	EQ 150MG BASE/ML	N62877 001 MAR 15, 1988
SOLOPAK	EQ 150MG BASE/ML	N62819 001 MAR 15, 1988
	EQ 150MG BASE/ML	N62852 001 MAR 17, 1988
STERIS	EQ 150MG BASE/ML	N62900 001 JUN 08, 1988
	EQ 150MG BASE/ML	N63079 001 MAR 05, 1990

CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%

AM PHARM PARTNERS	EQ 12MG BASE/ML	N50636 001 DEC 22, 1989

SOLUTION; TOPICAL
CLEOCIN T

PHARMACIA AND UPJOHN	EQ 1% BASE	N62363 001 FEB 08, 1982

CLINDAMYCIN PHOSPHATE

COPLEY PHARM	EQ 1% BASE	N62944 001 JAN 11, 1989

CLINDAMYCIN PHOSPHATE

SOLUTION; TOPICAL
CLINDAMYCIN PHOSPHATE

TEVA	EQ 1% BASE	N62930 001 JUN 28, 1989

CLIOQUINOL; NYSTATIN

OINTMENT; TOPICAL
NYSTAFORM

BAYER	10MG/GM;100,000 UNITS/GM	N50235 001

CLOFIBRATE

CAPSULE; ORAL
CLOFIBRATE

GENEVA PHARMS	500MG	N72191 001 MAY 02, 1988
WATSON LABS	500MG	N71603 001 SEP 18, 1987

CLONIDINE HYDROCHLORIDE

TABLET; ORAL
CLONIDINE HCL

AM THERAP	0.1MG	N70881 001 JUL 08, 1986
	0.2MG	N70882 001 JUL 08, 1986
	0.3MG	N70883 001 JUL 08, 1986
DURAMED	0.1MG	N71103 001 AUG 14, 1986
	0.2MG	N71102 001 AUG 14, 1986
	0.3MG	N71101 001 AUG 14, 1986
HALSEY	0.2MG	N70924 001 SEP 04, 1987
	0.3MG	N70923 001 SEP 04, 1987
INTERPHARM	0.1MG	N71252 001 OCT 01, 1986
	0.2MG	N71253 001 OCT 01, 1986

FDA data supplied by DrugPatentWatch.com

CLONIDINE HYDROCHLORIDE

TABLET; ORAL			
CLONIDINE HCL			
INTERPHARM	0.3MG	N71254 001	OCT 01, 1986
PAR PHARM	0.1MG	N70461 001	JUL 08, 1986
	0.2MG	N70460 001	JUL 08, 1986
	0.3MG	N70459 001	JUL 08, 1986
TEVA	0.1MG	N70747 001	JUL 08, 1986
	0.2MG	N70702 001	JUL 08, 1986
	0.3MG	N70659 001	JUL 08, 1986
WARNER CHILCOTT	0.1MG	N72138 001	JUN 13, 1988
	0.2MG	N72139 001	JUN 13, 1988
	0.3MG	N72140 001	JUN 13, 1988
WATSON LAB	0.1MG	N70395 001	MAR 23, 1987
	0.2MG	N70396 001	MAR 23, 1987
	0.3MG	N70397 001	MAR 23, 1987

CLORAZEPATE DIPOTASSIUM

CAPSULE; ORAL			
CLORAZEPATE DIPOTASSIUM			
ABLE	3.75MG	N71777 001	JUL 14, 1987
	7.5MG	N71778 001	JUL 14, 1987
	15MG	N71779 001	JUL 14, 1987
AM THERAP	3.75MG	N71429 001	JUN 23, 1987
	7.5MG	N71430 001	JUN 23, 1987
	15MG	N71431 001	JUN 23, 1987

CLORAZEPATE DIPOTASSIUM

CAPSULE; ORAL			
CLORAZEPATE DIPOTASSIUM			
GD SEARLE LLC	3.75MG	N71727 001	DEC 18, 1987
	7.5MG	N71728 001	DEC 18, 1987
	15MG	N71729 001	DEC 18, 1987
PUREPAC PHARM	3.75MG	N71924 001	APR 25, 1988
	7.5MG	N71925 001	APR 25, 1988
	15MG	N71926 001	APR 25, 1988
QUANTUM PHARMICS	3.75MG	N71549 001	SEP 12, 1988
	7.5MG	N71550 001	SEP 12, 1988
	15MG	N71522 001	SEP 12, 1988
USL PHARMA	3.75MG	N71242 001	JUN 23, 1987
	7.5MG	N71243 001	JUN 23, 1987
	15MG	N71244 001	JUN 23, 1987
WARNER CHILCOTT	3.75MG	N71774 001	MAR 01, 1988
	7.5MG	N71775 001	MAR 01, 1988
	15MG	N71776 001	MAR 01, 1988
WATSON LABS	3.75MG	N71878 001	MAR 15, 1988
	7.5MG	N71879 001	MAR 15, 1988
	15MG	N71860 001	MAR 15, 1988
TRANXENE			
ABBOTT	3.75MG	N17105 001	
	7.5MG	N17105 002	
	15MG	N17105 003	
TABLET; ORAL			
CLORAZEPATE DIPOTASSIUM			
AM THERAP	3.75MG	N71747 001	JUN 23, 1987

FDA data supplied by DrugPatentWatch.com

CLORAZEPATE DIPOTASSIUM

TABLET; ORAL

CLORAZEPATE DIPOTASSIUM		
AM THERAP	7.5MG	N71748 001 JUN 23, 1987
	15MG	N71749 001 JUN 23, 1987
GENEVA PHARMS	3.75MG	N72512 001 MAY 11, 1990
LEDERLE	3.75MG	N72013 001 DEC 15, 1987
	7.5MG	N72014 001 DEC 15, 1987
	15MG	N72015 001 DEC 15, 1987
PUREPAC PHARM	3.75MG	N72330 001 AUG 08, 1988
	7.5MG	N72331 001 AUG 08, 1988
	15MG	N72332 001 AUG 08, 1988
QUANTUM PHARMICS	3.75MG	N71730 001 OCT 26, 1987
	7.5MG	N71731 001 OCT 26, 1987
	15MG	N71702 001 OCT 26, 1987
WARNER CHILCOTT	3.75MG	N71828 001 MAR 03, 1988
	7.5MG	N71829 001 MAR 03, 1988
	15MG	N71830 001 MAR 03, 1988

CLOTRIMAZOLE

TABLET; VAGINAL

MYCELEX-G		
BAYER	500MG	N19069 001 APR 19, 1985

CLOXACILLIN SODIUM

CAPSULE; ORAL

CLOXACILLIN SODIUM		
APOTHECON	EQ 250MG BASE	N61452 001

CLOXACILLIN SODIUM

CAPSULE; ORAL

CLOXACILLIN SODIUM		
APOTHECON	EQ 500MG BASE	N61452 002
CLOXAPEN		
GLAXOSMITHKLINE	EQ 250MG BASE	N62233 001
	EQ 500MG BASE	N62233 002

FOR SOLUTION; ORAL

CLOXACILLIN SODIUM		
TEVA	EQ 125MG BASE/5ML	N62978 001 APR 06, 1989
TEGOPEN		
APOTHECON	EQ 125MG BASE/5ML	N50192 001
	EQ 125MG BASE/5ML	N61453 001

CLOZAPINE

TABLET; ORAL

CLOZAPINE		
GENEVA PHARMS	25MG	N74546 001 AUG 30, 1996
	100MG	N74546 002 AUG 30, 1996

COBALT CHLORIDE, CO-60; CYANOCOBALAMIN; CYANOCOBALAMIN, CO-60; INTRINSIC FACTOR

N/A; N/A

RUBRATOPE-60 KIT		
BRACCO	N/A;N/A;N/A;N/A	N16090 001

CODEINE PHOSPHATE; *MULTIPLE*

SEE ACETAMINOPHEN; ASPIRIN; CODEINE PHOSPHATE

SEE ACETAMINOPHEN; CODEINE PHOSPHATE

SEE BROMPHENIRAMINE MALEATE; CODEINE PHOSPHATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL
- PHERAZINE VC W/ CODEINE
  - HALSEY — 10MG/5ML;5MG/5ML; 6.25MG/5ML — N88870 001 — MAR 02, 1987
- PROMETHAZINE VC W/ CODEINE
  - CENCI — 10MG/5ML;5MG/5ML; 6.25MG/5ML — N88816 001 — NOV 22, 1985

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL
- PHERAZINE W/ CODEINE
  - HALSEY — 10MG/5ML;6.25MG/5ML — N88739 001 — DEC 23, 1988
- PROMETHAZINE W/ CODEINE
  - CENCI — 10MG/5ML;6.25MG/5ML — N88814 001 — NOV 22, 1985

CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

SYRUP; ORAL
- ACTIFED W/ CODEINE
  - GLAXOSMITHKLINE — 10MG/5ML;30MG/5ML; 1.25MG/5ML — N12575 003 — APR 04, 1984
- TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES W/ CODEINE
  - CENCI — 10MG/5ML;30MG/5ML; 1.25MG/5ML — N89018 001 — JUL 23, 1986

CODEINE POLISTIREX; *MULTIPLE*

SEE CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX

COLCHICINE; PROBENECID

TABLET; ORAL
- PROBEN-C
  - WATSON LABS — 0.5MG;500MG — N85552 001
- PROBENECID AND COLCHICINE
  - BEECHAM — 0.5MG;500MG — N84321 001

COLCHICINE; PROBENECID

TABLET; ORAL
- PROBENECID AND COLCHICINE
  - EON — 0.5MG;500MG — N86130 001
  - IMPAX LABS — 0.5MG;500MG — N83720 002
- PROBENECID W/ COLCHICINE
  - LEDERLE — 0.5MG;500MG — N86954 001
  - WATSON LAB — 0.5MG;500MG — N83221 001

COLISTIN SULFATE

SUSPENSION; ORAL
- COLY-MYCIN S
  - PARKE DAVIS — EQ 25MG BASE/5ML — N50355 001

COPPER

INTRAUTERINE DEVICE; INTRAUTERINE
- CU-7
  - GD SEARLE LLC — 89MG — N17408 001
- TATUM-T
  - GD SEARLE LLC — 120MG — N18205 001

CORTICOTROPIN

INJECTABLE; INJECTION
- ACTH
  - PARKEDALE — 25 UNITS/VIAL — N08317 002
  - 40 UNITS/VIAL — N08317 004
- ACTHAR
  - AVENTIS — 25 UNITS/VIAL — N07504 002
  - 40 UNITS/VIAL — N07504 003
- CORTICOTROPIN
  - STERIS — 40 UNITS/VIAL — N88772 001 — NOV 21, 1984
- PURIFIED CORTROPHIN GEL
  - ORGANON — 40 UNITS/ML — N08975 001
  - 80 UNITS/ML — N08975 002

CORTICOTROPIN-ZINC HYDROXIDE

INJECTABLE; INJECTION
- CORTROPHIN-ZINC
  - ORGANON — 40 UNITS/ML — N09854 001

FDA data supplied by DrugPatentWatch.com

CORTISONE ACETATE

INJECTABLE; INJECTION			
CORTISONE ACETATE			
PHARMACIA AND UPJOHN	25MG/ML	N08126	002
STERIS	25MG/ML	N83147	003
	25MG/ML	N85677	001
	50MG/ML	N83147	004
	50MG/ML	N85677	002
TABLET; ORAL			
CORTISONE ACETATE			
BARR	25MG	N83471	001
ELKINS SINN	25MG	N80836	001
EVERYLIFE	25MG	N84246	001
HEATHER	25MG	N85736	001
IMPAX LABS	25MG	N09458	001
INWOOD LABS	25MG	N80731	001
IVAX PHARMS	25MG	N80630	001
	25MG	N83536	001
LANNETT	25MG	N80694	001
PANRAY	5MG	N08284	002
	25MG	N08284	001
PUREPAC PHARM	25MG	N80493	001
VITARINE	25MG	N80333	001
WATSON LABS	25MG	N85884	001
WHITEWORTH TOWN PLSN	25MG	N80341	001

CROMOLYN SODIUM

CAPSULE; INHALATION			
INTAL			
AVENTIS	20MG	N16990	001
CAPSULE; ORAL			
GASTROCROM			
CELLTECH PHARMS	100MG	N19188	001
		DEC 22, 1989	

CRYPTENAMINE ACETATES

INJECTABLE; INJECTION			
UNITENSEN			
WALLACE LABS	260 CSR UNIT/ML	N08814	001

CRYPTENAMINE TANNATES

TABLET; ORAL			
UNITENSEN			
WALLACE LABS	260 CSR UNIT	N09217	001

CUPRIC SULFATE

INJECTABLE; INJECTION			
CUPRIC SULFATE			
AM PHARM PARTNERS	EQ 0.4MG COPPER/ML	N19350	001
		MAY 05, 1987	

CYANOCOBALAMIN

INJECTABLE; INJECTION			
BERUBIGEN			
PHARMACIA AND UPJOHN	1MG/ML	N06798	001
BETALIN 12			
LILLY	0.1MG/ML	N80855	001
	1MG/ML	N80855	002
COBAVITE			
STERIS	0.1MG/ML	N83013	001
	1MG/ML	N83064	001
CYANOCOBALAMIN			
AKORN	1MG/ML	N87969	001
		NOV 10, 1983	
AM PHARM PARTNERS	0.03MG/ML	N80510	003
	0.1MG/ML	N80510	001
	1MG/ML	N80510	002
	1MG/ML	N83075	001
AVENTIS PHARMS	1MG/ML	N80564	001
DELL LABS	0.03MG/ML	N80689	001
	0.1MG/ML	N80689	002
	1MG/ML	N80689	003
LUITPOLD	0.03MG/ML	N80668	001
SOLOPAK	1MG/ML	N87551	001
		FEB 29, 1984	
STERIS	0.1MG/ML	N83120	001
WARNER CHILCOTT	1MG/ML	N07085	002
REDISOL			
MERCK	1MG/ML	N06668	010
RUBIVITE			
BEL MAR	0.03MG/ML	N10791	004
	0.05MG/ML	N10791	001
	0.1MG/ML	N10791	002
	0.12MG/ML	N10791	005

FDA data supplied by DrugPatentWatch.com

CYANOCOBALAMIN

INJECTABLE; INJECTION

RUBIVITE		
BEL MAR	1MG/ML	N10791 003
RUBRAMIN PC		
BRISTOL MYERS SQUIBB	0.1MG/ML	N06799 002
	1MG/ML	N06799 004
RUVITE		
SAVAGE LABS	1MG/ML	N80570 002
VI-TWEL		
BERLEX	1MG/ML	N07012 002

CYANOCOBALAMIN; *MULTIPLE*

SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE; VITAMIN A; VITAMIN E

SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN E

SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PHYTONADIONE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A PALMITATE; VITAMIN E

SEE COBALT CHLORIDE, CO-60; CYANOCOBALAMIN; CYANOCOBALAMIN, CO-60; INTRINSIC FACTOR

CYANOCOBALAMIN; TANNIC ACID; ZINC ACETATE

INJECTABLE; INJECTION

DEPINAR		
ARMOUR PHARM	0.5MG/ML;2.3MG/ML;1MG/ML	N11208 001

CYANOCOBALAMIN, CO-60

CAPSULE; ORAL

RUBRATOPE-60		
BRACCO	0.5-1 uCi	N16090 002

CYANOCOBALAMIN, CO-60; *MULTIPLE*

SEE COBALT CHLORIDE, CO-60; CYANOCOBALAMIN; CYANOCOBALAMIN, CO-60; INTRINSIC FACTOR

CYCLACILLIN

FOR SUSPENSION; ORAL

CYCLAPEN-W		
WYETH AYERST	125MG/5ML	N50508 001
	250MG/5ML	N50508 002
	500MG/5ML	N50508 003

TABLET; ORAL

CYCLACILLIN		
TEVA	250MG	N62895 001 AUG 04, 1988
	500MG	N62895 002 AUG 04, 1988
CYCLAPEN-W		
WYETH AYERST	250MG	N50509 001
	500MG	N50509 002

CYCLIZINE LACTATE

INJECTABLE; INJECTION

MAREZINE		
GLAXOSMITHKLINE	50MG/ML	N09495 001

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL

FLEXERIL		
MERCK	5MG	N17821 001

CYCLOPENTOLATE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

AK-PENTOLATE		
AKORN	1%	N85555 001
CYCLOPENTOLATE HCL		
SOLA BARNES HIND	1%	N84150 001
	1%	N84863 001
PENTOLAIR		
PHARMAFAIR	0.5%	N88643 001 FEB 09, 1987

FDA data supplied by DrugPatentWatch.com

CYCLOPENTOLATE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC			
PENTOLAIR			
PHARMAFAIR	1%	N88150 001	FEB 25, 1983

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION			
CYTOXAN			
BRISTOL MYERS SQUIBB	100MG/VIAL	N12142 001	
	200MG/VIAL	N12142 002	
	500MG/VIAL	N12142 003	
	1GM/VIAL	N12142 004	AUG 30, 1982
	2GM/VIAL	N12142 005	AUG 30, 1982

CYCLOSPORINE

CAPSULE; ORAL			
NEORAL			
NOVARTIS	50MG	N50715 003	JUL 14, 1995
SOLUTION; ORAL			
CYCLOSPORINE			
ABBOTT	100MG/ML	N65025 001	MAR 03, 2000

CYCLOTHIAZIDE

TABLET; ORAL			
ANHYDRON			
LILLY	2MG	N13157 002	
FLUIDIL			
PHARMACIA AND UPJOHN	2MG	N18173 001	

CYCRIMINE HYDROCHLORIDE

TABLET; ORAL			
PAGITANE			
LILLY	1.25MG	N08951 001	
	2.5MG	N08951 002	

CYPROHEPTADINE HYDROCHLORIDE

SYRUP; ORAL			
CYPROHEPTADINE HCL			
HALSEY	2MG/5ML	N89199 001	JUL 03, 1986
MORTON GROVE	2MG/5ML	N87001 001	NOV 04, 1982
NASKA	2MG/5ML	N89021 001	DEC 21, 1987
TABLET; ORAL			
CYPROHEPTADINE HCL			
AM THERAP	4MG	N88798 001	FEB 15, 1985
ASCOT	4MG	N87685 001	OCT 25, 1982
DANBURY PHARMA	4MG	N86580 001	
DURAMED	4MG	N88232 001	OCT 25, 1983
GENEVA PHARMS	4MG	N86808 001	
HALSEY	4MG	N89057 001	JUL 03, 1986
KV PHARM	4MG	N86737 001	
MD PHARM	4MG	N87566 001	NOV 10, 1982
MYLAN	4MG	N86678 001	
PIONEER PHARMS	4MG	N87839 001	FEB 08, 1984
SUPERPHARM	4MG	N87405 001	
VITARINE	4MG	N87284 001	
WATSON LAB	4MG	N85245 001	
WATSON LABS	4MG	N86165 001	

CYSTEINE HYDROCHLORIDE

INJECTABLE; INJECTION			
CYSTEINE HCL			
FRESENIUS KABI	7.25%	N19523 001	OCT 22, 1986

CYTARABINE

INJECTABLE; INJECTION			
CYTARABINE			
QUAD PHARMS	100MG/VIAL	N71248 001	DEC 30, 1987

FDA data supplied by DrugPatentWatch.com

CYTARABINE

INJECTABLE; INJECTION		
CYTARABINE		
QUAD PHARMS	500MG/VIAL	N71249 001
		DEC 30, 1987

DACARBAZINE

INJECTABLE; INJECTION		
DACARBAZINE		
AM PHARM PARTNERS	100MG/VIAL	N70962 001
		AUG 28, 1986
	200MG/VIAL	N70990 001
		AUG 28, 1986
QUAD PHARMS	100MG/VIAL	N70821 001
		OCT 09, 1986
	200MG/VIAL	N70822 001
		OCT 09, 1986
	500MG/VIAL	N71563 001
		MAY 06, 1988

DANAZOL

CAPSULE; ORAL		
DANAZOL		
AM THERAP	200MG	N71569 001
		DEC 30, 1987

DAUNORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION		
CERUBIDINE		
AVENTIS	EQ 20MG BASE/VIAL	N61876 001
WYETH AYERST	EQ 20MG BASE/VIAL	N50484 001

DECAMETHONIUM BROMIDE

INJECTABLE; INJECTION		
SYNCURINE		
GLAXOSMITHKLINE	1MG/ML	N06931 002

DEMECLOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL		
DECLOMYCIN		
LEDERLE	150MG	N50262 001
SYRUP; ORAL		
DECLOMYCIN		
LEDERLE	75MG/5ML	N50257 001

DESERPIDINE

TABLET; ORAL		
HARMONYL		
ABBOTT	0.1MG	N10796 001
	0.25MG	N10796 002

DESERPIDINE; HYDROCHLOROTHIAZIDE

TABLET; ORAL		
ORETICYL 25		
ABBOTT	0.125MG;25MG	N12148 001
ORETICYL 50		
ABBOTT	0.125MG;50MG	N12148 003
ORETICYL FORTE		
ABBOTT	0.25MG;25MG	N12148 002

DESERPIDINE; METHYCLOTHIAZIDE

TABLET; ORAL		
METHYCLOTHIAZIDE AND DESERPIDINE		
WATSON LAB	0.25MG;5MG	N88486 001
		AUG 10, 1984
	0.5MG;5MG	N88452 001
		AUG 10, 1984

DESIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL		
PERTOFRANE		
AVENTIS	25MG	N13621 001
	50MG	N13621 002
TABLET; ORAL		
DESIPRAMINE HCL		
USL PHARMA	25MG	N71864 001
		SEP 09, 1987

FDA data supplied by DrugPatentWatch.com

DESIPRAMINE HYDROCHLORIDE

TABLET; ORAL		
DESIPRAMINE HCL		
USL PHARMA	50MG	N71865 001 SEP 09, 1987
	75MG	N71866 001 SEP 09, 1987
	100MG	N71867 001 SEP 09, 1987

DESLANOSIDE

INJECTABLE; INJECTION		
CEDILANID-D		
NOVARTIS	0.2MG/ML	N09282 002

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-21		
DESOGEN		
ORGANON	0.15MG;0.03MG	N20071 001 DEC 10, 1992

DESONIDE; *MULTIPLE*
SEE ACETIC ACID, GLACIAL; DESONIDE

DESOXIMETASONE

OINTMENT; TOPICAL		
TOPICORT		
MEDICIS	0.05%	N18594 001 JAN 17, 1985

DESOXYCORTICOSTERONE ACETATE

INJECTABLE; INJECTION		
DOCA		
ORGANON	5MG/ML	N01104 001
PELLET; IMPLANTATION		
PERCORTEN		
NOVARTIS	125MG	N05151 001

DESOXYCORTICOSTERONE PIVALATE

INJECTABLE; INJECTION		
PERCORTEN		
NOVARTIS	25MG/ML	N08822 001

DEXAMETHASONE

AEROSOL; TOPICAL		
AEROSEB-DEX		
ALLERGAN HERBERT	0.01%	N83296 002
ELIXIR; ORAL		
DEXAMETHASONE		
ALPHARMA	0.5MG/5ML	N88997 001 OCT 10, 1986
GEL; TOPICAL		
DECADERM		
MERCK	0.1%	N13538 001
SUSPENSION/DROPS; OPHTHALMIC		
DEXAMETHASONE		
STERIS	0.1%	N89170 001 MAY 09, 1989
TABLET; ORAL		
DEXAMETHASONE		
DANBURY PHARMA	0.75MG	N80968 001
GENEVA PHARMS	0.75MG	N80399 001
HALSEY	0.25MG	N84013 001
	0.25MG	N84764 001
	0.5MG	N84084 001
	0.5MG	N84766 001
	0.75MG	N84081 001
	0.75MG	N84765 001
	1.5MG	N84086 001
	1.5MG	N84763 001
IMPAX LABS	0.75MG	N85376 001
PHOENIX LABS NY	0.75MG	N83806 001
PVT FORM	0.75MG	N83420 001
ROXANE	0.25MG	N84614 001
UPSHER SMITH	0.75MG	N87534 001
	1.5MG	N87533 001
WATSON LAB	0.75MG	N84457 001
WATSON LABS	0.75MG	N85818 001
	1.5MG	N85840 001
WHITEWORTH TOWN PLSN	0.75MG	N84327 001

FDA data supplied by DrugPatentWatch.com

DEXAMETHASONE

TABLET; ORAL			
DEXONE 0.5			
SOLVAY	0.5MG	N84991	001
DEXONE 0.75			
SOLVAY	0.75MG	N84993	001
DEXONE 1.5			
SOLVAY	1.5MG	N84990	001
DEXONE 4			
SOLVAY	4MG	N84992	001
HEXADROL			
ORGANON	0.5MG	N12675	004
	0.75MG	N12675	007
	1.5MG	N12675	009

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC			
DEXACIDIN			
NOVARTIS	0.1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM	N62566	001
		FEB 22, 1985	
DEXASPORIN			
PHARMAFAIR	0.1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM	N62411	001
		MAY 16, 1983	
SUSPENSION/DROPS; OPHTHALMIC			
DEXASPORIN			
PHARMAFAIR	0.1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N62428	001
		MAY 18, 1983	

DEXAMETHASONE SODIUM PHOSPHATE

AEROSOL; NASAL			
DEXACORT			
CELLTECH PHARMS	EQ 0.1MG PHOSPHATE/INH	N14242	001
AEROSOL, METERED; INHALATION			
DEXACORT			
CELLTECH PHARMS	EQ 0.1MG PHOSPHATE/INH	N13413	001
CREAM; TOPICAL			
DECADRON			
MERCK	EQ 0.1% PHOSPHATE	N11983	002

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION			
DEXACEN-4			
CENT PHARMS	EQ 4MG PHOSPHATE/ML	N84342	001
DEXAMETHASONE			
AM PHARM PARTNERS	EQ 4MG PHOSPHATE/ML	N88448	001
		JAN 25, 1984	
DEXAMETHASONE SODIUM PHOSPHATE			
AKORN	EQ 4MG PHOSPHATE/ML	N84493	001
AM PHARM PARTNERS	EQ 4MG PHOSPHATE/ML	N87065	001
BEL MAR	EQ 4MG PHOSPHATE/ML	N84752	001
DELL LABS	EQ 4MG PHOSPHATE/ML	N83161	001
GENSIA SICOR PHARMS	EQ 4MG PHOSPHATE/ML	N81125	001
		AUG 31, 1990	
INTL MEDICATION	EQ 20MG PHOSPHATE/ML	N88522	001
		FEB 17, 1984	
QUAD PHARMS	EQ 4MG PHOSPHATE/ML	N89280	001
		MAR 18, 1987	
	EQ 10MG PHOSPHATE/ML	N89281	001
		MAR 18, 1987	
	EQ 20MG PHOSPHATE/ML	N89282	001
		MAR 18, 1987	
	EQ 24MG PHOSPHATE/ML	N89372	001
		MAR 18, 1987	
STERIS	EQ 4MG PHOSPHATE/ML	N83702	001
	EQ 4MG PHOSPHATE/ML	N84355	001
	EQ 24MG PHOSPHATE/ML	N85606	001
WYETH AYERST	EQ 4MG PHOSPHATE/ML	N85641	001
HEXADROL			
ORGANON	EQ 20MG PHOSPHATE/ML	N14694	004
OINTMENT; OPHTHALMIC			
DECADRON			
MERCK	EQ 0.05% PHOSPHATE	N11977	001
DEXAIR			
PHARMAFAIR	EQ 0.05% PHOSPHATE	N88071	001
		DEC 28, 1982	
SOLUTION/DROPS; OPHTHALMIC			
DEXAIR			
PHARMAFAIR	EQ 0.1% PHOSPHATE	N88433	001
		DEC 15, 1983	
DEXAMETHASONE SODIUM PHOSPHATE			
SOLA BARNES HIND	EQ 0.1% PHOSPHATE	N84170	001
	EQ 0.1% PHOSPHATE	N84173	001
SOLUTION/DROPS; OTIC			
DEXAMETHASONE SODIUM PHOSPHATE			
AKORN	EQ 0.1% PHOSPHATE	N84855	001

FDA data supplied by DrugPatentWatch.com

DEXAMETHASONE SODIUM PHOSPHATE; NEOMYCIN SULFATE

OINTMENT; OPHTHALMIC			
NEODECADRON			
MERCK	EQ 0.05% PHOSPHATE; EQ 3.5MG BASE/GM	N50324	001
SOLUTION/DROPS; OPHTHALMIC			
NEOMYCIN SULFATE AND DEXAMETHASONE SODIUM PHOSPHATE			
BAUSCH AND LOMB	EQ 0.1% PHOSPHATE; EQ 3.5MG BASE/ML	N64055	001
		OCT 30, 1995	
NEOMYCIN SULFATE-DEXAMETHASONE SODIUM PHOSPHATE			
ALCON UNIVERSAL	EQ 0.1% PHOSPHATE; EQ 3.5MG BASE/ML	N62714	001
		JUL 21, 1986	
PHARMAFAIR	EQ 0.1% PHOSPHATE; EQ 3.5MG BASE/ML	N62539	001
		JAN 10, 1985	

DEXBROMPHENIRAMINE MALEATE

SYRUP; ORAL			
DISOMER			
SCHERING	2MG/5ML	N11814	002
TABLET; ORAL			
DISOMER			
SCHERING	2MG	N11814	001

DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET; ORAL			
DISOPHROL			
SCHERING	2MG;60MG	N12394	002
TABLET, EXTENDED RELEASE; ORAL			
DISOBROM			
GENEVA PHARMS	6MG;120MG	N70770	001
		SEP 30, 1991	
RESPORAL			
PIONEER PHARMS	6MG;120MG	N89139	001
		JUN 16, 1988	

DEXPANTHENOL; *MULTIPLE*

SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE; VITAMIN A; VITAMIN E

SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN E

DEXTROAMPHETAMINE ADIPATE; *MULTIPLE*

SEE AMPHETAMINE ADIPATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE ADIPATE; DEXTROAMPHETAMINE SULFATE

DEXTROAMPHETAMINE RESIN COMPLEX; *MULTIPLE*

SEE AMPHETAMINE RESIN COMPLEX; DEXTROAMPHETAMINE RESIN COMPLEX

DEXTROAMPHETAMINE SULFATE

CAPSULE; ORAL			
DEXAMPEX			
TEVA	15MG	N85355	001
ELIXIR; ORAL			
DEXEDRINE			
GLAXOSMITHKLINE	5MG/5ML	N83902	001
TABLET; ORAL			
DEXAMPEX			
TEVA	5MG	N83735	001
	10MG	N83735	002
DEXTROAMPHETAMINE SULFATE			
GENEVA PHARMS	5MG	N85370	001
	10MG	N85371	001
HALSEY	10MG	N83930	001
LANNETT	5MG	N83903	001
	10MG	N83903	003
	15MG	N85652	001
MAST MM	5MG	N86521	001
PUREPAC PHARM	5MG	N84125	001
VITARINE	5MG	N84986	001
	10MG	N85892	001

FDA data supplied by DrugPatentWatch.com

DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

FERNDEX		
FERNDALE LABS	5MG	N84001 001

DEXTROAMPHETAMINE SULFATE; *MULTIPLE*

SEE AMPHETAMINE ADIPATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE ADIPATE; DEXTROAMPHETAMINE SULFATE

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PHERAZINE DM		
HALSEY	15MG/5ML;6.25MG/5ML	N88913 001
		MAR 02, 1987

DEXTROSE

INJECTABLE; INJECTION

DEXTROSE 10% IN PLASTIC CONTAINER		
MILES	10GM/100ML	N18504 001
DEXTROSE 2.5% IN PLASTIC CONTAINER		
B BRAUN	2.5GM/100ML	N19626 001
		FEB 02, 1988
DEXTROSE 38.5% IN PLASTIC CONTAINER		
ABBOTT	38.5GM/100ML	N18923 001
		SEP 19, 1984
DEXTROSE 50% IN PLASTIC CONTAINER		
ABBOTT	500MG/ML	N19445 001
		JUN 03, 1986
DEXTROSE 60%		
B BRAUN	60GM/100ML	N17995 002
		SEP 22, 1982
DEXTROSE 60% IN PLASTIC CONTAINER		
B BRAUN	60GM/100ML	N17995 001
BAXTER HLTHCARE	60GM/100ML	N20047 002
		JUL 02, 1991
DEXTROSE 7.7% IN PLASTIC CONTAINER		
B BRAUN	7.7GM/100ML	N19626 003
		FEB 02, 1988

DEXTROSE; *MULTIPLE*

SEE ALCOHOL; DEXTROSE

SEE AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

DEXTROSE; *MULTIPLE*

SEE AMINO ACIDS; DEXTROSE

SEE AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM ACETATE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

SEE AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

SEE AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SEE CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SEE CALCIUM CHLORIDE; DEXTROSE; SODIUM CHLORIDE; SODIUM LACTATE

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% IN PLASTIC CONTAINER		
B BRAUN	5GM/100ML;37MG/100ML	N19699 001
		SEP 29, 1989
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% IN PLASTIC CONTAINER		
B BRAUN	5GM/100ML;75MG/100ML	N19699 002
		SEP 29, 1989
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% IN PLASTIC CONTAINER		
B BRAUN	5GM/100ML;110MG/100ML	N19699 003
		SEP 29, 1989
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% IN PLASTIC CONTAINER		
B BRAUN	5GM/100ML;220MG/100ML	N19699 005
		SEP 29, 1989

FDA data supplied by DrugPatentWatch.com

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.075%

B BRAUN	5GM/100ML;75MG/100ML; 200MG/100ML	N18268 009

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;150MG/100ML; 200MG/100ML	N18268 004

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;220MG/100ML; 200MG/100ML	N18268 005

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;300MG/100ML; 200MG/100ML	N18268 006

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;75MG/100ML; 330MG/100ML	N18268 011 JAN 18, 1986

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;150MG/100ML; 330MG/100ML	N18268 012 JAN 18, 1986

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;220MG/100ML; 330MG/100ML	N18268 013 JAN 18, 1986

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.30% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;300MG/100ML; 330MG/100ML	N18268 014 JAN 18, 1986

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.075%

B BRAUN	5GM/100ML;75MG/100ML; 450MG/100ML	N18268 010

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;150MG/100ML; 450MG/100ML	N18268 001

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;220MG/100ML; 450MG/100ML	N18268 002

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;300MG/100ML; 450MG/100ML	N18268 003

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER

BAXTER HLTHCARE	5GM/100ML;224MG/100ML; 450MG/100ML	N18008 003

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ (K) IN PLASTIC CONTAINER

BAXTER HLTHCARE	5GM/100ML;300MG/100ML; 450MG/100ML	N18008 001

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER

BAXTER HLTHCARE	5GM/100ML;75MG/100ML; 450MG/100ML	N18008 002

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

B BRAUN	10GM/100ML;200MG/100ML	N18386 001

DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

B BRAUN	10GM/100ML;450MG/100ML	N18229 001

DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

B BRAUN	10GM/100ML;900MG/100ML	N18047 001

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

B BRAUN	2.5GM/100ML;450MG/100ML	N18030 001

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

B BRAUN	2.5GM/100ML;900MG/100ML	N18376 001

DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

ABBOTT	3.3GM/100ML;300MG/100ML	N18055 001

DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;110MG/100ML	N18030 005

DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;200MG/100ML	N18030 004
MILES	5GM/100ML;200MG/100ML	N18399 001

DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

ABBOTT	5GM/100ML;225MG/100ML	N19482 001 OCT 04, 1985

FDA data supplied by DrugPatentWatch.com

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION
DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
ABBOTT 5GM/100ML;300MG/100ML N19486 001 OCT 04, 1985
MILES 5GM/100ML;300MG/100ML N18501 001
DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;330MG/100ML N18030 003
DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
ABBOTT 5GM/100ML;450MG/100ML N19484 001 OCT 04, 1985
B BRAUN 5GM/100ML;450MG/100ML N18030 002
MILES 5GM/100ML;450MG/100ML N18400 001
DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
ABBOTT 5GM/100ML;900MG/100ML N19483 001 OCT 04, 1985
B BRAUN 5GM/100ML;900MG/100ML N18026 001
MILES 5GM/100ML;900MG/100ML N18500 001

DEXTROTHYROXINE SODIUM

TABLET; ORAL
CHOLOXIN
ABBOTT 1MG N12302 005
2MG N12302 002
4MG N12302 004
6MG N12302 006

DEZOCINE

INJECTABLE; INJECTION
DALGAN
ASTRAZENECA 5MG/ML N19082 001 DEC 29, 1989
10MG/ML N19082 002 DEC 29, 1989
15MG/ML N19082 003 DEC 29, 1989

DIATRIZOATE MEGLUMINE

INJECTABLE; INJECTION
ANGIOVIST 282
BERLEX 60% N87726 001 SEP 23, 1982

DIATRIZOATE MEGLUMINE

INJECTABLE; INJECTION
CARDIOGRAFIN
BRACCO 85% N11620 002
UROVIST MEGLUMINE DIU/CT
BERLEX 30% N87739 001 SEP 23, 1982

SOLUTION; URETERAL
UROVIST CYSTO
BERLEX 30% N87729 001 SEP 23, 1982
UROVIST CYSTO PEDIATRIC
BERLEX 30% N87731 001 SEP 23, 1982

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

INJECTABLE; INJECTION
ANGIOVIST 292
BERLEX 52%;8% N87724 001 SEP 23, 1982
ANGIOVIST 370
BERLEX 66%;10% N87723 001 SEP 23, 1982
DIATRIZOATE-60
INTL MEDICATION 52%;8% N88166 001 JUN 17, 1983
HYPAQUE-M,75%
AMERSHAM HLTH 50%;25% N10220 003
HYPAQUE-M,90%
AMERSHAM HLTH 60%;30% N10220 002
MD-60
MALLINCKRODT 52%;8% N87074 001
MD-76
MALLINCKRODT 66%;10% N87073 001

SOLUTION; ORAL, RECTAL
GASTROVIST
BERLEX 66%;10% N87728 001 SEP 23, 1982

DIATRIZOATE SODIUM

INJECTABLE; INJECTION
MD-50
MALLINCKRODT 50% N87075 001

FDA data supplied by DrugPatentWatch.com

DIATRIZOATE SODIUM

INJECTABLE; INJECTION
UROVIST SODIUM 300

BERLEX	50%	N87725 001 SEP 23, 1982

DIATRIZOATE SODIUM; *MULTIPLE*
SEE DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

DIAZEPAM

CAPSULE, EXTENDED RELEASE; ORAL
VALRELEASE

ROCHE	15MG	N18179 001

INJECTABLE; INJECTION
DIAZEPAM

AM PHARM PARTNERS	5MG/ML	N70662 001 JUN 25, 1986
LEDERLE	5MG/ML	N71308 001 JUL 17, 1987
MARSAM PHARMS LLC	5MG/ML	N72371 001 JAN 29, 1993
STERIS	5MG/ML	N70911 001 AUG 28, 1986
	5MG/ML	N70912 001 AUG 28, 1986
	5MG/ML	N70930 001 DEC 01, 1986
US ARMY	5MG/ML	N20124 001 DEC 05, 1990
WARNER CHILCOTT	5MG/ML	N71613 001 OCT 22, 1987
	5MG/ML	N71614 001 OCT 22, 1987

DIZAC

PHARMACIA AND UPJOHN	5MG/ML	N19287 001 JUN 18, 1993

TABLET; ORAL
DIAZEPAM

DURAMED	2MG	N70894 001 AUG 27, 1986
	5MG	N70895 001 AUG 27, 1986

DIAZEPAM

TABLET; ORAL
DIAZEPAM

DURAMED	10MG	N70896 001 AUG 27, 1986
FERNDALE LABS	2MG	N70903 001 APR 01, 1987
	5MG	N70904 001 APR 01, 1987
	10MG	N70905 001 APR 01, 1987
HALSEY	2MG	N70987 001 AUG 15, 1986
	5MG	N70996 001 AUG 15, 1986
	10MG	N70956 001 AUG 15, 1986
IVAX PHARMS	2MG	N70360 001 SEP 04, 1985
	5MG	N70361 001 SEP 04, 1985
	10MG	N70362 001 SEP 04, 1985
MARTEC	10MG	N72402 001 APR 25, 1989
PIONEER PHARMS	2MG	N70787 001 AUG 02, 1988
	5MG	N70788 001 AUG 02, 1988
	10MG	N70776 001 AUG 02, 1988
ROXANE	2MG	N70356 001 JUN 17, 1986
	5MG	N70357 001 JUN 17, 1986
	10MG	N70358 001 JUN 17, 1986
WARNER CHILCOTT	2MG	N70209 001 SEP 04, 1985
	5MG	N70210 001 SEP 04, 1985
	10MG	N70222 001 SEP 04, 1985
WATSON LABS	2MG	N70456 001 NOV 01, 1985
	5MG	N70457 001 NOV 01, 1985

FDA data supplied by DrugPatentWatch.com

DIAZEPAM

TABLET; ORAL			
DIAZEPAM			
WATSON LABS	10MG	N70458 001	NOV 01, 1985
Q-PAM			
QUANTUM PHARMICS	2MG	N70423 001	DEC 12, 1985
	2MG	N72431 001	APR 29, 1988
	5MG	N70424 001	DEC 12, 1985
	5MG	N72432 001	APR 29, 1988
	10MG	N70425 001	DEC 12, 1985
	10MG	N72433 001	APR 29, 1988

DIAZOXIDE

CAPSULE; ORAL			
PROGLYCEM			
BAKER NORTON	100MG	N17425 002	
INJECTABLE; INJECTION			
DIAZOXIDE			
AM PHARM PARTNERS	15MG/ML	N71519 001	AUG 26, 1987
QUAD PHARMS	15MG/ML	N71908 001	JAN 26, 1988

DIBUCAINE HYDROCHLORIDE

INJECTABLE; INJECTION			
HEAVY SOLUTION NUPERCAINE			
NOVARTIS	2.5MG/ML	N06203 001	

DICLOFENAC POTASSIUM

TABLET; ORAL			
CATAFLAM			
NOVARTIS	25MG	N20142 001	NOV 24, 1993

DICLOFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC			
DICLOFENAC SODIUM			
FALCON PHARMS	0.1%	N20809 001	MAY 04, 1998

DICLOXACILLIN SODIUM

CAPSULE; ORAL			
DYCILL			
GLAXOSMITHKLINE	EQ 250MG BASE	N60254 002	
	EQ 250MG BASE	N62238 001	
	EQ 500MG BASE	N60254 003	
	EQ 500MG BASE	N62238 002	
FOR SUSPENSION; ORAL			
DYNAPEN			
APOTHECON	EQ 62.5MG BASE/5ML	N50337 002	

DICUMAROL

CAPSULE; ORAL			
DICUMAROL			
LILLY	25MG	N05509 003	
	50MG	N05509 001	
TABLET; ORAL			
DICUMAROL			
ABBOTT	50MG	N05545 004	
	100MG	N05545 005	

DICYCLOMINE HYDROCHLORIDE

CAPSULE; ORAL			
DICYCLOMINE HCL			
HALSEY	10MG	N84505 001	OCT 21, 1986
PIONEER PHARMS	10MG	N89361 001	JAN 10, 1989
WATSON LAB	10MG	N83179 001	FEB 12, 1986
INJECTABLE; INJECTION			
DICYCLOMINE HCL			
STERIS	10MG/ML	N80614 001	FEB 11, 1986

FDA data supplied by DrugPatentWatch.com

DICYCLOMINE HYDROCHLORIDE

SYRUP; ORAL		
DICYCLOMINE HCL		
ALPHARMA	10MG/5ML	N84479 001
TABLET; ORAL		
DICYCLOMINE HCL		
HALSEY	20MG	N84600 001
		JUL 29, 1985
PIONEER PHARMS	20MG	N88585 001
		AUG 20, 1986
WATSON LAB	20MG	N84361 001
		FEB 06, 1986

DIDANOSINE

FOR SOLUTION; ORAL		
VIDEX		
BRISTOL MYERS SQUIBB	375MG/PACKET	N20155 006
		OCT 09, 1991

DIENESTROL

CREAM; VAGINAL		
DV		
AVENTIS PHARMS	0.01%	N83518 001
ESTRAGUARD		
SOLVAY	0.01%	N84436 001
SUPPOSITORY; VAGINAL		
DV		
AVENTIS PHARMS	0.7MG	N83517 001

DIETHYLCARBAMAZINE CITRATE

TABLET; ORAL		
HETRAZAN		
LEDERLE	50MG	N06459 001

DIETHYLPROPION HYDROCHLORIDE

TABLET; ORAL		
DIETHYLPROPION HCL		
CELLTECH PHARMS	25MG	N85544 001

DIETHYLPROPION HYDROCHLORIDE

TABLET; ORAL		
DIETHYLPROPION HCL		
EON	25MG	N85916 001
TEVA	25MG	N88642 001
		SEP 20, 1984
WATSON LABS	25MG	N85741 001
TENUATE		
AVENTIS PHARMS	25MG	N17668 001
TEPANIL		
3M	25MG	N11673 001
TABLET, EXTENDED RELEASE; ORAL		
TENUATE		
AVENTIS PHARMS	75MG	N17669 001
TEPANIL TEN-TAB		
3M	75MG	N17956 001

DIETHYLSTILBESTROL

INJECTABLE; INJECTION		
STILBESTROL		
BRISTOL MYERS SQUIBB	0.2MG/ML	N04056 003
	0.5MG/ML	N04056 004
	1MG/ML	N04056 005
	5MG/ML	N04056 006
SUPPOSITORY; VAGINAL		
DIETHYLSTILBESTROL		
LILLY	0.1MG	N04040 001
	0.5MG	N04040 002
STILBESTROL		
BRISTOL MYERS SQUIBB	0.1MG	N04056 001
	0.5MG	N04056 002
TABLET; ORAL		
DIETHYLSTILBESTROL		
LILLY	0.1MG	N04041 002
	0.5MG	N04041 003
	1MG	N04041 004
	5MG	N04041 005
STILBESTROL		
TABLICAPS	0.5MG	N83004 001
	1MG	N83002 001
	5MG	N83006 001
STILBETIN		
BRISTOL MYERS SQUIBB	0.1MG	N04056 007

FDA data supplied by DrugPatentWatch.com

DIETHYLSTILBESTROL

TABLET; ORAL			
STILBETIN			
BRISTOL MYERS SQUIBB	0.25MG	N04056 017	
	0.5MG	N04056 008	
	1MG	N04056 009	
	5MG	N04056 010	
TABLET, DELAYED RELEASE; ORAL			
DIETHYLSTILBESTROL			
LILLY	0.1MG	N04039 002	
	0.25MG	N04039 005	
	0.5MG	N04039 003	
	1MG	N04039 004	
	5MG	N04039 006	
STILBESTROL			
TABLICAPS	0.5MG	N83003 001	
	1MG	N83005 001	
	5MG	N83007 001	
STILBETIN			
BRISTOL MYERS SQUIBB	0.1MG	N04056 011	
	0.5MG	N04056 012	
	1MG	N04056 013	
	5MG	N04056 014	

DIETHYLSTILBESTROL DIPHOSPHATE

INJECTABLE; INJECTION			
STILPHOSTROL			
BAYER	250MG/5ML	N10010 001	
TABLET; ORAL			
STILPHOSTROL			
BAYER	50MG	N10010 002	

DIFENOXIN HYDROCHLORIDE; *MULTIPLE*
SEE ATROPINE SULFATE; DIFENOXIN HYDROCHLORIDE

DIFLUNISAL

TABLET; ORAL			
DIFLUNISAL			
PUREPAC PHARM	250MG	N74285 001	
		MAY 07, 1996	

DIFLUNISAL

TABLET; ORAL			
DIFLUNISAL			
PUREPAC PHARM	500MG	N74285 002	
		MAY 07, 1996	

DIGITOXIN

INJECTABLE; INJECTION			
CRYSTODIGIN			
LILLY	0.2MG/ML	N84100 005	

DIGOXIN

CAPSULE; ORAL			
LANOXICAPS			
GLAXO WELLCOME	0.15MG	N18118 004	
		SEP 24, 1984	
INJECTABLE; INJECTION			
DIGOXIN			
AM PHARM PARTNERS	0.25MG/ML	N83217 001	
TABLET; ORAL			
LANOXIN			
GLAXO WELLCOME	0.0625MG	N20405 001	
		SEP 30, 1997	
	0.1875MG	N20405 003	
		SEP 30, 1997	
	0.375MG	N20405 005	
		SEP 30, 1997	
	0.5MG	N20405 006	
		SEP 30, 1997	

DIHYDROCODEINE BITARTRATE; *MULTIPLE*
SEE ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

DIHYDROERGOTAMINE MESYLATE; HEPARIN SODIUM; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION			
EMBOLEX			
NOVARTIS	0.5MG/0.7ML;5,000 UNITS/0.7ML; 7.46MG/0.7ML	N18885 002	
		NOV 30, 1984	

FDA data supplied by DrugPatentWatch.com

DIHYDROERGOTAMINE MESYLATE; HEPARIN SODIUM; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
EMBOLEX
NOVARTIS 0.5MG/0.5ML;2,500 UNITS/0.5ML; 5.33MG/0.5ML N18885 001 NOV 30, 1984

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
CARDIZEM SR
AVENTIS PHARMS 180MG N19471 004 JAN 23, 1989

TABLET; ORAL
DILTIAZEM HCL
TEVA 30MG N74084 001 FEB 25, 1994
60MG N74084 002 FEB 25, 1994

DIMENHYDRINATE

INJECTABLE; INJECTION
DIMENHYDRINATE
ELKINS SINN 50MG/ML N84767 001
STERIS 50MG/ML N83531 001

LIQUID; ORAL
DIMENHYDRINATE
ALRA 12.5MG/4ML N80715 001

TABLET; ORAL
DIMENHYDRINATE
ANABOLIC 50MG N85985 001
HEATHER 50MG N80841 001
WATSON LABS 50MG N85166 001

DINOPROST TROMETHAMINE

INJECTABLE; INJECTION
PROSTIN F2 ALPHA
PHARMACIA AND UPJOHN EQ 5MG BASE/ML N17434 001

DIPHEMANIL METHYLSULFATE

TABLET; ORAL
PRANTAL
SCHERING 100MG N08114 004

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL
BENADRYL
PARKE DAVIS 25MG N05845 007
50MG N05845 001

DIPHENHYDRAMINE HCL
ALRA 25MG N80519 004
50MG N80519 003
ANABOLIC 25MG N83634 001
50MG N83275 001
ELKINS SINN 25MG N85701 001
50MG N85701 002
EON 25MG N80845 002
50MG N80845 001
HALSEY 50MG N87914 001 JUN 04, 1984
HEATHER 25MG N84524 001
50MG N83953 001
IMPAX LABS 50MG N80807 002
IVAX PHARMS 25MG N80762 001
50MG N80762 002
LANNETT 25MG N80868 001
50MG N80868 002
LEDERLE 25MG N86874 001
50MG N86875 001
NEWTRON PHARMS 25MG N86543 001
50MG N86544 001
PERRIGO 25MG N83061 001
50MG N83061 002
PIONEER PHARMS 25MG N89101 001 DEC 20, 1985
50MG N88880 001 DEC 20, 1985
PUREPAC PHARM 25MG N85156 001
50MG N85150 001
ROXANE 50MG N80635 001
SUPERPHARM 50MG N89041 001 MAY 15, 1985
TEVA 25MG N85874 001
50MG N85874 002

FDA data supplied by DrugPatentWatch.com

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL		
DIPHENHYDRAMINE HCL		
VANGARD	25MG	N88034 001
		OCT 27, 1982
	50MG	N87630 001
WATSON LAB	25MG	N83797 001
	50MG	N83797 002
WATSON LABS	25MG	N85138 001
	50MG	N85083 001
WEST WARD	50MG	N83567 001
WHITEWORTH TOWN PLSN	25MG	N83441 001
	50MG	N80800 001
ELIXIR; ORAL		
BELIX		
HALSEY	12.5MG/5ML	N86586 001
		OCT 03, 1983
BENADRYL		
PARKE DAVIS	12.5MG/5ML	N05845 004
DIBENIL		
CENCI	12.5MG/5ML	N88304 001
		DEC 16, 1983
DIPHEN		
USL PHARMA	12.5MG/5ML	N84640 001
DIPHENHYDRAMINE HCL		
BUNDY	12.5MG/5ML	N83674 001
CENCI	12.5MG/5ML	N87941 001
		DEC 17, 1982
KV PHARM	12.5MG/5ML	N85621 001
LEDERLE	12.5MG/5ML	N86937 001
NASKA	12.5MG/5ML	N88680 001
		MAY 31, 1985
PERRIGO	12.5MG/5ML	N83063 001
PUREPAC PHARM	12.5MG/5ML	N83237 001
		JAN 25, 1982
PVT FORM	12.5MG/5ML	N85287 001
HYDRAMINE		
ALPHARMA	12.5MG/5ML	N80763 002
INJECTABLE; INJECTION		
BENADRYL		
PARKE DAVIS	10MG/ML	N06146 001
DIPHENHYDRAMINE HCL		
AM PHARM PARTNERS	10MG/ML	N87066 001
BEL MAR	10MG/ML	N80822 001
ELKINS SINN	50MG/ML	N83183 001
STERIS	10MG/ML	N83533 001

DIPHENHYDRAMINE HYDROCHLORIDE

INJECTABLE; INJECTION		
DIPHENHYDRAMINE HCL PRESERVATIVE FREE		
AM PHARM PARTNERS	50MG/ML	N80586 002
SYRUP; ORAL		
ANTITUSSIVE		
PERRIGO	12.5MG/5ML	N71292 001
		APR 10, 1987
BELDIN		
HALSEY	12.5MG/5ML	N89179 001
		JUN 05, 1986
BENYLIN		
PARKE DAVIS	12.5MG/5ML	N06514 004
DIPHEN		
MORTON GROVE	12.5MG/5ML	N70118 001
		OCT 01, 1985
DIPHENHYDRAMINE HCL		
ALPHARMA	12.5MG/5ML	N70497 001
		APR 25, 1989
CUMBERLAND SWAN	12.5MG/5ML	N73611 001
		AUG 20, 1992
HI TECH PHARMA	12.5MG/5ML	N72416 001
		SEP 28, 1990
HYDRAMINE		
ALPHARMA	12.5MG/5ML	N70205 001
		JAN 28, 1986
SILPHEN		
SILARX	12.5MG/5ML	N72646 001
		FEB 27, 1992
VICKS FORMULA 44		
PROCTER AND GAMBLE	12.5MG/5ML	N70524 001
		JAN 14, 1987

DIPHENHYDRAMINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL		
BENYLIN		
PARKE DAVIS	12.5MG/5ML;30MG/5ML	N19014 001
		JUN 11, 1985

DIPHENOXYLATE HYDROCHLORIDE; *MULTIPLE*

SEE ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

DIPHENYLPYRALINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
HISPRIL
GLAXOSMITHKLINE 5MG N11945 001

DIPYRIDAMOLE

TABLET; ORAL
DIPYRIDAMOLE
PUREPAC PHARM 50MG N89426 001 JUL 12, 1990
75MG N89427 001 JUL 12, 1990

DISOPYRAMIDE PHOSPHATE

CAPSULE; ORAL
DISOPYRAMIDE PHOSPHATE
HALSEY EQ 100MG BASE N70351 001 DEC 17, 1985
EQ 150MG BASE N70352 001 DEC 17, 1985
INTERPHARM EQ 100MG BASE N71190 001 JAN 15, 1987
EQ 150MG BASE N71191 001 JAN 15, 1987
MYLAN EQ 100MG BASE N70138 001 JUN 14, 1985
EQ 150MG BASE N70139 001 JUN 14, 1985
SUPERPHARM EQ 150MG BASE N70941 001 FEB 09, 1987
WATSON LAB EQ 100MG BASE N70240 001 FEB 02, 1986
EQ 150MG BASE N70241 001 FEB 02, 1986

DISULFIRAM

TABLET; ORAL
ANTABUSE
* SIDMAK LABS 250MG N07883 003
* 500MG N07883 002
DISULFIRAM
DANBURY PHARMA 250MG N86889 001

DISULFIRAM

TABLET; ORAL
DISULFIRAM
DANBURY PHARMA 500MG N86890 001
PAR PHARM 250MG N88792 001 AUG 14, 1984
500MG N88793 001 AUG 14, 1984
WATSON LABS 250MG N87973 001 AUG 05, 1983
500MG N87974 001 AUG 05, 1983

DIVALPROEX SODIUM

TABLET, DELAYED RELEASE; ORAL
DEPAKOTE CP
ABBOTT EQ 250MG BASE N19794 001 JUL 11, 1990
EQ 500MG BASE N19794 002 JUL 11, 1990

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
DOPAMINE HCL
ABBOTT 40MG/ML N70656 001 JAN 24, 1989
80MG/ML N70657 001 JAN 24, 1989
AM PHARM PARTNERS 40MG/ML N18549 001 MAR 11, 1983
40MG/ML N70012 001 JUN 12, 1985
40MG/ML N70058 001 MAR 20, 1985
80MG/ML N70059 001 MAR 20, 1985
160MG/ML N70364 001 DEC 04, 1985
ASTRAZENECA 40MG/ML N70087 001 OCT 23, 1985
80MG/ML N70089 001 OCT 23, 1985
80MG/ML N70090 001 OCT 23, 1985

FDA data supplied by DrugPatentWatch.com

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOPAMINE HCL		
ASTRAZENECA	160MG/ML	N70093 001 OCT 23, 1985
	160MG/ML	N70094 001 OCT 23, 1985
SMITH AND NEPHEW	40MG/ML	N70011 001 AUG 29, 1985
	40MG/ML	N70046 001 AUG 29, 1985
	80MG/ML	N70047 001 AUG 29, 1985
WARNER CHILCOTT	40MG/ML	N18138 001
	40MG/ML	N70558 001 SEP 20, 1985
	80MG/ML	N70559 001 SEP 20, 1985

DOXEPIN HYDROCHLORIDE

CAPSULE; ORAL

DOXEPIN HCL		
HALSEY	EQ 25MG BASE	N71502 001 FEB 18, 1988
	EQ 50MG BASE	N71653 001 FEB 18, 1988
	EQ 75MG BASE	N71654 001 FEB 18, 1988
	EQ 100MG BASE	N71521 001 FEB 18, 1988
NEW RIVER	EQ 10MG BASE	N16987 001
	EQ 25MG BASE	N16987 002
	EQ 50MG BASE	N16987 003
	EQ 75MG BASE	N16987 006
	EQ 100MG BASE	N16987 004
	EQ 150MG BASE	N16987 007 APR 13, 1987
PUREPAC PHARM	EQ 10MG BASE	N73054 001 DEC 28, 1990
	EQ 25MG BASE	N72109 001 DEC 28, 1990
	EQ 50MG BASE	N73055 001 DEC 28, 1990
	EQ 75MG BASE	N72386 001 SEP 08, 1988

DOXEPIN HYDROCHLORIDE

CAPSULE; ORAL

DOXEPIN HCL		
PUREPAC PHARM	EQ 100MG BASE	N72110 001 SEP 08, 1988
	EQ 150MG BASE	N72387 001 SEP 08, 1988
QUANTUM PHARMICS	EQ 10MG BASE	N70972 001 SEP 29, 1987
	EQ 25MG BASE	N70973 001 SEP 29, 1987
	EQ 50MG BASE	N70931 001 SEP 29, 1987
	EQ 75MG BASE	N70932 001 SEP 29, 1987
	EQ 100MG BASE	N72375 001 MAR 15, 1989
	EQ 150MG BASE	N72376 001 MAR 15, 1989
WATSON LABS	EQ 10MG BASE	N70952 001 MAR 04, 1987
	EQ 25MG BASE	N70953 001 MAY 15, 1986
	EQ 50MG BASE	N70954 001 MAY 15, 1986
	EQ 75MG BASE	N71763 001 FEB 09, 1988
	EQ 100MG BASE	N70955 001 MAY 15, 1986
	EQ 150MG BASE	N71764 001 FEB 09, 1988

DOXYCYCLINE

FOR SUSPENSION; ORAL

DOXYCHEL		
RACHELLE	EQ 25MG BASE/5ML	N61720 001

DOXYCYCLINE HYCLATE

CAPSULE; ORAL

DOXY-LEMMON		
TEVA	EQ 50MG BASE	N62497 001 AUG 23, 1984
	EQ 100MG BASE	N62497 002 JUN 15, 1984

FDA data supplied by DrugPatentWatch.com

DOXYCYCLINE HYCLATE

CAPSULE; ORAL

DOXYCYCLINE HYCLATE		
HALSEY	EQ 50MG BASE	N62119 002
		MAY 24, 1985
	EQ 50MG BASE	N62418 001
		JAN 28, 1983
	EQ 100MG BASE	N62119 001
		MAY 24, 1985
	EQ 100MG BASE	N62418 002
		JAN 28, 1983
HEATHER	EQ 50MG BASE	N62463 001
		DEC 07, 1983
	EQ 100MG BASE	N62463 002
		DEC 07, 1983
INTERPHARM	EQ 50MG BASE	N62763 001
		SEP 02, 1988
	EQ 100MG BASE	N62763 002
		SEP 02, 1988
PAR PHARM	EQ 50MG BASE	N62434 001
		OCT 19, 1984
	EQ 100MG BASE	N62442 001
		DEC 22, 1983
PVT FORM	EQ 50MG BASE	N62631 001
		JUL 24, 1986
	EQ 100MG BASE	N62631 002
		JUL 24, 1986
RANBAXY	EQ 50MG BASE	N62479 001
		DEC 23, 1983
	EQ 100MG BASE	N62479 002
		DEC 23, 1983
SUPERPHARM	EQ 50MG BASE	N62469 001
		OCT 31, 1984
	EQ 100MG BASE	N62469 002
		OCT 31, 1984
WARNER CHILCOTT	EQ 50MG BASE	N62594 001
		DEC 05, 1985
	EQ 100MG BASE	N62594 002
		DEC 05, 1985
WATSON LABS	EQ 50MG BASE	N62142 001
	EQ 100MG BASE	N62142 002

CAPSULE, COATED PELLETS; ORAL

DOXYCYCLINE HYCLATE		
SIDMAK LABS NJ	EQ 100MG BASE	N63187 001
		JUN 30, 1992

INJECTABLE; INJECTION

DOXYCHEL HYCLATE		
RACHELLE	EQ 100MG BASE/VIAL	N61953 001

DOXYCYCLINE HYCLATE

INJECTABLE; INJECTION

DOXYCYCLINE		
BEDFORD	EQ 100MG BASE/VIAL	N62569 001
		MAR 09, 1988
	EQ 200MG BASE/VIAL	N62569 002
		MAR 09, 1988
ELKINS SINN	EQ 100MG BASE/VIAL	N62450 001
		OCT 27, 1983
	EQ 200MG BASE/VIAL	N62450 002
		OCT 27, 1983
DOXYCYCLINE HYCLATE		
LEDERLE	EQ 100MG BASE/VIAL	N62992 001
		FEB 16, 1989
	EQ 200MG BASE/VIAL	N62992 002
		FEB 16, 1989
QUAD PHARMS	EQ 100MG BASE/VIAL	N62643 001
		FEB 13, 1986
	EQ 200MG BASE/VIAL	N62643 002
		FEB 13, 1986

TABLET; ORAL

DOXY-LEMMON		
TEVA	EQ 100MG BASE	N62581 001
		MAR 15, 1985
DOXYCYCLINE HYCLATE		
HALSEY	EQ 100MG BASE	N62391 001
		SEP 30, 1982
HEATHER	EQ 100MG BASE	N62462 001
		MAY 11, 1983
INTERPHARM	EQ 100MG BASE	N62764 001
		SEP 02, 1988
SUPERPHARM	EQ 100MG BASE	N62494 001
		FEB 20, 1985
WARNER CHILCOTT	EQ 100MG BASE	N62593 001
		AUG 28, 1985
WATSON LABS	EQ 50MG BASE	N62392 001
		MAR 31, 1983
	EQ 100MG BASE	N62392 002
		MAR 31, 1983
DOXYCYCLINE HYLATE		
HALSEY	EQ 50MG BASE	N62269 003

FDA data supplied by DrugPatentWatch.com

DOXYLAMINE SUCCINATE

CAPSULE; ORAL			
UNISOM			
PFIZER	25MG	N19440 001	FEB 05, 1986
TABLET; ORAL			
DECAPRYN			
AVENTIS PHARMS	12.5MG	N06412 015	
	25MG	N06412 014	
DOXY-SLEEP-AID			
PAR PHARM	25MG	N70156 001	JUL 02, 1987
DOXYLAMINE SUCCINATE			
QUANTUM PHARMICS	25MG	N88603 001	AUG 07, 1984

DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL			
BENDECTIN			
* AVENTIS PHARMS	10MG;10MG	N10598 002	

DROMOSTANOLONE PROPIONATE

INJECTABLE; INJECTION			
DROLBAN			
LILLY	50MG/ML	N12936 001	

DROPERIDOL

INJECTABLE; INJECTION			
DROPERIDOL			
AM PHARM PARTNERS	2.5MG/ML	N70992 001	NOV 17, 1986
	2.5MG/ML	N70993 001	NOV 17, 1986
ASTRAZENECA	2.5MG/ML	N72018 001	OCT 20, 1988
	2.5MG/ML	N72019 001	OCT 19, 1988
	2.5MG/ML	N72020 001	OCT 19, 1988
	2.5MG/ML	N72021 001	OCT 19, 1988

DROPERIDOL

INJECTABLE; INJECTION			
DROPERIDOL			
QUAD PHARMS	2.5MG/ML	N71941 001	AUG 17, 1988
	2.5MG/ML	N71942 001	AUG 17, 1988
SMITH AND NEPHEW	2.5MG/ML	N71750 001	SEP 06, 1988
SOLOPAK	2.5MG/ML	N71754 001	SEP 06, 1988
	2.5MG/ML	N71755 001	SEP 06, 1988
STERIS	2.5MG/ML	N73520 001	NOV 27, 1991
	2.5MG/ML	N73521 001	NOV 27, 1991
	2.5MG/ML	N73523 001	NOV 27, 1991

DROPERIDOL; FENTANYL CITRATE

INJECTABLE; INJECTION			
FENTANYL CITRATE AND DROPERIDOL			
ASTRAZENECA	2.5MG/ML; EQ 0.05MG BASE/ML	N72027 001	APR 13, 1989
	2.5MG/ML; EQ 0.05MG BASE/ML	N72028 001	APR 13, 1989
INNOVAR			
AKORN MFG	2.5MG/ML; EQ 0.05MG BASE/ML	N16049 001	

DYCLONINE HYDROCHLORIDE

SOLUTION; TOPICAL			
DYCLONE			
ASTRAZENECA	0.5%	N09925 002	
	1%	N09925 001	

DYDROGESTERONE

TABLET; ORAL			
GYNOREST			
SOLVAY	5MG	N17388 001	

FDA data supplied by DrugPatentWatch.com

DYDROGESTERONE

TABLET; ORAL
GYNOREST
SOLVAY 10MG N17388 002

DYPHYLLINE

ELIXIR; ORAL
NEOTHYLLINE
TEVA 160MG/15ML N07794 003

INJECTABLE; INJECTION
NEOTHYLLINE
TEVA 250MG/ML N09088 001

TABLET; ORAL
NEOTHYLLINE
TEVA 200MG N07794 001
400MG N07794 002

EDETATE CALCIUM DISODIUM

TABLET; ORAL
CALCIUM DISODIUM VERSENATE
3M 500MG N08922 002

EDETATE DISODIUM

INJECTABLE; INJECTION
DISODIUM EDETATE
STERIS 150MG/ML N84356 001
SODIUM VERSENATE
3M 200MG/ML N10573 001

EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION
EDROPHONIUM CHLORIDE
STERIS 10MG/ML N40044 001
MAR 20, 1996

EDROPHONIUM CHLORIDE PRESERVATIVE FREE
STERIS 10MG/ML N40043 001
MAR 20, 1996

EFLORNITHINE HYDROCHLORIDE

INJECTABLE; INJECTION
ORNIDYL
AVENTIS PHARMS 200MG/ML N19879 002
NOV 28, 1990

EPINEPHRINE; ETIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
DURANEST
ASTRAZENECA 0.005MG/ML;0.5% N17751 004

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
ALPHACAINE HCL W/ EPINEPHRINE
CARLISLE 0.01MG/ML;2% N84720 001
0.02MG/ML;2% N84732 001
LIDOCAINE HCL W/ EPINEPHRINE
ABBOTT 0.01MG/ML;1% N83154 001
BEL MAR 0.01MG/ML;1% N80820 001
0.01MG/ML;2% N80757 001
INTL MEDICATION 0.01MG/ML;1% N86402 001
STERIS 0.01MG/ML;1% N80377 003
0.01MG/ML;1% N85463 001
0.01MG/ML;2% N80377 004
LIDOCATON
PHARMATON 0.02MG/ML;2% N84728 001
AUG 17, 1983
XYLOCAINE W/ EPINEPHRINE
ASTRAZENECA 0.005MG/ML;1% N10418 006
0.005MG/ML;1.5% N10418 010
0.005MG/ML;2% N10418 008
0.01MG/ML;2% N06488 003
0.02MG/ML;2% N06488 005

EPINEPHRINE; PROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
PROCAINE HCL W/ EPINEPHRINE
BEL MAR 0.02MG/ML;1% N80758 001
0.02MG/ML;2% N80759 001

FDA data supplied by DrugPatentWatch.com

EPINEPHRINE BITARTRATE

AEROSOL, METERED; INHALATION

MEDIHALER-EPI		
3M	0.3MG/INH	N10374 003

EPINEPHRINE BITARTRATE; ETIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

DURANEST		
ASTRAZENECA	0.005MG/ML;1.5%	N17751 007

EPINEPHRINE BITARTRATE; PRILOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CITANEST FORTE		
ASTRAZENECA	0.005MG/ML;4%	N14763 008

ERGOCALCIFEROL

CAPSULE; ORAL

DELTALIN		
LILLY	50,000 IU	N80884 001
VITAMIN D		
CHASE CHEM	50,000 IU	N80747 001
EVERYLIFE	50,000 IU	N80956 001
IMPAX LABS	50,000 IU	N80951 001
LANNETT	50,000 IU	N80825 001
VITARINE	50,000 IU	N84053 001
WEST WARD	50,000 IU	N83102 001

ERGOCALCIFEROL; *MULTIPLE*

SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE; VITAMIN A; VITAMIN E

SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN E

ERGOCALCIFEROL; *MULTIPLE*

SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PHYTONADIONE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A PALMITATE; VITAMIN E

ERGOLOID MESYLATES

TABLET; ORAL

ERGOLOID MESYLATES		
DANBURY PHARMA	1MG	N87244 001 AUG 16, 1982
HALSEY	1MG	N88891 001 NOV 01, 1985
WATSON LAB	1MG	N86433 001 MAY 27, 1982
GERIMAL		
WATSON LABS	1MG	N88207 001 MAR 22, 1984
HYDERGINE		
NOVARTIS	0.5MG	N17993 003

TABLET; SUBLINGUAL

ALKERGOT		
EON	0.5MG	N85153 001
	1MG	N87417 001
CIRCANOL		
3M	0.5MG	N84868 001
	1MG	N85809 001
DEAPRIL-ST		
BRISTOL MYERS SQUIBB	1MG	N85020 002
ERGOLOID MESYLATES		
DANBURY PHARMA	1MG	N87183 001
HALSEY	0.5MG	N87407 001
	1MG	N87552 001
KV PHARM	0.5MG	N85899 001
	0.5MG	N86265 001
	1MG	N85900 001
	1MG	N86264 001
LEDERLE	0.5MG	N86984 001
	1MG	N86985 001
SUPERPHARM	0.5MG	N89233 001 SEP 23, 1986
	1MG	N89234 001 SEP 23, 1986
VANGARD	0.5MG	N88013 001 SEP 20, 1982

FDA data supplied by DrugPatentWatch.com

ERGOLOID MESYLATES

TABLET; SUBLINGUAL
ERGOLOID MESYLATES

VANGARD	1MG	N88014 001 SEP 20, 1982
WATSON LAB	0.5MG	N84930 001
	1MG	N85177 001

HYDROGENATED ERGOT ALKALOIDS

IVAX PHARMS	0.5MG	N87186 001

ERGOTAMINE TARTRATE

AEROSOL, METERED; INHALATION
MEDIHALER ERGOTAMINE

3M	0.36MG/INH	N12102 001

TABLET; SUBLINGUAL
ERGOSTAT

PARKE DAVIS	2MG	N88337 001 JUN 08, 1984

WIGRETTES

ORGANON	2MG	N86750 001 JUL 29, 1982

ERGOTAMINE TARTRATE; *MULTIPLE*
SEE CAFFEINE; ERGOTAMINE TARTRATE

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS; ORAL
ERYC

PARKE DAVIS	250MG	N62546 001 JUL 25, 1985
	250MG	N62618 001 SEP 25, 1985
WARNER CHILCOTT	250MG	N62338 001

ERYC 125

PARKE DAVIS	125MG	N62648 001 OCT 24, 1985

ERYC SPRINKLES

FAULDING	125MG	N50593 001 JUL 22, 1985

OINTMENT; OPHTHALMIC
ERYTHROMYCIN

PHARMADERM	5MG/GM	N62446 001 SEP 26, 1983

ERYTHROMYCIN

OINTMENT; OPHTHALMIC
ERYTHROMYCIN

PHARMAFAIR	5MG/GM	N62481 001 APR 05, 1984

POWDER; FOR RX COMPOUNDING
ERYTHROMYCIN

PADDOCK	100%	N50610 001 NOV 07, 1986

SOLUTION; TOPICAL
ERYTHROMYCIN

ALPHARMA	1.5%	N62328 001 APR 19, 1982
	2%	N62327 001 APR 19, 1982
	2%	N62342 001 FEB 25, 1982
	2%	N62957 001 JUL 21, 1988
LILLY	2%	N50532 001
PHARMAFAIR	1.5%	N62485 001 JUL 11, 1984
	2%	N62616 001 JUL 25, 1985

TABLET, DELAYED RELEASE; ORAL
E-BASE

BARR	333MG	N63028 001 MAY 15, 1990

ILOTYCIN

DISTA	250MG	N61910 001

R-P MYCIN

SOLVAY	250MG	N61659 001

ROBIMYCIN

ROBINS AH	250MG	N61633 001

ERYTHROMYCIN ESTOLATE

CAPSULE; ORAL
ERYTHROMYCIN ESTOLATE

BARR	EQ 125MG BASE	N62162 001
DANBURY PHARMA	EQ 250MG BASE	N62087 001
IVAX PHARMS	EQ 250MG BASE	N62237 001

ILOSONE

LILLY	EQ 125MG BASE	N61897 001

FDA data supplied by DrugPatentWatch.com

ERYTHROMYCIN ESTOLATE

CAPSULE; ORAL			
ILOSONE			
LILLY	EQ 250MG BASE		N61897 002
FOR SUSPENSION; ORAL			
ILOSONE			
DISTA	EQ 125MG BASE/5ML		N61893 001
SUSPENSION; ORAL			
ERYTHROMYCIN ESTOLATE			
BARR	EQ 125MG BASE/5ML		N62169 001
			OCT 17, 1990
	EQ 250MG BASE/5ML		N62169 002
			OCT 17, 1990
LIFE LABS	EQ 250MG BASE/5ML		N62362 001
			DEC 17, 1982
ILOSONE			
LILLY	EQ 125MG BASE/5ML		N61894 001
	EQ 250MG BASE/5ML		N61894 002
SUSPENSION/DROPS; ORAL			
ILOSONE			
LILLY	EQ 100MG BASE/ML		N61894 003
TABLET; ORAL			
ILOSONE			
LILLY	EQ 500MG BASE		N61896 001
TABLET, CHEWABLE; ORAL			
ILOSONE			
DISTA	EQ 125MG BASE		N61895 001
	EQ 250MG BASE		N61895 002

ERYTHROMYCIN ESTOLATE; SULFISOXAZOLE ACETYL

SUSPENSION; ORAL			
ILOSONE SULFA			
LILLY	EQ 125MG BASE/5ML;		
	EQ 600MG BASE/5ML		N50599 001
			SEP 29, 1989

ERYTHROMYCIN ETHYLSUCCINATE

GRANULE; ORAL			
PEDIAMYCIN			
ROSS LABS	EQ 200MG BASE/5ML		N62305 001

ERYTHROMYCIN ETHYLSUCCINATE

SUSPENSION; ORAL			
E-MYCIN E			
PHARMACIA AND UPJOHN	EQ 200MG BASE/5ML		N62198 001
	EQ 400MG BASE/5ML		N62198 002
ERYTHROMYCIN ETHYLSUCCINATE			
DISTA	EQ 200MG BASE/5ML		N62177 001
	EQ 400MG BASE/5ML		N62177 002
NASKA	EQ 400MG BASE/5ML		N62674 001
			MAR 10, 1987
PARKE DAVIS	EQ 200MG BASE/5ML		N62231 001
	EQ 400MG BASE/5ML		N62231 002
PHARMAFAIR	EQ 200MG BASE/5ML		N62559 001
			MAR 15, 1985
	EQ 400MG BASE/5ML		N62558 001
			MAR 15, 1985
WYAMYCIN E			
WYETH AYERST	EQ 200MG BASE/5ML		N62123 002
	EQ 400MG BASE/5ML		N62123 001
SUSPENSION/DROPS; ORAL			
PEDIAMYCIN			
ROSS LABS	EQ 100MG BASE/2.5ML		N62305 002
TABLET; ORAL			
E.E.S. 400			
ABBOTT	EQ 400MG BASE		N61905 001
ERYTHROMYCIN ETHYLSUCCINATE			
BARR	EQ 400MG BASE		N62256 001
TABLET, CHEWABLE; ORAL			
PEDIAMYCIN			
ROSS LABS	EQ 200MG BASE		N62306 001

ERYTHROMYCIN GLUCEPTATE

INJECTABLE; INJECTION			
ILOTYCIN GLUCEPTATE			
DISTA	EQ 250MG BASE/VIAL		N50370 001
	EQ 500MG BASE/VIAL		N50370 002
	EQ 1GM BASE/VIAL		N50370 003

FDA data supplied by DrugPatentWatch.com

ERYTHROMYCIN LACTOBIONATE

INJECTABLE; INJECTION

ERYTHROCIN		
ABBOTT	EQ 500MG BASE/VIAL	N62586 001
		JAN 04, 1988
	EQ 1GM BASE/VIAL	N62586 002
		JAN 04, 1988
ERYTHROMYCIN LACTOBIONATE		
AM PHARM PARTNERS	EQ 500MG BASE/VIAL	N62604 001
		NOV 24, 1986
	EQ 1GM BASE/VIAL	N62604 002
		NOV 24, 1986
QUAD PHARMS	EQ 500MG BASE/VIAL	N62660 001
		NOV 24, 1986
	EQ 1GM BASE/VIAL	N62660 003
		NOV 24, 1986

ERYTHROMYCIN STEARATE

TABLET; ORAL

BRISTAMYCIN		
BRISTOL	EQ 250MG BASE	N61304 001
	EQ 250MG BASE	N61887 001
ERYPAR		
PARKE DAVIS	EQ 250MG BASE	N62032 001
	EQ 500MG BASE	N62032 002
WARNER CHILCOTT	EQ 250MG BASE	N62322 001
ERYTHROCIN STEARATE		
ABBOTT	EQ 125MG BASE	N60359 002
ERYTHROMYCIN STEARATE		
BARR	EQ 500MG BASE	N63179 001
		MAY 15, 1990
IVAX PHARMS	EQ 250MG BASE	N61461 001
	EQ 500MG BASE	N61461 002
LEDERLE	EQ 250MG BASE	N62089 001
	EQ 500MG BASE	N62089 002
PUREPAC PHARM	EQ 250MG BASE	N61743 001
ETHRIL 250		
BRISTOL MYERS SQUIBB	EQ 250MG BASE	N61605 001
ETHRIL 500		
BRISTOL MYERS SQUIBB	EQ 500MG BASE	N61605 002
PFIZER-E		
PFIZER	EQ 250MG BASE	N61791 001
	EQ 500MG BASE	N61791 002
WYAMYCIN S		
WYETH AYERST	EQ 250MG BASE	N61675 001
	EQ 500MG BASE	N61675 002

ESMOLOL HYDROCHLORIDE

INJECTABLE; INJECTION

BREVIBLOC		
BAXTER HLTHCARE CORP	100MG/ML	N19386 003
		DEC 31, 1986

ESTRADIOL

FILM, EXTENDED RELEASE; TRANSDERMAL

ESTRADIOL		
JOHNSON RW	0.05MG/24HR	N21048 001
		SEP 20, 1999
	0.075MG/24HR	N21048 002
		SEP 20, 1999
	0.1MG/24HR	N21048 003
		SEP 20, 1999
NOVARTIS	0.0375MG/24HR	N20538 001
		JUL 31, 1996
	0.05MG/24HR	N20538 003
		JUL 31, 1996
	0.075MG/24HR	N20538 002
		JUL 31, 1996
	0.1MG/24HR	N20538 004
		JUL 31, 1996

ESTRADIOL CYPIONATE

INJECTABLE; INJECTION

DEPO-ESTRADIOL		
PHARMACIA AND UPJOHN	1MG/ML	N85470 001
	3MG/ML	N85470 002
ESTRADIOL CYPIONATE		
QUAD PHARMS	5MG/ML	N89310 001
		FEB 09, 1987

ESTRADIOL VALERATE

INJECTABLE; INJECTION

ESTRADIOL VALERATE		
STERIS	10MG/ML	N83546 001

FDA data supplied by DrugPatentWatch.com

ESTRADIOL VALERATE; TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION
TESTOSTERONE ENANTHATE AND ESTRADIOL VALERATE

STERIS	8MG/ML;180MG/ML	N85860 001

ESTROGENS, CONJUGATED; MEPROBAMATE

TABLET; ORAL

MILPREM-200		
WALLACE PHARMS	0.45MG;200MG	N11045 002
MILPREM-400		
WALLACE PHARMS	0.45MG;400MG	N11045 001

ESTROGENS, ESTERIFIED

TABLET; ORAL

AMNESTROGEN		
BRISTOL MYERS SQUIBB	0.3MG	N83266 001
	0.625MG	N83266 002
	1.25MG	N83266 003
	2.5MG	N83266 004
ESTERIFIED ESTROGENS		
GENEVA PHARMS	1.25MG	N85302 001
PVT FORM	0.625MG	N83414 001
	1.25MG	N83765 001
	2.5MG	N85907 001
ESTRATAB		
SOLVAY	0.3MG	N86715 001
	0.625MG	N83209 001
	1.25MG	N83856 001
	2.5MG	N83857 001
EVEX		
SYNTEX (USA) INC LLC	0.625MG	N84215 001
	1.25MG	N83376 002
FEMOGEN		
PVT FORM	0.625MG	N85076 001
	1.25MG	N85008 001
	2.5MG	N85007 001

ESTROGENS, ESTERIFIED; *MULTIPLE*
SEE CHLORDIAZEPOXIDE; ESTROGENS, ESTERIFIED

ESTRONE

INJECTABLE; INJECTION

ESTROGENIC SUBSTANCE		
WYETH AYERST	2MG/ML	N83488 001
ESTRONE		
STERIS	2MG/ML	N83397 001
NATURAL ESTROGENIC SUBSTANCE-ESTRONE		
STERIS	2MG/ML	N85237 001
		NOV 23, 1982
THEELIN		
PARKEDALE	1MG/ML	N03977 001
	2MG/ML	N03977 002
	5MG/ML	N03977 003

ETHAMBUTOL HYDROCHLORIDE

TABLET; ORAL

MYAMBUTOL		
LEDERLE	200MG	N16320 002
	500MG	N16320 004

ETHCHLORVYNOL

CAPSULE; ORAL

ETHCHLORVYNOL		
BANNER PHARMACAPS	100MG	N84463 001
	200MG	N84463 002
	500MG	N84463 003
	750MG	N84463 004
PLACIDYL		
ABBOTT	100MG	N10021 004

ETHINAMATE

CAPSULE; ORAL

VALMID		
DISTA	500MG	N09750 001

ETHINYL ESTRADIOL

TABLET; ORAL

FEMINONE		
PHARMACIA AND UPJOHN	0.05MG	N16649 001
LYNORAL		
ORGANON	0.01MG	N05490 003

FDA data supplied by DrugPatentWatch.com

ETHINYL ESTRADIOL

TABLET; ORAL			
LYNORAL			
ORGANON	0.05MG	N05490	002

ETHINYL ESTRADIOL; *MULTIPLE*
SEE DESOGESTREL; ETHINYL ESTRADIOL

ETHINYL ESTRADIOL; FERROUS FUMARATE; NORETHINDRONE

TABLET; ORAL-28			
NORQUEST FE			
GD SEARLE LLC	0.035MG;75MG;1MG	N18926	001
		JUL 18, 1986	

ETHINYL ESTRADIOL; FERROUS FUMARATE; NORETHINDRONE ACETATE

TABLET; ORAL-28			
NORLESTRIN FE 1/50			
PARKE DAVIS	0.05MG;75MG;1MG	N16766	001
NORLESTRIN FE 2.5/50			
PARKE DAVIS	0.05MG;75MG;2.5MG	N16854	001

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21			
N.E.E. 1/35 21			
LPI	0.035MG;1MG	N71541	001
		DEC 14, 1987	
ORTHO-NOVUM 7/14-21			
JOHNSON RW	0.035MG,0.035MG;0.5MG,1MG	N19004	001
		APR 04, 1984	
OVCON-50			
WARNER CHILCOTT	0.05MG;1MG	N18128	001
TABLET; ORAL-28			
N.E.E. 1/35 28			
LPI	0.035MG;1MG	N71542	001
		DEC 14, 1987	

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL-21			
NORLESTRIN 21 1/50			
PARKE DAVIS	0.05MG;1MG	N16749	001
NORLESTRIN 21 2.5/50			
PARKE DAVIS	0.05MG;2.5MG	N16852	001
TABLET; ORAL-28			
NORLESTRIN 28 1/50			
PARKE DAVIS	0.05MG;1MG	N16723	001

ETHOPROPAZINE HYDROCHLORIDE

TABLET; ORAL			
PARSIDOL			
PARKE DAVIS	10MG	N09078	003
	50MG	N09078	006
	100MG	N09078	008

ETHOXZOLAMIDE

TABLET; ORAL			
CARDRASE			
PHARMACIA AND UPJOHN	62.5MG	N11047	002
	125MG	N11047	001
ETHAMIDE			
ALLERGAN	125MG	N16144	001

ETHYLESTRENOL

ELIXIR; ORAL			
MAXIBOLIN			
ORGANON	2MG/5ML	N14006	002
TABLET; ORAL			
MAXIBOLIN			
ORGANON	2MG	N14005	002

ETHYNODIOL DIACETATE; MESTRANOL

TABLET; ORAL-20			
OVULEN			
GD SEARLE LLC	1MG;0.1MG	N16029	002

FDA data supplied by DrugPatentWatch.com

ETHYNODIOL DIACETATE; MESTRANOL

TABLET; ORAL-21		
OVULEN-21		
GD SEARLE LLC	1MG;0.1MG	N16029 003
TABLET; ORAL-28		
OVULEN-28		
GD SEARLE LLC	1MG;0.1MG	N16705 001

ETIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION		
DURANEST		
ASTRAZENECA	0.5%	N17751 003

ETIDOCAINE HYDROCHLORIDE; *MULTIPLE*

SEE EPINEPHRINE; ETIDOCAINE HYDROCHLORIDE
SEE EPINEPHRINE BITARTRATE; ETIDOCAINE HYDROCHLORIDE

ETOPOSIDE

CAPSULE; ORAL		
VEPESID		
BRISTOL	100MG	N19557 002 DEC 30, 1986
INJECTABLE; INJECTION		
ETOPOSIDE		
GENSIA SICOR PHARMS	20MG/ML	N74510 001 JUN 29, 1995
PIERRE FABRE	20MG/ML	N74813 001 JUL 09, 1997
STERIS	20MG/ML	N74228 001 OCT 15, 1996

ETOPOSIDE PHOSPHATE

INJECTABLE; INJECTION		
ETOPOPHOS PRESERVATIVE FREE		
BRISTOL MYERS SQUIBB	EQ 500MG BASE/VIAL	N20906 001 FEB 27, 1998
	EQ 1GM BASE/VIAL	N20906 002 FEB 27, 1998

ETRETINATE

CAPSULE; ORAL		
TEGISON		
ROCHE	10MG	N19369 001 SEP 30, 1986
	25MG	N19369 002 SEP 30, 1986

EVANS BLUE

INJECTABLE; INJECTION		
EVANS BLUE		
* PARKE DAVIS	0.5%	N08041 001

FAMOTIDINE

INJECTABLE; INJECTION		
FAMOTIDINE		
APOTHECON	10MG/ML	N75707 001 APR 16, 2001
FAMOTIDINE PRESERVATIVE FREE		
APOTHECON	10MG/ML	N75708 001 APR 16, 2001
TABLET, ORALLY DISINTEGRATING; ORAL		
PEPCID RPD		
MERCK	20MG	N20752 001 MAY 28, 1998
	40MG	N20752 002 MAY 28, 1998

FENOFIBRATE

CAPSULE; ORAL		
LIPIDIL		
ABBOTT	100MG	N19304 001 DEC 31, 1993

FENOPROFEN CALCIUM

CAPSULE; ORAL		
FENOPROFEN CALCIUM		
AM THERAP	EQ 200MG BASE	N72307 001 AUG 22, 1988

FDA data supplied by DrugPatentWatch.com

FENOPROFEN CALCIUM

CAPSULE; ORAL
FENOPROFEN CALCIUM

AM THERAP	EQ 300MG BASE	N72308 001 AUG 22, 1988
DANBURY PHARMA	EQ 200MG BASE	N72981 001 AUG 19, 1991
	EQ 300MG BASE	N72982 001 AUG 19, 1991
HALSEY	EQ 200MG BASE	N72355 001 AUG 17, 1988
	EQ 300MG BASE	N72356 001 AUG 17, 1988
QUANTUM PHARMICS	EQ 200MG BASE	N72214 001 AUG 17, 1988
	EQ 300MG BASE	N71738 001 AUG 17, 1988
WARNER CHILCOTT	EQ 200MG BASE	N72946 001 APR 30, 1991
	EQ 300MG BASE	N72472 001 APR 30, 1991
WATSON LABS	EQ 200MG BASE	N72294 001 AUG 17, 1988
	EQ 300MG BASE	N72293 001 AUG 17, 1988

TABLET; ORAL
FENOPROFEN CALCIUM

AM THERAP	EQ 600MG BASE	N72309 001 AUG 17, 1988
HALSEY	EQ 600MG BASE	N72357 001 AUG 17, 1988
QUANTUM PHARMICS	EQ 600MG BASE	N72194 001 AUG 17, 1988
USL PHARMA	EQ 600MG BASE	N72362 001 AUG 17, 1988
WATSON LABS	EQ 600MG BASE	N72165 001 AUG 17, 1988

FENTANYL CITRATE

INJECTABLE; INJECTION
FENTANYL CITRATE

ABBOTT	EQ 0.05MG BASE/ML	N70636 001 APR 30, 1990
	EQ 0.05MG BASE/ML	N70637 001 APR 30, 1990

FENTANYL CITRATE

INJECTABLE; INJECTION
FENTANYL CITRATE

STERIS	EQ 0.05MG BASE/ML	N73488 001 JUN 30, 1992

FENTANYL CITRATE PRESERVATIVE FREE

MARSAM PHARMS LLC	EQ 0.05MG BASE/ML	N74917 001 FEB 03, 1998

FENTANYL CITRATE; *MULTIPLE*
SEE DROPERIDOL; FENTANYL CITRATE

FERROUS CITRATE, FE-59

INJECTABLE; INJECTION
FERROUS CITRATE FE 59

MALLINCKRODT	25 uCi/ML	N16729 001

FERROUS FUMARATE; *MULTIPLE*
SEE ETHINYL ESTRADIOL; FERROUS FUMARATE; NORETHINDRONE
SEE ETHINYL ESTRADIOL; FERROUS FUMARATE; NORETHINDRONE ACETATE

FERROUS SULFATE; FOLIC ACID

CAPSULE; ORAL
FOLVRON

LEDERLE	182MG;0.33MG	N06012 003

FIBRINOGEN, I-125

INJECTABLE; INJECTION
IBRIN

AMERSHAM HLTH	154 uCi/VIAL	N17879 001

RADIONUCLIDE-LABELED (125 I) FIBRINOGEN (HUMAN) SENSOR

ABBOTT	140 uCi/ML	N17787 001

FLECAINIDE ACETATE

TABLET; ORAL
TAMBOCOR

3M	200MG	N18830 002 OCT 31, 1985

FDA data supplied by DrugPatentWatch.com

FLOXURIDINE

INJECTABLE; INJECTION
FLOXURIDINE
QUAD PHARMS 500MG/VIAL N71055 001 AUG 24, 1987

FLUCONAZOLE

INJECTABLE; INJECTION
DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER
PFIZER 2MG/ML N19950 005 JUL 08, 1994
DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
PFIZER 2MG/ML N19950 004 JUL 08, 1994

FLUMETHASONE PIVALATE

CREAM; TOPICAL
LOCORTEN
NOVARTIS 0.03% N16379 001

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL
FLUOCET
ALPHARMA 0.025% N88360 001 JAN 16, 1984
FLUOCINOLONE ACETONIDE
ALPHARMA 0.01% N88361 001 JAN 16, 1984
CLAY PARK 0.01% N86810 001 MAR 04, 1982
0.025% N86811 001 MAR 04, 1982
PHARMADERM 0.01% N88047 001 DEC 16, 1982
0.025% N88045 001 DEC 16, 1982
PHARMAFAIR 0.01% N88499 001 AUG 02, 1984
0.025% N88506 001 AUG 02, 1984
USL PHARMA 0.01% N88757 001 FEB 11, 1985

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL
FLUOCINOLONE ACETONIDE
USL PHARMA 0.025% N88756 001 MAR 28, 1985
FLUONID
ALLERGAN HERBERT 0.025% N87156 002 SEP 06, 1984
FLUOTREX
SAVAGE LABS 0.01% N88174 001 MAY 06, 1983
0.025% N88173 001 MAR 09, 1983

GEL; TOPICAL
FLUONID
ALLERGAN HERBERT 0.025% N87300 001 MAY 27, 1982

OINTMENT; TOPICAL
FLUOCINOLONE ACETONIDE
PHARMADERM 0.025% N88046 001 DEC 16, 1982
PHARMAFAIR 0.025% N88507 001 FEB 27, 1984
USL PHARMA 0.025% N88742 001 FEB 08, 1985
FLUONID
ALLERGAN HERBERT 0.025% N87157 001 SEP 06, 1984
FLUOTREX
SAVAGE LABS 0.025% N88172 001 MAR 09, 1983

SOLUTION; TOPICAL
FLUOCINOLONE ACETONIDE
BAUSCH AND LOMB 0.01% N40059 001 DEC 20, 1993
MORTON GROVE 0.01% N88312 001 JAN 27, 1984
PHARMADERM 0.01% N88048 001 DEC 16, 1982
PHARMAFAIR 0.01% N88449 001 FEB 08, 1984
FLUOTREX
SAVAGE LABS 0.01% N88171 001 MAR 09, 1983

FDA data supplied by DrugPatentWatch.com

FLUOCINOLONE ACETONIDE; NEOMYCIN SULFATE

CREAM; TOPICAL			
NEO-SYNALAR			
MEDICIS	0.025%;EQ 3.5MG BASE/GM	N60700 001	

FLUOCINONIDE

CREAM; TOPICAL			
FLUOCINONIDE			
CLAY PARK	0.05%	N71790 001	
		JUL 13, 1988	

FLUOROMETHOLONE

CREAM; TOPICAL			
OXYLONE			
PHARMACIA AND UPJOHN	0.025%	N11748 001	

FLUOROURACIL

INJECTABLE; INJECTION			
ADRUCIL			
PHARMACIA AND UPJOHN	50MG/ML	N17959 001	
	50MG/ML	N81222 001	
		JUN 28, 1991	
FLUOROURACIL			
ABIC	50MG/ML	N88929 001	
		MAR 04, 1986	
AM PHARM PARTNERS	50MG/ML	N89152 001	
		MAR 21, 1986	
	50MG/ML	N89428 001	
		JAN 12, 1987	
	50MG/ML	N89519 001	
		MAR 12, 1987	
MARCHAR	50MG/ML	N87791 001	
		JAN 18, 1983	
QUAD PHARMS	50MG/ML	N89368 001	
		FEB 03, 1987	
	50MG/ML	N89455 001	
		FEB 03, 1987	
SMITH AND NEPHEW	50MG/ML	N88766 001	
		DEC 28, 1984	
	50MG/ML	N88767 001	
		DEC 28, 1984	

FLUOROURACIL

INJECTABLE; INJECTION			
FLUOROURACIL			
SMITH AND NEPHEW	50MG/ML	N89434 001	
		MAR 26, 1987	

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL			
PROZAC			
LILLY	EQ 60MG BASE	N18936 004	
		JUN 15, 1999	
TABLET; ORAL			
PROZAC			
LILLY	EQ 20MG BASE	N20974 002	
		MAR 09, 1999	

FLUOXYMESTERONE

TABLET; ORAL			
ANDROID-F			
ICN	10MG	N87196 001	
FLUOXYMESTERONE			
ICN	10MG	N88221 001	
		MAY 05, 1983	
WATSON LAB	2MG	N88260 001	
		DEC 06, 1983	
	5MG	N88265 001	
		DEC 06, 1983	
	10MG	N88309 001	
		DEC 06, 1983	
ORA-TESTRYL			
BRISTOL MYERS SQUIBB	2MG	N11359 001	
	5MG	N11359 002	

FLUPHENAZINE DECANOATE

INJECTABLE; INJECTION			
FLUPHENAZINE			
QUAD PHARMS	25MG/ML	N70762 001	
		FEB 20, 1986	

FDA data supplied by DrugPatentWatch.com

FLUPHENAZINE HYDROCHLORIDE

INJECTABLE; INJECTION		
FLUPHENAZINE HCL		
QUAD PHARMS	2.5MG/ML	N89800 001
		JUN 08, 1988
TABLET; ORAL		
FLUPHENAZINE HCL		
WATSON LAB	1MG	N88555 001
		DEC 18, 1987
	2.5MG	N88544 001
		DEC 18, 1987
	5MG	N88527 001
		DEC 18, 1987
	10MG	N88550 001
		DEC 18, 1987
PERMITIL		
SCHERING	0.25MG	N12034 001
	10MG	N12034 006
TABLET, EXTENDED RELEASE; ORAL		
PERMITIL		
SCHERING	1MG	N12419 004

FLUPREDNISOLONE

TABLET; ORAL		
ALPHADROL		
PHARMACIA AND UPJOHN	1.5MG	N12259 002

FLURANDRENOLIDE

LOTION; TOPICAL		
FLURANDRENOLIDE		
ALPHARMA	0.05%	N87203 001
		APR 29, 1982

FLURANDRENOLIDE; NEOMYCIN SULFATE

CREAM; TOPICAL		
CORDRAN-N		
LILLY	0.05%;EQ 3.5MG BASE/GM	N50346 001
OINTMENT; TOPICAL		
CORDRAN-N		
LILLY	0.05%;EQ 3.5MG BASE/GM	N50345 001

FLURAZEPAM HYDROCHLORIDE

CAPSULE; ORAL		
FLURAZEPAM HCL		
HALSEY	15MG	N70454 001
		AUG 04, 1986
	15MG	N71808 001
		JAN 07, 1988
	30MG	N70455 001
		AUG 04, 1986
	30MG	N71809 001
		JAN 07, 1988
PUREPAC PHARM	15MG	N71927 001
		SEP 09, 1987
	30MG	N71551 001
		SEP 09, 1987
SUPERPHARM	15MG	N71659 001
		AUG 04, 1988
	30MG	N71660 001
		AUG 04, 1988
USL PHARMA	15MG	N70562 001
		JUL 09, 1987
	30MG	N70563 001
		JUL 09, 1987
WARNER CHILCOTT	15MG	N71767 001
		DEC 04, 1987
	30MG	N71768 001
		DEC 04, 1987
WATSON LABS	15MG	N72368 001
		MAR 30, 1989

FLUVOXAMINE MALEATE

TABLET; ORAL		
LUVOX		
SOLVAY	150MG	N20243 004
		DEC 05, 1994

FOLIC ACID

TABLET; ORAL		
FOLIC ACID		
ANABOLIC	1MG	N84915 001
BARR	1MG	N89177 001
		JAN 08, 1986
EON	1MG	N84472 001
EVERYLIFE	1MG	N80755 001

FDA data supplied by DrugPatentWatch.com

FOLIC ACID

TABLET; ORAL
FOLIC ACID

HALSEY	1MG	N83598 001
IMPAX LABS	1MG	N80686 001
LANNETT	1MG	N80816 001
LILLY	1MG	N06135 003
PHARMERAL	1MG	N84158 001
PIONEER PHARMS	1MG	N88949 001 SEP 13, 1985
PUREPAC PHARM	1MG	N80784 001
UDL	1MG	N88199 001 MAR 29, 1983
USL PHARMA	1MG	N87828 001 MAY 13, 1982
VANGARD	1MG	N88730 001 MAR 23, 1984
VINTAGE PHARMS	1MG	N86296 001
WATSON LAB	1MG	N83141 001
WATSON LABS	1MG	N85141 002
WHITEWORTH TOWN PLSN	1MG	N80691 002

FOLVITE

LEDERLE	1MG	N05897 004

FOLIC ACID; *MULTIPLE*

SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE; VITAMIN A; VITAMIN E

SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN E

SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PHYTONADIONE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A PALMITATE; VITAMIN E

SEE FERROUS SULFATE; FOLIC ACID

FUROSEMIDE

INJECTABLE; INJECTION
FUROSEMIDE

AM PHARM PARTNERS	10MG/ML	N18507 001 JUL 30, 1982
	10MG/ML	N19036 001 AUG 13, 1984
ASTRAZENECA	10MG/ML	N70014 001 SEP 09, 1985
	10MG/ML	N70095 001 SEP 09, 1985
	10MG/ML	N70096 001 SEP 09, 1985
ORGANON	10MG/ML	N70017 001 DEC 15, 1986
SMITH AND NEPHEW	10MG/ML	N70023 001 FEB 05, 1986
	10MG/ML	N70078 001 FEB 05, 1986
STERIS	10MG/ML	N70019 001 SEP 22, 1986
	10MG/ML	N70604 001 JAN 02, 1987
WARNER CHILCOTT	10MG/ML	N18420 001 FEB 26, 1982
WYETH AYERST	10MG/ML	N18670 001 JUL 20, 1982

TABLET; ORAL
FUROSEMIDE

EON	40MG	N18750 002 JUL 30, 1984
HALSEY	20MG	N70043 001 SEP 26, 1985
	40MG	N18790 001 NOV 29, 1983
	80MG	N70100 001 JAN 26, 1988
SUPERPHARM	20MG	N18370 002 JUN 26, 1984
	40MG	N18370 001 FEB 10, 1983
WARNER CHILCOTT	20MG	N18419 001 JAN 31, 1983
	40MG	N18419 002 JAN 31, 1983
	80MG	N18419 003 NOV 13, 1984

FDA data supplied by DrugPatentWatch.com

FUROSEMIDE

TABLET; ORAL
FUROSEMIDE
WATSON LABS 20MG N18369 001 MAY 14, 1982
40MG N18369 002 MAY 14, 1982

GALLAMINE TRIETHIODIDE

INJECTABLE; INJECTION
FLAXEDIL
DAVIS AND GECK 20MG/ML N07842 001
100MG/ML N07842 002

GALLIUM CITRATE, GA-67

INJECTABLE; INJECTION
GALLIUM CITRATE GA 67
AMERSHAM HLTH 1mCi/ML N17700 001

GALLIUM NITRATE

INJECTABLE; INJECTION
GANITE
SOLOPAK 25MG/ML N19961 002 JAN 17, 1991

GEMFIBROZIL

CAPSULE; ORAL
GEMFIBROZIL
MYLAN 300MG N73466 001 JAN 25, 1993
PUREPAC PHARM 300MG N72929 001 JAN 29, 1993
LOPID
PARKE DAVIS PHARMS 200MG N18422 001
300MG N18422 002

TABLET; ORAL
GEMFIBROZIL
PUREPAC PHARM 600MG N74360 001 AUG 31, 1994

GEMFIBROZIL

TABLET; ORAL
GEMFIBROZIL
WATSON LABS 600MG N74156 001 OCT 24, 1994

GENTAMICIN SULFATE

CREAM; TOPICAL
GENTAFAIR
PHARMAFAIR EQ 0.1% BASE N62458 001 SEP 01, 1983
GENTAMICIN SULFATE
ALPHARMA EQ 0.1% BASE N62471 001 SEP 27, 1983
BAUSCH AND LOMB EQ 0.1% BASE N64056 001 APR 29, 1994
PHARMADERM EQ 1MG BASE/GM N62530 001 JUL 05, 1984

INJECTABLE; INJECTION
APOGEN
KING PHARMS EQ 10MG BASE/ML N62289 001
EQ 40MG BASE/ML N62289 002
BRISTAGEN
BRISTOL EQ 40MG BASE/ML N62288 001
GARAMYCIN
SCHERING EQ 10MG BASE/ML N61739 001
GENTAFAIR
PHARMAFAIR EQ 40MG BASE/ML N62493 001 AUG 28, 1985
GENTAMICIN
INTL MEDICATION EQ 1MG BASE/ML N62325 003 JUN 23, 1982
EQ 100MG BASE/100ML N62325 004 JUN 23, 1982
EQ 40MG BASE/ML N62325 001
GENTAMICIN SULFATE
ABBOTT EQ 60MG BASE/100ML N62413 006 AUG 11, 1983
EQ 70MG BASE/100ML N62413 007 AUG 11, 1983
EQ 80MG BASE/100ML N62413 008 AUG 11, 1983
EQ 90MG BASE/100ML N62413 009 AUG 11, 1983

FDA data supplied by DrugPatentWatch.com

GENTAMICIN SULFATE

INJECTABLE; INJECTION

GENTAMICIN SULFATE		
ABBOTT	EQ 100MG BASE/100ML	N62413 010
		AUG 11, 1983
	EQ 1.2MG BASE/ML	N62413 001
		AUG 11, 1983
	EQ 1.4MG BASE/ML	N62413 002
		AUG 11, 1983
	EQ 1.6MG BASE/ML	N62413 003
		AUG 11, 1983
	EQ 1.8MG BASE/ML	N62413 004
		AUG 11, 1983
	EQ 2MG BASE/ML	N62413 005
		AUG 11, 1983
GENSIA SICOR PHARMS	EQ 10MG BASE/ML	N63149 001
		NOV 21, 1991
	EQ 40MG BASE/ML	N63106 002
		NOV 21, 1991
SOLOPAK	EQ 10MG BASE/ML	N62507 001
		JUN 06, 1985
	EQ 40MG BASE/ML	N62507 002
		JUN 06, 1985
STERIS	EQ 10MG BASE/ML	N62318 002
	EQ 40MG BASE/ML	N62318 001
WYETH AYERST	EQ 10MG BASE/ML	N62264 001
	EQ 40MG BASE/ML	N62264 002
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER		
ABBOTT	EQ 60MG BASE/100ML	N62588 006
		JAN 06, 1986
	EQ 70MG BASE/100ML	N62588 007
		JAN 06, 1986
	EQ 80MG BASE/100ML	N62588 008
		JAN 06, 1986
	EQ 90MG BASE/100ML	N62588 009
		JAN 06, 1986
	EQ 100MG BASE/100ML	N62588 010
		JAN 06, 1986
	EQ 1.2MG BASE/ML	N62588 001
		JAN 06, 1986
	EQ 1.4MG BASE/ML	N62588 002
		JAN 06, 1986
	EQ 1.6MG BASE/ML	N62588 003
		JAN 06, 1986
	EQ 1.8MG BASE/ML	N62588 004
		JAN 06, 1986

GENTAMICIN SULFATE

INJECTABLE; INJECTION

GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER		
ABBOTT	EQ 2MG BASE/ML	N62588 005
		JAN 06, 1986
U-GENCIN		
PHARMACIA AND UPJOHN	EQ 10MG BASE/ML	N62248 001
	EQ 40MG BASE/ML	N62248 002

INJECTABLE; INTRATHECAL

GARAMYCIN		
SCHERING	EQ 2MG BASE/ML	N50505 001

OINTMENT; OPHTHALMIC

GENTACIDIN		
NOVARTIS	EQ 0.3% BASE	N62501 001
		JUL 26, 1984
GENTAFAIR		
PHARMAFAIR	EQ 3MG BASE/GM	N62443 001
		MAY 26, 1983

OINTMENT; TOPICAL

GARAMYCIN		
SCHERING	EQ 0.1% BASE	N60463 001
GENTAFAIR		
PHARMAFAIR	EQ 0.1% BASE	N62444 001
		MAY 26, 1983
GENTAMICIN SULFATE		
ALPHARMA	EQ 0.1% BASE	N62496 001
		MAR 14, 1984
BAUSCH AND LOMB	EQ 0.1% BASE	N64054 001
		APR 29, 1994
PHARMADERM	EQ 0.1% BASE	N62534 001
		OCT 10, 1984

SOLUTION/DROPS; OPHTHALMIC

GENTAFAIR		
PHARMAFAIR	EQ 0.3% BASE	N62440 001
		MAY 03, 1983
GENTAMICIN SULFATE		
ALCON UNIVERSAL	EQ 0.3% BASE	N62523 001
		NOV 25, 1985
PACO	EQ 3MG BASE/ML	N62932 001
		NOV 07, 1988

FDA data supplied by DrugPatentWatch.com

GENTIAN VIOLET

TAMPON; VAGINAL
GENAPAX
KEY PHARMS 5MG N85017 001

GLIPIZIDE

TABLET; ORAL
GLUCOTROL
PFIZER 2.5MG N17783 003
MAY 11, 1993

GLUCAGON HYDROCHLORIDE

INJECTABLE; INJECTION
GLUCAGON
LILLY EQ 10MG BASE/VIAL N12122 002
QUAD PHARMS EQ 1MG BASE/VIAL N71022 001
MAR 04, 1987
EQ 10MG BASE/VIAL N71023 001
MAR 04, 1987

GLUTETHIMIDE

CAPSULE; ORAL
DORIDEN
AVENTIS 500MG N09519 008

TABLET; ORAL
DORIDEN
AVENTIS 250MG N09519 002
500MG N09519 005
GLUTETHIMIDE
CELLTECH PHARMS 500MG N85171 001
DANBURY PHARMA 500MG N84362 001
GENEVA PHARMS 500MG N83234 002
HALSEY 250MG N89458 001
OCT 10, 1986
500MG N89459 001
OCT 10, 1986
LANNETT 250MG N83475 001
500MG N85571 001
VITARINE 500MG N87297 001
WATSON LABS 500MG N85763 001

GLYBURIDE

TABLET; ORAL
GLYNASE
* PHARMACIA AND UPJOHN 4.5MG N20051 003
SEP 24, 1993

GLYCINE

SOLUTION; IRRIGATION
GLYCINE 1.5% IN PLASTIC CONTAINER
BAXTER HLTHCARE 1.5GM/100ML N18522 001
FEB 19, 1982

GLYCOPYRROLATE

INJECTABLE; INJECTION
GLYCOPYRROLATE
ABBOTT 0.2MG/ML N89393 001
JUN 15, 1988
AM PHARM PARTNERS 0.2MG/ML N88475 001
JUN 12, 1984
GENSIA SICOR PHARMS 0.2MG/ML N81169 001
SEP 10, 1991
QUAD PHARMS 0.2MG/ML N89397 001
DEC 09, 1986
STERIS 0.2MG/ML N86947 001
JUN 24, 1983
ROBINUL
ROBINS AH 0.2MG/ML N14764 001

TABLET; ORAL
GLYCOPYRROLATE
DANBURY PHARMA 1MG N86902 001
2MG N86900 001
WATSON LAB 1MG N85562 001
2MG N85563 001
WATSON LABS 2MG N86178 001

GONADORELIN HYDROCHLORIDE

INJECTABLE; INJECTION
FACTREL
WYETH AYERST EQ 0.2MG BASE/VIAL N18123 002
SEP 30, 1982

FDA data supplied by DrugPatentWatch.com

GONADOTROPIN, CHORIONIC

INJECTABLE; INJECTION			
CHORIONIC GONADOTROPIN			
AM PHARM PARTNERS	5,000 UNITS/VIAL	N17067 001	
	15,000 UNITS/VIAL	N17067 004	
	20,000 UNITS/VIAL	N17067 003	
BEL MAR	5,000 UNITS/VIAL	N17054 001	
	10,000 UNITS/VIAL	N17054 002	
QUAD PHARMS	5,000 UNITS/VIAL	N89312 001	
		DEC 04, 1986	
	5,000 UNITS/VIAL	N89313 001	
		DEC 04, 1986	
	10,000 UNITS/VIAL	N89314 001	
		DEC 04, 1986	
	10,000 UNITS/VIAL	N89315 001	
		DEC 04, 1986	
	20,000 UNITS/VIAL	N89316 001	
		DEC 04, 1986	
STERIS	2,000 UNITS/VIAL	N17016 009	
		DEC 27, 1984	
	15,000 UNITS/VIAL	N17016 010	
		FEB 15, 1985	
	20,000 UNITS/VIAL	N17016 004	
FOLLUTEIN			
BRISTOL MYERS SQUIBB	10,000 UNITS/VIAL	N17056 001	

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OPHTHALMIC		
NEO-POLYCIN		
DOW PHARM	0.025MG/ML;EQ 1.75MG BASE/ML; 10,000 UNITS/ML	N60427 001
NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN		
IPHARM	0.025MG/ML;EQ 1.75MG BASE/ML; 10,000 UNITS/ML	N62818 001
		OCT 11, 1988
STERIS	0.025MG/ML;EQ 1.75MG BASE/ML; 10,000 UNITS/ML	N62788 001
		JUN 11, 1987
NEOMYCIN SULFATE AND POLYMYXIN B SULFATE GRAMICIDIN		
PHARMAFAIR	0.025MG/ML;EQ 1.75MG BASE/ML; 10,000 UNITS/ML	N62383 001
		AUG 31, 1982

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION		
KYTRIL		
ROCHE	EQ 3MG BASE/ML	N20239 001
		DEC 29, 1993
TABLET; ORAL		
KYTRIL		
ROCHE	EQ 2MG BASE	N20305 002
		JUN 15, 1998

GRISEOFULVIN, MICROCRYSTALLINE

CAPSULE; ORAL		
GRISACTIN		
WYETH AYERST	125MG	N50051 002
SUSPENSION; ORAL		
GRIFULVIN V		
JOHNSON AND JOHNSON	125MG/5ML	N50448 001
TABLET; ORAL		
GRIFULVIN V		
J AND J	125MG	N60618 001
	250MG	N60618 002
	500MG	N60618 003

GRISEOFULVIN, ULTRAMICROCRYSTALLINE

TABLET; ORAL		
GRISACTIN ULTRA		
WYETH AYERST	125MG	N62178 001
	250MG	N62178 002
ULTRAGRIS-165		
SIDMAK LABS NJ	165MG	N62645 001
		JUN 30, 1992
ULTRAGRIS-330		
SIDMAK LABS NJ	330MG	N62646 001
		JUN 30, 1992

GUANABENZ ACETATE

TABLET; ORAL		
WYTENSIN		
WYETH AYERST	EQ 16MG BASE	N18587 003
		SEP 07, 1982

FDA data supplied by DrugPatentWatch.com

GUANETHIDINE MONOSULFATE

TABLET; ORAL
GUANETHIDINE MONOSULFATE

WATSON LAB	EQ 10MG SULFATE	N86113 001 MAR 26, 1985
	EQ 25MG SULFATE	N86114 001 MAR 26, 1985

GUANETHIDINE MONOSULFATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL
ESIMIL

NOVARTIS	10MG;25MG	N13553 001

GUANFACINE HYDROCHLORIDE

TABLET; ORAL
TENEX

WYETH AYERST	EQ 3MG BASE	N19032 003 NOV 07, 1988

HALCINONIDE

CREAM; TOPICAL
HALOG

WESTWOOD SQUIBB	0.025%	N17818 001

OINTMENT; TOPICAL
HALOG

BRISTOL MYERS SQUIBB	0.025%	N18125 001

HALOFANTRINE HYDROCHLORIDE

TABLET; ORAL
HALFAN

GLAXOSMITHKLINE	250MG	N20250 001 JUL 24, 1992

HALOPERIDOL

TABLET; ORAL
HALDOL SOLUTAB

JOHNSON RW	1MG	N17079 001

HALOPERIDOL

TABLET; ORAL
HALOPERIDOL

DANBURY PHARMA	1MG	N70982 001 MAR 06, 1987
	10MG	N72113 001 AUG 27, 1991
	20MG	N72353 001 AUG 27, 1991
DURAMED	0.5MG	N71216 001 DEC 04, 1986
	1MG	N71217 001 DEC 04, 1986
	2MG	N71218 001 DEC 04, 1986
	5MG	N71219 001 DEC 04, 1986
	10MG	N71220 001 JUL 07, 1987
	20MG	N71221 001 JUL 07, 1987
HALSEY	0.5MG	N71156 001 JAN 02, 1987
	1MG	N71157 001 JAN 02, 1987
	2MG	N71172 001 JAN 02, 1987
	5MG	N71212 001 JAN 07, 1988
	10MG	N71173 001 JAN 07, 1988
	20MG	N71177 001 JAN 07, 1988
LEDERLE	0.5MG	N72727 001 SEP 19, 1989
	1MG	N72728 001 SEP 19, 1989
	2MG	N72729 001 SEP 19, 1989
	5MG	N72730 001 SEP 19, 1989
	10MG	N72731 001 SEP 19, 1989
	20MG	N72732 001 SEP 19, 1989
PAR PHARM	20MG	N71328 001 JUL 20, 1987

FDA data supplied by DrugPatentWatch.com

HALOPERIDOL

TABLET; ORAL
HALOPERIDOL

PUREPAC PHARM	0.5MG	N71071 001 NOV 03, 1986
	1MG	N71072 001 NOV 03, 1986
	2MG	N71073 001 NOV 03, 1986
	5MG	N71074 001 NOV 03, 1986
	10MG	N71075 001 AUG 04, 1987
	20MG	N71076 001 AUG 04, 1987
QUANTUM PHARMICS	0.5MG	N71255 001 FEB 17, 1987
	1MG	N71269 001 FEB 17, 1987
	2MG	N71256 001 FEB 17, 1987
	5MG	N71257 001 FEB 17, 1987
ROXANE	0.5MG	N71128 001 FEB 17, 1987
	1MG	N71129 001 FEB 17, 1987
	2MG	N71130 001 FEB 17, 1987
	5MG	N71131 001 FEB 17, 1987
	10MG	N71132 001 MAY 12, 1987
	20MG	N71133 001 MAY 12, 1987
ROYCE LABS	0.5MG	N71722 001 DEC 24, 1987
	1MG	N71723 001 DEC 24, 1987
	2MG	N71724 001 DEC 24, 1987
	5MG	N71725 001 DEC 24, 1987
	10MG	N72121 001 DEC 24, 1987
	20MG	N72122 001 DEC 24, 1987

HALOPERIDOL

TABLET; ORAL
HALOPERIDOL

SCS	0.5MG	N70720 001 JUN 10, 1986
	1MG	N70721 001 JUN 10, 1986
	2MG	N70722 001 JUN 10, 1986
	5MG	N70723 001 JUN 10, 1986
	10MG	N70724 001 JUN 10, 1986
	20MG	N70725 001 SEP 24, 1986
WATSON LAB	0.5MG	N71571 001 JUN 03, 1988
	1MG	N71572 001 JUN 03, 1988
	2MG	N71573 001 JUN 03, 1988
	5MG	N71374 001 JUN 03, 1988
	10MG	N71375 001 JUN 03, 1988
	20MG	N71376 001 JUN 03, 1988

HALOPERIDOL LACTATE

CONCENTRATE; ORAL
HALOPERIDOL

MORTON GROVE	EQ 2MG BASE/ML	N70710 001 MAR 07, 1986
SCS	EQ 2MG BASE/ML	N70726 001 JUN 10, 1986

HALOPERIDOL INTENSOL

ROXANE	EQ 2MG BASE/ML	N72045 001 APR 12, 1988

INJECTABLE; INJECTION
HALOPERIDOL

AM PHARM PARTNERS	EQ 5MG BASE/ML	N71187 001 JAN 20, 1987
MARSAM PHARMS LLC	EQ 5MG BASE/ML	N72516 001 FEB 25, 1993

FDA data supplied by DrugPatentWatch.com

HALOPERIDOL LACTATE

INJECTABLE; INJECTION		
HALOPERIDOL		
MARSAM PHARMS LLC	EQ 5MG BASE/ML	N72517 001 FEB 25, 1993
QUAD PHARMS	EQ 5MG BASE/ML	N71082 001 JAN 02, 1987
SMITH AND NEPHEW	EQ 5MG BASE/ML	N70802 001 DEC 14, 1987
SOLOPAK	EQ 5MG BASE/ML	N70800 001 DEC 14, 1987
	EQ 5MG BASE/ML	N70801 001 DEC 14, 1987
	EQ 5MG BASE/ML	N70864 001 DEC 14, 1987
STERIS	EQ 5MG BASE/ML	N70713 001 MAY 17, 1988
	EQ 5MG BASE/ML	N70744 001 MAY 17, 1988

HALOPROGIN

CREAM; TOPICAL		
HALOTEX		
WESTWOOD SQUIBB	1%	N16942 001
SOLUTION; TOPICAL		
HALOTEX		
WESTWOOD SQUIBB	1%	N16943 001

HALOTHANE

LIQUID; INHALATION		
HALOTHANE		
BH	99.99%	N84977 001

HEPARIN CALCIUM

INJECTABLE; INJECTION		
CALCIPARINE		
SANOFI SYNTHELABO	25,000 UNITS/ML	N18237 001

HEPARIN SODIUM

INJECTABLE; INJECTION		
HEP FLUSH KIT IN PLASTIC CONTAINER		
AM PHARM PARTNERS	10 UNITS/ML	N17029 017 DEC 05, 1985
	100 UNITS/ML	N17029 018 DEC 05, 1985
HEPARIN LOCK FLUSH		
ABBOTT	100 UNITS/ML	N05264 010
AM PHARM PARTNERS	100 UNITS/ML	N17651 010
INTL MEDICATION	10 UNITS/ML	N86357 001
	500 UNITS/ML	N86357 002
LUITPOLD	10 UNITS/ML	N89063 001 OCT 09, 1985
	100 UNITS/ML	N89064 001 OCT 09, 1985
PARKE DAVIS	10 UNITS/ML	N17346 006
SMITH AND NEPHEW	10 UNITS/ML	N87904 001 APR 20, 1983
	10 UNITS/ML	N87958 001 APR 20, 1983
	10 UNITS/ML	N88458 001 JUL 26, 1984
	10 UNITS/ML	N88580 001 OCT 25, 1984
	100 UNITS/ML	N87906 001 APR 20, 1983
	100 UNITS/ML	N87959 001 APR 20, 1983
	100 UNITS/ML	N88460 001 JUL 26, 1984
	100 UNITS/ML	N88581 001 OCT 25, 1984
SOLOPAK	10 UNITS/ML	N87903 001 APR 20, 1983
	10 UNITS/ML	N88457 001 OCT 25, 1984
	100 UNITS/ML	N87905 001 APR 20, 1983
	100 UNITS/ML	N88459 001 JUL 26, 1984
STERIS	100 UNITS/ML	N17064 001
HEPARIN LOCK FLUSH PRESERVATIVE FREE		
AM PHARM PARTNERS	10 UNITS/ML	N17029 011 SEP 22, 1987
	100 UNITS/ML	N17029 012 SEP 22, 1987

FDA data supplied by DrugPatentWatch.com

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN LOCK FLUSH PRESERVATIVE FREE IN PLASTIC CONTAINER		
AM PHARM PARTNERS	10 UNITS/ML	N17029 008
		SEP 22, 1987
	100 UNITS/ML	N17029 009
		SEP 22, 1987
HEPARIN SODIUM		
ABBOTT	10,000 UNITS/ML	N40095 001
		JUL 26, 1996
AKORN	1,000 UNITS/ML	N17486 001
	5,000 UNITS/ML	N17486 002
	10,000 UNITS/ML	N17486 003
	20,000 UNITS/ML	N17486 004
	40,000 UNITS/ML	N17486 005
AM PHARM PARTNERS	1,000 UNITS/ML	N17033 001
	1,000 UNITS/ML	N17651 005
	5,000 UNITS/ML	N17029 002
	5,000 UNITS/ML	N17979 003
	10,000 UNITS/ML	N17651 003
	20,000 UNITS/ML	N17651 008
CHAMBERLIN PARENTERL	1,000 UNITS/ML	N17130 001
	5,000 UNITS/ML	N17130 002
	10,000 UNITS/ML	N17130 003
	20,000 UNITS/ML	N17130 004
DELL LABS	1,000 UNITS/ML	N17540 001
	5,000 UNITS/ML	N17540 002
	10,000 UNITS/ML	N17540 003
	20,000 UNITS/ML	N17540 004
	40,000 UNITS/ML	N17540 005
LILLY	1,000 UNITS/ML	N05521 001
	20,000 UNITS/ML	N05521 004
LUITPOLD	1,000 UNITS/ML	N87452 001
		OCT 31, 1983
ORGANON	1,000 UNITS/ML	N00552 008
	5,000 UNITS/ML	N00552 009
	10,000 UNITS/ML	N00552 010
PARKE DAVIS	1,000 UNITS/ML	N17346 001
	5,000 UNITS/ML	N17346 002
	7,500 UNITS/ML	N17346 003
	10,000 UNITS/ML	N17346 004
	20,000 UNITS/ML	N17346 005
PHARM SPEC	1,000 UNITS/ML	N17780 001
	5,000 UNITS/ML	N17780 002
	10,000 UNITS/ML	N17780 003
	20,000 UNITS/ML	N17780 004
	40,000 UNITS/ML	N17780 005

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM		
SMITH AND NEPHEW	1,000 UNITS/ML	N88239 001
		JUL 26, 1984
SOLOPAK	1,000 UNITS/ML	N87043 001
	5,000 UNITS/ML	N87077 001
	10,000 UNITS/ML	N87107 001
	5,000 UNITS/0.5ML	N87395 001
	10,000 UNITS/0.5ML	N87363 001
STERIS	1,000 UNITS/ML	N17064 002
	2,500 UNITS/ML	N17064 015
	3,000 UNITS/ML	N17064 016
	4,000 UNITS/ML	N17064 017
	5,000 UNITS/ML	N17064 003
	6,000 UNITS/ML	N17064 018
	7,500 UNITS/ML	N17064 019
	10,000 UNITS/ML	N17064 004
	20,000 UNITS/ML	N17064 005
	40,000 UNITS/ML	N17064 006
WYETH AYERST	15,000 UNITS/ML	N17007 005
HEPARIN SODIUM 1,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER		
MCGAW	200 UNITS/100ML	N19130 001
		DEC 31, 1984
HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER		
B BRAUN	200 UNITS/100ML	N19042 001
		MAR 29, 1985
HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5%		
ABBOTT	10,000 UNITS/100ML	N18911 006
		JAN 30, 1985
HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER		
BAXTER HLTHCARE	2,000 UNITS/100ML	N18814 002
		JUL 09, 1985
HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.45%		
ABBOTT	10,000 UNITS/100ML	N18911 001
		JAN 30, 1985
	10,000 UNITS/100ML	N18916 005
		JAN 31, 1984
HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.9%		
ABBOTT	10,000 UNITS/100ML	N18911 003
		JAN 30, 1985
	10,000 UNITS/100ML	N18916 002
		JAN 31, 1984
HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5%		
ABBOTT	5,000 UNITS/100ML	N18911 007
		JAN 30, 1985

FDA data supplied by DrugPatentWatch.com

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER		
B BRAUN	5,000 UNITS/100ML	N19802 001 JUL 20, 1992
HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.9%		
ABBOTT	5,000 UNITS/100ML	N18911 005 JAN 30, 1985
	5,000 UNITS/100ML	N18916 003 JAN 31, 1984
HEPARIN SODIUM 2,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER		
MCGAW	200 UNITS/100ML	N19130 003 DEC 31, 1984
HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER		
B BRAUN	200 UNITS/100ML	N19042 002 MAR 29, 1985
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5%		
ABBOTT	5,000 UNITS/100ML	N18911 009 JAN 30, 1985
	10,000 UNITS/100ML	N18911 008 JAN 30, 1985
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER		
B BRAUN	5,000 UNITS/100ML	N19134 001 MAR 29, 1985
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER		
B BRAUN	5,000 UNITS/100ML	N19802 005 JUL 20, 1992
	10,000 UNITS/100ML	N19802 002 JUL 20, 1992
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9%		
ABBOTT	5,000 UNITS/100ML	N18911 004 JAN 30, 1985
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER		
ABBOTT	5,000 UNITS/100ML	N18916 009 JAN 31, 1984
B BRAUN	5,000 UNITS/100ML	N19135 001 MAR 29, 1985
	5,000 UNITS/100ML	N19802 003 JUL 20, 1992
HEPARIN SODIUM 5,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER		
BAXTER HLTHCARE	500 UNITS/100ML	N18609 003 APR 28, 1982

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM 5,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER		
MCGAW	1,000 UNITS/100ML	N19130 002 DEC 31, 1984
HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.45%		
ABBOTT	100 UNITS/ML	N18911 002 JAN 30, 1985
	100 UNITS/ML	N18916 004 JAN 31, 1984
HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9%		
ABBOTT	1,000 UNITS/100ML	N18916 001 JAN 31, 1984
HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER		
B BRAUN	1,000 UNITS/100ML	N19042 004 MAR 29, 1985
HEPARIN SODIUM PRESERVATIVE FREE		
PHARMA SERVE NY	1,000 UNITS/ML	N86129 001
LIPO-HEPIN		
3M	1,000 UNITS/ML	N17027 006
	1,000 UNITS/0.5ML	N17027 001
	5,000 UNITS/ML	N17027 008
	5,000 UNITS/0.5ML	N17027 002
	10,000 UNITS/ML	N17027 009
	7,500 UNITS/0.5ML	N17027 010
	10,000 UNITS/0.5ML	N17027 003
	20,000 UNITS/ML	N17027 007
	15,000 UNITS/0.5ML	N17027 011
	20,000 UNITS/0.5ML	N17027 004
	40,000 UNITS/ML	N17027 005
LIQUAEMIN LOCK FLUSH		
ORGANON	100 UNITS/ML	N00552 007
LIQUAEMIN SODIUM		
ORGANON	1,000 UNITS/ML	N00552 004
	5,000 UNITS/ML	N00552 003
	10,000 UNITS/ML	N00552 005
	20,000 UNITS/ML	N00552 001
	40,000 UNITS/ML	N00552 002
LIQUAEMIN SODIUM PRESERVATIVE FREE		
ORGANON	1,000 UNITS/ML	N00552 011 APR 11, 1986
	5,000 UNITS/ML	N00552 012 APR 11, 1986
	10,000 UNITS/ML	N00552 013 APR 11, 1986
PANHEPRIN		
ABBOTT	1,000 UNITS/ML	N05264 004

FDA data supplied by DrugPatentWatch.com

HEPARIN SODIUM

INJECTABLE; INJECTION

PANHEPRIN		
ABBOTT	5,000 UNITS/ML	N05264 006
	10,000 UNITS/ML	N05264 007
	20,000 UNITS/ML	N05264 008
	40,000 UNITS/ML	N05264 009
SODIUM HEPARIN		
AM PHARM PARTNERS	5,000 UNITS/ML	N17033 002
	10,000 UNITS/ML	N17033 003
	20,000 UNITS/ML	N17033 004

HEPARIN SODIUM; *MULTIPLE*

SEE DIHYDROERGOTAMINE MESYLATE; HEPARIN SODIUM; LIDOCAINE HYDROCHLORIDE

HETACILLIN

FOR SUSPENSION; ORAL

VERSAPEN		
BRISTOL	EQ 112.5MG AMPICIL/5ML	N50060 001
	EQ 225MG AMPICIL/5ML	N61398 002
	EQ 112.5MG AMPICIL/ML	N50060 003
	EQ 112.5MG AMPICIL/ML	N61398 001

HETACILLIN POTASSIUM

CAPSULE; ORAL

VERSAPEN-K		
BRISTOL	EQ 225MG AMPICIL	N61396 001
	EQ 450MG AMPICIL	N61396 002

HEXACHLOROPHENE

AEROSOL; TOPICAL

SEPTISOL		
VESTAL LABS	0.23%	N17424 001
TURGEX		
XTTRIUM	3%	N18375 001

EMULSION; TOPICAL

HEXA-GERM		
HUNTINGTON LABS	3%	N17411 001
PHISOHEX		
SANOFI SYNTHELABO	3%	N08402 001

HEXACHLOROPHENE

EMULSION; TOPICAL

SOY-DOME		
BAYER	3%	N17405 001
TURGEX		
XTTRIUM	3%	N19055 001
		NOV 30, 1984

SOLUTION; TOPICAL

DIAL		
DIAL	0.25%	N17421 002
GERMA-MEDICA		
HUNTINGTON LABS	1%	N17412 001
GERMA-MEDICA "MG"		
HUNTINGTON LABS	0.25%	N17412 002
SEPTI-SOFT		
CALGON	0.25%	N17460 001
SEPTISOL		
VESTAL LABS	0.25%	N17423 001

SPONGE; TOPICAL

HEXASCRUB		
PROF DSPLS	3%	N18363 001
PHISO-SCRUB		
SANOFI SYNTHELABO	3%	N17446 001
SCRUBTEAM SURGICAL SPONGEBRUSH		
3M	330MG	N17413 001

HEXAFLUORENIUM BROMIDE

INJECTABLE; INJECTION

MYLAXEN		
WALLACE LABS	20MG/ML	N09789 003

HEXOCYCLIUM METHYLSULFATE

TABLET; ORAL

TRAL		
ABBOTT	25MG	N10599 001

HEXYLCAINE HYDROCHLORIDE

SOLUTION; TOPICAL

CYCLAINE		
MERCK	5%	N08472 001

FDA data supplied by DrugPatentWatch.com

HISTAMINE PHOSPHATE

INJECTABLE; INJECTION		
HISTAMINE PHOSPHATE		
LILLY	EQ 0.1MG BASE/ML	N00734 003
	EQ 0.2MG BASE/ML	N00734 002
	EQ 1MG BASE/ML	N00734 001

HOMATROPINE METHYLBROMIDE

TABLET; ORAL		
HOMAPIN-10		
MISSION PHARMA	10MG	N86308 001
HOMAPIN-5		
MISSION PHARMA	5MG	N86309 001
TABLET, CHEWABLE; ORAL		
EQUIPIN		
MISSION PHARMA	3MG	N86310 001

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP; ORAL		
HYDROPANE		
HALSEY	1.5MG/5ML;5MG/5ML	N88066 001
		JUN 28, 1985

HYALURONIDASE

INJECTABLE; INJECTION		
WYDASE		
WYETH AYERST	150 UNITS/ML	N06343 002
	150 UNITS/VIAL	N06343 006
	1,500 UNITS/VIAL	N06343 005

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION		
APRESOLINE		
NOVARTIS	20MG/ML	N08303 003
HYDRALAZINE HCL		
AM PHARM PARTNERS	20MG/ML	N89532 001
		AUG 11, 1987
SMITH AND NEPHEW	20MG/ML	N88518 001
		APR 20, 1984

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION		
HYDRALAZINE HCL		
SOLOPAK	20MG/ML	N88517 001
		AUG 22, 1985
TABLET; ORAL		
DRALZINE		
TEVA	25MG	N84301 001
HYDRALAZINE HCL		
AMIDE PHARM	25MG	N88560 001
		OCT 04, 1984
	50MG	N88649 001
		OCT 18, 1984
ASCOT	25MG	N88310 001
		DEC 19, 1984
	50MG	N88311 001
		DEC 19, 1984
EON	50MG	N85088 001
HALSEY	10MG	N88728 001
		APR 11, 1985
	10MG	N89218 001
		JAN 22, 1986
	25MG	N84106 002
	25MG	N89130 001
		JAN 15, 1986
	50MG	N84107 002
	50MG	N89222 001
		JAN 22, 1986
	100MG	N88729 001
		APR 11, 1985
	100MG	N89178 001
		JAN 15, 1986
IMPAX LABS	25MG	N84922 001
IVAX PHARMS	10MG	N84443 001
	25MG	N84437 001
	50MG	N84469 002
	100MG	N84581 001
PUREPAC PHARM	25MG	N88177 001
		JUL 29, 1983
	50MG	N88178 001
		AUG 15, 1983
QUANTUM PHARMICS	10MG	N88671 001
		MAY 01, 1984
	25MG	N88657 001
		JUN 15, 1984
	50MG	N88652 001
		MAY 08, 1984

FDA data supplied by DrugPatentWatch.com

HYDRALAZINE HYDROCHLORIDE

TABLET; ORAL

HYDRALAZINE HCL		
QUANTUM PHARMICS	100MG	N88686 001 MAY 01, 1984
SUPERPHARM	10MG	N88787 001 AUG 28, 1984
	25MG	N88788 001 AUG 28, 1984
	50MG	N88789 001 AUG 28, 1984
USL PHARMA	25MG	N87780 001 MAR 29, 1982
	50MG	N87751 001 MAR 29, 1982
VANGARD	25MG	N87712 001
	50MG	N87908 001 MAY 07, 1982
VITARINE	25MG	N86088 001
WATSON LABS	25MG	N85532 002 MAY 24, 1982
	50MG	N85533 002 MAY 25, 1982
WEST WARD	25MG	N88240 001 MAY 27, 1983
	50MG	N88241 001 MAY 27, 1983

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

APRESAZIDE		
NOVARTIS	100MG;50MG	N84811 001
HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE		
SOLVAY	25MG;25MG	N87608 001 FEB 08, 1982
	50MG;50MG	N87213 001 FEB 08, 1982
	100MG;50MG	N87609 001 FEB 08, 1982
SUPERPHARM	25MG;25MG	N89200 001 FEB 09, 1987
WATSON LAB	25MG;25MG	N85457 001 MAR 04, 1982
	50MG;50MG	N85446 001 MAR 04, 1982

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE		
WATSON LAB	100MG;50MG	N85440 001 MAR 04, 1982
HYDRALAZINE HCL W/ HYDROCHLOROTHIAZIDE 100/50		
IVAX PHARMS	100MG;50MG	N88358 001 APR 10, 1984
HYDRALAZINE HCL W/ HYDROCHLOROTHIAZIDE 25/25		
IVAX PHARMS	25MG;25MG	N88356 001 APR 10, 1984
HYDRALAZINE HCL W/ HYDROCHLOROTHIAZIDE 50/50		
IVAX PHARMS	50MG;50MG	N88357 001 APR 10, 1984

TABLET; ORAL

APRESOLINE-ESIDRIX		
NOVARTIS	25MG;15MG	N12026 002
HYDRALAZINE AND HYDROCHLORTHIAZIDE		
WATSON LABS	25MG;15MG	N85827 001
HYDROCHLOROTHIAZIDE W/ HYDRALAZINE		
WATSON LAB	25MG;15MG	N85373 001

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

CAM-AP-ES		
ABC HOLDING	25MG;15MG;0.1MG	N84897 001
HYDRALAZINE HCL, HYDROCHLOROTHIAZIDE AND RESERPINE		
IVAX PHARMS	25MG;15MG;0.1MG	N84291 001
HYDRALAZINE HCL-HYDROCHLOROTHIAZIDE-RESERPINE		
MYLAN	25MG;15MG;0.1MG	N87085 001
HYDRALAZINE, HYDROCHLOROTHIAZIDE W/ RESERPINE		
WATSON LABS	25MG;15MG;0.1MG	N85771 001
HYDRAP-ES		
EON	25MG;15MG;0.1MG	N84876 001
HYDROCHLOROTHIAZIDE W/ RESERPINE AND HYDRALAZINE		
WATSON LAB	25MG;15MG;0.1MG	N83770 001
HYDROSERPINE PLUS (R-H-H)		
IVAX PHARMS	25MG;15MG;0.1MG	N83877 001
RESERPINE, HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE		
DANBURY PHARMA	25MG;15MG;0.1MG	N87556 001
HALSEY	25MG;15MG;0.1MG	N88570 001 APR 10, 1984
SOLVAY	25MG;15MG;0.1MG	N88376 001 OCT 28, 1983
WATSON LABS	25MG;15MG;0.1MG	N85549 001

FDA data supplied by DrugPatentWatch.com

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

RESERPINE, HYDROCHLOROTHIAZIDE, AND HYDRALAZINE HCL		
LEDERLE	25MG;15MG;0.1MG	N87709 001
		MAY 13, 1982
SER-A-GEN		
SOLVAY	25MG;15MG;0.1MG	N87210 001
SER-AP-ES		
NOVARTIS	25MG;15MG;0.1MG	N12193 005
UNIPRES		
SOLVAY	25MG;15MG;0.1MG	N85893 001
	25MG;15MG;0.1MG	N86298 001

HYDRALAZINE HYDROCHLORIDE; RESERPINE

TABLET; ORAL

DRALSERP		
EON	25MG;0.1MG	N84617 001
SERPASIL-APRESOLINE		
NOVARTIS	25MG;0.1MG	N09296 004
	50MG;0.2MG	N09296 002

HYDROCHLOROTHIAZIDE

SOLUTION; ORAL

HYDROCHLOROTHIAZIDE		
MORTON GROVE	50MG/5ML	N89661 001
		JUN 20, 1988
HYDROCHLOROTHIAZIDE INTENSOL		
ROXANE	100MG/ML	N88588 001
		JUL 02, 1984

TABLET; ORAL

HYDRO-D		
HALSEY	25MG	N86504 001
	50MG	N83891 002
HYDROCHLOROTHIAZIDE		
ALRA	25MG	N86369 001
	50MG	N83554 001
ASCOT	25MG	N87539 001
		FEB 03, 1982
	50MG	N87540 001
		FEB 03, 1982
BARR	50MG	N84771 001
DANBURY PHARMA	50MG	N83232 001
ELKINS SINN	50MG	N85152 002

HYDROCHLOROTHIAZIDE

TABLET; ORAL

HYDROCHLOROTHIAZIDE		
EON	25MG	N83899 001
HALSEY	25MG	N83972 001
	50MG	N83972 002
	100MG	N83972 003
HEATHER	50MG	N84135 001
IMPAX LABS	25MG	N84029 001
	50MG	N83607 002
	100MG	N85098 001
INWOOD LABS	25MG	N84776 001
	25MG	N85067 001
	50MG	N84776 002
IVAX PHARMS	50MG	N84658 001
MAST MM	25MG	N86192 001
	50MG	N86192 002
MYLAN	25MG	N84880 001
	50MG	N85112 001
PHARMERAL	25MG	N84325 001
	50MG	N84324 001
PVT FORM	50MG	N86597 001
ROXANE	25MG	N85004 001
	50MG	N85005 001
SOLVAY	25MG	N85323 001
SUPERPHARM	25MG	N88827 001
		DEC 28, 1984
	50MG	N88828 001
		DEC 28, 1984
	100MG	N88829 001
		DEC 28, 1984
TEVA	25MG	N88924 001
		FEB 07, 1985
	50MG	N88923 001
		FEB 07, 1985
USL PHARMA	25MG	N87827 001
		APR 19, 1982
	50MG	N87752 001
		APR 19, 1982
VANGARD	25MG	N87638 001
	50MG	N87610 001
WARNER CHILCOTT	25MG	N87586 001
		MAY 03, 1982
	50MG	N87587 001
		MAY 03, 1982
WATSON LAB	25MG	N83458 001
	50MG	N83456 001
	100MG	N85099 001

FDA data supplied by DrugPatentWatch.com

HYDROCHLOROTHIAZIDE

TABLET; ORAL

HYDROCHLOROTHIAZIDE			
WATSON LABS	25MG	N85232	002
	50MG	N85233	001
	50MG	N86087	001
	50MG	N86594	001
	100MG	N87002	001
WEST WARD	25MG	N84899	001
	50MG	N84878	001
WHITEWORTH TOWN PLSN	25MG	N83809	002
	50MG	N83809	001
	100MG	N85347	001
ZIDE			
SOLVAY	50MG	N83925	001

HYDROCHLOROTHIAZIDE; *MULTIPLE*

SEE BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE
SEE CAPTOPRIL; HYDROCHLOROTHIAZIDE
SEE DESERPIDINE; HYDROCHLOROTHIAZIDE
SEE GUANETHIDINE MONOSULFATE; HYDROCHLOROTHIAZIDE
SEE HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE
SEE HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL

AVALIDE			
SANOFI SYNTHELABO	12.5MG;75MG	N20758	001
		SEP 30, 1997	

HYDROCHLOROTHIAZIDE; LABETALOL HYDROCHLORIDE

TABLET; ORAL

NORMOZIDE			
SCHERING	25MG;100MG	N19046	001
		APR 06, 1987	
	25MG;200MG	N19046	002
		APR 06, 1987	
	25MG;300MG	N19046	003
		APR 06, 1987	
	25MG;400MG	N19046	004
		APR 06, 1987	
TRANDATE HCT			
GLAXOSMITHKLINE	25MG;100MG	N19174	001
		APR 10, 1987	

HYDROCHLOROTHIAZIDE; LABETALOL HYDROCHLORIDE

TABLET; ORAL

TRANDATE HCT			
GLAXOSMITHKLINE	25MG;200MG	N19174	002
		APR 10, 1987	
	25MG;300MG	N19174	003
		APR 10, 1987	
	25MG;400MG	N19174	004
		APR 10, 1987	

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

METHYLDOPA AND HYDROCHLOROTHIAZIDE			
INVAMED	15MG;250MG	N70829	001
		MAR 09, 1987	
	25MG;250MG	N70830	001
		MAR 09, 1987	
IVAX PHARMS	15MG;250MG	N71458	001
		MAR 08, 1988	
	25MG;250MG	N71459	001
		MAR 08, 1988	
	30MG;500MG	N71460	001
		MAR 08, 1988	
	50MG;500MG	N71461	001
		MAR 08, 1988	
PARKE DAVIS	15MG;250MG	N71897	001
		NOV 23, 1987	
	25MG;250MG	N71898	001
		NOV 23, 1987	
	30MG;500MG	N71899	001
		NOV 23, 1987	
	50MG;500MG	N71900	001
		NOV 23, 1987	
PUREPAC PHARM	15MG;250MG	N70853	001
		OCT 08, 1986	
	25MG;250MG	N70688	001
		APR 24, 1986	
	30MG;500MG	N70854	001
		OCT 08, 1986	
	50MG;500MG	N70689	001
		APR 24, 1986	
TEVA	15MG;250MG	N71819	001
		APR 08, 1988	
	25MG;250MG	N71820	001
		APR 08, 1988	

FDA data supplied by DrugPatentWatch.com

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

METHYLDOPA AND HYDROCHLOROTHIAZIDE			
TEVA	30MG;500MG	N71821 001	APR 08, 1988
	50MG;500MG	N71822 001	APR 08, 1988
WATSON LAB	15MG;250MG	N70365 001	MAR 19, 1986
	25MG;250MG	N70366 001	APR 16, 1986
	30MG;500MG	N70367 001	MAR 19, 1986
	50MG;500MG	N70368 001	APR 16, 1986
WATSON LABS	15MG;250MG	N71920 001	AUG 29, 1988
	25MG;250MG	N71921 001	AUG 29, 1988
	30MG;500MG	N71922 001	AUG 29, 1988
	50MG;500MG	N71923 001	AUG 29, 1988

HYDROCHLOROTHIAZIDE; PINDOLOL

TABLET; ORAL

VISKAZIDE			
NOVARTIS	25MG;5MG	N18872 001	JUL 22, 1987
	25MG;10MG	N18872 002	JUL 22, 1987

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

PROPRANOLOL HCL & HYDROCHLOROTHIAZIDE			
DURAMED	25MG;40MG	N71126 001	MAR 02, 1987
	25MG;80MG	N71127 001	MAR 02, 1987
PROPRANOLOL HCL AND HYDROCHLOROTHIAZIDE			
DANBURY PHARMA	25MG;40MG	N71498 001	DEC 18, 1991
	25MG;80MG	N71501 001	DEC 18, 1991

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

PROPRANOLOL HCL AND HYDROCHLOROTHIAZIDE			
IVAX PHARMS	25MG;40MG	N71552 001	DEC 01, 1988
	25MG;80MG	N71553 001	DEC 01, 1988
WARNER CHILCOTT	25MG;40MG	N71771 001	JAN 26, 1988
	25MG;80MG	N71772 001	JAN 26, 1988

HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

H.R.-50			
WHITEWORTH TOWN PLSN	50MG;0.125MG	N85338 001	
HYDRO-RESERP			
ABC HOLDING	50MG;0.125MG	N84714 002	JUN 29, 1982
HYDRO-SERP "25"			
EON	25MG;0.125MG	N84827 001	
HYDRO-SERP "50"			
EON	50MG;0.125MG	N85213 001	
HYDROCHLOROTHIAZIDE W/ RESERPINE			
DANBURY PHARMA	25MG;0.125MG	N84466 001	
	50MG;0.125MG	N84467 001	
IVAX PHARMS	25MG;0.1MG	N83572 001	
	25MG;0.125MG	N83571 001	
	50MG;0.1MG	N83568 001	
	50MG;0.125MG	N83573 001	
PHARMERAL	25MG;0.125MG	N85421 001	
	50MG;0.125MG	N85420 001	
ROXANE	50MG;0.125MG	N84603 001	
WATSON LAB	25MG;0.125MG	N85317 001	
	50MG;0.125MG	N83666 001	
WATSON LABS	25MG;0.125MG	N86330 002	
	50MG;0.125MG	N86331 001	
RESERPINE AND HYDROCHLOROTHIAZIDE			
BARR	25MG;0.125MG	N84580 001	
	50MG;0.125MG	N84579 001	
GENEVA PHARMS	50MG;0.125MG	N88200 001	JAN 31, 1984
RESERPINE AND HYDROCHLOROTHIAZIDE-50			
WEST WARD	50MG;0.125MG	N88189 001	MAY 10, 1984
SERPASIL-ESIDRIX #1			
NOVARTIS	25MG;0.1MG	N11878 003	

FDA data supplied by DrugPatentWatch.com

HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL
SERPASIL-ESIDRIX #2
NOVARTIS 50MG;0.1MG N11878 005

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET; ORAL
SPIRONOLACTONE + HYDROCHLOROTHIAZIDE
ASCOT 25MG;25MG N88025 001
NOV 23, 1984

SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE
PUREPAC PHARM 25MG;25MG N87999 001
NOV 06, 1985
SUPERPHARM 25MG;25MG N89137 001
AUG 26, 1985

SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE
IVAX PHARMS 25MG;25MG N87004 002
MAY 24, 1982
LEDERLE 25MG;25MG N87511 001
PUREPAC PHARM 25MG;25MG N88054 001
AUG 18, 1983
UPSHER SMITH 25MG;25MG N87553 001
USL PHARMA 25MG;25MG N87651 001
VANGARD 25MG;25MG N87655 001
WATSON LAB 25MG;25MG N85974 001
WATSON LABS 25MG;25MG N86026 001

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL
DYAZIDE
GLAXOSMITHKLINE 25MG;50MG N16042 002
TRIAMTERENE AND HYDROCHLOROTHIAZIDE
NOVARTIS 25MG;37.5MG N74857 001
SEP 09, 1997
VITARINE 25MG;50MG N71737 001
FEB 12, 1988

TABLET; ORAL
TRIAMTERENE AND HYDROCHLOROTHIAZIDE
AM THERAP 50MG;75MG N72022 001
APR 17, 1988
QUANTUM PHARMICS 50MG;75MG N71980 001
APR 17, 1988

HYDROCODONE BITARTRATE; *MULTIPLE*
SEE ACETAMINOPHEN; HYDROCODONE BITARTRATE
SEE ASPIRIN; HYDROCODONE BITARTRATE
SEE HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

HYDROCORTAMATE HYDROCHLORIDE

OINTMENT; TOPICAL
MAGNACORT
PFIZER 0.5% N10554 001

HYDROCORTISONE

AEROSOL; TOPICAL
AEROSEB-HC
ALLERGAN HERBERT 0.5% N85805 001

CREAM; TOPICAL
CORT-DOME
BAYER 0.5% N09585 003
1% N09585 001
DERMACORT
MONARCH PHARMS 1% N83011 002
ELDECORT
ICN 1% N80459 001
2.5% N84055 001
FLEXICORT
WESTWOOD SQUIBB 0.5% N87136 003
APR 08, 1982
1% N87136 002
APR 08, 1982
2.5% N87136 001
APR 08, 1982
H-CORT
PHARM ASSOC 0.5% N86823 001
HC #1
BAYER 0.5% N80438 001
HC #4
BAYER 1% N80438 002
HC (HYDROCORTISONE)
C AND M PHARMA 0.5% N80482 003
1% N80482 004
HYDROCORTISONE
ALPHARMA 2.5% N89754 001
FEB 01, 1989
AMBIX 1% N86080 001
2.5% N86271 001

FDA data supplied by DrugPatentWatch.com

HYDROCORTISONE

CREAM; TOPICAL

HYDROCORTISONE		
CLAY PARK	0.5%	N84970 002
	1%	N85026 001
EVERYLIFE	0.5%	N80452 001
G AND W LABS	1%	N84059 001
IVAX PHARMS	1%	N85733 001
NASKA	1%	N89706 001
		MAR 10, 1988
PHARMADERM	1%	N88845 001
		FEB 27, 1986
PHARMAFAIR	1%	N87838 001
		JUL 28, 1982
STIEFEL	1%	N86170 001
TEVA	0.5%	N80400 002
	1%	N80400 003
	1%	N85191 001
	2.5%	N80400 004
THAMES	0.5%	N86154 001
TOPIDERM	1%	N89273 001
		FEB 17, 1989
USL PHARMA	1%	N88027 001
		SEP 27, 1983
	2.5%	N88029 001
		SEP 27, 1983
WHITEWORTH TOWN PLSN	1%	N80496 002
NOGENIC HC		
IVAX PHARMS	1%	N87427 001
		APR 04, 1988
NUTRACORT		
HEALTHPOINT	0.5%	N80442 002
	1%	N80442 003
PROCTOCORT		
MONARCH PHARMS	1%	N83011 001
SYNACORT		
MEDICIS	0.5%	N87459 001

GEL; TOPICAL

NUTRACORT		
HEALTHPOINT	1%	N84698 001
PENECORT		
ALLERGAN HERBERT	1%	N88215 001
		JUN 06, 1984

INJECTABLE; INJECTION

CORTEF		
PHARMACIA AND UPJOHN	50MG/ML	N09864 001

HYDROCORTISONE

LOTION; TOPICAL

ACTICORT		
BAKER NORTON	1%	N86535 001
BALNEOL-HC		
SOLVAY	1%	N88041 001
		DEC 03, 1982
BETA-HC		
BETA DERMAC	1%	N89495 001
		JAN 25, 1988
CORT-DOME		
BAYER	0.5%	N09895 003
	1%	N09895 001
DERMACORT		
SOLVAY	0.5%	N84573 002
	1%	N86462 001
GLYCORT		
HERAN	1%	N87489 001
		OCT 03, 1983
H-CORT		
PHARM ASSOC	0.5%	N86824 001
HYDROCORTISONE		
ALPHARMA	0.5%	N87317 001
		JUN 07, 1982
	1%	N87315 001
		JUN 07, 1982
CLAY PARK	0.5%	N85662 001
	1%	N85663 001
MERICON	0.5%	N85282 001
	1%	N85282 002
		FEB 26, 1987
NASKA	1%	N89705 001
		APR 25, 1988
THAMES	1%	N89024 001
		FEB 12, 1986
NUTRACORT		
HEALTHPOINT	0.5%	N80443 002

OINTMENT; TOPICAL

HC (HYDROCORTISONE)		
C AND M PHARMA	0.5%	N80481 001
	1%	N80481 002
HYDROCORTISONE		
ALTANA	0.5%	N80489 002
AMBIX	1%	N86079 001
	2.5%	N86272 001
CLAY PARK	0.5%	N84969 003
	1%	N85028 001

FDA data supplied by DrugPatentWatch.com

HYDROCORTISONE

OINTMENT; TOPICAL
HYDROCORTISONE

NASKA	1%	N89704 001
		MAR 10, 1988
PHARMADERM	1%	N88842 001
		FEB 09, 1987
THAMES	0.5%	N86256 001
USL PHARMA	1%	N88061 001
		SEP 27, 1983
	2.5%	N88039 001
		SEP 27, 1983

HYTONE

DERMIK LABS	1%	N80474 003
	2.5%	N80474 004

PENECORT

ALLERGAN HERBERT	2.5%	N88217 001
		JUN 06, 1984

POWDER; FOR RX COMPOUNDING
H-CORT

TORCH	100%	N87834 001
		MAR 29, 1982

TABLET; ORAL
CORTRIL

PFIZER	10MG	N09127 005
	20MG	N09127 003

HYDROCORTISONE

ANABOLIC	20MG	N83140 001
BARR	20MG	N83999 001
DANBURY PHARMA	20MG	N80355 001
ELKINS SINN	20MG	N80624 001
EON	20MG	N80642 002
FERRANTE	10MG	N80568 001
	20MG	N80568 002
IMPAX LABS	20MG	N80781 001
INWOOD LABS	20MG	N80732 001
LANNETT	20MG	N85070 001
PANRAY	10MG	N09659 001
	20MG	N09659 002
PARKE DAVIS	20MG	N84243 001
PUREPAC PHARM	10MG	N84247 003
		AUG 31, 1982
	20MG	N80395 001
	20MG	N84247 002
ROXANE	10MG	N88539 001
		MAR 21, 1984

HYDROCORTISONE

TABLET; ORAL
HYDROCORTISONE

WHITEWORTH TOWN PLSN	10MG	N80344 001
	20MG	N80344 002

TABLET; VAGINAL
CORTRIL

PFIPHARMECS	10MG	N09796 001

HYDROCORTISONE; *MULTIPLE*
SEE ACETIC ACID, GLACIAL; HYDROCORTISONE
SEE BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OTIC
NEO-OTOSOL-HC

ALCON	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N62423 001
		AUG 25, 1983

NEOMYCIN SULFATE-POLYMYXIN B SULFATE-HYDROCORTISONE

PHARMAFAIR	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N62394 001
		SEP 29, 1982

OTOCORT

STERIS	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N60730 002

SUSPENSION/DROPS; OPHTHALMIC
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE

ALCON UNIVERSAL	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N62874 001
		MAY 11, 1988

NEOMYCIN SULFATE-POLYMYXIN B SULFATE-HYDROCORTISONE

PHARMAFAIR	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N62623 001
		SEP 24, 1985

SUSPENSION/DROPS; OTIC
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE

ALCON UNIVERSAL	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N62488 001
		NOV 06, 1985

FDA data supplied by DrugPatentWatch.com

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION/DROPS; OTIC

NEOMYCIN SULFATE, POLYMYXIN B SULFATE & HYDROCORTISONE			
PHARMAFAIR	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N62617 001	SEP 18, 1985
OTICAIR			
PHARMAFAIR	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N62399 001	NOV 18, 1982
OTOBIONE			
SCHERING	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N61816 001	
OTOCORT			
STERIS	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N62521 001	JUL 11, 1985

HYDROCORTISONE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OTIC

PYOCIDIN		
FORREST LABS	5MG/ML; EQ 10,000 UNITS BASE/ML	N61606 001

HYDROCORTISONE; UREA

CREAM; TOPICAL

ALPHADERM		
BIOGLAN	1%;10%	N86008 001
CALMURID HC		
PHARMACIA AND UPJOHN	1%;10%	N83947 001

HYDROCORTISONE ACETATE

CREAM; TOPICAL

HEMSOL-HC			
ABLE	1%	N81274 001	JUN 19, 1992
HYDROCORTISONE ACETATE			
CENCI	1%	N80419 001	JAN 25, 1982
PARKE DAVIS	1%	N89914 001	JAN 03, 1989
PUREPAC PHARM	0.5%	N86050 001	

HYDROCORTISONE ACETATE

CREAM; TOPICAL

HYDROCORTISONE ACETATE		
PUREPAC PHARM	1%	N86052 001

INJECTABLE; INJECTION

CORTEF ACETATE		
PHARMACIA AND UPJOHN	50MG/ML	N09378 002
CORTRIL		
PFIZER	25MG/ML	N09164 001
HYDROCORTISONE ACETATE		
AKORN	25MG/ML	N09637 001
	50MG/ML	N09637 002
BEL MAR	25MG/ML	N83739 001
	50MG/ML	N83739 002
STERIS	25MG/ML	N83759 001
	50MG/ML	N83759 002
	50MG/ML	N85214 001

OINTMENT; OPHTHALMIC, OTIC

HYDROCORTONE		
MERCK	1.5%	N09018 003

OINTMENT; TOPICAL

CORTEF ACETATE		
PHARMACIA AND UPJOHN	1%	N08917 002
*	2.5%	N08917 001

HYDROCORTISONE ACETATE; *MULTIPLE*

SEE BACITRACIN; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SEE CHLORAMPHENICOL; HYDROCORTISONE ACETATE; POLYMYXIN B SULFATE

HYDROCORTISONE ACETATE; NEOMYCIN SULFATE

CREAM; TOPICAL

NEO-CORTEF		
PHARMACIA AND UPJOHN	1%;EQ 3.5MG BASE/GM	N61049 001
	2.5%;EQ 3.5MG BASE/GM	N61049 002

OINTMENT; OPHTHALMIC

NEO-CORTEF		
PHARMACIA AND UPJOHN	0.5%;EQ 3.5MG BASE/GM	N60610 001
	1.5%;EQ 3.5MG BASE/GM	N60610 002

FDA data supplied by DrugPatentWatch.com

HYDROCORTISONE ACETATE; NEOMYCIN SULFATE

OINTMENT; TOPICAL			
NEO-CORTEF			
PHARMACIA AND UPJOHN	0.5%;EQ 3.5MG BASE/GM	N60751	001
	1%;EQ 3.5MG BASE/GM	N60751	002
	2.5%;EQ 3.5MG BASE/GM	N60751	003
SUSPENSION/DROPS; OPHTHALMIC			
COR-OTICIN			
AKORN	1.5%;EQ 3.5MG BASE/ML	N60188	001
NEO-CORTEF			
PHARMACIA AND UPJOHN	0.5%;EQ 3.5MG BASE/ML	N60612	002
	1.5%;EQ 3.5MG BASE/ML	N60612	001

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

LOTION; TOPICAL			
PRAMOSONE			
FERNDALE LABS	0.5%;1%	N83213	002

HYDROCORTISONE BUTYRATE

CREAM; TOPICAL			
LOCOID			
YAMANOUCHI	0.1%	N18795	001
		JAN 07, 1983	
OINTMENT; TOPICAL			
LOCOID			
YAMANOUCHI	0.1%	N19106	001
		JUL 03, 1984	
SOLUTION; TOPICAL			
LOCOID			
YAMANOUCHI	0.1%	N19819	001
		SEP 15, 1988	

HYDROCORTISONE SODIUM PHOSPHATE

INJECTABLE; INJECTION			
HYDROCORTISONE SODIUM PHOSPHATE			
QUAD PHARMS	EQ 50MG BASE/ML	N89581	001
		MAY 28, 1987	

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION			
A-HYDROCORT			
ABBOTT	EQ 1GM BASE/VIAL	N89580	001
		APR 11, 1989	
	EQ 100MG BASE/VIAL	N85928	001
	EQ 100MG BASE/VIAL	N89577	001
		APR 11, 1989	
	EQ 250MG BASE/VIAL	N89578	001
		APR 11, 1989	
	EQ 500MG BASE/VIAL	N89579	001
		APR 11, 1989	
HYDROCORTISONE SODIUM SUCCINATE			
AM PHARM PARTNERS	EQ 1GM BASE/VIAL	N88670	001
		JUN 08, 1984	
	EQ 100MG BASE/VIAL	N88667	001
		JUN 08, 1984	
	EQ 100MG BASE/VIAL	N88712	001
		JUN 08, 1984	
	EQ 250MG BASE/VIAL	N88668	001
		JUN 08, 1984	
	EQ 500MG BASE/VIAL	N88669	001
		JUN 08, 1984	
ELKINS SINN	EQ 1GM BASE/VIAL	N87569	001
	EQ 100MG BASE/VIAL	N86619	001
	EQ 250MG BASE/VIAL	N87567	001
	EQ 500MG BASE/VIAL	N87568	001
STERIS	EQ 1GM BASE/VIAL	N84748	001
	EQ 100MG BASE/VIAL	N84737	002
	EQ 100MG BASE/VIAL	N84738	001
	EQ 250MG BASE/VIAL	N84737	001
	EQ 500MG BASE/VIAL	N84747	001

HYDROFLUMETHIAZIDE

TABLET; ORAL			
HYDROFLUMETHIAZIDE			
WATSON LAB	50MG	N88031	001
		APR 06, 1983	
WATSON LABS	50MG	N88528	001
		AUG 15, 1984	

FDA data supplied by DrugPatentWatch.com

HYDROFLUMETHIAZIDE; RESERPINE

TABLET; ORAL			
HYDROFLUMETHIAZIDE AND RESERPINE			
USL PHARMA	50MG;0.125MG	N88195 001	
		OCT 26, 1983	
WATSON LAB	25MG;0.125MG	N88127 001	
		MAR 22, 1983	
	50MG;0.125MG	N88110 001	
		MAR 22, 1983	
RESERPINE AND HYDROFLUMETHIAZIDE			
IVAX PHARMS	50MG;0.125MG	N88932 001	
		JAN 11, 1985	

HYDROXOCOBALAMIN

INJECTABLE; INJECTION			
ALPHAREDISOL			
MERCK	1MG/ML	N80778 001	
HYDROXOCOBALAMIN			
AM PHARM PARTNERS	1MG/ML	N84921 001	
STERIS	1MG/ML	N85528 001	
HYDROXOMIN			
BEL MAR	1MG/ML	N84629 001	

HYDROXYPROGESTERONE CAPROATE

INJECTABLE; INJECTION			
DELALUTIN			
BRISTOL MYERS SQUIBB	125MG/ML	N10347 004	
	125MG/ML	N16911 001	
	250MG/ML	N10347 002	
	250MG/ML	N16911 002	
HYDROXYPROGESTERONE CAPROATE			
AKORN	125MG/ML	N18004 001	
QUAD PHARMS	125MG/ML	N89330 001	
		JAN 02, 1987	
	250MG/ML	N89331 001	
		JAN 02, 1987	
STERIS	125MG/ML	N17439 001	

HYDROXYSTILBAMIDINE ISETHIONATE

INJECTABLE; INJECTION			
HYDROXYSTILBAMIDINE ISETHIONATE			
AVENTIS PHARMS	225MG/AMP	N09166 001	

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION			
HYDROXYZINE HCL			
ABBOTT	50MG/ML	N86821 001	
ALTANA	25MG/ML	N87273 001	
		APR 20, 1982	
	50MG/ML	N87273 002	
		APR 20, 1982	
AM PHARM PARTNERS	25MG/ML	N88184 001	
		MAR 31, 1983	
	50MG/ML	N88185 001	
		MAR 31, 1983	
PHARMAFAIR	25MG/ML	N88862 001	
		FEB 14, 1986	
	25MG/ML	N89106 001	
		FEB 14, 1986	
	50MG/ML	N88881 001	
		FEB 14, 1986	
	50MG/ML	N89107 001	
		FEB 14, 1986	
SMITH AND NEPHEW	25MG/ML	N87592 001	
SOLOPAK	25MG/ML	N86822 001	
	25MG/ML	N87591 001	
	50MG/ML	N87310 001	
	50MG/ML	N87593 001	
	50MG/ML	N87595 001	
	50MG/ML	N87596 001	
STERIS	25MG/ML	N85778 001	
	25MG/ML	N87274 001	
	50MG/ML	N87274 002	
WYETH AYERST	25MG/ML	N86258 001	
	50MG/ML	N86258 002	
ORGATRAX			
ORGANON	25MG/ML	N87014 001	
	50MG/ML	N87014 002	
SYRUP; ORAL			
HYDROXYZINE HCL			
ALPHARMA	10MG/5ML	N88785 001	
		FEB 03, 1988	
KV PHARM	10MG/5ML	N87730 001	
		JUL 01, 1982	
TABLET; ORAL			
HYDROXYZINE HCL			
AMIDE PHARM	10MG	N89071 001	
		JUL 22, 1986	

FDA data supplied by DrugPatentWatch.com

HYDROXYZINE HYDROCHLORIDE

TABLET; ORAL

HYDROXYZINE HCL		
AMIDE PHARM	25MG	N89072 001
		JUL 22, 1986
	50MG	N89073 001
		JUL 22, 1986
EON	10MG	N87246 002
	25MG	N85247 001
	50MG	N87245 001
HALSEY	10MG	N88409 001
		NOV 15, 1983
	10MG	N89366 001
		MAY 02, 1988
	25MG	N87857 001
		APR 18, 1983
	25MG	N89117 001
		MAY 02, 1988
	50MG	N87860 001
		APR 18, 1983
	50MG	N89396 001
		MAY 02, 1988
	100MG	N87862 001
		APR 18, 1983
IVAX PHARMS	10MG	N87216 001
	25MG	N87410 001
	50MG	N87411 001
KV PHARM	10MG	N87819 001
		JUN 23, 1982
	25MG	N87820 001
		JUN 23, 1982
	50MG	N87821 001
		JUN 23, 1982
	100MG	N87822 001
		JUN 23, 1982
PAR PHARM	10MG	N87602 001
		JAN 22, 1982
	25MG	N87603 001
		JAN 22, 1982
	50MG	N87604 001
		JAN 22, 1982
PUREPAC PHARM	10MG	N88120 001
		SEP 25, 1984
	25MG	N88121 001
		SEP 25, 1984
	50MG	N88122 001
		SEP 25, 1984

HYDROXYZINE HYDROCHLORIDE

TABLET; ORAL

HYDROXYZINE HCL		
QUANTUM PHARMICS	10MG	N88540 001
		OCT 22, 1985
	25MG	N88551 001
		OCT 22, 1985
	50MG	N88529 001
		OCT 22, 1985
SUPERPHARM	10MG	N88794 001
		DEC 05, 1984
	25MG	N88795 001
		DEC 05, 1984
	50MG	N88796 001
		DEC 05, 1984
USL PHARMA	10MG	N89121 001
		MAR 20, 1986
	25MG	N89122 001
		MAR 20, 1986
	50MG	N89123 001
		MAR 20, 1986
WATSON LABS	10MG	N86827 001
	25MG	N86829 001
	50MG	N86836 001

HYDROXYZINE PAMOATE

CAPSULE; ORAL

HY-PAM "25"		
TEVA	EQ 25MG HCL	N88713 001
		MAR 04, 1985
HYDROXYZINE PAMOATE		
DANBURY PHARMA	EQ 50MG HCL	N87767 001
		AUG 16, 1982
	EQ 100MG HCL	N87790 001
		AUG 16, 1982
DURAMED	EQ 25MG HCL	N88593 001
		FEB 29, 1984
	EQ 50MG HCL	N88594 001
		FEB 29, 1984
	EQ 100MG HCL	N88595 001
		FEB 29, 1984
GENEVA PHARMS	EQ 50MG HCL	N81128 001
		JUN 28, 1991
	EQ 100MG HCL	N81129 001
		JUN 28, 1991

FDA data supplied by DrugPatentWatch.com

HYDROXYZINE PAMOATE

CAPSULE; ORAL

HYDROXYZINE PAMOATE			
PAR PHARM	EQ 25MG HCL	N87656 001	JUN 11, 1982
	EQ 25MG HCL	N89145 001	MAR 17, 1986
	EQ 50MG HCL	N87657 001	JUN 11, 1982
	EQ 50MG HCL	N89146 001	MAR 17, 1986
	EQ 100MG HCL	N87658 001	JUN 11, 1982
SUPERPHARM	EQ 25MG HCL	N89031 001	JAN 02, 1987
	EQ 50MG HCL	N89032 001	JAN 02, 1987
	EQ 100MG HCL	N89033 001	JAN 02, 1987
VANGARD	EQ 25MG HCL	N88392 001	SEP 19, 1983
	EQ 50MG HCL	N88393 001	SEP 19, 1983
WATSON LAB	EQ 25MG HCL	N86698 001	
	EQ 50MG HCL	N86695 001	
	EQ 100MG HCL	N86697 001	
WATSON LABS	EQ 25MG HCL	N86840 001	JUL 01, 1982
	EQ 50MG HCL	N86705 001	JUL 01, 1982
	EQ 100MG HCL	N86728 001	OCT 05, 1982

IBUPROFEN

CAPSULE; ORAL

MIDOL			
* BAYER	200MG	N70626 001	SEP 02, 1987
*	200MG	N71002 001	SEP 02, 1987

SUSPENSION; ORAL

IBU			
ABBOTT	100MG/5ML	N19784 001	DEC 18, 1989

IBUPROFEN

TABLET; ORAL

ACHES-N-PAIN			
LEDERLE	200MG	N71065 001	MAY 28, 1987
IBU-TAB			
ALRA	800MG	N71965 001	AUG 11, 1988
IBUPRIN			
SIDMAK LABS NJ	200MG	N71773 001	JUL 16, 1987
IBUPROFEN			
ABBOTT	600MG	N70556 001	JUN 14, 1985
	800MG	N71264 001	JUL 25, 1986
BARR	200MG	N70493 001	DEC 24, 1985
	200MG	N70908 001	SEP 26, 1986
	200MG	N71462 001	OCT 02, 1986
	400MG	N70079 001	JUL 24, 1985
	600MG	N70080 001	JUL 24, 1985
	800MG	N71448 001	FEB 18, 1987
DANBURY PHARMA	200MG	N71905 001	MAR 08, 1988
HALSEY	200MG	N71027 001	SEP 29, 1987
	300MG	N71028 001	MAR 23, 1987
	400MG	N71029 001	MAR 23, 1987
	600MG	N71030 001	MAR 23, 1987
	800MG	N72137 001	FEB 05, 1988
INVAMED	400MG	N72064 001	JAN 14, 1988
	600MG	N72065 001	JAN 14, 1988
	800MG	N71938 001	JAN 14, 1988
IVAX PHARMS	200MG	N71154 001	OCT 27, 1987

FDA data supplied by DrugPatentWatch.com

IBUPROFEN

TABLET; ORAL
IBUPROFEN

IVAX PHARMS	200MG	N72040 001 APR 29, 1988
LEDERLE	400MG	N70629 001 SEP 19, 1986
	600MG	N70630 001 SEP 19, 1986
MCNEIL	400MG	N70081 001 JUN 16, 1986
	600MG	N70476 001 JUN 16, 1986
PAR PHARM	300MG	N70328 001 AUG 06, 1985
PUREPAC PHARM	200MG	N71122 001 OCT 03, 1986
	200MG	N71664 001 FEB 03, 1987
	300MG	N71123 001 SEP 19, 1986
	400MG	N71124 001 SEP 19, 1986
	600MG	N71125 001 SEP 19, 1986
	800MG	N71964 001 FEB 01, 1988
SUPERPHARM	600MG	N70709 001 APR 25, 1986
TEVA	200MG	N73141 001 MAY 29, 1992
	400MG	N73343 001 JUN 30, 1992
	600MG	N73344 001 JUN 30, 1992
	800MG	N73345 001 JUN 30, 1992
WATSON LABS	200MG	N71765 001 SEP 04, 1987
	300MG	N71338 001 DEC 01, 1986
	400MG	N70038 001 SEP 06, 1985
	600MG	N70041 001 SEP 06, 1985
	800MG	N71911 001 OCT 13, 1987

IBUPROFEN

TABLET; ORAL
MIDOL

BAYER	200MG	N70591 001 SEP 02, 1987
	200MG	N71001 001 SEP 02, 1987

NUPRIN

BRISTOL MYERS	200MG	N72035 001 FEB 16, 1988
	200MG	N72036 001 FEB 16, 1988
MCNEIL	200MG	N19012 001 MAY 18, 1984
	200MG	N19012 002 JUL 29, 1987

RUFEN

BASF	600MG	N18197 002 MAR 05, 1984

IDOXURIDINE

OINTMENT; OPHTHALMIC
STOXIL

GLAXOSMITHKLINE	0.5%	N15868 001

SOLUTION/DROPS; OPHTHALMIC
STOXIL

GLAXOSMITHKLINE	0.1%	N13934 001

IFOSFAMIDE

INJECTABLE; INJECTION
IFEX

BRISTOL MYERS SQUIBB	1GM/VIAL	N19763 001 DEC 30, 1988
	3GM/VIAL	N19763 002 DEC 30, 1988

IMIPRAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
TOFRANIL

NOVARTIS	12.5MG/ML	N11838 002

FDA data supplied by DrugPatentWatch.com

IMIPRAMINE HYDROCHLORIDE

TABLET; ORAL

IMIPRAMINE HCL		
EON	10MG	N85200 001
	25MG	N84869 002
	50MG	N85133 001
LEDERLE	10MG	N86269 001
	25MG	N86267 001
	50MG	N86268 001
ROXANE	25MG	N83799 002
	50MG	N83799 003
USL PHARMA	25MG	N87776 001 FEB 10, 1982
VANGARD	10MG	N88036 001 NOV 03, 1982
	25MG	N87619 001 FEB 09, 1982
	50MG	N87631 001 JAN 04, 1982
WATSON LAB	10MG	N85220 001
	25MG	N84252 002
	50MG	N85221 001
WATSON LABS	10MG	N85875 001
	25MG	N85878 001
	50MG	N85877 001
WEST WARD	25MG	N88222 001 MAY 26, 1983
	50MG	N88223 001 MAY 26, 1983
JANIMINE		
ABBOTT	10MG	N17895 001
	25MG	N17895 002
	50MG	N17895 003
PRAMINE		
ALRA	10MG	N83827 001
	25MG	N83827 002
	50MG	N83827 003
PRESAMINE		
AVENTIS	10MG	N11836 006
	25MG	N11836 003
	50MG	N11836 007

INDAPAMIDE

TABLET; ORAL

INDAPAMIDE		
TEVA	1.25MG	N74665 001 APR 04, 1997

INDAPAMIDE

TABLET; ORAL

INDAPAMIDE		
TEVA	2.5MG	N74665 002 APR 04, 1997

INDECAINIDE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

DECABID		
LILLY	EQ 50MG BASE	N19693 001 DEC 29, 1989
	EQ 75MG BASE	N19693 002 DEC 29, 1989
	EQ 100MG BASE	N19693 003 DEC 29, 1989

INDOCYANINE GREEN

INJECTABLE; INJECTION

CARDIO-GREEN		
AKORN	10MG/VIAL	N11525 003
	40MG/VIAL	N11525 004

INDOMETHACIN

CAPSULE; ORAL

INDOMETHACIN		
DANBURY PHARMA	25MG	N72996 001 JUL 31, 1991
	50MG	N72997 001 JUL 31, 1991
DURAMED	25MG	N70326 001 OCT 18, 1985
	50MG	N70327 001 OCT 18, 1985
HALSEY	25MG	N70067 001 OCT 03, 1986
	25MG	N70782 001 JUN 03, 1987
	50MG	N70068 001 OCT 03, 1986
	50MG	N70635 001 JUN 03, 1987

FDA data supplied by DrugPatentWatch.com

INDOMETHACIN

CAPSULE; ORAL

INDOMETHACIN			
IVAX PHARMS	25MG	N18730 001	MAY 04, 1984
	50MG	N18730 002	MAY 04, 1984
PARKE DAVIS	25MG	N18806 001	NOV 23, 1984
	50MG	N18806 002	NOV 23, 1984
PIONEER PHARMS	25MG	N70813 001	AUG 11, 1986
	50MG	N70592 001	AUG 11, 1986
ROXANE	25MG	N70353 001	JUN 18, 1985
	50MG	N70354 001	JUN 18, 1985
SUPERPHARM	25MG	N70487 001	OCT 10, 1986
	50MG	N70488 001	OCT 10, 1986
WATSON LAB	25MG	N70784 001	AUG 20, 1986
	50MG	N70785 001	AUG 20, 1986
WATSON LABS	25MG	N18690 001	JUL 31, 1984
	25MG	N70529 001	OCT 18, 1985
	50MG	N18690 002	JUL 31, 1984
	50MG	N70530 001	OCT 18, 1985
	50MG	N71635 001	MAY 18, 1987

CAPSULE, EXTENDED RELEASE; ORAL

INDOCIN SR			
MERCK	75MG	N18185 001	FEB 23, 1982

INSULIN PORK

INJECTABLE; INJECTION

INSULIN			
NOVO NORDISK	40 UNITS/ML	N17926 001	

INSULIN PORK

INJECTABLE; INJECTION

REGULAR INSULIN			
NOVO NORDISK	100 UNITS/ML	N17926 003	

INSULIN PURIFIED BEEF

INJECTABLE; INJECTION

REGULAR ILETIN II			
LILLY	100 UNITS/ML	N18478 001	

INSULIN PURIFIED PORK

INJECTABLE; INJECTION

VELOSULIN			
NOVO NORDISK	100 UNITS/ML	N18193 001	

INSULIN PURIFIED PORK; INSULIN SUSP ISOPHANE PURIFIED PORK

INJECTABLE; INJECTION

INSULIN NORDISK MIXTARD (PORK)			
NOVO NORDISK	30 UNITS/ML;70 UNITS/ML	N18195 001	

INSULIN RECOMBINANT HUMAN

INJECTABLE; INJECTION

HUMULIN BR			
LILLY	100 UNITS/ML	N19529 001	APR 28, 1986

INSULIN RECOMBINANT PURIFIED HUMAN

INJECTABLE; INJECTION

NOVOLIN R			
NOVO NORDISK	100 UNITS/ML	N18778 001	AUG 30, 1983
VELOSULIN BR HUMAN			
NOVO NORDISK	100 UNITS/ML	N19450 001	MAY 30, 1986

FDA data supplied by DrugPatentWatch.com

INSULIN RECOMBINANT PURIFIED HUMAN; INSULIN SUSP ISOPHANE SEMISYNTHETIC PURIFIED HUMAN

INJECTABLE; INJECTION

MIXTARD HUMAN 70/30

NOVO NORDISK	30 UNITS/ML;70 UNITS/ML	N19585 001 MAR 11, 1988

NOVOLIN 70/30

NOVO NORDISK	30 UNITS/ML;70 UNITS/ML	N19441 001 JUL 11, 1986

INSULIN SUSP ISOPHANE BEEF

INJECTABLE; INJECTION

NPH INSULIN

NOVO NORDISK	40 UNITS/ML	N17929 001

INSULIN SUSP ISOPHANE BEEF/PORK

INJECTABLE; INJECTION

NPH ILETIN I (BEEF-PORK)

LILLY	40 UNITS/ML	N17936 001

INSULIN SUSP ISOPHANE PURIFIED BEEF

INJECTABLE; INJECTION

NPH ILETIN II

LILLY	100 UNITS/ML	N18479 001

INSULIN SUSP ISOPHANE PURIFIED PORK

INJECTABLE; INJECTION

INSULIN INSULATARD NPH NORDISK

NOVO NORDISK	100 UNITS/ML	N18194 001

INSULIN SUSP ISOPHANE PURIFIED PORK; *MULTIPLE*
SEE INSULIN PURIFIED PORK; INSULIN SUSP ISOPHANE PURIFIED PORK

INSULIN SUSP ISOPHANE SEMISYNTHETIC PURIFIED HUMAN

INJECTABLE; INJECTION

INSULATARD NPH HUMAN

NOVO NORDISK	100 UNITS/ML	N19449 001 MAY 30, 1986

INSULIN SUSP ISOPHANE SEMISYNTHETIC PURIFIED HUMAN

INJECTABLE; INJECTION

NOVOLIN N

NOVO NORDISK	100 UNITS/ML	N19065 001 JAN 23, 1985

INSULIN SUSP ISOPHANE SEMISYNTHETIC PURIFIED HUMAN; *MULTIPLE*
SEE INSULIN RECOMBINANT PURIFIED HUMAN; INSULIN SUSP ISOPHANE SEMISYNTHETIC PURIFIED HUMAN

INSULIN SUSP PROTAMINE ZINC BEEF/PORK

INJECTABLE; INJECTION

PROTAMINE, ZINC & ILETIN I (BEEF-PORK)

LILLY	40 UNITS/ML	N17932 001
	100 UNITS/ML	N17932 002

INSULIN SUSP PROTAMINE ZINC PURIFIED BEEF

INJECTABLE; INJECTION

PROTAMINE ZINC AND ILETIN II

LILLY	100 UNITS/ML	N18476 001

PROTAMINE ZINC INSULIN

BRISTOL MYERS SQUIBB	40 UNITS/ML	N17928 001
	100 UNITS/ML	N17928 003

INSULIN SUSP PROTAMINE ZINC PURIFIED PORK

INJECTABLE; INJECTION

PROTAMINE ZINC AND ILETIN II (PORK)

LILLY	100 UNITS/ML	N18346 001

INSULIN ZINC SUSP BEEF

INJECTABLE; INJECTION

LENTE INSULIN

NOVO NORDISK	40 UNITS/ML	N17998 001
	100 UNITS/ML	N17998 003

FDA data supplied by DrugPatentWatch.com

INSULIN ZINC SUSP EXTENDED BEEF

INJECTABLE; INJECTION
ULTRALENTE INSULIN
NOVO NORDISK 100 UNITS/ML N17997 003

INSULIN ZINC SUSP EXTENDED PURIFIED BEEF

INJECTABLE; INJECTION
ULTRALENTE
NOVO NORDISK 100 UNITS/ML N18385 001

INSULIN ZINC SUSP EXTENDED RECOMBINANT HUMAN

INJECTABLE; INJECTION
HUMULIN U
LILLY 40 UNITS/ML N19571 001
JUN 10, 1987

INSULIN ZINC SUSP PROMPT BEEF

INJECTABLE; INJECTION
SEMILENTE INSULIN
NOVO NORDISK 100 UNITS/ML N17996 003

INSULIN ZINC SUSP PROMPT PURIFIED PORK

INJECTABLE; INJECTION
SEMILENTE
NOVO NORDISK 100 UNITS/ML N18382 001

INSULIN ZINC SUSP PURIFIED BEEF

INJECTABLE; INJECTION
LENTE ILETIN II
LILLY 100 UNITS/ML N18477 001

INSULIN ZINC SUSP PURIFIED BEEF/PORK

INJECTABLE; INJECTION
LENTARD
NOVO NORDISK 100 UNITS/ML N18384 001

INSULIN ZINC SUSP SEMISYNTHETIC PURIFIED HUMAN

INJECTABLE; INJECTION
NOVOLIN L
NOVO NORDISK 100 UNITS/ML N18777 001
AUG 30, 1983

INTRINSIC FACTOR; *MULTIPLE*
SEE COBALT CHLORIDE, CO-60; CYANOCOBALAMIN; CYANOCOBALAMIN, CO-60; INTRINSIC FACTOR

INVERT SUGAR

INJECTABLE; INJECTION
TRAVERT 10% IN PLASTIC CONTAINER
BAXTER HLTHCARE 10GM/100ML N16717 001

IOCETAMIC ACID

TABLET; ORAL
CHOLEBRINE
MALLINCKRODT 750MG N17129 001

IODAMIDE MEGLUMINE

INJECTABLE; INJECTION
RENOVUE-65
BRACCO 65% N17902 001
RENOVUE-DIP
BRACCO 24% N17903 001

IODIPAMIDE SODIUM

INJECTABLE; INJECTION
CHOLOGRAFIN SODIUM
BRACCO 20% N09321 001

IODOHIPPURATE SODIUM, I-123

INJECTABLE; INJECTION
NEPHROFLOW
AMERSHAM HLTH 1mCi/ML N18289 001
DEC 28, 1984

FDA data supplied by DrugPatentWatch.com

IODOHIPPURATE SODIUM, I-131

INJECTABLE; INJECTION
HIPPUTOPE
BRACCO 1-2mCi/VIAL N15419 002
IODOHIPPURATE SODIUM I 131
CIS 0.2mCi/ML N17313 001

IODOXAMATE MEGLUMINE

INJECTABLE; INJECTION
CHOLOVUE
BRACCO 9.9% N18077 001
40.3% N18076 001

IOPAMIDOL

INJECTABLE; INJECTION
IOPAMIDOL-300
ABBOTT 61% N74638 001
APR 30, 1997

ISOVUE-200
BRACCO 41% N20327 001
OCT 12, 1994

IOPHENDYLATE

INJECTABLE; INJECTION
PANTOPAQUE
ALCON 100% N05319 001

IOTHALAMATE SODIUM

INJECTABLE; INJECTION
ANGIO-CONRAY
MALLINCKRODT 80% N13319 001

IOTROLAN

INJECTABLE; INTRATHECAL
OSMOVIST 190
BERLEX LABS 40.6% N19580 001
DEC 07, 1989

IOTROLAN

INJECTABLE; INTRATHECAL
OSMOVIST 240
BERLEX LABS 51.3% N19580 002
DEC 07, 1989

IPODATE CALCIUM

GRANULE; ORAL
ORAGRAFIN CALCIUM
BRACCO 3GM/PACKET N12968 001

IPODATE SODIUM

CAPSULE; ORAL
BILIVIST
BERLEX 500MG N87768 001
AUG 11, 1982

IRBESARTAN; *MULTIPLE*
SEE HYDROCHLOROTHIAZIDE; IRBESARTAN

IRON DEXTRAN

INJECTABLE; INJECTION
IRON DEXTRAN
FISONS EQ 50MG IRON/ML N10787 002

ISOETHARINE HYDROCHLORIDE

SOLUTION; INHALATION
BRONKOSOL
SANOFI SYNTHELABO 0.25% N12339 009
1% N12339 008

ISOETHARINE HCL
ALPHARMA 1% N87101 001
ASTRAZENECA 0.062% N87937 001
NOV 15, 1982
0.062% N89614 001
JUN 13, 1991
0.125% N87938 001
NOV 15, 1982

FDA data supplied by DrugPatentWatch.com

ISOETHARINE HYDROCHLORIDE

SOLUTION; INHALATION
ISOETHARINE HCL
ASTRAZENECA 0.125% N89615 001 JUN 13, 1991
0.167% N88470 001 MAR 14, 1984
0.167% N89616 001 JUN 13, 1991
0.2% N88471 001 MAR 14, 1984
0.2% N89617 001 JUN 13, 1991
0.25% N88472 001 MAR 14, 1984
0.25% N89618 001 JUN 13, 1991
BAXTER HLTHCARE 0.08% N88144 001 JUL 29, 1983
0.14% N88145 001 MAR 26, 1984
0.25% N88146 001 AUG 01, 1983
DEY 0.08% N88187 001 DEC 03, 1982
0.17% N87390 001
0.25% N88188 001 DEC 03, 1982
1% N86763 001
INTL MEDICATION 0.077% N86651 001
0.1% N86651 003
0.167% N86651 005
0.2% N86651 006
0.25% N86651 007
1% N86651 008
PARKE DAVIS 0.5% N85997 001
1% N85889 001
ROXANE 0.1% N87396 001
0.125% N87025 001
0.25% N88275 001 JUN 03, 1983

ISOETHARINE HCL S/F
DEY 0.08% N89817 001 NOV 22, 1988
0.1% N89818 001 NOV 22, 1988
0.17% N89819 001 NOV 22, 1988

ISOETHARINE HYDROCHLORIDE

SOLUTION; INHALATION
ISOETHARINE HCL S/F
DEY 0.25% N89820 001 NOV 22, 1988
1% N89252 001 SEP 15, 1986

ISOETHARINE MESYLATE

AEROSOL, METERED; INHALATION
BRONKOMETER
SANOFI SYNTHELABO 0.34MG/INH N12339 007
ISOETHARINE MESYLATE
ALPHARMA 0.34MG/INH N87858 001 AUG 21, 1984

ISOFLUROPHATE

OINTMENT; OPHTHALMIC
FLOROPRYL
MERCK 0.025% N10656 001

ISONIAZID

INJECTABLE; INJECTION
ISONIAZID
QUAD PHARMS 100MG/ML N89816 001 OCT 28, 1988
RIMIFON
ROCHE 25MG/ML N08420 002
100MG/ML N08420 003

SYRUP; ORAL
ISONIAZID
MIKART 50MG/5ML N81118 001 JUL 21, 1997
LANIAZID
LANNETT 50MG/5ML N89243 001 FEB 03, 1986
RIMIFON
ROCHE 50MG/5ML N08420 001

TABLET; ORAL
DOW-ISONIAZID
DOW PHARM 300MG N80330 002

FDA data supplied by DrugPatentWatch.com

ISONIAZID

TABLET; ORAL

HYZYD		
WALLACE LABS	100MG	N80134 003
	300MG	N80134 004
INH		
NOVARTIS	300MG	N80935 001
ISONIAZID		
ANABOLIC	100MG	N84050 001
DANBURY PHARMA	50MG	N80522 001
	100MG	N80523 001
DURAMED	100MG	N88231 001
		MAR 17, 1983
HALSEY	50MG	N83632 001
	100MG	N80136 001
IMPAX LABS	100MG	N80153 001
IVAX PHARMS	100MG	N80270 001
	300MG	N83610 001
LILLY	100MG	N08499 002
	300MG	N08499 003
MK LABS	100MG	N80941 001
PANRAY	50MG	N08428 001
	100MG	N08428 002
	300MG	N08428 003
PERRIGO	100MG	N83060 001
PHARMAVITE	100MG	N85091 001
PHOENIX LABS NY	50MG	N80368 001
	100MG	N80368 002
PUREPAC PHARM	50MG	N80132 003
		JUL 14, 1982
	100MG	N80132 004
		JUL 14, 1982
WATSON LAB	100MG	N80401 001
	300MG	N83178 001
WATSON LABS	100MG	N85790 001
	300MG	N85784 001
WHITEWORTH TOWN PLSN	100MG	N80120 002
NYDRAZID		
BRISTOL MYERS SQUIBB	100MG	N08392 003
STANOZIDE		
EVERYLIFE	100MG	N80126 001
	300MG	N80126 002

ISOPROPAMIDE IODIDE

TABLET; ORAL

DARBID		
GLAXOSMITHKLINE	EQ 5MG BASE	N10744 001

ISOPROTERENOL HYDROCHLORIDE

AEROSOL, METERED; INHALATION

ISOPROTERENOL HCL		
ALPHARMA	0.12MG/INH	N85904 001
ISUPREL		
SANOFI SYNTHELABO	0.103MG/INH	N11178 001

DISC; INHALATION

NORISODRINE AEROTROL		
ABBOTT	0.25%	N16814 001

INJECTABLE; INJECTION

ISOPROTERENOL HCL		
AM PHARM PARTNERS	0.2MG/ML	N83431 001

SOLUTION; INHALATION

AEROLONE		
LILLY	0.25%	N07245 001
ISOPROTERENOL HCL		
ARMOUR PHARM	0.031%	N87935 001
		NOV 18, 1982
	0.062%	N87936 001
		NOV 18, 1982
DEY	0.5%	N86764 001
		JAN 04, 1982
PARKE DAVIS	0.25%	N85994 001
	0.5%	N85540 001
ISUPREL		
SANOFI SYNTHELABO	0.5%	N06327 002
	1%	N06327 003
VAPO-ISO		
FISONS	0.5%	N16813 001

TABLET; RECTAL, SUBLINGUAL

ISUPREL		
SANOFI SYNTHELABO	10MG	N06328 001
	15MG	N06328 002

ISOPROTERENOL HYDROCHLORIDE; *MULTIPLE*

SEE ACETYLCYSTEINE; ISOPROTERENOL HYDROCHLORIDE

ISOPROTERENOL HYDROCHLORIDE; PHENYLEPHRINE BITARTRATE

AEROSOL, METERED; INHALATION

DUO-MEDIHALER		
3M	0.16MG/INH;0.24MG/INH	N13296 001

FDA data supplied by DrugPatentWatch.com

ISOPROTERENOL SULFATE

POWDER; INHALATION
NORISODRINE
ABBOTT 10% N06905 003
25% N06905 002

ISOSORBIDE DINITRATE

TABLET; ORAL
ISOSORBIDE DINITRATE
HALSEY 5MG N86166 002
SEP 19, 1986
10MG N86169 001
SEP 19, 1986
20MG N86167 001
SEP 19, 1986
30MG N87564 001
SEP 18, 1986
SUPERPHARM 5MG N89190 001
FEB 17, 1987
10MG N89191 001
FEB 17, 1987
20MG N89192 001
FEB 17, 1987
SORBITRATE
ASTRAZENECA 30MG N88124 001
AUG 21, 1990

TABLET; SUBLINGUAL
ISOSORBIDE DINITRATE
HALSEY 2.5MG N84204 001
SEP 18, 1986
5MG N86168 001
SEP 18, 1986
10MG N87545 001
SEP 18, 1986
SORBITRATE
ASTRAZENECA 2.5MG N16191 002
APR 01, 1996
5MG N16191 001
APR 01, 1996

TABLET, EXTENDED RELEASE; ORAL
ISORDIL
WYETH AYERST 40MG N12882 001
JUL 29, 1988

KANAMYCIN SULFATE

CAPSULE; ORAL
KANTREX
APOTHECON EQ 500MG BASE N60516 001
EQ 500MG BASE N61911 001

INJECTABLE; INJECTION
KANAMYCIN
ELKINS SINN EQ 75MG BASE/2ML N62324 001
EQ 500MG BASE/2ML N62324 002
EQ 1GM BASE/3ML N62324 003
KANAMYCIN SULFATE
AM PHARM PARTNERS EQ 75MG BASE/2ML N62504 001
APR 05, 1984
EQ 500MG BASE/2ML N62504 002
APR 05, 1984
EQ 1GM BASE/3ML N62504 003
APR 05, 1984
INTL MEDICATION EQ 500MG BASE/2ML N62466 001
SEP 30, 1983
EQ 1GM BASE/3ML N62466 002
SEP 30, 1983
LOCH EQ 1GM BASE/3ML N63025 001
JUL 31, 1992
EQ 75MG BASE/2ML N63021 001
JUL 31, 1992
EQ 500MG BASE/2ML N63022 001
JUL 31, 1992
PHARMAFAIR EQ 1GM BASE/3ML N62669 001
MAY 07, 1987
EQ 75MG BASE/2ML N62668 001
MAY 07, 1987
EQ 500MG BASE/2ML N62672 001
MAY 07, 1987
QUAD PHARMS EQ 75MG BASE/2ML N62642 001
FEB 03, 1986
EQ 500MG BASE/2ML N62642 002
FEB 03, 1986
EQ 1GM BASE/3ML N62642 003
FEB 03, 1986
SOLOPAK EQ 75MG BASE/2ML N62605 003
FEB 26, 1986
EQ 500MG BASE/2ML N62605 001
FEB 26, 1986
EQ 1GM BASE/3ML N62605 002
FEB 26, 1986
STERIS EQ 1GM BASE/3ML N62520 003
MAY 09, 1985

FDA data supplied by DrugPatentWatch.com

KANAMYCIN SULFATE

INJECTABLE; INJECTION		
KANAMYCIN SULFATE		
WARNER CHILCOTT	EQ 1GM BASE/3ML	N63092 001 OCT 11, 1989
KANTREX		
APOTHECON	EQ 75MG BASE/2ML	N61655 003
	EQ 75MG BASE/2ML	N62564 001 SEP 21, 1984
	EQ 500MG BASE/2ML	N61655 001
	EQ 500MG BASE/2ML	N62564 002 SEP 21, 1984
	EQ 1GM BASE/3ML	N61655 002
	EQ 1GM BASE/3ML	N62564 003 SEP 21, 1984
KLEBCIL		
KING PHARMS	EQ 75MG BASE/2ML	N62170 001
	EQ 500MG BASE/2ML	N62170 002
	EQ 1GM BASE/3ML	N62170 003

KETAMINE HYDROCHLORIDE

INJECTABLE; INJECTION		
KETAMINE HCL		
QUAD PHARMS	EQ 10MG BASE/ML	N71949 001 APR 11, 1988
	EQ 50MG BASE/ML	N71950 001 APR 11, 1988
	EQ 100MG BASE/ML	N71951 001 APR 11, 1988

KETOCONAZOLE

SUSPENSION; ORAL		
NIZORAL		
JANSSEN	100MG/5ML	N70767 001 NOV 07, 1986

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION		
KETOROLAC TROMETHAMINE		
APOTHECON	15MG/ML	N75348 001 NOV 28, 2000

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION		
KETOROLAC TROMETHAMINE		
APOTHECON	30MG/ML	N75348 002 NOV 28, 2000
BEDFORD	15MG/ML	N75230 002 OCT 25, 1999
	30MG/ML	N75230 001 OCT 25, 1999
TABLET; ORAL		
KETOROLAC TROMETHAMINE		
ROXANE	10MG	N74790 001 JUN 26, 1997

LABETALOL HYDROCHLORIDE

INJECTABLE; INJECTION		
LABETALOL HCL		
APOTHECON	5MG/ML	N75355 001 NOV 29, 1999
TABLET; ORAL		
NORMODYNE		
SCHERING	400MG	N18687 004 AUG 01, 1984
TRANDATE		
PROMETHEUS LABS	400MG	N18716 004 AUG 01, 1984

LABETALOL HYDROCHLORIDE; *MULTIPLE*

SEE HYDROCHLOROTHIAZIDE; LABETALOL HYDROCHLORIDE

LACTULOSE

SOLUTION; ORAL		
DUPHALAC		
SOLVAY	10GM/15ML	N72372 001 MAR 22, 1989
LACTULOSE		
MORTON GROVE	10GM/15ML	N71841 001 SEP 22, 1988
PACO	10GM/15ML	N73160 001 AUG 25, 1992

FDA data supplied by DrugPatentWatch.com

LACTULOSE

SOLUTION; ORAL, RECTAL

GENERLAC		
MORTON GROVE	10GM/15ML	N71842 001 SEP 27, 1988
LACTULOSE		
PACO	10GM/15ML	N72029 001 AUG 25, 1992
ROXANE	10GM/15ML	N73590 001 MAY 29, 1992
SOLVAY	10GM/15ML	N17906 001
PORTALAC		
SOLVAY	10GM/15ML	N72374 001 MAR 22, 1989

LAMOTRIGINE

TABLET; ORAL

LAMICTAL		
GLAXOSMITHKLINE	50MG	N20241 006 DEC 27, 1994
	250MG	N20241 004 DEC 27, 1994

LEUCOVORIN CALCIUM

FOR SOLUTION; ORAL

LEUCOVORIN CALCIUM		
IMMUNEX	EQ 60MG BASE/VIAL	N08107 003 JAN 30, 1987

INJECTABLE; INJECTION

LEUCOVORIN CALCIUM		
ABIC	EQ 3MG BASE/ML	N89352 001 JUN 01, 1988
	EQ 50MG BASE/VIAL	N89353 001 JUN 01, 1988
AM PHARM PARTNERS	EQ 50MG BASE/VIAL	N88939 001 DEC 01, 1986
IMMUNEX	EQ 3MG BASE/ML	N08107 001
QUAD PHARMS	EQ 5MG BASE/ML	N89503 001 OCT 05, 1987
	EQ 5MG BASE/ML	N89504 001 DEC 22, 1987
	EQ 50MG BASE/VIAL	N89496 001 MAR 05, 1987

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION

LEUCOVORIN CALCIUM		
QUAD PHARMS	EQ 100MG BASE/VIAL	N89636 001 DEC 24, 1987
WELLCOVORIN		
GLAXOSMITHKLINE	EQ 25MG BASE/VIAL	N89833 001 JAN 23, 1989
	EQ 50MG BASE/VIAL	N89465 001 JAN 23, 1989
	EQ 100MG BASE/VIAL	N89834 001 JAN 23, 1989

TABLET; ORAL

LEUCOVORIN CALCIUM		
PAR PHARM	EQ 5MG BASE	N71600 001 OCT 14, 1987
	EQ 25MG BASE	N71598 001 OCT 14, 1987
WELLCOVORIN		
GLAXOSMITHKLINE	EQ 5MG BASE	N18342 001 JUL 08, 1983
	EQ 25MG BASE	N18342 002 JUL 08, 1983

LEUPROLIDE ACETATE

INJECTABLE; INJECTION

LUPRON DEPOT-PED		
TAP PHARM	3.75MG/VIAL,7.5MG/VIAL	N20263 003 APR 16, 1993
	7.5MG/VIAL,7.5MG/VIAL	N20263 004 APR 16, 1993

LEVALLORPHAN TARTRATE

INJECTABLE; INJECTION

LORFAN		
ROCHE	1MG/ML	N10423 001

LEVODOPA

CAPSULE; ORAL

BENDOPA		
ICN	100MG	N16948 003

FDA data supplied by DrugPatentWatch.com

LEVODOPA

CAPSULE; ORAL
BENDOPA
ICN 250MG N16948 001
500MG N16948 002
DOPAR
SHIRE LABS 100MG N16913 003
250MG N16913 001
500MG N16913 002
LARODOPA
ROCHE 100MG N16912 002
250MG N16912 001
500MG N16912 006

TABLET; ORAL
DOPAR
SHIRE LABS 250MG N16913 004
500MG N16913 005

LEVODOPA; *MULTIPLE*
SEE CARBIDOPA; LEVODOPA

LEVONORDEFRIN; MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION
ARESTOCAINE HCL W/ LEVONORDEFRIN
SOLVAY 0.05MG/ML;2% N85010 001

LEVONORDEFRIN; PROCAINE HYDROCHLORIDE; PROPOXYCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
RAVOCAINE AND NOVOCAIN W/ NEO-COBEFRIN
EASTMAN KODAK 0.05MG/ML;2%;0.4% N08592 007

LEVONORGESTREL

IMPLANT; IMPLANTATION
NORPLANT
POPULATION COUNCIL 36MG/IMPLANT N19897 001
DEC 10, 1990

LEVOPROPOXYPHENE NAPSYLATE, ANHYDROUS

CAPSULE; ORAL
NOVRAD
LILLY EQ 50MG BASE N12928 006
EQ 100MG BASE N12928 004

SUSPENSION; ORAL
NOVRAD
LILLY EQ 50MG BASE/5ML N12928 002

LIDOCAINE

OINTMENT; TOPICAL
ALPHACAINE
CARLISLE 5% N84944 001
5% N84946 001

SUPPOSITORY; RECTAL
XYLOCAINE
ASTRAZENECA 100MG N13077 001

LIDOCAINE; *MULTIPLE*
SEE BACITRACIN ZINC; LIDOCAINE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
ALPHACAINE HCL
CARLISLE 2% N84721 001
LIDOCAINE HCL
ABBOTT 1.5% N88330 001
MAY 17, 1984
10% N87980 001
FEB 02, 1983
20% N89362 001
MAY 25, 1988
AKORN 1% N85037 001
2% N85037 002
AM PHARM PARTNERS 1% N80390 001
1% N80420 001
1% N86761 001
1.5% N80420 005
2% N17508 001
2% N80390 002

FDA data supplied by DrugPatentWatch.com

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
LIDOCAINE HCL

AM PHARM PARTNERS	2%	N80420 002
	2%	N80420 004
	2%	N86761 002
	4%	N17508 002
	20%	N17508 004
BEL MAR	1%	N80710 001
	2%	N80760 001
DELL LABS	1%	N83387 001
	2%	N83388 001
ELKINS SINN	0.5%	N85131 001
	4%	N84626 001
GD SEARLE LLC	1%	N83135 001
	2%	N83135 002
INTL MEDICATION	1%	N17701 002
	1GM/VIAL	N18543 001
	2%	N17701 001
	2GM/VIAL	N18543 002
MILES	1%	N80414 001
	2%	N80414 002
STERIS	1%	N80377 001
	1%	N83627 001
	2%	N80377 002
	2%	N83627 002

LIDOCAINE HCL 0.1% AND DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	100MG/100ML	N18461 001

LIDOCAINE HCL 0.2% IN DEXTROSE 5% IN PLASTIC CONTAINER

ABBOTT	200MG/100ML	N18954 001
		JUL 09, 1985

LIDOCAINE HCL PRESERVATIVE FREE

INTL MEDICATION	4%	N17702 002

LIDOCATON

PHARMATON	2%	N84727 001
		AUG 17, 1983

XYLOCAINE

ASTRAZENECA	1%	N10418 005
	1.5%	N10418 009
	2%	N06488 002
	2%	N10418 007

SOLUTION; ORAL
LIDOCAINE HCL VISCOUS

INTL MEDICATION	2%	N86389 001
		FEB 02, 1982

LIDOCAINE HYDROCHLORIDE

SOLUTION; TOPICAL
LARYNGOTRACHEAL ANESTHESIA KIT

KENDALL IL	4%	N87931 001
		JUN 10, 1983

LIDOCAINE HCL

PACO	4%	N89688 001
		JUN 30, 1989

PEDIATRIC LTA KIT

ABBOTT	2%	N88572 001
		JUL 31, 1984

LIDOCAINE HYDROCHLORIDE; *MULTIPLE*
SEE DIHYDROERGOTAMINE MESYLATE; HEPARIN SODIUM; LIDOCAINE HYDROCHLORIDE
SEE EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

LINCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION
LINCOMYCIN HCL

QUAD PHARMS	EQ 300MG BASE/ML	N62784 001
		MAR 14, 1988
STERIS	EQ 300MG BASE/ML	N63180 001
		APR 16, 1991

LINDANE

CREAM; TOPICAL
KWELL

REED AND CARNRICK	1%	N06309 001
	1%	N84218 001

LOTION; TOPICAL
GAMENE

SOLA BARNES HIND	1%	N84989 001

KWELL

REED AND CARNRICK	1%	N06309 003
	1%	N84218 002

SCABENE

STIEFEL	1%	N86769 001

SHAMPOO; TOPICAL
GAMENE

SOLA BARNES HIND	1%	N84988 001

FDA data supplied by DrugPatentWatch.com

LINDANE

SHAMPOO; TOPICAL		
KWELL		
REED AND CARNRICK	1%	N10718 001
	1%	N84219 001
SCABENE		
STIEFEL	1%	N87940 001 APR 08, 1983

LIOTHYRONINE SODIUM

TABLET; ORAL		
LIOTHYRONINE SODIUM		
WATSON LAB	EQ 0.025MG BASE	N85755 001 JAN 25, 1982
	EQ 0.05MG BASE	N85753 001 FEB 03, 1982

LIOTRIX (T4;T3)

TABLET; ORAL		
EUTHROID-0.5		
PARKE DAVIS	0.03MG;0.0075MG	N16680 001
EUTHROID-1		
PARKE DAVIS	0.06MG;0.015MG	N16680 002
EUTHROID-2		
PARKE DAVIS	0.12MG;0.03MG	N16680 003
EUTHROID-3		
PARKE DAVIS	0.18MG;0.045MG	N16680 004
THYROLAR-5		
FORREST LABS	0.25MG;0.0625MG	N16807 006

LITHIUM CARBONATE

CAPSULE; ORAL		
LITHIUM CARBONATE		
USL PHARMA	300MG	N72542 001 FEB 01, 1989
WATSON LAB	300MG	N70407 001 MAR 19, 1987
LITHONATE		
SOLVAY	300MG	N16782 001
TABLET; ORAL		
ESKALITH		
GLAXOSMITHKLINE	300MG	N17971 001

LITHIUM CARBONATE

TABLET; ORAL		
LITHANE		
BAYER	300MG	N18833 001 JUL 18, 1985
LITHOTABS		
SOLVAY	300MG	N16980 001

LITHIUM CITRATE

SYRUP; ORAL		
LITHONATE		
SOLVAY	EQ 300MG CARBONATE/5ML	N17672 001

LOPERAMIDE HYDROCHLORIDE

CAPSULE; ORAL		
IMODIUM		
MCNEIL CONS	2MG	N17690 001
LOPERAMIDE HCL		
ROXANE	2MG	N73080 001 NOV 27, 1991
SOLUTION; ORAL		
IMODIUM		
JANSSEN	1MG/5ML	N19037 001 JUL 31, 1984
LOPERAMIDE HCL		
ALPHARMA	1MG/5ML	N73187 001 SEP 15, 1992
WATSON LABS	1MG/5ML	N73062 001 MAY 28, 1993
TABLET; ORAL		
LOPERAMIDE HCL		
ABLE	2MG	N73528 001 NOV 30, 1993

LORAZEPAM

TABLET; ORAL		
LORAZ		
QUANTUM PHARMICS	0.5MG	N70200 001 AUG 09, 1985

FDA data supplied by DrugPatentWatch.com

LORAZEPAM

TABLET; ORAL

LORAZ		
QUANTUM PHARMICS	1MG	N70201 001 AUG 09, 1985
	2MG	N70202 001 AUG 09, 1985
LORAZEPAM		
AM THERAP	0.5MG	N70727 001 MAR 07, 1986
	1MG	N70728 001 MAR 07, 1986
	2MG	N70729 001 MAR 07, 1986
HALSEY	0.5MG	N70472 001 DEC 10, 1985
	0.5MG	N71434 001 SEP 01, 1987
	1MG	N70473 001 DEC 10, 1985
	1MG	N71435 001 SEP 01, 1987
	2MG	N70474 001 DEC 10, 1985
	2MG	N71436 001 SEP 01, 1987
PAR PHARM	0.5MG	N70675 001 DEC 01, 1986
	1MG	N70676 001 DEC 01, 1986
	2MG	N70677 001 DEC 01, 1986
SUPERPHARM	0.5MG	N71245 001 FEB 09, 1987
	1MG	N71246 001 FEB 09, 1987
	2MG	N71247 001 FEB 09, 1987
USL PHARMA	1MG	N70539 001 DEC 22, 1986
	2MG	N70540 001 DEC 22, 1986
WARNER CHILCOTT	1MG	N71038 001 JAN 12, 1988
	2MG	N71039 001 JAN 12, 1988
WATSON LABS	0.5MG	N71086 001 MAR 23, 1987

LOTEPREDNOL ETABONATE

SUSPENSION/DROPS; OPHTHALMIC

LOTEMAX		
PHARMOS	0.5%	N20841 001 MAR 09, 1998

LOXAPINE SUCCINATE

TABLET; ORAL

LOXITANE		
WATSON LABS	EQ 10MG BASE	N17525 006
	EQ 25MG BASE	N17525 007
	EQ 50MG BASE	N17525 008

LYPRESSIN

SOLUTION; NASAL

DIAPID		
NOVARTIS	0.185MG/ML	N16755 001

MAGNESIUM ACETATE; *MULTIPLE*

SEE AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; SODIUM CHLORIDE

SEE AMINO ACIDS; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE

SEE AMINO ACIDS; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

MAGNESIUM CHLORIDE; *MULTIPLE*

SEE AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

SEE AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM ACETATE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

SEE AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

SEE AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

SEE AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM ACETATE; POTASSIUM CHLORIDE; SODIUM ACETATE

SEE AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

SEE AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

FDA data supplied by DrugPatentWatch.com

MAGNESIUM CHLORIDE; *MULTIPLE*

SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SEE CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SEE CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INJECTION

ISOLYTE S PH 7.4 IN PLASTIC CONTAINER

B BRAUN	30MG/100ML;37MG/100ML;0.82MG/100ML; 370MG/100ML;530MG/100ML;500MG/100ML; 12MG/100ML	N19006 001	APR 04, 1984

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

SOLUTION; IRRIGATION

PHYSIOSOL IN PLASTIC CONTAINER

ABBOTT	14MG/100ML;37MG/100ML;222MG/100ML; 526MG/100ML;502MG/100ML	N18406 001	

SYNOVALYTE IN PLASTIC CONTAINER

BAXTER HLTHCARE	30MG/100ML;37MG/100ML;368MG/100ML; 526MG/100ML;502MG/100ML	N19326 001	JAN 25, 1985

MAGNESIUM TRISILICATE; *MULTIPLE*

SEE ALUMINUM HYDROXIDE; MAGNESIUM TRISILICATE

MANGANESE SULFATE

INJECTABLE; INJECTION

MANGANESE SULFATE

AM PHARM PARTNERS	EQ 0.1MG MANGANESE/ML	N19228 001	MAY 05, 1987

MANNITOL

INJECTABLE; INJECTION

MANNITOL 10%

ABBOTT	10GM/100ML	N16269 002	
MILES	10GM/100ML	N16472 002	

MANNITOL 15%

ABBOTT	15GM/100ML	N16269 003	
MILES	15GM/100ML	N16472 005	

MANNITOL 20%

ABBOTT	20GM/100ML	N16269 004	
MILES	20GM/100ML	N16472 004	

MANNITOL 25%

ABBOTT	12.5GM/50ML	N16269 005	
AM PHARM PARTNERS	12.5GM/50ML	N86754 001	
ASTRAZENECA	12.5GM/50ML	N89240 001	MAY 06, 1987
MERCK	12.5GM/50ML	N05620 001	
STERIS	12.5GM/50ML	N87460 001	JUN 27, 1983

MANNITOL 5%

ABBOTT	5GM/100ML	N16269 001	

SOLUTION; IRRIGATION

RESECTISOL

B BRAUN	5GM/100ML	N16704 002	

MANNITOL; SORBITOL

SOLUTION; IRRIGATION

SORBITOL-MANNITOL

ABBOTT	540MG/100ML;2.7GM/100ML	N80224 001	

MAPROTILINE HYDROCHLORIDE

TABLET; ORAL

MAPROTILINE HCL

AM THERAP	25MG	N72129 001	JAN 14, 1988
	50MG	N72130 001	JAN 14, 1988
	75MG	N72131 001	JAN 14, 1988
WATSON LAB	25MG	N71943 001	DEC 30, 1987
	50MG	N71944 001	DEC 30, 1987

FDA data supplied by DrugPatentWatch.com

MAPROTILINE HYDROCHLORIDE

TABLET; ORAL		
MAPROTILINE HCL		
WATSON LAB	75MG	N71945 001 DEC 30, 1987

MAZINDOL

TABLET; ORAL		
MAZANOR		
WYETH AYERST	2MG	N17980 001

MEBUTAMATE

TABLET; ORAL		
DORMATE		
WALLACE PHARMS	600MG	N17374 001

MECLIZINE HYDROCHLORIDE

TABLET; ORAL		
MECLIZINE HCL		
ANABOLIC	25MG	N85891 001
IVAX PHARMS	12.5MG	N83784 001
KV PHARM	12.5MG	N85524 001
	25MG	N85523 001
SUPERPHARM	12.5MG	N89113 001 AUG 20, 1985
	25MG	N89114 001 AUG 20, 1985
UDL	12.5MG	N88256 001 JUN 13, 1983
	25MG	N88257 001 JUN 13, 1983
VANGARD	12.5MG	N87877 001 APR 20, 1982
	25MG	N87620 001 JAN 04, 1982
WATSON LAB	12.5MG	N85195 001
WATSON LABS	12.5MG	N85269 001
TABLET, CHEWABLE; ORAL		
MECLIZINE HCL		
ANABOLIC	25MG	N86392 001
IVAX PHARMS	25MG	N84976 001

MECLOCYCLINE SULFOSALICYLATE

CREAM; TOPICAL		
MECLAN		
JOHNSON AND JOHNSON	1%	N50518 001

MECLOFENAMATE SODIUM

CAPSULE; ORAL		
MECLODIUM		
QUANTUM PHARMICS	EQ 50MG BASE	N71380 001 JUL 14, 1987
	EQ 100MG BASE	N71381 001 JUL 14, 1987
MECLOFENAMATE SODIUM		
AM THERAP	EQ 50MG BASE	N71362 001 FEB 10, 1987
	EQ 100MG BASE	N71363 001 FEB 10, 1987
BARR	EQ 50MG BASE	N72848 001 MAR 20, 1989
	EQ 100MG BASE	N72809 001 MAR 20, 1989
PAR PHARM	EQ 50MG BASE	N72077 001 MAR 10, 1988
	EQ 100MG BASE	N72078 001 MAR 10, 1988
USL PHARMA	EQ 50MG BASE	N71007 001 MAR 25, 1988
	EQ 100MG BASE	N71008 001 MAR 25, 1988
VITARINE	EQ 50MG BASE	N71710 001 JUN 15, 1988
	EQ 100MG BASE	N71684 001 JUN 15, 1988
WATSON LAB	EQ 50MG BASE	N70400 001 NOV 25, 1986
	EQ 100MG BASE	N70401 001 NOV 25, 1986
WATSON LABS	EQ 50MG BASE	N71640 001 AUG 11, 1987
	EQ 100MG BASE	N71641 001 AUG 11, 1987

FDA data supplied by DrugPatentWatch.com

MEDROXYPROGESTERONE ACETATE

INJECTABLE; INJECTION			
DEPO-PROVERA			
* PHARMACIA AND UPJOHN	100MG/ML		N12541 002
TABLET; ORAL			
CURRETAB			
SOLVAY	10MG		N85686 001
CYCRIN			
ESI	2.5MG		N81239 001 OCT 30, 1992
	5MG		N81240 001 OCT 30, 1992
	10MG		N89386 001 SEP 09, 1987

MEFLOQUINE HYDROCHLORIDE

TABLET; ORAL			
MEFLOQUINE HCL			
US ARMY WALTER REED	250MG		N19578 001 MAY 02, 1989

MEGESTROL ACETATE

TABLET; ORAL			
MEGESTROL ACETATE			
USL PHARMA	20MG		N70646 001 OCT 02, 1987
	40MG		N70647 001 OCT 02, 1987

MEGLUMINE; *MULTIPLE*
SEE CALCIUM; MEGLUMINE; METRIZOIC ACID

MEGLUMINE METRIZOATE; *MULTIPLE*
SEE CALCIUM METRIZOATE; MEGLUMINE METRIZOATE; METRIZOATE MAGNESIUM; METRIZOATE SODIUM

MENADIOL SODIUM DIPHOSPHATE

INJECTABLE; INJECTION			
KAPPADIONE			
LILLY	10MG/ML		N05725 001

MENADIOL SODIUM DIPHOSPHATE

INJECTABLE; INJECTION			
SYNKAYVITE			
ROCHE	5MG/ML		N03718 004
	10MG/ML		N03718 006
	37.5MG/ML		N03718 008
TABLET; ORAL			
SYNKAYVITE			
ROCHE	5MG		N03718 010

MENADIONE

TABLET; ORAL			
MENADIONE			
LILLY	5MG		N02139 003

MENOTROPINS (FSH;LH)

INJECTABLE; INJECTION			
HUMEGON			
ORGANON	75 IU/VIAL;75 IU/VIAL		N20328 001 SEP 01, 1994
	150 IU/VIAL;150 IU/VIAL		N20328 002 SEP 01, 1994
MENOTROPINS			
FERRING	75 IU/VIAL;75 IU/VIAL		N73598 001 JAN 30, 1997
	150 IU/VIAL;150 IU/VIAL		N73599 001 JAN 30, 1997

MEPENZOLATE BROMIDE

SOLUTION; ORAL			
CANTIL			
AVENTIS PHARMS	25MG/5ML		N10679 004

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION			
DEMEROL			
SANOFI SYNTHELABO	25MG/ML		N05010 007
	50MG/ML		N05010 002
	75MG/ML		N05010 009

FDA data supplied by DrugPatentWatch.com

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

DEMEROL		
SANOFI SYNTHELABO	100MG/ML	N05010 003
MEPERIDINE HCL		
ABBOTT	25MG/ML	N80388 001
	50MG/ML	N80385 001
	50MG/ML	N80387 001
	75MG/ML	N80389 001
	100MG/ML	N80386 001
ASTRAZENECA	25MG/ML	N89781 001 MAR 31, 1989
	50MG/ML	N89782 001 MAR 31, 1989
	50MG/ML	N89783 001 MAR 31, 1989
	50MG/ML	N89784 001 MAR 31, 1989
	75MG/ML	N89785 001 MAR 31, 1989
	100MG/ML	N89786 001 MAR 31, 1989
	100MG/ML	N89787 001 MAR 31, 1989
	100MG/ML	N89788 001 MAR 31, 1989
ELKINS SINN	25MG/ML	N88279 001 JUN 15, 1984
	50MG/ML	N88280 001 JUN 15, 1984
	75MG/ML	N88281 001 JUN 15, 1984
	100MG/ML	N88282 001 JUN 15, 1984
INTL MEDICATION	10MG/ML	N86332 001
PARKE DAVIS	50MG/ML	N80364 002
	75MG/ML	N80364 003
	100MG/ML	N80364 001

MEPERIDINE HYDROCHLORIDE; *MULTIPLE*
SEE ATROPINE SULFATE; MEPERIDINE HYDROCHLORIDE

MEPHENTERMINE SULFATE

INJECTABLE; INJECTION

WYAMINE SULFATE		
WYETH AYERST	EQ 30MG BASE/ML	N08248 001

MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

ARESTOCAINE HCL		
SOLVAY	3%	N84777 002 APR 18, 1982
MEPIVACAINE HCL		
INTL MEDICATION	1%	N87509 001 OCT 05, 1982

MEPIVACAINE HYDROCHLORIDE; *MULTIPLE*
SEE LEVONORDEFRIN; MEPIVACAINE HYDROCHLORIDE

MEPREDNISONE

TABLET; ORAL

BETAPAR		
SCHERING	4MG	N16053 002

MEPROBAMATE

CAPSULE; ORAL

EQUANIL		
WYETH AYERST	400MG	N12455 002

CAPSULE, EXTENDED RELEASE; ORAL

MEPROSPAN		
WALLACE PHARMS	200MG	N11284 001
	400MG	N11284 002

TABLET; ORAL

AMOSENE		
FERNDALE LABS	400MG	N84030 001
BAMATE		
ALRA	200MG	N80380 001
	400MG	N80380 002
MEPRIAM		
TEVA	400MG	N16069 001
MEPROBAMATE		
ANABOLIC	200MG	N84220 001
	400MG	N84589 001
BARR	600MG	N84230 001
DANBURY PHARMA	600MG	N84274 001
ELKINS SINN	200MG	N15426 002
	400MG	N15426 001
HALSEY	200MG	N80699 001

FDA data supplied by DrugPatentWatch.com

MEPROBAMATE

TABLET; ORAL
MEPROBAMATE

HALSEY	400MG	N80699 002
HEATHER	400MG	N16928 003
	600MG	N84329 001
ICN	200MG	N15139 006
	400MG	N15139 005
IMPAX LABS	200MG	N14322 002
	400MG	N14322 001
IVAX PHARMS	200MG	N15438 001
	400MG	N15438 002
	600MG	N84181 001
LANNETT	200MG	N14882 002
	400MG	N14882 001
LEDERLE	400MG	N86299 001
LEE KM	400MG	N89538 001
		NOV 25, 1987
MALLARD	400MG	N15072 002
MK LABS	200MG	N14368 004
	400MG	N14368 002
PARKE DAVIS	200MG	N84744 001
	400MG	N84744 002
PERRIGO	200MG	N84546 001
	400MG	N84547 001
PHARMAVITE	400MG	N84438 001
PHARMERAL	400MG	N84153 001
PUREPAC PHARM	200MG	N84804 001
	400MG	N84804 002
PVT FORM	400MG	N14601 001
SOLVAY	200MG	N84435 001
STANLABS PHARM	200MG	N14474 002
	400MG	N14474 004
USL PHARMA	200MG	N87825 001
		MAR 18, 1982
	400MG	N87826 001
		MAR 18, 1982
VANGARD	400MG	N88011 001
		JUL 14, 1982
WATSON LABS	600MG	N85719 001
WHITEWORTH TOWN PLSN	200MG	N83830 001
	400MG	N83442 001

NEURAMATE
HALSEY	200MG	N14359 002
	400MG	N14359 001

TRANMEP
SOLVAY	400MG	N84369 001

MEPROBAMATE; *MULTIPLE*
SEE ASPIRIN; MEPROBAMATE
SEE ESTROGENS, CONJUGATED; MEPROBAMATE

MERSALYL SODIUM; THEOPHYLLINE

INJECTABLE; INJECTION
MERSALYL-THEOPHYLLINE

STERIS	100MG/ML;50MG/ML	N84875 001

MESALAMINE

SUPPOSITORY; RECTAL
ROWASA

* SOLVAY	500MG	N19919 001	
		DEC 18, 1990	

MESTRANOL; *MULTIPLE*
SEE ETHYNODIOL DIACETATE; MESTRANOL

MESTRANOL; NORETHINDRONE

TABLET; ORAL-20
NORINYL

WATSON LABS	0.1MG;2MG	N13625 004

TABLET; ORAL-21
NORINYL 1+80 21-DAY

GD SEARLE LLC	0.08MG;1MG	N16724 001

ORTHO-NOVUM 1/80 21

JOHNSON RW	0.08MG;1MG	N16715 001

ORTHO-NOVUM 10-21

JOHNSON RW	0.06MG;10MG	N12728 001

ORTHO-NOVUM 2-21

JOHNSON RW	0.1MG;2MG	N12728 005

TABLET; ORAL-28
NORINYL 1+80 28-DAY

GD SEARLE LLC	0.08MG;1MG	N16725 001

ORTHO-NOVUM 1/80 28

JOHNSON RW	0.08MG;1MG	N16715 002

FDA data supplied by DrugPatentWatch.com

MESTRANOL; NORETHYNODREL

TABLET; ORAL		
ENOVID		
GD SEARLE LLC	0.075MG;5MG	N10976 008
	0.15MG;9.85MG	N10976 005
TABLET; ORAL-20		
ENOVID		
GD SEARLE LLC	0.075MG;5MG	N10976 004
ENOVID-E		
GD SEARLE LLC	0.1MG;2.5MG	N10976 006
TABLET; ORAL-21		
ENOVID-E 21		
GD SEARLE LLC	0.1MG;2.5MG	N10976 007

METAPROTERENOL SULFATE

SOLUTION; INHALATION		
METAPROTERENOL SULFATE		
ASTRAZENECA	0.4%	N71275 001 JUL 27, 1988
	0.6%	N71018 001 JUL 27, 1988
DEY	0.33%	N71806 001 AUG 05, 1988
	0.5%	N71805 001 AUG 05, 1988
	5%	N70805 001 AUG 17, 1987
MORTON GROVE	5%	N72190 001 JUN 07, 1988
PROMETA		
MURO	5%	N73340 001 MAR 30, 1992
SYRUP; ORAL		
ALUPENT		
BOEHRINGER INGELHEIM	10MG/5ML	N17571 001
METAPROTERENOL SULFATE		
COPLEY PHARM	10MG/5ML	N73034 001 AUG 30, 1991
MORTON GROVE	10MG/5ML	N71656 001 OCT 13, 1987
TEVA	10MG/5ML	N72761 001 FEB 27, 1992

METAPROTERENOL SULFATE

SYRUP; ORAL		
PROMETA		
MURO	10MG/5ML	N72023 001 SEP 15, 1988
TABLET; ORAL		
METAPROTERENOL SULFATE		
AM THERAP	10MG	N72054 001 JUN 23, 1988
	20MG	N72055 001 JUN 23, 1988
USL PHARMA	10MG	N71013 001 JAN 25, 1988
	20MG	N71014 001 JAN 25, 1988

METARAMINOL BITARTRATE

INJECTABLE; INJECTION		
METARAMINOL BITARTRATE		
AM PHARM PARTNERS	EQ 10MG BASE/ML	N80431 001
ELKINS SINN	EQ 10MG BASE/ML	N83363 001
GD SEARLE LLC	EQ 10MG BASE/ML	N86418 001
	EQ 20MG BASE/ML	N86418 002

METFORMIN HYDROCHLORIDE

TABLET; ORAL		
GLUCOPHAGE		
* BRISTOL MYERS SQUIBB	625MG	N20357 003 NOV 05, 1998
*	750MG	N20357 004 NOV 05, 1998

METHACYCLINE HYDROCHLORIDE

CAPSULE; ORAL		
RONDOMYCIN		
WALLACE LABS	EQ 140MG BASE	N60641 001
	EQ 280MG BASE	N60641 002
SYRUP; ORAL		
RONDOMYCIN		
WALLACE LABS	EQ 70MG BASE/5ML	N60641 003

FDA data supplied by DrugPatentWatch.com

METHADONE HYDROCHLORIDE

TABLET, DISPERSIBLE; ORAL			
WESTADONE			
EON	2.5MG	N17108	001
	5MG	N17108	002
	10MG	N17108	003
	40MG	N17108	004

METHAMPHETAMINE HYDROCHLORIDE

TABLET; ORAL			
METHAMPEX			
TEVA	10MG	N83889	001
METHAMPHETAMINE HCL			
REXAR	5MG	N84931	001
	10MG	N84931	002
TEVA	5MG	N86359	001

METHARBITAL

TABLET; ORAL			
GEMONIL			
ABBOTT	100MG	N08322	001

METHAZOLAMIDE

TABLET; ORAL			
METHAZOLAMIDE			
APPLIED ANAL	25MG	N40011	001
		JUL 17, 1997	
	50MG	N40011	002
		JUL 17, 1997	

METHDILAZINE

TABLET, CHEWABLE; ORAL			
TACARYL			
WESTWOOD SQUIBB	3.6MG	N11950	009

METHDILAZINE HYDROCHLORIDE

SYRUP; ORAL			
METHDILAZINE HCL			
ALPHARMA	4MG/5ML	N87122	001
SYRUP; ORAL			
TACARYL			
WESTWOOD SQUIBB	4MG/5ML	N11950	007
TABLET; ORAL			
TACARYL			
WESTWOOD SQUIBB	8MG	N11950	006

METHICILLIN SODIUM

INJECTABLE; INJECTION			
STAPHCILLIN			
APOTHECON	EQ 900MG BASE/VIAL	N50117	001
	EQ 900MG BASE/VIAL	N61449	001
	EQ 3.6GM BASE/VIAL	N50117	002
	EQ 3.6GM BASE/VIAL	N61449	002
	EQ 5.4GM BASE/VIAL	N50117	003
	EQ 5.4GM BASE/VIAL	N61449	003

METHIXENE HYDROCHLORIDE

TABLET; ORAL			
TREST			
NOVARTIS	1MG	N13420	001

METHOCARBAMOL

INJECTABLE; INJECTION			
METHOCARBAMOL			
MARSAM PHARMS LLC	100MG/ML	N89849	001
		DEC 27, 1991	
TABLET; ORAL			
DELAXIN			
FERNDALE LABS	500MG	N85454	001
FORBAXIN			
FORREST LABS	750MG	N85136	001
METHOCARBAMOL			
AM THERAP	500MG	N89417	001
		FEB 11, 1987	
	750MG	N89418	001
		FEB 11, 1987	
ASCOT	500MG	N87660	001
		OCT 27, 1982	

FDA data supplied by DrugPatentWatch.com

METHOCARBAMOL

TABLET; ORAL
METHOCARBAMOL

ASCOT	750MG	N87661 001 OCT 27, 1982
HALSEY	500MG	N84488 001
	750MG	N84486 001
HEATHER	500MG	N84675 001
	750MG	N84924 001
INWOOD LABS	500MG	N85137 001
IVAX PHARMS	500MG	N84648 001
	750MG	N84649 001
KV PHARM	500MG	N85660 001
	750MG	N85658 001
MYLAN	500MG	N84259 001
	750MG	N84323 001
PHARMERAL	500MG	N84231 002
	750MG	N84471 001
PIONEER PHARMS	500MG	N88731 001 DEC 13, 1985
	750MG	N89082 001 DEC 13, 1985
PUREPAC PHARM	500MG	N85718 001
	750MG	N85718 002
ROXANE	500MG	N88646 001 FEB 29, 1984
	750MG	N88647 001 FEB 29, 1984
SOLVAY	500MG	N84448 001
	750MG	N84449 001
UPSHER SMITH	500MG	N87453 001
	750MG	N87454 001
WATSON LAB	500MG	N83605 001
	750MG	N83605 002

METHOCARBAMOL; *MULTIPLE*
SEE ASPIRIN; METHOCARBAMOL

METHOTREXATE SODIUM

INJECTABLE; INJECTION
ABITREXATE

ABIC	EQ 25MG BASE/ML	N89161 001 MAR 10, 1987
	EQ 50MG BASE/VIAL	N89354 001 JUL 17, 1987

METHOTREXATE SODIUM

INJECTABLE; INJECTION
ABITREXATE

ABIC	EQ 100MG BASE/VIAL	N89355 001 JUL 17, 1987
	EQ 250MG BASE/VIAL	N89356 001 JUL 17, 1987
FOLEX PFS		
PHARMACIA AND UPJOHN	EQ 25MG BASE/ML	N81242 001 AUG 23, 1991
	EQ 25MG BASE/ML	N89180 001 JAN 03, 1986
METHOTREXATE SODIUM		
AM PHARM PARTNERS	EQ 2.5MG BASE/ML	N89323 001 JUN 13, 1986
	EQ 20MG BASE/VIAL	N88935 001 OCT 11, 1985
	EQ 25MG BASE/ML	N89263 001 JUN 13, 1986
	EQ 25MG BASE/ML	N89322 001 JUN 13, 1986
	EQ 50MG BASE/VIAL	N88936 001 OCT 11, 1985
	EQ 100MG BASE/VIAL	N88937 001 OCT 11, 1985
QUAD PHARMS	EQ 20MG BASE/VIAL	N89293 001 JUL 10, 1986
	EQ 25MG BASE/ML	N89308 001 JUL 10, 1986
	EQ 25MG BASE/ML	N89309 001 JUL 10, 1986
	EQ 50MG BASE/VIAL	N89294 001 JUL 10, 1986
	EQ 100MG BASE/VIAL	N89295 001 JUL 10, 1986
	EQ 250MG BASE/VIAL	N89296 001 JUL 10, 1986
MEXATE		
BRISTOL	EQ 20MG BASE/VIAL	N86358 001
	EQ 50MG BASE/VIAL	N86358 002
	EQ 100MG BASE/VIAL	N86358 003
	EQ 250MG BASE/VIAL	N86358 004
MEXATE-AQ PRESERVED		
BRISTOL MYERS SQUIBB	EQ 25MG BASE/ML	N89887 001 APR 14, 1989

FDA data supplied by DrugPatentWatch.com

METHOTRIMEPRAZINE

INJECTABLE; INJECTION		
LEVOPROME		
IMMUNEX	20MG/ML	N15865 001

METHOXAMINE HYDROCHLORIDE

INJECTABLE; INJECTION		
VASOXYL		
GLAXOSMITHKLINE	10MG/ML	N06772 002
	20MG/ML	N06772 001

METHOXSALEN

CAPSULE; ORAL		
METHOXSALEN		
GENEVA PHARMS	10MG	N87781 001 JUN 08, 1982

METHOXYFLURANE

LIQUID; INHALATION		
PENTHRANE		
ABBOTT	99.9%	N13056 001

METHSCOPOLAMINE BROMIDE

TABLET; ORAL		
METHSCOPOLAMINE BROMIDE		
PVT FORM	2.5MG	N80970 001

METHYCLOTHIAZIDE

TABLET; ORAL		
METHYCLOTHIAZIDE		
IVAX PHARMS	5MG	N87786 001 MAY 18, 1982
MYLAN	2.5MG	N87671 001 AUG 17, 1982
PAR PHARM	2.5MG	N89135 001 FEB 12, 1986
	5MG	N89136 001 FEB 12, 1986

METHYCLOTHIAZIDE

TABLET; ORAL		
METHYCLOTHIAZIDE		
USL PHARMA	5MG	N88745 001 MAR 21, 1985
WATSON LAB	2.5MG	N85487 001 MAR 11, 1982
	5MG	N85476 001 MAR 11, 1982
WATSON LABS	2.5MG	N88750 001 SEP 06, 1984

METHYCLOTHIAZIDE; *MULTIPLE*
SEE DESERPIDINE; METHYCLOTHIAZIDE

METHYCLOTHIAZIDE; PARGYLINE HYDROCHLORIDE

TABLET; ORAL		
EUTRON		
ABBOTT	5MG;25MG	N16047 001

METHYLDOPA

TABLET; ORAL		
METHYLDOPA		
DURAMED	250MG	N71006 001 DEC 16, 1986
	500MG	N71009 001 DEC 16, 1986
HALSEY	125MG	N70073 001 OCT 09, 1986
	125MG	N71751 001 MAR 28, 1988
	250MG	N70060 001 OCT 09, 1986
	250MG	N71752 001 MAR 28, 1988
	500MG	N70074 001 OCT 09, 1986
	500MG	N71753 001 MAR 28, 1988
LEDERLE	125MG	N70070 003 OCT 15, 1985
PARKE DAVIS	125MG	N70331 001 APR 15, 1986

FDA data supplied by DrugPatentWatch.com

METHYLDOPA

TABLET; ORAL
METHYLDOPA

PARKE DAVIS	250MG	N70332 001 APR 15, 1986
	500MG	N70333 001 APR 15, 1986
PUREPAC PHARM	125MG	N70749 001 FEB 07, 1986
	250MG	N70750 001 FEB 07, 1986
	500MG	N70452 001 FEB 07, 1986
ROXANE	125MG	N70192 001 APR 25, 1986
	250MG	N70193 001 APR 25, 1986
	500MG	N70194 001 APR 25, 1986
TEVA	125MG	N71105 001 DEC 05, 1986
	250MG	N71106 001 DEC 05, 1986
	500MG	N71067 001 DEC 05, 1986
WATSON LAB	125MG	N70245 001 FEB 25, 1986
	250MG	N70246 001 FEB 25, 1986
	500MG	N70247 001 FEB 25, 1986
WATSON LABS	125MG	N70260 001 JUN 24, 1985
	250MG	N70261 001 JUN 24, 1985
	500MG	N70262 001 JUN 24, 1985

METHYLDOPA; *MULTIPLE*
SEE CHLOROTHIAZIDE; METHYLDOPA
SEE HYDROCHLOROTHIAZIDE; METHYLDOPA

METHYLDOPATE HYDROCHLORIDE

INJECTABLE; INJECTION
METHYLDOPATE HCL

AM PHARM PARTNERS	50MG/ML	N70652 001 JUN 03, 1986
FAULDING	50MG/ML	N70691 001 JUN 19, 1987
	50MG/ML	N70849 001 JUN 19, 1987
MARSAM PHARMS LLC	50MG/ML	N71812 001 DEC 22, 1987
QUAD PHARMS	50MG/ML	N71024 001 SEP 18, 1986
SMITH AND NEPHEW	50MG/ML	N70841 001 JAN 02, 1987

METHYLPREDNISOLONE

TABLET; ORAL
METHYLPREDNISOLONE

EON	4MG	N87341 001
HEATHER	4MG	N85650 001
WATSON LABS	4MG	N86161 001 FEB 09, 1982
	16MG	N86159 001 FEB 09, 1982

METHYLPREDNISOLONE; NEOMYCIN SULFATE

OINTMENT; OPHTHALMIC
NEO-MEDROL

PHARMACIA AND UPJOHN	0.1%;EQ 3.5MG BASE/GM	N60645 001

METHYLPREDNISOLONE ACETATE

ENEMA; RECTAL
MEDROL

PHARMACIA AND UPJOHN	40MG/BOT	N18102 001

INJECTABLE; INJECTION
M-PREDROL

BEL MAR	40MG/ML	N86666 001
	80MG/ML	N87135 001

METHYLPREDNISOLONE ACETATE

AKORN	40MG/ML	N86903 001 OCT 20, 1982

FDA data supplied by DrugPatentWatch.com

METHYLPREDNISOLONE ACETATE

INJECTABLE; INJECTION			
METHYLPREDNISOLONE ACETATE			
AKORN	80MG/ML	N86903 002	
		OCT 20, 1982	
STERIS	20MG/ML	N87248 001	
	40MG/ML	N85374 001	
	40MG/ML	N85600 001	
	80MG/ML	N86507 001	
OINTMENT; TOPICAL			
MEDROL ACETATE			
PHARMACIA AND UPJOHN	1%	N12421 002	

METHYLPREDNISOLONE ACETATE; NEOMYCIN SULFATE

CREAM; TOPICAL		
NEO-MEDROL ACETATE		
PHARMACIA AND UPJOHN	0.25%;EQ 3.5MG BASE/GM	N60611 002
	1%;EQ 3.5MG BASE/GM	N60611 001

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION		
A-METHAPRED		
ABBOTT	EQ 1GM BASE/VIAL	N89576 001
		FEB 22, 1991
	EQ 40MG BASE/VIAL	N89573 001
		FEB 22, 1991
	EQ 125MG BASE/VIAL	N89574 001
		FEB 22, 1991
	EQ 500MG BASE/VIAL	N89575 001
		FEB 22, 1991
METHYLPREDNISOLONE		
ELKINS SINN	EQ 125MG BASE/VIAL	N86906 002
	EQ 500MG BASE/VIAL	N86906 003
	EQ 1GM BASE/VIAL	N86906 004
ORGANON	EQ 500MG BASE/VIAL	N87535 001
		JUN 25, 1982
	EQ 1GM BASE/VIAL	N87535 002
		JUN 25, 1982
METHYLPREDNISOLONE SODIUM SUCCINATE		
AM PHARM PARTNERS	EQ 1GM BASE/VIAL	N88679 001
		JUN 08, 1984
	EQ 1GM BASE/VIAL	N89188 001
		MAR 28, 1986

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION		
METHYLPREDNISOLONE SODIUM SUCCINATE		
AM PHARM PARTNERS	EQ 1GM BASE/VIAL	N89189 001
		MAR 28, 1986
	EQ 40MG BASE/VIAL	N88676 001
		JUN 08, 1984
	EQ 40MG BASE/VIAL	N89143 001
		MAR 28, 1986
	EQ 125MG BASE/VIAL	N88677 001
		JUN 08, 1984
	EQ 125MG BASE/VIAL	N89144 001
		MAR 28, 1986
	EQ 500MG BASE/VIAL	N88678 001
		JUN 08, 1984
	EQ 500MG BASE/VIAL	N89186 001
		MAR 28, 1986
	EQ 500MG BASE/VIAL	N89187 001
		MAR 28, 1986
ELKINS SINN	EQ 40MG BASE/VIAL	N86906 001
GENSIA SICOR PHARMS	EQ 1GM BASE/VIAL	N81268 001
		NOV 30, 1992
	EQ 500MG BASE/VIAL	N81267 001
		NOV 30, 1992
INTL MEDICATION	EQ 1GM BASE/VIAL	N87852 001
		FEB 09, 1983
	EQ 40MG BASE/VIAL	N87812 001
		FEB 09, 1983
	EQ 125MG BASE/VIAL	N87813 001
		FEB 09, 1983
	EQ 500MG BASE/VIAL	N87851 001
		FEB 09, 1983
QUAD PHARMS	EQ 1GM BASE/VIAL	N89267 001
		JAN 22, 1986
	EQ 40MG BASE/VIAL	N89264 001
		JAN 22, 1986
	EQ 125MG BASE/VIAL	N89265 001
		JAN 22, 1986
	EQ 500MG BASE/VIAL	N89266 001
		JAN 22, 1986
STERIS	EQ 1GM BASE/VIAL	N88524 001
		JUL 24, 1984
	EQ 40MG BASE/VIAL	N86953 001
		JUL 22, 1982
	EQ 125MG BASE/VIAL	N87030 001
		JUL 22, 1982
	EQ 500MG BASE/VIAL	N88523 001
		JUL 24, 1984

FDA data supplied by DrugPatentWatch.com

METHYLTESTOSTERONE

CAPSULE; ORAL
METHYLTESTOSTERONE
HEATHER 10MG N84967 001

TABLET; BUCCAL
ANDROID 5
ICN 5MG N87222 001
ORETON
SCHERING 10MG N80281 001

TABLET; BUCCAL/SUBLINGUAL
METANDREN
NOVARTIS 5MG N03240 004
10MG N03240 005
METHYLTESTOSTERONE
IMPAX LABS 10MG N84287 001
LILLY 10MG N80256 001
PUREPAC PHARM 10MG N80308 001
10MG N80475 001
PVT FORM 5MG N83836 001
TABLICAPS 10MG N85125 001
USL PHARMA 10MG N80271 001

TABLET; ORAL
METANDREN
NOVARTIS 10MG N03240 001
25MG N03240 003
METHYLTESTOSTERONE
DANBURY PHARMA 10MG N80933 001
25MG N80931 001
INWOOD LABS 10MG N80839 001
25MG N80973 001
KV PHARM 10MG N84312 001
LILLY 25MG N80256 002
PARKE DAVIS 10MG N84244 001
25MG N84241 001
PUREPAC PHARM 10MG N80309 001
10MG N80475 002
25MG N80310 001
25MG N80475 003
PVT FORM 5MG N80214 001
10MG N80214 002
25MG N80214 003
TABLICAPS 10MG N80313 001
25MG N85270 001
WEST WARD 10MG N84331 001
25MG N84331 002

METHYLTESTOSTERONE

TABLET; ORAL
METHYLTESTOSTERONE
WEST WARD 25MG N84642 001
ORETON METHYL
SCHERING 10MG N03158 001
25MG N03158 002

METHYPRYLON

CAPSULE; ORAL
NOLUDAR
ROCHE 300MG N09660 008

ELIXIR; ORAL
NOLUDAR
ROCHE 50MG/5ML N09660 007

TABLET; ORAL
NOLUDAR
ROCHE 50MG N09660 002
200MG N09660 004

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION
METOCLOPRAMIDE HCL
ABBOTT EQ 5MG BASE/ML N70506 001
JUN 22, 1989
AM PHARM PARTNERS EQ 10MG BASE/2ML N70293 001
JAN 24, 1986
BEDFORD EQ 5MG BASE/ML N72155 001
MAR 30, 1992
EQ 5MG BASE/ML N72244 001
MAR 30, 1992
EQ 5MG BASE/ML N72247 001
MAY 18, 1992
FAULDING EQ 5MG BASE/ML N71990 001
JAN 18, 1989
NORBROOK EQ 10MG BASE/2ML N70892 001
AUG 26, 1988
QUAD PHARMS EQ 10MG BASE/2ML N70671 001
MAY 27, 1986
SMITH AND NEPHEW EQ 10MG BASE/2ML N70622 001
MAR 02, 1987

FDA data supplied by DrugPatentWatch.com

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION		
METOCLOPRAMIDE HCL		
SMITH AND NEPHEW	EQ 5MG BASE/ML	N70623 001 MAR 02, 1987
REGLAN		
ROBINS AH	EQ 10MG BASE/ML	N17862 004 MAY 28, 1987
SOLUTION; ORAL		
METOCLOPRAMIDE HCL		
MORTON GROVE	EQ 5MG BASE/5ML	N70949 001 MAR 06, 1987
PACO	EQ 5MG BASE/5ML	N71665 001 DEC 05, 1988
TABLET; ORAL		
CLOPRA		
QUANTUM PHARMICS	EQ 5MG BASE	N72384 001 JUN 02, 1988
	EQ 10MG BASE	N70294 001 JUL 29, 1985
CLOPRA-"YELLOW"		
QUANTUM PHARMICS	EQ 10MG BASE	N70632 001 OCT 28, 1985
MAXOLON		
KING PHARMS	EQ 10MG BASE	N70106 001 MAR 04, 1986
METOCLOPRAMIDE HCL		
HALSEY	EQ 10MG BASE	N70660 001 FEB 10, 1987
	EQ 10MG BASE	N70906 001 OCT 28, 1986
INTERPHARM	EQ 10MG BASE	N71213 001 SEP 24, 1986
INVAMED	EQ 5MG BASE	N72436 001 JUN 22, 1989
	EQ 10MG BASE	N70850 001 FEB 03, 1987
MUTUAL PHARM	EQ 5MG BASE	N71536 002 JAN 16, 1997
	EQ 10MG BASE	N71536 001 APR 28, 1993
PAR PHARM	EQ 10MG BASE	N70342 001 MAR 25, 1986
SCHERING	EQ 10MG BASE	N70598 001 FEB 02, 1987

METOCLOPRAMIDE HYDROCHLORIDE

TABLET; ORAL		
METOCLOPRAMIDE HCL		
SUPERPHARM	EQ 10MG BASE	N70926 001 JUN 26, 1987
USL PHARMA	EQ 10MG BASE	N70339 001 JUL 29, 1985
WATSON LAB	EQ 10MG BASE	N70363 001 MAR 02, 1987
WATSON LABS	EQ 10MG BASE	N70453 001 JUN 06, 1986
	EQ 10MG BASE	N70645 001 MAY 11, 1987

METOCURINE IODIDE

INJECTABLE; INJECTION		
METOCURINE IODIDE		
QUAD PHARMS	2MG/ML	N89443 001 JUN 01, 1988
METUBINE IODIDE		
LILLY	2MG/ML	N06632 003

METOLAZONE

TABLET; ORAL		
DIULO		
GD SEARLE LLC	2.5MG	N18535 001
	5MG	N18535 002
	10MG	N18535 003

METOPROLOL FUMARATE

TABLET, EXTENDED RELEASE; ORAL		
LOPRESSOR		
NOVARTIS	EQ 100MG TARTRATE	N19786 001 DEC 27, 1989
	EQ 200MG TARTRATE	N19786 002 DEC 27, 1989
	EQ 300MG TARTRATE	N19786 003 DEC 27, 1989
	EQ 400MG TARTRATE	N19786 004 DEC 27, 1989

FDA data supplied by DrugPatentWatch.com

METOPROLOL TARTRATE

TABLET; ORAL
METOPROLOL TARTRATE

PUREPAC PHARM	50MG	N74380 001 JUL 29, 1994
	100MG	N74380 002 JUL 29, 1994

METOPROLOL TARTRATE; *MULTIPLE*
SEE CHLORTHALIDONE; METOPROLOL TARTRATE

METRIZAMIDE

INJECTABLE; INJECTION
AMIPAQUE

AMERSHAM HLTH	2.5GM/VIAL	N17982 003 SEP 12, 1983
	3.75GM/VIAL	N17982 001
	6.75GM/VIAL	N17982 002
	13.5GM/VIAL	N17982 004 SEP 12, 1983

METRIZOATE MAGNESIUM; *MULTIPLE*
SEE CALCIUM METRIZOATE; MEGLUMINE METRIZOATE; METRIZOATE MAGNESIUM; METRIZOATE SODIUM

METRIZOATE SODIUM; *MULTIPLE*
SEE CALCIUM METRIZOATE; MEGLUMINE METRIZOATE; METRIZOATE MAGNESIUM; METRIZOATE SODIUM

METRIZOIC ACID; *MULTIPLE*
SEE CALCIUM; MEGLUMINE; METRIZOIC ACID

METRONIDAZOLE

INJECTABLE; INJECTION
METRO I.V.

B BRAUN	500MG/100ML	N18674 001 AUG 31, 1982

METRONIDAZOLE

ABBOTT	500MG/100ML	N18889 001 NOV 18, 1983

METRONIDAZOLE

INJECTABLE; INJECTION
METRONIDAZOLE

AM PHARM PARTNERS	500MG/100ML	N70071 001 DEC 03, 1984
ELKINS SINN	500MG/100ML	N18907 001 MAR 30, 1984
INTL MEDICATION	500MG/100ML	N70004 001 MAY 08, 1985
STERIS	500MG/100ML	N70042 001 DEC 20, 1984
	500MG/100ML	N70170 001 APR 01, 1986

TABLET; ORAL
METRONIDAZOLE

HALSEY	250MG	N18818 001 FEB 16, 1983
	250MG	N70021 001 APR 02, 1985
	500MG	N18818 002 FEB 16, 1983
	500MG	N70593 001 FEB 27, 1986
SUPERPHARM	250MG	N70008 001 DEC 11, 1984
	500MG	N70009 001 DEC 11, 1984
WATSON LABS	250MG	N18599 001 SEP 17, 1982
	500MG	N18599 002 FEB 13, 1984

PROTOSTAT

JOHNSON RW	250MG	N18871 001 MAR 02, 1983
	500MG	N18871 002 MAR 02, 1983

SATRIC

SAVAGE LABS	250MG	N70029 001 MAR 19, 1985
	500MG	N70731 001 JUN 08, 1987

FDA data supplied by DrugPatentWatch.com

METRONIDAZOLE HYDROCHLORIDE

INJECTABLE; INJECTION
METRONIDAZOLE HCL
AM PHARM PARTNERS — EQ 500MG BASE/VIAL — N70295 001 OCT 15, 1985

METYRAPONE

TABLET; ORAL
METOPIRONE
NOVARTIS — 250MG — N12911 001

MEZLOCILLIN SODIUM MONOHYDRATE

INJECTABLE; INJECTION
MEZLIN
BAYER — EQ 1GM BASE/VIAL — N62333 001
EQ 1GM BASE/VIAL — N62372 005 JAN 13, 1983
EQ 2GM BASE/VIAL — N62333 002
EQ 2GM BASE/VIAL — N62372 001 MAY 13, 1982
EQ 3GM BASE/VIAL — N62333 003
EQ 3GM BASE/VIAL — N62372 002 MAY 13, 1982
EQ 4GM BASE/VIAL — N62333 004
EQ 4GM BASE/VIAL — N62372 003 MAY 13, 1982
EQ 20GM BASE/VIAL — N62372 004 MAR 02, 1988

MICONAZOLE

INJECTABLE; INJECTION
MONISTAT
JANSSEN — 10MG/ML — N18040 001

MICONAZOLE NITRATE

LOTION; TOPICAL
MONISTAT-DERM
JOHNSON AND JOHNSON — 2% — N17739 001

MICONAZOLE NITRATE

TAMPON; VAGINAL
MONISTAT 5
PERSONAL PRODS — 100MG — N18592 001 OCT 27, 1989

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION
MIDAZOLAM HCL
APOTHECON — EQ 1MG BASE/ML — N75620 001 NOV 01, 2000
EQ 5MG BASE/ML — N75620 002 NOV 01, 2000
EQ 5MG BASE/ML — N75641 001 OCT 19, 2000
ASTRAZENECA — EQ 5MG BASE/ML — N75263 001 JUN 26, 2000
BEDFORD — EQ 5MG BASE/ML — N75249 001 JUN 23, 2000
BEN VENUE — EQ 5MG BASE/ML — N75455 001 JUN 20, 2000

MILRINONE LACTATE

INJECTABLE; INJECTION
PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER
SANOFI SYNTHELABO — EQ 10MG BASE/100ML — N20343 001 AUG 09, 1994
EQ 15MG BASE/100ML — N20343 002 AUG 09, 1994

MINOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL
MINOCIN
LEDERLE — EQ 50MG BASE — N50315 002
EQ 100MG BASE — N50315 001
VECTRIN
MEDICIS — EQ 75MG BASE — N63067 002 SEP 15, 1999
EQ 100MG BASE — N63067 001 JUL 31, 1990

INJECTABLE; INJECTION
MINOCIN
LEDERLE — EQ 100MG BASE/VIAL — N62139 001

FDA data supplied by DrugPatentWatch.com

MINOCYCLINE HYDROCHLORIDE

TABLET; ORAL			
MINOCYCLINE HCL			
* LEDERLE	EQ 50MG BASE	N50451 003	AUG 10, 1982
*	EQ 100MG BASE	N50451 002	AUG 10, 1982

MINOXIDIL

TABLET; ORAL			
MINODYL			
QUANTUM PHARMICS	2.5MG	N72153 001	JUL 13, 1988
	10MG	N71534 001	MAR 19, 1987
MINOXIDIL			
ROYCE LABS	2.5MG	N71799 001	NOV 10, 1987
	10MG	N71796 001	NOV 10, 1987
USL PHARMA	2.5MG	N71537 001	DEC 16, 1988

MITOMYCIN

INJECTABLE; INJECTION			
MUTAMYCIN			
BRISTOL	5MG/VIAL	N50450 001	
	20MG/VIAL	N50450 002	

MOLINDONE HYDROCHLORIDE

CAPSULE; ORAL			
MOBAN			
ENDO PHARMS	5MG	N17111 001	
	10MG	N17111 002	
	25MG	N17111 003	

MOXALACTAM DISODIUM

INJECTABLE; INJECTION			
MOXAM			
LILLY	EQ 250MG BASE/VIAL	N50550 001	

MOXALACTAM DISODIUM

INJECTABLE; INJECTION			
MOXAM			
LILLY	EQ 500MG BASE/VIAL	N50550 002	
	EQ 1GM BASE/VIAL	N50550 003	
	EQ 2GM BASE/VIAL	N50550 004	
	EQ 10GM BASE/VIAL	N50550 008	

NABILONE

CAPSULE; ORAL			
CESAMET			
LILLY	1MG	N18677 001	DEC 26, 1985

NAFCILLIN SODIUM

FOR SOLUTION; ORAL			
UNIPEN			
WYETH AYERST	EQ 250MG BASE/5ML	N50199 001	
INJECTABLE; INJECTION			
NAFCILLIN SODIUM			
APOTHECON	EQ 500MG BASE/VIAL	N61984 001	
	EQ 1GM BASE/VIAL	N61984 002	
	EQ 2GM BASE/VIAL	N61984 003	
	EQ 4GM BASE/VIAL	N61984 005	
MARSAM PHARMS LLC	EQ 500MG BASE/VIAL	N62844 001	OCT 26, 1988
	EQ 1GM BASE/VIAL	N62844 002	OCT 26, 1988
	EQ 1.5GM BASE/VIAL	N62844 003	OCT 26, 1988
	EQ 2GM BASE/VIAL	N62844 004	OCT 26, 1988
	EQ 4GM BASE/VIAL	N62844 005	OCT 26, 1988
	EQ 10GM BASE/VIAL	N63008 001	SEP 29, 1988
NALLPEN			
GLAXOSMITHKLINE	EQ 500MG BASE/VIAL	N61999 001	
	EQ 1GM BASE/VIAL	N61999 002	
	EQ 1GM BASE/VIAL	N62755 001	DEC 19, 1986
	EQ 2GM BASE/VIAL	N61999 003	

FDA data supplied by DrugPatentWatch.com

NAFCILLIN SODIUM

INJECTABLE; INJECTION			
NALLPEN			
GLAXOSMITHKLINE	EQ 2GM BASE/VIAL	N62755 002	
		DEC 19, 1986	
	EQ 10GM BASE/VIAL	N61999 004	
UNIPEN			
WYETH AYERST	EQ 500MG BASE/VIAL	N50320 001	
	EQ 500MG BASE/VIAL	N62717 001	
		DEC 16, 1986	
	EQ 1GM BASE/VIAL	N62717 002	
		DEC 16, 1986	
	EQ 2GM BASE/VIAL	N50320 003	
	EQ 2GM BASE/VIAL	N62717 004	
		DEC 16, 1986	
	EQ 4GM BASE/VIAL	N50320 004	
	EQ 10GM BASE/VIAL	N50320 005	
	EQ 20GM BASE/VIAL	N50320 006	
UNIPEN IN PLASTIC CONTAINER			
WYETH AYERST	EQ 1GM BASE/VIAL	N50320 002	
TABLET; ORAL			
UNIPEN			
WYETH AYERST	EQ 500MG BASE	N50462 001	

NALBUPHINE HYDROCHLORIDE

INJECTABLE; INJECTION			
NALBUPHINE			
AM PHARM PARTNERS	10MG/ML	N70751 001	
		JUL 02, 1986	
	20MG/ML	N70752 001	
		SEP 24, 1986	
QUAD PHARMS	10MG/ML	N70692 001	
		MAR 25, 1986	
	20MG/ML	N70693 001	
		SEP 24, 1986	
NALBUPHINE HCL			
ASTRAZENECA	10MG/ML	N72070 001	
		APR 10, 1989	
	10MG/ML	N72071 001	
		APR 10, 1989	
	10MG/ML	N72072 001	
		APR 10, 1989	
	20MG/ML	N72073 001	
		APR 10, 1989	

NALBUPHINE HYDROCHLORIDE

INJECTABLE; INJECTION			
NALBUPHINE HCL			
ASTRAZENECA	20MG/ML	N72074 001	
		APR 10, 1989	
	20MG/ML	N72075 001	
		APR 10, 1989	

NALIDIXIC ACID

TABLET; ORAL			
NALIDIXIC ACID			
HALSEY	1GM	N70272 001	
		JUN 29, 1988	
	250MG	N70270 001	
		JUN 29, 1988	
	500MG	N70271 001	
		JUN 29, 1988	

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION			
NALOXONE			
ELKINS SINN	0.4MG/ML	N70496 001	
		SEP 24, 1986	
WYETH AYERST	0.02MG/ML	N70188 001	
		SEP 24, 1986	
	0.02MG/ML	N70189 001	
		SEP 24, 1986	
	0.4MG/ML	N70190 001	
		SEP 24, 1986	
	0.4MG/ML	N70191 001	
		SEP 24, 1986	
NALOXONE HCL			
ABBOTT	0.4MG/ML	N70172 001	
		SEP 24, 1986	
AM PHARM PARTNERS	0.02MG/ML	N70648 001	
		NOV 17, 1986	
	0.02MG/ML	N70661 001	
		NOV 17, 1986	
	0.4MG/ML	N70649 001	
		NOV 17, 1986	
	1MG/ML	N71604 001	
		DEC 16, 1988	
ASTRAZENECA	0.02MG/ML	N72081 001	
		APR 11, 1989	

FDA data supplied by DrugPatentWatch.com

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION

NALOXONE HCL		
ASTRAZENECA	0.02MG/ML	N72082 001 APR 11, 1989
	0.02MG/ML	N72083 001 APR 11, 1989
	0.02MG/ML	N72084 001 APR 11, 1989
	0.02MG/ML	N72085 001 APR 11, 1989
	0.4MG/ML	N72086 001 APR 11, 1989
	0.4MG/ML	N72087 001 APR 11, 1989
	0.4MG/ML	N72088 001 APR 11, 1989
	0.4MG/ML	N72089 001 APR 11, 1989
	0.4MG/ML	N72090 001 APR 11, 1989
	1MG/ML	N72091 001 APR 11, 1989
	1MG/ML	N72092 001 APR 11, 1989
	1MG/ML	N72093 001 APR 11, 1989
INTL MEDICATION	0.4MG/ML	N70417 001 SEP 24, 1986
	1MG/ML	N72115 001 APR 27, 1988
MARSAM PHARMS LLC	0.4MG/ML	N71811 001 JUL 19, 1988
QUAD PHARMS	0.02MG/ML	N70678 001 DEC 18, 1986
	0.4MG/ML	N70679 001 DEC 18, 1986
	1MG/ML	N70680 001 DEC 18, 1986
SMITH AND NEPHEW	0.02MG/ML	N71671 001 NOV 17, 1987
	0.4MG/ML	N71681 001 NOV 17, 1987
	0.4MG/ML	N71682 001 NOV 17, 1987
SOLOPAK	0.02MG/ML	N71672 001 NOV 17, 1987

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION

NALOXONE HCL		
SOLOPAK	0.4MG/ML	N71683 001 NOV 17, 1987
STERIS	0.4MG/ML	N71339 001 NOV 18, 1987
NARCAN		
BRISTOL MYERS SQUIBB	0.4MG/ML	N71083 001 JUL 28, 1988
	1MG/ML	N71084 001 JUL 28, 1988
	1MG/ML	N71311 001 JUL 28, 1988

NANDROLONE DECANOATE

INJECTABLE; INJECTION

NANDROLONE DECANOATE		
AKORN	100MG/ML	N87519 001 SEP 28, 1983
AM PHARM PARTNERS	100MG/ML	N88290 001 OCT 03, 1983
	200MG/ML	N88317 001 OCT 14, 1983
QUAD PHARMS	50MG/ML	N89248 001 JUN 25, 1986
	100MG/ML	N89249 001 JUN 25, 1986
	200MG/ML	N89250 001 JUN 25, 1986
STERIS	50MG/ML	N87598 001 OCT 06, 1983
	50MG/ML	N88554 001 FEB 10, 1986
	100MG/ML	N87599 001 OCT 06, 1983

NANDROLONE PHENPROPIONATE

INJECTABLE; INJECTION

DURABOLIN		
ORGANON	25MG/ML	N11891 001
	50MG/ML	N11891 002
NANDROLONE PHENPROPIONATE		
QUAD PHARMS	25MG/ML	N89297 001 OCT 01, 1986

FDA data supplied by DrugPatentWatch.com

NANDROLONE PHENPROPIONATE

INJECTABLE; INJECTION
NANDROLONE PHENPROPIONATE

QUAD PHARMS	50MG/ML	N89298 001 OCT 01, 1986
STERIS	25MG/ML	N86386 001 JUN 17, 1983
	50MG/ML	N87488 001 JUN 17, 1983

NAPHAZOLINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

NAFAZAIR		
PHARMAFAIR	0.1%	N88101 001 APR 15, 1983
NAPHCON FORTE		
ALCON	0.1%	N80229 001
OPCON		
BAUSCH AND LOMB	0.1%	N87506 001

NAPROXEN

TABLET; ORAL
NAPROXEN

HAMILTON PHARMS	250MG	N74110 001 OCT 30, 1992
	375MG	N74110 002 OCT 30, 1992
	500MG	N74110 003 OCT 30, 1992

NAPROXEN SODIUM

TABLET; ORAL
NAPROXEN SODIUM

HAMILTON PHARMS	EQ 250MG BASE	N74106 001 AUG 31, 1993
	EQ 500MG BASE	N74106 002 AUG 31, 1993
PUREPAC PHARM	EQ 250MG BASE	N74319 001 MAR 20, 1995
	EQ 500MG BASE	N74319 002 MAR 20, 1995

NEDOCROMIL SODIUM

SOLUTION; INHALATION
TILADE

AVENTIS	0.5%	N20750 001 OCT 01, 1997

NEFAZODONE HYDROCHLORIDE

TABLET; ORAL
SERZONE

BRISTOL MYERS SQUIBB	300MG	N20152 006 DEC 22, 1994

NEOMYCIN SULFATE

TABLET; ORAL

MYCIFRADIN		
PHARMACIA AND UPJOHN	EQ 350MG BASE	N60520 001
NEOBIOTIC		
PFIZER	EQ 350MG BASE	N60475 001
NEOMYCIN SULFATE		
BRISTOL MYERS SQUIBB	EQ 350MG BASE	N60365 001
EON	EQ 350MG BASE	N61586 001
LANNETT	EQ 350MG BASE	N60607 001
LILLY	EQ 350MG BASE	N60385 001
ROXANE	EQ 350MG BASE	N62173 001

NEOMYCIN SULFATE; *MULTIPLE*

SEE BACITRACIN; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SEE BACITRACIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SEE BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SEE BACITRACIN ZINC; LIDOCAINE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SEE BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SEE DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SEE DEXAMETHASONE SODIUM PHOSPHATE; NEOMYCIN SULFATE
SEE FLUOCINOLONE ACETONIDE; NEOMYCIN SULFATE
SEE FLURANDRENOLIDE; NEOMYCIN SULFATE
SEE GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SEE HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SEE HYDROCORTISONE ACETATE; NEOMYCIN SULFATE
SEE METHYLPREDNISOLONE; NEOMYCIN SULFATE
SEE METHYLPREDNISOLONE ACETATE; NEOMYCIN SULFATE

FDA data supplied by DrugPatentWatch.com

NEOMYCIN SULFATE; POLYMYXIN B SULFATE

CREAM; TOPICAL
NEOSPORIN
GLAXOSMITHKLINE — EQ 3.5MG BASE/GM; 10,000 UNITS/GM — N50176 002 — JAN 14, 1985

SOLUTION; IRRIGATION
NEOMYCIN AND POLYMYXIN B SULFATES
STERIS — EQ 40MG BASE/ML; 200,000 UNITS/ML — N62664 001 — APR 08, 1986

SOLUTION/DROPS; OPHTHALMIC
STATROL
ALCON — EQ 3.5MG BASE/ML; 16,250 UNITS/ML — N62339 001 — NOV 30, 1984

NEOMYCIN SULFATE; PREDNISOLONE ACETATE

OINTMENT; OPHTHALMIC
NEO-DELTA-CORTEF
PHARMACIA AND UPJOHN — EQ 3.5MG BASE/GM;0.25% — N61039 002
EQ 3.5MG BASE/GM;0.5% — N61039 001

SUSPENSION/DROPS; OPHTHALMIC
NEO-DELTA-CORTEF
PHARMACIA AND UPJOHN — EQ 3.5MG BASE/ML;0.25% — N61037 001

NEOMYCIN SULFATE; PREDNISOLONE SODIUM PHOSPHATE

OINTMENT; OPHTHALMIC
NEO-HYDELTRASOL
MERCK — EQ 3.5MG BASE/GM; EQ 0.25% PHOSPHATE — N50378 001

NEOMYCIN SULFATE; TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL
MYTREX A
SAVAGE LABS — EQ 3.5MG BASE/GM;0.1% — N62598 001 — JUL 21, 1986
NEOMYCIN SULFATE-TRIAMCINOLONE ACETONIDE
FOUGERA — EQ 3.5MG BASE/GM;0.1% — N62600 001 — JUL 21, 1986

NEOMYCIN SULFATE; TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL
NEOMYCIN SULFATE-TRIAMCINOLONE ACETONIDE
PHARMADERM — EQ 3.5MG BASE/GM;0.1% — N62595 001 — JUL 21, 1986

OINTMENT; TOPICAL
MYTREX A
SAVAGE LABS — EQ 3.5MG BASE/GM;0.1% — N62609 001 — MAY 23, 1986
NEOMYCIN SULFATE-TRIAMCINOLONE ACETONIDE
FOUGERA — EQ 3.5MG BASE/GM;0.1% — N62608 001 — MAY 23, 1986
PHARMADERM — EQ 3.5MG BASE/GM;0.1% — N62607 001 — MAY 23, 1986

NETILMICIN SULFATE

INJECTABLE; INJECTION
NETROMYCIN
SCHERING — EQ 10MG BASE/ML — N50544 001 — FEB 28, 1983
EQ 25MG BASE/ML — N50544 002 — FEB 28, 1983
EQ 100MG BASE/ML — N50544 003 — FEB 28, 1983

NIACIN

CAPSULE; ORAL
WAMPOCAP
WALLACE LABS — 500MG — N11073 003

TABLET; ORAL
NIACIN
DANBURY PHARMA — 500MG — N83305 001
EVERYLIFE — 500MG — N83203 001
GENEVA PHARMS — 500MG — N83306 001
HALSEY — 500MG — N83453 001
IMPAX LABS — 500MG — N83115 001
IVAX PHARMS — 500MG — N83180 001
PUREPAC PHARM — 500MG — N83271 001
WATSON LAB — 500MG — N83136 001
WATSON LABS — 500MG — N85172 001
WEST WARD — 500MG — N83718 001

FDA data supplied by DrugPatentWatch.com

NIACINAMIDE; *MULTIPLE*

SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE; VITAMIN A; VITAMIN E

SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN E

SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PHYTONADIONE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A PALMITATE; VITAMIN E

NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; TYROSINE

SUSPENSION; ORAL
TPN SUSPENSION
INTL MINERALS — 15MG/5ML;3.75MG/5ML; 600MG/5ML — N08378 003

NICLOSAMIDE

TABLET, CHEWABLE; ORAL
NICLOCIDE
BAYER — 500MG — N18669 001 MAY 14, 1982

NICOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL
HABITROL
NOVARTIS — 7MG/24HR — N20076 001 NOV 27, 1991
14MG/24HR — N20076 002 NOV 27, 1991
21MG/24HR — N20076 003 NOV 27, 1991

PROSTEP
ELAN PHARM — 11MG/24HR — N19983 001 JAN 28, 1992

NICOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL
PROSTEP
ELAN PHARM — 22MG/24HR — N19983 002 JAN 28, 1992

NIFEDIPINE

CAPSULE; ORAL
NIFEDIPINE
CHASE LABS NJ — 10MG — N72409 001 JUL 04, 1990
20MG — N73421 001 JUN 19, 1991

TABLET, EXTENDED RELEASE; ORAL
NIFEDIPINE
MYLAN — 30MG — N75108 001 DEC 17, 1999

NITROFURANTOIN

CAPSULE; ORAL
NITROFURANTOIN
WATSON LAB — 50MG — N84326 001
100MG — N84326 002

TABLET; ORAL
FURALAN
LANNETT — 50MG — N80017 001
100MG — N80017 002

NITROFURANTOIN
ELKINS SINN — 50MG — N80003 001
100MG — N80003 002
EON — 50MG — N80043 001
100MG — N80043 002
IVAX PHARMS — 50MG — N80078 002
100MG — N80078 001
WATSON LAB — 100MG — N80447 002
WATSON LABS — 50MG — N85797 001
100MG — N85796 001

FDA data supplied by DrugPatentWatch.com

NITROFURANTOIN SODIUM

INJECTABLE; INJECTION
IVADANTIN
PROCTER AND GAMBLE — EQ 180MG BASE/VIAL — N12402 001

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL
NITROFURANTOIN MACROCRYSTALLINE
WATSON LAB — 50MG — N70248 001 JUN 24, 1988
100MG — N70249 001 JUN 24, 1988

NITROFURAZONE

DRESSING; TOPICAL
ACTIN-N
SHERWOOD MEDCL — 0.2% — N17343 001

OINTMENT; TOPICAL
NITROFURAZONE
AMBIX — 0.2% — N86077 001
CLAY PARK — 0.2% — N84968 001
LANNETT — 0.2% — N84393 001

POWDER; TOPICAL
FURACIN
SHIRE PHARM — 0.2% — N83791 001

SOLUTION; TOPICAL
NITROFURAZONE
CLAY PARK — 0.2% — N85130 001

NITROGLYCERIN

AEROSOL; SUBLINGUAL
NITROLINGUAL
POHL BOSKAMP — 0.4MG/SPRAY — N18705 001 OCT 31, 1985

INJECTABLE; INJECTION
NITRO IV
POHL BOSKAMP — 5MG/ML — N18672 002 AUG 30, 1983

NITROGLYCERIN

INJECTABLE; INJECTION
NITRO-BID
AVENTIS PHARMS — 10MG/ML — N71159 001 FEB 28, 1990

NITROGLYCERIN
AM PHARM PARTNERS — 5MG/ML — N70077 001 DEC 13, 1985
5MG/ML — N71203 001 MAY 08, 1987
INTL MEDICATION — 5MG/ML — N70026 001 SEP 10, 1985
LUITPOLD — 5MG/ML — N71492 001 MAY 24, 1988
QUAD PHARMS — 5MG/ML — N71094 001 JUL 31, 1987
10MG/ML — N71095 001 JUL 31, 1987
SMITH AND NEPHEW — 5MG/ML — N70633 001 JUN 19, 1986
5MG/ML — N70634 001 JUN 19, 1986

NITROL
RORER — 0.8MG/ML — N18774 001 JAN 19, 1983

NITRONAL
POHL BOSKAMP — 1MG/ML — N18672 001 AUG 30, 1983

NITROSTAT
PARKE DAVIS — 0.8MG/ML — N18588 001
5MG/ML — N18588 002 DEC 23, 1983
5MG/ML — N70863 001 JAN 08, 1987
10MG/ML — N70871 001 JAN 08, 1987
10MG/ML — N70872 001 JAN 08, 1987

NONOXYNOL-9

AEROSOL; VAGINAL
DELFEN
PERSONAL PRODS — 12.5% — N14349 002

SPONGE; VAGINAL
TODAY
ALLENDALE PHARMS — 1GM — N18683 001 APR 01, 1983

FDA data supplied by DrugPatentWatch.com

NOREPINEPHRINE BITARTRATE; PROCAINE HYDROCHLORIDE; PROPOXYCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
RAVOCAINE AND NOVOCAIN W/ LEVOPHED
EASTMAN KODAK — EQ 0.033MG BASE/ML;2%; 0.4% — N08592 003

NORETHINDRONE

TABLET; ORAL
NORLUTIN
PARKE DAVIS — 5MG — N10895 002

NORETHINDRONE; *MULTIPLE*
SEE ETHINYL ESTRADIOL; FERROUS FUMARATE; NORETHINDRONE
SEE ETHINYL ESTRADIOL; NORETHINDRONE
SEE MESTRANOL; NORETHINDRONE

NORETHINDRONE ACETATE

TABLET; ORAL
NORLUTATE
PARKE DAVIS — 5MG — N12184 002

NORETHINDRONE ACETATE; *MULTIPLE*
SEE ETHINYL ESTRADIOL; FERROUS FUMARATE; NORETHINDRONE ACETATE
SEE ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

NORETHYNODREL; *MULTIPLE*
SEE MESTRANOL; NORETHYNODREL

NYSTATIN

CREAM; TOPICAL
CANDEX
BAYER — 100,000 UNITS/GM — N61810 001
MYKINAC
ALPHARMA — 100,000 UNITS/GM — N62387 001 JUL 29, 1982
NILSTAT
LEDERLE — 100,000 UNITS/GM — N61445 001
NYSTATIN
TEVA — 100,000 UNITS/GM — N61966 001

NYSTATIN

LOTION; TOPICAL
CANDEX
BAYER — 100,000 UNITS/ML — N50233 001

OINTMENT; TOPICAL
MYCOSTATIN
WESTWOOD SQUIBB — 100,000 UNITS/GM — N60571 001
MYKINAC
ALPHARMA — 100,000 UNITS/GM — N62731 001 SEP 22, 1986
NILSTAT
LEDERLE — 100,000 UNITS/GM — N61444 001

POWDER; ORAL
BARSTATIN 100
BARLAN — 100% — N62489 001 APR 27, 1988

SUPPOSITORY; VAGINAL
NYSERT
PROCTER AND GAMBLE — 100,000 UNITS — N50478 001

SUSPENSION; ORAL
NYSTATIN
ALPHARMA — 100,000 UNITS/ML — N62571 001 OCT 29, 1985
MORTON GROVE — 100,000 UNITS/ML — N62835 001 NOV 19, 1987
PHARMADERM — 100,000 UNITS/ML — N62518 001 JUL 06, 1984
PHARMAFAIR — 100,000 UNITS/ML — N62541 001 JAN 16, 1985
ROXANE — 100,000 UNITS/ML — N62832 001 DEC 27, 1991
TEVA — 100,000 UNITS/ML — N62670 001 JUN 18, 1987
100,000 UNITS/ML — N62776 001 DEC 17, 1987
THAMES — 100,000 UNITS/ML — N62876 001 FEB 29, 1988

TABLET; ORAL
NYSTATIN
EON — 500,000 UNITS — N62065 001
QUANTUM PHARMICS — 500,000 UNITS — N62525 001 OCT 29, 1984

FDA data supplied by DrugPatentWatch.com

NYSTATIN

TABLET; ORAL		
NYSTATIN		
USL PHARMA	500,000 UNITS	N62524 001
		NOV 26, 1985
WATSON LABS	500,000 UNITS	N62402 001
		DEC 16, 1982
TABLET; VAGINAL		
KOROSTATIN		
HOLLAND RANTOS	100,000 UNITS	N61718 001
MYCOSTATIN		
BRISTOL MYERS SQUIBB	100,000 UNITS	N60577 001
NYSTATIN		
EON	100,000 UNITS	N61965 001
QUANTUM PHARMICS	100,000 UNITS	N62509 001
		APR 03, 1984
TEVA	100,000 UNITS	N62502 001
		DEC 23, 1983
WATSON LABS	100,000 UNITS	N62176 001

NYSTATIN; *MULTIPLE*
SEE CLIOQUINOL; NYSTATIN

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL		
MYCOLOG-II		
APOTHECON	100,000 UNITS/GM;0.1%	N60576 002
		MAY 01, 1985
NYSTATIN AND TRIAMCINOLONE ACETONIDE		
ALPHARMA	100,000 UNITS/GM;0.1%	N63010 001
		DEC 20, 1988
CLAY PARK	100,000 UNITS/GM;0.1%	N62186 002
		JUN 06, 1985
PHARMAFAIR	100,000 UNITS/GM;0.1%	N62657 001
		JUL 30, 1986
NYSTATIN-TRIAMCINOLONE ACETONIDE		
PHARMADERM	100,000 UNITS/GM;0.1%	N62596 001
		OCT 08, 1985
OINTMENT; TOPICAL		
MYCO-TRIACET II		
TEVA	100,000 UNITS/GM;0.1%	N62045 002
		NOV 26, 1985

NYSTATIN; TRIAMCINOLONE ACETONIDE

OINTMENT; TOPICAL		
NYSTATIN AND TRIAMCINOLONE ACETONIDE		
CLAY PARK	100,000 UNITS/GM;0.1%	N62280 002
		OCT 10, 1985
PHARMAFAIR	100,000 UNITS/GM;0.1%	N62656 001
		JUL 30, 1986
NYSTATIN-TRIAMCINOLONE ACETONIDE		
PHARMADERM	100,000 UNITS/GM;0.1%	N62603 001
		OCT 09, 1985

ORPHENADRINE CITRATE

TABLET, EXTENDED RELEASE; ORAL		
ORPHENADRINE CITRATE		
ASCOT	100MG	N88067 001
		APR 06, 1983
GENEVA PHARMS	100MG	N85046 001
WATSON LAB	100MG	N84303 001

ORPHENADRINE HYDROCHLORIDE

TABLET; ORAL		
DISIPAL		
3M	50MG	N10653 001

OXACILLIN SODIUM

CAPSULE; ORAL		
OXACILLIN SODIUM		
APOTHECON	EQ 250MG BASE	N61450 002
	EQ 500MG BASE	N61450 001
PROSTAPHLIN		
APOTHECON	EQ 500MG BASE	N50118 002
FOR SOLUTION; ORAL		
PROSTAPHLIN		
APOTHECON	EQ 250MG BASE/5ML	N50194 001
INJECTABLE; INJECTION		
BACTOCILL		
GLAXOSMITHKLINE	EQ 500MG BASE/VIAL	N61334 009
		MAR 26, 1982
	EQ 1GM BASE/VIAL	N61334 006
		MAR 26, 1982

FDA data supplied by DrugPatentWatch.com

OXACILLIN SODIUM

INJECTABLE; INJECTION

BACTOCILL		
GLAXOSMITHKLINE	EQ 1GM BASE/VIAL	N62736 001 DEC 19, 1986
	EQ 2GM BASE/VIAL	N61334 007 MAR 26, 1982
	EQ 2GM BASE/VIAL	N62736 002 DEC 19, 1986
	EQ 4GM BASE/VIAL	N61334 008 MAR 26, 1982
	EQ 10GM BASE/VIAL	N61334 010
OXACILLIN SODIUM		
APOTHECON	EQ 250MG BASE/VIAL	N50195 001
	EQ 500MG BASE/VIAL	N50195 002
	EQ 1GM BASE/VIAL	N50195 003
	EQ 2GM BASE/VIAL	N50195 004
	EQ 4GM BASE/VIAL	N50195 005
ELKINS SINN	EQ 250MG BASE/VIAL	N62711 001 FEB 03, 1989
	EQ 500MG BASE/VIAL	N62711 002 FEB 03, 1989
	EQ 1GM BASE/VIAL	N62711 003 FEB 03, 1989
	EQ 2GM BASE/VIAL	N62711 004 FEB 03, 1989
	EQ 4GM BASE/VIAL	N62711 005 FEB 03, 1989
	EQ 10GM BASE/VIAL	N62711 006 FEB 03, 1989
IBI	EQ 125MG BASE/VIAL	N62798 003 DEC 11, 1995
	EQ 250MG BASE/VIAL	N62798 004 DEC 11, 1995
	EQ 500MG BASE/VIAL	N62798 005 DEC 11, 1995
	EQ 1GM BASE/VIAL	N62798 001 DEC 11, 1995
	EQ 2GM BASE/VIAL	N62798 002 DEC 11, 1995

OXAZEPAM

CAPSULE; ORAL

OXAZEPAM		
AM THERAP	10MG	N71955 001 MAR 03, 1988

OXAZEPAM

CAPSULE; ORAL

OXAZEPAM		
AM THERAP	15MG	N71956 001 MAR 03, 1988
	30MG	N71957 001 MAR 03, 1988
HALSEY	10MG	N70957 001 AUG 10, 1987
	15MG	N71025 001 AUG 10, 1987
	30MG	N71026 001 AUG 10, 1987
MYLAN	10MG	N71713 001 OCT 20, 1987
	15MG	N71714 001 OCT 20, 1987
	30MG	N71715 001 OCT 20, 1987
ZAXOPAM		
QUANTUM PHARMICS	10MG	N70650 001 MAR 01, 1988
	15MG	N70640 001 MAR 01, 1988
	30MG	N70641 001 MAR 01, 1988

TABLET; ORAL

OXAZEPAM		
DANBURY PHARMA	15MG	N71494 001 APR 21, 1987
HALSEY	15MG	N70683 001 JAN 16, 1987
PARKE DAVIS	15MG	N71508 001 FEB 02, 1987

OXPRENOLOL HYDROCHLORIDE

CAPSULE; ORAL

TRASICOR		
NOVARTIS	20MG	N18166 001 DEC 28, 1983
	40MG	N18166 002 DEC 28, 1983
	80MG	N18166 003 DEC 28, 1983

FDA data supplied by DrugPatentWatch.com

OXPRENOLOL HYDROCHLORIDE

CAPSULE; ORAL
TRASICOR
NOVARTIS 160MG N18166 004 DEC 28, 1983

OXTRIPHYLLINE

SOLUTION; ORAL
CHOLEDYL
PARKE DAVIS 100MG/5ML N09268 012 NOV 27, 1984
OXTRIPHYLLINE
MORTON GROVE 100MG/5ML N88243 001 DEC 05, 1983

SYRUP; ORAL
CHOLEDYL
PARKE DAVIS 50MG/5ML N09268 011
OXTRIPHYLLINE PEDIATRIC
MORTON GROVE 50MG/5ML N88242 001 DEC 05, 1983

TABLET, DELAYED RELEASE; ORAL
CHOLEDYL
PARKE DAVIS 100MG N09268 003
200MG N09268 007
OXTRIPHYLLINE
WATSON LAB 100MG N87866 001 AUG 25, 1983
200MG N87835 001 AUG 25, 1983

OXYBUTYNIN CHLORIDE

TABLET; ORAL
OXYBUTYNIN CHLORIDE
QUANTUM PHARMICS 5MG N72296 001 DEC 08, 1988
USL PHARMA 5MG N70746 001 MAR 10, 1988
WATSON LAB 5MG N72485 001 APR 19, 1989

OXYCODONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
OXYCONTIN
PURDUE PHARMA LP 160MG N20553 005 MAR 15, 2000
ROXICODONE
ROXANE 10MG N20932 001 OCT 26, 1998
30MG N20932 002 OCT 26, 1998

OXYCODONE HYDROCHLORIDE; *MULTIPLE*
SEE ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE
SEE ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE
SEE ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

OXYCODONE TEREPHTHALATE; *MULTIPLE*
SEE ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE
SEE ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

OXYPHENBUTAZONE

TABLET; ORAL
OXYPHENBUTAZONE
WATSON LAB 100MG N88399 001 SEP 17, 1984
TANDEARIL
NOVARTIS 100MG N12542 004 SEP 03, 1982

OXYPHENCYCLIMINE HYDROCHLORIDE

TABLET; ORAL
DARICON
PFIZER 10MG N11612 001

OXYPHENONIUM BROMIDE

TABLET; ORAL
ANTRENYL
NOVARTIS 5MG N08492 002

FDA data supplied by DrugPatentWatch.com

OXYTETRACYCLINE

TABLET; ORAL
TERRAMYCIN
PFIZER 250MG N50287 001

OXYTETRACYCLINE CALCIUM

SYRUP; ORAL
TERRAMYCIN
PFIZER EQ 125MG BASE/5ML N60595 001

OXYTETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL
OXY-KESSO-TETRA
FERRANTE EQ 250MG BASE N60179 001
OXYTETRACYCLINE HCL
IMPAX LABS EQ 250MG BASE N60760 001
PROTER EQ 250MG BASE N60869 001
PUREPAC PHARM EQ 250MG BASE N60634 001
WEST WARD EQ 250MG BASE N60770 001
TERRAMYCIN
PFIZER EQ 125MG BASE N50286 001

INJECTABLE; INJECTION
TERRAMYCIN
PFIZER EQ 250MG BASE/VIAL N60586 001
EQ 500MG BASE/VIAL N60586 002

OXYTETRACYCLINE HYDROCHLORIDE; POLYMYXIN B SULFATE

OINTMENT; OTIC
TERRAMYCIN W/ POLYMYXIN
PFIZER EQ 5MG BASE/GM; 10,000 UNITS/GM N61841 001

TABLET; VAGINAL
TERRAMYCIN-POLYMYXIN
PFIZER EQ 100MG BASE; 100,000 UNITS N61009 001

OXYTOCIN

INJECTABLE; INJECTION
OXYTOCIN
WYETH AYERST 10 USP UNITS/ML N18243 001
OXYTOCIN 10 USP UNITS IN DEXTROSE 5%
ABBOTT 1 USP UNIT/100ML N19185 004 MAR 29, 1985
2 USP UNITS/100ML N19185 003 MAR 29, 1985
OXYTOCIN 20 USP UNITS IN DEXTROSE 5%
ABBOTT 2 USP UNITS/100ML N19185 002 MAR 29, 1985
OXYTOCIN 5 USP UNITS IN DEXTROSE 5%
ABBOTT 1 USP UNIT/100ML N19185 001 MAR 29, 1985

SOLUTION; NASAL
SYNTOCINON
NOVARTIS 40 USP UNITS/ML N12285 001

PANCURONIUM BROMIDE

INJECTABLE; INJECTION
PANCURONIUM BROMIDE
ASTRAZENECA 1MG/ML N72210 001 MAR 31, 1988
2MG/ML N72211 001 MAR 31, 1988
2MG/ML N72212 001 MAR 31, 1988
2MG/ML N72213 001 MAR 31, 1988
QUAD PHARMS 1MG/ML N72209 001 JUN 03, 1988
2MG/ML N72208 001 JUN 03, 1988

PANTOTHENIC ACID; *MULTIPLE*
SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PHYTONADIONE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A PALMITATE; VITAMIN E

FDA data supplied by DrugPatentWatch.com

PARAMETHADIONE

SOLUTION; ORAL			
PARADIONE			
ABBOTT	300MG/ML	N06800	002

PARAMETHASONE ACETATE

TABLET; ORAL			
HALDRONE			
LILLY	1MG	N12772	005
	2MG	N12772	006

PARGYLINE HYDROCHLORIDE

TABLET; ORAL			
EUTONYL			
ABBOTT	10MG	N13448	002
	25MG	N13448	003
	50MG	N13448	004

PARGYLINE HYDROCHLORIDE; *MULTIPLE*
SEE METHYCLOTHIAZIDE; PARGYLINE HYDROCHLORIDE

PAROMOMYCIN SULFATE

CAPSULE; ORAL			
HUMATIN			
PARKEDALE	EQ 250MG BASE	N60521	001
SYRUP; ORAL			
HUMATIN			
PARKE DAVIS	EQ 125MG BASE/5ML	N60522	001

PAROXETINE HYDROCHLORIDE

CAPSULE; ORAL			
PAXIL			
GLAXOSMITHKLINE	EQ 10MG BASE	N20885	001
		OCT 09, 1998	
	EQ 20MG BASE	N20885	002
		OCT 09, 1998	
	EQ 30MG BASE	N20885	003
		OCT 09, 1998	

PAROXETINE HYDROCHLORIDE

CAPSULE; ORAL			
PAXIL			
GLAXOSMITHKLINE	EQ 40MG BASE	N20885	004
		OCT 09, 1998	
TABLET; ORAL			
PAXIL			
GLAXOSMITHKLINE	EQ 50MG BASE	N20031	004
		DEC 29, 1992	

PENBUTOLOL SULFATE

TABLET; ORAL			
LEVATOL			
SCHWARZ PHARMA	10MG	N18976	001
		DEC 30, 1987	

PENICILLIN G BENZATHINE

INJECTABLE; INJECTION			
BICILLIN L-A			
WYETH AYERST	300,000 UNITS/ML	N50131	001
SUSPENSION; ORAL			
BICILLIN			
WYETH AYERST	300,000 UNITS/5ML	N50126	002
TABLET; ORAL			
BICILLIN			
WYETH AYERST	200,000 UNITS	N50128	001

PENICILLIN G POTASSIUM

FOR SOLUTION; ORAL			
PENICILLIN			
TEVA	200,000 UNITS/5ML	N60307	002
	400,000 UNITS/5ML	N60307	004
PENICILLIN G POTASSIUM			
MYLAN	200,000 UNITS/5ML	N60752	003
	250,000 UNITS/5ML	N60752	002
	400,000 UNITS/5ML	N60752	001
PUREPAC PHARM	250,000 UNITS/5ML	N61740	001
	400,000 UNITS/5ML	N61740	002
PENICILLIN-2			
TEVA	250,000 UNITS/5ML	N60307	003

FDA data supplied by DrugPatentWatch.com

PENICILLIN G POTASSIUM

FOR SOLUTION; ORAL			
PENTIDS '200'			
APOTHECON	200,000 UNITS/5ML	N62149	001
PENTIDS '400'			
APOTHECON	400,000 UNITS/5ML	N62149	002
PFIZERPEN G			
PFIZER	400,000 UNITS/5ML	N60587	001
INJECTABLE; INJECTION			
PENICILLIN G POTASSIUM			
APOTHECON	1,000,000 UNITS/VIAL	N60362	001
	5,000,000 UNITS/VIAL	N60362	003
	10,000,000 UNITS/VIAL	N60362	004
	20,000,000 UNITS/VIAL	N60362	002
CONSOLIDATED PHARM	500,000 UNITS/VIAL	N60806	001
	1,000,000 UNITS/VIAL	N60806	002
	5,000,000 UNITS/VIAL	N60806	003
	10,000,000 UNITS/VIAL	N60806	004
LILLY	200,000 UNITS/VIAL	N60384	004
	500,000 UNITS/VIAL	N60384	003
	1,000,000 UNITS/VIAL	N60384	002
	5,000,000 UNITS/VIAL	N60384	001
	20,000,000 UNITS/VIAL	N60384	005
	20,000,000 UNITS/VIAL	N60601	001
PARKE DAVIS	1,000,000 UNITS/VIAL	N62003	001
	5,000,000 UNITS/VIAL	N62003	002
TABLET; ORAL			
PENICILLIN G POTASSIUM			
APOTHECON	250,000 UNITS	N60392	003
IVAX PHARMS	400,000 UNITS	N60073	004
LILLY	250,000 UNITS	N60403	001
MYLAN	200,000 UNITS	N60781	001
	250,000 UNITS	N60781	002
	400,000 UNITS	N60781	003
	500,000 UNITS	N60781	005
	800,000 UNITS	N60781	004
PUREPAC PHARM	200,000 UNITS	N61588	001
	250,000 UNITS	N61588	002
	400,000 UNITS	N61588	003
TEVA	200,000 UNITS	N60306	001
	250,000 UNITS	N60306	002
	400,000 UNITS	N60306	003
	500,000 UNITS	N60306	004
PENTIDS '200'			
APOTHECON	200,000 UNITS	N62155	001
PENTIDS '250'			
APOTHECON	250,000 UNITS	N62155	002

PENICILLIN G POTASSIUM

TABLET; ORAL			
PENTIDS '400'			
APOTHECON	400,000 UNITS	N60392	004
	400,000 UNITS	N62155	003
PENTIDS '800'			
APOTHECON	800,000 UNITS	N60392	005
	800,000 UNITS	N62155	004
PFIZERPEN G			
PFIZER	50,000 UNITS	N60075	001
	100,000 UNITS	N60075	002
	200,000 UNITS	N60075	003
	250,000 UNITS	N60075	004
	400,000 UNITS	N60075	005
	800,000 UNITS	N60075	006

PENICILLIN G PROCAINE

INJECTABLE; INJECTION			
DURACILLIN A.S.			
LILLY	300,000 UNITS/ML	N60093	001
PENICILLIN G PROCAINE			
CONSOLIDATED PHARM	300,000 UNITS/ML	N60800	001
	600,000 UNITS/1.2ML	N60800	002
PARKE DAVIS	300,000 UNITS/ML	N62029	001
PFIZER	300,000 UNITS/VIAL	N60099	001
	1,500,000 UNITS/VIAL	N60099	002
PFIZERPEN-AS			
PFIZER	300,000 UNITS/ML	N60286	001
	600,000 UNITS/ML	N60286	002

PENICILLIN G SODIUM

INJECTABLE; IM-IV			
PENICILLIN G SODIUM			
MARSAM PHARMS LLC	5,000,000 UNITS/VIAL	N63014	001
		SEP 13,	1988
INJECTABLE; INJECTION			
PENICILLIN G SODIUM			
BRISTOL MYERS SQUIBB	5,000,000 UNITS/VIAL	N61935	001
COPANOS	5,000,000 UNITS/VIAL	N61051	001
PHARMACIA AND UPJOHN	1,000,000 UNITS/VIAL	N61046	001

FDA data supplied by DrugPatentWatch.com

PENICILLIN V

FOR SUSPENSION; ORAL			
V-CILLIN			
LILLY	125MG/0.6ML		N60002 001

PENICILLIN V POTASSIUM

FOR SOLUTION; ORAL			
BETAPEN-VK			
APOTHECON	EQ 125MG BASE/5ML		N61149 001
	EQ 250MG BASE/5ML		N61149 002
PENAPAR-VK			
PARKE DAVIS	EQ 125MG BASE/5ML		N62002 001
	EQ 250MG BASE/5ML		N62002 002
PENICILLIN V POTASSIUM			
MYLAN	EQ 125MG BASE/5ML		N61624 002
	EQ 250MG BASE/5ML		N61624 001
PUREPAC PHARM	EQ 125MG BASE/5ML		N61758 001
	EQ 250MG BASE/5ML		N61758 002
PFIZERPEN VK			
PFIZER	EQ 125MG BASE/5ML		N61815 001
	EQ 250MG BASE/5ML		N61815 002
V-CILLIN K			
LILLY	EQ 125MG BASE/5ML		N60004 001
	EQ 250MG BASE/5ML		N60004 002
VEETIDS '125'			
APOTHECON	EQ 125MG BASE/5ML		N61206 001
	EQ 125MG BASE/5ML		N62153 001
VEETIDS '250'			
APOTHECON	EQ 250MG BASE/5ML		N61206 002
	EQ 250MG BASE/5ML		N62153 002
TABLET; ORAL			
PEN-VEE K			
WYETH AYERST	EQ 125MG BASE		N60006 001
PENAPAR-VK			
PARKE DAVIS	EQ 250MG BASE		N62001 001
	EQ 500MG BASE		N62001 002
PENICILLIN V POTASSIUM			
IVAX PHARMS	EQ 125MG BASE		N60518 001
	EQ 250MG BASE		N60518 002
	EQ 500MG BASE		N60518 003
MYLAN	EQ 250MG BASE		N61530 001
	EQ 500MG BASE		N61530 002
PUREPAC PHARM	EQ 125MG BASE		N61571 001
	EQ 250MG BASE		N61571 002
	EQ 500MG BASE		N61571 003

PENICILLIN V POTASSIUM

TABLET; ORAL			
PFIZERPEN VK			
PFIZER	EQ 250MG BASE		N61836 001
	EQ 500MG BASE		N61836 002
UTICILLIN VK			
PHARMACIA AND UPJOHN	EQ 500MG BASE		N61651 002
V-CILLIN K			
LILLY	EQ 125MG BASE		N60003 001
	EQ 250MG BASE		N60003 002
	EQ 500MG BASE		N60003 003
VEETIDS '250'			
APOTHECON	EQ 250MG BASE		N61164 001
	EQ 250MG BASE		N62156 002
VEETIDS '500'			
APOTHECON	EQ 500MG BASE		N61164 002
	EQ 500MG BASE		N62156 001

PENTAMIDINE ISETHIONATE

INJECTABLE; INJECTION			
PENTACARINAT			
ARMOUR PHARM	300MG/VIAL		N73447 001
			APR 28, 1994

PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL			
TALWIN 50			
SANOFI SYNTHELABO	EQ 50MG BASE		N16732 001

PENTETATE CALCIUM TRISODIUM YB-169

INJECTABLE; INJECTION			
YTTERBIUM YB 169 DTPA			
3M	2mCi/ML		N17518 001

PENTOBARBITAL

ELIXIR; ORAL			
NEMBUTAL			
ABBOTT	18.2MG/5ML		N83244 001

FDA data supplied by DrugPatentWatch.com

PENTOBARBITAL SODIUM

CAPSULE; ORAL			
NEMBUTAL SODIUM			
ABBOTT	50MG	N84093	001
PENTOBARBITAL SODIUM			
LANNETT	50MG	N85937	001
	100MG	N85915	001
VITARINE	100MG	N83284	001
WHITEWORTH TOWN PLSN	100MG	N83338	001
SODIUM PENTOBARBITAL			
ANABOLIC	100MG	N84590	001
ELKINS SINN	100MG	N83368	001
EVERYLIFE	100MG	N83259	001
HALSEY	100MG	N84677	001
IVAX PHARMS	50MG	N83461	001
	100MG	N83461	002
PARKE DAVIS	100MG	N84156	001
PERRIGO	100MG	N84560	001
PUREPAC PHARM	100MG	N83301	001
WATSON LABS	100MG	N85791	001
WYETH AYERST	100MG	N83239	001
INJECTABLE; INJECTION			
PENTOBARBITAL SODIUM			
ELKINS SINN	50MG/ML	N83270	001
SUPPOSITORY; RECTAL			
NEMBUTAL			
ABBOTT	30MG	N83247	001
		JAN 25, 1982	
	60MG	N83247	002
		JAN 25, 1982	
	120MG	N83247	003
		JAN 25, 1982	
	200MG	N83247	004
		JAN 25, 1982	
TABLET; ORAL			
PENTOBARBITAL SODIUM			
VITARINE	100MG	N83285	001
SODIUM PENTOBARBITAL			
ANABOLIC	100MG	N84238	001

PENTOLINIUM TARTRATE

INJECTABLE; INJECTION			
ANSOLYSEN			
WYETH AYERST	10MG/ML	N09372	001

PERFLUBRON

LIQUID; ORAL			
IMAGENT			
ALLIANCE PHARM	100%	N20091	001
		AUG 13, 1993	

PERMETHRIN

LOTION; TOPICAL			
NIX			
GLAXOSMITHKLINE	1%	N19435	001
		MAR 31, 1986	

PERPHENAZINE

CONCENTRATE; ORAL			
TRILAFON			
SCHERING	16MG/5ML	N11557	001
SYRUP; ORAL			
TRILAFON			
SCHERING	2MG/5ML	N11294	002
TABLET, EXTENDED RELEASE; ORAL			
TRILAFON			
SCHERING	8MG	N11361	002

PERPHENAZINE; *MULTIPLE*

SEE AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

PHENAZOPYRIDINE HYDROCHLORIDE; SULFAMETHOXAZOLE

TABLET; ORAL			
AZO GANTANOL			
ROCHE	100MG;500MG	N13294	001
		SEP 10, 1987	

PHENAZOPYRIDINE HYDROCHLORIDE; SULFISOXAZOLE

TABLET; ORAL			
AZO GANTRISIN			
ROCHE	50MG;500MG	N19358	001
		AUG 31, 1990	

FDA data supplied by DrugPatentWatch.com

PHENDIMETRAZINE TARTRATE

CAPSULE; ORAL			
PHENAZINE			
MAST MM	35MG	N86523	001
	35MG	N86524	001
	35MG	N86525	001
PHENDIMETRAZINE TARTRATE			
EON	35MG	N85633	001
	35MG	N85694	001
	35MG	N85702	001
VITARINE	35MG	N85634	001
	35MG	N85645	001
	35MG	N85670	001
	35MG	N86403	001
	35MG	N86408	001
	35MG	N86410	001
	35MG	N87424	001
SPRX-3			
SOLVAY	35MG	N85897	001
STATOBEX			
TEVA	35MG	N85507	001
CAPSULE, EXTENDED RELEASE; ORAL			
MELFIAT-105			
NUMARK	105MG	N87487	001
		OCT 13, 1982	
PHENDIMETRAZINE TARTRATE			
GENEVA PHARMS	105MG	N87378	001
GRAHAM DM	105MG	N87214	001
		MAY 26, 1982	
	105MG	N88020	001
		AUG 16, 1982	
	105MG	N88028	001
		AUG 16, 1982	
	105MG	N88062	001
		SEP 13, 1982	
	105MG	N88063	001
		SEP 10, 1982	
	105MG	N88111	001
		OCT 18, 1982	
SPRX-105			
NUMARK	105MG	N88024	001
		DEC 22, 1982	
TABLET; ORAL			
ADPHEN			
FERNDALE LABS	35MG	N83655	001
ALPHAZINE			
EON	35MG	N85034	001

PHENDIMETRAZINE TARTRATE

TABLET; ORAL			
DI-METREX			
PVT FORM	35MG	N85698	001
MELFIAT			
NUMARK	35MG	N83790	002
METRA			
FOREST PHARMS	35MG	N83754	001
PHENAZINE			
MAST MM	35MG	N87305	001
PHENAZINE-35			
ABC HOLDING	35MG	N85512	001
PHENDIMETRAZINE TARTRATE			
ANABOLIC	35MG	N86020	001
BARR	35MG	N83644	001
	35MG	N83684	001
	35MG	N83686	001
	35MG	N83687	001
	35MG	N84831	001
	35MG	N84834	001
	35MG	N84835	001
EON	35MG	N85402	001
	35MG	N85497	001
FERNDALE LABS	35MG	N86834	001
		SEP 15, 1983	
GENEVA PHARMS	35MG	N86365	001
	35MG	N86370	001
INWOOD LABS	35MG	N84740	001
	35MG	N84741	001
	35MG	N84742	001
	35MG	N84743	001
IVAX PHARMS	35MG	N83682	001
	35MG	N85611	001
	35MG	N85612	001
KV PHARM	35MG	N84138	001
	35MG	N84141	001
	35MG	N85525	001
MFG CHEMISTS	35MG	N85914	001
MIKART	35MG	N89452	001
		OCT 30, 1991	
NUMARK	35MG	N83790	001
PVT FORM	35MG	N85199	001
	35MG	N85697	001
SOLVAY	35MG	N83993	001
USL PHARMA	35MG	N83805	001
	35MG	N84398	001
	35MG	N84399	001
VITARINE	35MG	N85519	001

PHENDIMETRAZINE TARTRATE

TABLET; ORAL
PHENDIMETRAZINE TARTRATE

VITARINE	35MG	N86005 001
	35MG	N86106 001
WATSON LABS	35MG	N85767 001
	35MG	N85768 001
	35MG	N85770 001
	35MG	N85773 001

PLEGINE

WYETH AYERST	35MG	N12248 001

STATOBEX

TEVA	35MG	N86013 001

STATOBEX-G

TEVA	35MG	N85095 001

X-TROZINE

SHIRE RICHWOOD	35MG	N86550 001
	35MG	N86551 001
	35MG	N86552 001

PHENINDIONE

TABLET; ORAL
HEDULIN

AVENTIS PHARMS	50MG	N08767 002

PHENMETRAZINE HYDROCHLORIDE

TABLET; ORAL
PRELUDIN

BOEHRINGER INGELHEIM	25MG	N10460 005

TABLET, EXTENDED RELEASE; ORAL
PRELUDIN

BOEHRINGER INGELHEIM	50MG	N11752 004
	75MG	N11752 003

PHENPROCOUMON

TABLET; ORAL
LIQUAMAR

ORGANON	3MG	N11228 001

PHENSUXIMIDE

CAPSULE; ORAL
MILONTIN

PARKE DAVIS	500MG	N08855 004

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL
FASTIN

GLAXOSMITHKLINE	30MG	N17352 001

OBESTIN-30

FERNDALE LABS	30MG	N87144 001

OBY-TRIM

SHIRE RICHWOOD	30MG	N87764 001
		MAR 18, 1982

PHENTERMINE HCL

ABC HOLDING	30MG	N85411 001
DURAMED	30MG	N88948 001
		APR 25, 1986
EON	37.5MG	N88414 001
		OCT 19, 1983
IVAX PHARMS	30MG	N86329 001
LANNETT	30MG	N87022 001
		FEB 03, 1983
TEVA	30MG	N86911 001
	30MG	N87126 001
	30MG	N87777 001
		NOV 01, 1985
	30MG	N88612 001
		APR 04, 1984
	30MG	N88613 001
		APR 09, 1984
	30MG	N88614 001
		APR 09, 1984
USL PHARMA	30MG	N84487 001
		APR 09, 1982
	30MG	N88430 001
		MAR 27, 1984
VITARINE	30MG	N87202 001
	30MG	N87235 001
WATSON LABS	30MG	N86740 001
		MAR 21, 1985

TABLET; ORAL
PHENTERMINE HCL

EON	8MG	N85671 001
	8MG	N85689 001

FDA data supplied by DrugPatentWatch.com

PHENTERMINE HYDROCHLORIDE

TABLET; ORAL

PHENTERMINE HCL		
IVAX PHARMS	8MG	N85553 001
VITARINE	8MG	N86453 001
	8MG	N86456 001
WATSON LABS	8MG	N85739 001
TORA		
SOLVAY	8MG	N84035 001

PHENTERMINE RESIN COMPLEX

CAPSULE, EXTENDED RELEASE; ORAL

PHENTERMINE RESIN 30		
QUANTUM PHARMICS	EQ 30MG BASE	N89120 001
		FEB 04, 1988

PHENYL AMINOSALICYLATE

POWDER; ORAL

PHENY-PAS-TEBAMIN		
PURDUE FREDERICK	50%	N11695 002

TABLET; ORAL

PHENY-PAS-TEBAMIN		
PURDUE FREDERICK	500MG	N11695 003

PHENYLBUTAZONE

CAPSULE; ORAL

AZOLID		
AVENTIS	100MG	N87260 001
BUTAZOLIDIN		
NOVARTIS	100MG	N08319 009
PHENYLBUTAZONE		
GENEVA PHARMS	100MG	N87774 001
		JUN 16, 1982
HALSEY	100MG	N88994 001
		DEC 04, 1985
IVAX PHARMS	100MG	N88218 001
		JUN 24, 1983
WATSON LABS	100MG	N87756 001
		DEC 17, 1982

TABLET; ORAL

AZOLID		
AVENTIS	100MG	N87091 001

PHENYLBUTAZONE

TABLET; ORAL

BUTAZOLIDIN		
NOVARTIS	100MG	N08319 008
PHENYLBUTAZONE		
DANBURY PHARMA	100MG	N87674 001
		APR 21, 1982
GENEVA PHARMS	100MG	N84339 001
HALSEY	100MG	N88863 001
		DEC 04, 1985
WATSON LABS	100MG	N86151 001

PHENYLEPHRINE BITARTRATE; *MULTIPLE*
SEE ISOPROTERENOL HYDROCHLORIDE; PHENYLEPHRINE BITARTRATE

PHENYLEPHRINE HYDROCHLORIDE; *MULTIPLE*
SEE CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PHERAZINE VC		
HALSEY	5MG/5ML;6.25MG/5ML	N88868 001
		MAR 02, 1987
PROMETHAZINE VC PLAIN		
CENCI	5MG/5ML;6.25MG/5ML	N88815 001
		NOV 22, 1985

PHENYLPROPANOLAMINE HYDROCHLORIDE; *MULTIPLE*
SEE BROMPHENIRAMINE MALEATE; CODEINE PHOSPHATE; PHENYLPROPANOLAMINE HYDROCHLORIDE
SEE BROMPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE
SEE CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE
SEE CLEMASTINE FUMARATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

PHENYLPROPANOLAMINE POLISTIREX; *MULTIPLE*
SEE CHLORPHENIRAMINE POLISTIREX; PHENYLPROPANOLAMINE POLISTIREX

FDA data supplied by DrugPatentWatch.com

PHENYTOIN

SUSPENSION; ORAL
DILANTIN-30
PARKE DAVIS 30MG/5ML N08762 002

PHENYTOIN SODIUM

INJECTABLE; INJECTION
PHENYTOIN SODIUM
AM PHARM PARTNERS 50MG/ML N89003 001 MAY 31, 1985
MARSAM PHARMS LLC 50MG/ML N89501 001 OCT 13, 1987
50MG/ML N89779 001 NOV 27, 1992
SMITH AND NEPHEW 50MG/ML N88519 001 DEC 19, 1984
50MG/ML N88521 001 DEC 18, 1984
SOLOPAK 50MG/ML N88520 001 DEC 17, 1984
STERIS 50MG/ML N85434 001
WARNER CHILCOTT 50MG/ML N89900 001 MAR 30, 1990

PHENYTOIN SODIUM, EXTENDED

CAPSULE; ORAL
EXTENDED PHENYTOIN SODIUM
SIDMAK LABS NJ 100MG N89441 001 DEC 18, 1986
PHENYTEX
WATSON LAB 100MG N88711 001 DEC 21, 1984

PHENYTOIN SODIUM, PROMPT

CAPSULE; ORAL
DIPHENYLAN SODIUM
LANNETT 30MG N80857 001
100MG N80857 002
PHENYTOIN SODIUM
PHARMERAL 100MG N85435 001
WATSON LABS 100MG N85894 001
PROMPT PHENYTOIN SODIUM
DANBURY PHARMA 100MG N80905 001

PHOSPHORIC ACID; *MULTIPLE*
SEE AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; SODIUM CHLORIDE

PHYTONADIONE

INJECTABLE; INJECTION
KONAKION
ROCHE 1MG/0.5ML N11745 001
10MG/ML N11745 003
PHYTONADIONE
GLAXOSMITHKLINE 1MG/0.5ML N84060 001
10MG/ML N84060 002
VITAMIN K1
ABBOTT 10MG/ML N87956 001 JUL 25, 1983

PHYTONADIONE; *MULTIPLE*
SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PHYTONADIONE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A PALMITATE; VITAMIN E

PINACIDIL

CAPSULE, EXTENDED RELEASE; ORAL
PINDAC
LEO PHARM 12.5MG N19456 001 DEC 28, 1989
25MG N19456 002 DEC 28, 1989

PINDOLOL

TABLET; ORAL
PINDOLOL
PUREPAC PHARM 5MG N74125 001 APR 28, 1993
10MG N74125 002 APR 28, 1993

PINDOLOL; *MULTIPLE*
SEE HYDROCHLOROTHIAZIDE; PINDOLOL

FDA data supplied by DrugPatentWatch.com

PIPERACETAZINE

TABLET; ORAL			
QUIDE			
DOW PHARM	10MG	N13615 001	
	25MG	N13615 002	

PIPERACILLIN SODIUM

INJECTABLE; INJECTION			
PIPRACIL			
LEDERLE	EQ 40GM BASE/VIAL	N50545 006	SEP 30, 1985

PIPERAZINE CITRATE

SYRUP; ORAL			
ANTEPAR			
GLAXOSMITHKLINE	EQ 500MG BASE/5ML	N09102 001	
BRYREL			
SANOFI SYNTHELABO	EQ 500MG BASE/5ML	N17796 001	
PIPERAZINE CITRATE			
ALPHARMA	EQ 500MG BASE/5ML	N80774 001	
LANNETT	EQ 500MG BASE/5ML	N80963 001	
VERMIDOL			
SOLVAY	EQ 500MG BASE/5ML	N80992 001	
TABLET; ORAL			
ANTEPAR			
GLAXOSMITHKLINE	EQ 500MG BASE	N09102 003	
PIPERAZINE CITRATE			
IMPAX LABS	EQ 250MG BASE	N80874 001	

PIPOBROMAN

TABLET; ORAL			
VERCYTE			
ABBOTT	10MG	N16245 001	
	25MG	N16245 002	

PIROXICAM

CAPSULE; ORAL			
PIROXICAM			
ROXANE	10MG	N73651 001	FEB 26, 1993

PIROXICAM

CAPSULE; ORAL			
PIROXICAM			
ROXANE	20MG	N73651 002	FEB 26, 1993

POLYESTRADIOL PHOSPHATE

INJECTABLE; INJECTION			
ESTRADURIN			
WYETH AYERST	40MG/AMP	N10753 001	

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE, ANHYDROUS

FOR SOLUTION; ORAL			
COLYTE			
SCHWARZ PHARMA	120GM/PACKET;1.49GM/PACKET; 3.36GM/PACKET;2.92GM/PACKET; 11.36GM/PACKET	N18983 005	OCT 26, 1984
	227.1GM/PACKET;2.82GM/PACKET; 6.36GM/PACKET;5.53GM/PACKET; 21.5GM/PACKET	N18983 004	OCT 26, 1984
	360GM/PACKET;4.47GM/PACKET; 10.08GM/PACKET;8.76GM/PACKET; 34.08GM/PACKET	N18983 006	OCT 26, 1984
FOR SUSPENSION; ORAL			
PEG-LYTE			
INVAMED	236GM/BOT;2.97GM/BOT;6.74GM/BOT; 5.86GM/BOT;22.74GM/BOT	N73098 001	AUG 31, 1993

POLYMYXIN B SULFATE

INJECTABLE; INJECTION			
AEROSPORIN			
GLAXOSMITHKLINE	EQ 500,000 U BASE/VIAL	N62036 001	
POWDER; FOR RX COMPOUNDING			
POLYMYXIN B SULFATE			
PADDOCK	100,000,000 UNITS/BOT	N62455 001	JUL 27, 1983

FDA data supplied by DrugPatentWatch.com

POLYMYXIN B SULFATE; *MULTIPLE*

SEE BACITRACIN; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SEE BACITRACIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SEE BACITRACIN; POLYMYXIN B SULFATE
SEE BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SEE BACITRACIN ZINC; LIDOCAINE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SEE BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SEE BACITRACIN ZINC; POLYMYXIN B SULFATE
SEE CHLORAMPHENICOL; HYDROCORTISONE ACETATE; POLYMYXIN B SULFATE
SEE CHLORAMPHENICOL; POLYMYXIN B SULFATE
SEE DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SEE GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SEE HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SEE HYDROCORTISONE; POLYMYXIN B SULFATE
SEE NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SEE OXYTETRACYCLINE HYDROCHLORIDE; POLYMYXIN B SULFATE

POTASSIUM ACETATE; *MULTIPLE*

SEE AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM ACETATE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE
SEE AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; SODIUM CHLORIDE
SEE AMINO ACIDS; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE
SEE AMINO ACIDS; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE
SEE AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM ACETATE; POTASSIUM CHLORIDE; SODIUM ACETATE

POTASSIUM AMINOSALICYLATE

POWDER; ORAL
POTASSIUM AMINOSALICYLATE

HEXCEL	100%	N80098 001

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
K-LEASE

SAVAGE LABS	8MEQ	N73398 001 JAN 28, 1992

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
K-LEASE

SAVAGE LABS	10MEQ	N72427 001 MAR 28, 1990

FOR SUSPENSION, EXTENDED RELEASE; ORAL
MICRO-K LS

KV PHARM	20MEQ/PACKET	N19561 003 AUG 26, 1988

INJECTABLE; INJECTION
POTASSIUM CHLORIDE

ABBOTT	1MEQ/ML	N80205 003
	1MEQ/ML	N83345 003
	2.4MEQ/ML	N80205 004
	3.2MEQ/ML	N80205 005
AKORN	2MEQ/ML	N88286 001 SEP 05, 1985
AM PHARM PARTNERS	2MEQ/ML	N80204 001
	2MEQ/ML	N84290 001
	2MEQ/ML	N86713 001
	2MEQ/ML	N86714 001
	2MEQ/ML	N87787 001 APR 20, 1982
	2MEQ/ML	N87885 001 FEB 03, 1983
ELKINS SINN	2MEQ/ML	N80203 001
GD SEARLE LLC	1MEQ/ML	N86219 001
	2MEQ/ML	N86219 002
	2MEQ/ML	N86220 002
	3MEQ/ML	N86219 003
	3MEQ/ML	N86220 001
	4MEQ/ML	N86219 004
LILLY	2MEQ/ML	N07865 002
LUITPOLD	2MEQ/ML	N80221 001
	2MEQ/ML	N80736 001
MILES	1MEQ/ML	N80195 002
	2MEQ/ML	N80195 001
	3MEQ/ML	N80195 003
	4MEQ/ML	N80195 004
STERIS	2MEQ/ML	N86208 001
	2MEQ/ML	N89163 001 MAR 10, 1988
	2MEQ/ML	N89421 001 JAN 02, 1987
	3MEQ/ML	N86210 001

FDA data supplied by DrugPatentWatch.com

POTASSIUM CHLORIDE

INJECTABLE; INJECTION
POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER

ABBOTT	745MG/100ML	N20161 001 NOV 30, 1992
	14.9MG/ML	N20161 005 NOV 30, 1992

POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER

ABBOTT	1.49GM/100ML	N20161 002 NOV 30, 1992

TABLET, EXTENDED RELEASE; ORAL

KAON CL		
SAVAGE LABS	6.7MEQ	N17046 001
KAON CL-10		
SAVAGE LABS	10MEQ	N17046 002
TEN-K		
NOVARTIS	10MEQ	N19381 001 APR 16, 1986

POTASSIUM CHLORIDE; *MULTIPLE*
SEE AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE
SEE AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM ACETATE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE
SEE AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE
SEE AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE
SEE AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM ACETATE; POTASSIUM CHLORIDE; SODIUM ACETATE
SEE AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE
SEE AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE
SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE
SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE
SEE CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE
SEE CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE
SEE CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

POTASSIUM CHLORIDE; *MULTIPLE*
SEE CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE
SEE CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE
SEE CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE
SEE DEXTROSE; POTASSIUM CHLORIDE
SEE DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE
SEE MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE
SEE MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE
SEE POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE, ANHYDROUS

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION
POTASSIUM CHLORIDE 0.037% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

B BRAUN	37MG/100ML;900MG/100ML	N19708 001 SEP 29, 1989

POTASSIUM CHLORIDE 0.075% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

B BRAUN	75MG/100ML;900MG/100ML	N19708 002 SEP 29, 1989

POTASSIUM CHLORIDE 0.11% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

B BRAUN	110MG/100ML;900MG/100ML	N19708 003 SEP 29, 1989

POTASSIUM CHLORIDE 0.22% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

B BRAUN	220MG/100ML;900MG/100ML	N19708 005 SEP 29, 1989

POTASSIUM CHLORIDE 0.3% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

B BRAUN	300MG/100ML;900MG/100ML	N19708 006 SEP 29, 1989

SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER

B BRAUN	75MG/100ML;900MG/100ML	N18722 001 NOV 09, 1982
BAXTER HLTHCARE	75MG/100ML;900MG/100ML	N17648 004

SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER

B BRAUN	150MG/100ML;900MG/100ML	N18722 002 NOV 09, 1982

FDA data supplied by DrugPatentWatch.com

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER
B BRAUN 220MG/100ML;900MG/100ML N18722 003 NOV 09, 1982

SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
B BRAUN 300MG/100ML;900MG/100ML N18722 004 NOV 09, 1982

POTASSIUM CHLORIDE; SODIUM CHLORIDE; TROMETHAMINE

INJECTABLE; INJECTION
THAM-E
ABBOTT 370MG/VIAL;1.75GM/VIAL; 36GM/VIAL N13025 001

POTASSIUM CITRATE

FOR SOLUTION; ORAL
POTASSIUM CITRATE
MISSION PHARMA 10MEQ/PACKET N19647 002 OCT 13, 1988
20MEQ/PACKET N19647 001 OCT 13, 1988

POTASSIUM IODIDE

SOLUTION; ORAL
POTASSIUM IODIDE
ROXANE 1GM/ML N18551 001 FEB 19, 1982

POTASSIUM PHOSPHATE, DIBASIC; *MULTIPLE*
SEE AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE
SEE AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM ACETATE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE
SEE AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE
SEE AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

POTASSIUM PHOSPHATE, MONOBASIC; *MULTIPLE*
SEE MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

PRALIDOXIME CHLORIDE

INJECTABLE; INJECTION
PRALIDOXIME CHLORIDE
QUAD PHARMS 1GM/VIAL N72224 001 NOV 23, 1988
WYETH AYERST 300MG/ML N18799 001 DEC 13, 1982

TABLET; ORAL
PROTOPAM CHLORIDE
WYETH AYERST 500MG N14122 002

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET; ORAL
MIRAPEX
PHARMACIA AND UPJOHN 1.25MG N20667 004 JUL 01, 1997

PRAMOXINE HYDROCHLORIDE; *MULTIPLE*
SEE HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

PRAZEPAM

CAPSULE; ORAL
CENTRAX
PARKE DAVIS 5MG N18144 001
10MG N18144 002
20MG N18144 003 MAY 10, 1982

PRAZEPAM
USL PHARMA 5MG N70427 001 NOV 06, 1987
10MG N70428 001 NOV 06, 1987

TABLET; ORAL
CENTRAX
PARKE DAVIS 10MG N17415 001

FDA data supplied by DrugPatentWatch.com

PRAZOSIN HYDROCHLORIDE

CAPSULE; ORAL			
PRAZOSIN HCL			
AM THERAP	EQ 1MG BASE	N72782 001	
		MAY 16, 1989	
	EQ 2MG BASE	N72783 001	
		MAY 16, 1989	
	EQ 5MG BASE	N72784 001	
		MAY 16, 1989	
PUREPAC PHARM	EQ 1MG BASE	N72991 001	
		MAY 16, 1989	
	EQ 2MG BASE	N72921 001	
		MAY 16, 1989	
	EQ 5MG BASE	N72992 001	
		MAY 16, 1989	

PREDNISOLONE

CREAM; TOPICAL		
METI-DERM		
SCHERING	0.5%	N10209 002
TABLET; ORAL		
CORTALONE		
HALSEY	1MG	N80304 003
	2.5MG	N80304 002
	5MG	N80304 001
DELTA-CORTEF		
PHARMACIA AND UPJOHN	5MG	N09987 004
FERNISOLONE-P		
FERNDALE LABS	5MG	N83941 001
PREDNISOLONE		
BARR	5MG	N84426 002
BUNDY	5MG	N83675 001
ELKINS SINN	5MG	N80625 001
EON	5MG	N84773 001
EVERYLIFE	1MG	N84439 001
FERRANTE	2.5MG	N80562 001
	5MG	N80562 002
GENEVA PHARMS	5MG	N80339 001
HEATHER	5MG	N80326 001
ICN	5MG	N80236 001
IMPAX LABS	5MG	N80780 001
INWOOD LABS	5MG	N80748 001
IVAX PHARMS	5MG	N80378 001
PANRAY	1MG	N80351 001
	5MG	N80351 002

PREDNISOLONE

TABLET; ORAL		
PREDNISOLONE		
PERRIGO	5MG	N84542 001
PHOENIX LABS NY	5MG	N80322 001
PUREPAC PHARM	5MG	N80325 001
PVT FORM	5MG	N80211 001
ROXANE	5MG	N80327 002
SUPERPHARM	5MG	N88892 001
		FEB 26, 1985
TABLICAPS	5MG	N85170 001
TEVA	5MG	N80398 001
UDL	5MG	N87987 001
		JAN 18, 1983
VITARINE	5MG	N80534 001
WATSON LABS	5MG	N85085 002
	5MG	N85415 001
	5MG	N85416 001
WEST WARD	5MG	N80324 001
WHITEWORTH TOWN PLSN	5MG	N80342 001
STERANE		
PFIZER	5MG	N09996 001

PREDNISOLONE; *MULTIPLE*
SEE CHLORAMPHENICOL; PREDNISOLONE

PREDNISOLONE ACETATE

INJECTABLE; INJECTION		
METICORTELONE		
SCHERING	25MG/ML	N10255 002
PREDNISOLONE ACETATE		
AKORN	25MG/ML	N83032 001
	50MG/ML	N84492 001
BEL MAR	25MG/ML	N83738 001
	50MG/ML	N83738 002
CENT PHARMS	25MG/ML	N84717 001
	50MG/ML	N84717 002
STERIS	25MG/ML	N83654 001
	40MG/ML	N83767 001
STERANE		
PFIZER	25MG/ML	N11446 001

PREDNISOLONE ACETATE; *MULTIPLE*
SEE NEOMYCIN SULFATE; PREDNISOLONE ACETATE

FDA data supplied by DrugPatentWatch.com

PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM

OINTMENT; OPHTHALMIC			
PREDSULFAIR			
PHARMAFAIR	0.5%;10%	N88032 001	APR 15, 1983
SUSPENSION/DROPS; OPHTHALMIC			
PREDAMIDE			
AKORN	0.5%;10%	N88059 001	JUL 29, 1983
PREDSULFAIR			
PHARMAFAIR	0.5%;10%	N88007 001	APR 19, 1983
PREDSULFAIR II			
PHARMAFAIR	0.2%;10%	N88837 001	DEC 24, 1985
SULPHRIN			
BAUSCH AND LOMB	0.5%;10%	N88089 001	DEC 28, 1982

PREDNISOLONE SODIUM PHOSPHATE

INJECTABLE; INJECTION			
HYDELTRASOL			
MERCK	EQ 20MG PHOSPHATE/ML	N11583 002	
PREDNISOLONE SODIUM PHOSPHATE			
STERIS	EQ 20MG PHOSPHATE/ML	N80517 001	
OINTMENT; OPHTHALMIC, OTIC			
HYDELTRASOL			
MERCK	EQ 0.25% PHOSPHATE	N11028 001	
SOLUTION/DROPS; OPHTHALMIC			
METRETON			
SCHERING	EQ 0.5% PHOSPHATE	N83834 001	
PREDAIR			
PHARMAFAIR	EQ 0.11% PHOSPHATE	N88415 001	FEB 29, 1984
PREDAIR FORTE			
PHARMAFAIR	EQ 0.9% PHOSPHATE	N88165 001	MAR 28, 1983
PREDNISOLONE SODIUM PHOSPHATE			
AKORN	EQ 0.11% PHOSPHATE	N83358 001	
	EQ 0.9% PHOSPHATE	N83358 002	
ALCON UNIVERSAL	EQ 0.11% PHOSPHATE	N81043 001	OCT 24, 1991

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION/DROPS; OPHTHALMIC			
PREDNISOLONE SODIUM PHOSPHATE			
ALCON UNIVERSAL	EQ 0.9% PHOSPHATE	N81044 001	OCT 24, 1991
SOLA BARNES HIND	EQ 0.11% PHOSPHATE	N84171 001	
	EQ 0.9% PHOSPHATE	N84168 001	
	EQ 0.9% PHOSPHATE	N84169 001	
	EQ 0.9% PHOSPHATE	N84172 001	

PREDNISOLONE SODIUM PHOSPHATE; *MULTIPLE*
SEE NEOMYCIN SULFATE; PREDNISOLONE SODIUM PHOSPHATE

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC			
SULSTER			
AKORN	EQ 0.23% PHOSPHATE;10%	N74511 001	JUL 30, 1996

PREDNISOLONE TEBUTATE

INJECTABLE; INJECTION			
PREDNISOLONE TEBUTATE			
STERIS	20MG/ML	N83362 001	FEB 17, 1984

PREDNISONE

SOLUTION; ORAL			
PREDNISONE			
MORTON GROVE	5MG/5ML	N89726 001	AUG 02, 1988
SYRUP; ORAL			
LIQUID PRED			
MURO	5MG/5ML	N87611 002	SEP 07, 1982
TABLET; ORAL			
CORTAN			
HALSEY	20MG	N87480 001	
DELTA-DOME			
BAYER	5MG	N80293 001	

FDA data supplied by DrugPatentWatch.com

PREDNISONE

TABLET; ORAL

FERNISONE		
FERNDALE LABS	5MG	N83364 001
METICORTEN		
SCHERING	1MG	N09766 002
	5MG	N09766 001
ORASONE		
SOLVAY	1MG	N83009 001
	5MG	N83009 002
	10MG	N83009 003
	20MG	N83009 004
	50MG	N85999 001
PARACORT		
PARKE DAVIS	5MG	N10962 002
PREDNICEN-M		
SCHWARZ PHARMA	5MG	N84655 001
PREDNISONE		
AM THERAP	5MG	N89387 001
		NOV 06, 1986
	10MG	N89388 001
		NOV 06, 1986
	20MG	N89389 001
		NOV 06, 1986
BUNDY	5MG	N83676 001
DANBURY PHARMA	50MG	N86867 001
DURAMED	5MG	N88394 001
		OCT 04, 1983
	10MG	N88395 001
		OCT 04, 1983
	20MG	N88396 001
		OCT 04, 1983
ELKINS SINN	5MG	N80491 001
	20MG	N85811 001
EON	5MG	N84774 001
EVERYLIFE	1MG	N84440 001
	2.5MG	N84440 002
	5MG	N84440 003
FERRANTE	2.5MG	N80563 001
	5MG	N80563 002
GENEVA PHARMS	5MG	N80336 002
HALSEY	5MG	N80300 001
	5MG	N80701 001
	10MG	N86595 001
	20MG	N84634 001
	50MG	N86596 001
HEATHER	5MG	N80320 001
	10MG	N84341 001

PREDNISONE

TABLET; ORAL

PREDNISONE		
HEATHER	20MG	N84417 001
	20MG	N85543 001
	50MG	N86946 001
ICN	5MG	N80237 001
IMPAX LABS	5MG	N80782 001
INTERPHARM	5MG	N89597 001
		OCT 05, 1987
	10MG	N89598 001
		OCT 05, 1987
	20MG	N89599 001
		OCT 05, 1987
INWOOD LABS	1MG	N80328 001
	2.5MG	N80306 001
	5MG	N80279 001
IVAX PHARMS	5MG	N80283 001
	10MG	N84133 001
	20MG	N84134 001
KV PHARM	5MG	N84236 001
LANNETT	20MG	N84275 001
LEDERLE	5MG	N86968 001
NYLOS	5MG	N85115 001
PANRAY	1MG	N80350 001
	2.5MG	N80350 002
	5MG	N80350 003
PERRIGO	5MG	N83059 001
PHARMAVITE	5MG	N84662 002
PHOENIX LABS NY	5MG	N80321 001
	20MG	N83807 001
PUREPAC PHARM	5MG	N80353 001
	10MG	N86062 001
	20MG	N86061 001
PVT FORM	20MG	N85151 001
REXALL	5MG	N80232 001
ROXANE	20MG	N17109 001
	25MG	N87833 001
		MAY 04, 1982
SCHERER LABS	5MG	N80371 001
SPERTI	1MG	N80359 001
	2.5MG	N80359 002
	5MG	N80359 003
SUPERPHARM	5MG	N88865 001
		OCT 25, 1984
	10MG	N88866 001
		OCT 25, 1984

FDA data supplied by DrugPatentWatch.com

PREDNISONE

TABLET; ORAL		
PREDNISONE		
SUPERPHARM	20MG	N88867 001
		OCT 25, 1984
TEVA	5MG	N80397 001
UDL	5MG	N87984 001
		JAN 18, 1983
	10MG	N87985 001
		JAN 18, 1983
	20MG	N87986 001
		JAN 18, 1983
UPSHER SMITH	5MG	N87471 001
	20MG	N87470 001
VANGARD	5MG	N87682 001
		JAN 15, 1982
	20MG	N87701 001
		JAN 15, 1982
VITARINE	5MG	N80334 001
	5MG	N80506 001
WATSON LABS	5MG	N85084 002
WHITEWORTH TOWN PLSN	2.5MG	N84913 001
	5MG	N80343 001
	10MG	N89028 001
		JUL 24, 1986
	20MG	N84913 002
SERVISONE		
LEDERLE	5MG	N80223 001

PRILOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION		
CITANEST		
ASTRAZENECA	1%	N14763 004
	2%	N14763 005
	3%	N14763 003
CITANEST PLAIN		
ASTRAZENECA	4%	N14763 007

PRILOCAINE HYDROCHLORIDE; *MULTIPLE*
SEE EPINEPHRINE BITARTRATE; PRILOCAINE HYDROCHLORIDE

PRIMAQUINE PHOSPHATE; *MULTIPLE*
SEE CHLOROQUINE PHOSPHATE; PRIMAQUINE PHOSPHATE

PRIMIDONE

TABLET; ORAL		
PRIMIDONE		
WATSON LAB	250MG	N85052 001

PROBENECID

TABLET; ORAL		
BENEMID		
MERCK	500MG	N07898 004
PROBENECID		
LEDERLE	500MG	N86917 001
WATSON LABS	500MG	N86150 002
		APR 23, 1982

PROBENECID; *MULTIPLE*
SEE AMPICILLIN/AMPICILLIN TRIHYDRATE; PROBENECID
SEE COLCHICINE; PROBENECID

PROBUCOL

TABLET; ORAL		
LORELCO		
AVENTIS PHARMS	250MG	N17535 001
	500MG	N17535 002
		JUL 06, 1988

PROCAINAMIDE HYDROCHLORIDE

CAPSULE; ORAL		
PROCAINAMIDE HCL		
ASCOT	250MG	N87542 001
		JAN 08, 1982
	375MG	N87697 001
		MAR 01, 1983
	500MG	N87543 001
		JAN 08, 1982
LANNETT	500MG	N84696 001
LEDERLE	250MG	N86942 001
	375MG	N86952 001
	500MG	N86943 001
ROXANE	250MG	N88989 001
		APR 26, 1985

FDA data supplied by DrugPatentWatch.com

PROCAINAMIDE HYDROCHLORIDE

CAPSULE; ORAL		
PROCAINAMIDE HCL		
ROXANE	500MG	N88990 001 APR 26, 1985
VANGARD	250MG	N87643 001 JUN 01, 1982
	500MG	N87875 001 JUN 01, 1982
WATSON LAB	250MG	N83795 001
	500MG	N84357 001
WATSON LABS	250MG	N85167 001
	375MG	N87020 001
	500MG	N87021 001
PROCAN		
PARKE DAVIS	250MG	N85804 001
	375MG	N87502 001
	500MG	N85079 001
PROCAPAN		
PANRAY	250MG	N83553 002
INJECTABLE; INJECTION		
PROCAINAMIDE HCL		
AM PHARM PARTNERS	100MG/ML	N89415 001 NOV 17, 1986
	500MG/ML	N89416 001 NOV 17, 1986
PHARMAFAIR	100MG/ML	N88824 001 NOV 20, 1985
	500MG/ML	N88830 001 NOV 20, 1985
QUAD PHARMS	100MG/ML	N89256 001 MAY 30, 1986
	500MG/ML	N89257 001 MAY 30, 1986
SMITH AND NEPHEW	100MG/ML	N88530 001 MAR 04, 1985
	500MG/ML	N88531 001 MAR 04, 1985
SOLOPAK	500MG/ML	N88532 001 MAR 04, 1985
STERIS	100MG/ML	N87079 001
	500MG/ML	N87080 001
WARNER CHILCOTT	100MG/ML	N89528 001 MAY 03, 1988
	500MG/ML	N89529 001 MAY 03, 1988

PROCAINAMIDE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL		
PROCAINAMIDE HCL		
INVAMED	500MG	N89284 001 JUN 23, 1986
INWOOD LABS	500MG	N89840 001 MAR 06, 1989
SIDMAK LABS NJ	250MG	N88958 001 DEC 02, 1985
WATSON LAB	1GM	N89520 001 JAN 15, 1987
	250MG	N88533 001 DEC 03, 1984
	500MG	N88534 001 DEC 03, 1984
	750MG	N88535 001 NOV 03, 1984
PROCAN SR		
PARKE DAVIS	250MG	N86468 001
PARKEDALE	1GM	N88489 001 JAN 16, 1985
	500MG	N86065 001
	750MG	N87510 001 APR 01, 1982

PROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION		
PROCAINE HCL		
AM PHARM PARTNERS	1%	N80384 002
	2%	N80384 003
BEL MAR	1%	N80711 001
	2%	N80756 001
GD SEARLE LLC	1%	N86202 001
	2%	N86202 002
MILES	1%	N80415 001
	2%	N80415 002
STERIS	1%	N83535 001
	2%	N83535 002

PROCAINE HYDROCHLORIDE; *MULTIPLE*

SEE EPINEPHRINE; PROCAINE HYDROCHLORIDE

SEE LEVONORDEFRIN; PROCAINE HYDROCHLORIDE; PROPOXYCAINE HYDROCHLORIDE

SEE NOREPINEPHRINE BITARTRATE; PROCAINE HYDROCHLORIDE; PROPOXYCAINE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

PROCAINE HYDROCHLORIDE; TETRACYCLINE HYDROCHLORIDE

INJECTABLE; INJECTION

ACHROMYCIN		
LEDERLE	40MG/VIAL;100MG/VIAL	N50276 001
	40MG/VIAL;250MG/VIAL	N50276 003
TETRACYN		
PFIZER	40MG/VIAL;100MG/VIAL	N60285 002
	40MG/VIAL;250MG/VIAL	N60285 003

PROCAINE MERETHOXYLLINE; THEOPHYLLINE

INJECTABLE; INJECTION

DICURIN PROCAINE		
LILLY	100MG/ML;50MG/ML	N08869 001

PROCHLORPERAZINE EDISYLATE

CONCENTRATE; ORAL

COMPAZINE		
GLAXOSMITHKLINE	EQ 10MG BASE/ML	N11276 001
PROCHLORPERAZINE		
ALPHARMA	EQ 10MG BASE/ML	N87153 001 JUN 08, 1982
PROCHLORPERAZINE EDISYLATE		
MORTON GROVE	EQ 10MG BASE/ML	N88598 001 OCT 25, 1984

INJECTABLE; INJECTION

PROCHLORPERAZINE EDISYLATE		
ELKINS SINN	EQ 5MG BASE/ML	N89523 001 MAY 03, 1988
MARSAM PHARMS LLC	EQ 5MG BASE/ML	N89675 001 DEC 05, 1988
QUAD PHARMS	EQ 5MG BASE/ML	N89637 001 FEB 01, 1988
	EQ 5MG BASE/ML	N89638 001 FEB 01, 1988
SMITH AND NEPHEW	EQ 5MG BASE/ML	N89251 001 DEC 04, 1986
STERIS	EQ 5MG BASE/ML	N89605 001 JUL 08, 1987
	EQ 5MG BASE/ML	N89606 001 JUL 08, 1987
WYETH AYERST	EQ 5MG BASE/ML	N86348 001

PROCHLORPERAZINE EDISYLATE

SYRUP; ORAL

PROCHLORPERAZINE EDISYLATE		
ALPHARMA	EQ 5MG BASE/5ML	N87154 001 SEP 01, 1982
MORTON GROVE	EQ 5MG BASE/5ML	N88597 001 OCT 25, 1984

PROCHLORPERAZINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL

COMPAZINE		
GLAXOSMITHKLINE	EQ 75MG BASE	N11000 004

TABLET; ORAL

PROCHLORPERAZINE		
WATSON LAB	EQ 5MG BASE	N85580 001
	EQ 10MG BASE	N85178 001
	EQ 25MG BASE	N85579 001
PROCHLORPERAZINE MALEATE		
DURAMED	EQ 5MG BASE	N89484 001 JAN 20, 1987
	EQ 10MG BASE	N89485 001 JAN 20, 1987
	EQ 25MG BASE	N89486 001 JAN 20, 1987

PROCYCLIDINE HYDROCHLORIDE

TABLET; ORAL

KEMADRIN		
MONARCH PHARMS	2MG	N09818 005

PROGESTERONE

CAPSULE; ORAL

PROMETRIUM		
UNIMED PHARMS	300MG	N19781 003 OCT 15, 1999

INJECTABLE; INJECTION

PROGESTERONE		
LILLY	25MG/ML	N09238 002
	50MG/ML	N09238 001

FDA data supplied by DrugPatentWatch.com

PROMAZINE HYDROCHLORIDE

CONCENTRATE; ORAL		
SPARINE		
WYETH AYERST	30MG/ML	N10942 001
	100MG/ML	N10942 004
INJECTABLE; INJECTION		
PROMAZINE HCL		
STERIS	25MG/ML	N84510 001
	50MG/ML	N84517 001
SPARINE		
WYETH AYERST	25MG/ML	N10349 008
SYRUP; ORAL		
SPARINE		
WYETH AYERST	10MG/5ML	N10942 003
TABLET; ORAL		
SPARINE		
WYETH AYERST	10MG	N10348 006
	100MG	N10348 003
	200MG	N10348 004

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION		
PROMETHAZINE HCL		
ABBOTT	25MG/ML	N84223 001
	50MG/ML	N84222 001
AKORN	25MG/ML	N83955 002
	50MG/ML	N83955 001
MARSAM PHARMS LLC	25MG/ML	N89463 001
		MAY 02, 1988
	50MG/ML	N89477 001
		MAY 02, 1988
STERIS	25MG/ML	N83532 001
	50MG/ML	N83532 002
ZIPAN-25		
ALTANA	25MG/ML	N83997 001
ZIPAN-50		
ALTANA	50MG/ML	N83997 002
SUPPOSITORY; RECTAL		
PROMETHACON		
POLYMEDICA	50MG	N84902 001

PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL		
MYMETHAZINE FORTIS		
USL PHARMA	25MG/5ML	N87996 001
		JAN 18, 1983
PROMETH FORTIS		
ALPHARMA	25MG/5ML	N84772 001
PROMETHAZINE		
CENCI	6.25MG/5ML	N89013 001
		SEP 20, 1985
PROMETHAZINE HCL		
KV PHARM	6.25MG/5ML	N85388 001
	25MG/5ML	N85385 001
PHARM ASSOC	6.25MG/5ML	N87518 001
TABLET; ORAL		
PROMETHAZINE HCL		
ABBOTT	12.5MG	N84160 001
	25MG	N84166 001
	50MG	N84539 001
DANBURY PHARMA	12.5MG	N83712 001
EON	25MG	N85146 001
	50MG	N85146 002
GENEVA PHARMS	12.5MG	N84233 001
HALSEY	12.5MG	N84555 001
	25MG	N84554 001
	50MG	N84557 001
IMPAX LABS	25MG	N84214 002
		JUL 07, 1982
IVAX PHARMS	12.5MG	N83604 001
	25MG	N83603 001
	50MG	N83613 001
LANNETT	12.5MG	N80949 001
	25MG	N80949 002
	50MG	N80949 003
PVT FORM	12.5MG	N83214 001
	25MG	N83658 001
TABLICAPS	12.5MG	N84080 001
	25MG	N84027 001
TEVA	25MG	N89109 001
		SEP 10, 1985
WATSON LAB	12.5MG	N83401 001
	25MG	N83204 001
	50MG	N83403 001
WATSON LABS	12.5MG	N85986 001
	25MG	N85684 001
	50MG	N85664 001
REMSED		
BRISTOL MYERS SQUIBB	25MG	N83176 002

FDA data supplied by DrugPatentWatch.com

PROMETHAZINE HYDROCHLORIDE

TABLET; ORAL			
REMSED			
BRISTOL MYERS SQUIBB	50MG	N83176	001

PROMETHAZINE HYDROCHLORIDE; *MULTIPLE*

SEE CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE
SEE CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE
SEE DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE
SEE PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

PROPANTHELINE BROMIDE

INJECTABLE; INJECTION			
PRO-BANTHINE			
GD SEARLE LLC	30MG/VIAL	N08843	001
TABLET; ORAL			
PROPANTHELINE BROMIDE			
ASCOT	15MG	N87663	001
		OCT 25, 1982	
DANBURY PHARMA	15MG	N83029	002
GENEVA PHARMS	15MG	N80928	001
HEATHER	15MG	N85780	001
IMPAX LABS	15MG	N84541	002
MYLAN	15MG	N83706	001
PAR PHARM	15MG	N88377	001
		DEC 08, 1983	
PVT FORM	15MG	N80977	001
TABLICAPS	15MG	N84428	001
WATSON LAB	15MG	N83151	001

PROPARACAINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC			
KAINAIR			
PHARMAFAIR	0.5%	N88087	001
		JUN 07, 1983	
PROPARACAINE HCL			
SOLA BARNES HIND	0.5%	N84144	001
	0.5%	N84151	001

PROPIOLACTONE

SOLUTION; IRRIGATION			
BETAPRONE			
FORREST LABS	N/A	N11657	001

PROPIOMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION			
LARGON			
WYETH AYERST	20MG/ML	N12382	002

PROPOFOL

INJECTABLE; INJECTION			
DIPRIVAN			
ASTRAZENECA	10MG/ML	N19627	001
		OCT 02, 1989	

PROPOXYCAINE HYDROCHLORIDE; *MULTIPLE*

SEE LEVONORDEFRIN; PROCAINE HYDROCHLORIDE; PROPOXYCAINE HYDROCHLORIDE
SEE NOREPINEPHRINE BITARTRATE; PROCAINE HYDROCHLORIDE; PROPOXYCAINE HYDROCHLORIDE

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL			
PROPHENE 65			
HALSEY	65MG	N83538	002
PROPOXYPHENE HCL			
ALRA	65MG	N83184	001
ANABOLIC	65MG	N83185	001
DANBURY PHARMA	65MG	N80908	002
EON	32MG	N84014	001
	65MG	N83688	001
	65MG	N83870	002
	65MG	N86495	001
GENEVA PHARMS	65MG	N83125	002
HALSEY	65MG	N83186	001
IMPAX LABS	65MG	N83317	001
IVAX PHARMS	32MG	N83597	001
MYLAN	65MG	N83299	001
PUREPAC PHARM	65MG	N83278	001
PVT FORM	32MG	N83464	001

FDA data supplied by DrugPatentWatch.com

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL		
PROPOXYPHENE HCL		
PVT FORM	65MG	N83113 001
ROXANE	32MG	N83089 001
	65MG	N83089 002
WATSON LABS	65MG	N85190 001
PROPOXYPHENE HCL 65		
WARNER CHILCOTT	65MG	N83786 001

PROPOXYPHENE HYDROCHLORIDE; *MULTIPLE*

SEE ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE
SEE ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE

PROPOXYPHENE NAPSYLATE; *MULTIPLE*

SEE ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE
SEE ASPIRIN; PROPOXYPHENE NAPSYLATE

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL		
PROPRANOLOL HCL		
INWOOD LABS	60MG	N72499 001 APR 11, 1989
	80MG	N72500 001 APR 11, 1989
	120MG	N72501 001 APR 11, 1989
	160MG	N72502 001 APR 11, 1989
INJECTABLE; INJECTION		
PROPRANOLOL HCL		
SMITH AND NEPHEW	1MG/ML	N70135 001 APR 15, 1986
	1MG/ML	N70137 001 APR 15, 1986
SOLOPAK	1MG/ML	N70136 001 APR 15, 1986
SOLUTION; ORAL		
PROPRANOLOL HCL		
MORTON GROVE	20MG/5ML	N71984 001 MAR 03, 1989

PROPRANOLOL HYDROCHLORIDE

SOLUTION; ORAL		
PROPRANOLOL HCL		
MORTON GROVE	40MG/5ML	N71985 001 MAR 03, 1989
SUSPENSION; ORAL		
INDERAL		
WYETH AYERST	10MG/ML	N19536 001 DEC 12, 1986
TABLET; ORAL		
INDERAL		
WYETH AYERST	90MG	N16418 010 OCT 18, 1982
PROPRANOLOL HCL		
DANBURY PHARMA	60MG	N71098 001 OCT 06, 1986
	90MG	N71183 001 OCT 06, 1986
DURAMED	10MG	N70306 001 SEP 09, 1985
	20MG	N70307 001 SEP 09, 1985
	40MG	N70308 001 SEP 09, 1985
	60MG	N70309 001 OCT 01, 1986
	80MG	N70310 001 SEP 09, 1985
	90MG	N71327 001 OCT 01, 1986
HALSEY	10MG	N70319 001 OCT 22, 1985
	20MG	N70320 001 OCT 22, 1985
	40MG	N70103 001 OCT 22, 1985
	60MG	N70321 001 SEP 24, 1986
	80MG	N70322 001 AUG 04, 1986
INTERPHARM	10MG	N71368 001 MAY 05, 1987
	20MG	N71369 001 MAY 05, 1987
	40MG	N71370 001 MAY 05, 1987

FDA data supplied by DrugPatentWatch.com

PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL
PROPRANOLOL HCL

INTERPHARM	80MG	N71371 001 MAY 05, 1987
INVAMED	10MG	N71658 001 JUL 05, 1988
	20MG	N71687 001 JUL 05, 1988
	40MG	N71688 001 JUL 05, 1988
	60MG	N72197 001 JUL 05, 1988
	80MG	N71689 001 JUL 05, 1988
	90MG	N72198 001 JUL 05, 1988
IVAX PHARMS	10MG	N72063 001 JUL 29, 1988
	20MG	N72066 001 JUL 29, 1988
	40MG	N72067 001 JUL 29, 1988
	60MG	N72068 001 JUL 29, 1988
	80MG	N72069 001 JUL 29, 1988
LEDERLE	10MG	N70125 001 JUL 30, 1985
	10MG	N72117 001 JUN 23, 1988
	20MG	N70126 001 JUL 30, 1985
	20MG	N72118 001 JUN 23, 1988
	40MG	N70127 001 JUL 30, 1985
	40MG	N72119 001 JUN 23, 1988
	80MG	N72120 001 JUN 23, 1988
MYLAN	60MG	N72275 001 JUN 09, 1989
ROXANE	10MG	N70516 001 JUL 07, 1986
	20MG	N70517 001 JUL 07, 1986

PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL
PROPRANOLOL HCL

ROXANE	40MG	N70518 001 JUL 07, 1986
	60MG	N70519 001 SEP 24, 1986
	80MG	N70520 001 JUL 07, 1986
	90MG	N70521 001 SEP 24, 1986
SCHERING	10MG	N70120 001 AUG 06, 1985
	20MG	N70121 001 AUG 06, 1985
	40MG	N70122 001 AUG 06, 1985
	60MG	N70123 001 OCT 29, 1986
	80MG	N70124 001 AUG 06, 1985
SUPERPHARM	10MG	N71515 001 JUN 08, 1988
	20MG	N71516 001 JUN 08, 1988
	40MG	N71517 001 JUN 08, 1988
	80MG	N71518 001 JUN 08, 1988
TEVA	10MG	N70232 001 OCT 07, 1987
	20MG	N70233 001 JUN 23, 1986
WARNER CHILCOTT	10MG	N70438 001 SEP 15, 1986
	20MG	N70439 001 SEP 15, 1986
	40MG	N70440 001 SEP 15, 1986
	60MG	N70441 001 SEP 24, 1986
	80MG	N70442 001 SEP 15, 1986
WATSON LAB	10MG	N70378 001 MAR 19, 1987
	20MG	N70379 001 MAR 19, 1987

FDA data supplied by DrugPatentWatch.com

PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL			
PROPRANOLOL HCL			
WATSON LAB	40MG	N70380 001	
		MAR 19, 1987	
	60MG	N70381 001	
		MAR 19, 1987	
	80MG	N70382 001	
		MAR 19, 1987	
WATSON LABS	10MG	N70140 001	
		JUL 30, 1985	
	20MG	N70141 001	
		JUL 30, 1985	
	20MG	N70549 001	
		APR 11, 1986	
	40MG	N70142 001	
		JUL 30, 1985	
	60MG	N70143 001	
		JAN 15, 1987	
	80MG	N70144 001	
		JUL 30, 1985	

PROPRANOLOL HYDROCHLORIDE; *MULTIPLE*
SEE HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

PROPYLIODONE

SUSPENSION; INTRATRACHEAL		
DIONOSIL AQUEOUS		
GLAXOSMITHKLINE	50%	N09309 001
DIONOSIL OILY		
GLAXOSMITHKLINE	60%	N09309 002

PROPYLTHIOURACIL

TABLET; ORAL		
PROPYLTHIOURACIL		
ABBOTT	50MG	N84075 001
ANABOLIC	50MG	N80285 001
DANBURY PHARMA	50MG	N80932 001
HALSEY	50MG	N80015 001
	50MG	N83982 001
IVAX PHARMS	50MG	N80215 001
LANNETT	50MG	N80016 001
LILLY	50MG	N06213 001

PROPYLTHIOURACIL

TABLET; ORAL		
PROPYLTHIOURACIL		
PERRIGO	50MG	N84543 001
TABLICAPS	50MG	N80840 001
WATSON LABS	50MG	N85201 001

PROTAMINE SULFATE

INJECTABLE; INJECTION		
PROTAMINE SULFATE		
PHARMACIA AND UPJOHN	50MG/VIAL	N07413 001
	250MG/VIAL	N07413 002
		AUG 02, 1984
QUAD PHARMS	10MG/ML	N89306 001
		MAY 30, 1986
	50MG/VIAL	N89307 001
		MAY 30, 1986

PROTEIN HYDROLYSATE

INJECTABLE; INJECTION		
AMINOSOL 5%		
ABBOTT	5%	N05932 012
		JAN 31, 1985
HYPROTIGEN 5%		
B BRAUN	5%	N06170 003
		JAN 10, 1984

PROTIRELIN

INJECTABLE; INJECTION		
THYPINONE		
ABBOTT	0.5MG/ML	N17638 001

PROTOKYLOL HYDROCHLORIDE

TABLET; ORAL		
VENTAIRE		
AVENTIS PHARMS	2MG	N83459 001

FDA data supplied by DrugPatentWatch.com

PROTRIPTYLINE HYDROCHLORIDE

TABLET; ORAL			
VIVACTIL			
SIDMAK LABS	5MG	N16012	001
	10MG	N16012	002

PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL			
NOVAFED			
AVENTIS PHARMS	120MG	N17603	001
SUDAFED 12 HOUR			
* GLAXOSMITHKLINE	120MG	N17941	002

PSEUDOEPHEDRINE HYDROCHLORIDE; *MULTIPLE*
SEE CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE
SEE CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE
SEE DIPHENHYDRAMINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL			
ACTIFED			
GLAXOSMITHKLINE	120MG;5MG	N18996	001
		JUN 17, 1985	
TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES			
KV PHARM	120MG;5MG	N71798	001
		MAR 16, 1989	
SYRUP; ORAL			
ACTAHIST			
CENCI	30MG/5ML;1.25MG/5ML	N88344	001
		FEB 09, 1984	
HISTAFED			
CENCI	30MG/5ML;1.25MG/5ML	N88283	001
		APR 20, 1984	
MYFED			
USL PHARMA	30MG/5ML;1.25MG/5ML	N88116	001
		MAR 04, 1983	
TRILITRON			
NEWTRON PHARMS	30MG/5ML;1.25MG/5ML	N88474	001
		FEB 12, 1985	

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

TABLET; ORAL			
ALLERFED			
PVT FORM	60MG;2.5MG	N88860	001
		JAN 31, 1985	
TRIPHED			
TEVA	60MG;2.5MG	N88630	001
		MAY 17, 1984	
TRIPROLIDINE AND PSEUDOEPHEDRINE			
WATSON LAB	60MG;2.5MG	N88318	002
		JAN 13, 1984	
WEST WARD	60MG;2.5MG	N88117	001
		APR 19, 1983	
TRIPROLIDINE HCL AND PSEUDOEPHEDRINE HCL			
IVAX PHARMS	60MG;2.5MG	N85273	001
		DEC 12, 1984	

PSEUDOEPHEDRINE POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL			
PSEUDO-12			
CELLTECH PHARMS	EQ 60MG HCL/5ML	N19401	001
		JUN 19, 1987	

PSEUDOEPHEDRINE SULFATE; *MULTIPLE*
SEE DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

PYRIDOSTIGMINE BROMIDE

TABLET; ORAL			
PYRIDOSTIGMINE BROMIDE			
SOLVAY	30MG	N89572	001
		NOV 27, 1990	

PYRIDOXINE; *MULTIPLE*
SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE; VITAMIN A; VITAMIN E
SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PHYTONADIONE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A PALMITATE; VITAMIN E

FDA data supplied by DrugPatentWatch.com

PYRIDOXINE HYDROCHLORIDE

INJECTABLE; INJECTION		
HEXA-BETALIN		
LILLY	100MG/ML	N80854 001
PYRIDOXINE HCL		
AKORN	100MG/ML	N87967 001
		OCT 01, 1982
BEL MAR	100MG/ML	N80761 001
DELL LABS	50MG/ML	N83771 001
	100MG/ML	N83772 001
ELKINS SINN	100MG/ML	N80581 001
LUITPOLD	100MG/ML	N80669 001
STERIS	100MG/ML	N83760 001

PYRIDOXINE HYDROCHLORIDE; *MULTIPLE*

SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN E

SEE DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE

SEE NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; TYROSINE

PYRILAMINE MALEATE

TABLET; ORAL		
PYRILAMINE MALEATE		
WATSON LABS	25MG	N85231 001

PYRITHIONE ZINC

LOTION; TOPICAL		
HEAD & SHOULDERS CONDITIONER		
PROCTER AND GAMBLE	0.3%	N19412 002
		MAR 10, 1986

PYRVINIUM PAMOATE

SUSPENSION; ORAL		
POVAN		
PARKE DAVIS	EQ 50MG BASE/5ML	N11964 001

PYRVINIUM PAMOATE

TABLET; ORAL		
POVAN		
PARKE DAVIS	EQ 50MG BASE	N12485 002

QUINESTROL

TABLET; ORAL		
ESTROVIS		
PARKE DAVIS	0.1MG	N16768 002
	0.2MG	N16768 003

QUINETHAZONE; RESERPINE

TABLET; ORAL		
HYDROMOX R		
LEDERLE	50MG;0.125MG	N13927 001

QUINIDINE GLUCONATE

TABLET; ORAL		
QUINACT		
BERLEX	266MG	N85978 001
	400MG	N86099 001
TABLET, EXTENDED RELEASE; ORAL		
DURAQUIN		
WARNER CHILCOTT	330MG	N17917 001
QUINALAN		
LANNETT	324MG	N88081 001
		FEB 10, 1986
QUINATIME		
WATSON LAB	324MG	N87448 001
QUINIDINE GLUCONATE		
ASCOT	324MG	N88582 001
		JUN 17, 1985
GENEVA PHARMS	324MG	N89894 001
		DEC 15, 1988
HALSEY	324MG	N89476 001
		APR 10, 1987
ROXANE	324MG	N88431 001
		JAN 06, 1984
SUPERPHARM	324MG	N89164 001
		NOV 21, 1985

FDA data supplied by DrugPatentWatch.com

QUINIDINE GLUCONATE

TABLET, EXTENDED RELEASE; ORAL
QUINIDINE GLUCONATE

WATSON LABS	324MG	N87785 001
		JAN 24, 1983

QUINIDINE POLYGALACTURONATE

TABLET; ORAL
CARDIOQUIN

PURDUE FREDERICK	275MG	N11642 002

QUINIDINE SULFATE

CAPSULE; ORAL
CIN-QUIN

SOLVAY	200MG	N85296 001
	300MG	N85297 001

QUINIDINE SULFATE

LILLY	200MG	N85103 001

TABLET; ORAL
CIN-QUIN

SOLVAY	100MG	N85299 001
	200MG	N84932 001
	300MG	N85298 001

QUINIDINE SULFATE

BARR	200MG	N84177 001
DANBURY PHARMA	100MG	N85584 001
ELKINS SINN	200MG	N83622 001
EVERYLIFE	200MG	N83439 001
HALSEY	200MG	N83583 001
ICN	200MG	N83393 001
IMPAX LABS	200MG	N83347 001
IVAX PHARMS	200MG	N84549 001
KV PHARM	200MG	N85276 001
LEDERLE	200MG	N86176 001
LILLY	200MG	N85038 001
MUTUAL PHARM	300MG	N81031 001
		APR 14, 1989
PERRIGO	200MG	N85322 001
PHARMAVITE	200MG	N84627 001
PUREPAC PHARM	200MG	N84003 001
SCHERER LABS	200MG	N85068 001
USL PHARMA	200MG	N87837 001
		APR 14, 1982

QUINIDINE SULFATE

TABLET; ORAL
QUINIDINE SULFATE

VANGARD	200MG	N87909 001
		JUL 13, 1982
VINTAGE PHARMS	200MG	N83963 001
WARNER CHILCOTT	200MG	N83879 001
WEST WARD	200MG	N83862 001
WHITEWORTH TOWN PLSN	200MG	N85444 001

QUINORA

KEY PHARMS	200MG	N83576 001
SCHERING	300MG	N85222 001

RANITIDINE BISMUTH CITRATE

TABLET; ORAL
TRITEC

GLAXOSMITHKLINE	400MG	N20559 001
		AUG 08, 1996

RANITIDINE HYDROCHLORIDE

CAPSULE; ORAL
ZANTAC 150

GLAXOSMITHKLINE	EQ 150MG BASE	N20095 001
		MAR 08, 1994

INJECTABLE; INJECTION
ZANTAC IN PLASTIC CONTAINER

GLAXOSMITHKLINE	EQ 50MG BASE/100ML	N19593 001
		DEC 17, 1986

TABLET; ORAL
RANITIDINE HCL

BOEHRINGER INGELHEIM	EQ 150MG BASE	N74662 001
		AUG 29, 1997
	EQ 300MG BASE	N74662 002
		AUG 29, 1997

TABLET, EFFERVESCENT; ORAL
ZANTAC 75

WARNER LAMBERT	EQ 75MG BASE	N20745 001
		FEB 26, 1998

FDA data supplied by DrugPatentWatch.com

RAUWOLFIA SERPENTINA

TABLET; ORAL

HIWOLFIA		
BOWMAN PHARMS	50MG	N09276 003
	50MG	N09276 005
	100MG	N09276 004
HYSERPIN		
PHYS PRODS VA	50MG	N10581 001
KOGLUCOID		
PANRAY	50MG	N09278 001
	100MG	N09278 002
RAUDIXIN		
APOTHECON	50MG	N08842 001
	100MG	N08842 002
RAUSERPIN		
FERNDALE LABS	50MG	N09926 002
	100MG	N09926 004
RAUVAL		
PAL PAK	50MG	N09108 002
	100MG	N09108 004
RAUWOLFIA SERPENTINA		
BUNDY	50MG	N09477 001
	100MG	N09477 002
DANBURY PHARMA	50MG	N80907 001
	100MG	N80914 001
HALSEY	50MG	N80498 001
	100MG	N80498 002
ICN	50MG	N09668 001
	100MG	N09668 002
IMPAX LABS	50MG	N09273 001
	100MG	N09273 002
IVAX PHARMS	50MG	N11521 001
	100MG	N11521 002
PUREPAC PHARM	50MG	N80842 001
	100MG	N80842 002
PVT FORM	50MG	N80583 001
	100MG	N80583 002
SOLVAY	50MG	N80500 001
	100MG	N80500 002
TABLICAPS	50MG	N83867 001
	100MG	N83444 001
WOLFINA		
FOREST PHARMS	50MG	N09255 008
	100MG	N09255 006

RESCINNAMINE

CAPSULE; ORAL

CINNASIL		
PANRAY	0.5MG	N84736 001

RESERPINE

ELIXIR; ORAL

SERPASIL		
NOVARTIS	0.2MG/4ML	N09115 005

INJECTABLE; INJECTION

SANDRIL		
LILLY	2.5MG/ML	N10012 001
SERPASIL		
NOVARTIS	2.5MG/ML	N09434 002

TABLET; ORAL

HISERPIA		
BOWMAN PHARMS	0.1MG	N09631 002
	0.25MG	N09631 004
RAU-SED		
BRISTOL MYERS SQUIBB	0.1MG	N09357 001
	0.25MG	N09357 004
	0.5MG	N09357 006
	1MG	N09357 008
RESERPINE		
BARR	0.25MG	N80721 002
BELL PHARMA	0.1MG	N83058 001
	0.25MG	N83058 002
BUNDY	0.1MG	N09663 001
	0.25MG	N09663 003
DANBURY PHARMA	0.1MG	N80679 001
	0.25MG	N80393 001
	1MG	N80749 001
ELKINS SINN	0.1MG	N83145 001
	0.25MG	N83145 002
EVERYLIFE	0.1MG	N10441 001
	0.25MG	N10441 002
	0.5MG	N10441 003
	1MG	N10441 004
HALSEY	0.1MG	N80457 002
	0.25MG	N80457 001
	1MG	N80457 003
ICN	0.1MG	N09667 001
	0.25MG	N09667 002
IMPAX LABS	0.1MG	N09627 001

FDA data supplied by DrugPatentWatch.com

RESERPINE

TABLET; ORAL

RESERPINE			
IMPAX LABS	0.25MG	N09627	002
IVAX PHARMS	0.1MG	N11185	001
	0.25MG	N11185	002
MARSHALL PHARMA	0.1MG	N80492	001
	0.25MG	N80492	002
MK LABS	0.1MG	N80525	002
	0.25MG	N80525	001
MYLAN	1MG	N84974	001
PHARMAVITE	0.25MG	N84663	001
PUREPAC PHARM	0.1MG	N80753	002
	0.25MG	N80753	001
PVT FORM	0.1MG	N86117	001
	0.25MG	N80582	001
	0.25MG	N85775	001
	1MG	N80582	002
REXALL	0.25MG	N80637	001
ROXANE	0.1MG	N09859	001
	0.25MG	N09859	002
SOLVAY	0.25MG	N80446	001
TABLICAPS	0.25MG	N85207	001
TEVA	0.1MG	N89020	001
		MAR 07, 1985	
	0.25MG	N89019	001
		MAR 07, 1985	
WATSON LABS	0.25MG	N85401	001
WEST WARD	0.1MG	N80975	001
	0.25MG	N80975	002
	1MG	N80975	003
WHITEWORTH TOWN PLSN	0.1MG	N80723	001
	0.25MG	N80723	002
	1MG	N80723	003
SANDRIL			
LILLY	0.1MG	N09376	004
	0.25MG	N09376	001
SERPANRAY			
PANRAY	0.1MG	N09391	001
	0.25MG	N09391	002
	1MG	N09391	004
SERPASIL			
NOVARTIS	0.1MG	N09115	001
	0.25MG	N09115	003
	1MG	N09115	004
SERPATE			
VALE	0.1MG	N09453	001
	0.25MG	N09453	002

RESERPINE

TABLET; ORAL

SERPIVITE		
VITARINE	0.25MG	N09645 002

RESERPINE; *MULTIPLE*

SEE CHLOROTHIAZIDE; RESERPINE

SEE HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE

SEE HYDRALAZINE HYDROCHLORIDE; RESERPINE

SEE HYDROCHLOROTHIAZIDE; RESERPINE

SEE HYDROFLUMETHIAZIDE; RESERPINE

SEE QUINETHAZONE; RESERPINE

RESERPINE; TRICHLORMETHIAZIDE

TABLET; ORAL

NAQUIVAL		
SCHERING	0.1MG;4MG	N12265 003
TRICHLORMETHIAZIDE W/ RESERPINE		
WATSON LAB	0.1MG;4MG	N85248 001

RIBOFLAVIN; *MULTIPLE*

SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PHYTONADIONE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A PALMITATE; VITAMIN E

RIBOFLAVIN PHOSPHATE SODIUM; *MULTIPLE*

SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE; VITAMIN A; VITAMIN E

SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN E

FDA data supplied by DrugPatentWatch.com

RISPERIDONE

TABLET; ORAL		
RISPERDAL		
JANSSEN	5MG	N20272 005
		DEC 29, 1993

RITODRINE HYDROCHLORIDE

INJECTABLE; INJECTION		
RITODRINE HCL		
AM PHARM PARTNERS	10MG/ML	N71188 001
		JUL 23, 1987
	15MG/ML	N71189 001
		JUL 23, 1987
QUAD PHARMS	10MG/ML	N70700 001
		OCT 06, 1986
	15MG/ML	N70701 001
		OCT 06, 1986
YUTOPAR		
ASTRAZENECA	10MG/ML	N18580 001
	15MG/ML	N18580 002
TABLET; ORAL		
YUTOPAR		
ASTRAZENECA	10MG	N18555 001

ROSE BENGAL SODIUM, I-131

INJECTABLE; INJECTION		
ROBENGATOPE		
BRACCO	0.5mCi/VIAL	N16224 001
	1mCi/VIAL	N16224 002
	2mCi/VIAL	N16224 003
SODIUM ROSE BENGAL I 131		
SORIN	0.5mCi/ML	N17318 001

SAFFLOWER OIL

INJECTABLE; INJECTION		
LIPOSYN 10%		
ABBOTT	10%	N18203 001
LIPOSYN 20%		
ABBOTT	20%	N18614 001

SARALASIN ACETATE

INJECTABLE; INJECTION		
SARENIN		
PROCTER AND GAMBLE	EQ 0.6MG BASE/ML	N18009 001

SECOBARBITAL SODIUM

CAPSULE; ORAL		
SECOBARBITAL SODIUM		
ICN	100MG	N85477 001
IVAX PHARMS	100MG	N85869 001
LANNETT	50MG	N85909 001
	100MG	N85903 001
PARKE DAVIS	100MG	N84762 001
PUREPAC PHARM	100MG	N85867 001
VITARINE	100MG	N85898 001
	100MG	N86273 001
WHITEWORTH TOWN PLSN	100MG	N85798 001
WYETH AYERST	100MG	N86390 001
SODIUM SECOBARBITAL		
ANABOLIC	100MG	N84422 001
BARR	100MG	N84225 001
HALSEY	100MG	N84676 001
KV PHARM	100MG	N85285 001
PERRIGO	100MG	N84561 001
WATSON LABS	100MG	N85792 001
INJECTABLE; INJECTION		
SECONAL SODIUM		
LILLY	50MG/ML	N07392 002
SUPPOSITORY; RECTAL		
SECONAL SODIUM		
LILLY	30MG	N86530 001
	60MG	N86530 002
	120MG	N86530 003
	200MG	N86530 004

SECRETIN

INJECTABLE; INJECTION		
SECRETIN-FERRING		
FERRING	75CU/VIAL	N18290 001

FDA data supplied by DrugPatentWatch.com

SELENIUM SULFIDE

LOTION/SHAMPOO; TOPICAL
SELENIUM SULFIDE

IVAX PHARMS	2.5%	N85777 001
THAMES	2.5%	N86209 001

SELENOMETHIONINE, SE-75

INJECTABLE; INJECTION
SELENOMETHIONINE SE 75

AMERSHAM HLTH	250 uCi/ML	N17257 001
MALLINCKRODT	100 uCi/ML	N17098 001

SETHOTOPE

BRACCO	85-550 uCi/ML	N17047 001

SERACTIDE ACETATE

INJECTABLE; INJECTION
ACTHAR GEL-SYNTHETIC

ARMOUR PHARM	40 UNITS/ML	N17861 001
	80 UNITS/ML	N17861 002

SERTRALINE HYDROCHLORIDE

TABLET; ORAL
ZOLOFT

PFIZER	EQ 150MG BASE	N19839 003 DEC 30, 1991
	EQ 200MG BASE	N19839 004 DEC 30, 1991

SILVER SULFADIAZINE

DRESSING; TOPICAL
SILDAFLO

FRANKLIN PHARMS	1%	N19608 001 NOV 30, 1989

SODIUM ACETATE; *MULTIPLE*
SEE AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM ACETATE; POTASSIUM CHLORIDE; SODIUM ACETATE
SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE
SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

SODIUM ACETATE; *MULTIPLE*
SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE
SEE CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE
SEE CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE
SEE CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE
SEE MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE
SEE MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

SODIUM BICARBONATE

INJECTABLE; INJECTION
SODIUM BICARBONATE IN PLASTIC CONTAINER

ABBOTT	0.9MEQ/ML	N19443 001 JUN 03, 1986
	1MEQ/ML	N19443 002 JUN 03, 1986

SODIUM BICARBONATE; *MULTIPLE*
SEE POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE, ANHYDROUS

SODIUM CHLORIDE

INJECTABLE; INJECTION
BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AM PHARM PARTNERS	9MG/ML	N88909 001 FEB 07, 1985

SODIUM CHLORIDE

ABBOTT	20GM/100ML	N17013 001
B BRAUN	20GM/100ML	N17038 001

SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

B BRAUN	450MG/100ML	N18184 001
MILES	450MG/100ML	N18503 001

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

ABBOTT	9MG/ML	N19218 001 JUL 13, 1984
MILES	900MG/100ML	N18502 001

SODIUM CHLORIDE 23.4% IN PLASTIC CONTAINER

AM PHARM PARTNERS	234MG/ML	N19329 001 APR 22, 1987

FDA data supplied by DrugPatentWatch.com

SODIUM CHLORIDE

INJECTABLE; INJECTION
SODIUM CHLORIDE 3% IN PLASTIC CONTAINER
B BRAUN 3GM/100ML N19635 003
MAR 09, 1988

SODIUM CHLORIDE 5% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML N19635 004
MAR 09, 1988

SOLUTION; IRRIGATION
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
ABBOTT 450MG/100ML N18380 001
BAXTER HLTHCARE 450MG/100ML N18497 001
FEB 19, 1982

SODIUM CHLORIDE IN PLASTIC CONTAINER
MILES 900MG/100ML N18247 001

SODIUM CHLORIDE; *MULTIPLE*
SEE AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE
SEE AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM ACETATE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE
SEE AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE
SEE AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE
SEE AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; SODIUM CHLORIDE
SEE AMINO ACIDS; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE
SEE AMINO ACIDS; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE
SEE AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE
SEE AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE
SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE
SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE
SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE
SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE
SEE CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SODIUM CHLORIDE; *MULTIPLE*
SEE CALCIUM CHLORIDE; DEXTROSE; SODIUM CHLORIDE; SODIUM LACTATE
SEE CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE
SEE CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE
SEE CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE
SEE CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE
SEE CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE
SEE DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE
SEE DEXTROSE; SODIUM CHLORIDE
SEE MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE
SEE MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE
SEE POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE, ANHYDROUS
SEE POTASSIUM CHLORIDE; SODIUM CHLORIDE
SEE POTASSIUM CHLORIDE; SODIUM CHLORIDE; TROMETHAMINE

SODIUM CHROMATE, CR-51

INJECTABLE; INJECTION
CHROMITOPE SODIUM
BRACCO 2mCi/VIAL N13993 002

SODIUM CITRATE; *MULTIPLE*
SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE
SEE CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

SODIUM FLUORIDE, F-18

INJECTABLE; INTRAVENOUS
FLUORINE F-18
AMERSHAM HLTH 2mCi/ML N17042 001

SODIUM GLUCONATE; *MULTIPLE*
SEE MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

FDA data supplied by DrugPatentWatch.com

SODIUM GLUCONATE; *MULTIPLE*
SEE MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

SODIUM IODIDE, I-123

CAPSULE; ORAL
SODIUM IODIDE I 123

SYNCOR PHARMS	400 uCi	N18671 003 MAY 27, 1982

SODIUM IODIDE, I-131

CAPSULE; ORAL
SODIUM IODIDE I 131

CIS	50 uCi	N17316 001
	100 uCi	N17316 002
MALLINCKRODT	0.8-100mCi	N16515 002

SODIUM LACTATE

INJECTABLE; INJECTION
SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER

B BRAUN	1.87GM/100ML	N18186 001

SODIUM LACTATE; *MULTIPLE*
SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE
SEE CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE
SEE CALCIUM CHLORIDE; DEXTROSE; SODIUM CHLORIDE; SODIUM LACTATE
SEE CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SODIUM NITROPRUSSIDE

INJECTABLE; INJECTION
NIPRIDE

ROCHE	50MG/VIAL	N17546 001

NITROPRESS

ABBOTT	50MG/VIAL	N18450 001
	50MG/VIAL	N71555 001 NOV 16, 1987

SODIUM NITROPRUSSIDE

INJECTABLE; INJECTION
SODIUM NITROPRUSSIDE

AM PHARM PARTNERS	50MG/VIAL	N70031 001 JAN 17, 1985

SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE; *MULTIPLE*
SEE AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE
SEE AMINO ACIDS; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE
SEE AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE
SEE MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

SODIUM PHOSPHATE, P-32

SOLUTION; INJECTION, ORAL
PHOSPHOTOPE

BRACCO	1-8mCi/VIAL	N10927 001

SODIUM PHOSPHATE P 32

MALLINCKRODT	1.5mCi/VIAL	N11777 002

SODIUM POLYSTYRENE SULFONATE

POWDER; ORAL, RECTAL
SODIUM POLYSTYRENE SULFONATE

MORTON GROVE	453.6GM/BOT	N88786 001 SEP 11, 1984

SUSPENSION; ORAL, RECTAL
SODIUM POLYSTYRENE SULFONATE

MORTON GROVE	15GM/60ML	N88717 001 SEP 11, 1984
ROXANE	15GM/60ML	N88453 001 NOV 17, 1983

SODIUM SUCCINATE

INJECTABLE; INJECTION
SODIUM SUCCINATE

ELKINS SINN	30%	N80516 001

FDA data supplied by DrugPatentWatch.com

SODIUM SULFATE, ANHYDROUS; *MULTIPLE*
SEE POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE, ANHYDROUS

SODIUM TETRADECYL SULFATE

INJECTABLE; INJECTION
SOTRADECOL
ELKINS SINN 1% N05970 004
3% N05970 005

SOMATROPIN

INJECTABLE; INJECTION
ASELLACRIN 10
SERONO 10 IU/VIAL N17726 001
ASELLACRIN 2
SERONO 2 IU/VIAL N17726 002
JUL 21, 1983
CRESCORMON
GENENTECH 4 IU/VIAL N17992 001

SOMATROPIN RECOMBINANT

INJECTABLE; INJECTION
HUMATROPE
LILLY 2MG/VIAL N19640 001
JUN 23, 1987

SORBITOL

SOLUTION; IRRIGATION
SORBITOL 3% IN PLASTIC CONTAINER
BAXTER HLTHCARE 3GM/100ML N18512 001
MAY 27, 1982

SORBITOL; *MULTIPLE*
SEE MANNITOL; SORBITOL

SOTALOL HYDROCHLORIDE

TABLET; ORAL
BETAPACE
BERLEX LABS 320MG N19865 004
OCT 30, 1992

SOYBEAN OIL

INJECTABLE; INJECTION
TRAVAMULSION 10%
BAXTER HLTHCARE 10% N18660 001
FEB 26, 1982
TRAVAMULSION 20%
BAXTER HLTHCARE 20% N18758 001
FEB 15, 1983

SPIRAPRIL HYDROCHLORIDE

TABLET; ORAL
RENORMAX
SCHERING 3MG N20240 001
DEC 29, 1994
6MG N20240 002
DEC 29, 1994
12MG N20240 003
DEC 29, 1994
24MG N20240 004
DEC 29, 1994

SPIRONOLACTONE

TABLET; ORAL
SPIRONOLACTONE
ASCOT 25MG N87687 001
OCT 20, 1982
IVAX PHARMS 25MG N87108 001
LEDERLE 25MG N87634 001
PUREPAC PHARM 25MG N87998 001
OCT 14, 1983
25MG N88053 001
AUG 25, 1983
UPSHER SMITH 25MG N87554 001
VANGARD 25MG N87648 001
FEB 01, 1982

FDA data supplied by DrugPatentWatch.com

SPIRONOLACTONE

TABLET; ORAL
SPIRONOLACTONE

WARNER CHILCOTT	25MG	N87952 001 NOV 18, 1982
WATSON LAB	25MG	N86898 002 MAR 02, 1982
WATSON LABS	25MG	N87078 001

SPIRONOLACTONE; *MULTIPLE*
SEE HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

STAVUDINE

CAPSULE; ORAL
ZERIT

BRISTOL MYERS SQUIBB	5MG	N20412 001 JUN 24, 1994

STREPTOMYCIN SULFATE

INJECTABLE; INJECTION
STREPTOMYCIN SULFATE

COPANOS	EQ 500MG BASE/ML	N60684 001
LILLY	EQ 1GM BASE/2ML	N60404 001
	EQ 1GM BASE/VIAL	N60107 001
	EQ 5GM BASE/VIAL	N60107 002
PFIZER	EQ 1GM BASE/VIAL	N60076 001
	EQ 5GM BASE/VIAL	N60076 002

SUCCINYLCHOLINE CHLORIDE

INJECTABLE; INJECTION
ANECTINE

GLAXOSMITHKLINE	50MG/ML	N08453 003

SUCCINYLCHOLINE CHLORIDE

INTL MEDICATION	100MG/VIAL	N85400 001 FEB 04, 1982

SUCOSTRIN

APOTHECON	20MG/ML	N08847 001
	100MG/ML	N08847 003

SUFENTANIL CITRATE

INJECTABLE; INJECTION
SUFENTANIL CITRATE

STERIS	EQ 0.05MG BASE/ML	N74406 001 DEC 15, 1995

SULBACTAM SODIUM; *MULTIPLE*
SEE AMPICILLIN SODIUM; SULBACTAM SODIUM

SULCONAZOLE NITRATE

SOLUTION; TOPICAL
EXELDERM

WESTWOOD SQUIBB	1%	N18738 001 AUG 30, 1985

SULFACETAMIDE SODIUM

OINTMENT; OPHTHALMIC
BLEPH-10

ALLERGAN	10%	N84015 001

SODIUM SULAMYD

SCHERING	10%	N05963 002

SULFAIR 10

PHARMAFAIR	10%	N88000 001 DEC 22, 1982

SOLUTION/DROPS; OPHTHALMIC
OCUSULF-30

MIZA PHARMS USA	30%	N80660 002

SODIUM SULAMYD

SCHERING	10%	N05963 001
	30%	N05963 003

SODIUM SULFACETAMIDE

AKORN	10%	N83021 001
	15%	N83021 002
	30%	N83021 003
SOLA BARNES HIND	10%	N84143 001
	10%	N84145 001
	30%	N84146 001
	30%	N84147 001

SULFACETAMIDE SODIUM

PHARMAFAIR	10%	N88947 001 MAY 17, 1985

FDA data supplied by DrugPatentWatch.com

SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC		
SULFAIR 10		
PHARMAFAIR	10%	N87949 001 DEC 13, 1982
SULFAIR FORTE		
PHARMAFAIR	30%	N88385 001 OCT 13, 1983
SULFAIR-15		
PHARMAFAIR	15%	N88186 001 MAY 25, 1983
SULTEN-10		
BAUSCH AND LOMB	10%	N87818 001 FEB 03, 1983

SULFACETAMIDE SODIUM; *MULTIPLE*
SEE PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM
SEE PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SULFADIAZINE

TABLET; ORAL		
SULFADIAZINE		
ABBOTT	300MG	N04125 005
EVERYLIFE	500MG	N80088 001
IMPAX LABS	500MG	N80081 001
LANNETT	500MG	N80084 001
LEDERLE	500MG	N04054 001
LILLY	500MG	N04122 002

SULFADIAZINE; SULFAMERAZINE

SUSPENSION; ORAL		
SULFONAMIDES DUPLEX		
LILLY	250MG/5ML;250MG/5ML	N06317 007

SULFADIAZINE SODIUM

INJECTABLE; INJECTION		
SULFADIAZINE SODIUM		
LEDERLE	250MG/ML	N04054 002

SULFAMERAZINE; *MULTIPLE*
SEE SULFADIAZINE; SULFAMERAZINE

SULFAMETER

TABLET; ORAL		
SULLA		
BERLEX	500MG	N16000 002

SULFAMETHIZOLE

TABLET; ORAL		
MICROSUL		
FOREST PHARMS	1GM	N86012 001
PROKLAR		
FOREST PHARMS	500MG	N80273 001
THIOSULFIL		
WYETH AYERST	250MG	N08565 001

SULFAMETHOXAZOLE

SUSPENSION; ORAL		
GANTANOL		
ROCHE	500MG/5ML	N13664 002
TABLET; ORAL		
GANTANOL-DS		
ROCHE	1GM	N12715 003
SULFAMETHOXAZOLE		
ASCOT	500MG	N87662 001 OCT 20, 1982
BARR	500MG	N87189 001 JUL 25, 1983
GENEVA PHARMS	500MG	N85844 001
HEATHER	500MG	N86163 001
WATSON LAB	1GM	N86000 001
	500MG	N85053 001
UROBAK		
SHIONOGI	500MG	N87307 001

SULFAMETHOXAZOLE; *MULTIPLE*
SEE PHENAZOPYRIDINE HYDROCHLORIDE; SULFAMETHOXAZOLE

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE; INJECTION		
SULFAMETHOPRIM		
QUAD PHARMS	80MG/ML;16MG/ML	N71341 001 AUG 07, 1987

FDA data supplied by DrugPatentWatch.com

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE; INJECTION
SULFAMETHOXAZOLE AND TRIMETHOPRIM

AM PHARM PARTNERS	80MG/ML;16MG/ML	N70223 001 DEC 29, 1987
BEDFORD	80MG/ML;16MG/ML	N72383 001 APR 29, 1992
STERIS	80MG/ML;16MG/ML	N71556 001 DEC 29, 1987

SUSPENSION; ORAL
BACTRIM

WOMEN FIRST HLTHCARE	200MG/5ML;40MG/5ML	N17560 001

SULMEPRIM

USL PHARMA	200MG/5ML;40MG/5ML	N70063 001 AUG 01, 1986

SULMEPRIM PEDIATRIC

USL PHARMA	200MG/5ML;40MG/5ML	N70064 001 AUG 01, 1986

TRIMETH/SULFA

ALPHARMA	200MG/5ML;40MG/5ML	N72289 001 MAY 23, 1988
	200MG/5ML;40MG/5ML	N72398 001 MAY 23, 1988
NASKA	200MG/5ML;40MG/5ML	N72399 001 MAY 23, 1988

TABLET; ORAL
SULFAMETHOXAZOLE & TRIMETHOPRIM

HEATHER	400MG;80MG	N18946 001 AUG 10, 1984
	800MG;160MG	N18946 002 AUG 10, 1984

SULFAMETHOXAZOLE AND TRIMETHOPRIM

EON	400MG;80MG	N18598 003 MAY 19, 1982
HALSEY	400MG;80MG	N70006 001 NOV 14, 1984
INTERPHARM	400MG;80MG	N71299 001 OCT 27, 1987
	800MG;160MG	N71300 001 OCT 27, 1987
MARTEC	400MG;80MG	N72408 001 DEC 07, 1988
ROXANE	400MG;80MG	N72768 001 AUG 30, 1991
TEVA	400MG;80MG	N18242 001
	800MG;160MG	N18242 002

SULFAMETHOXAZOLE; TRIMETHOPRIM

TABLET; ORAL
SULFAMETHOXAZOLE AND TRIMETHOPRIM

USL PHARMA	400MG;80MG	N70203 001 NOV 08, 1985
	800MG;160MG	N70204 001 NOV 08, 1985
WATSON LABS	400MG;80MG	N70002 001 NOV 07, 1984
	800MG;160MG	N70000 001 NOV 07, 1984

SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH

HALSEY	800MG;160MG	N70007 001 NOV 14, 1984
MARTEC	800MG;160MG	N72417 001 DEC 07, 1988
ROXANE	800MG;160MG	N72769 001 AUG 30, 1991

SULFATRIM-DS

SUPERPHARM	800MG;160MG	N70066 001 JUN 24, 1985

SULFATRIM-SS

SUPERPHARM	400MG;80MG	N70065 002 JUN 24, 1985

UROPLUS DS

SHIONOGI	800MG;160MG	N71816 001 SEP 28, 1987

UROPLUS SS

SHIONOGI	400MG;80MG	N71815 001 SEP 28, 1987

SULFAPHENAZOLE

SUSPENSION; ORAL
SULFABID

PURDUE FREDERICK	500MG/5ML	N13093 001

TABLET; ORAL
SULFABID

PURDUE FREDERICK	500MG	N13092 002

SULFASALAZINE

SUSPENSION; ORAL
AZULFIDINE

PHARMACIA AND UPJOHN	250MG/5ML	N18605 001

FDA data supplied by DrugPatentWatch.com

SULFASALAZINE

TABLET; ORAL
S.A.S.-500
SOLVAY 500MG N83450 001
SULFASALAZINE
EON 500MG N86184 001
LEDERLE 500MG N80197 001
SUPERPHARM 500MG N89339 001
OCT 26, 1987
WATSON LAB 500MG N84964 001

TABLET, DELAYED RELEASE; ORAL
SULFASALAZINE
WATSON LAB 500MG N88052 001
MAY 24, 1983

SULFINPYRAZONE

CAPSULE; ORAL
SULFINPYRAZONE
VANGARD 200MG N88666 001
FEB 17, 1984

TABLET; ORAL
SULFINPYRAZONE
DANBURY PHARMA 100MG N87667 001
MAY 26, 1982
IVAX PHARMS 100MG N87769 001
JUN 01, 1982

SULFISOXAZOLE

TABLET; ORAL
GANTRISIN
ROCHE 500MG N06525 001
SOXAZOLE
ALRA 500MG N80366 001
SULFALAR
PARKE DAVIS 500MG N84955 001
SULFISOXAZOLE
BARR 500MG N84031 001
GENEVA PHARMS 500MG N85628 001
HEATHER 500MG N80189 001
IMPAX LABS 500MG N80109 001
LANNETT 500MG N80085 001
LEDERLE 500MG N87649 001

SULFISOXAZOLE

TABLET; ORAL
SULFISOXAZOLE
PHARMERAL 500MG N84385 001
PUREPAC PHARM 500MG N80087 001
VITARINE 500MG N87332 001
WATSON LABS 500MG N85534 001
WEST WARD 500MG N80379 001
SULSOXIN
SOLVAY 500MG N80040 001

SULFISOXAZOLE; *MULTIPLE*
SEE PHENAZOPYRIDINE HYDROCHLORIDE; SULFISOXAZOLE

SULFISOXAZOLE ACETYL

EMULSION; ORAL
LIPO GANTRISIN
ROCHE EQ 1GM BASE/5ML N09182 009

SULFISOXAZOLE ACETYL; *MULTIPLE*
SEE ERYTHROMYCIN ESTOLATE; SULFISOXAZOLE ACETYL

SULFISOXAZOLE DIOLAMINE

INJECTABLE; INJECTION
GANTRISIN
ROCHE EQ 400MG BASE/ML N06917 001

OINTMENT; OPHTHALMIC
GANTRISIN
ROCHE EQ 4% BASE N08414 002

SOLUTION/DROPS; OPHTHALMIC
GANTRISIN
ROCHE EQ 4% BASE N07757 002
SULFISOXAZOLE DIOLAMINE
SOLA BARNES HIND EQ 4% BASE N84148 001

SULFOXONE SODIUM

TABLET, DELAYED RELEASE; ORAL
DIASONE SODIUM
ABBOTT 165MG N06044 003

FDA data supplied by DrugPatentWatch.com

SULFUR

POWDER; TOPICAL
BENSULFOID
POYTHRESS 33.32% N02918 001

SUMATRIPTAN SUCCINATE

TABLET; ORAL
IMITREX
GLAXOSMITHKLINE EQ 100MG BASE N20132 001
JUN 01, 1995

SUTILAINS

OINTMENT; TOPICAL
TRAVASE
* ABBOTT 82,000 UNITS/GM N12828 001

TALBUTAL

TABLET; ORAL
LOTUSATE
SANOFI SYNTHELABO 120MG N09410 005

TAMOXIFEN CITRATE

TABLET; ORAL
TAMOXIFEN CITRATE
MYLAN EQ 10MG BASE N74732 001
JUN 26, 2000
PHARMACHEMIE EQ 10MG BASE N74539 001
MAY 31, 2000

TANNIC ACID; *MULTIPLE*
SEE CYANOCOBALAMIN; TANNIC ACID; ZINC ACETATE

TECHNETIUM TC-99M ALBUMIN AGGREGATED

INJECTABLE; INJECTION
TC 99M-LUNGAGGREGATE
AMERSHAM HLTH 5mCi/ML N17848 001

TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT

INJECTABLE; INJECTION
A-N STANNOUS AGGREGATED ALBUMIN
SYNCOR PHARMS N/A N17916 001
AN-MAA
CIS N/A N17792 001
LUNGAGGREGATE REAGENT
AMERSHAM HLTH N/A N17838 001
TECHNETIUM TC 99M MAA
AMERSHAM HLTH N/A N17773 001

TECHNETIUM TC-99M ALBUMIN MICROSPHERES KIT

INJECTABLE; INJECTION
INSTANT MICROSPHERES
3M N/A N17832 001

TECHNETIUM TC-99M ETIDRONATE KIT

INJECTABLE; INJECTION
CINTICHEM TECHNETIUM 99M HEDSPA
AMERSHAM HLTH N/A N17653 001
MPI STANNOUS DIPHOSPHONATE
AMERSHAM HLTH N/A N17667 001
OSTEOSCAN
MALLINCKRODT N/A N17454 001
TECHNETIUM TC 99M DIPHOSPHONATE-TIN KIT
AMERSHAM HLTH N/A N17562 001

TECHNETIUM TC-99M FERPENTETATE KIT

INJECTABLE; INJECTION
RENOTEC
BRACCO N/A N17045 001

TECHNETIUM TC-99M GLUCEPTATE KIT

INJECTABLE; INJECTION
GLUCOSCAN
BRISTOL MYERS SQUIBB N/A N17907 001

FDA data supplied by DrugPatentWatch.com

TECHNETIUM TC-99M LIDOFENIN KIT

INJECTABLE; INJECTION
TECHNESCAN HIDA

DRAXIMAGE	N/A	N18489 001 OCT 31, 1986

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE; INJECTION
AMERSCAN MDP KIT

AMERSHAM HLTH	N/A	N18335 001 AUG 05, 1982

TECHNETIUM TC-99M PENTETATE KIT

INJECTABLE; INJECTION
MPI DTPA KIT - CHELATE

AMERSHAM HLTH	N/A	N17255 001

TECHNETIUM TC-99M POLYPHOSPHATE KIT

INJECTABLE; INJECTION
SODIUM POLYPHOSPHATE-TIN KIT

AMERSHAM HLTH	N/A	N17664 001

TECHNETIUM TC-99M SODIUM PERTECHNETATE

SOLUTION; INJECTION, ORAL
SODIUM PERTECHNETATE TC 99M

AMERSHAM HLTH	2-100mCi/ML	N17471 001
CIS	12mCi/ML	N17321 001
	24mCi/ML	N17321 002
	48mCi/ML	N17321 003

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR

SOLUTION; INJECTION, ORAL
MINITEC

BRACCO	0.22-2.22 CI/GENERATOR	N17339 001

TECHNETIUM TC-99M SULFUR COLLOID

SOLUTION; INJECTION, ORAL
TECHNETIUM TC 99M SULFUR COLLOID

AMERSHAM HLTH	4mCi/ML	N17456 001

SOLUTION; ORAL
TECHNETIUM TC 99M SULFUR COLLOID

MALLINCKRODT	3mCi/ML	N17724 001

TECHNETIUM TC-99M SULFUR COLLOID KIT

SOLUTION; INJECTION, ORAL
TECHNETIUM TC 99M TSC

AMERSHAM HLTH	N/A	N17784 001

TESULOID

BRACCO	N/A	N16923 001

TEMAZEPAM

CAPSULE; ORAL
TEMAZ

QUANTUM PHARMICS	15MG	N70564 001 OCT 15, 1985
	30MG	N70547 001 OCT 15, 1985

TEMAZEPAM

DURAMED	15MG	N71708 001 SEP 29, 1988
	30MG	N71709 001 SEP 29, 1988
HALSEY	15MG	N71174 001 JUL 10, 1986
	30MG	N71175 001 JUL 10, 1986
USL PHARMA	15MG	N70489 001 JUL 07, 1986
	30MG	N70490 001 JUL 07, 1986
WATSON LAB	15MG	N70383 001 MAR 23, 1987
	30MG	N70384 001 MAR 23, 1987

FDA data supplied by DrugPatentWatch.com

TERBUTALINE SULFATE

AEROSOL, METERED; INHALATION		
BRETHAIRE		
NOVARTIS	0.2MG/INH	N18762 001
		AUG 17, 1984
BRICANYL		
AVENTIS PHARMS	0.2MG/INH	N18000 001
		MAR 19, 1985
INJECTABLE; INJECTION		
BRICANYL		
AVENTIS PHARMS	1MG/ML	N17466 001
TABLET; ORAL		
BRICANYL		
AVENTIS PHARMS	2.5MG	N17618 001
	5MG	N17618 002

TERIPARATIDE ACETATE

INJECTABLE; INJECTION		
PARATHAR		
AVENTIS	200 UNITS/VIAL	N19498 001
		DEC 23, 1987

TESTOLACTONE

INJECTABLE; INJECTION		
TESLAC		
BRISTOL MYERS SQUIBB	100MG/ML	N16119 001
TABLET; ORAL		
TESLAC		
BRISTOL MYERS SQUIBB	250MG	N16118 002

TESTOSTERONE

INJECTABLE; INJECTION		
TESTOSTERONE		
STERIS	25MG/ML	N86420 001
		MAY 10, 1983
	50MG/ML	N86419 001
		AUG 23, 1983

TESTOSTERONE CYPIONATE

INJECTABLE; INJECTION		
DEPO-TESTOSTERONE		
PHARMACIA AND UPJOHN	50MG/ML	N85635 001
TESTOSTERONE CYPIONATE		
QUAD PHARMS	100MG/ML	N89326 001
		OCT 28, 1988
	200MG/ML	N89327 001
		OCT 28, 1988
STERIS	100MG/ML	N84401 001
	200MG/ML	N84401 002

TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION		
DELATESTRYL		
BTG	200MG/ML	N09165 001
TESTOSTERONE ENANTHATE		
QUAD PHARMS	100MG/ML	N89324 001
		SEP 16, 1986
	200MG/ML	N89325 001
		SEP 16, 1986
STERIS	100MG/ML	N83667 001
	100MG/ML	N85599 001
	200MG/ML	N83667 002

TESTOSTERONE ENANTHATE; *MULTIPLE*
SEE ESTRADIOL VALERATE; TESTOSTERONE ENANTHATE

TESTOSTERONE PROPIONATE

INJECTABLE; INJECTION		
TESTOSTERONE PROPIONATE		
BEL MAR	25MG/ML	N80741 001
	50MG/ML	N80742 001
	100MG/ML	N80743 001
ELKINS SINN	25MG/ML	N80276 001
LILLY	50MG/ML	N80254 002
QUAD PHARMS	100MG/ML	N89283 001
		NOV 03, 1986
STERIS	25MG/ML	N85490 001
	50MG/ML	N85490 002
	100MG/ML	N83595 003

FDA data supplied by DrugPatentWatch.com

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL

CYCLOPAR			
WARNER CHILCOTT	250MG	N61725	001
	250MG	N62175	001
	250MG	N62332	001
	500MG	N61725	002
	500MG	N62332	002
PANMYCIN			
PHARMACIA AND UPJOHN	250MG	N60347	001
RETET			
SOLVAY	250MG	N61443	001
	500MG	N61443	002
ROBITET			
WYETH AYERST	250MG	N61734	001
	500MG	N61734	002
SUMYCIN			
APOTHECON	100MG	N60429	002
	125MG	N60429	004
TETRACHEL			
ANGUS	250MG	N60343	001
	500MG	N60343	003
TETRACYCLINE HCL			
ABBOTT	250MG	N61802	001
	500MG	N61802	002
DANBURY PHARMA	250MG	N62343	001
	500MG	N62343	002
ELKINS SINN	250MG	N60059	001
EON	250MG	N61471	001
FERRANTE	125MG	N60173	001
	250MG	N60173	002
HEATHER	250MG	N61148	001
	500MG	N61148	002
ICN	250MG	N60471	001
	500MG	N60471	002
PUREPAC PHARM	250MG	N60290	001
	500MG	N60290	002
PVT FORM	250MG	N62686	001
		JUL 24, 1986	
	500MG	N62686	002
		JUL 24, 1986	
SUPERPHARM	250MG	N62540	001
		MAR 21, 1985	
	500MG	N62540	002
		MAR 21, 1985	
WARNER CHILCOTT	250MG	N62300	001
	500MG	N62300	002
WATSON LABS	250MG	N62103	001

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL

TETRACYCLINE HCL			
WATSON LABS	500MG	N62103	002
WEST WARD	250MG	N60768	001
	500MG	N60768	002
WYETH AYERST	250MG	N61685	001
	500MG	N61685	002
TETRACYN			
PFIPHARMECS	250MG	N60082	003
	500MG	N60082	004

INJECTABLE; INJECTION

TETRACYN			
PFIZER	250MG/VIAL	N60096	001
	500MG/VIAL	N60096	002

OINTMENT; OPHTHALMIC

ACHROMYCIN			
STORZ	10MG/GM	N50266	001

SUSPENSION; ORAL

TETRACYCLINE HCL			
ALPHARMA	125MG/5ML	N60633	001
FERRANTE	125MG/5ML	N60174	001
PROTER	125MG/5ML	N60446	001
PUREPAC PHARM	125MG/5ML	N60291	001
TETRACYN			
PFIPHARMECS	125MG/5ML	N60095	001
TETRAMED			
IVAX PHARMS	125MG/5ML	N61468	001

SUSPENSION/DROPS; OPHTHALMIC

ACHROMYCIN			
STORZ	1%	N50268	001

TABLET; ORAL

PANMYCIN			
PHARMACIA AND UPJOHN	250MG	N61705	001
	500MG	N61705	002
SUMYCIN			
APOTHECON	50MG	N61147	003
	100MG	N61147	002

TETRACYCLINE HYDROCHLORIDE; *MULTIPLE*
SEE PROCAINE HYDROCHLORIDE; TETRACYCLINE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

TETRACYCLINE PHOSPHATE COMPLEX

CAPSULE; ORAL		
TETREX		
BRISTOL	EQ 250MG HCL	N50212 002
	EQ 500MG HCL	N50212 003

THALLOUS CHLORIDE, TL-201

INJECTABLE; INJECTION		
THALLOUS CHLORIDE TL 201		
BRACCO	1mCi/ML	N18548 001
		DEC 30, 1982

THEOPHYLLINE

CAPSULE; ORAL		
BRONKODYL		
SANOFI SYNTHELABO	100MG	N85264 001
	200MG	N85264 002
ELIXOPHYLLIN		
FORREST LABS	100MG	N85545 001
		JUL 31, 1984
	200MG	N83921 001
		JUL 31, 1984
SOMOPHYLLIN-T		
FISONS	100MG	N87155 001
		FEB 25, 1985
	200MG	N87155 002
		FEB 25, 1985
	250MG	N87155 003
		FEB 25, 1985
THEOPHYLLINE		
KV PHARM	100MG	N85263 001
	200MG	N85263 002
SCHERER RP	100MG	N84731 002
		NOV 07, 1986
	200MG	N84731 001
		NOV 07, 1986
	250MG	N84731 003
		NOV 07, 1986
CAPSULE, EXTENDED RELEASE; ORAL		
ELIXOPHYLLIN SR		
FORREST LABS	125MG	N86826 001
		JAN 29, 1985

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL		
ELIXOPHYLLIN SR		
FORREST LABS	250MG	N86826 002
		JAN 29, 1985
SLO-PHYLLIN		
AVENTIS	60MG	N85206 001
		MAY 24, 1982
	125MG	N85203 001
		MAY 24, 1982
	250MG	N85205 001
		MAY 24, 1982
SOMOPHYLLIN-CRT		
GRAHAM DM	50MG	N87763 001
		FEB 27, 1985
	100MG	N87194 001
	200MG	N88382 001
		FEB 27, 1985
	250MG	N87193 001
	300MG	N88383 001
		FEB 27, 1985
THEO-DUR		
SCHERING	50MG	N88022 001
		SEP 10, 1985
	75MG	N88015 001
		SEP 10, 1985
	125MG	N88016 001
		SEP 10, 1985
	200MG	N87995 001
		SEP 10, 1985
THEOBID		
WHITBY	260MG	N85983 001
		MAR 20, 1985
THEOBID JR.		
WHITBY	130MG	N87854 001
		MAR 20, 1985
THEOCLEAR L.A.-130		
SCHWARZ PHARMA	130MG	N86569 001
		MAY 27, 1982
THEOCLEAR L.A.-260		
SCHWARZ PHARMA	260MG	N86569 002
		MAY 27, 1982
THEOPHYL-SR		
JOHNSON RW	125MG	N86480 001
		FEB 08, 1985
	250MG	N86471 001
		FEB 08, 1985

FDA data supplied by DrugPatentWatch.com

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL

THEOPHYLLINE		
CENT PHARMS	125MG	N88654 001
		FEB 12, 1985
	250MG	N88689 001
		FEB 12, 1985
EON	260MG	N87462 001
		MAY 11, 1982
FAULDING	100MG	N89976 001
		JAN 04, 1995
	200MG	N89977 001
		JAN 04, 1995
	300MG	N89932 001
		JAN 04, 1995
THEOPHYLLINE-SR		
SCHERER RP	300MG	N88255 001
		JUN 12, 1986
THEOVENT		
SCHERING	125MG	N87010 001
		JAN 31, 1985
	250MG	N87910 001
		JAN 31, 1985

ELIXIR; ORAL

ELIXOMIN		
CENCI	80MG/15ML	N88303 001
		JAN 25, 1984
LANOPHYLLIN		
LANNETT	80MG/15ML	N84578 001
THEOLIXIR		
PANRAY	80MG/15ML	N84559 001
THEOPHYL-225		
JOHNSON RW	112.5MG/15ML	N86485 001
THEOPHYLLINE		
ALPHARMA	80MG/15ML	N89223 001
		MAY 27, 1988
CENCI	80MG/15ML	N87679 001
		APR 15, 1982
HALSEY	80MG/15ML	N85169 001
PERRIGO	80MG/15ML	N85952 001
ROXANE	80MG/15ML	N84739 001

INJECTABLE; INJECTION

THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER		
B BRAUN	40MG/100ML	N19083 001
		NOV 07, 1984

THEOPHYLLINE

INJECTABLE; INJECTION

THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER		
B BRAUN	80MG/100ML	N19083 002
		NOV 07, 1984
THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER		
B BRAUN	160MG/100ML	N19083 003
		NOV 07, 1984
THEOPHYLLINE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER		
B BRAUN	200MG/100ML	N19212 001
		NOV 07, 1984
	200MG/100ML	N19826 004
		AUG 14, 1992
THEOPHYLLINE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER		
B BRAUN	400MG/100ML	N19212 002
		NOV 07, 1984
	4MG/ML	N19212 003
		NOV 07, 1984
	400MG/100ML	N19826 005
		AUG 14, 1992

SUSPENSION; ORAL

ELIXICON		
FORREST LABS	100MG/5ML	N85502 001

SYRUP; ORAL

ACCURBRON		
AVENTIS PHARMS	150MG/15ML	N88746 001
		NOV 22, 1985
AQUAPHYLLIN		
FERNDALE LABS	80MG/15ML	N87917 001
		JAN 18, 1983
THEOCLEAR-80		
CENT PHARMS	80MG/15ML	N87095 001
		MAR 01, 1982
THEOPHYLLINE		
ALPHARMA	80MG/15ML	N86001 001
	150MG/15ML	N86545 001

TABLET; ORAL

THEOCLEAR-100		
CENT PHARMS	100MG	N85353 002
THEOCLEAR-200		
CENT PHARMS	200MG	N85353 001
THEOPHYL-225		
JOHNSON RW	225MG	N84726 001

FDA data supplied by DrugPatentWatch.com

THEOPHYLLINE

TABLET, CHEWABLE; ORAL
THEOPHYL
JOHNSON RW 100MG N86506 001 SEP 12, 1985

TABLET, EXTENDED RELEASE; ORAL
DURAPHYL
FORREST LABS 100MG N88503 001 APR 03, 1985
200MG N88504 001 APR 03, 1985
300MG N88505 001 APR 03, 1985
LABID
PROCTER AND GAMBLE 250MG N87225 001
SUSTAIRE
ROERIG 100MG N85665 001
300MG N85665 002

THEOPHYLLINE; *MULTIPLE*
SEE MERSALYL SODIUM; THEOPHYLLINE
SEE PROCAINE MERETHOXYLLINE; THEOPHYLLINE

THEOPHYLLINE SODIUM GLYCINATE

ELIXIR; ORAL
SYNOPHYLATE
CENT PHARMS EQ 165MG BASE/15ML N06333 008

TABLET; ORAL
ASBRON
NOVARTIS EQ 150MG BASE N85148 001

THIAMINE; *MULTIPLE*
SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE; VITAMIN A; VITAMIN E
SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PHYTONADIONE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A PALMITATE; VITAMIN E

THIAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
BETALIN S
LILLY 100MG/ML N80853 001
THIAMINE HCL
AKORN 100MG/ML N87968 001 OCT 01, 1982
AM PHARM PARTNERS 100MG/ML N80509 001
BEL MAR 100MG/ML N80718 001
200MG/ML N80712 001
DELL LABS 100MG/ML N83775 001
LUITPOLD 100MG/ML N80667 001
PARKE DAVIS 100MG/ML N80770 001
STERIS 100MG/ML N83534 001
200MG/ML N83534 002

THIAMINE HYDROCHLORIDE; *MULTIPLE*
SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E
SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN E

THIAMYLAL SODIUM

INJECTABLE; INJECTION
SURITAL
PARKEDALE 1GM/VIAL N07600 003
5GM/VIAL N07600 005
10GM/VIAL N07600 009

THIOPENTAL SODIUM

SUSPENSION; RECTAL
PENTOTHAL
ABBOTT 400MG/GM N11679 001

FDA data supplied by DrugPatentWatch.com

THIORIDAZINE HYDROCHLORIDE

CONCENTRATE; ORAL
THIORIDAZINE HCL

ALPHARMA	30MG/ML	N87766 001 APR 26, 1983
GENEVA PHARMS	30MG/ML	N88307 001 NOV 23, 1983
	100MG/ML	N88308 001 NOV 23, 1983
MORTON GROVE	30MG/ML	N88258 001 JUL 25, 1983
	100MG/ML	N88227 001 JUL 05, 1983

TABLET; ORAL
THIORIDAZINE HCL

DANBURY PHARMA	25MG	N88755 001 JUL 24, 1984
HALSEY	10MG	N88375 001 NOV 18, 1983
	15MG	N88461 001 NOV 18, 1983
	25MG	N87264 001 NOV 18, 1983
	100MG	N88379 001 NOV 16, 1983
	150MG	N88737 001 SEP 26, 1984
	200MG	N88738 001 OCT 16, 1984
IVAX PHARMS	50MG	N88194 001 APR 14, 1983
	100MG	N88273 001 OCT 03, 1983
MYLAN	10MG	N88332 001 JUN 27, 1983
	25MG	N88333 001 JUN 27, 1983
	50MG	N88334 001 JUN 27, 1983
	100MG	N88335 001 NOV 18, 1983
PAR PHARM	10MG	N88351 001 DEC 05, 1983
	15MG	N88352 001 DEC 05, 1983
	25MG	N88336 001 DEC 05, 1983

THIORIDAZINE HYDROCHLORIDE

TABLET; ORAL
THIORIDAZINE HCL

PAR PHARM	50MG	N88322 001 DEC 05, 1983
	100MG	N88480 001 DEC 29, 1983
	150MG	N89764 001 FEB 09, 1988
	200MG	N89765 001 FEB 09, 1988
ROXANE	10MG	N88663 001 MAR 15, 1984
	25MG	N88664 001 MAR 15, 1984
	50MG	N88665 001 MAR 15, 1984
	100MG	N89048 001 FEB 26, 1985
SUPERPHARM	10MG	N89103 001 JUL 02, 1985
	25MG	N89104 001 JUL 02, 1985
	50MG	N89105 001 JUL 02, 1985
TEVA	10MG	N88493 001 MAY 17, 1985
WATSON LAB	10MG	N88412 001 SEP 12, 1983
	15MG	N88345 001 JUL 28, 1983
	25MG	N88296 001 JUL 28, 1983
	50MG	N88323 001 JUL 28, 1983
	100MG	N88284 001 AUG 25, 1983
	150MG	N88410 001 MAR 05, 1984
	200MG	N88381 001 MAR 14, 1984
WATSON LABS	10MG	N88561 001 MAY 11, 1984
	15MG	N88562 001 MAY 11, 1984
WEST WARD	10MG	N88658 001 MAR 26, 1984

FDA data supplied by DrugPatentWatch.com

THIORIDAZINE HYDROCHLORIDE

TABLET; ORAL		
THIORIDAZINE HCL		
WEST WARD	15MG	N88659 001 MAR 26, 1984
	25MG	N88660 001 MAR 26, 1984
	50MG	N88661 001 MAR 26, 1984

THIOTEPA

INJECTABLE; INJECTION		
THIOTEPA		
IMMUNEX	15MG/VIAL	N11683 001

THIOTHIXENE

CAPSULE; ORAL		
THIOTHIXENE		
AM THERAP	1MG	N71884 001 AUG 12, 1987
	2MG	N71885 001 AUG 12, 1987
	5MG	N71886 001 AUG 12, 1987
	10MG	N71887 001 AUG 12, 1987
	20MG	N72200 001 DEC 17, 1987
WATSON LABS	2MG	N71626 001 JUN 25, 1987
	5MG	N71627 001 JUN 25, 1987
	10MG	N71628 001 JUN 25, 1987

THIOTHIXENE HYDROCHLORIDE

CONCENTRATE; ORAL		
THIOTHIXENE HCL		
ALPHARMA	EQ 5MG BASE/ML	N70969 001 OCT 16, 1987
PACO	EQ 1MG BASE/ML	N71917 001 SEP 20, 1989

THIOTHIXENE HYDROCHLORIDE

CONCENTRATE; ORAL		
THIOTHIXENE HCL		
PACO	EQ 5MG BASE/ML	N71939 001 DEC 16, 1988
TEVA	EQ 5MG BASE/ML	N71184 001 JUN 22, 1987
INJECTABLE; INJECTION		
NAVANE		
ROERIG	EQ 2MG BASE/ML	N16904 001

THYROGLOBULIN

TABLET; ORAL		
PROLOID		
PARKE DAVIS	16MG	N02245 009
	32MG	N02245 005
	65MG	N02245 002
	100MG	N02245 008
	130MG	N02245 010
	200MG	N02245 007
	325MG	N02245 004
THYROGLOBULIN		
IMPAX LABS	64.8MG	N80151 001

THYROTROPIN

INJECTABLE; INJECTION		
THYTROPAR		
AVENTIS	10 IU/VIAL	N08682 001

TICARCILLIN DISODIUM

INJECTABLE; INJECTION		
TICAR		
GLAXOSMITHKLINE	EQ 3GM BASE/VIAL	N62690 001 DEC 19, 1986
	EQ 6GM BASE/VIAL	N50497 003

FDA data supplied by DrugPatentWatch.com

TICLOPIDINE HYDROCHLORIDE

TABLET; ORAL
TICLID

SYNTEX (USA) INC LLC	125MG	N19979 001	MAR 24, 1993

TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC
TIMOLOL MALEATE

FALCON PHARMS	EQ 0.25% BASE	N74261 001	APR 28, 1995
	EQ 0.5% BASE	N74262 001	APR 28, 1995

TABLET; ORAL
TIMOLOL MALEATE

QUANTUM PHARMICS	5MG	N72466 001	MAY 19, 1989
	10MG	N72467 001	MAY 19, 1989
	20MG	N72468 001	MAY 19, 1989
TEVA	5MG	N72648 001	JUN 16, 1993
	10MG	N72649 001	JUN 16, 1993
	20MG	N72650 001	JUN 16, 1993
USL PHARMA	5MG	N72001 001	APR 11, 1989
	10MG	N72002 001	APR 11, 1989
	20MG	N72003 001	APR 11, 1989
WATSON LAB	5MG	N72269 001	APR 11, 1989
	10MG	N72270 001	APR 11, 1989
	20MG	N72271 001	APR 11, 1989

TIOCONAZOLE

CREAM; TOPICAL
TZ-3

PFIZER	1%	N18682 001	FEB 18, 1983

TOBRAMYCIN

SOLUTION/DROPS; OPHTHALMIC
TOBRAMYCIN

ALCON UNIVERSAL	0.3%	N63176 001	MAY 25, 1994

TOBRAMYCIN SULFATE

INJECTABLE; INJECTION
TOBRAMYCIN SULFATE

APOTHECON	EQ 40MG BASE/ML	N64026 001	MAY 31, 1994
ASTRAZENECA	EQ 10MG BASE/ML	N63119 001	OCT 31, 1994
	EQ 40MG BASE/ML	N63121 001	OCT 31, 1994
ELKINS SINN	EQ 10MG BASE/ML	N63128 001	NOV 27, 1991
	EQ 40MG BASE/ML	N63127 001	NOV 27, 1991
LEDERLE	EQ 10MG BASE/ML	N63113 001	APR 26, 1991

TOLAZAMIDE

TABLET; ORAL
TOLAZAMIDE

BARR	100MG	N70162 001	JAN 14, 1986
	250MG	N70163 001	JAN 14, 1986
	500MG	N70164 001	JAN 14, 1986
DURAMED	100MG	N70165 001	JAN 10, 1986
	250MG	N70166 001	JAN 10, 1986

FDA data supplied by DrugPatentWatch.com

TOLAZAMIDE

TABLET; ORAL			
TOLAZAMIDE			
DURAMED	500MG	N70167 001	JAN 10, 1986
INTERPHARM	250MG	N71270 001	SEP 23, 1986
	500MG	N71271 001	SEP 23, 1986
SUPERPHARM	250MG	N70763 001	JUN 16, 1986
	500MG	N70764 001	JUN 16, 1986
USL PHARMA	100MG	N71355 001	JAN 11, 1988
	250MG	N70168 001	APR 02, 1986
	500MG	N70169 001	APR 02, 1986
WATSON LAB	100MG	N70242 001	AUG 01, 1986
	250MG	N70243 001	AUG 01, 1986
	500MG	N70244 001	AUG 01, 1986

TOLBUTAMIDE

TABLET; ORAL			
ORINASE			
PHARMACIA AND UPJOHN	250MG	N10670 002	
	500MG	N10670 001	
TOLBUTAMIDE			
ALRA	500MG	N86141 001	
ASCOT	500MG	N87541 001	MAR 01, 1983
BARR	500MG	N87121 001	
EON	500MG	N12678 001	
PARKE DAVIS	500MG	N86047 001	
PUREPAC PHARM	500MG	N88950 001	JUN 17, 1985
SUPERPHARM	500MG	N88893 001	NOV 19, 1984
VANGARD	500MG	N87876 001	APR 20, 1982
WATSON LAB	250MG	N89110 001	MAY 29, 1987

TOLBUTAMIDE

TABLET; ORAL			
TOLBUTAMIDE			
WATSON LAB	500MG	N89111 001	MAY 29, 1987

TOLMETIN SODIUM

CAPSULE; ORAL			
TOLMETIN SODIUM			
GENEVA PHARMS	EQ 400MG BASE	N73462 001	APR 30, 1992
TABLET; ORAL			
TOLMETIN SODIUM			
TEVA	EQ 600MG BASE	N74729 001	FEB 27, 1997

TOPIRAMATE

CAPSULE; ORAL			
TOPAMAX SPRINKLE			
ORTHO MCNEIL	50MG	N20844 003	OCT 26, 1998
TABLET; ORAL			
TOPAMAX			
ORTHO MCNEIL	50MG	N20505 005	DEC 24, 1996
	300MG	N20505 003	DEC 24, 1996
	400MG	N20505 006	DEC 24, 1996

TRAMADOL HYDROCHLORIDE

TABLET; ORAL			
ULTRAM			
JOHNSON RW	100MG	N20281 001	MAR 03, 1995

FDA data supplied by DrugPatentWatch.com

TRANEXAMIC ACID

TABLET; ORAL			
CYKLOKAPRON			
PHARMACIA AND UPJOHN	500MG	N19280 001	
		DEC 30, 1986	

TRAZODONE HYDROCHLORIDE

TABLET; ORAL			
TRAZODONE HCL			
AM THERAP	50MG	N71139 001	
		OCT 29, 1986	
	100MG	N71140 001	
		OCT 29, 1986	
QUANTUM PHARMICS	100MG	N70921 001	
		DEC 01, 1986	
USL PHARMA	50MG	N70491 001	
		APR 29, 1987	
	100MG	N70492 001	
		APR 29, 1987	
WATSON LAB	50MG	N71112 001	
		NOV 17, 1986	
	100MG	N71113 001	
		NOV 17, 1986	
TRIALODINE			
QUANTUM PHARMICS	50MG	N70942 001	
		DEC 01, 1986	

TRETINOIN

SWAB; TOPICAL			
RETIN-A			
JOHNSON AND JOHNSON	0.05%	N16921 002	

TRIAMCINOLONE

TABLET; ORAL			
ARISTOCORT			
FUJISAWA HLTHCARE	16MG	N11161 010	
KENACORT			
BRISTOL MYERS SQUIBB	1MG	N11283 003	
	2MG	N11283 008	
TRIAMCINOLONE			
BARR	2MG	N84286 001	
	2MG	N84318 001	

TRIAMCINOLONE

TABLET; ORAL			
TRIAMCINOLONE			
BARR	4MG	N84267 001	
	4MG	N84319 001	
	8MG	N84268 001	
	8MG	N84320 001	
GENEVA PHARMS	4MG	N85601 001	
IMPAX LABS	4MG	N84340 001	
IVAX PHARMS	4MG	N83750 001	
MYLAN	2MG	N84406 001	
PUREPAC PHARM	2MG	N84020 002	
	4MG	N84020 003	
ROXANE	2MG	N84708 001	
	4MG	N84709 001	
	8MG	N84707 001	
TEVA	4MG	N84775 001	
WATSON LABS	4MG	N85834 001	

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL			
FLUTEX			
IVAX PHARMS	0.025%	N85539 001	
	0.1%	N85539 002	
	0.5%	N85539 003	
KENALOG-H			
APOTHECON	0.1%	N86240 001	
TRIACORT			
SOLVAY	0.1%	N87113 001	
TRIAMCINOLONE ACETONIDE			
ALPHARMA	0.025%	N87797 001	
		JUN 07, 1982	
MORTON GROVE	0.025%	N88094 001	
		SEP 01, 1983	
	0.1%	N88095 001	
		SEP 01, 1983	
	0.5%	N88096 001	
		SEP 01, 1983	
PHARMADERM	0.025%	N87990 001	
		JUL 07, 1983	
	0.1%	N87991 001	
		JUL 07, 1983	
	0.5%	N87992 001	
		JUL 07, 1983	
PHARMAFAIR	0.025%	N87921 001	
		AUG 10, 1982	

FDA data supplied by DrugPatentWatch.com

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

TRIAMCINOLONE ACETONIDE		
PHARMAFAIR	0.1%	N87912 001 AUG 10, 1982
	0.5%	N87922 001 AUG 10, 1982
TARO	0.025%	N40038 001 OCT 26, 1994
TOPIDERM	0.025%	N89274 001 FEB 21, 1989
	0.1%	N89275 001 FEB 21, 1989
	0.5%	N89276 001 FEB 21, 1989
TRIATEX		
IVAX PHARMS	0.025%	N87430 001 NOV 01, 1988
	0.1%	N87429 001 NOV 01, 1988
	0.5%	N87428 001 NOV 01, 1988
TRYMEX		
SAVAGE LABS	0.5%	N88198 001 MAR 25, 1983

GEL; TOPICAL

ARISTOGEL		
FUJISAWA HLTHCARE	0.1%	N83380 001

LOTION; TOPICAL

KENALOG		
BRISTOL MYERS SQUIBB	0.025%	N11602 003
	0.1%	N11602 001
TRIAMCINOLONE ACETONIDE		
ALPHARMA	0.025%	N87191 001 SEP 08, 1982
	0.1%	N87192 001 SEP 08, 1982

OINTMENT; TOPICAL

ARISTOCORT		
FUJISAWA HLTHCARE	0.5%	N80745 002
ARISTOCORT A		
FUJISAWA HLTHCARE	0.5%	N80745 003
	0.5%	N88781 001 OCT 05, 1984

TRIAMCINOLONE ACETONIDE

OINTMENT; TOPICAL

FLUTEX		
IVAX PHARMS	0.025%	N87375 001 NOV 01, 1988
	0.1%	N87377 001 NOV 01, 1988
	0.5%	N87376 001 NOV 01, 1988
KENALOG		
APOTHECON	0.5%	N83944 001
TRIAMCINOLONE ACETONIDE		
ALPHARMA	0.5%	N89913 001 DEC 23, 1988
G AND W LABS	0.025%	N89795 001 DEC 23, 1988
	0.1%	N89796 001 DEC 23, 1988
MORTON GROVE	0.025%	N88090 001 SEP 01, 1983
	0.1%	N88091 001 SEP 01, 1983
	0.5%	N88092 001 SEP 01, 1983
PHARMADERM	0.025%	N88692 001 AUG 02, 1984
	0.1%	N88690 001 AUG 02, 1984

TRIAMCINOLONE ACETONIDE; *MULTIPLE*

SEE NEOMYCIN SULFATE; TRIAMCINOLONE ACETONIDE
SEE NYSTATIN; TRIAMCINOLONE ACETONIDE

TRIAMCINOLONE DIACETATE

INJECTABLE; INJECTION

TRIAMCINOLONE DIACETATE		
AKORN	25MG/ML	N85122 001
	40MG/ML	N86394 001
STERIS	40MG/ML	N85529 001

SYRUP; ORAL

KENACORT		
BRISTOL MYERS SQUIBB	EQ 4MG BASE/5ML	N12515 001

TRIAMTERENE; *MULTIPLE*

SEE HYDROCHLOROTHIAZIDE; TRIAMTERENE

FDA data supplied by DrugPatentWatch.com

TRIAZOLAM

TABLET; ORAL
HALCION
PHARMACIA AND UPJOHN 0.5MG N17892 002
NOV 15, 1982

TRICHLORMETHIAZIDE

TABLET; ORAL
NAQUA
SCHERING 2MG N12265 001
TRICHLOREX
LANNETT 4MG N83436 001
4MG N85630 001
TRICHLORMAS
MAST MM 4MG N86259 001
TRICHLORMETHIAZIDE
DANBURY PHARMA 2MG N83847 001
4MG N83855 001
EON 4MG N86171 001
IMPAX LABS 4MG N83967 001
WATSON LAB 4MG N83462 001
WATSON LABS 2MG N86458 001
4MG N85962 001

TRICHLORMETHIAZIDE; *MULTIPLE*
SEE RESERPINE; TRICHLORMETHIAZIDE

TRICLOFOS SODIUM

SOLUTION; ORAL
TRICLOS
AVENTIS PHARMS 1.5GM/15ML N16830 001

TABLET; ORAL
TRICLOS
AVENTIS PHARMS 750MG N16809 002

TRIDIHEXETHYL CHLORIDE

INJECTABLE; INJECTION
PATHILON
LEDERLE 10MG/ML N09729 001

TRIDIHEXETHYL CHLORIDE

TABLET; ORAL
PATHILON
LEDERLE 25MG N09489 005

TRIFLUOPERAZINE HYDROCHLORIDE

CONCENTRATE; ORAL
TRIFLUOPERAZINE HCL
GENEVA PHARMS EQ 10MG BASE/ML N85787 001
APR 15, 1982
MORTON GROVE EQ 10MG BASE/ML N88143 001
JUL 26, 1983

INJECTABLE; INJECTION
TRIFLUOPERAZINE HCL
QUAD PHARMS EQ 2MG BASE/ML N89893 001
OCT 17, 1988

TABLET; ORAL
TRIFLUOPERAZINE HCL
DURAMED EQ 1MG BASE N88967 001
APR 23, 1985
EQ 2MG BASE N88968 001
APR 23, 1985
EQ 5MG BASE N88969 001
APR 23, 1985
EQ 10MG BASE N88970 001
APR 23, 1985
IVAX PHARMS EQ 1MG BASE N87612 001
NOV 19, 1982
EQ 2MG BASE N87613 001
NOV 19, 1982
EQ 5MG BASE N87328 001
NOV 19, 1982
EQ 10MG BASE N87614 001
NOV 19, 1982
WATSON LAB EQ 1MG BASE N85975 001
JUN 23, 1988
EQ 2MG BASE N85976 001
JUN 23, 1988
EQ 5MG BASE N85973 001
JUN 23, 1988
EQ 10MG BASE N88710 001
JUN 23, 1988

FDA data supplied by DrugPatentWatch.com

TRIFLUPROMAZINE

SUSPENSION; ORAL
VESPRIN
APOTHECON EQ 50MG HCL/5ML N11491 004

TRIFLUPROMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION
VESPRIN
APOTHECON 3MG/ML N11325 005

TABLET; ORAL
VESPRIN
BRISTOL MYERS SQUIBB 10MG N11123 001
25MG N11123 002
50MG N11123 003

TRIHEXYPHENIDYL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
ARTANE
LEDERLE 5MG N06773 010
5MG N12947 001

TABLET; ORAL
TREMIN
SCHERING 2MG N80381 001
5MG N80381 003
TRIHEXYPHENIDYL HCL
VANGARD 2MG N88035 001
JUL 30, 1982
WATSON LAB 2MG N85117 001
5MG N85105 001

TRILOSTANE

CAPSULE; ORAL
MODRASTANE
SANOFI SYNTHELABO 30MG N18719 002
DEC 31, 1984
60MG N18719 001
DEC 31, 1984

TRIMEPRAZINE TARTRATE

CAPSULE, EXTENDED RELEASE; ORAL
TEMARIL
ALLERGAN HERBERT EQ 5MG BASE N11316 004

SYRUP; ORAL
TEMARIL
ALLERGAN HERBERT EQ 2.5MG BASE/5ML N11316 003
TRIMEPRAZINE TARTRATE
ALPHARMA EQ 2.5MG BASE/5ML N85015 001
FEB 18, 1982
MORTON GROVE EQ 2.5MG BASE/5ML N88285 001
APR 11, 1985

TABLET; ORAL
TEMARIL
ALLERGAN HERBERT EQ 2.5MG BASE N11316 001

TRIMETHAPHAN CAMSYLATE

INJECTABLE; INJECTION
ARFONAD
ROCHE 50MG/ML N08983 001

TRIMETHOBENZAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION
TRIMETHOBENZAMIDE HCL
SMITH AND NEPHEW 100MG/ML N88960 001
APR 04, 1986
100MG/ML N89043 001
APR 04, 1986
SOLOPAK 100MG/ML N89094 001
APR 04, 1986
STERIS 100MG/ML N86577 001
OCT 19, 1982

TRIMETHOPRIM

TABLET; ORAL
TRIMETHOPRIM
HALSEY 100MG N70494 001
JAN 22, 1986
200MG N70495 001
SEP 24, 1986

FDA data supplied by DrugPatentWatch.com

TRIMETHOPRIM

TABLET; ORAL			
TRIMPEX 200			
ROCHE	200MG	N17952 002	NOV 09, 1982

TRIMETHOPRIM; *MULTIPLE*
SEE SULFAMETHOXAZOLE; TRIMETHOPRIM

TRIMETHOPRIM HYDROCHLORIDE

SOLUTION; ORAL			
PRIMSOL			
ASCENT PEDS	EQ 25MG BASE/5ML	N74374 001	JUN 23, 1995

TRIMIPRAMINE MALEATE

CAPSULE; ORAL			
TRIMIPRAMINE MALEATE			
USL PHARMA	EQ 25MG BASE	N71283 001	DEC 08, 1987
	EQ 50MG BASE	N71284 001	DEC 08, 1987
	EQ 100MG BASE	N71285 001	DEC 08, 1987

TRIPELENNAMINE HYDROCHLORIDE

TABLET; ORAL			
TRIPELENNAMINE HCL			
ANABOLIC	50MG	N83037 001	
BARR	50MG	N80744 001	
HEATHER	50MG	N83989 001	
IMPAX LABS	50MG	N80785 001	
PARKE DAVIS	25MG	N83625 001	
	50MG	N83626 001	
WATSON LAB	50MG	N80790 001	
WATSON LABS	50MG	N85188 001	
TABLET, EXTENDED RELEASE; ORAL			
PBZ-SR			
NOVARTIS	50MG	N10533 002	

TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE;SULFATHIAZOLE)

CREAM; VAGINAL			
TRIPLE SULFA			
FOUGERA	3.7%;2.86%;3.42%	N86424 001	
VAGILIA			
TEVA	3.7%;2.86%;3.42%	N88821 001	NOV 09, 1987
TABLET; VAGINAL			
TRIPLE SULFA			
FOUGERA	184MG;143.75MG;172.5MG	N88463 001	JAN 03, 1985
PHARMADERM	184MG;143.75MG;172.5MG	N88462 001	JAN 03, 1985

TRIPROLIDINE HYDROCHLORIDE

SYRUP; ORAL			
ACTIDIL			
GLAXOSMITHKLINE	1.25MG/5ML	N11496 002	JUL 01, 1983
MYIDYL			
USL PHARMA	1.25MG/5ML	N87963 001	JAN 18, 1983
TRIPROLIDINE HCL			
ALPHARMA	1.25MG/5ML	N85940 001	
HALSEY	1.25MG/5ML	N88735 001	JAN 17, 1985
PHARM ASSOC	1.25MG/5ML	N87514 001	FEB 10, 1982
TABLET; ORAL			
ACTIDIL			
GLAXOSMITHKLINE	2.5MG	N11110 002	JUL 01, 1983
TRIPROLIDINE HCL			
DANBURY PHARMA	2.5MG	N85094 001	
VITARINE	2.5MG	N85610 001	

TRIPROLIDINE HYDROCHLORIDE; *MULTIPLE*
SEE CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE
SEE PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

TRISULFAPYRIMIDINES (SULFADIAZINE;SULFAMERAZINE;SULFAMETHAZINE)

SUSPENSION; ORAL			
LANTRISUL			
LANNETT	167MG/5ML;167MG/5ML;167MG/5ML	N80123	002
NEOTRIZINE			
LILLY	167MG/5ML;167MG/5ML;167MG/5ML	N06317	012
SULFALOID			
FOREST PHARMS	167MG/5ML;167MG/5ML;167MG/5ML	N80100	001
SULFOSE			
WYETH AYERST	167MG/5ML;167MG/5ML;167MG/5ML	N80013	002
TERFONYL			
BRISTOL MYERS SQUIBB	167MG/5ML;167MG/5ML;167MG/5ML	N06904	002
TRIPLE SULFA			
ALPHARMA	167MG/5ML;167MG/5ML;167MG/5ML	N80280	001
TRIPLE SULFAS			
LEDERLE	167MG/5ML;167MG/5ML;167MG/5ML	N06920	003
TABLET; ORAL			
NEOTRIZINE			
LILLY	167MG;167MG;167MG	N06317	011
SULFA-TRIPLE #2			
IMPAX LABS	167MG;167MG;167MG	N80079	001
SULFALOID			
FOREST PHARMS	167MG;167MG;167MG	N80099	001
SULFOSE			
WYETH AYERST	167MG;167MG;167MG	N80013	001
TERFONYL			
BRISTOL MYERS SQUIBB	167MG;167MG;167MG	N06904	001
TRIPLE SULFA			
PUREPAC PHARM	167MG;167MG;167MG	N80086	001
TRIPLE SULFAS			
LEDERLE	167MG;167MG;167MG	N06920	002

TROGLITAZONE

TABLET; ORAL			
PRELAY			
SANKYO	200MG	N20719	001
		JAN 29, 1997	

TROGLITAZONE

TABLET; ORAL			
PRELAY			
SANKYO	300MG	N20719	003
		AUG 04, 1997	
	400MG	N20719	002
		JAN 29, 1997	
REZULIN			
PARKE DAVIS PHARMS	200MG	N20720	001
		JAN 29, 1997	
	300MG	N20720	003
		AUG 04, 1997	
	400MG	N20720	002
		JAN 29, 1997	

TROLEANDOMYCIN

SUSPENSION; ORAL			
TAO			
PFIZER	EQ 125MG BASE/5ML	N50332	001

TROMETHAMINE; *MULTIPLE*
SEE POTASSIUM CHLORIDE; SODIUM CHLORIDE; TROMETHAMINE

TROPICAMIDE

SOLUTION/DROPS; OPHTHALMIC			
MYDRIACYL			
ALCON	0.5%	N12111	002
	1%	N12111	004
MYDRIAFAIR			
PHARMAFAIR	0.5%	N88274	001
		SEP 16, 1983	
	1%	N88230	001
		SEP 16, 1983	
TROPICAMIDE			
AKORN	1%	N88447	001
		AUG 28, 1985	
STERIS	0.5%	N89171	001
		DEC 28, 1990	

TROVAFLOXACIN MESYLATE; *MULTIPLE*
SEE AZITHROMYCIN DIHYDRATE; TROVAFLOXACIN MESYLATE

FDA data supplied by DrugPatentWatch.com

TUBOCURARINE CHLORIDE

INJECTABLE; INJECTION
TUBOCURARINE CHLORIDE

LILLY	3MG/ML	N06325 001
QUAD PHARMS	3MG/ML	N89442 001 AUG 12, 1988

TYROPANOATE SODIUM

CAPSULE; ORAL
BILOPAQUE

AMERSHAM HLTH	750MG	N13731 001

TYROSINE; *MULTIPLE*
SEE NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; TYROSINE

UNDECOYLIUM CHLORIDE; UNDECOYLIUM CHLORIDE IODINE COMPLEX

SOLUTION; TOPICAL
VIRAC REX

CHESEBROUGH PONDS	0.5%;1.8%	N11914 001

UNDECOYLIUM CHLORIDE IODINE COMPLEX; *MULTIPLE*
SEE UNDECOYLIUM CHLORIDE; UNDECOYLIUM CHLORIDE IODINE COMPLEX

URACIL MUSTARD

CAPSULE; ORAL
URACIL MUSTARD

SHIRE PHARM	1MG	N12892 001

UREA

INJECTABLE; INJECTION
STERILE UREA

ABBOTT	40GM/VIAL	N17698 001

UREA; *MULTIPLE*
SEE HYDROCORTISONE; UREA

UREA, C-13

FOR SOLUTION; ORAL
MERETEK UBT KIT (W/ PRANACTIN)

MERETEK	125MG/VIAL	N20586 001 SEP 17, 1996

UROFOLLITROPIN

INJECTABLE; INTRAMUSCULAR
METRODIN

SERONO	75 IU/AMP	N19415 002 SEP 18, 1986
	150 IU/AMP	N19415 003 SEP 18, 1986

URSODIOL

CAPSULE; ORAL
ACTIGALL

NOVARTIS	150MG	N19594 001 DEC 31, 1987

VALPROIC ACID

CAPSULE; ORAL
VALPROIC ACID

PAR PHARM	250MG	N70431 001 FEB 28, 1986
SCHERER RP	250MG	N70195 001 JUL 02, 1987

VANCOMYCIN HYDROCHLORIDE

FOR SOLUTION; ORAL
VANCOLED

LEDERLE	EQ 500MG BASE/6ML	N63321 003 OCT 15, 1993

INJECTABLE; INJECTION
VANCOMYCIN HCL

ELKINS SINN	EQ 500MG BASE/VIAL	N62879 001 AUG 02, 1988
	EQ 1GM BASE/VIAL	N62879 002 AUG 02, 1988

FDA data supplied by DrugPatentWatch.com

VANCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION		
VANCOMYCIN HCL		
QUAD PHARMS	EQ 500MG BASE/VIAL	N62845 001 JUL 15, 1988
	EQ 1GM BASE/VIAL	N62845 002 JUL 15, 1988
VANCOR		
PHARMACIA AND UPJOHN	EQ 500MG BASE/VIAL	N62956 001 AUG 01, 1988
	EQ 1GM BASE/VIAL	N62956 002 AUG 01, 1988

VASOPRESSIN TANNATE

INJECTABLE; INJECTION		
PITRESSIN TANNATE		
PARKE DAVIS	5 PRESSOR UNITS/ML	N03402 001

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL		
EFFEXOR XR		
WYETH AYERST	EQ 100MG BASE	N20699 003 OCT 20, 1997
TABLET; ORAL		
EFFEXOR		
WYETH AYERST	EQ 12.5MG BASE	N20151 001 DEC 28, 1993

VERAPAMIL HYDROCHLORIDE

INJECTABLE; INJECTION		
CALAN		
GD SEARLE LLC	2.5MG/ML	N18925 001 MAR 30, 1984
	2.5MG/ML	N19038 001 MAR 30, 1984
VERAPAMIL HCL		
AM PHARM PARTNERS	2.5MG/ML	N70348 001 MAY 01, 1986
MARSAM PHARMS LLC	2.5MG/ML	N72233 001 FEB 26, 1993

VERAPAMIL HYDROCHLORIDE

INJECTABLE; INJECTION		
VERAPAMIL HCL		
MARSAM PHARMS LLC	2.5MG/ML	N73485 001 SEP 27, 1993
QUAD PHARMS	2.5MG/ML	N70672 001 MAR 07, 1986
SMITH AND NEPHEW	2.5MG/ML	N70696 001 JUL 31, 1987
	2.5MG/ML	N70697 001 JUL 31, 1987
SOLOPAK	2.5MG/ML	N70695 001 JUL 31, 1987
TABLET; ORAL		
CALAN		
GD SEARLE LLC	160MG	N18817 004 FEB 23, 1988
VERAPAMIL HCL		
HALSEY	80MG	N70482 001 SEP 24, 1986
	120MG	N70483 001 SEP 24, 1986
WARNER CHILCOTT	80MG	N70340 001 SEP 24, 1986
	120MG	N70341 001 SEP 24, 1986
WATSON LABS	40MG	N72799 001 APR 28, 1989
TABLET, EXTENDED RELEASE; ORAL		
VERAPAMIL HCL		
BARR	120MG	N75072 001 MAY 25, 1999
	240MG	N75072 003 MAY 25, 1999

VERATRUM VIRIDE

TABLET; ORAL		
VERTAVIS		
WALLACE LABS	130 CSR UNIT	N05691 002

FDA data supplied by DrugPatentWatch.com

VIDARABINE

INJECTABLE; INJECTION		
VIRA-A		
PARKEDALE	EQ 187.4MG BASE/ML	N50523 001

VINBLASTINE SULFATE

INJECTABLE; INJECTION		
VELBAN		
LILLY	10MG/VIAL	N12665 001
VINBLASTINE SULFATE		
AM PHARM PARTNERS	10MG/VIAL	N89011 001 NOV 18, 1985
QUAD PHARMS	1MG/ML	N89311 001 MAR 23, 1987
	10MG/VIAL	N89365 001 AUG 07, 1986

VINCRISTINE SULFATE

INJECTABLE; INJECTION		
ONCOVIN		
LILLY	1MG/VIAL	N14103 001
	5MG/VIAL	N14103 002
VINCREX		
BRISTOL MYERS SQUIBB	5MG/VIAL	N70867 001 JUL 12, 1988
VINCRISTINE SULFATE		
ABIC	1MG/ML	N70873 001 FEB 19, 1987
AM PHARM PARTNERS	1MG/ML	N70411 001 SEP 10, 1986
FAULDING	1MG/VIAL	N71559 001 APR 11, 1988
	2MG/VIAL	N71560 001 APR 11, 1988
	5MG/VIAL	N71561 001 APR 11, 1988
QUAD PHARMS	1MG/ML	N70777 001 APR 29, 1986
	1MG/ML	N70778 001 MAY 01, 1986
	1MG/VIAL	N71222 001 MAR 07, 1988
	2MG/VIAL	N71223 001 MAR 07, 1988

VINCRISTINE SULFATE

INJECTABLE; INJECTION		
VINCRISTINE SULFATE		
QUAD PHARMS	5MG/VIAL	N71937 001 MAR 07, 1988

VIOMYCIN SULFATE

INJECTABLE; INJECTION		
VIOCIN SULFATE		
PFIZER	EQ 1GM BASE/VIAL	N61086 001
	EQ 5GM BASE/VIAL	N61086 002

VITAMIN A

CAPSULE; ORAL		
AQUASOL A		
ASTRAZENECA	25,000 USP UNITS	N83080 002
	50,000 USP UNITS	N83080 001
VITAMIN A		
BANNER PHARMACAPS	50,000 USP UNITS	N83973 001
CHASE CHEM	50,000 IU	N83351 001
EVERYLIFE	50,000 IU	N83134 001
IMPAX LABS	50,000 USP UNITS	N80952 001

VITAMIN A; *MULTIPLE*

SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE; VITAMIN A; VITAMIN E

SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

VITAMIN A PALMITATE

CAPSULE; ORAL		
AFAXIN		
STERLING WINTHROP	EQ 50,000 UNITS BASE	N83187 001
ALPHALIN		
LILLY	EQ 50,000 UNITS BASE	N80883 001
DEL-VI-A		
DEL RAY LABS	EQ 50,000 UNITS BASE	N80830 001

FDA data supplied by DrugPatentWatch.com

VITAMIN A PALMITATE

CAPSULE; ORAL			
VI-DOM-A			
BAYER	EQ 50,000 UNITS BASE		N80972 001
VITAMIN A			
BANNER PHARMACAPS	EQ 50,000 UNITS BASE		N80702 001
BRISTOL MYERS SQUIBB	EQ 50,000 UNITS BASE		N80860 001
CHASE CHEM	EQ 50,000 UNITS BASE		N80746 001
	EQ 50,000 UNITS BASE		N83207 001
ELKINS SINN	EQ 50,000 UNITS BASE		N85479 001
EVERYLIFE	EQ 50,000 UNITS BASE		N80943 001
	EQ 50,000 UNITS BASE		N83114 001
IMPAX LABS	EQ 50,000 UNITS BASE		N80953 001
	EQ 50,000 UNITS BASE		N80955 001
IVAX PHARMS	EQ 50,000 UNITS BASE		N83035 001
	EQ 50,000 UNITS BASE		N83190 001
WEST WARD	EQ 50,000 UNITS BASE		N80967 001
WHARTON LABS	EQ 50,000 UNITS BASE		N83665 001
VITAMIN A PALMITATE			
BANNER PHARMACAPS	EQ 50,000 UNITS BASE		N83948 001
	EQ 50,000 UNITS BASE		N83981 001
VITAMIN A SOLUBILIZED			
TEVA	EQ 50,000 UNITS BASE		N80921 001
INJECTABLE; INJECTION			
VITAMIN A PALMITATE			
BEL MAR	EQ 50,000 UNITS BASE/ML		N80819 001

VITAMIN A PALMITATE; *MULTIPLE*

SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN E

SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PHYTONADIONE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A PALMITATE; VITAMIN E

VITAMIN E; *MULTIPLE*

SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE; VITAMIN A; VITAMIN E

SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

VITAMIN E; *MULTIPLE*

SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN E

SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PHYTONADIONE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A PALMITATE; VITAMIN E

WARFARIN POTASSIUM

TABLET; ORAL		
ATHROMBIN-K		
PURDUE FREDERICK	2MG	N11771 007
	5MG	N11771 004
	10MG	N11771 005
	25MG	N11771 006

WARFARIN SODIUM

INJECTABLE; INJECTION		
COUMADIN		
BRISTOL MYERS SQUIBB	50MG/VIAL	N09218 020
	75MG/VIAL	N09218 012
TABLET; ORAL		
ATHROMBIN		
PURDUE FREDERICK	5MG	N11771 003
	10MG	N11771 002
	25MG	N11771 001
PANWARFIN		
ABBOTT	2MG	N17020 001
	2.5MG	N17020 002
	5MG	N17020 003
	7.5MG	N17020 004
	10MG	N17020 005
WARFARIN SODIUM		
USL PHARMA	2MG	N88719 001 JUN 27, 1985
	2.5MG	N88720 001 AUG 06, 1985
	5MG	N88721 001 JUL 02, 1985
WATSON LAB	2MG	N86123 001 AUG 17, 1982

FDA data supplied by DrugPatentWatch.com

WARFARIN SODIUM

TABLET; ORAL
WARFARIN SODIUM

WATSON LAB	2.5MG	N86120 001 AUG 17, 1982
	5MG	N86119 001 AUG 17, 1982
	7.5MG	N86118 001 AUG 17, 1982
	10MG	N86122 001 AUG 17, 1982

WATER FOR INJECTION, STERILE

LIQUID; N/A
BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER

AM PHARM PARTNERS	100%	N89099 001 DEC 29, 1987
	100%	N89100 001 DEC 29, 1987

WATER FOR IRRIGATION, STERILE

LIQUID; IRRIGATION
STERILE WATER IN PLASTIC CONTAINER

MILES	100%	N18246 001

XENON, XE-133

GAS; INHALATION
XENON XE 133

AMERSHAM HLTH	1 CI/AMP	N17256 002
	10mCi/VIAL	N17687 002
	20mCi/VIAL	N17687 003

XENON XE 132 V.S.S.

AMERSHAM HLTH	10mCi/VIAL	N17687 001

INJECTABLE; INJECTION
XENON XE 133

AMERSHAM HLTH	1.3-1.7 CI/AMP	N17256 001
BRISTOL MYERS SQUIBB	6.3mCi/ML	N17283 001

SOLUTION; INHALATION, INJECTION
XENEISOL

MALLINCKRODT	18-25mCi/AMP	N17262 002

XYLOSE

POWDER; ORAL
XYLO-PFAN

SAVAGE LABS	25GM/BOT	N17605 001

ZIDOVUDINE

TABLET; ORAL
RETROVIR

GLAXOSMITHKLINE	200MG	N20518 001 DEC 19, 1995

ZINC ACETATE; *MULTIPLE*
SEE CYANOCOBALAMIN; TANNIC ACID; ZINC ACETATE

ZINC SULFATE

INJECTABLE; INJECTION
ZINC SULFATE

AM PHARM PARTNERS	EQ 1MG ZINC/ML	N19229 002 MAY 05, 1987

FDA data supplied by DrugPatentWatch.com

This data is provided to the Division of Data Management and Services from the Office of Orphan Products Development and is not edited prior to publication.

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **T-cell depleted stem cell enriched cellular product from peripheal blood stem cells**
Trade Name: NONE ASSIGNED
Designated Indication: *Treatment of chronic granulomatous disease*
Sponsor: Nexell Therapeutics Inc.
Address: 9 Parker, Irvine CA 92618-1605
Date Designated: 11/1/2001
Market Approval Date: Not currently Approved

Generic Name: **(R)-N-[2-(6-chloro-5-methoxy-1H-indol-3-yl)propyl]acetamide**
Trade Name: NONE ASSIGNED
Designated Indication: *Treatment of circadian rhythm sleep disorders in blind people with no light perception*
Sponsor: Phase 2 Discovery, Inc.
Address: 3130 Highland Avenue, Third Floor, Cincinnati OH 45219-2374
Date Designated: 10/3/2001
Market Approval Date: Not currently Approved

Generic Name: **1,5-(Butylimino)-1,5 dideoxy,D-glucitol**
Trade Name: NONE ASSIGNED
Designated Indication: *Treatment of Fabry's disease.*
Sponsor: Oxford GlycoSciences
Address: 10, The Quadrant, Abington Science Park, Abington, Oxfordshire OX14 3YS UK
Date Designated: 5/12/1998
Market Approval Date: Not currently Approved

Generic Name: **1,5-(Butylimino)-1,5 dideoxy,D-glucitol**
Trade Name: NONE ASSIGNED
Designated Indication: *Treatment of Gaucher disease.*
Sponsor: Oxford GlycoSciences
Address: 10, The Quadrant, Abington Science Park, Abington, Oxfordshire OX14 3YS UK
Date Designated: 5/29/1998
Market Approval Date: Not currently Approved

Generic Name: **1-(11-dodecylamino-10-hydroxyundecyl)-3,7-dimethylxanthine hydrogen methanesulfonate**
Trade Name: NONE ASSIGNED
Designated Indication: *Treatment of hormone refractory prostate carcinoma.*
Sponsor: Cell Therapeutics, Inc.
Address: 201 Elliott Avenue West, Suite 400, Seattle WA 98119
Date Designated: 1/18/2000
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **111Indium pentetreotide** — Trade Name: SomatoTher

Designated Indication: *Treatment of somatostatin receptor positive neuroendocrine tumors.*

Sponsor: Louisiana State University Medical Center
Address: 1600 Canal St.
10th Floor
New Orleans LA 70112

Date Designated: 6/10/1999
Market Approval Date: Not currently Approved

Generic Name: **15AU81** — Trade Name: Remodulin

Designated Indication: *Treatment of pulmonary arterial hypertension.*

Sponsor: United Therapeutics Corp.
Address: 68 T.W. Alexander Dr.
P.O. Box 14186
Research Triangle Park NC 27709

Date Designated: 6/4/1997
Market Approval Date: Not currently Approved

Generic Name: **166Ho-DOTMP** — Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of multiple myeloma.*

Sponsor: NeoRx Corporation
Address: 410 W. Harrison Street
Seattle WA 98119-4007

Date Designated: 2/10/1999
Market Approval Date: Not currently Approved

Generic Name: **2'-deoxycytidine** — Trade Name: NONE ASSIGNED

Designated Indication: *As a host-protective agent in the treatment of acute myelogenous leukemia.*

Sponsor: Grant, Steven M.D.
Address: Massey Cancer Center, VCU
P.O. Box 980230
Richmond VA 23298-0230

Date Designated: 9/9/1996
Market Approval Date: Not currently Approved

Generic Name: **2-0-desulfated heparin** — Trade Name: Aeropin

Designated Indication: *Treatment of cystic fibrosis.*

Sponsor: Kennedy & Hoidal, M.D.'s
Address: University of Utah Health Sciences Center
50 North Medical Drive, Room 4R240
Salt Lake City UT 84132

Date Designated: 9/17/1993
Market Approval Date: Not currently Approved

Generic Name: **2-chloroethyl-3-sarcosinamide-1-nitrosourea** — Trade Name: Sarmustine

Designated Indication: *Treatment for malignant glioma*

Sponsor: Pangene Corporation
Address: 5500 Stewart Avenue
Fremont CA 94538

Date Designated: 11/15/2001
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: | Trade Name: NONE ASSIGNED

Designated Indication: *Treatment for malignant gliomas*

Sponsor: Lawrence Panasci, MD
Address: Professor of Medicine, McGill University
3755 Cote Ste Catherine
Montreal, Quebec H3T 1E2

Date Designated: 8/3/2001
Market Approval Date: Not currently Approved

Generic Name: **2-methoxyestradiol** | Trade Name: Panzem

Designated Indication: *Treatment of multiple myeloma*

Sponsor: EntreMed, Inc.
Address: 9640 Medical Center Drive
Rockville MD 20850

Date Designated: 7/10/2001
Market Approval Date: Not currently Approved

Generic Name: **24,25 dihydroxycholecalciferol** | Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of uremic osteodystrophy.*

Sponsor: Lemmon Company
Address: 1510 Delp Drive
Kulpsville PA 19443

Date Designated: 2/27/1987
Market Approval Date: Not currently Approved

Generic Name: **3,4-diaminopyridine** | Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of Lambert-Eaton myasthenic syndrome.*

Sponsor: Jacobus Pharmaceutical Company
Address: 37 Cleveland Avenue
P.O. Box 5290
Princeton NJ 08540

Date Designated: 12/18/1990
Market Approval Date: Not currently Approved

Generic Name: **3,5,3'-triiodothyroacetate** | Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of well-differentiated papillary, follicular or combined papillary/follicular carcinomas of the thyroid gland.*

Sponsor: Elliot Danforth, Jr., M.D.
Address: University of Vermont
84 Beartown Road
Underhill VT 05489

Date Designated: 9/20/2000
Market Approval Date: Not currently Approved

Generic Name: **3-(3,5-Dimethyl-1H-2ylmethylene)-1,3-dihydro-indol-2-one** | Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of von Hippel-Lindau disease.*

Sponsor: Sugen, Inc.
Address: 230 East Grand Ave.
South San Francisco CA 94080

Date Designated: 3/23/2000
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **3-(3,5-dimethyl-1H-2ylmethylene)-1,3-dihydro-indol-2-one**
Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of Kaposi's sarcoma.*

Sponsor: Sugen, Inc.
Address: 230 East Grand Ave.
South San Francisco CA 94080-4811

Date Designated: 9/11/1998
Market Approval Date: Not currently Approved

Generic Name: **3-(4'aminoisoindoline-1'-one)-1-piperidine-2,6-dione**
Trade Name: Revimid (proposed)

Designated Indication: *Treatment for multiple myeloma*

Sponsor: Celegene Corporation
Address: 7 Powder Horn Drive
Warren NJ 07059

Date Designated: 9/20/2001
Market Approval Date: Not currently Approved

Generic Name: **4-aminosalicylic acid**
Trade Name: Pamisyl (P-D), Rezipas (Squibb)

Designated Indication: *Treatment of mild to moderate ulcerative colitis in patients intolerant to sulfasalazine.*

Sponsor: Beeken, Warren M.D.
Address: University Of Vermont
Given C-317
Burlington VT 05405

Date Designated: 12/13/1989
Market Approval Date: Not currently Approved

Generic Name: **40SD02**
Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of chronic iron overload resulting from conventional transfusional treatment of beta-thalassemia major and sickle cell anemia.*

Sponsor: Biomedical Frontiers, Inc.
Address: 1095 10th Ave., S.E.
Minneapolis MN 55414

Date Designated: 12/21/1998
Market Approval Date: Not currently Approved

Generic Name: **5,6-dihydro-5-azacytidine**
Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of malignant mesothelioma.*

Sponsor: ILEX Oncology, Inc.
Address: 4545 Horizon Hill Blvd.
San Antonio TX 78229-2263

Date Designated: 5/11/1992
Market Approval Date: Not currently Approved

Generic Name: **5-aza-2'-deoxycytidine**
Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of acute leukemia.*

Sponsor: SuperGen, Inc.
Address: 4140 Dublin Blvd.
Suite 200
Dublin CA 94568

Date Designated: 8/3/1987
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **506U78** | Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of chronic lymphocytic leukemia.*

Sponsor: Glaxo Wellcome, Inc.
Address: Five Moore Dr.
P.O. Box 13398
Research Triangle Park NC 27709-3398

Date Designated: 9/2/1999
Market Approval Date: Not currently Approved

Generic Name: **6-hydroxymethylacylfulvene** | Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of histologically confirmed advanced or metastatic pancreatic cancer.*

Sponsor: MGI Pharma, Inc.
Address: 6300 West Old Shakoppe Rd.
Suite 110
Bloomington MN 55438-2318

Date Designated: 4/6/1999
Market Approval Date: Not currently Approved

Generic Name: **6-hydroxymethylacylfulvene** | Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of ovarian cancer.*

Sponsor: MGI Pharma, Inc.
Address: 5775 West Old Shakoppe Rd.
Suite 100
Bloomington MN 55437-3107

Date Designated: 7/6/1999
Market Approval Date: Not currently Approved

Generic Name: **6-hydroxymethylacylfulvene** | Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of renal cell carcinoma.*

Sponsor: MGI Pharma, Inc.
Address: 6300 West Old Shakoppe Rd.
Suite 110
Bloomington MN 55438-2318

Date Designated: 7/27/1999
Market Approval Date: Not currently Approved

Generic Name: **8 Cyclopentyl 1,3-dipropylxanthine** | Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of cystic fibrosis.*

Sponsor: SciClone Pharmaceuticals, Inc.
Address: 901 Mariner's Island Boulevard
San Mateo CA 94404-1593

Date Designated: 3/24/1997
Market Approval Date: Not currently Approved

Generic Name: **8-methoxsalen** | Trade Name: Uvadex

Designated Indication: *For the prevention of acute rejection of cardiac allografts.*

Sponsor: Therakos, Inc.
Address: Oaklands Corporate Center
437 Creamery Way
Exton PA 19341

Date Designated: 5/12/1994
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **8-methoxsalen** Trade Name: Uvadex

Designated Indication: *For use in conjunction with the UVAR photopheresis to treat diffuse systemic sclerosis.*

Sponsor: Therakos, Inc.
Address: Oaklands Corporate Center
437 Creamery Way
Exton PA 19341

Date Designated: 6/22/1993
Market Approval Date: Not currently Approved

Generic Name: **9-cis retinoic acid** Trade Name: Panretin

Designated Indication: *Treatment of acute promyelocytic leukemia.*

Sponsor: Ligand Pharmaceuticals, Inc.
Address: 9393 Towne Centre Drive
Suite 100
San Diego CA 92121

Date Designated: 4/10/1992
Market Approval Date: Not currently Approved

Generic Name: **9-nitro-20-(S)-camptothecin** Trade Name: Camvirex

Designated Indication: *Treatment of pediatric HIV infection/AIDS*

Sponsor: NovoMed Pharmaceuticals, Inc.
Address: P.O. Box 900
Germantown MD 20875-0900

Date Designated: 5/15/2001
Market Approval Date: Not currently Approved

Generic Name: **9-nitro-20-(S)-camptothecin** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of pancreatic cancer.*

Sponsor: Stehlin Foundation for Cancer Research
Address: 1315 St. Joseph Parkway, Suite 1818
Houston TX 77002

Date Designated: 9/16/1996
Market Approval Date: Not currently Approved

Generic Name: **Abetimus** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of lupus nephritis.*

Sponsor: La Jolla Pharmaceutical Co.
Address: 6455 Nancy Ridge Dr.
San Diego CA 92121

Date Designated: 7/28/2000
Market Approval Date: Not currently Approved

Generic Name: **acetylcysteine** Trade Name: Acetadote

Designated Indication: *For the intravenous treatment of moderate to severe acetaminophen overdose*

Sponsor: Cumberland Pharmaceuticals Inc.
Address: 209 10th Street South
Suite 332
Nashville TN 37203

Date Designated: 10/19/2001
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Acetylcysteine** | Trade Name: Mucomyst/Mucomyst 10 IV

Designated Indication: *Intravenous treatment of patients presenting with moderate to severe acetaminophen overdose.*

Sponsor: Bristol-Myers Squibb Company
Address: P.O. Box 4500
Princeton NJ 08543-4500

Date Designated: 8/13/1987
Market Approval Date: Not currently Approved

Generic Name: **Aconiazide** | Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of tuberculosis.*

Sponsor: Lincoln Diagnostics
Address: P.O. Box 1128
Decatur IL 62525

Date Designated: 6/20/1988
Market Approval Date: Not currently Approved

Generic Name: **Adeno-associated viral vector containing the gene for human coagulation factor IX** | Trade Name: Coagulin-B

Designated Indication: *Intramuscular treatment of patients with moderate to severe hemophilia*

Sponsor: Avigen, Inc.
Address: 1301 Harbor Bay Parkway
Alameda CA 94502

Date Designated: 6/13/2001
Market Approval Date: Not currently Approved

Generic Name: **Adeno-associated viral vector containing the gene for human coagulation factor IX** | Trade Name: Coagulin-B

Designated Indication: *Intrahepatic treatment of patients with moderate to severe hemophilia*

Sponsor: Avigen, Inc.
Address: 1301 Harbor Bay Parkway
Alameda CA 94502

Date Designated: 6/13/2001
Market Approval Date: Not currently Approved

Generic Name: **Adeno-associated viral-based vector cystic fibrosis gene therapy** | Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of cystic fibrosis.*

Sponsor: Targeted Genetics Corporation
Address: 1100 Olive Way, Suite 100
Seattle WA 98101

Date Designated: 2/15/1995
Market Approval Date: Not currently Approved

Generic Name: **Adenovirus-based vector Factor VIII complementary DNA to somatic cells** | Trade Name: MiniAdFVIII

Designated Indication: *Treatment of hemophilia A.*

Sponsor: GenStar Therapeutics Corporation
Address: 10835 Altman Row
Suite 150
San Diego CA 92121

Date Designated: 12/15/1999
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **adenovirus-mediated herpes simplex virus-thymidine kinase gene**
Trade Name: NONE ASSIGNED

Designated Indication: *Use with gancyclovir in the treatment of malignant glioma*

Sponsor: Ark Therapeutics Ltd
Address: 6 Warren Mews
London W1T6AR UK

Date Designated: 7/31/2001
Market Approval Date: Not currently Approved

Generic Name: **Albendazole**
Trade Name: Albenza

Designated Indication: *Treatment of hydatid disease (cystic echinococcosis due to E. granulosus larvae or alveolar echinococcosis due to E. multilocularis larvae).*

Sponsor: SmithKline Beecham Pharmaceuticals
Address: One Franklin Plaza
P.O. Box 7929
Philadelphia PA 19101

Date Designated: 1/17/1996
Market Approval Date: 6/11/1996

Generic Name: **Albendazole**
Trade Name: Albenza

Designated Indication: *Treatment of neurocysticercosis due to Taenia solium as: 1) chemotherapy of parenchymal, subarachnoidal and racemose (cysts in spinal fluid) neurocysticercosis in symptomatic cases and 2) prophylaxis of epilepsy and other sequelae in asymptomatic neurocysticercosis.*

Sponsor: SmithKline Beecham Pharmaceuticals
Address: One Franklin Plaza
P.O. Box 7929
Philadelphia PA 19101

Date Designated: 1/18/1996
Market Approval Date: 6/11/1996

Generic Name: **Aldesleukin**
Trade Name: Proleukin

Designated Indication: *For the treatment non-Hodgkin's lymphoma.*

Sponsor: Chiron Corporation
Address: 4560 Horton St.
Emeryville CA 94608-2916

Date Designated: 11/24/1998
Market Approval Date: Not currently Approved

Generic Name: **Aldesleukin**
Trade Name: Proleukin

Designated Indication: *Treatment of metastatic melanoma.*

Sponsor: Chiron Corporation
Address: 4560 Horton Street
Emeryville CA 94608-2916

Date Designated: 9/10/1996
Market Approval Date: 1/9/1998

Generic Name: **Aldesleukin**
Trade Name: Proleukin

Designated Indication: *Treatment of primary immunodeficiency disease associated with T-cell defects.*

Sponsor: Chiron Corporation
Address: 4560 Horton Street
Emeryville CA 94608-2916

Date Designated: 3/22/1989
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Aldesleukin** Trade Name: Proleukin

Designated Indication: *Treatment of metastatic renal cell carcinoma.*

Sponsor: Chiron Corporation
Address: 4560 Horton Street
Emeryville CA 94608-2916

Date Designated: 9/14/1988
Market Approval Date: 5/5/1992

Generic Name: **Aldesleukin** Trade Name: Proleukin

Designated Indication: *Treatment of acute myelogenous leukemia.*

Sponsor: Chiron Corporation
Address: 4560 Horton St.
Emeryville CA 94608-2916

Date Designated: 7/31/1998
Market Approval Date: Not currently Approved

Generic Name: **alemtuzumab** Trade Name: Campath

Designated Indication: *Treatment of chronic lymphocytic leukemia.*

Sponsor: Millennium and ILEX Partners, LP
Address: 75 Sidney Street
Cambridge MA 02138

Date Designated: 10/20/1997
Market Approval Date: 5/7/2001

Generic Name: **Alendronate disodium** Trade Name: Fosamax

Designated Indication: *Treatment of the bone manifestations of Gaucher disease*

Sponsor: Richard J. Wenstrup, M.D.
Address: Division of Human Genetics
Children's Hospital Research Foundation
Cincinnati OH 45229-3039

Date Designated: 2/13/2001
Market Approval Date: Not currently Approved

Generic Name: **Alglucerase injection** Trade Name: Ceredase

Designated Indication: *For replacement therapy in patients with Gaucher's disease type I.*

Sponsor: Genzyme Corporation
Address: One Kendall Square
Cambridge MA 02139-1562

Date Designated: 3/11/1985
Market Approval Date: 4/5/1991

Generic Name: **Alglucerase injection** Trade Name: Ceredase

Designated Indication: *Replacement therapy in patients with Type II and III Gaucher's disease.*

Sponsor: Genzyme Corporation
Address: One Kendall Square
Cambridge MA 02139-1562

Date Designated: 7/21/1995
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Alitretinoin** — Trade Name: Panretin

Designated Indication: *Topical treatment of cutaneous lesions in patients with AIDS-related Kaposi's sarcoma.*

Sponsor: Ligand Pharmaceuticals Inc.
Address: 10275 Science Center Drive
San Diego CA 92121-1117

Date Designated: 3/24/1998
Market Approval Date: 2/2/1999

Generic Name: **Allogeneic human retinal pigment epithelial cells on gelatin microcarriers** — Trade Name: Spheramine

Designated Indication: *Treatment of Hoehn and Yahr stage 3 and 4 Parkinson's disease.*

Sponsor: Titan Pharmaceuticals, Inc.
Address: Post Office Plaza
50 Division Street, Suite 503
Somerville NJ 08876

Date Designated: 7/18/1997
Market Approval Date: Not currently Approved

Generic Name: **Allogeneic peripheral blood mononuclear cells sensitized against patient alloantigens by mixed lymphocyte culture** — Trade Name: CYTOIMPLANT

Designated Indication: *Treatment of pancreatic cancer.*

Sponsor: Applied Immunotherapeutics, LLC
Address: 14132 E. Firestone Boulevard
Santa Fe Springs CA 90670

Date Designated: 6/13/1997
Market Approval Date: Not currently Approved

Generic Name: **Allopurinol sodium** — Trade Name: Zyloprim for Injection

Designated Indication: *Management of patients with leukemia, lymphoma, and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels and who cannot tolerate oral therapy.*

Sponsor: Catalytica Pharmaceuticals, Inc
Address: PO Box 1887
Greenville NC 27835-1887

Date Designated: 10/16/1992
Market Approval Date: 5/17/1996

Generic Name: **Alpha-galactosidase A** — Trade Name: CC-galactosidase

Designated Indication: *Treatment of alpha-galactosidase A deficiency (Fabry's disease).*

Sponsor: Orphan Medical, Inc.
Address: 13911 Ridgedale Drive
Suite 475
Minnetonka MN 55305

Date Designated: 6/17/1991
Market Approval Date: Not currently Approved

Generic Name: **Alpha-galactosidase A** — Trade Name: Fabrase

Designated Indication: *Treatment of Fabry's disease.*

Sponsor: Desnick, Robert J. M.D.
Address: The Mount Sinai School Of Medicine
Fifth Avenue at 100th Street, Box 1203
New York NY 10029

Date Designated: 7/20/1990
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Alpha-galactosidase A** Trade Name: Replagal

Designated Indication: *Long-term enzyme replacement therapy for the treatment of Fabry disease.*

Sponsor: Transkaryotic Therapies Inc.
Address: 195 Albany St.
Cambridge MA 02139

Date Designated: 6/22/1998
Market Approval Date: Not currently Approved

Generic Name: **Alpha-melanocyte stimulating hormone** Trade Name: NONE ASSIGNED

Designated Indication: *Prevention and treatment of intrinsic acute renal failure due to ischemia.*

Sponsor: National Institute of Diabetes, and Digestive
Address: National Institutes of Health, 31 Center Drive
Building 31, Room 9N-222
Bethesda MD 20892-2560

Date Designated: 8/19/1997
Market Approval Date: Not currently Approved

Generic Name: **Alpha1-proteinase inhibitor (human)** Trade Name: Prolastin

Designated Indication: *For replacement therapy in the alpha-1-proteinase inhibitor congenital deficiency state.*

Sponsor: Bayer Corporation
Address: Pharmaceutical Division, Biological Products
400 Morgan Lane
New Haven CT 06516

Date Designated: 12/7/1984
Market Approval Date: 12/2/1987

Generic Name: **Alpha1-proteinase inhibitor (human)** Trade Name: NONE ASSIGNED

Designated Indication: *For slowing the progression of emphysema in alpha1-antitrypsin deficient patients.*

Sponsor: Aventis Behring L.L.C.
Address: 1020 First Ave.
PO Box 61501
King of Prussia PA 19406-0901

Date Designated: 11/24/1999
Market Approval Date: Not currently Approved

Generic Name: **Alronidase** Trade Name: Aldurazyme

Designated Indication: *Treatment of patients with mucopolysaccharidosis-I.*

Sponsor: BioMarin Pharmaceutical, Inc.
Address: 371 Bel Marin Keys Boulevard, Suite 210
Novato CA 94949-5608

Date Designated: 9/24/1997
Market Approval Date: Not currently Approved

Generic Name: **Altretamine** Trade Name: Hexalen

Designated Indication: *Treatment of advanced adenocarcinoma of the ovary.*

Sponsor: Medimmune Oncology, Inc.
Address: One Tower Bridge
100 Front Street, Suite 400
West Conshohocken PA 19428

Date Designated: 2/9/1984
Market Approval Date: 12/26/1990

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Amifostine** Trade Name: Ethyol

Designated Indication: *For use as a chemoprotective agent for cyclophosphamide in the treatment of advanced ovarian carcinoma.*

Sponsor: Medimmune Oncology, Inc.
Address: 35 West Watkins Mill Rd.
Gaithersburg MD 20878

Date Designated: 5/30/1990
Market Approval Date: Not currently Approved

Generic Name: **Amifostine** Trade Name: Ethyol

Designated Indication: *For the reduction of the incidence and severity of toxicities associated with cisplatin administration.*

Sponsor: Medimmune Oncology, Inc.
Address: 35 West Watkins Mill Rd.
Gaithersburg MD 20878

Date Designated: 11/24/1998
Market Approval Date: Not currently Approved

Generic Name: **Amifostine** Trade Name: Ethyol

Designated Indication: *Treatment of myelodysplastic syndromes.*

Sponsor: Medimmune Oncology, Inc.
Address: 35 West Watkins Mill Rd.
Gaithersburg MD 20878

Date Designated: 10/4/1999
Market Approval Date: Not currently Approved

Generic Name: **Amifostine** Trade Name: Ethyol

Designated Indication: *For use as a chemoprotective agent for cisplatin in the treatment of metastatic melanoma.*

Sponsor: Medimmune Oncology, Inc.
Address: 35 West Watkins Mills Rd.
Gaithersburg MD 20878

Date Designated: 5/30/1990
Market Approval Date: Not currently Approved

Generic Name: **Amifostine** Trade Name: Ethyol

Designated Indication: *For use as a chemoprotective agent for cisplatin in the treatment of advanced ovarian carcinoma.*

Sponsor: Medimmune Oncology, Inc.
Address: One Tower Bridge
100 Front Street, Suite 400
West Conshohocken PA 19428

Date Designated: 5/30/1990
Market Approval Date: 12/8/1995

Generic Name: **Amifostine** Trade Name: Ethyol

Designated Indication: *Reduction of the incidence of moderate to severe xerostomia in patients undergoing post-operative radiation treatment for head and neck cancer.*

Sponsor: Medimmune Oncology, Inc.
Address: One Tower Bridge
100 Front Street, Suite 400
Conshohocken PA 19428

Date Designated: 5/12/1998
Market Approval Date: 6/24/1999

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Aminocaproic acid**
Trade Name: Caprogel

Designated Indication: *For the topical treatment of traumatic hyphema of the eye.*

Sponsor: Eastern Virginia Medical School
Address: Department of Ophthalomology
880 Kempsville Road, Suite 2500
Norfolk VA 23502-3990

Date Designated: 1/6/1995
Market Approval Date: Not currently Approved

Generic Name: **Aminosalicylic acid**
Trade Name: Paser Granules

Designated Indication: *Treatment of tuberculosis infections.*

Sponsor: Jacobus Pharmaceutical Company
Address: 37 Cleveland Lane
P.O. Box 5290
Princeton NJ 08540

Date Designated: 2/19/1992
Market Approval Date: 6/30/1994

Generic Name: **Aminosidine**
Trade Name: Paromomycin

Designated Indication: *Treatment of visceral leishmaniasis (kala-azar).*

Sponsor: Kanyok, Thomas P. Pharm.D.
Address: University of Illinois at Chicago College of
833 South Wood Street (m/c886) Rm. 176
Chicago IL 60612

Date Designated: 9/9/1994
Market Approval Date: Not currently Approved

Generic Name: **Aminosidine**
Trade Name: Gabbromicina

Designated Indication: *Treatment of Mycobacterium avium complex.*

Sponsor: Kanyok, Thomas P. Pharm.D.
Address: University of Illinois at Chicago College of
833 South Wood Street (m/c886) Rm. 176
Chicago IL 60612

Date Designated: 11/15/1993
Market Approval Date: Not currently Approved

Generic Name: **Aminosidine**
Trade Name: Gabbromicina

Designated Indication: *Treatment of tuberculosis.*

Sponsor: Kanyok, Thomas P. Pharm.D.
Address: University Of Illinois At Chicago College of
833 South Wood Street (m/c886) Rm. 176
Chicago IL 60612

Date Designated: 5/14/1993
Market Approval Date: Not currently Approved

Generic Name: **Amiodarone**
Trade Name: Amio-Aqueous

Designated Indication: *Treatment of incessant ventricular tachycardia.*

Sponsor: Wyeth-Ayerst Research
Address: PO Box 8299
Philadelphia PA 19101-8299

Date Designated: 8/17/1993
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Amiodarone HCl** Trade Name: Cordarone

Designated Indication: *For the acute treatment and prophylaxis of life-threatening ventricular tachycardia or ventricular fibrillation.*

Sponsor: Wyeth-Ayerst Laboratories
Address: P.O. Box 8299
Philadelphia PA 19101

Date Designated: 3/16/1994
Market Approval Date: 8/3/1995

Generic Name: **Ammonium tetrathiomolybdate** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of Wilson's disease.*

Sponsor: Brewer, George J. M.D.
Address: University Of Michigan Medical School
4708 Medical Science Building II 0618
Ann Arbor MI 48109

Date Designated: 1/31/1994
Market Approval Date: Not currently Approved

Generic Name: **Amphotericin B lipid complex** Trade Name: Abelcet

Designated Indication: *Treatment of invasive fungal infections.*

Sponsor: Liposome Company, Inc.
Address: One Research Way
Princeton NJ 08540

Date Designated: 12/3/1996
Market Approval Date: 10/18/1996

Generic Name: **Anagrelide** Trade Name: Agrylin

Designated Indication: *Treatment of polycythemia vera.*

Sponsor: Roberts Pharmaceutical Corp.
Address: Meridian Center II
4 Industrial Way West
Eatontown NJ 07724-2274

Date Designated: 6/11/1985
Market Approval Date: Not currently Approved

Generic Name: **Anagrelide** Trade Name: Agrylin

Designated Indication: *Treatment of essential thrombocythemia.*

Sponsor: Roberts Pharmaceutical Corp.
Address: Meridian Center III
6 Industrial Way West
Eatontown NJ 07724

Date Designated: 1/27/1988
Market Approval Date: 3/14/1997

Generic Name: **Anagrelide** Trade Name: Agrylin

Designated Indication: *Treatment of thrombocytosis in chronic myelogenous leukemia.*

Sponsor: Roberts Pharmaceutical Corp.
Address: Meridian Center II
4 Industrial Way West
Eatontown NJ 07724-2274

Date Designated: 7/14/1986
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Ananain, comosain** Trade Name: Vianain

Designated Indication: *For the enzymatic debridement of severe burns.*

Sponsor: Genzyme Corporation
Address: One Kendall Square
Cambridge MA 02139

Date Designated: 1/21/1992
Market Approval Date: Not currently Approved

Generic Name: **Ancestim** Trade Name: Stemgen

Designated Indication: *For use in combination with filgrastim to decrease the number of phereses required to collect peripheral blood progenitor cells capable of providing rapid multi-lineage hematopoietic reconstitution following myelosuppressive or myeloablative therapy.*

Sponsor: Amgen, Inc.
Address: One Amgen Center Drive
Thousand Oaks CA 91320-1799

Date Designated: 7/5/1995
Market Approval Date: Not currently Approved

Generic Name: **Ancrod** Trade Name: Viprinex

Designated Indication: *To establish and maintain anticoagulation in heparin-intolerant patients undergoing cardiopulmonary bypass.*

Sponsor: Knoll Pharmaceutical Company
Address: 3000 Continental Dr., North
Mt. Olive NJ 07828

Date Designated: 10/20/1989
Market Approval Date: Not currently Approved

Generic Name: **Angiotensin 1-7** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of neutropenia associated with autologous bone marrow transplantation.*

Sponsor: Maret Pharmaceuticals
Address: 4041 MacArthur Blvd.
Suite 375
Newport Beach CA 92660

Date Designated: 2/16/2000
Market Approval Date: Not currently Approved

Generic Name: **Angiotensin 1-7** Trade Name: MARstem

Designated Indication: *Treatment of myelodysplastic syndrome*

Sponsor: Maret Pharmaceutical Corporation
Address: 4041 MacArthur Boulevard, Suite 375
Newport Beach CA 92660

Date Designated: 8/3/2001
Market Approval Date: Not currently Approved

Generic Name: **Anti-thymocyte Globulin (Rabbitt)** Trade Name: Thymoglobulin

Designated Indication: *Treatment of myelodysplastic syndrome (MDS)*

Sponsor: SangStat Medical Corporation
Address: 6300 Dumbarton Circle
Freemont CA 94555

Date Designated: 9/6/2000
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Serum Name: **Anti-thymocyte serum**
Trade Name: Nashville Rabbit Anti-thymocyte

Designated Indication: *Treatment of allograft rejection, including solid organ (kidney, liver, heart, lung, and pancreas) and bone marrow transplantation.*

Sponsor: Applied Medical Research
Address: 1600 Hayes Street
Nashville TN 37203

Date Designated: 6/2/1993
Market Approval Date: Not currently Approved

Generic Name: **Antiepilepsirine**
Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of drug resistant generalized tonic-clonic epilepsy in children and adults.*

Sponsor: Children's Hospital
Address: 700 Children's Drive
Columbus OH 43205

Date Designated: 3/23/1989
Market Approval Date: Not currently Approved

Generic Name: **Antihemophilic factor (human)**
Trade Name: Alphanate

Designated Indication: *Treatment of von Willebrand's disease.*

Sponsor: Alpha Therapeutic Corporation
Address: 5555 Valley Boulevard
Los Angeles CA 90032-3520

Date Designated: 1/5/1996
Market Approval Date: Not currently Approved

Generic Name: **Antihemophilic factor (recombinant)**
Trade Name: Kogenate

Designated Indication: *Prophylaxis and treatment of bleeding in individuals with hemophilia A or for prophylaxis when surgery is required in individuals with hemophilia A.*

Sponsor: Bayer Corporation
Address: 1884 Miles Avenue
Elkhart IN 46515

Date Designated: 9/25/1989
Market Approval Date: 2/25/1993

Generic Name: **Antihemophilic factor (recombinant)**
Trade Name: ReFacto

Designated Indication: *For the control and prevention of hemorrhagic episodes and for surgical prophylaxis in patients with hemophilia A (congenital factor VIII deficiency or classic hemophilia).*

Sponsor: Genetics Institute, Inc.
Address: 87 CambridgePark Drive
Cambridge MA 02140

Date Designated: 2/8/1996
Market Approval Date: Not currently Approved

Generic Name: **Antihemophilic factor/von Willebrand factor complex (human), dried, pasteurized**
Trade Name: Humate-P

Designated Indication: *Treatment and prevention of bleeding in hemophilia A (classical hemophilia) in adult patients; and treatment of spontaneous and trauma-induced bleeding episodes in severe von Willebrand disease, and in mild and moderate von Willebrand disease where use of desmopressin is known or suspected to be inadequate in adult and pediatric*

Sponsor: Aventis Behring L.L.C.
Address: 1020 First Avenue
PO Box 61501
King Of Prussia PA 19406-0901

Date Designated: 10/16/1992
Market Approval Date: 4/1/1999

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Antithrombin III (human)** Trade Name: ATnativ

Designated Indication: *For the treatment of patients with hereditary antithrombin III deficiency in connection with surgical or obstetrical procedures or when they suffer from thromboembolism.*

Sponsor: Pharmacia & Upjohn AB
Address: Lindhagensgatan 133
SE-112 87 Stockholm
Sweden SE

Date Designated: 2/8/1985
Market Approval Date: 12/13/1989

Generic Name: **Antithrombin III (human)** Trade Name: Thrombate III

Designated Indication: *For replacement therapy in congenital deficiency of AT-III for prevention and treatment of thrombosis and pulmonary emboli.*

Sponsor: Bayer Corporation
Address: Pharmaceutical Division, Biological Products
400 Morgan Lane
New Haven CT 06516

Date Designated: 11/26/1984
Market Approval Date: 12/30/1991

Generic Name: **Antithrombin III (human) concentrate IV** Trade Name: Kybernin P

Designated Indication: *For prophylaxis and treatment of thromboembolic episodes in patients with genetic AT-III deficiency.*

Sponsor: Aventis Behring L.L.C.
Address: 1020 First Ave.
PO Box 61501
King of Prussia PA 19406-0901

Date Designated: 7/2/1985
Market Approval Date: Not currently Approved

Generic Name: **Antithrombin III human** Trade Name: Antithrombin III human

Designated Indication: *Preventing or arresting episodes of thrombosis in patients with congenital AT-III deficiency and/or to prevent the occurrence of thrombosis in patients with AT-III deficiency who have undergone trauma or who are about to undergo surgery or parturition.*

Sponsor: American National Red Cross
Address: 9312 Old Georgetown Road
Bethesda MD 20814

Date Designated: 1/2/1986
Market Approval Date: Not currently Approved

Generic Name: **Antivenin, crotalidae polyvalent immune Fab (ovine)** Trade Name: CroFab

Designated Indication: *Treatment of envenomations inflicted by North American crotalid snakes.*

Sponsor: Protherics, Inc.
Address: 1207 17th Ave. S., Suite 103
Nashville TN 37212

Date Designated: 1/12/1994
Market Approval Date: 10/2/2000

Generic Name: **Antivenom (crotalidae) purified (avian)** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of envenomation by poisonous snakes belonging to the Crotalidae family.*

Sponsor: Ophidian Pharmaceuticals, Inc.
Address: 5445 East Cheryl Parkway
Madison WI 53711

Date Designated: 2/12/1991
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **AP1903** — Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of acute graft-versus-host disease in patients undergoing bone marrow transplantation.*

Sponsor: Ariad Gene Therapeutics, Inc.
Address: 26 Landsdowne St.
Cambridge MA 02139-4234

Date Designated: 11/24/1999
Market Approval Date: Not currently Approved

Generic Name: **APL 400-020 V-Beta DNA vaccine** — Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of cutaneous T cell lymphoma.*

Sponsor: Wyeth-Lederle Vaccines and Pediatrics
Address: 211 Bailey Rd.
West Henrietta NY 14586-9728

Date Designated: 3/8/1995
Market Approval Date: Not currently Approved

Generic Name: **Apomorphine** — Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of the on-off fluctuations associated with late-stage Parkinson's disease.*

Sponsor: Pentech Pharmaceuticals, Inc.
Address: 1110 Lake Cook Rd.
Suite 257
Buffalo Grove IL 60089

Date Designated: 7/17/1995
Market Approval Date: Not currently Approved

Generic Name: **Apomorphine HCl** — Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of the on-off fluctuations associated with late-stage Parkinson's disease.*

Sponsor: Mylan Pharmaceuticals, Inc.
Address: 781 Chestnut Ridge Rd.
PO Box 4310
Morgantown WV 26505-4310

Date Designated: 4/22/1993
Market Approval Date: Not currently Approved

Generic Name: **Aprotinin** — Trade Name: Trasylol

Designated Indication: *For prophylactic use to reduce perioperative blood loss and the homologous blood transfusion requirement in patients undergoing cardiopulmonary bypass surgery in the course of repeat coronary artery bypass graft surgery, and in selected cases of primary coronary artery bypass graft surgery where the risk of bleeding is especially high (impaired hemostasis) or where transfusion is unavailable or unacceptable.*

Sponsor: Bayer Corporation
Address: Pharmaceutical Division
400 Morgan Lane
West Haven CT 06516

Date Designated: 11/17/1993
Market Approval Date: 12/29/1993

Generic Name: **Arcitumomab** — Trade Name: 99m Tc-labeled CEA-Scan

Designated Indication: *Diagnosis and localization of primary, residual, recurrent and metastatic medullary thyroid carcinoma.*

Sponsor: Immunomedics, Inc.
Address: 300 American Road
Morris Plains NJ 07950

Date Designated: 5/10/1996
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Arginine butyrate** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of beta-hemoglobinopathies and beta-thalassemia.*

Sponsor: Perrine, Susan P., M.D.
Address: Boston University
Cancer Research Center
Boston MA 02118

Date Designated: 4/7/1992
Market Approval Date: Not currently Approved

Generic Name: **arsenic** Trade Name: Trisenox

Designated Indication: *Treatment of acute myelocytic leukemia subtypes M0, M1, M2, M4, M5, M6 and M7*

Sponsor: Cell Therapeutics, Inc.
Address: 201 Elliott Avenue West
Suite 400
Seattle WA 98119

Date Designated: 11/2/2001
Market Approval Date: Not currently Approved

Generic Name: **arsenic trioxide** Trade Name: Trisenox

Designated Indication: *Treatment of chronic myeloid leukemia*

Sponsor: Cell Therapeutics, Inc.
Address: 201 Elliott Avenue West
Suite 400
Seattle WA 98119

Date Designated: 10/18/2001
Market Approval Date: Not currently Approved

Generic Name: **Arsenic trioxide** Trade Name: Trisenox

Designated Indication: *Treatment of acute promyelocytic leukemia.*

Sponsor: Cell Therapeutics, Inc.
Address: 201 Elliott Ave. West
Suite 400
Seattle WA 98119

Date Designated: 3/3/1998
Market Approval Date: 9/25/2000

Generic Name: **arsenic trioxide** Trade Name: Trisenox

Designated Indication: *Treatment of myelodysplastic syndrome.*

Sponsor: Cell Therapeutics, Inc.
Address: 201 Elliott Avenue West
Suite 400
Seattle WA 98119

Date Designated: 7/17/2000
Market Approval Date: 9/25/2000

Generic Name: **Arsenic trioxide** Trade Name: Trisenox

Designated Indication: *Treatment of multiple myeloma.*

Sponsor: Cell Therapeutics, Inc.
Address: 201 Elliott Ave. West, Suite 400
Seattle WA 98119

Date Designated: 4/28/2000
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Artesunate** — Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of malaria.*

Sponsor: World Health Organisation
Address: Special Programme for Research and Training
Via Appia , Geneva 27
Switzerland CH

Date Designated: 7/19/1999
Market Approval Date: Not currently Approved

Generic Name: **Atovaquone** — Trade Name: Mepron

Designated Indication: *Primary prophylaxis of HIV-infected persons at high risk for developing Toxoplasma gondii encephalitis.*

Sponsor: Glaxo Wellcome Inc.
Address: 5 Moore Drive
PO Box 13398
Research Triangle Park NC 27709

Date Designated: 3/16/1993
Market Approval Date: Not currently Approved

Generic Name: **Atovaquone** — Trade Name: Mepron

Designated Indication: *Treatment and suppression of Toxoplasma gondii encephalitis.*

Sponsor: Glaxo Wellcome Inc.
Address: 5 Moore Drive
PO Box 13398
Research Triangle Park NC 27709-3398

Date Designated: 3/16/1993
Market Approval Date: Not currently Approved

Generic Name: **Atovaquone** — Trade Name: Mepron

Designated Indication: *Prevention of Pneumocystis carinii pneumonia (PCP) in high-risk, HIV-infected patients defined by a history of one or more episodes of PCP and/or a peripheral CD4+ (T4 helper/inducer) lymphocyte count less than or equal to*

Sponsor: Glaxo Wellcome Research and Development
Address: 5 Moore Drive
PO Box 13398
Research Triangle Park NC 27709

Date Designated: 8/14/1991
Market Approval Date: 1/5/1999

Generic Name: **Atovaquone** — Trade Name: Mepron

Designated Indication: *Treatment of AIDS associated Pneumocystis Carinii Pneumonia.*

Sponsor: Glaxo Wellcome Inc.
Address: 5 Moore Drive
Research Triangle Park NC 27709

Date Designated: 9/10/1990
Market Approval Date: 11/25/1992

Generic Name: **augmerosen** — Trade Name: Genasense

Designated Indication: *Treatment of multiple myeloma*

Sponsor: Genta Incorporated
Address: Two Oak Way
Berkeley Heights NJ 07922

Date Designated: 8/28/2001
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **augmerosen** Trade Name: Genasense

Designated Indication: *Treatment of acute myelocytic leukemia*

Sponsor: Genta Incorporated
Address: Two Oak Way
Berkeley Heights NJ 07922

Date Designated: 8/28/2001
Market Approval Date: Not currently Approved

Generic Name: **augmerosen** Trade Name: Genasense

Designated Indication: *Treatment of chronic lymphocytic leukemia*

Sponsor: Genta Incorporated
Address: Two Oak Way
Berkeley Heights NJ 07922

Date Designated: 8/28/2001
Market Approval Date: Not currently Approved

Generic Name: **Autologous DNP-conjugated tumor vaccine** Trade Name: M-Vax

Designated Indication: *For adjuvant therapy in melanoma patients with surgically resectable lymph node metastasis (Stage III and limited Stage IV disease).*

Sponsor: Avax Technologies, Inc.
Address: 9200 Indian Creek Parkway
Building 9, Suite 200
Overland Park KS 66210

Date Designated: 2/23/1999
Market Approval Date: Not currently Approved

Generic Name: **Autolymphocyte therapy** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of renal cell carcinoma.*

Sponsor: Cytogen Corporation
Address: 600 College Road East
CN 5308
Princeton NJ 08540-5308

Date Designated: 7/12/1994
Market Approval Date: Not currently Approved

Generic Name: **azacitidine** Trade Name: NONE ASSIGNED

Designated Indication: *Treatament of myelodysplastic syndromes*

Sponsor: Pharmion Corporation
Address: 4865 Riverbend Road
Boulder CO 80301

Date Designated: 12/3/2001
Market Approval Date: Not currently Approved

Generic Name: **Azathioprine** Trade Name: Imuran

Designated Indication: *Treatment of oral manifestations of graft-versus-host disease.*

Sponsor: Oral Solutions, Inc.
Address: 787 Seventh Ave., 48th Floor
New York NY 10019

Date Designated: 9/14/1999
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **B Lymphocyte Stimulator** Trade Name: BLyS

Designated Indication: *Treatment of common variable immunodeficiency (CVID)*

Sponsor: Human Genome Sciences, Inc.
Address: 9410 Key West Avenue
Rockville MD 20850

Date Designated: 2/21/2001
Market Approval Date: Not currently Approved

Generic Name: **Bacitracin** Trade Name: Altracin

Designated Indication: *Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.*

Sponsor: A. L. Laboratories, Inc.
Address: One Executive Drive
P.O. Box 1399
Fort Lee NJ 07024

Date Designated: 3/13/1984
Market Approval Date: Not currently Approved

Generic Name: **Baclofen** Trade Name: Lioresal Intrathecal

Designated Indication: *Treatment of intractable spasticity caused by spinal cord injury, multiple sclerosis, and other spinal diseases (including spinal ischemia, spinal tumor, transverse myelitis, cervical spondylosis, and degenerative myelopathy).*

Sponsor: Medtronic, Inc.
Address: 800 53rd Avenue N.E.
Minneapolis MN 55432

Date Designated: 11/10/1987
Market Approval Date: 6/25/1992

Generic Name: **Baclofen** Trade Name: Lioresal Intrathecal

Designated Indication: *Treatment of spasticity associated with cerebral palsy.*

Sponsor: Medtronic, Inc.
Address: 800 53rd Avenue N.E.
P.O. 1250
Minneapolis MN 55440-9087

Date Designated: 9/26/1994
Market Approval Date: Not currently Approved

Generic Name: **Baclofen** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of intractable spasticity due to multiple sclerosis or spinal cord injury.*

Sponsor: Infusaid, Inc.
Address: 1400 Providence Highway
Norwood MA 02062

Date Designated: 12/16/1991
Market Approval Date: Not currently Approved

Generic Name: **Basiliximab** Trade Name: Simulect

Designated Indication: *Prophylaxis of solid organ rejection.*

Sponsor: Novartis Pharmaceuticals Corporation
Address: 59 Route 10
East Hanover NJ 07936-1080

Date Designated: 12/12/1997
Market Approval Date: 5/12/1998

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **beclomethasone 17,21-dipropionate** Trade Name: NONE ASSIGNED

Designated Indication: *Prevention of gastrointestinal graft-versus-host disease*

Sponsor: Enteron Pharmaceuticals, Inc.
Address: 1680 Michigan Ave.
Suite 700
Miami FL 33139

Date Designated: 8/28/2001
Market Approval Date: Not currently Approved

Generic Name: **Beclomethasone dipropionate** Trade Name: NONE ASSIGNED

Designated Indication: *For oral administration in the treatment of intestinal graft-versus-host disease.*

Sponsor: George B. McDonald, M.D.
Address: Fred Hutchinson Cancer Research Center
1100 Fairview Avenue North (SC-113); PO
Seattle WA 98109

Date Designated: 3/27/1998
Market Approval Date: Not currently Approved

Generic Name: **Benzoate and phenylacetate** Trade Name: Ucephan

Designated Indication: *For adjunctive therapy in the prevention and treatment of hyperammonemia in patients with urea cycle enzymopathy due to carbamylphosphate synthetase, ornithine, transcarbamylase, or argininosuccinate synthetase*

Sponsor: B. Braun Medical Inc.
Address: 2525 McGaw Avenue
P.O. Box 19791
Irvine CA 92623

Date Designated: 1/21/1986
Market Approval Date: 12/23/1987

Generic Name: **benzoate/phenylacetate** Trade Name: Ammonul

Designated Indication: *For the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle.*

Sponsor: Medicis Pharmaceutical Corp.
Address: 8125 N. Hayden Road
Scottsdale AZ 85258

Date Designated: 11/22/1993
Market Approval Date: Not currently Approved

Generic Name: **Benzophenone-3, octylmethoxycinnamate, avobenzone, titanium dioxide, zinc oxide** Trade Name: Total Block VL SPF 75

Designated Indication: *For the prevention of visible light induced skin photosensitivity as a result of porfimer sodium photodynamic therapy*

Sponsor: Fallien Cosmeceuticals Ltd.
Address: 677 W. Dekalb Pike
King of Prussia PA 19406

Date Designated: 8/13/2001
Market Approval Date: Not currently Approved

Generic Name: **Benzydamine hydrochloride** Trade Name: Tantum

Designated Indication: *Prophylactic treatment of oral mucositis resulting from radiation therapy for head and neck cancer.*

Sponsor: Angelini Pharmaceuticals, Inc.
Address: 70 Grand Avenue
River Edge NJ 07661

Date Designated: 5/18/1998
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Benzylpenicillin, benzylpenicilloic, benzylpenilloic acid**
Trade Name: Pre-Pen/MDM

Designated Indication: *Assessing the risk of administrating penicillin when it is the preferred drug of choice in adult patients who have previously received penicillin and have a history of clinical sensitivity.*

Sponsor: Hollister-Stier Laboratories LLC
Address: PO Box 3145
Spokane WA 99220-3145

Date Designated: 9/29/1987
Market Approval Date: Not currently Approved

Generic Name: **Beractant**
Trade Name: Survanta intratracheal suspension

Designated Indication: *Treatment of neonatal respiratory distress syndrome.*

Sponsor: Ross Laboratories
Address: 625 Cleveland Avenue
Columbus OH 43215

Date Designated: 2/5/1986
Market Approval Date: 7/1/1991

Generic Name: **Beractant**
Trade Name: Survanta Intratracheal Suspension

Designated Indication: *Treatment of full-term newborn infants with respiratory failure caused by meconium aspiration syndrome, persistent pulmonary hypertension of the newborn, or pneumonia and sepsis.*

Sponsor: Ross Laboratories
Address: 625 Cleveland Avenue
Columbus OH 43215

Date Designated: 12/20/1993
Market Approval Date: Not currently Approved

Generic Name: **Beractant**
Trade Name: Survanta intratracheal suspension

Designated Indication: *Prevention of neonatal respiratory distress syndrome.*

Sponsor: Ross Laboratories
Address: 625 Cleveland Avenue
Columbus OH 43215

Date Designated: 2/5/1986
Market Approval Date: 7/1/1991

Generic Name: **Beraprost**
Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of pulmonary arterial hypertension associated with any New York Heart Association classification (Class I, II, III, or IV).*

Sponsor: United Therapeutics Corporation
Address: 68 T.W. Alexander Drive, PO Box 14186
Research Triangle Park NC 27709

Date Designated: 4/29/1999
Market Approval Date: Not currently Approved

Generic Name: **Beta alethine**
Trade Name: Betathine

Designated Indication: *Treatment of multiple myeloma.*

Sponsor: Dovetail Technologies, Inc.
Address: Bldg. 337, Paint Branch Drive
College Park MD 20742

Date Designated: 3/24/1997
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Beta alethine**
Trade Name: Betathine

Designated Indication: *Treatment of metastatic melanoma.*

Sponsor: Dovetail Technologies, Inc.
Address: Bldg. 337, Paint Branch Drive
College Park MD 20742

Date Designated: 3/24/1997
Market Approval Date: Not currently Approved

Generic Name: **Betaine**
Trade Name: Cystadane

Designated Indication: *Treatment of homocystinuria.*

Sponsor: Orphan Medical, Inc.
Address: 13911 Ridgedale Drive
Suite 475
Minnetonka MN 55305

Date Designated: 5/16/1994
Market Approval Date: 10/25/1996

Generic Name: **Bexarotene**
Trade Name: Targretin

Designated Indication: *Treatment of cutaneous manifestations of cutaneous T-cell lymphoma in patients who are refractory to at least one prior systemic therapy.*

Sponsor: Ligand Pharmaceuticals, Inc.
Address: 10275 Science Center Dr.
San Diego CA 92121

Date Designated: 6/18/1999
Market Approval Date: 12/29/1999

Generic Name: **Bindarit**
Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of lupus nephritis.*

Sponsor: Angelini Pharmaceuticals, Inc.
Address: 70 Grand Avenue
River Edge NJ 07661

Date Designated: 2/3/1998
Market Approval Date: Not currently Approved

Generic Name: **Bis(4-fluorophenyl)phenylacetamide**
Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of sickle cell disease.*

Sponsor: ICAgen Inc.
Address: Ion Channel Advances
PO Box 14487
Durham NC 27709

Date Designated: 3/2/2000
Market Approval Date: Not currently Approved

Generic Name: **Bispecific antibody 520c9x22**
Trade Name: NONE ASSIGNED

Designated Indication: *For in vivo serotherapy of patients with ovarian cancer.*

Sponsor: Medarex, Inc.
Address: 67 Beaver Avenue
Annandale NJ 08801-0953

Date Designated: 10/5/1993
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Bleomycin** | Trade Name: Blenoxane

Designated Indication: *Treatment of pancreatic cancer.*

Sponsor: Genetronics, Inc.
Address: 11199 Sorrento Valley Rd.
San Diego CA 92121-1334

Date Designated: 2/9/1999
Market Approval Date: Not currently Approved

Generic Name: **Bleomycin sulfate** | Trade Name: Blenoxane

Designated Indication: *Treatment of malignant pleural effusion.*

Sponsor: Bristol-Myers Squibb Pharmaceutical
Address: P.O. Box 4000
Princeton NJ 08543

Date Designated: 9/17/1993
Market Approval Date: 2/20/1996

Generic Name: **Bosentan** | Trade Name: Tracleer

Designated Indication: *Treatment of pulmonary arterial hypertension.*

Sponsor: Actelion Life Sciences Ltd.
Address: 1840 Gateway Dr.
2nd Floor
San Mateo CA 94404

Date Designated: 10/6/2000
Market Approval Date: 11/20/2001

Generic Name: **Botulinum toxin type A** | Trade Name: Dysport

Designated Indication: *Treatment of dynamic muscle contractures in pediatric cerebral palsy patients.*

Sponsor: Ipsen Limited
Address: 1 Bath Rd., Maidenhead
Berkshire SL6 4UH
England GB

Date Designated: 10/20/1999
Market Approval Date: Not currently Approved

Generic Name: **Botulinum toxin type A** | Trade Name: Botox

Designated Indication: *Treatment of cervical dystonia.*

Sponsor: Allergan, Inc.
Address: 2525 Dupont Drive
P.O. Box 19534
Irvine CA 92623-9534

Date Designated: 8/20/1986
Market Approval Date: 12/21/2000

Generic Name: **Botulinum toxin type A** | Trade Name: Dysport

Designated Indication: *Treatment of spasmodic torticollis (cervical dystonia).*

Sponsor: Ipsen Limited
Address: 1 Bath Road
Maidenhead, Berkshire
U.K. SL6 4UH GB

Date Designated: 8/12/1998
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Botulinum toxin type A** Trade Name: Botox

Designated Indication: *Treatment of dynamic muscle contracture in pediatric cerebral palsy patients.*

Sponsor: Allergan, Inc.
Address: 2525 Dupont Drive
P.O. Box 19534
Irvine CA 92623-9534

Date Designated: 12/6/1991
Market Approval Date: Not currently Approved

Generic Name: **Botulinum toxin type A** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of synkinetic closure of the eyelid associated with VII cranial nerve aberrant regeneration.*

Sponsor: Botulinum Toxin Research Associates, Inc.
Address: 1261 Furnace Brook Parkway
Quincy MA 02169

Date Designated: 9/15/1992
Market Approval Date: Not currently Approved

Generic Name: **Botulinum toxin type A** Trade Name: Dysport

Designated Indication: *Treatment of essential blepharospasm.*

Sponsor: Porton International, Inc.
Address: 1155 15th Street, N.W., #315
Washington DC 20005

Date Designated: 3/23/1989
Market Approval Date: Not currently Approved

Generic Name: **Botulinum toxin type A** Trade Name: Botox

Designated Indication: *Treatment of strabismus associated with dystonia in adults (patients 12 years of age and above).*

Sponsor: Allergan, Inc.
Address: 2525 Dupont Drive
P.O. Box 19534
Irvine CA 92713

Date Designated: 3/22/1984
Market Approval Date: 12/29/1989

Generic Name: **Botulinum toxin type A** Trade Name: Botox

Designated Indication: *Treatment of blepharospasm associated with dystonia in adults (patients 12 years of age and above).*

Sponsor: Allergan, Inc.
Address: 2525 Dupont Drive
P.O. Box 19534
Irvine CA 92713

Date Designated: 3/22/1984
Market Approval Date: 12/29/1989

Generic Name: **Botulinum toxin type B** Trade Name: NeuroBloc

Designated Indication: *Treatment of cervical dystonia.*

Sponsor: Elan Pharmaceuticals, Inc.
Address: 800 Gateway Blvd.
South San Francisco CA 94080

Date Designated: 1/16/1992
Market Approval Date: 12/8/2000

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Botulinum toxin type F** Trade Name: Dysport

Designated Indication: *Treatment of spasmodic torticollis (cervical dystonia).*

Sponsor: Ipsen Limited (name changed from
Address: Milford MA

Date Designated: 10/24/1991
Market Approval Date: Not currently Approved

Generic Name: **Botulinum toxin type F** Trade Name: Dysport

Designated Indication: *Treatment of essential blepharospasm.*

Sponsor: Ipsen Limited (name changed from
Address: Milford MA

Date Designated: 12/5/1991
Market Approval Date: Not currently Approved

Generic Name: **Botulism immune globulin** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of infant botulism.*

Sponsor: California Department of Health Services
Address: 2151 Berkeley Way
Berkeley CA 94704-1011

Date Designated: 1/31/1989
Market Approval Date: Not currently Approved

Generic Name: **Bovine colostrum** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of AIDS-related diarrhea.*

Sponsor: Hastings, Donald DVM
Address: 1030 North Parkview Drive
Bismarck ND 58501

Date Designated: 11/19/1990
Market Approval Date: Not currently Approved

Generic Name: **Bovine immunoglobulin concentrate, Cryptosporidium parvum** Trade Name: Sporidin-G

Designated Indication: *Treatment and symptomatic relief of Cryptosporidium parvum infection of the gastrointestinal tract in immunocompromised patients.*

Sponsor: GalaGen, Inc.
Address: 4001 Lexington Avenue North
Arden Hills MN 55126

Date Designated: 3/1/1994
Market Approval Date: Not currently Approved

Generic Name: **Bovine whey protein concentrate** Trade Name: Immuno-C

Designated Indication: *Treatment of cryptosporidiosis caused by the presence of Cryptosporidium parvum in the gastrointestinal tract of patients who are immunodeficient/immunocompromised or immunocompetent.*

Sponsor: Biomune Systems, Inc.
Address: 540 Arapeen Drive, Suite 202
Salt Lake City UT 84108

Date Designated: 9/30/1993
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Branched chain amino acids** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of amyotrophic lateral sclerosis.*

Sponsor: Mount Sinai Medical Center
Address: One Gustave L. Levy Place
New York NY 10029

Date Designated: 12/23/1988
Market Approval Date: Not currently Approved

Generic Name: **Brimonidine** Trade Name: Alphagan

Designated Indication: *Treatment of anterior ischemic optic neuropathy.*

Sponsor: Allergan, Inc.
Address: 2525 Dupont Dr.
P.O. Box 19534
Irvine CA 92623-9534

Date Designated: 2/7/2000
Market Approval Date: Not currently Approved

Generic Name: **Bromhexine** Trade Name: Bisolvon

Designated Indication: *Treatment of mild to moderate keratoconjunctivitis sicca in patients with Sjogren's syndrome.*

Sponsor: Boehringer Ingelheim Pharmaceuticals, Inc.
Address: 900 Ridgebury Road, Box 368
Ridgefield CT 06877-0368

Date Designated: 5/15/1989
Market Approval Date: Not currently Approved

Generic Name: **Broxuridine** Trade Name: Broxine/Neomark

Designated Indication: *Radiation sensitizer in the treatment of primary brain tumors.*

Sponsor: NeoPharm, Inc.
Address: 225 East Deerpath, Suite 250
Lake Forest IL 60045

Date Designated: 9/18/1995
Market Approval Date: Not currently Approved

Generic Name: **bryostatin-1** Trade Name: NONE ASSIGNED

Designated Indication: *For use in combination with paclitaxel in the treatment of esophageal cancer*

Sponsor: GPC Biotech, Inc.
Address: 610 Lincoln Street
Waltham MA 02451

Date Designated: 12/3/2001
Market Approval Date: Not currently Approved

Generic Name: **Buffered intrathecal electrolyte/dextrose injection** Trade Name: Elliotts B Solution

Designated Indication: *For use as a diluent in the intrathecal administration of methotrexate and cytarabine for the prevention or treatment meningeal leukemia and lymphocytic lymphoma.*

Sponsor: Orphan Medical, Inc.
Address: 13911 Ridgedale Drive
Suite 475
Minnetonka MN 55305

Date Designated: 8/24/1994
Market Approval Date: 9/27/1996

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Buprenorphine hydrochloride** Trade Name: Subutex

Designated Indication: *Treatment of opiate addiction in opiate users.*

Sponsor: Reckitt & Colman Pharmaceuticals, Inc.
Address: 1901 Huguenot Road
Richmond VA 23235

Date Designated: 6/15/1994
Market Approval Date: Not currently Approved

Generic Name: **Buprenorphine in combination with naloxone** Trade Name: Suboxone

Designated Indication: *Treatment of opiate addiction in opiate users.*

Sponsor: Reckitt & Colman Pharmaceuticals, Inc.
Address: 1901 Huguenot Road
Richmond VA 23235

Date Designated: 10/27/1994
Market Approval Date: Not currently Approved

Generic Name: **Busulfan** Trade Name: Spartaject

Designated Indication: *For use as preparative therapy for malignancies treated with bone marrow transplantation.*

Sponsor: Sparta Pharmaceuticals, Inc.
Address: 111 Rock Road
Horsham PA 19044-2310

Date Designated: 4/21/1994
Market Approval Date: Not currently Approved

Generic Name: **Busulfan** Trade Name: Spartaject

Designated Indication: *Treatment of primary brain malignancies.*

Sponsor: SuperGen, Inc.
Address: Two Annabel Lane, Suite 220
San Ramon CA 94583

Date Designated: 7/7/1997
Market Approval Date: Not currently Approved

Generic Name: **Busulfan** Trade Name: Busulfex

Designated Indication: *As preparative therapy in the treatment of malignancies with bone marrow transplantation.*

Sponsor: Orphan Medical, Inc.
Address: 13911 Ridgedale Drive
Suite 250
Minnetonka MN 55305

Date Designated: 7/28/1994
Market Approval Date: 2/4/1999

Generic Name: **Busulfan** Trade Name: Spartajet-Busulfan

Designated Indication: *Intrathecal therapy for neoplastic meningitis*

Sponsor: SuperGen, Inc.
Address: 4140 Dublin Boulevard
Dublin CA 94568

Date Designated: 3/5/2001
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Butyrylcholinesterase** Trade Name: NONE ASSIGNED

Designated Indication: *For the reduction and clearance of toxic blood levels of cocaine encountered during a drug overdose.*

Sponsor: Shire Laboratories Inc.
Address: 1550 East Gude Drive
Rockville MD 20850

Date Designated: 3/25/1992
Market Approval Date: Not currently Approved

Generic Name: **Butyrylcholinesterase** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of post-surgical apnea.*

Sponsor: Shire Laboratories Inc.
Address: 1550 East Gude Drive
Rockville MD 20850

Date Designated: 9/30/1992
Market Approval Date: Not currently Approved

Generic Name: **BW 12C** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of sickle cell disease.*

Sponsor: Burroughs Wellcome Company
Address: 3030 Cornwallis Road
P.O. Box 12700
Research Triangle Pk NC 27709

Date Designated: 10/23/1987
Market Approval Date: Not currently Approved

Generic Name: **C1 esterase inhibitor (human)** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment and prevention of angioedema caused by C1-esterase inhibitor deficiency.*

Sponsor: Alpha Therapeutic Corporation
Address: 5555 Valley Boulevard
Los Angeles CA 90032

Date Designated: 8/21/1996
Market Approval Date: Not currently Approved

Generic Name: **C1-esterase-inhibitor, human, pasteurized** Trade Name: Berinert P

Designated Indication: *Prevention and/or treatment of acute attacks of hereditary angioedema.*

Sponsor: Aventis Behring L.L.C.
Address: 1020 First Ave.
PO Box 61501
King of Prussia PA 19406-0901

Date Designated: 10/16/1992
Market Approval Date: Not currently Approved

Generic Immuno Name: **C1-inhibitor** Trade Name: C1-inhibitor (human) vapor heated,

Designated Indication: *Treatment of acute attacks of angioedema.*

Sponsor: Baxter Healthcare Corp.
Address: Hyland Division (Baxter Hyland)
550 North Brand Blvd.
Glendale CA 91203

Date Designated: 8/30/1990
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Immuno Name: **C1-inhibitor**
Trade Name: C1-inhibitor (human) vapor heated,

Designated Indication: *Prevention of acute attacks of angioedema, including short-term prophylaxis for patients requiring dental or other surgical procedures.*

Sponsor: Baxter Healthcare Corp.
Address: Hyland Division (Baxter Hyland)
550 North Brand Blvd.
Glendale CA 91203

Date Designated: 8/30/1990
Market Approval Date: Not currently Approved

Generic Name: **Caffeine**
Trade Name: Cafcit

Designated Indication: *Treatment of apnea of prematurity.*

Sponsor: O.P.R. Development, L.P.
Address: 1501 Wakarusa Drive
Lawrence KS 66047

Date Designated: 9/20/1988
Market Approval Date: 9/21/1999

Generic Name: **Calcitonin-human for injection**
Trade Name: Cibacalcin

Designated Indication: *Treatment of symptomatic Paget's disease (osteitis deformans).*

Sponsor: Novartis Pharmaceutical Corporation
Address: 59 Route 10
East Hanover NJ 07936

Date Designated: 1/20/1987
Market Approval Date: 10/31/1986

Generic Name: **Calcium acetate**
Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of hyperphosphatemia in end stage renal disease.*

Sponsor: Pharmedic Company
Address: 28101 Ballard Road, Suite F
Lake Forest IL 60045

Date Designated: 6/27/1989
Market Approval Date: Not currently Approved

Generic Name: **Calcium acetate**
Trade Name: Phos-Lo

Designated Indication: *Treatment of hyperphosphatemia in end stage renal failure.*

Sponsor: Braintree Laboratories
Address: 60 Columbian Street
P.O. Box 361
Braintree MA 02184

Date Designated: 12/22/1988
Market Approval Date: 12/10/1990

Generic Name: **Calcium carbonate**
Trade Name: R & D calcium carbonate/600

Designated Indication: *Treatment of hyperphosphatemia in patients with end stage renal disease.*

Sponsor: R & D Laboratories, Inc.
Address: 4204 Glencoe Avenue
Marina Del Rey CA 90292

Date Designated: 6/6/1990
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Calcium gluconate** | Trade Name: Calgonate

Designated Indication: *For use as a wash for hydrofluoric acid spills on human skin.*

Sponsor: Calgonate Corp.
Address: 190 Commerce Drive
Warwick RI 02886

Date Designated: 11/20/1997
Market Approval Date: Not currently Approved

Generic Name: **Calcium gluconate gel** | Trade Name: H-F Gel

Designated Indication: *For use in the emergency topical treatment of hydrogen fluoride (hydrofluoric acid) burns.*

Sponsor: LTR Pharmaceuticals, Inc.
Address: 145 Sakonnet Blvd.
Narragansett RI 02882

Date Designated: 5/21/1991
Market Approval Date: Not currently Approved

Generic Name: **Calcium gluconate gel 2.5%** | Trade Name: NONE ASSIGNED

Designated Indication: *Emergency topical treatment of hydrogen fluoride (hydrofluoric acid) burns.*

Sponsor: Paddock Laboratories, Inc.
Address: 3940 Quebec Avenue North
Minneapolis MN 55427

Date Designated: 9/10/1990
Market Approval Date: Not currently Approved

Generic Name: **Calfactant** | Trade Name: Infasurf

Designated Indication: *Acute respiratory distress syndrome (ARDS)*

Sponsor: ONY, Inc.
Address: Baird Research Park
1576 Sweet Home Road
Amherst NY 14228

Date Designated: 9/5/2000
Market Approval Date: Not currently Approved

Generic Name: **carbamic acid, [[4-[[3-[[4-[1-(4-hydroxyphenyl)-1-methyl-ethyl]phenoxy]methyl]phenyl]methoxy]-phenyl]iminomethyl]-,ethyl ester** | Trade Name: NONE ASSIGNED

Designated Indication: *Management of cystic fibrosis*

Sponsor: Boehringer Ingelheim Pharmaceuticals, Inc
Address: 900 Ridgebury Road
P.O. Box 368
Ridgefield CT 06877

Date Designated: 1/15/2002
Market Approval Date: Not currently Approved

Generic Name: **Carbamylglutamic acid** | Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of N-acetylglutamate synthetase deficiency.*

Sponsor: Orphan Europe
Address: Immeuble "Le Guillaumet"
60, avenue du General de Gaulle - Cedex 70
92046 Paris La Defense FR

Date Designated: 1/20/1998
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Carmustine** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of intracranial malignancies.*

Sponsor: Direct Therapeutics, Inc.
Address: 1001 Bayhill Dr., Suite 100
San Bruno CA 94066

Date Designated: 7/3/2000
Market Approval Date: Not currently Approved

Generic Name: **Cascara sagrada fluid extract** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of oral drug overdosage to speed lower bowel evacuation.*

Sponsor: Intramed Corporation
Address: 102 Tremont Way
Augusta GA 30907

Date Designated: 3/21/1989
Market Approval Date: Not currently Approved

Generic Name: **CDP571** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of Crohn's disease.*

Sponsor: Celltech Chiroscience Limited
Address: 216 Bath Road
Slough SL1 4EN
Berkshire UK

Date Designated: 12/11/1997
Market Approval Date: Not currently Approved

Generic Name: **Centruroides immune F(ab)2** Trade Name: Alacramyn

Designated Indication: *Treatment of scorpion envenomations requiring medical attention.*

Sponsor: Silanes Laboratories S.A. de C.V.
Address: Amores #1034 Col Del Valle
C.P. 03100 Mexico D.F.

Date Designated: 6/12/2000
Market Approval Date: Not currently Approved

Generic Name: **Ceramide trihexosidase/alpha-galactosidase A** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of Fabry's disease.*

Sponsor: Genzyme Corporation
Address: One Kendall Square
Cambridge MA 02139-1562

Date Designated: 1/19/1988
Market Approval Date: Not currently Approved

Generic Name: **Cetuximab** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of squamous cell cancer of the head and neck in patients who express epidermal growth factor receptor.*

Sponsor: ImClone Systems Incorporated
Address: Branchburg Corporate Center
22 Chubb Way
Somerville NJ 08876

Date Designated: 7/3/2000
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Chenodiol** Trade Name: Chenix

Designated Indication: *For patients with radiolucent stones in well opacifying gallbladders, in whom elective surgery would be undertaken except for the presence of increased surgical risk due to systemic disease or age.*

Sponsor: Solvay
Address: 901 Sawyer Road
Marietta GA 30062

Date Designated: 9/21/1984
Market Approval Date: 7/28/1983

Generic Name: **Chimeric (human-murine) G250 IgG monoclonal antibody** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of renal cell carcinoma.*

Sponsor: Wilex Biotechnology GmbH
Address: Grillparzerstrasse 10B
81675 Munich
Germany DE

Date Designated: 7/24/2000
Market Approval Date: Not currently Approved

Generic Name: **Chimeric, humanized monoclonal antibody to staphylococcus** Trade Name: NONE ASSIGNED

Designated Indication: *Prophylaxis of Staphylococcus epidermidis sepsis in low birth weight (1500 grams or less) infants.*

Sponsor: Biosynexus, Inc.
Address: 9610 Medical Center Drive
Suite 100
Rockville MD 20850

Date Designated: 8/3/2000
Market Approval Date: Not currently Approved

Generic Name: **Chlorhexidine gluconate mouthrinse** Trade Name: Peridex

Designated Indication: *For use in the amelioration of oral mucositis associated with cytoreductive therapy used in conditioning patients for bone marrow transplantation therapy.*

Sponsor: Procter & Gamble Company
Address: Sharon Wood Technical Center
11370 Reed Hartman Highway
Cincinnati OH 45241

Date Designated: 8/18/1986
Market Approval Date: Not currently Approved

Generic Name: **Choline chloride** Trade Name: Intrachol

Designated Indication: *Treatment of choline deficiency, specifically the choline deficiency, hepatic steatosis, and cholestasis, associated with long-term parenteral nutrition.*

Sponsor: Orphan Medical, Inc.
Address: 13911 Ridgedale Drive
Suite 250
Minnetonka MN 55305

Date Designated: 2/10/1994
Market Approval Date: Not currently Approved

Generic Name: **Chondrocyte-alginate gel suspension** Trade Name: NONE ASSIGNED

Designated Indication: *For use in correcting vesicoureteral reflux in the pediatric population.*

Sponsor: Curis, Inc.
Address: 61 Moulton Street
Cambridge MA 02138

Date Designated: 12/1/1997
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name:	**Ciliary neurotrophic factor**	Trade Name:	NONE ASSIGNED
Designated Indication:	*Treatment of amyotrophic lateral sclerosis.*		
Sponsor:	Regeneron Pharmaceuticals Inc	Date Designated:	1/30/1992
Address:	777 Old Saw Mill River Road Tarrytown NY 10591	Market Approval Date:	Not currently Approved

Generic Name:	**Cisplatin/epinephrine**	Trade Name:	IntraDose
Designated Indication:	*Treatment of metastatic malignant melanoma.*		
Sponsor:	Matrix Pharmaceutical, Inc.	Date Designated:	9/7/2000
Address:	34700 Campus Drive Fremont CA 94555-3612	Market Approval Date:	Not currently Approved

Generic Name:	**Cisplatin/epinephrine**	Trade Name:	IntraDose
Designated Indication:	*Treatment of squamous cell carcinoma of the head and neck.*		
Sponsor:	Matrix Pharmaceutical, Inc.	Date Designated:	4/3/2000
Address:	34700 Campus Drive Fremont CA 94555-3612	Market Approval Date:	Not currently Approved

Generic Name:	**Citric acid, glucono-delta-lactone and magnesium carbonate**	Trade Name:	Renacidin Irrigation
Designated Indication:	*Treatment of renal and bladder calculi of the apatite or struvite variety.*		
Sponsor:	United-Guardian, Inc.	Date Designated:	8/28/1989
Address:	P.O. Box 2500 Smithtown NY 11787	Market Approval Date:	10/2/1990

Generic Name:	**Cladribine**	Trade Name:	Leustatin Injection
Designated Indication:	*Treatment of chronic lymphocytic leukemia.*		
Sponsor:	R. W. Johnson Pharmaceutical Research	Date Designated:	12/31/1990
Address:	Route 202, P.O. Box 300 Raritan NJ 08869-0602	Market Approval Date:	Not currently Approved

Generic Name:	**Cladribine**	Trade Name:	Leustatin Injection
Designated Indication:	*Treatment of non-Hodgkin's lymphoma.*		
Sponsor:	R. W. Johnson Pharmaceutical Research	Date Designated:	4/19/1993
Address:	Route 202 South, P.O. Box 300 Raritan NJ 08869-0602	Market Approval Date:	Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Cladribine** — Trade Name: Mylinax

Designated Indication: *Treatment of the chronic progressive form of multiple sclerosis.*

Sponsor: R. W. Johnson Pharmaceutical Research
Address: Route 202
PO Box 300
Raritan NJ 08869-0602

Date Designated: 4/19/1994
Market Approval Date: Not currently Approved

Generic Name: **Cladribine** — Trade Name: Leustatin Injection

Designated Indication: *Treatment of hairy cell leukemia.*

Sponsor: R. W. Johnson Pharmaceutical Research
Address: Route 202, P.O. Box 300
Raritan NJ 08869

Date Designated: 11/15/1990
Market Approval Date: 2/26/1993

Generic Name: **Cladribine** — Trade Name: Leustatin

Designated Indication: *Treatment of acute myeloid leukemia.*

Sponsor: R. W. Johnson Pharmaceutical Research
Address: Route 202
P.O. Box 300
Raritan NJ 08869

Date Designated: 7/20/1990
Market Approval Date: Not currently Approved

Generic Name: **Clindamycin** — Trade Name: Cleocin

Designated Indication: *Treatment of Pneumocystis carinii pneumonia associated with AIDS patients.*

Sponsor: Pharmacia & Upjohn
Address: 7000 Portage Road
Unit 0633-298-113
Kalamazoo MI 49001-0199

Date Designated: 10/28/1988
Market Approval Date: Not currently Approved

Generic Name: **Clindamycin** — Trade Name: Cleocin

Designated Indication: *Prevention of Pneumocystis carinii pneumonia in AIDS patients.*

Sponsor: Pharmacia & Upjohn
Address: 7000 Portage Road
Unit 0633-298-113
Kalamazoo MI 49001-0199

Date Designated: 10/28/1988
Market Approval Date: Not currently Approved

Generic Name: **Clofazimine** — Trade Name: Lamprene

Designated Indication: *Treatment of lepromatous leprosy, including dapsone-resistant lepromatous leprosy and lepromatous leprosy complicated by erythema nodosum leprosum.*

Sponsor: Novartis Pharmaceutical Corporation
Address: 59 Route 10
East Hanover NJ 07936

Date Designated: 6/11/1984
Market Approval Date: 12/15/1986

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Clonazepam** | Trade Name: Klonopin

Designated Indication: *Treatment of hyperekplexia (startle disease).*

Sponsor: Hoffmann-La Roche, Inc.
Address: 340 Kingsland Street
Nutley NJ 07110

Date Designated: 8/4/1994
Market Approval Date: Not currently Approved

Generic Name: **Clonidine** | Trade Name: Duraclon

Designated Indication: *For continous epidural administration as adjunctive therapy with intraspinal opiates for the treatment of pain in cancer patients tolerant to, or unresponsive to, intraspinal opiates.*

Sponsor: Roxane Laboratories, Inc.
Address: PO Box 16532
Columbus OH 43216-6532

Date Designated: 1/24/1989
Market Approval Date: 10/2/1996

Generic Name: **Clostridial collagenase** | Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of advanced (involutional or residual stage) Dupuytren's disease.*

Sponsor: Hurst, L. M.D. & Badalamente, M. Ph.D.
Address: State University of New York at Stony Brook
School of Medicine, Health Sciences Center
Stony Brook NY 11794-8181

Date Designated: 5/23/1996
Market Approval Date: Not currently Approved

Generic Name: **Clotrimazole** | Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of sickle cell disease.*

Sponsor: Brugnara, Carlo M.D.
Address: The Children's Hospital
300 Longwood Avenue, Bader 760
Boston MA 02115

Date Designated: 4/24/1995
Market Approval Date: Not currently Approved

Generic Name: **Coagulation factor IX** | Trade Name: Mononine

Designated Indication: *Replacement treatment and prophylaxis of the hemorrhagic complications of hemophilia B.*

Sponsor: Armour Pharmaceutical Company
Address: 500 Arcola Road, P.O. Box 1200
Collegeville PA 19426

Date Designated: 6/27/1989
Market Approval Date: 8/20/1992

Generic Name: **Coagulation Factor IX (human)** | Trade Name: AlphaNine

Designated Indication: *For use as replacement therapy in patients with hemophilia B for the prevention and control of bleeding episodes, and during surgery to correct defective hemostasis.*

Sponsor: Alpha Therapeutic Corporation
Address: 5555 Valley Boulevard
Los Angeles CA 90032

Date Designated: 7/5/1990
Market Approval Date: 12/31/1990

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Coagulation Factor IX (recombinant)**
Trade Name: BeneFix
Designated Indication: *Treatment of hemophilia B.*
Sponsor: Genetics Institute, Inc.
Address: 87 Cambridge Park Drive, Cambridge MA 02140
Date Designated: 10/3/1994
Market Approval Date: 2/11/1997

Generic Name: **Coagulation factor VIIa (recombinant)**
Trade Name: NovoSeven
Designated Indication: *Treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX.*
Sponsor: Novo Nordisk Pharmaceuticals, Inc.
Address: 100 Overlook Center, Suite 200, Princeton NJ 08540-7810
Date Designated: 6/6/1988
Market Approval Date: 3/25/1999

Generic Name: **Coenzyme Q10**
Trade Name: NONE ASSIGNED
Designated Indication: *For the treatrment of Huntington's disease*
Sponsor: Vitaline Corporation
Address: 385 Williamson Way, Ashland OR 97520
Date Designated: 3/5/2001
Market Approval Date: Not currently Approved

Generic Name: **Colfosceril palmitate, cetyl alcohol, tyloxapol**
Trade Name: Exosurf
Designated Indication: *Treatment of adult respiratory distress syndrome.*
Sponsor: Glaxo Wellcome Research and Development
Address: 5 Moore Drive, P.O. Box 13398, Research Triangle Park NC 27709
Date Designated: 1/11/1993
Market Approval Date: Not currently Approved

Generic Name: **Colfosceril palmitate, cetyl alcohol, tyloxapol**
Trade Name: Exosurf Neonatal for Intratracheal Suspension
Designated Indication: *Prevention of hyaline membrane disease, also known as respiratory distress syndrome, in infants born at 32 weeks gestation or less.*
Sponsor: Glaxo Wellcome Inc.
Address: 5 Moore Drive, Research Triangle Park NC 27709
Date Designated: 10/20/1989
Market Approval Date: 8/2/1990

Generic Name: **Colfosceril palmitate, cetyl alcohol, tyloxapol**
Trade Name: Exosurf Neonatal for Intratracheal Suspension
Designated Indication: *Treatment of established hyaline membrane disease at all gestational ages.*
Sponsor: Glaxo Wellcome Inc.
Address: 5 Moore Drive, Research Triangle Park NC 27709
Date Designated: 10/20/1989
Market Approval Date: 8/2/1990

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name:	**Collagenase (lyophilized) for injection**	Trade Name:	Plaquase
Designated Indication:	*Treatment of Peyronie's disease.*		
Sponsor:	Advance Biofactures Corporation	Date Designated:	3/12/1996
Address:	35 Wilbur Street Lynbrook NY 11563-2358	Market Approval Date:	Not currently Approved

Generic Name:	**conjugate of human transferrin and a mutant diphtheria toxin (CRM 107)**	Trade Name:	NONE ASSIGNED
Designated Indication:	*Treatment of malignant tumors of the central nervous system*		
Sponsor:	INTELLIgene Expressions Inc.	Date Designated:	12/3/2001
Address:	1938-94 St. Edmonton, AB T6N 1J3	Market Approval Date:	Not currently Approved

Generic Name:	**Corticorelin ovine triflutate**	Trade Name:	Acthrel
Designated Indication:	*For use in differentiating pituitary and ectopic production of ACTH in patients with ACTH-dependent Cushings syndrome.*		
Sponsor:	Ferring Laboratories, Inc.	Date Designated:	11/24/1989
Address:	400 Rella Boulevard, Suite 201 Suffern NY 10901	Market Approval Date:	5/23/1996

Generic Name:	**Corticotropin-releasing factor, human**	Trade Name:	Xerecept
Designated Indication:	*Treatment of peritumoral brain edema.*		
Sponsor:	Neurobiological Technologies, Inc.	Date Designated:	4/6/1998
Address:	1387 Marina Way South Richmond CA 94804	Market Approval Date:	Not currently Approved

Generic Name:	**Coumarin**	Trade Name:	Onkolox
Designated Indication:	*Treatment of renal cell carcinoma.*		
Sponsor:	Drossapharm LTD	Date Designated:	12/22/1994
Address:	4002 Basel Switzerland CH	Market Approval Date:	Not currently Approved

Generic Name:	**Cromolyn sodium**	Trade Name:	Gastrocrom
Designated Indication:	*Treatment of mastocytosis.*		
Sponsor:	Fisons Corporation	Date Designated:	3/8/1984
Address:	755 Jefferson Rd P.O. Box 1710 Rochester NY 14603	Market Approval Date:	12/22/1989

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Cromolyn sodium 4% ophthalmic solution** Trade Name: Opticrom 4% ophthalmic solution

Designated Indication: *Treatment of vernal keratoconjunctivitis.*

Sponsor: Fisons Corporation
Address: 755 Jefferson Rd.
P.O. Box 1710
Rochester NY 14603

Date Designated: 7/24/1985
Market Approval Date: 10/3/1984

Generic Name: **Cryptosporidium hyperimmune bovine colostrum IgG concentrate** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of diarrhea in AIDS patients caused by infection with Cryptosporidium parvum.*

Sponsor: ImmuCell Corporation
Address: 56 Evergreen Drive
Portland ME 04103

Date Designated: 12/30/1991
Market Approval Date: Not currently Approved

Generic Name: **CT-2584 mesylate** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of adult soft tissue sarcoma.*

Sponsor: Cell Therapeutics, Inc.
Address: 201 Elliott Ave. West
Suite 400
Seattle WA 98119

Date Designated: 4/16/1999
Market Approval Date: Not currently Approved

Generic Name: **CT-2584 mesylate** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of malignant mesothelioma.*

Sponsor: Cell Therapeutics, Inc.
Address: 201 Elliott Ave. West
Seattle WA 98119

Date Designated: 4/16/1999
Market Approval Date: Not currently Approved

Generic Name: **CY-1503** Trade Name: Cylexin

Designated Indication: *Treatment of neonates and infants undergoing cardiopulmonary bypass during surgical repair of congenital heart lesions.*

Sponsor: Cytel Corporation
Address: 3525 John Hopkins Court
San Diego CA 92121

Date Designated: 7/18/1997
Market Approval Date: Not currently Approved

Generic Name: **CY-1503** Trade Name: Cylexin

Designated Indication: *Treatment of post-ischemic pulmonary reperfusion edema following surgical treatment for chronic thromboembolic pulmonary hypertension.*

Sponsor: Cytel Corporation
Address: 3525 John Hopkins Court
San Diego CA 92121

Date Designated: 12/22/1993
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **CY-1899** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of chronic active hepatitis B infection in HLA-A2 positive patients.*

Sponsor: Cytel Corporation
Address: 3525 John Hopkins Court
San Diego CA 92121

Date Designated: 3/16/1994
Market Approval Date: Not currently Approved

Generic Name: **Cyclosporine 2% ophthalmic ointment** Trade Name: NONE ASSIGNED

Designated Indication: *For use in corneal melting syndromes of known or presumed immunologic etiopathogenesis, including Mooren's ulcer.*

Sponsor: Allergan, Inc.
Address: 2525 Dupont Drive
P.O. Box 19534
Irvine CA 92623-9534

Date Designated: 8/1/1991
Market Approval Date: Not currently Approved

Generic Name: **Cyclosporine 2% ophthalmic ointment** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of patients at high risk of graft rejection following penetrating keratoplasty.*

Sponsor: Allergan, Inc.
Address: 2525 Dupont Drive
P.O. Box 19534
Irvine CA 92623-9534

Date Designated: 8/1/1991
Market Approval Date: Not currently Approved

Generic Name: **Cyclosporine in combination with omega-3 polyunsaturated fatty acids** Trade Name: NONE ASSIGNED

Designated Indication: *Prevention of solid organ graft rejection.*

Sponsor: RTP Pharma Corporation
Address: 200 Westpark Corporate Center
4364 South Alston Avenue
Durham NC 27713-2280

Date Designated: 12/6/2000
Market Approval Date: Not currently Approved

Generic Name: **Cyclosporine ophthalmic** Trade Name: Optimmune

Designated Indication: *Treatment of severe keratoconjunctivitis sicca associated with Sjogren's syndrome.*

Sponsor: University Of Georgia
Address: College Of Veterinary Medicine
Department of Small Animal Medicine
Athens GA 30602

Date Designated: 11/9/1988
Market Approval Date: Not currently Approved

Generic Name: **Cysteamine** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of nephropathic cystinosis.*

Sponsor: Thoene, Jess G., M.D.
Address: University of Michigan Medical School
300 NIB, 1192 SE
Ann Arbor MI 48109-0408

Date Designated: 5/1/1986
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Cysteamine** Trade Name: Cystagon

Designated Indication: *Treatment of nephropathic cystinosis.*

Sponsor: Mylan Laboratories, Inc.
Address: 781 Chestnut Ridge Road
P.O. Box 4310
Morgantown WV 26504

Date Designated: 1/25/1991
Market Approval Date: 8/15/1994

Generic Name: **Cysteamine hydrochloride** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of corneal cystine crystal accumulation in cystinosis patients.*

Sponsor: Sigma-Tau Pharmaceuticals, Inc.
Address: 800 South Frederick Avenue
Gaithersburg MD 20877

Date Designated: 8/19/1997
Market Approval Date: Not currently Approved

Generic Name: **Cystic fibrosis gene therapy** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of cystic fibrosis.*

Sponsor: Genzyme Corporation
Address: One Mountain Rd.
P.O. Box 9322
Framingham MA 01701-9322

Date Designated: 6/30/1992
Market Approval Date: Not currently Approved

Generic Name: **Cystic fibrosis Tr gene therapy (recombinant adenovirus)** Trade Name: AdGVCFTR.10

Designated Indication: *Treatment of cystic fibrosis.*

Sponsor: GenVec, Inc.
Address: 12111 Parklawn Drive
Rockville MD 20852

Date Designated: 3/9/1995
Market Approval Date: Not currently Approved

Generic Name: **Cystic fibrosis transmembrane conductance regulator gene** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of cystic fibrosis.*

Sponsor: Genetic Therapy, Inc.
Address: 938 Clopper Road
Gaithersburg MD 20878

Date Designated: 1/8/1993
Market Approval Date: Not currently Approved

Generic Name: **Cytarabine liposomal** Trade Name: DepoCyt

Designated Indication: *Treatment of neoplastic meningitis.*

Sponsor: DepoTech Corporation
Address: 10450 Science Center Drive
San Diego CA 92121

Date Designated: 6/2/1993
Market Approval Date: 4/1/1999

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Cytomegalovirus immune globulin (human)** Trade Name: CytoGam

Designated Indication: *Prevention or attenuation of primary cytomegalovirus disease in immunosuppressed recipients of organ transplants.*

Sponsor: Massachussetts Public Health Biologic
Address: 305 South Street
Boston MA 02130-3597

Date Designated: 8/3/1987
Market Approval Date: 12/4/1998

Generic Name: **Cytomegalovirus immune globulin intravenous (human)** Trade Name: NONE ASSIGNED

Designated Indication: *For use in conjunction with ganciclovir sodium for the treatment of cytomegalovirus pneumonia in bone marrow transplant patients.*

Sponsor: Bayer Corporation
Address: Pharmaceutical Division, Biological Products
400 Morgan Lane
New Haven CT 06516

Date Designated: 1/28/1991
Market Approval Date: Not currently Approved

Generic Name: **Daclizumab** Trade Name: Zenapax

Designated Indication: *Prevention of acute renal allograft rejection.*

Sponsor: Hoffmann-La Roche, Inc.
Address: 340 Kingsland Street
Nutley NJ 07110

Date Designated: 3/5/1993
Market Approval Date: 12/10/1997

Generic Name: **Dapsone** Trade Name: NONE ASSIGNED

Designated Indication: *Prophylaxis of toxoplasmosis in severely immunocompromised patients with CD4 counts below 100.*

Sponsor: Jacobus Pharmaceutical Company, Inc.
Address: 37 Cleveland Lane
P.O. Box 5290
Princeton NJ 08540

Date Designated: 11/7/1994
Market Approval Date: Not currently Approved

Generic Name: **Dapsone USP** Trade Name: Dapsone

Designated Indication: *For the combination treatment of Pneumocystis carinii pneumonia in conjunction with trimethoprim.*

Sponsor: Jacobus Pharmaceutical Company
Address: 37 Cleveland Lane
P.O. Box 5290
Princeton NJ 08540

Date Designated: 1/8/1992
Market Approval Date: Not currently Approved

Generic Name: **Dapsone USP** Trade Name: Dapsone

Designated Indication: *Prophylaxis for Pneumocystis carinii pneumonia.*

Sponsor: Jacobus Pharmaceutical Company
Address: 37 Cleveland Lane
P.O. Box 5290
Princeton NJ 08540

Date Designated: 12/24/1991
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Daunorubicin citrate liposome injection** Trade Name: DaunoXome

Designated Indication: *Treatment of patients with advanced HIV-associated Kaposi's sarcoma.*

Sponsor: NeXstar Pharmaceuticals, Inc.
Address: 650 Cliffside Drive
San Dimas CA 91773

Date Designated: 5/14/1993
Market Approval Date: 4/8/1996

Generic Name: **Decitabine** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of myelodysplastic syndromes.*

Sponsor: SuperGen, Inc.
Address: 4140 Dublin Blvd.
Suite 200
Dublin CA 94568

Date Designated: 3/8/1999
Market Approval Date: Not currently Approved

Generic Name: **Decitabine** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of chronic myelogenous leukemia.*

Sponsor: SuperGen, Inc.
Address: 4140 Dublin Blvd.
Suite 200
Dublin CA 94568

Date Designated: 3/8/1999
Market Approval Date: Not currently Approved

Generic Name: **deferiprone** Trade Name: Ferriprox

Designated Indication: *Treatment of iron overload in patients with hematologic disorders requiring chronic transfusion therapy*

Sponsor: Apotex Research Inc.
Address: 150 Signet Drive
Toronto, Canada M9L 1T9

Date Designated: 12/12/2001
Market Approval Date: Not currently Approved

Generic Name: **Defibrotide** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of thrombotic thrombocytopenic purpura.*

Sponsor: Crinos International
Address: Via Belvedere 1
Villa Guardia, Italy 22079

Date Designated: 7/5/1985
Market Approval Date: Not currently Approved

Generic Name: **Dehydroepiandrosterone** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of systemic lupus erythematosus (SLE) and the reduction in the use of steroids in steroid-dependent SLE patients.*

Sponsor: Genelabs Technologies, Inc.
Address: 505 Penobscot Drive
Redwood City CA 94063

Date Designated: 7/13/1994
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Dehydroepiandrosterone sulfate sodium** Trade Name: NONE ASSIGNED

Designated Indication: *To accelerate the re-epithelialization of donor sites in those hospitalized burn patients who must undergo autologous skin grafting.*

Sponsor: Pharmadigm, Inc.
Address: 2401 Foothill Drive
Salt Lake City UT 84109-1405

Date Designated: 1/28/1997
Market Approval Date: Not currently Approved

Generic Name: **Dehydroepiandrosterone sulfate sodium** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of serious burns requiring hospitalization.*

Sponsor: Pharmadigm, Inc.
Address: 2401 Foothill Drive
Salt Lake City UT 84109-1405

Date Designated: 1/29/1997
Market Approval Date: Not currently Approved

Generic Name: **Denileukin diftitox** Trade Name: Ontak

Designated Indication: *Treatment of patients with persistent or recurrent cutaneous T-cell lymphoma whose malignant cells express the CD25 component of the IL-2 receptor.*

Sponsor: Seragen, Inc.
Address: 97 South Street
Hopkinton MA 01748

Date Designated: 8/21/1996
Market Approval Date: 2/5/1999

Generic Name: **Deoxyribose, phosphorothioate** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of advanced malignant melanoma (Stages II,III, IV).*

Sponsor: Genta, Inc.
Address: 99 Hayden Ave., Suite 200
Lexington MA 02421-7966

Date Designated: 7/31/2000
Market Approval Date: Not currently Approved

Generic Name: **Deslorelin** Trade Name: Somagard

Designated Indication: *Treatment of central precocious puberty.*

Sponsor: Roberts Pharmaceutical Corp.
Address: Meridian Center II
Four Industrial Way West
Eatontown NJ 07724-2274

Date Designated: 11/5/1987
Market Approval Date: Not currently Approved

Generic Name: **Desmopressin acetate** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of mild hemophilia A and von Willebrand's disease.*

Sponsor: Aventis Behring L.L.C.
Address: 1020 First Avenue
PO Box 61501
King of Prussia PA 19406-0901

Date Designated: 1/22/1991
Market Approval Date: 3/7/1994

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Dexamethasone** | Trade Name: NONE ASSIGNED

Designated Indication: *For use in posterior segment drug delivery system in the treatment of idiopathic intermediate uveitis.*

Sponsor: Oculex Pharmaceuticals, Inc.
Address: 639 N. Pastoria Avenue
Sunnyvale CA 94086-2917

Date Designated: 9/11/1998
Market Approval Date: Not currently Approved

Generic Name: **Dexrazoxane** | Trade Name: Zinecard

Designated Indication: *For the prevention of cardiomyopathy associated with doxorubicin administration.*

Sponsor: Pharmacia & Upjohn
Address: 7000 Portage Road
Kalamazoo MI 49001-0199

Date Designated: 12/17/1991
Market Approval Date: 5/26/1995

Generic Name: **Dextran 70** | Trade Name: Dehydrex

Designated Indication: *Treatment of recurrent corneal erosion unresponsive to conventional therapy.*

Sponsor: Holles Laboratories, Inc.
Address: 30 Forest Notch
Cohasset MA 02025

Date Designated: 3/5/1990
Market Approval Date: Not currently Approved

Generic Name: **Dextran and deferoxamine** | Trade Name: Bio-Rescue

Designated Indication: *Treatment of acute iron poisoning.*

Sponsor: Biomedical Frontiers, Inc.
Address: 1095 10th Avenue S.E.
Minneapolis MN 55414

Date Designated: 3/8/1991
Market Approval Date: Not currently Approved

Generic Name: **Dextran sulfate (inhaled, aerosolized)** | Trade Name: Uendex

Designated Indication: *For use as an adjunct to the treatment of cystic fibrosis.*

Sponsor: Kennedy & Hoidal, M.D.'s
Address: University Of Utah Medical Center
50 North Medical Drive, Room 4R240
Salt Lake City UT 84132

Date Designated: 10/5/1999
Market Approval Date: Not currently Approved

Generic Name: **Dextran sulfate sodium** | Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of aquired immunodeficiency syndrome.*

Sponsor: Ueno Fine Chemicals Industry, Ltd.
Address: 2-31 Koraibashi, Higashi-ku
Osaka 541, Japan

Date Designated: 11/19/1987
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **DHA-paclitaxel** | Trade Name: Taxoprexin

Designated Indication: *Treatment of pancreatic cancer*

Sponsor: Protarga, Inc.
Address: 2200 Renaissance Blvd.
Suite 450
King of Prussia PA 19406

Date Designated: 9/25/2001
Market Approval Date: Not currently Approved

Generic Name: **Dianeal peritoneal dialysis solution with 1.1% amino acids** | Trade Name: Nutrineal (Peritoneal Dialysis Solution with 1.1% Amino Acid

Designated Indication: *For use as a nutritional supplement for the treatment of malnourishment in patients undergoing continuous ambulatory peritoneal dialysis.*

Sponsor: Baxter Healthcare Corporation
Address: 1620 Waukegan Road
McGaw Park IL 60085

Date Designated: 6/11/1992
Market Approval Date: Not currently Approved

Generic Name: **Diazepam viscous solution for rectal administration** | Trade Name: NONE ASSIGNED

Designated Indication: *For the management of selected, refractory, patients with epilepsy, on stable regimens of antiepileptic drugs (AEDs), who require intermittent use of diazepam to control bouts of increased seizure activity.*

Sponsor: Athena Neurosciences, Inc.
Address: 800f Gateway Boulevard
South San Francisco CA 94080

Date Designated: 2/25/1992
Market Approval Date: 7/29/1997

Generic Name: **Diethyldithiocarbamate** | Trade Name: Imuthiol

Designated Indication: *Treatment of AIDS.*

Sponsor: Connaught Laboratories
Address: Route 611, P.O. Box 187
Swiftwater PA 18370

Date Designated: 4/3/1986
Market Approval Date: Not currently Approved

Generic Name: **digitoxin** | Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of soft tissue sarcomas*

Sponsor: PrimeCyte, Inc.
Address: 130 Fifth Ave., N.
Seattle WA 98109-4933

Date Designated: 10/18/2001
Market Approval Date: Not currently Approved

Generic Name: **digitoxin** | Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of ovarian cancer*

Sponsor: PrimeCyte, Inc.
Address: 130 Fifth Ave., N.
Seattle WA 98109-4933

Date Designated: 11/2/2001
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Digoxin immune FAB (Ovine)** Trade Name: Digibind

Designated Indication: *Treatment of potentially life threatening digitalis intoxication in patients who are refractory to management by conventional therapy.*

Sponsor: Glaxo Wellcome Inc.
Address: 5 Moore Drive
Research Triangle Park NC 27709

Date Designated: 11/1/1984
Market Approval Date: 4/22/1986

Generic Name: **Digoxin immune fab(ovine)** Trade Name: Digidote

Designated Indication: *Treatment of life-threatening acute cardiac glycoside intoxication manifested by conduction disorders, ectopic ventricular activity and (in some cases) hyperkalemia.*

Sponsor: Boehringer Mannheim Corp.
Address: 1301 Piccard Drive
Rockville MD 20850

Date Designated: 3/11/1985
Market Approval Date: Not currently Approved

Generic Name: **Dihydrotestosterone** Trade Name: Androgel -DHT

Designated Indication: *Treatment of weight loss in AIDS patients with HIV-associated wasting.*

Sponsor: Unimed Pharmaceuticals, Inc.
Address: Four Parkway North
Deerfield IL 60015-2544

Date Designated: 2/5/1996
Market Approval Date: Not currently Approved

Generic Name: **Dimethyl sulfoxide** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of increased intracranial pressure in patients with severe, closed-head injury, also known as traumatic brain coma, for whom no other effective treatment is available.*

Sponsor: Pharma 21
Address: c/o Univ. of Calif., San Diego
9500 Gilman Dr.
La Jolla CA 92093-0624

Date Designated: 11/22/1994
Market Approval Date: Not currently Approved

Generic Name: **Dimethylsulfoxide** Trade Name: NONE ASSIGNED

Designated Indication: *Topical treatment for the prevention of soft tissue injury following extravastion of cytotoxic drugs.*

Sponsor: Cancer Technologies, Inc.
Address: 7301 East 22nd Street
Suite 10E
Tucson AZ 85710

Date Designated: 4/15/1997
Market Approval Date: Not currently Approved

Generic Name: **Dimethylsulfoxide** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of palmar-plantar erythrodysethesia syndrome.*

Sponsor: Cancer Technologies, Inc.
Address: 7301 East 22nd Street
Suite 10E
Tucson AZ 85710

Date Designated: 4/6/1998
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Dipalmitoylphosphatidylcholine /phosphatidylglycerol**
Trade Name: ALEC

Designated Indication: *Prevention and treatment of neonatal respiratory distress syndrome.*

Sponsor: Forum Products, Inc.
Address: 33 Flying Point Road
Southampton NY 11968

Date Designated: 7/28/1988
Market Approval Date: Not currently Approved

Generic Name: **Disaccharide tripeptide glycerol dipalmitoyl**
Trade Name: Immther

Designated Indication: *Treatment of pulmonary and hepatic metastases in patients with colorectal adenocarcinoma.*

Sponsor: ImmunoTherapeutics, Inc.
Address: 3505 Riverview Circle
Moorhead MN 56560

Date Designated: 3/1/1990
Market Approval Date: Not currently Approved

Generic Name: **Disodium clodronate**
Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of hypercalcemia of malignancy.*

Sponsor: Discovery Experimental & Development, Inc.
Address: 29949 S.R. 54 West
Wesley Chapel FL 33543

Date Designated: 6/16/1993
Market Approval Date: Not currently Approved

Generic Name: **Disodium clodronate tetrahydrate**
Trade Name: Bonefos

Designated Indication: *Treatment of increased bone resorption due to malignancy.*

Sponsor: Anthra Pharmaceuticals, Inc.
Address: 103 Carnegie Center, Suite 102
Princeton NJ 08540

Date Designated: 3/5/1990
Market Approval Date: Not currently Approved

Generic Name: **DMP 777**
Trade Name: NONE ASSIGNED

Designated Indication: *Therapeutic management of patients with lung disease attributable to cystic fibrosis.*

Sponsor: DuPont Pharmaceuticals Company
Address: Chestnut Run, Maple Run
Centre Rd.
Wilmington DE 19805

Date Designated: 6/4/1996
Market Approval Date: Not currently Approved

Generic Name: **DNA-lipid complex (DMRIE/DOPE)/plasmid vector (VCL-1102, Vical) expressing human interleukin-2**
Trade Name: Leuvectin

Designated Indication: *Treatment of renal cell carcinoma.*

Sponsor: Vical Incorporated
Address: 9373 Towne Center Dr.
Suite 100
San Diego CA 92121-3088

Date Designated: 4/28/2000
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **DNP-Modified autologous tumor vaccine**
Trade Name: O-Vax

Designated Indication: *Adjuvant therapy for the treatment of ovarian cancer*

Sponsor: AVAX Technologies, Inc.
Address: 9200 Indian Creek Parkway
Building 9, Suite 200
Overland Park KS 66210

Date Designated: 9/21/2000
Market Approval Date: Not currently Approved

Generic Name: **docosahexanoic acid-paclitaxel**
Trade Name: Taxoprexin

Designated Indication: *Treatment of hormone-refractory prostate cancer.*

Sponsor: Protarga, Inc.
Address: 1100 East Hector Street
Suite 450
Conshohocken PA 19428-2377

Date Designated: 3/5/2001
Market Approval Date: Not currently Approved

Generic Name: **Dornase alfa**
Trade Name: Pulmozyme

Designated Indication: *To reduce mucous viscosity and enable the clearance of airway secretions in patients with cystic fibrosis.*

Sponsor: Genentech, Inc.
Address: 460 Point San Bruno Boulevard
South San Francisco CA 94080

Date Designated: 1/16/1991
Market Approval Date: 12/30/1993

Generic Name: **Doxorubicin liposome**
Trade Name: Doxil

Designated Indication: *Treatment of ovarian cancer.*

Sponsor: Alza Corporation
Address: 1550 Plymouth St.
PO Box 7210
Mountain View CA 94039-7210

Date Designated: 11/4/1998
Market Approval Date: 6/28/1999

Generic Name: **Dronabinol**
Trade Name: Marinol

Designated Indication: *For the stimulation of appetite and prevention of weight loss in patients with a confirmed diagnosis of AIDS.*

Sponsor: Unimed Pharmaceuticals, Inc.
Address: 2150 East Lake Cook Road, Suite 210
Buffalo Grove IL 60089-1862

Date Designated: 1/15/1991
Market Approval Date: 12/22/1992

Generic Name: **Duramycin**
Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of cystic fibrosis.*

Sponsor: MoliChem Medicines Inc.
Address: 207 South Elliott Road PMB#231
Chapel Hill NC 27514

Date Designated: 12/11/1997
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Dynamine** | Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of Lambert Eaton myasthenic syndrome.*

Sponsor: Mayo Foundation
Address: 200 First Street Southwest
Rochester MN 55905

Date Designated: 2/5/1990
Market Approval Date: Not currently Approved

Generic Name: **Dynamine** | Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of hereditary motor and sensory neuropathy type I (Charcot-Marie-Tooth disease).*

Sponsor: Mayo Foundation
Address: 200 First Street Southwest
Rochester MN 55905

Date Designated: 10/16/1991
Market Approval Date: Not currently Approved

Generic Name: **Eflornithine HCl** | Trade Name: Ornidyl

Designated Indication: *Treatment of Trypanosoma brucei gambiense infection (sleeping sickness).*

Sponsor: Hoechst Marion Roussel
Address: P.O. Box 9627
Kansas City MO 64134

Date Designated: 4/23/1986
Market Approval Date: 11/28/1990

Generic Name: **Elcatonin** | Trade Name: NONE ASSIGNED

Designated Indication: *Intrathecal treatment of intractable pain.*

Sponsor: Innapharma, Inc.
Address: 10 Mountainview Road
Upper Saddle River NJ 07458

Date Designated: 9/25/1995
Market Approval Date: Not currently Approved

Generic Name: **Enadoline hydrochloride** | Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of severe head injury.*

Sponsor: Warner-Lambert Company
Address: Parke-Davis Pharmaceutical Research
2800 Plymouth Road
Ann Arbor MI 48105

Date Designated: 1/28/1997
Market Approval Date: Not currently Approved

Generic Name: **Encapsulated porcine islet preparation** | Trade Name: BetaRx

Designated Indication: *Treatment of type I diabetic patients who are already on immunosuppression.*

Sponsor: VivoRx
Address: 2825 Santa Monica Blvd.
2nd Floor
Santa Monica CA 90404-2429

Date Designated: 7/5/1995
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Epidermal growth factor (human)** Trade Name: NONE ASSIGNED

Designated Indication: *For acceleration of corneal epithelial regeneration and the healing of stromal tissue in the condition of non-healing corneal defects.*

Sponsor: Chiron Vision
Address: 500 Iolab Drive
Claremont CA 91711

Date Designated: 10/5/1987
Market Approval Date: Not currently Approved

Generic Name: **Epirubicin** Trade Name: Ellence

Designated Indication: *Treatment of breast cancer.*

Sponsor: Pharmacia & Upjohn Company
Address: 0634-298-113
7000 Portage Rd.
Kalamazoo MI 49001-0199

Date Designated: 9/14/1999
Market Approval Date: 9/15/1999

Generic Name: **Epoetin alfa** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of myelodysplastic syndrome.*

Sponsor: R. W. Johnson Pharmaceutical Research
Address: Route 202, P.O. Box 300
Raritan NJ 08869-0602

Date Designated: 12/20/1993
Market Approval Date: Not currently Approved

Generic Name: **Epoetin alfa** Trade Name: Epogen

Designated Indication: *Treatment of anemia associated with HIV infection or HIV treatment.*

Sponsor: Amgen, Inc.
Address: 1840 Dehavilland Drive
Thousand Oaks CA 91320

Date Designated: 7/1/1991
Market Approval Date: 12/31/1990

Generic Name: **Epoetin alfa** Trade Name: Epogen

Designated Indication: *Treatment of anemia associated with end stage renal disease.*

Sponsor: Amgen, Inc.
Address: 1840 Dehavilland Drive
Thousand Oaks CA 91320

Date Designated: 4/10/1989
Market Approval Date: 6/1/1989

Generic Name: **Epoetin alpha** Trade Name: Procrit

Designated Indication: *Treatment of anemia of prematurity in preterm infants.*

Sponsor: R. W. Johnson Pharmaceutical Research
Address: Route 202, P.O. Box 300
Raritan NJ 08869-0602

Date Designated: 7/21/1988
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Epoetin alpha** Trade Name: Procrit

Designated Indication: *Treatment of anemia associated with end stage renal disease.*

Sponsor: R. W. Johnson Pharmaceutical Research
Address: Route 202 South
P.O. Box 300
Raritan NJ 08869

Date Designated: 8/27/1987
Market Approval Date: Not currently Approved

Generic Name: **Epoetin alpha** Trade Name: Procrit

Designated Indication: *Treatment of HIV associated anemia related to HIV infection or HIV treatment.*

Sponsor: R. W. Johnson Pharmaceutical Research
Address: Route 202, P.O. Box 300
Raritan NJ 08869

Date Designated: 3/7/1989
Market Approval Date: Not currently Approved

Generic Name: **Epoetin beta** Trade Name: Marogen

Designated Indication: *Treatment of anemia associated with end stage renal disease.*

Sponsor: Chugai-USA, Inc.
Address: 3780 Hawthorn Court
Waukegan IL 60087

Date Designated: 10/22/1987
Market Approval Date: Not currently Approved

Generic Name: **Epoprostenol** Trade Name: Flolan

Designated Indication: *Treatment of secondary pulmonary hypertension due to intrinsic precapillary pulmonary vascular disease.*

Sponsor: GlaxoSmithKline
Address: Five Moore Dr.
PO Box 13398
Research Triangle Park NC 27709-3398

Date Designated: 3/22/1999
Market Approval Date: 4/14/2000

Generic Name: **Epoprostenol** Trade Name: Flolan

Designated Indication: *Treatment of primary pulmonary hypertension.*

Sponsor: Glaxo Wellcome Inc.
Address: 5 Moore Drive
Research Triangle Park NC 27709

Date Designated: 9/25/1985
Market Approval Date: 9/20/1995

Generic Name: **Erwinia L-asparaginase** Trade Name: Erwinase

Designated Indication: *Treatment of acute lymphocytic leukemia.*

Sponsor: Porton International, Inc.
Address: 7114 Springbrook Terrace, #200
Spotsylvania VA 22553

Date Designated: 7/30/1986
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Erythropoietin (recombinant human)**
Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of anemia associated with end stage renal disease.*

Sponsor: McDonnell Douglas Corp
Address: P.O. Box 516, 107/2 MS10
St. Louis MO 63166

Date Designated: 8/19/1987
Market Approval Date: Not currently Approved

Generic Name: **Etanercept**
Trade Name: Enbrel

Designated Indication: *Reduction in signs and symptoms of moderately to severely active polyarticular-course juvenile rheumatoid arthritis in patients who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs.*

Sponsor: Immunex Corporation
Address: 51 University St.
Seattle WA 98101-2936

Date Designated: 10/27/1998
Market Approval Date: 5/27/1999

Generic Name: **Etanercept**
Trade Name: Enbrel

Designated Indication: *Treatment of Wegener's granulomatosis.*

Sponsor: Immunex Corporation
Address: 51 University Street
Seattle WA 98101-2936

Date Designated: 4/6/1999
Market Approval Date: Not currently Approved

Generic Name: **Ethanolamine oleate**
Trade Name: Ethamolin

Designated Indication: *Treatment of patients with esophageal varices that have recently bled, to prevent rebleeding.*

Sponsor: Block Drug Company, Inc.
Address: 257 Cornelison Avenue
Jersey City NJ 07302

Date Designated: 3/22/1984
Market Approval Date: 12/22/1988

Generic Name: **Ethyl eicosapentaenoate**
Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of Huntington's disease.*

Sponsor: Laxdale Ltd.
Address: Kings Park House, Laurelhill Business Park
Polmaise Road, Stirling FK7 9JQ
United Kingdom UK

Date Designated: 4/6/2000
Market Approval Date: Not currently Approved

Generic Name: **Etidronate disodium**
Trade Name: Didronel

Designated Indication: *Treatment of hypercalcemia of malignancy inadequately managed by dietary modification and/or oral hydration.*

Sponsor: MGI Pharma, Inc.
Address: 6300 West Old Shakoppe Rd.
Suite 110
Bloomington MN 55438-2318

Date Designated: 3/21/1986
Market Approval Date: 4/21/1987

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Etiocholanedione** — Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of aplastic anemia.*

Sponsor: SuperGen, Inc.
Address: Two Annabel Lane, Suite 220
Suite 10
San Ramon CA 94583

Date Designated: 11/3/1995
Market Approval Date: Not currently Approved

Generic Name: **Etiocholanedione** — Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of Prader-Willi syndrome.*

Sponsor: SuperGen, Inc.
Address: Two Annabel Lane, Suite 220
San Ramon CA 94583

Date Designated: 5/7/1996
Market Approval Date: Not currently Approved

Generic Name: **Exemestane** — Trade Name: Aromasin

Designated Indication: *Treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.*

Sponsor: Pharmacia & Upjohn
Address: 7000 Portage Road
Mail Stop: 0636-298-113
Kalamazoo MI 49001-0199

Date Designated: 9/19/1991
Market Approval Date: 10/21/1999

Generic Name: **Exisulind** — Trade Name: NONE ASSIGNED

Designated Indication: *For the suppression and control of colonic adenomatous polyps in the inherited disease adenomatous polyposis coli.*

Sponsor: Cell Pathways, Inc.
Address: 702 Electronic Drive
Horsham PA 19044

Date Designated: 2/14/1994
Market Approval Date: Not currently Approved

Generic Name: **Factor XIII concentrate (human) pasteurized** — Trade Name: Fibrogammin P

Designated Indication: *Treatment of congenital factor XIII deficiency.*

Sponsor: Aventis Behring L.L.C.
Address: 1020 First Ave.
PO Box 61501
King of Prussia PA 19406-0901

Date Designated: 1/16/1985
Market Approval Date: Not currently Approved

Generic Name: **Fampridine** — Trade Name: Neurelan

Designated Indication: *Treatment of chronic, incomplete spinal cord injury.*

Sponsor: Acorda Therapeutics, Inc.
Address: 15 Skyline Dr.
Hawthorne NY 10532

Date Designated: 6/2/1997
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Fampridine** Trade Name: Neurelan

Designated Indication: *Relief of symptoms of multiple sclerosis.*

Sponsor: Acorda Therapeutics
Address: 15 Skyline Dr.
Hawthorne NY 10532

Date Designated: 6/2/1987
Market Approval Date: Not currently Approved

Generic Name: **Felbamate** Trade Name: Felbatol

Designated Indication: *Treatment of Lennox-Gastaut syndrome.*

Sponsor: Wallace Laboratories
Address: 301B College Road East
Princeton NJ 08540

Date Designated: 1/24/1989
Market Approval Date: 7/29/1993

Generic Name: **FIAU** Trade Name: NONE ASSIGNED

Designated Indication: *Adjunctive treatment of chronic active hepatitis B.*

Sponsor: Oclassen Pharmaceuticals, Inc.
Address: 100 Pelican Way
San Rafael CA 94901

Date Designated: 7/24/1992
Market Approval Date: Not currently Approved

Generic Name: **Fibrinogen (human)** Trade Name: NONE ASSIGNED

Designated Indication: *For the control of bleeding and prophylactic treatment of patients deficient in fibrinogen.*

Sponsor: Alpha Therapeutic Corporation
Address: 5555 Valley Boulevard
Los Angeles CA 90032

Date Designated: 8/23/1995
Market Approval Date: Not currently Approved

Generic Name: **Fibronectin (human plasma derived)** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of non-healing corneal ulcers or epithelial defects which have been unresponsive to conventional therapy and the underlying cause has been eliminated.*

Sponsor: Melville Biologics, Inc.
Address: 310 East 67th Street
New York NY 10021

Date Designated: 9/5/1988
Market Approval Date: Not currently Approved

Generic Name: **Filgrastim** Trade Name: Neupogen

Designated Indication: *Treatment of neutropenia associated with bone marrow transplants.*

Sponsor: Amgen, Inc.
Address: 1840 Dehavilland Drive
Thousand Oaks CA 91320

Date Designated: 10/1/1990
Market Approval Date: 6/15/1994

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name:	**Filgrastim**	Trade Name:	Neupogen
Designated Indication:	*Reduction in the duration of neutropenia, fever, antibiotic use, and hospitalization, following induction and consolidation treatment for acute myeloid leukemia.*		
Sponsor:	Amgen, Inc.	Date Designated:	11/7/1996
Address:	One Amgen Center Dr. Thousand Oaks CA 91320-1799	Market Approval Date:	4/2/1998

Generic Name:	**Filgrastim**	Trade Name:	Neupogen
Designated Indication:	*Treatment of patients with AIDS who, in addition, are afflicted with cytomegalovirus retinitis and are being treated with ganciclovir.*		
Sponsor:	Amgen, Inc.	Date Designated:	9/3/1991
Address:	One Amgen Center Dr. Thousand Oaks CA 91320-1799	Market Approval Date:	Not currently Approved

Generic Name:	**Filgrastim**	Trade Name:	Neupogen
Designated Indication:	*For use in the mobilization of peripheral blood progenitor cells for collection in patients who will receive myeloablative or myelosuppressive chemotherapy.*		
Sponsor:	Amgen, Inc.	Date Designated:	7/17/1995
Address:	1840 Dehavilland Drive Thousand Oaks CA 91320	Market Approval Date:	12/28/1995

Generic Name:	**Filgrastim**	Trade Name:	Neupogen
Designated Indication:	*Treatment of patients with severe chronic neutropenia (absolute neutrophil count less than 500/mm3).*		
Sponsor:	Amgen, Inc.	Date Designated:	11/7/1990
Address:	1840 Dehavilland Drive Thousand Oaks CA 91320	Market Approval Date:	12/19/1994

Generic Name:	**Flucinolone**	Trade Name:	NONE ASSIGNED
Designated Indication:	*Treatment uveitis involving the posterior segment of the eye.*		
Sponsor:	Bausch & Lomb Pharmaceuticals, Inc.	Date Designated:	7/31/2000
Address:	8500 Hidden River Parkway Tampa FL 33637	Market Approval Date:	Not currently Approved

Generic Name:	**Fludarabine phosphate**	Trade Name:	Fludara
Designated Indication:	*Treatment of chronic lymphocytic leukemia (CLL), including refractory CLL.*		
Sponsor:	Berlex Laboratories, Inc.	Date Designated:	4/18/1989
Address:	15049 San Pablo Avenue, P.O. Box 4099 Richmond CA 94804	Market Approval Date:	4/18/1991

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Fludarabine phosphate** Trade Name: Fludara

Designated Indication: *Treatment and management of patients with non-Hodgkins lymphoma.*

Sponsor: Berlex Laboratories, Inc.
Address: 15049 San Pablo Avenue
P.O. Box 4099
Richmond CA 94804-0099

Date Designated: 4/18/1989
Market Approval Date: Not currently Approved

Generic Name: **Flunarizine** Trade Name: Sibelium

Designated Indication: *Treatment of alternating hemiplegia.*

Sponsor: Janssen Research Foundation
Address:
P.O. Box 200
Titusville NJ 08560

Date Designated: 1/6/1986
Market Approval Date: Not currently Approved

Generic Name: **Fluorouracil** Trade Name: NONE ASSIGNED

Designated Indication: *For use in combination with interferon alpha-2a, recombinant, for the treatment of esophageal carcinoma.*

Sponsor: Hoffmann-La Roche, Inc.
Address: 340 Kingsland Street
Nutley NJ 07110-1199

Date Designated: 10/27/1989
Market Approval Date: Not currently Approved

Generic Name: **Fluorouracil** Trade Name: NONE ASSIGNED

Designated Indication: *For use in combination with interferon alpha-2a, recombinant, for the treatment of advanced colorectal carcinoma.*

Sponsor: Hoffmann-La Roche, Inc.
Address: 340 Kingsland Street
Nutley NJ 07110-1199

Date Designated: 4/18/1990
Market Approval Date: Not currently Approved

Generic Name: **Fluorouracil** Trade Name: Adrucil

Designated Indication: *For use in combination with leucovorin for therapy of metastatic adenocarcinoma of the colon and rectum.*

Sponsor: Lederle Laboratories
Address: Division of American Cyanamid Company
401 N. Middletown Road
Pearl River NY 10965

Date Designated: 2/6/1989
Market Approval Date: Not currently Approved

Generic Name: **Fluorouracil** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of glioblastoma multiforme.*

Sponsor: Ethypharm SA
Address: 194 Bureaux de la Colline - Batiment D
92213 Saint-Cloud Cedex
France FR

Date Designated: 6/29/2000
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Fluoxetine** | Trade Name: Prozac

Designated Indication: *Treatment of autism.*

Sponsor: Hollander, MD, Eric
Address: Mt. Sinai School of Medicine, Dept. of
Box 1230, One Gustave L. Levy Place
New York NY 10029-6574

Date Designated: 4/30/1999
Market Approval Date: Not currently Approved

Generic Name: **Follitropin alfa, recombinant** | Trade Name: Gonal-F

Designated Indication: *For the initiation and re-initiation of spermatogenesis in adult males with reproductive failure due to hypothalamic or pituitary dysfunction, hypogonadotropic hypogonadism. AMENDED indication 6/27/00: For the induction of spermatogenesis in men with primary and secondary hypogonadotropic hypogonadism in whom the cause of infertility is not due to primary testicular failure.*

Sponsor: Serono Laboratories, Inc.
Address: 100 Longwater Circle
Norwell MA 02061

Date Designated: 12/21/1998
Market Approval Date: 5/24/2000

Generic Name: **Fomepizole** | Trade Name: Antizole

Designated Indication: *Treatment of methanol or ethylene glycol poisoning.*

Sponsor: Orphan Medical, Inc.
Address: 13911 Ridgedale Drive
Suite 250
Minnetonka MN 55305

Date Designated: 12/22/1988
Market Approval Date: 12/4/1997

Generic Name: **Fomepizole** | Trade Name: Antizole

Designated Indication: *Treatment of methanol or ethylene glycol poisoning.*

Sponsor: Orphan Medical, Inc.
Address: 13911 Ridgedale Drive
Suite 250
Minnetonka MN 55305

Date Designated: 12/22/1988
Market Approval Date: 12/8/2000

Generic Name: **Fosphenytoin** | Trade Name: Cerebyx

Designated Indication: *For the acute treatment of patients with status epilepticus of the grand mal type.*

Sponsor: Warner-Lambert Company
Address: 2800 Plymouth Road
Ann Arbor MI 48106

Date Designated: 6/4/1991
Market Approval Date: 8/5/1996

Generic Name: **Fructose-1,6-diphosphate** | Trade Name: Cordox

Designated Indication: *Treatment of painful vaso-occlusive episodes associated with sickle cell disease.*

Sponsor: Questcor Pharmaceuticals, Inc.
Address: 3260 Whipple Road
Union City CA 94587-1217

Date Designated: 5/29/1998
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Gabapentin** Trade Name: Neurontin

Designated Indication: *Treatment of amyotrophic lateral sclerosis.*

Sponsor: Warner-Lambert Company
Address: Parke-Davis Pharmaceutical Research
2800 Plymouth Road
Ann Arbor MI 48105

Date Designated: 7/5/1995
Market Approval Date: Not currently Approved

Generic Name: **Gallium nitrate injection** Trade Name: Ganite

Designated Indication: *Treatment of hypercalcemia of malignancy.*

Sponsor: Solopak Pharmaceutical Co.
Address: 1845 Tonne Road
Elk Grove Village IL 60007

Date Designated: 12/5/1988
Market Approval Date: 1/17/1991

Generic Name: **Gamma hydroxybutyrate** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of narcolepsy and the auxiliary symptoms of cataplexy, sleep paralysis, hypnagogic hallucinations and automatic behavior.*

Sponsor: Biocraft Laboratories, Inc.
Address: 18-01 River Road
Fair Lawn NJ 07410

Date Designated: 12/3/1987
Market Approval Date: Not currently Approved

Generic Name: **Gammalinolenic acid** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of juvenile rheumatoid arthritis.*

Sponsor: Zurier, Robert B. M.D.
Address: University of Massachusetts Medical Center
55 Lake Avenue
Worcester MA 01655

Date Designated: 7/27/1994
Market Approval Date: Not currently Approved

Generic Name: **Ganaxolone** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of infantile spasms.*

Sponsor: Purdue Pharma L.P.
Address: 100 Connecticut Ave.
Norwalk CT 06850-3590

Date Designated: 5/25/1994
Market Approval Date: Not currently Approved

Generic Name: **Ganciclovir intravitreal implant** Trade Name: Vitrasert Implant

Designated Indication: *Treatment of cytomegalovirus retinitis.*

Sponsor: Bausch & Lomb Surgical; Chiron Vision
Address: 9342 Jeronimo Road
Irvine CA 92718-1903

Date Designated: 6/7/1995
Market Approval Date: 3/4/1996

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Ganciclovir sodium** Trade Name: Cytovene

Designated Indication: *Treatment of cytomegalovirus retinitis in immunocompromised patients with AIDS.*

Sponsor: Syntex (USA), Inc.
Address: 3401 Hillview Avenue
Palo Alto CA 94304

Date Designated: 10/31/1985
Market Approval Date: 6/23/1989

Generic Name: **Gavilimomab** Trade Name: NONE ASSIGNED

Designated Indication: *Acute graft-versus-host disease (aGVHD)*

Sponsor: Abgenix, Inc.
Address: 7601 Dumbarton Circle
Fremont CA 94555

Date Designated: 11/20/2000
Market Approval Date: Not currently Approved

Generic Name: **Gemtuzumab zogamicin** Trade Name: Mylotarg

Designated Indication: *Treatment of CD33-positive acute myeloid leukemia.*

Sponsor: Wyeth-Ayerst Laboratories
Address: PO Box 8299
Philadelphia PA 19101-8299

Date Designated: 11/24/1999
Market Approval Date: 5/17/2000

Generic Name: **Gene plasmid hVEGF165 driven by human cytomegalovirus, and [2,3-bis(oleoyl)propyl]trimethyl ammonium and dioleoyl phosphatidyl ethanolamine** Trade Name: Trinam

Designated Indication: *Prevention of complications due to neointimal hyperplasia disease in certain vascular anastomoses.*

Sponsor: Ark Therapeutics Ltd.
Address: 6 Warren Mews
London W1P 5DJ UK

Date Designated: 10/24/2000
Market Approval Date: Not currently Approved

Generic Name: **Gentamicin impregnated PMMA beads on surgical wire** Trade Name: Septopal

Designated Indication: *Treatment of chronic osteomyelitis of post-traumatic, postoperative, or hematogenous origin.*

Sponsor: Lipha Pharmaceuticals, Inc.
Address: 9 West 57th Street
Suite 3825
New York NY 10019-2701

Date Designated: 1/31/1991
Market Approval Date: Not currently Approved

Generic Name: **Gentamicin liposome injection** Trade Name: Maitec

Designated Indication: *Treatment of disseminated Mycobacterium avium-intracellulare infection.*

Sponsor: Liposome Company, Inc.
Address: One Research Way
Princeton NJ 08540

Date Designated: 7/10/1990
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Glatiramer acetate** | Trade Name: Copaxone

Designated Indication: *Treatment of multiple sclerosis.*

Sponsor: Teva Pharmaceuticals USA
Address: 1510 Delp Drive
Kulpsville PA 19443

Date Designated: 11/9/1987
Market Approval Date: 12/20/1996

Generic Name: **Glatiramer acetate for injection** | Trade Name: Copaxone

Designated Indication: *Treatment of primary-progressive multiple sclerosis*

Sponsor: TEVA Pharmaceuticals, USA
Address: 1090 Horsham Road
North Wales PA 19454

Date Designated: 6/5/2001
Market Approval Date: Not currently Approved

Generic Name: **Glutamine** | Trade Name: NONE ASSIGNED

Designated Indication: *For use with human growth hormone in the treatment of short bowel syndrome (nutrient malabsorption from the gastrointestinal tract resulting from an inadequate absorptive surface).*

Sponsor: Nutritional Restart Pharmaceutical, L.P.
Address: 4364 South Alston Avenue
Durham NC 27713

Date Designated: 3/6/1995
Market Approval Date: Not currently Approved

Generic Name: **Glyceryl trioleate and glyceryl trierucate** | Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of adrenoleukodystrophy.*

Sponsor: Moser, Hugo W. M.D.
Address: Johns Hopkins University
Kennedy Krieger Institute, 707 North
Baltimore MD 21205

Date Designated: 2/14/1995
Market Approval Date: Not currently Approved

Generic Name: **Gonadorelin acetate** | Trade Name: Lutrepulse

Designated Indication: *For induction of ovulation in women with hypothalamic amenorrhea due to a deficiency or absence in the quantity or pulse pattern of endogenous GnRH secretion.*

Sponsor: Ferring Laboratories, Inc.
Address: 400 Rella Boulevard, Suite 201
Suffern NY 10901

Date Designated: 4/22/1987
Market Approval Date: 10/10/1989

Generic Name: **Gossypol** | Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of cancer of the adrenal cortex.*

Sponsor: Reidenberg, Marcus M. M.D.
Address: The New York Hospital - Cornell Medical
525 East 68th Street, Box 70
New York NY 10021

Date Designated: 10/22/1990
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Gp100 adenoviral gene therapy** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of metastatic melanoma.*

Sponsor: Genzyme Corporation
Address: One Mountain Rd.
P.O. Box 9322
Framingham MA 01701-9322

Date Designated: 3/25/1997
Market Approval Date: Not currently Approved

Generic Name: **Growth hormone releasing factor** Trade Name: NONE ASSIGNED

Designated Indication: *For the long-term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion.*

Sponsor: ICN Pharmaceuticals, Inc.
Address: ICN Plaza
3300 Hyland Avenue
Costa Mesa CA 92626

Date Designated: 8/7/1989
Market Approval Date: Not currently Approved

Generic Name: **Guanfacine** Trade Name: Tenex

Designated Indication: *Treatment of fragile X syndrome.*

Sponsor: Watson Laboratories, Inc.
Address: 311 Bonnie Circle
PO Box 1900
Corona CA 91718-1900

Date Designated: 8/5/1999
Market Approval Date: Not currently Approved

Generic Name: **h5G1.1-mAb** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of dermatomyositis*

Sponsor: Alexion Pharmaceuticals, Inc.
Address: 352 Knotter Drive
Cheshire CT 06410

Date Designated: 9/21/2000
Market Approval Date: Not currently Approved

Generic Name: **h5G1.1mAb** Trade Name: NONE ASSIGNED

Designated Indication: *Idiopathic membranous glomerular nephropathy*

Sponsor: Alexion Pharmaceuticals, Inc.
Address: 352 Knotter Drive
Cheshire CT 06410

Date Designated: 3/5/2001
Market Approval Date: Not currently Approved

Generic Name: **Halofantrine** Trade Name: Halfan

Designated Indication: *Treatment of mild to moderate acute malaria caused by susceptible strains of P. falciparum and P. vivax.*

Sponsor: SmithKline Beecham Pharmaceuticals
Address: One Franklin Plaza
P.O. Box 7929
Philadelphia PA 19101

Date Designated: 11/4/1991
Market Approval Date: 7/24/1992

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Halofuginone** | Trade Name: Stenorol

Designated Indication: *Treatment of systemic sclerosis.*

Sponsor: Collgard Biopharmaceuticals Ltd.
Address: Textile House, 2 Koifman St.
Tel-Aviv 68012
Israel IL

Date Designated: 2/7/2000
Market Approval Date: Not currently Approved

Generic Name: **Heme arginate** | Trade Name: Normosang

Designated Indication: *Treatment of symptomatic stage of acute porphyria.*

Sponsor: Berlex Laboratories, Inc.
Address: 15049 San Pablo Avenue
Richmond CA 94804-0099

Date Designated: 3/10/1988
Market Approval Date: Not currently Approved

Generic Name: **Heme arginate** | Trade Name: Normosang

Designated Indication: *Treatment of myelodysplastic syndromes.*

Sponsor: Berlex Laboratories, Inc.
Address: 15049 San Pablo Avenue
Richmond CA 94804-0099

Date Designated: 3/1/1994
Market Approval Date: Not currently Approved

Generic Name: **Hemin** | Trade Name: Panhematin

Designated Indication: *Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria.*

Sponsor: Abbott Laboratories
Address: Diagnostics Division
Abbott Park IL 60064

Date Designated: 3/16/1984
Market Approval Date: 7/20/1983

Generic Name: **Hemin and zinc mesoporphyrin** | Trade Name: Hemex

Designated Indication: *Treatment of acute porphyric syndromes.*

Sponsor: Bonkovsky, Herbert L. M.D.
Address: University Of Massachusetts Medical Center
55 Lake Avenue North
Worcester MA 01655

Date Designated: 12/20/1993
Market Approval Date: Not currently Approved

Generic Name: **Hepatitis B immune globulin intravenous (human)** | Trade Name: Nabi-HB

Designated Indication: *Prophylaxis against hepatitis B virus reinfection in liver transplant patients.*

Sponsor: NABI
Address: 12280 Wilkins Avenue
Rockville MD 20852

Date Designated: 3/8/1995
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Herpes simplex virus gene** | Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of primary and metastatic brain tumors.*

Sponsor: Genetic Therapy, Inc.
Address: 938 Clopper Road
Gaithersburg MD 20878

Date Designated: 10/16/1992
Market Approval Date: Not currently Approved

Generic Name: **Histamine** | Trade Name: Maxamine

Designated Indication: *For use as an adjunct to cytokine therapy in the treatment of malignant melanoma.*

Sponsor: Maxim Pharmaceuticals, Inc.
Address: 8899 University Center Lane
Suite 400
San Diego CA 92122

Date Designated: 2/1/2000
Market Approval Date: Not currently Approved

Generic Name: **Histamine** | Trade Name: Maxamine

Designated Indication: *Adjunct to cytokine therapy in the treatment of acute myeloid leukemia.*

Sponsor: Maxim Pharmaceuticals, Inc.
Address: 8899 University Center Lane
Suite 400
San Diego CA 92122

Date Designated: 12/15/1999
Market Approval Date: Not currently Approved

Generic Name: **Histrelin** | Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of acute intermittent porphyria, hereditary coproporphyria, and variegate porphyria.*

Sponsor: Anderson, Karl E., M.D.
Address: University of Texas Medical Branch at
Route J-09, 700 The Strand
Galveston TX 77550

Date Designated: 5/3/1991
Market Approval Date: Not currently Approved

Generic Name: **Histrelin acetate** | Trade Name: Supprelin Injection

Designated Indication: *Treatment of central precocious puberty.*

Sponsor: Roberts Pharmaceutical Corp.
Address: Meridian Center III
6 Industrial Way West
Eatontown NJ 07724

Date Designated: 8/10/1988
Market Approval Date: 12/24/1991

Generic Name: **HLA-B7/Beta2M DNA Lipid (DMRIE/DOPE) Complex** | Trade Name: Allovectin-7

Designated Indication: *Treatment of invasive and metastatic melanoma (Stages II, III, and IV).*

Sponsor: Vical Incorporated
Address: 9373 Towne Centre Dr., Suite 100
San Diego CA 92121

Date Designated: 9/30/1999
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Hsp E7** — Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of recurrent respiratory papillomatosis (RRP)*

Sponsor: StressGen Biotechnologies, Inc.
Address: 409 2nd Avenue, Suite 201, Collegeville PA 19426-2655

Date Designated: 3/19/2001
Market Approval Date: Not currently Approved

Generic Name: **Hu1D10, humanized monoclonal antibody** — Trade Name: Remitogen

Designated Indication: *For use in the treatment of 1D10+ B cell non-Hodgkin's lymphoma*

Sponsor: Protein Design Labs, Inc.
Address: 34801 Campus Drive, Fremont CA 94555

Date Designated: 11/28/2001
Market Approval Date: Not currently Approved

Generic Name: **Human acid precursor alpha-glucosidase, recombinant** — Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of glycogen storage disease type II.*

Sponsor: Pharming/Genzyme LLC
Address: c/o Genzyme Corporation, 1 Mountain Rd., Framingham MA 01701-9322

Date Designated: 9/10/1996
Market Approval Date: Not currently Approved

Generic Name: **human anti-transforming growth factor beta 1 monoclonal antibody** — Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of systemic sclerosis*

Sponsor: Genzyme Corporation
Address: One Kendall Square, Cambridge MA 02139

Date Designated: 1/11/2002
Market Approval Date: Not currently Approved

Generic Name: **human gammaglobulin** — Trade Name: NONE ASSIGNED

Designated Indication: *Treatment for juvenile rheumatoid arthritis*

Sponsor: Protein Therapeutics, Inc
Address: 9040 S. Rita Rd., Suite 1100, Tucson AZ 84747

Date Designated: 5/25/2001
Market Approval Date: Not currently Approved

Generic Name: **Human T-lymphotropic virus type III Gp160 antigens** — Trade Name: Vaxsyn HIV-1

Designated Indication: *Treatment of AIDS.*

Sponsor: MicroGeneSys, Inc.
Address: 1000 Research Parkway, Meriden CT 06450

Date Designated: 11/20/1989
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Humanized anti-CD2 monoclonal antibody** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of graft-versus-host disease.*

Sponsor: MedImmune, Inc.
Address: 35 West Watkins Mill Rd.
Gaithersburg MD 20878

Date Designated: 11/13/1998
Market Approval Date: Not currently Approved

Generic Name: **Humanized anti-human CD2 MAb** Trade Name: MEDI-507

Designated Indication: *For the induction of donor-specific immunologic unresponsiveness resulting in prophylaxis of organ rejection without the need for chronic immunosuppressive therapy, in patients receiving allogeneic renal transplants.*

Sponsor: Biotransplant, Inc.
Address: Building 75, 3rd. Ave.
Charlestown Navy Yard
Charlestown MA 02129

Date Designated: 9/17/1998
Market Approval Date: Not currently Approved

Generic Name: **Humanized anti-tac** Trade Name: Zenapax

Designated Indication: *Prevention of acute graft-vs-host disease following bone marrow transplantation.*

Sponsor: Hoffmann-La Roche, Inc.
Address: 340 Kingsland Street
Nutley NJ 07110-1199

Date Designated: 3/5/1993
Market Approval Date: Not currently Approved

Generic Name: **Humanized MAb (IDEC-131) to CD40L** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of systemic lupus erythematosus.*

Sponsor: Idec Pharmaceuticals Corporation
Address: 3030 Callan Rd.
San Diego CA 92121

Date Designated: 2/9/1999
Market Approval Date: Not currently Approved

Generic Name: **humanized monoclonal antibody against Shiga-like toxin II** Trade Name: NONE ASSIGNED

Designated Indication: *To prevent the development of or to decrease the incidence and severity of hemolytic uremic syndrome and associated sequelae of Shiga-like toxin-producing E. coli.*

Sponsor: Teijin America, Inc.
Address: 600 Alexander Park
Suite 304
Princeton NJ 08540

Date Designated: 9/12/2001
Market Approval Date: Not currently Approved

Generic Name: **Hydroxocobalamin** Trade Name: CYANOKIT

Designated Indication: *Treatment of acute cyanide poisoning*

Sponsor: Orphan Medical, Inc.
Address: 13911 Ridgedale Drive
Suite 250
Minnetonka MN 55305

Date Designated: 9/22/2000
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Hydroxyurea** | Trade Name: Droxia

Designated Indication: *Treatment of patients with sickle cell anemia as shown by the presence of hemoglobin S.*

Sponsor: Bristol-Myers Squibb Pharmaceutical
Address: P.O. Box 4000
Princeton NJ 08543

Date Designated: 10/1/1990
Market Approval Date: 2/25/1998

Generic Name: **Hypericin** | Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of glioblastoma multiforme.*

Sponsor: Nexell Therapeutics
Address: 2751 Centerville Rd., Suite 210
Wilmington DE 19808

Date Designated: 8/3/2000
Market Approval Date: Not currently Approved

Generic Name: **Hypericin** | Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of cutaneous T-cell lymphoma.*

Sponsor: Nexell Therapeutics, Inc.
Address: 2751 Centerville Rd., Suite 210
Wilmington DE 19808

Date Designated: 2/7/2000
Market Approval Date: Not currently Approved

Generic Name: **Ibuprofen i.v. solution** | Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of patent ductus arteriosus.*

Sponsor: Farmacon-IL-LLC
Address: 1720 Post Road East
Suite 213
Westport CT 06880-5643

Date Designated: 10/29/1996
Market Approval Date: Not currently Approved

Generic Name: **Ibuprofen i.v. solution** | Trade Name: Salprofen

Designated Indication: *Prevention of patent ductus arteriosus.*

Sponsor: Farmacon-IL, LLC
Address: 1720 Post Road East
Suite 213
Westport CT 06880-5643

Date Designated: 10/29/1996
Market Approval Date: Not currently Approved

Generic Peritoneal Name: **Icodextrin 7.5% with Electrolytes Peritoneal Dialysis Solution** | Trade Name: Extraneal (with 7.5% Icodextrin) Dialysis Solutio

Designated Indication: *Treatment of those patients having end stage renal disease and requiring peritoneal dialysis treatment.*

Sponsor: Baxter Healthcare Corporation
Address: Renal Division
1620 Waukegan Road
McGaw Park IL 60085

Date Designated: 7/18/1997
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Idarubicin HCl for injection**
Trade Name: Idamycin

Designated Indication: *Treatment of acute myelogenous leukemia, also referred to as acute nonlymphocytic leukemia.*

Sponsor: Adria Laboratories, Inc.
Address: P.O. Box 16529
Columbus OH 43216

Date Designated: 7/25/1988
Market Approval Date: 9/27/1990

Generic Name: **Idarubicin HCl for injection**
Trade Name: Idamycin

Designated Indication: *Treatment of acute lymphoblastic leukemia in pediatric patients.*

Sponsor: Pharmacia & Upjohn
Address: 7000 Portage Road
Unit 0633-298-113
Kalamazoo MI 49001-0199

Date Designated: 2/12/1991
Market Approval Date: Not currently Approved

Generic Name: **Idoxuridine**
Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of nonparenchymatous sarcomas.*

Sponsor: NeoPharm, Inc.
Address: 225 East Deerpath, Suite 250
Lake Forest IL 60045

Date Designated: 4/8/1996
Market Approval Date: Not currently Approved

Generic Name: **iduronate-2-sulfatase**
Trade Name: NONE ASSIGNED

Designated Indication: *Long term enzyme replacement therapy for patients with MPS II (Hunter Syndrome)*

Sponsor: Transkaryotic Therapies Inc.
Address: 195 Albany Street
Cambridge MA 02139

Date Designated: 11/28/2001
Market Approval Date: Not currently Approved

Generic Name: **Ifosfamide**
Trade Name: Ifex

Designated Indication: *Treatment of testicular cancer.*

Sponsor: Bristol-Myers Squibb Pharmaceutical
Address: 5 Research Parkway, P.O. Box 5100
Wallingford CT 06492

Date Designated: 1/20/1987
Market Approval Date: 12/30/1988

Generic Name: **Ifosfamide**
Trade Name: Ifex

Designated Indication: *Treatment of soft tissue sarcomas.*

Sponsor: Bristol-Myers Squibb Pharmaceutical
Address: P.O. Box 4000
Princeton NJ 08543

Date Designated: 8/7/1985
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Ifosfamide** Trade Name: Ifex

Designated Indication: *Treatment of bone sarcomas.*

Sponsor: Bristol-Myers Squibb Pharmaceutical
Address: P.O. Box 4000
Princeton NJ 08543-4000

Date Designated: 8/7/1985
Market Approval Date: Not currently Approved

Generic Name: **IL-4 Pseudomonas Toxin Fusion Protein (IL-4(38-37)-PE38KDEL)** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of astrocytic glioma.*

Sponsor: Neurocrine Biosciences, Inc.
Address: 10555 Science Center Dr.
San Diego CA 92121

Date Designated: 4/6/2000
Market Approval Date: Not currently Approved

Generic Name: **IL13-PE38QQR** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of malignant glioma*

Sponsor: NeoPharm, Inc.
Address: 150 Field Drive
Suite 195
Lake Forest IL 60045

Date Designated: 11/2/2001
Market Approval Date: Not currently Approved

Generic Name: **Imatinib** Trade Name: Gleevec

Designated Indication: *Treatment of chronic myelogenous leukemia*

Sponsor: Novartis Pharmaceuticals Corporation
Address: 59 Route 10
East Hanover NJ 07936-1080

Date Designated: 1/31/2001
Market Approval Date: 5/10/2001

Generic Name: **imatinib mesylate** Trade Name: Gleevec

Designated Indication: *Treatment of gastrointestinal stromal tumors*

Sponsor: Novartis Pharmaceuticals Corp.
Address: One Health Plaza
East Hanover NJ 07936-1080

Date Designated: 11/1/2001
Market Approval Date: Not currently Approved

Generic Name: **Imciromab pentetate** Trade Name: Myoscint

Designated Indication: *Detecting early necrosis as an indication of rejection of orthotopic cardiac transplants.*

Sponsor: Centocor, Inc.
Address: 244 Great Valley Parkway
Malvern PA 19355

Date Designated: 1/25/1989
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Imexon** | Trade Name: n/a

Designated Indication: *Treatment of metastatic malignant melanoma*

Sponsor: AmpliMed Corporation
Address: 2321 Camino La Zorrela
Tucson AZ 85718

Date Designated: 8/3/2001
Market Approval Date: Not currently Approved

Generic Name: **Imexon** | Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of multiple myeloma.*

Sponsor: AmpliMed Corporation
Address: 2321 Camino La Zorrela
Tucson AZ 85718

Date Designated: 11/8/1996
Market Approval Date: Not currently Approved

Generic Name: **Imiglucerase** | Trade Name: Cerezyme

Designated Indication: *Replacement therapy in patients with types I, II, and III Gaucher's disease.*

Sponsor: Genzyme Corporation
Address: One Kendall Square
Cambridge MA 02139-1562

Date Designated: 11/5/1991
Market Approval Date: 5/23/1994

Generic Name: **Immune globulin intravenous, human** | Trade Name: Gamimune N

Designated Indication: *Infection prophylaxis in pediatric patients affected with the human immunodeficiency virus.*

Sponsor: Bayer Corporation
Address: Pharmaceutical Division, Biological Products
400 Morgan Lane
New Haven CT 06516

Date Designated: 2/18/1993
Market Approval Date: 12/27/1993

Generic Name: **Imported fire ant venom, allergenic extract** | Trade Name: NONE ASSIGNED

Designated Indication: *For skin testing of victims of fire ant stings to confirm fire ant sensitivity and if positive, for use as immunotherapy for the prevention of IgE-mediated anaphylactic reactions.*

Sponsor: ALK Laboratories, Inc.
Address: Research Center
27 Village Lane
Wallingford CT 06492

Date Designated: 5/12/1992
Market Approval Date: Not currently Approved

Generic Name: **Indium In 111 murine monoclonal antibody FAB to myosin** | Trade Name: Myoscint

Designated Indication: *To aid in the diagnosis of myocarditis.*

Sponsor: Centocor, Inc.
Address: 244 Great Valley Parkway
Malvern PA 19355

Date Designated: 8/7/1989
Market Approval Date: Not currently Approved

Generic Name: **Indium-In-111 murine MAb(2B8-MX-DTPA) &** | Trade Name: Melimmune

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Name: **Yttrium-Y90 murine MAb(2B8-MX-DTPA)** Name:

Designated Indication: *Treatment of B-cell non-Hodgkin's lymphoma.*

Sponsor: IDEC Pharmaceuticals Corporation
Address: 3030 Callan Road
San Diego CA 92121

Date Designated: 9/6/1994
Market Approval Date: Not currently Approved

Generic Name: **Infliximab** Trade Name: Remicade

Designated Indication: *Treatment of moderately to severely active Crohn's disease for the reduction of the signs and symptoms, in patients who have an inadequate response to conventional therapy; and treatment of patients with fistulizing Crohn's disease for the reduction in the number of draining enterocutaneous fistula(s).*

Sponsor: Centocor, Inc.
Address: 200 Great Valley Parkway
Malvern PA 19355-1307

Date Designated: 11/14/1995
Market Approval Date: 8/24/1998

Generic Name: **INH-A00021** Trade Name: NONE ASSIGNED

Designated Indication: *Reduction (prevention) of nosocomial bacteremia caused by staphylococci in very low birth weight infants.*

Sponsor: Inhibitex, Inc.
Address: 8995 Westside Parkway
Suite 150
Alpharetta GA 30004

Date Designated: 6/13/2001
Market Approval Date: Not currently Approved

Generic Name: **Inosine pranobex** Trade Name: Isoprinosine

Designated Indication: *Treatment of subacute sclerosing panencephalitis.*

Sponsor: Newport Pharmaceuticals
Address: 897 West Sixteenth Street
Newport Beach CA 92663

Date Designated: 9/20/1988
Market Approval Date: Not currently Approved

Generic Name: **Interferon alfa-2a** Trade Name: Roferon A

Designated Indication: *Treatment of chronic myelogenous leukemia.*

Sponsor: Hoffmann-La Roche, Inc.
Address: 340 Kingsland Street
Nutley NJ 07110

Date Designated: 6/6/1989
Market Approval Date: 10/19/1995

Generic Name: **Interferon alfa-2a (recombinant)** Trade Name: Roferon-A

Designated Indication: *Treatment of AIDS related Kaposi's sarcoma.*

Sponsor: Hoffmann-La Roche, Inc.
Address: 340 Kingsland Street
Nutley NJ 07110

Date Designated: 12/14/1987
Market Approval Date: 11/21/1988

Generic **Interferon alfa-2a (recombinant)** Trade Roferon-A

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Name: Name:

Designated Indication: *Treatment of renal cell carcinoma.*

Sponsor: Hoffmann-La Roche, Inc.
Address: 340 Kingsland Street
Nutley NJ 07110-1199

Date Designated: 4/18/1988
Market Approval Date: Not currently Approved

Generic Name: **Interferon alfa-2a (recombinant)** Trade Name: Roferon-A

Designated Indication: *For use in combination with fluorouracil for the treatment of esophageal carcinoma.*

Sponsor: Hoffmann-La Roche, Inc.
Address: 340 Kingsland Street
Nutley NJ 07110-1199

Date Designated: 10/27/1989
Market Approval Date: Not currently Approved

Generic Name: **Interferon alfa-2a (recombinant)** Trade Name: Roferon-A

Designated Indication: *For the concomitant administration with fluorouracil for the treatment of advanced colorectal cancer.*

Sponsor: Hoffmann-La Roche, Inc.
Address: 340 Kingsland Street
Nutley NJ 07110-1199

Date Designated: 5/14/1990
Market Approval Date: Not currently Approved

Generic Name: **Interferon alfa-2a (recombinant)** Trade Name: Roferon-A

Designated Indication: *For the treatment of metastatic malignant melanoma in combination with Teceleukin.*

Sponsor: Hoffmann-La Roche, Inc.
Address: 340 Kingsland Street
Nutley NJ 07110

Date Designated: 5/11/1990
Market Approval Date: Not currently Approved

Generic Name: **Interferon alfa-2a (recombinant)** Trade Name: Roferon-A

Designated Indication: *For the concomitant administration with Teceleukin for the treatment of metastatic renal cell carcinoma.*

Sponsor: Hoffmann-La Roche, Inc.
Address: 340 Kingsland Street
Nutley NJ 07119

Date Designated: 5/2/1990
Market Approval Date: Not currently Approved

Generic Name: **Interferon alfa-2b (recombinant)** Trade Name: Intron A

Designated Indication: *Treatment of AIDS-related Kaposi's sarcoma.*

Sponsor: Schering Corporation
Address: 2000 Galloping Hill Road
Kenilworth NJ 07033

Date Designated: 6/24/1987
Market Approval Date: 11/21/1988

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Interferon beta (recombinant human)**
Trade Name: Avonex
Designated Indication: *Treatment of primary brain tumors.*
Sponsor: Biogen, Inc.
Address: 14 Cambridge Center, Cambridge MA 02142
Date Designated: 1/13/1993
Market Approval Date: Not currently Approved

Generic Name: **Interferon beta-1a**
Trade Name: Avonex
Designated Indication: *Treatment of multiple sclerosis.*
Sponsor: Biogen, Inc.
Address: 14 Cambridge Center, Cambridge MA 02142
Date Designated: 12/16/1991
Market Approval Date: 5/17/1996

Generic Name: **Interferon Beta-1a**
Trade Name: Avonex
Designated Indication: *Treatment of juvenile rheumatoid arthritis.*
Sponsor: Biogen, Inc.
Address: 14 Cambridge Center, Cambridge MA 02142
Date Designated: 10/14/1998
Market Approval Date: Not currently Approved

Generic Name: **Interferon beta-1a**
Trade Name: Rebif
Designated Indication: *Treatment of patients with secondary progressive multiple sclerosis.*
Sponsor: Serono Laboratories, Inc.
Address: 100 Longwater Circle, Norwell MA 02061
Date Designated: 3/11/1996
Market Approval Date: Not currently Approved

Generic Name: **Interferon beta-1a (recombinant human)**
Trade Name: Avonex
Designated Indication: *Treatment of pulmonary fibrosis.*
Sponsor: Biogen, Inc.
Address: 14 Cambridge Center, Cambridge MA 02142
Date Designated: 1/7/1999
Market Approval Date: Not currently Approved

Generic Name: **Interferon beta-1a (recombinant human)**
Trade Name: NONE ASSIGNED
Designated Indication: *Treatment of acute non-A, non-B hepatitis.*
Sponsor: Biogen, Inc.
Address: 14 Cambridge Center, Cambridge MA 02142
Date Designated: 7/24/1992
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Interferon beta-1a (recombinant)**
Trade Name: Rebif

Designated Indication: *Treatment of symptomatic patients with AIDS including all patients with CD4 T-cell counts less than 200 cells per mm3.*

Sponsor: Serono Laboratories, Inc.
Address: 100 Longwater Circle
Norwell MA 02061

Date Designated: 12/2/1992
Market Approval Date: Not currently Approved

Generic Name: **Interferon beta-1b**
Trade Name: Betaseron

Designated Indication: *Treatment of multiple sclerosis.*

Sponsor: Chiron Corp. & Berlex Laboratories
Address: 4560 Horton Street
Emeryville CA 94608

Date Designated: 11/17/1988
Market Approval Date: 7/23/1993

Generic Name: **Interferon gamma 1-b**
Trade Name: Actimmune

Designated Indication: *Treatment of chronic granulomatous disease.*

Sponsor: Genentech, Inc.
Address: 460 Point San Bruno Boulevard
South San Francisco CA 94080

Date Designated: 9/30/1988
Market Approval Date: 12/20/1990

Generic Name: **Interferon gamma-1b**
Trade Name: Actimmune

Designated Indication: *Delaying time to disease progression in patients with severe, malignant osteopetrosis.*

Sponsor: InterMune , Inc.
Address: 3280 Bayshore Boulevard
Brisbane CA 94005

Date Designated: 9/30/1996
Market Approval Date: 2/10/2000

Generic Name: **Interferon gamma-1b**
Trade Name: Actimmune

Designated Indication: *Treatment of renal cell carcinoma.*

Sponsor: Genentech, Inc.
Address: 1 DNA Way
South San Francisco CA 94080-4990

Date Designated: 12/4/1995
Market Approval Date: Not currently Approved

Generic Name: **Interferon-alfa-1b**
Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of multiple myeloma*

Sponsor: Ernest C.Borden
Address: Center for Cancer Drud Discovery and
9500 Euclid Avenue
Clevland OH 44195

Date Designated: 4/17/2001
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Interleukin-1 receptor antagonist, human recombinant** Trade Name: Antril

Designated Indication: *Treatment of juvenile rheumatoid arthritis.*

Sponsor: Amgen, Inc.
Address: One Amgen Center Drive
Thousand Oaks CA 91320-1799

Date Designated: 9/23/1991
Market Approval Date: Not currently Approved

Generic Name: **Interleukin-1 receptor antagonist, human recombinant** Trade Name: Antril

Designated Indication: *Prevention and treatment of graft versus host disease in transplant recipients.*

Sponsor: Amgen, Inc.
Address: One Amgen Center Drive
Thousand Oaks CA 91320-1799

Date Designated: 10/16/1992
Market Approval Date: Not currently Approved

Generic Name: **Interleukin-2** Trade Name: Teleleukin

Designated Indication: *Treatment of metastatic malignant melanoma.*

Sponsor: Hoffmann-La Roche, Inc.
Address: 340 Kingsland Street
Nutley NJ 07110

Date Designated: 2/6/1990
Market Approval Date: Not currently Approved

Generic Name: **Interleukin-2** Trade Name: Teceleukin

Designated Indication: *In combination with interferon alfa-2a for the treatment of metastatic renal cell carcinoma.*

Sponsor: Hoffmann-La Roche, Inc.
Address: 340 Kingsland Street
Nutley NJ 07110

Date Designated: 5/3/1990
Market Approval Date: Not currently Approved

Generic Name: **Interleukin-2** Trade Name: Teceleukin

Designated Indication: *Treatment of metastatic renal cell carcinoma.*

Sponsor: Hoffmann-La Roche, Inc.
Address: 340 Kingsland Street
Nutley NJ 07110

Date Designated: 2/5/1990
Market Approval Date: Not currently Approved

Generic Name: **Interleukin-2** Trade Name: Teceleukin

Designated Indication: *In combination with interferon alfa-2a for the treatment of metastatic malignant melanoma.*

Sponsor: Hoffmann-La Roche, Inc.
Address: 340 Kingsland Street
Nutley NJ 07110

Date Designated: 5/11/1990
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Intraoral fluoride releasing system** Trade Name: IFRS

Designated Indication: *Prevention of dental caries due to radiation-induced xerostomia in patients with head and neck cancer*

Sponsor: Digestive Care, Inc.
Address: 1120 Win Drive
Bethlehem PA 18017

Date Designated: 7/31/2001
Market Approval Date: Not currently Approved

Generic Name: **Iobenguane Sulfate I 131** Trade Name: NONE ASSIGNED

Designated Indication: *For use as a diagnostic adjunct in patients with pheochromocytoma.*

Sponsor: University of Michigan
Address: UH B1 H410/0028
1500 E. Medical Center Drive
Ann Arbor MI 48109-0028

Date Designated: 11/14/1984
Market Approval Date: 3/21/1990

Generic Name: **Iodine 131 6B-iodomethyl-19-norcholesterol** Trade Name: NONE ASSIGNED

Designated Indication: *For use in adrenal cortical imaging.*

Sponsor: David E. Kuhl, M.D.
Address: University of Michigan Medical Center/1500
B1G412 /0028 University Hospital
Ann Arbor MI 48109-0028

Date Designated: 8/1/1984
Market Approval Date: Not currently Approved

Generic Name: **Iodine I 123 murine monoclonal antibody to alpha-fetoprotein** Trade Name: NONE ASSIGNED

Designated Indication: *Detection of hepatocellular carcinoma and hepatoblastoma.*

Sponsor: Immunomedics, Inc.
Address: 300 American Road
Morris Plains NJ 07950

Date Designated: 9/30/1988
Market Approval Date: Not currently Approved

Generic Name: **Iodine I 123 murine monoclonal antibody to alpha-fetoprotein** Trade Name: NONE ASSIGNED

Designated Indication: *Detection of alpha-fetoprotein producing germ cell tumors.*

Sponsor: Immunomedics, Inc.
Address: 300 American Road
Morris Plains NJ 07950

Date Designated: 9/30/1988
Market Approval Date: Not currently Approved

Generic Name: **Iodine I 123 murine monoclonal antibody to hCG** Trade Name: NONE ASSIGNED

Designated Indication: *Detection of hCG producing tumors such as germ cell and trophoblastic cell tumors.*

Sponsor: Immunomedics, Inc.
Address: 300 American Road
Morris Plains NJ 07950

Date Designated: 11/7/1988
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Iodine I 131 bis(indium-diethylenetriaminepentaacetic acid)tyrosyllysine/hMN-14 x m734 F(ab')2 bispecific monoclonal antibody**
Trade Name: Pentacea
Designated Indication: *Treatment of small-cell lung cancer.*
Sponsor: IBC Pharmaceuticals, L.L.C.
Address: 300 American Rd. Morris Plains NJ 07950
Date Designated: 2/22/2000
Market Approval Date: Not currently Approved

Generic Name: **Iodine I 131 murine monoclonal antibody IgG2a to B cell**
Trade Name: Immurait, Ll-2-I-131
Designated Indication: *Treatment of B-cell leukemia and B-cell lymphoma.*
Sponsor: Immunomedics, Inc.
Address: 300 American Road Morris Plains NJ 07950
Date Designated: 9/18/1989
Market Approval Date: Not currently Approved

Generic Name: **Iodine I 131 murine monoclonal antibody to alpha-fetoprotein**
Trade Name: NONE ASSIGNED
Designated Indication: *Treatment of hepatocellular carcinoma and hepatoblastoma.*
Sponsor: Immunomedics, Inc.
Address: 300 American Road Morris Plains NJ 07950
Date Designated: 9/30/1988
Market Approval Date: Not currently Approved

Generic Name: **Iodine I 131 murine monoclonal antibody to alpha-fetoprotein**
Trade Name: NONE ASSIGNED
Designated Indication: *Treatment of alpha-fetoprotein producing germ cell tumors.*
Sponsor: Immunomedics, Inc.
Address: 300 American Road Morris Plains NJ 07950
Date Designated: 9/30/1988
Market Approval Date: Not currently Approved

Generic Name: **Iodine I 131 murine monoclonal antibody to hCG**
Trade Name: NONE ASSIGNED
Designated Indication: *Treatment of hCG producing tumors such as germ cell and trophoblastic cell tumors.*
Sponsor: Immunomedics, Inc.
Address: 300 American Road Morris Plains NJ 07950
Date Designated: 11/7/1988
Market Approval Date: Not currently Approved

Generic Name: **Iodine I-131 radiolabeled chimeric MAb tumor necrosis treatment (TNT-1B)**
Trade Name: 131IchTNT-1
Designated Indication: *Treatment of glioblastoma multiforme and anaplastic astrocytoma.*
Sponsor: Peregrine Pharmaceuticals, Inc.
Address: 14282 Franklin Ave. Tustin CA 92780-7017
Date Designated: 2/12/1999
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Isobutyramide** | Trade Name: Isobutyramide oral solution

Designated Indication: *Treatment of beta-hemoglobinopathies and beta-thalassemia syndromes.*

Sponsor: Perrine, Susan P., M.D.
Address: Boston University, Cancer Research Center, Boston MA 02118

Date Designated: 12/18/1992
Market Approval Date: Not currently Approved

Generic Name: **Isobutyramide** | Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of sickle cell disease and beta thalassemia.*

Sponsor: Alpha Therapeutic Corporation
Address: 5555 Valley Boulevard, Los Angeles CA 90032

Date Designated: 5/25/1994
Market Approval Date: Not currently Approved

Generic Name: **Japanese encephalitis vaccine (live, attenuated)** | Trade Name: NONE ASSIGNED

Designated Indication: *Prevention of Japanese encephalitis.*

Sponsor: Boran Pharmaceuticals
Address: 3F, Koryo Academytel, 437-3, Ahyun-Dong, Mapo-Gu, Seoul 121-010, South Korea KR

Date Designated: 5/19/1999
Market Approval Date: Not currently Approved

Generic Name: **L-2-oxothiazolidine-4-carboxylic acid** | Trade Name: Procysteine

Designated Indication: *Treatment of amyotrophic lateral sclerosis.*

Sponsor: Transcend Therapeutics, Inc.
Address: 640 Memorial Drive, 3rd Floor West, Cambridge MA 02139

Date Designated: 7/30/1996
Market Approval Date: Not currently Approved

Generic Name: **L-2-oxothiazolidine-4-carboxylic acid** | Trade Name: Procysteine

Designated Indication: *Treatment of adult respiratory distress syndrome.*

Sponsor: Transcend Therapeutics, Inc.
Address: 640 Memorial Drive, 3rd Floor West, Cambridge MA 02139

Date Designated: 6/14/1994
Market Approval Date: Not currently Approved

Generic Name: **L-5-hydroxytryptophan** | Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of tetrahydrobiopterin deficiency.*

Sponsor: Watson Laboratories, Inc.
Address: 311 Bonnie Circle, P.O. Box 1900, Corona CA 91718-1900

Date Designated: 1/20/1999
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **L-baclofen** Trade Name: Neuralgon

Designated Indication: *Treatment of intractable spasticity associated with spinal cord injury or multiple sclerosis.*

Sponsor: Pharmascience Inc.
Address: 6111 Royalmount, Suite 100
Montreal, Quebec H4P 2T4
Canada CA

Date Designated: 12/17/1991
Market Approval Date: Not currently Approved

Generic Name: **L-baclofen** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of trigeminal neuralgia.*

Sponsor: Fromm, Gerhard M.D.
Address: University Of Pittsburgh School of Medicine
Pittsburgh PA 15261

Date Designated: 7/13/1990
Market Approval Date: Not currently Approved

Generic Name: **L-baclofen** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of trigeminal neuralgia.*

Sponsor: Pharmascience Inc.
Address: 6111 Royalmount, #100
Montreal, Quebec
Canada H4P 2T4 CA

Date Designated: 1/6/1998
Market Approval Date: Not currently Approved

Generic Name: **L-baclofen** Trade Name: Neuralgon

Designated Indication: *Treatment of intractable spasticity in children with cerebral palsy.*

Sponsor: Pharmascience Inc.
Address: 6111 Royalmount, Suite 100
Montreal, Quebec H4P 2T4
Canada CA

Date Designated: 1/30/1992
Market Approval Date: Not currently Approved

Generic Name: **L-cycloserine** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of Gaucher's disease.*

Sponsor: Lev, Meir M.D.
Address: The City College, City University Of NY
Convent Avenue at 138 Street
New York NY 10031

Date Designated: 8/1/1989
Market Approval Date: Not currently Approved

Generic Name: **L-cysteine** Trade Name: NONE ASSIGNED

Designated Indication: *For the prevention and lessening of photosensitivity in erythropoietic protoporphyria.*

Sponsor: Orphan Pharmaceuticals, U.S.A., Inc.
Address: 1101 Kermit Dr.
Suite 608
Nashville TN 37217

Date Designated: 5/16/1994
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **L-glutamine** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of sickle cell disease*

Sponsor: Orphan Drugs International, LLC (d.b.a. Hope
Address: PO Box 0401
Montrose CA 91021-0401

Date Designated: 8/1/2001
Market Approval Date: Not currently Approved

Generic Name: **L-glutamyl-L-tryptophan** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of AIDS-related Kaposi's sarcoma.*

Sponsor: Cytran Incorporated
Address: 10230 N.E. Points Dr.
Suite 530
Kirkland WA 98033-7869

Date Designated: 10/20/1999
Market Approval Date: Not currently Approved

Generic Name: **L-leucovorin** Trade Name: Isovorin

Designated Indication: *For use in combination chemotherapy with the approved agent 5-fluorouracil in the palliative treatment of metastatic adenocarcinoma of the colon and rectum.*

Sponsor: Lederle Laboratories
Address: Division of American Cyanamid Company
401 N. Middletown Road
Pearl River NY 10965

Date Designated: 12/18/1990
Market Approval Date: Not currently Approved

Generic Name: **L-leucovorin** Trade Name: Isovorin

Designated Indication: *For use in conjunction with high-dose methotrexate in the treatment of osteosarcoma.*

Sponsor: Lederle Laboratories
Address: Division of American Cyanamid Company
401 N. Middletown Road
Pearl River NY 10965

Date Designated: 8/1/1991
Market Approval Date: Not currently Approved

Generic Name: **L-threonine** Trade Name: Threostat

Designated Indication: *Treatment of amyotrophic lateral sclerosis.*

Sponsor: Tyson And Associates
Address: 12832 Chadron Avenue
Hawthorne CA 90250

Date Designated: 2/6/1989
Market Approval Date: Not currently Approved

Generic Name: **Lactic acid** Trade Name: Aphthaid

Designated Indication: *Treatment of severe aphthous stomatitis in severely, terminally immunocompromised patients.*

Sponsor: Frontier Pharmaceutical, Inc.
Address: SUNY Farmingdale
Conklin Hall
Farmingdale NY 11735

Date Designated: 6/29/1999
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **lactic acid bacteria (Lactobacilli, Bifidobacteria, and Steptococci)**
Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of active chronic pouchitis*

Sponsor: VSL Pharmaceuticals, Inc.
Address: 800 S. Frederick Avenue
Gaithersburg MD 20877

Date Designated: 1/15/2002
Market Approval Date: Not currently Approved

Generic Name: **lactic acid bacteria (Lactobacilli, Bifidobacteria, and Streptococcus species)**
Trade Name: NONE ASSIGNED

Designated Indication: *Prevention of disease relapse in patients with chronic pouchitis*

Sponsor: VSL Pharmaceuticals, Inc.
Address: 800 S. Frederick Ave.
Gaithersburg MD 20877

Date Designated: 1/15/2002
Market Approval Date: Not currently Approved

Generic Name: **Lamotrigine**
Trade Name: Lamictal

Designated Indication: *Treatment of Lennox-Gastaut syndrome.*

Sponsor: Glaxo Wellcome Research and Development
Address: 5 Moore Drive
P.O. Box 13398
Research Triangle Park NC 27709

Date Designated: 8/23/1995
Market Approval Date: 8/24/1998

Generic Name: **Lanreotide, Somatostatin**
Trade Name: Ipstyl

Designated Indication: *Treatment for acromegly*

Sponsor: IPSEN, Inc.
Address: 27 Maple Street
Milford MA 01757

Date Designated: 9/11/2000
Market Approval Date: Not currently Approved

Generic Name: **Latrodectus immune F(ab)2**
Trade Name: Aracmyn

Designated Indication: *Treatment of black widow spider envenomations*

Sponsor: Rare Disease Therapeutics, Inc.
Address: 1101 Kermit Drive, Suite 608
Nashville TN 37217

Date Designated: 6/18/2001
Market Approval Date: Not currently Approved

Generic Name: **Leflunomide**
Trade Name: NONE ASSIGNED

Designated Indication: *Prevention of acute and chronic rejection in patients who have received solid organ transplants.*

Sponsor: Williams, MD, James W.
Address: Rush-Presbyterian-St. Luke's Medical Ctr.,
1653 West Congress Parkway
Chicago IL 60612-3833

Date Designated: 10/18/1996
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Lepirudin** Trade Name: Refluden

Designated Indication: *Treatment of heparin-associated thrombocytopenia type II.*

Sponsor: Hoechst Marion Roussel
Address: Frankfurt am Main
Germany DE

Date Designated: 2/13/1997
Market Approval Date: 3/6/1998

Generic Name: **Leucovorin** Trade Name: Leucovorin calcium

Designated Indication: *For rescue use after high dose methotrexate therapy in the treatment of osteosarcoma.*

Sponsor: Immunex Corporation
Address: 51 University Street
Seattle WA 98101

Date Designated: 8/17/1988
Market Approval Date: 8/31/1988

Generic Name: **Leucovorin** Trade Name: Leucovorin calcium

Designated Indication: *For use in combination with 5-fluorouracil for the treatment of metastatic colorectal cancer.*

Sponsor: Immunex Corporation
Address: 51 University Street
Seattle WA 98101

Date Designated: 12/8/1986
Market Approval Date: 12/12/1991

Generic Name: **Leupeptin** Trade Name: NONE ASSIGNED

Designated Indication: *For use as an adjunct to microsurgical peripheral nerve repair.*

Sponsor: Neuromuscular Adjuncts, Inc.
Address: S.U.N.Y. at Stony Brook
H.S.C. T18-020
Stony Brook NY 11794-8181

Date Designated: 9/18/1990
Market Approval Date: Not currently Approved

Generic Name: **Leuprolide acetate** Trade Name: Lupron Injection

Designated Indication: *Treatment of central precocious puberty.*

Sponsor: Tap Pharmaceuticals, Inc.
Address: 2355 Waukegan Road
Deerfield IL 60015

Date Designated: 7/25/1988
Market Approval Date: 4/16/1993

Generic Name: **Levocarnitine** Trade Name: Carnitor

Designated Indication: *For the treatment of secondary carnitine deficiency in valproic acid toxicity.*

Sponsor: Sigma-Tau Pharmaceuticals, Inc.
Address: 800 South Frederick Avenue
Gaithersburg MD 20877

Date Designated: 11/15/1989
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name:	**Levocarnitine**	Trade Name:	Carnitor
Designated Indication:	*Treatment of zidovudine-induced mitochondrial myopathy.*		
Sponsor:	Sigma-Tau Pharmaceuticals, Inc.	Date Designated:	4/7/1997
Address:	800 S. Frederick Avenue, Suite 300 Gaithersburg MD 20877	Market Approval Date:	Not currently Approved

Generic Name:	**Levocarnitine**	Trade Name:	Carnitor
Designated Indication:	*Treatment of pediatric cardiomyopathy.*		
Sponsor:	Sigma-Tau Pharmaceuticals, Inc.	Date Designated:	11/22/1993
Address:	800 South Frederick Avenue Gaithersburg MD 20877	Market Approval Date:	Not currently Approved

Generic Name:	**Levocarnitine**	Trade Name:	Carnitor
Designated Indication:	*Treatment of primary and secondary carnitine deficiency of genetic origin.*		
Sponsor:	Sigma-Tau Pharmaceuticals, Inc.	Date Designated:	7/26/1984
Address:	800 South Frederick Avenue Gaithersburg MD 20877	Market Approval Date:	12/16/1992

Generic Name:	**Levocarnitine**	Trade Name:	Carnitor
Designated Indication:	*Treatment of manifestations of carnitine deficiency in patients with end stage renal disease who require dialysis.*		
Sponsor:	Sigma-Tau Pharmaceuticals, Inc.	Date Designated:	9/6/1988
Address:	800 South Frederick Avenue, Suite 300 Gaithersburg MD 20877	Market Approval Date:	12/15/1999

Generic Name:	**Levocarnitine**	Trade Name:	Carnitor
Designated Indication:	*Treatment of genetic carnitine deficiency.*		
Sponsor:	Sigma-Tau Pharmaceuticals, Inc.	Date Designated:	2/28/1984
Address:	800 South Frederick Avenue Gaithersburg MD 20877	Market Approval Date:	4/10/1986

Generic Name:	**Levocarnitine**	Trade Name:	Carnitor
Designated Indication:	*For the prevention of secondary carnitine deficiency in valproic acid toxicity.*		
Sponsor:	Sigma-Tau Pharmaceuticals, Inc.	Date Designated:	11/15/1989
Address:	800 South Frederick Avenue Gaithersburg MD 20877	Market Approval Date:	Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Levodopa and carbidopa** Trade Name: Duodopa

Designated Indication: *Treatment of late stage Parkinson's disease.*

Sponsor: Nouvel Pharma, Inc.
Address: 11384 Strang Line Road
Lenexa KS 66215

Date Designated: 1/18/2000
Market Approval Date: Not currently Approved

Generic Name: **Levomethadyl acetate hydrochloride** Trade Name: Orlaam

Designated Indication: *Treatment of heroin addicts suitable for maintenance on opiate agonists.*

Sponsor: Biodevelopment Corporation
Address: 8180 Greensboro Drive, Suite 1000
McLean VA 22102

Date Designated: 1/24/1985
Market Approval Date: 7/9/1993

Generic Name: **Lidocaine patch 5%** Trade Name: Lidoderm Patch

Designated Indication: *For relief of allodynia (painful hypersensitivity), and chronic pain in post-herpetic neuralgia.*

Sponsor: Teikoku Pharma USA, Inc.
Address: 745-D Camden Ave.
Campbell CA 95008-4146

Date Designated: 10/24/1995
Market Approval Date: 3/19/1999

Generic Name: **Liothyronine sodium injection** Trade Name: Triostat

Designated Indication: *Treatment of myxedema coma/precoma.*

Sponsor: SmithKline Beecham Pharmaceuticals
Address: One Franklin Plaza
P.O. Box 7929
Philadelphia PA 19101

Date Designated: 7/30/1990
Market Approval Date: 12/31/1991

Generic Name: **Lipid/DNA human cystic fibrosis gene** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of cystic fibrosis.*

Sponsor: Genzyme Corporation
Address: One Mountain Road
P.O. Box 9322
Framingham MA 01701-9322

Date Designated: 4/8/1996
Market Approval Date: Not currently Approved

Generic Name: **Liposomal amphotericin B** Trade Name: AmBisome

Designated Indication: *Treatment of cryptococcal meningitis.*

Sponsor: Fujisawa USA, Inc.
Address: 3 Parkway North Center
Deerfield IL 60015

Date Designated: 12/10/1996
Market Approval Date: 8/11/1997

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Liposomal amphotericin B**
Trade Name: AmBisome

Designated Indication: *Treatment of visceral leishmaniasis.*

Sponsor: Fujisawa USA, Inc.
Address: 3 Parkway North Center
Deerfield IL 60015

Date Designated: 12/6/1996
Market Approval Date: 8/11/1997

Generic Name: **Liposomal amphotericin B**
Trade Name: AmBisome

Designated Indication: *Treatment of histoplasmosis.*

Sponsor: Fujisawa USA, Inc.
Address: 3 Parkway North Center
Deerfield IL 60015

Date Designated: 12/10/1996
Market Approval Date: Not currently Approved

Generic Name: **Liposomal cyclosporin A**
Trade Name: Cyclospire

Designated Indication: *For aerosolized administration in the prevention and treatment of lung allograft rejection and pulmonary rejection events associated with bone marrow transplantation.*

Sponsor: Vernon Knight, M.D.
Address: Baylor College of Medicine, Dept. of
One Baylor Plaza
Houston TX 77030

Date Designated: 4/30/1998
Market Approval Date: Not currently Approved

Generic Name: **Liposomal N-Acetylglucosminyl-N-Acetylmuramly-L-Ala-D-isoGln-**
Trade Name: ImmTher

Designated Indication: *Treatment of Ewing's sarcoma.*

Sponsor: Endorex Corp.
Address: 900 North Shore Drive
Lake Bluff IL 60044

Date Designated: 6/10/1998
Market Approval Date: Not currently Approved

Generic Name: **Liposomal N-Acetylglucosminyl-N-Acetylmuramly-L-Ala-D-isoGln-**
Trade Name: ImmTher

Designated Indication: *Treatment of osteosarcoma.*

Sponsor: Endorex Corp.
Address: 900 North Shore Drive
Lake Bluff IL 60044

Date Designated: 6/10/1998
Market Approval Date: Not currently Approved

Generic Name: **Liposomal nystatin**
Trade Name: Nyotran

Designated Indication: *Treatment of invasive fungal infections.*

Sponsor: Aronex Pharmaceuticals, Inc.
Address: 8707 Technology Forest Place
The Woodlands TX 77381-1191

Date Designated: 6/13/2000
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Liposomal-cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane-Pt (II)**
Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of malignant mesothelioma.*

Sponsor: Antigenics Incorporated
Address: 34 Commerce Way
Woburn MA 01801

Date Designated: 9/1/1999
Market Approval Date: Not currently Approved

Generic Name: **Liposome encapsulated recombinant interleukin-2**
Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of cancers of the kidney and renal pelvis.*

Sponsor: Biomira USA, Inc.
Address: 1002 Eastpark Boulevard
Cranbury NJ 08512

Date Designated: 6/20/1994
Market Approval Date: Not currently Approved

Generic Name: **Liposome encapsulated recombinant interleukin-2**
Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of brain and CNS tumors.*

Sponsor: Biomira USA, Inc.
Address: 1002 Eastpark Boulevard
Cranbury NJ 08512

Date Designated: 11/25/1991
Market Approval Date: Not currently Approved

Generic Name: **Lisofylline**
Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of patients undergoing induction therapy for acute myeloid leukemia.*

Sponsor: Cell Therapeutics, Inc.
Address: 201 Elliot Avenue West
Suite 400
Seattle WA 98119

Date Designated: 6/10/1999
Market Approval Date: Not currently Approved

Generic Name: **Lodoxamide tromethamine**
Trade Name: Alomide Ophthalmic Solution

Designated Indication: *Treatment of vernal keratoconjunctivitis.*

Sponsor: Alcon Laboratories, Inc.
Address: 6201 South Freeway
Fort Worth TX 76134

Date Designated: 10/16/1991
Market Approval Date: 9/23/1993

Generic Name: **Lucinactant**
Trade Name: Surfaxin

Designated Indication: *Treatment of acute respiratory distress syndrome in adults.*

Sponsor: Discovery Laboratories, Inc.
Address: 350 South Main Street
Suite 307
Doylestown PA 18901

Date Designated: 7/17/1995
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Lucinactant** | Trade Name: Surfaxin

Designated Indication: *Treatment of meconium aspiration syndrome in newborn infants.*

Sponsor: Discovery Laboratories, Inc.
Address: 350 South Main Street
Suite 307
Doylestown PA 18901

Date Designated: 7/30/1996
Market Approval Date: Not currently Approved

Generic Name: **Lucinactant** | Trade Name: Surfaxin

Designated Indication: *Treatment of respiratory distress syndrome in premature infants.*

Sponsor: Discovery Laboratories, Inc.
Address: 350 South Main Street
Suite 307
Doylestown PA 18901

Date Designated: 10/18/1995
Market Approval Date: Not currently Approved

Generic Name: **Mafenide acetate solution** | Trade Name: Sulfamylon solution

Designated Indication: *For use as an adjunctive topical antimicrobial agent to control bacterial infection when used under moist dressings over meshed autografts on excised burn wounds.*

Sponsor: Mylan Laboratories, Inc.
Address: 781 Chestnut Ridge Road
P.O. Box 4310
Morgantown WV 26504-4310

Date Designated: 7/18/1990
Market Approval Date: 6/5/1998

Generic Name: **Marijuana** | Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of HIV-associated wasting syndrome.*

Sponsor: Multidisciplinary Association for
Address: 3 Francis St.
Belmont MA 02478

Date Designated: 5/25/1999
Market Approval Date: Not currently Approved

Generic Name: **MART-1 adenoviral gene therapy for malignant melanoma** | Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of metastatic melanoma.*

Sponsor: Genzyme Corporation
Address: One Mountain Road
P.O. Box 9322
Framingham MA 01701-9322

Date Designated: 3/28/1997
Market Approval Date: Not currently Approved

Generic Name: **Matrix metalloproteinase inhibitor** | Trade Name: Galardin

Designated Indication: *Treatment of corneal ulcers.*

Sponsor: Glycomed, Inc
Address: 860 Atlantic Avenue
Alameda CA 94501

Date Designated: 12/5/1991
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Mazindol** | Trade Name: Sanorex

Designated Indication: *Treatment of Duchenne muscular dystrophy.*

Sponsor: Collipp, Platon J. M.D.
Address: 176 Memorial Drive
Jesup GA 31545

Date Designated: 12/8/1986
Market Approval Date: Not currently Approved

Generic Name: **Mecamylamine** | Trade Name: Inversine

Designated Indication: *Treatment of Tourette's syndrome.*

Sponsor: Layton Bioscience, Inc.
Address: 709 E. Evelyn Avenue
Sunnyvale CA 94086

Date Designated: 10/14/1998
Market Approval Date: Not currently Approved

Generic Name: **Mecasermin** | Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of growth hormone insufficency syndrome.*

Sponsor: Genentech, Inc.
Address: 460 Point San Bruno Boulevard
South San Francisco CA 94080

Date Designated: 12/12/1995
Market Approval Date: Not currently Approved

Generic Name: **Mecasermin** | Trade Name: Myotrophin

Designated Indication: *Treatment of amyotrophic lateral sclerosis.*

Sponsor: Cephalon, Inc.
Address: 145 Brandywine Parkway
West Chester PA 19380-4245

Date Designated: 8/5/1991
Market Approval Date: Not currently Approved

Generic Name: **Medroxyprogesterone acetate** | Trade Name: Hematrol

Designated Indication: *Treatment of immune thrombocytopenic purpura.*

Sponsor: InKine Pharmaceutical Company, Inc.
Address: 1787 Sentry Parkway West
Building 18, Suite 440
Blue Bell PA 19422

Date Designated: 2/22/2001
Market Approval Date: Not currently Approved

Generic Name: **Mefloquine HCl** | Trade Name: Lariam

Designated Indication: *Treatment of acute malaria due to Plasmodium falciparum and Plasmodium vivax.*

Sponsor: Hoffmann-La Roche, Inc.
Address: 340 Kingsland Street
Nutley NJ 07110

Date Designated: 4/13/1988
Market Approval Date: 5/2/1989

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Mefloquine HCl** Trade Name: Mephaquin

Designated Indication: *Treatment of chloroquine-resistant Falciparummalaria.*

Sponsor: Mepha AG
Address: 4143 Dornach
POSTFASH 137
Aesch Basel, Switzerland CH

Date Designated: 7/22/1987
Market Approval Date: Not currently Approved

Generic Name: **Mefloquine HCl** Trade Name: Lariam

Designated Indication: *Prophylaxis of Plasmodium falciparum malaria which is resistant to other available drugs.*

Sponsor: Hoffmann-La Roche, Inc.
Address: 340 Kingsland Street
Nutley NJ 07110

Date Designated: 4/13/1988
Market Approval Date: 5/2/1989

Generic Name: **Mefloquine HCl** Trade Name: Mephaquin

Designated Indication: *Prevention of chloroquine-resistant Falciparum malaria.*

Sponsor: Mepha AG
Address: 4143 Dornach
POSTFASH 137
Aesch Basel, Switzerland CH

Date Designated: 7/22/1987
Market Approval Date: Not currently Approved

Generic Name: **Megestrol acetate** Trade Name: Megace

Designated Indication: *Treatment of patients with anorexia, cachexia, or significant weight loss (=/>10% of baseline body weight) and confirmed diagnosis of AIDS.*

Sponsor: Bristol-Myers Squibb Pharmaceutical
Address: 2400 West Lloyd Expressway
Evansville IN 47721

Date Designated: 4/13/1988
Market Approval Date: 9/10/1993

Generic Name: **Melanoma cell vaccine** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of invasive melanoma.*

Sponsor: Morton, Donald L. M.D.
Address: John Wayne Cancer Institute
2200 Santa Monica Boulevard
Santa Monica CA 90404

Date Designated: 10/13/1994
Market Approval Date: Not currently Approved

Generic Name: **Melanoma vaccine** Trade Name: Melacine

Designated Indication: *Treatment of stage III - IV melanoma.*

Sponsor: Ribi ImmunoChem Research, Inc.
Address: 533 Old Corvallis Road
Hamilton MT 59840

Date Designated: 12/20/1989
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Melatonin** | Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of circadian rhythm sleep disorders in blind people with no light perception.*

Sponsor: Sack, Robert, M.D.
Address: Oregon Health Sciences University
3181 S.W. Sam Jackson Park Road
Portland OR 97201

Date Designated: 11/15/1993
Market Approval Date: Not currently Approved

Generic Name: **Meropenem** | Trade Name: Merrem IV

Designated Indication: *Management of acute pulmonary exacerbations, in cystic fibrosis patients, due to respiratory tract infection with susceptible organisms.*

Sponsor: Zeneca Pharmaceuticals
Address: 1800 Concord Pike
PO Box 15437
Wilmington DE 19850-5437

Date Designated: 4/27/2000
Market Approval Date: Not currently Approved

Generic Name: **Mesna** | Trade Name: NONE ASSIGNED

Designated Indication: *Inhibition of the urotoxic effects induced by oxazaphosphorine compounds such as cyclophosphamide.*

Sponsor: Asta Medica , Inc.
Address: 890 East St.
Tewksbury MA 01876-1496

Date Designated: 12/16/1987
Market Approval Date: Not currently Approved

Generic Name: **Mesna** | Trade Name: Mesnex

Designated Indication: *For use as a prophylactic agent in reducing the incidence of ifosfamide-induced hemorrhagic cystitis.*

Sponsor: Degussa Corporation
Address: 65 Challenger Road
Ridgefield Park NJ 07660

Date Designated: 11/14/1985
Market Approval Date: 12/30/1988

Generic Name: **Methionine/L-methionine** | Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of AIDS myelopathy.*

Sponsor: Di Rocco, Alessandro M.D.
Address: Beth Israel Medical Center, Phillips
Philips Building, Suite 2R; 10 Union Square
New York NY 10003

Date Designated: 8/21/1996
Market Approval Date: Not currently Approved

Generic Name: **Methotrexate sodium** | Trade Name: Methotrexate

Designated Indication: *Treatment of osteogenic sarcoma.*

Sponsor: Lederle Laboratories
Address: Division of American Cyanamid Company
401 N. Middletown Road
Pearl River NY 10965

Date Designated: 10/21/1985
Market Approval Date: 4/7/1988

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Methotrexate with laurocapram** Trade Name: Methotrexate/azone

Designated Indication: *Topical treatment of mycosis fungoides.*

Sponsor: Durham Pharmaceuticals LLC
Address: 200 Westpark Corporate Center
4364 South Alston Avenue
Durham NC 27713-2280

Date Designated: 10/15/1990
Market Approval Date: Not currently Approved

Generic Name: **Methoxsalen** Trade Name: Uvadex

Designated Indication: *For use in conjunction with the UVAR photopheresis system to treat graft versus host disease.*

Sponsor: Therakos, Inc.
Address: 437 Creamery Way
Exton PA 19431

Date Designated: 10/14/1998
Market Approval Date: Not currently Approved

Generic Name: **metreleptin** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of leptin deficiency secondary to generalized lipodystrophy and partial familial lipodystrophy*

Sponsor: Amgen, Inc.
Address: One Amgen Center Drive
Thousand Oaks CA 91320-1799

Date Designated: 8/22/2001
Market Approval Date: Not currently Approved

Generic Name: **metreleptin** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of metabolic disorders secondary to lipodystrophy*

Sponsor: Amgen, Inc.,
Address: One Amgen Center Drive
Thousand Oaks CA 91320-1799

Date Designated: 8/22/2001
Market Approval Date: Not currently Approved

Generic Name: **Metronidazole** Trade Name: Metrogel

Designated Indication: *Treatment of perioral dermatitis.*

Sponsor: Galderma Laboratories, Inc.
Address: P.O. Box 331329
Fort Worth TX 76163

Date Designated: 10/24/1991
Market Approval Date: Not currently Approved

Generic Name: **Metronidazole (topical)** Trade Name: Metrogel

Designated Indication: *Treatment of acne rosacea.*

Sponsor: Galderma Laboratories, Inc.
Address: P.O. Box 331329
Fort Worth TX 76163

Date Designated: 10/22/1987
Market Approval Date: 11/22/1988

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Agent Name:	**Microbubble contrast agent**	Trade Name:	Filmix Neurosonographic Contrast
Designated Indication:	*Intraoperative aid in the identification and localization of intracranial tumors.*		
Sponsor:	Cav-Con, Inc.	Date Designated:	11/16/1990
Address:	55 Knollwood Road Farmington CT 06032	Market Approval Date:	Not currently Approved

Generic Name:	**Midodrine HCl**	Trade Name:	Amatine
Designated Indication:	*Treatment of patients with symptomatic orthostatic hypotension.*		
Sponsor:	Schier Ridgewood F.K.A. (Roberts	Date Designated:	12/5/1996
Address:	Meridian Center III 6 Industrial Way West Eatontown NJ 07724	Market Approval Date:	9/6/1996

Generic Name:	**Mitoguazone**	Trade Name:	apep
Designated Indication:	*Treatment of diffuse non-Hodgkin's lymphoma, including AIDS-related diffuse non-Hodgkin's lymphoma.*		
Sponsor:	ILEX Oncology, Inc.	Date Designated:	3/18/1994
Address:	4545 Horizon Hill Blvd. San Antonio TX 78229-2263	Market Approval Date:	Not currently Approved

Generic Name:	**Mitolactol**	Trade Name:	NONE ASSIGNED
Designated Indication:	*As adjuvant therapy in the treatment of primary brain tumors.*		
Sponsor:	Biopharmaceutics, Inc.	Date Designated:	7/12/1995
Address:	990 Station Road Bellport NY 11713	Market Approval Date:	Not currently Approved

Generic Name:	**Mitolactol**	Trade Name:	NONE ASSIGNED
Designated Indication:	*Treatment of recurrent invasive or metastatic squamous carcinoma of the cervix.*		
Sponsor:	Biopharmaceutics, Inc.	Date Designated:	1/23/1989
Address:	990 Station Road Bellport NY 11713	Market Approval Date:	Not currently Approved

Generic Name:	**Mitomycin-C**	Trade Name:	NONE ASSIGNED
Designated Indication:	*Treatment of refractory glaucoma as an adjunct to ab externo glaucoma surgery.*		
Sponsor:	IOP Inc.	Date Designated:	8/20/1993
Address:	3100 Airway Avenue, Suite 106 Costa Mesa CA 92626	Market Approval Date:	Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Mitoxantrone** — Trade Name: Novantrone

Designated Indication: *Treatment of hormone refractory prostate cancer.*

Sponsor: Immunex Corporation
Address: 51 University Street, Seattle WA 98101

Date Designated: 8/21/1996
Market Approval Date: 11/13/1996

Generic Name: **Mitoxantrone** — Trade Name: Novantrone

Designated Indication: *Treatment of progressive-relapsing multiple sclerosis.*

Sponsor: Immunex Corporation
Address: 51 University St., Seattle WA 98101

Date Designated: 8/13/1999
Market Approval Date: 10/13/2000

Generic Name: **Mitoxantrone** — Trade Name: Novantrone

Designated Indication: *Treatment of secondary-progressive multiple sclerosis.*

Sponsor: Immunex Corporation
Address: 51 University St., Seattle WA 98101

Date Designated: 8/13/1999
Market Approval Date: 10/13/2000

Generic Name: **Mitoxantrone HCl** — Trade Name: Novantrone

Designated Indication: *Treatment of acute myelogenous leukemia, also referred to as acute nonlymphocytic leukemia.*

Sponsor: Lederle Laboratories
Address: Division of American Cyanamid Company, 401 N. Middletown Road, Pearl River NY 10965

Date Designated: 7/13/1987
Market Approval Date: 12/23/1987

Generic Name: **MN14 monoclonal antibody to carcinoembryonic antigen** — Trade Name: Cea-Cide

Designated Indication: *Treatment of pancreatic cancer.*

Sponsor: Immunomedics, Inc.
Address: 300 American Road, Morris Plains NJ 07950

Date Designated: 11/24/1998
Market Approval Date: Not currently Approved

Generic Name: **MN14 monoclonal antibody to carcinoembryonic antigen** — Trade Name: Cea-Cide

Designated Indication: *For the treatment of small cell lung cancer.*

Sponsor: Immunomedics, Inc.
Address: 300 American Rd., Morris Plains NJ 07950

Date Designated: 9/18/1998
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Modafinil** — Trade Name: Provigil

Designated Indication: *Treatment of excessive daytime sleepiness in narcolepsy.*

Sponsor: Cephalon, Inc.
Address: 145 Brandywine Parkway
West Chester PA 19380

Date Designated: 3/15/1993
Market Approval Date: 12/24/1998

Generic Name: **Monoclonal antibodies PM-81 and AML-2-23** — Trade Name: NONE ASSIGNED

Designated Indication: *For the exogenous depletion of CD14 and CD15 positive acute myeloid leukemic bone marrow cells from patients undergoing bone marrow transplantation.*

Sponsor: Medarex, Inc.
Address: 67 Beaver Avenue
Annandale NJ 08801-0953

Date Designated: 3/12/1990
Market Approval Date: Not currently Approved

Generic Name: **Monoclonal antibody for immunization against lupus nephritis** — Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of lupus nephritis.*

Sponsor: VivoRx Autoimmune, Inc.
Address: 2825 Santa Monica Blvd., Suite 200
Santa Monica CA 90404

Date Designated: 1/7/1993
Market Approval Date: Not currently Approved

Generic Name: **Monoclonal antibody PM-81** — Trade Name: NONE ASSIGNED

Designated Indication: *Adjunctive treatment of acute myelogenous leukemia.*

Sponsor: Medarex, Inc.
Address: 519 Route 173 West
Bloomsbury NJ 08804

Date Designated: 6/27/1991
Market Approval Date: Not currently Approved

Generic Name: **Monoclonal antibody-B43.13** — Trade Name: Ovarex MAb-B43.13

Designated Indication: *Treatment of epithelial ovarian cancer.*

Sponsor: AltaRex US Corp.
Address: 610 Lincoln Street
Waltham MA 02451

Date Designated: 11/25/1996
Market Approval Date: Not currently Approved

Generic Name: **Monolaurin** — Trade Name: Glylorin

Designated Indication: *Treatment of congenital primary ichthyosis.*

Sponsor: Glaxo Wellcome Inc.
Address: 5 Moore Drive
PO Box 13398
Research Triangle Park NC 27709

Date Designated: 4/29/1993
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Monooctanoin** Trade Name: Moctanin

Designated Indication: *For dissolution of cholesterol gallstones retained in the common bile duct.*

Sponsor: Ethitek Pharmaceuticals, Inc.
Address: 7855 Gross Point Road, Unit L
Skokie IL 60077

Date Designated: 5/30/1984
Market Approval Date: 10/31/1985

Generic Name: **Morphine sulfate concentrate (preservative free)** Trade Name: Infumorph

Designated Indication: *For use in microinfusion devices for intraspinal administration in the treatment of intractable chronic pain.*

Sponsor: Elkins-Sinn, Inc.
Address: 2 Esterbrook Lane
Cherry Hill NJ 08003

Date Designated: 7/12/1990
Market Approval Date: 7/19/1991

Generic Name: **MTC-DOX for Injection** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of hepatocellular carcinoma*

Sponsor: FeRx Incorporated
Address: 4330 La Jolla Village Drive
Suite #250
San Diego CA 92122

Date Designated: 1/3/2001
Market Approval Date: Not currently Approved

Generic Name: **Multi-vitamin infusion (neonatal formula)** Trade Name: NONE ASSIGNED

Designated Indication: *For establishment and maintenance of total parenteral nutrition in very low birth weight infants.*

Sponsor: Astra Pharmaceuticals, L.P.
Address: 725 Chesterbrook Blvd.
Wayne PA 19087-5677

Date Designated: 12/12/1989
Market Approval Date: Not currently Approved

Generic Name: **muramyltripeptide, phosphatidyl-ethanolamine encased in multi-lamellar liposomes** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of children and adolescent osteosarcoma*

Sponsor: Jenner Biotherapies, Inc.
Address: 541 Kenosa Street
Walworth WI 53184

Date Designated: 6/5/2001
Market Approval Date: Not currently Approved

Generic Name: **Murine MAb (Lym-1) and Iodine 131-I radiolabeled murine MAb (Lym-1) to human B-cell lymphoma** Trade Name: Oncolym

Designated Indication: *Treatment of B-cell non-Hodgkin's lymphoma.*

Sponsor: Berlex Laboratories
Address: 15049 San Pablo Ave.
PO Box 4099
Richmond CA 94804-0099

Date Designated: 11/27/1998
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Murine MAb to polymorphic epithelial mucin, human milk fat globule 1**
Trade Name: Theragyn

Designated Indication: *Adjuvant treatment of ovarian cancer.*

Sponsor: Antisoma plc
Address: West Africa House
Hanger Lane Ealing
London W5 3QR UK

Date Designated: 3/22/1999
Market Approval Date: Not currently Approved

Generic Name: **Mycobacterium avium sensitin RS-10**
Trade Name: NONE ASSIGNED

Designated Indication: *For use in the diagnosis of invasive Mycobacterium avium disease in immunocompetent individuals.*

Sponsor: Statens Seruminstitut
Address: 5 Artillerivej
DK-2300 Copenhagen S
Denmark

Date Designated: 10/11/1995
Market Approval Date: Not currently Approved

Generic Name: **N-acetyl-procainamide**
Trade Name: NONE ASSIGNED

Designated Indication: *Prevention of life-threatening ventricular arrhythmias in patients with documented procainamide-induced lupus.*

Sponsor: NAPA of the Bahamas
Address: 3560 Pennsylvania Avenue, Suite 7
Dubuque IA 52002

Date Designated: 12/10/1996
Market Approval Date: Not currently Approved

Generic Name: **N-acetylcysteinate**
Trade Name: Nacystelyn Dry Powder Inhaler

Designated Indication: *For the management of cystic fibrosis*

Sponsor: Galephar Pharmaceutical Research, Inc.
Address: Road 198, No. 100 km. 14.7
Juncos Industrial Park
Juncos PR 00777-3873

Date Designated: 12/27/2000
Market Approval Date: Not currently Approved

Generic Name: **N-acetylgalactosamine-4-sulfatase, recombinant human**
Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of mucopolysaccharidosis Type VI (Maroteaux-Lamy syndrome).*

Sponsor: BioMarin Pharmaceutical, Inc.
Address: 11 Pimental Court
Novato CA 94949-5608

Date Designated: 2/17/1999
Market Approval Date: Not currently Approved

Generic Name: **Nafarelin acetate**
Trade Name: Synarel Nasal Solution

Designated Indication: *Treatment of central precocious puberty.*

Sponsor: Syntex (USA), Inc.
Address: 3401 Hillview Avenue
Palo Alto CA 94303

Date Designated: 7/20/1988
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Naltrexone HCl** Trade Name: Trexan

Designated Indication: *For blockade of the pharmacological effects of exogenously administered opioids as an adjunct to the maintenance of the opioid-free state in detoxified formerly opioid-dependent individuals.*

Sponsor: DuPont Pharmaceuticals
Address: E.I. Du Pont De Nemours & Co.
Wilmington DE 19880

Date Designated: 3/11/1985
Market Approval Date: 11/30/1984

Generic Name: **Natural human lymphoblastoid interferon-alpha** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of papillomavirus warts in the oral cavity of HIV positive patients.*

Sponsor: Amarillo Biosciences. Inc.
Address: 800 West 9th Avenue
Amarillo TX 79101-3206

Date Designated: 8/10/2000
Market Approval Date: Not currently Approved

Generic Name: **Natural human lymphoblastoid interferon-alpha** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of Behcet's disease.*

Sponsor: Amarillo Biosciences, Inc.
Address: 800 West Ninth Avenue
Amarillo TX 79101-3206

Date Designated: 1/18/2000
Market Approval Date: Not currently Approved

Generic Name: **NDROGE** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of postanoxic intention myoclonus.*

Sponsor: WATSON Laboratories, Inc.
Address: 33 Ralph Avenue
P.O. Box 30
Copiaque NY 11726-0030

Date Designated: 11/1/1984
Market Approval Date: Not currently Approved

Generic Name: **Nebacumab** Trade Name: Centoxin

Designated Indication: *Treatment of patients with gram-negative bacteremia which has progressed to endotoxin shock.*

Sponsor: Centocor, Inc.
Address: 200 Great Valley Parkway
Malvern PA 19355

Date Designated: 10/1/1986
Market Approval Date: Not currently Approved

Generic Name: **Neurotrophin-1** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of motor neuron disease/amyotrophic lateral sclerosis.*

Sponsor: Ericsson, Arthur Dale, M.D.
Address: 6560 Fannin, Scurlock Tower, Suite 720
Houston TX 77303

Date Designated: 9/13/1994
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **NG-29**
Trade Name: Somatrel

Designated Indication: *Diagnostic measure of the capacity of the pituitary gland to release growth hormone.*

Sponsor: Ferring Laboratories, Inc.
Address: 400 Rella Boulevard, Suite 201
Suffern NY 10901

Date Designated: 8/8/1989
Market Approval Date: Not currently Approved

Generic Name: **Nifedipine**
Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of interstitial cystitis.*

Sponsor: Fleischmann, Jonathan M.D.
Address: MetroHealth Medical Center
3395 Scranton Road
Cleveland OH 44109

Date Designated: 6/13/1991
Market Approval Date: Not currently Approved

Generic Name: **nitazoxanide**
Trade Name: Cryptaz

Designated Indication: *Treatment for intestinal amebiasis*

Sponsor: Romark Laboratories, L.C.
Address: 6200 Courtney Campbell Causeway
Suite 880
Tampa FL 33607

Date Designated: 10/23/2001
Market Approval Date: Not currently Approved

Generic Name: **Nitazoxanide**
Trade Name: Cryptaz

Designated Indication: *Treatment of cryptosporidiosis.*

Sponsor: Romark Laboratories, L.C.
Address: 6200 Courtney Campbell Causeway
Suite 880
Tampa FL 33607

Date Designated: 12/12/1996
Market Approval Date: Not currently Approved

Generic Name: **Nitisinone**
Trade Name: Orfadin

Designated Indication: *Treatment of tyrosinemia type 1.*

Sponsor: Swedish Orphan AB
Address: Drottninggatan 98
SE-111 60 Stockholm
Sweden SE

Date Designated: 5/16/1995
Market Approval Date: Not currently Approved

Generic Name: **Nitisinone**
Trade Name: Orfadin

Designated Indication: *Treatment of alkaptonuria*

Sponsor: Swedish Orphan AB
Address: Kungsgatan 37, 7th Floor
SE-111 56
Stockholm, Sweden

Date Designated: 10/19/2001
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Nitric oxide** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of acute respiratory distress syndrome in adults.*

Sponsor: INO Therapeutics, Inc.
Address: 54 Old Highway 22
Clinton NJ 08809

Date Designated: 7/10/1995
Market Approval Date: Not currently Approved

Generic Name: **Nitric oxide** Trade Name: INOmax

Designated Indication: *Treatment of persistent pulmonary hypertension in the newborn.*

Sponsor: INO Therapeutics, Inc.
Address: 54 Old Highway 22
Clinton NJ 08809

Date Designated: 6/22/1993
Market Approval Date: 12/23/1999

Generic Name: **Nitroprusside** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment and prevention of cerebral vasospasm following subarachnoid hemorrhage.*

Sponsor: Thomas, MD, Jeffrey Evan
Address: Thomas Jefferson University and Wills
834 Walnut Street, Suite 650
Philadelphia PA 19107-5102

Date Designated: 2/21/2001
Market Approval Date: Not currently Approved

Generic Name: **nolatrexed** Trade Name: THYMITAQ

Designated Indication: *Treatment of hepatocellular carcinoma*

Sponsor: Zarix, Inc.
Address: 1055 Westlakes Drive
Suite 200
Berwyn PA 19312

Date Designated: 10/18/2001
Market Approval Date: Not currently Approved

Generic Name: **Novel Acting Thrombolytic (NAT)** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of peripheral arterial occlusion (PAO)*

Sponsor: Amgen, Inc.
Address: One Amgen Center Drive
Thousand Oaks CA 91320-1799

Date Designated: 1/26/2001
Market Approval Date: Not currently Approved

Generic Name: **NZ-1002** Trade Name: NONE ASSIGNED

Designated Indication: *Enzyme replacement therapy in patients with all subtypes of Mucopolysaccharidosis I.*

Sponsor: Novazyme Pharmaceuticals, Inc.
Address: 800 Research Parkway
Suite 200
Oklahoma City OK 73104

Date Designated: 4/11/2001
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Octreotide** | Trade Name: Sandostatin LAR

Designated Indication: *Treatment of acromegaly.*

Sponsor: Novartis Pharmaceuticals Corporation
Address: 59 Route 10
East Hanover NJ 07936-1080

Date Designated: 8/24/1998
Market Approval Date: 11/25/1998

Generic Name: **Octreotide** | Trade Name: Sandostatin LAR

Designated Indication: *Treatment of diarrhea associated with vasoactive intestinal peptide tumors (VIPoma).*

Sponsor: Novartis Pharmaceuticals Corporation
Address: 59 Route 10
East Hanover NJ 07936-1080

Date Designated: 8/24/1998
Market Approval Date: 11/25/1998

Generic Name: **Octreotide** | Trade Name: Sandostatin LAR

Designated Indication: *Treatment of severe diarrhea and flushing associated with malignant carcinoid tumors.*

Sponsor: Novartis Pharmaceuticals Corporation
Address: 59 Route 10
East Hanover NJ 07936-1080

Date Designated: 8/24/1998
Market Approval Date: 11/25/1998

Generic Name: **Ofloxacin** | Trade Name: Ocuflox Ophthalmic Solution

Designated Indication: *Treatment of bacterial corneal ulcers.*

Sponsor: Allergan, Inc.
Address: 2525 Dupont Drive
P.O. Box 19534
Irvine CA 92713

Date Designated: 4/18/1991
Market Approval Date: 5/22/1996

Generic Name: **oglufanide disodium** | Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of ovarian cancer*

Sponsor: Cytran, Inc.
Address: 10230 NE Points Dr., NE
Suite 530
Kirkland WA 98033-7869

Date Designated: 9/24/2001
Market Approval Date: Not currently Approved

Generic Name: **OM 401** | Trade Name: Drepanol

Designated Indication: *Prophylactic treatment of sickle cell disease.*

Sponsor: Omex International, Inc.
Address: 6001 Savoy, Suite 110
Houston TX 77036

Date Designated: 10/24/1991
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Omega-3 (n-3) polyunsaturated fatty acid with all double bonds in the cis configuration**
Trade Name: NONE ASSIGNED

Designated Indication: *Prevention of organ graft rejection.*

Sponsor: Research Triangle Pharmaceuticals
Address: 4364 South Alston Avenue
Durham NC 27713

Date Designated: 11/22/1995
Market Approval Date: Not currently Approved

Generic Name: **Omega-3 (n-3) polyunsaturated fatty acids**
Trade Name: Omacor

Designated Indication: *Treatment of IgA nephropathy.*

Sponsor: Pronova Biocare, AS
Address: PO Box 420
1327 Lysaker
Norway

Date Designated: 5/4/2000
Market Approval Date: Not currently Approved

Generic Name: **Oncorad Ov103**
Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of ovarian cancer.*

Sponsor: Cytogen Corporation
Address: 600 College Road East
Princeton NJ 08540

Date Designated: 4/24/1990
Market Approval Date: Not currently Approved

Generic Name: **Oprelvekin**
Trade Name: Neumega

Designated Indication: *Prevention of severe chemotherapy-induced thrombocytopenia.*

Sponsor: Genetics Institute, Inc.
Address: 87 Cambridge Park Drive
Cambridge MA 02140

Date Designated: 12/17/1996
Market Approval Date: 11/25/1997

Generic Name: **Oxaliplatin**
Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of ovarian cancer.*

Sponsor: Debio Pharm S.A.
Address: Rue des Terreaux 17
CH-1000
Lausanne 9 Switzerland CH

Date Designated: 10/6/1992
Market Approval Date: Not currently Approved

Generic Name: **Oxandrolone**
Trade Name: Oxandrin

Designated Indication: *Treatment of patients with Duchenne's muscular dystrophy and Becker's muscular dystrophy.*

Sponsor: Bio-Technology General Corp.
Address: 70 Wood Avenue South
Iselin NJ 08830

Date Designated: 4/22/1997
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Oxandrolone** | Trade Name: Oxandrin

Designated Indication: *Adjunctive therapy for AIDS patients suffering from HIV-wasting syndrome.*

Sponsor: Bio-Technology General Corp.
Address: 70 Wood Avenue, South
Iselin NJ 08830

Date Designated: 9/6/1991
Market Approval Date: Not currently Approved

Generic Name: **Oxybate** | Trade Name: Xyrem

Designated Indication: *Treatment of narcolepsy.*

Sponsor: Orphan Medical, Inc.
Address: 13911 Ridgedale Drive
Suite 250
Minnetonka MN 55305

Date Designated: 11/7/1994
Market Approval Date: Not currently Approved

Generic Name: **Oxymorphone** | Trade Name: Numorphan H.P.

Designated Indication: *For relief of severe intractable pain in narcotic-tolerant patients.*

Sponsor: DuPont Merck Pharmaceutical Company
Address: P.O. Box 80027
Wilmington DE 19880

Date Designated: 3/19/1985
Market Approval Date: Not currently Approved

Generic Name: **Oxypurinol** | Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of hyperuricemia in patients intolerant to allopurinol.*

Sponsor: ILEX Oncology, Inc.
Address: 4545 Horizon Hill Blvd.
San Antonio TX 78229-2263

Date Designated: 11/9/1998
Market Approval Date: Not currently Approved

Generic Name: **p1-(uridine 5'-)-p4-(2'-deoxycytidine 5'-) tetraphosphate, tetrasodium salt** | Trade Name: NONE ASSIGNED

Designated Indication: *For the treatment of cystic fibrosis*

Sponsor: Inspire Pharmaceuticals, Inc.
Address: 4222 Emperor Blvd.
Suite 470
Durham NC 27703

Date Designated: 3/7/2001
Market Approval Date: Not currently Approved

Generic Name: **Paclitaxel** | Trade Name: Taxol

Designated Indication: *Treatment of AIDS-related Kaposi's sarcoma.*

Sponsor: Bristol-Myers Squibb Pharmaceutical
Address: 5 Research Parkway
P.O. Box 5100
Wallingford CT 06492-7660

Date Designated: 3/25/1997
Market Approval Date: 8/4/1997

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Paclitaxel** | Trade Name: Paxene

Designated Indication: *Treatment of AIDS-related Kaposi's sarcoma.*

Sponsor: Baker Norton Pharmaceuticals, Inc.
Address: 4400 Biscayne Boulevard, Miami FL 33137

Date Designated: 4/15/1997
Market Approval Date: Not currently Approved

Generic Name: **Papain, trypsin, and chymotrypsin** | Trade Name: Wobe-Mugos

Designated Indication: *Treatment of multiple myeloma.*

Sponsor: Marlyn Nutraceuticals, Inc.
Address: 14851 N. Scottsdale Rd., Scottsdale AZ 85254

Date Designated: 12/21/1998
Market Approval Date: Not currently Approved

Generic Name: **Parovirus B19 (recombinant VP1 and VP2; S.frugiperda cells) vaccine** | Trade Name: MEDI-491

Designated Indication: *Prevention of transient aplastic crisis in patients with sickle cell anemia.*

Sponsor: MedImmune, Inc.
Address: 35 West Watkins Mill Rd., Gaithersburg MD 20878

Date Designated: 5/7/1999
Market Approval Date: Not currently Approved

Generic Name: **Patul-end** | Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of patulous eustachian tube.*

Sponsor: Ear Foundation
Address: 2420 Castillo Street, Suite 100, Santa Barbara CA 93105

Date Designated: 2/18/1997
Market Approval Date: Not currently Approved

Generic Name: **PEG-glucocerebrosidase** | Trade Name: Lysodase

Designated Indication: *For use as chronic enzyme replacement therapy in patients with Gaucher's disease who are deficient in glucocerebrosidase.*

Sponsor: National Institute of Mental Health, NIH
Address: 49 Convent Dr. MSC4405, Bldg. 49, Room B1EE16, Bethesda MD 20892-4405

Date Designated: 12/9/1992
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **PEG-interleukin-2** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of primary immunodeficiencies associated with T-cell defects.*

Sponsor: Chiron Corporation
Address: 4560 Horton Street
Emeryville CA 94608

Date Designated: 2/1/1990
Market Approval Date: Not currently Approved

Generic Name: **Pegademase bovine** Trade Name: Adagen

Designated Indication: *For enzyme replacement therapy for ADA deficiency in patients with severe combined immunodeficiency.*

Sponsor: Enzon, Inc.
Address: 20 Kingsbridge Road
Piscataway NJ 08854

Date Designated: 5/29/1984
Market Approval Date: 3/21/1990

Generic Name: **Pegaspargase** Trade Name: Oncaspar

Designated Indication: *Treatment of acute lymphocytic leukemia.*

Sponsor: Enzon, Inc.
Address: 20 Kingsbridge Road
Piscataway NJ 08854

Date Designated: 10/20/1989
Market Approval Date: 2/1/1994

Generic Name: **Peginterferon alfa-2a** Trade Name: PEGASYS

Designated Indication: *Treatment of chronic myelogenous leukemia.*

Sponsor: Hoffman-La Roche Inc.
Address: 340 Kingsland St.
Nutley NJ 07110-1199

Date Designated: 9/30/1999
Market Approval Date: Not currently Approved

Generic Name: **Peginterferon alfa-2a** Trade Name: PEGASYS

Designated Indication: *Treatment of renal cell carcinoma.*

Sponsor: Hoffman-La Roche Inc.
Address: 340 Kingsland St.
Nutley NJ 07110-1199

Date Designated: 7/13/1998
Market Approval Date: Not currently Approved

Generic Name: **Pegvisomant** Trade Name: Somavert

Designated Indication: *Treatment of acromegaly.*

Sponsor: Sensus Corporation
Address: Suite 430,
98 San Jacinto Boulevard
Austin TX 78701

Date Designated: 6/24/1997
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Pegylated arginine deiminase** Trade Name: Melanocid

Designated Indication: *Treatment of invasive malignant melanoma.*

Sponsor: Phoenix Pharmacologics, Inc.
Address: 115 John Robert Thomas Dr.
Exton PA 19341

Date Designated: 4/12/1999
Market Approval Date: Not currently Approved

Generic Name: **Pegylated arginine deiminase** Trade Name: Hepacid

Designated Indication: *Treatment of hepatocellular carcinoma.*

Sponsor: Phoenix Pharmacologics, Inc.
Address: 115 John Robert Thomas Dr.
Exton PA 19341

Date Designated: 3/26/1999
Market Approval Date: Not currently Approved

Generic Name: **Pegylated recombinant human megakaryocyte growth and development factor** Trade Name: MEGAGEN

Designated Indication: *For reducing the period of thrombocytopenia in patients undergoing hematopoietic stem cell transplantation.*

Sponsor: Amgen, Inc.
Address: One Amgen Center Dr.
Thousand Oaks CA 91320-1789

Date Designated: 10/20/1997
Market Approval Date: Not currently Approved

Generic Name: **Peldesine** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of cutaneous T-cell lymphoma.*

Sponsor: BioCryst Pharmaceuticals, Inc.
Address: 2190 Parkway Lake Drive
Birmingham AL 35244

Date Designated: 10/5/1993
Market Approval Date: Not currently Approved

Generic Name: **pemetrexed disodium** Trade Name: Alimta

Designated Indication: *Treatment of malignant pleural mesothelioma*

Sponsor: Eli Lilly and Company
Address: Lilly Corporate Center
Indianapolis IN 46285

Date Designated: 8/28/2001
Market Approval Date: Not currently Approved

Generic Name: **Pentamidine isethionate** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of Pneumocystis carinii pneumonia.*

Sponsor: Aventis Behring L.L.C.
Address: 1020 First Avenue
PO Box 61501
King of Prussia PA 19406-0901

Date Designated: 10/29/1984
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Pentamidine isethionate** Trade Name: Nebupent

Designated Indication: *Prevention of Pneumocystis carinii pneumonia in patients at high risk of developing this disease.*

Sponsor: Fujisawa USA, Inc.
Address: 3 Parkway North Center
Deerfield IL 60015

Date Designated: 1/12/1988
Market Approval Date: 6/15/1989

Generic Name: **Pentamidine isethionate** Trade Name: Pentam 300

Designated Indication: *Treatment of Pneumocystis carinii pneumonia.*

Sponsor: Fujisawa USA, Inc.
Address: 3 Parkway North Center
Deerfield IL 60015

Date Designated: 2/28/1984
Market Approval Date: 10/16/1984

Generic Name: **Pentamidine isethionate (inhalation)** Trade Name: Pneumopent

Designated Indication: *Prevention of Pneumocystis carinii pneumonia in patients at high risk of developing this disease.*

Sponsor: Fisons Corporation
Address: 755 Jefferson Rd., P.O. Box 1710
Rochester NY 14603

Date Designated: 10/5/1987
Market Approval Date: Not currently Approved

Generic Name: **Pentastarch** Trade Name: Pentaspan

Designated Indication: *As an adjunct in leukapheresis to improve the harvesting and increase the yield of leukocytes by centrifugal means.*

Sponsor: Du Pont Pharmaceuticals
Address: E.I. Du Pont De Nemours & Co.
Wilmington DE 19898

Date Designated: 8/28/1985
Market Approval Date: 5/19/1987

Generic Name: **Pentosan polysulfate sodium** Trade Name: Elmiron

Designated Indication: *Treatment of interstitial cystitis.*

Sponsor: Alza Corporation
Address: 950 Page Mill Rd.
PO Box 10950
Palo Alto CA 94303-0802

Date Designated: 8/7/1985
Market Approval Date: 9/26/1996

Generic Name: **Pentostatin** Trade Name: Nipent

Designated Indication: *Treatment of peripheral T-cell lymphomas.*

Sponsor: SuperGen, Inc.
Address: 4140 Dublin Blvd.
Suite 200
Dublin CA 94568

Date Designated: 11/24/1999
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Pentostatin** Trade Name: Nipent

Designated Indication: *Treatment of cutaneous T-cell lymphoma.*

Sponsor: SuperGen, Inc.
Address: 4140 Dublin Blvd.
Suite 200
Dublin CA 94568

Date Designated: 3/27/1998
Market Approval Date: Not currently Approved

Generic Name: **Pentostatin** Trade Name: Nipent

Designated Indication: *Treatment of patients with chronic lymphocytic leukemia.*

Sponsor: SuperGen, Inc.
Address: 4140 Dublin Blvd.
Suite 200
Dublin CA 94568

Date Designated: 1/29/1991
Market Approval Date: Not currently Approved

Generic Name: **Pentostatin for injection** Trade Name: Nipent

Designated Indication: *Treatment of hairy cell leukemia.*

Sponsor: SuperGen, Inc.
Address: 4140 Dublin Blvd.
Suite 200
Dublin CA 94568

Date Designated: 9/10/1987
Market Approval Date: 10/11/1991

Generic Name: **Perflubron** Trade Name: LiquiVent

Designated Indication: *Treatment of acute respiratory distress disease (ARDS) in adults*

Sponsor: Alliance Pharmaceutical Corp.
Address: 3040 Science Park Road
San Diego CA 92191

Date Designated: 4/26/2001
Market Approval Date: Not currently Approved

Generic Name: **Pergolide** Trade Name: Permax

Designated Indication: *Treatment of Tourette's syndrome.*

Sponsor: Sallee, Floyd R. M.D., Ph.D.
Address: Medical University of South Carolina
171 Ashley Avenue, Room PH246
Charleston SC 29425

Date Designated: 11/20/1997
Market Approval Date: Not currently Approved

Generic Name: **Phenylacetate** Trade Name: NONE ASSIGNED

Designated Indication: *For use as an adjunct to surgery, radiation therapy and chemotherapy for the treatment of patients with primary or recurrent malignant glioma.*

Sponsor: Elan Pharmaceutical Research Corp.
Address: 1300 Gould Dr.
Gainesville GA 30504

Date Designated: 3/6/1998
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Phenylalanine ammonia-lyase** Trade Name: Phenylase

Designated Indication: *Treatment of hyperphenylalaninemia.*

Sponsor: Ibex Technologies, Inc.
Address: 5485 Pare
Montreal, Quebec
Canada H4P 1P7 CA

Date Designated: 3/8/1995
Market Approval Date: Not currently Approved

Generic Name: **Phenylbutyrate** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of acute promyelocytic leukemia.*

Sponsor: Elan Corporation
Address: 1300 Gould Dr.
Gainesville GA 30504

Date Designated: 1/19/2000
Market Approval Date: Not currently Approved

Generic Name: **Phosphocysteamine** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of cystinosis.*

Sponsor: Medea Research Laboratories
Address: Port Jefferson Business Center
200 Wilson Street, Building D-6
Port Jefferson NY 11776

Date Designated: 9/12/1988
Market Approval Date: Not currently Approved

Generic Name: **physostigmine salicylate** Trade Name: Antilirium

Designated Indication: *Treatment of Friedreich's and other inherited ataxias.*

Sponsor: Forest Pharmaceuticals, Inc.
Address: 150 East 58th Street
New York NY 10155

Date Designated: 1/16/1985
Market Approval Date: Not currently Approved

Generic Name: **Pilocarpine** Trade Name: Salagen

Designated Indication: *Treatment of xerostomia induced by radiation therapy for head and neck cancer.*

Sponsor: MGI Pharma, Inc.
Address: 6300 West Old Shakopee Rd.
Suite 110
Bloomington MN 55438-2318

Date Designated: 9/24/1990
Market Approval Date: 3/22/1994

Generic Name: **Pilocarpine HCl** Trade Name: Salagen

Designated Indication: *Treatment of xerostomia and keratoconjunctivitis sicca in Sjogren's syndrome patients.*

Sponsor: MGI Pharma, Inc.
Address: 6300 West Old Shakopee Rd.
Suite 110
Bloomington MN 55438-2318

Date Designated: 2/28/1992
Market Approval Date: 2/11/1998

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Piracetam** | Trade Name: Nootropil

Designated Indication: *Treatment of myoclonus.*

Sponsor: UCB Pharma, Inc.
Address: 1950 Lake Park Drive
Smyrna GA 30080

Date Designated: 10/2/1987
Market Approval Date: Not currently Approved

Generic Name: **Polifeprosan 20 with carmustine** | Trade Name: Gliadel

Designated Indication: *Treatment of malignant glioma.*

Sponsor: Guilford Pharmaceuticals, Inc.
Address: 6611 Tributary Street
Baltimore MD 21224

Date Designated: 12/13/1989
Market Approval Date: 9/23/1996

Generic Name: **Poloxamer 188** | Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of vasospasm in subarachnoid hemorrhage patients following surgical repair of a ruptured cerebral aneurysm.*

Sponsor: CytRx Corporation
Address: 154 Technology Parkway
Norcross GA 30092

Date Designated: 8/5/1997
Market Approval Date: Not currently Approved

Generic Name: **Poloxamer 188** | Trade Name: Flocor

Designated Indication: *Treatment of sickle cell crisis.*

Sponsor: CytRx Corporation
Address: 154 Technology Parkway
Norcross GA 30092

Date Designated: 6/27/1989
Market Approval Date: Not currently Approved

Generic Name: **Poloxamer 188** | Trade Name: Florcor

Designated Indication: *Treatment of severe burns requiring hospitalization.*

Sponsor: CytRx Corporation
Address: 154 Technology Parkway
Norcross GA 30092

Date Designated: 2/22/1990
Market Approval Date: Not currently Approved

Generic Name: **Poloxamer 331** | Trade Name: Protox

Designated Indication: *Initial therapy of toxoplasmosis in patients with AIDS.*

Sponsor: CytRx Corporation
Address: 154 Technology Parkway
Norcross GA 30092

Date Designated: 3/21/1991
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Poly I: poly C12U** Trade Name: Ampligen

Designated Indication: *Treatment of AIDS.*

Sponsor: Hemispherx Biopharma, Inc.
Address: One Penn Center
1617 JFK Boulevard
Philadelphia PA 19103

Date Designated: 7/19/1988
Market Approval Date: Not currently Approved

Generic Name: **Poly I: poly C12U** Trade Name: Ampligen

Designated Indication: *Treatment of chronic fatigue syndrome.*

Sponsor: Hemispherx Biopharma, Inc.
Address: One Penn Center
1617 JFK Boulevard
Philadelphia PA 19103

Date Designated: 12/9/1993
Market Approval Date: Not currently Approved

Generic Name: **Poly I: poly C12U** Trade Name: Ampligen

Designated Indication: *Treatment of invasive metastatic melanoma (stage IIb, III, IV).*

Sponsor: Hemispherx Biopharma, Inc.
Address: One Penn Center
1617 JFK Boulevard
Philadelphia PA 19103

Date Designated: 12/9/1993
Market Approval Date: Not currently Approved

Generic Name: **Poly I: poly C12U** Trade Name: Ampligen

Designated Indication: *Treatment of renal cell carcinoma.*

Sponsor: Hemispherx Biopharma, Inc.
Address: One Penn Center
1617 JFK Boulevard
Philadelphia PA 19103

Date Designated: 5/20/1991
Market Approval Date: Not currently Approved

Generic Name: **Poly-ICLC** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of primary brain tumors.*

Sponsor: Salazar, Andres M. M.D. and Levy, Hilton B.
Address: 3202 Cleveland Avenue N.W.
Washington DC 20008

Date Designated: 3/17/1997
Market Approval Date: Not currently Approved

Generic Name: **Polyethylene glycol (PEG)-uricase** Trade Name: NONE ASSIGNED

Designated Indication: *To control the clinical consequences of hyperuricemia in patients with severe gout in whom conventional therapy is contraindicated or has been ineffective.*

Sponsor: Bio-Technology General Corporation
Address: 70 Wood Avenue South
Iselin NJ 08830

Date Designated: 2/21/2001
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name:	**Polyethylene glycol-modified uricase**	Trade Name:	Zurase
Designated Indication:	*Prophylaxis of hyperuricemia in cancer patients prone to develop tumor lysis syndrome during chemotherapy.*		
Sponsor:	Phoenix Pharmacologics, Inc.	Date Designated:	9/14/1999
Address:	115 John Robert Thomas Dr. Exton PA 19341	Market Approval Date:	Not currently Approved

Generic Name:	**Polyethylene glycol-modified uricase**	Trade Name:	Zurase
Designated Indication:	*Treatment of tumor lysis syndrome in cancer patients undergoing chemotherapy.*		
Sponsor:	Phoenix Pharmacologics, Inc.	Date Designated:	12/21/1998
Address:	115 John Robert Thomas Dr. Exton PA 19341	Market Approval Date:	Not currently Approved

Generic Name:	**Polymeric oxygen**	Trade Name:	NONE ASSIGNED
Designated Indication:	*Treatment of sickle cell anemia.*		
Sponsor:	Capmed USA	Date Designated:	3/25/1992
Address:	P.O. Box 14 Bryn Mawr PA 19010	Market Approval Date:	Not currently Approved

Generic Name:	**Porcine fetal neural dopaminergic cells and/or precursors aseptically prepared and coated with anti-MHC-1 Ab for intracerebral implantation**	Trade Name:	NeuroCell-PD
Designated Indication:	*Treatment of Hoehn and Yahr stage 4 and 5 Parkinson's disease.*		
Sponsor:	Diacrin, Inc.	Date Designated:	12/17/1996
Address:	One Kendall Square Cambridge MA 02139-1562	Market Approval Date:	Not currently Approved

Generic Name:	**Porcine fetal neural dopaminergic cells and/or precursors aseptically prepared for intracerebral**	Trade Name:	NeuroCell-PD
Designated Indication:	*Treatment of Hoehn and Yahr stage 4 and 5 Parkinson's disease.*		
Sponsor:	Diacrin, Inc.	Date Designated:	12/17/1996
Address:	One Kendall Square Cambridge MA 02139-1562	Market Approval Date:	Not currently Approved

Generic Name:	**Porcine fetal neural gabaergic cells and/or precursors aseptically prepared and coated with anti-MHC-1 Ab for intracerebral implantation**	Trade Name:	NeuroCell-HD
Designated Indication:	*Treatment of Huntington's disease.*		
Sponsor:	Diacrin, Inc.	Date Designated:	12/10/1996
Address:	One Kendall Square Cambridge MA 02129-1562	Market Approval Date:	Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Porcine fetal neural gabaergic cells and/or precursors aseptically prepared for intracerebral implantation for Huntington's disease.**
Trade Name: NeuroCell-HD

Designated Indication: *Treatment of Huntington's disease.*

Sponsor: Diacrin, Inc.
Address: One Kendall Square
Cambridge MA 02139-1562

Date Designated: 12/10/1996
Market Approval Date: Not currently Approved

Generic Name: **Porcine Sertoli cells aseptically prepared for intracerebral co-implantation with fetal neural tissue**
Trade Name: N-Graft

Designated Indication: *Treatment of Hoehn and Yahr stage four and five Parkinson's disease.*

Sponsor: Titan Pharmaceuticals, Inc.
Address: Post Office Plaza
50 Division Street, Suite 503
Somerville NJ 08876

Date Designated: 6/24/1997
Market Approval Date: Not currently Approved

Generic Name: **porfimer**
Trade Name: Photofrin

Designated Indication: *For the ablation of High-Grade Dysplasia in Barrett's Esophagus in patients who are not considered to be candidates for esophagectomy*

Sponsor: Axcan Scandipharm Inc.
Address: 22 Inverness Parkway
Suite 310
Birmingham AL 35242

Date Designated: 10/19/2001
Market Approval Date: Not currently Approved

Generic Name: **Porfimer sodium**
Trade Name: Photofrin

Designated Indication: *For the photodynamic therapy of patients with transitional cell carcinoma in situ of the urinary bladder.*

Sponsor: QLT Phototherapeutics, Inc.
Address: Lederle Laboratories
401 North Middletown Road
Pearl River NY 10965

Date Designated: 11/15/1989
Market Approval Date: Not currently Approved

Generic Name: **Porfimer sodium**
Trade Name: Photofrin

Designated Indication: *For the photodynamic therapy of patients with primary or recurrent obstructing (either partially or completely) esophageal carcinoma.*

Sponsor: QLT Phototherapeutics, Inc.
Address: Lederle Laboratories
401 North Middletown Road
Pearl River NY 10965

Date Designated: 6/6/1989
Market Approval Date: 12/27/1995

Generic Name: **Porfiromycin**
Trade Name: Promycin

Designated Indication: *Treatment of head and neck cancer.*

Sponsor: Boehringer Ingelheim Pharmaceuticals, Inc.
Address: 900 Ridgebury Road
PO Box 368
Ridgefield CT 06877

Date Designated: 9/19/1995
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Porfiromycin** | Trade Name: Promycin

Designated Indication: *Treatment of cervical cancer.*

Sponsor: Boehringer Ingelheim Pharmaceuticals, Inc.
Address: 900 Ridgebury Road, PO Box 368, Ridgefield CT 06877

Date Designated: 3/13/1997
Market Approval Date: Not currently Approved

Generic Name: **Potassium citrate** | Trade Name: Urocit-K

Designated Indication: *For avoidance of the complication of calcium stone formation in patients with uric lithiasis.*

Sponsor: University of Texas Health Science Center at
Address: 5323 Harry Hines Blvd, Dallas TX 75235

Date Designated: 9/12/1985
Market Approval Date: 8/30/1985

Generic Name: **Potassium citrate** | Trade Name: Urocit-K

Designated Indication: *Prevention of uric acid nephrolithiasis.*

Sponsor: University of Texas Health Science Center at
Address: 5323 Harry Hines Boulevard, Dallas TX 75235

Date Designated: 11/1/1984
Market Approval Date: 8/30/1985

Generic Name: **Potassium citrate** | Trade Name: Urocit-K

Designated Indication: *Prevention of calcium renal stones in patients with hypocitraturia.*

Sponsor: University of Texas Health Science Center at
Address: 5323 Harry Hines Blvd, Dallas TX 75235

Date Designated: 9/16/1985
Market Approval Date: 8/30/1985

Generic Name: **Primaquine phosphate** | Trade Name: NONE ASSIGNED

Designated Indication: *For use in combination with clindamycin hydrochloride in the treatment of Pneumocystis carinii pneumonia associated with AIDS.*

Sponsor: Sanofi Winthrop, Inc.
Address: 90 Park Avenue, New York NY 10016

Date Designated: 7/23/1993
Market Approval Date: Not currently Approved

Generic Name: **Progesterone** | Trade Name: NONE ASSIGNED

Designated Indication: *Establishment and maintenance of pregnancy in women undergoing in vitro fertilization or embryo transfer procedures.*

Sponsor: Watson Laboratories, Inc.
Address: 311 Bonnie Circle, Corona CA 91720

Date Designated: 12/22/1994
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Prostaglandin E1 enol ester (AS-013)**
Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of Fontaine Stage IV chronic critical limb ischemia.*

Sponsor: Welfide International Corporation
Address: 5555 Valley Boulevard
Los Angeles CA 90032

Date Designated: 6/12/1998
Market Approval Date: Not currently Approved

Generic Name: **Protein C concentrate**
Trade Name: Protein C Concentrate (human) Vapor Heated, Immuno

Designated Indication: *For replacement therapy in congenital protein C deficiency for the prevention and treatment of thrombosis, pulmonary emboli, and purpura fulminans.*

Sponsor: Baxter Healthcare Corporation
Address: Hyland Division (Baxter Hyland)
550 North Brand Blvd.
Glendale CA 91203

Date Designated: 6/23/1992
Market Approval Date: Not currently Approved

Generic Name: **Protein C concentrate**
Trade Name: Protein C Concentrate (human) Vapor Heated, Immuno

Designated Indication: *For replacement therapy in patients with congenital or acquired protein C deficiency for the prevention and treatment of warfarin-induced skin necrosis during oral anticoagulation.*

Sponsor: Immuno Clinical Research Corp.
Address: 750 Lexington Avenue, 19th Floor
New York NY 10022

Date Designated: 6/19/1992
Market Approval Date: Not currently Approved

Generic Name: **Pulmonary surfactant replacement, porcine**
Trade Name: Curosurf

Designated Indication: *For the treatment and prevention of respiratory distress syndrome in premature infants.*

Sponsor: Dey Laboratories
Address: 2751 Napa Valley Corporate Drive
Napa CA 94558

Date Designated: 8/2/1993
Market Approval Date: Not currently Approved

Generic Name: **Purified extract of Pseudomonas aeruginosa**
Trade Name: ImmuDyn

Designated Indication: *Treatment of immune thrombocytopenia purpura where it is required to increase platelet counts.*

Sponsor: DynaGen, Inc.
Address: 99 Erie Street
Cambridge MA 02139

Date Designated: 9/22/1997
Market Approval Date: Not currently Approved

Generic Name: **Purified type II collagen**
Trade Name: Colloral

Designated Indication: *Treatment of juvenile rheumatoid arthritis.*

Sponsor: AutoImmune, Inc.
Address: 128 Spring Street
Lexington MA 02421

Date Designated: 2/9/1995
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **pVGI.1(VEGF2)**
Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of thromboangiitis obliterans.*

Sponsor: Vascular Genetics, Inc.
Address: 200 Westpark Corporate Center
4364 South Alston Ave.
Durham NC 27713-2280

Date Designated: 11/9/1999
Market Approval Date: Not currently Approved

Generic Name: **Pyruvate**
Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of interstitial lung disease.*

Sponsor: Cellular Sciences, Inc
Address: 84 park Avenue
P.O. Box 968
Flemington NJ 08822

Date Designated: 2/21/2001
Market Approval Date: Not currently Approved

Generic Name: **Radiolabeled monoclonal antibody to CD22 antigen on B-cells**
Trade Name: LymphoCIDE

Designated Indication: *Treatment of non-Hodgkin's lymphoma.*

Sponsor: Immunomedics, Inc.
Address: 300 American Rd.
Morris Plains NJ 07950

Date Designated: 7/13/1998
Market Approval Date: Not currently Approved

Generic Name: **Recombinant bactericidal/permeability-increasing protein**
Trade Name: Neuprex

Designated Indication: *Treatment of severe meningococcal disease.*

Sponsor: Xoma Corporation
Address: 2910 Seventh Street
Berkeley CA 94710

Date Designated: 6/22/1998
Market Approval Date: Not currently Approved

Generic Name: **Recombinant glycine2-human glucagon-like peptide-2**
Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of short bowel syndrome.*

Sponsor: NPS Allelix Corp.
Address: 6850 Goreway Dr.
Mississauga, Ontario
L4V 1V7 Canada CA

Date Designated: 6/29/2000
Market Approval Date: Not currently Approved

Generic Name: **Recombinant human acid alpha-glucosidase**
Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of glycogen storage disease type II.*

Sponsor: Genzyme Corporation
Address: 15 Pleasant Street
P.O. Box 9322
Framingham MA 01701-9322

Date Designated: 8/19/1997
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **recombinant human alpha 1-antitrypsin (rAAT)** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of cystic fibrosis*

Sponsor: Arriva Pharmaceuticals, Inc.
Address: 2020 Challenger Drive
Alameda CA 94501

Date Designated: 11/20/2001
Market Approval Date: Not currently Approved

Generic Name: **recombinant human alpha-1 antitrypsin** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of cystic fibrosis.*

Sponsor: PPL Therapeutics (Scotland) Limited
Address: Roslin, Edinburgh
EH25 9PP Scotland GB

Date Designated: 3/6/1998
Market Approval Date: Not currently Approved

Generic Name: **recombinant human alpha-1 antitrypsin (rAAT)** Trade Name: NONE ASSIGNED

Designated Indication: *To delay progression of chronic obstructive pulmonary disease resulting from AAT deficiency-mediated emphysema and bronchiectasis*

Sponsor: Baxter Healthcare Corporation
Address: 550 N. Brand Blvd.
Glendale CA 91203

Date Designated: 8/28/2001
Market Approval Date: Not currently Approved

Generic Name: **Recombinant Human Alpha-Fetoprotein (rhAFP)** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of myasthenia gravis*

Sponsor: Atlantic Biopharmaceuticals, Inc.
Address: 50 Church Street
5th floor
Cambridge MA 02138

Date Designated: 2/22/2001
Market Approval Date: Not currently Approved

Generic Name: **Recombinant human antithrombin III** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of antithrombin III dependent heparin resistance requiring anticoagulation.*

Sponsor: AT III LLC
Address: c/o Genzyme Corporation
15 Pleasant St. Connector, P.O. Box 9322
Framingham MA 01701

Date Designated: 4/6/2000
Market Approval Date: Not currently Approved

Generic Name: **Recombinant human C1-esterase inhibitor** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of (acute attacks of) angioedema caused by hereditary or acquired C1-esterase inhibitor deficiency.*

Sponsor: Pharming N.V.
Address: Cipalstreet 3
B-2440 Geel
Belgium BE

Date Designated: 2/23/1999
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Recombinant human C1-esterase inhibitor** Trade Name: NONE ASSIGNED

Designated Indication: *Prophylactic treatment of angioedema caused by hereditary or acquired C1-esterase inhibitor deficiency.*

Sponsor: Pharming N.V.
Address: Cipalstreet 3
B-2440 Geel
Belgium BE

Date Designated: 2/23/1999
Market Approval Date: Not currently Approved

Generic Name: **Recombinant human CD4 immunoglobulin G** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of AIDS resulting from infection with HIV-1.*

Sponsor: Genentech, Inc.
Address: 460 Point San Bruno Boulevard
South San Francisco CA 94080

Date Designated: 8/30/1990
Market Approval Date: Not currently Approved

Generic Name: **Recombinant human Clara Cell 10kDa protein** Trade Name: NONE ASSIGNED

Designated Indication: *Prevention of neonatal bronchopulmonary dysplasia in premature neonates with respiratory distress syndrome.*

Sponsor: Claragen, Inc.
Address: 335 Paint Branch Drive
College Park MD 20742

Date Designated: 7/13/1998
Market Approval Date: Not currently Approved

Generic Name: **recombinant human endostatin protein** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of neuroendocrine tumors.*

Sponsor: EntreMed, Inc.
Address: 9640 Medical Center Drive
Rockville MD 20850

Date Designated: 8/13/2001
Market Approval Date: Not currently Approved

Generic Name: **Recombinant human gelsolin** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of the respiratory symptoms of cystic fibrosis.*

Sponsor: Biogen, Inc.
Address: 14 Cambridge Center
Cambridge MA 02124

Date Designated: 1/12/1994
Market Approval Date: Not currently Approved

Generic Name: **Recombinant human gelsolin** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of acute and chronic respiratory symptoms of bronchiectasis.*

Sponsor: Biogen, Inc.
Address: 14 Cambridge Center
Cambridge MA 02142

Date Designated: 3/6/1995
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Recombinant human highly phosphorylated acid alpha-glucosidase**
Trade Name: TBD

Designated Indication: *For enzyme replacement therapy in patients with all subtypes of glycogen storage disease type II (GSDII, Pompe Disease)*

Sponsor: Novazyme Pharmaceuticals, Inc.
Address: 800 Research Parkway
Suite 200
Oklahoma City OK 73104

Date Designated: 9/20/2000
Market Approval Date: Not currently Approved

Generic Name: **Recombinant human insulin-like growth factor-I**
Trade Name: PV802

Designated Indication: *Treatment of short-bowel syndrome as a result of resection of the small bowel or as a result of congenital dysfunction of the intestines.*

Sponsor: GroPep Pty Ltd.
Address: Gate 11, Victoria Dr.
Adelaide SA 5000
Australia AU

Date Designated: 2/16/2000
Market Approval Date: Not currently Approved

Generic Name: **Recombinant human insulin-like growth factor-I**
Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of post-poliomyelitis syndrome.*

Sponsor: Cephalon, Inc.
Address: 145 Brandywine Parkway
West Chester PA 19380-4245

Date Designated: 10/13/1995
Market Approval Date: Not currently Approved

Generic Name: **Recombinant human insulin-like growth factor-I/insulin-like growth factor binding protein-3**
Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of major burns that require hospitalization.*

Sponsor: Celtrix Pharmaceuticals, Inc.
Address: 3055 Patrick Henry Dr.
Santa Clara CA 95054

Date Designated: 6/15/1999
Market Approval Date: Not currently Approved

Generic Name: **Recombinant human interleukin-12**
Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of renal cell carcinoma.*

Sponsor: Genetics Institute, Inc.
Address: 87 CambridgePark Drive
Cambridge MA 02140

Date Designated: 10/20/1997
Market Approval Date: Not currently Approved

Generic Name: **Recombinant human keratinocyte growth factor**
Trade Name: NONE ASSIGNED

Designated Indication: *Reducing the incidence and severity of radiation-induced xerostomia.*

Sponsor: Amgen Inc.
Address: One Amgen Center Dr.
Thousand Oaks CA 91320-1799

Date Designated: 12/20/1999
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Recombinant human luteinizing hormone** Trade Name: LHadi

Designated Indication: *For use in association with recombinant human follicle stimulating hormone for the treatment of women with chronic anovulation due to hypogonadotropic hypogonadism.*

Sponsor: Serono Laboratories, Inc.
Address: 100 Longwater Circle
Norwell MA 02061

Date Designated: 10/7/1994
Market Approval Date: Not currently Approved

Generic Name: **Recombinant human nerve growth factor** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of HIV-associated sensory neuropathy.*

Sponsor: Genentech, Inc.
Address: 1 DNA Way
South San Francisco CA 94080

Date Designated: 4/16/1999
Market Approval Date: Not currently Approved

Generic Name: **Recombinant human relaxin** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of progressive systemic sclerosis.*

Sponsor: Connetics Corporation
Address: 3400 West Bayshore Road
Palo Alto CA 94303

Date Designated: 11/3/1995
Market Approval Date: Not currently Approved

Generic Name: **Recombinant human superoxide dismutase** Trade Name: Oxsodrol

Designated Indication: *Prevention of bronchopulmonary dysplasia in premature neonates weighing less than 1500 grams.*

Sponsor: Bio-Technology General Corp.
Address: 70 Wood Avenue, South
Iselin NJ 08830

Date Designated: 4/18/1991
Market Approval Date: Not currently Approved

Generic Name: **Recombinant human thrombopoietin** Trade Name: NONE ASSIGNED

Designated Indication: *For use in accelerating platelet recovery in patients undergoing hematopoietic stem cell transplantation.*

Sponsor: Genentech, Inc.
Address: 1 DNA Way
South San Francisco CA 94080-4990

Date Designated: 9/29/1997
Market Approval Date: Not currently Approved

Generic Name: **Recombinant humanized MAb 5c8** Trade Name: NONE ASSIGNED

Designated Indication: *Prevention of rejection of pancreatic islet cell transplants.*

Sponsor: Biogen, Inc.
Address: 14 Cambridge Center
Cambridge MA 02142

Date Designated: 3/22/1999
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name:	**Recombinant humanized MAb 5c8**	Trade Name:	NONE ASSIGNED
Designated Indication:	*Prevention and treatment of Factor VIII/Factor IX inhibitors in patients with hemophilia A or B.*		
Sponsor:	Biogen, Inc.	Date Designated:	10/14/1998
Address:	14 Cambridge Center Cambridge MA 02142	Market Approval Date:	Not currently Approved

Generic Name:	**Recombinant humanized MAb 5c8**	Trade Name:	NONE ASSIGNED
Designated Indication:	*Prevention of rejection of solid organ transplants.*		
Sponsor:	Biogen, Inc.	Date Designated:	3/22/1999
Address:	14 Cambridge Center Cambridge MA 02142	Market Approval Date:	Not currently Approved

Generic Name:	**Recombinant humanized monclonal antibody 5c8**	Trade Name:	NONE ASSIGNED
Designated Indication:	*Treatment of immune thrombocytopenic purpura.*		
Sponsor:	Biogen, Inc.	Date Designated:	2/3/1998
Address:	14 Cambridge Center Cambridge MA 02142	Market Approval Date:	Not currently Approved

Generic Name:	**Recombinant humanized monoclonal antibody 5c8**	Trade Name:	NONE ASSIGNED
Designated Indication:	*Treatment of systemic lupus erythematosus.*		
Sponsor:	Biogen, Inc.	Date Designated:	2/18/1998
Address:	14 Cambridge Center Cambridge MA 02142	Market Approval Date:	Not currently Approved

Generic Name:	**Recombinant methionyl brain-derived neurotrophic factor**	Trade Name:	NONE ASSIGNED
Designated Indication:	*Treatment of amyotrophic lateral sclerosis.*		
Sponsor:	Amgen, Inc.	Date Designated:	11/28/1994
Address:	One Amgen Center Dr. Thousand Oaks CA 91320-1799	Market Approval Date:	Not currently Approved

Generic Name:	**Recombinant methionyl human stem cell factor**	Trade Name:	NONE ASSIGNED
Designated Indication:	*Treatment of primary bone marrow failure.*		
Sponsor:	Amgen, Inc.	Date Designated:	11/22/1995
Address:	One Amgen Center Drive Thousand Oaks CA 91320-1799	Market Approval Date:	Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Recombinant retroviral vector - glucocerebrosidase** Trade Name: NONE ASSIGNED

Designated Indication: *For use as enzyme replacement therapy for patients with types I, II, or III Gaucher disease.*

Sponsor: Genetic Therapy, Inc.
Address: 938 Clopper Road
Gaithersburg MD 20878

Date Designated: 11/15/1993
Market Approval Date: Not currently Approved

Generic Name: **Recombinant secretory leucocyte protease inhibitor** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of cystic fibrosis.*

Sponsor: Amgen, Inc.
Address: 3200 Walnut Street
Boulder CO 80301

Date Designated: 3/29/1991
Market Approval Date: Not currently Approved

Generic Name: **Recombinant secretory leucocyte protease inhibitor** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of congenital alpha-1 antitrypsin deficiency.*

Sponsor: Amgen Inc.
Address: 3200 Walnut Street
Boulder CO 80301

Date Designated: 3/29/1991
Market Approval Date: Not currently Approved

Generic Name: **Recombinant soluble human CD4 (rCD4)** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of AIDS in patients infected with HIV virus.*

Sponsor: Genentech, Inc.
Address: 460 Point San Bruno Boulevard
South San Francisco CA 94080

Date Designated: 3/23/1989
Market Approval Date: Not currently Approved

Generic Name: **Recombinant urate oxidase** Trade Name: NONE ASSIGNED

Designated Indication: *Prophylaxis of chemotherapy-induced hyperuricemia.*

Sponsor: Sanofi-Synthelabo Research
Address: 9 Great Valley Parkway
Malvern PA 19355

Date Designated: 10/11/2000
Market Approval Date: Not currently Approved

Generic Name: **Recombinant urate oxidase** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of malignancy-associated or chemotherapy-induced hyperuricemia.*

Sponsor: Sanofi-Synthelabo Research
Address: 9 Great Valley Parkway
Malvern PA 19355

Date Designated: 10/11/2000
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Recombinant vaccinia (human papillomavirus)**
Trade Name: TA-HPV

Designated Indication: *Treatment of cervical cancer.*

Sponsor: Cantab Pharmaceuticals Research Limited
Address: 310 Cambridge Science Park
Cambridge CB4 OWG
Great Britain GB

Date Designated: 8/24/1994
Market Approval Date: Not currently Approved

Generic Name: **Reduced L-glutathione**
Trade Name: Cachexon

Designated Indication: *Treatment of AIDS-associated cachexia.*

Sponsor: Telluride Pharmaceutical Corporation
Address: 146 Flanders Drive
Hillsborough NJ 08876

Date Designated: 2/14/1994
Market Approval Date: Not currently Approved

Generic Name: **Remacemide**
Trade Name: Ecovia

Designated Indication: *Treatment of Huntington's disease.*

Sponsor: AstraZeneca LP
Address: 725 Chesterbrook Blvd.
Wayne PA 19087-5677

Date Designated: 3/6/2000
Market Approval Date: Not currently Approved

Generic Name: **Respiratory Syncytial Virus Immune Globulin (human)**
Trade Name: Hypermune RSV

Designated Indication: *Treatment of respiratory syncytial virus lower respiratory tract infections in hospitalized infants and young children.*

Sponsor: MedImmune, Inc.
Address: 35 West Watkins Mill Road
Gaithersburg MD 20878

Date Designated: 9/27/1990
Market Approval Date: Not currently Approved

Generic Name: **Respiratory syncytial virus immune globulin (Human)**
Trade Name: Respigam

Designated Indication: *Prophylaxis of respiratory syncytial virus lower respiratory tract infections in infants and young children at high risk of RSV disease.*

Sponsor: MedImmune & Massachussetts Public Health
Address: 35 West Watkins Mill Road
Gaithersburg MD 20878

Date Designated: 9/27/1990
Market Approval Date: 1/18/1996

Generic Name: **Retroviral vector, R-GC and GC gene 1750**
Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of Gaucher disease.*

Sponsor: Genzyme Corporation
Address: One Mountain Road
P.O. Box 9322
Framingham MA 01701-9322

Date Designated: 5/6/1997
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Reviparin sodium** Trade Name: Clivarine

Designated Indication: *Treatment of deep vein thrombosis which may lead to pulmonary embolism in pediatric patients*

Sponsor: Knoll AG
Address: Ludwigshafen, Germany

Date Designated: 6/18/2001
Market Approval Date: Not currently Approved

Generic Name: **Reviparin sodium** Trade Name: Clivarine

Designated Indication: *Long-term treatment of acute deep vein trombosis with or without pulmonary embolism in pregnant patients*

Sponsor: Knoll AG
Address: Ludwigshafen, Germany

Date Designated: 6/18/2001
Market Approval Date: Not currently Approved

Generic Name: **RGG0853, E1A lipid complex** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of ovarian cancer.*

Sponsor: Targeted Genetics Corporation
Address: 1100 Olive Way, Suite 100
Seattle WA 98101

Date Designated: 9/15/1995
Market Approval Date: Not currently Approved

Generic Name: **Rho (D) immune globulin intravenous (human)** Trade Name: WinRho SD

Designated Indication: *Treatment of immune thrombocytopenic purpura.*

Sponsor: Rh Pharmaceuticals, Inc.
Address: 104 Chancellor Matheson Road
Winnipeg, Manitoba
Canada R3T 2N2 CA

Date Designated: 11/9/1993
Market Approval Date: 3/24/1995

Generic Name: **Ribavirin** Trade Name: Virazole

Designated Indication: *Treatment of hemorrhagic fever with renal syndrome.*

Sponsor: ICN Pharmaceuticals, Inc.
Address: ICN Plaza
3300 Hyland Avenue
Costa Mesa CA 92626

Date Designated: 4/12/1991
Market Approval Date: Not currently Approved

Generic Name: **Ricin (blocked) conjugated murine MCA (anti-B4)** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of B-cell leukemia and B-cell lymphoma.*

Sponsor: ImmunoGen, Inc.
Address: 148 Sidney Street
Cambridge MA 02139

Date Designated: 11/17/1988
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Ricin (blocked) conjugated murine mca (anti-b4)**
Trade Name: NONE ASSIGNED

Designated Indication: *For the ex-vivo purging of leukemic cells from the bone marrow of non-T cell acute lymphocytic leukemia patients who are in complete remission.*

Sponsor: ImmunoGen, Inc.
Address: 148 Sidney Street
Cambridge MA 02139

Date Designated: 1/24/1991
Market Approval Date: Not currently Approved

Generic Name: **Ricin (blocked) conjugated murine MCA (anti-my9)**
Trade Name: NONE ASSIGNED

Designated Indication: *For use in the ex-vivo treatment of autologous bone marrow and subsequent reinfusion in patients with acute myelogenous leukemia.*

Sponsor: ImmunoGen, Inc.
Address: 148 Sidney Street
Cambridge MA 02139

Date Designated: 2/1/1990
Market Approval Date: Not currently Approved

Generic Name: **Ricin (blocked) conjugated murine MCA (anti-my9)**
Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of myeloid leukemia, including AML, and blast crisis of CML.*

Sponsor: ImmunoGen, Inc.
Address: 148 Sidney Street
Cambridge MA 02139

Date Designated: 8/3/1989
Market Approval Date: Not currently Approved

Generic Name: **Ricin (blocked) conjugated murine MCA (n901)**
Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of small cell lung cancer.*

Sponsor: ImmunoGen, Inc.
Address: 148 Sidney Street
Cambridge MA 02139

Date Designated: 1/25/1991
Market Approval Date: Not currently Approved

Generic Name: **Ricin (blocked) conjugated murine monoclonal antibody (CD6)**
Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of cutaneous T-cell lymphomas, acute T-cell leukemia-lymphoma, and related mature T-cell malignancies.*

Sponsor: ImmunoGen, Inc.
Address: 148 Sidney Street
Cambridge MA 02139

Date Designated: 9/6/1994
Market Approval Date: Not currently Approved

Generic Name: **Rifabutin**
Trade Name: Mycobutin

Designated Indication: *Prevention of disseminated Mycobacterium avium complex disease in patients with advanced HIV infection.*

Sponsor: Adria Laboratories, Inc.
Address: P.O. Box 16529
Columbus OH 43216

Date Designated: 12/18/1989
Market Approval Date: 12/23/1992

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Rifabutin** | Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of disseminated Mycobacterium avium complex disease.*

Sponsor: Pharmacia & Upjohn
Address: 7000 Portage Road
Unit 0633-298-113
Kalamazoo MI 49001-0199

Date Designated: 12/18/1989
Market Approval Date: Not currently Approved

Generic Name: **Rifalazil** | Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of pulmonary tuberculosis.*

Sponsor: PathoGenesis Corporation
Address: 201 Elliott Avenue West
Suite 150
Seattle WA 98119

Date Designated: 4/13/1999
Market Approval Date: Not currently Approved

Generic Name: **Rifampin** | Trade Name: Rifadin I.V.

Designated Indication: *For antituberculosis treatment where use of the oral form of the drug is not feasible.*

Sponsor: Hoechst Marion Roussel
Address: P.O. Box 9627
Kansas City MO 64134

Date Designated: 12/9/1985
Market Approval Date: 5/25/1989

Generic Name: **Rifampin, isoniazid, pyrazinamide** | Trade Name: Rifater

Designated Indication: *For the short-course treatment of tuberculosis.*

Sponsor: Hoechst Marion Roussel
Address: P.O. Box 9627
Kansas City MO 64134

Date Designated: 9/12/1985
Market Approval Date: 5/31/1994

Generic Name: **Rifapentine** | Trade Name: Priftin

Designated Indication: *Prophylactic treatment of Mycobacterium avium complex in patients with AIDS and a CD4+ count less than or equal to 75/mm3.*

Sponsor: Hoechst Marion Roussel, Inc.
Address: P.O. Box 9627
Mail Station: H3-M2516
Kansas City MO 64134-0627

Date Designated: 3/12/1996
Market Approval Date: Not currently Approved

Generic Name: **Rifapentine** | Trade Name: Priftin

Designated Indication: *Treatment of Mycobacterium avium complex in patients with AIDS.*

Sponsor: Hoechst Marion Roussel , Inc.
Address: P.O. Box 9627
Mail Station: H3-M2516
Kansas City MO 64134-0627

Date Designated: 6/9/1995
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Rifapentine** | Trade Name: Priftin

Designated Indication: *Treatment of pulmonary tuberculosis.*

Sponsor: Hoechst Marion Roussel
Address: P.O. Box 9627
Mail Station: H3-M2516
Kansas City MO 64134-0627

Date Designated: 6/9/1995
Market Approval Date: 6/22/1998

Generic Name: **Rifaximin** | Trade Name: Normix

Designated Indication: *Treatment of hepatic encephalopathy.*

Sponsor: Salix Pharmaceuticals, Inc.
Address: 3600 W. Bayshore Road, Suite 205
Palo Alto CA 94303

Date Designated: 2/10/1998
Market Approval Date: Not currently Approved

Generic Name: **RII retinamide** | Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of myelodysplastic syndromes.*

Sponsor: Sparta Pharmaceuticals, Inc.
Address: 111 Rock Road
Horsham PA 19044-2310

Date Designated: 5/6/1993
Market Approval Date: Not currently Approved

Generic Name: **Riluzole** | Trade Name: Rilutek

Designated Indication: *Treatment of amyotrophic lateral sclerosis.*

Sponsor: Rhone-Poulenc Rorer Pharmaceuticals, Inc.
Address: 500 Arcola Road, P.O. Box 1200
Collegeville PA 19426

Date Designated: 3/16/1993
Market Approval Date: 12/12/1995

Generic Name: **Riluzole** | Trade Name: Rilutek

Designated Indication: *Treatment of Huntington's disease.*

Sponsor: Rhone-Poulenc Rorer Pharmaceuticals, Inc.
Address: 500 Arcola Road
PO Box 5096
Collegeville PA 19426-0800

Date Designated: 10/15/1996
Market Approval Date: Not currently Approved

Generic Name: **Rituximab** | Trade Name: Rituxan

Designated Indication: *Treatment of non-Hodgkin's B-cell lymphoma.*

Sponsor: IDEC Pharmaceuticals Corporation
Address: 3030 Callan Road
San Diego CA 92121

Date Designated: 6/13/1994
Market Approval Date: 11/26/1997

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **rSP-C lung surfactant** Trade Name: Venticute

Designated Indication: *Treatment of adult respiratory distress syndrome.*

Sponsor: Byk Gulden Pharmaceuticals
Address: Byk-Gulden StraBe 2
78467 Konstanz
Germany DE

Date Designated: 4/3/2000
Market Approval Date: Not currently Approved

Generic Name: **S-adenosylmethionine** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of AIDS-myelopathy.*

Sponsor: Di Rocco, Alessandro M.D.
Address: Beth Israel Medical Center, Phillips
Philips Building, Suite 2Q; 10 Union Square
New York NY 10003

Date Designated: 4/30/1998
Market Approval Date: Not currently Approved

Generic Name: **Sacrosidase** Trade Name: Sucraid

Designated Indication: *Treatment of congenital sucrase-isomaltase deficiency.*

Sponsor: Orphan Medical, Inc.
Address: 13911 Ridgedale Drive
Suite 475
Minnetonka MN 55305

Date Designated: 12/10/1993
Market Approval Date: 4/9/1998

Generic Name: **Sargramostim** Trade Name: Leukine

Designated Indication: *To reduce neutropenia and leukopenia and decrease the incidence of death due to infection in patients with acute myelogenous leukemia.*

Sponsor: Immunex Corporation
Address: 51 University Street
Seattle WA 98101

Date Designated: 3/6/1995
Market Approval Date: 9/15/1995

Generic Name: **Sargramostim** Trade Name: Leukine

Designated Indication: *Treatment of neutropenia associated with bone marrow transplant, for the treatment of graft failure and delay of engraftment, and for the promotion of early engraftment.*

Sponsor: Immunex Corporation
Address: 51 University Street
Seattle WA 98101

Date Designated: 5/3/1990
Market Approval Date: 3/5/1991

Generic Name: **Satumomab pendetide** Trade Name: Oncoscint CR/OV

Designated Indication: *Detection of ovarian carcinoma.*

Sponsor: Cytogen Corporation
Address: 600 College Road East
Princeton NJ 08540

Date Designated: 9/25/1989
Market Approval Date: 12/29/1992

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **SB-408075**
Trade Name: NONE ASSIGNED

Designated Indication: *For pancreatic cancer*

Sponsor: SmithKline Beecham Pharmaceuticals
Address: 1250 S. Collegeville Road
Collegeville PA 19426-0989

Date Designated: 12/7/2000
Market Approval Date: Not currently Approved

Generic Name: **SCH 58500**
Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of primary ovarian cancer.*

Sponsor: Schering Corporation
Address: 2000 Galloping Hill Rd.
Kenilworth NJ 07033

Date Designated: 4/12/1999
Market Approval Date: Not currently Approved

Generic Name: **Secalciferol**
Trade Name: Osteo-D

Designated Indication: *Treatment of familial hypophosphatemic rickets.*

Sponsor: Teva Pharmaceuticals USA
Address: 650 Cathill Rd.
Sellersville PA 18960

Date Designated: 7/26/1993
Market Approval Date: Not currently Approved

Generic Name: **Secretory leukocyte protease inhibitor**
Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of bronchopulmonary dysplasia.*

Sponsor: Synergen, Inc.
Address: 1885 33rd Street
Boulder CO 80301

Date Designated: 6/30/1992
Market Approval Date: Not currently Approved

Generic Name: **Selegiline HCl**
Trade Name: Eldepryl

Designated Indication: *As an adjuvant to levodopa and carbidopa treatment of idiopathic Parkinson's disease (paralysis agitans), postencephalitic Parkinsonism, and symptomatic Parkinsonism.*

Sponsor: Somerset Pharmaceuticals, Inc.
Address: 777 South Harbor Island Boulevard
Tampa FL 33602

Date Designated: 11/7/1984
Market Approval Date: 6/5/1989

Generic Name: **Sermorelin acetate**
Trade Name: Geref

Designated Indication: *Treatment of idiopathic or organic growth hormone deficiency in children with growth failure.*

Sponsor: Serono Laboratories, Inc.
Address: 100 Longwater Circle
Norwell MA 02061

Date Designated: 9/14/1988
Market Approval Date: 9/26/1997

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Sermorelin acetate** Trade Name: Geref

Designated Indication: *Adjunct to gonadotropin therapy in the induction of ovulation in women with anovulatory or oligo-ovulatory infertility who fail to ovulate in response to adequate treatment with clomiphene citrate alone and gonadotropin*

Sponsor: Serono Laboratories, Inc.
Address: 100 Longwater Circle
Norwell MA 02061

Date Designated: 2/13/1990
Market Approval Date: Not currently Approved

Generic Name: **Sermorelin acetate** Trade Name: Geref

Designated Indication: *Treatment of AIDS-associated catabolism/weight loss.*

Sponsor: Serono Laboratories, Inc.
Address: 100 Longwater Circle
Norwell MA 02061

Date Designated: 12/5/1991
Market Approval Date: Not currently Approved

Generic Name: **Serratia marcescens extract (polyribosomes)** Trade Name: Imuvert

Designated Indication: *Treatment of primary brain malignancies.*

Sponsor: Cell Technology, Inc.
Address: 1668 Valtec Lane
Boulder CO 80306

Date Designated: 9/7/1988
Market Approval Date: Not currently Approved

Generic Name: **Short chain fatty acid enema** Trade Name: Colomed

Designated Indication: *Treatment of chronic radiation proctitis.*

Sponsor: Richard I. Breuer, M.D.
Address: 1000 Central Street, Suite 615
Evanston IL 60201

Date Designated: 8/19/1997
Market Approval Date: Not currently Approved

Generic Name: **Short chain fatty acid solution** Trade Name: Colomed

Designated Indication: *Treatment of the active phase of ulcerative colitis with involvement restricted to the left side of the colon.*

Sponsor: Richard I. Breuer
Address: 1000 Central Street, Suite 615
Evanston IL 60201

Date Designated: 5/29/1990
Market Approval Date: Not currently Approved

Generic Name: **Silver sulfadiazine and cerium nitrate** Trade Name: Flammacerium

Designated Indication: *Prevention of mortality in severely burned patients.*

Sponsor: Synthes (USA)
Address: 1690 Russell Road
PO Box 1766
Paoli PA 19301

Date Designated: 11/17/1999
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Sodium 1,3-propanedisulfonate** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of secondary amyloidosis.*

Sponsor: Neurochem, Inc.
Address: 7220 Frederick Banting, Suite 100
Saint-Laurent, Quebec
Canada H4S 2A1 CA

Date Designated: 4/6/1999
Market Approval Date: Not currently Approved

Generic Name: **Sodium dichloroacetate** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of homozygous familial hypercholesterolemia.*

Sponsor: Stacpoole, Peter W. M.D., Ph.D.
Address: University of Florida
P.O. Box 100277
Gainesville FL 32610

Date Designated: 6/11/1990
Market Approval Date: Not currently Approved

Generic Name: **Sodium dichloroacetate** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of lactic acidosis in patients with severe malaria.*

Sponsor: Stacpoole, Peter W. M.D., Ph.D.
Address: University Of Florida
P.O. Box 100277
Gainesville FL 32610

Date Designated: 11/10/1994
Market Approval Date: Not currently Approved

Generic Name: **Sodium dichloroacetate** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of congenital lactic acidosis.*

Sponsor: Stacpoole, Peter W. M.D., Ph.D.
Address: University of Florida
P.O. Box 100277
Gainesville FL 32610

Date Designated: 6/11/1990
Market Approval Date: Not currently Approved

Generic Name: **Sodium dichloroacetate** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of congenital lactic acidosis.*

Sponsor: Questcor Pharmaceuticals, Inc.
Address: 26118 Research Road
Hayward CA 94545

Date Designated: 12/31/1997
Market Approval Date: Not currently Approved

Generic Name: **Sodium dichloroacetate** Trade Name: Ceresine

Designated Indication: *Treatment of severe head injury.*

Sponsor: Questcor Pharmaceuticals, Inc.
Address: 26118 Research Road
Hayward CA 94545

Date Designated: 6/14/1999
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Sodium Monomercaptoundecahydro-closo-dodecaborate** Trade Name: Borocell

Designated Indication: *For use in boron neutron capture therapy (BNCT) in the treatment of glioblastoma multiforme.*

Sponsor: Neutron Technology Corp.& Neutron R&D
Address: 877 Main Street, Suite 402
Boise ID 83702

Date Designated: 4/15/1992
Market Approval Date: Not currently Approved

Generic Name: **sodium phenylbutyrate** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment for sickling disorders, which include S-S hemoglobinopathy, S-C hemoglobinopathy, and S-thalassemia hemoglobinopathy.*

Sponsor: Medicis Pharmaceutical Corp.
Address: 8125 N. Hayden Road
Scottsdale AZ 85258

Date Designated: 7/2/1992
Market Approval Date: Not currently Approved

Generic Name: **Sodium phenylbutyrate** Trade Name: NONE ASSIGNED

Designated Indication: *For use as an adjuct to surgery, radiation therapy and chemotherapy for the treatment of patients with primary or recurrent malignant glioma.*

Sponsor: Elan Pharmaceutical Research Corporation
Address: 1300 Gould Dr.
Gainesville GA 30504

Date Designated: 4/24/1998
Market Approval Date: Not currently Approved

Generic Name: **sodium phenylbutyrate** Trade Name: Buphenyl

Designated Indication: *Treatment of urea cycle disorders: carbamylphosphate synthetase deficiency, ornithine transcarbamylase deficiency, and arginiosuccinic acid synthetase deficiency.*

Sponsor: Medicis Pharmaceutical Corp.
Address: 8125 N. Hayden Road
Scottsdale AZ 85258

Date Designated: 11/22/1993
Market Approval Date: 4/30/1996

Generic Name: **Sodium tetradecyl sulfate** Trade Name: Sotradecol

Designated Indication: *Treatment of bleeding esophageal varices.*

Sponsor: Elkins-Sinn, Inc.
Address: 2 Esterbrook Lane
Cherry Hill NJ 08003

Date Designated: 6/10/1986
Market Approval Date: Not currently Approved

Generic Name: **Soluble complement receptor type 1** Trade Name: NONE ASSIGNED

Designated Indication: *Prevention of post-cardiopulmonary bypass syndrome in children undergoing cardiopulmonary bypass.*

Sponsor: Avant Immunotherapeutics, Inc.
Address: 119 Fourth Ave.
Needham MA 02494-2725

Date Designated: 3/6/2000
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Soluble recombinant human complement receptor type 1** Trade Name: NONE ASSIGNED

Designated Indication: *Prevention or reduction of adult respiratory distress syndrome.*

Sponsor: T Cell Sciences, Inc.
Address: 119 Fourth Avenue
Needham Heights MA 02194

Date Designated: 11/21/1994
Market Approval Date: Not currently Approved

Generic Name: **Somatostatin** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of bleeding esophageal varices.*

Sponsor: UCB Pharmaceuticals, Inc.
Address: 1950 Lake Park Drive
Smyrna GA 30080

Date Designated: 12/22/1994
Market Approval Date: Not currently Approved

Generic Name: **Somatostatin** Trade Name: Zecnil

Designated Indication: *Adjunct to the non-operative management of secreting cutaneous fistulas of the stomach, duodenum, small intestine (jejunum and ileum), or pancreas.*

Sponsor: Ferring Laboratories, Inc.
Address: 400 Rella Boulevard, Suite 201
Suffern NY 10901

Date Designated: 6/20/1988
Market Approval Date: Not currently Approved

Generic Name: **Somatrem for injection** Trade Name: Protropin

Designated Indication: *Treatment of short stature associated with Turner's syndrome.*

Sponsor: Genentech, Inc.
Address: 460 Point San Bruno Boulevard
South San Francisco CA 94080

Date Designated: 12/9/1985
Market Approval Date: Not currently Approved

Generic Name: **Somatrem for injection** Trade Name: Protropin

Designated Indication: *For long-term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion.*

Sponsor: Genentech, Inc.
Address: 460 Point San Bruno Boulevard
South San Francisco CA 94080

Date Designated: 12/9/1985
Market Approval Date: 10/17/1985

Generic Name: **Somatropin** Trade Name: Genotropin

Designated Indication: *Treatment of adults with growth hormone deficiency.*

Sponsor: Pharmacia & Upjohn
Address: 7000 Portage Road
Kalamazoo MI 49001-0199

Date Designated: 9/6/1994
Market Approval Date: 10/31/1997

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Somatropin** Trade Name: Humatrope

Designated Indication: *Treatment of short stature associated with Turner syndrome.*

Sponsor: Eli Lilly and Company
Address: Lilly Corporate Center
Indianapolis IN 46285

Date Designated: 5/8/1990
Market Approval Date: 12/30/1996

Generic Name: **Somatropin** Trade Name: Nutropin

Designated Indication: *For use in the long-term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion.*

Sponsor: Genentech, Inc.
Address: 460 Point San Bruno Boulevard
South San Francisco CA 94080

Date Designated: 3/6/1987
Market Approval Date: 10/17/1985

Generic Name: **Somatropin (rDNA)** Trade Name: Saizen

Designated Indication: *For the enhancement of nitrogen retention in hospitalized patients suffering from severe burns.*

Sponsor: Serono Laboratories, Inc.
Address: 100 Longwater Circle
Norwell MA 02061

Date Designated: 5/3/1989
Market Approval Date: Not currently Approved

Generic Name: **Somatropin (r-DNA)** Trade Name: Serostim

Designated Indication: *For use alone or in combination with glutamine in the treatment of short bowel syndrome.*

Sponsor: Serono Laboratories, Inc.
Address: 100 Longwater Circle
Norwell MA 02061

Date Designated: 3/6/1995
Market Approval Date: Not currently Approved

Generic Name: **Somatropin (r-DNA) for injection** Trade Name: Serostim

Designated Indication: *Treatment of children with AIDS-associated failure-to-thrive including AIDS-associated wasting.*

Sponsor: Serono Laboratories, Inc.
Address: 100 Longwater Circle
Norwell MA 02061

Date Designated: 3/26/1996
Market Approval Date: Not currently Approved

Generic Name: **Somatropin (rDNA origin)** Trade Name: Saizen

Designated Indication: *Treatment of idiopathic or organic growth hormone deficiency in children with growth failure.*

Sponsor: Serono Laboratories, Inc.
Address: 100 Longwater Circle
Norwell MA 02061

Date Designated: 3/6/1987
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Somatropin (rDNA origin)**
Trade Name: Nutropin Depot

Designated Indication: *Long-term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion.*

Sponsor: Genentech, Inc.
Address: 1 DNA Way
South San Francisco CA 94080-4990

Date Designated: 10/28/1999
Market Approval Date: Not currently Approved

Generic Name: **Somatropin (rDNA origin) injection**
Trade Name: Norditropin

Designated Indication: *Treatment of growth failure in children due to inadequate growth hormone secretion.*

Sponsor: Novo Nordisk Pharmaceuticals
Address: 100 Overlook Center
Suite 200
Princeton NJ 08540

Date Designated: 7/10/1987
Market Approval Date: Not currently Approved

Generic Name: **somatropin [rDNA]**
Trade Name: Genotropin

Designated Indication: *Treatment of growth failure in children who were born small for gestational age.*

Sponsor: Pharmacia and Upjohn Company
Address: 7000 Portage Road
Kalamazoo MI 49001

Date Designated: 12/27/2000
Market Approval Date: 7/25/2001

Generic Name: **Somatropin [rDNA]**
Trade Name: Genotropin

Designated Indication: *Treatment of short stature in patients with Prader-Willi syndrome.*

Sponsor: Pharmacia & Upjohn
Address: 7000 Portage Rd.
0633-298-113
Kalamazoo MI 49001-0199

Date Designated: 7/6/1999
Market Approval Date: 6/20/2000

Generic Name: **Somatropin for injection**
Trade Name: Nutropin

Designated Indication: *Treatment of short stature associated with Turner's syndrome.*

Sponsor: Genentech, Inc.
Address: 460 Point San Bruno Boulevard
South San Francisco CA 94080

Date Designated: 3/23/1989
Market Approval Date: 12/30/1996

Generic Name: **Somatropin for injection**
Trade Name: Nutropin

Designated Indication: *Treatment of growth retardation associated with chronic renal failure.*

Sponsor: Genentech, Inc.
Address: 460 Point San Bruno Boulevard
South San Francisco CA 94080

Date Designated: 8/4/1989
Market Approval Date: 11/17/1993

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Somatropin for injection** Trade Name: Humatrope

Designated Indication: *For the long-term treatment of children who have growth failure due to inadequate secretion of normal endogenous growth hormone.*

Sponsor: Eli Lilly and Company
Address: Lilly Corporate Center
Indianapolis IN 46285

Date Designated: 6/12/1986
Market Approval Date: 3/8/1987

Generic Name: **Somatropin for injection** Trade Name: Serostim

Designated Indication: *Treatment of AIDS-associated catabolism/weight loss.*

Sponsor: Serono Laboratories, Inc.
Address: 100 Longwater Circle
Norwell MA 02061

Date Designated: 11/15/1991
Market Approval Date: 8/23/1996

Generic Name: **Somatropin for injection** Trade Name: Nutropin

Designated Indication: *As replacement therapy for growth hormone deficiency in adults after epiphyseal closure.*

Sponsor: Genentech, Inc.
Address: 460 Point San Bruno Boulevard
South San Francisco CA 94080

Date Designated: 11/18/1996
Market Approval Date: 12/15/1997

Generic Name: **Sotalol HCl** Trade Name: Betapace

Designated Indication: *Treatment of life-threatening ventricular tachyarrhythmias.*

Sponsor: Berlex Laboratories, Inc.
Address: 300 Fairfield Road
Wayne NJ 07470

Date Designated: 9/23/1988
Market Approval Date: 10/30/1992

Generic Name: **squalamine lactate** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of ovarian cancer refractory or resistant to standard chemotherapy*

Sponsor: Genaera Corporation
Address: 5110 Campus Drive
Plymouth Meeting PA 19462

Date Designated: 5/11/2001
Market Approval Date: Not currently Approved

Generic Name: **Sterile talc** Trade Name: Steritalc

Designated Indication: *Treatment of malignant pleural effusion.*

Sponsor: Novatech SA
Address: Avenue du Vent des Dames - Z.I. les Paluds
13685 Aubagne
France

Date Designated: 12/8/1997
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Sterile talc** | Trade Name: Steritalc

Designated Indication: *Treatment of pneumothorax.*

Sponsor: Novatech SA
Address: Avenue du Vent des Dames - Z.I. les Paluds
13685 Aubagne
France

Date Designated: 12/8/1997
Market Approval Date: Not currently Approved

Generic Name: **Sterile talc powder** | Trade Name: Sclerosol Intrapleural Aerosol

Designated Indication: *Treatment of malignant pleural effusion.*

Sponsor: Bryan Corporation
Address: 4 Plympton Street
Woburn MA 01801

Date Designated: 9/18/1995
Market Approval Date: 12/24/1997

Generic Name: **SU101** | Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of ovarian cancer.*

Sponsor: Sugen, Inc.
Address: 230 East Grand Ave.
South San Francisco CA 94080-4811

Date Designated: 3/12/1996
Market Approval Date: Not currently Approved

Generic Name: **SU101** | Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of malignant glioma.*

Sponsor: Sugen, Inc.
Address: 230 East Grand Ave.
South San Francisco CA 94080-4811

Date Designated: 5/25/1995
Market Approval Date: Not currently Approved

Generic Name: **Succimer** | Trade Name: Chemet

Designated Indication: *Prevention of cystine kidney stone formation in patients with homozygous cystinuria who are prone to stone development.*

Sponsor: Sanofi Winthrop, Inc.
Address: 90 Park Avenue
New York NY 10016-1389

Date Designated: 11/5/1990
Market Approval Date: Not currently Approved

Generic Name: **Succimer** | Trade Name: Chemet capsules

Designated Indication: *Treatment of lead poisoning in children.*

Sponsor: Bock Pharmacal Company
Address: P.O. Box 419056
Saint Louis MO 63141-9056

Date Designated: 5/9/1984
Market Approval Date: 12/22/1988

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Succimer** Trade Name: Chemet

Designated Indication: *Treatment of mercury intoxication.*

Sponsor: Sanofi Winthrop, Inc.
Address: 90 Park Avenue
New York NY 10016-1389

Date Designated: 3/22/1991
Market Approval Date: Not currently Approved

Generic Name: **Sucralfate suspension** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of oral complications of chemotherapy in bone marrow transplant patients.*

Sponsor: Darby Pharmaceuticals, Inc.
Address: 100 Banks Avenue
Rockville Centre NY 11570

Date Designated: 3/12/1990
Market Approval Date: Not currently Approved

Generic Name: **Sucralfate suspension** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of oral ulcerations and dysphagia in patients with epidermolysis bullosa.*

Sponsor: Darby Pharmaceuticals, Inc.
Address: 100 Banks Avenue
Rockville Centre NY 11570

Date Designated: 3/4/1991
Market Approval Date: Not currently Approved

Generic Name: **Sulfadiazine** Trade Name: NONE ASSIGNED

Designated Indication: *For use in combination with pyrimethamine for the treatment of Toxoplasma gondii encephalitis in patients with and without AIDS.*

Sponsor: Eon Labs Manufacturing, Inc.
Address: 227-15 North Conduit Avenue
Laurelton NY 11413

Date Designated: 3/14/1994
Market Approval Date: 7/29/1994

Generic Name: **Sulfapyridine** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of dermatitis herpetiformis.*

Sponsor: Jacobus Pharmaceutical Company
Address: 37 Cleveland Lane
P.O. Box 5290
Princeton NJ 08540

Date Designated: 9/10/1990
Market Approval Date: Not currently Approved

Generic Name: **Superoxide dismutase (human)** Trade Name: NONE ASSIGNED

Designated Indication: *For protection of donor organ tissue from damage or injury mediated by oxygen-derived free radicals that are generated during the necessary periods of ischemia (hypoxia, anoxia), and especially reperfusion, associated with the operative procedure.*

Sponsor: Pharmacia-Chiron Partnership
Address: 4560 Horton Street
Emeryville CA 94608

Date Designated: 3/6/1985
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Suramin** | Trade Name: Metaret

Designated Indication: *Treatment of hormone-refractory prostate cancer.*

Sponsor: Warner-Lambert Company
Address: Parke-Davis Pharmaceutical Research
2800 Plymouth Road
Ann Arbor MI 48105-2430

Date Designated: 5/6/1997
Market Approval Date: Not currently Approved

Generic Name: **Surface active extract of saline lavage of bovine lungs** | Trade Name: Infasurf

Designated Indication: *Treatment and prevention of respiratory failure due to pulmonary surfactant deficiency in preterm infants.*

Sponsor: ONY, Inc.
Address: 1576 Sweet Home Road
Amherst NY 14228

Date Designated: 6/7/1985
Market Approval Date: Not currently Approved

Generic Name: **Synsorb Pk** | Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of verocytotoxogenic E. coli infections.*

Sponsor: Synsorb Biotech Inc.
Address: 201, 1204 Kensington Road, N.W.
Calgary, Alberta
Canada T2N 3P5 CA

Date Designated: 7/17/1995
Market Approval Date: Not currently Approved

Generic Name: **Synthetic Human Parathyroid Hormone 1-34** | Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of hypoparathyroidism*

Sponsor: Orphan Pharmaceuticals, U.S., Inc.
Address: 1101 Kermit Drive,
Suite 608
Nashville TN 37217

Date Designated: 1/26/2001
Market Approval Date: Not currently Approved

Generic Name: **Synthetic human secretin** | Trade Name: NONE ASSIGNED

Designated Indication: *For use in the evaluation of exocrine pancreas function.*

Sponsor: ChiRhoClin, Inc.
Address: 1550 Gallaudet Ave.
Silver Spring MD 20905-4176

Date Designated: 6/16/1999
Market Approval Date: Not currently Approved

Generic Name: **Synthetic human secretin** | Trade Name: NONE ASSIGNED

Designated Indication: *For use in obtaining desquamated pancreatic cells for cytopathologic examination in pancreatic carcinoma.*

Sponsor: ChiRhoClin, Inc.
Address: 15500 Gallaudet Ave.
Silver Spring MD 20905-4176

Date Designated: 6/16/1999
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Synthetic human secretin** Trade Name: NONE ASSIGNED

Designated Indication: *For use in the diagnosis of gastrinoma associated with Zollinger-Ellison syndrome.*

Sponsor: ChiRhoClin, Inc.
Address: 15500 Gallaudet Ave.
Silver Spring MD 20905-4176

Date Designated: 6/16/1999
Market Approval Date: Not currently Approved

Generic Name: **Synthetic human secretin** Trade Name: NONE ASSIGNED

Designated Indication: *For use in conjunction with diagnostic procedures for pancreatic disorders to increase pancreatic fluid secretion.*

Sponsor: ChiRhoClin, Inc.
Address: 15500 Gallaudet Ave.
Silver Spring MD 20905-4176

Date Designated: 3/7/2000
Market Approval Date: Not currently Approved

Generic Name: **Synthetic porcine secretin** Trade Name: NONE ASSIGNED

Designated Indication: *For use in the evaluation of exocrine pancreas function.*

Sponsor: ChiRhoClin, Inc.
Address: 15500 Gallaudet Ave.
Silver Spring MD 20905-4176

Date Designated: 6/18/1999
Market Approval Date: Not currently Approved

Generic Name: **Synthetic porcine secretin** Trade Name: NONE ASSIGNED

Designated Indication: *For use in obtaining desquamated pancreatic cells for cytopathologic examination in pancreatic carcinoma.*

Sponsor: ChiRhoClin, Inc.
Address: 15500 Gallaudet Ave.
Silver Spring MD 20905-4176

Date Designated: 6/18/1999
Market Approval Date: Not currently Approved

Generic Name: **Synthetic porcine secretin** Trade Name: NONE ASSIGNED

Designated Indication: *For use in conjunction with diagnostic procedures for pancreatic disorders to increase pancreatic fluid secretion.*

Sponsor: ChiRhoClin, Inc.
Address: 15500 Gallaudet Ave.
Silver Spring MD 20905-4176

Date Designated: 3/7/2000
Market Approval Date: Not currently Approved

Generic Name: **Synthetic porcine secretin** Trade Name: NONE ASSIGNED

Designated Indication: *For use in the diagnosis of gastrinoma associated with Zollinger-Ellison syndrome.*

Sponsor: ChiRhoClin, Inc.
Address: 15500 Gallaudet Ave.
Silver Spring MD 20905-4176

Date Designated: 6/18/1999
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **T4 endonuclease V, liposome encapsulated**
Trade Name: NONE ASSIGNED

Designated Indication: *To prevent cutaneous neoplasms and other skin abnormalities in xeroderma pigmentosum.*

Sponsor: AGI Dermatics
Address: 205 Buffalo Avenue
Freeport NY 11520

Date Designated: 6/27/1989
Market Approval Date: Not currently Approved

Generic Name: **Tacrolimus**
Trade Name: Prograf

Designated Indication: *Prophylaxis of graft-versus-host-disease.*

Sponsor: Fujisawa USA, Inc.
Address: 3 Parkway North Center
Deerfield IL 60015

Date Designated: 4/6/1998
Market Approval Date: Not currently Approved

Generic Name: **Technetium Tc 99m pterotetramide**
Trade Name: NONE ASSIGNED

Designated Indication: *For the identification of ovarian carcinomas.*

Sponsor: Endocyte, Inc.
Address: 1205 Kent Ave.
Lafayette IN 47906

Date Designated: 2/16/2000
Market Approval Date: Not currently Approved

Generic Name: **Technetium Tc99m murine monoclonal antibody (IgG2a) to B cell**
Trade Name: LymphoScan

Designated Indication: *Diagnostic imaging in the evaluation of the extent of disease in patients with histologically confirmed diagnosis of non-Hodgkin's B-cell lymphoma, acute B-cell lymphoblastic leukemia (in children and adults), and chronic B-cell lymphocytic leukemia.*

Sponsor: Immunomedics, Inc.
Address: 300 American Road
Morris Plains NJ 07950

Date Designated: 4/7/1992
Market Approval Date: Not currently Approved

Generic Name: **Technetium Tc99m murine monoclonal antibody to hCG**
Trade Name: Immuraid, hCG-Tc-99m

Designated Indication: *Detection of hCG producing tumors such as germ cell and trophoblastic cell tumors.*

Sponsor: Immunomedics, Inc.
Address: 300 American Road
Morris Plains NJ 07950

Date Designated: 8/7/1989
Market Approval Date: Not currently Approved

Generic Name: **Technetium Tc99m murine monoclonal antibody to human AFP**
Trade Name: AFP-Scan

Designated Indication: *Detection of alpha-fetoprotein producing germ cell tumors.*

Sponsor: Immunomedics, Inc.
Address: 300 American Road
Morris Plains NJ 07950

Date Designated: 8/1/1989
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Technetium Tc99m murine monoclonal antibody to human alpha-fetoprotein**
Trade Name: Immuraid, AFP-Scan

Designated Indication: *Detection of hepatocellular carcinoma and hepatoblastoma.*

Sponsor: Immunomedics, Inc.
Address: 300 American Road
Morris Plains NJ 07950

Date Designated: 8/1/1989
Market Approval Date: Not currently Approved

Generic Name: **Technetium Tc99m rh-Annexin V**
Trade Name: Apomate

Designated Indication: *Diagnosis or assessment of rejection status in heart, heart-lung, single lung, or bilateral lung transplants.*

Sponsor: Theseus Imaging Corporation
Address: 124 Mount Auburn Street
Suite 200 North
Cambridge MA 02138

Date Designated: 11/3/2000
Market Approval Date: Not currently Approved

Generic Name: **Temoporfin**
Trade Name: Foscan

Designated Indication: *Palliative treatment of recurrent, refractory or second primary squamous cell carcinomas of the head and neck in patients considered to be incurable with surgery or radiotherapy.*

Sponsor: Scotia Pharmaceuticals Ltd.
Address: Scotia House, Castle Business Park
Stirling
Scotland FK9 4TZ GB

Date Designated: 10/28/1999
Market Approval Date: Not currently Approved

Generic Name: **Temozolomide**
Trade Name: Temodal

Designated Indication: *Treatment of advanced metastatic melanoma.*

Sponsor: Schering-Plough Research Institute
Address: 2000 Galloping Hill Rd.
Kenilworth NJ 07033

Date Designated: 10/14/1998
Market Approval Date: Not currently Approved

Generic Name: **Temozolomide**
Trade Name: Temodar

Designated Indication: *Treatment of recurrent malignant glioma.*

Sponsor: Schering-Plough Research Institute
Address: 2000 Galloping Hill Rd.
Kenilworth NJ 07033

Date Designated: 10/5/1998
Market Approval Date: 8/11/1999

Generic Name: **Teniposide**
Trade Name: Vumon for injection

Designated Indication: *Treatment of refractory childhood acute lymphocytic leukemia.*

Sponsor: Bristol-Myers Squibb Pharmaceutical
Address: 5 Research Parkway
P.O. Box 5100
Wallingford CT 06492

Date Designated: 11/1/1984
Market Approval Date: 7/14/1992

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Teriparatide** Trade Name: Parathar

Designated Indication: *Treatment of idiopathic osteoporosis.*

Sponsor: Henri Beaufour Institute USA, Inc.
Address: 27 Maple St.
Milford MA 01757

Date Designated: 10/28/1999
Market Approval Date: Not currently Approved

Generic Name: **Teriparatide** Trade Name: Parathar

Designated Indication: *Diagnostic agent to assist in establishing the diagnosis in patients presenting with clinical and laboratory evidence of hypocalcemia due to either hypoparathyroidism or pseudohypoparathyroidism.*

Sponsor: Rhone-Poulenc Rorer Pharmaceuticals, Inc.
Address: 500 Arcola Road
Collegeville PA 19426

Date Designated: 1/9/1987
Market Approval Date: 12/23/1987

Generic Name: **Terlipressin** Trade Name: Glypressin

Designated Indication: *Treatment of bleeding esophageal varices.*

Sponsor: Ferring Laboratories, Inc.
Address: 400 Rella Boulevard, Suite 201
Suffern NY 10901

Date Designated: 3/6/1986
Market Approval Date: Not currently Approved

Generic System Name: **Testosterone** Trade Name: TheraDerm Testosterone Transdermal

Designated Indication: *For use as physiologic testosterone replacement in androgen deficient HIV+ patients with an associated weight loss.*

Sponsor: Watson Laboratories
Address: Research Park
417 Wakara Way
Salt Lake City UT 84108

Date Designated: 9/22/1997
Market Approval Date: Not currently Approved

Generic Name: **Testosterone** Trade Name: Androgel

Designated Indication: *Treatment of weight loss in AIDS patients with HIV-associated wasting.*

Sponsor: Unimed Pharmaceuticals, Inc.
Address: Four Parkway North
Deerfield IL 60015-2544

Date Designated: 2/5/1996
Market Approval Date: Not currently Approved

Generic Name: **Testosterone propionate ointment 2%** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of vulvar dystrophies.*

Sponsor: Star Pharmaceuticals, Inc.
Address: 1990 N.W. 44th Street
Pompano Beach FL 33064

Date Designated: 7/31/1991
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Tetrabenazine** | Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of Huntington's disease.*

Sponsor: Lifehealth Limited
Address: 23 Winkfield Road
Windor, Berkshire
SL4 4BA UK

Date Designated: 12/11/1997
Market Approval Date: Not currently Approved

Generic Name: **Tetrabenazine** | Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of moderate/severe tardive dyskinesia.*

Sponsor: Lifehealth Limited
Address: 23 Winkfield Road
Windsor, Berkshire
SL4 4BA UK

Date Designated: 5/12/1998
Market Approval Date: Not currently Approved

Generic Name: **Tetraiodothyroacetic acid** | Trade Name: NONE ASSIGNED

Designated Indication: *Suppression of thyroid stimulating hormone in patients with well-differentiated cancer of the thyroid gland.*

Sponsor: Danforth, Jr., MD, Elliot
Address: University of Vermont
84 Beartown Rd.
Underhill VT 05489

Date Designated: 5/1/2000
Market Approval Date: Not currently Approved

Generic Name: **Thalidomide** | Trade Name: NONE ASSIGNED

Designated Indication: *Treatment and prevention of recurrent aphthous ulcers in severely, terminally immunocompromised patients.*

Sponsor: Andrulis Research Corporation
Address: 11800 Baltimore Avenue, Suite 113
Beltsville MD 20705

Date Designated: 5/15/1995
Market Approval Date: Not currently Approved

Generic Name: **Thalidomide** | Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of severe recurrent aphthous stomatitis in severely, terminally immunocompromised patients.*

Sponsor: Celgene Corporation
Address: P.O. Box 4914
7 Powder Horn Srive
Warren NJ 07059

Date Designated: 5/1/1995
Market Approval Date: Not currently Approved

Generic Name: **Thalidomide** | Trade Name: Thalomid

Designated Indication: *Treatment of Crohn's disease.*

Sponsor: Celgene Corporation
Address: 7 Powder Horn Dr.
Warren NJ 07059

Date Designated: 4/6/1999
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Thalidomide** | Trade Name: Thalomid

Designated Indication: *Treatment of multiple myeloma.*

Sponsor: Celgene Corporation
Address: 7 Powder Horn Dr.
Warren NJ 07059

Date Designated: 10/14/1998
Market Approval Date: Not currently Approved

Generic Name: **Thalidomide** | Trade Name: Thalomid

Designated Indication: *Treatment of erythema nodosum leprosum.*

Sponsor: Celgene Corporation
Address: P.O. Box 4914
7 Powder Horn Drive
Warren NJ 07059

Date Designated: 7/26/1995
Market Approval Date: 7/16/1998

Generic Name: **Thalidomide** | Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of Kaposi's sarcoma.*

Sponsor: Celgene Corporation
Address: 7 Powder Horn Dr.
Warren NJ 07059

Date Designated: 7/29/1998
Market Approval Date: Not currently Approved

Generic Name: **Thalidomide** | Trade Name: Synovir

Designated Indication: *Treatment of HIV-associated wasting syndrome.*

Sponsor: Celgene Corporation
Address: P.O. Box 4914
7 Powder Horn Drive
Warren NJ 07059

Date Designated: 3/11/1996
Market Approval Date: Not currently Approved

Generic Name: **Thalidomide** | Trade Name: NONE ASSIGNED

Designated Indication: *Treatment and maintenance of reactional lepromatous leprosy.*

Sponsor: Pediatric Pharmaceuticals, Inc.
Address: 718 Bradford Avenue
Westfield NJ 07090

Date Designated: 11/15/1988
Market Approval Date: Not currently Approved

Generic Name: **Thalidomide** | Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of graft versus host disease.*

Sponsor: Andrulis Research Corporation
Address: 11800 Baltimore Avenue, Suite 113
Beltsville MD 20705

Date Designated: 3/5/1990
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Thalidomide** Trade Name: NONE ASSIGNED

Designated Indication: *Prevention of graft versus host disease.*

Sponsor: Andrulis Research Corporation
Address: 11800 Baltimore Avenue, Suite 113
Beltsville MD 20705

Date Designated: 3/5/1990
Market Approval Date: Not currently Approved

Generic Name: **Thalidomide** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of graft versus host disease in patients receiving bone marrow transplantation.*

Sponsor: Pediatric Pharmaceuticals, Inc.
Address: 718 Bradford Avenue
Westfield NJ 07090

Date Designated: 9/19/1988
Market Approval Date: Not currently Approved

Generic Name: **Thalidomide** Trade Name: NONE ASSIGNED

Designated Indication: *Prevention of graft versus host disease in patients receiving bone marrow transplantation.*

Sponsor: Pediatric Pharmaceuticals, Inc.
Address: 718 Bradford Avenue
Westfield NJ 07090

Date Designated: 9/19/1988
Market Approval Date: Not currently Approved

Generic Name: **Thalidomide** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of primary brain malignancies.*

Sponsor: Celgene Corporation
Address: 7 Powder Horn Dr.
Warren NJ 07059

Date Designated: 2/27/1998
Market Approval Date: Not currently Approved

Generic Name: **Thalidomide** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of the clinical manifestations of mycobacterial infection caused by Mycobacterium tuberculosis and non-tuberculous mycobacteria.*

Sponsor: Celgene Corporation
Address: P.O. Box 4914
7 Powder Horn Drive
Warren NJ 07059

Date Designated: 1/12/1993
Market Approval Date: Not currently Approved

Generic Name: **Thymalfasin** Trade Name: Zadaxin

Designated Indication: *Treatment of chronic active hepatitis B.*

Sponsor: SciClone Pharmaceuticals, Inc.
Address: 901 Mariner's Island Blvd.
San Mateo CA 94404-1593

Date Designated: 5/3/1991
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Thymalfasin** — Trade Name: Zadaxin

Designated Indication: *Treatment of hepatocellular carcinoma.*

Sponsor: SciClone Pharmaceuticals, Inc.
Address: 901 Mariner's Blvd., Suite 205
San Mateo CA 94404

Date Designated: 3/6/2000
Market Approval Date: Not currently Approved

Generic Name: **Thymalfasin** — Trade Name: Zadaxin

Designated Indication: *Treatment of DiGeorge anomaly with immune defects.*

Sponsor: SciClone Pharmaceuticals, Inc.
Address: 901 Mariner's Island Blvd.
San Mateo CA 94404-1593

Date Designated: 1/8/1998
Market Approval Date: Not currently Approved

Generic Name: **Thyrotropin alfa** — Trade Name: Thyrogen

Designated Indication: *Treatment of well-differentiated papillary, follicular or combined papillary/follicular carcinomas of the thyroid*

Sponsor: Genzyme Corporation
Address: One Kendall Square
Cambridge MA 02139-1562

Date Designated: 8/3/2001
Market Approval Date: Not currently Approved

Generic Name: **Thyrotropin alpha** — Trade Name: Thyrogen

Designated Indication: *As an adjunct in the diagnosis of thyroid cancer.*

Sponsor: Genzyme Corporation
Address: One Kendall Square
Cambridge MA 02139

Date Designated: 2/24/1992
Market Approval Date: 11/30/1998

Generic Name: **Tiazofurin (2-Beta-D-ribofuranosyl-4-thiazolecarboxamide)** — Trade Name: NONE ASSIGNED

Designated Indication: *Chronic myelogenous leukemia (CML)*

Sponsor: ICN Pharmaceuticals, Inc. (ICN)
Address: 3300 Hyland Avenue
Costa Mesa CA 92626

Date Designated: 12/27/2000
Market Approval Date: Not currently Approved

Generic Name: **Tiopronin** — Trade Name: Thiola

Designated Indication: *Prevention of cystine nephrolithiasis in patients with homozygous cystinuria.*

Sponsor: Pak, Charles Y.C. M.D.
Address: The University of Texas Health Scienc Center
5323 Harry Hines Boulevard
Dallas TX 75235

Date Designated: 1/17/1986
Market Approval Date: 8/11/1988

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Tiratricol** | Trade Name: Triacana

Designated Indication: *For use in combination with levo-thyroxine to suppress thyroid stimulating hormone in patients with well-differentiated thyroid cancer who are intolerant to adequate doses of levo-thyroxine alone.*

Sponsor: Laphal Laboratoires
Address: 48 Bis, Rue des Belles-Feuilles
75116 Paris
France FR

Date Designated: 8/13/1991
Market Approval Date: Not currently Approved

Generic Name: **Tizanidine HCl** | Trade Name: Zanaflex

Designated Indication: *Treatment of spasticity associated with multiple sclerosis and spinal cord injury.*

Sponsor: Athena Neurosciences, Inc.
Address: 800 Gateway Boulevard
South San Francisco CA 94080

Date Designated: 1/31/1994
Market Approval Date: Not currently Approved

Generic Name: **Tobramycin** | Trade Name: Tobi

Designated Indication: *Treatment of bronchiectasis patients infected with Pseudomonas aeruginosa.*

Sponsor: Chiron Corporation
Address: 201 Elliott Avenue West
Suite 150
Seattle WA 98119

Date Designated: 6/18/1999
Market Approval Date: Not currently Approved

Generic Name: **Tobramycin for inhalation** | Trade Name: TOBI

Designated Indication: *Treatment of bronchopulmonary infections of Pseudomonas aeruginosa in cystic fibrosis patients.*

Sponsor: Pathogenesis Corporation
Address: 201 Elliott Avenue West, Suite 150
Seattle WA 98119

Date Designated: 10/13/1994
Market Approval Date: 12/22/1997

Generic Name: **Topiramate** | Trade Name: Topamax

Designated Indication: *Treatment of Lennox-Gastaut syndrome.*

Sponsor: R. W. Johnson Pharmaceutical Research
Address: Route 202, P.O. Box 300
Raritan NJ 08869-0602

Date Designated: 11/25/1992
Market Approval Date: 8/28/2001

Generic Name: **Toremifene** | Trade Name: Fareston

Designated Indication: *Hormonal therapy of metastatic carcinoma of the breast.*

Sponsor: Orion Corporation
Address: P.O. Box 65
02101 ESPOO
Finland

Date Designated: 9/19/1991
Market Approval Date: 5/29/1997

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Toremifene** | Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of desmoid tumors.*

Sponsor: Orion Corporation
Address: P.O. Box 65
02101 Espoo
Finland

Date Designated: 8/17/1993
Market Approval Date: Not currently Approved

Generic Name: **Tositumomab and iodine I 131 tositumomab** | Trade Name: Bexxar

Designated Indication: *Treatment of non-Hodgkin's B-cell lymphoma.*

Sponsor: Coulter Pharmaceutical, Inc.
Address: 550 California Avenue
Suite 200
Palo Alto CA 94306

Date Designated: 5/16/1994
Market Approval Date: Not currently Approved

Generic Name: **Tranexamic acid** | Trade Name: Cyklokapron

Designated Indication: *Treatment of patients with congenital coagulopathies who are undergoing surgical procedures (e.g. dental extractions).*

Sponsor: Pharmacia Inc.
Address: P.O. Box 16529
Columbus OH 43216

Date Designated: 10/29/1985
Market Approval Date: 12/30/1986

Generic Name: **Transforming growth factor-beta 2** | Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of full thickness macular holes.*

Sponsor: Celtrix Pharmaceuticals, Inc.
Address: 3055 Patrick Henry Drive
Santa Clara CA 95054

Date Designated: 12/18/1992
Market Approval Date: Not currently Approved

Generic Name: **Transgenic human alpha 1 antitrypsin** | Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of emphysema secondary to alpha 1 antitrypsin deficiency.*

Sponsor: PPL Therapeutics (Scotland) Limited
Address: Roslin, Edinburgh
EH25 9PP Scotland GB

Date Designated: 5/19/1999
Market Approval Date: Not currently Approved

Generic Name: **Trastuzumab** | Trade Name: Herceptin

Designated Indication: *Treatment of patients with pancreatic cancer that overexpress p185HER2.*

Sponsor: Genentech, Inc.
Address: 1 DNA Way
South San Francisco CA 94080-4990

Date Designated: 12/14/1999
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Treosulfan** | Trade Name: Ovastat

Designated Indication: *Treatment of ovarian cancer.*

Sponsor: Medac GmbH
Address: Fehlandtstrasse 3
D-20354 Hamburg
Germany DE

Date Designated: 5/16/1994
Market Approval Date: Not currently Approved

Generic Name: **Tretinoin** | Trade Name: Atragen

Designated Indication: *Treatment of acute and chronic leukemia.*

Sponsor: Aronex Pharmaceuticals, Inc.
Address: 8707 Technology Forest Place
The Woodlands TX 77381-1191

Date Designated: 1/14/1993
Market Approval Date: Not currently Approved

Generic Name: **Tretinoin** | Trade Name: Vesanoid

Designated Indication: *Treatment of acute promyelocytic leukemia.*

Sponsor: Hoffmann-La Roche, Inc.
Address: 340 Kingsland Street
Nutley NJ 07110

Date Designated: 10/24/1990
Market Approval Date: 11/22/1995

Generic Name: **Tretinoin** | Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of squamous metaplasia of the ocular surface epithelia (conjunctiva and/or cornea) with mucous deficiency and keratinization.*

Sponsor: Hannan Ophthalmic Marketing Services, Inc
Address: 34 Sherrill Rd.
Marshfield MA 02050

Date Designated: 4/15/1985
Market Approval Date: Not currently Approved

Generic Name: **tri-antennary glycotripeptide derivative of 5-fluorodeoxyuridine monophosphate** | Trade Name: NONE ASSIGNED

Designated Indication: *Treatment for hepatocellular carcinoma*

Sponsor: Cell Works Inc.
Address: 6200 Seaforth Street
Baltimore MD 21224-6506

Date Designated: 11/23/2001
Market Approval Date: Not currently Approved

Generic Name: **Trientine HCl** | Trade Name: Syprine

Designated Indication: *Treatment of patients with Wilson's disease who are intolerant, or inadequately responsive to penicillamine.*

Sponsor: Merck Sharp & Dohme Research
Address: Division Of Merck And Company
West Point PA 19486

Date Designated: 12/24/1984
Market Approval Date: 11/8/1985

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Trimetrexate** | Trade Name: Neutrexin

Designated Indication: *Treatment of metastatic osteogenic sarcoma.*

Sponsor: Medimmune Oncology, Inc.
Address: One Tower Bridge
100 Front St., Suite 400
West Conshohocken PA 19428

Date Designated: 8/10/2000
Market Approval Date: Not currently Approved

Generic Name: **Trimetrexate glucuronate** | Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of pancreatic adenocarcinoma.*

Sponsor: Medimmune Oncology, Inc.
Address: One Tower Bridge
100 Front Street, Suite 400
West Conshohocken PA 19428

Date Designated: 7/25/1985
Market Approval Date: Not currently Approved

Generic Name: **Trimetrexate glucuronate** | Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of metastatic colorectal adenocarcinoma.*

Sponsor: Medimmune Oncology, Inc.
Address: One Tower Bridge
100 Front Street, Suite 400
West Conshohocken PA 19428

Date Designated: 7/25/1985
Market Approval Date: Not currently Approved

Generic Name: **Trimetrexate glucuronate** | Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of metastatic carcinoma of the head and neck (i.e. buccal cavity, pharynx, and larynx).*

Sponsor: Medimmune Oncology, Inc.
Address: 35 West Watkins Mills Road
Gaithersburg MD 20878

Date Designated: 7/25/1985
Market Approval Date: Not currently Approved

Generic Name: **Trimetrexate glucuronate** | Trade Name: Neutrexin

Designated Indication: *Treatment of Pneumocystis carinii pneumonia in AIDS patients.*

Sponsor: Medimmune Oncology, Inc.
Address: One Tower Bridge
100 Front Street, Suite 400
West Conshohocken PA 19428

Date Designated: 5/15/1986
Market Approval Date: 12/17/1993

Generic Name: **Trimetrexate glucuronate** | Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of patients with advanced non-small cell carcinoma of the lung.*

Sponsor: Medimmune Oncology, Inc.
Address: One Tower Bridge
100 Front Street, Suite 400
West Conshohocken PA 19428

Date Designated: 1/13/1988
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Trisaccharides A and B** Trade Name: Biosynject

Designated Indication: *Treatment of moderate to severe clinical forms of hemolytic disease of the newborn arising from placental transfer of antibodies against blood group substances A and B.*

Sponsor: Chembiomed, Ltd.
Address: P.O. Box 8050, Station F
Edmonton, Alberta
Canada T6H 4NP CA

Date Designated: 4/12/1987
Market Approval Date: Not currently Approved

Generic Name: **Trisaccharides A and B** Trade Name: Biosynject

Designated Indication: *Prevention of ABO medical hemolytic reactions arising from ABO-incompatible bone marrow transplantation.*

Sponsor: Chembiomed, Ltd.
Address: P.O. Box 8050, Station F
Edmonton, Alberta
Canada T6H 4NP CA

Date Designated: 4/15/1988
Market Approval Date: Not currently Approved

Generic Name: **Trisaccharides A and B** Trade Name: Biosynject

Designated Indication: *For use in ABO-incompatible solid organ transplantation, including kidney, heart, liver and pancreas.*

Sponsor: Chembiomed, Ltd.
Address: P.O. Box 8050, Station F
Edmonton, Alberta
Canada T6H 4NP CA

Date Designated: 4/20/1987
Market Approval Date: Not currently Approved

Generic Name: **Trisodium citrate concentration** Trade Name: Hemocitrate

Designated Indication: *For use in leukapheresis procedures.*

Sponsor: Hemotec Medical Products, Inc.
Address: Box 19255
Johnston RI 02919

Date Designated: 6/15/1995
Market Approval Date: Not currently Approved

Generic Name: **Troleandomycin** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of severe steroid-requiring asthma.*

Sponsor: Szefler, Stanley M. M.D.
Address: National Jewish Center for Immunology and
1400 Jackson Street
Denver CO 80206

Date Designated: 9/21/1989
Market Approval Date: Not currently Approved

Generic Name: **Tumor necrosis factor-binding protein 1** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of symptomatic patients with AIDS including all patients with CD4 counts less than 200 cells per mm3.*

Sponsor: Serono Laboratories, Inc.
Address: 100 Longwater Circle
Norwell MA 02061

Date Designated: 1/6/1993
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Tumor necrosis factor-binding protein II**
Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of symptomatic patients with the AIDS including all patients with CD4 T-cell counts less than 200 cells per mm3.*

Sponsor: Serono Laboratories, Inc.
Address: 100 Longwater Circle
Norwell MA 02061

Date Designated: 1/6/1993
Market Approval Date: Not currently Approved

Generic Name: **Tyloxapol**
Trade Name: Supervent

Designated Indication: *Treatment of cystic fibrosis.*

Sponsor: Kennedy & Hoidal, M.D.'s
Address: University of Utah Health Sciences Center
50 North Medical Drive, Room 4R240
Salt Lake City UT 84132-0001

Date Designated: 3/8/1995
Market Approval Date: Not currently Approved

Generic Name: **Ubiquinone**
Trade Name: Ubiqgel

Designated Indication: *Treatment of mitochondrial cytopathies.*

Sponsor: Gel-Tec, Division of Tishcon Corp.
Address: 30 New York Ave.
PO Box 331
Westbury NY 11590

Date Designated: 12/14/1999
Market Approval Date: Not currently Approved

Generic Name: **Unconjugated Chimeric (human-murine) G250 IgG monoclonal antibody**
Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of renal cell carcinoma.*

Sponsor: Wilex Biotechnology GmbH
Address: Grillparzerstrasse 10B
81675 Munich
Germany DE

Date Designated: 3/22/2001
Market Approval Date: Not currently Approved

Generic Name: **Urofollitropin**
Trade Name: Metrodin

Designated Indication: *For induction of ovulation in patients with polycystic ovarian disease who have an elevated LH/FSH ratio and who have failed to respond to adequate clomiphene citrate therapy.*

Sponsor: Serono Laboratories, Inc.
Address: 100 Longwater Circle
Norwell MA 02061

Date Designated: 11/25/1987
Market Approval Date: 9/18/1986

Generic Name: **Urofollitropin**
Trade Name: Fertinex

Designated Indication: *For the initiation and re-initiation of spermatogenesis in adult males with reproductive failure due to hypothalamic or pituitary dysfunction, hypogonadotropic hypogonadism.*

Sponsor: Serono Laboratories, Inc.
Address: 100 Longwater Circle
Norwell MA 02061

Date Designated: 12/5/1997
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Urogastrone** | Trade Name: NONE ASSIGNED

Designated Indication: *For acceleration of corneal epithelial regeneration and healing of stromal incisions from corneal transplant surgery.*

Sponsor: Chiron Vision
Address: 500 Iolab Drive
Claremont CA 91711

Date Designated: 11/1/1984
Market Approval Date: Not currently Approved

Generic Name: **Ursodiol** | Trade Name: URSO

Designated Indication: *Treatment of patients with primary biliary cirrhosis.*

Sponsor: Axcan Pharma Inc.
Address: 597 Laurier Blvd
Mount St. Hilaire Quebec H7L 4S3
Canada CA

Date Designated: 6/20/1991
Market Approval Date: 12/10/1997

Generic Name: **Valine, isoleucine and leucine** | Trade Name: VIL

Designated Indication: *Treatment of hyperphenylalaninemia.*

Sponsor: Leas Research Products
Address: 78 Fallon Drive
North Haven CT 06473

Date Designated: 1/5/1996
Market Approval Date: Not currently Approved

Generic Name: **Valrubicin** | Trade Name: Valstar

Designated Indication: *Treatment of carcinoma in situ of the urinary bladder.*

Sponsor: Anthra Pharmaceuticals, Inc.
Address: 103 Carnegie Center, Suite 102
Princeton NJ 08540

Date Designated: 5/23/1994
Market Approval Date: 9/25/1998

Generic Name: **Vapreotide** | Trade Name: Octastatin

Designated Indication: *Treatment of gastrointestinal and pancreatic fistulas.*

Sponsor: Debiopharm S.A.
Address: 17 rue des Terreaux
CH-1000 Lausanne 9
Switzerland CH

Date Designated: 1/10/2000
Market Approval Date: Not currently Approved

Generic Name: **Vapreotide** | Trade Name: Octastatin

Designated Indication: *Treatment of esophageal variceal hemorrhage patients with portal hypertension.*

Sponsor: Debiopharm S.A.
Address: 17 rue des Terreaux
CH-1000 Lausanne 9
Switzerland CH

Date Designated: 1/10/2000
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Vapreotide** | Trade Name: Octastatin

Designated Indication: *Prevention of early postoperative complications following pancreatic resection.*

Sponsor: Debiopharm S.A.
Address: 17 rue des Terreaux
CH-1000 Lausanne 9
Switzerland CH

Date Designated: 3/6/2000
Market Approval Date: Not currently Approved

Generic Name: **Vasoactive intestinal peptide** | Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of Acute Respiratory Distress Syndrome.*

Sponsor: Sami I. Said, M.D.
Address: State University of New York at Stony Brook
Health Sciences Center T17, 040
Stony Brook NY 11794-8172

Date Designated: 3/9/2001
Market Approval Date: Not currently Approved

Generic Name: **Vasoactive intestinal polypeptide** | Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of acute esophageal food impaction.*

Sponsor: Research Triangle Pharmaceuticals
Address: 200 Westpark Corporate Center
4364 South Alston Avenue
Durham NC 27713-2280

Date Designated: 6/23/1993
Market Approval Date: Not currently Approved

Generic Name: **vigabatrin** | Trade Name: Sabril

Designated Indication: *Treatment of infantile spasms.*

Sponsor: Aventis Pharmaceuticals Inc.
Address: P.O. Box 9627
Kansas City MO 64137

Date Designated: 6/12/2000
Market Approval Date: Not currently Approved

Generic Name: **Virulizin** | Trade Name: Virulizin

Designated Indication: *Treatment of pancreatic cancer.*

Sponsor: Lorus Therapeutics Inc.
Address: 7100 Woodbine Avenue, Suite 215
Markham, ON L3R 5J2
Canada

Date Designated: 2/1/2001
Market Approval Date: Not currently Approved

Generic Name: **Xenogeneic hepatocytes** | Trade Name: HepatAssist Liver Assist System

Designated Indication: *Treatment of severe liver failure.*

Sponsor: Circe Biomedical, Inc.
Address: 99 Hayden Ave.
Lexington MA 02421-7995

Date Designated: 11/27/1998
Market Approval Date: Not currently Approved

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name: **Yttrium-90 radiolabeled humanized monoclonal anti-carcinoembroyonic antigen IgG antibody**
Trade Name: Cea-Cide
Designated Indication: *Treatment of ovarian carcinoma.*
Sponsor: Immunomedics, Inc.
Address: 300 American Rd.
Morris Plains NJ 07950
Date Designated: 8/3/1999
Market Approval Date: Not currently Approved

Generic Name: **Zalcitabine**
Trade Name: Hivid
Designated Indication: *Treatment of AIDS.*
Sponsor: Hoffmann-La Roche, Inc.
Address: 340 Kingsland Street
Nutley NJ 07110
Date Designated: 6/28/1988
Market Approval Date: 6/19/1992

Generic Name: **Zalcitabine**
Trade Name: NONE ASSIGNED
Designated Indication: *Treatment of AIDS.*
Sponsor: National Cancer Institute, DCT
Address: NIH, Executive Plaza North, Room 7-18
Bethesda MD 20892
Date Designated: 12/9/1986
Market Approval Date: Not currently Approved

Generic Name: **Zidovudine**
Trade Name: Retrovir
Designated Indication: *Treatment of AIDS related complex.*
Sponsor: Glaxo Wellcome Inc.
Address: 5 Moore Drive
Research Triangle Park NC 27709
Date Designated: 5/12/1987
Market Approval Date: 3/19/1987

Generic Name: **Zidovudine**
Trade Name: Retrovir
Designated Indication: *Treatment of AIDS.*
Sponsor: Glaxo Wellcome Inc.
Address: 5 Moore Drive
Research Triangle Park NC 27709
Date Designated: 7/17/1985
Market Approval Date: 3/19/1987

Generic Name: **Zinc acetate**
Trade Name: Galzin
Designated Indication: *Treatment of Wilson's disease.*
Sponsor: Lemmon Company
Address: 1510 Delp Drive
Kulpsville PA 19443
Date Designated: 11/6/1985
Market Approval Date: 1/28/1997

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2001

Generic Name:	**Zoledronate**	Trade Name:	Zometa, Zabel
Designated Indication:	*Treatment of tumor induced hypercalcemia.*		
Sponsor:	Novartis Pharmaceuticals Corp.	Date Designated:	8/18/2000
Address:	59 Route 10 East Hanover NJ 07936-1080	Market Approval Date:	8/20/2001

FDA data supplied by DrugPatentWatch.com

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

ACETAMINOPHEN; ASPIRIN; BUTALBITAL
CAPSULE OR TABLET; ORAL
160-165MG; 160-165MG; 50MG

ACETAMINOPHEN; ASPIRIN; BUTALBITAL
CAPSULE OR TABLET; ORAL
325MG; 325MG; 50MG

ACETAMINOPHEN; ASPIRIN; BUTALBITAL; CAFFEINE
CAPSULE OR TABLET; ORAL
160-165MG; 160-165MG; 50MG; 40MG

ACETAMINOPHEN; ASPIRIN; BUTALBITAL; CAFFEINE
CAPSULE OR TABLET; ORAL
325MG; 325MG; 50MG; 40MG

ACETAMINOPHEN; BUTALBITAL
CAPSULE OR TABLET; ORAL
325MG; 50MG
650MG; 50MG

ACETAMINOPHEN; BUTALBITAL; CAFFEINE
CAPSULE OR TABLET; ORAL
325MG; 50MG; 40MG
650MG; 50MG; 40MG
500MG; 50MG; 40MG

AMINOPHYLLINE
TABLET; ORAL
100MG
200MG

ASPIRIN; BUTALBITAL
CAPSULE OR TABLET; ORAL
325MG; 50MG
650MG; 50MG

ASPIRIN; BUTALBITAL; CAFFEINE
CAPSULE OR TABLET; ORAL
325MG; 50MG; 40MG
650MG; 50MG; 40MG

ASPIRIN; CAFFEINE; CARISOPRODOL
TABLET; ORAL
160MG; 32MG; 200MG

ASPIRIN; CAFFEINE; CARISOPRODOL; CODEINE PHOSPHATE
TABLET; ORAL
160MG; 32MG; 200MG; 16MG

ASPIRIN; CARISOPRODOL
TABLET; ORAL
325MG; 200MG

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE
TABLET; ORAL
325MG; 200MG; 16MG

ASPIRIN; MEPROBAMATE
TABLET; ORAL
325MG; 200MG

ASPIRIN; METHOCARBAMOL
TABLET; ORAL
325MG; 400MG

CHLOROTHIAZIDE
TABLET; ORAL
250MG

HYDROXYZINE HYDROCHLORIDE
TABLET; ORAL
10MG; 25MG; 50MG; 100MG

PREDNISONE
TABLET; ORAL
1MG; 2.5MG; 5MG; 10MG; 20MG; 25MG; 50MG

FDA data supplied by DrugPatentWatch.com

FDA data supplied by DrugPatentWatch.com

** 8 **

8-HOUR BAYER, ASPIRIN (OTC)
8-MOP, METHOXSALEN

** A **

A-HYDROCORT, HYDROCORTISONE SODIUM SUCCINATE
A-METHAPRED, METHYLPREDNISOLONE SODIUM SUCCINATE
A-N STANNOUS AGGREGATED ALBUMIN, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT
A-POXIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE
A.P.L., GONADOTROPIN, CHORIONIC
A/T/S, ERYTHROMYCIN
ABELCET, AMPHOTERICIN B
ABITREXATE, METHOTREXATE SODIUM
ABREVA, DOCOSANOL (OTC)
ACCOLATE, ZAFIRLUKAST
ACCUNEB, ALBUTEROL SULFATE
ACCUPRIL, QUINAPRIL HYDROCHLORIDE
ACCURBRON, THEOPHYLLINE
ACCURETIC, HYDROCHLOROTHIAZIDE
ACCUTANE, ISOTRETINOIN
ACEBUTOLOL HCL, ACEBUTOLOL HYDROCHLORIDE
ACEON, PERINDOPRIL ERBUMINE
ACEPHEN, ACETAMINOPHEN (OTC)
ACETAMINOPHEN AND CODEINE PHOSPHATE #2, ACETAMINOPHEN
ACETAMINOPHEN AND CODEINE PHOSPHATE #3, ACETAMINOPHEN
ACETAMINOPHEN AND CODEINE PHOSPHATE #4, ACETAMINOPHEN
ACETAMINOPHEN AND CODEINE PHOSPHATE NO. 2, ACETAMINOPHEN
ACETAMINOPHEN AND CODEINE PHOSPHATE NO. 3, ACETAMINOPHEN
ACETAMINOPHEN AND CODEINE PHOSPHATE NO. 4, ACETAMINOPHEN
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACETAMINOPHEN AND HYDROCODONE BITARTRATE, ACETAMINOPHEN
ACETAMINOPHEN W/ CODEINE #2, ACETAMINOPHEN
ACETAMINOPHEN W/ CODEINE #4, ACETAMINOPHEN
ACETAMINOPHEN W/ CODEINE NO. 2, ACETAMINOPHEN
ACETAMINOPHEN W/ CODEINE NO. 3, ACETAMINOPHEN
ACETAMINOPHEN W/ CODEINE PHOSPHATE #3, ACETAMINOPHEN
ACETAMINOPHEN W/ CODEINE PHOSPHATE, ACETAMINOPHEN
ACETAMINOPHEN W/ CODEINE, ACETAMINOPHEN
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
ACETAMINOPHEN, ASPIRIN AND CAFFEINE, ACETAMINOPHEN (OTC)
ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACETAMINOPHEN, BUTALBITAL AND CAFFEINE, ACETAMINOPHEN
ACETAMINOPHEN, BUTALBITAL, AND CAFFEINE, ACETAMINOPHEN
ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE, ACETAMINOPHEN
ACETASOL HC, ACETIC ACID, GLACIAL
ACETASOL, ACETIC ACID, GLACIAL
ACETATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM
ACETAZOLAMIDE, ACETAZOLAMIDE
ACETIC ACID 0.25% IN PLASTIC CONTAINER, ACETIC ACID, GLACIAL
ACETIC ACID 2% IN AQUEOUS ALUMINUM ACETATE, ACETIC ACID, GLACIAL
ACETIC ACID W/ HYDROCORTISONE, ACETIC ACID, GLACIAL
ACETIC ACID, ACETIC ACID, GLACIAL
ACETOHEXAMIDE, ACETOHEXAMIDE
ACETYLCYSTEINE, ACETYLCYSTEINE
ACHES-N-PAIN, IBUPROFEN (OTC)
ACHROMYCIN V, TETRACYCLINE HYDROCHLORIDE
ACHROMYCIN, HYDROCORTISONE
ACHROMYCIN, PROCAINE HYDROCHLORIDE
ACHROMYCIN, TETRACYCLINE HYDROCHLORIDE
ACILAC, LACTULOSE
ACIPHEX, RABEPRAZOLE SODIUM
ACLOVATE, ALCLOMETASONE DIPROPIONATE
ACOVA, ARGATROBAN
ACTAHIST, PSEUDOEPHEDRINE HYDROCHLORIDE
ACTH, CORTICOTROPIN
ACTHAR GEL-SYNTHETIC, SERACTIDE ACETATE
ACTHAR, CORTICOTROPIN
ACTHREL, CORTICORELIN OVINE TRIFLUTATE
ACTICORT, HYDROCORTISONE
ACTIDIL, TRIPROLIDINE HYDROCHLORIDE (OTC)
ACTIFED W/ CODEINE, CODEINE PHOSPHATE
ACTIFED, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
ACTIGALL, URSODIOL
ACTIN-N, NITROFURAZONE
ACTINEX, MASOPROCOL
ACTIQ, FENTANYL CITRATE
ACTISITE, TETRACYCLINE HYDROCHLORIDE
ACTIVELLE, ESTRADIOL
ACTONEL, RISEDRONATE SODIUM
ACTOS, PIOGLITAZONE HYDROCHLORIDE
ACTRON, KETOPROFEN (OTC)
ACULAR PRESERVATIVE FREE, KETOROLAC TROMETHAMINE
ACULAR, KETOROLAC TROMETHAMINE
ACUTECT, TECHNETIUM TC-99M APCITIDE
ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE, ACYCLOVIR SODIUM
ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
ACYCLOVIR, ACYCLOVIR
ACYCLOVIR, ACYCLOVIR SODIUM
ACYLANID, ACETYLDIGITOXIN
ADAGEN, PEGADEMASE BOVINE
ADALAT CC, NIFEDIPINE
ADALAT, NIFEDIPINE
ADDERALL 10, AMPHETAMINE ASPARTATE
ADDERALL 12.5, AMPHETAMINE ASPARTATE
ADDERALL 15, AMPHETAMINE ASPARTATE
ADDERALL 20, AMPHETAMINE ASPARTATE
ADDERALL 30, AMPHETAMINE ASPARTATE
ADDERALL 5, AMPHETAMINE ASPARTATE

FDA data supplied by DrugPatentWatch.com

ADDERALL 7.5, AMPHETAMINE ASPARTATE
ADDERALL XR 10, AMPHETAMINE ASPARTATE
ADDERALL XR 20, AMPHETAMINE ASPARTATE
ADDERALL XR 30, AMPHETAMINE ASPARTATE
ADENOCARD, ADENOSINE
ADENOSCAN, ADENOSINE
ADIPEX-P, PHENTERMINE HYDROCHLORIDE
ADPHEN, PHENDIMETRAZINE TARTRATE
ADRIAMYCIN PFS, DOXORUBICIN HYDROCHLORIDE
ADRIAMYCIN RDF, DOXORUBICIN HYDROCHLORIDE
ADRUCIL, FLUOROURACIL
ADVAIR DISKUS 100/50, FLUTICASONE PROPIONATE
ADVAIR DISKUS 250/50, FLUTICASONE PROPIONATE
ADVAIR DISKUS 500/50, FLUTICASONE PROPIONATE
ADVICOR, LOVASTATIN
ADVIL COLD AND SINUS, IBUPROFEN (OTC)
ADVIL LIQUI-GELS, IBUPROFEN POTASSIUM (OTC)
ADVIL MIGRAINE LIQUI-GELS, IBUPROFEN POTASSIUM (OTC)
ADVIL, IBUPROFEN (OTC)
AEROBID, FLUNISOLIDE
AEROLATE III, THEOPHYLLINE
AEROLATE JR, THEOPHYLLINE
AEROLATE SR, THEOPHYLLINE
AEROLATE, THEOPHYLLINE
AEROLONE, ISOPROTERENOL HYDROCHLORIDE
AEROSEB-DEX, DEXAMETHASONE
AEROSEB-HC, HYDROCORTISONE
AEROSPORIN, POLYMYXIN B SULFATE
AFAXIN, VITAMIN A PALMITATE
AFRINOL, PSEUDOEPHEDRINE SULFATE (OTC)
AGENERASE, AMPRENAVIR
AGGRASTAT, TIROFIBAN HYDROCHLORIDE
AGGRENOX, ASPIRIN
AGRYLIN, ANAGRELIDE HYDROCHLORIDE
AK-PENTOLATE, CYCLOPENTOLATE HYDROCHLORIDE
AKBETA, LEVOBUNOLOL HYDROCHLORIDE
AKINETON, BIPERIDEN HYDROCHLORIDE
AKINETON, BIPERIDEN LACTATE
AKNE-MYCIN, ERYTHROMYCIN
AKPENTOLATE, CYCLOPENTOLATE HYDROCHLORIDE
AKPRO, DIPIVEFRIN HYDROCHLORIDE
AKRINOL, ACRISORCIN
AKTOB, TOBRAMYCIN
ALA-CORT, HYDROCORTISONE
ALA-SCALP, HYDROCORTISONE
ALAMAST, PEMIROLAST POTASSIUM
ALBALON, NAPHAZOLINE HYDROCHLORIDE
ALBAMYCIN, NOVOBIOCIN SODIUM
ALBENZA, ALBENDAZOLE
ALBUMOTOPE 125 I, ALBUMIN IODINATED I-125 SERUM
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALBUTEROL, ALBUTEROL
ALCAINE, PROPARACAINE HYDROCHLORIDE
ALCOHOL 10% AND DEXTROSE 5%, ALCOHOL
ALCOHOL 5% AND DEXTROSE 5%, ALCOHOL
ALCOHOL 5% IN D5-W, ALCOHOL
ALCOHOL 5% IN DEXTROSE 5% IN WATER, ALCOHOL
ALCOHOL 5% IN DEXTROSE 5%, ALCOHOL
ALDACTAZIDE, HYDROCHLOROTHIAZIDE
ALDACTONE, SPIRONOLACTONE
ALDARA, IMIQUIMOD
ALDOCLOR-150, CHLOROTHIAZIDE
ALDOCLOR-250, CHLOROTHIAZIDE
ALDOMET, METHYLDOPA
ALDOMET, METHYLDOPATE HYDROCHLORIDE
ALDORIL 15, HYDROCHLOROTHIAZIDE
ALDORIL 25, HYDROCHLOROTHIAZIDE
ALDORIL D30, HYDROCHLOROTHIAZIDE
ALDORIL D50, HYDROCHLOROTHIAZIDE
ALESSE, ETHINYL ESTRADIOL
ALEVE COLD AND SINUS, NAPROXEN SODIUM (OTC)
ALEVE, NAPROXEN SODIUM (OTC)
ALFENTA, ALFENTANIL HYDROCHLORIDE
ALFENTANIL, ALFENTANIL HYDROCHLORIDE
ALKERAN, MELPHALAN
ALKERAN, MELPHALAN HYDROCHLORIDE
ALKERGOT, ERGOLOID MESYLATES
ALLAY, ACETAMINOPHEN
ALLEGRA, FEXOFENADINE HYDROCHLORIDE
ALLEGRA-D, FEXOFENADINE HYDROCHLORIDE
ALLERFED, PSEUDOEPHEDRINE HYDROCHLORIDE
ALLOPURINOL, ALLOPURINOL
ALOCRIL, NEDOCROMIL SODIUM
ALOMIDE, LODOXAMIDE TROMETHAMINE
ALOPRIM, ALLOPURINOL SODIUM
ALORA, ESTRADIOL
ALPHA CHYMAR, CHYMOTRYPSIN
ALPHACAINE HCL W/ EPINEPHRINE, EPINEPHRINE
ALPHACAINE HCL, LIDOCAINE HYDROCHLORIDE
ALPHACAINE, LIDOCAINE
ALPHADERM, HYDROCORTISONE
ALPHADROL, FLUPREDNISOLONE
ALPHAGAN P, BRIMONIDINE TARTRATE
ALPHAGAN, BRIMONIDINE TARTRATE
ALPHALIN, VITAMIN A PALMITATE
ALPHAREDISOL, HYDROXOCOBALAMIN
ALPHATREX, BETAMETHASONE DIPROPIONATE
ALPHAZINE, PHENDIMETRAZINE TARTRATE
ALPRAZOLAM, ALPRAZOLAM
ALPROSTADIL, ALPROSTADIL
ALREX, LOTEPREDNOL ETABONATE
ALTACE, RAMIPRIL
ALUMINUM HYDROXIDE AND MAGNESIUM TRISILICATE, ALUMINUM HYDROXIDE (OTC)
ALUPENT, METAPROTERENOL SULFATE
AMANTADINE HCL, AMANTADINE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

AMARYL, GLIMEPIRIDE
AMBENYL, BROMODIPHENHYDRAMINE HYDROCHLORIDE
AMBIEN, ZOLPIDEM TARTRATE
AMBISOME, AMPHOTERICIN B
AMBODRYL, BROMODIPHENHYDRAMINE HYDROCHLORIDE
AMCILL, AMPICILLIN/AMPICILLIN TRIHYDRATE
AMEN, MEDROXYPROGESTERONE ACETATE
AMERGE, NARATRIPTAN HYDROCHLORIDE
AMERSCAN MDP KIT, TECHNETIUM TC-99M MEDRONATE KIT
AMICAR, AMINOCAPROIC ACID
AMIDATE, ETOMIDATE
AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, AMIKACIN SULFATE
AMIKACIN SULFATE, AMIKACIN SULFATE
AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, AMIKACIN SULFATE
AMIKIN, AMIKACIN SULFATE
AMILORIDE HCL AND HYDROCHLOROTHIAZIDE, AMILORIDE HYDROCHLORIDE
AMILORIDE HCL, AMILORIDE HYDROCHLORIDE
AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE, AMINO ACIDS
AMINOACETIC ACID 1.5% IN PLASTIC CONTAINER, GLYCINE
AMINOCAPROIC ACID IN PLASTIC CONTAINER, AMINOCAPROIC ACID
AMINOCAPROIC ACID, AMINOCAPROIC ACID
AMINOCAPROIC, AMINOCAPROIC ACID
AMINOHIPPURATE SODIUM, AMINOHIPPURATE SODIUM
AMINOPHYLLIN, AMINOPHYLLINE
AMINOPHYLLINE DYE FREE, AMINOPHYLLINE
AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, AMINOPHYLLINE
AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%, AMINOPHYLLINE
AMINOPHYLLINE, AMINOPHYLLINE
AMINOSOL 5%, PROTEIN HYDROLYSATE
AMINOSYN 10% (PH6), AMINO ACIDS
AMINOSYN 10%, AMINO ACIDS
AMINOSYN 3.5% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN 3.5% M IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN 3.5% M, AMINO ACIDS
AMINOSYN 3.5% W/ DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN 3.5% W/ DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN 3.5%, AMINO ACIDS
AMINOSYN 4.25% W/ DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN 5%, AMINO ACIDS
AMINOSYN 7% (PH6), AMINO ACIDS
AMINOSYN 7% W/ ELECTROLYTES, AMINO ACIDS
AMINOSYN 7%, AMINO ACIDS
AMINOSYN 8.5% (PH6), AMINO ACIDS
AMINOSYN 8.5% W/ ELECTROLYTES, AMINO ACIDS
AMINOSYN 8.5%, AMINO ACIDS
AMINOSYN II 10% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 10% W/ ELECTROLYTES, AMINO ACIDS
AMINOSYN II 10%, AMINO ACIDS
AMINOSYN II 15% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 3.5% IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 3.5% IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 3.5% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 3.5% M IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 3.5% M IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 3.5% M, AMINO ACIDS
AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 3.5%, AMINO ACIDS
AMINOSYN II 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 4.25% M IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 4.25% W/ ELECT AND ADJUSTED PHOSPHATE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 5% IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 5%, AMINO ACIDS
AMINOSYN II 7% W/ ELECTROLYTES, AMINO ACIDS
AMINOSYN II 7%, AMINO ACIDS
AMINOSYN II 8.5% W/ ELECTROLYTES, AMINO ACIDS
AMINOSYN II 8.5%, AMINO ACIDS
AMINOSYN-HBC 7% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN-HBC 7%, AMINO ACIDS
AMINOSYN-HF 8%, AMINO ACIDS
AMINOSYN-PF 10%, AMINO ACIDS
AMINOSYN-PF 7%, AMINO ACIDS
AMINOSYN-RF 5.2%, AMINO ACIDS
AMIODARONE HCL, AMIODARONE HYDROCHLORIDE
AMIPAQUE, METRIZAMIDE
AMITID, AMITRIPTYLINE HYDROCHLORIDE
AMITRIL, AMITRIPTYLINE HYDROCHLORIDE
AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
AMMONIUM CHLORIDE 0.9% IN NORMAL SALINE, AMMONIUM CHLORIDE
AMMONIUM CHLORIDE 2.14%, AMMONIUM CHLORIDE
AMMONIUM CHLORIDE IN PLASTIC CONTAINER, AMMONIUM CHLORIDE
AMMONIUM CHLORIDE, AMMONIUM CHLORIDE
AMNESTROGEN, ESTROGENS, ESTERIFIED
AMOSENE, MEPROBAMATE
AMOXAPINE, AMOXAPINE
AMOXICILLIN PEDIATRIC, AMOXICILLIN
AMOXICILLIN, AMOXICILLIN
AMOXIL, AMOXICILLIN
AMPHETAMINE SULFATE, AMPHETAMINE SULFATE
AMPHICOL, CHLORAMPHENICOL
AMPHOTEC, AMPHOTERICIN B
AMPHOTERICIN B, AMPHOTERICIN B
AMPICILLIN SODIUM, AMPICILLIN SODIUM
AMPICILLIN TRIHYDRATE, AMPICILLIN/AMPICILLIN TRIHYDRATE
AMPICILLIN, AMPICILLIN/AMPICILLIN TRIHYDRATE
AMRINONE LACTATE, INAMRINONE LACTATE
AMRINONE, INAMRINONE LACTATE
AN-DTPA, TECHNETIUM TC-99M PENTETATE KIT
AN-MAA, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT
AN-SULFUR COLLOID, TECHNETIUM TC-99M SULFUR COLLOID KIT
ANADROL-50, OXYMETHOLONE
ANAFRANIL, CLOMIPRAMINE HYDROCHLORIDE
ANAPROX DS, NAPROXEN SODIUM
ANAPROX, NAPROXEN SODIUM
ANCEF IN DEXTROSE 5% IN PLASTIC CONTAINER, CEFAZOLIN SODIUM
ANCEF IN PLASTIC CONTAINER, CEFAZOLIN SODIUM
ANCEF IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, CEFAZOLIN SODIUM
ANCEF, CEFAZOLIN SODIUM
ANCOBON, FLUCYTOSINE
ANDRODERM, TESTOSTERONE
ANDROGEL, TESTOSTERONE
ANDROID 10, METHYLTESTOSTERONE
ANDROID 25, METHYLTESTOSTERONE
ANDROID 5, METHYLTESTOSTERONE
ANDROID-F, FLUOXYMESTERONE
ANECTINE, SUCCINYLCHOLINE CHLORIDE
ANESTACON, LIDOCAINE HYDROCHLORIDE
ANEXSIA 10/660, ACETAMINOPHEN
ANEXSIA 5/325, ACETAMINOPHEN
ANEXSIA 7.5/325, ACETAMINOPHEN
ANEXSIA 7.5/650, ACETAMINOPHEN
ANEXSIA, ACETAMINOPHEN
ANGIO-CONRAY, IOTHALAMATE SODIUM
ANGIOMAX, BIVALIRUDIN
ANGIOVIST 282, DIATRIZOATE MEGLUMINE
ANGIOVIST 292, DIATRIZOATE MEGLUMINE
ANGIOVIST 370, DIATRIZOATE MEGLUMINE
ANHYDRON, CYCLOTHIAZIDE
ANISOTROPINE METHYLBROMIDE, ANISOTROPINE METHYLBROMIDE
ANOQUAN, ACETAMINOPHEN
ANSAID, FLURBIPROFEN
ANSOLYSEN, PENTOLINIUM TARTRATE
ANSPOR, CEPHRADINE
ANTABUSE, DISULFIRAM
ANTAGON, GANIRELIX ACETATE
ANTAGONATE, CHLORPHENIRAMINE MALEATE
ANTEPAR, PIPERAZINE CITRATE
ANTITUSSIVE, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
ANTIVERT, MECLIZINE HYDROCHLORIDE
ANTIZOL, FOMEPIZOLE
ANTRENYL, OXYPHENONIUM BROMIDE
ANTURANE, SULFINPYRAZONE
ANUSOL HC, HYDROCORTISONE
ANZEMET, DOLASETRON MESYLATE MONOHYDRATE
APAP W/ CODEINE PHOSPHATE, ACETAMINOPHEN
APHTHASOL, AMLEXANOX
APOGEN, GENTAMICIN SULFATE
APRESAZIDE, HYDRALAZINE HYDROCHLORIDE
APRESOLINE, HYDRALAZINE HYDROCHLORIDE
APRESOLINE-ESIDRIX, HYDRALAZINE HYDROCHLORIDE
AQUAMEPHYTON, PHYTONADIONE
AQUAPHYLLIN, THEOPHYLLINE
AQUASOL A, VITAMIN A
AQUASOL A, VITAMIN A PALMITATE
AQUATAG, BENZTHIAZIDE
AQUATENSEN, METHYCLOTHIAZIDE
ARALEN HCL, CHLOROQUINE HYDROCHLORIDE
ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
ARALEN, CHLOROQUINE PHOSPHATE
ARAMINE, METARAMINOL BITARTRATE
ARAVA, LEFLUNOMIDE
ARDUAN, PIPECURONIUM BROMIDE
AREDIA, PAMIDRONATE DISODIUM
ARESTIN, MINOCYCLINE HYDROCHLORIDE
ARESTOCAINE HCL W/ LEVONORDEFRIN, LEVONORDEFRIN
ARESTOCAINE HCL, MEPIVACAINE HYDROCHLORIDE
ARFONAD, TRIMETHAPHAN CAMSYLATE
ARICEPT, DONEPEZIL HYDROCHLORIDE
ARIMIDEX, ANASTROZOLE
ARISTOCORT A, TRIAMCINOLONE ACETONIDE
ARISTOCORT, TRIAMCINOLONE
ARISTOCORT, TRIAMCINOLONE ACETONIDE
ARISTOCORT, TRIAMCINOLONE DIACETATE
ARISTOGEL, TRIAMCINOLONE ACETONIDE
ARISTOSPAN, TRIAMCINOLONE HEXACETONIDE
ARIXTRA, FONDAPARINUX SODIUM
AROMASIN, EXEMESTANE
ARTANE, TRIHEXYPHENIDYL HYDROCHLORIDE
ARTHROTEC, DICLOFENAC SODIUM
ASACOL, MESALAMINE
ASBRON, THEOPHYLLINE SODIUM GLYCINATE

FDA data supplied by DrugPatentWatch.com

ASELLACRIN 10, SOMATROPIN
ASELLACRIN 2, SOMATROPIN
ASENDIN, AMOXAPINE
ASPIRIN AND CAFFEINE W/ BUTALBITAL, ASPIRIN
ASTELIN, AZELASTINE HYDROCHLORIDE
ASTRAMORPH PF, MORPHINE SULFATE
ATACAND HCT, CANDESARTAN CILEXETIL
ATACAND, CANDESARTAN CILEXETIL
ATARAX, HYDROXYZINE HYDROCHLORIDE
ATENOLOL AND CHLORTHALIDONE, ATENOLOL
ATENOLOL, ATENOLOL
ATHROMBIN, WARFARIN SODIUM
ATHROMBIN-K, WARFARIN POTASSIUM
ATIVAN, LORAZEPAM
ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE
ATRACURIUM BESYLATE, ATRACURIUM BESYLATE
ATRIDOX, DOXYCYCLINE HYCLATE
ATROMID-S, CLOFIBRATE
ATROPEN, ATROPINE
ATROPINE AND DEMEROL, ATROPINE SULFATE
ATROPINE SULFATE ANSYR PLASTIC SYRINGE, ATROPINE SULFATE
ATROPINE SULFATE, ATROPINE SULFATE
ATROPINE, ATROPINE
ATROVENT, IPRATROPIUM BROMIDE
AUGMENTIN '125', AMOXICILLIN
AUGMENTIN '200', AMOXICILLIN
AUGMENTIN '250', AMOXICILLIN
AUGMENTIN '400', AMOXICILLIN
AUGMENTIN '500', AMOXICILLIN
AUGMENTIN '875', AMOXICILLIN
AUGMENTIN ES-600, AMOXICILLIN
AUREOMYCIN, CHLORTETRACYCLINE HYDROCHLORIDE
AVAGARD, ALCOHOL (OTC)
AVALIDE, HYDROCHLOROTHIAZIDE
AVANDIA, ROSIGLITAZONE MALEATE
AVAPRO, IRBESARTAN
AVC, SULFANILAMIDE
AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER, MOXIFLOXACIN HYDROCHLORIDE
AVELOX, MOXIFLOXACIN HYDROCHLORIDE
AVENTYL HCL, NORTRIPTYLINE HYDROCHLORIDE
AVIANE-21, ETHINYL ESTRADIOL
AVIANE-28, ETHINYL ESTRADIOL
AVITA, TRETINOIN
AXERT, ALMOTRIPTAN MALATE
AXID AR, NIZATIDINE (OTC)
AXID, NIZATIDINE
AXOTAL, ASPIRIN
AYGESTIN, NORETHINDRONE ACETATE
AZACTAM IN PLASTIC CONTAINER, AZTREONAM
AZACTAM, AZTREONAM
AZATHIOPRINE SODIUM, AZATHIOPRINE SODIUM
AZATHIOPRINE, AZATHIOPRINE
AZATHIOPRINE, AZATHIOPRINE SODIUM
AZDONE, ASPIRIN
AZELEX, AZELAIC ACID
AZLIN, AZLOCILLIN SODIUM
AZMACORT, TRIAMCINOLONE ACETONIDE
AZO GANTANOL, PHENAZOPYRIDINE HYDROCHLORIDE
AZO GANTRISIN, PHENAZOPYRIDINE HYDROCHLORIDE
AZOLID, PHENYLBUTAZONE
AZOPT, BRINZOLAMIDE
AZULFIDINE EN-TABS, SULFASALAZINE
AZULFIDINE, SULFASALAZINE

** B **

BACI-RX, BACITRACIN
BACIGUENT, BACITRACIN
BACIIM, BACITRACIN
BACITRACIN ZINC AND POLYMYXIN B SULFATE, BACITRACIN ZINC
BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE, BACITRACIN ZINC
BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE, BACITRACIN ZINC (OTC)
BACITRACIN ZINC-POLYMYXIN B SULFATE, BACITRACIN ZINC (OTC)
BACITRACIN, BACITRACIN
BACITRACIN, BACITRACIN (OTC)
BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE, BACITRACIN
BACITRACIN-NEOMYCIN-POLYMYXIN, BACITRACIN ZINC
BACLOFEN, BACLOFEN
BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER, WATER FOR INJECTION, STERILE
BACTOCILL IN PLASTIC CONTAINER, OXACILLIN SODIUM
BACTOCILL, OXACILLIN SODIUM
BACTRIM DS, SULFAMETHOXAZOLE
BACTRIM PEDIATRIC, SULFAMETHOXAZOLE
BACTRIM, SULFAMETHOXAZOLE
BACTROBAN, MUPIROCIN
BACTROBAN, MUPIROCIN CALCIUM
BAL, DIMERCAPROL
BALNEOL-HC, HYDROCORTISONE
BAMATE, MEPROBAMATE
BANAN, CEFPODOXIME PROXETIL
BANCAP HC, ACETAMINOPHEN
BANCAP, ACETAMINOPHEN
BANTHINE, METHANTHELINE BROMIDE
BAROS, SODIUM BICARBONATE
BARSTATIN 100, NYSTATIN
BAYCOL, CERIVASTATIN SODIUM
BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN, ASPIRIN (OTC)
BECLOVENT, BECLOMETHASONE DIPROPIONATE

FDA data supplied by DrugPatentWatch.com

BECONASE AQ, BECLOMETHASONE DIPROPIONATE MONOHYDRATE
BECONASE, BECLOMETHASONE DIPROPIONATE
BEEPEN-VK, PENICILLIN V POTASSIUM
BELDIN, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
BELIX, DIPHENHYDRAMINE HYDROCHLORIDE
BENADRYL PRESERVATIVE FREE, DIPHENHYDRAMINE HYDROCHLORIDE
BENADRYL, DIPHENHYDRAMINE HYDROCHLORIDE
BENDECTIN, DOXYLAMINE SUCCINATE
BENDOPA, LEVODOPA
BENEMID, PROBENECID
BENOQUIN, MONOBENZONE
BENOXINATE HCL, BENOXINATE HYDROCHLORIDE
BENSULFOID, SULFUR
BENTYL PRESERVATIVE FREE, DICYCLOMINE HYDROCHLORIDE
BENTYL, DICYCLOMINE HYDROCHLORIDE
BENYLIN, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
BENZACLIN, BENZOYL PEROXIDE
BENZAMYCIN PAK, BENZOYL PEROXIDE
BENZAMYCIN, BENZOYL PEROXIDE
BENZONATATE, BENZONATATE
BENZTHIAZIDE, BENZTHIAZIDE
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
BENZYL BENZOATE, BENZYL BENZOATE
BEPADIN, BEPRIDIL HYDROCHLORIDE
BEROCCA PN, ASCORBIC ACID
BERUBIGEN, CYANOCOBALAMIN
BETA-2, ISOETHARINE HYDROCHLORIDE
BETA-HC, HYDROCORTISONE
BETA-VAL, BETAMETHASONE VALERATE
BETADERM, BETAMETHASONE VALERATE
BETADINE, POVIDONE-IODINE
BETAGAN, LEVOBUNOLOL HYDROCHLORIDE
BETALIN 12, CYANOCOBALAMIN
BETALIN S, THIAMINE HYDROCHLORIDE
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
BETAMETHASONE SODIUM PHOSPHATE, BETAMETHASONE SODIUM PHOSPHATE
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
BETAPACE AF, SOTALOL HYDROCHLORIDE
BETAPACE, SOTALOL HYDROCHLORIDE
BETAPAR, MEPREDNISONE
BETAPEN-VK, PENICILLIN V POTASSIUM
BETAPRONE, PROPIOLACTONE
BETATREX, BETAMETHASONE VALERATE
BETAXOLOL HCL, BETAXOLOL HYDROCHLORIDE
BETAXOLOL, BETAXOLOL HYDROCHLORIDE
BETAXON, LEVOBETAXOLOL HYDROCHLORIDE
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
BETIMOL, TIMOLOL
BETOPTIC PILO, BETAXOLOL HYDROCHLORIDE
BETOPTIC S, BETAXOLOL HYDROCHLORIDE
BETOPTIC, BETAXOLOL HYDROCHLORIDE
BEXTRA, VALDECOXIB
BIAXIN XL, CLARITHROMYCIN
BIAXIN, CLARITHROMYCIN
BICILLIN C-R 900/300, PENICILLIN G BENZATHINE
BICILLIN C-R, PENICILLIN G BENZATHINE
BICILLIN L-A, PENICILLIN G BENZATHINE
BICILLIN, PENICILLIN G BENZATHINE
BICNU, CARMUSTINE
BILIVIST, IPODATE SODIUM
BILOPAQUE, TYROPANOATE SODIUM
BILTRICIDE, PRAZIQUANTEL
BIO-TROPIN, SOMATROPIN RECOMBINANT
BIOSCRUB, CHLORHEXIDINE GLUCONATE (OTC)
BIPHETAMINE 12.5, AMPHETAMINE RESIN COMPLEX
BIPHETAMINE 20, AMPHETAMINE RESIN COMPLEX
BIPHETAMINE 7.5, AMPHETAMINE RESIN COMPLEX
BIPHETAP, BROMPHENIRAMINE MALEATE
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
BLENOXANE, BLEOMYCIN SULFATE
BLEOMYCIN SULFATE, BLEOMYCIN SULFATE
BLEOMYCIN, BLEOMYCIN SULFATE
BLEPH-10, SULFACETAMIDE SODIUM
BLEPH-30, SULFACETAMIDE SODIUM
BLEPHAMIDE S.O.P., PREDNISOLONE ACETATE
BLEPHAMIDE, PREDNISOLONE ACETATE
BLOCADREN, TIMOLOL MALEATE
BONTRIL PDM, PHENDIMETRAZINE TARTRATE
BONTRIL, PHENDIMETRAZINE TARTRATE
BOROFAIR, ACETIC ACID, GLACIAL
BRANCHAMIN 4% IN PLASTIC CONTAINER, AMINO ACIDS
BRANCHAMIN 4%, AMINO ACIDS
BREATHTEK UBT FOR H-PYLORI, UREA, C-13
BRETHAIRE, TERBUTALINE SULFATE
BRETHINE, TERBUTALINE SULFATE
BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER, BRETYLIUM TOSYLATE
BRETYLIUM TOSYLATE IN DEXTROSE 5%, BRETYLIUM TOSYLATE
BRETYLIUM TOSYLATE IN PLASTIC CONTAINER, BRETYLIUM TOSYLATE
BRETYLIUM TOSYLATE, BRETYLIUM TOSYLATE
BRETYLOL, BRETYLIUM TOSYLATE
BREVIBLOC, ESMOLOL HYDROCHLORIDE
BREVICON 21-DAY, ETHINYL ESTRADIOL
BREVICON 28-DAY, ETHINYL ESTRADIOL
BREVITAL SODIUM, METHOHEXITAL SODIUM
BRIAN CARE, CHLORHEXIDINE GLUCONATE (OTC)
BRICANYL, TERBUTALINE SULFATE
BRISTACYCLINE, TETRACYCLINE HYDROCHLORIDE
BRISTAGEN, GENTAMICIN SULFATE
BRISTAMYCIN, ERYTHROMYCIN STEARATE
BROMANATE DC, BROMPHENIRAMINE MALEATE
BROMANATE DM, BROMPHENIRAMINE MALEATE
BROMANATE, BROMPHENIRAMINE MALEATE

FDA data supplied by DrugPatentWatch.com

BROMANYL, BROMODIPHENHYDRAMINE HYDROCHLORIDE
BROMATAPP, BROMPHENIRAMINE MALEATE (OTC)
BROMFED-DM, BROMPHENIRAMINE MALEATE
BROMOCRIPTINE MESYLATE, BROMOCRIPTINE MESYLATE
BROMPHENIRAMINE MALEATE, BROMPHENIRAMINE MALEATE
BROMPHERIL, DEXBROMPHENIRAMINE MALEATE (OTC)
BRONCHO SALINE, SODIUM CHLORIDE (OTC)
BRONITIN MIST, EPINEPHRINE BITARTRATE (OTC)
BRONKAID MIST, EPINEPHRINE (OTC)
BRONKODYL, THEOPHYLLINE
BRONKOMETER, ISOETHARINE MESYLATE
BRONKOSOL, ISOETHARINE HYDROCHLORIDE
BRYREL, PIPERAZINE CITRATE
BSS PLUS, CALCIUM CHLORIDE
BSS, CALCIUM CHLORIDE
BUCET, ACETAMINOPHEN
BUCLADIN-S, BUCLIZINE HYDROCHLORIDE
BUMETANIDE, BUMETANIDE
BUMEX, BUMETANIDE
BUPHENYL, SODIUM PHENYLBUTYRATE
BUPIVACAINE HCL AND EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE
BUPIVACAINE HCL KIT, BUPIVACAINE HYDROCHLORIDE
BUPIVACAINE HCL, BUPIVACAINE HYDROCHLORIDE
BUPIVACAINE, BUPIVACAINE HYDROCHLORIDE
BUPRENEX, BUPRENORPHINE HYDROCHLORIDE
BUPRENORPHINE HCL, BUPRENORPHINE HYDROCHLORIDE
BUPROPION HCL, BUPROPION HYDROCHLORIDE
BUSPAR, BUSPIRONE HYDROCHLORIDE
BUSPIRONE HCL, BUSPIRONE HYDROCHLORIDE
BUSULFEX, BUSULFAN
BUTABARB, BUTABARBITAL SODIUM
BUTABARBITAL SODIUM, BUTABARBITAL SODIUM
BUTABARBITAL, BUTABARBITAL SODIUM
BUTAL COMPOUND, ASPIRIN
BUTALAN, BUTABARBITAL SODIUM
BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN
BUTALBITAL ASPIRIN AND CAFFEINE, ASPIRIN
BUTALBITAL COMPOUND, ASPIRIN
BUTALBITAL W/ ASPIRIN & CAFFEINE, ASPIRIN
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
BUTALBITAL, ACETAMINOPHEN, AND CAFFEINE, ACETAMINOPHEN
BUTALBITAL, ACETAMINOPHEN, CAFFEINE, ACETAMINOPHEN
BUTALBITAL, APAP, AND CAFFEINE, ACETAMINOPHEN
BUTALBITAL, ASPIRIN & CAFFEINE, ASPIRIN
BUTALBITAL, ASPIRIN AND CAFFEINE, ASPIRIN
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE, ASPIRIN
BUTALBITAL; ACETAMINOPHEN; AND CAFFEINE WITH CODEINE PHOSPHATE, ACETAMINOPHEN
BUTAPAP, ACETAMINOPHEN
BUTAZOLIDIN, PHENYLBUTAZONE
BUTICAPS, BUTABARBITAL SODIUM
BUTISOL SODIUM, BUTABARBITAL SODIUM
BUTORPHANOL TARTRATE PRESERVATIVE FREE, BUTORPHANOL TARTRATE
BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE

** C **

C-SOLVE-2, ERYTHROMYCIN
CAFCIT, CAFFEINE CITRATE
CAFERGOT, CAFFEINE
CALAN, VERAPAMIL HYDROCHLORIDE
CALCIBIND, CELLULOSE SODIUM PHOSPHATE
CALCIJEX, CALCITRIOL
CALCIMAR, CALCITONIN, SALMON
CALCIPARINE, HEPARIN CALCIUM
CALCITONIN-SALMON, CALCITONIN, SALMON
CALCITRIOL, CALCITRIOL
CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
CALCIUM DISODIUM VERSENATE, EDETATE CALCIUM DISODIUM
CALCIUM GLUCEPTATE, CALCIUM GLUCEPTATE
CALDEROL, CALCIFEDIOL
CALMURID HC, HYDROCORTISONE
CAM-AP-ES, HYDRALAZINE HYDROCHLORIDE
CAM-METRAZINE, PHENDIMETRAZINE TARTRATE
CAMOQUIN HCL, AMODIAQUINE HYDROCHLORIDE
CAMPTOSAR, IRINOTECAN HYDROCHLORIDE
CANASA, MESALAMINE
CANCIDAS, CASPOFUNGIN ACETATE
CANDEX, NYSTATIN
CANTIL, MEPENZOLATE BROMIDE
CAP-PROFEN, IBUPROFEN (OTC)
CAPASTAT SULFATE, CAPREOMYCIN SULFATE
CAPITAL AND CODEINE, ACETAMINOPHEN
CAPITAL WITH CODEINE, ACETAMINOPHEN
CAPITROL, CHLOROXINE
CAPOTEN, CAPTOPRIL
CAPOZIDE 25/15, CAPTOPRIL
CAPOZIDE 25/25, CAPTOPRIL
CAPOZIDE 50/15, CAPTOPRIL
CAPOZIDE 50/25, CAPTOPRIL
CAPTOPRIL AND HYDROCHLOROTHIAZIDE, CAPTOPRIL
CAPTOPRIL, CAPTOPRIL
CARAC, FLUOROURACIL
CARAFATE, SUCRALFATE
CARBACHOL, CARBACHOL
CARBAMAZEPINE, CARBAMAZEPINE
CARBASTAT, CARBACHOL
CARBATROL, CARBAMAZEPINE
CARBIDOPA AND LEVODOPA, CARBIDOPA
CARBOCAINE W/ NEO-COBEFRIN, LEVONORDEFRIN
CARBOCAINE, MEPIVACAINE HYDROCHLORIDE
CARDENE SR, NICARDIPINE HYDROCHLORIDE
CARDENE, NICARDIPINE HYDROCHLORIDE
CARDIO-GREEN, INDOCYANINE GREEN
CARDIOGEN-82, RUBIDIUM CHLORIDE RB-82

FDA data supplied by DrugPatentWatch.com

CARDIOGRAFIN, DIATRIZOATE MEGLUMINE
CARDIOLITE, TECHNETIUM TC-99M SESTAMIBI KIT
CARDIOPLEGIC IN PLASTIC CONTAINER, CALCIUM CHLORIDE
CARDIOQUIN, QUINIDINE POLYGALACTURONATE
CARDIOTEC, TECHNETIUM TC-99M TEBOROXIME KIT
CARDIZEM CD, DILTIAZEM HYDROCHLORIDE
CARDIZEM SR, DILTIAZEM HYDROCHLORIDE
CARDIZEM, DILTIAZEM HYDROCHLORIDE
CARDRASE, ETHOXZOLAMIDE
CARDURA, DOXAZOSIN MESYLATE
CARISOPRODOL AND ASPIRIN, ASPIRIN
CARISOPRODOL COMPOUND, ASPIRIN
CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE, ASPIRIN
CARISOPRODOL, CARISOPRODOL
CARMOL HC, HYDROCORTISONE ACETATE
CARNITOR, LEVOCARNITINE
CARTEOLOL HCL, CARTEOLOL HYDROCHLORIDE
CARTIA XT, DILTIAZEM HYDROCHLORIDE
CARTROL, CARTEOLOL HYDROCHLORIDE
CASODEX, BICALUTAMIDE
CATAFLAM, DICLOFENAC POTASSIUM
CATAPRES, CLONIDINE HYDROCHLORIDE
CATAPRES-TTS-1, CLONIDINE
CATAPRES-TTS-2, CLONIDINE
CATAPRES-TTS-3, CLONIDINE
CATARASE, CHYMOTRYPSIN
CAVERJECT, ALPROSTADIL
CECLOR CD, CEFACLOR
CECLOR, CEFACLOR
CEDAX, CEFTIBUTEN DIHYDRATE
CEDILANID-D, DESLANOSIDE
CEENU, LOMUSTINE
CEFACLOR, CEFACLOR
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CEFADYL, CEPHAPIRIN SODIUM
CEFAZOLIN AND DEXTROSE, CEFAZOLIN SODIUM
CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
CEFIZOX IN DEXTROSE 5% IN PLASTIC CONTAINER, CEFTIZOXIME SODIUM
CEFIZOX IN PLASTIC CONTAINER, CEFTIZOXIME SODIUM
CEFIZOX, CEFTIZOXIME SODIUM
CEFMAX, CEFMENOXIME HYDROCHLORIDE
CEFOBID IN PLASTIC CONTAINER, CEFOPERAZONE SODIUM
CEFOBID, CEFOPERAZONE SODIUM
CEFOTAN IN PLASTIC CONTAINER, CEFOTETAN DISODIUM
CEFOTAN, CEFOTETAN DISODIUM
CEFOTAXIME, CEFOTAXIME SODIUM
CEFOXITIN, CEFOXITIN SODIUM
CEFPIRAMIDE SODIUM, CEFPIRAMIDE SODIUM
CEFTAZIDIME SODIUM IN PLASTIC CONTAINER, CEFTAZIDIME SODIUM
CEFTIN, CEFUROXIME AXETIL
CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER, CEFUROXIME SODIUM
CEFUROXIME SODIUM, CEFUROXIME SODIUM
CEFUROXIME, CEFUROXIME SODIUM
CEFZIL, CEFPROZIL
CELEBREX, CELECOXIB
CELESTONE SOLUSPAN, BETAMETHASONE ACETATE
CELESTONE, BETAMETHASONE
CELESTONE, BETAMETHASONE SODIUM PHOSPHATE
CELEXA, CITALOPRAM HYDROBROMIDE
CELLCEPT, MYCOPHENOLATE MOFETIL
CELLCEPT, MYCOPHENOLATE MOFETIL HYDROCHLORIDE
CELONTIN, METHSUXIMIDE
CENESTIN, ESTROGENS, CONJUGATED SYNTHETIC A
CENTRAX, PRAZEPAM
CEPHALEXIN, CEPHALEXIN
CEPHALOTHIN SODIUM W/ DEXTROSE IN PLASTIC CONTAINER, CEPHALOTHIN SODIUM
CEPHALOTHIN SODIUM W/ SODIUM CHLORIDE IN PLASTIC CONTAINER, CEPHALOTHIN SODIUM
CEPHALOTHIN SODIUM, CEPHALOTHIN SODIUM
CEPHALOTHIN, CEPHALOTHIN SODIUM
CEPHAPIRIN SODIUM, CEPHAPIRIN SODIUM
CEPHRADINE, CEPHRADINE
CEPHULAC, LACTULOSE
CEPTAZ, CEFTAZIDIME (ARGININE FORMULATION)
CERADON, CEFOTIAM HYDROCHLORIDE
CEREBYX, FOSPHENYTOIN SODIUM
CEREDASE, ALGLUCERASE
CERETEC, TECHNETIUM TC-99M EXAMETAZIME KIT
CEREZYME, IMIGLUCERASE
CERNEVIT-12, ALPHA-TOCOPHEROL
CERUBIDINE, DAUNORUBICIN HYDROCHLORIDE
CERUMENEX, TROLAMINE POLYPEPTIDE OLEATE CONDENSATE
CERVIDIL, DINOPROSTONE
CESAMET, NABILONE
CETACORT, HYDROCORTISONE
CETAMIDE, SULFACETAMIDE SODIUM
CETAPRED, PREDNISOLONE ACETATE
CETROTIDE, CETRORELIX
CHEMET, SUCCIMER
CHENIX, CHENODIOL
CHG SCRUB, CHLORHEXIDINE GLUCONATE (OTC)
CHIBROXIN, NORFLOXACIN
CHILDREN'S ADVIL, IBUPROFEN
CHILDREN'S ADVIL, IBUPROFEN (OTC)
CHILDREN'S ADVIL-FLAVORED, IBUPROFEN (OTC)
CHILDREN'S IBUPROFEN, IBUPROFEN (OTC)
CHILDREN'S MOTRIN COLD, IBUPROFEN (OTC)
CHILDREN'S MOTRIN, IBUPROFEN (OTC)
CHIROCAINE, LEVOBUPIVACAINE HYDROCHLORIDE
CHLOR-TRIMETON, CHLORPHENIRAMINE MALEATE
CHLOR-TRIMETON, CHLORPHENIRAMINE MALEATE (OTC)
CHLORAMPHENICOL SODIUM SUCCINATE, CHLORAMPHENICOL SODIUM SUCCINATE

FDA data supplied by DrugPatentWatch.com

CHLORAMPHENICOL, CHLORAMPHENICOL
CHLORAMPHENICOL, CHLORAMPHENICOL SODIUM SUCCINATE
CHLORAPREP, CHLORHEXIDINE GLUCONATE (OTC)
CHLORDIAZACHEL, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLORDIAZEPOXIDE AND AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
CHLORDIAZEPOXIDE HCL, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE (OTC)
CHLORMERODRIN HG 197, CHLORMERODRIN, HG-197
CHLOROFAIR, CHLORAMPHENICOL
CHLOROHENIRAMINE MALEATE AND PHENYLPROPANOLAMINE HCL, CHLORPHENIRAMINE MALEATE
CHLOROMYCETIN HYDROCORTISONE, CHLORAMPHENICOL
CHLOROMYCETIN PALMITATE, CHLORAMPHENICOL PALMITATE
CHLOROMYCETIN, CHLORAMPHENICOL
CHLOROMYCETIN, CHLORAMPHENICOL SODIUM SUCCINATE
CHLOROMYXIN, CHLORAMPHENICOL
CHLOROPROCAINE HCL, CHLOROPROCAINE HYDROCHLORIDE
CHLOROPTIC S.O.P., CHLORAMPHENICOL
CHLOROPTIC, CHLORAMPHENICOL
CHLOROPTIC-P S.O.P., CHLORAMPHENICOL
CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
CHLOROTHIAZIDE AND RESERPINE, CHLOROTHIAZIDE
CHLOROTHIAZIDE W/ RESERPINE, CHLOROTHIAZIDE
CHLOROTHIAZIDE, CHLOROTHIAZIDE
CHLOROTHIAZIDE-RESERPINE, CHLOROTHIAZIDE
CHLOROTRIANISENE, CHLOROTRIANISENE
CHLORPHENIRAMINE MALEATE AND PHENYLPROPANOLAMINE HCL, CHLORPHENIRAMINE MALEATE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE (OTC)
CHLORPROMAZINE HCL INTENSOL, CHLORPROMAZINE HYDROCHLORIDE
CHLORPROMAZINE HCL, CHLORPROMAZINE HYDROCHLORIDE
CHLORPROPAMIDE, CHLORPROPAMIDE
CHLORTHALIDONE, CHLORTHALIDONE
CHLORZOXAZONE, CHLORZOXAZONE
CHOLAC, LACTULOSE
CHOLEBRINE, IOCETAMIC ACID
CHOLEDYL SA, OXTRIPHYLLINE
CHOLEDYL, OXTRIPHYLLINE
CHOLESTYRAMINE LIGHT, CHOLESTYRAMINE
CHOLESTYRAMINE, CHOLESTYRAMINE
CHOLETEC, TECHNETIUM TC-99M MEBROFENIN KIT
CHOLOGRAFIN MEGLUMINE, IODIPAMIDE MEGLUMINE
CHOLOGRAFIN SODIUM, IODIPAMIDE SODIUM
CHOLOVUE, IODOXAMATE MEGLUMINE
CHOLOXIN, DEXTROTHYROXINE SODIUM
CHOLYBAR, CHOLESTYRAMINE
CHORIONIC GONADOTROPIN, GONADOTROPIN, CHORIONIC
CHROMALBIN, ALBUMIN CHROMATED CR-51 SERUM
CHROMIC CHLORIDE IN PLASTIC CONTAINER, CHROMIC CHLORIDE
CHROMIC CHLORIDE, CHROMIC CHLORIDE
CHROMITOPE SODIUM, SODIUM CHROMATE, CR-51
CHRONULAC, LACTULOSE
CHYMEX, BENTIROMIDE
CHYMODIACTIN, CHYMOPAPAIN
CIBACALCIN, CALCITONIN HUMAN
CIDA-STAT, CHLORHEXIDINE GLUCONATE (OTC)
CILOXAN, CIPROFLOXACIN HYDROCHLORIDE
CIMETIDINE HCL IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, CIMETIDINE HYDROCHLORIDE
CIMETIDINE HCL, CIMETIDINE
CIMETIDINE HCL, CIMETIDINE HYDROCHLORIDE
CIMETIDINE, CIMETIDINE
CIMETIDINE, CIMETIDINE (OTC)
CIN-QUIN, QUINIDINE SULFATE
CINNASIL, RESCINNAMINE
CINOBAC, CINOXACIN
CINOXACIN, CINOXACIN
CINTICHEM TECHNETIUM 99M HEDSPA, TECHNETIUM TC-99M ETIDRONATE KIT
CIPRO HC, CIPROFLOXACIN HYDROCHLORIDE
CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN
CIPRO IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, CIPROFLOXACIN
CIPRO, CIPROFLOXACIN
CIPRO, CIPROFLOXACIN HYDROCHLORIDE
CIRCANOL, ERGOLOID MESYLATES
CIS-MDP, TECHNETIUM TC-99M MEDRONATE KIT
CIS-PYRO, TECHNETIUM TC-99M PYROPHOSPHATE KIT
CISPLATIN, CISPLATIN
CITANEST FORTE, EPINEPHRINE BITARTRATE
CITANEST PLAIN, PRILOCAINE HYDROCHLORIDE
CITANEST, PRILOCAINE HYDROCHLORIDE
CLADRIBINE, CLADRIBINE
CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER, CEFOTAXIME SODIUM
CLAFORAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, CEFOTAXIME SODIUM
CLAFORAN, CEFOTAXIME SODIUM
CLARINEX, DESLORATADINE
CLARITIN REDITABS, LORATADINE
CLARITIN, LORATADINE
CLARITIN-D 24 HOUR, LORATADINE
CLARITIN-D, LORATADINE
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE (OTC)
CLEOCIN HCL, CLINDAMYCIN HYDROCHLORIDE
CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE
CLEOCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLEOCIN T, CLINDAMYCIN PHOSPHATE
CLEOCIN, CLINDAMYCIN HYDROCHLORIDE
CLEOCIN, CLINDAMYCIN PALMITATE HYDROCHLORIDE
CLEOCIN, CLINDAMYCIN PHOSPHATE

FDA data supplied by DrugPatentWatch.com

CLIMARA, ESTRADIOL
CLINDA-DERM, CLINDAMYCIN PHOSPHATE
CLINDAMYCIN HCL, CLINDAMYCIN HYDROCHLORIDE
CLINDAMYCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE
CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%, CLINDAMYCIN PHOSPHATE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLINDETS, CLINDAMYCIN PHOSPHATE
CLINIMIX 2.75/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 2.75/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/15 SULFITE FREE IN DEXTROSE 15% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/35 SULFITE FREE IN DEXTROSE 35% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 2.75/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 2.75/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 2.75/5 SULFITE-FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 4.25/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 4.25/20 SULFITE-FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 4.25/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 4.25/5 SULFITE-FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 5/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 5/15 SULFITE-FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 5/20 SULFITE-FREE W/ ELECT IN 20% DEXTROSE W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 5/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 5/35 SULFITE FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINISOL 15% SULFITE FREE IN PLASTIC CONTAINER, AMINO ACIDS
CLINORIL, SULINDAC
CLISTIN, CARBINOXAMINE MALEATE
CLOBETASOL PROPIONATE (EMOLLIENT), CLOBETASOL PROPIONATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLODERM, CLOCORTOLONE PIVALATE
CLOFIBRATE, CLOFIBRATE
CLOMID, CLOMIPHENE CITRATE
CLOMIPHENE CITRATE, CLOMIPHENE CITRATE
CLOMIPRAMINE HCL, CLOMIPRAMINE HYDROCHLORIDE
CLONAZEPAM, CLONAZEPAM
CLONIDINE HCL AND CHLORTHALIDONE, CHLORTHALIDONE
CLONIDINE HCL, CLONIDINE HYDROCHLORIDE
CLOPRA, METOCLOPRAMIDE HYDROCHLORIDE
CLOPRA-"YELLOW", METOCLOPRAMIDE HYDROCHLORIDE
CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
CLORPRES, CHLORTHALIDONE
CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CLOTRIMAZOLE, CLOTRIMAZOLE
CLOTRIMAZOLE, CLOTRIMAZOLE (OTC)
CLOXACILLIN SODIUM, CLOXACILLIN SODIUM
CLOXAPEN, CLOXACILLIN SODIUM
CLOZAPINE, CLOZAPINE
CLOZARIL, CLOZAPINE
CO-GESIC, ACETAMINOPHEN
CO-LAV, POLYETHYLENE GLYCOL 3350
COACTIN, AMDINOCILLIN
COBAVITE, CYANOCOBALAMIN
CODAMINE, HYDROCODONE BITARTRATE
CODEINE PHOSPHATE AND ACETAMINOPHEN, ACETAMINOPHEN
CODEINE, ASPIRIN, APAP FORMULA NO. 2, ACETAMINOPHEN
CODEINE, ASPIRIN, APAP FORMULA NO. 3, ACETAMINOPHEN
CODEINE, ASPIRIN, APAP FORMULA NO. 4, ACETAMINOPHEN
CODIMAL-L.A. 12, CHLORPHENIRAMINE MALEATE (OTC)
CODOXY, ASPIRIN
COGENTIN, BENZTROPINE MESYLATE
COGNEX, TACRINE HYDROCHLORIDE
COL-PROBENECID, COLCHICINE
COLAZAL, BALSALAZIDE DISODIUM
COLBENEMID, COLCHICINE
COLD CAPSULE IV, CHLORPHENIRAMINE MALEATE (OTC)
COLD CAPSULE V, CHLORPHENIRAMINE MALEATE (OTC)
COLESTID, COLESTIPOL HYDROCHLORIDE
COLGATE TOTAL, SODIUM FLUORIDE (OTC)
COLISTIMETHATE, COLISTIMETHATE SODIUM
COLOCORT, HYDROCORTISONE
COLONAID, ATROPINE SULFATE
COLOVAGE, POLYETHYLENE GLYCOL 3350
COLY-MYCIN M, COLISTIMETHATE SODIUM

FDA data supplied by DrugPatentWatch.com

COLY-MYCIN S, COLISTIN SULFATE
COLYTE WITH FLAVOR PACKS, POLYETHYLENE GLYCOL 3350
COLYTE, POLYETHYLENE GLYCOL 3350
COLYTE-FLAVORED, POLYETHYLENE GLYCOL 3350
COMBIPATCH, ESTRADIOL
COMBIPRES, CHLORTHALIDONE
COMBIVENT, ALBUTEROL SULFATE
COMBIVIR, LAMIVUDINE
COMPAZINE, PROCHLORPERAZINE
COMPAZINE, PROCHLORPERAZINE EDISYLATE
COMPAZINE, PROCHLORPERAZINE MALEATE
COMPOUND 65, ASPIRIN
COMPRO, PROCHLORPERAZINE
COMTAN, ENTACAPONE
CONCENTRAID, DESMOPRESSIN ACETATE
CONCERTA, METHYLPHENIDATE HYDROCHLORIDE
CONDYLOX, PODOFILOX
CONRAY 30, IOTHALAMATE MEGLUMINE
CONRAY 325, IOTHALAMATE SODIUM
CONRAY 400, IOTHALAMATE SODIUM
CONRAY 43, IOTHALAMATE MEGLUMINE
CONRAY, IOTHALAMATE MEGLUMINE
CONSTILAC, LACTULOSE
CONSTULOSE, LACTULOSE
CONTAC, CHLORPHENIRAMINE MALEATE (OTC)
COPAXONE, GLATIRAMER ACETATE
COPPER T MODEL TCU 380A, COPPER
COR-OTICIN, HYDROCORTISONE ACETATE
CORDARONE, AMIODARONE HYDROCHLORIDE
CORDRAN SP, FLURANDRENOLIDE
CORDRAN, FLURANDRENOLIDE
CORDRAN-N, FLURANDRENOLIDE
COREG, CARVEDILOL
CORGARD, NADOLOL
CORLOPAM, FENOLDOPAM MESYLATE
CORMAX, CLOBETASOL PROPIONATE
CORPHED, PSEUDOEPHEDRINE HYDROCHLORIDE
CORSYM, CHLORPHENIRAMINE POLISTIREX (OTC)
CORT-DOME, HYDROCORTISONE
CORTALONE, PREDNISOLONE
CORTAN, PREDNISONE
CORTEF ACETATE, HYDROCORTISONE ACETATE
CORTEF, HYDROCORTISONE
CORTEF, HYDROCORTISONE CYPIONATE
CORTENEMA, HYDROCORTISONE
CORTICOTROPIN, CORTICOTROPIN
CORTIFOAM, HYDROCORTISONE ACETATE
CORTISONE ACETATE, CORTISONE ACETATE
CORTISPORIN, BACITRACIN ZINC
CORTISPORIN, HYDROCORTISONE
CORTISPORIN, HYDROCORTISONE ACETATE
CORTONE, CORTISONE ACETATE
CORTRIL, HYDROCORTISONE
CORTRIL, HYDROCORTISONE ACETATE
CORTROPHIN-ZINC, CORTICOTROPIN-ZINC HYDROXIDE
CORTROSYN, COSYNTROPIN
CORVERT, IBUTILIDE FUMARATE
CORZIDE, BENDROFLUMETHIAZIDE
COSMEGEN, DACTINOMYCIN
COSOPT, DORZOLAMIDE HYDROCHLORIDE
COTAZYM, LIPASE
COTRIM D.S., SULFAMETHOXAZOLE
COTRIM, SULFAMETHOXAZOLE
COUMADIN, WARFARIN SODIUM
COVERA-HS, VERAPAMIL HYDROCHLORIDE
COZAAR, LOSARTAN POTASSIUM
CRESCORMON, SOMATROPIN
CRINONE, PROGESTERONE
CRIXIVAN, INDINAVIR SULFATE
CROLOM, CROMOLYN SODIUM
CROMOLYN SODIUM, CROMOLYN SODIUM
CROMOLYN SODIUM, CROMOLYN SODIUM (OTC)
CROMOPTIC, CROMOLYN SODIUM
CROTAN, CROTAMITON
CRYSELLE, ETHINYL ESTRADIOL
CRYSTODIGIN, DIGITOXIN
CU-7, COPPER
CUPRIC CHLORIDE IN PLASTIC CONTAINER, CUPRIC CHLORIDE
CUPRIC SULFATE, CUPRIC SULFATE
CUPRIMINE, PENICILLAMINE
CUROSURF, PORACTANT ALFA
CURRETAB, MEDROXYPROGESTERONE ACETATE
CUTIVATE, FLUTICASONE PROPIONATE
CYANOCOBALAMIN CO 57 SCHILLING TEST KIT, CYANOCOBALAMIN
CYANOCOBALAMIN, CYANOCOBALAMIN
CYCLACILLIN, CYCLACILLIN
CYCLAINE, HEXYLCAINE HYDROCHLORIDE
CYCLAPEN-W, CYCLACILLIN
CYCLESSA, DESOGESTREL
CYCLOBENZAPRINE HCL, CYCLOBENZAPRINE HYDROCHLORIDE
CYCLOCORT, AMCINONIDE
CYCLOGYL, CYCLOPENTOLATE HYDROCHLORIDE
CYCLOMYDRIL, CYCLOPENTOLATE HYDROCHLORIDE
CYCLOPAR, TETRACYCLINE HYDROCHLORIDE
CYCLOPENTOLATE HCL, CYCLOPENTOLATE HYDROCHLORIDE
CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
CYCLOSPORINE, CYCLOSPORINE
CYCRIN, MEDROXYPROGESTERONE ACETATE
CYKLOKAPRON, TRANEXAMIC ACID
CYLERT, PEMOLINE
CYPROHEPTADINE HCL, CYPROHEPTADINE HYDROCHLORIDE
CYSTADANE, BETAINE, ANHYDROUS
CYSTAGON, CYSTEAMINE BITARTRATE
CYSTEINE HCL, CYSTEINE HYDROCHLORIDE
CYSTO-CONRAY II, IOTHALAMATE MEGLUMINE
CYSTO-CONRAY, IOTHALAMATE MEGLUMINE

FDA data supplied by DrugPatentWatch.com

CYSTOGRAFIN DILUTE, DIATRIZOATE MEGLUMINE
CYSTOGRAFIN, DIATRIZOATE MEGLUMINE
CYTADREN, AMINOGLUTETHIMIDE
CYTARABINE, CYTARABINE
CYTOMEL, LIOTRIX (T4;T3)
CYTOSAR-U, CYTARABINE
CYTOTEC, MISOPROSTOL
CYTOVENE IV, GANCICLOVIR SODIUM
CYTOVENE, GANCICLOVIR
CYTOXAN, CYCLOPHOSPHAMIDE

** D **

D.H.E. 45, DIHYDROERGOTAMINE MESYLATE
DACARBAZINE, DACARBAZINE
DALGAN, DEZOCINE
DALMANE, FLURAZEPAM HYDROCHLORIDE
DANAZOL, DANAZOL
DANOCRINE, DANAZOL
DANTRIUM, DANTROLENE SODIUM
DAPSONE, DAPSONE
DARANIDE, DICHLORPHENAMIDE
DARAPRIM, PYRIMETHAMINE
DARBID, ISOPROPAMIDE IODIDE
DARICON, OXYPHENCYCLIMINE HYDROCHLORIDE
DARVOCET, ACETAMINOPHEN
DARVOCET-N 100, ACETAMINOPHEN
DARVOCET-N 50, ACETAMINOPHEN
DARVON COMPOUND, ASPIRIN
DARVON COMPOUND-65, ASPIRIN
DARVON W/ ASA, ASPIRIN
DARVON, PROPOXYPHENE HYDROCHLORIDE
DARVON-N W/ ASA, ASPIRIN
DARVON-N, PROPOXYPHENE NAPSYLATE
DAUNORUBICIN HCL, DAUNORUBICIN HYDROCHLORIDE
DAUNOXOME, DAUNORUBICIN CITRATE
DAYPRO, OXAPROZIN
DDAVP (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE
DDAVP, DESMOPRESSIN ACETATE
DEAPRIL-ST, ERGOLOID MESYLATES
DECA-DURABOLIN, NANDROLONE DECANOATE
DECABID, INDECAINIDE HYDROCHLORIDE
DECADERM, DEXAMETHASONE
DECADRON W/ XYLOCAINE, DEXAMETHASONE SODIUM PHOSPHATE
DECADRON, DEXAMETHASONE
DECADRON, DEXAMETHASONE SODIUM PHOSPHATE
DECADRON-LA, DEXAMETHASONE ACETATE
DECAPRYN, DOXYLAMINE SUCCINATE
DECASPRAY, DEXAMETHASONE
DECLOMYCIN, DEMECLOCYCLINE HYDROCHLORIDE
DEFINITY, PERFLUTREN
DEL-VI-A, VITAMIN A PALMITATE
DELALUTIN, HYDROXYPROGESTERONE CAPROATE
DELATESTRYL, TESTOSTERONE ENANTHATE
DELAXIN, METHOCARBAMOL
DELCOBESE, AMPHETAMINE ADIPATE
DELESTROGEN, ESTRADIOL VALERATE
DELFEN, NONOXYNOL-9 (OTC)
DELFLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX-LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX-LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX-LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELSYM, DEXTROMETHORPHAN POLISTIREX (OTC)
DELTA-CORTEF, PREDNISOLONE
DELTA-DOME, PREDNISONE
DELTALIN, ERGOCALCIFEROL
DELTASONE, PREDNISONE
DEMADEX, TORSEMIDE
DEMAZIN, CHLORPHENIRAMINE MALEATE (OTC)
DEMEROL, MEPERIDINE HYDROCHLORIDE
DEMI-REGROTON, CHLORTHALIDONE
DEMSER, METYROSINE
DEMULEN 1/35-21, ETHINYL ESTRADIOL
DEMULEN 1/35-28, ETHINYL ESTRADIOL
DEMULEN 1/50-21, ETHINYL ESTRADIOL
DEMULEN 1/50-28, ETHINYL ESTRADIOL
DENAVIR, PENCICLOVIR SODIUM
DENDRID, IDOXURIDINE
DEPACON, VALPROATE SODIUM
DEPAKENE, VALPROIC ACID
DEPAKOTE CP, DIVALPROEX SODIUM
DEPAKOTE ER, DIVALPROEX SODIUM

FDA data supplied by DrugPatentWatch.com

DEPAKOTE, DIVALPROEX SODIUM
DEPEN, PENICILLAMINE
DEPINAR, CYANOCOBALAMIN
DEPO-ESTRADIOL, ESTRADIOL CYPIONATE
DEPO-MEDROL, METHYLPREDNISOLONE ACETATE
DEPO-PROVERA, MEDROXYPROGESTERONE ACETATE
DEPO-TESTADIOL, ESTRADIOL CYPIONATE
DEPO-TESTOSTERONE, TESTOSTERONE CYPIONATE
DEPOCYT, CYTARABINE
DERMA-SMOOTHE/FS, FLUOCINOLONE ACETONIDE
DERMABET, BETAMETHASONE VALERATE
DERMACORT, HYDROCORTISONE
DERMATOP, PREDNICARBATE
DESFERAL, DEFEROXAMINE MESYLATE
DESIPRAMINE HCL, DESIPRAMINE HYDROCHLORIDE
DESMOPRESSIN ACETATE PRESERVATIVE FREE, DESMOPRESSIN ACETATE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DESOGEN, DESOGESTREL
DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
DESONIDE, DESONIDE
DESOWEN, DESONIDE
DESOXIMETASONE, DESOXIMETASONE
DESOXYN, METHAMPHETAMINE HYDROCHLORIDE
DESYREL, TRAZODONE HYDROCHLORIDE
DETROL LA, TOLTERODINE TARTRATE
DETROL, TOLTERODINE TARTRATE
DEXACEN-4, DEXAMETHASONE SODIUM PHOSPHATE
DEXACIDIN, DEXAMETHASONE
DEXACORT, DEXAMETHASONE SODIUM PHOSPHATE
DEXAIR, DEXAMETHASONE SODIUM PHOSPHATE
DEXAMETHASONE ACETATE, DEXAMETHASONE ACETATE
DEXAMETHASONE INTENSOL, DEXAMETHASONE
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DEXAMETHASONE, DEXAMETHASONE
DEXAMETHASONE, DEXAMETHASONE SODIUM PHOSPHATE
DEXAMPEX, DEXTROAMPHETAMINE SULFATE
DEXASPORIN, DEXAMETHASONE
DEXCHLORPHENIRAMINE MALEATE, DEXCHLORPHENIRAMINE MALEATE
DEXEDRINE, DEXTROAMPHETAMINE SULFATE
DEXFERRUM, IRON DEXTRAN
DEXONE 0.5, DEXAMETHASONE
DEXONE 0.75, DEXAMETHASONE
DEXONE 1.5, DEXAMETHASONE
DEXONE 4, DEXAMETHASONE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DEXTROSE 10% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 2.5% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 20% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 25%, DEXTROSE
DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 30% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 38.5% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 4% IN MODIFIED LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 40% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND ELECTROLYTE NO 75 IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND ELECTROLYTE NO.48 IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,

FDA data supplied by DrugPatentWatch.com

DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN ACETATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% IN SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.075%, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 10MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 15MEQ (K), DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ (K), DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 30MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 40MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ (K), DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.30% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.075%, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ (K) IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 50% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 60% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 60%, DEXTROSE
DEXTROSE 7.7% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 70% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSTAT, DEXTROAMPHETAMINE SULFATE
DHC PLUS, ACETAMINOPHEN
DI-ATRO, ATROPINE SULFATE
DI-METREX, PHENDIMETRAZINE TARTRATE
DIABETA, GLYBURIDE
DIABINESE, CHLORPROPAMIDE
DIAL, HEXACHLOROPHENE
DIALYTE CONCENTRATE W/ DEXTROSE 30% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIALYTE CONCENTRATE W/ DEXTROSE 50% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIALYTE LM/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIALYTE LM/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIALYTE LM/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIALYTE W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIALYTE W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIAMOX, ACETAZOLAMIDE
DIAMOX, ACETAZOLAMIDE SODIUM
DIANEAL 137 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE

FDA data supplied by DrugPatentWatch.com

DIANEAL 137 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL 137 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-1 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-1 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-1 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-1 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-2 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-2 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIAPID, LYPRESSIN
DIASONE SODIUM, SULFOXONE SODIUM
DIASTAT, DIAZEPAM
DIATRIZOATE MEGLUMINE, DIATRIZOATE MEGLUMINE
DIATRIZOATE-60, DIATRIZOATE MEGLUMINE
DIAZEPAM INTENSOL, DIAZEPAM
DIAZEPAM, DIAZEPAM
DIAZOXIDE, DIAZOXIDE
DIBENIL, DIPHENHYDRAMINE HYDROCHLORIDE
DIBENZYLINE, PHENOXYBENZAMINE HYDROCHLORIDE
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DICLOXACILLIN SODIUM, DICLOXACILLIN SODIUM
DICOPAC KIT, CYANOCOBALAMIN
DICUMAROL, DICUMAROL
DICURIN PROCAINE, PROCAINE MERETHOXYLLINE
DICYCLOMINE HCL, DICYCLOMINE HYDROCHLORIDE
DIDREX, BENZPHETAMINE HYDROCHLORIDE
DIDRONEL, ETIDRONATE DISODIUM
DIENESTROL, DIENESTROL
DIETHYLPROPION HCL, DIETHYLPROPION HYDROCHLORIDE
DIETHYLSTILBESTROL, DIETHYLSTILBESTROL
DIFFERIN, ADAPALENE
DIFLORASONE DIACETATE, DIFLORASONE DIACETATE
DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER, FLUCONAZOLE
DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
DIFLUCAN IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE
DIFLUCAN, FLUCONAZOLE
DIFLUNISAL, DIFLUNISAL
DIGOXIN PEDIATRIC, DIGOXIN
DIGOXIN, DIGOXIN
DILACOR XR, DILTIAZEM HYDROCHLORIDE
DILANTIN, PHENYTOIN
DILANTIN, PHENYTOIN SODIUM
DILANTIN, PHENYTOIN SODIUM, EXTENDED
DILANTIN-125, PHENYTOIN
DILANTIN-30, PHENYTOIN
DILATRATE-SR, ISOSORBIDE DINITRATE
DILAUDID, HYDROMORPHONE HYDROCHLORIDE
DILAUDID-HP, HYDROMORPHONE HYDROCHLORIDE
DILOR, DYPHYLLINE
DILOR-400, DYPHYLLINE
DILTIAZEM HCL, DILTIAZEM HYDROCHLORIDE
DIMENHYDRINATE, DIMENHYDRINATE
DIMETANE, BROMPHENIRAMINE MALEATE
DIMETANE, BROMPHENIRAMINE MALEATE (OTC)
DIMETANE-DC, BROMPHENIRAMINE MALEATE
DIMETANE-DX, BROMPHENIRAMINE MALEATE
DIMETANE-TEN, BROMPHENIRAMINE MALEATE
DIMETAPP, BROMPHENIRAMINE MALEATE (OTC)
DIONOSIL AQUEOUS, PROPYLIODONE
DIONOSIL OILY, PROPYLIODONE
DIOVAN HCT, HYDROCHLOROTHIAZIDE
DIOVAN, VALSARTAN
DIPENTUM, OLSALAZINE SODIUM
DIPHEN, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHEN, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
DIPHENHYDRAMINE HCL PRESERVATIVE FREE, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
DIPHENOXYLATE HCL AND ATROPINE SULFATE, ATROPINE SULFATE
DIPHENOXYLATE HCL W/ ATROPINE SULFATE, ATROPINE SULFATE
DIPHENYLAN SODIUM, PHENYTOIN SODIUM, PROMPT
DIPIVEFRIN HCL, DIPIVEFRIN HYDROCHLORIDE
DIPRIVAN, PROPOFOL
DIPROLENE AF, BETAMETHASONE DIPROPIONATE
DIPROLENE, BETAMETHASONE DIPROPIONATE
DIPROSONE, BETAMETHASONE DIPROPIONATE
DIPYRIDAMOLE, DIPYRIDAMOLE
DISCASE, CHYMOPAPAIN
DISIPAL, ORPHENADRINE HYDROCHLORIDE
DISOBROM, DEXBROMPHENIRAMINE MALEATE (OTC)
DISODIUM EDETATE, EDETATE DISODIUM
DISOMER, DEXBROMPHENIRAMINE MALEATE
DISOPHROL, DEXBROMPHENIRAMINE MALEATE (OTC)
DISOPYRAMIDE PHOSPHATE, DISOPYRAMIDE PHOSPHATE

FDA data supplied by DrugPatentWatch.com

DISULFIRAM, DISULFIRAM
DITATE-DS, ESTRADIOL VALERATE
DITROPAN XL, OXYBUTYNIN CHLORIDE
DITROPAN, OXYBUTYNIN CHLORIDE
DIUCARDIN, HYDROFLUMETHIAZIDE
DIULO, METOLAZONE
DIUPRES-250, CHLOROTHIAZIDE
DIUPRES-500, CHLOROTHIAZIDE
DIURIL, CHLOROTHIAZIDE
DIURIL, CHLOROTHIAZIDE SODIUM
DIUTENSEN-R, METHYCLOTHIAZIDE
DIZAC, DIAZEPAM
DOBUTAMINE HCL IN DEXTROSE 5% IN PLASTIC CONTAINER, DOBUTAMINE HYDROCHLORIDE
DOBUTAMINE HCL IN DEXTROSE 5%, DOBUTAMINE HYDROCHLORIDE
DOBUTAMINE HCL, DOBUTAMINE HYDROCHLORIDE
DOBUTREX, DOBUTAMINE HYDROCHLORIDE
DOCA, DESOXYCORTICOSTERONE ACETATE
DOLENE AP-65, ACETAMINOPHEN
DOLENE, PROPOXYPHENE HYDROCHLORIDE
DOLOBID, DIFLUNISAL
DOLOPHINE HCL, METHADONE HYDROCHLORIDE
DOMEBORO, ACETIC ACID, GLACIAL
DOPAMINE HCL AND DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE
DOPAMINE HCL AND DEXTROSE 5%, DOPAMINE HYDROCHLORIDE
DOPAMINE HCL IN DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE
DOPAMINE HCL IN DEXTROSE 5%, DOPAMINE HYDROCHLORIDE
DOPAMINE HCL, DOPAMINE HYDROCHLORIDE
DOPAR, LEVODOPA
DOPRAM, DOXAPRAM HYDROCHLORIDE
DORAL, QUAZEPAM
DORIDEN, GLUTETHIMIDE
DORMATE, MEBUTAMATE
DORYX, DOXYCYCLINE HYCLATE
DOSTINEX, CABERGOLINE
DOVONEX, CALCIPOTRIENE
DOW-ISONIAZID, ISONIAZID
DOXAPRAM HCL, DOXAPRAM HYDROCHLORIDE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
DOXEPIN HCL, DOXEPIN HYDROCHLORIDE
DOXIL, DOXORUBICIN HYDROCHLORIDE
DOXORUBICIN HCL, DOXORUBICIN HYDROCHLORIDE
DOXY 100, DOXYCYCLINE HYCLATE
DOXY 200, DOXYCYCLINE HYCLATE
DOXY-LEMMON, DOXYCYCLINE HYCLATE
DOXY-SLEEP-AID, DOXYLAMINE SUCCINATE (OTC)
DOXYCHEL HYCLATE, DOXYCYCLINE HYCLATE
DOXYCHEL, DOXYCYCLINE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DOXYCYCLINE HYLATE, DOXYCYCLINE HYCLATE
DOXYCYCLINE, DOXYCYCLINE
DOXYCYCLINE, DOXYCYCLINE HYCLATE
DOXYLAMINE SUCCINATE, DOXYLAMINE SUCCINATE
DOXYLAMINE SUCCINATE, DOXYLAMINE SUCCINATE (OTC)
DRALSERP, HYDRALAZINE HYDROCHLORIDE
DRALZINE, HYDRALAZINE HYDROCHLORIDE
DRICORT, HYDROCORTISONE ACETATE
DRISDOL, ERGOCALCIFEROL
DRIXORAL PLUS, ACETAMINOPHEN (OTC)
DRIXORAL, DEXBROMPHENIRAMINE MALEATE (OTC)
DRIZE, CHLORPHENIRAMINE MALEATE
DROLBAN, DROMOSTANOLONE PROPIONATE
DROPERIDOL, DROPERIDOL
DROXIA, HYDROXYUREA
DTIC-DOME, DACARBAZINE
DTPA, TECHNETIUM TC-99M PENTETATE KIT
DUO-MEDIHALER, ISOPROTERENOL HYDROCHLORIDE
DUONEB, ALBUTEROL SULFATE
DUPHALAC, LACTULOSE
DURABOLIN, NANDROLONE PHENPROPIONATE
DURACILLIN A.S., PENICILLIN G PROCAINE
DURACLON, CLONIDINE HYDROCHLORIDE
DURADYNE DHC, ACETAMINOPHEN
DURAGESIC, FENTANYL
DURAMORPH PF, MORPHINE SULFATE
DURANEST, EPINEPHRINE
DURANEST, EPINEPHRINE BITARTRATE
DURANEST, ETIDOCAINE HYDROCHLORIDE
DURAPHYL, THEOPHYLLINE
DURAQUIN, QUINIDINE GLUCONATE
DURICEF, CEFADROXIL/CEFADROXIL HEMIHYDRATE
DUTASTERIDE, DUTASTERIDE
DUVOID, BETHANECHOL CHLORIDE
DV, DIENESTROL
DYAZIDE, HYDROCHLOROTHIAZIDE
DYCILL, DICLOXACILLIN SODIUM
DYCLONE, DYCLONINE HYDROCHLORIDE
DYMELOR, ACETOHEXAMIDE
DYNA-HEX, CHLORHEXIDINE GLUCONATE (OTC)
DYNABAC, DIRITHROMYCIN
DYNACIRC CR, ISRADIPINE
DYNACIRC, ISRADIPINE
DYNAPEN, DICLOXACILLIN SODIUM
DYRENIUM, TRIAMTERENE

** E **

E-BASE, ERYTHROMYCIN
E-MYCIN E, ERYTHROMYCIN ETHYLSUCCINATE
E-MYCIN, ERYTHROMYCIN
E-SOLVE 2, ERYTHROMYCIN
E-Z PREP 220, POVIDONE-IODINE (OTC)
E-Z PREP, POVIDONE-IODINE (OTC)
E-Z SCRUB 201, POVIDONE-IODINE (OTC)

FDA data supplied by DrugPatentWatch.com

E-Z SCRUB 241, POVIDONE-IODINE (OTC)
E-Z SCRUB, CHLORHEXIDINE GLUCONATE (OTC)
E-Z SCRUB, HEXACHLOROPHENE
E-Z-EM PREP LYTE, POLYETHYLENE GLYCOL 3350
E.E.S. 200, ERYTHROMYCIN ETHYLSUCCINATE
E.E.S. 400, ERYTHROMYCIN ETHYLSUCCINATE
E.E.S., ERYTHROMYCIN ETHYLSUCCINATE
EC-NAPROSYN, NAPROXEN
ECONOCHLOR, CHLORAMPHENICOL
ECONOPRED PLUS, PREDNISOLONE ACETATE
ECONOPRED, PREDNISOLONE ACETATE
EDECRIN, ETHACRYNATE SODIUM
EDECRIN, ETHACRYNIC ACID
EDETATE DISODIUM, EDETATE DISODIUM
EDEX, ALPROSTADIL
EDROPHONIUM CHLORIDE PRESERVATIVE FREE, EDROPHONIUM CHLORIDE
EDROPHONIUM CHLORIDE, EDROPHONIUM CHLORIDE
EFFEXOR XR, VENLAFAXINE HYDROCHLORIDE
EFFEXOR, VENLAFAXINE HYDROCHLORIDE
EFIDAC 24 CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE (OTC)
EFIDAC 24 PSEUDOEPHEDRINE HCL, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
EFIDAC 24 PSEUDOEPHEDRINE HCL/BROMPHENIRAMINE MALEATE, BROMPHENIRAMINE MALEATE (OTC)
EFUDEX, FLUOROURACIL
ELASE-CHLOROMYCETIN, CHLORAMPHENICOL
ELAVIL, AMITRIPTYLINE HYDROCHLORIDE
ELDECORT, HYDROCORTISONE
ELDEPRYL, SELEGILINE HYDROCHLORIDE
ELIDEL, PIMECROLIMUS
ELIMITE, PERMETHRIN
ELIXICON, THEOPHYLLINE
ELIXOMIN, THEOPHYLLINE
ELIXOPHYLLIN SR, THEOPHYLLINE
ELIXOPHYLLIN, THEOPHYLLINE
ELLENCE, EPIRUBICIN HYDROCHLORIDE
ELLIOTTS B SOLUTION, CALCIUM CHLORIDE
ELMIRON, PENTOSAN POLYSULFATE SODIUM
ELOCON, MOMETASONE FUROATE
EMADINE, EMEDASTINE DIFUMARATE
EMBELINE E, CLOBETASOL PROPIONATE
EMBELINE, CLOBETASOL PROPIONATE
EMBOLEX, DIHYDROERGOTAMINE MESYLATE
EMCYT, ESTRAMUSTINE PHOSPHATE SODIUM
EMETE-CON, BENZQUINAMIDE HYDROCHLORIDE
EMGEL, ERYTHROMYCIN
EMLA, LIDOCAINE
EMPRACET W/ CODEINE PHOSPHATE #3, ACETAMINOPHEN
EMPRACET W/ CODEINE PHOSPHATE #4, ACETAMINOPHEN
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
ENALAPRILAT, ENALAPRILAT
ENDEP, AMITRIPTYLINE HYDROCHLORIDE
ENDOSOL EXTRA, CALCIUM CHLORIDE
ENDRATE, EDETATE DISODIUM
ENDURON, METHYCLOTHIAZIDE
ENDURONYL FORTE, DESERPIDINE
ENDURONYL, DESERPIDINE
ENFLURANE, ENFLURANE
ENLON, EDROPHONIUM CHLORIDE
ENLON-PLUS, ATROPINE SULFATE
ENOVID, MESTRANOL
ENOVID-E 21, MESTRANOL
ENOVID-E, MESTRANOL
ENPRESSE-21, ETHINYL ESTRADIOL
ENPRESSE-28, ETHINYL ESTRADIOL
ENTOCORT EC, BUDESONIDE
ENULOSE, LACTULOSE
EPI E Z PEN JR, EPINEPHRINE
EPICORT, HYDROCORTISONE
EPIFOAM, HYDROCORTISONE ACETATE
EPINEPHRINE, EPINEPHRINE (OTC)
EPIPEN E Z PEN, EPINEPHRINE
EPIPEN JR., EPINEPHRINE
EPIPEN, EPINEPHRINE
EPITOL, CARBAMAZEPINE
EPIVIR, LAMIVUDINE
EPIVIR-HBV, LAMIVUDINE
EQUAGESIC, ASPIRIN
EQUANIL, MEPROBAMATE
EQUIPIN, HOMATROPINE METHYLBROMIDE
ERCATAB, CAFFEINE
ERGAMISOL, LEVAMISOLE HYDROCHLORIDE
ERGOLOID MESYLATES, ERGOLOID MESYLATES
ERGOMAR, ERGOTAMINE TARTRATE
ERGOSTAT, ERGOTAMINE TARTRATE
ERY-TAB, ERYTHROMYCIN
ERYC 125, ERYTHROMYCIN
ERYC SPRINKLES, ERYTHROMYCIN
ERYC, ERYTHROMYCIN
ERYCETTE, ERYTHROMYCIN
ERYDERM, ERYTHROMYCIN
ERYGEL, ERYTHROMYCIN
ERYMAX, ERYTHROMYCIN
ERYPAR, ERYTHROMYCIN STEARATE
ERYPED, ERYTHROMYCIN ETHYLSUCCINATE
ERYTHRA-DERM, ERYTHROMYCIN
ERYTHRO-STATIN, ERYTHROMYCIN
ERYTHROCIN STEARATE, ERYTHROMYCIN STEARATE
ERYTHROCIN, ERYTHROMYCIN LACTOBIONATE
ERYTHROMYCIN ESTOLATE, ERYTHROMYCIN ESTOLATE
ERYTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYL, ERYTHROMYCIN ETHYLSUCCINATE
ERYTHROMYCIN ETHYLSUCCINATE, ERYTHROMYCIN ETHYLSUCCINATE
ERYTHROMYCIN LACTOBIONATE, ERYTHROMYCIN LACTOBIONATE

FDA data supplied by DrugPatentWatch.com

ERYTHROMYCIN STEARATE, ERYTHROMYCIN STEARATE
ERYTHROMYCIN, ERYTHROMYCIN
ERYTHROMYCIN, ERYTHROMYCIN LACTOBIONATE
ERYZOLE, ERYTHROMYCIN ETHYLSUCCINATE
ESCLIM, ESTRADIOL
ESGIC, ACETAMINOPHEN
ESGIC-PLUS, ACETAMINOPHEN
ESIDRIX, HYDROCHLOROTHIAZIDE
ESIMIL, GUANETHIDINE MONOSULFATE
ESKALITH CR, LITHIUM CARBONATE
ESKALITH, LITHIUM CARBONATE
ESTAZOLAM, ESTAZOLAM
ESTERIFIED ESTROGENS, ESTROGENS, ESTERIFIED
ESTINYL, ETHINYL ESTRADIOL
ESTRACE, ESTRADIOL
ESTRADERM, ESTRADIOL
ESTRADIOL CYPIONATE, ESTRADIOL CYPIONATE
ESTRADIOL VALERATE, ESTRADIOL VALERATE
ESTRADIOL, ESTRADIOL
ESTRADURIN, POLYESTRADIOL PHOSPHATE
ESTRAGUARD, DIENESTROL
ESTRATAB, ESTROGENS, ESTERIFIED
ESTRING, ESTRADIOL
ESTROGENIC SUBSTANCE, ESTRONE
ESTRONE, ESTRONE
ESTROPIPATE, ESTROPIPATE
ESTROSTEP 21, ETHINYL ESTRADIOL
ESTROSTEP FE, ETHINYL ESTRADIOL
ESTROVIS, QUINESTROL
ETHAMBUTOL HCL, ETHAMBUTOL HYDROCHLORIDE
ETHAMIDE, ETHOXZOLAMIDE
ETHAMOLIN, ETHANOLAMINE OLEATE
ETHCHLORVYNOL, ETHCHLORVYNOL
ETHIODOL, ETHIODIZED OIL
ETHMOZINE, MORICIZINE HYDROCHLORIDE
ETHOSUXIMIDE, ETHOSUXIMIDE
ETHRANE, ENFLURANE
ETHRIL 250, ERYTHROMYCIN STEARATE
ETHRIL 500, ERYTHROMYCIN STEARATE
ETHYOL, AMIFOSTINE
ETODOLAC, ETODOLAC
ETOMIDATE, ETOMIDATE
ETOPOPHOS PRESERVATIVE FREE, ETOPOSIDE PHOSPHATE
ETOPOSIDE, ETOPOSIDE
ETRAFON 2-10, AMITRIPTYLINE HYDROCHLORIDE
ETRAFON 2-25, AMITRIPTYLINE HYDROCHLORIDE
ETRAFON-A, AMITRIPTYLINE HYDROCHLORIDE
ETRAFON-FORTE, AMITRIPTYLINE HYDROCHLORIDE
EULEXIN, FLUTAMIDE
EURAX, CROTAMITON
EUTHROID-0.5, LIOTRIX (T4;T3)
EUTHROID-1, LIOTRIX (T4;T3)
EUTHROID-2, LIOTRIX (T4;T3)
EUTHROID-3, LIOTRIX (T4;T3)
EUTONYL, PARGYLINE HYDROCHLORIDE
EUTRON, METHYCLOTHIAZIDE
EVALOSE, LACTULOSE
EVANS BLUE, EVANS BLUE
EVEX, ESTROGENS, ESTERIFIED
EVISTA, RALOXIFENE HYDROCHLORIDE
EVOXAC, CEVIMELINE HYDROCHLORIDE
EXCEDRIN (MIGRAINE), ACETAMINOPHEN (OTC)
EXELDERM, SULCONAZOLE NITRATE
EXELON, RIVASTIGMINE TARTRATE
EXIDINE, CHLORHEXIDINE GLUCONATE (OTC)
EXNA, BENZTHIAZIDE
EXOSURF NEONATAL, CETYL ALCOHOL
EXSEL, SELENIUM SULFIDE
EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM, EXTENDED
EXTRA-STRENGTH AIM, SODIUM MONOFLUOROPHOSPHATE (OTC)

** F **

FACTREL, GONADORELIN HYDROCHLORIDE
FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER, FAMOTIDINE
FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE (OTC)
FAMVIR, FAMCICLOVIR
FANSIDAR, PYRIMETHAMINE
FARESTON, TOREMIFENE CITRATE
FASTIN, PHENTERMINE HYDROCHLORIDE
FELBATOL, FELBAMATE
FELDENE, PIROXICAM
FEMARA, LETROZOLE
FEMCET, ACETAMINOPHEN
FEMHRT, ETHINYL ESTRADIOL
FEMINONE, ETHINYL ESTRADIOL
FEMOGEN, ESTROGENS, ESTERIFIED
FEMPATCH, ESTRADIOL
FEMSTAT 3, BUTOCONAZOLE NITRATE (OTC)
FEMSTAT, BUTOCONAZOLE NITRATE
FENOPROFEN CALCIUM, FENOPROFEN CALCIUM
FENTANYL CITRATE AND DROPERIDOL, DROPERIDOL
FENTANYL CITRATE PRESERVATIVE FREE, FENTANYL CITRATE
FENTANYL CITRATE, FENTANYL CITRATE
FENTANYL, FENTANYL CITRATE
FERIDEX I.V., FERUMOXIDES
FERNDEX, DEXTROAMPHETAMINE SULFATE
FERNISOLONE-P, PREDNISOLONE
FERNISONE, PREDNISONE
FERRISELTZ, FERRIC AMMONIUM CITRATE
FERRLECIT, SODIUM FERRIC GLUCONATE COMPLEX
FERROUS CITRATE FE 59, FERROUS CITRATE, FE-59
FERTINEX, UROFOLLITROPIN

FDA data supplied by DrugPatentWatch.com

FIORICET W/ CODEINE, ACETAMINOPHEN
FIORICET, ACETAMINOPHEN
FIORINAL W/CODEINE NO 3, ASPIRIN
FIORINAL, ASPIRIN
FLAGYL ER, METRONIDAZOLE
FLAGYL I.V. RTU IN PLASTIC CONTAINER, METRONIDAZOLE
FLAGYL I.V., METRONIDAZOLE HYDROCHLORIDE
FLAGYL, METRONIDAZOLE
FLAREX, FLUOROMETHOLONE ACETATE
FLAVORED COLESTID, COLESTIPOL HYDROCHLORIDE
FLAXEDIL, GALLAMINE TRIETHIODIDE
FLECAINIDE ACETATE, FLECAINIDE ACETATE
FLEXERIL, CYCLOBENZAPRINE HYDROCHLORIDE
FLEXICORT, HYDROCORTISONE
FLOLAN, EPOPROSTENOL SODIUM
FLOMAX, TAMSULOSIN HYDROCHLORIDE
FLONASE, FLUTICASONE PROPIONATE
FLORINEF, FLUDROCORTISONE ACETATE
FLORONE E, DIFLORASONE DIACETATE
FLORONE, DIFLORASONE DIACETATE
FLOROPRYL, ISOFLUROPHATE
FLOVENT DISKUS 100, FLUTICASONE PROPIONATE
FLOVENT DISKUS 250, FLUTICASONE PROPIONATE
FLOVENT DISKUS 50, FLUTICASONE PROPIONATE
FLOVENT, FLUTICASONE PROPIONATE
FLOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER, OFLOXACIN
FLOXIN IN DEXTROSE 5%, OFLOXACIN
FLOXIN, OFLOXACIN
FLOXURIDINE, FLOXURIDINE
FLUDARA, FLUDARABINE PHOSPHATE
FLUDEOXYGLUCOSE F 18, FLUDEOXYGLUCOSE, F-18
FLUIDIL, CYCLOTHIAZIDE
FLUMADINE, RIMANTADINE HYDROCHLORIDE
FLUOCET, FLUOCINOLONE ACETONIDE
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUOCINONIDE EMULSIFIED BASE, FLUOCINONIDE
FLUOCINONIDE, FLUOCINONIDE
FLUONID, FLUOCINOLONE ACETONIDE
FLUOR-OP, FLUOROMETHOLONE
FLUORINE F-18, SODIUM FLUORIDE, F-18
FLUOROPLEX, FLUOROURACIL
FLUOROURACIL, FLUOROURACIL
FLUOTHANE, HALOTHANE
FLUOTREX, FLUOCINOLONE ACETONIDE
FLUOXETINE HCL, FLUOXETINE HYDROCHLORIDE
FLUOXETINE, FLUOXETINE HYDROCHLORIDE
FLUOXYMESTERONE, FLUOXYMESTERONE
FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
FLUPHENAZINE HCL, FLUPHENAZINE HYDROCHLORIDE
FLUPHENAZINE, FLUPHENAZINE DECANOATE
FLURANDRENOLIDE, FLURANDRENOLIDE
FLURAZEPAM HCL, FLURAZEPAM HYDROCHLORIDE
FLURBIPROFEN SODIUM, FLURBIPROFEN SODIUM
FLURBIPROFEN, FLURBIPROFEN
FLUTAMIDE, FLUTAMIDE
FLUTEX, TRIAMCINOLONE ACETONIDE
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
FML FORTE, FLUOROMETHOLONE
FML, FLUOROMETHOLONE
FML-S, FLUOROMETHOLONE
FOAMCOAT, ALUMINUM HYDROXIDE (OTC)
FOAMICON, ALUMINUM HYDROXIDE (OTC)
FOCALIN, DEXMETHYLPHENIDATE HYDROCHLORIDE
FOLEX PFS, METHOTREXATE SODIUM
FOLEX, METHOTREXATE SODIUM
FOLIC ACID, FOLIC ACID
FOLICET, FOLIC ACID
FOLLISTIM, FOLLITROPIN ALFA/BETA
FOLLUTEIN, GONADOTROPIN, CHORIONIC
FOLVITE, FOLIC ACID
FOLVRON, FERROUS SULFATE
FORADIL, FORMOTEROL FUMARATE
FORANE, ISOFLURANE
FORBAXIN, METHOCARBAMOL
FORTAZ IN PLASTIC CONTAINER, CEFTAZIDIME SODIUM
FORTAZ, CEFTAZIDIME
FORTOVASE, SAQUINAVIR
FOSAMAX, ALENDRONATE SODIUM
FOSCAVIR, FOSCARNET SODIUM
FOVANE, BENZTHIAZIDE
FRAGMIN, DALTEPARIN SODIUM
FREAMINE 8.5%, AMINO ACIDS
FREAMINE HBC 6.9%, AMINO ACIDS
FREAMINE II 8.5%, AMINO ACIDS
FREAMINE III 10%, AMINO ACIDS
FREAMINE III 3% W/ ELECTROLYTES, AMINO ACIDS
FREAMINE III 8.5% W/ ELECTROLYTES, AMINO ACIDS
FREAMINE III 8.5%, AMINO ACIDS
FROVA, FROVATRIPTAN SUCCINATE
FS SHAMPOO, FLUOCINOLONE ACETONIDE
FUDR, FLOXURIDINE
FULVICIN P/G 165, GRISEOFULVIN, ULTRAMICROCRYSTALLINE
FULVICIN P/G 330, GRISEOFULVIN, ULTRAMICROCRYSTALLINE
FULVICIN P/G, GRISEOFULVIN, ULTRAMICROCRYSTALLINE
FULVICIN-U/F, GRISEOFULVIN, MICROCRYSTALLINE
FUNDUSCEIN-25, FLUORESCEIN SODIUM
FUNGIZONE, AMPHOTERICIN B
FURACIN, NITROFURAZONE
FURADANTIN, NITROFURANTOIN
FURALAN, NITROFURANTOIN
FUROSEMIDE, FUROSEMIDE
FUROXONE, FURAZOLIDONE

** G **

GABITRIL, TIAGABINE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

GALLIUM CITRATE GA 67, GALLIUM CITRATE, GA-67
GALZIN, ZINC ACETATE
GAMENE, LINDANE
GAMOPHEN, HEXACHLOROPHENE
GANITE, GALLIUM NITRATE
GANTANOL, SULFAMETHOXAZOLE
GANTANOL-DS, SULFAMETHOXAZOLE
GANTRISIN PEDIATRIC, SULFISOXAZOLE ACETYL
GANTRISIN, SULFISOXAZOLE
GANTRISIN, SULFISOXAZOLE ACETYL
GANTRISIN, SULFISOXAZOLE DIOLAMINE
GARAMYCIN, GENTAMICIN SULFATE
GASTROCROM, CROMOLYN SODIUM
GASTROGRAFIN, DIATRIZOATE MEGLUMINE
GASTROMARK, FERUMOXSIL
GASTROVIST, DIATRIZOATE MEGLUMINE
GAVISCON, ALUMINUM HYDROXIDE (OTC)
GEMFIBROZIL, GEMFIBROZIL
GEMONIL, METHARBITAL
GEMZAR, GEMCITABINE HYDROCHLORIDE
GEN-XENE, CLORAZEPATE DIPOTASSIUM
GENAPAX, GENTIAN VIOLET
GENCEPT 0.5/35-21, ETHINYL ESTRADIOL
GENCEPT 0.5/35-28, ETHINYL ESTRADIOL
GENCEPT 1/35-21, ETHINYL ESTRADIOL
GENCEPT 1/35-28, ETHINYL ESTRADIOL
GENCEPT 10/11-21, ETHINYL ESTRADIOL
GENCEPT 10/11-28, ETHINYL ESTRADIOL
GENERLAC, LACTULOSE
GENESA, ARBUTAMINE HYDROCHLORIDE
GENOPTIC, GENTAMICIN SULFATE
GENOTROPIN PRESERVATIVE FREE, SOMATROPIN RECOMBINANT
GENOTROPIN, SOMATROPIN RECOMBINANT
GENTACIDIN, GENTAMICIN SULFATE
GENTAFAIR, GENTAMICIN SULFATE
GENTAK, GENTAMICIN SULFATE
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, GENTAMICIN SULFATE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
GENTAMICIN, GENTAMICIN SULFATE
GEOCILLIN, CARBENICILLIN INDANYL SODIUM
GEODON, ZIPRASIDONE HYDROCHLORIDE
GEOPEN, CARBENICILLIN DISODIUM
GEREF, SERMORELIN ACETATE
GERIMAL, ERGOLOID MESYLATES
GERMA-MEDICA "MG", HEXACHLOROPHENE
GERMA-MEDICA, HEXACHLOROPHENE
GLEEVEC, IMATINIB MESYLATE
GLIADEL, CARMUSTINE
GLIPIZIDE, GLIPIZIDE
GLOFIL-125, IOTHALAMATE SODIUM, I-125
GLUCAGEN, GLUCAGON HYDROCHLORIDE RECOMBINANT
GLUCAGON, GLUCAGON HYDROCHLORIDE
GLUCAGON, GLUCAGON RECOMBINANT
GLUCAMIDE, CHLORPROPAMIDE
GLUCOPHAGE XR, METFORMIN HYDROCHLORIDE
GLUCOPHAGE, METFORMIN HYDROCHLORIDE
GLUCOSCAN, TECHNETIUM TC-99M GLUCEPTATE KIT
GLUCOTROL XL, GLIPIZIDE
GLUCOTROL, GLIPIZIDE
GLUCOVANCE, GLYBURIDE
GLUTETHIMIDE, GLUTETHIMIDE
GLYBURIDE (MICRONIZED), GLYBURIDE
GLYBURIDE, GLYBURIDE
GLYCINE 1.5% IN PLASTIC CONTAINER, GLYCINE
GLYCOPREP, POLYETHYLENE GLYCOL 3350
GLYCOPYRROLATE, GLYCOPYRROLATE
GLYCORT, HYDROCORTISONE
GLYNASE, GLYBURIDE
GLYSET, MIGLITOL
GO-EVAC, POLYETHYLENE GLYCOL 3350
GOLYTELY, POLYETHYLENE GLYCOL 3350
GONAL-F, FOLLITROPIN ALFA
GONAL-F, FOLLITROPIN ALFA/BETA
GRIFULVIN V, GRISEOFULVIN, MICROCRYSTALLINE
GRIS-PEG, GRISEOFULVIN, ULTRAMICROCRYSTALLINE
GRISACTIN ULTRA, GRISEOFULVIN, ULTRAMICROCRYSTALLINE
GRISACTIN, GRISEOFULVIN, MICROCRYSTALLINE
GUANABENZ ACETATE, GUANABENZ ACETATE
GUANETHIDINE MONOSULFATE, GUANETHIDINE MONOSULFATE
GUANFACINE HCL, GUANFACINE HYDROCHLORIDE
GUANIDINE HCL, GUANIDINE HYDROCHLORIDE
GVS, GENTIAN VIOLET
GYNAZOLE-1, BUTOCONAZOLE NITRATE
GYNE-LOTRIMIN 3 COMBINATION PACK, CLOTRIMAZOLE (OTC)
GYNE-LOTRIMIN 3, CLOTRIMAZOLE (OTC)
GYNE-LOTRIMIN COMBINATION PACK, CLOTRIMAZOLE (OTC)
GYNE-LOTRIMIN, CLOTRIMAZOLE (OTC)
GYNE-SULF, TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE; SULFATHIAZOLE)
GYNIX, CLOTRIMAZOLE (OTC)
GYNODIOL, ESTRADIOL
GYNOREST, DYDROGESTERONE

** H **

H-CORT, HYDROCORTISONE
H.P. ACTHAR GEL, CORTICOTROPIN
H.R.-50, HYDROCHLOROTHIAZIDE
HABITROL, NICOTINE
HABITROL, NICOTINE (OTC)
HALCION, TRIAZOLAM
HALDOL SOLUTAB, HALOPERIDOL
HALDOL, HALOPERIDOL
HALDOL, HALOPERIDOL DECANOATE
HALDOL, HALOPERIDOL LACTATE

FDA data supplied by DrugPatentWatch.com

HALDRONE, PARAMETHASONE ACETATE
HALFAN, HALOFANTRINE HYDROCHLORIDE
HALOG, HALCINONIDE
HALOG-E, HALCINONIDE
HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
HALOPERIDOL INTENSOL, HALOPERIDOL LACTATE
HALOPERIDOL LACTATE, HALOPERIDOL LACTATE
HALOPERIDOL, HALOPERIDOL
HALOPERIDOL, HALOPERIDOL LACTATE
HALOTESTIN, FLUOXYMESTERONE
HALOTEX, HALOPROGIN
HALOTHANE, HALOTHANE
HARMONYL, DESERPIDINE
HC #1, HYDROCORTISONE
HC #4, HYDROCORTISONE
HC (HYDROCORTISONE), HYDROCORTISONE
HC (HYDROCORTISONE), HYDROCORTISONE (OTC)
HEAD & SHOULDERS CONDITIONER, PYRITHIONE ZINC (OTC)
HEAVY SOLUTION NUPERCAINE, DIBUCAINE HYDROCHLORIDE
HECTOROL, DOXERCALCIFEROL
HEDULIN, PHENINDIONE
HELICOSOL, UREA, C-13
HELIDAC, BISMUTH SUBSALICYLATE
HEMABATE, CARBOPROST TROMETHAMINE
HEMSOL-HC, HYDROCORTISONE ACETATE
HEP FLUSH KIT IN PLASTIC CONTAINER, HEPARIN SODIUM
HEP-LOCK U/P, HEPARIN SODIUM
HEP-LOCK, HEPARIN SODIUM
HEPARIN LOCK FLUSH IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN LOCK FLUSH PRESERVATIVE FREE IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN LOCK FLUSH PRESERVATIVE FREE, HEPARIN SODIUM
HEPARIN LOCK FLUSH, HEPARIN SODIUM
HEPARIN SODIUM 1,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 1,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5%, HEPARIN SODIUM
HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.45%, HEPARIN SODIUM
HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.9%, HEPARIN SODIUM
HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5%, HEPARIN SODIUM
HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.9%, HEPARIN SODIUM
HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 2,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 20,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5%, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9%, HEPARIN SODIUM
HEPARIN SODIUM 5,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 5,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.45%, HEPARIN SODIUM
HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9%, HEPARIN SODIUM
HEPARIN SODIUM IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
HEPARIN SODIUM, HEPARIN SODIUM
HEPATAMINE 8%, AMINO ACIDS
HEPATASOL 8%, AMINO ACIDS
HEPATOLITE, TECHNETIUM TC-99M DISOFENIN KIT
HEPFLUSH-10, HEPARIN SODIUM
HEPTALAC, LACTULOSE
HERPLEX, IDOXURIDINE
HETRAZAN, DIETHYLCARBAMAZINE CITRATE
HEXA-BETALIN, PYRIDOXINE HYDROCHLORIDE
HEXA-GERM, HEXACHLOROPHENE
HEXABRIX, IOXAGLATE MEGLUMINE
HEXADROL, DEXAMETHASONE
HEXADROL, DEXAMETHASONE SODIUM PHOSPHATE
HEXALEN, ALTRETAMINE
HEXASCRUB, HEXACHLOROPHENE
HI-COR, HYDROCORTISONE
HIBICLENS, CHLORHEXIDINE GLUCONATE (OTC)
HIBISTAT, CHLORHEXIDINE GLUCONATE (OTC)
HIPPURAN I 131, IODOHIPPURATE SODIUM, I-131
HIPPUTOPE, IODOHIPPURATE SODIUM, I-131

FDA data supplied by DrugPatentWatch.com

HIPREX, METHENAMINE HIPPURATE
HISERPIA, RESERPINE
HISPRIL, DIPHENYLPYRALINE HYDROCHLORIDE
HISTAFED, PSEUDOEPHEDRINE HYDROCHLORIDE
HISTALOG, BETAZOLE HYDROCHLORIDE
HISTAMINE PHOSPHATE, HISTAMINE PHOSPHATE
HIVID, ZALCITABINE
HIWOLFIA, RAUWOLFIA SERPENTINA
HMS, MEDRYSONE
HOMAPIN-10, HOMATROPINE METHYLBROMIDE
HOMAPIN-5, HOMATROPINE METHYLBROMIDE
HOMATROPRINE METHYLBROMIDE AND HYDROCODONE BITARTRATE, HOMATROPINE METHYLBROMIDE
HUMALOG MIX 50/50, INSULIN LISPRO
HUMALOG MIX 75/25, INSULIN LISPRO
HUMALOG PEN, INSULIN LISPRO
HUMALOG, INSULIN LISPRO
HUMATIN, PAROMOMYCIN SULFATE
HUMATROPE, SOMATROPIN RECOMBINANT
HUMEGON, MENOTROPINS (FSH;LH)
HUMORSOL, DEMECARIUM BROMIDE
HUMULIN 50/50, INSULIN RECOMBINANT HUMAN (OTC)
HUMULIN 70/30 PEN, INSULIN RECOMBINANT HUMAN (OTC)
HUMULIN 70/30, INSULIN RECOMBINANT HUMAN (OTC)
HUMULIN BR, INSULIN RECOMBINANT HUMAN (OTC)
HUMULIN L, INSULIN ZINC SUSP RECOMBINANT HUMAN (OTC)
HUMULIN N, INSULIN SUSP ISOPHANE RECOMBINANT HUMAN (OTC)
HUMULIN R PEN, INSULIN RECOMBINANT HUMAN (OTC)
HUMULIN R, INSULIN RECOMBINANT HUMAN
HUMULIN R, INSULIN RECOMBINANT HUMAN (OTC)
HUMULIN U, INSULIN ZINC SUSP EXTENDED RECOMBINANT HUMAN (OTC)
HY-PAM "25", HYDROXYZINE PAMOATE
HY-PHEN, ACETAMINOPHEN
HYCAMTIN, TOPOTECAN HYDROCHLORIDE
HYCODAN, HOMATROPINE METHYLBROMIDE
HYCOMINE PEDIATRIC, HYDROCODONE BITARTRATE
HYCOMINE, HYDROCODONE BITARTRATE
HYDELTRA-TBA, PREDNISOLONE TEBUTATE
HYDELTRASOL, PREDNISOLONE SODIUM PHOSPHATE
HYDERGINE LC, ERGOLOID MESYLATES
HYDERGINE, ERGOLOID MESYLATES
HYDRA-ZIDE, HYDRALAZINE HYDROCHLORIDE
HYDRALAZINE AND HYDROCHLORTHIAZIDE, HYDRALAZINE HYDROCHLORIDE
HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE, HYDRALAZINE HYDROCHLORIDE
HYDRALAZINE HCL W/ HYDROCHLOROTHIAZIDE 100/50, HYDRALAZINE HYDROCHLORIDE
HYDRALAZINE HCL W/ HYDROCHLOROTHIAZIDE 25/25, HYDRALAZINE HYDROCHLORIDE
HYDRALAZINE HCL W/ HYDROCHLOROTHIAZIDE 50/50, HYDRALAZINE HYDROCHLORIDE
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
HYDRALAZINE HCL, HYDROCHLOROTHIAZIDE AND RESERPINE, HYDRALAZINE HYDROCHLORIDE
HYDRALAZINE HCL-HYDROCHLOROTHIAZIDE-RESERPINE, HYDRALAZINE HYDROCHLORIDE
HYDRALAZINE, HYDROCHLOROTHIAZIDE W/ RESERPINE, HYDRALAZINE HYDROCHLORIDE
HYDRAMINE, DIPHENHYDRAMINE HYDROCHLORIDE
HYDRAMINE, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
HYDRAP-ES, HYDRALAZINE HYDROCHLORIDE
HYDREA, HYDROXYUREA
HYDRO-D, HYDROCHLOROTHIAZIDE
HYDRO-RESERP, HYDROCHLOROTHIAZIDE
HYDRO-RIDE, AMILORIDE HYDROCHLORIDE
HYDRO-SERP "25", HYDROCHLOROTHIAZIDE
HYDRO-SERP "50", HYDROCHLOROTHIAZIDE
HYDROCET, ACETAMINOPHEN
HYDROCHLOROTHIAZIDE INTENSOL, HYDROCHLOROTHIAZIDE
HYDROCHLOROTHIAZIDE W/ HYDRALAZINE, HYDRALAZINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE W/ RESERPINE AND HYDRALAZINE, HYDRALAZINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE W/ RESERPINE, HYDROCHLOROTHIAZIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE
HYDROCODONE COMPOUND, HOMATROPINE METHYLBROMIDE
HYDROCORTISONE ACETATE 1% AND PRAMOXINE HCL 1%, HYDROCORTISONE ACETATE
HYDROCORTISONE ACETATE, HYDROCORTISONE ACETATE
HYDROCORTISONE AND ACETIC ACID, ACETIC ACID, GLACIAL
HYDROCORTISONE IN ABSORBASE, HYDROCORTISONE
HYDROCORTISONE SODIUM PHOSPHATE, HYDROCORTISONE SODIUM PHOSPHATE
HYDROCORTISONE SODIUM SUCCINATE, HYDROCORTISONE SODIUM SUCCINATE
HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE
HYDROCORTISONE, HYDROCORTISONE
HYDROCORTONE, HYDROCORTISONE
HYDROCORTONE, HYDROCORTISONE ACETATE
HYDROCORTONE, HYDROCORTISONE SODIUM PHOSPHATE
HYDRODIURIL, HYDROCHLOROTHIAZIDE
HYDROFLUMETHIAZIDE AND RESERPINE, HYDROFLUMETHIAZIDE
HYDROFLUMETHIAZIDE, HYDROFLUMETHIAZIDE
HYDROGENATED ERGOT ALKALOIDS, ERGOLOID MESYLATES
HYDROMORPHONE HCL, HYDROMORPHONE HYDROCHLORIDE
HYDROMOX R, QUINETHAZONE
HYDROMOX, QUINETHAZONE
HYDROPANE, HOMATROPINE METHYLBROMIDE
HYDROPRES 25, HYDROCHLOROTHIAZIDE
HYDROPRES 50, HYDROCHLOROTHIAZIDE
HYDROSERPINE PLUS (R-H-H), HYDRALAZINE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

HYDROXOCOBALAMIN, HYDROXOCOBALAMIN
HYDROXOMIN, HYDROXOCOBALAMIN
HYDROXYCHLOROQINE SULFATE, HYDROXYCHLOROQUINE SULFATE
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
HYDROXYPROGESTERONE CAPROATE, HYDROXYPROGESTERONE CAPROATE
HYDROXYSTILBAMIDINE ISETHIONATE, HYDROXYSTILBAMIDINE ISETHIONATE
HYDROXYUREA, HYDROXYUREA
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
HYDROXYZINE, HYDROXYZINE HYDROCHLORIDE
HYGROTON, CHLORTHALIDONE
HYLOREL, GUANADREL SULFATE
HYPAQUE SODIUM 20%, DIATRIZOATE SODIUM
HYPAQUE, DIATRIZOATE MEGLUMINE
HYPAQUE, DIATRIZOATE SODIUM
HYPAQUE-76, DIATRIZOATE MEGLUMINE
HYPAQUE-CYSTO, DIATRIZOATE MEGLUMINE
HYPAQUE-M,75%, DIATRIZOATE MEGLUMINE
HYPAQUE-M,90%, DIATRIZOATE MEGLUMINE
HYPERSTAT, DIAZOXIDE
HYPROTIGEN 5%, PROTEIN HYDROLYSATE
HYSERPIN, RAUWOLFIA SERPENTINA
HYTONE, HYDROCORTISONE
HYTRIN, TERAZOSIN HYDROCHLORIDE
HYZAAR, HYDROCHLOROTHIAZIDE
HYZYD, ISONIAZID

** I **

IBRIN, FIBRINOGEN, I-125
IBU, IBUPROFEN
IBU-TAB 200, IBUPROFEN (OTC)
IBU-TAB, IBUPROFEN
IBUPRIN, IBUPROFEN (OTC)
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
IBUPROHM COLD AND SINUS, IBUPROFEN (OTC)
IBUPROHM, IBUPROFEN
IBUPROHM, IBUPROFEN (OTC)
IDAMYCIN PFS, IDARUBICIN HYDROCHLORIDE
IDAMYCIN, IDARUBICIN HYDROCHLORIDE
IFEX, IFOSFAMIDE
IFEX/MESNEX KIT, IFOSFAMIDE
ILETIN I, INSULIN PORK
ILETIN II, INSULIN PURIFIED PORK
ILOSONE SULFA, ERYTHROMYCIN ESTOLATE
ILOSONE, ERYTHROMYCIN ESTOLATE
ILOTYCIN GLUCEPTATE, ERYTHROMYCIN GLUCEPTATE
ILOTYCIN, ERYTHROMYCIN
IMAGENT, PERFLUBRON
IMDUR, ISOSORBIDE MONONITRATE
IMIPRAMINE HCL, IMIPRAMINE HYDROCHLORIDE
IMITREX, SUMATRIPTAN
IMITREX, SUMATRIPTAN SUCCINATE
IMODIUM A-D, LOPERAMIDE HYDROCHLORIDE (OTC)
IMODIUM ADVANCED, LOPERAMIDE HYDROCHLORIDE (OTC)
IMODIUM, LOPERAMIDE HYDROCHLORIDE
IMURAN, AZATHIOPRINE
IMURAN, AZATHIOPRINE SODIUM
INAPSINE, DROPERIDOL
INDAPAMIDE, INDAPAMIDE
INDERAL LA, PROPRANOLOL HYDROCHLORIDE
INDERAL, PROPRANOLOL HYDROCHLORIDE
INDERIDE LA 120/50, HYDROCHLOROTHIAZIDE
INDERIDE LA 160/50, HYDROCHLOROTHIAZIDE
INDERIDE LA 80/50, HYDROCHLOROTHIAZIDE
INDERIDE-40/25, HYDROCHLOROTHIAZIDE
INDERIDE-80/25, HYDROCHLOROTHIAZIDE
INDIUM IN-111 OXYQUINOLINE, INDIUM IN-111 OXYQUINOLINE
INDO-LEMMON, INDOMETHACIN
INDOCIN I.V., INDOMETHACIN SODIUM
INDOCIN SR, INDOMETHACIN
INDOCIN, INDOMETHACIN
INDOMETHACIN, INDOMETHACIN
INDOMETHEGAN, INDOMETHACIN
INFANTS' FEVERALL, ACETAMINOPHEN (OTC)
INFASURF PRESERVATIVE FREE, CALFACTANT
INFED, IRON DEXTRAN
INFLAMASE FORTE, PREDNISOLONE SODIUM PHOSPHATE
INFLAMASE MILD, PREDNISOLONE SODIUM PHOSPHATE
INFUMORPH, MORPHINE SULFATE
INFUVITE PEDIATRIC, ASCORBIC ACID
INH, ISONIAZID
INJECTAPAP, ACETAMINOPHEN
INNOFEM, ESTRADIOL
INNOHEP, TINZAPARIN SODIUM
INNOVAR, DROPERIDOL
INOCOR, INAMRINONE LACTATE
INOMAX, NITRIC OXIDE
INPERSOL-LC/LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
INPERSOL-LC/LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
INPERSOL-LC/LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
INPERSOL-LC/LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
INPERSOL-ZM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
INPERSOL-ZM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
INPERSOL-ZM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
INSTANT MICROSPHERES, TECHNETIUM TC-99M ALBUMIN MICROSPHERES KIT

FDA data supplied by DrugPatentWatch.com

INSULATARD NPH HUMAN, INSULIN SUSP ISOPHANE SEMISYNTHETIC PURIFIED HUMAN (OTC)
INSULIN INSULATARD NPH NORDISK, INSULIN SUSP ISOPHANE PURIFIED PORK (OTC)
INSULIN NORDISK MIXTARD (PORK), INSULIN PURIFIED PORK (OTC)
INSULIN, INSULIN PORK (OTC)
INTAL, CROMOLYN SODIUM
INTEGRILIN, EPTIFIBATIDE
INTRALIPID 10%, SOYBEAN OIL
INTRALIPID 20%, SOYBEAN OIL
INTRALIPID 30%, SOYBEAN OIL
INTROPIN, DOPAMINE HYDROCHLORIDE
INULIN AND SODIUM CHLORIDE, INULIN
INVAGESIC FORTE, ASPIRIN
INVAGESIC, ASPIRIN
INVANZ, ERTAPENEM SODIUM
INVERSINE, MECAMYLAMINE HYDROCHLORIDE
INVIRASE, SAQUINAVIR MESYLATE
IOBENGUANE SULFATE I 131, IOBENGUANE SULFATE I 131
IODOHIPPURATE SODIUM I 131, IODOHIPPURATE SODIUM, I-131
IODOTOPE, SODIUM IODIDE, I-131
IONAMIN, PHENTERMINE RESIN COMPLEX
IONOSOL B AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
IONOSOL T AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
IONTOCAINE, EPINEPHRINE
IOPAMIDOL, IOPAMIDOL
IOPAMIDOL-200 IN PLASTIC CONTAINER, IOPAMIDOL
IOPAMIDOL-200, IOPAMIDOL
IOPAMIDOL-250 IN PLASTIC CONTAINER, IOPAMIDOL
IOPAMIDOL-250, IOPAMIDOL
IOPAMIDOL-300 IN PLASTIC CONTAINER, IOPAMIDOL
IOPAMIDOL-300, IOPAMIDOL
IOPAMIDOL-370 IN PLASTIC CONTAINER, IOPAMIDOL
IOPAMIDOL-370, IOPAMIDOL
IOPIDINE, APRACLONIDINE HYDROCHLORIDE
IOSAT, POTASSIUM IODIDE (OTC)
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
IRON DEXTRAN, IRON DEXTRAN
IRRIGATING SOLUTION G IN PLASTIC CONTAINER, CITRIC ACID
ISMELIN, GUANETHIDINE MONOSULFATE
ISMO, ISOSORBIDE MONONITRATE
ISMOTIC, ISOSORBIDE
ISOCAINE HCL W/ LEVONORDEFRIN, LEVONORDEFRIN
ISOCAINE HCL, MEPIVACAINE HYDROCHLORIDE
ISOCLOR, CHLORPHENIRAMINE MALEATE (OTC)
ISOETHARINE HCL S/F, ISOETHARINE HYDROCHLORIDE
ISOETHARINE HCL, ISOETHARINE HYDROCHLORIDE
ISOETHARINE MESYLATE, ISOETHARINE MESYLATE
ISOFLURANE, ISOFLURANE
ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
ISOLYTE E IN PLASTIC CONTAINER, CALCIUM CHLORIDE
ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
ISOLYTE M IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
ISOLYTE M W/ DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
ISOLYTE P IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
ISOLYTE P W/ DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
ISOLYTE R W/ DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
ISOLYTE S IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
ISOLYTE S IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
ISOLYTE S PH 7.4 IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
ISOLYTE S W/ DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
ISONIAZID, ISONIAZID
ISOPAQUE 280, CALCIUM
ISOPAQUE 440, CALCIUM METRIZOATE
ISOPROTERENOL HCL, ISOPROTERENOL HYDROCHLORIDE
ISOPTIN SR, VERAPAMIL HYDROCHLORIDE
ISOPTIN, VERAPAMIL HYDROCHLORIDE
ISOPTO CETAMIDE, SULFACETAMIDE SODIUM
ISOPTO CETAPRED, PREDNISOLONE ACETATE
ISORDIL, ISOSORBIDE DINITRATE
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
ISOTONIC GENTAMICIN SULFATE IN PLASTIC CONTAINER, GENTAMICIN SULFATE
ISOVUE-128, IOPAMIDOL
ISOVUE-200, IOPAMIDOL
ISOVUE-250, IOPAMIDOL
ISOVUE-300, IOPAMIDOL
ISOVUE-370, IOPAMIDOL
ISOVUE-M 200, IOPAMIDOL
ISOVUE-M 300, IOPAMIDOL
ISUPREL, ISOPROTERENOL HYDROCHLORIDE
IV PERSANTINE, DIPYRIDAMOLE
IVADANTIN, NITROFURANTOIN SODIUM
IVY BLOCK, BENTOQUATAM (OTC)

** J **

JANIMINE, IMIPRAMINE HYDROCHLORIDE
JUNIOR STRENGTH ADVIL, IBUPROFEN (OTC)
JUNIOR STRENGTH IBUPROFEN, IBUPROFEN (OTC)
JUNIOR STRENGTH MOTRIN, IBUPROFEN (OTC)

** K **

K+10, POTASSIUM CHLORIDE
K+8, POTASSIUM CHLORIDE
K-DUR 10, POTASSIUM CHLORIDE

FDA data supplied by DrugPatentWatch.com

K-DUR 20, POTASSIUM CHLORIDE
K-LEASE, POTASSIUM CHLORIDE
K-TAB, POTASSIUM CHLORIDE
KADIAN, MORPHINE SULFATE
KAFOCIN, CEPHALOGLYCIN
KAINAIR, PROPARACAINE HYDROCHLORIDE
KALETRA, LOPINAVIR
KANAMYCIN SULFATE, KANAMYCIN SULFATE
KANAMYCIN, KANAMYCIN SULFATE
KANTREX, KANAMYCIN SULFATE
KAON CL, POTASSIUM CHLORIDE
KAON CL-10, POTASSIUM CHLORIDE
KAPPADIONE, MENADIOL SODIUM DIPHOSPHATE
KAYEXALATE, SODIUM POLYSTYRENE SULFONATE
KEFLET, CEPHALEXIN
KEFLEX, CEPHALEXIN
KEFLIN IN PLASTIC CONTAINER, CEPHALOTHIN SODIUM
KEFLIN, CEPHALOTHIN SODIUM
KEFTAB, CEPHALEXIN HYDROCHLORIDE
KEFUROX IN PLASTIC CONTAINER, CEFUROXIME SODIUM
KEFUROX, CEFUROXIME SODIUM
KEFZOL, CEFAZOLIN SODIUM
KEMADRIN, PROCYCLIDINE HYDROCHLORIDE
KENACORT, TRIAMCINOLONE
KENACORT, TRIAMCINOLONE DIACETATE
KENALOG IN ORABASE, TRIAMCINOLONE ACETONIDE
KENALOG, TRIAMCINOLONE ACETONIDE
KENALOG-10, TRIAMCINOLONE ACETONIDE
KENALOG-40, TRIAMCINOLONE ACETONIDE
KENALOG-H, TRIAMCINOLONE ACETONIDE
KEPPRA, LEVETIRACETAM
KERLEDEX, BETAXOLOL HYDROCHLORIDE
KERLONE, BETAXOLOL HYDROCHLORIDE
KESSO-GESIC, PROPOXYPHENE HYDROCHLORIDE
KETALAR, KETAMINE HYDROCHLORIDE
KETAMINE HCL, KETAMINE HYDROCHLORIDE
KETOCONAZOLE, KETOCONAZOLE
KETOPROFEN, KETOPROFEN
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
KINEVAC, SINCALIDE
KIONEX, SODIUM POLYSTYRENE SULFONATE
KLARON, SULFACETAMIDE SODIUM
KLEBCIL, KANAMYCIN SULFATE
KLONOPIN RAPIDLY DISINTEGRATING, CLONAZEPAM
KLONOPIN, CLONAZEPAM
KLOR-CON M10, POTASSIUM CHLORIDE
KLOR-CON M20, POTASSIUM CHLORIDE
KLOR-CON, POTASSIUM CHLORIDE
KLOROMIN, CHLORPHENIRAMINE MALEATE
KLOTRIX, POTASSIUM CHLORIDE
KOGLUCOID, RAUWOLFIA SERPENTINA
KONAKION, PHYTONADIONE
KOROSTATIN, NYSTATIN
KWELL, LINDANE
KYTRIL, GRANISETRON HYDROCHLORIDE

** L **

LABETALOL HCL, LABETALOL HYDROCHLORIDE
LABID, THEOPHYLLINE
LAC-HYDRIN, AMMONIUM LACTATE
LACRISERT, HYDROXYPROPYL CELLULOSE
LACTATED RINGER'S AND DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
LACTULOSE, LACTULOSE
LAMICTAL CD, LAMOTRIGINE
LAMICTAL, LAMOTRIGINE
LAMISIL AT, TERBINAFINE HYDROCHLORIDE (OTC)
LAMISIL, TERBINAFINE
LAMISIL, TERBINAFINE HYDROCHLORIDE
LAMISIL, TERBINAFINE HYDROCHLORIDE (OTC)
LAMPRENE, CLOFAZIMINE
LANABIOTIC, BACITRACIN (OTC)
LANABIOTIC, BACITRACIN ZINC (OTC)
LANIAZID, ISONIAZID
LANOPHYLLIN, THEOPHYLLINE
LANORINAL, ASPIRIN
LANOXICAPS, DIGOXIN
LANOXIN PEDIATRIC, DIGOXIN
LANOXIN, DIGOXIN
LANTRISUL, TRISULFAPYRIMIDINES (SULFADIAZINE;SULFAMERAZINE; SULFAMETHAZINE)
LANTUS, INSULIN GLARGINE
LARGON, PROPIOMAZINE HYDROCHLORIDE
LARIAM, MEFLOQUINE HYDROCHLORIDE
LARODOPA, LEVODOPA
LAROTID, AMOXICILLIN
LARYNG-O-JET KIT, LIDOCAINE HYDROCHLORIDE
LARYNGOTRACHEAL ANESTHESIA KIT, LIDOCAINE HYDROCHLORIDE
LASIX, FUROSEMIDE
LAXILOSE, LACTULOSE
LEDERCILLIN VK, PENICILLIN V POTASSIUM
LENTARD, INSULIN ZINC SUSP PURIFIED BEEF/PORK (OTC)
LENTE ILETIN II (PORK), INSULIN ZINC SUSP PURIFIED PORK (OTC)
LENTE ILETIN II, INSULIN ZINC SUSP PURIFIED BEEF (OTC)
LENTE INSULIN, INSULIN ZINC SUSP BEEF (OTC)
LENTE, INSULIN ZINC SUSP PURIFIED PORK (OTC)
LERITINE, ANILERIDINE HYDROCHLORIDE
LERITINE, ANILERIDINE PHOSPHATE
LESCOL XL, FLUVASTATIN SODIUM
LESCOL, FLUVASTATIN SODIUM
LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
LEUKERAN, CHLORAMBUCIL

FDA data supplied by DrugPatentWatch.com

LEUPROLIDE ACETATE, LEUPROLIDE ACETATE
LEUSTATIN, CLADRIBINE
LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
LEVAQUIN, LEVOFLOXACIN
LEVATOL, PENBUTOLOL SULFATE
LEVLITE, ETHINYL ESTRADIOL
LEVO-DROMORAN, LEVORPHANOL TARTRATE
LEVOBUNOLOL HCL, LEVOBUNOLOL HYDROCHLORIDE
LEVOCARNITINE, LEVOCARNITINE
LEVONORGESTREL, LEVONORGESTREL
LEVOPHED, NOREPINEPHRINE BITARTRATE
LEVOPROME, METHOTRIMEPRAZINE
LEVORA 0.15/30-21, ETHINYL ESTRADIOL
LEVORA 0.15/30-28, ETHINYL ESTRADIOL
LEVORPHANOL TARTRATE, LEVORPHANOL TARTRATE
LEVOXYL, LIOTRIX (T4;T3)
LEVULAN, AMINOLEVULINIC ACID HYDROCHLORIDE
LEXXEL, ENALAPRIL MALEATE
LIBRELEASE, CHLORDIAZEPOXIDE
LIBRITABS, CHLORDIAZEPOXIDE
LIBRIUM, CHLORDIAZEPOXIDE HYDROCHLORIDE
LIDEX, FLUOCINONIDE
LIDEX-E, FLUOCINONIDE
LIDOCAINE HCL 0.1% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL 0.2% IN DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL 0.2% IN DEXTROSE 5%, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL 0.4% IN DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL 0.4% IN DEXTROSE 5%, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL 0.8% IN DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL 5% AND DEXTROSE 7.5%, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL AND EPINEPHRINE, EPINEPHRINE
LIDOCAINE HCL IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL PRESERVATIVE FREE IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL VISCOUS, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL W/ EPINEPHRINE, EPINEPHRINE
LIDOCAINE HCL, LIDOCAINE HYDROCHLORIDE
LIDOCAINE VISCOUS, LIDOCAINE HYDROCHLORIDE
LIDOCAINE, LIDOCAINE
LIDOCATON, EPINEPHRINE
LIDOCATON, LIDOCAINE HYDROCHLORIDE
LIDODERM, LIDOCAINE
LIDOPEN, LIDOCAINE HYDROCHLORIDE
LIGNOSPAN FORTE, EPINEPHRINE BITARTRATE
LIGNOSPAN STANDARD, EPINEPHRINE BITARTRATE
LIMBITROL DS, AMITRIPTYLINE HYDROCHLORIDE
LIMBITROL, AMITRIPTYLINE HYDROCHLORIDE
LINCOCIN, LINCOMYCIN HYDROCHLORIDE
LINCOMYCIN HCL, LINCOMYCIN HYDROCHLORIDE
LINDANE, LINDANE
LIORESAL, BACLOFEN
LIOTHYRONINE SODIUM, LIOTRIX (T4;T3)
LIPIDIL, FENOFIBRATE
LIPITOR, ATORVASTATIN CALCIUM
LIPO GANTRISIN, SULFISOXAZOLE ACETYL
LIPO-HEPIN, HEPARIN SODIUM
LIPOSYN 10%, SAFFLOWER OIL
LIPOSYN 20%, SAFFLOWER OIL
LIPOSYN II 10%, SAFFLOWER OIL
LIPOSYN II 20%, SAFFLOWER OIL
LIPOSYN III 10%, SOYBEAN OIL
LIPOSYN III 20%, SOYBEAN OIL
LIPOSYN III 30%, SOYBEAN OIL
LIQUAEMIN LOCK FLUSH, HEPARIN SODIUM
LIQUAEMIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
LIQUAEMIN SODIUM, HEPARIN SODIUM
LIQUAMAR, PHENPROCOUMON
LIQUID PRED, PREDNISONE
LITHANE, LITHIUM CARBONATE
LITHIUM CARBONATE, LITHIUM CARBONATE
LITHIUM CITRATE, LITHIUM CITRATE
LITHOBID, LITHIUM CARBONATE
LITHONATE, LITHIUM CARBONATE
LITHONATE, LITHIUM CITRATE
LITHOSTAT, ACETOHYDROXAMIC ACID
LITHOTABS, LITHIUM CARBONATE
LIVOSTIN, LEVOCABASTINE HYDROCHLORIDE
LO-TROL, ATROPINE SULFATE
LO/OVRAL, ETHINYL ESTRADIOL
LO/OVRAL-28, ETHINYL ESTRADIOL
LOCHOLEST LIGHT, CHOLESTYRAMINE
LOCHOLEST, CHOLESTYRAMINE
LOCOID LIPOCREAM, HYDROCORTISONE BUTYRATE
LOCOID, HYDROCORTISONE BUTYRATE
LOCORTEN, FLUMETHASONE PIVALATE
LODINE XL, ETODOLAC
LODINE, ETODOLAC
LODOSYN, CARBIDOPA
LOESTRIN 21 1.5/30, ETHINYL ESTRADIOL
LOESTRIN 21 1/20, ETHINYL ESTRADIOL
LOESTRIN FE 1.5/30, ETHINYL ESTRADIOL
LOESTRIN FE 1/20, ETHINYL ESTRADIOL
LOGEN, ATROPINE SULFATE
LOMANATE, ATROPINE SULFATE
LOMOTIL, ATROPINE SULFATE

FDA data supplied by DrugPatentWatch.com

LONITEN, MINOXIDIL
LONOX, ATROPINE SULFATE
LOPERAMIDE HCL, LOPERAMIDE HYDROCHLORIDE
LOPERAMIDE HCL, LOPERAMIDE HYDROCHLORIDE (OTC)
LOPID, GEMFIBROZIL
LOPRESSIDONE, CHLORTHALIDONE
LOPRESSOR HCT, HYDROCHLOROTHIAZIDE
LOPRESSOR, METOPROLOL FUMARATE
LOPRESSOR, METOPROLOL TARTRATE
LOPROX, CICLOPIROX
LOPURIN, ALLOPURINOL
LORABID, LORACARBEF
LORAZ, LORAZEPAM
LORAZEPAM INTENSOL, LORAZEPAM
LORAZEPAM, LORAZEPAM
LORCET-HD, ACETAMINOPHEN
LORELCO, PROBUCOL
LORFAN, LEVALLORPHAN TARTRATE
LORTAB, ACETAMINOPHEN
LOTEMAX, LOTEPREDNOL ETABONATE
LOTENSIN HCT, BENAZEPRIL HYDROCHLORIDE
LOTENSIN, BENAZEPRIL HYDROCHLORIDE
LOTREL, AMLODIPINE BESYLATE
LOTRIMIN AF, CLOTRIMAZOLE (OTC)
LOTRIMIN ULTRA, BUTENAFINE HYDROCHLORIDE (OTC)
LOTRIMIN, CLOTRIMAZOLE
LOTRISONE, BETAMETHASONE DIPROPIONATE
LOTRONEX, ALOSETRON HYDROCHLORIDE
LOTUSATE, TALBUTAL
LOVASTATIN, LOVASTATIN
LOVENOX, ENOXAPARIN SODIUM
LOW-OGESTREL-21, ETHINYL ESTRADIOL
LOW-OGESTREL-28, ETHINYL ESTRADIOL
LOW-QUEL, ATROPINE SULFATE
LOXAPINE SUCCINATE, LOXAPINE SUCCINATE
LOXITANE C, LOXAPINE HYDROCHLORIDE
LOXITANE IM, LOXAPINE HYDROCHLORIDE
LOXITANE, LOXAPINE SUCCINATE
LOZOL, INDAPAMIDE
LTA II KIT, LIDOCAINE HYDROCHLORIDE
LUDIOMIL, MAPROTILINE HYDROCHLORIDE
LUFYLLIN, DYPHYLLINE
LUMENHANCE, MANGANESE CHLORIDE TETRAHYDRATE
LUMIGAN, BIMATOPROST
LUNELLE, ESTRADIOL CYPIONATE
LUNGAGGREGATE REAGENT, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT
LUPRON DEPOT, LEUPROLIDE ACETATE
LUPRON DEPOT-3, LEUPROLIDE ACETATE
LUPRON DEPOT-4, LEUPROLIDE ACETATE
LUPRON DEPOT-PED, LEUPROLIDE ACETATE
LUPRON, LEUPROLIDE ACETATE
LUTREPULSE KIT, GONADORELIN ACETATE
LUVOX, FLUVOXAMINE MALEATE
LUXIQ, BETAMETHASONE VALERATE
LYGEN, CHLORDIAZEPOXIDE HYDROCHLORIDE
LYMPHAZURIN, ISOSULFAN BLUE
LYNORAL, ETHINYL ESTRADIOL
LYOPHILIZED CYTOXAN, CYCLOPHOSPHAMIDE
LYSODREN, MITOTANE

** M **

M-PREDROL, METHYLPREDNISOLONE ACETATE
M-ZOLE 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
M-ZOLE 7 DUAL PACK, MICONAZOLE NITRATE (OTC)
M.V.C. 9+3, ASCORBIC ACID
M.V.I. PEDIATRIC, ASCORBIC ACID
M.V.I.-12 LYOPHILIZED, ASCORBIC ACID
M.V.I.-12, ASCORBIC ACID
MACROBID, NITROFURANTOIN
MACRODANTIN, NITROFURANTOIN, MACROCRYSTALLINE
MACROTEC, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT
MAGNACORT, HYDROCORTAMATE HYDROCHLORIDE
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MAGNESIUM SULFATE IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MAGNESIUM SULFATE, MAGNESIUM SULFATE
MAGNEVIST, GADOPENTETATE DIMEGLUMINE
MALARONE PEDIATRIC, ATOVAQUONE
MALARONE, ATOVAQUONE
MANDOL, CEFAMANDOLE NAFATE
MANGANESE CHLORIDE IN PLASTIC CONTAINER, MANGANESE CHLORIDE
MANGANESE SULFATE, MANGANESE SULFATE
MANNITOL 10% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER, MANNITOL
MANNITOL 10%, MANNITOL
MANNITOL 15% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 15% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.45%, MANNITOL
MANNITOL 15%, MANNITOL
MANNITOL 20% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 20%, MANNITOL
MANNITOL 25%, MANNITOL
MANNITOL 5% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 5% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.12%, MANNITOL
MANNITOL 5%, MANNITOL
MAOLATE, CHLORPHENESIN CARBAMATE
MAPROTILINE HCL, MAPROTILINE HYDROCHLORIDE
MARCAINE HCL PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HCL W/ EPINEPHRINE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HCL W/ EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HCL, BUPIVACAINE HYDROCHLORIDE
MARCAINE, BUPIVACAINE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

MAREZINE, CYCLIZINE LACTATE
MARINOL, DRONABINOL
MARPLAN, ISOCARBOXAZID
MATULANE, PROCARBAZINE HYDROCHLORIDE
MAVIK, TRANDOLAPRIL
MAXAIR, PIRBUTEROL ACETATE
MAXALT, RIZATRIPTAN BENZOATE
MAXALT-MLT, RIZATRIPTAN BENZOATE
MAXAQUIN, LOMEFLOXACIN HYDROCHLORIDE
MAXIBOLIN, ETHYLESTRENOL
MAXIDEX, DEXAMETHASONE
MAXIDEX, DEXAMETHASONE SODIUM PHOSPHATE
MAXIPIME, CEFEPIME HYDROCHLORIDE (ARGININE FORMULATION)
MAXITROL, DEXAMETHASONE
MAXOLON, METOCLOPRAMIDE HYDROCHLORIDE
MAXZIDE, HYDROCHLOROTHIAZIDE
MAXZIDE-25, HYDROCHLOROTHIAZIDE
MAZANOR, MAZINDOL
MD-50, DIATRIZOATE SODIUM
MD-60, DIATRIZOATE MEGLUMINE
MD-76, DIATRIZOATE MEGLUMINE
MD-76R, DIATRIZOATE MEGLUMINE
MD-GASTROVIEW, DIATRIZOATE MEGLUMINE
MDP-BRACCO, TECHNETIUM TC-99M MEDRONATE KIT
MEASURIN, ASPIRIN (OTC)
MEBENDAZOLE, MEBENDAZOLE
MECLAN, MECLOCYCLINE SULFOSALICYLATE
MECLIZINE HCL, MECLIZINE HYDROCHLORIDE
MECLODIUM, MECLOFENAMATE SODIUM
MECLOFENAMATE SODIUM, MECLOFENAMATE SODIUM
MECLOMEN, MECLOFENAMATE SODIUM
MEDIGESIC PLUS, ACETAMINOPHEN
MEDIHALER ERGOTAMINE, ERGOTAMINE TARTRATE
MEDIHALER-EPI, EPINEPHRINE BITARTRATE (OTC)
MEDIHALER-ISO, ISOPROTERENOL SULFATE
MEDIPREN, IBUPROFEN (OTC)
MEDROL ACETATE, METHYLPREDNISOLONE ACETATE
MEDROL, METHYLPREDNISOLONE
MEDROL, METHYLPREDNISOLONE ACETATE
MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE
MEFLOQUINE HCL, MEFLOQUINE HYDROCHLORIDE
MEFOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER, CEFOXITIN SODIUM
MEFOXIN IN PLASTIC CONTAINER, CEFOXITIN SODIUM
MEFOXIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, CEFOXITIN SODIUM
MEFOXIN, CEFOXITIN SODIUM
MEGACE, MEGESTROL ACETATE
MEGATOPE, ALBUMIN IODINATED I-131 SERUM
MEGESTROL ACETATE, MEGESTROL ACETATE
MELFIAT, PHENDIMETRAZINE TARTRATE
MELFIAT-105, PHENDIMETRAZINE TARTRATE
MELLARIL, THIORIDAZINE HYDROCHLORIDE
MELLARIL-S, THIORIDAZINE
MENADIONE, MENADIONE
MENEST, ESTROGENS, ESTERIFIED
MENOTROPINS, MENOTROPINS (FSH;LH)
MENRIUM 10-4, CHLORDIAZEPOXIDE
MENRIUM 5-2, CHLORDIAZEPOXIDE
MENRIUM 5-4, CHLORDIAZEPOXIDE
MENTAX, BUTENAFINE HYDROCHLORIDE
MEPERGAN, MEPERIDINE HYDROCHLORIDE
MEPERIDINE AND ATROPINE SULFATE, ATROPINE SULFATE
MEPERIDINE HCL PRESERVATIVE FREE, MEPERIDINE HYDROCHLORIDE
MEPERIDINE HCL, MEPERIDINE HYDROCHLORIDE
MEPHYTON, PHYTONADIONE
MEPIVACAINE HCL W/ LEVONORDEFRIN, LEVONORDEFRIN
MEPIVACAINE HCL, MEPIVACAINE HYDROCHLORIDE
MEPRIAM, MEPROBAMATE
MEPRO-ASPIRIN, ASPIRIN
MEPROBAMATE AND ASPIRIN, ASPIRIN
MEPROBAMATE, MEPROBAMATE
MEPRON, ATOVAQUONE
MEPROSPAN, MEPROBAMATE
MERETEK UBT KIT (W/ PRANACTIN), UREA, C-13
MERIDIA, SIBUTRAMINE HYDROCHLORIDE
MERREM I.V., MEROPENEM
MERSALYL-THEOPHYLLINE, MERSALYL SODIUM
MESANTOIN, MEPHENYTOIN
MESNA, MESNA
MESNEX, MESNA
MESTINON, PYRIDOSTIGMINE BROMIDE
METADATE CD, METHYLPHENIDATE HYDROCHLORIDE
METADATE ER, METHYLPHENIDATE HYDROCHLORIDE
METAHYDRIN, TRICHLORMETHIAZIDE
METANDREN, METHYLTESTOSTERONE
METAPROTERENOL SULFATE, METAPROTERENOL SULFATE
METARAMINOL BITARTRATE, METARAMINOL BITARTRATE
METASTRON, STRONTIUM CHLORIDE, SR-89
METATENSIN #2, RESERPINE
METATENSIN #4, RESERPINE
METHADONE HCL INTENSOL, METHADONE HYDROCHLORIDE
METHADONE HCL, METHADONE HYDROCHLORIDE
METHADOSE, METHADONE HYDROCHLORIDE
METHAMPEX, METHAMPHETAMINE HYDROCHLORIDE
METHAMPHETAMINE HCL, METHAMPHETAMINE HYDROCHLORIDE
METHAZOLAMIDE, METHAZOLAMIDE
METHDILAZINE HCL, METHDILAZINE HYDROCHLORIDE
METHERGINE, METHYLERGONOVINE MALEATE
METHIMAZOLE, METHIMAZOLE
METHOCARBAMOL AND ASPIRIN, ASPIRIN
METHOCARBAMOL, METHOCARBAMOL
METHOTREXATE LPF, METHOTREXATE SODIUM
METHOTREXATE PRESERVATIVE FREE, METHOTREXATE SODIUM
METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
METHOTREXATE SODIUM, METHOTREXATE SODIUM

FDA data supplied by DrugPatentWatch.com

METHOTREXATE, METHOTREXATE SODIUM
METHOXSALEN, METHOXSALEN
METHSCOPOLAMINE BROMIDE, METHSCOPOLAMINE BROMIDE
METHYCLOTHIAZIDE AND DESERPIDINE, DESERPIDINE
METHYCLOTHIAZIDE, METHYCLOTHIAZIDE
METHYLDOPA AND CHLOROTHIAZIDE, CHLOROTHIAZIDE
METHYLDOPA AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
METHYLDOPA, METHYLDOPA
METHYLDOPATE HCL, METHYLDOPATE HYDROCHLORIDE
METHYLIN ER, METHYLPHENIDATE HYDROCHLORIDE
METHYLPHENIDATE HCL, METHYLPHENIDATE HYDROCHLORIDE
METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE ACETATE
METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
METHYLPREDNISOLONE, METHYLPREDNISOLONE
METHYLPREDNISOLONE, METHYLPREDNISOLONE SODIUM SUCCINATE
METHYLTESTOSTERONE, METHYLTESTOSTERONE
METI-DERM, PREDNISOLONE
METICORTELONE, PREDNISOLONE ACETATE
METICORTEN, PREDNISONE
METIMYD, PREDNISOLONE ACETATE
METIPRANOLOL, METIPRANOLOL HYDROCHLORIDE
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
METOCLOPRAMIDE INTENSOL, METOCLOPRAMIDE HYDROCHLORIDE
METOCLOPRAMIDE, METOCLOPRAMIDE HYDROCHLORIDE
METOCURINE IODIDE, METOCURINE IODIDE
METOPIRONE, METYRAPONE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
METRA, PHENDIMETRAZINE TARTRATE
METRETON, PREDNISOLONE SODIUM PHOSPHATE
METRO I.V. IN PLASTIC CONTAINER, METRONIDAZOLE
METRO I.V., METRONIDAZOLE
METROCREAM, METRONIDAZOLE
METRODIN, UROFOLLITROPIN
METROGEL, METRONIDAZOLE
METROGEL-VAGINAL, METRONIDAZOLE
METROLOTION, METRONIDAZOLE
METROMIDOL, METRONIDAZOLE
METRONIDAZOLE HCL, METRONIDAZOLE HYDROCHLORIDE
METRONIDAZOLE IN PLASTIC CONTAINER, METRONIDAZOLE
METRONIDAZOLE, METRONIDAZOLE
METUBINE IODIDE, METOCURINE IODIDE
MEVACOR, LOVASTATIN
MEXATE, METHOTREXATE SODIUM
MEXATE-AQ PRESERVED, METHOTREXATE SODIUM
MEXATE-AQ, METHOTREXATE SODIUM
MEXILETINE HCL, MEXILETINE HYDROCHLORIDE
MEXITIL, MEXILETINE HYDROCHLORIDE
MEZLIN, MEZLOCILLIN SODIUM MONOHYDRATE
MIACALCIN, CALCITONIN, SALMON
MICARDIS HCT, HYDROCHLOROTHIAZIDE
MICARDIS, TELMISARTAN
MICONAZOLE 7, MICONAZOLE NITRATE (OTC)
MICONAZOLE NITRATE COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MICONAZOLE NITRATE, MICONAZOLE NITRATE
MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
MICORT-HC, HYDROCORTISONE ACETATE
MICRAININ, ASPIRIN
MICRO-K 10, POTASSIUM CHLORIDE
MICRO-K LS, POTASSIUM CHLORIDE
MICRO-K, POTASSIUM CHLORIDE
MICRODERM, CHLORHEXIDINE GLUCONATE (OTC)
MICROGESTIN FE 1.5/30, ETHINYL ESTRADIOL
MICROGESTIN FE 1/20, ETHINYL ESTRADIOL
MICROLITE, TECHNETIUM TC-99M ALBUMIN COLLOID KIT
MICRONASE, GLYBURIDE
MICRONOR, NORETHINDRONE
MICROSUL, SULFAMETHIZOLE
MICROZIDE, HYDROCHLOROTHIAZIDE
MIDAMOR, AMILORIDE HYDROCHLORIDE
MIDAZOLAM HCL, MIDAZOLAM HYDROCHLORIDE
MIDOL, IBUPROFEN (OTC)
MIFEPREX, MIFEPRISTONE
MIGERGOT, CAFFEINE
MIGRANAL, DIHYDROERGOTAMINE MESYLATE
MILONTIN, PHENSUXIMIDE
MILOPHENE, CLOMIPHENE CITRATE
MILPREM-200, ESTROGENS, CONJUGATED
MILPREM-400, ESTROGENS, CONJUGATED
MILTOWN, MEPROBAMATE
MINIPRESS XL, PRAZOSIN HYDROCHLORIDE
MINIPRESS, PRAZOSIN HYDROCHLORIDE
MINITEC, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
MINITRAN, NITROGLYCERIN
MINIZIDE, POLYTHIAZIDE
MINOCIN, MINOCYCLINE HYDROCHLORIDE
MINOCYCLINE HCL, MINOCYCLINE HYDROCHLORIDE
MINODYL, MINOXIDIL
MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
MINOXIDIL (FOR WOMEN), MINOXIDIL (OTC)
MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
MINOXIDIL EXTRA STRENGTH FOR MEN, MINOXIDIL (OTC)
MINOXIDIL, MINOXIDIL
MINTEZOL, THIABENDAZOLE
MIOCHOL, ACETYLCHOLINE CHLORIDE
MIOCHOL-E, ACETYLCHOLINE CHLORIDE
MIOSTAT, CARBACHOL
MIRADON, ANISINDIONE
MIRALAX, POLYETHYLENE GLYCOL 3350
MIRALUMA, TECHNETIUM TC-99M SESTAMIBI KIT
MIRAPEX, PRAMIPEXOLE DIHYDROCHLORIDE
MIRCETTE, DESOGESTREL
MIRENA, LEVONORGESTREL
MITHRACIN, PLICAMYCIN
MITOMYCIN, MITOMYCIN

FDA data supplied by DrugPatentWatch.com

MIVACRON IN DEXTROSE 5% IN PLASTIC CONTAINER, MIVACURIUM CHLORIDE
MIVACRON, MIVACURIUM CHLORIDE
MIXTARD HUMAN 70/30, INSULIN RECOMBINANT PURIFIED HUMAN (OTC)
MOBAN, MOLINDONE HYDROCHLORIDE
MOBIC, MELOXICAM
MOCTANIN, MONOCTANOIN
MODERIL, RESCINNAMINE
MODICON 21, ETHINYL ESTRADIOL
MODICON 28, ETHINYL ESTRADIOL
MODRASTANE, TRILOSTANE
MODURETIC 5-50, AMILORIDE HYDROCHLORIDE
MONISTAT 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MONISTAT 3, MICONAZOLE NITRATE
MONISTAT 3, MICONAZOLE NITRATE (OTC)
MONISTAT 5, MICONAZOLE NITRATE
MONISTAT 7 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MONISTAT 7, MICONAZOLE NITRATE (OTC)
MONISTAT DUAL- PAK, MICONAZOLE NITRATE
MONISTAT, MICONAZOLE
MONISTAT-3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MONISTAT-DERM, MICONAZOLE NITRATE
MONOCID, CEFONICID SODIUM
MONODOX, DOXYCYCLINE
MONOKET, ISOSORBIDE MONONITRATE
MONOPRIL, FOSINOPRIL SODIUM
MONOPRIL-HCT, FOSINOPRIL SODIUM
MONUROL, FOSFOMYCIN TROMETHAMINE
MORPHINE SULFATE, MORPHINE SULFATE
MOTOFEN HALF-STRENGTH, ATROPINE SULFATE
MOTOFEN, ATROPINE SULFATE
MOTRIN IB, IBUPROFEN (OTC)
MOTRIN MIGRAINE PAIN, IBUPROFEN (OTC)
MOTRIN, IBUPROFEN
MOXAM, MOXALACTAM DISODIUM
MPI DMSA KIDNEY REAGENT, TECHNETIUM TC-99M SUCCIMER KIT
MPI DTPA KIT - CHELATE, TECHNETIUM TC-99M PENTETATE KIT
MPI INDIUM DTPA IN 111, INDIUM IN-111 PENTETATE DISODIUM
MPI KRYPTON 81M GAS GENERATOR, KRYPTON, KR-81M
MPI STANNOUS DIPHOSPHONATE, TECHNETIUM TC-99M ETIDRONATE KIT
MS CONTIN, MORPHINE SULFATE
MUCOMYST W/ ISOPROTERENOL, ACETYLCYSTEINE
MUCOMYST, ACETYLCYSTEINE
MUCOSIL-10, ACETYLCYSTEINE
MUCOSIL-20, ACETYLCYSTEINE
MULTI-12, ALPHA-TOCOPHEROL ACETATE
MULTIFUGE, PIPERAZINE CITRATE
MUSE, ALPROSTADIL
MUSTARGEN, MECHLORETHAMINE HYDROCHLORIDE
MUTAMYCIN, MITOMYCIN
MVC PLUS, ASCORBIC ACID
MYAMBUTOL, ETHAMBUTOL HYDROCHLORIDE
MYBANIL, BROMODIPHENHYDRAMINE HYDROCHLORIDE
MYCELEX, CLOTRIMAZOLE
MYCELEX, CLOTRIMAZOLE (OTC)
MYCELEX-7 COMBINATION PACK, CLOTRIMAZOLE (OTC)
MYCELEX-7, CLOTRIMAZOLE (OTC)
MYCELEX-G, CLOTRIMAZOLE
MYCHEL, CHLORAMPHENICOL
MYCHEL-S, CHLORAMPHENICOL SODIUM SUCCINATE
MYCIFRADIN, NEOMYCIN SULFATE
MYCITRACIN, BACITRACIN
MYCO-TRIACET II, NYSTATIN
MYCOBUTIN, RIFABUTIN
MYCODONE, HOMATROPINE METHYLBROMIDE
MYCOLOG-II, NYSTATIN
MYCOSTATIN, NYSTATIN
MYDRIACYL, TROPICAMIDE
MYDRIAFAIR, TROPICAMIDE
MYFED, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
MYIDYL, TRIPROLIDINE HYDROCHLORIDE
MYKACET, NYSTATIN
MYKINAC, NYSTATIN
MYKROX, METOLAZONE
MYLARAMINE, DEXCHLORPHENIRAMINE MALEATE
MYLAXEN, HEXAFLUORENIUM BROMIDE
MYLERAN, BUSULFAN
MYLOTARG, GEMTUZUMAB OZOGAMICIN
MYMETHASONE, DEXAMETHASONE
MYMETHAZINE FORTIS, PROMETHAZINE HYDROCHLORIDE
MYOTONACHOL, BETHANECHOL CHLORIDE
MYOVIEW, TECHNETIUM TC-99M TETROFOSMIN KIT
MYPHETANE DC, BROMPHENIRAMINE MALEATE
MYPHETANE DX, BROMPHENIRAMINE MALEATE
MYPROIC ACID, VALPROIC ACID
MYSOLINE, PRIMIDONE
MYTELASE, AMBENONIUM CHLORIDE
MYTREX A, NEOMYCIN SULFATE
MYTREX F, NYSTATIN

** N **

N.E.E. 1/35 21, ETHINYL ESTRADIOL
N.E.E. 1/35 28, ETHINYL ESTRADIOL
NABUMETONE, NABUMETONE
NADOLOL, NADOLOL
NAFAZAIR, NAPHAZOLINE HYDROCHLORIDE
NAFCILLIN SODIUM, NAFCILLIN SODIUM
NAFTIN, NAFTIFINE HYDROCHLORIDE
NALBUPHINE HCL, NALBUPHINE HYDROCHLORIDE
NALBUPHINE, NALBUPHINE HYDROCHLORIDE
NALFON 200, FENOPROFEN CALCIUM
NALFON, FENOPROFEN CALCIUM
NALIDIXIC ACID, NALIDIXIC ACID
NALLPEN IN PLASTIC CONTAINER, NAFCILLIN SODIUM

FDA data supplied by DrugPatentWatch.com

NALLPEN, NAFCILLIN SODIUM
NALOXONE HCL AND PENTAZOCAINE, NALOXONE HYDROCHLORIDE
NALOXONE HCL, NALOXONE HYDROCHLORIDE
NALOXONE, NALOXONE HYDROCHLORIDE
NALTREXONE HCL, NALTREXONE HYDROCHLORIDE
NANDROLONE DECANOATE, NANDROLONE DECANOATE
NANDROLONE PHENPROPIONATE, NANDROLONE PHENPROPIONATE
NAPHAZOLINE HCL, NAPHAZOLINE HYDROCHLORIDE
NAPHCON FORTE, NAPHAZOLINE HYDROCHLORIDE
NAPHCON-A, NAPHAZOLINE HYDROCHLORIDE (OTC)
NAPRELAN, NAPROXEN SODIUM
NAPROSYN, NAPROXEN
NAPROXEN SODIUM, NAPROXEN SODIUM
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
NAPROXEN, NAPROXEN
NAQUA, TRICHLORMETHIAZIDE
NAQUIVAL, RESERPINE
NARCAN, NALOXONE HYDROCHLORIDE
NARDIL, PHENELZINE SULFATE
NAROPIN, ROPIVACAINE HYDROCHLORIDE MONOHYDRATE
NASACORT AQ, TRIAMCINOLONE ACETONIDE
NASACORT, TRIAMCINOLONE ACETONIDE
NASALCROM, CROMOLYN SODIUM (OTC)
NASALIDE, FLUNISOLIDE
NASAREL, FLUNISOLIDE
NASCOBAL, CYANOCOBALAMIN
NASONEX, MOMETASONE FUROATE MONOHYDRATE
NATACYN, NATAMYCIN
NATRECOR, NESIRITIDE
NATURAL ESTROGENIC SUBSTANCE-ESTRONE, ESTRONE
NATURETIN-10, BENDROFLUMETHIAZIDE
NATURETIN-2.5, BENDROFLUMETHIAZIDE
NATURETIN-5, BENDROFLUMETHIAZIDE
NAVANE, THIOTHIXENE
NAVANE, THIOTHIXENE HYDROCHLORIDE
NAVELBINE, VINORELBINE TARTRATE
NEBCIN, TOBRAMYCIN SULFATE
NEBUPENT, PENTAMIDINE ISETHIONATE
NEGGRAM, NALIDIXIC ACID
NEMBUTAL SODIUM, PENTOBARBITAL SODIUM
NEMBUTAL, PENTOBARBITAL
NEMBUTAL, PENTOBARBITAL SODIUM
NEO TECT KIT, TECHNETIUM TC-99M DEPREOTIDE
NEO-CORT-DOME, ACETIC ACID, GLACIAL
NEO-CORT-DOME, HYDROCORTISONE
NEO-CORTEF, HYDROCORTISONE ACETATE
NEO-DELTA-CORTEF, NEOMYCIN SULFATE
NEO-HYDELTRASOL, NEOMYCIN SULFATE
NEO-MEDROL ACETATE, METHYLPREDNISOLONE ACETATE
NEO-MEDROL, METHYLPREDNISOLONE
NEO-OTOSOL-HC, HYDROCORTISONE
NEO-POLYCIN, BACITRACIN ZINC
NEO-POLYCIN, GRAMICIDIN
NEO-RX, NEOMYCIN SULFATE
NEO-SYNALAR, FLUOCINOLONE ACETONIDE
NEOBIOTIC, NEOMYCIN SULFATE
NEODECADRON, DEXAMETHASONE SODIUM PHOSPHATE
NEOMYCIN & POLYMYXIN B SULFATES & BACITRACIN ZINC & HYDROCORTISONE, BACITRACIN ZINC
NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC, BACITRACIN ZINC
NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE, DEXAMETHASONE
NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN, GRAMICIDIN
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE, HYDROCORTISONE
NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE, BACITRACIN ZINC
NEOMYCIN AND POLYMYXIN B SULFATES, NEOMYCIN SULFATE
NEOMYCIN SULFATE AND DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
NEOMYCIN SULFATE AND POLYMYXIN B SULFATE GRAMICIDIN, GRAMICIDIN
NEOMYCIN SULFATE, NEOMYCIN SULFATE
NEOMYCIN SULFATE, POLYMYXIN B SULFATE & HYDROCORTISONE, HYDROCORTISONE
NEOMYCIN SULFATE-DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
NEOMYCIN SULFATE-POLYMYXIN B SULFATE-HYDROCORTISONE, HYDROCORTISONE
NEOMYCIN SULFATE-TRIAMCINOLONE ACETONIDE, NEOMYCIN SULFATE
NEOPAP, ACETAMINOPHEN (OTC)
NEOPASALATE, AMINOSALICYLATE SODIUM
NEOPHAM 6.4%, AMINO ACIDS
NEORAL, CYCLOSPORINE
NEOSAR, CYCLOPHOSPHAMIDE
NEOSCAN, GALLIUM CITRATE, GA-67
NEOSPORIN G.U. IRRIGANT, NEOMYCIN SULFATE
NEOSPORIN, BACITRACIN ZINC
NEOSPORIN, GRAMICIDIN
NEOSPORIN, NEOMYCIN SULFATE (OTC)
NEOTHYLLINE, DYPHYLLINE
NEOTRIZINE, TRISULFAPYRIMIDINES (SULFADIAZINE;SULFAMERAZINE; SULFAMETHAZINE)
NEPHRAMINE 5.4%, AMINO ACIDS
NEPHROFLOW, IODOHIPPURATE SODIUM, I-123
NEPTAZANE, METHAZOLAMIDE
NESACAINE, CHLOROPROCAINE HYDROCHLORIDE
NESACAINE-MPF, CHLOROPROCAINE HYDROCHLORIDE
NETROMYCIN, NETILMICIN SULFATE
NEURAMATE, MEPROBAMATE
NEUROLITE, TECHNETIUM TC-99M BICISATE KIT
NEURONTIN, GABAPENTIN
NEUTREXIN, TRIMETREXATE GLUCURONATE
NEXIUM, ESOMEPRAZOLE MAGNESIUM
NIACIN, NIACIN

FDA data supplied by DrugPatentWatch.com

NIACOR, NIACIN
NIASPAN TITRATION STARTER PACK, NIACIN
NIASPAN, NIACIN
NICARDIPINE HCL, NICARDIPINE HYDROCHLORIDE
NICLOCIDE, NICLOSAMIDE
NICODERM CQ, NICOTINE (OTC)
NICOLAR, NIACIN
NICORETTE (ORANGE), NICOTINE POLACRILEX (OTC)
NICORETTE (MINT), NICOTINE POLACRILEX (OTC)
NICORETTE (ORANGE), NICOTINE POLACRILEX (OTC)
NICORETTE, NICOTINE POLACRILEX (OTC)
NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)
NICOTINE, NICOTINE
NICOTROL, NICOTINE
NICOTROL, NICOTINE (OTC)
NIFEDIPINE, NIFEDIPINE
NILANDRON, NILUTAMIDE
NILSTAT, NYSTATIN
NIMBEX PRESERVATIVE FREE, CISATRACURIUM BESYLATE
NIMBEX, CISATRACURIUM BESYLATE
NIMOTOP, NIMODIPINE
NIPENT, PENTOSTATIN
NIPRIDE, SODIUM NITROPRUSSIDE
NITRO IV, NITROGLYCERIN
NITRO-BID, NITROGLYCERIN
NITRO-DUR, NITROGLYCERIN
NITROFURANTION, NITROFURANTOIN, MACROCRYSTALLINE
NITROFURANTOIN MACROCRYSTALLINE, NITROFURANTOIN, MACROCRYSTALLINE
NITROFURANTOIN, NITROFURANTOIN
NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
NITROFURAZONE, NITROFURAZONE
NITROGLYCERIN IN DEXTROSE 5%, NITROGLYCERIN
NITROGLYCERIN, NITROGLYCERIN
NITROL, NITROGLYCERIN
NITROLINGUAL PUMPSPRAY, NITROGLYCERIN
NITROLINGUAL, NITROGLYCERIN
NITRONAL, NITROGLYCERIN
NITROPRESS, SODIUM NITROPRUSSIDE
NITROSTAT, NITROGLYCERIN
NIX, PERMETHRIN
NIX, PERMETHRIN (OTC)
NIZORAL A-D, KETOCONAZOLE (OTC)
NIZORAL, KETOCONAZOLE
NOGENIC HC, HYDROCORTISONE
NOLUDAR, METHYPRYLON
NOLVADEX, TAMOXIFEN CITRATE
NOR-QD, NORETHINDRONE
NORCEPT-E 1/35 21, ETHINYL ESTRADIOL
NORCEPT-E 1/35 28, ETHINYL ESTRADIOL
NORCET, ACETAMINOPHEN
NORCO, ACETAMINOPHEN
NORCURON, VECURONIUM BROMIDE
NORDETTE-21, ETHINYL ESTRADIOL
NORDETTE-28, ETHINYL ESTRADIOL
NORDITROPIN, SOMATROPIN RECOMBINANT
NORETHIN 1/35E-21, ETHINYL ESTRADIOL
NORETHIN 1/35E-28, ETHINYL ESTRADIOL
NORETHIN 1/50M-21, MESTRANOL
NORETHIN 1/50M-28, MESTRANOL
NORETHINDRONE ACETATE, NORETHINDRONE ACETATE
NORETHINDRONE AND ETHINYL ESTRADIOL (10/11), ETHINYL ESTRADIOL
NORETHINDRONE AND ETHINYL ESTRADIOL (7/14), ETHINYL ESTRADIOL
NORETHINDRONE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
NORETHINDRONE AND MESTRANOL, MESTRANOL
NORFLEX, ORPHENADRINE CITRATE
NORGESIC FORTE, ASPIRIN
NORGESIC, ASPIRIN
NORINYL 1+35 21-DAY, ETHINYL ESTRADIOL
NORINYL 1+35 28-DAY, ETHINYL ESTRADIOL
NORINYL 1+50 21-DAY, MESTRANOL
NORINYL 1+50 28-DAY, MESTRANOL
NORINYL 1+80 21-DAY, MESTRANOL
NORINYL 1+80 28-DAY, MESTRANOL
NORINYL, MESTRANOL
NORISODRINE AEROTROL, ISOPROTERENOL HYDROCHLORIDE
NORISODRINE, ISOPROTERENOL SULFATE
NORITATE, METRONIDAZOLE
NORLESTRIN 21 1/50, ETHINYL ESTRADIOL
NORLESTRIN 21 2.5/50, ETHINYL ESTRADIOL
NORLESTRIN 28 1/50, ETHINYL ESTRADIOL
NORLESTRIN FE 1/50, ETHINYL ESTRADIOL
NORLESTRIN FE 2.5/50, ETHINYL ESTRADIOL
NORLUTATE, NORETHINDRONE ACETATE
NORLUTIN, NORETHINDRONE
NORMIFLO, ARDEPARIN SODIUM
NORMODYNE, LABETALOL HYDROCHLORIDE
NORMOSOL-M AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
NORMOSOL-R IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
NORMOZIDE, HYDROCHLOROTHIAZIDE
NOROXIN, NORFLOXACIN
NORPACE CR, DISOPYRAMIDE PHOSPHATE
NORPACE, DISOPYRAMIDE PHOSPHATE
NORPLANT II, LEVONORGESTREL
NORPLANT SYSTEM IN PLASTIC CONTAINER, LEVONORGESTREL
NORPLANT, LEVONORGESTREL
NORPRAMIN, DESIPRAMINE HYDROCHLORIDE
NORQUEST FE, ETHINYL ESTRADIOL
NORTRIPTYLINE HCL, NORTRIPTYLINE HYDROCHLORIDE
NORVASC, AMLODIPINE BESYLATE
NORVIR, RITONAVIR
NOVAFED, PSEUDOEPHEDRINE HYDROCHLORIDE
NOVAMINE 11.4%, AMINO ACIDS

FDA data supplied by DrugPatentWatch.com

NOVAMINE 15% SULFITE FREE IN PLASTIC CONTAINER, AMINO ACIDS
NOVAMINE 15%, AMINO ACIDS
NOVAMINE 8.5%, AMINO ACIDS
NOVANTRONE, MITOXANTRONE HYDROCHLORIDE
NOVOCAIN, PROCAINE HYDROCHLORIDE
NOVOLIN 70/30, INSULIN RECOMBINANT HUMAN (OTC)
NOVOLIN 70/30, INSULIN RECOMBINANT PURIFIED HUMAN (OTC)
NOVOLIN L, INSULIN ZINC SUSP RECOMBINANT HUMAN (OTC)
NOVOLIN L, INSULIN ZINC SUSP SEMISYNTHETIC PURIFIED HUMAN (OTC)
NOVOLIN N, INSULIN SUSP ISOPHANE RECOMBINANT HUMAN (OTC)
NOVOLIN N, INSULIN SUSP ISOPHANE SEMISYNTHETIC PURIFIED HUMAN (OTC)
NOVOLIN R, INSULIN RECOMBINANT HUMAN (OTC)
NOVOLIN R, INSULIN RECOMBINANT PURIFIED HUMAN (OTC)
NOVOLOG MIX 70/30, INSULIN ASPART
NOVOLOG, INSULIN ASPART
NOVRAD, LEVOPROPOXYPHENE NAPSYLATE, ANHYDROUS
NPH ILETIN I (BEEF-PORK), INSULIN SUSP ISOPHANE BEEF/PORK (OTC)
NPH ILETIN II (PORK), INSULIN SUSP ISOPHANE PURIFIED PORK (OTC)
NPH ILETIN II, INSULIN SUSP ISOPHANE PURIFIED BEEF (OTC)
NPH INSULIN, INSULIN SUSP ISOPHANE BEEF (OTC)
NPH PURIFIED PORK ISOPHANE INSULIN, INSULIN SUSP ISOPHANE PURIFIED PORK (OTC)
NUBAIN, NALBUPHINE HYDROCHLORIDE
NULYTELY, POLYETHYLENE GLYCOL 3350
NULYTELY-FLAVORED, POLYETHYLENE GLYCOL 3350
NUMORPHAN, OXYMORPHONE HYDROCHLORIDE
NUPRIN, IBUPROFEN (OTC)
NUROMAX, DOXACURIUM CHLORIDE
NUTRACORT, HYDROCORTISONE
NUTRILIPID 10%, SOYBEAN OIL
NUTRILIPID 20%, SOYBEAN OIL
NUTROPIN AQ, SOMATROPIN RECOMBINANT
NUTROPIN DEPOT, SOMATROPIN RECOMBINANT
NUTROPIN, SOMATROPIN RECOMBINANT
NUVARING, ETHINYL ESTRADIOL
NYDRAZID, ISONIAZID
NYSERT, NYSTATIN
NYSTAFORM, CLIOQUINOL
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
NYSTATIN, NYSTATIN
NYSTATIN-TRIAMCINOLONE ACETONIDE, NYSTATIN
NYSTEX, NYSTATIN
NYSTOP, NYSTATIN

** O **

OBESTIN-30, PHENTERMINE HYDROCHLORIDE
OBY-TRIM, PHENTERMINE HYDROCHLORIDE
OCL, POLYETHYLENE GLYCOL 3350
OCTOCAINE, EPINEPHRINE
OCTREOSCAN, INDIUM IN-111 PENTETREOTIDE KIT
OCUCLEAR, OXYMETAZOLINE HYDROCHLORIDE (OTC)
OCUFEN, FLURBIPROFEN SODIUM
OCUFLOX, OFLOXACIN
OCUMYCIN, BACITRACIN ZINC
OCUPRESS, CARTEOLOL HYDROCHLORIDE
OCUSERT PILO-20, PILOCARPINE
OCUSERT PILO-40, PILOCARPINE
OCUSULF-10, SULFACETAMIDE SODIUM
OCUSULF-30, SULFACETAMIDE SODIUM
OGEN .625, ESTROPIPATE
OGEN 1.25, ESTROPIPATE
OGEN 2.5, ESTROPIPATE
OGEN 5, ESTROPIPATE
OGEN, ESTROPIPATE
OGESTREL 0.5/50-21, ETHINYL ESTRADIOL
OGESTREL 0.5/50-28, ETHINYL ESTRADIOL
OLUX FOAM, CLOBETASOL PROPIONATE
OMEPRAZOLE, OMEPRAZOLE
OMNICEF, CEFDINIR
OMNIPAQUE 140, IOHEXOL
OMNIPAQUE 180, IOHEXOL
OMNIPAQUE 210, IOHEXOL
OMNIPAQUE 240, IOHEXOL
OMNIPAQUE 300, IOHEXOL
OMNIPAQUE 350, IOHEXOL
OMNIPAQUE 70, IOHEXOL
OMNIPEN (AMPICILLIN), AMPICILLIN/AMPICILLIN TRIHYDRATE
OMNIPEN-N, AMPICILLIN SODIUM
OMNISCAN, GADODIAMIDE
ONA MAST, PHENTERMINE HYDROCHLORIDE
ONA-MAST, PHENTERMINE HYDROCHLORIDE
ONCOVIN, VINCRISTINE SULFATE
OPCON, NAPHAZOLINE HYDROCHLORIDE
OPCON-A, NAPHAZOLINE HYDROCHLORIDE (OTC)
OPHTHAINE, PROPARACAINE HYDROCHLORIDE
OPHTHETIC, PROPARACAINE HYDROCHLORIDE
OPHTHOCHLOR, CHLORAMPHENICOL
OPHTHOCORT, CHLORAMPHENICOL
OPTICROM, CROMOLYN SODIUM
OPTIMARK IN PLASTIC CONTAINER, GADOVERSETAMIDE
OPTIMARK, GADOVERSETAMIDE
OPTIMINE, AZATADINE MALEATE
OPTIPRANOLOL, METIPRANOLOL HYDROCHLORIDE
OPTIRAY 160, IOVERSOL
OPTIRAY 240, IOVERSOL
OPTIRAY 300, IOVERSOL
OPTIRAY 320, IOVERSOL
OPTIRAY 350, IOVERSOL
OPTISON, PERFLUTREN
OPTIVAR, AZELASTINE HYDROCHLORIDE
OPTOMYCIN, CHLORAMPHENICOL

FDA data supplied by DrugPatentWatch.com

ORA-TESTRYL, FLUOXYMESTERONE
ORABASE HCA, HYDROCORTISONE ACETATE
ORACORT, TRIAMCINOLONE ACETONIDE
ORAGRAFIN CALCIUM, IPODATE CALCIUM
ORAGRAFIN SODIUM, IPODATE SODIUM
ORALONE, TRIAMCINOLONE ACETONIDE
ORAMORPH SR, MORPHINE SULFATE
ORAP, PIMOZIDE
ORAPRED, PREDNISOLONE SODIUM PHOSPHATE
ORASONE, PREDNISONE
ORETIC, HYDROCHLOROTHIAZIDE
ORETICYL 25, DESERPIDINE
ORETICYL 50, DESERPIDINE
ORETICYL FORTE, DESERPIDINE
ORETON METHYL, METHYLTESTOSTERONE
ORETON, METHYLTESTOSTERONE
ORGARAN, DANAPAROID SODIUM
ORGATRAX, HYDROXYZINE HYDROCHLORIDE
ORINASE DIAGNOSTIC, TOLBUTAMIDE SODIUM
ORINASE, TOLBUTAMIDE
ORLAAM, LEVOMETHADYL ACETATE HYDROCHLORIDE
ORLEX HC, ACETIC ACID, GLACIAL
ORLEX, ACETIC ACID, GLACIAL
ORNADE, CHLORPHENIRAMINE MALEATE
ORNIDYL, EFLORNITHINE HYDROCHLORIDE
ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE, ASPIRIN
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
ORPHENGESIC FORTE, ASPIRIN
ORPHENGESIC, ASPIRIN
ORTHO CYCLEN-21, ETHINYL ESTRADIOL
ORTHO CYCLEN-28, ETHINYL ESTRADIOL
ORTHO EVRA, ETHINYL ESTRADIOL
ORTHO TRI-CYCLEN, ETHINYL ESTRADIOL
ORTHO-CEPT, DESOGESTREL
ORTHO-EST, ESTROPIPATE
ORTHO-NOVUM 1/80 28, MESTRANOL
ORTHO-NOVUM 1/35-21, ETHINYL ESTRADIOL
ORTHO-NOVUM 1/35-28, ETHINYL ESTRADIOL
ORTHO-NOVUM 1/50 21, MESTRANOL
ORTHO-NOVUM 1/50 28, MESTRANOL
ORTHO-NOVUM 1/80 21, MESTRANOL
ORTHO-NOVUM 10-21, MESTRANOL
ORTHO-NOVUM 10/11-21, ETHINYL ESTRADIOL
ORTHO-NOVUM 10/11-28 IN PLASTIC CONTAINER, ETHINYL ESTRADIOL
ORTHO-NOVUM 2-21, MESTRANOL
ORTHO-NOVUM 7/14-21, ETHINYL ESTRADIOL
ORTHO-NOVUM 7/14-28, ETHINYL ESTRADIOL
ORTHO-NOVUM 7/7/7-21, ETHINYL ESTRADIOL
ORTHO-NOVUM 7/7/7-28, ETHINYL ESTRADIOL
ORTHO-PREFEST, ESTRADIOL
ORUDIS KT, KETOPROFEN (OTC)
ORUDIS, KETOPROFEN
ORUVAIL, KETOPROFEN
OSMITROL 10% IN WATER IN PLASTIC CONTAINER, MANNITOL
OSMITROL 10% IN WATER, MANNITOL
OSMITROL 15% IN WATER IN PLASTIC CONTAINER, MANNITOL
OSMITROL 15% IN WATER, MANNITOL
OSMITROL 20% IN WATER IN PLASTIC CONTAINER, MANNITOL
OSMITROL 20% IN WATER, MANNITOL
OSMITROL 5% IN WATER IN PLASTIC CONTAINER, MANNITOL
OSMITROL 5% IN WATER, MANNITOL
OSMOVIST 190, IOTROLAN
OSMOVIST 240, IOTROLAN
OSTEOLITE, TECHNETIUM TC-99M MEDRONATE KIT
OSTEOSCAN, TECHNETIUM TC-99M ETIDRONATE KIT
OTICAIR, HYDROCORTISONE
OTOBIONE, HYDROCORTISONE
OTOBIOTIC, HYDROCORTISONE
OTOCORT, HYDROCORTISONE
OVCON-35, ETHINYL ESTRADIOL
OVCON-50, ETHINYL ESTRADIOL
OVIDE, MALATHION
OVIDREL, CHORIOGONADOTROPIN ALFA
OVRAL, ETHINYL ESTRADIOL
OVRAL-28, ETHINYL ESTRADIOL
OVRETTE, NORGESTREL
OVULEN, ETHYNODIOL DIACETATE
OVULEN-21, ETHYNODIOL DIACETATE
OVULEN-28, ETHYNODIOL DIACETATE
OXACILLIN SODIUM, OXACILLIN SODIUM
OXANDRIN, OXANDROLONE
OXAPROZIN, OXAPROZIN
OXAZEPAM, OXAZEPAM
OXILAN-300, IOXILAN
OXILAN-350, IOXILAN
OXISTAT, OXICONAZOLE NITRATE
OXSORALEN, METHOXSALEN
OXSORALEN-ULTRA, METHOXSALEN
OXTRIPHYLLINE PEDIATRIC, OXTRIPHYLLINE
OXTRIPHYLLINE, OXTRIPHYLLINE
OXY-KESSO-TETRA, OXYTETRACYCLINE HYDROCHLORIDE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
OXYCET, ACETAMINOPHEN
OXYCODONE 2.5/APAP 500, ACETAMINOPHEN
OXYCODONE 5/APAP 500, ACETAMINOPHEN
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE AND ASPIRIN (HALF-STRENGTH), ASPIRIN
OXYCODONE AND ASPIRIN, ASPIRIN
OXYCONTIN, OXYCODONE HYDROCHLORIDE
OXYLONE, FLUOROMETHOLONE
OXYPHENBUTAZONE, OXYPHENBUTAZONE
OXYTETRACYCLINE HCL, OXYTETRACYCLINE HYDROCHLORIDE
OXYTOCIN 10 USP UNITS IN DEXTROSE 5%, OXYTOCIN
OXYTOCIN 20 USP UNITS IN DEXTROSE 5%, OXYTOCIN
OXYTOCIN 5 USP UNITS IN DEXTROSE 5%, OXYTOCIN
OXYTOCIN, OXYTOCIN

FDA data supplied by DrugPatentWatch.com

** P **

P.A.S. SODIUM, AMINOSALICYLATE SODIUM
PACERONE, AMIODARONE HYDROCHLORIDE
PACLITAXEL, PACLITAXEL
PAGITANE, CYCRIMINE HYDROCHLORIDE
PAMELOR, NORTRIPTYLINE HYDROCHLORIDE
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
PAMINE, METHSCOPOLAMINE BROMIDE
PANCURONIUM BROMIDE, PANCURONIUM BROMIDE
PANCURONIUM, PANCURONIUM BROMIDE
PANDEL, HYDROCORTISONE PROBUTATE
PANHEPRIN, HEPARIN SODIUM
PANMYCIN, TETRACYCLINE HYDROCHLORIDE
PANRETIN, ALITRETINOIN
PANTOPAQUE, IOPHENDYLATE
PANWARFIN, WARFARIN SODIUM
PAPA-DEINE #3, ACETAMINOPHEN
PAPA-DEINE #4, ACETAMINOPHEN
PARACAINE, PROPARACAINE HYDROCHLORIDE
PARACORT, PREDNISONE
PARADIONE, PARAMETHADIONE
PARAFLEX, CHLORZOXAZONE
PARAFON FORTE DSC, CHLORZOXAZONE
PARAPLATIN, CARBOPLATIN
PARASAL SODIUM, AMINOSALICYLATE SODIUM
PARASAL, AMINOSALICYLIC ACID
PARATHAR, TERIPARATIDE ACETATE
PAREDRINE, HYDROXYAMPHETAMINE HYDROBROMIDE
PAREMYD, HYDROXYAMPHETAMINE HYDROBROMIDE
PARLODEL, BROMOCRIPTINE MESYLATE
PARNATE, TRANYLCYPROMINE SULFATE
PAROMOMYCIN SULFATE, PAROMOMYCIN SULFATE
PARSIDOL, ETHOPROPAZINE HYDROCHLORIDE
PASER, AMINOSALICYLIC ACID
PASKALIUM, POTASSIUM AMINOSALICYLATE
PATANOL, OLOPATADINE HYDROCHLORIDE
PATHILON, TRIDIHEXETHYL CHLORIDE
PATHOCIL, DICLOXACILLIN SODIUM
PAVULON, PANCURONIUM BROMIDE
PAXIL CR, PAROXETINE HYDROCHLORIDE
PAXIL, PAROXETINE HYDROCHLORIDE
PAXIPAM, HALAZEPAM
PBZ, TRIPELENNAMINE CITRATE
PBZ, TRIPELENNAMINE HYDROCHLORIDE
PBZ-SR, TRIPELENNAMINE HYDROCHLORIDE
PCE, ERYTHROMYCIN
PEDIAMYCIN 400, ERYTHROMYCIN ETHYLSUCCINATE
PEDIAMYCIN, ERYTHROMYCIN ETHYLSUCCINATE
PEDIAPRED, PREDNISOLONE SODIUM PHOSPHATE
PEDIATRIC ADVIL, IBUPROFEN (OTC)
PEDIATRIC LTA KIT, LIDOCAINE HYDROCHLORIDE
PEDIAZOLE, ERYTHROMYCIN ETHYLSUCCINATE
PEDIOTIC, HYDROCORTISONE
PEG-LYTE, POLYETHYLENE GLYCOL 3350
PEGANONE, ETHOTOIN
PEMOLINE, PEMOLINE
PEN-VEE K, PENICILLIN V POTASSIUM
PENAPAR-VK, PENICILLIN V POTASSIUM
PENBRITIN, AMPICILLIN/AMPICILLIN TRIHYDRATE
PENBRITIN-S, AMPICILLIN SODIUM
PENECORT, HYDROCORTISONE
PENETREX, ENOXACIN
PENICILLIN G POTASSIUM IN PLASTIC CONTAINER, PENICILLIN G POTASSIUM
PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM
PENICILLIN G PROCAINE, PENICILLIN G PROCAINE
PENICILLIN G SODIUM, PENICILLIN G SODIUM
PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM
PENICILLIN, PENICILLIN G POTASSIUM
PENICILLIN-2, PENICILLIN G POTASSIUM
PENICILLIN-VK, PENICILLIN V POTASSIUM
PENLAC, CICLOPIROX
PENNTUSS, CHLORPHENIRAMINE POLISTIREX (OTC)
PENTACARINAT, PENTAMIDINE ISETHIONATE
PENTACEF, CEFTAZIDIME (ARGININE FORMULATION)
PENTAM, PENTAMIDINE ISETHIONATE
PENTAMIDINE ISETHIONATE, PENTAMIDINE ISETHIONATE
PENTASA, MESALAMINE
PENTAZOCINE AND NALOXONE HYDROCHLORIDES, NALOXONE HYDROCHLORIDE
PENTAZOCINE HCL AND ACETAMINOPHEN, ACETAMINOPHEN
PENTHRANE, METHOXYFLURANE
PENTIDS '200', PENICILLIN G POTASSIUM
PENTIDS '250', PENICILLIN G POTASSIUM
PENTIDS '400', PENICILLIN G POTASSIUM
PENTIDS '800', PENICILLIN G POTASSIUM
PENTOBARBITAL SODIUM, PENTOBARBITAL SODIUM
PENTOLAIR, CYCLOPENTOLATE HYDROCHLORIDE
PENTOTHAL, THIOPENTAL SODIUM
PENTOXIFYLLINE, PENTOXIFYLLINE
PENTOXIL, PENTOXIFYLLINE
PEPCID AC, FAMOTIDINE (OTC)
PEPCID COMPLETE, CALCIUM CARBONATE, PRECIPITATED (OTC)
PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER, FAMOTIDINE
PEPCID PRESERVATIVE FREE, FAMOTIDINE
PEPCID RPD, FAMOTIDINE
PEPCID, FAMOTIDINE
PEPTAVLON, PENTAGASTRIN
PERCHLORACAP, POTASSIUM PERCHLORATE
PERCOCET, ACETAMINOPHEN
PERCODAN, ASPIRIN
PERCODAN-DEMI, ASPIRIN
PERCORTEN, DESOXYCORTICOSTERONE ACETATE
PERCORTEN, DESOXYCORTICOSTERONE PIVALATE

FDA data supplied by DrugPatentWatch.com

PERGONAL, MENOTROPINS (FSH;LH)
PERIACTIN, CYPROHEPTADINE HYDROCHLORIDE
PERIDEX, CHLORHEXIDINE GLUCONATE
PERIOCHIP, CHLORHEXIDINE GLUCONATE
PERIOGARD, CHLORHEXIDINE GLUCONATE
PERIOSTAT, DOXYCYCLINE HYCLATE
PERMAPEN, PENICILLIN G BENZATHINE
PERMAX, PERGOLIDE MESYLATE
PERMETHRIN, PERMETHRIN
PERMETHRIN, PERMETHRIN (OTC)
PERMITIL, FLUPHENAZINE HYDROCHLORIDE
PERPHENAZINE AND AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
PERPHENAZINE, PERPHENAZINE
PERSANTINE, DIPYRIDAMOLE
PERTOFRANE, DESIPRAMINE HYDROCHLORIDE
PFIZER-E, ERYTHROMYCIN STEARATE
PFIZERPEN G, PENICILLIN G POTASSIUM
PFIZERPEN VK, PENICILLIN V POTASSIUM
PFIZERPEN, PENICILLIN G POTASSIUM
PFIZERPEN-A, AMPICILLIN/AMPICILLIN TRIHYDRATE
PFIZERPEN-AS, PENICILLIN G PROCAINE
PHARMASEAL SCRUB CARE, CHLORHEXIDINE GLUCONATE (OTC)
PHENAPHEN W/ CODEINE NO. 2, ACETAMINOPHEN
PHENAPHEN W/ CODEINE NO. 3, ACETAMINOPHEN
PHENAPHEN W/ CODEINE NO. 4, ACETAMINOPHEN
PHENAPHEN-650 W/ CODEINE, ACETAMINOPHEN
PHENAZINE, PHENDIMETRAZINE TARTRATE
PHENAZINE-35, PHENDIMETRAZINE TARTRATE
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PHENERGAN FORTIS, PROMETHAZINE HYDROCHLORIDE
PHENERGAN PLAIN, PROMETHAZINE HYDROCHLORIDE
PHENERGAN VC W/ CODEINE, CODEINE PHOSPHATE
PHENERGAN VC, PHENYLEPHRINE HYDROCHLORIDE
PHENERGAN W/ CODEINE, CODEINE PHOSPHATE
PHENERGAN W/ DEXTROMETHORPHAN, DEXTROMETHORPHAN HYDROBROMIDE
PHENERGAN, PROMETHAZINE HYDROCHLORIDE
PHENETRON, CHLORPHENIRAMINE MALEATE
PHENTERMINE HCL, PHENTERMINE HYDROCHLORIDE
PHENTERMINE RESIN 30, PHENTERMINE RESIN COMPLEX
PHENTOLAMINE MESYLATE, PHENTOLAMINE MESYLATE
PHENURONE, PHENACEMIDE
PHENY-PAS-TEBAMIN, PHENYL AMINOSALICYLATE
PHENYLBUTAZONE, PHENYLBUTAZONE
PHENYLPROPANOLAMINE HCL W/ CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE (OTC)
PHENYTEK, PHENYTOIN SODIUM, EXTENDED
PHENYTEX, PHENYTOIN SODIUM, EXTENDED
PHENYTOIN SODIUM, PHENYTOIN SODIUM
PHENYTOIN SODIUM, PHENYTOIN SODIUM, PROMPT
PHENYTOIN, PHENYTOIN
PHENYTOIN, PHENYTOIN SODIUM
PHERAZINE DM, DEXTROMETHORPHAN HYDROBROMIDE
PHERAZINE VC W/ CODEINE, CODEINE PHOSPHATE
PHERAZINE VC, PHENYLEPHRINE HYDROCHLORIDE
PHERAZINE W/ CODEINE, CODEINE PHOSPHATE
PHISO-SCRUB, HEXACHLOROPHENE
PHISOHEX, HEXACHLOROPHENE
PHOSLO GELCAPS, CALCIUM ACETATE
PHOSLO, CALCIUM ACETATE
PHOSPHOCOL P32, CHROMIC PHOSPHATE, P-32
PHOSPHOLINE IODIDE, ECHOTHIOPHATE IODIDE
PHOSPHOTEC, TECHNETIUM TC-99M PYROPHOSPHATE KIT
PHOSPHOTOPE, SODIUM PHOSPHATE, P-32
PHOTOFRIN, PORFIMER SODIUM
PHRENILIN FORTE, ACETAMINOPHEN
PHRENILIN WITH CAFFEINE AND CODEINE, ACETAMINOPHEN
PHRENILIN, ACETAMINOPHEN
PHYLLOCONTIN, AMINOPHYLLINE
PHYSIOLYTE IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
PHYSIOSOL IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
PHYSIOSOL PH 7.4 IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
PHYTONADIONE, PHYTONADIONE
PILOPINE HS, PILOCARPINE HYDROCHLORIDE
PINDAC, PINACIDIL
PINDOLOL, PINDOLOL
PIPERAZINE CITRATE, PIPERAZINE CITRATE
PIPRACIL, PIPERACILLIN SODIUM
PIROXICAM, PIROXICAM
PITOCIN, OXYTOCIN
PITRESSIN TANNATE, VASOPRESSIN TANNATE
PLACIDYL, ETHCHLORVYNOL
PLAN B, LEVONORGESTREL
PLAQUENIL, HYDROXYCHLOROQUINE SULFATE
PLASMA-LYTE 148 AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
PLASMA-LYTE 56 AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
PLASMA-LYTE 56 IN PLASTIC CONTAINER, MAGNESIUM ACETATE TETRAHYDRATE
PLASMA-LYTE A IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
PLASMA-LYTE M AND DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PLASMA-LYTE R IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PLATINOL, CISPLATIN
PLATINOL-AQ, CISPLATIN
PLAVIX, CLOPIDOGREL BISULFATE
PLEGINE, PHENDIMETRAZINE TARTRATE
PLEGISOL IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PLENDIL, FELODIPINE
PLETAL, CILOSTAZOL
PMB 200, ESTROGENS, CONJUGATED
PMB 400, ESTROGENS, CONJUGATED
POLARAMINE, DEXCHLORPHENIRAMINE MALEATE

FDA data supplied by DrugPatentWatch.com

POLOCAINE W/ LEVONORDEFRIN, LEVONORDEFRIN
POLOCAINE, MEPIVACAINE HYDROCHLORIDE
POLOCAINE-MPF, MEPIVACAINE HYDROCHLORIDE
POLY-PRED, NEOMYCIN SULFATE
POLY-RX, POLYMYXIN B SULFATE
POLYCILLIN, AMPICILLIN/AMPICILLIN TRIHYDRATE
POLYCILLIN-N, AMPICILLIN SODIUM
POLYCILLIN-PRB, AMPICILLIN/AMPICILLIN TRIHYDRATE
POLYMOX, AMOXICILLIN
POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
POLYSPORIN, BACITRACIN ZINC
POLYSPORIN, BACITRACIN ZINC (OTC)
POLYTRIM, POLYMYXIN B SULFATE
PONSTEL, MEFENAMIC ACID
PORTALAC, LACTULOSE
POTASSIUM ACETATE IN PLASTIC CONTAINER, POTASSIUM ACETATE
POTASSIUM AMINOSALICYLATE, POTASSIUM AMINOSALICYLATE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.037% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.075% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.11% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE

FDA data supplied by DrugPatentWatch.com

0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.22% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.3% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 20MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% IN PLASTIC

FDA data supplied by DrugPatentWatch.com

CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 40MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
POTASSIUM CITRATE, POTASSIUM CITRATE
POTASSIUM IODIDE, POTASSIUM IODIDE (OTC)
POVAN, PYRVINIUM PAMOATE
POVIDONE IODINE, POVIDONE-IODINE (OTC)
PRALIDOXIME CHLORIDE, PRALIDOXIME CHLORIDE
PRAMINE, IMIPRAMINE HYDROCHLORIDE
PRAMOSONE, HYDROCORTISONE ACETATE
PRANDIN, REPAGLINIDE
PRANTAL, DIPHEMANIL METHYLSULFATE
PRAVACHOL, PRAVASTATIN SODIUM
PRAZEPAM, PRAZEPAM
PRAZOSIN HCL, PRAZOSIN HYDROCHLORIDE
PRE-OP II, HEXACHLOROPHENE
PRE-OP, HEXACHLOROPHENE
PRE-PEN, BENZYL PENICILLOYL-POLYLYSINE
PRE-SATE, CHLORPHENTERMINE HYDROCHLORIDE
PRECEDEX, DEXMEDETOMIDINE
PRECEF, CEFORANIDE
PRECOSE, ACARBOSE
PRED FORTE, PREDNISOLONE ACETATE
PRED MILD, PREDNISOLONE ACETATE
PRED-G, GENTAMICIN SULFATE
PREDAIR FORTE, PREDNISOLONE SODIUM PHOSPHATE
PREDAIR, PREDNISOLONE SODIUM PHOSPHATE
PREDAMIDE, PREDNISOLONE ACETATE
PREDNICEN-M, PREDNISONE
PREDNISOLONE ACETATE, PREDNISOLONE ACETATE
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
PREDNISOLONE TEBUTATE, PREDNISOLONE TEBUTATE
PREDNISOLONE, PREDNISOLONE
PREDNISONE INTENSOL, PREDNISONE
PREDNISONE, PREDNISONE
PREDSULFAIR II, PREDNISOLONE ACETATE
PREDSULFAIR, PREDNISOLONE ACETATE
PREFRIN-A, PHENYLEPHRINE HYDROCHLORIDE
PREGNYL, GONADOTROPIN, CHORIONIC
PRELAY, TROGLITAZONE
PRELONE, PREDNISOLONE
PRELUDIN, PHENMETRAZINE HYDROCHLORIDE
PREMARIN, ESTROGENS, CONJUGATED
PREMPHASE (PREMARIN;CYCRIN 14/14), ESTROGENS, CONJUGATED
PREMPHASE 14/14, ESTROGENS, CONJUGATED
PREMPRO (PREMARIN;CYCRIN), ESTROGENS, CONJUGATED
PREMPRO, ESTROGENS, CONJUGATED
PREPIDIL, DINOPROSTONE
PRESAMINE, IMIPRAMINE HYDROCHLORIDE
PREVACARE R, CHLORHEXIDINE GLUCONATE (OTC)
PREVACID, LANSOPRAZOLE
PREVALITE, CHOLESTYRAMINE
PREVEN EMERGENCY CONTRACEPTIVE KIT, ETHINYL ESTRADIOL
PREVPAC, AMOXICILLIN
PRIFTIN, RIFAPENTINE
PRILOSEC, OMEPRAZOLE
PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER, MILRINONE LACTATE
PRIMACOR, MILRINONE LACTATE
PRIMAQUINE, PRIMAQUINE PHOSPHATE
PRIMATENE MIST, EPINEPHRINE (OTC)
PRIMAXIN, CILASTATIN SODIUM
PRIMIDONE, PRIMIDONE
PRIMSOL, TRIMETHOPRIM HYDROCHLORIDE
PRINCIPEN '125', AMPICILLIN/AMPICILLIN TRIHYDRATE
PRINCIPEN '250', AMPICILLIN/AMPICILLIN TRIHYDRATE
PRINCIPEN '500', AMPICILLIN/AMPICILLIN TRIHYDRATE
PRINCIPEN W/ PROBENECID, AMPICILLIN/AMPICILLIN TRIHYDRATE
PRINCIPEN, AMPICILLIN/AMPICILLIN TRIHYDRATE
PRINIVIL, LISINOPRIL
PRINZIDE, HYDROCHLOROTHIAZIDE
PRISCOLINE, TOLAZOLINE HYDROCHLORIDE
PRO-BANTHINE, PROPANTHELINE BROMIDE
PROAMATINE, MIDODRINE HYDROCHLORIDE
PROBALAN, PROBENECID
PROBAMPACIN, AMPICILLIN/AMPICILLIN TRIHYDRATE
PROBEN-C, COLCHICINE
PROBENECID AND COLCHICINE, COLCHICINE
PROBENECID W/ COLCHICINE, COLCHICINE
PROBENECID, PROBENECID
PROCAINAMIDE HCL, PROCAINAMIDE HYDROCHLORIDE
PROCAINE HCL W/ EPINEPHRINE, EPINEPHRINE
PROCAINE HCL, PROCAINE HYDROCHLORIDE
PROCALAMINE, AMINO ACIDS
PROCAN SR, PROCAINAMIDE HYDROCHLORIDE
PROCAN, PROCAINAMIDE HYDROCHLORIDE
PROCANBID, PROCAINAMIDE HYDROCHLORIDE
PROCAPAN, PROCAINAMIDE HYDROCHLORIDE
PROCARDIA XL, NIFEDIPINE
PROCARDIA, NIFEDIPINE
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE

FDA data supplied by DrugPatentWatch.com

PROCHLORPERAZINE, PROCHLORPERAZINE
PROCHLORPERAZINE, PROCHLORPERAZINE EDISYLATE
PROCHLORPERAZINE, PROCHLORPERAZINE MALEATE
PROCTOCORT, HYDROCORTISONE
PROCTOFOAM HC, HYDROCORTISONE ACETATE
PROFEN, IBUPROFEN (OTC)
PROFENAL, SUPROFEN
PROFERDEX, IRON DEXTRAN
PROGESTASERT, PROGESTERONE
PROGESTERONE, PROGESTERONE
PROGLYCEM, DIAZOXIDE
PROGRAF, TACROLIMUS
PROHANCE, GADOTERIDOL
PROKETAZINE, CARPHENAZINE MALEATE
PROKLAR, SULFAMETHIZOLE
PROLIXIN DECANOATE, FLUPHENAZINE DECANOATE
PROLIXIN ENANTHATE, FLUPHENAZINE ENANTHATE
PROLIXIN, FLUPHENAZINE HYDROCHLORIDE
PROLOID, THYROGLOBULIN
PROLOPRIM, TRIMETHOPRIM
PROMAPAR, CHLORPROMAZINE HYDROCHLORIDE
PROMAZINE HCL, PROMAZINE HYDROCHLORIDE
PROMETA, METAPROTERENOL SULFATE
PROMETH FORTIS, PROMETHAZINE HYDROCHLORIDE
PROMETH PLAIN, PROMETHAZINE HYDROCHLORIDE
PROMETH VC PLAIN, PHENYLEPHRINE HYDROCHLORIDE
PROMETH VC W/ CODEINE, CODEINE PHOSPHATE
PROMETH W/ CODEINE, CODEINE PHOSPHATE
PROMETH W/ DEXTROMETHORPHAN, DEXTROMETHORPHAN HYDROBROMIDE
PROMETHACON, PROMETHAZINE HYDROCHLORIDE
PROMETHAZINE HCL AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
PROMETHAZINE HCL AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN HYDROBROMIDE
PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE
PROMETHAZINE PLAIN, PROMETHAZINE HYDROCHLORIDE
PROMETHAZINE VC PLAIN, PHENYLEPHRINE HYDROCHLORIDE
PROMETHAZINE VC W/ CODEINE, CODEINE PHOSPHATE
PROMETHAZINE W/ CODEINE, CODEINE PHOSPHATE
PROMETHAZINE W/ DEXTROMETHORPHAN, DEXTROMETHORPHAN HYDROBROMIDE
PROMETHAZINE, PROMETHAZINE HYDROCHLORIDE
PROMETHEGAN, PROMETHAZINE HYDROCHLORIDE
PROMETRIUM, PROGESTERONE
PROMPT PHENYTOIN SODIUM, PHENYTOIN SODIUM, PROMPT
PRONESTYL, PROCAINAMIDE HYDROCHLORIDE
PRONESTYL-SR, PROCAINAMIDE HYDROCHLORIDE
PROPACET 100, ACETAMINOPHEN
PROPAFENONE HCL, PROPAFENONE HYDROCHLORIDE
PROPANTHELINE BROMIDE, PROPANTHELINE BROMIDE
PROPARACAINE HCL, PROPARACAINE HYDROCHLORIDE
PROPECIA, FINASTERIDE
PROPHENE 65, PROPOXYPHENE HYDROCHLORIDE
PROPINE, DIPIVEFRIN HYDROCHLORIDE
PROPOFOL, PROPOFOL
PROPOXYPHENE COMPOUND 65, ASPIRIN
PROPOXYPHENE COMPOUND-65, ASPIRIN
PROPOXYPHENE HCL 65, PROPOXYPHENE HYDROCHLORIDE
PROPOXYPHENE HCL AND ACETAMINOPHEN, ACETAMINOPHEN
PROPOXYPHENE HCL W/ ASPIRIN AND CAFFEINE, ASPIRIN
PROPOXYPHENE HCL, PROPOXYPHENE HYDROCHLORIDE
PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN, ACETAMINOPHEN
PROPRANOLOL HCL & HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
PROPRANOLOL HCL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
PROPRANOLOL HCL INTENSOL, PROPRANOLOL HYDROCHLORIDE
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
PROPULSID QUICKSOLV, CISAPRIDE MONOHYDRATE
PROPULSID, CISAPRIDE MONOHYDRATE
PROPYLTHIOURACIL, PROPYLTHIOURACIL
PROSCAR, FINASTERIDE
PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER, AMINO ACIDS
PROSOM, ESTAZOLAM
PROSTAPHLIN, OXACILLIN SODIUM
PROSTEP, NICOTINE
PROSTEP, NICOTINE (OTC)
PROSTIN E2, DINOPROSTONE
PROSTIN F2 ALPHA, DINOPROST TROMETHAMINE
PROSTIN VR PEDIATRIC, ALPROSTADIL
PROTAMINE SULFATE, PROTAMINE SULFATE
PROTAMINE ZINC AND ILETIN II (PORK), INSULIN SUSP PROTAMINE ZINC PURIFIED PORK (OTC)
PROTAMINE ZINC AND ILETIN II, INSULIN SUSP PROTAMINE ZINC PURIFIED BEEF (OTC)
PROTAMINE ZINC INSULIN, INSULIN SUSP PROTAMINE ZINC PURIFIED BEEF (OTC)
PROTAMINE, ZINC & ILETIN I (BEEF-PORK), INSULIN SUSP PROTAMINE ZINC BEEF/PORK (OTC)
PROTONIX IV, PANTOPRAZOLE SODIUM
PROTONIX, PANTOPRAZOLE SODIUM
PROTOPAM CHLORIDE, PRALIDOXIME CHLORIDE
PROTOPIC, TACROLIMUS
PROTOSTAT, METRONIDAZOLE
PROTROPIN, SOMATREM
PROVAL #3, ACETAMINOPHEN
PROVENTIL, ALBUTEROL
PROVENTIL, ALBUTEROL SULFATE
PROVENTIL-HFA, ALBUTEROL SULFATE
PROVERA, MEDROXYPROGESTERONE ACETATE
PROVIGIL, MODAFINIL
PROVOCHOLINE, METHACHOLINE CHLORIDE
PROZAC WEEKLY, FLUOXETINE HYDROCHLORIDE
PROZAC, FLUOXETINE HYDROCHLORIDE
PSEUDO-12, PSEUDOEPHEDRINE POLISTIREX (OTC)
PSEUDOEPHEDRINE HCL AND CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE (OTC)
PSEUDOEPHEDRINE HCL AND TRIPROLIDINE HCL, PSEUDOEPHEDRINE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

PSEUDOEPHEDRINE HCL, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
PSEUDOEPHEDRINE HCL/CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE (OTC)
PSORCON, DIFLORASONE DIACETATE
PULMICORT RESPULES, BUDESONIDE
PULMICORT, BUDESONIDE
PULMOLITE, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT
PURIFIED CORTROPHIN GEL, CORTICOTROPIN
PURINETHOL, MERCAPTOPURINE
PYLORI-CHEK BREATH TEST, UREA, C-13
PYOCIDIN, HYDROCORTISONE
PYOPEN, CARBENICILLIN DISODIUM
PYRAZINAMIDE, PYRAZINAMIDE
PYRIDAMAL 100, CHLORPHENIRAMINE MALEATE
PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
PYRIDOXINE HCL, PYRIDOXINE HYDROCHLORIDE
PYRILAMINE MALEATE, PYRILAMINE MALEATE
PYROLITE, TECHNETIUM TC-99M PYRO/TRIMETA PHOSPHATES KIT
PYTEST KIT, UREA, C-14
PYTEST, UREA, C-14

** Q **

Q-GESIC, ASPIRIN
Q-PAM, DIAZEPAM
QUADRAMET, SAMARIUM SM 153 LEXIDRONAM PENTASODIUM
QUARZAN, CLIDINIUM BROMIDE
QUELICIN PRESERVATIVE FREE, SUCCINYLCHOLINE CHLORIDE
QUELICIN, SUCCINYLCHOLINE CHLORIDE
QUESTRAN LIGHT, CHOLESTYRAMINE
QUESTRAN, CHOLESTYRAMINE
QUIBRON-T, THEOPHYLLINE
QUIBRON-T/SR, THEOPHYLLINE
QUIDE, PIPERACETAZINE
QUINACT, QUINIDINE GLUCONATE
QUINAGLUTE, QUINIDINE GLUCONATE
QUINALAN, QUINIDINE GLUCONATE
QUINATIME, QUINIDINE GLUCONATE
QUINIDEX, QUINIDINE SULFATE
QUINIDINE GLUCONATE, QUINIDINE GLUCONATE
QUINIDINE SULFATE, QUINIDINE SULFATE
QUINORA, QUINIDINE SULFATE
QUIXIN, LEVOFLOXACIN
QVAR 40, BECLOMETHASONE DIPROPIONATE
QVAR 80, BECLOMETHASONE DIPROPIONATE

** R **

R-GENE 10, ARGININE HYDROCHLORIDE
R-P MYCIN, ERYTHROMYCIN
RADIO-IODINATED (I 125) SERUM ALBUMIN (HUMAN), ALBUMIN IODINATED I-125 SERUM
RADIOIODINATED SERUM ALBUMIN (HUMAN) IHSA I 125, ALBUMIN IODINATED I-125 SERUM
RADIONUCLIDE-LABELED (125 I) FIBRINOGEN (HUMAN) SENSOR, FIBRINOGEN, I-125
RANITIDINE HCL, RANITIDINE HYDROCHLORIDE
RANITIDINE, RANITIDINE HYDROCHLORIDE
RANITIDINE, RANITIDINE HYDROCHLORIDE (OTC)
RAPAMUNE, SIROLIMUS
RAPLON, RAPACURONIUM BROMIDE
RAU-SED, RESERPINE
RAUDIXIN, RAUWOLFIA SERPENTINA
RAUSERPIN, RAUWOLFIA SERPENTINA
RAUTENSIN, ALSEROXYLON
RAUVAL, RAUWOLFIA SERPENTINA
RAUWILOID, ALSEROXYLON
RAUWOLFIA SERPENTINA, RAUWOLFIA SERPENTINA
RAVOCAINE AND NOVOCAIN W/ LEVOPHED, NOREPINEPHRINE BITARTRATE
RAVOCAINE AND NOVOCAIN W/ NEO-COBEFRIN, LEVONORDEFRIN
RAXAR, GREPAFLOXACIN HYDROCHLORIDE
RBC-SCAN, TECHNETIUM TC-99M RED BLOOD CELL KIT
REBETOL, RIBAVIRIN
REDISOL, CYANOCOBALAMIN
REFLUDAN, LEPIRUDIN
REGITINE, PHENTOLAMINE MESYLATE
REGLAN, METOCLOPRAMIDE HYDROCHLORIDE
REGONOL, PYRIDOSTIGMINE BROMIDE
REGROTON, CHLORTHALIDONE
REGULAR ILETIN II (PORK), INSULIN PURIFIED PORK (OTC)
REGULAR ILETIN II, INSULIN PURIFIED BEEF (OTC)
REGULAR INSULIN, INSULIN PORK (OTC)
REGULAR PURIFIED PORK INSULIN, INSULIN PURIFIED PORK (OTC)
RELA, CARISOPRODOL
RELAFEN, NABUMETONE
RELENZA, ZANAMIVIR
REMERON SOLTAB, MIRTAZAPINE
REMERON, MIRTAZAPINE
REMINYL, GALANTAMINE HYDROBROMIDE
REMSED, PROMETHAZINE HYDROCHLORIDE
RENACIDIN, CITRIC ACID
RENAGEL, SEVELAMER HYDROCHLORIDE
RENAMIN W/O ELECTROLYTES, AMINO ACIDS
RENESE, POLYTHIAZIDE
RENESE-R, POLYTHIAZIDE
RENO-30, DIATRIZOATE MEGLUMINE
RENO-60, DIATRIZOATE MEGLUMINE
RENO-DIP, DIATRIZOATE MEGLUMINE
RENOCAL-76, DIATRIZOATE MEGLUMINE
RENOGRAFIN-60, DIATRIZOATE MEGLUMINE
RENOGRAFIN-76, DIATRIZOATE MEGLUMINE
RENOQUID, SULFACYTINE
RENORMAX, SPIRAPRIL HYDROCHLORIDE
RENOTEC, TECHNETIUM TC-99M FERPENTETATE KIT
RENOVA, TRETINOIN

FDA data supplied by DrugPatentWatch.com

RENOVIST II, DIATRIZOATE MEGLUMINE
RENOVIST, DIATRIZOATE MEGLUMINE
RENOVUE-65, IODAMIDE MEGLUMINE
RENOVUE-DIP, IODAMIDE MEGLUMINE
REPRONEX, MENOTROPINS (FSH;LH)
REQUIP, ROPINIROLE HYDROCHLORIDE
RESCRIPTOR, DELAVIRDINE MESYLATE
RESCULA, UNOPROSTONE ISOPROPYL
RESECTISOL IN PLASTIC CONTAINER, MANNITOL
RESECTISOL, MANNITOL
RESERPINE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
RESERPINE AND HYDROCHLOROTHIAZIDE-50, HYDROCHLOROTHIAZIDE
RESERPINE AND HYDROFLUMETHIAZIDE, HYDROFLUMETHIAZIDE
RESERPINE, HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE, HYDRALAZINE HYDROCHLORIDE
RESERPINE, HYDROCHLOROTHIAZIDE, AND HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
RESERPINE, RESERPINE
RESPORAL, DEXBROMPHENIRAMINE MALEATE (OTC)
RESTORIL, TEMAZEPAM
RETET, TETRACYCLINE HYDROCHLORIDE
RETIN-A MICRO, TRETINOIN
RETIN-A, TRETINOIN
RETROVIR, ZIDOVUDINE
REV-EYES, DAPIPRAZOLE HYDROCHLORIDE
REVERSOL, EDROPHONIUM CHLORIDE
REVEX, NALMEFENE HYDROCHLORIDE
REVIA, NALTREXONE HYDROCHLORIDE
REZIPAS, AMINOSALICYLIC ACID RESIN COMPLEX
REZULIN, TROGLITAZONE
RHINOCORT, BUDESONIDE
RID MOUSSE, PIPERONYL BUTOXIDE (OTC)
RIDAURA, AURANOFIN
RIFADIN, RIFAMPIN
RIFAMATE, ISONIAZID
RIFAMPIN, RIFAMPIN
RIFATER, ISONIAZID
RILUTEK, RILUZOLE
RIMACTANE, RIFAMPIN
RIMADYL, CARPROFEN
RIMANTADINE HCL, RIMANTADINE HYDROCHLORIDE
RIMIFON, ISONIAZID
RIMSO-50, DIMETHYL SULFOXIDE
RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
RISPERDAL, RISPERIDONE
RITALIN, METHYLPHENIDATE HYDROCHLORIDE
RITALIN-SR, METHYLPHENIDATE HYDROCHLORIDE
RITODRINE HCL IN DEXTROSE 5% IN PLASTIC CONTAINER, RITODRINE HYDROCHLORIDE
RITODRINE HCL, RITODRINE HYDROCHLORIDE
ROBAXIN, METHOCARBAMOL
ROBAXIN-750, METHOCARBAMOL
ROBAXISAL, ASPIRIN
ROBENGATOPE, ROSE BENGAL SODIUM, I-131
ROBIMYCIN, ERYTHROMYCIN
ROBINUL FORTE, GLYCOPYRROLATE
ROBINUL, GLYCOPYRROLATE
ROBITET, TETRACYCLINE HYDROCHLORIDE
ROCALTROL, CALCITRIOL
ROCEPHIN KIT, CEFTRIAXONE SODIUM
ROCEPHIN W/ DEXTROSE IN PLASTIC CONTAINER, CEFTRIAXONE SODIUM
ROCEPHIN, CEFTRIAXONE SODIUM
ROGAINE (FOR MEN), MINOXIDIL (OTC)
ROGAINE (FOR WOMEN), MINOXIDIL (OTC)
ROGAINE EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
ROMAZICON, FLUMAZENIL
RONDOMYCIN, METHACYCLINE HYDROCHLORIDE
ROWASA, MESALAMINE
ROXICET 5/500, ACETAMINOPHEN
ROXICET, ACETAMINOPHEN
ROXICODONE, OXYCODONE HYDROCHLORIDE
ROXILOX, ACETAMINOPHEN
ROXIPRIN, ASPIRIN
RUBEX, DOXORUBICIN HYDROCHLORIDE
RUBIVITE, CYANOCOBALAMIN
RUBRAMIN PC, CYANOCOBALAMIN
RUBRATOPE-57 KIT, COBALT CHLORIDE, CO-57
RUBRATOPE-57, CYANOCOBALAMIN, CO-57
RUBRATOPE-60 KIT, COBALT CHLORIDE, CO-60
RUBRATOPE-60, CYANOCOBALAMIN, CO-60
RUFEN, IBUPROFEN
RUVITE, CYANOCOBALAMIN
RYTHMOL, PROPAFENONE HYDROCHLORIDE

** S **

S.A.S.-500, SULFASALAZINE
SAIZEN, SOMATROPIN RECOMBINANT
SALAGEN, PILOCARPINE HYDROCHLORIDE
SALPIX, ACETRIZOATE SODIUM
SALURON, HYDROFLUMETHIAZIDE
SALUTENSIN, HYDROFLUMETHIAZIDE
SALUTENSIN-DEMI, HYDROFLUMETHIAZIDE
SANDIMMUNE, CYCLOSPORINE
SANDOSTATIN LAR, OCTREOTIDE ACETATE
SANDOSTATIN, OCTREOTIDE ACETATE
SANDRIL, RESERPINE
SANOREX, MAZINDOL
SANSAC, ERYTHROMYCIN
SANSERT, METHYSERGIDE MALEATE
SARAFEM, FLUOXETINE HYDROCHLORIDE
SARENIN, SARALASIN ACETATE
SARISOL NO. 1, BUTABARBITAL SODIUM
SARISOL NO. 2, BUTABARBITAL SODIUM
SARISOL, BUTABARBITAL SODIUM

FDA data supplied by DrugPatentWatch.com

SATRIC, METRONIDAZOLE
SCABENE, LINDANE
SCANDONEST L, LEVONORDEFRIN
SCANDONEST PLAIN, MEPIVACAINE HYDROCHLORIDE
SCLEROSOL, TALC
SCRUBTEAM SURGICAL SPONGEBRUSH, HEXACHLOROPHENE
SECOBARBITAL SODIUM, SECOBARBITAL SODIUM
SECONAL SODIUM, SECOBARBITAL SODIUM
SECRETIN-FERRING, SECRETIN
SECTRAL, ACEBUTOLOL HYDROCHLORIDE
SEDAPAP, ACETAMINOPHEN
SEFFIN, CEPHALOTHIN SODIUM
SELEGILINE HCL, SELEGILINE HYDROCHLORIDE
SELENIUM SULFIDE, SELENIUM SULFIDE
SELENOMETHIONINE SE 75, SELENOMETHIONINE, SE-75
SELSUN, SELENIUM SULFIDE
SEMILENTE INSULIN, INSULIN ZINC SUSP PROMPT BEEF (OTC)
SEMILENTE, INSULIN ZINC SUSP PROMPT PURIFIED PORK (OTC)
SEMPREX-D, ACRIVASTINE
SENSORCAINE, BUPIVACAINE HYDROCHLORIDE
SEPTI-SOFT, HEXACHLOROPHENE
SEPTISOL, HEXACHLOROPHENE
SEPTOCAINE, ARTICAINE HYDROCHLORIDE
SEPTRA DS, SULFAMETHOXAZOLE
SEPTRA GRAPE, SULFAMETHOXAZOLE
SEPTRA, SULFAMETHOXAZOLE
SER-A-GEN, HYDRALAZINE HYDROCHLORIDE
SER-AP-ES, HYDRALAZINE HYDROCHLORIDE
SERAX, OXAZEPAM
SERENTIL, MESORIDAZINE BESYLATE
SEREVENT, SALMETEROL XINAFOATE
SEROMYCIN, CYCLOSERINE
SEROPHENE, CLOMIPHENE CITRATE
SEROQUEL, QUETIAPINE FUMARATE
SEROSTIM, SOMATROPIN RECOMBINANT
SERPALAN, RESERPINE
SERPANRAY, RESERPINE
SERPASIL, RESERPINE
SERPASIL-APRESOLINE, HYDRALAZINE HYDROCHLORIDE
SERPASIL-ESIDRIX #1, HYDROCHLOROTHIAZIDE
SERPASIL-ESIDRIX #2, HYDROCHLOROTHIAZIDE
SERPATE, RESERPINE
SERPIVITE, RESERPINE
SERVISONE, PREDNISONE
SERZONE, NEFAZODONE HYDROCHLORIDE
SETHOTOPE, SELENOMETHIONINE, SE-75
SHADE UVAGUARD, AVOBENZONE (OTC)
SILDAFLO, SILVER SULFADIAZINE
SILPHEN, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
SILVADENE, SILVER SULFADIAZINE
SINE-AID IB, IBUPROFEN (OTC)
SINEMET CR, CARBIDOPA
SINEMET, CARBIDOPA
SINEQUAN, DOXEPIN HYDROCHLORIDE
SINGULAIR, MONTELUKAST SODIUM
SINOGRAFIN, DIATRIZOATE MEGLUMINE
SKELAXIN, METAXALONE
SKELID, TILUDRONATE DISODIUM
SKIN EXPOSURE REDUCTION PASTE AGAINST CHEMICAL WARFARE AGENTS, PERFLUOROPOLYMETHYLISOPROPYL ETHER
SLO-BID, THEOPHYLLINE
SLO-PHYLLIN, THEOPHYLLINE
SLOW-K, POTASSIUM CHLORIDE
SODIUM ACETATE IN PLASTIC CONTAINER, SODIUM ACETATE, ANHYDROUS
SODIUM AMINOSALICYLATE, AMINOSALICYLATE SODIUM
SODIUM BICARBONATE IN PLASTIC CONTAINER, SODIUM BICARBONATE
SODIUM BUTABARBITAL, BUTABARBITAL SODIUM
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.224%, POTASSIUM CHLORIDE
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% IN STERILE PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 23.4% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 3% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 5% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE, SODIUM CHLORIDE
SODIUM CHROMATE CR 51, SODIUM CHROMATE, CR-51
SODIUM HEPARIN, HEPARIN SODIUM
SODIUM IODIDE I 123, SODIUM IODIDE, I-123
SODIUM IODIDE I 131, SODIUM IODIDE, I-131
SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER, SODIUM LACTATE
SODIUM LACTATE 1/6 MOLAR IN PLASTIC CONTAINER, SODIUM LACTATE
SODIUM LACTATE IN PLASTIC CONTAINER, SODIUM LACTATE
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
SODIUM P.A.S., AMINOSALICYLATE SODIUM
SODIUM PENTOBARBITAL, PENTOBARBITAL SODIUM
SODIUM PERTECHNETATE TC 99M, TECHNETIUM TC-99M SODIUM PERTECHNETATE
SODIUM PHOSPHATE P 32, SODIUM PHOSPHATE, P-32
SODIUM PHOSPHATES IN PLASTIC CONTAINER, SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE
SODIUM POLYPHOSPHATE-TIN KIT, TECHNETIUM TC-99M POLYPHOSPHATE KIT

FDA data supplied by DrugPatentWatch.com

SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE
SODIUM ROSE BENGAL I 131, ROSE BENGAL SODIUM, I-131
SODIUM SECOBARBITAL, SECOBARBITAL SODIUM
SODIUM SUCCINATE, SODIUM SUCCINATE
SODIUM SULAMYD, SULFACETAMIDE SODIUM
SODIUM SULFACETAMIDE, SULFACETAMIDE SODIUM
SODIUM THIOSULFATE, SODIUM THIOSULFATE
SODIUM VERSENATE, EDETATE DISODIUM
SOLAGE, MEQUINOL
SOLARAZE, DICLOFENAC SODIUM
SOLATENE, BETA-CAROTENE
SOLU-CORTEF, HYDROCORTISONE SODIUM SUCCINATE
SOLU-MEDROL, METHYLPREDNISOLONE SODIUM SUCCINATE
SOMA COMPOUND W/ CODEINE, ASPIRIN
SOMA COMPOUND, ASPIRIN
SOMA, CARISOPRODOL
SOMOPHYLLIN, AMINOPHYLLINE
SOMOPHYLLIN-CRT, THEOPHYLLINE
SOMOPHYLLIN-DF, AMINOPHYLLINE
SOMOPHYLLIN-T, THEOPHYLLINE
SONATA, ZALEPLON
SONAZINE, CHLORPROMAZINE HYDROCHLORIDE
SONORX, SIMETHICONE-CELLULOSE
SORBITOL 3% IN PLASTIC CONTAINER, SORBITOL
SORBITOL 3.3% IN PLASTIC CONTAINER, SORBITOL
SORBITOL-MANNITOL IN PLASTIC CONTAINER, MANNITOL
SORBITOL-MANNITOL, MANNITOL
SORBITRATE, ISOSORBIDE DINITRATE
SORIATANE, ACITRETIN
SORINE, SOTALOL HYDROCHLORIDE
SOSOL, SULFISOXAZOLE
SOTALOL HCL, SOTALOL HYDROCHLORIDE
SOTRADECOL, SODIUM TETRADECYL SULFATE
SOXAZOLE, SULFISOXAZOLE
SOY-DOME, HEXACHLOROPHENE
SOYACAL 10%, SOYBEAN OIL
SOYACAL 20%, SOYBEAN OIL
SPARINE, PROMAZINE HYDROCHLORIDE
SPECTAMINE, IOFETAMINE HYDROCHLORIDE I-123
SPECTAZOLE, ECONAZOLE NITRATE
SPECTRACEF, CEFDITOREN PIVOXIL
SPECTROBID, BACAMPICILLIN HYDROCHLORIDE
SPIRONOLACTONE + HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPIRONOLACTONE, SPIRONOLACTONE
SPIRONOLACTONE/HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPORANOX, ITRACONAZOLE
SPRX-105, PHENDIMETRAZINE TARTRATE
SPRX-3, PHENDIMETRAZINE TARTRATE
SPS, SODIUM POLYSTYRENE SULFONATE
SSD AF, SILVER SULFADIAZINE
SSD, SILVER SULFADIAZINE
STADOL PRESERVATIVE FREE, BUTORPHANOL TARTRATE
STADOL, BUTORPHANOL TARTRATE
STANOZIDE, ISONIAZID
STAPHCILLIN, METHICILLIN SODIUM
STARLIX, NATEGLINIDE
STATICIN, ERYTHROMYCIN
STATOBEX, PHENDIMETRAZINE TARTRATE
STATOBEX-G, PHENDIMETRAZINE TARTRATE
STATROL, NEOMYCIN SULFATE
STELAZINE, TRIFLUOPERAZINE HYDROCHLORIDE
STERANE, PREDNISOLONE
STERANE, PREDNISOLONE ACETATE
STERI-STAT, CHLORHEXIDINE GLUCONATE (OTC)
STERILE UREA, UREA
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, WATER FOR INJECTION, STERILE
STERILE WATER IN PLASTIC CONTAINER, WATER FOR IRRIGATION, STERILE
STERILE WATER, WATER FOR IRRIGATION, STERILE
STIE-CORT, HYDROCORTISONE
STILBESTROL, DIETHYLSTILBESTROL
STILBETIN, DIETHYLSTILBESTROL
STILPHOSTROL, DIETHYLSTILBESTROL DIPHOSPHATE
STIMATE, DESMOPRESSIN ACETATE
STOXIL, IDOXURIDINE
STREPTOMYCIN SULFATE, STREPTOMYCIN SULFATE
STRIFON FORTE DSC, CHLORZOXAZONE
STROMECTOL, IVERMECTIN
SUBLIMAZE PRESERVATIVE FREE, FENTANYL CITRATE
SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
SUCOSTRIN, SUCCINYLCHOLINE CHLORIDE
SUCRAID, SACROSIDASE
SUCRALFATE, SUCRALFATE
SUDAFED 12 HOUR, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
SUFENTA, SUFENTANIL CITRATE
SUFENTANIL CITRATE, SUFENTANIL CITRATE
SULAR, NISOLDIPINE
SULF-10, SULFACETAMIDE SODIUM
SULF-15, SULFACETAMIDE SODIUM
SULFA-TRIPLE #2, TRISULFAPYRIMIDINES (SULFADIAZINE; SULFAMERAZINE;SULFAMETHAZINE)
SULFABID, SULFAPHENAZOLE
SULFACEL-15, SULFACETAMIDE SODIUM
SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
SULFADIAZINE SODIUM, SULFADIAZINE SODIUM
SULFADIAZINE, TRISULFAPYRIMIDINES (SULFADIAZINE; SULFAMERAZINE;SULFAMETHAZINE)
SULFAIR 10, SULFACETAMIDE SODIUM
SULFAIR FORTE, SULFACETAMIDE SODIUM
SULFAIR-15, SULFACETAMIDE SODIUM
SULFALAR, SULFISOXAZOLE

FDA data supplied by DrugPatentWatch.com

SULFALOID, TRISULFAPYRIMIDINES (SULFADIAZINE;SULFAMERAZINE; SULFAMETHAZINE)
SULFAMETHOPRIM, SULFAMETHOXAZOLE
SULFAMETHOPRIM-DS, SULFAMETHOXAZOLE
SULFAMETHOXAZOLE & TRIMETHOPRIM, SULFAMETHOXAZOLE
SULFAMETHOXAZOLE AND TRIMETHOPRIM AND PENAZOPYRIDINE HCL, PHENAZOPYRIDINE HYDROCHLORIDE
SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH, SULFAMETHOXAZOLE
SULFAMETHOXAZOLE AND TRIMETHOPRIM SINGLE STRENGTH, SULFAMETHOXAZOLE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
SULFAMETHOXAZOLE, SULFAMETHOXAZOLE
SULFAMYLON, MAFENIDE ACETATE
SULFANILAMIDE, SULFANILAMIDE
SULFAPYRIDINE, SULFAPYRIDINE
SULFASALAZINE, SULFASALAZINE
SULFATRIM PEDIATRIC, SULFAMETHOXAZOLE
SULFATRIM, SULFAMETHOXAZOLE
SULFATRIM-DS, SULFAMETHOXAZOLE
SULFATRIM-SS, SULFAMETHOXAZOLE
SULFENTANIL CITRATE, SUFENTANIL CITRATE
SULFINPYRAZONE, SULFINPYRAZONE
SULFISOXAZOLE DIOLAMINE, SULFISOXAZOLE DIOLAMINE
SULFISOXAZOLE, SULFISOXAZOLE
SULFONAMIDES DUPLEX, TRISULFAPYRIMIDINES (SULFADIAZINE; SULFAMERAZINE;SULFAMETHAZINE)
SULFOSE, TRISULFAPYRIMIDINES (SULFADIAZINE;SULFAMERAZINE; SULFAMETHAZINE)
SULINDAC, SULINDAC
SULLA, SULFAMETER
SULMEPRIM PEDIATRIC, SULFAMETHOXAZOLE
SULMEPRIM, SULFAMETHOXAZOLE
SULPHRIN, PREDNISOLONE ACETATE
SULSOXIN, SULFISOXAZOLE
SULSTER, PREDNISOLONE SODIUM PHOSPHATE
SULTEN-10, SULFACETAMIDE SODIUM
SULTRIN, TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE; SULFATHIAZOLE)
SUMYCIN, TETRACYCLINE HYDROCHLORIDE
SUPPRELIN, HISTRELIN ACETATE
SUPRANE, DESFLURANE
SUPRAX, CEFIXIME
SURITAL, THIAMYLAL SODIUM
SURMONTIL, TRIMIPRAMINE MALEATE
SURVANTA, BERACTANT
SUS-PHRINE SULFITE-FREE, EPINEPHRINE
SUSTAIRE, THEOPHYLLINE
SUSTIVA, EFAVIRENZ
SYMADINE, AMANTADINE HYDROCHLORIDE
SYMMETREL, AMANTADINE HYDROCHLORIDE
SYNACORT, HYDROCORTISONE
SYNALAR, FLUOCINOLONE ACETONIDE
SYNALAR-HP, FLUOCINOLONE ACETONIDE
SYNALGOS-DC, ASPIRIN
SYNALGOS-DC-A, ACETAMINOPHEN
SYNAREL, NAFARELIN ACETATE
SYNCURINE, DECAMETHONIUM BROMIDE
SYNERCID, DALFOPRISTIN
SYNKAYVITE, MENADIOL SODIUM DIPHOSPHATE
SYNOPHYLATE, THEOPHYLLINE SODIUM GLYCINATE
SYNOVALYTE IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
SYNTOCINON, OXYTOCIN
SYPRINE, TRIENTINE HYDROCHLORIDE

** T **

T-PHYL, THEOPHYLLINE
T-STAT, ERYTHROMYCIN
TAB-PROFEN, IBUPROFEN (OTC)
TACARYL, METHDILAZINE
TACARYL, METHDILAZINE HYDROCHLORIDE
TACE, CHLOROTRIANISENE
TAGAMET HB 200, CIMETIDINE (OTC)
TAGAMET HB, CIMETIDINE (OTC)
TAGAMET HCL IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, CIMETIDINE HYDROCHLORIDE
TAGAMET, CIMETIDINE
TAGAMET, CIMETIDINE HYDROCHLORIDE
TALACEN, ACETAMINOPHEN
TALWIN 50, PENTAZOCINE HYDROCHLORIDE
TALWIN COMPOUND, ASPIRIN
TALWIN NX, NALOXONE HYDROCHLORIDE
TALWIN, PENTAZOCINE LACTATE
TAMBOCOR, FLECAINIDE ACETATE
TAMIFLU, OSELTAMIVIR PHOSPHATE
TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
TANDEARIL, OXYPHENBUTAZONE
TAO, TROLEANDOMYCIN
TAPAZOLE, METHIMAZOLE
TARACTAN, CHLORPROTHIXENE
TARGRETIN, BEXAROTENE
TARKA, TRANDOLAPRIL
TASMAR, TOLCAPONE
TATUM-T, COPPER
TAVIST ALLERGY/SINUS/HEADACHE, ACETAMINOPHEN (OTC)
TAVIST D, CLEMASTINE FUMARATE
TAVIST, CLEMASTINE FUMARATE
TAVIST-1, CLEMASTINE FUMARATE
TAVIST-1, CLEMASTINE FUMARATE (OTC)
TAVIST-D, CLEMASTINE FUMARATE (OTC)
TAXOL, PACLITAXEL
TAXOTERE, DOCETAXEL
TAZICEF, CEFTAZIDIME
TAZIDIME IN PLASTIC CONTAINER, CEFTAZIDIME
TAZIDIME, CEFTAZIDIME

FDA data supplied by DrugPatentWatch.com

TAZORAC, TAZAROTENE
TC 99M-LUNGAGGREGATE, TECHNETIUM TC-99M ALBUMIN AGGREGATED
TECHNECOLL, TECHNETIUM TC-99M SULFUR COLLOID KIT
TECHNELITE, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
TECHNESCAN GLUCEPTATE, TECHNETIUM TC-99M GLUCEPTATE KIT
TECHNESCAN HDP, TECHNETIUM TC-99M OXIDRONATE KIT
TECHNESCAN HIDA, TECHNETIUM TC-99M LIDOFENIN KIT
TECHNESCAN MAA, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT
TECHNESCAN MAG3, TECHNETIUM TC-99M MERTIATIDE KIT
TECHNESCAN MDP KIT, TECHNETIUM TC-99M MEDRONATE KIT
TECHNESCAN PYP KIT, TECHNETIUM TC-99M PYROPHOSPHATE KIT
TECHNETIUM TC 99M ALBUMIN AGGREGATED KIT, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT
TECHNETIUM TC 99M DIPHOSPHONATE-TIN KIT, TECHNETIUM TC-99M ETIDRONATE KIT
TECHNETIUM TC 99M GENERATOR, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
TECHNETIUM TC 99M HSA, TECHNETIUM TC-99M ALBUMIN KIT
TECHNETIUM TC 99M MAA, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT
TECHNETIUM TC 99M MPI MDP, TECHNETIUM TC-99M MEDRONATE KIT
TECHNETIUM TC 99M SULFUR COLLOID, TECHNETIUM TC-99M SULFUR COLLOID
TECHNETIUM TC 99M TSC, TECHNETIUM TC-99M SULFUR COLLOID KIT
TECHNETIUM TC-99M PENTETATE KIT, TECHNETIUM TC-99M PENTETATE KIT
TECZEM, DILTIAZEM MALATE
TEEBACIN, AMINOSALICYLATE SODIUM
TEGISON, ETRETINATE
TEGOPEN, CLOXACILLIN SODIUM
TEGRETOL, CARBAMAZEPINE
TEGRETOL-XR, CARBAMAZEPINE
TELDRIN, CHLORPHENIRAMINE MALEATE (OTC)
TELEPAQUE, IOPANOIC ACID
TEMARIL, TRIMEPRAZINE TARTRATE
TEMAZ, TEMAZEPAM
TEMAZEPAM, TEMAZEPAM
TEMODAR, TEMOZOLOMIDE
TEMOVATE E, CLOBETASOL PROPIONATE
TEMOVATE, CLOBETASOL PROPIONATE
TEN-K, POTASSIUM CHLORIDE
TENATHAN, BETHANIDINE SULFATE
TENCON, ACETAMINOPHEN
TENEX, GUANFACINE HYDROCHLORIDE
TENORETIC 100, ATENOLOL
TENORETIC 50, ATENOLOL
TENORMIN, ATENOLOL
TENSILON PRESERVATIVE FREE, EDROPHONIUM CHLORIDE
TENSILON, EDROPHONIUM CHLORIDE
TENUATE DOSPAN, DIETHYLPROPION HYDROCHLORIDE
TENUATE, DIETHYLPROPION HYDROCHLORIDE
TEPANIL TEN-TAB, DIETHYLPROPION HYDROCHLORIDE
TEPANIL, DIETHYLPROPION HYDROCHLORIDE
TEQUIN, GATIFLOXACIN
TERAZOL 3, TERCONAZOLE
TERAZOL 7, TERCONAZOLE
TERAZOSIN HCL, TERAZOSIN HYDROCHLORIDE
TERBUTALINE SULFATE, TERBUTALINE SULFATE
TERFONYL, TRISULFAPYRIMIDINES (SULFADIAZINE;SULFAMERAZINE; SULFAMETHAZINE)
TERRA-CORTRIL, HYDROCORTISONE ACETATE
TERRAMYCIN W/ POLYMYXIN B SULFATE, OXYTETRACYCLINE HYDROCHLORIDE
TERRAMYCIN W/ POLYMYXIN, OXYTETRACYCLINE HYDROCHLORIDE
TERRAMYCIN, LIDOCAINE HYDROCHLORIDE
TERRAMYCIN, OXYTETRACYCLINE
TERRAMYCIN, OXYTETRACYCLINE CALCIUM
TERRAMYCIN, OXYTETRACYCLINE HYDROCHLORIDE
TERRAMYCIN-POLYMYXIN, OXYTETRACYCLINE HYDROCHLORIDE
TESLAC, TESTOLACTONE
TESLASCAN, MANGAFODIPIR TRISODIUM
TESSALON, BENZONATATE
TESTODERM, TESTOSTERONE
TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
TESTOSTERONE CYPIONATE-ESTRADIOL CYPIONATE, ESTRADIOL CYPIONATE
TESTOSTERONE ENANTHATE AND ESTRADIOL VALERATE, ESTRADIOL VALERATE
TESTOSTERONE ENANTHATE, TESTOSTERONE ENANTHATE
TESTOSTERONE PROPIONATE, TESTOSTERONE PROPIONATE
TESTOSTERONE, TESTOSTERONE
TESTRED, METHYLTESTOSTERONE
TESULOID, TECHNETIUM TC-99M SULFUR COLLOID KIT
TETRACHEL, TETRACYCLINE HYDROCHLORIDE
TETRACYCLINE HCL, TETRACYCLINE HYDROCHLORIDE
TETRACYN, PROCAINE HYDROCHLORIDE
TETRACYN, TETRACYCLINE HYDROCHLORIDE
TETRAMED, TETRACYCLINE HYDROCHLORIDE
TETREX, TETRACYCLINE PHOSPHATE COMPLEX
TEVETEN HCT, EPROSARTAN MESYLATE
TEVETEN, EPROSARTAN MESYLATE
TEXACORT, HYDROCORTISONE
THALITONE, CHLORTHALIDONE
THALLOUS CHLORIDE TL 201, THALLOUS CHLORIDE, TL-201
THALOMID, THALIDOMIDE
THAM, TROMETHAMINE
THAM-E, POTASSIUM CHLORIDE
THEELIN, ESTRONE
THEO-24, THEOPHYLLINE
THEO-DUR, THEOPHYLLINE
THEOBID JR., THEOPHYLLINE
THEOBID, THEOPHYLLINE
THEOCHRON, THEOPHYLLINE
THEOCLEAR L.A.-130, THEOPHYLLINE
THEOCLEAR L.A.-260, THEOPHYLLINE
THEOCLEAR-100, THEOPHYLLINE

FDA data supplied by DrugPatentWatch.com

THEOCLEAR-200, THEOPHYLLINE
THEOCLEAR-80, THEOPHYLLINE
THEOLAIR, THEOPHYLLINE
THEOLAIR-SR, THEOPHYLLINE
THEOLIXIR, THEOPHYLLINE
THEOPHYL, THEOPHYLLINE
THEOPHYL-225, THEOPHYLLINE
THEOPHYL-SR, THEOPHYLLINE
THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THEOPHYLLINE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THEOPHYLLINE 0.32% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THEOPHYLLINE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THEOPHYLLINE, THEOPHYLLINE
THEOPHYLLINE-SR, THEOPHYLLINE
THEOVENT, THEOPHYLLINE
THERMAZENE, SILVER SULFADIAZINE
THIAMINE HCL, THIAMINE HYDROCHLORIDE
THIOGUANINE, THIOGUANINE
THIOPLEX, THIOTEPA
THIORIDAZINE HCL INTENSOL, THIORIDAZINE HYDROCHLORIDE
THIORIDAZINE HCL, THIORIDAZINE HYDROCHLORIDE
THIOSULFIL, SULFAMETHIZOLE
THIOTEPA, THIOTEPA
THIOTHIXENE HCL INTENSOL, THIOTHIXENE HYDROCHLORIDE
THIOTHIXENE HCL, THIOTHIXENE HYDROCHLORIDE
THIOTHIXENE, THIOTHIXENE
THORAZINE, CHLORPROMAZINE
THORAZINE, CHLORPROMAZINE HYDROCHLORIDE
THYPINONE, PROTIRELIN
THYREL TRH, PROTIRELIN
THYRO-BLOCK, POTASSIUM IODIDE (OTC)
THYROGEN, THYROTROPIN ALFA
THYROGLOBULIN, THYROGLOBULIN
THYROLAR-0.25, LIOTRIX (T4;T3)
THYROLAR-0.5, LIOTRIX (T4;T3)
THYROLAR-1, LIOTRIX (T4;T3)
THYROLAR-2, LIOTRIX (T4;T3)
THYROLAR-3, LIOTRIX (T4;T3)
THYROLAR-5, LIOTRIX (T4;T3)
THYTROPAR, THYROTROPIN
TIAMATE, DILTIAZEM MALATE
TIAZAC, DILTIAZEM HYDROCHLORIDE
TICAR, TICARCILLIN DISODIUM
TICLID, TICLOPIDINE HYDROCHLORIDE
TICLOPIDINE HCL, TICLOPIDINE HYDROCHLORIDE
TIGAN, TRIMETHOBENZAMIDE HYDROCHLORIDE
TIKOSYN, DOFETILIDE
TILADE, NEDOCROMIL SODIUM
TIMENTIN IN PLASTIC CONTAINER, CLAVULANATE POTASSIUM
TIMENTIN, CLAVULANATE POTASSIUM
TIMOLIDE 10-25, HYDROCHLOROTHIAZIDE
TIMOLOL MALEATE, TIMOLOL MALEATE
TIMOPTIC IN OCUDOSE, TIMOLOL MALEATE
TIMOPTIC, TIMOLOL MALEATE
TIMOPTIC-XE, TIMOLOL MALEATE
TINDAL, ACETOPHENAZINE MALEATE
TIOCONAZOLE, TIOCONAZOLE (OTC)
TIOPRONIN, TIOPRONIN
TIS-U-SOL IN PLASTIC CONTAINER, MAGNESIUM SULFATE
TIS-U-SOL, MAGNESIUM SULFATE
TOBI, TOBRAMYCIN
TOBRADEX, DEXAMETHASONE
TOBRAMYCIN AND DEXAMETHASONE, DEXAMETHASONE
TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, TOBRAMYCIN SULFATE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
TOBRAMYCIN, TOBRAMYCIN
TOBRAMYCIN, TOBRAMYCIN SULFATE
TOBRASONE, FLUOROMETHOLONE ACETATE
TOBREX, TOBRAMYCIN
TODAY, NONOXYNOL-9 (OTC)
TOFRANIL, IMIPRAMINE HYDROCHLORIDE
TOFRANIL-PM, IMIPRAMINE PAMOATE
TOLAZAMIDE, TOLAZAMIDE
TOLBUTAMIDE, TOLBUTAMIDE
TOLECTIN 600, TOLMETIN SODIUM
TOLECTIN DS, TOLMETIN SODIUM
TOLECTIN, TOLMETIN SODIUM
TOLINASE, TOLAZAMIDE
TOLMETIN SODIUM, TOLMETIN SODIUM
TONOCARD, TOCAINIDE HYDROCHLORIDE
TOPAMAX SPRINKLE, TOPIRAMATE
TOPAMAX, TOPIRAMATE
TOPICORT LP, DESOXIMETASONE
TOPICORT, DESOXIMETASONE
TOPICYCLINE, TETRACYCLINE HYDROCHLORIDE
TOPOSAR, ETOPOSIDE
TOPROL-XL, METOPROLOL SUCCINATE
TORA, PHENTERMINE HYDROCHLORIDE
TORADOL, KETOROLAC TROMETHAMINE
TORECAN, THIETHYLPERAZINE MALATE
TORECAN, THIETHYLPERAZINE MALEATE
TORNALATE, BITOLTEROL MESYLATE
TOTACILLIN, AMPICILLIN/AMPICILLIN TRIHYDRATE

FDA data supplied by DrugPatentWatch.com

TOTACILLIN-N, AMPICILLIN SODIUM
TPN ELECTROLYTES IN PLASTIC CONTAINER, CALCIUM CHLORIDE
TPN SUSPENSION, NIACINAMIDE
TRACLEER, BOSENTAN
TRACRIUM PRESERVATIVE FREE, ATRACURIUM BESYLATE
TRACRIUM, ATRACURIUM BESYLATE
TRAL, HEXOCYCLIUM METHYLSULFATE
TRANCOPAL, CHLORMEZANONE
TRANDATE HCT, HYDROCHLOROTHIAZIDE
TRANDATE, LABETALOL HYDROCHLORIDE
TRANMEP, MEPROBAMATE
TRANSDERM SCOP, SCOPOLAMINE
TRANSDERM-NITRO, NITROGLYCERIN
TRANXENE SD, CLORAZEPATE DIPOTASSIUM
TRANXENE, CLORAZEPATE DIPOTASSIUM
TRASICOR, OXPRENOLOL HYDROCHLORIDE
TRASYLOL, APROTININ BOVINE
TRAVAMULSION 10%, SOYBEAN OIL
TRAVAMULSION 20%, SOYBEAN OIL
TRAVASE, SUTILAINS
TRAVASOL 10% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 10% W/O ELECTROLYTES, AMINO ACIDS
TRAVASOL 2.75% IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 2.75% IN DEXTROSE 15% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 2.75% IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 2.75% IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 2.75% IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 3.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 3.5% W/ ELECTROLYTES, AMINO ACIDS
TRAVASOL 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 4.25% IN DEXTROSE 15% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 4.25% IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 5.5% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 5.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 5.5% W/ ELECTROLYTES, AMINO ACIDS
TRAVASOL 5.5% W/O ELECTROLYTES, AMINO ACIDS
TRAVASOL 8.5% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 8.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 8.5% W/ ELECTROLYTES, AMINO ACIDS
TRAVASOL 8.5% W/O ELECTROLYTES, AMINO ACIDS
TRAVATAN, TRAVOPROST
TRAVERT 10% IN PLASTIC CONTAINER, INVERT SUGAR
TRAZODONE HCL, TRAZODONE HYDROCHLORIDE
TRECATOR-SC, ETHIONAMIDE
TRELSTAR DEPOT, TRIPTORELIN PAMOATE
TRELSTAR, TRIPTORELIN PAMOATE
TREMIN, TRIHEXYPHENIDYL HYDROCHLORIDE
TRENTAL, PENTOXIFYLLINE
TREST, METHIXENE HYDROCHLORIDE
TRETINOIN, TRETINOIN
TREXALL, METHOTREXATE SODIUM
TRI-NASAL, TRIAMCINOLONE ACETONIDE
TRI-NORINYL 21-DAY, ETHINYL ESTRADIOL
TRI-NORINYL 28-DAY, ETHINYL ESTRADIOL
TRIACET, TRIAMCINOLONE ACETONIDE
TRIACIN-C, CODEINE PHOSPHATE
TRIACORT, TRIAMCINOLONE ACETONIDE
TRIAD, ACETAMINOPHEN
TRIALODINE, TRAZODONE HYDROCHLORIDE
TRIAMCINOLONE ACETONIDE IN ABSORBASE, TRIAMCINOLONE ACETONIDE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
TRIAMCINOLONE DIACETATE, TRIAMCINOLONE DIACETATE
TRIAMCINOLONE, TRIAMCINOLONE
TRIAMINIC-12, CHLORPHENIRAMINE MALEATE (OTC)
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TRIAPRIN, ACETAMINOPHEN
TRIATEX, TRIAMCINOLONE ACETONIDE
TRIAVIL 2-10, AMITRIPTYLINE HYDROCHLORIDE
TRIAVIL 2-25, AMITRIPTYLINE HYDROCHLORIDE
TRIAVIL 4-10, AMITRIPTYLINE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

TRIAVIL 4-25, AMITRIPTYLINE HYDROCHLORIDE
TRIAVIL 4-50, AMITRIPTYLINE HYDROCHLORIDE
TRIAZOLAM, TRIAZOLAM
TRICHLOREX, TRICHLORMETHIAZIDE
TRICHLORMAS, TRICHLORMETHIAZIDE
TRICHLORMETHIAZIDE W/ RESERPINE, RESERPINE
TRICHLORMETHIAZIDE, TRICHLORMETHIAZIDE
TRICLOS, TRICLOFOS SODIUM
TRICOR (MICRONIZED), FENOFIBRATE
TRICOR, FENOFIBRATE
TRIDERM, TRIAMCINOLONE ACETONIDE
TRIDESILON, ACETIC ACID, GLACIAL
TRIDESILON, DESONIDE
TRIDIL, NITROGLYCERIN
TRIDIONE, TRIMETHADIONE
TRIFLUOPERAZINE HCL, TRIFLUOPERAZINE HYDROCHLORIDE
TRIFLURIDINE, TRIFLURIDINE
TRIHEXYPHENIDYL HCL, TRIHEXYPHENIDYL HYDROCHLORIDE
TRILAFON, PERPHENAZINE
TRILEPTAL, OXCARBAZEPINE
TRILITRON, PSEUDOEPHEDRINE HYDROCHLORIDE
TRIMEPRAZINE TARTRATE, TRIMEPRAZINE TARTRATE
TRIMETH/SULFA, SULFAMETHOXAZOLE
TRIMETHOBENZAMIDE HCL, TRIMETHOBENZAMIDE HYDROCHLORIDE
TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
TRIMETHOPRIM, TRIMETHOPRIM
TRIMIPRAMINE MALEATE, TRIMIPRAMINE MALEATE
TRIMOX, AMOXICILLIN
TRIMPEX 200, TRIMETHOPRIM
TRIMPEX, TRIMETHOPRIM
TRINALIN, AZATADINE MALEATE
TRIOSTAT, LIOTRIX (T4;T3)
TRIPELENNAMINE HCL, TRIPELENNAMINE HYDROCHLORIDE
TRIPHASIL-21, ETHINYL ESTRADIOL
TRIPHASIL-28, ETHINYL ESTRADIOL
TRIPHED, PSEUDOEPHEDRINE HYDROCHLORIDE
TRIPLE SULFA, TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE; SULFATHIAZOLE)
TRIPLE SULFA, TRISULFAPYRIMIDINES (SULFADIAZINE; SULFAMERAZINE;SULFAMETHAZINE)
TRIPLE SULFAS, TRISULFAPYRIMIDINES (SULFADIAZINE; SULFAMERAZINE;SULFAMETHAZINE)
TRIPLE SULFOID, TRISULFAPYRIMIDINES (SULFADIAZINE; SULFAMERAZINE;SULFAMETHAZINE)
TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES W/ CODEINE, CODEINE PHOSPHATE
TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
TRIPROLIDINE AND PSEUDOEPHEDRINE, PSEUDOEPHEDRINE HYDROCHLORIDE
TRIPROLIDINE AND PSEUDOEPHEDRINE, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
TRIPROLIDINE HCL AND PSEUDOEPHEDRINE HCL, PSEUDOEPHEDRINE HYDROCHLORIDE
TRIPROLIDINE HCL, PSEUDOEPHEDRINE HCL AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
TRIPROLIDINE HCL, TRIPROLIDINE HYDROCHLORIDE
TRISENOX, ARSENIC TRIOXIDE
TRISORALEN, TRIOXSALEN
TRITEC, RANITIDINE BISMUTH CITRATE
TRIVAGIZOLE 3, CLOTRIMAZOLE (OTC)
TRIVORA-21, ETHINYL ESTRADIOL
TRIVORA-28, ETHINYL ESTRADIOL
TRIZIVIR, ABACAVIR SULFATE
TROBICIN, SPECTINOMYCIN HYDROCHLORIDE
TROPHAMINE 10%, AMINO ACIDS
TROPHAMINE, AMINO ACIDS
TROPICACYL, TROPICAMIDE
TROPICAMIDE, TROPICAMIDE
TROVAN PRESERVATIVE FREE, ALATROFLOXACIN MESYLATE
TROVAN, TROVAFLOXACIN MESYLATE
TROVAN/ZITHROMAX COMPLIANCE PAK, AZITHROMYCIN DIHYDRATE
TRUPHYLLINE, AMINOPHYLLINE
TRUSOPT, DORZOLAMIDE HYDROCHLORIDE
TRYMEX, TRIAMCINOLONE ACETONIDE
TRYSUL, TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE; SULFATHIAZOLE)
TUBOCURARINE CHLORIDE, TUBOCURARINE CHLORIDE
TURGEX, HEXACHLOROPHENE
TUSSIGON, HOMATROPINE METHYLBROMIDE
TUSSIONEX, CHLORPHENIRAMINE POLISTIREX
TYCOLET, ACETAMINOPHEN
TYLENOL W/ CODEINE NO. 1, ACETAMINOPHEN
TYLENOL W/ CODEINE NO. 2, ACETAMINOPHEN
TYLENOL W/ CODEINE NO. 3, ACETAMINOPHEN
TYLENOL W/ CODEINE NO. 4, ACETAMINOPHEN
TYLENOL W/ CODEINE, ACETAMINOPHEN
TYLENOL, ACETAMINOPHEN (OTC)
TYLOX, ACETAMINOPHEN
TYLOX-325, ACETAMINOPHEN
TYMTRAN, CERULETIDE DIETHYLAMINE
TYZINE, TETRAHYDROZOLINE HYDROCHLORIDE
TZ-3, TIOCONAZOLE (OTC)

** U **

U-CORT, HYDROCORTISONE ACETATE
U-GENCIN, GENTAMICIN SULFATE
UCEPHAN, SODIUM BENZOATE
ULO, CHLOPHEDIANOL HYDROCHLORIDE
ULTANE, SEVOFLURANE
ULTIVA, REMIFENTANIL HYDROCHLORIDE
ULTRA-TECHNEKOW FM, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
ULTRACEF, CEFADROXIL/CEFADROXIL HEMIHYDRATE

FDA data supplied by DrugPatentWatch.com

ULTRACET, ACETAMINOPHEN
ULTRAGRIS-165, GRISEOFULVIN, ULTRAMICROCRYSTALLINE
ULTRAGRIS-330, GRISEOFULVIN, ULTRAMICROCRYSTALLINE
ULTRALENTE INSULIN, INSULIN ZINC SUSP EXTENDED BEEF (OTC)
ULTRALENTE, INSULIN ZINC SUSP EXTENDED PURIFIED BEEF (OTC)
ULTRAM, TRAMADOL HYDROCHLORIDE
ULTRATAG, TECHNETIUM TC-99M RED BLOOD CELL KIT
ULTRAVATE, HALOBETASOL PROPIONATE
ULTRAVIST 150, IOPROMIDE
ULTRAVIST 240, IOPROMIDE
ULTRAVIST 300, IOPROMIDE
ULTRAVIST 370, IOPROMIDE
UNASYN, AMPICILLIN SODIUM
UNI-DUR, THEOPHYLLINE
UNIPEN IN PLASTIC CONTAINER, NAFCILLIN SODIUM
UNIPEN, NAFCILLIN SODIUM
UNIPHYL, THEOPHYLLINE
UNIPRES, HYDRALAZINE HYDROCHLORIDE
UNIRETIC, HYDROCHLOROTHIAZIDE
UNISOM, DOXYLAMINE SUCCINATE (OTC)
UNITENSEN, CRYPTENAMINE ACETATES
UNITENSEN, CRYPTENAMINE TANNATES
UNITHROID, LIOTRIX (T4;T3)
UNIVASC, MOEXIPRIL HYDROCHLORIDE
URACIL MUSTARD, URACIL MUSTARD
UREAPHIL, UREA
URECHOLINE, BETHANECHOL CHLORIDE
URESE, BENZTHIAZIDE
UREX, METHENAMINE HIPPURATE
URISPAS, FLAVOXATE HYDROCHLORIDE
UROBAK, SULFAMETHOXAZOLE
UROLOGIC G IN PLASTIC CONTAINER, CITRIC ACID
UROPLUS DS, SULFAMETHOXAZOLE
UROPLUS SS, SULFAMETHOXAZOLE
UROVIST CYSTO PEDIATRIC, DIATRIZOATE MEGLUMINE
UROVIST CYSTO, DIATRIZOATE MEGLUMINE
UROVIST MEGLUMINE DIU/CT, DIATRIZOATE MEGLUMINE
UROVIST SODIUM 300, DIATRIZOATE SODIUM
URSO, URSODIOL
URSODIOL, URSODIOL
UTICILLIN VK, PENICILLIN V POTASSIUM
UTICORT, BETAMETHASONE BENZOATE
UTIMOX, AMOXICILLIN
UVADEX, METHOXSALEN

** V **

V-CILLIN K, PENICILLIN V POTASSIUM
V-CILLIN, PENICILLIN V
VAGIFEM, ESTRADIOL
VAGILIA, TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE; SULFATHIAZOLE)
VAGISTAT-1, TIOCONAZOLE (OTC)
VALCYTE, VALGANCICLOVIR HYDROCHLORIDE
VALISONE, BETAMETHASONE VALERATE
VALIUM, DIAZEPAM
VALMID, ETHINAMATE
VALNAC, BETAMETHASONE VALERATE
VALPIN 50, ANISOTROPINE METHYLBROMIDE
VALPROIC ACID, VALPROIC ACID
VALRELEASE, DIAZEPAM
VALSTAR PRESERVATIVE FREE, VALRUBICIN
VALTREX, VALACYCLOVIR HYDROCHLORIDE
VANCENASE AQ, BECLOMETHASONE DIPROPIONATE MONOHYDRATE
VANCENASE, BECLOMETHASONE DIPROPIONATE
VANCERIL DOUBLE STRENGTH, BECLOMETHASONE DIPROPIONATE
VANCERIL, BECLOMETHASONE DIPROPIONATE
VANCOCIN HCL IN PLASTIC CONTAINER, VANCOMYCIN HYDROCHLORIDE
VANCOCIN HCL, VANCOMYCIN HYDROCHLORIDE
VANCOLED, VANCOMYCIN HYDROCHLORIDE
VANCOMYCIN HCL, VANCOMYCIN HYDROCHLORIDE
VANCOR, VANCOMYCIN HYDROCHLORIDE
VANIQA, EFLORNITHINE HYDROCHLORIDE
VANOBID, CANDICIDIN
VANSIL, OXAMNIQUINE
VANTIN, CEFPODOXIME PROXETIL
VAPO-ISO, ISOPROTERENOL HYDROCHLORIDE
VASCOR, BEPRIDIL HYDROCHLORIDE
VASCORAY, IOTHALAMATE MEGLUMINE
VASERETIC, ENALAPRIL MALEATE
VASOCIDIN, PREDNISOLONE ACETATE
VASOCIDIN, PREDNISOLONE SODIUM PHOSPHATE
VASOCON, NAPHAZOLINE HYDROCHLORIDE
VASOCON-A, ANTAZOLINE PHOSPHATE (OTC)
VASOTEC, ENALAPRIL MALEATE
VASOTEC, ENALAPRILAT
VASOXYL, METHOXAMINE HYDROCHLORIDE
VECTRIN, MINOCYCLINE HYDROCHLORIDE
VECURONIUM BROMIDE, VECURONIUM BROMIDE
VEETIDS '125', PENICILLIN V POTASSIUM
VEETIDS '250', PENICILLIN V POTASSIUM
VEETIDS '500', PENICILLIN V POTASSIUM
VEETIDS, PENICILLIN V POTASSIUM
VEINAMINE 8%, AMINO ACIDS
VELBAN, VINBLASTINE SULFATE
VELOSEF '125', CEPHRADINE
VELOSEF '250', CEPHRADINE
VELOSEF '500', CEPHRADINE
VELOSEF, CEPHRADINE
VELOSULIN BR HUMAN, INSULIN RECOMBINANT PURIFIED HUMAN (OTC)
VELOSULIN BR, INSULIN RECOMBINANT HUMAN
VELOSULIN, INSULIN PURIFIED PORK (OTC)
VELTANE, BROMPHENIRAMINE MALEATE
VENOFER, IRON SUCROSE
VENTAIRE, PROTOKYLOL HYDROCHLORIDE
VENTOLIN HFA, ALBUTEROL SULFATE

FDA data supplied by DrugPatentWatch.com

VENTOLIN ROTACAPS, ALBUTEROL SULFATE
VENTOLIN, ALBUTEROL
VENTOLIN, ALBUTEROL SULFATE
VEPESID, ETOPOSIDE
VERAPAMIL HCL, VERAPAMIL HYDROCHLORIDE
VERCYTE, PIPOBROMAN
VERELAN PM, VERAPAMIL HYDROCHLORIDE
VERELAN, VERAPAMIL HYDROCHLORIDE
VERILOID, ALKAVERVIR
VERMIDOL, PIPERAZINE CITRATE
VERMOX, MEBENDAZOLE
VERSAPEN, HETACILLIN
VERSAPEN-K, HETACILLIN POTASSIUM
VERSED, MIDAZOLAM HYDROCHLORIDE
VERTAVIS, VERATRUM VIRIDE
VESANOID, TRETINOIN
VESPRIN, TRIFLUPROMAZINE
VESPRIN, TRIFLUPROMAZINE HYDROCHLORIDE
VEXOL, RIMEXOLONE
VI-DOM-A, VITAMIN A PALMITATE
VI-TWEL, CYANOCOBALAMIN
VIADUR, LEUPROLIDE ACETATE
VIAGRA, SILDENAFIL CITRATE
VIBISONE, CYANOCOBALAMIN
VIBRA-TABS, DOXYCYCLINE HYCLATE
VIBRAMYCIN, DOXYCYCLINE
VIBRAMYCIN, DOXYCYCLINE CALCIUM
VIBRAMYCIN, DOXYCYCLINE HYCLATE
VICKS FORMULA 44, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
VICODIN ES, ACETAMINOPHEN
VICODIN HP, ACETAMINOPHEN
VICODIN, ACETAMINOPHEN
VICOPRIN, ASPIRIN
VICOPROFEN, HYDROCODONE BITARTRATE
VIDEX EC, DIDANOSINE
VIDEX, DIDANOSINE
VINBLASTINE SULFATE, VINBLASTINE SULFATE
VINCASAR PFS, VINCRISTINE SULFATE
VINCREX, VINCRISTINE SULFATE
VINCRISTINE SULFATE PFS, VINCRISTINE SULFATE
VINCRISTINE SULFATE, VINCRISTINE SULFATE
VIOCIN SULFATE, VIOMYCIN SULFATE
VIOXX, ROFECOXIB
VIRA-A, VIDARABINE
VIRAC REX, UNDECOYLIUM CHLORIDE
VIRACEPT, NELFINAVIR MESYLATE
VIRAMUNE, NEVIRAPINE
VIRAZOLE, RIBAVIRIN
VIREAD, TENOFOVIR DISOPROXIL FUMARATE
VIRILON, METHYLTESTOSTERONE
VIROPTIC, TRIFLURIDINE
VISICOL, SODIUM PHOSPHATE, DIBASIC, ANHYDROUS
VISINE L.R., OXYMETAZOLINE HYDROCHLORIDE (OTC)
VISINE-A, NAPHAZOLINE HYDROCHLORIDE (OTC)
VISIPAQUE 270, IODIXANOL
VISIPAQUE 320, IODIXANOL
VISKAZIDE, HYDROCHLOROTHIAZIDE
VISKEN, PINDOLOL
VISTARIL, HYDROXYZINE HYDROCHLORIDE
VISTARIL, HYDROXYZINE PAMOATE
VISTIDE, CIDOFOVIR
VISUDYNE, VERTEPORFIN
VITAMIN A PALMITATE, VITAMIN A PALMITATE
VITAMIN A SOLUBILIZED, VITAMIN A PALMITATE
VITAMIN A, VITAMIN A
VITAMIN A, VITAMIN A PALMITATE
VITAMIN D, ERGOCALCIFEROL
VITAMIN K1, PHYTONADIONE
VITAPED, ASCORBIC ACID
VITRASERT, GANCICLOVIR
VITRAVENE PRESERVATIVE FREE, FOMIVIRSEN SODIUM
VIVACTIL, PROTRIPTYLINE HYDROCHLORIDE
VIVELLE, ESTRADIOL
VIVELLE-DOT, ESTRADIOL
VOLMAX, ALBUTEROL SULFATE
VOLTAREN, DICLOFENAC SODIUM
VOLTAREN-XR, DICLOFENAC SODIUM
VONTROL, DIPHENIDOL HYDROCHLORIDE
VOSOL HC, ACETIC ACID, GLACIAL
VOSOL, ACETIC ACID, GLACIAL
VUMON, TENIPOSIDE

** W **

WAMPOCAP, NIACIN
WARFARIN SODIUM, WARFARIN SODIUM
WELCHOL, COLESEVELAM HYDROCHLORIDE
WELLBUTRIN SR, BUPROPION HYDROCHLORIDE
WELLBUTRIN, BUPROPION HYDROCHLORIDE
WELLCOVORIN, LEUCOVORIN CALCIUM
WESTADONE, METHADONE HYDROCHLORIDE
WESTCORT, HYDROCORTISONE VALERATE
WIGRAINE, CAFFEINE
WIGRETTES, ERGOTAMINE TARTRATE
WINSTROL, STANOZOLOL
WOLFINA, RAUWOLFIA SERPENTINA
WYAMINE SULFATE, MEPHENTERMINE SULFATE
WYAMYCIN E, ERYTHROMYCIN ETHYLSUCCINATE
WYAMYCIN S, ERYTHROMYCIN STEARATE
WYCILLIN, PENICILLIN G PROCAINE
WYDASE, HYALURONIDASE
WYGESIC, ACETAMINOPHEN
WYMOX, AMOXICILLIN
WYTENSIN, GUANABENZ ACETATE

** X **

FDA data supplied by DrugPatentWatch.com

X-TROZINE L.A., PHENDIMETRAZINE TARTRATE
X-TROZINE, PHENDIMETRAZINE TARTRATE
XALATAN, LATANOPROST
XANAX, ALPRAZOLAM
XELODA, CAPECITABINE
XENEISOL, XENON, XE-133
XENICAL, ORLISTAT
XENON XE 127, XENON, XE-127
XENON XE 133, XENON, XE-133
XENON XE 133-V.S.S., XENON, XE-133
XOPENEX, LEVALBUTEROL HYDROCHLORIDE
XYLO-PFAN, XYLOSE
XYLOCAINE 1.5% W/ DEXTROSE 7.5%, LIDOCAINE HYDROCHLORIDE
XYLOCAINE 4% PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
XYLOCAINE 5% W/ GLUCOSE 7.5%, LIDOCAINE HYDROCHLORIDE
XYLOCAINE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
XYLOCAINE VISCOUS, LIDOCAINE HYDROCHLORIDE
XYLOCAINE W/ EPINEPHRINE, EPINEPHRINE
XYLOCAINE, LIDOCAINE
XYLOCAINE, LIDOCAINE HYDROCHLORIDE
XYLOSE, XYLOSE

** Y **

YASMIN, DROSPIRENONE
YTTERBIUM YB 169 DTPA, PENTETATE CALCIUM TRISODIUM YB-169
YUTOPAR, RITODRINE HYDROCHLORIDE

** Z **

ZADITOR, KETOTIFEN FUMARATE
ZAGAM, SPARFLOXACIN
ZANAFLEX, TIZANIDINE HYDROCHLORIDE
ZANOSAR, STREPTOZOCIN
ZANTAC 150, RANITIDINE HYDROCHLORIDE
ZANTAC 300, RANITIDINE HYDROCHLORIDE
ZANTAC 75, RANITIDINE HYDROCHLORIDE (OTC)
ZANTAC IN PLASTIC CONTAINER, RANITIDINE HYDROCHLORIDE
ZANTAC, RANITIDINE HYDROCHLORIDE
ZARONTIN, ETHOSUXIMIDE
ZAROXOLYN, METOLAZONE
ZAXOPAM, OXAZEPAM
ZEBETA, BISOPROLOL FUMARATE
ZEFAZONE IN PLASTIC CONTAINER, CEFMETAZOLE SODIUM
ZEFAZONE, CEFMETAZOLE SODIUM
ZEMPLAR, PARICALCITOL
ZEMURON (P/F), ROCURONIUM BROMIDE
ZEMURON, ROCURONIUM BROMIDE
ZERIT, STAVUDINE
ZESTORETIC, HYDROCHLOROTHIAZIDE
ZESTRIL, LISINOPRIL
ZIAC, BISOPROLOL FUMARATE
ZIAGEN, ABACAVIR SULFATE
ZIBA-RX, BACITRACIN ZINC
ZIDE, HYDROCHLOROTHIAZIDE
ZINACEF IN PLASTIC CONTAINER, CEFUROXIME SODIUM
ZINACEF, CEFUROXIME SODIUM
ZINC BACITRACIN,NEOMYCIN SULFATE,POLYMYXIN B SULFATE & HYDROCORTISONE, BACITRACIN ZINC
ZINC CHLORIDE IN PLASTIC CONTAINER, ZINC CHLORIDE
ZINC SULFATE, ZINC SULFATE
ZINECARD, DEXRAZOXANE HYDROCHLORIDE
ZIPAN-25, PROMETHAZINE HYDROCHLORIDE
ZIPAN-50, PROMETHAZINE HYDROCHLORIDE
ZITHROMAX, AZITHROMYCIN DIHYDRATE
ZOCOR, SIMVASTATIN
ZOFRAN IN PLASTIC CONTAINER, ONDANSETRON HYDROCHLORIDE
ZOFRAN ODT, ONDANSETRON
ZOFRAN PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
ZOFRAN, ONDANSETRON HYDROCHLORIDE
ZOLADEX, GOSERELIN ACETATE
ZOLOFT, SERTRALINE HYDROCHLORIDE
ZOLYSE, CHYMOTRYPSIN
ZOMETA, ZOLEDRONIC ACID
ZOMIG, ZOLMITRIPTAN
ZOMIG-ZMT, ZOLMITRIPTAN
ZONALON, DOXEPIN HYDROCHLORIDE
ZONEGRAN, ZONISAMIDE
ZOSYN IN PLASTIC CONTAINER, PIPERACILLIN SODIUM
ZOSYN, PIPERACILLIN SODIUM
ZOVIA 1/35E-21, ETHINYL ESTRADIOL
ZOVIA 1/35E-28, ETHINYL ESTRADIOL
ZOVIA 1/50E-21, ETHINYL ESTRADIOL
ZOVIA 1/50E-28, ETHINYL ESTRADIOL
ZOVIRAX, ACYCLOVIR
ZOVIRAX, ACYCLOVIR SODIUM
ZYBAN, BUPROPION HYDROCHLORIDE
ZYFLO, ZILEUTON
ZYLOPRIM, ALLOPURINOL
ZYPREXA ZYDIS, OLANZAPINE
ZYPREXA, OLANZAPINE
ZYRTEC, CETIRIZINE HYDROCHLORIDE
ZYRTEC-D 12 HOUR, CETIRIZINE HYDROCHLORIDE
ZYVOX, LINEZOLID

FDA data supplied by DrugPatentWatch.com

** 3 **

3M
* 3M CO
SCRUBTEAM SURGICAL SPONGEBRUSH, HEXACHLOROPHENE
* 3M HEALTH CARE INC
AVAGARD, ALCOHOL (OTC)
* 3M MEDICAL PRODUCTS DIV
INSTANT MICROSPHERES, TECHNETIUM TC-99M ALBUMIN MICROSPHERES KIT
YTTERBIUM YB 169 DTPA, PENTETATE CALCIUM TRISODIUM YB-169
* 3M PHARMACEUTICALS INC
ALDARA, IMIQUIMOD
CALCIUM DISODIUM VERSENATE, EDETATE CALCIUM DISODIUM
CIRCANOL, ERGOLOID MESYLATES
DISIPAL, ORPHENADRINE HYDROCHLORIDE
DUO-MEDIHALER, ISOPROTERENOL HYDROCHLORIDE
ISOPROTERENOL HCL, ISOPROTERENOL HYDROCHLORIDE
LIPO-HEPIN, HEPARIN SODIUM
MAXAIR, PIRBUTEROL ACETATE
MEDIHALER ERGOTAMINE, ERGOTAMINE TARTRATE
MEDIHALER-EPI, EPINEPHRINE BITARTRATE (OTC)
MEDIHALER-ISO, ISOPROTERENOL SULFATE
METROGEL-VAGINAL, METRONIDAZOLE
MINITRAN, NITROGLYCERIN
NORFLEX, ORPHENADRINE CITRATE
NORGESIC FORTE, ASPIRIN
NORGESIC, ASPIRIN
PROVENTIL-HFA, ALBUTEROL SULFATE
QVAR 40, BECLOMETHASONE DIPROPIONATE
QVAR 80, BECLOMETHASONE DIPROPIONATE
RAUWILOID, ALSEROXYLON
SODIUM VERSENATE, EDETATE DISODIUM
TAMBOCOR, FLECAINIDE ACETATE
TEPANIL TEN-TAB, DIETHYLPROPION HYDROCHLORIDE
TEPANIL, DIETHYLPROPION HYDROCHLORIDE
THEOLAIR, THEOPHYLLINE
THEOLAIR-SR, THEOPHYLLINE
ULO, CHLOPHEDIANOL HYDROCHLORIDE
UREX, METHENAMINE HIPPURATE
VERILOID, ALKAVERVIR

** A **

AAIPHARMA
* AAIPHARMA INC
THIOTEPA, THIOTEPA

AB GENERICS
* AB GENERICS LP
MORPHINE SULFATE, MORPHINE SULFATE

ABANA
* ABANA PHARMACEUTICALS INC
NORCET, ACETAMINOPHEN

ABBOTT
* ABBOTT LABORATORIES
A-METHAPRED, METHYLPREDNISOLONE SODIUM SUCCINATE
ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM
ACETYLCYSTEINE, ACETYLCYSTEINE
ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
ACYCLOVIR, ACYCLOVIR SODIUM
ALCOHOL 5% IN D5-W, ALCOHOL
ALFENTANIL, ALFENTANIL HYDROCHLORIDE
AMIDATE, ETOMIDATE
AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, AMIKACIN SULFATE
AMIKACIN SULFATE, AMIKACIN SULFATE
AMINOCAPROIC ACID IN PLASTIC CONTAINER, AMINOCAPROIC ACID
AMINOPHYLLINE, AMINOPHYLLINE
AMINOSYN 10% (PH6), AMINO ACIDS
AMINOSYN 10%, AMINO ACIDS
AMINOSYN 3.5% M, AMINO ACIDS
AMINOSYN 3.5%, AMINO ACIDS
AMINOSYN 5%, AMINO ACIDS
AMINOSYN 7% (PH6), AMINO ACIDS
AMINOSYN 7% W/ ELECTROLYTES, AMINO ACIDS
AMINOSYN 7%, AMINO ACIDS
AMINOSYN 8.5% (PH6), AMINO ACIDS
AMINOSYN 8.5% W/ ELECTROLYTES, AMINO ACIDS
AMINOSYN 8.5%, AMINO ACIDS
AMINOSYN II 10%, AMINO ACIDS
AMINOSYN II 3.5% IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 3.5% IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 3.5% M IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 3.5%, AMINO ACIDS
AMINOSYN II 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 4.25% M IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 4.25% W/ ELECT AND ADJUSTED PHOSPHATE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS

FDA data supplied by DrugPatentWatch.com

AMINOSYN II 5% IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 5%, AMINO ACIDS
AMINOSYN II 7%, AMINO ACIDS
AMINOSYN II 8.5%, AMINO ACIDS
AMINOSYN-HF 8%, AMINO ACIDS
AMINOSYN-PF 7%, AMINO ACIDS
AMINOSYN-RF 5.2%, AMINO ACIDS
AMMONIUM CHLORIDE IN PLASTIC CONTAINER, AMMONIUM CHLORIDE
AMPHOTERICIN B, AMPHOTERICIN B
ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE
ATRACURIUM BESYLATE, ATRACURIUM BESYLATE
ATROPINE AND DEMEROL, ATROPINE SULFATE
BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER, WATER FOR INJECTION, STERILE
BIAXIN XL, CLARITHROMYCIN
BIAXIN, CLARITHROMYCIN
BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER, BRETYLIUM TOSYLATE
BUMETANIDE, BUMETANIDE
BUPIVACAINE HCL KIT, BUPIVACAINE HYDROCHLORIDE
BUPIVACAINE HCL, BUPIVACAINE HYDROCHLORIDE
BUPIVACAINE, BUPIVACAINE HYDROCHLORIDE
BUPRENORPHINE HCL, BUPRENORPHINE HYDROCHLORIDE
BUTORPHANOL TARTRATE PRESERVATIVE FREE, BUTORPHANOL TARTRATE
BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
CARTROL, CARTEOLOL HYDROCHLORIDE
CIMETIDINE HCL IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, CIMETIDINE HYDROCHLORIDE
CIMETIDINE HCL, CIMETIDINE HYDROCHLORIDE
CLINDAMYCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE
CYCLOSPORINE, CYCLOSPORINE
DEMEROL, MEPERIDINE HYDROCHLORIDE
DEPAKOTE ER, DIVALPROEX SODIUM
DEPAKOTE, DIVALPROEX SODIUM
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DEXTROSE 50% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 70% IN PLASTIC CONTAINER, DEXTROSE
DIAZEPAM, DIAZEPAM
DIGOXIN PEDIATRIC, DIGOXIN
DIGOXIN, DIGOXIN
DILTIAZEM HCL, DILTIAZEM HYDROCHLORIDE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DIPYRIDAMOLE, DIPYRIDAMOLE
DOBUTAMINE HCL IN DEXTROSE 5% IN PLASTIC CONTAINER, DOBUTAMINE HYDROCHLORIDE
DOBUTAMINE HCL IN DEXTROSE 5%, DOBUTAMINE HYDROCHLORIDE
DOBUTAMINE HCL, DOBUTAMINE HYDROCHLORIDE
DOPAMINE HCL IN DEXTROSE 5%, DOPAMINE HYDROCHLORIDE
DOPAMINE HCL, DOPAMINE HYDROCHLORIDE
DROPERIDOL, DROPERIDOL
EDROPHONIUM CHLORIDE, EDROPHONIUM CHLORIDE
ENALAPRILAT, ENALAPRILAT
ERYTHROCIN, ERYTHROMYCIN LACTOBIONATE
ETOPOSIDE, ETOPOSIDE
FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE
FENTANYL CITRATE PRESERVATIVE FREE, FENTANYL CITRATE
FUROSEMIDE, FUROSEMIDE
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, GENTAMICIN SULFATE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
GLYCINE 1.5% IN PLASTIC CONTAINER, GLYCINE
HEPARIN LOCK FLUSH, HEPARIN SODIUM
HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
HEPARIN SODIUM, HEPARIN SODIUM
HYDROMORPHONE HCL, HYDROMORPHONE HYDROCHLORIDE
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
IONOSOL B AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
IONOSOL T AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
IOPAMIDOL-200 IN PLASTIC CONTAINER, IOPAMIDOL
IOPAMIDOL-200, IOPAMIDOL
IOPAMIDOL-250 IN PLASTIC CONTAINER, IOPAMIDOL
IOPAMIDOL-250, IOPAMIDOL
IOPAMIDOL-300 IN PLASTIC CONTAINER, IOPAMIDOL
IOPAMIDOL-300, IOPAMIDOL
IOPAMIDOL-370 IN PLASTIC CONTAINER, IOPAMIDOL
IOPAMIDOL-370, IOPAMIDOL
ISOFLURANE, ISOFLURANE
ISUPREL, ISOPROTERENOL HYDROCHLORIDE
KALETRA, LOPINAVIR
KETAMINE HCL, KETAMINE HYDROCHLORIDE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LABETALOL HCL, LABETALOL HYDROCHLORIDE
LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
LEVOPHED, NOREPINEPHRINE BITARTRATE
LIDOCAINE HCL PRESERVATIVE FREE IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL, LIDOCAINE HYDROCHLORIDE
LIPOSYN II 20%, SAFFLOWER OIL
LIPOSYN III 10%, SOYBEAN OIL
LIPOSYN III 20%, SOYBEAN OIL
LORAZEPAM, LORAZEPAM
MAGNESIUM SULFATE, MAGNESIUM SULFATE
MARCAINE HCL PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HCL W/ EPINEPHRINE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HCL W/ EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HCL, BUPIVACAINE HYDROCHLORIDE
MARCAINE, BUPIVACAINE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

METHYLDOPATE HCL, METHYLDOPATE HYDROCHLORIDE
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
MIDAZOLAM HCL, MIDAZOLAM HYDROCHLORIDE
MIVACRON IN DEXTROSE 5% IN PLASTIC CONTAINER, MIVACURIUM CHLORIDE
MIVACRON, MIVACURIUM CHLORIDE
NALBUPHINE HCL, NALBUPHINE HYDROCHLORIDE
NALOXONE HCL, NALOXONE HYDROCHLORIDE
NIMBEX PRESERVATIVE FREE, CISATRACURIUM BESYLATE
NIMBEX, CISATRACURIUM BESYLATE
NITROGLYCERIN IN DEXTROSE 5%, NITROGLYCERIN
NITROGLYCERIN, NITROGLYCERIN
NITROPRESS, SODIUM NITROPRUSSIDE
NORVIR, RITONAVIR
NOVOCAIN, PROCAINE HYDROCHLORIDE
NUROMAX, DOXACURIUM CHLORIDE
OMNICEF, CEFDINIR
PANCURONIUM BROMIDE, PANCURONIUM BROMIDE
PENTAMIDINE ISETHIONATE, PENTAMIDINE ISETHIONATE
POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
PRECEDEX, DEXMEDETOMIDINE
PROCAINAMIDE HCL, PROCAINAMIDE HYDROCHLORIDE
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE
QUELICIN PRESERVATIVE FREE, SUCCINYLCHOLINE CHLORIDE
QUELICIN, SUCCINYLCHOLINE CHLORIDE
RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
RITODRINE HCL IN DEXTROSE 5% IN PLASTIC CONTAINER, RITODRINE HYDROCHLORIDE
SODIUM ACETATE IN PLASTIC CONTAINER, SODIUM ACETATE, ANHYDROUS
SODIUM PHOSPHATES IN PLASTIC CONTAINER, SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE
SORBITOL-MANNITOL IN PLASTIC CONTAINER, MANNITOL
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, WATER FOR INJECTION, STERILE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
SULFENTANIL CITRATE, SUFENTANIL CITRATE
TALWIN, PENTAZOCINE LACTATE
TAZICEF, CEFTAZIDIME
THIAMINE HCL, THIAMINE HYDROCHLORIDE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
TRACRIUM PRESERVATIVE FREE, ATRACURIUM BESYLATE
TRACRIUM, ATRACURIUM BESYLATE
TRICOR, FENOFIBRATE
TRIMETHOBENZAMIDE HCL, TRIMETHOBENZAMIDE HYDROCHLORIDE
ULTANE, SEVOFLURANE
ULTIVA, REMIFENTANIL HYDROCHLORIDE
VANCOMYCIN HCL, VANCOMYCIN HYDROCHLORIDE
VECURONIUM BROMIDE, VECURONIUM BROMIDE
VERAPAMIL HCL, VERAPAMIL HYDROCHLORIDE
ZEMPLAR, PARICALCITOL
ZYFLO, ZILEUTON

* ABBOTT LABORATORIES HOSP PRODUCTS DIV

A-HYDROCORT, HYDROCORTISONE SODIUM SUCCINATE
A-METHAPRED, METHYLPREDNISOLONE SODIUM SUCCINATE
ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
AMIKACIN SULFATE, AMIKACIN SULFATE
AMINOCAPROIC ACID, AMINOCAPROIC ACID
AMINOPHYLLINE, AMINOPHYLLINE
AMINOSYN II 10% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 15% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 3.5% IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 3.5% IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 3.5% M IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 4.25% W/ ELECT AND ADJUSTED PHOSPHATE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 5% IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN-HBC 7%, AMINO ACIDS
AMRINONE, INAMRINONE LACTATE
ATROPINE SULFATE ANSYR PLASTIC SYRINGE, ATROPINE SULFATE
BRETYLIUM TOSYLATE IN PLASTIC CONTAINER, BRETYLIUM TOSYLATE
BRETYLIUM TOSYLATE, BRETYLIUM TOSYLATE
BUPIVACAINE HCL AND EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

CALCIJEX, CALCITRIOL
CHROMIC CHLORIDE IN PLASTIC CONTAINER, CHROMIC CHLORIDE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CORLOPAM, FENOLDOPAM MESYLATE
CUPRIC CHLORIDE IN PLASTIC CONTAINER, CUPRIC CHLORIDE
DEXTROSE 25%, DEXTROSE
DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 50% IN PLASTIC CONTAINER, DEXTROSE
DIAZEPAM, DIAZEPAM
DOBUTAMINE HCL, DOBUTAMINE HYDROCHLORIDE
DOPAMINE HCL IN DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE
DOPAMINE HCL, DOPAMINE HYDROCHLORIDE
ENFLURANE, ENFLURANE
ERYTHROCIN, ERYTHROMYCIN LACTOBIONATE
FENTANYL CITRATE AND DROPERIDOL, DROPERIDOL
FENTANYL CITRATE, FENTANYL CITRATE
HEPARIN LOCK FLUSH IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN LOCK FLUSH, HEPARIN SODIUM
HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
ISOPROTERENOL HCL, ISOPROTERENOL HYDROCHLORIDE
LIDOCAINE HCL 0.2% IN DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL 0.4% IN DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL 0.8% IN DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL 5% AND DEXTROSE 7.5%, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL AND EPINEPHRINE, EPINEPHRINE
LIDOCAINE HCL, LIDOCAINE HYDROCHLORIDE
LIPOSYN III 30%, SOYBEAN OIL
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MAGNESIUM SULFATE IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MANGANESE CHLORIDE IN PLASTIC CONTAINER, MANGANESE CHLORIDE
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
NALBUPHINE HCL, NALBUPHINE HYDROCHLORIDE
NALOXONE HCL, NALOXONE HYDROCHLORIDE
NITROGLYCERIN IN DEXTROSE 5%, NITROGLYCERIN
NITROPRESS, SODIUM NITROPRUSSIDE
PANCURONIUM BROMIDE, PANCURONIUM BROMIDE
PANHEPRIN, HEPARIN SODIUM
PENTHRANE, METHOXYFLURANE
PENTOTHAL, THIOPENTAL SODIUM
PHENYTOIN SODIUM, PHENYTOIN SODIUM
POTASSIUM ACETATE IN PLASTIC CONTAINER, POTASSIUM ACETATE
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
POTASSIUM CHLORIDE 20MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
POTASSIUM CHLORIDE 40MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE
RITODRINE HCL, RITODRINE HYDROCHLORIDE
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM LACTATE IN PLASTIC CONTAINER, SODIUM LACTATE
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, WATER FOR INJECTION, STERILE
THAM, TROMETHAMINE
THAM-E, POTASSIUM CHLORIDE
TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, TOBRAMYCIN SULFATE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
TPN ELECTROLYTES IN PLASTIC CONTAINER, CALCIUM CHLORIDE
TUBOCURARINE CHLORIDE, TUBOCURARINE CHLORIDE
UREAPHIL, UREA
VANCOMYCIN HCL, VANCOMYCIN HYDROCHLORIDE
ZINC CHLORIDE IN PLASTIC CONTAINER, ZINC CHLORIDE

* ABBOTT LABORATORIES PHARMACEUTICAL PRODUCTS DIV

A-HYDROCORT, HYDROCORTISONE SODIUM SUCCINATE
A-METHAPRED, METHYLPREDNISOLONE SODIUM SUCCINATE
A-POXIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE
ACETIC ACID 0.25% IN PLASTIC CONTAINER, ACETIC ACID, GLACIAL
AKINETON, BIPERIDEN HYDROCHLORIDE
AKINETON, BIPERIDEN LACTATE
AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, AMINOPHYLLINE
AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%, AMINOPHYLLINE
AMINOSOL 5%, PROTEIN HYDROLYSATE
AMINOSYN 3.5% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN 3.5% M IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN 3.5% W/ DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN 3.5% W/ DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN 4.25% W/ DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 10% W/ ELECTROLYTES, AMINO ACIDS
AMINOSYN II 3.5% IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO

FDA data supplied by DrugPatentWatch.com

ACIDS
AMINOSYN II 3.5% IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 3.5% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 3.5% M IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 3.5% M IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 3.5% M, AMINO ACIDS
AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 4.25% M IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 5% IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 7% W/ ELECTROLYTES, AMINO ACIDS
AMINOSYN II 8.5% W/ ELECTROLYTES, AMINO ACIDS
AMINOSYN-HBC 7% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN-PF 10%, AMINO ACIDS
AMMONIUM CHLORIDE, AMMONIUM CHLORIDE
BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
BIAXIN, CLARITHROMYCIN
BRETYLIUM TOSYLATE IN DEXTROSE 5%, BRETYLIUM TOSYLATE
BUPIVACAINE HCL, BUPIVACAINE HYDROCHLORIDE
CALCIUM GLUCEPTATE, CALCIUM GLUCEPTATE
CEPHALOTHIN SODIUM, CEPHALOTHIN SODIUM
CHLOROPROCAINE HCL, CHLOROPROCAINE HYDROCHLORIDE
CHLORPROMAZINE HCL, CHLORPROMAZINE HYDROCHLORIDE
CHLORTHALIDONE, CHLORTHALIDONE
CHOLOXIN, DEXTROTHYROXINE SODIUM
CHYMODIACTIN, CHYMOPAPAIN
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CYLERT, PEMOLINE
DEPACON, VALPROATE SODIUM
DEPAKENE, VALPROIC ACID
DEPAKOTE CP, DIVALPROEX SODIUM
DEPAKOTE, DIVALPROEX SODIUM
DESOXYN, METHAMPHETAMINE HYDROCHLORIDE
DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 20% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 30% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 38.5% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 40% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% AND RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 50% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 60% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 70% IN PLASTIC CONTAINER, DEXTROSE
DIASONE SODIUM, SULFOXONE SODIUM
DICUMAROL, DICUMAROL
DILAUDID, HYDROMORPHONE HYDROCHLORIDE
DILAUDID-HP, HYDROMORPHONE HYDROCHLORIDE
DISCASE, CHYMOPAPAIN
DROPERIDOL, DROPERIDOL
E-MYCIN, ERYTHROMYCIN
E.E.S. 200, ERYTHROMYCIN ETHYLSUCCINATE
E.E.S. 400, ERYTHROMYCIN ETHYLSUCCINATE
E.E.S., ERYTHROMYCIN ETHYLSUCCINATE
ENDRATE, EDETATE DISODIUM
ENDURON, METHYCLOTHIAZIDE
ENDURONYL FORTE, DESERPIDINE
ENDURONYL, DESERPIDINE
ERY-TAB, ERYTHROMYCIN
ERYDERM, ERYTHROMYCIN
ERYPED, ERYTHROMYCIN ETHYLSUCCINATE
ERYTHROCIN STEARATE, ERYTHROMYCIN STEARATE
ERYTHROCIN, ERYTHROMYCIN LACTOBIONATE
ERYTHROMYCIN, ERYTHROMYCIN
EUTONYL, PARGYLINE HYDROCHLORIDE
EUTRON, METHYCLOTHIAZIDE
FENTANYL CITRATE, FENTANYL CITRATE
GEMONIL, METHARBITAL
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, GENTAMICIN SULFATE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
GLYCOPYRROLATE, GLYCOPYRROLATE
HALOTHANE, HALOTHANE
HARMONYL, DESERPIDINE
HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5%, HEPARIN SODIUM
HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.45%, HEPARIN SODIUM
HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.9%, HEPARIN SODIUM

FDA data supplied by DrugPatentWatch.com

HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5%, HEPARIN SODIUM
HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.9%, HEPARIN SODIUM
HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5%, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9%, HEPARIN SODIUM
HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.45%, HEPARIN SODIUM
HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9%, HEPARIN SODIUM
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
HYTRIN, TERAZOSIN HYDROCHLORIDE
IBU, IBUPROFEN
IBUPROFEN, IBUPROFEN
ISOPROTERENOL HCL, ISOPROTERENOL HYDROCHLORIDE
ISOPTIN SR, VERAPAMIL HYDROCHLORIDE
ISOPTIN, VERAPAMIL HYDROCHLORIDE
JANIMINE, IMIPRAMINE HYDROCHLORIDE
K-TAB, POTASSIUM CHLORIDE
LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
LIDOCAINE HCL 0.2% IN DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL 0.2% IN DEXTROSE 5%, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL 0.4% IN DEXTROSE 5%, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL AND EPINEPHRINE, EPINEPHRINE
LIDOCAINE HCL IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL W/ EPINEPHRINE, EPINEPHRINE
LIDOCAINE HCL, LIDOCAINE HYDROCHLORIDE
LIPIDIL, FENOFIBRATE
LIPOSYN 10%, SAFFLOWER OIL
LIPOSYN 20%, SAFFLOWER OIL
LIPOSYN II 10%, SAFFLOWER OIL
LOPURIN, ALLOPURINOL
LTA II KIT, LIDOCAINE HYDROCHLORIDE
MANNITOL 10% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 10%, MANNITOL
MANNITOL 15% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 15%, MANNITOL
MANNITOL 20% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 20%, MANNITOL
MANNITOL 25%, MANNITOL
MANNITOL 5% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 5%, MANNITOL
MAVIK, TRANDOLAPRIL
MEPERIDINE HCL PRESERVATIVE FREE, MEPERIDINE HYDROCHLORIDE
MEPERIDINE HCL, MEPERIDINE HYDROCHLORIDE
MERIDIA, SIBUTRAMINE HYDROCHLORIDE
METRONIDAZOLE IN PLASTIC CONTAINER, METRONIDAZOLE
METRONIDAZOLE, METRONIDAZOLE
MORPHINE SULFATE, MORPHINE SULFATE
NALOXONE HCL, NALOXONE HYDROCHLORIDE
NEMBUTAL SODIUM, PENTOBARBITAL SODIUM
NEMBUTAL, PENTOBARBITAL
NEMBUTAL, PENTOBARBITAL SODIUM
NITROPRESS, SODIUM NITROPRUSSIDE
NORISODRINE AEROTROL, ISOPROTERENOL HYDROCHLORIDE
NORISODRINE, ISOPROTERENOL SULFATE
NORMOSOL-M AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
NORMOSOL-R IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
NORVIR, RITONAVIR
OCL, POLYETHYLENE GLYCOL 3350
ORETIC, HYDROCHLOROTHIAZIDE
ORETICYL 25, DESERPIDINE
ORETICYL 50, DESERPIDINE
ORETICYL FORTE, DESERPIDINE
OXYTOCIN 10 USP UNITS IN DEXTROSE 5%, OXYTOCIN
OXYTOCIN 20 USP UNITS IN DEXTROSE 5%, OXYTOCIN
OXYTOCIN 5 USP UNITS IN DEXTROSE 5%, OXYTOCIN
PANWARFIN, WARFARIN SODIUM
PARADIONE, PARAMETHADIONE
PCE, ERYTHROMYCIN
PEDIATRIC LTA KIT, LIDOCAINE HYDROCHLORIDE
PEGANONE, ETHOTOIN
PHENURONE, PHENACEMIDE
PHENYTOIN SODIUM, PHENYTOIN SODIUM
PHYSIOSOL IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
PHYSIOSOL PH 7.4 IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
PLACIDYL, ETHCHLORVYNOL
PLEGISOL IN PLASTIC CONTAINER, CALCIUM CHLORIDE
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE

FDA data supplied by DrugPatentWatch.com

0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PROCAINE HCL, PROCAINE HYDROCHLORIDE
PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE
PROPYLTHIOURACIL, PROPYLTHIOURACIL
PROSOM, ESTAZOLAM
RADIONUCLIDE-LABELED (125 I) FIBRINOGEN (HUMAN) SENSOR, FIBRINOGEN, I-125
RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
RYTHMOL, PROPAFENONE HYDROCHLORIDE
SELSUN, SELENIUM SULFIDE
SODIUM BICARBONATE IN PLASTIC CONTAINER, SODIUM BICARBONATE
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE, SODIUM CHLORIDE
SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER, SODIUM LACTATE
SORBITOL-MANNITOL IN PLASTIC CONTAINER, MANNITOL
SORBITOL-MANNITOL, MANNITOL
STERILE UREA, UREA
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, WATER FOR INJECTION, STERILE
STERILE WATER IN PLASTIC CONTAINER, WATER FOR IRRIGATION, STERILE
SULFADIAZINE, TRISULFAPYRIMIDINES (SULFADIAZINE; SULFAMERAZINE;SULFAMETHAZINE)
TARKA, TRANDOLAPRIL
TETRACYCLINE HCL, TETRACYCLINE HYDROCHLORIDE
THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THYPINONE, PROTIRELIN
TPN ELECTROLYTES IN PLASTIC CONTAINER, CALCIUM CHLORIDE
TRAL, HEXOCYCLIUM METHYLSULFATE
TRANXENE SD, CLORAZEPATE DIPOTASSIUM
TRANXENE, CLORAZEPATE DIPOTASSIUM
TRAVASE, SUTILAINS
TRICOR (MICRONIZED), FENOFIBRATE
TRIDIONE, TRIMETHADIONE
UROLOGIC G IN PLASTIC CONTAINER, CITRIC ACID
VERAPAMIL HCL, VERAPAMIL HYDROCHLORIDE
VERCYTE, PIPOBROMAN
VICODIN ES, ACETAMINOPHEN
VICODIN HP, ACETAMINOPHEN
VICODIN, ACETAMINOPHEN
VICOPRIN, ASPIRIN
VICOPROFEN, HYDROCODONE BITARTRATE
VITAMIN K1, PHYTONADIONE

ABC HOLDING

* ABC HOLDING CORP
CAM-AP-ES, HYDRALAZINE HYDROCHLORIDE
CAM-METRAZINE, PHENDIMETRAZINE TARTRATE
CHLOROTHIAZIDE, CHLOROTHIAZIDE
CYPROHEPTADINE HCL, CYPROHEPTADINE HYDROCHLORIDE
DIETHYLPROPION HCL, DIETHYLPROPION HYDROCHLORIDE
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
HYDRO-RESERP, HYDROCHLOROTHIAZIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
MECLIZINE HCL, MECLIZINE HYDROCHLORIDE
PHENAZINE-35, PHENDIMETRAZINE TARTRATE
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PHENTERMINE HCL, PHENTERMINE HYDROCHLORIDE
TRICHLORMETHIAZIDE, TRICHLORMETHIAZIDE

ABIC

* ABIC LTD
ABITREXATE, METHOTREXATE SODIUM
FLUOROURACIL, FLUOROURACIL
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
VINCRISTINE SULFATE, VINCRISTINE SULFATE

FDA data supplied by DrugPatentWatch.com

ABLE
* ABLE LABORATORIES INC
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
CARISOPRODOL, CARISOPRODOL
CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
DIPHENOXYLATE HCL AND ATROPINE SULFATE, ATROPINE SULFATE
HEMSOL-HC, HYDROCORTISONE ACETATE
LITHIUM CARBONATE, LITHIUM CARBONATE
LOPERAMIDE HCL, LOPERAMIDE HYDROCHLORIDE (OTC)
METHYLPHENIDATE HCL, METHYLPHENIDATE HYDROCHLORIDE
PHENTERMINE HCL, PHENTERMINE HYDROCHLORIDE
PROCHLORPERAZINE, PROCHLORPERAZINE
PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN, ACETAMINOPHEN
SULFAMETHOXAZOLE AND TRIMETHOPRIM AND PENAZOPYRIDINE HCL, PHENAZOPYRIDINE HYDROCHLORIDE

ACTELION
* ACTELION LTD
TRACLEER, BOSENTAN

ADV CARE
* ADVANCED CARE PRODUCTS DIV ORTHO PHARMACEUTICAL CORP
MONISTAT 7 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MONISTAT 7, MICONAZOLE NITRATE (OTC)
MONISTAT-3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)

ADV MAGNETICS
* ADVANCED MAGNETICS INC
FERIDEX I.V., FERUMOXIDES
GASTROMARK, FERUMOXSIL

ADVANCED CARE PRODS
* ADVANCED CARE PRODUCTS
MONISTAT 3, MICONAZOLE NITRATE (OTC)
MONISTAT 7, MICONAZOLE NITRATE (OTC)

AESGEN
* AESGEN INC
ACYCLOVIR, ACYCLOVIR
ETODOLAC, ETODOLAC

AGOURON
* AGOURON PHARMACEUTICALS INC
RESCRIPTOR, DELAVIRDINE MESYLATE
VIRACEPT, NELFINAVIR MESYLATE

AH ROBINS INC
* AH ROBINS INC
EXNA, BENZTHIAZIDE

AKORN
* AKORN INC
AK-PENTOLATE, CYCLOPENTOLATE HYDROCHLORIDE
AKBETA, LEVOBUNOLOL HYDROCHLORIDE
AKPENTOLATE, CYCLOPENTOLATE HYDROCHLORIDE
AKPRO, DIPIVEFRIN HYDROCHLORIDE
AKTOB, TOBRAMYCIN
ALFENTA, ALFENTANIL HYDROCHLORIDE
BACITRACIN ZINC AND POLYMYXIN B SULFATE, BACITRACIN ZINC
BAL, DIMERCAPROL
BETAXOLOL, BETAXOLOL HYDROCHLORIDE
CARDIO-GREEN, INDOCYANINE GREEN
CHLORAMPHENICOL, CHLORAMPHENICOL
COR-OTICIN, HYDROCORTISONE ACETATE
CROMOLYN SODIUM, CROMOLYN SODIUM
CYANOCOBALAMIN, CYANOCOBALAMIN
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
ENDOSOL EXTRA, CALCIUM CHLORIDE
ERYTHROMYCIN, ERYTHROMYCIN
GENTAK, GENTAMICIN SULFATE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
HEPARIN SODIUM, HEPARIN SODIUM
HYDROCORTISONE ACETATE, HYDROCORTISONE ACETATE
HYDROXYPROGESTERONE CAPROATE, HYDROXYPROGESTERONE CAPROATE
INAPSINE, DROPERIDOL
LIDOCAINE HCL, LIDOCAINE HYDROCHLORIDE
LORAZEPAM, LORAZEPAM
METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE ACETATE
NANDROLONE DECANOATE, NANDROLONE DECANOATE
OCUSERT PILO-20, PILOCARPINE
OCUSERT PILO-40, PILOCARPINE
PAREDRINE, HYDROXYAMPHETAMINE HYDROBROMIDE
PAREMYD, HYDROXYAMPHETAMINE HYDROBROMIDE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PREDAMIDE, PREDNISOLONE ACETATE
PREDNISOLONE ACETATE, PREDNISOLONE ACETATE
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE
PYRIDOXINE HCL, PYRIDOXINE HYDROCHLORIDE
SODIUM SULFACETAMIDE, SULFACETAMIDE SODIUM
SUFENTA, SUFENTANIL CITRATE
SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
SULSTER, PREDNISOLONE SODIUM PHOSPHATE
THIAMINE HCL, THIAMINE HYDROCHLORIDE
TIMOLOL MALEATE, TIMOLOL MALEATE
TRIAMCINOLONE DIACETATE, TRIAMCINOLONE DIACETATE
TROPICACYL, TROPICAMIDE
TROPICAMIDE, TROPICAMIDE

AKORN MFG
* AKORN MANUFACTURING INC
INNOVAR, DROPERIDOL
SUBLIMAZE PRESERVATIVE FREE, FENTANYL CITRATE

FDA data supplied by DrugPatentWatch.com

AL HIKMA
* AL HIKMA PHARMACEUTICALS
NAPROXEN SODIUM, NAPROXEN SODIUM

ALCON
* ALCON LABORATORIES INC
ALCAINE, PROPARACAINE HYDROCHLORIDE
ALOMIDE, LODOXAMIDE TROMETHAMINE
AZOPT, BRINZOLAMIDE
BETADINE, POVIDONE-IODINE
BETAXON, LEVOBETAXOLOL HYDROCHLORIDE
BETOPTIC PILO, BETAXOLOL HYDROCHLORIDE
BETOPTIC S, BETAXOLOL HYDROCHLORIDE
BETOPTIC, BETAXOLOL HYDROCHLORIDE
BSS PLUS, CALCIUM CHLORIDE
BSS, CALCIUM CHLORIDE
CARTEOLOL HCL, CARTEOLOL HYDROCHLORIDE
CETAMIDE, SULFACETAMIDE SODIUM
CETAPRED, PREDNISOLONE ACETATE
CHLORAMPHENICOL, CHLORAMPHENICOL
CILOXAN, CIPROFLOXACIN HYDROCHLORIDE
CIPRO HC, CIPROFLOXACIN HYDROCHLORIDE
CROMOLYN SODIUM, CROMOLYN SODIUM
CYCLOGYL, CYCLOPENTOLATE HYDROCHLORIDE
CYCLOMYDRIL, CYCLOPENTOLATE HYDROCHLORIDE
DENDRID, IDOXURIDINE
ECONOCHLOR, CHLORAMPHENICOL
ECONOPRED, PREDNISOLONE ACETATE
EMADINE, EMEDASTINE DIFUMARATE
FLAREX, FLUOROMETHOLONE ACETATE
IOPIDINE, APRACLONIDINE HYDROCHLORIDE
ISMOTIC, ISOSORBIDE
ISOPTO CETAMIDE, SULFACETAMIDE SODIUM
ISOPTO CETAPRED, PREDNISOLONE ACETATE
MAXIDEX, DEXAMETHASONE
MAXIDEX, DEXAMETHASONE SODIUM PHOSPHATE
MAXITROL, DEXAMETHASONE
MIOSTAT, CARBACHOL
MYDRIACYL, TROPICAMIDE
NAPHCON FORTE, NAPHAZOLINE HYDROCHLORIDE
NAPHCON-A, NAPHAZOLINE HYDROCHLORIDE (OTC)
NATACYN, NATAMYCIN
NEO-OTOSOL-HC, HYDROCORTISONE
PANTOPAQUE, IOPHENDYLATE
PATANOL, OLOPATADINE HYDROCHLORIDE
PILOPINE HS, PILOCARPINE HYDROCHLORIDE
PROFENAL, SUPROFEN
STATROL, NEOMYCIN SULFATE
TOBRADEX, DEXAMETHASONE
TOBRASONE, FLUOROMETHOLONE ACETATE
TOBREX, TOBRAMYCIN
TRIFLURIDINE, TRIFLURIDINE
VEXOL, RIMEXOLONE
ZOLYSE, CHYMOTRYPSIN

ALCON UNIVERSAL
* ALCON UNIVERSAL LTD
CYCLOPENTOLATE HCL, CYCLOPENTOLATE HYDROCHLORIDE
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE, DEXAMETHASONE
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE, HYDROCORTISONE
NEOMYCIN SULFATE-DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
TOBRAMYCIN, TOBRAMYCIN
TRAVATAN, TRAVOPROST
TROPICAMIDE, TROPICAMIDE

ALIMENTERICS
* ALIMENTERICS INC
PYLORI-CHEK BREATH TEST, UREA, C-13

ALLEGIANCE HLTHCARE
* ALLEGIANCE HEALTHCARE CORP
POVIDONE IODINE, POVIDONE-IODINE (OTC)

ALLENDALE PHARMS
* ALLENDALE PHARMACEUTICALS
TODAY, NONOXYNOL-9 (OTC)

ALLERGAN
* ALLERGAN
BLEPH-10, SULFACETAMIDE SODIUM
BLEPH-30, SULFACETAMIDE SODIUM
GENOPTIC, GENTAMICIN SULFATE
* ALLERGAN INC
ACULAR PRESERVATIVE FREE, KETOROLAC TROMETHAMINE
ACULAR, KETOROLAC TROMETHAMINE
ALBALON, NAPHAZOLINE HYDROCHLORIDE
ALOCRIL, NEDOCROMIL SODIUM
ALPHAGAN P, BRIMONIDINE TARTRATE
ALPHAGAN, BRIMONIDINE TARTRATE
AZELEX, AZELAIC ACID
ELIMITE, PERMETHRIN
LUMIGAN, BIMATOPROST
OCUFLOX, OFLOXACIN
OPTICROM, CROMOLYN SODIUM
POLYTRIM, POLYMYXIN B SULFATE

FDA data supplied by DrugPatentWatch.com

TAZORAC, TAZAROTENE
* ALLERGAN PHARMACEUTICAL
BETAGAN, LEVOBUNOLOL HYDROCHLORIDE
BLEPH-10, SULFACETAMIDE SODIUM
BLEPHAMIDE S.O.P., PREDNISOLONE ACETATE
BLEPHAMIDE, PREDNISOLONE ACETATE
CHLOROPTIC S.O.P., CHLORAMPHENICOL
CHLOROPTIC, CHLORAMPHENICOL
CHLOROPTIC-P S.O.P., CHLORAMPHENICOL
ETHAMIDE, ETHOXZOLAMIDE
FML FORTE, FLUOROMETHOLONE
FML, FLUOROMETHOLONE
FML-S, FLUOROMETHOLONE
HERPLEX, IDOXURIDINE
HMS, MEDRYSONE
OCUFEN, FLURBIPROFEN SODIUM
OPHTHETIC, PROPARACAINE HYDROCHLORIDE
POLY-PRED, NEOMYCIN SULFATE
PRED FORTE, PREDNISOLONE ACETATE
PRED MILD, PREDNISOLONE ACETATE
PRED-G, GENTAMICIN SULFATE
PREFRIN-A, PHENYLEPHRINE HYDROCHLORIDE
PROPINE, DIPIVEFRIN HYDROCHLORIDE

ALLERGAN HERBERT
* ALLERGAN HERBERT DIV ALLERGAN INC
AEROSEB-DEX, DEXAMETHASONE
AEROSEB-HC, HYDROCORTISONE
ERYGEL, ERYTHROMYCIN
ERYMAX, ERYTHROMYCIN
EXSEL, SELENIUM SULFIDE
FLUONID, FLUOCINOLONE ACETONIDE
FLUOROPLEX, FLUOROURACIL
PENECORT, HYDROCORTISONE
* ALLERGAN HERBERT SKIN CARE DIV ALLERGAN INC
FLUOROPLEX, FLUOROURACIL
NAFTIN, NAFTIFINE HYDROCHLORIDE
PENECORT, HYDROCORTISONE
TEMARIL, TRIMEPRAZINE TARTRATE

ALLIANCE PHARM
* ALLIANCE PHARMACEUTICAL CORP
IMAGENT, PERFLUBRON

ALPHA THERA
* ALPHA THERAPEUTIC CORP
SOYACAL 10%, SOYBEAN OIL
SOYACAL 20%, SOYBEAN OIL

ALPHAPHARM
* ALPHAPHARM PARTY LTD
ALPRAZOLAM, ALPRAZOLAM
AMIODARONE HCL, AMIODARONE HYDROCHLORIDE
CLONAZEPAM, CLONAZEPAM
FLECAINIDE ACETATE, FLECAINIDE ACETATE
FLUOXETINE HCL, FLUOXETINE HYDROCHLORIDE
GLIPIZIDE, GLIPIZIDE
INDAPAMIDE, INDAPAMIDE
NAPROXEN, NAPROXEN
SELEGILINE HCL, SELEGILINE HYDROCHLORIDE
TRIAZOLAM, TRIAZOLAM

ALPHARMA
* ALPHARMA INC
SULFATRIM PEDIATRIC, SULFAMETHOXAZOLE
SULFATRIM, SULFAMETHOXAZOLE
* ALPHARMA USPD INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACETASOL HC, ACETIC ACID, GLACIAL
ACETASOL, ACETIC ACID, GLACIAL
ACYCLOVIR, ACYCLOVIR
ALBUTEROL SULFATE, ALBUTEROL SULFATE
AMANTADINE HCL, AMANTADINE HYDROCHLORIDE
AMINOPHYLLINE DYE FREE, AMINOPHYLLINE
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
BROMANATE DC, BROMPHENIRAMINE MALEATE
BROMANATE DM, BROMPHENIRAMINE MALEATE
BROMANATE, BROMPHENIRAMINE MALEATE
BROMANYL, BROMODIPHENHYDRAMINE HYDROCHLORIDE
BROMPHENIRAMINE MALEATE, BROMPHENIRAMINE MALEATE
BUTABARB, BUTABARBITAL SODIUM
CAPITAL AND CODEINE, ACETAMINOPHEN
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
CHLORPROMAZINE HCL, CHLORPROMAZINE HYDROCHLORIDE
CIMETIDINE HCL, CIMETIDINE HYDROCHLORIDE
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CODAMINE, HYDROCODONE BITARTRATE
CONSTULOSE, LACTULOSE
CROMOLYN SODIUM, CROMOLYN SODIUM
CROMOLYN SODIUM, CROMOLYN SODIUM (OTC)
CYPROHEPTADINE HCL, CYPROHEPTADINE HYDROCHLORIDE
DEXAMETHASONE, DEXAMETHASONE
DICYCLOMINE HCL, DICYCLOMINE HYDROCHLORIDE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
ENULOSE, LACTULOSE
EPINEPHRINE, EPINEPHRINE (OTC)
ERYTHROMYCIN ESTOLATE, ERYTHROMYCIN ESTOLATE
ERYTHROMYCIN ETHYLSUCCINATE, ERYTHROMYCIN ETHYLSUCCINATE
ERYTHROMYCIN, ERYTHROMYCIN
FLUOCET, FLUOCINOLONE ACETONIDE
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUOCINONIDE, FLUOCINONIDE
FLURANDRENOLIDE, FLURANDRENOLIDE
GENTAMICIN SULFATE, GENTAMICIN SULFATE

FDA data supplied by DrugPatentWatch.com

HALOPERIDOL, HALOPERIDOL LACTATE
HYDRAMINE, DIPHENHYDRAMINE HYDROCHLORIDE
HYDRAMINE, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
HYDROCODONE COMPOUND, HOMATROPINE METHYLBROMIDE
HYDROCORTISONE, HYDROCORTISONE
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
ISOETHARINE HCL, ISOETHARINE HYDROCHLORIDE
ISOETHARINE MESYLATE, ISOETHARINE MESYLATE
ISOPROTERENOL HCL, ISOPROTERENOL HYDROCHLORIDE
LIDOCAINE HCL VISCOUS, LIDOCAINE HYDROCHLORIDE
LINDANE, LINDANE
LOMANATE, ATROPINE SULFATE
LOPERAMIDE HCL, LOPERAMIDE HYDROCHLORIDE (OTC)
M-ZOLE 7 DUAL PACK, MICONAZOLE NITRATE (OTC)
METHDILAZINE HCL, METHDILAZINE HYDROCHLORIDE
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
MYKINAC, NYSTATIN
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
NYSTATIN, NYSTATIN
PERMETHRIN, PERMETHRIN
PERMETHRIN, PERMETHRIN (OTC)
PHENYTOIN, PHENYTOIN
PIPERAZINE CITRATE, PIPERAZINE CITRATE
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
PROCHLORPERAZINE, PROCHLORPERAZINE EDISYLATE
PROMETH FORTIS, PROMETHAZINE HYDROCHLORIDE
PROMETH PLAIN, PROMETHAZINE HYDROCHLORIDE
PROMETH VC PLAIN, PHENYLEPHRINE HYDROCHLORIDE
PROMETH VC W/ CODEINE, CODEINE PHOSPHATE
PROMETH W/ CODEINE, CODEINE PHOSPHATE
PROMETH W/ DEXTROMETHORPHAN, DEXTROMETHORPHAN HYDROBROMIDE
SELENIUM SULFIDE, SELENIUM SULFIDE
TETRACYCLINE HCL, TETRACYCLINE HYDROCHLORIDE
THEOPHYLLINE, THEOPHYLLINE
THIORIDAZINE HCL, THIORIDAZINE HYDROCHLORIDE
THIOTHIXENE HCL, THIOTHIXENE HYDROCHLORIDE
TRIACIN-C, CODEINE PHOSPHATE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
TRIMEPRAZINE TARTRATE, TRIMEPRAZINE TARTRATE
TRIMETH/SULFA, SULFAMETHOXAZOLE
TRIPLE SULFA, TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE; SULFATHIAZOLE)
TRIPLE SULFA, TRISULFAPYRIMIDINES (SULFADIAZINE; SULFAMERAZINE;SULFAMETHAZINE)
TRIPROLIDINE HCL, TRIPROLIDINE HYDROCHLORIDE

ALPHARMA US PHARM
* ALPHARMA US PHARMACEUTICAL DIV
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
HYDROCORTISONE, HYDROCORTISONE
INFANTS' FEVERALL, ACETAMINOPHEN (OTC)
M-ZOLE 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MICONAZOLE 7, MICONAZOLE NITRATE (OTC)
MICONAZOLE NITRATE, MICONAZOLE NITRATE
MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
MYKACET, NYSTATIN

ALRA
* ALRA LABORATORIES INC
ACETAZOLAMIDE, ACETAZOLAMIDE
BAMATE, MEPROBAMATE
CHOLAC, LACTULOSE
COMPOUND 65, ASPIRIN
CONSTILAC, LACTULOSE
DIMENHYDRINATE, DIMENHYDRINATE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
ERYZOLE, ERYTHROMYCIN ETHYLSUCCINATE
GEN-XENE, CLORAZEPATE DIPOTASSIUM
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IBU-TAB 200, IBUPROFEN (OTC)
IBU-TAB, IBUPROFEN
K+10, POTASSIUM CHLORIDE
K+8, POTASSIUM CHLORIDE
LYGEN, CHLORDIAZEPOXIDE HYDROCHLORIDE
PRAMINE, IMIPRAMINE HYDROCHLORIDE
PROPOXYPHENE HCL, PROPOXYPHENE HYDROCHLORIDE
SOXAZOLE, SULFISOXAZOLE
TOLBUTAMIDE, TOLBUTAMIDE

ALTANA
* ALTANA INC
BACITRACIN, BACITRACIN
BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE, BACITRACIN
BACITRACIN-NEOMYCIN-POLYMYXIN, BACITRACIN ZINC
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CHLORAMPHENICOL, CHLORAMPHENICOL
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE (EMOLLIENT), CLOBETASOL PROPIONATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
DESONIDE, DESONIDE
DESOXIMETASONE, DESOXIMETASONE
DIFLORASONE DIACETATE, DIFLORASONE DIACETATE
ERYTHROMYCIN, ERYTHROMYCIN
FLUOCINONIDE, FLUOCINONIDE
HYDROCORTISONE ACETATE, HYDROCORTISONE ACETATE
HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE
HYDROCORTISONE, HYDROCORTISONE

FDA data supplied by DrugPatentWatch.com

HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
NITROGLYCERIN, NITROGLYCERIN
NYSTATIN, NYSTATIN
SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
TOBRAMYCIN, TOBRAMYCIN
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
ZIPAN-25, PROMETHAZINE HYDROCHLORIDE
ZIPAN-50, PROMETHAZINE HYDROCHLORIDE

ALZA
* ALZA CORP
CONCERTA, METHYLPHENIDATE HYDROCHLORIDE
DITROPAN XL, OXYBUTYNIN CHLORIDE
DITROPAN, OXYBUTYNIN CHLORIDE
DOXIL, DOXORUBICIN HYDROCHLORIDE
DURAGESIC, FENTANYL
EFIDAC 24 CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE (OTC)
EFIDAC 24 PSEUDOEPHEDRINE HCL, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
EFIDAC 24 PSEUDOEPHEDRINE HCL/BROMPHENIRAMINE MALEATE, BROMPHENIRAMINE MALEATE (OTC)
ELMIRON, PENTOSAN POLYSULFATE SODIUM
PROGESTASERT, PROGESTERONE
TESTODERM, TESTOSTERONE
VIADUR, LEUPROLIDE ACETATE

AM PHARM PARTNERS
* AMERICAN PHARMACEUTICAL PARTNERS INC
ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
AMINOCAPROIC ACID, AMINOCAPROIC ACID
AMINOPHYLLINE, AMINOPHYLLINE
AMPHOTERICIN B, AMPHOTERICIN B
BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER, WATER FOR INJECTION, STERILE
BRETYLIUM TOSYLATE, BRETYLIUM TOSYLATE
CALCIUM GLUCEPTATE, CALCIUM GLUCEPTATE
CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
CEFIZOX, CEFTIZOXIME SODIUM
CEFOTAXIME, CEFOTAXIME SODIUM
CEFOXITIN, CEFOXITIN SODIUM
CEFUROXIME SODIUM, CEFUROXIME SODIUM
CEFUROXIME, CEFUROXIME SODIUM
CEPHALOTHIN SODIUM, CEPHALOTHIN SODIUM
CEPHAPIRIN SODIUM, CEPHAPIRIN SODIUM
CHLORAMPHENICOL SODIUM SUCCINATE, CHLORAMPHENICOL SODIUM SUCCINATE
CHLORPROMAZINE HCL, CHLORPROMAZINE HYDROCHLORIDE
CHORIONIC GONADOTROPIN, GONADOTROPIN, CHORIONIC
CHROMIC CHLORIDE, CHROMIC CHLORIDE
CISPLATIN, CISPLATIN
CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%, CLINDAMYCIN PHOSPHATE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CUPRIC SULFATE, CUPRIC SULFATE
CYANOCOBALAMIN, CYANOCOBALAMIN
DACARBAZINE, DACARBAZINE
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DEXAMETHASONE, DEXAMETHASONE SODIUM PHOSPHATE
DIAZEPAM, DIAZEPAM
DIAZOXIDE, DIAZOXIDE
DIGOXIN, DIGOXIN
DIPHENHYDRAMINE HCL PRESERVATIVE FREE, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DIPYRIDAMOLE, DIPYRIDAMOLE
DOPAMINE HCL, DOPAMINE HYDROCHLORIDE
DOXORUBICIN HCL, DOXORUBICIN HYDROCHLORIDE
DOXY 100, DOXYCYCLINE HYCLATE
DOXY 200, DOXYCYCLINE HYCLATE
DROPERIDOL, DROPERIDOL
ERYTHROMYCIN LACTOBIONATE, ERYTHROMYCIN LACTOBIONATE
ETOPOSIDE, ETOPOSIDE
FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE
FLOXURIDINE, FLOXURIDINE
FLUOROURACIL, FLUOROURACIL
FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
FLUPHENAZINE HCL, FLUPHENAZINE HYDROCHLORIDE
FOLIC ACID, FOLIC ACID
FUROSEMIDE, FUROSEMIDE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
GLYCOPYRROLATE, GLYCOPYRROLATE
HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
HALOPERIDOL, HALOPERIDOL LACTATE
HEP FLUSH KIT IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN LOCK FLUSH PRESERVATIVE FREE IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN LOCK FLUSH PRESERVATIVE FREE, HEPARIN SODIUM
HEPARIN LOCK FLUSH, HEPARIN SODIUM
HEPARIN SODIUM IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
HEPARIN SODIUM, HEPARIN SODIUM
HEPFLUSH-10, HEPARIN SODIUM
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
HYDROCORTISONE SODIUM SUCCINATE, HYDROCORTISONE SODIUM SUCCINATE
HYDROXOCOBALAMIN, HYDROXOCOBALAMIN
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
IOPAMIDOL-250, IOPAMIDOL
IOPAMIDOL-300, IOPAMIDOL
IOPAMIDOL-370, IOPAMIDOL
ISOPROTERENOL HCL, ISOPROTERENOL HYDROCHLORIDE
KANAMYCIN SULFATE, KANAMYCIN SULFATE

FDA data supplied by DrugPatentWatch.com

LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
LIDOCAINE HCL IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL, LIDOCAINE HYDROCHLORIDE
M.V.C. 9+3, ASCORBIC ACID
MAGNESIUM SULFATE, MAGNESIUM SULFATE
MANGANESE SULFATE, MANGANESE SULFATE
MANNITOL 25%, MANNITOL
MESNA, MESNA
METARAMINOL BITARTRATE, METARAMINOL BITARTRATE
METHOTREXATE SODIUM, METHOTREXATE SODIUM
METHYLDOPATE HCL, METHYLDOPATE HYDROCHLORIDE
METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
METRONIDAZOLE HCL, METRONIDAZOLE HYDROCHLORIDE
METRONIDAZOLE, METRONIDAZOLE
MIDAZOLAM HCL, MIDAZOLAM HYDROCHLORIDE
NALBUPHINE, NALBUPHINE HYDROCHLORIDE
NALOXONE HCL, NALOXONE HYDROCHLORIDE
NANDROLONE DECANOATE, NANDROLONE DECANOATE
NEBUPENT, PENTAMIDINE ISETHIONATE
NITROGLYCERIN, NITROGLYCERIN
OXYTOCIN, OXYTOCIN
PENTAM, PENTAMIDINE ISETHIONATE
PHENYTOIN SODIUM, PHENYTOIN SODIUM
POTASSIUM CHLORIDE IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PROCAINAMIDE HCL, PROCAINAMIDE HYDROCHLORIDE
PROCAINE HCL, PROCAINE HYDROCHLORIDE
PROGESTERONE, PROGESTERONE
PROTAMINE SULFATE, PROTAMINE SULFATE
PYRIDOXINE HCL, PYRIDOXINE HYDROCHLORIDE
RITODRINE HCL, RITODRINE HYDROCHLORIDE
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 23.4% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM HEPARIN, HEPARIN SODIUM
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, WATER FOR INJECTION, STERILE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
THIAMINE HCL, THIAMINE HYDROCHLORIDE
VANCOMYCIN HCL, VANCOMYCIN HYDROCHLORIDE
VERAPAMIL HCL, VERAPAMIL HYDROCHLORIDE
VIBISONE, CYANOCOBALAMIN
VINBLASTINE SULFATE, VINBLASTINE SULFATE
VINCRISTINE SULFATE, VINCRISTINE SULFATE
ZINC SULFATE, ZINC SULFATE

AM THERAP
* AMERICAN THERAPEUTICS INC
ACETAMINOPHEN AND CODEINE PHOSPHATE NO. 2, ACETAMINOPHEN
ACETAMINOPHEN AND CODEINE PHOSPHATE NO. 3, ACETAMINOPHEN
ACETAMINOPHEN AND CODEINE PHOSPHATE NO. 4, ACETAMINOPHEN
ALBUTEROL SULFATE, ALBUTEROL SULFATE
AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
CLONIDINE HCL, CLONIDINE HYDROCHLORIDE
CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
CYPROHEPTADINE HCL, CYPROHEPTADINE HYDROCHLORIDE
DANAZOL, DANAZOL
FENOPROFEN CALCIUM, FENOPROFEN CALCIUM
LORAZEPAM, LORAZEPAM
MAPROTILINE HCL, MAPROTILINE HYDROCHLORIDE
MECLOFENAMATE SODIUM, MECLOFENAMATE SODIUM
METAPROTERENOL SULFATE, METAPROTERENOL SULFATE
METHOCARBAMOL, METHOCARBAMOL
OXAZEPAM, OXAZEPAM
PRAZOSIN HCL, PRAZOSIN HYDROCHLORIDE
PREDNISONE, PREDNISONE
THIOTHIXENE, THIOTHIXENE
TRAZODONE HCL, TRAZODONE HYDROCHLORIDE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

AMARIN PHARMS
* AMARIN PHARMACEUTICALS INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
AMEN, MEDROXYPROGESTERONE ACETATE
BONTRIL PDM, PHENDIMETRAZINE TARTRATE
MOTOFEN HALF-STRENGTH, ATROPINE SULFATE
MOTOFEN, ATROPINE SULFATE
PHRENILIN FORTE, ACETAMINOPHEN
PHRENILIN WITH CAFFEINE AND CODEINE, ACETAMINOPHEN
PHRENILIN, ACETAMINOPHEN

AMBIX
* AMBIX LABORATORIES DIV ORGANICS CORP AMERICA
HYDROCORTISONE, HYDROCORTISONE
NITROFURAZONE, NITROFURAZONE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

AMERSHAM HLTH
* AMERSHAM HEALTH
AMERSCAN MDP KIT, TECHNETIUM TC-99M MEDRONATE KIT
AMIPAQUE, METRIZAMIDE
BILOPAQUE, TYROPANOATE SODIUM
CERETEC, TECHNETIUM TC-99M EXAMETAZIME KIT
CINTICHEM TECHNETIUM 99M HEDSPA, TECHNETIUM TC-99M ETIDRONATE KIT
DICOPAC KIT, CYANOCOBALAMIN
FERRISELTZ, FERRIC AMMONIUM CITRATE
FLUORINE F-18, SODIUM FLUORIDE, F-18
GALLIUM CITRATE GA 67, GALLIUM CITRATE, GA-67
HYPAQUE SODIUM 20%, DIATRIZOATE SODIUM
HYPAQUE, DIATRIZOATE MEGLUMINE
HYPAQUE, DIATRIZOATE SODIUM
HYPAQUE-76, DIATRIZOATE MEGLUMINE

FDA data supplied by DrugPatentWatch.com

HYPAQUE-CYSTO, DIATRIZOATE MEGLUMINE
HYPAQUE-M,75%, DIATRIZOATE MEGLUMINE
HYPAQUE-M,90%, DIATRIZOATE MEGLUMINE
IBRIN, FIBRINOGEN, I-125
INDIUM IN-111 OXYQUINOLINE, INDIUM IN-111 OXYQUINOLINE
INDOMETHACIN, INDOMETHACIN
ISOPAQUE 280, CALCIUM
ISOPAQUE 440, CALCIUM METRIZOATE
LUNGAGGREGATE REAGENT, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT
METASTRON, STRONTIUM CHLORIDE, SR-89
MPI DMSA KIDNEY REAGENT, TECHNETIUM TC-99M SUCCIMER KIT
MPI DTPA KIT - CHELATE, TECHNETIUM TC-99M PENTETATE KIT
MPI INDIUM DTPA IN 111, INDIUM IN-111 PENTETATE DISODIUM
MPI KRYPTON 81M GAS GENERATOR, KRYPTON, KR-81M
MPI STANNOUS DIPHOSPHONATE, TECHNETIUM TC-99M ETIDRONATE KIT
MYOVIEW, TECHNETIUM TC-99M TETROFOSMIN KIT
NEOSCAN, GALLIUM CITRATE, GA-67
NEPHROFLOW, IODOHIPPURATE SODIUM, I-123
OMNIPAQUE 140, IOHEXOL
OMNIPAQUE 180, IOHEXOL
OMNIPAQUE 210, IOHEXOL
OMNIPAQUE 240, IOHEXOL
OMNIPAQUE 300, IOHEXOL
OMNIPAQUE 350, IOHEXOL
OMNIPAQUE 70, IOHEXOL
OMNISCAN, GADODIAMIDE
SELENOMETHIONINE SE 75, SELENOMETHIONINE, SE-75
SODIUM IODIDE I 123, SODIUM IODIDE, I-123
SODIUM PERTECHNETATE TC 99M, TECHNETIUM TC-99M SODIUM PERTECHNETATE
SODIUM POLYPHOSPHATE-TIN KIT, TECHNETIUM TC-99M POLYPHOSPHATE KIT
TC 99M-LUNGAGGREGATE, TECHNETIUM TC-99M ALBUMIN AGGREGATED
TECHNETIUM TC 99M DIPHOSPHONATE-TIN KIT, TECHNETIUM TC-99M ETIDRONATE KIT
TECHNETIUM TC 99M GENERATOR, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
TECHNETIUM TC 99M HSA, TECHNETIUM TC-99M ALBUMIN KIT
TECHNETIUM TC 99M MAA, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT
TECHNETIUM TC 99M MPI MDP, TECHNETIUM TC-99M MEDRONATE KIT
TECHNETIUM TC 99M SULFUR COLLOID, TECHNETIUM TC-99M SULFUR COLLOID
TECHNETIUM TC 99M TSC, TECHNETIUM TC-99M SULFUR COLLOID KIT
TECHNETIUM TC-99M PENTETATE KIT, TECHNETIUM TC-99M PENTETATE KIT
TELEPAQUE, IOPANOIC ACID
TESLASCAN, MANGAFODIPIR TRISODIUM
THALLOUS CHLORIDE TL 201, THALLOUS CHLORIDE, TL-201
VISIPAQUE 270, IODIXANOL
VISIPAQUE 320, IODIXANOL
XENON XE 133, XENON, XE-133
XENON XE 133-V.S.S., XENON, XE-133

AMIDE PHARM
* AMIDE PHARMACEUTICAL INC
BETAXOLOL HCL, BETAXOLOL HYDROCHLORIDE
CARISOPRODOL AND ASPIRIN, ASPIRIN
CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE, ASPIRIN
CARISOPRODOL, CARISOPRODOL
CHLORZOXAZONE, CHLORZOXAZONE
DIGOXIN, DIGOXIN
GUANFACINE HCL, GUANFACINE HYDROCHLORIDE
HOMATROPRINE METHYLBROMIDE AND HYDROCODONE BITARTRATE, HOMATROPINE METHYLBROMIDE
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
MEPERIDINE HCL, MEPERIDINE HYDROCHLORIDE
NALOXONE HCL AND PENTAZOCAINE, NALOXONE HYDROCHLORIDE
NALTREXONE HCL, NALTREXONE HYDROCHLORIDE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
PEMOLINE, PEMOLINE
PHENTERMINE HCL, PHENTERMINE HYDROCHLORIDE
URSODIOL, URSODIOL

ANABOLIC
* ANABOLIC INC
BROMPHENIRAMINE MALEATE, BROMPHENIRAMINE MALEATE
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE, ASPIRIN
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
DIMENHYDRINATE, DIMENHYDRINATE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
FOLIC ACID, FOLIC ACID
HYDROCORTISONE, HYDROCORTISONE
ISONIAZID, ISONIAZID
MECLIZINE HCL, MECLIZINE HYDROCHLORIDE
MEPROBAMATE, MEPROBAMATE
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PROPOXYPHENE HCL, PROPOXYPHENE HYDROCHLORIDE
PROPYLTHIOURACIL, PROPYLTHIOURACIL
SODIUM PENTOBARBITAL, PENTOBARBITAL SODIUM
SODIUM SECOBARBITAL, SECOBARBITAL SODIUM
TRIPELENNAMINE HCL, TRIPELENNAMINE HYDROCHLORIDE

ANBEX
* ANBEX INC
IOSAT, POTASSIUM IODIDE (OTC)

ANDRX
* ANDRX CORP
DILTIAZEM HCL, DILTIAZEM HYDROCHLORIDE

ANDRX PHARM
* ANDRX PHARMACEUTICALS LLC

FDA data supplied by DrugPatentWatch.com

ETODOLAC, ETODOLAC

ANDRX PHARMS
* ANDRX PHARMACEUTICALS INC
CARTIA XT, DILTIAZEM HYDROCHLORIDE
KETOPROFEN, KETOPROFEN
OMEPRAZOLE, OMEPRAZOLE

ANESTA
* ANESTA CORP
ACTIQ, FENTANYL CITRATE
FENTANYL, FENTANYL CITRATE

ANGELINI
* ANGELINI PHARMACEUTICALS INC
REV-EYES, DAPIPRAZOLE HYDROCHLORIDE

ANGUS
* ANGUS CHEMICAL CO
MYCHEL-S, CHLORAMPHENICOL SODIUM SUCCINATE
TETRACHEL, TETRACYCLINE HYDROCHLORIDE

ANTHRA
* ANTHRA PHARMACEUTICALS INC
VALSTAR PRESERVATIVE FREE, VALRUBICIN

APOTEX
* APOTEX CORP
BUTORPHANOL TARTRATE PRESERVATIVE FREE, BUTORPHANOL TARTRATE
BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
DILTIAZEM HCL, DILTIAZEM HYDROCHLORIDE
FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
MIDAZOLAM HCL, MIDAZOLAM HYDROCHLORIDE
SELEGILINE HCL, SELEGILINE HYDROCHLORIDE

APOTHECON
* APOTHECON INC DIV BRISTOL MYERS SQUIBB
ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
ACYCLOVIR, ACYCLOVIR
AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, AMIKACIN SULFATE
AMIKIN, AMIKACIN SULFATE
AMOXICILLIN, AMOXICILLIN
AMPICILLIN SODIUM, AMPICILLIN SODIUM
BETAPEN-VK, PENICILLIN V POTASSIUM
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
CAPOZIDE 25/15, CAPTOPRIL
CAPOZIDE 25/25, CAPTOPRIL
CAPOZIDE 50/15, CAPTOPRIL
CAPOZIDE 50/25, CAPTOPRIL
CAPTOPRIL, CAPTOPRIL
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CEFADYL, CEPHAPIRIN SODIUM
CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
CEPHALEXIN, CEPHALEXIN
CLOXACILLIN SODIUM, CLOXACILLIN SODIUM
CORGARD, NADOLOL
DESYREL, TRAZODONE HYDROCHLORIDE
DICLOXACILLIN SODIUM, DICLOXACILLIN SODIUM
DILTIAZEM HCL, DILTIAZEM HYDROCHLORIDE
DYNAPEN, DICLOXACILLIN SODIUM
ENALAPRIL MALEATE, ENALAPRIL MALEATE
FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE
FUNGIZONE, AMPHOTERICIN B
KANTREX, KANAMYCIN SULFATE
KENALOG IN ORABASE, TRIAMCINOLONE ACETONIDE
KENALOG, TRIAMCINOLONE ACETONIDE
KENALOG-10, TRIAMCINOLONE ACETONIDE
KENALOG-40, TRIAMCINOLONE ACETONIDE
KENALOG-H, TRIAMCINOLONE ACETONIDE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
KLOTRIX, POTASSIUM CHLORIDE
LABETALOL HCL, LABETALOL HYDROCHLORIDE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
MIDAZOLAM HCL, MIDAZOLAM HYDROCHLORIDE
MUCOMYST, ACETYLCYSTEINE
MYCOLOG-II, NYSTATIN
MYCOSTATIN, NYSTATIN
NAFCILLIN SODIUM, NAFCILLIN SODIUM
NATURETIN-10, BENDROFLUMETHIAZIDE
NATURETIN-2.5, BENDROFLUMETHIAZIDE
NATURETIN-5, BENDROFLUMETHIAZIDE
NYDRAZID, ISONIAZID
OPHTHAINE, PROPARACAINE HYDROCHLORIDE
OXACILLIN SODIUM, OXACILLIN SODIUM
PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM
POLYCILLIN, AMPICILLIN/AMPICILLIN TRIHYDRATE
POLYCILLIN-PRB, AMPICILLIN/AMPICILLIN TRIHYDRATE
POLYMOX, AMOXICILLIN
PRECEF, CEFORANIDE
PRINCIPEN, AMPICILLIN/AMPICILLIN TRIHYDRATE
PROLIXIN ENANTHATE, FLUPHENAZINE ENANTHATE
PROLIXIN, FLUPHENAZINE HYDROCHLORIDE
PRONESTYL, PROCAINAMIDE HYDROCHLORIDE
PRONESTYL-SR, PROCAINAMIDE HYDROCHLORIDE
PROSTAPHLIN, OXACILLIN SODIUM
QUESTRAN, CHOLESTYRAMINE
RAUDIXIN, RAUWOLFIA SERPENTINA
SELEGILINE HCL, SELEGILINE HYDROCHLORIDE
STADOL PRESERVATIVE FREE, BUTORPHANOL TARTRATE
STADOL, BUTORPHANOL TARTRATE
STAPHCILLIN, METHICILLIN SODIUM

FDA data supplied by DrugPatentWatch.com

SUCOSTRIN, SUCCINYLCHOLINE CHLORIDE
SUMYCIN, TETRACYCLINE HYDROCHLORIDE
TEGOPEN, CLOXACILLIN SODIUM
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
TRIMOX, AMOXICILLIN
ULTRACEF, CEFADROXIL/CEFADROXIL HEMIHYDRATE
VEETIDS, PENICILLIN V POTASSIUM
VELOSEF '125', CEPHRADINE
VELOSEF '250', CEPHRADINE
VELOSEF, CEPHRADINE
VESPRIN, TRIFLUPROMAZINE HYDROCHLORIDE

* APOTHECON SUB BRISTOL MYERS SQUIBB CO
ATENOLOL, ATENOLOL
OXACILLIN SODIUM, OXACILLIN SODIUM
PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM
PENTIDS '200', PENICILLIN G POTASSIUM
PENTIDS '250', PENICILLIN G POTASSIUM
PENTIDS '400', PENICILLIN G POTASSIUM
PENTIDS '800', PENICILLIN G POTASSIUM
PRINCIPEN '125', AMPICILLIN/AMPICILLIN TRIHYDRATE
PRINCIPEN '250', AMPICILLIN/AMPICILLIN TRIHYDRATE
PRINCIPEN '500', AMPICILLIN/AMPICILLIN TRIHYDRATE
PRINCIPEN W/ PROBENECID, AMPICILLIN/AMPICILLIN TRIHYDRATE
TRIMOX, AMOXICILLIN
VEETIDS '125', PENICILLIN V POTASSIUM
VEETIDS '250', PENICILLIN V POTASSIUM
VEETIDS '500', PENICILLIN V POTASSIUM
VESPRIN, TRIFLUPROMAZINE

APOTHEKERNES
* APOTHEKERNES LABORATORIUM A/S
BACITRACIN, BACITRACIN

APPLIED ANAL
* APPLIED ANALYTICAL INDUSTRIES
METHAZOLAMIDE, METHAZOLAMIDE

* APPLIED ANALYTICAL INDUSTRIES INC
AZATHIOPRINE, AZATHIOPRINE
ESTRADIOL, ESTRADIOL
KETOCONAZOLE, KETOCONAZOLE

ARBROOK
* ARBROOK INC
GAMOPHEN, HEXACHLOROPHENE

ARCUM
* ARCUM PHARMACEUTICAL CORP
VITAMIN A PALMITATE, VITAMIN A PALMITATE

ARMENPHARM
* ARMENPHARM LTD
MYCHEL, CHLORAMPHENICOL

ARMOUR PHARM

* ARMOUR PHARMACEUTICAL CO
ACTHAR GEL-SYNTHETIC, SERACTIDE ACETATE
DEPINAR, CYANOCOBALAMIN
ISOPROTERENOL HCL, ISOPROTERENOL HYDROCHLORIDE
PENTACARINAT, PENTAMIDINE ISETHIONATE

ARMSTRONG PHARMS
* ARMSTRONG PHARMACEUTICALS INC
ALBUTEROL, ALBUTEROL

ASCENT PEDS
* ASCENT PEDIATRICS INC
ORAPRED, PREDNISOLONE SODIUM PHOSPHATE
PRIMSOL, TRIMETHOPRIM HYDROCHLORIDE

ASCHER
* BF ASCHER AND CO INC
DRIZE, CHLORPHENIRAMINE MALEATE
HY-PHEN, ACETAMINOPHEN

ASCOT
* ASCOT HOSP PHARMACEUTICALS INC DIV TRAVENOL LABORATORIES INC
ACETAZOLAMIDE, ACETAZOLAMIDE
AMINOPHYLLINE, AMINOPHYLLINE
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
CHLORDIAZEPOXIDE HCL, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLORTHALIDONE, CHLORTHALIDONE
CYPROHEPTADINE HCL, CYPROHEPTADINE HYDROCHLORIDE
DIPHENOXYLATE HCL AND ATROPINE SULFATE, ATROPINE SULFATE
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
METHOCARBAMOL, METHOCARBAMOL
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
PROCAINAMIDE HCL, PROCAINAMIDE HYDROCHLORIDE
PROPANTHELINE BROMIDE, PROPANTHELINE BROMIDE
QUINIDINE GLUCONATE, QUINIDINE GLUCONATE
SPIRONOLACTONE + HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPIRONOLACTONE, SPIRONOLACTONE
SULFAMETHOXAZOLE, SULFAMETHOXAZOLE
TOLBUTAMIDE, TOLBUTAMIDE

ASLUNG PHARM
* ASLUNG PHARMACEUTICAL LP
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE

ASTA
* ASTA MEDICA INC
CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
OPTIVAR, AZELASTINE HYDROCHLORIDE

* ASTA PHARMA AG
MESNEX, MESNA

ASTRAZENECA

FDA data supplied by DrugPatentWatch.com

* ASTRAZENECA LP
AMIKACIN SULFATE, AMIKACIN SULFATE
AQUASOL A, VITAMIN A
ASTRAMORPH PF, MORPHINE SULFATE
BRETYLIUM TOSYLATE, BRETYLIUM TOSYLATE
CALCITONIN-SALMON, CALCITONIN, SALMON
CITANEST FORTE, EPINEPHRINE BITARTRATE
CITANEST PLAIN, PRILOCAINE HYDROCHLORIDE
CITANEST, PRILOCAINE HYDROCHLORIDE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
DALGAN, DEZOCINE
DOBUTAMINE HCL, DOBUTAMINE HYDROCHLORIDE
DOPAMINE HCL, DOPAMINE HYDROCHLORIDE
DROPERIDOL, DROPERIDOL
DURANEST, EPINEPHRINE
DURANEST, EPINEPHRINE BITARTRATE
DURANEST, ETIDOCAINE HYDROCHLORIDE
DYCLONE, DYCLONINE HYDROCHLORIDE
EMLA, LIDOCAINE
ENTOCORT EC, BUDESONIDE
FENTANYL CITRATE AND DROPERIDOL, DROPERIDOL
FOSCAVIR, FOSCARNET SODIUM
FUROSEMIDE, FUROSEMIDE
ISOETHARINE HCL, ISOETHARINE HYDROCHLORIDE
M.V.I.-12 LYOPHILIZED, ASCORBIC ACID
MANNITOL 25%, MANNITOL
MEPERIDINE HCL PRESERVATIVE FREE, MEPERIDINE HYDROCHLORIDE
MEPERIDINE HCL, MEPERIDINE HYDROCHLORIDE
METAPROTERENOL SULFATE, METAPROTERENOL SULFATE
NALBUPHINE HCL, NALBUPHINE HYDROCHLORIDE
NALOXONE HCL, NALOXONE HYDROCHLORIDE
NAROPIN, ROPIVACAINE HYDROCHLORIDE MONOHYDRATE
NESACAINE, CHLOROPROCAINE HYDROCHLORIDE
NESACAINE-MPF, CHLOROPROCAINE HYDROCHLORIDE
NEXIUM, ESOMEPRAZOLE MAGNESIUM
PANCURONIUM BROMIDE, PANCURONIUM BROMIDE
POLOCAINE, MEPIVACAINE HYDROCHLORIDE
POLOCAINE-MPF, MEPIVACAINE HYDROCHLORIDE
PRILOSEC, OMEPRAZOLE
PULMICORT RESPULES, BUDESONIDE
RHINOCORT, BUDESONIDE
SENSORCAINE, BUPIVACAINE HYDROCHLORIDE
SEROQUEL, QUETIAPINE FUMARATE
TENORMIN, ATENOLOL
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
TOPROL-XL, METOPROLOL SUCCINATE
XYLOCAINE 1.5% W/ DEXTROSE 7.5%, LIDOCAINE HYDROCHLORIDE
XYLOCAINE 4% PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
XYLOCAINE 5% W/ GLUCOSE 7.5%, LIDOCAINE HYDROCHLORIDE
XYLOCAINE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
XYLOCAINE VISCOUS, LIDOCAINE HYDROCHLORIDE
XYLOCAINE W/ EPINEPHRINE, EPINEPHRINE
XYLOCAINE, LIDOCAINE
XYLOCAINE, LIDOCAINE HYDROCHLORIDE
YUTOPAR, RITODRINE HYDROCHLORIDE
* ASTRAZENECA PHARMACEUTICALS LP
ATACAND HCT, CANDESARTAN CILEXETIL
ATACAND, CANDESARTAN CILEXETIL
CEFOTAN IN PLASTIC CONTAINER, CEFOTETAN DISODIUM
CEFOTAN, CEFOTETAN DISODIUM
ELAVIL, AMITRIPTYLINE HYDROCHLORIDE
LEXXEL, ENALAPRIL MALEATE
MIDAZOLAM HCL, MIDAZOLAM HYDROCHLORIDE
NOLVADEX, TAMOXIFEN CITRATE
PLENDIL, FELODIPINE
PULMICORT, BUDESONIDE
SORBITRATE, ISOSORBIDE DINITRATE
TENORETIC 100, ATENOLOL
TENORETIC 50, ATENOLOL
TENORMIN, ATENOLOL
TONOCARD, TOCAINIDE HYDROCHLORIDE
ZOMIG-ZMT, ZOLMITRIPTAN
* ASTRAZENECA UK LTD
ACCOLATE, ZAFIRLUKAST
ARIMIDEX, ANASTROZOLE
CASODEX, BICALUTAMIDE
DIPRIVAN, PROPOFOL
MERREM I.V., MEROPENEM
SULAR, NISOLDIPINE
ZESTORETIC, HYDROCHLOROTHIAZIDE
ZESTRIL, LISINOPRIL
ZOLADEX, GOSERELIN ACETATE

ATRIX
* ATRIX LABORATORIES INC
ATRIDOX, DOXYCYCLINE HYCLATE

AVENTIS
* AVENTIS PHARMACEUTICAL PRODUCTS INC
ACTHAR, CORTICOTROPIN
AZMACORT, TRIAMCINOLONE ACETONIDE
AZOLID, PHENYLBUTAZONE
CALCIMAR, CALCITONIN, SALMON
CERUBIDINE, DAUNORUBICIN HYDROCHLORIDE
DDAVP (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE
DDAVP, DESMOPRESSIN ACETATE
DORIDEN, GLUTETHIMIDE
INTAL, CROMOLYN SODIUM
LOVENOX, ENOXAPARIN SODIUM
LOZOL, INDAPAMIDE
NASACORT AQ, TRIAMCINOLONE ACETONIDE
NASACORT, TRIAMCINOLONE ACETONIDE
NICOLAR, NIACIN
PARATHAR, TERIPARATIDE ACETATE
PENETREX, ENOXACIN
PERTOFRANE, DESIPRAMINE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

PRESAMINE, IMIPRAMINE HYDROCHLORIDE
RILUTEK, RILUZOLE
SLO-BID, THEOPHYLLINE
SLO-PHYLLIN, THEOPHYLLINE
SYNERCID, DALFOPRISTIN
TAXOTERE, DOCETAXEL
THYTROPAR, THYROTROPIN
TILADE, NEDOCROMIL SODIUM

AVENTIS BEHRING
* AVENTIS BEHRING LLC
FLURBIPROFEN SODIUM, FLURBIPROFEN SODIUM
STIMATE, DESMOPRESSIN ACETATE

AVENTIS PHARMS
* AVENTIS PHARMACEUTICALS INC
A/T/S, ERYTHROMYCIN
ACCURBRON, THEOPHYLLINE
ALLEGRA, FEXOFENADINE HYDROCHLORIDE
ALLEGRA-D, FEXOFENADINE HYDROCHLORIDE
AMARYL, GLIMEPIRIDE
ANZEMET, DOLASETRON MESYLATE MONOHYDRATE
ARAVA, LEFLUNOMIDE
BENDECTIN, DOXYLAMINE SUCCINATE
BENTYL PRESERVATIVE FREE, DICYCLOMINE HYDROCHLORIDE
BENTYL, DICYCLOMINE HYDROCHLORIDE
BRICANYL, TERBUTALINE SULFATE
CANTIL, MEPENZOLATE BROMIDE
CARAFATE, SUCRALFATE
CARDIZEM CD, DILTIAZEM HYDROCHLORIDE
CARDIZEM SR, DILTIAZEM HYDROCHLORIDE
CARDIZEM, DILTIAZEM HYDROCHLORIDE
CEPHULAC, LACTULOSE
CHRONULAC, LACTULOSE
CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER, CEFOTAXIME SODIUM
CLAFORAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, CEFOTAXIME SODIUM
CLAFORAN, CEFOTAXIME SODIUM
CLOMID, CLOMIPHENE CITRATE
CYANOCOBALAMIN, CYANOCOBALAMIN
DECAPRYN, DOXYLAMINE SUCCINATE
DEMI-REGROTON, CHLORTHALIDONE
DERMATOP, PREDNICARBATE
DIABETA, GLYBURIDE
DV, DIENESTROL
GAVISCON, ALUMINUM HYDROXIDE (OTC)
GLYBURIDE (MICRONIZED), GLYBURIDE
HEDULIN, PHENINDIONE
HIPREX, METHENAMINE HIPPURATE
HYDROXYSTILBAMIDINE ISETHIONATE, HYDROXYSTILBAMIDINE ISETHIONATE
HYGROTON, CHLORTHALIDONE
INTAL, CROMOLYN SODIUM
LANTUS, INSULIN GLARGINE
LASIX, FUROSEMIDE
LORELCO, PROBUCOL
METAHYDRIN, TRICHLORMETHIAZIDE
METATENSIN #2, RESERPINE
METATENSIN #4, RESERPINE
NICODERM CQ, NICOTINE (OTC)
NILANDRON, NILUTAMIDE
NITRO-BID, NITROGLYCERIN
NORPRAMIN, DESIPRAMINE HYDROCHLORIDE
NOVAFED, PSEUDOEPHEDRINE HYDROCHLORIDE
ORNIDYL, EFLORNITHINE HYDROCHLORIDE
PENLAC, CICLOPIROX
PRIFTIN, RIFAPENTINE
REGROTON, CHLORTHALIDONE
RIFADIN, RIFAMPIN
RIFAMATE, ISONIAZID
RIFATER, ISONIAZID
TACE, CHLOROTRIANISENE
TENUATE DOSPAN, DIETHYLPROPION HYDROCHLORIDE
TENUATE, DIETHYLPROPION HYDROCHLORIDE
TRENTAL, PENTOXIFYLLINE
TRICLOS, TRICLOPOS SODIUM
VANOBID, CANDICIDIN
VENTAIRE, PROTOKYLOL HYDROCHLORIDE

AXCAN SCANDIPHARM
* AXCAN SCANDIPHARM INC
CANASA, MESALAMINE
CHENIX, CHENODIOL
PHOTOFRIN, PORFIMER SODIUM
URSO, URSODIOL

AYERST
* AYERST LABORATORIES INC
PHOSPHOLINE IODIDE, ECHOTHIOPHATE IODIDE
PREMARIN, ESTROGENS, CONJUGATED

** B **

B BRAUN
* B BRAUN MEDICAL INC
ACETATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
ACETIC ACID 0.25% IN PLASTIC CONTAINER, ACETIC ACID, GLACIAL
ALCOHOL 10% AND DEXTROSE 5%, ALCOHOL
ALCOHOL 5% AND DEXTROSE 5%, ALCOHOL
AMMONIUM CHLORIDE 2.14%, AMMONIUM CHLORIDE
BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER, BRETYLIUM TOSYLATE
CEFAZOLIN AND DEXTROSE, CEFAZOLIN SODIUM
CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER, CEFUROXIME SODIUM

FDA data supplied by DrugPatentWatch.com

DEXTROSE 10% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 2.5% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 4% IN MODIFIED LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN ACETATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.075%, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.30% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.075%, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 60% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 60%, DEXTROSE
DEXTROSE 7.7% IN PLASTIC CONTAINER, DEXTROSE
DIALYTE CONCENTRATE W/ DEXTROSE 30% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIALYTE CONCENTRATE W/ DEXTROSE 50% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIALYTE LM/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIALYTE LM/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIALYTE LM/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIALYTE W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIALYTE W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DOPAMINE HCL AND DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE
DOPAMINE HCL AND DEXTROSE 5%, DOPAMINE HYDROCHLORIDE
FREAMINE 8.5%, AMINO ACIDS
FREAMINE HBC 6.9%, AMINO ACIDS
FREAMINE II 8.5%, AMINO ACIDS
FREAMINE III 10%, AMINO ACIDS
FREAMINE III 3% W/ ELECTROLYTES, AMINO ACIDS
FREAMINE III 8.5% W/ ELECTROLYTES, AMINO ACIDS
FREAMINE III 8.5%, AMINO ACIDS
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, GENTAMICIN SULFATE
GLYCINE 1.5% IN PLASTIC CONTAINER, GLYCINE
HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC

FDA data supplied by DrugPatentWatch.com

CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPATAMINE 8%, AMINO ACIDS
HYPROTIGEN 5%, PROTEIN HYDROLYSATE
ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
ISOLYTE E IN PLASTIC CONTAINER, CALCIUM CHLORIDE
ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
ISOLYTE M IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
ISOLYTE M W/ DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
ISOLYTE P IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
ISOLYTE P W/ DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
ISOLYTE R W/ DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
ISOLYTE S IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
ISOLYTE S IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
ISOLYTE S PH 7.4 IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
ISOLYTE S W/ DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
LIDOCAINE HCL 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
MANNITOL 10% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER, MANNITOL
MANNITOL 10%, MANNITOL
MANNITOL 15% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 15% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.45%, MANNITOL
MANNITOL 15%, MANNITOL
MANNITOL 20% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 20%, MANNITOL
MANNITOL 5% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 5% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.12%, MANNITOL
MANNITOL 5%, MANNITOL
METRO I.V. IN PLASTIC CONTAINER, METRONIDAZOLE
METRO I.V., METRONIDAZOLE
NEPHRAMINE 5.4%, AMINO ACIDS
NUTRILIPID 10%, SOYBEAN OIL
NUTRILIPID 20%, SOYBEAN OIL
PHYSIOLYTE IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.037% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.075% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE

FDA data supplied by DrugPatentWatch.com

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.11% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.22% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.3% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PROCALAMINE, AMINO ACIDS
RESECTISOL IN PLASTIC CONTAINER, MANNITOL
RESECTISOL, MANNITOL
RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 3% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 5% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE, SODIUM CHLORIDE
SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER, SODIUM LACTATE
SODIUM LACTATE 1/6 MOLAR IN PLASTIC CONTAINER, SODIUM LACTATE
SORBITOL 3.3% IN PLASTIC CONTAINER, SORBITOL
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, WATER FOR INJECTION, STERILE
STERILE WATER IN PLASTIC CONTAINER, WATER FOR IRRIGATION,

FDA data supplied by DrugPatentWatch.com

STERILE
THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THEOPHYLLINE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THEOPHYLLINE 0.32% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THEOPHYLLINE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
TROPHAMINE 10%, AMINO ACIDS
TROPHAMINE, AMINO ACIDS
UCEPHAN, SODIUM BENZOATE

BAKER NORTON
* BAKER NORTON
PROGLYCEM, DIAZOXIDE
* BAKER NORTON PHARMACEUTICALS INC
ACTICORT, HYDROCORTISONE
PACLITAXEL, PACLITAXEL
PROGLYCEM, DIAZOXIDE

BALLARD MEDCL
* BALLARD MEDICAL PRODUCTS INC
PYTEST KIT, UREA, C-14
PYTEST, UREA, C-14

BANNER PHARMACAPS
* BANNER PHARMACAPS INC
BENZONATATE, BENZONATATE
CHLOROTRIANISENE, CHLOROTRIANISENE
CLOFIBRATE, CLOFIBRATE
ETHCHLORVYNOL, ETHCHLORVYNOL
VALPROIC ACID, VALPROIC ACID
VITAMIN A PALMITATE, VITAMIN A PALMITATE
VITAMIN A, VITAMIN A
VITAMIN A, VITAMIN A PALMITATE
VITAMIN D, ERGOCALCIFEROL

BARLAN
* BARLAN PHARMACAL CO INC
BARSTATIN 100, NYSTATIN

BARR
* BARR LABORATORIES INC
ACETOHEXAMIDE, ACETOHEXAMIDE
AMILORIDE HCL AND HYDROCHLOROTHIAZIDE, AMILORIDE HYDROCHLORIDE
AMINOPHYLLINE, AMINOPHYLLINE
AMIODARONE HCL, AMIODARONE HYDROCHLORIDE
BROMPHENIRAMINE MALEATE, BROMPHENIRAMINE MALEATE
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CEPHALEXIN, CEPHALEXIN
CEPHRADINE, CEPHRADINE
CHLORDIAZEPOXIDE HCL, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLORPROPAMIDE, CHLORPROPAMIDE
CHLORZOXAZONE, CHLORZOXAZONE
CORTISONE ACETATE, CORTISONE ACETATE
DANAZOL, DANAZOL
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DIAZEPAM, DIAZEPAM
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DIPYRIDAMOLE, DIPYRIDAMOLE
E-BASE, ERYTHROMYCIN
ERYTHROMYCIN ESTOLATE, ERYTHROMYCIN ESTOLATE
ERYTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYL, ERYTHROMYCIN ETHYLSUCCINATE
ERYTHROMYCIN ETHYLSUCCINATE, ERYTHROMYCIN ETHYLSUCCINATE
ERYTHROMYCIN STEARATE, ERYTHROMYCIN STEARATE
ERYTHROMYCIN, ERYTHROMYCIN
ESTRADIOL, ESTRADIOL
ESTROPIPATE, ESTROPIPATE
ETHAMBUTOL HCL, ETHAMBUTOL HYDROCHLORIDE
FLUOXETINE, FLUOXETINE HYDROCHLORIDE
FLUTAMIDE, FLUTAMIDE
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
FOLIC ACID, FOLIC ACID
GENCEPT 0.5/35-21, ETHINYL ESTRADIOL
GENCEPT 0.5/35-28, ETHINYL ESTRADIOL
GENCEPT 1/35-21, ETHINYL ESTRADIOL
GENCEPT 1/35-28, ETHINYL ESTRADIOL
GENCEPT 10/11-21, ETHINYL ESTRADIOL
GENCEPT 10/11-28, ETHINYL ESTRADIOL
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROCORTISONE, HYDROCORTISONE
HYDROXYUREA, HYDROXYUREA
HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
ISONIAZID, ISONIAZID
MECLOFENAMATE SODIUM, MECLOFENAMATE SODIUM
MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE
MEGESTROL ACETATE, MEGESTROL ACETATE
MEPERIDINE HCL, MEPERIDINE HYDROCHLORIDE
MEPROBAMATE, MEPROBAMATE
METHOTREXATE SODIUM, METHOTREXATE SODIUM
NALTREXONE HCL, NALTREXONE HYDROCHLORIDE
NORETHINDRONE ACETATE, NORETHINDRONE ACETATE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PREDNISOLONE, PREDNISOLONE
PROPRANOLOL HCL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

FDA data supplied by DrugPatentWatch.com

QUINIDINE SULFATE, QUINIDINE SULFATE
RESERPINE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
RESERPINE, RESERPINE
SODIUM SECOBARBITAL, SECOBARBITAL SODIUM
SULFAMETHOXAZOLE, SULFAMETHOXAZOLE
SULFINPYRAZONE, SULFINPYRAZONE
SULFISOXAZOLE, SULFISOXAZOLE
TETRACYCLINE HCL, TETRACYCLINE HYDROCHLORIDE
TOLAZAMIDE, TOLAZAMIDE
TOLBUTAMIDE, TOLBUTAMIDE
TRAZODONE HCL, TRAZODONE HYDROCHLORIDE
TREXALL, METHOTREXATE SODIUM
TRIAMCINOLONE, TRIAMCINOLONE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TRIPELENNAMINE HCL, TRIPELENNAMINE HYDROCHLORIDE
VERAPAMIL HCL, VERAPAMIL HYDROCHLORIDE
WARFARIN SODIUM, WARFARIN SODIUM

* BARR PHARMACEUTICALS
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM

BARTOR

* BARTOR PHARMACAL CO
TESTOSTERONE, TESTOSTERONE

BASF

* BASF CORP
IBU, IBUPROFEN
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
LOPURIN, ALLOPURINOL
RUFEN, IBUPROFEN
SSD AF, SILVER SULFADIAZINE
SSD, SILVER SULFADIAZINE

BAUSCH AND LOMB

* BAUSCH AND LOMB INC
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALREX, LOTEPREDNOL ETABONATE
CARTEOLOL HCL, CARTEOLOL HYDROCHLORIDE
LOTEMAX, LOTEPREDNOL ETABONATE
OPCON-A, NAPHAZOLINE HYDROCHLORIDE (OTC)
SULPHRIN, PREDNISOLONE ACETATE
SULTEN-10, SULFACETAMIDE SODIUM
TIMOLOL MALEATE, TIMOLOL MALEATE

* BAUSCH AND LOMB PHARMACEUTICALS INC
ACETIC ACID 2% IN AQUEOUS ALUMINUM ACETATE, ACETIC ACID, GLACIAL
BACITRACIN ZINC AND POLYMYXIN B SULFATE, BACITRACIN ZINC
BETAXOLOL HCL, BETAXOLOL HYDROCHLORIDE
CROLOM, CROMOLYN SODIUM
CROMOLYN SODIUM, CROMOLYN SODIUM
CROMOLYN SODIUM, CROMOLYN SODIUM (OTC)
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DEXASPORIN, DEXAMETHASONE
DIPIVEFRIN HCL, DIPIVEFRIN HYDROCHLORIDE
ERYTHROMYCIN, ERYTHROMYCIN
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
HYDROCORTISONE AND ACETIC ACID, ACETIC ACID, GLACIAL
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
LEVOBUNOLOL HCL, LEVOBUNOLOL HYDROCHLORIDE
MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
NAFAZAIR, NAPHAZOLINE HYDROCHLORIDE
NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC, BACITRACIN ZINC
NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE, DEXAMETHASONE
NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN, GRAMICIDIN
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE, HYDROCORTISONE
NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE, BACITRACIN ZINC
NEOMYCIN SULFATE AND DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
NYSTATIN, NYSTATIN
OPCON, NAPHAZOLINE HYDROCHLORIDE
OPTIPRANOLOL, METIPRANOLOL HYDROCHLORIDE
OTICAIR, HYDROCORTISONE
PENTOLAIR, CYCLOPENTOLATE HYDROCHLORIDE
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
PROPARACAINE HCL, PROPARACAINE HYDROCHLORIDE
SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
TIMOLOL MALEATE, TIMOLOL MALEATE
TOBRAMYCIN AND DEXAMETHASONE, DEXAMETHASONE
TOBRAMYCIN, TOBRAMYCIN
TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
TROPICAMIDE, TROPICAMIDE

* BAUSCH AND LOMB SURGICAL INC
VITRASERT, GANCICLOVIR

BAXTER HLTHCARE

* BAXTER HEALTHCARE CORP
ACETIC ACID 0.25% IN PLASTIC CONTAINER, ACETIC ACID, GLACIAL
ALCOHOL 5% IN DEXTROSE 5% IN WATER, ALCOHOL
AMINOACETIC ACID 1.5% IN PLASTIC CONTAINER, GLYCINE
ANCEF IN DEXTROSE 5% IN PLASTIC CONTAINER, CEFAZOLIN SODIUM
ANCEF IN PLASTIC CONTAINER, CEFAZOLIN SODIUM
ANCEF IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, CEFAZOLIN SODIUM
BACTOCILL IN PLASTIC CONTAINER, OXACILLIN SODIUM
BRANCHAMIN 4% IN PLASTIC CONTAINER, AMINO ACIDS

FDA data supplied by DrugPatentWatch.com

BRANCHAMIN 4%, AMINO ACIDS
BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER, BRETYLIUM TOSYLATE
CARDIOPLEGIC IN PLASTIC CONTAINER, CALCIUM CHLORIDE
CEFTAZIDIME SODIUM IN PLASTIC CONTAINER, CEFTAZIDIME SODIUM
CEPHALOTHIN SODIUM W/ DEXTROSE IN PLASTIC CONTAINER, CEPHALOTHIN SODIUM
CEPHALOTHIN SODIUM W/ SODIUM CHLORIDE IN PLASTIC CONTAINER, CEPHALOTHIN SODIUM
CERNEVIT-12, ALPHA-TOCOPHEROL
CLINDAMYCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE
CLINIMIX 2.75/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 2.75/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/15 SULFITE FREE IN DEXTROSE 15% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/35 SULFITE FREE IN DEXTROSE 35% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 2.75/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 2.75/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 2.75/5 SULFITE-FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 4.25/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 4.25/20 SULFITE-FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 4.25/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 4.25/5 SULFITE-FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 5/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 5/15 SULFITE-FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 5/20 SULFITE-FREE W/ ELECT IN 20% DEXTROSE W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 5/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 5/35 SULFITE FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 20% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 30% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 40% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND ELECTROLYTE NO 75 IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND ELECTROLYTE NO.48 IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% IN SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 10MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 15MEQ (K), DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ (K), DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 30MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 40MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ (K), DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE

FDA data supplied by DrugPatentWatch.com

30MEQ IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ (K) IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 50% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 60% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 70% IN PLASTIC CONTAINER, DEXTROSE
DIANEAL 137 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL 137 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL 137 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-1 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-1 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-1 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-1 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-2 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-2 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DOBUTAMINE HCL IN DEXTROSE 5% IN PLASTIC CONTAINER, DOBUTAMINE HYDROCHLORIDE
DOPAMINE HCL IN DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE
FLAGYL I.V. RTU IN PLASTIC CONTAINER, METRONIDAZOLE
GLYCINE 1.5% IN PLASTIC CONTAINER, GLYCINE
HEPARIN SODIUM 1,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 20,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 5,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPATASOL 8%, AMINO ACIDS
IRRIGATING SOLUTION G IN PLASTIC CONTAINER, CITRIC ACID
ISOETHARINE HCL, ISOETHARINE HYDROCHLORIDE
ISOTONIC GENTAMICIN SULFATE IN PLASTIC CONTAINER, GENTAMICIN SULFATE
LACTATED RINGER'S AND DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
LIDOCAINE HCL 0.1% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
NALLPEN IN PLASTIC CONTAINER, NAFCILLIN SODIUM
NITROGLYCERIN IN DEXTROSE 5%, NITROGLYCERIN
NOVAMINE 15% SULFITE FREE IN PLASTIC CONTAINER, AMINO ACIDS
OSMITROL 10% IN WATER IN PLASTIC CONTAINER, MANNITOL
OSMITROL 10% IN WATER, MANNITOL
OSMITROL 15% IN WATER IN PLASTIC CONTAINER, MANNITOL
OSMITROL 15% IN WATER, MANNITOL
OSMITROL 20% IN WATER IN PLASTIC CONTAINER, MANNITOL
OSMITROL 20% IN WATER, MANNITOL
OSMITROL 5% IN WATER IN PLASTIC CONTAINER, MANNITOL
OSMITROL 5% IN WATER, MANNITOL
PENICILLIN G POTASSIUM IN PLASTIC CONTAINER, PENICILLIN G POTASSIUM
PLASMA-LYTE 148 AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
PLASMA-LYTE 56 AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
PLASMA-LYTE 56 IN PLASTIC CONTAINER, MAGNESIUM ACETATE TETRAHYDRATE
PLASMA-LYTE A IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
PLASMA-LYTE M AND DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PLASMA-LYTE R IN PLASTIC CONTAINER, CALCIUM CHLORIDE
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE

FDA data supplied by DrugPatentWatch.com

0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
RENAMIN W/O ELECTROLYTES, AMINO ACIDS
RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.224%, POTASSIUM CHLORIDE
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% IN STERILE PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 3% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 5% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM HEPARIN, HEPARIN SODIUM
SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER, SODIUM LACTATE
SORBITOL 3% IN PLASTIC CONTAINER, SORBITOL
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, WATER FOR INJECTION, STERILE
STERILE WATER IN PLASTIC CONTAINER, WATER FOR IRRIGATION, STERILE
STERILE WATER, WATER FOR IRRIGATION, STERILE
SYNOVALYTE IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
TIS-U-SOL IN PLASTIC CONTAINER, MAGNESIUM SULFATE
TIS-U-SOL, MAGNESIUM SULFATE
TRAVAMULSION 10%, SOYBEAN OIL
TRAVAMULSION 20%, SOYBEAN OIL
TRAVASOL 10% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 10% W/O ELECTROLYTES, AMINO ACIDS
TRAVASOL 2.75% IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 2.75% IN DEXTROSE 15% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 2.75% IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 2.75% IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 2.75% IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 3.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 3.5% W/ ELECTROLYTES, AMINO ACIDS
TRAVASOL 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 4.25% IN DEXTROSE 15% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 4.25% IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 10%

FDA data supplied by DrugPatentWatch.com

IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 5.5% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 5.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 5.5% W/ ELECTROLYTES, AMINO ACIDS
TRAVASOL 5.5% W/O ELECTROLYTES, AMINO ACIDS
TRAVASOL 8.5% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 8.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 8.5% W/ ELECTROLYTES, AMINO ACIDS
TRAVASOL 8.5% W/O ELECTROLYTES, AMINO ACIDS
TRAVERT 10% IN PLASTIC CONTAINER, INVERT SUGAR
VANCOCIN HCL IN PLASTIC CONTAINER, VANCOMYCIN HYDROCHLORIDE

* BAXTER HEALTHCARE INTERNATIONAL SPECIALTY THERAPIES DIV
FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER, FAMOTIDINE
PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER, AMINO ACIDS

BAXTER HLTHCARE CORP

* BAXTER HEALTHCARE CORP ANESTHESIA CRITICAL CARE
AMRINONE LACTATE, INAMRINONE LACTATE
ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE
ATRACURIUM BESYLATE, ATRACURIUM BESYLATE
BREVIBLOC, ESMOLOL HYDROCHLORIDE
ENLON, EDROPHONIUM CHLORIDE
ENLON-PLUS, ATROPINE SULFATE
ETHRANE, ENFLURANE
FORANE, ISOFLURANE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
MIDAZOLAM HCL, MIDAZOLAM HYDROCHLORIDE
REVEX, NALMEFENE HYDROCHLORIDE
SUPRANE, DESFLURANE

BAYER

* BAYER CORP
ADALAT CC, NIFEDIPINE
ADALAT, NIFEDIPINE
ANTAGONATE, CHLORPHENIRAMINE MALEATE
AZLIN, AZLOCILLIN SODIUM
BILTRICIDE, PRAZIQUANTEL
CANDEX, NYSTATIN
CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN
CIPRO IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, CIPROFLOXACIN
CIPRO, CIPROFLOXACIN
CIPRO, CIPROFLOXACIN HYDROCHLORIDE
CORT-DOME, HYDROCORTISONE
DELTA-DOME, PREDNISONE
DOMEBORO, ACETIC ACID, GLACIAL
DTIC-DOME, DACARBAZINE
HC #1, HYDROCORTISONE
HC #4, HYDROCORTISONE
LITHANE, LITHIUM CARBONATE
MEZLIN, MEZLOCILLIN SODIUM MONOHYDRATE
MYCELEX, CLOTRIMAZOLE
MYCELEX, CLOTRIMAZOLE (OTC)
MYCELEX-7 COMBINATION PACK, CLOTRIMAZOLE (OTC)
MYCELEX-7, CLOTRIMAZOLE (OTC)
MYCELEX-G, CLOTRIMAZOLE
NEO-CORT-DOME, ACETIC ACID, GLACIAL
NEO-CORT-DOME, HYDROCORTISONE
NICLOCIDE, NICLOSAMIDE
NIMOTOP, NIMODIPINE
NYSTAFORM, CLIOQUINOL
PRECOSE, ACARBOSE
RADIO-IODINATED (I 125) SERUM ALBUMIN (HUMAN), ALBUMIN IODINATED I-125 SERUM
SOY-DOME, HEXACHLOROPHENE
STILPHOSTROL, DIETHYLSTILBESTROL DIPHOSPHATE
TRASYLOL, APROTININ BOVINE
TRIDESILON, ACETIC ACID, GLACIAL
VI-DOM-A, VITAMIN A PALMITATE

* BAYER CORP CONSUMER CARE DIV
8-HOUR BAYER, ASPIRIN (OTC)
ACTRON, KETOPROFEN (OTC)
ALEVE COLD AND SINUS, NAPROXEN SODIUM (OTC)
ALEVE, NAPROXEN SODIUM (OTC)
BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN, ASPIRIN (OTC)
MEASURIN, ASPIRIN (OTC)
MIDOL, IBUPROFEN (OTC)
MYCELEX, CLOTRIMAZOLE
MYCELEX, CLOTRIMAZOLE (OTC)

* BAYER CORP PHARMACEUTICAL DIV
AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER, MOXIFLOXACIN HYDROCHLORIDE
AVELOX, MOXIFLOXACIN HYDROCHLORIDE
BAYCOL, CERIVASTATIN SODIUM
CIPRO, CIPROFLOXACIN

BECTON DICKINSON

* BECTON DICKINSON AND CO
E-Z PREP 220, POVIDONE-IODINE (OTC)
E-Z PREP, POVIDONE-IODINE (OTC)
E-Z SCRUB 201, POVIDONE-IODINE (OTC)
E-Z SCRUB 241, POVIDONE-IODINE (OTC)
E-Z SCRUB, HEXACHLOROPHENE

* BECTON DICKINSON SURGICAL SYSTEM

FDA data supplied by DrugPatentWatch.com

E-Z SCRUB, CHLORHEXIDINE GLUCONATE (OTC)

BEDFORD
* BEDFORD LABORATORIES DIV BEN VENUE LABORATORIES INC
ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM
ACETYLCYSTEINE, ACETYLCYSTEINE
ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
ALPROSTADIL, ALPROSTADIL
AMIKACIN SULFATE, AMIKACIN SULFATE
AMRINONE, INAMRINONE LACTATE
ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE
ATRACURIUM BESYLATE, ATRACURIUM BESYLATE
AZATHIOPRINE SODIUM, AZATHIOPRINE SODIUM
BLEOMYCIN, BLEOMYCIN SULFATE
BUMETANIDE, BUMETANIDE
BUTORPHANOL TARTRATE PRESERVATIVE FREE, BUTORPHANOL TARTRATE
BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
CERUBIDINE, DAUNORUBICIN HYDROCHLORIDE
CHLOROPROCAINE HCL, CHLOROPROCAINE HYDROCHLORIDE
CISPLATIN, CISPLATIN
CLADRIBINE, CLADRIBINE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CYCLOSPORINE, CYCLOSPORINE
CYTARABINE, CYTARABINE
DACARBAZINE, DACARBAZINE
DAUNORUBICIN HCL, DAUNORUBICIN HYDROCHLORIDE
DESMOPRESSIN ACETATE PRESERVATIVE FREE, DESMOPRESSIN ACETATE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DILTIAZEM HCL, DILTIAZEM HYDROCHLORIDE
DIPYRIDAMOLE, DIPYRIDAMOLE
DOBUTAMINE HCL, DOBUTAMINE HYDROCHLORIDE
DOXORUBICIN HCL, DOXORUBICIN HYDROCHLORIDE
DOXYCYCLINE, DOXYCYCLINE HYCLATE
ENALAPRILAT, ENALAPRILAT
ETOMIDATE, ETOMIDATE
ETOPOSIDE, ETOPOSIDE
FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE
FLOXURIDINE, FLOXURIDINE
FLUOROURACIL, FLUOROURACIL
FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
HALOPERIDOL, HALOPERIDOL LACTATE
KETAMINE HCL, KETAMINE HYDROCHLORIDE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LABETALOL HCL, LABETALOL HYDROCHLORIDE
LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
LEVOCARNITINE, LEVOCARNITINE
METHOTREXATE SODIUM, METHOTREXATE SODIUM
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
MIDAZOLAM HCL, MIDAZOLAM HYDROCHLORIDE
MITOMYCIN, MITOMYCIN
PACLITAXEL, PACLITAXEL
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
PHENTOLAMINE MESYLATE, PHENTOLAMINE MESYLATE
POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
RIFAMPIN, RIFAMPIN
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
THIOTEPA, THIOTEPA
VECURONIUM BROMIDE, VECURONIUM BROMIDE
VERAPAMIL HCL, VERAPAMIL HYDROCHLORIDE
VINBLASTINE SULFATE, VINBLASTINE SULFATE

BEDFORD LABS
* BEDFORD LABORATORIES INC
LEUPROLIDE ACETATE, LEUPROLIDE ACETATE

BEECHAM
* BEECHAM LABORATORIES DIV BEECHAM INC
PROBENECID AND COLCHICINE, COLCHICINE

BEL MAR
* BEL MAR LABORATORIES INC
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
CHORIONIC GONADOTROPIN, GONADOTROPIN, CHORIONIC
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
HYDROCORTISONE ACETATE, HYDROCORTISONE ACETATE
HYDROXOMIN, HYDROXOCOBALAMIN
LIDOCAINE HCL W/ EPINEPHRINE, EPINEPHRINE
LIDOCAINE HCL, LIDOCAINE HYDROCHLORIDE
M-PREDROL, METHYLPREDNISOLONE ACETATE
PREDNISOLONE ACETATE, PREDNISOLONE ACETATE
PROCAINE HCL W/ EPINEPHRINE, EPINEPHRINE
PROCAINE HCL, PROCAINE HYDROCHLORIDE
PYRIDAMAL 100, CHLORPHENIRAMINE MALEATE
PYRIDOXINE HCL, PYRIDOXINE HYDROCHLORIDE
RUBIVITE, CYANOCOBALAMIN
TESTOSTERONE PROPIONATE, TESTOSTERONE PROPIONATE
THIAMINE HCL, THIAMINE HYDROCHLORIDE
VITAMIN A PALMITATE, VITAMIN A PALMITATE

BELL PHARMA
* BELL PHARMACAL CORP
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
RESERPINE, RESERPINE

BEN VENUE
* BEN VENUE LABORATORIES INC
FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
MIDAZOLAM HCL, MIDAZOLAM HYDROCHLORIDE

BERLEX

FDA data supplied by DrugPatentWatch.com

* BERLEX LABORATORIES INC SUB SCHERING AG
ANGIOVIST 282, DIATRIZOATE MEGLUMINE
ANGIOVIST 292, DIATRIZOATE MEGLUMINE
ANGIOVIST 370, DIATRIZOATE MEGLUMINE
BILIVIST, IPODATE SODIUM
FLUDARA, FLUDARABINE PHOSPHATE
GASTROVIST, DIATRIZOATE MEGLUMINE
MAGNEVIST, GADOPENTETATE DIMEGLUMINE
QUINACT, QUINIDINE GLUCONATE
SULLA, SULFAMETER
UROVIST CYSTO PEDIATRIC, DIATRIZOATE MEGLUMINE
UROVIST CYSTO, DIATRIZOATE MEGLUMINE
UROVIST MEGLUMINE DIU/CT, DIATRIZOATE MEGLUMINE
UROVIST SODIUM 300, DIATRIZOATE SODIUM
VI-TWEL, CYANOCOBALAMIN

BERLEX LABS
* BERLEX LABORATORIES INC
BETAPACE AF, SOTALOL HYDROCHLORIDE
BETAPACE, SOTALOL HYDROCHLORIDE
CLIMARA, ESTRADIOL
LEVLITE, ETHINYL ESTRADIOL
MAGNEVIST, GADOPENTETATE DIMEGLUMINE
MIRENA, LEVONORGESTREL
OSMOVIST 190, IOTROLAN
OSMOVIST 240, IOTROLAN
QUINAGLUTE, QUINIDINE GLUCONATE
REFLUDAN, LEPIRUDIN
ULTRAVIST 150, IOPROMIDE
ULTRAVIST 240, IOPROMIDE
ULTRAVIST 300, IOPROMIDE
ULTRAVIST 370, IOPROMIDE
YASMIN, DROSPIRENONE

BERTEK PHARMS
* BERTEK PHARMACEUTICALS INC
AVITA, TRETINOIN
MENTAX, BUTENAFINE HYDROCHLORIDE
SULFAMYLON, MAFENIDE ACETATE

BETA DERMAC
* BETA DERMACEUTICALS INC
BETA-HC, HYDROCORTISONE

BH
* BH CHEMICALS INC
HALOTHANE, HALOTHANE

BIGMAR
* BIGMAR INC
DAUNORUBICIN HCL, DAUNORUBICIN HYDROCHLORIDE
FLUOROURACIL, FLUOROURACIL
LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
METHOTREXATE PRESERVATIVE FREE, METHOTREXATE SODIUM
METHOTREXATE, METHOTREXATE SODIUM

BIO TECH GEN
* BIO TECHNOLOGY GENERAL CORP
BIO-TROPIN, SOMATROPIN RECOMBINANT
OXANDRIN, OXANDROLONE

BIOCHEMIE
* BIOCHEMIE GMBH
AMOXICILLIN, AMOXICILLIN
AMPICILLIN TRIHYDRATE, AMPICILLIN/AMPICILLIN TRIHYDRATE
PENICILLIN G SODIUM, PENICILLIN G SODIUM
PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM

BIOGLAN
* BIOGLAN LABORATORIES LTD
ALPHADERM, HYDROCORTISONE

BIOGLAN PHARMA
* BIOGLAN PHARMA INC
C-SOLVE-2, ERYTHROMYCIN
ZONALON, DOXEPIN HYDROCHLORIDE

BIOGLAN PHARMA PLC
* BIOGLAN PHARMA PLC
SOLARAZE, DICLOFENAC SODIUM

BIONICHE (CANADA)
* BIONICHE PHARMA (CANADA) LTD
KETAMINE HCL, KETAMINE HYDROCHLORIDE

BIOVAIL
* BIOVAIL CORP INTERNATIONAL
TIAZAC, DILTIAZEM HYDROCHLORIDE
* BIOVAIL LABORATORIES INC
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DILTIAZEM HCL, DILTIAZEM HYDROCHLORIDE
NIFEDIPINE, NIFEDIPINE
PENTOXIFYLLINE, PENTOXIFYLLINE
* BIOVAIL TECHNOLOGIES
CEDAX, CEFTIBUTEN DIHYDRATE

BLAIREX
* BLAIREX LABORATORIES INC
BRONCHO SALINE, SODIUM CHLORIDE (OTC)

BLUE RIDGE
* BLUE RIDGE LABORATORIES INC
CARAFATE, SUCRALFATE

BLULINE
* BLULINE LABORATORIES INC

FDA data supplied by DrugPatentWatch.com

EPICORT, HYDROCORTISONE
MULTIFUGE, PIPERAZINE CITRATE

BOEHRINGER INGELHEIM
* BOEHRINGER INGELHEIM
ALUPENT, METAPROTERENOL SULFATE
CATAPRES, CLONIDINE HYDROCHLORIDE
CATAPRES-TTS-1, CLONIDINE
CATAPRES-TTS-2, CLONIDINE
CATAPRES-TTS-3, CLONIDINE
MEXITIL, MEXILETINE HYDROCHLORIDE
MICARDIS HCT, HYDROCHLOROTHIAZIDE
MICARDIS, TELMISARTAN
* BOEHRINGER INGELHEIM CORP
RANITIDINE HCL, RANITIDINE HYDROCHLORIDE
* BOEHRINGER INGELHEIM PHARMACEUTICALS INC
AGGRENOX, ASPIRIN
ALUPENT, METAPROTERENOL SULFATE
ATROVENT, IPRATROPIUM BROMIDE
COMBIPRES, CHLORTHALIDONE
COMBIVENT, ALBUTEROL SULFATE
FLOMAX, TAMSULOSIN HYDROCHLORIDE
IV PERSANTINE, DIPYRIDAMOLE
MOBIC, MELOXICAM
PERSANTINE, DIPYRIDAMOLE
PRELUDIN, PHENMETRAZINE HYDROCHLORIDE
VIRAMUNE, NEVIRAPINE

BONE CARE
* BONE CARE INTERNATIONAL INC
HECTOROL, DOXERCALCIFEROL

BOWMAN PHARMS
* BOWMAN PHARMACEUTICALS INC
HISERPIA, RESERPINE
HIWOLFIA, RAUWOLFIA SERPENTINA

BRACCO
* BRACCO DIAGNOSTICS INC
CARDIOGEN-82, RUBIDIUM CHLORIDE RB-82
CARDIOGRAFIN, DIATRIZOATE MEGLUMINE
CARDIOTEC, TECHNETIUM TC-99M TEBOROXIME KIT
CHLORMERODRIN HG 197, CHLORMERODRIN, HG-197
CHOLETEC, TECHNETIUM TC-99M MEBROFENIN KIT
CHOLOGRAFIN MEGLUMINE, IODIPAMIDE MEGLUMINE
CHOLOGRAFIN SODIUM, IODIPAMIDE SODIUM
CHOLOVUE, IODOXAMATE MEGLUMINE
CHROMITOPE SODIUM, SODIUM CHROMATE, CR-51
CYSTOGRAFIN DILUTE, DIATRIZOATE MEGLUMINE
CYSTOGRAFIN, DIATRIZOATE MEGLUMINE
DIATRIZOATE MEGLUMINE, DIATRIZOATE MEGLUMINE
GASTROGRAFIN, DIATRIZOATE MEGLUMINE
HIPPUTOPE, IODOHIPPURATE SODIUM, I-131
IODOTOPE, SODIUM IODIDE, I-131
ISOVUE-128, IOPAMIDOL
ISOVUE-200, IOPAMIDOL
ISOVUE-250, IOPAMIDOL
ISOVUE-300, IOPAMIDOL
ISOVUE-370, IOPAMIDOL
ISOVUE-M 200, IOPAMIDOL
ISOVUE-M 300, IOPAMIDOL
KINEVAC, SINCALIDE
LUMENHANCE, MANGANESE CHLORIDE TETRAHYDRATE
MACROTEC, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT
MDP-BRACCO, TECHNETIUM TC-99M MEDRONATE KIT
MINITEC, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
ORAGRAFIN CALCIUM, IPODATE CALCIUM
ORAGRAFIN SODIUM, IPODATE SODIUM
PHOSPHOTEC, TECHNETIUM TC-99M PYROPHOSPHATE KIT
PHOSPHOTOPE, SODIUM PHOSPHATE, P-32
PROHANCE, GADOTERIDOL
RENO-30, DIATRIZOATE MEGLUMINE
RENO-60, DIATRIZOATE MEGLUMINE
RENO-DIP, DIATRIZOATE MEGLUMINE
RENOCAL-76, DIATRIZOATE MEGLUMINE
RENOGRAFIN-60, DIATRIZOATE MEGLUMINE
RENOGRAFIN-76, DIATRIZOATE MEGLUMINE
RENOTEC, TECHNETIUM TC-99M FERPENTETATE KIT
RENOVIST II, DIATRIZOATE MEGLUMINE
RENOVIST, DIATRIZOATE MEGLUMINE
RENOVUE-65, IODAMIDE MEGLUMINE
RENOVUE-DIP, IODAMIDE MEGLUMINE
ROBENGATOPE, ROSE BENGAL SODIUM, I-131
RUBRATOPE-57 KIT, COBALT CHLORIDE, CO-57
RUBRATOPE-57, CYANOCOBALAMIN, CO-57
RUBRATOPE-60 KIT, COBALT CHLORIDE, CO-60
RUBRATOPE-60, CYANOCOBALAMIN, CO-60
SETHOTOPE, SELENOMETHIONINE, SE-75
SINOGRAFIN, DIATRIZOATE MEGLUMINE
SONORX, SIMETHICONE-CELLULOSE
TESULOID, TECHNETIUM TC-99M SULFUR COLLOID KIT
THALLOUS CHLORIDE TL 201, THALLOUS CHLORIDE, TL-201

BRADLEY PHARMS
* BRADLEY PHARMACEUTICALS INC
PAMINE, METHSCOPOLAMINE BROMIDE

BRAINTREE
* BRAINTREE LABORATORIES INC
GOLYTELY, POLYETHYLENE GLYCOL 3350
MIRALAX, POLYETHYLENE GLYCOL 3350
NULYTELY, POLYETHYLENE GLYCOL 3350
NULYTELY-FLAVORED, POLYETHYLENE GLYCOL 3350
PHOSLO GELCAPS, CALCIUM ACETATE
PHOSLO, CALCIUM ACETATE

BRIGHTSTONE

FDA data supplied by DrugPatentWatch.com

* BRIGHTSTONE PHARMA INC
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE

BRISTOL
* BRISTOL LABORATORIES INC DIV BRISTOL MYERS CO
BETAPEN-VK, PENICILLIN V POTASSIUM
BICNU, CARMUSTINE
BRISTACYCLINE, TETRACYCLINE HYDROCHLORIDE
BRISTAGEN, GENTAMICIN SULFATE
BRISTAMYCIN, ERYTHROMYCIN STEARATE
CEPHALOTHIN SODIUM, CEPHALOTHIN SODIUM
LYSODREN, MITOTANE
MEXATE, METHOTREXATE SODIUM
MUTAMYCIN, MITOMYCIN
POLYCILLIN, AMPICILLIN/AMPICILLIN TRIHYDRATE
POLYCILLIN-N, AMPICILLIN SODIUM
POLYCILLIN-PRB, AMPICILLIN/AMPICILLIN TRIHYDRATE
PRECEF, CEFORANIDE
TETREX, TETRACYCLINE PHOSPHATE COMPLEX
ULTRACEF, CEFADROXIL/CEFADROXIL HEMIHYDRATE
VEPESID, ETOPOSIDE
VERSAPEN, HETACILLIN
VERSAPEN-K, HETACILLIN POTASSIUM

BRISTOL MYERS
* BRISTOL MYERS CO
MEXATE-AQ, METHOTREXATE SODIUM
MUTAMYCIN, MITOMYCIN
PLATINOL, CISPLATIN
PLATINOL-AQ, CISPLATIN
QUESTRAN LIGHT, CHOLESTYRAMINE
QUESTRAN, CHOLESTYRAMINE
* BRISTOL MYERS PRODUCTS INC
EXCEDRIN (MIGRAINE), ACETAMINOPHEN (OTC)
NUPRIN, IBUPROFEN (OTC)

BRISTOL MYERS SQUIBB
* BRISTOL MYERS SQUIBB
AZACTAM, AZTREONAM
DELALUTIN, HYDROXYPROGESTERONE CAPROATE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
FOLLUTEIN, GONADOTROPIN, CHORIONIC
GLUCOVANCE, GLYBURIDE
HALOG, HALCINONIDE
MEGACE, MEGESTROL ACETATE
MEXATE-AQ PRESERVED, METHOTREXATE SODIUM
MONOPRIL-HCT, FOSINOPRIL SODIUM
ORA-TESTRYL, FLUOXYMESTERONE
PRAVACHOL, PRAVASTATIN SODIUM
STILBESTROL, DIETHYLSTILBESTROL
STILBETIN, DIETHYLSTILBESTROL
TESLAC, TESTOLACTONE
VINCREX, VINCRISTINE SULFATE
* BRISTOL MYERS SQUIBB CO
AMITID, AMITRIPTYLINE HYDROCHLORIDE
AMNESTROGEN, ESTROGENS, ESTERIFIED
AZACTAM IN PLASTIC CONTAINER, AZTREONAM
CAPOTEN, CAPTOPRIL
CEENU, LOMUSTINE
DROXIA, HYDROXYUREA
DURICEF, CEFADROXIL/CEFADROXIL HEMIHYDRATE
ESTRACE, ESTRADIOL
ETHRIL 250, ERYTHROMYCIN STEARATE
ETHRIL 500, ERYTHROMYCIN STEARATE
ETOPOPHOS PRESERVATIVE FREE, ETOPOSIDE PHOSPHATE
FUNGIZONE, AMPHOTERICIN B
GLUCOPHAGE XR, METFORMIN HYDROCHLORIDE
HYDREA, HYDROXYUREA
KENACORT, TRIAMCINOLONE
KENACORT, TRIAMCINOLONE DIACETATE
MYCOSTATIN, NYSTATIN
NEOMYCIN SULFATE, NEOMYCIN SULFATE
NYDRAZID, ISONIAZID
PROLIXIN DECANOATE, FLUPHENAZINE DECANOATE
PROTAMINE ZINC INSULIN, INSULIN SUSP PROTAMINE ZINC PURIFIED BEEF (OTC)
RAU-SED, RESERPINE
REZIPAS, AMINOSALICYLIC ACID RESIN COMPLEX
RUBEX, DOXORUBICIN HYDROCHLORIDE
RUBRAMIN PC, CYANOCOBALAMIN
TERFONYL, TRISULFAPYRIMIDINES (SULFADIAZINE;SULFAMERAZINE; SULFAMETHAZINE)
TESLAC, TESTOLACTONE
TUBOCURARINE CHLORIDE, TUBOCURARINE CHLORIDE
VAGISTAT-1, TIOCONAZOLE (OTC)
VELOSEF, CEPHRADINE
VEPESID, ETOPOSIDE
VESPRIN, TRIFLUPROMAZINE HYDROCHLORIDE
VIDEX EC, DIDANOSINE
VITAMIN A, VITAMIN A PALMITATE
* BRISTOL MYERS SQUIBB CO PHARMACEUTICAL RESEARCH INSTITUTE
BLENOXANE, BLEOMYCIN SULFATE
BUSPAR, BUSPIRONE HYDROCHLORIDE
CEFZIL, CEFPROZIL
CYTOXAN, CYCLOPHOSPHAMIDE
DEAPRIL-ST, ERGOLOID MESYLATES
DOVONEX, CALCIPOTRIENE
ESTRACE, ESTRADIOL
ETOPOPHOS PRESERVATIVE FREE, ETOPOSIDE PHOSPHATE

FDA data supplied by DrugPatentWatch.com

GLUCOPHAGE, METFORMIN HYDROCHLORIDE
IFEX, IFOSFAMIDE
IFEX/MESNEX KIT, IFOSFAMIDE
KENALOG, TRIAMCINOLONE ACETONIDE
LYOPHILIZED CYTOXAN, CYCLOPHOSPHAMIDE
MAXIPIME, CEFEPIME HYDROCHLORIDE (ARGININE FORMULATION)
MONOPRIL, FOSINOPRIL SODIUM
PARAPLATIN, CARBOPLATIN
SERZONE, NEFAZODONE HYDROCHLORIDE
STADOL, BUTORPHANOL TARTRATE
TAXOL, PACLITAXEL
TEQUIN, GATIFLOXACIN
VIDEX, DIDANOSINE
VUMON, TENIPOSIDE
ZERIT, STAVUDINE

* BRISTOL MYERS SQUIBB MEDICAL IMAGING
DEFINITY, PERFLUTREN
GALLIUM CITRATE GA 67, GALLIUM CITRATE, GA-67
NEUROLITE, TECHNETIUM TC-99M BICISATE KIT
TECHNELITE, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
THALLOUS CHLORIDE TL 201, THALLOUS CHLORIDE, TL-201
XENON XE 133, XENON, XE-133

* BRISTOL MYERS SQUIBB PHARMA CO
CARDIOLITE, TECHNETIUM TC-99M SESTAMIBI KIT
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
COUMADIN, WARFARIN SODIUM
GLUCOSCAN, TECHNETIUM TC-99M GLUCEPTATE KIT
INNOHEP, TINZAPARIN SODIUM
LODOSYN, CARBIDOPA
MIRALUMA, TECHNETIUM TC-99M SESTAMIBI KIT
NARCAN, NALOXONE HYDROCHLORIDE
OXYCODONE 2.5/APAP 500, ACETAMINOPHEN
OXYCODONE 5/APAP 500, ACETAMINOPHEN
REMSED, PROMETHAZINE HYDROCHLORIDE
REVIA, NALTREXONE HYDROCHLORIDE
SINEMET CR, CARBIDOPA
SINEMET, CARBIDOPA
SUSTIVA, EFAVIRENZ

* BRISTOL MYERS SQUIBB SPA
PENICILLIN G SODIUM, PENICILLIN G SODIUM

BRYAN

* BRYAN CORP
SCLEROSOL, TALC

BTG

* BTG PHARMACEUTICALS CORP SUB BIOTECHNOLOGY GENERAL CORP
DELATESTRYL, TESTOSTERONE ENANTHATE

BUNDY

* CM BUNDY CO
BUTABARBITAL, BUTABARBITAL SODIUM
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
MECLIZINE HCL, MECLIZINE HYDROCHLORIDE
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
RAUWOLFIA SERPENTINA, RAUWOLFIA SERPENTINA
RESERPINE, RESERPINE

** C **

C AND M PHARMA

* C AND M PHARMACAL INC
HC (HYDROCORTISONE), HYDROCORTISONE
HC (HYDROCORTISONE), HYDROCORTISONE (OTC)
HI-COR, HYDROCORTISONE

CADEMA

* CADEMA MEDICAL PRODUCTS INC
RBC-SCAN, TECHNETIUM TC-99M RED BLOOD CELL KIT

CALGON

* CALGON CORP DIV MERCK AND CO INC
SEPTI-SOFT, HEXACHLOROPHENE

CAMALL

* CAMALL CO INC
CAM-METRAZINE, PHENDIMETRAZINE TARTRATE
PHENTERMINE HCL, PHENTERMINE HYDROCHLORIDE

CARACO

* CARACO PHARMACEUTICAL LABORATORIES LTD
CARBAMAZEPINE, CARBAMAZEPINE
CLONAZEPAM, CLONAZEPAM
FLURBIPROFEN, FLURBIPROFEN
METOPROLOL TARTRATE, METOPROLOL TARTRATE
PAROMOMYCIN SULFATE, PAROMOMYCIN SULFATE

CARLISLE

* CARLISLE LABORATORIES INC
ALPHACAINE HCL W/ EPINEPHRINE, EPINEPHRINE
ALPHACAINE HCL, LIDOCAINE HYDROCHLORIDE
ALPHACAINE, LIDOCAINE

CARLSBAD

* CARLSBAD TECHNOLOGY INC
ACYCLOVIR, ACYCLOVIR
DICLOFENAC SODIUM, DICLOFENAC SODIUM
FAMOTIDINE, FAMOTIDINE

CARNRICK

* CARNRICK LABORATORIES INC DIV GW CARNRICK CO
CAPITAL WITH CODEINE, ACETAMINOPHEN
SKELAXIN, METAXALONE

CAROLINA MEDCL

FDA data supplied by DrugPatentWatch.com

* CAROLINA MEDICAL PRODUCTS CO
HYDROCORTISONE IN ABSORBASE, HYDROCORTISONE
ISONIAZID, ISONIAZID
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE
SPS, SODIUM POLYSTYRENE SULFONATE
TRIAMCINOLONE ACETONIDE IN ABSORBASE, TRIAMCINOLONE ACETONIDE

CATALYTICA PHARMS
* CATALYTICA PHARMACEUTICALS INC
ALOPRIM, ALLOPURINOL SODIUM

CELGENE
* CELGENE CORP
THALOMID, THALIDOMIDE

CELL THERAP
* CELL THERAPEUTICS INC
TRISENOX, ARSENIC TRIOXIDE

CELLTECH MFG
* CELLTECH MANUFACTURING INC
METADATE ER, METHYLPHENIDATE HYDROCHLORIDE
METHYLPHENIDATE HCL, METHYLPHENIDATE HYDROCHLORIDE

CELLTECH PHARMS
* CELLTECH PHARMACEUTICALS INC
ALBUTEROL SULFATE, ALBUTEROL SULFATE
AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
BIPHETAMINE 12.5, AMPHETAMINE RESIN COMPLEX
BIPHETAMINE 20, AMPHETAMINE RESIN COMPLEX
BIPHETAMINE 7.5, AMPHETAMINE RESIN COMPLEX
CORSYM, CHLORPHENIRAMINE POLISTIREX (OTC)
DELSYM, DEXTROMETHORPHAN POLISTIREX (OTC)
DEXACORT, DEXAMETHASONE SODIUM PHOSPHATE
DIETHYLPROPION HCL, DIETHYLPROPION HYDROCHLORIDE
GASTROCROM, CROMOLYN SODIUM
GLUTETHIMIDE, GLUTETHIMIDE
IONAMIN, PHENTERMINE RESIN COMPLEX
METADATE CD, METHYLPHENIDATE HYDROCHLORIDE
METADATE ER, METHYLPHENIDATE HYDROCHLORIDE
MYKROX, METOLAZONE
PEDIAPRED, PREDNISOLONE SODIUM PHOSPHATE
PSEUDO-12, PSEUDOEPHEDRINE POLISTIREX (OTC)
SEMPREX-D, ACRIVASTINE
TUSSIONEX, CHLORPHENIRAMINE POLISTIREX
ZAROXOLYN, METOLAZONE

CENCI
* CENCI POWDER PRODUCTS INC
THEOPHYLLINE, THEOPHYLLINE
* HR CENCI LABORATORIES INC
ACTAHIST, PSEUDOEPHEDRINE HYDROCHLORIDE
DIBENIL, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
ELIXOMIN, THEOPHYLLINE
HISTAFED, PSEUDOEPHEDRINE HYDROCHLORIDE
HYDROCORTISONE ACETATE, HYDROCORTISONE ACETATE
PROMETHAZINE VC PLAIN, PHENYLEPHRINE HYDROCHLORIDE
PROMETHAZINE VC W/ CODEINE, CODEINE PHOSPHATE
PROMETHAZINE W/ CODEINE, CODEINE PHOSPHATE
PROMETHAZINE, PROMETHAZINE HYDROCHLORIDE
TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES W/ CODEINE, CODEINE PHOSPHATE

CENT PHARMS
* CENTRAL PHARMACEUTICALS INC
ACETAMINOPHEN AND HYDROCODONE BITARTRATE, ACETAMINOPHEN
AZDONE, ASPIRIN
CO-GESIC, ACETAMINOPHEN
DEXACEN-4, DEXAMETHASONE SODIUM PHOSPHATE
PHENYLPROPANOLAMINE HCL W/ CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE (OTC)
PREDNISOLONE ACETATE, PREDNISOLONE ACETATE
PSEUDOEPHEDRINE HCL AND CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE (OTC)
SYNOPHYLATE, THEOPHYLLINE SODIUM GLYCINATE
THEOCLEAR-100, THEOPHYLLINE
THEOCLEAR-200, THEOPHYLLINE
THEOCLEAR-80, THEOPHYLLINE
THEOPHYLLINE, THEOPHYLLINE

CENTURY PHARMS
* CENTURY PHARMACEUTICALS INC
P.A.S. SODIUM, AMINOSALICYLATE SODIUM

CEPH INTL
* CEPH INTERNATIONAL CORP
CECLOR, CEFACLOR
KEFLEX, CEPHALEXIN

CEPHALON
* CEPHALON INC
GABITRIL, TIAGABINE HYDROCHLORIDE
PROVIGIL, MODAFINIL

CHAMBERLIN PARENTERL
* CHAMBERLIN PARENTERAL CORP
HEPARIN SODIUM, HEPARIN SODIUM

CHASE CHEM
* CHASE CHEMICAL CO LP
VITAMIN A, VITAMIN A
VITAMIN A, VITAMIN A PALMITATE
VITAMIN D, ERGOCALCIFEROL

CHASE LABS NJ

FDA data supplied by DrugPatentWatch.com

* CHASE LABORATORIES INC
NIFEDIPINE, NIFEDIPINE

CHESEBROUGH PONDS
* CHESEBROUGH PONDS INC
EXTRA-STRENGTH AIM, SODIUM MONOFLUOROPHOSPHATE (OTC)
VIRAC REX, UNDECOYLIUM CHLORIDE

CHIRON
* CHIRON CORP
TOBI, TOBRAMYCIN

CIBA
* CIBA VISION CORP DIV NOVARTIS CO
CATARASE, CHYMOTRYPSIN

CIS
* CIS BIOINDUSTRIES COMPAGNIE
SODIUM IODIDE I 131, SODIUM IODIDE, I-131
* CIS US INC
AN-DTPA, TECHNETIUM TC-99M PENTETATE KIT
AN-MAA, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT
AN-SULFUR COLLOID, TECHNETIUM TC-99M SULFUR COLLOID KIT
CIS-MDP, TECHNETIUM TC-99M MEDRONATE KIT
CIS-PYRO, TECHNETIUM TC-99M PYROPHOSPHATE KIT
HEPATOLITE, TECHNETIUM TC-99M DISOFENIN KIT
IOBENGUANE SULFATE I 131, IOBENGUANE SULFATE I 131
IODOHIPPURATE SODIUM I 131, IODOHIPPURATE SODIUM, I-131
MICROLITE, TECHNETIUM TC-99M ALBUMIN COLLOID KIT
OSTEOLITE, TECHNETIUM TC-99M MEDRONATE KIT
PULMOLITE, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT
PYROLITE, TECHNETIUM TC-99M PYRO/TRIMETA PHOSPHATES KIT
SELENOMETHIONINE SE 75, SELENOMETHIONINE, SE-75
SODIUM PERTECHNETATE TC 99M, TECHNETIUM TC-99M SODIUM PERTECHNETATE

CLAY PARK
* CLAY PARK LABORATORIES INC
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
ERYTHROMYCIN, ERYTHROMYCIN
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUOCINONIDE, FLUOCINONIDE
GENTAMICIN, GENTAMICIN SULFATE
HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE
HYDROCORTISONE, HYDROCORTISONE
NITROFURAZONE, NITROFURAZONE
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
NYSTATIN, NYSTATIN
PERMETHRIN, PERMETHRIN (OTC)
SELENIUM SULFIDE, SELENIUM SULFIDE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
TRIDESILON, DESONIDE
TRIPLE SULFA, TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE; SULFATHIAZOLE)

CLINTEC NUTR
* CLINTEC NUTRITION CO SUB CLINIQUE
CLINISOL 15% SULFITE FREE IN PLASTIC CONTAINER, AMINO ACIDS

CLONMEL
* CLONMEL HEALTHCARE
AMOXICILLIN, AMOXICILLIN
AMPICILLIN TRIHYDRATE, AMPICILLIN/AMPICILLIN TRIHYDRATE
PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM

COLGATE
* COLGATE ORAL PHARMACEUTICALS INC
ORABASE HCA, HYDROCORTISONE ACETATE
PERIOGARD, CHLORHEXIDINE GLUCONATE

COLGATE PALMOLIVE
* COLGATE PALMOLIVE
COLGATE TOTAL, SODIUM FLUORIDE (OTC)

COLLAGENEX
* COLLAGENEX INC
PERIOSTAT, DOXYCYCLINE HYCLATE

COLLAGENEX PHARMS
* COLLAGENEX PHARMACEUTICALS INC
PERIOSTAT, DOXYCYCLINE HYCLATE

COLUMBIA RES LABS
* COLUMBIA RESEARCH LABORATORIES INC
CRINONE, PROGESTERONE

COMBE
* COMBE INC
BACITRACIN, BACITRACIN (OTC)
LANABIOTIC, BACITRACIN (OTC)
LANABIOTIC, BACITRACIN ZINC (OTC)

CONNETICS
* CONNETICS CORP
LUXIQ, BETAMETHASONE VALERATE
OLUX FOAM, CLOBETASOL PROPIONATE

CONSOLIDATED MIDLAND
* CONSOLIDATED MIDLAND CORP
TEEBACIN, AMINOSALICYLATE SODIUM

CONSOLIDATED PHARM
* CONSOLIDATED PHARMACEUTICAL GROUP INC
AMOXICILLIN, AMOXICILLIN

FDA data supplied by DrugPatentWatch.com

AMPICILLIN SODIUM, AMPICILLIN SODIUM
AMPICILLIN TRIHYDRATE, AMPICILLIN/AMPICILLIN TRIHYDRATE
PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM
PENICILLIN G PROCAINE, PENICILLIN G PROCAINE
PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM

CONTROLLED THERAP
* CONTROLLED THERAPEUTICS (SCOTLAND) LTD
CERVIDIL, DINOPROSTONE

COOK IMAGING
* COOK IMAGING CORP
IOPAMIDOL-200, IOPAMIDOL
IOPAMIDOL-250, IOPAMIDOL
IOPAMIDOL-300, IOPAMIDOL
IOPAMIDOL-370, IOPAMIDOL
OXILAN-300, IOXILAN
OXILAN-350, IOXILAN

COPANOS
* JOHN D COPANOS AND CO INC
PENICILLIN G SODIUM, PENICILLIN G SODIUM
STREPTOMYCIN SULFATE, STREPTOMYCIN SULFATE

COPLEY PHARM
* COPLEY PHARMACEUTICAL INC
ACYCLOVIR, ACYCLOVIR
ALBUTEROL SULFATE, ALBUTEROL SULFATE
AMANTADINE HCL, AMANTADINE HYDROCHLORIDE
AMIODARONE HCL, AMIODARONE HYDROCHLORIDE
AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
ATENOLOL, ATENOLOL
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
BROMATAPP, BROMPHENIRAMINE MALEATE (OTC)
BROMPHERIL, DEXBROMPHENIRAMINE MALEATE (OTC)
CAPTOPRIL, CAPTOPRIL
CHOLESTYRAMINE LIGHT, CHOLESTYRAMINE
CHOLESTYRAMINE, CHOLESTYRAMINE
CIMETIDINE HCL, CIMETIDINE HYDROCHLORIDE
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CO-LAV, POLYETHYLENE GLYCOL 3350
DESONIDE, DESONIDE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DILTIAZEM HCL, DILTIAZEM HYDROCHLORIDE
DOXEPIN HCL, DOXEPIN HYDROCHLORIDE
DOXYLAMINE SUCCINATE, DOXYLAMINE SUCCINATE (OTC)
ETHOSUXIMIDE, ETHOSUXIMIDE
EVALOSE, LACTULOSE
FLUOCINONIDE, FLUOCINONIDE
FLUPHENAZINE HCL, FLUPHENAZINE HYDROCHLORIDE
GO-EVAC, POLYETHYLENE GLYCOL 3350
GUANABENZ ACETATE, GUANABENZ ACETATE
GYNIX, CLOTRIMAZOLE (OTC)
HALOPERIDOL, HALOPERIDOL LACTATE
HEPTALAC, LACTULOSE
HYDROCORTISONE ACETATE 1% AND PRAMOXINE HCL 1%, HYDROCORTISONE ACETATE
HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE
HYDROCORTISONE, HYDROCORTISONE
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
LIDOCAINE HCL, LIDOCAINE HYDROCHLORIDE
MEBENDAZOLE, MEBENDAZOLE
METAPROTERENOL SULFATE, METAPROTERENOL SULFATE
METHAZOLAMIDE, METHAZOLAMIDE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
NABUMETONE, NABUMETONE
NADOLOL, NADOLOL
NAPROXEN SODIUM, NAPROXEN SODIUM
NAPROXEN, NAPROXEN
PEMOLINE, PEMOLINE
PIROXICAM, PIROXICAM
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PREDNISOLONE, PREDNISOLONE
PROCAINAMIDE HCL, PROCAINAMIDE HYDROCHLORIDE
PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE
QUINIDINE SULFATE, QUINIDINE SULFATE
THIORIDAZINE HCL, THIORIDAZINE HYDROCHLORIDE
THIOTHIXENE HCL, THIOTHIXENE HYDROCHLORIDE
TRETINOIN, TRETINOIN
URSODIOL, URSODIOL
VALPROIC ACID, VALPROIC ACID

COR
* COR THERAPEUTICS INC
INTEGRILIN, EPTIFIBATIDE

COREPHARMA
* COREPHARMA LLC
CARISOPRODOL, CARISOPRODOL
RIMANTADINE HCL, RIMANTADINE HYDROCHLORIDE

CUMBERLAND SWAN
* CUMBERLAND SWAN INC
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)

CYTOGEN
* CYTOGEN CORP
QUADRAMET, SAMARIUM SM 153 LEXIDRONAM PENTASODIUM

** D **

FDA data supplied by DrugPatentWatch.com

DAIICHI
* DAIICHI PHARMACEUTICAL CO LTD
FLOXIN, OFLOXACIN
* DAIICHI PHARMACEUTICAL CORP
EVOXAC, CEVIMELINE HYDROCHLORIDE

DAINIPPON
* DAINIPPON PHARMACEUTICAL USA CORP
ZONEGRAN, ZONISAMIDE

DANBURY PHARMA
* DANBURY PHARMACAL INC
ACETAZOLAMIDE, ACETAZOLAMIDE
ACETOHEXAMIDE, ACETOHEXAMIDE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALLOPURINOL, ALLOPURINOL
AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
AMOXAPINE, AMOXAPINE
ATENOLOL AND CHLORTHALIDONE, ATENOLOL
ATENOLOL, ATENOLOL
BACLOFEN, BACLOFEN
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
BROMPHENIRAMINE MALEATE, BROMPHENIRAMINE MALEATE
BUSPIRONE HCL, BUSPIRONE HYDROCHLORIDE
BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN
CAPTOPRIL AND HYDROCHLOROTHIAZIDE, CAPTOPRIL
CAPTOPRIL, CAPTOPRIL
CARISOPRODOL, CARISOPRODOL
CHLORDIAZEPOXIDE AND AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
CHLOROTHIAZIDE, CHLOROTHIAZIDE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
CHLORPROPAMIDE, CHLORPROPAMIDE
CHLORTHALIDONE, CHLORTHALIDONE
CHLORZOXAZONE, CHLORZOXAZONE
CIMETIDINE, CIMETIDINE
CIMETIDINE, CIMETIDINE (OTC)
CLINDAMYCIN HCL, CLINDAMYCIN HYDROCHLORIDE
CLONIDINE HCL, CLONIDINE HYDROCHLORIDE
COL-PROBENECID, COLCHICINE
CYCLOBENZAPRINE HCL, CYCLOBENZAPRINE HYDROCHLORIDE
CYPROHEPTADINE HCL, CYPROHEPTADINE HYDROCHLORIDE
DEXAMETHASONE, DEXAMETHASONE
DIAZEPAM, DIAZEPAM
DIFLUNISAL, DIFLUNISAL
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DISOPYRAMIDE PHOSPHATE, DISOPYRAMIDE PHOSPHATE
DISULFIRAM, DISULFIRAM
DOXEPIN HCL, DOXEPIN HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
ERGOLOID MESYLATES, ERGOLOID MESYLATES
ERYTHROMYCIN ESTOLATE, ERYTHROMYCIN ESTOLATE
FAMOTIDINE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE (OTC)
FENOPROFEN CALCIUM, FENOPROFEN CALCIUM
FLURAZEPAM HCL, FLURAZEPAM HYDROCHLORIDE
FOLIC ACID, FOLIC ACID
FUROSEMIDE, FUROSEMIDE
GLUTETHIMIDE, GLUTETHIMIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
HALOPERIDOL, HALOPERIDOL
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE W/ RESERPINE, HYDROCHLOROTHIAZIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROCORTISONE, HYDROCORTISONE
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
INDOMETHACIN, INDOMETHACIN
ISONIAZID, ISONIAZID
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
LORAZEPAM, LORAZEPAM
MECLOFENAMATE SODIUM, MECLOFENAMATE SODIUM
MEPROBAMATE, MEPROBAMATE
METAPROTERENOL SULFATE, METAPROTERENOL SULFATE
METHOCARBAMOL, METHOCARBAMOL
METHYLDOPA AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
METHYLDOPA, METHYLDOPA
METHYLPHENIDATE HCL, METHYLPHENIDATE HYDROCHLORIDE
METHYLTESTOSTERONE, METHYLTESTOSTERONE
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
METRONIDAZOLE, METRONIDAZOLE
MEXILETINE HCL, MEXILETINE HYDROCHLORIDE
MINOCYCLINE HCL, MINOCYCLINE HYDROCHLORIDE
MINOXIDIL, MINOXIDIL
NALIDIXIC ACID, NALIDIXIC ACID
NAPROXEN SODIUM, NAPROXEN SODIUM
NAPROXEN, NAPROXEN
NIACIN, NIACIN
NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
NORTRIPTYLINE HCL, NORTRIPTYLINE HYDROCHLORIDE
OXAZEPAM, OXAZEPAM
PERPHENAZINE AND AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
PHENYLBUTAZONE, PHENYLBUTAZONE
PIROXICAM, PIROXICAM
PRAZOSIN HCL, PRAZOSIN HYDROCHLORIDE
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
PRIMIDONE, PRIMIDONE
PROBENECID, PROBENECID
PROCAINAMIDE HCL, PROCAINAMIDE HYDROCHLORIDE
PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

PROMPT PHENYTOIN SODIUM, PHENYTOIN SODIUM, PROMPT
PROPANTHELINE BROMIDE, PROPANTHELINE BROMIDE
PROPOXYPHENE HCL, PROPOXYPHENE HYDROCHLORIDE
PROPRANOLOL HCL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
PROPYLTHIOURACIL, PROPYLTHIOURACIL
QUINIDINE GLUCONATE, QUINIDINE GLUCONATE
QUINIDINE SULFATE, QUINIDINE SULFATE
RAUWOLFIA SERPENTINA, RAUWOLFIA SERPENTINA
RESERPINE, HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE, HYDRALAZINE HYDROCHLORIDE
RESERPINE, RESERPINE
SPIRONOLACTONE/HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH, SULFAMETHOXAZOLE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
SULFASALAZINE, SULFASALAZINE
SULFINPYRAZONE, SULFINPYRAZONE
SULINDAC, SULINDAC
TEMAZEPAM, TEMAZEPAM
TETRACYCLINE HCL, TETRACYCLINE HYDROCHLORIDE
THIORIDAZINE HCL, THIORIDAZINE HYDROCHLORIDE
THIOTHIXENE, THIOTHIXENE
TICLOPIDINE HCL, TICLOPIDINE HYDROCHLORIDE
TIMOLOL MALEATE, TIMOLOL MALEATE
TOLAZAMIDE, TOLAZAMIDE
TOLBUTAMIDE, TOLBUTAMIDE
TRAZODONE HCL, TRAZODONE HYDROCHLORIDE
TRIAMCINOLONE, TRIAMCINOLONE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TRICHLORMETHIAZIDE, TRICHLORMETHIAZIDE
TRIHEXYPHENIDYL HCL, TRIHEXYPHENIDYL HYDROCHLORIDE
TRIMETHOPRIM, TRIMETHOPRIM
TRIPELENNAMINE HCL, TRIPELENNAMINE HYDROCHLORIDE
TRIPROLIDINE HCL, TRIPROLIDINE HYDROCHLORIDE
VERAPAMIL HCL, VERAPAMIL HYDROCHLORIDE

DAVIS AND GECK
* DAVIS AND GECK DIV AMERICAN CYANAMID CO
FLAXEDIL, GALLAMINE TRIETHIODIDE
PRE-OP II, HEXACHLOROPHENE
PRE-OP, HEXACHLOROPHENE

DEL RAY LABS
* DEL RAY LABORATORIES INC
ALA-CORT, HYDROCORTISONE
ALA-SCALP, HYDROCORTISONE
DEL-VI-A, VITAMIN A PALMITATE
TRIDERM, TRIAMCINOLONE ACETONIDE

DELL LABS
* DELL LABORATORIES INC
CYANOCOBALAMIN, CYANOCOBALAMIN
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
HEPARIN SODIUM, HEPARIN SODIUM
LIDOCAINE HCL W/ EPINEPHRINE, EPINEPHRINE
LIDOCAINE HCL, LIDOCAINE HYDROCHLORIDE
PYRIDOXINE HCL, PYRIDOXINE HYDROCHLORIDE
THIAMINE HCL, THIAMINE HYDROCHLORIDE

DENTSPLY PHARM
* DENTSPLY PHARMACEUTICAL
CITANEST FORTE, EPINEPHRINE BITARTRATE
CITANEST PLAIN, PRILOCAINE HYDROCHLORIDE
DURANEST, EPINEPHRINE BITARTRATE
POLOCAINE W/ LEVONORDEFRIN, LEVONORDEFRIN
POLOCAINE, MEPIVACAINE HYDROCHLORIDE
XYLOCAINE W/ EPINEPHRINE, EPINEPHRINE
XYLOCAINE, LIDOCAINE HYDROCHLORIDE

DEPROCO
* DEPROCO INC
LIGNOSPAN FORTE, EPINEPHRINE BITARTRATE
LIGNOSPAN STANDARD, EPINEPHRINE BITARTRATE
SCANDONEST L, LEVONORDEFRIN
SCANDONEST PLAIN, MEPIVACAINE HYDROCHLORIDE
SEPTOCAINE, ARTICAINE HYDROCHLORIDE

DERMIK LABS
* DERMIK LABORATORIES INC
BENZACLIN, BENZOYL PEROXIDE
BENZAMYCIN PAK, BENZOYL PEROXIDE
BENZAMYCIN, BENZOYL PEROXIDE
CARAC, FLUOROURACIL
HYTONE, HYDROCORTISONE
NORITATE, METRONIDAZOLE
PSORCON, DIFLORASONE DIACETATE
* DERMIK LABORATORIES INC SUB RORER
HYTONE, HYDROCORTISONE
KLARON, SULFACETAMIDE SODIUM

DESERET
* DESERET MEDICAL INC DIV BECTON DICKINSON AND CO
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE (OTC)

DEXCEL LTD
* DEXCEL LTD
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE

DEXCEL PHARMA
* DEXCEL PHARMA TECHNOLOGIES LTD
PERIOCHIP, CHLORHEXIDINE GLUCONATE

DEY
* DEY LP

FDA data supplied by DrugPatentWatch.com

ACCUNEB, ALBUTEROL SULFATE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
CROMOLYN SODIUM, CROMOLYN SODIUM
CUROSURF, PORACTANT ALFA
DUONEB, ALBUTEROL SULFATE
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
ISOETHARINE HCL S/F, ISOETHARINE HYDROCHLORIDE
ISOETHARINE HCL, ISOETHARINE HYDROCHLORIDE
ISOPROTERENOL HCL, ISOPROTERENOL HYDROCHLORIDE
METAPROTERENOL SULFATE, METAPROTERENOL SULFATE
MUCOSIL-10, ACETYLCYSTEINE
MUCOSIL-20, ACETYLCYSTEINE

DHL
* DHL LABORATORIES INC
DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE

DIAL
* DIAL CORP DIV GREYHOUND CO
DIAL, HEXACHLOROPHENE

DIATIDE RES LABS
* DIATIDE RESEARCH LABORATORIES DIV BERLEX LABS INC
ACUTECT, TECHNETIUM TC-99M APCITIDE
NEO TECT KIT, TECHNETIUM TC-99M DEPREOTIDE

DISTA
* DISTA PRODUCTS CO DIV ELI LILLY AND CO
ERYTHROMYCIN ETHYLSUCCINATE, ERYTHROMYCIN ETHYLSUCCINATE
ILOSONE, ERYTHROMYCIN ESTOLATE
ILOTYCIN GLUCEPTATE, ERYTHROMYCIN GLUCEPTATE
ILOTYCIN, ERYTHROMYCIN
NALFON 200, FENOPROFEN CALCIUM
NALFON, FENOPROFEN CALCIUM
VALMID, ETHINAMATE

DOW PHARM
* DOW PHARMACEUTICAL CORP SUB DOW CHEMICAL CO
DOW-ISONIAZID, ISONIAZID
NEO-POLYCIN, BACITRACIN ZINC
NEO-POLYCIN, GRAMICIDIN
QUIDE, PIPERACETAZINE

DOWNSTATE CLINCL
* DOWNSTATE CLINICAL PET CENTER
FLUDEOXYGLUCOSE F 18, FLUDEOXYGLUCOSE, F-18

DPT
* DPT LABORATORIES INC
EMBELINE, CLOBETASOL PROPIONATE

DR REDDYS LABS INC
* DR REDDYS LABORATORIES INC
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)

DR REDDYS LABS LTD
* DR REDDYS LABORATORIES LTD
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
FAMOTIDINE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE (OTC)
FLUOXETINE, FLUOXETINE HYDROCHLORIDE
OXAPROZIN, OXAPROZIN
RANITIDINE HCL, RANITIDINE HYDROCHLORIDE
RANITIDINE, RANITIDINE HYDROCHLORIDE (OTC)

DRAXIMAGE
* DRAXIMAGE INC
DTPA, TECHNETIUM TC-99M PENTETATE KIT
TECHNESCAN GLUCEPTATE, TECHNETIUM TC-99M GLUCEPTATE KIT
TECHNESCAN HIDA, TECHNETIUM TC-99M LIDOFENIN KIT
TECHNESCAN MDP KIT, TECHNETIUM TC-99M MEDRONATE KIT
TECHNETIUM TC 99M ALBUMIN AGGREGATED KIT, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT

DRAXIS HLTH
* DRAXIS HEALTH INC
FLUOCINONIDE, FLUOCINONIDE

DUNHALL
* DUNHALL PHARMACEUTICALS INC
TRIAPRIN, ACETAMINOPHEN

DURA
* DURA PHARMACEUTICALS INC
FURADANTIN, NITROFURANTOIN

DURAMED
* DURAMED PHARMACEUTICALS INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
AMINOPHYLLINE, AMINOPHYLLINE
AVIANE-21, ETHINYL ESTRADIOL
AVIANE-28, ETHINYL ESTRADIOL
CENESTIN, ESTROGENS, CONJUGATED SYNTHETIC A
CHLORPROPAMIDE, CHLORPROPAMIDE
CIMETIDINE HCL, CIMETIDINE
CLONIDINE HCL, CLONIDINE HYDROCHLORIDE
CRYSELLE, ETHINYL ESTRADIOL
CYPROHEPTADINE HCL, CYPROHEPTADINE HYDROCHLORIDE
DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
DIAZEPAM, DIAZEPAM
ENPRESSE-21, ETHINYL ESTRADIOL
ENPRESSE-28, ETHINYL ESTRADIOL
ESTROPIPATE, ESTROPIPATE
GLIPIZIDE, GLIPIZIDE
GYNODIOL, ESTRADIOL

FDA data supplied by DrugPatentWatch.com

HALOPERIDOL, HALOPERIDOL
HYDROXYUREA, HYDROXYUREA
HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
INDOMETHACIN, INDOMETHACIN
ISONIAZID, ISONIAZID
LOPERAMIDE HCL, LOPERAMIDE HYDROCHLORIDE (OTC)
MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE
MEPERIDINE HCL, MEPERIDINE HYDROCHLORIDE
METHOTREXATE SODIUM, METHOTREXATE SODIUM
METHYLDOPA, METHYLDOPA
METHYLPREDNISOLONE, METHYLPREDNISOLONE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
PHENTERMINE HCL, PHENTERMINE HYDROCHLORIDE
PREDNISONE, PREDNISONE
PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE
PROPRANOLOL HCL & HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
TEMAZEPAM, TEMAZEPAM
TOLAZAMIDE, TOLAZAMIDE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TRIFLUOPERAZINE HCL, TRIFLUOPERAZINE HYDROCHLORIDE

DUSA
* DUSA PHARMACEUTICAL INC
LEVULAN, AMINOLEVULINIC ACID HYDROCHLORIDE

DYNAPHARM
* DYNAPHARM INC
COLOVAGE, POLYETHYLENE GLYCOL 3350

** E **

E Z EM
* E Z EM CO INC
E-Z-EM PREP LYTE, POLYETHYLENE GLYCOL 3350

EASTMAN KODAK
* EASTMAN KODAK CO
CARBOCAINE W/ NEO-COBEFRIN, LEVONORDEFRIN
CARBOCAINE, MEPIVACAINE HYDROCHLORIDE
LIDOCAINE HCL AND EPINEPHRINE, EPINEPHRINE
RAVOCAINE AND NOVOCAIN W/ LEVOPHED, NOREPINEPHRINE BITARTRATE
RAVOCAINE AND NOVOCAIN W/ NEO-COBEFRIN, LEVONORDEFRIN

ECOLAB
* ECOLAB INC
CHG SCRUB, CHLORHEXIDINE GLUCONATE (OTC)
CIDA-STAT, CHLORHEXIDINE GLUCONATE (OTC)

EGIS
* EGIS PHARMACEUTICALS
PIROXICAM, PIROXICAM

EGIS PHARMS
* EGIS PHARMACEUTICALS LTD
CAPTOPRIL, CAPTOPRIL

EISAI
* EISAI INC
ACIPHEX, RABEPRAZOLE SODIUM
ARICEPT, DONEPEZIL HYDROCHLORIDE

ELAN PHARM
* ELAN PHARMACEUTICAL RESEARCH CORP
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
KETOPROFEN, KETOPROFEN
NAPRELAN, NAPROXEN SODIUM
NIFEDIPINE, NIFEDIPINE
PROSTEP, NICOTINE
PROSTEP, NICOTINE (OTC)
VERELAN PM, VERAPAMIL HYDROCHLORIDE
VERELAN, VERAPAMIL HYDROCHLORIDE

ELAN PHARMS
* ELAN PHARMACEUTICALS
DURACLON, CLONIDINE HYDROCHLORIDE
FROVA, FROVATRIPTAN SUCCINATE
ORAMORPH SR, MORPHINE SULFATE
ZANAFLEX, TIZANIDINE HYDROCHLORIDE
* ELAN PHARMACEUTICALS INC
ROXICODONE, OXYCODONE HYDROCHLORIDE

ELKINS SINN
* ELKINS SINN DIV AH ROBINS CO INC
AMIKACIN SULFATE, AMIKACIN SULFATE
AMINOCAPROIC ACID, AMINOCAPROIC ACID
AMINOPHYLLINE, AMINOPHYLLINE
AMPICILLIN SODIUM, AMPICILLIN SODIUM
BRETYLIUM TOSYLATE, BRETYLIUM TOSYLATE
CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
CEPHAPIRIN SODIUM, CEPHAPIRIN SODIUM
CHLORAMPHENICOL, CHLORAMPHENICOL SODIUM SUCCINATE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CORTISONE ACETATE, CORTISONE ACETATE
CYANOCOBALAMIN, CYANOCOBALAMIN
DEXAMETHASONE, DEXAMETHASONE SODIUM PHOSPHATE
DIAZEPAM, DIAZEPAM
DIGOXIN, DIGOXIN
DIMENHYDRINATE, DIMENHYDRINATE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DIPYRIDAMOLE, DIPYRIDAMOLE
DOBUTAMINE HCL, DOBUTAMINE HYDROCHLORIDE
DOPAMINE HCL, DOPAMINE HYDROCHLORIDE
DOXYCYCLINE, DOXYCYCLINE HYCLATE

FDA data supplied by DrugPatentWatch.com

DURAMORPH PF, MORPHINE SULFATE
ERYTHROMYCIN, ERYTHROMYCIN LACTOBIONATE
FENTANYL CITRATE PRESERVATIVE FREE, FENTANYL CITRATE
FUROSEMIDE, FUROSEMIDE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
HEP-LOCK U/P, HEPARIN SODIUM
HEP-LOCK, HEPARIN SODIUM
HEPARIN SODIUM, HEPARIN SODIUM
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROCORTISONE SODIUM SUCCINATE, HYDROCORTISONE SODIUM SUCCINATE
HYDROCORTISONE, HYDROCORTISONE
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
HYDROXYZINE, HYDROXYZINE HYDROCHLORIDE
INFUMORPH, MORPHINE SULFATE
ISOPROTERENOL HCL, ISOPROTERENOL HYDROCHLORIDE
KANAMYCIN, KANAMYCIN SULFATE
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
LIDOCAINE HCL AND EPINEPHRINE, EPINEPHRINE
LIDOCAINE HCL PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL, LIDOCAINE HYDROCHLORIDE
LORAZEPAM, LORAZEPAM
MEPERIDINE HCL, MEPERIDINE HYDROCHLORIDE
MEPROBAMATE, MEPROBAMATE
METARAMINOL BITARTRATE, METARAMINOL BITARTRATE
METHYLDOPATE HCL, METHYLDOPATE HYDROCHLORIDE
METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
METHYLPREDNISOLONE, METHYLPREDNISOLONE SODIUM SUCCINATE
METRONIDAZOLE, METRONIDAZOLE
NALOXONE HCL, NALOXONE HYDROCHLORIDE
NALOXONE, NALOXONE HYDROCHLORIDE
NITROFURANTOIN, NITROFURANTOIN
OXACILLIN SODIUM, OXACILLIN SODIUM
PANCURONIUM, PANCURONIUM BROMIDE
PENTAMIDINE ISETHIONATE, PENTAMIDINE ISETHIONATE
PENTOBARBITAL SODIUM, PENTOBARBITAL SODIUM
PHENYTOIN, PHENYTOIN SODIUM
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
PROCAINAMIDE HCL, PROCAINAMIDE HYDROCHLORIDE
PROCAINE HCL, PROCAINE HYDROCHLORIDE
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
PROCHLORPERAZINE, PROCHLORPERAZINE EDISYLATE
PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE
PROTAMINE SULFATE, PROTAMINE SULFATE
PYRIDOXINE HCL, PYRIDOXINE HYDROCHLORIDE
QUINIDINE SULFATE, QUINIDINE SULFATE
RESERPINE, RESERPINE
SECOBARBITAL SODIUM, SECOBARBITAL SODIUM
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
SODIUM PENTOBARBITAL, PENTOBARBITAL SODIUM
SODIUM SUCCINATE, SODIUM SUCCINATE
SOTRADECOL, SODIUM TETRADECYL SULFATE
SUFENTANIL CITRATE, SUFENTANIL CITRATE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
TESTOSTERONE PROPIONATE, TESTOSTERONE PROPIONATE
TETRACYCLINE HCL, TETRACYCLINE HYDROCHLORIDE
THIAMINE HCL, THIAMINE HYDROCHLORIDE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
VANCOMYCIN HCL, VANCOMYCIN HYDROCHLORIDE
VITAMIN A, VITAMIN A PALMITATE

ELKINS SINN PHARM
* ELKINS SINN PHARMACEUTICAL CO
CHLORPROMAZINE HCL, CHLORPROMAZINE HYDROCHLORIDE
IOPAMIDOL, IOPAMIDOL
NALOXONE, NALOXONE HYDROCHLORIDE

ENDO LABS
* ENDO LABORATORIES INC DIV DUPONT MERCK PHARMACEUTICAL CO
CAPTOPRIL, CAPTOPRIL
* ENDO LABORATORIES LLC
CAPTOPRIL AND HYDROCHLOROTHIAZIDE, CAPTOPRIL

ENDO PHARMS
* ENDO PHARMACEUTICALS INC
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE, ASPIRIN
CIMETIDINE HCL, CIMETIDINE HYDROCHLORIDE
CIMETIDINE, CIMETIDINE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
ETODOLAC, ETODOLAC
GLIPIZIDE, GLIPIZIDE
HYCODAN, HOMATROPINE METHYLBROMIDE
HYCOMINE PEDIATRIC, HYDROCODONE BITARTRATE
HYCOMINE, HYDROCODONE BITARTRATE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
MOBAN, MOLINDONE HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
NARCAN, NALOXONE HYDROCHLORIDE
NUBAIN, NALBUPHINE HYDROCHLORIDE
NUMORPHAN, OXYMORPHONE HYDROCHLORIDE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
PERCOCET, ACETAMINOPHEN
PERCODAN, ASPIRIN
PERCODAN-DEMI, ASPIRIN
SELEGILINE HCL, SELEGILINE HYDROCHLORIDE
SYMMETREL, AMANTADINE HYDROCHLORIDE
VALPIN 50, ANISOTROPINE METHYLBROMIDE

ENVIRODERM
* ENVIRODERM PHARMACEUTICALS INC
IVY BLOCK, BENTOQUATAM (OTC)

ENZON

FDA data supplied by DrugPatentWatch.com

* ENZON INC
ADAGEN, PEGADEMASE BOVINE

EON
* EON LABORATORIES MANUFACTURING INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ALKERGOT, ERGOLOID MESYLATES
ALPHAZINE, PHENDIMETRAZINE TARTRATE
AMIODARONE HCL, AMIODARONE HYDROCHLORIDE
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
BUMETANIDE, BUMETANIDE
BUPROPION HCL, BUPROPION HYDROCHLORIDE
BUTABARBITAL SODIUM, BUTABARBITAL SODIUM
CAPTOPRIL, CAPTOPRIL
CARISOPRODOL AND ASPIRIN, ASPIRIN
CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE, ASPIRIN
CARISOPRODOL, CARISOPRODOL
CHLORDIAZEPOXIDE HCL, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLOROTHIAZIDE, CHLOROTHIAZIDE
CHLORPROPAMIDE, CHLORPROPAMIDE
CHLORTHALIDONE, CHLORTHALIDONE
CHOLESTYRAMINE LIGHT, CHOLESTYRAMINE
CHOLESTYRAMINE, CHOLESTYRAMINE
CLONAZEPAM, CLONAZEPAM
CYCLOSPORINE, CYCLOSPORINE
DESIPRAMINE HCL, DESIPRAMINE HYDROCHLORIDE
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
DIETHYLPROPION HCL, DIETHYLPROPION HYDROCHLORIDE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENOXYLATE HCL W/ ATROPINE SULFATE, ATROPINE SULFATE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
DOXYCYCLINE, DOXYCYCLINE
DRALSERP, HYDRALAZINE HYDROCHLORIDE
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
ETODOLAC, ETODOLAC
FAMOTIDINE, FAMOTIDINE
FLUTAMIDE, FLUTAMIDE
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
FOLIC ACID, FOLIC ACID
FUROSEMIDE, FUROSEMIDE
GUANABENZ ACETATE, GUANABENZ ACETATE
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
HYDRAP-ES, HYDRALAZINE HYDROCHLORIDE
HYDRO-SERP "25", HYDROCHLOROTHIAZIDE
HYDRO-SERP "50", HYDROCHLOROTHIAZIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROCORTISONE, HYDROCORTISONE
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
IMIPRAMINE HCL, IMIPRAMINE HYDROCHLORIDE
INDOCIN SR, INDOMETHACIN
ISONIAZID, ISONIAZID
LABETALOL HCL, LABETALOL HYDROCHLORIDE
LOCHOLEST LIGHT, CHOLESTYRAMINE
LOCHOLEST, CHOLESTYRAMINE
LOVASTATIN, LOVASTATIN
MEPRO-ASPIRIN, ASPIRIN
MEPROBAMATE, MEPROBAMATE
METHADONE HCL, METHADONE HYDROCHLORIDE
METHIMAZOLE, METHIMAZOLE
METHOCARBAMOL, METHOCARBAMOL
METHYLPREDNISOLONE, METHYLPREDNISOLONE
METRONIDAZOLE, METRONIDAZOLE
NALTREXONE HCL, NALTREXONE HYDROCHLORIDE
NEOMYCIN SULFATE, NEOMYCIN SULFATE
NITROFURANTOIN, NITROFURANTOIN
NYSTATIN, NYSTATIN
ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE, ASPIRIN
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
OXAPROZIN, OXAPROZIN
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PHENTERMINE HCL, PHENTERMINE HYDROCHLORIDE
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
PROBENECID AND COLCHICINE, COLCHICINE
PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE
PROPOXYPHENE COMPOUND 65, ASPIRIN
PROPOXYPHENE HCL, PROPOXYPHENE HYDROCHLORIDE
PSEUDOEPHEDRINE HCL AND TRIPROLIDINE HCL, PSEUDOEPHEDRINE HYDROCHLORIDE
QUINIDINE SULFATE, QUINIDINE SULFATE
RESERPINE, RESERPINE
RIFAMPIN, RIFAMPIN
SOTALOL HCL, SOTALOL HYDROCHLORIDE
SULFADIAZINE, TRISULFAPYRIMIDINES (SULFADIAZINE; SULFAMERAZINE;SULFAMETHAZINE)
SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH, SULFAMETHOXAZOLE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
SULFASALAZINE, SULFASALAZINE
TETRACYCLINE HCL, TETRACYCLINE HYDROCHLORIDE
THEOPHYLLINE, THEOPHYLLINE
TICLOPIDINE HCL, TICLOPIDINE HYDROCHLORIDE
TOLBUTAMIDE, TOLBUTAMIDE
TRICHLORMETHIAZIDE, TRICHLORMETHIAZIDE
WESTADONE, METHADONE HYDROCHLORIDE

ERSANA
* ERSANA INC SUB ER SQUIBB AND SONS
VELOSEF '250', CEPHRADINE
VELOSEF '500', CEPHRADINE

FDA data supplied by DrugPatentWatch.com

ESI
* ESI PHARMACAL
CYCRIN, MEDROXYPROGESTERONE ACETATE

ESI LEDERLE
* ESI LEDERLE GENERICS
VECURONIUM BROMIDE, VECURONIUM BROMIDE
* ESI LEDERLE INC
ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE, ACYCLOVIR SODIUM
ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
ACYCLOVIR, ACYCLOVIR
ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE
ATRACURIUM BESYLATE, ATRACURIUM BESYLATE
CEFOXITIN, CEFOXITIN SODIUM
ESTRADIOL, ESTRADIOL
FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE
MIDAZOLAM HCL, MIDAZOLAM HYDROCHLORIDE
MITOMYCIN, MITOMYCIN
MORPHINE SULFATE, MORPHINE SULFATE
PENTOXIFYLLINE, PENTOXIFYLLINE
SELEGILINE HCL, SELEGILINE HYDROCHLORIDE

ETHITEK
* ETHITEK PHARMACEUTICALS CO
MOCTANIN, MONOCTANOIN

EVERYLIFE
* EVERYLIFE
APAP W/ CODEINE PHOSPHATE, ACETAMINOPHEN
CORTISONE ACETATE, CORTISONE ACETATE
FOLIC ACID, FOLIC ACID
HYDROCORTISONE, HYDROCORTISONE
NIACIN, NIACIN
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
QUINIDINE SULFATE, QUINIDINE SULFATE
RESERPINE, RESERPINE
SECOBARBITAL SODIUM, SECOBARBITAL SODIUM
SODIUM PENTOBARBITAL, PENTOBARBITAL SODIUM
STANOZIDE, ISONIAZID
SULFADIAZINE, TRISULFAPYRIMIDINES (SULFADIAZINE; SULFAMERAZINE;SULFAMETHAZINE)
VITAMIN A, VITAMIN A
VITAMIN A, VITAMIN A PALMITATE
VITAMIN D, ERGOCALCIFEROL

** F **

FALCON PHARMS
* FALCON PHARMACEUTICALS INC
TIMOLOL MALEATE, TIMOLOL MALEATE
* FALCON PHARMACEUTICALS LTD
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DIPIVEFRIN HCL, DIPIVEFRIN HYDROCHLORIDE
ECONOPRED PLUS, PREDNISOLONE ACETATE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
LEVOBUNOLOL HCL, LEVOBUNOLOL HYDROCHLORIDE
MAXITROL, DEXAMETHASONE
METIPRANOLOL, METIPRANOLOL HYDROCHLORIDE
TIMOLOL MALEATE, TIMOLOL MALEATE
TOBREX, TOBRAMYCIN
TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE, POLYMYXIN B SULFATE

FAULDING
* FAULDING PHARMACEUTICAL CO
ACETYLCYSTEINE, ACETYLCYSTEINE
ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
AMIKACIN SULFATE, AMIKACIN SULFATE
BLEOMYCIN, BLEOMYCIN SULFATE
BRETYLOL, BRETYLIUM TOSYLATE
BUTORPHANOL TARTRATE PRESERVATIVE FREE, BUTORPHANOL TARTRATE
CYTARABINE, CYTARABINE
DACARBAZINE, DACARBAZINE
DROPERIDOL, DROPERIDOL
ENALAPRILAT, ENALAPRILAT
FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE
INTROPIN, DOPAMINE HYDROCHLORIDE
IOPAMIDOL, IOPAMIDOL
LABETALOL HCL, LABETALOL HYDROCHLORIDE
MEPERIDINE HCL PRESERVATIVE FREE, MEPERIDINE HYDROCHLORIDE
METHYLDOPATE HCL, METHYLDOPATE HYDROCHLORIDE
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
MIDAZOLAM HCL, MIDAZOLAM HYDROCHLORIDE
MITOMYCIN, MITOMYCIN
TRIDIL, NITROGLYCERIN
VINBLASTINE SULFATE, VINBLASTINE SULFATE
VINCRISTINE SULFATE PFS, VINCRISTINE SULFATE
VINCRISTINE SULFATE, VINCRISTINE SULFATE
* FAULDING PHARMACEUTICALS SUB FH FAULDING AND CO LTD
ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE
ATRACURIUM BESYLATE, ATRACURIUM BESYLATE
* FH FAULDING AND CO LTD
DORYX, DOXYCYCLINE HYCLATE
ERYC SPRINKLES, ERYTHROMYCIN
ERYC, ERYTHROMYCIN
THEOPHYLLINE, THEOPHYLLINE

FAULDING PHARMS
* FAULDING PHARMACEUTICALS INC
KADIAN, MORPHINE SULFATE
SERAX, OXAZEPAM

FDA data supplied by DrugPatentWatch.com

FERNDALE LABS
* FERNDALE LABORATORIES INC
ADPHEN, PHENDIMETRAZINE TARTRATE
AMOSENE, MEPROBAMATE
AQUAPHYLLIN, THEOPHYLLINE
DELAXIN, METHOCARBAMOL
DIAZEPAM, DIAZEPAM
FERNDEX, DEXTROAMPHETAMINE SULFATE
FERNISOLONE-P, PREDNISOLONE
FERNISONE, PREDNISONE
HYDROCORTISONE ACETATE, HYDROCORTISONE ACETATE
LOCOID, HYDROCORTISONE BUTYRATE
MICORT-HC, HYDROCORTISONE ACETATE
OBESTIN-30, PHENTERMINE HYDROCHLORIDE
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PRAMOSONE, HYDROCORTISONE ACETATE
RAUSERPIN, RAUWOLFIA SERPENTINA
STRIFON FORTE DSC, CHLORZOXAZONE

FERRANTE
* JOHN J FERRANTE
AMPHICOL, CHLORAMPHENICOL
CHLORDIAZEPOXIDE HCL, CHLORDIAZEPOXIDE HYDROCHLORIDE
HYDROCORTISONE, HYDROCORTISONE
OXY-KESSO-TETRA, OXYTETRACYCLINE HYDROCHLORIDE
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
TETRACYCLINE HCL, TETRACYCLINE HYDROCHLORIDE

FERRING
* FERRING PHARMACEUTICALS INC
ACTHREL, CORTICORELIN OVINE TRIFLUTATE
CONCENTRAID, DESMOPRESSIN ACETATE
LUTREPULSE KIT, GONADORELIN ACETATE
MENOTROPINS, MENOTROPINS (FSH;LH)
REPRONEX, MENOTROPINS (FSH;LH)
SECRETIN-FERRING, SECRETIN
THYREL TRH, PROTIRELIN

FIRST HORIZON
* FIRST HORIZON PHARMACEUTICAL CORP
COGNEX, TACRINE HYDROCHLORIDE
PONSTEL, MEFENAMIC ACID
ROBINUL FORTE, GLYCOPYRROLATE
ROBINUL, GLYCOPYRROLATE

FISONS
* FISONS CORP
IRON DEXTRAN, IRON DEXTRAN
ISOCLOR, CHLORPHENIRAMINE MALEATE (OTC)
PENNTUSS, CHLORPHENIRAMINE POLISTIREX (OTC)
SOMOPHYLLIN, AMINOPHYLLINE
SOMOPHYLLIN-DF, AMINOPHYLLINE
SOMOPHYLLIN-T, THEOPHYLLINE
VAPO-ISO, ISOPROTERENOL HYDROCHLORIDE

FLEMING PHARMS
* FLEMING AND CO PHARMACEUTICALS INC
AEROLATE III, THEOPHYLLINE
AEROLATE JR, THEOPHYLLINE
AEROLATE SR, THEOPHYLLINE
AEROLATE, THEOPHYLLINE

FLEMINGTON PHARM
* FLEMINGTON PHARMACEUTICAL CORP
NIFEDIPINE, NIFEDIPINE

FONDA BV
* FONDA BV
ARIXTRA, FONDAPARINUX SODIUM

FOREST LABS
* FOREST LABORATORIES INC
CELEXA, CITALOPRAM HYDROBROMIDE
FLUMADINE, RIMANTADINE HYDROCHLORIDE
TESSALON, BENZONATATE

FOREST PHARMS
* FOREST PHARMACEUTICALS INC
BANCAP HC, ACETAMINOPHEN
BANCAP, ACETAMINOPHEN
DURADYNE DHC, ACETAMINOPHEN
ESGIC, ACETAMINOPHEN
METRA, PHENDIMETRAZINE TARTRATE
MICROSUL, SULFAMETHIZOLE
PROKLAR, SULFAMETHIZOLE
SULFALOID, TRISULFAPYRIMIDINES (SULFADIAZINE;SULFAMERAZINE; SULFAMETHAZINE)
WOLFINA, RAUWOLFIA SERPENTINA

FORREST LABS
* FORREST LABORATORIES INC
AMBENYL, BROMODIPHENHYDRAMINE HYDROCHLORIDE
BETAPRONE, PROPIOLACTONE
DURAPHYL, THEOPHYLLINE
ELIXICON, THEOPHYLLINE
ELIXOPHYLLIN SR, THEOPHYLLINE
ELIXOPHYLLIN, THEOPHYLLINE
FORBAXIN, METHOCARBAMOL
PYOCIDIN, HYDROCORTISONE
SUS-PHRINE SULFITE-FREE, EPINEPHRINE
THYROLAR-0.25, LIOTRIX (T4;T3)
THYROLAR-0.5, LIOTRIX (T4;T3)
THYROLAR-1, LIOTRIX (T4;T3)
THYROLAR-2, LIOTRIX (T4;T3)

FDA data supplied by DrugPatentWatch.com

THYROLAR-3, LIOTRIX (T4;T3)
THYROLAR-5, LIOTRIX (T4;T3)

FOUGERA
* E FOUGERA DIV ALTANA INC
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
ERYTHROMYCIN, ERYTHROMYCIN
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUOCINONIDE, FLUOCINONIDE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
HYDROCORTISONE, HYDROCORTISONE
LIDOCAINE, LIDOCAINE
NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE, DEXAMETHASONE
NEOMYCIN SULFATE-TRIAMCINOLONE ACETONIDE, NEOMYCIN SULFATE
NYSTATIN, NYSTATIN
NYSTATIN-TRIAMCINOLONE ACETONIDE, NYSTATIN
TIMOLOL MALEATE, TIMOLOL MALEATE
TRIPLE SULFA, TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE; SULFATHIAZOLE)

FRANKLIN PHARMS
* FRANKLIN PHARMACEUTICALS INC
SILDAFLO, SILVER SULFADIAZINE

FRESENIUS
* FRESENIUS USA INC
INPERSOL-LC/LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
INPERSOL-LC/LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
INPERSOL-LC/LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
INPERSOL-LC/LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE

FRESENIUS KABI
* FRESENIUS KABI CLAYTON L P
AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE, AMINO ACIDS
CYSTEINE HCL, CYSTEINE HYDROCHLORIDE
INTRALIPID 10%, SOYBEAN OIL
INTRALIPID 20%, SOYBEAN OIL
INTRALIPID 30%, SOYBEAN OIL
NEOPHAM 6.4%, AMINO ACIDS
VITAPED, ASCORBIC ACID
* FRESENIUS KABI CLAYTON R&D INC
NOVAMINE 11.4%, AMINO ACIDS
NOVAMINE 15%, AMINO ACIDS
NOVAMINE 8.5%, AMINO ACIDS
VEINAMINE 8%, AMINO ACIDS

FRESENIUS MEDCL
* FRESENIUS MEDICAL CARE NORTH AMERICA
DELFLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX-LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX-LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX-LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
INPERSOL-ZM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
INPERSOL-ZM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
INPERSOL-ZM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE

FUJISAWA HLTHCARE
* FUJISAWA HEALTHCARE INC
ADENOCARD, ADENOSINE
ADENOSCAN, ADENOSINE
AMBISOME, AMPHOTERICIN B
ARISTOCORT A, TRIAMCINOLONE ACETONIDE
ARISTOCORT, TRIAMCINOLONE
ARISTOCORT, TRIAMCINOLONE ACETONIDE
ARISTOCORT, TRIAMCINOLONE DIACETATE
ARISTOGEL, TRIAMCINOLONE ACETONIDE
CEFIZOX IN DEXTROSE 5% IN PLASTIC CONTAINER, CEFTIZOXIME SODIUM
CEFIZOX IN PLASTIC CONTAINER, CEFTIZOXIME SODIUM
CEFIZOX, CEFTIZOXIME SODIUM
CYCLOCORT, AMCINONIDE

FDA data supplied by DrugPatentWatch.com

PROGRAF, TACROLIMUS
PROTOPIC, TACROLIMUS

** G **

G AND W LABS
* G AND W LABORATORIES INC
ACEPHEN, ACETAMINOPHEN (OTC)
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
GYNE-SULF, TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE; SULFATHIAZOLE)
HYDROCORTISONE, HYDROCORTISONE
INDOMETHEGAN, INDOMETHACIN
MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
MIGERGOT, CAFFEINE
PROCHLORPERAZINE, PROCHLORPERAZINE
PROMETHEGAN, PROMETHAZINE HYDROCHLORIDE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
TRUPHYLLINE, AMINOPHYLLINE

GALDERMA LABS LP
* GALDERMA LABORATORIES L P
FS SHAMPOO, FLUOCINOLONE ACETONIDE
* GALDERMA LABORATORIES LP
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
DESOWEN, DESONIDE
DIFFERIN, ADAPALENE
METROCREAM, METRONIDAZOLE
METROGEL, METRONIDAZOLE
METROLOTION, METRONIDAZOLE

GD SEARLE LLC
* GD SEARLE LLC
ALDACTAZIDE, HYDROCHLOROTHIAZIDE
ALDACTONE, SPIRONOLACTONE
AMINOPHYLLIN, AMINOPHYLLINE
AMMONIUM CHLORIDE, AMMONIUM CHLORIDE
ARTHROTEC, DICLOFENAC SODIUM
BEXTRA, VALDECOXIB
CALAN, VERAPAMIL HYDROCHLORIDE
CELEBREX, CELECOXIB
CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
COVERA-HS, VERAPAMIL HYDROCHLORIDE
CU-7, COPPER
CYTOTEC, MISOPROSTOL
DAYPRO, OXAPROZIN
DEMULEN 1/35-21, ETHINYL ESTRADIOL
DEMULEN 1/35-28, ETHINYL ESTRADIOL
DEMULEN 1/50-21, ETHINYL ESTRADIOL
DEMULEN 1/50-28, ETHINYL ESTRADIOL
DIULO, METOLAZONE
ENOVID, MESTRANOL
ENOVID-E 21, MESTRANOL
ENOVID-E, MESTRANOL
FLAGYL ER, METRONIDAZOLE
FLAGYL, METRONIDAZOLE
LIDOCAINE HCL, LIDOCAINE HYDROCHLORIDE
LOMOTIL, ATROPINE SULFATE
METARAMINOL BITARTRATE, METARAMINOL BITARTRATE
NORINYL 1+50 28-DAY, MESTRANOL
NORINYL 1+80 21-DAY, MESTRANOL
NORINYL 1+80 28-DAY, MESTRANOL
NORPACE CR, DISOPYRAMIDE PHOSPHATE
NORPACE, DISOPYRAMIDE PHOSPHATE
NORQUEST FE, ETHINYL ESTRADIOL
OVULEN, ETHYNODIOL DIACETATE
OVULEN-21, ETHYNODIOL DIACETATE
OVULEN-28, ETHYNODIOL DIACETATE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PRO-BANTHINE, PROPANTHELINE BROMIDE
PROCAINE HCL, PROCAINE HYDROCHLORIDE
SYNAREL, NAFARELIN ACETATE
TATUM-T, COPPER

GELTEX
* GELTEX PHARMACEUTICALS INC
RENAGEL, SEVELAMER HYDROCHLORIDE

GEN ELECTRIC
* GENERAL ELECTRIC CO
XENON XE 133, XENON, XE-133

GENENTECH
* GENENTECH INC
CRESCORMON, SOMATROPIN
NUTROPIN AQ, SOMATROPIN RECOMBINANT
NUTROPIN DEPOT, SOMATROPIN RECOMBINANT
NUTROPIN, SOMATROPIN RECOMBINANT
PROTROPIN, SOMATREM

GENEVA PHARMS
* GENEVA PHARMACEUTICALS INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALLOPURINOL, ALLOPURINOL
ALPRAZOLAM, ALPRAZOLAM
AMILORIDE HCL AND HYDROCHLOROTHIAZIDE, AMILORIDE HYDROCHLORIDE
AMINOPHYLLINE, AMINOPHYLLINE
AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
AMOXAPINE, AMOXAPINE
ATENOLOL, ATENOLOL
BROMPHENIRAMINE MALEATE, BROMPHENIRAMINE MALEATE
BUTABARBITAL SODIUM, BUTABARBITAL SODIUM
BUTAL COMPOUND, ASPIRIN
CAPTOPRIL, CAPTOPRIL

FDA data supplied by DrugPatentWatch.com

CARBIDOPA AND LEVODOPA, CARBIDOPA
CARISOPRODOL, CARISOPRODOL
CHLORDIAZEPOXIDE HCL, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLORPHENIRAMINE MALEATE AND PHENYLPROPANOLAMINE HCL, CHLORPHENIRAMINE MALEATE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE (OTC)
CHLORPROMAZINE HCL, CHLORPROMAZINE HYDROCHLORIDE
CHLORPROPAMIDE, CHLORPROPAMIDE
CHLORTHALIDONE, CHLORTHALIDONE
CHLORZOXAZONE, CHLORZOXAZONE
CIMETIDINE, CIMETIDINE
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE (OTC)
CLOFIBRATE, CLOFIBRATE
CLOMIPRAMINE HCL, CLOMIPRAMINE HYDROCHLORIDE
CLONIDINE HCL, CLONIDINE HYDROCHLORIDE
CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
CLOZAPINE, CLOZAPINE
CORPHED, PSEUDOEPHEDRINE HYDROCHLORIDE
CYCLOBENZAPRINE HCL, CYCLOBENZAPRINE HYDROCHLORIDE
CYPROHEPTADINE HCL, CYPROHEPTADINE HYDROCHLORIDE
DESIPRAMINE HCL, DESIPRAMINE HYDROCHLORIDE
DEXAMETHASONE, DEXAMETHASONE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DIAZEPAM, DIAZEPAM
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DIFLUNISAL, DIFLUNISAL
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DIPYRIDAMOLE, DIPYRIDAMOLE
DISOBROM, DEXBROMPHENIRAMINE MALEATE (OTC)
DISOPYRAMIDE PHOSPHATE, DISOPYRAMIDE PHOSPHATE
DOXEPIN HCL, DOXEPIN HYDROCHLORIDE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
ERCATAB, CAFFEINE
ESTERIFIED ESTROGENS, ESTROGENS, ESTERIFIED
ETODOLAC, ETODOLAC
FAMOTIDINE, FAMOTIDINE
FENOPROFEN CALCIUM, FENOPROFEN CALCIUM
FLUOXETINE, FLUOXETINE HYDROCHLORIDE
FLUPHENAZINE HCL, FLUPHENAZINE HYDROCHLORIDE
FLURAZEPAM HCL, FLURAZEPAM HYDROCHLORIDE
FLURBIPROFEN, FLURBIPROFEN
FUROSEMIDE, FUROSEMIDE
GLIPIZIDE, GLIPIZIDE
GLUTETHIMIDE, GLUTETHIMIDE
HALOPERIDOL, HALOPERIDOL
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
IMIPRAMINE HCL, IMIPRAMINE HYDROCHLORIDE
INDOMETHACIN, INDOMETHACIN
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
KETOPROFEN, KETOPROFEN
LONOX, ATROPINE SULFATE
LOPERAMIDE HCL, LOPERAMIDE HYDROCHLORIDE
LORAZEPAM, LORAZEPAM
LOVASTATIN, LOVASTATIN
MECLIZINE HCL, MECLIZINE HYDROCHLORIDE
MECLOFENAMATE SODIUM, MECLOFENAMATE SODIUM
MEPROBAMATE, MEPROBAMATE
METHAZOLAMIDE, METHAZOLAMIDE
METHOCARBAMOL, METHOCARBAMOL
METHOXSALEN, METHOXSALEN
METHYCLOTHIAZIDE, METHYCLOTHIAZIDE
METHYLDOPA AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
METHYLDOPA, METHYLDOPA
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
METRONIDAZOLE, METRONIDAZOLE
MEXILETINE HCL, MEXILETINE HYDROCHLORIDE
NAPROXEN SODIUM, NAPROXEN SODIUM
NAPROXEN, NAPROXEN
NIACIN, NIACIN
NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
NORTRIPTYLINE HCL, NORTRIPTYLINE HYDROCHLORIDE
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
OXAPROZIN, OXAPROZIN
OXAZEPAM, OXAZEPAM
PERPHENAZINE AND AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
PERPHENAZINE, PERPHENAZINE
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PHENYLBUTAZONE, PHENYLBUTAZONE
PINDOLOL, PINDOLOL
PRAZOSIN HCL, PRAZOSIN HYDROCHLORIDE
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
PROCAINAMIDE HCL, PROCAINAMIDE HYDROCHLORIDE
PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE
PROPANTHELINE BROMIDE, PROPANTHELINE BROMIDE
PROPOXYPHENE COMPOUND-65, ASPIRIN
PROPOXYPHENE HCL AND ACETAMINOPHEN, ACETAMINOPHEN
PROPOXYPHENE HCL, PROPOXYPHENE HYDROCHLORIDE
PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN, ACETAMINOPHEN
PROPRANOLOL HCL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
QUINIDINE GLUCONATE, QUINIDINE GLUCONATE
QUINIDINE SULFATE, QUINIDINE SULFATE
RANITIDINE HCL, RANITIDINE HYDROCHLORIDE
RESERPINE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
RIMACTANE, RIFAMPIN

FDA data supplied by DrugPatentWatch.com

SONAZINE, CHLORPROMAZINE HYDROCHLORIDE
SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPIRONOLACTONE, SPIRONOLACTONE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
SULFAMETHOXAZOLE, SULFAMETHOXAZOLE
SULFISOXAZOLE, SULFISOXAZOLE
SULINDAC, SULINDAC
TEMAZEPAM, TEMAZEPAM
TERAZOSIN HCL, TERAZOSIN HYDROCHLORIDE
THIORIDAZINE HCL, THIORIDAZINE HYDROCHLORIDE
THIOTHIXENE, THIOTHIXENE
TIMOLOL MALEATE, TIMOLOL MALEATE
TOLAZAMIDE, TOLAZAMIDE
TOLBUTAMIDE, TOLBUTAMIDE
TOLMETIN SODIUM, TOLMETIN SODIUM
TRAZODONE HCL, TRAZODONE HYDROCHLORIDE
TRIAMCINOLONE, TRIAMCINOLONE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TRIFLUOPERAZINE HCL, TRIFLUOPERAZINE HYDROCHLORIDE
VERAPAMIL HCL, VERAPAMIL HYDROCHLORIDE

GENEVA PHARMS TECH

* GENEVA PHARMACEUTICALS TECHNOLOGY CORP
AMANTADINE HCL, AMANTADINE HYDROCHLORIDE
ATENOLOL, ATENOLOL
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
BUPROPION HCL, BUPROPION HYDROCHLORIDE
CAPTOPRIL, CAPTOPRIL
CIMETIDINE, CIMETIDINE
CLOMIPRAMINE HCL, CLOMIPRAMINE HYDROCHLORIDE
CLONAZEPAM, CLONAZEPAM
CYCLOBENZAPRINE HCL, CYCLOBENZAPRINE HYDROCHLORIDE
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
ETODOLAC, ETODOLAC
FOAMICON, ALUMINUM HYDROXIDE (OTC)
GEMFIBROZIL, GEMFIBROZIL
GLIPIZIDE, GLIPIZIDE
GLYBURIDE (MICRONIZED), GLYBURIDE
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
INDAPAMIDE, INDAPAMIDE
INVAGESIC FORTE, ASPIRIN
INVAGESIC, ASPIRIN
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
METHYLPREDNISOLONE, METHYLPREDNISOLONE
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
NADOLOL, NADOLOL
NAPROXEN SODIUM, NAPROXEN SODIUM
NAPROXEN, NAPROXEN
NORTRIPTYLINE HCL, NORTRIPTYLINE HYDROCHLORIDE
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
PEMOLINE, PEMOLINE
PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE
TICLOPIDINE HCL, TICLOPIDINE HYDROCHLORIDE
TRIFLUOPERAZINE HCL, TRIFLUOPERAZINE HYDROCHLORIDE
WARFARIN SODIUM, WARFARIN SODIUM

GENPHARM

* GENPHARM INC
ACYCLOVIR, ACYCLOVIR
ALBUTEROL, ALBUTEROL
AZATHIOPRINE, AZATHIOPRINE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
ETODOLAC, ETODOLAC
ETOPOSIDE, ETOPOSIDE
FAMOTIDINE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE (OTC)
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
GUANFACINE HCL, GUANFACINE HYDROCHLORIDE
LOVASTATIN, LOVASTATIN
METHIMAZOLE, METHIMAZOLE
NICARDIPINE HCL, NICARDIPINE HYDROCHLORIDE
OXAPROZIN, OXAPROZIN
RANITIDINE HCL, RANITIDINE HYDROCHLORIDE
RANITIDINE, RANITIDINE HYDROCHLORIDE (OTC)
SOTALOL HCL, SOTALOL HYDROCHLORIDE
TICLOPIDINE HCL, TICLOPIDINE HYDROCHLORIDE
* GENPHARM PHARMACEUTICALS INC
ATENOLOL, ATENOLOL
PINDOLOL, PINDOLOL
PIROXICAM, PIROXICAM

GENSIA

* GENSIA LABORATORIES LTD
VECURONIUM BROMIDE, VECURONIUM BROMIDE

GENSIA AUTOMEDICS

* GENSIA AUTOMEDICS INC
GENESA, ARBUTAMINE HYDROCHLORIDE

GENSIA SICOR PHARMS

* GENSIA SICOR PHARMACEUTICALS INC
ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
ACYCLOVIR, ACYCLOVIR SODIUM
ALPROSTADIL, ALPROSTADIL
AMIKACIN SULFATE, AMIKACIN SULFATE
AMINOPHYLLINE, AMINOPHYLLINE
AMPHOTERICIN B, AMPHOTERICIN B
ATRACURIUM BESYLATE, ATRACURIUM BESYLATE
BLEOMYCIN, BLEOMYCIN SULFATE
BUMETANIDE, BUMETANIDE
CIMETIDINE HCL, CIMETIDINE HYDROCHLORIDE
CISPLATIN, CISPLATIN

FDA data supplied by DrugPatentWatch.com

CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CYTARABINE, CYTARABINE
DACARBAZINE, DACARBAZINE
DAUNORUBICIN HCL, DAUNORUBICIN HYDROCHLORIDE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DILTIAZEM HCL, DILTIAZEM HYDROCHLORIDE
DIPYRIDAMOLE, DIPYRIDAMOLE
DOBUTAMINE HCL, DOBUTAMINE HYDROCHLORIDE
DOPAMINE HCL, DOPAMINE HYDROCHLORIDE
DOXORUBICIN HCL, DOXORUBICIN HYDROCHLORIDE
ENALAPRILAT, ENALAPRILAT
ERYTHROMYCIN LACTOBIONATE, ERYTHROMYCIN LACTOBIONATE
ETOPOSIDE, ETOPOSIDE
FLUOROURACIL, FLUOROURACIL
FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
GLYCOPYRROLATE, GLYCOPYRROLATE
HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
HALOPERIDOL, HALOPERIDOL LACTATE
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
LEUPROLIDE ACETATE, LEUPROLIDE ACETATE
LEVOCARNITINE, LEVOCARNITINE
MESNA, MESNA
METHYLDOPATE HCL, METHYLDOPATE HYDROCHLORIDE
METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
PANCURONIUM BROMIDE, PANCURONIUM BROMIDE
PROPOFOL, PROPOFOL
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
THIOTEPA, THIOTEPA
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
VINCRISTINE SULFATE PFS, VINCRISTINE SULFATE

GENZYME
* GENZYME CORP
CEREDASE, ALGLUCERASE
CEREZYME, IMIGLUCERASE
LEUPROLIDE ACETATE, LEUPROLIDE ACETATE
THYROGEN, THYROTROPIN ALFA

GILBERT LABS
* GILBERT LABORATORIES
ACETAMINOPHEN, BUTALBITAL AND CAFFEINE, ACETAMINOPHEN

GILEAD
* GILEAD SCIENCES INC
DAUNOXOME, DAUNORUBICIN CITRATE
VIREAD, TENOFOVIR DISOPROXIL FUMARATE
VISTIDE, CIDOFOVIR

GLAXO WELLCOME
* GLAXO WELLCOME INC
LANOXICAPS, DIGOXIN
LANOXIN, DIGOXIN

GLAXOSMITHKLINE
* GLAXOSMITHKLINE
ABREVA, DOCOSANOL (OTC)
ACLOVATE, ALCLOMETASONE DIPROPIONATE
ACTIDIL, TRIPROLIDINE HYDROCHLORIDE (OTC)
ACTIFED W/ CODEINE, CODEINE PHOSPHATE
ACTIFED, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
ADVAIR DISKUS 100/50, FLUTICASONE PROPIONATE
ADVAIR DISKUS 250/50, FLUTICASONE PROPIONATE
ADVAIR DISKUS 500/50, FLUTICASONE PROPIONATE
AEROSPORIN, POLYMYXIN B SULFATE
AGENERASE, AMPRENAVIR
ALBENZA, ALBENDAZOLE
ALKERAN, MELPHALAN
ALKERAN, MELPHALAN HYDROCHLORIDE
AMERGE, NARATRIPTAN HYDROCHLORIDE
AMOXIL, AMOXICILLIN
ANCEF, CEFAZOLIN SODIUM
ANECTINE, SUCCINYLCHOLINE CHLORIDE
ANSPOR, CEPHRADINE
ANTEPAR, PIPERAZINE CITRATE
APHTHASOL, AMLEXANOX
AUGMENTIN '125', AMOXICILLIN
AUGMENTIN '200', AMOXICILLIN
AUGMENTIN '250', AMOXICILLIN
AUGMENTIN '400', AMOXICILLIN
AUGMENTIN '500', AMOXICILLIN
AUGMENTIN '875', AMOXICILLIN
AUGMENTIN ES-600, AMOXICILLIN
AVANDIA, ROSIGLITAZONE MALEATE
BACTOCILL, OXACILLIN SODIUM
BACTROBAN, MUPIROCIN
BACTROBAN, MUPIROCIN CALCIUM
BECLOVENT, BECLOMETHASONE DIPROPIONATE
BECONASE AQ, BECLOMETHASONE DIPROPIONATE MONOHYDRATE
BECONASE, BECLOMETHASONE DIPROPIONATE
BEEPEN-VK, PENICILLIN V POTASSIUM
CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
CEFTIN, CEFUROXIME AXETIL
CEPTAZ, CEFTAZIDIME (ARGININE FORMULATION)
CLOXAPEN, CLOXACILLIN SODIUM
COMBIVIR, LAMIVUDINE
COMPAZINE, PROCHLORPERAZINE
COMPAZINE, PROCHLORPERAZINE EDISYLATE
COMPAZINE, PROCHLORPERAZINE MALEATE

FDA data supplied by DrugPatentWatch.com

CONTAC, CHLORPHENIRAMINE MALEATE (OTC)
COREG, CARVEDILOL
CUTIVATE, FLUTICASONE PROPIONATE
DARAPRIM, PYRIMETHAMINE
DARBID, ISOPROPAMIDE IODIDE
DEXEDRINE, DEXTROAMPHETAMINE SULFATE
DIONOSIL AQUEOUS, PROPYLIODONE
DIONOSIL OILY, PROPYLIODONE
DUTASTERIDE, DUTASTERIDE
DYAZIDE, HYDROCHLOROTHIAZIDE
DYCILL, DICLOXACILLIN SODIUM
EMGEL, ERYTHROMYCIN
EMPRACET W/ CODEINE PHOSPHATE #3, ACETAMINOPHEN
EMPRACET W/ CODEINE PHOSPHATE #4, ACETAMINOPHEN
EPIVIR, LAMIVUDINE
EPIVIR-HBV, LAMIVUDINE
ESKALITH CR, LITHIUM CARBONATE
ESKALITH, LITHIUM CARBONATE
EXOSURF NEONATAL, CETYL ALCOHOL
FASTIN, PHENTERMINE HYDROCHLORIDE
FLOLAN, EPOPROSTENOL SODIUM
FLONASE, FLUTICASONE PROPIONATE
FLOVENT DISKUS 100, FLUTICASONE PROPIONATE
FLOVENT DISKUS 250, FLUTICASONE PROPIONATE
FLOVENT DISKUS 50, FLUTICASONE PROPIONATE
FLOVENT, FLUTICASONE PROPIONATE
FORTAZ IN PLASTIC CONTAINER, CEFTAZIDIME SODIUM
FORTAZ, CEFTAZIDIME
HALFAN, HALOFANTRINE HYDROCHLORIDE
HISPRIL, DIPHENYLPYRALINE HYDROCHLORIDE
HYCAMTIN, TOPOTECAN HYDROCHLORIDE
IMITREX, SUMATRIPTAN
IMITREX, SUMATRIPTAN SUCCINATE
LAMICTAL CD, LAMOTRIGINE
LAMICTAL, LAMOTRIGINE
LANOXIN PEDIATRIC, DIGOXIN
LANOXIN, DIGOXIN
LAROTID, AMOXICILLIN
LEUKERAN, CHLORAMBUCIL
LOTRONEX, ALOSETRON HYDROCHLORIDE
MALARONE PEDIATRIC, ATOVAQUONE
MALARONE, ATOVAQUONE
MAREZINE, CYCLIZINE LACTATE
MEPRON, ATOVAQUONE
MONOCID, CEFONICID SODIUM
MYLERAN, BUSULFAN
NALLPEN, NAFCILLIN SODIUM
NAVELBINE, VINORELBINE TARTRATE
NEOSPORIN, NEOMYCIN SULFATE (OTC)
NICORETTE (ORANGE), NICOTINE POLACRILEX (OTC)
NICORETTE (MINT), NICOTINE POLACRILEX (OTC)
NICORETTE (ORANGE), NICOTINE POLACRILEX (OTC)
NICORETTE, NICOTINE POLACRILEX (OTC)
NIX, PERMETHRIN
ORNADE, CHLORPHENIRAMINE MALEATE
OXISTAT, OXICONAZOLE NITRATE
PARNATE, TRANYLCYPROMINE SULFATE
PAXIL CR, PAROXETINE HYDROCHLORIDE
PAXIL, PAROXETINE HYDROCHLORIDE
PENTACEF, CEFTAZIDIME (ARGININE FORMULATION)
PHYTONADIONE, PHYTONADIONE
POLYSPORIN, BACITRACIN ZINC (OTC)
PURINETHOL, MERCAPTOPURINE
PYOPEN, CARBENICILLIN DISODIUM
RELAFEN, NABUMETONE
RELENZA, ZANAMIVIR
REQUIP, ROPINIROLE HYDROCHLORIDE
RETROVIR, ZIDOVUDINE
SEFFIN, CEPHALOTHIN SODIUM
SEREVENT, SALMETEROL XINAFOATE
STELAZINE, TRIFLUOPERAZINE HYDROCHLORIDE
STOXIL, IDOXURIDINE
SUDAFED 12 HOUR, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
SYNCURINE, DECAMETHONIUM BROMIDE
TAGAMET HB 200, CIMETIDINE (OTC)
TAGAMET HB, CIMETIDINE (OTC)
TAGAMET HCL IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, CIMETIDINE HYDROCHLORIDE
TAGAMET, CIMETIDINE
TAGAMET, CIMETIDINE HYDROCHLORIDE
TELDRIN, CHLORPHENIRAMINE MALEATE (OTC)
TEMOVATE E, CLOBETASOL PROPIONATE
TEMOVATE, CLOBETASOL PROPIONATE
THIOGUANINE, THIOGUANINE
THORAZINE, CHLORPROMAZINE
THORAZINE, CHLORPROMAZINE HYDROCHLORIDE
TICAR, TICARCILLIN DISODIUM
TIMENTIN IN PLASTIC CONTAINER, CLAVULANATE POTASSIUM
TIMENTIN, CLAVULANATE POTASSIUM
TOTACILLIN, AMPICILLIN/AMPICILLIN TRIHYDRATE
TOTACILLIN-N, AMPICILLIN SODIUM
TRANDATE HCT, HYDROCHLOROTHIAZIDE
TRITEC, RANITIDINE BISMUTH CITRATE
TRIZIVIR, ABACAVIR SULFATE
URISPAS, FLAVOXATE HYDROCHLORIDE
VALTREX, VALACYCLOVIR HYDROCHLORIDE
VASOXYL, METHOXAMINE HYDROCHLORIDE
VENTOLIN HFA, ALBUTEROL SULFATE
VENTOLIN ROTACAPS, ALBUTEROL SULFATE
VENTOLIN, ALBUTEROL
VENTOLIN, ALBUTEROL SULFATE
VONTROL, DIPHENIDOL HYDROCHLORIDE
WELLBUTRIN SR, BUPROPION HYDROCHLORIDE
WELLBUTRIN, BUPROPION HYDROCHLORIDE
WELLCOVORIN, LEUCOVORIN CALCIUM
ZANTAC 150, RANITIDINE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

ZANTAC 300, RANITIDINE HYDROCHLORIDE
ZANTAC IN PLASTIC CONTAINER, RANITIDINE HYDROCHLORIDE
ZANTAC, RANITIDINE HYDROCHLORIDE
ZIAGEN, ABACAVIR SULFATE
ZINACEF IN PLASTIC CONTAINER, CEFUROXIME SODIUM
ZINACEF, CEFUROXIME SODIUM
ZOFRAN IN PLASTIC CONTAINER, ONDANSETRON HYDROCHLORIDE
ZOFRAN ODT, ONDANSETRON
ZOFRAN PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
ZOFRAN, ONDANSETRON HYDROCHLORIDE
ZOVIRAX, ACYCLOVIR
ZOVIRAX, ACYCLOVIR SODIUM
ZYBAN, BUPROPION HYDROCHLORIDE

GLENWOOD
* GLENWOOD INC
MYOTONACHOL, BETHANECHOL CHLORIDE
PASKALIUM, POTASSIUM AMINOSALICYLATE
RENOQUID, SULFACYTINE

GOLDLINE
* GOLDLINE LABORATORIES INC
GLYCOPREP, POLYETHYLENE GLYCOL 3350

GRAHAM CHEM
* GRAHAM CHEMICAL CO
LIDOCAINE HCL AND EPINEPHRINE, EPINEPHRINE
LIDOCAINE HCL, LIDOCAINE HYDROCHLORIDE
LIDOCAINE, LIDOCAINE
MEPIVACAINE HCL W/ LEVONORDEFRIN, LEVONORDEFRIN
MEPIVACAINE HCL, MEPIVACAINE HYDROCHLORIDE

GRAHAM DM
* DM GRAHAM LABORATORIES INC
BUTALBITAL, ACETAMINOPHEN, CAFFEINE, ACETAMINOPHEN
COLD CAPSULE IV, CHLORPHENIRAMINE MALEATE (OTC)
COLD CAPSULE V, CHLORPHENIRAMINE MALEATE (OTC)
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PSEUDOEPHEDRINE HCL/CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE (OTC)
SOMOPHYLLIN-CRT, THEOPHYLLINE

GRIFFEN
* KW GRIFFEN CO
BIOSCRUB, CHLORHEXIDINE GLUCONATE (OTC)

GRUPPO LEPETIT
* GRUPPO LEPETIT SPA SUB MERRELL DOW PHARMACEUTICALS INC
CHLORAMPHENICOL SODIUM SUCCINATE, CHLORAMPHENICOL SODIUM SUCCINATE

GUARDIAN DRUG
* GUARDIAN DRUG CO INC
FOAMCOAT, ALUMINUM HYDROXIDE (OTC)

GUILFORD PHARMS
* GUILFORD PHARMACEUTICALS INC
GLIADEL, CARMUSTINE

GYNETICS
* GYNETICS INC
PREVEN EMERGENCY CONTRACEPTIVE KIT, ETHINYL ESTRADIOL

GYNOPHARMA
* GYNOPHARMA INC
NORCEPT-E 1/35 21, ETHINYL ESTRADIOL
NORCEPT-E 1/35 28, ETHINYL ESTRADIOL

** H **

HALLMARK PHARMS
* HALLMARK PHARMACEUTICALS
CAPTOPRIL, CAPTOPRIL

HALOCARBON
* HALOCARBON LABORATORIES DIV HALOCARBON PRODUCTS CORP
HALOTHANE, HALOTHANE

HALOCARBON PRODS
* HALOCARBON PRODUCTS CORP
ISOFLURANE, ISOFLURANE

HALSEY
* HALSEY DRUG CO INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACETAMINOPHEN W/ CODEINE PHOSPHATE, ACETAMINOPHEN
ACETAMINOPHEN W/ CODEINE, ACETAMINOPHEN
ALLOPURINOL, ALLOPURINOL
AMINOPHYLLINE, AMINOPHYLLINE
AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
BELDIN, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
BELIX, DIPHENHYDRAMINE HYDROCHLORIDE
BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN
BUTALBITAL, APAP, AND CAFFEINE, ACETAMINOPHEN
BUTALBITAL, ASPIRIN & CAFFEINE, ASPIRIN
CHLORDIAZEPOXIDE AND AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
CHLORDIAZEPOXIDE HCL, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
CHLORPROPAMIDE, CHLORPROPAMIDE
CHLORTHALIDONE, CHLORTHALIDONE
CLONIDINE HCL, CLONIDINE HYDROCHLORIDE
CODOXY, ASPIRIN
CORTALONE, PREDNISOLONE
CORTAN, PREDNISONE
CYCLOBENZAPRINE HCL, CYCLOBENZAPRINE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

CYPROHEPTADINE HCL, CYPROHEPTADINE HYDROCHLORIDE
DEXAMETHASONE, DEXAMETHASONE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DIAZEPAM, DIAZEPAM
DICYCLOMINE HCL, DICYCLOMINE HYDROCHLORIDE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENOXYLATE HCL AND ATROPINE SULFATE, ATROPINE SULFATE
DISOPYRAMIDE PHOSPHATE, DISOPYRAMIDE PHOSPHATE
DOXEPIN HCL, DOXEPIN HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DOXYCYCLINE HYLATE, DOXYCYCLINE HYCLATE
DOXYCYCLINE, DOXYCYCLINE
ERGOLOID MESYLATES, ERGOLOID MESYLATES
FENOPROFEN CALCIUM, FENOPROFEN CALCIUM
FLURAZEPAM HCL, FLURAZEPAM HYDROCHLORIDE
FOLIC ACID, FOLIC ACID
FUROSEMIDE, FUROSEMIDE
GLUTETHIMIDE, GLUTETHIMIDE
HALOPERIDOL, HALOPERIDOL
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
HYDRO-D, HYDROCHLOROTHIAZIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE
HYDROPANE, HOMATROPINE METHYLBROMIDE
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
INDOMETHACIN, INDOMETHACIN
ISONIAZID, ISONIAZID
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
KLOROMIN, CHLORPHENIRAMINE MALEATE
LORAZEPAM, LORAZEPAM
LOW-QUEL, ATROPINE SULFATE
MEPERIDINE HCL, MEPERIDINE HYDROCHLORIDE
MEPROBAMATE, MEPROBAMATE
METHOCARBAMOL, METHOCARBAMOL
METHYLDOPA, METHYLDOPA
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
METRONIDAZOLE, METRONIDAZOLE
NALIDIXIC ACID, NALIDIXIC ACID
NEURAMATE, MEPROBAMATE
NIACIN, NIACIN
OXAZEPAM, OXAZEPAM
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE AND ASPIRIN, ASPIRIN
PERPHENAZINE AND AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
PHENYLBUTAZONE, PHENYLBUTAZONE
PHERAZINE DM, DEXTROMETHORPHAN HYDROBROMIDE
PHERAZINE VC W/ CODEINE, CODEINE PHOSPHATE
PHERAZINE VC, PHENYLEPHRINE HYDROCHLORIDE
PHERAZINE W/ CODEINE, CODEINE PHOSPHATE
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE
PROPHENE 65, PROPOXYPHENE HYDROCHLORIDE
PROPOXYPHENE HCL, PROPOXYPHENE HYDROCHLORIDE
PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN, ACETAMINOPHEN
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
PROPYLTHIOURACIL, PROPYLTHIOURACIL
QUINIDINE GLUCONATE, QUINIDINE GLUCONATE
QUINIDINE SULFATE, QUINIDINE SULFATE
RAUWOLFIA SERPENTINA, RAUWOLFIA SERPENTINA
RESERPINE, HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE, HYDRALAZINE HYDROCHLORIDE
RESERPINE, RESERPINE
SARISOL NO. 1, BUTABARBITAL SODIUM
SARISOL NO. 2, BUTABARBITAL SODIUM
SARISOL, BUTABARBITAL SODIUM
SODIUM PENTOBARBITAL, PENTOBARBITAL SODIUM
SODIUM SECOBARBITAL, SECOBARBITAL SODIUM
SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPIRONOLACTONE, SPIRONOLACTONE
SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH, SULFAMETHOXAZOLE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
TEMAZEPAM, TEMAZEPAM
TETRACYCLINE HCL, TETRACYCLINE HYDROCHLORIDE
THEOPHYLLINE, THEOPHYLLINE
THIORIDAZINE HCL, THIORIDAZINE HYDROCHLORIDE
TRIMETHOPRIM, TRIMETHOPRIM
TRIPROLIDINE HCL, TRIPROLIDINE HYDROCHLORIDE
VERAPAMIL HCL, VERAPAMIL HYDROCHLORIDE

HAMILTON PHARMS
* HAMILTON PHARMACEUTICALS LTD
NAPROXEN SODIUM, NAPROXEN SODIUM
NAPROXEN, NAPROXEN

HANFORD GC
* GC HANFORD MANUFACTURING CO
AMPICILLIN SODIUM, AMPICILLIN SODIUM
CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
CEFUROXIME SODIUM, CEFUROXIME SODIUM

HEALTHPOINT
* HEALTHPOINT LTD
AKNE-MYCIN, ERYTHROMYCIN
CETACORT, HYDROCORTISONE
CLODERM, CLOCORTOLONE PIVALATE
CORMAX, CLOBETASOL PROPIONATE
EMBELINE E, CLOBETASOL PROPIONATE
EMBELINE, CLOBETASOL PROPIONATE
NUTRACORT, HYDROCORTISONE

FDA data supplied by DrugPatentWatch.com

SANSAC, ERYTHROMYCIN

HEATHER
* HEATHER DRUG CO INC
CORTISONE ACETATE, CORTISONE ACETATE
DIMENHYDRINATE, DIMENHYDRINATE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENOXYLATE HCL AND ATROPINE SULFATE, ATROPINE SULFATE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
MEPROBAMATE, MEPROBAMATE
METHOCARBAMOL, METHOCARBAMOL
METHYLPREDNISOLONE, METHYLPREDNISOLONE
METHYLTESTOSTERONE, METHYLTESTOSTERONE
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
PROPANTHELINE BROMIDE, PROPANTHELINE BROMIDE
SULFAMETHOXAZOLE & TRIMETHOPRIM, SULFAMETHOXAZOLE
SULFAMETHOXAZOLE, SULFAMETHOXAZOLE
SULFISOXAZOLE, SULFISOXAZOLE
TETRACYCLINE HCL, TETRACYCLINE HYDROCHLORIDE
TRIPELENNAMINE HCL, TRIPELENNAMINE HYDROCHLORIDE

HERAN
* HERAN PHARMACEUTICAL INC
GLYCORT, HYDROCORTISONE

HERCON LABS
* HERCON LABORATORIES CORP
NITROGLYCERIN, NITROGLYCERIN

HEXCEL
* HEXCEL CHEMICAL PRODUCTS
POTASSIUM AMINOSALICYLATE, POTASSIUM AMINOSALICYLATE
SODIUM AMINOSALICYLATE, AMINOSALICYLATE SODIUM

HI TECH PHARMA
* HI TECH PHARMACAL CO INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ALBUTEROL SULFATE, ALBUTEROL SULFATE
AMANTADINE HCL, AMANTADINE HYDROCHLORIDE
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
CIMETIDINE HCL, CIMETIDINE HYDROCHLORIDE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
ERYTHRO-STATIN, ERYTHROMYCIN
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
LACTULOSE, LACTULOSE
LIDOCAINE HCL, LIDOCAINE HYDROCHLORIDE
LOPERAMIDE HCL, LOPERAMIDE HYDROCHLORIDE (OTC)
MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
PROMETHAZINE HCL AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
PROMETHAZINE HCL AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN HYDROBROMIDE
PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
THIORIDAZINE HCL, THIORIDAZINE HYDROCHLORIDE

HIGH TECH PHARMA
* HIGH TECHNOLOGY PHARMACAL CO INC
VALPROIC ACID, VALPROIC ACID

HILL DERMAC
* HILL DERMACEUTICALS INC
DERMA-SMOOTHE/FS, FLUOCINOLONE ACETONIDE

HLR
* HLR TECHNOLOGY
ACCUTANE, ISOTRETINOIN
FORTOVASE, SAQUINAVIR
INVIRASE, SAQUINAVIR MESYLATE
ROCEPHIN KIT, CEFTRIAXONE SODIUM
ROCEPHIN W/ DEXTROSE IN PLASTIC CONTAINER, CEFTRIAXONE SODIUM
ROCEPHIN, CEFTRIAXONE SODIUM
ROMAZICON, FLUMAZENIL
SORIATANE, ACITRETIN
VERSED, MIDAZOLAM HYDROCHLORIDE
XELODA, CAPECITABINE
XENICAL, ORLISTAT

HOLLAND RANTOS
* HOLLAND RANTOS CO INC
KOROSTATIN, NYSTATIN

HOLLISTER STIER LABS
* HOLLISTER STIER LABORATORIES
PRE-PEN, BENZYL PENICILLOYL-POLYLYSINE

HUNTINGTON LABS
* HUNTINGTON LABORATORIES INC
GERMA-MEDICA "MG", HEXACHLOROPHENE
GERMA-MEDICA, HEXACHLOROPHENE
HEXA-GERM, HEXACHLOROPHENE

** I **

IBI
* ISTITUTO BIOCHIMICO ITALIANO SPA
AMPICILLIN SODIUM, AMPICILLIN SODIUM
OXACILLIN SODIUM, OXACILLIN SODIUM

ICN
* ICN PHARMACEUTICALS INC
8-MOP, METHOXSALEN
AMINOPHYLLINE, AMINOPHYLLINE
ANCOBON, FLUCYTOSINE

FDA data supplied by DrugPatentWatch.com

ANDROID 10, METHYLTESTOSTERONE
ANDROID 25, METHYLTESTOSTERONE
ANDROID 5, METHYLTESTOSTERONE
ANDROID-F, FLUOXYMESTERONE
BENDOPA, LEVODOPA
BENOQUIN, MONOBENZONE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
CODEINE PHOSPHATE AND ACETAMINOPHEN, ACETAMINOPHEN
DALMANE, FLURAZEPAM HYDROCHLORIDE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENOXYLATE HCL W/ ATROPINE SULFATE, ATROPINE SULFATE
EFUDEX, FLUOROURACIL
ELDECORT, HYDROCORTISONE
FLUOXYMESTERONE, FLUOXYMESTERONE
FOLIC ACID, FOLIC ACID
LEVO-DROMORAN, LEVORPHANOL TARTRATE
LIBRELEASE, CHLORDIAZEPOXIDE
LIBRITABS, CHLORDIAZEPOXIDE
LIBRIUM, CHLORDIAZEPOXIDE HYDROCHLORIDE
LIMBITROL DS, AMITRIPTYLINE HYDROCHLORIDE
LIMBITROL, AMITRIPTYLINE HYDROCHLORIDE
MEPROBAMATE, MEPROBAMATE
MESTINON, PYRIDOSTIGMINE BROMIDE
OXSORALEN, METHOXSALEN
OXSORALEN-ULTRA, METHOXSALEN
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
PROPOXYPHENE HCL, PROPOXYPHENE HYDROCHLORIDE
QUINIDINE SULFATE, QUINIDINE SULFATE
RAUWOLFIA SERPENTINA, RAUWOLFIA SERPENTINA
RESERPINE, RESERPINE
SECOBARBITAL SODIUM, SECOBARBITAL SODIUM
SODIUM PENTOBARBITAL, PENTOBARBITAL SODIUM
SULFISOXAZOLE, SULFISOXAZOLE
TENSILON PRESERVATIVE FREE, EDROPHONIUM CHLORIDE
TENSILON, EDROPHONIUM CHLORIDE
TESTRED, METHYLTESTOSTERONE
TETRACYCLINE HCL, TETRACYCLINE HYDROCHLORIDE
TRISORALEN, TRIOXSALEN
VIRAZOLE, RIBAVIRIN

ICN PUERTO RICO
* ICN PUERTO RICO INC
FLUOROURACIL, FLUOROURACIL

IMMUNEX
* IMMUNEX CORP
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
LEVOPROME, METHOTRIMEPRAZINE
NOVANTRONE, MITOXANTRONE HYDROCHLORIDE
THIOPLEX, THIOTEPA
THIOTEPA, THIOTEPA

IMP
* IMP INC
SPECTAMINE, IOFETAMINE HYDROCHLORIDE I-123

IMPAX LABS
* IMPAX LABORATORIES INC
AMINOPHYLLINE, AMINOPHYLLINE
CHLORDIAZEPOXIDE HCL, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
CORTISONE ACETATE, CORTISONE ACETATE
DEXAMETHASONE, DEXAMETHASONE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
FOLIC ACID, FOLIC ACID
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROCORTISONE, HYDROCORTISONE
ISONIAZID, ISONIAZID
MEPROBAMATE, MEPROBAMATE
METHOCARBAMOL, METHOCARBAMOL
METHYLTESTOSTERONE, METHYLTESTOSTERONE
MINOCYCLINE HCL, MINOCYCLINE HYDROCHLORIDE
NIACIN, NIACIN
OXYTETRACYCLINE HCL, OXYTETRACYCLINE HYDROCHLORIDE
PENTOXIFYLLINE, PENTOXIFYLLINE
PIPERAZINE CITRATE, PIPERAZINE CITRATE
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
PROBENECID AND COLCHICINE, COLCHICINE
PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE
PROPANTHELINE BROMIDE, PROPANTHELINE BROMIDE
PROPOXYPHENE HCL, PROPOXYPHENE HYDROCHLORIDE
PROPYLTHIOURACIL, PROPYLTHIOURACIL
PYRILAMINE MALEATE, PYRILAMINE MALEATE
QUINIDINE SULFATE, QUINIDINE SULFATE
RAUWOLFIA SERPENTINA, RAUWOLFIA SERPENTINA
RESERPINE, RESERPINE
SULFA-TRIPLE #2, TRISULFAPYRIMIDINES (SULFADIAZINE; SULFAMERAZINE;SULFAMETHAZINE)
SULFADIAZINE, TRISULFAPYRIMIDINES (SULFADIAZINE; SULFAMERAZINE;SULFAMETHAZINE)
SULFISOXAZOLE, SULFISOXAZOLE
TERBUTALINE SULFATE, TERBUTALINE SULFATE
TETRACYCLINE HCL, TETRACYCLINE HYDROCHLORIDE
THYROGLOBULIN, THYROGLOBULIN
TRIAMCINOLONE, TRIAMCINOLONE
TRICHLORMETHIAZIDE, TRICHLORMETHIAZIDE
TRIPELENNAMINE HCL, TRIPELENNAMINE HYDROCHLORIDE
VITAMIN A, VITAMIN A
VITAMIN A, VITAMIN A PALMITATE
VITAMIN D, ERGOCALCIFEROL

IMPAX PHARM
* IMPAX PHARMACEUTICALS

FDA data supplied by DrugPatentWatch.com

ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
SOTALOL HCL, SOTALOL HYDROCHLORIDE

INALCO
* INALCO SPA
LACTULOSE, LACTULOSE

INGRAM PHARM
* INGRAM PHARMACEUTICAL CO
DRICORT, HYDROCORTISONE ACETATE
HYDROCORTISONE, HYDROCORTISONE

INKINE
* INKINE PHARMACEUTICAL CO INC
VISICOL, SODIUM PHOSPHATE, DIBASIC, ANHYDROUS

INO
* INO THERAPEUTICS INC
INOMAX, NITRIC OXIDE

INTERMUNE PHARMS
* INTERMUNE PHARMACEUTICALS INC
AMPHOTEC, AMPHOTERICIN B

INTERPHARM
* INTERPHARM INC
CLONIDINE HCL, CLONIDINE HYDROCHLORIDE
DISOPYRAMIDE PHOSPHATE, DISOPYRAMIDE PHOSPHATE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
NAPROXEN, NAPROXEN
PREDNISONE, PREDNISONE
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
TOLAZAMIDE, TOLAZAMIDE

INTL MEDICATION
* INTERNATIONAL MEDICATION SYSTEM
AMINOPHYLLINE, AMINOPHYLLINE
BRETYLIUM TOSYLATE, BRETYLIUM TOSYLATE
DIPHENHYDRAMINE HCL PRESERVATIVE FREE, DIPHENHYDRAMINE HYDROCHLORIDE
DOPAMINE HCL, DOPAMINE HYDROCHLORIDE
FUROSEMIDE, FUROSEMIDE
ISOPROTERENOL HCL, ISOPROTERENOL HYDROCHLORIDE
LARYNG-O-JET KIT, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL W/ EPINEPHRINE, EPINEPHRINE
LIDOCAINE HCL, LIDOCAINE HYDROCHLORIDE
MANNITOL 25%, MANNITOL
MEPERIDINE HCL PRESERVATIVE FREE, MEPERIDINE HYDROCHLORIDE
MEPIVACAINE HCL, MEPIVACAINE HYDROCHLORIDE
NALOXONE HCL, NALOXONE HYDROCHLORIDE
PHYTONADIONE, PHYTONADIONE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PROCAINAMIDE HCL, PROCAINAMIDE HYDROCHLORIDE
VERAPAMIL HCL, VERAPAMIL HYDROCHLORIDE
* INTERNATIONAL MEDICATION SYSTEMS LTD
AMINOPHYLLINE, AMINOPHYLLINE
AMPICILLIN SODIUM, AMPICILLIN SODIUM
CEPHALOTHIN, CEPHALOTHIN SODIUM
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DIATRIZOATE-60, DIATRIZOATE MEGLUMINE
DILTIAZEM HCL, DILTIAZEM HYDROCHLORIDE
FUROSEMIDE, FUROSEMIDE
GENTAMICIN, GENTAMICIN SULFATE
HEPARIN LOCK FLUSH, HEPARIN SODIUM
HYDROCORTISONE SODIUM SUCCINATE, HYDROCORTISONE SODIUM SUCCINATE
ISOETHARINE HCL, ISOETHARINE HYDROCHLORIDE
KANAMYCIN SULFATE, KANAMYCIN SULFATE
LIDOCAINE HCL VISCOUS, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL, LIDOCAINE HYDROCHLORIDE
MEPERIDINE HCL, MEPERIDINE HYDROCHLORIDE
METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
METRONIDAZOLE, METRONIDAZOLE
NALOXONE HCL, NALOXONE HYDROCHLORIDE
NITROGLYCERIN, NITROGLYCERIN
SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE

INTL MINERALS
* INTERNATIONAL MINERALS CHEMICAL CORP
TPN SUSPENSION, NIACINAMIDE

INVAMED
* INVAMED INC
FAMOTIDINE, FAMOTIDINE
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
METHAZOLAMIDE, METHAZOLAMIDE
METHYLDOPA AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
OXAPROZIN, OXAPROZIN
PEG-LYTE, POLYETHYLENE GLYCOL 3350
PROCAINAMIDE HCL, PROCAINAMIDE HYDROCHLORIDE
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
TERAZOSIN HCL, TERAZOSIN HYDROCHLORIDE

INWOOD LABS
* INWOOD LABORATORIES INC SUB FOREST LABORATORIES INC

FDA data supplied by DrugPatentWatch.com

CARBAMAZEPINE, CARBAMAZEPINE
CORTISONE ACETATE, CORTISONE ACETATE
DIPHENOXYLATE HCL AND ATROPINE SULFATE, ATROPINE SULFATE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROCORTISONE, HYDROCORTISONE
INDOMETHACIN, INDOMETHACIN
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
METHOCARBAMOL, METHOCARBAMOL
METHYLTESTOSTERONE, METHYLTESTOSTERONE
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
PROCAINAMIDE HCL, PROCAINAMIDE HYDROCHLORIDE
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
THEOCHRON, THEOPHYLLINE
THEOPHYLLINE, THEOPHYLLINE

IOMED
* IOMED INC
IONTOCAINE, EPINEPHRINE

IPHARM
* IPHARM DIV LYPHOMED INC
NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN, GRAMICIDIN

IPR
* IPR PHARMACEUTICALS INC
ATENOLOL AND CHLORTHALIDONE, ATENOLOL
ATENOLOL, ATENOLOL
ZOMIG, ZOLMITRIPTAN

ISO TEX
* ISO TEX DIAGNOSTICS INC
ALBUMOTOPE 125 I, ALBUMIN IODINATED I-125 SERUM
CHROMALBIN, ALBUMIN CHROMATED CR-51 SERUM
MEGATOPE, ALBUMIN IODINATED I-131 SERUM

IVAX PHARMS
* IVAX PHARMACEUTICALS INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACETAMINOPHEN W/ CODEINE PHOSPHATE #3, ACETAMINOPHEN
ACYCLOVIR, ACYCLOVIR
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALBUTEROL, ALBUTEROL
ALLAY, ACETAMINOPHEN
ALPRAZOLAM, ALPRAZOLAM
AMPICILLIN TRIHYDRATE, AMPICILLIN/AMPICILLIN TRIHYDRATE
BACLOFEN, BACLOFEN
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
BROMPHENIRAMINE MALEATE, BROMPHENIRAMINE MALEATE
BUMETANIDE, BUMETANIDE
BUTALBITAL COMPOUND, ASPIRIN
C-SOLVE-2, ERYTHROMYCIN
CAPTOPRIL AND HYDROCHLOROTHIAZIDE, CAPTOPRIL
CAPTOPRIL, CAPTOPRIL
CEFACLOR, CEFACLOR
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CEPHALEXIN, CEPHALEXIN
CEPHRADINE, CEPHRADINE
CHLORAMPHENICOL, CHLORAMPHENICOL
CHLORDIAZEPOXIDE HCL, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
CHLORPROMAZINE HCL, CHLORPROMAZINE HYDROCHLORIDE
CHLORPROPAMIDE, CHLORPROPAMIDE
CHLORTHALIDONE, CHLORTHALIDONE
CHOLESTYRAMINE, CHOLESTYRAMINE
CIMETIDINE, CIMETIDINE
CIMETIDINE, CIMETIDINE (OTC)
CLOZAPINE, CLOZAPINE
CORTISONE ACETATE, CORTISONE ACETATE
CROMOLYN SODIUM, CROMOLYN SODIUM
CYPROHEPTADINE HCL, CYPROHEPTADINE HYDROCHLORIDE
DIAZEPAM, DIAZEPAM
DILTIAZEM HCL, DILTIAZEM HYDROCHLORIDE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENOXYLATE HCL W/ ATROPINE SULFATE, ATROPINE SULFATE
DISOPYRAMIDE PHOSPHATE, DISOPYRAMIDE PHOSPHATE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
ERYTHROMYCIN ESTOLATE, ERYTHROMYCIN ESTOLATE
ERYTHROMYCIN STEARATE, ERYTHROMYCIN STEARATE
ESTAZOLAM, ESTAZOLAM
ETODOLAC, ETODOLAC
FAMOTIDINE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE (OTC)
FENOPROFEN CALCIUM, FENOPROFEN CALCIUM
FLURBIPROFEN, FLURBIPROFEN
FLUTAMIDE, FLUTAMIDE
FLUTEX, TRIAMCINOLONE ACETONIDE
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
FOLIC ACID, FOLIC ACID
FUROSEMIDE, FUROSEMIDE
GLIPIZIDE, GLIPIZIDE
GUANABENZ ACETATE, GUANABENZ ACETATE
HYDRALAZINE HCL W/ HYDROCHLOROTHIAZIDE 100/50, HYDRALAZINE HYDROCHLORIDE
HYDRALAZINE HCL W/ HYDROCHLOROTHIAZIDE 25/25, HYDRALAZINE HYDROCHLORIDE
HYDRALAZINE HCL W/ HYDROCHLOROTHIAZIDE 50/50, HYDRALAZINE HYDROCHLORIDE
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
HYDRALAZINE HCL, HYDROCHLOROTHIAZIDE AND RESERPINE, HYDRALAZINE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

HYDROCHLOROTHIAZIDE W/ RESERPINE, HYDROCHLOROTHIAZIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROCORTISONE, HYDROCORTISONE
HYDROGENATED ERGOT ALKALOIDS, ERGOLOID MESYLATES
HYDROSERPINE PLUS (R-H-H), HYDRALAZINE HYDROCHLORIDE
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
INDAPAMIDE, INDAPAMIDE
INDOMETHACIN, INDOMETHACIN
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
ISONIAZID, ISONIAZID
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
LABETALOL HCL, LABETALOL HYDROCHLORIDE
MECLIZINE HCL, MECLIZINE HYDROCHLORIDE
MEPROBAMATE, MEPROBAMATE
METHOCARBAMOL AND ASPIRIN, ASPIRIN
METHOCARBAMOL, METHOCARBAMOL
METHYCLOTHIAZIDE, METHYCLOTHIAZIDE
METHYLDOPA AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
METHYLDOPA, METHYLDOPA
METRONIDAZOLE, METRONIDAZOLE
NADOLOL, NADOLOL
NAPROXEN SODIUM, NAPROXEN SODIUM
NAPROXEN, NAPROXEN
NIACIN, NIACIN
NICARDIPINE HCL, NICARDIPINE HYDROCHLORIDE
NITROFURANTOIN, NITROFURANTOIN
NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
NOGENIC HC, HYDROCORTISONE
OXAZEPAM, OXAZEPAM
PACLITAXEL, PACLITAXEL
PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM
PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM
PERPHENAZINE AND AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
PERPHENAZINE, PERPHENAZINE
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PHENTERMINE HCL, PHENTERMINE HYDROCHLORIDE
PHENYLBUTAZONE, PHENYLBUTAZONE
PINDOLOL, PINDOLOL
PIROXICAM, PIROXICAM
PRAZOSIN HCL, PRAZOSIN HYDROCHLORIDE
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
PROBENECID AND COLCHICINE, COLCHICINE
PROBENECID, PROBENECID
PROCAINAMIDE HCL, PROCAINAMIDE HYDROCHLORIDE
PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE
PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE
PROMPT PHENYTOIN SODIUM, PHENYTOIN SODIUM, PROMPT
PROPOXYPHENE COMPOUND 65, ASPIRIN
PROPOXYPHENE HCL, PROPOXYPHENE HYDROCHLORIDE
PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN, ACETAMINOPHEN
PROPRANOLOL HCL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
PROPYLTHIOURACIL, PROPYLTHIOURACIL
QUINIDINE SULFATE, QUINIDINE SULFATE
RANITIDINE HCL, RANITIDINE HYDROCHLORIDE
RANITIDINE, RANITIDINE HYDROCHLORIDE (OTC)
RAUWOLFIA SERPENTINA, RAUWOLFIA SERPENTINA
RESERPINE AND HYDROFLUMETHIAZIDE, HYDROFLUMETHIAZIDE
RESERPINE, RESERPINE
SECOBARBITAL SODIUM, SECOBARBITAL SODIUM
SELEGILINE HCL, SELEGILINE HYDROCHLORIDE
SELENIUM SULFIDE, SELENIUM SULFIDE
SODIUM BUTABARBITAL, BUTABARBITAL SODIUM
SODIUM PENTOBARBITAL, PENTOBARBITAL SODIUM
SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPIRONOLACTONE, SPIRONOLACTONE
SULFINPYRAZONE, SULFINPYRAZONE
SULFISOXAZOLE, SULFISOXAZOLE
TERAZOSIN HCL, TERAZOSIN HYDROCHLORIDE
TETRACYCLINE HCL, TETRACYCLINE HYDROCHLORIDE
TETRAMED, TETRACYCLINE HYDROCHLORIDE
THIORIDAZINE HCL, THIORIDAZINE HYDROCHLORIDE
TOLAZAMIDE, TOLAZAMIDE
TOLBUTAMIDE, TOLBUTAMIDE
TOLMETIN SODIUM, TOLMETIN SODIUM
TRIAMCINOLONE, TRIAMCINOLONE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TRIATEX, TRIAMCINOLONE ACETONIDE
TRIFLUOPERAZINE HCL, TRIFLUOPERAZINE HYDROCHLORIDE
TRIPROLIDINE HCL AND PSEUDOEPHEDRINE HCL, PSEUDOEPHEDRINE HYDROCHLORIDE
VERAPAMIL HCL, VERAPAMIL HYDROCHLORIDE
VITAMIN A, VITAMIN A PALMITATE

IVAX RES
* IVAX RESEARCH INC
NASALIDE, FLUNISOLIDE
NASAREL, FLUNISOLIDE

** J **

J AND J
* JOHNSON AND JOHNSON CONSUMER PRODUCTS INC
ERYCETTE, ERYTHROMYCIN
GRIFULVIN V, GRISEOFULVIN, MICROCRYSTALLINE
* JOHNSON AND JOHNSON MEDICAL INC
MICRODERM, CHLORHEXIDINE GLUCONATE (OTC)
PREVACARE R, CHLORHEXIDINE GLUCONATE (OTC)

JACOBUS

FDA data supplied by DrugPatentWatch.com

* JACOBUS PHARMACEUTICAL CO
DAPSONE, DAPSONE
PASER, AMINOSALICYLIC ACID

JANSSEN
* JANSSEN PHARMACEUTICA INC
ERGAMISOL, LEVAMISOLE HYDROCHLORIDE
IMODIUM, LOPERAMIDE HYDROCHLORIDE
MONISTAT, MICONAZOLE
NIZORAL, KETOCONAZOLE
* JANSSEN RESEARCH FDN
NIZORAL, KETOCONAZOLE
REMINYL, GALANTAMINE HYDROBROMIDE
RISPERDAL, RISPERIDONE
* JANSSEN RESEARCH FDN DIV JOHNSON AND JOHNSON
PROPULSID QUICKSOLV, CISAPRIDE MONOHYDRATE
PROPULSID, CISAPRIDE MONOHYDRATE
SPORANOX, ITRACONAZOLE

JOHNSON AND JOHNSON
* JOHNSON AND JOHNSON CONSUMER COMPANIES INC
GRIFULVIN V, GRISEOFULVIN, MICROCRYSTALLINE
MECLAN, MECLOCYCLINE SULFOSALICYLATE
MONISTAT-DERM, MICONAZOLE NITRATE
RENOVA, TRETINOIN
RETIN-A MICRO, TRETINOIN
RETIN-A, TRETINOIN
SPECTAZOLE, ECONAZOLE NITRATE

JOHNSON RW
* RW JOHNSON PHARMACEUTICAL RESEARCH INSTITUTE
DIENESTROL, DIENESTROL
ESTRADIOL, ESTRADIOL
ORTHO EVRA, ETHINYL ESTRADIOL
ORTHO-PREFEST, ESTRADIOL
ULTRACET, ACETAMINOPHEN
ULTRAM, TRAMADOL HYDROCHLORIDE
* RW JOHNSON PHARMACEUTICAL RESEARCH INSTITUTE DIV ORTHO PHARM
CLISTIN, CARBINOXAMINE MALEATE
FLOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER, OFLOXACIN
FLOXIN IN DEXTROSE 5%, OFLOXACIN
FLOXIN, OFLOXACIN
HALDOL SOLUTAB, HALOPERIDOL
INJECTAPAP, ACETAMINOPHEN
LEUSTATIN, CLADRIBINE
LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
LEVAQUIN, LEVOFLOXACIN
MICRONOR, NORETHINDRONE
MODICON 21, ETHINYL ESTRADIOL
MODICON 28, ETHINYL ESTRADIOL
MONISTAT 3, MICONAZOLE NITRATE
ORTHO CYCLEN-21, ETHINYL ESTRADIOL
ORTHO CYCLEN-28, ETHINYL ESTRADIOL
ORTHO TRI-CYCLEN, ETHINYL ESTRADIOL
ORTHO-CEPT, DESOGESTREL
ORTHO-NOVUM 1/80 28, MESTRANOL
ORTHO-NOVUM 1/35-21, ETHINYL ESTRADIOL
ORTHO-NOVUM 1/35-28, ETHINYL ESTRADIOL
ORTHO-NOVUM 1/50 21, MESTRANOL
ORTHO-NOVUM 1/50 28, MESTRANOL
ORTHO-NOVUM 1/80 21, MESTRANOL
ORTHO-NOVUM 10-21, MESTRANOL
ORTHO-NOVUM 10/11-21, ETHINYL ESTRADIOL
ORTHO-NOVUM 10/11-28 IN PLASTIC CONTAINER, ETHINYL ESTRADIOL
ORTHO-NOVUM 2-21, MESTRANOL
ORTHO-NOVUM 7/14-21, ETHINYL ESTRADIOL
ORTHO-NOVUM 7/14-28, ETHINYL ESTRADIOL
ORTHO-NOVUM 7/7/7-21, ETHINYL ESTRADIOL
ORTHO-NOVUM 7/7/7-28, ETHINYL ESTRADIOL
PARAFLEX, CHLORZOXAZONE
PARAFON FORTE DSC, CHLORZOXAZONE
PROTOSTAT, METRONIDAZOLE
SALPIX, ACETRIZOATE SODIUM
SULTRIN, TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE; SULFATHIAZOLE)
TERAZOL 3, TERCONAZOLE
TERAZOL 7, TERCONAZOLE
THEOPHYL, THEOPHYLLINE
THEOPHYL-225, THEOPHYLLINE
THEOPHYL-SR, THEOPHYLLINE
TOLECTIN 600, TOLMETIN SODIUM
TOLECTIN DS, TOLMETIN SODIUM
TOLECTIN, TOLMETIN SODIUM
TYCOLET, ACETAMINOPHEN
TYLENOL W/ CODEINE NO. 1, ACETAMINOPHEN
TYLENOL W/ CODEINE NO. 2, ACETAMINOPHEN
TYLENOL W/ CODEINE NO. 3, ACETAMINOPHEN
TYLENOL W/ CODEINE NO. 4, ACETAMINOPHEN
TYLENOL W/ CODEINE, ACETAMINOPHEN
TYLOX, ACETAMINOPHEN
TYLOX-325, ACETAMINOPHEN
VASCOR, BEPRIDIL HYDROCHLORIDE

JONES PHARMA
* JONES PHARMA INC SUB KING PHARMACEUTICALS INC
CYTOMEL, LIOTRIX (T4;T3)
LEVOXYL, LIOTRIX (T4;T3)
METHIMAZOLE, METHIMAZOLE
TRIOSTAT, LIOTRIX (T4;T3)
TUSSIGON, HOMATROPINE METHYLBROMIDE

JVL
* JVL CORP
METOCLOPRAMIDE, METOCLOPRAMIDE HYDROCHLORIDE

** K **

FDA data supplied by DrugPatentWatch.com

KALAPHARM
* KALAPHARM INC
FUROSEMIDE, FUROSEMIDE
GENTAMICIN SULFATE, GENTAMICIN SULFATE

KENDALL IL
* KENDALL CO
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE (OTC)
LARYNGOTRACHEAL ANESTHESIA KIT, LIDOCAINE HYDROCHLORIDE

KENDALL LP
* KENDALL CO LP
THERMAZENE, SILVER SULFADIAZINE

KENWOOD LABS
* KENWOOD LABORATORIES DIV BRADLEY PHARMACEUTICALS
CARMOL HC, HYDROCORTISONE ACETATE
TYZINE, TETRAHYDROZOLINE HYDROCHLORIDE

KEY PHARMS
* KEY PHARMACEUTICALS INC SUB SCHERING PLOUGH CORP
GENAPAX, GENTIAN VIOLET
K-DUR 10, POTASSIUM CHLORIDE
K-DUR 20, POTASSIUM CHLORIDE
NITRO-DUR, NITROGLYCERIN
QUINORA, QUINIDINE SULFATE
THEO-DUR, THEOPHYLLINE

KIEL
* KIEL LABORATORIES INC
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE

KING PHARMS
* KING PHARMACEUTICALS INC
ALTACE, RAMIPRIL
AMINOPHYLLINE, AMINOPHYLLINE
APOGEN, GENTAMICIN SULFATE
BICILLIN C-R 900/300, PENICILLIN G BENZATHINE
BICILLIN C-R, PENICILLIN G BENZATHINE
BICILLIN L-A, PENICILLIN G BENZATHINE
CORZIDE, BENDROFLUMETHIAZIDE
CROMOPTIC, CROMOLYN SODIUM
DELESTROGEN, ESTRADIOL VALERATE
FLORINEF, FLUDROCORTISONE ACETATE
FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
KLEBCIL, KANAMYCIN SULFATE
LORABID, LORACARBEF
MAXOLON, METOCLOPRAMIDE HYDROCHLORIDE
NALBUPHINE HCL, NALBUPHINE HYDROCHLORIDE
PHENTERMINE HCL, PHENTERMINE HYDROCHLORIDE
PROCANBID, PROCAINAMIDE HYDROCHLORIDE
QUINIDINE SULFATE, QUINIDINE SULFATE
SILVADENE, SILVER SULFADIAZINE
TIGAN, TRIMETHOBENZAMIDE HYDROCHLORIDE
WYCILLIN, PENICILLIN G PROCAINE

KOS
* KOS PHARMACEUTICALS INC
ADVICOR, LOVASTATIN
NIASPAN TITRATION STARTER PACK, NIACIN
NIASPAN, NIACIN

KREMERS URBAN
* KREMERS URBAN CO
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE

KRKA DD NOVO MESTO
* KRKA DD NOVO MESTO
ENALAPRIL MALEATE, ENALAPRIL MALEATE

KV PHARM
* KV PHARMACEUTICAL CO
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACETIC ACID W/ HYDROCORTISONE, ACETIC ACID, GLACIAL
ACETIC ACID, ACETIC ACID, GLACIAL
AMINOPHYLLINE, AMINOPHYLLINE
BROMPHENIRAMINE MALEATE, BROMPHENIRAMINE MALEATE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
CHLORPROMAZINE HCL, CHLORPROMAZINE HYDROCHLORIDE
CHLORTHALIDONE, CHLORTHALIDONE
CYPROHEPTADINE HCL, CYPROHEPTADINE HYDROCHLORIDE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENOXYLATE HCL W/ ATROPINE SULFATE, ATROPINE SULFATE
DISOPYRAMIDE PHOSPHATE, DISOPYRAMIDE PHOSPHATE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
ERGOLOID MESYLATES, ERGOLOID MESYLATES
GYNAZOLE-1, BUTOCONAZOLE NITRATE
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
MECLIZINE HCL, MECLIZINE HYDROCHLORIDE
METHOCARBAMOL, METHOCARBAMOL
METHYLTESTOSTERONE, METHYLTESTOSTERONE
MICRO-K 10, POTASSIUM CHLORIDE
MICRO-K LS, POTASSIUM CHLORIDE
MICRO-K, POTASSIUM CHLORIDE
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE
PSEUDOEPHEDRINE HCL AND CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE (OTC)
QUINIDINE SULFATE, QUINIDINE SULFATE
SODIUM SECOBARBITAL, SECOBARBITAL SODIUM

FDA data supplied by DrugPatentWatch.com

THEOPHYLLINE, THEOPHYLLINE
TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)

** L **

LABS AF
* LABORATORIOS APLICACIONES FARMACEUTICAS SA DE CV
METROMIDOL, METRONIDAZOLE

LABS ATRAL
* LABORATORIOS ATRAL SARL
AMOXICILLIN, AMOXICILLIN
CEPHALEXIN, CEPHALEXIN
TETRACYCLINE HCL, TETRACYCLINE HYDROCHLORIDE

LACHMAN CONSULT
* LACHMAN CONSULTANT SERVICES INC
LACTULOSE, LACTULOSE

LAFAYETTE PHARMS
* LAFAYETTE PHARMACEUTICALS INC
BAROS, SODIUM BICARBONATE

LANNETT
* LANNETT CO INC
ACETAZOLAMIDE, ACETAZOLAMIDE
AMINOPHYLLINE, AMINOPHYLLINE
AMPHETAMINE SULFATE, AMPHETAMINE SULFATE
BENZYL BENZOATE, BENZYL BENZOATE
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
BUTALAN, BUTABARBITAL SODIUM
CORTISONE ACETATE, CORTISONE ACETATE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DICYCLOMINE HCL, DICYCLOMINE HYDROCHLORIDE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENOXYLATE HCL AND ATROPINE SULFATE, ATROPINE SULFATE
DIPHENYLAN SODIUM, PHENYTOIN SODIUM, PROMPT
FOLIC ACID, FOLIC ACID
FURALAN, NITROFURANTOIN
GLUTETHIMIDE, GLUTETHIMIDE
HYDROCORTISONE, HYDROCORTISONE
LANIAZID, ISONIAZID
LANOPHYLLIN, THEOPHYLLINE
LANORINAL, ASPIRIN
LANTRISUL, TRISULFAPYRIMIDINES (SULFADIAZINE;SULFAMERAZINE; SULFAMETHAZINE)
MEPROBAMATE, MEPROBAMATE
METHOCARBAMOL, METHOCARBAMOL
METHYLTESTOSTERONE, METHYLTESTOSTERONE
NEOMYCIN SULFATE, NEOMYCIN SULFATE
NITROFURAZONE, NITROFURAZONE
PENTOBARBITAL SODIUM, PENTOBARBITAL SODIUM
PHENETRON, CHLORPHENIRAMINE MALEATE
PHENTERMINE HCL, PHENTERMINE HYDROCHLORIDE
PIPERAZINE CITRATE, PIPERAZINE CITRATE
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
PRIMIDONE, PRIMIDONE
PROBALAN, PROBENECID
PROCAINAMIDE HCL, PROCAINAMIDE HYDROCHLORIDE
PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE
PROPYLTHIOURACIL, PROPYLTHIOURACIL
QUINALAN, QUINIDINE GLUCONATE
QUINIDINE SULFATE, QUINIDINE SULFATE
SECOBARBITAL SODIUM, SECOBARBITAL SODIUM
SERPALAN, RESERPINE
SODIUM BUTABARBITAL, BUTABARBITAL SODIUM
SODIUM P.A.S., AMINOSALICYLATE SODIUM
SULFADIAZINE, TRISULFAPYRIMIDINES (SULFADIAZINE; SULFAMERAZINE;SULFAMETHAZINE)
SULFISOXAZOLE, SULFISOXAZOLE
TRICHLOREX, TRICHLORMETHIAZIDE
TRIPELENNAMINE HCL, TRIPELENNAMINE HYDROCHLORIDE
VELTANE, BROMPHENIRAMINE MALEATE
VITAMIN D, ERGOCALCIFEROL

LAYTON
* LAYTON BIOSCIENCE INC
INVERSINE, MECAMYLAMINE HYDROCHLORIDE

LEDERLE
* LEDERLE LABORATORIES DIV AMERICAN CYANAMID CO
ACETAMINOPHEN W/ CODEINE, ACETAMINOPHEN
ACHES-N-PAIN, IBUPROFEN (OTC)
ACHROMYCIN V, TETRACYCLINE HYDROCHLORIDE
ACHROMYCIN, HYDROCORTISONE
ACHROMYCIN, PROCAINE HYDROCHLORIDE
ACHROMYCIN, TETRACYCLINE HYDROCHLORIDE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALPRAZOLAM, ALPRAZOLAM
AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
AMPICILLIN, AMPICILLIN/AMPICILLIN TRIHYDRATE
ARISTOCORT, TRIAMCINOLONE DIACETATE
ARISTOSPAN, TRIAMCINOLONE HEXACETONIDE
ARTANE, TRIHEXYPHENIDYL HYDROCHLORIDE
ASENDIN, AMOXAPINE
ATENOLOL, ATENOLOL
AUREOMYCIN, CHLORTETRACYCLINE HYDROCHLORIDE
CEFACLOR, CEFACLOR
CHLORDIAZEPOXIDE HCL, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLOROTHIAZIDE, CHLOROTHIAZIDE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
CHLORPROMAZINE HCL, CHLORPROMAZINE HYDROCHLORIDE
CHLORPROPAMIDE, CHLORPROPAMIDE
CHLORTHALIDONE, CHLORTHALIDONE

FDA data supplied by DrugPatentWatch.com

CLONIDINE HCL, CLONIDINE HYDROCHLORIDE
CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
DECLOMYCIN, DEMECLOCYCLINE HYDROCHLORIDE
DIAMOX, ACETAZOLAMIDE
DIAZEPAM, DIAZEPAM
DILTIAZEM HCL, DILTIAZEM HYDROCHLORIDE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENOXYLATE HCL AND ATROPINE SULFATE, ATROPINE SULFATE
DIPYRIDAMOLE, DIPYRIDAMOLE
DOLENE AP-65, ACETAMINOPHEN
DOLENE, PROPOXYPHENE HYDROCHLORIDE
DOXEPIN HCL, DOXEPIN HYDROCHLORIDE
ERGOLOID MESYLATES, ERGOLOID MESYLATES
ERYTHROMYCIN STEARATE, ERYTHROMYCIN STEARATE
FENOPROFEN CALCIUM, FENOPROFEN CALCIUM
FOLVITE, FOLIC ACID
FOLVRON, FERROUS SULFATE
FUROSEMIDE, FUROSEMIDE
GEMFIBROZIL, GEMFIBROZIL
HALOPERIDOL, HALOPERIDOL
HETRAZAN, DIETHYLCARBAMAZINE CITRATE
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROMOX R, QUINETHAZONE
HYDROMOX, QUINETHAZONE
IBUPROFEN, IBUPROFEN
IMIPRAMINE HCL, IMIPRAMINE HYDROCHLORIDE
INDOMETHACIN, INDOMETHACIN
KETOPROFEN, KETOPROFEN
LEDERCILLIN VK, PENICILLIN V POTASSIUM
MEPROBAMATE, MEPROBAMATE
METHOCARBAMOL, METHOCARBAMOL
METHOTREXATE LPF, METHOTREXATE SODIUM
METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
METHOTREXATE SODIUM, METHOTREXATE SODIUM
METHYLDOPA AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
METHYLDOPA, METHYLDOPA
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
MINOCIN, MINOCYCLINE HYDROCHLORIDE
MINOCYCLINE HCL, MINOCYCLINE HYDROCHLORIDE
MYAMBUTOL, ETHAMBUTOL HYDROCHLORIDE
NAPROXEN, NAPROXEN
NEPTAZANE, METHAZOLAMIDE
NILSTAT, NYSTATIN
PATHILON, TRIDIHEXETHYL CHLORIDE
PIPRACIL, PIPERACILLIN SODIUM
PRAZOSIN HCL, PRAZOSIN HYDROCHLORIDE
PREDNISONE, PREDNISONE
PROBENECID W/ COLCHICINE, COLCHICINE
PROBENECID, PROBENECID
PROCAINAMIDE HCL, PROCAINAMIDE HYDROCHLORIDE
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
PROPYLTHIOURACIL, PROPYLTHIOURACIL
PYRAZINAMIDE, PYRAZINAMIDE
QUINIDINE SULFATE, QUINIDINE SULFATE
RESERPINE, HYDROCHLOROTHIAZIDE, AND HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
SERVISONE, PREDNISONE
SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPIRONOLACTONE, SPIRONOLACTONE
SULFADIAZINE SODIUM, SULFADIAZINE SODIUM
SULFADIAZINE, TRISULFAPYRIMIDINES (SULFADIAZINE; SULFAMERAZINE;SULFAMETHAZINE)
SULFASALAZINE, SULFASALAZINE
SULFISOXAZOLE, SULFISOXAZOLE
SULINDAC, SULINDAC
SUPRAX, CEFIXIME
TOLBUTAMIDE, TOLBUTAMIDE
TRIPLE SULFAS, TRISULFAPYRIMIDINES (SULFADIAZINE; SULFAMERAZINE;SULFAMETHAZINE)
VANCOLED, VANCOMYCIN HYDROCHLORIDE
VERAPAMIL HCL, VERAPAMIL HYDROCHLORIDE
ZEBETA, BISOPROLOL FUMARATE
ZIAC, BISOPROLOL FUMARATE

* LEDERLE PARENTERALS INC
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
DIAMOX, ACETAZOLAMIDE SODIUM
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
ERYTHROMYCIN LACTOBIONATE, ERYTHROMYCIN LACTOBIONATE
FUROSEMIDE, FUROSEMIDE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
VANCOLED, VANCOMYCIN HYDROCHLORIDE

* LEDERLE PIPERACILLIN INC DIV AMERICAN CYANAMID CO
ZOSYN IN PLASTIC CONTAINER, PIPERACILLIN SODIUM

LEE KM

* KM LEE LABORATORIES INC
MEPROBAMATE, MEPROBAMATE

LEINER

* LEINER HEALTH PRODUCTS INC
CIMETIDINE, CIMETIDINE (OTC)
IBUPROFEN, IBUPROFEN (OTC)
LOPERAMIDE HCL, LOPERAMIDE HYDROCHLORIDE (OTC)
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
RANITIDINE, RANITIDINE HYDROCHLORIDE (OTC)

LEK LJUBLJANA

* LEK LJUBLJANA PHARMACEUTICAL AND CHEMICAL CO
CIMETIDINE, CIMETIDINE

LEK PHARM

* LEK PHARMACEUTICAL AND CHEMICAL CO DD
ACYCLOVIR, ACYCLOVIR
BROMOCRIPTINE MESYLATE, BROMOCRIPTINE MESYLATE
CIMETIDINE, CIMETIDINE (OTC)

FDA data supplied by DrugPatentWatch.com

ENALAPRIL MALEATE, ENALAPRIL MALEATE

LEO PHARM
* LEO PHARMACEUTICAL PRODUCTS LTD
PINDAC, PINACIDIL

LIFE LABS
* LIFE LABORATORIES INC
ERYTHROMYCIN ESTOLATE, ERYTHROMYCIN ESTOLATE

LIGAND
* LIGAND PHARMACEUTICALS INC
PANRETIN, ALITRETINOIN
TARGRETIN, BEXAROTENE

LILLY
* ELI LILLY AND CO
AEROLONE, ISOPROTERENOL HYDROCHLORIDE
ALPHALIN, VITAMIN A PALMITATE
AMPICILLIN SODIUM, AMPICILLIN SODIUM
ANHYDRON, CYCLOTHIAZIDE
AVENTYL HCL, NORTRIPTYLINE HYDROCHLORIDE
AXID, NIZATIDINE
BACITRACIN, BACITRACIN
BETALIN 12, CYANOCOBALAMIN
BETALIN S, THIAMINE HYDROCHLORIDE
BREVITAL SODIUM, METHOHEXITAL SODIUM
CALCIUM GLUCEPTATE, CALCIUM GLUCEPTATE
CAPASTAT SULFATE, CAPREOMYCIN SULFATE
CECLOR CD, CEFACLOR
CECLOR, CEFACLOR
CESAMET, NABILONE
CINOBAC, CINOXACIN
CORDRAN-N, FLURANDRENOLIDE
CRYSTODIGIN, DIGITOXIN
DARVOCET, ACETAMINOPHEN
DARVOCET-N 100, ACETAMINOPHEN
DARVOCET-N 50, ACETAMINOPHEN
DARVON COMPOUND, ASPIRIN
DARVON COMPOUND-65, ASPIRIN
DARVON W/ ASA, ASPIRIN
DARVON, PROPOXYPHENE HYDROCHLORIDE
DARVON-N W/ ASA, ASPIRIN
DARVON-N, PROPOXYPHENE NAPSYLATE
DECABID, INDECAINIDE HYDROCHLORIDE
DELTALIN, ERGOCALCIFEROL
DICUMAROL, DICUMAROL
DICURIN PROCAINE, PROCAINE MERETHOXYLLINE
DIETHYLSTILBESTROL, DIETHYLSTILBESTROL
DOBUTREX, DOBUTAMINE HYDROCHLORIDE
DROLBAN, DROMOSTANOLONE PROPIONATE
DURACILLIN A.S., PENICILLIN G PROCAINE
ERYTHROMYCIN, ERYTHROMYCIN
EVISTA, RALOXIFENE HYDROCHLORIDE
FOLIC ACID, FOLIC ACID
GEMZAR, GEMCITABINE HYDROCHLORIDE
GLUCAGON, GLUCAGON HYDROCHLORIDE
GLUCAGON, GLUCAGON RECOMBINANT
HALDRONE, PARAMETHASONE ACETATE
HEPARIN SODIUM, HEPARIN SODIUM
HEXA-BETALIN, PYRIDOXINE HYDROCHLORIDE
HISTALOG, BETAZOLE HYDROCHLORIDE
HISTAMINE PHOSPHATE, HISTAMINE PHOSPHATE
HUMALOG MIX 50/50, INSULIN LISPRO
HUMALOG MIX 75/25, INSULIN LISPRO
HUMALOG PEN, INSULIN LISPRO
HUMALOG, INSULIN LISPRO
HUMATROPE, SOMATROPIN RECOMBINANT
HUMULIN 50/50, INSULIN RECOMBINANT HUMAN (OTC)
HUMULIN 70/30 PEN, INSULIN RECOMBINANT HUMAN (OTC)
HUMULIN 70/30, INSULIN RECOMBINANT HUMAN (OTC)
HUMULIN BR, INSULIN RECOMBINANT HUMAN (OTC)
HUMULIN L, INSULIN ZINC SUSP RECOMBINANT HUMAN (OTC)
HUMULIN N, INSULIN SUSP ISOPHANE RECOMBINANT HUMAN (OTC)
HUMULIN R PEN, INSULIN RECOMBINANT HUMAN (OTC)
HUMULIN R, INSULIN RECOMBINANT HUMAN
HUMULIN R, INSULIN RECOMBINANT HUMAN (OTC)
HUMULIN U, INSULIN ZINC SUSP EXTENDED RECOMBINANT HUMAN (OTC)
ILETIN I, INSULIN PORK
ILETIN II, INSULIN PURIFIED PORK
ILOSONE SULFA, ERYTHROMYCIN ESTOLATE
ILOSONE, ERYTHROMYCIN ESTOLATE
ISONIAZID, ISONIAZID
KAFOCIN, CEPHALOGLYCIN
KAPPADIONE, MENADIOL SODIUM DIPHOSPHATE
KEFLET, CEPHALEXIN
KEFLEX, CEPHALEXIN
KEFLIN IN PLASTIC CONTAINER, CEPHALOTHIN SODIUM
KEFLIN, CEPHALOTHIN SODIUM
KEFTAB, CEPHALEXIN HYDROCHLORIDE
KEFUROX IN PLASTIC CONTAINER, CEFUROXIME SODIUM
KEFUROX, CEFUROXIME SODIUM
KEFZOL, CEFAZOLIN SODIUM
LENTE ILETIN II (PORK), INSULIN ZINC SUSP PURIFIED PORK (OTC)
LENTE ILETIN II, INSULIN ZINC SUSP PURIFIED BEEF (OTC)
MANDOL, CEFAMANDOLE NAFATE
MENADIONE, MENADIONE
METHYLTESTOSTERONE, METHYLTESTOSTERONE
METUBINE IODIDE, METOCURINE IODIDE
MOXAM, MOXALACTAM DISODIUM
NEBCIN, TOBRAMYCIN SULFATE
NEOMYCIN SULFATE, NEOMYCIN SULFATE
NEOTRIZINE, TRISULFAPYRIMIDINES (SULFADIAZINE;SULFAMERAZINE; SULFAMETHAZINE)

FDA data supplied by DrugPatentWatch.com

NPH ILETIN I (BEEF-PORK), INSULIN SUSP ISOPHANE BEEF/PORK (OTC)
NPH ILETIN II (PORK), INSULIN SUSP ISOPHANE PURIFIED PORK (OTC)
NPH ILETIN II, INSULIN SUSP ISOPHANE PURIFIED BEEF (OTC)
ONCOVIN, VINCRISTINE SULFATE
PAGITANE, CYCRIMINE HYDROCHLORIDE
PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM
PERMAX, PERGOLIDE MESYLATE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PROGESTERONE, PROGESTERONE
PROPYLTHIOURACIL, PROPYLTHIOURACIL
PROTAMINE SULFATE, PROTAMINE SULFATE
PROTAMINE ZINC AND ILETIN II (PORK), INSULIN SUSP PROTAMINE ZINC PURIFIED PORK (OTC)
PROTAMINE ZINC AND ILETIN II, INSULIN SUSP PROTAMINE ZINC PURIFIED BEEF (OTC)
PROTAMINE, ZINC & ILETIN I (BEEF-PORK), INSULIN SUSP PROTAMINE ZINC BEEF/PORK (OTC)
PROZAC WEEKLY, FLUOXETINE HYDROCHLORIDE
PROZAC, FLUOXETINE HYDROCHLORIDE
QUINIDINE GLUCONATE, QUINIDINE GLUCONATE
QUINIDINE SULFATE, QUINIDINE SULFATE
REGULAR ILETIN II (PORK), INSULIN PURIFIED PORK (OTC)
REGULAR ILETIN II, INSULIN PURIFIED BEEF (OTC)
SANDRIL, RESERPINE
SECONAL SODIUM, SECOBARBITAL SODIUM
SEROMYCIN, CYCLOSERINE
STREPTOMYCIN SULFATE, STREPTOMYCIN SULFATE
SULFADIAZINE, TRISULFAPYRIMIDINES (SULFADIAZINE; SULFAMERAZINE;SULFAMETHAZINE)
SULFAPYRIDINE, SULFAPYRIDINE
SULFONAMIDES DUPLEX, TRISULFAPYRIMIDINES (SULFADIAZINE; SULFAMERAZINE;SULFAMETHAZINE)
TAPAZOLE, METHIMAZOLE
TAZIDIME IN PLASTIC CONTAINER, CEFTAZIDIME
TAZIDIME, CEFTAZIDIME
TESTOSTERONE PROPIONATE, TESTOSTERONE PROPIONATE
TUBOCURARINE CHLORIDE, TUBOCURARINE CHLORIDE
V-CILLIN K, PENICILLIN V POTASSIUM
V-CILLIN, PENICILLIN V
VANCOCIN HCL, VANCOMYCIN HYDROCHLORIDE
VELBAN, VINBLASTINE SULFATE
ZYPREXA ZYDIS, OLANZAPINE
ZYPREXA, OLANZAPINE

ELI LILLY INDUSTRIES INC
DARVON-N, PROPOXYPHENE NAPSYLATE
DYMELOR, ACETOHEXAMIDE
NOVRAD, LEVOPROPOXYPHENE NAPSYLATE, ANHYDROUS

LILLY RESEARCH LABORATORIES DIV ELI LILLY AND CO
CECLOR, CEFACLOR
ILOSONE, ERYTHROMYCIN ESTOLATE
PROZAC, FLUOXETINE HYDROCHLORIDE
SARAFEM, FLUOXETINE HYDROCHLORIDE

LILLY RES LABS
* LILLY RESEARCH LABORATORIES
DYNABAC, DIRITHROMYCIN

LIPOSOME
* LIPOSOME CO INC
ABELCET, AMPHOTERICIN B

LNK
* LNK INTERNATIONAL INC
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
IBUPROFEN, IBUPROFEN (OTC)
METRONIDAZOLE, METRONIDAZOLE

LOCH
* LOCH PHARMACEUTICALS INC
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
FOLIC ACID, FOLIC ACID
KANAMYCIN SULFATE, KANAMYCIN SULFATE

LOREX
* LOREX PHARMACEUTICALS
AMBIEN, ZOLPIDEM TARTRATE
KERLEDEX, BETAXOLOL HYDROCHLORIDE
KERLONE, BETAXOLOL HYDROCHLORIDE

LPI
* LPI HOLDINGS INC
N.E.E. 1/35 21, ETHINYL ESTRADIOL
N.E.E. 1/35 28, ETHINYL ESTRADIOL

LUITPOLD
* LUITPOLD PHARMACEUTICALS INC
ACETYLCYSTEINE, ACETYLCYSTEINE
AMINOCAPROIC ACID, AMINOCAPROIC ACID
AMINOPHYLLINE, AMINOPHYLLINE
BRETYLIUM TOSYLATE, BRETYLIUM TOSYLATE
CIMETIDINE HCL, CIMETIDINE HYDROCHLORIDE
CYANOCOBALAMIN, CYANOCOBALAMIN
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DEXFERRUM, IRON DEXTRAN
DOBUTAMINE HCL, DOBUTAMINE HYDROCHLORIDE
DOPAMINE HCL, DOPAMINE HYDROCHLORIDE
DROPERIDOL, DROPERIDOL
FUROSEMIDE, FUROSEMIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
HEPARIN LOCK FLUSH, HEPARIN SODIUM
HEPARIN SODIUM, HEPARIN SODIUM
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
LEVOCARNITINE, LEVOCARNITINE
LIDOCAINE HCL, LIDOCAINE HYDROCHLORIDE
MANNITOL 25%, MANNITOL
METHYLDOPATE HCL, METHYLDOPATE HYDROCHLORIDE
NITROGLYCERIN, NITROGLYCERIN
PIPERAZINE CITRATE, PIPERAZINE CITRATE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PYRIDOXINE HCL, PYRIDOXINE HYDROCHLORIDE
THIAMINE HCL, THIAMINE HYDROCHLORIDE
VENOFER, IRON SUCROSE
VERAPAMIL HCL, VERAPAMIL HYDROCHLORIDE

LYNE
* LYNE LABORATORIES INC
XYLOSE, XYLOSE

** M **

MALLARD
* MALLARD INC
MEPROBAMATE, MEPROBAMATE

MALLINCKRODT
* MALLINCKRODT CHEMICAL INC
ANEXSIA 10/660, ACETAMINOPHEN
ANEXSIA 7.5/650, ACETAMINOPHEN
ANEXSIA, ACETAMINOPHEN
BONTRIL, PHENDIMETRAZINE TARTRATE
BUCET, ACETAMINOPHEN
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
BUTALBITAL, ACETAMINOPHEN, CAFFEINE, ACETAMINOPHEN
FEMCET, ACETAMINOPHEN
HYDROCET, ACETAMINOPHEN
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
LORCET-HD, ACETAMINOPHEN
LORTAB, ACETAMINOPHEN
MEPERIDINE HCL PRESERVATIVE FREE, MEPERIDINE HYDROCHLORIDE
METHADONE HCL, METHADONE HYDROCHLORIDE
METHADOSE, METHADONE HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
TENCON, ACETAMINOPHEN
TRIAD, ACETAMINOPHEN
* MALLINCKRODT INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ANEXSIA 5/325, ACETAMINOPHEN
ANEXSIA 7.5/325, ACETAMINOPHEN
FERROUS CITRATE FE 59, FERROUS CITRATE, FE-59
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
MD-50, DIATRIZOATE SODIUM
MEPERIDINE HCL, MEPERIDINE HYDROCHLORIDE
METHYLIN ER, METHYLPHENIDATE HYDROCHLORIDE
METHYLPHENIDATE HCL, METHYLPHENIDATE HYDROCHLORIDE
OPTIMARK IN PLASTIC CONTAINER, GADOVERSETAMIDE
OPTIMARK, GADOVERSETAMIDE
OPTISON, PERFLUTREN
OSTEOSCAN, TECHNETIUM TC-99M ETIDRONATE KIT
OXYCET, ACETAMINOPHEN
PEMOLINE, PEMOLINE
PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN, ACETAMINOPHEN
SELENOMETHIONINE SE 75, SELENOMETHIONINE, SE-75
XENEISOL, XENON, XE-133
* MALLINCKRODT MEDICAL INC
ANGIO-CONRAY, IOTHALAMATE SODIUM
CHOLEBRINE, IOCETAMIC ACID
CONRAY 30, IOTHALAMATE MEGLUMINE
CONRAY 325, IOTHALAMATE SODIUM
CONRAY 400, IOTHALAMATE SODIUM
CONRAY 43, IOTHALAMATE MEGLUMINE
CONRAY, IOTHALAMATE MEGLUMINE
CYANOCOBALAMIN CO 57 SCHILLING TEST KIT, CYANOCOBALAMIN
CYSTO-CONRAY II, IOTHALAMATE MEGLUMINE
CYSTO-CONRAY, IOTHALAMATE MEGLUMINE
GALLIUM CITRATE GA 67, GALLIUM CITRATE, GA-67
HEXABRIX, IOXAGLATE MEGLUMINE
HIPPURAN I 131, IODOHIPPURATE SODIUM, I-131
MD-60, DIATRIZOATE MEGLUMINE
MD-76, DIATRIZOATE MEGLUMINE
MD-76R, DIATRIZOATE MEGLUMINE
MD-GASTROVIEW, DIATRIZOATE MEGLUMINE
OCTREOSCAN, INDIUM IN-111 PENTETREOTIDE KIT
OPTIRAY 160, IOVERSOL
OPTIRAY 240, IOVERSOL
OPTIRAY 300, IOVERSOL
OPTIRAY 320, IOVERSOL
OPTIRAY 350, IOVERSOL
PERCHLORACAP, POTASSIUM PERCHLORATE
PHOSPHOCOL P32, CHROMIC PHOSPHATE, P-32
RADIOIODINATED SERUM ALBUMIN (HUMAN) IHSA I 125, ALBUMIN IODINATED I-125 SERUM
SODIUM CHROMATE CR 51, SODIUM CHROMATE, CR-51
SODIUM IODIDE I 123, SODIUM IODIDE, I-123
SODIUM IODIDE I 131, SODIUM IODIDE, I-131
SODIUM PERTECHNETATE TC 99M, TECHNETIUM TC-99M SODIUM PERTECHNETATE
SODIUM PHOSPHATE P 32, SODIUM PHOSPHATE, P-32
TECHNECOLL, TECHNETIUM TC-99M SULFUR COLLOID KIT
TECHNESCAN HDP, TECHNETIUM TC-99M OXIDRONATE KIT
TECHNESCAN MAA, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT
TECHNESCAN MAG3, TECHNETIUM TC-99M MERTIATIDE KIT
TECHNESCAN PYP KIT, TECHNETIUM TC-99M PYROPHOSPHATE KIT
TECHNETIUM TC 99M SULFUR COLLOID, TECHNETIUM TC-99M SULFUR COLLOID
THALLOUS CHLORIDE TL 201, THALLOUS CHLORIDE, TL-201
ULTRA-TECHNEKOW FM, TECHNETIUM TC-99M SODIUM PERTECHNETATE

FDA data supplied by DrugPatentWatch.com

GENERATOR
ULTRATAG, TECHNETIUM TC-99M RED BLOOD CELL KIT
VASCORAY, IOTHALAMATE MEGLUMINE
XENON XE 127, XENON, XE-127
XENON XE 133, XENON, XE-133

MARCHAR
* MARCHAR LABORATORIES INC LTD
FLUOROURACIL, FLUOROURACIL

MARSAM PHARMS LLC
* MARSAM PHARMACEUTICALS LLC
AMPICILLIN SODIUM, AMPICILLIN SODIUM
ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE
ATRACURIUM BESYLATE, ATRACURIUM BESYLATE
CEFACLOR, CEFACLOR
CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
CEFUROXIME SODIUM, CEFUROXIME SODIUM
CHLORPROMAZINE HCL, CHLORPROMAZINE HYDROCHLORIDE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
DIAZEPAM, DIAZEPAM
DOBUTAMINE HCL, DOBUTAMINE HYDROCHLORIDE
ETOPOSIDE, ETOPOSIDE
FENTANYL CITRATE PRESERVATIVE FREE, FENTANYL CITRATE
FUROSEMIDE, FUROSEMIDE
HALOPERIDOL, HALOPERIDOL LACTATE
HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
HEPARIN SODIUM, HEPARIN SODIUM
ISOFLURANE, ISOFLURANE
LORAZEPAM, LORAZEPAM
METHOCARBAMOL, METHOCARBAMOL
METHYLDOPATE HCL, METHYLDOPATE HYDROCHLORIDE
NAFCILLIN SODIUM, NAFCILLIN SODIUM
NALOXONE HCL, NALOXONE HYDROCHLORIDE
OXACILLIN SODIUM, OXACILLIN SODIUM
PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM
PENICILLIN G SODIUM, PENICILLIN G SODIUM
PHENYTOIN SODIUM, PHENYTOIN SODIUM
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
VERAPAMIL HCL, VERAPAMIL HYDROCHLORIDE

MARSHALL PHARMA
* MARSHALL PHARMACAL CORP
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
RESERPINE, RESERPINE
SODIUM BUTABARBITAL, BUTABARBITAL SODIUM

MARTEC
* MARTEC PHARMACEUTICALS INC
ATENOLOL AND CHLORTHALIDONE, ATENOLOL
ATENOLOL, ATENOLOL
DIAZEPAM, DIAZEPAM
PINDOLOL, PINDOLOL
SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH, SULFAMETHOXAZOLE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
* MARTEC SCIENTIFIC INC
DICLOFENAC SODIUM, DICLOFENAC SODIUM

MAST MM
* MM MAST AND CO
CHLORDIAZEPOXIDE HCL, CHLORDIAZEPOXIDE HYDROCHLORIDE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
ONA MAST, PHENTERMINE HYDROCHLORIDE
ONA-MAST, PHENTERMINE HYDROCHLORIDE
PHENAZINE, PHENDIMETRAZINE TARTRATE
TETRACYCLINE HCL, TETRACYCLINE HYDROCHLORIDE
TRICHLORMAS, TRICHLORMETHIAZIDE

MATRIX MEDCL
* MATRIX MEDICAL CORP
STERI-STAT, CHLORHEXIDINE GLUCONATE (OTC)

MAYRAND
* MAYRAND INC
SEDAPAP, ACETAMINOPHEN

MCGAW
* MCGAW INC
AMMONIUM CHLORIDE 0.9% IN NORMAL SALINE, AMMONIUM CHLORIDE
HEPARIN SODIUM 1,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 2,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 5,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM

MCNEIL
* MCNEIL CONSUMER PRODUCTS CO DIV MCNEILAB INC
CHILDREN'S MOTRIN, IBUPROFEN (OTC)
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
IMODIUM A-D, LOPERAMIDE HYDROCHLORIDE (OTC)
IMODIUM ADVANCED, LOPERAMIDE HYDROCHLORIDE (OTC)
JUNIOR STRENGTH MOTRIN, IBUPROFEN (OTC)
MEDIPREN, IBUPROFEN (OTC)
METHOCARBAMOL AND ASPIRIN, ASPIRIN
MOTRIN IB, IBUPROFEN (OTC)
MOTRIN MIGRAINE PAIN, IBUPROFEN (OTC)
MOTRIN, IBUPROFEN
NUPRIN, IBUPROFEN (OTC)

FDA data supplied by DrugPatentWatch.com

SINE-AID IB, IBUPROFEN (OTC)
TYLENOL, ACETAMINOPHEN (OTC)
* MCNEIL PHARMACEUTICAL CO DIV MCNEILAB INC
CLISTIN, CARBINOXAMINE MALEATE

MCNEIL CONS
* MCNEIL CONSUMER HEALTHCARE
CHILDREN'S MOTRIN COLD, IBUPROFEN (OTC)
IMODIUM ADVANCED, LOPERAMIDE HYDROCHLORIDE (OTC)
IMODIUM, LOPERAMIDE HYDROCHLORIDE
MOTRIN, IBUPROFEN
NIZORAL A-D, KETOCONAZOLE (OTC)
NIZORAL, KETOCONAZOLE
VERMOX, MEBENDAZOLE

MD PHARM
* MD PHARMACEUTICAL INC
CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
CYPROHEPTADINE HCL, CYPROHEPTADINE HYDROCHLORIDE
DI-ATRO, ATROPINE SULFATE

MEAD JOHNSON
* MEAD JOHNSON AND CO SUB BRISTOL MYERS CO
MUCOMYST W/ ISOPROTERENOL, ACETYLCYSTEINE

MEDI FLEX HOSP
* MEDI FLEX HOSP PRODUCTS INC
CHLORAPREP, CHLORHEXIDINE GLUCONATE (OTC)

MEDICIS
* MEDICIS PHARMACEUTICAL CORP
BUPHENYL, SODIUM PHENYLBUTYRATE
LIDEX, FLUOCINONIDE
LIDEX-E, FLUOCINONIDE
LOPROX, CICLOPIROX
NEO-SYNALAR, FLUOCINOLONE ACETONIDE
OVIDE, MALATHION
SYNACORT, HYDROCORTISONE
SYNALAR, FLUOCINOLONE ACETONIDE
SYNALAR-HP, FLUOCINOLONE ACETONIDE
TOPICORT LP, DESOXIMETASONE
TOPICORT, DESOXIMETASONE
VECTRIN, MINOCYCLINE HYDROCHLORIDE

MEDIMMUNE ONCOLOGY
* MEDIMMUNE ONCOLOGY INC
ETHYOL, AMIFOSTINE
NEUTREXIN, TRIMETREXATE GLUCURONATE

MEDS (TMC)
* MEDICINES CO (TMC)
ANGIOMAX, BIVALIRUDIN

MEDTRONIC
* MEDTRONIC INC
LIORESAL, BACLOFEN

MEPHA
* MEPHA AG
PIROXICAM, PIROXICAM

MERCK
* MERCK AND CO INC
ALDOCLOR-150, CHLOROTHIAZIDE
ALDOCLOR-250, CHLOROTHIAZIDE
ALDOMET, METHYLDOPA
ALDOMET, METHYLDOPATE HYDROCHLORIDE
ALDORIL 15, HYDROCHLOROTHIAZIDE
ALDORIL 25, HYDROCHLOROTHIAZIDE
ALDORIL D30, HYDROCHLOROTHIAZIDE
ALDORIL D50, HYDROCHLOROTHIAZIDE
ALPHAREDISOL, HYDROXOCOBALAMIN
AMINOHIPPURATE SODIUM, AMINOHIPPURATE SODIUM
AQUAMEPHYTON, PHYTONADIONE
ARAMINE, METARAMINOL BITARTRATE
BENEMID, PROBENECID
COGENTIN, BENZTROPINE MESYLATE
COLBENEMID, COLCHICINE
CORTONE, CORTISONE ACETATE
CUPRIMINE, PENICILLAMINE
CYCLAINE, HEXYLCAINE HYDROCHLORIDE
DARANIDE, DICHLORPHENAMIDE
DECADERM, DEXAMETHASONE
DECADRON W/ XYLOCAINE, DEXAMETHASONE SODIUM PHOSPHATE
DECADRON, DEXAMETHASONE
DECADRON, DEXAMETHASONE SODIUM PHOSPHATE
DECASPRAY, DEXAMETHASONE
DEMSER, METYROSINE
DIUPRES-250, CHLOROTHIAZIDE
DIUPRES-500, CHLOROTHIAZIDE
DIURIL, CHLOROTHIAZIDE
DIURIL, CHLOROTHIAZIDE SODIUM
DOLOBID, DIFLUNISAL
EDECRIN, ETHACRYNATE SODIUM
EDECRIN, ETHACRYNIC ACID
FLEXERIL, CYCLOBENZAPRINE HYDROCHLORIDE
FLOROPRYL, ISOFLUROPHATE
FOSAMAX, ALENDRONATE SODIUM
HUMORSOL, DEMECARIUM BROMIDE
HYDELTRA-TBA, PREDNISOLONE TEBUTATE
HYDELTRASOL, PREDNISOLONE SODIUM PHOSPHATE
HYDROCORTONE, HYDROCORTISONE
HYDROCORTONE, HYDROCORTISONE ACETATE
HYDROCORTONE, HYDROCORTISONE SODIUM PHOSPHATE
HYDRODIURIL, HYDROCHLOROTHIAZIDE
HYDROPRES 25, HYDROCHLOROTHIAZIDE
HYDROPRES 50, HYDROCHLOROTHIAZIDE

FDA data supplied by DrugPatentWatch.com

HYZAAR, HYDROCHLOROTHIAZIDE
INVANZ, ERTAPENEM SODIUM
LERITINE, ANILERIDINE HYDROCHLORIDE
LERITINE, ANILERIDINE PHOSPHATE
MANNITOL 25%, MANNITOL
MAXALT, RIZATRIPTAN BENZOATE
MAXALT-MLT, RIZATRIPTAN BENZOATE
MEFOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER, CEFOXITIN SODIUM
MEFOXIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, CEFOXITIN SODIUM
MEFOXIN, CEFOXITIN SODIUM
MEPHYTON, PHYTONADIONE
MIDAMOR, AMILORIDE HYDROCHLORIDE
MINTEZOL, THIABENDAZOLE
MUSTARGEN, MECHLORETHAMINE HYDROCHLORIDE
NEO-HYDELTRASOL, NEOMYCIN SULFATE
NEODECADRON, DEXAMETHASONE SODIUM PHOSPHATE
PERIACTIN, CYPROHEPTADINE HYDROCHLORIDE
PRIMAXIN, CILASTATIN SODIUM
PROSCAR, FINASTERIDE
REDISOL, CYANOCOBALAMIN
SINGULAIR, MONTELUKAST SODIUM
SYPRINE, TRIENTINE HYDROCHLORIDE
TIAMATE, DILTIAZEM MALATE
TIMOLIDE 10-25, HYDROCHLOROTHIAZIDE

* MERCK RESEARCH LABORATORIES DIV MERCK CO INC
AGGRASTAT, TIROFIBAN HYDROCHLORIDE
ALDOMET, METHYLDOPA
BLOCADREN, TIMOLOL MALEATE
CHIBROXIN, NORFLOXACIN
CLINORIL, SULINDAC
COSMEGEN, DACTINOMYCIN
COSOPT, DORZOLAMIDE HYDROCHLORIDE
COZAAR, LOSARTAN POTASSIUM
CRIXIVAN, INDINAVIR SULFATE
DECADRON-LA, DEXAMETHASONE ACETATE
INDOCIN I.V., INDOMETHACIN SODIUM
INDOCIN SR, INDOMETHACIN
INDOCIN, INDOMETHACIN
LACRISERT, HYDROXYPROPYL CELLULOSE
MEFOXIN IN PLASTIC CONTAINER, CEFOXITIN SODIUM
MEVACOR, LOVASTATIN
MODURETIC 5-50, AMILORIDE HYDROCHLORIDE
NOROXIN, NORFLOXACIN
PEPCID AC, FAMOTIDINE (OTC)
PEPCID COMPLETE, CALCIUM CARBONATE, PRECIPITATED (OTC)
PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER, FAMOTIDINE
PEPCID PRESERVATIVE FREE, FAMOTIDINE
PEPCID RPD, FAMOTIDINE
PEPCID, FAMOTIDINE
PRINIVIL, LISINOPRIL
PRINZIDE, HYDROCHLOROTHIAZIDE
PROPECIA, FINASTERIDE
SINGULAIR, MONTELUKAST SODIUM
STROMECTOL, IVERMECTIN
TECZEM, DILTIAZEM MALATE
TIMOPTIC IN OCUDOSE, TIMOLOL MALEATE
TIMOPTIC, TIMOLOL MALEATE
TIMOPTIC-XE, TIMOLOL MALEATE
TRUSOPT, DORZOLAMIDE HYDROCHLORIDE
VASERETIC, ENALAPRIL MALEATE
VASOTEC, ENALAPRIL MALEATE
VASOTEC, ENALAPRILAT
VIOXX, ROFECOXIB
ZOCOR, SIMVASTATIN

MERCK RES
* MERCK RESEARCH LABORATORIES
CANCIDAS, CASPOFUNGIN ACETATE

MERETEK
* MERETEK DIAGNOSTICS INC
BREATHTEK UBT FOR H-PYLORI, UREA, C-13
MERETEK UBT KIT (W/ PRANACTIN), UREA, C-13

MERICON
* MERICON INDUSTRIES INC
HYDROCORTISONE, HYDROCORTISONE

MERIDIAN MEDCL TECHN
* MERIDIAN MEDICAL TECHNOLOGIES INC
ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
ATROPEN, ATROPINE
BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
DILTIAZEM HCL, DILTIAZEM HYDROCHLORIDE
EPI E Z PEN JR, EPINEPHRINE
EPIPEN E Z PEN, EPINEPHRINE
EPIPEN JR., EPINEPHRINE
EPIPEN, EPINEPHRINE
LIDOPEN, LIDOCAINE HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
PRALIDOXIME CHLORIDE, PRALIDOXIME CHLORIDE

METABOLIC SOLUTIONS
* METABOLIC SOLUTIONS INC
HELICOSOL, UREA, C-13

METHAPHARM
* METHAPHARM INC
PROVOCHOLINE, METHACHOLINE CHLORIDE

MFG CHEMISTS
* MANUFACTURING CHEMISTS INC
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE

MGI PHARMA INC

FDA data supplied by DrugPatentWatch.com

* MGI PHARMA INC
DIDRONEL, ETIDRONATE DISODIUM
HEXALEN, ALTRETAMINE
SALAGEN, PILOCARPINE HYDROCHLORIDE

MIKART
* MIKART INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACETAMINOPHEN, BUTALBITAL, AND CAFFEINE, ACETAMINOPHEN
ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE, ACETAMINOPHEN
AMANTADINE HCL, AMANTADINE HYDROCHLORIDE
AMINOCAPROIC ACID, AMINOCAPROIC ACID
AMINOCAPROIC, AMINOCAPROIC ACID
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
BUTAPAP, ACETAMINOPHEN
ESGIC-PLUS, ACETAMINOPHEN
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
ISONIAZID, ISONIAZID
METHAZOLAMIDE, METHAZOLAMIDE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PYRAZINAMIDE, PYRAZINAMIDE
TRIHEXYPHENIDYL HCL, TRIHEXYPHENIDYL HYDROCHLORIDE

MILES
* MILES LABORATORIES INC
ALCOHOL 5% IN DEXTROSE 5%, ALCOHOL
DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
LIDOCAINE HCL, LIDOCAINE HYDROCHLORIDE
MANNITOL 10%, MANNITOL
MANNITOL 15%, MANNITOL
MANNITOL 20%, MANNITOL
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PROCAINE HCL, PROCAINE HYDROCHLORIDE
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE IN PLASTIC CONTAINER, SODIUM CHLORIDE
STERILE WATER IN PLASTIC CONTAINER, WATER FOR IRRIGATION, STERILE

MILEX
* MILEX PRODUCTS INC
MILOPHENE, CLOMIPHENE CITRATE

MINRAD
* MINRAD INC
ENFLURANE, ENFLURANE
ISOFLURANE, ISOFLURANE

MISSION PHARMA
* MISSION PHARMACAL CO
CALCIBIND, CELLULOSE SODIUM PHOSPHATE
EQUIPIN, HOMATROPINE METHYLBROMIDE
FOLICET, FOLIC ACID
HOMAPIN-10, HOMATROPINE METHYLBROMIDE
HOMAPIN-5, HOMATROPINE METHYLBROMIDE
LITHOSTAT, ACETOHYDROXAMIC ACID
POTASSIUM CITRATE, POTASSIUM CITRATE
TIOPRONIN, TIOPRONIN

MIZA PHARMS USA
* MIZA PHARMACEUTICALS USA INC
OCUSULF-10, SULFACETAMIDE SODIUM
OCUSULF-30, SULFACETAMIDE SODIUM
TROPICAMIDE, TROPICAMIDE

MJ PHARMS
* MJ PHARMACEUTICALS LTD
CEPHALEXIN, CEPHALEXIN

MK LABS
* MK LABORATORIES INC
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
FOLIC ACID, FOLIC ACID
ISONIAZID, ISONIAZID
KESSO-GESIC, PROPOXYPHENE HYDROCHLORIDE
MEPROBAMATE, MEPROBAMATE
NIACIN, NIACIN
RESERPINE, RESERPINE
SOSOL, SULFISOXAZOLE
VITAMIN A, VITAMIN A PALMITATE

MONARCH PHARMS
* MONARCH PHARMACEUTICALS INC
CORTISPORIN, BACITRACIN ZINC
CORTISPORIN, HYDROCORTISONE
CORTISPORIN, HYDROCORTISONE ACETATE
DERMACORT, HYDROCORTISONE
KEMADRIN, PROCYCLIDINE HYDROCHLORIDE
MENEST, ESTROGENS, ESTERIFIED
NEOSPORIN G.U. IRRIGANT, NEOMYCIN SULFATE
NEOSPORIN, BACITRACIN ZINC
NEOSPORIN, GRAMICIDIN
PEDIOTIC, HYDROCORTISONE

FDA data supplied by DrugPatentWatch.com

POLYSPORIN, BACITRACIN ZINC
PROCTOCORT, HYDROCORTISONE
PROLOPRIM, TRIMETHOPRIM
QUIBRON-T, THEOPHYLLINE
QUIBRON-T/SR, THEOPHYLLINE
SEPTRA DS, SULFAMETHOXAZOLE
SEPTRA GRAPE, SULFAMETHOXAZOLE
SEPTRA, SULFAMETHOXAZOLE
THALITONE, CHLORTHALIDONE
VIROPTIC, TRIFLURIDINE

MORTON GROVE
* MORTON GROVE ACQUISITION CORP
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
* MORTON GROVE PHARMACEUTICALS INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACETIC ACID, ACETIC ACID, GLACIAL
ALBUTEROL SULFATE, ALBUTEROL SULFATE
AMANTADINE HCL, AMANTADINE HYDROCHLORIDE
AMINOPHYLLINE, AMINOPHYLLINE
BIPHETAP, BROMPHENIRAMINE MALEATE
BUTABARBITAL SODIUM, BUTABARBITAL SODIUM
CHLORPROMAZINE HCL, CHLORPROMAZINE HYDROCHLORIDE
CIMETIDINE HCL, CIMETIDINE HYDROCHLORIDE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CROMOLYN SODIUM, CROMOLYN SODIUM
CYPROHEPTADINE HCL, CYPROHEPTADINE HYDROCHLORIDE
DIPHEN, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
DOXEPIN HCL, DOXEPIN HYDROCHLORIDE
ERYTHROMYCIN, ERYTHROMYCIN
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FUROSEMIDE, FUROSEMIDE
GENERLAC, LACTULOSE
HALOPERIDOL, HALOPERIDOL LACTATE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROCORTISONE AND ACETIC ACID, ACETIC ACID, GLACIAL
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
LACTULOSE, LACTULOSE
LIDOCAINE HCL, LIDOCAINE HYDROCHLORIDE
LINDANE, LINDANE
LITHIUM CITRATE, LITHIUM CITRATE
LOPERAMIDE HCL, LOPERAMIDE HYDROCHLORIDE (OTC)
METAPROTERENOL SULFATE, METAPROTERENOL SULFATE
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
MYBANIL, BROMODIPHENHYDRAMINE HYDROCHLORIDE
MYCODONE, HOMATROPINE METHYLBROMIDE
MYLARAMINE, DEXCHLORPHENIRAMINE MALEATE
MYMETHASONE, DEXAMETHASONE
MYPHETANE DC, BROMPHENIRAMINE MALEATE
MYPHETANE DX, BROMPHENIRAMINE MALEATE
MYPROIC ACID, VALPROIC ACID
NYSTATIN, NYSTATIN
OXTRIPHYLLINE PEDIATRIC, OXTRIPHYLLINE
OXTRIPHYLLINE, OXTRIPHYLLINE
PREDNISONE, PREDNISONE
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
PROMETHAZINE PLAIN, PROMETHAZINE HYDROCHLORIDE
PROMETHAZINE VC PLAIN, PHENYLEPHRINE HYDROCHLORIDE
PROMETHAZINE VC W/ CODEINE, CODEINE PHOSPHATE
PROMETHAZINE W/ CODEINE, CODEINE PHOSPHATE
PROMETHAZINE W/ DEXTROMETHORPHAN, DEXTROMETHORPHAN HYDROBROMIDE
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
SELENIUM SULFIDE, SELENIUM SULFIDE
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE
THEOPHYLLINE, THEOPHYLLINE
THIORIDAZINE HCL, THIORIDAZINE HYDROCHLORIDE
TRETINOIN, TRETINOIN
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
TRIFLUOPERAZINE HCL, TRIFLUOPERAZINE HYDROCHLORIDE
TRIMEPRAZINE TARTRATE, TRIMEPRAZINE TARTRATE
TRIPROLIDINE HCL, PSEUDOEPHEDRINE HCL AND CODEINE PHOSPHATE, CODEINE PHOSPHATE

MOUNT SINAI MEDCTR
* MOUNT SINAI MEDCTR
THALLOUS CHLORIDE TL 201, THALLOUS CHLORIDE, TL-201

MOVA
* MOVA PHARMACEUTICALS CORP
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ALBUTEROL SULFATE, ALBUTEROL SULFATE
CAPTOPRIL, CAPTOPRIL
CIMETIDINE HCL, CIMETIDINE HYDROCHLORIDE
CIMETIDINE, CIMETIDINE
GLYBURIDE (MICRONIZED), GLYBURIDE
LORAZEPAM, LORAZEPAM
NAPROXEN, NAPROXEN

MURO
* MURO PHARMACEUTICAL INC
BROMFED-DM, BROMPHENIRAMINE MALEATE
LIQUID PRED, PREDNISONE
PRELONE, PREDNISOLONE
PROMETA, METAPROTERENOL SULFATE
TRI-NASAL, TRIAMCINOLONE ACETONIDE
VOLMAX, ALBUTEROL SULFATE

MUTUAL PHARM
* MUTUAL PHARMACEUTICAL CO INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACETAZOLAMIDE, ACETAZOLAMIDE
ALBUTEROL SULFATE, ALBUTEROL SULFATE

FDA data supplied by DrugPatentWatch.com

ALLOPURINOL, ALLOPURINOL
AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
ATENOLOL AND CHLORTHALIDONE, ATENOLOL
ATENOLOL, ATENOLOL
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
CARISOPRODOL, CARISOPRODOL
CHLORTHALIDONE, CHLORTHALIDONE
CHLORZOXAZONE, CHLORZOXAZONE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
ERGOLOID MESYLATES, ERGOLOID MESYLATES
FAMOTIDINE, FAMOTIDINE
FENOPROFEN CALCIUM, FENOPROFEN CALCIUM
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
IMIPRAMINE HCL, IMIPRAMINE HYDROCHLORIDE
INDOMETHACIN, INDOMETHACIN
LABETALOL HCL, LABETALOL HYDROCHLORIDE
LORAZEPAM, LORAZEPAM
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
METRONIDAZOLE, METRONIDAZOLE
MINOXIDIL, MINOXIDIL
NYSTATIN, NYSTATIN
PINDOLOL, PINDOLOL
PIROXICAM, PIROXICAM
PREDNISONE, PREDNISONE
PROPAFENONE HCL, PROPAFENONE HYDROCHLORIDE
QUINIDINE GLUCONATE, QUINIDINE GLUCONATE
QUINIDINE SULFATE, QUINIDINE SULFATE
SOTALOL HCL, SOTALOL HYDROCHLORIDE
SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPIRONOLACTONE, SPIRONOLACTONE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
SULFASALAZINE, SULFASALAZINE
SULINDAC, SULINDAC
THIORIDAZINE HCL, THIORIDAZINE HYDROCHLORIDE
TOLAZAMIDE, TOLAZAMIDE
TOLMETIN SODIUM, TOLMETIN SODIUM
TRAZODONE HCL, TRAZODONE HYDROCHLORIDE
VERAPAMIL HCL, VERAPAMIL HYDROCHLORIDE

MUTUAL PHARMA

* MUTUAL PHARMACAL CO
KETOCONAZOLE, KETOCONAZOLE

MYLAN

* MYLAN LABORATORIES INC
ACYCLOVIR, ACYCLOVIR
CAPTOPRIL, CAPTOPRIL
ETODOLAC, ETODOLAC
IBUPROFEN, IBUPROFEN
TERAZOSIN HCL, TERAZOSIN HYDROCHLORIDE

* MYLAN PHARMACEUTICALS INC
ACEBUTOLOL HCL, ACEBUTOLOL HYDROCHLORIDE
ACYCLOVIR, ACYCLOVIR
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALLOPURINOL, ALLOPURINOL
ALPRAZOLAM, ALPRAZOLAM
AMILORIDE HCL AND HYDROCHLOROTHIAZIDE, AMILORIDE HYDROCHLORIDE
AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
AMOXICILLIN, AMOXICILLIN
AMPICILLIN TRIHYDRATE, AMPICILLIN/AMPICILLIN TRIHYDRATE
ATENOLOL AND CHLORTHALIDONE, ATENOLOL
ATENOLOL, ATENOLOL
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
BUPROPION HCL, BUPROPION HYDROCHLORIDE
BUSPIRONE HCL, BUSPIRONE HYDROCHLORIDE
BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
CAPTOPRIL AND HYDROCHLOROTHIAZIDE, CAPTOPRIL
CARBIDOPA AND LEVODOPA, CARBIDOPA
CHLORDIAZEPOXIDE AND AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
CHLORDIAZEPOXIDE HCL, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLOROTHIAZIDE, CHLOROTHIAZIDE
CHLOROTHIAZIDE-RESERPINE, CHLOROTHIAZIDE
CHLORPROPAMIDE, CHLORPROPAMIDE
CHLORTHALIDONE, CHLORTHALIDONE
CIMETIDINE, CIMETIDINE
CLOMIPRAMINE HCL, CLOMIPRAMINE HYDROCHLORIDE
CLONAZEPAM, CLONAZEPAM
CLONIDINE HCL, CLONIDINE HYDROCHLORIDE
CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
CLORPRES, CHLORTHALIDONE
CLOZAPINE, CLOZAPINE
CYCLOBENZAPRINE HCL, CYCLOBENZAPRINE HYDROCHLORIDE
CYPROHEPTADINE HCL, CYPROHEPTADINE HYDROCHLORIDE
CYSTAGON, CYSTEAMINE BITARTRATE
DIAZEPAM, DIAZEPAM
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DICYCLOMINE HCL, DICYCLOMINE HYDROCHLORIDE
DILTIAZEM HCL, DILTIAZEM HYDROCHLORIDE
DIPHENOXYLATE HCL AND ATROPINE SULFATE, ATROPINE SULFATE
DISOPYRAMIDE PHOSPHATE, DISOPYRAMIDE PHOSPHATE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
DOXEPIN HCL, DOXEPIN HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
ERYTHROMYCIN ETHYLSUCCINATE, ERYTHROMYCIN ETHYLSUCCINATE
ERYTHROMYCIN STEARATE, ERYTHROMYCIN STEARATE

FDA data supplied by DrugPatentWatch.com

ESTRADIOL, ESTRADIOL
ESTROPIPATE, ESTROPIPATE
ETODOLAC, ETODOLAC
EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM, EXTENDED
FAMOTIDINE, FAMOTIDINE
FENOPROFEN CALCIUM, FENOPROFEN CALCIUM
FLUPHENAZINE HCL, FLUPHENAZINE HYDROCHLORIDE
FLURAZEPAM HCL, FLURAZEPAM HYDROCHLORIDE
FLURBIPROFEN, FLURBIPROFEN
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
FUROSEMIDE, FUROSEMIDE
GEMFIBROZIL, GEMFIBROZIL
GLIPIZIDE, GLIPIZIDE
GLYBURIDE (MICRONIZED), GLYBURIDE
GUANFACINE HCL, GUANFACINE HYDROCHLORIDE
HALOPERIDOL, HALOPERIDOL
HYDRALAZINE HCL-HYDROCHLOROTHIAZIDE-RESERPINE, HYDRALAZINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROXYCHLOROQINE SULFATE, HYDROXYCHLOROQUINE SULFATE
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
INDAPAMIDE, INDAPAMIDE
INDOMETHACIN, INDOMETHACIN
KETOCONAZOLE, KETOCONAZOLE
KETOPROFEN, KETOPROFEN
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LOPERAMIDE HCL, LOPERAMIDE HYDROCHLORIDE
LORAZEPAM, LORAZEPAM
LOVASTATIN, LOVASTATIN
MAPROTILINE HCL, MAPROTILINE HYDROCHLORIDE
MAXZIDE, HYDROCHLOROTHIAZIDE
MAXZIDE-25, HYDROCHLOROTHIAZIDE
MECLOFENAMATE SODIUM, MECLOFENAMATE SODIUM
MEPROBAMATE, MEPROBAMATE
METHOCARBAMOL, METHOCARBAMOL
METHOTREXATE SODIUM, METHOTREXATE SODIUM
METHYCLOTHIAZIDE, METHYCLOTHIAZIDE
METHYLDOPA AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
METHYLDOPA, METHYLDOPA
METOPROLOL TARTRATE, METOPROLOL TARTRATE
NADOLOL, NADOLOL
NAPROXEN SODIUM, NAPROXEN SODIUM
NAPROXEN, NAPROXEN
NICARDIPINE HCL, NICARDIPINE HYDROCHLORIDE
NIFEDIPINE, NIFEDIPINE
NITROFURANTION, NITROFURANTOIN, MACROCRYSTALLINE
NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
NITROGLYCERIN, NITROGLYCERIN
NORTRIPTYLINE HCL, NORTRIPTYLINE HYDROCHLORIDE
OXAPROZIN, OXAPROZIN
OXAZEPAM, OXAZEPAM
PACLITAXEL, PACLITAXEL
PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM
PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM
PENTOXIFYLLINE, PENTOXIFYLLINE
PERPHENAZINE AND AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
PHENYTEK, PHENYTOIN SODIUM, EXTENDED
PINDOLOL, PINDOLOL
PIROXICAM, PIROXICAM
PRAZOSIN HCL, PRAZOSIN HYDROCHLORIDE
PROBENECID, PROBENECID
PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE
PROPANTHELINE BROMIDE, PROPANTHELINE BROMIDE
PROPOXYPHENE HCL AND ACETAMINOPHEN, ACETAMINOPHEN
PROPOXYPHENE HCL, PROPOXYPHENE HYDROCHLORIDE
PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN, ACETAMINOPHEN
PROPRANOLOL HCL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
RANITIDINE HCL, RANITIDINE HYDROCHLORIDE
RESERPINE, RESERPINE
SOTALOL HCL, SOTALOL HYDROCHLORIDE
SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPIRONOLACTONE, SPIRONOLACTONE
SULFAMYLON, MAFENIDE ACETATE
SULINDAC, SULINDAC
TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
TEMAZEPAM, TEMAZEPAM
TETRACYCLINE HCL, TETRACYCLINE HYDROCHLORIDE
THIORIDAZINE HCL, THIORIDAZINE HYDROCHLORIDE
THIOTHIXENE, THIOTHIXENE
TICLOPIDINE HCL, TICLOPIDINE HYDROCHLORIDE
TIMOLOL MALEATE, TIMOLOL MALEATE
TOLAZAMIDE, TOLAZAMIDE
TOLBUTAMIDE, TOLBUTAMIDE
TOLMETIN SODIUM, TOLMETIN SODIUM
TRAZODONE HCL, TRAZODONE HYDROCHLORIDE
TRIAMCINOLONE, TRIAMCINOLONE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TRIFLUOPERAZINE HCL, TRIFLUOPERAZINE HYDROCHLORIDE
VERAPAMIL HCL, VERAPAMIL HYDROCHLORIDE
ZAGAM, SPARFLOXACIN

MYLAN TECHNOLOGIES

* MYLAN TECHNOLOGIES INC
BUSPIRONE HCL, BUSPIRONE HYDROCHLORIDE
ESTRADIOL, ESTRADIOL
NITROGLYCERIN, NITROGLYCERIN
TERAZOSIN HCL, TERAZOSIN HYDROCHLORIDE

** N **

NASKA

* NASKA PHARMACAL CO INC DIV RUGBY DARBY GROUP COSMETICS
BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE,

FDA data supplied by DrugPatentWatch.com

BACITRACIN ZINC (OTC)
BACITRACIN ZINC-POLYMYXIN B SULFATE, BACITRACIN ZINC (OTC)
BACITRACIN, BACITRACIN (OTC)
CYPROHEPTADINE HCL, CYPROHEPTADINE HYDROCHLORIDE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
ERYTHROMYCIN ETHYLSUCCINATE, ERYTHROMYCIN ETHYLSUCCINATE
HYDROCORTISONE, HYDROCORTISONE
TRIMETH/SULFA, SULFAMETHOXAZOLE

NASTECH PHARM
* NASTECH PHARMACEUTICAL CO INC
NASCOBAL, CYANOCOBALAMIN

NEOSAN PHARMS
* NEOSAN PHARMACEUTICALS
AQUASOL A, VITAMIN A PALMITATE
M.V.I. PEDIATRIC, ASCORBIC ACID
M.V.I.-12, ASCORBIC ACID

NEPHRON
* NEPHRON CORP
ALBUTEROL SULFATE, ALBUTEROL SULFATE
BETA-2, ISOETHARINE HYDROCHLORIDE
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
* NEPHRON PHARMACEUTICALS CORP
METAPROTERENOL SULFATE, METAPROTERENOL SULFATE

NEW RIVER
* NEW RIVER PHARMACEUTICALS INC
DOXEPIN HCL, DOXEPIN HYDROCHLORIDE
ERGOMAR, ERGOTAMINE TARTRATE
PROFERDEX, IRON DEXTRAN
TRIAVIL 2-10, AMITRIPTYLINE HYDROCHLORIDE
TRIAVIL 2-25, AMITRIPTYLINE HYDROCHLORIDE
TRIAVIL 4-10, AMITRIPTYLINE HYDROCHLORIDE
TRIAVIL 4-25, AMITRIPTYLINE HYDROCHLORIDE
TRIAVIL 4-50, AMITRIPTYLINE HYDROCHLORIDE

NEWTRON PHARMS
* NEWTRON PHARMACEUTICALS INC
BROMPHENIRAMINE MALEATE, BROMPHENIRAMINE MALEATE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
TRILITRON, PSEUDOEPHEDRINE HYDROCHLORIDE

NMC
* NMC LABORATORIES INC
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOTRIMAZOLE, CLOTRIMAZOLE (OTC)
FLUOCINONIDE EMULSIFIED BASE, FLUOCINONIDE
FLUOCINONIDE, FLUOCINONIDE
HYDROCORTISONE, HYDROCORTISONE
MYKACET, NYSTATIN
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
VALNAC, BETAMETHASONE VALERATE

NORBROOK
* NORBROOK LABORATORIES LTD
METHOTREXATE SODIUM, METHOTREXATE SODIUM
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE

NOVARTIS
* NOVARTIS CONSUMER HEALTH INC
ASBRON, THEOPHYLLINE SODIUM GLYCINATE
CONTAC, CHLORPHENIRAMINE MALEATE (OTC)
DENAVIR, PENCICLOVIR SODIUM
HABITROL, NICOTINE
HABITROL, NICOTINE (OTC)
LAMISIL AT, TERBINAFINE HYDROCHLORIDE (OTC)
LAMISIL, TERBINAFINE HYDROCHLORIDE (OTC)
RAUTENSIN, ALSEROXYLON
TAVIST ALLERGY/SINUS/HEADACHE, ACETAMINOPHEN (OTC)
TRANSDERM SCOP, SCOPOLAMINE
* NOVARTIS OPHTHALMICS INC
CARBASTAT, CARBACHOL
CATARASE, CHYMOTRYPSIN
DEXACIDIN, DEXAMETHASONE
FLUOR-OP, FLUOROMETHOLONE
FUNDUSCEIN-25, FLUORESCEIN SODIUM
GENTACIDIN, GENTAMICIN SULFATE
INFLAMASE FORTE, PREDNISOLONE SODIUM PHOSPHATE
INFLAMASE MILD, PREDNISOLONE SODIUM PHOSPHATE
LIVOSTIN, LEVOCABASTINE HYDROCHLORIDE
MIOCHOL, ACETYLCHOLINE CHLORIDE
MIOCHOL-E, ACETYLCHOLINE CHLORIDE
OCUPRESS, CARTEOLOL HYDROCHLORIDE
RESCULA, UNOPROSTONE ISOPROPYL
SULF-10, SULFACETAMIDE SODIUM
SULF-15, SULFACETAMIDE SODIUM
VASOCIDIN, PREDNISOLONE ACETATE
VASOCIDIN, PREDNISOLONE SODIUM PHOSPHATE
VASOCON, NAPHAZOLINE HYDROCHLORIDE
VASOCON-A, ANTAZOLINE PHOSPHATE (OTC)
VITRAVENE PRESERVATIVE FREE, FOMIVIRSEN SODIUM
VOLTAREN, DICLOFENAC SODIUM
ZADITOR, KETOTIFEN FUMARATE
* NOVARTIS PHARMACEUTICALS CORP
ACTIGALL, URSODIOL
ACYLANID, ACETYLDIGITOXIN
ANTRENYL, OXYPHENONIUM BROMIDE
ANTURANE, SULFINPYRAZONE
APRESAZIDE, HYDRALAZINE HYDROCHLORIDE
APRESOLINE, HYDRALAZINE HYDROCHLORIDE
APRESOLINE-ESIDRIX, HYDRALAZINE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

AREDIA, PAMIDRONATE DISODIUM
BRETHAIRE, TERBUTALINE SULFATE
BRETHINE, TERBUTALINE SULFATE
BUTAZOLIDIN, PHENYLBUTAZONE
CAFERGOT, CAFFEINE
CATAFLAM, DICLOFENAC POTASSIUM
CEDILANID-D, DESLANOSIDE
CIBACALCIN, CALCITONIN HUMAN
CLOZARIL, CLOZAPINE
COMBIPATCH, ESTRADIOL
CYTADREN, AMINOGLUTETHIMIDE
D.H.E. 45, DIHYDROERGOTAMINE MESYLATE
DESFERAL, DEFEROXAMINE MESYLATE
DIAPID, LYPRESSIN
DIOVAN HCT, HYDROCHLOROTHIAZIDE
DIOVAN, VALSARTAN
DYNACIRC CR, ISRADIPINE
DYNACIRC, ISRADIPINE
ELIDEL, PIMECROLIMUS
EMBOLEX, DIHYDROERGOTAMINE MESYLATE
ESIDRIX, HYDROCHLOROTHIAZIDE
ESIMIL, GUANETHIDINE MONOSULFATE
ESTRADERM, ESTRADIOL
ESTRADIOL, ESTRADIOL
EXELON, RIVASTIGMINE TARTRATE
FAMVIR, FAMCICLOVIR
FEMARA, LETROZOLE
FIORICET W/ CODEINE, ACETAMINOPHEN
FIORICET, ACETAMINOPHEN
FIORINAL W/CODEINE NO 3, ASPIRIN
FIORINAL, ASPIRIN
FOCALIN, DEXMETHYLPHENIDATE HYDROCHLORIDE
FORADIL, FORMOTEROL FUMARATE
GLEEVEC, IMATINIB MESYLATE
HEAVY SOLUTION NUPERCAINE, DIBUCAINE HYDROCHLORIDE
HYDERGINE LC, ERGOLOID MESYLATES
HYDERGINE, ERGOLOID MESYLATES
IMIPRAMINE HCL, IMIPRAMINE HYDROCHLORIDE
INH, ISONIAZID
ISMELIN, GUANETHIDINE MONOSULFATE
LAMISIL, TERBINAFINE
LAMISIL, TERBINAFINE HYDROCHLORIDE
LAMPRENE, CLOFAZIMINE
LESCOL XL, FLUVASTATIN SODIUM
LESCOL, FLUVASTATIN SODIUM
LIORESAL, BACLOFEN
LOCORTEN, FLUMETHASONE PIVALATE
LOPRESSIDONE, CHLORTHALIDONE
LOPRESSOR HCT, HYDROCHLOROTHIAZIDE
LOPRESSOR, METOPROLOL FUMARATE
LOPRESSOR, METOPROLOL TARTRATE
LOTENSIN HCT, BENAZEPRIL HYDROCHLORIDE
LOTENSIN, BENAZEPRIL HYDROCHLORIDE
LOTREL, AMLODIPINE BESYLATE
LUDIOMIL, MAPROTILINE HYDROCHLORIDE
MELLARIL, THIORIDAZINE HYDROCHLORIDE
MELLARIL-S, THIORIDAZINE
MESANTOIN, MEPHENYTOIN
METANDREN, METHYLTESTOSTERONE
METHERGINE, METHYLERGONOVINE MALEATE
METOPIRONE, METYRAPONE
MIACALCIN, CALCITONIN, SALMON
MIGRANAL, DIHYDROERGOTAMINE MESYLATE
NEORAL, CYCLOSPORINE
PARLODEL, BROMOCRIPTINE MESYLATE
PBZ, TRIPELENNAMINE CITRATE
PBZ, TRIPELENNAMINE HYDROCHLORIDE
PBZ-SR, TRIPELENNAMINE HYDROCHLORIDE
PERCORTEN, DESOXYCORTICOSTERONE ACETATE
PERCORTEN, DESOXYCORTICOSTERONE PIVALATE
PRISCOLINE, TOLAZOLINE HYDROCHLORIDE
REGITINE, PHENTOLAMINE MESYLATE
RITALIN, METHYLPHENIDATE HYDROCHLORIDE
RITALIN-SR, METHYLPHENIDATE HYDROCHLORIDE
SANDIMMUNE, CYCLOSPORINE
SANDOSTATIN LAR, OCTREOTIDE ACETATE
SANDOSTATIN, OCTREOTIDE ACETATE
SANOREX, MAZINDOL
SANSERT, METHYSERGIDE MALEATE
SER-AP-ES, HYDRALAZINE HYDROCHLORIDE
SERENTIL, MESORIDAZINE BESYLATE
SERPASIL, RESERPINE
SERPASIL-APRESOLINE, HYDRALAZINE HYDROCHLORIDE
SERPASIL-ESIDRIX #1, HYDROCHLOROTHIAZIDE
SERPASIL-ESIDRIX #2, HYDROCHLOROTHIAZIDE
SLOW-K, POTASSIUM CHLORIDE
STARLIX, NATEGLINIDE
SYNTOCINON, OXYTOCIN
TANDEARIL, OXYPHENBUTAZONE
TAVIST D, CLEMASTINE FUMARATE
TAVIST, CLEMASTINE FUMARATE
TAVIST-1, CLEMASTINE FUMARATE
TAVIST-1, CLEMASTINE FUMARATE (OTC)
TAVIST-D, CLEMASTINE FUMARATE (OTC)
TEGRETOL, CARBAMAZEPINE
TEGRETOL-XR, CARBAMAZEPINE
TEN-K, POTASSIUM CHLORIDE
TOFRANIL, IMIPRAMINE HYDROCHLORIDE
TORECAN, THIETHYLPERAZINE MALATE
TORECAN, THIETHYLPERAZINE MALEATE
TRANSDERM-NITRO, NITROGLYCERIN
TRASICOR, OXPRENOLOL HYDROCHLORIDE
TREST, METHIXENE HYDROCHLORIDE
TRIAMINIC-12, CHLORPHENIRAMINE MALEATE (OTC)
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TRILEPTAL, OXCARBAZEPINE

FDA data supplied by DrugPatentWatch.com

VISKAZIDE, HYDROCHLOROTHIAZIDE
VISKEN, PINDOLOL
VIVELLE, ESTRADIOL
VIVELLE-DOT, ESTRADIOL
VOLTAREN, DICLOFENAC SODIUM
VOLTAREN-XR, DICLOFENAC SODIUM
ZOMETA, ZOLEDRONIC ACID

NOVAVAX
* NOVAVAX INC
AVC, SULFANILAMIDE

NOVEN
* NOVEN PHARMACEUTICALS INC
LIDOCAINE, LIDOCAINE

NOVEX
* NOVEX PHARMA
BETAXOLOL, BETAXOLOL HYDROCHLORIDE
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
CIMETIDINE HCL, CIMETIDINE HYDROCHLORIDE
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE
CROMOLYN SODIUM, CROMOLYN SODIUM
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
LEVOBUNOLOL HCL, LEVOBUNOLOL HYDROCHLORIDE
METAPROTERENOL SULFATE, METAPROTERENOL SULFATE
MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
MINOXIDIL (FOR WOMEN), MINOXIDIL (OTC)
MINOXIDIL EXTRA STRENGTH FOR MEN, MINOXIDIL (OTC)
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
TIMOLOL MALEATE, TIMOLOL MALEATE

NOVO NORDISK
* NOVO NORDISK PHARMACEUTICALS INC
ACTIVELLE, ESTRADIOL
GLUCAGEN, GLUCAGON HYDROCHLORIDE RECOMBINANT
INNOFEM, ESTRADIOL
INSULATARD NPH HUMAN, INSULIN SUSP ISOPHANE SEMISYNTHETIC PURIFIED HUMAN (OTC)
INSULIN INSULATARD NPH NORDISK, INSULIN SUSP ISOPHANE PURIFIED PORK (OTC)
INSULIN NORDISK MIXTARD (PORK), INSULIN PURIFIED PORK (OTC)
INSULIN, INSULIN PORK (OTC)
LENTARD, INSULIN ZINC SUSP PURIFIED BEEF/PORK (OTC)
LENTE INSULIN, INSULIN ZINC SUSP BEEF (OTC)
LENTE, INSULIN ZINC SUSP PURIFIED PORK (OTC)
MIXTARD HUMAN 70/30, INSULIN RECOMBINANT PURIFIED HUMAN (OTC)
NORDITROPIN, SOMATROPIN RECOMBINANT
NOVOLIN 70/30, INSULIN RECOMBINANT HUMAN (OTC)
NOVOLIN 70/30, INSULIN RECOMBINANT PURIFIED HUMAN (OTC)
NOVOLIN L, INSULIN ZINC SUSP RECOMBINANT HUMAN (OTC)
NOVOLIN L, INSULIN ZINC SUSP SEMISYNTHETIC PURIFIED HUMAN (OTC)
NOVOLIN N, INSULIN SUSP ISOPHANE RECOMBINANT HUMAN (OTC)
NOVOLIN N, INSULIN SUSP ISOPHANE SEMISYNTHETIC PURIFIED HUMAN (OTC)
NOVOLIN R, INSULIN RECOMBINANT HUMAN (OTC)
NOVOLIN R, INSULIN RECOMBINANT PURIFIED HUMAN (OTC)
NOVOLOG MIX 70/30, INSULIN ASPART
NOVOLOG, INSULIN ASPART
NPH INSULIN, INSULIN SUSP ISOPHANE BEEF (OTC)
NPH PURIFIED PORK ISOPHANE INSULIN, INSULIN SUSP ISOPHANE PURIFIED PORK (OTC)
PRANDIN, REPAGLINIDE
REGULAR INSULIN, INSULIN PORK (OTC)
REGULAR PURIFIED PORK INSULIN, INSULIN PURIFIED PORK (OTC)
SEMILENTE INSULIN, INSULIN ZINC SUSP PROMPT BEEF (OTC)
SEMILENTE, INSULIN ZINC SUSP PROMPT PURIFIED PORK (OTC)
ULTRALENTE INSULIN, INSULIN ZINC SUSP EXTENDED BEEF (OTC)
ULTRALENTE, INSULIN ZINC SUSP EXTENDED PURIFIED BEEF (OTC)
VAGIFEM, ESTRADIOL
VELOSULIN BR HUMAN, INSULIN RECOMBINANT PURIFIED HUMAN (OTC)
VELOSULIN BR, INSULIN RECOMBINANT HUMAN
VELOSULIN, INSULIN PURIFIED PORK (OTC)

NOVOCOL
* NOVOCOL PHARMACEUTICAL INC
ISOCAINE HCL W/ LEVONORDEFRIN, LEVONORDEFRIN
ISOCAINE HCL, MEPIVACAINE HYDROCHLORIDE

NUMARK
* NUMARK LABORATORIES INC
MELFIAT, PHENDIMETRAZINE TARTRATE
MELFIAT-105, PHENDIMETRAZINE TARTRATE
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
SPRX-105, PHENDIMETRAZINE TARTRATE

NYLOS
* NYLOS TRADING CO INC
BROMPHENIRAMINE MALEATE, BROMPHENIRAMINE MALEATE
METHOCARBAMOL, METHOCARBAMOL
PREDNISONE, PREDNISONE
TRIHEXYPHENIDYL HCL, TRIHEXYPHENIDYL HYDROCHLORIDE
TRIPELENNAMINE HCL, TRIPELENNAMINE HYDROCHLORIDE

** O **

OCLASSEN
* OCLASSEN PHARMACEUTICALS INC
CONDYLOX, PODOFILOX
CORDRAN SP, FLURANDRENOLIDE
CORDRAN, FLURANDRENOLIDE
MONODOX, DOXYCYCLINE

ODYSSEY PHARMS

FDA data supplied by DrugPatentWatch.com

* ODYSSEY PHARMACEUTICALS INC
ANTABUSE, DISULFIRAM
NYSTATIN, NYSTATIN
URECHOLINE, BETHANECHOL CHLORIDE
VIVACTIL, PROTRIPTYLINE HYDROCHLORIDE

OHM
* OHM CORP
IBUPROFEN, IBUPROFEN (OTC)

OHM LABS
* OHM LABORATORIES INC
CHLORZOXAZONE, CHLORZOXAZONE
IBUPROFEN, IBUPROFEN
IBUPROHM COLD AND SINUS, IBUPROFEN (OTC)
IBUPROHM, IBUPROFEN
IBUPROHM, IBUPROFEN (OTC)
LOPERAMIDE HCL, LOPERAMIDE HYDROCHLORIDE (OTC)

ON SITE ALZA
* ON SITE ALZA JOINT VENTURE
ACTISITE, TETRACYCLINE HYDROCHLORIDE

ONY
* ONY INC
INFASURF PRESERVATIVE FREE, CALFACTANT

OPR DEVELOP LP
* OPR DEVELOPMENT LP
CAFCIT, CAFFEINE CITRATE

OPTOPICS
* OPTOPICS LABORATORIES CORP
OPTOMYCIN, CHLORAMPHENICOL
PARACAINE, PROPARACAINE HYDROCHLORIDE
SULFACEL-15, SULFACETAMIDE SODIUM

ORAPHARMA
* ORAPHARMA INC
ARESTIN, MINOCYCLINE HYDROCHLORIDE

ORGANICS LAGRANGE
* ORGANICS LAGRANGE INC
CORTICOTROPIN, CORTICOTROPIN

ORGANON
* ORGANON INC SUB AKZO NOBEL INC
MIRCETTE, DESOGESTREL
RAPLON, RAPACURONIUM BROMIDE
* ORGANON INC SUB AKZONA INC
ARDUAN, PIPECURONIUM BROMIDE
CALDEROL, CALCIFEDIOL
CORTROPHIN-ZINC, CORTICOTROPIN-ZINC HYDROXIDE
CORTROSYN, COSYNTROPIN
COTAZYM, LIPASE
DECA-DURABOLIN, NANDROLONE DECANOATE
DESOGEN, DESOGESTREL
DOCA, DESOXYCORTICOSTERONE ACETATE
DURABOLIN, NANDROLONE PHENPROPIONATE
FOLLISTIM, FOLLITROPIN ALFA/BETA
FUROSEMIDE, FUROSEMIDE
HEPARIN SODIUM, HEPARIN SODIUM
HEXADROL, DEXAMETHASONE
HEXADROL, DEXAMETHASONE SODIUM PHOSPHATE
HUMEGON, MENOTROPINS (FSH;LH)
LIQUAEMIN LOCK FLUSH, HEPARIN SODIUM
LIQUAEMIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
LIQUAEMIN SODIUM, HEPARIN SODIUM
LIQUAMAR, PHENPROCOUMON
LYNORAL, ETHINYL ESTRADIOL
MAXIBOLIN, ETHYLESTRENOL
METHYLPREDNISOLONE, METHYLPREDNISOLONE SODIUM SUCCINATE
NORCURON, VECURONIUM BROMIDE
ORGARAN, DANAPAROID SODIUM
ORGATRAX, HYDROXYZINE HYDROCHLORIDE
PAVULON, PANCURONIUM BROMIDE
PREGNYL, GONADOTROPIN, CHORIONIC
PURIFIED CORTROPHIN GEL, CORTICOTROPIN
REGONOL, PYRIDOSTIGMINE BROMIDE
REMERON, MIRTAZAPINE
REVERSOL, EDROPHONIUM CHLORIDE
SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
WIGRAINE, CAFFEINE
WIGRETTES, ERGOTAMINE TARTRATE
ZEMURON (P/F), ROCURONIUM BROMIDE
ZEMURON, ROCURONIUM BROMIDE

ORGANON INC
* ORGANON INC
ANTAGON, GANIRELIX ACETATE
CYCLESSA, DESOGESTREL
NUVARING, ETHINYL ESTRADIOL
REMERON SOLTAB, MIRTAZAPINE

ORION
* ORION CORP
COMTAN, ENTACAPONE
FARESTON, TOREMIFENE CITRATE

ORPHAN MEDCL
* ORPHAN MEDICAL INC
ANTIZOL, FOMEPIZOLE
BUSULFEX, BUSULFAN
CYSTADANE, BETAINE, ANHYDROUS
ELLIOTTS B SOLUTION, CALCIUM CHLORIDE
SUCRAID, SACROSIDASE

FDA data supplied by DrugPatentWatch.com

ORTHO MCNEIL
* ORTHO MCNEIL PHARMACEUTICAL
HALDOL, HALOPERIDOL
HALDOL, HALOPERIDOL DECANOATE
HALDOL, HALOPERIDOL LACTATE
TOPAMAX SPRINKLE, TOPIRAMATE
TOPAMAX, TOPIRAMATE

OTSUKA
* OTSUKA PHARMACEUTICAL CO LTD
PLETAL, CILOSTAZOL
RAXAR, GREPAFLOXACIN HYDROCHLORIDE

OXFORD PHARM
* OXFORD PHARMACEUTICAL SERVICES INC
MARPLAN, ISOCARBOXAZID

** P **

PACIFIC PHARMA
* PACIFIC PHARMA
TIMOLOL MALEATE, TIMOLOL MALEATE
* PACIFIC PHARMA INC
TIMOLOL MALEATE, TIMOLOL MALEATE

PACO
* PACO PHARMACEUTICAL SERVICES INC
LACTULOSE, LACTULOSE
* PACO RESEARCH CORP
GENTAMICIN SULFATE, GENTAMICIN SULFATE
LIDOCAINE HCL, LIDOCAINE HYDROCHLORIDE
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
THIOTHIXENE HCL, THIOTHIXENE HYDROCHLORIDE

PADDOCK
* PADDOCK LABORATORIES INC
BACITRACIN, BACITRACIN
CLINDA-DERM, CLINDAMYCIN PHOSPHATE
COLOCORT, HYDROCORTISONE
COMPRO, PROCHLORPERAZINE
ERYTHRA-DERM, ERYTHROMYCIN
ERYTHROMYCIN, ERYTHROMYCIN
HYDROCORTISONE, HYDROCORTISONE
KIONEX, SODIUM POLYSTYRENE SULFONATE
NYSTATIN, NYSTATIN
NYSTOP, NYSTATIN
POLYMYXIN B SULFATE, POLYMYXIN B SULFATE

PAL PAK
* PAL PAK INC
AMINOPHYLLINE, AMINOPHYLLINE
RAUVAL, RAUWOLFIA SERPENTINA
TRIPLE SULFOID, TRISULFAPYRIMIDINES (SULFADIAZINE; SULFAMERAZINE;SULFAMETHAZINE)

PANRAY
* PANRAY CORP SUB ORMONT DRUG AND CHEMICAL CO INC
AMINOPHYLLINE, AMINOPHYLLINE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
CINNASIL, RESCINNAMINE
CORTISONE ACETATE, CORTISONE ACETATE
HYDROCORTISONE, HYDROCORTISONE
ISONIAZID, ISONIAZID
KOGLUCOID, RAUWOLFIA SERPENTINA
PARASAL SODIUM, AMINOSALICYLATE SODIUM
PARASAL, AMINOSALICYLIC ACID
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
PROCAPAN, PROCAINAMIDE HYDROCHLORIDE
SERPANRAY, RESERPINE
THEOLIXIR, THEOPHYLLINE

PAR PHARM
* PAR PHARMACEUTICAL INC
ACEBUTOLOL HCL, ACEBUTOLOL HYDROCHLORIDE
ALLOPURINOL, ALLOPURINOL
AMILORIDE HCL, AMILORIDE HYDROCHLORIDE
AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
BROMPHENIRAMINE MALEATE, BROMPHENIRAMINE MALEATE
BUSPIRONE HCL, BUSPIRONE HYDROCHLORIDE
CAPTOPRIL, CAPTOPRIL
CARISOPRODOL AND ASPIRIN, ASPIRIN
CHLORDIAZEPOXIDE AND AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
CHLORPROPAMIDE, CHLORPROPAMIDE
CHLORZOXAZONE, CHLORZOXAZONE
CLOMIPHENE CITRATE, CLOMIPHENE CITRATE
CLONIDINE HCL AND CHLORTHALIDONE, CHLORTHALIDONE
CLONIDINE HCL, CLONIDINE HYDROCHLORIDE
CYPROHEPTADINE HCL, CYPROHEPTADINE HYDROCHLORIDE
DEXAMETHASONE, DEXAMETHASONE
DIAZEPAM, DIAZEPAM
DIPHENOXYLATE HCL AND ATROPINE SULFATE, ATROPINE SULFATE
DISULFIRAM, DISULFIRAM
DOXEPIN HCL, DOXEPIN HYDROCHLORIDE
DOXY-SLEEP-AID, DOXYLAMINE SUCCINATE (OTC)
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DOXYCYCLINE, DOXYCYCLINE
FENOPROFEN CALCIUM, FENOPROFEN CALCIUM
FLUPHENAZINE HCL, FLUPHENAZINE HYDROCHLORIDE
FLURAZEPAM HCL, FLURAZEPAM HYDROCHLORIDE
HALOPERIDOL, HALOPERIDOL
HYDRA-ZIDE, HYDRALAZINE HYDROCHLORIDE
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

HYDRO-RIDE, AMILORIDE HYDROCHLORIDE
HYDROFLUMETHIAZIDE, HYDROFLUMETHIAZIDE
HYDROXYUREA, HYDROXYUREA
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
IMIPRAMINE HCL, IMIPRAMINE HYDROCHLORIDE
INDOMETHACIN, INDOMETHACIN
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
LORAZEPAM, LORAZEPAM
MECLIZINE HCL, MECLIZINE HYDROCHLORIDE
MECLOFENAMATE SODIUM, MECLOFENAMATE SODIUM
MEGESTROL ACETATE, MEGESTROL ACETATE
MEPROBAMATE AND ASPIRIN, ASPIRIN
METAPROTERENOL SULFATE, METAPROTERENOL SULFATE
METHOCARBAMOL AND ASPIRIN, ASPIRIN
METHOCARBAMOL, METHOCARBAMOL
METHYCLOTHIAZIDE, METHYCLOTHIAZIDE
METHYLDOPA AND CHLOROTHIAZIDE, CHLOROTHIAZIDE
METHYLDOPA AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
METHYLDOPA, METHYLDOPA
METHYLPREDNISOLONE, METHYLPREDNISOLONE
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
METRONIDAZOLE, METRONIDAZOLE
MINOXIDIL, MINOXIDIL
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
NYSTATIN, NYSTATIN
ORPHENGESIC FORTE, ASPIRIN
ORPHENGESIC, ASPIRIN
PERPHENAZINE AND AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
PROPANTHELINE BROMIDE, PROPANTHELINE BROMIDE
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
RANITIDINE HCL, RANITIDINE HYDROCHLORIDE
RESERPINE AND HYDROFLUMETHIAZIDE, HYDROFLUMETHIAZIDE
SULFAMETHOPRIM, SULFAMETHOXAZOLE
SULFAMETHOPRIM-DS, SULFAMETHOXAZOLE
SULFINPYRAZONE, SULFINPYRAZONE
TEMAZEPAM, TEMAZEPAM
THIORIDAZINE HCL, THIORIDAZINE HYDROCHLORIDE
TOLAZAMIDE, TOLAZAMIDE
TRICHLORMETHIAZIDE, TRICHLORMETHIAZIDE
VALPROIC ACID, VALPROIC ACID

PARKE DAVIS

* PARKE DAVIS
ACCURETIC, HYDROCHLOROTHIAZIDE
LOESTRIN 21 1.5/30, ETHINYL ESTRADIOL
LOESTRIN 21 1/20, ETHINYL ESTRADIOL
* PARKE DAVIS DIV WARNER LAMBERT CO
ACCUPRIL, QUINAPRIL HYDROCHLORIDE
AMBODRYL, BROMODIPHENHYDRAMINE HYDROCHLORIDE
AMCILL, AMPICILLIN/AMPICILLIN TRIHYDRATE
BENADRYL PRESERVATIVE FREE, DIPHENHYDRAMINE HYDROCHLORIDE
BENADRYL, DIPHENHYDRAMINE HYDROCHLORIDE
BENYLIN, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
CAMOQUIN HCL, AMODIAQUINE HYDROCHLORIDE
CELONTIN, METHSUXIMIDE
CENTRAX, PRAZEPAM
CEREBYX, FOSPHENYTOIN SODIUM
CHLORDIAZEPOXIDE HCL, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHOLEDYL SA, OXTRIPHYLLINE
CHOLEDYL, OXTRIPHYLLINE
CHOLYBAR, CHOLESTYRAMINE
COLY-MYCIN S, COLISTIN SULFATE
DILANTIN, PHENYTOIN
DILANTIN, PHENYTOIN SODIUM, EXTENDED
DILANTIN-125, PHENYTOIN
DILANTIN-30, PHENYTOIN
DIPHENOXYLATE HCL AND ATROPINE SULFATE, ATROPINE SULFATE
ERGOSTAT, ERGOTAMINE TARTRATE
ERYC 125, ERYTHROMYCIN
ERYC, ERYTHROMYCIN
ERYPAR, ERYTHROMYCIN STEARATE
ERYTHROMYCIN ETHYLSUCCINATE, ERYTHROMYCIN ETHYLSUCCINATE
ESTROVIS, QUINESTROL
EUTHROID-0.5, LIOTRIX (T4;T3)
EUTHROID-1, LIOTRIX (T4;T3)
EUTHROID-2, LIOTRIX (T4;T3)
EUTHROID-3, LIOTRIX (T4;T3)
EVANS BLUE, EVANS BLUE
HEPARIN LOCK FLUSH, HEPARIN SODIUM
HEPARIN SODIUM, HEPARIN SODIUM
HUMATIN, PAROMOMYCIN SULFATE
HYDROCORTISONE ACETATE, HYDROCORTISONE ACETATE
HYDROCORTISONE, HYDROCORTISONE
INDOMETHACIN, INDOMETHACIN
ISOPROTERENOL HCL, ISOPROTERENOL HYDROCHLORIDE
LOESTRIN FE 1.5/30, ETHINYL ESTRADIOL
LOESTRIN FE 1/20, ETHINYL ESTRADIOL
MECLOMEN, MECLOFENAMATE SODIUM
MEPERIDINE HCL, MEPERIDINE HYDROCHLORIDE
MEPROBAMATE, MEPROBAMATE
METHYLDOPA AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
METHYLDOPA, METHYLDOPA
METHYLTESTOSTERONE, METHYLTESTOSTERONE
MILONTIN, PHENSUXIMIDE
NARDIL, PHENELZINE SULFATE
NEURONTIN, GABAPENTIN
NITROSTAT, NITROGLYCERIN
NORLUTATE, NORETHINDRONE ACETATE
NORLUTIN, NORETHINDRONE
OXAZEPAM, OXAZEPAM

FDA data supplied by DrugPatentWatch.com

PARACORT, PREDNISONE
PARSIDOL, ETHOPROPAZINE HYDROCHLORIDE
PENAPAR-VK, PENICILLIN V POTASSIUM
PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM
PENICILLIN G PROCAINE, PENICILLIN G PROCAINE
PITRESSIN TANNATE, VASOPRESSIN TANNATE
POVAN, PYRVINIUM PAMOATE
PRE-SATE, CHLORPHENTERMINE HYDROCHLORIDE
PROCAN SR, PROCAINAMIDE HYDROCHLORIDE
PROCAN, PROCAINAMIDE HYDROCHLORIDE
PROLOID, THYROGLOBULIN
PROMAPAR, CHLORPROMAZINE HYDROCHLORIDE
SECOBARBITAL SODIUM, SECOBARBITAL SODIUM
SODIUM PENTOBARBITAL, PENTOBARBITAL SODIUM
SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SULFALAR, SULFISOXAZOLE
THIAMINE HCL, THIAMINE HYDROCHLORIDE
TOLBUTAMIDE, TOLBUTAMIDE
TRIPELENNAMINE HCL, TRIPELENNAMINE HYDROCHLORIDE
UTICORT, BETAMETHASONE BENZOATE
UTIMOX, AMOXICILLIN
ZARONTIN, ETHOSUXIMIDE

* PARKE DAVIS LABORATORIES DIV WARNER LAMBERT CO
NORLESTRIN 21 1/50, ETHINYL ESTRADIOL
NORLESTRIN 21 2.5/50, ETHINYL ESTRADIOL
NORLESTRIN 28 1/50, ETHINYL ESTRADIOL
NORLESTRIN FE 1/50, ETHINYL ESTRADIOL
NORLESTRIN FE 2.5/50, ETHINYL ESTRADIOL

* PARKE DAVIS PHARMACEUTICAL RESEARCH DIV WARNER LAMBERT CO
CHLOROMYCETIN PALMITATE, CHLORAMPHENICOL PALMITATE
CHLOROMYCETIN, CHLORAMPHENICOL
CHLOROMYXIN, CHLORAMPHENICOL
DILANTIN, PHENYTOIN SODIUM
ELASE-CHLOROMYCETIN, CHLORAMPHENICOL
ESTROSTEP 21, ETHINYL ESTRADIOL
ESTROSTEP FE, ETHINYL ESTRADIOL
FEMPATCH, ESTRADIOL
ISOETHARINE HCL, ISOETHARINE HYDROCHLORIDE
NEURONTIN, GABAPENTIN
NITROSTAT, NITROGLYCERIN
UTICORT, BETAMETHASONE BENZOATE
ZARONTIN, ETHOSUXIMIDE

PARKE DAVIS PHARMS
* PARKE DAVIS PHARMACEUTICALS LTD
FEMHRT, ETHINYL ESTRADIOL
LOPID, GEMFIBROZIL
REZULIN, TROGLITAZONE

PARKEDALE
* PARKEDALE PHARMACEUTICALS INC
ACTH, CORTICOTROPIN
ANUSOL HC, HYDROCORTISONE
CHLOROMYCETIN HYDROCORTISONE, CHLORAMPHENICOL
CHLOROMYCETIN, CHLORAMPHENICOL
CHLOROMYCETIN, CHLORAMPHENICOL SODIUM SUCCINATE
COLY-MYCIN M, COLISTIMETHATE SODIUM
COLY-MYCIN S, COLISTIN SULFATE
HUMATIN, PAROMOMYCIN SULFATE
KETALAR, KETAMINE HYDROCHLORIDE
OPHTHOCHLOR, CHLORAMPHENICOL
OPHTHOCORT, CHLORAMPHENICOL
PITOCIN, OXYTOCIN
PROCAN SR, PROCAINAMIDE HYDROCHLORIDE
SURITAL, THIAMYLAL SODIUM
THEELIN, ESTRONE
VIRA-A, VIDARABINE

PARNELL
* PARNELL PHARMACEUTICALS INC
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

PEACHTREE
* PEACHTREE PHARMACEUTICALS
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN

PEDINOL
* PEDINOL PHARMACAL INC
GRIS-PEG, GRISEOFULVIN, ULTRAMICROCRYSTALLINE

PENNEX
* PENNEX PRODUCTS CO INC
ALUMINUM HYDROXIDE AND MAGNESIUM TRISILICATE, ALUMINUM HYDROXIDE (OTC)

PERRIGO
* L PERRIGO CO
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
ACETAMINOPHEN, ASPIRIN AND CAFFEINE, ACETAMINOPHEN (OTC)
ANTITUSSIVE, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
CAP-PROFEN, IBUPROFEN (OTC)
CHILDREN'S IBUPROFEN, IBUPROFEN (OTC)
CIMETIDINE, CIMETIDINE (OTC)
CROMOLYN SODIUM, CROMOLYN SODIUM (OTC)
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DOXYLAMINE SUCCINATE, DOXYLAMINE SUCCINATE (OTC)
IBUPROFEN, IBUPROFEN (OTC)
ISONIAZID, ISONIAZID
LOPERAMIDE HCL, LOPERAMIDE HYDROCHLORIDE (OTC)
MEPROBAMATE, MEPROBAMATE
MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
PROPYLTHIOURACIL, PROPYLTHIOURACIL

FDA data supplied by DrugPatentWatch.com

QUINIDINE SULFATE, QUINIDINE SULFATE
SODIUM PENTOBARBITAL, PENTOBARBITAL SODIUM
SODIUM SECOBARBITAL, SECOBARBITAL SODIUM
TAB-PROFEN, IBUPROFEN (OTC)
THEOPHYLLINE, THEOPHYLLINE
TIOCONAZOLE, TIOCONAZOLE (OTC)

* PERRIGO CO
CIMETIDINE, CIMETIDINE (OTC)
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE (OTC)
IBUPROFEN, IBUPROFEN (OTC)
JUNIOR STRENGTH IBUPROFEN, IBUPROFEN (OTC)
LOPERAMIDE HCL, LOPERAMIDE HYDROCHLORIDE (OTC)
MICONAZOLE NITRATE COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
MINOXIDIL (FOR WOMEN), MINOXIDIL (OTC)
PSEUDOEPHEDRINE HCL, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)

PERSONAL PRODS

* PERSONAL PRODUCTS CO
DELFEN, NONOXYNOL-9 (OTC)
MONISTAT 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MONISTAT 5, MICONAZOLE NITRATE
MONISTAT DUAL- PAK, MICONAZOLE NITRATE

PFIPHARMECS

* PFIPHARMECS DIV PFIZER INC
CORTRIL, HYDROCORTISONE
TETRACYN, TETRACYCLINE HYDROCHLORIDE

PFIZER

* PFIZER AGRICULTURAL DIV
ANTIVERT, MECLIZINE HYDROCHLORIDE
NORVASC, AMLODIPINE BESYLATE
VIAGRA, SILDENAFIL CITRATE

* PFIZER CENTRAL RESEARCH
DIFLUCAN, FLUCONAZOLE
GEODON, ZIPRASIDONE HYDROCHLORIDE
TROVAN, TROVAFLOXACIN MESYLATE
ZITHROMAX, AZITHROMYCIN DIHYDRATE

* PFIZER CHEMICALS DIV PFIZER INC
DIFLUCAN, FLUCONAZOLE
TROVAN PRESERVATIVE FREE, ALATROFLOXACIN MESYLATE
ZITHROMAX, AZITHROMYCIN DIHYDRATE

* PFIZER INC
CEFOBID, CEFOPERAZONE SODIUM
DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER, FLUCONAZOLE
DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
DIFLUCAN IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE
EMETE-CON, BENZQUINAMIDE HYDROCHLORIDE
GLUCOTROL XL, GLIPIZIDE
GLUCOTROL, GLIPIZIDE
LIPITOR, ATORVASTATIN CALCIUM
LITHIUM CARBONATE, LITHIUM CARBONATE
MINIPRESS XL, PRAZOSIN HYDROCHLORIDE
MINIZIDE, POLYTHIAZIDE
NEURONTIN, GABAPENTIN
PROCARDIA, NIFEDIPINE
RENESE, POLYTHIAZIDE
RID MOUSSE, PIPERONYL BUTOXIDE (OTC)
UNASYN, AMPICILLIN SODIUM
VISINE-A, NAPHAZOLINE HYDROCHLORIDE (OTC)
ZITHROMAX, AZITHROMYCIN DIHYDRATE
ZYRTEC, CETIRIZINE HYDROCHLORIDE
ZYRTEC-D 12 HOUR, CETIRIZINE HYDROCHLORIDE

* PFIZER LABORATORIES DIV PFIZER INC
BACITRACIN, BACITRACIN
CARDURA, DOXAZOSIN MESYLATE
CEFOBID IN PLASTIC CONTAINER, CEFOPERAZONE SODIUM
CEFOBID, CEFOPERAZONE SODIUM
CORTRIL, HYDROCORTISONE
CORTRIL, HYDROCORTISONE ACETATE
DARICON, OXYPHENCYCLIMINE HYDROCHLORIDE
DIABINESE, CHLORPROPAMIDE
FELDENE, PIROXICAM
FOVANE, BENZTHIAZIDE
GEOCILLIN, CARBENICILLIN INDANYL SODIUM
MAGNACORT, HYDROCORTAMATE HYDROCHLORIDE
MINIPRESS, PRAZOSIN HYDROCHLORIDE
MITHRACIN, PLICAMYCIN
MODERIL, RESCINNAMINE
NEOBIOTIC, NEOMYCIN SULFATE
PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM
PENICILLIN G PROCAINE, PENICILLIN G PROCAINE
PERMAPEN, PENICILLIN G BENZATHINE
PFIZER-E, ERYTHROMYCIN STEARATE
PFIZERPEN G, PENICILLIN G POTASSIUM
PFIZERPEN VK, PENICILLIN V POTASSIUM
PFIZERPEN, PENICILLIN G POTASSIUM
PFIZERPEN-A, AMPICILLIN/AMPICILLIN TRIHYDRATE
PFIZERPEN-AS, PENICILLIN G PROCAINE
PROCARDIA XL, NIFEDIPINE
RENESE-R, POLYTHIAZIDE
SINEQUAN, DOXEPIN HYDROCHLORIDE
SPECTROBID, BACAMPICILLIN HYDROCHLORIDE
STERANE, PREDNISOLONE
STERANE, PREDNISOLONE ACETATE
STREPTOMYCIN SULFATE, STREPTOMYCIN SULFATE
TAO, TROLEANDOMYCIN
TERRA-CORTRIL, HYDROCORTISONE ACETATE
TERRAMYCIN W/ POLYMYXIN B SULFATE, OXYTETRACYCLINE HYDROCHLORIDE
TERRAMYCIN W/ POLYMYXIN, OXYTETRACYCLINE HYDROCHLORIDE
TERRAMYCIN, LIDOCAINE HYDROCHLORIDE
TERRAMYCIN, OXYTETRACYCLINE

FDA data supplied by DrugPatentWatch.com

TERRAMYCIN, OXYTETRACYCLINE CALCIUM
TERRAMYCIN, OXYTETRACYCLINE HYDROCHLORIDE
TERRAMYCIN-POLYMYXIN, OXYTETRACYCLINE HYDROCHLORIDE
TETRACYN, PROCAINE HYDROCHLORIDE
TETRACYN, TETRACYCLINE HYDROCHLORIDE
TZ-3, TIOCONAZOLE (OTC)
UNASYN, AMPICILLIN SODIUM
UNISOM, DOXYLAMINE SUCCINATE (OTC)
URESE, BENZTHIAZIDE
VANSIL, OXAMNIQUINE
VIBRA-TABS, DOXYCYCLINE HYCLATE
VIBRAMYCIN, DOXYCYCLINE
VIBRAMYCIN, DOXYCYCLINE CALCIUM
VIBRAMYCIN, DOXYCYCLINE HYCLATE
VIOCIN SULFATE, VIOMYCIN SULFATE
VISINE L.R., OXYMETAZOLINE HYDROCHLORIDE (OTC)
VISTARIL, HYDROXYZINE HYDROCHLORIDE
VISTARIL, HYDROXYZINE PAMOATE

* PFIZER PHARMACEUTICALS INC
TAO, TROLEANDOMYCIN
TROVAN/ZITHROMAX COMPLIANCE PAK, AZITHROMYCIN DIHYDRATE
ZOLOFT, SERTRALINE HYDROCHLORIDE

* PFIZER PHARMACEUTICALS PRODUCTION CORP LTD
TIKOSYN, DOFETILIDE

PHARM ASSOC

* PHARMACEUTICAL ASSOC INC
NORTRIPTYLINE HCL, NORTRIPTYLINE HYDROCHLORIDE
PERPHENAZINE, PERPHENAZINE

* PHARMACEUTICAL ASSOC INC DIV BEACH PRODUCTS
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
AMANTADINE HCL, AMANTADINE HYDROCHLORIDE
BROMPHENIRAMINE MALEATE, BROMPHENIRAMINE MALEATE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
CHLORPROMAZINE HCL, CHLORPROMAZINE HYDROCHLORIDE
CIMETIDINE HCL, CIMETIDINE HYDROCHLORIDE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
ETHOSUXIMIDE, ETHOSUXIMIDE
FLUPHENAZINE HCL, FLUPHENAZINE HYDROCHLORIDE
H-CORT, HYDROCORTISONE
HALOPERIDOL, HALOPERIDOL LACTATE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
LACTULOSE, LACTULOSE
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
PROMETHAZINE HCL AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE
THEOPHYLLINE, THEOPHYLLINE
THIORIDAZINE HCL, THIORIDAZINE HYDROCHLORIDE
TRIHEXYPHENIDYL HCL, TRIHEXYPHENIDYL HYDROCHLORIDE
TRIPROLIDINE HCL, TRIPROLIDINE HYDROCHLORIDE
VALPROIC ACID, VALPROIC ACID

PHARM FORM

* PHARMACEUTICAL FORMULATIONS INC
CIMETIDINE, CIMETIDINE (OTC)
IBUPROFEN, IBUPROFEN (OTC)

PHARM SPEC

* PHARMACEUTICAL SPECIALIST ASSOC
GENTAMICIN SULFATE, GENTAMICIN SULFATE
HEPARIN SODIUM, HEPARIN SODIUM

PHARM VENTURES

* PHARMACEUTICAL VENTURES LTD
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
TRIHEXYPHENIDYL HCL, TRIHEXYPHENIDYL HYDROCHLORIDE

PHARMA SERVE NY

* PHARMA SERVE INC SUB TORIGIAN LABORATORIES
AMINOPHYLLINE, AMINOPHYLLINE
HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE

PHARMA TEK

* PHARMA TEK INC
AMPHOTERICIN B, AMPHOTERICIN B
BACI-RX, BACITRACIN
BACIIM, BACITRACIN
COLISTIMETHATE, COLISTIMETHATE SODIUM
HYDROCORTISONE ACETATE, HYDROCORTISONE ACETATE
HYDROCORTISONE, HYDROCORTISONE
NEO-RX, NEOMYCIN SULFATE
POLY-RX, POLYMYXIN B SULFATE
POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
STREPTOMYCIN SULFATE, STREPTOMYCIN SULFATE
TOBRAMYCIN, TOBRAMYCIN SULFATE
ZIBA-RX, BACITRACIN ZINC

PHARMACHEMIE

* PHARMACHEMIE BV
CISPLATIN, CISPLATIN
DOXORUBICIN HCL, DOXORUBICIN HYDROCHLORIDE
ETOPOSIDE, ETOPOSIDE
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
TAMOXIFEN CITRATE, TAMOXIFEN CITRATE

PHARMACHEMIE USA

* PHARMACHEMIE USA INC
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
METHOTREXATE SODIUM, METHOTREXATE SODIUM

PHARMACIA AND UPJOHN

* PHARMACIA AND UPJOHN CO
ADRIAMYCIN PFS, DOXORUBICIN HYDROCHLORIDE
ADRIAMYCIN RDF, DOXORUBICIN HYDROCHLORIDE
ADRUCIL, FLUOROURACIL

FDA data supplied by DrugPatentWatch.com

ALBAMYCIN, NOVOBIOCIN SODIUM
ALPHADROL, FLUPREDNISOLONE
ANSAID, FLURBIPROFEN
AROMASIN, EXEMESTANE
AXERT, ALMOTRIPTAN MALATE
AZULFIDINE EN-TABS, SULFASALAZINE
AZULFIDINE, SULFASALAZINE
BACIGUENT, BACITRACIN
BACITRACIN, BACITRACIN
BERUBIGEN, CYANOCOBALAMIN
BLEOMYCIN SULFATE, BLEOMYCIN SULFATE
CALMURID HC, HYDROCORTISONE
CAMPTOSAR, IRINOTECAN HYDROCHLORIDE
CARDRASE, ETHOXZOLAMIDE
CAVERJECT, ALPROSTADIL
CLEOCIN HCL, CLINDAMYCIN HYDROCHLORIDE
CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE
CLEOCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLEOCIN T, CLINDAMYCIN PHOSPHATE
CLEOCIN, CLINDAMYCIN HYDROCHLORIDE
CLEOCIN, CLINDAMYCIN PALMITATE HYDROCHLORIDE
CLEOCIN, CLINDAMYCIN PHOSPHATE
COLESTID, COLESTIPOL HYDROCHLORIDE
CORTEF ACETATE, HYDROCORTISONE ACETATE
CORTEF, HYDROCORTISONE
CORTEF, HYDROCORTISONE CYPIONATE
CORTISONE ACETATE, CORTISONE ACETATE
CORVERT, IBUTILIDE FUMARATE
CYKLOKAPRON, TRANEXAMIC ACID
CYTOSAR-U, CYTARABINE
DELTA-CORTEF, PREDNISOLONE
DELTASONE, PREDNISONE
DEPO-ESTRADIOL, ESTRADIOL CYPIONATE
DEPO-MEDROL, METHYLPREDNISOLONE ACETATE
DEPO-PROVERA, MEDROXYPROGESTERONE ACETATE
DEPO-TESTADIOL, ESTRADIOL CYPIONATE
DEPO-TESTOSTERONE, TESTOSTERONE CYPIONATE
DETROL LA, TOLTERODINE TARTRATE
DETROL, TOLTERODINE TARTRATE
DIDREX, BENZPHETAMINE HYDROCHLORIDE
DIPENTUM, OLSALAZINE SODIUM
DIZAC, DIAZEPAM
DOSTINEX, CABERGOLINE
E-MYCIN E, ERYTHROMYCIN ETHYLSUCCINATE
EMCYT, ESTRAMUSTINE PHOSPHATE SODIUM
ESTRING, ESTRADIOL
FEMINONE, ETHINYL ESTRADIOL
FLAVORED COLESTID, COLESTIPOL HYDROCHLORIDE
FLORONE E, DIFLORASONE DIACETATE
FLORONE, DIFLORASONE DIACETATE
FLUIDIL, CYCLOTHIAZIDE
FOLEX PFS, METHOTREXATE SODIUM
FOLEX, METHOTREXATE SODIUM
FRAGMIN, DALTEPARIN SODIUM
GENOTROPIN PRESERVATIVE FREE, SOMATROPIN RECOMBINANT
GENOTROPIN, SOMATROPIN RECOMBINANT
GLYNASE, GLYBURIDE
GLYSET, MIGLITOL
HALCION, TRIAZOLAM
HALOTESTIN, FLUOXYMESTERONE
HEMABATE, CARBOPROST TROMETHAMINE
HEPARIN SODIUM, HEPARIN SODIUM
HYLOREL, GUANADREL SULFATE
IDAMYCIN PFS, IDARUBICIN HYDROCHLORIDE
IDAMYCIN, IDARUBICIN HYDROCHLORIDE
LINCOCIN, LINCOMYCIN HYDROCHLORIDE
LONITEN, MINOXIDIL
LUNELLE, ESTRADIOL CYPIONATE
MAOLATE, CHLORPHENESIN CARBAMATE
MEDROL ACETATE, METHYLPREDNISOLONE ACETATE
MEDROL, METHYLPREDNISOLONE
MEDROL, METHYLPREDNISOLONE ACETATE
MICRONASE, GLYBURIDE
MIRAPEX, PRAMIPEXOLE DIHYDROCHLORIDE
MYCIFRADIN, NEOMYCIN SULFATE
MYCITRACIN, BACITRACIN
MYCOBUTIN, RIFABUTIN
NEO-CORTEF, HYDROCORTISONE ACETATE
NEO-DELTA-CORTEF, NEOMYCIN SULFATE
NEO-MEDROL ACETATE, METHYLPREDNISOLONE ACETATE
NEO-MEDROL, METHYLPREDNISOLONE
NEOSAR, CYCLOPHOSPHAMIDE
NICOTROL, NICOTINE
NICOTROL, NICOTINE (OTC)
NORMIFLO, ARDEPARIN SODIUM
OGEN .625, ESTROPIPATE
OGEN 1.25, ESTROPIPATE
OGEN 2.5, ESTROPIPATE
OGEN 5, ESTROPIPATE
OGEN, ESTROPIPATE
ORINASE DIAGNOSTIC, TOLBUTAMIDE SODIUM
ORINASE, TOLBUTAMIDE
OXYLONE, FLUOROMETHOLONE
PANMYCIN, TETRACYCLINE HYDROCHLORIDE
PENICILLIN G SODIUM, PENICILLIN G SODIUM
PREPIDIL, DINOPROSTONE
PROSTIN E2, DINOPROSTONE
PROSTIN F2 ALPHA, DINOPROST TROMETHAMINE
PROSTIN VR PEDIATRIC, ALPROSTADIL
PROTAMINE SULFATE, PROTAMINE SULFATE
PROVERA, MEDROXYPROGESTERONE ACETATE
PSORCON, DIFLORASONE DIACETATE
R-GENE 10, ARGININE HYDROCHLORIDE
ROGAINE (FOR MEN), MINOXIDIL (OTC)
ROGAINE (FOR WOMEN), MINOXIDIL (OTC)

FDA data supplied by DrugPatentWatch.com

ROGAINE EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
SOLU-CORTEF, HYDROCORTISONE SODIUM SUCCINATE
SOLU-MEDROL, METHYLPREDNISOLONE SODIUM SUCCINATE
TOLINASE, TOLAZAMIDE
TOPOSAR, ETOPOSIDE
TRELSTAR DEPOT, TRIPTORELIN PAMOATE
TRELSTAR, TRIPTORELIN PAMOATE
TROBICIN, SPECTINOMYCIN HYDROCHLORIDE
TYMTRAN, CERULETIDE DIETHYLAMINE
U-GENCIN, GENTAMICIN SULFATE
UTICILLIN VK, PENICILLIN V POTASSIUM
VANCOR, VANCOMYCIN HYDROCHLORIDE
VANTIN, CEFPODOXIME PROXETIL
VINCASAR PFS, VINCRISTINE SULFATE
XALATAN, LATANOPROST
XANAX, ALPRAZOLAM
ZANOSAR, STREPTOZOCIN
ZEFAZONE IN PLASTIC CONTAINER, CEFMETAZOLE SODIUM
ZEFAZONE, CEFMETAZOLE SODIUM
ZINECARD, DEXRAZOXANE HYDROCHLORIDE
ZYVOX, LINEZOLID

* PHARMACIA AND UPJOHN CO NUTRITION DIV
ELLENCE, EPIRUBICIN HYDROCHLORIDE

PHARMACIA UPJOHN

* PHARMACIA AND UPJOHN CONSUMER HEALTHCARE
NASALCROM, CROMOLYN SODIUM (OTC)

PHARMADERM

* PHARMADERM DIV ALTANA INC
BACITRACIN, BACITRACIN
BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE, BACITRACIN
BACITRACIN-NEOMYCIN-POLYMYXIN, BACITRACIN ZINC
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
ERYTHROMYCIN, ERYTHROMYCIN
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
HYDROCORTISONE, HYDROCORTISONE
NEOMYCIN SULFATE-TRIAMCINOLONE ACETONIDE, NEOMYCIN SULFATE
NYSTATIN, NYSTATIN
NYSTATIN-TRIAMCINOLONE ACETONIDE, NYSTATIN
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
TRIPLE SULFA, TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE; SULFATHIAZOLE)

PHARMAFAIR

* PHARMAFAIR INC
BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE, BACITRACIN ZINC
BACITRACIN, BACITRACIN
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
BOROFAIR, ACETIC ACID, GLACIAL
CARBACHOL, CARBACHOL
CHLOROFAIR, CHLORAMPHENICOL
DEXAIR, DEXAMETHASONE SODIUM PHOSPHATE
DEXASPORIN, DEXAMETHASONE
ERYTHROMYCIN ETHYLSUCCINATE, ERYTHROMYCIN ETHYLSUCCINATE
ERYTHROMYCIN, ERYTHROMYCIN
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
GENTAFAIR, GENTAMICIN SULFATE
HYDROCORTISONE, HYDROCORTISONE
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
KAINAIR, PROPARACAINE HYDROCHLORIDE
KANAMYCIN SULFATE, KANAMYCIN SULFATE
MYDRIAFAIR, TROPICAMIDE
NAFAZAIR, NAPHAZOLINE HYDROCHLORIDE
NEOMYCIN & POLYMYXIN B SULFATES & BACITRACIN ZINC & HYDROCORTISONE, BACITRACIN ZINC
NEOMYCIN SULFATE AND POLYMYXIN B SULFATE GRAMICIDIN, GRAMICIDIN
NEOMYCIN SULFATE, POLYMYXIN B SULFATE & HYDROCORTISONE, HYDROCORTISONE
NEOMYCIN SULFATE-DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
NEOMYCIN SULFATE-POLYMYXIN B SULFATE-HYDROCORTISONE, HYDROCORTISONE
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
NYSTATIN, NYSTATIN
OCUMYCIN, BACITRACIN ZINC
OTICAIR, HYDROCORTISONE
PENTOLAIR, CYCLOPENTOLATE HYDROCHLORIDE
PREDAIR FORTE, PREDNISOLONE SODIUM PHOSPHATE
PREDAIR, PREDNISOLONE SODIUM PHOSPHATE
PREDSULFAIR II, PREDNISOLONE ACETATE
PREDSULFAIR, PREDNISOLONE ACETATE
PROCAINAMIDE HCL, PROCAINAMIDE HYDROCHLORIDE
SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
SULFAIR 10, SULFACETAMIDE SODIUM
SULFAIR FORTE, SULFACETAMIDE SODIUM
SULFAIR-15, SULFACETAMIDE SODIUM
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
ZINC BACITRACIN,NEOMYCIN SULFATE,POLYMYXIN B SULFATE & HYDROCORTISONE, BACITRACIN ZINC

PHARMASEAL

* PHARMASEAL DIV BAXTER HEALTHCARE CORP
PHARMASEAL SCRUB CARE, CHLORHEXIDINE GLUCONATE (OTC)

PHARMATON

* PHARMATON LTD
LIDOCATON, EPINEPHRINE
LIDOCATON, LIDOCAINE HYDROCHLORIDE

PHARMAVITE

FDA data supplied by DrugPatentWatch.com

* PHARMAVITE PHARMACEUTICALS
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
ISONIAZID, ISONIAZID
MEPROBAMATE, MEPROBAMATE
PREDNISONE, PREDNISONE
QUINIDINE SULFATE, QUINIDINE SULFATE
RESERPINE, RESERPINE

PHARMERAL
* PHARMERAL INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
BUTALBITAL W/ ASPIRIN & CAFFEINE, ASPIRIN
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
FOLIC ACID, FOLIC ACID
HYDROCHLOROTHIAZIDE W/ RESERPINE, HYDROCHLOROTHIAZIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
MEPROBAMATE, MEPROBAMATE
METHOCARBAMOL, METHOCARBAMOL
PHENYTOIN SODIUM, PHENYTOIN SODIUM, PROMPT
SULFISOXAZOLE, SULFISOXAZOLE

PHARMOS
* PHARMOS CORP
LOTEMAX, LOTEPREDNOL ETABONATE

PHOENIX LABS NY
* PHOENIX LABORATORIES INC
BROMPHENIRAMINE MALEATE, BROMPHENIRAMINE MALEATE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
DEXAMETHASONE, DEXAMETHASONE
ISONIAZID, ISONIAZID
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE

PHYS PRODS VA
* PHYSICIANS PRODUCTS CO INC DIV INTERNATIONAL LATEX CORP
HYSERPIN, RAUWOLFIA SERPENTINA

PIERRE FABRE
* PIERRE FABRE MEDICAMENT
ETOPOSIDE, ETOPOSIDE

PIONEER PHARMS
* PIONEER PHARMACEUTICALS INC
BROMPHENIRAMINE MALEATE, BROMPHENIRAMINE MALEATE
CARISOPRODOL, CARISOPRODOL
CHLORDIAZEPOXIDE HCL, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
CHLORTHALIDONE, CHLORTHALIDONE
CHLORZOXAZONE, CHLORZOXAZONE
CYPROHEPTADINE HCL, CYPROHEPTADINE HYDROCHLORIDE
DIAZEPAM, DIAZEPAM
DICYCLOMINE HCL, DICYCLOMINE HYDROCHLORIDE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
FOLIC ACID, FOLIC ACID
INDOMETHACIN, INDOMETHACIN
METHOCARBAMOL, METHOCARBAMOL
RESPORAL, DEXBROMPHENIRAMINE MALEATE (OTC)

PLANTEX
* PLANTEX USA INC DIV IKAPHARM INC
SULFAMETHOXAZOLE AND TRIMETHOPRIM SINGLE STRENGTH, SULFAMETHOXAZOLE

POHL BOSKAMP
* G POHL BOSKAMP GMBH AND CO
NITRO IV, NITROGLYCERIN
NITROLINGUAL PUMPSPRAY, NITROGLYCERIN
NITROLINGUAL, NITROGLYCERIN
NITRONAL, NITROGLYCERIN

POINT HOLDINGS
* POINT HOLDINGS INC
ETODOLAC, ETODOLAC

POLYMEDICA
* POLYMEDICA INDUSTRIES INC
ANESTACON, LIDOCAINE HYDROCHLORIDE
NEOPAP, ACETAMINOPHEN (OTC)
PROMETHACON, PROMETHAZINE HYDROCHLORIDE

POPULATION COUNCIL
* POPULATION COUNCIL
COPPER T MODEL TCU 380A, COPPER
MIFEPREX, MIFEPRISTONE
NORPLANT, LEVONORGESTREL
* POPULATION COUNCIL CENTER FOR BIOMEDICAL RESEARCH
NORPLANT II, LEVONORGESTREL

POYTHRESS
* WILLIAM P POYTHRESS AND CO INC
BENSULFOID, SULFUR

PROCTER AND GAMBLE
* PROCTER AND GAMBLE CO
DANTRIUM, DANTROLENE SODIUM
HEAD & SHOULDERS CONDITIONER, PYRITHIONE ZINC (OTC)
MACRODANTIN, NITROFURANTOIN, MACROCRYSTALLINE
VICKS FORMULA 44, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
* PROCTER AND GAMBLE PHARMACEUTICALS INC SUB PROCTER AND GAMBL
ACTONEL, RISEDRONATE SODIUM
ASACOL, MESALAMINE
DANTRIUM, DANTROLENE SODIUM
DIDRONEL, ETIDRONATE DISODIUM
FURADANTIN, NITROFURANTOIN
IVADANTIN, NITROFURANTOIN SODIUM

FDA data supplied by DrugPatentWatch.com

LABID, THEOPHYLLINE
MACROBID, NITROFURANTOIN
NYSERT, NYSTATIN
ORLEX HC, ACETIC ACID, GLACIAL
ORLEX, ACETIC ACID, GLACIAL
SARENIN, SARALASIN ACETATE

PROF DSPLS
* PROFESSIONAL DISPOSABLES INC
HEXASCRUB, HEXACHLOROPHENE

PROMETHEUS LABS
* PROMETHEUS LABORATORIES INC
HELIDAC, BISMUTH SUBSALICYLATE
IMURAN, AZATHIOPRINE
IMURAN, AZATHIOPRINE SODIUM
RIDAURA, AURANOFIN
TRANDATE, LABETALOL HYDROCHLORIDE
ZYLOPRIM, ALLOPURINOL

PROTER
* PROTER LABORATORY SPA
OXYTETRACYCLINE HCL, OXYTETRACYCLINE HYDROCHLORIDE
TETRACYCLINE HCL, TETRACYCLINE HYDROCHLORIDE

PURDUE FREDERICK
* PURDUE FREDERICK CO
ATHROMBIN, WARFARIN SODIUM
ATHROMBIN-K, WARFARIN POTASSIUM
CARDIOQUIN, QUINIDINE POLYGALACTURONATE
CERUMENEX, TROLAMINE POLYPEPTIDE OLEATE CONDENSATE
DHC PLUS, ACETAMINOPHEN
MS CONTIN, MORPHINE SULFATE
PHENY-PAS-TEBAMIN, PHENYL AMINOSALICYLATE
PHYLLOCONTIN, AMINOPHYLLINE
SULFABID, SULFAPHENAZOLE
T-PHYL, THEOPHYLLINE
UNIPHYL, THEOPHYLLINE

PURDUE PHARMA LP
* PURDUE PHARMA LP
CHIROCAINE, LEVOBUPIVACAINE HYDROCHLORIDE
OXYCONTIN, OXYCODONE HYDROCHLORIDE

PUREPAC PHARM
* PUREPAC PHARMACEUTICAL CO DIV PUREPAC INC
ACETAMINOPHEN AND CODEINE PHOSPHATE #3, ACETAMINOPHEN
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACYCLOVIR, ACYCLOVIR
ALLOPURINOL, ALLOPURINOL
ALPRAZOLAM, ALPRAZOLAM
AMINOPHYLLINE, AMINOPHYLLINE
AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
AMPICILLIN TRIHYDRATE, AMPICILLIN/AMPICILLIN TRIHYDRATE
ASPIRIN AND CAFFEINE W/ BUTALBITAL, ASPIRIN
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
CAPTOPRIL, CAPTOPRIL
CARBAMAZEPINE, CARBAMAZEPINE
CARBIDOPA AND LEVODOPA, CARBIDOPA
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CEPHALEXIN, CEPHALEXIN
CHLORDIAZEPOXIDE HCL, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
CHLORPROMAZINE HCL, CHLORPROMAZINE HYDROCHLORIDE
CHLORTHALIDONE, CHLORTHALIDONE
CLONAZEPAM, CLONAZEPAM
CLONIDINE HCL, CLONIDINE HYDROCHLORIDE
CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
CORTISONE ACETATE, CORTISONE ACETATE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DIAZEPAM, DIAZEPAM
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DIFLUNISAL, DIFLUNISAL
DILTIAZEM HCL, DILTIAZEM HYDROCHLORIDE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DIPYRIDAMOLE, DIPYRIDAMOLE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
DOXEPIN HCL, DOXEPIN HYDROCHLORIDE
ERYTHROMYCIN STEARATE, ERYTHROMYCIN STEARATE
ETODOLAC, ETODOLAC
FAMOTIDINE, FAMOTIDINE
FENOPROFEN CALCIUM, FENOPROFEN CALCIUM
FLURAZEPAM HCL, FLURAZEPAM HYDROCHLORIDE
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
FOLIC ACID, FOLIC ACID
GEMFIBROZIL, GEMFIBROZIL
HALOPERIDOL, HALOPERIDOL
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROCORTISONE ACETATE, HYDROCORTISONE ACETATE
HYDROCORTISONE, HYDROCORTISONE
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
INDAPAMIDE, INDAPAMIDE
ISONIAZID, ISONIAZID
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
LORAZEPAM, LORAZEPAM
LOVASTATIN, LOVASTATIN
MEPROBAMATE, MEPROBAMATE
METHOCARBAMOL, METHOCARBAMOL
METHYLDOPA AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
METHYLDOPA, METHYLDOPA
METHYLPHENIDATE HCL, METHYLPHENIDATE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

METHYLTESTOSTERONE, METHYLTESTOSTERONE
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
NAPROXEN SODIUM, NAPROXEN SODIUM
NAPROXEN, NAPROXEN
NIACIN, NIACIN
NIFEDIPINE, NIFEDIPINE
OXAPROZIN, OXAPROZIN
OXAZEPAM, OXAZEPAM
OXYTETRACYCLINE HCL, OXYTETRACYCLINE HYDROCHLORIDE
PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM
PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM
PENTOXIFYLLINE, PENTOXIFYLLINE
PHENTERMINE HCL, PHENTERMINE HYDROCHLORIDE
PINDOLOL, PINDOLOL
PRAZOSIN HCL, PRAZOSIN HYDROCHLORIDE
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
PROPOXYPHENE HCL, PROPOXYPHENE HYDROCHLORIDE
PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN, ACETAMINOPHEN
PROPRANOLOL HCL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
PROPYLTHIOURACIL, PROPYLTHIOURACIL
QUINIDINE SULFATE, QUINIDINE SULFATE
RAUWOLFIA SERPENTINA, RAUWOLFIA SERPENTINA
RESERPINE, RESERPINE
SECOBARBITAL SODIUM, SECOBARBITAL SODIUM
SODIUM PENTOBARBITAL, PENTOBARBITAL SODIUM
SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPIRONOLACTONE, SPIRONOLACTONE
SULFISOXAZOLE, SULFISOXAZOLE
TEMAZEPAM, TEMAZEPAM
TETRACYCLINE HCL, TETRACYCLINE HYDROCHLORIDE
TICLOPIDINE HCL, TICLOPIDINE HYDROCHLORIDE
TOLBUTAMIDE, TOLBUTAMIDE
TOLMETIN SODIUM, TOLMETIN SODIUM
TRAZODONE HCL, TRAZODONE HYDROCHLORIDE
TRIAMCINOLONE, TRIAMCINOLONE
TRIPLE SULFA, TRISULFAPYRIMIDINES (SULFADIAZINE; SULFAMERAZINE;SULFAMETHAZINE)
VERAPAMIL HCL, VERAPAMIL HYDROCHLORIDE

PVT FORM
* PRIVATE FORMULATIONS INC
ALLERFED, PSEUDOEPHEDRINE HYDROCHLORIDE
BENZTHIAZIDE, BENZTHIAZIDE
BROMPHENIRAMINE MALEATE, BROMPHENIRAMINE MALEATE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
CHLORPROMAZINE HCL, CHLORPROMAZINE HYDROCHLORIDE
DEXAMETHASONE, DEXAMETHASONE
DI-METREX, PHENDIMETRAZINE TARTRATE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENOXYLATE HCL W/ ATROPINE SULFATE, ATROPINE SULFATE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
ESTERIFIED ESTROGENS, ESTROGENS, ESTERIFIED
FEMOGEN, ESTROGENS, ESTERIFIED
FOLIC ACID, FOLIC ACID
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
MEPROBAMATE, MEPROBAMATE
METHSCOPOLAMINE BROMIDE, METHSCOPOLAMINE BROMIDE
METHYLTESTOSTERONE, METHYLTESTOSTERONE
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
PROFEN, IBUPROFEN (OTC)
PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE
PROPANTHELINE BROMIDE, PROPANTHELINE BROMIDE
PROPOXYPHENE HCL, PROPOXYPHENE HYDROCHLORIDE
QUINIDINE SULFATE, QUINIDINE SULFATE
RAUWOLFIA SERPENTINA, RAUWOLFIA SERPENTINA
RESERPINE, RESERPINE
TETRACYCLINE HCL, TETRACYCLINE HYDROCHLORIDE

** Q **

QLT
* QLT INC
VISUDYNE, VERTEPORFIN

QUAD PHARMS
* QUAD PHARMACEUTICALS INC
ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM
ACETYLCYSTEINE, ACETYLCYSTEINE
AMINOCAPROIC ACID, AMINOCAPROIC ACID
AMINOHIPPURATE SODIUM, AMINOHIPPURATE SODIUM
AZATHIOPRINE, AZATHIOPRINE SODIUM
BACITRACIN, BACITRACIN
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
BRETYLIUM TOSYLATE, BRETYLIUM TOSYLATE
CHORIONIC GONADOTROPIN, GONADOTROPIN, CHORIONIC
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CYTARABINE, CYTARABINE
DACARBAZINE, DACARBAZINE
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DIAZOXIDE, DIAZOXIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DROPERIDOL, DROPERIDOL
ERYTHROMYCIN LACTOBIONATE, ERYTHROMYCIN LACTOBIONATE
ESTRADIOL CYPIONATE, ESTRADIOL CYPIONATE
FLOXURIDINE, FLOXURIDINE
FLUOROURACIL, FLUOROURACIL

FDA data supplied by DrugPatentWatch.com

FLUPHENAZINE HCL, FLUPHENAZINE HYDROCHLORIDE
FLUPHENAZINE, FLUPHENAZINE DECANOATE
GLUCAGON, GLUCAGON HYDROCHLORIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
HALOPERIDOL, HALOPERIDOL LACTATE
HYDROCORTISONE SODIUM PHOSPHATE, HYDROCORTISONE SODIUM PHOSPHATE
HYDROXYPROGESTERONE CAPROATE, HYDROXYPROGESTERONE CAPROATE
ISONIAZID, ISONIAZID
KANAMYCIN SULFATE, KANAMYCIN SULFATE
KETAMINE HCL, KETAMINE HYDROCHLORIDE
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
LINCOMYCIN HCL, LINCOMYCIN HYDROCHLORIDE
METHOTREXATE SODIUM, METHOTREXATE SODIUM
METHYLDOPATE HCL, METHYLDOPATE HYDROCHLORIDE
METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
METOCURINE IODIDE, METOCURINE IODIDE
NALBUPHINE, NALBUPHINE HYDROCHLORIDE
NALOXONE HCL, NALOXONE HYDROCHLORIDE
NANDROLONE DECANOATE, NANDROLONE DECANOATE
NANDROLONE PHENPROPIONATE, NANDROLONE PHENPROPIONATE
NITROGLYCERIN, NITROGLYCERIN
PANCURONIUM BROMIDE, PANCURONIUM BROMIDE
PRALIDOXIME CHLORIDE, PRALIDOXIME CHLORIDE
PROCAINAMIDE HCL, PROCAINAMIDE HYDROCHLORIDE
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
PROTAMINE SULFATE, PROTAMINE SULFATE
RITODRINE HCL, RITODRINE HYDROCHLORIDE
SULFAMETHOPRIM, SULFAMETHOXAZOLE
TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
TESTOSTERONE ENANTHATE, TESTOSTERONE ENANTHATE
TESTOSTERONE PROPIONATE, TESTOSTERONE PROPIONATE
TRIFLUOPERAZINE HCL, TRIFLUOPERAZINE HYDROCHLORIDE
TUBOCURARINE CHLORIDE, TUBOCURARINE CHLORIDE
VANCOMYCIN HCL, VANCOMYCIN HYDROCHLORIDE
VERAPAMIL HCL, VERAPAMIL HYDROCHLORIDE
VINBLASTINE SULFATE, VINBLASTINE SULFATE
VINCRISTINE SULFATE, VINCRISTINE SULFATE

QUANTUM PHARMICS
* QUANTUM PHARMICS LTD
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
BUTALBITAL ASPIRIN AND CAFFEINE, ASPIRIN
CLOPRA, METOCLOPRAMIDE HYDROCHLORIDE
CLOPRA-"YELLOW", METOCLOPRAMIDE HYDROCHLORIDE
CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
DOXEPIN HCL, DOXEPIN HYDROCHLORIDE
DOXYLAMINE SUCCINATE, DOXYLAMINE SUCCINATE
FENOPROFEN CALCIUM, FENOPROFEN CALCIUM
HALOPERIDOL, HALOPERIDOL
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
LORAZ, LORAZEPAM
MECLODIUM, MECLOFENAMATE SODIUM
MINODYL, MINOXIDIL
NYSTATIN, NYSTATIN
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
PHENTERMINE RESIN 30, PHENTERMINE RESIN COMPLEX
Q-GESIC, ASPIRIN
Q-PAM, DIAZEPAM
TEMAZ, TEMAZEPAM
TIMOLOL MALEATE, TIMOLOL MALEATE
TRAZODONE HCL, TRAZODONE HYDROCHLORIDE
TRIALODINE, TRAZODONE HYDROCHLORIDE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
ZAXOPAM, OXAZEPAM

QUESTCOR PHARMS
* QUESTCOR PHARMACEUTICALS INC
ETHAMOLIN, ETHANOLAMINE OLEATE
GLOFIL-125, IOTHALAMATE SODIUM, I-125
H.P. ACTHAR GEL, CORTICOTROPIN
INULIN AND SODIUM CHLORIDE, INULIN

** R **

R AND D LABS
* R AND D LABORATORIES INC
FERRLECIT, SODIUM FERRIC GLUCONATE COMPLEX

R AND S PHARMA
* R AND S PHARMA INC
DIPHENOXYLATE HCL AND ATROPINE SULFATE, ATROPINE SULFATE

RACHELLE
* RACHELLE LABORATORIES INC
CHLORDIAZACHEL, CHLORDIAZEPOXIDE HYDROCHLORIDE
DOXYCHEL HYCLATE, DOXYCYCLINE HYCLATE
DOXYCHEL, DOXYCYCLINE

RANBAXY
* RANBAXY LABORATORIES LTD
ACYCLOVIR, ACYCLOVIR
AMOXICILLIN, AMOXICILLIN
CEPHALEXIN, CEPHALEXIN
CLINDAMYCIN HCL, CLINDAMYCIN HYDROCHLORIDE
DOXYCYCLINE, DOXYCYCLINE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
ETODOLAC, ETODOLAC
LORAZEPAM, LORAZEPAM
MINOCYCLINE HCL, MINOCYCLINE HYDROCHLORIDE
RANITIDINE, RANITIDINE HYDROCHLORIDE
RANITIDINE, RANITIDINE HYDROCHLORIDE (OTC)
* RANBAXY PHARMACEUTICALS INC

FDA data supplied by DrugPatentWatch.com

AMOXICILLIN, AMOXICILLIN
CEFACLOR, CEFACLOR
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
PENTAZOCINE AND NALOXONE HYDROCHLORIDES, NALOXONE HYDROCHLORIDE
RANITIDINE HCL, RANITIDINE HYDROCHLORIDE
RANITIDINE, RANITIDINE HYDROCHLORIDE (OTC)

RATIOPHARM
* RATIOPHARM GMBH AND CO ARZNEIMITTEL
SUCRALFATE, SUCRALFATE

RECKITT BENCKISER
* RECKITT BENCKISER PHARMACEUTICALS INC
BUPRENEX, BUPRENORPHINE HYDROCHLORIDE

REED AND CARNRICK
* REED AND CARNRICK PHARMACEUTICALS DIV BLOCK DRUG CO INC
KWELL, LINDANE

RES INDS
* RESEARCH INDUSTRIES CORP
RIMSO-50, DIMETHYL SULFOXIDE

REXALL
* REXALL DRUG CO
PREDNISONE, PREDNISONE
RESERPINE, RESERPINE

REXAR
* REXAR PHARMACAL
METHAMPHETAMINE HCL, METHAMPHETAMINE HYDROCHLORIDE

RHODIA
* RHODIA LTD
ISOFLURANE, ISOFLURANE

ROACO
* TJ ROACO LTD
BETADERM, BETAMETHASONE VALERATE

ROBINS AH
* AH ROBINS CO
DIMETANE-DC, BROMPHENIRAMINE MALEATE
DIMETANE-DX, BROMPHENIRAMINE MALEATE
DOPRAM, DOXAPRAM HYDROCHLORIDE
ISMO, ISOSORBIDE MONONITRATE
PHENAPHEN W/ CODEINE NO. 2, ACETAMINOPHEN
PHENAPHEN W/ CODEINE NO. 3, ACETAMINOPHEN
PHENAPHEN W/ CODEINE NO. 4, ACETAMINOPHEN
PHENAPHEN-650 W/ CODEINE, ACETAMINOPHEN
QUINIDEX, QUINIDINE SULFATE
REGLAN, METOCLOPRAMIDE HYDROCHLORIDE
ROBAXIN, METHOCARBAMOL
ROBAXISAL, ASPIRIN
ROBIMYCIN, ERYTHROMYCIN
ROBINUL, GLYCOPYRROLATE
TENATHAN, BETHANIDINE SULFATE

ROCHE
* HOFFMANN LA ROCHE INC
ARFONAD, TRIMETHAPHAN CAMSYLATE
AZO GANTANOL, PHENAZOPYRIDINE HYDROCHLORIDE
AZO GANTRISIN, PHENAZOPYRIDINE HYDROCHLORIDE
BEROCCA PN, ASCORBIC ACID
BUMEX, BUMETANIDE
COACTIN, AMDINOCILLIN
DEMADEX, TORSEMIDE
ENDEP, AMITRIPTYLINE HYDROCHLORIDE
FANSIDAR, PYRIMETHAMINE
FUDR, FLOXURIDINE
GANTANOL, SULFAMETHOXAZOLE
GANTANOL-DS, SULFAMETHOXAZOLE
GANTRISIN PEDIATRIC, SULFISOXAZOLE ACETYL
GANTRISIN, SULFISOXAZOLE
GANTRISIN, SULFISOXAZOLE ACETYL
GANTRISIN, SULFISOXAZOLE DIOLAMINE
HIVID, ZALCITABINE
KLONOPIN RAPIDLY DISINTEGRATING, CLONAZEPAM
KLONOPIN, CLONAZEPAM
KONAKION, PHYTONADIONE
KYTRIL, GRANISETRON HYDROCHLORIDE
LARIAM, MEFLOQUINE HYDROCHLORIDE
LARODOPA, LEVODOPA
LIPO GANTRISIN, SULFISOXAZOLE ACETYL
LORFAN, LEVALLORPHAN TARTRATE
MENRIUM 10-4, CHLORDIAZEPOXIDE
MENRIUM 5-2, CHLORDIAZEPOXIDE
MENRIUM 5-4, CHLORDIAZEPOXIDE
NIPRIDE, SODIUM NITROPRUSSIDE
NOLUDAR, METHYPRYLON
QUARZAN, CLIDINIUM BROMIDE
RIMADYL, CARPROFEN
RIMIFON, ISONIAZID
ROCALTROL, CALCITRIOL
ROCEPHIN, CEFTRIAXONE SODIUM
SOLATENE, BETA-CAROTENE
SYNKAYVITE, MENADIOL SODIUM DIPHOSPHATE
TAMIFLU, OSELTAMIVIR PHOSPHATE
TARACTAN, CHLORPROTHIXENE
TASMAR, TOLCAPONE
TEGISON, ETRETINATE
TRIMPEX 200, TRIMETHOPRIM
TRIMPEX, TRIMETHOPRIM
VALIUM, DIAZEPAM

FDA data supplied by DrugPatentWatch.com

VALRELEASE, DIAZEPAM
VERSED, MIDAZOLAM HYDROCHLORIDE
VESANOID, TRETINOIN

ROCHE GLOBAL DEV
* ROCHE GLOBAL DEVELOPMENT DIV SYNTEX (USA) LLC
CELLCEPT, MYCOPHENOLATE MOFETIL
CELLCEPT, MYCOPHENOLATE MOFETIL HYDROCHLORIDE

ROERIG
* ROERIG DIV PFIZER INC
ATARAX, HYDROXYZINE HYDROCHLORIDE
EMETE-CON, BENZQUINAMIDE HYDROCHLORIDE
GEOPEN, CARBENICILLIN DISODIUM
NAVANE, THIOTHIXENE
NAVANE, THIOTHIXENE HYDROCHLORIDE
SUSTAIRE, THEOPHYLLINE

RORER
* RORER PHARMACEUTICAL CORP SUB RORER GROUP
NITROL, NITROGLYCERIN

ROSS LABS
* ROSS LABORATORIES DIV ABBOTT LABORATORIES INC
PEDIAMYCIN 400, ERYTHROMYCIN ETHYLSUCCINATE
PEDIAMYCIN, ERYTHROMYCIN ETHYLSUCCINATE
PEDIAZOLE, ERYTHROMYCIN ETHYLSUCCINATE
SURVANTA, BERACTANT

ROXANE
* ROXANE LABORATORIES INC
ACETAMINOPHEN AND CODEINE PHOSPHATE NO. 4, ACETAMINOPHEN
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACETAMINOPHEN W/ CODEINE NO. 2, ACETAMINOPHEN
ACETAMINOPHEN W/ CODEINE NO. 3, ACETAMINOPHEN
ACETAMINOPHEN W/ CODEINE, ACETAMINOPHEN
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
ACETYLCYSTEINE, ACETYLCYSTEINE
ACYCLOVIR, ACYCLOVIR
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALPRAZOLAM, ALPRAZOLAM
AMINOPHYLLINE, AMINOPHYLLINE
AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
AZATHIOPRINE, AZATHIOPRINE
CHLORDIAZEPOXIDE HCL, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
CHLORPROMAZINE HCL INTENSOL, CHLORPROMAZINE HYDROCHLORIDE
CHLORPROMAZINE HCL, CHLORPROMAZINE HYDROCHLORIDE
CIMETIDINE HCL, CIMETIDINE HYDROCHLORIDE
CIMETIDINE, CIMETIDINE
CROMOLYN SODIUM, CROMOLYN SODIUM
CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
DEXAMETHASONE INTENSOL, DEXAMETHASONE
DEXAMETHASONE, DEXAMETHASONE
DIAZEPAM INTENSOL, DIAZEPAM
DIAZEPAM, DIAZEPAM
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DIFLUNISAL, DIFLUNISAL
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENOXYLATE HCL AND ATROPINE SULFATE, ATROPINE SULFATE
DOLOPHINE HCL, METHADONE HYDROCHLORIDE
FUROSEMIDE, FUROSEMIDE
HALOPERIDOL INTENSOL, HALOPERIDOL LACTATE
HALOPERIDOL, HALOPERIDOL
HYDROCHLOROTHIAZIDE INTENSOL, HYDROCHLOROTHIAZIDE
HYDROCHLOROTHIAZIDE W/ RESERPINE, HYDROCHLOROTHIAZIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROCORTISONE, HYDROCORTISONE
HYDROMORPHONE HCL, HYDROMORPHONE HYDROCHLORIDE
HYDROXYUREA, HYDROXYUREA
IMIPRAMINE HCL, IMIPRAMINE HYDROCHLORIDE
INDOMETHACIN, INDOMETHACIN
ISOETHARINE HCL, ISOETHARINE HYDROCHLORIDE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LACTULOSE, LACTULOSE
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
LEVORPHANOL TARTRATE, LEVORPHANOL TARTRATE
LIDOCAINE HCL, LIDOCAINE HYDROCHLORIDE
LIDOCAINE VISCOUS, LIDOCAINE HYDROCHLORIDE
LITHIUM CARBONATE, LITHIUM CARBONATE
LITHIUM CITRATE, LITHIUM CITRATE
LOPERAMIDE HCL, LOPERAMIDE HYDROCHLORIDE
LOPERAMIDE HCL, LOPERAMIDE HYDROCHLORIDE (OTC)
LORAZEPAM INTENSOL, LORAZEPAM
LORAZEPAM, LORAZEPAM
MEGESTROL ACETATE, MEGESTROL ACETATE
MEPERIDINE HCL, MEPERIDINE HYDROCHLORIDE
MEPROBAMATE, MEPROBAMATE
METHADONE HCL INTENSOL, METHADONE HYDROCHLORIDE
METHADONE HCL, METHADONE HYDROCHLORIDE
METHOCARBAMOL, METHOCARBAMOL
METHOTREXATE SODIUM, METHOTREXATE SODIUM
METHYLDOPA, METHYLDOPA
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
METOCLOPRAMIDE INTENSOL, METOCLOPRAMIDE HYDROCHLORIDE
NAPROXEN SODIUM, NAPROXEN SODIUM
NAPROXEN, NAPROXEN
NEOMYCIN SULFATE, NEOMYCIN SULFATE
NYSTATIN, NYSTATIN
ORLAAM, LEVOMETHADYL ACETATE HYDROCHLORIDE
OXYCODONE AND ASPIRIN (HALF-STRENGTH), ASPIRIN
PIROXICAM, PIROXICAM
POTASSIUM IODIDE, POTASSIUM IODIDE (OTC)
PREDNISOLONE, PREDNISOLONE
PREDNISONE INTENSOL, PREDNISONE
PREDNISONE, PREDNISONE

FDA data supplied by DrugPatentWatch.com

PROCAINAMIDE HCL, PROCAINAMIDE HYDROCHLORIDE
PROPANTHELINE BROMIDE, PROPANTHELINE BROMIDE
PROPOXYPHENE HCL, PROPOXYPHENE HYDROCHLORIDE
PROPRANOLOL HCL INTENSOL, PROPRANOLOL HYDROCHLORIDE
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
QUINIDINE GLUCONATE, QUINIDINE GLUCONATE
QUINIDINE SULFATE, QUINIDINE SULFATE
RESERPINE, RESERPINE
ROXICET 5/500, ACETAMINOPHEN
ROXICET, ACETAMINOPHEN
ROXICODONE, OXYCODONE HYDROCHLORIDE
ROXILOX, ACETAMINOPHEN
ROXIPRIN, ASPIRIN
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE
SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH, SULFAMETHOXAZOLE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
SULFISOXAZOLE, SULFISOXAZOLE
TETRACYCLINE HCL, TETRACYCLINE HYDROCHLORIDE
THEOPHYLLINE, THEOPHYLLINE
THIORIDAZINE HCL INTENSOL, THIORIDAZINE HYDROCHLORIDE
THIORIDAZINE HCL, THIORIDAZINE HYDROCHLORIDE
THIOTHIXENE HCL INTENSOL, THIOTHIXENE HYDROCHLORIDE
TRIAMCINOLONE, TRIAMCINOLONE
TRIAZOLAM, TRIAZOLAM

ROYCE LABS
* ROYCE LABORATORIES INC
HALOPERIDOL, HALOPERIDOL
MINOXIDIL, MINOXIDIL

** S **

SABEX
* SABEX INC
INFUVITE PEDIATRIC, ASCORBIC ACID
MULTI-12, ALPHA-TOCOPHEROL ACETATE

SALIX
* SALIX PHARMACEUTICALS INC
COLAZAL, BALSALAZIDE DISODIUM

SANKYO
* SANKYO PHARMA INC
WELCHOL, COLESEVELAM HYDROCHLORIDE
* SANKYO USA CORP
BANAN, CEFPODOXIME PROXETIL
PRELAY, TROGLITAZONE

SANO
* SANO CORP
NICOTINE, NICOTINE

SANOFI SYNTHELABO
* SANOFI SYNTHELABO INC
ARALEN HCL, CHLOROQUINE HYDROCHLORIDE
ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
ARALEN, CHLOROQUINE PHOSPHATE
AVALIDE, HYDROCHLOROTHIAZIDE
AVAPRO, IRBESARTAN
BRONKODYL, THEOPHYLLINE
BRONKOMETER, ISOETHARINE MESYLATE
BRONKOSOL, ISOETHARINE HYDROCHLORIDE
BRYREL, PIPERAZINE CITRATE
CALCIPARINE, HEPARIN CALCIUM
CHEMET, SUCCIMER
DANOCRINE, DANAZOL
DEMEROL, MEPERIDINE HYDROCHLORIDE
DRISDOL, ERGOCALCIFEROL
INOCOR, INAMRINONE LACTATE
ISUPREL, ISOPROTERENOL HYDROCHLORIDE
KAYEXALATE, SODIUM POLYSTYRENE SULFONATE
LOTUSATE, TALBUTAL
MODRASTANE, TRILOSTANE
MYTELASE, AMBENONIUM CHLORIDE
NEGGRAM, NALIDIXIC ACID
PHISO-SCRUB, HEXACHLOROPHENE
PHISOHEX, HEXACHLOROPHENE
PLAQUENIL, HYDROXYCHLOROQUINE SULFATE
PLAVIX, CLOPIDOGREL BISULFATE
PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER, MILRINONE LACTATE
PRIMACOR, MILRINONE LACTATE
PRIMAQUINE, PRIMAQUINE PHOSPHATE
SKELID, TILUDRONATE DISODIUM
TALACEN, ACETAMINOPHEN
TALWIN 50, PENTAZOCINE HYDROCHLORIDE
TALWIN COMPOUND, ASPIRIN
TALWIN NX, NALOXONE HYDROCHLORIDE
TORNALATE, BITOLTEROL MESYLATE
TRANCOPAL, CHLORMEZANONE
WINSTROL, STANOZOLOL

SANTEN
* SANTEN INC
ALAMAST, PEMIROLAST POTASSIUM
QUIXIN, LEVOFLOXACIN

SANTEN OY
* SANTEN OY
BETIMOL, TIMOLOL

SAVAGE LABS
* SAVAGE LABORATORIES INC DIV ALTANA INC
ALPHATREX, BETAMETHASONE DIPROPIONATE
AXOTAL, ASPIRIN

FDA data supplied by DrugPatentWatch.com

BETATREX, BETAMETHASONE VALERATE
CHYMEX, BENTIROMIDE
DILOR, DYPHYLLINE
DILOR-400, DYPHYLLINE
DITATE-DS, ESTRADIOL VALERATE
ETHIODOL, ETHIODIZED OIL
FLUOTREX, FLUOCINOLONE ACETONIDE
GVS, GENTIAN VIOLET
K-LEASE, POTASSIUM CHLORIDE
KAON CL, POTASSIUM CHLORIDE
KAON CL-10, POTASSIUM CHLORIDE
MYTREX A, NEOMYCIN SULFATE
MYTREX F, NYSTATIN
NYSTEX, NYSTATIN
PANDEL, HYDROCORTISONE PROBUTATE
RUVITE, CYANOCOBALAMIN
SATRIC, METRONIDAZOLE
TRYMEX, TRIAMCINOLONE ACETONIDE
TRYSUL, TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE; SULFATHIAZOLE)
XYLO-PFAN, XYLOSE

SCHEIN
* SCHEIN PHARMACEUTICAL INC
INFED, IRON DEXTRAN
PROGESTERONE, PROGESTERONE

SCHERER LABS
* SCHERER LABORATORIES INC
CODEINE, ASPIRIN, APAP FORMULA NO. 2, ACETAMINOPHEN
CODEINE, ASPIRIN, APAP FORMULA NO. 3, ACETAMINOPHEN
CODEINE, ASPIRIN, APAP FORMULA NO. 4, ACETAMINOPHEN
MEPROBAMATE, MEPROBAMATE
PREDNISONE, PREDNISONE
QUINIDINE SULFATE, QUINIDINE SULFATE

SCHERER RP
* RP SCHERER CORP
NIFEDIPINE, NIFEDIPINE
* RP SCHERER NORTH AMERICA
NIFEDIPINE, NIFEDIPINE
THEOPHYLLINE, THEOPHYLLINE
VALPROIC ACID, VALPROIC ACID
* RP SCHERER NORTH AMERICA DIV RP SCHERER CORP
DIPHENOXYLATE HCL W/ ATROPINE SULFATE, ATROPINE SULFATE
THEOPHYLLINE-SR, THEOPHYLLINE
VALPROIC ACID, VALPROIC ACID

SCHERING
* SCHERING CORP
CLARITIN REDITABS, LORATADINE
CLARITIN, LORATADINE
CLARITIN-D 24 HOUR, LORATADINE
DIPROLENE AF, BETAMETHASONE DIPROPIONATE
GUANIDINE HCL, GUANIDINE HYDROCHLORIDE
IMDUR, ISOSORBIDE MONONITRATE
LOTRISONE, BETAMETHASONE DIPROPIONATE
QUINORA, QUINIDINE SULFATE
RENORMAX, SPIRAPRIL HYDROCHLORIDE
TEMODAR, TEMOZOLOMIDE
THEO-DUR, THEOPHYLLINE
UNI-DUR, THEOPHYLLINE
VALISONE, BETAMETHASONE VALERATE
VANCENASE AQ, BECLOMETHASONE DIPROPIONATE MONOHYDRATE
VANCERIL DOUBLE STRENGTH, BECLOMETHASONE DIPROPIONATE
* SCHERING CORP SUB SCHERING PLOUGH CORP
AKRINOL, ACRISORCIN
BETAPAR, MEPREDNISONE
CELESTONE SOLUSPAN, BETAMETHASONE ACETATE
CELESTONE, BETAMETHASONE
CELESTONE, BETAMETHASONE SODIUM PHOSPHATE
CHLOR-TRIMETON, CHLORPHENIRAMINE MALEATE
CLARITIN, LORATADINE
CLARITIN-D, LORATADINE
DIPROLENE, BETAMETHASONE DIPROPIONATE
DIPROSONE, BETAMETHASONE DIPROPIONATE
DISOMER, DEXBROMPHENIRAMINE MALEATE
DISOPHROL, DEXBROMPHENIRAMINE MALEATE (OTC)
ELOCON, MOMETASONE FUROATE
ESTINYL, ETHINYL ESTRADIOL
ETRAFON 2-10, AMITRIPTYLINE HYDROCHLORIDE
ETRAFON 2-25, AMITRIPTYLINE HYDROCHLORIDE
ETRAFON-A, AMITRIPTYLINE HYDROCHLORIDE
ETRAFON-FORTE, AMITRIPTYLINE HYDROCHLORIDE
EULEXIN, FLUTAMIDE
FULVICIN P/G 165, GRISEOFULVIN, ULTRAMICROCRYSTALLINE
FULVICIN P/G 330, GRISEOFULVIN, ULTRAMICROCRYSTALLINE
FULVICIN P/G, GRISEOFULVIN, ULTRAMICROCRYSTALLINE
FULVICIN-U/F, GRISEOFULVIN, MICROCRYSTALLINE
GARAMYCIN, GENTAMICIN SULFATE
HYPERSTAT, DIAZOXIDE
LOTRIMIN, CLOTRIMAZOLE
METI-DERM, PREDNISOLONE
METICORTELONE, PREDNISOLONE ACETATE
METICORTEN, PREDNISONE
METIMYD, PREDNISOLONE ACETATE
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
METRETON, PREDNISOLONE SODIUM PHOSPHATE
MIRADON, ANISINDIONE
NAQUA, TRICHLORMETHIAZIDE
NAQUIVAL, RESERPINE
NETROMYCIN, NETILMICIN SULFATE
NORMODYNE, LABETALOL HYDROCHLORIDE
NORMOZIDE, HYDROCHLOROTHIAZIDE
OPTIMINE, AZATADINE MALEATE
ORETON METHYL, METHYLTESTOSTERONE

FDA data supplied by DrugPatentWatch.com

ORETON, METHYLTESTOSTERONE
OTOBIONE, HYDROCORTISONE
OTOBIOTIC, HYDROCORTISONE
PAXIPAM, HALAZEPAM
PERMITIL, FLUPHENAZINE HYDROCHLORIDE
POLARAMINE, DEXCHLORPHENIRAMINE MALEATE
PRANTAL, DIPHEMANIL METHYLSULFATE
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
PROVENTIL, ALBUTEROL
PROVENTIL, ALBUTEROL SULFATE
RELA, CARISOPRODOL
SODIUM SULAMYD, SULFACETAMIDE SODIUM
THEOVENT, THEOPHYLLINE
TINDAL, ACETOPHENAZINE MALEATE
TREMIN, TRIHEXYPHENIDYL HYDROCHLORIDE
TRILAFON, PERPHENAZINE
TRINALIN, AZATADINE MALEATE
UNI-DUR, THEOPHYLLINE
VALISONE, BETAMETHASONE VALERATE
VANCENASE AQ, BECLOMETHASONE DIPROPIONATE MONOHYDRATE
VANCENASE, BECLOMETHASONE DIPROPIONATE
VANCERIL, BECLOMETHASONE DIPROPIONATE

SCHERING PLOUGH
* SCHERING PLOUGH CORP
CLARINEX, DESLORATADINE
NASONEX, MOMETASONE FUROATE MONOHYDRATE
* SCHERING PLOUGH HEALTHCARE PRODUCTS INC
AFRINOL, PSEUDOEPHEDRINE SULFATE (OTC)
CHLOR-TRIMETON, CHLORPHENIRAMINE MALEATE
CHLOR-TRIMETON, CHLORPHENIRAMINE MALEATE (OTC)
DEMAZIN, CHLORPHENIRAMINE MALEATE (OTC)
DISOPHROL, DEXBROMPHENIRAMINE MALEATE (OTC)
DRIXORAL PLUS, ACETAMINOPHEN (OTC)
DRIXORAL, DEXBROMPHENIRAMINE MALEATE (OTC)
GYNE-LOTRIMIN 3 COMBINATION PACK, CLOTRIMAZOLE (OTC)
GYNE-LOTRIMIN 3, CLOTRIMAZOLE (OTC)
GYNE-LOTRIMIN COMBINATION PACK, CLOTRIMAZOLE (OTC)
GYNE-LOTRIMIN, CLOTRIMAZOLE (OTC)
LOTRIMIN AF, CLOTRIMAZOLE (OTC)
LOTRIMIN ULTRA, BUTENAFINE HYDROCHLORIDE (OTC)
LOTRIMIN, CLOTRIMAZOLE
OCUCLEAR, OXYMETAZOLINE HYDROCHLORIDE (OTC)
SHADE UVAGUARD, AVOBENZONE (OTC)

SCHERING PLOUGH RES
* SCHERING PLOUGH RESEARCH INSTITUTE
LOTRISONE, BETAMETHASONE DIPROPIONATE
REBETOL, RIBAVIRIN

SCHWARZ
* SCHWARZ GMBH
MONOKET, ISOSORBIDE MONONITRATE

SCHWARZ PHARMA
* SCHWARZ PHARMA AG
EDEX, ALPROSTADIL
* SCHWARZ PHARMA INC
CO-GESIC, ACETAMINOPHEN
CODIMAL-L.A. 12, CHLORPHENIRAMINE MALEATE (OTC)
COLYTE WITH FLAVOR PACKS, POLYETHYLENE GLYCOL 3350
COLYTE, POLYETHYLENE GLYCOL 3350
COLYTE-FLAVORED, POLYETHYLENE GLYCOL 3350
CORTIFOAM, HYDROCORTISONE ACETATE
DILATRATE-SR, ISOSORBIDE DINITRATE
EPIFOAM, HYDROCORTISONE ACETATE
LEVATOL, PENBUTOLOL SULFATE
PREDNICEN-M, PREDNISONE
PROCTOFOAM HC, HYDROCORTISONE ACETATE
REGLAN, METOCLOPRAMIDE HYDROCHLORIDE
ROBAXIN, METHOCARBAMOL
ROBAXIN-750, METHOCARBAMOL
THEOCLEAR L.A.-130, THEOPHYLLINE
THEOCLEAR L.A.-260, THEOPHYLLINE
UNIRETIC, HYDROCHLOROTHIAZIDE
UNIVASC, MOEXIPRIL HYDROCHLORIDE

SCIOS
* SCIOS INC
NATRECOR, NESIRITIDE

SCS
* SCS PHARMACEUTICALS
ATENOLOL, ATENOLOL
CARBIDOPA AND LEVODOPA, CARBIDOPA
FLAGYL I.V. RTU IN PLASTIC CONTAINER, METRONIDAZOLE
FLAGYL I.V., METRONIDAZOLE HYDROCHLORIDE
HALOPERIDOL, HALOPERIDOL
HALOPERIDOL, HALOPERIDOL LACTATE
OGESTREL 0.5/50-21, ETHINYL ESTRADIOL
OGESTREL 0.5/50-28, ETHINYL ESTRADIOL
PIROXICAM, PIROXICAM

SEPRACOR
* SEPRACOR INC
XOPENEX, LEVALBUTEROL HYDROCHLORIDE

SEPTODONT
* SEPTODONT INC
OCTOCAINE, EPINEPHRINE

SERONO
* SERONO LABORATORIES INC
ASELLACRIN 10, SOMATROPIN
ASELLACRIN 2, SOMATROPIN
FERTINEX, UROFOLLITROPIN

FDA data supplied by DrugPatentWatch.com

GEREF, SERMORELIN ACETATE
GONAL-F, FOLLITROPIN ALFA
GONAL-F, FOLLITROPIN ALFA/BETA
METRODIN, UROFOLLITROPIN
OVIDREL, CHORIOGONADOTROPIN ALFA
PERGONAL, MENOTROPINS (FSH;LH)
SAIZEN, SOMATROPIN RECOMBINANT
SEROPHENE, CLOMIPHENE CITRATE
SEROSTIM, SOMATROPIN RECOMBINANT

SERONO INC
* SERONO INC
CETROTIDE, CETRORELIX

SHERWOOD MEDCL
* SHERWOOD MEDICAL CO
ACTIN-N, NITROFURAZONE

SHIONOGI
* SHIONOGI USA INC
UROBAK, SULFAMETHOXAZOLE
UROPLUS DS, SULFAMETHOXAZOLE
UROPLUS SS, SULFAMETHOXAZOLE

SHIRE LABS
* SHIRE LABORATORIES INC
ADDERALL 10, AMPHETAMINE ASPARTATE
ADDERALL 12.5, AMPHETAMINE ASPARTATE
ADDERALL 15, AMPHETAMINE ASPARTATE
ADDERALL 20, AMPHETAMINE ASPARTATE
ADDERALL 30, AMPHETAMINE ASPARTATE
ADDERALL 5, AMPHETAMINE ASPARTATE
ADDERALL 7.5, AMPHETAMINE ASPARTATE
ADDERALL XR 10, AMPHETAMINE ASPARTATE
ADDERALL XR 20, AMPHETAMINE ASPARTATE
ADDERALL XR 30, AMPHETAMINE ASPARTATE
AGRYLIN, ANAGRELIDE HYDROCHLORIDE
BANTHINE, METHANTHELINE BROMIDE
CARBATROL, CARBAMAZEPINE
DOPAR, LEVODOPA
ETHMOZINE, MORICIZINE HYDROCHLORIDE
FURACIN, NITROFURAZONE
FUROXONE, FURAZOLIDONE
PENTASA, MESALAMINE
PRO-BANTHINE, PROPANTHELINE BROMIDE
SALURON, HYDROFLUMETHIAZIDE
SALUTENSIN, HYDROFLUMETHIAZIDE
SALUTENSIN-DEMI, HYDROFLUMETHIAZIDE
SUPPRELIN, HISTRELIN ACETATE
TOPICYCLINE, TETRACYCLINE HYDROCHLORIDE

SHIRE PHARM
* SHIRE PHARMACEUTICAL DEVELOPMENT INC
ANOQUAN, ACETAMINOPHEN
FURACIN, NITROFURAZONE
PROAMATINE, MIDODRINE HYDROCHLORIDE
URACIL MUSTARD, URACIL MUSTARD

SHIRE RICHWOOD
* SHIRE RICHWOOD INC
DEXTROSTAT, DEXTROAMPHETAMINE SULFATE
OBY-TRIM, PHENTERMINE HYDROCHLORIDE
X-TROZINE L.A., PHENDIMETRAZINE TARTRATE
X-TROZINE, PHENDIMETRAZINE TARTRATE

SIDMAK LABS
* SIDMAK LABORATORIES INC
ALBUTEROL, ALBUTEROL
ANTABUSE, DISULFIRAM
CYCLOSPORINE, CYCLOSPORINE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
KETOCONAZOLE, KETOCONAZOLE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
NAPROXEN, NAPROXEN
SURMONTIL, TRIMIPRAMINE MALEATE
URECHOLINE, BETHANECHOL CHLORIDE
VIVACTIL, PROTRIPTYLINE HYDROCHLORIDE

SIDMAK LABS NJ
ALBUTEROL SULFATE, ALBUTEROL SULFATE
AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
ATENOLOL AND CHLORTHALIDONE, ATENOLOL
ATENOLOL, ATENOLOL
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
CARBAMAZEPINE, CARBAMAZEPINE
CHLORPROPAMIDE, CHLORPROPAMIDE
CHLORTHALIDONE, CHLORTHALIDONE
CIMETIDINE, CIMETIDINE
CYCLOBENZAPRINE HCL, CYCLOBENZAPRINE HYDROCHLORIDE
CYPROHEPTADINE HCL, CYPROHEPTADINE HYDROCHLORIDE
DESIPRAMINE HCL, DESIPRAMINE HYDROCHLORIDE
DEXCHLORPHENIRAMINE MALEATE, DEXCHLORPHENIRAMINE MALEATE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM, EXTENDED
FLURBIPROFEN, FLURBIPROFEN
GLIPIZIDE, GLIPIZIDE
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
IBUPRIN, IBUPROFEN (OTC)
IBUPROFEN, IBUPROFEN
INDOMETHACIN, INDOMETHACIN
MECLIZINE HCL, MECLIZINE HYDROCHLORIDE
METHYLDOPA, METHYLDOPA
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
METRONIDAZOLE, METRONIDAZOLE

FDA data supplied by DrugPatentWatch.com

NAPROXEN SODIUM, NAPROXEN SODIUM
NAPROXEN, NAPROXEN
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
PENTOXIFYLLINE, PENTOXIFYLLINE
PROCAINAMIDE HCL, PROCAINAMIDE HYDROCHLORIDE
PROPRANOLOL HCL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
THEOPHYLLINE, THEOPHYLLINE
TRAZODONE HCL, TRAZODONE HYDROCHLORIDE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
ULTRAGRIS-165, GRISEOFULVIN, ULTRAMICROCRYSTALLINE
ULTRAGRIS-330, GRISEOFULVIN, ULTRAMICROCRYSTALLINE
VERAPAMIL HCL, VERAPAMIL HYDROCHLORIDE

SIGHT PHARMS
* SIGHT PHARMACEUTICALS INC
MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
MINOXIDIL (FOR WOMEN), MINOXIDIL (OTC)

SIGMA TAU
* SIGMA TAU PHARMACEUTICALS INC
CARNITOR, LEVOCARNITINE
MATULANE, PROCARBAZINE HYDROCHLORIDE

SILARX
* SILARX PHARMACEUTICALS INC
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE
DOXEPIN HCL, DOXEPIN HYDROCHLORIDE
HALOPERIDOL, HALOPERIDOL LACTATE
METAPROTERENOL SULFATE, METAPROTERENOL SULFATE
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
SILPHEN, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)

SIRIUS LABS
* SIRIUS LABORATORIES INC
TEXACORT, HYDROCORTISONE

SKYEPHARMA
* SKYEPHARMA INC
DEPOCYT, CYTARABINE

SMITH AND NEPHEW
* SMITH AND NEPHEW SOLOPAK DIV SMITH AND NEPHEW
AMINOPHYLLINE, AMINOPHYLLINE
DOPAMINE HCL, DOPAMINE HYDROCHLORIDE
DROPERIDOL, DROPERIDOL
FLUOROURACIL, FLUOROURACIL
FUROSEMIDE, FUROSEMIDE
HALOPERIDOL, HALOPERIDOL LACTATE
HEPARIN LOCK FLUSH, HEPARIN SODIUM
HEPARIN SODIUM, HEPARIN SODIUM
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
METHYLDOPATE HCL, METHYLDOPATE HYDROCHLORIDE
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
NALOXONE HCL, NALOXONE HYDROCHLORIDE
NITROGLYCERIN, NITROGLYCERIN
PHENYTOIN SODIUM, PHENYTOIN SODIUM
PROCAINAMIDE HCL, PROCAINAMIDE HYDROCHLORIDE
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
TRIMETHOBENZAMIDE HCL, TRIMETHOBENZAMIDE HYDROCHLORIDE
VERAPAMIL HCL, VERAPAMIL HYDROCHLORIDE

SOAPCO
* SOAPCO INC
BRIAN CARE, CHLORHEXIDINE GLUCONATE (OTC)

SOLA BARNES HIND
* SOLA BARNES HIND
ALPHA CHYMAR, CHYMOTRYPSIN
BENOXINATE HCL, BENOXINATE HYDROCHLORIDE
CYCLOPENTOLATE HCL, CYCLOPENTOLATE HYDROCHLORIDE
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
GAMENE, LINDANE
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
PROPARACAINE HCL, PROPARACAINE HYDROCHLORIDE
SODIUM SULFACETAMIDE, SULFACETAMIDE SODIUM
SULFISOXAZOLE DIOLAMINE, SULFISOXAZOLE DIOLAMINE

SOLOPAK
* SOLOPAK LABORATORIES INC
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
DROPERIDOL, DROPERIDOL
GENTAMICIN SULFATE, GENTAMICIN SULFATE
HALOPERIDOL, HALOPERIDOL LACTATE
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
KANAMYCIN SULFATE, KANAMYCIN SULFATE
* SOLOPAK MEDICAL PRODUCTS INC
CYANOCOBALAMIN, CYANOCOBALAMIN
HALOPERIDOL, HALOPERIDOL LACTATE
HEPARIN LOCK FLUSH, HEPARIN SODIUM
HEPARIN SODIUM, HEPARIN SODIUM
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
NALOXONE HCL, NALOXONE HYDROCHLORIDE
PHENYTOIN SODIUM, PHENYTOIN SODIUM
PROCAINAMIDE HCL, PROCAINAMIDE HYDROCHLORIDE
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
TRIMETHOBENZAMIDE HCL, TRIMETHOBENZAMIDE HYDROCHLORIDE
VERAPAMIL HCL, VERAPAMIL HYDROCHLORIDE
* SOLOPAK PHARMACEUTICALS INC
GANITE, GALLIUM NITRATE

FDA data supplied by DrugPatentWatch.com

SOLVAY
* SOLVAY PHARMACEUTICALS
AQUATAG, BENZTHIAZIDE
ARESTOCAINE HCL W/ LEVONORDEFRIN, LEVONORDEFRIN
ARESTOCAINE HCL, MEPIVACAINE HYDROCHLORIDE
ATROPINE, ATROPINE
BALNEOL-HC, HYDROCORTISONE
BUTABARBITAL SODIUM, BUTABARBITAL SODIUM
CIN-QUIN, QUINIDINE SULFATE
CORTENEMA, HYDROCORTISONE
CURRETAB, MEDROXYPROGESTERONE ACETATE
DERMACORT, HYDROCORTISONE
DEXONE 0.5, DEXAMETHASONE
DEXONE 0.75, DEXAMETHASONE
DEXONE 1.5, DEXAMETHASONE
DEXONE 4, DEXAMETHASONE
DUPHALAC, LACTULOSE
ESTRAGUARD, DIENESTROL
ESTRATAB, ESTROGENS, ESTERIFIED
GYNOREST, DYDROGESTERONE
HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE, HYDRALAZINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LACTULOSE, LACTULOSE
LITHOBID, LITHIUM CARBONATE
LITHONATE, LITHIUM CARBONATE
LITHONATE, LITHIUM CITRATE
LITHOTABS, LITHIUM CARBONATE
LUVOX, FLUVOXAMINE MALEATE
MEPROBAMATE, MEPROBAMATE
METHOCARBAMOL, METHOCARBAMOL
ORASONE, PREDNISONE
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PORTALAC, LACTULOSE
PROVAL #3, ACETAMINOPHEN
PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
R-P MYCIN, ERYTHROMYCIN
RAUWOLFIA SERPENTINA, RAUWOLFIA SERPENTINA
RESERPINE, HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE, HYDRALAZINE HYDROCHLORIDE
RESERPINE, RESERPINE
RETET, TETRACYCLINE HYDROCHLORIDE
ROWASA, MESALAMINE
S.A.S.-500, SULFASALAZINE
SER-A-GEN, HYDRALAZINE HYDROCHLORIDE
SPRX-3, PHENDIMETRAZINE TARTRATE
SULSOXIN, SULFISOXAZOLE
SYMADINE, AMANTADINE HYDROCHLORIDE
TORA, PHENTERMINE HYDROCHLORIDE
TRANMEP, MEPROBAMATE
TRIACORT, TRIAMCINOLONE ACETONIDE
UNIPRES, HYDRALAZINE HYDROCHLORIDE
VERMIDOL, PIPERAZINE CITRATE
ZIDE, HYDROCHLOROTHIAZIDE

SOLVAY PHARMA
* SOLVAY PHARMA INC
ACEON, PERINDOPRIL ERBUMINE

SOMERSET
* SOMERSET PHARMACEUTICALS INC
ELDEPRYL, SELEGILINE HYDROCHLORIDE
SELEGILINE HCL, SELEGILINE HYDROCHLORIDE

SORIN
* SORIN BIOMEDICA SPA
SODIUM ROSE BENGAL I 131, ROSE BENGAL SODIUM, I-131

SPEAR PHARMS
* SPEAR PHARMACEUTICALS INC
TRETINOIN, TRETINOIN

SPERTI
* SPERTI DRUG PRODUCTS INC
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE

SSL INTL
* SSL INTERNATIONAL
HIBICLENS, CHLORHEXIDINE GLUCONATE (OTC)
HIBISTAT, CHLORHEXIDINE GLUCONATE (OTC)

STANLABS PHARM
* STANLABS PHARMACEUTICAL CO SUB SIMPAK CORP
MEPROBAMATE, MEPROBAMATE

STAR PHARMS FL
* STAR PHARMACEUTICALS INC
VIRILON, METHYLTESTOSTERONE

STASON
* STASON INDUSTRIAL CORP
ACYCLOVIR, ACYCLOVIR
CAPTOPRIL, CAPTOPRIL
SELEGILINE HCL, SELEGILINE HYDROCHLORIDE

STERIS
* STERIS LABORATORIES INC
AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
BETAMETHASONE SODIUM PHOSPHATE, BETAMETHASONE SODIUM PHOSPHATE
BROMPHENIRAMINE MALEATE, BROMPHENIRAMINE MALEATE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
CHLORPROMAZINE HCL, CHLORPROMAZINE HYDROCHLORIDE
CHORIONIC GONADOTROPIN, GONADOTROPIN, CHORIONIC

FDA data supplied by DrugPatentWatch.com

CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
COBAVITE, CYANOCOBALAMIN
CORTICOTROPIN, CORTICOTROPIN
CORTISONE ACETATE, CORTISONE ACETATE
CYANOCOBALAMIN, CYANOCOBALAMIN
DEXAMETHASONE ACETATE, DEXAMETHASONE ACETATE
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DEXAMETHASONE, DEXAMETHASONE
DIAZEPAM, DIAZEPAM
DICYCLOMINE HCL, DICYCLOMINE HYDROCHLORIDE
DIMENHYDRINATE, DIMENHYDRINATE
DIPHENHYDRAMINE HCL PRESERVATIVE FREE, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DISODIUM EDETATE, EDETATE DISODIUM
DOBUTAMINE HCL, DOBUTAMINE HYDROCHLORIDE
DOXAPRAM HCL, DOXAPRAM HYDROCHLORIDE
DROPERIDOL, DROPERIDOL
EDETATE DISODIUM, EDETATE DISODIUM
EDROPHONIUM CHLORIDE PRESERVATIVE FREE, EDROPHONIUM CHLORIDE
EDROPHONIUM CHLORIDE, EDROPHONIUM CHLORIDE
ESTRADIOL CYPIONATE, ESTRADIOL CYPIONATE
ESTRADIOL VALERATE, ESTRADIOL VALERATE
ESTRONE, ESTRONE
ETOPOSIDE, ETOPOSIDE
FENTANYL CITRATE, FENTANYL CITRATE
FLUOROURACIL, FLUOROURACIL
FUROSEMIDE, FUROSEMIDE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
GLYCOPYRROLATE, GLYCOPYRROLATE
HALOPERIDOL, HALOPERIDOL LACTATE
HEPARIN LOCK FLUSH, HEPARIN SODIUM
HEPARIN SODIUM, HEPARIN SODIUM
HYDROCORTISONE ACETATE, HYDROCORTISONE ACETATE
HYDROCORTISONE SODIUM SUCCINATE, HYDROCORTISONE SODIUM SUCCINATE
HYDROMORPHONE HCL, HYDROMORPHONE HYDROCHLORIDE
HYDROXOCOBALAMIN, HYDROXOCOBALAMIN
HYDROXYPROGESTERONE CAPROATE, HYDROXYPROGESTERONE CAPROATE
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
KANAMYCIN SULFATE, KANAMYCIN SULFATE
LIDOCAINE HCL W/ EPINEPHRINE, EPINEPHRINE
LIDOCAINE HCL, LIDOCAINE HYDROCHLORIDE
LINCOMYCIN HCL, LINCOMYCIN HYDROCHLORIDE
LORAZEPAM, LORAZEPAM
MANNITOL 25%, MANNITOL
MEPERIDINE HCL PRESERVATIVE FREE, MEPERIDINE HYDROCHLORIDE
MEPERIDINE HCL, MEPERIDINE HYDROCHLORIDE
MEPIVACAINE HCL, MEPIVACAINE HYDROCHLORIDE
MERSALYL-THEOPHYLLINE, MERSALYL SODIUM
METHOCARBAMOL, METHOCARBAMOL
METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE ACETATE
METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
METRONIDAZOLE, METRONIDAZOLE
MORPHINE SULFATE, MORPHINE SULFATE
MVC PLUS, ASCORBIC ACID
NALOXONE HCL, NALOXONE HYDROCHLORIDE
NANDROLONE DECANOATE, NANDROLONE DECANOATE
NANDROLONE PHENPROPIONATE, NANDROLONE PHENPROPIONATE
NATURAL ESTROGENIC SUBSTANCE-ESTRONE, ESTRONE
NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN, GRAMICIDIN
NEOMYCIN AND POLYMYXIN B SULFATES, NEOMYCIN SULFATE
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
OTOCORT, HYDROCORTISONE
PENTAMIDINE ISETHIONATE, PENTAMIDINE ISETHIONATE
PHENYTOIN SODIUM, PHENYTOIN SODIUM
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PREDNISOLONE ACETATE, PREDNISOLONE ACETATE
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
PREDNISOLONE TEBUTATE, PREDNISOLONE TEBUTATE
PROCAINAMIDE HCL, PROCAINAMIDE HYDROCHLORIDE
PROCAINE HCL, PROCAINE HYDROCHLORIDE
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
PROMAZINE HCL, PROMAZINE HYDROCHLORIDE
PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE
PYRIDOXINE HCL, PYRIDOXINE HYDROCHLORIDE
SUFENTANIL CITRATE, SUFENTANIL CITRATE
SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
TESTOSTERONE CYPIONATE-ESTRADIOL CYPIONATE, ESTRADIOL CYPIONATE
TESTOSTERONE ENANTHATE AND ESTRADIOL VALERATE, ESTRADIOL VALERATE
TESTOSTERONE ENANTHATE, TESTOSTERONE ENANTHATE
TESTOSTERONE PROPIONATE, TESTOSTERONE PROPIONATE
TESTOSTERONE, TESTOSTERONE
THIAMINE HCL, THIAMINE HYDROCHLORIDE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
TRIAMCINOLONE DIACETATE, TRIAMCINOLONE DIACETATE
TRIMETHOBENZAMIDE HCL, TRIMETHOBENZAMIDE HYDROCHLORIDE
TROPICAMIDE, TROPICAMIDE
VECURONIUM BROMIDE, VECURONIUM BROMIDE

STERLING
* STERLING HEALTH DIV STERLING WINTHROP INC
BRONKAID MIST, EPINEPHRINE (OTC)

STERLING WINTHROP
* STERLING WINTHROP INC
AFAXIN, VITAMIN A PALMITATE
CARBOCAINE, MEPIVACAINE HYDROCHLORIDE

STEVENS J

FDA data supplied by DrugPatentWatch.com

* JEROME STEVENS PHARMACEUTICALS INC
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE, ASPIRIN
CEPHALEXIN, CEPHALEXIN
METHOCARBAMOL AND ASPIRIN, ASPIRIN
ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE, ASPIRIN
UNITHROID, LIOTRIX (T4;T3)

STIEFEL
* STIEFEL LABORATORIES INC
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLINDETS, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
ERYTHROMYCIN, ERYTHROMYCIN
HYDROCORTISONE, HYDROCORTISONE
SCABENE, LINDANE
STIE-CORT, HYDROCORTISONE

STORZ
* STORZ OPHTHALMICS INC SUB AMERICAN CYANAMID CO
ACHROMYCIN, TETRACYCLINE HYDROCHLORIDE

STUART PHARMS
* STUART PHARMACEUTICALS DIV ICI AMERICAS
BUCLADIN-S, BUCLIZINE HYDROCHLORIDE

SUMMERS
* SUMMERS LABORATORIES INC
CROTAN, CROTAMITON

SUPERGEN
* SUPERGEN INC
DAUNORUBICIN HCL, DAUNORUBICIN HYDROCHLORIDE
ETOPOSIDE, ETOPOSIDE
MITOMYCIN, MITOMYCIN
NIPENT, PENTOSTATIN

SUPERPHARM
* SUPERPHARM CORP
ACETAMINOPHEN AND CODEINE PHOSPHATE #2, ACETAMINOPHEN
ACETAMINOPHEN AND CODEINE PHOSPHATE #3, ACETAMINOPHEN
ACETAMINOPHEN AND CODEINE PHOSPHATE #4, ACETAMINOPHEN
ALLOPURINOL, ALLOPURINOL
AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
CHLORDIAZEPOXIDE HCL, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
CHLORPROPAMIDE, CHLORPROPAMIDE
CHLORTHALIDONE, CHLORTHALIDONE
CYPROHEPTADINE HCL, CYPROHEPTADINE HYDROCHLORIDE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DISOPYRAMIDE PHOSPHATE, DISOPYRAMIDE PHOSPHATE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
ERGOLOID MESYLATES, ERGOLOID MESYLATES
FLURAZEPAM HCL, FLURAZEPAM HYDROCHLORIDE
FUROSEMIDE, FUROSEMIDE
HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE, HYDRALAZINE HYDROCHLORIDE
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
IBUPROFEN, IBUPROFEN
INDOMETHACIN, INDOMETHACIN
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
LOGEN, ATROPINE SULFATE
LORAZEPAM, LORAZEPAM
MECLIZINE HCL, MECLIZINE HYDROCHLORIDE
METHOCARBAMOL, METHOCARBAMOL
METHYLDOPA, METHYLDOPA
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
METRONIDAZOLE, METRONIDAZOLE
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN, ACETAMINOPHEN
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
QUINIDINE GLUCONATE, QUINIDINE GLUCONATE
QUINIDINE SULFATE, QUINIDINE SULFATE
SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPIRONOLACTONE, SPIRONOLACTONE
SULFASALAZINE, SULFASALAZINE
SULFATRIM-DS, SULFAMETHOXAZOLE
SULFATRIM-SS, SULFAMETHOXAZOLE
TETRACYCLINE HCL, TETRACYCLINE HYDROCHLORIDE
THIORIDAZINE HCL, THIORIDAZINE HYDROCHLORIDE
TOLAZAMIDE, TOLAZAMIDE
TOLBUTAMIDE, TOLBUTAMIDE
TRIPROLIDINE HCL AND PSEUDOEPHEDRINE HCL, PSEUDOEPHEDRINE HYDROCHLORIDE

SUPPOSITORIA
* SUPPOSITORIA LABORATORIES INC
ACETAMINOPHEN, ACETAMINOPHEN (OTC)

SYNCOR PHARMS
* SYNCOR PHARMACEUTICALS INC
A-N STANNOUS AGGREGATED ALBUMIN, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT
SODIUM IODIDE I 123, SODIUM IODIDE, I-123

SYNTEX (USA) INC LLC
* SYNTEX (USA) INC LLC
AEROBID, FLUNISOLIDE
ANAPROX DS, NAPROXEN SODIUM
ANAPROX, NAPROXEN SODIUM
CARDENE SR, NICARDIPINE HYDROCHLORIDE
CARDENE, NICARDIPINE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

CYTOVENE IV, GANCICLOVIR SODIUM
CYTOVENE, GANCICLOVIR
EC-NAPROSYN, NAPROXEN
EVEX, ESTROGENS, ESTERIFIED
FEMSTAT 3, BUTOCONAZOLE NITRATE (OTC)
FEMSTAT, BUTOCONAZOLE NITRATE
NAPROSYN, NAPROXEN
TICLID, TICLOPIDINE HYDROCHLORIDE
TORADOL, KETOROLAC TROMETHAMINE
VALCYTE, VALGANCICLOVIR HYDROCHLORIDE

SYNTHON PHARMS
* SYNTHON PHARMACEUTICALS LTD
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE

SYOSSET
* SYOSSET LABORATORIES INC
E-SOLVE 2, ERYTHROMYCIN
HYDROCORTISONE, HYDROCORTISONE

** T **

TABLICAPS
* TABLICAPS INC
AMINOPHYLLINE, AMINOPHYLLINE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
FOLIC ACID, FOLIC ACID
MEPROBAMATE, MEPROBAMATE
METHOCARBAMOL, METHOCARBAMOL
METHYLTESTOSTERONE, METHYLTESTOSTERONE
NIACIN, NIACIN
PREDNISOLONE, PREDNISOLONE
PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE
PROPANTHELINE BROMIDE, PROPANTHELINE BROMIDE
PROPYLTHIOURACIL, PROPYLTHIOURACIL
RAUWOLFIA SERPENTINA, RAUWOLFIA SERPENTINA
RESERPINE, RESERPINE
STILBESTROL, DIETHYLSTILBESTROL

TAKEDA
* TAKEDA CHEMICAL INDUSTRIES LTD
CERADON, CEFOTIAM HYDROCHLORIDE

TAKEDA PHARMS NA
* TAKEDA PHARMACEUTICALS NORTH AMERICA INC
ACTOS, PIOGLITAZONE HYDROCHLORIDE

TAP PHARM
* TAP PHARMACEUTICAL PRODUCTS INC
CEFMAX, CEFMENOXIME HYDROCHLORIDE
LUPRON DEPOT, LEUPROLIDE ACETATE
LUPRON DEPOT-3, LEUPROLIDE ACETATE
LUPRON DEPOT-4, LEUPROLIDE ACETATE
LUPRON DEPOT-PED, LEUPROLIDE ACETATE
LUPRON, LEUPROLIDE ACETATE
PREVACID, LANSOPRAZOLE
PREVPAC, AMOXICILLIN
SPECTRACEF, CEFDITOREN PIVOXIL

TARO
* TARO PHARMACEUTICAL INDUSTRIES LTD
ACETAZOLAMIDE, ACETAZOLAMIDE
CARBAMAZEPINE, CARBAMAZEPINE
CLOMIPRAMINE HCL, CLOMIPRAMINE HYDROCHLORIDE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
ETODOLAC, ETODOLAC
KETOCONAZOLE, KETOCONAZOLE
* TARO PHARMACEUTICALS INC
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOTRIMAZOLE, CLOTRIMAZOLE
CLOTRIMAZOLE, CLOTRIMAZOLE (OTC)
DESOXIMETASONE, DESOXIMETASONE
DIFLORASONE DIACETATE, DIFLORASONE DIACETATE
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUOCINONIDE, FLUOCINONIDE
HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE
MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
NORTRIPTYLINE HCL, NORTRIPTYLINE HYDROCHLORIDE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
WARFARIN SODIUM, WARFARIN SODIUM
* TARO PHARMACEUTICALS USA INC
AMIODARONE HCL, AMIODARONE HYDROCHLORIDE
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CLOBETASOL PROPIONATE (EMOLLIENT), CLOBETASOL PROPIONATE
CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CLOTRIMAZOLE, CLOTRIMAZOLE
CLOTRIMAZOLE, CLOTRIMAZOLE (OTC)
DERMABET, BETAMETHASONE VALERATE
DESONIDE, DESONIDE
DIFLORASONE DIACETATE, DIFLORASONE DIACETATE
FLUOCINONIDE, FLUOCINONIDE
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
NYSTATIN, NYSTATIN
ORACORT, TRIAMCINOLONE ACETONIDE
TRIVAGIZOLE 3, CLOTRIMAZOLE (OTC)

TARO PHARM INDS
* TARO PHARMACEUTICAL INDUSTRIES LTD
CARBAMAZEPINE, CARBAMAZEPINE
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
ETODOLAC, ETODOLAC

TAYLOR

FDA data supplied by DrugPatentWatch.com

* TAYLOR PHARMACEUTICALS
LABETALOL HCL, LABETALOL HYDROCHLORIDE
LORAZEPAM, LORAZEPAM
MIDAZOLAM HCL, MIDAZOLAM HYDROCHLORIDE
NAPHAZOLINE HCL, NAPHAZOLINE HYDROCHLORIDE

TAYLOR PHARMA
* TAYLOR PHARMACAL CO
DILTIAZEM HCL, DILTIAZEM HYDROCHLORIDE
MIDAZOLAM HCL, MIDAZOLAM HYDROCHLORIDE
PROPARACAINE HCL, PROPARACAINE HYDROCHLORIDE
TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE, POLYMYXIN B SULFATE

TECHNILAB
* TECHNILAB INC
ACILAC, LACTULOSE
LAXILOSE, LACTULOSE

TEIKOKU PHARMA USA
* TEIKOKU PHARMA USA INC
LIDODERM, LIDOCAINE

TEVA
* TEVA PHARMACEUTICALS USA INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACETAMINOPHEN W/ CODEINE #2, ACETAMINOPHEN
ACETAMINOPHEN W/ CODEINE #4, ACETAMINOPHEN
ACYCLOVIR, ACYCLOVIR
ADIPEX-P, PHENTERMINE HYDROCHLORIDE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALPRAZOLAM, ALPRAZOLAM
AMILORIDE HCL AND HYDROCHLOROTHIAZIDE, AMILORIDE HYDROCHLORIDE
AMIODARONE HCL, AMIODARONE HYDROCHLORIDE
AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
AMOXICILLIN PEDIATRIC, AMOXICILLIN
AMOXICILLIN, AMOXICILLIN
AMPICILLIN TRIHYDRATE, AMPICILLIN/AMPICILLIN TRIHYDRATE
ATENOLOL, ATENOLOL
BACLOFEN, BACLOFEN
BETA-VAL, BETAMETHASONE VALERATE
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
BUPROPION HCL, BUPROPION HYDROCHLORIDE
BUTABARBITAL SODIUM, BUTABARBITAL SODIUM
CALCITRIOL, CALCITRIOL
CAPTOPRIL AND HYDROCHLOROTHIAZIDE, CAPTOPRIL
CAPTOPRIL, CAPTOPRIL
CARBIDOPA AND LEVODOPA, CARBIDOPA
CEFACLOR, CEFACLOR
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
CEFUROXIME, CEFUROXIME SODIUM
CEPHALEXIN, CEPHALEXIN
CEPHRADINE, CEPHRADINE
CHLORDIAZEPOXIDE HCL, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
CHLORPROPAMIDE, CHLORPROPAMIDE
CHLORTHALIDONE, CHLORTHALIDONE
CHLORZOXAZONE, CHLORZOXAZONE
CHOLESTYRAMINE LIGHT, CHOLESTYRAMINE
CHOLESTYRAMINE, CHOLESTYRAMINE
CIMETIDINE HCL, CIMETIDINE HYDROCHLORIDE
CIMETIDINE, CIMETIDINE
CINOXACIN, CINOXACIN
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE (OTC)
CLINDAMYCIN HCL, CLINDAMYCIN HYDROCHLORIDE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLOFIBRATE, CLOFIBRATE
CLOMIPRAMINE HCL, CLOMIPRAMINE HYDROCHLORIDE
CLONAZEPAM, CLONAZEPAM
CLONIDINE HCL, CLONIDINE HYDROCHLORIDE
CLOTRIMAZOLE, CLOTRIMAZOLE
CLOXACILLIN SODIUM, CLOXACILLIN SODIUM
COPAXONE, GLATIRAMER ACETATE
COTRIM D.S., SULFAMETHOXAZOLE
COTRIM, SULFAMETHOXAZOLE
CYCLACILLIN, CYCLACILLIN
DELCOBESE, AMPHETAMINE ADIPATE
DEXAMPEX, DEXTROAMPHETAMINE SULFATE
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DICLOXACILLIN SODIUM, DICLOXACILLIN SODIUM
DIETHYLPROPION HCL, DIETHYLPROPION HYDROCHLORIDE
DIFLUNISAL, DIFLUNISAL
DILTIAZEM HCL, DILTIAZEM HYDROCHLORIDE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DISOPYRAMIDE PHOSPHATE, DISOPYRAMIDE PHOSPHATE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
DOXY-LEMMON, DOXYCYCLINE HYCLATE
DRALZINE, HYDRALAZINE HYDROCHLORIDE
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
EPITOL, CARBAMAZEPINE
ESTAZOLAM, ESTAZOLAM
ETODOLAC, ETODOLAC
FAMOTIDINE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE (OTC)
FLUOCINONIDE, FLUOCINONIDE
FLUOXETINE, FLUOXETINE HYDROCHLORIDE
FLURBIPROFEN, FLURBIPROFEN
FLUTAMIDE, FLUTAMIDE

FDA data supplied by DrugPatentWatch.com

GALZIN, ZINC ACETATE
GEMFIBROZIL, GEMFIBROZIL
GLIPIZIDE, GLIPIZIDE
GLUCAMIDE, CHLORPROPAMIDE
GLYBURIDE (MICRONIZED), GLYBURIDE
GLYBURIDE, GLYBURIDE
HALOPERIDOL, HALOPERIDOL LACTATE
HY-PAM "25", HYDROXYZINE PAMOATE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROCORTISONE, HYDROCORTISONE
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
IMIPRAMINE HCL, IMIPRAMINE HYDROCHLORIDE
INDAPAMIDE, INDAPAMIDE
INDO-LEMMON, INDOMETHACIN
INDOMETHACIN, INDOMETHACIN
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
KETOCONAZOLE, KETOCONAZOLE
KETOPROFEN, KETOPROFEN
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LABETALOL HCL, LABETALOL HYDROCHLORIDE
LOPERAMIDE HCL, LOPERAMIDE HYDROCHLORIDE
LOPERAMIDE HCL, LOPERAMIDE HYDROCHLORIDE (OTC)
LOVASTATIN, LOVASTATIN
MEGESTROL ACETATE, MEGESTROL ACETATE
MEPRIAM, MEPROBAMATE
METAPROTERENOL SULFATE, METAPROTERENOL SULFATE
METHAMPEX, METHAMPHETAMINE HYDROCHLORIDE
METHAMPHETAMINE HCL, METHAMPHETAMINE HYDROCHLORIDE
METHYLDOPA AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
METHYLDOPA, METHYLDOPA
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
METRONIDAZOLE, METRONIDAZOLE
MEXILETINE HCL, MEXILETINE HYDROCHLORIDE
MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
MINOCYCLINE HCL, MINOCYCLINE HYDROCHLORIDE
MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
MYCO-TRIACET II, NYSTATIN
NABUMETONE, NABUMETONE
NAPROXEN SODIUM, NAPROXEN SODIUM
NAPROXEN, NAPROXEN
NEOMYCIN SULFATE, NEOMYCIN SULFATE
NEOTHYLLINE, DYPHYLLINE
NICARDIPINE HCL, NICARDIPINE HYDROCHLORIDE
NIFEDIPINE, NIFEDIPINE
NORTRIPTYLINE HCL, NORTRIPTYLINE HYDROCHLORIDE
NYSTATIN, NYSTATIN
ORAP, PIMOZIDE
OXACILLIN SODIUM, OXACILLIN SODIUM
PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM
PENICILLIN, PENICILLIN G POTASSIUM
PENICILLIN-2, PENICILLIN G POTASSIUM
PENICILLIN-VK, PENICILLIN V POTASSIUM
PENTOXIFYLLINE, PENTOXIFYLLINE
PHENTERMINE HCL, PHENTERMINE HYDROCHLORIDE
PINDOLOL, PINDOLOL
PIROXICAM, PIROXICAM
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
PROBAMPACIN, AMPICILLIN/AMPICILLIN TRIHYDRATE
PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE
PROPACET 100, ACETAMINOPHEN
PROPOXYPHENE COMPOUND 65, ASPIRIN
PROPOXYPHENE HCL, PROPOXYPHENE HYDROCHLORIDE
PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN, ACETAMINOPHEN
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
RANITIDINE HCL, RANITIDINE HYDROCHLORIDE
RESERPINE, RESERPINE
SELEGILINE HCL, SELEGILINE HYDROCHLORIDE
SOTALOL HCL, SOTALOL HYDROCHLORIDE
STATOBEX, PHENDIMETRAZINE TARTRATE
STATOBEX-G, PHENDIMETRAZINE TARTRATE
SUCRALFATE, SUCRALFATE
SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH, SULFAMETHOXAZOLE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
SULFANILAMIDE, SULFANILAMIDE
SULINDAC, SULINDAC
TERAZOSIN HCL, TERAZOSIN HYDROCHLORIDE
THIORIDAZINE HCL, THIORIDAZINE HYDROCHLORIDE
THIOTHIXENE HCL, THIOTHIXENE HYDROCHLORIDE
TICLOPIDINE HCL, TICLOPIDINE HYDROCHLORIDE
TIMOLOL MALEATE, TIMOLOL MALEATE
TOLMETIN SODIUM, TOLMETIN SODIUM
TRAZODONE HCL, TRAZODONE HYDROCHLORIDE
TRIACET, TRIAMCINOLONE ACETONIDE
TRIAMCINOLONE, TRIAMCINOLONE
TRIMETHOPRIM, TRIMETHOPRIM
TRIPHED, PSEUDOEPHEDRINE HYDROCHLORIDE
VAGILIA, TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE; SULFATHIAZOLE)
VITAMIN A SOLUBILIZED, VITAMIN A PALMITATE

THAMES

* THAMES PHARMACAL CO INC
ACETIC ACID, ACETIC ACID, GLACIAL
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUOCINONIDE, FLUOCINONIDE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
HYDROCORTISONE AND ACETIC ACID, ACETIC ACID, GLACIAL

FDA data supplied by DrugPatentWatch.com

HYDROCORTISONE, HYDROCORTISONE
LIDOCAINE, LIDOCAINE
NITROFURAZONE, NITROFURAZONE
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
NYSTATIN, NYSTATIN
ORALONE, TRIAMCINOLONE ACETONIDE
SELENIUM SULFIDE, SELENIUM SULFIDE
THEOPHYLLINE, THEOPHYLLINE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
U-CORT, HYDROCORTISONE ACETATE

THERAKOS
* THERAKOS INC
UVADEX, METHOXSALEN

TOPIDERM
* TOPIDERM INC
HYDROCORTISONE, HYDROCORTISONE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

TORCH
* TORCH LABORATORIES INC
H-CORT, HYDROCORTISONE

TORPHARM
* TORPHARM INC
CAPTOPRIL, CAPTOPRIL
CIMETIDINE, CIMETIDINE
CIMETIDINE, CIMETIDINE (OTC)
CLONAZEPAM, CLONAZEPAM
DILTIAZEM HCL, DILTIAZEM HYDROCHLORIDE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
ETODOLAC, ETODOLAC
FAMOTIDINE, FAMOTIDINE
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
GEMFIBROZIL, GEMFIBROZIL
GLIPIZIDE, GLIPIZIDE
PENTOXIFYLLINE, PENTOXIFYLLINE
RANITIDINE HCL, RANITIDINE HYDROCHLORIDE
RANITIDINE, RANITIDINE HYDROCHLORIDE (OTC)
SELEGILINE HCL, SELEGILINE HYDROCHLORIDE
TERAZOSIN HCL, TERAZOSIN HYDROCHLORIDE
TICLOPIDINE HCL, TICLOPIDINE HYDROCHLORIDE

TRIGEN
* TRIGEN LABORATORIES INC
INDAPAMIDE, INDAPAMIDE
METHYLPREDNISOLONE, METHYLPREDNISOLONE
PREDNISONE, PREDNISONE
PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE

TX BIOTECH
* TEXAS BIOTECHNOLOGY CORP
ACOVA, ARGATROBAN

TYCO HLTHCARE
* TYCO HEALTHCARE GROUP LP
ANAFRANIL, CLOMIPRAMINE HYDROCHLORIDE
PAMELOR, NORTRIPTYLINE HYDROCHLORIDE
RESTORIL, TEMAZEPAM
TOFRANIL, IMIPRAMINE HYDROCHLORIDE
TOFRANIL-PM, IMIPRAMINE PAMOATE

** U **

UCB
* UCB PHARMA INC
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
KEPPRA, LEVETIRACETAM
LORTAB, ACETAMINOPHEN
THEO-24, THEOPHYLLINE

UDL
* UDL LABORATORIES INC
ALBUTEROL SULFATE, ALBUTEROL SULFATE
FOLIC ACID, FOLIC ACID
HALOPERIDOL LACTATE, HALOPERIDOL LACTATE
MECLIZINE HCL, MECLIZINE HYDROCHLORIDE
METHADONE HCL, METHADONE HYDROCHLORIDE
METOCLOPRAMIDE, METOCLOPRAMIDE HYDROCHLORIDE
NYSTATIN, NYSTATIN
PHENYTOIN, PHENYTOIN
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
VALPROIC ACID, VALPROIC ACID

UNIMED
* UNIMED INC
ANADROL-50, OXYMETHOLONE
MARINOL, DRONABINOL

UNIMED PHARMS
* UNIMED PHARMACEUTICALS INC
ANDROGEL, TESTOSTERONE
MAXAQUIN, LOMEFLOXACIN HYDROCHLORIDE
PROMETRIUM, PROGESTERONE
TEVETEN HCT, EPROSARTAN MESYLATE
TEVETEN, EPROSARTAN MESYLATE

UNITED GUARDIAN
* UNITED GUARDIAN INC
RENACIDIN, CITRIC ACID

UNIV AZ CANCER CTR
* UNIV ARIZONA CANCER CENTER

FDA data supplied by DrugPatentWatch.com

ACTINEX, MASOPROCOL

UPSHER SMITH
* UPSHER SMITH LABORATORIES INC
DEXAMETHASONE, DEXAMETHASONE
KLOR-CON M10, POTASSIUM CHLORIDE
KLOR-CON M20, POTASSIUM CHLORIDE
KLOR-CON, POTASSIUM CHLORIDE
METHOCARBAMOL, METHOCARBAMOL
NIACOR, NIACIN
PACERONE, AMIODARONE HYDROCHLORIDE
PENTOXIL, PENTOXIFYLLINE
PREDNISONE, PREDNISONE
PREVALITE, CHOLESTYRAMINE
SORINE, SOTALOL HYDROCHLORIDE
SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPIRONOLACTONE, SPIRONOLACTONE

US ARMY
* UNITED STATES ARMY OFFICE SURGEON GENERAL
ATROPINE SULFATE, ATROPINE SULFATE
SODIUM THIOSULFATE, SODIUM THIOSULFATE
* US ARMY MEDICAL RESEARCH MATERIEL COMMAND
DIAZEPAM, DIAZEPAM
SKIN EXPOSURE REDUCTION PASTE AGAINST CHEMICAL WARFARE AGENTS, PERFLUOROPOLYMETHYLISOPROPYL ETHER

US ARMY WALTER REED
* UNITED STATES ARMY WALTER REED ARMY INSTITUTE RESEARCH
MEFLOQUINE HCL, MEFLOQUINE HYDROCHLORIDE

US CHEM
* US CHEMICAL MARKETING GROUP INC
MEDIGESIC PLUS, ACETAMINOPHEN

US SURGCL
* UNITED STATES SURGICAL DIV TYCO HEALTHCARE GROUP LP
LYMPHAZURIN, ISOSULFAN BLUE

USL PHARMA
* USL PHARMA INC
ACETAMINOPHEN W/ CODEINE PHOSPHATE, ACETAMINOPHEN
ACETOHEXAMIDE, ACETOHEXAMIDE
AMANTADINE HCL, AMANTADINE HYDROCHLORIDE
AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
BACLOFEN, BACLOFEN
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
BROMPHENIRAMINE MALEATE, BROMPHENIRAMINE MALEATE
CARBAMAZEPINE, CARBAMAZEPINE
CHLORDIAZEPOXIDE AND AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
CHLORDIAZEPOXIDE HCL, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLORPROMAZINE HCL, CHLORPROMAZINE HYDROCHLORIDE
CHLORPROPAMIDE, CHLORPROPAMIDE
CHLORTHALIDONE, CHLORTHALIDONE
CLOFIBRATE, CLOFIBRATE
CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
DESIPRAMINE HCL, DESIPRAMINE HYDROCHLORIDE
DIPHEN, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENOXYLATE HCL W/ ATROPINE SULFATE, ATROPINE SULFATE
FENOPROFEN CALCIUM, FENOPROFEN CALCIUM
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUOXYMESTERONE, FLUOXYMESTERONE
FLURAZEPAM HCL, FLURAZEPAM HYDROCHLORIDE
FOLIC ACID, FOLIC ACID
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROCORTISONE, HYDROCORTISONE
HYDROFLUMETHIAZIDE AND RESERPINE, HYDROFLUMETHIAZIDE
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
IMIPRAMINE HCL, IMIPRAMINE HYDROCHLORIDE
LITHIUM CARBONATE, LITHIUM CARBONATE
LORAZEPAM, LORAZEPAM
MECLOFENAMATE SODIUM, MECLOFENAMATE SODIUM
MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE
MEGESTROL ACETATE, MEGESTROL ACETATE
MEPROBAMATE, MEPROBAMATE
METAPROTERENOL SULFATE, METAPROTERENOL SULFATE
METHYCLOTHIAZIDE, METHYCLOTHIAZIDE
METHYLTESTOSTERONE, METHYLTESTOSTERONE
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
MINOXIDIL, MINOXIDIL
MYFED, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
MYIDYL, TRIPROLIDINE HYDROCHLORIDE
MYMETHAZINE FORTIS, PROMETHAZINE HYDROCHLORIDE
NYSTATIN, NYSTATIN
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PHENTERMINE HCL, PHENTERMINE HYDROCHLORIDE
PRAZEPAM, PRAZEPAM
QUINIDINE SULFATE, QUINIDINE SULFATE
SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
SULMEPRIM PEDIATRIC, SULFAMETHOXAZOLE
SULMEPRIM, SULFAMETHOXAZOLE
TEMAZEPAM, TEMAZEPAM
TIMOLOL MALEATE, TIMOLOL MALEATE
TOLAZAMIDE, TOLAZAMIDE
TRAZODONE HCL, TRAZODONE HYDROCHLORIDE
TRIMIPRAMINE MALEATE, TRIMIPRAMINE MALEATE
VALPROIC ACID, VALPROIC ACID
WARFARIN SODIUM, WARFARIN SODIUM

** V **

VALE

FDA data supplied by DrugPatentWatch.com

* VALE CHEMICAL CO INC
AMINOPHYLLINE, AMINOPHYLLINE
SERPATE, RESERPINE

VANGARD
* VANGARD LABORATORIES INC DIV MIDWAY MEDICAL CO
ACETAZOLAMIDE, ACETAZOLAMIDE
AMINOPHYLLINE, AMINOPHYLLINE
AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
CHLORDIAZEPOXIDE HCL, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLORPROMAZINE HCL, CHLORPROMAZINE HYDROCHLORIDE
CHLORTHALIDONE, CHLORTHALIDONE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
ERGOLOID MESYLATES, ERGOLOID MESYLATES
FOLIC ACID, FOLIC ACID
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
IMIPRAMINE HCL, IMIPRAMINE HYDROCHLORIDE
LO-TROL, ATROPINE SULFATE
MECLIZINE HCL, MECLIZINE HYDROCHLORIDE
MEPROBAMATE, MEPROBAMATE
PAPA-DEINE #3, ACETAMINOPHEN
PAPA-DEINE #4, ACETAMINOPHEN
PREDNISONE, PREDNISONE
PROCAINAMIDE HCL, PROCAINAMIDE HYDROCHLORIDE
QUINIDINE SULFATE, QUINIDINE SULFATE
SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPIRONOLACTONE, SPIRONOLACTONE
SULFINPYRAZONE, SULFINPYRAZONE
TOLBUTAMIDE, TOLBUTAMIDE
TRIHEXYPHENIDYL HCL, TRIHEXYPHENIDYL HYDROCHLORIDE

VERSAPHARM
* VERSAPHARM INC
RIFAMPIN, RIFAMPIN

VESTAL LABS
* VESTAL LABORATORIES DIV CHEMED CORP
SEPTISOL, HEXACHLOROPHENE

VINTAGE PHARMS
* VINTAGE PHARMACEUTICALS INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
AMINOPHYLLINE, AMINOPHYLLINE
AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
CARISOPRODOL, CARISOPRODOL
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
FOLIC ACID, FOLIC ACID
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
LACTULOSE, LACTULOSE
MECLIZINE HCL, MECLIZINE HYDROCHLORIDE
MEPERIDINE HCL, MEPERIDINE HYDROCHLORIDE
METHYLPREDNISOLONE, METHYLPREDNISOLONE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
PEMOLINE, PEMOLINE
PERPHENAZINE, PERPHENAZINE
PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN, ACETAMINOPHEN
QUINIDINE SULFATE, QUINIDINE SULFATE
TRIHEXYPHENIDYL HCL, TRIHEXYPHENIDYL HYDROCHLORIDE

VITARINE
* VITARINE PHARMACEUTICALS INC
ACETAMINOPHEN W/ CODEINE PHOSPHATE, ACETAMINOPHEN
AMPICILLIN, AMPICILLIN/AMPICILLIN TRIHYDRATE
BROMPHENIRAMINE MALEATE, BROMPHENIRAMINE MALEATE
CEPHALEXIN, CEPHALEXIN
CEPHRADINE, CEPHRADINE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
CORTISONE ACETATE, CORTISONE ACETATE
CYPROHEPTADINE HCL, CYPROHEPTADINE HYDROCHLORIDE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
GLUTETHIMIDE, GLUTETHIMIDE
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
MECLOFENAMATE SODIUM, MECLOFENAMATE SODIUM
PENTOBARBITAL SODIUM, PENTOBARBITAL SODIUM
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PHENTERMINE HCL, PHENTERMINE HYDROCHLORIDE
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
SECOBARBITAL SODIUM, SECOBARBITAL SODIUM
SERPIVITE, RESERPINE
SULFISOXAZOLE, SULFISOXAZOLE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TRIPROLIDINE HCL, TRIPROLIDINE HYDROCHLORIDE
VITAMIN D, ERGOCALCIFEROL

VIVUS
* VIVUS INC
MUSE, ALPROSTADIL

** W **

WALLACE LABS
* WALLACE LABORATORIES DIV CARTER WALLACE INC
AQUATENSEN, METHYCLOTHIAZIDE
BEPADIN, BEPRIDIL HYDROCHLORIDE
BUTICAPS, BUTABARBITAL SODIUM
BUTISOL SODIUM, BUTABARBITAL SODIUM
COLONAID, ATROPINE SULFATE
DEPEN, PENICILLAMINE
DIUTENSEN-R, METHYCLOTHIAZIDE
DORAL, QUAZEPAM

FDA data supplied by DrugPatentWatch.com

FELBATOL, FELBAMATE
HYZYD, ISONIAZID
LUFYLLIN, DYPHYLLINE
MILTOWN, MEPROBAMATE
MYLAXEN, HEXAFLUORENIUM BROMIDE
NEOPASALATE, AMINOSALICYLATE SODIUM
RONDOMYCIN, METHACYCLINE HYDROCHLORIDE
SOMA, CARISOPRODOL
THYRO-BLOCK, POTASSIUM IODIDE (OTC)
UNITENSEN, CRYPTENAMINE ACETATES
UNITENSEN, CRYPTENAMINE TANNATES
VERTAVIS, VERATRUM VIRIDE
VOSOL HC, ACETIC ACID, GLACIAL
VOSOL, ACETIC ACID, GLACIAL
WAMPOCAP, NIACIN

WALLACE PHARMS
* WALLACE PHARMACEUTICALS DIV CARTER WALLACE INC
DORMATE, MEBUTAMATE
MEPROSPAN, MEPROBAMATE
MICRAININ, ASPIRIN
MILPREM-200, ESTROGENS, CONJUGATED
MILPREM-400, ESTROGENS, CONJUGATED
MILTOWN, MEPROBAMATE
SOMA COMPOUND W/ CODEINE, ASPIRIN
SOMA COMPOUND, ASPIRIN
* WALLACE PHARMACEUTICALS DIV MEDPOINTE HEALTHCARE INC
ASTELIN, AZELASTINE HYDROCHLORIDE

WARNER CHILCOTT
* WARNER CHILCOTT BERMUDA LTD
CHOLEDYL SA, OXTRIPHYLLINE
DORYX, DOXYCYCLINE HYCLATE
* WARNER CHILCOTT DIV WARNER LAMBERT CO
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACETAMINOPHEN W/ CODEINE PHOSPHATE, ACETAMINOPHEN
ALBUTEROL SULFATE, ALBUTEROL SULFATE
AMITRIL, AMITRIPTYLINE HYDROCHLORIDE
CARBAMAZEPINE, CARBAMAZEPINE
CHLORTHALIDONE, CHLORTHALIDONE
CLONIDINE HCL, CLONIDINE HYDROCHLORIDE
CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
CYCLOPAR, TETRACYCLINE HYDROCHLORIDE
DIAZEPAM, DIAZEPAM
DOPAMINE HCL, DOPAMINE HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DURAQUIN, QUINIDINE GLUCONATE
ERYPAR, ERYTHROMYCIN STEARATE
FENOPROFEN CALCIUM, FENOPROFEN CALCIUM
FLURAZEPAM HCL, FLURAZEPAM HYDROCHLORIDE
FUROSEMIDE, FUROSEMIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
KANAMYCIN SULFATE, KANAMYCIN SULFATE
LORAZEPAM, LORAZEPAM
PHENYTOIN SODIUM, PHENYTOIN SODIUM
PROCAINAMIDE HCL, PROCAINAMIDE HYDROCHLORIDE
PROPOXYPHENE HCL 65, PROPOXYPHENE HYDROCHLORIDE
PROPRANOLOL HCL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
QUINIDINE SULFATE, QUINIDINE SULFATE
SPIRONOLACTONE, SPIRONOLACTONE
VERAPAMIL HCL, VERAPAMIL HYDROCHLORIDE
* WARNER CHILCOTT INC
CARBAMAZEPINE, CARBAMAZEPINE
CYANOCOBALAMIN, CYANOCOBALAMIN
ERYC, ERYTHROMYCIN
ESTRACE, ESTRADIOL
FLURAZEPAM HCL, FLURAZEPAM HYDROCHLORIDE
FLURBIPROFEN, FLURBIPROFEN
OVCON-35, ETHINYL ESTRADIOL
OVCON-50, ETHINYL ESTRADIOL
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
SULINDAC, SULINDAC
TETRACYCLINE HCL, TETRACYCLINE HYDROCHLORIDE

WARNER LAMBERT
* WARNER LAMBERT CO
ZANTAC 75, RANITIDINE HYDROCHLORIDE (OTC)
* WARNER LAMBERT CO CONSUMER PRODUCTS DIV
NIX, PERMETHRIN (OTC)
* WARNER LAMBERT CONSUMER HEALTHCARE
ZANTAC 75, RANITIDINE HYDROCHLORIDE (OTC)

WARNER WELLCOME
* WARNER WELLCOME CONSUMER HEALTH PRODUCTS
SUDAFED 12 HOUR, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)

WARRICK PHARMS
* WARRICK PHARMACEUTICALS
CROMOLYN SODIUM, CROMOLYN SODIUM
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE

WATSON LAB
* WATSON LABORATORIES INC
ACETAZOLAMIDE, ACETAZOLAMIDE
ALLOPURINOL, ALLOPURINOL
AMANTADINE HCL, AMANTADINE HYDROCHLORIDE
ANISOTROPINE METHYLBROMIDE, ANISOTROPINE METHYLBROMIDE
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
CARISOPRODOL COMPOUND, ASPIRIN
CARISOPRODOL, CARISOPRODOL
CHLOROTHIAZIDE W/ RESERPINE, CHLOROTHIAZIDE
CHLOROTHIAZIDE, CHLOROTHIAZIDE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
CHLORPROPAMIDE, CHLORPROPAMIDE
CHLORTHALIDONE, CHLORTHALIDONE

FDA data supplied by DrugPatentWatch.com

CLOMIPRAMINE HCL, CLOMIPRAMINE HYDROCHLORIDE
CLONIDINE HCL, CLONIDINE HYDROCHLORIDE
CYPROHEPTADINE HCL, CYPROHEPTADINE HYDROCHLORIDE
DEXAMETHASONE, DEXAMETHASONE
DICYCLOMINE HCL, DICYCLOMINE HYDROCHLORIDE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DISOPYRAMIDE PHOSPHATE, DISOPYRAMIDE PHOSPHATE
ERGOLOID MESYLATES, ERGOLOID MESYLATES
FLUOXYMESTERONE, FLUOXYMESTERONE
FLUPHENAZINE HCL, FLUPHENAZINE HYDROCHLORIDE
FOLIC ACID, FOLIC ACID
GLIPIZIDE, GLIPIZIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
GUANETHIDINE MONOSULFATE, GUANETHIDINE MONOSULFATE
HALOPERIDOL, HALOPERIDOL
HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE, HYDRALAZINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE W/ HYDRALAZINE, HYDRALAZINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE W/ RESERPINE AND HYDRALAZINE, HYDRALAZINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE W/ RESERPINE, HYDROCHLOROTHIAZIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROFLUMETHIAZIDE AND RESERPINE, HYDROFLUMETHIAZIDE
HYDROFLUMETHIAZIDE, HYDROFLUMETHIAZIDE
HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
IMIPRAMINE HCL, IMIPRAMINE HYDROCHLORIDE
INDOMETHACIN, INDOMETHACIN
ISONIAZID, ISONIAZID
LIOTHYRONINE SODIUM, LIOTRIX (T4;T3)
LITHIUM CARBONATE, LITHIUM CARBONATE
MAPROTILINE HCL, MAPROTILINE HYDROCHLORIDE
MECLIZINE HCL, MECLIZINE HYDROCHLORIDE
MECLOFENAMATE SODIUM, MECLOFENAMATE SODIUM
METHOCARBAMOL, METHOCARBAMOL
METHYCLOTHIAZIDE AND DESERPIDINE, DESERPIDINE
METHYCLOTHIAZIDE, METHYCLOTHIAZIDE
METHYLDOPA AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
METHYLDOPA, METHYLDOPA
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
NIACIN, NIACIN
NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)
NITROFURANTOIN MACROCRYSTALLINE, NITROFURANTOIN, MACROCRYSTALLINE
NITROFURANTOIN, NITROFURANTOIN
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
OXTRIPHYLLINE, OXTRIPHYLLINE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
OXYPHENBUTAZONE, OXYPHENBUTAZONE
PERPHENAZINE AND AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
PHENYTEX, PHENYTOIN SODIUM, EXTENDED
PRIMIDONE, PRIMIDONE
PROBENECID W/ COLCHICINE, COLCHICINE
PROCAINAMIDE HCL, PROCAINAMIDE HYDROCHLORIDE
PROCHLORPERAZINE, PROCHLORPERAZINE MALEATE
PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE
PROPANTHELINE BROMIDE, PROPANTHELINE BROMIDE
PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN, ACETAMINOPHEN
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
QUINATIME, QUINIDINE GLUCONATE
SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPIRONOLACTONE, SPIRONOLACTONE
SULFAMETHOXAZOLE, SULFAMETHOXAZOLE
SULFASALAZINE, SULFASALAZINE
TEMAZEPAM, TEMAZEPAM
THIORIDAZINE HCL, THIORIDAZINE HYDROCHLORIDE
TIMOLOL MALEATE, TIMOLOL MALEATE
TOLAZAMIDE, TOLAZAMIDE
TOLBUTAMIDE, TOLBUTAMIDE
TRAZODONE HCL, TRAZODONE HYDROCHLORIDE
TRICHLORMETHIAZIDE W/ RESERPINE, RESERPINE
TRICHLORMETHIAZIDE, TRICHLORMETHIAZIDE
TRIFLUOPERAZINE HCL, TRIFLUOPERAZINE HYDROCHLORIDE
TRIHEXYPHENIDYL HCL, TRIHEXYPHENIDYL HYDROCHLORIDE
TRIPELENNAMINE HCL, TRIPELENNAMINE HYDROCHLORIDE
TRIPROLIDINE AND PSEUDOEPHEDRINE, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
WARFARIN SODIUM, WARFARIN SODIUM

WATSON LABS

* WATSON LABORATORIES
LORTAB, ACETAMINOPHEN
MICROGESTIN FE 1.5/30, ETHINYL ESTRADIOL
MICROGESTIN FE 1/20, ETHINYL ESTRADIOL
OXAPROZIN, OXAPROZIN
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
PENTAZOCINE HCL AND ACETAMINOPHEN, ACETAMINOPHEN
PROPAFENONE HCL, PROPAFENONE HYDROCHLORIDE

* WATSON LABORATORIES INC
ACEBUTOLOL HCL, ACEBUTOLOL HYDROCHLORIDE
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACETAMINOPHEN W/ CODEINE PHOSPHATE, ACETAMINOPHEN
ACYCLOVIR, ACYCLOVIR
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALLOPURINOL, ALLOPURINOL
ALORA, ESTRADIOL
ALPRAZOLAM, ALPRAZOLAM
AMILORIDE HCL AND HYDROCHLOROTHIAZIDE, AMILORIDE HYDROCHLORIDE
AMINOPHYLLINE, AMINOPHYLLINE
AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
AMOXAPINE, AMOXAPINE
ANDRODERM, TESTOSTERONE
BACLOFEN, BACLOFEN
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE

FDA data supplied by DrugPatentWatch.com

BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
BREVICON 21-DAY, ETHINYL ESTRADIOL
BREVICON 28-DAY, ETHINYL ESTRADIOL
BROMPHENIRAMINE MALEATE, BROMPHENIRAMINE MALEATE
BUTABARBITAL SODIUM, BUTABARBITAL SODIUM
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
BUTALBITAL, ASPIRIN AND CAFFEINE, ASPIRIN
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE, ASPIRIN
CAPTOPRIL, CAPTOPRIL
CARBIDOPA AND LEVODOPA, CARBIDOPA
CARISOPRODOL, CARISOPRODOL
CHLORDIAZEPOXIDE HCL, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLOROHENIRAMINE MALEATE AND PHENYLPROPANOLAMINE HCL, CHLORPHENIRAMINE MALEATE
CHLOROTHIAZIDE, CHLOROTHIAZIDE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
CHLORPROMAZINE HCL, CHLORPROMAZINE HYDROCHLORIDE
CHLORPROPAMIDE, CHLORPROPAMIDE
CHLORTHALIDONE, CHLORTHALIDONE
CHLORZOXAZONE, CHLORZOXAZONE
CLOFIBRATE, CLOFIBRATE
CLOMIPRAMINE HCL, CLOMIPRAMINE HYDROCHLORIDE
CLONAZEPAM, CLONAZEPAM
CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
CORTISONE ACETATE, CORTISONE ACETATE
CYCLOBENZAPRINE HCL, CYCLOBENZAPRINE HYDROCHLORIDE
CYPROHEPTADINE HCL, CYPROHEPTADINE HYDROCHLORIDE
DEXAMETHASONE, DEXAMETHASONE
DIAZEPAM, DIAZEPAM
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
DICYCLOMINE HCL, DICYCLOMINE HYDROCHLORIDE
DIETHYLPROPION HCL, DIETHYLPROPION HYDROCHLORIDE
DILACOR XR, DILTIAZEM HYDROCHLORIDE
DIMENHYDRINATE, DIMENHYDRINATE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENOXYLATE HCL AND ATROPINE SULFATE, ATROPINE SULFATE
DIPYRIDAMOLE, DIPYRIDAMOLE
DISULFIRAM, DISULFIRAM
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
DOXEPIN HCL, DOXEPIN HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
ERYTHROMYCIN STEARATE, ERYTHROMYCIN STEARATE
ESTAZOLAM, ESTAZOLAM
ESTRADIOL, ESTRADIOL
ESTROPIPATE, ESTROPIPATE
ETODOLAC, ETODOLAC
FENOPROFEN CALCIUM, FENOPROFEN CALCIUM
FLURAZEPAM HCL, FLURAZEPAM HYDROCHLORIDE
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
FOLIC ACID, FOLIC ACID
FUROSEMIDE, FUROSEMIDE
GEMFIBROZIL, GEMFIBROZIL
GERIMAL, ERGOLOID MESYLATES
GLIPIZIDE, GLIPIZIDE
GLUTETHIMIDE, GLUTETHIMIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
GUANABENZ ACETATE, GUANABENZ ACETATE
GUANFACINE HCL, GUANFACINE HYDROCHLORIDE
HYDRALAZINE AND HYDROCHLORTHIAZIDE, HYDRALAZINE HYDROCHLORIDE
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
HYDRALAZINE, HYDROCHLOROTHIAZIDE W/ RESERPINE, HYDRALAZINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE W/ RESERPINE, HYDROCHLOROTHIAZIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROFLUMETHIAZIDE, HYDROFLUMETHIAZIDE
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
IMIPRAMINE HCL, IMIPRAMINE HYDROCHLORIDE
INDAPAMIDE, INDAPAMIDE
INDOMETHACIN, INDOMETHACIN
ISONIAZID, ISONIAZID
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LABETALOL HCL, LABETALOL HYDROCHLORIDE
LEVORA 0.15/30-21, ETHINYL ESTRADIOL
LEVORA 0.15/30-28, ETHINYL ESTRADIOL
LOPERAMIDE HCL, LOPERAMIDE HYDROCHLORIDE (OTC)
LORAZEPAM, LORAZEPAM
LOW-OGESTREL-21, ETHINYL ESTRADIOL
LOW-OGESTREL-28, ETHINYL ESTRADIOL
LOXAPINE SUCCINATE, LOXAPINE SUCCINATE
LOXITANE C, LOXAPINE HYDROCHLORIDE
LOXITANE IM, LOXAPINE HYDROCHLORIDE
LOXITANE, LOXAPINE SUCCINATE
MAPROTILINE HCL, MAPROTILINE HYDROCHLORIDE
MECLIZINE HCL, MECLIZINE HYDROCHLORIDE
MECLOFENAMATE SODIUM, MECLOFENAMATE SODIUM
MEPERIDINE HCL, MEPERIDINE HYDROCHLORIDE
MEPROBAMATE, MEPROBAMATE
METHOCARBAMOL, METHOCARBAMOL
METHYCLOTHIAZIDE, METHYCLOTHIAZIDE
METHYLDOPA AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
METHYLDOPA, METHYLDOPA
METHYLPREDNISOLONE, METHYLPREDNISOLONE
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
METRONIDAZOLE, METRONIDAZOLE
MEXILETINE HCL, MEXILETINE HYDROCHLORIDE
MICROZIDE, HYDROCHLOROTHIAZIDE

FDA data supplied by DrugPatentWatch.com

MORPHINE SULFATE, MORPHINE SULFATE
NAPROXEN SODIUM, NAPROXEN SODIUM
NAPROXEN, NAPROXEN
NIACIN, NIACIN
NICARDIPINE HCL, NICARDIPINE HYDROCHLORIDE
NITROFURANTOIN, NITROFURANTOIN
NOR-QD, NORETHINDRONE
NORCO, ACETAMINOPHEN
NORETHIN 1/35E-21, ETHINYL ESTRADIOL
NORETHIN 1/35E-28, ETHINYL ESTRADIOL
NORETHIN 1/50M-21, MESTRANOL
NORETHIN 1/50M-28, MESTRANOL
NORETHINDRONE AND ETHINYL ESTRADIOL (10/11), ETHINYL ESTRADIOL
NORETHINDRONE AND ETHINYL ESTRADIOL (7/14), ETHINYL ESTRADIOL
NORETHINDRONE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
NORETHINDRONE AND MESTRANOL, MESTRANOL
NORINYL 1+35 21-DAY, ETHINYL ESTRADIOL
NORINYL 1+35 28-DAY, ETHINYL ESTRADIOL
NORINYL 1+50 21-DAY, MESTRANOL
NORINYL, MESTRANOL
NYSTATIN, NYSTATIN
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE AND ASPIRIN, ASPIRIN
PEMOLINE, PEMOLINE
PENTAZOCINE AND NALOXONE HYDROCHLORIDES, NALOXONE HYDROCHLORIDE
PENTOXIFYLLINE, PENTOXIFYLLINE
PERPHENAZINE AND AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PHENTERMINE HCL, PHENTERMINE HYDROCHLORIDE
PHENYLBUTAZONE, PHENYLBUTAZONE
PHENYTOIN SODIUM, PHENYTOIN SODIUM, PROMPT
PINDOLOL, PINDOLOL
PIROXICAM, PIROXICAM
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
PROBEN-C, COLCHICINE
PROBENECID, PROBENECID
PROCAINAMIDE HCL, PROCAINAMIDE HYDROCHLORIDE
PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE
PROPOXYPHENE HCL AND ACETAMINOPHEN, ACETAMINOPHEN
PROPOXYPHENE HCL W/ ASPIRIN AND CAFFEINE, ASPIRIN
PROPOXYPHENE HCL, PROPOXYPHENE HYDROCHLORIDE
PROPRANOLOL HCL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
PROPYLTHIOURACIL, PROPYLTHIOURACIL
PYRILAMINE MALEATE, PYRILAMINE MALEATE
QUINIDINE GLUCONATE, QUINIDINE GLUCONATE
QUINIDINE SULFATE, QUINIDINE SULFATE
RANITIDINE HCL, RANITIDINE HYDROCHLORIDE
RANITIDINE, RANITIDINE HYDROCHLORIDE (OTC)
RESERPINE, HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE, HYDRALAZINE HYDROCHLORIDE
RESERPINE, RESERPINE
SODIUM PENTOBARBITAL, PENTOBARBITAL SODIUM
SODIUM SECOBARBITAL, SECOBARBITAL SODIUM
SOTALOL HCL, SOTALOL HYDROCHLORIDE
SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPIRONOLACTONE, SPIRONOLACTONE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
SULFASALAZINE, SULFASALAZINE
SULFISOXAZOLE, SULFISOXAZOLE
TETRACYCLINE HCL, TETRACYCLINE HYDROCHLORIDE
THIORIDAZINE HCL, THIORIDAZINE HYDROCHLORIDE
THIOTHIXENE, THIOTHIXENE
TOLBUTAMIDE, TOLBUTAMIDE
TRI-NORINYL 21-DAY, ETHINYL ESTRADIOL
TRI-NORINYL 28-DAY, ETHINYL ESTRADIOL
TRIAMCINOLONE, TRIAMCINOLONE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TRIAZOLAM, TRIAZOLAM
TRICHLORMETHIAZIDE, TRICHLORMETHIAZIDE
TRIPELENNAMINE HCL, TRIPELENNAMINE HYDROCHLORIDE
TRIVORA-21, ETHINYL ESTRADIOL
TRIVORA-28, ETHINYL ESTRADIOL
VERAPAMIL HCL, VERAPAMIL HYDROCHLORIDE
ZOVIA 1/35E-21, ETHINYL ESTRADIOL
ZOVIA 1/35E-28, ETHINYL ESTRADIOL
ZOVIA 1/50E-21, ETHINYL ESTRADIOL
ZOVIA 1/50E-28, ETHINYL ESTRADIOL

WE PHARMS
* WE PHARMACEUTICALS INC
PREDNISOLONE, PREDNISOLONE

WELLSPRING PHARM
* WELLSPRING PHARMACEUTICAL CORP
DIBENZYLINE, PHENOXYBENZAMINE HYDROCHLORIDE
DUVOID, BETHANECHOL CHLORIDE
DYRENIUM, TRIAMTERENE

WENDT
* WENDT LABORATORIES INC
NITROFURAZONE, NITROFURAZONE

WEST WARD
* WEST WARD PHARMACEUTICAL CORP
AMINOPHYLLINE, AMINOPHYLLINE
AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
BUTALBITAL, ACETAMINOPHEN, AND CAFFEINE, ACETAMINOPHEN
BUTALBITAL, ASPIRIN AND CAFFEINE, ASPIRIN
BUTALBITAL; ACETAMINOPHEN; AND CAFFEINE WITH CODEINE

FDA data supplied by DrugPatentWatch.com

PHOSPHATE, ACETAMINOPHEN
CAPTOPRIL, CAPTOPRIL
CARISOPRODOL, CARISOPRODOL
CHLORDIAZEPOXIDE HCL, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
CHLOROTHIAZIDE AND RESERPINE, CHLOROTHIAZIDE
CHLOROTHIAZIDE, CHLOROTHIAZIDE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
CHLORPROMAZINE HCL, CHLORPROMAZINE HYDROCHLORIDE
CORTISONE ACETATE, CORTISONE ACETATE
CYANOCOBALAMIN, CYANOCOBALAMIN
DICYCLOMINE HCL, DICYCLOMINE HYDROCHLORIDE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENOXYLATE HCL AND ATROPINE SULFATE, ATROPINE SULFATE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
ETHAMBUTOL HCL, ETHAMBUTOL HYDROCHLORIDE
FLURAZEPAM HCL, FLURAZEPAM HYDROCHLORIDE
FOLIC ACID, FOLIC ACID
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROCORTISONE, HYDROCORTISONE
IMIPRAMINE HCL, IMIPRAMINE HYDROCHLORIDE
ISONIAZID, ISONIAZID
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
MEPROBAMATE, MEPROBAMATE
METHOCARBAMOL, METHOCARBAMOL
METHYLTESTOSTERONE, METHYLTESTOSTERONE
NIACIN, NIACIN
OXYTETRACYCLINE HCL, OXYTETRACYCLINE HYDROCHLORIDE
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
PROPOXYPHENE HCL, PROPOXYPHENE HYDROCHLORIDE
PROPYLTHIOURACIL, PROPYLTHIOURACIL
QUINIDINE SULFATE, QUINIDINE SULFATE
RESERPINE AND HYDROCHLOROTHIAZIDE-50, HYDROCHLOROTHIAZIDE
RESERPINE, RESERPINE
SODIUM BUTABARBITAL, BUTABARBITAL SODIUM
SODIUM SECOBARBITAL, SECOBARBITAL SODIUM
SULFISOXAZOLE, SULFISOXAZOLE
TETRACYCLINE HCL, TETRACYCLINE HYDROCHLORIDE
THIORIDAZINE HCL, THIORIDAZINE HYDROCHLORIDE
TRIHEXYPHENIDYL HCL, TRIHEXYPHENIDYL HYDROCHLORIDE
TRIPROLIDINE AND PSEUDOEPHEDRINE, PSEUDOEPHEDRINE HYDROCHLORIDE
VITAMIN A, VITAMIN A
VITAMIN A, VITAMIN A PALMITATE
VITAMIN D, ERGOCALCIFEROL

WESTWARD
* WESTWARD PHARMACEUTICAL CORP
CEFAZOLIN SODIUM, CEFAZOLIN SODIUM

WESTWOOD SQUIBB
* WESTWOOD SQUIBB PHARMACEUTICALS INC
CAPITROL, CHLOROXINE
DOVONEX, CALCIPOTRIENE
EURAX, CROTAMITON
EXELDERM, SULCONAZOLE NITRATE
FLEXICORT, HYDROCORTISONE
HALOG, HALCINONIDE
HALOG-E, HALCINONIDE
HALOTEX, HALOPROGIN
LAC-HYDRIN, AMMONIUM LACTATE
MYCOSTATIN, NYSTATIN
SOLAGE, MEQUINOL
STATICIN, ERYTHROMYCIN
T-STAT, ERYTHROMYCIN
TACARYL, METHDILAZINE
TACARYL, METHDILAZINE HYDROCHLORIDE
ULTRAVATE, HALOBETASOL PROPIONATE
WESTCORT, HYDROCORTISONE VALERATE

WESTWOOD SQUIBB CLTN
* WESTWOOD SQUIBB COLTON HOLDINGS PARTNERSHIP
VANIQA, EFLORNITHINE HYDROCHLORIDE

WHARTON LABS
* WHARTON LABORATORIES INC DIV US ETHICALS
VITAMIN A, VITAMIN A PALMITATE

WHITBY
* WHITBY PHARMACEUTICALS INC
THEOBID JR., THEOPHYLLINE
THEOBID, THEOPHYLLINE

WHITEHALL LABS
* WHITEHALL LABORATORIES INC DIV AMERICAN HOME PRODUCTS CORP
ADVIL COLD AND SINUS, IBUPROFEN (OTC)
ADVIL, IBUPROFEN (OTC)

WHITEHALL ROBINS
* WHITEHALL ROBINS HEALTHCARE
ADVIL LIQUI-GELS, IBUPROFEN POTASSIUM (OTC)
ADVIL MIGRAINE LIQUI-GELS, IBUPROFEN POTASSIUM (OTC)
AXID AR, NIZATIDINE (OTC)
CHILDREN'S ADVIL, IBUPROFEN
CHILDREN'S ADVIL, IBUPROFEN (OTC)
CHILDREN'S ADVIL-FLAVORED, IBUPROFEN (OTC)
DIMETANE, BROMPHENIRAMINE MALEATE
DIMETANE, BROMPHENIRAMINE MALEATE (OTC)
DIMETAPP, BROMPHENIRAMINE MALEATE (OTC)
JUNIOR STRENGTH ADVIL, IBUPROFEN (OTC)
ORUDIS KT, KETOPROFEN (OTC)
PEDIATRIC ADVIL, IBUPROFEN (OTC)
* WHITEHALL ROBINS HEALTHCARE DIV AMERICAN HOME PRODUCTS CORP
BRONITIN MIST, EPINEPHRINE BITARTRATE (OTC)

FDA data supplied by DrugPatentWatch.com

PRIMATENE MIST, EPINEPHRINE (OTC)

WHITEWORTH TOWN PLSN
* WHITEWORTH TOWNE PAULSEN INC
ACETAMINOPHEN W/ CODEINE PHOSPHATE, ACETAMINOPHEN
BUTABARBITAL SODIUM, BUTABARBITAL SODIUM
CORTISONE ACETATE, CORTISONE ACETATE
DEXAMETHASONE, DEXAMETHASONE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
FOLIC ACID, FOLIC ACID
H.R.-50, HYDROCHLOROTHIAZIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROCORTISONE, HYDROCORTISONE
ISONIAZID, ISONIAZID
MEPROBAMATE, MEPROBAMATE
NITROFURANTOIN, NITROFURANTOIN
PENTOBARBITAL SODIUM, PENTOBARBITAL SODIUM
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE
PROPOXYPHENE HCL, PROPOXYPHENE HYDROCHLORIDE
QUINIDINE SULFATE, QUINIDINE SULFATE
RESERPINE, RESERPINE
SECOBARBITAL SODIUM, SECOBARBITAL SODIUM

WOCKHARDT
* WOCKHARDT AMERICAS INC
CAPTOPRIL, CAPTOPRIL
ENALAPRIL MALEATE, ENALAPRIL MALEATE
FAMOTIDINE, FAMOTIDINE
RANITIDINE HCL, RANITIDINE HYDROCHLORIDE
* WOCKHARDT LTD
NIACIN, NIACIN

WOMEN FIRST HLTHCARE
* WOMEN FIRST HEALTHCARE INC
BACTRIM DS, SULFAMETHOXAZOLE
BACTRIM PEDIATRIC, SULFAMETHOXAZOLE
BACTRIM, SULFAMETHOXAZOLE
EQUAGESIC, ASPIRIN
ESCLIM, ESTRADIOL
ORTHO-EST, ESTROPIPATE
SYNALGOS-DC, ASPIRIN
SYNALGOS-DC-A, ACETAMINOPHEN
WYGESIC, ACETAMINOPHEN

WOMENS CAPITAL
* WOMENS CAPITAL CORP
PLAN B, LEVONORGESTREL

WYETH AYERST
* WYETH AYERST LABORATORIES
A.P.L., GONADOTROPIN, CHORIONIC
ALESSE, ETHINYL ESTRADIOL
ANSOLYSEN, PENTOLINIUM TARTRATE
ATIVAN, LORAZEPAM
ATROMID-S, CLOFIBRATE
AYGESTIN, NORETHINDRONE ACETATE
BICILLIN L-A, PENICILLIN G BENZATHINE
BICILLIN, PENICILLIN G BENZATHINE
CEFPIRAMIDE SODIUM, CEFPIRAMIDE SODIUM
CHLORPROMAZINE HCL, CHLORPROMAZINE HYDROCHLORIDE
CORDARONE, AMIODARONE HYDROCHLORIDE
CYANOCOBALAMIN, CYANOCOBALAMIN
CYCLAPEN-W, CYCLACILLIN
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DIGOXIN, DIGOXIN
DIMENHYDRINATE, DIMENHYDRINATE
DIMETANE-TEN, BROMPHENIRAMINE MALEATE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DIUCARDIN, HYDROFLUMETHIAZIDE
EFFEXOR XR, VENLAFAXINE HYDROCHLORIDE
EFFEXOR, VENLAFAXINE HYDROCHLORIDE
EQUANIL, MEPROBAMATE
ESTRADURIN, POLYESTRADIOL PHOSPHATE
ESTROGENIC SUBSTANCE, ESTRONE
FACTREL, GONADORELIN HYDROCHLORIDE
FLUOTHANE, HALOTHANE
FUROSEMIDE, FUROSEMIDE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
GRISACTIN ULTRA, GRISEOFULVIN, ULTRAMICROCRYSTALLINE
GRISACTIN, GRISEOFULVIN, MICROCRYSTALLINE
HEPARIN LOCK FLUSH, HEPARIN SODIUM
HEPARIN SODIUM, HEPARIN SODIUM
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
INDERAL LA, PROPRANOLOL HYDROCHLORIDE
INDERAL, PROPRANOLOL HYDROCHLORIDE
INDERIDE LA 120/50, HYDROCHLOROTHIAZIDE
INDERIDE LA 160/50, HYDROCHLOROTHIAZIDE
INDERIDE LA 80/50, HYDROCHLOROTHIAZIDE
INDERIDE-40/25, HYDROCHLOROTHIAZIDE
INDERIDE-80/25, HYDROCHLOROTHIAZIDE
ISORDIL, ISOSORBIDE DINITRATE
LARGON, PROPIOMAZINE HYDROCHLORIDE
LEVONORGESTREL, LEVONORGESTREL
LIDOCAINE HCL, LIDOCAINE HYDROCHLORIDE
LO/OVRAL, ETHINYL ESTRADIOL
LO/OVRAL-28, ETHINYL ESTRADIOL
LODINE XL, ETODOLAC
LODINE, ETODOLAC
MAZANOR, MAZINDOL
MEPERGAN, MEPERIDINE HYDROCHLORIDE
MEPERIDINE AND ATROPINE SULFATE, ATROPINE SULFATE
MEPERIDINE HCL, MEPERIDINE HYDROCHLORIDE
MYLOTARG, GEMTUZUMAB OZOGAMICIN

FDA data supplied by DrugPatentWatch.com

NALOXONE, NALOXONE HYDROCHLORIDE
NORDETTE-21, ETHINYL ESTRADIOL
NORDETTE-28, ETHINYL ESTRADIOL
NORPLANT SYSTEM IN PLASTIC CONTAINER, LEVONORGESTREL
OMNIPEN (AMPICILLIN), AMPICILLIN/AMPICILLIN TRIHYDRATE
OMNIPEN-N, AMPICILLIN SODIUM
ORUDIS, KETOPROFEN
OVRAL, ETHINYL ESTRADIOL
OVRAL-28, ETHINYL ESTRADIOL
OVRETTE, NORGESTREL
OXYTOCIN, OXYTOCIN
PATHOCIL, DICLOXACILLIN SODIUM
PEN-VEE K, PENICILLIN V POTASSIUM
PENBRITIN, AMPICILLIN/AMPICILLIN TRIHYDRATE
PENBRITIN-S, AMPICILLIN SODIUM
PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM
PEPTAVLON, PENTAGASTRIN
PHENERGAN FORTIS, PROMETHAZINE HYDROCHLORIDE
PHENERGAN PLAIN, PROMETHAZINE HYDROCHLORIDE
PHENERGAN VC W/ CODEINE, CODEINE PHOSPHATE
PHENERGAN VC, PHENYLEPHRINE HYDROCHLORIDE
PHENERGAN W/ CODEINE, CODEINE PHOSPHATE
PHENERGAN W/ DEXTROMETHORPHAN, DEXTROMETHORPHAN HYDROBROMIDE
PHENERGAN, PROMETHAZINE HYDROCHLORIDE
PLEGINE, PHENDIMETRAZINE TARTRATE
PMB 200, ESTROGENS, CONJUGATED
PMB 400, ESTROGENS, CONJUGATED
PRALIDOXIME CHLORIDE, PRALIDOXIME CHLORIDE
PREMARIN, ESTROGENS, CONJUGATED
PREMPHASE (PREMARIN;CYCRIN 14/14), ESTROGENS, CONJUGATED
PREMPHASE 14/14, ESTROGENS, CONJUGATED
PREMPRO (PREMARIN;CYCRIN), ESTROGENS, CONJUGATED
PREMPRO, ESTROGENS, CONJUGATED
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
PROKETAZINE, CARPHENAZINE MALEATE
PROTONIX IV, PANTOPRAZOLE SODIUM
PROTONIX, PANTOPRAZOLE SODIUM
PROTOPAM CHLORIDE, PRALIDOXIME CHLORIDE
RAPAMUNE, SIROLIMUS
ROBITET, TETRACYCLINE HYDROCHLORIDE
SECOBARBITAL SODIUM, SECOBARBITAL SODIUM
SECTRAL, ACEBUTOLOL HYDROCHLORIDE
SODIUM PENTOBARBITAL, PENTOBARBITAL SODIUM
SODIUM SECOBARBITAL, SECOBARBITAL SODIUM
SONATA, ZALEPLON
SPARINE, PROMAZINE HYDROCHLORIDE
SULFOSE, TRISULFAPYRIMIDINES (SULFADIAZINE;SULFAMERAZINE; SULFAMETHAZINE)
TENEX, GUANFACINE HYDROCHLORIDE
TETRACYCLINE HCL, TETRACYCLINE HYDROCHLORIDE
THIAMINE HCL, THIAMINE HYDROCHLORIDE
THIOSULFIL, SULFAMETHIZOLE
TRECATOR-SC, ETHIONAMIDE
TRIPHASIL-21, ETHINYL ESTRADIOL
TRIPHASIL-28, ETHINYL ESTRADIOL
UNIPEN IN PLASTIC CONTAINER, NAFCILLIN SODIUM
UNIPEN, NAFCILLIN SODIUM
WYAMINE SULFATE, MEPHENTERMINE SULFATE
WYAMYCIN E, ERYTHROMYCIN ETHYLSUCCINATE
WYAMYCIN S, ERYTHROMYCIN STEARATE
WYDASE, HYALURONIDASE
WYMOX, AMOXICILLIN
WYTENSIN, GUANABENZ ACETATE
ZOSYN, PIPERACILLIN SODIUM

* WYETH AYERST RESEARCH
CERUBIDINE, DAUNORUBICIN HYDROCHLORIDE
ORUVAIL, KETOPROFEN

** X **

XANODYNE PHARM
* XANODYNE PHARMACAL INC
AMICAR, AMINOCAPROIC ACID

XCEL PHARMS
* XCEL PHARMACEUTICALS
DIASTAT, DIAZEPAM
MYSOLINE, PRIMIDONE

XTTRIUM
* XTTRIUM LABORATORIES INC
DYNA-HEX, CHLORHEXIDINE GLUCONATE (OTC)
EXIDINE, CHLORHEXIDINE GLUCONATE (OTC)
TURGEX, HEXACHLOROPHENE

** Y **

YAMANOUCHI
* YAMANOUCHI EUROPE BV
LOCOID LIPOCREAM, HYDROCORTISONE BUTYRATE
LOCOID, HYDROCORTISONE BUTYRATE

YOSHITOMI
* YOSHITOMI PHARMACEUTICAL INDUSTRIES LTD
CEPHALEXIN, CEPHALEXIN

** Z **

ZAMBON
* ZAMBON CORP
MONUROL, FOSFOMYCIN TROMETHAMINE

ZILA
* ZILA PHARMACEUTICALS INC
PERIDEX, CHLORHEXIDINE GLUCONATE

FDA data supplied by DrugPatentWatch.com

APPENDIX C

UNIFORM TERMS

DOSAGE FORMS

AEROSOL
AEROSOL, METERED
BAR, CHEWABLE
CAPSULE
CAPSULE, COATED PELLETS
CAPSULE, DELAYED REL PELLETS
CAPSULE, EXTENDED RELEASE
CONCENTRATE
CREAM
CREAM, AUGMENTED
CREAM, SUPPOSITORY
DISC
DRESSING
DRUG DELIVERY SYSTEM
ELIXIR
EMULSION
ENEMA
FIBER, EXTENDED RELEASE
FILM, EXTENDED RELEASE
FOR SOLUTION
FOR SUSPENSION
FOR SUSPENSION, EXTENDED RELEASE
GAS
GEL
GEL, METERED
GRANULE
GRANULE, DELAYED RELEASE
GRANULE, EFFERVESCENT
GUM, CHEWING
IMPLANT
INHALANT
INJECTABLE
INJECTABLE, LIPID COMPLEX
INJECTABLE, LIPOSOMAL
INSERT
INSERT, EXTENDED RELEASE
INTRAUTERINE DEVICE
JELLY
LIQUID
LIQUID, EXTENDED RELEASE
LOTION
LOTION, AUGMENTED
LOTION, SHAMPOO
N/A
OIL
OINTMENT
OINTMENT, AUGMENTED
PASTE
PASTILLE
PELLET
POWDER
POWDER, METERED
RING
SHAMPOO
SOAP
SOLUTION
SOLUTION FOR SLUSH
SOLUTION/DROPS
SOLUTION, CONCENTRATE
SOLUTION, GEL FORMING/DROPS
SPONGE
SPRAY
SPRAY, METERED
SUPPOSITORY
SUSPENSION
SUSPENSION/DROPS
SUSPENSION, EXTENDED RELEASE
SWAB
SYRUP
TABLET
TABLET, CHEWABLE
TABLET, COATED PARTICLES
TABLET, DELAYED RELEASE
TABLET, DISPERSIBLE
TABLET, EFFERVESCENT
TABLET, EXTENDED RELEASE
TABLET, ORALLY DISINTEGRATING
TAMPON
TAPE
TROCHE/LOZENGE

FDA data supplied by DrugPatentWatch.com

APPENDIX C

UNIFORM TERMS

ROUTES OF ADMINISTRATION

BUCCAL
BUCCAL/SUBLINGUAL
DENTAL
ENDOCERVICAL
FOR RX COMPOUNDING
IM-IV
IMPLANTATION
INHALATION
INJECTION
INTRACRANIAL
INTRALYMPHATIC
INTRAMUSCULAR
INTRAOCULAR
INTRAPERITONEAL
INTRAPLEURAL
INTRATHECAL
INTRATRACHEAL
INTRAUTERINE
INTRAVASCULAR
INTRAVENOUS
INTRAVESICAL
IONTOPHORESIS
IRRIGATION
IV (INFUSION)
N/A
NASAL
OPHTHALMIC
ORAL
ORAL-20
ORAL-21
ORAL-28
OTIC
PERFUSION, BILIARY
PERFUSION, CARDIAC
PERIODONTAL
RECTAL
SPINAL
SUBCUTANEOUS
SUBLINGUAL
TOPICAL
TOPICAL, VAGINAL
TRANSDERMAL
URETERAL
URETHRAL
VAGINAL

ABBREVIATIONS

AMP	AMPULE	GM	GRAM	ML	MILLILITER
AMPICIL	AMPICILLIN	HBR	HYDROBROMIDE	N/A	NOT APPLICABLE
APPROX	APPROXIMATELY	HCL	HYDROCHLORIDE	PPM	PARTS PER MILLION
BOT	BOTTLE	HR	HOUR	REL	RELEASE
CI	CURIE	INH	INHALATION	SQ CM	SQUARE CENTIMETER
CSR	CAROTID SINUS REFLEX	IU	INTERNATIONAL UNITS	U	UNITS
CU	CLINICAL UNITS	KIU	KALLIKREIN INHIBITOR UNITS	UCI	MICROCURIE
DIPROP	DIPROPIONATE			UGM	MICROGRAM
EQ	EQUIVALENT TO	MCI	MILLICURIE	UMOLAR	MICROMOLAR
ELECT	ELECTROLYTE	MEQ	MILLIEQUIVALENT	USP	UNITED STATES PHARMACOPEIA
ER	EXTENDED RELEASE	MG	MILLIGRAM		

FDA data supplied by DrugPatentWatch.com

PATENT AND EXCLUSIVITY INFORMATION ADDENDUM

This *Addendum* identifies drugs that qualify under the Drug Price Competition and Patent Term Restoration Act (1984 Amendments) for periods of exclusivity, during which abbreviated new drug applications (ANDAs) and applications described in Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (the Act) for those drug products may, in some instances, not be submitted or made effective as described below, and provides patent information concerning the listed drug products. Those drugs that have qualified for Orphan Drug Exclusivity pursuant to Section 527 of the Act and those drugs that have qualified for Pediatric Exclusivity pursuant to Section 505A are also included in this *Addendum*. This section is arranged in alphabetical order by active ingredient name. For those drug products with multiple active ingredients, only the first active ingredient (in alphabetical order) will appear. For an explanation of the codes used in the *Addendum*, see the *Patent and Exclusivity Terms* page. Exclusivity prevents the submission or effective approval of ANDAs or applications described in Section 505(b)(2) of the Act. It does not prevent the submission or approval of a second full NDA. Applications qualifying for periods of exclusivity are:

(1) A new drug application approved after September 24, 1984, for a drug product all active ingredients (including any ester or salt of the active ingredient) of which had never been approved in any other new drug application under Section 505 (b) (2) of the Act. No subsequent ANDA or application described in Section 505(b)(2) of the Act for the same drug may be *submitted* for a period of *five years* from the date of approval of the original application, except that such an application may be *submitted* after *four years* if it contains a certification that a patent claiming the drug is invalid or will not be infringed by the product for which approval is sought.

(2) A new drug application approved after September 24, 1984, for a drug product containing an active ingredient (including any ester or salt of that active ingredient) that has been approved in an earlier new drug application and that includes reports of new clinical investigations (other than bioavailability studies). Such investigations must have been conducted or sponsored by the applicant and must have been essential to approval of the application. If these requirements are met, the approval of a subsequent ANDA or an application described in Section 505(b)(2) of the Act may not be *made effective* for the same drug or use, if for a new indication, before the expiration of *three years* from the date of approval of the original application. If an applicant has exclusivity for a new use or indication, this does not preclude the approval of an ANDA application or 505(b)(2) application for the drug product with indications not covered by the exclusivity.

(3) A supplement to a new drug application for a drug containing a previously approved active ingredient including any ester or salt of the active ingredient) approved after September 24, 1984, that contains reports of new clinical investigations (other than bioavailability studies) essential to the approval of the supplement and conducted or sponsored by the applicant. The approval of a subsequent application for a change approved in the supplement may not be *made effective* for *three years* from the date of approval of the original supplement.

FDA data supplied by DrugPatentWatch.com

The Act requires that patent information must now be filed with all newly submitted Section 505 drug applications, and that no NDA may be approved after September 24, 1984, without the submission of pertinent patent information to the Agency. The patent numbers and the expiration dates of appropriate patents claiming drug products that are the subject of approved applications will be published in this *Addendum* or in the monthly Cumulative Supplement to this publication. Patent information on unapproved applications or on patents beyond the scope of the Act (i.e., process or manufacturing patents) will not be published.

The patents that FDA regards as covered by the statutory provisions for submission of patent information are: patents that claim the active ingredient or ingredients; drug product patents, which include formulation/composition patents; and use patents for a particular approved indication or method of using the product. NDA holders or applicants amending or supplementing applications with formulation/composition patent information are asked to declare that the patent(s) is appropriate for publication and refers to an approved product or one for which approval is being sought. The Agency asks all applicants or application holders with use patents to provide information as to the approved indications or uses covered by such patents. This information will be included in the Cumulative Supplement to the List as it becomes available.

Since all parts of this publication are subject to changes, additions, or deletions, the *Addendum* must be used in conjunction with the most current Cumulative Supplement.

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
021205 001	ABACAVIR SULFATE;TRIZIVIR	5034394	JUN 26, 2009		NCE	DEC 17, 2003
		5089500	JUN 26, 2009	U-248	PED	JUN 17, 2004
		5047407	NOV 17, 2009			
		5905082	MAY 18, 2016			
		4724232	SEP 17, 2005			
		4818538	SEP 17, 2005			
		4833130	SEP 17, 2005			
		4837208	SEP 17, 2005			
		4828838	SEP 17, 2005			
		5034394*PED	DEC 26, 2009			
		5047407*PED	MAY 17, 2010			
		5089500*PED	DEC 26, 2009	U-248		
		5905082*PED	NOV 18, 2016			
		6180639	JAN 30, 2018	U-248		
		6294540	MAY 14, 2018	U-65		
		6294540*PED	NOV 14, 2018	U-65		
		6180639*PED	JUL 30, 2018	U-248		
020977 001	ABACAVIR SULFATE;ZIAGEN	5089500	JUN 26, 2009	U-248	PED	JUN 17, 2004
		5089500*PED	DEC 26, 2009		NCE	DEC 17, 2003
		5034394	JUN 26, 2009			
		5034394*PED	DEC 26, 2009			
		6294540	MAY 14, 2018	U-65		
		6294540*PED	NOV 14, 2018	U-65		
020978 001	ABACAVIR SULFATE;ZIAGEN	5089500	JUN 26, 2009	U-248	PED	JUN 17, 2004
		5089500*PED	DEC 26, 2009		NCE	DEC 17, 2003
		5034394	JUN 26, 2009			
		5034394*PED	DEC 26, 2009			
		6294978	MAY 14, 2018	U-65		
		6294978*PED	NOV 14, 2018	U-65		
		6294540*PED	NOV 14, 2018	U-65		
		6294540	MAY 14, 2018	U-65		
020482 001	ACARBOSE;PRECOSE	4904769	FEB 27, 2007			
020482 002	ACARBOSE;PRECOSE	4904769	FEB 27, 2007			
020482 004	ACARBOSE;PRECOSE	4904769	FEB 27, 2007			
020802 001	ACETAMINOPHEN;EXCEDRIN (MIGRAINE)	5972916	JUL 14, 2017	U-296		
		4943565	JUL 24, 2007			
021082 001	ACETAMINOPHEN;TAVIST ALLERGY/SINUS/HEADACHE				NC	MAR 01, 2004
019872 001	ACETAMINOPHEN;TYLENOL	5004613	JUL 27, 2007			
		4820522	JUL 27, 2007			
		4968509	NOV 06, 2007			
021123 001	ACETAMINOPHEN;ULTRACET	5336691	AUG 09, 2011		NC	AUG 15, 2004
019806 001	ACRIVASTINE;SEMPREX-D	4501893	FEB 01, 2003			
		4650807	MAR 26, 2008	U-93		
020338 001	ADAPALENE;DIFFERIN	4717720	MAY 31, 2010			
		RE34440	MAR 31, 2010	U-275		
020380 001	ADAPALENE;DIFFERIN	4717720	MAY 31, 2010			
		RE34440	MAY 31, 2010	U-275		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020748 001	ADAPALENE;DIFFERIN	4717720	MAY 31, 2010		NDF	MAY 26, 2003
		RE34440	MAY 31, 2010	U-275		
019937 002	ADENOSINE;ADENOCARD	4673563	JUN 16, 2004	U-38		
020059 001	ADENOSINE;ADENOSCAN	5070877	MAY 18, 2009	U-116		
		5731296	MAR 24, 2015	U-221		
020760 001	ALATROFLOXACIN MESYLATE;TROVAN PRESERVATIVE FREE	5164402	NOV 17, 2009	U-282	NCE	DEC 18, 2002
		5763454	JUN 15, 2015	U-282		
		6080756	JUL 05, 2016			
		6194429	JUL 23, 2018			
020760 002	ALATROFLOXACIN MESYLATE;TROVAN PRESERVATIVE FREE	5164402	NOV 17, 2009	U-282	NCE	DEC 18, 2002
		5763454	JUN 15, 2015	U-282		
		6080756	JUL 05, 2016			
		6194429	JUL 23, 2018			
020666 001	ALBENDAZOLE;ALBENZA				ODE	JUN 11, 2003
020949 001	ALBUTEROL SULFATE;ACCUNEB				NP	APR 30, 2004
020949 002	ALBUTEROL SULFATE;ACCUNEB				NP	APR 30, 2004
020291 001	ALBUTEROL SULFATE;COMBIVENT	5603918	JUN 09, 2015			
020950 001	ALBUTEROL SULFATE;DUONEB				NP	MAR 21, 2004
018062 001	ALBUTEROL SULFATE;PROVENTIL	4499108	JUN 08, 2003			
020503 001	ALBUTEROL SULFATE;PROVENTIL-HFA	5439670	JUL 06, 2010		I-262	JUN 02, 2002
		5605674	FEB 25, 2014			
		5225183	JUL 06, 2010			
		5766573	JUN 16, 2015			
019621 001	ALBUTEROL SULFATE;VENTOLIN	4594359	JUN 10, 2003			
020983 001	ALBUTEROL SULFATE;VENTOLIN HFA	6251368	DEC 04, 2012		I-262	JUN 02, 2002
019604 001	ALBUTEROL SULFATE;VOLMAX	4751071	JUN 14, 2005			
		4777049	OCT 11, 2005			
		4851229	JUN 14, 2005			
019604 002	ALBUTEROL SULFATE;VOLMAX	4751071	JUN 14, 2005			
		4777049	OCT 11, 2005			
		4851229	JUN 14, 2005			
021074 001	ALCOHOL;AVAGARD	5897031	JUN 21, 2016		NC	JUN 07, 2004
020560 001	ALENDRONATE SODIUM;FOSAMAX	5358941	DEC 02, 2012		M-3	NOV 24, 2002
		4621077	AUG 06, 2007	U-114	I-272	JUN 16, 2002
		5681590	DEC 02, 2012		I-309	SEP 29, 2003
		5804570	FEB 17, 2015			
		5849726	JUN 06, 2015			
		6008207	JUN 06, 2015	U-303		
		6090410	DEC 02, 2012			
		6194004	DEC 02, 2012			
020560 002	ALENDRONATE SODIUM;FOSAMAX	5358941	DEC 02, 2012		M-3	NOV 24, 2002
		4621077	AUG 06, 2007	U-114	I-272	JUN 16, 2002
		5681590	DEC 02, 2012			
		5849726	JUN 06, 2015			
		6008207	JUN 06, 2015	U-303		
		6090410	DEC 02, 2012			
020560 003	ALENDRONATE SODIUM;FOSAMAX	5358941	DEC 02, 2012		M-3	NOV 24, 2002
		4621077	AUG 06, 2007	U-114	I-272	JUN 16, 2002
		5681590	DEC 02, 2012			
		5804570	FEB 17, 2015			
		5849726	JUN 06, 2015			
		6008207	JUN 06, 2015	U-303		
		6090410	DEC 02, 2012			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020560 004	ALENDRONATE SODIUM;FOSAMAX	6015801	JUL 17, 2018	U-353	NS	OCT 20, 2003
		4621077	AUG 06, 2007	U-114	D-61	OCT 20, 2003
		5358941	DEC 02, 2012		D-62	OCT 20, 2003
		5681590	DEC 02, 2012			
		5804570	FEB 17, 2015			
		5849726	JUN 06, 2015			
		6008207	JUN 06, 2015			
		6090410	DEC 02, 2012			
		5994329	JUL 17, 2018			
		6225294	JUL 17, 2018			
020560 005	ALENDRONATE SODIUM;FOSAMAX	6015801	JUL 17, 2018	U-353	NS	OCT 20, 2003
		4621077	AUG 06, 2007	U-114	D-61	OCT 20, 2003
		5358941	DEC 02, 2012		D-62	OCT 20, 2003
		5681590	DEC 02, 2012			
		5804570	FEB 17, 2015			
		5849726	JUN 06, 2015			
		5994329	JUL 17, 2018			
		6008207	JUN 06, 2015			
		6090410	DEC 02, 2012			
		6225294	JUL 17, 2018			
020886 001	ALITRETINOIN;PANRETIN				ODE	FEB 02, 2006
					NCE	FEB 02, 2004
020298 001	ALLOPURINOL SODIUM;ALOPRIM				ODE	MAY 17, 2003
021001 001	ALMOTRIPTAN MALATE;AXERT	5565447	MAR 27, 2014		NCE	MAY 07, 2006
021001 002	ALMOTRIPTAN MALATE;AXERT	5565447	MAR 27, 2014		NCE	MAY 07, 2006
021107 001	ALOSETRON HYDROCHLORIDE;LOTRONEX	5360800	FEB 02, 2010		NCE	FEB 09, 2005
		6284770	OCT 05, 2018	U-405		
018276 001	ALPRAZOLAM;XANAX	4508726	SEP 16, 2002	U-46		
018276 002	ALPRAZOLAM;XANAX	4508726	SEP 16, 2002	U-46		
018276 003	ALPRAZOLAM;XANAX	4508726	SEP 16, 2002	U-46		
018276 004	ALPRAZOLAM;XANAX	5061494	OCT 29, 2008			
		4508726	SEP 16, 2002	U-46		
020379 001	ALPROSTADIL;CAVERJECT	5741523	APR 21, 2015			
020379 002	ALPROSTADIL;CAVERJECT	5741523	APR 21, 2015			
020379 003	ALPROSTADIL;CAVERJECT	5741523	APR 21, 2015			
020379 004	ALPROSTADIL;CAVERJECT	5741523	APR 21, 2015			
020700 001	ALPROSTADIL;MUSE	5242391	SEP 07, 2010	U-155		
		4801587	JAN 31, 2007	U-155		
		5474535	DEC 12, 2012	U-155		
020700 002	ALPROSTADIL;MUSE	4801587	JAN 31, 2007	U-155		
		5242391	SEP 07, 2010	U-155		
		5474535	DEC 12, 2012	U-155		
020700 003	ALPROSTADIL;MUSE	4801587	JAN 31, 2007	U-155		
		5474535	DEC 12, 2012	U-155		
		5242391	SEP 07, 2010	U-155		
020700 004	ALPROSTADIL;MUSE	4801587	JAN 31, 2007	U-155		
		5242391	SEP 07, 2010	U-155		
		5474535	DEC 12, 2012	U-155		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020221 001	AMIFOSTINE;ETHYOL	5424471	JUL 31, 2012		I-283	JUN 24, 2002
		5591731	JUL 31, 2012		ODE	JUN 24, 2006
		5994409	DEC 08, 2017	U-305	ODE	DEC 08, 2002
020221 002	AMIFOSTINE;ETHYOL	5242471	JUL 31, 2012		I-283	JUN 24, 2002
		5591731	JUL 31, 2012		ODE	JUN 24, 2006
		5994409	DEC 08, 2017	U-305	ODE	DEC 08, 2002
020965 001	AMINOLEVULINIC ACID HYDROCHLORIDE;LEVULAN	5079262	JUL 28, 2009	U-289	NCE	DEC 03, 2004
		5211938	MAY 18, 2010	U-289		
		5422093	JUL 28, 2009	U-289		
020377 001	AMIODARONE HYDROCHLORIDE;CORDARONE				ODE	AUG 03, 2002
020511 001	AMLEXANOX;APHTHASOL	5362737	NOV 08, 2011	U-243		
020364 002	AMLODIPINE BESYLATE;LOTREL	4410520	AUG 11, 2003			
		4879303	MAR 25, 2007			
		4572909	JUL 31, 2006			
		6162802	DEC 19, 2017	U-367		
020364 003	AMLODIPINE BESYLATE;LOTREL	4410520	AUG 11, 2003			
		4879303	MAR 25, 2007			
		4572909	JUL 31, 2006			
		6162802	DEC 19, 2017	U-367		
020364 004	AMLODIPINE BESYLATE;LOTREL	4410520	AUG 11, 2003			
		4879303	MAR 25, 2007			
		4572909	JUL 31, 2006			
		6162802	DEC 19, 2017	U-367		
019787 001	AMLODIPINE BESYLATE;NORVASC	4879303	MAR 25, 2007			
		4572909	JUL 31, 2006			
		4879303*PED	SEP 25, 2007			
		4572909*PED	JAN 31, 2007			
019787 002	AMLODIPINE BESYLATE;NORVASC	4879303	MAR 25, 2007			
		4572909	JUL 31, 2006			
		4879303*PED	SEP 25, 2007			
		4572909*PED	JAN 31, 2007			
019787 003	AMLODIPINE BESYLATE;NORVASC	4879303	MAR 25, 2007			
		4572909	JUL 31, 2006			
		4879303*PED	SEP 25, 2007			
		4572909*PED	JAN 31, 2007			
020508 001	AMMONIUM LACTATE;LAC-HYDRIN				M-4	AUG 25, 2003
					PED	FEB 25, 2004
021303 001	AMPHETAMINE ASPARTATE;ADDERALL XR 10				NDF	OCT 11, 2004
021303 002	AMPHETAMINE ASPARTATE;ADDERALL XR 20				NDF	OCT 11, 2004
021303 003	AMPHETAMINE ASPARTATE;ADDERALL XR 30				NDF	OCT 11, 2004
050724 001	AMPHOTERICIN B;ABELCET				ODE	OCT 18, 2003
050740 001	AMPHOTERICIN B;AMBISOME				ODE	AUG 11, 2004
021007 001	AMPRENAVIR;AGENERASE	5723490	MAR 03, 2013	U-257	NCE	APR 15, 2004
		5646180	JUL 08, 2014	U-257		
		5585397	DEC 17, 2013			
021007 002	AMPRENAVIR;AGENERASE	5723490	MAR 03, 2015	U-257	NCE	APR 15, 2004
		5646180	JUL 08, 2014	U-257		
		5585397	DEC 17, 2013			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
021039 001	AMPRENAVIR;AGENERASE	5585397	DEC 17, 2013		NCE	APR 15, 2004
		5723490	MAR 03, 2015	U-257		
		5646180	JUL 08, 2014	U-257		
020333 001	ANAGRELIDE HYDROCHLORIDE;AGRYLIN				ODE	MAR 14, 2004
					NCE	MAR 14, 2002
020333 002	ANAGRELIDE HYDROCHLORIDE;AGRYLIN				ODE	MAR 14, 2004
					NCE	MAR 14, 2002
020541 001	ANASTROZOLE;ARIMIDEX	RE36617	DEC 27, 2009		I-312	SEP 01, 2003
019779 001	APRACLONIDINE HYDROCHLORIDE;IOPIDINE	5212196	MAY 18, 2010	U-120		
		4517199	MAY 14, 2002	U-15		
020258 001	APRACLONIDINE HYDROCHLORIDE;IOPIDINE	4517199	MAY 14, 2002	U-15		
020420 001	ARBUTAMINE HYDROCHLORIDE;GENESA	5108363	APR 28, 2009	U-220	NCE	SEP 12, 2002
		5234404	AUG 10, 2010	U-220		
		5395970	MAR 07, 2012			
020227 002	ARDEPARIN SODIUM;NORMIFLO				NCE	MAY 23, 2002
020883 001	ARGATROBAN;ACOVA	5214052	MAR 13, 2012		NCE	JUN 30, 2005
021248 001	ARSENIC TRIOXIDE;TRISENOX				ODE	SEP 25, 2007
					NCE	SEP 25, 2005
020971 001	ARTICAINE HYDROCHLORIDE;SEPTOCAINE				NC	APR 03, 2003
020884 001	ASPIRIN;AGGRENOX	6015577	JAN 18, 2017	U-302	NC	NOV 22, 2002
021317 001	ASPIRIN;BAYER EXTRA STRENGTH ASPIRIN FOR				NP	OCT 18, 2004
012365 005	ASPIRIN;SOMA COMPOUND	4534973	AUG 13, 2002			
012366 002	ASPIRIN;SOMA COMPOUND W/ CODEINE	4534974	AUG 13, 2002			
020702 001	ATORVASTATIN CALCIUM;LIPITOR	4681893	SEP 24, 2009	U-161	I-281	DEC 02, 2002
		5273995	DEC 28, 2010	U-162	PED	JUN 02, 2003
		5686104	NOV 11, 2014	U-213		
		5969156	JUL 08, 2016			
		6126971	JAN 19, 2013			
		4681893*PED	MAR 24, 2010	U-161		
		5273995*PED	JUN 28, 2011	U-162		
		5686104*PED	MAY 11, 2015	U-213		
		5969156*PED	JAN 08, 2017			
		6126971*PED	JUL 19, 2013			
020702 002	ATORVASTATIN CALCIUM;LIPITOR	4681893	SEP 24, 2009	U-161	I-281	DEC 02, 2002
		5273995	DEC 28, 2010	U-162	PED	JUN 02, 2003
		5686104	NOV 11, 2014	U-213		
		5969156	JUL 08, 2016			
		6126971	JAN 19, 2013			
		4681893*PED	MAR 24, 2010	U-161		
		5273995*PED	JUN 28, 2011	U-162		
		5686104*PED	MAY 11, 2015	U-213		
		5969156*PED	JAN 18, 2017			
		6126971*PED	JUL 19, 2013			
020702 003	ATORVASTATIN CALCIUM;LIPITOR	4681893	SEP 24, 2009	U-161	I-281	DEC 02, 2002
		5273995	DEC 28, 2010	U-162	PED	JUN 02, 2003
		5686104	NOV 11, 2014	U-213		
		5969156	JUL 08, 2016			
		6126971	JAN 19, 2013			
		4681893*PED	MAR 24, 2010	U-161		
		5273995*PED	JUN 28, 2011	U-162		
		5686104*PED	MAY 11, 2015	U-213		
		5969156*PED	JAN 08, 2017			
		6126971*PED	JUL 19, 2013			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020702 004	ATORVASTATIN CALCIUM;LIPITOR	4681893	SEP 24, 2009	U-161	I-281	DEC 02, 2002
		5273995	DEC 28, 2010	U-162	PED	JUN 02, 2003
		5686104	NOV 11, 2014	U-213		
		5969156	JUL 08, 2016			
		6126971	JAN 19, 2013			
		4681893*PED	MAR 24, 2010	U-161		
		5273995*PED	JUN 28, 2011	U-162		
		5686104*PED	MAY 11, 2015	U-213		
		5969156*PED	JAN 08, 2017			
		6126971*PED	JUL 19, 2013			
021078 001	ATOVAQUONE;MALARONE	6166046	NOV 25, 2013	U-406	NC	JUL 14, 2003
		5053432	OCT 01, 2008			
		6291488	NOV 25, 2013			
021078 002	ATOVAQUONE;MALARONE PEDIATRIC	6166046	NOV 25, 2013		NC	JUL 14, 2003
		5053432	OCT 01, 2008			
		6291488	NOV 25, 2013	U-406		
020259 001	ATOVAQUONE;MEPRON	4981874	AUG 15, 2009	U-69		
		5053432	OCT 01, 2008			
020500 001	ATOVAQUONE;MEPRON	4981874	AUG 15, 2009	U-69	ODE	JAN 05, 2006
		5053432	OCT 01, 2008		I-255	JAN 05, 2002
019677 001	ATROPINE SULFATE;ENLON-PLUS	4952586	AUG 28, 2007	U-54		
019678 001	ATROPINE SULFATE;ENLON-PLUS	4952586	AUG 28, 2007	U-54		
019459 001	AVOBENZONE;PHOTOPLEX	4387089	JUN 07, 2002			
020045 001	AVOBENZONE;SHADE UVAGUARD	4387089	JUN 07, 2002			
		4522807	JUN 11, 2002			
020114 001	AZELASTINE HYDROCHLORIDE;ASTELIN	5164194	OCT 16, 2011	U-207		
021127 001	AZELASTINE HYDROCHLORIDE;OPTIVAR	5164194	NOV 01, 2010		NDF	MAY 22, 2003
		5164194*PED	MAY 01, 2011		PED	MAY 01, 2002
					PED	NOV 22, 2003
020610 001	BALSALAZIDE DISODIUM;COLAZAL				NCE	JUL 18, 2005
020911 002	BECLOMETHASONE DIPROPIONATE;QVAR 40	5776432	JUL 07, 2015			
		5605674	FEB 25, 2014			
		5695743	JUL 06, 2010			
		5683677	NOV 04, 2014			
		5766573	NOV 28, 2009	U-356		
020911 001	BECLOMETHASONE DIPROPIONATE;QVAR 80	5776432	JUL 07, 2015			
		5605674	FEB 25, 2014			
		5695743	JUL 06, 2010			
		5683677	NOV 04, 2014			
		5766573	NOV 28, 2009	U-356		
019851 001	BENAZEPRIL HYDROCHLORIDE;LOTENSIN	4410520	AUG 11, 2003			
019851 002	BENAZEPRIL HYDROCHLORIDE;LOTENSIN	4410520	AUG 11, 2003			
019851 003	BENAZEPRIL HYDROCHLORIDE;LOTENSIN	4410520	AUG 11, 2003			
019851 004	BENAZEPRIL HYDROCHLORIDE;LOTENSIN	4410520	AUG 11, 2003			
020033 001	BENAZEPRIL HYDROCHLORIDE;LOTENSIN HCT	4410520	AUG 11, 2003			
020033 002	BENAZEPRIL HYDROCHLORIDE;LOTENSIN HCT	4410520	AUG 11, 2003			
020033 003	BENAZEPRIL HYDROCHLORIDE;LOTENSIN HCT	4410520	AUG 11, 2003			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020033 004	BENAZEPRIL HYDROCHLORIDE;LOTENSIN HCT	4410520	AUG 11, 2003			
020032 001	BERACTANT;SURVANTA	4397839	JUL 01, 2005			
020576 001	BETAINE, ANHYDROUS;CYSTADANE				ODE	OCT 25, 2003
019408 001	BETAMETHASONE DIPROPIONATE;DIPROLENE	4489070	MAY 13, 2003			
019408 002	BETAMETHASONE DIPROPIONATE;DIPROLENE	4489070	MAY 13, 2003			
019716 001	BETAMETHASONE DIPROPIONATE;DIPROLENE	4775529	MAY 21, 2007			
019555 001	BETAMETHASONE DIPROPIONATE;DIPROLENE AF	4489071	DEC 09, 2003			
020010 001	BETAMETHASONE DIPROPIONATE;LOTRISONE				NP	DEC 08, 2003
020619 001	BETAXOLOL HYDROCHLORIDE;BETOPTIC PILO	5635172	JUN 03, 2014	U-191		
019845 001	BETAXOLOL HYDROCHLORIDE;BETOPTIC S	4911920	MAR 27, 2007			
021055 001	BEXAROTENE;TARGRETIN	5780676	JUL 14, 2015		NCE	DEC 29, 2004
		5466861	NOV 14, 2012		ODE	DEC 29, 2006
021056 001	BEXAROTENE;TARGRETIN	5780676	JUL 14, 2015		NCE	DEC 29, 2004
		5962731	OCT 05, 2016		NDF	JUN 28, 2003
		5466861	NOV 14, 2012		ODE	DEC 29, 2006
020498 001	BICALUTAMIDE;CASODEX	4636505	OCT 01, 2008			
021275 001	BIMATOPROST;LUMIGAN	5688819	SEP 21, 2012		NCE	MAR 16, 2006
020873 001	BIVALIRUDIN;ANGIOMAX				NCE	DEC 15, 2005
050443 001	BLEOMYCIN SULFATE;BLENOXANE				ODE	FEB 20, 2003
050443 002	BLEOMYCIN SULFATE;BLENOXANE				ODE	FEB 20, 2003
021290 001	BOSENTAN;TRACLEER				ODE	NOV 20, 2008
					NCE	NOV 20, 2006
021290 002	BOSENTAN;TRACLEER				ODE	NOV 20, 2008
					NCE	NOV 20, 2006
020490 001	BRIMONIDINE TARTRATE;ALPHAGAN				PED	MAR 06, 2002
020613 001	BRIMONIDINE TARTRATE;ALPHAGAN	6194415	JUN 28, 2015	U-394	PED	MAR 06, 2002
		6248741	JUN 28, 2015	U-394		
		6194415*PED	DEC 28, 2015	U-394		
		6248741*PED	DEC 28, 2015	U-394		
021262 001	BRIMONIDINE TARTRATE;ALPHAGAN P	6194415*PED	DEC 28, 2015	U-395	NP	MAR 16, 2004
		5736165	APR 07, 2015	U-399	PED	SEP 16, 2004
		5736165*PED	OCT 07, 2015	U-399	PED	MAR 06, 2002
		6248741	JUN 28, 2015	U-395		
		6194415	JUN 28, 2015	U-395		
		6248741*PED	DEC 28, 2015	U-395		
		5424078	JUN 13, 2012			
		5424078*PED	DEC 13, 2012			
020816 001	BRINZOLAMIDE;AZOPT	5240923	AUG 31, 2010	U-224	NCE	APR 01, 2003
		5378703	APR 01, 2012	U-224		
		5461081	OCT 24, 2012	U-225		
020535 002	BROMFENAC SODIUM;DURACT				NCE	JUL 15, 2002
019672 001	BROMPHENIRAMINE MALEATE;EFIDAC 24 PSEUDOEPHEDRINE HCL/BRO	4673405	MAR 18, 2003			
		4810502	MAR 14, 2006			
		4662880	MAR 14, 2006			
		4801461	MAR 14, 2006			
021324 001	BUDESONIDE;ENTOCORT EC	5643602	JUL 01, 2014		NP	OCT 02, 2004
020441 002	BUDESONIDE;PULMICORT	4524769	JUN 25, 2002			
		4668218	APR 11, 2006			
		4907583	MAR 13, 2007			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020441 003	BUDESONIDE;PULMICORT	4524769	JUN 25, 2002			
		4668218	APR 11, 2006			
		4907583	MAR 13, 2007			
020929 001	BUDESONIDE;PULMICORT RESPULES	4787536	FEB 27, 2006		NDF	AUG 08, 2003
020929 002	BUDESONIDE;PULMICORT RESPULES	4787536	FEB 27, 2006		NDF	AUG 08, 2003
020746 001	BUDESONIDE;RHINOCORT	6291445	APR 29, 2017		NDF	OCT 01, 2002
020746 002	BUDESONIDE;RHINOCORT				NDF	OCT 01, 2002
020358 001	BUPROPION HYDROCHLORIDE;WELLBUTRIN SR	5358970	AUG 12, 2013		M-10	JUN 11, 2004
		5427798	AUG 12, 2013			
		RE33994	AUG 18, 2004			
		5763493	AUG 12, 2013			
		5731000	AUG 12, 2013			
020358 002	BUPROPION HYDROCHLORIDE;WELLBUTRIN SR	5427798	AUG 12, 2013		M-10	JUN 11, 2004
		5358970	AUG 12, 2013			
		RE33994	AUG 18, 2004			
		5763493	AUG 12, 2013			
		5731000	AUG 12, 2013			
020358 003	BUPROPION HYDROCHLORIDE;WELLBUTRIN SR	5358970	AUG 12, 2013		M-10	JUN 11, 2004
		RE33994	AUG 18, 2004			
		5427798	AUG 12, 2013			
		5731000	AUG 12, 2013			
		5763493	AUG 12, 2013			
020711 002	BUPROPION HYDROCHLORIDE;ZYBAN	5358970	AUG 12, 2013		D-54	SEP 10, 2002
		5427798	AUG 12, 2013			
		RE33994	AUG 18, 2004			
		5731000	AUG 12, 2013			
		5763493	AUG 12, 2013			
020711 003	BUPROPION HYDROCHLORIDE;ZYBAN	5358970	AUG 12, 2013		D-54	SEP 10, 2002
		5427798	AUG 12, 2013			
		RE33994	AUG 18, 2004			
		5731000	AUG 12, 2013			
		5763493	AUG 12, 2013			
018731 001	BUSPIRONE HYDROCHLORIDE;BUSPAR	5015646	MAY 14, 2008			
		5015646*PED	NOV 14, 2008			
018731 002	BUSPIRONE HYDROCHLORIDE;BUSPAR	5015646	MAY 14, 2008			
		5015646*PED	NOV 14, 2008			
018731 003	BUSPIRONE HYDROCHLORIDE;BUSPAR	5015646	MAY 14, 2008			
		5015646*PED	NOV 14, 2008			
018731 004	BUSPIRONE HYDROCHLORIDE;BUSPAR	5015646	MAY 14, 2008			
		5015646*PED	NOV 14, 2008			
021190 001	BUSPIRONE HYDROCHLORIDE;BUSPAR	5015646	MAY 14, 2008			
		5015646*PED	NOV 14, 2008			
021190 002	BUSPIRONE HYDROCHLORIDE;BUSPAR	5015646*PED	NOV 14, 2008			
		5015646	MAY 14, 2008			
021190 003	BUSPIRONE HYDROCHLORIDE;BUSPAR	5015646	MAY 14, 2008			
		5015646*PED	NOV 14, 2008			
021190 004	BUSPIRONE HYDROCHLORIDE;BUSPAR	5015646	MAY 14, 2008			
		5015646*PED	NOV 14, 2008			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
076008 001	BUSPIRONE HYDROCHLORIDE;BUSPIRONE HCL				PC	JAN 28, 2002
020954 001	BUSULFAN;BUSULFEX	5430057	SEP 30, 2013	U-263	ODE	FEB 04, 2006
		5559148	MAY 24, 2015	U-264	NDF	FEB 04, 2002
020524 001	BUTENAFINE HYDROCHLORIDE;MENTAX	5021458	OCT 18, 2010	U-177	I-333	JUN 06, 2004
020664 001	CABERGOLINE;DOSTINEX	4526892	DEC 29, 2005			
020793 001	CAFFEINE CITRATE;CAFCIT				ODE	SEP 21, 2006
					NE	SEP 21, 2002
020273 001	CALCIPOTRIENE;DOVONEX	4866048	DEC 29, 2007			
020554 001	CALCIPOTRIENE;DOVONEX	4866048	DEC 29, 2007			
020611 001	CALCIPOTRIENE;DOVONEX	4866048	DEC 29, 2007			
020313 002	CALCITONIN, SALMON;MIACALCIN	5733569	MAR 31, 2015	U-227		
		5759565	MAR 31, 2015			
018874 001	CALCITRIOL;CALCIJEX	6051567	AUG 02, 2019		PED	MAY 16, 2005
		6051567*PED	FEB 02, 2020		M-14	NOV 16, 2004
		6265392	AUG 02, 2019			
		6274169	AUG 02, 2019			
		6274169*PED	FEB 02, 2020			
		6265392*PED	FEB 02, 2020			
018874 002	CALCITRIOL;CALCIJEX	6051567	AUG 02, 2019		PED	MAY 16, 2005
		6051567*PED	FEB 02, 2020		M-14	NOV 16, 2004
		6265392	AUG 02, 2019			
		6274169	AUG 02, 2019			
		6274169*PED	FEB 02, 2020			
		6265392*PED	FEB 02, 2020			
019976 001	CALCIUM ACETATE;PHOSLO	4870105	APR 07, 2007	U-381		
021160 001	CALCIUM ACETATE;PHOSLO	4870105	APR 07, 2007	U-381		
021160 002	CALCIUM ACETATE;PHOSLO	4870105	APR 07, 2007	U-381		
021160 003	CALCIUM ACETATE;PHOSLO GELCAPS	4870105	APR 07, 2007	U-381		
020958 001	CALCIUM CARBONATE, PRECIPITATED;PEPCID COMPLETE	5229137	MAY 16, 2012	U-349	NC	OCT 15, 2003
		5817340	DEC 01, 2012		PED	APR 15, 2004
		5989588	SEP 30, 2015	U-349		
		5989588*PED	MAR 30, 2018	U-349		
		5229137*PED	NOV 16, 2012			
		5817340*PED	JUN 01, 2013			
018469 001	CALCIUM CHLORIDE;BSS PLUS	4550022	OCT 29, 2002			
020577 001	CALCIUM CHLORIDE;ELLIOTTS B SOLUTION				ODE	SEP 27, 2003
020521 001	CALFACTANT;INFASURF PRESERVATIVE FREE				NCE	JUL 01, 2003
020838 001	CANDESARTAN CILEXETIL;ATACAND	5196444	APR 18, 2011	U-3	NCE	JUN 04, 2003
		5534534	JUL 09, 2013			
		5703110	APR 18, 2011			
		5705517	APR 18, 2011			
020838 002	CANDESARTAN CILEXETIL;ATACAND	5196444	APR 18, 2011	U-3	NCE	JUN 04, 2003
		5534534	JUL 09, 2013			
		5703110	APR 18, 2011			
		5705517	APR 18, 2011			
020838 003	CANDESARTAN CILEXETIL;ATACAND	5196444	APR 18, 2011	U-3	NCE	JUN 04, 2003
		5534534	JUL 09, 2013			
		5703110	APR 18, 2011			
		5705517	APR 18, 2011			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020838 004	CANDESARTAN CILEXETIL;ATACAND	5196444	APR 18, 2011	U-3	NCE	JUN 04, 2003
		5534534	JUL 09, 2013			
		5703110	APR 18, 2011			
		5705517	APR 18, 2011			
021093 001	CANDESARTAN CILEXETIL;ATACAND HCT	5705517	APR 18, 2011	U-3	NCE	JUN 04, 2003
		5721263	FEB 24, 2015	U-3	NC	SEP 05, 2003
		5958961	JUN 06, 2014	U-3		
		5196444	APR 18, 2011	U-3		
		5534534	JUL 09, 2013			
		5703110	APR 18, 2011	U-3		
021093 002	CANDESARTAN CILEXETIL;ATACAND HCT	5705517	APR 18, 2011	U-3	NCE	JUN 04, 2003
		5721263	FEB 24, 2015	U-3	NC	SEP 05, 2003
		5958961	JUN 06, 2014	U-3		
		5196444	APR 18, 2011	U-3		
		5534534	JUL 09, 2013			
		5703110	APR 18, 2011	U-3		
020896 001	CAPECITABINE;XELODA	5472949	DEC 14, 2013	U-271	NCE	APR 30, 2003
		4966891	JAN 13, 2011	U-272	I-323	APR 30, 2004
					I-341	SEP 07, 2004
020896 002	CAPECITABINE;XELODA	5472949	DEC 14, 2013	U-271	NCE	APR 30, 2003
		4966891	JAN 13, 2011	U-272	I-323	APR 30, 2004
					I-341	SEP 07, 2004
018343 001	CAPTOPRIL;CAPOTEN	5238924	AUG 24, 2010	U-92		
018343 002	CAPTOPRIL;CAPOTEN	5238924	AUG 24, 2010	U-92		
018343 003	CAPTOPRIL;CAPOTEN	5238924	AUG 24, 2010	U-92		
018343 004	CAPTOPRIL;CAPOTEN	5238924	AUG 24, 2010	U-92		
018343 005	CAPTOPRIL;CAPOTEN	5238924	AUG 24, 2010	U-92		
018343 006	CAPTOPRIL;CAPOTEN	5238924	AUG 24, 2010	U-92		
018343 007	CAPTOPRIL;CAPOTEN	5238924	AUG 24, 2010	U-92		
020712 001	CARBAMAZEPINE;CARBATROL	5326570	JUL 05, 2011	U-215		
		5912013	JUN 15, 2016	U-277		
020712 002	CARBAMAZEPINE;CARBATROL	5326570	JUL 05, 2011	U-215		
		5912013	JUN 15, 2016	U-277		
020234 001	CARBAMAZEPINE;TEGRETOL-XR	RE34990	JUL 29, 2007			
		5284662	FEB 08, 2011			
020234 002	CARBAMAZEPINE;TEGRETOL-XR	RE34990	JUL 29, 2007			
		5284662	FEB 08, 2011			
020234 003	CARBAMAZEPINE;TEGRETOL-XR	RE34990	JUL 29, 2007			
		5284662	FEB 08, 2011			
019856 001	CARBIDOPA;SINEMET CR	4900755	JUN 16, 2006			
		4832957	JUN 16, 2006			
019856 002	CARBIDOPA;SINEMET CR	4900755	JUN 16, 2006			
		4832957	JUN 16, 2006			
019880 001	CARBOPLATIN;PARAPLATIN	4657927	APR 14, 2004	U-175		
019880 002	CARBOPLATIN;PARAPLATIN	4657927	APR 14, 2004	U-175		
019880 003	CARBOPLATIN;PARAPLATIN	4657927	APR 14, 2004	U-175		
020637 001	CARMUSTINE;GLIADEL	5179189	JAN 19, 2010		ODE	SEP 23, 2003
		4789724	JUL 12, 2005			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020297 001	CARVEDILOL;COREG	4503067	MAR 05, 2007	U-3	I-343	NOV 01, 2004
		5760069	JUN 07, 2015	U-233		
		5902821	FEB 07, 2016	U-313		
020297 002	CARVEDILOL;COREG	4503067	MAR 05, 2007	U-3	I-343	NOV 01, 2004
		5760069	JUN 07, 2015	U-233		
		5902821	FEB 07, 2016	U-313		
020297 003	CARVEDILOL;COREG	4503067	MAR 05, 2007	U-3	I-343	NOV 01, 2004
		5760069	JUN 07, 2015	U-233		
		5902821	FEB 07, 2016	U-313		
020297 004	CARVEDILOL;COREG	4503067	MAR 05, 2007	U-3	I-343	NOV 01, 2004
		5760069	JUN 07, 2015	U-233		
		5902821	FEB 07, 2016	U-313		
021227 001	CASPOFUNGIN ACETATE;CANCIDAS	5952300	MAR 28, 2017		NCE	JAN 26, 2006
		5378804	MAR 16, 2013			
		5514650	MAR 16, 2013			
		5792746	MAR 16, 2013			
		6136783	MAR 28, 2017			
021227 002	CASPOFUNGIN ACETATE;CANCIDAS	5952300	MAR 28, 2017		NCE	JAN 26, 2006
		5378804	MAR 16, 2013			
		5514650	MAR 16, 2013			
		5792746	MAR 16, 2013			
		6136783	MAR 28, 2017			
021222 001	CEFDITOREN PIVOXIL;SPECTRACEF				NCE	AUG 29, 2006
020998 001	CELECOXIB;CELEBREX	5760068	JUN 02, 2015	U-19	I-284	DEC 23, 2002
		5466823	NOV 30, 2013		NCE	DEC 31, 2003
		5563165	NOV 30, 2013		I-338	OCT 17, 2004
		5972986	OCT 14, 2017	U-299		
		5760068	JUN 02, 2015	U-299		
020998 002	CELECOXIB;CELEBREX	5760068	JUN 02, 2015	U-19	I-284	DEC 23, 2002
		5466823	NOV 30, 2013		NCE	DEC 31, 2003
		5563165	NOV 30, 2013		I-338	OCT 17, 2004
		5760068	JUN 02, 2015	U-299		
		5972986	OCT 14, 2017	U-299		
020740 001	CERIVASTATIN SODIUM;BAYCOL	5006530	JAN 17, 2009		D-59	JUL 21, 2003
		5177080	NOV 26, 2011		I-303	JUL 21, 2003
					NCE	JUN 26, 2002
020740 002	CERIVASTATIN SODIUM;BAYCOL	5006530	JAN 17, 2009		D-59	JUL 21, 2003
		5177080	NOV 26, 2011		I-303	JUL 21, 2003
					NCE	JUN 26, 2002
020740 003	CERIVASTATIN SODIUM;BAYCOL	5006530	JAN 17, 2009		D-59	JUL 21, 2003
		5177080	NOV 26, 2011		I-303	JUL 21, 2003
					NCE	JUN 26, 2002
020740 004	CERIVASTATIN SODIUM;BAYCOL	5006530	JAN 17, 2009		D-59	JUL 21, 2003
		5177080	NOV 26, 2011		I-303	JUL 21, 2003
					NCE	JUN 26, 2002
020740 005	CERIVASTATIN SODIUM;BAYCOL	5006530	JAN 17, 2009		D-59	JUL 21, 2003
		5177080	NOV 26, 2011		I-303	JUL 21, 2003
					NS	MAY 24, 2002

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020740 006	CERIVASTATIN SODIUM;BAYCOL	5006530	JAN 17, 2009		D-59	JUL 21, 2003
		5177080	JAN 26, 2011		I-303	JUL 21, 2003
					NS	JUL 21, 2003
019835 001	CETIRIZINE HYDROCHLORIDE;ZYRTEC	4525358	JUN 25, 2007			
019835 002	CETIRIZINE HYDROCHLORIDE;ZYRTEC	4525358	JUN 25, 2007			
020346 001	CETIRIZINE HYDROCHLORIDE;ZYRTEC	4525358	JUN 25, 2007			
021197 001	CETRORELIX;CETROTIDE	4800191	JUL 17, 2007		NCE	AUG 11, 2005
		5198533	JUL 17, 2007			
		6319192	APR 23, 2018	U-426		
021197 002	CETRORELIX;CETROTIDE	4800191	JUL 17, 2007		NCE	AUG 11, 2005
		5198533	JUL 17, 2007			
		6319192	APR 23, 2018	U-426		
020044 001	CETYL ALCOHOL;EXOSURF NEONATAL	4312860	AUG 20, 2003			
		4826821	MAY 02, 2006			
		5110806	MAY 02, 2006			
020989 002	CEVIMELINE HYDROCHLORIDE;EVOXAC	4855290	AUG 08, 2006		NCE	JAN 11, 2005
		5340821	AUG 23, 2011	U-309		
		5580880	JUN 06, 2015	U-310		
020832 001	CHLORHEXIDINE GLUCONATE;CHLORAPREP				NC	JUL 14, 2003
019746 002	CHLORPHENIRAMINE MALEATE;EFIDAC 24 CHLORPHENIRAMINE MALEAT	4576604	MAR 18, 2003			
		4673405	MAR 18, 2003			
		4857330	AUG 15, 2006			
019111 001	CHLORPHENIRAMINE POLISTIREX;TUSSIONEX	4762709	AUG 09, 2005			
019574 001	CHLORTHALIDONE;THALITONE	4933360	JUN 12, 2007			
071621 001	CHOLESTYRAMINE;CHOLYBAR	4778676	OCT 18, 2005			
071739 001	CHOLESTYRAMINE;CHOLYBAR	4778676	OCT 18, 2005			
021149 001	CHORIOGONADOTROPIN ALFA;OVIDREL	5767251	JUN 16, 2015		NP	SEP 20, 2003
021022 001	CICLOPIROX;PENLAC	4957730	SEP 18, 2007	U-379	NDF	DEC 17, 2002
020638 001	CIDOFOVIR;VISTIDE	5142051	JUN 26, 2010			
020863 001	CILOSTAZOL;PLETAL				NCE	JAN 15, 2004
020863 002	CILOSTAZOL;PLETAL				NCE	JAN 15, 2004
019992 001	CIPROFLOXACIN HYDROCHLORIDE;CILOXAN	4670444	DEC 09, 2003			
020369 001	CIPROFLOXACIN HYDROCHLORIDE;CILOXAN	4670444	JUN 02, 2004	U-223		
019537 001	CIPROFLOXACIN HYDROCHLORIDE;CIPRO	5286754	FEB 15, 2011			
		4670444	DEC 09, 2003	U-36		
019537 002	CIPROFLOXACIN HYDROCHLORIDE;CIPRO	4670444	DEC 09, 2003	U-36		
		5286754	FEB 15, 2011			
019537 003	CIPROFLOXACIN HYDROCHLORIDE;CIPRO	4670444	DEC 09, 2003	U-36		
		5286754	FEB 15, 2011			
019537 004	CIPROFLOXACIN HYDROCHLORIDE;CIPRO	4670444	DEC 09, 2003	U-36		
		5286754	FEB 15, 2011			
020805 001	CIPROFLOXACIN HYDROCHLORIDE;CIPRO HC	4670444	DEC 09, 2003			
		4844902	FEB 11, 2008			
019847 001	CIPROFLOXACIN;CIPRO	4670444	DEC 09, 2003			
		4705789	NOV 10, 2004			
		4808583	FEB 28, 2006			
020780 001	CIPROFLOXACIN;CIPRO	5695784	DEC 09, 2014			
		4670444	DEC 09, 2003			
		6136347	JAN 06, 2013	U-362		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020780 002	CIPROFLOXACIN;CIPRO	5695784	DEC 09, 2014			
		4670444	DEC 09, 2003			
		6136347	JAN 06, 2013	U-362		
019857 001	CIPROFLOXACIN;CIPRO IN DEXTROSE 5%	4670444	DEC 09, 2003			
		4705789	NOV 10, 2004			
		4957922	SEP 18, 2007			
		4808583	FEB 28, 2006			
019858 001	CIPROFLOXACIN;CIPRO IN SODIUM CHLORIDE 0.9%	4670444	DEC 09, 2003			
		4705789	NOV 10, 2004			
		4957922	SEP 18, 2007			
		4808583	FEB 28, 2006			
020210 001	CISAPRIDE MONOHYDRATE;PROPULSID	4962115	OCT 09, 2007	U-79		
020210 002	CISAPRIDE MONOHYDRATE;PROPULSID	4962115	OCT 09, 2007	U-79		
020398 001	CISAPRIDE MONOHYDRATE;PROPULSID	4962115	OCT 09, 2007	U-79		
020767 001	CISAPRIDE MONOHYDRATE;PROPULSID QUICKSOLV	4962115	OCT 09, 2007	U-79		
		5648093	JUL 15, 2014			
020551 001	CISATRACURIUM BESYLATE;NIMBEX	5453510	SEP 26, 2012	U-127		
020551 002	CISATRACURIUM BESYLATE;NIMBEX PRESERVATIVE FREE	5453510	SEP 26, 2012	U-127		
020551 003	CISATRACURIUM BESYLATE;NIMBEX PRESERVATIVE FREE	5453510	SEP 26, 2012	U-127		
018057 001	CISPLATIN;PLATINOL	5562925	MAY 08, 2012			
018057 002	CISPLATIN;PLATINOL	5562925	MAY 08, 2012			
018057 003	CISPLATIN;PLATINOL-AQ	5562925	MAY 08, 2012			
018057 004	CISPLATIN;PLATINOL-AQ	5562925	MAY 08, 2012			
020822 001	CITALOPRAM HYDROBROMIDE;CELEXA				NCE	JUL 17, 2003
020822 002	CITALOPRAM HYDROBROMIDE;CELEXA				NCE	JUL 17, 2003
020822 003	CITALOPRAM HYDROBROMIDE;CELEXA				NCE	JUL 17, 2003
020822 004	CITALOPRAM HYDROBROMIDE;CELEXA				NCE	JUL 17, 2003
021046 001	CITALOPRAM HYDROBROMIDE;CELEXA				NCE	JUL 17, 2003
021142 001	CLOBETASOL PROPIONATE;OLUX FOAM				NDF	MAY 26, 2003
020615 001	CLONIDINE HYDROCHLORIDE;DURACLON				ODE	OCT 02, 2003
018891 001	CLONIDINE;CATAPRES-TTS-1	4559222	MAY 04, 2003			
018891 002	CLONIDINE;CATAPRES-TTS-2	4559222	MAY 04, 2003			
018891 003	CLONIDINE;CATAPRES-TTS-3	4559222	MAY 04, 2003			
020839 001	CLOPIDOGREL BISULFATE;PLAVIX	5576328	JAN 31, 2014	U-432	NCE	NOV 17, 2002
		4529596	JUL 05, 2003			
		4847265	NOV 17, 2011			
021141 001	COLESEVELAM HYDROCHLORIDE;WELCHOL	5624963	APR 29, 2014	U-323	NCE	MAY 26, 2005
		5679717	APR 29, 2014	U-323		
		5693675	DEC 02, 2014			
		5607669	JUN 10, 2014	U-323		
		5917007	APR 29, 2014	U-323		
		5919832	JUN 10, 2014			
021176 001	COLESEVELAM HYDROCHLORIDE;WELCHOL	5919832	JUN 10, 2014		NCE	MAY 26, 2005
		5917007	APR 29, 2014	U-323		
		5607669	JUN 10, 2014	U-323		
		5693675	DEC 02, 2014			
		5679717	APR 29, 2014	U-323		
		5624963	APR 29, 2014	U-323		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020479 001	CROMOLYN SODIUM;GASTROCROM	4515805	MAY 07, 2002	U-130		
019722 001	CYANOCOBALAMIN;NASCOBAL	4724231	APR 16, 2005	U-157		
012142 006	CYCLOPHOSPHAMIDE;LYOPHILIZED CYTOXAN	4537883	NOV 12, 2002			
012142 007	CYCLOPHOSPHAMIDE;LYOPHILIZED CYTOXAN	4537883	NOV 12, 2002			
012142 008	CYCLOPHOSPHAMIDE;LYOPHILIZED CYTOXAN	4537883	NOV 12, 2002			
012142 009	CYCLOPHOSPHAMIDE;LYOPHILIZED CYTOXAN	4537883	NOV 12, 2002			
012142 010	CYCLOPHOSPHAMIDE;LYOPHILIZED CYTOXAN	4537883	NOV 12, 2002			
021041 001	CYTARABINE;DEPOCYT				ODE	APR 01, 2006
					NP	APR 01, 2002
020287 001	DALTEPARIN SODIUM;FRAGMIN	4303651	JAN 04, 2005		I-263	MAY 25, 2002
					I-259	MAR 30, 2002
					D-60	AUG 03, 2003
020287 003	DALTEPARIN SODIUM;FRAGMIN	4303651	JAN 04, 2005		I-263	MAY 25, 2002
					I-259	MAR 30, 2002
					D-60	AUG 03, 2003
020287 004	DALTEPARIN SODIUM;FRAGMIN				I-263	MAY 25, 2002
					I-259	MAR 30, 2002
					D-60	AUG 03, 2003
020430 001	DANAPAROID SODIUM;ORGARAN	5164377	OCT 03, 2010			
019849 001	DAPIPRAZOLE HYDROCHLORIDE;REV-EYES	4252721	FEB 07, 2003			
050704 002	DAUNORUBICIN CITRATE;DAUNOXOME				ODE	APR 08, 2003
020705 001	DELAVIRDINE MESYLATE;RESCRIPTOR	5563142	OCT 08, 2013		NCE	APR 04, 2002
		6177101	JUN 11, 2018			
020118 001	DESFLURANE;SUPRANE	4762856	FEB 02, 2007	U-67		
021165 001	DESLORATADINE;CLARINEX	4659716	APR 21, 2004	U-427	NCE	DEC 21, 2006
		4863931	SEP 15, 2008			
		4804666	FEB 14, 2006	U-428		
		5595997	DEC 30, 2014	U-429		
017922 001	DESMOPRESSIN ACETATE;DDAVP	5500413	JUN 29, 2013			
		5674850	DEC 23, 2013			
		5763407	JUN 29, 2013			
017922 002	DESMOPRESSIN ACETATE;DDAVP	5500413	JUN 29, 2013			
		5674850	DEC 23, 2013			
		5763407	JUN 29, 2013			
018938 001	DESMOPRESSIN ACETATE;DDAVP	5500413	JUN 29, 2013			
		5763407	JUN 29, 2013			
018938 002	DESMOPRESSIN ACETATE;DDAVP	5500413	JUN 29, 2013			
		5763407	JUN 29, 2013			
019955 001	DESMOPRESSIN ACETATE;DDAVP	5500413	JUN 29, 2013			
		5047398	SEP 10, 2008			
		5674850	DEC 23, 2013			
		5763407	JUN 29, 2013			
019955 002	DESMOPRESSIN ACETATE;DDAVP	5500413	JUN 29, 2013			
		5047398	SEP 10, 2008			
		5674850	DEC 23, 2013			
		5763407	JUN 29, 2013			
017922 003	DESMOPRESSIN ACETATE;DDAVP (NEEDS NO REFRIGERATION)	5674850	DEC 23, 2013			
		5500413	JUN 29, 2013			
		5482931	JUN 29, 2013			
		5763407	JUN 29, 2013			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
021090 001	DESOGESTREL;CYCLESSA	4616006	OCT 07, 2003		NP	DEC 20, 2003
		4544554	SEP 26, 2003			
		4628051	SEP 26, 2003			
020713 001	DESOGESTREL;MIRCETTE	4921843	OCT 20, 2008			
		RE35724	OCT 20, 2008			
021038 001	DEXMEDETOMIDINE;PRECEDEX	4910214	JUL 15, 2008	U-421	NCE	DEC 17, 2004
021278 001	DEXMETHYLPHENIDATE HYDROCHLORIDE;FOCALIN	5922736	DEC 04, 2015	U-423	NP	NOV 13, 2004
		5908850	DEC 04, 2015	U-422		
		6255325	DEC 04, 2015	U-424		
021278 002	DEXMETHYLPHENIDATE HYDROCHLORIDE;FOCALIN	5922736	DEC 04, 2015	U-423	NP	NOV 13, 2004
		5908850	DEC 04, 2015	U-422		
		6255325	DEC 04, 2015	U-424		
021278 003	DEXMETHYLPHENIDATE HYDROCHLORIDE;FOCALIN	5908850	DEC 04, 2015	U-422	NP	NOV 13, 2004
		5922736	DEC 04, 2015	U-423		
		6255325	DEC 04, 2015	U-424		
020212 001	DEXRAZOXANE HYDROCHLORIDE;ZINECARD	5242901	SEP 07, 2010	U-339	ODE	MAY 26, 2002
		4963551	DEC 21, 2007			
		4275063	JUN 23, 2003			
020212 002	DEXRAZOXANE HYDROCHLORIDE;ZINECARD	5242901	SEP 07, 2010	U-339	ODE	MAY 26, 2002
		4963551	DEC 21, 2007			
		4275063	JUN 23, 2003			
019082 001	DEZOCINE;DALGAN	4605671	AUG 12, 2003			
019082 002	DEZOCINE;DALGAN	4605671	AUG 12, 2003			
019082 003	DEZOCINE;DALGAN	4605671	AUG 12, 2003			
020648 001	DIAZEPAM;DIASTAT	5462740	OCT 31, 2012		ODE	JUL 29, 2004
020648 002	DIAZEPAM;DIASTAT	5462740	OCT 31, 2012		ODE	JUL 29, 2004
020648 003	DIAZEPAM;DIASTAT	5462740	OCT 31, 2012		ODE	JUL 29, 2004
020648 004	DIAZEPAM;DIASTAT	5462740	OCT 31, 2012		ODE	JUL 29, 2004
020648 005	DIAZEPAM;DIASTAT	5462740	OCT 31, 2012		ODE	JUL 29, 2004
020607 001	DICLOFENAC SODIUM;ARTHROTEC	5698225	FEB 03, 2017	U-392		
		5601843	FEB 11, 2014			
020607 002	DICLOFENAC SODIUM;ARTHROTEC	5698225	FEB 03, 2017	U-392		
		5601843	FEB 11, 2014			
020809 001	DICLOFENAC SODIUM;DICLOFENAC SODIUM	5603929	NOV 16, 2014	U-239		
		5653972	NOV 16, 2014	U-239		
021005 001	DICLOFENAC SODIUM;SOLARAZE	5639738	JUN 17, 2014	U-402	NP	OCT 16, 2003
		5792753	AUG 11, 2015			
		5852002	JUN 17, 2014	U-402		
		5914322	AUG 11, 2015			
		5929048	JUL 27, 2016	U-402		
		5985850	NOV 16, 2016			
020037 001	DICLOFENAC SODIUM;VOLTAREN	4960799	OCT 03, 2007			
		4829088	APR 14, 2007			
020154 002	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248	D-58	OCT 28, 2002
		5616566	AUG 29, 2006	U-180	PED	APR 28, 2003
		5254539	AUG 29, 2006	U-248		
		5880106	JUL 22, 2011			
		4861759*PED	MAR 01, 2007	U-248		
		5254539*PED	MAR 01, 2007	U-248		
		5616566*PED	MAR 01, 2007	U-180		
		5880106*PED	JAN 22, 2012			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020154 003	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248	D-58	OCT 28, 2002
		5616566	AUG 29, 2006	U-180	PED	APR 28, 2003
		5254539	AUG 29, 2006	U-248		
		5880106	JUL 22, 2011			
		4861759*PED	MAR 01, 2007	U-248		
		5254539*PED	MAR 01, 2007	U-248		
		5616566*PED	MAR 01, 2007	U-180		
		5880106*PED	JAN 22, 2012			
020154 004	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248	D-58	OCT 28, 2002
		5616566	AUG 29, 2006	U-180	PED	APR 28, 2003
		5254539	AUG 29, 2006	U-248		
		5880106	JUL 22, 2011			
		4861759*PED	MAR 01, 2007	U-248		
		5254539*PED	MAR 01, 2007	U-248		
		5616566*PED	MAR 01, 2007	U-180		
		5880106*PED	JAN 22, 2012			
020154 005	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248	D-58	OCT 28, 2002
		5616566	AUG 29, 2006	U-180	PED	APR 28, 2003
		5254539	AUG 29, 2006	U-248		
		5880106	JUL 22, 2011			
		4861759*PED	MAR 01, 2007	U-248		
		5254539*PED	MAR 01, 2007	U-248		
		5616566*PED	MAR 01, 2007	U-180		
		5880106*PED	JAN 22, 2012			
020154 006	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248	NS	OCT 28, 2002
		5254539	AUG 29, 2006	U-248	PED	APR 28, 2003
		5880106	JUL 22, 2011			
		4861759*PED	MAR 01, 2007	U-248		
		5254539*PED	MAR 01, 2007	U-248		
		5616566*PED	MAR 01, 2007	U-180		
		5880106*PED	JAN 22, 2012			
		5616566	AUG 29, 2006	U-180		
020155 003	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248		
		5616566	AUG 29, 2006	U-180		
		5254539	AUG 29, 2006	U-248		
		4861759*PED	MAR 01, 2007	U-248		
		5254539*PED	MAR 01, 2007	U-248		
		5616566*PED	MAR 01, 2007	U-180		
020155 004	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248		
		5616566	AUG 29, 2006	U-180		
		5254539	AUG 29, 2006	U-248		
		4861759*PED	MAR 01, 2007	U-248		
		5254539*PED	MAR 01, 2007	U-248		
		5616566*PED	MAR 01, 2007	U-180		
020155 005	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248		
		5616566	AUG 29, 2006	U-180		
		5254539	AUG 29, 2006	U-248		
		4861759*PED	MAR 01, 2007	U-248		
		5254539*PED	MAR 01, 2007	U-248		
		5616566*PED	MAR 01, 2007	U-180		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020155 006	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-52		
		4861759*PED	MAR 01, 2007	U-248		
		5254539*PED	MAR 01, 2007	U-248		
		5616566*PED	MAR 01, 2007	U-180		
		5616566	AUG 29, 2006	U-180		
		5254539	AUG 29, 2006	U-248		
020156 001	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248		
		5616566	AUG 29, 2006	U-180		
		5254539	AUG 29, 2006	U-248		
		4861759*PED	MAR 01, 2007	U-248		
		5254539*PED	MAR 01, 2007	U-248		
		5616566*PED	MAR 01, 2007	U-180		
021183 001	DIDANOSINE;VIDEX EC	4861759	AUG 29, 2006	U-248	NDF	OCT 31, 2003
		5254539	AUG 29, 2006	U-248	PED	MAY 01, 2004
		4861759*PED	MAR 01, 2007	U-248		
		5254539*PED	MAR 01, 2007	U-248		
021183 002	DIDANOSINE;VIDEX EC	4861759	AUG 29, 2006	U-248	NDF	OCT 31, 2003
		5254539	AUG 29, 2006	U-248	PED	MAY 01, 2004
		4861759*PED	MAR 01, 2007	U-248		
		5254539*PED	MAR 01, 2007	U-248		
021183 003	DIDANOSINE;VIDEX EC	4861759	AUG 29, 2006	U-248	NDF	OCT 31, 2003
		5254539	AUG 29, 2006	U-248	PED	MAY 01, 2004
		4861759*PED	MAR 01, 2007	U-248		
		5254539*PED	MAR 01, 2007	U-248		
021183 004	DIDANOSINE;VIDEX EC	4861759	AUG 29, 2006	U-248	NDF	OCT 31, 2003
		5254539	AUG 29, 2006	U-248	PED	MAY 01, 2004
		4861759*PED	MAR 01, 2007	U-248		
		5254539*PED	MAR 01, 2007	U-248		
020148 001	DIHYDROERGOTAMINE MESYLATE;MIGRANAL	5169849	DEC 08, 2009	U-227		
020062 001	DILTIAZEM HYDROCHLORIDE;CARDIZEM CD	5286497	MAY 20, 2011			
		4894240	JAN 16, 2007			
		5470584	MAY 20, 2011			
		5364620	NOV 14, 2011	U-3		
		5439689	AUG 08, 2012	U-107		
		5002776	MAR 26, 2008			
020062 002	DILTIAZEM HYDROCHLORIDE;CARDIZEM CD	5286497	MAY 20, 2011			
		5364620	NOV 14, 2011	U-3		
		5470584	MAY 20, 2011			
		5002776	MAR 26, 2008			
		4894240	JAN 16, 2007			
		5439689	AUG 08, 2012	U-107		
020062 003	DILTIAZEM HYDROCHLORIDE;CARDIZEM CD	5286497	MAY 20, 2011			
		5439689	AUG 08, 2012	U-107		
		4894240	JAN 16, 2007			
		5002776	MAR 26, 2008			
		5364620	NOV 14, 2011	U-3		
		5470584	MAY 20, 2011			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020062 004	DILTIAZEM HYDROCHLORIDE;CARDIZEM CD	5286497	MAY 20, 2011			
		4894240	JAN 16, 2007			
		5002776	MAR 26, 2008			
		5364620	NOV 14, 2011	U-3		
		5439689	AUG 08, 2012	U-107		
		5470584	MAY 20, 2011			
019471 001	DILTIAZEM HYDROCHLORIDE;CARDIZEM SR	4721619	JAN 26, 2005			
019471 002	DILTIAZEM HYDROCHLORIDE;CARDIZEM SR	4721619	JAN 26, 2005			
019471 003	DILTIAZEM HYDROCHLORIDE;CARDIZEM SR	4721619	JAN 26, 2005			
019471 004	DILTIAZEM HYDROCHLORIDE;CARDIZEM SR	4721619	JAN 26, 2005			
020092 001	DILTIAZEM HYDROCHLORIDE;DILACOR XR	4839177	DEC 09, 2006			
		5422123	JUN 06, 2012			
020092 002	DILTIAZEM HYDROCHLORIDE;DILACOR XR	4839177	DEC 09, 2006			
		5422123	JUN 06, 2012			
020092 003	DILTIAZEM HYDROCHLORIDE;DILACOR XR	4839177	DEC 09, 2006			
		5422123	JUN 06, 2012			
020939 001	DILTIAZEM HYDROCHLORIDE;DILTIAZEM HCL	5288505	JUN 26, 2011			
		5529791	JUN 25, 2013			
020939 002	DILTIAZEM HYDROCHLORIDE;DILTIAZEM HCL	5288505	JUN 26, 2011			
		5529791	JUN 25, 2013			
020939 003	DILTIAZEM HYDROCHLORIDE;DILTIAZEM HCL	5288505	JUN 26, 2011			
		5529791	JUN 25, 2013			
020939 004	DILTIAZEM HYDROCHLORIDE;DILTIAZEM HCL	5288505	JUN 26, 2011			
		5529791	JUN 25, 2013			
020401 001	DILTIAZEM HYDROCHLORIDE;TIAZAC	5529791	JUN 25, 2013			
		6162463	APR 28, 2018			
020401 002	DILTIAZEM HYDROCHLORIDE;TIAZAC	5529791	JUN 25, 2013			
		6162463	APR 28, 2018			
020401 003	DILTIAZEM HYDROCHLORIDE;TIAZAC	5529791	JUN 25, 2013			
		6162463	APR 28, 2018			
020401 004	DILTIAZEM HYDROCHLORIDE;TIAZAC	5529791	JUN 25, 2013			
		6162463	APR 28, 2018			
020401 005	DILTIAZEM HYDROCHLORIDE;TIAZAC	5529791	JUN 25, 2013			
		6162463	APR 28, 2018			
020401 006	DILTIAZEM HYDROCHLORIDE;TIAZAC	6162463	APR 28, 2018			
020507 001	DILTIAZEM MALATE;TECZEM	4968507	JUL 25, 2006			
		4880631	SEP 24, 2007			
		4983598	JAN 08, 2008			
020506 001	DILTIAZEM MALATE;TIAMATE	4880631	SEP 24, 2007			
		4968507	JUL 25, 2006			
020506 002	DILTIAZEM MALATE;TIAMATE	4880631	SEP 24, 2007			
		4968507	JUL 25, 2006			
020506 003	DILTIAZEM MALATE;TIAMATE	4880631	SEP 24, 2007			
		4968507	JUL 25, 2006			
020411 001	DINOPROSTONE;CERVIDIL	4931288	JAN 16, 2007			
		5269321	DEC 14, 2010	U-110		
019617 001	DINOPROSTONE;PREPIDIL	4680312	JUL 14, 2004			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
018723 001	DIVALPROEX SODIUM;DEPAKOTE	5212326	JAN 29, 2008			
		4988731	JAN 29, 2008			
018723 002	DIVALPROEX SODIUM;DEPAKOTE	5212326	JAN 29, 2008			
		4988731	JAN 29, 2008			
018723 003	DIVALPROEX SODIUM;DEPAKOTE	5212326	JAN 29, 2008			
		4988731	JAN 29, 2008			
019680 001	DIVALPROEX SODIUM;DEPAKOTE	5212326	JAN 29, 2008			
		4988731	JAN 29, 2008			
019794 001	DIVALPROEX SODIUM;DEPAKOTE CP	4988731	JAN 29, 2008			
		5212326	JAN 29, 2008			
019794 002	DIVALPROEX SODIUM;DEPAKOTE CP	4988731	JAN 29, 2008			
		5212326	JAN 29, 2008			
021168 001	DIVALPROEX SODIUM;DEPAKOTE ER	4988731	JAN 29, 2008		NP	AUG 04, 2003
		4913906	APR 03, 2007			
020449 001	DOCETAXEL;TAXOTERE	4814470	MAY 14, 2010		I-282	DEC 23, 2002
		5438072	NOV 22, 2013			
		5698582	JUL 03, 2012			
		5714512	JUL 03, 2012			
020941 001	DOCOSANOL;ABREVA				NCE	JUL 25, 2005
020931 001	DOFETILIDE;TIKOSYN	6124363	OCT 09, 2018		NCE	OCT 01, 2004
020931 002	DOFETILIDE;TIKOSYN	6124363	OCT 09, 2018		NCE	OCT 01, 2004
020931 003	DOFETILIDE;TIKOSYN	6124363	OCT 09, 2018		NCE	OCT 01, 2004
020623 001	DOLASETRON MESYLATE MONOHYDRATE;ANZEMET	4906755	JUL 02, 2011		NCE	SEP 11, 2002
020623 002	DOLASETRON MESYLATE MONOHYDRATE;ANZEMET	4906755	JUL 02, 2011		NCE	SEP 11, 2002
020624 001	DOLASETRON MESYLATE MONOHYDRATE;ANZEMET	4906755	JUL 02, 2011		NCE	SEP 11, 2002
020690 001	DONEPEZIL HYDROCHLORIDE;ARICEPT	4895841	NOV 25, 2010			
		6140321	DEC 30, 2016			
		6245911	DEC 01, 2018			
		5985864	DEC 30, 2016			
020690 002	DONEPEZIL HYDROCHLORIDE;ARICEPT	4895841	NOV 25, 2010			
		6140321	DEC 30, 2016			
		6245911	DEC 01, 2018			
		5985864	DEC 30, 2016			
020869 001	DORZOLAMIDE HYDROCHLORIDE;COSOPT	4797413	APR 28, 2008	U-103		
		4619939	OCT 28, 2003	U-104		
		6248735	APR 17, 2011			
020408 001	DORZOLAMIDE HYDROCHLORIDE;TRUSOPT	4797413	APR 28, 2008	U-103		
		4619939	OCT 28, 2003	U-104		
019946 001	DOXACURIUM CHLORIDE;NUROMAX	4701460	MAR 06, 2005			
020862 001	DOXERCALCIFEROL;HECTOROL	5602116	APR 03, 2115	U-278	NCE	JUN 09, 2004
		5707980	FEB 11, 2117	U-278		
021027 001	DOXERCALCIFEROL;HECTOROL	5602116	APR 03, 2115	U-321	NDF	APR 06, 2003
		5707980	FEB 11, 2117	U-321	NCE	JUN 09, 2004
050718 001	DOXORUBICIN HYDROCHLORIDE;DOXIL				ODE	JUN 28, 2006
021098 001	DROSPIRENONE;YASMIN				NC	MAY 11, 2004
021319 001	DUTASTERIDE;DUTASTERIDE				NCE	NOV 20, 2006
020972 001	EFAVIRENZ;SUSTIVA	5811423	AUG 07, 2012	U-256	NCE	SEP 17, 2003
		5519021	MAY 21, 2013			
		5663169	SEP 02, 2014	U-257		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020972 002	EFAVIRENZ;SUSTIVA	5811423	AUG 07, 2012	U-256	NCE	SEP 17, 2003
		5519021	MAY 21, 2013			
		5663169	SEP 02, 2014	U-257		
020972 003	EFAVIRENZ;SUSTIVA	5519021	MAY 21, 2013		NCE	SEP 17, 2003
		5663169	SEP 02, 2014	U-257		
		5811423	AUG 07, 2012	U-256		
021360 001	EFAVIRENZ;SUSTIVA				NCE	SEP 17, 2003
021360 002	EFAVIRENZ;SUSTIVA				NCE	SEP 17, 2003
021145 001	EFLORNITHINE HYDROCHLORIDE;VANIQA	4720489	JAN 19, 2005	U-334	NP	JUL 27, 2003
		5648394	JUL 15, 2014	U-334		
020706 001	EMEDASTINE DIFUMARATE;EMADINE	4430343	AUG 14, 2005	U-403	NCE	DEC 29, 2002
		5441958	DEC 08, 2013	U-404		
020668 001	ENALAPRIL MALEATE;LEXXEL	4803081	APR 03, 2007			
		4703038	OCT 07, 2005	U-3		
		4803081*PED	OCT 03, 2007			
020668 002	ENALAPRIL MALEATE;LEXXEL	4703038	OCT 07, 2005	U-3		
		4803081	APR 03, 2007			
		4803081*PED	OCT 03, 2007			
018998 001	ENALAPRIL MALEATE;VASOTEC				M-7	FEB 13, 2004
					PED	AUG 13, 2004
018998 002	ENALAPRIL MALEATE;VASOTEC				M-7	FEB 13, 2004
					PED	AUG 13, 2004
018998 003	ENALAPRIL MALEATE;VASOTEC				M-7	FEB 13, 2004
					PED	AUG 13, 2004
018998 005	ENALAPRIL MALEATE;VASOTEC				M-7	FEB 13, 2004
					PED	AUG 13, 2004
019616 004	ENOXACIN;PENETREX	4442101	FEB 04, 2002			
019616 005	ENOXACIN;PENETREX	4442101	FEB 04, 2002			
020164 001	ENOXAPARIN SODIUM;LOVENOX	4692435	DEC 24, 2004	U-123	I-315	NOV 17, 2003
		5389618	FEB 14, 2012			
020164 002	ENOXAPARIN SODIUM;LOVENOX	4692435	DEC 24, 2004	U-123	I-315	NOV 17, 2003
		5389618	FEB 14, 2012			
020164 003	ENOXAPARIN SODIUM;LOVENOX	4692435	DEC 24, 2004	U-123	I-315	NOV 17, 2003
		5389618	FEB 14, 2012			
020164 004	ENOXAPARIN SODIUM;LOVENOX	4692435	DEC 24, 2004	U-123	I-315	NOV 17, 2003
		5389618	FEB 14, 2012			
020164 005	ENOXAPARIN SODIUM;LOVENOX	4692435	DEC 24, 2004	U-123	I-315	NOV 17, 2003
		5389618	FEB 14, 2012			
020164 006	ENOXAPARIN SODIUM;LOVENOX	4692435	DEC 24, 2004	U-123		
		5389618	FEB 14, 2012			
020164 007	ENOXAPARIN SODIUM;LOVENOX	4692435	DEC 24, 2004	U-123		
		5389618	FEB 14, 2012			
020164 008	ENOXAPARIN SODIUM;LOVENOX	4692435	DEC 24, 2004	U-123		
		5389618	FEB 14, 2012			
020796 001	ENTACAPONE;COMTAN				NCE	OCT 19, 2004
050778 001	EPIRUBICIN HYDROCHLORIDE;ELLENCE				ODE	SEP 15, 2006
020444 001	EPOPROSTENOL SODIUM;FLOLAN	4539333	SEP 03, 2002		ODE	APR 14, 2007
		4883812	MAY 12, 2006	U-185	I-296	APR 14, 2003
					ODE	SEP 20, 2002

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020444 002	EPOPROSTENOL SODIUM;FLOLAN	4539333	SEP 03, 2002		ODE	APR 14, 2007
		4883812	MAY 12, 2006	U-185	I-296	APR 14, 2003
					ODE	SEP 20, 2002
020738 004	EPROSARTAN MESYLATE;TEVETEN	5656650	AUG 12, 2014	U-3	NCE	DEC 22, 2002
		5185351	FEB 09, 2010	U-3		
020738 005	EPROSARTAN MESYLATE;TEVETEN	5656650	AUG 12, 2014	U-3	NCE	DEC 22, 2002
		5185351	FEB 09, 2010	U-3		
021268 001	EPROSARTAN MESYLATE;TEVETEN HCT	5185351	FEB 09, 2010	U-3	NC	NOV 01, 2004
					NCE	DEC 22, 2002
021268 002	EPROSARTAN MESYLATE;TEVETEN HCT	5185351	FEB 09, 2010	U-3	NC	NOV 01, 2004
					NCE	DEC 22, 2002
020718 001	EPTIFIBATIDE;INTEGRILIN	5756451	NOV 11, 2014		NCE	MAY 18, 2003
		5686570	NOV 11, 2014		D-66	JUN 08, 2004
		5807825	SEP 15, 2015	U-244		
020718 002	EPTIFIBATIDE;INTEGRILIN	5756451	NOV 11, 2014		NCE	MAY 18, 2003
		5686570	NOV 11, 2014		D-66	JUN 08, 2004
		5807825	SEP 15, 2015	U-244		
021337 001	ERTAPENEM SODIUM;INVANZ	5478820	FEB 02, 2013		NCE	NOV 21, 2006
		5652233	FEB 02, 2013			
		5952323	MAY 15, 2017			
019386 001	ESMOLOL HYDROCHLORIDE;BREVIBLOC	4593119	JUN 03, 2003			
		5017609	MAY 21, 2008			
		6310094	JAN 12, 2021			
019386 002	ESMOLOL HYDROCHLORIDE;BREVIBLOC	4593119	JUN 03, 2003			
		5017609	MAY 21, 2008			
019386 003	ESMOLOL HYDROCHLORIDE;BREVIBLOC	5017609	MAY 21, 2008			
		4593119	JUN 03, 2003			
021153 001	ESOMEPRAZOLE MAGNESIUM;NEXIUM	4738974	APR 19, 2005	U-373	NP	FEB 20, 2004
		4636499	MAY 30, 2005	U-373		
		5900424	MAY 04, 2016	U-373		
		4786505	APR 20, 2007	U-373		
		4853230	APR 20, 2007	U-373		
		5714504	FEB 03, 2015	U-373		
		5877192	MAY 27, 2014	U-373		
		5093342	FEB 02, 2010	U-373		
		5599794	FEB 04, 2014	U-373		
		5629305	FEB 04, 2014	U-373		
		5690960	NOV 25, 2014	U-373		
		6147103	OCT 09, 2018			
		6166213	OCT 09, 2018			
		6191148	OCT 09, 2018			
021153 002	ESOMEPRAZOLE MAGNESIUM;NEXIUM	4738974	APR 19, 2005	U-373	NP	FEB 20, 2004
		4636499	MAY 30, 2005	U-373		
		5900424	MAY 04, 2016	U-373		
		4786505	APR 20, 2007	U-373		
		4853230	APR 20, 2007	U-373		
		5714504	FEB 03, 2015	U-373		
		5877192	MAY 27, 2014	U-373		
		5093342	FEB 02, 2010	U-373		
		5599794	FEB 04, 2014	U-373		
		5629305	FEB 04, 2014	U-373		
		5690960	NOV 25, 2014	U-373		
		6147103	OCT 09, 2018			
		6166213	OCT 09, 2018			
		6191148	OCT 09, 2018			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020874 001	ESTRADIOL CYPIONATE;LUNELLE				NP	OCT 05, 2003
020907 001	ESTRADIOL;ACTIVELLE	RE36247	MAY 02, 2006		I-295	APR 11, 2003
020655 001	ESTRADIOL;ALORA	5122383	MAY 17, 2011			
		5227169	MAY 17, 2011			
		5212199	MAY 17, 2011			
		5164190	DEC 11, 2010			
020655 002	ESTRADIOL;ALORA	5122383	MAY 17, 2011			
		5227169	MAY 17, 2011			
		5212199	MAY 17, 2011			
		5164190	DEC 11, 2010			
020655 003	ESTRADIOL;ALORA	5122383	MAY 17, 2011			
		5227169	MAY 17, 2011			
		5212199	MAY 17, 2011			
		5164190	DEC 11, 2010			
020375 001	ESTRADIOL;CLIMARA	5223261	JUN 29, 2010		I-254	MAR 05, 2002
020375 002	ESTRADIOL;CLIMARA	5223261	JUN 29, 2010		I-254	MAR 05, 2002
020375 003	ESTRADIOL;CLIMARA	5223261	JUN 29, 2010		I-254	MAR 05, 2002
020375 004	ESTRADIOL;CLIMARA	5223261	JUN 29, 2010		I-254	MAR 05, 2002
020870 001	ESTRADIOL;COMBIPATCH	5474783	DEC 12, 2012			
		5656286	AUG 12, 2014			
		5958446	DEC 12, 2012			
		6024976	JAN 07, 2014			
020870 002	ESTRADIOL;COMBIPATCH	5474783	DEC 12, 2012			
		5656286	AUG 12, 2014			
		5958446	DEC 12, 2012			
		6024976	JAN 07, 2014			
020847 001	ESTRADIOL;ESCLIM	4842864	MAR 25, 2008			
020847 002	ESTRADIOL;ESCLIM	4842864	MAR 25, 2008			
020847 003	ESTRADIOL;ESCLIM	4842864	MAR 25, 2008			
020847 004	ESTRADIOL;ESCLIM	4842864	MAR 25, 2008			
020847 005	ESTRADIOL;ESCLIM	4842864	MAR 25, 2008			
086069 001	ESTRADIOL;ESTRACE	4436738	MAR 15, 2002			
020472 001	ESTRADIOL;ESTRING	4871543	JUN 12, 2007	U-306		
		5188835	JUN 12, 2007	U-306		
020417 001	ESTRADIOL;FEMPATCH	4906463	MAR 06, 2007			
		5006342	APR 09, 2008			
021040 001	ESTRADIOL;ORTHO-PREFEST	5108995	APR 28, 2009	U-311		
		5382573	JAN 17, 2012			
020908 001	ESTRADIOL;VAGIFEM				NP	MAR 26, 2002
020323 001	ESTRADIOL;VIVELLE	4814168	MAR 04, 2008		I-254	AUG 16, 2003
		4994267	MAR 04, 2008			
		4994278	MAR 04, 2008			
		5300291	APR 05, 2011			
020323 002	ESTRADIOL;VIVELLE	4994278	MAR 04, 2008		I-254	AUG 16, 2003
		4814168	MAR 04, 2008			
		4994267	MAR 04, 2008			
		5300291	APR 05, 2011			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020323 003	ESTRADIOL;VIVELLE	4814168	MAR 04, 2008		I-254	AUG 16, 2003
		4994267	MAR 04, 2008			
		4994278	MAR 04, 2008			
		5300291	APR 05, 2011			
020323 004	ESTRADIOL;VIVELLE	4814168	MAR 04, 2008		I-254	AUG 16, 2003
		4994267	MAR 04, 2008			
		4994278	MAR 04, 2008			
		5300291	APR 05, 2011			
020323 005	ESTRADIOL;VIVELLE	4994278	MAR 04, 2008		NS	AUG 16, 2003
		5300291	APR 05, 2011		I-254	AUG 16, 2003
		4814168	MAR 04, 2008			
		4994267	MAR 04, 2008			
020538 005	ESTRADIOL;VIVELLE-DOT	6024976	JAN 07, 2014			
		5474783	DEC 12, 2012			
		5656286	AUG 12, 2014			
		5958446	DEC 12, 2012			
020538 006	ESTRADIOL;VIVELLE-DOT	6024976	JAN 07, 2014			
		5474783	DEC 12, 2012			
		5656286	AUG 12, 2014			
		5958446	DEC 12, 2012			
020538 007	ESTRADIOL;VIVELLE-DOT	6024976	JAN 07, 2014			
		5474783	DEC 12, 2012			
		5656286	AUG 12, 2014			
		5958446	DEC 12, 2012			
020538 008	ESTRADIOL;VIVELLE-DOT	6024976	JAN 07, 2014			
		5474783	DEC 12, 2012			
		5656286	AUG 12, 2014			
		5958446	DEC 12, 2012			
020992 002	ESTROGENS, CONJUGATED SYNTHETIC A;CENESTIN	5908638	JUL 26, 2015		NP	MAR 24, 2002
020992 003	ESTROGENS, CONJUGATED SYNTHETIC A;CENESTIN	5908638	JUL 26, 2015		NP	MAR 24, 2002
020992 004	ESTROGENS, CONJUGATED SYNTHETIC A;CENESTIN	5908638	JUL 26, 2015		NP	MAR 24, 2002
010971 005	ESTROGENS, CONJUGATED;PMB 200	5210081	FEB 26, 2012			
010971 003	ESTROGENS, CONJUGATED;PMB 400	5210081	FEB 26, 2012			
004782 001	ESTROGENS, CONJUGATED;PREMARIN	5210081	FEB 26, 2012			
004782 002	ESTROGENS, CONJUGATED;PREMARIN	5210081	FEB 26, 2012			
004782 003	ESTROGENS, CONJUGATED;PREMARIN	5210081	FEB 26, 2012			
004782 004	ESTROGENS, CONJUGATED;PREMARIN	5210081	FEB 26, 2012			
004782 005	ESTROGENS, CONJUGATED;PREMARIN	5210081	FEB 26, 2012			
010402 001	ESTROGENS, CONJUGATED;PREMARIN	5210081	FEB 26, 2012			
020216 001	ESTROGENS, CONJUGATED;PREMARIN	5210081	FEB 26, 2012			
020303 002	ESTROGENS, CONJUGATED;PREMPHASE (PREMARIN;CYCRIN 14/14)	5210081	FEB 26, 2012			
020527 002	ESTROGENS, CONJUGATED;PREMPHASE 14/14	5547948	JAN 17, 2015			
		5210081	FEB 26, 2012			
020527 001	ESTROGENS, CONJUGATED;PREMPRO	5547948	JAN 17, 2015			
		RE36247	MAY 02, 2006	U-284		
		5210081	FEB 26, 2012			
020527 003	ESTROGENS, CONJUGATED;PREMPRO	5547948	JAN 17, 2015			
		RE36247	MAY 02, 2006	U-284		
		5210081	FEB 26, 2012			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020303 001	ESTROGENS, CONJUGATED;PREMPRO (PREMARIN;CYCRIN)	5210081	FEB 26, 2012			
		RE36247	MAY 02, 2006	U-284		
020130 002	ETHINYL ESTRADIOL;ESTROSTEP FE	4962098	OCT 09, 2007	U-112	I-331	JUL 01, 2004
		5010070	APR 23, 2008			
020130 001	ETHINYL ESTRADIOL;ESTROSTEP 21	4962098	OCT 09, 2007	U-112	I-331	JUL 01, 2004
		5010070	APR 23, 2008			
021065 001	ETHINYL ESTRADIOL;FEMHRT	5208225	MAY 04, 2010	U-283	NP	OCT 15, 2002
021065 002	ETHINYL ESTRADIOL;FEMHRT	5208225	MAY 04, 2010	U-283	NP	OCT 15, 2002
021065 003	ETHINYL ESTRADIOL;FEMHRT	5208225	MAY 04, 2010	U-283	NP	OCT 15, 2002
021187 001	ETHINYL ESTRADIOL;NUVARING				NP	OCT 03, 2004
021180 001	ETHINYL ESTRADIOL;ORTHO EVRA				NP	NOV 20, 2004
019697 001	ETHINYL ESTRADIOL;ORTHO TRI-CYCLEN	4544554	SEP 26, 2003	U-66		
		4616006	SEP 26, 2003	U-66		
		4628051	SEP 26, 2003	U-66		
		4530839	SEP 26, 2003	U-112		
019697 002	ETHINYL ESTRADIOL;ORTHO TRI-CYCLEN	4544554	SEP 26, 2003	U-66		
		4616006	SEP 26, 2003	U-66		
		4628051	SEP 26, 2003	U-66		
		4530839	SEP 26, 2003	U-112		
018985 001	ETHINYL ESTRADIOL;ORTHO-NOVUM 7/7/7-21	4530839	SEP 26, 2003			
		4544554	SEP 26, 2003			
		4616006	SEP 26, 2003			
		4628051	SEP 26, 2003			
018985 002	ETHINYL ESTRADIOL;ORTHO-NOVUM 7/7/7-28	4530839	SEP 26, 2003			
		4544554	SEP 26, 2003			
		4616006	SEP 26, 2003			
		4628051	SEP 26, 2003			
020946 001	ETHINYL ESTRADIOL;PREVEN EMERGENCY CONTRACEPTIVE KI	6156742	DEC 05, 2020	U-374		
020584 001	ETODOLAC;LODINE XL	4966768*PED	APR 30, 2008		I-321	AUG 11, 2003
		4966768	OCT 30, 2007		PED	FEB 11, 2004
020584 002	ETODOLAC;LODINE XL	4966768*PED	APR 30, 2008		I-321	AUG 11, 2003
		4966768	OCT 30, 2007		PED	FEB 11, 2004
020584 003	ETODOLAC;LODINE XL	4966768*PED	APR 30, 2008		I-321	AUG 11, 2003
		4966768	OCT 30, 2007		PED	FEB 11, 2004
020457 001	ETOPOSIDE PHOSPHATE;ETOPOPHOS PRESERVATIVE FREE	5041424	AUG 20, 2008	U-135		
		RE35524	MAY 17, 2010			
020906 001	ETOPOSIDE PHOSPHATE;ETOPOPHOS PRESERVATIVE FREE	5041424	AUG 20, 2008	U-135		
		RE35524	MAY 17, 2010			
020906 002	ETOPOSIDE PHOSPHATE;ETOPOPHOS PRESERVATIVE FREE	5041424	AUG 20, 2008	U-135		
		RE35524	MAY 17, 2010			
020753 001	EXEMESTANE;AROMASIN	4808616	JUL 07, 2006		NCE	OCT 21, 2004
		4904650	JUL 07, 2006		ODE	OCT 21, 2006
020363 001	FAMCICLOVIR;FAMVIR	5246937	SEP 21, 2010	U-96		
020363 002	FAMCICLOVIR;FAMVIR	5246937	SEP 21, 2010	U-96		
020363 003	FAMCICLOVIR;FAMVIR	5246937	SEP 21, 2010	U-96		
020325 001	FAMOTIDINE;PEPCID AC	5667794	MAY 02, 2015	U-205	PED	MAY 09, 2002
		5854267	DEC 29, 2015	U-267		
		5667794*PED	NOV 02, 2015	U-205		
		5854267*PED	JUN 29, 2016	U-267		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020801 001	FAMOTIDINE;PEPCID AC	5667794	MAY 02, 2015			
		5854267	DEC 29, 2015	U-267		
		5075114	DEC 24, 2008			
		5075114*PED	JUN 24, 2009			
		5667794*PED	NOV 02, 2015			
		5854267*PED	JUN 29, 2016			
020902 001	FAMOTIDINE;PEPCID AC	5854267	DEC 29, 2015	U-368	PED	MAY 09, 2002
		5854267*PED	JUN 29, 2016	U-368		
		5667794	MAY 02, 2015	U-368		
		5667794*PED	NOV 02, 2015	U-368		
		4820524	FEB 20, 2007			
		4820524*PED	AUG 20, 2007			
020189 001	FELBAMATE;FELBATOL	4978680	SEP 26, 2009	U-83		
		5082861	SEP 26, 2009	U-83		
020189 002	FELBAMATE;FELBATOL	4978680	SEP 26, 2009	U-83		
		5082861	SEP 26, 2009	U-83		
020189 003	FELBAMATE;FELBATOL	4978680	SEP 26, 2009	U-83		
		5082861	SEP 26, 2009	U-83		
019834 001	FELODIPINE;PLENDIL	4803081	APR 03, 2007			
		4803081*PED	OCT 03, 2007			
019834 002	FELODIPINE;PLENDIL	4803081	APR 03, 2007			
		4803081*PED	OCT 03, 2007			
019834 004	FELODIPINE;PLENDIL	4803081	APR 03, 2007			
		4803081*PED	OCT 03, 2007			
021203 001	FENOFIBRATE;TRICOR	4895726	JAN 19, 2009		I-298	APR 24, 2003
		6277405	JAN 09, 2018			
		6074670	JAN 09, 2018			
021203 003	FENOFIBRATE;TRICOR	4895726	JAN 19, 2009		I-298	APR 24, 2003
		6277405	JAN 09, 2018			
		6074670	JAN 09, 2018			
019304 002	FENOFIBRATE;TRICOR (MICRONIZED)	4895726	JAN 19, 2009		I-298	APR 24, 2003
019304 003	FENOFIBRATE;TRICOR (MICRONIZED)	4895726	JAN 19, 2009		I-298	APR 24, 2003
019304 004	FENOFIBRATE;TRICOR (MICRONIZED)	4895726	JAN 19, 2009		I-298	APR 24, 2003
019922 001	FENOLDOPAM MESYLATE;CORLOPAM				NCE	SEP 23, 2002
020747 001	FENTANYL CITRATE;ACTIQ	4671953	MAY 01, 2005	U-253		
020747 002	FENTANYL CITRATE;ACTIQ	4671953	MAY 01, 2005	U-253		
020747 003	FENTANYL CITRATE;ACTIQ	4671953	MAY 01, 2005	U-253		
020747 004	FENTANYL CITRATE;ACTIQ	4671953	MAY 01, 2005	U-253		
020747 005	FENTANYL CITRATE;ACTIQ	4671953	MAY 01, 2005	U-253		
020747 006	FENTANYL CITRATE;ACTIQ	4671953	MAY 01, 2005	U-253		
020195 001	FENTANYL CITRATE;FENTANYL	4671953	MAY 01, 2005	U-87		
020195 002	FENTANYL CITRATE;FENTANYL	4671953	MAY 01, 2005	U-87		
020195 003	FENTANYL CITRATE;FENTANYL	4671953	MAY 01, 2005	U-87		
020195 007	FENTANYL CITRATE;FENTANYL	4671953	MAY 01, 2005	U-87		
019813 001	FENTANYL;DURAGESIC	4588580	JUL 23, 2004	U-43		
019813 002	FENTANYL;DURAGESIC	4588580	JUL 23, 2004	U-43		
019813 003	FENTANYL;DURAGESIC	4588580	JUL 23, 2004	U-43		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
019813 004	FENTANYL;DURAGESIC	4588580	JUL 23, 2004	U-43		
020416 001	FERUMOXIDES;FERIDEX I.V.	4951675	AUG 28, 2007	U-143		
		5102652	FEB 06, 2009			
		5248492	SEP 28, 2010			
		4770183	SEP 13, 2005	U-145		
		4827945	MAY 09, 2006	U-144		
		5055288	OCT 08, 2008			
		5219554	JUN 15, 2010			
020410 001	FERUMOXSIL;GASTROMARK	5069216	MAY 09, 2006	U-171		
		5219554	JUN 15, 2010			
		4827945	MAY 09, 2006	U-170		
		4951675	SEP 13, 2005	U-169		
		5055288	OCT 08, 2008			
		4695392	SEP 22, 2004			
		4695393	SEP 22, 2004			
		4770183	SEP 13, 2005	U-169		
020625 001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	5578610	NOV 26, 2013	U-192		
		5855912	FEB 28, 2015			
		5738872	FEB 28, 2015			
		5932247	FEB 28, 2015			
		6037353	MAR 14, 2017	U-138		
		6113942	FEB 28, 2015			
		6187791	MAY 11, 2012	U-138		
020872 001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	5578610	NOV 26, 2013	U-139	NDF	FEB 25, 2003
		5932247	FEB 28, 2015			
		5855912	FEB 28, 2015			
		6037353	MAR 14, 2017	U-138		
		6113942	FEB 28, 2015			
		6187791	MAY 11, 2012	U-138		
020872 002	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	5578610	NOV 26, 2013	U-139	NDF	FEB 25, 2003
		5932247	FEB 28, 2015			
		5855912	FEB 28, 2015			
		6037353	MAR 14, 2017	U-138		
		6113942	FEB 28, 2015			
		6187791	MAY 11, 2012	U-138		
020872 004	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	5578610	NOV 26, 2013	U-139	NDF	FEB 25, 2003
		5932247	FEB 28, 2015			
		5855912	FEB 28, 2015			
		6037353	MAR 14, 2017	U-138		
		6113942	FEB 28, 2015			
		6187791	MAY 11, 2012	U-138		
020786 001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA-D	5578610	NOV 26, 2013			
		5855912	FEB 28, 2015			
		6037353	MAR 14, 2017	U-138		
		6039974	JUL 31, 2018			
		6113942	FEB 28, 2015			
		6187791	MAY 11, 2012	U-138		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020788 001	FINASTERIDE;PROPECIA	4760071	JUN 19, 2006			
		5571817	NOV 05, 2013	U-259		
		5547957	OCT 15, 2013	U-236		
		5886184	NOV 19, 2012			
020180 001	FINASTERIDE;PROSCAR	4760071	JUN 19, 2006	U-262		
		5886184	NOV 19, 2012			
		5942519	OCT 23, 2018	U-280		
018830 001	FLECAINIDE ACETATE;TAMBOCOR	4642384	FEB 10, 2004			
018830 002	FLECAINIDE ACETATE;TAMBOCOR	4642384	FEB 10, 2004			
018830 003	FLECAINIDE ACETATE;TAMBOCOR	4642384	FEB 10, 2004			
018830 004	FLECAINIDE ACETATE;TAMBOCOR	4642384	FEB 10, 2004			
019949 001	FLUCONAZOLE;DIFLUCAN	4404216	JAN 29, 2004			
019949 002	FLUCONAZOLE;DIFLUCAN	4404216	JAN 29, 2004			
019949 003	FLUCONAZOLE;DIFLUCAN	4404216	JAN 29, 2004			
019949 004	FLUCONAZOLE;DIFLUCAN	4404216	JAN 29, 2004			
020090 001	FLUCONAZOLE;DIFLUCAN	4404216	JAN 29, 2004			
020090 002	FLUCONAZOLE;DIFLUCAN	4404216	JAN 29, 2004			
019950 003	FLUCONAZOLE;DIFLUCAN IN DEXTROSE 5%	4404216	JAN 29, 2004			
019950 005	FLUCONAZOLE;DIFLUCAN IN DEXTROSE 5%	4404216	JAN 29, 2004			
019950 001	FLUCONAZOLE;DIFLUCAN IN SODIUM CHLORIDE 0.9%	4404216	JAN 29, 2004			
019950 002	FLUCONAZOLE;DIFLUCAN IN SODIUM CHLORIDE 0.9%	4404216	JAN 29, 2004			
019950 004	FLUCONAZOLE;DIFLUCAN IN SODIUM CHLORIDE 0.9%	4404216	JAN 29, 2004			
020038 001	FLUDARABINE PHOSPHATE;FLUDARA	4357324	FEB 24, 2003			
020073 001	FLUMAZENIL;ROMAZICON	4316839	OCT 10, 2004			
018340 001	FLUNISOLIDE;AEROBID	4933168	JUN 12, 2007			
018148 001	FLUNISOLIDE;NASALIDE	4933168	JUN 12, 2007			
020409 001	FLUNISOLIDE;NASAREL	4782047	MAY 22, 2006			
		4983595	MAY 22, 2006			
		4933168	JUN 12, 2007			
019452 001	FLUOCINOLONE ACETONIDE;DERMA-SMOOTHE/FS				I-265	AUG 18, 2002
					I-340	OCT 10, 2004
021112 001	FLUOCINOLONE ACETONIDE;TRI-LUMA				NC	JAN 18, 2005
020985 001	FLUOROURACIL;CARAC	4690825	OCT 04, 2005		NP	OCT 27, 2003
074803 001	FLUOXETINE HYDROCHLORIDE;FLUOXETINE				PC	JAN 29, 2002
075049 001	FLUOXETINE HYDROCHLORIDE;FLUOXETINE				PC	JAN 29, 2002
075465 003	FLUOXETINE HYDROCHLORIDE;FLUOXETINE				PC	JAN 29, 2002
075506 001	FLUOXETINE HYDROCHLORIDE;FLUOXETINE				PC	JAN 29, 2002
075755 001	FLUOXETINE HYDROCHLORIDE;FLUOXETINE HCL				PC	JAN 29, 2002
075755 002	FLUOXETINE HYDROCHLORIDE;FLUOXETINE HCL				PC	JAN 29, 2002
018936 001	FLUOXETINE HYDROCHLORIDE;PROZAC	4626549	DEC 02, 2003	U-154		
		4626549*PED	JUN 02, 2004	U-154		
018936 003	FLUOXETINE HYDROCHLORIDE;PROZAC	4626549	DEC 02, 2003	U-154		
		4626549*PED	JUN 02, 2004	U-154		
018936 004	FLUOXETINE HYDROCHLORIDE;PROZAC	4626549	DEC 02, 2003	U-154		
		4626549*PED	JUN 02, 2004	U-154		
018936 006	FLUOXETINE HYDROCHLORIDE;PROZAC	4626549	DEC 02, 2003	U-154		
		4626549*PED	JUN 02, 2004	U-154		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020101 001	FLUOXETINE HYDROCHLORIDE;PROZAC	4626549	DEC 02, 2003	U-154		
		4626549*PED	JUN 02, 2004	U-154		
020974 001	FLUOXETINE HYDROCHLORIDE;PROZAC	4626549	DEC 02, 2003	U-154		
		4626549*PED	JUN 02, 2004	U-154		
020974 002	FLUOXETINE HYDROCHLORIDE;PROZAC	4626549	DEC 02, 2003	U-154		
		4626549*PED	JUN 02, 2004	U-154		
021235 001	FLUOXETINE HYDROCHLORIDE;PROZAC WEEKLY				NDF	FEB 26, 2004
018936 007	FLUOXETINE HYDROCHLORIDE;SARAFEM	4971998	NOV 20, 2007	U-338	NP	JUL 06, 2003
		5114976	MAY 19, 2009	U-341	PED	JAN 06, 2004
		5744501	MAY 19, 2009	U-342		
		4971998*PED	MAY 20, 2008	U-338		
		5114976*PED	NOV 19, 2009	U-341		
		5744501*PED	NOV 19, 2009	U-342		
018936 008	FLUOXETINE HYDROCHLORIDE;SARAFEM	4971998	NOV 20, 2007	U-338	NP	JUL 06, 2003
		5114976	MAY 19, 2009	U-341	PED	JAN 06, 2004
		5744501	MAY 19, 2009	U-342		
		4971998*PED	MAY 20, 2008	U-338		
		5114976*PED	NOV 19, 2009	U-341		
		5744501*PED	NOV 19, 2009	U-342		
021077 001	FLUTICASONE PROPIONATE;ADVAIR DISKUS 100/50	4335121	NOV 14, 2003		NC	AUG 24, 2003
		5270305	SEP 07, 2010	U-387		
		4992474	FEB 12, 2008	U-211		
		5225445	FEB 12, 2008	U-211		
		5126375	FEB 12, 2008			
		5290815	MAR 01, 2011	U-386		
021077 002	FLUTICASONE PROPIONATE;ADVAIR DISKUS 250/50	4335121	NOV 14, 2003		NC	AUG 24, 2003
		5270305	SEP 07, 2010	U-387		
		4992474	FEB 12, 2008	U-211		
		5225445	FEB 12, 2008	U-211		
		5126375	FEB 12, 2008			
		5290815	MAR 01, 2011	U-386		
021077 003	FLUTICASONE PROPIONATE;ADVAIR DISKUS 500/50	4335121	NOV 14, 2003		NC	AUG 24, 2003
		5270305	SEP 07, 2010	U-387		
		4992474	FEB 12, 2008	U-211		
		5225445	FEB 12, 2008	U-211		
		5126375	FEB 12, 2008			
		5290815	MAR 01, 2011	U-386		
019957 001	FLUTICASONE PROPIONATE;CUTIVATE	4335121	NOV 14, 2003			
019958 001	FLUTICASONE PROPIONATE;CUTIVATE	4335121	NOV 14, 2003		I-267	JUN 17, 2002
020121 001	FLUTICASONE PROPIONATE;FLONASE	4335121	NOV 14, 2003			
020548 001	FLUTICASONE PROPIONATE;FLOVENT	4335121	NOV 14, 2003			
020548 002	FLUTICASONE PROPIONATE;FLOVENT	4335121	NOV 14, 2003			
020548 003	FLUTICASONE PROPIONATE;FLOVENT	4335121	NOV 14, 2003			
020549 001	FLUTICASONE PROPIONATE;FLOVENT	4335121	NOV 14, 2003	U-409		
020549 002	FLUTICASONE PROPIONATE;FLOVENT	4335121	NOV 14, 2003	U-409		
020549 003	FLUTICASONE PROPIONATE;FLOVENT	4335121	NOV 14, 2003	U-409		
020833 002	FLUTICASONE PROPIONATE;FLOVENT DISKUS 100	4335121	NOV 14, 2003	U-409		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020833 003	FLUTICASONE PROPIONATE;FLOVENT DISKUS 250	4335121	NOV 14, 2003	U-409		
020833 001	FLUTICASONE PROPIONATE;FLOVENT DISKUS 50	4335121	NOV 14, 2003	U-409		
020261 001	FLUVASTATIN SODIUM;LESCOL	5354772	OCT 11, 2011	U-109		
		5356896	DEC 12, 2011			
020261 002	FLUVASTATIN SODIUM;LESCOL	5354772	OCT 11, 2011	U-109		
		5356896	DEC 12, 2011			
021192 001	FLUVASTATIN SODIUM;LESCOL XL	5354772	OCT 11, 2011	U-413	NDF	OCT 06, 2003
		5356896	DEC 12, 2011			
020582 001	FOLLITROPIN ALFA/BETA;FOLLISTIM	5270057	MAR 20, 2011		I-306	FEB 07, 2005
		4589402	JUL 26, 2004	U-206		
		5767251	JUN 16, 2015			
020582 002	FOLLITROPIN ALFA/BETA;FOLLISTIM	5270057	MAR 20, 2011		I-306	FEB 07, 2005
		4589402	JUL 26, 2004	U-206		
		5767251	JUN 16, 2015			
020378 001	FOLLITROPIN ALFA/BETA;GONAL-F	4589402	JUL 26, 2004	U-242	ODE	MAY 24, 2007
		5767251	JUN 16, 2015		I-306	MAY 24, 2003
020378 002	FOLLITROPIN ALFA/BETA;GONAL-F	4589402	JUL 26, 2004	U-242	ODE	MAY 24, 2007
		5767251	JUN 16, 2015		I-306	MAY 24, 2003
020378 003	FOLLITROPIN ALFA/BETA;GONAL-F	4589402	JUL 26, 2004	U-242	I-306	MAY 24, 2003
		5767251	JUN 16, 2015		ODE	MAY 24, 2007
020696 001	FOMEPIZOLE;ANTIZOL				NCE	DEC 04, 2002
					ODE	DEC 04, 2004
					ODE	DEC 08, 2007
					I-319	DEC 08, 2003
020961 001	FOMIVIRSEN SODIUM;VITRAVENE PRESERVATIVE FREE				NCE	AUG 26, 2003
021345 001	FONDAPARINUX SODIUM;ARIXTRA				NCE	DEC 07, 2006
020831 001	FORMOTEROL FUMARATE;FORADIL				NCE	FEB 16, 2006
021279 001	FORMOTEROL FUMARATE;FORADIL				I-342	SEP 25, 2004
					NCE	FEB 16, 2006
019915 002	FOSINOPRIL SODIUM;MONOPRIL	4337201	DEC 04, 2002			
		5006344	JUL 10, 2009			
019915 003	FOSINOPRIL SODIUM;MONOPRIL	4337201	DEC 04, 2002			
		5006344	JUL 10, 2009			
019915 004	FOSINOPRIL SODIUM;MONOPRIL	4337201	DEC 04, 2002			
		5006344	JUL 10, 2009			
020286 001	FOSINOPRIL SODIUM;MONOPRIL-HCT	4337201	DEC 04, 2002			
		5006344	JUL 10, 2009			
020286 002	FOSINOPRIL SODIUM;MONOPRIL-HCT	4337201	DEC 04, 2002			
		5006344	JUL 10, 2009			
020450 001	FOSPHENYTOIN SODIUM;CEREBYX	4260769	APR 07, 2003		ODE	AUG 05, 2003
		4925860	AUG 05, 2007			
021006 001	FROVATRIPTAN SUCCINATE;FROVA	5464864	NOV 07, 2012	U-436	NCE	NOV 08, 2006
		5616603	APR 01, 2014	U-436		
		5637611	JUN 10, 2014	U-436		
		5827871	OCT 27, 2015	U-436		
		5962501	DEC 16, 2013	U-436		
		5917054	DEC 16, 2013	U-437		
		5618947	DEC 08, 2014	U-437		
		5618948	APR 08, 2014	U-437		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020235 001	GABAPENTIN;NEURONTIN	5084479	JAN 02, 2010	U-125	PED	MAR 29, 2002
		4894476*PED	NOV 02, 2008		I-311	OCT 12, 2003
		5084479*PED	JUL 02, 2010	U-125	PED	APR 12, 2004
		4894476	MAY 02, 2008			
		6054482	APR 25, 2017			
		6054482*PED	OCT 25, 2017			
020235 002	GABAPENTIN;NEURONTIN	4894476	MAY 02, 2008		PED	MAR 29, 2002
		5084479	JAN 02, 2010	U-125	I-311	OCT 12, 2003
		5084479*PED	JUL 02, 2010	U-125	PED	APR 12, 2004
		4894476*PED	NOV 02, 2008			
		6054482	APR 25, 2017			
		6054482*PED	OCT 25, 2017			
020235 003	GABAPENTIN;NEURONTIN	5084479	JAN 02, 2010	U-125	PED	MAR 29, 2002
		4894476	MAY 02, 2008		I-311	OCT 12, 2003
		5084479*PED	JUL 02, 2010		PED	APR 12, 2004
		4894476*PED	NOV 02, 2008			
		6054482	APR 25, 2017			
		6054482*PED	OCT 25, 2017			
020882 001	GABAPENTIN;NEURONTIN	4894476	MAY 02, 2008		I-311	OCT 12, 2003
		5084479	JAN 02, 2010	U-258	PED	APR 12, 2004
		5084479*PED	JUL 02, 2010	U-258		
		4894476*PED	NOV 02, 2008			
		6054482	APR 25, 2017			
		6054482*PED	OCT 25, 2017			
020882 002	GABAPENTIN;NEURONTIN	4894476	MAY 02, 2008		I-311	OCT 12, 2003
		5084479	JAN 02, 2010	U-258	PED	APR 12, 2004
		4894476*PED	NOV 02, 2008			
		5084479*PED	JUL 02, 2010	U-258		
		6054482	APR 25, 2017			
		6054482*PED	OCT 25, 2017			
021129 001	GABAPENTIN;NEURONTIN	4894476	MAY 02, 2008		I-311	OCT 12, 2003
		5084479	JAN 02, 2010	U-258	PED	APR 12, 2004
		4894476*PED	NOV 02, 2008			
		5084479*PED	JUL 02, 2010	U-258		
020123 001	GADODIAMIDE;OMNISCAN	4687659	MAY 04, 2007	U-76		
019596 001	GADOPENTETATE DIMEGLUMINE;MAGNEVIST	4647447	MAR 03, 2004			
		4963344	MAR 03, 2004			
		4957939	MAR 03, 2004			
		5362475	NOV 08, 2011			
		5560903	OCT 01, 2013			
021037 001	GADOPENTETATE DIMEGLUMINE;MAGNEVIST	5362475	NOV 08, 2011			
		5560903	OCT 01, 2013			
		4647447	MAR 03, 2004			
		4957939	MAR 03, 2004			
		4963344	MAR 03, 2004			
020131 001	GADOTERIDOL;PROHANCE	4885363	DEC 05, 2006			
020937 001	GADOVERSETAMIDE;OPTIMARK	5130120	JUL 14, 2009		NCE	DEC 08, 2004
		5137711	JUL 14, 2009			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020975 001	GADOVERSETAMIDE;OPTIMARK	5130120	JUL 14, 2009		NCE	DEC 08, 2004
		5137711	JUL 14, 2009			
020976 001	GADOVERSETAMIDE;OPTIMARK	5130120	JUL 14, 2009		NCE	DEC 08, 2004
		5137711	JUL 14, 2009			
021169 001	GALANTAMINE HYDROBROMIDE;REMINYL	4663318	JAN 15, 2006		NCE	FEB 28, 2006
		6099863	JUN 06, 2017			
021169 002	GALANTAMINE HYDROBROMIDE;REMINYL	4663318	JAN 15, 2006		NCE	FEB 28, 2006
		6099863	JUN 06, 2017			
021169 003	GALANTAMINE HYDROBROMIDE;REMINYL	4663318	JAN 15, 2006		NCE	FEB 28, 2006
		6099863	JUN 06, 2017			
021224 001	GALANTAMINE HYDROBROMIDE;REMINYL	4663318	JAN 15, 2006		NCE	FEB 28, 2006
019961 002	GALLIUM NITRATE;GANITE	4529593	JAN 17, 2005	U-49		
019661 001	GANCICLOVIR SODIUM;CYTOVENE IV	4355032	JUN 23, 2003	U-64		
020460 001	GANCICLOVIR;CYTOVENE	4355032	JUN 23, 2003	U-64		
		4642346	JUN 24, 2005			
020460 002	GANCICLOVIR;CYTOVENE	4355032	JUN 23, 2003	U-64		
		4642346	JUN 24, 2005			
020569 001	GANCICLOVIR;VITRASERT	5378475	JAN 03, 2012		ODE	MAR 04, 2003
021057 001	GANIRELIX ACETATE;ANTAGON	4801577	FEB 05, 2007		NCE	JUL 29, 2004
		5767082	JUN 16, 2015			
021061 001	GATIFLOXACIN;TEQUIN	4980470	DEC 25, 2007		D-69	OCT 12, 2004
021061 002	GATIFLOXACIN;TEQUIN	4980470	DEC 25, 2007		D-69	OCT 12, 2004
021062 001	GATIFLOXACIN;TEQUIN	4980470	DEC 25, 2007		NCE	DEC 17, 2004
					D-69	OCT 12, 2004
021062 002	GATIFLOXACIN;TEQUIN	4980470	DEC 25, 2007		NCE	DEC 17, 2004
					D-69	OCT 12, 2004
020509 001	GEMCITABINE HYDROCHLORIDE;GEMZAR	4808614	MAY 15, 2010			
		5464826	NOV 07, 2012	U-146		
020509 002	GEMCITABINE HYDROCHLORIDE;GEMZAR	5464826	NOV 07, 2012	U-146		
		4808614	MAY 15, 2010			
021174 001	GEMTUZUMAB OZOGAMICIN;MYLOTARG	5606040	FEB 25, 2014		ODE	MAY 17, 2007
		5693762	DEC 02, 2014		NCE	MAY 17, 2005
		5739116	APR 14, 2015			
		5767285	JUN 16, 2015			
		5773001	JUN 30, 2015	U-320		
		4970198	NOV 30, 2007			
		5079233	JAN 07, 2009			
		5585089	DEC 17, 2013			
020622 001	GLATIRAMER ACETATE;COPAXONE	5981589	MAY 24, 2014		ODE	DEC 20, 2003
		6054430	MAY 24, 2014			
020496 001	GLIMEPIRIDE;AMARYL	4379785	APR 06, 2005	U-118		
020496 002	GLIMEPIRIDE;AMARYL	4379785	APR 06, 2005	U-118		
020496 003	GLIMEPIRIDE;AMARYL	4379785	APR 06, 2005	U-118		
020329 001	GLIPIZIDE;GLUCOTROL XL	5591454	JAN 07, 2014	U-150		
		5024843	SEP 05, 2009			
		5091190	JUN 18, 2008	U-111		
		4612008	SEP 16, 2003			
		5082668	SEP 16, 2003			
		5545413	JUL 02, 2008	U-150		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020329 002	GLIPIZIDE;GLUCOTROL XL	5591454	JAN 07, 2014	U-150		
		5082668	SEP 16, 2003			
		5091190	JUN 18, 2008	U-111		
		5545413	JUL 02, 2008	U-150		
		5024843	SEP 05, 2009			
		4612008	SEP 16, 2003			
021178 001	GLYBURIDE;GLUCOVANCE	6303146	JUL 14, 2019	U-412	NC	JUL 31, 2003
021178 002	GLYBURIDE;GLUCOVANCE	6303146	JUL 14, 2019	U-412	NC	JUL 31, 2003
021178 003	GLYBURIDE;GLUCOVANCE	6303146	JUL 14, 2019	U-412	NC	JUL 31, 2003
020051 001	GLYBURIDE;GLYNASE	4916163	APR 10, 2007			
		4735805	APR 05, 2005			
020051 002	GLYBURIDE;GLYNASE	4735805	APR 05, 2005			
		4916163	APR 10, 2007			
020051 003	GLYBURIDE;GLYNASE	4735805	APR 05, 2005			
		4916163	APR 10, 2007			
020051 004	GLYBURIDE;GLYNASE	4916163	APR 10, 2007			
		4735805	APR 05, 2005			
019726 001	GOSERELIN ACETATE;ZOLADEX	5366734	NOV 22, 2011			
		4767628	AUG 30, 2005			
020578 001	GOSERELIN ACETATE;ZOLADEX	4767628	AUG 30, 2005			
		5366734	NOV 22, 2011			
020239 001	GRANISETRON HYDROCHLORIDE;KYTRIL	4886808	DEC 29, 2007	U-89		
		6294548	MAY 04, 2019			
020239 002	GRANISETRON HYDROCHLORIDE;KYTRIL	4886808	DEC 29, 2007	U-89		
		6294548	MAY 04, 2019			
020305 001	GRANISETRON HYDROCHLORIDE;KYTRIL	4886808	DEC 29, 2007	U-105	I-264	JUL 27, 2002
020305 002	GRANISETRON HYDROCHLORIDE;KYTRIL				I-264	JUL 27, 2002
021238 001	GRANISETRON HYDROCHLORIDE;KYTRIL	4886808	DEC 29, 2007	U-105	I-264	JUL 27, 2002
020695 001	GREPAFLOXACIN HYDROCHLORIDE;RAXAR	5563138	OCT 08, 2013		NCE	NOV 06, 2002
019967 001	HALOBETASOL PROPIONATE;ULTRAVATE	4619921	DEC 17, 2004			
019968 001	HALOBETASOL PROPIONATE;ULTRAVATE	4619921	DEC 17, 2004			
020125 001	HYDROCHLOROTHIAZIDE;ACCURETIC	4344949	OCT 03, 2002	U-3	NC	DEC 28, 2002
		4743450	FEB 24, 2007			
020125 002	HYDROCHLOROTHIAZIDE;ACCURETIC	4743450	FEB 24, 2007		NC	DEC 28, 2002
		4344949	OCT 03, 2002	U-3		
020125 003	HYDROCHLOROTHIAZIDE;ACCURETIC	4344949	OCT 03, 2002	U-3	NC	DEC 28, 2002
		4743450	FEB 24, 2007			
020758 001	HYDROCHLOROTHIAZIDE;AVALIDE	5270317	MAR 20, 2011		NCE	SEP 30, 2002
		5994348	JUN 07, 2015			
020758 002	HYDROCHLOROTHIAZIDE;AVALIDE	5270317	MAR 20, 2011		NCE	SEP 30, 2002
		5994348	JUN 07, 2015			
020758 003	HYDROCHLOROTHIAZIDE;AVALIDE	5270317	MAR 20, 2011		NCE	SEP 30, 2002
		5994348	JUN 07, 2015			
020818 001	HYDROCHLOROTHIAZIDE;DIOVAN HCT	5399578	MAR 21, 2012	U-3		
020818 002	HYDROCHLOROTHIAZIDE;DIOVAN HCT	5399578	MAR 21, 2012	U-3		
020387 001	HYDROCHLOROTHIAZIDE;HYZAAR	5153197	OCT 06, 2009	U-3		
		5138069	AUG 11, 2009			
		5608075	MAR 04, 2014			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020387 002	HYDROCHLOROTHIAZIDE;HYZAAR	5138069	AUG 11, 2009			
		5153197	OCT 06, 2009	U-3		
		5608075	MAR 04, 2014			
019129 001	HYDROCHLOROTHIAZIDE;MAXZIDE	4444769	JUL 27, 2002			
019129 003	HYDROCHLOROTHIAZIDE;MAXZIDE-25	4444769	JUL 27, 2002			
021162 001	HYDROCHLOROTHIAZIDE;MICARDIS HCT	5591762	JAN 07, 2014	U-3	NC	NOV 17, 2003
021162 002	HYDROCHLOROTHIAZIDE;MICARDIS HCT	5591762	JAN 07, 2014	U-3	NC	NOV 17, 2003
019778 001	HYDROCHLOROTHIAZIDE;PRINZIDE	4374829*PED	JUN 29, 2002			
019778 002	HYDROCHLOROTHIAZIDE;PRINZIDE	4374829*PED	JUN 29, 2002	U-3		
019778 003	HYDROCHLOROTHIAZIDE;PRINZIDE	4374829*PED	JUN 29, 2002	U-3		
020729 001	HYDROCHLOROTHIAZIDE;UNIRETIC	4743450	FEB 24, 2007			
020729 002	HYDROCHLOROTHIAZIDE;UNIRETIC	4743450	FEB 24, 2007			
019888 001	HYDROCHLOROTHIAZIDE;ZESTORETIC	4374829*PED	JUN 29, 2002	U-3		
019888 002	HYDROCHLOROTHIAZIDE;ZESTORETIC	4374829*PED	JUN 29, 2002	U-3		
019888 003	HYDROCHLOROTHIAZIDE;ZESTORETIC	4374829*PED	JUN 29, 2002	U-3		
020716 001	HYDROCODONE BITARTRATE;VICOPROFEN	4587252	DEC 18, 2004	U-55		
020769 001	HYDROCORTISONE BUTYRATE;LOCOID LIPOCREAM	5635497	JUN 03, 2014			
016295 002	HYDROXYUREA;DROXIA				ODE	FEB 25, 2005
016295 003	HYDROXYUREA;DROXIA				ODE	FEB 25, 2005
016295 004	HYDROXYUREA;DROXIA				ODE	FEB 25, 2005
020402 002	IBUPROFEN POTASSIUM;ADVIL MIGRAINE LIQUI-GELS				NP	MAR 16, 2003
019771 001	IBUPROFEN;ADVIL COLD AND SINUS	4552899	APR 09, 2004			
		4552899*PED	OCT 09, 2004			
019833 002	IBUPROFEN;CHILDREN'S ADVIL	4788220	NOV 29, 2005			
		4788220*PED	MAY 29, 2006			
020589 001	IBUPROFEN;CHILDREN'S ADVIL	4788220	JUL 08, 2007			
		4788220*PED	JAN 08, 2008			
020516 001	IBUPROFEN;CHILDREN'S MOTRIN	5374659	DEC 20, 2011			
		5374659*PED	JUN 20, 2012			
020601 001	IBUPROFEN;CHILDREN'S MOTRIN	5215755	JUN 01, 2010			
		5215755*PED	DEC 01, 2010			
020603 001	IBUPROFEN;CHILDREN'S MOTRIN	5374659	DEC 20, 2011			
		5374659*PED	JUN 20, 2012			
021128 001	IBUPROFEN;CHILDREN'S MOTRIN COLD	6211246	JUN 10, 2019		NP	AUG 01, 2003
074567 001	IBUPROFEN;IBUPROHM COLD AND SINUS				PC	APR 06, 2002
020601 003	IBUPROFEN;JUNIOR STRENGTH MOTRIN	5215755	JUN 01, 2010			
		5215755*PED	DEC 01, 2010			
019842 001	IBUPROFEN;MOTRIN	5374659	DEC 20, 2011			
		5374659*PED	JUN 20, 2012			
020135 001	IBUPROFEN;MOTRIN	5215755	JUN 01, 2010			
		5320855	JUN 14, 2011			
		5215755*PED	DEC 01, 2010			
		5320855*PED	DEC 14, 2011			
020135 002	IBUPROFEN;MOTRIN	5215755	JUN 01, 2010			
		5320855	JUN 14, 2011			
		5215755*PED	DEC 01, 2010			
		5320855*PED	DEC 14, 2011			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
019012 004	IBUPROFEN;MOTRIN MIGRAINE PAIN				NP	FEB 26, 2003
020491 001	IBUTILIDE FUMARATE;CORVERT	5155268	DEC 28, 2009		D-50	MAY 13, 2002
019763 001	IFOSFAMIDE;IFEX	4882452	MAR 03, 2008			
019763 002	IFOSFAMIDE;IFEX	4882452	MAR 03, 2008			
019763 003	IFOSFAMIDE;IFEX/MESNEX KIT	4882452	MAR 03, 2008			
		5696172	OCT 06, 2013			
019763 004	IFOSFAMIDE;IFEX/MESNEX KIT	4882452	MAR 03, 2008			
		5696172	OCT 06, 2013			
021335 001	IMATINIB MESYLATE;GLEEVEC	5521184	MAY 28, 2013		NCE	MAY 10, 2006
					ODE	MAY 10, 2008
					ODE	FEB 01, 2009
021335 002	IMATINIB MESYLATE;GLEEVEC	5521184	MAY 28, 2013		NCE	MAY 10, 2006
					ODE	MAY 10, 2008
					ODE	FEB 01, 2009
020367 001	IMIGLUCERASE;CEREZYME	5236838	AUG 17, 2010			
		5549892	AUG 27, 2013	U-252		
020723 001	IMIQUIMOD;ALDARA	4689338	AUG 25, 2009	U-172	NCE	FEB 27, 2002
		5238944	AUG 24, 2010			
019693 001	INDECAINIDE HYDROCHLORIDE;DECABID	4452745	JUN 05, 2003			
019693 002	INDECAINIDE HYDROCHLORIDE;DECABID	4452745	JUN 05, 2003			
019693 003	INDECAINIDE HYDROCHLORIDE;DECABID	4452745	JUN 05, 2003			
020685 001	INDINAVIR SULFATE;CRIXIVAN	5413999	MAY 09, 2012	U-132		
020685 003	INDINAVIR SULFATE;CRIXIVAN	5413999	MAY 09, 2012	U-132		
020685 005	INDINAVIR SULFATE;CRIXIVAN	5413999	MAY 09, 2012	U-132		
020685 006	INDINAVIR SULFATE;CRIXIVAN	5413999	MAY 09, 2012	U-132		
020986 001	INSULIN ASPART;NOVOLOG				NCE	JUN 07, 2005
					NR	DEC 21, 2004
021172 001	INSULIN ASPART;NOVOLOG MIX 70/30				NC	NOV 01, 2004
021081 001	INSULIN GLARGINE;LANTUS	5656722	SEP 12, 2014		PED	OCT 20, 2005
		5656722*PED	MAR 12, 2015		NCE	APR 20, 2005
020563 001	INSULIN LISPRO;HUMALOG	5474978	JUN 16, 2014		D-56	APR 04, 2003
		5514646	MAY 07, 2013	U-111		
021018 001	INSULIN LISPRO;HUMALOG MIX 50/50	5461031	JUN 26, 2014		NC	DEC 22, 2002
		5474978	JUN 16, 2014			
		5514646	MAY 07, 2013			
		5747642	JUN 16, 2014			
021017 001	INSULIN LISPRO;HUMALOG MIX 75/25	5474978	JUN 16, 2014		NC	DEC 22, 2002
		5747642	JUN 16, 2014			
		5461031	JUN 16, 2014			
		5514646	MAY 07, 2013			
020563 002	INSULIN LISPRO;HUMALOG PEN	5474978	JUN 16, 2014		D-56	APR 04, 2003
		5514646	MAY 07, 2013	U-111		
021028 001	INSULIN RECOMBINANT HUMAN;VELOSULIN BR				NP	JUL 19, 2002
020084 001	IOBENGUANE SULFATE I 131;IOBENGUANE SULFATE I 131	4584187	APR 22, 2003			
020351 001	IODIXANOL;VISIPAQUE 270	5349085	SEP 20, 2011			
020808 001	IODIXANOL;VISIPAQUE 270	5349085	SEP 20, 2011			
020351 002	IODIXANOL;VISIPAQUE 320	5349085	SEP 20, 2011			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020808 002	IODIXANOL;VISIPAQUE 320	5349085	SEP 20, 2011			
020220 004	IOPROMIDE;ULTRAVIST 150	4364921	MAR 06, 2005	U-113		
020220 003	IOPROMIDE;ULTRAVIST 240	4364921	MAR 06, 2005	U-113		
020220 002	IOPROMIDE;ULTRAVIST 300	4364921	MAR 06, 2005	U-113		
020220 001	IOPROMIDE;ULTRAVIST 370	4364921	MAR 06, 2005	U-113		
019710 003	IOVERSOL;OPTIRAY 160	4396598	OCT 26, 2002	U-31		
019710 002	IOVERSOL;OPTIRAY 240	4396598	OCT 26, 2002	U-30		
020923 001	IOVERSOL;OPTIRAY 240	4396598	DEC 30, 2002			
019710 004	IOVERSOL;OPTIRAY 300	4396598	OCT 26, 2002	U-61		
019710 001	IOVERSOL;OPTIRAY 320	4396598	OCT 26, 2002	U-28		
				U-29		
020923 002	IOVERSOL;OPTIRAY 320	4396598	DEC 30, 2002			
019710 005	IOVERSOL;OPTIRAY 350	4396598	OCT 26, 2002	U-62		
020923 003	IOVERSOL;OPTIRAY 350	4396598	DEC 30, 2002			
020316 001	IOXILAN;OXILAN-300	4954348	DEC 21, 2009			
020316 002	IOXILAN;OXILAN-350	4954348	DEC 21, 2009			
020394 001	IPRATROPIUM BROMIDE;ATROVENT				I-327	OCT 27, 2003
020757 001	IRBESARTAN;AVAPRO	6342247	JUN 07, 2015		NCE	SEP 30, 2002
		5270317	MAR 20, 2011			
020757 002	IRBESARTAN;AVAPRO	6342247	JUN 07, 2015		NCE	SEP 30, 2002
		5270317	MAR 20, 2011			
020757 003	IRBESARTAN;AVAPRO	6342247	JUN 07, 2015		NCE	SEP 30, 2002
		5270317	MAR 20, 2011			
020571 001	IRINOTECAN HYDROCHLORIDE;CAMPTOSAR	4604463	AUG 20, 2007		I-299	APR 20, 2003
040024 001	IRON DEXTRAN;DEXFERRUM	5624668	SEP 29, 2015			
021135 001	IRON SUCROSE;VENOFER				NP	NOV 07, 2003
018662 002	ISOTRETINOIN;ACCUTANE	4464394*PED	FEB 07, 2002			
018662 003	ISOTRETINOIN;ACCUTANE	4464394*PED	FEB 07, 2002			
018662 004	ISOTRETINOIN;ACCUTANE	4464394*PED	FEB 07, 2002			
019546 001	ISRADIPINE;DYNACIRC	4466972	AUG 21, 2003	U-3		
019546 002	ISRADIPINE;DYNACIRC	4466972	AUG 21, 2003	U-3		
020336 001	ISRADIPINE;DYNACIRC CR	4816263	OCT 02, 2007	U-3		
		4466972	AUG 21, 2003	U-3		
		4783337	SEP 16, 2003	U-3		
		4946687	AUG 07, 2007			
		5030456	JUL 09, 2008			
		4950486	AUG 21, 2007			
020336 002	ISRADIPINE;DYNACIRC CR	4816263	OCT 02, 2007	U-3		
		4783337	SEP 16, 2003	U-3		
		4946687	AUG 07, 2007			
		4466972	AUG 21, 2003	U-3		
		4950486	AUG 21, 2007			
		5030456	JUL 09, 2008			
020083 001	ITRACONAZOLE;SPORANOX	5633015	MAY 27, 2014			
020657 001	ITRACONAZOLE;SPORANOX	5707975	JAN 13, 2015		I-332	MAY 09, 2004
		4727064	FEB 23, 2005			
020966 001	ITRACONAZOLE;SPORANOX	4791111	DEC 23, 2005		I-332	MAY 09, 2004
		4727064	FEB 23, 2005			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
019084 001	KETOCONAZOLE;NIZORAL	4942162	FEB 11, 2003			
019927 001	KETOCONAZOLE;NIZORAL	4942162	FEB 11, 2003			
020310 001	KETOCONAZOLE;NIZORAL A-D	4942162	FEB 11, 2003	U-245		
		5456851	APR 07, 2014			
019700 001	KETOROLAC TROMETHAMINE;ACULAR	4454151	MAR 22, 2002	U-75		
		5110493	MAY 05, 2009			
		4454151*PED	SEP 22, 2002	U-75		
		5110493*PED	NOV 05, 2009	U-75		
				U-75		
020811 001	KETOROLAC TROMETHAMINE;ACULAR PRESERVATIVE FREE	4454151	MAR 22, 2002			
		4454151*PED	SEP 22, 2002			
021066 001	KETOTIFEN FUMARATE;ZADITOR				NCE	JUL 02, 2004
020857 001	LAMIVUDINE;COMBIVIR	4828838*PED	MAR 17, 2006			
		4833130*PED	MAR 17, 2006			
		4837208	SEP 17, 2005			
		5047407*PED	AUG 08, 2009			
		4724232*PED	MAR 17, 2006			
		4818538*PED	MAR 17, 2006			
		5859021*PED	NOV 15, 2012	U-248		
		5905082*PED	NOV 18, 2016	U-248		
		6113920	OCT 23, 2017	U-257		
		6113920*PED	APR 23, 2018	U-257		
		4724232	SEP 17, 2005			
		4818538	SEP 17, 2005			
		4828838	SEP 17, 2005			
		4833130	SEP 17, 2005			
		5047407	FEB 08, 2009			
		5859021	MAY 15, 2012	U-248		
		5905082	MAY 18, 2016	U-248		
		4837208*PED	MAR 17, 2006			
		6180639	JAN 30, 2018	U-248		
		6180639*PED	JUL 30, 2018	U-248		
020564 001	LAMIVUDINE;EPIVIR	5047407	NOV 17, 2009			
		5905082	MAY 18, 2016			
		5905082*PED	NOV 18, 2016			
		5047407*PED	MAY 17, 2010			
		6180639	JAN 30, 2018	U-248		
		6180639*PED	JUL 30, 2018	U-248		
020596 001	LAMIVUDINE;EPIVIR	5047407	NOV 17, 2009			
		6004968	MAR 20, 2018			
		6004968*PED	SEP 20, 2018			
		5047407*PED	MAY 17, 2010			
		6180639	JAN 30, 2018	U-248		
		6180639*PED	JUL 30, 2018	U-248		
021003 001	LAMIVUDINE;EPIVIR-HBV	5047407	FEB 08, 2009		PED	JUN 08, 2002
		5532246	JUL 02, 2013	U-250	I-339	AUG 16, 2004
		5905082	MAY 18, 2016		PED	FEB 16, 2005
		5047407*PED	AUG 08, 2009			
		5532246*PED	JAN 02, 2014	U-250		
		5905082*PED	NOV 18, 2016			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
021004 001	LAMIVUDINE;EPIVIR-HBV	5047407	FEB 08, 2009		PED	JUN 08, 2002
		5532246	JUL 02, 2013	U-250	PED	FEB 16, 2005
		6004968	MAR 20, 2018		I-339	AUG 16, 2004
		5047407*PED	AUG 08, 2009			
		5532246*PED	JAN 02, 2014	U-250		
		6004968*PED	SEP 20, 2018			
020241 001	LAMOTRIGINE;LAMICTAL	4602017	JUL 22, 2008	U-106	ODE	AUG 24, 2005
020241 002	LAMOTRIGINE;LAMICTAL	4602017	JUL 22, 2008	U-106	ODE	AUG 24, 2005
020241 003	LAMOTRIGINE;LAMICTAL	4602017	JUL 22, 2008	U-106	ODE	AUG 24, 2005
020241 004	LAMOTRIGINE;LAMICTAL	4602017	JUL 22, 2008	U-106	ODE	AUG 24, 2005
020241 005	LAMOTRIGINE;LAMICTAL	4602017	JUL 22, 2008	U-106	ODE	AUG 24, 2005
020241 006	LAMOTRIGINE;LAMICTAL	4602017	JUL 22, 2008	U-106	ODE	AUG 24, 2005
020764 001	LAMOTRIGINE;LAMICTAL CD	5698226	JAN 29, 2012		ODE	AUG 24, 2005
		4602017	JUL 22, 2008	U-106		
020764 002	LAMOTRIGINE;LAMICTAL CD	5698226	JAN 29, 2012		ODE	AUG 24, 2005
		4602017	JUL 22, 2008	U-106		
020764 003	LAMOTRIGINE;LAMICTAL CD	5698226	JAN 29, 2012		ODE	AUG 24, 2005
		4602017	JUL 22, 2008	U-106		
020406 001	LANSOPRAZOLE;PREVACID	5093132	SEP 03, 2008		M-1	JUL 06, 2002
		5045321	SEP 03, 2008		I-316	NOV 30, 2003
		4689333	JUL 29, 2005	U-126		
		5026560	JUN 25, 2008			
		4628098	MAY 10, 2009			
		5433959	SEP 03, 2008			
020406 002	LANSOPRAZOLE;PREVACID	4689333	JUL 29, 2005	U-126	M-1	JUL 06, 2002
		5026560	JUN 25, 2008		I-316	NOV 30, 2003
		5045321	SEP 03, 2008			
		5093132	SEP 03, 2008			
		4628098	MAY 10, 2009			
		5433959	SEP 03, 2008			
021281 001	LANSOPRAZOLE;PREVACID				I-316	NOV 30, 2003
					M-1	JUL 06, 2002
021281 002	LANSOPRAZOLE;PREVACID				I-316	NOV 30, 2003
					M-1	JUL 06, 2002
020597 001	LATANOPROST;XALATAN	5296504	MAR 22, 2011	U-260		
		5422368	MAR 22, 2011	U-260		
		4599353	JUL 28, 2006	U-260		
020905 001	LEFLUNOMIDE;ARAVA	5679709	OCT 21, 2014	U-247	NCE	SEP 10, 2003
020905 002	LEFLUNOMIDE;ARAVA	5679709	OCT 21, 2014	U-247	NCE	SEP 10, 2003
020905 003	LEFLUNOMIDE;ARAVA	5679709	OCT 21, 2014	U-247	NCE	SEP 10, 2003
020807 001	LEPIRUDIN;REFLUDAN	5180668	JAN 19, 2010		ODE	MAR 06, 2005
					NCE	MAR 06, 2003
020726 001	LETROZOLE;FEMARA	4978672	JUN 03, 2011	U-203	NCE	JUL 25, 2002
					I-318	JAN 10, 2004
021343 001	LEUPROLIDE ACETATE;ELIGARD				NP	JAN 23, 2005
019732 001	LEUPROLIDE ACETATE;LUPRON DEPOT	5631020	MAY 20, 2014			
		5631021	NOV 01, 2004			
		4652441	NOV 01, 2004			
		4677191	JUL 03, 2005			
		4728721	MAY 01, 2006			
		4917893	NOV 01, 2004			
		5330767	NOV 01, 2004			
		5476663	NOV 01, 2004			
		4849228	JUL 18, 2006			
		5575987	SEP 02, 2013			
		5716640	SEP 02, 2013			
		6036976	DEC 13, 2013			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020011 001	LEUPROLIDE ACETATE;LUPRON DEPOT	5631020	NOV 01, 2004			
		5631021	MAY 20, 2014			
		4677191	JUL 03, 2005			
		4728721	MAY 01, 2006			
		4917893	NOV 01, 2004			
		5330767	NOV 01, 2004			
		4652441	NOV 01, 2004			
		4849228	JUL 18, 2006			
		5476663	NOV 01, 2004			
		5575987	SEP 02, 2013			
		5716640	SEP 02, 2013			
020517 001	LEUPROLIDE ACETATE;LUPRON DEPOT	5643607	JAN 02, 2013			
		5631020	MAY 20, 2014			
		5631021	NOV 01, 2004			
		4728721	MAY 01, 2006			
		5476663	NOV 01, 2004			
		5575987	NOV 19, 2013			
		5480656	JAN 02, 2013			
		4849228	JUL 18, 2006			
		5330767	NOV 01, 2004			
		5716640	SEP 02, 2013			
		5814342	FEB 01, 2011			
		6036976	DEC 13, 2016			
020263 002	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5631020	MAY 20, 2014			
		5631021	NOV 01, 2004			
		4917893	NOV 01, 2004			
		4652441	NOV 01, 2004			
		4677191	JUL 03, 2005			
		4728721	MAY 01, 2006			
		5330767	NOV 01, 2004			
		5476663	NOV 01, 2004			
		5575987	SEP 02, 2013			
		4849228	JUL 18, 2006			
		5716640	SEP 02, 2013			
		6036976	DEC 13, 2013			
020263 003	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5631020	MAY 20, 2014			
		5631021	NOV 01, 2004			
		4728721	MAY 01, 2006			
		4917893	NOV 01, 2004			
		4652441	NOV 01, 2004			
		4677191	JUL 03, 2005			
		5330767	NOV 01, 2004			
		4849228	JUL 18, 2006			
		5575987	SEP 02, 2013			
		5476663	NOV 01, 2004			
		5716640	SEP 02, 2013			
		6036976	DEC 13, 2013			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020263 004	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5631020	MAY 20, 2014			
		5631021	NOV 01, 2004			
		4677191	JUL 03, 2005			
		4728721	MAY 01, 2006			
		5330767	NOV 01, 2004			
		4917893	NOV 01, 2004			
		4652441	NOV 01, 2004			
		5476663	NOV 01, 2004			
		4849228	JUL 18, 2006			
		5575987	SEP 02, 2013			
		5716640	SEP 02, 2013			
		6036976	DEC 13, 2013			
020263 005	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5631020	MAY 20, 2014			
		5631021	NOV 01, 2004			
		4652441	NOV 01, 2004			
		5330767	NOV 01, 2004			
		4917893	NOV 01, 2004			
		4677191	JUL 03, 2005			
		4728721	MAY 01, 2006			
		5476663	NOV 01, 2004			
		4849228	JUL 18, 2006			
		5575987	SEP 02, 2013			
		5716640	SEP 02, 2013			
		6036976	DEC 13, 2013			
020263 006	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5631020	MAY 20, 2014			
		5631021	NOV 01, 2004			
		4652441	NOV 01, 2004			
		5330767	NOV 01, 2004			
		4917893	NOV 01, 2004			
		4677191	JUL 03, 2005			
		4728721	MAY 01, 2006			
		5476663	NOV 01, 2004			
		5575987	SEP 02, 2013			
		4849228	JUL 18, 2006			
		5716640	SEP 02, 2013			
		6036976	DEC 13, 2013			
020708 001	LEUPROLIDE ACETATE;LUPRON DEPOT-3	5631020	MAY 20, 2014			
		5631021	NOV 01, 2004			
		4728721	MAY 01, 2006			
		4849228	JUL 18, 2006			
		4954298	NOV 01, 2004			
		5330767	NOV 01, 2004			
		5476663	NOV 01, 2004			
		5480656	JAN 02, 2013			
		5575987	NOV 19, 2013			
		5643607	JAN 02, 2013			
		5716640	SEP 02, 2013			
		5814342	FEB 01, 2011			
		6036976	DEC 13, 2016			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020517 002	LEUPROLIDE ACETATE;LUPRON DEPOT-4	5631021	NOV 01, 2004			
		5476663	NOV 01, 2004			
		5480656	JAN 02, 2013			
		5575987	NOV 19, 2013			
		5330767	NOV 01, 2004			
		5643607	JAN 02, 2013			
		4728721	MAY 01, 2006			
		4849228	JUL 18, 2006			
		5631020	MAY 20, 2014			
		5716640	SEP 02, 2013			
		5814342	FEB 01, 2011			
		6036976	DEC 13, 2016			
021088 001	LEUPROLIDE ACETATE;VIADUR	5728396	JAN 30, 2017	U-316	NP	MAR 03, 2003
		5932547	JUN 13, 2017			
		5985305	JAN 30, 2017			
		6113938	JUL 24, 2018			
		6124261	JUN 13, 2017			
		6132420	JAN 30, 2017			
		6156331	JAN 30, 2017			
		6235712	JUN 13, 2017			
020837 001	LEVALBUTEROL HYDROCHLORIDE;XOPENEX	6083993	JAN 05, 2010	U-332	NP	MAR 25, 2002
		5362555	NOV 08, 2011		I-347	JAN 30, 2005
		5547994	AUG 20, 2013	U-332		
		5760090	JAN 05, 2010	U-332		
		5844002	JAN 05, 2010	U-332		
020837 002	LEVALBUTEROL HYDROCHLORIDE;XOPENEX	6083993	JAN 05, 2010	U-332	NP	MAR 25, 2002
		5362755	NOV 08, 2011	U-332	I-347	JAN 30, 2005
		5547994	AUG 20, 2013	U-332		
		5760090	JAN 05, 2010	U-332		
		5844002	JAN 05, 2010	U-332		
020035 001	LEVAMISOLE HYDROCHLORIDE;ERGAMISOL	4584305	JUN 18, 2004	U-42		
021035 001	LEVETIRACETAM;KEPPRA	4943639	JUL 06, 2006		NCE	NOV 30, 2004
		4837223	JUN 06, 2006			
021035 002	LEVETIRACETAM;KEPPRA	4943639	JUL 06, 2006		NCE	NOV 30, 2004
		4837223	JUN 06, 2006			
021035 003	LEVETIRACETAM;KEPPRA	4943639	JUL 06, 2006		NCE	NOV 30, 2004
		4837223	JUN 06, 2006			
021114 001	LEVOBETAXOLOL HYDROCHLORIDE;BETAXON	4911920	MAR 27, 2007	U-369	NP	FEB 23, 2003
		5540918	JUL 30, 2013			
020997 001	LEVOBUPIVACAINE HYDROCHLORIDE;CHIROCAINE	5708011	OCT 13, 2014	U-276	NP	AUG 05, 2002
020997 002	LEVOBUPIVACAINE HYDROCHLORIDE;CHIROCAINE	5708011	OCT 13, 2014	U-276	NP	AUG 05, 2002
020997 003	LEVOBUPIVACAINE HYDROCHLORIDE;CHIROCAINE	5708011	OCT 13, 2014	U-276	NP	AUG 05, 2002
020219 001	LEVOCABASTINE HYDROCHLORIDE;LIVOSTIN	4369184	DEC 02, 2004			
020182 001	LEVOCARNITINE;CARNITOR	6335369	JAN 18, 2022	U-433	I-280	DEC 15, 2002
					ODE	DEC 15, 2006
020634 001	LEVOFLOXACIN;LEVAQUIN	5053407	DEC 20, 2010		I-305	FEB 02, 2003
020634 002	LEVOFLOXACIN;LEVAQUIN	5053407	DEC 20, 2010		I-305	FEB 02, 2003

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020634 003	LEVOFLOXACIN;LEVAQUIN	5053407	DEC 20, 2010			
020635 001	LEVOFLOXACIN;LEVAQUIN	5053407	DEC 20, 2010		I-305	FEB 02, 2003
020635 002	LEVOFLOXACIN;LEVAQUIN IN DEXTROSE 5%	5053407	DEC 20, 2010		I-305	FEB 02, 2003
020635 003	LEVOFLOXACIN;LEVAQUIN IN DEXTROSE 5%	5053407	DEC 20, 2010		I-305	FEB 02, 2003
021199 001	LEVOFLOXACIN;QUIXIN	4382892	SEP 02, 2003		NDF	AUG 18, 2003
		5503407	OCT 01, 2008			
		4551456	NOV 14, 2003			
		5053407	OCT 01, 2008			
021225 001	LEVONORGESTREL;MIRENA				NP	DEC 06, 2003
021045 001	LEVONORGESTREL;PLAN B				NP	JUL 28, 2002
019941 001	LIDOCAINE;EMLA	4529601	JUL 16, 2002		I-260	MAR 11, 2002
		4562060	DEC 31, 2002		I-314	JAN 28, 2003
020575 001	LIDOCAINE;LIDOCAINE	5446070	FEB 27, 2011			
		5234957	FEB 27, 2011			
		5332576	JUL 26, 2011			
020575 002	LIDOCAINE;LIDOCAINE	5332576	JUL 26, 2011			
		5234957	FEB 27, 2011			
		5446070	FEB 27, 2011			
020612 001	LIDOCAINE;LIDODERM				NP	MAR 19, 2002
					ODE	MAR 19, 2006
021130 001	LINEZOLID;ZYVOX	5688792	NOV 18, 2014	U-319	NCE	APR 18, 2005
021130 002	LINEZOLID;ZYVOX	5688792	NOV 18, 2014	U-319	NCE	APR 18, 2005
021131 001	LINEZOLID;ZYVOX	5688792	NOV 18, 2014	U-319	NCE	APR 18, 2005
021132 001	LINEZOLID;ZYVOX	5688792	NOV 18, 2014	U-319	NCE	APR 18, 2005
019558 001	LISINOPRIL;PRINIVIL	4374829*PED	JUN 29, 2002			
019558 002	LISINOPRIL;PRINIVIL	4374829*PED	JUN 29, 2002			
019558 003	LISINOPRIL;PRINIVIL	4374829*PED	JUN 29, 2002			
019558 004	LISINOPRIL;PRINIVIL	4374829*PED	JUN 29, 2002			
019558 006	LISINOPRIL;PRINIVIL	4374829*PED	JUN 29, 2002			
019777 001	LISINOPRIL;ZESTRIL	4374829*PED	JUN 29, 2002		I-288	FEB 07, 2003
					PED	AUG 07, 2003
019777 002	LISINOPRIL;ZESTRIL	4374829*PED	JUN 29, 2002		I-288	FEB 07, 2003
					PED	AUG 07, 2003
019777 003	LISINOPRIL;ZESTRIL	4374829*PED	JUN 29, 2002		I-288	FEB 07, 2003
					PED	AUG 07, 2003
019777 004	LISINOPRIL;ZESTRIL	4374829*PED	JUN 29, 2002		I-288	FEB 07, 2003
					PED	AUG 07, 2003
019777 005	LISINOPRIL;ZESTRIL	4374829*PED	JUN 29, 2002		I-288	FEB 07, 2003
					PED	AUG 07, 2003
019777 006	LISINOPRIL;ZESTRIL	4374829*PED	JUN 29, 2002		I-288	FEB 07, 2003
					PED	AUG 07, 2003
020191 001	LODOXAMIDE TROMETHAMINE;ALOMIDE	5457126	OCT 10, 2012	U-117		
020013 001	LOMEFLOXACIN HYDROCHLORIDE;MAXAQUIN	4528287	FEB 21, 2006	U-36		
020448 001	LOPERAMIDE HYDROCHLORIDE;IMODIUM A-D	5489436	FEB 06, 2013			
020606 001	LOPERAMIDE HYDROCHLORIDE;IMODIUM ADVANCED	5248505	JUL 28, 2010			
		5612054	SEP 28, 2010			
		5489436	FEB 06, 2013			
		5679376	OCT 21, 2014			
		5716641	MAY 21, 2012	U-226		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
021140 001	LOPERAMIDE HYDROCHLORIDE;IMODIUM ADVANCED	5248505	SEP 28, 2010	U-434		
		6103260	JUL 17, 2017			
		5612054	SEP 28, 2010			
021226 001	LOPINAVIR;KALETRA	5914332	DEC 13, 2015	U-351	NC	SEP 15, 2003
		5635523	JUN 30, 2014	U-352		
		5541206	JUL 30, 2013	U-348		
		5674882	OCT 07, 2014	U-344		
		5886036	DEC 29, 2012	U-345		
		6037157	JUN 26, 2016	U-346		
		5846987	DEC 29, 2012	U-350		
		5648497	JUL 15, 2014			
		6232333	NOV 07, 2017			
		6284767	FEB 14, 2016	U-401		
021251 001	LOPINAVIR;KALETRA	5541206	JUL 30, 2013	U-348	NC	SEP 15, 2003
		5914332	DEC 13, 2005	U-351		
		5635523	JUN 03, 2014	U-352		
		5846987	DEC 29, 2012	U-350		
		5648497	JUL 15, 2014			
		5674882	OCT 07, 2014	U-344		
		5886036	DEC 29, 2012	U-345		
		6037157	JUN 26, 2016	U-346		
		6284767	FEB 14, 2016	U-401		
019658 001	LORATADINE;CLARITIN	4282233	JUN 19, 2002	U-77		
		4659716	APR 21, 2004	U-142		
		4863931	SEP 15, 2008			
		4282233*PED	DEC 19, 2002	U-77		
		4659716*PED	OCT 21, 2004	U-142		
		4863931*PED	MAR 15, 2009			
020641 001	LORATADINE;CLARITIN	4659716	APR 21, 2004	U-142		
		4282233	JUN 19, 2002	U-77		
		4863931	SEP 15, 2008			
		4659716*PED	OCT 21, 2004	U-142		
		4863931*PED	MAR 15, 2009			
		4282233*PED	DEC 19, 2002	U-77		
		6132758	JUN 01, 2018			
020704 001	LORATADINE;CLARITIN REDITABS	4659716	APR 21, 2004	U-142		
		4282233	JUN 19, 2002	U-77		
		4863931	SEP 15, 2008			
		4659716*PED	OCT 21, 2004	U-142		
		4282233*PED	DEC 19, 2002	U-77		
		4863931*PED	MAR 15, 2009			
019670 001	LORATADINE;CLARITIN-D	4282233	JUN 19, 2002	U-77		
		4659716	APR 21, 2004	U-142		
		4863931	SEP 15, 2008			
		4282233*PED	DEC 19, 2002	U-77		
		4659716*PED	OCT 21, 2004	U-142		
		4863931*PED	MAR 15, 2009			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020470 001	LORATADINE;CLARITIN-D 24 HOUR	4659716	APR 21, 2004	U-142		
		4282233	JUN 19, 2002	U-77		
		5314697*PED	APR 23, 2013			
		4863931	SEP 15, 2008			
		4659716*PED	OCT 21, 2004	U-142		
		4282233*PED	DEC 19, 2002	U-77		
		4863931*PED	MAR 15, 2009			
		5314697	APR 23, 2013			
020386 001	LOSARTAN POTASSIUM;COZAAR	5138069	AUG 11, 2009			
		5153197	OCT 06, 2009	U-3		
		5608075	MAR 04, 2014			
020386 002	LOSARTAN POTASSIUM;COZAAR	5153197	OCT 06, 2009	U-3		
		5138069	AUG 11, 2009			
		5608075	MAR 04, 2014			
020386 003	LOSARTAN POTASSIUM;COZAAR	5138069	AUG 11, 2009			
		5153197	OCT 06, 2009	U-3		
		5608075	MAR 04, 2014			
020803 001	LOTEPREDNOL ETABONATE;ALREX	4996335	MAR 09, 2012		NCE	MAR 09, 2003
		5540930	OCT 25, 2013			
020583 001	LOTEPREDNOL ETABONATE;LOTEMAX	4996335	MAR 09, 2012		NCE	MAR 09, 2003
		5540930	OCT 25, 2013			
020841 001	LOTEPREDNOL ETABONATE;LOTEMAX	4996335	FEB 26, 2008		NCE	MAR 09, 2003
		5540930	OCT 25, 2013			
021249 001	LOVASTATIN;ADVICOR				NC	DEC 17, 2004
021249 002	LOVASTATIN;ADVICOR				NC	DEC 17, 2004
021249 003	LOVASTATIN;ADVICOR				NC	DEC 17, 2004
019643 002	LOVASTATIN;MEVACOR				I-250	MAR 11, 2002
					PED	SEP 11, 2002
019643 003	LOVASTATIN;MEVACOR				I-250	MAR 11, 2002
					PED	SEP 11, 2002
019643 004	LOVASTATIN;MEVACOR				I-250	MAR 11, 2002
					PED	SEP 11, 2002
021047 001	LUTEINIZING HORMONE;REPRONEX				NP	AUG 27, 2002
021047 002	LUTEINIZING HORMONE;REPRONEX				NP	AUG 27, 2002
019832 003	MAFENIDE ACETATE;SULFAMYLON				ODE	JUN 05, 2005
020652 001	MANGAFODIPIR TRISODIUM;TESLASCAN	4933456	JUN 12, 2007		NCE	NOV 26, 2002
		4992554	FEB 12, 2008			
		5091169	FEB 25, 2009			
		5223243	JUN 29, 2010	U-237		
		4647447	MAR 03, 2004	U-238		
019940 001	MASOPROCOL;ACTINEX	4695590	APR 17, 2008			
		5008294	APR 15, 2008	U-68		
019591 001	MEFLOQUINE HYDROCHLORIDE;LARIAM	4579855	OCT 01, 2004			
020264 001	MEGESTROL ACETATE;MEGACE	5338732	AUG 16, 2011			
075671 001	MEGESTROL ACETATE;MEGESTROL ACETATE				PC	JAN 12, 2002
020938 001	MELOXICAM;MOBIC				NCE	APR 13, 2005
020207 001	MELPHALAN HYDROCHLORIDE;ALKERAN	4997651	NOV 18, 2008			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020922 001	MEQUINOL;SOLAGE	5194247	MAR 16, 2010	U-294	NC	DEC 10, 2004
		5470567	MAR 19, 2010	U-294		
019651 001	MESALAMINE;ASACOL	5541170	JUL 30, 2013	U-141		
		5541171	JUL 30, 2013	U-141		
020049 001	MESALAMINE;PENTASA	4496553	JAN 29, 2002	U-78		
		4980173	JAN 29, 2002	U-78		
019618 001	MESALAMINE;ROWASA	4657900	APR 14, 2004			
		RE33239	MAY 12, 2004			
019884 001	MESNA;MESNEX	5696172	OCT 06, 2013			
020357 001	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				PED	APR 22, 2002
					M-6	APR 19, 2004
020357 002	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				PED	APR 22, 2002
					M-6	APR 19, 2004
020357 003	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				PED	APR 22, 2002
					M-6	APR 19, 2004
020357 004	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				PED	APR 22, 2002
					M-6	APR 19, 2004
020357 005	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				PED	APR 22, 2002
					M-6	APR 19, 2004
021202 001	METFORMIN HYDROCHLORIDE;GLUCOPHAGE XR				NDF	OCT 13, 2003
020969 001	METHOXSALEN;UVADEX	4845075	APR 11, 2009		NP	FEB 25, 2002
		5036102	JUL 30, 2008	U-273		
		4999375	MAR 12, 2008			
021121 001	METHYLPHENIDATE HYDROCHLORIDE;CONCERTA	5082668	SEP 16, 2003		NP	AUG 01, 2003
		4783337	SEP 16, 2003	U-372		
		4612008	SEP 16, 2003			
		4519801	JUL 12, 2002			
021121 002	METHYLPHENIDATE HYDROCHLORIDE;CONCERTA	5082668	SEP 16, 2003		NP	AUG 01, 2003
		4783337	SEP 16, 2003	U-372		
		4612008	SEP 16, 2003			
		4519801	JUL 12, 2002			
021121 003	METHYLPHENIDATE HYDROCHLORIDE;CONCERTA	5082668	SEP 16, 2003		NP	AUG 01, 2003
		4783337	SEP 16, 2003	U-372		
		4612008	SEP 16, 2003			
		4519801	JUL 12, 2002			
021259 001	METHYLPHENIDATE HYDROCHLORIDE;METADATE CD				NDF	APR 03, 2004
017862 001	METOCLOPRAMIDE HYDROCHLORIDE;REGLAN	4536386	AUG 20, 2002	U-9		
017862 004	METOCLOPRAMIDE HYDROCHLORIDE;REGLAN	4536386	AUG 20, 2002	U-9		
019532 001	METOLAZONE;MYKROX	4517179	APR 29, 2003			
019786 003	METOPROLOL FUMARATE;LOPRESSOR	4892739	JAN 09, 2007			
019786 004	METOPROLOL FUMARATE;LOPRESSOR	4892739	JAN 09, 2007			
019962 001	METOPROLOL SUCCINATE;TOPROL-XL	5001161	MAR 19, 2008		I-194	FEB 05, 2004
		4957745	SEP 18, 2007	U-107		
		5081154	JAN 14, 2009			
		4927640	MAY 22, 2007			
		5246714	SEP 21, 2010			
019962 002	METOPROLOL SUCCINATE;TOPROL-XL	5001161	MAR 19, 2008		I-194	FEB 05, 2004
		4957745	SEP 18, 2007	U-107		
		5081154	JAN 14, 2009			
		4927640	MAY 22, 2007			
		5246714	SEP 21, 2010			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
019962 003	METOPROLOL SUCCINATE;TOPROL-XL	4957745	SEP 18, 2007	U-107	I-194	FEB 05, 2004
		5001161	MAR 19, 2008			
		5081154	JAN 14, 2009			
		4927640	MAY 27, 2007			
		5246714	SEP 21, 2010			
019962 004	METOPROLOL SUCCINATE;TOPROL-XL	4957745	SEP 18, 2007	U-107	NS	FEB 05, 2004
		5001161	MAR 19, 2008	U-107	I-194	FEB 05, 2004
		5081154	JAN 14, 2009	U-107		
		4927640	MAY 22, 2007			
		5246714	SEP 21, 2010			
019737 001	METRONIDAZOLE;METROGEL	4837378	JUN 06, 2006			
020208 001	METRONIDAZOLE;METROGEL-VAGINAL	5536743	JUL 16, 2013	U-137		
		4837378	JUN 06, 2006			
		5840744	JAN 15, 2008	U-370		
020968 001	MICONAZOLE NITRATE;MONISTAT DUAL- PAK	5514698	MAR 21, 2014		NP	JUN 30, 2002
021308 001	MICONAZOLE NITRATE;MONISTAT 1 COMBINATION PACK	6153635	NOV 28, 2020			
		5514698	MAR 21, 2014			
020942 001	MIDAZOLAM HYDROCHLORIDE;VERSED				PED	APR 15, 2002
019815 001	MIDODRINE HYDROCHLORIDE;PROAMATINE				ODE	SEP 06, 2003
019815 002	MIDODRINE HYDROCHLORIDE;PROAMATINE				ODE	SEP 06, 2003
020687 001	MIFEPRISTONE;MIFEPREX	4386085	JAN 08, 2002		NCE	SEP 28, 2005
		4447424	JAN 08, 2002			
		4626531	OCT 12, 2004			
020682 001	MIGLITOL;GLYSET	4639436	JAN 27, 2009	U-111		
020682 002	MIGLITOL;GLYSET	4639436	JAN 27, 2009	U-111		
020682 003	MIGLITOL;GLYSET	4639436	JAN 27, 2009	U-111		
019436 001	MILRINONE LACTATE;PRIMACOR	4313951*PED	MAY 26, 2002			
020343 001	MILRINONE LACTATE;PRIMACOR IN DEXTROSE 5%	4313951*PED	MAY 26, 2002			
020343 002	MILRINONE LACTATE;PRIMACOR IN DEXTROSE 5%	4313951*PED	MAY 26, 2002			
020343 003	MILRINONE LACTATE;PRIMACOR IN DEXTROSE 5%	4313951*PED	MAY 26, 2002			
020415 001	MIRTAZAPINE;REMERON	5977099	JUN 16, 2017			
020415 002	MIRTAZAPINE;REMERON	5977099	JUN 16, 2017			
020415 003	MIRTAZAPINE;REMERON	5977099	JUN 16, 2017			
021208 001	MIRTAZAPINE;REMERON SOLTAB	5977099	JUN 26, 2017			
		5178878	JAN 12, 2010			
021208 002	MIRTAZAPINE;REMERON SOLTAB	5977099	JUN 16, 2017			
		5178878	JAN 12, 2010			
021208 003	MIRTAZAPINE;REMERON SOLTAB	5977099	JUN 16, 2017			
		5178878	JAN 12, 2010			
019297 001	MITOXANTRONE HYDROCHLORIDE;NOVANTRONE	4820738	APR 11, 2006	U-98	ODE	NOV 13, 2003
		4617319	JUN 13, 2005	U-390	I-324	OCT 13, 2003
021120 001	MITOXANTRONE HYDROCHLORIDE;NOVANTRONE				ODE	OCT 13, 2007
020098 001	MIVACURIUM CHLORIDE;MIVACRON	4761418	JAN 22, 2006			
020098 002	MIVACURIUM CHLORIDE;MIVACRON IN DEXTROSE 5%	4761418	JAN 22, 2006			
020717 001	MODAFINIL;PROVIGIL	RE37516	OCT 06, 2014	U-255	ODE	DEC 24, 2005
		4927855	MAY 22, 2007	U-255	NCE	DEC 24, 2003
020717 002	MODAFINIL;PROVIGIL	RE37516	OCT 06, 2014	U-255	ODE	DEC 24, 2005
		4927855	MAY 22, 2007	U-255	NCE	DEC 24, 2003

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020312 001	MOEXIPRIL HYDROCHLORIDE;UNIVASC	4743450	FEB 24, 2007			
020312 002	MOEXIPRIL HYDROCHLORIDE;UNIVASC	4743450	FEB 24, 2007			
020762 001	MOMETASONE FUROATE MONOHYDRATE;NASONEX	5837699	JAN 27, 2014	U-249	I-285	DEC 02, 2002
		6127353	OCT 03, 2017		PED	JUN 02, 2003
		4472393*PED	MAR 18, 2002			
		5837699*PED	JUL 27, 2014	U-249		
		6127353*PED	APR 03, 2018			
019543 001	MOMETASONE FUROATE;ELOCON	4472393*PED	MAR 18, 2002			
019625 001	MOMETASONE FUROATE;ELOCON	4808610	OCT 02, 2006			
		4472393*PED	MAR 18, 2002			
		4808610*PED	APR 02, 2007			
019796 001	MOMETASONE FUROATE;ELOCON	4775529	MAY 21, 2007			
		4472393*PED	MAR 18, 2002			
		4775529*PED	NOV 21, 2007			
020829 002	MONTELUKAST SODIUM;SINGULAIR	5565473	FEB 03, 2012	U-228	NCE	FEB 20, 2003
		5565473*PED	AUG 03, 2012	U-228	PED	AUG 20, 2003
020830 001	MONTELUKAST SODIUM;SINGULAIR	5565473	FEB 03, 2012	U-228	NCE	FEB 20, 2003
		5565473*PED	AUG 03, 2012	U-228	PED	AUG 20, 2003
020830 002	MONTELUKAST SODIUM;SINGULAIR	5565473	FEB 03, 2012	U-228	I-300	MAR 03, 2003
		5565473*PED	AUG 03, 2012	U-228	NS	MAR 03, 2003
					NCE	FEB 20, 2003
					PED	SEP 03, 2003
					PED	AUG 20, 2003
					PED	SEP 03, 2003
020616 001	MORPHINE SULFATE;KADIAN	5202128	APR 13, 2010			
		5378474	MAR 23, 2010			
020616 002	MORPHINE SULFATE;KADIAN	5378474	MAR 23, 2010			
		5202128	APR 13, 2010			
020616 003	MORPHINE SULFATE;KADIAN	5202128	APR 13, 2010			
		5378474	MAR 23, 2010			
021085 001	MOXIFLOXACIN HYDROCHLORIDE;AVELOX	4990517	JUN 30, 2009	U-298	NCE	DEC 10, 2004
		5607942	MAR 04, 2014	U-298	I-329	APR 27, 2004
		5849752	DEC 05, 2016	U-298		
021277 001	MOXIFLOXACIN HYDROCHLORIDE;AVELOX IN SODIUM CHLORIDE 0.8%				NCE	DEC 10, 2004
					NDF	NOV 30, 2004
					I-329	APR 27, 2004
075179 001	NABUMETONE;NABUMETONE				PC	FEB 23, 2002
075189 001	NABUMETONE;NABUMETONE				PC	FEB 16, 2002
075189 002	NABUMETONE;NABUMETONE				PC	FEB 23, 2002
019583 001	NABUMETONE;RELAFEN	4420639	DEC 13, 2002			
		4420639*PED	JUN 13, 2003			
019583 002	NABUMETONE;RELAFEN	4420639	DEC 13, 2002			
		4420639*PED	JUN 13, 2003			
021076 001	NAPROXEN SODIUM;ALEVE COLD AND SINUS				NC	NOV 29, 2002
020353 001	NAPROXEN SODIUM;NAPRELAN	5637320	JUN 10, 2014			
020353 002	NAPROXEN SODIUM;NAPRELAN	5637320	JUN 10, 2014			
020353 003	NAPROXEN SODIUM;NAPRELAN	5637320	JUN 10, 2014			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020763 001	NARATRIPTAN HYDROCHLORIDE;AMERGE	4997841	AUG 12, 2008	U-232	NCE	FEB 10, 2003
020763 002	NARATRIPTAN HYDROCHLORIDE;AMERGE	4997841	AUG 12, 2008	U-232	NCE	FEB 10, 2003
021204 001	NATEGLINIDE;STARLIX	RE34878	MAR 28, 2006		NCE	DEC 22, 2005
		5463116	OCT 21, 2012			
		5488150	JAN 30, 2013			
021204 002	NATEGLINIDE;STARLIX	RE34878	MAR 28, 2006		NCE	DEC 22, 2005
		5463116	OCT 21, 2012			
		5488150	JAN 30, 2013			
021009 001	NEDOCROMIL SODIUM;ALOCRIL	4474787	OCT 02, 2006	U-304	NP	DEC 08, 2002
		4760072	JUL 26, 2005			
019660 001	NEDOCROMIL SODIUM;TILADE	4474787	OCT 02, 2006			
		4760072	JUL 26, 2005			
020152 001	NEFAZODONE HYDROCHLORIDE;SERZONE	4338317	MAR 16, 2003			
		5256664	APR 28, 2012			
020152 002	NEFAZODONE HYDROCHLORIDE;SERZONE	4338317	MAR 16, 2003			
		5256664	APR 28, 2012			
020152 003	NEFAZODONE HYDROCHLORIDE;SERZONE	4338317	MAR 16, 2003			
		5256664	APR 28, 2012			
020152 004	NEFAZODONE HYDROCHLORIDE;SERZONE	4338317	MAR 16, 2003			
		5256664	APR 28, 2012			
020152 005	NEFAZODONE HYDROCHLORIDE;SERZONE	4338317	MAR 16, 2003			
		5256664	APR 28, 2012			
020152 006	NEFAZODONE HYDROCHLORIDE;SERZONE	4338317	MAR 16, 2003			
		5256664	APR 28, 2012			
020778 001	NELFINAVIR MESYLATE;VIRACEPT	5484926	OCT 07, 2013		D-52	NOV 24, 2002
		5952343	OCT 07, 2013	U-257	NCE	MAR 14, 2002
020779 001	NELFINAVIR MESYLATE;VIRACEPT	5484926	OCT 07, 2013		D-52	NOV 24, 2002
		5952343	OCT 07, 2013	U-257	NCE	MAR 14, 2002
020920 001	NESIRITIDE;NATRECOR	5114923	MAY 19, 2009		NCE	AUG 10, 2006
		5674710	OCT 07, 2014			
020636 001	NEVIRAPINE;VIRAMUNE	5366972	NOV 22, 2011	U-167		
020933 001	NEVIRAPINE;VIRAMUNE	5366972	NOV 22, 2011			
020381 001	NIACIN;NIASPAN	6080428	MAY 27, 2017	U-331		
		6129930	SEP 20, 2013	U-354		
020381 002	NIACIN;NIASPAN	6080428	MAY 27, 2017	U-331		
		6129930	SEP 20, 2013	U-354		
020381 003	NIACIN;NIASPAN	6080428	MAY 27, 2017	U-331		
		6129930	SEP 20, 2013	U-354		
020381 004	NIACIN;NIASPAN	6080428	MAY 27, 2017	U-331		
		6129930	SEP 20, 2013	U-354		
020381 005	NIACIN;NIASPAN TITRATION STARTER PACK	6080428	MAY 27, 2017	U-331		
019734 001	NICARDIPINE HYDROCHLORIDE;CARDENE	4880823	NOV 14, 2006			
		5164405	NOV 17, 2009			
020005 001	NICARDIPINE HYDROCHLORIDE;CARDENE SR	5198226	MAR 30, 2010			
020005 002	NICARDIPINE HYDROCHLORIDE;CARDENE SR	5198226	MAR 30, 2010			
020005 003	NICARDIPINE HYDROCHLORIDE;CARDENE SR	5198226	MAR 30, 2010			
020076 001	NICOTINE;HABITROL	4597961	JAN 23, 2005	U-56		
		5016652	MAY 21, 2008			
		5834011	MAY 01, 2007	U-355		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020076 002	NICOTINE;HABITROL	4597961	JAN 23, 2005	U-56		
		5016652	MAY 21, 2008			
		5834011	MAY 01, 2007	U-355		
020076 003	NICOTINE;HABITROL	4597961	JAN 23, 2005	U-56		
		5016652	MAY 21, 2008			
		5834011	MAY 01, 2007	U-355		
020076 004	NICOTINE;HABITROL	5834011	MAY 01, 2007	U-355		
020076 005	NICOTINE;HABITROL	5834011	MAY 01, 2007	U-355		
020076 006	NICOTINE;HABITROL	5834011	MAY 01, 2007	U-355		
020165 004	NICOTINE;NICODERM CQ	5004610	JUN 14, 2008			
		5344656	JUN 14, 2008			
		5342623	JUN 14, 2008			
		5364630	JUN 14, 2008			
		5462745	JUN 14, 2008			
		5508038	APR 16, 2013			
		6165497	JUN 14, 2008	U-388		
		5633008	JUN 14, 2008	U-389		
020165 005	NICOTINE;NICODERM CQ	5004610	JUN 14, 2008			
		5344656	JUN 14, 2008			
		5342623	JUN 14, 2008			
		5364630	JUN 14, 2008			
		5462745	JUN 14, 2008			
		5508038	APR 16, 2013			
		5633008	JUN 14, 2008	U-389		
		6165497	JUN 14, 2008	U-388		
020165 006	NICOTINE;NICODERM CQ	5004610	JUN 14, 2008			
		5344656	JUN 14, 2008			
		5342623	JUN 14, 2008			
		5364630	JUN 14, 2008			
		5462745	JUN 14, 2008			
		5508038	APR 16, 2013			
		5633008	JUN 14, 2008	U-389		
		6165497	JUN 14, 2008	U-388		
020385 001	NICOTINE;NICOTROL	5656255	AUG 12, 2014			
020536 001	NICOTINE;NICOTROL	5501236	JUN 08, 2010			
		6098632	JUN 08, 2010			
020714 001	NICOTINE;NICOTROL	5400808	JUN 08, 2010			
		4917120	APR 17, 2007			
		4800903	JAN 31, 2006			
		4793366	DEC 27, 2005			
		5167242	JUN 08, 2010			
		5501236	JUN 08, 2010			
		6098632	JUN 08, 2010			
019983 001	NICOTINE;PROSTEP	4946853	AUG 07, 2007	U-56		
019983 002	NICOTINE;PROSTEP	4946853	AUG 07, 2007	U-56		
020198 001	NIFEDIPINE;ADALAT CC	4892741	JUN 08, 2008			
		5264446	NOV 23, 2010			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020198 002	NIFEDIPINE;ADALAT CC	4892741	JUN 08, 2008			
		5264446	NOV 23, 2010			
020198 003	NIFEDIPINE;ADALAT CC	4892741	JUN 08, 2008			
		5264446	NOV 23, 2010			
019684 001	NIFEDIPINE;PROCARDIA XL	4765989	SEP 16, 2003			
		5264446	NOV 23, 2010			
		4612008	SEP 16, 2003			
		4783337	SEP 16, 2003			
019684 002	NIFEDIPINE;PROCARDIA XL	4765989	SEP 16, 2003			
		5264446	NOV 23, 2010			
		4612008	SEP 16, 2003			
		4783337	SEP 16, 2003			
019684 003	NIFEDIPINE;PROCARDIA XL	4765989	SEP 16, 2003			
		5264446	NOV 23, 2010			
		4612008	SEP 16, 2003			
		4783337	SEP 16, 2003			
018869 001	NIMODIPINE;NIMOTOP	4406906	SEP 27, 2002	U-22		
020356 001	NISOLDIPINE;SULAR	4892741	JUN 08, 2008			
020356 002	NISOLDIPINE;SULAR	4892741	JUN 08, 2008			
020356 003	NISOLDIPINE;SULAR	4892741	JUN 08, 2008			
020356 004	NISOLDIPINE;SULAR	4892741	JUN 08, 2008			
021232 001	NITISINONE;ORFADIN				NCE	JAN 18, 2007
					ODE	JAN 18, 2009
021232 002	NITISINONE;ORFADIN				NCE	JAN 18, 2007
					ODE	JAN 18, 2009
021232 003	NITISINONE;ORFADIN				NCE	JAN 18, 2007
					ODE	JAN 18, 2009
020845 002	NITRIC OXIDE;INOMAX	5485827	JAN 23, 2013	U-297	ODE	DEC 23, 2006
					NCE	DEC 23, 2004
020845 003	NITRIC OXIDE;INOMAX	5485827	JAN 23, 2013	U-297	ODE	DEC 23, 2006
					NCE	DEC 23, 2004
020064 001	NITROFURANTOIN;MACROBID	4772473	JUN 16, 2006			
		4798725	JUN 16, 2006			
020145 001	NITROGLYCERIN;NITRO-DUR	5186938	FEB 16, 2010			
020145 002	NITROGLYCERIN;NITRO-DUR	5186938	FEB 16, 2010			
020145 003	NITROGLYCERIN;NITRO-DUR	5186938	FEB 16, 2010			
020145 004	NITROGLYCERIN;NITRO-DUR	5186938	FEB 16, 2010			
020145 005	NITROGLYCERIN;NITRO-DUR	5186938	FEB 16, 2010			
020145 006	NITROGLYCERIN;NITRO-DUR	5186938	FEB 16, 2010			
018705 002	NITROGLYCERIN;NITROLINGUAL PUMPSPRAY	5186925	FEB 16, 2010			
021134 001	NITROGLYCERIN;NITROSTAT				NDF	MAY 01, 2003
021134 002	NITROGLYCERIN;NITROSTAT				NDF	MAY 01, 2003
021134 003	NITROGLYCERIN;NITROSTAT				NDF	MAY 01, 2003
019508 001	NIZATIDINE;AXID	4375547	APR 12, 2002			
019508 002	NIZATIDINE;AXID	4375547	APR 12, 2002			
020555 001	NIZATIDINE;AXID AR	4375547	OCT 02, 2002			
019757 001	NORFLOXACIN;CHIBROXIN	4551456	NOV 14, 2003	U-57		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
019384 002	NORFLOXACIN;NOROXIN	4639458	JAN 22, 2005			
019667 001	OCTREOTIDE ACETATE;SANDOSTATIN	4395403	OCT 21, 2002			
		5753618	MAY 19, 2015			
019667 002	OCTREOTIDE ACETATE;SANDOSTATIN	4395403	OCT 21, 2002			
		5753618	MAY 19, 2015			
019667 003	OCTREOTIDE ACETATE;SANDOSTATIN	4395403	OCT 21, 2002			
		5753618	MAY 19, 2015			
019667 004	OCTREOTIDE ACETATE;SANDOSTATIN	4395403	OCT 21, 2002			
		5753618	MAY 19, 2015			
019667 005	OCTREOTIDE ACETATE;SANDOSTATIN	4395403	OCT 21, 2002			
021008 001	OCTREOTIDE ACETATE;SANDOSTATIN LAR	5688530	NOV 18, 2014	U-268	ODE	NOV 25, 2005
		4395403	NOV 21, 2002	U-269		
		5538739	JUL 23, 2013			
		5639480	JUN 17, 2014			
		5922338	JUL 13, 2016			
		5922682	JUL 13, 2016			
021008 002	OCTREOTIDE ACETATE;SANDOSTATIN LAR	5688530	NOV 18, 2014	U-268	ODE	NOV 25, 2005
		4395403	NOV 21, 2002	U-269		
		5538739	JUL 23, 2013			
		5639480	JUN 17, 2014			
		5922338	JUL 13, 2016			
		5922682	JUL 13, 2016			
021008 003	OCTREOTIDE ACETATE;SANDOSTATIN LAR	5688530	NOV 18, 2014	U-268	ODE	NOV 25, 2005
		4395403	NOV 21, 2002	U-269		
		5538739	JUL 23, 2013			
		5639480	JUN 17, 2014			
		5922338	JUL 13, 2016			
		5922682	JUL 13, 2016			
019735 001	OFLOXACIN;FLOXIN	4382892	SEP 02, 2003			
019735 002	OFLOXACIN;FLOXIN	4382892	SEP 02, 2003			
019735 003	OFLOXACIN;FLOXIN	4382892	SEP 02, 2003			
020799 001	OFLOXACIN;FLOXIN	5401741	MAR 27, 2012	U-407		
019921 001	OFLOXACIN;OCUFLOX	4382892	SEP 02, 2003		ODE	MAY 22, 2003
		4551456	NOV 14, 2003	U-80		
020592 001	OLANZAPINE;ZYPREXA	5229382	APR 23, 2011	U-149	I-297	MAR 17, 2003
		5605897	FEB 25, 2014	U-176	I-313	NOV 09, 2003
		5736541	MAR 24, 2015	U-307		
		5919485	MAR 24, 2015	U-308		
		5817656	APR 23, 2011	U-360		
		5817657	APR 23, 2011	U-363		
		5627178	APR 23, 2011	U-364		
		5817655	APR 23, 2011	U-364		
		6251895	SEP 23, 2017			
020592 002	OLANZAPINE;ZYPREXA	5229382	APR 23, 2011	U-149	I-297	MAR 17, 2003
		5605897	FEB 25, 2014	U-176	I-313	NOV 09, 2003
		5736541	MAR 24, 2015	U-307		
		5919485	MAR 24, 2015	U-308		
		5817656	APR 23, 2011	U-360		
		5817657	APR 23, 2011	U-363		
		5627178	APR 23, 2011	U-364		
		5817655	APR 23, 2011	U-364		
		6251895	SEP 23, 2017			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020592 003	OLANZAPINE;ZYPREXA	5229382	APR 23, 2011	U-149	I-297	MAR 17, 2003
		5605897	FEB 25, 2014	U-176	I-313	NOV 09, 2003
		5736541	MAR 24, 2015	U-307		
		5919485	MAR 24, 2015	U-308		
		5817656	APR 23, 2011	U-360		
		5817657	APR 23, 2011	U-363		
		5627178	APR 23, 2011	U-364		
		5817655	APR 23, 2011	U-364		
		6251895	SEP 23, 2017			
020592 004	OLANZAPINE;ZYPREXA	5229382	APR 23, 2011	U-149	I-297	MAR 17, 2003
		5605897	FEB 25, 2014	U-176	I-313	NOV 09, 2003
		5736541	MAR 24, 2015	U-307		
		5919485	MAR 24, 2015	U-308		
		5817656	APR 23, 2011	U-360		
		5817657	APR 23, 2011	U-363		
		5627178	APR 23, 2011	U-364		
		5817655	APR 23, 2011	U-364		
		6251895	SEP 23, 2017			
020592 005	OLANZAPINE;ZYPREXA	5736541	MAR 24, 2015	U-307	I-297	MAR 17, 2003
		5919485	MAR 24, 2015	U-308	I-313	NOV 09, 2003
		5817656	APR 23, 2011	U-360		
		5817657	APR 23, 2011	U-363		
		5627178	APR 23, 2011	U-364		
		5817655	APR 23, 2011	U-364		
		5229382	APR 23, 2011	U-149		
		5605897	FEB 25, 2014	U-176		
		6251895	SEP 23, 2017			
020592 006	OLANZAPINE;ZYPREXA	5736541	MAR 24, 2015	U-307	I-297	MAR 17, 2003
		5919485	MAR 24, 2015	U-308	I-313	NOV 09, 2003
		5817656	APR 23, 2011	U-360		
		5817657	APR 23, 2011	U-363		
		5627178	APR 23, 2011	U-364		
		5817655	APR 23, 2011	U-364		
		6251895	SEP 23, 2017			
		5229382	APR 23, 2011	U-149		
		5605897	FEB 25, 2014	U-176		
021086 001	OLANZAPINE;ZYPREXA ZYDIS	5457895	SEP 30, 2013			
		5229382	APR 23, 2011	U-324		
		5605897	FEB 25, 2014	U-325		
		5627178	APR 23, 2011	U-326		
		5736541	MAR 24, 2015	U-328		
		5817655	APR 23, 2011	U-327		
		5817656	APR 23, 2011	U-326		
		6020487	SEP 23, 2017			
		6251895	SEP 23, 2017			
021086 002	OLANZAPINE;ZYPREXA ZYDIS	5457895	SEP 30, 2013			
		5229382	APR 23, 2011	U-324		
		5605897	FEB 25, 2014	U-325		
		5627178	APR 23, 2011	U-326		
		5736541	MAR 24, 2015	U-328		
		5817655	APR 23, 2011	U-327		
		5817656	APR 23, 2011	U-326		
		6020487	SEP 23, 2017			
		6251895	SEP 23, 2017			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
021086 003	OLANZAPINE;ZYPREXA ZYDIS	5457895	SEP 30, 2013			
		5736541	MAR 24, 2015	U-328		
		5817655	APR 23, 2011	U-327		
		5817656	APR 23, 2011	U-326		
		5229382	APR 23, 2011	U-324		
		5605897	FEB 25, 2014	U-325		
		5627178	APR 23, 2011	U-326		
		6020487	SEP 23, 2017			
		6251895	SEP 23, 2017			
021086 004	OLANZAPINE;ZYPREXA ZYDIS	5457895	SEP 30, 2013			
		5229382	APR 23, 2011	U-324		
		5605897	FEB 25, 2014	U-325		
		5627178	APR 23, 2011	U-326		
		5736541	MAR 24, 2015	U-328		
		5817655	APR 23, 2011	U-327		
		5817656	APR 23, 2011	U-326		
		6020487	SEP 23, 2017			
		6251895	SEP 23, 2017			
020688 001	OLOPATADINE HYDROCHLORIDE;PATANOL	5641805	JUN 06, 2015	U-184	I-301	MAR 20, 2003
		4871865	OCT 03, 2006			
		4923892	MAY 08, 2007	U-174		
		5116863	DEC 18, 2010			
019715 001	OLSALAZINE SODIUM;DIPENTUM	4559330	JUL 31, 2004	U-58		
019810 001	OMEPRAZOLE;PRILOSEC	5629305	FEB 04, 2014	U-188		
		4786505	APR 20, 2007	U-108		
		4853230	APR 20, 2007	U-108		
		4636499	MAY 30, 2005			
		5093342	FEB 02, 2010	U-166		
		5599794	FEB 04, 2014	U-166		
		6150380	NOV 10, 2018			
		6147103	OCT 09, 2018			
		6166213	OCT 09, 2018			
		6191148	OCT 09, 2018			
		4636499*PED	JAN 30, 2006			
		4786505*PED	OCT 20, 2007	U-108		
		4853230*PED	OCT 20, 2007	U-108		
		5093342*PED	AUG 02, 2010	U-166		
		5599794*PED	AUG 04, 2014	U-166		
		5629305*PED	AUG 04, 2014	U-188		
		6147103*PED	APR 09, 2019			
		6150380*PED	MAY 10, 2019			
		6166213*PED	APR 09, 2018			
		6191148*PED	APR 09, 2019			
		4508905	APR 02, 2002			
		4508905*PED	OCT 02, 2002			
019810 002	OMEPRAZOLE;PRILOSEC	4786505	APR 20, 2007	U-108		
		4853230	APR 20, 2007	U-108		
		4636499	MAY 30, 2005			
		5093342	FEB 02, 2010	U-166		
		5599794	FEB 04, 2014	U-166		
		5629305	FEB 04, 2014	U-188		
		6150380	NOV 10, 2018			
		6147103	OCT 09, 2018			
		6166213	OCT 09, 2018			
		6191148	OCT 09, 2018			
		4636499*PED	JAN 30, 2006			
		4786505*PED	OCT 20, 2007	U-108		
		4853230*PED	OCT 20, 2007	U-108		
		5093342*PED	AUG 02, 2010	U-166		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
		5599794*PED	AUG 04, 2014			
		5629305*PED	AUG 04, 2014	U-166		
		6147103*PED	APR 09, 2019	U-188		
		6150380*PED	MAY 10, 2019			
		6166213*PED	APR 09, 2018			
		6191148*PED	APR 09, 2019			
		4508905	APR 02, 2002			
		4508905*PED	OCT 02, 2002			
019810 003	OMEPRAZOLE;PRILOSEC	5629305	FEB 04, 2014	U-188		
		4853230	APR 20, 2007	U-108		
		4786505	APR 20, 2007	U-108		
		4636499	MAY 30, 2005			
		5093342	FEB 02, 2010	U-166		
		5599794	FEB 04, 2014	U-166		
		6150380	NOV 10, 2018			
		6147103	OCT 09, 2018			
		6166213	NOV 10, 2018			
		6191148	OCT 09, 2018			
		4636499*PED	JAN 30, 2006			
		4786505*PED	OCT 20, 2007	U-108		
		4853230*PED	OCT 20, 2007	U-108		
		5093342*PED	AUG 02, 2010	U-166		
		5599794*PED	AUG 04, 2014	U-166		
		5629305*PED	AUG 04, 2014	U-188		
		6147103*PED	APR 09, 2019			
		6150380*PED	MAY 10, 2019			
		6166213*PED	APR 09, 2018			
		6191148*PED	APR 09, 2019			
		4508905	APR 02, 2002			
		4508905*PED	OCT 02, 2002			
020007 001	ONDANSETRON HYDROCHLORIDE;ZOFRAN	5578628	FEB 16, 2005	U-44		
		4753789	JUN 24, 2006	U-44		
		4695578	JAN 25, 2005			
020103 001	ONDANSETRON HYDROCHLORIDE;ZOFRAN	5578628	FEB 16, 2005	U-44	I-269	AUG 27, 2002
		4753789	JUN 24, 2006	U-44		
		5344658	SEP 06, 2011			
		4695578	JAN 25, 2005			
020103 002	ONDANSETRON HYDROCHLORIDE;ZOFRAN	5578628	FEB 16, 2005	U-44	I-269	AUG 27, 2002
		4753789	JUN 24, 2006	U-44		
		5344658	SEP 06, 2011			
		4695578	JAN 25, 2005			
020103 003	ONDANSETRON HYDROCHLORIDE;ZOFRAN	5578628	FEB 16, 2005	U-44	I-269	AUG 27, 2002
		5344658	SEP 06, 2011			
		4753789	JUN 24, 2006	U-44		
		4695578	JAN 25, 2005			
020403 001	ONDANSETRON HYDROCHLORIDE;ZOFRAN	5578628	FEB 16, 2005	U-44		
		4753789	JUN 24, 2006	U-44		
		4695578	JAN 25, 2005			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020605 001	ONDANSETRON HYDROCHLORIDE;ZOFRAN	5578628	FEB 16, 2005	U-44		
		4753789	JUN 24, 2006	U-44		
		4695578	JAN 25, 2005	U-183		
020007 003	ONDANSETRON HYDROCHLORIDE;ZOFRAN PRESERVATIVE FREE	5578628	FEB 16, 2005	U-44		
020781 001	ONDANSETRON;ZOFRAN ODT	5578628	FEB 16, 2005	U-330		
		5955488	NOV 14, 2015			
		4695578	JAN 25, 2005	U-330		
		4753789	JUN 24, 2006	U-330		
		6063802	NOV 14, 2015			
020781 002	ONDANSETRON;ZOFRAN ODT	5578628	FEB 16, 2005	U-330		
		5955488	NOV 14, 2015			
		4695578	JAN 25, 2005	U-330		
		4753789	JUN 24, 2006	U-330		
		6063802	NOV 14, 2015			
020766 001	ORLISTAT;XENICAL	4598089	JUN 18, 2004		NCE	APR 23, 2004
		6004996	JAN 06, 2018			
021087 001	OSELTAMIVIR PHOSPHATE;TAMIFLU	5763483	DEC 27, 2016		NCE	OCT 27, 2004
		5866601	FEB 02, 2016		I-317	NOV 17, 2003
		5952375	FEB 02, 2016			
021246 001	OSELTAMIVIR PHOSPHATE;TAMIFLU	5763483	DEC 27, 2016	U-376	I-317	NOV 17, 2003
		5866601	FEB 02, 2016		NDF	DEC 14, 2003
		5952375	FEB 02, 2016		NCE	OCT 27, 2004
015539 002	OXAZEPAM;SERAX	4620974	NOV 04, 2003			
015539 004	OXAZEPAM;SERAX	4620974	NOV 04, 2003			
015539 006	OXAZEPAM;SERAX	4620974	NOV 04, 2003			
021014 001	OXCARBAZEPINE;TRILEPTAL				NCE	JAN 14, 2005
021014 002	OXCARBAZEPINE;TRILEPTAL				NCE	JAN 14, 2005
021014 003	OXCARBAZEPINE;TRILEPTAL				NCE	JAN 14, 2005
020897 001	OXYBUTYNIN CHLORIDE;DITROPAN XL	4783337	SEP 16, 2003		PED	JUN 16, 2002
		5674895	MAY 22, 2015			
		5082668	SEP 16, 2003			
		5840754	MAY 22, 2015			
		4612008	SEP 16, 2003			
		4519801	JUL 12, 2002			
		5912268	MAY 22, 2015			
		6124355	MAY 22, 2015	U-378		
		6262115	MAY 22, 2015	U-393		
		4783337*PED	MAR 16, 2004			
		4519801*PED	JAN 12, 2003			
		4612008*PED	MAR 16, 2004			
		5082668*PED	MAR 16, 2004			
		5674895*PED	NOV 22, 2015			
		5840754*PED	NOV 22, 2015			
		5912268*PED	NOV 22, 2015			
		6124355*PED	NOV 22, 2015	U-378		
		6262115*PED	NOV 22, 2015	U-393		
020897 002	OXYBUTYNIN CHLORIDE;DITROPAN XL	5840754	MAY 22, 2015		PED	JUN 16, 2002
		5674895	MAY 22, 2015			
		5082668	SEP 16, 2003			
		4783337	SEP 16, 2003			
		4612008	SEP 16, 2003			
		4519801	JUL 12, 2002			
		5912268	MAY 22, 2015			
		6124355	MAY 22, 2015	U-378		
		6262115	MAY 22, 2015	U-393		
		4783337*PED	MAR 16, 2004			
		4519801*PED	JAN 12, 2003			
		4612008*PED	MAR 16, 2004			
		5082668*PED	MAR 16, 2004			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
		5674895*PED	NOV 22, 2015			
		5840754*PED	NOV 22, 2015			
		5912268*PED	NOV 22, 2015			
		6124355*PED	NOV 22, 2015	U-378		
		6262115*PED	NOV 22, 2015	U-393		
020897 003	OXYBUTYNIN CHLORIDE;DITROPAN XL	5912268	MAY 22, 2015		PED	JUN 16, 2002
		4612008	SEP 16, 2003			
		4519801	JUL 12, 2002			
		5840754	MAY 22, 2015			
		5674895	MAY 22, 2015			
		5082668	SEP 16, 2003			
		4783337	SEP 16, 2003			
		6124355	MAY 22, 2015	U-378		
		6262115	MAY 22, 2015	U-393		
		4783337*PED	MAR 16, 2004			
		4519801*PED	JAN 12, 2003			
		4612008*PED	MAR 16, 2004			
		5082668*PED	MAR 16, 2004			
		5674895*PED	NOV 22, 2015			
		5840754*PED	NOV 22, 2015			
		5912268*PED	NOV 22, 2015			
		6124355*PED	NOV 22, 2015	U-378		
		6262115*PED	NOV 22, 2015	U-393		
020553 001	OXYCODONE HYDROCHLORIDE;OXYCONTIN	4970075	NOV 13, 2007			
		5266331	FEB 05, 2008			
		4861598	AUG 29, 2006			
		5549912	FEB 05, 2008			
		5508042	APR 16, 2013			
		5656295	FEB 05, 2008			
020553 002	OXYCODONE HYDROCHLORIDE;OXYCONTIN	4970075	NOV 13, 2007			
		5266331	FEB 05, 2008			
		5549912	FEB 05, 2008			
		4861598	AUG 29, 2006			
		5508042	APR 16, 2013			
		5656295	FEB 05, 2008			
020553 003	OXYCODONE HYDROCHLORIDE;OXYCONTIN	4861598	AUG 29, 2006			
		4970075	NOV 13, 2007			
		5266331	FEB 05, 2008			
		5549912	FEB 05, 2008			
		5508042	APR 16, 2013			
		5656295	FEB 05, 2008			
020553 004	OXYCODONE HYDROCHLORIDE;OXYCONTIN	5508042	APR 16, 2013			
		5656295	FEB 05, 2008			
		4861598	AUG 29, 2006			
		4970075	NOV 13, 2007			
		5266331	FEB 05, 2008			
		5549912	FEB 05, 2008			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020553 005	OXYCODONE HYDROCHLORIDE;OXYCONTIN	4861598	AUG 29, 2006			
		4970075	NOV 13, 2007			
		5266331	FEB 05, 2008			
		5549912	FEB 05, 2008			
		5508042	APR 16, 2013			
		5656295	FEB 05, 2008			
020262 001	PACLITAXEL;TAXOL	5641803	AUG 03, 2012	U-198	D-57	JUN 20, 2003
		5670537	AUG 03, 2012	U-198	I-270	OCT 25, 2002
		5496804	MAR 09, 2013	U-204	ODE	AUG 04, 2004
		6150398	MAY 08, 2011	U-380	I-230	JAN 08, 2002
020036 001	PAMIDRONATE DISODIUM;AREDIA	4711880	JUL 29, 2005		D-68	AUG 20, 2004
020036 003	PAMIDRONATE DISODIUM;AREDIA	4711880	JUL 29, 2005		D-68	AUG 20, 2004
020036 004	PAMIDRONATE DISODIUM;AREDIA	4711880	JUL 29, 2005		D-68	AUG 20, 2004
075290 001	PAMIDRONATE DISODIUM;PAMIDRONATE DISODIUM				PC	MAY 05, 2002
075290 003	PAMIDRONATE DISODIUM;PAMIDRONATE DISODIUM				PC	MAY 05, 2002
020987 001	PANTOPRAZOLE SODIUM;PROTONIX	4758579	JUL 19, 2005		NCE	FEB 02, 2005
					I-330	JUN 12, 2004
020988 001	PANTOPRAZOLE SODIUM;PROTONIX IV	4758579	JUL 19, 2005		NDF	MAR 22, 2004
					NCE	FEB 02, 2005
					I-337	OCT 19, 2004
020819 001	PARICALCITOL;ZEMPLAR	5246925	APR 17, 2012	U-314	NCE	APR 17, 2003
		5587497	DEC 24, 2013			
		6136799	APR 08, 2018			
020031 001	PAROXETINE HYDROCHLORIDE;PAXIL	4721723	DEC 29, 2006	U-12	I-261	MAY 17, 2002
		5872132	MAY 19, 2015		I-326	APR 13, 2004
		5900423	MAY 19, 2015		I-345	DEC 14, 2004
		5789449	JAN 06, 2009	U-285		
		6063927	APR 23, 2019			
		6080759	MAY 19, 2015			
		6113944	DEC 14, 2014			
		6121291	MAR 17, 2017	U-286		
		6133289	MAY 19, 2015	U-358		
		6172233	JAN 15, 2018			
		6121291	MAR 17, 2017	U-431		
020031 002	PAROXETINE HYDROCHLORIDE;PAXIL	4721723	DEC 29, 2006	U-12	I-261	MAY 17, 2002
		5872132	MAY 19, 2015		I-326	APR 13, 2004
		5900423	MAY 19, 2015		I-345	DEC 14, 2004
		5789449	JAN 06, 2009	U-285		
		6063927	APR 23, 2019			
		6080759	MAY 19, 2015			
		6113944	DEC 14, 2014			
		6121291	MAR 17, 2017	U-286		
		6133289	MAY 19, 2015	U-358		
		6172233	JAN 15, 2018			
		6121291	MAR 17, 2017	U-431		
020031 003	PAROXETINE HYDROCHLORIDE;PAXIL	4721723	DEC 29, 2006		I-261	MAY 17, 2002
		5872132	MAY 19, 2015		I-326	APR 13, 2004
		5900423	MAY 19, 2015		I-345	DEC 14, 2004
		5789449	JAN 06, 2009	U-285		
		6063927	APR 23, 2019			
		6080759	MAY 19, 2015			
		6113944	DEC 14, 2014			
		6121291	MAR 17, 2017	U-286		
		6133289	MAY 19, 2015	U-358		
		6172233	JAN 15, 2018			
		6121291	MAR 17, 2017	U-431		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020031 004	PAROXETINE HYDROCHLORIDE;PAXIL	4721723	DEC 29, 2006		I-261	MAY 17, 2002
		5872132	MAY 19, 2015		I-326	APR 13, 2004
		5900423	MAY 19, 2015		I-345	DEC 14, 2004
		5789449	JAN 06, 2009	U-285		
		6063927	APR 23, 2019			
		6080759	MAY 19, 2015			
		6113944	DEC 14, 2014			
		6133289	MAY 15, 2015	U-358		
020031 005	PAROXETINE HYDROCHLORIDE;PAXIL	4721723	DEC 29, 2006	U-12	I-261	MAY 17, 2002
		5872132	MAY 19, 2015		I-326	APR 13, 2004
		5900423	MAY 19, 2015		I-345	DEC 14, 2004
		5789449	JAN 06, 2009	U-285		
		6063927	APR 23, 2019			
		6080759	MAY 19, 2015			
		6113944	DEC 14, 2014			
		6121291	MAR 17, 2017	U-286		
		6133289	MAY 15, 2015	U-358		
		6172233	JAN 15, 2018			
		6121291	MAR 17, 2017	U-431		
020710 001	PAROXETINE HYDROCHLORIDE;PAXIL	4721723	DEC 29, 2006		I-261	MAY 17, 2002
		5811436	SEP 22, 2015			
		5872132	MAY 19, 2015			
		5900423	MAY 19, 2015			
		5789449	JAN 06, 2009	U-285		
		6063927	APR 23, 2019			
		6080759	MAY 19, 2015			
		6121291	MAR 17, 2017	U-286		
		6133289	MAY 19, 2015			
		6172233	JAN 15, 2018	U-358		
		6121291	MAR 17, 2017			
				U-431		
020885 001	PAROXETINE HYDROCHLORIDE;PAXIL	5872132	MAY 19, 2015		I-261	MAY 17, 2002
		5900423	MAY 19, 2015			
		5789449	JAN 06, 2009	U-285		
		4721723	DEC 29, 2006	U-12		
		6063927	APR 23, 2019			
		6080759	MAY 19, 2015			
		6121291	MAR 17, 2017	U-286		
		6133289	MAY 19, 2015	U-358		
		6172233	JAN 15, 2018			
		6121291	MAR 17, 2017	U-431		
020885 002	PAROXETINE HYDROCHLORIDE;PAXIL	5872132	MAY 19, 2015		I-261	MAY 17, 2002
		5900423	MAY 19, 2015			
		5789449	JAN 06, 2009	U-285		
		4721723	DEC 29, 2006	U-12		
		6063927	APR 23, 2019			
		6080759	MAY 19, 2015			
		6121291	MAR 17, 2017	U-286		
		6133289	MAY 19, 2015	U-358		
		6172233	JAN 15, 2018			
		6121291	MAR 17, 2017	U-431		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020885 003	PAROXETINE HYDROCHLORIDE;PAXIL	5872132	MAY 19, 2015		I-261	MAY 17, 2002
		5900423	MAY 19, 2015			
		5789449	JAN 06, 2009	U-285		
		4721723	DEC 29, 2006	U-12		
		6063927	APR 23, 2019			
		6080759	MAY 19, 2015			
		6121291	MAR 17, 2017	U-286		
		6133289	MAY 19, 2015			
		6172233	JAN 15, 2018	U-358		
		6121291	MAR 17, 2017	U-431		
020885 004	PAROXETINE HYDROCHLORIDE;PAXIL	5872132	MAY 19, 2015		I-261	MAY 17, 2002
		5900423	MAY 19, 2015			
		5789449	JAN 06, 2009	U-285		
		4721723	DEC 29, 2006	U-12		
		6062927	APR 23, 2019			
		6080759	MAY 19, 2015			
		6121291	MAR 17, 2017	U-286		
		6133289	MAY 19, 2015	U-358		
		6172233	JAN 15, 2018			
		6121291	MAR 17, 2017	U-431		
020936 001	PAROXETINE HYDROCHLORIDE;PAXIL CR	5872132	MAY 19, 2015		NDF	FEB 16, 2002
		4839177	JUN 13, 2006			
		5422123	JUN 06, 2012			
		4721723	DEC 29, 2006			
		5900423	MAY 19, 2015			
		5789449	JAN 06, 2009	U-286		
		6063927	APR 23, 2019			
		6080759	MAY 19, 2015			
		6121291	MAR 17, 2017	U-286		
		6133289	MAY 19, 2015	U-286		
		6172233	JAN 15, 2018			
020936 002	PAROXETINE HYDROCHLORIDE;PAXIL CR	5872132	MAY 19, 2015		NDF	FEB 16, 2002
		4839177	JUN 13, 2006			
		5422123	JUN 06, 2012			
		4721723	DEC 29, 2006			
		5900423	MAY 19, 2015			
		5789449	JAN 06, 2009	U-286		
		6063927	APR 23, 2019			
		6080759	MAY 19, 2015			
		6121291	MAR 17, 2017	U-286		
		6133289	MAY 19, 2015	U-286		
		6172233	JAN 15, 2018			
020936 003	PAROXETINE HYDROCHLORIDE;PAXIL CR	4721723	DEC 29, 2006		NDF	FEB 16, 2002
		4839177	JUN 13, 2006			
		5422123	JUN 06, 2012			
		5789449	JAN 06, 2009	U-286		
		5872132	MAY 19, 2015			
		5900423	MAY 19, 2015			
		6063927	APR 23, 2019			
		6080759	MAY 19, 2015			
		6121291	MAR 17, 2017	U-286		
		6133289	MAY 19, 2015	U-286		
		6172233	JAN 15, 2018			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
021079 001	PEMIROLAST POTASSIUM;ALAMAST	5034230	DEC 23, 2008	U-184	PED	MAR 24, 2005
		5034230*PED	JUN 23, 2009	U-184	NCE	SEP 24, 2004
020629 001	PENCICLOVIR SODIUM;DENAVIR	5075445	DEC 24, 2008			
020193 001	PENTOSAN POLYSULFATE SODIUM;ELMIRON	5180715	JAN 19, 2010	U-159	ODE	SEP 26, 2003
021084 001	PERFLUOROPOLYMETHYLISOPROPYL ETHER;SKIN EXPOSURE REDUCTION PAST[illegible]A	[illegible]	MAY 30, 2015		NCE	FEB 17, 2005
021064 001	PERFLUTREN;DEFINITY	5527521	APR 05, 2011		NCE	JUL 31, 2006
		5547656	APR 05, 2011			
		5769080	JUL 20, 2010			
019385 001	PERGOLIDE MESYLATE;PERMAX	4797405	OCT 26, 2007			
		5114948	OCT 19, 2009			
019385 002	PERGOLIDE MESYLATE;PERMAX	4797405	OCT 26, 2007			
		5114948	OCT 19, 2009			
019385 003	PERGOLIDE MESYLATE;PERMAX	4797405	OCT 26, 2007			
		5114948	OCT 19, 2009			
020184 001	PERINDOPRIL ERBUMINE;ACEON	4508729	AUG 21, 2006			
020184 002	PERINDOPRIL ERBUMINE;ACEON	4508729	AUG 21, 2006			
020184 003	PERINDOPRIL ERBUMINE;ACEON	4508729	AUG 21, 2006			
020237 001	PILOCARPINE HYDROCHLORIDE;SALAGEN				ODE	FEB 11, 2005
021302 001	PIMECROLIMUS;ELIDEL	5912238	JUN 15, 2016		NCE	DEC 13, 2006
		5912238*PED	DEC 15, 2016		PED	JUN 13, 2007
021073 001	PIOGLITAZONE HYDROCHLORIDE;ACTOS	6303640	AUG 09, 2016	U-425	NCE	JUL 15, 2004
		4687777	JAN 17, 2006			
		6211205	JUN 19, 2016	U-410		
		6166043	JUN 19, 2016	U-415		
		5965584	JUN 19, 2016	U-417		
		6150384	JUN 19, 2016	U-419		
		6329404	JUN 19, 2016	U-430		
		6150383	JUN 19, 2016	U-418		
		6172090	JUN 19, 2016	U-416		
		6166042	JUN 19, 2016	U-414		
		6271243	JUN 19, 2016	U-411		
021073 002	PIOGLITAZONE HYDROCHLORIDE;ACTOS	6303640	AUG 09, 2016	U-425	NCE	JUL 15, 2004
		4687777	JAN 17, 2006			
		6211205	JUN 19, 2016	U-410		
		6166043	JUN 19, 2016	U-415		
		5965584	JUN 19, 2016	U-417		
		6150384	JUN 19, 2016	U-419		
		6329404	JUN 19, 2016	U-430		
		6150383	JUN 19, 2016	U-418		
		6172090	JUN 19, 2016	U-416		
		6166042	JUN 19, 2016	U-414		
		6271243	JUN 19, 2016	U-411		
021073 003	PIOGLITAZONE HYDROCHLORIDE;ACTOS	6303640	AUG 09, 2016	U-425	NCE	JUL 15, 2004
		4687777	JAN 17, 2006			
		6211205	JUN 19, 2016	U-410		
		6166043	JUN 19, 2016	U-415		
		5965584	JUN 19, 2016	U-417		
		6150384	JUN 19, 2016			
		6329404	JUN 19, 2016	U-430		
		6150383	JUN 19, 2016	U-418		
		6172090	JUN 19, 2016	U-416		
		6166042	JUN 19, 2016	U-414		
		6271243	JUN 19, 2016	U-411		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020014 001	PIRBUTEROL ACETATE;MAXAIR	4664107	MAY 12, 2004			
020529 001	PODOFILOX;CONDYLOX	4680399	JUL 14, 2004			
		5057616	OCT 15, 2008			
020698 001	POLYETHYLENE GLYCOL 3350;MIRALAX	5710183	JUL 14, 2015	U-265	NP	FEB 18, 2002
		6048901	APR 20, 2019	U-343		
020744 001	PORACTANT ALFA;CUROSURF				NCE	NOV 18, 2004
020451 001	PORFIMER SODIUM;PHOTOFRIN	4866168	MAR 10, 2004		ODE	DEC 27, 2002
		5028621	MAR 10, 2004			
		5438071	AUG 01, 2012			
		4649151	MAR 10, 2004			
		4932934	JUN 12, 2007	U-128		
		5145863	DEC 15, 2009	U-129		
019439 002	POTASSIUM CHLORIDE;K-DUR 10	4863743	SEP 05, 2006	U-99		
019439 001	POTASSIUM CHLORIDE;K-DUR 20	4863743	SEP 05, 2006	U-99		
074726 001	POTASSIUM CHLORIDE;KLOR-CON M20				PC	FEB 28, 2002
020667 001	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4843086	NOV 23, 2007	U-231	NCE	JUL 01, 2002
		4886812	MAR 25, 2011			
020667 002	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4843086	NOV 23, 2007	U-231	NCE	JUL 01, 2002
		4886812	MAR 25, 2011			
020667 003	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4843086	NOV 23, 2007	U-231	NCE	JUL 01, 2002
		4886812	MAR 25, 2011			
020667 004	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4843086	NOV 23, 2007	U-231	NCE	JUL 01, 2002
		4886812	MAR 25, 2011			
020667 005	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4843086	NOV 23, 2007	U-231	NCE	JUL 01, 2002
		4886812	MAR 25, 2011			
020667 006	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4843086	NOV 23, 2007	U-231		
		4886812	MAR 25, 2011			
019898 002	PRAVASTATIN SODIUM;PRAVACHOL	4346227	OCT 20, 2005		I-281	JUN 09, 2003
		5180589	JUL 09, 2008		I-304	JAN 18, 2003
		5030447	JUL 09, 2008		I-287	FEB 10, 2003
		5622985	APR 22, 2014	U-335	I-286	JAN 18, 2003
					D-51	JAN 18, 2003
					D-70	DEC 18, 2004
019898 003	PRAVASTATIN SODIUM;PRAVACHOL	4346227	OCT 20, 2005		I-281	JUN 09, 2003
		5030447	JUL 09, 2008		I-304	JAN 18, 2003
		5180589	JUL 09, 2008		I-287	FEB 10, 2003
		5622985	APR 22, 2014	U-335	I-286	JAN 18, 2003
					D-51	JAN 18, 2003
					D-70	DEC 18, 2004
019898 004	PRAVASTATIN SODIUM;PRAVACHOL	4346227	OCT 20, 2005		I-281	JUN 09, 2003
		5030447	JUL 09, 2008		I-304	JAN 18, 2003
		5180589	JUL 09, 2008		I-287	FEB 10, 2003
		5622985	APR 22, 2014	U-335	I-286	JAN 18, 2003
					D-51	JAN 18, 2003
					D-70	DEC 18, 2004
019898 008	PRAVASTATIN SODIUM;PRAVACHOL				NS	DEC 18, 2004
					D-70	DEC 18, 2004

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
019775 001	PRAZOSIN HYDROCHLORIDE;MINIPRESS XL	4783337	SEP 16, 2003			
		4612008	SEP 16, 2003			
		4765989	SEP 16, 2003			
		5082668	SEP 16, 2003			
019775 002	PRAZOSIN HYDROCHLORIDE;MINIPRESS XL	4612008	SEP 16, 2003			
		4783337	SEP 16, 2003			
		4765989	SEP 16, 2003			
		5082668	SEP 16, 2003			
019157 001	PREDNISOLONE SODIUM PHOSPHATE;PEDIAPRED	4448774	DEC 22, 2002			
020545 001	PROCAINAMIDE HYDROCHLORIDE;PROCANBID	5656296	AUG 12, 2014			
020545 002	PROCAINAMIDE HYDROCHLORIDE;PROCANBID	5656296	AUG 12, 2014			
020701 001	PROGESTERONE;CRINONE	4615697	OCT 07, 2003	U-208		
		5543150	SEP 15, 2013	U-209		
020701 002	PROGESTERONE;CRINONE	4615697	OCT 07, 2003	U-208		
		5543150	SEP 15, 2013	U-209		
019627 002	PROPOFOL;DIPRIVAN	5714520	MAR 22, 2015		I-322	FEB 20, 2004
		5714520*PED	SEP 22, 2015		PED	AUG 20, 2004
		5731355	MAR 22, 2015	U-217		
		5731355*PED	SEP 22, 2015	U-217		
		5731356	MAR 22, 2015	U-218		
		5731356*PED	SEP 22, 2015	U-218		
		5908869	MAR 22, 2015	U-270		
		5908869*PED	SEP 22, 2015	U-270		
019536 001	PROPRANOLOL HYDROCHLORIDE;INDERAL	4600708	JUL 19, 2005			
020021 002	PSEUDOEPHEDRINE HYDROCHLORIDE;EFIDAC 24 PSEUDOEPHEDRINE HCL	4801461	MAR 14, 2006			
		4576604	MAR 18, 2003			
020639 001	QUETIAPINE FUMARATE;SEROQUEL	4879288	SEP 26, 2011		NCE	SEP 26, 2002
020639 002	QUETIAPINE FUMARATE;SEROQUEL	4879288	SEP 26, 2011		NCE	SEP 26, 2002
020639 003	QUETIAPINE FUMARATE;SEROQUEL	4879288	SEP 26, 2011		NCE	SEP 26, 2002
020639 004	QUETIAPINE FUMARATE;SEROQUEL	4879288	SEP 26, 2011		NCE	SEP 26, 2002
020639 005	QUETIAPINE FUMARATE;SEROQUEL	4879288	SEP 26, 2011		NCE	SEP 26, 2002
019885 001	QUINAPRIL HYDROCHLORIDE;ACCUPRIL	4344949	OCT 03, 2002	U-3		
		4743450	FEB 24, 2007			
		5684016	NOV 04, 2014	U-210		
		5747504	APR 10, 2005	U-210		
019885 002	QUINAPRIL HYDROCHLORIDE;ACCUPRIL	4344949	OCT 03, 2002	U-3		
		4743450	FEB 24, 2007			
		5684016	NOV 04, 2014	U-210		
		5747504	APR 10, 2005	U-210		
019885 003	QUINAPRIL HYDROCHLORIDE;ACCUPRIL	4344949	OCT 03, 2002	U-3		
		4743450	FEB 24, 2007			
		5684016	NOV 04, 2014	U-210		
		5747504	APR 10, 2005	U-210		
019885 004	QUINAPRIL HYDROCHLORIDE;ACCUPRIL	4344949	OCT 03, 2002	U-3		
		4743450	FEB 24, 2007			
		5684016	NOV 04, 2014	U-210		
		5747504	APR 10, 2005	U-210		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020973 002	RABEPRAZOLE SODIUM;ACIPHEX	5045552	SEP 03, 2008	U-385	NCE	AUG 19, 2004
		5035899	APR 04, 2009	U-385	I-346	FEB 12, 2005
020815 001	RALOXIFENE HYDROCHLORIDE;EVISTA	4418068	APR 03, 2002		I-271	SEP 30, 2002
		5393763	JUL 28, 2012	U-114	NCE	DEC 09, 2002
		5457117	JUL 28, 2012	U-114		
		5478847	MAR 02, 2014	U-114		
		5641790	JUN 24, 2014			
		5629425	SEP 19, 2014			
		5731327	MAR 24, 2015			
		5731342	JAN 27, 2017			
		5747510	MAR 02, 2014			
		5811120	MAR 02, 2014			
		5972383	MAR 02, 2014	U-287		
019901 001	RAMIPRIL;ALTACE	4587258	JAN 27, 2005		I-310	OCT 04, 2003
		5061722	OCT 19, 2008			
019901 002	RAMIPRIL;ALTACE	4587258	JAN 27, 2005		I-310	OCT 04, 2003
		5061722	OCT 19, 2008			
019901 003	RAMIPRIL;ALTACE	4587258	JAN 27, 2005		I-310	OCT 04, 2003
		5061722	OCT 19, 2008			
019901 004	RAMIPRIL;ALTACE	5061722	OCT 19, 2008		I-310	OCT 04, 2003
		4587258	JAN 27, 2005			
020559 001	RANITIDINE BISMUTH CITRATE;TRITEC	5629297	MAY 13, 2014	U-186		
		5008256	JUL 17, 2009			
		5256684	OCT 26, 2010	U-199		
		5403830	APR 04, 2012	U-200		
		5407688	APR 04, 2012	U-201		
		5601848	FEB 11, 2014	U-202		
		5456925	OCT 10, 2012			
019090 001	RANITIDINE HYDROCHLORIDE;ZANTAC	4585790	MAY 11, 2004		D-53	OCT 29, 2002
		4521431	JUN 04, 2002		PED	APR 29, 2003
		4521431*PED	DEC 04, 2002			
		4585790*PED	NOV 11, 2004			
019593 001	RANITIDINE HYDROCHLORIDE;ZANTAC	4585790	MAY 11, 2004		D-53	OCT 29, 2002
		4521431	JUN 04, 2002	U-121	PED	APR 29, 2003
		4521431*PED	DEC 04, 2002			
019593 002	RANITIDINE HYDROCHLORIDE;ZANTAC	4585790	MAY 11, 2004		D-53	OCT 29, 2002
		4521431	JUN 04, 2002	U-121	PED	APR 29, 2003
		4521431*PED	DEC 04, 2002			
		4585790*PED	NOV 11, 2004			
019675 001	RANITIDINE HYDROCHLORIDE;ZANTAC	4585790	MAY 11, 2004		D-53	OCT 29, 2002
		4521431	JUN 04, 2002		PED	APR 29, 2003
		5068249	NOV 26, 2008			
		5068249*PED	MAY 26, 2009			
		4521431*PED	DEC 04, 2002			
		4585790*PED	NOV 11, 2004			
018703 001	RANITIDINE HYDROCHLORIDE;ZANTAC 150	4880636	MAY 13, 2008		D-53	OCT 29, 2002
		4521431	JUN 04, 2002		PED	APR 29, 2003
		4521431*PED	DEC 04, 2002			
		4880636*PED	NOV 13, 2008			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020095 001	RANITIDINE HYDROCHLORIDE;ZANTAC 150	5028432	FEB 22, 2010		D-53	OCT 29, 2002
		4521431	JUN 04, 2002		PED	APR 29, 2003
		4521431*PED	DEC 04, 2002			
		5028432*PED	AUG 22, 2010			
020251 001	RANITIDINE HYDROCHLORIDE;ZANTAC 150	5102665	JUN 23, 2009		D-53	OCT 29, 2002
		4521431	JUN 04, 2002		PED	APR 29, 2003
		4521431*PED	DEC 04, 2002			
		5102665*PED	DEC 23, 2009			
020251 002	RANITIDINE HYDROCHLORIDE;ZANTAC 150	5102665	JUN 23, 2009		D-53	OCT 29, 2002
		4521431	JUN 04, 2002		PED	APR 29, 2003
		4521431*PED	DEC 04, 2002			
		5102665*PED	DEC 23, 2009			
018703 002	RANITIDINE HYDROCHLORIDE;ZANTAC 300	4880636	MAY 13, 2008		D-53	OCT 29, 2002
		4521431	JUN 04, 2002		PED	APR 29, 2003
		4521431*PED	DEC 04, 2002			
		4880636*PED	NOV 13, 2008			
020095 002	RANITIDINE HYDROCHLORIDE;ZANTAC 300	5028432	FEB 22, 2010		D-53	OCT 29, 2002
		4521431	JUN 04, 2002		PED	APR 29, 2003
		4521431*PED	DEC 04, 2002			
		5028432*PED	AUG 22, 2010			
020520 001	RANITIDINE HYDROCHLORIDE;ZANTAC 75	4521431	JUN 04, 2002			
		4880636	MAY 13, 2008			
		4880636*PED	NOV 13, 2008			
		4521431*PED	DEC 04, 2002			
020984 001	RAPACURONIUM BROMIDE;RAPLON	5418226	APR 14, 2013		NCE	AUG 18, 2004
020984 002	RAPACURONIUM BROMIDE;RAPLON	5418226	APR 14, 2013		NCE	AUG 18, 2004
020630 001	REMIFENTANIL HYDROCHLORIDE;ULTIVA	5019583*PED	AUG 15, 2009		NPP	OCT 15, 2002
		5466700	AUG 30, 2013	U-156	PED	APR 15, 2003
		5019583	FEB 15, 2009		PED	JAN 12, 2002
		5466700*PED	MAR 01, 2014	U-156		
020630 002	REMIFENTANIL HYDROCHLORIDE;ULTIVA	5019583	FEB 15, 2009		NPP	OCT 15, 2002
		5466700	AUG 30, 2013	U-156	PED	APR 15, 2003
		5019583*PED	AUG 15, 2009		PED	JAN 12, 2002
		5466700*PED	MAR 01, 2014			
020630 003	REMIFENTANIL HYDROCHLORIDE;ULTIVA	5019583	FEB 15, 2009		NPP	OCT 15, 2002
		5466700	AUG 30, 2013	U-156	PED	APR 15, 2003
		5019583*PED	AUG 15, 2009		PED	JAN 12, 2002
		5466700*PED	MAR 01, 2014	U-156		
020741 001	REPAGLINIDE;PRANDIN	5216167	OCT 10, 2006		NCE	DEC 22, 2002
		5312924	OCT 10, 2006			
		4873080	OCT 10, 2006			
		6143769	MAR 24, 2009			
020741 002	REPAGLINIDE;PRANDIN	5216007	OCT 10, 2006		NCE	DEC 22, 2002
		5312924	OCT 10, 2006	U-214		
		4873080	OCT 10, 2006			
		6143769	MAR 14, 2009			
020741 003	REPAGLINIDE;PRANDIN	5216167	OCT 10, 2006		NCE	DEC 22, 2002
		5312924	OCT 10, 2006	U-214		
		4873080	OCT 10, 2006			
		6143769	MAR 14, 2009			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020903 001	RIBAVIRIN;REBETOL	5767097	JAN 23, 2016	U-235	PED	JUN 09, 2002
		5914128	DEC 22, 2017			
		6051252	DEC 22, 2017			
		6063772	JAN 23, 2016	U-375		
		6172046	SEP 21, 2017	U-377		
		5767097*PED	JUL 23, 2016	U-235		
		5914128*PED	JUN 22, 2018			
		6051252*PED	JUN 22, 2018			
		6063772*PED	JUL 23, 2016	U-375		
		6172046*PED	MAR 21, 2018	U-377		
		6335032	DEC 22, 2017			
		6335032*PED	JUN 22, 2018			
		6337090	DEC 22, 2017			
		6337090*PED	JUN 22, 2018			
020903 002	RIBAVIRIN;REBETOL	6335032	DEC 22, 2017			
		6335032*PED	JUN 22, 2018			
		5767097	JAN 23, 2016	U-235		
		5767097*PED	JUL 23, 2016	U-235		
		5914128	DEC 22, 2017			
		5914128*PED	JUN 22, 2018			
		6051252	DEC 22, 2017			
		6051252*PED	JUN 22, 2018			
		6063772	JAN 23, 2016	U-375		
		6063772*PED	JUL 23, 2016			
		6172046	SEP 21, 2017	U-377		
		6172046*PED	MAR 21, 2018	U-377		
		6337090	DEC 22, 2017			
		6337090*PED	JUN 22, 2018			
018859 001	RIBAVIRIN;VIRAZOLE	6150337	NOV 21, 2017	U-400		
021024 001	RIFAPENTINE;PRIFTIN				NCE	JUN 22, 2003
					ODE	JUN 22, 2005
020599 001	RILUZOLE;RILUTEK				ODE	DEC 12, 2002
020474 001	RIMEXOLONE;VEXOL	4686214	JUL 22, 2008	U-100		
020835 001	RISEDRONATE SODIUM;ACTONEL	5583122	DEC 10, 2013	U-222	I-292	APR 14, 2003
		6096342	MAR 12, 2017		I-291	APR 14, 2003
		6165513	JUN 10, 2018		I-290	APR 14, 2003
					I-293	APR 14, 2003
					NCE	MAR 27, 2003
020835 002	RISEDRONATE SODIUM;ACTONEL	5583122	DEC 10, 2013	U-222	I-292	APR 14, 2003
		6096342	MAR 12, 2017		NCE	MAR 27, 2003
		6165513	JUN 10, 2018		I-291	APR 14, 2003
					I-293	APR 14, 2003
					I-290	APR 14, 2003
020272 001	RISPERIDONE;RISPERDAL	4804663	DEC 29, 2007	U-90		
020272 002	RISPERIDONE;RISPERDAL	4804663	DEC 29, 2007	U-90		
020272 003	RISPERIDONE;RISPERDAL	4804663	DEC 29, 2007	U-90		
020272 004	RISPERIDONE;RISPERDAL	4804663	DEC 29, 2007	U-90		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020272 005	RISPERIDONE;RISPERDAL	4804663	DEC 29, 2007	U-90		
020272 007	RISPERIDONE;RISPERDAL	4804663	DEC 29, 2007	U-90		
020272 008	RISPERIDONE;RISPERDAL	4804663	DEC 29, 2007	U-90		
020588 001	RISPERIDONE;RISPERDAL	4804663	DEC 29, 2007	U-90		
		5453425	JUL 11, 2014			
		5616587	JUL 11, 2014			
020659 001	RITONAVIR;NORVIR	5635523	JUN 03, 2014	U-190		
		5484801	JAN 28, 2014			
		5541206	JUL 30, 2013	U-140		
		5648497	JUL 15, 2014			
		5846987	DEC 29, 2012	U-190		
		6037157	JUN 26, 2016			
		5674882	OCT 07, 2014			
		5886036	DEC 29, 2012			
020680 001	RITONAVIR;NORVIR	5635523	JUN 03, 2014	U-190		
		5541206	JUL 30, 2013	U-140		
		5648497	JUL 15, 2014			
		5846987	DEC 29, 2012	U-190		
		5948436	SEP 13, 2013			
020945 001	RITONAVIR;NORVIR	5648497	JUL 15, 2014			
		5846987	DEC 29, 2012	U-347		
		5541206	JUL 30, 2013	U-348		
		5635523	JUN 03, 2014	U-347		
		6232333	NOV 07, 2017			
020823 003	RIVASTIGMINE TARTRATE;EXELON	4948807	AUG 14, 2007	U-322	NCE	APR 21, 2005
		5602176	FEB 11, 2014	U-322		
020823 004	RIVASTIGMINE TARTRATE;EXELON	4948807	AUG 14, 2007	U-322	NCE	APR 21, 2005
		5602176	FEB 11, 2014	U-322		
020823 005	RIVASTIGMINE TARTRATE;EXELON	4948807	AUG 14, 2007	U-322	NCE	APR 21, 2005
		5602176	FEB 11, 2014	U-322		
020823 006	RIVASTIGMINE TARTRATE;EXELON	4948807	AUG 14, 2007	U-322	NCE	APR 21, 2005
		5602176	FEB 11, 2014	U-322		
021025 001	RIVASTIGMINE TARTRATE;EXELON	4948807	AUG 14, 2007	U-322	NCE	APR 21, 2005
		5602176	FEB 11, 2014	U-322		
020864 001	RIZATRIPTAN BENZOATE;MAXALT	5298520	JAN 28, 2012	U-240	NCE	JUN 29, 2003
		5602162	FEB 11, 2014			
020864 002	RIZATRIPTAN BENZOATE;MAXALT	5298520	JAN 28, 2012	U-240	NCE	JUN 29, 2003
		5602162	FEB 11, 2014			
020865 001	RIZATRIPTAN BENZOATE;MAXALT-MLT	5298520	JAN 28, 2012	U-240	NCE	JUN 29, 2003
		5602162	FEB 11, 2014	U-240		
		5457895	OCT 01, 2013			
020865 002	RIZATRIPTAN BENZOATE;MAXALT-MLT	5298520	JAN 28, 2012	U-240	NCE	JUN 29, 2003
		5602162	FEB 11, 2014	U-240		
		5457895	OCT 01, 2013			
020214 002	ROCURONIUM BROMIDE;ZEMURON	4894369	APR 13, 2008			
020214 001	ROCURONIUM BROMIDE;ZEMURON (P/F)	4894369	APR 13, 2008			
021042 001	ROFECOXIB;VIOXX	5474995	JUN 24, 2013	U-266	NCE	MAY 20, 2004
		5691374	NOV 25, 2017			
		6063811	MAY 16, 2017	U-266		
		6239173	JUN 24, 2013			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
021042 002	ROFECOXIB;VIOXX	5474995	JUN 24, 2013	U-266	NCE	MAY 20, 2004
		5691374	NOV 25, 2017			
		6063811	MAY 16, 2017	U-266		
		6239173	JUN 24, 2013			
021042 003	ROFECOXIB;VIOXX	6239173	JUN 24, 2013		NCE	MAY 20, 2004
		5474995	JUN 24, 2013	U-266		
		5691374	NOV 25, 2017			
021052 001	ROFECOXIB;VIOXX	5474995	JUN 24, 2013	U-266	NCE	MAY 20, 2004
		5691374	NOV 25, 2017			
		6063811	MAY 16, 2017	U-266		
		6239173	JUN 24, 2013			
021052 002	ROFECOXIB;VIOXX	5474995	JUN 24, 2013	U-266	NCE	MAY 20, 2004
		5691374	NOV 25, 2017			
		6063811	MAY 16, 2017	U-266		
		6239173	JUN 24, 2013			
020658 001	ROPINIROLE HYDROCHLORIDE;REQUIP	4452808	DEC 07, 2002		NCE	SEP 19, 2002
		4824860	MAY 19, 2008	U-212		
020658 002	ROPINIROLE HYDROCHLORIDE;REQUIP	4452808	DEC 07, 2002		NCE	SEP 19, 2002
		4824860	MAY 19, 2008	U-212		
020658 003	ROPINIROLE HYDROCHLORIDE;REQUIP	4452808	DEC 07, 2002		NCE	SEP 19, 2002
		4824860	MAY 19, 2008	U-212		
020658 004	ROPINIROLE HYDROCHLORIDE;REQUIP	4452808	DEC 07, 2002		NCE	SEP 19, 2002
		4824860	MAY 19, 2008	U-212		
020658 005	ROPINIROLE HYDROCHLORIDE;REQUIP	4452808	DEC 07, 2002		NCE	SEP 19, 2002
		4824860	MAY 19, 2008	U-212		
020533 001	ROPIVACAINE HYDROCHLORIDE MONOHYDRATE;NAROPIN	4870086	JUL 28, 2010		D-64	NOV 02, 2003
		4695576	SEP 22, 2004			
020533 003	ROPIVACAINE HYDROCHLORIDE MONOHYDRATE;NAROPIN	4695576	SEP 22, 2004		D-64	NOV 02, 2003
		4870086	JUL 28, 2010			
020533 004	ROPIVACAINE HYDROCHLORIDE MONOHYDRATE;NAROPIN	4695576	SEP 22, 2004		D-64	NOV 02, 2003
		4870086	JUL 28, 2010			
020533 005	ROPIVACAINE HYDROCHLORIDE MONOHYDRATE;NAROPIN	4695576	SEP 22, 2004		D-64	NOV 02, 2003
		4870086	JUL 28, 2010			
021071 002	ROSIGLITAZONE MALEATE;AVANDIA	5002953	AUG 30, 2008	U-329	I-289	APR 03, 2003
		5741803	APR 21, 2015	U-329	NCE	MAY 25, 2004
		6288095	FEB 11, 2017	U-420		
021071 003	ROSIGLITAZONE MALEATE;AVANDIA	5002953	AUG 30, 2008	U-329	I-289	APR 03, 2003
		5741803	APR 21, 2015	U-329	NCE	MAY 25, 2004
		6288095	FEB 11, 2017	U-420		
021071 004	ROSIGLITAZONE MALEATE;AVANDIA	5002953	AUG 30, 2008	U-329	I-289	APR 03, 2003
		5741803	APR 21, 2015	U-329	NCE	MAY 25, 2004
		6288095	FEB 11, 2017	U-420		
019414 001	RUBIDIUM CHLORIDE RB-82;CARDIOGEN-82	4400358	AUG 23, 2002			
020772 001	SACROSIDASE;SUCRAID				ODE	APR 09, 2005
					NCE	APR 09, 2003
020236 001	SALMETEROL XINAFOATE;SEREVENT	4992474	FEB 12, 2008		M-5	JUN 30, 2003
		5380922	JAN 10, 2012			
		5225445	FEB 12, 2008	U-182		
		5126375	FEB 12, 2008			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020692 001	SALMETEROL XINAFOATE;SEREVENT	4992474	FEB 12, 2008		M-5	JUN 30, 2003
		5225445	FEB 12, 2008	U-211		
		5380922	JAN 10, 2012			
		5590645	MAR 01, 2011			
		5126375	FEB 12, 2008			
		D342994	JAN 04, 2008			
		5290815	MAR 01, 2011	U-386		
020570 001	SAMARIUM SM 153 LEXIDRONAM PENTASODIUM;QUADRAMET	4898724	FEB 06, 2007	U-187	NCE	MAR 28, 2002
020628 001	SAQUINAVIR MESYLATE;INVIRASE	5196438	NOV 19, 2010			
020828 001	SAQUINAVIR;FORTOVASE	5196438	NOV 19, 2010			
019863 001	SERMORELIN ACETATE;GEREF	4517181	MAY 14, 2002			
		4703035	DEC 28, 2004	U-47		
020443 001	SERMORELIN ACETATE;GEREF	4517181	MAY 14, 2002		ODE	SEP 26, 2004
		4703035	DEC 28, 2004			
020443 002	SERMORELIN ACETATE;GEREF	4517181	MAY 14, 2002		ODE	SEP 26, 2004
		4703035	DEC 28, 2004			
019839 001	SERTRALINE HYDROCHLORIDE;ZOLOFT	5248699	AUG 13, 2012	U-12	I-279	DEC 07, 2002
		4536518	DEC 30, 2005	U-152	M-11	AUG 06, 2004
		4962128	NOV 02, 2009	U-12	PED	JUN 07, 2003
		4536518*PED	JUN 30, 2006	U-152	PED	FEB 06, 2005
		4962128*PED	MAY 02, 2010	U-12		
		5248699*PED	FEB 13, 2012	U-12		
		4962128	NOV 02, 2009	U-152		
		4962128*PED	MAY 02, 2010	U-152		
019839 002	SERTRALINE HYDROCHLORIDE;ZOLOFT	5248699	AUG 13, 2012	U-12	I-279	DEC 07, 2002
		4536518	DEC 30, 2005	U-152	M-11	AUG 06, 2004
		4962128	NOV 02, 2009	U-12	PED	JUN 07, 2003
		4536518*PED	JUN 30, 2006	U-152	PED	FEB 06, 2005
		4962128*PED	MAY 02, 2010	U-12		
		5248699*PED	FEB 13, 2012	U-12		
		4962128	NOV 02, 2009	U-152		
		4962128*PED	MAY 02, 2010	U-152		
019839 003	SERTRALINE HYDROCHLORIDE;ZOLOFT	5248699	AUG 13, 2012	U-12	I-279	DEC 07, 2002
		4536518	DEC 30, 2005	U-152	PED	JUN 07, 2003
		4962128	NOV 02, 2009	U-12	PED	FEB 06, 2005
		4536518*PED	JUN 30, 2006	U-152	M-11	AUG 06, 2004
		4962128*PED	MAY 02, 2010	U-12		
		5248699*PED	FEB 13, 2012	U-12		
		4962128	NOV 02, 2009	U-152		
		4962128*PED	MAY 02, 2010	U-152		
019839 004	SERTRALINE HYDROCHLORIDE;ZOLOFT	5248699	AUG 13, 2012	U-12	I-279	DEC 07, 2002
		4536518	DEC 30, 2005	U-152	PED	JUN 07, 2003
		4962128	NOV 02, 2009	U-12	PED	FEB 06, 2005
		4536518*PED	JUN 30, 2006	U-152	M-11	AUG 06, 2004
		4962128*PED	MAY 02, 2010	U-12		
		5248699*PED	FEB 13, 2012	U-12		
		4962128	NOV 02, 2009	U-152		
		4962128*PED	MAY 02, 2010	U-152		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
019839 005	SERTRALINE HYDROCHLORIDE;ZOLOFT	5248699	AUG 13, 2012	U-12	I-279	DEC 07, 2002
		4536518	DEC 30, 2005	U-152	M-11	AUG 06, 2004
		4962128	NOV 02, 2009	U-12	PED	JUN 07, 2003
		4536518*PED	JUN 30, 2006	U-152	PED	FEB 06, 2005
		4962128*PED	MAY 02, 2010	U-12		
		5248699*PED	FEB 13, 2012	U-12		
		4962128	NOV 02, 2009	U-152		
		4962128*PED	MAY 02, 2010	U-152		
020990 001	SERTRALINE HYDROCHLORIDE;ZOLOFT	4536518	DEC 30, 2005	U-286	M-11	AUG 06, 2004
		4536518*PED	JUN 30, 2006	U-286	PED	FEB 06, 2005
020926 001	SEVELAMER HYDROCHLORIDE;RENAGEL	5496545	AUG 11, 2013	U-246	NCE	OCT 30, 2003
		5667775	SEP 16, 2014	U-246		
021179 001	SEVELAMER HYDROCHLORIDE;RENAGEL	5496545	AUG 11, 2013	U-246	NCE	OCT 30, 2003
		5667775	SEP 16, 2014	U-246		
021179 002	SEVELAMER HYDROCHLORIDE;RENAGEL	5496545	AUG 11, 2013	U-246	NCE	OCT 30, 2003
		5667775	SEP 16, 2014	U-246		
020478 001	SEVOFLURANE;ULTANE	5990176	JAN 27, 2017			
		6074668	JAN 09, 2018			
		5990176*PED	JUL 27, 2017			
		6074668*PED	JUL 09, 2018			
		6288127	JAN 27, 2017			
		6288127*PED	JUL 27, 2017			
020632 001	SIBUTRAMINE HYDROCHLORIDE;MERIDIA	4746680	JUN 11, 2002		NCE	NOV 22, 2002
		4929629	MAY 29, 2007		D-65	FEB 16, 2004
					M-9	FEB 16, 2004
020632 002	SIBUTRAMINE HYDROCHLORIDE;MERIDIA	4746680	JUN 11, 2002		NCE	NOV 22, 2002
		4929629	MAY 29, 2007		D-65	FEB 16, 2004
					M-9	FEB 16, 2004
020632 003	SIBUTRAMINE HYDROCHLORIDE;MERIDIA	4746680	JUN 11, 2002		NCE	NOV 22, 2002
		4929629	MAY 29, 2007		D-65	FEB 16, 2004
					M-9	FEB 16, 2004
020895 001	SILDENAFIL CITRATE;VIAGRA	5250534	JUN 18, 2011		NCE	MAR 27, 2003
020895 002	SILDENAFIL CITRATE;VIAGRA	5250534	JUN 18, 2011		NCE	MAR 27, 2003
020895 003	SILDENAFIL CITRATE;VIAGRA	5250534	JUN 18, 2011		NCE	MAR 27, 2003
019608 001	SILVER SULFADIAZINE;SILDAFLO	4563184	JAN 07, 2003			
019766 001	SIMVASTATIN;ZOCOR	4444784	DEC 23, 2005	U-59	I-277	NOV 22, 2002
		RE36481	JUL 10, 2007	U-300	I-278	NOV 22, 2002
		RE36520	MAY 26, 2009	U-300	I-273	AUG 05, 2002
		4444784*PED	JUN 23, 2006	U-59	PED	FEB 05, 2003
		RE36481*PED	JAN 10, 2008	U-300	PED	MAY 22, 2003
		RE36520*PED	NOV 26, 2009	U-300	PED	MAY 22, 2003
019766 002	SIMVASTATIN;ZOCOR	4444784	DEC 23, 2005	U-59	I-277	NOV 22, 2002
		RE36481	JUL 10, 2007	U-300	I-278	NOV 22, 2002
		RE36520	MAY 26, 2009	U-300	I-273	AUG 05, 2002
		4444784*PED	JUN 23, 2006	U-59	PED	FEB 05, 2003
		RE36481*PED	JAN 10, 2008	U-300	PED	MAY 22, 2003
		RE36520*PED	NOV 26, 2009	U-300	PED	MAY 22, 2003

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
019766 003	SIMVASTATIN;ZOCOR	4444784	DEC 23, 2005	U-59	I-277	NOV 22, 2002
		RE36481	JUL 10, 2007	U-300	I-278	NOV 22, 2002
		RE36520	MAY 26, 2009	U-300	I-273	AUG 05, 2002
		4444784*PED	JUN 23, 2006	U-59	PED	FEB 05, 2003
		RE36481*PED	JAN 10, 2008	U-300	PED	MAY 22, 2003
		RE36520*PED	NOV 26, 2009	U-300	PED	MAY 22, 2003
019766 004	SIMVASTATIN;ZOCOR	4444784	DEC 23, 2005	U-59	I-277	NOV 22, 2002
		RE36481	JUL 10, 2007	U-300	I-278	NOV 22, 2002
		RE36520	MAY 26, 2009	U-300	I-273	AUG 05, 2002
		4444784*PED	JUN 23, 2006	U-59	PED	FEB 05, 2003
		RE36481*PED	JAN 10, 2008	U-300	PED	MAY 22, 2003
		RE36520*PED	NOV 26, 2009	U-300	PED	MAY 22, 2003
019766 005	SIMVASTATIN;ZOCOR	4444784	DEC 23, 2005	U-59	I-277	NOV 22, 2002
		RE36481	JUL 10, 2007	U-300	I-278	NOV 22, 2002
		RE36520	MAY 26, 2009	U-300	I-273	AUG 05, 2002
		4444784*PED	JUN 23, 2006	U-59	PED	FEB 05, 2003
		RE36481*PED	JAN 10, 2008	U-300	PED	MAY 22, 2003
		RE36520*PED	NOV 26, 2009	U-300	PED	MAY 22, 2003
021083 001	SIROLIMUS;RAPAMUNE	5100899	JUN 06, 2009	U-290	NCE	SEP 15, 2004
		5212155	MAY 18, 2010	U-291		
		5308847	MAY 03, 2011	U-292		
		5403833	APR 04, 2012	U-293		
		5536729	SEP 30, 2013			
020955 001	SODIUM FERRIC GLUCONATE COMPLEX;FERRLECIT				NCE	FEB 18, 2004
020572 001	SODIUM PHENYLBUTYRATE;BUPHENYL	4457942	AUG 20, 2002	U-136		
020573 001	SODIUM PHENYLBUTYRATE;BUPHENYL	4457942	AUG 20, 2002	U-136	ODE	APR 30, 2003
021097 001	SODIUM PHOSPHATE, DIBASIC, ANHYDROUS;VISICOL	5616346	MAY 18, 2013	U-359	NP	SEP 21, 2003
019107 001	SOMATREM;PROTROPIN	4658021	APR 14, 2004			
020280 006	SOMATROPIN RECOMBINANT;GENOTROPIN	5633352	MAR 10, 2015		I-302	JUN 20, 2003
		4968299	JUN 28, 2008		ODE	OCT 31, 2004
					ODE	JUN 20, 2007
					I-334	JUL 25, 2004
					ODE	JUL 25, 2008
020280 007	SOMATROPIN RECOMBINANT;GENOTROPIN	5633352	MAR 10, 2015		I-302	JUN 20, 2003
		4968299	JUN 28, 2008		ODE	JUN 20, 2007
					I-334	JUL 25, 2004
					ODE	JUL 25, 2008
020280 001	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVATIVE FREE	5633352	MAR 10, 2015		I-302	JUN 20, 2003
		5435076	APR 16, 2013		ODE	JUN 20, 2007
		5716338	FEB 10, 2015		I-334	JUL 25, 2004
		6152897	JUN 11, 2018		ODE	JUL 25, 2008
020280 002	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVATIVE FREE	5633352	MAR 10, 2015		I-302	JUN 20, 2003
		5435076	APR 16, 2013		ODE	JUN 20, 2007
		5716338	FEB 10, 2015		I-334	JUL 25, 2004
		6152897	JUN 11, 2018		ODE	JUL 25, 2008
020280 003	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVATIVE FREE	5633352	MAR 10, 2015		I-302	JUN 20, 2003
		5435076	APR 16, 2013		ODE	JUN 20, 2007
		5716338	FEB 10, 2015		I-334	JUL 25, 2004
		6152897	JUN 11, 2018		ODE	JUL 25, 2008

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020280 004	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVATIVE FREE	5633352	MAR 10, 2015		ODE	OCT 31, 2004
					ODE	JUN 20, 2007
					I-334	JUL 25, 2004
					ODE	JUL 25, 2008
020280 005	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVATIVE FREE	5633352	MAR 10, 2015		I-302	JUN 20, 2003
		5435076	APR 16, 2013		ODE	JUN 20, 2007
		5716338	FEB 10, 2015		I-334	JUL 25, 2004
		6152897	JUN 11, 2018		ODE	JUL 25, 2008
020280 008	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVATIVE FREE	5633352	MAR 10, 2015		I-302	JUN 20, 2003
		5435076	APR 16, 2013		ODE	JUN 20, 2007
		5716338	FEB 10, 2015		I-334	JUL 25, 2004
		6152897	JUN 11, 2018		ODE	JUL 25, 2008
020280 009	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVATIVE FREE	5633352	MAR 10, 2015		I-302	JUN 20, 2003
		5435076	APR 16, 2013		ODE	JUN 20, 2007
		5716338	FEB 10, 2015		I-334	JUL 25, 2004
		6152897	JUN 11, 2018		ODE	JUL 25, 2008
020280 010	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVATIVE FREE	5633352	MAR 10, 2015		I-302	JUN 20, 2003
		5435076	APR 16, 2013		ODE	JUN 20, 2007
		5716338	FEB 10, 2015		I-334	JUL 25, 2004
					ODE	JUL 25, 2008
020280 011	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVATIVE FREE	5633352	MAR 10, 2015		I-302	JUN 20, 2003
		5716338	FEB 10, 2015		ODE	JUN 20, 2007
		5435076	APR 16, 2013		I-334	JUL 25, 2004
					ODE	JUL 25, 2008
020280 012	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVATIVE FREE	5633352	MAR 10, 2015		I-302	JUN 20, 2003
		5435076	APR 16, 2013		ODE	JUN 20, 2007
		5716338	FEB 10, 2015		I-334	JUL 25, 2004
					ODE	JUL 25, 2008
020280 013	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVATIVE FREE	5633352	MAR 10, 2015		I-302	JUN 20, 2003
		5435076	APR 16, 2013		ODE	JUN 20, 2007
		5716338	FEB 10, 2015		I-334	JUL 25, 2004
					ODE	JUL 25, 2008
019640 001	SOMATROPIN RECOMBINANT;HUMATROPE				ODE	DEC 30, 2003
019640 004	SOMATROPIN RECOMBINANT;HUMATROPE				ODE	DEC 30, 2003
019640 005	SOMATROPIN RECOMBINANT;HUMATROPE				ODE	DEC 30, 2003
019640 006	SOMATROPIN RECOMBINANT;HUMATROPE				ODE	DEC 30, 2003
019640 007	SOMATROPIN RECOMBINANT;HUMATROPE				ODE	DEC 30, 2003
019721 001	SOMATROPIN RECOMBINANT;NORDITROPIN	5633352	MAY 27, 2014			
019721 002	SOMATROPIN RECOMBINANT;NORDITROPIN	5633352	MAY 27, 2014			
019676 001	SOMATROPIN RECOMBINANT;NUTROPIN				D-55	APR 13, 2003
					M-2	DEC 01, 2002
					ODE	OCT 29, 2004
019676 002	SOMATROPIN RECOMBINANT;NUTROPIN				D-55	APR 13, 2003
					M-2	DEC 01, 2002
					ODE	OCT 29, 2004
020168 001	SOMATROPIN RECOMBINANT;NUTROPIN				ODE	DEC 30, 2003
020168 002	SOMATROPIN RECOMBINANT;NUTROPIN				ODE	DEC 30, 2003

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020522 001	SOMATROPIN RECOMBINANT;NUTROPIN AQ				D-55	APR 13, 2003
					M-2	DEC 01, 2002
021075 001	SOMATROPIN RECOMBINANT;NUTROPIN DEPOT	5656297	JUL 25, 2014		NP	DEC 22, 2002
		5654010	AUG 05, 2014			
		6051259	DEC 02, 2012	U-340		
021075 002	SOMATROPIN RECOMBINANT;NUTROPIN DEPOT	5656297	JUL 25, 2014		NP	DEC 22, 2002
		5654010	AUG 05, 2014			
		6051259	DEC 02, 2012	U-340		
021075 003	SOMATROPIN RECOMBINANT;NUTROPIN DEPOT	5656297	JUL 25, 2014		NP	DEC 22, 2002
		5654010	AUG 05, 2014			
		6051259	DEC 02, 2012	U-340		
020604 001	SOMATROPIN RECOMBINANT;SEROSTIM				ODE	AUG 23, 2003
020604 002	SOMATROPIN RECOMBINANT;SEROSTIM				ODE	AUG 23, 2003
019865 001	SOTALOL HYDROCHLORIDE;BETAPACE				PED	APR 01, 2005
					M-13	OCT 01, 2004
019865 002	SOTALOL HYDROCHLORIDE;BETAPACE				PED	APR 01, 2005
					M-13	OCT 01, 2004
019865 003	SOTALOL HYDROCHLORIDE;BETAPACE				PED	APR 01, 2005
					M-13	OCT 01, 2004
019865 004	SOTALOL HYDROCHLORIDE;BETAPACE				PED	APR 01, 2005
					M-13	OCT 01, 2004
019865 005	SOTALOL HYDROCHLORIDE;BETAPACE				PED	APR 01, 2005
					M-13	OCT 01, 2004
021151 001	SOTALOL HYDROCHLORIDE;BETAPACE AF				NP	FEB 22, 2003
					PED	AUG 22, 2003
021151 002	SOTALOL HYDROCHLORIDE;BETAPACE AF				NP	FEB 22, 2003
					PED	AUG 22, 2003
021151 003	SOTALOL HYDROCHLORIDE;BETAPACE AF				NP	FEB 22, 2003
					PED	AUG 22, 2003
020677 001	SPARFLOXACIN;ZAGAM	4795751	OCT 28, 2006	U-160		
020240 001	SPIRAPRIL HYDROCHLORIDE;RENORMAX	4470972	SEP 11, 2003	U-3		
020240 002	SPIRAPRIL HYDROCHLORIDE;RENORMAX	4470972	SEP 11, 2003	U-3		
020240 003	SPIRAPRIL HYDROCHLORIDE;RENORMAX	4470972	SEP 11, 2003	U-3		
020240 004	SPIRAPRIL HYDROCHLORIDE;RENORMAX	4470972	SEP 11, 2003	U-3		
020412 001	STAVUDINE;ZERIT	4978655	JUN 24, 2008	U-94		
		4978655*PED	DEC 24, 2008	U-94		
020412 002	STAVUDINE;ZERIT	4978655	JUN 24, 2008	U-94		
		4978655*PED	DEC 24, 2008	U-94		
020412 003	STAVUDINE;ZERIT	4978655	JUN 24, 2008	U-94		
		4978655*PED	DEC 24, 2008			
020412 004	STAVUDINE;ZERIT	4978655	JUN 24, 2008	U-94		
		4978655*PED	DEC 24, 2008	U-94		
020412 005	STAVUDINE;ZERIT	4978655	JUN 24, 2008	U-94		
		4978655*PED	DEC 24, 2008	U-94		
020413 001	STAVUDINE;ZERIT	4978655	JUN 24, 2008			
007073 002	SULFASALAZINE;AZULFIDINE EN-TABS				I-308	AUG 18, 2003
020080 001	SUMATRIPTAN SUCCINATE;IMITREX	4816470	DEC 28, 2006	U-72		
		5037845	AUG 06, 2008	U-72		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020132 001	SUMATRIPTAN SUCCINATE;IMITREX	4816470	DEC 28, 2006	U-72		
		5037845	AUG 06, 2008	U-72		
020132 002	SUMATRIPTAN SUCCINATE;IMITREX	4816470	DEC 28, 2006	U-72		
		5037845	AUG 06, 2008	U-72		
020132 003	SUMATRIPTAN SUCCINATE;IMITREX	5037845	AUG 06, 2008	U-72		
		4816470	DEC 28, 2006	U-72		
020626 001	SUMATRIPTAN;IMITREX	4816470	DEC 28, 2006	U-72		
		5037845	AUG 06, 2008			
		5307953	DEC 02, 2012			
		5554639	SEP 10, 2013	U-232		
		5705520	DEC 10, 2011	U-232		
020626 002	SUMATRIPTAN;IMITREX	4816470	DEC 28, 2006	U-72		
		5037845	AUG 06, 2008			
		5307953	DEC 02, 2012			
		5554639	SEP 10, 2013	U-232		
		5705520	DEC 10, 2011	U-232		
020626 003	SUMATRIPTAN;IMITREX	4816470	DEC 28, 2006	U-72		
		5037845	AUG 06, 2008			
		5307953	DEC 02, 2012			
		5554639	SEP 10, 2013	U-232		
		5705520	DEC 10, 2011	U-232		
019387 001	SUPROFEN;PROFENAL	4559343	DEC 17, 2002			
020070 001	TACRINE HYDROCHLORIDE;COGNEX	4631286	OCT 25, 2004	U-97		
		4816456	SEP 09, 2007			
020070 002	TACRINE HYDROCHLORIDE;COGNEX	4631286	OCT 25, 2004	U-97		
		4816456	SEP 09, 2007			
020070 003	TACRINE HYDROCHLORIDE;COGNEX	4631286	OCT 25, 2004	U-97		
		4816456	SEP 09, 2007			
020070 004	TACRINE HYDROCHLORIDE;COGNEX	4631286	OCT 25, 2004	U-97		
		4816456	SEP 09, 2007			
020587 001	TALC;SCLEROSOL				NCE	DEC 24, 2002
					ODE	DEC 24, 2004
017970 001	TAMOXIFEN CITRATE;NOLVADEX	4536516	AUG 20, 2002			
017970 002	TAMOXIFEN CITRATE;NOLVADEX	4536516	AUG 20, 2002			
020579 001	TAMSULOSIN HYDROCHLORIDE;FLOMAX	4868216	SEP 19, 2006	U-181	NCE	APR 15, 2002
		4731478	OCT 27, 2004			
		4703063	OCT 27, 2009			
		4772475	FEB 27, 2006			
020600 001	TAZAROTENE;TAZORAC	5089509	FEB 18, 2009	U-193	NCE	JUN 13, 2002
020600 002	TAZAROTENE;TAZORAC	5089509	FEB 18, 2009	U-193	NCE	JUN 13, 2002
021184 001	TAZAROTENE;TAZORAC				NCE	JUN 13, 2002
					NDF	SEP 29, 2003
021184 002	TAZAROTENE;TAZORAC				NCE	JUN 13, 2002
					NDF	SEP 29, 2003
					I-344	OCT 11, 2004
020887 001	TECHNETIUM TC-99M APCITIDE;ACUTECT	5508020	APR 16, 2013		NCE	SEP 14, 2003
		5645815	JUL 08, 2014			
		5443815	AUG 22, 2012			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020256 001	TECHNETIUM TC-99M BICISATE KIT;NEUROLITE	5279811	NOV 23, 2008	U-101		
		5431900	JUL 11, 2012	U-336		
021012 001	TECHNETIUM TC-99M DEPREOTIDE;NEO TECT KIT				NCE	AUG 03, 2004
019829 001	TECHNETIUM TC-99M EXAMETAZIME KIT;CERETEC	4615876	OCT 07, 2003			
		4789736	DEC 06, 2005			
018321 001	TECHNETIUM TC-99M OXIDRONATE KIT;TECHNESCAN HDP	4497744	FEB 05, 2002			
019981 001	TECHNETIUM TC-99M RED BLOOD CELL KIT;ULTRATAG	4755375	JUL 05, 2005	U-51		
019785 001	TECHNETIUM TC-99M SESTAMIBI KIT;CARDIOLITE	4452774	SEP 09, 2004			
		4894445	JAN 16, 2007	U-337		
		5324824	JAN 16, 2007			
		4885100	SEP 11, 2007			
		4988827	JAN 29, 2008			
019785 003	TECHNETIUM TC-99M SESTAMIBI KIT;MIRALUMA	4452774	SEP 09, 2004			
		4894445	JAN 16, 2007	U-337		
		5324824	JAN 16, 2007			
		4885100	SEP 11, 2007			
		4988827	JAN 29, 2008			
019928 001	TECHNETIUM TC-99M TEBOROXIME KIT;CARDIOTEC	4705849	NOV 10, 2004			
020372 001	TECHNETIUM TC-99M TETROFOSMIN KIT;MYOVIEW	5045302	AUG 14, 2008			
020850 001	TELMISARTAN;MICARDIS	5591762	JAN 07, 2014	U-3	NCE	NOV 10, 2003
020850 002	TELMISARTAN;MICARDIS	5591762	JAN 07, 2014	U-3	NCE	NOV 10, 2003
018163 003	TEMAZEPAM;RESTORIL	5030632	JUL 09, 2008	U-70		
		5326758	JUL 09, 2008	U-70		
		5211954	MAY 18, 2010			
021029 001	TEMOZOLOMIDE;TEMODAR	5260291	NOV 09, 2010		NCE	AUG 11, 2004
					ODE	AUG 11, 2006
021029 002	TEMOZOLOMIDE;TEMODAR	5260291	NOV 09, 2010		NCE	AUG 11, 2004
					ODE	AUG 11, 2006
021029 003	TEMOZOLOMIDE;TEMODAR	5260291	NOV 09, 2010		NCE	AUG 11, 2004
					ODE	AUG 11, 2006
021029 004	TEMOZOLOMIDE;TEMODAR	5260291	NOV 09, 2010		NCE	AUG 11, 2004
					ODE	AUG 11, 2006
021356 001	TENOFOVIR DISOPROXIL FUMARATE;VIREAD	5977089	JUL 25, 2017	U-248	NCE	OCT 26, 2006
		6043230	JUL 25, 2017	U-248		
		5935946	JUL 25, 2017	U-248		
		4808716	APR 25, 2006	U-248		
		6057305	MAY 02, 2017	U-248		
		5922695	JUL 25, 2017	U-248		
019057 001	TERAZOSIN HYDROCHLORIDE;HYTRIN	5412095	APR 29, 2013			
		5212176	JUN 29, 2010			
		5294615	APR 29, 2013	U-165		
				U-3		
019057 002	TERAZOSIN HYDROCHLORIDE;HYTRIN	5412095	APR 29, 2013			
		5212176	JUN 29, 2010			
		5294615	APR 29, 2013	U-165		
				U-3		
019057 003	TERAZOSIN HYDROCHLORIDE;HYTRIN	5412095	APR 29, 2013			
		5212176	JUN 29, 2010			
		5294615	APR 29, 2013	U-165		
				U-3		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
019057 004	TERAZOSIN HYDROCHLORIDE;HYTRIN	5412095	APR 29, 2013			
		5212176	JUN 29, 2010			
		5294615	APR 29, 2013	U-165		
				U-3		
020347 001	TERAZOSIN HYDROCHLORIDE;HYTRIN	5212176	JUN 29, 2010			
		5412095	APR 29, 2013			
		5294615	APR 29, 2013	U-165		
				U-3		
020347 002	TERAZOSIN HYDROCHLORIDE;HYTRIN	5212176	JUN 29, 2010			
		5412095	APR 29, 2013			
		5294615	APR 29, 2013	U-165		
				U-3		
020347 003	TERAZOSIN HYDROCHLORIDE;HYTRIN	5212176	JUN 29, 2010			
		5412095	APR 29, 2013			
		5294615	APR 29, 2013	U-165		
				U-3		
020347 004	TERAZOSIN HYDROCHLORIDE;HYTRIN	5212176	JUN 29, 2010			
		5412095	APR 29, 2013			
		5294615	APR 29, 2013	U-165		
				U-3		
020192 001	TERBINAFINE HYDROCHLORIDE;LAMISIL	4755534	DEC 30, 2006	U-73		
020539 001	TERBINAFINE HYDROCHLORIDE;LAMISIL	4755534	DEC 30, 2006	U-73		
		4680291	JUL 14, 2004	U-281		
020749 001	TERBINAFINE HYDROCHLORIDE;LAMISIL	4755534	DEC 30, 2006			
020980 001	TERBINAFINE HYDROCHLORIDE;LAMISIL	4680291	JUL 14, 2004	U-73		
		4755534	DEC 30, 2006	U-73		
021124 001	TERBINAFINE HYDROCHLORIDE;LAMISIL AT	4680291	JUL 14, 2004	U-73		
		4755534	DEC 30, 2006	U-73		
		5681849	OCT 28, 2014			
020489 001	TESTOSTERONE;ANDRODERM	4863970	SEP 05, 2006			
		4983395	JAN 08, 2009			
		5152997	OCT 06, 2009			
		5164190	NOV 17, 2008			
		4849224	JUL 18, 2006			
		4855294	AUG 08, 2006			
021015 001	TESTOSTERONE;ANDROGEL				NDF	FEB 28, 2003
019762 001	TESTOSTERONE;TESTODERM	4704282	NOV 03, 2004			
		4725439	FEB 16, 2005			
		4867982	FEB 16, 2005			
		5840327	AUG 15, 2016			
019762 002	TESTOSTERONE;TESTODERM	4704282	NOV 03, 2004			
		4867982	FEB 16, 2005			
		4725439	FEB 16, 2005			
		5840327	AUG 15, 2016			
020785 001	THALIDOMIDE;THALOMID	6045501	AUG 28, 2018	U-371	NCE	JUL 16, 2003
					ODE	JUL 16, 2005
020898 001	THYROTROPIN ALFA;THYROGEN	5674711	AUG 31, 2010		ODE	NOV 30, 2005
		5602006	FEB 11, 2014		NCE	NOV 30, 2003
		5658760	AUG 19, 2014			
		5240832	AUG 31, 2010			
		6114144	NOV 24, 2015			
		5840566	NOV 24, 2015			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020646 001	TIAGABINE HYDROCHLORIDE;GABITRIL	5010090	OCT 07, 2008		NCE	SEP 30, 2002
		5354760	MAR 24, 2012			
020646 002	TIAGABINE HYDROCHLORIDE;GABITRIL	5010090	OCT 07, 2008		NCE	SEP 30, 2002
		5354760	MAR 24, 2012			
020646 003	TIAGABINE HYDROCHLORIDE;GABITRIL	5010090	OCT 07, 2008		NCE	SEP 30, 2002
		5354760	MAR 24, 2012			
020646 004	TIAGABINE HYDROCHLORIDE;GABITRIL	5010090	OCT 07, 2008		NCE	SEP 30, 2002
		5354760	MAR 24, 2012			
020646 005	TIAGABINE HYDROCHLORIDE;GABITRIL	5010090	OCT 07, 2008		NCE	SEP 30, 2002
		5354760	MAR 24, 2012			
019979 001	TICLOPIDINE HYDROCHLORIDE;TICLID	4591592	MAY 27, 2003			
019979 002	TICLOPIDINE HYDROCHLORIDE;TICLID	4591592	MAY 27, 2003			
020707 001	TILUDRONATE DISODIUM;SKELID	4876248	JAN 30, 2010		NCE	MAR 07, 2002
		4980171	APR 06, 2009			
020963 001	TIMOLOL MALEATE;TIMOLOL MALEATE	6174524	MAR 26, 2019			
020963 002	TIMOLOL MALEATE;TIMOLOL MALEATE	6174524	MAR 26, 2019			
020330 001	TIMOLOL MALEATE;TIMOPTIC-XE	4861760	AUG 29, 2006			
		4861760	SEP 25, 2006			
020330 002	TIMOLOL MALEATE;TIMOPTIC-XE	4861760	AUG 29, 2006			
		4861760	SEP 25, 2006			
020439 001	TIMOLOL;BETIMOL	5231095	JUL 27, 2010			
020439 002	TIMOLOL;BETIMOL	5231095	JUL 27, 2010			
020484 001	TINZAPARIN SODIUM;INNOHEP				NCE	JUL 14, 2005
020912 001	TIROFIBAN HYDROCHLORIDE;AGGRASTAT	5292756	MAY 14, 2012	U-230	NCE	MAY 14, 2003
		5658929	MAR 08, 2011			
		5733919	OCT 23, 2016			
		5880136	SEP 27, 2010	U-254		
		5965581	OCT 23, 2016			
		5972967	OCT 23, 2016			
		5978698	OCT 08, 2017			
		6136794	JAN 29, 2019			
020913 001	TIROFIBAN HYDROCHLORIDE;AGGRASTAT	5292756	MAY 14, 2012	U-230	NCE	MAY 14, 2003
		5658929	MAR 08, 2011			
		5733919	OCT 23, 2016			
		5880136	SEP 27, 2010	U-254		
		5965581	OCT 23, 2016			
		5972967	OCT 23, 2016			
		5978698	OCT 08, 2017			
		6136794	JAN 29, 2019			
050753 001	TOBRAMYCIN;TOBI				ODE	DEC 22, 2004
020697 001	TOLCAPONE;TASMAR	5236952	AUG 17, 2010		NCE	JAN 29, 2003
		5476875	DEC 19, 2012	U-219		
020697 002	TOLCAPONE;TASMAR	5236952	AUG 17, 2010		NCE	JAN 29, 2003
		5476875	DEC 19, 2012	U-219		
020771 001	TOLTERODINE TARTRATE;DETROL	5382600	JAN 17, 2012		NCE	MAR 25, 2003
		5559269	NOV 05, 2013	U-318		
020771 002	TOLTERODINE TARTRATE;DETROL	5382600	JAN 17, 2012		NCE	MAR 25, 2003
		5559269	NOV 05, 2013	U-318		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
021228 001	TOLTERODINE TARTRATE;DETROL LA	5559269	MAY 05, 2015	U-318	NDF	DEC 22, 2003
		5382600	JAN 17, 2012		NCE	MAR 25, 2003
021228 002	TOLTERODINE TARTRATE;DETROL LA	5559269	MAY 05, 2015	U-318	NDF	DEC 22, 2003
		5382600	JAN 17, 2012		NCE	MAR 25, 2003
020505 001	TOPIRAMATE;TOPAMAX	4513006	SEP 26, 2003		I-266	JUL 23, 2002
					I-274	OCT 01, 2002
					ODE	AUG 28, 2008
					I-335	AUG 28, 2004
020505 002	TOPIRAMATE;TOPAMAX	4513006	SEP 26, 2003		I-266	JUL 23, 2002
					I-274	OCT 01, 2002
					ODE	AUG 28, 2008
					I-335	AUG 28, 2004
020505 003	TOPIRAMATE;TOPAMAX	4513006	SEP 26, 2003		I-266	JUL 23, 2002
					I-274	OCT 01, 2002
					ODE	AUG 28, 2008
					I-335	AUG 28, 2004
020505 004	TOPIRAMATE;TOPAMAX	4513006	SEP 26, 2003		I-274	OCT 01, 2002
					I-266	JUL 23, 2002
					ODE	AUG 28, 2008
					I-335	AUG 28, 2004
020505 005	TOPIRAMATE;TOPAMAX	4513006	SEP 26, 2003		I-274	OCT 01, 2002
					I-266	JUL 23, 2002
					ODE	AUG 28, 2008
					I-335	AUG 28, 2004
020505 006	TOPIRAMATE;TOPAMAX	4513006	SEP 26, 2003		I-274	OCT 01, 2002
					I-266	JUL 23, 2002
					ODE	AUG 28, 2008
					I-335	AUG 28, 2004
020844 001	TOPIRAMATE;TOPAMAX SPRINKLE	4513006	SEP 26, 2003		I-274	OCT 01, 2002
					I-266	JUL 23, 2002
					ODE	AUG 28, 2008
					I-335	AUG 28, 2004
020844 002	TOPIRAMATE;TOPAMAX SPRINKLE	4513006	SEP 26, 2003		I-274	OCT 01, 2002
					I-266	JUL 23, 2002
					ODE	AUG 28, 2008
					I-335	AUG 28, 2004
020844 003	TOPIRAMATE;TOPAMAX SPRINKLE	4513006	SEP 26, 2003		I-274	OCT 01, 2002
					I-266	JUL 23, 2002
					ODE	AUG 28, 2008
					I-335	AUG 28, 2004
020671 001	TOPOTECAN HYDROCHLORIDE;HYCAMTIN	5004758	MAY 28, 2010			
020497 001	TOREMIFENE CITRATE;FARESTON	4696949	SEP 29, 2009	U-196	ODE	MAY 29, 2004
					NCE	MAY 29, 2002
020136 001	TORSEMIDE;DEMADEX	RE34672	AUG 11, 2006			
020136 002	TORSEMIDE;DEMADEX	RE34672	AUG 11, 2006			
020136 003	TORSEMIDE;DEMADEX	RE34672	AUG 11, 2006			
020136 004	TORSEMIDE;DEMADEX	RE34672	AUG 11, 2006			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020137 002	TORSEMIDE;DEMADEX	RE34672	AUG 11, 2006			
		4861786	JUL 08, 2007			
020281 001	TRAMADOL HYDROCHLORIDE;ULTRAM	6339105	OCT 12, 2019	U-435	PED	FEB 21, 2002
		6339105*PED	APR 12, 2020	U-435		
020281 002	TRAMADOL HYDROCHLORIDE;ULTRAM	6339105	OCT 12, 2019	U-435	PED	FEB 21, 2002
		6339105*PED	APR 12, 2020	U-435	D-63	DEC 23, 2002
					PED	JUN 23, 2003
020528 001	TRANDOLAPRIL;MAVIK	4933361	JUN 12, 2007			
		5744496	APR 28, 2015	U-229		
020528 002	TRANDOLAPRIL;MAVIK	4933361	JUN 12, 2007			
		5744496	APR 28, 2015	U-229		
020528 003	TRANDOLAPRIL;MAVIK	5744496	APR 28, 2015	U-229		
		4933361	JUN 12, 2007			
020591 001	TRANDOLAPRIL;TARKA	4933361	JUN 12, 2007			
		5721244	FEB 24, 2015			
020591 002	TRANDOLAPRIL;TARKA	4933361	JUN 12, 2007			
		5721244	FEB 24, 2015			
020591 003	TRANDOLAPRIL;TARKA	4933361	JUN 12, 2007			
		5721244	FEB 24, 2015			
020591 004	TRANDOLAPRIL;TARKA	4933361	JUN 12, 2007			
		5721244	FEB 24, 2015			
021257 001	TRAVOPROST;TRAVATAN	6011062	DEC 22, 2014	U-382	NCE	MAR 16, 2006
		5631287	DEC 22, 2014	U-382		
		5849792	DEC 22, 2014	U-383		
		5889052	AUG 03, 2013	U-383		
		6235781	JUN 15, 2019	U-382		
020404 003	TRETINOIN;AVITA	4971800	NOV 20, 2007	U-178		
		5045317	SEP 03, 2008	U-179		
019963 001	TRETINOIN;RENOVA	4603146	JUL 29, 2003	U-131		
		RE36068	JUL 29, 2003	U-131		
021108 001	TRETINOIN;RENOVA	RE36068	JUL 29, 2003	U-131	NP	AUG 31, 2003
		4603146	JUL 29, 2003	U-131		
020475 001	TRETINOIN;RETIN-A MICRO	4690825	OCT 04, 2005	U-134		
		5955109	SEP 21, 2016	U-134		
020438 001	TRETINOIN;VESANOID				ODE	NOV 22, 2002
019798 001	TRIAMCINOLONE ACETONIDE;NASACORT	4767612	JAN 23, 2007	U-85		
020468 001	TRIAMCINOLONE ACETONIDE;NASACORT AQ	5976573	JUL 03, 2016	U-295		
		6143329	JUL 03, 2016			
074973 001	TRIMETHOPRIM HYDROCHLORIDE;PRIMSOL	5763449	AUG 07, 2016			
		5962461	AUG 07, 2016			
020326 001	TRIMETREXATE GLUCURONATE;NEUTREXIN	4694007	MAY 20, 2006	U-91		
		4376858	MAY 09, 2004			
		6017922	MAY 18, 2018			
020326 002	TRIMETREXATE GLUCURONATE;NEUTREXIN	6017922	MAY 18, 2018			
021288 001	TRIPTORELIN PAMOATE;TRELSTAR	5225205	JUL 20, 2010		NP	JUN 29, 2004
		5192741	MAR 09, 2010		NCE	JUN 15, 2005

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020715 001	TRIPTORELIN PAMOATE;TRELSTAR DEPOT	5225205	JUL 20, 2010		NCE	JUN 15, 2005
		5776885	JUL 07, 2015			
020719 001	TROGLITAZONE;PRELAY	4572912	NOV 09, 2008		I-275	JUN 16, 2002
		5602133	SEP 15, 2013	U-173	NCE	JAN 29, 2002
		5859037	NOV 13, 2017	U-251		
		6011049	NOV 13, 2017	U-301		
		6046202	SEP 15, 2013	U-317		
020719 002	TROGLITAZONE;PRELAY	4572912	NOV 09, 2008		I-275	JUN 16, 2002
		5602133	SEP 15, 2013	U-173	NCE	JAN 29, 2002
		5859037	NOV 13, 2017	U-251		
		6011049	NOV 13, 2017	U-301		
		6046202	SEP 15, 2013	U-317		
020719 003	TROGLITAZONE;PRELAY	5602133	SEP 15, 2013	U-173	I-275	JUN 16, 2002
		4572912	NOV 09, 2008		NCE	JAN 29, 2002
		5859037	NOV 13, 2017	U-251		
		6011049	NOV 13, 2017	U-301		
		6046202	SEP 15, 2013	U-317		
020720 001	TROGLITAZONE;REZULIN	5602133	SEP 15, 2013	U-173	I-276	JUN 16, 2002
		4572912	NOV 09, 2008		NCE	JAN 29, 2002
		5859037	NOV 13, 2017	U-251		
		6011049	NOV 13, 2017	U-301		
		6046202	SEP 15, 2013	U-317		
020720 002	TROGLITAZONE;REZULIN	5602133	SEP 15, 2013	U-173	I-276	JUN 16, 2002
		4572912	NOV 09, 2008		NCE	JAN 29, 2002
		5859037	NOV 13, 2017	U-251		
		6011049	NOV 13, 2017	U-301		
		6046202	SEP 15, 2013	U-317		
020720 003	TROGLITAZONE;REZULIN	5602133	SEP 15, 2013	U-173	I-276	JUN 16, 2002
		4572912	NOV 09, 2008		NCE	JAN 29, 2002
		5859037	NOV 13, 2017	U-251		
		6011049	NOV 13, 2017	U-301		
		6046202	SEP 15, 2013	U-317		
020759 001	TROVAFLOXACIN MESYLATE;TROVAN	5164402	DEC 18, 2011	U-282	NCE	DEC 18, 2002
		5763454	JUN 15, 2015	U-282		
		6187341	JAN 20, 2019			
020759 002	TROVAFLOXACIN MESYLATE;TROVAN	5164402	DEC 18, 2011	U-282	NCE	DEC 18, 2002
		5763454	JUN 15, 2015	U-282		
		6187341	JAN 20, 2019			
021214 001	UNOPROSTONE ISOPROPYL;RESCULA	5001153	SEP 19, 2008		NCE	AUG 03, 2005
		5151444	MAR 19, 2008	U-333		
		5166178	NOV 24, 2009	U-333		
		5212200	MAY 18, 2010	U-333		
		5208256	MAY 21, 2011	U-333		
		5221763	JUN 22, 2010			
020586 002	UREA, C-13;BREATHTEK UBT FOR H-PYLORI	4830010	OCT 27, 2009	U-147		
		5140993	AUG 24, 2009			
				U-148		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
021092 001	UREA, C-13;HELICOSOL				NP	DEC 17, 2002
020586 001	UREA, C-13;MERETEK UBT KIT (W/ PRANACTIN)	4830010	OCT 27, 2009	U-147		
		5140993	AUG 24, 2009	U-148		
020617 001	UREA, C-14;PYTEST	4830010	MAY 15, 2006	U-195	NCE	MAY 09, 2002
020617 002	UREA, C-14;PYTEST KIT	4830010	MAY 15, 2006	U-195	NCE	MAY 09, 2002
019415 004	UROFOLLITROPIN;FERTINEX	5767067	JUN 16, 2015			
		4845077	JUL 04, 2006	U-408		
		4725579	FEB 21, 2005	U-408		
019415 005	UROFOLLITROPIN;FERTINEX	5767067	JUN 16, 2015			
		4845077	JUL 04, 2006	U-408		
		4725579	FEB 21, 2005	U-408		
020675 001	URSODIOL;URSO	4859660	AUG 22, 2006		ODE	DEC 10, 2004
020487 001	VALACYCLOVIR HYDROCHLORIDE;VALTREX	4957924	JUN 23, 2009			
		5879706	JAN 19, 2016			
		6107302	JAN 19, 2016			
020487 002	VALACYCLOVIR HYDROCHLORIDE;VALTREX	5879706	JAN 19, 2016			
		6107302	JAN 19, 2016			
		4957924	JUN 23, 2009			
020550 001	VALACYCLOVIR HYDROCHLORIDE;VALTREX				D-67	JUN 25, 2004
020550 002	VALACYCLOVIR HYDROCHLORIDE;VALTREX				D-67	JUN 25, 2004
021341 002	VALDECOXIB;BEXTRA				NCE	NOV 16, 2006
021341 003	VALDECOXIB;BEXTRA				NCE	NOV 16, 2006
021304 001	VALGANCICLOVIR HYDROCHLORIDE;VALCYTE	6083953	JUL 28, 2014	U-384	NE	MAR 29, 2004
020892 001	VALRUBICIN;VALSTAR PRESERVATIVE FREE				NCE	SEP 25, 2003
					ODE	SEP 25, 2005
020665 001	VALSARTAN;DIOVAN	5399578	MAR 21, 2012	U-3		
020665 002	VALSARTAN;DIOVAN	5399578	MAR 21, 2012	U-3		
021283 001	VALSARTAN;DIOVAN	5399578	MAR 21, 2012			
021283 002	VALSARTAN;DIOVAN	5399578	MAR 21, 2012			
021283 003	VALSARTAN;DIOVAN	5399578	MAR 21, 2012			
020151 001	VENLAFAXINE HYDROCHLORIDE;EFFEXOR	4535186	DEC 13, 2007		I-325	MAY 02, 2004
020151 002	VENLAFAXINE HYDROCHLORIDE;EFFEXOR	4535186	DEC 13, 2007		I-325	MAY 02, 2004
020151 003	VENLAFAXINE HYDROCHLORIDE;EFFEXOR	4535186	DEC 13, 2007		I-325	MAY 02, 2004
020151 004	VENLAFAXINE HYDROCHLORIDE;EFFEXOR	4535186	DEC 13, 2007		I-325	MAY 02, 2004
020151 005	VENLAFAXINE HYDROCHLORIDE;EFFEXOR	4535186	DEC 13, 2007		I-325	MAY 02, 2004
020151 006	VENLAFAXINE HYDROCHLORIDE;EFFEXOR	4535186	DEC 13, 2007		I-325	MAY 02, 2004
020699 001	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	4535186	DEC 13, 2007		I-251	MAR 11, 2002
		6274171	MAR 20, 2017		I-325	MAY 02, 2004
		5916923	JUN 28, 2013	U-398		
020699 002	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	4535186	DEC 13, 2007		I-251	MAR 11, 2002
		6274171	MAR 20, 2017		I-325	MAY 02, 2004
		5916923	JUN 28, 2013	U-398		
020699 003	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	4535186	DEC 13, 2007		I-251	MAR 11, 2002
		6274171	MAR 20, 2017			
		5916923	JUN 28, 2013	U-398		
020699 004	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	4535186	DEC 13, 2007		I-251	MAR 11, 2002
		6274171	MAR 20, 2017		I-325	MAY 02, 2004
		5916923	JUN 28, 2013	U-398		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020552 001	VERAPAMIL HYDROCHLORIDE;COVERA-HS	4612008	DEC 21, 2004			
		4783337	SEP 16, 2003			
		5190765	AUG 14, 2007			
		5160744	JUN 27, 2011			
		5252338	JUN 27, 2011			
		5232705	AUG 31, 2010			
		5200196	JAN 22, 2008			
		5141752	JUN 27, 2006			
		5082668	JAN 21, 2009			
		5030456	NOV 07, 2008			
		4946687	OCT 02, 2007			
		5785994	OCT 22, 2009	U-315		
		6096339	APR 04, 2017	U-365		
		6146662	NOV 14, 2017	U-366		
020552 002	VERAPAMIL HYDROCHLORIDE;COVERA-HS	4612008	DEC 21, 2004			
		4783337	SEP 16, 2003			
		5190765	AUG 14, 2007			
		5160744	JUN 27, 2011			
		5252338	JUN 27, 2011			
		5232705	AUG 31, 2010			
		5200196	JAN 22, 2008			
		5141752	JUN 27, 2006			
		5082668	JAN 21, 2009			
		5030456	NOV 07, 2008			
		4946687	OCT 02, 2007			
		5785994	OCT 22, 2009	U-315		
		6096339	APR 04, 2017	U-365		
		6146662	NOV 14, 2017	U-366		
019614 001	VERAPAMIL HYDROCHLORIDE;VERELAN	4863742	JUN 19, 2007	U-3		
019614 002	VERAPAMIL HYDROCHLORIDE;VERELAN	4863742	JUN 19, 2007	U-3		
019614 003	VERAPAMIL HYDROCHLORIDE;VERELAN	4863742	JUN 19, 2007	U-3		
019614 004	VERAPAMIL HYDROCHLORIDE;VERELAN	4863742	JUN 19, 2007			
020943 001	VERAPAMIL HYDROCHLORIDE;VERELAN PM	4863742	JUN 19, 2007			
020943 002	VERAPAMIL HYDROCHLORIDE;VERELAN PM	4863742	JUN 19, 2007			
020943 003	VERAPAMIL HYDROCHLORIDE;VERELAN PM	4863742	JUN 19, 2007			
021119 001	VERTEPORFIN;VISUDYNE	5707608	AUG 02, 2015		NCE	APR 12, 2005
		6074666	FEB 05, 2012		I-336	AUG 22, 2004
		4920143	APR 24, 2007			
		5095030	APR 24, 2007			
		5214036	MAY 25, 2010			
		5770619	JAN 06, 2015	U-357		
		5798349	AUG 25, 2015	U-357		
		5756541	MAR 11, 2016	U-357		
		4833790	JAN 20, 2007	U-357		
		5283255	JAN 20, 2007	U-357		
014103 003	VINCRISTINE SULFATE;ONCOVIN	4619935	OCT 28, 2003			
020388 001	VINORELBINE TARTRATE;NAVELBINE	4307100	JUL 08, 2002			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020547 001	ZAFIRLUKAST;ACCOLATE	5612367	MAR 18, 2014	U-189	I-328	SEP 17, 2002
		5583152	SEP 26, 2010			
		4859692	SEP 26, 2010			
		5319097	DEC 11, 2011			
		5294636	DEC 11, 2011			
		5482963	JAN 09, 2013			
		6143775	DEC 11, 2011			
020547 003	ZAFIRLUKAST;ACCOLATE	4859692	SEP 26, 2010		NS	SEP 17, 2002
		5294636	DEC 11, 2011		I-328	SEP 17, 2002
		5319097	DEC 11, 2011			
		5482963	JAN 09, 2013			
		5583152	SEP 26, 2010			
		5612367	MAR 18, 2014	U-189		
		6143775	DEC 11, 2011			
020199 001	ZALCITABINE;HIVID	5028595	JUL 02, 2008	U-65		
		4879277	NOV 07, 2006	U-65		
020199 002	ZALCITABINE;HIVID	4879277	NOV 07, 2006	U-65		
		5028595	JUL 02, 2008	U-65		
020859 001	ZALEPLON;SONATA	4626538	JUN 23, 2003		NCE	AUG 13, 2004
					M-8	FEB 22, 2004
020859 002	ZALEPLON;SONATA	4626538	JUN 23, 2003		NCE	AUG 13, 2004
					M-8	FEB 22, 2004
021036 001	ZANAMIVIR;RELENZA	D379506	MAY 27, 2011		I-294	APR 26, 2003
		4778054	OCT 18, 2005		NCE	JUL 26, 2004
		4811731	JUL 29, 2006			
		5035237	JUL 30, 2008			
		5360817	NOV 01, 2011			
		5648379	JUL 15, 2014	U-274		
		4627432	DEC 09, 2003			
019655 001	ZIDOVUDINE;RETROVIR	4724232	SEP 17, 2005			
		4833130	SEP 17, 2005			
		4828838	SEP 17, 2005			
		4818538	SEP 17, 2005			
		4837208	SEP 17, 2005			
019910 001	ZIDOVUDINE;RETROVIR	4833130	SEP 17, 2005			
		4818538	SEP 17, 2005			
		4837208	SEP 17, 2005			
		4724232	SEP 17, 2005			
019951 001	ZIDOVUDINE;RETROVIR	4833130	SEP 17, 2005			
		4818538	SEP 17, 2005			
		4724232	SEP 17, 2005			
		4837208	SEP 17, 2005			
020518 001	ZIDOVUDINE;RETROVIR	4828838	SEP 17, 2005			
		4837208	SEP 17, 2005			
		4724232	SEP 17, 2005			
		4818538	SEP 17, 2005			
		4833130	SEP 17, 2005			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020518 002	ZIDOVUDINE;RETROVIR	4724232	SEP 17, 2005			
		4818538	SEP 17, 2005			
		4833130	SEP 17, 2005			
		4828838	SEP 17, 2005			
		4837208	SEP 17, 2005			
020471 001	ZILEUTON;ZYFLO	4873259	DEC 10, 2010	U-168		
020471 003	ZILEUTON;ZYFLO	4873259	DEC 10, 2010	U-168		
020458 001	ZINC ACETATE;GALZIN				ODE	JAN 28, 2004
020458 002	ZINC ACETATE;GALZIN				ODE	JAN 28, 2004
020825 001	ZIPRASIDONE HYDROCHLORIDE;GEODON	4831031	MAR 02, 2007		NCE	FEB 05, 2006
		5312925	SEP 01, 2012			
020825 002	ZIPRASIDONE HYDROCHLORIDE;GEODON	4831031	MAR 02, 2007		NCE	FEB 05, 2006
		5312925	SEP 01, 2012			
020825 003	ZIPRASIDONE HYDROCHLORIDE;GEODON	4831031	MAR 02, 2007		NCE	FEB 05, 2006
		5312925	SEP 01, 2012			
020825 004	ZIPRASIDONE HYDROCHLORIDE;GEODON	4831031	MAR 02, 2007		NCE	FEB 05, 2006
		5312925	SEP 01, 2012			
021223 001	ZOLEDRONIC ACID;ZOMETA	4939130	NOV 13, 2007	U-53	NCE	AUG 20, 2006
		4777163	JUL 24, 2007		ODE	AUG 20, 2008
020768 001	ZOLMITRIPTAN;ZOMIG	5466699	NOV 14, 2012		NCE	NOV 25, 2002
		5863935	NOV 14, 2012			
020768 002	ZOLMITRIPTAN;ZOMIG	5466699	NOV 14, 2012		NCE	NOV 25, 2002
		5863935	NOV 14, 2012			
021231 001	ZOLMITRIPTAN;ZOMIG-ZMT				NDF	FEB 13, 2004
019908 001	ZOLPIDEM TARTRATE;AMBIEN	4382938	OCT 21, 2006	U-74		
019908 002	ZOLPIDEM TARTRATE;AMBIEN	4382938	OCT 21, 2006	U-74		
020789 001	ZONISAMIDE;ZONEGRAN				NCE	MAR 27, 2005

FDA data supplied by DrugPatentWatch.com

PATENT AND EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE EXCLUSIVITY COLUMN, THE FOLLOWING ABBREVIATIONS HAVE BEEN DEVELOPED. PLEASE REFER BACK TO THIS PAGE FOR AN EXPLANATION OF THE PATENT AND EXCLUSIVITY ABBREVIATIONS FOUND IN THE ADDENDUM.

ABBREVIATIONS

D	NEW DOSING SCHEDULE (SEE REFERENCES, BELOW)
I	NEW INDICATION (SEE REFERENCES, BELOW)
NC	NEW COMBINATION
NCE	NEW CHEMICAL ENTITY
NDF	NEW DOSAGE FORM
NE	NEW ESTER OR SALT OF AN ACTIVE INGREDIENT
NP	NEW PRODUCT
NP*	NEW PRODUCT (MINT FLAVORED)
NPP	NEW PATIENT POPULATION
NR	NEW ROUTE
NS	NEW STRENGTH
ODE	ORPHAN DRUG EXCLUSIVITY
PED	PEDIATRIC EXCLUSIVITY
PC	PATENT CHALLENGE
U	PATENT USE CODE (SEE REFERENCES, BELOW)

REFERENCES
NEW DOSING SCHEDULE

D-1	ONCE A DAY APPLICATION
D-2	ONCE DAILY DOSING
D-3	SEVEN DAYS/SEVEN DAYS/SEVEN DAYS DOSING SCHEDULE
D-4	SEVEN DAYS/FOURTEEN DAYS DOSING SCHEDULE
D-5	TEN DAYS/ELEVEN DAYS DOSING SCHEDULE
D-6	SEVEN DAYS/NINE DAYS/FIVE DAYS DOSING SCHEDULE
D-7	BID DOSING
D-8	INTRAVENOUS, EPIDURAL AND INTRATHECAL DOSING
D-9	NARCOTIC OVERDOSE IN ADULTS
D-10	NARCOTIC OVERDOSE IN CHILDREN
D-11	POSTOPERATIVE NARCOTIC DEPRESSION IN CHILDREN
D-12	BEDTIME DOSING OF 800MG FOR TREATMENT OF ACTIVE DUODENAL ULCER
D-13	INCREASED MAXIMUM DAILY DOSAGE RECOMMENDATION
D-14	BEDTIME DOSING OF 800MG FOR TREATMENT OF ACTIVE BENIGN GASTRIC ULCER
D-15	SINGLE DAILY DOSE OF 25MG/37.5MG
D-16	CONTINUOUS INTRAVENOUS INFUSION
D-17	400MG EVERY 12 HOURS FOR THREE DAYS FOR UNCOMPLICATED URINARY TRACT INFECTIONS
D-18	LOWER RECOMMENDED STARTING DOSE GUIDELINES
D-19	BOLUS DOSING GUIDELINES
D-20	SINGLE 32MG DOSE
D-21	ALTERNATIVE DOSAGE OF 300MG ONCE DAILY AFTER THE EVENING MEAL
D-22	REDUCTION IN INFUSION TIME FROM 24 TO 4 HOURS FOR THE 60MG DOSE
D-23	INCREASE MAXIMUM DOSE AND VARIATIONS IN THE DOSING REGIMEN
D-24	FOR OVARIAN CANCER THE RECOMMENDED REGIMEN IS 135MG/M^2 OR 175MG/M^2 INTRAVENOUSLY OVER THREE HOURS EVERY THREE WEEKS
D-25	ADDITIONAL DOSAGE REGIMEN EQUAL TO HALF OF THE ORIGINAL DOSING REGIMEN
D-26	ONCE WEEKLY APPLICATION
D-27	BID DOSING IN PATIENTS 12 YEARS OF AGE AND OLDER FOR PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH MODERATELY EMETOGENIC CANCER CHEMOTHERAPY

FDA data supplied by DrugPatentWatch.com

PATENT AND EXCLUSIVITY TERMS

REFERENCES

NEW DOSING SCHEDULE

D-28 USE OF ISOVUE-370 IN EXCRETORY UROGRAPHY AT EQUIVALENT GRAMS OF IODINE TO THE CURRENTLY APPROVED ISOVUE-250 AND ISOVUE-300
D-29 INCREASE OF CUMULATIVE DOSE TO 0.3MMOL/KG FOR MRI OF THE CNS IN ADULTS
D-30 5000 IU DOSE FOR PHOPHYLAXIS AGAINST DEEP VEIN THROMBOSIS
D-31 CHANGE IN RECOMMENDED TOTAL DAILY DOSE TO 80MG (40MG BID)
D-32 REMOVAL OF THE RESTRICTIONS LIMITING TREATMENT TO TWO CONSECUTIVE WEEKS AND TO SMALL AREAS
D-33 ONCE DAILY DOSING FOR PLAQUE PSORIASIS
D-34 EVERY FOUR MONTHS DOSAGE REGIMEN
D-35 FOR A ONE WEEK DOSING PERIOD FOR INTERDIGITAL TINEA PEDIS
D-36 FOR A SINGLE 2MG DOSE AS AN ALTERNATIVE TO THE 1MG DOSE GIVE TWICE DAILY
D-37 DOSING REGIMEN FOR ADMINISTRATION EITHER ONCE DAILY (QD) OR TWICE DAILY (BID)
D-38 CONTINUOUS INFUSION AS AN ALTERNATE METHOD OF ADMINISTRATION
D-39 CHANGE IN TIME TO TAKE THE DRUG PRIOR TO A MEAL TO PREVENT MEAL-INDUCED HEARTBURN SYMPTOMS FROM " ...1/2-1 HOUR BEFORE EATING..." TO "...RIGHT BEFORE EATING OR UP TO 60 MIN BEFORE CONSUMING..."
D-40 ONCE-A-DAY DOSING REGIMEN
D-41 DRUG MAY BE DOSED RIGHT BEFORE A MEAL OR ANY TIME UP TO 30 MIN BEFORE EATING OR DRINKING FOOD AND BEVERAGES THAT WOULD BE EXPECTED TO CAUSE SYMPTOMS
D-42 TEN DAY DOSING REGIMEN FOR TRIPLE THERAPY, PREVACID IN COMBINATION WITH CLARITHROMYCIN AND AMOXICCLIN, FOR THE ERADICATION OF H. PYLORI IN PATIENTS WITH DUODENAL ULCER DISEASE
D-43 INITIATION OF TREATMENT WITH 900MG/DAY BY DELETION OF THE REQUIREMENT TO TITRATE TO 900MG/DAY OVER A 3-DAY PERIOD
D-44 IN A CLINICAL TRIAL, FEWER DISCONTINUATIONS DUE TO ADVERSE EVENTS, ESPECIALLY DIZZINESS AND VERTIGO, WERE OBSERVED WHEN TITRATING THE DOSE IN INCREMENTS OF 50MG/DAY EVERY THREE DAYS UNTIL AN EFFECTIVE DOSE (NOT EXCEEDING 400MG/DAY) WAS REACHED
D-45 ONCE DAILY DOSING FOR MAINTENANCE ONLY
D-46 NEW DOSING REGIMEN OF 80MG DAILY
D-47 PREVENTION OF HEARTBURN SYMPTOMS WHEN ADMINISTERED FROM 15 MINUTES UP TO, BUT NOT NCLUDING, HOUR PRIOR TO A PROVOCATIVE MEAL
D-48 ADMINISTRATION OF CISATRICURIUM, A NEUROMUSCULAR BLOCKING AGENT AT DOSES OF 3 AND 4X THE ED95 OF CISATRICUNIUM FOLLOWING INDUCTION WITH THIOPENTAL
D-49 PEDIATRIC DOSING GUIDELINES
D-50 INFORMATION FOR USE OF CORVERT IN POST-CARDIAC SURGERY PATIENTS
D-51 OPTIONAL STARTING DOSE OF 40MG/DAY
D-52 ALTERNATE DOSING REGIMEN OF 1250MG TWICE DAILY
D-53 USE IN PEDIATRIC PATIENTS FROM 1 MONTH TO 16 YEARS OF AGE
D-54 USE OF ZYBAN FOR MAINTENANCE THERAPY. TREATMENT UP TO 6 MONTHS WAS SHOWN EFFICACIOUS
D-55 ADDITION OF A HIGHER DOSE OF NUTROPIN FOR PUBERTAL PATIENTS (PUBERTAL DOSE LESS THAN OR EQUAL TO 0.7MG/KG/WEEK)
D-56 ADDITION OF POSTPRANDIAL DOSING
D-57 3-HOUR INFUSION OF TAXOL GIVEN EVERY THREE WEEKS AT A DOSE OF 175MG/M2 FOLLOWED BY CISPLATIN AT A DOSE OF 75MG/M2 FOR THE FIRST-LINE TREATMENT OF ADVANCED OVARIAN CANCER
D-58 CHANGE IN DOSING INTERVAL TO ONCE-DAILY ADMINISTRATION
D-59 REDUCTION OF ELEVATED LDL-C IN A NEW, HIGHER STRENGTH TABLET, 0.8MG, AND FOR EXTENSION OF THE DOSAGE RANGE TO 0.8MG DAILY
D-60 ADDITION OF A POST-OPERATIVE DOSING REGIMEN
D-61 ONCE WEEKLY DOSING FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
D-62 ONCE WEEKLY DOSING FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
D-63 TO ALLOW A TITRATION DOSING REGIMEN USING A 25MG DOSE
D-64 INCREASING DOSAGE FOR NERVE BLOCK ANESTHESIA USING NAROPIN 7.5MG/ML AND FOR EXTENDING THE DURATION OF TREATMENT FOR POSTOPERATIVE ANALGESIA USING NAROPIN 2MG/ML
D-65 CHANGE DOSING AND ADMINISTRATION TO INDICATE MAINTENANCE OF WEIGHT LOSS OVER AN 18 MONTH PERIOD THUS EXTENDING THE USE OF THIS DRUG FROM ONE TO TWO YEARS
D-66 DOSING RECOMMENDATIONS FOR PATIENTS UNDERGOING PCI
D-67 SHORTER TREATMENT COURSE OF THREE DAYS IN THE TREATMENT OF RECURRENT EPISODES OF GENITAL HERPES
D-68 CHANGE OF ADMIN RATE FOR INFUSION OF AREDIA FOR TREATMENT OF MODERATE AND SEVERE HYPERCALCEMIA OF MALIGNANCY FROM 24 HOURS TO 2 HOURS UP TO BUT NOT INCLUDING 24 HOURS

FDA data supplied by DrugPatentWatch.com

PATENT AND EXCLUSIVITY TERMS

REFERENCES

NEW DOSING SCHEDULE

D-69 SHORTENED DOSING REGIMEN TO 5 DAYS FOR THE TREATMENT OF ACUTE EXACERBATION OF CHRONIC BRONCHITIS
D-70 80MG ONCE DAILY DOSING REGIMEN

NEW INDICATION

I-1 DYSMENORRHEA
I-2 CHOLANGIOPANCREATOGRAPHY
I-3 INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY
I-4 PERIPHERAL VENOGRAPHY (PHLEBOGRAPHY)
I-5 HYSTEROSALPINGOGRAPHY
I-6 TREATMENT OF JUVENILE ARTHRITIS
I-7 BIOPSY PROVEN MINIMAL CHANGE NEPHROTIC SYNDROME IN CHILDREN
I-8 ADULT INTRAVENOUS CONTRAST-ENHANCED COMPUTED TOMOGRAPHY OF THE HEAD AND BODY
I-9 PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING
I-10 PREVENTION OF POSTOPERATIVE DEEP VENOUS THROMBOSIS AND PULMONARY EMBOLISM IN TOTAL HIP REPLACEMENT SURGERY
I-11 RELIEF OF MILD TO MODERATE PAIN
I-12 TREATMENT OF CUTANEOUS CANDIDIASIS
I-13 URINARY TRACT INFECTION (UTI) PREVENTION FOR PERIODS UP TO FIVE MONTHS IN WOMEN WITH A HISTORY OF RECURRENT UTI
I-14 SEBORRHEIC DERMATITIS
I-15 PHOTOPHERESIS IN THE PALLIATIVE TREATMENT OF SKIN MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PERSONS NOT RESPONSIVE TO OTHER TREATMENT
I-16 STIMULATE THE DEVELOPMENT OF MULTIPLE FOLLICLES/OOCYTES IN OVULATORY PATIENTS PARTICIPATING IN AN *IN VITRO* FERTILIZATION PROGRAM
I-17 MANAGEMENT OF CONGESTIVE HEART FAILURE
I-18 ENDOSCOPIC RETROGRADE PANCREATOGRAPHY
I-19 HERNIOGRAPHY
I-20 KNEE ARTHROGRAPHY
I-21 HIGH DOSE METHOTREXATE WITH LEUCOVORIN RESCUE IN COMBINATION WITH OTHER CHEMOTHERAPEUTIC AGENTS TO DELAY RECURRENCE IN PATIENTS WITH NONMETASTATIC OSTEOSARCOMA WHO HAVE UNDERGONE SURGICAL RESECTION OR AMPUTATION FOR THE PRIMARY TUMOR
I-22 RESCUE AFTER HIGH-DOSE METHOTREXATE THERAPY IN OSTEOSARCOMA
I-23 SHORT-TERM TREATMENT OF ACTIVE BENIGN GASTRIC ULCER
I-24 TREATMENT OF RHEUMATOID ARTHRITIS
I-25 ADULT INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY OF THE HEAD, NECK, ABDOMINAL, RENAL AND PERIPHERAL VESSELS
I-26 TREATMENT OF LIVER FLUKES
I-27 ADJUNCTIVE THERAPY TO DIET TO REDUCE THE RISK OF CORONARY ARTERY DISEASE
I-28 SELECTIVE ADULT VISCERAL ARTERIOGRAPHY
I-29 METASTATIC BREAST CANCER IN PREMENOPAUSAL WOMEN AS AN ALTERNATIVE TO OOPHORECTOMY OR OVARIAN IRRADIATION
I-30 TREATMENT OF TINEA PEDIS
I-31 CONTRAST ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS IN THE SPINE AND ASSOCIATED TISSUES
I-32 PEDIATRIC MYELOGRAPHY
I-33 ORAL USE OF DILUTED OMNIPAQUE INJECTION IN ADULTS FOR CONTRAST ENHANCED COMPUTED TOMOGRAPHY OF THE ABDOMEN
I-34 ORAL USE IN ADULTS FOR PASS-THROUGH EXAMINATION OF THE GASTROINTESTINAL TRACT
I-35 PEDIATRIC CONTRAST ENHANCEMENT OF COMPUTED TOMOGRAPHIC HEAD IMAGING
I-36 ARTHROGRAPHY OF THE SHOULDER JOINTS IN ADULTS
I-37 RADIOGRAPHY OF THE TEMPOROMANDIBULAR JOINT IN ADULTS
I-38 CONTRAST ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS OF THE CENTRAL NERVOUS SYSTEM IN CHILDREN (2 YEARS OF AGE AND OLDER)
I-39 TREATMENT OF ACUTE MYOCARDIAL INFARCTION

FDA data supplied by DrugPatentWatch.com

PATENT AND EXCLUSIVITY TERMS

REFERENCES

NEW INDICATION

I-40	PRIMARY NOCTURNAL ENURESIS
I-41	MIGRAINE HEADACHE PROPHYLAXIS
I-42	HERPES ZOSTER
I-43	HERPES SIMPLEX ENCEPHALITIS
I-44	MAINTENANCE THERAPY IN HEALED DUODENAL ULCER PATIENTS AT DOSE OF 1 GRAM TWICE DAILY
I-45	ACUTE TREATMENT OF VARICELLA ZOSTER VIRUS
I-46	USE IN PEDIATRIC COMPUTED TOMOGRAPHIC HEAD AND BODY IMAGING
I-47	TREATMENT OF PEDIATRIC PATIENTS WITH SYMPTOMATIC HUMAN IMMUNODEFICIENCY VIRUS (HIV) DISEASE
I-48	PEDIATRIC ANGIOCARDIOGRAPHY
I-49	TREATMENT OF TRAVELERS' DIARRHEA DUE TO SUSCEPTIBLE STRAINS OF ENTEROTOXIGENIC ESCHERICHIA COLI
I-50	FOR USE IN WOMEN WITH AXILLARY NODE-NEGATIVE BREAST CANCER
I-51	TREATMENT OF PRIMARY DYSMENORRHEA AND FOR THE TREATMENT OF IDIOPATHIC HEAVY MENSTRUAL BLOOD LOSS
I-52	PEDIATRIC EXCRETORY UROGRAPHY
I-53	TREATMENT OF PANIC DISORDER, WITH OR WITHOUT AGORAPHOBIA
I-54	RENAL CONCENTRATION CAPACITY TEST
I-55	HYPERTENSION
I-56	EROSIVE GASTROESOPHAGEAL REFLUX DISEASE
I-57	SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER
I-58	INITIAL TREATMENT OF ADVANCED OVARIAN CARCINOMA IN COMBINATION WITH OTHER APPROVED CHEMOTHERAPEUTIC AGENTS
I-59	ENDOSCOPICALLY DIAGNOSED ESOPHAGITIS, INCLUDING EROSIVE AND ULCERATIVE ESOPHAGITIS, AND ASSOCIATED HEARTBURN DUE TO GASTROESOPHAGEAL REFLUX DISEASE
I-60	SINGLE APPLICATION TREATMENT OF HEAD LICE IN CHILDREN TWO MONTHS TO TWO YEARS IN AGE
I-61	FEMALE ANDROGENETIC ALOPECIA
I-62	PREVENTION AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
I-63	ONCE DAILY TREATMENT AS INITIAL THERAPY IN THE TREATMENT OF HYPERTENSION
I-64	PREVENTION OF SUPRAVENTRICULAR TACHYCARDIAS
I-65	PREVENTION OF UPPER GASTROINTESTINAL BLEEDING IN CRITICALLY ILL PATIENTS
I-66	UNCOMPLICATED GONORRHEA
I-67	TREATMENT OF ACUTE ASTHMATIC ATTACKS IN CHILDREN SIX YEARS OF AGE AND OLDER
I-68	CENTRAL PRECOCIOUS PUBERTY
I-69	SHORT TERM TREATMENT OF PATIENTS WITH SYMPTOMS OF GASTROESOPHAGEAL REFLUX DISEASE (GERD), AND FOR THE SHORT TERM TREATMENT OF ESOPHAGITIS DUE TO GERD INCLUDING ULCERATIVE DISEASE DIAGNOSED BY ENDOSCOPY
I-70	USE IN COMBINATION WITH 5-FLUOROURACIL TO PROLONG SURVIVAL IN THE PALLIATIVE TREATMENT OF PATIENTS WITH ADVANCED COLORECTAL CANCER
I-71	VARICELLA INFECTIONS (CHICKENPOX)
I-72	PREVENTION OF CMV DISEASE IN TRANSPLANT PATIENTS AT RISK FOR CMV DISEASE
I-73	INITIATE AND MAINTAIN MONITORED ANESTHESIA CARE (MAC) SEDATION DURING DIAGNOSTIC PROCEDURES
I-74	INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY
I-75	TREATMENT OF ENDOSCOPICALLY DIAGNOSED EROSIVE ESOPHAGITIS
I-76	PREVENTION OF OSTEOPOROSIS
I-77	DERMAL INFECTIONS-TINEA PEDIS, TINEA CORPORIS, TINEA CRURIS DUE TO EPIDERMOPHYTON FLOCCOSUM
I-78	CONTRAST ENHANCED COMPUTED TOMOGRAPHIC IMAGING OF THE HEAD AND BODY AND INTRAVENOUS EXCRETORY UROGRAPHY
I-79	MANAGEMENT OF CHRONIC STABLE ANGINA AND ANGINA DUE TO CORONARY ARTERY SPASM
I-80	DIAGNOSIS AND LOCALIZATION OF ISCHEMIA AND CORONARY HEART DISEASE
I-81	PROPHYLAXIS IN DESIGNATED IMMUNOCOMPROMISED CONDITIONS TO REDUCE THE INCIDENCE OF OROPHARYNGEAL CANDIDIASIS
I-82	TREATMENT OF TRAVELERS' DIARRHEA
I-83	ANGIOCARDIOGRAPHY, CONTRAST ENHANCED COMPUTED TOMOGRAPHIC IMAGING OF THE HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY IN CHILDREN
I-84	INTRAOPERATIVE AND POSTOPERATIVE TACHYCARDIA AND/OR HYPERTENSION
I-85	TREATMENT OF ANOREXIA ASSOCIATED WITH WEIGHT LOSS IN PATIENTS WITH AIDS
I-86	TREATMENT OF SECONDARY CARNITINE DEFICIENCY
I-87	RENAL IMAGING AGENT FOR USE IN CHILDREN
I-88	MANAGEMENT OF ENDOMETRIOSIS
I-89	EPIDURAL USE IN LABOR AND DELIVERY AS AN ANALGESIC ADJUNCT TO BUPIVACAINE

FDA data supplied by DrugPatentWatch.com

PATENT AND EXCLUSIVITY TERMS

REFERENCES

NEW INDICATION

I-90 INTENSIVE CARE UNIT SEDATION
I-91 MONOTHERAPY USE FOR HYPERTENSION
I-92 ADJUNCTIVE THERAPY IN THE MANAGEMENT OF HEART FAILURE
I-93 PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN CHILDREN AGES 4-11 YEARS
I-94 USE WITH MRI IN ADULTS TO PROVIDE CONTRAST ENHANCEMENT AND FACILITATE VISUALIZATION OF LESIONS IN THE BODY [EXCLUDING THE HEART]
I-95 TREATMENT OF LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION
I-96 TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA
I-97 ORAL OR RECTAL USE IN CHILDREN FOR THE EXAMINATION OF THE GASTROINTESTINAL TRACT
I-98 TREATMENT OF CHILDREN WHO HAVE GROWTH FAILURE ASSOCIATED WITH CHRONIC RENAL INSUFFICIENCY
I-99 PEDIATRIC ANESTHESIA IN CHILDREN 3 YEARS AND OLDER
I-100 TO DECREASE THE INCIDENCE OF CANDIDIASIS IN PATIENTS UNDERGOING BONE MARROW TRANSPLANTATION WHO RECEIVE CYTOTOXIC CHEMOTHERAPY AND/OR RADIATION THERAPY
I-101 TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN-DEPENDENT DIABETES MELLITUS AND RETINOPATHY
I-102 TREATMENT OF OBSESSIVE-COMPULSIVE
I-103 PROPHYLAXIS AGAINST PNEUMOCYSTIS CARINII PNEUMONIA IN INDIVIDUALS WHO ARE IMMUNOCOMPROMISED AND CONSIDERED TO BE AT RISK OF DEVELOPING PNEUMOCYSTIS CARINII PNEUMONIA
I-104 TREATMENT OF PULMONARY AND EXTRAPULMONARY ASPERGILLOSIS IN PATIENTS WHO ARE INTOLERANT OF OR WHO ARE REFRACTORY TO AMPHOTERICIN B THERAPY
I-105 TREATMENT OF METASTATIC CARCINOMA OF THE BREAST AFTER FAILURE OF FIRST-LINE OR SUBSEQUENT CHEMOTHERAPY
I-106 TREATMENT OF ACROMEGALY
I-107 VAGINAL CANDIDIASIS
I-108 EXPANDED USE-FOR ICU PATIENTS UNDERGOING LONG-TERM INFUSION DURING MECHANICAL VENTILATION
I-109 TYPHOID FEVER
I-110 PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH RADIOTHERAPY
I-111 TREATMENT OF PAGET'S DISEASE OF BONE
I-112 MANAGEMENT OF MODERATE TO SEVERE PAIN
I-113 TREATMENT OF PROSTATITIS
I-114 USE IN CHILDREN TO VISUALIZE LESIONS WITH ABNORMAL VASCULARITY IN THE BRAIN (INTRACRANIAL LESIONS), SPINE AND ASSOCIATED TISSUE
I-115 USE IN MRI IN ADULTS TO VISUALIZE LESIONS IN THE HEAD AND NECK
I-116 MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS
I-117 TO SLOW THE PROGRESSION OF CORONARY ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE
I-118 PREVENTION OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, FOLLOWING KNEE REPLACEMENT SURGERY
I-119 TREATMENT OF ANEMIA CAUSED BY UTERINE LEIOMYOMATA IN WOMEN WHO FAIL IRON THERAPY
I-120 MAINTENANCE THERAPY FOR GASTRIC ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING ACUTE ULCERS
I-121 EXPANDED PATIENT POPULATION - USE IN ICU PATIENTS
I-122 PSORIASIS OF THE SCALP
I-123 RELIEF OF MILD TO MODERATE PAIN IN PATIENTS AGED 6 MONTHS AND OLDER
I-124 LEUCOCYTE LABELED SCINTIGRAPHY AS AN ADJUNCT IN THE LOCALIZATION OF INTRA-ABDOMINAL INFECTION AND INFLAMMATORY BOWEL DISEASE
I-125 EXPANSION OF CONSCIOUS SEDATION INDICATION TO INCLUDE SHORT THERAPEUTIC PROCEDURES
I-126 ADJUNCT TO THALLIUM-201 MYOCARDIAL PERFUSION IN PATIENTS UNABLE TO EXERCISE ADEQUATELY
I-127 TREATMENT OF ACYCLOVIR-RESISTANT HERPES IN IMMUNOCOMPROMISED PATIENTS
I-128 IN PATIENTS WITH CORONARY HEART DISEASE AND HYPERCHOLESTEROLEMIA: TO REDUCE THE RISK OF TOTAL MORTALITY BY REDUCING CORONARY DEATH; REDUCE THE RISK OF NON-FATAL MYOCARDIAL INFARCTION; REDUCE THE RISK FOR UNDERGOING MYOCARDIAL REVASCULARIZATION PROCEDURES; REDUCTION OF ELEVATED TOTAL AND LDL CHOLESTEROL LEVELS IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (TYPES IIA AND IIB)
I-129 TREATMENT OF ALCOHOL DEPENDENCE
I-130 MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS
I-131 PERIPHERAL ARTERIOGRAPHY
I-132 TREATMENT OF MANIC PHASE OF BIPOLAR DISORDER
I-133 MANAGEMENT OF CHRONIC STABLE ANGINA
I-134 HEART FAILURE POST MYOCARDIAL INFARCTION

FDA data supplied by DrugPatentWatch.com

PATENT AND EXCLUSIVITY TERMS

REFERENCES

NEW INDICATION

I-135 BONE METASTASES ASSOCIATED WITH MULTIPLE MYELOMA
I-136 IDIOPATHIC CHRONIC URTICARIA
I-137 PREVENTION OF MEAL-INDUCED HEARTBURN, ACID INDIGESTION, AND SOUR STOMACH WHEN TAKEN 30 MINUTES PRIOR TO CONSUMING FOOD OR BEVERAGES
I-138 TREATMENT OF ACUTE RECURRENT GENITAL HERPES
I-139 PALLIATIVE TREATMENT OF ADVANCED BREAST CANCER IN PRE- AND PERIMENOPAUSAL WOMEN
I-140 PREVENTION OF CYTOMEGALOVIRUS (CMV) DISEASE IN INDIVIDUALS WITH HIV INFECTION AT RISK FOR DEVELOPING CMV DISEASE
I-141 TREATMENT OF HEMODYNAMICALLY STABLE PATIENTS WITHIN 24 HOURS OF ACUTE MYOCARDIAL INFARCTION TO IMPROVE SURVIVAL
I-142 LOCALIZE MYOCARDIAL ISCHEMIA (REVERSIBLE DEFECT) AND INFARCTION (NON-REVERSIBLE DEFECTS) IN EVALUATING MYOCARDIAL FUNCTION
I-143 EPISODIC TREATMENT OF RECURRENT GENITAL HERPES IN IMMUNOCOMPETENT ADULTS
I-144 ENHANCEMENT OF MRI OF THE ADULT BODY INTERNAL ORGANS
I-145 0.1MMOL/KG AS A SINGLE INTRAVENOUS BOLUS FOR MRI OF THE CNS IN CHILDREN
I-146 CONTRAST ENHANCEMENT AND FACILITATION OF VISUALIZATION OF EXTRACRANIAL HEAD AND NECK LESIONS
I-147 PREVENTION OF GALLSTONE FORMATION IN OBESE PATIENTS EXPERIENCING RAPID WEIGHT LOSS
I-148 TREATMENT OF ACUTE PNEUMOCYSTIC CARINII PNEUMONIA (PCP) IN HIV-INFECTED PATIENTS WHOSE ALVEOLAR-ARTERIAL OXYGEN DIFFERENCE ($AaDO_2$) IS LESS THAN OR EQUAL TO 55 TORR
I-149 TREATMENT OF PATIENTS WITH NON-SMALL CELL LUNG CANCER
I-150 TREATMENT OF OBSESSIVE COMPULSIVE DISORDER AND PANIC DISORDER
I-151 PREVENTION OF AND PREVENTION OF FURTHER POSTOPERATIVE NAUSEA AND VOMITING IN PEDIATRIC PATIENTS RECEIVING GENERAL ANESTHESIA
I-152 SLOWING THE PROGRESSION OF CORONARY ATHEROSCLEROSIS AND REDUCING THE RISK OF ACUTE CORONARY EVENTS
I-153 MANAGEMENT OF SEVERE SPASTICITY [ENCOMPASSES SPINAL AND CEREBRAL ORIGIN]
I-154 PATIENT POPULATION ALTERED TO INCLUDE PEDIATRIC USE
I-155 TREATMENT OF ONCHOMYCOSIS DUE TO DERMATOPHYTES (TINEA UNGUIUM) OF THE TOENAIL WITH OR WITHOUT FINGERNAIL INVOLVEMENT
I-156 ADDITIONAL DATA REGARDING THE SAFE USE OF NORVASC IN PATIENTS WITH HEART FAILURE
I-157 TREATMENT OF ACUTE UNCOMPLICATED CYSTITIS IN FEMALES
I-158 TREATMENT OF OSTEOLYTIC BONE METASTASES OF BREAST CANCER
I-159 FOR HYPERCHOLESTEROLEMIC PATIENTS WITHOUT CLINICALLY EVIDENT HEART DISEASE REDUCE THE RISK OF MYOCARDIAL INFARCTION, REVASCULARIZATION, AND DEATH DUE TO CARDIOVASCULAR CAUSES WITH NO INCREASE IN DEATH FROM NON-CARDIOVASCULAR CAUSES
I-160 TREATMENT OF BACTERIAL CORNEAL ULCERS
I-161 TREATMENT OF ADULT-ONSET OR CHILDHOOD-ONSET ADULT GROWTH HORMONE DEFICIENCY
I-162 FOR USE IN PATIENTS 6-11 YEARS OF AGE
I-163 TREATMENT OF PHOTOPHOBIA
I-164 CHRONIC BACTERIAL PROSTATITIS
I-165 MANAGEMENT OF ADULTS WITH ACTIVE, CLASSIC AND DEFINITIVE RHEUMATOID ARTHRITIS WHO HAVE HAD AN INSUFFICIENT THERAPEUTIC RESPONSE TO OR ARE INTOLERANT OF AN ADEQUATE TRIAL OF FULL DOSES OF ONE OR MORE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS
I-166 TREATMENT OF BULIMIA
I-167 COMPLICATED INTRA-ABDOMINAL INFECTIONS (USED IN COMBINATION WITH METRONIDAZOLE) CAUSED BY MIXED AEROBIC/ANAEROBIC PATHOGENS
I-168 MANAGEMENT OF LOCALLY CONFINED STAGE B2-C METASTATIC CARCINOMA OF THE PROSTATE (IN COMBINATION WITH LHRH AGONISTS)
I-169 USE IN COMBINATION WITH CORTICOSTEROIDS AS INITIAL CHEMOTHERAPY FOR THE TREATMENT OF PATIENTS WITH PAIN RELATED TO ADVANCED HORMONE-REFRACTORY PROSTATE CANCER
I-170 PROPHYLACTIC USE DURING HEAD LICE EPIDEMICS
I-171 RELIEF OF SYMPTOMS OF THE COMMON COLD
I-172 TREATMENT OF INITIAL EPISODE OF GENITAL HERPES
I-173 PREOPERATIVELY FOR THE PREVENTION OF INFECTION IN TRANSRECTAL PROSTATE BIOPSY
I-174 PELVIC INFLAMMATORY DISEASE
I-175 TREATMENT OF TINEA CORPORIS AND TINEA CRURIS
I-176 TREATMENT OF POSTOPERATIVE INFLAMMATION IN PATIENTS WHO HAVE UNDERGONE CATARACT EXTRACTION

FDA data supplied by DrugPatentWatch.com

PATENT AND EXCLUSIVITY TERMS

REFERENCES

NEW INDICATION

I-177 TREATMENT OF MODERATE ACNE VULGARIS IN FEMALES, GREATER OR EQUAL TO 15 YEARS OF AGE, WHO HAVE NO KNOWN CONTRAINDICATIONS TO ORAL CONTRACEPTIVE THERAPY, DESIRE CONTRACEPTION, HAVE ACHIEVED MENARCHE AND ARE UNRESPONSIVE TO TOPICAL ANTI-ACNE MEDICATIONS

I-178 TREATMENT OF ONCHOMYCOSIS OF THE FINGERNAIL WITHOUT CONCOMITANT ONCHOMYCOSIS OF THE TOENAIL WITH A PULSE DOSING REGIMEN

I-179 NOSOCOMIAL PNEUMONIA-MILD TO MODERATE AND SEVERE CAUSED BY HAEMOPHILUS INFLUENZAE OR KLEBSIELLA PNEUMONIAE

I-180 TREATMENT OF PLANTAR TINEA PEDIS (MOCCASIN TYPE)

I-181 TREATMENT OF PATIENTS WITH COMPLEX PARTIAL SEIZURES WITH AND WITHOUT SECONDARY GENERALIZATION

I-182 TREATMENT OF GROWTH FAILURE ASSOCIATED WITH TURNER SYNDROME

I-183 MAINTENANCE THERAPY IN THE MANAGEMENT OF MILD TO MODERATE ASTHMA IN PEDIATRIC PATIENTS AGES 6-11

I-184 TREATMENT OF PANIC DISORDER AT A RECOMMENDED DOSE RANGE OF 1 TO 2 MG/DAY (MAXIMUM OF 4MG)

I-185 PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN

I-186 TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR CAUSED BY OR PRESUMED TO BE CAUSED BY PITYROSPORUM ORBICULARE (ALSO KNOWN AS MALASSEZIA FURFUR OR M. ORBICULARE)

I-187 PREVENTION OF FRACTURES IN THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS

I-188 TREATMENT OF ACUTE SINUSITIS AND ACUTE EXACERBATION OF CHRONIC SINUSITIS

I-189 TREATMENT OF ACUTE OTITIS MEDIA IN PEDIATRIC PATIENTS

I-190 PLANAR IMAGING AS A SECOND LINE DIAGNOSTIC DRUG AFTER MAMMOGRAPHY TO ASSIST IN THE EVALUATION OF BREAST LESIONS IN PATIENTS WITH AN ABNORMAL MAMMOGRAM OR A PALPABLE BREAST MASS

I-191 ENDOMETRIAL THINNING AGENT PRIOR TO ENDOMETRIAL ABLATION FOR DYSFUNCTIONAL UTERINE BLEEDING

I-192 THE PREVENTION OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING ABDOMINAL SURGERY WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS AND A NEW DOSAGE REGIMEN, 40MG ONCE DAILY, FOR THIS INDICATION

I-193 TREATMENT OF PANIC DISORDER IN A RECOMMENDED DOSE RANGE OF 50 TO 200MG/DAY

I-194 CONGESTIVE HEART FAILURE

I-195 USE OF LANSOPRAZOLE IN COMBINATION WITH CLARITHROMYCIN AND AMOXICILLIN FOR THE ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH ACTIVE DUODENAL ULCER DISEASE OR A ONE-YEAR HISTORY OF DUODENAL ULCER

I-196 ACUTE TREATMENT OF ACTIVE BENIGN GASTRIC ULCER

I-197 MAINTENANCE OF HEALING OF DUODENAL ULCER

I-198 USE OF LANSOPRAZOLE IN COMBINATION WITH AMOXICILLIN FOR THE ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH ACTIVE DUODENAL ULCER DISEASE OR A ONE-YEAR HISTORY OF A DUODENAL ULCER

I-199 MONOTHERAPY AND COMBINATION THERAPY WITH SULFONYLUREAS IN THE TREATMENT OF TYPE II DIABETES

I-200 TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR

I-201 EMPIRICAL THERAPY FOR FEBRILE NEUTROPENIC PATIENTS

I-202 SECOND-LINE TREATMENT OF AIDS-RELATED KAPOSI'S SARCOMA

I-203 MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS

I-204 USE IN PEDIATRIC PATIENTS BETWEEN THE AGES OF 6 AND 11 FOR THE TREATMENT OF THE NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS

I-205 INITIAL ANTICONVULSANT TREATMENT OF STATUS EPILEPTICUS

I-206 TREATMENT OF EDEMA ASSOCIATED WITH CHRONIC RENAL FAILURE

I-207 FOR THE SUPPRESSION OF RECURRENT EPISODES OF GENITAL HERPES IN IMMUNOCOMPETENT ADULTS

I-208 TREATMENT OF OBSESSIVE COMPULSIVE DISORDER IN THE PEDIATRIC POPULATION

I-209 PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA (PSVT)

I-210 TO SLOW THE PROGRESSION OF CORONARY ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE AS PART OF A TREATENT STRATEGY TO LOWER TOTAL AND LDL CHOLESTEROL TO TARGET LEVELS

I-211 FOR USE IN THE PEDIATRIC POPULATION

I-212 TREATMENT OF SYMPTOMS OF DRY MOUTH IN PATIENTS WITH SJOGREN'S SYNDROME

I-213 TEMPORARY RELIEF OF PAIN AND PHOTOPHOBIA IN PATIENTS UNDERGOING CORNEAL REFRACTIVE SURGERY

I-214 TREATMENT OF OSTEOPOROSIS

I-215 PRE-PROCEDURAL APPLICATION TO ADULT MALE GENITAL SKIN PRIOR TO SITE-SPECIFIC SUBCUTANEOUS INFILTRATION WITH LIDOCAINE FOR THE REMOVAL OF GENITAL WARTS

FDA data supplied by DrugPatentWatch.com

PATENT AND EXCLUSIVITY TERMS

REFERENCES

NEW INDICATION

I-216 FOR THE LONG-TERM TWICE-DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD, INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA

I-217 PREVENTION (DURING AND FOLLOWING HOSPITALIZATION) OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING HIP REPLACEMENT SURGERY

I-218 USE OF LIPITOR AS AN ADJUNCTIVE THERAPY TO DIET FOR THE TREATMENT OF PATIENTS WITH ELEVATED SERUM TRIGLYCERIDE LEVELS (FREDERICKSON TYPE IV)

I-219 USE OF LIPITOR BY PATIENTS WITH PRIMARY DYSBETALIPOPROTEINEMIA (FREDERICKSON TYPE III) WHO DO NOT RESPOND ADEQUATELY TO DIET

I-220 TREATMENT OF EPISODIC HEARTBURN, ACID INDIGESTION AND SOUR STOMACH

I-221 TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH) IN MEN WITH AN ENLARGED PROSTATE TO IMPROVE SYMPTOMS, REDUCE THE RISK OF ACUTE URINARY RETENTION AND REDUCE THE RISK OF THE NEED OF SURGERY

I-222 PREVENTION OF ISCHEMIC COMPLICATIONS OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCTION, WHEN CONCURRENTLY ADMINISTERED WITH ASPIRIN

I-223 USE IN THE SYMPTOMATIC RELIEF OF RHINORRHEA ASSOICATED WITH ALLERGIC AND NONALLERGIC PERENNIAL RHINITIS IN CHILDREN AGE 6-11 YEARS

I-224 FOR THE USE IN PEDIATRIC PATIENTS 4 TO 11 YEARS OF AGE FOR THE MANAGEMENT OF THE NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS

I-225 USE IN PATIENTS WITH PREVIOUS MI AND NORMAL CHOLESTEROL LEVELS, TO REDUCE RISK OF RECURRENT MI, MYOCARDIAL REVASCULARIZATION, AND CEREBROVASCULAR DISEASE EVENTS

I-226 FIRST-LINE THERAPY FOR THE TREATMENT OF ADVANCED CARCINOMA OF THE OVARY IN COMBINATION WITH CISPLATIN

I-227 SHORT-TERM TREATMENT OF SYMPTOMATIC GASTROESOPHAGEAL REFLUX DISEASE (GERD)

I-228 PREVENTION OF MEAL INDUCED HEARTBURN AT A DOSE OF 75MG TAKEN 30-60 MIN PRIOR TO A MEAL

I-229 PRILOSEC (OMEPRAZOLE), AMOXICILLIN AND CLARITHROMYCIN FOR THE ERADICATION OF H. PYLORI IN PATIENTS WITH DUODENAL ULCER DISEASE

I-230 IN COMBINATION WITH CISPLATIN, FOR THE FIRST-LINE TREATMENT OF NON-SMALL CELL LUNG CANCER IN PATIENTS WHO ARE NOT CANDIDATES FOR POTENTIALLY CURATIVE SURGERY AND/OR RADIATION

I-231 TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR CHEMOTHERAPY

I-232 TREATMENT OF RECURRENT MUCOCUTANEOUS HERPES SIMPLEX INFECTIONS IN HIV-AFFECTED PATIENTS AT A DOSE OF 500MG TWICE DAILY

I-233 PROPHYLACTIC USE TO REDUCE PERIOPERATIVE BLOOD LOSS AND THE NEED FOR BLOOD TRANSFUSION IN PATIENTS UNDERGOING CARDIOPULMONARY BYPASS IN THE COURSE OF CORONARY ARTERY BYPASS GRAFT SURGERY

I-234 FOR USE IN COMBINATION WITH CISPLATIN FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH INOPERABLE LOCALLY ADVANCED (STAGE IIIA OR IIIB) OR METASTATIC (STAGE IV) NON-SMALL CELL LUNG CANCER

I-235 PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN PATIENTS 12 YEARS OF AGE AND OLDER

I-236 PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER

I-237 MAINTENANCE TREATMENT OF ASTHMA AND PREVENTION OF BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER

I-238 ADJUNCTIVE TREATMENT OF LENNOX-GASTAUT SYNDROME IN PEDIATRIC AND ADULT PATIENTS

I-239 TREATMENT OF PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA

I-240 MANAGEMENT OF SECONDARY HYPERPARATHYROIDISM AND RESULTANT METABOLIC BONE DISEASE IN PATIENTS WITH MODERATE TO SEVERE CHRONIC RENAL FAILURE (Ccr 15 TO 55ML MIN) NOT YET ON DIALYSIS

I-241 USE IN PHOTODYNAMIC THERAPY (PDT) FOR REDUCTION OF OBSTRUCTION AND PALLIATION OF SYMPTOMS IN PATIENTS WITH COMPLETELY OR PARTIALLY OBSTRUCTING ENDOBRONCHIAL NONSMALL CELL LUNG CANCER

I-242 TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH THE MENOPAUSE AND IN THE TREATMENT OF VULVAR AND VAGINAL ATROPHY IN WOMEN WITH AN INTACT UTERUS

I-243 USE IN THE SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH THE COMMON COLD IN CHILDREN AGE 5 TO 11 YEARS

I-244 REDUCE THE INCIDENCE OF BREAST CANCER IN WOMEN AT HIGH RISK FOR BREAST CANCER

I-245 TREATMENT OF ACUTE SINUSITIS

I-246 TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTIONS

I-247 USE IN CONVERSION TO MONOTHERAPY IN ADULTS WITH PARTIAL SEIZURES WHO ARE RECEIVING TREATMENT WITH A SINGLE ENZYME-INDUCING ANTIEPILEPTIC DRUG

FDA data supplied by DrugPatentWatch.com

PATENT AND EXCLUSIVITY TERMS

REFERENCES

NEW INDICATION

I-248 INPATIENT TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITH/WITHOUT PULMONARY EMBOLISM WHEN ADMIN IN CONJUNCTION WITH WARFARIN SODIUM AND OUTPATIENT TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITHOUT PULMONARY EMBOLISM WHEN ADMINISTERED IN CONJUNCITON WITH WARFARIN SODIUM

I-249 TREATMENT OF CHRONIC HEPATITIS C IN PATIENTS WITH COMPENSATED LIVER DISEASE PREVIOUSLY UNTREATED WITH ALPHA INTERFERON THERAPY

I-250 PRIMARY PREVENTION OF CORONARY HEART DISEASE IN PATIENTS WITHOUT SYMPTOMATIC CARDIOVASCULAR DISEASE WHO HAVE AVERAGE TO MODERATELY ELEVATED TOTAL-C AND LDL-C AND BELOW AVERAGE HDL-C

I-251 TREATMENT OF GENERALIZED ANXIETY DISORDER

I-252 NEW COMBINATION USE OF PRECOSE FOR PATIENTS WITH TYPE 2 DIABETES TREATED WITH DIET PLUS METFORMIN

I-253 COMBINATION USE OF PRECOSE FOR PATIENTS WITH TYPE 2 DIABETES TREATED WITH DIET PLUS INSULIN

I-254 PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS (LOSS OF BONE MASS)

I-255 PREVENTION OF PNEUMOCYSTIS CARINII PNEUMONIA (PCP)

I-256 USE IN TREATMENT OF SMALL CELL LUNG CANCER SENSITIVE DISEASE AFTER FAILURE OF FIRST-LINE CHEMOTHERAPY

I-257 TREATMENT OF CHRONIC HEPATITIS B ASSOCIATED WITH EVIDENCE OF HEPATITIS B VIRAL REPLICATION AND ACTIVE LIVER INFLAMMATION

I-258 FOR PERENNIAL NONALLERGIC RHINITIS FOR AGES FOUR AND ABOVE

I-259 PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT), WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING HIP REPLACEMENT SURGERY

I-260 EXPANDED PEDIATRIC USE IN CHILDREN YOUNGER THAN ONE MONTH OF AGE TO BIRTH (WITH A GESTATIONAL AGE OF 37 WEEKS OR GREATER)

I-261 TREATMENT OF SOCIAL ANXIETY DISORDER

I-262 TREATMENT OR PREVENTION OF BRONCHOSPASM WITH REVERSIBLE OBSTRUCTIVE AIRWAY DISEASE AND FOR THE PREVENTION OF EXERCISE INDUCED BRONCHOSPASM IN CHILDREN AGES 4-12

I-263 TREATMENT OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCTION FOR THE PREVENTION OF ISCHEMIC COMPLICATIONS IN PATIENTS ON CONCURRENT ASPIRIN THERAPY

I-264 PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH RADIATION, INCLUDING TOTAL BODY IRRADIATION (TBI) AND FRACTIONATED ABDOMINAL RADIATION

I-265 TREATMENT OF ATOPIC DERMATITIS IN PEDIATRIC PATIENTS 6 YEARS AND OLDER

I-266 USE OF TOPAMAX AS ADJUNCTIVE THERAPY IN PEDIATRIC PATIENTS AGES 2-16 YEARS WITH PARTIAL ONSET SEIZURES

I-267 USE IN PEDIATRIC PATIENTS 3 MONTHS OLD AND OLDER-FOR CORTICOSTEROID-RESPONSIVE DERMATOSES

I-268 PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA IN PATIENTS 7-11 YEARS OF AGE

I-269 PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH HIGHLY EMETOGENIC CANCER CHEMOTHERAPY, INCLUDING CISPLATIN

I-270 ADJUVANT TREATMENT OF NODE-POSITIVE BREAST CANCER ADMINISTERED SEQUENTIALLY TO STANDARD DOXORUBICIN-CONTAINING COMBINATION CHEMOTHERAPY

I-271 TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN

I-272 TREATMENT OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS IN MEN AND WOMEN RECEIVING GLUCOCORTICOIDS IN A DAILY DOSE EQUIVALENT TO 7.5MG OR GREATER OF PREDNISONE AND WHO HAVE LOW BONE MINERAL DENSITY

I-273 ADJUNCT TO DIET TO INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (HETEROZYGOUS FAMILIAL AND NONFAMILIAL) AND MIXED DYSLIPIDEMIA (FREDERICKSON TYPES IIA AND IIB)

I-274 USE OF TOPAMAX AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES

I-275 USE IN COMBINATION WITH METFORMIN AND SULFONYLUREAS IN PATIENTS WITH TYPE 2 DIABETES

I-276 USE OF REZULIN IN COMBINATION WITH METFORMIN AND SULFONYLUREAS IN PATIENTS WITH TYPE 2 DIABETES

I-277 TREATMENT OF TYPE III HYPERLIPOPROTEINEMIA

I-278 TREATMENT OF PATIENTS WITH ISOLATED HYPERTRIGLYCERIDEMIA (FREDERICKSON TYPE IV)

I-279 TREATMENT OF POST-TRAUMATIC STRESS DISORDER

I-280 USE OF CARNITOR INJECTION FOR THE PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS

I-281 INCREASING HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (HETEROZYGOUS FAMILIAL AND NON-FAMILIAL) AND MIXED DYSLIPIDEMIA (FREDERICKSON TYPES IIa and IIb)

FDA data supplied by DrugPatentWatch.com

PATENT AND EXCLUSIVITY TERMS

REFERENCES

NEW INDICATION

I-282 TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER AFTER FAILURE OF PRIOR PLATINUM-BASED CHEMOTHERAPY

I-283 TO REDUCE THE INCIDENCE OF MODERATE TO SEVERE XEROSTOMIA IN PATIENTS UNDERGOING POST-OPERATIVE RADIATION TREATMENT FOR HEAD AND NECK CANCER, WHERE THE RADIATION PORT INCLUDES A SUBSTANTIAL PORTION OF THE PAROTID GLANDS

I-284 TO REDUCE THE NUMBER OF ADENOMATOUS COLORECTAL POLYPS IN FAMILIAL ADENOMATOUS POLYPOSIS PATIENTS AS AN ADJUNCT TO USUAL CARE

I-285 TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL RHINITIS IN ADULTS AND CHILDREN 3 YEARS OF AGE AND OLDER

I-286 TREATMENT OF PATIENTS WITH FREDERICKSON TYPE III

I-287 USE OF PRAVASTATIN IN PATIENTS WITH EVIDENT CORONARY HEART DISEASE TO REDUCE THE RISK OF TOTAL MORTALITY BY REDUCING CORONARY DEATH

I-288 CHANGES SEVERAL SECTIONS OF THE PACKAGE INSERT TO INCORPORATE STATEMENTS CONCERNING THE USE OF HIGH DOSES OF LISINOPRIL TO REDUCE THE RISK OF THE COMBINED OUTCOMES OF MORTALITY AND HOSPITALIZATION IN PATIENTS WITH CONGESTIVE HEART FAILURE

I-289 USE OF AVANDIA IN COMBINATION WITH A SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES MELLLITUS WHEN DIET AND EXERCISE WITH EITHER SINGLE AGENT DOES NOT ACHIEVE ADEQUATE GLYCEMIC CONTROL

I-290 TREATMENT OF CORTICOSTEOID-INDUCED OSTEOPOROSIS

I-291 PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS

I-292 TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS

I-293 TREATMENT OF CORTICOSTEROID-INDUCED OSTEOPOROSIS

I-294 TREATMENT OF UNCOMPLICATED ACUTE ILLNESS DUE TO INFLUENZA A AND B IN PEDIATRIC PATIENTS 7 YEARS AND OLDER WHO HAVE BEEN SYMPTOMATIC FOR NO MORE THAN 2 DAYS

I-295 PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS FOR WOMEN WITH AN INTACT UTERUS

I-296 LONG-TERM INTRAVENOUS TREATMENT OF PULMONARY HYPERTENSION ASSOCIATED WITH THE SCLERODERMA SPECTRUM OF DISEASE IN NYHA CLASS III AND CLASS IV PATIENTS WHO DO NOT RESPOND TO CONVENTIONAL THERAPY

I-297 SHORT-TERM TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDER

I-298 TREATMENT OF PATIENTS WITH FREDERICKSON TYPE IIA AND IIB HYPERLIPOPROTEINEMIA

I-299 USE OF CAMPTOSAR AS A COMPONENT OF FIRST-LINE THERAPY IN COMBINATION WITH 5-FLUROURACIL AND LEUCOVARIN FOR PATIENTS WITH METASTATIC CARCINOMA OF THE COLON OR RECTUM

I-300 PROPHYLAXIS FOR ASTHMA IN CHILDREN 2-5 YEARS OF AGE

I-301 TREATMENT OF SIGNS AND SYMPTOMS OF ALLERGIC CONJUNCTIVITIS

I-302 TREATMENT OF PEDIATRIC PATIENTS WITH PRADER-WILLI SYNDROME

I-303 INCREASING HDL-CHOLESTEROL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA AND MIXED DYSLIPIDEMIAS

I-304 TREATMENT OF PATIENTS WITH FREDERICKSON TYPE IV

I-305 TREATMENT OF LEVOFLOXACIN SUSCEPTIBLE STRAINS OF PENICILLIN-RESISTANT STREPTOCOCCUS PNEUMONIAE IN PATIENTS WITH COMMUNITY ACQUIRED PNEUMONIA

I-306 INDUCTION OF SPERMATOGENESIS IN MEN WITH PRIMARY AND SECONDARY HYPOGONADOTROPIC HYPOGONADISM IN WHOM THE CAUSE OF INFERTILITY IS NOT DUE TO PRIMARY TESTICULAR FAILURE

I-307 NEW COMBINATION USE OF METFORMIN AND INSULIN IN TYPE 2 DIABETES

I-308 TREATMENT OF PEDIATRIC PATIENTS WITH POLYARTICULAR COURSE JUVENILE RHEUMOTOID ARTHRITIS WHO RESPONDED INADEQUATELY TO SALICYLATES OR OTHER NSAIDS

I-309 INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS

I-310 REDUCTION IN RISK OF MYOCARDIAL INFARCTION, STROKE, AND DEATH FROM CARDIOVASCULAR CAUSES

I-311 ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL SEIZURES IN PEDIATRIC PATIENTS AGE 3 TO 12 YEARS.

I-312 FIRST LINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE OR HORMONE RECEPTOR UNKNOWN LOCALLY ADVANCED OR METASTATIC BREAST CANCER

I-313 EXTENSION OF INDICATION TO PROVIDE FOR MAINTENANCE OF RESPONSE

I-314 TOPICAL ANESTHETIC FOR SUPERFICIAL MINOR SURGERY OF GENITAL MUCOUS MEMBRANES AND AS AN ADJUNCT FOR LOCAL INFILTRATION ANESTHESIA IN GENITAL MUCOUS MEMBRANES

I-315 THROMBOPROPHYLAXIS OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN MEDICAL PATIENTS WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS DUE TO SEVERELY RESTRICTED MOBILITY DURING ACUTE ILLNESS

I-316 TREATMENT OF NSAID-ASSOCIATED GASTRIC ULCER PATIENTS WHO CONTINUE NSAID USE AND REDUCING RISK OF NSAID-ASSOCIATED GASTRIC ULCERS IN PATIENTS WITH HISTORY OF DOCUMENTED GASTRIC ULCER WHO REQUIRE USE OF AN NSAID

FDA data supplied by DrugPatentWatch.com

PATENT AND EXCLUSIVITY TERMS

REFERENCES

NEW INDICATION

I-317	PROPHYLAXIS OF INFLUENZA IN ADULTS AND ADOLESCENTS 13 YEARS AND OLDER
I-318	FIRSTLINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE OR HORMONE RECEPTOR UNKNOWN LOCALLY ADVANCED OR METASTATIC BREAST CANCER
I-319	USE FOR SUSPECTED OR CONFIRMED METHANOL POISONING, EITHER ALONE OR IN COMBINATION WITH HEMODIALYSIS
I-320	TREATMENT OF TYPE 2 DIABETES IN PEDIATRIC PATIENTS (AGES 10-16 YEARS)
I-321	JUVENILE RHEUMATOID ARTHRITIS
I-322	USE OF DIPRIVAN IN PATIENTS 3 MONTHS TO 16 YEARS
I-323	COLORECTAL CANCER
I-324	REDUCING NEUROLOGIC DISABILITY AND/OR FREQUENCY OF CLINICAL RELAPSES IN PATIENTS WITH SECONDARY (CHRONIC) PROGRESSIVE, PROGRESSIVE RELAPSING, OR WORSENING RELAPSING-REMITTING MULTIPLE SCLEROSIS
I-325	PREVENTION OF RELAPSE AND RECURRENCE OF DEPRESSION
I-326	GENERALIZED ANXIETY DISORDER
I-327	SYMPTOMATIC RELIEF OF RHINOORRHEA ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN PATIENTS 5 YEARS AND OLDER
I-328	PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA IN PATIENTS 5-6 YEARS OF AGE
I-329	UNCOMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS
I-330	MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS AND CONTROL OF DAYTIME AND NIGHTTIME HEARTBURN SYSTOMS IN PATIENTS WITH GERD
I-331	TREATMENT OF MODERATE ACNE VULGARIS
I-332	EMPIRIC THERAPY IN FEBRILE NEUTROPENIC PATIENTS WITH SUSPECTED FUNGAL INFECTIONS (ETFN)
I-333	TOPICAL TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR DUE TO MALASSEZIA FURFUR (FORMERLY PITYROSPORUM ORBICULARE)
I-334	LONG-TERM TREATMENT OF GROWTH FAILURE IN CHILDREN BORN SMALL FOR GESTATIONAL AGE WHO FAIL TO MANIFEST CATCH-UP GROWTH BY TWO YEARS OF AGE
I-335	ADJUNCTIVE THERAPY IN PATIENTS TWO YEARS AND OLDER WITH SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME
I-336	EXPANSION OF INDICATION TO INCLUDE THE TREATMENT OF PATIENTS WITH PREDOMINATELY CLASSIC SUBFOVEAL CHOROIDAL NEOVASCULARIZATION DUE TO PATHOLOGIC MYOPIA OR PRESUMED OCULAR HISTOPLASMOSIS
I-337	PATHOLOGICAL HYPERSECRETION ASSOCIATED WITH ZOLLINGER-ELLISON SNYDROME
I-338	MANAGEMENT OF ACUTE PAIN IN ADULTS AND TREATMENT OF PRIMARY DYSMENORRHEA
I-339	TREATMENT OF HEPATITIS B IN PEDIATRIC PATIENTS AGES 2-17 YEARS
I-340	ATOPIC DERMATITIS IN PEDIATRIC PATIENTS AGES 2-5
I-341	BREAST CANCER COMBINATION THERAPY
I-342	USE OF FORADIL FOR LONG-TERM, TWICE DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHO-CONSTRICTION IN PATIENTS WITH COPD INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
I-343	USE OF COREG FOR SEVERE HEART FAILURE
I-344	ACNE VULGARIS
I-345	TREATMENT OF POSTTRAUMATIC STRESS DISORDER
I-346	TREATMENT OF SYMPTOMATIC GASTRO ESOPHAGEAL REFLUX DISEASE (GERD)
I-347	TREATMENT OR PREVENTION OF BRONCHOSPASM IN CHILDREN 6 YEARS OF AGE AND OLDER WITH OBSTRUCTIVE AIRWAY DISEASE

MISCELLANEOUS EXCLUSIVITY CODES

M-1	INFORMATION REGARDING SUPERIORITY CLAIM OVER RANITIDINE FOR DAY AND NIGHT HEARTBURN ADDED TO CLINICAL STUDIES SECTION
M-2	APPROVAL FOR ADDTION TO CLINICAL PHARMACOLOGY SECTION OF THE LABEL REGARDING (1) IMPROVEMENT IN BONE MINERAL DENSITY IN CHILDHOOD-ONSET ADULT GROWTH HORMONE DEFICIENT PATIENTS AND (2) INCREASES IN SERUM ALKALINE PHOSPHATASE

FDA data supplied by DrugPatentWatch.com

PATENT AND EXCLUSIVITY TERMS

REFERENCES

MISCELLANEOUS EXCLUSIVITY CODES

M-3	ADDITION OF EFFICACY AND SAFETY INFORMATION IN WHICH FOSAMAX WAS USED CONCOMITANTLY WITH ESTROGEN ALONE OR WITH ESTROGEN PLUS PROGESTIN
M-4	CHANGES TO PEDIATRIC USE SECTION TO PROVIDE INFORMATION REGARDING SAFETY AND EFFICACY IN PEDIATRIC PATIENTS AS YOUNG AS 2 YEARS OLD
M-5	INFORMATION REGARDING EFFECTS IN PATIENTS WITH ASTHMA ON CONCOMITANT INHALED CORTICOSTEROIDS IN CLINICAL PHARMACOLOGY SECTION
M-6	ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES DONE WITH GLUCOPHAGE/GLYBURIDE COMBINATION ADDED TO CLIN PHARM AND DOSING AND ADMIN
M-7	CLINICAL PHARMACOLOGY IN PEDIATRIC PATIENTS; DOSAGE AND ADMINISTRATION INFORMATION
M-8	ADDITIONAL INFORMATION FOR THE USE OF SONATA CAPSULES FOR UP TO 5 WEEKS (35 NIGHTS) OF TREATMENT IN A CONTROLLED TRIAL SETTING
M-9	ADDITION TO THE CLINICAL STUDIES SECTION OF THE LABELING OF TEXT AND TWO TABLES CONTAINING INFORMATION FOR THE PRESCRIBING PHYSICIAN ON BLOOD PRESSURE, HEART RATE, AND HEART RATE VARIABILITY
M-10	INFORMATION REGARDING MAINTENANCE OF AN ANTIDEPRESSANT EFFECT UP TO 1 YEAR OF DOSING
M-11	USE FOR LONG-TERM TREATMENT OF POSTTRAUMATIC STRESS DISORDER
M-12	NEW LANGUAGE FOR PEDIATRIC USE
M-13	INFORMATION FROM PEDIATRIC STUDIES ADDED TO CLINICAL PHARMACOLOGY, PRECAUTIONS, AND DOSAGE AND ADMINISTRATION
M-14	ADDITIONAL CLINICAL TRIAL INFORMATION ADDED TO PEDIATRIC USE SUBSECTION

REFERENCES

PATENT USE CODE

U-1	PREVENTION OF PREGNANCY
U-2	TREATMENT OR PROPHYLAXIS OF ANGINA PECTORIS AND ARRHYTHMIA
U-3	TREATMENT OF HYPERTENSION
U-4	PROVIDING PREVENTION AND TREATMENT OF EMESIS AND NAUSEA IN MAMMALS
U-5	METHOD OF PRODUCING BRONCHODILATION
U-6	METHOD OF PRODUCING SYMPATHOMIMETIC EFFECTS
U-7	INCREASING CARDIAC CONTRACTILITY
U-8	ACUTE MYOCARDIAL INFARCTION
U-9	CONTROL OF EMESIS ASSOCIATED WITH ANY CANCER CHEMOTHERAPY AGENT
U-10	DIAGNOSTIC METHOD FOR DISTINGUISHING BETWEEN HYPOTHALAMIC MALFUNCTIONS OR LESIONS IN HUMANS
U-11	TREATMENT OR PROPHYLAXIS OF CARDIAC DISORDERS
U-12	METHOD OF TREATING [A] HUMAN SUFFERING FROM DEPRESSION
U-13	A METHOD FOR TREATING ANXIETY IN A HUMAN SUBJECT IN NEED OF SUCH TREATMENT
U-14	ADJUNCTIVE THERAPY FOR THE PREVENTION AND TREATMENT OF HYPERAMMONEMIA IN THE CHRONIC MANAGEMENT OF PATIENTS WITH UREA CYCLE ENZYMOPATHIES
U-15	METHOD OF LOWERING INTRAOCULAR PRESSURE
U-16	USE IN LUNG SCANNING PROCEDURES
U-17	TREATMENT OF VENTRICULAR AND SUPRAVENTRICULAR ARRHYTHMIAS
U-18	METHOD FOR INHIBITING GASTRIC SECRETION IN MAMMALS
U-19	TREATMENT OF INFLAMMATION
U-20	A PROCESS FOR TREATING A PATIENT SUFFERING FROM PARKINSON'S SYNDROME AND IN NEED OF TREATMENT
U-21	TREATMENT OF HUMANS SUFFERING UNDESIRED UROTOXIC SIDE EFFECTS CAUSED BY CYTOSTATICALLY ACTIVE ALKYLATING AGENTS

FDA data supplied by DrugPatentWatch.com

PATENT AND EXCLUSIVITY TERMS

REFERENCES

PATENT USE CODE

U-22	METHOD OF COMBATTING PATHOLOGICALLY REDUCED CEREBRAL FUNCTIONS AND PERFORMANCE WEAKNESSES, CEREBRAL INSUFFICIENCY AND DISORDERS IN CEREBRAL CIRCULATION AND METABOLISM IN WARM-BLOODED ANIMALS
U-23	METHOD FOR TREATING PROSTATIC CARCINOMA COMPRISING ADMINISTERING FLUTAMIDE
U-24	METHOD FOR TREATING PROSTATE ADENOCARCINOMA COMPRISING ADMINISTERING AN ANTIANDROGEN INCLUDING FLUTAMIDE AND AN LHRH AGONIST
U-25	REDUCING CHOLESTEROL IN CHOLELITHIASIS PATIENTS
U-26	REDUCING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF
U-27	DISSOLVING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF
U-28	CEREBRAL, CORONARY, PERIPHERAL, VISCERAL AND RENAL ARTERIOGRAPHY, AORTOGRAPHY AND LEFT VENTRICULOGRAPHY
U-29	CT IMAGING OF THE HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY
U-30	CEREBRAL ANGIOGRAPHY, AND VENOGRAPHY
U-31	INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY
U-32	PALLIATIVE TREATMENT OF PATIENTS WITH OVARIAN CARCINOMA RECURRENT AFTER PRIOR CHEMOTHERAPY, INCLUDING PATIENTS WHO HAVE BEEN PREVIOUSLY TREATED WITH CISPLATIN
U-33	TREATING VIRAL INFECTIONS IN A MAMMAL
U-34	TREATING VIRAL INFECTIONS IN A WARM-BLOODED ANIMAL
U-35	TREATING CYTOMEGALOVIRUS IN A HUMAN WITH AN INJECTABLE COMPOSITION
U-36	METHODS OF TREATING BACTERIAL ILLNESSES
U-37	METHOD OF TREATING GASTROINTESTINAL DISEASE
U-38	TREATMENT OF PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA
U-39	ANGINA PECTORIS
U-40	METHOD OF TREATMENT OF BURNS
U-41	METHOD OF TREATING CARDIAC ARRHYTHMIAS
U-42	ADJUVANT TREATMENT IN COMBINATION WITH FLUOROURACIL AFTER SURGICAL RESECTION IN PATIENTS WITH DUKES' STAGE C COLON CANCER
U-43	MANAGEMENT OF CHRONIC PAIN IN PATIENTS REQUIRING OPIOID ANALGESIA
U-44	RELIEF OF NAUSEA AND VOMITING
U-45	TREATMENT OF INFLAMMATION AND ANALGESIA
U-46	TREATMENT OF PANIC DISORDER
U-47	STIMULATION OF THE RELEASE OF GROWTH HORMONE
U-48	ANALGESIA
U-49	SYMPTOMATIC CANCER-RELATED HYPERCALCEMIA
U-50	USE IN TREATING INFLAMMATORY DERMATOSES
U-51	BLOOD POOL IMAGING, INCLUDING CARDIAC FIRST PASS AND GATED EQUILIBRIUM IMAGING AND FOR DETECTION OF SITES OF GASTROINTESTINAL BLEEDING
U-52	TREATMENT OF ADULT AND PEDIATRIC PATIENTS (OVER SIX MONTHS OF AGE) WITH ADVANCED HIV INFECTION
U-53	HYPERCALCEMIA OF MALIGNANCY
U-54	REVERSAL AGENT OR ANTAGONIST OF NONDEPOLARIZING NEUROMUSCULAR BLOCKING AGENTS
U-55	TREATMENT OF PAIN
U-56	AID TO SMOKING CESSATION
U-57	OPHTHALMIC USE OF NORFLOXACIN
U-58	METHOD OF TREATING INFLAMMATORY INTESTINAL DISEASES
U-59	METHOD OF TREATING HYPERCHOLESTEROLEMIA
U-60	NASAL ADMINISTRATION OF BUTORPHANOL
U-61	CEREBRAL AND PERIPHERAL ARTERIOGRAPHY AND CT IMAGING OF THE HEAD
U-62	CORONARY ARTERIOGRAPHY, LEFT VENTRICULOGRAPHY, CT IMAGING OF THE BODY, INTRAVENOUS EXCRETORY UROGRAPHY, INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY AND VENOGRAPHY
U-63	ISOPRENALINE ANTAGONISM ON THE HEART RATE OR BLOOD PRESSURE
U-64	TREATMENT OF VIRAL INFECTIONS
U-65	METHOD OF TREATMENT OF A PATIENT INFECTED WITH HIV
U-66	TRIPHASIC REGIMEN
U-67	METHOD OF INDUCING ANESTHESIA IN A WARM BLOODED ANIMAL
U-68	TREATMENT OF ACTINIC KERATOSIS
U-69	TREATMENT OF PNEUMOCYSTIS CARINII INFECTIONS
U-70	TREATMENT OF TRANSIENT INSOMNIA
U-71	METHOD OF TREATMENT OF HEART FAILURE

FDA data supplied by DrugPatentWatch.com

PATENT AND EXCLUSIVITY TERMS

REFERENCES

PATENT USE CODE

U-72	TREATMENT OF MIGRAINE
U-73	METHOD OF TREATING DISEASES OR INFECTIONS CAUSED BY MYCETES
U-74	METHOD OF PROVIDING HYPNOTIC EFFECT
U-75	RELIEF OF OCULAR ITCHING DUE TO SEASONAL ALLERGIC CONJUNCTIVITIS
U-76	USE TO IMAGE A SUBJECT WITH A MAGNETIC RESONANCE IMAGING SYSTEM
U-77	TREATMENT OF SYMPTOMS OF SEASONAL ALLERGIC RHINITIS
U-78	ULCERATIVE COLITIS
U-79	SYMPTOMATIC TREATMENT OF PATIENTS WITH NOCTURNAL HEARTBURN DUE TO GERD
U-80	METHOD OF TREATING OCULAR BACTERIAL INFECTIONS
U-81	RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS
U-82	TREATMENT FOR DEMENTIA IN PATIENTS WITH ALZHEIMER'S DISEASE
U-83	TREATMENT OF SEIZURES
U-84	A METHOD OF BLOCKING THE UPTAKE OF MONOAMINES BY BRAIN NEURONS IN ANIMALS
U-85	NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS
U-86	METHOD OF TREATING CERTAIN FORMS OF EPILEPSY
U-87	METHOD FOR NONINVASIVE ADMINISTRATION OF SEDATIVES, ANALGESICS, AND ANESTHETICS
U-88	TREATMENT OF MODERATE PLAQUE PSORIASIS
U-89	TREATMENT OR PROPHYLAXIS OF EMESIS
U-90	TREATMENT OF PSYCHOTIC DISORDERS
U-91	ALTERNATIVE THERAPY TO TRIMETHOPRIM-SULFAMETHOXAZOLE FOR TREATMENT OF MODERATE-TO-SEVERE PNEUMOCYSTIS CARINII PNEUMONIA IN IMMUNOCOMPROMISED AND AIDS PATIENTS
U-92	TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN DEPENDENT DIABETES MELLITUS AND RETINOPATHY
U-93	USE AS AN ANTIHISTAMINE/ DECONGESTANT
U-94	TREATMENT OF ADULTS WITH ADVANCED HIV INFECTION WHO ARE INTOLERANT OF APPROVED THERAPIES WITH PROVEN CLINICAL BENEFIT OR WHO HAVE EXPERIENCED SIGNIFICANT CLINICAL OR IMMUNOLOGIC DETERIORATION WHILE RECEIVING THESE THERAPIES OR FOR WHOM SUCH THERAPIES ARE CONTRAINDICATED
U-95	SHORT TERM MANAGEMENT OF MODERATE PRURITUS IN ADULTS WITH ATOPIC DERMATITIS AND LICHEN SIMPLEX CHRONICUS
U-96	METHOD OF TREATING VARICELLA ZOSTER (SHINGLES) INFECTIONS
U-97	A METHOD OF TREATING A PATIENT IN NEED OF MEMORY ENHANCEMENT
U-98	A METHOD OF INDUCING REGRESSION OF LEUKEMIA CELL GROWTH IN A MAMMAL
U-99	METHOD OF PROVIDING POTASSIUM TO A SUBJECT IN NEED OF POTASSIUM
U-100	METHOD OF TREATING OCULAR INFLAMMATION
U-101	ADJUNCT TO CONVENTIONAL CT OR MRI IMAGING IN THE LOCALIZATION OF STROKE IN PATIENTS IN WHOM STROKE HAS ALREADY BEEN DIAGNOSED
U-102	METHOD OF HORMONALLY TREATING MENOPAUSAL OR POST-MENOPAUSAL DISORDERS IN WOMEN
U-103	TREATMENT OF OCULAR HYPERTENSION
U-104	TREATMENT OF AQUEOUS HUMOR FORMATION AND INTRAOCULAR PRESSURE
U-105	EMESIS
U-106	TREATMENT OF EPILEPSY
U-107	TREATMENT OF HYPERTENSION AND ANGINA PECTORIS
U-108	SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER, GASTROESOPHAGEAL REFLUX DISEASE (GERD), SEVERE EROSIVE ESOPHAGITIS, POORLY RESPONSIVE SYMPTOMATIC GERD, PATHOLOGICAL HYPERSECRETORY CONDITIONS AND MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS
U-109	USE AS AN ADJUNCT TO DIET IN THE TREATMENT OF ELEVATED TOTAL CHOLESTEROL AND LDL-C LEVELS IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA WHOSE RESPONSE TO DIETARY RESTRICTION OF SATURATED FAT AND CHOLESTEROL AND OTHER NONPHARMACOLOGICAL MEASURES HAS NOT BEEN ADEQUATE
U-110	USE AS A RETRIEVABLE PESSARY
U-111	DIABETES
U-112	CONTRACEPTION
U-113	METHOD OF CONDUCTING A RADIOLOGICAL EXAMINATION OF A PATIENT BY ADMINISTERING TO SAID PATIENT A RADIOPAQUE AMOUNT OF IOPROMIDE
U-114	USE FOR INHIBITING BONE RESORPTION
U-115	USE OF VASODILATORS TO EFFECT AND ENHANCE AN ERECTION (AND THUS TREAT ERECTILE DYSFUNCTION), BY INJECTION INTO THE PENIS
U-116	METHOD OF MYOCARDIAL IMAGING
U-117	TREATMENT OF OCULAR ALLERGIC RESPONSE IN HUMAN EYES

FDA data supplied by DrugPatentWatch.com

PATENT AND EXCLUSIVITY TERMS

REFERENCES

PATENT USE CODE

U-118 METHOD OF LOWERING BLOOD SUGAR LEVEL
U-119 TREATMENT OF NASAL HYPERSECRETION
U-120 CONTROLLING OR PREVENTING POST-OPERATIVE INTRAOCULAR PRESSURE RISES ASSOCIATED WITH OPHTHALMIC LASER SURGICAL PROCEDURES
U-121 METHOD OF TREATING CONDITIONS MEDIATED THROUGH HISTAMINE H2-RECEPTORS
U-122 A THERAPEUTIC METHOD FOR CONTROLLING THROMBOSIS
U-123 METHOD FOR CONTROLLING THROMBOSIS AND DECREASING BLOOD HYPERCOAGULATION AND HEMORRHAGING RISKS
U-124 TREATMENT OF ACNE
U-125 TREATING NEUROGENERATIVE DISEASES
U-126 TREATMENT OF GASTRITIS
U-127 METHOD OF PRODUCING NEUROMUSCULAR BLOCKADE
U-128 METHODS FOR TREATMENT OF TUMORS
U-129 METHOD TO DESTROY OR IMPAIR TARGET CELLS
U-130 MANAGEMENT OF PATIENTS WITH MASTOCYTOSIS
U-131 PHOTODAMAGED SKIN
U-132 INHIBITING HIV PROTEASE
U-133 MANAGEMENT OF OBESITY INCLUDING WEIGHT LOSS AND MAINTENANCE IN PATIENTS ON A REDUCED-CALORIE DIET
U-134 TREATMENT OF ACNE VULGARIS
U-135 ANTITUMOR AGENT
U-136 PROCESS FOR WASTE NITROGEN REMOVAL
U-137 METHOD OF TREATING BACTERIAL VAGINOSIS
U-138 TREATMENT OF ALLERGIC RHINITIS
U-139 TREATMENT OF ALLERGIC REACTIONS
U-140 USE OF NORVIR TO INHIBIT HIV PROTEASE OR TO INHIBIT AN HIV INFECTION
U-141 TREATMENT OF ULCERATIVE COLITIS
U-142 METHOD OF TREATING ALLERGIC REACTIONS IN A MAMMAL BY USING THIS ACTIVE METABOLITE
U-143 BIODEGRADABLE SUPERPARAMAGNETIC METAL OXIDES AS CONTRAST AGENTS FOR MR IMAGING
U-144 BIOLOGICALLY DEGRADABLE SUPERPARAMAGNETIC MATERIALS FOR USE IN CLINICAL APPLICATIONS
U-145 BIOLOGICALLY DEGRADABLE SUPERPARAMAGNETIC PARTICLES FOR USE AS NUCLEAR MAGNETIC RESONANCE IMAGING AGENTS
U-146 METHOD OF TREATING SUSCEPTIBLE NEOPLASMS IN MAMMALS
U-147 DETECTION OF GASTROINTESTINAL DISORDERS AND THE SUBSEQUENT BREATH COLLECTION AND MEASUREMENT OF $^{13}CO_2$
U-148 DEVICE FOR COLLECTING A BREATH SAMPLE
U-149 METHOD OF TREATING AN ANIMAL, INCLUDING A HUMAN SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS, ACUTE MANIA OR MILD ANXIETY STATES
U-150 METHOD OF USE FOR CONTROLLING HYPERGLYCEMIA BY ADMINISTRATION OF THIS SUSTAINED RELEASE DOSAGE FORM OF GLIPIZIDE
U-151 RELIEF OF SYMPTOMS OF THE COMMON COLD
U-152 METHOD OF TREATING ANXIETY RELATED DISORDERS INCLUDING OBSESSIVE COMPULSIVE DISORDER
U-153 TREATMENT OF INITIAL EPISODE GENITAL HERPES
U-154 METHOD OF TREATING ANIMALS SUFFERING FROM AN APPETITE DISORDER
U-155 TREATMENT OF ERECTILE DYSFUNCTION
U-156 METHOD OF PROVIDING ANESTHESIA
U-157 TREATMENT OF A HUMAN SUFFERING FROM VITAMIN B12 DEFICIENCY
U-158 ANGINA
U-159 TREATMENT OF INTERSTITIAL CYSTITIS
U-160 TREATMENT OF BACTERIAL INFECTIOUS DISEASE
U-161 METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS IN A PATIENT
U-162 METHOD OF USE TO INHIBIT CHOLESTEROL SYNTHESIS IN A HUMAN SUFFERING FROM HYPERCHOLESTEROLEMIA
U-163 METHOD OF USING TROGLITAZONE TO TREAT IMPAIRED GLUCOSE TOLERANCE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS
U-164 METHOD OF USING TROGLITAZONE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS IN A DEFINED POPULATION OF PATIENTS
U-165 TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA
U-166 TREATMENT OF H. PYLORI ASSOCIATED DUODENAL ULCER
U-167 METHOD FOR TREATING HIV-1 INFECTION

FDA data supplied by DrugPatentWatch.com

PATENT AND EXCLUSIVITY TERMS

REFERENCES

PATENT USE CODE

U-168	METHOD OF INHIBITING LIPOXYGENASE ACTIVITY IN A MAMMAL WHICH IS THE MODE OF ACTION IN THE TREATMENT OF ASTHMA
U-169	METHODS OF USING THE COMPOUND/DRUG PRODUCT AS A CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING
U-170	METHOD OF OBTAINING AN MR IMAGE USING THE COMPOSITION/DRUG PRODUCT AS A CONTRAST AGENT
U-171	METHODS OF USING THE COMPOUND/DRUG PRODUCT AS AN ORAL CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING OF THE GASTROINTESTINAL TRACT
U-172	TREATMENT OF GENITAL WARTS
U-173	ADMINISTRATION TO A HOST SUFFERING FROM GESTATIONAL DIABETES
U-174	USE AS AN ANTIHISTAMINE AGENT
U-175	METHOD OF TREATING MALIGNANT TUMORS
U-176	METHOD OF TREATING A PATIENT SUFFERING FROM LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSIS
U-177	FUNGICIDE
U-178	FACILITATED ADHERENCE OF AGENTS TO SKIN
U-179	ENHANCED CUTANEOUS PENETRATION OF A DERMALLY-APPLIED PHARMACOLOGICALLY ACTIVE AGENT
U-180	TREATMENT OF ADULT AND PEDIATRIC PATIENTS (OVER SIX MONTHS OF AGE) WITH ADVANCED HIV INFECTION
U-181	PRODUCING ALPHA ADRENERGIC ANTAGONISTIC ACTION IN A HOST
U-182	USE OF SALMETEROL IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION
U-183	TREATMENT OF CONDITIONS CAUSED BY DISTURBANCE OF NEURONAL 5HT FUNCTION
U-184	TREATING ALLERGIC EYE DISEASES IN HUMANS
U-185	METHOD OF TREATING HYPERTENSION
U-186	METHOD FOR TREATING GI DISORDERS CAUSED BY H. PYLORI WHICH COMPRISES ADMINISTRATION OF RANITIDINE BISMUTH CITRATE AND CLARITHROMYCIN FOR A GREATER THAN ADDITIVE EFFECT
U-187	THERAPEUTIC TREATMENT OF CALCIFIC TUMORS
U-188	TREATMENT OF H. PYLORI ASSOCIATED DUODENAL ULCER
U-189	ENHANCEMENT OF THE BIOAVAILABILITY OF THE DRUG SUBSTANCE
U-190	USE OF RITONAVIR IN COMBINATION WITH ANY REVERSE TRANSCRIPTASE INHIBITOR
U-191	METHOD OF TREATMENT FOR CONTROLLING AND LOWERING INTRAOCULAR PRESSURE IN A HUMAN
U-192	USE IN TREATING ALLERGIC REACTIONS
U-193	PSORIASIS
U-194	TREATING AGINA PECTORIS AND HIGH BLOOD PRESSURE
U-195	METHOD FOR THE DIAGNOSIS OF GASTROINTESTINAL DISORDERS BY UREA ISOTOAC OR NITROGEN LABELED CARBON
U-196	TREATMENT OF METASTIC BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH ESTROGEN RECEPTOR POSITIVE TUMORS
U-197	USE IN COMBINATION WITH CERTAIN LHRH ANALOGUES FOR THE TREATMENT OF ADVANCED PROSTATE CANCER
U-198	TREATMENT METASTATIC CARCINOMA OF OVARY AFTER FIRST-LINE FAILURE OR SUBSEQUENT CHEMOTHERAPY, TREATMENT OF BREAST CANCER AFTER FAILURE OF COMBINATION CHEMOTHERAPY FOR METASTATIC DISEASE AND SECOND-LINE TREATMENT OF AIDS-RELATED KAPOSI'S SARCOMA
U-199	METHOD OF TREATING INFECTIOUS UPPER GI TRACT DISORDERS CAUSED BY CAMPYLOBACTER PYLORDIS INFECTION COMPRISING ADMINISTRATION OF A BISMUTH AGENT AND AN ANTIMICROBIAL AGENT
U-200	METHOD OF TREATING GI DISORDERS COMPRISING ADMINISTRATION OF A BISMUTH-CONTAINING AGENT AND H2 RECEPTOR BLOCKING ANTI-SECRETORY AGENT
U-201	METHOD OF TREATING GI DISORDERS COMPRISING ADMINISTRATION OF CAMPYLOBACTER-INHIBITING ANTIMICROBIAL AGENT AND H2 RECEPTOR BLOCKING ANTI-SECRETORY AGENT
U-202	METHOD OF TREATING PEPTIC ULCER DISEASE CAUSED BY CAMPYLOBACTER PYLORIDIS COMPRISING ORAL ADMINISTRATION OF 50 TO 5,000MG BISMUTH DAILY FOR 3-56 DAYS
U-203	TREATMENT OF ADVANCED BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH DISEASE PROGRESSION FOLLOWING ANTIESTROGEN THERAPY
U-204	USE OF TAXOL IN COMBINATION WITH G-CSF FOR TREATMENT OF PATIENTS WITH AIDS-RELATED KAPOSI'S SARCOMA
U-205	METHOD FOR TREATING HEARTBURN
U-206	METHOD OF USING FSH ALONE, WITHOUT THE PRESENCE OF EXOGENOUS LH, IN IN VITRO FERTILIZATION
U-207	USE AS NASAL SPRAY
U-208	VAGINAL ADMINISTRATION USING SPECIFIED FORMULATION
U-209	VAGINAL ADMINISTRATION OF PROGESTERONE USING SPECIFIED FORMULATION
U-210	METHOD OF TREATING CONGESTIVE HEART FAILURE
U-211	USE IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION

FDA data supplied by DrugPatentWatch.com

PATENT AND EXCLUSIVITY TERMS

REFERENCES

PATENT USE CODE

U-212	METHOD OF TREATMENT OF PARKINSON'S DISEASE
U-213	METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS AND TREATING HYPERCHOLESTEROLEMIA AND METHOD FOR TREATING HYPERLIPIDEMIA
U-214	USE AS A BLOOD GLUCOSE-LOWERING AGENT
U-215	TREATMENT OF EPILEPSY TWICE DAILY. TREATING A PATIENT BY ADMINISTERING CARBAMAZEPINE IN A DOSAGE FORM CAPABLE OF MAINTAINING BLOOD CONCENTRATION FROM 4-12MCG/ML OVER 12 HOURS
U-216	TREATMENT OF ADENOCARCINOMA, INCLUDING STAGE B2-C, BY ADMINISTERING AN AGONIST OF LR-RH AND FLUTAMIDE
U-217	METHOD OF PRODUCING ANESTHESIA
U-218	METHOD FOR LIMITING THE POTENTIAL FOR MICROBIAL GROWTH IN THE DRUG PRODUCT
U-219	TREATMENT OF PARKISON'S DISEASE
U-220	METHOD OF DIAGNOSIS
U-221	SELECTIVE VASODILATION BY CONTINUOUS ADENOSINE INFUSION
U-222	METHOD OF TREATING PAGET'S DISEASE USING ACTONEL
U-223	TREATMENT OF BACTERIAL CONJUNCTIVITIS CAUSED BY SUSCEPTIBLE STRAINS OF MICROORGANISMS
U-224	CONTROLLING INTRAOCULAR PRESSURE
U-225	METHOD FOR DELIVERY
U-226	METHOD OF ENHANCING THE DISSOLUTION PROFILE OF A PHARMACEUTICAL FROM A SOLID DOSAGE FORM CONTAINING THE PHARMACEUTICAL AND SIMETHICONE
U-227	NASAL ADMINISTRATION
U-228	ASTHMA
U-229	CARDIAC INSUFFICIENCY (CONGESTIVE HEART FAILURE)
U-230	PREVENTION OF ACUTE CARDIAC ISCHEMIC EVENTS
U-231	USE IN PARKINSON'S DISEASE
U-232	METHOD OF TREATING MIGRAINE
U-233	DECREASING MORTALITY CAUSED BY CONGESTIVE HEART FAILURE
U-234	METHOD OF USING RIBAVIRIN TO TREAT VIRAL INFECTIONS IN MAMMALS
U-235	METHOD OF MODULATING TH1 AND TH2 RESPONSE IN ACTIVATED T CELLS OF A HUMAN COMPRISING ADMINISTERING RIBAVIRIN TO THE T CELLS IN A DOSAGE WHICH PROMOTES THE TH1 RESPONSE AND SUPPRESSES THE TH2 RESPONSE
U-236	TREATING MALE PATTERN BALDNESS WITH 0.05 TO 3 MG/DAY
U-237	METHOD OF PERFORMING NMR IMAGING WITH A PATIENT COMPRISING ADMINISTERING TO THE PATIENT AN EFFECTIVE AMOUNT OF CONTRAST AGENT DISCLOSED IN THE CLAIMS
U-238	IMAGING A BODY TISSUE AND SUBJECTING TO NMR TOMOGRAPHY, ADMINISTERING AN AMOUNT OF PHARMACEUTICAL AGENT FOR AFFECTING THE RELAXATION TIMES OF ATOMS IN BODY TISSUES UNDERGOING NMR DIAGNOSIS, WHEREBY THE IMAGE CONTRAST IN ENHANCED....
U-239	TREATING OR CONTROLLING OCULAR INFLAMMATION WHICH COMPRISES TOPICALLY ADMINISTERING TO THE AFFECTED EYE A COMPOSITION COMPRISING AN NSAID, A POLYMERIC QUATERNARY AMMONIUM COMPOUND AND BORIC ACID
U-240	TREATMENT OF ACUTE MIGRAINE ATTACKS
U-241	FOR SHORT-TERM TREATMENT ACTIVE DUODENAL ULCER, MAINTENANCE THERAPY FOR DUODENAL ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING OF ACTIVE ULCER, SHORT- TERM TREATMENT ACTIVE BENIGN GASTRIC ULCER & GERD, PATHOLOGICAL HYPERSECRETORY CONDITIONS
U-242	USE OF FOLLITROPIN ALPHA ALONE IN IN-VITRO FERTILIZATION
U-243	TOPICAL ADMINISTRATION
U-244	PLATELET AGGREGATION INHIBITORS
U-245	TREATMENT OF SEBORRHEA DERMATITIS IN HUMANS
U-246	PHOSPHATE BINDING
U-247	TREATMENT OF RHEUMATOID ARTHRITIS
U-248	TREATMENT OF HIV
U-249	METHOD OF TREATING ALLERGIC OR NON-ALLERGIC RHINITIS IN PATIENTS BY ADMINISTERING AEROSOLIZED PARTICLES OF MOMETASONE FUROATE
U-250	TREATMENT OF HEPATITIS B INFECTION
U-251	USE OF TROGLITAZONE IN COMBINATION WITH SULFONYLUREAS IN THE TREATMENT OF TYPE II DIABETES
U-252	METHOD OF TREATING A HUMAN SUBJECT HAVING GAUCHER'S DISEASE
U-253	ORAL TRANSMUCOSAL USE
U-254	USE OF AGGRASTAT IN COMBINATION WITH HEPARIN
U-255	IMPROVED WAKEFULNESS IN PATIENTS WITH EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH NARCOLEPSY

FDA data supplied by DrugPatentWatch.com

PATENT AND EXCLUSIVITY TERMS

REFERENCES

PATENT USE CODE

U-256	TREATMENT OF HIV INFECITON IN COMBINATION WITH ONE OR MORE ADDITIONAL HIV ANTIVIRAL AGENTS
U-257	TREATMENT OF HIV INFECTION
U-258	TREATMENT OF NEURODEGENERATIVE DISEASES
U-259	TREATMENT OF ANDROGENIC ALOPECIA BY ORAL ADMINISTRATION OF DRUG SUBSTANCE
U-260	REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA AND OCULAR HYPERTENSION WHO ARE INTOLERANT OF OTHER IOP LOWERING MEDICATIONS OR INSUFFICIENTLY RESPONSIVE TO ANOTHER IOP LOWERING MEDICATION
U-261	TREATING BENIGN PROSTATIC HYPERPLASIA WITH A GENUS OF COMPOUNDS, INCLUDING FINASTERIDE
U-262	TREATING BENIGN PROSTATIC HYPERTROPHY WITH FINASTERIDE
U-263	METHOD OF TREATING A MALIGNANT CONDITION THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING LEUKEMIA OR LYMPHOMA IN A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVENOUS ADMINISTRATION OF BUSULFAN.
U-264	METHOD OF TREATING A MALIGNANT DISEASE THROUGH PARENTERAL ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN.
U-265	USE AS A LAXATIVE
U-266	RELIEF OF THE SIGNS AND SYMPTOMS OF OSTEOARTHRITIS; MANAGEMENT OF ACUTE PAIN IN ADULTS; TREATMENT OF PRIMARY DYSMENORRHEA
U-267	PREVENTING HEARTBURN EPISODES FOLLOWING INGESTION OF HEARTBURN-INDUCING FOOD/BEVERAGE, COMPRISING ADMIN TO PT, 30 MIN PRIOR TO CONSUMPTION BY THE PT THE FOOD/BEVERAGE, A COMPOSITION COMPRISING 10MG FAMOTIDINE
U-268	ACROMEGALY
U-269	EXCESS GH-SECRETION OR GASTRO-INTESTINAL DISORDERS
U-270	METHOD FOR IMPROVING THE TIME FOR ADMINISTRATION OR THE TIME BETWEEN CHANGES OF GIVING SETS FOR THE DRUG PRODUCT
U-271	METHOD OF TREATING TUMORS
U-272	METHOD OF TREATING CARCINOMA
U-273	CUTANEOUS T-CELL LYMPHOMA
U-274	ZANAMIVIR FOR INHALATION
U-275	METHOD OF USE OF THE DRUG SUBSTANCE
U-276	METHOD OF USE OF LEVOBUPIVACAINE
U-277	NEUROLOGICAL AND OTHER DISORDERS (TREATMENT OF EPILEPSY, BID ORAL DOSING)
U-278	METHOD OF USE OF THE INDICATION OF THE DRUG PRODUCT
U-279	METHOD OF USE OF THE APPROVED PRODUCT
U-280	TREATING PRECIPITATED ACUTE URINARY RETENTION WITH FINASTERIDE
U-281	ANTIMYCOTIC USES, SPECIFICALLY, TREATMENT OF ONYCHOMYCOSIS
U-282	METHOD OF TREATING BACTERIAL INFECTIONS
U-283	METHOD FOR TREATING MENOPAUSAL SYMPTOMS IN A POSTMENOPAUSAL FEMALE
U-284	MENOPAUSAL AND POSTMENOPAUSAL DISORDERS (INCLUDING VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE, AND VULVAR AND VAGINAL ATROPHY) AND OSTEOPOROSIS
U-285	DEPRESSION AND SOCIAL ANXIETY DISORDER/SOCIAL PHOBIA
U-286	DEPRESSION
U-287	TREATMENT OR PREVENTION OF OSTEOPOROSIS
U-288	THERAPY OF INFLUENZA
U-289	TREATMENT OF NON-HYPERKERATOTIC ACTINIC KERATOSES OF FACE AND SCALP
U-290	INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS)
U-291	INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH CYCLOSPORIN
U-292	INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH AZATHIOPRINE
U-293	INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH A CORTICOSTEROID
U-294	TREATMENT OF HYPERPIGMENTARY DISORDERS
U-295	TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS
U-296	TREATING MIGRAINE PAIN AND ONE OR MORE OF A CLUSTER OF SYMPTOMS CHARACTERISTIC OF A MIGRAINE ATTACK SYMPTOMS BEING SELECTED FROM PHOTOPHOBIA, PHONOPHOBIA, NAUSEA AND FUNCTIONAL DISABILITY
U-297	PREVENTION OR TREATMENT OF REVERSIBLE VASOCONSTRICTION BY THE INHALATION OF NITRIC OXIDE WITH AN OXYGEN CONTAINING GAS
U-298	METHOD OF COMBATING BACTERIA IN A PATIENT
U-299	TREATMENT OF ADENOMATOUS POLYPS

FDA data supplied by DrugPatentWatch.com

PATENT AND EXCLUSIVITY TERMS

REFERENCES

PATENT USE CODE

U-300	INDICATED FOR THE REDUCTION OF ELEVATED TOTAL AND LDL CHOLESTEROL LEVELS IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA
U-301	USE OF TROGLITAZONE IN COMBINATION WITH SULFONYLUREAS AND BIGUANIDES IN THE TREATMENT OF TYPE II DIABETES
U-302	TO REDUCE THE RISK OF STROKE IN PATIENTS WHO HAVE HAD TRANSIENT ISCHEMIA OF THE BRAIN OR COMPLETED ISCHEMIC STROKE DUE TO THROMBOSIS
U-303	METHOD OF USE PATENT-PRODUCT APPROVED FOR TREATMENT OF OSTEOPORISIS, PAGET'S DISEASE, PREVENTION AND TREATMENT OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS
U-304	A METHOD OF TREATMENT OF A CONDITION INVOLVING AN ANTIBODY ANTIGEN REACTION
U-305	METHODS FOR USING THE DRUG PRODUCT
U-306	TREATMENT OF POST-MENOPAUSAL UROGENITAL SYMPTOMS ASSOCIATED WITH ESTROGEN DEFICIENCY
U-307	CLAIMS AN OLANZAPINE POLYMORPH USEFUL FOR TREATING ANY NUMBER OF LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES, EMPLOYING OLANZAPINE AS PER THE INDICATION OF THIS NDA
U-308	CLAIMS A SOLID ORAL FORMULATION INCLUDING TABLETS AND GRANULES OF OLANZAPINE USEFUL FOR TREATING ANY NUMBER OF LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES, EMPLOYING OLANZAPINE AS PER THE INDICATION OF THIS NDA
U-309	TREATING SJOEGREN SYNDROME
U-310	TREATMENT OF XEROSTOMIA
U-311	HORMONE REPLACEMENT
U-312	PANIC DISORDER OBSESSIVE-COMPULSIVE DISORDER POSTTRAUMATIC STRESS DISORDER
U-313	TREATMENT OF CONGESTIVE HEART FAILURE
U-314	METHOD FOR TREATING HYPERPARATHYROIDISM WHICH COMPRISES SUPPRESSING PARATHYROID ACTIVITY
U-315	METHOD FOR ADMINISTERING DRUG TO GASTROINTESTINAL TRACT
U-316	METHOD OF TREATING A SUBJECT SUFFERING FROM PROSTATE CANCER
U-317	METHOD OF USING TROGLITAZONE TO TREAT PATIENTS HAVING INSULIN RESISTANCE
U-318	TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER WITH SYMPTOMS OF URINARY FREQUENCY, URGENCY, OR URGE INCONTINENCE
U-319	TREATMENT OF MICROBIAL INFECTIONS
U-320	INHIBITING OR ELIMINATING ACUTE MYELOID LEUKEMIA
U-321	REDUCTION OF ELEVATED IPTH LEVELS IN THE MGT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS UNDERGONG CHRONIC RENAL DIALYSIS
U-322	TREATMENT OF ALZHEIMER'S DEMENTIA
U-323	USE AS A BILE ACID SEQUESTRANT
U-324	METHOD OF TREATING AN ANIMAL, INCLUDING A HUMAN, SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS OR ACUTE MANIA EMPLOYING OLANZAPINE
U-325	METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED CONDITIONS, INCLUDING "BIPOLAR DISORDER NOS" EMPLOYING OLANZAPINE
U-326	METHOD OF TREATING SCHIZOPHRENIA AND BIPOLAR DISORDER
U-327	METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED PSYCHOTIC CONDITIONS EMPLOYING OLANZAPINE
U-328	METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED CONDITIONS INCLUDING "A PSYCHOTIC CONDITION" EMPLOYING AN OLANZAPINE POLYMORPH
U-329	USE OF AVANDIA AS MONOTHERAPY, IN COMBINATION WITH METFORMIN, AND IN COMBINATION WITH SULFONYLUREAS TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
U-330	TREATMENT OF NAUSEA AND VOMITING
U-331	METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
U-332	TREATMENT OR PREVENTION OF BRONCHOSPASM
U-333	METHOD OF TREATING OCULAR HYPERTENSION
U-334	TREATMENT OF EXCESSIVE FEMALE FACIAL HAIR
U-335	USE OF PRAVASTATIN SODIUM FOR SECONDARY PREVENTION OF CORONARY EVENTS IN MEN AND WOMEN WHO HAVE HAD A MYOCARDIAL INFARCTION AND HAVE NORMAL CHOLESTEROL LEVELS
U-336	DIAGNOSTIC RADIOIMAGING
U-337	USE OF CARDIOLITE/MIRALUMA KIT FOR THE PREPARATION OF TC99M SESTAMIBI
U-338	METHODS FOR TREATING DISTURBANCES OF MOOD, DISTURBANCES OF APPETITE, DEPRESSED MOOD, OR CARBOHYDRATE CRAVING ALL ASSOCIATED WITH PREMENSTRUAL SYNDROME
U-339	PREVENTION OF CARDIO-TOXICITY CAUSED BY THE ADMINISTRATION OF DOXORUBICIN
U-340	THE LONG TERM TREATMENT OF GROWTH FAILURE DUE TO LACK OF ADEQUATE ENDOGENOUS GROWTH HORMONE SECRETION IN CHILDREN

FDA data supplied by DrugPatentWatch.com

PATENT AND EXCLUSIVITY TERMS

REFERENCES

PATENT USE CODE

U-341	METHOD FOR ENHANCING THE TREATMENT OF ... LATE LUTEAL PHASE DYSPHORIC DISORDER
U-342	METHOD FOR TREATMENT OF LATE LUTEAL PHASE DYSPHORIC DISORDER
U-343	REDUCTION OF INTESTINAL GAS, CRAMPING AND ANORECTAL IRRITATION
U-344	METHOD FOR INHIBITING HIV INFECTION BY ADMINISTERING RITONAVIR IN COMBINATION WITH ANOTHER HIV PROTEASE INHIBITOR
U-345	RITONAVIR AND ANOTHER HIV PROTEASE INHIBITOR FOR CONCOMITANT ADMINISTRATION FOR THE TREATMENT OF AN HIV INFECTION
U-346	METHOD FOR INHIBITING CYTOCHROME P450 MONOOXYGENASE WITH RITONAVIR AND A METHOD FOR IMPROVING THE PHARMCOKINETICS OF A DRUG THAT IS METABOLIZED BY CYTOCHROME P450 MONOOXYGENASE BY ADMIN THE DRUG AND RITONAVIR
U-347	METHOD OF USE IN COMBINATION WITH REVERSE TRANSCRIPTASE INHIBITORS
U-348	METHOD OF USE FOR INHIBITING HIV INFECTION
U-349	METHOD OF USE WHICH IS SUBJECT OF THE APPLICATION
U-350	PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR CONCOMITANT ADMIN WITH A REVERSE TRANSCRIPTASE INHIBITOR
U-351	INHIBITING PROTEASE WITH LOPINAVIR AND INHIBITING AN HIV INFECTION WITH LOPINAVIR
U-352	INHIBITING HIV INFECTION BY ADMINISTERING RITONAVIR IN COMBINATION WITH A REVERSE TRANSCRIPTASE INHIBITOR
U-353	PREVENTION AND TREATMENT OF OSTEOPOROSIS
U-354	METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID WITHOUT CAUSING TREATMENT-LIMITING ELEVATIONS IN URIC ACID OR GLUCOSE LEVELS OR CAUSING LIVER DAMAGE, BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
U-355	METHOD OF ASSISTING PERSON TO QUIT SMOKING...TRANSDERMALLY ADMIN NICOTINE VIA..PATCH ADHERED TO SKIN AT DOSING RATE APPROX SAME AS ABSORBED FROM SMOKING
U-356	DELIVERING A MEDICINAL AEROSOL FORMULATION USING CFC-FREE PROPELLANT 134A.
U-357	USE OF THE DRUG PRODUCT IN PHOTODYNAMIC THERAPEUTIC PROTOCOLS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND RELATED CONDITIONS INVOLVING UNWANTED NEOVASCULATURE IN THE EYE
U-358	DEPRESSION, OBSESSIVE COMPULSIVE DISORDER, PANIC DISORDER AND SOCIAL ANXIETY DISORDER
U-359	METHOD OF USE OF VISICOL
U-360	METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF PATHOLOGICAL PSYCHOLOGICAL CONDITIONS INCLUDING MENTAL DISORDERS EMPLOYING OLANZAPINE AS PER THE INDICATION WHICH IS THE SUBJECT MATTER OF THIS SNDA-011
U-361	MANAGEMENT OF ANXIETY DISORDERS AND THE SHORT-TERM RELIEF OF THE SYMPTOMS OF ANXIETY
U-362	USE OF APPROVED FORMULATIONS TO TREAT ALL APPROVED DISEASE INDICATIONS
U-363	METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF PATHOLOGICAL PSYCHOLOGICAL CONDITIONS THAT RELATE TO THE USE OF A PSYCHOACTIVE SUBSTANCE EMPLOYING OLANZAPINE AS PER THE INDICATION WHICH IS THE SUBJECT MATER OF THIS SNDA-011
U-364	TREATING A PATIENT SUFFERING FROM OR SUSCEPTIBLE TO ANY NUMBER OF LISTED CONDITIONS INCLUDING PSYCHOSIS, EMPLOYING OLANZAPINE AS PER THE INDICATION WHICH IS THE SUBJECT MATTER OF THIS SNDA-011
U-365	METHOD FOR THE TREATMENT OF CARDIOVASCULAR DISEASE THROUGH THE ADMINISTRATION OF A CALCIUM BLOCKING VASODILATOR IN OUR EXTENDED, CONTROLLED RELEASE FORMULATION
U-366	METHOD FOR THE TREATMENT OF CARDIOVASCULAR DISEASE THROUGH THE ADMINISTRATION OF A CALCIUM BLOCKING VASODILATOR IN A DELAYED RELEASE FORMULATION
U-367	TREATMENT OF CARDIOVASCULAR DISORDERS
U-368	HEARTBURN
U-369	METHOD OF CONTROLLING AND LOWERING INTRAOCULAR PRESSURE
U-370	INTRAVAGINAL TREATMENT OF VAGINAL INFECTIONS WITH BUFFERED METRONIDAZOLE COMPOSITIONS
U-371	APPROVAL FOR MARKETING ONLY UNDER A SPECIAL RESTRICTION PROGRAM APPROVED BY FDA CALLED "SYSTEM FOR THALIDOMIDE EDUCATION AND PRESCRIBING SAFETY" (S.T.E.P.S.)
U-372	METHOD FOR ADMINISTERING A BENEFICIAL DRUG TO THE GI TRACT OF AN ANIMAL, WHICH METHOD COMPRISES ADMITTING AN OSMOTIC DEVICE ORALLY INTO THE ANIMAL...
U-373	GENERAL USE CLAIM SUBMITTED FOR 12 NEXIUM PATIENTS STATING "PERTINENT TO THE CAPSULE FORMULATION FOR NEXIUM AND ITS INDICATIONS FOR THE TREATMENT OFGERD AND ERADICATION OF H.PYLORI TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE
U-374	KIT ADAPTED AND DESIGNED TO PROVIDE BOTH DATA ON THE CURRENT REPRODUCTIVE STATUS OF A PATIENT AND CONTRACEPTION FOR THOSE WHO ARE NOT PREGNANT, BUT RECENTLY ENGAGED IN UNPROTECTED SEX
U-375	METHOD OF USING RIBAVIRIN FOR TREATING A DISEASE RESPONSIVE TO RIBAVIRIN, E.G. HEPATITIS C

FDA data supplied by DrugPatentWatch.com

PATENT AND EXCLUSIVITY TERMS

REFERENCES

PATENT USE CODE

U-376 TREATMENT OF INFLUENZA
U-377 METHOD OF TREATING PT WITH CHRONIC HEPATITIS C HAVING HCV GENOTYPE 1 AND VIRAL LOAD GREATER THAN 2 MILLION COPIES/ML TO ERADICATE DETECTABLE HCV-RNA BY ADMIN COMBINATION OF RIBAVIRIN AND INTERFERON ALFA-2B FOR A LEAST 24 WEEKS
U-378 METHOD FOR TREATING INCONTINENCE
U-379 METHOD OF TREATING ONYCHROMYCOSIS
U-380 COMBINATIONS OF TAXOL (PACLITAXEL) AND CISPLATIN WHICH ARE SUITABLE FOR THE TREATMENT OF OVARIAN AND NON-SMALL CELL LUNG CARCINOMAS
U-381 TREATMENT OF HYPERPHOSPHATEMIA
U-382 METHOD OF STABLIZING PROSTAGLANDIN
U-383 METHOD FOR TREATING GLAUCOMA AND OCULAR HYPERTENSION
U-384 TREATMENT OF CMV RETINITIS
U-385 TREATMENT OF PEPTIC ULCERS
U-386 TREATMENT OF PATIENTS SUFFERING FROM A LATE ASTHMATIC REACTION OR LATE PHASE ASTHMA
U-387 TREATMENT OF PATIENTS WITH RESPIRATORY DISORDERS
U-388 SMOKING CESSATION AID APPLIED TO THE SKIN
U-389 SMOKING CESSATION AID APPLIED TO THE SKIN ON WAKING AND REMOVED PRIOR TO SLEEP AFTER ABOUT 16 HOURS
U-390 METHOD OF USING THE DRUG TO TREAT NEUROIMMUNOLOGIC DISEASES (INCLUDING MULTIPLE SCLEROSIS)
U-391 USE OF CASODEX IN COMBINATION WITH LHRH AGONISTS FOR THE TREATMENT OF PROSTATE CANCER
U-392 TREATMENT OF PATIENTS FOR INFLAMMATION
U-393 MANAGEMENT OF INCONTINENCE, MGT OF HORMONE REPLACEMENT THERAPY, TREATMENT OF INVOLUNTARY INCONTINENCE, MGT OVERACTIVE BLADDER AND INCREASING COMPLIANCE IN SUCH PT
U-394 METHOD OF USE OF ALPHAGAN
U-395 METHOD OF USE OF ALPHAGAN P
U-396 METHOD OF TREATING PEOPLE SUFFERING FROM DEPRESSION
U-397 METHOD OF TREATING PEOPLE SUFFERING FROM DEPRESSION WITHOUT AN INCREASE IN NAUSEA
U-398 TREATMENT OF GENERALIZED ANXIETY DISORDER
U-399 IN-THE-EYE USE OF CHLORINE DIOXIDE CONTAINING COMPOSITIONS
U-400 USE OF RIBAVIRIN TO INCREASE TYPE 1 CYTOKINE RESPONSE AND SUPPRESS TYPE 2 CYTOKINE RESP0NSE TO LYMPHOCYTES, INCLUDING METHODS THAT TAKE ADVANTAGE OF SUCH MODULATION TO TREAT INFECTIONS AND INFESTATIONS
U-401 USE OF LOPINAVIR IN COMBINATION WITH REVERSE TRANSCRIPTASE INHIBITORS FOR TREATING HIV INFECTION AND IN COMBO WITH OTHER HIV PROTEASE INHIBITORS
U-402 TREATMENT OF ACTINIC KERATOSES
U-403 ANTI-ALLERGIC FOR VARIOUS ALLERGIC DISEASES
U-404 TREATMENT OF ALLERGIC CONJUNCTIVITIS
U-405 METHOD OF USE OF LOTRONEX
U-406 METHOD OF USE OF ATOVAQUONE AND PROGUANIL
U-407 METHOD OF TREATING OTOPATHY
U-408 FOR INDUCING OVULATION IN CONJUNCTION WITH A GONADOTROPIN RELEASING FACTOR ANTAGONIST AND RECRUITING OOCYTES FOR IN-VITRO FERTILIZATION
U-409 METHOD OF TREATING INFLAMMATION USING DRUG SUBSTANCE
U-410 METHOD OF REDUCING AMOUNT OF RESPECTIVE ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (INCLUDING PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
U-411 METHOD OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (WHICH INCLUDES PIOGLITAZONE) IN COMBINATION WITH AN INSULIN PREPARATION
U-412 TREATMENT OF TYPE 2 DIABETES
U-413 USE OF THE ACTIVE INGREDIENT FOR INHIBITING THE BIOSYNTHESIS OF CHOLESTEROL AND TREATMENT OF ATHEROSCLEROSIS
U-414 A METHOD OF TREATING GLYCOMETABOLISM DISORDERS BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE
U-415 A METHOD FOR REDUCING THE AMOUNT OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE AS SAID ACTIVE COMPONENTS

FDA data supplied by DrugPatentWatch.com

PATENT AND EXCLUSIVITY TERMS

REFERENCES

PATENT USE CODE

U-416	A METHOD FOR REDUCING SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE AS SAID ACTIVE COMPONENTS
U-417	COMBINATION USE OF AD-4833 WITH A BIGUANIDE
U-418	A METHOD OF TREATING LIPID METABOLISM DISORDERS BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (WHICH INCLUDES PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
U-419	A METHOD OF TREATING LIPID METABOLISM DISORDERS BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE
U-420	METHOD OF TREATMENT OF TYPE II DIABETES
U-421	USE FOR SEDATION
U-422	METHOD OF TREATING AT LEAST ONE OF ATTENTION DEFICIT DISORDER AND ATTENTION DEFICIT HYPERACTIVITY DISORDER
U-423	METHOD OF TREATING AT LEAST ONE OF ATTENTION DEFICIT DISORDER, ATTENTION DEFICIT HYPERACTIVITY DISORDER, OR AIDS RELATED DEMENTIA
U-424	FOR ONCE DAILY, BOLUS ADMINISTRATION TO A PATIENT IN ORDER TO ENGENDER TREATMENT FOR A NERVOUS DISORDER FOR SUBSTANTIALLY AN ENTIRE DAY ON A CHRONIC BASIS
U-425	METHOD OF REDUCING SIDE EFFECTS OF ACTIVE COMPONENTS ADMIN TO A DIABETIC BY ADMIN A CHEMICAL COMPOUND HAVING FORMULA (INCL PIOGLITAZONE) IN COMBINATION WITH AN INSULIN ECRETION ENHANCER
U-426	PREVENTION OF PREMATURE LH SURGES IN WOMEN UNDERGOING CONTROLLED OVARIAN STIMULATION
U-427	METHOD OF TREATING ALLERGIC REACTIONS IN MAMMALS
U-428	METHOD OF TREATING ALLERGY IN A MAMMAL USING THIS ACTIVE METABOLITE
U-429	METHOD OF USING DESLORATADINE TO TREAT ALLERGIC RHINITIS
U-430	METHOD OF TREATING A DIABETIC BY ADMINISTERING AN INSULIN SENSITIZER IN COMBINATION WITH AN INSULIN SECRETION ENHANCER, AND A DRUG PRODUCT COMPRISING AN INSULIN SENSITIZER AND AN INSULIN SECRETION ENHANCER
U-431	POSTTRAUMATIC STRESS DISORDER
U-432	REDUCTION OF ATHEROSCLEROTIC EVENTS (MYOCARDIAL INFARCTION, STROKE, AND VASCULAR DEATH) IN PATIENTS WITH ATHEROSCLEROSIS DOCUMENTED BY RECENT STROKE, RECENT MYOCARDIAL INFARCTION, OR ESTABLISHED PERIPHERAL ARTERIAL DISEASE
U-433	USE OF LEVOCARITINE IN PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS
U-434	CONTROLLED SYMPTOMS OF DIARRHEA, BLOATING PRESSURE AND CRAMPS, COMMONLY REFERRED TO AS GAS
U-435	A TITRATION DOSING REGIMEN FOR THE TREATMENT OF PAIN USING AN INITIAL DOSE OF ABOUT 25MG
U-436	ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS
U-437	METHOD OF USE EQUAL TO PROCESS OF PREPARATION

*U.S. Government Printing Office: 2002 — 491-214/40008

FDA data supplied by DrugPatentWatch.com

New 22nd Edition



APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

22nd EDITION

Superintendent of Documents Subscription Order Form

Order Processing Code
* 8392

Charge your order. It's easy! MasterCard VISA

☐ **Yes,** enter my subscription as follows:

___ subscriptions of **APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS,** ADP, and the monthly Cumulative Supplements, for $105.00 per year.

The total cost of my order is $____. Price includes regular shipping and handling and is subject to change. International customers please add 25%.

For privacy protection, check the box below:

☐ Do not make my name available to other mailers.

Please choose method of payment:

☐ Check payable to Superintendent of Documents
☐ GPO Deposit Account ☐☐☐☐☐☐-☐

☐ VISA or MasterCard
☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐

Company or personal name

Additional address/attention line

Street address

City, State, ZIP Code

( ) Daytime phone including area code

Purchase Order No. (optional)

(Credit card expiration date)

Thank you for your order!

(Authorizing Signature)

(10/01)

Mail To: Superintendent of Documents, Government Printing Office, P.O. Box 371954 Pittsburgh, PA 15250-7954
To **FAX** your charge order, call (202) 512-2250.
To charge your subscription call (202) 512-1800.